0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	side	_	_	O
6	effects	_	_	O
7	and	_	_	O
8	the	_	_	O
9	effect	_	_	O
10	on	_	_	O
11	aqueous	_	_	O
12	humor	_	_	O
13	dynamics	_	_	O
14	of	_	_	O
15	0.005	_	_	O
16	%	_	_	O
17	latanoprost	_	_	O
18	applied	_	_	O
19	topically	_	_	O
20	once	_	_	O
21	daily	_	_	O
22	with	_	_	O
23	0.5	_	_	O
24	%	_	_	O
25	timolol	_	_	O
26	given	_	_	O
27	twice	_	_	O
28	daily	_	_	O
29	for	_	_	O
30	12	_	_	O
31	months	_	_	O
32	to	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	pigmentary	_	_	O
36	glaucoma	_	_	O
37	.	_	_	O

38	Prospective	_	_	O
39	,	_	_	O
40	randomized	_	_	O
41	,	_	_	O
42	double-masked	_	_	O
43	,	_	_	O
44	clinical	_	_	O
45	study	_	_	O
46	.	_	_	O

47	Thirty-six	_	_	O
48	patients	_	_	O
49	affected	_	_	O
50	with	_	_	O
51	bilateral	_	_	O
52	pigmentary	_	_	O
53	glaucoma	_	_	O
54	controlled	_	_	O
55	with	_	_	O
56	no	_	_	O
57	more	_	_	O
58	than	_	_	O
59	a	_	_	O
60	single	_	_	O
61	hypotensive	_	_	O
62	medication	_	_	O
63	were	_	_	O
64	enrolled	_	_	O
65	in	_	_	O
66	the	_	_	O
67	study	_	_	O
68	.	_	_	O

69	The	_	_	O
70	sample	_	_	O
71	population	_	_	O
72	was	_	_	O
73	randomly	_	_	O
74	divided	_	_	O
75	into	_	_	O
76	2	_	_	O
77	age-	_	_	O
78	and	_	_	O
79	gender-matched	_	_	O
80	groups	_	_	O
81	each	_	_	O
82	of	_	_	O
83	18	_	_	O
84	patients	_	_	O
85	.	_	_	O

86	Group	_	_	O
87	1	_	_	O
88	received	_	_	O
89	0.005	_	_	O
90	%	_	_	O
91	latanoprost	_	_	O
92	eyedrops	_	_	O
93	once	_	_	O
94	daily	_	_	O
95	and	_	_	O
96	the	_	_	O
97	vehicle	_	_	O
98	(	_	_	O
99	placebo	_	_	O
100	)	_	_	O
101	once	_	_	O
102	daily	_	_	O
103	;	_	_	O
104	group	_	_	O
105	2	_	_	O
106	was	_	_	O
107	assigned	_	_	O
108	to	_	_	O
109	timolol	_	_	O
110	0.5	_	_	O
111	%	_	_	O
112	eyedrops	_	_	O
113	twice	_	_	O
114	daily	_	_	O
115	.	_	_	O

116	Diurnal	_	_	O
117	curves	_	_	O
118	of	_	_	O
119	intraocular	_	_	O
120	pressure	_	_	O
121	(	_	_	O
122	IOP	_	_	O
123	)	_	_	O
124	were	_	_	O
125	performed	_	_	O
126	on	_	_	O
127	the	_	_	O
128	baseline	_	_	O
129	day	_	_	O
130	and	_	_	O
131	after	_	_	O
132	0.5	_	_	O
133	,	_	_	O
134	3	_	_	O
135	,	_	_	O
136	6	_	_	O
137	,	_	_	O
138	and	_	_	O
139	12	_	_	O
140	months	_	_	O
141	of	_	_	O
142	treatment	_	_	O
143	.	_	_	O

144	The	_	_	O
145	IOP	_	_	O
146	measurements	_	_	O
147	were	_	_	O
148	performed	_	_	O
149	at	_	_	O
150	8:00	_	_	O
151	AM	_	_	O
152	,	_	_	O
153	12:00	_	_	O
154	noon	_	_	O
155	,	_	_	O
156	4:00	_	_	O
157	PM	_	_	O
158	,	_	_	O
159	and	_	_	O
160	8:00	_	_	O
161	PM	_	_	O
162	.	_	_	O

163	Outflow	_	_	O
164	facility	_	_	O
165	(	_	_	O
166	C	_	_	O
167	)	_	_	O
168	was	_	_	O
169	measured	_	_	O
170	on	_	_	O
171	the	_	_	O
172	baseline	_	_	O
173	day	_	_	O
174	and	_	_	O
175	on	_	_	O
176	the	_	_	O
177	last	_	_	O
178	day	_	_	O
179	of	_	_	O
180	the	_	_	O
181	study	_	_	O
182	with	_	_	O
183	a	_	_	O
184	Schiotz	_	_	O
185	electronic	_	_	O
186	tonometer	_	_	O
187	.	_	_	O

188	A	_	_	O
189	two-tailed	_	_	O
190	Student	_	_	O
191	's	_	_	O
192	t	_	_	O
193	test	_	_	O
194	for	_	_	O
195	paired	_	_	O
196	or	_	_	O
197	unpaired	_	_	O
198	data	_	_	O
199	was	_	_	O
200	used	_	_	O
201	for	_	_	O
202	statistical	_	_	O
203	evaluation	_	_	O
204	of	_	_	O
205	differences	_	_	O
206	between	_	_	O
207	treatment	_	_	O
208	and	_	_	O
209	baseline	_	_	O
210	values	_	_	O
211	or	_	_	O
212	between	_	_	O
213	the	_	_	O
214	latanoprost	_	_	O
215	and	_	_	O
216	timolol	_	_	O
217	group	_	_	O
218	.	_	_	O

219	Diurnal	_	_	O
220	IOP	_	_	O
221	measurements	_	_	O
222	were	_	_	O
223	compared	_	_	O
224	hour	_	_	O
225	by	_	_	O
226	hour	_	_	O
227	.	_	_	O

228	Mean	_	_	O
229	values	_	_	O
230	of	_	_	O
231	the	_	_	O
232	two	_	_	O
233	eyes	_	_	O
234	IOP	_	_	O
235	and	_	_	O
236	C	_	_	O
237	were	_	_	O
238	used	_	_	O
239	for	_	_	O
240	analysis	_	_	O
241	.	_	_	O

242	Compared	_	_	B-Premise
243	with	_	_	I-Premise
244	baseline	_	_	I-Premise
245	measurements	_	_	I-Premise
246	,	_	_	I-Premise
247	both	_	_	I-Premise
248	latanoprost	_	_	I-Premise
249	and	_	_	I-Premise
250	timolol	_	_	I-Premise
251	caused	_	_	I-Premise
252	a	_	_	I-Premise
253	significant	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	<	_	_	I-Premise
257	0.001	_	_	I-Premise
258	)	_	_	I-Premise
259	reduction	_	_	I-Premise
260	of	_	_	I-Premise
261	IOP	_	_	I-Premise
262	at	_	_	I-Premise
263	each	_	_	I-Premise
264	hour	_	_	I-Premise
265	of	_	_	I-Premise
266	diurnal	_	_	I-Premise
267	curve	_	_	I-Premise
268	throughout	_	_	I-Premise
269	the	_	_	I-Premise
270	duration	_	_	I-Premise
271	of	_	_	I-Premise
272	therapy	_	_	I-Premise
273	.	_	_	I-Premise

274	Reduction	_	_	B-Premise
275	of	_	_	I-Premise
276	IOP	_	_	I-Premise
277	was	_	_	I-Premise
278	6.0	_	_	I-Premise
279	+/-	_	_	I-Premise
280	4.5	_	_	I-Premise
281	and	_	_	I-Premise
282	5.9	_	_	I-Premise
283	+/-	_	_	I-Premise
284	4.6	_	_	I-Premise
285	with	_	_	I-Premise
286	latanoprost	_	_	I-Premise
287	and	_	_	I-Premise
288	4.8	_	_	I-Premise
289	+/-	_	_	I-Premise
290	3.0	_	_	I-Premise
291	and	_	_	I-Premise
292	4.6	_	_	I-Premise
293	+/-	_	_	I-Premise
294	3.1	_	_	I-Premise
295	with	_	_	I-Premise
296	timolol	_	_	I-Premise
297	after	_	_	I-Premise
298	6	_	_	I-Premise
299	and	_	_	I-Premise
300	12	_	_	I-Premise
301	months	_	_	I-Premise
302	,	_	_	I-Premise
303	respectively	_	_	I-Premise
304	.	_	_	I-Premise

305	Comparison	_	_	B-Premise
306	of	_	_	I-Premise
307	mean	_	_	I-Premise
308	diurnal	_	_	I-Premise
309	measurements	_	_	I-Premise
310	with	_	_	I-Premise
311	latanoprost	_	_	I-Premise
312	and	_	_	I-Premise
313	timolol	_	_	I-Premise
314	showed	_	_	I-Premise
315	a	_	_	I-Premise
316	statistical	_	_	I-Premise
317	significant	_	_	I-Premise
318	(	_	_	I-Premise
319	P	_	_	I-Premise
320	<	_	_	I-Premise
321	0.001	_	_	I-Premise
322	)	_	_	I-Premise
323	difference	_	_	I-Premise
324	at	_	_	I-Premise
325	3	_	_	I-Premise
326	,	_	_	I-Premise
327	6	_	_	I-Premise
328	,	_	_	I-Premise
329	and	_	_	I-Premise
330	12	_	_	I-Premise
331	months	_	_	I-Premise
332	.	_	_	I-Premise

333	Mean	_	_	B-Premise
334	C	_	_	I-Premise
335	was	_	_	I-Premise
336	found	_	_	I-Premise
337	to	_	_	I-Premise
338	be	_	_	I-Premise
339	significantly	_	_	I-Premise
340	enhanced	_	_	I-Premise
341	(	_	_	I-Premise
342	+30	_	_	I-Premise
343	%	_	_	I-Premise
344	)	_	_	I-Premise
345	only	_	_	I-Premise
346	in	_	_	I-Premise
347	the	_	_	I-Premise
348	latanoprost-treated	_	_	I-Premise
349	group	_	_	I-Premise
350	compared	_	_	I-Premise
351	with	_	_	I-Premise
352	the	_	_	I-Premise
353	baseline	_	_	I-Premise
354	(	_	_	I-Premise
355	P	_	_	I-Premise
356	=	_	_	I-Premise
357	0.017	_	_	I-Premise
358	)	_	_	I-Premise
359	.	_	_	I-Premise

360	Mean	_	_	B-Premise
361	conjunctival	_	_	I-Premise
362	hyperemia	_	_	I-Premise
363	was	_	_	I-Premise
364	graded	_	_	I-Premise
365	at	_	_	I-Premise
366	0.3	_	_	I-Premise
367	in	_	_	I-Premise
368	latanoprost-treated	_	_	I-Premise
369	eyes	_	_	I-Premise
370	and	_	_	I-Premise
371	0.2	_	_	I-Premise
372	in	_	_	I-Premise
373	timolol-treated	_	_	I-Premise
374	eyes	_	_	I-Premise
375	.	_	_	I-Premise

376	A	_	_	B-Premise
377	remarkable	_	_	I-Premise
378	change	_	_	I-Premise
379	in	_	_	I-Premise
380	iris	_	_	I-Premise
381	color	_	_	I-Premise
382	was	_	_	I-Premise
383	observed	_	_	I-Premise
384	in	_	_	I-Premise
385	both	_	_	I-Premise
386	eyes	_	_	I-Premise
387	of	_	_	I-Premise
388	1	_	_	I-Premise
389	of	_	_	I-Premise
390	the	_	_	I-Premise
391	18	_	_	I-Premise
392	patients	_	_	I-Premise
393	treated	_	_	I-Premise
394	with	_	_	I-Premise
395	latanoprost	_	_	I-Premise
396	and	_	_	I-Premise
397	none	_	_	I-Premise
398	of	_	_	I-Premise
399	the	_	_	I-Premise
400	18	_	_	I-Premise
401	patients	_	_	I-Premise
402	who	_	_	I-Premise
403	received	_	_	I-Premise
404	timolol	_	_	I-Premise
405	.	_	_	I-Premise

406	Darkening	_	_	O
407	of	_	_	O
408	the	_	_	O
409	peripheral	_	_	O
410	iris	_	_	O
411	stroma	_	_	O
412	was	_	_	O
413	suspected	_	_	O
414	in	_	_	O
415	two	_	_	O
416	patients	_	_	O
417	treated	_	_	O
418	with	_	_	O
419	latanoprost	_	_	O
420	.	_	_	O

421	In	_	_	B-Premise
422	the	_	_	I-Premise
423	timolol	_	_	I-Premise
424	group	_	_	I-Premise
425	,	_	_	I-Premise
426	heart	_	_	I-Premise
427	rate	_	_	I-Premise
428	was	_	_	I-Premise
429	significantly	_	_	I-Premise
430	reduced	_	_	I-Premise
431	from	_	_	I-Premise
432	72	_	_	I-Premise
433	+/-	_	_	I-Premise
434	9	_	_	I-Premise
435	at	_	_	I-Premise
436	baseline	_	_	I-Premise
437	to	_	_	I-Premise
438	67	_	_	I-Premise
439	+/-	_	_	I-Premise
440	10	_	_	I-Premise
441	beats	_	_	I-Premise
442	per	_	_	I-Premise
443	minute	_	_	I-Premise
444	at	_	_	I-Premise
445	12	_	_	I-Premise
446	months	_	_	I-Premise
447	.	_	_	I-Premise

448	Although	_	_	O
449	further	_	_	B-Claim
450	studies	_	_	I-Claim
451	may	_	_	I-Claim
452	need	_	_	I-Claim
453	to	_	_	I-Claim
454	confirm	_	_	I-Claim
455	these	_	_	I-Claim
456	data	_	_	I-Claim
457	on	_	_	I-Claim
458	a	_	_	I-Claim
459	larger	_	_	I-Claim
460	sample	_	_	I-Claim
461	and	_	_	I-Claim
462	to	_	_	I-Claim
463	evaluate	_	_	I-Claim
464	the	_	_	I-Claim
465	side	_	_	I-Claim
466	effect	_	_	I-Claim
467	of	_	_	I-Claim
468	increased	_	_	I-Claim
469	iris	_	_	I-Claim
470	pigmentation	_	_	I-Claim
471	on	_	_	I-Claim
472	long-term	_	_	I-Claim
473	follow-up	_	_	I-Claim
474	,	_	_	I-Claim
475	in	_	_	B-Claim
476	patients	_	_	I-Claim
477	with	_	_	I-Claim
478	pigmentary	_	_	I-Claim
479	glaucoma	_	_	I-Claim
480	,	_	_	I-Claim
481	0.005	_	_	I-Claim
482	%	_	_	I-Claim
483	latanoprost	_	_	I-Claim
484	taken	_	_	I-Claim
485	once	_	_	I-Claim
486	daily	_	_	I-Claim
487	was	_	_	I-Claim
488	well	_	_	I-Claim
489	tolerated	_	_	I-Claim
490	and	_	_	I-Claim
491	more	_	_	I-Claim
492	effective	_	_	I-Claim
493	in	_	_	I-Claim
494	reducing	_	_	I-Claim
495	IOP	_	_	I-Claim
496	than	_	_	I-Claim
497	0.5	_	_	I-Claim
498	%	_	_	I-Claim
499	timolol	_	_	I-Claim
500	taken	_	_	I-Claim
501	twice	_	_	I-Claim
502	daily	_	_	I-Claim
503	.	_	_	I-Claim


0	Data	_	_	O
1	from	_	_	O
2	experimental	_	_	O
3	studies	_	_	O
4	suggest	_	_	O
5	that	_	_	O
6	octreotide	_	_	B-Claim
7	,	_	_	I-Claim
8	the	_	_	I-Claim
9	long	_	_	I-Claim
10	acting	_	_	I-Claim
11	somatostatin	_	_	I-Claim
12	analogue	_	_	I-Claim
13	,	_	_	I-Claim
14	improves	_	_	I-Claim
15	survival	_	_	I-Claim
16	of	_	_	I-Claim
17	animals	_	_	I-Claim
18	with	_	_	I-Claim
19	pancreatic	_	_	I-Claim
20	cancer	_	_	I-Claim
21	.	_	_	I-Claim

22	To	_	_	O
23	assess	_	_	O
24	the	_	_	O
25	antitumour	_	_	O
26	effect	_	_	O
27	of	_	_	O
28	octreotide	_	_	O
29	,	_	_	O
30	a	_	_	O
31	randomized	_	_	O
32	trial	_	_	O
33	was	_	_	O
34	performed	_	_	O
35	comparing	_	_	O
36	octreotide	_	_	O
37	with	_	_	O
38	supportive	_	_	O
39	care	_	_	O
40	in	_	_	O
41	advanced	_	_	O
42	pancreatic	_	_	O
43	cancer	_	_	O
44	patients	_	_	O
45	.	_	_	O

46	All	_	_	O
47	patients	_	_	O
48	,	_	_	O
49	aged	_	_	O
50	59-75	_	_	O
51	years	_	_	O
52	,	_	_	O
53	were	_	_	O
54	not	_	_	O
55	liable	_	_	O
56	to	_	_	O
57	radical	_	_	O
58	surgical	_	_	O
59	treatment	_	_	O
60	and	_	_	O
61	were	_	_	O
62	not	_	_	O
63	submitted	_	_	O
64	to	_	_	O
65	other	_	_	O
66	treatments	_	_	O
67	(	_	_	O
68	chemo	_	_	O
69	and/or	_	_	O
70	radiotherapy	_	_	O
71	)	_	_	O
72	.	_	_	O

73	Six	_	_	O
74	patients	_	_	O
75	were	_	_	O
76	enrolled	_	_	O
77	,	_	_	O
78	4	_	_	O
79	of	_	_	O
80	these	_	_	O
81	treated	_	_	O
82	with	_	_	O
83	octreotide	_	_	O
84	(	_	_	O
85	500	_	_	O
86	micrograms	_	_	O
87	two	_	_	O
88	times	_	_	O
89	a	_	_	O
90	day	_	_	O
91	subcutaneous	_	_	O
92	for	_	_	O
93	six	_	_	O
94	months	_	_	O
95	)	_	_	O
96	and	_	_	O
97	the	_	_	O
98	other	_	_	O
99	2	_	_	O
100	were	_	_	O
101	inserted	_	_	O
102	a	_	_	O
103	control	_	_	O
104	group	_	_	O
105	.	_	_	O

106	The	_	_	B-Premise
107	patients	_	_	I-Premise
108	treated	_	_	I-Premise
109	with	_	_	I-Premise
110	octreotide	_	_	I-Premise
111	showed	_	_	I-Premise
112	a	_	_	I-Premise
113	significant	_	_	I-Premise
114	advantage	_	_	I-Premise
115	in	_	_	I-Premise
116	quality	_	_	I-Premise
117	of	_	_	I-Premise
118	life	_	_	I-Premise
119	(	_	_	I-Premise
120	restored	_	_	I-Premise
121	appetite	_	_	I-Premise
122	,	_	_	I-Premise
123	improvement	_	_	I-Premise
124	of	_	_	I-Premise
125	digestion	_	_	I-Premise
126	and	_	_	I-Premise
127	intestine	_	_	I-Premise
128	function	_	_	I-Premise
129	,	_	_	I-Premise
130	remission	_	_	I-Premise
131	of	_	_	I-Premise
132	abdominal	_	_	I-Premise
133	pain	_	_	I-Premise
134	and	_	_	I-Premise
135	preservation	_	_	I-Premise
136	of	_	_	I-Premise
137	baseline	_	_	I-Premise
138	body	_	_	I-Premise
139	weight	_	_	I-Premise
140	)	_	_	I-Premise
141	with	_	_	I-Premise
142	a	_	_	I-Premise
143	mean	_	_	I-Premise
144	>	_	_	I-Premise
145	80	_	_	I-Premise
146	of	_	_	I-Premise
147	karnofsky	_	_	I-Premise
148	performance	_	_	I-Premise
149	score	_	_	I-Premise
150	.	_	_	I-Premise

151	Monitoring	_	_	B-Premise
152	of	_	_	I-Premise
153	tumour	_	_	I-Premise
154	size	_	_	I-Premise
155	changes	_	_	I-Premise
156	(	_	_	I-Premise
157	US-TC	_	_	I-Premise
158	)	_	_	I-Premise
159	over	_	_	I-Premise
160	the	_	_	I-Premise
161	6	_	_	I-Premise
162	months	_	_	I-Premise
163	study	_	_	I-Premise
164	period	_	_	I-Premise
165	,	_	_	I-Premise
166	showed	_	_	I-Premise
167	slackened	_	_	I-Premise
168	neoplastic	_	_	I-Premise
169	growth	_	_	I-Premise
170	in	_	_	I-Premise
171	all	_	_	I-Premise
172	treated	_	_	I-Premise
173	patients	_	_	I-Premise
174	,	_	_	I-Premise
175	whereas	_	_	B-Premise
176	neoplasm	_	_	I-Premise
177	grew	_	_	I-Premise
178	according	_	_	I-Premise
179	to	_	_	I-Premise
180	an	_	_	I-Premise
181	almost	_	_	I-Premise
182	exponential	_	_	I-Premise
183	trend	_	_	I-Premise
184	in	_	_	I-Premise
185	untreated	_	_	I-Premise
186	patients	_	_	I-Premise
187	.	_	_	O

188	Also	_	_	O
189	survival	_	_	B-Premise
190	was	_	_	I-Premise
191	better	_	_	I-Premise
192	in	_	_	I-Premise
193	treated	_	_	I-Premise
194	patients	_	_	I-Premise
195	:	_	_	O
196	in	_	_	O
197	particular	_	_	O
198	,	_	_	O
199	2	_	_	O
200	patients	_	_	O
201	out	_	_	O
202	of	_	_	O
203	4	_	_	O
204	who	_	_	O
205	completed	_	_	O
206	the	_	_	O
207	study	_	_	O
208	underwent	_	_	O
209	follow-up	_	_	O
210	until	_	_	O
211	they	_	_	O
212	died	_	_	O
213	12	_	_	O
214	and	_	_	O
215	16	_	_	O
216	months	_	_	O
217	after	_	_	O
218	beginning	_	_	O
219	of	_	_	O
220	treatment	_	_	O
221	,	_	_	O
222	respectively	_	_	O
223	.	_	_	O

224	Karnofsky	_	_	B-Premise
225	performance	_	_	I-Premise
226	score	_	_	I-Premise
227	was	_	_	I-Premise
228	particularly	_	_	I-Premise
229	high	_	_	I-Premise
230	in	_	_	I-Premise
231	both	_	_	I-Premise
232	patients	_	_	I-Premise
233	.	_	_	I-Premise

234	This	_	_	O
235	supports	_	_	O
236	the	_	_	O
237	view	_	_	O
238	that	_	_	O
239	octreotide	_	_	B-Claim
240	is	_	_	I-Claim
241	endowed	_	_	I-Claim
242	with	_	_	I-Claim
243	antiproliferative	_	_	I-Claim
244	activity	_	_	I-Claim
245	.	_	_	I-Claim

246	In	_	_	O
247	conclusion	_	_	O
248	octreotide	_	_	B-Claim
249	therapy	_	_	I-Claim
250	seems	_	_	I-Claim
251	to	_	_	I-Claim
252	confer	_	_	I-Claim
253	a	_	_	I-Claim
254	survival	_	_	I-Claim
255	benefit	_	_	I-Claim
256	and	_	_	I-Claim
257	a	_	_	I-Claim
258	better	_	_	I-Claim
259	quality	_	_	I-Claim
260	of	_	_	I-Claim
261	life	_	_	I-Claim
262	in	_	_	I-Claim
263	advanced	_	_	I-Claim
264	pancreatic	_	_	I-Claim
265	tumour	_	_	I-Claim
266	.	_	_	I-Claim

267	Additional	_	_	O
268	studies	_	_	O
269	are	_	_	O
270	needed	_	_	O
271	to	_	_	O
272	confirm	_	_	O
273	these	_	_	O
274	results	_	_	O
275	and	_	_	O
276	to	_	_	O
277	clarify	_	_	O
278	other	_	_	O
279	questions	_	_	O
280	about	_	_	O
281	dose	_	_	O
282	and	_	_	O
283	somatostatin	_	_	O
284	receptors	_	_	O
285	in	_	_	O
286	this	_	_	O
287	kind	_	_	O
288	of	_	_	O
289	tumour	_	_	O
290	.	_	_	O


0	In	_	_	O
1	a	_	_	O
2	prospective	_	_	O
3	randomized	_	_	O
4	study	_	_	O
5	,	_	_	O
6	287	_	_	O
7	patients	_	_	O
8	with	_	_	O
9	advanced	_	_	O
10	non-small	_	_	O
11	cell	_	_	O
12	lung	_	_	O
13	cancer	_	_	O
14	(	_	_	O
15	NSCLC	_	_	O
16	)	_	_	O
17	stage	_	_	O
18	IIIb	_	_	O
19	or	_	_	O
20	IV	_	_	O
21	with	_	_	O
22	ECOG	_	_	O
23	performance	_	_	O
24	status	_	_	O
25	(	_	_	O
26	PS	_	_	O
27	)	_	_	O
28	0-1	_	_	O
29	or	_	_	O
30	2	_	_	O
31	were	_	_	O
32	randomly	_	_	O
33	assigned	_	_	O
34	to	_	_	O
35	receive	_	_	O
36	either	_	_	O
37	best	_	_	O
38	supportive	_	_	O
39	care	_	_	O
40	(	_	_	O
41	BSC	_	_	O
42	)	_	_	O
43	or	_	_	O
44	supportive	_	_	O
45	care	_	_	O
46	plus	_	_	O
47	combination	_	_	O
48	chemotherapy	_	_	O
49	(	_	_	O
50	IEP	_	_	O
51	regimen	_	_	O
52	:	_	_	O
53	ifosfamide	_	_	O
54	3	_	_	O
55	gm/m2	_	_	O
56	IV	_	_	O
57	with	_	_	O
58	mesna	_	_	O
59	uroprotection	_	_	O
60	,	_	_	O
61	epirubicin	_	_	O
62	60	_	_	O
63	mg/m2	_	_	O
64	IV	_	_	O
65	on	_	_	O
66	day	_	_	O
67	1	_	_	O
68	and	_	_	O
69	cisplatin	_	_	O
70	60	_	_	O
71	mg/m2	_	_	O
72	IV	_	_	O
73	on	_	_	O
74	day	_	_	O
75	2	_	_	O
76	;	_	_	O
77	or	_	_	O
78	MVP	_	_	O
79	regimen	_	_	O
80	:	_	_	O
81	mitomycin-C	_	_	O
82	8	_	_	O
83	mg/m2	_	_	O
84	,	_	_	O
85	cisplatin	_	_	O
86	100	_	_	O
87	mg/m2	_	_	O
88	IV	_	_	O
89	on	_	_	O
90	day	_	_	O
91	1	_	_	O
92	,	_	_	O
93	vinblastine	_	_	O
94	4	_	_	O
95	mg/m2	_	_	O
96	IV	_	_	O
97	on	_	_	O
98	days	_	_	O
99	1	_	_	O
100	and	_	_	O
101	15	_	_	O
102	)	_	_	O
103	.	_	_	O

104	Serial	_	_	O
105	assessment	_	_	O
106	of	_	_	O
107	Karnofsky	_	_	O
108	performance	_	_	O
109	status	_	_	O
110	(	_	_	O
111	KPS	_	_	O
112	)	_	_	O
113	,	_	_	O
114	modified	_	_	O
115	Functional	_	_	O
116	Living	_	_	O
117	Index-Cancer	_	_	O
118	(	_	_	O
119	T-FLIC	_	_	O
120	)	_	_	O
121	and	_	_	O
122	modified	_	_	O
123	Quality	_	_	O
124	of	_	_	O
125	Life-Index	_	_	O
126	(	_	_	O
127	T-QLI	_	_	O
128	)	_	_	O
129	were	_	_	O
130	used	_	_	O
131	to	_	_	O
132	estimate	_	_	O
133	the	_	_	O
134	quality	_	_	O
135	of	_	_	O
136	life	_	_	O
137	.	_	_	O

138	Interviews	_	_	O
139	were	_	_	O
140	done	_	_	O
141	at	_	_	O
142	entry	_	_	O
143	,	_	_	O
144	at	_	_	O
145	the	_	_	O
146	third	_	_	O
147	month	_	_	O
148	and	_	_	O
149	at	_	_	O
150	2	_	_	O
151	months	_	_	O
152	post	_	_	O
153	complete	_	_	O
154	treatment	_	_	O
155	.	_	_	O

156	At	_	_	O
157	least	_	_	O
158	two	_	_	O
159	courses	_	_	O
160	of	_	_	O
161	chemotherapy	_	_	O
162	were	_	_	O
163	considered	_	_	O
164	to	_	_	O
165	be	_	_	O
166	adequate	_	_	O
167	for	_	_	O
168	response	_	_	O
169	evaluation	_	_	O
170	.	_	_	O

171	Patients	_	_	O
172	were	_	_	O
173	treated	_	_	O
174	for	_	_	O
175	a	_	_	O
176	total	_	_	O
177	of	_	_	O
178	four	_	_	O
179	to	_	_	O
180	six	_	_	O
181	courses	_	_	O
182	or	_	_	O
183	until	_	_	O
184	progression	_	_	O
185	of	_	_	O
186	disease	_	_	O
187	.	_	_	O

188	Partial	_	_	B-Premise
189	response	_	_	I-Premise
190	rates	_	_	I-Premise
191	were	_	_	I-Premise
192	40	_	_	I-Premise
193	and	_	_	I-Premise
194	41.7	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	IEP	_	_	I-Premise
198	and	_	_	I-Premise
199	MVP	_	_	I-Premise
200	arms	_	_	I-Premise
201	.	_	_	I-Premise

202	Median	_	_	B-Premise
203	survival	_	_	I-Premise
204	durations	_	_	I-Premise
205	were	_	_	I-Premise
206	5.9	_	_	I-Premise
207	and	_	_	I-Premise
208	8.1	_	_	I-Premise
209	months	_	_	I-Premise
210	for	_	_	I-Premise
211	the	_	_	I-Premise
212	IEP	_	_	I-Premise
213	and	_	_	I-Premise
214	MVP	_	_	I-Premise
215	chemotherapy	_	_	I-Premise
216	arms	_	_	I-Premise
217	,	_	_	I-Premise
218	and	_	_	I-Premise
219	4.1	_	_	I-Premise
220	months	_	_	I-Premise
221	for	_	_	I-Premise
222	BSC	_	_	I-Premise
223	(	_	_	I-Premise
224	log-rank	_	_	I-Premise
225	test	_	_	I-Premise
226	:	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.0003	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	One	_	_	B-Premise
233	year	_	_	I-Premise
234	survival	_	_	I-Premise
235	was	_	_	I-Premise
236	13	_	_	I-Premise
237	,	_	_	I-Premise
238	29.8	_	_	I-Premise
239	and	_	_	I-Premise
240	39.3	_	_	I-Premise
241	%	_	_	I-Premise
242	for	_	_	I-Premise
243	the	_	_	I-Premise
244	BSC	_	_	I-Premise
245	,	_	_	I-Premise
246	IEP	_	_	I-Premise
247	and	_	_	I-Premise
248	MVP	_	_	I-Premise
249	regimens	_	_	I-Premise
250	,	_	_	I-Premise
251	respectively	_	_	I-Premise
252	.	_	_	I-Premise

253	Two	_	_	B-Premise
254	years	_	_	I-Premise
255	survival	_	_	I-Premise
256	was	_	_	I-Premise
257	7.8	_	_	I-Premise
258	,	_	_	I-Premise
259	6.4	_	_	I-Premise
260	and	_	_	I-Premise
261	13.1	_	_	I-Premise
262	%	_	_	I-Premise
263	for	_	_	I-Premise
264	the	_	_	I-Premise
265	BSC	_	_	I-Premise
266	,	_	_	I-Premise
267	IEP	_	_	I-Premise
268	and	_	_	I-Premise
269	MVP	_	_	I-Premise
270	regimens	_	_	I-Premise
271	,	_	_	I-Premise
272	respectively	_	_	I-Premise
273	.	_	_	I-Premise

274	Improvement	_	_	B-Premise
275	in	_	_	I-Premise
276	quality	_	_	I-Premise
277	of	_	_	I-Premise
278	life	_	_	I-Premise
279	(	_	_	I-Premise
280	QOL	_	_	I-Premise
281	)	_	_	I-Premise
282	scores	_	_	I-Premise
283	at	_	_	I-Premise
284	the	_	_	I-Premise
285	first	_	_	I-Premise
286	,	_	_	I-Premise
287	second	_	_	I-Premise
288	and	_	_	I-Premise
289	third	_	_	I-Premise
290	interview	_	_	I-Premise
291	were	_	_	I-Premise
292	seen	_	_	I-Premise
293	in	_	_	I-Premise
294	chemotherapy	_	_	I-Premise
295	arms	_	_	I-Premise
296	only	_	_	I-Premise
297	,	_	_	I-Premise
298	not	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	BSC	_	_	I-Premise
302	arm	_	_	I-Premise
303	.	_	_	I-Premise

304	We	_	_	O
305	conclude	_	_	O
306	that	_	_	O
307	combination	_	_	B-Claim
308	chemotherapy	_	_	I-Claim
309	improves	_	_	I-Claim
310	the	_	_	I-Claim
311	quality	_	_	I-Claim
312	of	_	_	I-Claim
313	life	_	_	I-Claim
314	as	_	_	I-Claim
315	well	_	_	I-Claim
316	as	_	_	I-Claim
317	prolonging	_	_	I-Claim
318	the	_	_	I-Claim
319	survival	_	_	I-Claim
320	of	_	_	I-Claim
321	patients	_	_	I-Claim
322	with	_	_	I-Claim
323	advanced	_	_	I-Claim
324	NSCLC	_	_	I-Claim
325	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	a	_	_	O
8	slow-release	_	_	O
9	formulation	_	_	O
10	of	_	_	O
11	cytarabine	_	_	O
12	(	_	_	O
13	DepoCyt	_	_	O
14	;	_	_	O
15	Chiron	_	_	O
16	Corp	_	_	O
17	,	_	_	O
18	Emeryville	_	_	O
19	,	_	_	O
20	CA	_	_	O
21	,	_	_	O
22	and	_	_	O
23	Skye	_	_	O
24	Pharma	_	_	O
25	,	_	_	O
26	Inc	_	_	O
27	,	_	_	O
28	San	_	_	O
29	Diego	_	_	O
30	,	_	_	O
31	CA	_	_	O
32	)	_	_	O
33	that	_	_	O
34	maintains	_	_	O
35	cytotoxic	_	_	O
36	concentrations	_	_	O
37	of	_	_	O
38	cytarabine	_	_	O
39	(	_	_	O
40	ara-C	_	_	O
41	)	_	_	O
42	in	_	_	O
43	the	_	_	O
44	CSF	_	_	O
45	of	_	_	O
46	most	_	_	O
47	patients	_	_	O
48	for	_	_	O
49	more	_	_	O
50	than	_	_	O
51	14	_	_	O
52	days	_	_	O
53	.	_	_	O

54	Twenty-eight	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	lymphoma	_	_	O
58	and	_	_	O
59	a	_	_	O
60	positive	_	_	O
61	CSF	_	_	O
62	cytology	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	DepoCyt	_	_	O
68	50	_	_	O
69	mg	_	_	O
70	once	_	_	O
71	every	_	_	O
72	2	_	_	O
73	weeks	_	_	O
74	or	_	_	O
75	free	_	_	O
76	ara-C	_	_	O
77	50	_	_	O
78	mg	_	_	O
79	twice	_	_	O
80	a	_	_	O
81	week	_	_	O
82	for	_	_	O
83	1	_	_	O
84	month	_	_	O
85	.	_	_	O

86	Patients	_	_	O
87	whose	_	_	O
88	CSF	_	_	O
89	cytology	_	_	O
90	converted	_	_	O
91	to	_	_	O
92	negative	_	_	O
93	and	_	_	O
94	who	_	_	O
95	did	_	_	O
96	not	_	_	O
97	have	_	_	O
98	neurologic	_	_	O
99	progression	_	_	O
100	received	_	_	O
101	an	_	_	O
102	additional	_	_	O
103	3	_	_	O
104	months	_	_	O
105	of	_	_	O
106	consolidation	_	_	O
107	therapy	_	_	O
108	and	_	_	O
109	then	_	_	O
110	4	_	_	O
111	months	_	_	O
112	of	_	_	O
113	maintenance	_	_	O
114	therapy	_	_	O
115	.	_	_	O

116	All	_	_	O
117	patients	_	_	O
118	received	_	_	O
119	dexamethasone	_	_	O
120	4	_	_	O
121	mg	_	_	O
122	orally	_	_	O
123	bid	_	_	O
124	on	_	_	O
125	days	_	_	O
126	1	_	_	O
127	through	_	_	O
128	5	_	_	O
129	of	_	_	O
130	each	_	_	O
131	2-week	_	_	O
132	cycle	_	_	O
133	.	_	_	O

134	The	_	_	B-Premise
135	response	_	_	I-Premise
136	rate	_	_	I-Premise
137	was	_	_	I-Premise
138	71	_	_	I-Premise
139	%	_	_	I-Premise
140	for	_	_	I-Premise
141	DepoCyt	_	_	I-Premise
142	and	_	_	I-Premise
143	15	_	_	I-Premise
144	%	_	_	I-Premise
145	for	_	_	I-Premise
146	ara-C	_	_	I-Premise
147	on	_	_	I-Premise
148	an	_	_	I-Premise
149	intent-to-treat	_	_	I-Premise
150	basis	_	_	I-Premise
151	(	_	_	I-Premise
152	P	_	_	I-Premise
153	=.006	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	All	_	_	B-Premise
157	of	_	_	I-Premise
158	the	_	_	I-Premise
159	patients	_	_	I-Premise
160	on	_	_	I-Premise
161	the	_	_	I-Premise
162	DepoCyt	_	_	I-Premise
163	arm	_	_	I-Premise
164	but	_	_	I-Premise
165	only	_	_	I-Premise
166	53	_	_	I-Premise
167	%	_	_	I-Premise
168	of	_	_	I-Premise
169	those	_	_	I-Premise
170	on	_	_	I-Premise
171	the	_	_	I-Premise
172	ara-C	_	_	I-Premise
173	arm	_	_	I-Premise
174	were	_	_	I-Premise
175	able	_	_	I-Premise
176	to	_	_	I-Premise
177	complete	_	_	I-Premise
178	the	_	_	I-Premise
179	planned	_	_	I-Premise
180	1-month	_	_	I-Premise
181	induction	_	_	I-Premise
182	therapy	_	_	I-Premise
183	regimen	_	_	I-Premise
184	.	_	_	I-Premise

185	Time	_	_	B-Premise
186	to	_	_	I-Premise
187	neurologic	_	_	I-Premise
188	progression	_	_	I-Premise
189	and	_	_	I-Premise
190	survival	_	_	I-Premise
191	trend	_	_	I-Premise
192	in	_	_	I-Premise
193	favor	_	_	I-Premise
194	of	_	_	I-Premise
195	DepoCyt	_	_	I-Premise
196	(	_	_	I-Premise
197	median	_	_	I-Premise
198	,	_	_	I-Premise
199	78.5	_	_	I-Premise
200	v	_	_	I-Premise
201	42	_	_	I-Premise
202	days	_	_	I-Premise
203	and	_	_	I-Premise
204	99.5	_	_	I-Premise
205	v	_	_	I-Premise
206	63	_	_	I-Premise
207	days	_	_	I-Premise
208	,	_	_	I-Premise
209	respectively	_	_	I-Premise
210	;	_	_	I-Premise
211	P	_	_	I-Premise
212	>	_	_	I-Premise
213	.05	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	DepoCyt	_	_	B-Premise
217	treatment	_	_	I-Premise
218	was	_	_	I-Premise
219	associated	_	_	I-Premise
220	with	_	_	I-Premise
221	an	_	_	I-Premise
222	improved	_	_	I-Premise
223	mean	_	_	I-Premise
224	change	_	_	I-Premise
225	in	_	_	I-Premise
226	Karnofsky	_	_	I-Premise
227	performance	_	_	I-Premise
228	score	_	_	I-Premise
229	at	_	_	I-Premise
230	the	_	_	I-Premise
231	end	_	_	I-Premise
232	of	_	_	I-Premise
233	induction	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	=.041	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	The	_	_	B-Premise
240	major	_	_	I-Premise
241	adverse	_	_	I-Premise
242	events	_	_	I-Premise
243	on	_	_	I-Premise
244	both	_	_	I-Premise
245	arms	_	_	I-Premise
246	were	_	_	I-Premise
247	headache	_	_	I-Premise
248	and	_	_	I-Premise
249	arachnoiditis	_	_	I-Premise
250	,	_	_	I-Premise
251	which	_	_	I-Premise
252	were	_	_	I-Premise
253	often	_	_	I-Premise
254	caused	_	_	I-Premise
255	by	_	_	I-Premise
256	the	_	_	I-Premise
257	underlying	_	_	I-Premise
258	disease	_	_	I-Premise
259	.	_	_	I-Premise

260	DepoCyt	_	_	B-Claim
261	injected	_	_	I-Claim
262	once	_	_	I-Claim
263	every	_	_	I-Claim
264	2	_	_	I-Claim
265	weeks	_	_	I-Claim
266	produced	_	_	I-Claim
267	a	_	_	I-Claim
268	high	_	_	I-Claim
269	response	_	_	I-Claim
270	rate	_	_	I-Claim
271	and	_	_	I-Claim
272	a	_	_	I-Claim
273	better	_	_	I-Claim
274	quality	_	_	I-Claim
275	of	_	_	I-Claim
276	life	_	_	I-Claim
277	as	_	_	I-Claim
278	measured	_	_	I-Claim
279	by	_	_	I-Claim
280	Karnofsky	_	_	I-Claim
281	score	_	_	I-Claim
282	relative	_	_	I-Claim
283	to	_	_	I-Claim
284	that	_	_	I-Claim
285	produced	_	_	I-Claim
286	by	_	_	I-Claim
287	free	_	_	I-Claim
288	ara-C	_	_	I-Claim
289	injected	_	_	I-Claim
290	twice	_	_	I-Claim
291	a	_	_	I-Claim
292	week	_	_	I-Claim
293	.	_	_	I-Claim


0	For	_	_	B-Claim
1	several	_	_	I-Claim
2	decades	_	_	I-Claim
3	,	_	_	I-Claim
4	both	_	_	I-Claim
5	preoperative	_	_	I-Claim
6	intra-arterial	_	_	I-Claim
7	chemotherapy	_	_	I-Claim
8	and	_	_	I-Claim
9	preoperative	_	_	I-Claim
10	irradiation	_	_	I-Claim
11	have	_	_	I-Claim
12	been	_	_	I-Claim
13	accepted	_	_	I-Claim
14	treatments	_	_	I-Claim
15	for	_	_	I-Claim
16	patients	_	_	I-Claim
17	with	_	_	I-Claim
18	tumors	_	_	I-Claim
19	of	_	_	I-Claim
20	the	_	_	I-Claim
21	head	_	_	I-Claim
22	and	_	_	I-Claim
23	neck	_	_	I-Claim
24	.	_	_	I-Claim

25	Unfortunately	_	_	O
26	,	_	_	O
27	arguments	_	_	O
28	have	_	_	O
29	often	_	_	O
30	been	_	_	O
31	put	_	_	O
32	forward	_	_	O
33	in	_	_	O
34	favor	_	_	O
35	of	_	_	O
36	one	_	_	O
37	or	_	_	O
38	other	_	_	O
39	of	_	_	O
40	the	_	_	O
41	two	_	_	O
42	methods	_	_	O
43	,	_	_	O
44	but	_	_	O
45	without	_	_	O
46	the	_	_	O
47	performance	_	_	O
48	of	_	_	O
49	an	_	_	O
50	objective	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	investigation	_	_	O
54	.	_	_	O

55	To	_	_	O
56	resolve	_	_	O
57	this	_	_	O
58	situation	_	_	O
59	,	_	_	O
60	the	_	_	O
61	authors	_	_	O
62	have	_	_	O
63	carried	_	_	O
64	out	_	_	O
65	a	_	_	O
66	multicenter	_	_	O
67	,	_	_	O
68	randomized	_	_	O
69	prospective	_	_	O
70	study	_	_	O
71	of	_	_	O
72	selected	_	_	O
73	patients	_	_	O
74	with	_	_	O
75	a	_	_	O
76	view	_	_	O
77	to	_	_	O
78	deciding	_	_	O
79	which	_	_	O
80	method	_	_	O
81	affords	_	_	O
82	better	_	_	O
83	results	_	_	O
84	in	_	_	O
85	complex	_	_	O
86	tumor	_	_	O
87	therapy	_	_	O
88	from	_	_	O
89	the	_	_	O
90	aspects	_	_	O
91	of	_	_	O
92	survival	_	_	O
93	and	_	_	O
94	postoperative	_	_	O
95	quality	_	_	O
96	of	_	_	O
97	life	_	_	O
98	.	_	_	O

99	One	_	_	O
100	hundred	_	_	O
101	thirty-one	_	_	O
102	patients	_	_	O
103	with	_	_	O
104	operable	_	_	O
105	sublingual	_	_	O
106	or	_	_	O
107	lingual	_	_	O
108	squamous	_	_	O
109	cell	_	_	O
110	carcinoma	_	_	O
111	in	_	_	O
112	stages	_	_	O
113	T2NXM0	_	_	O
114	to	_	_	O
115	T4MXM0	_	_	O
116	were	_	_	O
117	randomized	_	_	O
118	into	_	_	O
119	2	_	_	O
120	groups	_	_	O
121	:	_	_	O
122	1	_	_	O
123	group	_	_	O
124	participated	_	_	O
125	in	_	_	O
126	preoperative	_	_	O
127	chemotherapy	_	_	O
128	with	_	_	O
129	cisplatin	_	_	O
130	and	_	_	O
131	epirubicin	_	_	O
132	(	_	_	O
133	total	_	_	O
134	doses	_	_	O
135	:	_	_	O
136	200	_	_	O
137	mg	_	_	O
138	cisplatin	_	_	O
139	,	_	_	O
140	120	_	_	O
141	mg	_	_	O
142	epirubicin	_	_	O
143	)	_	_	O
144	via	_	_	O
145	the	_	_	O
146	external	_	_	O
147	carotid	_	_	O
148	artery	_	_	O
149	,	_	_	O
150	whereas	_	_	O
151	the	_	_	O
152	other	_	_	O
153	group	_	_	O
154	received	_	_	O
155	preoperative	_	_	O
156	radiation	_	_	O
157	therapy	_	_	O
158	(	_	_	O
159	46	_	_	O
160	grays	_	_	O
161	)	_	_	O
162	.	_	_	O

163	Following	_	_	O
164	subsequent	_	_	O
165	radical	_	_	O
166	surgery	_	_	O
167	,	_	_	O
168	the	_	_	O
169	patients	_	_	O
170	received	_	_	O
171	regular	_	_	O
172	follow-up	_	_	O
173	for	_	_	O
174	5	_	_	O
175	years	_	_	O
176	.	_	_	O

177	By	_	_	O
178	the	_	_	O
179	end	_	_	O
180	of	_	_	O
181	the	_	_	O
182	5	_	_	O
183	years	_	_	O
184	,	_	_	O
185	95	_	_	O
186	of	_	_	O
187	the	_	_	O
188	131	_	_	O
189	patients	_	_	O
190	had	_	_	O
191	conformed	_	_	O
192	to	_	_	O
193	the	_	_	O
194	protocol	_	_	O
195	.	_	_	O

196	Of	_	_	O
197	those	_	_	O
198	95	_	_	O
199	,	_	_	O
200	47	_	_	O
201	had	_	_	O
202	received	_	_	O
203	preoperative	_	_	O
204	chemotherapy	_	_	O
205	and	_	_	O
206	48	_	_	O
207	preoperative	_	_	O
208	irradiation	_	_	O
209	.	_	_	O

210	After	_	_	B-Premise
211	5	_	_	I-Premise
212	years	_	_	I-Premise
213	,	_	_	I-Premise
214	18	_	_	I-Premise
215	of	_	_	I-Premise
216	the	_	_	I-Premise
217	47	_	_	I-Premise
218	patients	_	_	I-Premise
219	who	_	_	I-Premise
220	received	_	_	I-Premise
221	chemotherapy	_	_	I-Premise
222	and	_	_	I-Premise
223	15	_	_	I-Premise
224	of	_	_	I-Premise
225	the	_	_	I-Premise
226	48	_	_	I-Premise
227	patients	_	_	I-Premise
228	who	_	_	I-Premise
229	received	_	_	I-Premise
230	irradiation	_	_	I-Premise
231	were	_	_	I-Premise
232	still	_	_	I-Premise
233	alive	_	_	I-Premise
234	and	_	_	I-Premise
235	tumor	_	_	I-Premise
236	free	_	_	I-Premise
237	.	_	_	I-Premise

238	A	_	_	B-Premise
239	few	_	_	I-Premise
240	more	_	_	I-Premise
241	patients	_	_	I-Premise
242	had	_	_	I-Premise
243	died	_	_	I-Premise
244	of	_	_	I-Premise
245	recurrence	_	_	I-Premise
246	or	_	_	I-Premise
247	regional	_	_	I-Premise
248	metastasis	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	chemotherapy	_	_	I-Premise
252	group	_	_	I-Premise
253	(	_	_	I-Premise
254	23	_	_	I-Premise
255	patients	_	_	I-Premise
256	)	_	_	I-Premise
257	than	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	irradiation	_	_	I-Premise
261	group	_	_	I-Premise
262	(	_	_	I-Premise
263	20	_	_	I-Premise
264	patients	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Occurrence	_	_	B-Premise
268	of	_	_	I-Premise
269	a	_	_	I-Premise
270	second	_	_	I-Premise
271	carcinoma	_	_	I-Premise
272	was	_	_	I-Premise
273	3	_	_	I-Premise
274	times	_	_	I-Premise
275	as	_	_	I-Premise
276	frequent	_	_	I-Premise
277	in	_	_	I-Premise
278	the	_	_	I-Premise
279	irradiation	_	_	I-Premise
280	group	_	_	I-Premise
281	(	_	_	I-Premise
282	9	_	_	I-Premise
283	patients	_	_	I-Premise
284	)	_	_	I-Premise
285	as	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	chemotherapy	_	_	I-Premise
289	group	_	_	I-Premise
290	(	_	_	I-Premise
291	3	_	_	I-Premise
292	patients	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Overall	_	_	O
296	,	_	_	O
297	the	_	_	B-Claim
298	survival	_	_	I-Claim
299	rates	_	_	I-Claim
300	were	_	_	I-Claim
301	by-and-large	_	_	I-Claim
302	the	_	_	I-Claim
303	same	_	_	I-Claim
304	for	_	_	I-Claim
305	the	_	_	I-Claim
306	two	_	_	I-Claim
307	groups	_	_	I-Claim
308	.	_	_	I-Claim

309	Regarding	_	_	B-Claim
310	postoperative	_	_	I-Claim
311	quality	_	_	I-Claim
312	of	_	_	I-Claim
313	life	_	_	I-Claim
314	,	_	_	I-Claim
315	the	_	_	I-Claim
316	chemotherapy	_	_	I-Claim
317	group	_	_	I-Claim
318	presented	_	_	I-Claim
319	a	_	_	I-Claim
320	more	_	_	I-Claim
321	favorable	_	_	I-Claim
322	picture	_	_	I-Claim
323	.	_	_	I-Claim

324	The	_	_	B-Claim
325	long	_	_	I-Claim
326	term	_	_	I-Claim
327	survival	_	_	I-Claim
328	results	_	_	I-Claim
329	subsequent	_	_	I-Claim
330	to	_	_	I-Claim
331	preoperative	_	_	I-Claim
332	intra-arterial	_	_	I-Claim
333	chemotherapy	_	_	I-Claim
334	or	_	_	I-Claim
335	preoperative	_	_	I-Claim
336	radiotherapy	_	_	I-Claim
337	were	_	_	I-Claim
338	practically	_	_	I-Claim
339	the	_	_	I-Claim
340	same	_	_	I-Claim
341	.	_	_	I-Claim

342	Regarding	_	_	B-Claim
343	postoperative	_	_	I-Claim
344	quality	_	_	I-Claim
345	of	_	_	I-Claim
346	life	_	_	I-Claim
347	,	_	_	I-Claim
348	patients	_	_	I-Claim
349	who	_	_	I-Claim
350	underwent	_	_	I-Claim
351	intra-arterial	_	_	I-Claim
352	chemotherapy	_	_	I-Claim
353	appeared	_	_	I-Claim
354	to	_	_	I-Claim
355	be	_	_	I-Claim
356	in	_	_	I-Claim
357	a	_	_	I-Claim
358	slightly	_	_	I-Claim
359	more	_	_	I-Claim
360	favorable	_	_	I-Claim
361	situation	_	_	I-Claim
362	.	_	_	I-Claim

363	The	_	_	O
364	authors	_	_	O
365	consider	_	_	O
366	it	_	_	O
367	important	_	_	O
368	to	_	_	O
369	stress	_	_	O
370	these	_	_	O
371	findings	_	_	O
372	,	_	_	O
373	as	_	_	O
374	they	_	_	O
375	are	_	_	O
376	not	_	_	O
377	aware	_	_	O
378	of	_	_	O
379	a	_	_	O
380	similar	_	_	O
381	randomized	_	_	O
382	study	_	_	O
383	of	_	_	O
384	patients	_	_	O
385	with	_	_	O
386	tumors	_	_	O
387	of	_	_	O
388	the	_	_	O
389	oral	_	_	O
390	cavity	_	_	O
391	.	_	_	O


0	A	_	_	B-Claim
1	combination	_	_	I-Claim
2	of	_	_	I-Claim
3	mitoxantrone	_	_	I-Claim
4	plus	_	_	I-Claim
5	prednisone	_	_	I-Claim
6	is	_	_	I-Claim
7	preferable	_	_	I-Claim
8	to	_	_	I-Claim
9	prednisone	_	_	I-Claim
10	alone	_	_	I-Claim
11	for	_	_	I-Claim
12	reduction	_	_	I-Claim
13	of	_	_	I-Claim
14	pain	_	_	I-Claim
15	in	_	_	I-Claim
16	men	_	_	I-Claim
17	with	_	_	I-Claim
18	metastatic	_	_	I-Claim
19	,	_	_	I-Claim
20	hormone-resistant	_	_	I-Claim
21	,	_	_	I-Claim
22	prostate	_	_	I-Claim
23	cancer	_	_	I-Claim
24	.	_	_	I-Claim

25	The	_	_	O
26	purpose	_	_	O
27	of	_	_	O
28	this	_	_	O
29	study	_	_	O
30	was	_	_	O
31	to	_	_	O
32	assess	_	_	O
33	the	_	_	O
34	effects	_	_	O
35	of	_	_	O
36	these	_	_	O
37	treatments	_	_	O
38	on	_	_	O
39	health-related	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	HQL	_	_	O
45	)	_	_	O
46	.	_	_	O

47	Men	_	_	O
48	with	_	_	O
49	metastatic	_	_	O
50	prostate	_	_	O
51	cancer	_	_	O
52	(	_	_	O
53	n	_	_	O
54	=	_	_	O
55	161	_	_	O
56	)	_	_	O
57	were	_	_	O
58	randomized	_	_	O
59	to	_	_	O
60	receive	_	_	O
61	either	_	_	O
62	daily	_	_	O
63	prednisone	_	_	O
64	alone	_	_	O
65	or	_	_	O
66	mitoxantrone	_	_	O
67	(	_	_	O
68	every	_	_	O
69	3	_	_	O
70	weeks	_	_	O
71	)	_	_	O
72	plus	_	_	O
73	prednisone	_	_	O
74	.	_	_	O

75	Those	_	_	O
76	who	_	_	O
77	received	_	_	O
78	prednisone	_	_	O
79	alone	_	_	O
80	could	_	_	O
81	have	_	_	O
82	mitoxantrone	_	_	O
83	added	_	_	O
84	after	_	_	O
85	6	_	_	O
86	weeks	_	_	O
87	if	_	_	O
88	there	_	_	O
89	was	_	_	O
90	no	_	_	O
91	improvement	_	_	O
92	in	_	_	O
93	pain	_	_	O
94	.	_	_	O

95	HQL	_	_	O
96	was	_	_	O
97	assessed	_	_	O
98	before	_	_	O
99	treatment	_	_	O
100	initiation	_	_	O
101	and	_	_	O
102	then	_	_	O
103	every	_	_	O
104	3	_	_	O
105	weeks	_	_	O
106	using	_	_	O
107	the	_	_	O
108	European	_	_	O
109	Organization	_	_	O
110	for	_	_	O
111	Research	_	_	O
112	and	_	_	O
113	Treatment	_	_	O
114	of	_	_	O
115	Cancer	_	_	O
116	Quality-of-Life	_	_	O
117	Questionnaire	_	_	O
118	C30	_	_	O
119	(	_	_	O
120	EORTC	_	_	O
121	QLQ-C30	_	_	O
122	)	_	_	O
123	and	_	_	O
124	the	_	_	O
125	Quality	_	_	O
126	of	_	_	O
127	Life	_	_	O
128	Module-Prostate	_	_	O
129	14	_	_	O
130	(	_	_	O
131	QOLM-P14	_	_	O
132	)	_	_	O
133	,	_	_	O
134	a	_	_	O
135	trial-specific	_	_	O
136	module	_	_	O
137	developed	_	_	O
138	for	_	_	O
139	this	_	_	O
140	study	_	_	O
141	.	_	_	O

142	An	_	_	O
143	intent-to-treat	_	_	O
144	analysis	_	_	O
145	was	_	_	O
146	used	_	_	O
147	to	_	_	O
148	determine	_	_	O
149	the	_	_	O
150	mean	_	_	O
151	duration	_	_	O
152	of	_	_	O
153	HQL	_	_	O
154	improvement	_	_	O
155	and	_	_	O
156	differences	_	_	O
157	in	_	_	O
158	improvement	_	_	O
159	duration	_	_	O
160	between	_	_	O
161	groups	_	_	O
162	of	_	_	O
163	patients	_	_	O
164	.	_	_	O

165	At	_	_	B-Premise
166	6	_	_	I-Premise
167	weeks	_	_	I-Premise
168	,	_	_	I-Premise
169	both	_	_	I-Premise
170	groups	_	_	I-Premise
171	showed	_	_	I-Premise
172	improvement	_	_	I-Premise
173	in	_	_	I-Premise
174	several	_	_	I-Premise
175	HQL	_	_	I-Premise
176	domains	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	O
179	only	_	_	B-Premise
180	physical	_	_	I-Premise
181	functioning	_	_	I-Premise
182	and	_	_	I-Premise
183	pain	_	_	I-Premise
184	were	_	_	I-Premise
185	better	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	mitoxantrone-plus-prednisone	_	_	I-Premise
189	group	_	_	I-Premise
190	than	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	prednisone-alone	_	_	I-Premise
194	group	_	_	I-Premise
195	.	_	_	I-Premise

196	After	_	_	B-Premise
197	6	_	_	I-Premise
198	weeks	_	_	I-Premise
199	,	_	_	I-Premise
200	patients	_	_	I-Premise
201	taking	_	_	I-Premise
202	prednisone	_	_	I-Premise
203	showed	_	_	I-Premise
204	no	_	_	I-Premise
205	improvement	_	_	I-Premise
206	in	_	_	I-Premise
207	HQL	_	_	I-Premise
208	scores	_	_	I-Premise
209	,	_	_	I-Premise
210	whereas	_	_	I-Premise
211	those	_	_	I-Premise
212	taking	_	_	I-Premise
213	mitoxantrone	_	_	I-Premise
214	plus	_	_	I-Premise
215	prednisone	_	_	I-Premise
216	showed	_	_	I-Premise
217	significant	_	_	I-Premise
218	improvements	_	_	I-Premise
219	in	_	_	I-Premise
220	global	_	_	I-Premise
221	quality	_	_	I-Premise
222	of	_	_	I-Premise
223	life	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	=.009	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	four	_	_	I-Premise
230	functioning	_	_	I-Premise
231	domains	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	nine	_	_	I-Premise
235	symptoms	_	_	I-Premise
236	(	_	_	I-Premise
237	.001	_	_	I-Premise
238	<	_	_	I-Premise
239	P	_	_	I-Premise
240	<	_	_	I-Premise
241	.	_	_	I-Premise

242	01	_	_	I-Premise
243	)	_	_	I-Premise
244	,	_	_	I-Premise
245	and	_	_	O
246	the	_	_	B-Premise
247	improvement	_	_	I-Premise
248	(	_	_	I-Premise
249	>	_	_	I-Premise
250	10	_	_	I-Premise
251	units	_	_	I-Premise
252	on	_	_	I-Premise
253	a	_	_	I-Premise
254	scale	_	_	I-Premise
255	of	_	_	I-Premise
256	0	_	_	I-Premise
257	to100	_	_	I-Premise
258	)	_	_	I-Premise
259	lasted	_	_	I-Premise
260	longer	_	_	I-Premise
261	than	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	prednisone-alone	_	_	I-Premise
265	group	_	_	I-Premise
266	(	_	_	I-Premise
267	.004	_	_	I-Premise
268	<	_	_	I-Premise
269	P	_	_	I-Premise
270	<	_	_	I-Premise
271	.05	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	B-Premise
275	addition	_	_	I-Premise
276	of	_	_	I-Premise
277	mitoxantrone	_	_	I-Premise
278	to	_	_	I-Premise
279	prednisone	_	_	I-Premise
280	after	_	_	I-Premise
281	failure	_	_	I-Premise
282	of	_	_	I-Premise
283	prednisone	_	_	I-Premise
284	alone	_	_	I-Premise
285	was	_	_	I-Premise
286	associated	_	_	I-Premise
287	with	_	_	I-Premise
288	improvements	_	_	I-Premise
289	in	_	_	I-Premise
290	pain	_	_	I-Premise
291	,	_	_	I-Premise
292	pain	_	_	I-Premise
293	impact	_	_	I-Premise
294	,	_	_	I-Premise
295	pain	_	_	I-Premise
296	relief	_	_	I-Premise
297	,	_	_	I-Premise
298	insomnia	_	_	I-Premise
299	,	_	_	I-Premise
300	and	_	_	I-Premise
301	global	_	_	I-Premise
302	quality	_	_	I-Premise
303	of	_	_	I-Premise
304	life	_	_	I-Premise
305	(	_	_	I-Premise
306	.001	_	_	I-Premise
307	<	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	.003	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Treatment	_	_	B-Claim
314	with	_	_	I-Claim
315	mitoxantrone	_	_	I-Claim
316	plus	_	_	I-Claim
317	prednisone	_	_	I-Claim
318	was	_	_	I-Claim
319	associated	_	_	I-Claim
320	with	_	_	I-Claim
321	greater	_	_	I-Claim
322	and	_	_	I-Claim
323	longer-lasting	_	_	I-Claim
324	improvement	_	_	I-Claim
325	in	_	_	I-Claim
326	several	_	_	I-Claim
327	HQL	_	_	I-Claim
328	domains	_	_	I-Claim
329	and	_	_	I-Claim
330	symptoms	_	_	I-Claim
331	than	_	_	I-Claim
332	treatment	_	_	I-Claim
333	with	_	_	I-Claim
334	prednisone	_	_	I-Claim
335	alone	_	_	I-Claim
336	.	_	_	I-Claim


0	In	_	_	B-Claim
1	endocrine	_	_	I-Claim
2	therapy	_	_	I-Claim
3	trials	_	_	I-Claim
4	in	_	_	I-Claim
5	advanced	_	_	I-Claim
6	breast	_	_	I-Claim
7	cancer	_	_	I-Claim
8	,	_	_	I-Claim
9	patients	_	_	I-Claim
10	with	_	_	I-Claim
11	response	_	_	I-Claim
12	(	_	_	I-Claim
13	complete	_	_	I-Claim
14	response/partial	_	_	I-Claim
15	response	_	_	I-Claim
16	[	_	_	I-Claim
17	CR/PR	_	_	I-Claim
18	]	_	_	I-Claim
19	)	_	_	I-Claim
20	and	_	_	I-Claim
21	patients	_	_	I-Claim
22	with	_	_	I-Claim
23	stable	_	_	I-Claim
24	disease	_	_	I-Claim
25	for	_	_	I-Claim
26	at	_	_	I-Claim
27	least	_	_	I-Claim
28	6	_	_	I-Claim
29	months	_	_	I-Claim
30	(	_	_	I-Claim
31	SD	_	_	I-Claim
32	(	_	_	I-Claim
33	6m	_	_	I-Claim
34	)	_	_	I-Claim
35	)	_	_	I-Claim
36	have	_	_	I-Claim
37	shown	_	_	I-Claim
38	similar	_	_	I-Claim
39	survival	_	_	I-Claim
40	and	_	_	I-Claim
41	therefore	_	_	I-Claim
42	are	_	_	I-Claim
43	often	_	_	I-Claim
44	defined	_	_	I-Claim
45	as	_	_	I-Claim
46	a	_	_	I-Claim
47	population	_	_	I-Claim
48	with	_	_	I-Claim
49	clinical	_	_	I-Claim
50	benefit	_	_	I-Claim
51	(	_	_	I-Claim
52	patients	_	_	I-Claim
53	with	_	_	I-Claim
54	CR/PR	_	_	I-Claim
55	or	_	_	I-Claim
56	SD	_	_	I-Claim
57	(	_	_	I-Claim
58	6m	_	_	I-Claim
59	)	_	_	I-Claim
60	)	_	_	I-Claim
61	.	_	_	I-Claim

62	We	_	_	O
63	evaluated	_	_	O
64	the	_	_	O
65	impact	_	_	O
66	of	_	_	O
67	response	_	_	O
68	and/or	_	_	O
69	clinical	_	_	O
70	benefit	_	_	O
71	on	_	_	O
72	quality	_	_	O
73	of	_	_	O
74	life	_	_	O
75	(	_	_	O
76	QL	_	_	O
77	)	_	_	O
78	in	_	_	O
79	postmenopausal	_	_	O
80	patients	_	_	O
81	under	_	_	O
82	second-line	_	_	O
83	endocrine	_	_	O
84	treatment	_	_	O
85	after	_	_	O
86	failure	_	_	O
87	of	_	_	O
88	tamoxifen	_	_	O
89	.	_	_	O

90	One	_	_	O
91	hundred	_	_	O
92	twenty-eight	_	_	O
93	of	_	_	O
94	177	_	_	O
95	eligible	_	_	O
96	patients	_	_	O
97	of	_	_	O
98	a	_	_	O
99	randomized	_	_	O
100	trial	_	_	O
101	(	_	_	O
102	Swiss	_	_	O
103	Group	_	_	O
104	for	_	_	O
105	Clinical	_	_	O
106	Cancer	_	_	O
107	Research	_	_	O
108	20/90	_	_	O
109	)	_	_	O
110	receiving	_	_	O
111	either	_	_	O
112	formestane	_	_	O
113	(	_	_	O
114	250	_	_	O
115	mg	_	_	O
116	intramuscularly	_	_	O
117	biweekly	_	_	O
118	)	_	_	O
119	or	_	_	O
120	megestrol	_	_	O
121	acetate	_	_	O
122	(	_	_	O
123	160	_	_	O
124	mg	_	_	O
125	orally	_	_	O
126	daily	_	_	O
127	)	_	_	O
128	were	_	_	O
129	analyzed	_	_	O
130	.	_	_	O

131	The	_	_	O
132	baseline	_	_	O
133	characteristics	_	_	O
134	(	_	_	O
135	with	_	_	O
136	the	_	_	O
137	exception	_	_	O
138	of	_	_	O
139	site	_	_	O
140	of	_	_	O
141	metastases	_	_	O
142	)	_	_	O
143	were	_	_	O
144	balanced	_	_	O
145	among	_	_	O
146	patients	_	_	O
147	with	_	_	O
148	CR/PR	_	_	O
149	,	_	_	O
150	SD	_	_	O
151	(	_	_	O
152	6m	_	_	O
153	)	_	_	O
154	,	_	_	O
155	and	_	_	O
156	progressive	_	_	O
157	disease	_	_	O
158	(	_	_	O
159	PD	_	_	O
160	)	_	_	O
161	.	_	_	O

162	Patients	_	_	O
163	completed	_	_	O
164	QL	_	_	O
165	indicators	_	_	O
166	at	_	_	O
167	baseline	_	_	O
168	and	_	_	O
169	at	_	_	O
170	1	_	_	O
171	,	_	_	O
172	3	_	_	O
173	,	_	_	O
174	5	_	_	O
175	,	_	_	O
176	7	_	_	O
177	,	_	_	O
178	9	_	_	O
179	,	_	_	O
180	and	_	_	O
181	11	_	_	O
182	months	_	_	O
183	.	_	_	O

184	Responders	_	_	O
185	were	_	_	O
186	separately	_	_	O
187	compared	_	_	O
188	with	_	_	O
189	nonresponders	_	_	O
190	(	_	_	O
191	patients	_	_	O
192	with	_	_	O
193	SD	_	_	O
194	(	_	_	O
195	6m	_	_	O
196	)	_	_	O
197	or	_	_	O
198	PD	_	_	O
199	)	_	_	O
200	and	_	_	O
201	with	_	_	O
202	patients	_	_	O
203	with	_	_	O
204	SD	_	_	O
205	(	_	_	O
206	6m	_	_	O
207	)	_	_	O
208	,	_	_	O
209	and	_	_	O
210	patients	_	_	O
211	with	_	_	O
212	clinical	_	_	O
213	benefit	_	_	O
214	were	_	_	O
215	compared	_	_	O
216	with	_	_	O
217	patients	_	_	O
218	with	_	_	O
219	PD	_	_	O
220	by	_	_	O
221	analysis	_	_	O
222	of	_	_	O
223	covariance	_	_	O
224	with	_	_	O
225	adjustment	_	_	O
226	for	_	_	O
227	baseline	_	_	O
228	scores	_	_	O
229	.	_	_	O

230	Overall	_	_	O
231	,	_	_	O
232	88	_	_	O
233	%	_	_	O
234	(	_	_	O
235	557	_	_	O
236	of	_	_	O
237	634	_	_	O
238	)	_	_	O
239	of	_	_	O
240	expected	_	_	O
241	QL	_	_	O
242	forms	_	_	O
243	were	_	_	O
244	received	_	_	O
245	.	_	_	O

246	In	_	_	O
247	the	_	_	O
248	comparison	_	_	O
249	of	_	_	O
250	responders	_	_	O
251	versus	_	_	O
252	patients	_	_	O
253	with	_	_	O
254	both	_	_	O
255	SD	_	_	O
256	(	_	_	O
257	6m	_	_	O
258	)	_	_	O
259	and	_	_	O
260	PD	_	_	O
261	,	_	_	O
262	responders	_	_	B-Premise
263	indicated	_	_	I-Premise
264	better	_	_	I-Premise
265	physical	_	_	I-Premise
266	well-being	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	.	_	_	I-Premise

271	004	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	mood	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	=.02	_	_	I-Premise
278	)	_	_	I-Premise
279	at	_	_	I-Premise
280	month	_	_	I-Premise
281	3	_	_	I-Premise
282	.	_	_	I-Premise

283	Compared	_	_	B-Premise
284	only	_	_	I-Premise
285	with	_	_	I-Premise
286	patients	_	_	I-Premise
287	with	_	_	I-Premise
288	SD	_	_	I-Premise
289	(	_	_	I-Premise
290	6m	_	_	I-Premise
291	)	_	_	I-Premise
292	,	_	_	I-Premise
293	responders	_	_	I-Premise
294	showed	_	_	I-Premise
295	no	_	_	I-Premise
296	significant	_	_	I-Premise
297	difference	_	_	I-Premise
298	in	_	_	I-Premise
299	baseline	_	_	I-Premise
300	QL	_	_	I-Premise
301	and	_	_	I-Premise
302	time	_	_	I-Premise
303	to	_	_	I-Premise
304	treatment	_	_	I-Premise
305	failure	_	_	I-Premise
306	(	_	_	I-Premise
307	328.5	_	_	I-Premise
308	v	_	_	I-Premise
309	340	_	_	I-Premise
310	days	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	While	_	_	B-Premise
314	under	_	_	I-Premise
315	treatment	_	_	I-Premise
316	,	_	_	I-Premise
317	responders	_	_	I-Premise
318	reported	_	_	I-Premise
319	significantly	_	_	I-Premise
320	better	_	_	I-Premise
321	physical	_	_	I-Premise
322	well-being	_	_	I-Premise
323	(	_	_	I-Premise
324	months	_	_	I-Premise
325	3	_	_	I-Premise
326	to	_	_	I-Premise
327	11	_	_	I-Premise
328	)	_	_	I-Premise
329	,	_	_	I-Premise
330	mood	_	_	I-Premise
331	(	_	_	I-Premise
332	months	_	_	I-Premise
333	5	_	_	I-Premise
334	to	_	_	I-Premise
335	11	_	_	I-Premise
336	)	_	_	I-Premise
337	,	_	_	I-Premise
338	coping	_	_	I-Premise
339	(	_	_	I-Premise
340	months	_	_	I-Premise
341	5	_	_	I-Premise
342	to	_	_	I-Premise
343	9	_	_	I-Premise
344	)	_	_	I-Premise
345	,	_	_	I-Premise
346	and	_	_	I-Premise
347	appetite	_	_	I-Premise
348	(	_	_	I-Premise
349	months	_	_	I-Premise
350	7	_	_	I-Premise
351	to	_	_	I-Premise
352	11	_	_	I-Premise
353	)	_	_	I-Premise
354	and	_	_	I-Premise
355	less	_	_	I-Premise
356	dizziness	_	_	I-Premise
357	(	_	_	I-Premise
358	month	_	_	I-Premise
359	9	_	_	I-Premise
360	)	_	_	I-Premise
361	than	_	_	I-Premise
362	patients	_	_	I-Premise
363	with	_	_	I-Premise
364	SD	_	_	I-Premise
365	(	_	_	I-Premise
366	6m	_	_	I-Premise
367	)	_	_	I-Premise
368	.	_	_	I-Premise

369	The	_	_	B-Premise
370	changes	_	_	I-Premise
371	between	_	_	I-Premise
372	baseline	_	_	I-Premise
373	and	_	_	I-Premise
374	months	_	_	I-Premise
375	5	_	_	I-Premise
376	and	_	_	I-Premise
377	7	_	_	I-Premise
378	,	_	_	I-Premise
379	respectively	_	_	I-Premise
380	,	_	_	I-Premise
381	indicated	_	_	I-Premise
382	improvement	_	_	I-Premise
383	in	_	_	I-Premise
384	responders	_	_	I-Premise
385	but	_	_	I-Premise
386	heterogeneous	_	_	I-Premise
387	patterns	_	_	I-Premise
388	in	_	_	I-Premise
389	patients	_	_	I-Premise
390	with	_	_	I-Premise
391	SD	_	_	I-Premise
392	(	_	_	I-Premise
393	6m	_	_	I-Premise
394	)	_	_	I-Premise
395	.	_	_	I-Premise

396	Although	_	_	B-Premise
397	the	_	_	I-Premise
398	CR/PR	_	_	I-Premise
399	and	_	_	I-Premise
400	SD	_	_	I-Premise
401	(	_	_	I-Premise
402	6m	_	_	I-Premise
403	)	_	_	I-Premise
404	groups	_	_	I-Premise
405	had	_	_	I-Premise
406	similar	_	_	I-Premise
407	times	_	_	I-Premise
408	to	_	_	I-Premise
409	treatment	_	_	I-Premise
410	failure	_	_	I-Premise
411	,	_	_	I-Premise
412	patients	_	_	B-Claim
413	with	_	_	I-Claim
414	CR/PR	_	_	I-Claim
415	reported	_	_	I-Claim
416	better	_	_	I-Claim
417	QL	_	_	I-Claim
418	,	_	_	I-Claim
419	suggesting	_	_	I-Claim
420	more	_	_	I-Claim
421	beneficial	_	_	I-Claim
422	response	_	_	I-Claim
423	to	_	_	I-Claim
424	second-line	_	_	I-Claim
425	endocrine	_	_	I-Claim
426	treatment	_	_	I-Claim
427	.	_	_	I-Claim

428	Patients	_	_	O
429	'	_	_	O
430	subjective	_	_	O
431	perspective	_	_	O
432	should	_	_	O
433	be	_	_	O
434	taken	_	_	O
435	into	_	_	O
436	account	_	_	O
437	in	_	_	O
438	this	_	_	O
439	mainly	_	_	O
440	palliative	_	_	O
441	setting	_	_	O
442	.	_	_	O

443	Future	_	_	O
444	trials	_	_	O
445	should	_	_	O
446	be	_	_	O
447	designed	_	_	O
448	so	_	_	O
449	that	_	_	O
450	the	_	_	O
451	CR/PR	_	_	O
452	and	_	_	O
453	SD	_	_	O
454	(	_	_	O
455	6m	_	_	O
456	)	_	_	O
457	groups	_	_	O
458	are	_	_	O
459	investigated	_	_	O
460	separately	_	_	O
461	.	_	_	O


0	Extracellular	_	_	O
1	adenosine	_	_	O
2	5'-triphosphate	_	_	O
3	(	_	_	O
4	ATP	_	_	O
5	)	_	_	O
6	is	_	_	O
7	involved	_	_	O
8	in	_	_	O
9	the	_	_	O
10	regulation	_	_	O
11	of	_	_	O
12	a	_	_	O
13	variety	_	_	O
14	of	_	_	O
15	biologic	_	_	O
16	processes	_	_	O
17	,	_	_	O
18	including	_	_	O
19	neurotransmission	_	_	O
20	,	_	_	O
21	muscle	_	_	O
22	contraction	_	_	O
23	,	_	_	O
24	and	_	_	O
25	liver	_	_	O
26	glucose	_	_	O
27	metabolism	_	_	O
28	,	_	_	O
29	via	_	_	O
30	purinergic	_	_	O
31	receptors	_	_	O
32	.	_	_	O

33	In	_	_	B-Claim
34	nonrandomized	_	_	I-Claim
35	studies	_	_	I-Claim
36	involving	_	_	I-Claim
37	patients	_	_	I-Claim
38	with	_	_	I-Claim
39	different	_	_	I-Claim
40	tumor	_	_	I-Claim
41	types	_	_	I-Claim
42	including	_	_	I-Claim
43	non-small-cell	_	_	I-Claim
44	lung	_	_	I-Claim
45	cancer	_	_	I-Claim
46	(	_	_	I-Claim
47	NSCLC	_	_	I-Claim
48	)	_	_	I-Claim
49	,	_	_	I-Claim
50	ATP	_	_	I-Claim
51	infusion	_	_	I-Claim
52	appeared	_	_	I-Claim
53	to	_	_	I-Claim
54	inhibit	_	_	I-Claim
55	loss	_	_	I-Claim
56	of	_	_	I-Claim
57	weight	_	_	I-Claim
58	and	_	_	I-Claim
59	deterioration	_	_	I-Claim
60	of	_	_	I-Claim
61	quality	_	_	I-Claim
62	of	_	_	I-Claim
63	life	_	_	I-Claim
64	(	_	_	I-Claim
65	QOL	_	_	I-Claim
66	)	_	_	I-Claim
67	and	_	_	I-Claim
68	performance	_	_	I-Claim
69	status	_	_	I-Claim
70	.	_	_	I-Claim

71	We	_	_	O
72	conducted	_	_	O
73	a	_	_	O
74	randomized	_	_	O
75	clinical	_	_	O
76	trial	_	_	O
77	to	_	_	O
78	evaluate	_	_	O
79	the	_	_	O
80	effects	_	_	O
81	of	_	_	O
82	ATP	_	_	O
83	in	_	_	O
84	patients	_	_	O
85	with	_	_	O
86	advanced	_	_	O
87	NSCLC	_	_	O
88	(	_	_	O
89	stage	_	_	O
90	IIIB	_	_	O
91	or	_	_	O
92	IV	_	_	O
93	)	_	_	O
94	.	_	_	O

95	Fifty-eight	_	_	O
96	patients	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	either	_	_	O
103	10	_	_	O
104	intravenous	_	_	O
105	30-hour	_	_	O
106	ATP	_	_	O
107	infusions	_	_	O
108	,	_	_	O
109	with	_	_	O
110	the	_	_	O
111	infusions	_	_	O
112	given	_	_	O
113	at	_	_	O
114	2-	_	_	O
115	to	_	_	O
116	4-week	_	_	O
117	intervals	_	_	O
118	,	_	_	O
119	or	_	_	O
120	no	_	_	O
121	ATP	_	_	O
122	.	_	_	O

123	Outcome	_	_	O
124	parameters	_	_	O
125	were	_	_	O
126	assessed	_	_	O
127	every	_	_	O
128	4	_	_	O
129	weeks	_	_	O
130	until	_	_	O
131	28	_	_	O
132	weeks	_	_	O
133	.	_	_	O

134	Between-group	_	_	O
135	differences	_	_	O
136	were	_	_	O
137	tested	_	_	O
138	for	_	_	O
139	statistical	_	_	O
140	significance	_	_	O
141	by	_	_	O
142	use	_	_	O
143	of	_	_	O
144	repeated-measures	_	_	O
145	analysis	_	_	O
146	,	_	_	O
147	and	_	_	O
148	reported	_	_	O
149	P	_	_	O
150	values	_	_	O
151	are	_	_	O
152	two-sided	_	_	O
153	.	_	_	O

154	Twenty-eight	_	_	O
155	patients	_	_	O
156	were	_	_	O
157	allocated	_	_	O
158	to	_	_	O
159	receive	_	_	O
160	ATP	_	_	O
161	treatment	_	_	O
162	and	_	_	O
163	30	_	_	O
164	received	_	_	O
165	no	_	_	O
166	ATP	_	_	O
167	.	_	_	O

168	Mean	_	_	B-Premise
169	weight	_	_	I-Premise
170	changes	_	_	I-Premise
171	per	_	_	I-Premise
172	4-week	_	_	I-Premise
173	period	_	_	I-Premise
174	were	_	_	I-Premise
175	-1.0	_	_	I-Premise
176	kg	_	_	I-Premise
177	(	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	confidence	_	_	I-Premise
181	interval	_	_	I-Premise
182	[	_	_	I-Premise
183	CI	_	_	I-Premise
184	]	_	_	I-Premise
185	=	_	_	I-Premise
186	-1.5	_	_	I-Premise
187	to	_	_	I-Premise
188	-0.5	_	_	I-Premise
189	)	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	control	_	_	I-Premise
193	group	_	_	I-Premise
194	and	_	_	I-Premise
195	0.2	_	_	I-Premise
196	kg	_	_	I-Premise
197	(	_	_	I-Premise
198	95	_	_	I-Premise
199	%	_	_	I-Premise
200	CI	_	_	I-Premise
201	=	_	_	I-Premise
202	-0.2	_	_	I-Premise
203	to	_	_	I-Premise
204	+0.6	_	_	I-Premise
205	)	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	ATP	_	_	I-Premise
209	group	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=.002	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	Serum	_	_	B-Premise
216	albumin	_	_	I-Premise
217	concentration	_	_	I-Premise
218	declined	_	_	I-Premise
219	by	_	_	I-Premise
220	-1.2	_	_	I-Premise
221	g/L	_	_	I-Premise
222	(	_	_	I-Premise
223	95	_	_	I-Premise
224	%	_	_	I-Premise
225	CI=	_	_	I-Premise
226	-2.0	_	_	I-Premise
227	to	_	_	I-Premise
228	-0.4	_	_	I-Premise
229	)	_	_	I-Premise
230	per	_	_	I-Premise
231	4	_	_	I-Premise
232	weeks	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	control	_	_	I-Premise
236	group	_	_	I-Premise
237	but	_	_	I-Premise
238	remained	_	_	I-Premise
239	stable	_	_	I-Premise
240	(	_	_	I-Premise
241	0.0	_	_	I-Premise
242	g/L	_	_	I-Premise
243	;	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	=	_	_	I-Premise
248	-0.3	_	_	I-Premise
249	to	_	_	I-Premise
250	+0.3	_	_	I-Premise
251	)	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	ATP	_	_	I-Premise
255	group	_	_	I-Premise
256	(	_	_	I-Premise
257	P	_	_	I-Premise
258	=.006	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	Elbow	_	_	B-Premise
262	flexor	_	_	I-Premise
263	muscle	_	_	I-Premise
264	strength	_	_	I-Premise
265	declined	_	_	I-Premise
266	by	_	_	I-Premise
267	-5.5	_	_	I-Premise
268	%	_	_	I-Premise
269	(	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	CI	_	_	I-Premise
273	=	_	_	I-Premise
274	-9.6	_	_	I-Premise
275	%	_	_	I-Premise
276	to	_	_	I-Premise
277	-1	_	_	I-Premise
278	.	_	_	I-Premise

279	4	_	_	I-Premise
280	%	_	_	I-Premise
281	)	_	_	I-Premise
282	per	_	_	I-Premise
283	4	_	_	I-Premise
284	weeks	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	control	_	_	I-Premise
288	group	_	_	I-Premise
289	but	_	_	I-Premise
290	remained	_	_	I-Premise
291	stable	_	_	I-Premise
292	(	_	_	I-Premise
293	0.0	_	_	I-Premise
294	%	_	_	I-Premise
295	;	_	_	I-Premise
296	95	_	_	I-Premise
297	%	_	_	I-Premise
298	CI=	_	_	I-Premise
299	-1.4	_	_	I-Premise
300	%	_	_	I-Premise
301	to	_	_	I-Premise
302	+1.4	_	_	I-Premise
303	%	_	_	I-Premise
304	)	_	_	I-Premise
305	in	_	_	I-Premise
306	the	_	_	I-Premise
307	ATP	_	_	I-Premise
308	group	_	_	I-Premise
309	(	_	_	I-Premise
310	P	_	_	I-Premise
311	=.01	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	A	_	_	B-Premise
315	similar	_	_	I-Premise
316	pattern	_	_	I-Premise
317	was	_	_	I-Premise
318	observed	_	_	I-Premise
319	for	_	_	I-Premise
320	knee	_	_	I-Premise
321	extensor	_	_	I-Premise
322	muscles	_	_	I-Premise
323	(	_	_	I-Premise
324	P	_	_	I-Premise
325	=.02	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	The	_	_	B-Premise
329	effects	_	_	I-Premise
330	of	_	_	I-Premise
331	ATP	_	_	I-Premise
332	on	_	_	I-Premise
333	body	_	_	I-Premise
334	weight	_	_	I-Premise
335	,	_	_	I-Premise
336	muscle	_	_	I-Premise
337	strength	_	_	I-Premise
338	,	_	_	I-Premise
339	and	_	_	I-Premise
340	albumin	_	_	I-Premise
341	concentration	_	_	I-Premise
342	were	_	_	I-Premise
343	especially	_	_	I-Premise
344	marked	_	_	I-Premise
345	in	_	_	I-Premise
346	cachectic	_	_	I-Premise
347	patients	_	_	I-Premise
348	(	_	_	I-Premise
349	P	_	_	I-Premise
350	=.0002	_	_	I-Premise
351	,	_	_	I-Premise
352	P	_	_	I-Premise
353	=.0001	_	_	I-Premise
354	,	_	_	I-Premise
355	and	_	_	I-Premise
356	P	_	_	I-Premise
357	=	_	_	I-Premise
358	.	_	_	I-Premise

359	0001	_	_	I-Premise
360	,	_	_	I-Premise
361	respectively	_	_	I-Premise
362	,	_	_	I-Premise
363	for	_	_	I-Premise
364	ATP	_	_	I-Premise
365	versus	_	_	I-Premise
366	no	_	_	I-Premise
367	ATP	_	_	I-Premise
368	)	_	_	I-Premise
369	.	_	_	I-Premise

370	QOL	_	_	B-Premise
371	score	_	_	I-Premise
372	changes	_	_	I-Premise
373	per	_	_	I-Premise
374	4-week	_	_	I-Premise
375	period	_	_	I-Premise
376	in	_	_	I-Premise
377	the	_	_	I-Premise
378	ATP	_	_	I-Premise
379	group	_	_	I-Premise
380	showed	_	_	I-Premise
381	overall	_	_	I-Premise
382	less	_	_	I-Premise
383	deterioration	_	_	I-Premise
384	than	_	_	I-Premise
385	in	_	_	I-Premise
386	the	_	_	I-Premise
387	control	_	_	I-Premise
388	group-physical	_	_	I-Premise
389	scores	_	_	I-Premise
390	(	_	_	I-Premise
391	-0.2	_	_	I-Premise
392	%	_	_	I-Premise
393	versus	_	_	I-Premise
394	-2.4	_	_	I-Premise
395	%	_	_	I-Premise
396	;	_	_	I-Premise
397	P	_	_	I-Premise
398	=	_	_	I-Premise
399	.	_	_	I-Premise

400	0002	_	_	I-Premise
401	)	_	_	I-Premise
402	;	_	_	I-Premise
403	functional	_	_	I-Premise
404	scores	_	_	I-Premise
405	(	_	_	I-Premise
406	+0.4	_	_	I-Premise
407	%	_	_	I-Premise
408	versus	_	_	I-Premise
409	-5.5	_	_	I-Premise
410	%	_	_	I-Premise
411	;	_	_	I-Premise
412	P	_	_	I-Premise
413	=.02	_	_	I-Premise
414	)	_	_	I-Premise
415	;	_	_	I-Premise
416	psychologic	_	_	I-Premise
417	scores	_	_	I-Premise
418	(	_	_	I-Premise
419	-0.7	_	_	I-Premise
420	%	_	_	I-Premise
421	versus	_	_	I-Premise
422	-2.4	_	_	I-Premise
423	%	_	_	I-Premise
424	;	_	_	I-Premise
425	P	_	_	I-Premise
426	=.11	_	_	I-Premise
427	)	_	_	I-Premise
428	;	_	_	I-Premise
429	overall	_	_	I-Premise
430	QOL	_	_	I-Premise
431	score	_	_	I-Premise
432	(	_	_	I-Premise
433	+0.1	_	_	I-Premise
434	%	_	_	I-Premise
435	versus	_	_	I-Premise
436	-3.5	_	_	I-Premise
437	%	_	_	I-Premise
438	;	_	_	I-Premise
439	P	_	_	I-Premise
440	=.0001	_	_	I-Premise
441	)	_	_	I-Premise
442	.	_	_	I-Premise

443	This	_	_	O
444	randomized	_	_	O
445	trial	_	_	O
446	demonstrates	_	_	O
447	that	_	_	O
448	ATP	_	_	B-Claim
449	has	_	_	I-Claim
450	beneficial	_	_	I-Claim
451	effects	_	_	I-Claim
452	on	_	_	I-Claim
453	weight	_	_	I-Claim
454	,	_	_	I-Claim
455	muscle	_	_	I-Claim
456	strength	_	_	I-Claim
457	,	_	_	I-Claim
458	and	_	_	I-Claim
459	QOL	_	_	I-Claim
460	in	_	_	I-Claim
461	patients	_	_	I-Claim
462	with	_	_	I-Claim
463	advanced	_	_	I-Claim
464	NSCLC	_	_	I-Claim
465	.	_	_	I-Claim


0	Oral	_	_	B-Claim
1	carbonic	_	_	I-Claim
2	anhydrase	_	_	I-Claim
3	inhibitors	_	_	I-Claim
4	used	_	_	I-Claim
5	to	_	_	I-Claim
6	treat	_	_	I-Claim
7	glaucoma	_	_	I-Claim
8	have	_	_	I-Claim
9	significant	_	_	I-Claim
10	systemic	_	_	I-Claim
11	side	_	_	I-Claim
12	effects	_	_	I-Claim
13	.	_	_	I-Claim

14	Brinzolamide	_	_	O
15	1.0	_	_	O
16	%	_	_	O
17	,	_	_	O
18	a	_	_	O
19	new	_	_	O
20	topical	_	_	O
21	ocular	_	_	O
22	carbonic	_	_	O
23	anhydrase	_	_	O
24	inhibitor	_	_	O
25	,	_	_	O
26	is	_	_	O
27	effective	_	_	O
28	apparently	_	_	O
29	without	_	_	O
30	significant	_	_	O
31	systemic	_	_	O
32	side	_	_	O
33	effects	_	_	O
34	.	_	_	O

35	This	_	_	O
36	study	_	_	O
37	was	_	_	O
38	performed	_	_	O
39	to	_	_	O
40	establish	_	_	O
41	the	_	_	O
42	long-term	_	_	O
43	safety	_	_	O
44	and	_	_	O
45	efficacy	_	_	O
46	of	_	_	O
47	brinzolamide	_	_	O
48	1.0	_	_	O
49	%	_	_	O
50	two	_	_	O
51	and	_	_	O
52	three	_	_	O
53	times	_	_	O
54	daily	_	_	O
55	for	_	_	O
56	primary	_	_	O
57	open-angle	_	_	O
58	glaucoma	_	_	O
59	and	_	_	O
60	ocular	_	_	O
61	hypertension	_	_	O
62	.	_	_	O

63	An	_	_	O
64	18-month	_	_	O
65	,	_	_	O
66	multicenter	_	_	O
67	,	_	_	O
68	double-masked	_	_	O
69	,	_	_	O
70	parallel	_	_	O
71	,	_	_	O
72	controlled	_	_	O
73	study	_	_	O
74	was	_	_	O
75	conducted	_	_	O
76	.	_	_	O

77	Patients	_	_	O
78	were	_	_	O
79	randomized	_	_	O
80	to	_	_	O
81	brinzolamide	_	_	O
82	two	_	_	O
83	or	_	_	O
84	three	_	_	O
85	times	_	_	O
86	daily	_	_	O
87	or	_	_	O
88	timolol	_	_	O
89	0.5	_	_	O
90	%	_	_	O
91	twice	_	_	O
92	daily	_	_	O
93	in	_	_	O
94	a	_	_	O
95	2:2:1	_	_	O
96	ratio	_	_	O
97	(	_	_	O
98	n	_	_	O
99	=	_	_	O
100	150	_	_	O
101	,	_	_	O
102	153	_	_	O
103	,	_	_	O
104	and	_	_	O
105	75	_	_	O
106	,	_	_	O
107	respectively	_	_	O
108	)	_	_	O
109	.	_	_	O

110	Intraocular	_	_	O
111	pressure	_	_	O
112	was	_	_	O
113	measured	_	_	O
114	at	_	_	O
115	8:00	_	_	O
116	AM	_	_	O
117	at	_	_	O
118	eligibility	_	_	O
119	and	_	_	O
120	months	_	_	O
121	1	_	_	O
122	,	_	_	O
123	3	_	_	O
124	,	_	_	O
125	6	_	_	O
126	,	_	_	O
127	9	_	_	O
128	,	_	_	O
129	12	_	_	O
130	,	_	_	O
131	15	_	_	O
132	,	_	_	O
133	and	_	_	O
134	18	_	_	O
135	.	_	_	O

136	Efficacy	_	_	O
137	was	_	_	O
138	based	_	_	O
139	on	_	_	O
140	intraocular	_	_	O
141	pressure	_	_	O
142	reduction	_	_	O
143	from	_	_	O
144	baseline	_	_	O
145	.	_	_	O

146	Safety	_	_	O
147	was	_	_	O
148	also	_	_	O
149	evaluated	_	_	O
150	.	_	_	O

151	All	_	_	B-Premise
152	regimens	_	_	I-Premise
153	produced	_	_	I-Premise
154	clinically	_	_	I-Premise
155	relevant	_	_	I-Premise
156	and	_	_	I-Premise
157	statistically	_	_	I-Premise
158	significant	_	_	I-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	<	_	_	I-Premise
162	.05	_	_	I-Premise
163	)	_	_	I-Premise
164	intraocular	_	_	I-Premise
165	pressure	_	_	I-Premise
166	reductions	_	_	I-Premise
167	from	_	_	I-Premise
168	baseline	_	_	I-Premise
169	.	_	_	I-Premise

170	Mean	_	_	B-Premise
171	changes	_	_	I-Premise
172	in	_	_	I-Premise
173	intraocular	_	_	I-Premise
174	pressure	_	_	I-Premise
175	trough	_	_	I-Premise
176	measurements	_	_	I-Premise
177	ranged	_	_	I-Premise
178	from	_	_	I-Premise
179	-2.7	_	_	I-Premise
180	to	_	_	I-Premise
181	-3.9	_	_	I-Premise
182	mm	_	_	I-Premise
183	Hg	_	_	I-Premise
184	with	_	_	I-Premise
185	brinzolamide	_	_	I-Premise
186	twice-daily	_	_	I-Premise
187	dosing	_	_	I-Premise
188	and	_	_	I-Premise
189	-2.8	_	_	I-Premise
190	to	_	_	I-Premise
191	-3.8	_	_	I-Premise
192	mm	_	_	I-Premise
193	Hg	_	_	I-Premise
194	three	_	_	I-Premise
195	times	_	_	I-Premise
196	daily	_	_	I-Premise
197	dosing	_	_	I-Premise
198	compared	_	_	I-Premise
199	with	_	_	I-Premise
200	-4.7	_	_	I-Premise
201	to	_	_	I-Premise
202	-5.6	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	with	_	_	I-Premise
206	timolol	_	_	I-Premise
207	.	_	_	I-Premise

208	The	_	_	O
209	intraocular	_	_	O
210	pressure	_	_	O
211	reductions	_	_	O
212	with	_	_	O
213	brinzolamide	_	_	O
214	two	_	_	O
215	and	_	_	O
216	three	_	_	O
217	times	_	_	O
218	daily	_	_	O
219	were	_	_	O
220	clinically	_	_	O
221	and	_	_	O
222	statistically	_	_	O
223	equivalent	_	_	O
224	.	_	_	O

225	One	_	_	O
226	hundred	_	_	O
227	forty-four	_	_	O
228	patients	_	_	O
229	were	_	_	O
230	discontinued	_	_	O
231	from	_	_	O
232	the	_	_	O
233	study	_	_	O
234	after	_	_	O
235	randomization	_	_	O
236	with	_	_	O
237	the	_	_	O
238	most	_	_	O
239	common	_	_	O
240	reasons	_	_	O
241	being	_	_	O
242	the	_	_	O
243	occurrence	_	_	O
244	of	_	_	O
245	an	_	_	O
246	adverse	_	_	O
247	event	_	_	O
248	(	_	_	O
249	46	_	_	O
250	)	_	_	O
251	,	_	_	O
252	inadequate	_	_	O
253	intraocular	_	_	O
254	pressure	_	_	O
255	control	_	_	O
256	(	_	_	O
257	23	_	_	O
258	)	_	_	O
259	,	_	_	O
260	patient	_	_	O
261	decision	_	_	O
262	unrelated	_	_	O
263	to	_	_	O
264	study	_	_	O
265	medication	_	_	O
266	(	_	_	O
267	11	_	_	O
268	)	_	_	O
269	,	_	_	O
270	lost	_	_	O
271	to	_	_	O
272	follow-up	_	_	O
273	(	_	_	O
274	16	_	_	O
275	)	_	_	O
276	,	_	_	O
277	and	_	_	O
278	noncompliance	_	_	O
279	(	_	_	O
280	9	_	_	O
281	)	_	_	O
282	.	_	_	O

283	Adverse	_	_	B-Premise
284	events	_	_	I-Premise
285	were	_	_	I-Premise
286	nonserious	_	_	I-Premise
287	and	_	_	I-Premise
288	resolved	_	_	I-Premise
289	without	_	_	I-Premise
290	sequelae	_	_	I-Premise
291	.	_	_	I-Premise

292	There	_	_	O
293	were	_	_	O
294	no	_	_	O
295	clinically	_	_	O
296	relevant	_	_	O
297	changes	_	_	O
298	in	_	_	O
299	safety	_	_	O
300	parameters	_	_	O
301	.	_	_	O

302	Brinzolamide	_	_	B-Claim
303	produced	_	_	I-Claim
304	less	_	_	I-Claim
305	ocular	_	_	I-Claim
306	discomfort	_	_	I-Claim
307	(	_	_	I-Claim
308	burning/stinging	_	_	I-Claim
309	)	_	_	I-Claim
310	than	_	_	I-Claim
311	timolol	_	_	I-Claim
312	,	_	_	I-Claim
313	and	_	_	I-Claim
314	total	_	_	I-Claim
315	carbonic	_	_	I-Claim
316	anhydrase	_	_	I-Claim
317	inhibition	_	_	I-Claim
318	levels	_	_	I-Claim
319	remained	_	_	I-Claim
320	below	_	_	I-Claim
321	that	_	_	I-Claim
322	known	_	_	I-Claim
323	to	_	_	I-Claim
324	cause	_	_	I-Claim
325	systemic	_	_	I-Claim
326	side	_	_	I-Claim
327	effects	_	_	I-Claim
328	.	_	_	I-Claim

329	Brinzolamide	_	_	B-Claim
330	produced	_	_	I-Claim
331	significant	_	_	I-Claim
332	and	_	_	I-Claim
333	equivalent	_	_	I-Claim
334	reductions	_	_	I-Claim
335	in	_	_	I-Claim
336	intraocular	_	_	I-Claim
337	pressure	_	_	I-Claim
338	when	_	_	I-Claim
339	dosed	_	_	I-Claim
340	two	_	_	I-Claim
341	and	_	_	I-Claim
342	three	_	_	I-Claim
343	times	_	_	I-Claim
344	daily	_	_	I-Claim
345	for	_	_	I-Claim
346	18	_	_	I-Claim
347	months	_	_	I-Claim
348	.	_	_	I-Claim

349	Brinzolamide	_	_	B-Claim
350	was	_	_	I-Claim
351	safe	_	_	I-Claim
352	and	_	_	I-Claim
353	well	_	_	I-Claim
354	tolerated	_	_	I-Claim
355	by	_	_	I-Claim
356	patients	_	_	I-Claim
357	,	_	_	I-Claim
358	with	_	_	I-Claim
359	minimal	_	_	I-Claim
360	ocular	_	_	I-Claim
361	discomfort	_	_	I-Claim
362	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	,	_	_	O
4	double-blind	_	_	O
5	,	_	_	O
6	randomized	_	_	O
7	,	_	_	O
8	multicenter	_	_	O
9	study	_	_	O
10	evaluated	_	_	O
11	the	_	_	O
12	efficacy	_	_	O
13	,	_	_	O
14	pharmacodynamics	_	_	O
15	,	_	_	O
16	and	_	_	O
17	safety	_	_	O
18	of	_	_	O
19	the	_	_	O
20	oral	_	_	O
21	aromatase	_	_	O
22	inactivator	_	_	O
23	exemestane	_	_	O
24	(	_	_	O
25	EXE	_	_	O
26	)	_	_	O
27	versus	_	_	O
28	megestrol	_	_	O
29	acetate	_	_	O
30	(	_	_	O
31	MA	_	_	O
32	)	_	_	O
33	in	_	_	O
34	postmenopausal	_	_	O
35	women	_	_	O
36	with	_	_	O
37	progressive	_	_	O
38	advanced	_	_	O
39	breast	_	_	O
40	cancer	_	_	O
41	who	_	_	O
42	experienced	_	_	O
43	failure	_	_	O
44	of	_	_	O
45	tamoxifen	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	769	_	_	O
51	patients	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	EXE	_	_	O
56	25	_	_	O
57	mg/d	_	_	O
58	(	_	_	O
59	n	_	_	O
60	=	_	_	O
61	366	_	_	O
62	)	_	_	O
63	or	_	_	O
64	MA	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	403	_	_	O
69	)	_	_	O
70	40	_	_	O
71	mg	_	_	O
72	four	_	_	O
73	times	_	_	O
74	daily	_	_	O
75	.	_	_	O

76	Tumor	_	_	O
77	response	_	_	O
78	,	_	_	O
79	duration	_	_	O
80	of	_	_	O
81	tumor	_	_	O
82	control	_	_	O
83	,	_	_	O
84	tumor-related	_	_	O
85	signs	_	_	O
86	and	_	_	O
87	symptoms	_	_	O
88	(	_	_	O
89	TRSS	_	_	O
90	)	_	_	O
91	,	_	_	O
92	quality	_	_	O
93	of	_	_	O
94	life	_	_	O
95	(	_	_	O
96	QOL	_	_	O
97	)	_	_	O
98	,	_	_	O
99	survival	_	_	O
100	,	_	_	O
101	and	_	_	O
102	tolerability	_	_	O
103	were	_	_	O
104	evaluated	_	_	O
105	.	_	_	O

106	Overall	_	_	B-Premise
107	objective	_	_	I-Premise
108	response	_	_	I-Premise
109	(	_	_	I-Premise
110	OR	_	_	I-Premise
111	)	_	_	I-Premise
112	rates	_	_	I-Premise
113	were	_	_	I-Premise
114	higher	_	_	I-Premise
115	in	_	_	I-Premise
116	patients	_	_	I-Premise
117	treated	_	_	I-Premise
118	with	_	_	I-Premise
119	EXE	_	_	I-Premise
120	than	_	_	I-Premise
121	in	_	_	I-Premise
122	those	_	_	I-Premise
123	treated	_	_	I-Premise
124	with	_	_	I-Premise
125	MA	_	_	I-Premise
126	(	_	_	I-Premise
127	15.0	_	_	I-Premise
128	%	_	_	I-Premise
129	v	_	_	I-Premise
130	12.4	_	_	I-Premise
131	%	_	_	I-Premise
132	)	_	_	I-Premise
133	;	_	_	I-Premise
134	a	_	_	B-Premise
135	similar	_	_	I-Premise
136	trend	_	_	I-Premise
137	was	_	_	I-Premise
138	noted	_	_	I-Premise
139	in	_	_	I-Premise
140	patients	_	_	I-Premise
141	with	_	_	I-Premise
142	visceral	_	_	I-Premise
143	metastases	_	_	I-Premise
144	(	_	_	I-Premise
145	13.5	_	_	I-Premise
146	%	_	_	I-Premise
147	v	_	_	I-Premise
148	10.5	_	_	I-Premise
149	%	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	Median	_	_	B-Premise
153	survival	_	_	I-Premise
154	time	_	_	I-Premise
155	was	_	_	I-Premise
156	significantly	_	_	I-Premise
157	longer	_	_	I-Premise
158	with	_	_	I-Premise
159	EXE	_	_	I-Premise
160	(	_	_	I-Premise
161	median	_	_	I-Premise
162	not	_	_	I-Premise
163	reached	_	_	I-Premise
164	)	_	_	I-Premise
165	than	_	_	I-Premise
166	with	_	_	I-Premise
167	MA	_	_	I-Premise
168	(	_	_	I-Premise
169	123.4	_	_	I-Premise
170	weeks	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=.039	_	_	I-Premise
174	)	_	_	I-Premise
175	,	_	_	I-Premise
176	as	_	_	I-Premise
177	were	_	_	I-Premise
178	the	_	_	I-Premise
179	median	_	_	I-Premise
180	duration	_	_	I-Premise
181	of	_	_	I-Premise
182	overall	_	_	I-Premise
183	success	_	_	I-Premise
184	(	_	_	I-Premise
185	OR	_	_	I-Premise
186	or	_	_	I-Premise
187	stable	_	_	I-Premise
188	disease	_	_	I-Premise
189	>	_	_	I-Premise
190	or	_	_	I-Premise
191	=	_	_	I-Premise
192	24	_	_	I-Premise
193	weeks	_	_	I-Premise
194	;	_	_	I-Premise
195	60.1	_	_	I-Premise
196	v	_	_	I-Premise
197	49.1	_	_	I-Premise
198	weeks	_	_	I-Premise
199	;	_	_	I-Premise
200	P	_	_	I-Premise
201	=.025	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	time	_	_	I-Premise
205	to	_	_	I-Premise
206	tumor	_	_	I-Premise
207	progression	_	_	I-Premise
208	(	_	_	I-Premise
209	20.3	_	_	I-Premise
210	v	_	_	I-Premise
211	16.6	_	_	I-Premise
212	weeks	_	_	I-Premise
213	;	_	_	I-Premise
214	P	_	_	I-Premise
215	=.037	_	_	I-Premise
216	)	_	_	I-Premise
217	,	_	_	I-Premise
218	and	_	_	I-Premise
219	time	_	_	I-Premise
220	to	_	_	I-Premise
221	treatment	_	_	I-Premise
222	failure	_	_	I-Premise
223	(	_	_	I-Premise
224	16.3	_	_	I-Premise
225	v	_	_	I-Premise
226	15.7	_	_	I-Premise
227	weeks	_	_	I-Premise
228	;	_	_	I-Premise
229	P	_	_	I-Premise
230	=.042	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Compared	_	_	B-Premise
234	with	_	_	I-Premise
235	MA	_	_	I-Premise
236	,	_	_	I-Premise
237	there	_	_	I-Premise
238	were	_	_	I-Premise
239	similar	_	_	I-Premise
240	or	_	_	I-Premise
241	greater	_	_	I-Premise
242	improvements	_	_	I-Premise
243	in	_	_	I-Premise
244	pain	_	_	I-Premise
245	,	_	_	I-Premise
246	TRSS	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	QOL	_	_	I-Premise
250	with	_	_	I-Premise
251	EXE	_	_	I-Premise
252	.	_	_	I-Premise

253	Both	_	_	B-Claim
254	drugs	_	_	I-Claim
255	were	_	_	I-Claim
256	well	_	_	I-Claim
257	tolerated	_	_	I-Claim
258	.	_	_	I-Claim

259	Grade	_	_	B-Premise
260	3	_	_	I-Premise
261	or	_	_	I-Premise
262	4	_	_	I-Premise
263	weight	_	_	I-Premise
264	changes	_	_	I-Premise
265	were	_	_	I-Premise
266	more	_	_	I-Premise
267	common	_	_	I-Premise
268	with	_	_	I-Premise
269	MA	_	_	I-Premise
270	(	_	_	I-Premise
271	17.1	_	_	I-Premise
272	%	_	_	I-Premise
273	v	_	_	I-Premise
274	7.6	_	_	I-Premise
275	%	_	_	I-Premise
276	;	_	_	I-Premise
277	P	_	_	I-Premise
278	=.001	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	EXE	_	_	B-Claim
282	prolongs	_	_	I-Claim
283	survival	_	_	I-Claim
284	time	_	_	I-Claim
285	,	_	_	I-Claim
286	time	_	_	I-Claim
287	to	_	_	I-Claim
288	tumor	_	_	I-Claim
289	progression	_	_	I-Claim
290	,	_	_	I-Claim
291	and	_	_	I-Claim
292	time	_	_	I-Claim
293	to	_	_	I-Claim
294	treatment	_	_	I-Claim
295	failure	_	_	I-Claim
296	compared	_	_	I-Claim
297	with	_	_	I-Claim
298	MA	_	_	I-Claim
299	and	_	_	I-Claim
300	offers	_	_	I-Claim
301	a	_	_	I-Claim
302	well-tolerated	_	_	I-Claim
303	treatment	_	_	I-Claim
304	option	_	_	I-Claim
305	for	_	_	I-Claim
306	postmenopausal	_	_	I-Claim
307	women	_	_	I-Claim
308	with	_	_	I-Claim
309	progressive	_	_	I-Claim
310	advanced	_	_	I-Claim
311	breast	_	_	I-Claim
312	cancer	_	_	I-Claim
313	who	_	_	I-Claim
314	experienced	_	_	I-Claim
315	failure	_	_	I-Claim
316	of	_	_	I-Claim
317	tamoxifen	_	_	I-Claim
318	.	_	_	I-Claim


0	Suramin	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	novel	_	_	I-Claim
4	agent	_	_	I-Claim
5	that	_	_	I-Claim
6	has	_	_	I-Claim
7	demonstrated	_	_	I-Claim
8	preliminary	_	_	I-Claim
9	evidence	_	_	I-Claim
10	of	_	_	I-Claim
11	antitumor	_	_	I-Claim
12	activity	_	_	I-Claim
13	in	_	_	I-Claim
14	hormone-refractory	_	_	I-Claim
15	prostate	_	_	I-Claim
16	cancer	_	_	I-Claim
17	(	_	_	I-Claim
18	HRPC	_	_	I-Claim
19	)	_	_	I-Claim
20	.	_	_	I-Claim

21	A	_	_	O
22	prospective	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	was	_	_	O
27	designed	_	_	O
28	to	_	_	O
29	evaluate	_	_	O
30	pain	_	_	O
31	and	_	_	O
32	opioid	_	_	O
33	analgesic	_	_	O
34	intake	_	_	O
35	as	_	_	O
36	surrogates	_	_	O
37	for	_	_	O
38	antitumor	_	_	O
39	response	_	_	O
40	in	_	_	O
41	HRPC	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	significant	_	_	O
45	,	_	_	O
46	opioid	_	_	O
47	analgesic-dependent	_	_	O
48	pain	_	_	O
49	.	_	_	O

50	A	_	_	O
51	double-blind	_	_	O
52	,	_	_	O
53	placebo-controlled	_	_	O
54	trial	_	_	O
55	randomized	_	_	O
56	patients	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	a	_	_	O
60	78-day	_	_	O
61	,	_	_	O
62	outpatient	_	_	O
63	regimen	_	_	O
64	of	_	_	O
65	either	_	_	O
66	suramin	_	_	O
67	plus	_	_	O
68	hydrocortisone	_	_	O
69	(	_	_	O
70	HC	_	_	O
71	,	_	_	O
72	40	_	_	O
73	mg/d	_	_	O
74	)	_	_	O
75	or	_	_	O
76	placebo	_	_	O
77	plus	_	_	O
78	HC	_	_	O
79	.	_	_	O

80	Treatment	_	_	O
81	assignment	_	_	O
82	was	_	_	O
83	unblinded	_	_	O
84	when	_	_	O
85	either	_	_	O
86	disease	_	_	O
87	progression	_	_	O
88	or	_	_	O
89	dose-limiting	_	_	O
90	toxicity	_	_	O
91	occurred	_	_	O
92	;	_	_	O
93	placebo	_	_	O
94	patients	_	_	O
95	were	_	_	O
96	allowed	_	_	O
97	to	_	_	O
98	cross-over	_	_	O
99	to	_	_	O
100	open-label	_	_	O
101	suramin	_	_	O
102	plus	_	_	O
103	HC	_	_	O
104	.	_	_	O

105	In	_	_	O
106	addition	_	_	O
107	to	_	_	O
108	pain	_	_	O
109	and	_	_	O
110	opioid	_	_	O
111	analgesic	_	_	O
112	intake	_	_	O
113	,	_	_	O
114	prostate-specific	_	_	O
115	antigen	_	_	O
116	(	_	_	O
117	PSA	_	_	O
118	)	_	_	O
119	response	_	_	O
120	,	_	_	O
121	time	_	_	O
122	to	_	_	O
123	disease	_	_	O
124	progression	_	_	O
125	,	_	_	O
126	quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	,	_	_	O
130	performance	_	_	O
131	status	_	_	O
132	,	_	_	O
133	and	_	_	O
134	survival	_	_	O
135	were	_	_	O
136	compared	_	_	O
137	.	_	_	O

138	Overall	_	_	B-Premise
139	mean	_	_	I-Premise
140	reductions	_	_	I-Premise
141	in	_	_	I-Premise
142	combined	_	_	I-Premise
143	pain	_	_	I-Premise
144	and	_	_	I-Premise
145	opioid	_	_	I-Premise
146	analgesic	_	_	I-Premise
147	intake	_	_	I-Premise
148	were	_	_	I-Premise
149	greater	_	_	I-Premise
150	for	_	_	I-Premise
151	suramin	_	_	I-Premise
152	plus	_	_	I-Premise
153	HC	_	_	I-Premise
154	(	_	_	I-Premise
155	rank	_	_	I-Premise
156	sum	_	_	I-Premise
157	P	_	_	I-Premise
158	=.0001	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	Pain	_	_	B-Premise
162	response	_	_	I-Premise
163	was	_	_	I-Premise
164	achieved	_	_	I-Premise
165	in	_	_	I-Premise
166	a	_	_	I-Premise
167	higher	_	_	I-Premise
168	proportion	_	_	I-Premise
169	of	_	_	I-Premise
170	patients	_	_	I-Premise
171	receiving	_	_	I-Premise
172	suramin	_	_	I-Premise
173	than	_	_	I-Premise
174	placebo	_	_	I-Premise
175	(	_	_	I-Premise
176	43	_	_	I-Premise
177	%	_	_	I-Premise
178	v	_	_	I-Premise
179	28	_	_	I-Premise
180	%	_	_	I-Premise
181	;	_	_	I-Premise
182	P	_	_	I-Premise
183	=.001	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	and	_	_	O
187	duration	_	_	B-Premise
188	of	_	_	I-Premise
189	response	_	_	I-Premise
190	was	_	_	I-Premise
191	longer	_	_	I-Premise
192	for	_	_	I-Premise
193	suramin	_	_	I-Premise
194	responders	_	_	I-Premise
195	(	_	_	I-Premise
196	median	_	_	I-Premise
197	,	_	_	I-Premise
198	240	_	_	I-Premise
199	v	_	_	I-Premise
200	69	_	_	I-Premise
201	days	_	_	I-Premise
202	;	_	_	I-Premise
203	P	_	_	I-Premise
204	=.0027	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Time	_	_	B-Premise
208	to	_	_	I-Premise
209	disease	_	_	I-Premise
210	progression	_	_	I-Premise
211	was	_	_	I-Premise
212	longer	_	_	I-Premise
213	(	_	_	I-Premise
214	relative	_	_	I-Premise
215	risk	_	_	I-Premise
216	=	_	_	I-Premise
217	1.5	_	_	I-Premise
218	;	_	_	I-Premise
219	95	_	_	I-Premise
220	%	_	_	I-Premise
221	confidence	_	_	I-Premise
222	interval	_	_	I-Premise
223	,	_	_	I-Premise
224	1.2	_	_	I-Premise
225	to	_	_	I-Premise
226	1.9	_	_	I-Premise
227	)	_	_	I-Premise
228	and	_	_	O
229	the	_	_	B-Premise
230	proportion	_	_	I-Premise
231	of	_	_	I-Premise
232	patients	_	_	I-Premise
233	with	_	_	I-Premise
234	a	_	_	I-Premise
235	greater	_	_	I-Premise
236	than	_	_	I-Premise
237	50	_	_	I-Premise
238	%	_	_	I-Premise
239	decline	_	_	I-Premise
240	in	_	_	I-Premise
241	PSA	_	_	I-Premise
242	was	_	_	I-Premise
243	higher	_	_	I-Premise
244	(	_	_	I-Premise
245	33	_	_	I-Premise
246	%	_	_	I-Premise
247	v	_	_	I-Premise
248	16	_	_	I-Premise
249	%	_	_	I-Premise
250	;	_	_	I-Premise
251	P	_	_	I-Premise
252	=.01	_	_	I-Premise
253	)	_	_	I-Premise
254	in	_	_	I-Premise
255	patients	_	_	I-Premise
256	who	_	_	I-Premise
257	received	_	_	I-Premise
258	suramin	_	_	I-Premise
259	.	_	_	I-Premise

260	Neither	_	_	B-Premise
261	quality	_	_	I-Premise
262	of	_	_	I-Premise
263	life	_	_	I-Premise
264	nor	_	_	I-Premise
265	performance	_	_	I-Premise
266	status	_	_	I-Premise
267	was	_	_	I-Premise
268	decreased	_	_	I-Premise
269	by	_	_	I-Premise
270	suramin	_	_	I-Premise
271	treatment	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	O
274	overall	_	_	B-Premise
275	survival	_	_	I-Premise
276	was	_	_	I-Premise
277	similar	_	_	I-Premise
278	.	_	_	I-Premise

279	Most	_	_	B-Premise
280	adverse	_	_	I-Premise
281	events	_	_	I-Premise
282	were	_	_	I-Premise
283	of	_	_	I-Premise
284	mild	_	_	I-Premise
285	or	_	_	I-Premise
286	moderate	_	_	I-Premise
287	intensity	_	_	I-Premise
288	and	_	_	I-Premise
289	were	_	_	I-Premise
290	easily	_	_	I-Premise
291	managed	_	_	I-Premise
292	medically	_	_	I-Premise
293	.	_	_	I-Premise

294	Outpatient	_	_	B-Claim
295	treatment	_	_	I-Claim
296	with	_	_	I-Claim
297	suramin	_	_	I-Claim
298	plus	_	_	I-Claim
299	HC	_	_	I-Claim
300	is	_	_	I-Claim
301	well	_	_	I-Claim
302	tolerated	_	_	I-Claim
303	and	_	_	I-Claim
304	provides	_	_	I-Claim
305	moderate	_	_	I-Claim
306	palliative	_	_	I-Claim
307	benefit	_	_	I-Claim
308	and	_	_	I-Claim
309	delay	_	_	I-Claim
310	in	_	_	I-Claim
311	disease	_	_	I-Claim
312	progression	_	_	I-Claim
313	for	_	_	I-Claim
314	patients	_	_	I-Claim
315	with	_	_	I-Claim
316	symptomatic	_	_	I-Claim
317	HRPC	_	_	I-Claim
318	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	whether	_	_	O
3	treatment	_	_	O
4	with	_	_	O
5	single-agent	_	_	O
6	docetaxel	_	_	O
7	would	_	_	O
8	result	_	_	O
9	in	_	_	O
10	longer	_	_	O
11	survival	_	_	O
12	than	_	_	O
13	would	_	_	O
14	best	_	_	O
15	supportive	_	_	O
16	care	_	_	O
17	in	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	non-small-cell	_	_	O
21	lung	_	_	O
22	cancer	_	_	O
23	who	_	_	O
24	had	_	_	O
25	previously	_	_	O
26	been	_	_	O
27	treated	_	_	O
28	with	_	_	O
29	platinum-based	_	_	O
30	chemotherapy	_	_	O
31	.	_	_	O

32	Secondary	_	_	O
33	end	_	_	O
34	points	_	_	O
35	included	_	_	O
36	assessment	_	_	O
37	of	_	_	O
38	response	_	_	O
39	(	_	_	O
40	docetaxel	_	_	O
41	arm	_	_	O
42	only	_	_	O
43	)	_	_	O
44	,	_	_	O
45	toxicity	_	_	O
46	,	_	_	O
47	and	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	.	_	_	O

52	Patients	_	_	O
53	with	_	_	O
54	performance	_	_	O
55	statuses	_	_	O
56	of	_	_	O
57	0	_	_	O
58	to	_	_	O
59	2	_	_	O
60	and	_	_	O
61	stage	_	_	O
62	IIIB/IV	_	_	O
63	non-small-cell	_	_	O
64	lung	_	_	O
65	cancer	_	_	O
66	with	_	_	O
67	either	_	_	O
68	measurable	_	_	O
69	or	_	_	O
70	evaluable	_	_	O
71	lesions	_	_	O
72	were	_	_	O
73	eligible	_	_	O
74	for	_	_	O
75	entry	_	_	O
76	onto	_	_	O
77	the	_	_	O
78	study	_	_	O
79	if	_	_	O
80	they	_	_	O
81	had	_	_	O
82	undergone	_	_	O
83	one	_	_	O
84	or	_	_	O
85	more	_	_	O
86	platinum-based	_	_	O
87	chemotherapy	_	_	O
88	regimens	_	_	O
89	and	_	_	O
90	if	_	_	O
91	they	_	_	O
92	had	_	_	O
93	adequate	_	_	O
94	hematology	_	_	O
95	and	_	_	O
96	biochemistry	_	_	O
97	parameters	_	_	O
98	.	_	_	O

99	They	_	_	O
100	were	_	_	O
101	excluded	_	_	O
102	if	_	_	O
103	they	_	_	O
104	had	_	_	O
105	symptomatic	_	_	O
106	brain	_	_	O
107	metastases	_	_	O
108	or	_	_	O
109	if	_	_	O
110	they	_	_	O
111	had	_	_	O
112	previously	_	_	O
113	been	_	_	O
114	treated	_	_	O
115	with	_	_	O
116	paclitaxel	_	_	O
117	.	_	_	O

118	Patients	_	_	O
119	were	_	_	O
120	stratified	_	_	O
121	by	_	_	O
122	performance	_	_	O
123	status	_	_	O
124	and	_	_	O
125	best	_	_	O
126	response	_	_	O
127	to	_	_	O
128	cisplatin	_	_	O
129	chemotherapy	_	_	O
130	and	_	_	O
131	were	_	_	O
132	then	_	_	O
133	randomized	_	_	O
134	to	_	_	O
135	treatment	_	_	O
136	with	_	_	O
137	docetaxel	_	_	O
138	100	_	_	O
139	mg/m	_	_	O
140	(	_	_	O
141	2	_	_	O
142	)	_	_	O
143	(	_	_	O
144	49	_	_	O
145	patients	_	_	O
146	)	_	_	O
147	or	_	_	O
148	75	_	_	O
149	mg/m	_	_	O
150	(	_	_	O
151	2	_	_	O
152	)	_	_	O
153	(	_	_	O
154	55	_	_	O
155	patients	_	_	O
156	)	_	_	O
157	or	_	_	O
158	best	_	_	O
159	supportive	_	_	O
160	care	_	_	O
161	.	_	_	O

162	Patients	_	_	O
163	in	_	_	O
164	both	_	_	O
165	arms	_	_	O
166	were	_	_	O
167	assessed	_	_	O
168	every	_	_	O
169	3	_	_	O
170	weeks	_	_	O
171	.	_	_	O

172	One	_	_	O
173	hundred	_	_	O
174	four	_	_	O
175	patients	_	_	O
176	(	_	_	O
177	103	_	_	O
178	of	_	_	O
179	whom	_	_	O
180	were	_	_	O
181	eligible	_	_	O
182	for	_	_	O
183	entry	_	_	O
184	onto	_	_	O
185	the	_	_	O
186	study	_	_	O
187	)	_	_	O
188	were	_	_	O
189	well	_	_	O
190	balanced	_	_	O
191	for	_	_	O
192	prognostic	_	_	O
193	factors	_	_	O
194	.	_	_	O

195	Of	_	_	O
196	84	_	_	O
197	patients	_	_	O
198	with	_	_	O
199	measurable	_	_	O
200	lesions	_	_	O
201	,	_	_	O
202	six	_	_	O
203	(	_	_	O
204	7	_	_	O
205	.	_	_	O

206	1	_	_	O
207	%	_	_	O
208	)	_	_	O
209	achieved	_	_	O
210	partial	_	_	O
211	responses	_	_	O
212	(	_	_	O
213	three	_	_	O
214	patients	_	_	O
215	at	_	_	O
216	each	_	_	O
217	dose	_	_	O
218	level	_	_	O
219	)	_	_	O
220	.	_	_	O

221	Time	_	_	B-Premise
222	to	_	_	I-Premise
223	progression	_	_	I-Premise
224	was	_	_	I-Premise
225	longer	_	_	I-Premise
226	for	_	_	I-Premise
227	docetaxel	_	_	I-Premise
228	patients	_	_	I-Premise
229	than	_	_	I-Premise
230	for	_	_	I-Premise
231	best	_	_	I-Premise
232	supportive	_	_	I-Premise
233	care	_	_	I-Premise
234	patients	_	_	I-Premise
235	(	_	_	I-Premise
236	10.6	_	_	I-Premise
237	v	_	_	I-Premise
238	6.7	_	_	I-Premise
239	weeks	_	_	I-Premise
240	,	_	_	I-Premise
241	respectively	_	_	I-Premise
242	;	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	.001	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	as	_	_	I-Premise
249	was	_	_	I-Premise
250	median	_	_	I-Premise
251	survival	_	_	I-Premise
252	(	_	_	I-Premise
253	7.0	_	_	I-Premise
254	v	_	_	I-Premise
255	4.6	_	_	I-Premise
256	months	_	_	I-Premise
257	;	_	_	I-Premise
258	log-rank	_	_	I-Premise
259	test	_	_	I-Premise
260	,	_	_	I-Premise
261	P	_	_	I-Premise
262	=.047	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	difference	_	_	I-Premise
267	was	_	_	I-Premise
268	more	_	_	I-Premise
269	significant	_	_	I-Premise
270	for	_	_	I-Premise
271	docetaxel	_	_	I-Premise
272	75	_	_	I-Premise
273	mg/m	_	_	I-Premise
274	(	_	_	I-Premise
275	2	_	_	I-Premise
276	)	_	_	I-Premise
277	patients	_	_	I-Premise
278	,	_	_	I-Premise
279	compared	_	_	I-Premise
280	with	_	_	I-Premise
281	corresponding	_	_	I-Premise
282	best	_	_	I-Premise
283	supportive	_	_	I-Premise
284	care	_	_	I-Premise
285	patients	_	_	I-Premise
286	(	_	_	I-Premise
287	7.5	_	_	I-Premise
288	v	_	_	I-Premise
289	4.6	_	_	I-Premise
290	months	_	_	I-Premise
291	;	_	_	I-Premise
292	log-rank	_	_	I-Premise
293	test	_	_	I-Premise
294	,	_	_	I-Premise
295	P	_	_	I-Premise
296	=.010	_	_	I-Premise
297	;	_	_	I-Premise
298	1-year	_	_	I-Premise
299	survival	_	_	I-Premise
300	,	_	_	I-Premise
301	37	_	_	I-Premise
302	%	_	_	I-Premise
303	v	_	_	I-Premise
304	11	_	_	I-Premise
305	%	_	_	I-Premise
306	;	_	_	I-Premise
307	chi	_	_	I-Premise
308	(	_	_	I-Premise
309	2	_	_	I-Premise
310	)	_	_	I-Premise
311	test	_	_	I-Premise
312	,	_	_	I-Premise
313	P	_	_	I-Premise
314	=.003	_	_	I-Premise
315	)	_	_	I-Premise
316	.	_	_	I-Premise

317	Febrile	_	_	B-Premise
318	neutropenia	_	_	I-Premise
319	occurred	_	_	I-Premise
320	in	_	_	I-Premise
321	11	_	_	I-Premise
322	patients	_	_	I-Premise
323	treated	_	_	I-Premise
324	with	_	_	I-Premise
325	docetaxel	_	_	I-Premise
326	100	_	_	I-Premise
327	mg/m	_	_	I-Premise
328	(	_	_	I-Premise
329	2	_	_	I-Premise
330	)	_	_	I-Premise
331	,	_	_	I-Premise
332	three	_	_	I-Premise
333	of	_	_	I-Premise
334	whom	_	_	I-Premise
335	died	_	_	I-Premise
336	,	_	_	I-Premise
337	and	_	_	I-Premise
338	in	_	_	I-Premise
339	one	_	_	I-Premise
340	patient	_	_	I-Premise
341	treated	_	_	I-Premise
342	with	_	_	I-Premise
343	docetaxel	_	_	I-Premise
344	75	_	_	I-Premise
345	mg/m	_	_	I-Premise
346	(	_	_	I-Premise
347	2	_	_	I-Premise
348	)	_	_	I-Premise
349	.	_	_	I-Premise

350	Grade	_	_	B-Premise
351	3	_	_	I-Premise
352	or	_	_	I-Premise
353	4	_	_	I-Premise
354	nonhematologic	_	_	I-Premise
355	toxicity	_	_	I-Premise
356	,	_	_	I-Premise
357	with	_	_	I-Premise
358	the	_	_	I-Premise
359	exception	_	_	I-Premise
360	of	_	_	I-Premise
361	diarrhea	_	_	I-Premise
362	,	_	_	I-Premise
363	occurred	_	_	I-Premise
364	at	_	_	I-Premise
365	a	_	_	I-Premise
366	similar	_	_	I-Premise
367	rate	_	_	I-Premise
368	in	_	_	I-Premise
369	both	_	_	I-Premise
370	the	_	_	I-Premise
371	docetaxel	_	_	I-Premise
372	and	_	_	I-Premise
373	best	_	_	I-Premise
374	supportive	_	_	I-Premise
375	care	_	_	I-Premise
376	groups	_	_	I-Premise
377	.	_	_	I-Premise

378	Treatment	_	_	B-Claim
379	with	_	_	I-Claim
380	docetaxel	_	_	I-Claim
381	is	_	_	I-Claim
382	associated	_	_	I-Claim
383	with	_	_	I-Claim
384	significant	_	_	I-Claim
385	prolongation	_	_	I-Claim
386	of	_	_	I-Claim
387	survival	_	_	I-Claim
388	,	_	_	I-Claim
389	and	_	_	O
390	at	_	_	B-Claim
391	a	_	_	I-Claim
392	dose	_	_	I-Claim
393	of	_	_	I-Claim
394	75	_	_	I-Claim
395	mg/m	_	_	I-Claim
396	(	_	_	I-Claim
397	2	_	_	I-Claim
398	)	_	_	I-Claim
399	,	_	_	I-Claim
400	the	_	_	I-Claim
401	benefits	_	_	I-Claim
402	of	_	_	I-Claim
403	docetaxel	_	_	I-Claim
404	therapy	_	_	I-Claim
405	outweigh	_	_	I-Claim
406	the	_	_	I-Claim
407	risks	_	_	I-Claim
408	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	on	_	_	O
5	intraocular	_	_	O
6	pressure	_	_	O
7	(	_	_	O
8	IOP	_	_	O
9	)	_	_	O
10	and	_	_	O
11	side	_	_	O
12	effects	_	_	O
13	of	_	_	O
14	monotherapy	_	_	O
15	with	_	_	O
16	either	_	_	O
17	latanoprost	_	_	O
18	or	_	_	O
19	dorzolamide	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	glaucoma	_	_	O
24	or	_	_	O
25	ocular	_	_	O
26	hypertension	_	_	O
27	.	_	_	O

28	224	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	open	_	_	O
32	angle	_	_	O
33	glaucoma	_	_	O
34	or	_	_	O
35	ocular	_	_	O
36	hypertension	_	_	O
37	were	_	_	O
38	recruited	_	_	O
39	to	_	_	O
40	a	_	_	O
41	3	_	_	O
42	month	_	_	O
43	open	_	_	O
44	labelled	_	_	O
45	study	_	_	O
46	.	_	_	O

47	Previous	_	_	O
48	glaucoma	_	_	O
49	medications	_	_	O
50	were	_	_	O
51	washed	_	_	O
52	out	_	_	O
53	and	_	_	O
54	the	_	_	O
55	patients	_	_	O
56	were	_	_	O
57	randomised	_	_	O
58	to	_	_	O
59	receive	_	_	O
60	either	_	_	O
61	latanoprost	_	_	O
62	0.005	_	_	O
63	%	_	_	O
64	once	_	_	O
65	daily	_	_	O
66	or	_	_	O
67	dorzolamide	_	_	O
68	2	_	_	O
69	%	_	_	O
70	three	_	_	O
71	times	_	_	O
72	daily	_	_	O
73	.	_	_	O

74	Of	_	_	O
75	224	_	_	O
76	patients	_	_	O
77	213	_	_	O
78	were	_	_	O
79	included	_	_	O
80	in	_	_	O
81	the	_	_	O
82	analysis	_	_	O
83	of	_	_	O
84	efficacy	_	_	O
85	.	_	_	O

86	After	_	_	B-Premise
87	3	_	_	I-Premise
88	months	_	_	I-Premise
89	,	_	_	I-Premise
90	latanoprost	_	_	I-Premise
91	reduced	_	_	I-Premise
92	mean	_	_	I-Premise
93	baseline	_	_	I-Premise
94	diurnal	_	_	I-Premise
95	IOP	_	_	I-Premise
96	from	_	_	I-Premise
97	27.2	_	_	I-Premise
98	(	_	_	I-Premise
99	SD	_	_	I-Premise
100	3.0	_	_	I-Premise
101	)	_	_	I-Premise
102	mm	_	_	I-Premise
103	Hg	_	_	I-Premise
104	by	_	_	I-Premise
105	8.5	_	_	I-Premise
106	(	_	_	I-Premise
107	3.3	_	_	I-Premise
108	)	_	_	I-Premise
109	mm	_	_	I-Premise
110	Hg	_	_	I-Premise
111	.	_	_	I-Premise

112	The	_	_	B-Premise
113	corresponding	_	_	I-Premise
114	figures	_	_	I-Premise
115	for	_	_	I-Premise
116	dorzolamide	_	_	I-Premise
117	were	_	_	I-Premise
118	27.2	_	_	I-Premise
119	(	_	_	I-Premise
120	3.4	_	_	I-Premise
121	)	_	_	I-Premise
122	and	_	_	I-Premise
123	5.6	_	_	I-Premise
124	(	_	_	I-Premise
125	2.6	_	_	I-Premise
126	)	_	_	I-Premise
127	mm	_	_	I-Premise
128	Hg	_	_	I-Premise
129	.	_	_	I-Premise

130	The	_	_	B-Premise
131	difference	_	_	I-Premise
132	of	_	_	I-Premise
133	2.9	_	_	I-Premise
134	mm	_	_	I-Premise
135	Hg	_	_	I-Premise
136	(	_	_	I-Premise
137	95	_	_	I-Premise
138	%	_	_	I-Premise
139	CI	_	_	I-Premise
140	:	_	_	I-Premise
141	2.3-3.6	_	_	I-Premise
142	)	_	_	I-Premise
143	was	_	_	I-Premise
144	highly	_	_	I-Premise
145	significant	_	_	I-Premise
146	(	_	_	I-Premise
147	p	_	_	I-Premise
148	<	_	_	I-Premise
149	0.001	_	_	I-Premise
150	,	_	_	I-Premise
151	ANCOVA	_	_	I-Premise
152	)	_	_	I-Premise
153	.	_	_	I-Premise

154	Latanoprost	_	_	B-Premise
155	reduced	_	_	I-Premise
156	IOP	_	_	I-Premise
157	at	_	_	I-Premise
158	peak	_	_	I-Premise
159	by	_	_	I-Premise
160	8.6	_	_	I-Premise
161	mm	_	_	I-Premise
162	Hg	_	_	I-Premise
163	(	_	_	I-Premise
164	32	_	_	I-Premise
165	%	_	_	I-Premise
166	)	_	_	I-Premise
167	compared	_	_	I-Premise
168	with	_	_	I-Premise
169	6.2	_	_	I-Premise
170	mm	_	_	I-Premise
171	Hg	_	_	I-Premise
172	(	_	_	I-Premise
173	23	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	for	_	_	I-Premise
177	dorzolamide	_	_	I-Premise
178	,	_	_	I-Premise
179	and	_	_	I-Premise
180	the	_	_	I-Premise
181	difference	_	_	I-Premise
182	of	_	_	I-Premise
183	2.4	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	was	_	_	I-Premise
187	significant	_	_	I-Premise
188	(	_	_	I-Premise
189	p	_	_	I-Premise
190	<	_	_	I-Premise
191	0.001	_	_	I-Premise
192	,	_	_	I-Premise
193	ANCOVA	_	_	I-Premise
194	)	_	_	I-Premise
195	.	_	_	I-Premise

196	The	_	_	B-Premise
197	corresponding	_	_	I-Premise
198	figures	_	_	I-Premise
199	at	_	_	I-Premise
200	trough	_	_	I-Premise
201	were	_	_	I-Premise
202	8.1	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	(	_	_	I-Premise
206	31	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	for	_	_	I-Premise
210	latanoprost	_	_	I-Premise
211	and	_	_	I-Premise
212	4.7	_	_	I-Premise
213	mm	_	_	I-Premise
214	Hg	_	_	I-Premise
215	(	_	_	I-Premise
216	17	_	_	I-Premise
217	%	_	_	I-Premise
218	)	_	_	I-Premise
219	for	_	_	I-Premise
220	dorzolamide	_	_	I-Premise
221	,	_	_	I-Premise
222	a	_	_	I-Premise
223	significant	_	_	I-Premise
224	difference	_	_	I-Premise
225	of	_	_	I-Premise
226	3.4	_	_	I-Premise
227	mm	_	_	I-Premise
228	Hg	_	_	I-Premise
229	(	_	_	I-Premise
230	p	_	_	I-Premise
231	<	_	_	I-Premise
232	0.001	_	_	I-Premise
233	,	_	_	I-Premise
234	ANCOVA	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	Both	_	_	B-Claim
238	drugs	_	_	I-Claim
239	were	_	_	I-Claim
240	well	_	_	I-Claim
241	tolerated	_	_	I-Claim
242	systemically	_	_	I-Claim
243	and	_	_	I-Claim
244	locally	_	_	I-Claim
245	.	_	_	I-Claim

246	Latanoprost	_	_	B-Claim
247	was	_	_	I-Claim
248	superior	_	_	I-Claim
249	to	_	_	I-Claim
250	dorzolamide	_	_	I-Claim
251	in	_	_	I-Claim
252	reducing	_	_	I-Claim
253	the	_	_	I-Claim
254	IOP	_	_	I-Claim
255	,	_	_	I-Claim
256	judged	_	_	I-Claim
257	both	_	_	I-Claim
258	from	_	_	I-Claim
259	the	_	_	I-Claim
260	effect	_	_	I-Claim
261	on	_	_	I-Claim
262	IOP	_	_	I-Claim
263	at	_	_	I-Claim
264	peak	_	_	I-Claim
265	and	_	_	I-Claim
266	trough	_	_	I-Claim
267	and	_	_	I-Claim
268	by	_	_	I-Claim
269	the	_	_	I-Claim
270	effect	_	_	I-Claim
271	on	_	_	I-Claim
272	diurnal	_	_	I-Claim
273	IOP	_	_	I-Claim
274	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	study	_	_	O
4	was	_	_	O
5	performed	_	_	O
6	to	_	_	O
7	determine	_	_	O
8	the	_	_	O
9	superiority	_	_	O
10	of	_	_	O
11	doxorubicin	_	_	O
12	(	_	_	O
13	DOX	_	_	O
14	)	_	_	O
15	and	_	_	O
16	vinorelbine	_	_	O
17	(	_	_	O
18	VNB	_	_	O
19	)	_	_	O
20	(	_	_	O
21	arm	_	_	O
22	1	_	_	O
23	)	_	_	O
24	versus	_	_	O
25	DOX	_	_	O
26	alone	_	_	O
27	(	_	_	O
28	arm	_	_	O
29	2	_	_	O
30	)	_	_	O
31	in	_	_	O
32	metastatic	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	(	_	_	O
36	MBC	_	_	O
37	)	_	_	O
38	for	_	_	O
39	overall	_	_	O
40	survival	_	_	O
41	(	_	_	O
42	OS	_	_	O
43	)	_	_	O
44	,	_	_	O
45	time	_	_	O
46	to	_	_	O
47	treatment	_	_	O
48	failure	_	_	O
49	(	_	_	O
50	TTF	_	_	O
51	)	_	_	O
52	,	_	_	O
53	toxicity	_	_	O
54	,	_	_	O
55	and	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	(	_	_	O
60	QOL	_	_	O
61	)	_	_	O
62	.	_	_	O

63	Three	_	_	O
64	hundred	_	_	O
65	three	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	to	_	_	O
70	DOX	_	_	O
71	50	_	_	O
72	mg/m	_	_	O
73	(	_	_	O
74	2	_	_	O
75	)	_	_	O
76	intravenously	_	_	O
77	(	_	_	O
78	IV	_	_	O
79	)	_	_	O
80	on	_	_	O
81	day	_	_	O
82	1	_	_	O
83	and	_	_	O
84	VNB	_	_	O
85	25	_	_	O
86	mg/m	_	_	O
87	(	_	_	O
88	2	_	_	O
89	)	_	_	O
90	IV	_	_	O
91	on	_	_	O
92	days	_	_	O
93	1	_	_	O
94	and	_	_	O
95	8	_	_	O
96	(	_	_	O
97	arm	_	_	O
98	1	_	_	O
99	)	_	_	O
100	or	_	_	O
101	DOX	_	_	O
102	70	_	_	O
103	mg/m	_	_	O
104	(	_	_	O
105	2	_	_	O
106	)	_	_	O
107	IV	_	_	O
108	on	_	_	O
109	day	_	_	O
110	1	_	_	O
111	(	_	_	O
112	arm	_	_	O
113	2	_	_	O
114	)	_	_	O
115	.	_	_	O

116	Both	_	_	O
117	regimens	_	_	O
118	were	_	_	O
119	given	_	_	O
120	every	_	_	O
121	3	_	_	O
122	weeks	_	_	O
123	until	_	_	O
124	a	_	_	O
125	cumulative	_	_	O
126	DOX	_	_	O
127	dose	_	_	O
128	of	_	_	O
129	450	_	_	O
130	mg/m	_	_	O
131	(	_	_	O
132	2	_	_	O
133	)	_	_	O
134	.	_	_	O

135	After	_	_	O
136	16	_	_	O
137	of	_	_	O
138	the	_	_	O
139	first	_	_	O
140	65	_	_	O
141	randomized	_	_	O
142	patients	_	_	O
143	experienced	_	_	O
144	febrile	_	_	O
145	neutropenia	_	_	O
146	(	_	_	O
147	FN	_	_	O
148	)	_	_	O
149	,	_	_	O
150	the	_	_	O
151	doses	_	_	O
152	were	_	_	O
153	reduced	_	_	O
154	to	_	_	O
155	DOX	_	_	O
156	40	_	_	O
157	mg/m	_	_	O
158	(	_	_	O
159	2	_	_	O
160	)	_	_	O
161	on	_	_	O
162	day	_	_	O
163	1	_	_	O
164	and	_	_	O
165	VNB	_	_	O
166	20	_	_	O
167	mg/m	_	_	O
168	(	_	_	O
169	2	_	_	O
170	)	_	_	O
171	on	_	_	O
172	days	_	_	O
173	1	_	_	O
174	and	_	_	O
175	8	_	_	O
176	versus	_	_	O
177	DOX	_	_	O
178	60	_	_	O
179	mg/m	_	_	O
180	(	_	_	O
181	2	_	_	O
182	)	_	_	O
183	on	_	_	O
184	day	_	_	O
185	1	_	_	O
186	.	_	_	O

187	Eligible	_	_	O
188	patients	_	_	O
189	were	_	_	O
190	vinca	_	_	O
191	alkaloid	_	_	O
192	and	_	_	O
193	anthracycline	_	_	O
194	naive	_	_	O
195	.	_	_	O

196	Chemotherapy	_	_	O
197	was	_	_	O
198	first-line	_	_	O
199	or	_	_	O
200	second-line	_	_	O
201	for	_	_	O
202	MBC	_	_	O
203	.	_	_	O

204	Three	_	_	O
205	patients	_	_	O
206	were	_	_	O
207	ineligible	_	_	O
208	.	_	_	O

209	Thus	_	_	O
210	,	_	_	O
211	300	_	_	O
212	patients	_	_	O
213	were	_	_	O
214	assessable	_	_	O
215	for	_	_	O
216	toxicity	_	_	O
217	and	_	_	O
218	to	_	_	O
219	determine	_	_	O
220	time	_	_	O
221	to	_	_	O
222	disease	_	_	O
223	progression	_	_	O
224	(	_	_	O
225	TTP	_	_	O
226	)	_	_	O
227	,	_	_	O
228	TTF	_	_	O
229	,	_	_	O
230	and	_	_	O
231	OS	_	_	O
232	.	_	_	O

233	Two	_	_	O
234	hundred	_	_	O
235	eighty-nine	_	_	O
236	patients	_	_	O
237	were	_	_	O
238	assessable	_	_	O
239	for	_	_	O
240	response	_	_	O
241	,	_	_	O
242	and	_	_	O
243	99	_	_	O
244	responders	_	_	O
245	were	_	_	O
246	assessable	_	_	O
247	for	_	_	O
248	response	_	_	O
249	duration	_	_	O
250	(	_	_	O
251	RD	_	_	O
252	)	_	_	O
253	.	_	_	O

254	The	_	_	B-Premise
255	response	_	_	I-Premise
256	rates	_	_	I-Premise
257	,	_	_	I-Premise
258	QOL	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	I-Premise
261	median	_	_	I-Premise
262	RD	_	_	I-Premise
263	,	_	_	I-Premise
264	TTP	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	TTF	_	_	I-Premise
268	were	_	_	I-Premise
269	not	_	_	I-Premise
270	significantly	_	_	I-Premise
271	different	_	_	I-Premise
272	between	_	_	I-Premise
273	the	_	_	I-Premise
274	arms	_	_	I-Premise
275	.	_	_	I-Premise

276	Median	_	_	B-Premise
277	OS	_	_	I-Premise
278	was	_	_	I-Premise
279	13.8	_	_	I-Premise
280	months	_	_	I-Premise
281	for	_	_	I-Premise
282	arm	_	_	I-Premise
283	1	_	_	I-Premise
284	versus	_	_	I-Premise
285	14.4	_	_	I-Premise
286	months	_	_	I-Premise
287	for	_	_	I-Premise
288	arm	_	_	I-Premise
289	2	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=.4	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Grade	_	_	B-Premise
296	3	_	_	I-Premise
297	or	_	_	I-Premise
298	4	_	_	I-Premise
299	granulocytopenia	_	_	I-Premise
300	was	_	_	I-Premise
301	equivalent	_	_	I-Premise
302	in	_	_	I-Premise
303	both	_	_	I-Premise
304	arms	_	_	I-Premise
305	but	_	_	I-Premise
306	more	_	_	I-Premise
307	grade	_	_	I-Premise
308	3/4	_	_	I-Premise
309	neurotoxicity	_	_	I-Premise
310	,	_	_	I-Premise
311	mild	_	_	I-Premise
312	venous	_	_	I-Premise
313	toxicity	_	_	I-Premise
314	,	_	_	I-Premise
315	and	_	_	I-Premise
316	FN	_	_	I-Premise
317	were	_	_	I-Premise
318	seen	_	_	I-Premise
319	on	_	_	I-Premise
320	arm	_	_	I-Premise
321	1	_	_	I-Premise
322	.	_	_	I-Premise

323	The	_	_	B-Claim
324	survival	_	_	I-Claim
325	with	_	_	I-Claim
326	DOX	_	_	I-Claim
327	and	_	_	I-Claim
328	VNB	_	_	I-Claim
329	is	_	_	I-Claim
330	not	_	_	I-Claim
331	superior	_	_	I-Claim
332	to	_	_	I-Claim
333	DOX	_	_	I-Claim
334	alone	_	_	I-Claim
335	in	_	_	I-Claim
336	MBC	_	_	I-Claim
337	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	additional	_	_	O
4	intraocular	_	_	O
5	pressure-lowering	_	_	O
6	effect	_	_	O
7	of	_	_	O
8	latanoprost	_	_	O
9	0.005	_	_	O
10	%	_	_	O
11	administered	_	_	O
12	once	_	_	O
13	daily	_	_	O
14	with	_	_	O
15	that	_	_	O
16	of	_	_	O
17	pilocarpine	_	_	O
18	2	_	_	O
19	%	_	_	O
20	administered	_	_	O
21	three	_	_	O
22	times	_	_	O
23	daily	_	_	O
24	in	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	primary	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	currently	_	_	O
34	on	_	_	O
35	monotherapy	_	_	O
36	with	_	_	O
37	timolol	_	_	O
38	0.5	_	_	O
39	%	_	_	O
40	twice	_	_	O
41	daily	_	_	O
42	.	_	_	O

43	In	_	_	O
44	a	_	_	O
45	6-month	_	_	O
46	,	_	_	O
47	multicenter	_	_	O
48	,	_	_	O
49	randomized	_	_	O
50	,	_	_	O
51	open-label	_	_	O
52	study	_	_	O
53	242	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	POAG	_	_	O
57	or	_	_	O
58	OH	_	_	O
59	whose	_	_	O
60	IOP	_	_	O
61	was	_	_	O
62	not	_	_	O
63	controlled	_	_	O
64	with	_	_	O
65	timolol	_	_	O
66	0.5	_	_	O
67	%	_	_	O
68	b.i.d	_	_	O
69	.	_	_	O

70	were	_	_	O
71	enrolled	_	_	O
72	.	_	_	O

73	Eyes	_	_	O
74	had	_	_	O
75	not	_	_	O
76	been	_	_	O
77	treated	_	_	O
78	with	_	_	O
79	pilocarpine	_	_	O
80	and	_	_	O
81	latanoprost	_	_	O
82	for	_	_	O
83	at	_	_	O
84	least	_	_	O
85	2	_	_	O
86	years	_	_	O
87	.	_	_	O

88	An	_	_	O
89	analysis	_	_	O
90	of	_	_	O
91	covariance	_	_	O
92	with	_	_	O
93	diurnal	_	_	O
94	IOP	_	_	O
95	change	_	_	O
96	from	_	_	O
97	baseline	_	_	O
98	to	_	_	O
99	month	_	_	O
100	6	_	_	O
101	for	_	_	O
102	study	_	_	O
103	eyes	_	_	O
104	was	_	_	O
105	performed	_	_	O
106	.	_	_	O

107	Four	_	_	O
108	patients	_	_	O
109	on	_	_	O
110	latanoprost	_	_	O
111	0.005	_	_	O
112	%	_	_	O
113	and	_	_	O
114	35	_	_	O
115	on	_	_	O
116	pilocarpine	_	_	O
117	2	_	_	O
118	%	_	_	O
119	did	_	_	O
120	not	_	_	O
121	complete	_	_	O
122	the	_	_	O
123	study	_	_	O
124	(	_	_	O
125	P	_	_	O
126	<	_	_	O
127	0.001	_	_	O
128	)	_	_	O
129	.	_	_	O

130	Two	_	_	O
131	hundred	_	_	O
132	and	_	_	O
133	forty	_	_	O
134	patients	_	_	O
135	were	_	_	O
136	included	_	_	O
137	in	_	_	O
138	the	_	_	O
139	intent-to-treat	_	_	O
140	analysis	_	_	O
141	.	_	_	O

142	For	_	_	B-Premise
143	both	_	_	I-Premise
144	treatments	_	_	I-Premise
145	the	_	_	I-Premise
146	diurnal	_	_	I-Premise
147	IOP	_	_	I-Premise
148	reduction	_	_	I-Premise
149	after	_	_	I-Premise
150	6	_	_	I-Premise
151	months	_	_	I-Premise
152	was	_	_	I-Premise
153	statistically	_	_	I-Premise
154	significant	_	_	I-Premise
155	(	_	_	I-Premise
156	P	_	_	I-Premise
157	<	_	_	I-Premise
158	0.001	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	IOP	_	_	B-Premise
162	(	_	_	I-Premise
163	mean+/-SD	_	_	I-Premise
164	)	_	_	I-Premise
165	was	_	_	I-Premise
166	reduced	_	_	I-Premise
167	from	_	_	I-Premise
168	23.3+/-2.8	_	_	I-Premise
169	to	_	_	I-Premise
170	17.8+/-2.8	_	_	I-Premise
171	(	_	_	I-Premise
172	-5.6	_	_	I-Premise
173	)	_	_	I-Premise
174	mmHg	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	latanoprost	_	_	I-Premise
178	0.005	_	_	I-Premise
179	%	_	_	I-Premise
180	group	_	_	I-Premise
181	and	_	_	I-Premise
182	from	_	_	I-Premise
183	23.0+/-3.2	_	_	I-Premise
184	to	_	_	I-Premise
185	18.5+/-2.4	_	_	I-Premise
186	(	_	_	I-Premise
187	-4.8	_	_	I-Premise
188	)	_	_	I-Premise
189	mmHg	_	_	I-Premise
190	in	_	_	I-Premise
191	pilocarpine	_	_	I-Premise
192	2	_	_	I-Premise
193	%	_	_	I-Premise
194	t.i.d.-treated	_	_	I-Premise
195	eyes	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	mean	_	_	I-Premise
199	difference	_	_	I-Premise
200	of	_	_	I-Premise
201	-0.8	_	_	I-Premise
202	mmHg	_	_	I-Premise
203	(	_	_	I-Premise
204	per	_	_	I-Premise
205	protocol	_	_	I-Premise
206	,	_	_	I-Premise
207	PP	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	-1.6	_	_	I-Premise
211	mmHg	_	_	I-Premise
212	(	_	_	I-Premise
213	intend-to-treat	_	_	I-Premise
214	,	_	_	I-Premise
215	ITT	_	_	I-Premise
216	)	_	_	I-Premise
217	was	_	_	I-Premise
218	statistically	_	_	I-Premise
219	significant	_	_	I-Premise
220	(	_	_	I-Premise
221	P	_	_	I-Premise
222	<	_	_	I-Premise
223	0.04	_	_	I-Premise
224	,	_	_	I-Premise
225	PP	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0.001	_	_	I-Premise
230	,	_	_	I-Premise
231	ITT	_	_	I-Premise
232	)	_	_	I-Premise
233	in	_	_	I-Premise
234	favor	_	_	I-Premise
235	of	_	_	I-Premise
236	latanoprost	_	_	I-Premise
237	0.005	_	_	I-Premise
238	%	_	_	I-Premise
239	.	_	_	I-Premise

240	Two	_	_	B-Premise
241	eyes	_	_	I-Premise
242	treated	_	_	I-Premise
243	with	_	_	I-Premise
244	latanoprost	_	_	I-Premise
245	showed	_	_	I-Premise
246	an	_	_	I-Premise
247	iris	_	_	I-Premise
248	color	_	_	I-Premise
249	change	_	_	I-Premise
250	.	_	_	I-Premise

251	Thirty-six	_	_	B-Premise
252	patients	_	_	I-Premise
253	in	_	_	I-Premise
254	the	_	_	I-Premise
255	latanoprost	_	_	I-Premise
256	group	_	_	I-Premise
257	and	_	_	I-Premise
258	106	_	_	I-Premise
259	in	_	_	I-Premise
260	the	_	_	I-Premise
261	pilocarpine	_	_	I-Premise
262	2	_	_	I-Premise
263	%	_	_	I-Premise
264	group	_	_	I-Premise
265	reported	_	_	I-Premise
266	ocular	_	_	I-Premise
267	adverse	_	_	I-Premise
268	events	_	_	I-Premise
269	(	_	_	I-Premise
270	P	_	_	I-Premise
271	<	_	_	I-Premise
272	0.001	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	From	_	_	B-Claim
276	the	_	_	I-Claim
277	data	_	_	I-Claim
278	we	_	_	I-Claim
279	conclude	_	_	I-Claim
280	that	_	_	I-Claim
281	the	_	_	I-Claim
282	additivity	_	_	I-Claim
283	of	_	_	I-Claim
284	latanoprost	_	_	I-Claim
285	0.005	_	_	I-Claim
286	%	_	_	I-Claim
287	is	_	_	I-Claim
288	at	_	_	I-Claim
289	least	_	_	I-Claim
290	as	_	_	I-Claim
291	effective	_	_	I-Claim
292	as	_	_	I-Claim
293	pilocarpine	_	_	I-Claim
294	2	_	_	I-Claim
295	%	_	_	I-Claim
296	t.i.d	_	_	I-Claim
297	.	_	_	I-Claim

298	in	_	_	I-Claim
299	reducing	_	_	I-Claim
300	IOP	_	_	I-Claim
301	when	_	_	I-Claim
302	added	_	_	I-Claim
303	to	_	_	I-Claim
304	eyes	_	_	I-Claim
305	currently	_	_	I-Claim
306	on	_	_	I-Claim
307	monotherapy	_	_	I-Claim
308	with	_	_	I-Claim
309	timolol	_	_	I-Claim
310	0.5	_	_	I-Claim
311	%	_	_	I-Claim
312	b.i.d	_	_	I-Claim
313	.	_	_	I-Claim

314	Latanoprost	_	_	B-Claim
315	was	_	_	I-Claim
316	better	_	_	I-Claim
317	tolerated	_	_	I-Claim
318	than	_	_	I-Claim
319	pilocarpine	_	_	I-Claim
320	2	_	_	I-Claim
321	%	_	_	I-Claim
322	eye	_	_	I-Claim
323	drops	_	_	I-Claim
324	in	_	_	I-Claim
325	this	_	_	I-Claim
326	study	_	_	I-Claim
327	.	_	_	I-Claim

328	The	_	_	B-Claim
329	increase	_	_	I-Claim
330	in	_	_	I-Claim
331	iris	_	_	I-Claim
332	pigmentation	_	_	I-Claim
333	requires	_	_	I-Claim
334	further	_	_	I-Claim
335	investigation	_	_	I-Claim
336	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	project	_	_	O
5	was	_	_	O
6	to	_	_	O
7	identify	_	_	O
8	clinical	_	_	O
9	and	_	_	O
10	quality	_	_	O
11	of	_	_	O
12	life	_	_	O
13	(	_	_	O
14	QL	_	_	O
15	)	_	_	O
16	factors	_	_	O
17	that	_	_	O
18	together	_	_	O
19	predict	_	_	O
20	survival	_	_	O
21	and	_	_	O
22	response	_	_	O
23	to	_	_	O
24	chemotherapy	_	_	O
25	in	_	_	O
26	advanced	_	_	O
27	breast	_	_	O
28	cancer	_	_	O
29	.	_	_	O

30	Potential	_	_	O
31	prognostic	_	_	O
32	factors	_	_	O
33	were	_	_	O
34	studied	_	_	O
35	in	_	_	O
36	187	_	_	O
37	women	_	_	O
38	with	_	_	O
39	baseline	_	_	O
40	QL	_	_	O
41	data	_	_	O
42	from	_	_	O
43	a	_	_	O
44	trial	_	_	O
45	of	_	_	O
46	paclitaxel	_	_	O
47	versus	_	_	O
48	doxorubicin	_	_	O
49	as	_	_	O
50	first-line	_	_	O
51	chemotherapy	_	_	O
52	.	_	_	O

53	Demographic	_	_	O
54	and	_	_	O
55	clinical	_	_	O
56	factors	_	_	O
57	studied	_	_	O
58	were	_	_	O
59	age	_	_	O
60	,	_	_	O
61	performance	_	_	O
62	status	_	_	O
63	,	_	_	O
64	dominant	_	_	O
65	site	_	_	O
66	of	_	_	O
67	disease	_	_	O
68	and	_	_	O
69	preceding	_	_	O
70	disease-free	_	_	O
71	interval	_	_	O
72	(	_	_	O
73	DFI	_	_	O
74	)	_	_	O
75	.	_	_	O

76	Factors	_	_	O
77	from	_	_	O
78	the	_	_	O
79	EORTC	_	_	O
80	QLQ-C30	_	_	O
81	were	_	_	O
82	all	_	_	O
83	function	_	_	O
84	scales	_	_	O
85	,	_	_	O
86	fatigue	_	_	O
87	,	_	_	O
88	nausea/vomiting	_	_	O
89	,	_	_	O
90	pain	_	_	O
91	,	_	_	O
92	dyspnoea	_	_	O
93	,	_	_	O
94	insomnia	_	_	O
95	,	_	_	O
96	loss	_	_	O
97	of	_	_	O
98	appetite	_	_	O
99	and	_	_	O
100	global	_	_	O
101	QL	_	_	O
102	.	_	_	O

103	The	_	_	O
104	proportional	_	_	O
105	hazards	_	_	O
106	regression	_	_	O
107	model	_	_	O
108	with	_	_	O
109	stratification	_	_	O
110	for	_	_	O
111	treatment	_	_	O
112	,	_	_	O
113	and	_	_	O
114	the	_	_	O
115	logistic	_	_	O
116	regression	_	_	O
117	model	_	_	O
118	adjusting	_	_	O
119	for	_	_	O
120	treatment	_	_	O
121	arm	_	_	O
122	were	_	_	O
123	used	_	_	O
124	for	_	_	O
125	univariate	_	_	O
126	and	_	_	O
127	multivariate	_	_	O
128	analyses	_	_	O
129	of	_	_	O
130	survival	_	_	O
131	and	_	_	O
132	response	_	_	O
133	to	_	_	O
134	treatment	_	_	O
135	,	_	_	O
136	respectively	_	_	O
137	.	_	_	O

138	For	_	_	B-Premise
139	survival	_	_	I-Premise
140	,	_	_	I-Premise
141	multiple	_	_	I-Premise
142	sites	_	_	I-Premise
143	of	_	_	I-Premise
144	visceral	_	_	I-Premise
145	disease	_	_	I-Premise
146	,	_	_	I-Premise
147	pain	_	_	I-Premise
148	,	_	_	I-Premise
149	global	_	_	I-Premise
150	QL	_	_	I-Premise
151	and	_	_	I-Premise
152	fatigue	_	_	I-Premise
153	were	_	_	I-Premise
154	significant	_	_	I-Premise
155	prognostic	_	_	I-Premise
156	factors	_	_	I-Premise
157	in	_	_	I-Premise
158	the	_	_	I-Premise
159	univariate	_	_	I-Premise
160	analysis	_	_	I-Premise
161	.	_	_	I-Premise

162	The	_	_	B-Premise
163	final	_	_	I-Premise
164	multivariate	_	_	I-Premise
165	model	_	_	I-Premise
166	predicted	_	_	I-Premise
167	poor	_	_	I-Premise
168	survival	_	_	I-Premise
169	with	_	_	I-Premise
170	multiple	_	_	I-Premise
171	sites	_	_	I-Premise
172	of	_	_	I-Premise
173	visceral	_	_	I-Premise
174	disease	_	_	I-Premise
175	(	_	_	I-Premise
176	P=0.003	_	_	I-Premise
177	)	_	_	I-Premise
178	,	_	_	I-Premise
179	DFI	_	_	I-Premise
180	<	_	_	I-Premise
181	/=2	_	_	I-Premise
182	years	_	_	I-Premise
183	(	_	_	I-Premise
184	P=0.026	_	_	I-Premise
185	)	_	_	I-Premise
186	and	_	_	I-Premise
187	pain	_	_	I-Premise
188	(	_	_	I-Premise
189	P=0.003	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	For	_	_	B-Premise
193	response	_	_	I-Premise
194	,	_	_	I-Premise
195	age	_	_	I-Premise
196	,	_	_	I-Premise
197	dyspnoea	_	_	I-Premise
198	,	_	_	I-Premise
199	fatigue	_	_	I-Premise
200	and	_	_	I-Premise
201	global	_	_	I-Premise
202	QL	_	_	I-Premise
203	were	_	_	I-Premise
204	significant	_	_	I-Premise
205	predictive	_	_	I-Premise
206	factors	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	univariate	_	_	I-Premise
210	analysis	_	_	I-Premise
211	.	_	_	I-Premise

212	The	_	_	B-Premise
213	final	_	_	I-Premise
214	multivariate	_	_	I-Premise
215	model	_	_	I-Premise
216	for	_	_	I-Premise
217	response	_	_	I-Premise
218	selected	_	_	I-Premise
219	DFI	_	_	I-Premise
220	(	_	_	I-Premise
221	P=0.009	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	multiple	_	_	I-Premise
225	sites	_	_	I-Premise
226	of	_	_	I-Premise
227	visceral	_	_	I-Premise
228	disease	_	_	I-Premise
229	(	_	_	I-Premise
230	P=0.037	_	_	I-Premise
231	)	_	_	I-Premise
232	and	_	_	I-Premise
233	dyspnoea	_	_	I-Premise
234	(	_	_	I-Premise
235	P=	_	_	I-Premise
236	<	_	_	I-Premise
237	0.001	_	_	I-Premise
238	)	_	_	I-Premise
239	using	_	_	I-Premise
240	forward	_	_	I-Premise
241	selection	_	_	I-Premise
242	,	_	_	I-Premise
243	but	_	_	B-Premise
244	model	_	_	I-Premise
245	instability	_	_	I-Premise
246	was	_	_	I-Premise
247	indicated	_	_	I-Premise
248	by	_	_	I-Premise
249	the	_	_	I-Premise
250	inclusion	_	_	I-Premise
251	of	_	_	I-Premise
252	fatigue	_	_	I-Premise
253	and	_	_	I-Premise
254	emotional	_	_	I-Premise
255	function	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	final	_	_	I-Premise
259	model	_	_	I-Premise
260	when	_	_	I-Premise
261	backward	_	_	I-Premise
262	selection	_	_	I-Premise
263	was	_	_	I-Premise
264	used	_	_	I-Premise
265	.	_	_	I-Premise

266	In	_	_	O
267	addition	_	_	O
268	to	_	_	O
269	known	_	_	O
270	clinical	_	_	O
271	factors	_	_	O
272	,	_	_	O
273	patient-assessed	_	_	B-Claim
274	QL	_	_	I-Claim
275	variables	_	_	I-Claim
276	appear	_	_	I-Claim
277	to	_	_	I-Claim
278	be	_	_	I-Claim
279	prognostic	_	_	I-Claim
280	for	_	_	I-Claim
281	survival	_	_	I-Claim
282	and	_	_	I-Claim
283	response	_	_	I-Claim
284	to	_	_	I-Claim
285	chemotherapy	_	_	I-Claim
286	in	_	_	I-Claim
287	women	_	_	I-Claim
288	with	_	_	I-Claim
289	advanced	_	_	I-Claim
290	breast	_	_	I-Claim
291	cancer	_	_	I-Claim
292	.	_	_	I-Claim

293	However	_	_	B-Claim
294	,	_	_	I-Claim
295	identification	_	_	I-Claim
296	of	_	_	I-Claim
297	prognostic	_	_	I-Claim
298	factors	_	_	I-Claim
299	from	_	_	I-Claim
300	responses	_	_	I-Claim
301	to	_	_	I-Claim
302	questionnaires	_	_	I-Claim
303	may	_	_	I-Claim
304	be	_	_	I-Claim
305	unstable	_	_	I-Claim
306	,	_	_	I-Claim
307	and	_	_	I-Claim
308	their	_	_	I-Claim
309	reliability	_	_	I-Claim
310	and	_	_	I-Claim
311	clinical	_	_	I-Claim
312	utility	_	_	I-Claim
313	should	_	_	I-Claim
314	be	_	_	I-Claim
315	tested	_	_	I-Claim
316	prospectively	_	_	I-Claim
317	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	previous	_	_	O
3	study	_	_	O
4	of	_	_	O
5	treatment	_	_	O
6	for	_	_	O
7	advanced	_	_	O
8	colorectal	_	_	O
9	cancer	_	_	O
10	,	_	_	O
11	the	_	_	O
12	LV5FU2	_	_	O
13	regimen	_	_	O
14	,	_	_	O
15	comprising	_	_	O
16	leucovorin	_	_	O
17	(	_	_	O
18	LV	_	_	O
19	)	_	_	O
20	plus	_	_	O
21	bolus	_	_	O
22	and	_	_	O
23	infusional	_	_	O
24	fluorouracil	_	_	O
25	(	_	_	O
26	5FU	_	_	O
27	)	_	_	O
28	every	_	_	O
29	2	_	_	O
30	weeks	_	_	O
31	,	_	_	O
32	was	_	_	O
33	superior	_	_	O
34	to	_	_	O
35	the	_	_	O
36	standard	_	_	O
37	North	_	_	O
38	Central	_	_	O
39	Cancer	_	_	O
40	Treatment	_	_	O
41	Group/Mayo	_	_	O
42	Clinic	_	_	O
43	5-day	_	_	O
44	bolus	_	_	O
45	5FU/LV	_	_	O
46	regimen	_	_	O
47	.	_	_	O

48	This	_	_	O
49	phase	_	_	O
50	III	_	_	O
51	study	_	_	O
52	investigated	_	_	O
53	the	_	_	O
54	effect	_	_	O
55	of	_	_	O
56	combining	_	_	O
57	oxaliplatin	_	_	O
58	with	_	_	O
59	LV5FU2	_	_	O
60	,	_	_	O
61	with	_	_	O
62	progression-free	_	_	O
63	survival	_	_	O
64	as	_	_	O
65	the	_	_	O
66	primary	_	_	O
67	end	_	_	O
68	point	_	_	O
69	.	_	_	O

70	Four	_	_	O
71	hundred	_	_	O
72	twenty	_	_	O
73	previously	_	_	O
74	untreated	_	_	O
75	patients	_	_	O
76	with	_	_	O
77	measurable	_	_	O
78	disease	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	a	_	_	O
84	2-hour	_	_	O
85	infusion	_	_	O
86	of	_	_	O
87	LV	_	_	O
88	(	_	_	O
89	200	_	_	O
90	mg/m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	/d	_	_	O
95	)	_	_	O
96	followed	_	_	O
97	by	_	_	O
98	a	_	_	O
99	5FU	_	_	O
100	bolus	_	_	O
101	(	_	_	O
102	400	_	_	O
103	mg/m	_	_	O
104	(	_	_	O
105	2	_	_	O
106	)	_	_	O
107	/d	_	_	O
108	)	_	_	O
109	and	_	_	O
110	22-hour	_	_	O
111	infusion	_	_	O
112	(	_	_	O
113	600	_	_	O
114	mg/m	_	_	O
115	(	_	_	O
116	2	_	_	O
117	)	_	_	O
118	/d	_	_	O
119	)	_	_	O
120	for	_	_	O
121	2	_	_	O
122	consecutive	_	_	O
123	days	_	_	O
124	every	_	_	O
125	2	_	_	O
126	weeks	_	_	O
127	,	_	_	O
128	either	_	_	O
129	alone	_	_	O
130	or	_	_	O
131	together	_	_	O
132	with	_	_	O
133	oxaliplatin	_	_	O
134	85	_	_	O
135	mg/m	_	_	O
136	(	_	_	O
137	2	_	_	O
138	)	_	_	O
139	as	_	_	O
140	a	_	_	O
141	2-hour	_	_	O
142	infusion	_	_	O
143	on	_	_	O
144	day	_	_	O
145	1	_	_	O
146	.	_	_	O

147	Patients	_	_	B-Premise
148	allocated	_	_	I-Premise
149	to	_	_	I-Premise
150	oxaliplatin	_	_	I-Premise
151	plus	_	_	I-Premise
152	LV5FU2	_	_	I-Premise
153	had	_	_	I-Premise
154	significantly	_	_	I-Premise
155	longer	_	_	I-Premise
156	progression-free	_	_	I-Premise
157	survival	_	_	I-Premise
158	(	_	_	I-Premise
159	median	_	_	I-Premise
160	,	_	_	I-Premise
161	9.0	_	_	I-Premise
162	v	_	_	I-Premise
163	6.2	_	_	I-Premise
164	months	_	_	I-Premise
165	;	_	_	I-Premise
166	P	_	_	I-Premise
167	=.0003	_	_	I-Premise
168	)	_	_	I-Premise
169	and	_	_	I-Premise
170	better	_	_	I-Premise
171	response	_	_	I-Premise
172	rate	_	_	I-Premise
173	(	_	_	I-Premise
174	50.7	_	_	I-Premise
175	%	_	_	I-Premise
176	v	_	_	I-Premise
177	22.3	_	_	I-Premise
178	%	_	_	I-Premise
179	;	_	_	I-Premise
180	P	_	_	I-Premise
181	=.0001	_	_	I-Premise
182	)	_	_	I-Premise
183	when	_	_	I-Premise
184	compared	_	_	I-Premise
185	with	_	_	I-Premise
186	the	_	_	I-Premise
187	control	_	_	I-Premise
188	arm	_	_	I-Premise
189	.	_	_	I-Premise

190	The	_	_	B-Premise
191	improvement	_	_	I-Premise
192	in	_	_	I-Premise
193	overall	_	_	I-Premise
194	survival	_	_	I-Premise
195	did	_	_	I-Premise
196	not	_	_	I-Premise
197	reach	_	_	I-Premise
198	significance	_	_	I-Premise
199	(	_	_	I-Premise
200	median	_	_	I-Premise
201	,	_	_	I-Premise
202	16.2	_	_	I-Premise
203	v	_	_	I-Premise
204	14.7	_	_	I-Premise
205	months	_	_	I-Premise
206	;	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.	_	_	I-Premise

210	12	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	LV5FU2	_	_	B-Premise
214	plus	_	_	I-Premise
215	oxaliplatin	_	_	I-Premise
216	gave	_	_	I-Premise
217	higher	_	_	I-Premise
218	frequencies	_	_	I-Premise
219	of	_	_	I-Premise
220	National	_	_	I-Premise
221	Cancer	_	_	I-Premise
222	Institute	_	_	I-Premise
223	common	_	_	I-Premise
224	toxicity	_	_	I-Premise
225	criteria	_	_	I-Premise
226	grade	_	_	I-Premise
227	3/4	_	_	I-Premise
228	neutropenia	_	_	I-Premise
229	(	_	_	I-Premise
230	41	_	_	I-Premise
231	.	_	_	I-Premise

232	7	_	_	I-Premise
233	%	_	_	I-Premise
234	v	_	_	I-Premise
235	5.3	_	_	I-Premise
236	%	_	_	I-Premise
237	of	_	_	I-Premise
238	patients	_	_	I-Premise
239	)	_	_	I-Premise
240	,	_	_	I-Premise
241	grade	_	_	I-Premise
242	3/4	_	_	I-Premise
243	diarrhea	_	_	I-Premise
244	(	_	_	I-Premise
245	11.9	_	_	I-Premise
246	%	_	_	I-Premise
247	v	_	_	I-Premise
248	5.3	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	grade	_	_	I-Premise
254	3	_	_	I-Premise
255	neurosensory	_	_	I-Premise
256	toxicity	_	_	I-Premise
257	(	_	_	I-Premise
258	18.2	_	_	I-Premise
259	%	_	_	I-Premise
260	v	_	_	I-Premise
261	0	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	but	_	_	I-Premise
266	this	_	_	I-Premise
267	did	_	_	I-Premise
268	not	_	_	I-Premise
269	result	_	_	I-Premise
270	in	_	_	I-Premise
271	impairment	_	_	I-Premise
272	of	_	_	I-Premise
273	quality	_	_	I-Premise
274	of	_	_	I-Premise
275	life	_	_	I-Premise
276	(	_	_	I-Premise
277	QoL	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Survival	_	_	B-Premise
281	without	_	_	I-Premise
282	disease	_	_	I-Premise
283	progression	_	_	I-Premise
284	or	_	_	I-Premise
285	deterioration	_	_	I-Premise
286	in	_	_	I-Premise
287	global	_	_	I-Premise
288	health	_	_	I-Premise
289	status	_	_	I-Premise
290	was	_	_	I-Premise
291	longer	_	_	I-Premise
292	in	_	_	I-Premise
293	patients	_	_	I-Premise
294	allocated	_	_	I-Premise
295	to	_	_	I-Premise
296	oxaliplatin	_	_	I-Premise
297	treatment	_	_	I-Premise
298	(	_	_	I-Premise
299	P	_	_	I-Premise
300	=.004	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	B-Claim
304	LV5FU2-oxaliplatin	_	_	I-Claim
305	combination	_	_	I-Claim
306	seems	_	_	I-Claim
307	beneficial	_	_	I-Claim
308	as	_	_	I-Claim
309	first-line	_	_	I-Claim
310	therapy	_	_	I-Claim
311	in	_	_	I-Claim
312	advanced	_	_	I-Claim
313	colorectal	_	_	I-Claim
314	cancer	_	_	I-Claim
315	,	_	_	I-Claim
316	demonstrating	_	_	I-Claim
317	a	_	_	I-Claim
318	prolonged	_	_	I-Claim
319	progression-free	_	_	I-Claim
320	survival	_	_	I-Claim
321	with	_	_	I-Claim
322	acceptable	_	_	I-Claim
323	tolerability	_	_	I-Claim
324	and	_	_	I-Claim
325	maintenance	_	_	I-Claim
326	of	_	_	I-Claim
327	QoL	_	_	I-Claim
328	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	short-	_	_	O
4	and	_	_	O
5	intermediate-term	_	_	O
6	results	_	_	O
7	of	_	_	O
8	two	_	_	O
9	commonly	_	_	O
10	used	_	_	O
11	glaucoma	_	_	O
12	surgical	_	_	O
13	procedures	_	_	O
14	,	_	_	O
15	trabeculectomy	_	_	O
16	and	_	_	O
17	Ahmed	_	_	O
18	glaucoma	_	_	O
19	valve	_	_	O
20	implant	_	_	O
21	.	_	_	O

22	A	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	was	_	_	O
27	performed	_	_	O
28	at	_	_	O
29	two	_	_	O
30	international	_	_	O
31	centers	_	_	O
32	.	_	_	O

33	One	_	_	O
34	eye	_	_	O
35	each	_	_	O
36	of	_	_	O
37	consecutive	_	_	O
38	patients	_	_	O
39	requiring	_	_	O
40	glaucoma	_	_	O
41	surgery	_	_	O
42	for	_	_	O
43	intraocular	_	_	O
44	pressure	_	_	O
45	control	_	_	O
46	was	_	_	O
47	randomized	_	_	O
48	to	_	_	O
49	receive	_	_	O
50	either	_	_	O
51	trabeculectomy	_	_	O
52	or	_	_	O
53	the	_	_	O
54	Ahmed	_	_	O
55	implant	_	_	O
56	.	_	_	O

57	Of	_	_	O
58	the	_	_	O
59	117	_	_	O
60	patients	_	_	O
61	,	_	_	O
62	62	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	trabeculectomy	_	_	O
67	and	_	_	O
68	55	_	_	O
69	to	_	_	O
70	the	_	_	O
71	Ahmed	_	_	O
72	implant	_	_	O
73	.	_	_	O

74	With	_	_	B-Premise
75	a	_	_	I-Premise
76	mean	_	_	I-Premise
77	follow-up	_	_	I-Premise
78	of	_	_	I-Premise
79	9.7	_	_	I-Premise
80	months	_	_	I-Premise
81	,	_	_	I-Premise
82	the	_	_	I-Premise
83	trabeculectomy	_	_	I-Premise
84	group	_	_	I-Premise
85	had	_	_	I-Premise
86	statistically	_	_	I-Premise
87	lower	_	_	I-Premise
88	intraocular	_	_	I-Premise
89	pressures	_	_	I-Premise
90	at	_	_	I-Premise
91	weeks	_	_	I-Premise
92	6	_	_	I-Premise
93	to	_	_	I-Premise
94	15	_	_	I-Premise
95	(	_	_	I-Premise
96	12.6	_	_	I-Premise
97	mm	_	_	I-Premise
98	Hg	_	_	I-Premise
99	vs	_	_	I-Premise
100	16.4	_	_	I-Premise
101	mm	_	_	I-Premise
102	Hg	_	_	I-Premise
103	)	_	_	I-Premise
104	and	_	_	I-Premise
105	months	_	_	I-Premise
106	11	_	_	I-Premise
107	to	_	_	I-Premise
108	13	_	_	I-Premise
109	(	_	_	I-Premise
110	11.4	_	_	I-Premise
111	mm	_	_	I-Premise
112	Hg	_	_	I-Premise
113	vs	_	_	I-Premise
114	17.2	_	_	I-Premise
115	mm	_	_	I-Premise
116	Hg	_	_	I-Premise
117	)	_	_	I-Premise
118	than	_	_	I-Premise
119	the	_	_	I-Premise
120	Ahmed	_	_	I-Premise
121	implant	_	_	I-Premise
122	group	_	_	I-Premise
123	.	_	_	I-Premise

124	Compared	_	_	B-Premise
125	with	_	_	I-Premise
126	preoperative	_	_	I-Premise
127	status	_	_	I-Premise
128	,	_	_	I-Premise
129	no	_	_	I-Premise
130	statistically	_	_	I-Premise
131	significant	_	_	I-Premise
132	differences	_	_	I-Premise
133	between	_	_	I-Premise
134	groups	_	_	I-Premise
135	were	_	_	I-Premise
136	noted	_	_	I-Premise
137	for	_	_	I-Premise
138	visual	_	_	I-Premise
139	acuity	_	_	I-Premise
140	,	_	_	I-Premise
141	visual	_	_	I-Premise
142	field	_	_	I-Premise
143	,	_	_	I-Premise
144	lens	_	_	I-Premise
145	status	_	_	I-Premise
146	,	_	_	I-Premise
147	and	_	_	I-Premise
148	final	_	_	I-Premise
149	anterior	_	_	I-Premise
150	chamber	_	_	I-Premise
151	depth	_	_	I-Premise
152	.	_	_	I-Premise

153	The	_	_	B-Premise
154	cumulative	_	_	I-Premise
155	probabilities	_	_	I-Premise
156	of	_	_	I-Premise
157	success	_	_	I-Premise
158	(	_	_	I-Premise
159	intraocular	_	_	I-Premise
160	pressure	_	_	I-Premise
161	<	_	_	I-Premise
162	21	_	_	I-Premise
163	mm	_	_	I-Premise
164	Hg	_	_	I-Premise
165	and	_	_	I-Premise
166	at	_	_	I-Premise
167	least	_	_	I-Premise
168	15	_	_	I-Premise
169	%	_	_	I-Premise
170	reduction	_	_	I-Premise
171	in	_	_	I-Premise
172	intraocular	_	_	I-Premise
173	pressure	_	_	I-Premise
174	from	_	_	I-Premise
175	preoperative	_	_	I-Premise
176	level	_	_	I-Premise
177	)	_	_	I-Premise
178	were	_	_	I-Premise
179	83.6	_	_	I-Premise
180	%	_	_	I-Premise
181	for	_	_	I-Premise
182	trabeculectomy	_	_	I-Premise
183	and	_	_	I-Premise
184	88.1	_	_	I-Premise
185	%	_	_	I-Premise
186	for	_	_	I-Premise
187	Ahmed	_	_	I-Premise
188	implant	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	=.43	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	However	_	_	O
195	,	_	_	O
196	the	_	_	B-Premise
197	Ahmed	_	_	I-Premise
198	implant	_	_	I-Premise
199	group	_	_	I-Premise
200	had	_	_	I-Premise
201	a	_	_	I-Premise
202	greater	_	_	I-Premise
203	adjunctive	_	_	I-Premise
204	medication	_	_	I-Premise
205	requirement	_	_	I-Premise
206	.	_	_	I-Premise

207	On	_	_	B-Premise
208	the	_	_	I-Premise
209	last	_	_	I-Premise
210	visit	_	_	I-Premise
211	,	_	_	I-Premise
212	10	_	_	I-Premise
213	of	_	_	I-Premise
214	the	_	_	I-Premise
215	trabeculectomy	_	_	I-Premise
216	eyes	_	_	I-Premise
217	and	_	_	I-Premise
218	19	_	_	I-Premise
219	of	_	_	I-Premise
220	the	_	_	I-Premise
221	Ahmed	_	_	I-Premise
222	implant	_	_	I-Premise
223	eyes	_	_	I-Premise
224	required	_	_	I-Premise
225	at	_	_	I-Premise
226	least	_	_	I-Premise
227	one	_	_	I-Premise
228	topical	_	_	I-Premise
229	medication	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=.01	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	There	_	_	B-Premise
236	was	_	_	I-Premise
237	no	_	_	I-Premise
238	statistically	_	_	I-Premise
239	significant	_	_	I-Premise
240	difference	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	rate	_	_	I-Premise
244	of	_	_	I-Premise
245	complications	_	_	I-Premise
246	between	_	_	I-Premise
247	the	_	_	I-Premise
248	two	_	_	I-Premise
249	groups	_	_	I-Premise
250	.	_	_	I-Premise

251	Lower	_	_	B-Premise
252	mean	_	_	I-Premise
253	intraocular	_	_	I-Premise
254	pressures	_	_	I-Premise
255	were	_	_	I-Premise
256	noted	_	_	I-Premise
257	for	_	_	I-Premise
258	the	_	_	I-Premise
259	trabeculectomy	_	_	I-Premise
260	group	_	_	I-Premise
261	.	_	_	I-Premise

262	All	_	_	B-Premise
263	other	_	_	I-Premise
264	results	_	_	I-Premise
265	,	_	_	I-Premise
266	including	_	_	I-Premise
267	success	_	_	I-Premise
268	(	_	_	I-Premise
269	as	_	_	I-Premise
270	defined	_	_	I-Premise
271	in	_	_	I-Premise
272	this	_	_	I-Premise
273	study	_	_	I-Premise
274	)	_	_	I-Premise
275	and	_	_	I-Premise
276	frequency	_	_	I-Premise
277	of	_	_	I-Premise
278	complications	_	_	I-Premise
279	,	_	_	I-Premise
280	were	_	_	I-Premise
281	comparable	_	_	I-Premise
282	between	_	_	I-Premise
283	the	_	_	I-Premise
284	two	_	_	I-Premise
285	groups	_	_	I-Premise
286	.	_	_	I-Premise


0	Postoperative	_	_	B-Claim
1	adjuvant	_	_	I-Claim
2	chemoradiation	_	_	I-Claim
3	treatment	_	_	I-Claim
4	after	_	_	I-Claim
5	curative	_	_	I-Claim
6	resection	_	_	I-Claim
7	for	_	_	I-Claim
8	rectal	_	_	I-Claim
9	cancer	_	_	I-Claim
10	was	_	_	I-Claim
11	needed	_	_	I-Claim
12	to	_	_	I-Claim
13	reduce	_	_	I-Claim
14	recurrence	_	_	I-Claim
15	and	_	_	I-Claim
16	improve	_	_	I-Claim
17	a	_	_	I-Claim
18	survival	_	_	I-Claim
19	rate	_	_	I-Claim
20	.	_	_	I-Claim

21	Intravenous	_	_	B-Claim
22	5-fluorouracil	_	_	I-Claim
23	(	_	_	I-Claim
24	5-FU	_	_	I-Claim
25	)	_	_	I-Claim
26	and	_	_	I-Claim
27	leucovorin	_	_	I-Claim
28	has	_	_	I-Claim
29	been	_	_	I-Claim
30	a	_	_	I-Claim
31	mainstay	_	_	I-Claim
32	of	_	_	I-Claim
33	chemotherapy	_	_	I-Claim
34	,	_	_	I-Claim
35	but	_	_	O
36	oral	_	_	B-Claim
37	5-FU	_	_	I-Claim
38	derivatives	_	_	I-Claim
39	have	_	_	I-Claim
40	been	_	_	I-Claim
41	shown	_	_	I-Claim
42	a	_	_	I-Claim
43	comparable	_	_	I-Claim
44	antitumor	_	_	I-Claim
45	activity	_	_	I-Claim
46	.	_	_	I-Claim

47	Intravenous	_	_	O
48	5-FU	_	_	O
49	and	_	_	O
50	oral	_	_	O
51	doxifluridine	_	_	O
52	were	_	_	O
53	compared	_	_	O
54	with	_	_	O
55	respect	_	_	O
56	to	_	_	O
57	therapeutic	_	_	O
58	efficacy	_	_	O
59	,	_	_	O
60	drug	_	_	O
61	toxicity	_	_	O
62	,	_	_	O
63	and	_	_	O
64	quality	_	_	O
65	of	_	_	O
66	life	_	_	O
67	.	_	_	O

68	A	_	_	O
69	total	_	_	O
70	of	_	_	O
71	166	_	_	O
72	patients	_	_	O
73	were	_	_	O
74	randomized	_	_	O
75	to	_	_	O
76	receive	_	_	O
77	intravenous	_	_	O
78	5-FU	_	_	O
79	(	_	_	O
80	450	_	_	O
81	mg/m2/day	_	_	O
82	)	_	_	O
83	or	_	_	O
84	oral	_	_	O
85	doxifluridine	_	_	O
86	(	_	_	O
87	900	_	_	O
88	mg/m2/day	_	_	O
89	)	_	_	O
90	in	_	_	O
91	combination	_	_	O
92	with	_	_	O
93	leucovorin	_	_	O
94	(	_	_	O
95	20	_	_	O
96	mg/m2/day	_	_	O
97	)	_	_	O
98	for	_	_	O
99	depth	_	_	O
100	of	_	_	O
101	invasion	_	_	O
102	,	_	_	O
103	nodal	_	_	O
104	status	_	_	O
105	,	_	_	O
106	metastasis	_	_	O
107	(	_	_	O
108	TNM	_	_	O
109	)	_	_	O
110	stage	_	_	O
111	II	_	_	O
112	and	_	_	O
113	III	_	_	O
114	patients	_	_	O
115	between	_	_	O
116	October	_	_	O
117	1997	_	_	O
118	and	_	_	O
119	February	_	_	O
120	1999	_	_	O
121	.	_	_	O

122	Consecutive	_	_	O
123	daily	_	_	O
124	intravenous	_	_	O
125	infusion	_	_	O
126	for	_	_	O
127	5	_	_	O
128	days	_	_	O
129	per	_	_	O
130	every	_	_	O
131	month	_	_	O
132	for	_	_	O
133	a	_	_	O
134	total	_	_	O
135	of	_	_	O
136	12	_	_	O
137	cycles	_	_	O
138	(	_	_	O
139	IV	_	_	O
140	arm	_	_	O
141	,	_	_	O
142	n	_	_	O
143	=	_	_	O
144	74	_	_	O
145	)	_	_	O
146	and	_	_	O
147	oral	_	_	O
148	doxifluridine	_	_	O
149	daily	_	_	O
150	for	_	_	O
151	3	_	_	O
152	weeks	_	_	O
153	and	_	_	O
154	1	_	_	O
155	week	_	_	O
156	rest	_	_	O
157	for	_	_	O
158	a	_	_	O
159	total	_	_	O
160	of	_	_	O
161	12	_	_	O
162	cycles	_	_	O
163	(	_	_	O
164	oral	_	_	O
165	arm	_	_	O
166	,	_	_	O
167	n	_	_	O
168	=	_	_	O
169	92	_	_	O
170	)	_	_	O
171	.	_	_	O

172	Drug	_	_	O
173	toxicity	_	_	O
174	and	_	_	O
175	quality	_	_	O
176	of	_	_	O
177	life	_	_	O
178	were	_	_	O
179	observed	_	_	O
180	.	_	_	O

181	Quality	_	_	O
182	of	_	_	O
183	life	_	_	O
184	was	_	_	O
185	scored	_	_	O
186	according	_	_	O
187	to	_	_	O
188	22	_	_	O
189	daily	_	_	O
190	activity	_	_	O
191	items	_	_	O
192	(	_	_	O
193	good	_	_	O
194	,	_	_	O
195	>	_	_	O
196	or	_	_	O
197	=71	_	_	O
198	;	_	_	O
199	fair	_	_	O
200	,	_	_	O
201	<	_	_	O
202	70	_	_	O
203	;	_	_	O
204	poor	_	_	O
205	,	_	_	O
206	<	_	_	O
207	52	_	_	O
208	)	_	_	O
209	.	_	_	O

210	There	_	_	O
211	was	_	_	O
212	no	_	_	O
213	difference	_	_	O
214	of	_	_	O
215	sex	_	_	O
216	between	_	_	O
217	two	_	_	O
218	groups	_	_	O
219	(	_	_	O
220	IV	_	_	O
221	arm	_	_	O
222	:	_	_	O
223	male/female	_	_	O
224	=	_	_	O
225	45/29	_	_	O
226	,	_	_	O
227	oral	_	_	O
228	arm	_	_	O
229	:	_	_	O
230	male/female	_	_	O
231	=	_	_	O
232	59/33	_	_	O
233	)	_	_	O
234	.	_	_	O

235	The	_	_	O
236	mean	_	_	O
237	age	_	_	O
238	was	_	_	O
239	52.3	_	_	O
240	vs.	_	_	O
241	59.5	_	_	O
242	,	_	_	O
243	respectively	_	_	O
244	.	_	_	O

245	There	_	_	O
246	was	_	_	O
247	also	_	_	O
248	no	_	_	O
249	difference	_	_	O
250	of	_	_	O
251	TNM	_	_	O
252	stage	_	_	O
253	distribution	_	_	O
254	and	_	_	O
255	type	_	_	O
256	of	_	_	O
257	operation	_	_	O
258	between	_	_	O
259	groups	_	_	O
260	(	_	_	O
261	P	_	_	O
262	>	_	_	O
263	.05	_	_	O
264	)	_	_	O
265	.	_	_	O

266	Mean	_	_	B-Premise
267	numbers	_	_	I-Premise
268	of	_	_	I-Premise
269	chemotherapy	_	_	I-Premise
270	cycles	_	_	I-Premise
271	were	_	_	I-Premise
272	6.5+/-3.7	_	_	I-Premise
273	(	_	_	I-Premise
274	IV	_	_	I-Premise
275	arm	_	_	I-Premise
276	)	_	_	I-Premise
277	vs.	_	_	I-Premise
278	7.2+/-4.3	_	_	I-Premise
279	(	_	_	I-Premise
280	oral	_	_	I-Premise
281	arm	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	respectively	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	rate	_	_	I-Premise
288	of	_	_	I-Premise
289	recurrence	_	_	I-Premise
290	was	_	_	I-Premise
291	9/74	_	_	I-Premise
292	(	_	_	I-Premise
293	12.1	_	_	I-Premise
294	%	_	_	I-Premise
295	)	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	IV	_	_	I-Premise
299	arm	_	_	I-Premise
300	and	_	_	I-Premise
301	6/92	_	_	I-Premise
302	(	_	_	I-Premise
303	6.5	_	_	I-Premise
304	%	_	_	I-Premise
305	)	_	_	I-Premise
306	in	_	_	I-Premise
307	the	_	_	I-Premise
308	oral	_	_	I-Premise
309	arm	_	_	I-Premise
310	,	_	_	I-Premise
311	respectively	_	_	I-Premise
312	(	_	_	I-Premise
313	P	_	_	I-Premise
314	=	_	_	I-Premise
315	.937	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	Local	_	_	B-Premise
319	recurrence	_	_	I-Premise
320	was	_	_	I-Premise
321	2/74	_	_	I-Premise
322	(	_	_	I-Premise
323	stage	_	_	I-Premise
324	III	_	_	I-Premise
325	;	_	_	I-Premise
326	2.7	_	_	I-Premise
327	%	_	_	I-Premise
328	)	_	_	I-Premise
329	in	_	_	I-Premise
330	the	_	_	I-Premise
331	IV	_	_	I-Premise
332	arm	_	_	I-Premise
333	and	_	_	I-Premise
334	1/92	_	_	I-Premise
335	(	_	_	I-Premise
336	stage	_	_	I-Premise
337	II	_	_	I-Premise
338	;	_	_	I-Premise
339	1.1	_	_	I-Premise
340	%	_	_	I-Premise
341	)	_	_	I-Premise
342	in	_	_	I-Premise
343	the	_	_	I-Premise
344	oral	_	_	I-Premise
345	arm	_	_	I-Premise
346	,	_	_	I-Premise
347	respectively	_	_	I-Premise
348	.	_	_	I-Premise

349	Systemic	_	_	B-Premise
350	recurrence	_	_	I-Premise
351	was	_	_	I-Premise
352	7/74	_	_	I-Premise
353	(	_	_	I-Premise
354	stage	_	_	I-Premise
355	III	_	_	I-Premise
356	;	_	_	I-Premise
357	9.4	_	_	I-Premise
358	%	_	_	I-Premise
359	)	_	_	I-Premise
360	in	_	_	I-Premise
361	the	_	_	I-Premise
362	IV	_	_	I-Premise
363	arm	_	_	I-Premise
364	and	_	_	I-Premise
365	5/92	_	_	I-Premise
366	(	_	_	I-Premise
367	stage	_	_	I-Premise
368	III	_	_	I-Premise
369	;	_	_	I-Premise
370	5.4	_	_	I-Premise
371	%	_	_	I-Premise
372	)	_	_	I-Premise
373	in	_	_	I-Premise
374	the	_	_	I-Premise
375	oral	_	_	I-Premise
376	arm	_	_	I-Premise
377	,	_	_	I-Premise
378	respectively	_	_	I-Premise
379	.	_	_	I-Premise

380	The	_	_	B-Premise
381	most	_	_	I-Premise
382	common	_	_	I-Premise
383	site	_	_	I-Premise
384	of	_	_	I-Premise
385	systemic	_	_	I-Premise
386	recurrence	_	_	I-Premise
387	was	_	_	I-Premise
388	the	_	_	I-Premise
389	liver	_	_	I-Premise
390	.	_	_	I-Premise

391	Toxicity	_	_	B-Premise
392	profile	_	_	I-Premise
393	was	_	_	I-Premise
394	as	_	_	I-Premise
395	follows	_	_	I-Premise
396	:	_	_	I-Premise
397	leukopenia	_	_	I-Premise
398	(	_	_	I-Premise
399	30/74	_	_	I-Premise
400	vs.	_	_	I-Premise
401	17/92	_	_	I-Premise
402	)	_	_	I-Premise
403	and	_	_	I-Premise
404	alopecia	_	_	I-Premise
405	(	_	_	I-Premise
406	21/74	_	_	I-Premise
407	vs.	_	_	I-Premise
408	13/92	_	_	I-Premise
409	)	_	_	I-Premise
410	were	_	_	I-Premise
411	statistically	_	_	I-Premise
412	more	_	_	I-Premise
413	common	_	_	I-Premise
414	in	_	_	I-Premise
415	the	_	_	I-Premise
416	IV	_	_	I-Premise
417	arm	_	_	I-Premise
418	.	_	_	I-Premise

419	Diarrhea	_	_	B-Premise
420	was	_	_	I-Premise
421	more	_	_	I-Premise
422	common	_	_	I-Premise
423	in	_	_	I-Premise
424	the	_	_	I-Premise
425	oral	_	_	I-Premise
426	arm	_	_	I-Premise
427	.	_	_	I-Premise

428	Poor	_	_	B-Premise
429	quality	_	_	I-Premise
430	of	_	_	I-Premise
431	life	_	_	I-Premise
432	score	_	_	I-Premise
433	between	_	_	I-Premise
434	two	_	_	I-Premise
435	groups	_	_	I-Premise
436	was	_	_	I-Premise
437	observed	_	_	I-Premise
438	at	_	_	I-Premise
439	1	_	_	I-Premise
440	month	_	_	I-Premise
441	(	_	_	I-Premise
442	23.9	_	_	I-Premise
443	%	_	_	I-Premise
444	vs.	_	_	I-Premise
445	13	_	_	I-Premise
446	%	_	_	I-Premise
447	)	_	_	I-Premise
448	and	_	_	I-Premise
449	2	_	_	I-Premise
450	months	_	_	I-Premise
451	(	_	_	I-Premise
452	15.8	_	_	I-Premise
453	%	_	_	I-Premise
454	vs.	_	_	I-Premise
455	3.7	_	_	I-Premise
456	%	_	_	I-Premise
457	)	_	_	I-Premise
458	after	_	_	I-Premise
459	chemotherapy	_	_	I-Premise
460	.	_	_	I-Premise

461	Good	_	_	B-Premise
462	quality	_	_	I-Premise
463	of	_	_	I-Premise
464	life	_	_	I-Premise
465	score	_	_	I-Premise
466	was	_	_	I-Premise
467	observed	_	_	I-Premise
468	at	_	_	I-Premise
469	1	_	_	I-Premise
470	month	_	_	I-Premise
471	(	_	_	I-Premise
472	19.5	_	_	I-Premise
473	%	_	_	I-Premise
474	vs.	_	_	I-Premise
475	49	_	_	I-Premise
476	%	_	_	I-Premise
477	)	_	_	I-Premise
478	and	_	_	I-Premise
479	2	_	_	I-Premise
480	months	_	_	I-Premise
481	(	_	_	I-Premise
482	47	_	_	I-Premise
483	%	_	_	I-Premise
484	vs.	_	_	I-Premise
485	72	_	_	I-Premise
486	%	_	_	I-Premise
487	)	_	_	I-Premise
488	,	_	_	I-Premise
489	respectively	_	_	I-Premise
490	(	_	_	I-Premise
491	P	_	_	I-Premise
492	<	_	_	I-Premise
493	.05	_	_	I-Premise
494	)	_	_	I-Premise
495	.	_	_	I-Premise

496	Oral	_	_	B-Claim
497	doxifluridine	_	_	I-Claim
498	with	_	_	I-Claim
499	leucovorin	_	_	I-Claim
500	shows	_	_	I-Claim
501	a	_	_	I-Claim
502	comparable	_	_	I-Claim
503	therapeutic	_	_	I-Claim
504	efficacy	_	_	I-Claim
505	to	_	_	I-Claim
506	intravenous	_	_	I-Claim
507	5-FU	_	_	I-Claim
508	regimen	_	_	I-Claim
509	with	_	_	I-Claim
510	high	_	_	I-Claim
511	quality	_	_	I-Claim
512	of	_	_	I-Claim
513	life	_	_	I-Claim
514	as	_	_	I-Claim
515	postoperative	_	_	I-Claim
516	adjuvant	_	_	I-Claim
517	therapy	_	_	I-Claim
518	.	_	_	I-Claim

519	The	_	_	B-Claim
520	oral	_	_	I-Claim
521	regimen	_	_	I-Claim
522	also	_	_	I-Claim
523	can	_	_	I-Claim
524	be	_	_	I-Claim
525	safely	_	_	I-Claim
526	given	_	_	I-Claim
527	with	_	_	I-Claim
528	appropriate	_	_	I-Claim
529	toxicity	_	_	I-Claim
530	and	_	_	I-Claim
531	tolerability	_	_	I-Claim
532	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	randomised	_	_	O
5	trial	_	_	O
6	was	_	_	O
7	to	_	_	O
8	evaluate	_	_	O
9	the	_	_	O
10	activity	_	_	O
11	and	_	_	O
12	toxicity	_	_	O
13	of	_	_	O
14	a	_	_	O
15	biweekly	_	_	O
16	regimen	_	_	O
17	including	_	_	O
18	6S-leucovorin-modulated	_	_	O
19	5-fluorouracil	_	_	O
20	(	_	_	O
21	LFA-5-FU	_	_	O
22	)	_	_	O
23	,	_	_	O
24	combined	_	_	O
25	with	_	_	O
26	either	_	_	O
27	irinotecan	_	_	O
28	(	_	_	O
29	CPT-11	_	_	O
30	+	_	_	O
31	LFA	_	_	O
32	5-FU	_	_	O
33	)	_	_	O
34	or	_	_	O
35	raltitrexed	_	_	O
36	(	_	_	O
37	Tomudex	_	_	O
38	)	_	_	O
39	(	_	_	O
40	TOM	_	_	O
41	+	_	_	O
42	LFA-5-FU	_	_	O
43	)	_	_	O
44	,	_	_	O
45	in	_	_	O
46	advanced	_	_	O
47	colorectal	_	_	O
48	cancer	_	_	O
49	patients	_	_	O
50	,	_	_	O
51	and	_	_	O
52	to	_	_	O
53	make	_	_	O
54	a	_	_	O
55	preliminary	_	_	O
56	comparison	_	_	O
57	of	_	_	O
58	both	_	_	O
59	these	_	_	O
60	experimental	_	_	O
61	regimens	_	_	O
62	with	_	_	O
63	a	_	_	O
64	biweekly	_	_	O
65	administration	_	_	O
66	of	_	_	O
67	LFA-5-FU	_	_	O
68	modulated	_	_	O
69	by	_	_	O
70	methotrexate	_	_	O
71	(	_	_	O
72	MTX	_	_	O
73	+	_	_	O
74	LFA-5-FU	_	_	O
75	)	_	_	O
76	.	_	_	O

77	One	_	_	O
78	hundred	_	_	O
79	fifty-nine	_	_	O
80	patients	_	_	O
81	with	_	_	O
82	advanced	_	_	O
83	colorectal	_	_	O
84	carcinoma	_	_	O
85	previously	_	_	O
86	untreated	_	_	O
87	for	_	_	O
88	the	_	_	O
89	metastatic	_	_	O
90	disease	_	_	O
91	(	_	_	O
92	34	_	_	O
93	of	_	_	O
94	them	_	_	O
95	previously	_	_	O
96	exposed	_	_	O
97	to	_	_	O
98	adjuvant	_	_	O
99	5-FU	_	_	O
100	)	_	_	O
101	were	_	_	O
102	randomly	_	_	O
103	allocated	_	_	O
104	to	_	_	O
105	receive	_	_	O
106	:	_	_	O
107	CPT-11	_	_	O
108	,	_	_	O
109	200	_	_	O
110	mg/m2	_	_	O
111	i.v	_	_	O
112	.	_	_	O

113	on	_	_	O
114	day	_	_	O
115	1	_	_	O
116	,	_	_	O
117	followed	_	_	O
118	on	_	_	O
119	day	_	_	O
120	2	_	_	O
121	by	_	_	O
122	LFA	_	_	O
123	,	_	_	O
124	250	_	_	O
125	mg/m2	_	_	O
126	i.v	_	_	O
127	.	_	_	O

128	infusion	_	_	O
129	and	_	_	O
130	5-FU	_	_	O
131	,	_	_	O
132	850	_	_	O
133	mg/m2	_	_	O
134	s	_	_	O
135	i.v	_	_	O
136	.	_	_	O

137	bolus	_	_	O
138	(	_	_	O
139	arm	_	_	O
140	A	_	_	O
141	)	_	_	O
142	;	_	_	O
143	TOM	_	_	O
144	,	_	_	O
145	3	_	_	O
146	mg/m2	_	_	O
147	i.v	_	_	O
148	.	_	_	O

149	on	_	_	O
150	day	_	_	O
151	1	_	_	O
152	,	_	_	O
153	followed	_	_	O
154	on	_	_	O
155	day	_	_	O
156	2	_	_	O
157	by	_	_	O
158	LFA	_	_	O
159	,	_	_	O
160	250	_	_	O
161	mg/m2	_	_	O
162	i.v	_	_	O
163	.	_	_	O

164	infusion	_	_	O
165	and	_	_	O
166	5-FU	_	_	O
167	,	_	_	O
168	1050	_	_	O
169	mg/m2	_	_	O
170	i.v	_	_	O
171	.	_	_	O

172	bolus	_	_	O
173	(	_	_	O
174	arm	_	_	O
175	B	_	_	O
176	)	_	_	O
177	;	_	_	O
178	or	_	_	O
179	MTX	_	_	O
180	,	_	_	O
181	750	_	_	O
182	mg/m2	_	_	O
183	i.v	_	_	O
184	.	_	_	O

185	on	_	_	O
186	day	_	_	O
187	1	_	_	O
188	,	_	_	O
189	followed	_	_	O
190	on	_	_	O
191	day	_	_	O
192	2	_	_	O
193	by	_	_	O
194	LFA	_	_	O
195	,	_	_	O
196	250	_	_	O
197	mg/m2	_	_	O
198	i.v	_	_	O
199	.	_	_	O

200	infusion	_	_	O
201	and	_	_	O
202	5-FU	_	_	O
203	,	_	_	O
204	800	_	_	O
205	mg/m2	_	_	O
206	i.v	_	_	O
207	.	_	_	O

208	bolus	_	_	O
209	(	_	_	O
210	arm	_	_	O
211	C	_	_	O
212	)	_	_	O
213	.	_	_	O

214	Courses	_	_	O
215	were	_	_	O
216	repeated	_	_	O
217	every	_	_	O
218	two	_	_	O
219	weeks	_	_	O
220	in	_	_	O
221	all	_	_	O
222	arms	_	_	O
223	of	_	_	O
224	the	_	_	O
225	trial	_	_	O
226	.	_	_	O

227	Response	_	_	O
228	rate	_	_	O
229	(	_	_	O
230	RR	_	_	O
231	)	_	_	O
232	was	_	_	O
233	evaluated	_	_	O
234	after	_	_	O
235	every	_	_	O
236	four	_	_	O
237	courses	_	_	O
238	.	_	_	O

239	The	_	_	O
240	sample	_	_	O
241	size	_	_	O
242	was	_	_	O
243	defined	_	_	O
244	to	_	_	O
245	have	_	_	O
246	an	_	_	O
247	80	_	_	O
248	%	_	_	O
249	power	_	_	O
250	to	_	_	O
251	detect	_	_	O
252	a	_	_	O
253	35	_	_	O
254	%	_	_	O
255	RR	_	_	O
256	for	_	_	O
257	each	_	_	O
258	experimental	_	_	O
259	treatment	_	_	O
260	,	_	_	O
261	and	_	_	O
262	to	_	_	O
263	show	_	_	O
264	a	_	_	O
265	difference	_	_	O
266	of	_	_	O
267	at	_	_	O
268	least	_	_	O
269	4	_	_	O
270	%	_	_	O
271	in	_	_	O
272	RR	_	_	O
273	with	_	_	O
274	the	_	_	O
275	standard	_	_	O
276	treatment	_	_	O
277	if	_	_	O
278	the	_	_	O
279	true	_	_	O
280	difference	_	_	O
281	is	_	_	O
282	15	_	_	O
283	%	_	_	O
284	or	_	_	O
285	more	_	_	O
286	.	_	_	O

287	The	_	_	O
288	RRs	_	_	O
289	were	_	_	O
290	:	_	_	O
291	34	_	_	O
292	%	_	_	O
293	(	_	_	O
294	95	_	_	O
295	%	_	_	O
296	confidence	_	_	O
297	interval	_	_	O
298	(	_	_	O
299	95	_	_	O
300	%	_	_	O
301	,	_	_	O
302	CI	_	_	O
303	)	_	_	O
304	:	_	_	O
305	21	_	_	O
306	%	_	_	O
307	-48	_	_	O
308	%	_	_	O
309	)	_	_	O
310	in	_	_	O
311	arm	_	_	O
312	A	_	_	O
313	,	_	_	O
314	including	_	_	O
315	3	_	_	O
316	complete	_	_	O
317	responses	_	_	O
318	(	_	_	O
319	CRs	_	_	O
320	)	_	_	O
321	and	_	_	O
322	15	_	_	O
323	partial	_	_	O
324	responses	_	_	O
325	(	_	_	O
326	PRs	_	_	O
327	)	_	_	O
328	,	_	_	O
329	24	_	_	O
330	%	_	_	O
331	(	_	_	O
332	95	_	_	O
333	%	_	_	O
334	CI	_	_	O
335	:	_	_	O
336	14	_	_	O
337	%	_	_	O
338	-38	_	_	O
339	%	_	_	O
340	)	_	_	O
341	in	_	_	O
342	arm	_	_	O
343	B	_	_	O
344	,	_	_	O
345	including	_	_	O
346	2	_	_	O
347	CRs	_	_	O
348	and	_	_	O
349	11	_	_	O
350	PRs	_	_	O
351	,	_	_	O
352	and	_	_	O
353	24	_	_	O
354	%	_	_	O
355	(	_	_	O
356	95	_	_	O
357	%	_	_	O
358	CI	_	_	O
359	:	_	_	O
360	14	_	_	O
361	%	_	_	O
362	-38	_	_	O
363	%	_	_	O
364	)	_	_	O
365	,	_	_	O
366	with	_	_	O
367	2	_	_	O
368	CRs	_	_	O
369	and	_	_	O
370	11	_	_	O
371	PRs	_	_	O
372	,	_	_	O
373	in	_	_	O
374	arm	_	_	O
375	C.	_	_	O
376	After	_	_	B-Premise
377	a	_	_	I-Premise
378	median	_	_	I-Premise
379	follow-up	_	_	I-Premise
380	time	_	_	I-Premise
381	of	_	_	I-Premise
382	62	_	_	I-Premise
383	(	_	_	I-Premise
384	range	_	_	I-Premise
385	18-108	_	_	I-Premise
386	)	_	_	I-Premise
387	weeks	_	_	I-Premise
388	,	_	_	I-Premise
389	the	_	_	I-Premise
390	median	_	_	I-Premise
391	time	_	_	I-Premise
392	to	_	_	I-Premise
393	progression	_	_	I-Premise
394	was	_	_	I-Premise
395	38	_	_	I-Premise
396	,	_	_	I-Premise
397	25	_	_	I-Premise
398	,	_	_	I-Premise
399	and	_	_	I-Premise
400	27	_	_	I-Premise
401	weeks	_	_	I-Premise
402	for	_	_	I-Premise
403	arm	_	_	I-Premise
404	A	_	_	I-Premise
405	,	_	_	I-Premise
406	B	_	_	I-Premise
407	,	_	_	I-Premise
408	and	_	_	I-Premise
409	C	_	_	I-Premise
410	,	_	_	I-Premise
411	respectively	_	_	I-Premise
412	.	_	_	I-Premise

413	With	_	_	B-Premise
414	94	_	_	I-Premise
415	patients	_	_	I-Premise
416	still	_	_	I-Premise
417	alive	_	_	I-Premise
418	,	_	_	I-Premise
419	the	_	_	I-Premise
420	one-year	_	_	I-Premise
421	probability	_	_	I-Premise
422	of	_	_	I-Premise
423	survival	_	_	I-Premise
424	was	_	_	I-Premise
425	61	_	_	I-Premise
426	%	_	_	I-Premise
427	,	_	_	I-Premise
428	54	_	_	I-Premise
429	%	_	_	I-Premise
430	,	_	_	I-Premise
431	and	_	_	I-Premise
432	59	_	_	I-Premise
433	%	_	_	I-Premise
434	,	_	_	I-Premise
435	respectively	_	_	I-Premise
436	.	_	_	I-Premise

437	WHO	_	_	B-Premise
438	grade	_	_	I-Premise
439	3	_	_	I-Premise
440	or	_	_	I-Premise
441	4	_	_	I-Premise
442	neutropenia	_	_	I-Premise
443	and	_	_	I-Premise
444	diarrhoea	_	_	I-Premise
445	affected	_	_	I-Premise
446	46	_	_	I-Premise
447	%	_	_	I-Premise
448	and	_	_	I-Premise
449	16	_	_	I-Premise
450	%	_	_	I-Premise
451	,	_	_	I-Premise
452	respectively	_	_	I-Premise
453	,	_	_	I-Premise
454	of	_	_	I-Premise
455	patients	_	_	I-Premise
456	treated	_	_	I-Premise
457	with	_	_	I-Premise
458	CPT-11	_	_	I-Premise
459	+	_	_	I-Premise
460	LFA	_	_	I-Premise
461	5-FU	_	_	I-Premise
462	.	_	_	I-Premise

463	Median	_	_	B-Premise
464	relative	_	_	I-Premise
465	dose	_	_	I-Premise
466	intensity	_	_	I-Premise
467	over	_	_	I-Premise
468	eight	_	_	I-Premise
469	cycles	_	_	I-Premise
470	(	_	_	I-Premise
471	DI8	_	_	I-Premise
472	)	_	_	I-Premise
473	was	_	_	I-Premise
474	78	_	_	I-Premise
475	%	_	_	I-Premise
476	for	_	_	I-Premise
477	CPT-11	_	_	I-Premise
478	and	_	_	I-Premise
479	82	_	_	I-Premise
480	%	_	_	I-Premise
481	for	_	_	I-Premise
482	5-FU	_	_	I-Premise
483	.	_	_	I-Premise

484	Severe	_	_	B-Premise
485	toxicities	_	_	I-Premise
486	of	_	_	I-Premise
487	TOM	_	_	I-Premise
488	+	_	_	I-Premise
489	LFA-5-FU	_	_	I-Premise
490	were	_	_	I-Premise
491	neutropenia	_	_	I-Premise
492	(	_	_	I-Premise
493	16	_	_	I-Premise
494	%	_	_	I-Premise
495	)	_	_	I-Premise
496	and	_	_	I-Premise
497	diarrhoea	_	_	I-Premise
498	(	_	_	I-Premise
499	16	_	_	I-Premise
500	%	_	_	I-Premise
501	)	_	_	I-Premise
502	,	_	_	I-Premise
503	but	_	_	I-Premise
504	median	_	_	I-Premise
505	relative	_	_	I-Premise
506	DI8	_	_	I-Premise
507	was	_	_	I-Premise
508	93	_	_	I-Premise
509	%	_	_	I-Premise
510	for	_	_	I-Premise
511	TOM	_	_	I-Premise
512	,	_	_	I-Premise
513	and	_	_	I-Premise
514	82	_	_	I-Premise
515	%	_	_	I-Premise
516	for	_	_	I-Premise
517	5-FU	_	_	I-Premise
518	.	_	_	I-Premise

519	CPT-11	_	_	B-Premise
520	+	_	_	I-Premise
521	LFA-5-FU	_	_	I-Premise
522	compares	_	_	I-Premise
523	favorably	_	_	I-Premise
524	in	_	_	I-Premise
525	term	_	_	I-Premise
526	of	_	_	I-Premise
527	activity	_	_	I-Premise
528	and	_	_	I-Premise
529	toxicity	_	_	I-Premise
530	with	_	_	I-Premise
531	other	_	_	I-Premise
532	combination	_	_	I-Premise
533	regimens	_	_	I-Premise
534	including	_	_	I-Premise
535	CPT-11	_	_	I-Premise
536	and	_	_	I-Premise
537	continuous	_	_	I-Premise
538	infusional	_	_	I-Premise
539	5-FU	_	_	I-Premise
540	.	_	_	I-Premise

541	The	_	_	B-Claim
542	hypothesis	_	_	I-Claim
543	of	_	_	I-Claim
544	a	_	_	I-Claim
545	RR	_	_	I-Claim
546	15	_	_	I-Claim
547	%	_	_	I-Claim
548	higher	_	_	I-Claim
549	than	_	_	I-Claim
550	the	_	_	I-Claim
551	MTX	_	_	I-Claim
552	+	_	_	I-Claim
553	LFA-5-FU	_	_	I-Claim
554	treatment	_	_	I-Claim
555	can	_	_	I-Claim
556	not	_	_	I-Claim
557	be	_	_	I-Claim
558	ruled	_	_	I-Claim
559	out	_	_	I-Claim
560	after	_	_	I-Claim
561	this	_	_	I-Claim
562	interim	_	_	I-Claim
563	analysis	_	_	I-Claim
564	.	_	_	I-Claim

565	The	_	_	B-Claim
566	TOM	_	_	I-Claim
567	+	_	_	I-Claim
568	LFA	_	_	I-Claim
569	5-FU	_	_	I-Claim
570	regimen	_	_	I-Claim
571	showed	_	_	I-Claim
572	a	_	_	I-Claim
573	RR	_	_	I-Claim
574	and	_	_	I-Claim
575	a	_	_	I-Claim
576	toxicity	_	_	I-Claim
577	profile	_	_	I-Claim
578	very	_	_	I-Claim
579	close	_	_	I-Claim
580	to	_	_	I-Claim
581	the	_	_	I-Claim
582	MTX	_	_	I-Claim
583	+	_	_	I-Claim
584	LFA	_	_	I-Claim
585	5-FU	_	_	I-Claim
586	combination	_	_	I-Claim
587	,	_	_	I-Claim
588	and	_	_	I-Claim
589	does	_	_	I-Claim
590	not	_	_	I-Claim
591	deserve	_	_	I-Claim
592	further	_	_	I-Claim
593	evaluation	_	_	I-Claim
594	in	_	_	I-Claim
595	advanced	_	_	I-Claim
596	colorectal	_	_	I-Claim
597	cancer	_	_	I-Claim
598	patients	_	_	I-Claim
599	.	_	_	I-Claim


0	To	_	_	O
1	report	_	_	O
2	a	_	_	O
3	randomized	_	_	O
4	clinical	_	_	O
5	trial	_	_	O
6	of	_	_	O
7	postoperative	_	_	O
8	subconjunctival	_	_	O
9	injections	_	_	O
10	of	_	_	O
11	low-dose	_	_	O
12	5-fluorouracil	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	undergoing	_	_	O
16	primary	_	_	O
17	trabeculectomy	_	_	O
18	.	_	_	O

19	In	_	_	O
20	a	_	_	O
21	prospective	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	,	_	_	O
27	40	_	_	O
28	eyes	_	_	O
29	of	_	_	O
30	40	_	_	O
31	patients	_	_	O
32	were	_	_	O
33	randomized	_	_	O
34	to	_	_	O
35	the	_	_	O
36	low-dose	_	_	O
37	5-fluorouracil	_	_	O
38	group	_	_	O
39	and	_	_	O
40	received	_	_	O
41	three	_	_	O
42	subconjunctival	_	_	O
43	injections	_	_	O
44	of	_	_	O
45	5	_	_	O
46	mg	_	_	O
47	each	_	_	O
48	over	_	_	O
49	11	_	_	O
50	postoperative	_	_	O
51	days	_	_	O
52	,	_	_	O
53	and	_	_	O
54	40	_	_	O
55	eyes	_	_	O
56	of	_	_	O
57	40	_	_	O
58	patients	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	trabeculectomy	_	_	O
63	without	_	_	O
64	5-fluorouracil	_	_	O
65	.	_	_	O

66	Mean	_	_	B-Premise
67	(	_	_	I-Premise
68	+/-SD	_	_	I-Premise
69	)	_	_	I-Premise
70	preoperative	_	_	I-Premise
71	and	_	_	I-Premise
72	1-year	_	_	I-Premise
73	postoperative	_	_	I-Premise
74	intraocular	_	_	I-Premise
75	pressures	_	_	I-Premise
76	in	_	_	I-Premise
77	the	_	_	I-Premise
78	5-fluorouracil	_	_	I-Premise
79	group	_	_	I-Premise
80	were	_	_	I-Premise
81	26.9	_	_	I-Premise
82	(	_	_	I-Premise
83	+/-9.5	_	_	I-Premise
84	)	_	_	I-Premise
85	and	_	_	I-Premise
86	15.3	_	_	I-Premise
87	(	_	_	I-Premise
88	+/-5.8	_	_	I-Premise
89	)	_	_	I-Premise
90	mm	_	_	I-Premise
91	Hg	_	_	I-Premise
92	,	_	_	I-Premise
93	respectively	_	_	I-Premise
94	.	_	_	I-Premise

95	In	_	_	B-Premise
96	the	_	_	I-Premise
97	control	_	_	I-Premise
98	group	_	_	I-Premise
99	these	_	_	I-Premise
100	were	_	_	I-Premise
101	25.9	_	_	I-Premise
102	(	_	_	I-Premise
103	+/-8.1	_	_	I-Premise
104	)	_	_	I-Premise
105	mm	_	_	I-Premise
106	Hg	_	_	I-Premise
107	,	_	_	I-Premise
108	and	_	_	I-Premise
109	15.8	_	_	I-Premise
110	(	_	_	I-Premise
111	+/-5.1	_	_	I-Premise
112	)	_	_	I-Premise
113	mm	_	_	I-Premise
114	Hg	_	_	I-Premise
115	,	_	_	I-Premise
116	respectively	_	_	I-Premise
117	.	_	_	I-Premise

118	The	_	_	B-Premise
119	patients	_	_	I-Premise
120	who	_	_	I-Premise
121	received	_	_	I-Premise
122	5-fluorouracil	_	_	I-Premise
123	had	_	_	I-Premise
124	a	_	_	I-Premise
125	mean	_	_	I-Premise
126	reduction	_	_	I-Premise
127	in	_	_	I-Premise
128	intraocular	_	_	I-Premise
129	pressure	_	_	I-Premise
130	of	_	_	I-Premise
131	11.5	_	_	I-Premise
132	(	_	_	I-Premise
133	+/-9.1	_	_	I-Premise
134	)	_	_	I-Premise
135	mm	_	_	I-Premise
136	Hg	_	_	I-Premise
137	at	_	_	I-Premise
138	a	_	_	I-Premise
139	median	_	_	I-Premise
140	follow-up	_	_	I-Premise
141	of	_	_	I-Premise
142	52.3	_	_	I-Premise
143	weeks	_	_	I-Premise
144	.	_	_	I-Premise

145	The	_	_	B-Premise
146	control	_	_	I-Premise
147	group	_	_	I-Premise
148	had	_	_	I-Premise
149	a	_	_	I-Premise
150	mean	_	_	I-Premise
151	reduction	_	_	I-Premise
152	in	_	_	I-Premise
153	intraocular	_	_	I-Premise
154	pressure	_	_	I-Premise
155	of	_	_	I-Premise
156	10.2	_	_	I-Premise
157	(	_	_	I-Premise
158	+/-8.7	_	_	I-Premise
159	)	_	_	I-Premise
160	mm	_	_	I-Premise
161	Hg	_	_	I-Premise
162	at	_	_	I-Premise
163	a	_	_	I-Premise
164	median	_	_	I-Premise
165	follow-up	_	_	I-Premise
166	of	_	_	I-Premise
167	52.6	_	_	I-Premise
168	weeks	_	_	I-Premise
169	.	_	_	I-Premise

170	These	_	_	B-Premise
171	differences	_	_	I-Premise
172	were	_	_	I-Premise
173	not	_	_	I-Premise
174	statistically	_	_	I-Premise
175	significant	_	_	I-Premise
176	.	_	_	I-Premise

177	Three	_	_	B-Premise
178	postoperative	_	_	I-Premise
179	subconjunctival	_	_	I-Premise
180	5-fluorouracil	_	_	I-Premise
181	injections	_	_	I-Premise
182	of	_	_	I-Premise
183	5	_	_	I-Premise
184	mg	_	_	I-Premise
185	each	_	_	I-Premise
186	after	_	_	I-Premise
187	trabeculectomy	_	_	I-Premise
188	in	_	_	I-Premise
189	eyes	_	_	I-Premise
190	at	_	_	I-Premise
191	low	_	_	I-Premise
192	risk	_	_	I-Premise
193	for	_	_	I-Premise
194	failure	_	_	I-Premise
195	had	_	_	I-Premise
196	no	_	_	I-Premise
197	statistically	_	_	I-Premise
198	or	_	_	I-Premise
199	clinically	_	_	I-Premise
200	significant	_	_	I-Premise
201	effect	_	_	I-Premise
202	on	_	_	I-Premise
203	reduction	_	_	I-Premise
204	of	_	_	I-Premise
205	intraocular	_	_	I-Premise
206	pressure	_	_	I-Premise
207	with	_	_	I-Premise
208	1-year	_	_	I-Premise
209	follow-up	_	_	I-Premise
210	.	_	_	I-Premise

211	Enhancement	_	_	B-Claim
212	of	_	_	I-Claim
213	success	_	_	I-Claim
214	in	_	_	I-Claim
215	this	_	_	I-Claim
216	group	_	_	I-Claim
217	of	_	_	I-Claim
218	patients	_	_	I-Claim
219	may	_	_	I-Claim
220	require	_	_	I-Claim
221	a	_	_	I-Claim
222	larger	_	_	I-Claim
223	total	_	_	I-Claim
224	dose	_	_	I-Claim
225	of	_	_	I-Claim
226	5-fluorouracil	_	_	I-Claim
227	.	_	_	I-Claim


0	We	_	_	O
1	have	_	_	O
2	recently	_	_	O
3	suggested	_	_	O
4	that	_	_	O
5	bolus	_	_	O
6	5-fluorouracil	_	_	O
7	(	_	_	O
8	5-FU	_	_	O
9	)	_	_	O
10	may	_	_	O
11	work	_	_	O
12	via	_	_	O
13	a	_	_	O
14	RNA	_	_	O
15	directed	_	_	O
16	mechanism	_	_	O
17	while	_	_	O
18	continuous	_	_	O
19	infusion	_	_	O
20	5-FU	_	_	O
21	may	_	_	O
22	kill	_	_	O
23	cells	_	_	O
24	via	_	_	O
25	a	_	_	O
26	thymidylate	_	_	O
27	synthase	_	_	O
28	related	_	_	O
29	pathway	_	_	O
30	.	_	_	O

31	It	_	_	O
32	may	_	_	O
33	thus	_	_	O
34	be	_	_	O
35	possible	_	_	O
36	to	_	_	O
37	selectively	_	_	O
38	modulate	_	_	O
39	each	_	_	O
40	schedule	_	_	O
41	biochemically	_	_	O
42	.	_	_	O

43	We	_	_	O
44	have	_	_	O
45	compared	_	_	O
46	an	_	_	O
47	alternating	_	_	O
48	regimen	_	_	O
49	of	_	_	O
50	bolus	_	_	O
51	and	_	_	O
52	continuous	_	_	O
53	infusion	_	_	O
54	5-FU	_	_	O
55	,	_	_	O
56	selectively	_	_	O
57	modulated	_	_	O
58	for	_	_	O
59	the	_	_	O
60	schedule	_	_	O
61	of	_	_	O
62	administration	_	_	O
63	,	_	_	O
64	with	_	_	O
65	modulated	_	_	O
66	bolus	_	_	O
67	5-FU	_	_	O
68	in	_	_	O
69	advanced	_	_	O
70	colorectal	_	_	O
71	cancer	_	_	O
72	patients	_	_	O
73	.	_	_	O

74	Two	_	_	O
75	hundred	_	_	O
76	fourteen	_	_	O
77	patients	_	_	O
78	from	_	_	O
79	nineteen	_	_	O
80	Italian	_	_	O
81	centers	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	the	_	_	O
86	control	_	_	O
87	arm	_	_	O
88	consisting	_	_	O
89	of	_	_	O
90	biweekly	_	_	O
91	cycles	_	_	O
92	of	_	_	O
93	MTX	_	_	O
94	,	_	_	O
95	200	_	_	O
96	mg/m2	_	_	O
97	on	_	_	O
98	day	_	_	O
99	1	_	_	O
100	,	_	_	O
101	followed	_	_	O
102	by	_	_	O
103	bolus	_	_	O
104	5-FU	_	_	O
105	600	_	_	O
106	mg/m2	_	_	O
107	on	_	_	O
108	day	_	_	O
109	2	_	_	O
110	and	_	_	O
111	6-S-leucovorin	_	_	O
112	rescue	_	_	O
113	,	_	_	O
114	or	_	_	O
115	to	_	_	O
116	the	_	_	O
117	experimental	_	_	O
118	arm	_	_	O
119	consisting	_	_	O
120	of	_	_	O
121	two	_	_	O
122	biweekly	_	_	O
123	cycles	_	_	O
124	of	_	_	O
125	the	_	_	O
126	same	_	_	O
127	regimen	_	_	O
128	as	_	_	O
129	in	_	_	O
130	the	_	_	O
131	control	_	_	O
132	arm	_	_	O
133	alternated	_	_	O
134	to	_	_	O
135	three	_	_	O
136	weeks	_	_	O
137	of	_	_	O
138	continuous	_	_	O
139	infusion	_	_	O
140	5-FU	_	_	O
141	(	_	_	O
142	200	_	_	O
143	mg/m2	_	_	O
144	day	_	_	O
145	)	_	_	O
146	+	_	_	O
147	weekly	_	_	O
148	bolus	_	_	O
149	6-S-leucovorin	_	_	O
150	,	_	_	O
151	20	_	_	O
152	mg/m2	_	_	O
153	.	_	_	O

154	Nine	_	_	B-Premise
155	CR	_	_	I-Premise
156	and	_	_	I-Premise
157	twenty-seven	_	_	I-Premise
158	PR	_	_	I-Premise
159	were	_	_	I-Premise
160	obtained	_	_	I-Premise
161	on	_	_	I-Premise
162	one	_	_	I-Premise
163	hundred	_	_	I-Premise
164	eleven	_	_	I-Premise
165	evaluable	_	_	I-Premise
166	patients	_	_	I-Premise
167	treated	_	_	I-Premise
168	in	_	_	I-Premise
169	experimental	_	_	I-Premise
170	arm	_	_	I-Premise
171	(	_	_	I-Premise
172	RR	_	_	I-Premise
173	=	_	_	I-Premise
174	32	_	_	I-Premise
175	%	_	_	I-Premise
176	,	_	_	I-Premise
177	95	_	_	I-Premise
178	%	_	_	I-Premise
179	confidence	_	_	I-Premise
180	interval	_	_	I-Premise
181	(	_	_	I-Premise
182	95	_	_	I-Premise
183	%	_	_	I-Premise
184	CI	_	_	I-Premise
185	)	_	_	I-Premise
186	:	_	_	I-Premise
187	24	_	_	I-Premise
188	%	_	_	I-Premise
189	-42	_	_	I-Premise
190	%	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	while	_	_	I-Premise
194	two	_	_	I-Premise
195	CR	_	_	I-Premise
196	and	_	_	I-Premise
197	eleven	_	_	I-Premise
198	PR	_	_	I-Premise
199	were	_	_	I-Premise
200	observed	_	_	I-Premise
201	among	_	_	I-Premise
202	one	_	_	I-Premise
203	hundred	_	_	I-Premise
204	three	_	_	I-Premise
205	evaluable	_	_	I-Premise
206	patients	_	_	I-Premise
207	in	_	_	I-Premise
208	control	_	_	I-Premise
209	arm	_	_	I-Premise
210	(	_	_	I-Premise
211	RR	_	_	I-Premise
212	=	_	_	I-Premise
213	13	_	_	I-Premise
214	%	_	_	I-Premise
215	,	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	:	_	_	I-Premise
220	7	_	_	I-Premise
221	%	_	_	I-Premise
222	-21	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	WHO	_	_	B-Premise
227	grade	_	_	I-Premise
228	3-4	_	_	I-Premise
229	toxicity	_	_	I-Premise
230	occurred	_	_	I-Premise
231	in	_	_	I-Premise
232	13	_	_	I-Premise
233	%	_	_	I-Premise
234	of	_	_	I-Premise
235	cycles	_	_	I-Premise
236	of	_	_	I-Premise
237	experimental	_	_	I-Premise
238	arm	_	_	I-Premise
239	and	_	_	I-Premise
240	in	_	_	I-Premise
241	8	_	_	I-Premise
242	%	_	_	I-Premise
243	of	_	_	I-Premise
244	cycles	_	_	I-Premise
245	in	_	_	I-Premise
246	control	_	_	I-Premise
247	arm	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	PFS	_	_	I-Premise
251	was	_	_	I-Premise
252	significantly	_	_	I-Premise
253	longer	_	_	I-Premise
254	in	_	_	I-Premise
255	experimental	_	_	I-Premise
256	arm	_	_	I-Premise
257	(	_	_	I-Premise
258	6.2	_	_	I-Premise
259	vs.	_	_	I-Premise
260	4.3	_	_	I-Premise
261	months	_	_	I-Premise
262	,	_	_	I-Premise
263	odds	_	_	I-Premise
264	ratio	_	_	I-Premise
265	0.66	_	_	I-Premise
266	,	_	_	I-Premise
267	P	_	_	I-Premise
268	=	_	_	I-Premise
269	0.003	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	while	_	_	O
273	the	_	_	B-Premise
274	overall	_	_	I-Premise
275	survival	_	_	I-Premise
276	was	_	_	I-Premise
277	similar	_	_	I-Premise
278	in	_	_	I-Premise
279	both	_	_	I-Premise
280	arms	_	_	I-Premise
281	(	_	_	I-Premise
282	14.8	_	_	I-Premise
283	months	_	_	I-Premise
284	in	_	_	I-Premise
285	experimental	_	_	I-Premise
286	arm	_	_	I-Premise
287	vs.	_	_	I-Premise
288	14.1	_	_	I-Premise
289	months	_	_	I-Premise
290	in	_	_	I-Premise
291	control	_	_	I-Premise
292	arm	_	_	I-Premise
293	)	_	_	I-Premise
294	;	_	_	I-Premise
295	quality	_	_	B-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	was	_	_	I-Claim
299	similar	_	_	I-Claim
300	as	_	_	I-Claim
301	well	_	_	I-Claim
302	.	_	_	I-Claim

303	Eighty	_	_	B-Premise
304	percent	_	_	I-Premise
305	of	_	_	I-Premise
306	patients	_	_	I-Premise
307	receiving	_	_	I-Premise
308	second-line	_	_	I-Premise
309	chemotherapy	_	_	I-Premise
310	in	_	_	I-Premise
311	control	_	_	I-Premise
312	arm	_	_	I-Premise
313	were	_	_	I-Premise
314	treated	_	_	I-Premise
315	with	_	_	I-Premise
316	continuous	_	_	I-Premise
317	infusion	_	_	I-Premise
318	5-FU	_	_	I-Premise
319	.	_	_	I-Premise

320	Alternating	_	_	O
321	,	_	_	O
322	schedule-specific	_	_	B-Claim
323	biochemical	_	_	I-Claim
324	modulation	_	_	I-Claim
325	of	_	_	I-Claim
326	FU	_	_	I-Claim
327	is	_	_	I-Claim
328	more	_	_	I-Claim
329	active	_	_	I-Claim
330	than	_	_	I-Claim
331	MTX	_	_	I-Claim
332	--	_	_	I-Claim
333	>	_	_	I-Claim
334	5-FU	_	_	I-Claim
335	as	_	_	I-Claim
336	first-line	_	_	I-Claim
337	treatment	_	_	I-Claim
338	of	_	_	I-Claim
339	advanced	_	_	I-Claim
340	colorectal	_	_	I-Claim
341	cancer	_	_	I-Claim
342	.	_	_	I-Claim

343	However	_	_	B-Claim
344	,	_	_	I-Claim
345	the	_	_	I-Claim
346	overall	_	_	I-Claim
347	survival	_	_	I-Claim
348	was	_	_	I-Claim
349	similar	_	_	I-Claim
350	suggesting	_	_	I-Claim
351	that	_	_	I-Claim
352	alternating	_	_	I-Claim
353	bolus	_	_	I-Claim
354	and	_	_	I-Claim
355	infusional	_	_	I-Claim
356	5-FU	_	_	I-Claim
357	upfront	_	_	I-Claim
358	may	_	_	I-Claim
359	be	_	_	I-Claim
360	as	_	_	I-Claim
361	effective	_	_	I-Claim
362	as	_	_	I-Claim
363	giving	_	_	I-Claim
364	them	_	_	I-Claim
365	in	_	_	I-Claim
366	sequence	_	_	I-Claim
367	as	_	_	I-Claim
368	first-	_	_	I-Claim
369	and	_	_	I-Claim
370	second-line	_	_	I-Claim
371	treatment	_	_	I-Claim
372	.	_	_	I-Claim


0	Increased	_	_	B-Claim
1	intraocular	_	_	I-Claim
2	pressure	_	_	I-Claim
3	(	_	_	I-Claim
4	IOP	_	_	I-Claim
5	)	_	_	I-Claim
6	has	_	_	I-Claim
7	been	_	_	I-Claim
8	shown	_	_	I-Claim
9	to	_	_	I-Claim
10	be	_	_	I-Claim
11	one	_	_	I-Claim
12	of	_	_	I-Claim
13	the	_	_	I-Claim
14	most	_	_	I-Claim
15	important	_	_	I-Claim
16	risk	_	_	I-Claim
17	factors	_	_	I-Claim
18	for	_	_	I-Claim
19	developing	_	_	I-Claim
20	glaucoma	_	_	I-Claim
21	.	_	_	I-Claim

22	Yet	_	_	O
23	it	_	_	O
24	has	_	_	O
25	not	_	_	O
26	been	_	_	O
27	clearly	_	_	O
28	demonstrated	_	_	O
29	that	_	_	O
30	IOP-lowering	_	_	O
31	treatment	_	_	O
32	can	_	_	O
33	reduce	_	_	O
34	the	_	_	O
35	incidence	_	_	O
36	of	_	_	O
37	glaucoma	_	_	O
38	damage	_	_	O
39	in	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	ocular	_	_	O
43	hypertension	_	_	O
44	.	_	_	O

45	The	_	_	O
46	aim	_	_	O
47	of	_	_	O
48	the	_	_	O
49	current	_	_	O
50	paper	_	_	O
51	was	_	_	O
52	to	_	_	O
53	report	_	_	O
54	the	_	_	O
55	results	_	_	O
56	of	_	_	O
57	a	_	_	O
58	long-term	_	_	O
59	study	_	_	O
60	addressing	_	_	O
61	this	_	_	O
62	very	_	_	O
63	problem	_	_	O
64	.	_	_	O

65	We	_	_	O
66	conducted	_	_	O
67	a	_	_	O
68	randomised	_	_	O
69	,	_	_	O
70	double-masked	_	_	O
71	study	_	_	O
72	comparing	_	_	O
73	timolol	_	_	O
74	and	_	_	O
75	placebo	_	_	O
76	treatment	_	_	O
77	in	_	_	O
78	90	_	_	O
79	patients	_	_	O
80	with	_	_	O
81	ocular	_	_	O
82	hypertension	_	_	O
83	plus	_	_	O
84	some	_	_	O
85	additional	_	_	O
86	risk	_	_	O
87	factor	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	were	_	_	O
91	followed	_	_	O
92	at	_	_	O
93	3-month	_	_	O
94	intervals	_	_	O
95	prospectively	_	_	O
96	for	_	_	O
97	10	_	_	O
98	years	_	_	O
99	or	_	_	O
100	until	_	_	O
101	glaucomatous	_	_	O
102	field	_	_	O
103	loss	_	_	O
104	could	_	_	O
105	be	_	_	O
106	demonstrated	_	_	O
107	with	_	_	O
108	computerised	_	_	O
109	perimetry	_	_	O
110	.	_	_	O

111	A	_	_	O
112	post-study	_	_	O
113	analysis	_	_	O
114	was	_	_	O
115	performed	_	_	O
116	including	_	_	O
117	all	_	_	O
118	available	_	_	O
119	data	_	_	O
120	,	_	_	O
121	thus	_	_	O
122	extending	_	_	O
123	maximum	_	_	O
124	follow-up	_	_	O
125	to	_	_	O
126	17	_	_	O
127	years	_	_	O
128	.	_	_	O

129	After	_	_	B-Premise
130	5	_	_	I-Premise
131	years	_	_	I-Premise
132	of	_	_	I-Premise
133	follow-up	_	_	I-Premise
134	eight	_	_	I-Premise
135	patients	_	_	I-Premise
136	in	_	_	I-Premise
137	the	_	_	I-Premise
138	placebo	_	_	I-Premise
139	group	_	_	I-Premise
140	and	_	_	I-Premise
141	five	_	_	I-Premise
142	patients	_	_	I-Premise
143	in	_	_	I-Premise
144	the	_	_	I-Premise
145	timolol	_	_	I-Premise
146	group	_	_	I-Premise
147	had	_	_	I-Premise
148	developed	_	_	I-Premise
149	glaucomatous	_	_	I-Premise
150	field	_	_	I-Premise
151	loss	_	_	I-Premise
152	(	_	_	I-Premise
153	NS	_	_	I-Premise
154	)	_	_	I-Premise
155	;	_	_	I-Premise
156	the	_	_	B-Premise
157	corresponding	_	_	I-Premise
158	figures	_	_	I-Premise
159	after	_	_	I-Premise
160	10	_	_	I-Premise
161	years	_	_	I-Premise
162	were	_	_	I-Premise
163	15	_	_	I-Premise
164	patients	_	_	I-Premise
165	in	_	_	I-Premise
166	the	_	_	I-Premise
167	placebo	_	_	I-Premise
168	group	_	_	I-Premise
169	and	_	_	I-Premise
170	seven	_	_	I-Premise
171	patients	_	_	I-Premise
172	in	_	_	I-Premise
173	the	_	_	I-Premise
174	timolol	_	_	I-Premise
175	group	_	_	I-Premise
176	.	_	_	I-Premise

177	Survival	_	_	B-Premise
178	analysis	_	_	I-Premise
179	showed	_	_	I-Premise
180	a	_	_	I-Premise
181	tendency	_	_	I-Premise
182	but	_	_	I-Premise
183	no	_	_	I-Premise
184	statistically	_	_	I-Premise
185	significant	_	_	I-Premise
186	difference	_	_	I-Premise
187	between	_	_	I-Premise
188	treatment	_	_	I-Premise
189	groups	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	=	_	_	I-Premise
193	0.07	_	_	I-Premise
194	)	_	_	I-Premise
195	.	_	_	I-Premise

196	Study	_	_	B-Premise
197	attrition	_	_	I-Premise
198	was	_	_	I-Premise
199	large	_	_	I-Premise
200	.	_	_	I-Premise

201	Eighteen	_	_	B-Premise
202	patients	_	_	I-Premise
203	in	_	_	I-Premise
204	each	_	_	I-Premise
205	group	_	_	I-Premise
206	had	_	_	I-Premise
207	developed	_	_	I-Premise
208	glaucomatous	_	_	I-Premise
209	field	_	_	I-Premise
210	loss	_	_	I-Premise
211	when	_	_	I-Premise
212	also	_	_	I-Premise
213	post-study	_	_	I-Premise
214	data	_	_	I-Premise
215	were	_	_	I-Premise
216	included	_	_	I-Premise
217	.	_	_	I-Premise

218	IOP	_	_	B-Premise
219	reduction	_	_	I-Premise
220	was	_	_	I-Premise
221	greater	_	_	I-Premise
222	in	_	_	I-Premise
223	eyes	_	_	I-Premise
224	passing	_	_	I-Premise
225	the	_	_	I-Premise
226	10-year	_	_	I-Premise
227	visit	_	_	I-Premise
228	without	_	_	I-Premise
229	field	_	_	I-Premise
230	loss	_	_	I-Premise
231	(	_	_	I-Premise
232	5.7	_	_	I-Premise
233	mmHg	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	than	_	_	I-Premise
237	in	_	_	I-Premise
238	those	_	_	I-Premise
239	that	_	_	I-Premise
240	reached	_	_	I-Premise
241	an	_	_	I-Premise
242	end-point	_	_	I-Premise
243	(	_	_	I-Premise
244	2.3	_	_	I-Premise
245	mmHg	_	_	I-Premise
246	;	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	0.0002	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	In	_	_	B-Claim
253	this	_	_	I-Claim
254	long-term	_	_	I-Claim
255	study	_	_	I-Claim
256	we	_	_	I-Claim
257	found	_	_	I-Claim
258	a	_	_	I-Claim
259	tendency	_	_	I-Claim
260	but	_	_	I-Claim
261	failed	_	_	I-Claim
262	to	_	_	I-Claim
263	prove	_	_	I-Claim
264	a	_	_	I-Claim
265	beneficial	_	_	I-Claim
266	effect	_	_	I-Claim
267	of	_	_	I-Claim
268	topical	_	_	I-Claim
269	timolol	_	_	I-Claim
270	treatment	_	_	I-Claim
271	in	_	_	I-Claim
272	patients	_	_	I-Claim
273	with	_	_	I-Claim
274	elevated	_	_	I-Claim
275	IOP	_	_	I-Claim
276	,	_	_	I-Claim
277	normal	_	_	I-Claim
278	visual	_	_	I-Claim
279	fields	_	_	I-Claim
280	and	_	_	I-Claim
281	some	_	_	I-Claim
282	additional	_	_	I-Claim
283	risk	_	_	I-Claim
284	factor	_	_	I-Claim
285	.	_	_	I-Claim

286	The	_	_	B-Premise
287	intent-to-treat	_	_	I-Premise
288	analysis	_	_	I-Premise
289	showed	_	_	I-Premise
290	no	_	_	I-Premise
291	difference	_	_	I-Premise
292	between	_	_	I-Premise
293	treatment	_	_	I-Premise
294	groups	_	_	I-Premise
295	.	_	_	I-Premise

296	The	_	_	B-Premise
297	high	_	_	I-Premise
298	attrition	_	_	I-Premise
299	shows	_	_	I-Premise
300	the	_	_	I-Premise
301	difficulties	_	_	I-Premise
302	associated	_	_	I-Premise
303	with	_	_	I-Premise
304	very	_	_	I-Premise
305	long	_	_	I-Premise
306	follow-up	_	_	I-Premise
307	.	_	_	I-Premise


0	To	_	_	O
1	compare	_	_	O
2	viscocanalostomy	_	_	O
3	,	_	_	O
4	a	_	_	O
5	nonpenetrating	_	_	O
6	procedure	_	_	O
7	for	_	_	O
8	glaucoma	_	_	O
9	treatment	_	_	O
10	,	_	_	O
11	with	_	_	O
12	trabeculectomy	_	_	O
13	.	_	_	O

14	Randomized	_	_	O
15	controlled	_	_	O
16	trial	_	_	O
17	.	_	_	O

18	Twenty	_	_	O
19	white	_	_	O
20	subjects	_	_	O
21	(	_	_	O
22	20	_	_	O
23	eyes	_	_	O
24	)	_	_	O
25	with	_	_	O
26	open-angle	_	_	O
27	glaucoma	_	_	O
28	with	_	_	O
29	no	_	_	O
30	history	_	_	O
31	of	_	_	O
32	surgery	_	_	O
33	were	_	_	O
34	enrolled	_	_	O
35	.	_	_	O

36	Ten	_	_	O
37	subjects	_	_	O
38	were	_	_	O
39	randomly	_	_	O
40	assigned	_	_	O
41	to	_	_	O
42	viscocanalostomy	_	_	O
43	according	_	_	O
44	to	_	_	O
45	Stegmann	_	_	O
46	's	_	_	O
47	technique	_	_	O
48	and	_	_	O
49	10	_	_	O
50	subjects	_	_	O
51	to	_	_	O
52	a	_	_	O
53	modified	_	_	O
54	Cairns	_	_	O
55	trabeculectomy	_	_	O
56	.	_	_	O

57	A	_	_	O
58	complete	_	_	O
59	ophthalmologic	_	_	O
60	examination	_	_	O
61	was	_	_	O
62	performed	_	_	O
63	the	_	_	O
64	day	_	_	O
65	before	_	_	O
66	surgery	_	_	O
67	and	_	_	O
68	postoperatively	_	_	O
69	.	_	_	O

70	Further	_	_	O
71	visits	_	_	O
72	were	_	_	O
73	scheduled	_	_	O
74	monthly	_	_	O
75	for	_	_	O
76	6	_	_	O
77	to	_	_	O
78	8	_	_	O
79	months	_	_	O
80	after	_	_	O
81	surgery	_	_	O
82	.	_	_	O

83	Success	_	_	O
84	was	_	_	O
85	defined	_	_	O
86	as	_	_	O
87	intraocular	_	_	O
88	pressure	_	_	O
89	(	_	_	O
90	IOP	_	_	O
91	)	_	_	O
92	between	_	_	O
93	7	_	_	O
94	and	_	_	O
95	20	_	_	O
96	mmHg	_	_	O
97	,	_	_	O
98	with	_	_	O
99	no	_	_	O
100	medication	_	_	O
101	.	_	_	O

102	After	_	_	B-Premise
103	a	_	_	I-Premise
104	mean	_	_	I-Premise
105	follow-up	_	_	I-Premise
106	of	_	_	I-Premise
107	6	_	_	I-Premise
108	months	_	_	I-Premise
109	(	_	_	I-Premise
110	range	_	_	I-Premise
111	,	_	_	I-Premise
112	6-8	_	_	I-Premise
113	months	_	_	I-Premise
114	)	_	_	I-Premise
115	,	_	_	I-Premise
116	success	_	_	I-Premise
117	was	_	_	I-Premise
118	obtained	_	_	I-Premise
119	in	_	_	I-Premise
120	5	_	_	I-Premise
121	of	_	_	I-Premise
122	10	_	_	I-Premise
123	cases	_	_	I-Premise
124	in	_	_	I-Premise
125	the	_	_	I-Premise
126	trabeculectomy	_	_	I-Premise
127	group	_	_	I-Premise
128	and	_	_	I-Premise
129	in	_	_	I-Premise
130	0	_	_	I-Premise
131	of	_	_	I-Premise
132	10	_	_	I-Premise
133	case	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	viscocanalostomy	_	_	I-Premise
137	group	_	_	I-Premise
138	.	_	_	I-Premise

139	With	_	_	B-Premise
140	Kaplan-Meier	_	_	I-Premise
141	's	_	_	I-Premise
142	method	_	_	I-Premise
143	,	_	_	I-Premise
144	subjects	_	_	I-Premise
145	with	_	_	I-Premise
146	viscocanalostomy	_	_	I-Premise
147	showed	_	_	I-Premise
148	shorter	_	_	I-Premise
149	postoperative	_	_	I-Premise
150	IOP-reduction	_	_	I-Premise
151	periods	_	_	I-Premise
152	than	_	_	I-Premise
153	subjects	_	_	I-Premise
154	undergoing	_	_	I-Premise
155	trabeculectomy	_	_	I-Premise
156	.	_	_	I-Premise

157	According	_	_	B-Claim
158	to	_	_	I-Claim
159	the	_	_	I-Claim
160	results	_	_	I-Claim
161	of	_	_	I-Claim
162	this	_	_	I-Claim
163	short-term	_	_	I-Claim
164	study	_	_	I-Claim
165	,	_	_	I-Claim
166	trabeculectomy	_	_	I-Claim
167	was	_	_	I-Claim
168	more	_	_	I-Claim
169	effective	_	_	I-Claim
170	than	_	_	I-Claim
171	viscocanalostomy	_	_	I-Claim
172	in	_	_	I-Claim
173	lowering	_	_	I-Claim
174	IOP	_	_	I-Claim
175	in	_	_	I-Claim
176	glaucomatous	_	_	I-Claim
177	eyes	_	_	I-Claim
178	of	_	_	I-Claim
179	white	_	_	I-Claim
180	patients	_	_	I-Claim
181	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	reducing	_	_	O
9	effect	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	latanoprost	_	_	O
14	0.005	_	_	O
15	%	_	_	O
16	once	_	_	O
17	daily	_	_	O
18	with	_	_	O
19	unoprostone	_	_	O
20	0.12	_	_	O
21	%	_	_	O
22	twice	_	_	O
23	daily	_	_	O
24	in	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	primary	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	(	_	_	O
31	POAG	_	_	O
32	)	_	_	O
33	or	_	_	O
34	ocular	_	_	O
35	hypertension	_	_	O
36	(	_	_	O
37	OH	_	_	O
38	)	_	_	O
39	.	_	_	O

40	An	_	_	O
41	8-week	_	_	O
42	,	_	_	O
43	double-masked	_	_	O
44	,	_	_	O
45	randomized	_	_	O
46	,	_	_	O
47	parallel-group	_	_	O
48	,	_	_	O
49	single-center	_	_	O
50	clinical	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	A	_	_	O
54	total	_	_	O
55	of	_	_	O
56	108	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	POAG	_	_	O
60	or	_	_	O
61	OH	_	_	O
62	were	_	_	O
63	enrolled	_	_	O
64	.	_	_	O

65	After	_	_	O
66	completing	_	_	O
67	a	_	_	O
68	wash-out	_	_	O
69	of	_	_	O
70	ocular	_	_	O
71	hypotensive	_	_	O
72	medications	_	_	O
73	,	_	_	O
74	patients	_	_	O
75	were	_	_	O
76	randomized	_	_	O
77	to	_	_	O
78	receive	_	_	O
79	either	_	_	O
80	latanoprost	_	_	O
81	once	_	_	O
82	daily	_	_	O
83	in	_	_	O
84	the	_	_	O
85	evening	_	_	O
86	plus	_	_	O
87	placebo	_	_	O
88	once	_	_	O
89	daily	_	_	O
90	in	_	_	O
91	the	_	_	O
92	morning	_	_	O
93	,	_	_	O
94	or	_	_	O
95	unoprostone	_	_	O
96	twice	_	_	O
97	daily	_	_	O
98	(	_	_	O
99	morning	_	_	O
100	and	_	_	O
101	evening	_	_	O
102	)	_	_	O
103	.	_	_	O

104	IOP	_	_	O
105	was	_	_	O
106	measured	_	_	O
107	at	_	_	O
108	10:00	_	_	O
109	AM	_	_	O
110	and	_	_	O
111	at	_	_	O
112	5:00	_	_	O
113	PM	_	_	O
114	at	_	_	O
115	baseline	_	_	O
116	and	_	_	O
117	at	_	_	O
118	week	_	_	O
119	8	_	_	O
120	,	_	_	O
121	and	_	_	O
122	before	_	_	O
123	12:00	_	_	O
124	noon	_	_	O
125	at	_	_	O
126	week	_	_	O
127	2	_	_	O
128	.	_	_	O

129	Ocular	_	_	O
130	and	_	_	O
131	systemic	_	_	O
132	safety	_	_	O
133	assessments	_	_	O
134	were	_	_	O
135	performed	_	_	O
136	.	_	_	O

137	From	_	_	B-Premise
138	an	_	_	I-Premise
139	overall	_	_	I-Premise
140	baseline	_	_	I-Premise
141	of	_	_	I-Premise
142	24.1	_	_	I-Premise
143	mmHg	_	_	I-Premise
144	,	_	_	I-Premise
145	latanoprost	_	_	I-Premise
146	reduced	_	_	I-Premise
147	IOP	_	_	I-Premise
148	by	_	_	I-Premise
149	6.7	_	_	I-Premise
150	mmHg	_	_	I-Premise
151	(	_	_	I-Premise
152	28	_	_	I-Premise
153	%	_	_	I-Premise
154	)	_	_	I-Premise
155	and	_	_	I-Premise
156	unoprostone	_	_	I-Premise
157	reduced	_	_	I-Premise
158	IOP	_	_	I-Premise
159	by	_	_	I-Premise
160	3.3	_	_	I-Premise
161	mmHg	_	_	I-Premise
162	(	_	_	I-Premise
163	14	_	_	I-Premise
164	%	_	_	I-Premise
165	)	_	_	I-Premise
166	.	_	_	I-Premise

167	The	_	_	B-Premise
168	difference	_	_	I-Premise
169	between	_	_	I-Premise
170	the	_	_	I-Premise
171	groups	_	_	I-Premise
172	of	_	_	I-Premise
173	3.4	_	_	I-Premise
174	mmHg	_	_	I-Premise
175	was	_	_	I-Premise
176	significant	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	:	_	_	I-Premise
180	<	_	_	I-Premise
181	0.001	_	_	I-Premise
182	,	_	_	I-Premise
183	analysis	_	_	I-Premise
184	of	_	_	I-Premise
185	covariance	_	_	I-Premise
186	;	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	confidence	_	_	I-Premise
190	interval	_	_	I-Premise
191	[	_	_	I-Premise
192	CI	_	_	I-Premise
193	]	_	_	I-Premise
194	:	_	_	I-Premise
195	-4.7	_	_	I-Premise
196	to	_	_	I-Premise
197	-2.1	_	_	I-Premise
198	)	_	_	I-Premise
199	in	_	_	I-Premise
200	favor	_	_	I-Premise
201	of	_	_	I-Premise
202	latanoprost	_	_	I-Premise
203	.	_	_	I-Premise

204	A	_	_	B-Premise
205	>	_	_	I-Premise
206	/=30	_	_	I-Premise
207	%	_	_	I-Premise
208	reduction	_	_	I-Premise
209	in	_	_	I-Premise
210	mean	_	_	I-Premise
211	IOP	_	_	I-Premise
212	from	_	_	I-Premise
213	baseline	_	_	I-Premise
214	was	_	_	I-Premise
215	achieved	_	_	I-Premise
216	by	_	_	I-Premise
217	44	_	_	I-Premise
218	%	_	_	I-Premise
219	of	_	_	I-Premise
220	latanoprost-treated	_	_	I-Premise
221	patients	_	_	I-Premise
222	compared	_	_	I-Premise
223	with	_	_	I-Premise
224	8	_	_	I-Premise
225	%	_	_	I-Premise
226	of	_	_	I-Premise
227	unoprostone-treated	_	_	I-Premise
228	patients	_	_	I-Premise
229	.	_	_	I-Premise

230	The	_	_	O
231	incidence	_	_	O
232	of	_	_	O
233	adverse	_	_	O
234	events	_	_	O
235	was	_	_	O
236	low	_	_	O
237	and	_	_	O
238	comparable	_	_	O
239	between	_	_	O
240	the	_	_	O
241	groups	_	_	O
242	.	_	_	O

243	Latanoprost	_	_	B-Claim
244	administered	_	_	I-Claim
245	once	_	_	I-Claim
246	daily	_	_	I-Claim
247	was	_	_	I-Claim
248	significantly	_	_	I-Claim
249	more	_	_	I-Claim
250	effective	_	_	I-Claim
251	in	_	_	I-Claim
252	reducing	_	_	I-Claim
253	IOP	_	_	I-Claim
254	compared	_	_	I-Claim
255	with	_	_	I-Claim
256	unoprostone	_	_	I-Claim
257	administered	_	_	I-Claim
258	twice	_	_	I-Claim
259	daily	_	_	I-Claim
260	in	_	_	I-Claim
261	patients	_	_	I-Claim
262	with	_	_	I-Claim
263	POAG	_	_	I-Claim
264	and	_	_	I-Claim
265	OH	_	_	I-Claim
266	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	on	_	_	O
5	intraocular	_	_	O
6	pressure	_	_	O
7	of	_	_	O
8	latanoprost	_	_	O
9	versus	_	_	O
10	timolol	_	_	O
11	plus	_	_	O
12	dorzolamide	_	_	O
13	in	_	_	O
14	open-angle	_	_	O
15	glaucoma	_	_	O
16	.	_	_	O

17	Thirty-five	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	open-angle	_	_	O
21	glaucoma	_	_	O
22	were	_	_	O
23	randomized	_	_	O
24	,	_	_	O
25	18	_	_	O
26	to	_	_	O
27	latanoprost	_	_	O
28	once	_	_	O
29	daily	_	_	O
30	and	_	_	O
31	17	_	_	O
32	to	_	_	O
33	timolol	_	_	O
34	plus	_	_	O
35	dorzolamide	_	_	O
36	twice	_	_	O
37	daily	_	_	O
38	.	_	_	O

39	Intraocular	_	_	O
40	pressure	_	_	O
41	and	_	_	O
42	ocular	_	_	O
43	side	_	_	O
44	effects	_	_	O
45	were	_	_	O
46	recorded	_	_	O
47	at	_	_	O
48	baseline	_	_	O
49	,	_	_	O
50	and	_	_	O
51	after	_	_	O
52	2	_	_	O
53	weeks	_	_	O
54	and	_	_	O
55	3	_	_	O
56	months	_	_	O
57	of	_	_	O
58	treatment	_	_	O
59	.	_	_	O

60	Latanoprost	_	_	B-Premise
61	reduced	_	_	I-Premise
62	the	_	_	I-Premise
63	intraocular	_	_	I-Premise
64	pressure	_	_	I-Premise
65	1.09	_	_	I-Premise
66	and	_	_	I-Premise
67	1.58	_	_	I-Premise
68	mm	_	_	I-Premise
69	Hg	_	_	I-Premise
70	more	_	_	I-Premise
71	than	_	_	I-Premise
72	timolol	_	_	I-Premise
73	plus	_	_	I-Premise
74	dorzolamide	_	_	I-Premise
75	after	_	_	I-Premise
76	2	_	_	I-Premise
77	weeks	_	_	I-Premise
78	and	_	_	I-Premise
79	3	_	_	I-Premise
80	months	_	_	I-Premise
81	of	_	_	I-Premise
82	treatment	_	_	I-Premise
83	,	_	_	I-Premise
84	respectively	_	_	I-Premise
85	.	_	_	I-Premise

86	These	_	_	B-Premise
87	differences	_	_	I-Premise
88	were	_	_	I-Premise
89	statistically	_	_	I-Premise
90	significant	_	_	I-Premise
91	(	_	_	I-Premise
92	p	_	_	I-Premise
93	<	_	_	I-Premise
94	0.05	_	_	I-Premise
95	)	_	_	I-Premise
96	at	_	_	I-Premise
97	the	_	_	I-Premise
98	end	_	_	I-Premise
99	of	_	_	I-Premise
100	the	_	_	I-Premise
101	study	_	_	I-Premise
102	.	_	_	I-Premise

103	After	_	_	B-Premise
104	3	_	_	I-Premise
105	months	_	_	I-Premise
106	of	_	_	I-Premise
107	treatment	_	_	I-Premise
108	,	_	_	I-Premise
109	32.3	_	_	I-Premise
110	%	_	_	I-Premise
111	of	_	_	I-Premise
112	the	_	_	I-Premise
113	eyes	_	_	I-Premise
114	in	_	_	I-Premise
115	the	_	_	I-Premise
116	latanoprost	_	_	I-Premise
117	group	_	_	I-Premise
118	reduced	_	_	I-Premise
119	the	_	_	I-Premise
120	intraocular	_	_	I-Premise
121	pressure	_	_	I-Premise
122	in	_	_	I-Premise
123	30	_	_	I-Premise
124	%	_	_	I-Premise
125	or	_	_	I-Premise
126	more	_	_	I-Premise
127	with	_	_	I-Premise
128	respect	_	_	I-Premise
129	to	_	_	I-Premise
130	baseline	_	_	I-Premise
131	,	_	_	I-Premise
132	while	_	_	I-Premise
133	15.6	_	_	I-Premise
134	%	_	_	I-Premise
135	of	_	_	I-Premise
136	the	_	_	I-Premise
137	eyes	_	_	I-Premise
138	in	_	_	I-Premise
139	the	_	_	I-Premise
140	timolol	_	_	I-Premise
141	plus	_	_	I-Premise
142	dorzolamide	_	_	I-Premise
143	group	_	_	I-Premise
144	achieved	_	_	I-Premise
145	this	_	_	I-Premise
146	reduction	_	_	I-Premise
147	.	_	_	I-Premise

148	Latanoprost	_	_	B-Claim
149	administered	_	_	I-Claim
150	once	_	_	I-Claim
151	daily	_	_	I-Claim
152	reduced	_	_	I-Claim
153	the	_	_	I-Claim
154	intraocular	_	_	I-Claim
155	pressure	_	_	I-Claim
156	at	_	_	I-Claim
157	least	_	_	I-Claim
158	as	_	_	I-Claim
159	well	_	_	I-Claim
160	as	_	_	I-Claim
161	timolol	_	_	I-Claim
162	plus	_	_	I-Claim
163	dorzolamide	_	_	I-Claim
164	twice	_	_	I-Claim
165	daily	_	_	I-Claim
166	in	_	_	I-Claim
167	patients	_	_	I-Claim
168	with	_	_	I-Claim
169	open-angle	_	_	I-Claim
170	glaucoma	_	_	I-Claim
171	.	_	_	I-Claim


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	equivalence	_	_	O
4	of	_	_	O
5	three	_	_	O
6	versus	_	_	O
7	four	_	_	O
8	cycles	_	_	O
9	of	_	_	O
10	bleomycin	_	_	O
11	,	_	_	O
12	etoposide	_	_	O
13	,	_	_	O
14	and	_	_	O
15	cisplatin	_	_	O
16	(	_	_	O
17	BEP	_	_	O
18	)	_	_	O
19	and	_	_	O
20	of	_	_	O
21	the	_	_	O
22	5-day	_	_	O
23	schedule	_	_	O
24	versus	_	_	O
25	3	_	_	O
26	days	_	_	O
27	per	_	_	O
28	cycle	_	_	O
29	in	_	_	O
30	good-prognosis	_	_	O
31	germ	_	_	O
32	cell	_	_	O
33	cancer	_	_	O
34	.	_	_	O

35	The	_	_	O
36	study	_	_	O
37	was	_	_	O
38	designed	_	_	O
39	as	_	_	O
40	a	_	_	O
41	2	_	_	O
42	x	_	_	O
43	2	_	_	O
44	factorial	_	_	O
45	trial	_	_	O
46	.	_	_	O

47	The	_	_	O
48	aim	_	_	O
49	was	_	_	O
50	to	_	_	O
51	rule	_	_	O
52	out	_	_	O
53	a	_	_	O
54	5	_	_	O
55	%	_	_	O
56	decrease	_	_	O
57	in	_	_	O
58	the	_	_	O
59	2-year	_	_	O
60	progression-free	_	_	O
61	survival	_	_	O
62	(	_	_	O
63	PFS	_	_	O
64	)	_	_	O
65	rate	_	_	O
66	.	_	_	O

67	The	_	_	O
68	study	_	_	O
69	included	_	_	O
70	the	_	_	O
71	assessment	_	_	O
72	of	_	_	O
73	patient	_	_	O
74	quality	_	_	O
75	of	_	_	O
76	life	_	_	O
77	.	_	_	O

78	A	_	_	O
79	cycle	_	_	O
80	of	_	_	O
81	BEP	_	_	O
82	consisted	_	_	O
83	of	_	_	O
84	etoposide	_	_	O
85	500	_	_	O
86	mg/m	_	_	O
87	(	_	_	O
88	2	_	_	O
89	)	_	_	O
90	,	_	_	O
91	administered	_	_	O
92	at	_	_	O
93	either	_	_	O
94	100	_	_	O
95	mg/m	_	_	O
96	(	_	_	O
97	2	_	_	O
98	)	_	_	O
99	days	_	_	O
100	1	_	_	O
101	through	_	_	O
102	5	_	_	O
103	or	_	_	O
104	165	_	_	O
105	mg/m	_	_	O
106	(	_	_	O
107	2	_	_	O
108	)	_	_	O
109	days	_	_	O
110	1	_	_	O
111	through	_	_	O
112	3	_	_	O
113	,	_	_	O
114	cisplatin	_	_	O
115	100	_	_	O
116	mg/m	_	_	O
117	(	_	_	O
118	2	_	_	O
119	)	_	_	O
120	,	_	_	O
121	administered	_	_	O
122	at	_	_	O
123	either	_	_	O
124	20	_	_	O
125	mg/m	_	_	O
126	(	_	_	O
127	2	_	_	O
128	)	_	_	O
129	days	_	_	O
130	1	_	_	O
131	through	_	_	O
132	5	_	_	O
133	or	_	_	O
134	50	_	_	O
135	mg/m	_	_	O
136	(	_	_	O
137	2	_	_	O
138	)	_	_	O
139	days	_	_	O
140	1	_	_	O
141	and	_	_	O
142	2	_	_	O
143	.	_	_	O

144	Bleomycin	_	_	O
145	30	_	_	O
146	mg	_	_	O
147	was	_	_	O
148	administered	_	_	O
149	on	_	_	O
150	days	_	_	O
151	1	_	_	O
152	,	_	_	O
153	8	_	_	O
154	,	_	_	O
155	and	_	_	O
156	15	_	_	O
157	during	_	_	O
158	cycles	_	_	O
159	1	_	_	O
160	through	_	_	O
161	3	_	_	O
162	.	_	_	O

163	The	_	_	O
164	randomization	_	_	O
165	procedure	_	_	O
166	allowed	_	_	O
167	some	_	_	O
168	investigators	_	_	O
169	to	_	_	O
170	participate	_	_	O
171	only	_	_	O
172	in	_	_	O
173	the	_	_	O
174	comparison	_	_	O
175	of	_	_	O
176	three	_	_	O
177	versus	_	_	O
178	four	_	_	O
179	cycles	_	_	O
180	.	_	_	O

181	From	_	_	O
182	March	_	_	O
183	1995	_	_	O
184	until	_	_	O
185	April	_	_	O
186	1998	_	_	O
187	,	_	_	O
188	812	_	_	O
189	patients	_	_	O
190	were	_	_	O
191	randomly	_	_	O
192	assigned	_	_	O
193	to	_	_	O
194	receive	_	_	O
195	three	_	_	O
196	or	_	_	O
197	four	_	_	O
198	cycles	_	_	O
199	:	_	_	O
200	of	_	_	O
201	these	_	_	O
202	,	_	_	O
203	681	_	_	O
204	were	_	_	O
205	also	_	_	O
206	randomly	_	_	O
207	assigned	_	_	O
208	to	_	_	O
209	the	_	_	O
210	5-day	_	_	O
211	or	_	_	O
212	the	_	_	O
213	3-day	_	_	O
214	schedule	_	_	O
215	.	_	_	O

216	Histology	_	_	O
217	,	_	_	O
218	marker	_	_	O
219	values	_	_	O
220	,	_	_	O
221	and	_	_	O
222	disease	_	_	O
223	extent	_	_	O
224	are	_	_	O
225	well	_	_	O
226	balanced	_	_	O
227	in	_	_	O
228	the	_	_	O
229	treatment	_	_	O
230	arms	_	_	O
231	of	_	_	O
232	the	_	_	O
233	two	_	_	O
234	comparisons	_	_	O
235	.	_	_	O

236	The	_	_	B-Premise
237	projected	_	_	I-Premise
238	2-year	_	_	I-Premise
239	PFS	_	_	I-Premise
240	is	_	_	I-Premise
241	90.4	_	_	I-Premise
242	%	_	_	I-Premise
243	on	_	_	I-Premise
244	three	_	_	I-Premise
245	cycles	_	_	I-Premise
246	and	_	_	I-Premise
247	89.4	_	_	I-Premise
248	%	_	_	I-Premise
249	on	_	_	I-Premise
250	four	_	_	I-Premise
251	cycles	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Premise
254	difference	_	_	I-Premise
255	in	_	_	I-Premise
256	PFS	_	_	I-Premise
257	between	_	_	I-Premise
258	three	_	_	I-Premise
259	and	_	_	I-Premise
260	four	_	_	I-Premise
261	cycles	_	_	I-Premise
262	is	_	_	I-Premise
263	-1.0	_	_	I-Premise
264	%	_	_	I-Premise
265	(	_	_	I-Premise
266	80	_	_	I-Premise
267	%	_	_	I-Premise
268	confidence	_	_	I-Premise
269	limit	_	_	I-Premise
270	[	_	_	I-Premise
271	CL	_	_	I-Premise
272	]	_	_	I-Premise
273	,	_	_	I-Premise
274	-3.8	_	_	I-Premise
275	%	_	_	I-Premise
276	,	_	_	I-Premise
277	+1.8	_	_	I-Premise
278	%	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	Equivalence	_	_	B-Claim
282	for	_	_	I-Claim
283	three	_	_	I-Claim
284	versus	_	_	I-Claim
285	four	_	_	I-Claim
286	cycles	_	_	I-Claim
287	is	_	_	I-Claim
288	claimed	_	_	I-Claim
289	because	_	_	I-Claim
290	both	_	_	I-Claim
291	the	_	_	I-Claim
292	upper	_	_	I-Claim
293	and	_	_	I-Claim
294	lower	_	_	I-Claim
295	bounds	_	_	I-Claim
296	of	_	_	I-Claim
297	the	_	_	I-Claim
298	80	_	_	I-Claim
299	%	_	_	I-Claim
300	CL	_	_	I-Claim
301	are	_	_	I-Claim
302	less	_	_	I-Claim
303	than	_	_	I-Claim
304	5	_	_	I-Claim
305	%	_	_	I-Claim
306	.	_	_	I-Claim

307	In	_	_	B-Premise
308	the	_	_	I-Premise
309	5-	_	_	I-Premise
310	versus	_	_	I-Premise
311	3-day	_	_	I-Premise
312	comparison	_	_	I-Premise
313	,	_	_	I-Premise
314	the	_	_	I-Premise
315	projected	_	_	I-Premise
316	2-year	_	_	I-Premise
317	PFS	_	_	I-Premise
318	is	_	_	I-Premise
319	88.8	_	_	I-Premise
320	%	_	_	I-Premise
321	and	_	_	I-Premise
322	89.7	_	_	I-Premise
323	%	_	_	I-Premise
324	,	_	_	I-Premise
325	respectively	_	_	I-Premise
326	(	_	_	I-Premise
327	difference	_	_	I-Premise
328	,	_	_	I-Premise
329	-0.9	_	_	I-Premise
330	%	_	_	I-Premise
331	,	_	_	I-Premise
332	(	_	_	I-Premise
333	80	_	_	I-Premise
334	%	_	_	I-Premise
335	CL	_	_	I-Premise
336	,	_	_	I-Premise
337	-4.1	_	_	I-Premise
338	%	_	_	I-Premise
339	,	_	_	I-Premise
340	+2.2	_	_	I-Premise
341	%	_	_	I-Premise
342	)	_	_	I-Premise
343	.	_	_	I-Premise

344	Hence	_	_	O
345	,	_	_	O
346	equivalence	_	_	B-Claim
347	is	_	_	I-Claim
348	claimed	_	_	I-Claim
349	in	_	_	I-Claim
350	this	_	_	I-Claim
351	comparison	_	_	I-Claim
352	also	_	_	I-Claim
353	.	_	_	I-Claim

354	Frequencies	_	_	B-Premise
355	of	_	_	I-Premise
356	hematologic	_	_	I-Premise
357	and	_	_	I-Premise
358	nonhematologic	_	_	I-Premise
359	toxicities	_	_	I-Premise
360	were	_	_	I-Premise
361	essentially	_	_	I-Premise
362	similar	_	_	I-Premise
363	.	_	_	I-Premise

364	Quality	_	_	B-Premise
365	of	_	_	I-Premise
366	life	_	_	I-Premise
367	was	_	_	I-Premise
368	maintained	_	_	I-Premise
369	better	_	_	I-Premise
370	in	_	_	I-Premise
371	patients	_	_	I-Premise
372	receiving	_	_	I-Premise
373	three	_	_	I-Premise
374	cycles	_	_	I-Premise
375	;	_	_	I-Premise
376	no	_	_	B-Premise
377	differences	_	_	I-Premise
378	were	_	_	I-Premise
379	detected	_	_	I-Premise
380	between	_	_	I-Premise
381	3	_	_	I-Premise
382	and	_	_	I-Premise
383	5	_	_	I-Premise
384	days	_	_	I-Premise
385	of	_	_	I-Premise
386	treatment	_	_	I-Premise
387	.	_	_	I-Premise

388	We	_	_	O
389	conclude	_	_	O
390	that	_	_	O
391	three	_	_	B-Claim
392	cycles	_	_	I-Claim
393	of	_	_	I-Claim
394	BEP	_	_	I-Claim
395	,	_	_	I-Claim
396	with	_	_	I-Claim
397	etoposide	_	_	I-Claim
398	at	_	_	I-Claim
399	500	_	_	I-Claim
400	mg/m	_	_	I-Claim
401	(	_	_	I-Claim
402	2	_	_	I-Claim
403	)	_	_	I-Claim
404	,	_	_	I-Claim
405	is	_	_	I-Claim
406	sufficient	_	_	I-Claim
407	therapy	_	_	I-Claim
408	in	_	_	I-Claim
409	good-prognosis	_	_	I-Claim
410	germ	_	_	I-Claim
411	cell	_	_	I-Claim
412	cancer	_	_	I-Claim
413	and	_	_	O
414	that	_	_	O
415	the	_	_	B-Claim
416	administration	_	_	I-Claim
417	of	_	_	I-Claim
418	the	_	_	I-Claim
419	chemotherapy	_	_	I-Claim
420	in	_	_	I-Claim
421	3	_	_	I-Claim
422	days	_	_	I-Claim
423	has	_	_	I-Claim
424	no	_	_	I-Claim
425	detrimental	_	_	I-Claim
426	effect	_	_	I-Claim
427	on	_	_	I-Claim
428	the	_	_	I-Claim
429	effectiveness	_	_	I-Claim
430	of	_	_	I-Claim
431	the	_	_	I-Claim
432	BEP	_	_	I-Claim
433	regimen	_	_	I-Claim
434	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	topotecan	_	_	O
6	in	_	_	O
7	combination	_	_	O
8	with	_	_	O
9	standard	_	_	O
10	chemotherapy	_	_	O
11	in	_	_	O
12	previously	_	_	O
13	untreated	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	extensive-stage	_	_	O
17	small-cell	_	_	O
18	lung	_	_	O
19	cancer	_	_	O
20	(	_	_	O
21	SCLC	_	_	O
22	)	_	_	O
23	,	_	_	O
24	the	_	_	O
25	Eastern	_	_	O
26	Cooperative	_	_	O
27	Oncology	_	_	O
28	Group	_	_	O
29	(	_	_	O
30	ECOG	_	_	O
31	)	_	_	O
32	conducted	_	_	O
33	a	_	_	O
34	phase	_	_	O
35	III	_	_	O
36	trial	_	_	O
37	.	_	_	O

38	Eligible	_	_	O
39	patients	_	_	O
40	had	_	_	O
41	measurable	_	_	O
42	or	_	_	O
43	assessable	_	_	O
44	disease	_	_	O
45	and	_	_	O
46	an	_	_	O
47	ECOG	_	_	O
48	performance	_	_	O
49	status	_	_	O
50	of	_	_	O
51	0	_	_	O
52	to	_	_	O
53	2	_	_	O
54	;	_	_	O
55	stable	_	_	O
56	brain	_	_	O
57	metastases	_	_	O
58	were	_	_	O
59	allowed	_	_	O
60	.	_	_	O

61	All	_	_	O
62	patients	_	_	O
63	received	_	_	O
64	four	_	_	O
65	cycles	_	_	O
66	of	_	_	O
67	cisplatin	_	_	O
68	and	_	_	O
69	etoposide	_	_	O
70	every	_	_	O
71	3	_	_	O
72	weeks	_	_	O
73	(	_	_	O
74	step	_	_	O
75	1	_	_	O
76	;	_	_	O
77	PE	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Patients	_	_	O
81	with	_	_	O
82	stable	_	_	O
83	or	_	_	O
84	responding	_	_	O
85	disease	_	_	O
86	were	_	_	O
87	then	_	_	O
88	randomized	_	_	O
89	to	_	_	O
90	observation	_	_	O
91	or	_	_	O
92	four	_	_	O
93	cycles	_	_	O
94	of	_	_	O
95	topotecan	_	_	O
96	(	_	_	O
97	1.5	_	_	O
98	mg/m	_	_	O
99	(	_	_	O
100	2	_	_	O
101	)	_	_	O
102	/d	_	_	O
103	for	_	_	O
104	5	_	_	O
105	days	_	_	O
106	,	_	_	O
107	every	_	_	O
108	3	_	_	O
109	weeks	_	_	O
110	;	_	_	O
111	step	_	_	O
112	2	_	_	O
113	)	_	_	O
114	.	_	_	O

115	A	_	_	O
116	total	_	_	O
117	of	_	_	O
118	402	_	_	O
119	eligible	_	_	O
120	patients	_	_	O
121	were	_	_	O
122	registered	_	_	O
123	to	_	_	O
124	step	_	_	O
125	1	_	_	O
126	,	_	_	O
127	and	_	_	O
128	223	_	_	O
129	eligible	_	_	O
130	patients	_	_	O
131	were	_	_	O
132	registered	_	_	O
133	to	_	_	O
134	step	_	_	O
135	2	_	_	O
136	(	_	_	O
137	observation	_	_	O
138	,	_	_	O
139	n	_	_	O
140	=	_	_	O
141	111	_	_	O
142	;	_	_	O
143	topotecan	_	_	O
144	,	_	_	O
145	n	_	_	O
146	=	_	_	O
147	112	_	_	O
148	)	_	_	O
149	.	_	_	O

150	Complete	_	_	B-Premise
151	and	_	_	I-Premise
152	partial	_	_	I-Premise
153	response	_	_	I-Premise
154	rates	_	_	I-Premise
155	to	_	_	I-Premise
156	induction	_	_	I-Premise
157	PE	_	_	I-Premise
158	were	_	_	I-Premise
159	3	_	_	I-Premise
160	%	_	_	I-Premise
161	and	_	_	I-Premise
162	32	_	_	I-Premise
163	%	_	_	I-Premise
164	,	_	_	I-Premise
165	respectively	_	_	I-Premise
166	.	_	_	I-Premise

167	A	_	_	B-Premise
168	7	_	_	I-Premise
169	%	_	_	I-Premise
170	response	_	_	I-Premise
171	rate	_	_	I-Premise
172	was	_	_	I-Premise
173	observed	_	_	I-Premise
174	with	_	_	I-Premise
175	topotecan	_	_	I-Premise
176	(	_	_	I-Premise
177	complete	_	_	I-Premise
178	response	_	_	I-Premise
179	,	_	_	I-Premise
180	2	_	_	I-Premise
181	%	_	_	I-Premise
182	;	_	_	I-Premise
183	partial	_	_	I-Premise
184	response	_	_	I-Premise
185	,	_	_	I-Premise
186	5	_	_	I-Premise
187	%	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	The	_	_	B-Premise
191	median	_	_	I-Premise
192	survival	_	_	I-Premise
193	time	_	_	I-Premise
194	for	_	_	I-Premise
195	all	_	_	I-Premise
196	402	_	_	I-Premise
197	eligible	_	_	I-Premise
198	patients	_	_	I-Premise
199	was	_	_	I-Premise
200	9.6	_	_	I-Premise
201	months	_	_	I-Premise
202	.	_	_	I-Premise

203	Progression-free	_	_	B-Premise
204	survival	_	_	I-Premise
205	(	_	_	I-Premise
206	PFS	_	_	I-Premise
207	)	_	_	I-Premise
208	from	_	_	I-Premise
209	date	_	_	I-Premise
210	of	_	_	I-Premise
211	randomization	_	_	I-Premise
212	on	_	_	I-Premise
213	step	_	_	I-Premise
214	2	_	_	I-Premise
215	was	_	_	I-Premise
216	significantly	_	_	I-Premise
217	better	_	_	I-Premise
218	with	_	_	I-Premise
219	topotecan	_	_	I-Premise
220	compared	_	_	I-Premise
221	with	_	_	I-Premise
222	observation	_	_	I-Premise
223	(	_	_	I-Premise
224	3.6	_	_	I-Premise
225	months	_	_	I-Premise
226	v	_	_	I-Premise
227	2.3	_	_	I-Premise
228	months	_	_	I-Premise
229	;	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	.001	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	However	_	_	O
236	,	_	_	O
237	overall	_	_	B-Premise
238	survival	_	_	I-Premise
239	from	_	_	I-Premise
240	date	_	_	I-Premise
241	of	_	_	I-Premise
242	randomization	_	_	I-Premise
243	on	_	_	I-Premise
244	step	_	_	I-Premise
245	2	_	_	I-Premise
246	was	_	_	I-Premise
247	not	_	_	I-Premise
248	significantly	_	_	I-Premise
249	different	_	_	I-Premise
250	between	_	_	I-Premise
251	the	_	_	I-Premise
252	observation	_	_	I-Premise
253	and	_	_	I-Premise
254	topotecan	_	_	I-Premise
255	arms	_	_	I-Premise
256	(	_	_	I-Premise
257	8.9	_	_	I-Premise
258	months	_	_	I-Premise
259	v	_	_	I-Premise
260	9.3	_	_	I-Premise
261	months	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=.43	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Grade	_	_	B-Premise
268	4	_	_	I-Premise
269	neutropenia	_	_	I-Premise
270	and	_	_	I-Premise
271	thrombocytopenia	_	_	I-Premise
272	occurred	_	_	I-Premise
273	in	_	_	I-Premise
274	50	_	_	I-Premise
275	%	_	_	I-Premise
276	and	_	_	I-Premise
277	3	_	_	I-Premise
278	%	_	_	I-Premise
279	,	_	_	I-Premise
280	respectively	_	_	I-Premise
281	,	_	_	I-Premise
282	of	_	_	I-Premise
283	PE	_	_	I-Premise
284	patients	_	_	I-Premise
285	in	_	_	I-Premise
286	step	_	_	I-Premise
287	1	_	_	I-Premise
288	and	_	_	I-Premise
289	60	_	_	I-Premise
290	%	_	_	I-Premise
291	and	_	_	I-Premise
292	13	_	_	I-Premise
293	%	_	_	I-Premise
294	of	_	_	I-Premise
295	topotecan	_	_	I-Premise
296	patients	_	_	I-Premise
297	in	_	_	I-Premise
298	step	_	_	I-Premise
299	2	_	_	I-Premise
300	.	_	_	I-Premise

301	Grade	_	_	B-Premise
302	4/5	_	_	I-Premise
303	infection	_	_	I-Premise
304	was	_	_	I-Premise
305	observed	_	_	I-Premise
306	in	_	_	I-Premise
307	4.6	_	_	I-Premise
308	%	_	_	I-Premise
309	of	_	_	I-Premise
310	PE	_	_	I-Premise
311	patients	_	_	I-Premise
312	and	_	_	I-Premise
313	1.8	_	_	I-Premise
314	%	_	_	I-Premise
315	of	_	_	I-Premise
316	topotecan	_	_	I-Premise
317	patients	_	_	I-Premise
318	.	_	_	I-Premise

319	Grade	_	_	B-Premise
320	3/4	_	_	I-Premise
321	anemia	_	_	I-Premise
322	developed	_	_	I-Premise
323	in	_	_	I-Premise
324	22	_	_	I-Premise
325	%	_	_	I-Premise
326	of	_	_	I-Premise
327	patients	_	_	I-Premise
328	who	_	_	I-Premise
329	received	_	_	I-Premise
330	topotecan	_	_	I-Premise
331	.	_	_	I-Premise

332	No	_	_	B-Premise
333	difference	_	_	I-Premise
334	in	_	_	I-Premise
335	quality	_	_	I-Premise
336	of	_	_	I-Premise
337	life	_	_	I-Premise
338	between	_	_	I-Premise
339	topotecan	_	_	I-Premise
340	and	_	_	I-Premise
341	observation	_	_	I-Premise
342	was	_	_	I-Premise
343	observed	_	_	I-Premise
344	at	_	_	I-Premise
345	any	_	_	I-Premise
346	assessment	_	_	I-Premise
347	time	_	_	I-Premise
348	or	_	_	I-Premise
349	for	_	_	I-Premise
350	any	_	_	I-Premise
351	of	_	_	I-Premise
352	the	_	_	I-Premise
353	subscale	_	_	I-Premise
354	scores	_	_	I-Premise
355	.	_	_	I-Premise

356	Four	_	_	B-Claim
357	cycles	_	_	I-Claim
358	of	_	_	I-Claim
359	PE	_	_	I-Claim
360	induction	_	_	I-Claim
361	therapy	_	_	I-Claim
362	followed	_	_	I-Claim
363	by	_	_	I-Claim
364	four	_	_	I-Claim
365	cycles	_	_	I-Claim
366	of	_	_	I-Claim
367	topotecan	_	_	I-Claim
368	improved	_	_	I-Claim
369	PFS	_	_	I-Claim
370	but	_	_	I-Claim
371	failed	_	_	I-Claim
372	to	_	_	I-Claim
373	improve	_	_	I-Claim
374	overall	_	_	I-Claim
375	survival	_	_	I-Claim
376	or	_	_	I-Claim
377	quality	_	_	I-Claim
378	of	_	_	I-Claim
379	life	_	_	I-Claim
380	in	_	_	I-Claim
381	extensive-stage	_	_	I-Claim
382	SCLC	_	_	I-Claim
383	.	_	_	I-Claim

384	Four	_	_	B-Claim
385	cycles	_	_	I-Claim
386	of	_	_	I-Claim
387	standard	_	_	I-Claim
388	PE	_	_	I-Claim
389	remains	_	_	I-Claim
390	an	_	_	I-Claim
391	appropriate	_	_	I-Claim
392	first-line	_	_	I-Claim
393	treatment	_	_	I-Claim
394	for	_	_	I-Claim
395	extensive-stage	_	_	I-Claim
396	SCLC	_	_	I-Claim
397	patients	_	_	I-Claim
398	with	_	_	I-Claim
399	good	_	_	I-Claim
400	performance	_	_	I-Claim
401	status	_	_	I-Claim
402	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	)	_	_	O
6	-lowering	_	_	O
7	effect	_	_	O
8	and	_	_	O
9	side	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	latanoprost	_	_	O
13	0.005	_	_	O
14	%	_	_	O
15	once	_	_	O
16	daily	_	_	O
17	with	_	_	O
18	unoprostone	_	_	O
19	0.12	_	_	O
20	%	_	_	O
21	twice	_	_	O
22	daily	_	_	O
23	.	_	_	O

24	Sixty	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	primary	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	were	_	_	O
34	randomized	_	_	O
35	to	_	_	O
36	receive	_	_	O
37	either	_	_	O
38	latanoprost	_	_	O
39	once	_	_	O
40	daily	_	_	O
41	in	_	_	O
42	the	_	_	O
43	evening	_	_	O
44	and	_	_	O
45	placebo	_	_	O
46	once	_	_	O
47	daily	_	_	O
48	in	_	_	O
49	the	_	_	O
50	morning	_	_	O
51	,	_	_	O
52	or	_	_	O
53	unoprostone	_	_	O
54	twice	_	_	O
55	daily	_	_	O
56	in	_	_	O
57	the	_	_	O
58	morning	_	_	O
59	and	_	_	O
60	evening	_	_	O
61	.	_	_	O

62	The	_	_	O
63	study	_	_	O
64	was	_	_	O
65	double	_	_	O
66	masked	_	_	O
67	and	_	_	O
68	followed	_	_	O
69	a	_	_	O
70	crossover	_	_	O
71	design	_	_	O
72	with	_	_	O
73	two	_	_	O
74	treatment	_	_	O
75	periods	_	_	O
76	of	_	_	O
77	1	_	_	O
78	month	_	_	O
79	separated	_	_	O
80	by	_	_	O
81	a	_	_	O
82	3-week	_	_	O
83	washout	_	_	O
84	period	_	_	O
85	.	_	_	O

86	The	_	_	O
87	intraocular	_	_	O
88	pressure	_	_	O
89	was	_	_	O
90	measured	_	_	O
91	at	_	_	O
92	9	_	_	O
93	AM	_	_	O
94	and	_	_	O
95	5	_	_	O
96	PM	_	_	O
97	on	_	_	O
98	the	_	_	O
99	baseline	_	_	O
100	and	_	_	O
101	day	_	_	O
102	28	_	_	O
103	visits	_	_	O
104	,	_	_	O
105	and	_	_	O
106	at	_	_	O
107	9	_	_	O
108	AM	_	_	O
109	on	_	_	O
110	day	_	_	O
111	2	_	_	O
112	and	_	_	O
113	day	_	_	O
114	14	_	_	O
115	visits	_	_	O
116	of	_	_	O
117	each	_	_	O
118	treatment	_	_	O
119	period	_	_	O
120	.	_	_	O

121	The	_	_	O
122	9	_	_	O
123	AM	_	_	O
124	measurement	_	_	O
125	was	_	_	O
126	taken	_	_	O
127	2	_	_	O
128	hours	_	_	O
129	and	_	_	O
130	13	_	_	O
131	hours	_	_	O
132	after	_	_	O
133	the	_	_	O
134	last	_	_	O
135	drop	_	_	O
136	of	_	_	O
137	unoprostone	_	_	O
138	and	_	_	O
139	latanoprost	_	_	O
140	,	_	_	O
141	and	_	_	O
142	the	_	_	O
143	5	_	_	O
144	PM	_	_	O
145	measurement	_	_	O
146	was	_	_	O
147	at	_	_	O
148	10	_	_	O
149	and	_	_	O
150	21	_	_	O
151	hours	_	_	O
152	,	_	_	O
153	respectively	_	_	O
154	.	_	_	O

155	The	_	_	O
156	mean	_	_	O
157	of	_	_	O
158	the	_	_	O
159	measurements	_	_	O
160	was	_	_	O
161	calculated	_	_	O
162	.	_	_	O

163	Safety	_	_	O
164	parameters	_	_	O
165	were	_	_	O
166	also	_	_	O
167	recorded	_	_	O
168	.	_	_	O

169	Fifty-six	_	_	O
170	patients	_	_	O
171	completed	_	_	O
172	both	_	_	O
173	treatment	_	_	O
174	periods	_	_	O
175	and	_	_	O
176	had	_	_	O
177	intraocular	_	_	O
178	pressure	_	_	O
179	data	_	_	O
180	available	_	_	O
181	for	_	_	O
182	evaluation	_	_	O
183	.	_	_	O

184	After	_	_	B-Premise
185	1	_	_	I-Premise
186	month	_	_	I-Premise
187	of	_	_	I-Premise
188	treatment	_	_	I-Premise
189	,	_	_	I-Premise
190	latanoprost	_	_	I-Premise
191	significantly	_	_	I-Premise
192	reduced	_	_	I-Premise
193	intraocular	_	_	I-Premise
194	pressure	_	_	I-Premise
195	(	_	_	I-Premise
196	mean	_	_	I-Premise
197	+/-	_	_	I-Premise
198	SEM	_	_	I-Premise
199	)	_	_	I-Premise
200	by	_	_	I-Premise
201	6.1	_	_	I-Premise
202	+/-	_	_	I-Premise
203	0.5	_	_	I-Premise
204	mm	_	_	I-Premise
205	Hg	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	<	_	_	I-Premise
209	.001	_	_	I-Premise
210	)	_	_	I-Premise
211	and	_	_	I-Premise
212	unoprostone	_	_	I-Premise
213	by	_	_	I-Premise
214	4.2	_	_	I-Premise
215	+/-	_	_	I-Premise
216	0.4	_	_	I-Premise
217	mm	_	_	I-Premise
218	Hg	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	.001	_	_	I-Premise
223	)	_	_	I-Premise
224	adjusted	_	_	I-Premise
225	from	_	_	I-Premise
226	an	_	_	I-Premise
227	overall	_	_	I-Premise
228	baseline	_	_	I-Premise
229	of	_	_	I-Premise
230	22.3	_	_	I-Premise
231	+/-	_	_	I-Premise
232	0.5	_	_	I-Premise
233	mm	_	_	I-Premise
234	Hg	_	_	I-Premise
235	and	_	_	I-Premise
236	23.2	_	_	I-Premise
237	+/-	_	_	I-Premise
238	0.4	_	_	I-Premise
239	mm	_	_	I-Premise
240	Hg	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	difference	_	_	I-Premise
246	of	_	_	I-Premise
247	1.9	_	_	I-Premise
248	mm	_	_	I-Premise
249	Hg	_	_	I-Premise
250	between	_	_	I-Premise
251	treatments	_	_	I-Premise
252	was	_	_	I-Premise
253	statistically	_	_	I-Premise
254	significant	_	_	I-Premise
255	in	_	_	I-Premise
256	favor	_	_	I-Premise
257	of	_	_	I-Premise
258	latanoprost	_	_	I-Premise
259	[	_	_	I-Premise
260	P	_	_	I-Premise
261	=.003	_	_	I-Premise
262	,	_	_	I-Premise
263	analysis	_	_	I-Premise
264	of	_	_	I-Premise
265	covariance	_	_	I-Premise
266	(	_	_	I-Premise
267	ANCOVA	_	_	I-Premise
268	)	_	_	I-Premise
269	]	_	_	I-Premise
270	.	_	_	I-Premise

271	Unadjusted	_	_	B-Premise
272	analysis	_	_	I-Premise
273	of	_	_	I-Premise
274	responders	_	_	I-Premise
275	using	_	_	I-Premise
276	the	_	_	I-Premise
277	percentage	_	_	I-Premise
278	decrease	_	_	I-Premise
279	in	_	_	I-Premise
280	intraocular	_	_	I-Premise
281	pressure	_	_	I-Premise
282	showed	_	_	I-Premise
283	that	_	_	I-Premise
284	the	_	_	I-Premise
285	proportion	_	_	I-Premise
286	of	_	_	I-Premise
287	responders	_	_	I-Premise
288	in	_	_	I-Premise
289	the	_	_	I-Premise
290	latanoprost-treated	_	_	I-Premise
291	group	_	_	I-Premise
292	was	_	_	I-Premise
293	greater	_	_	I-Premise
294	than	_	_	I-Premise
295	in	_	_	I-Premise
296	the	_	_	I-Premise
297	unoprostone-treated	_	_	I-Premise
298	group	_	_	I-Premise
299	.	_	_	I-Premise

300	Adverse	_	_	B-Premise
301	ocular	_	_	I-Premise
302	symptoms	_	_	I-Premise
303	and	_	_	I-Premise
304	findings	_	_	I-Premise
305	were	_	_	I-Premise
306	mild	_	_	I-Premise
307	in	_	_	I-Premise
308	both	_	_	I-Premise
309	treatment	_	_	I-Premise
310	groups	_	_	I-Premise
311	.	_	_	I-Premise

312	Eye	_	_	B-Premise
313	redness	_	_	I-Premise
314	and	_	_	I-Premise
315	ocular	_	_	I-Premise
316	irritation	_	_	I-Premise
317	were	_	_	I-Premise
318	the	_	_	I-Premise
319	most	_	_	I-Premise
320	frequently	_	_	I-Premise
321	reported	_	_	I-Premise
322	events	_	_	I-Premise
323	.	_	_	I-Premise

324	Latanoprost	_	_	B-Claim
325	once	_	_	I-Claim
326	daily	_	_	I-Claim
327	was	_	_	I-Claim
328	significantly	_	_	I-Claim
329	more	_	_	I-Claim
330	effective	_	_	I-Claim
331	in	_	_	I-Claim
332	reducing	_	_	I-Claim
333	intraocular	_	_	I-Claim
334	pressure	_	_	I-Claim
335	compared	_	_	I-Claim
336	with	_	_	I-Claim
337	unoprostone	_	_	I-Claim
338	twice	_	_	I-Claim
339	daily	_	_	I-Claim
340	after	_	_	I-Claim
341	1	_	_	I-Claim
342	month	_	_	I-Claim
343	of	_	_	I-Claim
344	treatment	_	_	I-Claim
345	in	_	_	I-Claim
346	patients	_	_	I-Claim
347	with	_	_	I-Claim
348	primary	_	_	I-Claim
349	open-angle	_	_	I-Claim
350	glaucoma	_	_	I-Claim
351	and	_	_	I-Claim
352	ocular	_	_	I-Claim
353	hypertension	_	_	I-Claim
354	.	_	_	I-Claim

355	Both	_	_	B-Claim
356	drugs	_	_	I-Claim
357	were	_	_	I-Claim
358	well	_	_	I-Claim
359	tolerated	_	_	I-Claim
360	with	_	_	I-Claim
361	few	_	_	I-Claim
362	ocular	_	_	I-Claim
363	adverse	_	_	I-Claim
364	events	_	_	I-Claim
365	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	oral	_	_	O
8	bexarotene	_	_	O
9	(	_	_	O
10	Targretin	_	_	O
11	capsules	_	_	O
12	;	_	_	O
13	Ligand	_	_	O
14	Pharmaceuticals	_	_	O
15	Incorporated	_	_	O
16	,	_	_	O
17	San	_	_	O
18	Diego	_	_	O
19	,	_	_	O
20	Calif	_	_	O
21	)	_	_	O
22	.	_	_	O

23	The	_	_	O
24	effects	_	_	O
25	of	_	_	O
26	2	_	_	O
27	randomized	_	_	O
28	doses	_	_	O
29	of	_	_	O
30	6.5	_	_	O
31	mg/m	_	_	O
32	(	_	_	O
33	2	_	_	O
34	)	_	_	O
35	per	_	_	O
36	day	_	_	O
37	(	_	_	O
38	with	_	_	O
39	crossover	_	_	O
40	for	_	_	O
41	progression	_	_	O
42	)	_	_	O
43	vs	_	_	O
44	650	_	_	O
45	mg/m	_	_	O
46	(	_	_	O
47	2	_	_	O
48	)	_	_	O
49	per	_	_	O
50	day	_	_	O
51	(	_	_	O
52	later	_	_	O
53	modified	_	_	O
54	to	_	_	O
55	300	_	_	O
56	mg/m	_	_	O
57	(	_	_	O
58	2	_	_	O
59	)	_	_	O
60	per	_	_	O
61	day	_	_	O
62	)	_	_	O
63	were	_	_	O
64	evaluated	_	_	O
65	in	_	_	O
66	an	_	_	O
67	open-label	_	_	O
68	,	_	_	O
69	multicenter	_	_	O
70	,	_	_	O
71	phase	_	_	O
72	2	_	_	O
73	and	_	_	O
74	3	_	_	O
75	study	_	_	O
76	conducted	_	_	O
77	between	_	_	O
78	February	_	_	O
79	1997	_	_	O
80	and	_	_	O
81	November	_	_	O
82	1998	_	_	O
83	.	_	_	O

84	Eighteen	_	_	O
85	international	_	_	O
86	cutaneous	_	_	O
87	T-cell	_	_	O
88	lymphoma	_	_	O
89	clinics	_	_	O
90	at	_	_	O
91	academic	_	_	O
92	referral	_	_	O
93	centers	_	_	O
94	.	_	_	O

95	Fifty-eight	_	_	O
96	patients	_	_	O
97	with	_	_	O
98	biopsy-proven	_	_	O
99	stage	_	_	O
100	IA	_	_	O
101	through	_	_	O
102	IIA	_	_	O
103	cutaneous	_	_	O
104	T-cell	_	_	O
105	lymphoma	_	_	O
106	that	_	_	O
107	was	_	_	O
108	refractory	_	_	O
109	to	_	_	O
110	(	_	_	O
111	or	_	_	O
112	patients	_	_	O
113	were	_	_	O
114	intolerant	_	_	O
115	of	_	_	O
116	)	_	_	O
117	treatment	_	_	O
118	or	_	_	O
119	had	_	_	O
120	reached	_	_	O
121	at	_	_	O
122	least	_	_	O
123	a	_	_	O
124	6-month	_	_	O
125	response	_	_	O
126	plateau	_	_	O
127	under	_	_	O
128	at	_	_	O
129	least	_	_	O
130	2	_	_	O
131	forms	_	_	O
132	of	_	_	O
133	prior	_	_	O
134	therapy	_	_	O
135	(	_	_	O
136	median	_	_	O
137	of	_	_	O
138	3.5	_	_	O
139	prior	_	_	O
140	therapies	_	_	O
141	)	_	_	O
142	.	_	_	O

143	Bexarotene	_	_	O
144	(	_	_	O
145	Targretin	_	_	O
146	capsules	_	_	O
147	)	_	_	O
148	administered	_	_	O
149	once	_	_	O
150	daily	_	_	O
151	with	_	_	O
152	meal	_	_	O
153	for	_	_	O
154	16	_	_	O
155	weeks	_	_	O
156	or	_	_	O
157	longer	_	_	O
158	.	_	_	O

159	Primary	_	_	O
160	end	_	_	O
161	point	_	_	O
162	classification	_	_	O
163	of	_	_	O
164	overall	_	_	O
165	response	_	_	O
166	rate	_	_	O
167	of	_	_	O
168	complete	_	_	O
169	and	_	_	O
170	partial	_	_	O
171	remissions	_	_	O
172	determined	_	_	O
173	by	_	_	O
174	either	_	_	O
175	the	_	_	O
176	Physician	_	_	O
177	's	_	_	O
178	Global	_	_	O
179	Assessment	_	_	O
180	of	_	_	O
181	Clinical	_	_	O
182	Condition	_	_	O
183	or	_	_	O
184	the	_	_	O
185	objective	_	_	O
186	Composite	_	_	O
187	Assessment	_	_	O
188	of	_	_	O
189	Index	_	_	O
190	Lesion	_	_	O
191	Severity	_	_	O
192	.	_	_	O

193	Body	_	_	O
194	surface	_	_	O
195	area	_	_	O
196	,	_	_	O
197	time	_	_	O
198	to	_	_	O
199	response	_	_	O
200	,	_	_	O
201	duration	_	_	O
202	of	_	_	O
203	disease	_	_	O
204	control	_	_	O
205	,	_	_	O
206	time	_	_	O
207	to	_	_	O
208	disease	_	_	O
209	progression	_	_	O
210	,	_	_	O
211	individual	_	_	O
212	index	_	_	O
213	lesion	_	_	O
214	signs	_	_	O
215	and	_	_	O
216	symptoms	_	_	O
217	,	_	_	O
218	and	_	_	O
219	quality	_	_	O
220	of	_	_	O
221	life	_	_	O
222	parameters	_	_	O
223	were	_	_	O
224	secondary	_	_	O
225	outcomes	_	_	O
226	.	_	_	O

227	Responses	_	_	B-Premise
228	(	_	_	I-Premise
229	>	_	_	I-Premise
230	or	_	_	I-Premise
231	=	_	_	I-Premise
232	50	_	_	I-Premise
233	%	_	_	I-Premise
234	improvement	_	_	I-Premise
235	)	_	_	I-Premise
236	were	_	_	I-Premise
237	seen	_	_	I-Premise
238	in	_	_	I-Premise
239	3	_	_	I-Premise
240	(	_	_	I-Premise
241	20	_	_	I-Premise
242	%	_	_	I-Premise
243	)	_	_	I-Premise
244	of	_	_	I-Premise
245	15	_	_	I-Premise
246	patients	_	_	I-Premise
247	with	_	_	I-Premise
248	an	_	_	I-Premise
249	initial	_	_	I-Premise
250	dose	_	_	I-Premise
251	at	_	_	I-Premise
252	6.5	_	_	I-Premise
253	mg/m	_	_	I-Premise
254	(	_	_	I-Premise
255	2	_	_	I-Premise
256	)	_	_	I-Premise
257	per	_	_	I-Premise
258	day	_	_	I-Premise
259	(	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	confidence	_	_	I-Premise
263	interval	_	_	I-Premise
264	[	_	_	I-Premise
265	CI	_	_	I-Premise
266	]	_	_	I-Premise
267	,	_	_	I-Premise
268	0	_	_	I-Premise
269	%	_	_	I-Premise
270	-40	_	_	I-Premise
271	%	_	_	I-Premise
272	)	_	_	I-Premise
273	,	_	_	I-Premise
274	15	_	_	I-Premise
275	(	_	_	I-Premise
276	54	_	_	I-Premise
277	%	_	_	I-Premise
278	)	_	_	I-Premise
279	of	_	_	I-Premise
280	28	_	_	I-Premise
281	patients	_	_	I-Premise
282	at	_	_	I-Premise
283	300	_	_	I-Premise
284	mg/m	_	_	I-Premise
285	(	_	_	I-Premise
286	2	_	_	I-Premise
287	)	_	_	I-Premise
288	per	_	_	I-Premise
289	day	_	_	I-Premise
290	(	_	_	I-Premise
291	95	_	_	I-Premise
292	%	_	_	I-Premise
293	CI	_	_	I-Premise
294	,	_	_	I-Premise
295	35	_	_	I-Premise
296	%	_	_	I-Premise
297	-72	_	_	I-Premise
298	%	_	_	I-Premise
299	)	_	_	I-Premise
300	,	_	_	I-Premise
301	and	_	_	I-Premise
302	10	_	_	I-Premise
303	(	_	_	I-Premise
304	67	_	_	I-Premise
305	%	_	_	I-Premise
306	)	_	_	I-Premise
307	of	_	_	I-Premise
308	15	_	_	I-Premise
309	patients	_	_	I-Premise
310	at	_	_	I-Premise
311	above	_	_	I-Premise
312	300	_	_	I-Premise
313	mg/m	_	_	I-Premise
314	(	_	_	I-Premise
315	2	_	_	I-Premise
316	)	_	_	I-Premise
317	per	_	_	I-Premise
318	day	_	_	I-Premise
319	(	_	_	I-Premise
320	95	_	_	I-Premise
321	%	_	_	I-Premise
322	CI	_	_	I-Premise
323	,	_	_	I-Premise
324	43	_	_	I-Premise
325	%	_	_	I-Premise
326	-91	_	_	I-Premise
327	%	_	_	I-Premise
328	)	_	_	I-Premise
329	.	_	_	I-Premise

330	The	_	_	B-Premise
331	rate	_	_	I-Premise
332	of	_	_	I-Premise
333	progressive	_	_	I-Premise
334	disease	_	_	I-Premise
335	was	_	_	I-Premise
336	47	_	_	I-Premise
337	%	_	_	I-Premise
338	,	_	_	I-Premise
339	21	_	_	I-Premise
340	%	_	_	I-Premise
341	,	_	_	I-Premise
342	and	_	_	I-Premise
343	13	_	_	I-Premise
344	%	_	_	I-Premise
345	at	_	_	I-Premise
346	the	_	_	I-Premise
347	same	_	_	I-Premise
348	dose	_	_	I-Premise
349	levels	_	_	I-Premise
350	,	_	_	I-Premise
351	respectively	_	_	I-Premise
352	.	_	_	I-Premise

353	Eight	_	_	B-Premise
354	(	_	_	I-Premise
355	73	_	_	I-Premise
356	%	_	_	I-Premise
357	)	_	_	I-Premise
358	of	_	_	I-Premise
359	11	_	_	I-Premise
360	patients	_	_	I-Premise
361	crossing	_	_	I-Premise
362	over	_	_	I-Premise
363	from	_	_	I-Premise
364	6.5	_	_	I-Premise
365	mg/m	_	_	I-Premise
366	(	_	_	I-Premise
367	2	_	_	I-Premise
368	)	_	_	I-Premise
369	per	_	_	I-Premise
370	day	_	_	I-Premise
371	to	_	_	I-Premise
372	higher	_	_	I-Premise
373	doses	_	_	I-Premise
374	subsequently	_	_	I-Premise
375	responded	_	_	I-Premise
376	.	_	_	I-Premise

377	The	_	_	B-Premise
378	median	_	_	I-Premise
379	duration	_	_	I-Premise
380	of	_	_	I-Premise
381	response	_	_	I-Premise
382	from	_	_	I-Premise
383	start	_	_	I-Premise
384	of	_	_	I-Premise
385	therapy	_	_	I-Premise
386	could	_	_	I-Premise
387	not	_	_	I-Premise
388	be	_	_	I-Premise
389	estimated	_	_	I-Premise
390	for	_	_	I-Premise
391	the	_	_	I-Premise
392	15	_	_	I-Premise
393	patients	_	_	I-Premise
394	at	_	_	I-Premise
395	300	_	_	I-Premise
396	mg/m	_	_	I-Premise
397	(	_	_	I-Premise
398	2	_	_	I-Premise
399	)	_	_	I-Premise
400	per	_	_	I-Premise
401	day	_	_	I-Premise
402	owing	_	_	I-Premise
403	to	_	_	I-Premise
404	low	_	_	I-Premise
405	relapse	_	_	I-Premise
406	rates	_	_	I-Premise
407	in	_	_	I-Premise
408	2	_	_	I-Premise
409	patients	_	_	I-Premise
410	(	_	_	I-Premise
411	13	_	_	I-Premise
412	%	_	_	I-Premise
413	)	_	_	I-Premise
414	;	_	_	I-Premise
415	at	_	_	I-Premise
416	higher	_	_	I-Premise
417	doses	_	_	I-Premise
418	it	_	_	I-Premise
419	was	_	_	I-Premise
420	516	_	_	I-Premise
421	days	_	_	I-Premise
422	.	_	_	I-Premise

423	The	_	_	B-Premise
424	following	_	_	I-Premise
425	drug-related	_	_	I-Premise
426	adverse	_	_	I-Premise
427	effects	_	_	I-Premise
428	were	_	_	I-Premise
429	reversible	_	_	I-Premise
430	and	_	_	I-Premise
431	treatable	_	_	I-Premise
432	:	_	_	I-Premise
433	hypertriglyceridemia	_	_	I-Premise
434	(	_	_	I-Premise
435	46	_	_	I-Premise
436	patients	_	_	I-Premise
437	[	_	_	I-Premise
438	79	_	_	I-Premise
439	%	_	_	I-Premise
440	]	_	_	I-Premise
441	)	_	_	I-Premise
442	,	_	_	I-Premise
443	hypercholesterolemia	_	_	I-Premise
444	(	_	_	I-Premise
445	28	_	_	I-Premise
446	patients	_	_	I-Premise
447	[	_	_	I-Premise
448	48	_	_	I-Premise
449	%	_	_	I-Premise
450	]	_	_	I-Premise
451	)	_	_	I-Premise
452	,	_	_	I-Premise
453	headache	_	_	I-Premise
454	(	_	_	I-Premise
455	27	_	_	I-Premise
456	patients	_	_	I-Premise
457	[	_	_	I-Premise
458	47	_	_	I-Premise
459	%	_	_	I-Premise
460	]	_	_	I-Premise
461	)	_	_	I-Premise
462	,	_	_	I-Premise
463	central	_	_	I-Premise
464	hypothyroidism	_	_	I-Premise
465	(	_	_	I-Premise
466	23	_	_	I-Premise
467	patients	_	_	I-Premise
468	[	_	_	I-Premise
469	40	_	_	I-Premise
470	%	_	_	I-Premise
471	]	_	_	I-Premise
472	)	_	_	I-Premise
473	,	_	_	I-Premise
474	asthenia	_	_	I-Premise
475	(	_	_	I-Premise
476	21	_	_	I-Premise
477	patients	_	_	I-Premise
478	[	_	_	I-Premise
479	36	_	_	I-Premise
480	%	_	_	I-Premise
481	]	_	_	I-Premise
482	)	_	_	I-Premise
483	,	_	_	I-Premise
484	and	_	_	I-Premise
485	leukopenia	_	_	I-Premise
486	(	_	_	I-Premise
487	16	_	_	I-Premise
488	patients	_	_	I-Premise
489	[	_	_	I-Premise
490	28	_	_	I-Premise
491	%	_	_	I-Premise
492	]	_	_	I-Premise
493	)	_	_	I-Premise
494	.	_	_	I-Premise

495	No	_	_	B-Premise
496	cases	_	_	I-Premise
497	of	_	_	I-Premise
498	drug-related	_	_	I-Premise
499	neutropenic	_	_	I-Premise
500	fever	_	_	I-Premise
501	,	_	_	I-Premise
502	sepsis	_	_	I-Premise
503	,	_	_	I-Premise
504	or	_	_	I-Premise
505	death	_	_	I-Premise
506	occurred	_	_	I-Premise
507	.	_	_	I-Premise

508	Pancreatitis	_	_	B-Premise
509	occurred	_	_	I-Premise
510	in	_	_	I-Premise
511	3	_	_	I-Premise
512	patients	_	_	I-Premise
513	with	_	_	I-Premise
514	triglyceride	_	_	I-Premise
515	levels	_	_	I-Premise
516	higher	_	_	I-Premise
517	than	_	_	I-Premise
518	14.69	_	_	I-Premise
519	mmol/L	_	_	I-Premise
520	(	_	_	I-Premise
521	1300	_	_	I-Premise
522	mg/dL	_	_	I-Premise
523	)	_	_	I-Premise
524	,	_	_	I-Premise
525	all	_	_	I-Premise
526	of	_	_	I-Premise
527	whom	_	_	I-Premise
528	were	_	_	I-Premise
529	taking	_	_	I-Premise
530	300	_	_	I-Premise
531	mg/m	_	_	I-Premise
532	(	_	_	I-Premise
533	2	_	_	I-Premise
534	)	_	_	I-Premise
535	or	_	_	I-Premise
536	more	_	_	I-Premise
537	of	_	_	I-Premise
538	oral	_	_	I-Premise
539	bexarotene	_	_	I-Premise
540	per	_	_	I-Premise
541	day	_	_	I-Premise
542	.	_	_	I-Premise

543	Bexarotene	_	_	B-Claim
544	(	_	_	I-Claim
545	Targretin	_	_	I-Claim
546	capsules	_	_	I-Claim
547	)	_	_	I-Claim
548	(	_	_	I-Claim
549	the	_	_	I-Claim
550	first	_	_	I-Claim
551	retinoid	_	_	I-Claim
552	X	_	_	I-Claim
553	receptor-selective	_	_	I-Claim
554	rexinoid	_	_	I-Claim
555	)	_	_	I-Claim
556	was	_	_	I-Claim
557	well	_	_	I-Claim
558	tolerated	_	_	I-Claim
559	and	_	_	I-Claim
560	effective	_	_	I-Claim
561	as	_	_	I-Claim
562	an	_	_	I-Claim
563	oral	_	_	I-Claim
564	treatment	_	_	I-Claim
565	for	_	_	I-Claim
566	15	_	_	I-Claim
567	(	_	_	I-Claim
568	54	_	_	I-Claim
569	%	_	_	I-Claim
570	)	_	_	I-Claim
571	of	_	_	I-Claim
572	28	_	_	I-Claim
573	patients	_	_	I-Claim
574	with	_	_	I-Claim
575	refractory	_	_	I-Claim
576	or	_	_	I-Claim
577	persistent	_	_	I-Claim
578	early-stage	_	_	I-Claim
579	cutaneous	_	_	I-Claim
580	T-cell	_	_	I-Claim
581	lymphoma	_	_	I-Claim
582	at	_	_	I-Claim
583	doses	_	_	I-Claim
584	of	_	_	I-Claim
585	300	_	_	I-Claim
586	mg/m	_	_	I-Claim
587	(	_	_	I-Claim
588	2	_	_	I-Claim
589	)	_	_	I-Claim
590	per	_	_	I-Claim
591	day	_	_	I-Claim
592	.	_	_	I-Claim

593	Hypertriglyceridemia	_	_	B-Claim
594	and	_	_	I-Claim
595	hypothyroidism	_	_	I-Claim
596	require	_	_	I-Claim
597	monitoring	_	_	I-Claim
598	but	_	_	I-Claim
599	are	_	_	I-Claim
600	reversible	_	_	I-Claim
601	and	_	_	I-Claim
602	manageable	_	_	I-Claim
603	with	_	_	I-Claim
604	concomitant	_	_	I-Claim
605	medication	_	_	I-Claim
606	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	treatment	_	_	O
3	for	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	clinically	_	_	O
7	resectable	_	_	O
8	rectal	_	_	O
9	cancer	_	_	O
10	is	_	_	O
11	surgery	_	_	O
12	.	_	_	O

13	Postoperative	_	_	B-Claim
14	radiochemotherapy	_	_	I-Claim
15	is	_	_	I-Claim
16	recommended	_	_	I-Claim
17	for	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	advanced	_	_	I-Claim
21	disease	_	_	I-Claim
22	(	_	_	I-Claim
23	pT3/4	_	_	I-Claim
24	or	_	_	I-Claim
25	pN+	_	_	I-Claim
26	)	_	_	I-Claim
27	.	_	_	I-Claim

28	In	_	_	B-Claim
29	recent	_	_	I-Claim
30	years	_	_	I-Claim
31	,	_	_	I-Claim
32	encouraging	_	_	I-Claim
33	results	_	_	I-Claim
34	of	_	_	I-Claim
35	preoperative	_	_	I-Claim
36	radiotherapy	_	_	I-Claim
37	have	_	_	I-Claim
38	been	_	_	I-Claim
39	reported	_	_	I-Claim
40	.	_	_	I-Claim

41	This	_	_	O
42	prospective	_	_	O
43	randomized	_	_	O
44	phase-III	_	_	O
45	trial	_	_	O
46	(	_	_	O
47	CAO/ARO/AIO-94	_	_	O
48	)	_	_	O
49	compares	_	_	O
50	the	_	_	O
51	efficacy	_	_	O
52	of	_	_	O
53	neoadjuvant	_	_	O
54	radiochemotherapy	_	_	O
55	to	_	_	O
56	standard	_	_	O
57	postoperative	_	_	O
58	radiochemotherapy	_	_	O
59	.	_	_	O

60	We	_	_	O
61	report	_	_	O
62	on	_	_	O
63	the	_	_	O
64	design	_	_	O
65	of	_	_	O
66	the	_	_	O
67	study	_	_	O
68	and	_	_	O
69	first	_	_	O
70	results	_	_	O
71	with	_	_	O
72	regard	_	_	O
73	to	_	_	O
74	toxicity	_	_	O
75	of	_	_	O
76	radiochemotherapy	_	_	O
77	and	_	_	O
78	postoperative	_	_	O
79	morbidity	_	_	O
80	.	_	_	O

81	Patients	_	_	O
82	with	_	_	O
83	locally	_	_	O
84	advanced	_	_	O
85	operable	_	_	O
86	rectal	_	_	O
87	cancer	_	_	O
88	(	_	_	O
89	uT3/4	_	_	O
90	or	_	_	O
91	uN+	_	_	O
92	,	_	_	O
93	Mason	_	_	O
94	CS	_	_	O
95	III/IV	_	_	O
96	)	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	pre-	_	_	O
102	or	_	_	O
103	postoperative	_	_	O
104	radiochemotherapy	_	_	O
105	:	_	_	O
106	A	_	_	O
107	total	_	_	O
108	dose	_	_	O
109	of	_	_	O
110	50.4	_	_	O
111	Gy	_	_	O
112	(	_	_	O
113	single	_	_	O
114	dose	_	_	O
115	1.8	_	_	O
116	Gy	_	_	O
117	)	_	_	O
118	was	_	_	O
119	applied	_	_	O
120	to	_	_	O
121	the	_	_	O
122	tumor	_	_	O
123	and	_	_	O
124	the	_	_	O
125	pelvic	_	_	O
126	lymph	_	_	O
127	nodes	_	_	O
128	.	_	_	O

129	5-FU	_	_	O
130	(	_	_	O
131	1,000	_	_	O
132	mg/m2/d	_	_	O
133	)	_	_	O
134	was	_	_	O
135	administered	_	_	O
136	concomitantly	_	_	O
137	in	_	_	O
138	the	_	_	O
139	first	_	_	O
140	and	_	_	O
141	fifth	_	_	O
142	week	_	_	O
143	of	_	_	O
144	radiation	_	_	O
145	as	_	_	O
146	120-h	_	_	O
147	continuous	_	_	O
148	infusion	_	_	O
149	.	_	_	O

150	Four	_	_	O
151	additional	_	_	O
152	cycles	_	_	O
153	of	_	_	O
154	5-FU	_	_	O
155	chemotherapy	_	_	O
156	(	_	_	O
157	500	_	_	O
158	mg/m2/d	_	_	O
159	,	_	_	O
160	i.v	_	_	O
161	.	_	_	O

162	bolus	_	_	O
163	)	_	_	O
164	were	_	_	O
165	applied	_	_	O
166	.	_	_	O

167	Radiochemotherapy	_	_	O
168	was	_	_	O
169	identical	_	_	O
170	in	_	_	O
171	both	_	_	O
172	arms	_	_	O
173	except	_	_	O
174	for	_	_	O
175	a	_	_	O
176	small-volume	_	_	O
177	boost	_	_	O
178	of	_	_	O
179	5.4	_	_	O
180	Gy	_	_	O
181	in	_	_	O
182	the	_	_	O
183	postoperative	_	_	O
184	setting	_	_	O
185	.	_	_	O

186	Time	_	_	O
187	interval	_	_	O
188	between	_	_	O
189	radiochemotherapy	_	_	O
190	and	_	_	O
191	surgery	_	_	O
192	was	_	_	O
193	4-6	_	_	O
194	weeks	_	_	O
195	in	_	_	O
196	both	_	_	O
197	arms	_	_	O
198	.	_	_	O

199	Techniques	_	_	O
200	of	_	_	O
201	surgery	_	_	O
202	were	_	_	O
203	standardized	_	_	O
204	and	_	_	O
205	included	_	_	O
206	total	_	_	O
207	mesorectal	_	_	O
208	excision	_	_	O
209	.	_	_	O

210	In	_	_	O
211	addition	_	_	O
212	,	_	_	O
213	stratification	_	_	O
214	according	_	_	O
215	to	_	_	O
216	surgeons	_	_	O
217	involved	_	_	O
218	has	_	_	O
219	been	_	_	O
220	provided	_	_	O
221	for	_	_	O
222	.	_	_	O

223	Primary	_	_	O
224	endpoints	_	_	O
225	of	_	_	O
226	the	_	_	O
227	study	_	_	O
228	are	_	_	O
229	5-year	_	_	O
230	overall-survival	_	_	O
231	,	_	_	O
232	local	_	_	O
233	and	_	_	O
234	distant	_	_	O
235	control	_	_	O
236	,	_	_	O
237	secondary	_	_	O
238	endpoints	_	_	O
239	include	_	_	O
240	rate	_	_	O
241	of	_	_	O
242	curative	_	_	O
243	(	_	_	O
244	R0	_	_	O
245	)	_	_	O
246	resections	_	_	O
247	and	_	_	O
248	sphincter	_	_	O
249	saving	_	_	O
250	procedures	_	_	O
251	,	_	_	O
252	toxicity	_	_	O
253	of	_	_	O
254	radiochemotherapy	_	_	O
255	,	_	_	O
256	surgical	_	_	O
257	complications	_	_	O
258	and	_	_	O
259	quality	_	_	O
260	of	_	_	O
261	life	_	_	O
262	.	_	_	O

263	As	_	_	O
264	of	_	_	O
265	15th	_	_	O
266	November	_	_	O
267	2000	_	_	O
268	,	_	_	O
269	628	_	_	O
270	patients	_	_	O
271	were	_	_	O
272	randomized	_	_	O
273	from	_	_	O
274	26	_	_	O
275	participating	_	_	O
276	institutions	_	_	O
277	:	_	_	O
278	310	_	_	O
279	patients	_	_	O
280	were	_	_	O
281	randomized	_	_	O
282	to	_	_	O
283	postoperative	_	_	O
284	radiochemotherapy	_	_	O
285	,	_	_	O
286	318	_	_	O
287	patients	_	_	O
288	to	_	_	O
289	preoperative	_	_	O
290	radiochemotherapy	_	_	O
291	.	_	_	O

292	Acute	_	_	B-Premise
293	toxicity	_	_	I-Premise
294	(	_	_	I-Premise
295	WHO	_	_	I-Premise
296	)	_	_	I-Premise
297	of	_	_	I-Premise
298	radiochemotherapy	_	_	I-Premise
299	was	_	_	I-Premise
300	low	_	_	I-Premise
301	,	_	_	I-Premise
302	with	_	_	I-Premise
303	less	_	_	I-Premise
304	than	_	_	I-Premise
305	15	_	_	I-Premise
306	%	_	_	I-Premise
307	of	_	_	I-Premise
308	patients	_	_	I-Premise
309	experiencing	_	_	I-Premise
310	Grade	_	_	I-Premise
311	3	_	_	I-Premise
312	or	_	_	I-Premise
313	higher	_	_	I-Premise
314	toxicity	_	_	I-Premise
315	:	_	_	O
316	The	_	_	B-Premise
317	principal	_	_	I-Premise
318	toxicity	_	_	I-Premise
319	was	_	_	I-Premise
320	diarrhea	_	_	I-Premise
321	,	_	_	I-Premise
322	with	_	_	I-Premise
323	12	_	_	I-Premise
324	%	_	_	I-Premise
325	in	_	_	I-Premise
326	the	_	_	I-Premise
327	postoperative	_	_	I-Premise
328	radiochemotherapy	_	_	I-Premise
329	arm	_	_	I-Premise
330	and	_	_	I-Premise
331	10	_	_	I-Premise
332	%	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	preoperative	_	_	I-Premise
336	radiochemotherapy	_	_	I-Premise
337	arm	_	_	I-Premise
338	having	_	_	I-Premise
339	Grade-3	_	_	I-Premise
340	,	_	_	I-Premise
341	and	_	_	I-Premise
342	1	_	_	I-Premise
343	%	_	_	I-Premise
344	in	_	_	I-Premise
345	either	_	_	I-Premise
346	arm	_	_	I-Premise
347	having	_	_	I-Premise
348	Grade-4	_	_	I-Premise
349	diarrhea	_	_	I-Premise
350	.	_	_	I-Premise

351	Erythema	_	_	B-Premise
352	,	_	_	I-Premise
353	nausea	_	_	I-Premise
354	and	_	_	I-Premise
355	leukopenia	_	_	I-Premise
356	were	_	_	I-Premise
357	the	_	_	I-Premise
358	next	_	_	I-Premise
359	common	_	_	I-Premise
360	toxicities	_	_	I-Premise
361	,	_	_	I-Premise
362	with	_	_	I-Premise
363	less	_	_	I-Premise
364	than	_	_	I-Premise
365	3	_	_	I-Premise
366	%	_	_	I-Premise
367	of	_	_	I-Premise
368	patients	_	_	I-Premise
369	in	_	_	I-Premise
370	either	_	_	I-Premise
371	arm	_	_	I-Premise
372	suffering	_	_	I-Premise
373	Grade	_	_	I-Premise
374	3	_	_	I-Premise
375	or	_	_	I-Premise
376	greater	_	_	I-Premise
377	leukopenia	_	_	I-Premise
378	or	_	_	I-Premise
379	nausea	_	_	I-Premise
380	.	_	_	I-Premise

381	Postoperative	_	_	B-Premise
382	complication	_	_	I-Premise
383	rates	_	_	I-Premise
384	were	_	_	I-Premise
385	similar	_	_	I-Premise
386	in	_	_	I-Premise
387	both	_	_	I-Premise
388	arms	_	_	I-Premise
389	,	_	_	I-Premise
390	with	_	_	I-Premise
391	12	_	_	I-Premise
392	%	_	_	I-Premise
393	(	_	_	I-Premise
394	postoperative	_	_	I-Premise
395	radiochemotherapy	_	_	I-Premise
396	)	_	_	I-Premise
397	and	_	_	I-Premise
398	13	_	_	I-Premise
399	%	_	_	I-Premise
400	(	_	_	I-Premise
401	preoperative	_	_	I-Premise
402	radiochemotherapy	_	_	I-Premise
403	)	_	_	I-Premise
404	of	_	_	I-Premise
405	patients	_	_	I-Premise
406	,	_	_	I-Premise
407	respectively	_	_	I-Premise
408	,	_	_	I-Premise
409	suffering	_	_	I-Premise
410	from	_	_	I-Premise
411	anastomotic	_	_	I-Premise
412	leakage	_	_	I-Premise
413	,	_	_	I-Premise
414	4	_	_	I-Premise
415	%	_	_	I-Premise
416	(	_	_	I-Premise
417	postoperative	_	_	I-Premise
418	radiochemotherapy	_	_	I-Premise
419	)	_	_	I-Premise
420	and	_	_	I-Premise
421	3	_	_	I-Premise
422	%	_	_	I-Premise
423	(	_	_	I-Premise
424	preoperative	_	_	I-Premise
425	radiochemotherapy	_	_	I-Premise
426	)	_	_	I-Premise
427	from	_	_	I-Premise
428	postoperative	_	_	I-Premise
429	bleeding	_	_	I-Premise
430	,	_	_	I-Premise
431	and	_	_	I-Premise
432	6	_	_	I-Premise
433	%	_	_	I-Premise
434	(	_	_	I-Premise
435	postoperative	_	_	I-Premise
436	radiochemotherapy	_	_	I-Premise
437	)	_	_	I-Premise
438	and	_	_	I-Premise
439	5	_	_	I-Premise
440	%	_	_	I-Premise
441	(	_	_	I-Premise
442	preoperative	_	_	I-Premise
443	radiochemotherapy	_	_	I-Premise
444	)	_	_	I-Premise
445	from	_	_	I-Premise
446	delayed	_	_	I-Premise
447	wound	_	_	I-Premise
448	healing	_	_	I-Premise
449	.	_	_	I-Premise

450	The	_	_	B-Claim
451	patient	_	_	I-Claim
452	accrual	_	_	I-Claim
453	of	_	_	I-Claim
454	our	_	_	I-Claim
455	trial	_	_	I-Claim
456	is	_	_	I-Claim
457	satisfactory	_	_	I-Claim
458	,	_	_	I-Claim
459	neoadjuvant	_	_	B-Claim
460	radiochemotherapy	_	_	I-Claim
461	is	_	_	I-Claim
462	well	_	_	I-Claim
463	tolerated	_	_	I-Claim
464	and	_	_	I-Claim
465	bears	_	_	I-Claim
466	no	_	_	I-Claim
467	higher	_	_	I-Claim
468	risk	_	_	I-Claim
469	for	_	_	I-Claim
470	postoperative	_	_	I-Claim
471	morbidity	_	_	I-Claim
472	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	comparatively	_	_	O
3	,	_	_	O
4	in	_	_	O
5	terms	_	_	O
6	of	_	_	O
7	quality-adjusted	_	_	O
8	survival	_	_	O
9	,	_	_	O
10	three	_	_	O
11	front-line	_	_	O
12	treatments	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	stage	_	_	O
17	B-	_	_	O
18	or	_	_	O
19	C-chronic	_	_	O
20	lymphocytic	_	_	O
21	leukemia	_	_	O
22	(	_	_	O
23	CLL	_	_	O
24	)	_	_	O
25	.	_	_	O

26	To	_	_	O
27	describe	_	_	O
28	better	_	_	O
29	and	_	_	O
30	compare	_	_	O
31	the	_	_	O
32	survival	_	_	O
33	after	_	_	O
34	randomization	_	_	O
35	of	_	_	O
36	patients	_	_	O
37	from	_	_	O
38	the	_	_	O
39	CLL90	_	_	O
40	trial	_	_	O
41	that	_	_	O
42	randomly	_	_	O
43	compared	_	_	O
44	ChOP	_	_	O
45	(	_	_	O
46	cyclophosphamide	_	_	O
47	,	_	_	O
48	doxorubicin	_	_	O
49	,	_	_	O
50	oncovin	_	_	O
51	,	_	_	O
52	prednisone	_	_	O
53	)	_	_	O
54	,	_	_	O
55	CAP	_	_	O
56	(	_	_	O
57	cyclophosphamide	_	_	O
58	,	_	_	O
59	doxorubicin	_	_	O
60	,	_	_	O
61	prednisone	_	_	O
62	)	_	_	O
63	and	_	_	O
64	fludarabine	_	_	O
65	in	_	_	O
66	advanced	_	_	O
67	CLL	_	_	O
68	,	_	_	O
69	we	_	_	O
70	performed	_	_	O
71	a	_	_	O
72	quality-adjusted	_	_	O
73	survival	_	_	O
74	analysis	_	_	O
75	.	_	_	O

76	This	_	_	O
77	consisted	_	_	O
78	of	_	_	O
79	defining	_	_	O
80	four	_	_	O
81	clinical	_	_	O
82	states	_	_	O
83	(	_	_	O
84	toxicity	_	_	O
85	,	_	_	O
86	treatment	_	_	O
87	free	_	_	O
88	of	_	_	O
89	toxicity	_	_	O
90	,	_	_	O
91	no	_	_	O
92	treatment	_	_	O
93	nor	_	_	O
94	symptoms	_	_	O
95	,	_	_	O
96	relapse	_	_	O
97	)	_	_	O
98	,	_	_	O
99	then	_	_	O
100	summing	_	_	O
101	up	_	_	O
102	the	_	_	O
103	average	_	_	O
104	times	_	_	O
105	spent	_	_	O
106	in	_	_	O
107	each	_	_	O
108	state	_	_	O
109	weighted	_	_	O
110	by	_	_	O
111	utility	_	_	O
112	coefficients	_	_	O
113	that	_	_	O
114	reflect	_	_	O
115	relative	_	_	O
116	value	_	_	O
117	according	_	_	O
118	to	_	_	O
119	quality	_	_	O
120	of	_	_	O
121	life	_	_	O
122	.	_	_	O

123	The	_	_	O
124	resulting	_	_	O
125	quality-adjusted	_	_	O
126	time	_	_	O
127	without	_	_	O
128	symptoms	_	_	O
129	or	_	_	O
130	toxicity	_	_	O
131	(	_	_	O
132	Q-TWIST	_	_	O
133	)	_	_	O
134	was	_	_	O
135	compared	_	_	O
136	between	_	_	O
137	randomized	_	_	O
138	groups	_	_	O
139	,	_	_	O
140	and	_	_	O
141	sensitivity	_	_	O
142	(	_	_	O
143	threshold	_	_	O
144	)	_	_	O
145	analyses	_	_	O
146	to	_	_	O
147	the	_	_	O
148	choice	_	_	O
149	of	_	_	O
150	utility	_	_	O
151	coefficients	_	_	O
152	was	_	_	O
153	performed	_	_	O
154	.	_	_	O

155	Over	_	_	B-Premise
156	73	_	_	I-Premise
157	months	_	_	I-Premise
158	after	_	_	I-Premise
159	randomization	_	_	I-Premise
160	,	_	_	I-Premise
161	the	_	_	I-Premise
162	fludarabine	_	_	I-Premise
163	group	_	_	I-Premise
164	gained	_	_	I-Premise
165	a	_	_	I-Premise
166	mean	_	_	I-Premise
167	of	_	_	I-Premise
168	45	_	_	I-Premise
169	days	_	_	I-Premise
170	of	_	_	I-Premise
171	toxicity-free	_	_	I-Premise
172	survival	_	_	I-Premise
173	at	_	_	I-Premise
174	CAP	_	_	I-Premise
175	,	_	_	I-Premise
176	and	_	_	I-Premise
177	61	_	_	I-Premise
178	days	_	_	I-Premise
179	over	_	_	I-Premise
180	ChOP	_	_	I-Premise
181	.	_	_	I-Premise

182	The	_	_	B-Premise
183	mean	_	_	I-Premise
184	TWIST	_	_	I-Premise
185	was	_	_	I-Premise
186	27.05	_	_	I-Premise
187	months	_	_	I-Premise
188	with	_	_	I-Premise
189	CAP	_	_	I-Premise
190	,	_	_	I-Premise
191	31.5	_	_	I-Premise
192	months	_	_	I-Premise
193	with	_	_	I-Premise
194	ChOP	_	_	I-Premise
195	and	_	_	I-Premise
196	32.95	_	_	I-Premise
197	months	_	_	I-Premise
198	with	_	_	I-Premise
199	fludarabine	_	_	I-Premise
200	.	_	_	I-Premise

201	The	_	_	B-Premise
202	threshold	_	_	I-Premise
203	analyses	_	_	I-Premise
204	showed	_	_	I-Premise
205	that	_	_	I-Premise
206	,	_	_	I-Premise
207	whatever	_	_	I-Premise
208	the	_	_	I-Premise
209	utility	_	_	I-Premise
210	weights	_	_	I-Premise
211	,	_	_	I-Premise
212	the	_	_	I-Premise
213	mean	_	_	I-Premise
214	Q-TWIST	_	_	I-Premise
215	was	_	_	I-Premise
216	always	_	_	I-Premise
217	greater	_	_	I-Premise
218	with	_	_	I-Premise
219	ChOP	_	_	I-Premise
220	or	_	_	I-Premise
221	fludarabine	_	_	I-Premise
222	as	_	_	I-Premise
223	compared	_	_	I-Premise
224	to	_	_	I-Premise
225	CAP	_	_	I-Premise
226	.	_	_	I-Premise

227	Fludarabine	_	_	B-Claim
228	was	_	_	I-Claim
229	consistently	_	_	I-Claim
230	a	_	_	I-Claim
231	better	_	_	I-Claim
232	treatment	_	_	I-Claim
233	than	_	_	I-Claim
234	ChOP	_	_	I-Claim
235	,	_	_	I-Claim
236	except	_	_	B-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	unlikely	_	_	I-Premise
240	case	_	_	I-Premise
241	of	_	_	I-Premise
242	high	_	_	I-Premise
243	utility	_	_	I-Premise
244	weights	_	_	I-Premise
245	attributed	_	_	I-Premise
246	to	_	_	I-Premise
247	toxicity	_	_	I-Premise
248	and	_	_	I-Premise
249	low	_	_	I-Premise
250	utility	_	_	I-Premise
251	weights	_	_	I-Premise
252	attributed	_	_	I-Premise
253	to	_	_	I-Premise
254	treatment	_	_	I-Premise
255	.	_	_	I-Premise

256	Nevertheless	_	_	O
257	,	_	_	O
258	from	_	_	B-Premise
259	a	_	_	I-Premise
260	clinical	_	_	I-Premise
261	point	_	_	I-Premise
262	of	_	_	I-Premise
263	view	_	_	I-Premise
264	,	_	_	I-Premise
265	differences	_	_	I-Premise
266	between	_	_	I-Premise
267	ChOP	_	_	I-Premise
268	and	_	_	I-Premise
269	fludarabine	_	_	I-Premise
270	were	_	_	I-Premise
271	moderate	_	_	I-Premise
272	or	_	_	I-Premise
273	event	_	_	I-Premise
274	slight	_	_	I-Premise
275	(	_	_	I-Premise
276	mean	_	_	I-Premise
277	difference	_	_	I-Premise
278	in	_	_	I-Premise
279	TWIST	_	_	I-Premise
280	of	_	_	I-Premise
281	1.45	_	_	I-Premise
282	months	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	We	_	_	O
286	conclude	_	_	O
287	that	_	_	O
288	patients	_	_	B-Claim
289	with	_	_	I-Claim
290	advanced	_	_	I-Claim
291	CLL	_	_	I-Claim
292	have	_	_	I-Claim
293	a	_	_	I-Claim
294	moderate	_	_	I-Claim
295	benefit	_	_	I-Claim
296	in	_	_	I-Claim
297	terms	_	_	I-Claim
298	of	_	_	I-Claim
299	Q-TWIST	_	_	I-Claim
300	when	_	_	I-Claim
301	treated	_	_	I-Claim
302	with	_	_	I-Claim
303	fludarabine	_	_	I-Claim
304	over	_	_	I-Claim
305	ChOP	_	_	I-Claim
306	.	_	_	I-Claim

307	These	_	_	B-Claim
308	two	_	_	I-Claim
309	treatments	_	_	I-Claim
310	are	_	_	I-Claim
311	always	_	_	I-Claim
312	superior	_	_	I-Claim
313	to	_	_	I-Claim
314	CAP	_	_	I-Claim
315	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure-lowering	_	_	O
5	effect	_	_	O
6	of	_	_	O
7	latanoprost	_	_	O
8	with	_	_	O
9	that	_	_	O
10	of	_	_	O
11	dorzolamide	_	_	O
12	when	_	_	O
13	added	_	_	O
14	to	_	_	O
15	timolol	_	_	O
16	.	_	_	O

17	This	_	_	O
18	randomized	_	_	O
19	,	_	_	O
20	open-label	_	_	O
21	study	_	_	O
22	with	_	_	O
23	two	_	_	O
24	parallel	_	_	O
25	groups	_	_	O
26	was	_	_	O
27	conducted	_	_	O
28	in	_	_	O
29	five	_	_	O
30	centers	_	_	O
31	in	_	_	O
32	Greece	_	_	O
33	.	_	_	O

34	The	_	_	O
35	study	_	_	O
36	enrolled	_	_	O
37	148	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	inadequately	_	_	O
41	controlled	_	_	O
42	open-angle	_	_	O
43	or	_	_	O
44	pseudoexfoliation	_	_	O
45	glaucoma	_	_	O
46	(	_	_	O
47	intraocular	_	_	O
48	pressure	_	_	O
49	of	_	_	O
50	at	_	_	O
51	least	_	_	O
52	22	_	_	O
53	mm	_	_	O
54	Hg	_	_	O
55	)	_	_	O
56	or	_	_	O
57	ocular	_	_	O
58	hypertension	_	_	O
59	(	_	_	O
60	intraocular	_	_	O
61	pressure	_	_	O
62	of	_	_	O
63	at	_	_	O
64	least	_	_	O
65	27	_	_	O
66	mm	_	_	O
67	Hg	_	_	O
68	)	_	_	O
69	who	_	_	O
70	were	_	_	O
71	receiving	_	_	O
72	monotherapy	_	_	O
73	with	_	_	O
74	a	_	_	O
75	beta-blocker	_	_	O
76	or	_	_	O
77	dual	_	_	O
78	therapy	_	_	O
79	in	_	_	O
80	which	_	_	O
81	one	_	_	O
82	of	_	_	O
83	the	_	_	O
84	agents	_	_	O
85	was	_	_	O
86	a	_	_	O
87	beta-blocker	_	_	O
88	.	_	_	O

89	The	_	_	O
90	patients	_	_	O
91	were	_	_	O
92	switched	_	_	O
93	to	_	_	O
94	timolol	_	_	O
95	0.5	_	_	O
96	%	_	_	O
97	twice	_	_	O
98	daily	_	_	O
99	for	_	_	O
100	2	_	_	O
101	to	_	_	O
102	4	_	_	O
103	weeks	_	_	O
104	(	_	_	O
105	run-in	_	_	O
106	period	_	_	O
107	)	_	_	O
108	before	_	_	O
109	the	_	_	O
110	start	_	_	O
111	of	_	_	O
112	the	_	_	O
113	study	_	_	O
114	(	_	_	O
115	baseline	_	_	O
116	)	_	_	O
117	.	_	_	O

118	At	_	_	O
119	baseline	_	_	O
120	,	_	_	O
121	the	_	_	O
122	patients	_	_	O
123	were	_	_	O
124	randomized	_	_	O
125	to	_	_	O
126	receive	_	_	O
127	latanoprost	_	_	O
128	0.005	_	_	O
129	%	_	_	O
130	once	_	_	O
131	daily	_	_	O
132	or	_	_	O
133	dorzolamide	_	_	O
134	2	_	_	O
135	%	_	_	O
136	twice	_	_	O
137	daily	_	_	O
138	as	_	_	O
139	add-on	_	_	O
140	therapy	_	_	O
141	to	_	_	O
142	timolol	_	_	O
143	.	_	_	O

144	The	_	_	O
145	intraocular	_	_	O
146	pressure	_	_	O
147	was	_	_	O
148	recorded	_	_	O
149	at	_	_	O
150	9:30	_	_	O
151	AM	_	_	O
152	,	_	_	O
153	12:30	_	_	O
154	PM	_	_	O
155	,	_	_	O
156	and	_	_	O
157	3:30	_	_	O
158	PM	_	_	O
159	at	_	_	O
160	baseline	_	_	O
161	and	_	_	O
162	at	_	_	O
163	3	_	_	O
164	months	_	_	O
165	.	_	_	O

166	Safety	_	_	O
167	was	_	_	O
168	followed	_	_	O
169	throughout	_	_	O
170	the	_	_	O
171	study	_	_	O
172	.	_	_	O

173	The	_	_	B-Premise
174	diurnal	_	_	I-Premise
175	intraocular	_	_	I-Premise
176	pressure	_	_	I-Premise
177	reduction	_	_	I-Premise
178	was	_	_	I-Premise
179	significant	_	_	I-Premise
180	in	_	_	I-Premise
181	both	_	_	I-Premise
182	groups	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	<	_	_	I-Premise
186	0.001	_	_	I-Premise
187	)	_	_	I-Premise
188	.	_	_	I-Premise

189	The	_	_	B-Premise
190	mean	_	_	I-Premise
191	intraocular	_	_	I-Premise
192	pressure	_	_	I-Premise
193	reduction	_	_	I-Premise
194	from	_	_	I-Premise
195	baseline	_	_	I-Premise
196	was	_	_	I-Premise
197	32	_	_	I-Premise
198	%	_	_	I-Premise
199	for	_	_	I-Premise
200	the	_	_	I-Premise
201	latanoprost	_	_	I-Premise
202	plus	_	_	I-Premise
203	timolol	_	_	I-Premise
204	group	_	_	I-Premise
205	and	_	_	I-Premise
206	20	_	_	I-Premise
207	%	_	_	I-Premise
208	for	_	_	I-Premise
209	the	_	_	I-Premise
210	dorzolamide	_	_	I-Premise
211	plus	_	_	I-Premise
212	timolol	_	_	I-Premise
213	group	_	_	I-Premise
214	.	_	_	I-Premise

215	The	_	_	B-Premise
216	least	_	_	I-Premise
217	square	_	_	I-Premise
218	estimate	_	_	I-Premise
219	of	_	_	I-Premise
220	the	_	_	I-Premise
221	mean	_	_	I-Premise
222	diurnal	_	_	I-Premise
223	intraocular	_	_	I-Premise
224	pressure	_	_	I-Premise
225	reduction	_	_	I-Premise
226	after	_	_	I-Premise
227	3	_	_	I-Premise
228	months	_	_	I-Premise
229	was	_	_	I-Premise
230	-7.06	_	_	I-Premise
231	mm	_	_	I-Premise
232	Hg	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	latanoprost	_	_	I-Premise
236	plus	_	_	I-Premise
237	timolol	_	_	I-Premise
238	group	_	_	I-Premise
239	and	_	_	I-Premise
240	-4.44	_	_	I-Premise
241	mm	_	_	I-Premise
242	Hg	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	dorzolamide	_	_	I-Premise
246	plus	_	_	I-Premise
247	timolol	_	_	I-Premise
248	group	_	_	I-Premise
249	(	_	_	I-Premise
250	P	_	_	I-Premise
251	<	_	_	I-Premise
252	0.001	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Drugs	_	_	B-Claim
256	administered	_	_	I-Claim
257	in	_	_	I-Claim
258	both	_	_	I-Claim
259	treatment	_	_	I-Claim
260	groups	_	_	I-Claim
261	were	_	_	I-Claim
262	well	_	_	I-Claim
263	tolerated	_	_	I-Claim
264	.	_	_	I-Claim

265	This	_	_	B-Claim
266	study	_	_	I-Claim
267	clearly	_	_	I-Claim
268	showed	_	_	I-Claim
269	that	_	_	I-Claim
270	the	_	_	I-Claim
271	additive	_	_	I-Claim
272	diurnal	_	_	I-Claim
273	intraocular	_	_	I-Claim
274	pressure-lowering	_	_	I-Claim
275	effect	_	_	I-Claim
276	of	_	_	I-Claim
277	latanoprost	_	_	I-Claim
278	is	_	_	I-Claim
279	superior	_	_	I-Claim
280	to	_	_	I-Claim
281	that	_	_	I-Claim
282	of	_	_	I-Claim
283	dorzolamide	_	_	I-Claim
284	in	_	_	I-Claim
285	patients	_	_	I-Claim
286	treated	_	_	I-Claim
287	with	_	_	I-Claim
288	timolol	_	_	I-Claim
289	.	_	_	I-Claim


0	In	_	_	B-Claim
1	a	_	_	I-Claim
2	randomized	_	_	I-Claim
3	clinical	_	_	I-Claim
4	trial	_	_	I-Claim
5	in	_	_	I-Claim
6	patients	_	_	I-Claim
7	with	_	_	I-Claim
8	advanced	_	_	I-Claim
9	non-small-cell	_	_	I-Claim
10	lung	_	_	I-Claim
11	cancer	_	_	I-Claim
12	(	_	_	I-Claim
13	NSCLC	_	_	I-Claim
14	)	_	_	I-Claim
15	,	_	_	I-Claim
16	infusion	_	_	I-Claim
17	with	_	_	I-Claim
18	adenosine	_	_	I-Claim
19	5'-triphosphate	_	_	I-Claim
20	(	_	_	I-Claim
21	ATP	_	_	I-Claim
22	)	_	_	I-Claim
23	inhibited	_	_	I-Claim
24	loss	_	_	I-Claim
25	of	_	_	I-Claim
26	body	_	_	I-Claim
27	weight	_	_	I-Claim
28	and	_	_	I-Claim
29	quality	_	_	I-Claim
30	of	_	_	I-Claim
31	life	_	_	I-Claim
32	.	_	_	I-Claim

33	In	_	_	O
34	the	_	_	O
35	present	_	_	O
36	article	_	_	O
37	,	_	_	O
38	the	_	_	O
39	effects	_	_	O
40	of	_	_	O
41	ATP	_	_	O
42	on	_	_	O
43	body	_	_	O
44	composition	_	_	O
45	,	_	_	O
46	energy	_	_	O
47	intake	_	_	O
48	,	_	_	O
49	and	_	_	O
50	energy	_	_	O
51	expenditure	_	_	O
52	as	_	_	O
53	secondary	_	_	O
54	outcome	_	_	O
55	measures	_	_	O
56	in	_	_	O
57	the	_	_	O
58	same	_	_	O
59	patients	_	_	O
60	are	_	_	O
61	reported	_	_	O
62	.	_	_	O

63	Patients	_	_	O
64	with	_	_	O
65	NSCLC	_	_	O
66	,	_	_	O
67	stage	_	_	O
68	IIIB	_	_	O
69	or	_	_	O
70	IV	_	_	O
71	,	_	_	O
72	were	_	_	O
73	randomized	_	_	O
74	to	_	_	O
75	receive	_	_	O
76	either	_	_	O
77	10	_	_	O
78	intravenous	_	_	O
79	,	_	_	O
80	30-hour	_	_	O
81	ATP	_	_	O
82	infusions	_	_	O
83	every	_	_	O
84	2	_	_	O
85	to	_	_	O
86	4	_	_	O
87	weeks	_	_	O
88	or	_	_	O
89	no	_	_	O
90	ATP	_	_	O
91	.	_	_	O

92	Fat	_	_	O
93	mass	_	_	O
94	(	_	_	O
95	FM	_	_	O
96	)	_	_	O
97	,	_	_	O
98	fat-free	_	_	O
99	mass	_	_	O
100	(	_	_	O
101	FFM	_	_	O
102	)	_	_	O
103	,	_	_	O
104	and	_	_	O
105	arm	_	_	O
106	muscle	_	_	O
107	area	_	_	O
108	were	_	_	O
109	assessed	_	_	O
110	at	_	_	O
111	4-week	_	_	O
112	intervals	_	_	O
113	for	_	_	O
114	28	_	_	O
115	weeks	_	_	O
116	.	_	_	O

117	Food	_	_	O
118	intake	_	_	O
119	,	_	_	O
120	body	_	_	O
121	cell	_	_	O
122	mass	_	_	O
123	(	_	_	O
124	BCM	_	_	O
125	)	_	_	O
126	,	_	_	O
127	and	_	_	O
128	resting	_	_	O
129	energy	_	_	O
130	expenditure	_	_	O
131	(	_	_	O
132	REE	_	_	O
133	)	_	_	O
134	were	_	_	O
135	assessed	_	_	O
136	at	_	_	O
137	8-week	_	_	O
138	intervals	_	_	O
139	for	_	_	O
140	16	_	_	O
141	weeks	_	_	O
142	.	_	_	O

143	Between-group	_	_	O
144	differences	_	_	O
145	were	_	_	O
146	tested	_	_	O
147	for	_	_	O
148	statistical	_	_	O
149	significance	_	_	O
150	by	_	_	O
151	repeated-measures	_	_	O
152	analysis	_	_	O
153	of	_	_	O
154	covariance	_	_	O
155	.	_	_	O

156	Fifty-eight	_	_	O
157	patients	_	_	O
158	were	_	_	O
159	randomized	_	_	O
160	(	_	_	O
161	28	_	_	O
162	ATP	_	_	O
163	,	_	_	O
164	30	_	_	O
165	control	_	_	O
166	)	_	_	O
167	.	_	_	O

168	No	_	_	B-Premise
169	change	_	_	I-Premise
170	in	_	_	I-Premise
171	body	_	_	I-Premise
172	composition	_	_	I-Premise
173	over	_	_	I-Premise
174	the	_	_	I-Premise
175	28-week	_	_	I-Premise
176	follow-up	_	_	I-Premise
177	period	_	_	I-Premise
178	was	_	_	I-Premise
179	found	_	_	I-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	ATP	_	_	I-Premise
183	group	_	_	I-Premise
184	,	_	_	I-Premise
185	whereas	_	_	I-Premise
186	,	_	_	I-Premise
187	per	_	_	I-Premise
188	4	_	_	I-Premise
189	weeks	_	_	I-Premise
190	,	_	_	I-Premise
191	the	_	_	I-Premise
192	control	_	_	I-Premise
193	group	_	_	I-Premise
194	lost	_	_	I-Premise
195	0.6	_	_	I-Premise
196	kg	_	_	I-Premise
197	of	_	_	I-Premise
198	FM	_	_	I-Premise
199	(	_	_	I-Premise
200	P	_	_	I-Premise
201	=.004	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	0.5	_	_	I-Premise
205	kg	_	_	I-Premise
206	of	_	_	I-Premise
207	FFM	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=.02	_	_	I-Premise
211	)	_	_	I-Premise
212	,	_	_	I-Premise
213	1.8	_	_	I-Premise
214	%	_	_	I-Premise
215	of	_	_	I-Premise
216	arm	_	_	I-Premise
217	muscle	_	_	I-Premise
218	area	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	=.02	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	and	_	_	I-Premise
225	0.6	_	_	I-Premise
226	%	_	_	I-Premise
227	of	_	_	I-Premise
228	BCM/kg	_	_	I-Premise
229	body	_	_	I-Premise
230	weight	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	=.054	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	decreased	_	_	I-Premise
237	568	_	_	I-Premise
238	KJ/d	_	_	I-Premise
239	in	_	_	I-Premise
240	energy	_	_	I-Premise
241	intake	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=.0001	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Appetite	_	_	B-Premise
248	also	_	_	I-Premise
249	remained	_	_	I-Premise
250	stable	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	ATP	_	_	I-Premise
254	group	_	_	I-Premise
255	but	_	_	I-Premise
256	decreased	_	_	I-Premise
257	significantly	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	control	_	_	I-Premise
261	group	_	_	I-Premise
262	(	_	_	I-Premise
263	P	_	_	I-Premise
264	=.0004	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	No	_	_	B-Premise
268	significant	_	_	I-Premise
269	differences	_	_	I-Premise
270	in	_	_	I-Premise
271	REE	_	_	I-Premise
272	between	_	_	I-Premise
273	the	_	_	I-Premise
274	ATP	_	_	I-Premise
275	and	_	_	I-Premise
276	control	_	_	I-Premise
277	groups	_	_	I-Premise
278	were	_	_	I-Premise
279	observed	_	_	I-Premise
280	.	_	_	I-Premise

281	The	_	_	B-Claim
282	inhibition	_	_	I-Claim
283	of	_	_	I-Claim
284	weight	_	_	I-Claim
285	loss	_	_	I-Claim
286	by	_	_	I-Claim
287	ATP	_	_	I-Claim
288	infusions	_	_	I-Claim
289	in	_	_	I-Claim
290	patients	_	_	I-Claim
291	with	_	_	I-Claim
292	advanced	_	_	I-Claim
293	NSCLC	_	_	I-Claim
294	is	_	_	I-Claim
295	attributed	_	_	I-Claim
296	to	_	_	I-Claim
297	counteracting	_	_	I-Claim
298	the	_	_	I-Claim
299	loss	_	_	I-Claim
300	of	_	_	I-Claim
301	both	_	_	I-Claim
302	metabolically	_	_	I-Claim
303	active	_	_	I-Claim
304	and	_	_	I-Claim
305	inactive	_	_	I-Claim
306	tissues	_	_	I-Claim
307	.	_	_	I-Claim

308	These	_	_	B-Premise
309	effects	_	_	I-Premise
310	are	_	_	I-Premise
311	partly	_	_	I-Premise
312	ascribed	_	_	I-Premise
313	to	_	_	I-Premise
314	maintenance	_	_	I-Premise
315	of	_	_	I-Premise
316	energy	_	_	I-Premise
317	intake	_	_	I-Premise
318	.	_	_	I-Premise


0	Laparoscopic-assisted	_	_	B-Claim
1	colectomy	_	_	I-Claim
2	(	_	_	I-Claim
3	LAC	_	_	I-Claim
4	)	_	_	I-Claim
5	has	_	_	I-Claim
6	emerged	_	_	I-Claim
7	as	_	_	I-Claim
8	the	_	_	I-Claim
9	preferred	_	_	I-Claim
10	minimally	_	_	I-Claim
11	invasive	_	_	I-Claim
12	surgical	_	_	I-Claim
13	strategy	_	_	I-Claim
14	for	_	_	I-Claim
15	diseases	_	_	I-Claim
16	of	_	_	I-Claim
17	the	_	_	I-Claim
18	colon	_	_	I-Claim
19	.	_	_	I-Claim

20	The	_	_	B-Claim
21	safety	_	_	I-Claim
22	and	_	_	I-Claim
23	efficacy	_	_	I-Claim
24	of	_	_	I-Claim
25	LAC	_	_	I-Claim
26	for	_	_	I-Claim
27	colon	_	_	I-Claim
28	cancer	_	_	I-Claim
29	are	_	_	I-Claim
30	unknown	_	_	I-Claim
31	,	_	_	I-Claim
32	and	_	_	O
33	the	_	_	B-Claim
34	nature	_	_	I-Claim
35	and	_	_	I-Claim
36	magnitude	_	_	I-Claim
37	of	_	_	I-Claim
38	any	_	_	I-Claim
39	quality-of-life	_	_	I-Claim
40	(	_	_	I-Claim
41	QOL	_	_	I-Claim
42	)	_	_	I-Claim
43	benefit	_	_	I-Claim
44	resulting	_	_	I-Claim
45	from	_	_	I-Claim
46	LAC	_	_	I-Claim
47	for	_	_	I-Claim
48	colon	_	_	I-Claim
49	cancer	_	_	I-Claim
50	is	_	_	I-Claim
51	also	_	_	I-Claim
52	unknown	_	_	I-Claim
53	.	_	_	I-Claim

54	To	_	_	O
55	compare	_	_	O
56	short-term	_	_	O
57	QOL	_	_	O
58	outcomes	_	_	O
59	after	_	_	O
60	LAC	_	_	O
61	vs	_	_	O
62	open	_	_	O
63	colectomy	_	_	O
64	for	_	_	O
65	colon	_	_	O
66	cancer	_	_	O
67	.	_	_	O

68	Multicenter	_	_	O
69	,	_	_	O
70	randomized	_	_	O
71	controlled	_	_	O
72	trial	_	_	O
73	(	_	_	O
74	Clinical	_	_	O
75	Outcomes	_	_	O
76	of	_	_	O
77	Surgical	_	_	O
78	Therapy	_	_	O
79	[	_	_	O
80	COST	_	_	O
81	]	_	_	O
82	)	_	_	O
83	.	_	_	O

84	Between	_	_	O
85	September	_	_	O
86	1994	_	_	O
87	and	_	_	O
88	February	_	_	O
89	1999	_	_	O
90	,	_	_	O
91	37	_	_	O
92	of	_	_	O
93	48	_	_	O
94	centers	_	_	O
95	provided	_	_	O
96	data	_	_	O
97	for	_	_	O
98	the	_	_	O
99	QOL	_	_	O
100	component	_	_	O
101	of	_	_	O
102	the	_	_	O
103	trial	_	_	O
104	for	_	_	O
105	449	_	_	O
106	consecutive	_	_	O
107	patients	_	_	O
108	with	_	_	O
109	clinically	_	_	O
110	resectable	_	_	O
111	colon	_	_	O
112	cancer	_	_	O
113	.	_	_	O

114	Scores	_	_	O
115	on	_	_	O
116	the	_	_	O
117	Symptoms	_	_	O
118	Distress	_	_	O
119	Scale	_	_	O
120	(	_	_	O
121	SDS	_	_	O
122	)	_	_	O
123	,	_	_	O
124	Quality	_	_	O
125	of	_	_	O
126	Life	_	_	O
127	Index	_	_	O
128	,	_	_	O
129	and	_	_	O
130	a	_	_	O
131	single-item	_	_	O
132	global	_	_	O
133	rating	_	_	O
134	scale	_	_	O
135	at	_	_	O
136	2	_	_	O
137	days	_	_	O
138	,	_	_	O
139	2	_	_	O
140	weeks	_	_	O
141	,	_	_	O
142	and	_	_	O
143	2	_	_	O
144	months	_	_	O
145	postoperative	_	_	O
146	;	_	_	O
147	duration	_	_	O
148	of	_	_	O
149	postoperative	_	_	O
150	in-hospital	_	_	O
151	analgesic	_	_	O
152	use	_	_	O
153	;	_	_	O
154	and	_	_	O
155	length	_	_	O
156	of	_	_	O
157	stay	_	_	O
158	.	_	_	O

159	Of	_	_	O
160	449	_	_	O
161	patients	_	_	O
162	,	_	_	O
163	428	_	_	O
164	provided	_	_	O
165	QOL	_	_	O
166	data	_	_	O
167	.	_	_	O

168	In	_	_	B-Premise
169	an	_	_	I-Premise
170	intention-to-treat	_	_	I-Premise
171	analysis	_	_	I-Premise
172	comparing	_	_	I-Premise
173	SDS	_	_	I-Premise
174	pain	_	_	I-Premise
175	intensity	_	_	I-Premise
176	,	_	_	I-Premise
177	SDS	_	_	I-Premise
178	summary	_	_	I-Premise
179	,	_	_	I-Premise
180	QOL	_	_	I-Premise
181	Index	_	_	I-Premise
182	summary	_	_	I-Premise
183	,	_	_	I-Premise
184	and	_	_	I-Premise
185	global	_	_	I-Premise
186	rating	_	_	I-Premise
187	scale	_	_	I-Premise
188	scores	_	_	I-Premise
189	at	_	_	I-Premise
190	each	_	_	I-Premise
191	time	_	_	I-Premise
192	point	_	_	I-Premise
193	,	_	_	I-Premise
194	the	_	_	I-Premise
195	only	_	_	I-Premise
196	statistically	_	_	I-Premise
197	significant	_	_	I-Premise
198	difference	_	_	I-Premise
199	observed	_	_	I-Premise
200	between	_	_	I-Premise
201	groups	_	_	I-Premise
202	was	_	_	I-Premise
203	the	_	_	I-Premise
204	global	_	_	I-Premise
205	rating	_	_	I-Premise
206	scale	_	_	I-Premise
207	score	_	_	I-Premise
208	for	_	_	I-Premise
209	2	_	_	I-Premise
210	weeks	_	_	I-Premise
211	postsurgery	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	mean	_	_	I-Premise
215	(	_	_	I-Premise
216	median	_	_	I-Premise
217	)	_	_	I-Premise
218	global	_	_	I-Premise
219	rating	_	_	I-Premise
220	scale	_	_	I-Premise
221	scores	_	_	I-Premise
222	for	_	_	I-Premise
223	2	_	_	I-Premise
224	weeks	_	_	I-Premise
225	postsurgery	_	_	I-Premise
226	were	_	_	I-Premise
227	76.9	_	_	I-Premise
228	(	_	_	I-Premise
229	80	_	_	I-Premise
230	)	_	_	I-Premise
231	for	_	_	I-Premise
232	LAC	_	_	I-Premise
233	vs	_	_	I-Premise
234	74.4	_	_	I-Premise
235	(	_	_	I-Premise
236	75	_	_	I-Premise
237	)	_	_	I-Premise
238	for	_	_	I-Premise
239	open	_	_	I-Premise
240	colectomy	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=.009	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	While	_	_	B-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	hospital	_	_	I-Premise
250	,	_	_	I-Premise
251	patients	_	_	I-Premise
252	assigned	_	_	I-Premise
253	to	_	_	I-Premise
254	LAC	_	_	I-Premise
255	required	_	_	I-Premise
256	fewer	_	_	I-Premise
257	days	_	_	I-Premise
258	of	_	_	I-Premise
259	both	_	_	I-Premise
260	parenteral	_	_	I-Premise
261	analgesics	_	_	I-Premise
262	compared	_	_	I-Premise
263	with	_	_	I-Premise
264	patients	_	_	I-Premise
265	assigned	_	_	I-Premise
266	to	_	_	I-Premise
267	open	_	_	I-Premise
268	colectomy	_	_	I-Premise
269	(	_	_	I-Premise
270	mean	_	_	I-Premise
271	[	_	_	I-Premise
272	median	_	_	I-Premise
273	]	_	_	I-Premise
274	,	_	_	I-Premise
275	3.2	_	_	I-Premise
276	[	_	_	I-Premise
277	3	_	_	I-Premise
278	]	_	_	I-Premise
279	vs	_	_	I-Premise
280	4.0	_	_	I-Premise
281	[	_	_	I-Premise
282	4	_	_	I-Premise
283	]	_	_	I-Premise
284	days	_	_	I-Premise
285	;	_	_	I-Premise
286	P	_	_	I-Premise
287	<	_	_	I-Premise
288	.001	_	_	I-Premise
289	)	_	_	I-Premise
290	and	_	_	I-Premise
291	oral	_	_	I-Premise
292	analgesics	_	_	I-Premise
293	(	_	_	I-Premise
294	mean	_	_	I-Premise
295	[	_	_	I-Premise
296	median	_	_	I-Premise
297	]	_	_	I-Premise
298	,	_	_	I-Premise
299	1.9	_	_	I-Premise
300	[	_	_	I-Premise
301	1	_	_	I-Premise
302	]	_	_	I-Premise
303	vs	_	_	I-Premise
304	2.2	_	_	I-Premise
305	[	_	_	I-Premise
306	2	_	_	I-Premise
307	]	_	_	I-Premise
308	days	_	_	I-Premise
309	;	_	_	I-Premise
310	P	_	_	I-Premise
311	=.03	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	Only	_	_	B-Claim
315	minimal	_	_	I-Claim
316	short-term	_	_	I-Claim
317	QOL	_	_	I-Claim
318	benefits	_	_	I-Claim
319	were	_	_	I-Claim
320	found	_	_	I-Claim
321	with	_	_	I-Claim
322	LAC	_	_	I-Claim
323	for	_	_	I-Claim
324	colon	_	_	I-Claim
325	cancer	_	_	I-Claim
326	compared	_	_	I-Claim
327	with	_	_	I-Claim
328	standard	_	_	I-Claim
329	open	_	_	I-Claim
330	colectomy	_	_	I-Claim
331	.	_	_	I-Claim

332	Until	_	_	B-Claim
333	ongoing	_	_	I-Claim
334	trials	_	_	I-Claim
335	establish	_	_	I-Claim
336	that	_	_	I-Claim
337	LAC	_	_	I-Claim
338	is	_	_	I-Claim
339	as	_	_	I-Claim
340	effective	_	_	I-Claim
341	as	_	_	I-Claim
342	open	_	_	I-Claim
343	colectomy	_	_	I-Claim
344	in	_	_	I-Claim
345	preventing	_	_	I-Claim
346	recurrence	_	_	I-Claim
347	and	_	_	I-Claim
348	death	_	_	I-Claim
349	from	_	_	I-Claim
350	colon	_	_	I-Claim
351	cancer	_	_	I-Claim
352	,	_	_	I-Claim
353	this	_	_	I-Claim
354	procedure	_	_	I-Claim
355	should	_	_	I-Claim
356	not	_	_	I-Claim
357	be	_	_	I-Claim
358	offered	_	_	I-Claim
359	to	_	_	I-Claim
360	patients	_	_	I-Claim
361	with	_	_	I-Claim
362	colon	_	_	I-Claim
363	cancer	_	_	I-Claim
364	.	_	_	I-Claim


0	Many	_	_	O
1	physicians	_	_	O
2	recommend	_	_	O
3	either	_	_	O
4	brimonidine	_	_	O
5	or	_	_	O
6	latanoprost	_	_	O
7	as	_	_	O
8	firstline	_	_	O
9	therapy	_	_	O
10	for	_	_	O
11	chronic	_	_	O
12	open-angle	_	_	O
13	glaucoma	_	_	O
14	or	_	_	O
15	ocular	_	_	O
16	hypertension	_	_	O
17	.	_	_	O

18	However	_	_	O
19	,	_	_	O
20	a	_	_	O
21	search	_	_	O
22	of	_	_	O
23	MEDLINE	_	_	O
24	indicates	_	_	O
25	that	_	_	O
26	there	_	_	O
27	have	_	_	O
28	been	_	_	O
29	few	_	_	O
30	head-to-head	_	_	O
31	comparisons	_	_	O
32	of	_	_	O
33	the	_	_	O
34	2	_	_	O
35	monotherapies	_	_	O
36	in	_	_	O
37	a	_	_	O
38	clinical	_	_	O
39	setting	_	_	O
40	.	_	_	O

41	This	_	_	O
42	study	_	_	O
43	compared	_	_	O
44	the	_	_	O
45	clinical	_	_	O
46	efficacy	_	_	O
47	and	_	_	O
48	tolerability	_	_	O
49	of	_	_	O
50	brimonidine	_	_	O
51	0.2	_	_	O
52	%	_	_	O
53	twice	_	_	O
54	daily	_	_	O
55	with	_	_	O
56	those	_	_	O
57	of	_	_	O
58	latanoprost	_	_	O
59	0.005	_	_	O
60	%	_	_	O
61	once	_	_	O
62	daily	_	_	O
63	as	_	_	O
64	monotherapy	_	_	O
65	in	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	open-angle	_	_	O
69	glaucoma	_	_	O
70	or	_	_	O
71	ocular	_	_	O
72	hypertension	_	_	O
73	.	_	_	O

74	In	_	_	O
75	this	_	_	O
76	3-month	_	_	O
77	,	_	_	O
78	multicenter	_	_	O
79	,	_	_	O
80	double-masked	_	_	O
81	,	_	_	O
82	parallel-group	_	_	O
83	,	_	_	O
84	4-visit	_	_	O
85	study	_	_	O
86	,	_	_	O
87	treatment-naive	_	_	O
88	and	_	_	O
89	previously	_	_	O
90	treated	_	_	O
91	patients	_	_	O
92	with	_	_	O
93	open-angle	_	_	O
94	glaucoma	_	_	O
95	or	_	_	O
96	ocular	_	_	O
97	hypertension	_	_	O
98	and	_	_	O
99	bilateral	_	_	O
100	intraocular	_	_	O
101	pressure	_	_	O
102	(	_	_	O
103	IOP	_	_	O
104	)	_	_	O
105	after	_	_	O
106	washout	_	_	O
107	of	_	_	O
108	between	_	_	O
109	22	_	_	O
110	and	_	_	O
111	34	_	_	O
112	mm	_	_	O
113	Hg	_	_	O
114	were	_	_	O
115	randomized	_	_	O
116	to	_	_	O
117	receive	_	_	O
118	either	_	_	O
119	brimonidine	_	_	O
120	or	_	_	O
121	latanoprost	_	_	O
122	.	_	_	O

123	Patients	_	_	O
124	who	_	_	O
125	had	_	_	O
126	received	_	_	O
127	previous	_	_	O
128	treatment	_	_	O
129	with	_	_	O
130	either	_	_	O
131	study	_	_	O
132	drug	_	_	O
133	were	_	_	O
134	excluded	_	_	O
135	from	_	_	O
136	the	_	_	O
137	study	_	_	O
138	.	_	_	O

139	The	_	_	O
140	primary	_	_	O
141	outcome	_	_	O
142	measure	_	_	O
143	was	_	_	O
144	response	_	_	O
145	rate	_	_	O
146	,	_	_	O
147	defined	_	_	O
148	as	_	_	O
149	the	_	_	O
150	percentage	_	_	O
151	of	_	_	O
152	patients	_	_	O
153	achieving	_	_	O
154	>	_	_	O
155	or	_	_	O
156	=	_	_	O
157	20	_	_	O
158	%	_	_	O
159	reduction	_	_	O
160	in	_	_	O
161	IOP	_	_	O
162	from	_	_	O
163	baseline	_	_	O
164	to	_	_	O
165	month	_	_	O
166	3	_	_	O
167	.	_	_	O

168	Secondary	_	_	O
169	outcome	_	_	O
170	measures	_	_	O
171	were	_	_	O
172	mean	_	_	O
173	IOP	_	_	O
174	reduction	_	_	O
175	from	_	_	O
176	baseline	_	_	O
177	to	_	_	O
178	month	_	_	O
179	3	_	_	O
180	and	_	_	O
181	clinical	_	_	O
182	success	_	_	O
183	,	_	_	O
184	defined	_	_	O
185	as	_	_	O
186	the	_	_	O
187	investigator	_	_	O
188	's	_	_	O
189	recommendation	_	_	O
190	that	_	_	O
191	the	_	_	O
192	patient	_	_	O
193	continue	_	_	O
194	using	_	_	O
195	the	_	_	O
196	assigned	_	_	O
197	study	_	_	O
198	medication	_	_	O
199	.	_	_	O

200	A	_	_	O
201	total	_	_	O
202	of	_	_	O
203	127	_	_	O
204	patients	_	_	O
205	(	_	_	O
206	55	_	_	O
207	treatment	_	_	O
208	naive	_	_	O
209	)	_	_	O
210	were	_	_	O
211	enrolled	_	_	O
212	,	_	_	O
213	66	_	_	O
214	in	_	_	O
215	the	_	_	O
216	brimonidine	_	_	O
217	group	_	_	O
218	and	_	_	O
219	61	_	_	O
220	in	_	_	O
221	the	_	_	O
222	latanoprost	_	_	O
223	group	_	_	O
224	.	_	_	O

225	After	_	_	B-Premise
226	3	_	_	I-Premise
227	months	_	_	I-Premise
228	of	_	_	I-Premise
229	treatment	_	_	I-Premise
230	,	_	_	I-Premise
231	80	_	_	I-Premise
232	%	_	_	I-Premise
233	of	_	_	I-Premise
234	patients	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	brimonidine	_	_	I-Premise
238	group	_	_	I-Premise
239	and	_	_	I-Premise
240	74	_	_	I-Premise
241	%	_	_	I-Premise
242	of	_	_	I-Premise
243	patients	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	latanoprost	_	_	I-Premise
247	group	_	_	I-Premise
248	had	_	_	I-Premise
249	achieved	_	_	I-Premise
250	>	_	_	I-Premise
251	or	_	_	I-Premise
252	=	_	_	I-Premise
253	20	_	_	I-Premise
254	%	_	_	I-Premise
255	reduction	_	_	I-Premise
256	in	_	_	I-Premise
257	IOP	_	_	I-Premise
258	from	_	_	I-Premise
259	baseline	_	_	I-Premise
260	.	_	_	I-Premise

261	The	_	_	B-Premise
262	mean	_	_	I-Premise
263	reduction	_	_	I-Premise
264	in	_	_	I-Premise
265	IOP	_	_	I-Premise
266	from	_	_	I-Premise
267	baseline	_	_	I-Premise
268	at	_	_	I-Premise
269	month	_	_	I-Premise
270	3	_	_	I-Premise
271	was	_	_	I-Premise
272	6.8	_	_	I-Premise
273	mm	_	_	I-Premise
274	Hg	_	_	I-Premise
275	with	_	_	I-Premise
276	brimonidine	_	_	I-Premise
277	and	_	_	I-Premise
278	6.5	_	_	I-Premise
279	mm	_	_	I-Premise
280	Hg	_	_	I-Premise
281	with	_	_	I-Premise
282	latanoprost	_	_	I-Premise
283	(	_	_	I-Premise
284	27.8	_	_	I-Premise
285	%	_	_	I-Premise
286	vs	_	_	I-Premise
287	27.0	_	_	I-Premise
288	%	_	_	I-Premise
289	,	_	_	I-Premise
290	respectively	_	_	I-Premise
291	)	_	_	I-Premise
292	.	_	_	I-Premise

293	Among	_	_	B-Premise
294	treatment-naive	_	_	I-Premise
295	patients	_	_	I-Premise
296	,	_	_	I-Premise
297	a	_	_	I-Premise
298	significantly	_	_	I-Premise
299	higher	_	_	I-Premise
300	percentage	_	_	I-Premise
301	of	_	_	I-Premise
302	brimonidine-treated	_	_	I-Premise
303	patients	_	_	I-Premise
304	achieved	_	_	I-Premise
305	>	_	_	I-Premise
306	or	_	_	I-Premise
307	=	_	_	I-Premise
308	20	_	_	I-Premise
309	%	_	_	I-Premise
310	decrease	_	_	I-Premise
311	in	_	_	I-Premise
312	IOP	_	_	I-Premise
313	compared	_	_	I-Premise
314	with	_	_	I-Premise
315	latanoprost-treated	_	_	I-Premise
316	patients	_	_	I-Premise
317	(	_	_	I-Premise
318	88	_	_	I-Premise
319	%	_	_	I-Premise
320	vs	_	_	I-Premise
321	59	_	_	I-Premise
322	%	_	_	I-Premise
323	,	_	_	I-Premise
324	respectively	_	_	I-Premise
325	;	_	_	I-Premise
326	P	_	_	I-Premise
327	=	_	_	I-Premise
328	0.01	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	In	_	_	B-Premise
332	previously	_	_	I-Premise
333	treated	_	_	I-Premise
334	patients	_	_	I-Premise
335	,	_	_	I-Premise
336	a	_	_	I-Premise
337	higher	_	_	I-Premise
338	percentage	_	_	I-Premise
339	of	_	_	I-Premise
340	the	_	_	I-Premise
341	latanoprost	_	_	I-Premise
342	group	_	_	I-Premise
343	achieved	_	_	I-Premise
344	>	_	_	I-Premise
345	or	_	_	I-Premise
346	=	_	_	I-Premise
347	20	_	_	I-Premise
348	%	_	_	I-Premise
349	reduction	_	_	I-Premise
350	in	_	_	I-Premise
351	IOP	_	_	I-Premise
352	compared	_	_	I-Premise
353	with	_	_	I-Premise
354	the	_	_	I-Premise
355	brimonidine	_	_	I-Premise
356	group	_	_	I-Premise
357	(	_	_	I-Premise
358	88	_	_	I-Premise
359	%	_	_	I-Premise
360	vs	_	_	I-Premise
361	74	_	_	I-Premise
362	%	_	_	I-Premise
363	,	_	_	I-Premise
364	respectively	_	_	I-Premise
365	)	_	_	I-Premise
366	;	_	_	I-Premise
367	however	_	_	B-Premise
368	,	_	_	I-Premise
369	the	_	_	I-Premise
370	difference	_	_	I-Premise
371	was	_	_	I-Premise
372	not	_	_	I-Premise
373	statistically	_	_	I-Premise
374	significant	_	_	I-Premise
375	.	_	_	I-Premise

376	Significantly	_	_	B-Premise
377	more	_	_	I-Premise
378	patients	_	_	I-Premise
379	in	_	_	I-Premise
380	the	_	_	I-Premise
381	brimonidine	_	_	I-Premise
382	group	_	_	I-Premise
383	achieved	_	_	I-Premise
384	clinical	_	_	I-Premise
385	success	_	_	I-Premise
386	at	_	_	I-Premise
387	month	_	_	I-Premise
388	3	_	_	I-Premise
389	compared	_	_	I-Premise
390	with	_	_	I-Premise
391	patients	_	_	I-Premise
392	in	_	_	I-Premise
393	the	_	_	I-Premise
394	latanoprost	_	_	I-Premise
395	group	_	_	I-Premise
396	(	_	_	I-Premise
397	91	_	_	I-Premise
398	%	_	_	I-Premise
399	vs	_	_	I-Premise
400	74	_	_	I-Premise
401	%	_	_	I-Premise
402	;	_	_	I-Premise
403	P	_	_	I-Premise
404	=	_	_	I-Premise
405	0.01	_	_	I-Premise
406	)	_	_	I-Premise
407	.	_	_	I-Premise

408	At	_	_	B-Premise
409	peak	_	_	I-Premise
410	effect	_	_	I-Premise
411	,	_	_	I-Premise
412	brimonidine	_	_	I-Premise
413	twice	_	_	I-Premise
414	daily	_	_	I-Premise
415	was	_	_	I-Premise
416	as	_	_	I-Premise
417	effective	_	_	I-Premise
418	as	_	_	I-Premise
419	latanoprost	_	_	I-Premise
420	once	_	_	I-Premise
421	daily	_	_	I-Premise
422	in	_	_	I-Premise
423	lowering	_	_	I-Premise
424	IOP	_	_	I-Premise
425	.	_	_	I-Premise

426	In	_	_	B-Premise
427	treatment-naive	_	_	I-Premise
428	patients	_	_	I-Premise
429	,	_	_	I-Premise
430	latanoprost	_	_	I-Premise
431	was	_	_	I-Premise
432	associated	_	_	I-Premise
433	with	_	_	I-Premise
434	a	_	_	I-Premise
435	significantly	_	_	I-Premise
436	higher	_	_	I-Premise
437	rate	_	_	I-Premise
438	of	_	_	I-Premise
439	nonresponse	_	_	I-Premise
440	after	_	_	I-Premise
441	3	_	_	I-Premise
442	months	_	_	I-Premise
443	of	_	_	I-Premise
444	treatment	_	_	I-Premise
445	compared	_	_	I-Premise
446	with	_	_	I-Premise
447	brimonidine	_	_	I-Premise
448	.	_	_	I-Premise

449	This	_	_	B-Claim
450	suggests	_	_	I-Claim
451	that	_	_	I-Claim
452	brimonidine	_	_	I-Claim
453	may	_	_	I-Claim
454	be	_	_	I-Claim
455	the	_	_	I-Claim
456	more	_	_	I-Claim
457	reliable	_	_	I-Claim
458	choice	_	_	I-Claim
459	for	_	_	I-Claim
460	first-line	_	_	I-Claim
461	therapy	_	_	I-Claim
462	of	_	_	I-Claim
463	newly	_	_	I-Claim
464	diagnosed	_	_	I-Claim
465	open-angle	_	_	I-Claim
466	glaucoma	_	_	I-Claim
467	or	_	_	I-Claim
468	ocular	_	_	I-Claim
469	hypertension	_	_	I-Claim
470	.	_	_	I-Claim

471	In	_	_	B-Premise
472	previously	_	_	I-Premise
473	treated	_	_	I-Premise
474	patients	_	_	I-Premise
475	,	_	_	I-Premise
476	however	_	_	I-Premise
477	,	_	_	I-Premise
478	latanoprost	_	_	I-Premise
479	provided	_	_	I-Premise
480	greater	_	_	I-Premise
481	mean	_	_	I-Premise
482	IOP	_	_	I-Premise
483	reduction	_	_	I-Premise
484	than	_	_	I-Premise
485	did	_	_	I-Premise
486	brimonidine	_	_	I-Premise
487	.	_	_	I-Premise

488	Significantly	_	_	B-Claim
489	more	_	_	I-Claim
490	patients	_	_	I-Claim
491	achieved	_	_	I-Claim
492	clinical	_	_	I-Claim
493	success	_	_	I-Claim
494	with	_	_	I-Claim
495	brimonidine	_	_	I-Claim
496	monotherapy	_	_	I-Claim
497	than	_	_	I-Claim
498	with	_	_	I-Claim
499	latanoprost	_	_	I-Claim
500	monotherapy	_	_	I-Claim
501	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	first-line	_	_	O
8	,	_	_	O
9	single-agent	_	_	O
10	trastuzumab	_	_	O
11	in	_	_	O
12	women	_	_	O
13	with	_	_	O
14	HER2-overexpressing	_	_	O
15	metastatic	_	_	O
16	breast	_	_	O
17	cancer	_	_	O
18	.	_	_	O

19	One	_	_	O
20	hundred	_	_	O
21	fourteen	_	_	O
22	women	_	_	O
23	with	_	_	O
24	HER2-overexpressing	_	_	O
25	metastatic	_	_	O
26	breast	_	_	O
27	cancer	_	_	O
28	were	_	_	O
29	randomized	_	_	O
30	to	_	_	O
31	receive	_	_	O
32	first-line	_	_	O
33	treatment	_	_	O
34	with	_	_	O
35	trastuzumab	_	_	O
36	4	_	_	O
37	mg/kg	_	_	O
38	loading	_	_	O
39	dose	_	_	O
40	,	_	_	O
41	followed	_	_	O
42	by	_	_	O
43	2	_	_	O
44	mg/kg	_	_	O
45	weekly	_	_	O
46	,	_	_	O
47	or	_	_	O
48	a	_	_	O
49	higher	_	_	O
50	8	_	_	O
51	mg/kg	_	_	O
52	loading	_	_	O
53	dose	_	_	O
54	,	_	_	O
55	followed	_	_	O
56	by	_	_	O
57	4	_	_	O
58	mg/kg	_	_	O
59	weekly	_	_	O
60	.	_	_	O

61	The	_	_	B-Premise
62	objective	_	_	I-Premise
63	response	_	_	I-Premise
64	rate	_	_	I-Premise
65	was	_	_	I-Premise
66	26	_	_	I-Premise
67	%	_	_	I-Premise
68	(	_	_	I-Premise
69	95	_	_	I-Premise
70	%	_	_	I-Premise
71	confidence	_	_	I-Premise
72	interval	_	_	I-Premise
73	[	_	_	I-Premise
74	CI	_	_	I-Premise
75	]	_	_	I-Premise
76	,	_	_	I-Premise
77	18.2	_	_	I-Premise
78	%	_	_	I-Premise
79	to	_	_	I-Premise
80	34.4	_	_	I-Premise
81	%	_	_	I-Premise
82	)	_	_	I-Premise
83	,	_	_	I-Premise
84	with	_	_	I-Premise
85	seven	_	_	I-Premise
86	complete	_	_	I-Premise
87	and	_	_	I-Premise
88	23	_	_	I-Premise
89	partial	_	_	I-Premise
90	responses	_	_	I-Premise
91	.	_	_	I-Premise

92	Response	_	_	B-Premise
93	rates	_	_	I-Premise
94	in	_	_	I-Premise
95	111	_	_	I-Premise
96	assessable	_	_	I-Premise
97	patients	_	_	I-Premise
98	with	_	_	I-Premise
99	3+	_	_	I-Premise
100	and	_	_	I-Premise
101	2+	_	_	I-Premise
102	HER2	_	_	I-Premise
103	overexpression	_	_	I-Premise
104	by	_	_	I-Premise
105	immunohistochemistry	_	_	I-Premise
106	(	_	_	I-Premise
107	IHC	_	_	I-Premise
108	)	_	_	I-Premise
109	were	_	_	I-Premise
110	35	_	_	I-Premise
111	%	_	_	I-Premise
112	(	_	_	I-Premise
113	95	_	_	I-Premise
114	%	_	_	I-Premise
115	CI	_	_	I-Premise
116	,	_	_	I-Premise
117	24.4	_	_	I-Premise
118	%	_	_	I-Premise
119	to	_	_	I-Premise
120	44.7	_	_	I-Premise
121	%	_	_	I-Premise
122	)	_	_	I-Premise
123	and	_	_	I-Premise
124	none	_	_	I-Premise
125	(	_	_	I-Premise
126	95	_	_	I-Premise
127	%	_	_	I-Premise
128	CI	_	_	I-Premise
129	,	_	_	I-Premise
130	0	_	_	I-Premise
131	%	_	_	I-Premise
132	to	_	_	I-Premise
133	15.5	_	_	I-Premise
134	%	_	_	I-Premise
135	)	_	_	I-Premise
136	,	_	_	I-Premise
137	respectively	_	_	I-Premise
138	.	_	_	I-Premise

139	The	_	_	B-Premise
140	clinical	_	_	I-Premise
141	benefit	_	_	I-Premise
142	rates	_	_	I-Premise
143	in	_	_	I-Premise
144	assessable	_	_	I-Premise
145	patients	_	_	I-Premise
146	with	_	_	I-Premise
147	3+	_	_	I-Premise
148	and	_	_	I-Premise
149	2+	_	_	I-Premise
150	HER2	_	_	I-Premise
151	overexpression	_	_	I-Premise
152	were	_	_	I-Premise
153	48	_	_	I-Premise
154	%	_	_	I-Premise
155	and	_	_	I-Premise
156	7	_	_	I-Premise
157	%	_	_	I-Premise
158	,	_	_	I-Premise
159	respectively	_	_	I-Premise
160	.	_	_	I-Premise

161	The	_	_	B-Premise
162	response	_	_	I-Premise
163	rates	_	_	I-Premise
164	in	_	_	I-Premise
165	108	_	_	I-Premise
166	assessable	_	_	I-Premise
167	patients	_	_	I-Premise
168	with	_	_	I-Premise
169	and	_	_	I-Premise
170	without	_	_	I-Premise
171	HER2	_	_	I-Premise
172	gene	_	_	I-Premise
173	amplification	_	_	I-Premise
174	by	_	_	I-Premise
175	fluorescence	_	_	I-Premise
176	in	_	_	I-Premise
177	situ	_	_	I-Premise
178	hybridization	_	_	I-Premise
179	(	_	_	I-Premise
180	FISH	_	_	I-Premise
181	)	_	_	I-Premise
182	analysis	_	_	I-Premise
183	were	_	_	I-Premise
184	34	_	_	I-Premise
185	%	_	_	I-Premise
186	(	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	CI	_	_	I-Premise
190	,	_	_	I-Premise
191	23.9	_	_	I-Premise
192	%	_	_	I-Premise
193	to	_	_	I-Premise
194	45.7	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	7	_	_	I-Premise
199	%	_	_	I-Premise
200	(	_	_	I-Premise
201	95	_	_	I-Premise
202	%	_	_	I-Premise
203	CI	_	_	I-Premise
204	,	_	_	I-Premise
205	0.8	_	_	I-Premise
206	%	_	_	I-Premise
207	to	_	_	I-Premise
208	22.8	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	.	_	_	I-Premise

214	Seventeen	_	_	B-Premise
215	(	_	_	I-Premise
216	57	_	_	I-Premise
217	%	_	_	I-Premise
218	)	_	_	I-Premise
219	of	_	_	I-Premise
220	30	_	_	I-Premise
221	patients	_	_	I-Premise
222	with	_	_	I-Premise
223	an	_	_	I-Premise
224	objective	_	_	I-Premise
225	response	_	_	I-Premise
226	and	_	_	I-Premise
227	22	_	_	I-Premise
228	(	_	_	I-Premise
229	51	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	of	_	_	I-Premise
233	43	_	_	I-Premise
234	patients	_	_	I-Premise
235	with	_	_	I-Premise
236	clinical	_	_	I-Premise
237	benefit	_	_	I-Premise
238	had	_	_	I-Premise
239	not	_	_	I-Premise
240	experienced	_	_	I-Premise
241	disease	_	_	I-Premise
242	progression	_	_	I-Premise
243	at	_	_	I-Premise
244	follow-up	_	_	I-Premise
245	at	_	_	I-Premise
246	12	_	_	I-Premise
247	months	_	_	I-Premise
248	or	_	_	I-Premise
249	later	_	_	I-Premise
250	.	_	_	I-Premise

251	The	_	_	B-Premise
252	most	_	_	I-Premise
253	common	_	_	I-Premise
254	treatment-related	_	_	I-Premise
255	adverse	_	_	I-Premise
256	events	_	_	I-Premise
257	were	_	_	I-Premise
258	chills	_	_	I-Premise
259	(	_	_	I-Premise
260	25	_	_	I-Premise
261	%	_	_	I-Premise
262	of	_	_	I-Premise
263	patients	_	_	I-Premise
264	)	_	_	I-Premise
265	,	_	_	I-Premise
266	asthenia	_	_	I-Premise
267	(	_	_	I-Premise
268	23	_	_	I-Premise
269	%	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	fever	_	_	I-Premise
273	(	_	_	I-Premise
274	22	_	_	I-Premise
275	%	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	pain	_	_	I-Premise
279	(	_	_	I-Premise
280	18	_	_	I-Premise
281	%	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	and	_	_	I-Premise
285	nausea	_	_	I-Premise
286	(	_	_	I-Premise
287	14	_	_	I-Premise
288	%	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Cardiac	_	_	B-Premise
292	dysfunction	_	_	I-Premise
293	occurred	_	_	I-Premise
294	in	_	_	I-Premise
295	two	_	_	I-Premise
296	patients	_	_	I-Premise
297	(	_	_	I-Premise
298	2	_	_	I-Premise
299	%	_	_	I-Premise
300	)	_	_	I-Premise
301	;	_	_	I-Premise
302	both	_	_	I-Premise
303	had	_	_	I-Premise
304	histories	_	_	I-Premise
305	of	_	_	I-Premise
306	cardiac	_	_	I-Premise
307	disease	_	_	I-Premise
308	and	_	_	I-Premise
309	did	_	_	I-Premise
310	not	_	_	I-Premise
311	require	_	_	I-Premise
312	additional	_	_	I-Premise
313	intervention	_	_	I-Premise
314	after	_	_	I-Premise
315	discontinuation	_	_	I-Premise
316	of	_	_	I-Premise
317	trastuzumab	_	_	I-Premise
318	.	_	_	I-Premise

319	There	_	_	B-Claim
320	was	_	_	I-Claim
321	no	_	_	I-Claim
322	clear	_	_	I-Claim
323	evidence	_	_	I-Claim
324	of	_	_	I-Claim
325	a	_	_	I-Claim
326	dose-response	_	_	I-Claim
327	relationship	_	_	I-Claim
328	for	_	_	I-Claim
329	response	_	_	I-Claim
330	,	_	_	I-Claim
331	survival	_	_	I-Claim
332	,	_	_	I-Claim
333	or	_	_	I-Claim
334	adverse	_	_	I-Claim
335	events	_	_	I-Claim
336	.	_	_	I-Claim

337	Single-agent	_	_	B-Claim
338	trastuzumab	_	_	I-Claim
339	is	_	_	I-Claim
340	active	_	_	I-Claim
341	and	_	_	I-Claim
342	well	_	_	I-Claim
343	tolerated	_	_	I-Claim
344	as	_	_	I-Claim
345	first-line	_	_	I-Claim
346	treatment	_	_	I-Claim
347	of	_	_	I-Claim
348	women	_	_	I-Claim
349	with	_	_	I-Claim
350	metastatic	_	_	I-Claim
351	breast	_	_	I-Claim
352	cancer	_	_	I-Claim
353	with	_	_	I-Claim
354	HER2	_	_	I-Claim
355	3+	_	_	I-Claim
356	overexpression	_	_	I-Claim
357	by	_	_	I-Claim
358	IHC	_	_	I-Claim
359	or	_	_	I-Claim
360	gene	_	_	I-Claim
361	amplification	_	_	I-Claim
362	by	_	_	I-Claim
363	FISH	_	_	I-Claim
364	.	_	_	I-Claim


0	Older	_	_	B-Claim
1	patients	_	_	I-Claim
2	,	_	_	I-Claim
3	even	_	_	I-Claim
4	if	_	_	I-Claim
5	fit	_	_	I-Claim
6	,	_	_	I-Claim
7	are	_	_	I-Claim
8	often	_	_	I-Claim
9	considered	_	_	I-Claim
10	incapable	_	_	I-Claim
11	of	_	_	I-Claim
12	tolerating	_	_	I-Claim
13	platinum-based	_	_	I-Claim
14	systemic	_	_	I-Claim
15	therapy	_	_	I-Claim
16	.	_	_	I-Claim

17	We	_	_	O
18	performed	_	_	O
19	a	_	_	O
20	retrospective	_	_	O
21	analysis	_	_	O
22	of	_	_	O
23	Eastern	_	_	O
24	Cooperative	_	_	O
25	Oncology	_	_	O
26	Group	_	_	O
27	(	_	_	O
28	ECOG	_	_	O
29	)	_	_	O
30	5592	_	_	O
31	,	_	_	O
32	a	_	_	O
33	phase	_	_	O
34	III	_	_	O
35	randomized	_	_	O
36	trial	_	_	O
37	of	_	_	O
38	platinum-based	_	_	O
39	chemotherapy	_	_	O
40	regimens	_	_	O
41	for	_	_	O
42	non-small-cell	_	_	O
43	lung	_	_	O
44	cancer	_	_	O
45	(	_	_	O
46	NSCLC	_	_	O
47	)	_	_	O
48	,	_	_	O
49	and	_	_	O
50	compared	_	_	O
51	outcomes	_	_	O
52	in	_	_	O
53	enrollees	_	_	O
54	70	_	_	O
55	years	_	_	O
56	of	_	_	O
57	age	_	_	O
58	and	_	_	O
59	older	_	_	O
60	with	_	_	O
61	those	_	_	O
62	in	_	_	O
63	younger	_	_	O
64	patients	_	_	O
65	.	_	_	O

66	ECOG	_	_	O
67	carried	_	_	O
68	out	_	_	O
69	a	_	_	O
70	randomized	_	_	O
71	phase	_	_	O
72	III	_	_	O
73	trial	_	_	O
74	of	_	_	O
75	cisplatin	_	_	O
76	plus	_	_	O
77	either	_	_	O
78	etoposide	_	_	O
79	or	_	_	O
80	paclitaxel	_	_	O
81	in	_	_	O
82	chemotherapy-naïve	_	_	O
83	NSCLC	_	_	O
84	patients	_	_	O
85	with	_	_	O
86	stages	_	_	O
87	III	_	_	O
88	(	_	_	O
89	B	_	_	O
90	)	_	_	O
91	or	_	_	O
92	IV	_	_	O
93	disease	_	_	O
94	.	_	_	O

95	Toxic	_	_	O
96	effects	_	_	O
97	,	_	_	O
98	response	_	_	O
99	rates	_	_	O
100	,	_	_	O
101	and	_	_	O
102	survival	_	_	O
103	rates	_	_	O
104	were	_	_	O
105	compared	_	_	O
106	between	_	_	O
107	age	_	_	O
108	groups	_	_	O
109	.	_	_	O

110	All	_	_	O
111	P	_	_	O
112	values	_	_	O
113	were	_	_	O
114	two-sided	_	_	O
115	.	_	_	O

116	A	_	_	O
117	total	_	_	O
118	of	_	_	O
119	574	_	_	O
120	patients	_	_	O
121	enrolled	_	_	O
122	from	_	_	O
123	August	_	_	O
124	1993	_	_	O
125	through	_	_	O
126	December	_	_	O
127	1994	_	_	O
128	were	_	_	O
129	evaluable	_	_	O
130	.	_	_	O

131	Eighty-six	_	_	O
132	(	_	_	O
133	15	_	_	O
134	%	_	_	O
135	)	_	_	O
136	were	_	_	O
137	70	_	_	O
138	years	_	_	O
139	old	_	_	O
140	or	_	_	O
141	older	_	_	O
142	.	_	_	O

143	Older	_	_	B-Premise
144	patients	_	_	I-Premise
145	had	_	_	I-Premise
146	a	_	_	I-Premise
147	higher	_	_	I-Premise
148	incidence	_	_	I-Premise
149	of	_	_	I-Premise
150	cardiovascular	_	_	I-Premise
151	(	_	_	I-Premise
152	P	_	_	I-Premise
153	=.009	_	_	I-Premise
154	)	_	_	I-Premise
155	and	_	_	I-Premise
156	respiratory	_	_	I-Premise
157	(	_	_	I-Premise
158	P	_	_	I-Premise
159	=.04	_	_	I-Premise
160	)	_	_	I-Premise
161	comorbidities	_	_	I-Premise
162	and	_	_	I-Premise
163	nonanalgesic	_	_	I-Premise
164	medication	_	_	I-Premise
165	use	_	_	I-Premise
166	(	_	_	I-Premise
167	P	_	_	I-Premise
168	=.02	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	Leukopenia	_	_	B-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	<	_	_	I-Premise
175	.001	_	_	I-Premise
176	)	_	_	I-Premise
177	and	_	_	I-Premise
178	neuropsychiatric	_	_	I-Premise
179	toxicity	_	_	I-Premise
180	(	_	_	I-Premise
181	P	_	_	I-Premise
182	=.002	_	_	I-Premise
183	)	_	_	I-Premise
184	were	_	_	I-Premise
185	more	_	_	I-Premise
186	common	_	_	I-Premise
187	in	_	_	I-Premise
188	elderly	_	_	I-Premise
189	men	_	_	I-Premise
190	than	_	_	I-Premise
191	in	_	_	I-Premise
192	younger	_	_	I-Premise
193	men	_	_	I-Premise
194	.	_	_	I-Premise

195	Elderly	_	_	B-Premise
196	women	_	_	I-Premise
197	lost	_	_	I-Premise
198	more	_	_	I-Premise
199	weight	_	_	I-Premise
200	than	_	_	I-Premise
201	younger	_	_	I-Premise
202	women	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=.006	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Other	_	_	B-Premise
209	toxic	_	_	I-Premise
210	effects	_	_	I-Premise
211	were	_	_	I-Premise
212	similar	_	_	I-Premise
213	in	_	_	I-Premise
214	older	_	_	I-Premise
215	and	_	_	I-Premise
216	younger	_	_	I-Premise
217	patients	_	_	I-Premise
218	.	_	_	I-Premise

219	The	_	_	B-Premise
220	proportions	_	_	I-Premise
221	with	_	_	I-Premise
222	clinical	_	_	I-Premise
223	partial	_	_	I-Premise
224	or	_	_	I-Premise
225	complete	_	_	I-Premise
226	response	_	_	I-Premise
227	(	_	_	I-Premise
228	21.5	_	_	I-Premise
229	%	_	_	I-Premise
230	versus	_	_	I-Premise
231	23.3	_	_	I-Premise
232	%	_	_	I-Premise
233	;	_	_	I-Premise
234	Fisher	_	_	I-Premise
235	's	_	_	I-Premise
236	exact	_	_	I-Premise
237	test	_	_	I-Premise
238	,	_	_	I-Premise
239	P	_	_	I-Premise
240	=.66	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	median	_	_	I-Premise
244	time	_	_	I-Premise
245	to	_	_	I-Premise
246	progression	_	_	I-Premise
247	(	_	_	I-Premise
248	4.37	_	_	I-Premise
249	versus	_	_	I-Premise
250	4.30	_	_	I-Premise
251	months	_	_	I-Premise
252	;	_	_	I-Premise
253	log-rank	_	_	I-Premise
254	test	_	_	I-Premise
255	,	_	_	I-Premise
256	P	_	_	I-Premise
257	=.29	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	I-Premise
261	survival	_	_	I-Premise
262	distribution	_	_	I-Premise
263	(	_	_	I-Premise
264	log-rank	_	_	I-Premise
265	test	_	_	I-Premise
266	,	_	_	I-Premise
267	P	_	_	I-Premise
268	=.29	_	_	I-Premise
269	;	_	_	I-Premise
270	median	_	_	I-Premise
271	survival	_	_	I-Premise
272	,	_	_	I-Premise
273	9.05	_	_	I-Premise
274	versus	_	_	I-Premise
275	8.53	_	_	I-Premise
276	months	_	_	I-Premise
277	;	_	_	I-Premise
278	1-year	_	_	I-Premise
279	survival	_	_	I-Premise
280	,	_	_	I-Premise
281	38	_	_	I-Premise
282	%	_	_	I-Premise
283	versus	_	_	I-Premise
284	29	_	_	I-Premise
285	%	_	_	I-Premise
286	;	_	_	I-Premise
287	and	_	_	I-Premise
288	2-year	_	_	I-Premise
289	survival	_	_	I-Premise
290	,	_	_	I-Premise
291	14	_	_	I-Premise
292	%	_	_	I-Premise
293	versus	_	_	I-Premise
294	12	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	were	_	_	I-Premise
298	similar	_	_	I-Premise
299	in	_	_	I-Premise
300	patients	_	_	I-Premise
301	younger	_	_	I-Premise
302	than	_	_	I-Premise
303	70	_	_	I-Premise
304	years	_	_	I-Premise
305	and	_	_	I-Premise
306	70	_	_	I-Premise
307	years	_	_	I-Premise
308	old	_	_	I-Premise
309	or	_	_	I-Premise
310	older	_	_	I-Premise
311	.	_	_	I-Premise

312	Baseline	_	_	B-Premise
313	quality-of-life	_	_	I-Premise
314	and	_	_	I-Premise
315	treatment-outcome	_	_	I-Premise
316	indices	_	_	I-Premise
317	were	_	_	I-Premise
318	similar	_	_	I-Premise
319	.	_	_	I-Premise

320	Equivalent	_	_	B-Premise
321	declines	_	_	I-Premise
322	over	_	_	I-Premise
323	time	_	_	I-Premise
324	in	_	_	I-Premise
325	functional	_	_	I-Premise
326	well-being	_	_	I-Premise
327	occurred	_	_	I-Premise
328	in	_	_	I-Premise
329	both	_	_	I-Premise
330	groups	_	_	I-Premise
331	.	_	_	I-Premise

332	Response	_	_	B-Claim
333	rate	_	_	I-Claim
334	,	_	_	I-Claim
335	toxicity	_	_	I-Claim
336	,	_	_	I-Claim
337	and	_	_	I-Claim
338	survival	_	_	I-Claim
339	in	_	_	I-Claim
340	fit	_	_	I-Claim
341	,	_	_	I-Claim
342	elderly	_	_	I-Claim
343	NSCLC	_	_	I-Claim
344	patients	_	_	I-Claim
345	receiving	_	_	I-Claim
346	platinum-based	_	_	I-Claim
347	treatment	_	_	I-Claim
348	appear	_	_	I-Claim
349	to	_	_	I-Claim
350	be	_	_	I-Claim
351	similar	_	_	I-Claim
352	to	_	_	I-Claim
353	those	_	_	I-Claim
354	in	_	_	I-Claim
355	younger	_	_	I-Claim
356	patients	_	_	I-Claim
357	,	_	_	I-Claim
358	although	_	_	B-Claim
359	patients	_	_	I-Claim
360	70	_	_	I-Claim
361	years	_	_	I-Claim
362	old	_	_	I-Claim
363	or	_	_	I-Claim
364	older	_	_	I-Claim
365	have	_	_	I-Claim
366	more	_	_	I-Claim
367	comorbidities	_	_	I-Claim
368	and	_	_	I-Claim
369	can	_	_	I-Claim
370	expect	_	_	I-Claim
371	more	_	_	I-Claim
372	leukopenia	_	_	I-Claim
373	and	_	_	I-Claim
374	neuropsychiatric	_	_	I-Claim
375	toxicity	_	_	I-Claim
376	.	_	_	I-Claim

377	Advanced	_	_	B-Claim
378	age	_	_	I-Claim
379	alone	_	_	I-Claim
380	should	_	_	I-Claim
381	not	_	_	I-Claim
382	preclude	_	_	I-Claim
383	appropriate	_	_	I-Claim
384	NSCLC	_	_	I-Claim
385	treatment	_	_	I-Claim
386	.	_	_	I-Claim


0	SIR-Spheres	_	_	O
1	are	_	_	O
2	radioactive	_	_	O
3	yttrium90	_	_	O
4	microspheres	_	_	O
5	(	_	_	O
6	SIR-Spheres	_	_	O
7	,	_	_	O
8	Sirtex	_	_	O
9	Medical	_	_	O
10	Limited	_	_	O
11	,	_	_	O
12	Australia	_	_	O
13	)	_	_	O
14	used	_	_	O
15	to	_	_	O
16	selectively	_	_	O
17	target	_	_	O
18	high	_	_	O
19	levels	_	_	O
20	of	_	_	O
21	ionising	_	_	O
22	radiation	_	_	O
23	to	_	_	O
24	tumors	_	_	O
25	within	_	_	O
26	the	_	_	O
27	liver	_	_	O
28	.	_	_	O

29	This	_	_	O
30	trial	_	_	O
31	was	_	_	O
32	designed	_	_	O
33	to	_	_	O
34	measure	_	_	O
35	any	_	_	O
36	increased	_	_	O
37	patient	_	_	O
38	benefit	_	_	O
39	by	_	_	O
40	adding	_	_	O
41	a	_	_	O
42	single	_	_	O
43	administration	_	_	O
44	of	_	_	O
45	SIR-Spheres	_	_	O
46	to	_	_	O
47	a	_	_	O
48	regimen	_	_	O
49	of	_	_	O
50	regional	_	_	O
51	hepatic	_	_	O
52	artery	_	_	O
53	chemotherapy	_	_	O
54	(	_	_	O
55	HAC	_	_	O
56	)	_	_	O
57	administered	_	_	O
58	as	_	_	O
59	a	_	_	O
60	12	_	_	O
61	day	_	_	O
62	infusion	_	_	O
63	of	_	_	O
64	floxuridine	_	_	O
65	and	_	_	O
66	repeated	_	_	O
67	at	_	_	O
68	monthly	_	_	O
69	intervals	_	_	O
70	,	_	_	O
71	vs.	_	_	O
72	the	_	_	O
73	same	_	_	O
74	chemotherapy	_	_	O
75	alone	_	_	O
76	.	_	_	O

77	A	_	_	O
78	phase	_	_	O
79	III	_	_	O
80	randomised	_	_	O
81	clinical	_	_	O
82	trial	_	_	O
83	entering	_	_	O
84	74	_	_	O
85	patients	_	_	O
86	was	_	_	O
87	undertaken	_	_	O
88	on	_	_	O
89	patients	_	_	O
90	with	_	_	O
91	bi-lobar	_	_	O
92	non-resectable	_	_	O
93	liver	_	_	O
94	metastases	_	_	O
95	from	_	_	O
96	primary	_	_	O
97	adenocarcinoma	_	_	O
98	of	_	_	O
99	the	_	_	O
100	large	_	_	O
101	bowel	_	_	O
102	.	_	_	O

103	Patient	_	_	O
104	benefit	_	_	O
105	criteria	_	_	O
106	assessed	_	_	O
107	in	_	_	O
108	the	_	_	O
109	trial	_	_	O
110	were	_	_	O
111	tumor	_	_	O
112	response	_	_	O
113	,	_	_	O
114	time	_	_	O
115	to	_	_	O
116	disease	_	_	O
117	progression	_	_	O
118	in	_	_	O
119	the	_	_	O
120	liver	_	_	O
121	,	_	_	O
122	overall	_	_	O
123	survival	_	_	O
124	,	_	_	O
125	quality	_	_	O
126	of	_	_	O
127	life	_	_	O
128	,	_	_	O
129	and	_	_	O
130	treatment	_	_	O
131	related	_	_	O
132	toxicity	_	_	O
133	.	_	_	O

134	Tumor	_	_	O
135	response	_	_	O
136	was	_	_	O
137	measured	_	_	O
138	by	_	_	O
139	serial	_	_	O
140	changes	_	_	O
141	in	_	_	O
142	both	_	_	O
143	cross-sectional	_	_	O
144	tumor	_	_	O
145	areas	_	_	O
146	and	_	_	O
147	total	_	_	O
148	tumor	_	_	O
149	volumes	_	_	O
150	,	_	_	O
151	provided	_	_	O
152	any	_	_	O
153	response	_	_	O
154	lasted	_	_	O
155	not	_	_	O
156	less	_	_	O
157	than	_	_	O
158	three	_	_	O
159	months	_	_	O
160	as	_	_	O
161	well	_	_	O
162	as	_	_	O
163	changes	_	_	O
164	in	_	_	O
165	serum	_	_	O
166	carcino-embryonic	_	_	O
167	antigen	_	_	O
168	(	_	_	O
169	CEA	_	_	O
170	)	_	_	O
171	.	_	_	O

172	The	_	_	B-Premise
173	partial	_	_	I-Premise
174	and	_	_	I-Premise
175	complete	_	_	I-Premise
176	response	_	_	I-Premise
177	rate	_	_	I-Premise
178	(	_	_	I-Premise
179	PR	_	_	I-Premise
180	+	_	_	I-Premise
181	CR	_	_	I-Premise
182	)	_	_	I-Premise
183	was	_	_	I-Premise
184	significantly	_	_	I-Premise
185	greater	_	_	I-Premise
186	for	_	_	I-Premise
187	patients	_	_	I-Premise
188	receiving	_	_	I-Premise
189	SIR-Spheres	_	_	I-Premise
190	when	_	_	I-Premise
191	measured	_	_	I-Premise
192	by	_	_	I-Premise
193	tumor	_	_	I-Premise
194	areas	_	_	I-Premise
195	(	_	_	I-Premise
196	44	_	_	I-Premise
197	%	_	_	I-Premise
198	)	_	_	I-Premise
199	vs.	_	_	I-Premise
200	17.6	_	_	I-Premise
201	%	_	_	I-Premise
202	,	_	_	I-Premise
203	P	_	_	I-Premise
204	=	_	_	I-Premise
205	0.01	_	_	I-Premise
206	)	_	_	I-Premise
207	tumor	_	_	I-Premise
208	volumes	_	_	I-Premise
209	(	_	_	I-Premise
210	50	_	_	I-Premise
211	%	_	_	I-Premise
212	vs.	_	_	I-Premise
213	24	_	_	I-Premise
214	%	_	_	I-Premise
215	,	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	0.03	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	CEA	_	_	I-Premise
222	(	_	_	I-Premise
223	72	_	_	I-Premise
224	%	_	_	I-Premise
225	vs.	_	_	I-Premise
226	47	_	_	I-Premise
227	%	_	_	I-Premise
228	,	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	0.004	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	The	_	_	B-Premise
235	median	_	_	I-Premise
236	time	_	_	I-Premise
237	to	_	_	I-Premise
238	disease	_	_	I-Premise
239	progression	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	liver	_	_	I-Premise
243	was	_	_	I-Premise
244	significantly	_	_	I-Premise
245	longer	_	_	I-Premise
246	for	_	_	I-Premise
247	patients	_	_	I-Premise
248	receiving	_	_	I-Premise
249	SIR-Spheres	_	_	I-Premise
250	in	_	_	I-Premise
251	comparison	_	_	I-Premise
252	to	_	_	I-Premise
253	patients	_	_	I-Premise
254	receiving	_	_	I-Premise
255	HAC	_	_	I-Premise
256	alone	_	_	I-Premise
257	when	_	_	I-Premise
258	measured	_	_	I-Premise
259	by	_	_	I-Premise
260	either	_	_	I-Premise
261	tumor	_	_	I-Premise
262	areas	_	_	I-Premise
263	(	_	_	I-Premise
264	9.7	_	_	I-Premise
265	vs.	_	_	I-Premise
266	15.9	_	_	I-Premise
267	months	_	_	I-Premise
268	,	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	0.001	_	_	I-Premise
272	)	_	_	I-Premise
273	,	_	_	I-Premise
274	tumor	_	_	I-Premise
275	volumes	_	_	I-Premise
276	(	_	_	I-Premise
277	7.6	_	_	I-Premise
278	vs.	_	_	I-Premise
279	12.0	_	_	I-Premise
280	months	_	_	I-Premise
281	,	_	_	I-Premise
282	P	_	_	I-Premise
283	=	_	_	I-Premise
284	0.04	_	_	I-Premise
285	)	_	_	I-Premise
286	or	_	_	I-Premise
287	CEA	_	_	I-Premise
288	(	_	_	I-Premise
289	5.7	_	_	I-Premise
290	vs.	_	_	I-Premise
291	6.7	_	_	I-Premise
292	months	_	_	I-Premise
293	,	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	0.06	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	The	_	_	B-Premise
300	one	_	_	I-Premise
301	,	_	_	I-Premise
302	two	_	_	I-Premise
303	,	_	_	I-Premise
304	three	_	_	I-Premise
305	and	_	_	I-Premise
306	five-year	_	_	I-Premise
307	survival	_	_	I-Premise
308	for	_	_	I-Premise
309	patients	_	_	I-Premise
310	receiving	_	_	I-Premise
311	SIR-Spheres	_	_	I-Premise
312	was	_	_	I-Premise
313	72	_	_	I-Premise
314	%	_	_	I-Premise
315	,	_	_	I-Premise
316	39	_	_	I-Premise
317	%	_	_	I-Premise
318	,	_	_	I-Premise
319	17	_	_	I-Premise
320	%	_	_	I-Premise
321	and	_	_	I-Premise
322	3.5	_	_	I-Premise
323	%	_	_	I-Premise
324	,	_	_	I-Premise
325	compared	_	_	I-Premise
326	to	_	_	I-Premise
327	68	_	_	I-Premise
328	%	_	_	I-Premise
329	,	_	_	I-Premise
330	29	_	_	I-Premise
331	%	_	_	I-Premise
332	,	_	_	I-Premise
333	6.5	_	_	I-Premise
334	%	_	_	I-Premise
335	and	_	_	I-Premise
336	0	_	_	I-Premise
337	%	_	_	I-Premise
338	for	_	_	I-Premise
339	HAC	_	_	I-Premise
340	alone	_	_	I-Premise
341	.	_	_	I-Premise

342	Cox	_	_	B-Premise
343	regression	_	_	I-Premise
344	analysis	_	_	I-Premise
345	suggests	_	_	I-Premise
346	an	_	_	I-Premise
347	improvement	_	_	I-Premise
348	in	_	_	I-Premise
349	survival	_	_	I-Premise
350	for	_	_	I-Premise
351	patients	_	_	I-Premise
352	treated	_	_	I-Premise
353	with	_	_	I-Premise
354	SIR-Spheres	_	_	I-Premise
355	who	_	_	I-Premise
356	survive	_	_	I-Premise
357	more	_	_	I-Premise
358	than	_	_	I-Premise
359	15	_	_	I-Premise
360	months	_	_	I-Premise
361	(	_	_	I-Premise
362	P	_	_	I-Premise
363	=	_	_	I-Premise
364	0.06	_	_	I-Premise
365	)	_	_	I-Premise
366	.	_	_	I-Premise

367	There	_	_	B-Premise
368	was	_	_	I-Premise
369	no	_	_	I-Premise
370	increase	_	_	I-Premise
371	in	_	_	I-Premise
372	grade	_	_	I-Premise
373	3-4	_	_	I-Premise
374	treatment	_	_	I-Premise
375	related	_	_	I-Premise
376	toxicity	_	_	I-Premise
377	and	_	_	I-Premise
378	no	_	_	I-Premise
379	loss	_	_	I-Premise
380	of	_	_	I-Premise
381	quality	_	_	I-Premise
382	of	_	_	I-Premise
383	life	_	_	I-Premise
384	for	_	_	I-Premise
385	patients	_	_	I-Premise
386	receiving	_	_	I-Premise
387	SIR-Spheres	_	_	I-Premise
388	in	_	_	I-Premise
389	comparison	_	_	I-Premise
390	to	_	_	I-Premise
391	patients	_	_	I-Premise
392	receiving	_	_	I-Premise
393	HAC	_	_	I-Premise
394	alone	_	_	I-Premise
395	.	_	_	I-Premise

396	The	_	_	B-Claim
397	combination	_	_	I-Claim
398	of	_	_	I-Claim
399	a	_	_	I-Claim
400	single	_	_	I-Claim
401	injection	_	_	I-Claim
402	of	_	_	I-Claim
403	SIR-Spheres	_	_	I-Claim
404	plus	_	_	I-Claim
405	HAC	_	_	I-Claim
406	is	_	_	I-Claim
407	substantially	_	_	I-Claim
408	more	_	_	I-Claim
409	effective	_	_	I-Claim
410	in	_	_	I-Claim
411	increasing	_	_	I-Claim
412	tumor	_	_	I-Claim
413	responses	_	_	I-Claim
414	and	_	_	I-Claim
415	progression	_	_	I-Claim
416	free	_	_	I-Claim
417	survival	_	_	I-Claim
418	than	_	_	I-Claim
419	the	_	_	I-Claim
420	same	_	_	I-Claim
421	regimen	_	_	I-Claim
422	of	_	_	I-Claim
423	HAC	_	_	I-Claim
424	alone	_	_	I-Claim
425	.	_	_	I-Claim


0	Phase	_	_	B-Claim
1	II	_	_	I-Claim
2	and	_	_	I-Claim
3	III	_	_	I-Claim
4	studies	_	_	I-Claim
5	have	_	_	I-Claim
6	shown	_	_	I-Claim
7	that	_	_	I-Claim
8	the	_	_	I-Claim
9	addition	_	_	I-Claim
10	of	_	_	I-Claim
11	interleukin-2	_	_	I-Claim
12	(	_	_	I-Claim
13	IL-2	_	_	I-Claim
14	)	_	_	I-Claim
15	and	_	_	I-Claim
16	interferon	_	_	I-Claim
17	alpha-2b	_	_	I-Claim
18	(	_	_	I-Claim
19	IFN	_	_	I-Claim
20	alpha-2b	_	_	I-Claim
21	)	_	_	I-Claim
22	in	_	_	I-Claim
23	multiagent	_	_	I-Claim
24	chemotherapy	_	_	I-Claim
25	(	_	_	I-Claim
26	CT	_	_	I-Claim
27	)	_	_	I-Claim
28	for	_	_	I-Claim
29	advanced	_	_	I-Claim
30	melanoma	_	_	I-Claim
31	increases	_	_	I-Claim
32	overall	_	_	I-Claim
33	response	_	_	I-Claim
34	(	_	_	I-Claim
35	OR	_	_	I-Claim
36	)	_	_	I-Claim
37	,	_	_	I-Claim
38	albeit	_	_	I-Claim
39	without	_	_	I-Claim
40	clear	_	_	I-Claim
41	evidence	_	_	I-Claim
42	of	_	_	I-Claim
43	an	_	_	I-Claim
44	improvement	_	_	I-Claim
45	in	_	_	I-Claim
46	overall	_	_	I-Claim
47	survival	_	_	I-Claim
48	(	_	_	I-Claim
49	OS	_	_	I-Claim
50	)	_	_	I-Claim
51	.	_	_	I-Claim

52	Treatment	_	_	B-Claim
53	with	_	_	I-Claim
54	high-dose	_	_	I-Claim
55	IL-2	_	_	I-Claim
56	can	_	_	I-Claim
57	cause	_	_	I-Claim
58	severe	_	_	I-Claim
59	toxicity	_	_	I-Claim
60	and	_	_	I-Claim
61	is	_	_	I-Claim
62	normally	_	_	I-Claim
63	administered	_	_	I-Claim
64	in	_	_	I-Claim
65	an	_	_	I-Claim
66	inpatient	_	_	I-Claim
67	setting	_	_	I-Claim
68	.	_	_	I-Claim

69	We	_	_	O
70	conducted	_	_	O
71	a	_	_	O
72	multicenter	_	_	O
73	prospective	_	_	O
74	randomized	_	_	O
75	clinical	_	_	O
76	trial	_	_	O
77	in	_	_	O
78	outpatients	_	_	O
79	with	_	_	O
80	metastatic	_	_	O
81	melanoma	_	_	O
82	to	_	_	O
83	compare	_	_	O
84	CT	_	_	O
85	with	_	_	O
86	biochemotherapy	_	_	O
87	(	_	_	O
88	bioCT	_	_	O
89	)	_	_	O
90	using	_	_	O
91	immunomodulant	_	_	O
92	doses	_	_	O
93	of	_	_	O
94	IL-2	_	_	O
95	and	_	_	O
96	IFN	_	_	O
97	alpha-2b	_	_	O
98	.	_	_	O

99	One	_	_	O
100	hundred	_	_	O
101	seventy-six	_	_	O
102	eligible	_	_	O
103	patients	_	_	O
104	with	_	_	O
105	advanced	_	_	O
106	melanoma	_	_	O
107	were	_	_	O
108	randomized	_	_	O
109	to	_	_	O
110	receive	_	_	O
111	CT	_	_	O
112	(	_	_	O
113	cisplatin	_	_	O
114	and	_	_	O
115	dacarbazine	_	_	O
116	with	_	_	O
117	or	_	_	O
118	without	_	_	O
119	carmustine	_	_	O
120	every	_	_	O
121	21	_	_	O
122	days	_	_	O
123	)	_	_	O
124	or	_	_	O
125	bioCT	_	_	O
126	comprising	_	_	O
127	the	_	_	O
128	same	_	_	O
129	CT	_	_	O
130	regimen	_	_	O
131	followed	_	_	O
132	by	_	_	O
133	low-dose	_	_	O
134	subcutaneous	_	_	O
135	IL-2	_	_	O
136	for	_	_	O
137	8	_	_	O
138	days	_	_	O
139	and	_	_	O
140	IFN	_	_	O
141	alpha-2b	_	_	O
142	three	_	_	O
143	times	_	_	O
144	a	_	_	O
145	week	_	_	O
146	,	_	_	O
147	both	_	_	O
148	for	_	_	O
149	six	_	_	O
150	cycles	_	_	O
151	.	_	_	O

152	At	_	_	B-Premise
153	a	_	_	I-Premise
154	median	_	_	I-Premise
155	follow-up	_	_	I-Premise
156	of	_	_	I-Premise
157	18	_	_	I-Premise
158	(	_	_	I-Premise
159	CT	_	_	I-Premise
160	)	_	_	I-Premise
161	and	_	_	I-Premise
162	16	_	_	I-Premise
163	(	_	_	I-Premise
164	bioCT	_	_	I-Premise
165	)	_	_	I-Premise
166	months	_	_	I-Premise
167	,	_	_	I-Premise
168	median	_	_	I-Premise
169	OS	_	_	I-Premise
170	was	_	_	I-Premise
171	9.5	_	_	I-Premise
172	versus	_	_	I-Premise
173	11.0	_	_	I-Premise
174	months	_	_	I-Premise
175	(	_	_	I-Premise
176	P	_	_	I-Premise
177	=.51	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	respectively	_	_	I-Premise
181	.	_	_	I-Premise

182	In	_	_	B-Premise
183	the	_	_	I-Premise
184	89	_	_	I-Premise
185	CT-arm	_	_	I-Premise
186	patients	_	_	I-Premise
187	,	_	_	I-Premise
188	18	_	_	I-Premise
189	ORs	_	_	I-Premise
190	(	_	_	I-Premise
191	20.2	_	_	I-Premise
192	%	_	_	I-Premise
193	)	_	_	I-Premise
194	(	_	_	I-Premise
195	three	_	_	I-Premise
196	complete	_	_	I-Premise
197	responders	_	_	I-Premise
198	[	_	_	I-Premise
199	CRs	_	_	I-Premise
200	]	_	_	I-Premise
201	and	_	_	I-Premise
202	15	_	_	I-Premise
203	partial	_	_	I-Premise
204	responders	_	_	I-Premise
205	[	_	_	I-Premise
206	PRs	_	_	I-Premise
207	]	_	_	I-Premise
208	)	_	_	I-Premise
209	were	_	_	I-Premise
210	observed	_	_	I-Premise
211	according	_	_	I-Premise
212	to	_	_	I-Premise
213	World	_	_	I-Premise
214	Health	_	_	I-Premise
215	Organization	_	_	I-Premise
216	criteria	_	_	I-Premise
217	.	_	_	I-Premise

218	In	_	_	B-Premise
219	the	_	_	I-Premise
220	87	_	_	I-Premise
221	bioCT-arm	_	_	I-Premise
222	patients	_	_	I-Premise
223	,	_	_	I-Premise
224	22	_	_	I-Premise
225	ORs	_	_	I-Premise
226	(	_	_	I-Premise
227	25.3	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	(	_	_	I-Premise
231	three	_	_	I-Premise
232	CRs	_	_	I-Premise
233	and	_	_	I-Premise
234	19	_	_	I-Premise
235	PRs	_	_	I-Premise
236	)	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	=.70	_	_	I-Premise
240	)	_	_	I-Premise
241	were	_	_	I-Premise
242	recorded	_	_	I-Premise
243	.	_	_	I-Premise

244	Treatment-related	_	_	B-Premise
245	toxicity	_	_	I-Premise
246	was	_	_	I-Premise
247	fairly	_	_	I-Premise
248	similar	_	_	I-Premise
249	in	_	_	I-Premise
250	both	_	_	I-Premise
251	arms	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Claim
254	addition	_	_	I-Claim
255	of	_	_	I-Claim
256	low-dose	_	_	I-Claim
257	immunotherapy	_	_	I-Claim
258	did	_	_	I-Claim
259	not	_	_	I-Claim
260	produce	_	_	I-Claim
261	a	_	_	I-Claim
262	statistically	_	_	I-Claim
263	significant	_	_	I-Claim
264	advantage	_	_	I-Claim
265	in	_	_	I-Claim
266	OS	_	_	I-Claim
267	,	_	_	I-Claim
268	time	_	_	I-Claim
269	to	_	_	I-Claim
270	progression	_	_	I-Claim
271	,	_	_	I-Claim
272	or	_	_	I-Claim
273	OR	_	_	I-Claim
274	.	_	_	I-Claim

275	However	_	_	B-Claim
276	,	_	_	I-Claim
277	the	_	_	I-Claim
278	11-month	_	_	I-Claim
279	median	_	_	I-Claim
280	OS	_	_	I-Claim
281	in	_	_	I-Claim
282	the	_	_	I-Claim
283	bioCT	_	_	I-Claim
284	arm	_	_	I-Claim
285	does	_	_	I-Claim
286	not	_	_	I-Claim
287	differ	_	_	I-Claim
288	greatly	_	_	I-Claim
289	from	_	_	I-Claim
290	the	_	_	I-Claim
291	best	_	_	I-Claim
292	results	_	_	I-Claim
293	with	_	_	I-Claim
294	high-dose	_	_	I-Claim
295	IL-2-containing	_	_	I-Claim
296	regimens	_	_	I-Claim
297	reported	_	_	I-Claim
298	in	_	_	I-Claim
299	the	_	_	I-Claim
300	literature	_	_	I-Claim
301	.	_	_	I-Claim

302	Furthermore	_	_	O
303	,	_	_	O
304	our	_	_	B-Claim
305	treatment	_	_	I-Claim
306	schedule	_	_	I-Claim
307	was	_	_	I-Claim
308	carried	_	_	I-Claim
309	out	_	_	I-Claim
310	on	_	_	I-Claim
311	outpatients	_	_	I-Claim
312	and	_	_	I-Claim
313	had	_	_	I-Claim
314	an	_	_	I-Claim
315	acceptable	_	_	I-Claim
316	level	_	_	I-Claim
317	of	_	_	I-Claim
318	toxicity	_	_	I-Claim
319	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	treatment	_	_	O
6	with	_	_	O
7	latanoprost	_	_	O
8	or	_	_	O
9	brimonidine	_	_	O
10	on	_	_	O
11	intraocular	_	_	O
12	pressure	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	glaucoma	_	_	O
17	or	_	_	O
18	ocular	_	_	O
19	hypertension	_	_	O
20	and	_	_	O
21	intraocular	_	_	O
22	pressure	_	_	O
23	inadequately	_	_	O
24	controlled	_	_	O
25	by	_	_	O
26	monotherapy	_	_	O
27	or	_	_	O
28	dual	_	_	O
29	therapy	_	_	O
30	.	_	_	O

31	Three	_	_	O
32	hundred	_	_	O
33	seventy-nine	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	primary	_	_	O
37	open-angle	_	_	O
38	glaucoma	_	_	O
39	or	_	_	O
40	ocular	_	_	O
41	hypertension	_	_	O
42	were	_	_	O
43	recruited	_	_	O
44	for	_	_	O
45	this	_	_	O
46	6-month	_	_	O
47	prospective	_	_	O
48	,	_	_	O
49	randomized	_	_	O
50	,	_	_	O
51	observer-masked	_	_	O
52	multicenter	_	_	O
53	study	_	_	O
54	involving	_	_	O
55	30	_	_	O
56	eye	_	_	O
57	clinics	_	_	O
58	.	_	_	O

59	All	_	_	O
60	patients	_	_	O
61	were	_	_	O
62	receiving	_	_	O
63	monotherapy	_	_	O
64	or	_	_	O
65	dual	_	_	O
66	therapy	_	_	O
67	that	_	_	O
68	did	_	_	O
69	not	_	_	O
70	adequately	_	_	O
71	control	_	_	O
72	intraocular	_	_	O
73	pressure	_	_	O
74	.	_	_	O

75	After	_	_	O
76	appropriate	_	_	O
77	washout	_	_	O
78	periods	_	_	O
79	,	_	_	O
80	patients	_	_	O
81	were	_	_	O
82	randomized	_	_	O
83	to	_	_	O
84	treatment	_	_	O
85	with	_	_	O
86	latanoprost	_	_	O
87	once	_	_	O
88	daily	_	_	O
89	or	_	_	O
90	brimonidine	_	_	O
91	twice	_	_	O
92	daily	_	_	O
93	.	_	_	O

94	The	_	_	O
95	main	_	_	O
96	outcome	_	_	O
97	measure	_	_	O
98	was	_	_	O
99	change	_	_	O
100	in	_	_	O
101	mean	_	_	O
102	diurnal	_	_	O
103	intraocular	_	_	O
104	pressure	_	_	O
105	after	_	_	O
106	6	_	_	O
107	months	_	_	O
108	of	_	_	O
109	treatment	_	_	O
110	compared	_	_	O
111	with	_	_	O
112	baseline	_	_	O
113	.	_	_	O

114	Of	_	_	O
115	the	_	_	O
116	379	_	_	O
117	randomized	_	_	O
118	patients	_	_	O
119	,	_	_	O
120	375	_	_	O
121	were	_	_	O
122	included	_	_	O
123	in	_	_	O
124	the	_	_	O
125	intent-to-treat	_	_	O
126	analysis	_	_	O
127	.	_	_	O

128	From	_	_	B-Premise
129	an	_	_	I-Premise
130	overall	_	_	I-Premise
131	baseline	_	_	I-Premise
132	mean	_	_	I-Premise
133	intraocular	_	_	I-Premise
134	pressure	_	_	I-Premise
135	of	_	_	I-Premise
136	25.0	_	_	I-Premise
137	mm	_	_	I-Premise
138	Hg	_	_	I-Premise
139	,	_	_	I-Premise
140	latanoprost	_	_	I-Premise
141	monotherapy	_	_	I-Premise
142	reduced	_	_	I-Premise
143	mean	_	_	I-Premise
144	diurnal	_	_	I-Premise
145	intraocular	_	_	I-Premise
146	pressure	_	_	I-Premise
147	by	_	_	I-Premise
148	7.1	_	_	I-Premise
149	+/-	_	_	I-Premise
150	3.3	_	_	I-Premise
151	mm	_	_	I-Premise
152	Hg	_	_	I-Premise
153	(	_	_	I-Premise
154	mean	_	_	I-Premise
155	+/-	_	_	I-Premise
156	SD	_	_	I-Premise
157	,	_	_	I-Premise
158	P	_	_	I-Premise
159	<	_	_	I-Premise
160	0.001	_	_	I-Premise
161	)	_	_	I-Premise
162	,	_	_	I-Premise
163	whereas	_	_	I-Premise
164	brimonidine	_	_	I-Premise
165	monotherapy	_	_	I-Premise
166	yielded	_	_	I-Premise
167	an	_	_	I-Premise
168	intraocular-pressure	_	_	I-Premise
169	reduction	_	_	I-Premise
170	of	_	_	I-Premise
171	5.2	_	_	I-Premise
172	+/-	_	_	I-Premise
173	3.5	_	_	I-Premise
174	mm	_	_	I-Premise
175	Hg	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	<	_	_	I-Premise
179	0.001	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	This	_	_	B-Premise
183	1.9	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	difference	_	_	I-Premise
187	in	_	_	I-Premise
188	intraocular-pressure	_	_	I-Premise
189	reduction	_	_	I-Premise
190	was	_	_	I-Premise
191	significantly	_	_	I-Premise
192	in	_	_	I-Premise
193	favor	_	_	I-Premise
194	of	_	_	I-Premise
195	latanoprost	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	<	_	_	I-Premise
199	0.001	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Ocular	_	_	B-Premise
203	allergy	_	_	I-Premise
204	(	_	_	I-Premise
205	P	_	_	I-Premise
206	<	_	_	I-Premise
207	0.001	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	systemic	_	_	I-Premise
211	side	_	_	I-Premise
212	effects	_	_	I-Premise
213	(	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	0.005	_	_	I-Premise
217	)	_	_	I-Premise
218	were	_	_	I-Premise
219	reported	_	_	I-Premise
220	significantly	_	_	I-Premise
221	less	_	_	I-Premise
222	frequently	_	_	I-Premise
223	by	_	_	I-Premise
224	latanoprost-treated	_	_	I-Premise
225	patients	_	_	I-Premise
226	compared	_	_	I-Premise
227	with	_	_	I-Premise
228	brimonidine-treated	_	_	I-Premise
229	patients	_	_	I-Premise
230	.	_	_	I-Premise

231	Both	_	_	B-Claim
232	latanoprost	_	_	I-Claim
233	and	_	_	I-Claim
234	brimonidine	_	_	I-Claim
235	reduced	_	_	I-Claim
236	intraocular	_	_	I-Claim
237	pressure	_	_	I-Claim
238	in	_	_	I-Claim
239	patients	_	_	I-Claim
240	with	_	_	I-Claim
241	glaucoma	_	_	I-Claim
242	or	_	_	I-Claim
243	ocular	_	_	I-Claim
244	hypertension	_	_	I-Claim
245	after	_	_	I-Claim
246	6	_	_	I-Claim
247	months	_	_	I-Claim
248	of	_	_	I-Claim
249	treatment	_	_	I-Claim
250	.	_	_	I-Claim

251	However	_	_	B-Claim
252	,	_	_	I-Claim
253	latanoprost	_	_	I-Claim
254	once	_	_	I-Claim
255	daily	_	_	I-Claim
256	was	_	_	I-Claim
257	significantly	_	_	I-Claim
258	more	_	_	I-Claim
259	effective	_	_	I-Claim
260	than	_	_	I-Claim
261	brimonidine	_	_	I-Claim
262	twice	_	_	I-Claim
263	daily	_	_	I-Claim
264	in	_	_	I-Claim
265	reducing	_	_	I-Claim
266	mean	_	_	I-Claim
267	diurnal	_	_	I-Claim
268	intraocular	_	_	I-Claim
269	pressure	_	_	I-Claim
270	.	_	_	I-Claim

271	Latanoprost	_	_	B-Claim
272	was	_	_	I-Claim
273	better	_	_	I-Claim
274	tolerated	_	_	I-Claim
275	with	_	_	I-Claim
276	less	_	_	I-Claim
277	frequently	_	_	I-Claim
278	occurring	_	_	I-Claim
279	ocular	_	_	I-Claim
280	allergy	_	_	I-Claim
281	and	_	_	I-Claim
282	systemic	_	_	I-Claim
283	side	_	_	I-Claim
284	effects	_	_	I-Claim
285	.	_	_	I-Claim


0	Low	_	_	B-Claim
1	anterior	_	_	I-Claim
2	resection	_	_	I-Claim
3	with	_	_	I-Claim
4	coloanal	_	_	I-Claim
5	anastomosis	_	_	I-Claim
6	prevents	_	_	I-Claim
7	a	_	_	I-Claim
8	definitive	_	_	I-Claim
9	stoma	_	_	I-Claim
10	in	_	_	I-Claim
11	patients	_	_	I-Claim
12	with	_	_	I-Claim
13	distal	_	_	I-Claim
14	rectal	_	_	I-Claim
15	cancer	_	_	I-Claim
16	.	_	_	I-Claim

17	However	_	_	B-Premise
18	,	_	_	I-Premise
19	imperative	_	_	I-Premise
20	stool	_	_	I-Premise
21	urge	_	_	I-Premise
22	,	_	_	I-Premise
23	stool	_	_	I-Premise
24	fragmentation	_	_	I-Premise
25	,	_	_	I-Premise
26	prolonged	_	_	I-Premise
27	stooling	_	_	I-Premise
28	sessions	_	_	I-Premise
29	,	_	_	I-Premise
30	and	_	_	I-Premise
31	minor	_	_	I-Premise
32	problems	_	_	I-Premise
33	of	_	_	I-Premise
34	incontinence	_	_	I-Premise
35	are	_	_	I-Premise
36	frequently	_	_	I-Premise
37	observed	_	_	I-Premise
38	in	_	_	I-Premise
39	the	_	_	I-Premise
40	postoperative	_	_	I-Premise
41	situation	_	_	I-Premise
42	and	_	_	I-Premise
43	negatively	_	_	I-Premise
44	affect	_	_	I-Premise
45	quality	_	_	I-Premise
46	of	_	_	I-Premise
47	life	_	_	I-Premise
48	.	_	_	I-Premise

49	Therefore	_	_	O
50	,	_	_	O
51	the	_	_	O
52	colonic	_	_	O
53	J-pouch	_	_	O
54	was	_	_	O
55	originally	_	_	O
56	constructed	_	_	O
57	to	_	_	O
58	create	_	_	O
59	a	_	_	O
60	stool	_	_	O
61	reservoir	_	_	O
62	.	_	_	O

63	In	_	_	O
64	a	_	_	O
65	randomized	_	_	O
66	,	_	_	O
67	prospective	_	_	O
68	study	_	_	O
69	,	_	_	O
70	the	_	_	O
71	short	_	_	O
72	(	_	_	O
73	5	_	_	O
74	cm	_	_	O
75	)	_	_	O
76	colonic	_	_	O
77	J-pouch	_	_	O
78	was	_	_	O
79	tested	_	_	O
80	for	_	_	O
81	function	_	_	O
82	and	_	_	O
83	continence	_	_	O
84	vs.	_	_	O
85	straight	_	_	O
86	coloanal	_	_	O
87	anastomosis	_	_	O
88	.	_	_	O

89	Over	_	_	O
90	a	_	_	O
91	period	_	_	O
92	of	_	_	O
93	30	_	_	O
94	months	_	_	O
95	,	_	_	O
96	74	_	_	O
97	consecutive	_	_	O
98	patients	_	_	O
99	(	_	_	O
100	55	_	_	O
101	males	_	_	O
102	)	_	_	O
103	with	_	_	O
104	rectal	_	_	O
105	cancer	_	_	O
106	in	_	_	O
107	the	_	_	O
108	lower	_	_	O
109	and	_	_	O
110	middle	_	_	O
111	third	_	_	O
112	of	_	_	O
113	the	_	_	O
114	rectum	_	_	O
115	were	_	_	O
116	included	_	_	O
117	and	_	_	O
118	randomized	_	_	O
119	into	_	_	O
120	two	_	_	O
121	groups	_	_	O
122	.	_	_	O

123	Anastomosis	_	_	O
124	was	_	_	O
125	performed	_	_	O
126	either	_	_	O
127	as	_	_	O
128	a	_	_	O
129	coloanal	_	_	O
130	or	_	_	O
131	a	_	_	O
132	colon-pouch-anal	_	_	O
133	anastomosis	_	_	O
134	.	_	_	O

135	The	_	_	O
136	standardized	_	_	O
137	surgical	_	_	O
138	procedure	_	_	O
139	included	_	_	O
140	mobilization	_	_	O
141	of	_	_	O
142	the	_	_	O
143	left	_	_	O
144	hemicolon	_	_	O
145	,	_	_	O
146	central	_	_	O
147	ligation	_	_	O
148	of	_	_	O
149	the	_	_	O
150	inferior	_	_	O
151	mesenteric	_	_	O
152	artery	_	_	O
153	and	_	_	O
154	vein	_	_	O
155	,	_	_	O
156	preaortal	_	_	O
157	lymph	_	_	O
158	node	_	_	O
159	dissection	_	_	O
160	,	_	_	O
161	autonomic	_	_	O
162	nerve	_	_	O
163	preservation	_	_	O
164	,	_	_	O
165	and	_	_	O
166	total	_	_	O
167	mesorectal	_	_	O
168	excision	_	_	O
169	.	_	_	O

170	The	_	_	O
171	anastomosis	_	_	O
172	was	_	_	O
173	performed	_	_	O
174	at	_	_	O
175	the	_	_	O
176	upper	_	_	O
177	anal	_	_	O
178	canal	_	_	O
179	or	_	_	O
180	at	_	_	O
181	the	_	_	O
182	intersphincteric	_	_	O
183	level	_	_	O
184	.	_	_	O

185	All	_	_	O
186	patients	_	_	O
187	were	_	_	O
188	evaluated	_	_	O
189	preoperatively	_	_	O
190	and	_	_	O
191	six	_	_	O
192	months	_	_	O
193	postoperatively	_	_	O
194	for	_	_	O
195	fecal	_	_	O
196	continence	_	_	O
197	,	_	_	O
198	including	_	_	O
199	sphincter	_	_	O
200	manometry	_	_	O
201	and	_	_	O
202	defecation	_	_	O
203	habits	_	_	O
204	.	_	_	O

205	In	_	_	O
206	addition	_	_	O
207	,	_	_	O
208	quality	_	_	O
209	of	_	_	O
210	life	_	_	O
211	was	_	_	O
212	determined	_	_	O
213	by	_	_	O
214	use	_	_	O
215	of	_	_	O
216	a	_	_	O
217	standardized	_	_	O
218	questionnaire	_	_	O
219	(	_	_	O
220	European	_	_	O
221	Organization	_	_	O
222	for	_	_	O
223	Research	_	_	O
224	and	_	_	O
225	Treatment	_	_	O
226	of	_	_	O
227	Cancer	_	_	O
228	,	_	_	O
229	EORTC-QLQ-C30	_	_	O
230	)	_	_	O
231	.	_	_	O

232	Thirty-seven	_	_	O
233	patients	_	_	O
234	were	_	_	O
235	randomized	_	_	O
236	into	_	_	O
237	each	_	_	O
238	group	_	_	O
239	.	_	_	O

240	In	_	_	O
241	general	_	_	O
242	,	_	_	O
243	problems	_	_	B-Premise
244	with	_	_	I-Premise
245	continence	_	_	I-Premise
246	for	_	_	I-Premise
247	liquids	_	_	I-Premise
248	or	_	_	I-Premise
249	gas	_	_	I-Premise
250	occurred	_	_	I-Premise
251	less	_	_	I-Premise
252	frequently	_	_	I-Premise
253	in	_	_	I-Premise
254	the	_	_	I-Premise
255	colonic	_	_	I-Premise
256	J-pouch	_	_	I-Premise
257	group	_	_	I-Premise
258	6	_	_	I-Premise
259	months	_	_	I-Premise
260	after	_	_	I-Premise
261	surgery	_	_	I-Premise
262	.	_	_	I-Premise

263	The	_	_	B-Premise
264	frequency	_	_	I-Premise
265	of	_	_	I-Premise
266	bowel	_	_	I-Premise
267	movements	_	_	I-Premise
268	was	_	_	I-Premise
269	lower	_	_	I-Premise
270	in	_	_	I-Premise
271	the	_	_	I-Premise
272	J-pouch	_	_	I-Premise
273	group	_	_	I-Premise
274	(	_	_	I-Premise
275	2.5	_	_	I-Premise
276	per	_	_	I-Premise
277	day	_	_	I-Premise
278	)	_	_	I-Premise
279	than	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	coloanal	_	_	I-Premise
283	group	_	_	I-Premise
284	(	_	_	I-Premise
285	4.7	_	_	I-Premise
286	per	_	_	I-Premise
287	day	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Importantly	_	_	O
291	,	_	_	O
292	in	_	_	B-Premise
293	a	_	_	I-Premise
294	manometric	_	_	I-Premise
295	study	_	_	I-Premise
296	at	_	_	I-Premise
297	the	_	_	I-Premise
298	same	_	_	I-Premise
299	postoperative	_	_	I-Premise
300	point	_	_	I-Premise
301	,	_	_	I-Premise
302	neorectal	_	_	I-Premise
303	capacity	_	_	I-Premise
304	was	_	_	I-Premise
305	decreased	_	_	I-Premise
306	to	_	_	I-Premise
307	a	_	_	I-Premise
308	similar	_	_	I-Premise
309	degree	_	_	I-Premise
310	in	_	_	I-Premise
311	both	_	_	I-Premise
312	groups	_	_	I-Premise
313	compared	_	_	I-Premise
314	with	_	_	I-Premise
315	the	_	_	I-Premise
316	preoperative	_	_	I-Premise
317	rectal	_	_	I-Premise
318	volume	_	_	I-Premise
319	.	_	_	I-Premise

320	Thus	_	_	O
321	,	_	_	O
322	the	_	_	B-Premise
323	expected	_	_	I-Premise
324	and	_	_	I-Premise
325	postulated	_	_	I-Premise
326	reservoir	_	_	I-Premise
327	effect	_	_	I-Premise
328	could	_	_	I-Premise
329	not	_	_	I-Premise
330	be	_	_	I-Premise
331	achieved	_	_	I-Premise
332	by	_	_	I-Premise
333	forming	_	_	I-Premise
334	a	_	_	I-Premise
335	5-cm	_	_	I-Premise
336	colonic	_	_	I-Premise
337	J-pouch	_	_	I-Premise
338	.	_	_	I-Premise

339	The	_	_	B-Claim
340	colonic	_	_	I-Claim
341	J-pouch	_	_	I-Claim
342	was	_	_	I-Claim
343	superior	_	_	I-Claim
344	with	_	_	I-Claim
345	regard	_	_	I-Claim
346	to	_	_	I-Claim
347	continence	_	_	I-Claim
348	for	_	_	I-Claim
349	gas	_	_	I-Claim
350	and	_	_	I-Claim
351	liquids	_	_	I-Claim
352	compared	_	_	I-Claim
353	with	_	_	I-Claim
354	a	_	_	I-Claim
355	straight	_	_	I-Claim
356	coloanal	_	_	I-Claim
357	anastomosis	_	_	I-Claim
358	.	_	_	I-Claim

359	Furthermore	_	_	O
360	,	_	_	O
361	stool	_	_	B-Claim
362	frequency	_	_	I-Claim
363	was	_	_	I-Claim
364	significantly	_	_	I-Claim
365	lower	_	_	I-Claim
366	in	_	_	I-Claim
367	the	_	_	I-Claim
368	J-pouch	_	_	I-Claim
369	group	_	_	I-Claim
370	than	_	_	I-Claim
371	in	_	_	I-Claim
372	the	_	_	I-Claim
373	coloanal	_	_	I-Claim
374	reconstruction	_	_	I-Claim
375	group	_	_	I-Claim
376	.	_	_	I-Claim

377	However	_	_	O
378	,	_	_	O
379	because	_	_	B-Premise
380	neorectal	_	_	I-Premise
381	capacity	_	_	I-Premise
382	decreased	_	_	I-Premise
383	equally	_	_	I-Premise
384	in	_	_	I-Premise
385	both	_	_	I-Premise
386	groups	_	_	I-Premise
387	,	_	_	I-Premise
388	we	_	_	B-Claim
389	speculate	_	_	I-Claim
390	that	_	_	I-Claim
391	the	_	_	I-Claim
392	advantage	_	_	I-Claim
393	of	_	_	I-Claim
394	the	_	_	I-Claim
395	colonic	_	_	I-Claim
396	J-pouch	_	_	I-Claim
397	is	_	_	I-Claim
398	not	_	_	I-Claim
399	in	_	_	I-Claim
400	the	_	_	I-Claim
401	creation	_	_	I-Claim
402	of	_	_	I-Claim
403	a	_	_	I-Claim
404	larger	_	_	I-Claim
405	neorectal	_	_	I-Claim
406	reservoir	_	_	I-Claim
407	but	_	_	I-Claim
408	rather	_	_	I-Claim
409	may	_	_	I-Claim
410	be	_	_	I-Claim
411	related	_	_	I-Claim
412	to	_	_	I-Claim
413	decreased	_	_	I-Claim
414	motility	_	_	I-Claim
415	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	protracted	_	_	O
3	venous	_	_	O
4	infusion	_	_	O
5	(	_	_	O
6	PVI	_	_	O
7	)	_	_	O
8	fluorouracil	_	_	O
9	(	_	_	O
10	5-FU	_	_	O
11	)	_	_	O
12	with	_	_	O
13	PVI	_	_	O
14	5-FU	_	_	O
15	plus	_	_	O
16	mitomycin	_	_	O
17	(	_	_	O
18	MMC	_	_	O
19	)	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	advanced	_	_	O
24	pancreatic	_	_	O
25	cancer	_	_	O
26	in	_	_	O
27	a	_	_	O
28	multicenter	_	_	O
29	,	_	_	O
30	prospectively	_	_	O
31	randomized	_	_	O
32	study	_	_	O
33	.	_	_	O

34	Two	_	_	O
35	hundred	_	_	O
36	eight	_	_	O
37	patients	_	_	O
38	were	_	_	O
39	randomized	_	_	O
40	to	_	_	O
41	PVI	_	_	O
42	5-FU	_	_	O
43	(	_	_	O
44	300	_	_	O
45	mg/m	_	_	O
46	(	_	_	O
47	2	_	_	O
48	)	_	_	O
49	/d	_	_	O
50	for	_	_	O
51	a	_	_	O
52	maximum	_	_	O
53	of	_	_	O
54	24	_	_	O
55	weeks	_	_	O
56	)	_	_	O
57	or	_	_	O
58	PVI	_	_	O
59	5-FU	_	_	O
60	plus	_	_	O
61	MMC	_	_	O
62	(	_	_	O
63	7	_	_	O
64	mg/m	_	_	O
65	(	_	_	O
66	2	_	_	O
67	)	_	_	O
68	every	_	_	O
69	6	_	_	O
70	weeks	_	_	O
71	for	_	_	O
72	four	_	_	O
73	courses	_	_	O
74	)	_	_	O
75	.	_	_	O

76	The	_	_	O
77	major	_	_	O
78	end	_	_	O
79	points	_	_	O
80	were	_	_	O
81	tumor	_	_	O
82	response	_	_	O
83	,	_	_	O
84	survival	_	_	O
85	,	_	_	O
86	toxicity	_	_	O
87	,	_	_	O
88	and	_	_	O
89	quality	_	_	O
90	of	_	_	O
91	life	_	_	O
92	(	_	_	O
93	QOL	_	_	O
94	)	_	_	O
95	.	_	_	O

96	The	_	_	O
97	two	_	_	O
98	treatment	_	_	O
99	groups	_	_	O
100	were	_	_	O
101	balanced	_	_	O
102	for	_	_	O
103	baseline	_	_	O
104	demographic	_	_	O
105	factors	_	_	O
106	,	_	_	O
107	and	_	_	O
108	62	_	_	O
109	%	_	_	O
110	had	_	_	O
111	metastatic	_	_	O
112	disease	_	_	O
113	.	_	_	O

114	The	_	_	B-Premise
115	overall	_	_	I-Premise
116	response	_	_	I-Premise
117	rate	_	_	I-Premise
118	was	_	_	I-Premise
119	8.4	_	_	I-Premise
120	%	_	_	I-Premise
121	(	_	_	I-Premise
122	95	_	_	I-Premise
123	%	_	_	I-Premise
124	confidence	_	_	I-Premise
125	interval	_	_	I-Premise
126	[	_	_	I-Premise
127	CI	_	_	I-Premise
128	]	_	_	I-Premise
129	)	_	_	I-Premise
130	3.2	_	_	I-Premise
131	%	_	_	I-Premise
132	to	_	_	I-Premise
133	13.7	_	_	I-Premise
134	%	_	_	I-Premise
135	for	_	_	I-Premise
136	patients	_	_	I-Premise
137	treated	_	_	I-Premise
138	with	_	_	I-Premise
139	PVI	_	_	I-Premise
140	5-FU	_	_	I-Premise
141	alone	_	_	I-Premise
142	compared	_	_	I-Premise
143	with	_	_	I-Premise
144	17.6	_	_	I-Premise
145	%	_	_	I-Premise
146	;	_	_	I-Premise
147	95	_	_	I-Premise
148	%	_	_	I-Premise
149	CI	_	_	I-Premise
150	10.3	_	_	I-Premise
151	%	_	_	I-Premise
152	to	_	_	I-Premise
153	25.1	_	_	I-Premise
154	%	_	_	I-Premise
155	for	_	_	I-Premise
156	PVI	_	_	I-Premise
157	5-FU	_	_	I-Premise
158	plus	_	_	I-Premise
159	MMC	_	_	I-Premise
160	(	_	_	I-Premise
161	P	_	_	I-Premise
162	=.04	_	_	I-Premise
163	)	_	_	I-Premise
164	.	_	_	I-Premise

165	Median	_	_	B-Premise
166	failure-free	_	_	I-Premise
167	survival	_	_	I-Premise
168	was	_	_	I-Premise
169	2.8	_	_	I-Premise
170	months	_	_	I-Premise
171	for	_	_	I-Premise
172	PVI	_	_	I-Premise
173	5-FU	_	_	I-Premise
174	and	_	_	I-Premise
175	3.8	_	_	I-Premise
176	months	_	_	I-Premise
177	for	_	_	I-Premise
178	PVI	_	_	I-Premise
179	5-FU	_	_	I-Premise
180	plus	_	_	I-Premise
181	MMC	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	=.14	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	Median	_	_	B-Premise
188	survival	_	_	I-Premise
189	was	_	_	I-Premise
190	5.1	_	_	I-Premise
191	months	_	_	I-Premise
192	for	_	_	I-Premise
193	PVI	_	_	I-Premise
194	5-FU	_	_	I-Premise
195	and	_	_	I-Premise
196	6.5	_	_	I-Premise
197	months	_	_	I-Premise
198	for	_	_	I-Premise
199	PVI	_	_	I-Premise
200	5-FU	_	_	I-Premise
201	plus	_	_	I-Premise
202	MMC	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=.34	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Toxicities	_	_	B-Premise
209	in	_	_	I-Premise
210	both	_	_	I-Premise
211	arms	_	_	I-Premise
212	were	_	_	I-Premise
213	mild	_	_	I-Premise
214	.	_	_	I-Premise

215	There	_	_	B-Premise
216	was	_	_	I-Premise
217	an	_	_	I-Premise
218	increased	_	_	I-Premise
219	incidence	_	_	I-Premise
220	of	_	_	I-Premise
221	neutropenia	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	5-FU	_	_	I-Premise
225	plus	_	_	I-Premise
226	MMC	_	_	I-Premise
227	arm	_	_	I-Premise
228	(	_	_	I-Premise
229	P	_	_	I-Premise
230	<	_	_	I-Premise
231	.01	_	_	I-Premise
232	)	_	_	I-Premise
233	,	_	_	I-Premise
234	although	_	_	I-Premise
235	no	_	_	I-Premise
236	differences	_	_	I-Premise
237	in	_	_	I-Premise
238	infection	_	_	I-Premise
239	were	_	_	I-Premise
240	seen	_	_	I-Premise
241	.	_	_	I-Premise

242	No	_	_	B-Premise
243	patients	_	_	I-Premise
244	developed	_	_	I-Premise
245	hemolytic	_	_	I-Premise
246	uremic	_	_	I-Premise
247	syndrome	_	_	I-Premise
248	.	_	_	I-Premise

249	Global	_	_	B-Claim
250	QOL	_	_	I-Claim
251	improved	_	_	I-Claim
252	significantly	_	_	I-Claim
253	after	_	_	I-Claim
254	24	_	_	I-Claim
255	weeks	_	_	I-Claim
256	of	_	_	I-Claim
257	treatment	_	_	I-Claim
258	compared	_	_	I-Claim
259	with	_	_	I-Claim
260	baseline	_	_	I-Claim
261	for	_	_	I-Claim
262	patients	_	_	I-Claim
263	receiving	_	_	I-Claim
264	5-FU	_	_	I-Claim
265	plus	_	_	I-Claim
266	MMC	_	_	I-Claim
267	,	_	_	I-Claim
268	although	_	_	B-Premise
269	there	_	_	I-Premise
270	was	_	_	I-Premise
271	no	_	_	I-Premise
272	statistically	_	_	I-Premise
273	significant	_	_	I-Premise
274	difference	_	_	I-Premise
275	in	_	_	I-Premise
276	QOL	_	_	I-Premise
277	between	_	_	I-Premise
278	arms	_	_	I-Premise
279	.	_	_	I-Premise

280	PVI	_	_	B-Claim
281	5-FU	_	_	I-Claim
282	plus	_	_	I-Claim
283	MMC	_	_	I-Claim
284	resulted	_	_	I-Claim
285	in	_	_	I-Claim
286	a	_	_	I-Claim
287	superior	_	_	I-Claim
288	response	_	_	I-Claim
289	rate	_	_	I-Claim
290	in	_	_	I-Claim
291	comparison	_	_	I-Claim
292	with	_	_	I-Claim
293	PVI	_	_	I-Claim
294	5-FU	_	_	I-Claim
295	alone	_	_	I-Claim
296	in	_	_	I-Claim
297	advanced	_	_	I-Claim
298	pancreatic	_	_	I-Claim
299	cancer	_	_	I-Claim
300	,	_	_	I-Claim
301	but	_	_	B-Claim
302	this	_	_	I-Claim
303	did	_	_	I-Claim
304	not	_	_	I-Claim
305	translate	_	_	I-Claim
306	into	_	_	I-Claim
307	a	_	_	I-Claim
308	survival	_	_	I-Claim
309	advantage	_	_	I-Claim
310	.	_	_	I-Claim

311	These	_	_	B-Claim
312	results	_	_	I-Claim
313	emphasize	_	_	I-Claim
314	the	_	_	I-Claim
315	importance	_	_	I-Claim
316	of	_	_	I-Claim
317	chemotherapy	_	_	I-Claim
318	in	_	_	I-Claim
319	this	_	_	I-Claim
320	setting	_	_	I-Claim
321	and	_	_	I-Claim
322	the	_	_	I-Claim
323	continuing	_	_	I-Claim
324	value	_	_	I-Claim
325	of	_	_	I-Claim
326	the	_	_	I-Claim
327	fluoropyrimidines	_	_	I-Claim
328	in	_	_	I-Claim
329	pancreatic	_	_	I-Claim
330	cancer	_	_	I-Claim
331	.	_	_	I-Claim


0	The	_	_	B-Claim
1	role	_	_	I-Claim
2	of	_	_	I-Claim
3	adjuvant	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	in	_	_	I-Claim
6	postmenopausal	_	_	I-Claim
7	patients	_	_	I-Claim
8	with	_	_	I-Claim
9	lymph	_	_	I-Claim
10	node-negative	_	_	I-Claim
11	breast	_	_	I-Claim
12	cancer	_	_	I-Claim
13	is	_	_	I-Claim
14	controversial	_	_	I-Claim
15	.	_	_	I-Claim

16	After	_	_	O
17	demonstrating	_	_	O
18	the	_	_	O
19	efficacy	_	_	O
20	of	_	_	O
21	chemotherapy	_	_	O
22	combined	_	_	O
23	with	_	_	O
24	tamoxifen	_	_	O
25	for	_	_	O
26	postmenopausal	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	lymph	_	_	O
30	node-positive	_	_	O
31	disease	_	_	O
32	,	_	_	O
33	the	_	_	O
34	International	_	_	O
35	Breast	_	_	O
36	Cancer	_	_	O
37	Study	_	_	O
38	Group	_	_	O
39	launched	_	_	O
40	a	_	_	O
41	randomized	_	_	O
42	trial	_	_	O
43	(	_	_	O
44	Trial	_	_	O
45	IX	_	_	O
46	)	_	_	O
47	to	_	_	O
48	evaluate	_	_	O
49	the	_	_	O
50	role	_	_	O
51	of	_	_	O
52	adjuvant	_	_	O
53	chemotherapy	_	_	O
54	preceding	_	_	O
55	treatment	_	_	O
56	with	_	_	O
57	tamoxifen	_	_	O
58	for	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	lymph	_	_	O
62	node-negative	_	_	O
63	disease	_	_	O
64	.	_	_	O

65	After	_	_	O
66	stratification	_	_	O
67	by	_	_	O
68	estrogen	_	_	O
69	receptor	_	_	O
70	(	_	_	O
71	ER	_	_	O
72	)	_	_	O
73	status	_	_	O
74	,	_	_	O
75	patients	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	three	_	_	O
82	28-day	_	_	O
83	courses	_	_	O
84	of	_	_	O
85	classical	_	_	O
86	adjuvant	_	_	I-Claim
87	CMF	_	_	O
88	chemotherapy	_	_	O
89	(	_	_	O
90	cyclophosphamide	_	_	O
91	at	_	_	O
92	100	_	_	O
93	mg/m	_	_	O
94	(	_	_	O
95	2	_	_	O
96	)	_	_	O
97	on	_	_	O
98	days	_	_	O
99	1-14	_	_	O
100	,	_	_	O
101	orally	_	_	O
102	;	_	_	O
103	methotrexate	_	_	O
104	at	_	_	O
105	40	_	_	O
106	mg/m	_	_	O
107	(	_	_	O
108	2	_	_	O
109	)	_	_	O
110	on	_	_	O
111	days	_	_	O
112	1	_	_	O
113	and	_	_	O
114	8	_	_	O
115	,	_	_	O
116	intravenously	_	_	O
117	;	_	_	O
118	and	_	_	O
119	5-fluorouracil	_	_	O
120	at	_	_	O
121	600	_	_	O
122	mg/m	_	_	O
123	(	_	_	O
124	2	_	_	O
125	)	_	_	O
126	on	_	_	O
127	days	_	_	O
128	1	_	_	O
129	and	_	_	O
130	8	_	_	O
131	,	_	_	O
132	intravenously	_	_	O
133	)	_	_	O
134	followed	_	_	O
135	by	_	_	O
136	tamoxifen	_	_	O
137	(	_	_	O
138	20	_	_	O
139	mg/day	_	_	O
140	,	_	_	O
141	orally	_	_	O
142	for	_	_	O
143	57	_	_	O
144	months	_	_	O
145	)	_	_	O
146	(	_	_	O
147	CMF	_	_	O
148	--	_	_	O
149	>	_	_	O
150	tamoxifen	_	_	O
151	)	_	_	O
152	or	_	_	O
153	to	_	_	O
154	receive	_	_	O
155	tamoxifen	_	_	O
156	alone	_	_	O
157	(	_	_	O
158	20	_	_	O
159	mg/day	_	_	O
160	,	_	_	O
161	orally	_	_	O
162	for	_	_	O
163	60	_	_	O
164	months	_	_	O
165	)	_	_	O
166	.	_	_	O

167	We	_	_	O
168	enrolled	_	_	O
169	1669	_	_	O
170	eligible	_	_	O
171	patients	_	_	O
172	,	_	_	O
173	382	_	_	O
174	(	_	_	O
175	23	_	_	O
176	%	_	_	O
177	)	_	_	O
178	with	_	_	O
179	ER-negative	_	_	O
180	tumors	_	_	O
181	,	_	_	O
182	1217	_	_	O
183	(	_	_	O
184	73	_	_	O
185	%	_	_	O
186	)	_	_	O
187	with	_	_	O
188	ER-positive	_	_	O
189	tumors	_	_	O
190	,	_	_	O
191	and	_	_	O
192	70	_	_	O
193	(	_	_	O
194	4	_	_	O
195	%	_	_	O
196	)	_	_	O
197	with	_	_	O
198	unknown	_	_	O
199	ER	_	_	O
200	status	_	_	O
201	.	_	_	O

202	The	_	_	O
203	median	_	_	O
204	follow-up	_	_	O
205	was	_	_	O
206	71	_	_	O
207	months	_	_	O
208	.	_	_	O

209	All	_	_	O
210	statistical	_	_	O
211	tests	_	_	O
212	were	_	_	O
213	two-sided	_	_	O
214	.	_	_	O

215	The	_	_	B-Premise
216	added	_	_	I-Premise
217	benefit	_	_	I-Premise
218	of	_	_	I-Premise
219	CMF	_	_	I-Premise
220	followed	_	_	I-Premise
221	by	_	_	I-Premise
222	tamoxifen	_	_	I-Premise
223	over	_	_	I-Premise
224	tamoxifen	_	_	I-Premise
225	alone	_	_	I-Premise
226	was	_	_	I-Premise
227	statistically	_	_	I-Premise
228	significantly	_	_	I-Premise
229	dependent	_	_	I-Premise
230	on	_	_	I-Premise
231	ER	_	_	I-Premise
232	status	_	_	I-Premise
233	(	_	_	I-Premise
234	tests	_	_	I-Premise
235	for	_	_	I-Premise
236	interaction	_	_	I-Premise
237	:	_	_	I-Premise
238	P	_	_	I-Premise
239	=.01	_	_	I-Premise
240	for	_	_	I-Premise
241	disease-free	_	_	I-Premise
242	survival	_	_	I-Premise
243	[	_	_	I-Premise
244	DFS	_	_	I-Premise
245	]	_	_	I-Premise
246	and	_	_	I-Premise
247	P	_	_	I-Premise
248	=.07	_	_	I-Premise
249	for	_	_	I-Premise
250	overall	_	_	I-Premise
251	survival	_	_	I-Premise
252	[	_	_	I-Premise
253	OS	_	_	I-Premise
254	]	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	For	_	_	B-Premise
258	patients	_	_	I-Premise
259	with	_	_	I-Premise
260	ER-negative	_	_	I-Premise
261	tumors	_	_	I-Premise
262	,	_	_	I-Premise
263	the	_	_	I-Premise
264	addition	_	_	I-Premise
265	of	_	_	I-Premise
266	CMF	_	_	I-Premise
267	statistically	_	_	I-Premise
268	significantly	_	_	I-Premise
269	improved	_	_	I-Premise
270	DFS	_	_	I-Premise
271	(	_	_	I-Premise
272	5-year	_	_	I-Premise
273	DFS	_	_	I-Premise
274	=	_	_	I-Premise
275	84	_	_	I-Premise
276	%	_	_	I-Premise
277	for	_	_	I-Premise
278	CMF	_	_	I-Premise
279	--	_	_	I-Premise
280	>	_	_	I-Premise
281	tamoxifen	_	_	I-Premise
282	versus	_	_	I-Premise
283	69	_	_	I-Premise
284	%	_	_	I-Premise
285	for	_	_	I-Premise
286	tamoxifen	_	_	I-Premise
287	alone	_	_	I-Premise
288	;	_	_	I-Premise
289	difference	_	_	I-Premise
290	=	_	_	I-Premise
291	15	_	_	I-Premise
292	%	_	_	I-Premise
293	;	_	_	I-Premise
294	95	_	_	I-Premise
295	%	_	_	I-Premise
296	confidence	_	_	I-Premise
297	interval	_	_	I-Premise
298	[	_	_	I-Premise
299	CI	_	_	I-Premise
300	]	_	_	I-Premise
301	=	_	_	I-Premise
302	6	_	_	I-Premise
303	%	_	_	I-Premise
304	to	_	_	I-Premise
305	24	_	_	I-Premise
306	%	_	_	I-Premise
307	;	_	_	I-Premise
308	risk	_	_	I-Premise
309	ratio	_	_	I-Premise
310	[	_	_	I-Premise
311	RR	_	_	I-Premise
312	]	_	_	I-Premise
313	=	_	_	I-Premise
314	0.52	_	_	I-Premise
315	;	_	_	I-Premise
316	95	_	_	I-Premise
317	%	_	_	I-Premise
318	CI	_	_	I-Premise
319	=	_	_	I-Premise
320	0.34	_	_	I-Premise
321	to	_	_	I-Premise
322	0.79	_	_	I-Premise
323	;	_	_	I-Premise
324	P	_	_	I-Premise
325	=.003	_	_	I-Premise
326	)	_	_	I-Premise
327	and	_	_	I-Premise
328	OS	_	_	I-Premise
329	(	_	_	I-Premise
330	5-year	_	_	I-Premise
331	OS	_	_	I-Premise
332	=	_	_	I-Premise
333	89	_	_	I-Premise
334	%	_	_	I-Premise
335	for	_	_	I-Premise
336	CMF	_	_	I-Premise
337	--	_	_	I-Premise
338	>	_	_	I-Premise
339	tamoxifen	_	_	I-Premise
340	versus	_	_	I-Premise
341	81	_	_	I-Premise
342	%	_	_	I-Premise
343	for	_	_	I-Premise
344	tamoxifen	_	_	I-Premise
345	alone	_	_	I-Premise
346	;	_	_	I-Premise
347	difference	_	_	I-Premise
348	=	_	_	I-Premise
349	8	_	_	I-Premise
350	%	_	_	I-Premise
351	;	_	_	I-Premise
352	95	_	_	I-Premise
353	%	_	_	I-Premise
354	CI	_	_	I-Premise
355	=	_	_	I-Premise
356	0	_	_	I-Premise
357	%	_	_	I-Premise
358	to	_	_	I-Premise
359	16	_	_	I-Premise
360	%	_	_	I-Premise
361	;	_	_	I-Premise
362	RR	_	_	I-Premise
363	=	_	_	I-Premise
364	0.51	_	_	I-Premise
365	;	_	_	I-Premise
366	95	_	_	I-Premise
367	%	_	_	I-Premise
368	CI	_	_	I-Premise
369	=	_	_	I-Premise
370	0.30	_	_	I-Premise
371	to	_	_	I-Premise
372	0.87	_	_	I-Premise
373	;	_	_	I-Premise
374	P	_	_	I-Premise
375	=.01	_	_	I-Premise
376	)	_	_	I-Premise
377	.	_	_	I-Premise

378	By	_	_	B-Premise
379	contrast	_	_	I-Premise
380	,	_	_	I-Premise
381	for	_	_	I-Premise
382	patients	_	_	I-Premise
383	with	_	_	I-Premise
384	ER-positive	_	_	I-Premise
385	tumors	_	_	I-Premise
386	,	_	_	I-Premise
387	addition	_	_	I-Premise
388	of	_	_	I-Premise
389	CMF	_	_	I-Premise
390	provided	_	_	I-Premise
391	no	_	_	I-Premise
392	benefit	_	_	I-Premise
393	in	_	_	I-Premise
394	terms	_	_	I-Premise
395	of	_	_	I-Premise
396	DFS	_	_	I-Premise
397	(	_	_	I-Premise
398	5-year	_	_	I-Premise
399	DFS	_	_	I-Premise
400	=	_	_	I-Premise
401	84	_	_	I-Premise
402	%	_	_	I-Premise
403	for	_	_	I-Premise
404	CMF	_	_	I-Premise
405	--	_	_	I-Premise
406	>	_	_	I-Premise
407	tamoxifen	_	_	I-Premise
408	versus	_	_	I-Premise
409	85	_	_	I-Premise
410	%	_	_	I-Premise
411	for	_	_	I-Premise
412	tamoxifen	_	_	I-Premise
413	alone	_	_	I-Premise
414	;	_	_	I-Premise
415	difference	_	_	I-Premise
416	=	_	_	I-Premise
417	-1	_	_	I-Premise
418	;	_	_	I-Premise
419	95	_	_	I-Premise
420	%	_	_	I-Premise
421	CI	_	_	I-Premise
422	=	_	_	I-Premise
423	-6	_	_	I-Premise
424	%	_	_	I-Premise
425	to	_	_	I-Premise
426	4	_	_	I-Premise
427	%	_	_	I-Premise
428	;	_	_	I-Premise
429	RR	_	_	I-Premise
430	=	_	_	I-Premise
431	0.99	_	_	I-Premise
432	;	_	_	I-Premise
433	95	_	_	I-Premise
434	%	_	_	I-Premise
435	CI	_	_	I-Premise
436	=	_	_	I-Premise
437	0.75	_	_	I-Premise
438	to	_	_	I-Premise
439	1.30	_	_	I-Premise
440	;	_	_	I-Premise
441	P	_	_	I-Premise
442	=.92	_	_	I-Premise
443	)	_	_	I-Premise
444	or	_	_	I-Premise
445	OS	_	_	I-Premise
446	(	_	_	I-Premise
447	5-year	_	_	I-Premise
448	OS	_	_	I-Premise
449	=	_	_	I-Premise
450	95	_	_	I-Premise
451	%	_	_	I-Premise
452	for	_	_	I-Premise
453	CMF	_	_	I-Premise
454	--	_	_	I-Premise
455	>	_	_	I-Premise
456	tamoxifen	_	_	I-Premise
457	versus	_	_	I-Premise
458	93	_	_	I-Premise
459	%	_	_	I-Premise
460	for	_	_	I-Premise
461	tamoxifen	_	_	I-Premise
462	alone	_	_	I-Premise
463	;	_	_	I-Premise
464	difference	_	_	I-Premise
465	=	_	_	I-Premise
466	2	_	_	I-Premise
467	%	_	_	I-Premise
468	;	_	_	I-Premise
469	95	_	_	I-Premise
470	%	_	_	I-Premise
471	CI	_	_	I-Premise
472	=	_	_	I-Premise
473	-1	_	_	I-Premise
474	%	_	_	I-Premise
475	to	_	_	I-Premise
476	5	_	_	I-Premise
477	%	_	_	I-Premise
478	;	_	_	I-Premise
479	RR	_	_	I-Premise
480	=	_	_	I-Premise
481	0.95	_	_	I-Premise
482	;	_	_	I-Premise
483	95	_	_	I-Premise
484	%	_	_	I-Premise
485	CI	_	_	I-Premise
486	=	_	_	I-Premise
487	0.64	_	_	I-Premise
488	to	_	_	I-Premise
489	1.40	_	_	I-Premise
490	;	_	_	I-Premise
491	P	_	_	I-Premise
492	=.80	_	_	I-Premise
493	)	_	_	I-Premise
494	.	_	_	I-Premise

495	Postmenopausal	_	_	B-Claim
496	patients	_	_	I-Claim
497	with	_	_	I-Claim
498	lymph	_	_	I-Claim
499	node-negative	_	_	I-Claim
500	breast	_	_	I-Claim
501	cancer	_	_	I-Claim
502	benefited	_	_	I-Claim
503	substantially	_	_	I-Claim
504	from	_	_	I-Claim
505	adjuvant	_	_	I-Claim
506	chemotherapy	_	_	I-Claim
507	if	_	_	I-Claim
508	their	_	_	I-Claim
509	cancer	_	_	I-Claim
510	was	_	_	I-Claim
511	ER-negative	_	_	I-Claim
512	(	_	_	I-Claim
513	i.e.	_	_	I-Claim
514	,	_	_	I-Claim
515	endocrine-nonresponsive	_	_	I-Claim
516	)	_	_	I-Claim
517	.	_	_	I-Claim

518	In	_	_	B-Claim
519	contrast	_	_	I-Claim
520	,	_	_	I-Claim
521	if	_	_	I-Claim
522	their	_	_	I-Claim
523	cancer	_	_	I-Claim
524	was	_	_	I-Claim
525	ER-positive	_	_	I-Claim
526	(	_	_	I-Claim
527	i.e.	_	_	I-Claim
528	,	_	_	I-Claim
529	endocrine-responsive	_	_	I-Claim
530	)	_	_	I-Claim
531	,	_	_	I-Claim
532	they	_	_	I-Claim
533	obtained	_	_	I-Claim
534	no	_	_	I-Claim
535	benefit	_	_	I-Claim
536	from	_	_	I-Claim
537	the	_	_	I-Claim
538	combination	_	_	I-Claim
539	treatment	_	_	I-Claim
540	compared	_	_	I-Claim
541	with	_	_	I-Claim
542	tamoxifen	_	_	I-Claim
543	alone	_	_	I-Claim
544	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure-lowering	_	_	O
5	efficacy	_	_	O
6	and	_	_	O
7	the	_	_	O
8	postoperative	_	_	O
9	complication	_	_	O
10	profile	_	_	O
11	of	_	_	O
12	viscocanalostomy	_	_	O
13	versus	_	_	O
14	trabeculectomy	_	_	O
15	.	_	_	O

16	Sixty	_	_	O
17	eyes	_	_	O
18	of	_	_	O
19	60	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	medically	_	_	O
23	uncontrolled	_	_	O
24	open-angle	_	_	O
25	glaucoma	_	_	O
26	were	_	_	O
27	randomized	_	_	O
28	either	_	_	O
29	to	_	_	O
30	the	_	_	O
31	viscocanalostomy	_	_	O
32	or	_	_	O
33	to	_	_	O
34	the	_	_	O
35	trabeculectomy	_	_	O
36	group	_	_	O
37	of	_	_	O
38	the	_	_	O
39	trial	_	_	O
40	.	_	_	O

41	Viscocanalostomy	_	_	O
42	was	_	_	O
43	performed	_	_	O
44	according	_	_	O
45	to	_	_	O
46	Stegmann	_	_	O
47	's	_	_	O
48	technique	_	_	O
49	using	_	_	O
50	high-molecular-weight	_	_	O
51	sodium	_	_	O
52	hyaluronate	_	_	O
53	to	_	_	O
54	fill	_	_	O
55	the	_	_	O
56	ostia	_	_	O
57	of	_	_	O
58	the	_	_	O
59	Schlemm	_	_	O
60	canal	_	_	O
61	.	_	_	O

62	For	_	_	O
63	trabeculectomy	_	_	O
64	,	_	_	O
65	a	_	_	O
66	modified	_	_	O
67	Cairns-trabeculectomy	_	_	O
68	was	_	_	O
69	performed	_	_	O
70	.	_	_	O

71	Examinations	_	_	O
72	were	_	_	O
73	performed	_	_	O
74	before	_	_	O
75	surgery	_	_	O
76	and	_	_	O
77	postoperatively	_	_	O
78	daily	_	_	O
79	for	_	_	O
80	1	_	_	O
81	week	_	_	O
82	.	_	_	O

83	Follow-up	_	_	O
84	visits	_	_	O
85	were	_	_	O
86	scheduled	_	_	O
87	1	_	_	O
88	,	_	_	O
89	6	_	_	O
90	,	_	_	O
91	and	_	_	O
92	12	_	_	O
93	months	_	_	O
94	after	_	_	O
95	surgery	_	_	O
96	.	_	_	O

97	The	_	_	O
98	mean	_	_	O
99	(	_	_	O
100	SD	_	_	O
101	)	_	_	O
102	preoperative	_	_	O
103	intraocular	_	_	O
104	pressure	_	_	O
105	was	_	_	O
106	27.1	_	_	O
107	(	_	_	O
108	7.1	_	_	O
109	)	_	_	O
110	mm	_	_	O
111	Hg	_	_	O
112	for	_	_	O
113	all	_	_	O
114	patients	_	_	O
115	enrolled	_	_	O
116	.	_	_	O

117	One	_	_	B-Premise
118	day	_	_	I-Premise
119	after	_	_	I-Premise
120	surgery	_	_	I-Premise
121	,	_	_	I-Premise
122	mean	_	_	I-Premise
123	(	_	_	I-Premise
124	SD	_	_	I-Premise
125	)	_	_	I-Premise
126	intraocular	_	_	I-Premise
127	pressure	_	_	I-Premise
128	was	_	_	I-Premise
129	15.9	_	_	I-Premise
130	(	_	_	I-Premise
131	5.2	_	_	I-Premise
132	)	_	_	I-Premise
133	for	_	_	I-Premise
134	the	_	_	I-Premise
135	trabeculectomy	_	_	I-Premise
136	group	_	_	I-Premise
137	(	_	_	I-Premise
138	P	_	_	I-Premise
139	<	_	_	I-Premise
140	0.001	_	_	I-Premise
141	)	_	_	I-Premise
142	and	_	_	I-Premise
143	15.7	_	_	I-Premise
144	(	_	_	I-Premise
145	3.6	_	_	I-Premise
146	)	_	_	I-Premise
147	for	_	_	I-Premise
148	the	_	_	I-Premise
149	viscocanalostomy	_	_	I-Premise
150	group	_	_	I-Premise
151	(	_	_	I-Premise
152	P	_	_	I-Premise
153	<	_	_	I-Premise
154	0.001	_	_	I-Premise
155	)	_	_	I-Premise
156	,	_	_	I-Premise
157	respectively	_	_	I-Premise
158	.	_	_	I-Premise

159	The	_	_	B-Premise
160	success	_	_	I-Premise
161	rate	_	_	I-Premise
162	,	_	_	I-Premise
163	defined	_	_	I-Premise
164	as	_	_	I-Premise
165	an	_	_	I-Premise
166	intraocular	_	_	I-Premise
167	pressure	_	_	I-Premise
168	lower	_	_	I-Premise
169	than	_	_	I-Premise
170	22	_	_	I-Premise
171	mm	_	_	I-Premise
172	Hg	_	_	I-Premise
173	without	_	_	I-Premise
174	medication	_	_	I-Premise
175	,	_	_	I-Premise
176	was	_	_	I-Premise
177	56.7	_	_	I-Premise
178	%	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	trabeculectomy	_	_	I-Premise
182	group	_	_	I-Premise
183	and	_	_	I-Premise
184	30	_	_	I-Premise
185	%	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	viscocanalostomy	_	_	I-Premise
189	group	_	_	I-Premise
190	at	_	_	I-Premise
191	12	_	_	I-Premise
192	months	_	_	I-Premise
193	postoperatively	_	_	I-Premise
194	(	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	0.041	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	The	_	_	B-Premise
201	number	_	_	I-Premise
202	of	_	_	I-Premise
203	postoperative	_	_	I-Premise
204	complications	_	_	I-Premise
205	was	_	_	I-Premise
206	lower	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	viscocanalostomy	_	_	I-Premise
210	group	_	_	I-Premise
211	than	_	_	I-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	trabeculectomy	_	_	I-Premise
215	group	_	_	I-Premise
216	.	_	_	I-Premise

217	In	_	_	B-Claim
218	eyes	_	_	I-Claim
219	with	_	_	I-Claim
220	open-angle	_	_	I-Claim
221	glaucoma	_	_	I-Claim
222	,	_	_	I-Claim
223	viscocanalostomy	_	_	I-Claim
224	is	_	_	I-Claim
225	less	_	_	I-Claim
226	effective	_	_	I-Claim
227	in	_	_	I-Claim
228	reducing	_	_	I-Claim
229	intraocular	_	_	I-Claim
230	pressure	_	_	I-Claim
231	than	_	_	I-Claim
232	standard	_	_	I-Claim
233	filtering	_	_	I-Claim
234	surgery	_	_	I-Claim
235	.	_	_	I-Claim

236	However	_	_	O
237	,	_	_	O
238	postoperative	_	_	B-Claim
239	complications	_	_	I-Claim
240	are	_	_	I-Claim
241	more	_	_	I-Claim
242	frequent	_	_	I-Claim
243	after	_	_	I-Claim
244	filtering	_	_	I-Claim
245	surgery	_	_	I-Claim
246	.	_	_	I-Claim


0	Chemotherapy	_	_	B-Claim
1	is	_	_	I-Claim
2	moderately	_	_	I-Claim
3	efficient	_	_	I-Claim
4	as	_	_	I-Claim
5	a	_	_	I-Claim
6	treatment	_	_	I-Claim
7	for	_	_	I-Claim
8	pancreatic	_	_	I-Claim
9	adenocarcinoma	_	_	I-Claim
10	,	_	_	I-Claim
11	but	_	_	B-Claim
12	patient	_	_	I-Claim
13	survival	_	_	I-Claim
14	and	_	_	I-Claim
15	quality	_	_	I-Claim
16	of	_	_	I-Claim
17	life	_	_	I-Claim
18	has	_	_	I-Claim
19	improved	_	_	I-Claim
20	with	_	_	I-Claim
21	this	_	_	I-Claim
22	modality	_	_	I-Claim
23	in	_	_	I-Claim
24	some	_	_	I-Claim
25	trials	_	_	I-Claim
26	.	_	_	I-Claim

27	In	_	_	O
28	a	_	_	O
29	previous	_	_	O
30	phase	_	_	O
31	II	_	_	O
32	trial	_	_	O
33	,	_	_	O
34	5-fluorouracil	_	_	O
35	(	_	_	O
36	5-FU	_	_	O
37	)	_	_	O
38	plus	_	_	O
39	cisplatin	_	_	O
40	(	_	_	O
41	FUP	_	_	O
42	)	_	_	O
43	yielded	_	_	O
44	a	_	_	O
45	26.5	_	_	O
46	%	_	_	O
47	response	_	_	O
48	rate	_	_	O
49	and	_	_	O
50	a	_	_	O
51	29	_	_	O
52	%	_	_	O
53	survival	_	_	O
54	rate	_	_	O
55	at	_	_	O
56	1	_	_	O
57	year	_	_	O
58	.	_	_	O

59	The	_	_	O
60	present	_	_	O
61	study	_	_	O
62	aimed	_	_	O
63	to	_	_	O
64	compare	_	_	O
65	FUP	_	_	O
66	with	_	_	O
67	5-FU	_	_	O
68	alone	_	_	O
69	,	_	_	O
70	which	_	_	O
71	was	_	_	O
72	the	_	_	O
73	control	_	_	O
74	arm	_	_	O
75	in	_	_	O
76	former	_	_	O
77	Mayo	_	_	O
78	Clinic	_	_	O
79	trials	_	_	O
80	.	_	_	O

81	Patients	_	_	O
82	with	_	_	O
83	untreated	_	_	O
84	cytologically	_	_	O
85	or	_	_	O
86	histologically	_	_	O
87	proven	_	_	O
88	metastatic	_	_	O
89	or	_	_	O
90	locally	_	_	O
91	advanced	_	_	O
92	adenocarcinoma	_	_	O
93	of	_	_	O
94	the	_	_	O
95	pancreas	_	_	O
96	were	_	_	O
97	deemed	_	_	O
98	measurable	_	_	O
99	or	_	_	O
100	evaluable	_	_	O
101	.	_	_	O

102	Chemotherapy	_	_	O
103	regimens	_	_	O
104	consisted	_	_	O
105	of	_	_	O
106	a	_	_	O
107	control	_	_	O
108	FU	_	_	O
109	arm	_	_	O
110	(	_	_	O
111	5-FU	_	_	O
112	500	_	_	O
113	mg/m	_	_	O
114	(	_	_	O
115	2	_	_	O
116	)	_	_	O
117	/day	_	_	O
118	for	_	_	O
119	5	_	_	O
120	days	_	_	O
121	)	_	_	O
122	and	_	_	O
123	the	_	_	O
124	investigational	_	_	O
125	FUP	_	_	O
126	arm	_	_	O
127	(	_	_	O
128	continuous	_	_	O
129	5-FU	_	_	O
130	1000	_	_	O
131	mg/m	_	_	O
132	(	_	_	O
133	2	_	_	O
134	)	_	_	O
135	/day	_	_	O
136	for	_	_	O
137	5	_	_	O
138	days	_	_	O
139	plus	_	_	O
140	cisplatin	_	_	O
141	100	_	_	O
142	mg/m	_	_	O
143	(	_	_	O
144	2	_	_	O
145	)	_	_	O
146	on	_	_	O
147	day	_	_	O
148	1	_	_	O
149	or	_	_	O
150	day	_	_	O
151	2	_	_	O
152	)	_	_	O
153	.	_	_	O

154	In	_	_	O
155	both	_	_	O
156	arms	_	_	O
157	,	_	_	O
158	chemotherapy	_	_	O
159	was	_	_	O
160	repeated	_	_	O
161	at	_	_	O
162	day	_	_	O
163	29	_	_	O
164	.	_	_	O

165	Two-hundred	_	_	O
166	and	_	_	O
167	seven	_	_	O
168	patients	_	_	O
169	from	_	_	O
170	18	_	_	O
171	centres	_	_	O
172	were	_	_	O
173	randomised	_	_	O
174	:	_	_	O
175	103	_	_	O
176	in	_	_	O
177	the	_	_	O
178	FU	_	_	O
179	arm	_	_	O
180	and	_	_	O
181	104	_	_	O
182	in	_	_	O
183	FUP	_	_	O
184	arm	_	_	O
185	.	_	_	O

186	Treatment	_	_	O
187	arms	_	_	O
188	were	_	_	O
189	balanced	_	_	O
190	with	_	_	O
191	respect	_	_	O
192	to	_	_	O
193	performance	_	_	O
194	status	_	_	O
195	grade	_	_	O
196	0-1	_	_	O
197	(	_	_	O
198	83	_	_	O
199	%	_	_	O
200	versus	_	_	O
201	86	_	_	O
202	%	_	_	O
203	,	_	_	O
204	respectively	_	_	O
205	)	_	_	O
206	and	_	_	O
207	the	_	_	O
208	presence	_	_	O
209	of	_	_	O
210	metastases	_	_	O
211	(	_	_	O
212	92	_	_	O
213	%	_	_	O
214	versus	_	_	O
215	89	_	_	O
216	%	_	_	O
217	,	_	_	O
218	respectively	_	_	O
219	)	_	_	O
220	.	_	_	O

221	The	_	_	O
222	median	_	_	O
223	number	_	_	O
224	of	_	_	O
225	cycles	_	_	O
226	administered	_	_	O
227	was	_	_	O
228	two	_	_	O
229	in	_	_	O
230	both	_	_	O
231	arms	_	_	O
232	(	_	_	O
233	range	_	_	O
234	0-14	_	_	O
235	)	_	_	O
236	.	_	_	O

237	Five	_	_	O
238	patients	_	_	O
239	did	_	_	O
240	not	_	_	O
241	receive	_	_	O
242	any	_	_	O
243	chemotherapy	_	_	O
244	and	_	_	O
245	45	_	_	O
246	received	_	_	O
247	only	_	_	O
248	one	_	_	O
249	cycle	_	_	O
250	.	_	_	O

251	Toxicity	_	_	B-Premise
252	(	_	_	I-Premise
253	WHO	_	_	I-Premise
254	grade	_	_	I-Premise
255	3-4	_	_	I-Premise
256	)	_	_	I-Premise
257	was	_	_	I-Premise
258	lower	_	_	I-Premise
259	with	_	_	I-Premise
260	FU	_	_	I-Premise
261	than	_	_	I-Premise
262	with	_	_	I-Premise
263	FUP	_	_	I-Premise
264	(	_	_	I-Premise
265	20	_	_	I-Premise
266	%	_	_	I-Premise
267	versus	_	_	I-Premise
268	48	_	_	I-Premise
269	%	_	_	I-Premise
270	,	_	_	I-Premise
271	P	_	_	I-Premise
272	<	_	_	I-Premise
273	0.001	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	as	_	_	I-Premise
277	was	_	_	I-Premise
278	neutropenia	_	_	I-Premise
279	(	_	_	I-Premise
280	6	_	_	I-Premise
281	%	_	_	I-Premise
282	versus	_	_	I-Premise
283	23	_	_	I-Premise
284	%	_	_	I-Premise
285	)	_	_	I-Premise
286	,	_	_	I-Premise
287	vomiting	_	_	I-Premise
288	(	_	_	I-Premise
289	4	_	_	I-Premise
290	%	_	_	I-Premise
291	versus	_	_	I-Premise
292	17	_	_	I-Premise
293	%	_	_	I-Premise
294	)	_	_	I-Premise
295	and	_	_	I-Premise
296	toxicity-related	_	_	I-Premise
297	deaths	_	_	I-Premise
298	(	_	_	I-Premise
299	one	_	_	I-Premise
300	versus	_	_	I-Premise
301	four	_	_	I-Premise
302	early	_	_	I-Premise
303	in	_	_	I-Premise
304	the	_	_	I-Premise
305	trial	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	The	_	_	B-Premise
309	response	_	_	I-Premise
310	rate	_	_	I-Premise
311	was	_	_	I-Premise
312	low	_	_	I-Premise
313	in	_	_	I-Premise
314	both	_	_	I-Premise
315	arms	_	_	I-Premise
316	,	_	_	I-Premise
317	but	_	_	I-Premise
318	superior	_	_	I-Premise
319	in	_	_	I-Premise
320	the	_	_	I-Premise
321	FUP	_	_	I-Premise
322	arm	_	_	I-Premise
323	:	_	_	I-Premise
324	12	_	_	I-Premise
325	%	_	_	I-Premise
326	versus	_	_	I-Premise
327	0	_	_	I-Premise
328	%	_	_	I-Premise
329	(	_	_	I-Premise
330	intention-to-treat	_	_	I-Premise
331	analysis	_	_	I-Premise
332	,	_	_	I-Premise
333	P	_	_	I-Premise
334	<	_	_	I-Premise
335	0.01	_	_	I-Premise
336	)	_	_	I-Premise
337	.	_	_	I-Premise

338	The	_	_	B-Premise
339	survival	_	_	I-Premise
340	rates	_	_	I-Premise
341	at	_	_	I-Premise
342	6	_	_	I-Premise
343	months	_	_	I-Premise
344	were	_	_	I-Premise
345	28	_	_	I-Premise
346	%	_	_	I-Premise
347	and	_	_	I-Premise
348	38	_	_	I-Premise
349	%	_	_	I-Premise
350	for	_	_	I-Premise
351	the	_	_	I-Premise
352	FU	_	_	I-Premise
353	and	_	_	I-Premise
354	FUP	_	_	I-Premise
355	arms	_	_	I-Premise
356	,	_	_	I-Premise
357	respectively	_	_	I-Premise
358	,	_	_	I-Premise
359	and	_	_	I-Premise
360	1-year	_	_	I-Premise
361	survival	_	_	I-Premise
362	rates	_	_	I-Premise
363	were	_	_	I-Premise
364	9	_	_	I-Premise
365	%	_	_	I-Premise
366	and	_	_	I-Premise
367	17	_	_	I-Premise
368	%	_	_	I-Premise
369	(	_	_	I-Premise
370	log-rank	_	_	I-Premise
371	test	_	_	I-Premise
372	,	_	_	I-Premise
373	P	_	_	I-Premise
374	=	_	_	I-Premise
375	0.10	_	_	I-Premise
376	)	_	_	I-Premise
377	.	_	_	I-Premise

378	One-year	_	_	B-Premise
379	progression-free	_	_	I-Premise
380	survival	_	_	I-Premise
381	was	_	_	I-Premise
382	0	_	_	I-Premise
383	%	_	_	I-Premise
384	with	_	_	I-Premise
385	FU	_	_	I-Premise
386	versus	_	_	I-Premise
387	10	_	_	I-Premise
388	%	_	_	I-Premise
389	with	_	_	I-Premise
390	FUP	_	_	I-Premise
391	(	_	_	I-Premise
392	log-rank	_	_	I-Premise
393	test	_	_	I-Premise
394	,	_	_	I-Premise
395	P	_	_	I-Premise
396	=	_	_	I-Premise
397	0.0001	_	_	I-Premise
398	)	_	_	I-Premise
399	.	_	_	I-Premise

400	In	_	_	B-Claim
401	advanced	_	_	I-Claim
402	pancreatic	_	_	I-Claim
403	carcinomas	_	_	I-Claim
404	with	_	_	I-Claim
405	a	_	_	I-Claim
406	poor	_	_	I-Claim
407	prognosis	_	_	I-Claim
408	,	_	_	I-Claim
409	FUP	_	_	I-Claim
410	was	_	_	I-Claim
411	superior	_	_	I-Claim
412	to	_	_	I-Claim
413	FU	_	_	I-Claim
414	in	_	_	I-Claim
415	terms	_	_	I-Claim
416	of	_	_	I-Claim
417	response	_	_	I-Claim
418	and	_	_	I-Claim
419	progression-free	_	_	I-Claim
420	survival	_	_	I-Claim
421	,	_	_	I-Claim
422	but	_	_	I-Claim
423	not	_	_	I-Claim
424	in	_	_	I-Claim
425	terms	_	_	I-Claim
426	of	_	_	I-Claim
427	overall	_	_	I-Claim
428	survival	_	_	I-Claim
429	.	_	_	I-Claim

430	The	_	_	O
431	low	_	_	O
432	response	_	_	O
433	rate	_	_	O
434	is	_	_	O
435	partly	_	_	O
436	related	_	_	O
437	to	_	_	O
438	the	_	_	O
439	number	_	_	O
440	of	_	_	O
441	patients	_	_	O
442	who	_	_	O
443	received	_	_	O
444	only	_	_	O
445	one	_	_	O
446	cycle	_	_	O
447	of	_	_	O
448	chemotherapy	_	_	O
449	.	_	_	O

450	A	_	_	B-Claim
451	more	_	_	I-Claim
452	effective	_	_	I-Claim
453	,	_	_	I-Claim
454	better	_	_	I-Claim
455	tolerated	_	_	I-Claim
456	version	_	_	I-Claim
457	of	_	_	I-Claim
458	this	_	_	I-Claim
459	FUP	_	_	I-Claim
460	combination	_	_	I-Claim
461	is	_	_	I-Claim
462	needed	_	_	I-Claim
463	.	_	_	I-Claim


0	Amitriptyline	_	_	B-Claim
1	is	_	_	I-Claim
2	the	_	_	I-Claim
3	most	_	_	I-Claim
4	common	_	_	I-Claim
5	analgesic	_	_	I-Claim
6	adjuvant	_	_	I-Claim
7	used	_	_	I-Claim
8	in	_	_	I-Claim
9	cancer	_	_	I-Claim
10	patients	_	_	I-Claim
11	with	_	_	I-Claim
12	neuropathic	_	_	I-Claim
13	pain	_	_	I-Claim
14	,	_	_	I-Claim
15	even	_	_	O
16	though	_	_	O
17	no	_	_	B-Claim
18	specific	_	_	I-Claim
19	studies	_	_	I-Claim
20	have	_	_	I-Claim
21	demonstrated	_	_	I-Claim
22	a	_	_	I-Claim
23	benefit	_	_	I-Claim
24	.	_	_	I-Claim

25	A	_	_	O
26	randomized	_	_	O
27	placebo-controlled	_	_	O
28	,	_	_	O
29	double-blind	_	_	O
30	crossover	_	_	O
31	study	_	_	O
32	was	_	_	O
33	designed	_	_	O
34	to	_	_	O
35	evidence	_	_	O
36	the	_	_	O
37	effects	_	_	O
38	of	_	_	O
39	amitriptyline	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	neuropathic	_	_	O
44	cancer	_	_	O
45	pain	_	_	O
46	.	_	_	O

47	Sixteen	_	_	O
48	advanced	_	_	O
49	cancer	_	_	O
50	patients	_	_	O
51	with	_	_	O
52	neuropathic	_	_	O
53	pain	_	_	O
54	on	_	_	O
55	systemic	_	_	O
56	morphine	_	_	O
57	therapy	_	_	O
58	,	_	_	O
59	no	_	_	O
60	longer	_	_	O
61	receiving	_	_	O
62	oncologic	_	_	O
63	treatment	_	_	O
64	,	_	_	O
65	presenting	_	_	O
66	moderate	_	_	O
67	pain	_	_	O
68	(	_	_	O
69	about	_	_	O
70	4	_	_	O
71	or	_	_	O
72	more	_	_	O
73	,	_	_	O
74	but	_	_	O
75	less	_	_	O
76	than	_	_	O
77	7	_	_	O
78	,	_	_	O
79	on	_	_	O
80	a	_	_	O
81	numerical	_	_	O
82	scale	_	_	O
83	of	_	_	O
84	0-10	_	_	O
85	)	_	_	O
86	in	_	_	O
87	the	_	_	O
88	last	_	_	O
89	week	_	_	O
90	,	_	_	O
91	and	_	_	O
92	given	_	_	O
93	a	_	_	O
94	stable	_	_	O
95	morphine	_	_	O
96	dose	_	_	O
97	in	_	_	O
98	the	_	_	O
99	last	_	_	O
100	2	_	_	O
101	days	_	_	O
102	were	_	_	O
103	admitted	_	_	O
104	to	_	_	O
105	the	_	_	O
106	study	_	_	O
107	.	_	_	O

108	During	_	_	O
109	the	_	_	O
110	first	_	_	O
111	week	_	_	O
112	of	_	_	O
113	study	_	_	O
114	,	_	_	O
115	patients	_	_	O
116	were	_	_	O
117	administered	_	_	O
118	25	_	_	O
119	mg	_	_	O
120	of	_	_	O
121	amitriptyline	_	_	O
122	or	_	_	O
123	equivalent	_	_	O
124	drops	_	_	O
125	of	_	_	O
126	placebo	_	_	O
127	at	_	_	O
128	night	_	_	O
129	for	_	_	O
130	3	_	_	O
131	days	_	_	O
132	and	_	_	O
133	50	_	_	O
134	mg	_	_	O
135	for	_	_	O
136	the	_	_	O
137	following	_	_	O
138	4	_	_	O
139	days	_	_	O
140	.	_	_	O

141	Doses	_	_	O
142	for	_	_	O
143	patients	_	_	O
144	aged	_	_	O
145	more	_	_	O
146	than	_	_	O
147	65	_	_	O
148	years	_	_	O
149	were	_	_	O
150	15	_	_	O
151	mg	_	_	O
152	(	_	_	O
153	first	_	_	O
154	3	_	_	O
155	days	_	_	O
156	)	_	_	O
157	and	_	_	O
158	30	_	_	O
159	mg	_	_	O
160	(	_	_	O
161	3	_	_	O
162	days	_	_	O
163	after	_	_	O
164	)	_	_	O
165	.	_	_	O

166	After	_	_	O
167	a	_	_	O
168	week	_	_	O
169	,	_	_	O
170	a	_	_	O
171	crossover	_	_	O
172	took	_	_	O
173	place	_	_	O
174	for	_	_	O
175	the	_	_	O
176	second	_	_	O
177	week	_	_	O
178	,	_	_	O
179	with	_	_	O
180	the	_	_	O
181	other	_	_	O
182	treatment	_	_	O
183	at	_	_	O
184	an	_	_	O
185	inverse	_	_	O
186	sequence	_	_	O
187	.	_	_	O

188	Opioid	_	_	O
189	consumption	_	_	O
190	,	_	_	O
191	pain	_	_	O
192	intensity	_	_	O
193	,	_	_	O
194	symptoms	_	_	O
195	and	_	_	O
196	adverse	_	_	O
197	effects	_	_	O
198	,	_	_	O
199	mood	_	_	O
200	,	_	_	O
201	sleep	_	_	O
202	,	_	_	O
203	patient	_	_	O
204	's	_	_	O
205	preference	_	_	O
206	,	_	_	O
207	quality	_	_	O
208	of	_	_	O
209	life	_	_	O
210	before	_	_	O
211	starting	_	_	O
212	the	_	_	O
213	study	_	_	O
214	,	_	_	O
215	the	_	_	O
216	first	_	_	O
217	week	_	_	O
218	after	_	_	O
219	and	_	_	O
220	the	_	_	O
221	second	_	_	O
222	week	_	_	O
223	after	_	_	O
224	were	_	_	O
225	recorded	_	_	O
226	.	_	_	O

227	No	_	_	B-Premise
228	significant	_	_	I-Premise
229	benefits	_	_	I-Premise
230	in	_	_	I-Premise
231	analgesia	_	_	I-Premise
232	were	_	_	I-Premise
233	found	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	global	_	_	I-Premise
237	pain	_	_	I-Premise
238	intensity	_	_	I-Premise
239	of	_	_	I-Premise
240	the	_	_	I-Premise
241	previous	_	_	I-Premise
242	week	_	_	I-Premise
243	of	_	_	I-Premise
244	treatment	_	_	I-Premise
245	,	_	_	I-Premise
246	the	_	_	I-Premise
247	least	_	_	I-Premise
248	pain	_	_	I-Premise
249	intensity	_	_	I-Premise
250	or	_	_	I-Premise
251	the	_	_	I-Premise
252	pain	_	_	I-Premise
253	evaluated	_	_	I-Premise
254	just	_	_	I-Premise
255	after	_	_	I-Premise
256	a	_	_	I-Premise
257	week	_	_	I-Premise
258	of	_	_	I-Premise
259	treatment	_	_	I-Premise
260	,	_	_	I-Premise
261	at	_	_	I-Premise
262	the	_	_	I-Premise
263	moment	_	_	I-Premise
264	of	_	_	I-Premise
265	the	_	_	I-Premise
266	visit	_	_	I-Premise
267	,	_	_	I-Premise
268	when	_	_	I-Premise
269	amitriptyline	_	_	I-Premise
270	was	_	_	I-Premise
271	compared	_	_	I-Premise
272	with	_	_	I-Premise
273	placebo	_	_	I-Premise
274	.	_	_	I-Premise

275	A	_	_	B-Premise
276	significant	_	_	I-Premise
277	difference	_	_	I-Premise
278	was	_	_	I-Premise
279	evidenced	_	_	I-Premise
280	for	_	_	I-Premise
281	the	_	_	I-Premise
282	worst	_	_	I-Premise
283	pain	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	0.035	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	No	_	_	B-Premise
291	differences	_	_	I-Premise
292	in	_	_	I-Premise
293	opioid	_	_	I-Premise
294	doses	_	_	I-Premise
295	during	_	_	I-Premise
296	the	_	_	I-Premise
297	period	_	_	I-Premise
298	of	_	_	I-Premise
299	study	_	_	I-Premise
300	were	_	_	I-Premise
301	found	_	_	I-Premise
302	.	_	_	I-Premise

303	Drowsiness	_	_	B-Premise
304	,	_	_	I-Premise
305	confusion	_	_	I-Premise
306	and	_	_	I-Premise
307	dry	_	_	I-Premise
308	mouth	_	_	I-Premise
309	were	_	_	I-Premise
310	significantly	_	_	I-Premise
311	more	_	_	I-Premise
312	intense	_	_	I-Premise
313	with	_	_	I-Premise
314	amitriptyline	_	_	I-Premise
315	than	_	_	I-Premise
316	with	_	_	I-Premise
317	placebo	_	_	I-Premise
318	(	_	_	I-Premise
319	P	_	_	I-Premise
320	<	_	_	I-Premise
321	0.036	_	_	I-Premise
322	,	_	_	I-Premise
323	0.003	_	_	I-Premise
324	,	_	_	I-Premise
325	and	_	_	I-Premise
326	0.034	_	_	I-Premise
327	,	_	_	I-Premise
328	respectively	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	There	_	_	B-Premise
332	were	_	_	I-Premise
333	no	_	_	I-Premise
334	substantial	_	_	I-Premise
335	differences	_	_	I-Premise
336	between	_	_	I-Premise
337	the	_	_	I-Premise
338	two	_	_	I-Premise
339	treatments	_	_	I-Premise
340	in	_	_	I-Premise
341	Spitzer	_	_	I-Premise
342	's	_	_	I-Premise
343	quality	_	_	I-Premise
344	of	_	_	I-Premise
345	life	_	_	I-Premise
346	score	_	_	I-Premise
347	and	_	_	I-Premise
348	for	_	_	I-Premise
349	each	_	_	I-Premise
350	item	_	_	I-Premise
351	.	_	_	I-Premise

352	No	_	_	B-Premise
353	differences	_	_	I-Premise
354	in	_	_	I-Premise
355	patients	_	_	I-Premise
356	'	_	_	I-Premise
357	preference	_	_	I-Premise
358	for	_	_	I-Premise
359	the	_	_	I-Premise
360	two	_	_	I-Premise
361	treatment	_	_	I-Premise
362	periods	_	_	I-Premise
363	were	_	_	I-Premise
364	found	_	_	I-Premise
365	.	_	_	I-Premise

366	The	_	_	B-Claim
367	analgesic	_	_	I-Claim
368	effects	_	_	I-Claim
369	of	_	_	I-Claim
370	amitriptyline	_	_	I-Claim
371	were	_	_	I-Claim
372	slight	_	_	I-Claim
373	and	_	_	I-Claim
374	associated	_	_	I-Claim
375	with	_	_	I-Claim
376	adverse	_	_	I-Claim
377	effects	_	_	I-Claim
378	.	_	_	I-Claim

379	In	_	_	O
380	light	_	_	O
381	of	_	_	O
382	the	_	_	O
383	results	_	_	O
384	obtained	_	_	O
385	in	_	_	O
386	the	_	_	O
387	study	_	_	O
388	,	_	_	O
389	the	_	_	B-Claim
390	extensive	_	_	I-Claim
391	use	_	_	I-Claim
392	of	_	_	I-Claim
393	the	_	_	I-Claim
394	drug	_	_	I-Claim
395	for	_	_	I-Claim
396	cancer	_	_	I-Claim
397	pain	_	_	I-Claim
398	should	_	_	I-Claim
399	be	_	_	I-Claim
400	questioned	_	_	I-Claim
401	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	patients	_	_	O
4	with	_	_	O
5	locally	_	_	O
6	advanced	_	_	O
7	non-small	_	_	O
8	cell	_	_	O
9	lung	_	_	O
10	cancer	_	_	O
11	unsuitable	_	_	O
12	for	_	_	O
13	resection	_	_	O
14	or	_	_	O
15	radical	_	_	O
16	radiotherapy	_	_	O
17	,	_	_	O
18	and	_	_	O
19	with	_	_	O
20	minimal	_	_	O
21	thoracic	_	_	O
22	symptoms	_	_	O
23	,	_	_	O
24	should	_	_	O
25	be	_	_	O
26	given	_	_	O
27	palliative	_	_	O
28	thoracic	_	_	O
29	radiotherapy	_	_	O
30	immediately	_	_	O
31	or	_	_	O
32	as	_	_	O
33	needed	_	_	O
34	to	_	_	O
35	treat	_	_	O
36	symptoms	_	_	O
37	.	_	_	O

38	Multicentre	_	_	O
39	randomised	_	_	O
40	controlled	_	_	O
41	trial	_	_	O
42	.	_	_	O

43	23	_	_	O
44	centres	_	_	O
45	in	_	_	O
46	the	_	_	O
47	United	_	_	O
48	Kingdom	_	_	O
49	,	_	_	O
50	Ireland	_	_	O
51	,	_	_	O
52	and	_	_	O
53	South	_	_	O
54	Africa	_	_	O
55	.	_	_	O

56	230	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	previously	_	_	O
60	untreated	_	_	O
61	,	_	_	O
62	non-small	_	_	O
63	cell	_	_	O
64	lung	_	_	O
65	cancer	_	_	O
66	that	_	_	O
67	is	_	_	O
68	locally	_	_	O
69	too	_	_	O
70	advanced	_	_	O
71	for	_	_	O
72	resection	_	_	O
73	or	_	_	O
74	radical	_	_	O
75	radiotherapy	_	_	O
76	with	_	_	O
77	curative	_	_	O
78	intent	_	_	O
79	,	_	_	O
80	with	_	_	O
81	minimal	_	_	O
82	thoracic	_	_	O
83	symptoms	_	_	O
84	,	_	_	O
85	and	_	_	O
86	with	_	_	O
87	no	_	_	O
88	indication	_	_	O
89	for	_	_	O
90	immediate	_	_	O
91	thoracic	_	_	O
92	radiotherapy	_	_	O
93	.	_	_	O

94	All	_	_	O
95	patients	_	_	O
96	were	_	_	O
97	given	_	_	O
98	supportive	_	_	O
99	treatment	_	_	O
100	and	_	_	O
101	were	_	_	O
102	randomised	_	_	O
103	to	_	_	O
104	receive	_	_	O
105	palliative	_	_	O
106	thoracic	_	_	O
107	radiotherapy	_	_	O
108	either	_	_	O
109	immediately	_	_	O
110	or	_	_	O
111	delayed	_	_	O
112	until	_	_	O
113	needed	_	_	O
114	to	_	_	O
115	treat	_	_	O
116	symptoms	_	_	O
117	.	_	_	O

118	The	_	_	O
119	recommended	_	_	O
120	regimens	_	_	O
121	were	_	_	O
122	17	_	_	O
123	Gy	_	_	O
124	in	_	_	O
125	two	_	_	O
126	fractions	_	_	O
127	one	_	_	O
128	week	_	_	O
129	apart	_	_	O
130	or	_	_	O
131	10	_	_	O
132	Gy	_	_	O
133	as	_	_	O
134	a	_	_	O
135	single	_	_	O
136	dose	_	_	O
137	.	_	_	O

138	Primary	_	_	O
139	--	_	_	O
140	patients	_	_	O
141	alive	_	_	O
142	and	_	_	O
143	without	_	_	O
144	moderate	_	_	O
145	or	_	_	O
146	severe	_	_	O
147	cough	_	_	O
148	,	_	_	O
149	chest	_	_	O
150	pain	_	_	O
151	,	_	_	O
152	haemoptysis	_	_	O
153	,	_	_	O
154	or	_	_	O
155	dyspnoea	_	_	O
156	six	_	_	O
157	months	_	_	O
158	from	_	_	O
159	randomisation	_	_	O
160	,	_	_	O
161	as	_	_	O
162	recorded	_	_	O
163	by	_	_	O
164	clinicians	_	_	O
165	.	_	_	O

166	Secondary	_	_	O
167	--	_	_	O
168	quality	_	_	O
169	of	_	_	O
170	life	_	_	O
171	,	_	_	O
172	adverse	_	_	O
173	events	_	_	O
174	,	_	_	O
175	survival	_	_	O
176	.	_	_	O

177	From	_	_	O
178	December	_	_	O
179	1992	_	_	O
180	to	_	_	O
181	May	_	_	O
182	1999	_	_	O
183	,	_	_	O
184	230	_	_	O
185	patients	_	_	O
186	were	_	_	O
187	randomised	_	_	O
188	.	_	_	O

189	104/115	_	_	O
190	of	_	_	O
191	the	_	_	O
192	patients	_	_	O
193	in	_	_	O
194	the	_	_	O
195	immediate	_	_	O
196	treatment	_	_	O
197	group	_	_	O
198	received	_	_	O
199	thoracic	_	_	O
200	radiotherapy	_	_	O
201	(	_	_	O
202	90	_	_	O
203	received	_	_	O
204	one	_	_	O
205	of	_	_	O
206	the	_	_	O
207	recommended	_	_	O
208	regimens	_	_	O
209	)	_	_	O
210	.	_	_	O

211	In	_	_	O
212	the	_	_	O
213	delayed	_	_	O
214	treatment	_	_	O
215	group	_	_	O
216	,	_	_	O
217	48/115	_	_	O
218	(	_	_	O
219	42	_	_	O
220	%	_	_	O
221	)	_	_	O
222	patients	_	_	O
223	received	_	_	O
224	thoracic	_	_	O
225	radiotherapy	_	_	O
226	(	_	_	O
227	29	_	_	O
228	received	_	_	O
229	one	_	_	O
230	of	_	_	O
231	the	_	_	O
232	recommended	_	_	O
233	regimens	_	_	O
234	)	_	_	O
235	;	_	_	O
236	64	_	_	O
237	(	_	_	O
238	56	_	_	O
239	%	_	_	O
240	)	_	_	O
241	died	_	_	O
242	without	_	_	O
243	receiving	_	_	O
244	thoracic	_	_	O
245	radiotherapy	_	_	O
246	;	_	_	O
247	the	_	_	O
248	remaining	_	_	O
249	three	_	_	O
250	(	_	_	O
251	3	_	_	O
252	%	_	_	O
253	)	_	_	O
254	were	_	_	O
255	alive	_	_	O
256	at	_	_	O
257	the	_	_	O
258	end	_	_	O
259	of	_	_	O
260	the	_	_	O
261	study	_	_	O
262	without	_	_	O
263	having	_	_	O
264	received	_	_	O
265	the	_	_	O
266	treatment	_	_	O
267	.	_	_	O

268	For	_	_	O
269	patients	_	_	O
270	who	_	_	O
271	received	_	_	O
272	thoracic	_	_	O
273	radiotherapy	_	_	O
274	,	_	_	O
275	the	_	_	O
276	median	_	_	O
277	time	_	_	O
278	to	_	_	O
279	start	_	_	O
280	was	_	_	O
281	15	_	_	O
282	days	_	_	O
283	in	_	_	O
284	the	_	_	O
285	immediate	_	_	O
286	treatment	_	_	O
287	group	_	_	O
288	and	_	_	O
289	125	_	_	O
290	days	_	_	O
291	in	_	_	O
292	the	_	_	O
293	delayed	_	_	O
294	treatment	_	_	O
295	group	_	_	O
296	.	_	_	O

297	The	_	_	B-Premise
298	primary	_	_	I-Premise
299	outcome	_	_	I-Premise
300	measure	_	_	I-Premise
301	was	_	_	I-Premise
302	achieved	_	_	I-Premise
303	in	_	_	I-Premise
304	28	_	_	I-Premise
305	%	_	_	I-Premise
306	of	_	_	I-Premise
307	the	_	_	I-Premise
308	immediate	_	_	I-Premise
309	treatment	_	_	I-Premise
310	group	_	_	I-Premise
311	and	_	_	I-Premise
312	26	_	_	I-Premise
313	%	_	_	I-Premise
314	of	_	_	I-Premise
315	patients	_	_	I-Premise
316	from	_	_	I-Premise
317	the	_	_	I-Premise
318	delayed	_	_	I-Premise
319	treatment	_	_	I-Premise
320	group	_	_	I-Premise
321	(	_	_	I-Premise
322	27/97	_	_	I-Premise
323	and	_	_	I-Premise
324	27/103	_	_	I-Premise
325	,	_	_	I-Premise
326	respectively	_	_	I-Premise
327	;	_	_	I-Premise
328	absolute	_	_	I-Premise
329	difference	_	_	I-Premise
330	1.6	_	_	I-Premise
331	%	_	_	I-Premise
332	,	_	_	I-Premise
333	95	_	_	I-Premise
334	%	_	_	I-Premise
335	confidence	_	_	I-Premise
336	interval	_	_	I-Premise
337	-10.7	_	_	I-Premise
338	%	_	_	I-Premise
339	to	_	_	I-Premise
340	13.9	_	_	I-Premise
341	%	_	_	I-Premise
342	)	_	_	I-Premise
343	.	_	_	I-Premise

344	No	_	_	B-Premise
345	evidence	_	_	I-Premise
346	of	_	_	I-Premise
347	a	_	_	I-Premise
348	difference	_	_	I-Premise
349	was	_	_	I-Premise
350	observed	_	_	I-Premise
351	between	_	_	I-Premise
352	the	_	_	I-Premise
353	two	_	_	I-Premise
354	treatment	_	_	I-Premise
355	groups	_	_	I-Premise
356	in	_	_	I-Premise
357	terms	_	_	I-Premise
358	of	_	_	I-Premise
359	activity	_	_	I-Premise
360	level	_	_	I-Premise
361	,	_	_	I-Premise
362	anxiety	_	_	I-Premise
363	,	_	_	I-Premise
364	depression	_	_	I-Premise
365	,	_	_	I-Premise
366	and	_	_	I-Premise
367	psychological	_	_	I-Premise
368	distress	_	_	I-Premise
369	,	_	_	I-Premise
370	as	_	_	I-Premise
371	recorded	_	_	I-Premise
372	by	_	_	I-Premise
373	the	_	_	I-Premise
374	patients	_	_	I-Premise
375	.	_	_	I-Premise

376	Adverse	_	_	B-Premise
377	events	_	_	I-Premise
378	were	_	_	I-Premise
379	more	_	_	I-Premise
380	common	_	_	I-Premise
381	in	_	_	I-Premise
382	the	_	_	I-Premise
383	immediate	_	_	I-Premise
384	treatment	_	_	I-Premise
385	group	_	_	I-Premise
386	.	_	_	I-Premise

387	Neither	_	_	B-Premise
388	group	_	_	I-Premise
389	had	_	_	I-Premise
390	a	_	_	I-Premise
391	survival	_	_	I-Premise
392	advantage	_	_	I-Premise
393	(	_	_	I-Premise
394	hazard	_	_	I-Premise
395	ratio	_	_	I-Premise
396	0.95	_	_	I-Premise
397	,	_	_	I-Premise
398	0.73	_	_	I-Premise
399	to	_	_	I-Premise
400	1.24	_	_	I-Premise
401	;	_	_	I-Premise
402	P=0.71	_	_	I-Premise
403	)	_	_	I-Premise
404	.	_	_	I-Premise

405	Median	_	_	B-Premise
406	survival	_	_	I-Premise
407	was	_	_	I-Premise
408	8.3	_	_	I-Premise
409	months	_	_	I-Premise
410	and	_	_	I-Premise
411	7.9	_	_	I-Premise
412	months	_	_	I-Premise
413	,	_	_	I-Premise
414	and	_	_	O
415	the	_	_	B-Premise
416	survival	_	_	I-Premise
417	rates	_	_	I-Premise
418	were	_	_	I-Premise
419	31	_	_	I-Premise
420	%	_	_	I-Premise
421	and	_	_	I-Premise
422	29	_	_	I-Premise
423	%	_	_	I-Premise
424	at	_	_	I-Premise
425	12	_	_	I-Premise
426	months	_	_	I-Premise
427	,	_	_	I-Premise
428	for	_	_	I-Premise
429	the	_	_	I-Premise
430	immediate	_	_	I-Premise
431	and	_	_	I-Premise
432	delayed	_	_	I-Premise
433	treatment	_	_	I-Premise
434	groups	_	_	I-Premise
435	,	_	_	I-Premise
436	respectively	_	_	I-Premise
437	.	_	_	I-Premise

438	In	_	_	B-Claim
439	minimally	_	_	I-Claim
440	symptomatic	_	_	I-Claim
441	patients	_	_	I-Claim
442	with	_	_	I-Claim
443	locally	_	_	I-Claim
444	advanced	_	_	I-Claim
445	non-small	_	_	I-Claim
446	cell	_	_	I-Claim
447	lung	_	_	I-Claim
448	cancer	_	_	I-Claim
449	,	_	_	I-Claim
450	no	_	_	I-Claim
451	persuasive	_	_	I-Claim
452	evidence	_	_	I-Claim
453	was	_	_	I-Claim
454	found	_	_	I-Claim
455	to	_	_	I-Claim
456	indicate	_	_	I-Claim
457	that	_	_	I-Claim
458	giving	_	_	I-Claim
459	immediate	_	_	I-Claim
460	palliative	_	_	I-Claim
461	thoracic	_	_	I-Claim
462	radiotherapy	_	_	I-Claim
463	improves	_	_	I-Claim
464	symptom	_	_	I-Claim
465	control	_	_	I-Claim
466	,	_	_	I-Claim
467	quality	_	_	I-Claim
468	of	_	_	I-Claim
469	life	_	_	I-Claim
470	,	_	_	I-Claim
471	or	_	_	I-Claim
472	survival	_	_	I-Claim
473	when	_	_	I-Claim
474	compared	_	_	I-Claim
475	with	_	_	I-Claim
476	delaying	_	_	I-Claim
477	until	_	_	I-Claim
478	symptoms	_	_	I-Claim
479	require	_	_	I-Claim
480	treatment	_	_	I-Claim
481	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcome	_	_	O
4	of	_	_	O
5	treatment	_	_	O
6	of	_	_	O
7	mediastinoscopy-verified	_	_	O
8	N2	_	_	O
9	non-small-cell	_	_	O
10	lung	_	_	O
11	cancer	_	_	O
12	treated	_	_	O
13	with	_	_	O
14	induction	_	_	O
15	chemotherapy	_	_	O
16	followed	_	_	O
17	by	_	_	O
18	either	_	_	O
19	surgery	_	_	O
20	or	_	_	O
21	radiotherapy	_	_	O
22	(	_	_	O
23	RT	_	_	O
24	)	_	_	O
25	,	_	_	O
26	with	_	_	O
27	both	_	_	O
28	options	_	_	O
29	followed	_	_	O
30	by	_	_	O
31	consolidation	_	_	O
32	chemotherapy	_	_	O
33	.	_	_	O

34	A	_	_	O
35	randomized	_	_	O
36	Phase	_	_	O
37	III	_	_	O
38	trial	_	_	O
39	for	_	_	O
40	Stage	_	_	O
41	IIIA	_	_	O
42	(	_	_	O
43	T1-T3N2M0	_	_	O
44	)	_	_	O
45	non-small	_	_	O
46	cell	_	_	O
47	lung	_	_	O
48	cancer	_	_	O
49	was	_	_	O
50	conducted	_	_	O
51	by	_	_	O
52	the	_	_	O
53	Radiation	_	_	O
54	Therapy	_	_	O
55	Oncology	_	_	O
56	Group	_	_	O
57	(	_	_	O
58	RTOG	_	_	O
59	)	_	_	O
60	and	_	_	O
61	Eastern	_	_	O
62	Cooperative	_	_	O
63	Oncology	_	_	O
64	Group	_	_	O
65	between	_	_	O
66	April	_	_	O
67	1990	_	_	O
68	and	_	_	O
69	April	_	_	O
70	1994	_	_	O
71	.	_	_	O

72	After	_	_	O
73	documentation	_	_	O
74	of	_	_	O
75	N2	_	_	O
76	disease	_	_	O
77	by	_	_	O
78	mediastinoscopy	_	_	O
79	or	_	_	O
80	anterior	_	_	O
81	mediastinotomy	_	_	O
82	,	_	_	O
83	patients	_	_	O
84	received	_	_	O
85	induction	_	_	O
86	chemotherapy	_	_	O
87	with	_	_	O
88	cisplatin	_	_	O
89	,	_	_	O
90	vinblastine	_	_	O
91	,	_	_	O
92	and	_	_	O
93	mitomycin-C.	_	_	O
94	Mitomycin-C	_	_	O
95	was	_	_	O
96	later	_	_	O
97	dropped	_	_	O
98	from	_	_	O
99	the	_	_	O
100	induction	_	_	O
101	regimen	_	_	O
102	.	_	_	O

103	Patients	_	_	O
104	were	_	_	O
105	then	_	_	O
106	randomized	_	_	O
107	to	_	_	O
108	surgery	_	_	O
109	or	_	_	O
110	RT	_	_	O
111	(	_	_	O
112	64	_	_	O
113	Gy	_	_	O
114	in	_	_	O
115	7	_	_	O
116	weeks	_	_	O
117	)	_	_	O
118	followed	_	_	O
119	by	_	_	O
120	cisplatin	_	_	O
121	and	_	_	O
122	vinblastine	_	_	O
123	.	_	_	O

124	RTOG	_	_	O
125	89-01	_	_	O
126	accrued	_	_	O
127	75	_	_	O
128	patients	_	_	O
129	,	_	_	O
130	of	_	_	O
131	whom	_	_	O
132	73	_	_	O
133	were	_	_	O
134	eligible	_	_	O
135	and	_	_	O
136	analyzable	_	_	O
137	.	_	_	O

138	Twelve	_	_	O
139	patients	_	_	O
140	received	_	_	O
141	induction	_	_	O
142	chemotherapy	_	_	O
143	but	_	_	O
144	were	_	_	O
145	not	_	_	O
146	randomized	_	_	O
147	to	_	_	O
148	RT	_	_	O
149	or	_	_	O
150	surgery	_	_	O
151	thereafter	_	_	O
152	.	_	_	O

153	Forty-five	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	randomized	_	_	O
157	to	_	_	O
158	postinduction	_	_	O
159	RT	_	_	O
160	or	_	_	O
161	surgery	_	_	O
162	.	_	_	O

163	Of	_	_	O
164	the	_	_	O
165	analyzable	_	_	O
166	patients	_	_	O
167	,	_	_	O
168	90	_	_	O
169	%	_	_	O
170	had	_	_	O
171	a	_	_	O
172	Karnofsky	_	_	O
173	performance	_	_	O
174	score	_	_	O
175	of	_	_	O
176	90-100	_	_	O
177	,	_	_	O
178	18	_	_	O
179	%	_	_	O
180	had	_	_	O
181	weight	_	_	O
182	loss	_	_	O
183	>	_	_	O
184	5	_	_	O
185	%	_	_	O
186	,	_	_	O
187	37	_	_	O
188	%	_	_	O
189	had	_	_	O
190	squamous	_	_	O
191	cell	_	_	O
192	histologic	_	_	O
193	features	_	_	O
194	,	_	_	O
195	and	_	_	O
196	54	_	_	O
197	%	_	_	O
198	had	_	_	O
199	bulky	_	_	O
200	N2	_	_	O
201	disease	_	_	O
202	.	_	_	O

203	The	_	_	O
204	distribution	_	_	O
205	of	_	_	O
206	bulky	_	_	O
207	N2	_	_	O
208	disease	_	_	O
209	was	_	_	O
210	uniform	_	_	O
211	among	_	_	O
212	the	_	_	O
213	treatment	_	_	O
214	arms	_	_	O
215	.	_	_	O

216	The	_	_	B-Premise
217	incidence	_	_	I-Premise
218	of	_	_	I-Premise
219	Grade	_	_	I-Premise
220	4	_	_	I-Premise
221	toxicity	_	_	I-Premise
222	was	_	_	I-Premise
223	56	_	_	I-Premise
224	%	_	_	I-Premise
225	in	_	_	I-Premise
226	patients	_	_	I-Premise
227	receiving	_	_	I-Premise
228	mitomycin-C	_	_	I-Premise
229	and	_	_	I-Premise
230	29	_	_	I-Premise
231	%	_	_	I-Premise
232	in	_	_	I-Premise
233	those	_	_	I-Premise
234	who	_	_	I-Premise
235	did	_	_	I-Premise
236	not	_	_	I-Premise
237	.	_	_	I-Premise

238	Only	_	_	B-Premise
239	1	_	_	I-Premise
240	patient	_	_	I-Premise
241	in	_	_	I-Premise
242	each	_	_	I-Premise
243	group	_	_	I-Premise
244	had	_	_	I-Premise
245	acute	_	_	I-Premise
246	nonhematologic	_	_	I-Premise
247	toxicity	_	_	I-Premise
248	greater	_	_	I-Premise
249	than	_	_	I-Premise
250	Grade	_	_	I-Premise
251	3	_	_	I-Premise
252	(	_	_	I-Premise
253	nausea	_	_	I-Premise
254	and	_	_	I-Premise
255	vomiting	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	No	_	_	B-Premise
259	acute	_	_	I-Premise
260	Grade	_	_	I-Premise
261	4	_	_	I-Premise
262	radiation	_	_	I-Premise
263	toxicity	_	_	I-Premise
264	developed	_	_	I-Premise
265	.	_	_	I-Premise

266	The	_	_	B-Premise
267	incidences	_	_	I-Premise
268	of	_	_	I-Premise
269	long-term	_	_	I-Premise
270	toxicity	_	_	I-Premise
271	were	_	_	I-Premise
272	equivalent	_	_	I-Premise
273	across	_	_	I-Premise
274	the	_	_	I-Premise
275	arms	_	_	I-Premise
276	.	_	_	I-Premise

277	Three	_	_	B-Premise
278	treatment-related	_	_	I-Premise
279	deaths	_	_	I-Premise
280	occurred	_	_	I-Premise
281	:	_	_	I-Premise
282	2	_	_	I-Premise
283	patients	_	_	I-Premise
284	in	_	_	I-Premise
285	the	_	_	I-Premise
286	surgical	_	_	I-Premise
287	arms	_	_	I-Premise
288	(	_	_	I-Premise
289	one	_	_	I-Premise
290	late	_	_	I-Premise
291	pulmonary	_	_	I-Premise
292	toxicity	_	_	I-Premise
293	and	_	_	I-Premise
294	one	_	_	I-Premise
295	pulmonary	_	_	I-Premise
296	embolus	_	_	I-Premise
297	)	_	_	I-Premise
298	,	_	_	I-Premise
299	and	_	_	I-Premise
300	1	_	_	I-Premise
301	patient	_	_	I-Premise
302	in	_	_	I-Premise
303	the	_	_	I-Premise
304	radiation	_	_	I-Premise
305	arm	_	_	I-Premise
306	(	_	_	I-Premise
307	radiation	_	_	I-Premise
308	pneumonitis	_	_	I-Premise
309	)	_	_	I-Premise
310	.	_	_	I-Premise

311	Induction	_	_	B-Premise
312	chemotherapy	_	_	I-Premise
313	was	_	_	I-Premise
314	completed	_	_	I-Premise
315	in	_	_	I-Premise
316	78	_	_	I-Premise
317	%	_	_	I-Premise
318	of	_	_	I-Premise
319	the	_	_	I-Premise
320	patients	_	_	I-Premise
321	.	_	_	I-Premise

322	Complete	_	_	B-Premise
323	resection	_	_	I-Premise
324	was	_	_	I-Premise
325	performed	_	_	I-Premise
326	in	_	_	I-Premise
327	73	_	_	I-Premise
328	%	_	_	I-Premise
329	of	_	_	I-Premise
330	26	_	_	I-Premise
331	patients	_	_	I-Premise
332	undergoing	_	_	I-Premise
333	thoracotomy	_	_	I-Premise
334	.	_	_	I-Premise

335	Consolidation	_	_	B-Premise
336	chemotherapy	_	_	I-Premise
337	was	_	_	I-Premise
338	completed	_	_	I-Premise
339	in	_	_	I-Premise
340	75	_	_	I-Premise
341	%	_	_	I-Premise
342	of	_	_	I-Premise
343	the	_	_	I-Premise
344	patients	_	_	I-Premise
345	.	_	_	I-Premise

346	No	_	_	B-Premise
347	statistically	_	_	I-Premise
348	significant	_	_	I-Premise
349	difference	_	_	I-Premise
350	was	_	_	I-Premise
351	found	_	_	I-Premise
352	among	_	_	I-Premise
353	the	_	_	I-Premise
354	treatment	_	_	I-Premise
355	arms	_	_	I-Premise
356	.	_	_	I-Premise

357	The	_	_	B-Premise
358	overall	_	_	I-Premise
359	progression-free	_	_	I-Premise
360	survival	_	_	I-Premise
361	rate	_	_	I-Premise
362	was	_	_	I-Premise
363	53	_	_	I-Premise
364	%	_	_	I-Premise
365	at	_	_	I-Premise
366	1	_	_	I-Premise
367	year	_	_	I-Premise
368	and	_	_	I-Premise
369	17	_	_	I-Premise
370	%	_	_	I-Premise
371	at	_	_	I-Premise
372	3	_	_	I-Premise
373	years	_	_	I-Premise
374	.	_	_	I-Premise

375	The	_	_	B-Premise
376	median	_	_	I-Premise
377	progression-free	_	_	I-Premise
378	survival	_	_	I-Premise
379	was	_	_	I-Premise
380	14	_	_	I-Premise
381	months	_	_	I-Premise
382	.	_	_	I-Premise

383	No	_	_	B-Premise
384	difference	_	_	I-Premise
385	in	_	_	I-Premise
386	the	_	_	I-Premise
387	1-year	_	_	I-Premise
388	survival	_	_	I-Premise
389	rate	_	_	I-Premise
390	(	_	_	I-Premise
391	70	_	_	I-Premise
392	%	_	_	I-Premise
393	vs.	_	_	I-Premise
394	66	_	_	I-Premise
395	%	_	_	I-Premise
396	)	_	_	I-Premise
397	or	_	_	I-Premise
398	median	_	_	I-Premise
399	survival	_	_	I-Premise
400	time	_	_	I-Premise
401	(	_	_	I-Premise
402	19.4	_	_	I-Premise
403	vs.	_	_	I-Premise
404	17.4	_	_	I-Premise
405	months	_	_	I-Premise
406	)	_	_	I-Premise
407	between	_	_	I-Premise
408	the	_	_	I-Premise
409	surgery	_	_	I-Premise
410	and	_	_	I-Premise
411	RT	_	_	I-Premise
412	arms	_	_	I-Premise
413	.	_	_	I-Premise

414	The	_	_	B-Premise
415	median	_	_	I-Premise
416	survival	_	_	I-Premise
417	in	_	_	I-Premise
418	the	_	_	I-Premise
419	patients	_	_	I-Premise
420	receiving	_	_	I-Premise
421	induction	_	_	I-Premise
422	chemotherapy	_	_	I-Premise
423	only	_	_	I-Premise
424	was	_	_	I-Premise
425	8.9	_	_	I-Premise
426	months	_	_	I-Premise
427	.	_	_	I-Premise

428	Mitomycin-C	_	_	B-Premise
429	had	_	_	I-Premise
430	no	_	_	I-Premise
431	impact	_	_	I-Premise
432	on	_	_	I-Premise
433	survival	_	_	I-Premise
434	(	_	_	I-Premise
435	p	_	_	I-Premise
436	=	_	_	I-Premise
437	0.75	_	_	I-Premise
438	)	_	_	I-Premise
439	.	_	_	I-Premise

440	No	_	_	B-Premise
441	statistically	_	_	I-Premise
442	significant	_	_	I-Premise
443	difference	_	_	I-Premise
444	was	_	_	I-Premise
445	noted	_	_	I-Premise
446	in	_	_	I-Premise
447	the	_	_	I-Premise
448	time	_	_	I-Premise
449	to	_	_	I-Premise
450	local	_	_	I-Premise
451	failure	_	_	I-Premise
452	between	_	_	I-Premise
453	the	_	_	I-Premise
454	surgical	_	_	I-Premise
455	and	_	_	I-Premise
456	RT	_	_	I-Premise
457	arms	_	_	I-Premise
458	.	_	_	I-Premise

459	The	_	_	B-Claim
460	patient	_	_	I-Claim
461	accrual	_	_	I-Claim
462	to	_	_	I-Claim
463	this	_	_	I-Claim
464	trial	_	_	I-Claim
465	made	_	_	I-Claim
466	its	_	_	I-Claim
467	results	_	_	I-Claim
468	inconclusive	_	_	I-Claim
469	,	_	_	I-Claim
470	but	_	_	O
471	several	_	_	O
472	observations	_	_	O
473	are	_	_	O
474	notable	_	_	O
475	.	_	_	O

476	In	_	_	O
477	this	_	_	O
478	trial	_	_	O
479	,	_	_	O
480	histologic	_	_	B-Claim
481	confirmation	_	_	I-Claim
482	of	_	_	I-Claim
483	N2	_	_	I-Claim
484	disease	_	_	I-Claim
485	in	_	_	I-Claim
486	the	_	_	I-Claim
487	surgical	_	_	I-Claim
488	and	_	_	I-Claim
489	nonsurgical	_	_	I-Claim
490	arms	_	_	I-Claim
491	eliminated	_	_	I-Claim
492	the	_	_	I-Claim
493	usual	_	_	I-Claim
494	biases	_	_	I-Claim
495	from	_	_	I-Claim
496	clinical	_	_	I-Claim
497	staging	_	_	I-Claim
498	.	_	_	I-Claim

499	In	_	_	O
500	this	_	_	O
501	setting	_	_	O
502	,	_	_	O
503	local	_	_	B-Claim
504	control	_	_	I-Claim
505	and	_	_	I-Claim
506	survival	_	_	I-Claim
507	were	_	_	I-Claim
508	essentially	_	_	I-Claim
509	equal	_	_	I-Claim
510	between	_	_	I-Claim
511	the	_	_	I-Claim
512	surgical	_	_	I-Claim
513	and	_	_	I-Claim
514	RT	_	_	I-Claim
515	arms	_	_	I-Claim
516	.	_	_	I-Claim

517	The	_	_	B-Claim
518	3-	_	_	I-Claim
519	and	_	_	I-Claim
520	5-year	_	_	I-Claim
521	survival	_	_	I-Claim
522	rates	_	_	I-Claim
523	of	_	_	I-Claim
524	nonsurgical	_	_	I-Claim
525	therapy	_	_	I-Claim
526	were	_	_	I-Claim
527	comparable	_	_	I-Claim
528	to	_	_	I-Claim
529	published	_	_	I-Claim
530	surgical	_	_	I-Claim
531	trials	_	_	I-Claim
532	of	_	_	I-Claim
533	N2	_	_	I-Claim
534	disease	_	_	I-Claim
535	.	_	_	I-Claim


0	Mucositis	_	_	B-Premise
1	occurs	_	_	I-Premise
2	in	_	_	I-Premise
3	almost	_	_	I-Premise
4	all	_	_	I-Premise
5	patients	_	_	I-Premise
6	treated	_	_	I-Premise
7	with	_	_	I-Premise
8	radiotherapy	_	_	I-Premise
9	for	_	_	I-Premise
10	head	_	_	I-Premise
11	and	_	_	I-Premise
12	neck	_	_	I-Premise
13	cancer	_	_	I-Premise
14	.	_	_	I-Premise

15	The	_	_	O
16	aim	_	_	O
17	of	_	_	O
18	this	_	_	O
19	multicenter	_	_	O
20	,	_	_	O
21	double-blind	_	_	O
22	,	_	_	O
23	prospective	_	_	O
24	,	_	_	O
25	randomized	_	_	O
26	trial	_	_	O
27	was	_	_	O
28	to	_	_	O
29	evaluate	_	_	O
30	the	_	_	O
31	clinical	_	_	O
32	efficacy	_	_	O
33	of	_	_	O
34	an	_	_	O
35	economically	_	_	O
36	viable	_	_	O
37	antimicrobial	_	_	O
38	lozenge	_	_	O
39	(	_	_	O
40	bacitracin	_	_	O
41	,	_	_	O
42	clotrimazole	_	_	O
43	,	_	_	O
44	and	_	_	O
45	gentamicin	_	_	O
46	[	_	_	O
47	BcoG	_	_	O
48	]	_	_	O
49	)	_	_	O
50	in	_	_	O
51	the	_	_	O
52	alleviation	_	_	O
53	of	_	_	O
54	radiation-induced	_	_	O
55	mucositis	_	_	O
56	in	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	head	_	_	O
60	and	_	_	O
61	neck	_	_	O
62	cancer	_	_	O
63	.	_	_	O

64	One	_	_	O
65	hundred	_	_	O
66	thirty-seven	_	_	O
67	eligible	_	_	O
68	patients	_	_	O
69	were	_	_	O
70	randomized	_	_	O
71	to	_	_	O
72	treatment	_	_	O
73	with	_	_	O
74	either	_	_	O
75	antimicrobial	_	_	O
76	lozenge	_	_	O
77	(	_	_	O
78	69	_	_	O
79	patients	_	_	O
80	)	_	_	O
81	or	_	_	O
82	placebo	_	_	O
83	lozenge	_	_	O
84	(	_	_	O
85	68	_	_	O
86	patients	_	_	O
87	)	_	_	O
88	.	_	_	O

89	The	_	_	O
90	primary	_	_	O
91	end	_	_	O
92	point	_	_	O
93	of	_	_	O
94	the	_	_	O
95	study	_	_	O
96	was	_	_	O
97	the	_	_	O
98	time	_	_	O
99	to	_	_	O
100	development	_	_	O
101	of	_	_	O
102	severe	_	_	O
103	mucositis	_	_	O
104	from	_	_	O
105	the	_	_	O
106	start	_	_	O
107	of	_	_	O
108	radiotherapy	_	_	O
109	.	_	_	O

110	Secondary	_	_	O
111	end	_	_	O
112	points	_	_	O
113	included	_	_	O
114	severity	_	_	O
115	and	_	_	O
116	duration	_	_	O
117	of	_	_	O
118	mucositis	_	_	O
119	,	_	_	O
120	pain	_	_	O
121	measurement	_	_	O
122	,	_	_	O
123	radiation	_	_	O
124	therapy	_	_	O
125	interruption	_	_	O
126	,	_	_	O
127	and	_	_	O
128	quality	_	_	O
129	of	_	_	O
130	life	_	_	O
131	.	_	_	O

132	Mucositis	_	_	O
133	was	_	_	O
134	scored	_	_	O
135	using	_	_	O
136	a	_	_	O
137	validated	_	_	O
138	mucositis	_	_	O
139	scoring	_	_	O
140	system	_	_	O
141	.	_	_	O

142	Toxicity	_	_	B-Premise
143	profiles	_	_	I-Premise
144	were	_	_	I-Premise
145	similar	_	_	I-Premise
146	between	_	_	I-Premise
147	the	_	_	I-Premise
148	two	_	_	I-Premise
149	arms	_	_	I-Premise
150	of	_	_	I-Premise
151	the	_	_	I-Premise
152	study	_	_	I-Premise
153	.	_	_	I-Premise

154	The	_	_	B-Premise
155	median	_	_	I-Premise
156	time	_	_	I-Premise
157	to	_	_	I-Premise
158	development	_	_	I-Premise
159	of	_	_	I-Premise
160	severe	_	_	I-Premise
161	mucositis	_	_	I-Premise
162	from	_	_	I-Premise
163	the	_	_	I-Premise
164	start	_	_	I-Premise
165	of	_	_	I-Premise
166	radiotherapy	_	_	I-Premise
167	was	_	_	I-Premise
168	3.61	_	_	I-Premise
169	weeks	_	_	I-Premise
170	on	_	_	I-Premise
171	BCoG	_	_	I-Premise
172	and	_	_	I-Premise
173	3.96	_	_	I-Premise
174	weeks	_	_	I-Premise
175	on	_	_	I-Premise
176	placebo	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=.61	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	There	_	_	B-Premise
183	were	_	_	I-Premise
184	no	_	_	I-Premise
185	statistically	_	_	I-Premise
186	significant	_	_	I-Premise
187	differences	_	_	I-Premise
188	between	_	_	I-Premise
189	the	_	_	I-Premise
190	arms	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	extent	_	_	I-Premise
194	of	_	_	I-Premise
195	severe	_	_	I-Premise
196	mucositis	_	_	I-Premise
197	as	_	_	I-Premise
198	measured	_	_	I-Premise
199	by	_	_	I-Premise
200	physician	_	_	I-Premise
201	,	_	_	I-Premise
202	in	_	_	I-Premise
203	oral	_	_	I-Premise
204	toxicities	_	_	I-Premise
205	as	_	_	I-Premise
206	recorded	_	_	I-Premise
207	by	_	_	I-Premise
208	patients	_	_	I-Premise
209	,	_	_	I-Premise
210	or	_	_	I-Premise
211	in	_	_	I-Premise
212	radiotherapy	_	_	I-Premise
213	delays	_	_	I-Premise
214	.	_	_	I-Premise

215	This	_	_	O
216	study	_	_	O
217	was	_	_	O
218	conducted	_	_	O
219	on	_	_	O
220	the	_	_	O
221	basis	_	_	O
222	of	_	_	O
223	a	_	_	O
224	pilot	_	_	O
225	study	_	_	O
226	that	_	_	O
227	demonstrated	_	_	O
228	the	_	_	O
229	BCoG	_	_	O
230	lozenge	_	_	O
231	to	_	_	O
232	be	_	_	O
233	tolerable	_	_	O
234	and	_	_	O
235	microbiologically	_	_	O
236	efficacious	_	_	O
237	.	_	_	O

238	A	_	_	O
239	validated	_	_	O
240	mucositis	_	_	O
241	scoring	_	_	O
242	system	_	_	O
243	was	_	_	O
244	used	_	_	O
245	.	_	_	O

246	However	_	_	O
247	,	_	_	O
248	in	_	_	B-Claim
249	this	_	_	I-Claim
250	group	_	_	I-Claim
251	of	_	_	I-Claim
252	patients	_	_	I-Claim
253	treated	_	_	I-Claim
254	with	_	_	I-Claim
255	conventional	_	_	I-Claim
256	radiotherapy	_	_	I-Claim
257	,	_	_	I-Claim
258	the	_	_	I-Claim
259	lozenge	_	_	I-Claim
260	did	_	_	I-Claim
261	not	_	_	I-Claim
262	impact	_	_	I-Claim
263	significantly	_	_	I-Claim
264	on	_	_	I-Claim
265	the	_	_	I-Claim
266	severity	_	_	I-Claim
267	of	_	_	I-Claim
268	mucositis	_	_	I-Claim
269	.	_	_	I-Claim

270	Whether	_	_	B-Claim
271	such	_	_	I-Claim
272	a	_	_	I-Claim
273	lozenge	_	_	I-Claim
274	would	_	_	I-Claim
275	be	_	_	I-Claim
276	beneficial	_	_	I-Claim
277	in	_	_	I-Claim
278	treatment	_	_	I-Claim
279	situations	_	_	I-Claim
280	where	_	_	I-Claim
281	rate	_	_	I-Claim
282	of	_	_	I-Claim
283	severe	_	_	I-Claim
284	mucositis	_	_	I-Claim
285	is	_	_	I-Claim
286	higher	_	_	I-Claim
287	(	_	_	I-Claim
288	ie	_	_	I-Claim
289	,	_	_	I-Claim
290	in	_	_	I-Claim
291	patients	_	_	I-Claim
292	treated	_	_	I-Claim
293	with	_	_	I-Claim
294	unconventional	_	_	I-Claim
295	fractionation	_	_	I-Claim
296	or	_	_	I-Claim
297	with	_	_	I-Claim
298	concomitant	_	_	I-Claim
299	chemotherapy	_	_	I-Claim
300	)	_	_	I-Claim
301	is	_	_	I-Claim
302	unknown	_	_	I-Claim
303	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	intraoperative	_	_	O
8	5-fluorouracil	_	_	O
9	(	_	_	O
10	5-FU	_	_	O
11	)	_	_	O
12	or	_	_	O
13	Intraoperative	_	_	O
14	mitomycin	_	_	O
15	C	_	_	O
16	(	_	_	O
17	MMC	_	_	O
18	)	_	_	O
19	in	_	_	O
20	eyes	_	_	O
21	undergoing	_	_	O
22	primary	_	_	O
23	trabeculectomy	_	_	O
24	.	_	_	O

25	Prospective	_	_	O
26	double-masked	_	_	O
27	randomized	_	_	O
28	clinical	_	_	O
29	trial	_	_	O
30	.	_	_	O

31	One	_	_	O
32	hundred	_	_	O
33	fifteen	_	_	O
34	eyes	_	_	O
35	of	_	_	O
36	103	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	uncontrolled	_	_	O
40	intraocular	_	_	O
41	pressure	_	_	O
42	(	_	_	O
43	IOP	_	_	O
44	)	_	_	O
45	despite	_	_	O
46	maximally	_	_	O
47	tolerated	_	_	O
48	medical	_	_	O
49	therapy	_	_	O
50	or	_	_	O
51	laser	_	_	O
52	were	_	_	O
53	prospectively	_	_	O
54	randomized	_	_	O
55	in	_	_	O
56	a	_	_	O
57	double-masked	_	_	O
58	fashion	_	_	O
59	to	_	_	O
60	one	_	_	O
61	of	_	_	O
62	two	_	_	O
63	treatment	_	_	O
64	groups	_	_	O
65	in	_	_	O
66	a	_	_	O
67	single	_	_	O
68	institution	_	_	O
69	setting	_	_	O
70	.	_	_	O

71	Subject	_	_	O
72	's	_	_	O
73	eyes	_	_	O
74	underwent	_	_	O
75	primary	_	_	O
76	trabeculectomy	_	_	O
77	with	_	_	O
78	either	_	_	O
79	topical	_	_	O
80	5-FU	_	_	O
81	(	_	_	O
82	50	_	_	O
83	mg/ml	_	_	O
84	for	_	_	O
85	5	_	_	O
86	minutes	_	_	O
87	)	_	_	O
88	or	_	_	O
89	topical	_	_	O
90	MMC	_	_	O
91	(	_	_	O
92	0.2	_	_	O
93	mg/ml	_	_	O
94	for	_	_	O
95	2	_	_	O
96	minutes	_	_	O
97	)	_	_	O
98	.	_	_	O

99	Primary	_	_	O
100	outcome	_	_	O
101	measures	_	_	O
102	included	_	_	O
103	the	_	_	O
104	number	_	_	O
105	of	_	_	O
106	eyes	_	_	O
107	achieving	_	_	O
108	target	_	_	O
109	pressures	_	_	O
110	of	_	_	O
111	21	_	_	O
112	,	_	_	O
113	18	_	_	O
114	,	_	_	O
115	15	_	_	O
116	,	_	_	O
117	and	_	_	O
118	12	_	_	O
119	mm	_	_	O
120	Hg	_	_	O
121	at	_	_	O
122	6	_	_	O
123	and	_	_	O
124	12	_	_	O
125	months	_	_	O
126	postoperatively	_	_	O
127	.	_	_	O

128	Secondary	_	_	O
129	outcome	_	_	O
130	measures	_	_	O
131	included	_	_	O
132	IOP	_	_	O
133	,	_	_	O
134	best-corrected	_	_	O
135	visual	_	_	O
136	acuity	_	_	O
137	,	_	_	O
138	complications	_	_	O
139	,	_	_	O
140	and	_	_	O
141	interventions	_	_	O
142	.	_	_	O

143	Of	_	_	O
144	the	_	_	O
145	115	_	_	O
146	eyes	_	_	O
147	,	_	_	O
148	57	_	_	O
149	received	_	_	O
150	5-FU	_	_	O
151	while	_	_	O
152	58	_	_	O
153	received	_	_	O
154	MMC	_	_	O
155	.	_	_	O

156	A	_	_	B-Premise
157	target	_	_	I-Premise
158	IOP	_	_	I-Premise
159	of	_	_	I-Premise
160	21	_	_	I-Premise
161	mm	_	_	I-Premise
162	Hg	_	_	I-Premise
163	at	_	_	I-Premise
164	6	_	_	I-Premise
165	months	_	_	I-Premise
166	was	_	_	I-Premise
167	achieved	_	_	I-Premise
168	in	_	_	I-Premise
169	53	_	_	I-Premise
170	of	_	_	I-Premise
171	56	_	_	I-Premise
172	(	_	_	I-Premise
173	95	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	eyes	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	5-FU	_	_	I-Premise
180	group	_	_	I-Premise
181	and	_	_	I-Premise
182	54	_	_	I-Premise
183	of	_	_	I-Premise
184	57	_	_	I-Premise
185	(	_	_	I-Premise
186	95	_	_	I-Premise
187	%	_	_	I-Premise
188	)	_	_	I-Premise
189	eyes	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	MMC	_	_	I-Premise
193	group	_	_	I-Premise
194	(	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	1.00	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	At	_	_	B-Premise
201	12	_	_	I-Premise
202	months	_	_	I-Premise
203	,	_	_	I-Premise
204	45	_	_	I-Premise
205	of	_	_	I-Premise
206	48	_	_	I-Premise
207	(	_	_	I-Premise
208	94	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	eyes	_	_	I-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	5-FU	_	_	I-Premise
215	group	_	_	I-Premise
216	met	_	_	I-Premise
217	a	_	_	I-Premise
218	target	_	_	I-Premise
219	IOP	_	_	I-Premise
220	of	_	_	I-Premise
221	21	_	_	I-Premise
222	mm	_	_	I-Premise
223	Hg	_	_	I-Premise
224	while	_	_	I-Premise
225	48	_	_	I-Premise
226	of	_	_	I-Premise
227	54	_	_	I-Premise
228	(	_	_	I-Premise
229	89	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	eyes	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	MMC	_	_	I-Premise
236	group	_	_	I-Premise
237	did	_	_	I-Premise
238	(	_	_	I-Premise
239	P	_	_	I-Premise
240	=.49	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Premise
244	most	_	_	I-Premise
245	common	_	_	I-Premise
246	complications	_	_	I-Premise
247	in	_	_	I-Premise
248	each	_	_	I-Premise
249	group	_	_	I-Premise
250	were	_	_	I-Premise
251	persistent	_	_	I-Premise
252	choroidal	_	_	I-Premise
253	effusions	_	_	I-Premise
254	and	_	_	I-Premise
255	bleb	_	_	I-Premise
256	leak	_	_	I-Premise
257	.	_	_	I-Premise

258	Our	_	_	B-Claim
259	study	_	_	I-Claim
260	suggests	_	_	I-Claim
261	that	_	_	I-Claim
262	intraoperative	_	_	I-Claim
263	topical	_	_	I-Claim
264	5-FU	_	_	I-Claim
265	is	_	_	I-Claim
266	at	_	_	I-Claim
267	least	_	_	I-Claim
268	as	_	_	I-Claim
269	effective	_	_	I-Claim
270	as	_	_	I-Claim
271	intraoperative	_	_	I-Claim
272	topical	_	_	I-Claim
273	MMC	_	_	I-Claim
274	in	_	_	I-Claim
275	reducing	_	_	I-Claim
276	IOP	_	_	I-Claim
277	of	_	_	I-Claim
278	eyes	_	_	I-Claim
279	undergoing	_	_	I-Claim
280	primary	_	_	I-Claim
281	trabeculectomy	_	_	I-Claim
282	.	_	_	I-Claim


0	Increased	_	_	B-Claim
1	expression	_	_	I-Claim
2	of	_	_	I-Claim
3	metalloproteinases	_	_	I-Claim
4	is	_	_	I-Claim
5	associated	_	_	I-Claim
6	with	_	_	I-Claim
7	poor	_	_	I-Claim
8	prognosis	_	_	I-Claim
9	in	_	_	I-Claim
10	small-cell	_	_	I-Claim
11	lung	_	_	I-Claim
12	cancer	_	_	I-Claim
13	(	_	_	I-Claim
14	SCLC	_	_	I-Claim
15	)	_	_	I-Claim
16	.	_	_	I-Claim

17	This	_	_	O
18	trial	_	_	O
19	was	_	_	O
20	undertaken	_	_	O
21	to	_	_	O
22	determine	_	_	O
23	whether	_	_	O
24	adjuvant	_	_	O
25	treatment	_	_	O
26	with	_	_	O
27	the	_	_	O
28	metalloproteinase	_	_	O
29	inhibitor	_	_	O
30	marimastat	_	_	O
31	could	_	_	O
32	prolong	_	_	O
33	survival	_	_	O
34	in	_	_	O
35	responding	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	SCLC	_	_	O
39	after	_	_	O
40	chemotherapy	_	_	O
41	.	_	_	O

42	SCLC	_	_	O
43	patients	_	_	O
44	in	_	_	O
45	complete	_	_	O
46	or	_	_	O
47	partial	_	_	O
48	remission	_	_	O
49	were	_	_	O
50	eligible	_	_	O
51	.	_	_	O

52	They	_	_	O
53	were	_	_	O
54	stratified	_	_	O
55	by	_	_	O
56	radiotherapy	_	_	O
57	(	_	_	O
58	early	_	_	O
59	,	_	_	O
60	late	_	_	O
61	,	_	_	O
62	or	_	_	O
63	none	_	_	O
64	)	_	_	O
65	,	_	_	O
66	stage	_	_	O
67	(	_	_	O
68	extensive	_	_	O
69	or	_	_	O
70	limited	_	_	O
71	)	_	_	O
72	,	_	_	O
73	response	_	_	O
74	(	_	_	O
75	complete	_	_	O
76	or	_	_	O
77	partial	_	_	O
78	)	_	_	O
79	,	_	_	O
80	and	_	_	O
81	cooperative	_	_	O
82	group	_	_	O
83	(	_	_	O
84	National	_	_	O
85	Cancer	_	_	O
86	Institute	_	_	O
87	of	_	_	O
88	Canada-Clinical	_	_	O
89	Trials	_	_	O
90	Group	_	_	O
91	or	_	_	O
92	European	_	_	O
93	Organization	_	_	O
94	for	_	_	O
95	Research	_	_	O
96	and	_	_	O
97	Treatment	_	_	O
98	of	_	_	O
99	Cancer	_	_	O
100	)	_	_	O
101	.	_	_	O

102	They	_	_	O
103	were	_	_	O
104	randomized	_	_	O
105	to	_	_	O
106	receive	_	_	O
107	marimastat	_	_	O
108	10	_	_	O
109	mg	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	orally	_	_	O
113	bid	_	_	O
114	for	_	_	O
115	up	_	_	O
116	to	_	_	O
117	2	_	_	O
118	years	_	_	O
119	.	_	_	O

120	There	_	_	O
121	were	_	_	O
122	532	_	_	O
123	eligible	_	_	O
124	patients	_	_	O
125	(	_	_	O
126	266	_	_	O
127	marimastat	_	_	O
128	and	_	_	O
129	266	_	_	O
130	placebo	_	_	O
131	)	_	_	O
132	.	_	_	O

133	Stage	_	_	O
134	was	_	_	O
135	limited	_	_	O
136	for	_	_	O
137	279	_	_	O
138	patients	_	_	O
139	(	_	_	O
140	52	_	_	O
141	%	_	_	O
142	)	_	_	O
143	and	_	_	O
144	extensive	_	_	O
145	for	_	_	O
146	253	_	_	O
147	(	_	_	O
148	48	_	_	O
149	%	_	_	O
150	)	_	_	O
151	.	_	_	O

152	Best	_	_	B-Premise
153	response	_	_	I-Premise
154	to	_	_	I-Premise
155	induction	_	_	I-Premise
156	therapy	_	_	I-Premise
157	was	_	_	I-Premise
158	complete	_	_	I-Premise
159	remission	_	_	I-Premise
160	for	_	_	I-Premise
161	176	_	_	I-Premise
162	patients	_	_	I-Premise
163	(	_	_	I-Premise
164	33	_	_	I-Premise
165	%	_	_	I-Premise
166	)	_	_	I-Premise
167	,	_	_	I-Premise
168	partial	_	_	I-Premise
169	remission	_	_	I-Premise
170	for	_	_	I-Premise
171	341	_	_	I-Premise
172	(	_	_	I-Premise
173	64	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	and	_	_	I-Premise
178	15	_	_	I-Premise
179	patients	_	_	I-Premise
180	(	_	_	I-Premise
181	3	_	_	I-Premise
182	%	_	_	I-Premise
183	)	_	_	I-Premise
184	had	_	_	I-Premise
185	undergone	_	_	I-Premise
186	surgical	_	_	I-Premise
187	resection	_	_	I-Premise
188	.	_	_	I-Premise

189	The	_	_	B-Premise
190	median	_	_	I-Premise
191	time	_	_	I-Premise
192	to	_	_	I-Premise
193	progression	_	_	I-Premise
194	for	_	_	I-Premise
195	marimastat	_	_	I-Premise
196	patients	_	_	I-Premise
197	was	_	_	I-Premise
198	4.3	_	_	I-Premise
199	months	_	_	I-Premise
200	compared	_	_	I-Premise
201	with	_	_	I-Premise
202	4.4	_	_	I-Premise
203	months	_	_	I-Premise
204	for	_	_	I-Premise
205	placebo	_	_	I-Premise
206	patients	_	_	I-Premise
207	(	_	_	I-Premise
208	P	_	_	I-Premise
209	=.81	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	Median	_	_	B-Premise
213	survivals	_	_	I-Premise
214	for	_	_	I-Premise
215	marimastat	_	_	I-Premise
216	and	_	_	I-Premise
217	placebo	_	_	I-Premise
218	patients	_	_	I-Premise
219	were	_	_	I-Premise
220	9.3	_	_	I-Premise
221	months	_	_	I-Premise
222	and	_	_	I-Premise
223	9.7	_	_	I-Premise
224	months	_	_	I-Premise
225	,	_	_	I-Premise
226	respectively	_	_	I-Premise
227	(	_	_	I-Premise
228	P	_	_	I-Premise
229	=.90	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Toxicity	_	_	B-Premise
233	was	_	_	I-Premise
234	generally	_	_	I-Premise
235	limited	_	_	I-Premise
236	to	_	_	I-Premise
237	musculoskeletal	_	_	I-Premise
238	symptoms	_	_	I-Premise
239	(	_	_	I-Premise
240	18	_	_	I-Premise
241	%	_	_	I-Premise
242	grade	_	_	I-Premise
243	3/4	_	_	I-Premise
244	for	_	_	I-Premise
245	marimastat	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Dose	_	_	B-Premise
249	modifications	_	_	I-Premise
250	for	_	_	I-Premise
251	musculoskeletal	_	_	I-Premise
252	toxicity	_	_	I-Premise
253	were	_	_	I-Premise
254	required	_	_	I-Premise
255	in	_	_	I-Premise
256	90	_	_	I-Premise
257	patients	_	_	I-Premise
258	(	_	_	I-Premise
259	33	_	_	I-Premise
260	%	_	_	I-Premise
261	)	_	_	I-Premise
262	on	_	_	I-Premise
263	the	_	_	I-Premise
264	marimastat	_	_	I-Premise
265	arm	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	87	_	_	I-Premise
269	(	_	_	I-Premise
270	32	_	_	I-Premise
271	%	_	_	I-Premise
272	)	_	_	I-Premise
273	permanently	_	_	I-Premise
274	stopped	_	_	I-Premise
275	marimastat	_	_	I-Premise
276	because	_	_	I-Premise
277	of	_	_	I-Premise
278	toxicity	_	_	I-Premise
279	.	_	_	I-Premise

280	Patients	_	_	B-Premise
281	on	_	_	I-Premise
282	marimastat	_	_	I-Premise
283	had	_	_	I-Premise
284	significantly	_	_	I-Premise
285	poorer	_	_	I-Premise
286	quality	_	_	I-Premise
287	of	_	_	I-Premise
288	life	_	_	I-Premise
289	at	_	_	I-Premise
290	3	_	_	I-Premise
291	and	_	_	I-Premise
292	6	_	_	I-Premise
293	months	_	_	I-Premise
294	.	_	_	I-Premise

295	Treatment	_	_	B-Claim
296	with	_	_	I-Claim
297	marimastat	_	_	I-Claim
298	after	_	_	I-Claim
299	induction	_	_	I-Claim
300	therapy	_	_	I-Claim
301	for	_	_	I-Claim
302	SCLC	_	_	I-Claim
303	did	_	_	I-Claim
304	not	_	_	I-Claim
305	result	_	_	I-Claim
306	in	_	_	I-Claim
307	improved	_	_	I-Claim
308	survival	_	_	I-Claim
309	and	_	_	I-Claim
310	had	_	_	I-Claim
311	a	_	_	I-Claim
312	negative	_	_	I-Claim
313	impact	_	_	I-Claim
314	on	_	_	I-Claim
315	quality	_	_	I-Claim
316	of	_	_	I-Claim
317	life	_	_	I-Claim
318	.	_	_	I-Claim


0	Morbidity	_	_	B-Claim
1	associated	_	_	I-Claim
2	with	_	_	I-Claim
3	wound	_	_	I-Claim
4	complications	_	_	I-Claim
5	may	_	_	I-Claim
6	translate	_	_	I-Claim
7	into	_	_	I-Claim
8	disability	_	_	I-Claim
9	and	_	_	I-Claim
10	quality-of-life	_	_	I-Claim
11	disadvantages	_	_	I-Claim
12	for	_	_	I-Claim
13	patients	_	_	I-Claim
14	treated	_	_	I-Claim
15	with	_	_	I-Claim
16	radiotherapy	_	_	I-Claim
17	(	_	_	I-Claim
18	RT	_	_	I-Claim
19	)	_	_	I-Claim
20	for	_	_	I-Claim
21	soft	_	_	I-Claim
22	tissue	_	_	I-Claim
23	sarcoma	_	_	I-Claim
24	(	_	_	I-Claim
25	STS	_	_	I-Claim
26	)	_	_	I-Claim
27	of	_	_	I-Claim
28	the	_	_	I-Claim
29	extremities	_	_	I-Claim
30	.	_	_	I-Claim

31	Functional	_	_	O
32	outcome	_	_	O
33	and	_	_	O
34	health	_	_	O
35	status	_	_	O
36	of	_	_	O
37	extremity	_	_	O
38	STS	_	_	O
39	patients	_	_	O
40	randomized	_	_	O
41	in	_	_	O
42	a	_	_	O
43	phase	_	_	O
44	III	_	_	O
45	trial	_	_	O
46	comparing	_	_	O
47	preoperative	_	_	O
48	versus	_	_	O
49	postoperative	_	_	O
50	RT	_	_	O
51	is	_	_	O
52	described	_	_	O
53	.	_	_	O

54	One	_	_	O
55	hundred	_	_	O
56	ninety	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	extremity	_	_	O
60	STS	_	_	O
61	were	_	_	O
62	randomized	_	_	O
63	after	_	_	O
64	stratification	_	_	O
65	by	_	_	O
66	tumor	_	_	O
67	size	_	_	O
68	dichotomized	_	_	O
69	at	_	_	O
70	10	_	_	O
71	cm	_	_	O
72	.	_	_	O

73	Function	_	_	O
74	and	_	_	O
75	quality	_	_	O
76	of	_	_	O
77	life	_	_	O
78	were	_	_	O
79	measured	_	_	O
80	by	_	_	O
81	the	_	_	O
82	Musculoskeletal	_	_	O
83	Tumor	_	_	O
84	Society	_	_	O
85	Rating	_	_	O
86	Scale	_	_	O
87	(	_	_	O
88	MSTS	_	_	O
89	)	_	_	O
90	,	_	_	O
91	the	_	_	O
92	Toronto	_	_	O
93	Extremity	_	_	O
94	Salvage	_	_	O
95	Score	_	_	O
96	(	_	_	O
97	TESS	_	_	O
98	)	_	_	O
99	,	_	_	O
100	and	_	_	O
101	the	_	_	O
102	Short	_	_	O
103	Form-36	_	_	O
104	(	_	_	O
105	SF-36	_	_	O
106	)	_	_	O
107	at	_	_	O
108	randomization	_	_	O
109	,	_	_	O
110	6	_	_	O
111	weeks	_	_	O
112	,	_	_	O
113	and	_	_	O
114	3	_	_	O
115	,	_	_	O
116	6	_	_	O
117	,	_	_	O
118	12	_	_	O
119	,	_	_	O
120	and	_	_	O
121	24	_	_	O
122	months	_	_	O
123	after	_	_	O
124	surgery	_	_	O
125	.	_	_	O

126	One	_	_	O
127	hundred	_	_	O
128	eighty-five	_	_	O
129	patients	_	_	O
130	had	_	_	O
131	function	_	_	O
132	data	_	_	O
133	.	_	_	O

134	Patients	_	_	B-Premise
135	treated	_	_	I-Premise
136	with	_	_	I-Premise
137	postoperative	_	_	I-Premise
138	RT	_	_	I-Premise
139	had	_	_	I-Premise
140	better	_	_	I-Premise
141	function	_	_	I-Premise
142	with	_	_	I-Premise
143	higher	_	_	I-Premise
144	MSTS	_	_	I-Premise
145	(	_	_	I-Premise
146	25.8	_	_	I-Premise
147	v	_	_	I-Premise
148	21.3	_	_	I-Premise
149	,	_	_	I-Premise
150	P	_	_	I-Premise
151	<	_	_	I-Premise
152	.01	_	_	I-Premise
153	)	_	_	I-Premise
154	,	_	_	I-Premise
155	TESS	_	_	I-Premise
156	(	_	_	I-Premise
157	69.8	_	_	I-Premise
158	v	_	_	I-Premise
159	60.6	_	_	I-Premise
160	,	_	_	I-Premise
161	P	_	_	I-Premise
162	=.01	_	_	I-Premise
163	)	_	_	I-Premise
164	,	_	_	I-Premise
165	and	_	_	I-Premise
166	SF-36	_	_	I-Premise
167	bodily	_	_	I-Premise
168	pain	_	_	I-Premise
169	(	_	_	I-Premise
170	67.7	_	_	I-Premise
171	v	_	_	I-Premise
172	58.5	_	_	I-Premise
173	,	_	_	I-Premise
174	P	_	_	I-Premise
175	=.03	_	_	I-Premise
176	)	_	_	I-Premise
177	scores	_	_	I-Premise
178	at	_	_	I-Premise
179	6	_	_	I-Premise
180	weeks	_	_	I-Premise
181	after	_	_	I-Premise
182	surgery	_	_	I-Premise
183	.	_	_	I-Premise

184	There	_	_	O
185	were	_	_	O
186	no	_	_	O
187	differences	_	_	O
188	at	_	_	O
189	later	_	_	O
190	time	_	_	O
191	points	_	_	O
192	.	_	_	O

193	Scores	_	_	B-Premise
194	on	_	_	I-Premise
195	the	_	_	I-Premise
196	physical	_	_	I-Premise
197	function	_	_	I-Premise
198	,	_	_	I-Premise
199	role-physical	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	general	_	_	I-Premise
203	health	_	_	I-Premise
204	subscales	_	_	I-Premise
205	of	_	_	I-Premise
206	the	_	_	I-Premise
207	SF-36	_	_	I-Premise
208	were	_	_	I-Premise
209	significantly	_	_	I-Premise
210	lower	_	_	I-Premise
211	than	_	_	I-Premise
212	Canadian	_	_	I-Premise
213	normative	_	_	I-Premise
214	data	_	_	I-Premise
215	at	_	_	I-Premise
216	all	_	_	I-Premise
217	time	_	_	I-Premise
218	points	_	_	I-Premise
219	.	_	_	I-Premise

220	After	_	_	O
221	treatment	_	_	O
222	arm	_	_	O
223	was	_	_	O
224	controlled	_	_	O
225	for	_	_	O
226	,	_	_	O
227	MSTS	_	_	O
228	change	_	_	O
229	scores	_	_	O
230	were	_	_	O
231	predicted	_	_	O
232	by	_	_	O
233	a	_	_	O
234	lower-extremity	_	_	O
235	tumor	_	_	O
236	,	_	_	O
237	a	_	_	O
238	large	_	_	O
239	resection	_	_	O
240	specimen	_	_	O
241	,	_	_	O
242	and	_	_	O
243	motor	_	_	O
244	nerve	_	_	O
245	sacrifice	_	_	O
246	;	_	_	O
247	TESS	_	_	O
248	change	_	_	O
249	scores	_	_	O
250	were	_	_	O
251	predicted	_	_	O
252	by	_	_	O
253	lower-extremity	_	_	O
254	tumor	_	_	O
255	and	_	_	O
256	prior	_	_	O
257	incomplete	_	_	O
258	excision	_	_	O
259	.	_	_	O

260	When	_	_	B-Premise
261	wound	_	_	I-Premise
262	complication	_	_	I-Premise
263	was	_	_	I-Premise
264	included	_	_	I-Premise
265	in	_	_	I-Premise
266	the	_	_	I-Premise
267	model	_	_	I-Premise
268	,	_	_	I-Premise
269	patients	_	_	I-Premise
270	with	_	_	I-Premise
271	complications	_	_	I-Premise
272	had	_	_	I-Premise
273	lower	_	_	I-Premise
274	MSTS	_	_	I-Premise
275	and	_	_	I-Premise
276	TESS	_	_	I-Premise
277	scores	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	first	_	_	I-Premise
281	2	_	_	I-Premise
282	years	_	_	I-Premise
283	after	_	_	I-Premise
284	treatment	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Claim
287	timing	_	_	I-Claim
288	of	_	_	I-Claim
289	RT	_	_	I-Claim
290	has	_	_	I-Claim
291	minimal	_	_	I-Claim
292	impact	_	_	I-Claim
293	on	_	_	I-Claim
294	the	_	_	I-Claim
295	function	_	_	I-Claim
296	of	_	_	I-Claim
297	STS	_	_	I-Claim
298	patients	_	_	I-Claim
299	in	_	_	I-Claim
300	the	_	_	I-Claim
301	first	_	_	I-Claim
302	year	_	_	I-Claim
303	after	_	_	I-Claim
304	surgery	_	_	I-Claim
305	.	_	_	O

306	Tumor	_	_	B-Claim
307	characteristics	_	_	I-Claim
308	and	_	_	I-Claim
309	wound	_	_	I-Claim
310	complications	_	_	I-Claim
311	have	_	_	I-Claim
312	a	_	_	I-Claim
313	detrimental	_	_	I-Claim
314	effect	_	_	I-Claim
315	on	_	_	I-Claim
316	patient	_	_	I-Claim
317	function	_	_	I-Claim
318	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	doublet	_	_	O
3	,	_	_	O
4	vinorelbine-cisplatin	_	_	O
5	,	_	_	O
6	was	_	_	O
7	compared	_	_	O
8	with	_	_	O
9	a	_	_	O
10	triplet	_	_	O
11	of	_	_	O
12	vinorelbine-ifosfamide-cisplatin	_	_	O
13	,	_	_	O
14	in	_	_	O
15	terms	_	_	O
16	of	_	_	O
17	survival	_	_	O
18	,	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	advanced	_	_	O
23	non-small-cell	_	_	O
24	lung	_	_	O
25	cancer	_	_	O
26	(	_	_	O
27	NSCLC	_	_	O
28	)	_	_	O
29	.	_	_	O

30	From	_	_	O
31	February	_	_	O
32	1998	_	_	O
33	to	_	_	O
34	June	_	_	O
35	1999	_	_	O
36	,	_	_	O
37	259	_	_	O
38	chemonaïve	_	_	O
39	patients	_	_	O
40	entered	_	_	O
41	the	_	_	O
42	study	_	_	O
43	and	_	_	O
44	were	_	_	O
45	randomised	_	_	O
46	to	_	_	O
47	receive	_	_	O
48	either	_	_	O
49	vinorelbine-cisplatin	_	_	O
50	(	_	_	O
51	NP	_	_	O
52	;	_	_	O
53	vinorelbine	_	_	O
54	30	_	_	O
55	mg/m	_	_	O
56	(	_	_	O
57	2	_	_	O
58	)	_	_	O
59	on	_	_	O
60	days	_	_	O
61	1	_	_	O
62	,	_	_	O
63	8	_	_	O
64	and	_	_	O
65	15	_	_	O
66	with	_	_	O
67	cisplatin	_	_	O
68	80	_	_	O
69	mg/m	_	_	O
70	(	_	_	O
71	2	_	_	O
72	)	_	_	O
73	on	_	_	O
74	day	_	_	O
75	1	_	_	O
76	)	_	_	O
77	or	_	_	O
78	vinorelbine-ifosfamide-cisplatin	_	_	O
79	(	_	_	O
80	NIP	_	_	O
81	;	_	_	O
82	vinorelbine	_	_	O
83	25	_	_	O
84	mg/m	_	_	O
85	(	_	_	O
86	2	_	_	O
87	)	_	_	O
88	on	_	_	O
89	days	_	_	O
90	1	_	_	O
91	and	_	_	O
92	8	_	_	O
93	,	_	_	O
94	ifosfamide	_	_	O
95	3	_	_	O
96	g/m	_	_	O
97	(	_	_	O
98	2	_	_	O
99	)	_	_	O
100	on	_	_	O
101	day	_	_	O
102	1	_	_	O
103	and	_	_	O
104	cisplatin	_	_	O
105	75	_	_	O
106	mg/m	_	_	O
107	(	_	_	O
108	2	_	_	O
109	)	_	_	O
110	on	_	_	O
111	day	_	_	O
112	1	_	_	O
113	)	_	_	O
114	,	_	_	O
115	with	_	_	O
116	both	_	_	O
117	regimens	_	_	O
118	being	_	_	O
119	repeated	_	_	O
120	every	_	_	O
121	3	_	_	O
122	weeks	_	_	O
123	.	_	_	O

124	All	_	_	O
125	patients	_	_	O
126	had	_	_	O
127	stage	_	_	O
128	IV	_	_	O
129	or	_	_	O
130	relapsed	_	_	O
131	disease	_	_	O
132	and	_	_	O
133	a	_	_	O
134	performance	_	_	O
135	score	_	_	O
136	of	_	_	O
137	0	_	_	O
138	or	_	_	O
139	1	_	_	O
140	.	_	_	O

141	The	_	_	B-Premise
142	overall	_	_	I-Premise
143	response	_	_	I-Premise
144	rate	_	_	I-Premise
145	was	_	_	I-Premise
146	34.6	_	_	I-Premise
147	%	_	_	I-Premise
148	for	_	_	I-Premise
149	NP	_	_	I-Premise
150	and	_	_	I-Premise
151	35.7	_	_	I-Premise
152	%	_	_	I-Premise
153	for	_	_	I-Premise
154	NIP	_	_	I-Premise
155	.	_	_	I-Premise

156	Median	_	_	B-Premise
157	and	_	_	I-Premise
158	1-year	_	_	I-Premise
159	survival	_	_	I-Premise
160	rates	_	_	I-Premise
161	were	_	_	I-Premise
162	10.0	_	_	I-Premise
163	months	_	_	I-Premise
164	and	_	_	I-Premise
165	38.4	_	_	I-Premise
166	%	_	_	I-Premise
167	for	_	_	I-Premise
168	NP	_	_	I-Premise
169	,	_	_	I-Premise
170	and	_	_	I-Premise
171	8.2	_	_	I-Premise
172	months	_	_	I-Premise
173	and	_	_	I-Premise
174	33.7	_	_	I-Premise
175	%	_	_	I-Premise
176	for	_	_	I-Premise
177	NIP	_	_	I-Premise
178	,	_	_	I-Premise
179	respectively	_	_	I-Premise
180	.	_	_	I-Premise

181	A	_	_	O
182	median	_	_	O
183	of	_	_	O
184	four	_	_	O
185	cycles	_	_	O
186	was	_	_	O
187	administered	_	_	O
188	in	_	_	O
189	each	_	_	O
190	arm	_	_	O
191	.	_	_	O

192	The	_	_	B-Premise
193	major	_	_	I-Premise
194	World	_	_	I-Premise
195	Health	_	_	I-Premise
196	Organization	_	_	I-Premise
197	grade	_	_	I-Premise
198	3-4	_	_	I-Premise
199	toxicities	_	_	I-Premise
200	for	_	_	I-Premise
201	NP	_	_	I-Premise
202	and	_	_	I-Premise
203	NIP	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	,	_	_	I-Premise
207	were	_	_	I-Premise
208	:	_	_	I-Premise
209	neutropenia	_	_	I-Premise
210	(	_	_	I-Premise
211	20.3	_	_	I-Premise
212	%	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	9	_	_	I-Premise
216	%	_	_	I-Premise
217	of	_	_	I-Premise
218	cycles	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	anaemia	_	_	I-Premise
222	(	_	_	I-Premise
223	4.1	_	_	I-Premise
224	%	_	_	I-Premise
225	compared	_	_	I-Premise
226	with	_	_	I-Premise
227	5	_	_	I-Premise
228	%	_	_	I-Premise
229	of	_	_	I-Premise
230	cycles	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	nausea	_	_	I-Premise
234	and	_	_	I-Premise
235	vomiting	_	_	I-Premise
236	(	_	_	I-Premise
237	22.2	_	_	I-Premise
238	%	_	_	I-Premise
239	compared	_	_	I-Premise
240	with	_	_	I-Premise
241	19.4	_	_	I-Premise
242	%	_	_	I-Premise
243	of	_	_	I-Premise
244	patients	_	_	I-Premise
245	)	_	_	I-Premise
246	and	_	_	I-Premise
247	alopecia	_	_	I-Premise
248	(	_	_	I-Premise
249	5.6	_	_	I-Premise
250	%	_	_	I-Premise
251	compared	_	_	I-Premise
252	with	_	_	I-Premise
253	29.8	_	_	I-Premise
254	%	_	_	I-Premise
255	of	_	_	I-Premise
256	patients	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Four	_	_	B-Premise
260	toxic	_	_	I-Premise
261	deaths	_	_	I-Premise
262	occurred	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	NP	_	_	I-Premise
266	arm	_	_	I-Premise
267	and	_	_	I-Premise
268	eight	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	NIP	_	_	I-Premise
272	arm	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	B-Premise
275	different	_	_	I-Premise
276	schedules	_	_	I-Premise
277	of	_	_	I-Premise
278	vinorelbine	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	two	_	_	I-Premise
282	arms	_	_	I-Premise
283	led	_	_	I-Premise
284	to	_	_	I-Premise
285	a	_	_	I-Premise
286	greater	_	_	I-Premise
287	survival	_	_	I-Premise
288	in	_	_	I-Premise
289	the	_	_	I-Premise
290	NP	_	_	I-Premise
291	arm	_	_	I-Premise
292	without	_	_	I-Premise
293	impairing	_	_	I-Premise
294	the	_	_	I-Premise
295	tolerance	_	_	I-Premise
296	profile	_	_	I-Premise
297	,	_	_	I-Premise
298	although	_	_	B-Premise
299	this	_	_	I-Premise
300	is	_	_	I-Premise
301	not	_	_	I-Premise
302	statistically	_	_	I-Premise
303	significant	_	_	I-Premise
304	.	_	_	I-Premise

305	This	_	_	B-Claim
306	confirms	_	_	I-Claim
307	that	_	_	I-Claim
308	the	_	_	I-Claim
309	two-drug	_	_	I-Claim
310	combination	_	_	I-Claim
311	NP	_	_	I-Claim
312	is	_	_	I-Claim
313	a	_	_	I-Claim
314	reference	_	_	I-Claim
315	treatment	_	_	I-Claim
316	for	_	_	I-Claim
317	metastatic	_	_	I-Claim
318	NSCLC	_	_	I-Claim
319	.	_	_	I-Claim

320	The	_	_	B-Claim
321	role	_	_	I-Claim
322	of	_	_	I-Claim
323	three-drug	_	_	I-Claim
324	combinations	_	_	I-Claim
325	remains	_	_	I-Claim
326	questionable	_	_	I-Claim
327	in	_	_	I-Claim
328	this	_	_	I-Claim
329	subset	_	_	I-Claim
330	of	_	_	I-Claim
331	patients	_	_	I-Claim
332	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	effect	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	latanoprost	_	_	O
14	0.005	_	_	O
15	%	_	_	O
16	once	_	_	O
17	daily	_	_	O
18	with	_	_	O
19	that	_	_	O
20	of	_	_	O
21	unoprostone	_	_	O
22	0.15	_	_	O
23	%	_	_	O
24	twice	_	_	O
25	daily	_	_	O
26	for	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	primary	_	_	O
30	open-angle	_	_	O
31	glaucoma	_	_	O
32	or	_	_	O
33	ocular	_	_	O
34	hypertension	_	_	O
35	.	_	_	O

36	Randomized	_	_	O
37	clinical	_	_	O
38	trial	_	_	O
39	.	_	_	O

40	In	_	_	O
41	a	_	_	O
42	prospective	_	_	O
43	,	_	_	O
44	8-week	_	_	O
45	,	_	_	O
46	investigator-masked	_	_	O
47	,	_	_	O
48	parallel-group	_	_	O
49	study	_	_	O
50	conducted	_	_	O
51	at	_	_	O
52	numerous	_	_	O
53	centers	_	_	O
54	in	_	_	O
55	the	_	_	O
56	United	_	_	O
57	States	_	_	O
58	,	_	_	O
59	165	_	_	O
60	previously	_	_	O
61	treated	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	IOP	_	_	O
65	>	_	_	O
66	or=	_	_	O
67	25	_	_	O
68	mm	_	_	O
69	Hg	_	_	O
70	in	_	_	O
71	one	_	_	O
72	or	_	_	O
73	both	_	_	O
74	eyes	_	_	O
75	after	_	_	O
76	washout	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	receive	_	_	O
82	either	_	_	O
83	latanoprost	_	_	O
84	0.005	_	_	O
85	%	_	_	O
86	once	_	_	O
87	daily	_	_	O
88	in	_	_	O
89	the	_	_	O
90	evening	_	_	O
91	or	_	_	O
92	unoprostone	_	_	O
93	0.15	_	_	O
94	%	_	_	O
95	twice	_	_	O
96	daily	_	_	O
97	.	_	_	O

98	Observations	_	_	O
99	procedures	_	_	O
100	were	_	_	O
101	Goldmann	_	_	O
102	applanation	_	_	O
103	tonometry	_	_	O
104	,	_	_	O
105	best-corrected	_	_	O
106	visual	_	_	O
107	acuity	_	_	O
108	,	_	_	O
109	slit	_	_	O
110	lamp	_	_	O
111	biomicroscopy	_	_	O
112	,	_	_	O
113	and	_	_	O
114	ophthalmoscopy	_	_	O
115	.	_	_	O

116	The	_	_	O
117	main	_	_	O
118	outcome	_	_	O
119	measure	_	_	O
120	was	_	_	O
121	change	_	_	O
122	in	_	_	O
123	the	_	_	O
124	mean	_	_	O
125	of	_	_	O
126	the	_	_	O
127	IOPs	_	_	O
128	measured	_	_	O
129	at	_	_	O
130	8:00	_	_	O
131	AM	_	_	O
132	,	_	_	O
133	12	_	_	O
134	noon	_	_	O
135	,	_	_	O
136	and	_	_	O
137	4:00	_	_	O
138	PM	_	_	O
139	between	_	_	O
140	baseline	_	_	O
141	(	_	_	O
142	before	_	_	O
143	treatment	_	_	O
144	)	_	_	O
145	and	_	_	O
146	after	_	_	O
147	8	_	_	O
148	weeks	_	_	O
149	of	_	_	O
150	treatment	_	_	O
151	.	_	_	O

152	The	_	_	B-Premise
153	change	_	_	I-Premise
154	in	_	_	I-Premise
155	the	_	_	I-Premise
156	mean	_	_	I-Premise
157	+/-	_	_	I-Premise
158	SD	_	_	I-Premise
159	of	_	_	I-Premise
160	the	_	_	I-Premise
161	IOPs	_	_	I-Premise
162	measured	_	_	I-Premise
163	at	_	_	I-Premise
164	8:00	_	_	I-Premise
165	AM	_	_	I-Premise
166	,	_	_	I-Premise
167	12	_	_	I-Premise
168	noon	_	_	I-Premise
169	,	_	_	I-Premise
170	and	_	_	I-Premise
171	4:00	_	_	I-Premise
172	PM	_	_	I-Premise
173	was	_	_	I-Premise
174	-7.2	_	_	I-Premise
175	+/-	_	_	I-Premise
176	3.2	_	_	I-Premise
177	mm	_	_	I-Premise
178	Hg	_	_	I-Premise
179	(	_	_	I-Premise
180	28	_	_	I-Premise
181	%	_	_	I-Premise
182	)	_	_	I-Premise
183	for	_	_	I-Premise
184	latanoprost	_	_	I-Premise
185	(	_	_	I-Premise
186	25.3	_	_	I-Premise
187	+/-	_	_	I-Premise
188	2.8	_	_	I-Premise
189	mm	_	_	I-Premise
190	Hg	_	_	I-Premise
191	at	_	_	I-Premise
192	baseline	_	_	I-Premise
193	to	_	_	I-Premise
194	18.2	_	_	I-Premise
195	+/-	_	_	I-Premise
196	2.8	_	_	I-Premise
197	mm	_	_	I-Premise
198	Hg	_	_	I-Premise
199	at	_	_	I-Premise
200	8	_	_	I-Premise
201	weeks	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	-3.9	_	_	I-Premise
205	+/-	_	_	I-Premise
206	2.6	_	_	I-Premise
207	mm	_	_	I-Premise
208	Hg	_	_	I-Premise
209	(	_	_	I-Premise
210	15	_	_	I-Premise
211	%	_	_	I-Premise
212	)	_	_	I-Premise
213	for	_	_	I-Premise
214	unoprostone	_	_	I-Premise
215	(	_	_	I-Premise
216	25.5	_	_	I-Premise
217	+/-	_	_	I-Premise
218	3.3	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	at	_	_	I-Premise
222	baseline	_	_	I-Premise
223	to	_	_	I-Premise
224	21.6	_	_	I-Premise
225	+/-	_	_	I-Premise
226	4.0	_	_	I-Premise
227	mm	_	_	I-Premise
228	Hg	_	_	I-Premise
229	;	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	or=.001	_	_	I-Premise
233	.	_	_	I-Premise

234	No	_	_	B-Premise
235	serious	_	_	I-Premise
236	adverse	_	_	I-Premise
237	event	_	_	I-Premise
238	related	_	_	I-Premise
239	to	_	_	I-Premise
240	either	_	_	I-Premise
241	medication	_	_	I-Premise
242	was	_	_	I-Premise
243	reported	_	_	I-Premise
244	.	_	_	I-Premise

245	Over	_	_	B-Claim
246	an	_	_	I-Claim
247	8-week	_	_	I-Claim
248	period	_	_	I-Claim
249	,	_	_	I-Claim
250	latanoprost	_	_	I-Claim
251	0.005	_	_	I-Claim
252	%	_	_	I-Claim
253	once	_	_	I-Claim
254	daily	_	_	I-Claim
255	lowered	_	_	I-Claim
256	IOP	_	_	I-Claim
257	more	_	_	I-Claim
258	than	_	_	I-Claim
259	unoprostone	_	_	I-Claim
260	0.15	_	_	I-Claim
261	%	_	_	I-Claim
262	twice	_	_	I-Claim
263	daily	_	_	I-Claim
264	in	_	_	I-Claim
265	patients	_	_	I-Claim
266	with	_	_	I-Claim
267	elevated	_	_	I-Claim
268	IOP	_	_	I-Claim
269	.	_	_	I-Claim

270	Both	_	_	B-Claim
271	agents	_	_	I-Claim
272	were	_	_	I-Claim
273	safe	_	_	I-Claim
274	and	_	_	I-Claim
275	well	_	_	I-Claim
276	tolerated	_	_	I-Claim
277	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	a	_	_	O
6	progressive	_	_	O
7	upper-body	_	_	O
8	exercise	_	_	O
9	program	_	_	O
10	on	_	_	O
11	lymphedema	_	_	O
12	secondary	_	_	O
13	to	_	_	O
14	breast	_	_	O
15	cancer	_	_	O
16	treatment	_	_	O
17	.	_	_	O

18	Fourteen	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	survivors	_	_	O
22	with	_	_	O
23	unilateral	_	_	O
24	upper	_	_	O
25	extremity	_	_	O
26	lymphedema	_	_	O
27	were	_	_	O
28	randomly	_	_	O
29	assigned	_	_	O
30	to	_	_	O
31	an	_	_	O
32	exercise	_	_	O
33	(	_	_	O
34	n	_	_	O
35	=	_	_	O
36	7	_	_	O
37	)	_	_	O
38	or	_	_	O
39	control	_	_	O
40	group	_	_	O
41	(	_	_	O
42	n	_	_	O
43	=	_	_	O
44	7	_	_	O
45	)	_	_	O
46	.	_	_	O

47	The	_	_	O
48	exercise	_	_	O
49	group	_	_	O
50	followed	_	_	O
51	a	_	_	O
52	progressive	_	_	O
53	,	_	_	O
54	8-week	_	_	O
55	upper-body	_	_	O
56	exercise	_	_	O
57	program	_	_	O
58	consisting	_	_	O
59	of	_	_	O
60	resistance	_	_	O
61	training	_	_	O
62	plus	_	_	O
63	aerobic	_	_	O
64	exercise	_	_	O
65	using	_	_	O
66	a	_	_	O
67	Monark	_	_	O
68	Rehab	_	_	O
69	Trainer	_	_	O
70	arm	_	_	O
71	ergometer	_	_	O
72	.	_	_	O

73	Lymphedema	_	_	O
74	was	_	_	O
75	assessed	_	_	O
76	by	_	_	O
77	arm	_	_	O
78	circumference	_	_	O
79	and	_	_	O
80	measurement	_	_	O
81	of	_	_	O
82	arm	_	_	O
83	volume	_	_	O
84	by	_	_	O
85	water	_	_	O
86	displacement	_	_	O
87	.	_	_	O

88	Patients	_	_	O
89	were	_	_	O
90	evaluated	_	_	O
91	on	_	_	O
92	five	_	_	O
93	occasions	_	_	O
94	over	_	_	O
95	the	_	_	O
96	experimental	_	_	O
97	period	_	_	O
98	.	_	_	O

99	The	_	_	O
100	Medical	_	_	O
101	Outcomes	_	_	O
102	Trust	_	_	O
103	Short-Form	_	_	O
104	36	_	_	O
105	Survey	_	_	O
106	was	_	_	O
107	used	_	_	O
108	to	_	_	O
109	measure	_	_	O
110	quality	_	_	O
111	of	_	_	O
112	life	_	_	O
113	before	_	_	O
114	and	_	_	O
115	after	_	_	O
116	the	_	_	O
117	intervention	_	_	O
118	.	_	_	O

119	Significance	_	_	O
120	was	_	_	O
121	set	_	_	O
122	at	_	_	O
123	alpha	_	_	O
124	<	_	_	O
125	or	_	_	O
126	=	_	_	O
127	0.01	_	_	O
128	.	_	_	O

129	No	_	_	B-Premise
130	changes	_	_	I-Premise
131	were	_	_	I-Premise
132	found	_	_	I-Premise
133	in	_	_	I-Premise
134	arm	_	_	I-Premise
135	circumference	_	_	I-Premise
136	or	_	_	I-Premise
137	arm	_	_	I-Premise
138	volume	_	_	I-Premise
139	as	_	_	I-Premise
140	a	_	_	I-Premise
141	result	_	_	I-Premise
142	of	_	_	I-Premise
143	the	_	_	I-Premise
144	exercise	_	_	I-Premise
145	program	_	_	I-Premise
146	.	_	_	I-Premise

147	Three	_	_	B-Premise
148	of	_	_	I-Premise
149	the	_	_	I-Premise
150	quality-of-life	_	_	I-Premise
151	domains	_	_	I-Premise
152	showed	_	_	I-Premise
153	trends	_	_	I-Premise
154	toward	_	_	I-Premise
155	increases	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	exercise	_	_	I-Premise
159	group	_	_	I-Premise
160	:	_	_	I-Premise
161	physical	_	_	I-Premise
162	functioning	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	=.050	_	_	I-Premise
166	)	_	_	I-Premise
167	,	_	_	I-Premise
168	general	_	_	I-Premise
169	health	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=.048	_	_	I-Premise
173	)	_	_	I-Premise
174	,	_	_	I-Premise
175	and	_	_	I-Premise
176	vitality	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=.023	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	Mental	_	_	B-Premise
183	health	_	_	I-Premise
184	increased	_	_	I-Premise
185	,	_	_	I-Premise
186	although	_	_	I-Premise
187	not	_	_	I-Premise
188	significantly	_	_	I-Premise
189	,	_	_	I-Premise
190	for	_	_	I-Premise
191	all	_	_	I-Premise
192	subjects	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	=.019	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	Arm	_	_	B-Premise
199	volume	_	_	I-Premise
200	measured	_	_	I-Premise
201	by	_	_	I-Premise
202	water	_	_	I-Premise
203	displacement	_	_	I-Premise
204	was	_	_	I-Premise
205	correlated	_	_	I-Premise
206	with	_	_	I-Premise
207	calculated	_	_	I-Premise
208	arm	_	_	I-Premise
209	volume	_	_	I-Premise
210	(	_	_	I-Premise
211	r	_	_	I-Premise
212	=.973	_	_	I-Premise
213	,	_	_	I-Premise
214	P	_	_	I-Premise
215	<	_	_	I-Premise
216	.001	_	_	I-Premise
217	)	_	_	I-Premise
218	,	_	_	I-Premise
219	although	_	_	B-Premise
220	the	_	_	I-Premise
221	exercise	_	_	I-Premise
222	and	_	_	I-Premise
223	control	_	_	I-Premise
224	group	_	_	I-Premise
225	means	_	_	I-Premise
226	were	_	_	I-Premise
227	significantly	_	_	I-Premise
228	different	_	_	I-Premise
229	(	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	.001	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	Participation	_	_	B-Claim
236	in	_	_	I-Claim
237	an	_	_	I-Claim
238	upper-body	_	_	I-Claim
239	exercise	_	_	I-Claim
240	program	_	_	I-Claim
241	caused	_	_	I-Claim
242	no	_	_	I-Claim
243	changes	_	_	I-Claim
244	in	_	_	I-Claim
245	arm	_	_	I-Claim
246	circumference	_	_	I-Claim
247	or	_	_	I-Claim
248	arm	_	_	I-Claim
249	volume	_	_	I-Claim
250	in	_	_	I-Claim
251	women	_	_	I-Claim
252	with	_	_	I-Claim
253	lymphedema	_	_	I-Claim
254	after	_	_	I-Claim
255	breast	_	_	I-Claim
256	cancer	_	_	I-Claim
257	,	_	_	I-Claim
258	and	_	_	I-Claim
259	they	_	_	I-Claim
260	may	_	_	I-Claim
261	have	_	_	I-Claim
262	experienced	_	_	I-Claim
263	an	_	_	I-Claim
264	increase	_	_	I-Claim
265	in	_	_	I-Claim
266	quality	_	_	I-Claim
267	of	_	_	I-Claim
268	life	_	_	I-Claim
269	.	_	_	I-Claim

270	Additional	_	_	B-Claim
271	studies	_	_	I-Claim
272	should	_	_	I-Claim
273	be	_	_	I-Claim
274	done	_	_	I-Claim
275	in	_	_	I-Claim
276	this	_	_	I-Claim
277	area	_	_	I-Claim
278	to	_	_	I-Claim
279	determine	_	_	I-Claim
280	the	_	_	I-Claim
281	optimum	_	_	I-Claim
282	training	_	_	I-Claim
283	program	_	_	I-Claim
284	.	_	_	I-Claim


0	Randomized	_	_	B-Claim
1	trials	_	_	I-Claim
2	in	_	_	I-Claim
3	fluorouracil	_	_	I-Claim
4	(	_	_	I-Claim
5	FU	_	_	I-Claim
6	)	_	_	I-Claim
7	-refractory	_	_	I-Claim
8	colorectal	_	_	I-Claim
9	cancer	_	_	I-Claim
10	demonstrate	_	_	I-Claim
11	significant	_	_	I-Claim
12	survival	_	_	I-Claim
13	advantages	_	_	I-Claim
14	for	_	_	I-Claim
15	patients	_	_	I-Claim
16	receiving	_	_	I-Claim
17	irinotecan	_	_	I-Claim
18	.	_	_	I-Claim

19	We	_	_	O
20	prospectively	_	_	O
21	compared	_	_	O
22	the	_	_	O
23	efficacy	_	_	O
24	and	_	_	O
25	tolerability	_	_	O
26	of	_	_	O
27	two	_	_	O
28	irinotecan	_	_	O
29	regimens	_	_	O
30	(	_	_	O
31	once	_	_	O
32	a	_	_	O
33	week	_	_	O
34	for	_	_	O
35	4	_	_	O
36	weeks	_	_	O
37	followed	_	_	O
38	by	_	_	O
39	a	_	_	O
40	2-week	_	_	O
41	rest	_	_	O
42	period	_	_	O
43	[	_	_	O
44	weekly	_	_	O
45	]	_	_	O
46	v	_	_	O
47	once	_	_	O
48	every	_	_	O
49	3	_	_	O
50	weeks	_	_	O
51	)	_	_	O
52	in	_	_	O
53	such	_	_	O
54	patients	_	_	O
55	.	_	_	O

56	This	_	_	O
57	multicenter	_	_	O
58	,	_	_	O
59	open-label	_	_	O
60	,	_	_	O
61	phase	_	_	O
62	III	_	_	O
63	study	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	patients	_	_	O
67	in	_	_	O
68	a	_	_	O
69	1:2	_	_	O
70	ratio	_	_	O
71	to	_	_	O
72	irinotecan	_	_	O
73	given	_	_	O
74	either	_	_	O
75	weekly	_	_	O
76	(	_	_	O
77	125	_	_	O
78	mg/m	_	_	O
79	(	_	_	O
80	2	_	_	O
81	)	_	_	O
82	)	_	_	O
83	or	_	_	O
84	once	_	_	O
85	every	_	_	O
86	3	_	_	O
87	weeks	_	_	O
88	(	_	_	O
89	350	_	_	O
90	mg/m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	,	_	_	O
95	or	_	_	O
96	300	_	_	O
97	mg/m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	in	_	_	O
102	patients	_	_	O
103	who	_	_	O
104	were	_	_	O
105	>	_	_	O
106	/=	_	_	O
107	70	_	_	O
108	years	_	_	O
109	of	_	_	O
110	age	_	_	O
111	,	_	_	O
112	who	_	_	O
113	had	_	_	O
114	Eastern	_	_	O
115	Cooperative	_	_	O
116	Oncology	_	_	O
117	Group	_	_	O
118	performance	_	_	O
119	status	_	_	O
120	equal	_	_	O
121	to	_	_	O
122	2	_	_	O
123	,	_	_	O
124	or	_	_	O
125	who	_	_	O
126	had	_	_	O
127	prior	_	_	O
128	pelvic	_	_	O
129	irradiation	_	_	O
130	)	_	_	O
131	.	_	_	O

132	With	_	_	B-Premise
133	median	_	_	I-Premise
134	follow-up	_	_	I-Premise
135	of	_	_	I-Premise
136	15.8	_	_	I-Premise
137	months	_	_	I-Premise
138	,	_	_	I-Premise
139	there	_	_	I-Premise
140	was	_	_	I-Premise
141	no	_	_	I-Premise
142	significant	_	_	I-Premise
143	difference	_	_	I-Premise
144	in	_	_	I-Premise
145	1-year	_	_	I-Premise
146	survival	_	_	I-Premise
147	(	_	_	I-Premise
148	46	_	_	I-Premise
149	%	_	_	I-Premise
150	v	_	_	I-Premise
151	41	_	_	I-Premise
152	%	_	_	I-Premise
153	,	_	_	I-Premise
154	respectively	_	_	I-Premise
155	;	_	_	I-Premise
156	P	_	_	I-Premise
157	=.42	_	_	I-Premise
158	)	_	_	I-Premise
159	,	_	_	I-Premise
160	median	_	_	I-Premise
161	survival	_	_	I-Premise
162	(	_	_	I-Premise
163	9.9	_	_	I-Premise
164	v	_	_	I-Premise
165	9.9	_	_	I-Premise
166	months	_	_	I-Premise
167	,	_	_	I-Premise
168	respectively	_	_	I-Premise
169	;	_	_	I-Premise
170	P	_	_	I-Premise
171	=.43	_	_	I-Premise
172	)	_	_	I-Premise
173	,	_	_	I-Premise
174	or	_	_	I-Premise
175	median	_	_	I-Premise
176	time	_	_	I-Premise
177	to	_	_	I-Premise
178	progression	_	_	I-Premise
179	(	_	_	I-Premise
180	4.0	_	_	I-Premise
181	v	_	_	I-Premise
182	3.0	_	_	I-Premise
183	months	_	_	I-Premise
184	,	_	_	I-Premise
185	respectively	_	_	I-Premise
186	;	_	_	I-Premise
187	P	_	_	I-Premise
188	=.54	_	_	I-Premise
189	)	_	_	I-Premise
190	between	_	_	I-Premise
191	the	_	_	I-Premise
192	two	_	_	I-Premise
193	regimens	_	_	I-Premise
194	.	_	_	I-Premise

195	Grade	_	_	B-Premise
196	3/4	_	_	I-Premise
197	diarrhea	_	_	I-Premise
198	occurred	_	_	I-Premise
199	in	_	_	I-Premise
200	36	_	_	I-Premise
201	%	_	_	I-Premise
202	of	_	_	I-Premise
203	patients	_	_	I-Premise
204	treated	_	_	I-Premise
205	weekly	_	_	I-Premise
206	and	_	_	I-Premise
207	in	_	_	I-Premise
208	19	_	_	I-Premise
209	%	_	_	I-Premise
210	of	_	_	I-Premise
211	those	_	_	I-Premise
212	treated	_	_	I-Premise
213	once	_	_	I-Premise
214	every	_	_	I-Premise
215	3	_	_	I-Premise
216	weeks	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=.002	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Grade	_	_	B-Premise
223	3/4	_	_	I-Premise
224	neutropenia	_	_	I-Premise
225	occurred	_	_	I-Premise
226	in	_	_	I-Premise
227	29	_	_	I-Premise
228	%	_	_	I-Premise
229	of	_	_	I-Premise
230	patients	_	_	I-Premise
231	treated	_	_	I-Premise
232	weekly	_	_	I-Premise
233	and	_	_	I-Premise
234	34	_	_	I-Premise
235	%	_	_	I-Premise
236	of	_	_	I-Premise
237	those	_	_	I-Premise
238	treated	_	_	I-Premise
239	once	_	_	I-Premise
240	every	_	_	I-Premise
241	3	_	_	I-Premise
242	weeks	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	=.35	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Treatment-related	_	_	B-Premise
249	mortality	_	_	I-Premise
250	occurred	_	_	I-Premise
251	in	_	_	I-Premise
252	five	_	_	I-Premise
253	patients	_	_	I-Premise
254	(	_	_	I-Premise
255	5.3	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	receiving	_	_	I-Premise
259	irinotecan	_	_	I-Premise
260	weekly	_	_	I-Premise
261	and	_	_	I-Premise
262	three	_	_	I-Premise
263	patients	_	_	I-Premise
264	(	_	_	I-Premise
265	1.6	_	_	I-Premise
266	%	_	_	I-Premise
267	)	_	_	I-Premise
268	given	_	_	I-Premise
269	therapy	_	_	I-Premise
270	once	_	_	I-Premise
271	every	_	_	I-Premise
272	3	_	_	I-Premise
273	weeks	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	=.12	_	_	I-Premise
277	)	_	_	I-Premise
278	.	_	_	I-Premise

279	Global	_	_	B-Premise
280	quality	_	_	I-Premise
281	of	_	_	I-Premise
282	life	_	_	I-Premise
283	was	_	_	I-Premise
284	not	_	_	I-Premise
285	statistically	_	_	I-Premise
286	different	_	_	I-Premise
287	between	_	_	I-Premise
288	treatment	_	_	I-Premise
289	groups	_	_	I-Premise
290	.	_	_	I-Premise

291	Irinotecan	_	_	B-Claim
292	schedules	_	_	I-Claim
293	of	_	_	I-Claim
294	weekly	_	_	I-Claim
295	and	_	_	I-Claim
296	of	_	_	I-Claim
297	once	_	_	I-Claim
298	every	_	_	I-Claim
299	3	_	_	I-Claim
300	weeks	_	_	I-Claim
301	demonstrated	_	_	I-Claim
302	similar	_	_	I-Claim
303	efficacy	_	_	I-Claim
304	and	_	_	I-Claim
305	quality	_	_	I-Claim
306	of	_	_	I-Claim
307	life	_	_	I-Claim
308	in	_	_	I-Claim
309	patients	_	_	I-Claim
310	with	_	_	I-Claim
311	FU-refractory	_	_	I-Claim
312	,	_	_	I-Claim
313	metastatic	_	_	I-Claim
314	colorectal	_	_	I-Claim
315	cancer	_	_	I-Claim
316	.	_	_	I-Claim

317	The	_	_	B-Claim
318	regimen	_	_	I-Claim
319	of	_	_	I-Claim
320	once	_	_	I-Claim
321	every	_	_	I-Claim
322	3	_	_	I-Claim
323	weeks	_	_	I-Claim
324	was	_	_	I-Claim
325	associated	_	_	I-Claim
326	with	_	_	I-Claim
327	a	_	_	I-Claim
328	significantly	_	_	I-Claim
329	lower	_	_	I-Claim
330	incidence	_	_	I-Claim
331	of	_	_	I-Claim
332	severe	_	_	I-Claim
333	diarrhea	_	_	I-Claim
334	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	a	_	_	O
6	standard	_	_	O
7	anthracycline-based	_	_	O
8	regimen	_	_	O
9	to	_	_	O
10	a	_	_	O
11	dose-intensified	_	_	O
12	anthracycline	_	_	O
13	regimen	_	_	O
14	in	_	_	O
15	locally	_	_	O
16	advanced	_	_	O
17	breast	_	_	O
18	cancer	_	_	O
19	.	_	_	O

20	Locally	_	_	O
21	advanced	_	_	O
22	breast	_	_	O
23	cancer	_	_	O
24	patients	_	_	O
25	were	_	_	O
26	randomly	_	_	O
27	assigned	_	_	O
28	onto	_	_	O
29	a	_	_	O
30	study	_	_	O
31	comparing	_	_	O
32	cyclophosphamide	_	_	O
33	(	_	_	O
34	C	_	_	O
35	;	_	_	O
36	75	_	_	O
37	mg/m	_	_	O
38	(	_	_	O
39	2	_	_	O
40	)	_	_	O
41	orally	_	_	O
42	days	_	_	O
43	1	_	_	O
44	to	_	_	O
45	14	_	_	O
46	)	_	_	O
47	,	_	_	O
48	epirubicin	_	_	O
49	(	_	_	O
50	E	_	_	O
51	;	_	_	O
52	60	_	_	O
53	mg/m	_	_	O
54	(	_	_	O
55	2	_	_	O
56	)	_	_	O
57	intravenously	_	_	O
58	[	_	_	O
59	IV	_	_	O
60	]	_	_	O
61	days	_	_	O
62	1	_	_	O
63	,	_	_	O
64	8	_	_	O
65	)	_	_	O
66	,	_	_	O
67	and	_	_	O
68	fluorouracil	_	_	O
69	(	_	_	O
70	F	_	_	O
71	;	_	_	O
72	500	_	_	O
73	mg/m	_	_	O
74	(	_	_	O
75	2	_	_	O
76	)	_	_	O
77	IV	_	_	O
78	days	_	_	O
79	1	_	_	O
80	,	_	_	O
81	8	_	_	O
82	)	_	_	O
83	six	_	_	O
84	cycles	_	_	O
85	every	_	_	O
86	28	_	_	O
87	days	_	_	O
88	versus	_	_	O
89	E	_	_	O
90	(	_	_	O
91	120	_	_	O
92	mg/m	_	_	O
93	(	_	_	O
94	2	_	_	O
95	)	_	_	O
96	IV	_	_	O
97	day	_	_	O
98	1	_	_	O
99	)	_	_	O
100	,	_	_	O
101	C	_	_	O
102	(	_	_	O
103	830	_	_	O
104	mg/m	_	_	O
105	(	_	_	O
106	2	_	_	O
107	)	_	_	O
108	IV	_	_	O
109	day	_	_	O
110	1	_	_	O
111	)	_	_	O
112	,	_	_	O
113	and	_	_	O
114	granulocyte	_	_	O
115	colony-stimulating	_	_	O
116	factor	_	_	O
117	(	_	_	O
118	filgrastim	_	_	O
119	;	_	_	O
120	5	_	_	O
121	micro	_	_	O
122	g/kg/d	_	_	O
123	subcutaneously	_	_	O
124	days	_	_	O
125	2	_	_	O
126	to	_	_	O
127	13	_	_	O
128	)	_	_	O
129	six	_	_	O
130	cycles	_	_	O
131	every	_	_	O
132	14	_	_	O
133	days	_	_	O
134	.	_	_	O

135	The	_	_	O
136	study	_	_	O
137	was	_	_	O
138	designed	_	_	O
139	to	_	_	O
140	detect	_	_	O
141	a	_	_	O
142	15	_	_	O
143	%	_	_	O
144	improvement	_	_	O
145	;	_	_	O
146	that	_	_	O
147	is	_	_	O
148	,	_	_	O
149	from	_	_	O
150	50	_	_	O
151	%	_	_	O
152	to	_	_	O
153	65	_	_	O
154	%	_	_	O
155	in	_	_	O
156	median	_	_	O
157	progression-free	_	_	O
158	survival	_	_	O
159	(	_	_	O
160	PFS	_	_	O
161	)	_	_	O
162	in	_	_	O
163	favor	_	_	O
164	of	_	_	O
165	the	_	_	O
166	dose-intensified	_	_	O
167	regimen	_	_	O
168	.	_	_	O

169	A	_	_	O
170	total	_	_	O
171	of	_	_	O
172	448	_	_	O
173	patients	_	_	O
174	were	_	_	O
175	enrolled	_	_	O
176	over	_	_	O
177	a	_	_	O
178	period	_	_	O
179	of	_	_	O
180	3	_	_	O
181	years	_	_	O
182	.	_	_	O

183	The	_	_	O
184	median	_	_	O
185	dose	_	_	O
186	intensity	_	_	O
187	delivered	_	_	O
188	for	_	_	O
189	C	_	_	O
190	and	_	_	O
191	E	_	_	O
192	reached	_	_	O
193	,	_	_	O
194	respectively	_	_	O
195	,	_	_	O
196	85	_	_	O
197	%	_	_	O
198	and	_	_	O
199	87	_	_	O
200	%	_	_	O
201	of	_	_	O
202	that	_	_	O
203	planned	_	_	O
204	in	_	_	O
205	the	_	_	O
206	CEF	_	_	O
207	arm	_	_	O
208	and	_	_	O
209	96	_	_	O
210	%	_	_	O
211	and	_	_	O
212	95	_	_	O
213	%	_	_	O
214	of	_	_	O
215	that	_	_	O
216	planned	_	_	O
217	in	_	_	O
218	the	_	_	O
219	EC	_	_	O
220	arm	_	_	O
221	.	_	_	O

222	The	_	_	B-Premise
223	dose-intensified	_	_	I-Premise
224	arm	_	_	I-Premise
225	was	_	_	I-Premise
226	slightly	_	_	I-Premise
227	more	_	_	I-Premise
228	emetogenic	_	_	I-Premise
229	and	_	_	I-Premise
230	generated	_	_	I-Premise
231	more	_	_	I-Premise
232	grade	_	_	I-Premise
233	3	_	_	I-Premise
234	to	_	_	I-Premise
235	4	_	_	I-Premise
236	anemia	_	_	I-Premise
237	but	_	_	I-Premise
238	less	_	_	I-Premise
239	febrile	_	_	I-Premise
240	neutropenia	_	_	I-Premise
241	episodes	_	_	I-Premise
242	.	_	_	I-Premise

243	After	_	_	O
244	a	_	_	O
245	median	_	_	O
246	follow-up	_	_	O
247	of	_	_	O
248	5.5	_	_	O
249	years	_	_	O
250	,	_	_	O
251	277	_	_	O
252	events	_	_	O
253	have	_	_	O
254	been	_	_	O
255	reported	_	_	O
256	.	_	_	O

257	The	_	_	B-Premise
258	median	_	_	I-Premise
259	PFS	_	_	I-Premise
260	was	_	_	I-Premise
261	34	_	_	I-Premise
262	and	_	_	I-Premise
263	33.7	_	_	I-Premise
264	months	_	_	I-Premise
265	for	_	_	I-Premise
266	CEF	_	_	I-Premise
267	and	_	_	I-Premise
268	EC	_	_	I-Premise
269	,	_	_	I-Premise
270	respectively	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	=.68	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	and	_	_	I-Premise
277	the	_	_	I-Premise
278	5-year	_	_	I-Premise
279	survival	_	_	I-Premise
280	rate	_	_	I-Premise
281	was	_	_	I-Premise
282	53	_	_	I-Premise
283	%	_	_	I-Premise
284	and	_	_	I-Premise
285	51	_	_	I-Premise
286	%	_	_	I-Premise
287	for	_	_	I-Premise
288	CEF	_	_	I-Premise
289	and	_	_	I-Premise
290	EC	_	_	I-Premise
291	,	_	_	I-Premise
292	respectively	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=.94	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Dose-intensified	_	_	B-Claim
299	EC	_	_	I-Claim
300	does	_	_	I-Claim
301	not	_	_	I-Claim
302	provide	_	_	I-Claim
303	a	_	_	I-Claim
304	measurable	_	_	I-Claim
305	therapeutic	_	_	I-Claim
306	benefit	_	_	I-Claim
307	over	_	_	I-Claim
308	CEF	_	_	I-Claim
309	as	_	_	I-Claim
310	neoadjuvant	_	_	I-Claim
311	chemotherapy	_	_	I-Claim
312	for	_	_	I-Claim
313	unselected	_	_	I-Claim
314	locally	_	_	I-Claim
315	advanced	_	_	I-Claim
316	breast	_	_	I-Claim
317	cancer	_	_	I-Claim
318	patients	_	_	I-Claim
319	.	_	_	I-Claim


0	Vinorelbine	_	_	B-Claim
1	prolongs	_	_	I-Claim
2	survival	_	_	I-Claim
3	and	_	_	I-Claim
4	improves	_	_	I-Claim
5	quality	_	_	I-Claim
6	of	_	_	I-Claim
7	life	_	_	I-Claim
8	in	_	_	I-Claim
9	elderly	_	_	I-Claim
10	patients	_	_	I-Claim
11	with	_	_	I-Claim
12	advanced	_	_	I-Claim
13	non-small-cell	_	_	I-Claim
14	lung	_	_	I-Claim
15	cancer	_	_	I-Claim
16	(	_	_	I-Claim
17	NSCLC	_	_	I-Claim
18	)	_	_	I-Claim
19	.	_	_	I-Claim

20	Some	_	_	B-Claim
21	studies	_	_	I-Claim
22	have	_	_	I-Claim
23	also	_	_	I-Claim
24	suggested	_	_	I-Claim
25	that	_	_	I-Claim
26	gemcitabine	_	_	I-Claim
27	is	_	_	I-Claim
28	well	_	_	I-Claim
29	tolerated	_	_	I-Claim
30	and	_	_	I-Claim
31	effective	_	_	I-Claim
32	in	_	_	I-Claim
33	such	_	_	I-Claim
34	patients	_	_	I-Claim
35	.	_	_	I-Claim

36	We	_	_	O
37	compared	_	_	O
38	the	_	_	O
39	effectiveness	_	_	O
40	and	_	_	O
41	toxicity	_	_	O
42	of	_	_	O
43	the	_	_	O
44	combination	_	_	O
45	of	_	_	O
46	vinorelbine	_	_	O
47	plus	_	_	O
48	gemcitabine	_	_	O
49	with	_	_	O
50	those	_	_	O
51	of	_	_	O
52	each	_	_	O
53	drug	_	_	O
54	given	_	_	O
55	alone	_	_	O
56	in	_	_	O
57	an	_	_	O
58	open-label	_	_	O
59	,	_	_	O
60	randomized	_	_	O
61	phase	_	_	O
62	III	_	_	O
63	trial	_	_	O
64	in	_	_	O
65	elderly	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	advanced	_	_	O
69	NSCLC	_	_	O
70	.	_	_	O

71	Patients	_	_	O
72	aged	_	_	O
73	70	_	_	O
74	years	_	_	O
75	and	_	_	O
76	older	_	_	O
77	,	_	_	O
78	enrolled	_	_	O
79	between	_	_	O
80	December	_	_	O
81	1997	_	_	O
82	and	_	_	O
83	November	_	_	O
84	2000	_	_	O
85	,	_	_	O
86	were	_	_	O
87	randomly	_	_	O
88	assigned	_	_	O
89	to	_	_	O
90	receive	_	_	O
91	intravenous	_	_	O
92	vinorelbine	_	_	O
93	(	_	_	O
94	30	_	_	O
95	mg/m	_	_	O
96	(	_	_	O
97	2	_	_	O
98	)	_	_	O
99	of	_	_	O
100	body	_	_	O
101	surface	_	_	O
102	area	_	_	O
103	)	_	_	O
104	,	_	_	O
105	gemcitabine	_	_	O
106	(	_	_	O
107	1200	_	_	O
108	mg/m	_	_	O
109	(	_	_	O
110	2	_	_	O
111	)	_	_	O
112	)	_	_	O
113	,	_	_	O
114	or	_	_	O
115	vinorelbine	_	_	O
116	(	_	_	O
117	25	_	_	O
118	mg/m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	)	_	_	O
123	plus	_	_	O
124	gemcitabine	_	_	O
125	(	_	_	O
126	1000	_	_	O
127	mg/m	_	_	O
128	(	_	_	O
129	2	_	_	O
130	)	_	_	O
131	)	_	_	O
132	.	_	_	O

133	All	_	_	O
134	treatments	_	_	O
135	were	_	_	O
136	delivered	_	_	O
137	on	_	_	O
138	days	_	_	O
139	1	_	_	O
140	and	_	_	O
141	8	_	_	O
142	every	_	_	O
143	3	_	_	O
144	weeks	_	_	O
145	for	_	_	O
146	a	_	_	O
147	maximum	_	_	O
148	of	_	_	O
149	six	_	_	O
150	cycles	_	_	O
151	.	_	_	O

152	The	_	_	O
153	primary	_	_	O
154	endpoint	_	_	O
155	was	_	_	O
156	survival	_	_	O
157	.	_	_	O

158	Survival	_	_	O
159	curves	_	_	O
160	were	_	_	O
161	drawn	_	_	O
162	using	_	_	O
163	the	_	_	O
164	Kaplan-Meier	_	_	O
165	method	_	_	O
166	and	_	_	O
167	analyzed	_	_	O
168	by	_	_	O
169	the	_	_	O
170	Mantel-Haenszel	_	_	O
171	test	_	_	O
172	.	_	_	O

173	Secondary	_	_	O
174	endpoints	_	_	O
175	were	_	_	O
176	quality	_	_	O
177	of	_	_	O
178	life	_	_	O
179	and	_	_	O
180	toxicity	_	_	O
181	.	_	_	O

182	Of	_	_	O
183	698	_	_	O
184	patients	_	_	O
185	available	_	_	O
186	for	_	_	O
187	intention-to-treat	_	_	O
188	analysis	_	_	O
189	,	_	_	O
190	233	_	_	O
191	were	_	_	O
192	assigned	_	_	O
193	to	_	_	O
194	receive	_	_	O
195	vinorelbine	_	_	O
196	,	_	_	O
197	233	_	_	O
198	to	_	_	O
199	gemcitabine	_	_	O
200	,	_	_	O
201	and	_	_	O
202	232	_	_	O
203	to	_	_	O
204	vinorelbine	_	_	O
205	plus	_	_	O
206	gemcitabine	_	_	O
207	.	_	_	O

208	Compared	_	_	B-Premise
209	with	_	_	I-Premise
210	each	_	_	I-Premise
211	single	_	_	I-Premise
212	drug	_	_	I-Premise
213	,	_	_	I-Premise
214	the	_	_	I-Premise
215	combination	_	_	I-Premise
216	treatment	_	_	I-Premise
217	did	_	_	I-Premise
218	not	_	_	I-Premise
219	improve	_	_	I-Premise
220	survival	_	_	I-Premise
221	.	_	_	I-Premise

222	The	_	_	B-Premise
223	hazard	_	_	I-Premise
224	ratio	_	_	I-Premise
225	of	_	_	I-Premise
226	death	_	_	I-Premise
227	for	_	_	I-Premise
228	patients	_	_	I-Premise
229	receiving	_	_	I-Premise
230	the	_	_	I-Premise
231	combination	_	_	I-Premise
232	treatment	_	_	I-Premise
233	was	_	_	I-Premise
234	1.17	_	_	I-Premise
235	(	_	_	I-Premise
236	95	_	_	I-Premise
237	%	_	_	I-Premise
238	confidence	_	_	I-Premise
239	interval	_	_	I-Premise
240	[	_	_	I-Premise
241	CI	_	_	I-Premise
242	]	_	_	I-Premise
243	=	_	_	I-Premise
244	0.95	_	_	I-Premise
245	to	_	_	I-Premise
246	1.44	_	_	I-Premise
247	)	_	_	I-Premise
248	that	_	_	I-Premise
249	of	_	_	I-Premise
250	patients	_	_	I-Premise
251	receiving	_	_	I-Premise
252	vinorelbine	_	_	I-Premise
253	and	_	_	I-Premise
254	1.06	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	=	_	_	I-Premise
260	0.86	_	_	I-Premise
261	to	_	_	I-Premise
262	1.29	_	_	I-Premise
263	)	_	_	I-Premise
264	that	_	_	I-Premise
265	of	_	_	I-Premise
266	patients	_	_	I-Premise
267	receiving	_	_	I-Premise
268	gemcitabine	_	_	I-Premise
269	.	_	_	I-Premise

270	Although	_	_	B-Premise
271	quality	_	_	I-Premise
272	of	_	_	I-Premise
273	life	_	_	I-Premise
274	was	_	_	I-Premise
275	similar	_	_	I-Premise
276	across	_	_	I-Premise
277	the	_	_	I-Premise
278	three	_	_	I-Premise
279	treatment	_	_	I-Premise
280	arms	_	_	I-Premise
281	,	_	_	I-Premise
282	the	_	_	B-Premise
283	combination	_	_	I-Premise
284	treatment	_	_	I-Premise
285	was	_	_	I-Premise
286	more	_	_	I-Premise
287	toxic	_	_	I-Premise
288	than	_	_	I-Premise
289	the	_	_	I-Premise
290	two	_	_	I-Premise
291	drugs	_	_	I-Premise
292	given	_	_	I-Premise
293	singly	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Claim
296	combination	_	_	I-Claim
297	of	_	_	I-Claim
298	vinorelbine	_	_	I-Claim
299	plus	_	_	I-Claim
300	gemcitabine	_	_	I-Claim
301	is	_	_	I-Claim
302	not	_	_	I-Claim
303	more	_	_	I-Claim
304	effective	_	_	I-Claim
305	than	_	_	I-Claim
306	single-agent	_	_	I-Claim
307	vinorelbine	_	_	I-Claim
308	or	_	_	I-Claim
309	gemcitabine	_	_	I-Claim
310	in	_	_	I-Claim
311	the	_	_	I-Claim
312	treatment	_	_	I-Claim
313	of	_	_	I-Claim
314	elderly	_	_	I-Claim
315	patients	_	_	I-Claim
316	with	_	_	I-Claim
317	advanced	_	_	I-Claim
318	NSCLC	_	_	I-Claim
319	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	multicenter	_	_	O
4	,	_	_	O
5	phase	_	_	O
6	III	_	_	O
7	study	_	_	O
8	compared	_	_	O
9	doxorubicin	_	_	O
10	and	_	_	O
11	docetaxel	_	_	O
12	(	_	_	O
13	AT	_	_	O
14	)	_	_	O
15	with	_	_	O
16	doxorubicin	_	_	O
17	and	_	_	O
18	cyclophosphamide	_	_	O
19	(	_	_	O
20	AC	_	_	O
21	)	_	_	O
22	as	_	_	O
23	first-line	_	_	O
24	chemotherapy	_	_	O
25	(	_	_	O
26	CT	_	_	O
27	)	_	_	O
28	in	_	_	O
29	metastatic	_	_	O
30	breast	_	_	O
31	cancer	_	_	O
32	(	_	_	O
33	MBC	_	_	O
34	)	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	(	_	_	O
38	n	_	_	O
39	=	_	_	O
40	429	_	_	O
41	)	_	_	O
42	were	_	_	O
43	randomly	_	_	O
44	assigned	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	doxorubicin	_	_	O
48	50	_	_	O
49	mg/m	_	_	O
50	(	_	_	O
51	2	_	_	O
52	)	_	_	O
53	plus	_	_	O
54	docetaxel	_	_	O
55	75	_	_	O
56	mg/m	_	_	O
57	(	_	_	O
58	2	_	_	O
59	)	_	_	O
60	(	_	_	O
61	n	_	_	O
62	=	_	_	O
63	214	_	_	O
64	)	_	_	O
65	or	_	_	O
66	doxorubicin	_	_	O
67	60	_	_	O
68	mg/m	_	_	O
69	(	_	_	O
70	2	_	_	O
71	)	_	_	O
72	plus	_	_	O
73	cyclophosphamide	_	_	O
74	600	_	_	O
75	mg/m	_	_	O
76	(	_	_	O
77	2	_	_	O
78	)	_	_	O
79	(	_	_	O
80	n	_	_	O
81	=	_	_	O
82	215	_	_	O
83	)	_	_	O
84	on	_	_	O
85	day	_	_	O
86	1	_	_	O
87	,	_	_	O
88	every	_	_	O
89	3	_	_	O
90	weeks	_	_	O
91	for	_	_	O
92	up	_	_	O
93	to	_	_	O
94	eight	_	_	O
95	cycles	_	_	O
96	.	_	_	O

97	Time	_	_	B-Premise
98	to	_	_	I-Premise
99	progression	_	_	I-Premise
100	(	_	_	I-Premise
101	TTP	_	_	I-Premise
102	;	_	_	I-Premise
103	primary	_	_	I-Premise
104	end	_	_	I-Premise
105	point	_	_	I-Premise
106	)	_	_	I-Premise
107	and	_	_	I-Premise
108	time	_	_	I-Premise
109	to	_	_	I-Premise
110	treatment	_	_	I-Premise
111	failure	_	_	I-Premise
112	(	_	_	I-Premise
113	TTF	_	_	I-Premise
114	)	_	_	I-Premise
115	were	_	_	I-Premise
116	significantly	_	_	I-Premise
117	longer	_	_	I-Premise
118	with	_	_	I-Premise
119	AT	_	_	I-Premise
120	than	_	_	I-Premise
121	AC	_	_	I-Premise
122	(	_	_	I-Premise
123	median	_	_	I-Premise
124	TTP	_	_	I-Premise
125	,	_	_	I-Premise
126	37.3	_	_	I-Premise
127	v	_	_	I-Premise
128	31.9	_	_	I-Premise
129	weeks	_	_	I-Premise
130	;	_	_	I-Premise
131	log-rank	_	_	I-Premise
132	P	_	_	I-Premise
133	=.014	_	_	I-Premise
134	;	_	_	I-Premise
135	median	_	_	I-Premise
136	TTF	_	_	I-Premise
137	,	_	_	I-Premise
138	25.6	_	_	I-Premise
139	v	_	_	I-Premise
140	23.7	_	_	I-Premise
141	weeks	_	_	I-Premise
142	;	_	_	I-Premise
143	log-rank	_	_	I-Premise
144	P	_	_	I-Premise
145	=.048	_	_	I-Premise
146	)	_	_	I-Premise
147	.	_	_	I-Premise

148	The	_	_	B-Premise
149	overall	_	_	I-Premise
150	response	_	_	I-Premise
151	rate	_	_	I-Premise
152	(	_	_	I-Premise
153	ORR	_	_	I-Premise
154	)	_	_	I-Premise
155	was	_	_	I-Premise
156	significantly	_	_	I-Premise
157	greater	_	_	I-Premise
158	for	_	_	I-Premise
159	patients	_	_	I-Premise
160	taking	_	_	I-Premise
161	AT	_	_	I-Premise
162	(	_	_	I-Premise
163	59	_	_	I-Premise
164	%	_	_	I-Premise
165	,	_	_	I-Premise
166	with	_	_	I-Premise
167	10	_	_	I-Premise
168	%	_	_	I-Premise
169	complete	_	_	I-Premise
170	response	_	_	I-Premise
171	[	_	_	I-Premise
172	CR	_	_	I-Premise
173	]	_	_	I-Premise
174	,	_	_	I-Premise
175	49	_	_	I-Premise
176	%	_	_	I-Premise
177	partial	_	_	I-Premise
178	response	_	_	I-Premise
179	[	_	_	I-Premise
180	PR	_	_	I-Premise
181	]	_	_	I-Premise
182	)	_	_	I-Premise
183	than	_	_	I-Premise
184	for	_	_	I-Premise
185	those	_	_	I-Premise
186	taking	_	_	I-Premise
187	AC	_	_	I-Premise
188	(	_	_	I-Premise
189	47	_	_	I-Premise
190	%	_	_	I-Premise
191	,	_	_	I-Premise
192	with	_	_	I-Premise
193	7	_	_	I-Premise
194	%	_	_	I-Premise
195	CR	_	_	I-Premise
196	,	_	_	I-Premise
197	39	_	_	I-Premise
198	%	_	_	I-Premise
199	PR	_	_	I-Premise
200	)	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	=.009	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	The	_	_	B-Premise
207	ORR	_	_	I-Premise
208	was	_	_	I-Premise
209	also	_	_	I-Premise
210	higher	_	_	I-Premise
211	with	_	_	I-Premise
212	AT	_	_	I-Premise
213	in	_	_	I-Premise
214	patients	_	_	I-Premise
215	with	_	_	I-Premise
216	visceral	_	_	I-Premise
217	involvement	_	_	I-Premise
218	(	_	_	I-Premise
219	58	_	_	I-Premise
220	%	_	_	I-Premise
221	v	_	_	I-Premise
222	41	_	_	I-Premise
223	%	_	_	I-Premise
224	;	_	_	I-Premise
225	liver	_	_	I-Premise
226	,	_	_	I-Premise
227	62	_	_	I-Premise
228	%	_	_	I-Premise
229	v	_	_	I-Premise
230	42	_	_	I-Premise
231	%	_	_	I-Premise
232	;	_	_	I-Premise
233	lung	_	_	I-Premise
234	,	_	_	I-Premise
235	58	_	_	I-Premise
236	%	_	_	I-Premise
237	v	_	_	I-Premise
238	35	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	three	_	_	I-Premise
243	or	_	_	I-Premise
244	more	_	_	I-Premise
245	organs	_	_	I-Premise
246	involved	_	_	I-Premise
247	(	_	_	I-Premise
248	59	_	_	I-Premise
249	%	_	_	I-Premise
250	v	_	_	I-Premise
251	40	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	or	_	_	I-Premise
256	prior	_	_	I-Premise
257	adjuvant	_	_	I-Premise
258	CT	_	_	I-Premise
259	(	_	_	I-Premise
260	53	_	_	I-Premise
261	%	_	_	I-Premise
262	v	_	_	I-Premise
263	41	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Overall	_	_	B-Premise
268	survival	_	_	I-Premise
269	(	_	_	I-Premise
270	OS	_	_	I-Premise
271	)	_	_	I-Premise
272	was	_	_	I-Premise
273	comparable	_	_	I-Premise
274	in	_	_	I-Premise
275	both	_	_	I-Premise
276	arms	_	_	I-Premise
277	.	_	_	I-Premise

278	Grade	_	_	B-Premise
279	3/4	_	_	I-Premise
280	neutropenia	_	_	I-Premise
281	was	_	_	I-Premise
282	frequent	_	_	I-Premise
283	in	_	_	I-Premise
284	both	_	_	I-Premise
285	groups	_	_	I-Premise
286	,	_	_	I-Premise
287	although	_	_	B-Premise
288	febrile	_	_	I-Premise
289	neutropenia	_	_	I-Premise
290	and	_	_	I-Premise
291	infections	_	_	I-Premise
292	were	_	_	I-Premise
293	more	_	_	I-Premise
294	frequent	_	_	I-Premise
295	for	_	_	I-Premise
296	patients	_	_	I-Premise
297	taking	_	_	I-Premise
298	AT	_	_	I-Premise
299	(	_	_	I-Premise
300	respectively	_	_	I-Premise
301	,	_	_	I-Premise
302	33	_	_	I-Premise
303	%	_	_	I-Premise
304	v	_	_	I-Premise
305	10	_	_	I-Premise
306	%	_	_	I-Premise
307	,	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	.001	_	_	I-Premise
311	;	_	_	I-Premise
312	8	_	_	I-Premise
313	%	_	_	I-Premise
314	v	_	_	I-Premise
315	2	_	_	I-Premise
316	%	_	_	I-Premise
317	,	_	_	I-Premise
318	P	_	_	I-Premise
319	=.01	_	_	I-Premise
320	)	_	_	I-Premise
321	.	_	_	I-Premise

322	Severe	_	_	B-Premise
323	nonhematologic	_	_	I-Premise
324	toxicity	_	_	I-Premise
325	was	_	_	I-Premise
326	infrequent	_	_	I-Premise
327	in	_	_	I-Premise
328	both	_	_	I-Premise
329	groups	_	_	I-Premise
330	,	_	_	I-Premise
331	including	_	_	I-Premise
332	grade	_	_	I-Premise
333	3/4	_	_	I-Premise
334	cardiac	_	_	I-Premise
335	events	_	_	I-Premise
336	(	_	_	I-Premise
337	AT	_	_	I-Premise
338	,	_	_	I-Premise
339	3	_	_	I-Premise
340	%	_	_	I-Premise
341	;	_	_	I-Premise
342	AC	_	_	I-Premise
343	,	_	_	I-Premise
344	4	_	_	I-Premise
345	%	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	AT	_	_	B-Claim
349	significantly	_	_	I-Claim
350	improves	_	_	I-Claim
351	TTP	_	_	I-Claim
352	and	_	_	I-Claim
353	ORR	_	_	I-Claim
354	compared	_	_	I-Claim
355	with	_	_	I-Claim
356	AC	_	_	I-Claim
357	in	_	_	I-Claim
358	patients	_	_	I-Claim
359	with	_	_	I-Claim
360	MBC	_	_	I-Claim
361	,	_	_	I-Claim
362	but	_	_	B-Claim
363	there	_	_	I-Claim
364	is	_	_	I-Claim
365	no	_	_	I-Claim
366	difference	_	_	I-Claim
367	in	_	_	I-Claim
368	OS	_	_	I-Claim
369	.	_	_	I-Claim

370	AT	_	_	B-Claim
371	represents	_	_	I-Claim
372	a	_	_	I-Claim
373	valid	_	_	I-Claim
374	option	_	_	I-Claim
375	for	_	_	I-Claim
376	the	_	_	I-Claim
377	treatment	_	_	I-Claim
378	of	_	_	I-Claim
379	MBC	_	_	I-Claim
380	.	_	_	I-Claim


0	Androgen	_	_	B-Claim
1	deprivation	_	_	I-Claim
2	therapy	_	_	I-Claim
3	is	_	_	I-Claim
4	a	_	_	I-Claim
5	common	_	_	I-Claim
6	treatment	_	_	I-Claim
7	in	_	_	I-Claim
8	men	_	_	I-Claim
9	with	_	_	I-Claim
10	prostate	_	_	I-Claim
11	cancer	_	_	I-Claim
12	that	_	_	I-Claim
13	may	_	_	I-Claim
14	cause	_	_	I-Claim
15	fatigue	_	_	I-Claim
16	,	_	_	I-Claim
17	functional	_	_	I-Claim
18	decline	_	_	I-Claim
19	,	_	_	I-Claim
20	increased	_	_	I-Claim
21	body	_	_	I-Claim
22	fatness	_	_	I-Claim
23	,	_	_	I-Claim
24	and	_	_	I-Claim
25	loss	_	_	I-Claim
26	of	_	_	I-Claim
27	lean	_	_	I-Claim
28	body	_	_	I-Claim
29	tissue	_	_	I-Claim
30	.	_	_	I-Claim

31	These	_	_	B-Claim
32	physical	_	_	I-Claim
33	changes	_	_	I-Claim
34	can	_	_	I-Claim
35	negatively	_	_	I-Claim
36	affect	_	_	I-Claim
37	health-related	_	_	I-Claim
38	quality	_	_	I-Claim
39	of	_	_	I-Claim
40	life	_	_	I-Claim
41	.	_	_	I-Claim

42	Resistance	_	_	B-Claim
43	exercise	_	_	I-Claim
44	may	_	_	I-Claim
45	help	_	_	I-Claim
46	to	_	_	I-Claim
47	counter	_	_	I-Claim
48	some	_	_	I-Claim
49	of	_	_	I-Claim
50	these	_	_	I-Claim
51	side	_	_	I-Claim
52	effects	_	_	I-Claim
53	by	_	_	I-Claim
54	reducing	_	_	I-Claim
55	fatigue	_	_	I-Claim
56	,	_	_	I-Claim
57	elevating	_	_	I-Claim
58	mood	_	_	I-Claim
59	,	_	_	I-Claim
60	building	_	_	I-Claim
61	muscle	_	_	I-Claim
62	mass	_	_	I-Claim
63	,	_	_	I-Claim
64	and	_	_	I-Claim
65	reducing	_	_	I-Claim
66	body	_	_	I-Claim
67	fat	_	_	I-Claim
68	.	_	_	I-Claim

69	In	_	_	O
70	a	_	_	O
71	two-site	_	_	O
72	study	_	_	O
73	,	_	_	O
74	155	_	_	O
75	men	_	_	O
76	with	_	_	O
77	prostate	_	_	O
78	cancer	_	_	O
79	who	_	_	O
80	were	_	_	O
81	scheduled	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	androgen	_	_	O
85	deprivation	_	_	O
86	therapy	_	_	O
87	for	_	_	O
88	at	_	_	O
89	least	_	_	O
90	3	_	_	O
91	months	_	_	O
92	after	_	_	O
93	recruitment	_	_	O
94	were	_	_	O
95	randomly	_	_	O
96	assigned	_	_	O
97	to	_	_	O
98	an	_	_	O
99	intervention	_	_	O
100	group	_	_	O
101	that	_	_	O
102	participated	_	_	O
103	in	_	_	O
104	a	_	_	O
105	resistance	_	_	O
106	exercise	_	_	O
107	program	_	_	O
108	three	_	_	O
109	times	_	_	O
110	per	_	_	O
111	week	_	_	O
112	for	_	_	O
113	12	_	_	O
114	weeks	_	_	O
115	(	_	_	O
116	82	_	_	O
117	men	_	_	O
118	)	_	_	O
119	or	_	_	O
120	to	_	_	O
121	a	_	_	O
122	waiting	_	_	O
123	list	_	_	O
124	control	_	_	O
125	group	_	_	O
126	(	_	_	O
127	73	_	_	O
128	men	_	_	O
129	)	_	_	O
130	.	_	_	O

131	The	_	_	O
132	primary	_	_	O
133	outcomes	_	_	O
134	were	_	_	O
135	fatigue	_	_	O
136	and	_	_	O
137	disease-specific	_	_	O
138	quality	_	_	O
139	of	_	_	O
140	life	_	_	O
141	as	_	_	O
142	assessed	_	_	O
143	by	_	_	O
144	self-reported	_	_	O
145	questionnaires	_	_	O
146	after	_	_	O
147	12	_	_	O
148	weeks	_	_	O
149	.	_	_	O

150	Secondary	_	_	O
151	outcomes	_	_	O
152	were	_	_	O
153	muscular	_	_	O
154	fitness	_	_	O
155	and	_	_	O
156	body	_	_	O
157	composition	_	_	O
158	.	_	_	O

159	Men	_	_	B-Premise
160	assigned	_	_	I-Premise
161	to	_	_	I-Premise
162	resistance	_	_	I-Premise
163	exercise	_	_	I-Premise
164	had	_	_	I-Premise
165	less	_	_	I-Premise
166	interference	_	_	I-Premise
167	from	_	_	I-Premise
168	fatigue	_	_	I-Premise
169	on	_	_	I-Premise
170	activities	_	_	I-Premise
171	of	_	_	I-Premise
172	daily	_	_	I-Premise
173	living	_	_	I-Premise
174	(	_	_	I-Premise
175	P	_	_	I-Premise
176	=.002	_	_	I-Premise
177	)	_	_	I-Premise
178	and	_	_	I-Premise
179	higher	_	_	I-Premise
180	quality	_	_	I-Premise
181	of	_	_	I-Premise
182	life	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	=.001	_	_	I-Premise
186	)	_	_	I-Premise
187	than	_	_	I-Premise
188	men	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	control	_	_	I-Premise
192	group	_	_	I-Premise
193	.	_	_	I-Premise

194	Men	_	_	B-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	intervention	_	_	I-Premise
198	group	_	_	I-Premise
199	demonstrated	_	_	I-Premise
200	higher	_	_	I-Premise
201	levels	_	_	I-Premise
202	of	_	_	I-Premise
203	upper	_	_	I-Premise
204	body	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=.009	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	lower	_	_	I-Premise
211	body	_	_	I-Premise
212	(	_	_	I-Premise
213	P	_	_	I-Premise
214	<	_	_	I-Premise
215	.001	_	_	I-Premise
216	)	_	_	I-Premise
217	muscular	_	_	I-Premise
218	fitness	_	_	I-Premise
219	than	_	_	I-Premise
220	men	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	control	_	_	I-Premise
224	group	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	12-week	_	_	I-Premise
228	resistance	_	_	I-Premise
229	exercise	_	_	I-Premise
230	intervention	_	_	I-Premise
231	did	_	_	I-Premise
232	not	_	_	I-Premise
233	improve	_	_	I-Premise
234	body	_	_	I-Premise
235	composition	_	_	I-Premise
236	as	_	_	I-Premise
237	measured	_	_	I-Premise
238	by	_	_	I-Premise
239	changes	_	_	I-Premise
240	in	_	_	I-Premise
241	body	_	_	I-Premise
242	weight	_	_	I-Premise
243	,	_	_	I-Premise
244	body	_	_	I-Premise
245	mass	_	_	I-Premise
246	index	_	_	I-Premise
247	,	_	_	I-Premise
248	waist	_	_	I-Premise
249	circumference	_	_	I-Premise
250	,	_	_	I-Premise
251	or	_	_	I-Premise
252	subcutaneous	_	_	I-Premise
253	skinfolds	_	_	I-Premise
254	.	_	_	I-Premise

255	Resistance	_	_	B-Claim
256	exercise	_	_	I-Claim
257	reduces	_	_	I-Claim
258	fatigue	_	_	I-Claim
259	and	_	_	I-Claim
260	improves	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	and	_	_	I-Claim
265	muscular	_	_	I-Claim
266	fitness	_	_	I-Claim
267	in	_	_	I-Claim
268	men	_	_	I-Claim
269	with	_	_	I-Claim
270	prostate	_	_	I-Claim
271	cancer	_	_	I-Claim
272	receiving	_	_	I-Claim
273	androgen	_	_	I-Claim
274	deprivation	_	_	I-Claim
275	therapy	_	_	I-Claim
276	.	_	_	I-Claim

277	This	_	_	B-Claim
278	form	_	_	I-Claim
279	of	_	_	I-Claim
280	exercise	_	_	I-Claim
281	can	_	_	I-Claim
282	be	_	_	I-Claim
283	an	_	_	I-Claim
284	important	_	_	I-Claim
285	component	_	_	I-Claim
286	of	_	_	I-Claim
287	supportive	_	_	I-Claim
288	care	_	_	I-Claim
289	for	_	_	I-Claim
290	these	_	_	I-Claim
291	patients	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	exercise	_	_	O
6	training	_	_	O
7	on	_	_	O
8	cardiopulmonary	_	_	O
9	function	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	(	_	_	O
15	QOL	_	_	O
16	)	_	_	O
17	in	_	_	O
18	postmenopausal	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	survivors	_	_	O
22	who	_	_	O
23	had	_	_	O
24	completed	_	_	O
25	surgery	_	_	O
26	,	_	_	O
27	radiotherapy	_	_	O
28	,	_	_	O
29	and/or	_	_	O
30	chemotherapy	_	_	O
31	with	_	_	O
32	or	_	_	O
33	without	_	_	O
34	current	_	_	O
35	hormone	_	_	O
36	therapy	_	_	O
37	use	_	_	O
38	.	_	_	O

39	Fifty-three	_	_	O
40	postmenopausal	_	_	O
41	breast	_	_	O
42	cancer	_	_	O
43	survivors	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	an	_	_	O
49	exercise	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	25	_	_	O
54	)	_	_	O
55	or	_	_	O
56	control	_	_	O
57	(	_	_	O
58	n	_	_	O
59	=	_	_	O
60	28	_	_	O
61	)	_	_	O
62	group	_	_	O
63	.	_	_	O

64	The	_	_	O
65	exercise	_	_	O
66	group	_	_	O
67	trained	_	_	O
68	on	_	_	O
69	cycle	_	_	O
70	ergometers	_	_	O
71	three	_	_	O
72	times	_	_	O
73	per	_	_	O
74	week	_	_	O
75	for	_	_	O
76	15	_	_	O
77	weeks	_	_	O
78	at	_	_	O
79	a	_	_	O
80	power	_	_	O
81	output	_	_	O
82	that	_	_	O
83	elicited	_	_	O
84	the	_	_	O
85	ventilatory	_	_	O
86	equivalent	_	_	O
87	for	_	_	O
88	carbon	_	_	O
89	dioxide	_	_	O
90	.	_	_	O

91	The	_	_	O
92	control	_	_	O
93	group	_	_	O
94	did	_	_	O
95	not	_	_	O
96	train	_	_	O
97	.	_	_	O

98	The	_	_	O
99	primary	_	_	O
100	outcomes	_	_	O
101	were	_	_	O
102	changes	_	_	O
103	in	_	_	O
104	peak	_	_	O
105	oxygen	_	_	O
106	consumption	_	_	O
107	and	_	_	O
108	overall	_	_	O
109	QOL	_	_	O
110	from	_	_	O
111	baseline	_	_	O
112	to	_	_	O
113	postintervention	_	_	O
114	.	_	_	O

115	Peak	_	_	O
116	oxygen	_	_	O
117	consumption	_	_	O
118	was	_	_	O
119	assessed	_	_	O
120	by	_	_	O
121	a	_	_	O
122	graded	_	_	O
123	exercise	_	_	O
124	test	_	_	O
125	using	_	_	O
126	gas	_	_	O
127	exchange	_	_	O
128	analysis	_	_	O
129	.	_	_	O

130	Overall	_	_	O
131	QOL	_	_	O
132	was	_	_	O
133	assessed	_	_	O
134	by	_	_	O
135	the	_	_	O
136	Functional	_	_	O
137	Assessment	_	_	O
138	of	_	_	O
139	Cancer	_	_	O
140	Therapy-Breast	_	_	O
141	scale	_	_	O
142	.	_	_	O

143	Fifty-two	_	_	O
144	participants	_	_	O
145	completed	_	_	O
146	the	_	_	O
147	trial	_	_	O
148	.	_	_	O

149	The	_	_	O
150	exercise	_	_	O
151	group	_	_	O
152	completed	_	_	O
153	98.4	_	_	O
154	%	_	_	O
155	of	_	_	O
156	the	_	_	O
157	exercise	_	_	O
158	sessions	_	_	O
159	.	_	_	O

160	Baseline	_	_	O
161	values	_	_	O
162	for	_	_	O
163	peak	_	_	O
164	oxygen	_	_	O
165	consumption	_	_	O
166	(	_	_	O
167	P	_	_	O
168	=.254	_	_	O
169	)	_	_	O
170	and	_	_	O
171	overall	_	_	O
172	QOL	_	_	O
173	(	_	_	O
174	P	_	_	O
175	=.286	_	_	O
176	)	_	_	O
177	did	_	_	O
178	not	_	_	O
179	differ	_	_	O
180	between	_	_	O
181	groups	_	_	O
182	.	_	_	O

183	Peak	_	_	B-Premise
184	oxygen	_	_	I-Premise
185	consumption	_	_	I-Premise
186	increased	_	_	I-Premise
187	by	_	_	I-Premise
188	0.24	_	_	I-Premise
189	L/min	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	exercise	_	_	I-Premise
193	group	_	_	I-Premise
194	,	_	_	I-Premise
195	whereas	_	_	B-Premise
196	it	_	_	I-Premise
197	decreased	_	_	I-Premise
198	by	_	_	I-Premise
199	0.05	_	_	I-Premise
200	L/min	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	(	_	_	I-Premise
206	mean	_	_	I-Premise
207	difference	_	_	I-Premise
208	,	_	_	I-Premise
209	0.29	_	_	I-Premise
210	L/min	_	_	I-Premise
211	;	_	_	I-Premise
212	95	_	_	I-Premise
213	%	_	_	I-Premise
214	confidence	_	_	I-Premise
215	interval	_	_	I-Premise
216	[	_	_	I-Premise
217	CI	_	_	I-Premise
218	]	_	_	I-Premise
219	,	_	_	I-Premise
220	0.18	_	_	I-Premise
221	to	_	_	I-Premise
222	0.40	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	.001	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	Overall	_	_	B-Premise
230	QOL	_	_	I-Premise
231	increased	_	_	I-Premise
232	by	_	_	I-Premise
233	9.1	_	_	I-Premise
234	points	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	exercise	_	_	I-Premise
238	group	_	_	I-Premise
239	compared	_	_	I-Premise
240	with	_	_	I-Premise
241	0.3	_	_	I-Premise
242	points	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	control	_	_	I-Premise
246	group	_	_	I-Premise
247	(	_	_	I-Premise
248	mean	_	_	I-Premise
249	difference	_	_	I-Premise
250	,	_	_	I-Premise
251	8.8	_	_	I-Premise
252	points	_	_	I-Premise
253	;	_	_	I-Premise
254	95	_	_	I-Premise
255	%	_	_	I-Premise
256	CI	_	_	I-Premise
257	,	_	_	I-Premise
258	3.6	_	_	I-Premise
259	to	_	_	I-Premise
260	14.0	_	_	I-Premise
261	;	_	_	I-Premise
262	P	_	_	I-Premise
263	=.001	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	Pearson	_	_	B-Premise
267	correlations	_	_	I-Premise
268	indicated	_	_	I-Premise
269	that	_	_	I-Premise
270	change	_	_	I-Premise
271	in	_	_	I-Premise
272	peak	_	_	I-Premise
273	oxygen	_	_	I-Premise
274	consumption	_	_	I-Premise
275	correlated	_	_	I-Premise
276	with	_	_	I-Premise
277	change	_	_	I-Premise
278	in	_	_	I-Premise
279	overall	_	_	I-Premise
280	QOL	_	_	I-Premise
281	(	_	_	I-Premise
282	r	_	_	I-Premise
283	=	_	_	I-Premise
284	0.45	_	_	I-Premise
285	;	_	_	I-Premise
286	P	_	_	I-Premise
287	<	_	_	I-Premise
288	.01	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Exercise	_	_	B-Claim
292	training	_	_	I-Claim
293	had	_	_	I-Claim
294	beneficial	_	_	I-Claim
295	effects	_	_	I-Claim
296	on	_	_	I-Claim
297	cardiopulmonary	_	_	I-Claim
298	function	_	_	I-Claim
299	and	_	_	I-Claim
300	QOL	_	_	I-Claim
301	in	_	_	I-Claim
302	postmenopausal	_	_	I-Claim
303	breast	_	_	I-Claim
304	cancer	_	_	I-Claim
305	survivors	_	_	I-Claim
306	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	viscocanalostomy	_	_	O
8	and	_	_	O
9	trabeculectomy	_	_	O
10	in	_	_	O
11	adults	_	_	O
12	with	_	_	O
13	uncontrolled	_	_	O
14	open-angle	_	_	O
15	glaucoma	_	_	O
16	.	_	_	O

17	Single-masked	_	_	O
18	,	_	_	O
19	parallel-group	_	_	O
20	,	_	_	O
21	prospective	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	24-month	_	_	O
25	trial	_	_	O
26	,	_	_	O
27	with	_	_	O
28	90	_	_	O
29	%	_	_	O
30	power	_	_	O
31	to	_	_	O
32	detect	_	_	O
33	a	_	_	O
34	clinically	_	_	O
35	important	_	_	O
36	difference	_	_	O
37	between	_	_	O
38	groups	_	_	O
39	.	_	_	O

40	Fifty	_	_	O
41	consecutive	_	_	O
42	patients	_	_	O
43	(	_	_	O
44	50	_	_	O
45	eyes	_	_	O
46	)	_	_	O
47	with	_	_	O
48	primary	_	_	O
49	open-angle	_	_	O
50	or	_	_	O
51	pseudoexfoliative	_	_	O
52	glaucoma	_	_	O
53	.	_	_	O

54	Eyes	_	_	O
55	were	_	_	O
56	assigned	_	_	O
57	randomly	_	_	O
58	to	_	_	O
59	either	_	_	O
60	viscocanalostomy	_	_	O
61	(	_	_	O
62	group	_	_	O
63	1	_	_	O
64	)	_	_	O
65	or	_	_	O
66	trabeculectomy	_	_	O
67	(	_	_	O
68	group	_	_	O
69	2	_	_	O
70	)	_	_	O
71	with	_	_	O
72	no	_	_	O
73	intraoperative	_	_	O
74	antifibrotics	_	_	O
75	in	_	_	O
76	the	_	_	O
77	study	_	_	O
78	eye	_	_	O
79	.	_	_	O

80	In	_	_	O
81	group	_	_	O
82	1	_	_	O
83	,	_	_	O
84	no	_	_	O
85	further	_	_	O
86	intervention	_	_	O
87	was	_	_	O
88	allowed	_	_	O
89	,	_	_	O
90	whereas	_	_	O
91	trabeculectomy	_	_	O
92	eyes	_	_	O
93	could	_	_	O
94	receive	_	_	O
95	subconjunctival	_	_	O
96	5-fluorouracil	_	_	O
97	(	_	_	O
98	5-FU	_	_	O
99	)	_	_	O
100	injections	_	_	O
101	or	_	_	O
102	laser	_	_	O
103	suture	_	_	O
104	lysis	_	_	O
105	after	_	_	O
106	surgery	_	_	O
107	.	_	_	O

108	Success	_	_	O
109	rate	_	_	O
110	based	_	_	O
111	on	_	_	O
112	intraocular	_	_	O
113	pressure	_	_	O
114	(	_	_	O
115	IOP	_	_	O
116	)	_	_	O
117	,	_	_	O
118	visual	_	_	O
119	acuity	_	_	O
120	,	_	_	O
121	discomfort	_	_	O
122	,	_	_	O
123	and	_	_	O
124	other	_	_	O
125	complications	_	_	O
126	.	_	_	O

127	At	_	_	B-Premise
128	the	_	_	I-Premise
129	end	_	_	I-Premise
130	of	_	_	I-Premise
131	the	_	_	I-Premise
132	24-month	_	_	I-Premise
133	follow-up	_	_	I-Premise
134	,	_	_	I-Premise
135	IOP	_	_	I-Premise
136	of	_	_	I-Premise
137	21	_	_	I-Premise
138	mmHg	_	_	I-Premise
139	or	_	_	I-Premise
140	less	_	_	I-Premise
141	and	_	_	I-Premise
142	more	_	_	I-Premise
143	than	_	_	I-Premise
144	6	_	_	I-Premise
145	mmHg	_	_	I-Premise
146	was	_	_	I-Premise
147	achieved	_	_	I-Premise
148	in	_	_	I-Premise
149	76	_	_	I-Premise
150	%	_	_	I-Premise
151	in	_	_	I-Premise
152	group	_	_	I-Premise
153	1	_	_	I-Premise
154	(	_	_	I-Premise
155	n	_	_	I-Premise
156	=	_	_	I-Premise
157	19	_	_	I-Premise
158	)	_	_	I-Premise
159	and	_	_	I-Premise
160	in	_	_	I-Premise
161	80	_	_	I-Premise
162	%	_	_	I-Premise
163	in	_	_	I-Premise
164	group	_	_	I-Premise
165	2	_	_	I-Premise
166	(	_	_	I-Premise
167	n	_	_	I-Premise
168	=	_	_	I-Premise
169	20	_	_	I-Premise
170	;	_	_	I-Premise
171	log-rank	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	0.60	_	_	I-Premise
175	)	_	_	I-Premise
176	;	_	_	I-Premise
177	an	_	_	B-Premise
178	IOP	_	_	I-Premise
179	between	_	_	I-Premise
180	6	_	_	I-Premise
181	and	_	_	I-Premise
182	16	_	_	I-Premise
183	mmHg	_	_	I-Premise
184	was	_	_	I-Premise
185	obtained	_	_	I-Premise
186	in	_	_	I-Premise
187	56	_	_	I-Premise
188	%	_	_	I-Premise
189	in	_	_	I-Premise
190	group	_	_	I-Premise
191	1	_	_	I-Premise
192	(	_	_	I-Premise
193	n	_	_	I-Premise
194	=	_	_	I-Premise
195	14	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	in	_	_	I-Premise
199	72	_	_	I-Premise
200	%	_	_	I-Premise
201	in	_	_	I-Premise
202	group	_	_	I-Premise
203	2	_	_	I-Premise
204	(	_	_	I-Premise
205	n	_	_	I-Premise
206	=	_	_	I-Premise
207	18	_	_	I-Premise
208	;	_	_	I-Premise
209	log-rank	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	0.17	_	_	I-Premise
213	;	_	_	I-Premise
214	Kaplan-Meier	_	_	I-Premise
215	cumulative	_	_	I-Premise
216	probability	_	_	I-Premise
217	of	_	_	I-Premise
218	success	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	Complications	_	_	B-Premise
222	of	_	_	I-Premise
223	viscocanalostomy	_	_	I-Premise
224	included	_	_	I-Premise
225	one	_	_	I-Premise
226	intraoperative	_	_	I-Premise
227	conversion	_	_	I-Premise
228	into	_	_	I-Premise
229	trabeculectomy	_	_	I-Premise
230	;	_	_	I-Premise
231	microruptures	_	_	I-Premise
232	in	_	_	I-Premise
233	Descemet	_	_	I-Premise
234	's	_	_	I-Premise
235	membrane	_	_	I-Premise
236	in	_	_	I-Premise
237	five	_	_	I-Premise
238	eyes	_	_	I-Premise
239	;	_	_	I-Premise
240	three	_	_	I-Premise
241	cases	_	_	I-Premise
242	of	_	_	I-Premise
243	iris	_	_	I-Premise
244	incarceration	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	Decemet	_	_	I-Premise
248	's	_	_	I-Premise
249	window	_	_	I-Premise
250	,	_	_	I-Premise
251	two	_	_	I-Premise
252	of	_	_	I-Premise
253	which	_	_	I-Premise
254	caused	_	_	I-Premise
255	early	_	_	I-Premise
256	failure	_	_	I-Premise
257	of	_	_	I-Premise
258	the	_	_	I-Premise
259	procedure	_	_	I-Premise
260	requiring	_	_	I-Premise
261	reoperation	_	_	I-Premise
262	;	_	_	I-Premise
263	and	_	_	I-Premise
264	a	_	_	I-Premise
265	1-mm	_	_	I-Premise
266	to	_	_	I-Premise
267	2-mm	_	_	I-Premise
268	transient	_	_	I-Premise
269	self-resolving	_	_	I-Premise
270	hyphema	_	_	I-Premise
271	in	_	_	I-Premise
272	three	_	_	I-Premise
273	cases	_	_	I-Premise
274	.	_	_	O

275	Complications	_	_	B-Premise
276	of	_	_	I-Premise
277	trabeculectomy	_	_	I-Premise
278	included	_	_	I-Premise
279	one	_	_	I-Premise
280	case	_	_	I-Premise
281	of	_	_	I-Premise
282	postoperative	_	_	I-Premise
283	bleb	_	_	I-Premise
284	bleeding	_	_	I-Premise
285	with	_	_	I-Premise
286	early	_	_	I-Premise
287	transient	_	_	I-Premise
288	IOP	_	_	I-Premise
289	spike	_	_	I-Premise
290	;	_	_	I-Premise
291	one	_	_	I-Premise
292	early	_	_	I-Premise
293	hyphema	_	_	I-Premise
294	;	_	_	I-Premise
295	five	_	_	I-Premise
296	cases	_	_	I-Premise
297	of	_	_	I-Premise
298	postoperative	_	_	I-Premise
299	hypotony	_	_	I-Premise
300	,	_	_	I-Premise
301	two	_	_	I-Premise
302	of	_	_	I-Premise
303	which	_	_	I-Premise
304	had	_	_	I-Premise
305	a	_	_	I-Premise
306	positive	_	_	I-Premise
307	Seidel	_	_	I-Premise
308	test	_	_	I-Premise
309	from	_	_	I-Premise
310	the	_	_	I-Premise
311	conjunctival	_	_	I-Premise
312	suture	_	_	I-Premise
313	;	_	_	I-Premise
314	three	_	_	I-Premise
315	cases	_	_	I-Premise
316	of	_	_	I-Premise
317	transient	_	_	I-Premise
318	choroidal	_	_	I-Premise
319	detachment	_	_	I-Premise
320	,	_	_	I-Premise
321	two	_	_	I-Premise
322	of	_	_	I-Premise
323	which	_	_	I-Premise
324	had	_	_	I-Premise
325	shallow	_	_	I-Premise
326	anterior	_	_	I-Premise
327	chamber	_	_	I-Premise
328	.	_	_	I-Premise

329	No	_	_	B-Premise
330	patient	_	_	I-Premise
331	required	_	_	I-Premise
332	reoperation	_	_	I-Premise
333	.	_	_	I-Premise

334	Two	_	_	B-Premise
335	eyes	_	_	I-Premise
336	required	_	_	I-Premise
337	argon	_	_	I-Premise
338	laser	_	_	I-Premise
339	suture	_	_	I-Premise
340	lysis	_	_	I-Premise
341	,	_	_	I-Premise
342	and	_	_	I-Premise
343	nine	_	_	I-Premise
344	underwent	_	_	I-Premise
345	one	_	_	I-Premise
346	or	_	_	I-Premise
347	more	_	_	I-Premise
348	5-FU	_	_	I-Premise
349	injections	_	_	I-Premise
350	,	_	_	I-Premise
351	which	_	_	I-Premise
352	caused	_	_	I-Premise
353	punctate	_	_	I-Premise
354	keratopathy	_	_	I-Premise
355	in	_	_	I-Premise
356	three	_	_	I-Premise
357	eyes	_	_	I-Premise
358	.	_	_	I-Premise

359	Viscocanalostomy	_	_	B-Claim
360	is	_	_	I-Claim
361	an	_	_	I-Claim
362	effective	_	_	I-Claim
363	IOP-lowering	_	_	I-Claim
364	procedure	_	_	I-Claim
365	in	_	_	I-Claim
366	white	_	_	I-Claim
367	adults	_	_	I-Claim
368	affected	_	_	I-Claim
369	by	_	_	I-Claim
370	open-angle	_	_	I-Claim
371	glaucoma	_	_	I-Claim
372	.	_	_	I-Claim

373	Trabeculectomy	_	_	B-Claim
374	with	_	_	I-Claim
375	postoperative	_	_	I-Claim
376	5-FU	_	_	I-Claim
377	can	_	_	I-Claim
378	probably	_	_	I-Claim
379	provides	_	_	I-Claim
380	lower	_	_	I-Claim
381	IOPs	_	_	I-Claim
382	but	_	_	I-Claim
383	,	_	_	I-Claim
384	with	_	_	I-Claim
385	more	_	_	I-Claim
386	numerous	_	_	I-Claim
387	complications	_	_	I-Claim
388	,	_	_	I-Claim
389	greater	_	_	I-Claim
390	discomfort	_	_	I-Claim
391	,	_	_	I-Claim
392	and	_	_	I-Claim
393	more	_	_	I-Claim
394	intensive	_	_	I-Claim
395	postoperative	_	_	I-Claim
396	management	_	_	I-Claim
397	.	_	_	I-Claim


0	Imatinib	_	_	B-Claim
1	(	_	_	I-Claim
2	Gleevec	_	_	I-Claim
3	)	_	_	I-Claim
4	,	_	_	I-Claim
5	a	_	_	I-Claim
6	highly	_	_	I-Claim
7	effective	_	_	I-Claim
8	specific	_	_	I-Claim
9	tyrosine	_	_	I-Claim
10	kinase	_	_	I-Claim
11	inhibitor	_	_	I-Claim
12	,	_	_	I-Claim
13	demonstrates	_	_	I-Claim
14	a	_	_	I-Claim
15	better	_	_	I-Claim
16	side	_	_	I-Claim
17	effect	_	_	I-Claim
18	profile	_	_	I-Claim
19	than	_	_	I-Claim
20	interferon-alpha	_	_	I-Claim
21	(	_	_	I-Claim
22	IFN	_	_	I-Claim
23	)	_	_	I-Claim
24	,	_	_	I-Claim
25	which	_	_	I-Claim
26	impairs	_	_	I-Claim
27	patients	_	_	I-Claim
28	'	_	_	I-Claim
29	quality	_	_	I-Claim
30	of	_	_	I-Claim
31	life	_	_	I-Claim
32	(	_	_	I-Claim
33	QoL	_	_	I-Claim
34	)	_	_	I-Claim
35	.	_	_	I-Claim

36	This	_	_	O
37	phase	_	_	O
38	III	_	_	O
39	international	_	_	O
40	study	_	_	O
41	evaluated	_	_	O
42	QoL	_	_	O
43	outcomes	_	_	O
44	in	_	_	O
45	1,106	_	_	O
46	newly	_	_	O
47	diagnosed	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	chronic-phase	_	_	O
51	chronic	_	_	O
52	myeloid	_	_	O
53	leukemia	_	_	O
54	(	_	_	O
55	CML	_	_	O
56	)	_	_	O
57	who	_	_	O
58	were	_	_	O
59	randomized	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	either	_	_	O
63	imatinib	_	_	O
64	400	_	_	O
65	mg	_	_	O
66	daily	_	_	O
67	or	_	_	O
68	IFN	_	_	O
69	up	_	_	O
70	to	_	_	O
71	5	_	_	O
72	MU/m	_	_	O
73	(	_	_	O
74	2	_	_	O
75	)	_	_	O
76	/d	_	_	O
77	with	_	_	O
78	cytarabine	_	_	O
79	(	_	_	O
80	Ara-C	_	_	O
81	)	_	_	O
82	20	_	_	O
83	mg/m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	/d	_	_	O
88	added	_	_	O
89	for	_	_	O
90	10	_	_	O
91	days	_	_	O
92	every	_	_	O
93	month	_	_	O
94	(	_	_	O
95	IFN	_	_	O
96	+	_	_	O
97	LDAC	_	_	O
98	)	_	_	O
99	.	_	_	O

100	Crossover	_	_	O
101	to	_	_	O
102	the	_	_	O
103	other	_	_	O
104	treatment	_	_	O
105	arm	_	_	O
106	was	_	_	O
107	permitted	_	_	O
108	due	_	_	O
109	to	_	_	O
110	a	_	_	O
111	lack	_	_	O
112	of	_	_	O
113	efficacy	_	_	O
114	or	_	_	O
115	treatment	_	_	O
116	intolerance	_	_	O
117	.	_	_	O

118	QoL	_	_	O
119	was	_	_	O
120	assessed	_	_	O
121	with	_	_	O
122	the	_	_	O
123	Functional	_	_	O
124	Assessment	_	_	O
125	of	_	_	O
126	Cancer	_	_	O
127	Therapy-Biologic	_	_	O
128	Response	_	_	O
129	Modifiers	_	_	O
130	(	_	_	O
131	FACT-BRM	_	_	O
132	)	_	_	O
133	at	_	_	O
134	baseline	_	_	O
135	,	_	_	O
136	monthly	_	_	O
137	for	_	_	O
138	6	_	_	O
139	months	_	_	O
140	and	_	_	O
141	then	_	_	O
142	at	_	_	O
143	months	_	_	O
144	9	_	_	O
145	,	_	_	O
146	12	_	_	O
147	,	_	_	O
148	and	_	_	O
149	18	_	_	O
150	.	_	_	O

151	The	_	_	O
152	Trial	_	_	O
153	Outcome	_	_	O
154	Index	_	_	O
155	(	_	_	O
156	TOI	_	_	O
157	;	_	_	O
158	a	_	_	O
159	composite	_	_	O
160	endpoint	_	_	O
161	of	_	_	O
162	physical/functional/treatment-specific	_	_	O
163	subscales	_	_	O
164	)	_	_	O
165	was	_	_	O
166	the	_	_	O
167	primary	_	_	O
168	endpoint	_	_	O
169	.	_	_	O

170	Secondary	_	_	O
171	endpoints	_	_	O
172	measured	_	_	O
173	were	_	_	O
174	social/family	_	_	O
175	well-being	_	_	O
176	(	_	_	O
177	SFWB	_	_	O
178	)	_	_	O
179	and	_	_	O
180	emotional	_	_	O
181	well-being	_	_	O
182	(	_	_	O
183	EWB	_	_	O
184	)	_	_	O
185	.	_	_	O

186	QoL	_	_	O
187	was	_	_	O
188	analyzed	_	_	O
189	for	_	_	O
190	the	_	_	O
191	first	_	_	O
192	18	_	_	O
193	months	_	_	O
194	of	_	_	O
195	treatment	_	_	O
196	using	_	_	O
197	mixed	_	_	O
198	effects	_	_	O
199	growth	_	_	O
200	curve	_	_	O
201	models	_	_	O
202	.	_	_	O

203	The	_	_	O
204	primary	_	_	O
205	analyses	_	_	O
206	were	_	_	O
207	intention-to-treat	_	_	O
208	(	_	_	O
209	ITT	_	_	O
210	)	_	_	O
211	;	_	_	O
212	secondary	_	_	O
213	analyses	_	_	O
214	incorporated	_	_	O
215	crossover	_	_	O
216	as	_	_	O
217	a	_	_	O
218	time-dependent	_	_	O
219	covariate	_	_	O
220	.	_	_	O

221	A	_	_	O
222	total	_	_	O
223	of	_	_	O
224	1,049	_	_	O
225	patients	_	_	O
226	completed	_	_	O
227	at	_	_	O
228	least	_	_	O
229	one	_	_	O
230	QoL	_	_	O
231	assessment	_	_	O
232	.	_	_	O

233	Two	_	_	B-Premise
234	hundred	_	_	I-Premise
235	sixty-one	_	_	I-Premise
236	patients	_	_	I-Premise
237	(	_	_	I-Premise
238	50	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	crossed	_	_	I-Premise
242	over	_	_	I-Premise
243	from	_	_	I-Premise
244	IFN	_	_	I-Premise
245	to	_	_	I-Premise
246	imatinib	_	_	I-Premise
247	and	_	_	I-Premise
248	11	_	_	I-Premise
249	(	_	_	I-Premise
250	2	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	crossed	_	_	I-Premise
254	over	_	_	I-Premise
255	from	_	_	I-Premise
256	imatinib	_	_	I-Premise
257	to	_	_	I-Premise
258	IFN	_	_	I-Premise
259	.	_	_	I-Premise

260	There	_	_	B-Premise
261	was	_	_	I-Premise
262	a	_	_	I-Premise
263	significant	_	_	I-Premise
264	decline	_	_	I-Premise
265	in	_	_	I-Premise
266	TOI	_	_	I-Premise
267	scores	_	_	I-Premise
268	for	_	_	I-Premise
269	the	_	_	I-Premise
270	IFN	_	_	I-Premise
271	treatment	_	_	I-Premise
272	arm	_	_	I-Premise
273	compared	_	_	I-Premise
274	with	_	_	I-Premise
275	preservation	_	_	I-Premise
276	of	_	_	I-Premise
277	baseline	_	_	I-Premise
278	TOI	_	_	I-Premise
279	scores	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	imatinib	_	_	I-Premise
283	arm	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	.001	_	_	I-Premise
288	,	_	_	I-Premise
289	ITT	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	Mean	_	_	B-Premise
293	social/family	_	_	I-Premise
294	and	_	_	I-Premise
295	EWB	_	_	I-Premise
296	scores	_	_	I-Premise
297	were	_	_	I-Premise
298	22.8	_	_	I-Premise
299	and	_	_	I-Premise
300	19.5	_	_	I-Premise
301	,	_	_	I-Premise
302	respectively	_	_	I-Premise
303	,	_	_	I-Premise
304	for	_	_	I-Premise
305	imatinib	_	_	I-Premise
306	and	_	_	I-Premise
307	21.6	_	_	I-Premise
308	and	_	_	I-Premise
309	17.6	_	_	I-Premise
310	,	_	_	I-Premise
311	respectively	_	_	I-Premise
312	,	_	_	I-Premise
313	for	_	_	I-Premise
314	IFN	_	_	I-Premise
315	(	_	_	I-Premise
316	P	_	_	I-Premise
317	<	_	_	I-Premise
318	.001	_	_	I-Premise
319	,	_	_	I-Premise
320	ITT	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	After	_	_	B-Premise
324	crossing	_	_	I-Premise
325	over	_	_	I-Premise
326	from	_	_	I-Premise
327	IFN	_	_	I-Premise
328	to	_	_	I-Premise
329	imatinib	_	_	I-Premise
330	,	_	_	I-Premise
331	patients	_	_	I-Premise
332	experienced	_	_	I-Premise
333	a	_	_	I-Premise
334	significant	_	_	I-Premise
335	(	_	_	I-Premise
336	P	_	_	I-Premise
337	<	_	_	I-Premise
338	.001	_	_	I-Premise
339	)	_	_	I-Premise
340	increase	_	_	I-Premise
341	in	_	_	I-Premise
342	TOI	_	_	I-Premise
343	scores	_	_	I-Premise
344	.	_	_	I-Premise

345	Imatinib	_	_	B-Claim
346	offers	_	_	I-Claim
347	clear	_	_	I-Claim
348	QoL	_	_	I-Claim
349	advantages	_	_	I-Claim
350	over	_	_	I-Claim
351	IFN	_	_	I-Claim
352	as	_	_	I-Claim
353	first-line	_	_	I-Claim
354	treatment	_	_	I-Claim
355	of	_	_	I-Claim
356	chronic-phase	_	_	I-Claim
357	CML	_	_	I-Claim
358	.	_	_	I-Claim

359	In	_	_	O
360	addition	_	_	O
361	,	_	_	O
362	patients	_	_	B-Claim
363	who	_	_	I-Claim
364	crossed	_	_	I-Claim
365	over	_	_	I-Claim
366	to	_	_	I-Claim
367	imatinib	_	_	I-Claim
368	reported	_	_	I-Claim
369	higher	_	_	I-Claim
370	QoL	_	_	I-Claim
371	than	_	_	I-Claim
372	those	_	_	I-Claim
373	who	_	_	I-Claim
374	remained	_	_	I-Claim
375	on	_	_	I-Claim
376	IFN	_	_	I-Claim
377	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	docetaxel	_	_	O
4	plus	_	_	O
5	platinum	_	_	O
6	regimens	_	_	O
7	improve	_	_	O
8	survival	_	_	O
9	and	_	_	O
10	affect	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	(	_	_	O
15	QoL	_	_	O
16	)	_	_	O
17	in	_	_	O
18	advanced	_	_	O
19	non-small-cell	_	_	O
20	lung	_	_	O
21	cancer	_	_	O
22	(	_	_	O
23	NSCLC	_	_	O
24	)	_	_	O
25	compared	_	_	O
26	with	_	_	O
27	vinorelbine	_	_	O
28	plus	_	_	O
29	cisplatin	_	_	O
30	as	_	_	O
31	first-line	_	_	O
32	chemotherapy	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	(	_	_	O
36	n	_	_	O
37	=	_	_	O
38	1,218	_	_	O
39	)	_	_	O
40	with	_	_	O
41	stage	_	_	O
42	IIIB	_	_	O
43	to	_	_	O
44	IV	_	_	O
45	NSCLC	_	_	O
46	were	_	_	O
47	randomly	_	_	O
48	assigned	_	_	O
49	to	_	_	O
50	receive	_	_	O
51	docetaxel	_	_	O
52	75	_	_	O
53	mg/m2	_	_	O
54	and	_	_	O
55	cisplatin	_	_	O
56	75	_	_	O
57	mg/m2	_	_	O
58	every	_	_	O
59	3	_	_	O
60	weeks	_	_	O
61	(	_	_	O
62	DC	_	_	O
63	)	_	_	O
64	;	_	_	O
65	docetaxel	_	_	O
66	75	_	_	O
67	mg/m2	_	_	O
68	and	_	_	O
69	carboplatin	_	_	O
70	area	_	_	O
71	under	_	_	O
72	the	_	_	O
73	curve	_	_	O
74	of	_	_	O
75	6	_	_	O
76	mg/mL	_	_	O
77	*	_	_	O
78	min	_	_	O
79	every	_	_	O
80	3	_	_	O
81	weeks	_	_	O
82	(	_	_	O
83	DCb	_	_	O
84	)	_	_	O
85	;	_	_	O
86	or	_	_	O
87	vinorelbine	_	_	O
88	25	_	_	O
89	mg/m2/wk	_	_	O
90	and	_	_	O
91	cisplatin	_	_	O
92	100	_	_	O
93	mg/m2	_	_	O
94	every	_	_	O
95	4	_	_	O
96	weeks	_	_	O
97	(	_	_	O
98	VC	_	_	O
99	)	_	_	O
100	.	_	_	O

101	Patients	_	_	B-Premise
102	treated	_	_	I-Premise
103	with	_	_	I-Premise
104	DC	_	_	I-Premise
105	had	_	_	I-Premise
106	a	_	_	I-Premise
107	median	_	_	I-Premise
108	survival	_	_	I-Premise
109	of	_	_	I-Premise
110	11.3	_	_	I-Premise
111	v	_	_	I-Premise
112	10.1	_	_	I-Premise
113	months	_	_	I-Premise
114	for	_	_	I-Premise
115	VC-treated	_	_	I-Premise
116	patients	_	_	I-Premise
117	(	_	_	I-Premise
118	P	_	_	I-Premise
119	=.044	_	_	I-Premise
120	;	_	_	I-Premise
121	hazard	_	_	I-Premise
122	ratio	_	_	I-Premise
123	,	_	_	I-Premise
124	1.183	_	_	I-Premise
125	[	_	_	I-Premise
126	97.2	_	_	I-Premise
127	%	_	_	I-Premise
128	confidence	_	_	I-Premise
129	interval	_	_	I-Premise
130	,	_	_	I-Premise
131	0.989	_	_	I-Premise
132	to	_	_	I-Premise
133	1.416	_	_	I-Premise
134	]	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	The	_	_	B-Premise
138	2-year	_	_	I-Premise
139	survival	_	_	I-Premise
140	rate	_	_	I-Premise
141	was	_	_	I-Premise
142	21	_	_	I-Premise
143	%	_	_	I-Premise
144	for	_	_	I-Premise
145	DC-treated	_	_	I-Premise
146	patients	_	_	I-Premise
147	and	_	_	I-Premise
148	14	_	_	I-Premise
149	%	_	_	I-Premise
150	for	_	_	I-Premise
151	VC-treated	_	_	I-Premise
152	patients	_	_	I-Premise
153	.	_	_	I-Premise

154	Overall	_	_	B-Premise
155	response	_	_	I-Premise
156	rate	_	_	I-Premise
157	was	_	_	I-Premise
158	31.6	_	_	I-Premise
159	%	_	_	I-Premise
160	for	_	_	I-Premise
161	DC-treated	_	_	I-Premise
162	patients	_	_	I-Premise
163	v	_	_	I-Premise
164	24.5	_	_	I-Premise
165	%	_	_	I-Premise
166	for	_	_	I-Premise
167	VC-treated	_	_	I-Premise
168	patients	_	_	I-Premise
169	(	_	_	I-Premise
170	P	_	_	I-Premise
171	=.029	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Median	_	_	B-Premise
175	survival	_	_	I-Premise
176	(	_	_	I-Premise
177	9.4	_	_	I-Premise
178	v	_	_	I-Premise
179	9.9	_	_	I-Premise
180	months	_	_	I-Premise
181	[	_	_	I-Premise
182	for	_	_	I-Premise
183	VC	_	_	I-Premise
184	]	_	_	I-Premise
185	;	_	_	I-Premise
186	P	_	_	I-Premise
187	=.657	_	_	I-Premise
188	;	_	_	I-Premise
189	hazard	_	_	I-Premise
190	ratio	_	_	I-Premise
191	,	_	_	I-Premise
192	1.048	_	_	I-Premise
193	[	_	_	I-Premise
194	97.2	_	_	I-Premise
195	confidence	_	_	I-Premise
196	interval	_	_	I-Premise
197	,	_	_	I-Premise
198	0.877	_	_	I-Premise
199	to	_	_	I-Premise
200	1.253	_	_	I-Premise
201	]	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	response	_	_	I-Premise
205	(	_	_	I-Premise
206	23.9	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	with	_	_	I-Premise
210	DCb	_	_	I-Premise
211	were	_	_	I-Premise
212	similar	_	_	I-Premise
213	to	_	_	I-Premise
214	those	_	_	I-Premise
215	results	_	_	I-Premise
216	for	_	_	I-Premise
217	VC	_	_	I-Premise
218	.	_	_	I-Premise

219	Neutropenia	_	_	B-Premise
220	,	_	_	I-Premise
221	thrombocytopenia	_	_	I-Premise
222	,	_	_	I-Premise
223	infection	_	_	I-Premise
224	,	_	_	I-Premise
225	and	_	_	I-Premise
226	febrile	_	_	I-Premise
227	neutropenia	_	_	I-Premise
228	were	_	_	I-Premise
229	similar	_	_	I-Premise
230	with	_	_	I-Premise
231	all	_	_	I-Premise
232	three	_	_	I-Premise
233	regimens	_	_	I-Premise
234	.	_	_	I-Premise

235	Grade	_	_	B-Premise
236	3	_	_	I-Premise
237	to	_	_	I-Premise
238	4	_	_	I-Premise
239	anemia	_	_	I-Premise
240	,	_	_	I-Premise
241	nausea	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	vomiting	_	_	I-Premise
245	were	_	_	I-Premise
246	more	_	_	I-Premise
247	common	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	.01	_	_	I-Premise
252	)	_	_	I-Premise
253	with	_	_	I-Premise
254	VC	_	_	I-Premise
255	than	_	_	I-Premise
256	with	_	_	I-Premise
257	DC	_	_	I-Premise
258	or	_	_	I-Premise
259	DCb	_	_	I-Premise
260	.	_	_	I-Premise

261	Patients	_	_	B-Premise
262	treated	_	_	I-Premise
263	with	_	_	I-Premise
264	either	_	_	I-Premise
265	docetaxel	_	_	I-Premise
266	regimen	_	_	I-Premise
267	had	_	_	I-Premise
268	consistently	_	_	I-Premise
269	improved	_	_	I-Premise
270	QoL	_	_	I-Premise
271	compared	_	_	I-Premise
272	with	_	_	I-Premise
273	VC-treated	_	_	I-Premise
274	patients	_	_	I-Premise
275	,	_	_	I-Premise
276	who	_	_	I-Premise
277	experienced	_	_	I-Premise
278	deterioration	_	_	I-Premise
279	in	_	_	I-Premise
280	QoL	_	_	I-Premise
281	.	_	_	I-Premise

282	DC	_	_	B-Claim
283	resulted	_	_	I-Claim
284	in	_	_	I-Claim
285	a	_	_	I-Claim
286	more	_	_	I-Claim
287	favorable	_	_	I-Claim
288	overall	_	_	I-Claim
289	response	_	_	I-Claim
290	and	_	_	I-Claim
291	survival	_	_	I-Claim
292	rate	_	_	I-Claim
293	than	_	_	I-Claim
294	VC	_	_	I-Claim
295	.	_	_	I-Claim

296	Both	_	_	B-Claim
297	DC	_	_	I-Claim
298	and	_	_	I-Claim
299	DCb	_	_	I-Claim
300	were	_	_	I-Claim
301	better	_	_	I-Claim
302	tolerated	_	_	I-Claim
303	and	_	_	I-Claim
304	provided	_	_	I-Claim
305	patients	_	_	I-Claim
306	with	_	_	I-Claim
307	consistently	_	_	I-Claim
308	improved	_	_	I-Claim
309	QoL	_	_	I-Claim
310	compared	_	_	I-Claim
311	with	_	_	I-Claim
312	VC	_	_	I-Claim
313	.	_	_	I-Claim

314	These	_	_	B-Claim
315	findings	_	_	I-Claim
316	demonstrate	_	_	I-Claim
317	that	_	_	I-Claim
318	a	_	_	I-Claim
319	docetaxel	_	_	I-Claim
320	plus	_	_	I-Claim
321	platinum	_	_	I-Claim
322	combination	_	_	I-Claim
323	is	_	_	I-Claim
324	an	_	_	I-Claim
325	effective	_	_	I-Claim
326	treatment	_	_	I-Claim
327	option	_	_	I-Claim
328	with	_	_	I-Claim
329	a	_	_	I-Claim
330	favorable	_	_	I-Claim
331	therapeutic	_	_	I-Claim
332	index	_	_	I-Claim
333	for	_	_	I-Claim
334	first-line	_	_	I-Claim
335	treatment	_	_	I-Claim
336	of	_	_	I-Claim
337	advanced	_	_	I-Claim
338	or	_	_	I-Claim
339	metastatic	_	_	I-Claim
340	NSCLC	_	_	I-Claim
341	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	relative	_	_	O
5	dose-intensity	_	_	O
6	of	_	_	O
7	cyclophosphamide	_	_	O
8	,	_	_	O
9	doxorubicin	_	_	O
10	,	_	_	O
11	vincristine	_	_	O
12	,	_	_	O
13	and	_	_	O
14	prednisone	_	_	O
15	(	_	_	O
16	CHOP	_	_	O
17	)	_	_	O
18	chemotherapy	_	_	O
19	could	_	_	O
20	be	_	_	O
21	improved	_	_	O
22	by	_	_	O
23	prophylactic	_	_	O
24	administration	_	_	O
25	of	_	_	O
26	granulocyte	_	_	O
27	colony-stimulating	_	_	O
28	factor	_	_	O
29	(	_	_	O
30	G-CSF	_	_	O
31	)	_	_	O
32	in	_	_	O
33	elderly	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	aggressive	_	_	O
37	non-Hodgkin	_	_	O
38	's	_	_	O
39	lymphoma	_	_	O
40	(	_	_	O
41	NHL	_	_	O
42	)	_	_	O
43	.	_	_	O

44	Patients	_	_	O
45	aged	_	_	O
46	65	_	_	O
47	to	_	_	O
48	90	_	_	O
49	years	_	_	O
50	(	_	_	O
51	median	_	_	O
52	,	_	_	O
53	72	_	_	O
54	years	_	_	O
55	)	_	_	O
56	with	_	_	O
57	stage	_	_	O
58	II	_	_	O
59	to	_	_	O
60	IV	_	_	O
61	aggressive	_	_	O
62	NHL	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	to	_	_	O
67	receive	_	_	O
68	standard	_	_	O
69	CHOP	_	_	O
70	every	_	_	O
71	3	_	_	O
72	weeks	_	_	O
73	or	_	_	O
74	CHOP	_	_	O
75	plus	_	_	O
76	G-CSF	_	_	O
77	every	_	_	O
78	3	_	_	O
79	weeks	_	_	O
80	on	_	_	O
81	days	_	_	O
82	2	_	_	O
83	to	_	_	O
84	11	_	_	O
85	of	_	_	O
86	each	_	_	O
87	cycle	_	_	O
88	.	_	_	O

89	In	_	_	B-Premise
90	389	_	_	I-Premise
91	eligible	_	_	I-Premise
92	patients	_	_	I-Premise
93	,	_	_	I-Premise
94	the	_	_	I-Premise
95	relative	_	_	I-Premise
96	dose	_	_	I-Premise
97	intensities	_	_	I-Premise
98	(	_	_	I-Premise
99	RDIs	_	_	I-Premise
100	)	_	_	I-Premise
101	of	_	_	I-Premise
102	cyclophosphamide	_	_	I-Premise
103	(	_	_	I-Premise
104	median	_	_	I-Premise
105	,	_	_	I-Premise
106	96.3	_	_	I-Premise
107	%	_	_	I-Premise
108	v	_	_	I-Premise
109	93.9	_	_	I-Premise
110	%	_	_	I-Premise
111	;	_	_	I-Premise
112	P	_	_	I-Premise
113	=.01	_	_	I-Premise
114	)	_	_	I-Premise
115	and	_	_	I-Premise
116	doxorubicin	_	_	I-Premise
117	(	_	_	I-Premise
118	median	_	_	I-Premise
119	,	_	_	I-Premise
120	95.4	_	_	I-Premise
121	%	_	_	I-Premise
122	v	_	_	I-Premise
123	93.3	_	_	I-Premise
124	%	_	_	I-Premise
125	;	_	_	I-Premise
126	P	_	_	I-Premise
127	=.04	_	_	I-Premise
128	)	_	_	I-Premise
129	were	_	_	I-Premise
130	higher	_	_	I-Premise
131	in	_	_	I-Premise
132	patients	_	_	I-Premise
133	treated	_	_	I-Premise
134	with	_	_	I-Premise
135	CHOP	_	_	I-Premise
136	plus	_	_	I-Premise
137	G-CSF	_	_	I-Premise
138	.	_	_	I-Premise

139	The	_	_	B-Premise
140	complete	_	_	I-Premise
141	response	_	_	I-Premise
142	rates	_	_	I-Premise
143	were	_	_	I-Premise
144	55	_	_	I-Premise
145	%	_	_	I-Premise
146	and	_	_	I-Premise
147	52	_	_	I-Premise
148	%	_	_	I-Premise
149	for	_	_	I-Premise
150	CHOP	_	_	I-Premise
151	and	_	_	I-Premise
152	CHOP	_	_	I-Premise
153	plus	_	_	I-Premise
154	G-CSF	_	_	I-Premise
155	,	_	_	I-Premise
156	respectively	_	_	I-Premise
157	(	_	_	I-Premise
158	P	_	_	I-Premise
159	=.63	_	_	I-Premise
160	)	_	_	I-Premise
161	.	_	_	I-Premise

162	The	_	_	B-Premise
163	actuarial	_	_	I-Premise
164	overall	_	_	I-Premise
165	survival	_	_	I-Premise
166	at	_	_	I-Premise
167	5	_	_	I-Premise
168	years	_	_	I-Premise
169	was	_	_	I-Premise
170	22	_	_	I-Premise
171	%	_	_	I-Premise
172	with	_	_	I-Premise
173	CHOP	_	_	I-Premise
174	alone	_	_	I-Premise
175	,	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	24	_	_	I-Premise
179	%	_	_	I-Premise
180	with	_	_	I-Premise
181	CHOP	_	_	I-Premise
182	plus	_	_	I-Premise
183	G-CSF	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=.76	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	with	_	_	I-Premise
190	a	_	_	I-Premise
191	median	_	_	I-Premise
192	follow-up	_	_	I-Premise
193	of	_	_	I-Premise
194	33	_	_	I-Premise
195	months	_	_	I-Premise
196	.	_	_	I-Premise

197	Patients	_	_	B-Premise
198	treated	_	_	I-Premise
199	with	_	_	I-Premise
200	CHOP	_	_	I-Premise
201	plus	_	_	I-Premise
202	G-CSF	_	_	I-Premise
203	had	_	_	I-Premise
204	an	_	_	I-Premise
205	identical	_	_	I-Premise
206	incidence	_	_	I-Premise
207	of	_	_	I-Premise
208	infections	_	_	I-Premise
209	,	_	_	I-Premise
210	with	_	_	I-Premise
211	World	_	_	I-Premise
212	Health	_	_	I-Premise
213	Organization	_	_	I-Premise
214	grade	_	_	I-Premise
215	3	_	_	I-Premise
216	to	_	_	I-Premise
217	4	_	_	I-Premise
218	(	_	_	I-Premise
219	34	_	_	I-Premise
220	of	_	_	I-Premise
221	1,191	_	_	I-Premise
222	cycles	_	_	I-Premise
223	v	_	_	I-Premise
224	36	_	_	I-Premise
225	of	_	_	I-Premise
226	1,195	_	_	I-Premise
227	cycles	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Only	_	_	B-Premise
231	the	_	_	I-Premise
232	cumulative	_	_	I-Premise
233	days	_	_	I-Premise
234	with	_	_	I-Premise
235	antibiotics	_	_	I-Premise
236	were	_	_	I-Premise
237	fewer	_	_	I-Premise
238	with	_	_	I-Premise
239	CHOP	_	_	I-Premise
240	plus	_	_	I-Premise
241	G-CSF	_	_	I-Premise
242	(	_	_	I-Premise
243	median	_	_	I-Premise
244	,	_	_	I-Premise
245	0	_	_	I-Premise
246	v	_	_	I-Premise
247	6	_	_	I-Premise
248	days	_	_	I-Premise
249	;	_	_	I-Premise
250	P	_	_	I-Premise
251	=.006	_	_	I-Premise
252	)	_	_	I-Premise
253	than	_	_	I-Premise
254	with	_	_	I-Premise
255	CHOP	_	_	I-Premise
256	alone	_	_	I-Premise
257	.	_	_	I-Premise

258	The	_	_	B-Premise
259	number	_	_	I-Premise
260	of	_	_	I-Premise
261	hospital	_	_	I-Premise
262	admissions	_	_	I-Premise
263	and	_	_	I-Premise
264	the	_	_	I-Premise
265	number	_	_	I-Premise
266	of	_	_	I-Premise
267	days	_	_	I-Premise
268	in	_	_	I-Premise
269	hospital	_	_	I-Premise
270	were	_	_	I-Premise
271	not	_	_	I-Premise
272	different	_	_	I-Premise
273	.	_	_	I-Premise

274	In	_	_	B-Claim
275	elderly	_	_	I-Claim
276	patients	_	_	I-Claim
277	,	_	_	I-Claim
278	G-CSF	_	_	I-Claim
279	improved	_	_	I-Claim
280	the	_	_	I-Claim
281	RDI	_	_	I-Claim
282	of	_	_	I-Claim
283	CHOP	_	_	I-Claim
284	,	_	_	I-Claim
285	but	_	_	B-Premise
286	this	_	_	I-Premise
287	did	_	_	I-Premise
288	not	_	_	I-Premise
289	lead	_	_	I-Premise
290	to	_	_	I-Premise
291	a	_	_	I-Premise
292	higher	_	_	I-Premise
293	complete	_	_	I-Premise
294	response	_	_	I-Premise
295	rate	_	_	I-Premise
296	or	_	_	I-Premise
297	better	_	_	I-Premise
298	overall	_	_	I-Premise
299	survival	_	_	I-Premise
300	.	_	_	I-Premise

301	G-CSF	_	_	B-Claim
302	did	_	_	I-Claim
303	not	_	_	I-Claim
304	prevent	_	_	I-Claim
305	serious	_	_	I-Claim
306	infections	_	_	I-Claim
307	.	_	_	I-Claim


0	In	_	_	B-Premise
1	a	_	_	I-Premise
2	multinational	_	_	I-Premise
3	trial	_	_	I-Premise
4	of	_	_	I-Premise
5	anaemic	_	_	I-Premise
6	patients	_	_	I-Premise
7	with	_	_	I-Premise
8	cancer	_	_	I-Premise
9	receiving	_	_	I-Premise
10	nonplatinum-containing	_	_	I-Premise
11	chemotherapy	_	_	I-Premise
12	,	_	_	I-Premise
13	epoetin-alfa	_	_	I-Premise
14	effectively	_	_	I-Premise
15	increased	_	_	I-Premise
16	haemoglobin	_	_	I-Premise
17	levels	_	_	I-Premise
18	,	_	_	I-Premise
19	reduced	_	_	I-Premise
20	red	_	_	I-Premise
21	blood	_	_	I-Premise
22	cell	_	_	I-Premise
23	transfusion	_	_	I-Premise
24	requirements	_	_	I-Premise
25	,	_	_	I-Premise
26	and	_	_	I-Premise
27	improved	_	_	I-Premise
28	QOL	_	_	I-Premise
29	.	_	_	I-Premise

30	Although	_	_	O
31	the	_	_	O
32	study	_	_	O
33	was	_	_	O
34	not	_	_	O
35	designed	_	_	O
36	or	_	_	O
37	powered	_	_	O
38	to	_	_	O
39	evaluate	_	_	O
40	survival	_	_	O
41	,	_	_	O
42	a	_	_	B-Premise
43	survival	_	_	I-Premise
44	trend	_	_	I-Premise
45	was	_	_	I-Premise
46	noted	_	_	I-Premise
47	favouring	_	_	I-Premise
48	epoetin-alfa	_	_	I-Premise
49	compared	_	_	I-Premise
50	with	_	_	I-Premise
51	placebo	_	_	I-Premise
52	(	_	_	I-Premise
53	median	_	_	I-Premise
54	survival	_	_	I-Premise
55	17	_	_	I-Premise
56	vs	_	_	I-Premise
57	11	_	_	I-Premise
58	months	_	_	I-Premise
59	[	_	_	I-Premise
60	p	_	_	I-Premise
61	=	_	_	I-Premise
62	0.126	_	_	I-Premise
63	]	_	_	I-Premise
64	)	_	_	I-Premise
65	.	_	_	I-Premise

66	To	_	_	O
67	determine	_	_	O
68	the	_	_	O
69	incremental	_	_	O
70	cost	_	_	O
71	utility	_	_	O
72	of	_	_	O
73	epoetin-alfa	_	_	O
74	versus	_	_	O
75	placebo	_	_	O
76	in	_	_	O
77	anaemic	_	_	O
78	patients	_	_	O
79	with	_	_	O
80	stage	_	_	O
81	IV	_	_	O
82	breast	_	_	O
83	cancer	_	_	O
84	from	_	_	O
85	a	_	_	O
86	UK	_	_	O
87	National	_	_	O
88	Health	_	_	O
89	Service	_	_	O
90	perspective	_	_	O
91	.	_	_	O

92	Patient	_	_	O
93	data	_	_	O
94	regarding	_	_	O
95	transfusions	_	_	O
96	,	_	_	O
97	epoetin-alfa	_	_	O
98	usage	_	_	O
99	,	_	_	O
100	chemotherapy	_	_	O
101	treatment	_	_	O
102	cycles	_	_	O
103	,	_	_	O
104	and	_	_	O
105	adverse	_	_	O
106	events	_	_	O
107	were	_	_	O
108	recorded	_	_	O
109	,	_	_	O
110	with	_	_	O
111	survival	_	_	O
112	follow-up	_	_	O
113	for	_	_	O
114	12-36	_	_	O
115	months	_	_	O
116	post-study	_	_	O
117	.	_	_	O

118	Stage	_	_	O
119	IV	_	_	O
120	breast	_	_	O
121	cancer	_	_	O
122	therapy	_	_	O
123	costs	_	_	O
124	were	_	_	O
125	collected	_	_	O
126	by	_	_	O
127	surveying	_	_	O
128	UK	_	_	O
129	oncologists	_	_	O
130	,	_	_	O
131	and	_	_	O
132	utilities	_	_	O
133	for	_	_	O
134	associated	_	_	O
135	health	_	_	O
136	states	_	_	O
137	were	_	_	O
138	from	_	_	O
139	published	_	_	O
140	sources	_	_	O
141	.	_	_	O

142	Costs	_	_	O
143	were	_	_	O
144	in	_	_	O
145	British	_	_	O
146	pounds	_	_	O
147	and	_	_	O
148	year	_	_	O
149	2000	_	_	O
150	values	_	_	O
151	.	_	_	O

152	Costs	_	_	O
153	and	_	_	O
154	benefits	_	_	O
155	were	_	_	O
156	jointly	_	_	O
157	determined	_	_	O
158	for	_	_	O
159	the	_	_	O
160	stage	_	_	O
161	IV	_	_	O
162	breast	_	_	O
163	cancer	_	_	O
164	subgroup	_	_	O
165	(	_	_	O
166	n	_	_	O
167	=	_	_	O
168	55	_	_	O
169	)	_	_	O
170	.	_	_	O

171	Incremental	_	_	O
172	cost-utility	_	_	O
173	ratios	_	_	O
174	(	_	_	O
175	ICURs	_	_	O
176	)	_	_	O
177	were	_	_	O
178	calculated	_	_	O
179	assuming	_	_	O
180	a	_	_	O
181	6	_	_	O
182	%	_	_	O
183	annual	_	_	O
184	discount	_	_	O
185	rate	_	_	O
186	for	_	_	O
187	costs	_	_	O
188	and	_	_	O
189	a	_	_	O
190	1.5	_	_	O
191	%	_	_	O
192	annual	_	_	O
193	discount	_	_	O
194	rate	_	_	O
195	for	_	_	O
196	benefits	_	_	O
197	.	_	_	O

198	Bootstrap	_	_	O
199	simulations	_	_	O
200	(	_	_	O
201	10,000	_	_	O
202	iterations	_	_	O
203	)	_	_	O
204	were	_	_	O
205	conducted	_	_	O
206	to	_	_	O
207	account	_	_	O
208	for	_	_	O
209	uncertainty	_	_	O
210	,	_	_	O
211	and	_	_	O
212	sensitivity	_	_	O
213	analyses	_	_	O
214	were	_	_	O
215	conducted	_	_	O
216	to	_	_	O
217	establish	_	_	O
218	robustness	_	_	O
219	.	_	_	O

220	The	_	_	B-Premise
221	ICUR	_	_	I-Premise
222	for	_	_	I-Premise
223	epoetin-alfa	_	_	I-Premise
224	treatment	_	_	I-Premise
225	was	_	_	I-Premise
226	pounds	_	_	I-Premise
227	8,851	_	_	I-Premise
228	per	_	_	I-Premise
229	QALY	_	_	I-Premise
230	,	_	_	I-Premise
231	with	_	_	I-Premise
232	a	_	_	I-Premise
233	99	_	_	I-Premise
234	%	_	_	I-Premise
235	probability	_	_	I-Premise
236	of	_	_	I-Premise
237	a	_	_	I-Premise
238	positive	_	_	I-Premise
239	net	_	_	I-Premise
240	benefit	_	_	I-Premise
241	in	_	_	I-Premise
242	QALYs	_	_	I-Premise
243	(	_	_	I-Premise
244	net	_	_	I-Premise
245	benefit	_	_	I-Premise
246	=	_	_	I-Premise
247	0.4805	_	_	I-Premise
248	years	_	_	I-Premise
249	of	_	_	I-Premise
250	perfect	_	_	I-Premise
251	life	_	_	I-Premise
252	)	_	_	I-Premise
253	and	_	_	I-Premise
254	a	_	_	I-Premise
255	94	_	_	I-Premise
256	%	_	_	I-Premise
257	probability	_	_	I-Premise
258	of	_	_	I-Premise
259	being	_	_	I-Premise
260	acceptable	_	_	I-Premise
261	using	_	_	I-Premise
262	a	_	_	I-Premise
263	threshold	_	_	I-Premise
264	ICUR	_	_	I-Premise
265	of	_	_	I-Premise
266	pounds	_	_	I-Premise
267	30,000/QALY	_	_	I-Premise
268	.	_	_	I-Premise

269	The	_	_	B-Premise
270	main	_	_	I-Premise
271	cost	_	_	I-Premise
272	drivers	_	_	I-Premise
273	distinguishing	_	_	I-Premise
274	epoetin-alfa	_	_	I-Premise
275	from	_	_	I-Premise
276	placebo	_	_	I-Premise
277	were	_	_	I-Premise
278	the	_	_	I-Premise
279	costs	_	_	I-Premise
280	of	_	_	I-Premise
281	drug	_	_	I-Premise
282	and	_	_	I-Premise
283	patient	_	_	I-Premise
284	care	_	_	I-Premise
285	due	_	_	I-Premise
286	to	_	_	I-Premise
287	increased	_	_	I-Premise
288	survival	_	_	I-Premise
289	.	_	_	I-Premise

290	The	_	_	B-Claim
291	available	_	_	I-Claim
292	data	_	_	I-Claim
293	suggest	_	_	I-Claim
294	a	_	_	I-Claim
295	high	_	_	I-Claim
296	probability	_	_	I-Claim
297	of	_	_	I-Claim
298	favourable	_	_	I-Claim
299	cost-utility	_	_	I-Claim
300	outcomes	_	_	I-Claim
301	with	_	_	I-Claim
302	epoetin-alfa	_	_	I-Claim
303	treatment	_	_	I-Claim
304	for	_	_	I-Claim
305	anaemia	_	_	I-Claim
306	in	_	_	I-Claim
307	patients	_	_	I-Claim
308	with	_	_	I-Claim
309	stage	_	_	I-Claim
310	IV	_	_	I-Claim
311	breast	_	_	I-Claim
312	cancer	_	_	I-Claim
313	receiving	_	_	I-Claim
314	nonplatinum-containing	_	_	I-Claim
315	chemotherapy	_	_	I-Claim
316	.	_	_	I-Claim

317	Additional	_	_	B-Claim
318	studies	_	_	I-Claim
319	are	_	_	I-Claim
320	warranted	_	_	I-Claim
321	.	_	_	I-Claim


0	In	_	_	B-Claim
1	advanced	_	_	I-Claim
2	not	_	_	I-Claim
3	selected	_	_	I-Claim
4	NSCLC	_	_	I-Claim
5	chemotherapy	_	_	I-Claim
6	achieved	_	_	I-Claim
7	an	_	_	I-Claim
8	advantage	_	_	I-Claim
9	of	_	_	I-Claim
10	approximately	_	_	I-Claim
11	1-2	_	_	I-Claim
12	months	_	_	I-Claim
13	on	_	_	I-Claim
14	median	_	_	I-Claim
15	survival	_	_	I-Claim
16	versus	_	_	I-Claim
17	best	_	_	I-Claim
18	supportive	_	_	I-Claim
19	care	_	_	I-Claim
20	.	_	_	I-Claim

21	Chemotherapy	_	_	B-Claim
22	seems	_	_	I-Claim
23	to	_	_	I-Claim
24	improve	_	_	I-Claim
25	symptoms	_	_	I-Claim
26	control	_	_	I-Claim
27	,	_	_	I-Claim
28	even	_	_	O
29	if	_	_	O
30	randomised	_	_	O
31	studies	_	_	O
32	with	_	_	O
33	quality	_	_	O
34	of	_	_	O
35	life	_	_	O
36	as	_	_	O
37	first	_	_	O
38	endpoint	_	_	O
39	are	_	_	O
40	lacking	_	_	O
41	and	_	_	O
42	often	_	_	O
43	chemotherapy	_	_	O
44	toxicity	_	_	O
45	compromises	_	_	O
46	the	_	_	O
47	frail	_	_	O
48	cost/benefit	_	_	O
49	ratio	_	_	O
50	.	_	_	O

51	The	_	_	O
52	aim	_	_	O
53	of	_	_	O
54	the	_	_	O
55	present	_	_	O
56	study	_	_	O
57	is	_	_	O
58	to	_	_	O
59	evaluate	_	_	O
60	the	_	_	O
61	impact	_	_	O
62	on	_	_	O
63	QoL	_	_	O
64	,	_	_	O
65	substituting	_	_	O
66	cisplatin	_	_	O
67	,	_	_	O
68	a	_	_	O
69	pivot	_	_	O
70	drug	_	_	O
71	in	_	_	O
72	NSCLC	_	_	O
73	therapy	_	_	O
74	,	_	_	O
75	with	_	_	O
76	carboplatin	_	_	O
77	,	_	_	O
78	an	_	_	O
79	analogue	_	_	O
80	with	_	_	O
81	an	_	_	O
82	improved	_	_	O
83	toxicity	_	_	O
84	profile	_	_	O
85	.	_	_	O

86	The	_	_	O
87	combination	_	_	O
88	of	_	_	O
89	cisplatin	_	_	O
90	with	_	_	O
91	Mitomycin	_	_	O
92	and	_	_	O
93	Vinblastine	_	_	O
94	was	_	_	O
95	one	_	_	O
96	of	_	_	O
97	the	_	_	O
98	most	_	_	O
99	frequently	_	_	O
100	used	_	_	O
101	in	_	_	O
102	the	_	_	O
103	palliative	_	_	O
104	setting	_	_	O
105	at	_	_	O
106	the	_	_	O
107	time	_	_	O
108	of	_	_	O
109	design	_	_	O
110	of	_	_	O
111	our	_	_	O
112	study	_	_	O
113	.	_	_	O

114	Patients	_	_	O
115	were	_	_	O
116	randomized	_	_	O
117	to	_	_	O
118	receive	_	_	O
119	MVP	_	_	O
120	regimen	_	_	O
121	(	_	_	O
122	Mitomycin-C	_	_	O
123	8	_	_	O
124	mg/m2	_	_	O
125	d1	_	_	O
126	,	_	_	O
127	Vinblastine	_	_	O
128	4	_	_	O
129	mg/m2	_	_	O
130	d	_	_	O
131	1-8	_	_	O
132	,	_	_	O
133	Cisplatin	_	_	O
134	100	_	_	O
135	mg/m2	_	_	O
136	d1	_	_	O
137	)	_	_	O
138	or	_	_	O
139	MVC	_	_	O
140	regimen	_	_	O
141	(	_	_	O
142	Mitomycin-C	_	_	O
143	8	_	_	O
144	mg/m2	_	_	O
145	d1	_	_	O
146	,	_	_	O
147	Vinblastine	_	_	O
148	4	_	_	O
149	mg/m2	_	_	O
150	d	_	_	O
151	1-8	_	_	O
152	,	_	_	O
153	Carboplatin	_	_	O
154	300	_	_	O
155	mg/m2	_	_	O
156	d1	_	_	O
157	)	_	_	O
158	every	_	_	O
159	3	_	_	O
160	weeks	_	_	O
161	.	_	_	O

162	The	_	_	O
163	QoL	_	_	O
164	was	_	_	O
165	evaluated	_	_	O
166	by	_	_	O
167	the	_	_	O
168	Spitzer	_	_	O
169	QL-Index	_	_	O
170	and	_	_	O
171	by	_	_	O
172	the	_	_	O
173	EORTC	_	_	O
174	QLQ-C30+LC	_	_	O
175	13	_	_	O
176	questionnaires	_	_	O
177	before	_	_	O
178	chemotherapy	_	_	O
179	,	_	_	O
180	after	_	_	O
181	one	_	_	O
182	cycle	_	_	O
183	,	_	_	O
184	after	_	_	O
185	three	_	_	O
186	cycles	_	_	O
187	,	_	_	O
188	and	_	_	O
189	then	_	_	O
190	every	_	_	O
191	6	_	_	O
192	weeks	_	_	O
193	in	_	_	O
194	the	_	_	O
195	first	_	_	O
196	6	_	_	O
197	months	_	_	O
198	and	_	_	O
199	every	_	_	O
200	3	_	_	O
201	months	_	_	O
202	thenafter	_	_	O
203	.	_	_	O

204	From	_	_	O
205	September	_	_	O
206	1994	_	_	O
207	to	_	_	O
208	July	_	_	O
209	1997	_	_	O
210	,	_	_	O
211	153	_	_	O
212	consecutive	_	_	O
213	patients	_	_	O
214	were	_	_	O
215	randomized	_	_	O
216	to	_	_	O
217	MVP	_	_	O
218	(	_	_	O
219	75	_	_	O
220	patients	_	_	O
221	)	_	_	O
222	or	_	_	O
223	MVC	_	_	O
224	arm	_	_	O
225	(	_	_	O
226	78	_	_	O
227	patients	_	_	O
228	)	_	_	O
229	.	_	_	O

230	Despite	_	_	B-Premise
231	difficulties	_	_	I-Premise
232	in	_	_	I-Premise
233	carrying	_	_	I-Premise
234	out	_	_	I-Premise
235	and	_	_	I-Premise
236	analysing	_	_	I-Premise
237	QoL	_	_	I-Premise
238	items	_	_	I-Premise
239	in	_	_	I-Premise
240	such	_	_	I-Premise
241	patients	_	_	I-Premise
242	,	_	_	I-Premise
243	the	_	_	I-Premise
244	global	_	_	I-Premise
245	QoL	_	_	I-Premise
246	evaluated	_	_	I-Premise
247	by	_	_	I-Premise
248	the	_	_	I-Premise
249	Spitzer	_	_	I-Premise
250	's	_	_	I-Premise
251	questionnaire	_	_	I-Premise
252	suggested	_	_	I-Premise
253	an	_	_	I-Premise
254	advantage	_	_	I-Premise
255	for	_	_	I-Premise
256	MVC	_	_	I-Premise
257	regimen	_	_	I-Premise
258	(	_	_	I-Premise
259	P=0.05	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	a	_	_	I-Premise
263	significant	_	_	I-Premise
264	difference	_	_	I-Premise
265	was	_	_	I-Premise
266	observed	_	_	I-Premise
267	in	_	_	I-Premise
268	global	_	_	I-Premise
269	health	_	_	I-Premise
270	subdomain	_	_	I-Premise
271	(	_	_	I-Premise
272	P=0.04	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	The	_	_	B-Premise
276	disease-related	_	_	I-Premise
277	symptoms	_	_	I-Premise
278	improved	_	_	I-Premise
279	with	_	_	I-Premise
280	time	_	_	I-Premise
281	,	_	_	I-Premise
282	and	_	_	O
283	the	_	_	B-Premise
284	benefits	_	_	I-Premise
285	lasted	_	_	I-Premise
286	for	_	_	I-Premise
287	the	_	_	I-Premise
288	entire	_	_	I-Premise
289	treatment	_	_	I-Premise
290	period	_	_	I-Premise
291	.	_	_	I-Premise

292	When	_	_	B-Premise
293	evaluated	_	_	I-Premise
294	with	_	_	I-Premise
295	the	_	_	I-Premise
296	EORTC	_	_	I-Premise
297	questionnaire	_	_	I-Premise
298	there	_	_	I-Premise
299	was	_	_	I-Premise
300	significantly	_	_	I-Premise
301	less	_	_	I-Premise
302	nausea	_	_	I-Premise
303	and	_	_	I-Premise
304	vomiting	_	_	I-Premise
305	(	_	_	I-Premise
306	P=0.0001	_	_	I-Premise
307	)	_	_	I-Premise
308	,	_	_	I-Premise
309	appetite	_	_	I-Premise
310	loss	_	_	I-Premise
311	(	_	_	I-Premise
312	P=0.01	_	_	I-Premise
313	)	_	_	I-Premise
314	,	_	_	I-Premise
315	insomnia	_	_	I-Premise
316	(	_	_	I-Premise
317	P=0.03	_	_	I-Premise
318	)	_	_	I-Premise
319	,	_	_	I-Premise
320	constipation	_	_	I-Premise
321	(	_	_	I-Premise
322	P=0.01	_	_	I-Premise
323	)	_	_	I-Premise
324	and	_	_	I-Premise
325	peripheral	_	_	I-Premise
326	neuropathy	_	_	I-Premise
327	(	_	_	I-Premise
328	P=0.01	_	_	I-Premise
329	)	_	_	I-Premise
330	in	_	_	I-Premise
331	favour	_	_	I-Premise
332	of	_	_	I-Premise
333	MVC	_	_	I-Premise
334	,	_	_	I-Premise
335	and	_	_	I-Premise
336	a	_	_	I-Premise
337	trend	_	_	I-Premise
338	for	_	_	I-Premise
339	less	_	_	I-Premise
340	hair	_	_	I-Premise
341	loss	_	_	I-Premise
342	(	_	_	I-Premise
343	P=0.05	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	The	_	_	B-Premise
347	advantage	_	_	I-Premise
348	lasted	_	_	I-Premise
349	for	_	_	I-Premise
350	all	_	_	I-Premise
351	the	_	_	I-Premise
352	duration	_	_	I-Premise
353	of	_	_	I-Premise
354	chemotherapy	_	_	I-Premise
355	.	_	_	I-Premise

356	No	_	_	B-Premise
357	differences	_	_	I-Premise
358	were	_	_	I-Premise
359	observed	_	_	I-Premise
360	in	_	_	I-Premise
361	global	_	_	I-Premise
362	quality	_	_	I-Premise
363	of	_	_	I-Premise
364	life	_	_	I-Premise
365	subdomain	_	_	I-Premise
366	(	_	_	I-Premise
367	P=0.40	_	_	I-Premise
368	)	_	_	I-Premise
369	between	_	_	I-Premise
370	the	_	_	I-Premise
371	two	_	_	I-Premise
372	regimen	_	_	I-Premise
373	.	_	_	I-Premise

374	QoL	_	_	O
375	was	_	_	O
376	the	_	_	O
377	first	_	_	O
378	endpoint	_	_	O
379	and	_	_	O
380	the	_	_	O
381	statistical	_	_	O
382	power	_	_	O
383	was	_	_	O
384	inadequate	_	_	O
385	to	_	_	O
386	assess	_	_	O
387	other	_	_	O
388	parameters	_	_	O
389	.	_	_	O

390	However	_	_	O
391	,	_	_	O
392	we	_	_	B-Premise
393	reported	_	_	I-Premise
394	a	_	_	I-Premise
395	response	_	_	I-Premise
396	rate	_	_	I-Premise
397	of	_	_	I-Premise
398	43.1	_	_	I-Premise
399	and	_	_	I-Premise
400	38.6	_	_	I-Premise
401	%	_	_	I-Premise
402	,	_	_	I-Premise
403	respectively	_	_	I-Premise
404	,	_	_	I-Premise
405	in	_	_	I-Premise
406	MVP	_	_	I-Premise
407	and	_	_	I-Premise
408	MVC	_	_	I-Premise
409	arm	_	_	I-Premise
410	(	_	_	I-Premise
411	P=0.59	_	_	I-Premise
412	)	_	_	I-Premise
413	and	_	_	I-Premise
414	a	_	_	I-Premise
415	median	_	_	I-Premise
416	survival	_	_	I-Premise
417	of	_	_	I-Premise
418	10.2	_	_	I-Premise
419	and	_	_	I-Premise
420	7.2	_	_	I-Premise
421	months	_	_	I-Premise
422	,	_	_	I-Premise
423	respectively	_	_	I-Premise
424	,	_	_	I-Premise
425	for	_	_	I-Premise
426	cisplatin	_	_	I-Premise
427	and	_	_	I-Premise
428	carboplatin	_	_	I-Premise
429	arm	_	_	I-Premise
430	(	_	_	I-Premise
431	P=0.39	_	_	I-Premise
432	)	_	_	I-Premise
433	.	_	_	I-Premise

434	The	_	_	B-Premise
435	carboplatin	_	_	I-Premise
436	containing	_	_	I-Premise
437	regimen	_	_	I-Premise
438	(	_	_	I-Premise
439	MVC	_	_	I-Premise
440	)	_	_	I-Premise
441	has	_	_	I-Premise
442	a	_	_	I-Premise
443	significant	_	_	I-Premise
444	better	_	_	I-Premise
445	toxicity	_	_	I-Premise
446	profile	_	_	I-Premise
447	than	_	_	I-Premise
448	the	_	_	I-Premise
449	cisplatin	_	_	I-Premise
450	containing	_	_	I-Premise
451	(	_	_	I-Premise
452	MVP	_	_	I-Premise
453	)	_	_	I-Premise
454	regimen	_	_	I-Premise
455	as	_	_	I-Premise
456	proven	_	_	I-Premise
457	both	_	_	I-Premise
458	by	_	_	I-Premise
459	the	_	_	I-Premise
460	EORTC	_	_	I-Premise
461	questionnaires	_	_	I-Premise
462	and	_	_	I-Premise
463	by	_	_	I-Premise
464	the	_	_	I-Premise
465	WHO	_	_	I-Premise
466	toxicity	_	_	I-Premise
467	data	_	_	I-Premise
468	reported	_	_	I-Premise
469	by	_	_	I-Premise
470	physicians	_	_	I-Premise
471	.	_	_	I-Premise

472	No	_	_	B-Claim
473	significant	_	_	I-Claim
474	differences	_	_	I-Claim
475	in	_	_	I-Claim
476	terms	_	_	I-Claim
477	of	_	_	I-Claim
478	response	_	_	I-Claim
479	rate	_	_	I-Claim
480	,	_	_	I-Claim
481	time	_	_	I-Claim
482	to	_	_	I-Claim
483	progression	_	_	I-Claim
484	and	_	_	I-Claim
485	overall	_	_	I-Claim
486	survival	_	_	I-Claim
487	were	_	_	I-Claim
488	observed	_	_	I-Claim
489	between	_	_	I-Claim
490	the	_	_	I-Claim
491	two	_	_	I-Claim
492	regimen	_	_	I-Claim
493	.	_	_	I-Claim

494	The	_	_	B-Claim
495	two	_	_	I-Claim
496	chemotherapy	_	_	I-Claim
497	regimen	_	_	I-Claim
498	showed	_	_	I-Claim
499	a	_	_	I-Claim
500	similar	_	_	I-Claim
501	effectiveness	_	_	I-Claim
502	in	_	_	I-Claim
503	symptom	_	_	I-Claim
504	palliation	_	_	I-Claim
505	when	_	_	I-Claim
506	evaluated	_	_	I-Claim
507	with	_	_	I-Claim
508	C30	_	_	I-Claim
509	addendum	_	_	I-Claim
510	of	_	_	I-Claim
511	EORTC	_	_	I-Claim
512	QOL	_	_	I-Claim
513	questionnaire	_	_	I-Claim
514	.	_	_	I-Claim

515	With	_	_	B-Premise
516	the	_	_	I-Premise
517	Spitzer	_	_	I-Premise
518	's	_	_	I-Premise
519	questionnaires	_	_	I-Premise
520	a	_	_	I-Premise
521	trend	_	_	I-Premise
522	towards	_	_	I-Premise
523	an	_	_	I-Premise
524	improved	_	_	I-Premise
525	quality	_	_	I-Premise
526	of	_	_	I-Premise
527	life	_	_	I-Premise
528	index	_	_	I-Premise
529	was	_	_	I-Premise
530	observed	_	_	I-Premise
531	during	_	_	I-Premise
532	treatment	_	_	I-Premise
533	with	_	_	I-Premise
534	the	_	_	I-Premise
535	carboplatin	_	_	I-Premise
536	combination	_	_	I-Premise
537	in	_	_	I-Premise
538	comparison	_	_	I-Premise
539	to	_	_	I-Premise
540	the	_	_	I-Premise
541	cisplatin	_	_	I-Premise
542	combination	_	_	I-Premise
543	.	_	_	I-Premise

544	This	_	_	B-Premise
545	difference	_	_	I-Premise
546	,	_	_	I-Premise
547	however	_	_	I-Premise
548	,	_	_	I-Premise
549	was	_	_	I-Premise
550	not	_	_	I-Premise
551	observed	_	_	I-Premise
552	when	_	_	I-Premise
553	the	_	_	I-Premise
554	global	_	_	I-Premise
555	quality	_	_	I-Premise
556	of	_	_	I-Premise
557	life	_	_	I-Premise
558	was	_	_	I-Premise
559	evaluated	_	_	I-Premise
560	with	_	_	I-Premise
561	the	_	_	I-Premise
562	EORTC	_	_	I-Premise
563	patients	_	_	I-Premise
564	compiled	_	_	I-Premise
565	questionnaires	_	_	I-Premise
566	.	_	_	I-Premise

567	A	_	_	B-Claim
568	carboplatin	_	_	I-Claim
569	containing	_	_	I-Claim
570	regimen	_	_	I-Claim
571	with	_	_	I-Claim
572	better	_	_	I-Claim
573	toxicity	_	_	I-Claim
574	profile	_	_	I-Claim
575	and	_	_	I-Claim
576	a	_	_	I-Claim
577	similar	_	_	I-Claim
578	potentiality	_	_	I-Claim
579	for	_	_	I-Claim
580	symptoms	_	_	I-Claim
581	control	_	_	I-Claim
582	offers	_	_	I-Claim
583	an	_	_	I-Claim
584	option	_	_	I-Claim
585	in	_	_	I-Claim
586	comparison	_	_	I-Claim
587	to	_	_	I-Claim
588	similar	_	_	I-Claim
589	cisplatin	_	_	I-Claim
590	containing	_	_	I-Claim
591	combinations	_	_	I-Claim
592	in	_	_	I-Claim
593	the	_	_	I-Claim
594	palliative	_	_	I-Claim
595	treatment	_	_	I-Claim
596	of	_	_	I-Claim
597	advanced	_	_	I-Claim
598	NSCLC	_	_	I-Claim
599	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	intraocular	_	_	O
6	pressure	_	_	O
7	(	_	_	O
8	IOP	_	_	O
9	)	_	_	O
10	control	_	_	O
11	of	_	_	O
12	the	_	_	O
13	Baerveldt-350	_	_	O
14	implant	_	_	O
15	with	_	_	O
16	tube	_	_	O
17	ligature	_	_	O
18	and	_	_	O
19	the	_	_	O
20	Ahmed	_	_	O
21	valve	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	refractory	_	_	O
26	glaucoma	_	_	O
27	.	_	_	O

28	Four	_	_	O
29	hundred	_	_	O
30	seventy	_	_	O
31	glaucoma	_	_	O
32	drainage	_	_	O
33	device	_	_	O
34	procedures	_	_	O
35	from	_	_	O
36	July	_	_	O
37	1995	_	_	O
38	to	_	_	O
39	July	_	_	O
40	2001	_	_	O
41	(	_	_	O
42	6	_	_	O
43	years	_	_	O
44	)	_	_	O
45	were	_	_	O
46	reviewed	_	_	O
47	retrospectively	_	_	O
48	.	_	_	O

49	Thirty-two	_	_	O
50	cases	_	_	O
51	of	_	_	O
52	Baerveldt-350	_	_	O
53	implantation	_	_	O
54	performed	_	_	O
55	in	_	_	O
56	patients	_	_	O
57	with	_	_	O
58	glaucoma	_	_	O
59	refractory	_	_	O
60	to	_	_	O
61	medical	_	_	O
62	treatment	_	_	O
63	and	_	_	O
64	filtering	_	_	O
65	procedures	_	_	O
66	,	_	_	O
67	without	_	_	O
68	previous	_	_	O
69	drainage	_	_	O
70	device	_	_	O
71	or	_	_	O
72	cyclodestructive	_	_	O
73	procedures	_	_	O
74	,	_	_	O
75	and	_	_	O
76	with	_	_	O
77	a	_	_	O
78	minimum	_	_	O
79	of	_	_	O
80	1-year	_	_	O
81	follow-up	_	_	O
82	were	_	_	O
83	identified	_	_	O
84	.	_	_	O

85	Thirty-two	_	_	O
86	cases	_	_	O
87	of	_	_	O
88	Ahmed	_	_	O
89	valve	_	_	O
90	implantation	_	_	O
91	were	_	_	O
92	matched	_	_	O
93	case	_	_	O
94	by	_	_	O
95	case	_	_	O
96	with	_	_	O
97	32	_	_	O
98	Baerveldt-350	_	_	O
99	cases	_	_	O
100	for	_	_	O
101	age	_	_	O
102	,	_	_	O
103	race	_	_	O
104	,	_	_	O
105	gender	_	_	O
106	,	_	_	O
107	glaucoma	_	_	O
108	subtype	_	_	O
109	,	_	_	O
110	previous	_	_	O
111	ocular	_	_	O
112	history	_	_	O
113	,	_	_	O
114	preoperative	_	_	O
115	IOP	_	_	O
116	,	_	_	O
117	and	_	_	O
118	surgeon	_	_	O
119	who	_	_	O
120	performed	_	_	O
121	the	_	_	O
122	implantation	_	_	O
123	.	_	_	O

124	The	_	_	O
125	two	_	_	O
126	groups	_	_	O
127	were	_	_	O
128	compared	_	_	O
129	for	_	_	O
130	IOP	_	_	O
131	control	_	_	O
132	,	_	_	O
133	visual	_	_	O
134	outcome	_	_	O
135	,	_	_	O
136	complication	_	_	O
137	rate	_	_	O
138	,	_	_	O
139	and	_	_	O
140	surgical	_	_	O
141	success	_	_	O
142	rate	_	_	O
143	.	_	_	O

144	Surgical	_	_	B-Premise
145	success	_	_	I-Premise
146	rate	_	_	I-Premise
147	was	_	_	I-Premise
148	defined	_	_	I-Premise
149	as	_	_	I-Premise
150	an	_	_	I-Premise
151	IOP	_	_	I-Premise
152	reduction	_	_	I-Premise
153	greater	_	_	I-Premise
154	than	_	_	I-Premise
155	or	_	_	I-Premise
156	equal	_	_	I-Premise
157	to	_	_	I-Premise
158	30	_	_	I-Premise
159	%	_	_	I-Premise
160	and	_	_	I-Premise
161	final	_	_	I-Premise
162	IOP	_	_	I-Premise
163	more	_	_	I-Premise
164	than	_	_	I-Premise
165	5	_	_	I-Premise
166	mm	_	_	I-Premise
167	Hg	_	_	I-Premise
168	and	_	_	I-Premise
169	less	_	_	I-Premise
170	than	_	_	I-Premise
171	22	_	_	I-Premise
172	mm	_	_	I-Premise
173	Hg	_	_	I-Premise
174	,	_	_	I-Premise
175	without	_	_	I-Premise
176	devastating	_	_	I-Premise
177	complications	_	_	I-Premise
178	.	_	_	I-Premise

179	Over	_	_	B-Premise
180	a	_	_	I-Premise
181	follow-up	_	_	I-Premise
182	period	_	_	I-Premise
183	of	_	_	I-Premise
184	1	_	_	I-Premise
185	year	_	_	I-Premise
186	,	_	_	I-Premise
187	no	_	_	I-Premise
188	statistically	_	_	I-Premise
189	significant	_	_	I-Premise
190	differences	_	_	I-Premise
191	were	_	_	I-Premise
192	detected	_	_	I-Premise
193	between	_	_	I-Premise
194	the	_	_	I-Premise
195	Baerveldt-350	_	_	I-Premise
196	implant	_	_	I-Premise
197	versus	_	_	I-Premise
198	Ahmed	_	_	I-Premise
199	valve	_	_	I-Premise
200	for	_	_	I-Premise
201	IOP	_	_	I-Premise
202	control	_	_	I-Premise
203	(	_	_	I-Premise
204	12.1	_	_	I-Premise
205	+/-	_	_	I-Premise
206	5.3	_	_	I-Premise
207	mm	_	_	I-Premise
208	Hg	_	_	I-Premise
209	vs	_	_	I-Premise
210	13.6	_	_	I-Premise
211	+/-	_	_	I-Premise
212	5.6	_	_	I-Premise
213	mm	_	_	I-Premise
214	Hg	_	_	I-Premise
215	respectively	_	_	I-Premise
216	,	_	_	I-Premise
217	at	_	_	I-Premise
218	a	_	_	I-Premise
219	power	_	_	I-Premise
220	of	_	_	I-Premise
221	90	_	_	I-Premise
222	%	_	_	I-Premise
223	to	_	_	I-Premise
224	detect	_	_	I-Premise
225	a	_	_	I-Premise
226	difference	_	_	I-Premise
227	of	_	_	I-Premise
228	3.2	_	_	I-Premise
229	mm	_	_	I-Premise
230	Hg	_	_	I-Premise
231	between	_	_	I-Premise
232	the	_	_	I-Premise
233	two	_	_	I-Premise
234	groups	_	_	I-Premise
235	and	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	0.05	_	_	I-Premise
239	)	_	_	I-Premise
240	,	_	_	I-Premise
241	surgical	_	_	I-Premise
242	success	_	_	I-Premise
243	rate	_	_	I-Premise
244	(	_	_	I-Premise
245	65.6	_	_	I-Premise
246	%	_	_	I-Premise
247	vs.	_	_	I-Premise
248	65.6	_	_	I-Premise
249	%	_	_	I-Premise
250	respectively	_	_	I-Premise
251	,	_	_	I-Premise
252	complete	_	_	I-Premise
253	and	_	_	I-Premise
254	qualified	_	_	I-Premise
255	combined	_	_	I-Premise
256	)	_	_	I-Premise
257	,	_	_	I-Premise
258	postoperative	_	_	I-Premise
259	hypotony	_	_	I-Premise
260	rate	_	_	I-Premise
261	(	_	_	I-Premise
262	37.5	_	_	I-Premise
263	%	_	_	I-Premise
264	vs.	_	_	I-Premise
265	34.4	_	_	I-Premise
266	%	_	_	I-Premise
267	respectively	_	_	I-Premise
268	)	_	_	I-Premise
269	,	_	_	I-Premise
270	and	_	_	I-Premise
271	visual	_	_	I-Premise
272	acuity	_	_	I-Premise
273	changes	_	_	I-Premise
274	of	_	_	I-Premise
275	more	_	_	I-Premise
276	than	_	_	I-Premise
277	1	_	_	I-Premise
278	line	_	_	I-Premise
279	in	_	_	I-Premise
280	Snellen	_	_	I-Premise
281	visual	_	_	I-Premise
282	acuity	_	_	I-Premise
283	(	_	_	I-Premise
284	43.3	_	_	I-Premise
285	%	_	_	I-Premise
286	vs.	_	_	I-Premise
287	29.0	_	_	I-Premise
288	%	_	_	I-Premise
289	respectively	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	In	_	_	B-Claim
293	a	_	_	I-Claim
294	case-controlled	_	_	I-Claim
295	comparison	_	_	I-Claim
296	,	_	_	I-Claim
297	the	_	_	I-Claim
298	Baerveldt-350	_	_	I-Claim
299	implant	_	_	I-Claim
300	and	_	_	I-Claim
301	the	_	_	I-Claim
302	Ahmed	_	_	I-Claim
303	valve	_	_	I-Claim
304	had	_	_	I-Claim
305	similar	_	_	I-Claim
306	IOP	_	_	I-Claim
307	control	_	_	I-Claim
308	and	_	_	I-Claim
309	surgical	_	_	I-Claim
310	outcomes	_	_	I-Claim
311	in	_	_	I-Claim
312	patients	_	_	I-Claim
313	with	_	_	I-Claim
314	refractory	_	_	I-Claim
315	glaucoma	_	_	I-Claim
316	at	_	_	I-Claim
317	1-year	_	_	I-Claim
318	follow-up	_	_	I-Claim
319	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	the	_	_	O
6	fixed	_	_	O
7	dorzolamide	_	_	O
8	2	_	_	O
9	%	_	_	O
10	/timolol	_	_	O
11	0.5	_	_	O
12	%	_	_	O
13	combination	_	_	O
14	(	_	_	O
15	COSOPT	_	_	O
16	)	_	_	O
17	versus	_	_	O
18	latanoprost	_	_	O
19	0.005	_	_	O
20	%	_	_	O
21	(	_	_	O
22	XALATAN	_	_	O
23	)	_	_	O
24	.	_	_	O

25	Two	_	_	O
26	3-month	_	_	O
27	,	_	_	O
28	parallel	_	_	O
29	group	_	_	O
30	,	_	_	O
31	randomized	_	_	O
32	,	_	_	O
33	observer-masked	_	_	O
34	and	_	_	O
35	patient-masked	_	_	O
36	,	_	_	O
37	multicentre	_	_	O
38	,	_	_	O
39	clinical	_	_	O
40	trials	_	_	O
41	were	_	_	O
42	performed	_	_	O
43	in	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	ocular	_	_	O
47	hypertension	_	_	O
48	or	_	_	O
49	open-angle	_	_	O
50	glaucoma	_	_	O
51	.	_	_	O

52	Study	_	_	O
53	1	_	_	O
54	(	_	_	O
55	n=256	_	_	O
56	)	_	_	O
57	was	_	_	O
58	conducted	_	_	O
59	in	_	_	O
60	the	_	_	O
61	United	_	_	O
62	States	_	_	O
63	and	_	_	O
64	Study	_	_	O
65	2	_	_	O
66	(	_	_	O
67	n=288	_	_	O
68	)	_	_	O
69	was	_	_	O
70	conducted	_	_	O
71	in	_	_	O
72	Europe/Israel	_	_	O
73	.	_	_	O

74	Patients	_	_	O
75	could	_	_	O
76	be	_	_	O
77	included	_	_	O
78	whether	_	_	O
79	or	_	_	O
80	not	_	_	O
81	they	_	_	O
82	were	_	_	O
83	currently	_	_	O
84	taking	_	_	O
85	ocular	_	_	O
86	hypotensive	_	_	O
87	therapy	_	_	O
88	,	_	_	O
89	and	_	_	O
90	regardless	_	_	O
91	of	_	_	O
92	the	_	_	O
93	effectiveness	_	_	O
94	of	_	_	O
95	any	_	_	O
96	previous	_	_	O
97	therapy	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	washed	_	_	O
102	out	_	_	O
103	from	_	_	O
104	their	_	_	O
105	usual	_	_	O
106	ocular	_	_	O
107	hypotensive	_	_	O
108	medications	_	_	O
109	and	_	_	O
110	then	_	_	O
111	those	_	_	O
112	with	_	_	O
113	a	_	_	O
114	baseline	_	_	O
115	intraocular	_	_	O
116	pressure	_	_	O
117	(	_	_	O
118	IOP	_	_	O
119	)	_	_	O
120	>	_	_	O
121	/=	_	_	O
122	24	_	_	O
123	mmHg	_	_	O
124	were	_	_	O
125	randomized	_	_	O
126	to	_	_	O
127	either	_	_	O
128	the	_	_	O
129	dorzolamide/timolol	_	_	O
130	combination	_	_	O
131	eye	_	_	O
132	drops	_	_	O
133	twice	_	_	O
134	daily	_	_	O
135	or	_	_	O
136	latanoprost	_	_	O
137	eye	_	_	O
138	drops	_	_	O
139	once	_	_	O
140	daily	_	_	O
141	in	_	_	O
142	both	_	_	O
143	eyes	_	_	O
144	.	_	_	O

145	Efficacy	_	_	O
146	was	_	_	O
147	assessed	_	_	O
148	by	_	_	O
149	daytime	_	_	O
150	diurnal	_	_	O
151	IOP	_	_	O
152	(	_	_	O
153	the	_	_	O
154	mean	_	_	O
155	of	_	_	O
156	measurements	_	_	O
157	made	_	_	O
158	at	_	_	O
159	0800	_	_	O
160	,	_	_	O
161	1000	_	_	O
162	,	_	_	O
163	1400	_	_	O
164	and	_	_	O
165	1600	_	_	O
166	h	_	_	O
167	)	_	_	O
168	.	_	_	O

169	At	_	_	B-Premise
170	baseline	_	_	I-Premise
171	,	_	_	I-Premise
172	the	_	_	I-Premise
173	mean	_	_	I-Premise
174	daytime	_	_	I-Premise
175	diurnal	_	_	I-Premise
176	IOP	_	_	I-Premise
177	was	_	_	I-Premise
178	26.1	_	_	I-Premise
179	mmHg	_	_	I-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	dorzolamide/timolol	_	_	I-Premise
183	combination	_	_	I-Premise
184	group	_	_	I-Premise
185	versus	_	_	I-Premise
186	25.6	_	_	I-Premise
187	mmHg	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	latanoprost	_	_	I-Premise
191	group	_	_	I-Premise
192	in	_	_	I-Premise
193	Study	_	_	I-Premise
194	1	_	_	I-Premise
195	,	_	_	I-Premise
196	and	_	_	I-Premise
197	25.3	_	_	I-Premise
198	mmHg	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	dorzolamide/timolol	_	_	I-Premise
202	combination	_	_	I-Premise
203	group	_	_	I-Premise
204	versus	_	_	I-Premise
205	24.7	_	_	I-Premise
206	mmHg	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	latanoprost	_	_	I-Premise
210	group	_	_	I-Premise
211	in	_	_	I-Premise
212	Study	_	_	I-Premise
213	2	_	_	I-Premise
214	.	_	_	I-Premise

215	After	_	_	B-Premise
216	3	_	_	I-Premise
217	months	_	_	I-Premise
218	,	_	_	I-Premise
219	the	_	_	I-Premise
220	mean	_	_	I-Premise
221	daytime	_	_	I-Premise
222	diurnal	_	_	I-Premise
223	IOP	_	_	I-Premise
224	was	_	_	I-Premise
225	18.9	_	_	I-Premise
226	mmHg	_	_	I-Premise
227	for	_	_	I-Premise
228	the	_	_	I-Premise
229	dorzolamide/timolol	_	_	I-Premise
230	combination	_	_	I-Premise
231	versus	_	_	I-Premise
232	18.4	_	_	I-Premise
233	mmHg	_	_	I-Premise
234	for	_	_	I-Premise
235	latanoprost	_	_	I-Premise
236	in	_	_	I-Premise
237	Study	_	_	I-Premise
238	1	_	_	I-Premise
239	,	_	_	I-Premise
240	and	_	_	I-Premise
241	17.4	_	_	I-Premise
242	mmHg	_	_	I-Premise
243	for	_	_	I-Premise
244	the	_	_	I-Premise
245	dorzolamide/timolol	_	_	I-Premise
246	combination	_	_	I-Premise
247	versus	_	_	I-Premise
248	17.5	_	_	I-Premise
249	for	_	_	I-Premise
250	latanoprost	_	_	I-Premise
251	in	_	_	I-Premise
252	Study	_	_	I-Premise
253	2	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Premise
256	difference	_	_	I-Premise
257	between	_	_	I-Premise
258	treatments	_	_	I-Premise
259	in	_	_	I-Premise
260	mean	_	_	I-Premise
261	IOP	_	_	I-Premise
262	change	_	_	I-Premise
263	at	_	_	I-Premise
264	3	_	_	I-Premise
265	months	_	_	I-Premise
266	was	_	_	I-Premise
267	-0.04	_	_	I-Premise
268	mmHg	_	_	I-Premise
269	[	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	confidence	_	_	I-Premise
273	interval	_	_	I-Premise
274	(	_	_	I-Premise
275	CI	_	_	I-Premise
276	)	_	_	I-Premise
277	-0.85	_	_	I-Premise
278	,	_	_	I-Premise
279	0.77	_	_	I-Premise
280	]	_	_	I-Premise
281	in	_	_	I-Premise
282	Study	_	_	I-Premise
283	1	_	_	I-Premise
284	,	_	_	I-Premise
285	and	_	_	I-Premise
286	-0.57	_	_	I-Premise
287	mmHg	_	_	I-Premise
288	(	_	_	I-Premise
289	95	_	_	I-Premise
290	%	_	_	I-Premise
291	CI	_	_	I-Premise
292	-1.31	_	_	I-Premise
293	,	_	_	I-Premise
294	0.16	_	_	I-Premise
295	)	_	_	I-Premise
296	in	_	_	I-Premise
297	Study	_	_	I-Premise
298	2	_	_	I-Premise
299	.	_	_	I-Premise

300	The	_	_	B-Premise
301	probability	_	_	I-Premise
302	that	_	_	I-Premise
303	the	_	_	I-Premise
304	true	_	_	I-Premise
305	difference	_	_	I-Premise
306	lay	_	_	I-Premise
307	between	_	_	I-Premise
308	-1.5	_	_	I-Premise
309	and	_	_	I-Premise
310	1.5	_	_	I-Premise
311	mmHg	_	_	I-Premise
312	,	_	_	I-Premise
313	the	_	_	I-Premise
314	predefined	_	_	I-Premise
315	bounds	_	_	I-Premise
316	for	_	_	I-Premise
317	equivalence	_	_	I-Premise
318	,	_	_	I-Premise
319	was	_	_	I-Premise
320	>	_	_	I-Premise
321	0.950	_	_	I-Premise
322	in	_	_	I-Premise
323	both	_	_	I-Premise
324	studies	_	_	I-Premise
325	.	_	_	I-Premise

326	Both	_	_	B-Claim
327	treatments	_	_	I-Claim
328	were	_	_	I-Claim
329	well	_	_	I-Claim
330	tolerated	_	_	I-Claim
331	over	_	_	I-Claim
332	3	_	_	I-Claim
333	months	_	_	I-Claim
334	,	_	_	I-Claim
335	although	_	_	B-Premise
336	ocular	_	_	I-Premise
337	stinging	_	_	I-Premise
338	occurred	_	_	I-Premise
339	more	_	_	I-Premise
340	frequently	_	_	I-Premise
341	with	_	_	I-Premise
342	the	_	_	I-Premise
343	dorzolamide/timolol	_	_	I-Premise
344	combination	_	_	I-Premise
345	.	_	_	I-Premise

346	The	_	_	B-Claim
347	dorzolamide/timolol	_	_	I-Claim
348	combination	_	_	I-Claim
349	and	_	_	I-Claim
350	latanoprost	_	_	I-Claim
351	were	_	_	I-Claim
352	equally	_	_	I-Claim
353	effective	_	_	I-Claim
354	at	_	_	I-Claim
355	lowering	_	_	I-Claim
356	IOP	_	_	I-Claim
357	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	hypofractionated	_	_	O
7	thoracic	_	_	O
8	radiotherapy	_	_	O
9	(	_	_	O
10	TRT	_	_	O
11	)	_	_	O
12	is	_	_	O
13	comparable	_	_	O
14	to	_	_	O
15	more	_	_	O
16	standard	_	_	O
17	fractionated	_	_	O
18	radiotherapy	_	_	O
19	(	_	_	O
20	RT	_	_	O
21	)	_	_	O
22	in	_	_	O
23	advanced	_	_	O
24	non-small-cell	_	_	O
25	lung	_	_	O
26	cancer	_	_	O
27	(	_	_	O
28	NSCLC	_	_	O
29	)	_	_	O
30	.	_	_	O

31	A	_	_	O
32	total	_	_	O
33	of	_	_	O
34	421	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	locally	_	_	O
38	advanced	_	_	O
39	stage	_	_	O
40	III	_	_	O
41	or	_	_	O
42	stage	_	_	O
43	IV	_	_	O
44	NSCLC	_	_	O
45	tumors	_	_	O
46	were	_	_	O
47	included	_	_	O
48	.	_	_	O

49	Inclusion	_	_	O
50	criteria	_	_	O
51	were	_	_	O
52	inoperable	_	_	O
53	,	_	_	O
54	disease	_	_	O
55	too	_	_	O
56	advanced	_	_	O
57	for	_	_	O
58	curative	_	_	O
59	radiotherapy	_	_	O
60	,	_	_	O
61	and	_	_	O
62	chest	_	_	O
63	symptoms	_	_	O
64	or	_	_	O
65	central	_	_	O
66	tumor	_	_	O
67	threatening	_	_	O
68	the	_	_	O
69	airways	_	_	O
70	.	_	_	O

71	Patients	_	_	O
72	were	_	_	O
73	randomly	_	_	O
74	assigned	_	_	O
75	to	_	_	O
76	three	_	_	O
77	arms	_	_	O
78	:	_	_	O
79	A	_	_	O
80	,	_	_	O
81	17	_	_	O
82	Gy	_	_	O
83	per	_	_	O
84	two	_	_	O
85	fractions	_	_	O
86	(	_	_	O
87	n	_	_	O
88	=	_	_	O
89	146	_	_	O
90	)	_	_	O
91	;	_	_	O
92	B	_	_	O
93	,	_	_	O
94	42	_	_	O
95	Gy	_	_	O
96	per	_	_	O
97	15	_	_	O
98	fractions	_	_	O
99	(	_	_	O
100	n	_	_	O
101	=	_	_	O
102	145	_	_	O
103	)	_	_	O
104	;	_	_	O
105	and	_	_	O
106	C	_	_	O
107	,	_	_	O
108	50	_	_	O
109	Gy	_	_	O
110	per	_	_	O
111	25	_	_	O
112	fractions	_	_	O
113	(	_	_	O
114	n	_	_	O
115	=	_	_	O
116	130	_	_	O
117	)	_	_	O
118	.	_	_	O

119	Four	_	_	O
120	hundred	_	_	O
121	seven	_	_	O
122	patients	_	_	O
123	were	_	_	O
124	eligible	_	_	O
125	for	_	_	O
126	the	_	_	O
127	study	_	_	O
128	;	_	_	O
129	395	_	_	O
130	patients	_	_	O
131	(	_	_	O
132	97	_	_	O
133	%	_	_	O
134	)	_	_	O
135	participated	_	_	O
136	in	_	_	O
137	the	_	_	O
138	health-related	_	_	O
139	quality-of-life	_	_	O
140	(	_	_	O
141	HRQOL	_	_	O
142	)	_	_	O
143	study	_	_	O
144	.	_	_	O

145	The	_	_	O
146	European	_	_	O
147	Organization	_	_	O
148	for	_	_	O
149	Research	_	_	O
150	and	_	_	O
151	Treatment	_	_	O
152	of	_	_	O
153	Cancer	_	_	O
154	(	_	_	O
155	EORTC	_	_	O
156	)	_	_	O
157	Quality	_	_	O
158	of	_	_	O
159	Life	_	_	O
160	Questionnaire	_	_	O
161	(	_	_	O
162	QLQ	_	_	O
163	)	_	_	O
164	-C30	_	_	O
165	and	_	_	O
166	EORTC	_	_	O
167	QLQ-lung	_	_	O
168	cancer-specific	_	_	O
169	module	_	_	O
170	(	_	_	O
171	LC13	_	_	O
172	)	_	_	O
173	were	_	_	O
174	used	_	_	O
175	to	_	_	O
176	investigate	_	_	O
177	airway	_	_	O
178	symptom	_	_	O
179	relief	_	_	O
180	and	_	_	O
181	changes	_	_	O
182	in	_	_	O
183	HRQOL	_	_	O
184	.	_	_	O

185	Assessments	_	_	O
186	were	_	_	O
187	performed	_	_	O
188	before	_	_	O
189	TRT	_	_	O
190	and	_	_	O
191	until	_	_	O
192	week	_	_	O
193	54	_	_	O
194	.	_	_	O

195	Clinicians	_	_	O
196	'	_	_	O
197	assessments	_	_	O
198	of	_	_	O
199	symptom	_	_	O
200	improvement	_	_	O
201	were	_	_	O
202	at	_	_	O
203	2	_	_	O
204	,	_	_	O
205	6	_	_	O
206	,	_	_	O
207	and	_	_	O
208	14	_	_	O
209	weeks	_	_	O
210	after	_	_	O
211	completion	_	_	O
212	of	_	_	O
213	TRT	_	_	O
214	.	_	_	O

215	The	_	_	O
216	patients	_	_	O
217	were	_	_	O
218	observed	_	_	O
219	for	_	_	O
220	a	_	_	O
221	minimum	_	_	O
222	of	_	_	O
223	3	_	_	O
224	years	_	_	O
225	.	_	_	O

226	Results	_	_	O
227	Baseline	_	_	O
228	prognostic	_	_	O
229	data	_	_	O
230	were	_	_	O
231	equally	_	_	O
232	distributed	_	_	O
233	in	_	_	O
234	the	_	_	O
235	treatment	_	_	O
236	groups	_	_	O
237	.	_	_	O

238	Patient	_	_	O
239	compliance	_	_	O
240	with	_	_	O
241	respect	_	_	O
242	to	_	_	O
243	the	_	_	O
244	HRQOL	_	_	O
245	investigation	_	_	O
246	was	_	_	O
247	minimum	_	_	O
248	74	_	_	O
249	%	_	_	O
250	.	_	_	O

251	HRQOL	_	_	B-Premise
252	and	_	_	I-Premise
253	symptom	_	_	I-Premise
254	relief	_	_	I-Premise
255	were	_	_	I-Premise
256	equivalent	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	treatment	_	_	I-Premise
260	arms	_	_	I-Premise
261	.	_	_	I-Premise

262	No	_	_	B-Premise
263	significant	_	_	I-Premise
264	difference	_	_	I-Premise
265	in	_	_	I-Premise
266	survival	_	_	I-Premise
267	among	_	_	I-Premise
268	arms	_	_	I-Premise
269	A	_	_	I-Premise
270	,	_	_	I-Premise
271	B	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	I-Premise
274	C	_	_	I-Premise
275	was	_	_	I-Premise
276	found	_	_	I-Premise
277	,	_	_	I-Premise
278	with	_	_	I-Premise
279	median	_	_	I-Premise
280	survival	_	_	I-Premise
281	8.2	_	_	I-Premise
282	,	_	_	I-Premise
283	7.0	_	_	I-Premise
284	,	_	_	I-Premise
285	and	_	_	I-Premise
286	6.8	_	_	I-Premise
287	months	_	_	I-Premise
288	,	_	_	I-Premise
289	respectively	_	_	I-Premise
290	.	_	_	I-Premise

291	Our	_	_	B-Claim
292	data	_	_	I-Claim
293	indicate	_	_	I-Claim
294	that	_	_	I-Claim
295	protracted	_	_	I-Claim
296	palliative	_	_	I-Claim
297	TRT	_	_	I-Claim
298	renders	_	_	I-Claim
299	no	_	_	I-Claim
300	improvement	_	_	I-Claim
301	in	_	_	I-Claim
302	symptom	_	_	I-Claim
303	relief	_	_	I-Claim
304	,	_	_	I-Claim
305	HRQOL	_	_	I-Claim
306	,	_	_	I-Claim
307	or	_	_	I-Claim
308	survival	_	_	I-Claim
309	when	_	_	I-Claim
310	compared	_	_	I-Claim
311	with	_	_	I-Claim
312	short-term	_	_	I-Claim
313	hypofractionated	_	_	I-Claim
314	treatment	_	_	I-Claim
315	in	_	_	I-Claim
316	advanced	_	_	I-Claim
317	NSCLC	_	_	I-Claim
318	.	_	_	I-Claim


0	During	_	_	B-Premise
1	the	_	_	I-Premise
2	last	_	_	I-Premise
3	decade	_	_	I-Premise
4	,	_	_	I-Premise
5	survival	_	_	I-Premise
6	rates	_	_	I-Premise
7	for	_	_	I-Premise
8	breast	_	_	I-Premise
9	cancer	_	_	I-Premise
10	have	_	_	I-Premise
11	increased	_	_	I-Premise
12	as	_	_	I-Premise
13	a	_	_	I-Premise
14	result	_	_	I-Premise
15	of	_	_	I-Premise
16	earlier	_	_	I-Premise
17	detection	_	_	I-Premise
18	and	_	_	I-Premise
19	increased	_	_	I-Premise
20	use	_	_	I-Premise
21	of	_	_	I-Premise
22	adjuvant	_	_	I-Premise
23	therapy	_	_	I-Premise
24	.	_	_	I-Premise

25	Limited	_	_	O
26	data	_	_	O
27	exist	_	_	O
28	on	_	_	O
29	the	_	_	O
30	psychosocial	_	_	O
31	aspects	_	_	O
32	of	_	_	O
33	the	_	_	O
34	transitional	_	_	O
35	period	_	_	O
36	between	_	_	O
37	the	_	_	O
38	end	_	_	O
39	of	_	_	O
40	primary	_	_	O
41	treatment	_	_	O
42	and	_	_	O
43	survivorship	_	_	O
44	.	_	_	O

45	We	_	_	O
46	investigated	_	_	O
47	the	_	_	O
48	baseline	_	_	O
49	psychosocial	_	_	O
50	status	_	_	O
51	of	_	_	O
52	women	_	_	O
53	enrolled	_	_	O
54	in	_	_	O
55	a	_	_	O
56	randomized	_	_	O
57	trial	_	_	O
58	testing	_	_	O
59	two	_	_	O
60	psychosocial	_	_	O
61	interventions	_	_	O
62	for	_	_	O
63	women	_	_	O
64	at	_	_	O
65	the	_	_	O
66	end	_	_	O
67	of	_	_	O
68	primary	_	_	O
69	treatment	_	_	O
70	.	_	_	O

71	Participants	_	_	O
72	,	_	_	O
73	identified	_	_	O
74	within	_	_	O
75	1	_	_	O
76	month	_	_	O
77	after	_	_	O
78	surgery	_	_	O
79	(	_	_	O
80	registration	_	_	O
81	)	_	_	O
82	,	_	_	O
83	provided	_	_	O
84	demographic	_	_	O
85	information	_	_	O
86	and	_	_	O
87	limited	_	_	O
88	measures	_	_	O
89	of	_	_	O
90	quality	_	_	O
91	of	_	_	O
92	life	_	_	O
93	.	_	_	O

94	They	_	_	O
95	were	_	_	O
96	followed	_	_	O
97	until	_	_	O
98	they	_	_	O
99	finished	_	_	O
100	primary	_	_	O
101	treatment	_	_	O
102	(	_	_	O
103	enrollment	_	_	O
104	)	_	_	O
105	,	_	_	O
106	at	_	_	O
107	which	_	_	O
108	time	_	_	O
109	they	_	_	O
110	completed	_	_	O
111	a	_	_	O
112	mailed	_	_	O
113	baseline	_	_	O
114	survey	_	_	O
115	that	_	_	O
116	included	_	_	O
117	standardized	_	_	O
118	measures	_	_	O
119	of	_	_	O
120	quality	_	_	O
121	of	_	_	O
122	life	_	_	O
123	(	_	_	O
124	including	_	_	O
125	standardized	_	_	O
126	scales	_	_	O
127	of	_	_	O
128	physical	_	_	O
129	and	_	_	O
130	emotional	_	_	O
131	functioning	_	_	O
132	)	_	_	O
133	,	_	_	O
134	mood	_	_	O
135	,	_	_	O
136	symptoms	_	_	O
137	,	_	_	O
138	and	_	_	O
139	sexual	_	_	O
140	functioning	_	_	O
141	.	_	_	O

142	A	_	_	O
143	total	_	_	O
144	of	_	_	O
145	558	_	_	O
146	patients	_	_	O
147	(	_	_	O
148	mean	_	_	O
149	age	_	_	O
150	=	_	_	O
151	56.9	_	_	O
152	years	_	_	O
153	)	_	_	O
154	were	_	_	O
155	enrolled	_	_	O
156	in	_	_	O
157	the	_	_	O
158	study	_	_	O
159	between	_	_	O
160	July	_	_	O
161	1	_	_	O
162	,	_	_	O
163	1999	_	_	O
164	,	_	_	O
165	and	_	_	O
166	June	_	_	O
167	30	_	_	O
168	,	_	_	O
169	2002	_	_	O
170	.	_	_	O

171	Health	_	_	O
172	outcomes	_	_	O
173	were	_	_	O
174	examined	_	_	O
175	according	_	_	O
176	to	_	_	O
177	treatment	_	_	O
178	received	_	_	O
179	:	_	_	O
180	mastectomy	_	_	O
181	with	_	_	O
182	and	_	_	O
183	without	_	_	O
184	chemotherapy	_	_	O
185	,	_	_	O
186	and	_	_	O
187	lumpectomy	_	_	O
188	with	_	_	O
189	and	_	_	O
190	without	_	_	O
191	chemotherapy	_	_	O
192	.	_	_	O

193	All	_	_	O
194	statistical	_	_	O
195	tests	_	_	O
196	were	_	_	O
197	two-sided	_	_	O
198	.	_	_	O

199	Among	_	_	B-Premise
200	all	_	_	I-Premise
201	treatment	_	_	I-Premise
202	groups	_	_	I-Premise
203	,	_	_	I-Premise
204	patients	_	_	I-Premise
205	who	_	_	I-Premise
206	had	_	_	I-Premise
207	a	_	_	I-Premise
208	mastectomy	_	_	I-Premise
209	had	_	_	I-Premise
210	the	_	_	I-Premise
211	poorest	_	_	I-Premise
212	physical	_	_	I-Premise
213	functioning	_	_	I-Premise
214	at	_	_	I-Premise
215	registration	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	<	_	_	I-Premise
219	.001	_	_	I-Premise
220	)	_	_	I-Premise
221	and	_	_	I-Premise
222	at	_	_	I-Premise
223	enrollment	_	_	I-Premise
224	(	_	_	I-Premise
225	P=.05	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	At	_	_	B-Premise
229	enrollment	_	_	I-Premise
230	,	_	_	I-Premise
231	mood	_	_	I-Premise
232	and	_	_	I-Premise
233	emotional	_	_	I-Premise
234	functioning	_	_	I-Premise
235	were	_	_	I-Premise
236	similar	_	_	I-Premise
237	among	_	_	I-Premise
238	all	_	_	I-Premise
239	patients	_	_	I-Premise
240	,	_	_	I-Premise
241	with	_	_	I-Premise
242	no	_	_	I-Premise
243	differences	_	_	I-Premise
244	by	_	_	I-Premise
245	type	_	_	I-Premise
246	of	_	_	I-Premise
247	treatment	_	_	I-Premise
248	received	_	_	I-Premise
249	.	_	_	I-Premise

250	At	_	_	B-Premise
251	enrollment	_	_	I-Premise
252	,	_	_	I-Premise
253	symptoms	_	_	I-Premise
254	,	_	_	I-Premise
255	including	_	_	I-Premise
256	muscle	_	_	I-Premise
257	stiffness	_	_	I-Premise
258	,	_	_	I-Premise
259	breast	_	_	I-Premise
260	sensitivity	_	_	I-Premise
261	,	_	_	I-Premise
262	aches	_	_	I-Premise
263	and	_	_	I-Premise
264	pains	_	_	I-Premise
265	,	_	_	I-Premise
266	tendency	_	_	I-Premise
267	to	_	_	I-Premise
268	take	_	_	I-Premise
269	naps	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	difficulty	_	_	I-Premise
273	concentrating	_	_	I-Premise
274	,	_	_	I-Premise
275	were	_	_	I-Premise
276	common	_	_	I-Premise
277	among	_	_	I-Premise
278	patients	_	_	I-Premise
279	in	_	_	I-Premise
280	all	_	_	I-Premise
281	groups	_	_	I-Premise
282	and	_	_	I-Premise
283	were	_	_	I-Premise
284	statistically	_	_	I-Premise
285	significantly	_	_	I-Premise
286	associated	_	_	I-Premise
287	with	_	_	I-Premise
288	poor	_	_	I-Premise
289	physical	_	_	I-Premise
290	functioning	_	_	I-Premise
291	and	_	_	I-Premise
292	emotional	_	_	I-Premise
293	well-being	_	_	I-Premise
294	.	_	_	I-Premise

295	Sexual	_	_	B-Premise
296	functioning	_	_	I-Premise
297	was	_	_	I-Premise
298	worse	_	_	I-Premise
299	for	_	_	I-Premise
300	women	_	_	I-Premise
301	who	_	_	I-Premise
302	received	_	_	I-Premise
303	chemotherapy	_	_	I-Premise
304	than	_	_	I-Premise
305	for	_	_	I-Premise
306	those	_	_	I-Premise
307	who	_	_	I-Premise
308	did	_	_	I-Premise
309	not	_	_	I-Premise
310	,	_	_	I-Premise
311	regardless	_	_	I-Premise
312	of	_	_	I-Premise
313	type	_	_	I-Premise
314	of	_	_	I-Premise
315	surgery	_	_	I-Premise
316	(	_	_	I-Premise
317	P	_	_	I-Premise
318	<	_	_	I-Premise
319	.001	_	_	I-Premise
320	)	_	_	I-Premise
321	.	_	_	I-Premise

322	At	_	_	B-Claim
323	the	_	_	I-Claim
324	end	_	_	I-Claim
325	of	_	_	I-Claim
326	primary	_	_	I-Claim
327	treatment	_	_	I-Claim
328	for	_	_	I-Claim
329	breast	_	_	I-Claim
330	cancer	_	_	I-Claim
331	,	_	_	I-Claim
332	women	_	_	I-Claim
333	in	_	_	I-Claim
334	all	_	_	I-Claim
335	treatment	_	_	I-Claim
336	groups	_	_	I-Claim
337	report	_	_	I-Claim
338	good	_	_	I-Claim
339	emotional	_	_	I-Claim
340	functioning	_	_	I-Claim
341	but	_	_	I-Claim
342	report	_	_	I-Claim
343	decreased	_	_	I-Claim
344	physical	_	_	I-Claim
345	functioning	_	_	I-Claim
346	,	_	_	I-Claim
347	particularly	_	_	I-Claim
348	among	_	_	I-Claim
349	women	_	_	I-Claim
350	who	_	_	I-Claim
351	have	_	_	I-Claim
352	a	_	_	I-Claim
353	mastectomy	_	_	I-Claim
354	or	_	_	I-Claim
355	receive	_	_	I-Claim
356	chemotherapy	_	_	I-Claim
357	.	_	_	I-Claim

358	Clinical	_	_	B-Claim
359	interventions	_	_	I-Claim
360	to	_	_	I-Claim
361	address	_	_	I-Claim
362	common	_	_	I-Claim
363	symptoms	_	_	I-Claim
364	associated	_	_	I-Claim
365	with	_	_	I-Claim
366	treatment	_	_	I-Claim
367	should	_	_	I-Claim
368	be	_	_	I-Claim
369	considered	_	_	I-Claim
370	to	_	_	I-Claim
371	improve	_	_	I-Claim
372	physical	_	_	I-Claim
373	and	_	_	I-Claim
374	emotional	_	_	I-Claim
375	functioning	_	_	I-Claim
376	at	_	_	I-Claim
377	the	_	_	I-Claim
378	end	_	_	I-Claim
379	of	_	_	I-Claim
380	primary	_	_	I-Claim
381	treatment	_	_	I-Claim
382	for	_	_	I-Claim
383	breast	_	_	I-Claim
384	cancer	_	_	I-Claim
385	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	longitudinal	_	_	O
4	effects	_	_	O
5	of	_	_	O
6	treatment	_	_	O
7	on	_	_	O
8	intraocular	_	_	O
9	pressure	_	_	O
10	(	_	_	O
11	IOP	_	_	O
12	)	_	_	O
13	and	_	_	O
14	visual	_	_	O
15	field	_	_	O
16	performance	_	_	O
17	in	_	_	O
18	Japanese	_	_	O
19	normal-tension	_	_	O
20	glaucoma	_	_	O
21	(	_	_	O
22	NTG	_	_	O
23	)	_	_	O
24	between	_	_	O
25	latanoprost	_	_	O
26	and	_	_	O
27	timolol	_	_	O
28	.	_	_	O

29	This	_	_	O
30	is	_	_	O
31	an	_	_	O
32	open-label	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	study	_	_	O
37	.	_	_	O

38	A	_	_	O
39	total	_	_	O
40	of	_	_	O
41	62	_	_	O
42	NTG	_	_	O
43	patients	_	_	O
44	were	_	_	O
45	prospectively	_	_	O
46	,	_	_	O
47	consecutively	_	_	O
48	enrolled	_	_	O
49	.	_	_	O

50	All	_	_	O
51	study	_	_	O
52	subjects	_	_	O
53	were	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	to	_	_	O
57	0.005	_	_	O
58	%	_	_	O
59	latanoprost	_	_	O
60	instillation	_	_	O
61	once	_	_	O
62	daily	_	_	O
63	in	_	_	O
64	the	_	_	O
65	morning	_	_	O
66	or	_	_	O
67	0.5	_	_	O
68	%	_	_	O
69	timolol	_	_	O
70	instillation	_	_	O
71	twice	_	_	O
72	daily	_	_	O
73	for	_	_	O
74	a	_	_	O
75	prospective	_	_	O
76	3-year	_	_	O
77	follow-up	_	_	O
78	,	_	_	O
79	and	_	_	O
80	underwent	_	_	O
81	a	_	_	O
82	routine	_	_	O
83	ocular	_	_	O
84	examination	_	_	O
85	every	_	_	O
86	month	_	_	O
87	.	_	_	O

88	Automated	_	_	O
89	perimetry	_	_	O
90	was	_	_	O
91	performed	_	_	O
92	every	_	_	O
93	6	_	_	O
94	months	_	_	O
95	using	_	_	O
96	Humphrey	_	_	O
97	field	_	_	O
98	analysers	_	_	O
99	.	_	_	O

100	Stereophotographs	_	_	O
101	of	_	_	O
102	optic	_	_	O
103	discs	_	_	O
104	were	_	_	O
105	also	_	_	O
106	obtained	_	_	O
107	every	_	_	O
108	6	_	_	O
109	months	_	_	O
110	.	_	_	O

111	Percentage	_	_	B-Premise
112	of	_	_	I-Premise
113	IOP	_	_	I-Premise
114	reduction	_	_	I-Premise
115	or	_	_	I-Premise
116	the	_	_	I-Premise
117	magnitude	_	_	I-Premise
118	of	_	_	I-Premise
119	IOP	_	_	I-Premise
120	reduction	_	_	I-Premise
121	showed	_	_	I-Premise
122	no	_	_	I-Premise
123	intergroup	_	_	I-Premise
124	differences	_	_	I-Premise
125	either	_	_	I-Premise
126	at	_	_	I-Premise
127	any	_	_	I-Premise
128	time	_	_	I-Premise
129	point	_	_	I-Premise
130	(	_	_	I-Premise
131	13-15	_	_	I-Premise
132	%	_	_	I-Premise
133	)	_	_	I-Premise
134	.	_	_	I-Premise

135	In	_	_	B-Premise
136	the	_	_	I-Premise
137	visual	_	_	I-Premise
138	field	_	_	I-Premise
139	,	_	_	I-Premise
140	the	_	_	I-Premise
141	estimated	_	_	I-Premise
142	rate	_	_	I-Premise
143	of	_	_	I-Premise
144	change	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	MD	_	_	I-Premise
148	value	_	_	I-Premise
149	(	_	_	I-Premise
150	dB/year	_	_	I-Premise
151	)	_	_	I-Premise
152	was	_	_	I-Premise
153	-0.34+/-0.17	_	_	I-Premise
154	(	_	_	I-Premise
155	SE	_	_	I-Premise
156	)	_	_	I-Premise
157	for	_	_	I-Premise
158	the	_	_	I-Premise
159	latanoprost	_	_	I-Premise
160	group	_	_	I-Premise
161	,	_	_	I-Premise
162	and	_	_	I-Premise
163	-0.10+/-0.18	_	_	I-Premise
164	(	_	_	I-Premise
165	SE	_	_	I-Premise
166	)	_	_	I-Premise
167	for	_	_	I-Premise
168	the	_	_	I-Premise
169	timolol	_	_	I-Premise
170	group	_	_	I-Premise
171	.	_	_	I-Premise

172	The	_	_	B-Premise
173	estimated	_	_	I-Premise
174	rate	_	_	I-Premise
175	of	_	_	I-Premise
176	change	_	_	I-Premise
177	in	_	_	I-Premise
178	MD	_	_	I-Premise
179	showed	_	_	I-Premise
180	no	_	_	I-Premise
181	significant	_	_	I-Premise
182	difference	_	_	I-Premise
183	from	_	_	I-Premise
184	zero	_	_	I-Premise
185	in	_	_	I-Premise
186	both	_	_	I-Premise
187	groups	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	there	_	_	I-Premise
191	were	_	_	I-Premise
192	no	_	_	I-Premise
193	statistical	_	_	I-Premise
194	intergroup	_	_	I-Premise
195	differences	_	_	I-Premise
196	.	_	_	I-Premise

197	No	_	_	B-Premise
198	changes	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	optic	_	_	I-Premise
202	nerve	_	_	I-Premise
203	head	_	_	I-Premise
204	topography	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	vertical	_	_	I-Premise
208	cup-to-disc	_	_	I-Premise
209	ratio	_	_	I-Premise
210	and	_	_	I-Premise
211	rim	_	_	I-Premise
212	area	_	_	I-Premise
213	measured	_	_	I-Premise
214	by	_	_	I-Premise
215	image-analysis	_	_	I-Premise
216	techniques	_	_	I-Premise
217	were	_	_	I-Premise
218	observed	_	_	I-Premise
219	in	_	_	I-Premise
220	either	_	_	I-Premise
221	group	_	_	I-Premise
222	.	_	_	I-Premise

223	There	_	_	B-Premise
224	were	_	_	I-Premise
225	no	_	_	I-Premise
226	patients	_	_	I-Premise
227	who	_	_	I-Premise
228	dropped	_	_	I-Premise
229	out	_	_	I-Premise
230	due	_	_	I-Premise
231	to	_	_	I-Premise
232	the	_	_	I-Premise
233	side	_	_	I-Premise
234	effects	_	_	I-Premise
235	of	_	_	I-Premise
236	treatment	_	_	I-Premise
237	regimens	_	_	I-Premise
238	.	_	_	I-Premise

239	Both	_	_	B-Claim
240	latanoprost	_	_	I-Claim
241	and	_	_	I-Claim
242	timolol	_	_	I-Claim
243	single	_	_	I-Claim
244	treatments	_	_	I-Claim
245	reduced	_	_	I-Claim
246	IOP	_	_	I-Claim
247	by	_	_	I-Claim
248	13-15	_	_	I-Claim
249	%	_	_	I-Claim
250	at	_	_	I-Claim
251	their	_	_	I-Claim
252	trough	_	_	I-Claim
253	effects	_	_	I-Claim
254	for	_	_	I-Claim
255	3	_	_	I-Claim
256	years	_	_	I-Claim
257	in	_	_	I-Claim
258	Japanese	_	_	I-Claim
259	NTG	_	_	I-Claim
260	patients	_	_	I-Claim
261	;	_	_	O
262	both	_	_	B-Claim
263	showed	_	_	I-Claim
264	similar	_	_	I-Claim
265	effects	_	_	I-Claim
266	on	_	_	I-Claim
267	visual	_	_	I-Claim
268	field	_	_	I-Claim
269	performance	_	_	I-Claim
270	.	_	_	I-Claim


0	The	_	_	O
1	World	_	_	O
2	Health	_	_	O
3	Organization	_	_	O
4	(	_	_	O
5	WHO	_	_	O
6	)	_	_	O
7	guidelines	_	_	O
8	for	_	_	O
9	the	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	cancer	_	_	O
13	pain	_	_	O
14	recommend	_	_	O
15	nonopioid	_	_	O
16	analgesics	_	_	O
17	as	_	_	O
18	first-line	_	_	O
19	therapy	_	_	O
20	,	_	_	O
21	so-called	_	_	O
22	weak	_	_	O
23	analgesics	_	_	O
24	combined	_	_	O
25	with	_	_	O
26	nonopioid	_	_	O
27	analgesics	_	_	O
28	as	_	_	O
29	second-line	_	_	O
30	therapy	_	_	O
31	,	_	_	O
32	and	_	_	O
33	so-called	_	_	O
34	strong	_	_	O
35	opioids	_	_	O
36	(	_	_	O
37	with	_	_	O
38	nonopioid	_	_	O
39	analgesics	_	_	O
40	)	_	_	O
41	only	_	_	O
42	as	_	_	O
43	third-line	_	_	O
44	therapy	_	_	O
45	.	_	_	O

46	However	_	_	O
47	,	_	_	O
48	these	_	_	O
49	guidelines	_	_	O
50	can	_	_	O
51	be	_	_	O
52	questioned	_	_	O
53	with	_	_	O
54	regard	_	_	O
55	to	_	_	O
56	the	_	_	O
57	extent	_	_	O
58	of	_	_	O
59	efficacy	_	_	O
60	as	_	_	O
61	well	_	_	O
62	as	_	_	O
63	the	_	_	O
64	rationale	_	_	O
65	for	_	_	O
66	not	_	_	O
67	using	_	_	O
68	strong	_	_	O
69	opioids	_	_	O
70	as	_	_	O
71	first-line	_	_	O
72	treatment	_	_	O
73	,	_	_	O
74	especially	_	_	O
75	in	_	_	O
76	terminal	_	_	O
77	cancer	_	_	O
78	patients	_	_	O
79	.	_	_	O

80	The	_	_	O
81	purpose	_	_	O
82	of	_	_	O
83	this	_	_	O
84	randomized	_	_	O
85	study	_	_	O
86	was	_	_	O
87	to	_	_	O
88	prospectively	_	_	O
89	compare	_	_	O
90	the	_	_	O
91	efficacy	_	_	O
92	and	_	_	O
93	tolerability	_	_	O
94	of	_	_	O
95	strong	_	_	O
96	opioids	_	_	O
97	as	_	_	O
98	first-line	_	_	O
99	agents	_	_	O
100	with	_	_	O
101	the	_	_	O
102	recommendations	_	_	O
103	of	_	_	O
104	the	_	_	O
105	WHO	_	_	O
106	in	_	_	O
107	terminal	_	_	O
108	cancer	_	_	O
109	patients	_	_	O
110	.	_	_	O

111	One	_	_	O
112	hundred	_	_	O
113	patients	_	_	O
114	with	_	_	O
115	mild-moderate	_	_	O
116	pain	_	_	O
117	were	_	_	O
118	randomized	_	_	O
119	to	_	_	O
120	treatment	_	_	O
121	according	_	_	O
122	to	_	_	O
123	WHO	_	_	O
124	guidelines	_	_	O
125	or	_	_	O
126	to	_	_	O
127	treatment	_	_	O
128	with	_	_	O
129	strong	_	_	O
130	opioids	_	_	O
131	.	_	_	O

132	Evaluated	_	_	O
133	outcomes	_	_	O
134	included	_	_	O
135	pain	_	_	O
136	intensity	_	_	O
137	,	_	_	O
138	need	_	_	O
139	for	_	_	O
140	change	_	_	O
141	in	_	_	O
142	therapy	_	_	O
143	,	_	_	O
144	quality	_	_	O
145	of	_	_	O
146	life	_	_	O
147	,	_	_	O
148	Karnofsky	_	_	O
149	Performance	_	_	O
150	Status	_	_	O
151	,	_	_	O
152	general	_	_	O
153	condition	_	_	O
154	of	_	_	O
155	the	_	_	O
156	patient	_	_	O
157	,	_	_	O
158	and	_	_	O
159	adverse	_	_	O
160	events	_	_	O
161	.	_	_	O

162	No	_	_	B-Premise
163	between-treatment	_	_	I-Premise
164	differences	_	_	I-Premise
165	were	_	_	I-Premise
166	observed	_	_	I-Premise
167	for	_	_	I-Premise
168	changes	_	_	I-Premise
169	in	_	_	I-Premise
170	quality	_	_	I-Premise
171	of	_	_	I-Premise
172	life	_	_	I-Premise
173	or	_	_	I-Premise
174	performance	_	_	I-Premise
175	status	_	_	I-Premise
176	,	_	_	I-Premise
177	but	_	_	O
178	patients	_	_	B-Premise
179	started	_	_	I-Premise
180	on	_	_	I-Premise
181	strong	_	_	I-Premise
182	opioids	_	_	I-Premise
183	had	_	_	I-Premise
184	significantly	_	_	I-Premise
185	better	_	_	I-Premise
186	pain	_	_	I-Premise
187	relief	_	_	I-Premise
188	than	_	_	I-Premise
189	patients	_	_	I-Premise
190	treated	_	_	I-Premise
191	according	_	_	I-Premise
192	to	_	_	I-Premise
193	WHO	_	_	I-Premise
194	guidelines	_	_	I-Premise
195	(	_	_	I-Premise
196	P=0.041	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	Additionally	_	_	B-Premise
200	,	_	_	I-Premise
201	patients	_	_	I-Premise
202	started	_	_	I-Premise
203	on	_	_	I-Premise
204	strong	_	_	I-Premise
205	opioids	_	_	I-Premise
206	required	_	_	I-Premise
207	significantly	_	_	I-Premise
208	fewer	_	_	I-Premise
209	changes	_	_	I-Premise
210	in	_	_	I-Premise
211	therapy	_	_	I-Premise
212	,	_	_	I-Premise
213	had	_	_	I-Premise
214	greater	_	_	I-Premise
215	reduction	_	_	I-Premise
216	in	_	_	I-Premise
217	pain	_	_	I-Premise
218	when	_	_	I-Premise
219	a	_	_	I-Premise
220	change	_	_	I-Premise
221	was	_	_	I-Premise
222	initiated	_	_	I-Premise
223	,	_	_	I-Premise
224	and	_	_	I-Premise
225	reported	_	_	I-Premise
226	greater	_	_	I-Premise
227	satisfaction	_	_	I-Premise
228	with	_	_	I-Premise
229	treatment	_	_	I-Premise
230	than	_	_	I-Premise
231	the	_	_	I-Premise
232	comparator	_	_	I-Premise
233	group	_	_	I-Premise
234	(	_	_	I-Premise
235	P=0.041	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Strong	_	_	B-Claim
239	opioids	_	_	I-Claim
240	were	_	_	I-Claim
241	safe	_	_	I-Claim
242	and	_	_	I-Claim
243	well-tolerated	_	_	I-Claim
244	,	_	_	I-Claim
245	with	_	_	I-Claim
246	no	_	_	I-Claim
247	development	_	_	I-Claim
248	of	_	_	I-Claim
249	tolerance	_	_	I-Claim
250	or	_	_	I-Claim
251	serious	_	_	I-Claim
252	adverse	_	_	I-Claim
253	events	_	_	I-Claim
254	.	_	_	I-Claim

255	These	_	_	B-Claim
256	data	_	_	I-Claim
257	suggest	_	_	I-Claim
258	the	_	_	I-Claim
259	utility	_	_	I-Claim
260	of	_	_	I-Claim
261	strong	_	_	I-Claim
262	opioids	_	_	I-Claim
263	for	_	_	I-Claim
264	first-line	_	_	I-Claim
265	treatment	_	_	I-Claim
266	of	_	_	I-Claim
267	pain	_	_	I-Claim
268	in	_	_	I-Claim
269	patients	_	_	I-Claim
270	with	_	_	I-Claim
271	terminal	_	_	I-Claim
272	cancer	_	_	I-Claim
273	.	_	_	I-Claim


0	Research	_	_	B-Claim
1	suggests	_	_	I-Claim
2	that	_	_	I-Claim
3	stress-reduction	_	_	I-Claim
4	programs	_	_	I-Claim
5	tailored	_	_	I-Claim
6	to	_	_	I-Claim
7	the	_	_	I-Claim
8	cancer	_	_	I-Claim
9	setting	_	_	I-Claim
10	help	_	_	I-Claim
11	patients	_	_	I-Claim
12	cope	_	_	I-Claim
13	with	_	_	I-Claim
14	the	_	_	I-Claim
15	effects	_	_	I-Claim
16	of	_	_	I-Claim
17	treatment	_	_	I-Claim
18	and	_	_	I-Claim
19	improve	_	_	I-Claim
20	their	_	_	I-Claim
21	quality	_	_	I-Claim
22	of	_	_	I-Claim
23	life	_	_	I-Claim
24	.	_	_	I-Claim

25	Yoga	_	_	O
26	,	_	_	O
27	an	_	_	O
28	ancient	_	_	O
29	Eastern	_	_	O
30	science	_	_	O
31	,	_	_	O
32	incorporates	_	_	O
33	stress-reduction	_	_	O
34	techniques	_	_	O
35	that	_	_	O
36	include	_	_	O
37	regulated	_	_	O
38	breathing	_	_	O
39	,	_	_	O
40	visual	_	_	O
41	imagery	_	_	O
42	,	_	_	O
43	and	_	_	O
44	meditation	_	_	O
45	as	_	_	O
46	well	_	_	O
47	as	_	_	O
48	various	_	_	O
49	postures	_	_	O
50	.	_	_	O

51	The	_	_	O
52	authors	_	_	O
53	examined	_	_	O
54	the	_	_	O
55	effects	_	_	O
56	of	_	_	O
57	the	_	_	O
58	Tibetan	_	_	O
59	yoga	_	_	O
60	(	_	_	O
61	TY	_	_	O
62	)	_	_	O
63	practices	_	_	O
64	of	_	_	O
65	Tsa	_	_	O
66	lung	_	_	O
67	and	_	_	O
68	Trul	_	_	O
69	khor	_	_	O
70	,	_	_	O
71	which	_	_	O
72	incorporate	_	_	O
73	controlled	_	_	O
74	breathing	_	_	O
75	and	_	_	O
76	visualization	_	_	O
77	,	_	_	O
78	mindfulness	_	_	O
79	techniques	_	_	O
80	,	_	_	O
81	and	_	_	O
82	low-impact	_	_	O
83	postures	_	_	O
84	in	_	_	O
85	patients	_	_	O
86	with	_	_	O
87	lymphoma	_	_	O
88	.	_	_	O

89	Thirty-nine	_	_	O
90	patients	_	_	O
91	with	_	_	O
92	lymphoma	_	_	O
93	who	_	_	O
94	were	_	_	O
95	undergoing	_	_	O
96	treatment	_	_	O
97	or	_	_	O
98	who	_	_	O
99	had	_	_	O
100	concluded	_	_	O
101	treatment	_	_	O
102	within	_	_	O
103	the	_	_	O
104	past	_	_	O
105	12	_	_	O
106	months	_	_	O
107	were	_	_	O
108	assigned	_	_	O
109	to	_	_	O
110	a	_	_	O
111	TY	_	_	O
112	group	_	_	O
113	or	_	_	O
114	to	_	_	O
115	a	_	_	O
116	wait-list	_	_	O
117	control	_	_	O
118	group	_	_	O
119	.	_	_	O

120	Patients	_	_	O
121	in	_	_	O
122	the	_	_	O
123	TY	_	_	O
124	group	_	_	O
125	participated	_	_	O
126	in	_	_	O
127	7	_	_	O
128	weekly	_	_	O
129	yoga	_	_	O
130	sessions	_	_	O
131	,	_	_	O
132	and	_	_	O
133	patients	_	_	O
134	in	_	_	O
135	the	_	_	O
136	wait-list	_	_	O
137	control	_	_	O
138	group	_	_	O
139	were	_	_	O
140	free	_	_	O
141	to	_	_	O
142	participate	_	_	O
143	in	_	_	O
144	the	_	_	O
145	TY	_	_	O
146	program	_	_	O
147	after	_	_	O
148	the	_	_	O
149	3-month	_	_	O
150	follow-up	_	_	O
151	assessment	_	_	O
152	.	_	_	O

153	Eighty	_	_	O
154	nine	_	_	O
155	percent	_	_	O
156	of	_	_	O
157	TY	_	_	O
158	participants	_	_	O
159	completed	_	_	O
160	at	_	_	O
161	least	_	_	O
162	2-3	_	_	O
163	three	_	_	O
164	yoga	_	_	O
165	sessions	_	_	O
166	,	_	_	O
167	and	_	_	O
168	58	_	_	O
169	%	_	_	O
170	completed	_	_	O
171	at	_	_	O
172	least	_	_	O
173	5	_	_	O
174	sessions	_	_	O
175	.	_	_	O

176	Patients	_	_	B-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	TY	_	_	I-Premise
180	group	_	_	I-Premise
181	reported	_	_	I-Premise
182	significantly	_	_	I-Premise
183	lower	_	_	I-Premise
184	sleep	_	_	I-Premise
185	disturbance	_	_	I-Premise
186	scores	_	_	I-Premise
187	during	_	_	I-Premise
188	follow-up	_	_	I-Premise
189	compared	_	_	I-Premise
190	with	_	_	I-Premise
191	patients	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	wait-list	_	_	I-Premise
195	control	_	_	I-Premise
196	group	_	_	I-Premise
197	(	_	_	I-Premise
198	5.8	_	_	I-Premise
199	vs.	_	_	I-Premise
200	8.1	_	_	I-Premise
201	;	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	0.004	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	This	_	_	B-Premise
208	included	_	_	I-Premise
209	better	_	_	I-Premise
210	subjective	_	_	I-Premise
211	sleep	_	_	I-Premise
212	quality	_	_	I-Premise
213	(	_	_	I-Premise
214	P	_	_	I-Premise
215	<	_	_	I-Premise
216	0.02	_	_	I-Premise
217	)	_	_	I-Premise
218	,	_	_	I-Premise
219	faster	_	_	I-Premise
220	sleep	_	_	I-Premise
221	latency	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	<	_	_	I-Premise
225	0.01	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	longer	_	_	I-Premise
229	sleep	_	_	I-Premise
230	duration	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	0.03	_	_	I-Premise
235	)	_	_	I-Premise
236	,	_	_	I-Premise
237	and	_	_	I-Premise
238	less	_	_	I-Premise
239	use	_	_	I-Premise
240	of	_	_	I-Premise
241	sleep	_	_	I-Premise
242	medications	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	0.02	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	There	_	_	B-Premise
250	were	_	_	I-Premise
251	no	_	_	I-Premise
252	significant	_	_	I-Premise
253	differences	_	_	I-Premise
254	between	_	_	I-Premise
255	groups	_	_	I-Premise
256	in	_	_	I-Premise
257	terms	_	_	I-Premise
258	of	_	_	I-Premise
259	intrusion	_	_	I-Premise
260	or	_	_	I-Premise
261	avoidance	_	_	I-Premise
262	,	_	_	I-Premise
263	state	_	_	I-Premise
264	anxiety	_	_	I-Premise
265	,	_	_	I-Premise
266	depression	_	_	I-Premise
267	,	_	_	I-Premise
268	or	_	_	I-Premise
269	fatigue	_	_	I-Premise
270	.	_	_	I-Premise

271	The	_	_	B-Claim
272	participation	_	_	I-Claim
273	rates	_	_	I-Claim
274	suggested	_	_	I-Claim
275	that	_	_	I-Claim
276	a	_	_	I-Claim
277	TY	_	_	I-Claim
278	program	_	_	I-Claim
279	is	_	_	I-Claim
280	feasible	_	_	I-Claim
281	for	_	_	I-Claim
282	patients	_	_	I-Claim
283	with	_	_	I-Claim
284	cancer	_	_	I-Claim
285	and	_	_	I-Claim
286	that	_	_	I-Claim
287	such	_	_	I-Claim
288	a	_	_	I-Claim
289	program	_	_	I-Claim
290	significantly	_	_	I-Claim
291	improves	_	_	I-Claim
292	sleep-related	_	_	I-Claim
293	outcomes	_	_	I-Claim
294	.	_	_	I-Claim

295	However	_	_	B-Premise
296	,	_	_	I-Premise
297	there	_	_	I-Premise
298	were	_	_	I-Premise
299	no	_	_	I-Premise
300	significant	_	_	I-Premise
301	differences	_	_	I-Premise
302	between	_	_	I-Premise
303	groups	_	_	I-Premise
304	for	_	_	I-Premise
305	the	_	_	I-Premise
306	other	_	_	I-Premise
307	outcomes	_	_	I-Premise
308	.	_	_	I-Premise


0	Recombinant	_	_	B-Claim
1	human	_	_	I-Claim
2	erythropoietin	_	_	I-Claim
3	(	_	_	I-Claim
4	r-HuEPO	_	_	I-Claim
5	)	_	_	I-Claim
6	corrects	_	_	I-Claim
7	cancer-related	_	_	I-Claim
8	anemia	_	_	I-Claim
9	and	_	_	I-Claim
10	,	_	_	I-Claim
11	thereby	_	_	I-Claim
12	,	_	_	I-Claim
13	improves	_	_	I-Claim
14	quality	_	_	I-Claim
15	of	_	_	I-Claim
16	life	_	_	I-Claim
17	.	_	_	I-Claim

18	The	_	_	O
19	purpose	_	_	O
20	of	_	_	O
21	the	_	_	O
22	present	_	_	O
23	study	_	_	O
24	was	_	_	O
25	to	_	_	O
26	measure	_	_	O
27	the	_	_	O
28	impact	_	_	O
29	of	_	_	O
30	erythropoietin	_	_	O
31	on	_	_	O
32	hemoglobin	_	_	O
33	and	_	_	O
34	mood	_	_	O
35	state	_	_	O
36	in	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	metastatic	_	_	O
40	breast	_	_	O
41	cancer	_	_	O
42	and	_	_	O
43	mild	_	_	O
44	anemia	_	_	O
45	(	_	_	O
46	Hgb	_	_	O
47	<	_	_	O
48	12.0	_	_	O
49	g/dL	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Women	_	_	O
53	were	_	_	O
54	randomized	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	usual	_	_	O
58	care	_	_	O
59	(	_	_	O
60	G1	_	_	O
61	)	_	_	O
62	or	_	_	O
63	usual	_	_	O
64	care	_	_	O
65	plus	_	_	O
66	r-HuEPO	_	_	O
67	(	_	_	O
68	G2	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Usual	_	_	O
72	care	_	_	O
73	included	_	_	O
74	transfusions	_	_	O
75	as	_	_	O
76	necessary	_	_	O
77	and	_	_	O
78	fatigue	_	_	O
79	education	_	_	O
80	.	_	_	O

81	R-HuEPO	_	_	O
82	was	_	_	O
83	begun	_	_	O
84	at	_	_	O
85	40,000U	_	_	O
86	subcutaneously	_	_	O
87	per	_	_	O
88	week	_	_	O
89	.	_	_	O

90	At	_	_	O
91	4	_	_	O
92	weeks	_	_	O
93	,	_	_	O
94	the	_	_	O
95	dose	_	_	O
96	was	_	_	O
97	increased	_	_	O
98	to	_	_	O
99	60,000U	_	_	O
100	if	_	_	O
101	Hgb	_	_	O
102	had	_	_	O
103	not	_	_	O
104	increased	_	_	O
105	>	_	_	O
106	or	_	_	O
107	=	_	_	O
108	1.0	_	_	O
109	g/dL	_	_	O
110	.	_	_	O

111	The	_	_	O
112	drug	_	_	O
113	was	_	_	O
114	discontinued	_	_	O
115	at	_	_	O
116	8	_	_	O
117	weeks	_	_	O
118	if	_	_	O
119	hemoglobin	_	_	O
120	improvement	_	_	O
121	was	_	_	O
122	<	_	_	O
123	1.0	_	_	O
124	g/dL	_	_	O
125	.	_	_	O

126	The	_	_	O
127	study	_	_	O
128	was	_	_	O
129	terminated	_	_	O
130	early	_	_	O
131	(	_	_	O
132	n	_	_	O
133	=	_	_	O
134	27	_	_	O
135	,	_	_	O
136	G1	_	_	O
137	=	_	_	O
138	13	_	_	O
139	,	_	_	O
140	G2	_	_	O
141	=	_	_	O
142	14	_	_	O
143	)	_	_	O
144	when	_	_	O
145	4/14	_	_	O
146	(	_	_	O
147	28.5	_	_	O
148	%	_	_	O
149	)	_	_	O
150	subjects	_	_	O
151	in	_	_	O
152	G2	_	_	O
153	developed	_	_	O
154	thrombotic	_	_	O
155	events	_	_	O
156	(	_	_	O
157	deep	_	_	O
158	vein	_	_	O
159	thrombosis	_	_	O
160	[	_	_	O
161	DVT	_	_	O
162	]	_	_	O
163	in	_	_	O
164	1	_	_	O
165	;	_	_	O
166	DVT	_	_	O
167	plus	_	_	O
168	pulmonary	_	_	O
169	embolism	_	_	O
170	[	_	_	O
171	PE	_	_	O
172	]	_	_	O
173	in	_	_	O
174	1	_	_	O
175	;	_	_	O
176	DVT	_	_	O
177	plus	_	_	O
178	PE	_	_	O
179	1	_	_	O
180	month	_	_	O
181	after	_	_	O
182	drug	_	_	O
183	discontinuation	_	_	O
184	in	_	_	O
185	1	_	_	O
186	;	_	_	O
187	and	_	_	O
188	brachial	_	_	O
189	vein	_	_	O
190	thrombosis	_	_	O
191	with	_	_	O
192	infected	_	_	O
193	Mediport	_	_	O
194	in	_	_	O
195	1	_	_	O
196	)	_	_	O
197	.	_	_	O

198	In	_	_	B-Premise
199	all	_	_	I-Premise
200	four	_	_	I-Premise
201	patients	_	_	I-Premise
202	,	_	_	I-Premise
203	Hgb	_	_	I-Premise
204	levels	_	_	I-Premise
205	were	_	_	I-Premise
206	normal	_	_	I-Premise
207	at	_	_	I-Premise
208	the	_	_	I-Premise
209	time	_	_	I-Premise
210	of	_	_	I-Premise
211	the	_	_	I-Premise
212	event	_	_	I-Premise
213	.	_	_	I-Premise

214	No	_	_	B-Premise
215	patient	_	_	I-Premise
216	in	_	_	I-Premise
217	G1	_	_	I-Premise
218	developed	_	_	I-Premise
219	a	_	_	I-Premise
220	thrombotic	_	_	I-Premise
221	event	_	_	I-Premise
222	.	_	_	I-Premise

223	There	_	_	B-Premise
224	were	_	_	I-Premise
225	no	_	_	I-Premise
226	significant	_	_	I-Premise
227	differences	_	_	I-Premise
228	in	_	_	I-Premise
229	demographic	_	_	I-Premise
230	characteristics	_	_	I-Premise
231	or	_	_	I-Premise
232	current	_	_	I-Premise
233	chemotherapy	_	_	I-Premise
234	regimen	_	_	I-Premise
235	in	_	_	I-Premise
236	G1	_	_	I-Premise
237	vs.	_	_	I-Premise
238	G2	_	_	I-Premise
239	.	_	_	I-Premise

240	The	_	_	O
241	decision	_	_	O
242	to	_	_	O
243	terminate	_	_	O
244	the	_	_	O
245	trial	_	_	O
246	was	_	_	O
247	made	_	_	O
248	after	_	_	O
249	considerable	_	_	O
250	deliberation	_	_	O
251	.	_	_	O

252	The	_	_	B-Premise
253	increased	_	_	I-Premise
254	incidence	_	_	I-Premise
255	of	_	_	I-Premise
256	thrombotic	_	_	I-Premise
257	events	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	r-HuEPO	_	_	I-Premise
261	(	_	_	I-Premise
262	G2	_	_	I-Premise
263	)	_	_	I-Premise
264	arm	_	_	I-Premise
265	of	_	_	I-Premise
266	this	_	_	I-Premise
267	study	_	_	I-Premise
268	exceeds	_	_	I-Premise
269	that	_	_	I-Premise
270	in	_	_	I-Premise
271	prior	_	_	I-Premise
272	studies	_	_	I-Premise
273	in	_	_	I-Premise
274	this	_	_	I-Premise
275	population	_	_	I-Premise
276	and	_	_	I-Premise
277	prior	_	_	I-Premise
278	r-HuEPO	_	_	I-Premise
279	trials	_	_	I-Premise
280	.	_	_	I-Premise

281	This	_	_	B-Claim
282	may	_	_	I-Claim
283	relate	_	_	I-Claim
284	to	_	_	I-Claim
285	the	_	_	I-Claim
286	administration	_	_	I-Claim
287	of	_	_	I-Claim
288	r-HuEPO	_	_	I-Claim
289	in	_	_	I-Claim
290	this	_	_	I-Claim
291	high-risk	_	_	I-Claim
292	population	_	_	I-Claim
293	,	_	_	I-Claim
294	but	_	_	B-Claim
295	the	_	_	I-Claim
296	small	_	_	I-Claim
297	sample	_	_	I-Claim
298	size	_	_	I-Claim
299	and	_	_	I-Claim
300	possible	_	_	I-Claim
301	predisposing	_	_	I-Claim
302	risk	_	_	I-Claim
303	factors	_	_	I-Claim
304	preclude	_	_	I-Claim
305	definitive	_	_	I-Claim
306	conclusions	_	_	I-Claim
307	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	intraoperative	_	_	O
8	mitomycin	_	_	O
9	C	_	_	O
10	(	_	_	O
11	MMC	_	_	O
12	)	_	_	O
13	in	_	_	O
14	eyes	_	_	O
15	undergoing	_	_	O
16	Ahmed	_	_	O
17	Glaucoma	_	_	O
18	Valve	_	_	O
19	implantation	_	_	O
20	.	_	_	O

21	Randomized	_	_	O
22	controlled	_	_	O
23	clinical	_	_	O
24	trial	_	_	O
25	.	_	_	O

26	Sixty	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	refractory	_	_	O
30	glaucoma	_	_	O
31	.	_	_	O

32	Sixty	_	_	O
33	eyes	_	_	O
34	of	_	_	O
35	60	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	refractory	_	_	O
39	glaucoma	_	_	O
40	were	_	_	O
41	randomized	_	_	O
42	to	_	_	O
43	receive	_	_	O
44	intraoperative	_	_	O
45	MMC	_	_	O
46	(	_	_	O
47	0.5	_	_	O
48	mg/ml	_	_	O
49	for	_	_	O
50	5	_	_	O
51	minutes	_	_	O
52	)	_	_	O
53	(	_	_	O
54	n	_	_	O
55	=	_	_	O
56	34	_	_	O
57	)	_	_	O
58	or	_	_	O
59	balanced	_	_	O
60	salt	_	_	O
61	solution	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	26	_	_	O
66	)	_	_	O
67	during	_	_	O
68	Ahmed	_	_	O
69	Glaucoma	_	_	O
70	Valve	_	_	O
71	implantation	_	_	O
72	.	_	_	O

73	Surgical	_	_	O
74	success	_	_	O
75	was	_	_	O
76	defined	_	_	O
77	according	_	_	O
78	to	_	_	O
79	2	_	_	O
80	different	_	_	O
81	criteria	_	_	O
82	:	_	_	O
83	(	_	_	O
84	1	_	_	O
85	)	_	_	O
86	postoperative	_	_	O
87	intraocular	_	_	O
88	pressure	_	_	O
89	(	_	_	O
90	IOP	_	_	O
91	)	_	_	O
92	between	_	_	O
93	6	_	_	O
94	and	_	_	O
95	21	_	_	O
96	mmHg	_	_	O
97	,	_	_	O
98	with	_	_	O
99	or	_	_	O
100	without	_	_	O
101	antiglaucoma	_	_	O
102	medications	_	_	O
103	,	_	_	O
104	and	_	_	O
105	(	_	_	O
106	2	_	_	O
107	)	_	_	O
108	IOP	_	_	O
109	reduction	_	_	O
110	of	_	_	O
111	at	_	_	O
112	least	_	_	O
113	30	_	_	O
114	%	_	_	O
115	relative	_	_	O
116	to	_	_	O
117	preoperative	_	_	O
118	values	_	_	O
119	.	_	_	O

120	Eyes	_	_	O
121	requiring	_	_	O
122	additional	_	_	O
123	glaucoma	_	_	O
124	surgery	_	_	O
125	,	_	_	O
126	developing	_	_	O
127	phthisis	_	_	O
128	,	_	_	O
129	or	_	_	O
130	showing	_	_	O
131	loss	_	_	O
132	of	_	_	O
133	light	_	_	O
134	perception	_	_	O
135	were	_	_	O
136	classified	_	_	O
137	as	_	_	O
138	failures	_	_	O
139	.	_	_	O

140	Success	_	_	O
141	rates	_	_	O
142	in	_	_	O
143	both	_	_	O
144	groups	_	_	O
145	were	_	_	O
146	compared	_	_	O
147	using	_	_	O
148	Kaplan-Meier	_	_	O
149	survival	_	_	O
150	curves	_	_	O
151	and	_	_	O
152	the	_	_	O
153	log	_	_	O
154	rank	_	_	O
155	test	_	_	O
156	.	_	_	O

157	Other	_	_	O
158	outcome	_	_	O
159	measures	_	_	O
160	were	_	_	O
161	mean	_	_	O
162	IOP	_	_	O
163	,	_	_	O
164	number	_	_	O
165	of	_	_	O
166	glaucoma	_	_	O
167	medications	_	_	O
168	,	_	_	O
169	and	_	_	O
170	complications	_	_	O
171	.	_	_	O

172	After	_	_	B-Premise
173	a	_	_	I-Premise
174	mean	_	_	I-Premise
175	follow-up	_	_	I-Premise
176	of	_	_	I-Premise
177	12.3	_	_	I-Premise
178	months	_	_	I-Premise
179	,	_	_	I-Premise
180	Kaplan-Meier	_	_	I-Premise
181	survival	_	_	I-Premise
182	analysis	_	_	I-Premise
183	showed	_	_	I-Premise
184	a	_	_	I-Premise
185	probability	_	_	I-Premise
186	of	_	_	I-Premise
187	success	_	_	I-Premise
188	of	_	_	I-Premise
189	59	_	_	I-Premise
190	%	_	_	I-Premise
191	at	_	_	I-Premise
192	18	_	_	I-Premise
193	months	_	_	I-Premise
194	for	_	_	I-Premise
195	the	_	_	I-Premise
196	MMC	_	_	I-Premise
197	group	_	_	I-Premise
198	and	_	_	I-Premise
199	61	_	_	I-Premise
200	%	_	_	I-Premise
201	for	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	when	_	_	I-Premise
206	the	_	_	I-Premise
207	first	_	_	I-Premise
208	criterion	_	_	I-Premise
209	for	_	_	I-Premise
210	success	_	_	I-Premise
211	was	_	_	I-Premise
212	used	_	_	I-Premise
213	(	_	_	I-Premise
214	IOP	_	_	I-Premise
215	between	_	_	I-Premise
216	6	_	_	I-Premise
217	and	_	_	I-Premise
218	21	_	_	I-Premise
219	mmHg	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	When	_	_	B-Premise
223	an	_	_	I-Premise
224	IOP	_	_	I-Premise
225	reduction	_	_	I-Premise
226	of	_	_	I-Premise
227	at	_	_	I-Premise
228	least	_	_	I-Premise
229	30	_	_	I-Premise
230	%	_	_	I-Premise
231	was	_	_	I-Premise
232	used	_	_	I-Premise
233	as	_	_	I-Premise
234	the	_	_	I-Premise
235	criterion	_	_	I-Premise
236	to	_	_	I-Premise
237	define	_	_	I-Premise
238	success	_	_	I-Premise
239	,	_	_	I-Premise
240	the	_	_	I-Premise
241	Kaplan-Meier	_	_	I-Premise
242	survival	_	_	I-Premise
243	analysis	_	_	I-Premise
244	demonstrated	_	_	I-Premise
245	a	_	_	I-Premise
246	probability	_	_	I-Premise
247	of	_	_	I-Premise
248	success	_	_	I-Premise
249	at	_	_	I-Premise
250	18	_	_	I-Premise
251	months	_	_	I-Premise
252	of	_	_	I-Premise
253	62	_	_	I-Premise
254	%	_	_	I-Premise
255	for	_	_	I-Premise
256	the	_	_	I-Premise
257	MMC	_	_	I-Premise
258	group	_	_	I-Premise
259	and	_	_	I-Premise
260	67	_	_	I-Premise
261	%	_	_	I-Premise
262	for	_	_	I-Premise
263	the	_	_	I-Premise
264	control	_	_	I-Premise
265	group	_	_	I-Premise
266	.	_	_	I-Premise

267	There	_	_	B-Premise
268	were	_	_	I-Premise
269	no	_	_	I-Premise
270	significant	_	_	I-Premise
271	differences	_	_	I-Premise
272	in	_	_	I-Premise
273	survival	_	_	I-Premise
274	rates	_	_	I-Premise
275	between	_	_	I-Premise
276	the	_	_	I-Premise
277	2	_	_	I-Premise
278	groups	_	_	I-Premise
279	with	_	_	I-Premise
280	either	_	_	I-Premise
281	criterion	_	_	I-Premise
282	(	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	0.75	_	_	I-Premise
286	and	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	0.37	_	_	I-Premise
290	,	_	_	I-Premise
291	respectively	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	After	_	_	B-Premise
295	15	_	_	I-Premise
296	days	_	_	I-Premise
297	postoperatively	_	_	I-Premise
298	,	_	_	I-Premise
299	the	_	_	I-Premise
300	mean	_	_	I-Premise
301	IOP	_	_	I-Premise
302	did	_	_	I-Premise
303	not	_	_	I-Premise
304	significantly	_	_	I-Premise
305	differ	_	_	I-Premise
306	for	_	_	I-Premise
307	both	_	_	I-Premise
308	MMC	_	_	I-Premise
309	and	_	_	I-Premise
310	control	_	_	I-Premise
311	eyes	_	_	I-Premise
312	.	_	_	I-Premise

313	Mean	_	_	B-Premise
314	numbers	_	_	I-Premise
315	of	_	_	I-Premise
316	postoperative	_	_	I-Premise
317	antiglaucoma	_	_	I-Premise
318	medications	_	_	I-Premise
319	were	_	_	I-Premise
320	similar	_	_	I-Premise
321	in	_	_	I-Premise
322	MMC-treated	_	_	I-Premise
323	eyes	_	_	I-Premise
324	and	_	_	I-Premise
325	controls	_	_	I-Premise
326	.	_	_	I-Premise

327	There	_	_	B-Premise
328	was	_	_	I-Premise
329	no	_	_	I-Premise
330	significant	_	_	I-Premise
331	difference	_	_	I-Premise
332	between	_	_	I-Premise
333	the	_	_	I-Premise
334	incidences	_	_	I-Premise
335	of	_	_	I-Premise
336	postoperative	_	_	I-Premise
337	complications	_	_	I-Premise
338	in	_	_	I-Premise
339	both	_	_	I-Premise
340	groups	_	_	I-Premise
341	.	_	_	I-Premise

342	Mitomycin	_	_	B-Claim
343	C	_	_	I-Claim
344	did	_	_	I-Claim
345	not	_	_	I-Claim
346	increase	_	_	I-Claim
347	the	_	_	I-Claim
348	short-	_	_	I-Claim
349	or	_	_	I-Claim
350	intermediate-term	_	_	I-Claim
351	success	_	_	I-Claim
352	rates	_	_	I-Claim
353	of	_	_	I-Claim
354	Ahmed	_	_	I-Claim
355	Glaucoma	_	_	I-Claim
356	Valve	_	_	I-Claim
357	implantation	_	_	I-Claim
358	.	_	_	I-Claim


0	The	_	_	O
1	newer	_	_	O
2	ocular	_	_	O
3	hypotensive	_	_	O
4	agents	_	_	O
5	available	_	_	O
6	to	_	_	O
7	treat	_	_	O
8	glaucoma	_	_	O
9	and	_	_	O
10	ocular	_	_	O
11	hypertension	_	_	O
12	(	_	_	O
13	OHT	_	_	O
14	)	_	_	O
15	include	_	_	O
16	latanoprost	_	_	O
17	,	_	_	O
18	a	_	_	O
19	prostaglandin	_	_	O
20	F	_	_	O
21	(	_	_	O
22	2alpha	_	_	O
23	)	_	_	O
24	analogue	_	_	O
25	,	_	_	O
26	and	_	_	O
27	the	_	_	O
28	fixed	_	_	O
29	combination	_	_	O
30	of	_	_	O
31	dorzolamide	_	_	O
32	hydrochloride	_	_	O
33	,	_	_	O
34	a	_	_	O
35	carbonic	_	_	O
36	anhydrase	_	_	O
37	inhibitor	_	_	O
38	,	_	_	O
39	and	_	_	O
40	timolol	_	_	O
41	maleate	_	_	O
42	,	_	_	O
43	a	_	_	O
44	beta-blocker	_	_	O
45	.	_	_	O

46	The	_	_	O
47	aim	_	_	O
48	of	_	_	O
49	this	_	_	O
50	study	_	_	O
51	was	_	_	O
52	to	_	_	O
53	compare	_	_	O
54	the	_	_	O
55	efficacy	_	_	O
56	and	_	_	O
57	tolerability	_	_	O
58	of	_	_	O
59	latanoprost	_	_	O
60	with	_	_	O
61	that	_	_	O
62	of	_	_	O
63	the	_	_	O
64	fixed	_	_	O
65	combination	_	_	O
66	of	_	_	O
67	dorzolamide	_	_	O
68	and	_	_	O
69	timolol	_	_	O
70	over	_	_	O
71	8	_	_	O
72	weeks	_	_	O
73	.	_	_	O

74	This	_	_	O
75	interventional	_	_	O
76	,	_	_	O
77	8-week	_	_	O
78	,	_	_	O
79	randomized	_	_	O
80	,	_	_	O
81	open-label	_	_	O
82	,	_	_	O
83	parallel-group	_	_	O
84	study	_	_	O
85	was	_	_	O
86	conducted	_	_	O
87	at	_	_	O
88	18	_	_	O
89	centers	_	_	O
90	in	_	_	O
91	6	_	_	O
92	Latin	_	_	O
93	American	_	_	O
94	countries	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	with	_	_	O
98	unilateral	_	_	O
99	or	_	_	O
100	bilateral	_	_	O
101	primary	_	_	O
102	open-angle	_	_	O
103	,	_	_	O
104	pigmentary	_	_	O
105	,	_	_	O
106	or	_	_	O
107	exfoliative	_	_	O
108	glaucoma	_	_	O
109	or	_	_	O
110	OHT	_	_	O
111	were	_	_	O
112	randomized	_	_	O
113	to	_	_	O
114	receive	_	_	O
115	latanoprost	_	_	O
116	,	_	_	O
117	1	_	_	O
118	drop	_	_	O
119	in	_	_	O
120	the	_	_	O
121	affected	_	_	O
122	eye	_	_	O
123	QD	_	_	O
124	(	_	_	O
125	evening	_	_	O
126	)	_	_	O
127	,	_	_	O
128	or	_	_	O
129	fixed	_	_	O
130	combination	_	_	O
131	dorzolamide/timolol	_	_	O
132	,	_	_	O
133	1	_	_	O
134	drop	_	_	O
135	in	_	_	O
136	the	_	_	O
137	affected	_	_	O
138	eye	_	_	O
139	BID	_	_	O
140	(	_	_	O
141	morning	_	_	O
142	and	_	_	O
143	evening	_	_	O
144	)	_	_	O
145	.	_	_	O

146	Medications	_	_	O
147	were	_	_	O
148	self-administered	_	_	O
149	,	_	_	O
150	1	_	_	O
151	drop	_	_	O
152	per	_	_	O
153	affected	_	_	O
154	eye	_	_	O
155	.	_	_	O

156	At	_	_	O
157	baseline	_	_	O
158	and	_	_	O
159	week	_	_	O
160	8	_	_	O
161	,	_	_	O
162	intraocular	_	_	O
163	pressure	_	_	O
164	(	_	_	O
165	IOP	_	_	O
166	)	_	_	O
167	was	_	_	O
168	measured	_	_	O
169	3	_	_	O
170	times	_	_	O
171	each	_	_	O
172	at	_	_	O
173	8:30	_	_	O
174	am	_	_	O
175	,	_	_	O
176	10:00	_	_	O
177	am	_	_	O
178	,	_	_	O
179	2:00	_	_	O
180	pm	_	_	O
181	,	_	_	O
182	and	_	_	O
183	5:00	_	_	O
184	pm	_	_	O
185	and	_	_	O
186	after	_	_	O
187	the	_	_	O
188	water-drinking	_	_	O
189	test	_	_	O
190	,	_	_	O
191	which	_	_	O
192	estimates	_	_	O
193	the	_	_	O
194	IOP	_	_	O
195	peak	_	_	O
196	of	_	_	O
197	diurnal	_	_	O
198	tension	_	_	O
199	curve	_	_	O
200	,	_	_	O
201	performed	_	_	O
202	following	_	_	O
203	the	_	_	O
204	5:00	_	_	O
205	pm	_	_	O
206	IOP	_	_	O
207	assessment	_	_	O
208	.	_	_	O

209	The	_	_	O
210	primary	_	_	O
211	efficacy	_	_	O
212	outcome	_	_	O
213	was	_	_	O
214	change	_	_	O
215	in	_	_	O
216	diurnal	_	_	O
217	IOP	_	_	O
218	(	_	_	O
219	the	_	_	O
220	mean	_	_	O
221	of	_	_	O
222	IOP	_	_	O
223	measurements	_	_	O
224	)	_	_	O
225	from	_	_	O
226	baseline	_	_	O
227	to	_	_	O
228	week	_	_	O
229	8	_	_	O
230	.	_	_	O

231	Adverse	_	_	O
232	effect	_	_	O
233	(	_	_	O
234	AE	_	_	O
235	)	_	_	O
236	data	_	_	O
237	were	_	_	O
238	recorded	_	_	O
239	at	_	_	O
240	each	_	_	O
241	visit	_	_	O
242	.	_	_	O

243	A	_	_	O
244	total	_	_	O
245	of	_	_	O
246	229	_	_	O
247	patients	_	_	O
248	were	_	_	O
249	randomized	_	_	O
250	(	_	_	O
251	latanoprost	_	_	O
252	,	_	_	O
253	n	_	_	O
254	=	_	_	O
255	112	_	_	O
256	;	_	_	O
257	dorzolamide/timolol	_	_	O
258	,	_	_	O
259	n	_	_	O
260	=	_	_	O
261	117	_	_	O
262	)	_	_	O
263	.	_	_	O

264	Mean	_	_	B-Premise
265	baseline	_	_	I-Premise
266	diurnal	_	_	I-Premise
267	IOP	_	_	I-Premise
268	values	_	_	I-Premise
269	were	_	_	I-Premise
270	similar	_	_	I-Premise
271	between	_	_	I-Premise
272	the	_	_	I-Premise
273	2	_	_	I-Premise
274	groups	_	_	I-Premise
275	.	_	_	I-Premise

276	Mean	_	_	B-Premise
277	(	_	_	I-Premise
278	SD	_	_	I-Premise
279	)	_	_	I-Premise
280	diurnal	_	_	I-Premise
281	IOP	_	_	I-Premise
282	reductions	_	_	I-Premise
283	at	_	_	I-Premise
284	week	_	_	I-Premise
285	8	_	_	I-Premise
286	before	_	_	I-Premise
287	the	_	_	I-Premise
288	water-drinking	_	_	I-Premise
289	test	_	_	I-Premise
290	were	_	_	I-Premise
291	6.9	_	_	I-Premise
292	(	_	_	I-Premise
293	3.0	_	_	I-Premise
294	)	_	_	I-Premise
295	mm	_	_	I-Premise
296	Hg	_	_	I-Premise
297	for	_	_	I-Premise
298	the	_	_	I-Premise
299	latanoprost	_	_	I-Premise
300	group	_	_	I-Premise
301	and	_	_	I-Premise
302	6.4	_	_	I-Premise
303	(	_	_	I-Premise
304	3.2	_	_	I-Premise
305	)	_	_	I-Premise
306	mm	_	_	I-Premise
307	Hg	_	_	I-Premise
308	for	_	_	I-Premise
309	the	_	_	I-Premise
310	dorzolamide/timolol	_	_	I-Premise
311	group	_	_	I-Premise
312	.	_	_	I-Premise

313	Mean	_	_	B-Premise
314	IOP	_	_	I-Premise
315	values	_	_	I-Premise
316	were	_	_	I-Premise
317	similar	_	_	I-Premise
318	at	_	_	I-Premise
319	all	_	_	I-Premise
320	time	_	_	I-Premise
321	points	_	_	I-Premise
322	except	_	_	I-Premise
323	at	_	_	I-Premise
324	5:00	_	_	I-Premise
325	pm	_	_	I-Premise
326	,	_	_	I-Premise
327	when	_	_	I-Premise
328	levels	_	_	I-Premise
329	were	_	_	I-Premise
330	significantly	_	_	I-Premise
331	lower	_	_	I-Premise
332	in	_	_	I-Premise
333	latanoprost-treated	_	_	I-Premise
334	patients	_	_	I-Premise
335	(	_	_	I-Premise
336	P	_	_	I-Premise
337	=	_	_	I-Premise
338	0.025	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	After	_	_	B-Premise
342	the	_	_	I-Premise
343	water-drinking	_	_	I-Premise
344	test	_	_	I-Premise
345	,	_	_	I-Premise
346	the	_	_	I-Premise
347	increase	_	_	I-Premise
348	in	_	_	I-Premise
349	IOP	_	_	I-Premise
350	values	_	_	I-Premise
351	was	_	_	I-Premise
352	similar	_	_	I-Premise
353	between	_	_	I-Premise
354	groups	_	_	I-Premise
355	at	_	_	I-Premise
356	baseline	_	_	I-Premise
357	but	_	_	I-Premise
358	lower	_	_	I-Premise
359	in	_	_	I-Premise
360	latanoprost-treated	_	_	I-Premise
361	patients	_	_	I-Premise
362	at	_	_	I-Premise
363	week	_	_	I-Premise
364	8	_	_	I-Premise
365	(	_	_	I-Premise
366	adjusted	_	_	I-Premise
367	difference	_	_	I-Premise
368	,	_	_	I-Premise
369	1.08	_	_	I-Premise
370	mm	_	_	I-Premise
371	Hg	_	_	I-Premise
372	;	_	_	I-Premise
373	P	_	_	I-Premise
374	=	_	_	I-Premise
375	0.012	_	_	I-Premise
376	)	_	_	I-Premise
377	.	_	_	I-Premise

378	Fewer	_	_	B-Premise
379	patients	_	_	I-Premise
380	treated	_	_	I-Premise
381	with	_	_	I-Premise
382	latanoprost	_	_	I-Premise
383	reported	_	_	I-Premise
384	ocular	_	_	I-Premise
385	or	_	_	I-Premise
386	systemic	_	_	I-Premise
387	AEs	_	_	I-Premise
388	(	_	_	I-Premise
389	P	_	_	I-Premise
390	=	_	_	I-Premise
391	0.025	_	_	I-Premise
392	and	_	_	I-Premise
393	P	_	_	I-Premise
394	<	_	_	I-Premise
395	0.001	_	_	I-Premise
396	,	_	_	I-Premise
397	respectively	_	_	I-Premise
398	)	_	_	I-Premise
399	.	_	_	I-Premise

400	In	_	_	B-Claim
401	this	_	_	I-Claim
402	study	_	_	I-Claim
403	of	_	_	I-Claim
404	patients	_	_	I-Claim
405	with	_	_	I-Claim
406	unilateral	_	_	I-Claim
407	or	_	_	I-Claim
408	bilateral	_	_	I-Claim
409	primary	_	_	I-Claim
410	open-angle	_	_	I-Claim
411	,	_	_	I-Claim
412	pigmentary	_	_	I-Claim
413	,	_	_	I-Claim
414	or	_	_	I-Claim
415	exfoliative	_	_	I-Claim
416	glaucoma	_	_	I-Claim
417	or	_	_	I-Claim
418	OHT	_	_	I-Claim
419	IOP	_	_	I-Claim
420	reductions	_	_	I-Claim
421	generally	_	_	I-Claim
422	were	_	_	I-Claim
423	similar	_	_	I-Claim
424	between	_	_	I-Claim
425	treatment	_	_	I-Claim
426	groups	_	_	I-Claim
427	,	_	_	I-Claim
428	except	_	_	B-Claim
429	at	_	_	I-Claim
430	5:00	_	_	I-Claim
431	pm	_	_	I-Claim
432	,	_	_	I-Claim
433	when	_	_	I-Claim
434	the	_	_	I-Claim
435	mean	_	_	I-Claim
436	IOP	_	_	I-Claim
437	level	_	_	I-Claim
438	was	_	_	I-Claim
439	significantly	_	_	I-Claim
440	lower	_	_	I-Claim
441	in	_	_	I-Claim
442	latanoprost-treated	_	_	I-Claim
443	patients	_	_	I-Claim
444	.	_	_	I-Claim

445	Latanoprost	_	_	B-Claim
446	was	_	_	I-Claim
447	better	_	_	I-Claim
448	tolerated	_	_	I-Claim
449	than	_	_	I-Claim
450	fixed-combination	_	_	I-Claim
451	dorzolamide	_	_	I-Claim
452	and	_	_	I-Claim
453	timolol	_	_	I-Claim
454	.	_	_	I-Claim


0	Malnutrition	_	_	B-Claim
1	occurs	_	_	I-Claim
2	frequently	_	_	I-Claim
3	in	_	_	I-Claim
4	patients	_	_	I-Claim
5	with	_	_	I-Claim
6	cancer	_	_	I-Claim
7	of	_	_	I-Claim
8	the	_	_	I-Claim
9	gastrointestinal	_	_	I-Claim
10	(	_	_	I-Claim
11	GI	_	_	I-Claim
12	)	_	_	I-Claim
13	or	_	_	I-Claim
14	head	_	_	I-Claim
15	and	_	_	I-Claim
16	neck	_	_	I-Claim
17	area	_	_	I-Claim
18	and	_	_	I-Claim
19	can	_	_	I-Claim
20	lead	_	_	I-Claim
21	to	_	_	I-Claim
22	negative	_	_	I-Claim
23	outcomes	_	_	I-Claim
24	.	_	_	I-Claim

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	this	_	_	O
29	study	_	_	O
30	is	_	_	O
31	to	_	_	O
32	determine	_	_	O
33	the	_	_	O
34	impact	_	_	O
35	of	_	_	O
36	early	_	_	O
37	and	_	_	O
38	intensive	_	_	O
39	nutrition	_	_	O
40	intervention	_	_	O
41	(	_	_	O
42	NI	_	_	O
43	)	_	_	O
44	on	_	_	O
45	body	_	_	O
46	weight	_	_	O
47	,	_	_	O
48	body	_	_	O
49	composition	_	_	O
50	,	_	_	O
51	nutritional	_	_	O
52	status	_	_	O
53	,	_	_	O
54	global	_	_	O
55	quality	_	_	O
56	of	_	_	O
57	life	_	_	O
58	(	_	_	O
59	QoL	_	_	O
60	)	_	_	O
61	and	_	_	O
62	physical	_	_	O
63	function	_	_	O
64	compared	_	_	O
65	to	_	_	O
66	usual	_	_	O
67	practice	_	_	O
68	in	_	_	O
69	oncology	_	_	O
70	outpatients	_	_	O
71	receiving	_	_	O
72	radiotherapy	_	_	O
73	to	_	_	O
74	the	_	_	O
75	GI	_	_	O
76	or	_	_	O
77	head	_	_	O
78	and	_	_	O
79	neck	_	_	O
80	area	_	_	O
81	.	_	_	O

82	Outpatients	_	_	O
83	commencing	_	_	O
84	at	_	_	O
85	least	_	_	O
86	20	_	_	O
87	fractions	_	_	O
88	of	_	_	O
89	radiotherapy	_	_	O
90	to	_	_	O
91	the	_	_	O
92	GI	_	_	O
93	or	_	_	O
94	head	_	_	O
95	and	_	_	O
96	neck	_	_	O
97	area	_	_	O
98	were	_	_	O
99	randomised	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	intensive	_	_	O
103	,	_	_	O
104	individualised	_	_	O
105	nutrition	_	_	O
106	counselling	_	_	O
107	by	_	_	O
108	a	_	_	O
109	dietitian	_	_	O
110	using	_	_	O
111	a	_	_	O
112	standard	_	_	O
113	protocol	_	_	O
114	and	_	_	O
115	oral	_	_	O
116	supplements	_	_	O
117	if	_	_	O
118	required	_	_	O
119	,	_	_	O
120	or	_	_	O
121	the	_	_	O
122	usual	_	_	O
123	practice	_	_	O
124	of	_	_	O
125	the	_	_	O
126	centre	_	_	O
127	(	_	_	O
128	general	_	_	O
129	advice	_	_	O
130	and	_	_	O
131	nutrition	_	_	O
132	booklet	_	_	O
133	)	_	_	O
134	.	_	_	O

135	Outcome	_	_	O
136	parameters	_	_	O
137	were	_	_	O
138	measured	_	_	O
139	at	_	_	O
140	baseline	_	_	O
141	and	_	_	O
142	4	_	_	O
143	,	_	_	O
144	8	_	_	O
145	and	_	_	O
146	12	_	_	O
147	weeks	_	_	O
148	after	_	_	O
149	commencing	_	_	O
150	radiotherapy	_	_	O
151	using	_	_	O
152	valid	_	_	O
153	and	_	_	O
154	reliable	_	_	O
155	tools	_	_	O
156	.	_	_	O

157	A	_	_	O
158	total	_	_	O
159	of	_	_	O
160	60	_	_	O
161	patients	_	_	O
162	(	_	_	O
163	51	_	_	O
164	M	_	_	O
165	:	_	_	O
166	9	_	_	O
167	F	_	_	O
168	;	_	_	O
169	mean	_	_	O
170	age	_	_	O
171	61.9+/-14.0	_	_	O
172	years	_	_	O
173	)	_	_	O
174	were	_	_	O
175	randomised	_	_	O
176	to	_	_	O
177	receive	_	_	O
178	either	_	_	O
179	NI	_	_	O
180	(	_	_	O
181	n=29	_	_	O
182	)	_	_	O
183	or	_	_	O
184	usual	_	_	O
185	care	_	_	O
186	(	_	_	O
187	UC	_	_	O
188	)	_	_	O
189	(	_	_	O
190	n=31	_	_	O
191	)	_	_	O
192	.	_	_	O

193	The	_	_	B-Premise
194	NI	_	_	I-Premise
195	group	_	_	I-Premise
196	had	_	_	I-Premise
197	statistically	_	_	I-Premise
198	smaller	_	_	I-Premise
199	deteriorations	_	_	I-Premise
200	in	_	_	I-Premise
201	weight	_	_	I-Premise
202	(	_	_	I-Premise
203	P	_	_	I-Premise
204	<	_	_	I-Premise
205	0.001	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	nutritional	_	_	I-Premise
209	status	_	_	I-Premise
210	(	_	_	I-Premise
211	P=0.020	_	_	I-Premise
212	)	_	_	I-Premise
213	and	_	_	I-Premise
214	global	_	_	I-Premise
215	QoL	_	_	I-Premise
216	(	_	_	I-Premise
217	P=0.009	_	_	I-Premise
218	)	_	_	I-Premise
219	compared	_	_	I-Premise
220	with	_	_	I-Premise
221	those	_	_	I-Premise
222	receiving	_	_	I-Premise
223	UC	_	_	I-Premise
224	.	_	_	I-Premise

225	Clinically	_	_	B-Premise
226	,	_	_	I-Premise
227	but	_	_	I-Premise
228	not	_	_	I-Premise
229	statistically	_	_	I-Premise
230	significant	_	_	I-Premise
231	differences	_	_	I-Premise
232	in	_	_	I-Premise
233	fat-free	_	_	I-Premise
234	mass	_	_	I-Premise
235	were	_	_	I-Premise
236	observed	_	_	I-Premise
237	between	_	_	I-Premise
238	the	_	_	I-Premise
239	groups	_	_	I-Premise
240	(	_	_	I-Premise
241	P=0.195	_	_	I-Premise
242	)	_	_	I-Premise
243	.	_	_	I-Premise

244	Early	_	_	B-Claim
245	and	_	_	I-Claim
246	intensive	_	_	I-Claim
247	NI	_	_	I-Claim
248	appears	_	_	I-Claim
249	beneficial	_	_	I-Claim
250	in	_	_	I-Claim
251	terms	_	_	I-Claim
252	of	_	_	I-Claim
253	minimising	_	_	I-Claim
254	weight	_	_	I-Claim
255	loss	_	_	I-Claim
256	,	_	_	I-Claim
257	deterioration	_	_	I-Claim
258	in	_	_	I-Claim
259	nutritional	_	_	I-Claim
260	status	_	_	I-Claim
261	,	_	_	I-Claim
262	global	_	_	I-Claim
263	QoL	_	_	I-Claim
264	and	_	_	I-Claim
265	physical	_	_	I-Claim
266	function	_	_	I-Claim
267	in	_	_	I-Claim
268	oncology	_	_	I-Claim
269	outpatients	_	_	I-Claim
270	receiving	_	_	I-Claim
271	radiotherapy	_	_	I-Claim
272	to	_	_	I-Claim
273	the	_	_	I-Claim
274	GI	_	_	I-Claim
275	or	_	_	I-Claim
276	head	_	_	I-Claim
277	and	_	_	I-Claim
278	neck	_	_	I-Claim
279	area	_	_	I-Claim
280	.	_	_	I-Claim

281	Weight	_	_	B-Claim
282	maintenance	_	_	I-Claim
283	in	_	_	I-Claim
284	this	_	_	I-Claim
285	population	_	_	I-Claim
286	leads	_	_	I-Claim
287	to	_	_	I-Claim
288	beneficial	_	_	I-Claim
289	outcomes	_	_	I-Claim
290	and	_	_	I-Claim
291	suggests	_	_	I-Claim
292	that	_	_	I-Claim
293	this	_	_	I-Claim
294	,	_	_	I-Claim
295	rather	_	_	I-Claim
296	than	_	_	I-Claim
297	weight	_	_	I-Claim
298	gain	_	_	I-Claim
299	,	_	_	I-Claim
300	may	_	_	I-Claim
301	be	_	_	I-Claim
302	a	_	_	I-Claim
303	more	_	_	I-Claim
304	appropriate	_	_	I-Claim
305	aim	_	_	I-Claim
306	of	_	_	I-Claim
307	NI	_	_	I-Claim
308	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	Baerveldt	_	_	O
8	and	_	_	O
9	Ahmed	_	_	O
10	glaucoma	_	_	O
11	drainage	_	_	O
12	implants	_	_	O
13	in	_	_	O
14	Asian	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	refractory	_	_	O
18	glaucoma	_	_	O
19	.	_	_	O

20	Retrospective	_	_	O
21	nonrandomized	_	_	O
22	study	_	_	O
23	.	_	_	O

24	Forty-one	_	_	O
25	patients	_	_	O
26	.	_	_	O

27	The	_	_	O
28	authors	_	_	O
29	reviewed	_	_	O
30	the	_	_	O
31	insertion	_	_	O
32	of	_	_	O
33	18	_	_	O
34	Ahmed	_	_	O
35	glaucoma	_	_	O
36	valved	_	_	O
37	(	_	_	O
38	AGV-S2	_	_	O
39	)	_	_	O
40	implants	_	_	O
41	and	_	_	O
42	24	_	_	O
43	350	_	_	O
44	mm	_	_	O
45	(	_	_	O
46	2	_	_	O
47	)	_	_	O
48	Baerveldt	_	_	O
49	glaucoma	_	_	O
50	implants	_	_	O
51	performed	_	_	O
52	by	_	_	O
53	a	_	_	O
54	single	_	_	O
55	surgeon	_	_	O
56	at	_	_	O
57	the	_	_	O
58	Department	_	_	O
59	of	_	_	O
60	Ophthalmology	_	_	O
61	,	_	_	O
62	National	_	_	O
63	University	_	_	O
64	Hospital	_	_	O
65	,	_	_	O
66	Singapore	_	_	O
67	,	_	_	O
68	from	_	_	O
69	January	_	_	O
70	1	_	_	O
71	,	_	_	O
72	2000	_	_	O
73	,	_	_	O
74	to	_	_	O
75	December	_	_	O
76	31	_	_	O
77	,	_	_	O
78	2000	_	_	O
79	.	_	_	O

80	A	_	_	O
81	total	_	_	O
82	of	_	_	O
83	42	_	_	O
84	glaucoma	_	_	O
85	drainage	_	_	O
86	implants	_	_	O
87	was	_	_	O
88	inserted	_	_	O
89	into	_	_	O
90	the	_	_	O
91	eyes	_	_	O
92	of	_	_	O
93	41	_	_	O
94	patients	_	_	O
95	.	_	_	O

96	All	_	_	O
97	patients	_	_	O
98	had	_	_	O
99	at	_	_	O
100	least	_	_	O
101	6	_	_	O
102	months	_	_	O
103	of	_	_	O
104	follow-up	_	_	O
105	.	_	_	O

106	Intraocular	_	_	O
107	pressure	_	_	O
108	(	_	_	O
109	IOP	_	_	O
110	)	_	_	O
111	,	_	_	O
112	visual	_	_	O
113	acuity	_	_	O
114	,	_	_	O
115	and	_	_	O
116	complications	_	_	O
117	.	_	_	O

118	Both	_	_	B-Premise
119	drainage	_	_	I-Premise
120	implants	_	_	I-Premise
121	achieved	_	_	I-Premise
122	remarkable	_	_	I-Premise
123	reductions	_	_	I-Premise
124	in	_	_	I-Premise
125	IOP	_	_	I-Premise
126	;	_	_	I-Premise
127	from	_	_	I-Premise
128	pretreatment	_	_	I-Premise
129	IOP	_	_	I-Premise
130	of	_	_	I-Premise
131	40.1+/-13.8	_	_	I-Premise
132	mmHg	_	_	I-Premise
133	and	_	_	I-Premise
134	43.7+/-9.3	_	_	I-Premise
135	mmHg	_	_	I-Premise
136	to	_	_	I-Premise
137	postoperative	_	_	I-Premise
138	IOP	_	_	I-Premise
139	of	_	_	I-Premise
140	17.4+/-6.2	_	_	I-Premise
141	and	_	_	I-Premise
142	14.9+/-5.5	_	_	I-Premise
143	mmHg	_	_	I-Premise
144	in	_	_	I-Premise
145	the	_	_	I-Premise
146	Baerveldt	_	_	I-Premise
147	and	_	_	I-Premise
148	Ahmed	_	_	I-Premise
149	groups	_	_	I-Premise
150	,	_	_	I-Premise
151	respectively	_	_	I-Premise
152	.	_	_	I-Premise

153	A	_	_	B-Premise
154	decrease	_	_	I-Premise
155	in	_	_	I-Premise
156	IOP	_	_	I-Premise
157	of	_	_	I-Premise
158	56.6	_	_	I-Premise
159	%	_	_	I-Premise
160	and	_	_	I-Premise
161	65.9	_	_	I-Premise
162	%	_	_	I-Premise
163	had	_	_	I-Premise
164	been	_	_	I-Premise
165	achieved	_	_	I-Premise
166	.	_	_	I-Premise

167	Success	_	_	B-Premise
168	rates	_	_	I-Premise
169	were	_	_	I-Premise
170	20	_	_	I-Premise
171	(	_	_	I-Premise
172	83.3	_	_	I-Premise
173	%	_	_	I-Premise
174	)	_	_	I-Premise
175	for	_	_	I-Premise
176	Baerveldt	_	_	I-Premise
177	and	_	_	I-Premise
178	12	_	_	I-Premise
179	(	_	_	I-Premise
180	66.7	_	_	I-Premise
181	%	_	_	I-Premise
182	)	_	_	I-Premise
183	for	_	_	I-Premise
184	Ahmed	_	_	I-Premise
185	implants	_	_	I-Premise
186	,	_	_	I-Premise
187	whereas	_	_	I-Premise
188	qualified	_	_	I-Premise
189	success	_	_	I-Premise
190	occurred	_	_	I-Premise
191	in	_	_	I-Premise
192	1	_	_	I-Premise
193	(	_	_	I-Premise
194	4.2	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	Baerveldt	_	_	I-Premise
198	and	_	_	I-Premise
199	3	_	_	I-Premise
200	(	_	_	I-Premise
201	16.7	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	Ahmed	_	_	I-Premise
205	implants	_	_	I-Premise
206	.	_	_	I-Premise

207	Conversely	_	_	B-Premise
208	,	_	_	I-Premise
209	failure	_	_	I-Premise
210	to	_	_	I-Premise
211	control	_	_	I-Premise
212	IOP	_	_	I-Premise
213	occurred	_	_	I-Premise
214	in	_	_	I-Premise
215	3	_	_	I-Premise
216	(	_	_	I-Premise
217	12.5	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	Baerveldt	_	_	I-Premise
221	implants	_	_	I-Premise
222	and	_	_	I-Premise
223	3	_	_	I-Premise
224	(	_	_	I-Premise
225	16.7	_	_	I-Premise
226	%	_	_	I-Premise
227	)	_	_	I-Premise
228	Ahmed	_	_	I-Premise
229	implants	_	_	I-Premise
230	.	_	_	I-Premise

231	More	_	_	B-Premise
232	than	_	_	I-Premise
233	80	_	_	I-Premise
234	%	_	_	I-Premise
235	of	_	_	I-Premise
236	the	_	_	I-Premise
237	patients	_	_	I-Premise
238	had	_	_	I-Premise
239	maintained	_	_	I-Premise
240	or	_	_	I-Premise
241	improved	_	_	I-Premise
242	visual	_	_	I-Premise
243	function	_	_	I-Premise
244	,	_	_	I-Premise
245	whereas	_	_	I-Premise
246	only	_	_	I-Premise
247	4	_	_	I-Premise
248	(	_	_	I-Premise
249	16.0	_	_	I-Premise
250	%	_	_	I-Premise
251	)	_	_	I-Premise
252	of	_	_	I-Premise
253	the	_	_	I-Premise
254	patients	_	_	I-Premise
255	with	_	_	I-Premise
256	Baerveldt	_	_	I-Premise
257	implants	_	_	I-Premise
258	and	_	_	I-Premise
259	2	_	_	I-Premise
260	(	_	_	I-Premise
261	16.7	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	patients	_	_	I-Premise
265	with	_	_	I-Premise
266	Ahmed	_	_	I-Premise
267	implants	_	_	I-Premise
268	had	_	_	I-Premise
269	loss	_	_	I-Premise
270	of	_	_	I-Premise
271	more	_	_	I-Premise
272	than	_	_	I-Premise
273	1	_	_	I-Premise
274	Snellen	_	_	I-Premise
275	line	_	_	I-Premise
276	.	_	_	I-Premise

277	Both	_	_	B-Claim
278	Baerveldt	_	_	I-Claim
279	and	_	_	I-Claim
280	Ahmed	_	_	I-Claim
281	glaucoma	_	_	I-Claim
282	drainage	_	_	I-Claim
283	implants	_	_	I-Claim
284	performed	_	_	I-Claim
285	well	_	_	I-Claim
286	in	_	_	I-Claim
287	terms	_	_	I-Claim
288	of	_	_	I-Claim
289	IOP	_	_	I-Claim
290	control	_	_	I-Claim
291	,	_	_	I-Claim
292	preservation	_	_	I-Claim
293	of	_	_	I-Claim
294	visual	_	_	I-Claim
295	function	_	_	I-Claim
296	,	_	_	I-Claim
297	and	_	_	I-Claim
298	having	_	_	I-Claim
299	low	_	_	I-Claim
300	complication	_	_	I-Claim
301	rates	_	_	I-Claim
302	.	_	_	I-Claim


0	Bone	_	_	B-Claim
1	metastases	_	_	I-Claim
2	occur	_	_	I-Claim
3	in	_	_	I-Claim
4	most	_	_	I-Claim
5	women	_	_	I-Claim
6	with	_	_	I-Claim
7	advanced	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	and	_	_	I-Claim
11	can	_	_	I-Claim
12	lead	_	_	I-Claim
13	to	_	_	I-Claim
14	considerable	_	_	I-Claim
15	morbidity	_	_	I-Claim
16	and	_	_	I-Claim
17	a	_	_	I-Claim
18	rapid	_	_	I-Claim
19	deterioration	_	_	I-Claim
20	in	_	_	I-Claim
21	the	_	_	I-Claim
22	patient	_	_	I-Claim
23	's	_	_	I-Claim
24	quality	_	_	I-Claim
25	of	_	_	I-Claim
26	life	_	_	I-Claim
27	.	_	_	I-Claim

28	It	_	_	O
29	was	_	_	O
30	the	_	_	O
31	aim	_	_	O
32	of	_	_	O
33	the	_	_	O
34	present	_	_	O
35	study	_	_	O
36	to	_	_	O
37	assess	_	_	O
38	changes	_	_	O
39	in	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	and	_	_	O
44	bone	_	_	O
45	pain	_	_	O
46	due	_	_	O
47	to	_	_	O
48	intravenous	_	_	O
49	(	_	_	O
50	i.v	_	_	O
51	.	_	_	O
52	)	_	_	O

53	ibandronate	_	_	O
54	,	_	_	O
55	a	_	_	O
56	potent	_	_	O
57	third-generation	_	_	O
58	bisphosphonate	_	_	O
59	.	_	_	O

60	In	_	_	O
61	a	_	_	O
62	phase	_	_	O
63	III	_	_	O
64	randomised	_	_	O
65	,	_	_	O
66	double-blind	_	_	O
67	,	_	_	O
68	placebo-controlled	_	_	O
69	trial	_	_	O
70	in	_	_	O
71	patients	_	_	O
72	with	_	_	O
73	bone	_	_	O
74	metastases	_	_	O
75	due	_	_	O
76	to	_	_	O
77	breast	_	_	O
78	cancer	_	_	O
79	,	_	_	O
80	466	_	_	O
81	women	_	_	O
82	were	_	_	O
83	randomised	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	placebo	_	_	O
87	,	_	_	O
88	2	_	_	O
89	mg	_	_	O
90	ibandronate	_	_	O
91	or	_	_	O
92	6	_	_	O
93	mg	_	_	O
94	ibandronate	_	_	O
95	for	_	_	O
96	up	_	_	O
97	to	_	_	O
98	96	_	_	O
99	weeks	_	_	O
100	.	_	_	O

101	Treatment	_	_	O
102	was	_	_	O
103	administered	_	_	O
104	i.v	_	_	O
105	.	_	_	O

106	at	_	_	O
107	3-	_	_	O
108	or	_	_	O
109	4-weekly	_	_	O
110	intervals	_	_	O
111	.	_	_	O

112	Clinical	_	_	O
113	endpoints	_	_	O
114	included	_	_	O
115	the	_	_	O
116	incidence	_	_	O
117	of	_	_	O
118	adverse	_	_	O
119	events	_	_	O
120	,	_	_	O
121	quality	_	_	O
122	of	_	_	O
123	life	_	_	O
124	(	_	_	O
125	assessed	_	_	O
126	using	_	_	O
127	the	_	_	O
128	European	_	_	O
129	Organisation	_	_	O
130	for	_	_	O
131	the	_	_	O
132	Research	_	_	O
133	and	_	_	O
134	Treatment	_	_	O
135	of	_	_	O
136	Cancer	_	_	O
137	(	_	_	O
138	EORTC	_	_	O
139	)	_	_	O
140	Quality	_	_	O
141	of	_	_	O
142	Life	_	_	O
143	Scale	_	_	O
144	-	_	_	O
145	Core	_	_	O
146	30	_	_	O
147	questionnaire	_	_	O
148	(	_	_	O
149	QLQ-C30	_	_	O
150	)	_	_	O
151	)	_	_	O
152	,	_	_	O
153	and	_	_	O
154	bone	_	_	O
155	pain	_	_	O
156	(	_	_	O
157	assessed	_	_	O
158	on	_	_	O
159	a	_	_	O
160	5-point	_	_	O
161	scale	_	_	O
162	from	_	_	O
163	0=none	_	_	O
164	to	_	_	O
165	4=intolerable	_	_	O
166	)	_	_	O
167	.	_	_	O

168	Ibandronate	_	_	B-Premise
169	was	_	_	I-Premise
170	generally	_	_	I-Premise
171	well	_	_	I-Premise
172	tolerated	_	_	I-Premise
173	.	_	_	I-Premise

174	Compared	_	_	B-Premise
175	with	_	_	I-Premise
176	baseline	_	_	I-Premise
177	measurements	_	_	I-Premise
178	,	_	_	I-Premise
179	the	_	_	I-Premise
180	bone	_	_	I-Premise
181	pain	_	_	I-Premise
182	score	_	_	I-Premise
183	was	_	_	I-Premise
184	increased	_	_	I-Premise
185	at	_	_	I-Premise
186	the	_	_	I-Premise
187	last	_	_	I-Premise
188	assessment	_	_	I-Premise
189	in	_	_	I-Premise
190	both	_	_	I-Premise
191	the	_	_	I-Premise
192	placebo	_	_	I-Premise
193	and	_	_	I-Premise
194	2	_	_	I-Premise
195	mg	_	_	I-Premise
196	ibandronate	_	_	I-Premise
197	groups	_	_	I-Premise
198	,	_	_	I-Premise
199	but	_	_	B-Premise
200	was	_	_	I-Premise
201	significantly	_	_	I-Premise
202	reduced	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	patients	_	_	I-Premise
206	receiving	_	_	I-Premise
207	6	_	_	I-Premise
208	mg	_	_	I-Premise
209	ibandronate	_	_	I-Premise
210	(	_	_	I-Premise
211	-0.28+/-1.11	_	_	I-Premise
212	,	_	_	I-Premise
213	P	_	_	I-Premise
214	<	_	_	I-Premise
215	0.001	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	A	_	_	B-Premise
219	significant	_	_	I-Premise
220	improvement	_	_	I-Premise
221	in	_	_	I-Premise
222	quality	_	_	I-Premise
223	of	_	_	I-Premise
224	life	_	_	I-Premise
225	was	_	_	I-Premise
226	demonstrated	_	_	I-Premise
227	for	_	_	I-Premise
228	patients	_	_	I-Premise
229	treated	_	_	I-Premise
230	with	_	_	I-Premise
231	ibandronate	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	<	_	_	I-Premise
235	0.05	_	_	I-Premise
236	)	_	_	I-Premise
237	for	_	_	I-Premise
238	all	_	_	I-Premise
239	global	_	_	I-Premise
240	health	_	_	I-Premise
241	status	_	_	I-Premise
242	.	_	_	I-Premise

243	Overall	_	_	B-Premise
244	,	_	_	I-Premise
245	at	_	_	I-Premise
246	the	_	_	I-Premise
247	last	_	_	I-Premise
248	assessment	_	_	I-Premise
249	,	_	_	I-Premise
250	the	_	_	I-Premise
251	6	_	_	I-Premise
252	mg	_	_	I-Premise
253	ibandronate	_	_	I-Premise
254	group	_	_	I-Premise
255	showed	_	_	I-Premise
256	significantly	_	_	I-Premise
257	better	_	_	I-Premise
258	functioning	_	_	I-Premise
259	compared	_	_	I-Premise
260	with	_	_	I-Premise
261	placebo	_	_	I-Premise
262	(	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	0.004	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	had	_	_	I-Premise
270	significantly	_	_	I-Premise
271	better	_	_	I-Premise
272	scores	_	_	I-Premise
273	on	_	_	I-Premise
274	the	_	_	I-Premise
275	domains	_	_	I-Premise
276	of	_	_	I-Premise
277	physical	_	_	I-Premise
278	,	_	_	I-Premise
279	emotional	_	_	I-Premise
280	,	_	_	I-Premise
281	and	_	_	I-Premise
282	social	_	_	I-Premise
283	functioning	_	_	I-Premise
284	,	_	_	I-Premise
285	and	_	_	I-Premise
286	in	_	_	I-Premise
287	global	_	_	I-Premise
288	health	_	_	I-Premise
289	status	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	<	_	_	I-Premise
293	0.05	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	Significant	_	_	B-Premise
297	improvements	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	symptoms	_	_	I-Premise
301	of	_	_	I-Premise
302	fatigue	_	_	I-Premise
303	and	_	_	I-Premise
304	pain	_	_	I-Premise
305	were	_	_	I-Premise
306	also	_	_	I-Premise
307	observed	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	6	_	_	I-Premise
311	mg	_	_	I-Premise
312	ibandronate	_	_	I-Premise
313	group	_	_	I-Premise
314	.	_	_	I-Premise

315	I.v	_	_	B-Claim
316	.	_	_	I-Claim

317	ibandronate	_	_	I-Claim
318	treatment	_	_	I-Claim
319	leads	_	_	I-Claim
320	to	_	_	I-Claim
321	significant	_	_	I-Claim
322	improvements	_	_	I-Claim
323	in	_	_	I-Claim
324	quality	_	_	I-Claim
325	of	_	_	I-Claim
326	life	_	_	I-Claim
327	,	_	_	I-Claim
328	and	_	_	I-Claim
329	is	_	_	I-Claim
330	an	_	_	I-Claim
331	effective	_	_	I-Claim
332	and	_	_	I-Claim
333	well-tolerated	_	_	I-Claim
334	palliative	_	_	I-Claim
335	treatment	_	_	I-Claim
336	in	_	_	I-Claim
337	patients	_	_	I-Claim
338	with	_	_	I-Claim
339	bone	_	_	I-Claim
340	metastases	_	_	I-Claim
341	due	_	_	I-Claim
342	to	_	_	I-Claim
343	breast	_	_	I-Claim
344	cancer	_	_	I-Claim
345	.	_	_	I-Claim


0	Advice	_	_	B-Claim
1	to	_	_	I-Claim
2	rest	_	_	I-Claim
3	and	_	_	I-Claim
4	take	_	_	I-Claim
5	things	_	_	I-Claim
6	easy	_	_	I-Claim
7	if	_	_	I-Claim
8	patients	_	_	I-Claim
9	become	_	_	I-Claim
10	fatigued	_	_	I-Claim
11	during	_	_	I-Claim
12	radiotherapy	_	_	I-Claim
13	may	_	_	I-Claim
14	be	_	_	I-Claim
15	detrimental	_	_	I-Claim
16	.	_	_	I-Claim

17	Aerobic	_	_	B-Premise
18	walking	_	_	I-Premise
19	improves	_	_	I-Premise
20	physical	_	_	I-Premise
21	functioning	_	_	I-Premise
22	and	_	_	I-Premise
23	has	_	_	I-Premise
24	been	_	_	I-Premise
25	an	_	_	I-Premise
26	intervention	_	_	I-Premise
27	for	_	_	I-Premise
28	chemotherapy-related	_	_	I-Premise
29	fatigue	_	_	I-Premise
30	.	_	_	I-Premise

31	A	_	_	O
32	prospective	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	controlled	_	_	O
37	trial	_	_	O
38	was	_	_	O
39	performed	_	_	O
40	to	_	_	O
41	determine	_	_	O
42	whether	_	_	O
43	aerobic	_	_	O
44	exercise	_	_	O
45	would	_	_	O
46	reduce	_	_	O
47	the	_	_	O
48	incidence	_	_	O
49	of	_	_	O
50	fatigue	_	_	O
51	and	_	_	O
52	prevent	_	_	O
53	deterioration	_	_	O
54	in	_	_	O
55	physical	_	_	O
56	functioning	_	_	O
57	during	_	_	O
58	radiotherapy	_	_	O
59	for	_	_	O
60	localized	_	_	O
61	prostate	_	_	O
62	carcinoma	_	_	O
63	.	_	_	O

64	Sixty-six	_	_	O
65	men	_	_	O
66	were	_	_	O
67	randomized	_	_	O
68	before	_	_	O
69	they	_	_	O
70	received	_	_	O
71	radical	_	_	O
72	radiotherapy	_	_	O
73	for	_	_	O
74	localized	_	_	O
75	prostate	_	_	O
76	carcinoma	_	_	O
77	,	_	_	O
78	with	_	_	O
79	33	_	_	O
80	men	_	_	O
81	randomized	_	_	O
82	to	_	_	O
83	an	_	_	O
84	exercise	_	_	O
85	group	_	_	O
86	and	_	_	O
87	33	_	_	O
88	men	_	_	O
89	randomized	_	_	O
90	to	_	_	O
91	a	_	_	O
92	control	_	_	O
93	group	_	_	O
94	.	_	_	O

95	Outcome	_	_	O
96	measures	_	_	O
97	were	_	_	O
98	fatigue	_	_	O
99	and	_	_	O
100	distance	_	_	O
101	walked	_	_	O
102	in	_	_	O
103	a	_	_	O
104	modified	_	_	O
105	shuttle	_	_	O
106	test	_	_	O
107	before	_	_	O
108	and	_	_	O
109	after	_	_	O
110	radiotherapy	_	_	O
111	.	_	_	O

112	There	_	_	B-Premise
113	were	_	_	I-Premise
114	no	_	_	I-Premise
115	significant	_	_	I-Premise
116	between	_	_	I-Premise
117	group	_	_	I-Premise
118	differences	_	_	I-Premise
119	noted	_	_	I-Premise
120	with	_	_	I-Premise
121	regard	_	_	I-Premise
122	to	_	_	I-Premise
123	fatigue	_	_	I-Premise
124	scores	_	_	I-Premise
125	at	_	_	I-Premise
126	baseline	_	_	I-Premise
127	(	_	_	I-Premise
128	P	_	_	I-Premise
129	=	_	_	I-Premise
130	0.55	_	_	I-Premise
131	)	_	_	I-Premise
132	or	_	_	I-Premise
133	after	_	_	I-Premise
134	4	_	_	I-Premise
135	weeks	_	_	I-Premise
136	of	_	_	I-Premise
137	radiotherapy	_	_	I-Premise
138	(	_	_	I-Premise
139	P	_	_	I-Premise
140	=	_	_	I-Premise
141	0.18	_	_	I-Premise
142	)	_	_	I-Premise
143	.	_	_	I-Premise

144	Men	_	_	B-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	control	_	_	I-Premise
148	group	_	_	I-Premise
149	had	_	_	I-Premise
150	significant	_	_	I-Premise
151	increases	_	_	I-Premise
152	in	_	_	I-Premise
153	fatigue	_	_	I-Premise
154	scores	_	_	I-Premise
155	from	_	_	I-Premise
156	baseline	_	_	I-Premise
157	to	_	_	I-Premise
158	the	_	_	I-Premise
159	end	_	_	I-Premise
160	of	_	_	I-Premise
161	radiotherapy	_	_	I-Premise
162	(	_	_	I-Premise
163	P	_	_	I-Premise
164	=	_	_	I-Premise
165	0.013	_	_	I-Premise
166	)	_	_	I-Premise
167	,	_	_	I-Premise
168	with	_	_	I-Premise
169	no	_	_	I-Premise
170	significant	_	_	I-Premise
171	increases	_	_	I-Premise
172	observed	_	_	I-Premise
173	in	_	_	I-Premise
174	the	_	_	I-Premise
175	exercise	_	_	I-Premise
176	group	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	0.203	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	A	_	_	B-Premise
184	nonsignificant	_	_	I-Premise
185	reduction	_	_	I-Premise
186	(	_	_	I-Premise
187	2.4	_	_	I-Premise
188	%	_	_	I-Premise
189	)	_	_	I-Premise
190	in	_	_	I-Premise
191	shuttle	_	_	I-Premise
192	test	_	_	I-Premise
193	distance	_	_	I-Premise
194	at	_	_	I-Premise
195	the	_	_	I-Premise
196	end	_	_	I-Premise
197	of	_	_	I-Premise
198	radiotherapy	_	_	I-Premise
199	was	_	_	I-Premise
200	observed	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	;	_	_	I-Premise
206	however	_	_	I-Premise
207	,	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	exercise	_	_	I-Premise
211	group	_	_	I-Premise
212	,	_	_	I-Premise
213	there	_	_	I-Premise
214	was	_	_	I-Premise
215	a	_	_	I-Premise
216	significant	_	_	I-Premise
217	increase	_	_	I-Premise
218	(	_	_	I-Premise
219	13.2	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	in	_	_	I-Premise
223	distance	_	_	I-Premise
224	walked	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	0.0003	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	Men	_	_	B-Premise
232	who	_	_	I-Premise
233	followed	_	_	I-Premise
234	advice	_	_	I-Premise
235	to	_	_	I-Premise
236	rest	_	_	I-Premise
237	and	_	_	I-Premise
238	take	_	_	I-Premise
239	things	_	_	I-Premise
240	easy	_	_	I-Premise
241	if	_	_	I-Premise
242	they	_	_	I-Premise
243	became	_	_	I-Premise
244	fatigued	_	_	I-Premise
245	demonstrated	_	_	I-Premise
246	a	_	_	I-Premise
247	slight	_	_	I-Premise
248	deterioration	_	_	I-Premise
249	in	_	_	I-Premise
250	physical	_	_	I-Premise
251	functioning	_	_	I-Premise
252	and	_	_	I-Premise
253	a	_	_	I-Premise
254	significant	_	_	I-Premise
255	increase	_	_	I-Premise
256	in	_	_	I-Premise
257	fatigue	_	_	I-Premise
258	at	_	_	I-Premise
259	the	_	_	I-Premise
260	end	_	_	I-Premise
261	of	_	_	I-Premise
262	radiotherapy	_	_	I-Premise
263	.	_	_	I-Premise

264	Home-based	_	_	B-Claim
265	,	_	_	I-Claim
266	moderate-intensity	_	_	I-Claim
267	walking	_	_	I-Claim
268	produced	_	_	I-Claim
269	a	_	_	I-Claim
270	significant	_	_	I-Claim
271	improvement	_	_	I-Claim
272	in	_	_	I-Claim
273	physical	_	_	I-Claim
274	functioning	_	_	I-Claim
275	with	_	_	I-Claim
276	no	_	_	I-Claim
277	significant	_	_	I-Claim
278	increase	_	_	I-Claim
279	in	_	_	I-Claim
280	fatigue	_	_	I-Claim
281	.	_	_	I-Claim

282	Improved	_	_	B-Claim
283	physical	_	_	I-Claim
284	functioning	_	_	I-Claim
285	may	_	_	I-Claim
286	be	_	_	I-Claim
287	necessary	_	_	I-Claim
288	to	_	_	I-Claim
289	combat	_	_	I-Claim
290	radiation	_	_	I-Claim
291	fatigue	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	cisplatin	_	_	O
4	plus	_	_	O
5	paclitaxel	_	_	O
6	(	_	_	O
7	C+P	_	_	O
8	)	_	_	O
9	improved	_	_	O
10	response	_	_	O
11	rate	_	_	O
12	,	_	_	O
13	progression-free	_	_	O
14	survival	_	_	O
15	(	_	_	O
16	PFS	_	_	O
17	)	_	_	O
18	,	_	_	O
19	or	_	_	O
20	survival	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	cisplatin	_	_	O
24	alone	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	stage	_	_	O
29	IVB	_	_	O
30	,	_	_	O
31	recurrent	_	_	O
32	,	_	_	O
33	or	_	_	O
34	persistent	_	_	O
35	squamous	_	_	O
36	cell	_	_	O
37	carcinoma	_	_	O
38	of	_	_	O
39	the	_	_	O
40	cervix	_	_	O
41	.	_	_	O

42	PATIENTS	_	_	O
43	AND	_	_	O
44	METHODS	_	_	O
45	Eligible	_	_	O
46	:	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	measurable	_	_	O
50	disease	_	_	O
51	,	_	_	O
52	performance	_	_	O
53	status	_	_	O
54	(	_	_	O
55	PS	_	_	O
56	)	_	_	O
57	0	_	_	O
58	to	_	_	O
59	2	_	_	O
60	,	_	_	O
61	and	_	_	O
62	adequate	_	_	O
63	hematologic	_	_	O
64	,	_	_	O
65	hepatic	_	_	O
66	,	_	_	O
67	and	_	_	O
68	renal	_	_	O
69	function	_	_	O
70	received	_	_	O
71	either	_	_	O
72	cisplatin	_	_	O
73	50	_	_	O
74	mg/m2	_	_	O
75	or	_	_	O
76	C+P	_	_	O
77	(	_	_	O
78	cisplatin	_	_	O
79	50	_	_	O
80	mg/m2	_	_	O
81	plus	_	_	O
82	paclitaxel	_	_	O
83	135	_	_	O
84	mg/m2	_	_	O
85	)	_	_	O
86	every	_	_	O
87	3	_	_	O
88	weeks	_	_	O
89	for	_	_	O
90	six	_	_	O
91	cycles	_	_	O
92	.	_	_	O

93	Tumor	_	_	O
94	measurements	_	_	O
95	and	_	_	O
96	quality-of-life	_	_	O
97	(	_	_	O
98	QOL	_	_	O
99	)	_	_	O
100	assessments	_	_	O
101	were	_	_	O
102	obtained	_	_	O
103	before	_	_	O
104	each	_	_	O
105	treatment	_	_	O
106	cycle	_	_	O
107	.	_	_	O

108	Of	_	_	O
109	280	_	_	O
110	patients	_	_	O
111	entered	_	_	O
112	,	_	_	O
113	6	_	_	O
114	%	_	_	O
115	were	_	_	O
116	ineligible	_	_	O
117	.	_	_	O

118	Among	_	_	O
119	264	_	_	O
120	eligible	_	_	O
121	patients	_	_	O
122	,	_	_	O
123	134	_	_	O
124	received	_	_	O
125	cisplatin	_	_	O
126	and	_	_	O
127	130	_	_	O
128	received	_	_	O
129	C+P	_	_	O
130	.	_	_	O

131	Groups	_	_	O
132	were	_	_	O
133	well	_	_	O
134	matched	_	_	O
135	with	_	_	O
136	respect	_	_	O
137	to	_	_	O
138	age	_	_	O
139	,	_	_	O
140	ethnicity	_	_	O
141	,	_	_	O
142	PS	_	_	O
143	,	_	_	O
144	tumor	_	_	O
145	grade	_	_	O
146	,	_	_	O
147	disease	_	_	O
148	site	_	_	O
149	,	_	_	O
150	and	_	_	O
151	number	_	_	O
152	of	_	_	O
153	cycles	_	_	O
154	received	_	_	O
155	.	_	_	O

156	The	_	_	O
157	majority	_	_	O
158	of	_	_	O
159	all	_	_	O
160	patients	_	_	O
161	had	_	_	O
162	prior	_	_	O
163	radiation	_	_	O
164	therapy	_	_	O
165	(	_	_	O
166	cisplatin	_	_	O
167	,	_	_	O
168	92	_	_	O
169	%	_	_	O
170	;	_	_	O
171	C+P	_	_	O
172	,	_	_	O
173	91	_	_	O
174	%	_	_	O
175	)	_	_	O
176	.	_	_	O

177	Objective	_	_	B-Premise
178	responses	_	_	I-Premise
179	occurred	_	_	I-Premise
180	in	_	_	I-Premise
181	19	_	_	I-Premise
182	%	_	_	I-Premise
183	(	_	_	I-Premise
184	6	_	_	I-Premise
185	%	_	_	I-Premise
186	complete	_	_	I-Premise
187	plus	_	_	I-Premise
188	13	_	_	I-Premise
189	%	_	_	I-Premise
190	partial	_	_	I-Premise
191	)	_	_	I-Premise
192	of	_	_	I-Premise
193	patients	_	_	I-Premise
194	receiving	_	_	I-Premise
195	cisplatin	_	_	I-Premise
196	versus	_	_	I-Premise
197	36	_	_	I-Premise
198	%	_	_	I-Premise
199	(	_	_	I-Premise
200	15	_	_	I-Premise
201	%	_	_	I-Premise
202	complete	_	_	I-Premise
203	plus	_	_	I-Premise
204	21	_	_	I-Premise
205	%	_	_	I-Premise
206	partial	_	_	I-Premise
207	)	_	_	I-Premise
208	receiving	_	_	I-Premise
209	C+P	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	.002	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	The	_	_	B-Premise
217	median	_	_	I-Premise
218	PFS	_	_	I-Premise
219	was	_	_	I-Premise
220	2.8	_	_	I-Premise
221	and	_	_	I-Premise
222	4.8	_	_	I-Premise
223	months	_	_	I-Premise
224	,	_	_	I-Premise
225	respectively	_	_	I-Premise
226	,	_	_	I-Premise
227	for	_	_	I-Premise
228	cisplatin	_	_	I-Premise
229	versus	_	_	I-Premise
230	C+P	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	.001	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	There	_	_	B-Premise
238	was	_	_	I-Premise
239	no	_	_	I-Premise
240	difference	_	_	I-Premise
241	in	_	_	I-Premise
242	median	_	_	I-Premise
243	survival	_	_	I-Premise
244	(	_	_	I-Premise
245	8.8	_	_	I-Premise
246	months	_	_	I-Premise
247	v	_	_	I-Premise
248	9.7	_	_	I-Premise
249	months	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Grade	_	_	B-Premise
253	3	_	_	I-Premise
254	to	_	_	I-Premise
255	4	_	_	I-Premise
256	anemia	_	_	I-Premise
257	and	_	_	I-Premise
258	neutropenia	_	_	I-Premise
259	were	_	_	I-Premise
260	more	_	_	I-Premise
261	common	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	combination	_	_	I-Premise
265	arm	_	_	I-Premise
266	.	_	_	I-Premise

267	There	_	_	B-Premise
268	was	_	_	I-Premise
269	no	_	_	I-Premise
270	significant	_	_	I-Premise
271	difference	_	_	I-Premise
272	in	_	_	I-Premise
273	QOL	_	_	I-Premise
274	scores	_	_	I-Premise
275	,	_	_	I-Premise
276	although	_	_	B-Premise
277	a	_	_	I-Premise
278	disproportionate	_	_	I-Premise
279	number	_	_	I-Premise
280	of	_	_	I-Premise
281	patients	_	_	I-Premise
282	(	_	_	I-Premise
283	cisplatin	_	_	I-Premise
284	,	_	_	I-Premise
285	n	_	_	I-Premise
286	=	_	_	I-Premise
287	50	_	_	I-Premise
288	;	_	_	I-Premise
289	C+P	_	_	I-Premise
290	,	_	_	I-Premise
291	n	_	_	I-Premise
292	=	_	_	I-Premise
293	33	_	_	I-Premise
294	)	_	_	I-Premise
295	dropped	_	_	I-Premise
296	out	_	_	I-Premise
297	of	_	_	I-Premise
298	the	_	_	I-Premise
299	QOL	_	_	I-Premise
300	component	_	_	I-Premise
301	,	_	_	I-Premise
302	presumably	_	_	I-Premise
303	because	_	_	I-Premise
304	of	_	_	I-Premise
305	increasing	_	_	I-Premise
306	disease	_	_	I-Premise
307	,	_	_	I-Premise
308	deteriorating	_	_	I-Premise
309	health	_	_	I-Premise
310	status	_	_	I-Premise
311	,	_	_	I-Premise
312	or	_	_	I-Premise
313	early	_	_	I-Premise
314	death	_	_	I-Premise
315	.	_	_	I-Premise

316	C+P	_	_	B-Claim
317	is	_	_	I-Claim
318	superior	_	_	I-Claim
319	to	_	_	I-Claim
320	cisplatin	_	_	I-Claim
321	alone	_	_	I-Claim
322	with	_	_	I-Claim
323	respect	_	_	I-Claim
324	to	_	_	I-Claim
325	response	_	_	I-Claim
326	rate	_	_	I-Claim
327	and	_	_	I-Claim
328	PFS	_	_	I-Claim
329	with	_	_	I-Claim
330	sustained	_	_	I-Claim
331	QOL	_	_	I-Claim
332	.	_	_	I-Claim


0	Metal	_	_	O
1	stent	_	_	O
2	placement	_	_	O
3	and	_	_	O
4	single	_	_	O
5	dose	_	_	O
6	brachytherapy	_	_	O
7	are	_	_	O
8	commonly	_	_	O
9	used	_	_	O
10	treatment	_	_	O
11	modalities	_	_	O
12	for	_	_	O
13	the	_	_	O
14	palliation	_	_	O
15	of	_	_	O
16	inoperable	_	_	O
17	oesophageal	_	_	O
18	carcinoma	_	_	O
19	.	_	_	O

20	We	_	_	O
21	investigated	_	_	O
22	generic	_	_	O
23	and	_	_	O
24	disease-specific	_	_	O
25	health-related	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	(	_	_	O
30	HRQoL	_	_	O
31	)	_	_	O
32	after	_	_	O
33	these	_	_	O
34	palliative	_	_	O
35	treatments	_	_	O
36	.	_	_	O

37	Patients	_	_	O
38	with	_	_	O
39	dysphagia	_	_	O
40	from	_	_	O
41	inoperable	_	_	O
42	oesophageal	_	_	O
43	carcinoma	_	_	O
44	were	_	_	O
45	randomised	_	_	O
46	to	_	_	O
47	placement	_	_	O
48	of	_	_	O
49	a	_	_	O
50	covered	_	_	O
51	Ultraflex	_	_	O
52	stent	_	_	O
53	(	_	_	O
54	n	_	_	O
55	=	_	_	O
56	108	_	_	O
57	)	_	_	O
58	or	_	_	O
59	single	_	_	O
60	dose	_	_	O
61	(	_	_	O
62	12	_	_	O
63	Gy	_	_	O
64	)	_	_	O
65	brachytherapy	_	_	O
66	(	_	_	O
67	n	_	_	O
68	=	_	_	O
69	101	_	_	O
70	)	_	_	O
71	.	_	_	O

72	We	_	_	O
73	obtained	_	_	O
74	longitudinal	_	_	O
75	data	_	_	O
76	on	_	_	O
77	disease-specific	_	_	O
78	(	_	_	O
79	dysphagia	_	_	O
80	score	_	_	O
81	,	_	_	O
82	European	_	_	O
83	Organisation	_	_	O
84	for	_	_	O
85	Research	_	_	O
86	and	_	_	O
87	Treatment	_	_	O
88	of	_	_	O
89	Cancer	_	_	O
90	(	_	_	O
91	EORTC	_	_	O
92	)	_	_	O
93	OES-23	_	_	O
94	,	_	_	O
95	visual	_	_	O
96	analogue	_	_	O
97	pain	_	_	O
98	scale	_	_	O
99	)	_	_	O
100	and	_	_	O
101	generic	_	_	O
102	(	_	_	O
103	EORTC	_	_	O
104	Quality	_	_	O
105	of	_	_	O
106	Life-Core	_	_	O
107	30	_	_	O
108	Questionnaire	_	_	O
109	(	_	_	O
110	QLQ-C30	_	_	O
111	)	_	_	O
112	,	_	_	O
113	Euroqol	_	_	O
114	(	_	_	O
115	EQ	_	_	O
116	)	_	_	O
117	-5D	_	_	O
118	)	_	_	O
119	HRQoL	_	_	O
120	at	_	_	O
121	monthly	_	_	O
122	home	_	_	O
123	visits	_	_	O
124	by	_	_	O
125	a	_	_	O
126	specially-trained	_	_	O
127	research	_	_	O
128	nurse	_	_	O
129	.	_	_	O

130	We	_	_	O
131	compared	_	_	O
132	HRQoL	_	_	O
133	between	_	_	O
134	the	_	_	O
135	two	_	_	O
136	treatments	_	_	O
137	and	_	_	O
138	analysed	_	_	O
139	changes	_	_	O
140	in	_	_	O
141	HRQoL	_	_	O
142	during	_	_	O
143	follow-up	_	_	O
144	.	_	_	O

145	Dysphagia	_	_	B-Premise
146	improved	_	_	I-Premise
147	more	_	_	I-Premise
148	rapidly	_	_	I-Premise
149	after	_	_	I-Premise
150	stent	_	_	I-Premise
151	placement	_	_	I-Premise
152	than	_	_	I-Premise
153	after	_	_	I-Premise
154	brachytherapy	_	_	I-Premise
155	,	_	_	I-Premise
156	but	_	_	B-Premise
157	long-term	_	_	I-Premise
158	relief	_	_	I-Premise
159	of	_	_	I-Premise
160	dysphagia	_	_	I-Premise
161	was	_	_	I-Premise
162	better	_	_	I-Premise
163	after	_	_	I-Premise
164	brachytherapy	_	_	I-Premise
165	.	_	_	I-Premise

166	For	_	_	B-Premise
167	generic	_	_	I-Premise
168	HRQoL	_	_	I-Premise
169	,	_	_	I-Premise
170	there	_	_	I-Premise
171	was	_	_	I-Premise
172	an	_	_	I-Premise
173	overall	_	_	I-Premise
174	significant	_	_	I-Premise
175	difference	_	_	I-Premise
176	in	_	_	I-Premise
177	favour	_	_	I-Premise
178	of	_	_	I-Premise
179	brachytherapy	_	_	I-Premise
180	on	_	_	I-Premise
181	four	_	_	I-Premise
182	out	_	_	I-Premise
183	of	_	_	I-Premise
184	five	_	_	I-Premise
185	functional	_	_	I-Premise
186	scales	_	_	I-Premise
187	of	_	_	I-Premise
188	the	_	_	I-Premise
189	EORTC	_	_	I-Premise
190	QLQ-C30	_	_	I-Premise
191	(	_	_	I-Premise
192	role	_	_	I-Premise
193	,	_	_	I-Premise
194	emotional	_	_	I-Premise
195	,	_	_	I-Premise
196	cognitive	_	_	I-Premise
197	and	_	_	I-Premise
198	social	_	_	I-Premise
199	)	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	<	_	_	I-Premise
203	0.05	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Generic	_	_	B-Premise
207	HRQoL	_	_	I-Premise
208	deteriorated	_	_	I-Premise
209	over	_	_	I-Premise
210	time	_	_	I-Premise
211	on	_	_	I-Premise
212	all	_	_	I-Premise
213	functional	_	_	I-Premise
214	scales	_	_	I-Premise
215	of	_	_	I-Premise
216	the	_	_	I-Premise
217	EORTC	_	_	I-Premise
218	QLQ	_	_	I-Premise
219	C-30	_	_	I-Premise
220	and	_	_	I-Premise
221	EQ-5D	_	_	I-Premise
222	,	_	_	I-Premise
223	in	_	_	I-Premise
224	particular	_	_	I-Premise
225	physical	_	_	I-Premise
226	and	_	_	I-Premise
227	role	_	_	I-Premise
228	functioning	_	_	I-Premise
229	(	_	_	I-Premise
230	on	_	_	I-Premise
231	average	_	_	I-Premise
232	-23	_	_	I-Premise
233	and	_	_	I-Premise
234	-24	_	_	I-Premise
235	on	_	_	I-Premise
236	a	_	_	I-Premise
237	100	_	_	I-Premise
238	points	_	_	I-Premise
239	scale	_	_	I-Premise
240	during	_	_	I-Premise
241	0.5	_	_	I-Premise
242	years	_	_	I-Premise
243	of	_	_	I-Premise
244	follow-up	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	This	_	_	B-Premise
248	decline	_	_	I-Premise
249	was	_	_	I-Premise
250	more	_	_	I-Premise
251	pronounced	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	stent	_	_	I-Premise
255	group	_	_	I-Premise
256	.	_	_	I-Premise

257	Major	_	_	B-Premise
258	improvements	_	_	I-Premise
259	were	_	_	I-Premise
260	seen	_	_	I-Premise
261	on	_	_	I-Premise
262	the	_	_	I-Premise
263	dysphagia	_	_	I-Premise
264	and	_	_	I-Premise
265	eating	_	_	I-Premise
266	scales	_	_	I-Premise
267	of	_	_	I-Premise
268	the	_	_	I-Premise
269	EORTC	_	_	I-Premise
270	OES-23	_	_	I-Premise
271	,	_	_	I-Premise
272	in	_	_	I-Premise
273	contrast	_	_	I-Premise
274	to	_	_	I-Premise
275	other	_	_	I-Premise
276	scales	_	_	I-Premise
277	of	_	_	I-Premise
278	this	_	_	I-Premise
279	disease-specific	_	_	I-Premise
280	measure	_	_	I-Premise
281	,	_	_	I-Premise
282	which	_	_	I-Premise
283	remained	_	_	I-Premise
284	almost	_	_	I-Premise
285	stable	_	_	I-Premise
286	during	_	_	I-Premise
287	follow-up	_	_	I-Premise
288	.	_	_	I-Premise

289	Reported	_	_	B-Premise
290	levels	_	_	I-Premise
291	of	_	_	I-Premise
292	chest	_	_	I-Premise
293	or	_	_	I-Premise
294	abdominal	_	_	I-Premise
295	pain	_	_	I-Premise
296	remained	_	_	I-Premise
297	stable	_	_	I-Premise
298	during	_	_	I-Premise
299	follow-up	_	_	I-Premise
300	in	_	_	I-Premise
301	both	_	_	I-Premise
302	treatment	_	_	I-Premise
303	groups	_	_	I-Premise
304	,	_	_	I-Premise
305	general	_	_	B-Premise
306	pain	_	_	I-Premise
307	levels	_	_	I-Premise
308	increased	_	_	I-Premise
309	to	_	_	I-Premise
310	a	_	_	I-Premise
311	minor	_	_	I-Premise
312	extent	_	_	I-Premise
313	.	_	_	I-Premise

314	The	_	_	B-Claim
315	effects	_	_	I-Claim
316	of	_	_	I-Claim
317	single	_	_	I-Claim
318	dose	_	_	I-Claim
319	brachytherapy	_	_	I-Claim
320	on	_	_	I-Claim
321	HRQoL	_	_	I-Claim
322	compared	_	_	I-Claim
323	favourably	_	_	I-Claim
324	to	_	_	I-Claim
325	those	_	_	I-Claim
326	of	_	_	I-Claim
327	stent	_	_	I-Claim
328	placement	_	_	I-Claim
329	for	_	_	I-Claim
330	the	_	_	I-Claim
331	palliation	_	_	I-Claim
332	of	_	_	I-Claim
333	oesophageal	_	_	I-Claim
334	cancer	_	_	I-Claim
335	.	_	_	I-Claim

336	Future	_	_	B-Claim
337	studies	_	_	I-Claim
338	on	_	_	I-Claim
339	palliative	_	_	I-Claim
340	care	_	_	I-Claim
341	for	_	_	I-Claim
342	oesophageal	_	_	I-Claim
343	cancer	_	_	I-Claim
344	should	_	_	I-Claim
345	at	_	_	I-Claim
346	least	_	_	I-Claim
347	include	_	_	I-Claim
348	generic	_	_	I-Claim
349	HRQoL	_	_	I-Claim
350	scales	_	_	I-Claim
351	,	_	_	I-Claim
352	since	_	_	B-Premise
353	these	_	_	I-Premise
354	were	_	_	I-Premise
355	more	_	_	I-Premise
356	responsive	_	_	I-Premise
357	in	_	_	I-Premise
358	measuring	_	_	I-Premise
359	patients	_	_	I-Premise
360	'	_	_	I-Premise
361	functioning	_	_	I-Premise
362	and	_	_	I-Premise
363	well-being	_	_	I-Premise
364	during	_	_	I-Premise
365	follow-up	_	_	I-Premise
366	than	_	_	I-Premise
367	disease-specific	_	_	I-Premise
368	HRQoL	_	_	I-Premise
369	scales	_	_	I-Premise
370	.	_	_	I-Premise


0	To	_	_	O
1	determine	_	_	O
2	if	_	_	O
3	the	_	_	O
4	type	_	_	O
5	of	_	_	O
6	embolic	_	_	O
7	material	_	_	O
8	used	_	_	O
9	for	_	_	O
10	uterine	_	_	O
11	artery	_	_	O
12	embolization	_	_	O
13	(	_	_	O
14	UAE	_	_	O
15	)	_	_	O
16	for	_	_	O
17	leiomyomas	_	_	O
18	has	_	_	O
19	an	_	_	O
20	impact	_	_	O
21	on	_	_	O
22	short-term	_	_	O
23	recovery	_	_	O
24	or	_	_	O
25	the	_	_	O
26	effectiveness	_	_	O
27	of	_	_	O
28	embolization	_	_	O
29	.	_	_	O

30	One	_	_	O
31	hundred	_	_	O
32	patients	_	_	O
33	were	_	_	O
34	randomly	_	_	O
35	assigned	_	_	O
36	to	_	_	O
37	undergo	_	_	O
38	UAE	_	_	O
39	with	_	_	O
40	polyvinyl	_	_	O
41	alcohol	_	_	O
42	(	_	_	O
43	PVA	_	_	O
44	)	_	_	O
45	particles	_	_	O
46	or	_	_	O
47	tris-acryl	_	_	O
48	gelatin	_	_	O
49	microspheres	_	_	O
50	.	_	_	O

51	Short-term	_	_	O
52	,	_	_	O
53	in-hospital	_	_	O
54	medication	_	_	O
55	use	_	_	O
56	and	_	_	O
57	pain	_	_	O
58	levels	_	_	O
59	were	_	_	O
60	recorded	_	_	O
61	.	_	_	O

62	After	_	_	O
63	discharge	_	_	O
64	,	_	_	O
65	symptom	_	_	O
66	severity	_	_	O
67	,	_	_	O
68	temperature	_	_	O
69	,	_	_	O
70	and	_	_	O
71	medications	_	_	O
72	used	_	_	O
73	were	_	_	O
74	recorded	_	_	O
75	daily	_	_	O
76	for	_	_	O
77	1	_	_	O
78	week	_	_	O
79	and	_	_	O
80	symptom	_	_	O
81	levels	_	_	O
82	were	_	_	O
83	measured	_	_	O
84	for	_	_	O
85	weeks	_	_	O
86	2-4	_	_	O
87	.	_	_	O

88	Three	_	_	O
89	months	_	_	O
90	after	_	_	O
91	embolization	_	_	O
92	,	_	_	O
93	contrast	_	_	O
94	material-enhanced	_	_	O
95	magnetic	_	_	O
96	resonance	_	_	O
97	imaging	_	_	O
98	examinations	_	_	O
99	were	_	_	O
100	evaluated	_	_	O
101	blindly	_	_	O
102	to	_	_	O
103	determine	_	_	O
104	the	_	_	O
105	extent	_	_	O
106	of	_	_	O
107	leiomyoma	_	_	O
108	infarction	_	_	O
109	.	_	_	O

110	Symptom	_	_	O
111	and	_	_	O
112	quality	_	_	O
113	of	_	_	O
114	life	_	_	O
115	(	_	_	O
116	QOL	_	_	O
117	)	_	_	O
118	status	_	_	O
119	was	_	_	O
120	determined	_	_	O
121	with	_	_	O
122	use	_	_	O
123	of	_	_	O
124	questionnaires	_	_	O
125	.	_	_	O

126	Analysis	_	_	O
127	was	_	_	O
128	completed	_	_	O
129	with	_	_	O
130	use	_	_	O
131	of	_	_	O
132	chi	_	_	O
133	(	_	_	O
134	2	_	_	O
135	)	_	_	O
136	analysis	_	_	O
137	,	_	_	O
138	Fisher	_	_	O
139	exact	_	_	O
140	tests	_	_	O
141	,	_	_	O
142	Student	_	_	O
143	t	_	_	O
144	tests	_	_	O
145	,	_	_	O
146	and	_	_	O
147	analysis	_	_	O
148	of	_	_	O
149	variance	_	_	O
150	as	_	_	O
151	appropriate	_	_	O
152	.	_	_	O

153	Regression	_	_	O
154	analysis	_	_	O
155	was	_	_	O
156	used	_	_	O
157	to	_	_	O
158	analyze	_	_	O
159	the	_	_	O
160	impact	_	_	O
161	on	_	_	O
162	outcome	_	_	O
163	of	_	_	O
164	baseline	_	_	O
165	factors	_	_	O
166	(	_	_	O
167	other	_	_	O
168	than	_	_	O
169	type	_	_	O
170	of	_	_	O
171	embolic	_	_	O
172	agent	_	_	O
173	)	_	_	O
174	.	_	_	O

175	No	_	_	O
176	significant	_	_	O
177	differences	_	_	O
178	were	_	_	O
179	noted	_	_	O
180	at	_	_	O
181	baseline	_	_	O
182	between	_	_	O
183	the	_	_	O
184	two	_	_	O
185	treatment	_	_	O
186	groups	_	_	O
187	.	_	_	O

188	On	_	_	B-Premise
189	average	_	_	I-Premise
190	,	_	_	I-Premise
191	there	_	_	I-Premise
192	were	_	_	I-Premise
193	significantly	_	_	I-Premise
194	higher	_	_	I-Premise
195	volumes	_	_	I-Premise
196	of	_	_	I-Premise
197	tris-acryl	_	_	I-Premise
198	microspheres	_	_	I-Premise
199	used	_	_	I-Premise
200	(	_	_	I-Premise
201	9.0	_	_	I-Premise
202	mL	_	_	I-Premise
203	vs	_	_	I-Premise
204	3.0	_	_	I-Premise
205	mL	_	_	I-Premise
206	;	_	_	I-Premise
207	P	_	_	I-Premise
208	=.0001	_	_	I-Premise
209	)	_	_	I-Premise
210	,	_	_	I-Premise
211	whereas	_	_	O
212	microcatheter	_	_	B-Premise
213	occlusion	_	_	I-Premise
214	was	_	_	I-Premise
215	more	_	_	I-Premise
216	common	_	_	I-Premise
217	with	_	_	I-Premise
218	PVA	_	_	I-Premise
219	(	_	_	I-Premise
220	28	_	_	I-Premise
221	%	_	_	I-Premise
222	vs	_	_	I-Premise
223	4	_	_	I-Premise
224	%	_	_	I-Premise
225	,	_	_	I-Premise
226	P	_	_	I-Premise
227	=.001	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	There	_	_	B-Premise
231	were	_	_	I-Premise
232	no	_	_	I-Premise
233	differences	_	_	I-Premise
234	in	_	_	I-Premise
235	pain	_	_	I-Premise
236	severity	_	_	I-Premise
237	,	_	_	I-Premise
238	other	_	_	I-Premise
239	postprocedural	_	_	I-Premise
240	symptoms	_	_	I-Premise
241	,	_	_	I-Premise
242	or	_	_	I-Premise
243	medication	_	_	I-Premise
244	use	_	_	I-Premise
245	between	_	_	I-Premise
246	the	_	_	I-Premise
247	two	_	_	I-Premise
248	treatment	_	_	I-Premise
249	groups	_	_	I-Premise
250	.	_	_	I-Premise

251	There	_	_	B-Premise
252	were	_	_	I-Premise
253	also	_	_	I-Premise
254	no	_	_	I-Premise
255	differences	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	frequency	_	_	I-Premise
259	of	_	_	I-Premise
260	incompletely	_	_	I-Premise
261	infarcted	_	_	I-Premise
262	leiomyomas	_	_	I-Premise
263	,	_	_	I-Premise
264	degree	_	_	I-Premise
265	of	_	_	I-Premise
266	improvement	_	_	I-Premise
267	in	_	_	I-Premise
268	symptom	_	_	I-Premise
269	score	_	_	I-Premise
270	,	_	_	I-Premise
271	patient	_	_	I-Premise
272	satisfaction	_	_	I-Premise
273	,	_	_	I-Premise
274	or	_	_	I-Premise
275	QOL	_	_	I-Premise
276	.	_	_	I-Premise

277	No	_	_	B-Claim
278	substantive	_	_	I-Claim
279	differences	_	_	I-Claim
280	were	_	_	I-Claim
281	detected	_	_	I-Claim
282	between	_	_	I-Claim
283	outcomes	_	_	I-Claim
284	of	_	_	I-Claim
285	embolization	_	_	I-Claim
286	with	_	_	I-Claim
287	PVA	_	_	I-Claim
288	particles	_	_	I-Claim
289	or	_	_	I-Claim
290	tris-acryl	_	_	I-Claim
291	gelatin	_	_	I-Claim
292	microspheres	_	_	I-Claim
293	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	a	_	_	O
6	seated	_	_	O
7	exercise	_	_	O
8	program	_	_	O
9	on	_	_	O
10	fatigue	_	_	O
11	and	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	(	_	_	O
16	QOL	_	_	O
17	)	_	_	O
18	in	_	_	O
19	women	_	_	O
20	with	_	_	O
21	metastatic	_	_	O
22	breast	_	_	O
23	cancer	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	,	_	_	O
27	controlled	_	_	O
28	,	_	_	O
29	longitudinal	_	_	O
30	trial	_	_	O
31	.	_	_	O

32	Outpatient	_	_	O
33	clinic	_	_	O
34	of	_	_	O
35	a	_	_	O
36	comprehensive	_	_	O
37	cancer	_	_	O
38	center	_	_	O
39	.	_	_	O

40	Convenience	_	_	O
41	sample	_	_	O
42	of	_	_	O
43	38	_	_	O
44	women	_	_	O
45	who	_	_	O
46	were	_	_	O
47	beginning	_	_	O
48	outpatient	_	_	O
49	chemotherapy	_	_	O
50	.	_	_	O

51	Subjects	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	a	_	_	O
56	control	_	_	O
57	or	_	_	O
58	intervention	_	_	O
59	group	_	_	O
60	;	_	_	O
61	the	_	_	O
62	intervention	_	_	O
63	was	_	_	O
64	performance	_	_	O
65	of	_	_	O
66	a	_	_	O
67	seated	_	_	O
68	exercise	_	_	O
69	program	_	_	O
70	using	_	_	O
71	home	_	_	O
72	videotape	_	_	O
73	three	_	_	O
74	times	_	_	O
75	per	_	_	O
76	week	_	_	O
77	for	_	_	O
78	four	_	_	O
79	cycles	_	_	O
80	of	_	_	O
81	chemotherapy	_	_	O
82	.	_	_	O

83	All	_	_	O
84	subjects	_	_	O
85	completed	_	_	O
86	the	_	_	O
87	Functional	_	_	O
88	Assessment	_	_	O
89	of	_	_	O
90	Chronic	_	_	O
91	Illness	_	_	O
92	Therapy	_	_	O
93	Fatigue	_	_	O
94	Version	_	_	O
95	IV	_	_	O
96	(	_	_	O
97	FACIT	_	_	O
98	F	_	_	O
99	)	_	_	O
100	at	_	_	O
101	baseline	_	_	O
102	and	_	_	O
103	at	_	_	O
104	the	_	_	O
105	time	_	_	O
106	of	_	_	O
107	the	_	_	O
108	next	_	_	O
109	three	_	_	O
110	cycles	_	_	O
111	.	_	_	O

112	Subjects	_	_	O
113	were	_	_	O
114	asked	_	_	O
115	to	_	_	O
116	document	_	_	O
117	the	_	_	O
118	frequency	_	_	O
119	,	_	_	O
120	duration	_	_	O
121	,	_	_	O
122	and	_	_	O
123	intensity	_	_	O
124	of	_	_	O
125	all	_	_	O
126	exercise	_	_	O
127	participation	_	_	O
128	on	_	_	O
129	monthly	_	_	O
130	calendars	_	_	O
131	.	_	_	O

132	Exercise	_	_	O
133	,	_	_	O
134	fatigue	_	_	O
135	,	_	_	O
136	and	_	_	O
137	QOL	_	_	O
138	.	_	_	O

139	32	_	_	O
140	subjects	_	_	O
141	,	_	_	O
142	16	_	_	O
143	per	_	_	O
144	group	_	_	O
145	,	_	_	O
146	completed	_	_	O
147	the	_	_	O
148	study	_	_	O
149	follow-up	_	_	O
150	.	_	_	O

151	With	_	_	B-Premise
152	a	_	_	I-Premise
153	mixed	_	_	I-Premise
154	modeling	_	_	I-Premise
155	approach	_	_	I-Premise
156	,	_	_	I-Premise
157	total	_	_	I-Premise
158	FACIT	_	_	I-Premise
159	F	_	_	I-Premise
160	scores	_	_	I-Premise
161	for	_	_	I-Premise
162	the	_	_	I-Premise
163	entire	_	_	I-Premise
164	sample	_	_	I-Premise
165	declined	_	_	I-Premise
166	at	_	_	I-Premise
167	a	_	_	I-Premise
168	significant	_	_	I-Premise
169	rate	_	_	I-Premise
170	(	_	_	I-Premise
171	p	_	_	I-Premise
172	=	_	_	I-Premise
173	0.003	_	_	I-Premise
174	)	_	_	I-Premise
175	beginning	_	_	I-Premise
176	with	_	_	I-Premise
177	cycle	_	_	I-Premise
178	3	_	_	I-Premise
179	but	_	_	B-Premise
180	at	_	_	I-Premise
181	a	_	_	I-Premise
182	slower	_	_	I-Premise
183	rate	_	_	I-Premise
184	for	_	_	I-Premise
185	the	_	_	I-Premise
186	experimental	_	_	I-Premise
187	group	_	_	I-Premise
188	(	_	_	I-Premise
189	p	_	_	I-Premise
190	=	_	_	I-Premise
191	0.02	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	Fatigue	_	_	B-Premise
195	scores	_	_	I-Premise
196	indicated	_	_	I-Premise
197	less	_	_	I-Premise
198	increase	_	_	I-Premise
199	and	_	_	I-Premise
200	physical	_	_	I-Premise
201	well-being	_	_	I-Premise
202	subscale	_	_	I-Premise
203	scores	_	_	I-Premise
204	showed	_	_	I-Premise
205	less	_	_	I-Premise
206	decline	_	_	I-Premise
207	for	_	_	I-Premise
208	the	_	_	I-Premise
209	experimental	_	_	I-Premise
210	group	_	_	I-Premise
211	(	_	_	I-Premise
212	p	_	_	I-Premise
213	=	_	_	I-Premise
214	0.008	_	_	I-Premise
215	and	_	_	I-Premise
216	p	_	_	I-Premise
217	=	_	_	I-Premise
218	0.02	_	_	I-Premise
219	,	_	_	I-Premise
220	respectively	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	Women	_	_	B-Premise
224	with	_	_	I-Premise
225	advanced	_	_	I-Premise
226	breast	_	_	I-Premise
227	cancer	_	_	I-Premise
228	randomized	_	_	I-Premise
229	to	_	_	I-Premise
230	the	_	_	I-Premise
231	seated	_	_	I-Premise
232	exercise	_	_	I-Premise
233	intervention	_	_	I-Premise
234	had	_	_	I-Premise
235	a	_	_	I-Premise
236	slower	_	_	I-Premise
237	decline	_	_	I-Premise
238	in	_	_	I-Premise
239	total	_	_	I-Premise
240	and	_	_	I-Premise
241	physical	_	_	I-Premise
242	well-being	_	_	I-Premise
243	and	_	_	I-Premise
244	less	_	_	I-Premise
245	increase	_	_	I-Premise
246	in	_	_	I-Premise
247	fatigue	_	_	I-Premise
248	scores	_	_	I-Premise
249	starting	_	_	I-Premise
250	with	_	_	I-Premise
251	the	_	_	I-Premise
252	third	_	_	I-Premise
253	cycle	_	_	I-Premise
254	of	_	_	I-Premise
255	chemotherapy	_	_	I-Premise
256	.	_	_	I-Premise

257	Seated	_	_	B-Claim
258	exercise	_	_	I-Claim
259	may	_	_	I-Claim
260	be	_	_	I-Claim
261	a	_	_	I-Claim
262	feasible	_	_	I-Claim
263	exercise	_	_	I-Claim
264	program	_	_	I-Claim
265	for	_	_	I-Claim
266	women	_	_	I-Claim
267	with	_	_	I-Claim
268	advanced	_	_	I-Claim
269	cancer	_	_	I-Claim
270	for	_	_	I-Claim
271	controlling	_	_	I-Claim
272	fatigue	_	_	I-Claim
273	and	_	_	I-Claim
274	improving	_	_	I-Claim
275	physical	_	_	I-Claim
276	well-being	_	_	I-Claim
277	.	_	_	I-Claim


0	Epoetin	_	_	B-Claim
1	alfa	_	_	I-Claim
2	administered	_	_	I-Claim
3	at	_	_	I-Claim
4	40,000	_	_	I-Claim
5	U	_	_	I-Claim
6	once	_	_	I-Claim
7	weekly	_	_	I-Claim
8	(	_	_	I-Claim
9	qw	_	_	I-Claim
10	)	_	_	I-Claim
11	to	_	_	I-Claim
12	anemic	_	_	I-Claim
13	cancer	_	_	I-Claim
14	patients	_	_	I-Claim
15	receiving	_	_	I-Claim
16	chemotherapy	_	_	I-Claim
17	increases	_	_	I-Claim
18	hemoglobin	_	_	I-Claim
19	levels	_	_	I-Claim
20	,	_	_	I-Claim
21	improves	_	_	I-Claim
22	quality	_	_	I-Claim
23	of	_	_	I-Claim
24	life	_	_	I-Claim
25	(	_	_	I-Claim
26	QOL	_	_	I-Claim
27	)	_	_	I-Claim
28	,	_	_	I-Claim
29	and	_	_	I-Claim
30	reduces	_	_	I-Claim
31	transfusions	_	_	I-Claim
32	.	_	_	I-Claim

33	The	_	_	O
34	benefit	_	_	O
35	of	_	_	O
36	epoetin	_	_	O
37	alfa	_	_	O
38	in	_	_	O
39	maintaining	_	_	O
40	hemoglobin	_	_	O
41	levels	_	_	O
42	in	_	_	O
43	cancer	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	hemoglobin	_	_	O
47	less	_	_	O
48	than	_	_	O
49	12	_	_	O
50	g/dL	_	_	O
51	has	_	_	O
52	not	_	_	O
53	been	_	_	O
54	evaluated	_	_	O
55	.	_	_	O

56	Breast	_	_	O
57	cancer	_	_	O
58	patients	_	_	O
59	(	_	_	O
60	N	_	_	O
61	=	_	_	O
62	354	_	_	O
63	)	_	_	O
64	receiving	_	_	O
65	chemotherapy	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	assigned	_	_	O
69	in	_	_	O
70	1:1	_	_	O
71	ratio	_	_	O
72	to	_	_	O
73	epoetin	_	_	O
74	alfa	_	_	O
75	(	_	_	O
76	40,000	_	_	O
77	U	_	_	O
78	qw	_	_	O
79	)	_	_	O
80	or	_	_	O
81	standard	_	_	O
82	of	_	_	O
83	care	_	_	O
84	(	_	_	O
85	SOC	_	_	O
86	)	_	_	O
87	.	_	_	O

88	QOL	_	_	O
89	was	_	_	O
90	assessed	_	_	O
91	at	_	_	O
92	baseline	_	_	O
93	and	_	_	O
94	week	_	_	O
95	12	_	_	O
96	.	_	_	O

97	Hemoglobin	_	_	O
98	responses	_	_	O
99	,	_	_	O
100	transfusion	_	_	O
101	requirements	_	_	O
102	,	_	_	O
103	and	_	_	O
104	prognostic	_	_	O
105	factors	_	_	O
106	for	_	_	O
107	responses	_	_	O
108	were	_	_	O
109	measured	_	_	O
110	.	_	_	O

111	At	_	_	B-Premise
112	week	_	_	I-Premise
113	12	_	_	I-Premise
114	,	_	_	I-Premise
115	Functional	_	_	I-Premise
116	Assessment	_	_	I-Premise
117	of	_	_	I-Premise
118	Cancer	_	_	I-Premise
119	Therapy-Anemia	_	_	I-Premise
120	(	_	_	I-Premise
121	FACT-An	_	_	I-Premise
122	;	_	_	I-Premise
123	mean	_	_	I-Premise
124	,	_	_	I-Premise
125	2.16	_	_	I-Premise
126	+/-	_	_	I-Premise
127	12.84	_	_	I-Premise
128	for	_	_	I-Premise
129	epoetin	_	_	I-Premise
130	alfa	_	_	I-Premise
131	v	_	_	I-Premise
132	-4.43	_	_	I-Premise
133	+/-	_	_	I-Premise
134	13.42	_	_	I-Premise
135	for	_	_	I-Premise
136	SOC	_	_	I-Premise
137	)	_	_	I-Premise
138	and	_	_	I-Premise
139	FACT-An	_	_	I-Premise
140	fatigue	_	_	I-Premise
141	(	_	_	I-Premise
142	mean	_	_	I-Premise
143	,	_	_	I-Premise
144	1.85	_	_	I-Premise
145	+/-	_	_	I-Premise
146	10.52	_	_	I-Premise
147	for	_	_	I-Premise
148	epoetin	_	_	I-Premise
149	alfa	_	_	I-Premise
150	v	_	_	I-Premise
151	-3.55	_	_	I-Premise
152	+/-	_	_	I-Premise
153	11.14	_	_	I-Premise
154	for	_	_	I-Premise
155	SOC	_	_	I-Premise
156	)	_	_	I-Premise
157	change	_	_	I-Premise
158	scores	_	_	I-Premise
159	were	_	_	I-Premise
160	significantly	_	_	I-Premise
161	higher	_	_	I-Premise
162	in	_	_	I-Premise
163	the	_	_	I-Premise
164	epoetin	_	_	I-Premise
165	alfa	_	_	I-Premise
166	group	_	_	I-Premise
167	(	_	_	I-Premise
168	P	_	_	I-Premise
169	<	_	_	I-Premise
170	.0001	_	_	I-Premise
171	)	_	_	I-Premise
172	.	_	_	I-Premise

173	Hemoglobin	_	_	B-Premise
174	responses	_	_	I-Premise
175	defined	_	_	I-Premise
176	as	_	_	I-Premise
177	mean	_	_	I-Premise
178	hemoglobin	_	_	I-Premise
179	>	_	_	I-Premise
180	or	_	_	I-Premise
181	=	_	_	I-Premise
182	12	_	_	I-Premise
183	g/dL	_	_	I-Premise
184	or	_	_	I-Premise
185	a	_	_	I-Premise
186	>	_	_	I-Premise
187	or	_	_	I-Premise
188	=	_	_	I-Premise
189	2	_	_	I-Premise
190	g/dL	_	_	I-Premise
191	increase	_	_	I-Premise
192	compared	_	_	I-Premise
193	with	_	_	I-Premise
194	baseline	_	_	I-Premise
195	were	_	_	I-Premise
196	significantly	_	_	I-Premise
197	higher	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	epoetin	_	_	I-Premise
201	alfa	_	_	I-Premise
202	group	_	_	I-Premise
203	versus	_	_	I-Premise
204	SOC	_	_	I-Premise
205	:	_	_	I-Premise
206	52.0	_	_	I-Premise
207	%	_	_	I-Premise
208	v	_	_	I-Premise
209	5.1	_	_	I-Premise
210	%	_	_	I-Premise
211	and	_	_	I-Premise
212	65.7	_	_	I-Premise
213	%	_	_	I-Premise
214	v	_	_	I-Premise
215	6.3	_	_	I-Premise
216	%	_	_	I-Premise
217	,	_	_	I-Premise
218	respectively	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	.0001	_	_	I-Premise
223	for	_	_	I-Premise
224	both	_	_	I-Premise
225	comparisons	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Percentage	_	_	B-Premise
229	transfused	_	_	I-Premise
230	was	_	_	I-Premise
231	significantly	_	_	I-Premise
232	lower	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	epoetin	_	_	I-Premise
236	alfa	_	_	I-Premise
237	group	_	_	I-Premise
238	compared	_	_	I-Premise
239	with	_	_	I-Premise
240	SOC	_	_	I-Premise
241	(	_	_	I-Premise
242	8.6	_	_	I-Premise
243	%	_	_	I-Premise
244	v	_	_	I-Premise
245	22.9	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	More	_	_	B-Premise
250	than	_	_	I-Premise
251	90	_	_	I-Premise
252	%	_	_	I-Premise
253	of	_	_	I-Premise
254	patients	_	_	I-Premise
255	did	_	_	I-Premise
256	not	_	_	I-Premise
257	require	_	_	I-Premise
258	a	_	_	I-Premise
259	dose	_	_	I-Premise
260	increase	_	_	I-Premise
261	and	_	_	I-Premise
262	28.7	_	_	I-Premise
263	%	_	_	I-Premise
264	had	_	_	I-Premise
265	a	_	_	I-Premise
266	dose	_	_	I-Premise
267	reduction	_	_	I-Premise
268	.	_	_	I-Premise

269	Epoetin	_	_	B-Claim
270	alfa	_	_	I-Claim
271	administered	_	_	I-Claim
272	at	_	_	I-Claim
273	40,000	_	_	I-Claim
274	U	_	_	I-Claim
275	qw	_	_	I-Claim
276	is	_	_	I-Claim
277	effective	_	_	I-Claim
278	in	_	_	I-Claim
279	improving	_	_	I-Claim
280	QOL	_	_	I-Claim
281	,	_	_	I-Claim
282	maintaining	_	_	I-Claim
283	hemoglobin	_	_	I-Claim
284	level	_	_	I-Claim
285	,	_	_	I-Claim
286	and	_	_	I-Claim
287	reducing	_	_	I-Claim
288	transfusion	_	_	I-Claim
289	requirements	_	_	I-Claim
290	in	_	_	I-Claim
291	breast	_	_	I-Claim
292	cancer	_	_	I-Claim
293	patients	_	_	I-Claim
294	.	_	_	I-Claim

295	The	_	_	B-Claim
296	high	_	_	I-Claim
297	effectiveness	_	_	I-Claim
298	observed	_	_	I-Claim
299	could	_	_	I-Claim
300	be	_	_	I-Claim
301	attributed	_	_	I-Claim
302	in	_	_	I-Claim
303	part	_	_	I-Claim
304	to	_	_	I-Claim
305	early	_	_	I-Claim
306	treatment	_	_	I-Claim
307	with	_	_	I-Claim
308	epoetin	_	_	I-Claim
309	alfa	_	_	I-Claim
310	.	_	_	I-Claim


0	Increased	_	_	O
1	attention	_	_	O
2	has	_	_	O
3	focused	_	_	O
4	on	_	_	O
5	exercise	_	_	O
6	as	_	_	O
7	a	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	intervention	_	_	O
12	for	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	survivors	_	_	O
16	during	_	_	O
17	and	_	_	O
18	after	_	_	O
19	adjuvant	_	_	O
20	therapy	_	_	O
21	.	_	_	O

22	Our	_	_	O
23	objective	_	_	O
24	was	_	_	O
25	to	_	_	O
26	examine	_	_	O
27	the	_	_	O
28	effects	_	_	O
29	of	_	_	O
30	an	_	_	O
31	oncologist	_	_	O
32	's	_	_	O
33	recommendation	_	_	O
34	to	_	_	O
35	exercise	_	_	O
36	on	_	_	O
37	self-reported	_	_	O
38	exercise	_	_	O
39	behavior	_	_	O
40	in	_	_	O
41	newly	_	_	O
42	diagnosed	_	_	O
43	breast	_	_	O
44	cancer	_	_	O
45	survivors	_	_	O
46	attending	_	_	O
47	their	_	_	O
48	first	_	_	O
49	adjuvant	_	_	O
50	therapy	_	_	O
51	consultation	_	_	O
52	.	_	_	O

53	Using	_	_	O
54	a	_	_	O
55	single-blinded	_	_	O
56	,	_	_	O
57	3-armed	_	_	O
58	,	_	_	O
59	randomized	_	_	O
60	controlled	_	_	O
61	trial	_	_	O
62	,	_	_	O
63	450	_	_	O
64	breast	_	_	O
65	cancer	_	_	O
66	survivors	_	_	O
67	were	_	_	O
68	randomly	_	_	O
69	assigned	_	_	O
70	to	_	_	O
71	receive	_	_	O
72	an	_	_	O
73	oncologist	_	_	O
74	exercise	_	_	O
75	recommendation	_	_	O
76	only	_	_	O
77	,	_	_	O
78	an	_	_	O
79	oncologist	_	_	O
80	exercise	_	_	O
81	recommendation	_	_	O
82	plus	_	_	O
83	referral	_	_	O
84	to	_	_	O
85	an	_	_	O
86	exercise	_	_	O
87	specialist	_	_	O
88	,	_	_	O
89	or	_	_	O
90	usual	_	_	O
91	care	_	_	O
92	.	_	_	O

93	The	_	_	O
94	primary	_	_	O
95	outcome	_	_	O
96	was	_	_	O
97	self-reported	_	_	O
98	total	_	_	O
99	exercise	_	_	O
100	(	_	_	O
101	in	_	_	O
102	metabolic	_	_	O
103	equivalent	_	_	O
104	[	_	_	O
105	MET	_	_	O
106	]	_	_	O
107	hours	_	_	O
108	per	_	_	O
109	week	_	_	O
110	)	_	_	O
111	at	_	_	O
112	5	_	_	O
113	weeks	_	_	O
114	postconsultation	_	_	O
115	.	_	_	O

116	The	_	_	O
117	follow-up	_	_	O
118	assessment	_	_	O
119	rate	_	_	O
120	was	_	_	O
121	73	_	_	O
122	%	_	_	O
123	(	_	_	O
124	329	_	_	O
125	of	_	_	O
126	450	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Intention-to-treat	_	_	B-Premise
130	analysis	_	_	I-Premise
131	based	_	_	I-Premise
132	on	_	_	I-Premise
133	participants	_	_	I-Premise
134	with	_	_	I-Premise
135	follow-up	_	_	I-Premise
136	data	_	_	I-Premise
137	indicated	_	_	I-Premise
138	a	_	_	I-Premise
139	significant	_	_	I-Premise
140	difference	_	_	I-Premise
141	in	_	_	I-Premise
142	total	_	_	I-Premise
143	exercise	_	_	I-Premise
144	in	_	_	I-Premise
145	favor	_	_	I-Premise
146	of	_	_	I-Premise
147	the	_	_	I-Premise
148	recommendation-only	_	_	I-Premise
149	group	_	_	I-Premise
150	over	_	_	I-Premise
151	the	_	_	I-Premise
152	usual	_	_	I-Premise
153	care	_	_	I-Premise
154	group	_	_	I-Premise
155	(	_	_	I-Premise
156	mean	_	_	I-Premise
157	difference	_	_	I-Premise
158	,	_	_	I-Premise
159	3.4	_	_	I-Premise
160	MET	_	_	I-Premise
161	hr	_	_	I-Premise
162	per	_	_	I-Premise
163	week	_	_	I-Premise
164	;	_	_	I-Premise
165	95	_	_	I-Premise
166	%	_	_	I-Premise
167	confidence	_	_	I-Premise
168	interval	_	_	I-Premise
169	[	_	_	I-Premise
170	CI	_	_	I-Premise
171	]	_	_	I-Premise
172	,	_	_	I-Premise
173	0.7-6.1	_	_	I-Premise
174	MET	_	_	I-Premise
175	hr	_	_	I-Premise
176	per	_	_	I-Premise
177	week	_	_	I-Premise
178	;	_	_	I-Premise
179	p	_	_	I-Premise
180	=	_	_	I-Premise
181	.011	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	There	_	_	B-Premise
185	was	_	_	I-Premise
186	no	_	_	I-Premise
187	significant	_	_	I-Premise
188	difference	_	_	I-Premise
189	between	_	_	I-Premise
190	the	_	_	I-Premise
191	recommendation-plus-referral	_	_	I-Premise
192	group	_	_	I-Premise
193	and	_	_	I-Premise
194	the	_	_	I-Premise
195	usual	_	_	I-Premise
196	care	_	_	I-Premise
197	group	_	_	I-Premise
198	(	_	_	I-Premise
199	mean	_	_	I-Premise
200	difference	_	_	I-Premise
201	,	_	_	I-Premise
202	1.5	_	_	I-Premise
203	MET	_	_	I-Premise
204	hr	_	_	I-Premise
205	per	_	_	I-Premise
206	week	_	_	I-Premise
207	;	_	_	I-Premise
208	95	_	_	I-Premise
209	%	_	_	I-Premise
210	CI	_	_	I-Premise
211	,	_	_	I-Premise
212	-1.0	_	_	I-Premise
213	to	_	_	I-Premise
214	4.0	_	_	I-Premise
215	MET	_	_	I-Premise
216	hr	_	_	I-Premise
217	per	_	_	I-Premise
218	week	_	_	I-Premise
219	;	_	_	I-Premise
220	p	_	_	I-Premise
221	=	_	_	I-Premise
222	.244	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Ancillary	_	_	B-Premise
226	on-treatment	_	_	I-Premise
227	analyzes	_	_	I-Premise
228	showed	_	_	I-Premise
229	that	_	_	I-Premise
230	participants	_	_	I-Premise
231	who	_	_	I-Premise
232	recalled	_	_	I-Premise
233	an	_	_	I-Premise
234	exercise	_	_	I-Premise
235	recommendation	_	_	I-Premise
236	reported	_	_	I-Premise
237	significantly	_	_	I-Premise
238	more	_	_	I-Premise
239	total	_	_	I-Premise
240	exercise	_	_	I-Premise
241	than	_	_	I-Premise
242	participants	_	_	I-Premise
243	who	_	_	I-Premise
244	did	_	_	I-Premise
245	not	_	_	I-Premise
246	recall	_	_	I-Premise
247	an	_	_	I-Premise
248	exercise	_	_	I-Premise
249	recommendation	_	_	I-Premise
250	(	_	_	I-Premise
251	mean	_	_	I-Premise
252	difference	_	_	I-Premise
253	,	_	_	I-Premise
254	4.1	_	_	I-Premise
255	MET	_	_	I-Premise
256	hr	_	_	I-Premise
257	per	_	_	I-Premise
258	week	_	_	I-Premise
259	:	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	CI	_	_	I-Premise
263	,	_	_	I-Premise
264	1.9-6.4	_	_	I-Premise
265	MET	_	_	I-Premise
266	hr	_	_	I-Premise
267	per	_	_	I-Premise
268	week	_	_	I-Premise
269	;	_	_	I-Premise
270	p	_	_	I-Premise
271	<	_	_	I-Premise
272	.001	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	Our	_	_	B-Claim
276	findings	_	_	I-Claim
277	suggest	_	_	I-Claim
278	that	_	_	I-Claim
279	an	_	_	I-Claim
280	oncologist	_	_	I-Claim
281	recommendation	_	_	I-Claim
282	may	_	_	I-Claim
283	increase	_	_	I-Claim
284	exercise	_	_	I-Claim
285	behavior	_	_	I-Claim
286	in	_	_	I-Claim
287	newly	_	_	I-Claim
288	diagnosed	_	_	I-Claim
289	breast	_	_	I-Claim
290	cancer	_	_	I-Claim
291	survivors	_	_	I-Claim
292	,	_	_	I-Claim
293	particularly	_	_	I-Claim
294	if	_	_	I-Claim
295	it	_	_	I-Claim
296	is	_	_	I-Claim
297	recalled	_	_	I-Claim
298	1	_	_	I-Claim
299	week	_	_	I-Claim
300	after	_	_	I-Claim
301	the	_	_	I-Claim
302	recommendation	_	_	I-Claim
303	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	viscocanalostomy	_	_	O
8	and	_	_	O
9	trabeculectomy	_	_	O
10	in	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	primary	_	_	O
14	open-angle	_	_	O
15	glaucoma	_	_	O
16	(	_	_	O
17	POAG	_	_	O
18	)	_	_	O
19	.	_	_	O

20	Department	_	_	O
21	of	_	_	O
22	Ophthalmology	_	_	O
23	,	_	_	O
24	Ankara	_	_	O
25	Education	_	_	O
26	and	_	_	O
27	Research	_	_	O
28	Hospital	_	_	O
29	,	_	_	O
30	Ankara	_	_	O
31	,	_	_	O
32	Turkey	_	_	O
33	.	_	_	O

34	In	_	_	O
35	this	_	_	O
36	prospective	_	_	O
37	randomized	_	_	O
38	trial	_	_	O
39	,	_	_	O
40	50	_	_	O
41	eyes	_	_	O
42	of	_	_	O
43	50	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	medically	_	_	O
47	uncontrolled	_	_	O
48	POAG	_	_	O
49	were	_	_	O
50	randomized	_	_	O
51	to	_	_	O
52	have	_	_	O
53	a	_	_	O
54	trabeculectomy	_	_	O
55	(	_	_	O
56	25	_	_	O
57	eyes	_	_	O
58	)	_	_	O
59	or	_	_	O
60	a	_	_	O
61	viscocanalostomy	_	_	O
62	(	_	_	O
63	25	_	_	O
64	eyes	_	_	O
65	)	_	_	O
66	.	_	_	O

67	Visual	_	_	O
68	acuity	_	_	O
69	,	_	_	O
70	intraocular	_	_	O
71	pressure	_	_	O
72	(	_	_	O
73	IOP	_	_	O
74	)	_	_	O
75	,	_	_	O
76	and	_	_	O
77	slitlamp	_	_	O
78	examinations	_	_	O
79	were	_	_	O
80	performed	_	_	O
81	before	_	_	O
82	surgery	_	_	O
83	and	_	_	O
84	1	_	_	O
85	day	_	_	O
86	,	_	_	O
87	1	_	_	O
88	week	_	_	O
89	,	_	_	O
90	1	_	_	O
91	,	_	_	O
92	3	_	_	O
93	,	_	_	O
94	and	_	_	O
95	6	_	_	O
96	months	_	_	O
97	,	_	_	O
98	and	_	_	O
99	1	_	_	O
100	,	_	_	O
101	2	_	_	O
102	,	_	_	O
103	and	_	_	O
104	3	_	_	O
105	years	_	_	O
106	postoperatively	_	_	O
107	.	_	_	O

108	At	_	_	B-Premise
109	3	_	_	I-Premise
110	years	_	_	I-Premise
111	,	_	_	I-Premise
112	the	_	_	I-Premise
113	mean	_	_	I-Premise
114	IOP	_	_	I-Premise
115	was	_	_	I-Premise
116	16.0	_	_	I-Premise
117	mmHg	_	_	I-Premise
118	+/-	_	_	I-Premise
119	7.07	_	_	I-Premise
120	(	_	_	I-Premise
121	SD	_	_	I-Premise
122	)	_	_	I-Premise
123	in	_	_	I-Premise
124	the	_	_	I-Premise
125	trabeculectomy	_	_	I-Premise
126	group	_	_	I-Premise
127	and	_	_	I-Premise
128	17.8	_	_	I-Premise
129	+/-	_	_	I-Premise
130	4.6	_	_	I-Premise
131	mmHg	_	_	I-Premise
132	in	_	_	I-Premise
133	the	_	_	I-Premise
134	viscocanalostomy	_	_	I-Premise
135	group	_	_	I-Premise
136	(	_	_	I-Premise
137	P=.694	_	_	I-Premise
138	)	_	_	I-Premise
139	.	_	_	I-Premise

140	Complete	_	_	B-Premise
141	success	_	_	I-Premise
142	(	_	_	I-Premise
143	IOP	_	_	I-Premise
144	6	_	_	I-Premise
145	to	_	_	I-Premise
146	21	_	_	I-Premise
147	mm	_	_	I-Premise
148	Hg	_	_	I-Premise
149	without	_	_	I-Premise
150	medication	_	_	I-Premise
151	)	_	_	I-Premise
152	was	_	_	I-Premise
153	achieved	_	_	I-Premise
154	in	_	_	I-Premise
155	66.2	_	_	I-Premise
156	%	_	_	I-Premise
157	of	_	_	I-Premise
158	eyes	_	_	I-Premise
159	at	_	_	I-Premise
160	6	_	_	I-Premise
161	months	_	_	I-Premise
162	and	_	_	I-Premise
163	55.1	_	_	I-Premise
164	%	_	_	I-Premise
165	at	_	_	I-Premise
166	3	_	_	I-Premise
167	years	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	trabeculectomy	_	_	I-Premise
171	group	_	_	I-Premise
172	and	_	_	I-Premise
173	in	_	_	I-Premise
174	52.9	_	_	I-Premise
175	%	_	_	I-Premise
176	and	_	_	I-Premise
177	35.3	_	_	I-Premise
178	%	_	_	I-Premise
179	,	_	_	I-Premise
180	respectively	_	_	I-Premise
181	,	_	_	I-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	viscocanalostomy	_	_	I-Premise
185	group	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	>	_	_	I-Premise
189	.05	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Qualified	_	_	B-Premise
193	success	_	_	I-Premise
194	(	_	_	I-Premise
195	IOP	_	_	I-Premise
196	6	_	_	I-Premise
197	to	_	_	I-Premise
198	21	_	_	I-Premise
199	mmHg	_	_	I-Premise
200	with	_	_	I-Premise
201	medication	_	_	I-Premise
202	)	_	_	I-Premise
203	was	_	_	I-Premise
204	achieved	_	_	I-Premise
205	in	_	_	I-Premise
206	95.8	_	_	I-Premise
207	%	_	_	I-Premise
208	of	_	_	I-Premise
209	eyes	_	_	I-Premise
210	at	_	_	I-Premise
211	6	_	_	I-Premise
212	months	_	_	I-Premise
213	and	_	_	I-Premise
214	79.2	_	_	I-Premise
215	%	_	_	I-Premise
216	at	_	_	I-Premise
217	3	_	_	I-Premise
218	years	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	trabeculectomy	_	_	I-Premise
222	group	_	_	I-Premise
223	and	_	_	I-Premise
224	in	_	_	I-Premise
225	90.7	_	_	I-Premise
226	%	_	_	I-Premise
227	and	_	_	I-Premise
228	73.9	_	_	I-Premise
229	%	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	,	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	viscocanalostomy	_	_	I-Premise
236	group	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	>	_	_	I-Premise
240	.05	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	Postoperative	_	_	B-Premise
244	hypotony	_	_	I-Premise
245	and	_	_	I-Premise
246	cataract	_	_	I-Premise
247	formation	_	_	I-Premise
248	occurred	_	_	I-Premise
249	more	_	_	I-Premise
250	frequently	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	trabeculectomy	_	_	I-Premise
254	group	_	_	I-Premise
255	than	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	viscocanalostomy	_	_	I-Premise
259	group	_	_	I-Premise
260	(	_	_	I-Premise
261	P=.002	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Primary	_	_	B-Claim
265	trabeculectomy	_	_	I-Claim
266	lowered	_	_	I-Claim
267	IOP	_	_	I-Claim
268	more	_	_	I-Claim
269	than	_	_	I-Claim
270	viscocanalostomy	_	_	I-Claim
271	in	_	_	I-Claim
272	POAG	_	_	I-Claim
273	patients	_	_	I-Claim
274	.	_	_	I-Claim

275	However	_	_	O
276	,	_	_	O
277	the	_	_	B-Claim
278	complication	_	_	I-Claim
279	rate	_	_	I-Claim
280	was	_	_	I-Claim
281	lower	_	_	I-Claim
282	in	_	_	I-Claim
283	the	_	_	I-Claim
284	viscocanalostomy	_	_	I-Claim
285	group	_	_	I-Claim
286	.	_	_	I-Claim


0	Chemotherapy	_	_	O
1	with	_	_	O
2	a	_	_	O
3	platinum	_	_	O
4	agent	_	_	O
5	and	_	_	O
6	a	_	_	O
7	taxane	_	_	O
8	(	_	_	O
9	paclitaxel	_	_	O
10	)	_	_	O
11	is	_	_	O
12	considered	_	_	O
13	the	_	_	O
14	standard	_	_	O
15	of	_	_	O
16	care	_	_	O
17	for	_	_	O
18	treatment	_	_	O
19	of	_	_	O
20	ovarian	_	_	O
21	carcinoma	_	_	O
22	.	_	_	O

23	We	_	_	O
24	compared	_	_	O
25	the	_	_	O
26	combination	_	_	O
27	of	_	_	O
28	docetaxel-carboplatin	_	_	O
29	with	_	_	O
30	the	_	_	O
31	combination	_	_	O
32	of	_	_	O
33	paclitaxel-carboplatin	_	_	O
34	as	_	_	O
35	first-line	_	_	O
36	chemotherapy	_	_	O
37	for	_	_	O
38	stage	_	_	O
39	Ic-IV	_	_	O
40	epithelial	_	_	O
41	ovarian	_	_	O
42	or	_	_	O
43	primary	_	_	O
44	peritoneal	_	_	O
45	cancer	_	_	O
46	.	_	_	O

47	We	_	_	O
48	randomly	_	_	O
49	assigned	_	_	O
50	1077	_	_	O
51	patients	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	docetaxel	_	_	O
55	at	_	_	O
56	75	_	_	O
57	mg/m2	_	_	O
58	of	_	_	O
59	body	_	_	O
60	surface	_	_	O
61	area	_	_	O
62	(	_	_	O
63	1-hour	_	_	O
64	intravenous	_	_	O
65	infusion	_	_	O
66	)	_	_	O
67	or	_	_	O
68	paclitaxel	_	_	O
69	at	_	_	O
70	175	_	_	O
71	mg/m2	_	_	O
72	(	_	_	O
73	3-hour	_	_	O
74	intravenous	_	_	O
75	infusion	_	_	O
76	)	_	_	O
77	.	_	_	O

78	Both	_	_	O
79	treatments	_	_	O
80	then	_	_	O
81	were	_	_	O
82	followed	_	_	O
83	by	_	_	O
84	carboplatin	_	_	O
85	to	_	_	O
86	an	_	_	O
87	area	_	_	O
88	under	_	_	O
89	the	_	_	O
90	plasma	_	_	O
91	concentration-time	_	_	O
92	curve	_	_	O
93	of	_	_	O
94	5	_	_	O
95	.	_	_	O

96	The	_	_	O
97	treatments	_	_	O
98	were	_	_	O
99	repeated	_	_	O
100	every	_	_	O
101	3	_	_	O
102	weeks	_	_	O
103	for	_	_	O
104	six	_	_	O
105	cycles	_	_	O
106	;	_	_	O
107	in	_	_	O
108	responding	_	_	O
109	patients	_	_	O
110	,	_	_	O
111	an	_	_	O
112	additional	_	_	O
113	three	_	_	O
114	cycles	_	_	O
115	of	_	_	O
116	single-agent	_	_	O
117	carboplatin	_	_	O
118	was	_	_	O
119	permitted	_	_	O
120	.	_	_	O

121	Survival	_	_	O
122	curves	_	_	O
123	were	_	_	O
124	calculated	_	_	O
125	by	_	_	O
126	the	_	_	O
127	Kaplan-Meier	_	_	O
128	method	_	_	O
129	,	_	_	O
130	and	_	_	O
131	hazard	_	_	O
132	ratios	_	_	O
133	were	_	_	O
134	estimated	_	_	O
135	with	_	_	O
136	the	_	_	O
137	Cox	_	_	O
138	proportional	_	_	O
139	hazards	_	_	O
140	model	_	_	O
141	.	_	_	O

142	All	_	_	O
143	statistical	_	_	O
144	tests	_	_	O
145	were	_	_	O
146	two-sided	_	_	O
147	.	_	_	O

148	After	_	_	B-Premise
149	a	_	_	I-Premise
150	median	_	_	I-Premise
151	follow-up	_	_	I-Premise
152	of	_	_	I-Premise
153	23	_	_	I-Premise
154	months	_	_	I-Premise
155	,	_	_	I-Premise
156	both	_	_	I-Premise
157	groups	_	_	I-Premise
158	had	_	_	I-Premise
159	similar	_	_	I-Premise
160	progression-free	_	_	I-Premise
161	survival	_	_	I-Premise
162	(	_	_	I-Premise
163	medians	_	_	I-Premise
164	of	_	_	I-Premise
165	15.0	_	_	I-Premise
166	months	_	_	I-Premise
167	for	_	_	I-Premise
168	docetaxel-carboplatin	_	_	I-Premise
169	and	_	_	I-Premise
170	14.8	_	_	I-Premise
171	months	_	_	I-Premise
172	for	_	_	I-Premise
173	paclitaxel-carboplatin	_	_	I-Premise
174	;	_	_	I-Premise
175	hazard	_	_	I-Premise
176	ratio	_	_	I-Premise
177	[	_	_	I-Premise
178	HR	_	_	I-Premise
179	]	_	_	I-Premise
180	docetaxel-paclitaxel	_	_	I-Premise
181	=	_	_	I-Premise
182	0.97	_	_	I-Premise
183	,	_	_	I-Premise
184	95	_	_	I-Premise
185	%	_	_	I-Premise
186	confidence	_	_	I-Premise
187	interval	_	_	I-Premise
188	[	_	_	I-Premise
189	CI	_	_	I-Premise
190	]	_	_	I-Premise
191	=	_	_	I-Premise
192	0.83	_	_	I-Premise
193	to	_	_	I-Premise
194	1.13	_	_	I-Premise
195	;	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	.707	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	overall	_	_	I-Premise
202	survival	_	_	I-Premise
203	rates	_	_	I-Premise
204	at	_	_	I-Premise
205	2	_	_	I-Premise
206	years	_	_	I-Premise
207	(	_	_	I-Premise
208	64.2	_	_	I-Premise
209	%	_	_	I-Premise
210	and	_	_	I-Premise
211	68.9	_	_	I-Premise
212	%	_	_	I-Premise
213	,	_	_	I-Premise
214	respectively	_	_	I-Premise
215	;	_	_	I-Premise
216	HR	_	_	I-Premise
217	=	_	_	I-Premise
218	1.13	_	_	I-Premise
219	,	_	_	I-Premise
220	95	_	_	I-Premise
221	%	_	_	I-Premise
222	CI	_	_	I-Premise
223	=	_	_	I-Premise
224	0.92	_	_	I-Premise
225	to	_	_	I-Premise
226	1.39	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	.238	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	objective	_	_	I-Premise
235	tumor	_	_	I-Premise
236	(	_	_	I-Premise
237	58.7	_	_	I-Premise
238	%	_	_	I-Premise
239	and	_	_	I-Premise
240	59.5	_	_	I-Premise
241	%	_	_	I-Premise
242	,	_	_	I-Premise
243	respectively	_	_	I-Premise
244	;	_	_	I-Premise
245	difference	_	_	I-Premise
246	between	_	_	I-Premise
247	docetaxel	_	_	I-Premise
248	and	_	_	I-Premise
249	paclitaxel	_	_	I-Premise
250	=	_	_	I-Premise
251	-0.8	_	_	I-Premise
252	%	_	_	I-Premise
253	,	_	_	I-Premise
254	95	_	_	I-Premise
255	%	_	_	I-Premise
256	CI	_	_	I-Premise
257	=	_	_	I-Premise
258	-8.6	_	_	I-Premise
259	%	_	_	I-Premise
260	to	_	_	I-Premise
261	7.1	_	_	I-Premise
262	%	_	_	I-Premise
263	;	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.868	_	_	I-Premise
267	)	_	_	I-Premise
268	and	_	_	I-Premise
269	CA-125	_	_	I-Premise
270	(	_	_	I-Premise
271	75.8	_	_	I-Premise
272	%	_	_	I-Premise
273	and	_	_	I-Premise
274	76.8	_	_	I-Premise
275	%	_	_	I-Premise
276	,	_	_	I-Premise
277	respectively	_	_	I-Premise
278	;	_	_	I-Premise
279	difference	_	_	I-Premise
280	docetaxel-paclitaxel	_	_	I-Premise
281	=	_	_	I-Premise
282	-1.0	_	_	I-Premise
283	%	_	_	I-Premise
284	,	_	_	I-Premise
285	95	_	_	I-Premise
286	%	_	_	I-Premise
287	CI	_	_	I-Premise
288	=	_	_	I-Premise
289	-7.2	_	_	I-Premise
290	%	_	_	I-Premise
291	to	_	_	I-Premise
292	5.1	_	_	I-Premise
293	%	_	_	I-Premise
294	;	_	_	I-Premise
295	P	_	_	I-Premise
296	=	_	_	I-Premise
297	.794	_	_	I-Premise
298	)	_	_	I-Premise
299	response	_	_	I-Premise
300	rates	_	_	I-Premise
301	.	_	_	I-Premise

302	However	_	_	B-Premise
303	,	_	_	I-Premise
304	docetaxel-carboplatin	_	_	I-Premise
305	was	_	_	I-Premise
306	associated	_	_	I-Premise
307	with	_	_	I-Premise
308	substantially	_	_	I-Premise
309	less	_	_	I-Premise
310	overall	_	_	I-Premise
311	and	_	_	I-Premise
312	grade	_	_	I-Premise
313	2	_	_	I-Premise
314	or	_	_	I-Premise
315	higher	_	_	I-Premise
316	neurotoxicity	_	_	I-Premise
317	than	_	_	I-Premise
318	paclitaxel-carboplatin	_	_	I-Premise
319	(	_	_	I-Premise
320	grade	_	_	I-Premise
321	>	_	_	I-Premise
322	or	_	_	I-Premise
323	=2	_	_	I-Premise
324	neurosensory	_	_	I-Premise
325	toxicity	_	_	I-Premise
326	in	_	_	I-Premise
327	11	_	_	I-Premise
328	%	_	_	I-Premise
329	versus	_	_	I-Premise
330	30	_	_	I-Premise
331	%	_	_	I-Premise
332	,	_	_	I-Premise
333	difference	_	_	I-Premise
334	=	_	_	I-Premise
335	19	_	_	I-Premise
336	%	_	_	I-Premise
337	,	_	_	I-Premise
338	95	_	_	I-Premise
339	%	_	_	I-Premise
340	CI	_	_	I-Premise
341	=	_	_	I-Premise
342	15	_	_	I-Premise
343	%	_	_	I-Premise
344	to	_	_	I-Premise
345	24	_	_	I-Premise
346	%	_	_	I-Premise
347	;	_	_	I-Premise
348	P	_	_	I-Premise
349	<	_	_	I-Premise
350	.001	_	_	I-Premise
351	;	_	_	I-Premise
352	grade	_	_	I-Premise
353	>	_	_	I-Premise
354	or	_	_	I-Premise
355	=2	_	_	I-Premise
356	neuromotor	_	_	I-Premise
357	toxicity	_	_	I-Premise
358	in	_	_	I-Premise
359	3	_	_	I-Premise
360	%	_	_	I-Premise
361	versus	_	_	I-Premise
362	7	_	_	I-Premise
363	%	_	_	I-Premise
364	,	_	_	I-Premise
365	difference	_	_	I-Premise
366	=	_	_	I-Premise
367	4	_	_	I-Premise
368	%	_	_	I-Premise
369	,	_	_	I-Premise
370	95	_	_	I-Premise
371	%	_	_	I-Premise
372	CI	_	_	I-Premise
373	=	_	_	I-Premise
374	1	_	_	I-Premise
375	%	_	_	I-Premise
376	to	_	_	I-Premise
377	7	_	_	I-Premise
378	%	_	_	I-Premise
379	;	_	_	I-Premise
380	P	_	_	I-Premise
381	<	_	_	I-Premise
382	.001	_	_	I-Premise
383	)	_	_	I-Premise
384	.	_	_	I-Premise

385	Treatment	_	_	B-Premise
386	with	_	_	I-Premise
387	docetaxel-carboplatin	_	_	I-Premise
388	was	_	_	I-Premise
389	associated	_	_	I-Premise
390	with	_	_	I-Premise
391	statistically	_	_	I-Premise
392	significantly	_	_	I-Premise
393	more	_	_	I-Premise
394	grade	_	_	I-Premise
395	3-4	_	_	I-Premise
396	neutropenia	_	_	I-Premise
397	(	_	_	I-Premise
398	94	_	_	I-Premise
399	%	_	_	I-Premise
400	versus	_	_	I-Premise
401	84	_	_	I-Premise
402	%	_	_	I-Premise
403	,	_	_	I-Premise
404	difference	_	_	I-Premise
405	=	_	_	I-Premise
406	11	_	_	I-Premise
407	%	_	_	I-Premise
408	,	_	_	I-Premise
409	95	_	_	I-Premise
410	%	_	_	I-Premise
411	CI	_	_	I-Premise
412	=	_	_	I-Premise
413	7	_	_	I-Premise
414	%	_	_	I-Premise
415	to	_	_	I-Premise
416	14	_	_	I-Premise
417	%	_	_	I-Premise
418	;	_	_	I-Premise
419	P	_	_	I-Premise
420	<	_	_	I-Premise
421	.001	_	_	I-Premise
422	)	_	_	I-Premise
423	and	_	_	I-Premise
424	neutropenic	_	_	I-Premise
425	complications	_	_	I-Premise
426	than	_	_	I-Premise
427	treatment	_	_	I-Premise
428	with	_	_	I-Premise
429	paclitaxel-carboplatin	_	_	I-Premise
430	,	_	_	I-Premise
431	although	_	_	B-Premise
432	myelosuppression	_	_	I-Premise
433	did	_	_	I-Premise
434	not	_	_	I-Premise
435	influence	_	_	I-Premise
436	dose	_	_	I-Premise
437	delivery	_	_	I-Premise
438	or	_	_	I-Premise
439	patient	_	_	I-Premise
440	safety	_	_	I-Premise
441	.	_	_	I-Premise

442	Global	_	_	B-Premise
443	quality	_	_	I-Premise
444	of	_	_	I-Premise
445	life	_	_	I-Premise
446	was	_	_	I-Premise
447	similar	_	_	I-Premise
448	in	_	_	I-Premise
449	both	_	_	I-Premise
450	arms	_	_	I-Premise
451	,	_	_	I-Premise
452	but	_	_	B-Premise
453	substantive	_	_	I-Premise
454	differences	_	_	I-Premise
455	in	_	_	I-Premise
456	many	_	_	I-Premise
457	symptom	_	_	I-Premise
458	scores	_	_	I-Premise
459	favored	_	_	I-Premise
460	docetaxel	_	_	I-Premise
461	.	_	_	I-Premise

462	Docetaxel-carboplatin	_	_	B-Claim
463	appears	_	_	I-Claim
464	to	_	_	I-Claim
465	be	_	_	I-Claim
466	similar	_	_	I-Claim
467	to	_	_	I-Claim
468	paclitaxel-carboplatin	_	_	I-Claim
469	in	_	_	I-Claim
470	terms	_	_	I-Claim
471	of	_	_	I-Claim
472	progression-free	_	_	I-Claim
473	survival	_	_	I-Claim
474	and	_	_	I-Claim
475	response	_	_	I-Claim
476	,	_	_	I-Claim
477	although	_	_	B-Claim
478	longer	_	_	I-Claim
479	follow-up	_	_	I-Claim
480	is	_	_	I-Claim
481	required	_	_	I-Claim
482	for	_	_	I-Claim
483	a	_	_	I-Claim
484	definitive	_	_	I-Claim
485	statement	_	_	I-Claim
486	on	_	_	I-Claim
487	survival	_	_	I-Claim
488	.	_	_	I-Claim

489	Thus	_	_	B-Claim
490	,	_	_	I-Claim
491	docetaxel-carboplatin	_	_	I-Claim
492	represents	_	_	I-Claim
493	an	_	_	I-Claim
494	alternative	_	_	I-Claim
495	first-line	_	_	I-Claim
496	chemotherapy	_	_	I-Claim
497	regimen	_	_	I-Claim
498	for	_	_	I-Claim
499	patients	_	_	I-Claim
500	with	_	_	I-Claim
501	newly	_	_	I-Claim
502	diagnosed	_	_	I-Claim
503	ovarian	_	_	I-Claim
504	cancer	_	_	I-Claim
505	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	randomized	_	_	O
4	trial	_	_	O
5	compared	_	_	O
6	two	_	_	O
7	chemotherapy	_	_	O
8	regimens	_	_	O
9	,	_	_	O
10	gemcitabine	_	_	O
11	plus	_	_	O
12	carboplatin	_	_	O
13	and	_	_	O
14	mitomycin	_	_	O
15	,	_	_	O
16	ifosfamide	_	_	O
17	,	_	_	O
18	and	_	_	O
19	cisplatin	_	_	O
20	,	_	_	O
21	in	_	_	O
22	chemotherapy-naive	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	advanced	_	_	O
26	non-small-cell	_	_	O
27	lung	_	_	O
28	cancer	_	_	O
29	(	_	_	O
30	NSCLC	_	_	O
31	)	_	_	O
32	.	_	_	O

33	The	_	_	O
34	regimens	_	_	O
35	were	_	_	O
36	compared	_	_	O
37	with	_	_	O
38	regard	_	_	O
39	to	_	_	O
40	effects	_	_	O
41	on	_	_	O
42	survival	_	_	O
43	,	_	_	O
44	response	_	_	O
45	rates	_	_	O
46	,	_	_	O
47	toxicity	_	_	O
48	,	_	_	O
49	and	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	.	_	_	O

54	Eligible	_	_	O
55	patients	_	_	O
56	had	_	_	O
57	previously	_	_	O
58	untreated	_	_	O
59	stage	_	_	O
60	IIIB	_	_	O
61	or	_	_	O
62	IV	_	_	O
63	NSCLC	_	_	O
64	suitable	_	_	O
65	for	_	_	O
66	cisplatin-based	_	_	O
67	chemotherapy	_	_	O
68	.	_	_	O

69	Randomly	_	_	O
70	assigned	_	_	O
71	patients	_	_	O
72	were	_	_	O
73	to	_	_	O
74	receive	_	_	O
75	four	_	_	O
76	cycles	_	_	O
77	,	_	_	O
78	each	_	_	O
79	at	_	_	O
80	3-week	_	_	O
81	intervals	_	_	O
82	,	_	_	O
83	of	_	_	O
84	carboplatin	_	_	O
85	area	_	_	O
86	under	_	_	O
87	the	_	_	O
88	curve	_	_	O
89	of	_	_	O
90	5	_	_	O
91	on	_	_	O
92	day	_	_	O
93	1	_	_	O
94	plus	_	_	O
95	gemcitabine	_	_	O
96	1,200	_	_	O
97	mg/m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	on	_	_	O
102	days	_	_	O
103	1	_	_	O
104	and	_	_	O
105	8	_	_	O
106	(	_	_	O
107	GCa	_	_	O
108	)	_	_	O
109	or	_	_	O
110	mitomycin	_	_	O
111	6	_	_	O
112	mg/m	_	_	O
113	(	_	_	O
114	2	_	_	O
115	)	_	_	O
116	,	_	_	O
117	ifosfamide	_	_	O
118	3g/m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	,	_	_	O
123	and	_	_	O
124	cisplatin	_	_	O
125	50	_	_	O
126	mg/m	_	_	O
127	(	_	_	O
128	2	_	_	O
129	)	_	_	O
130	on	_	_	O
131	day	_	_	O
132	1	_	_	O
133	(	_	_	O
134	MIC	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Between	_	_	O
138	February	_	_	O
139	1999	_	_	O
140	and	_	_	O
141	August	_	_	O
142	2001	_	_	O
143	,	_	_	O
144	422	_	_	O
145	patients	_	_	O
146	(	_	_	O
147	GCa	_	_	O
148	,	_	_	O
149	n	_	_	O
150	=	_	_	O
151	212	_	_	O
152	;	_	_	O
153	MIC	_	_	O
154	,	_	_	O
155	n	_	_	O
156	=	_	_	O
157	210	_	_	O
158	)	_	_	O
159	were	_	_	O
160	randomly	_	_	O
161	assigned	_	_	O
162	in	_	_	O
163	the	_	_	O
164	United	_	_	O
165	Kingdom	_	_	O
166	.	_	_	O

167	The	_	_	O
168	majority	_	_	O
169	of	_	_	O
170	patients	_	_	O
171	received	_	_	O
172	the	_	_	O
173	intended	_	_	O
174	four	_	_	O
175	cycles	_	_	O
176	(	_	_	O
177	GCa	_	_	O
178	,	_	_	O
179	64	_	_	O
180	%	_	_	O
181	;	_	_	O
182	MIC	_	_	O
183	,	_	_	O
184	61	_	_	O
185	%	_	_	O
186	)	_	_	O
187	.	_	_	O

188	There	_	_	B-Premise
189	was	_	_	I-Premise
190	a	_	_	I-Premise
191	significant	_	_	I-Premise
192	survival	_	_	I-Premise
193	advantage	_	_	I-Premise
194	for	_	_	I-Premise
195	GCa	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	MIC	_	_	I-Premise
199	(	_	_	I-Premise
200	hazard	_	_	I-Premise
201	ratio	_	_	I-Premise
202	,	_	_	I-Premise
203	0.76	_	_	I-Premise
204	;	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	CI	_	_	I-Premise
208	,	_	_	I-Premise
209	0.61	_	_	I-Premise
210	to	_	_	I-Premise
211	0	_	_	I-Premise
212	.	_	_	I-Premise

213	93	_	_	I-Premise
214	;	_	_	I-Premise
215	P	_	_	I-Premise
216	=	_	_	I-Premise
217	.008	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	Median	_	_	B-Premise
221	survival	_	_	I-Premise
222	was	_	_	I-Premise
223	10	_	_	I-Premise
224	months	_	_	I-Premise
225	with	_	_	I-Premise
226	GCa	_	_	I-Premise
227	and	_	_	I-Premise
228	7.6	_	_	I-Premise
229	months	_	_	I-Premise
230	with	_	_	I-Premise
231	MIC	_	_	I-Premise
232	(	_	_	I-Premise
233	difference	_	_	I-Premise
234	,	_	_	I-Premise
235	2.4	_	_	I-Premise
236	months	_	_	I-Premise
237	;	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	CI	_	_	I-Premise
241	,	_	_	I-Premise
242	1.0	_	_	I-Premise
243	to	_	_	I-Premise
244	4.0	_	_	I-Premise
245	)	_	_	I-Premise
246	,	_	_	I-Premise
247	and	_	_	I-Premise
248	1-year	_	_	I-Premise
249	survival	_	_	I-Premise
250	was	_	_	I-Premise
251	40	_	_	I-Premise
252	%	_	_	I-Premise
253	with	_	_	I-Premise
254	GCa	_	_	I-Premise
255	and	_	_	I-Premise
256	30	_	_	I-Premise
257	%	_	_	I-Premise
258	with	_	_	I-Premise
259	MIC	_	_	I-Premise
260	(	_	_	I-Premise
261	difference	_	_	I-Premise
262	,	_	_	I-Premise
263	10	_	_	I-Premise
264	%	_	_	I-Premise
265	;	_	_	I-Premise
266	95	_	_	I-Premise
267	%	_	_	I-Premise
268	CI	_	_	I-Premise
269	,	_	_	I-Premise
270	3	_	_	I-Premise
271	%	_	_	I-Premise
272	to	_	_	I-Premise
273	18	_	_	I-Premise
274	%	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	Overall	_	_	B-Premise
278	response	_	_	I-Premise
279	rates	_	_	I-Premise
280	were	_	_	I-Premise
281	similar	_	_	I-Premise
282	(	_	_	I-Premise
283	42	_	_	I-Premise
284	%	_	_	I-Premise
285	for	_	_	I-Premise
286	GCa	_	_	I-Premise
287	v	_	_	I-Premise
288	41	_	_	I-Premise
289	%	_	_	I-Premise
290	for	_	_	I-Premise
291	MIC	_	_	I-Premise
292	;	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.84	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	More	_	_	B-Premise
299	thrombocytopenia	_	_	I-Premise
300	occurred	_	_	I-Premise
301	with	_	_	I-Premise
302	GCa	_	_	I-Premise
303	(	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	.03	_	_	I-Premise
307	)	_	_	I-Premise
308	,	_	_	I-Premise
309	but	_	_	B-Premise
310	this	_	_	I-Premise
311	was	_	_	I-Premise
312	not	_	_	I-Premise
313	associated	_	_	I-Premise
314	with	_	_	I-Premise
315	increased	_	_	I-Premise
316	hospital	_	_	I-Premise
317	admission	_	_	I-Premise
318	or	_	_	I-Premise
319	fatality	_	_	I-Premise
320	.	_	_	I-Premise

321	GCa	_	_	B-Premise
322	caused	_	_	I-Premise
323	less	_	_	I-Premise
324	nausea	_	_	I-Premise
325	,	_	_	I-Premise
326	vomiting	_	_	I-Premise
327	,	_	_	I-Premise
328	constipation	_	_	I-Premise
329	,	_	_	I-Premise
330	and	_	_	I-Premise
331	alopecia	_	_	I-Premise
332	and	_	_	I-Premise
333	was	_	_	I-Premise
334	associated	_	_	I-Premise
335	with	_	_	I-Premise
336	fewer	_	_	I-Premise
337	admissions	_	_	I-Premise
338	for	_	_	I-Premise
339	administration	_	_	I-Premise
340	and	_	_	I-Premise
341	better	_	_	I-Premise
342	quality	_	_	I-Premise
343	of	_	_	I-Premise
344	life	_	_	I-Premise
345	.	_	_	I-Premise

346	In	_	_	B-Claim
347	patients	_	_	I-Claim
348	with	_	_	I-Claim
349	advanced	_	_	I-Claim
350	NSCLC	_	_	I-Claim
351	,	_	_	I-Claim
352	GCa	_	_	I-Claim
353	chemotherapy	_	_	I-Claim
354	was	_	_	I-Claim
355	shown	_	_	I-Claim
356	to	_	_	I-Claim
357	be	_	_	I-Claim
358	a	_	_	I-Claim
359	better-tolerated	_	_	I-Claim
360	treatment	_	_	I-Claim
361	that	_	_	I-Claim
362	conferred	_	_	I-Claim
363	a	_	_	I-Claim
364	survival	_	_	I-Claim
365	advantage	_	_	I-Claim
366	over	_	_	I-Claim
367	MIC	_	_	I-Claim
368	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	randomized	_	_	O
3	clinical	_	_	O
4	trial	_	_	O
5	,	_	_	O
6	the	_	_	O
7	authors	_	_	O
8	compared	_	_	O
9	the	_	_	O
10	use	_	_	O
11	of	_	_	O
12	postoperative	_	_	O
13	subconjunctival	_	_	O
14	injections	_	_	O
15	of	_	_	O
16	5-fluorouracil	_	_	O
17	(	_	_	O
18	5-FU	_	_	O
19	)	_	_	O
20	in	_	_	O
21	19	_	_	O
22	eyes	_	_	O
23	with	_	_	O
24	a	_	_	O
25	single	_	_	O
26	intraoperative	_	_	O
27	application	_	_	O
28	of	_	_	O
29	subconjunctival	_	_	O
30	mitomycin	_	_	O
31	(	_	_	O
32	MMC	_	_	O
33	)	_	_	O
34	at	_	_	O
35	the	_	_	O
36	filtering	_	_	O
37	site	_	_	O
38	in	_	_	O
39	20	_	_	O
40	eyes	_	_	O
41	at	_	_	O
42	high	_	_	O
43	risk	_	_	O
44	for	_	_	O
45	failure	_	_	O
46	of	_	_	O
47	glaucoma	_	_	O
48	filtering	_	_	O
49	surgery	_	_	O
50	.	_	_	O

51	Six	_	_	B-Premise
52	months	_	_	I-Premise
53	after	_	_	I-Premise
54	surgery	_	_	I-Premise
55	,	_	_	I-Premise
56	intraocular	_	_	I-Premise
57	pressures	_	_	I-Premise
58	averaged	_	_	I-Premise
59	10.9	_	_	I-Premise
60	+/-	_	_	I-Premise
61	5.3	_	_	I-Premise
62	mmHg	_	_	I-Premise
63	(	_	_	I-Premise
64	mean	_	_	I-Premise
65	+/-	_	_	I-Premise
66	standard	_	_	I-Premise
67	deviation	_	_	I-Premise
68	)	_	_	I-Premise
69	in	_	_	I-Premise
70	the	_	_	I-Premise
71	MMC-treated	_	_	I-Premise
72	eyes	_	_	I-Premise
73	versus	_	_	I-Premise
74	14.2	_	_	I-Premise
75	+/-	_	_	I-Premise
76	5.5	_	_	I-Premise
77	mmHg	_	_	I-Premise
78	in	_	_	I-Premise
79	the	_	_	I-Premise
80	5-FU-treated	_	_	I-Premise
81	eyes	_	_	I-Premise
82	(	_	_	I-Premise
83	P	_	_	I-Premise
84	=	_	_	I-Premise
85	0.08	_	_	I-Premise
86	)	_	_	I-Premise
87	and	_	_	I-Premise
88	were	_	_	I-Premise
89	less	_	_	I-Premise
90	than	_	_	I-Premise
91	or	_	_	I-Premise
92	equal	_	_	I-Premise
93	to	_	_	I-Premise
94	12	_	_	I-Premise
95	mmHg	_	_	I-Premise
96	in	_	_	I-Premise
97	60.0	_	_	I-Premise
98	%	_	_	I-Premise
99	of	_	_	I-Premise
100	MMC-treated	_	_	I-Premise
101	eyes	_	_	I-Premise
102	and	_	_	I-Premise
103	21.1	_	_	I-Premise
104	%	_	_	I-Premise
105	of	_	_	I-Premise
106	5-FU-treated	_	_	I-Premise
107	eyes	_	_	I-Premise
108	(	_	_	I-Premise
109	P	_	_	I-Premise
110	=	_	_	I-Premise
111	0.03	_	_	I-Premise
112	)	_	_	I-Premise
113	.	_	_	I-Premise

114	Mitomycin-treated	_	_	O
115	eyes	_	_	O
116	were	_	_	O
117	receiving	_	_	O
118	an	_	_	O
119	average	_	_	O
120	of	_	_	O
121	0.3	_	_	O
122	+/-	_	_	O
123	0.5	_	_	O
124	medications	_	_	O
125	for	_	_	O
126	intraocular	_	_	O
127	pressure	_	_	O
128	control	_	_	O
129	,	_	_	O
130	and	_	_	O
131	5-FU-treated	_	_	O
132	eyes	_	_	O
133	were	_	_	O
134	receiving	_	_	O
135	an	_	_	O
136	average	_	_	O
137	of	_	_	O
138	1.1	_	_	O
139	+/-	_	_	O
140	1.1	_	_	O
141	medications	_	_	O
142	(	_	_	O
143	P	_	_	O
144	=	_	_	O
145	0.01	_	_	O
146	)	_	_	O
147	.	_	_	O

148	Drug-induced	_	_	B-Premise
149	corneal	_	_	I-Premise
150	epithelial	_	_	I-Premise
151	defects	_	_	I-Premise
152	were	_	_	I-Premise
153	seen	_	_	I-Premise
154	in	_	_	I-Premise
155	nine	_	_	I-Premise
156	5-FU-treated	_	_	I-Premise
157	eyes	_	_	I-Premise
158	and	_	_	I-Premise
159	in	_	_	I-Premise
160	no	_	_	I-Premise
161	MMC-treated	_	_	I-Premise
162	eyes	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	=	_	_	I-Premise
166	0.0004	_	_	I-Premise
167	)	_	_	I-Premise
168	.	_	_	I-Premise

169	These	_	_	B-Claim
170	results	_	_	I-Claim
171	suggest	_	_	I-Claim
172	that	_	_	I-Claim
173	intraoperative	_	_	I-Claim
174	MMC	_	_	I-Claim
175	may	_	_	I-Claim
176	be	_	_	I-Claim
177	a	_	_	I-Claim
178	viable	_	_	I-Claim
179	alternative	_	_	I-Claim
180	to	_	_	I-Claim
181	postoperative	_	_	I-Claim
182	5-FU	_	_	I-Claim
183	,	_	_	I-Claim
184	with	_	_	I-Claim
185	lower	_	_	I-Claim
186	overall	_	_	I-Claim
187	intraocular	_	_	I-Claim
188	pressures	_	_	I-Claim
189	,	_	_	I-Claim
190	decreased	_	_	I-Claim
191	dependence	_	_	I-Claim
192	on	_	_	I-Claim
193	postoperative	_	_	I-Claim
194	ocular	_	_	I-Claim
195	antihypertensive	_	_	I-Claim
196	medications	_	_	I-Claim
197	,	_	_	I-Claim
198	and	_	_	I-Claim
199	decreased	_	_	I-Claim
200	corneal	_	_	I-Claim
201	toxicity	_	_	I-Claim
202	.	_	_	I-Claim


0	The	_	_	B-Claim
1	role	_	_	I-Claim
2	of	_	_	I-Claim
3	high-dose	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	(	_	_	I-Claim
6	HDCT	_	_	I-Claim
7	)	_	_	I-Claim
8	in	_	_	I-Claim
9	metastatic	_	_	I-Claim
10	breast	_	_	I-Claim
11	cancer	_	_	I-Claim
12	remains	_	_	I-Claim
13	controversial	_	_	I-Claim
14	.	_	_	I-Claim

15	Trials	_	_	B-Claim
16	with	_	_	I-Claim
17	late	_	_	I-Claim
18	intensification	_	_	I-Claim
19	HDCT	_	_	I-Claim
20	have	_	_	I-Claim
21	failed	_	_	I-Claim
22	to	_	_	I-Claim
23	show	_	_	I-Claim
24	an	_	_	I-Claim
25	advantage	_	_	I-Claim
26	in	_	_	I-Claim
27	overall	_	_	I-Claim
28	survival	_	_	I-Claim
29	.	_	_	I-Claim

30	This	_	_	O
31	study	_	_	O
32	was	_	_	O
33	initiated	_	_	O
34	to	_	_	O
35	compare	_	_	O
36	up-front	_	_	O
37	tandem	_	_	O
38	HDCT	_	_	O
39	and	_	_	O
40	standard	_	_	O
41	combination	_	_	O
42	therapy	_	_	O
43	in	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	metastatic	_	_	O
47	breast	_	_	O
48	cancer	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	without	_	_	O
52	prior	_	_	O
53	chemotherapy	_	_	O
54	for	_	_	O
55	metastatic	_	_	O
56	disease	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	assigned	_	_	O
60	to	_	_	O
61	standard	_	_	O
62	combination	_	_	O
63	therapy	_	_	O
64	with	_	_	O
65	doxorubicin	_	_	O
66	and	_	_	O
67	paclitaxel	_	_	O
68	(	_	_	O
69	AT	_	_	O
70	)	_	_	O
71	or	_	_	O
72	double	_	_	O
73	HDCT	_	_	O
74	with	_	_	O
75	cyclophosphamide	_	_	O
76	,	_	_	O
77	mitoxantrone	_	_	O
78	,	_	_	O
79	and	_	_	O
80	etoposide	_	_	O
81	followed	_	_	O
82	by	_	_	O
83	peripheral-blood	_	_	O
84	stem-cell	_	_	O
85	transplantation	_	_	O
86	.	_	_	O

87	HDCT	_	_	O
88	was	_	_	O
89	repeated	_	_	O
90	after	_	_	O
91	6	_	_	O
92	weeks	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	stratified	_	_	O
97	by	_	_	O
98	menopausal	_	_	O
99	and	_	_	O
100	hormone-receptor	_	_	O
101	status	_	_	O
102	.	_	_	O

103	The	_	_	O
104	primary	_	_	O
105	objective	_	_	O
106	was	_	_	O
107	to	_	_	O
108	compare	_	_	O
109	complete	_	_	O
110	response	_	_	O
111	(	_	_	O
112	CR	_	_	O
113	)	_	_	O
114	rates	_	_	O
115	.	_	_	O

116	A	_	_	O
117	total	_	_	O
118	of	_	_	O
119	93	_	_	O
120	patients	_	_	O
121	were	_	_	O
122	enrolled	_	_	O
123	onto	_	_	O
124	the	_	_	O
125	trial	_	_	O
126	.	_	_	O

127	Intent-to-treat	_	_	B-Premise
128	CR	_	_	I-Premise
129	rates	_	_	I-Premise
130	for	_	_	I-Premise
131	patients	_	_	I-Premise
132	randomized	_	_	I-Premise
133	to	_	_	I-Premise
134	HDCT	_	_	I-Premise
135	and	_	_	I-Premise
136	AT	_	_	I-Premise
137	were	_	_	I-Premise
138	12.5	_	_	I-Premise
139	%	_	_	I-Premise
140	and	_	_	I-Premise
141	11.1	_	_	I-Premise
142	%	_	_	I-Premise
143	,	_	_	I-Premise
144	respectively	_	_	I-Premise
145	(	_	_	I-Premise
146	P	_	_	I-Premise
147	=	_	_	I-Premise
148	.84	_	_	I-Premise
149	)	_	_	I-Premise
150	.	_	_	I-Premise

151	Objective	_	_	B-Premise
152	response	_	_	I-Premise
153	rates	_	_	I-Premise
154	were	_	_	I-Premise
155	66.7	_	_	I-Premise
156	%	_	_	I-Premise
157	for	_	_	I-Premise
158	patients	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	high-dose	_	_	I-Premise
162	group	_	_	I-Premise
163	and	_	_	I-Premise
164	64.4	_	_	I-Premise
165	%	_	_	I-Premise
166	for	_	_	I-Premise
167	patients	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	AT	_	_	I-Premise
171	arm	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.82	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	In	_	_	B-Premise
179	an	_	_	I-Premise
180	intent-to-treat	_	_	I-Premise
181	analysis	_	_	I-Premise
182	,	_	_	I-Premise
183	there	_	_	I-Premise
184	were	_	_	I-Premise
185	no	_	_	I-Premise
186	significant	_	_	I-Premise
187	differences	_	_	I-Premise
188	between	_	_	I-Premise
189	the	_	_	I-Premise
190	two	_	_	I-Premise
191	treatments	_	_	I-Premise
192	in	_	_	I-Premise
193	median	_	_	I-Premise
194	time	_	_	I-Premise
195	to	_	_	I-Premise
196	progression	_	_	I-Premise
197	(	_	_	I-Premise
198	HDCT	_	_	I-Premise
199	,	_	_	I-Premise
200	11.1	_	_	I-Premise
201	months	_	_	I-Premise
202	;	_	_	I-Premise
203	AT	_	_	I-Premise
204	,	_	_	I-Premise
205	10.6	_	_	I-Premise
206	months	_	_	I-Premise
207	;	_	_	I-Premise
208	P	_	_	I-Premise
209	=	_	_	I-Premise
210	.67	_	_	I-Premise
211	)	_	_	I-Premise
212	,	_	_	I-Premise
213	duration	_	_	I-Premise
214	of	_	_	I-Premise
215	response	_	_	I-Premise
216	(	_	_	I-Premise
217	HDCT	_	_	I-Premise
218	,	_	_	I-Premise
219	13.9	_	_	I-Premise
220	months	_	_	I-Premise
221	;	_	_	I-Premise
222	AT	_	_	I-Premise
223	,	_	_	I-Premise
224	14.3	_	_	I-Premise
225	months	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.98	_	_	I-Premise
230	)	_	_	I-Premise
231	,	_	_	I-Premise
232	and	_	_	I-Premise
233	overall	_	_	I-Premise
234	survival	_	_	I-Premise
235	(	_	_	I-Premise
236	HDCT	_	_	I-Premise
237	,	_	_	I-Premise
238	26.9	_	_	I-Premise
239	months	_	_	I-Premise
240	;	_	_	I-Premise
241	AT	_	_	I-Premise
242	,	_	_	I-Premise
243	23.4	_	_	I-Premise
244	months	_	_	I-Premise
245	;	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.60	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	HDCT	_	_	B-Premise
252	was	_	_	I-Premise
253	associated	_	_	I-Premise
254	with	_	_	I-Premise
255	significantly	_	_	I-Premise
256	more	_	_	I-Premise
257	myelosuppression	_	_	I-Premise
258	,	_	_	I-Premise
259	infection	_	_	I-Premise
260	,	_	_	I-Premise
261	diarrhea	_	_	I-Premise
262	,	_	_	I-Premise
263	stomatitis	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	nausea	_	_	I-Premise
267	and	_	_	I-Premise
268	vomiting	_	_	I-Premise
269	,	_	_	I-Premise
270	whereas	_	_	I-Premise
271	patients	_	_	I-Premise
272	treated	_	_	I-Premise
273	with	_	_	I-Premise
274	AT	_	_	I-Premise
275	developed	_	_	I-Premise
276	more	_	_	I-Premise
277	neurotoxicity	_	_	I-Premise
278	.	_	_	I-Premise

279	This	_	_	B-Claim
280	trial	_	_	I-Claim
281	failed	_	_	I-Claim
282	to	_	_	I-Claim
283	show	_	_	I-Claim
284	a	_	_	I-Claim
285	benefit	_	_	I-Claim
286	for	_	_	I-Claim
287	up-front	_	_	I-Claim
288	tandem	_	_	I-Claim
289	HDCT	_	_	I-Claim
290	compared	_	_	I-Claim
291	with	_	_	I-Claim
292	standard	_	_	I-Claim
293	combination	_	_	I-Claim
294	therapy	_	_	I-Claim
295	.	_	_	I-Claim

296	HDCT	_	_	B-Claim
297	was	_	_	I-Claim
298	associated	_	_	I-Claim
299	with	_	_	I-Claim
300	more	_	_	I-Claim
301	acute	_	_	I-Claim
302	adverse	_	_	I-Claim
303	effects	_	_	I-Claim
304	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	impact	_	_	O
4	of	_	_	O
5	dietary	_	_	O
6	counseling	_	_	O
7	or	_	_	O
8	nutritional	_	_	O
9	supplements	_	_	O
10	on	_	_	O
11	outcomes	_	_	O
12	in	_	_	O
13	cancer	_	_	O
14	patients	_	_	O
15	:	_	_	O
16	nutritional	_	_	O
17	,	_	_	O
18	morbidity	_	_	O
19	,	_	_	O
20	and	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QoL	_	_	O
26	)	_	_	O
27	during	_	_	O
28	and	_	_	O
29	3	_	_	O
30	months	_	_	O
31	after	_	_	O
32	radiotherapy	_	_	O
33	.	_	_	O

34	A	_	_	O
35	total	_	_	O
36	of	_	_	O
37	111	_	_	O
38	colorectal	_	_	O
39	cancer	_	_	O
40	outpatients	_	_	O
41	referred	_	_	O
42	for	_	_	O
43	radiotherapy	_	_	O
44	,	_	_	O
45	stratified	_	_	O
46	by	_	_	O
47	staging	_	_	O
48	,	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	:	_	_	O
53	group	_	_	O
54	1	_	_	O
55	(	_	_	O
56	G1	_	_	O
57	;	_	_	O
58	n	_	_	O
59	=	_	_	O
60	37	_	_	O
61	)	_	_	O
62	,	_	_	O
63	dietary	_	_	O
64	counseling	_	_	O
65	(	_	_	O
66	regular	_	_	O
67	foods	_	_	O
68	)	_	_	O
69	;	_	_	O
70	group	_	_	O
71	2	_	_	O
72	(	_	_	O
73	G2	_	_	O
74	;	_	_	O
75	n	_	_	O
76	=	_	_	O
77	37	_	_	O
78	)	_	_	O
79	,	_	_	O
80	protein	_	_	O
81	supplements	_	_	O
82	;	_	_	O
83	and	_	_	O
84	group	_	_	O
85	3	_	_	O
86	(	_	_	O
87	G3	_	_	O
88	;	_	_	O
89	n	_	_	O
90	=	_	_	O
91	37	_	_	O
92	)	_	_	O
93	,	_	_	O
94	ad	_	_	O
95	libitum	_	_	O
96	intake	_	_	O
97	.	_	_	O

98	Nutritional	_	_	O
99	intake	_	_	O
100	(	_	_	O
101	diet	_	_	O
102	history	_	_	O
103	)	_	_	O
104	,	_	_	O
105	status	_	_	O
106	(	_	_	O
107	Ottery	_	_	O
108	's	_	_	O
109	Subjective	_	_	O
110	Global	_	_	O
111	Assessment	_	_	O
112	)	_	_	O
113	,	_	_	O
114	and	_	_	O
115	QoL	_	_	O
116	(	_	_	O
117	European	_	_	O
118	Organisation	_	_	O
119	for	_	_	O
120	Research	_	_	O
121	and	_	_	O
122	Treatment	_	_	O
123	of	_	_	O
124	Cancer	_	_	O
125	Quality	_	_	O
126	of	_	_	O
127	Life	_	_	O
128	Questionnaire	_	_	O
129	version	_	_	O
130	3.0	_	_	O
131	)	_	_	O
132	were	_	_	O
133	evaluated	_	_	O
134	at	_	_	O
135	baseline	_	_	O
136	,	_	_	O
137	at	_	_	O
138	the	_	_	O
139	end	_	_	O
140	,	_	_	O
141	and	_	_	O
142	3	_	_	O
143	months	_	_	O
144	after	_	_	O
145	radiotherapy	_	_	O
146	.	_	_	O

147	At	_	_	B-Premise
148	radiotherapy	_	_	I-Premise
149	completion	_	_	I-Premise
150	,	_	_	I-Premise
151	energy	_	_	I-Premise
152	intake	_	_	I-Premise
153	increased	_	_	I-Premise
154	in	_	_	I-Premise
155	G1/G2	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	<	_	_	I-Premise
159	or	_	_	I-Premise
160	=	_	_	I-Premise
161	.04	_	_	I-Premise
162	)	_	_	I-Premise
163	,	_	_	I-Premise
164	G1	_	_	I-Premise
165	more	_	_	I-Premise
166	than	_	_	I-Premise
167	G2	_	_	I-Premise
168	(	_	_	I-Premise
169	P	_	_	I-Premise
170	=	_	_	I-Premise
171	.001	_	_	I-Premise
172	)	_	_	I-Premise
173	,	_	_	I-Premise
174	and	_	_	I-Premise
175	decreased	_	_	I-Premise
176	in	_	_	I-Premise
177	G3	_	_	I-Premise
178	(	_	_	I-Premise
179	P	_	_	I-Premise
180	<	_	_	I-Premise
181	.01	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	Protein	_	_	B-Premise
185	intake	_	_	I-Premise
186	increased	_	_	I-Premise
187	in	_	_	I-Premise
188	G1/G2	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	<	_	_	I-Premise
192	or	_	_	I-Premise
193	=	_	_	I-Premise
194	.007	_	_	I-Premise
195	)	_	_	I-Premise
196	,	_	_	I-Premise
197	G1	_	_	I-Premise
198	less	_	_	I-Premise
199	than	_	_	I-Premise
200	G2	_	_	I-Premise
201	(	_	_	I-Premise
202	not	_	_	I-Premise
203	significant	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	and	_	_	I-Premise
207	decreased	_	_	I-Premise
208	in	_	_	I-Premise
209	G3	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	<	_	_	I-Premise
213	.01	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	At	_	_	B-Premise
217	3	_	_	I-Premise
218	months	_	_	I-Premise
219	,	_	_	I-Premise
220	G1	_	_	I-Premise
221	maintained	_	_	I-Premise
222	nutritional	_	_	I-Premise
223	intake	_	_	I-Premise
224	and	_	_	I-Premise
225	G2/G3	_	_	I-Premise
226	returned	_	_	I-Premise
227	to	_	_	I-Premise
228	baseline	_	_	I-Premise
229	.	_	_	I-Premise

230	After	_	_	B-Premise
231	radiotherapy	_	_	I-Premise
232	and	_	_	I-Premise
233	at	_	_	I-Premise
234	3	_	_	I-Premise
235	months	_	_	I-Premise
236	,	_	_	I-Premise
237	rates	_	_	I-Premise
238	of	_	_	I-Premise
239	anorexia	_	_	I-Premise
240	,	_	_	I-Premise
241	nausea	_	_	I-Premise
242	,	_	_	I-Premise
243	vomiting	_	_	I-Premise
244	,	_	_	I-Premise
245	and	_	_	I-Premise
246	diarrhea	_	_	I-Premise
247	were	_	_	I-Premise
248	higher	_	_	I-Premise
249	in	_	_	I-Premise
250	G3	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.05	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	At	_	_	B-Premise
258	radiotherapy	_	_	I-Premise
259	completion	_	_	I-Premise
260	,	_	_	I-Premise
261	in	_	_	I-Premise
262	G1	_	_	I-Premise
263	all	_	_	I-Premise
264	QoL	_	_	I-Premise
265	function	_	_	I-Premise
266	scores	_	_	I-Premise
267	improved	_	_	I-Premise
268	proportionally	_	_	I-Premise
269	to	_	_	I-Premise
270	adequate	_	_	I-Premise
271	intake	_	_	I-Premise
272	or	_	_	I-Premise
273	nutritional	_	_	I-Premise
274	status	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	<	_	_	I-Premise
278	.05	_	_	I-Premise
279	)	_	_	I-Premise
280	;	_	_	I-Premise
281	whereas	_	_	I-Premise
282	in	_	_	I-Premise
283	G2	_	_	I-Premise
284	only	_	_	I-Premise
285	three	_	_	I-Premise
286	of	_	_	I-Premise
287	six	_	_	I-Premise
288	function	_	_	I-Premise
289	scores	_	_	I-Premise
290	improved	_	_	I-Premise
291	proportionally	_	_	I-Premise
292	to	_	_	I-Premise
293	protein	_	_	I-Premise
294	intake	_	_	I-Premise
295	(	_	_	I-Premise
296	P	_	_	I-Premise
297	=	_	_	I-Premise
298	.04	_	_	I-Premise
299	)	_	_	I-Premise
300	,	_	_	I-Premise
301	and	_	_	I-Premise
302	in	_	_	I-Premise
303	G3	_	_	I-Premise
304	all	_	_	I-Premise
305	scores	_	_	I-Premise
306	worsened	_	_	I-Premise
307	(	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	.05	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	At	_	_	B-Premise
314	3	_	_	I-Premise
315	months	_	_	I-Premise
316	,	_	_	I-Premise
317	G1	_	_	I-Premise
318	patients	_	_	I-Premise
319	maintained/improved	_	_	I-Premise
320	function	_	_	I-Premise
321	,	_	_	I-Premise
322	symptoms	_	_	I-Premise
323	,	_	_	I-Premise
324	and	_	_	I-Premise
325	single-item	_	_	I-Premise
326	scores	_	_	I-Premise
327	(	_	_	I-Premise
328	P	_	_	I-Premise
329	<	_	_	I-Premise
330	.02	_	_	I-Premise
331	)	_	_	I-Premise
332	;	_	_	I-Premise
333	in	_	_	I-Premise
334	G2	_	_	I-Premise
335	,	_	_	I-Premise
336	only	_	_	I-Premise
337	few	_	_	I-Premise
338	function	_	_	I-Premise
339	and	_	_	I-Premise
340	symptom	_	_	I-Premise
341	scales	_	_	I-Premise
342	improved	_	_	I-Premise
343	(	_	_	I-Premise
344	P	_	_	I-Premise
345	<	_	_	I-Premise
346	.05	_	_	I-Premise
347	)	_	_	I-Premise
348	;	_	_	I-Premise
349	in	_	_	I-Premise
350	G3	_	_	I-Premise
351	,	_	_	I-Premise
352	QoL	_	_	I-Premise
353	remained	_	_	I-Premise
354	as	_	_	I-Premise
355	poor	_	_	I-Premise
356	as	_	_	I-Premise
357	after	_	_	I-Premise
358	radiotherapy	_	_	I-Premise
359	.	_	_	I-Premise

360	In	_	_	B-Premise
361	G1/G2	_	_	I-Premise
362	,	_	_	I-Premise
363	respectively	_	_	I-Premise
364	,	_	_	I-Premise
365	improvement/deterioration	_	_	I-Premise
366	of	_	_	I-Premise
367	QoL	_	_	I-Premise
368	correlated	_	_	I-Premise
369	with	_	_	I-Premise
370	better	_	_	I-Premise
371	or	_	_	I-Premise
372	poorer	_	_	I-Premise
373	intake	_	_	I-Premise
374	or	_	_	I-Premise
375	nutritional	_	_	I-Premise
376	status	_	_	I-Premise
377	(	_	_	I-Premise
378	P	_	_	I-Premise
379	<	_	_	I-Premise
380	.003	_	_	I-Premise
381	)	_	_	I-Premise
382	.	_	_	I-Premise

383	During	_	_	B-Claim
384	radiotherapy	_	_	I-Claim
385	,	_	_	I-Claim
386	both	_	_	I-Claim
387	interventions	_	_	I-Claim
388	positively	_	_	I-Claim
389	influenced	_	_	I-Claim
390	outcomes	_	_	I-Claim
391	;	_	_	I-Claim
392	dietary	_	_	B-Claim
393	counseling	_	_	I-Claim
394	was	_	_	I-Claim
395	of	_	_	I-Claim
396	similar	_	_	I-Claim
397	or	_	_	I-Claim
398	higher	_	_	I-Claim
399	benefit	_	_	I-Claim
400	,	_	_	I-Claim
401	whereas	_	_	I-Claim
402	even	_	_	I-Claim
403	3	_	_	I-Claim
404	months	_	_	I-Claim
405	after	_	_	I-Claim
406	RT	_	_	I-Claim
407	,	_	_	I-Claim
408	it	_	_	I-Claim
409	was	_	_	I-Claim
410	the	_	_	I-Claim
411	only	_	_	I-Claim
412	method	_	_	I-Claim
413	to	_	_	I-Claim
414	sustain	_	_	I-Claim
415	a	_	_	I-Claim
416	significant	_	_	I-Claim
417	impact	_	_	I-Claim
418	on	_	_	I-Claim
419	patient	_	_	I-Claim
420	outcomes	_	_	I-Claim
421	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	palliation	_	_	O
4	of	_	_	O
5	chest	_	_	O
6	symptoms	_	_	O
7	from	_	_	O
8	a	_	_	O
9	10	_	_	O
10	Gy	_	_	O
11	single	_	_	O
12	fraction	_	_	O
13	(	_	_	O
14	regimen	_	_	O
15	1	_	_	O
16	)	_	_	O
17	was	_	_	O
18	equivalent	_	_	O
19	to	_	_	O
20	that	_	_	O
21	from	_	_	O
22	30	_	_	O
23	Gy	_	_	O
24	in	_	_	O
25	10	_	_	O
26	fractions	_	_	O
27	(	_	_	O
28	regimen	_	_	O
29	2	_	_	O
30	)	_	_	O
31	.	_	_	O

32	Patients	_	_	O
33	with	_	_	O
34	cytologically	_	_	O
35	proven	_	_	O
36	,	_	_	O
37	symptomatic	_	_	O
38	lung	_	_	O
39	cancer	_	_	O
40	not	_	_	O
41	amenable	_	_	O
42	to	_	_	O
43	curative	_	_	O
44	therapy	_	_	O
45	,	_	_	O
46	with	_	_	O
47	performance	_	_	O
48	status	_	_	O
49	0-3	_	_	O
50	,	_	_	O
51	were	_	_	O
52	randomised	_	_	O
53	to	_	_	O
54	receive	_	_	O
55	either	_	_	O
56	30	_	_	O
57	Gy	_	_	O
58	in	_	_	O
59	10	_	_	O
60	fractions	_	_	O
61	or	_	_	O
62	a	_	_	O
63	10	_	_	O
64	Gy	_	_	O
65	single	_	_	O
66	fraction	_	_	O
67	.	_	_	O

68	Local	_	_	O
69	symptoms	_	_	O
70	were	_	_	O
71	scored	_	_	O
72	on	_	_	O
73	a	_	_	O
74	physician-assessed	_	_	O
75	,	_	_	O
76	five-point	_	_	O
77	categorical	_	_	O
78	scale	_	_	O
79	and	_	_	O
80	summed	_	_	O
81	to	_	_	O
82	produce	_	_	O
83	a	_	_	O
84	total	_	_	O
85	symptom	_	_	O
86	score	_	_	O
87	(	_	_	O
88	TSS	_	_	O
89	)	_	_	O
90	.	_	_	O

91	This	_	_	O
92	,	_	_	O
93	performance	_	_	O
94	status	_	_	O
95	,	_	_	O
96	Hospital	_	_	O
97	Anxiety	_	_	O
98	and	_	_	O
99	Depression	_	_	O
100	(	_	_	O
101	HAD	_	_	O
102	)	_	_	O
103	score	_	_	O
104	and	_	_	O
105	Spitzer	_	_	O
106	's	_	_	O
107	quality-of-life	_	_	O
108	index	_	_	O
109	were	_	_	O
110	noted	_	_	O
111	before	_	_	O
112	treatment	_	_	O
113	,	_	_	O
114	at	_	_	O
115	1	_	_	O
116	month	_	_	O
117	after	_	_	O
118	treatment	_	_	O
119	and	_	_	O
120	every	_	_	O
121	2	_	_	O
122	months	_	_	O
123	thereafter	_	_	O
124	.	_	_	O

125	Palliation	_	_	O
126	was	_	_	O
127	defined	_	_	O
128	as	_	_	O
129	an	_	_	O
130	improvement	_	_	O
131	of	_	_	O
132	one	_	_	O
133	point	_	_	O
134	or	_	_	O
135	more	_	_	O
136	in	_	_	O
137	the	_	_	O
138	categorical	_	_	O
139	scale	_	_	O
140	.	_	_	O

141	Equivalence	_	_	O
142	was	_	_	O
143	defined	_	_	O
144	as	_	_	O
145	less	_	_	O
146	than	_	_	O
147	20	_	_	O
148	%	_	_	O
149	difference	_	_	O
150	in	_	_	O
151	the	_	_	O
152	number	_	_	O
153	achieving	_	_	O
154	an	_	_	O
155	improvement	_	_	O
156	in	_	_	O
157	the	_	_	O
158	TSS	_	_	O
159	.	_	_	O

160	We	_	_	O
161	randomised	_	_	O
162	149	_	_	O
163	patients	_	_	O
164	and	_	_	O
165	analysed	_	_	O
166	74	_	_	O
167	in	_	_	O
168	each	_	_	O
169	arm	_	_	O
170	.	_	_	O

171	According	_	_	O
172	to	_	_	O
173	the	_	_	O
174	design	_	_	O
175	criteria	_	_	O
176	,	_	_	O
177	palliation	_	_	O
178	was	_	_	O
179	equivalent	_	_	O
180	between	_	_	O
181	the	_	_	O
182	two	_	_	O
183	arms	_	_	O
184	.	_	_	O

185	TSS	_	_	B-Premise
186	improved	_	_	I-Premise
187	in	_	_	I-Premise
188	49	_	_	I-Premise
189	patients	_	_	I-Premise
190	(	_	_	I-Premise
191	77	_	_	I-Premise
192	%	_	_	I-Premise
193	)	_	_	I-Premise
194	on	_	_	I-Premise
195	regimen	_	_	I-Premise
196	1	_	_	I-Premise
197	,	_	_	I-Premise
198	and	_	_	I-Premise
199	in	_	_	I-Premise
200	57	_	_	I-Premise
201	(	_	_	I-Premise
202	92	_	_	I-Premise
203	%	_	_	I-Premise
204	)	_	_	I-Premise
205	patients	_	_	I-Premise
206	on	_	_	I-Premise
207	regimen	_	_	I-Premise
208	2	_	_	I-Premise
209	,	_	_	I-Premise
210	a	_	_	I-Premise
211	difference	_	_	I-Premise
212	of	_	_	I-Premise
213	15	_	_	I-Premise
214	%	_	_	I-Premise
215	(	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	confidence	_	_	I-Premise
219	interval	_	_	I-Premise
220	[	_	_	I-Premise
221	CI	_	_	I-Premise
222	]	_	_	I-Premise
223	3-28	_	_	I-Premise
224	)	_	_	I-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	proportion	_	_	I-Premise
228	improving	_	_	I-Premise
229	between	_	_	I-Premise
230	the	_	_	I-Premise
231	two	_	_	I-Premise
232	regimens	_	_	I-Premise
233	.	_	_	I-Premise

234	A	_	_	B-Premise
235	complete	_	_	I-Premise
236	resolution	_	_	I-Premise
237	of	_	_	I-Premise
238	all	_	_	I-Premise
239	symptoms	_	_	I-Premise
240	was	_	_	I-Premise
241	achieved	_	_	I-Premise
242	in	_	_	I-Premise
243	three	_	_	I-Premise
244	(	_	_	I-Premise
245	5	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	on	_	_	I-Premise
249	regimen	_	_	I-Premise
250	1	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	in	_	_	I-Premise
254	14	_	_	I-Premise
255	(	_	_	I-Premise
256	23	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	patients	_	_	I-Premise
260	on	_	_	I-Premise
261	regimen	_	_	I-Premise
262	2	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	<	_	_	I-Premise
266	0.001	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	a	_	_	I-Premise
270	difference	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	proportion	_	_	I-Premise
274	between	_	_	I-Premise
275	the	_	_	I-Premise
276	two	_	_	I-Premise
277	regimens	_	_	I-Premise
278	of	_	_	I-Premise
279	21	_	_	I-Premise
280	%	_	_	I-Premise
281	(	_	_	I-Premise
282	95	_	_	I-Premise
283	%	_	_	I-Premise
284	CI	_	_	I-Premise
285	10-33	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	A	_	_	B-Premise
289	significantly	_	_	I-Premise
290	higher	_	_	I-Premise
291	proportion	_	_	I-Premise
292	of	_	_	I-Premise
293	patients	_	_	I-Premise
294	experienced	_	_	I-Premise
295	palliation	_	_	I-Premise
296	and	_	_	I-Premise
297	complete	_	_	I-Premise
298	resolution	_	_	I-Premise
299	of	_	_	I-Premise
300	chest	_	_	I-Premise
301	pain	_	_	I-Premise
302	and	_	_	I-Premise
303	dyspnoea	_	_	I-Premise
304	with	_	_	I-Premise
305	regimen	_	_	I-Premise
306	2	_	_	I-Premise
307	.	_	_	I-Premise

308	No	_	_	B-Premise
309	differences	_	_	I-Premise
310	were	_	_	I-Premise
311	observed	_	_	I-Premise
312	in	_	_	I-Premise
313	toxicity	_	_	I-Premise
314	.	_	_	I-Premise

315	The	_	_	B-Premise
316	median	_	_	I-Premise
317	survival	_	_	I-Premise
318	was	_	_	I-Premise
319	22.7	_	_	I-Premise
320	weeks	_	_	I-Premise
321	for	_	_	I-Premise
322	regimen	_	_	I-Premise
323	1	_	_	I-Premise
324	and	_	_	I-Premise
325	28.3	_	_	I-Premise
326	weeks	_	_	I-Premise
327	for	_	_	I-Premise
328	regimen	_	_	I-Premise
329	2	_	_	I-Premise
330	(	_	_	I-Premise
331	P	_	_	I-Premise
332	=	_	_	I-Premise
333	0.197	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	Although	_	_	B-Claim
337	this	_	_	I-Claim
338	trial	_	_	I-Claim
339	met	_	_	I-Claim
340	the	_	_	I-Claim
341	pre-determined	_	_	I-Claim
342	criteria	_	_	I-Claim
343	for	_	_	I-Claim
344	equivalence	_	_	I-Claim
345	between	_	_	I-Claim
346	the	_	_	I-Claim
347	two	_	_	I-Claim
348	palliative	_	_	I-Claim
349	regimens	_	_	I-Claim
350	,	_	_	I-Claim
351	significantly	_	_	B-Claim
352	more	_	_	I-Claim
353	patients	_	_	I-Claim
354	achieved	_	_	I-Claim
355	complete	_	_	I-Claim
356	resolution	_	_	I-Claim
357	of	_	_	I-Claim
358	symptoms	_	_	I-Claim
359	and	_	_	I-Claim
360	palliation	_	_	I-Claim
361	of	_	_	I-Claim
362	chest	_	_	I-Claim
363	pain	_	_	I-Claim
364	and	_	_	I-Claim
365	dyspnoea	_	_	I-Claim
366	with	_	_	I-Claim
367	the	_	_	I-Claim
368	fractionated	_	_	I-Claim
369	regimen	_	_	I-Claim
370	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	latanoprost	_	_	O
8	or	_	_	O
9	brimonidine	_	_	O
10	in	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	elevated	_	_	O
14	intraocular	_	_	O
15	pressure	_	_	O
16	(	_	_	O
17	IOP	_	_	O
18	)	_	_	O
19	.	_	_	O

20	This	_	_	O
21	prospective	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	,	_	_	O
25	masked-evaluator	_	_	O
26	,	_	_	O
27	parallel-group	_	_	O
28	,	_	_	O
29	multicenter	_	_	O
30	study	_	_	O
31	in	_	_	O
32	the	_	_	O
33	United	_	_	O
34	States	_	_	O
35	included	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	primary	_	_	O
39	open	_	_	O
40	angle	_	_	O
41	glaucoma	_	_	O
42	or	_	_	O
43	ocular	_	_	O
44	hypertension	_	_	O
45	.	_	_	O

46	Patients	_	_	O
47	received	_	_	O
48	latanoprost	_	_	O
49	0.005	_	_	O
50	%	_	_	O
51	once	_	_	O
52	daily	_	_	O
53	(	_	_	O
54	8:00	_	_	O
55	AM	_	_	O
56	;	_	_	O
57	n	_	_	O
58	=	_	_	O
59	152	_	_	O
60	)	_	_	O
61	or	_	_	O
62	brimonidine	_	_	O
63	tartrate	_	_	O
64	0.2	_	_	O
65	%	_	_	O
66	twice	_	_	O
67	daily	_	_	O
68	(	_	_	O
69	8:00	_	_	O
70	AM	_	_	O
71	and	_	_	O
72	8:00	_	_	O
73	PM	_	_	O
74	;	_	_	O
75	n	_	_	O
76	=	_	_	O
77	151	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Patients	_	_	O
81	underwent	_	_	O
82	evaluation	_	_	O
83	at	_	_	O
84	screening	_	_	O
85	,	_	_	O
86	baseline	_	_	O
87	(	_	_	O
88	randomization	_	_	O
89	)	_	_	O
90	,	_	_	O
91	and	_	_	O
92	after	_	_	O
93	0.5	_	_	O
94	,	_	_	O
95	3	_	_	O
96	,	_	_	O
97	and	_	_	O
98	6	_	_	O
99	months	_	_	O
100	of	_	_	O
101	treatment	_	_	O
102	.	_	_	O

103	IOP	_	_	O
104	was	_	_	O
105	measured	_	_	O
106	at	_	_	O
107	8:00	_	_	O
108	AM	_	_	O
109	,	_	_	O
110	10:00	_	_	O
111	AM	_	_	O
112	,	_	_	O
113	noon	_	_	O
114	,	_	_	O
115	and	_	_	O
116	4:00	_	_	O
117	PM	_	_	O
118	at	_	_	O
119	baseline	_	_	O
120	and	_	_	O
121	the	_	_	O
122	months	_	_	O
123	3	_	_	O
124	and	_	_	O
125	6	_	_	O
126	visits	_	_	O
127	,	_	_	O
128	and	_	_	O
129	at	_	_	O
130	8:00	_	_	O
131	AM	_	_	O
132	only	_	_	O
133	at	_	_	O
134	week	_	_	O
135	2	_	_	O
136	.	_	_	O

137	The	_	_	O
138	main	_	_	O
139	outcome	_	_	O
140	measure	_	_	O
141	was	_	_	O
142	the	_	_	O
143	difference	_	_	O
144	in	_	_	O
145	diurnal	_	_	O
146	IOP	_	_	O
147	change	_	_	O
148	from	_	_	O
149	baseline	_	_	O
150	to	_	_	O
151	month	_	_	O
152	6	_	_	O
153	between	_	_	O
154	treatment	_	_	O
155	groups	_	_	O
156	.	_	_	O

157	Adverse	_	_	O
158	events	_	_	O
159	were	_	_	O
160	recorded	_	_	O
161	at	_	_	O
162	each	_	_	O
163	visit	_	_	O
164	.	_	_	O

165	Baseline	_	_	O
166	mean	_	_	O
167	diurnal	_	_	O
168	IOP	_	_	O
169	levels	_	_	O
170	were	_	_	O
171	similar	_	_	O
172	between	_	_	O
173	groups	_	_	O
174	.	_	_	O

175	At	_	_	B-Premise
176	month	_	_	I-Premise
177	6	_	_	I-Premise
178	,	_	_	I-Premise
179	the	_	_	I-Premise
180	adjusted	_	_	I-Premise
181	mean	_	_	I-Premise
182	(	_	_	I-Premise
183	+/-	_	_	I-Premise
184	SEM	_	_	I-Premise
185	)	_	_	I-Premise
186	diurnal	_	_	I-Premise
187	IOP	_	_	I-Premise
188	reduction	_	_	I-Premise
189	was	_	_	I-Premise
190	5.7	_	_	I-Premise
191	+/-	_	_	I-Premise
192	0.3	_	_	I-Premise
193	mm	_	_	I-Premise
194	Hg	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	latanoprost	_	_	I-Premise
198	group	_	_	I-Premise
199	and	_	_	I-Premise
200	3.1	_	_	I-Premise
201	+/-	_	_	I-Premise
202	0.3	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	in	_	_	I-Premise
206	patients	_	_	I-Premise
207	receiving	_	_	I-Premise
208	brimonidine	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	0.001	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	The	_	_	B-Premise
216	mean	_	_	I-Premise
217	difference	_	_	I-Premise
218	in	_	_	I-Premise
219	diurnal	_	_	I-Premise
220	IOP	_	_	I-Premise
221	reduction	_	_	I-Premise
222	was	_	_	I-Premise
223	2.5	_	_	I-Premise
224	+/-	_	_	I-Premise
225	0.3	_	_	I-Premise
226	mm	_	_	I-Premise
227	Hg	_	_	I-Premise
228	(	_	_	I-Premise
229	95	_	_	I-Premise
230	%	_	_	I-Premise
231	CI	_	_	I-Premise
232	:	_	_	I-Premise
233	1.9	_	_	I-Premise
234	,	_	_	I-Premise
235	3.2	_	_	I-Premise
236	;	_	_	I-Premise
237	P	_	_	I-Premise
238	<	_	_	I-Premise
239	0.001	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Five	_	_	B-Premise
243	times	_	_	I-Premise
244	more	_	_	I-Premise
245	patients	_	_	I-Premise
246	receiving	_	_	I-Premise
247	brimonidine	_	_	I-Premise
248	than	_	_	I-Premise
249	latanoprost	_	_	I-Premise
250	were	_	_	I-Premise
251	withdrawn	_	_	I-Premise
252	from	_	_	I-Premise
253	the	_	_	I-Premise
254	study	_	_	I-Premise
255	due	_	_	I-Premise
256	to	_	_	I-Premise
257	adverse	_	_	I-Premise
258	events	_	_	I-Premise
259	.	_	_	I-Premise

260	Latanoprost	_	_	B-Claim
261	instilled	_	_	I-Claim
262	once	_	_	I-Claim
263	daily	_	_	I-Claim
264	is	_	_	I-Claim
265	more	_	_	I-Claim
266	effective	_	_	I-Claim
267	and	_	_	I-Claim
268	better	_	_	I-Claim
269	tolerated	_	_	I-Claim
270	than	_	_	I-Claim
271	brimonidine	_	_	I-Claim
272	administered	_	_	I-Claim
273	twice	_	_	I-Claim
274	daily	_	_	I-Claim
275	for	_	_	I-Claim
276	the	_	_	I-Claim
277	treatment	_	_	I-Claim
278	of	_	_	I-Claim
279	patients	_	_	I-Claim
280	with	_	_	I-Claim
281	glaucoma	_	_	I-Claim
282	or	_	_	I-Claim
283	ocular	_	_	I-Claim
284	hypertension	_	_	I-Claim
285	.	_	_	I-Claim

286	During	_	_	B-Claim
287	therapy	_	_	I-Claim
288	,	_	_	I-Claim
289	the	_	_	I-Claim
290	range	_	_	I-Claim
291	of	_	_	I-Claim
292	daily	_	_	I-Claim
293	fluctuation	_	_	I-Claim
294	of	_	_	I-Claim
295	IOP	_	_	I-Claim
296	is	_	_	I-Claim
297	less	_	_	I-Claim
298	for	_	_	I-Claim
299	latanoprost	_	_	I-Claim
300	compared	_	_	I-Claim
301	with	_	_	I-Claim
302	brimonidine	_	_	I-Claim
303	.	_	_	I-Claim


0	Impaired	_	_	B-Claim
1	cognition	_	_	I-Claim
2	,	_	_	I-Claim
3	fatigue	_	_	I-Claim
4	,	_	_	I-Claim
5	and	_	_	I-Claim
6	diminished	_	_	I-Claim
7	quality	_	_	I-Claim
8	of	_	_	I-Claim
9	life	_	_	I-Claim
10	(	_	_	I-Claim
11	QOL	_	_	I-Claim
12	)	_	_	I-Claim
13	are	_	_	I-Claim
14	commonly	_	_	I-Claim
15	associated	_	_	I-Claim
16	with	_	_	I-Claim
17	breast	_	_	I-Claim
18	cancer	_	_	I-Claim
19	chemotherapy	_	_	I-Claim
20	.	_	_	I-Claim

21	This	_	_	O
22	randomized	_	_	O
23	,	_	_	O
24	double-blind	_	_	O
25	,	_	_	O
26	placebo-controlled	_	_	O
27	pilot	_	_	O
28	trial	_	_	O
29	assessed	_	_	O
30	the	_	_	O
31	feasibility	_	_	O
32	of	_	_	O
33	quantifying	_	_	O
34	the	_	_	O
35	effects	_	_	O
36	of	_	_	O
37	epoetin	_	_	O
38	alfa	_	_	O
39	on	_	_	O
40	cognitive	_	_	O
41	function	_	_	O
42	and	_	_	O
43	mood	_	_	O
44	,	_	_	O
45	and	_	_	O
46	evaluated	_	_	O
47	its	_	_	O
48	effects	_	_	O
49	on	_	_	O
50	fatigue	_	_	O
51	and	_	_	O
52	QOL	_	_	O
53	in	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	breast	_	_	O
57	cancer	_	_	O
58	treated	_	_	O
59	with	_	_	O
60	anthracycline-based	_	_	O
61	adjuvant	_	_	O
62	or	_	_	O
63	neoadjuvant	_	_	O
64	chemotherapy	_	_	O
65	.	_	_	O

66	Patients	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	to	_	_	O
70	receive	_	_	O
71	epoetin	_	_	O
72	alfa	_	_	O
73	40,000	_	_	O
74	U	_	_	O
75	subcutaneously	_	_	O
76	once	_	_	O
77	weekly	_	_	O
78	or	_	_	O
79	placebo	_	_	O
80	at	_	_	O
81	the	_	_	O
82	beginning	_	_	O
83	of	_	_	O
84	4	_	_	O
85	cycles	_	_	O
86	of	_	_	O
87	chemotherapy	_	_	O
88	administered	_	_	O
89	over	_	_	O
90	12	_	_	O
91	weeks	_	_	O
92	.	_	_	O

93	Cognitive	_	_	O
94	function	_	_	O
95	was	_	_	O
96	assessed	_	_	O
97	by	_	_	O
98	Executive	_	_	O
99	Interview	_	_	O
100	(	_	_	O
101	EXIT25	_	_	O
102	)	_	_	O
103	and	_	_	O
104	Clock	_	_	O
105	Drawing	_	_	O
106	Tasks	_	_	O
107	;	_	_	O
108	mood	_	_	O
109	by	_	_	O
110	Profile	_	_	O
111	of	_	_	O
112	Mood	_	_	O
113	States	_	_	O
114	;	_	_	O
115	anemia-related	_	_	O
116	symptoms	_	_	O
117	,	_	_	O
118	including	_	_	O
119	fatigue	_	_	O
120	,	_	_	O
121	by	_	_	O
122	the	_	_	O
123	Functional	_	_	O
124	Assessment	_	_	O
125	of	_	_	O
126	Cancer	_	_	O
127	Therapy-Anemia	_	_	O
128	(	_	_	O
129	FACT-An	_	_	O
130	)	_	_	O
131	subscale	_	_	O
132	;	_	_	O
133	and	_	_	O
134	QOL	_	_	O
135	by	_	_	O
136	Linear	_	_	O
137	Analog	_	_	O
138	Scale	_	_	O
139	Assessment	_	_	O
140	.	_	_	O

141	Ninety-four	_	_	O
142	patients	_	_	O
143	were	_	_	O
144	evaluable	_	_	O
145	for	_	_	O
146	efficacy	_	_	O
147	and	_	_	O
148	safety	_	_	O
149	.	_	_	O

150	Mean	_	_	B-Premise
151	change	_	_	I-Premise
152	in	_	_	I-Premise
153	EXIT25	_	_	I-Premise
154	scores	_	_	I-Premise
155	from	_	_	I-Premise
156	baseline	_	_	I-Premise
157	to	_	_	I-Premise
158	cycle	_	_	I-Premise
159	4	_	_	I-Premise
160	in	_	_	I-Premise
161	the	_	_	I-Premise
162	epoetin	_	_	I-Premise
163	alfa	_	_	I-Premise
164	group	_	_	I-Premise
165	was	_	_	I-Premise
166	1.3	_	_	I-Premise
167	+/-	_	_	I-Premise
168	3.3	_	_	I-Premise
169	;	_	_	I-Premise
170	the	_	_	B-Premise
171	mean	_	_	I-Premise
172	change	_	_	I-Premise
173	was	_	_	I-Premise
174	0.3	_	_	I-Premise
175	+/-	_	_	I-Premise
176	2.4	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	placebo	_	_	I-Premise
180	group	_	_	I-Premise
181	(	_	_	I-Premise
182	a	_	_	I-Premise
183	negative	_	_	I-Premise
184	change	_	_	I-Premise
185	indicates	_	_	I-Premise
186	improved	_	_	I-Premise
187	executive	_	_	I-Premise
188	function	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	There	_	_	B-Premise
192	was	_	_	I-Premise
193	no	_	_	I-Premise
194	difference	_	_	I-Premise
195	between	_	_	I-Premise
196	groups	_	_	I-Premise
197	in	_	_	I-Premise
198	mean	_	_	I-Premise
199	change	_	_	I-Premise
200	in	_	_	I-Premise
201	EXIT25	_	_	I-Premise
202	score	_	_	I-Premise
203	from	_	_	I-Premise
204	baseline	_	_	I-Premise
205	to	_	_	I-Premise
206	6-month	_	_	I-Premise
207	follow-up	_	_	I-Premise
208	assessment	_	_	I-Premise
209	.	_	_	I-Premise

210	Mean	_	_	B-Premise
211	hemoglobin	_	_	I-Premise
212	levels	_	_	I-Premise
213	were	_	_	I-Premise
214	higher	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	epoetin	_	_	I-Premise
218	alfa	_	_	I-Premise
219	group	_	_	I-Premise
220	compared	_	_	I-Premise
221	with	_	_	I-Premise
222	the	_	_	I-Premise
223	placebo	_	_	I-Premise
224	group	_	_	I-Premise
225	after	_	_	I-Premise
226	4	_	_	I-Premise
227	cycles	_	_	I-Premise
228	of	_	_	I-Premise
229	chemotherapy	_	_	I-Premise
230	.	_	_	I-Premise

231	Epoetin	_	_	B-Premise
232	alfa	_	_	I-Premise
233	recipients	_	_	I-Premise
234	had	_	_	I-Premise
235	less	_	_	I-Premise
236	of	_	_	I-Premise
237	a	_	_	I-Premise
238	decrease	_	_	I-Premise
239	in	_	_	I-Premise
240	FACT-An	_	_	I-Premise
241	subscale	_	_	I-Premise
242	scores	_	_	I-Premise
243	from	_	_	I-Premise
244	baseline	_	_	I-Premise
245	to	_	_	I-Premise
246	cycle	_	_	I-Premise
247	4	_	_	I-Premise
248	and	_	_	I-Premise
249	improvement	_	_	I-Premise
250	in	_	_	I-Premise
251	FACT-An	_	_	I-Premise
252	subscale	_	_	I-Premise
253	scores	_	_	I-Premise
254	at	_	_	I-Premise
255	6-month	_	_	I-Premise
256	follow-up	_	_	I-Premise
257	assessment	_	_	I-Premise
258	compared	_	_	I-Premise
259	with	_	_	I-Premise
260	placebo	_	_	I-Premise
261	.	_	_	I-Premise

262	Epoetin	_	_	B-Claim
263	alfa	_	_	I-Claim
264	therapy	_	_	I-Claim
265	was	_	_	I-Claim
266	well	_	_	I-Claim
267	tolerated	_	_	I-Claim
268	.	_	_	I-Claim

269	These	_	_	B-Claim
270	data	_	_	I-Claim
271	suggest	_	_	I-Claim
272	that	_	_	I-Claim
273	epoetin	_	_	I-Claim
274	alfa	_	_	I-Claim
275	may	_	_	I-Claim
276	have	_	_	I-Claim
277	attenuated	_	_	I-Claim
278	the	_	_	I-Claim
279	cognitive	_	_	I-Claim
280	impairment	_	_	I-Claim
281	and	_	_	I-Claim
282	fatigue	_	_	I-Claim
283	that	_	_	I-Claim
284	occurred	_	_	I-Claim
285	during	_	_	I-Claim
286	adjuvant	_	_	I-Claim
287	breast	_	_	I-Claim
288	cancer	_	_	I-Claim
289	chemotherapy	_	_	I-Claim
290	.	_	_	I-Claim


0	To	_	_	O
1	pilot	_	_	O
2	an	_	_	O
3	investigation	_	_	O
4	of	_	_	O
5	individualized	_	_	O
6	homeopathy	_	_	O
7	for	_	_	O
8	symptoms	_	_	O
9	of	_	_	O
10	estrogen	_	_	O
11	withdrawal	_	_	O
12	in	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	survivors	_	_	O
16	.	_	_	O

17	Randomized	_	_	O
18	,	_	_	O
19	double-blinded	_	_	O
20	,	_	_	O
21	placebo-controlled	_	_	O
22	trial	_	_	O
23	.	_	_	O

24	Outpatient	_	_	O
25	department	_	_	O
26	of	_	_	O
27	a	_	_	O
28	National	_	_	O
29	Health	_	_	O
30	Service	_	_	O
31	(	_	_	O
32	NHS	_	_	O
33	)	_	_	O
34	homeopathic	_	_	O
35	hospital	_	_	O
36	.	_	_	O

37	Fifty-seven	_	_	O
38	(	_	_	O
39	57	_	_	O
40	)	_	_	O
41	women	_	_	O
42	met	_	_	O
43	inclusion	_	_	O
44	criteria	_	_	O
45	and	_	_	O
46	53	_	_	O
47	were	_	_	O
48	randomized	_	_	O
49	to	_	_	O
50	the	_	_	O
51	study	_	_	O
52	.	_	_	O

53	After	_	_	O
54	2	_	_	O
55	weeks	_	_	O
56	of	_	_	O
57	baseline	_	_	O
58	assessment	_	_	O
59	,	_	_	O
60	all	_	_	O
61	participants	_	_	O
62	received	_	_	O
63	a	_	_	O
64	consultation	_	_	O
65	plus	_	_	O
66	either	_	_	O
67	oral	_	_	O
68	homeopathic	_	_	O
69	medicine	_	_	O
70	or	_	_	O
71	placebo	_	_	O
72	,	_	_	O
73	assessed	_	_	O
74	every	_	_	O
75	4	_	_	O
76	weeks	_	_	O
77	for	_	_	O
78	16	_	_	O
79	weeks	_	_	O
80	.	_	_	O

81	The	_	_	O
82	primary	_	_	O
83	outcome	_	_	O
84	measures	_	_	O
85	were	_	_	O
86	the	_	_	O
87	activity	_	_	O
88	score	_	_	O
89	and	_	_	O
90	profile	_	_	O
91	score	_	_	O
92	of	_	_	O
93	the	_	_	O
94	Measure	_	_	O
95	Yourself	_	_	O
96	Medical	_	_	O
97	Outcome	_	_	O
98	Profile	_	_	O
99	(	_	_	O
100	MYMOP	_	_	O
101	)	_	_	O
102	.	_	_	O

103	Eighty-five	_	_	O
104	percent	_	_	O
105	(	_	_	O
106	85	_	_	O
107	%	_	_	O
108	)	_	_	O
109	(	_	_	O
110	45/53	_	_	O
111	)	_	_	O
112	of	_	_	O
113	women	_	_	O
114	completed	_	_	O
115	the	_	_	O
116	study	_	_	O
117	.	_	_	O

118	There	_	_	B-Premise
119	was	_	_	I-Premise
120	no	_	_	I-Premise
121	evidence	_	_	I-Premise
122	of	_	_	I-Premise
123	a	_	_	I-Premise
124	difference	_	_	I-Premise
125	seen	_	_	I-Premise
126	between	_	_	I-Premise
127	groups	_	_	I-Premise
128	for	_	_	I-Premise
129	either	_	_	I-Premise
130	activity	_	_	I-Premise
131	(	_	_	I-Premise
132	adjusted	_	_	I-Premise
133	difference	_	_	I-Premise
134	=-0.4	_	_	I-Premise
135	,	_	_	I-Premise
136	95	_	_	I-Premise
137	%	_	_	I-Premise
138	confidence	_	_	I-Premise
139	interval	_	_	I-Premise
140	CI	_	_	I-Premise
141	-1.0	_	_	I-Premise
142	to	_	_	I-Premise
143	0.2	_	_	I-Premise
144	,	_	_	I-Premise
145	p	_	_	I-Premise
146	=	_	_	I-Premise
147	0.17	_	_	I-Premise
148	)	_	_	I-Premise
149	or	_	_	I-Premise
150	profile	_	_	I-Premise
151	scores	_	_	I-Premise
152	(	_	_	I-Premise
153	adjusted	_	_	I-Premise
154	difference	_	_	I-Premise
155	=	_	_	I-Premise
156	-0.4	_	_	I-Premise
157	,	_	_	I-Premise
158	95	_	_	I-Premise
159	%	_	_	I-Premise
160	CI	_	_	I-Premise
161	-0.9	_	_	I-Premise
162	to	_	_	I-Premise
163	0.1	_	_	I-Premise
164	,	_	_	I-Premise
165	p	_	_	I-Premise
166	=	_	_	I-Premise
167	0.13	_	_	I-Premise
168	)	_	_	I-Premise
169	using	_	_	I-Premise
170	this	_	_	I-Premise
171	trial	_	_	I-Premise
172	design	_	_	I-Premise
173	,	_	_	I-Premise
174	although	_	_	B-Claim
175	post	_	_	I-Claim
176	hoc	_	_	I-Claim
177	power	_	_	I-Claim
178	calculations	_	_	I-Claim
179	suggests	_	_	I-Claim
180	that	_	_	I-Claim
181	65-175	_	_	I-Claim
182	would	_	_	I-Claim
183	be	_	_	I-Claim
184	needed	_	_	I-Claim
185	per	_	_	I-Claim
186	group	_	_	I-Claim
187	to	_	_	I-Claim
188	detect	_	_	I-Claim
189	differences	_	_	I-Claim
190	of	_	_	I-Claim
191	this	_	_	I-Claim
192	magnitude	_	_	I-Claim
193	with	_	_	I-Claim
194	sufficient	_	_	I-Claim
195	precision	_	_	I-Claim
196	.	_	_	I-Claim

197	Clinically	_	_	B-Premise
198	relevant	_	_	I-Premise
199	improvements	_	_	I-Premise
200	in	_	_	I-Premise
201	symptoms	_	_	I-Premise
202	and	_	_	I-Premise
203	mood	_	_	I-Premise
204	disturbance	_	_	I-Premise
205	were	_	_	I-Premise
206	seen	_	_	I-Premise
207	for	_	_	I-Premise
208	both	_	_	I-Premise
209	groups	_	_	I-Premise
210	over	_	_	I-Premise
211	the	_	_	I-Premise
212	study	_	_	I-Premise
213	period	_	_	I-Premise
214	.	_	_	I-Premise

215	Improvements	_	_	B-Claim
216	were	_	_	I-Claim
217	seen	_	_	I-Claim
218	for	_	_	I-Claim
219	symptom	_	_	I-Claim
220	scores	_	_	I-Claim
221	over	_	_	I-Claim
222	the	_	_	I-Claim
223	study	_	_	I-Claim
224	period	_	_	I-Claim
225	.	_	_	I-Claim

226	However	_	_	B-Claim
227	,	_	_	I-Claim
228	presuming	_	_	I-Claim
229	these	_	_	I-Claim
230	improvements	_	_	I-Claim
231	were	_	_	I-Claim
232	caused	_	_	I-Claim
233	by	_	_	I-Claim
234	the	_	_	I-Claim
235	individualized	_	_	I-Claim
236	homeopathic	_	_	I-Claim
237	approach	_	_	I-Claim
238	,	_	_	I-Claim
239	the	_	_	I-Claim
240	study	_	_	I-Claim
241	failed	_	_	I-Claim
242	to	_	_	I-Claim
243	show	_	_	I-Claim
244	clearly	_	_	I-Claim
245	that	_	_	I-Claim
246	the	_	_	I-Claim
247	specific	_	_	I-Claim
248	effect	_	_	I-Claim
249	of	_	_	I-Claim
250	the	_	_	I-Claim
251	remedy	_	_	I-Claim
252	added	_	_	I-Claim
253	further	_	_	I-Claim
254	to	_	_	I-Claim
255	the	_	_	I-Claim
256	nonspecific	_	_	I-Claim
257	effects	_	_	I-Claim
258	of	_	_	I-Claim
259	the	_	_	I-Claim
260	consultation	_	_	I-Claim
261	.	_	_	I-Claim

262	Future	_	_	B-Claim
263	trial	_	_	I-Claim
264	design	_	_	I-Claim
265	must	_	_	I-Claim
266	ensure	_	_	I-Claim
267	adequate	_	_	I-Claim
268	power	_	_	I-Claim
269	to	_	_	I-Claim
270	account	_	_	I-Claim
271	for	_	_	I-Claim
272	the	_	_	I-Claim
273	nonspecific	_	_	I-Claim
274	impact	_	_	I-Claim
275	of	_	_	I-Claim
276	such	_	_	I-Claim
277	complex	_	_	I-Claim
278	individualized	_	_	I-Claim
279	interventions	_	_	I-Claim
280	while	_	_	I-Claim
281	pragmatic	_	_	I-Claim
282	designs	_	_	I-Claim
283	may	_	_	I-Claim
284	more	_	_	I-Claim
285	readily	_	_	I-Claim
286	answer	_	_	I-Claim
287	questions	_	_	I-Claim
288	of	_	_	I-Claim
289	clinical	_	_	I-Claim
290	and	_	_	I-Claim
291	cost	_	_	I-Claim
292	effectiveness	_	_	I-Claim
293	.	_	_	O


0	To	_	_	O
1	carry	_	_	O
2	out	_	_	O
3	a	_	_	O
4	preliminary	_	_	O
5	trial	_	_	O
6	evaluating	_	_	O
7	the	_	_	O
8	effectiveness	_	_	O
9	of	_	_	O
10	two	_	_	O
11	types	_	_	O
12	of	_	_	O
13	homeopathy	_	_	O
14	for	_	_	O
15	the	_	_	O
16	treatment	_	_	O
17	of	_	_	O
18	menopausal	_	_	O
19	symptoms	_	_	O
20	in	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	survivors	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	,	_	_	O
27	double-blinded	_	_	O
28	,	_	_	O
29	placebo-controlled	_	_	O
30	.	_	_	O

31	Private	_	_	O
32	medical	_	_	O
33	clinic	_	_	O
34	,	_	_	O
35	Seattle	_	_	O
36	,	_	_	O
37	WA	_	_	O
38	.	_	_	O

39	Women	_	_	O
40	with	_	_	O
41	a	_	_	O
42	history	_	_	O
43	of	_	_	O
44	breast	_	_	O
45	cancer	_	_	O
46	who	_	_	O
47	had	_	_	O
48	completed	_	_	O
49	all	_	_	O
50	surgery	_	_	O
51	,	_	_	O
52	chemotherapy	_	_	O
53	,	_	_	O
54	and	_	_	O
55	radiation	_	_	O
56	treatment	_	_	O
57	and	_	_	O
58	who	_	_	O
59	had	_	_	O
60	an	_	_	O
61	average	_	_	O
62	of	_	_	O
63	at	_	_	O
64	least	_	_	O
65	three	_	_	O
66	hot	_	_	O
67	flashes	_	_	O
68	per	_	_	O
69	day	_	_	O
70	for	_	_	O
71	the	_	_	O
72	previous	_	_	O
73	month	_	_	O
74	.	_	_	O

75	Subjects	_	_	O
76	were	_	_	O
77	randomized	_	_	O
78	to	_	_	O
79	receive	_	_	O
80	either	_	_	O
81	an	_	_	O
82	individualized	_	_	O
83	homeopathic	_	_	O
84	single	_	_	O
85	remedy	_	_	O
86	,	_	_	O
87	a	_	_	O
88	homeopathic	_	_	O
89	combination	_	_	O
90	medicine	_	_	O
91	,	_	_	O
92	or	_	_	O
93	placebo	_	_	O
94	.	_	_	O

95	Patients	_	_	O
96	were	_	_	O
97	seen	_	_	O
98	by	_	_	O
99	homeopathic	_	_	O
100	providers	_	_	O
101	every	_	_	O
102	2	_	_	O
103	months	_	_	O
104	for	_	_	O
105	1	_	_	O
106	year	_	_	O
107	.	_	_	O

108	Hot	_	_	O
109	flash	_	_	O
110	frequency	_	_	O
111	and	_	_	O
112	severity	_	_	O
113	,	_	_	O
114	Kupperman	_	_	O
115	Menopausal	_	_	O
116	Index	_	_	O
117	(	_	_	O
118	KMI	_	_	O
119	)	_	_	O
120	,	_	_	O
121	Short	_	_	O
122	Form	_	_	O
123	36	_	_	O
124	(	_	_	O
125	SF-36	_	_	O
126	)	_	_	O
127	.	_	_	O

128	There	_	_	B-Premise
129	was	_	_	I-Premise
130	no	_	_	I-Premise
131	significant	_	_	I-Premise
132	difference	_	_	I-Premise
133	found	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	primary	_	_	I-Premise
137	outcome	_	_	I-Premise
138	measure	_	_	I-Premise
139	,	_	_	I-Premise
140	the	_	_	I-Premise
141	hot	_	_	I-Premise
142	flash	_	_	I-Premise
143	severity	_	_	I-Premise
144	score	_	_	I-Premise
145	,	_	_	I-Premise
146	although	_	_	B-Premise
147	there	_	_	I-Premise
148	was	_	_	I-Premise
149	a	_	_	I-Premise
150	positive	_	_	I-Premise
151	trend	_	_	I-Premise
152	in	_	_	I-Premise
153	the	_	_	I-Premise
154	single	_	_	I-Premise
155	remedy	_	_	I-Premise
156	group	_	_	I-Premise
157	during	_	_	I-Premise
158	the	_	_	I-Premise
159	first	_	_	I-Premise
160	3	_	_	I-Premise
161	months	_	_	I-Premise
162	of	_	_	I-Premise
163	the	_	_	I-Premise
164	study	_	_	I-Premise
165	(	_	_	I-Premise
166	p	_	_	I-Premise
167	=	_	_	I-Premise
168	0.1	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	A	_	_	B-Premise
172	statistically	_	_	I-Premise
173	significant	_	_	I-Premise
174	improvement	_	_	I-Premise
175	in	_	_	I-Premise
176	general	_	_	I-Premise
177	health	_	_	I-Premise
178	score	_	_	I-Premise
179	in	_	_	I-Premise
180	both	_	_	I-Premise
181	homeopathy	_	_	I-Premise
182	groups	_	_	I-Premise
183	(	_	_	I-Premise
184	p	_	_	I-Premise
185	<	_	_	I-Premise
186	0.05	_	_	I-Premise
187	)	_	_	I-Premise
188	on	_	_	I-Premise
189	the	_	_	I-Premise
190	SF-36	_	_	I-Premise
191	after	_	_	I-Premise
192	1	_	_	I-Premise
193	year	_	_	I-Premise
194	was	_	_	I-Premise
195	found	_	_	I-Premise
196	.	_	_	I-Premise

197	Evidence	_	_	B-Premise
198	of	_	_	I-Premise
199	a	_	_	I-Premise
200	homeopathic	_	_	I-Premise
201	drug	_	_	I-Premise
202	proving	_	_	I-Premise
203	in	_	_	O
204	the	_	_	O
205	subjects	_	_	I-Premise
206	receiving	_	_	I-Premise
207	the	_	_	I-Premise
208	homeopathic	_	_	I-Premise
209	combination	_	_	I-Premise
210	medicine	_	_	I-Premise
211	who	_	_	I-Premise
212	were	_	_	I-Premise
213	not	_	_	I-Premise
214	taking	_	_	I-Premise
215	tamoxifen	_	_	I-Premise
216	also	_	_	I-Premise
217	was	_	_	I-Premise
218	found	_	_	I-Premise
219	.	_	_	I-Premise

220	Small	_	_	B-Claim
221	sample	_	_	I-Claim
222	size	_	_	I-Claim
223	precludes	_	_	I-Claim
224	definitive	_	_	I-Claim
225	answers	_	_	I-Claim
226	,	_	_	I-Claim
227	but	_	_	B-Claim
228	results	_	_	I-Claim
229	from	_	_	I-Claim
230	this	_	_	I-Claim
231	preliminary	_	_	I-Claim
232	trial	_	_	I-Claim
233	suggest	_	_	I-Claim
234	that	_	_	I-Claim
235	homeopathy	_	_	I-Claim
236	may	_	_	I-Claim
237	be	_	_	I-Claim
238	of	_	_	I-Claim
239	value	_	_	I-Claim
240	in	_	_	I-Claim
241	the	_	_	I-Claim
242	treatment	_	_	I-Claim
243	of	_	_	I-Claim
244	menopausal	_	_	I-Claim
245	symptoms	_	_	I-Claim
246	and	_	_	I-Claim
247	improving	_	_	I-Claim
248	quality	_	_	I-Claim
249	of	_	_	I-Claim
250	life	_	_	I-Claim
251	,	_	_	I-Claim
252	especially	_	_	I-Claim
253	in	_	_	I-Claim
254	those	_	_	I-Claim
255	women	_	_	I-Claim
256	not	_	_	I-Claim
257	on	_	_	I-Claim
258	tamoxifen	_	_	I-Claim
259	.	_	_	I-Claim

260	Larger	_	_	B-Claim
261	studies	_	_	I-Claim
262	should	_	_	I-Claim
263	be	_	_	I-Claim
264	carried	_	_	I-Claim
265	out	_	_	I-Claim
266	that	_	_	I-Claim
267	also	_	_	I-Claim
268	include	_	_	I-Claim
269	healthy	_	_	I-Claim
270	women	_	_	I-Claim
271	who	_	_	I-Claim
272	want	_	_	I-Claim
273	to	_	_	I-Claim
274	avoid	_	_	I-Claim
275	hormone	_	_	I-Claim
276	replacement	_	_	I-Claim
277	therapy	_	_	I-Claim
278	.	_	_	I-Claim


0	Facial	_	_	B-Claim
1	hirsutism	_	_	I-Claim
2	is	_	_	I-Claim
3	one	_	_	I-Claim
4	of	_	_	I-Claim
5	the	_	_	I-Claim
6	characteristic	_	_	I-Claim
7	features	_	_	I-Claim
8	of	_	_	I-Claim
9	polycystic	_	_	I-Claim
10	ovary	_	_	I-Claim
11	syndrome	_	_	I-Claim
12	(	_	_	I-Claim
13	PCOS	_	_	I-Claim
14	)	_	_	I-Claim
15	,	_	_	I-Claim
16	and	_	_	I-Claim
17	this	_	_	I-Claim
18	can	_	_	I-Claim
19	lead	_	_	I-Claim
20	to	_	_	I-Claim
21	high	_	_	I-Claim
22	levels	_	_	I-Claim
23	of	_	_	I-Claim
24	depression	_	_	I-Claim
25	and	_	_	I-Claim
26	anxiety	_	_	I-Claim
27	.	_	_	I-Claim

28	To	_	_	O
29	evaluate	_	_	O
30	the	_	_	O
31	impact	_	_	O
32	of	_	_	O
33	laser	_	_	O
34	treatment	_	_	O
35	on	_	_	O
36	the	_	_	O
37	severity	_	_	O
38	of	_	_	O
39	facial	_	_	O
40	hirsutism	_	_	O
41	and	_	_	O
42	on	_	_	O
43	psychological	_	_	O
44	morbidity	_	_	O
45	in	_	_	O
46	women	_	_	O
47	with	_	_	O
48	PCOS	_	_	O
49	.	_	_	O

50	A	_	_	O
51	randomized	_	_	O
52	controlled	_	_	O
53	trial	_	_	O
54	of	_	_	O
55	five	_	_	O
56	high-fluence	_	_	O
57	treatments	_	_	O
58	(	_	_	O
59	intervention	_	_	O
60	)	_	_	O
61	vs.	_	_	O
62	five	_	_	O
63	low-fluence	_	_	O
64	treatments	_	_	O
65	(	_	_	O
66	control	_	_	O
67	)	_	_	O
68	was	_	_	O
69	performed	_	_	O
70	over	_	_	O
71	6	_	_	O
72	months	_	_	O
73	in	_	_	O
74	a	_	_	O
75	National	_	_	O
76	Health	_	_	O
77	Service	_	_	O
78	teaching	_	_	O
79	hospital	_	_	O
80	.	_	_	O

81	Subjects	_	_	O
82	were	_	_	O
83	88	_	_	O
84	women	_	_	O
85	with	_	_	O
86	facial	_	_	O
87	hirsutism	_	_	O
88	due	_	_	O
89	to	_	_	O
90	PCOS	_	_	O
91	recruited	_	_	O
92	from	_	_	O
93	hospital	_	_	O
94	outpatient	_	_	O
95	clinics	_	_	O
96	and	_	_	O
97	a	_	_	O
98	patient	_	_	O
99	support	_	_	O
100	group	_	_	O
101	in	_	_	O
102	2001-2002	_	_	O
103	.	_	_	O

104	The	_	_	O
105	main	_	_	O
106	outcomes	_	_	O
107	were	_	_	O
108	self-reported	_	_	O
109	severity	_	_	O
110	of	_	_	O
111	facial	_	_	O
112	hair	_	_	O
113	(	_	_	O
114	measured	_	_	O
115	on	_	_	O
116	a	_	_	O
117	scale	_	_	O
118	of	_	_	O
119	1-10	_	_	O
120	)	_	_	O
121	,	_	_	O
122	depression	_	_	O
123	,	_	_	O
124	anxiety	_	_	O
125	(	_	_	O
126	measured	_	_	O
127	on	_	_	O
128	the	_	_	O
129	Hospital	_	_	O
130	Anxiety	_	_	O
131	and	_	_	O
132	Depression	_	_	O
133	Scale	_	_	O
134	)	_	_	O
135	and	_	_	O
136	quality	_	_	O
137	of	_	_	O
138	life	_	_	O
139	(	_	_	O
140	measured	_	_	O
141	on	_	_	O
142	the	_	_	O
143	WHOQOL-BREF	_	_	O
144	)	_	_	O
145	.	_	_	O

146	Self-reported	_	_	B-Premise
147	severity	_	_	I-Premise
148	of	_	_	I-Premise
149	facial	_	_	I-Premise
150	hair	_	_	I-Premise
151	in	_	_	I-Premise
152	the	_	_	I-Premise
153	intervention	_	_	I-Premise
154	group	_	_	I-Premise
155	(	_	_	I-Premise
156	n	_	_	I-Premise
157	=	_	_	I-Premise
158	51	_	_	I-Premise
159	)	_	_	I-Premise
160	fell	_	_	I-Premise
161	from	_	_	I-Premise
162	7.3	_	_	I-Premise
163	to	_	_	I-Premise
164	3.6	_	_	I-Premise
165	over	_	_	I-Premise
166	the	_	_	I-Premise
167	6-month	_	_	I-Premise
168	study	_	_	I-Premise
169	period	_	_	I-Premise
170	;	_	_	I-Premise
171	for	_	_	I-Premise
172	the	_	_	I-Premise
173	control	_	_	I-Premise
174	group	_	_	I-Premise
175	(	_	_	I-Premise
176	n	_	_	I-Premise
177	=	_	_	I-Premise
178	37	_	_	I-Premise
179	)	_	_	I-Premise
180	the	_	_	I-Premise
181	corresponding	_	_	I-Premise
182	scores	_	_	I-Premise
183	were	_	_	I-Premise
184	7.1	_	_	I-Premise
185	and	_	_	I-Premise
186	6.1	_	_	I-Premise
187	.	_	_	I-Premise

188	The	_	_	B-Premise
189	change	_	_	I-Premise
190	was	_	_	I-Premise
191	significantly	_	_	I-Premise
192	greater	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	intervention	_	_	I-Premise
196	group	_	_	I-Premise
197	[	_	_	I-Premise
198	ancova	_	_	I-Premise
199	F	_	_	I-Premise
200	(	_	_	I-Premise
201	(	_	_	I-Premise
202	1,83	_	_	I-Premise
203	)	_	_	I-Premise
204	)	_	_	I-Premise
205	=	_	_	I-Premise
206	24.5	_	_	I-Premise
207	,	_	_	I-Premise
208	P	_	_	I-Premise
209	<	_	_	I-Premise
210	0.05	_	_	I-Premise
211	]	_	_	I-Premise
212	.	_	_	I-Premise

213	Self-reported	_	_	B-Premise
214	time	_	_	I-Premise
215	spent	_	_	I-Premise
216	on	_	_	I-Premise
217	hair	_	_	I-Premise
218	removal	_	_	I-Premise
219	declined	_	_	I-Premise
220	from	_	_	I-Premise
221	112	_	_	I-Premise
222	to	_	_	I-Premise
223	21	_	_	I-Premise
224	min	_	_	I-Premise
225	per	_	_	I-Premise
226	week	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	intervention	_	_	I-Premise
230	group	_	_	I-Premise
231	and	_	_	I-Premise
232	from	_	_	I-Premise
233	92	_	_	I-Premise
234	to	_	_	I-Premise
235	56	_	_	I-Premise
236	min	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	control	_	_	I-Premise
240	group	_	_	I-Premise
241	[	_	_	I-Premise
242	F	_	_	I-Premise
243	(	_	_	I-Premise
244	(	_	_	I-Premise
245	1,80	_	_	I-Premise
246	)	_	_	I-Premise
247	)	_	_	I-Premise
248	=	_	_	I-Premise
249	10.2	_	_	I-Premise
250	,	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	/=	_	_	I-Premise
254	0.05	_	_	I-Premise
255	]	_	_	I-Premise
256	.	_	_	I-Premise

257	Mean	_	_	B-Premise
258	depression	_	_	I-Premise
259	scores	_	_	I-Premise
260	fell	_	_	I-Premise
261	from	_	_	I-Premise
262	6.7	_	_	I-Premise
263	to	_	_	I-Premise
264	3.6	_	_	I-Premise
265	in	_	_	I-Premise
266	the	_	_	I-Premise
267	intervention	_	_	I-Premise
268	group	_	_	I-Premise
269	,	_	_	I-Premise
270	compared	_	_	I-Premise
271	with	_	_	I-Premise
272	6.1	_	_	I-Premise
273	to	_	_	I-Premise
274	5.4	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	control	_	_	I-Premise
278	group	_	_	I-Premise
279	[	_	_	I-Premise
280	F	_	_	I-Premise
281	(	_	_	I-Premise
282	(	_	_	I-Premise
283	1,83	_	_	I-Premise
284	)	_	_	I-Premise
285	)	_	_	I-Premise
286	=	_	_	I-Premise
287	14.7	_	_	I-Premise
288	,	_	_	I-Premise
289	P	_	_	I-Premise
290	<	_	_	I-Premise
291	0.05	_	_	I-Premise
292	]	_	_	I-Premise
293	.	_	_	I-Premise

294	A	_	_	B-Premise
295	similar	_	_	I-Premise
296	change	_	_	I-Premise
297	was	_	_	I-Premise
298	seen	_	_	I-Premise
299	for	_	_	I-Premise
300	mean	_	_	I-Premise
301	anxiety	_	_	I-Premise
302	scores	_	_	I-Premise
303	:	_	_	I-Premise
304	intervention	_	_	I-Premise
305	11.1	_	_	I-Premise
306	to	_	_	I-Premise
307	8.2	_	_	I-Premise
308	,	_	_	I-Premise
309	control	_	_	I-Premise
310	9.6	_	_	I-Premise
311	to	_	_	I-Premise
312	9.3	_	_	I-Premise
313	[	_	_	I-Premise
314	F	_	_	I-Premise
315	(	_	_	I-Premise
316	(	_	_	I-Premise
317	1,84	_	_	I-Premise
318	)	_	_	I-Premise
319	)	_	_	I-Premise
320	=	_	_	I-Premise
321	17.8	_	_	I-Premise
322	,	_	_	I-Premise
323	P	_	_	I-Premise
324	<	_	_	I-Premise
325	0.05	_	_	I-Premise
326	]	_	_	I-Premise
327	.	_	_	I-Premise

328	Psychological	_	_	B-Premise
329	quality	_	_	I-Premise
330	of	_	_	I-Premise
331	life	_	_	I-Premise
332	also	_	_	I-Premise
333	improved	_	_	I-Premise
334	more	_	_	I-Premise
335	in	_	_	I-Premise
336	the	_	_	I-Premise
337	intervention	_	_	I-Premise
338	group	_	_	I-Premise
339	,	_	_	I-Premise
340	from	_	_	I-Premise
341	49.6	_	_	I-Premise
342	to	_	_	I-Premise
343	61.2	_	_	I-Premise
344	vs.	_	_	I-Premise
345	50.1	_	_	I-Premise
346	to	_	_	I-Premise
347	51.5	_	_	I-Premise
348	in	_	_	I-Premise
349	the	_	_	I-Premise
350	control	_	_	I-Premise
351	group	_	_	I-Premise
352	[	_	_	I-Premise
353	F	_	_	I-Premise
354	(	_	_	I-Premise
355	(	_	_	I-Premise
356	1,84	_	_	I-Premise
357	)	_	_	I-Premise
358	)	_	_	I-Premise
359	=	_	_	I-Premise
360	10.9	_	_	I-Premise
361	,	_	_	I-Premise
362	P	_	_	I-Premise
363	<	_	_	I-Premise
364	0.05	_	_	I-Premise
365	]	_	_	I-Premise
366	.	_	_	I-Premise

367	Laser	_	_	B-Claim
368	treatment	_	_	I-Claim
369	appeared	_	_	I-Claim
370	to	_	_	I-Claim
371	reduce	_	_	I-Claim
372	the	_	_	I-Claim
373	severity	_	_	I-Claim
374	of	_	_	I-Claim
375	facial	_	_	I-Claim
376	hair	_	_	I-Claim
377	and	_	_	I-Claim
378	time	_	_	I-Claim
379	spent	_	_	I-Claim
380	on	_	_	I-Claim
381	hair	_	_	I-Claim
382	removal	_	_	I-Claim
383	as	_	_	I-Claim
384	well	_	_	I-Claim
385	as	_	_	I-Claim
386	alleviating	_	_	I-Claim
387	depression	_	_	I-Claim
388	and	_	_	I-Claim
389	anxiety	_	_	I-Claim
390	in	_	_	I-Claim
391	women	_	_	I-Claim
392	with	_	_	I-Claim
393	PCOS	_	_	I-Claim
394	.	_	_	I-Claim

395	These	_	_	B-Claim
396	findings	_	_	I-Claim
397	suggest	_	_	I-Claim
398	that	_	_	I-Claim
399	ways	_	_	I-Claim
400	of	_	_	I-Claim
401	making	_	_	I-Claim
402	this	_	_	I-Claim
403	method	_	_	I-Claim
404	of	_	_	I-Claim
405	hair	_	_	I-Claim
406	removal	_	_	I-Claim
407	more	_	_	I-Claim
408	widely	_	_	I-Claim
409	available	_	_	I-Claim
410	to	_	_	I-Claim
411	women	_	_	I-Claim
412	with	_	_	I-Claim
413	facial	_	_	I-Claim
414	hirsutism	_	_	I-Claim
415	should	_	_	I-Claim
416	be	_	_	I-Claim
417	considered	_	_	I-Claim
418	.	_	_	I-Claim


0	For	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	anthracycline-pretreated	_	_	I-Claim
4	metastatic	_	_	I-Claim
5	breast	_	_	I-Claim
6	carcinoma	_	_	I-Claim
7	,	_	_	I-Claim
8	capecitabine	_	_	I-Claim
9	plus	_	_	I-Claim
10	docetaxel	_	_	I-Claim
11	significantly	_	_	I-Claim
12	increased	_	_	I-Claim
13	overall	_	_	I-Claim
14	survival	_	_	I-Claim
15	compared	_	_	I-Claim
16	with	_	_	I-Claim
17	docetaxel	_	_	I-Claim
18	alone	_	_	I-Claim
19	.	_	_	I-Claim

20	The	_	_	O
21	current	_	_	O
22	study	_	_	O
23	evaluated	_	_	O
24	the	_	_	O
25	cost-effectiveness	_	_	O
26	of	_	_	O
27	the	_	_	O
28	capecitabine/docetaxel	_	_	O
29	combination	_	_	O
30	versus	_	_	O
31	docetaxel	_	_	O
32	monotherapy	_	_	O
33	,	_	_	O
34	comparing	_	_	O
35	the	_	_	O
36	gain	_	_	O
37	in	_	_	O
38	quality-adjusted	_	_	O
39	survival	_	_	O
40	with	_	_	O
41	associated	_	_	O
42	health	_	_	O
43	care	_	_	O
44	costs	_	_	O
45	.	_	_	O

46	Patients	_	_	O
47	were	_	_	O
48	randomized	_	_	O
49	to	_	_	O
50	receive	_	_	O
51	21-day	_	_	O
52	cycles	_	_	O
53	of	_	_	O
54	oral	_	_	O
55	capecitabine	_	_	O
56	1250	_	_	O
57	mg/m2	_	_	O
58	twice	_	_	O
59	daily	_	_	O
60	,	_	_	O
61	on	_	_	O
62	Days	_	_	O
63	1-14	_	_	O
64	,	_	_	O
65	plus	_	_	O
66	docetaxel	_	_	O
67	75	_	_	O
68	mg/m2	_	_	O
69	Day	_	_	O
70	1	_	_	O
71	(	_	_	O
72	n	_	_	O
73	=	_	_	O
74	255	_	_	O
75	)	_	_	O
76	,	_	_	O
77	or	_	_	O
78	docetaxel	_	_	O
79	100	_	_	O
80	mg/m2	_	_	O
81	on	_	_	O
82	Day	_	_	O
83	1	_	_	O
84	(	_	_	O
85	n	_	_	O
86	=	_	_	O
87	256	_	_	O
88	)	_	_	O
89	.	_	_	O

90	Health	_	_	O
91	and	_	_	O
92	cost	_	_	O
93	outcomes	_	_	O
94	in	_	_	O
95	the	_	_	O
96	two	_	_	O
97	arms	_	_	O
98	were	_	_	O
99	compared	_	_	O
100	,	_	_	O
101	and	_	_	O
102	cost-effectiveness	_	_	O
103	was	_	_	O
104	estimated	_	_	O
105	.	_	_	O

106	Data	_	_	O
107	on	_	_	O
108	survival	_	_	O
109	time	_	_	O
110	and	_	_	O
111	medical	_	_	O
112	care	_	_	O
113	resource	_	_	O
114	use	_	_	O
115	were	_	_	O
116	prospectively	_	_	O
117	collected	_	_	O
118	in	_	_	O
119	the	_	_	O
120	trial	_	_	O
121	.	_	_	O

122	Costs	_	_	O
123	associated	_	_	O
124	with	_	_	O
125	medical	_	_	O
126	care	_	_	O
127	resource	_	_	O
128	use	_	_	O
129	and	_	_	O
130	quality-of-life	_	_	O
131	adjustments	_	_	O
132	were	_	_	O
133	obtained	_	_	O
134	from	_	_	O
135	the	_	_	O
136	published	_	_	O
137	literature	_	_	O
138	.	_	_	O

139	The	_	_	O
140	incremental	_	_	O
141	cost-effectiveness	_	_	O
142	ratio	_	_	O
143	was	_	_	O
144	calculated	_	_	O
145	as	_	_	O
146	the	_	_	O
147	cost	_	_	O
148	per	_	_	O
149	quality-adjusted	_	_	O
150	life	_	_	O
151	year	_	_	O
152	(	_	_	O
153	QALY	_	_	O
154	)	_	_	O
155	gained	_	_	O
156	.	_	_	O

157	Capecitabine/docetaxel	_	_	B-Premise
158	increased	_	_	I-Premise
159	the	_	_	I-Premise
160	median	_	_	I-Premise
161	overall	_	_	I-Premise
162	survival	_	_	I-Premise
163	by	_	_	I-Premise
164	3	_	_	I-Premise
165	months	_	_	I-Premise
166	compared	_	_	I-Premise
167	with	_	_	I-Premise
168	docetaxel	_	_	I-Premise
169	alone	_	_	I-Premise
170	(	_	_	I-Premise
171	14.5	_	_	I-Premise
172	vs.	_	_	I-Premise
173	11.5	_	_	I-Premise
174	months	_	_	I-Premise
175	)	_	_	I-Premise
176	.	_	_	I-Premise

177	The	_	_	B-Premise
178	mean	_	_	I-Premise
179	quality-adjusted	_	_	I-Premise
180	survival	_	_	I-Premise
181	was	_	_	I-Premise
182	increased	_	_	I-Premise
183	by	_	_	I-Premise
184	1.8	_	_	I-Premise
185	months	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	capecitabine/docetaxel	_	_	I-Premise
189	group	_	_	I-Premise
190	.	_	_	I-Premise

191	The	_	_	B-Premise
192	total	_	_	I-Premise
193	medical-resource	_	_	I-Premise
194	utilization	_	_	I-Premise
195	cost	_	_	I-Premise
196	per	_	_	I-Premise
197	patient	_	_	I-Premise
198	was	_	_	I-Premise
199	8.9	_	_	I-Premise
200	%	_	_	I-Premise
201	higher	_	_	I-Premise
202	with	_	_	I-Premise
203	the	_	_	I-Premise
204	combination	_	_	I-Premise
205	:	_	_	I-Premise
206	24,475	_	_	I-Premise
207	dollars	_	_	I-Premise
208	for	_	_	I-Premise
209	combination	_	_	I-Premise
210	therapy	_	_	I-Premise
211	versus	_	_	I-Premise
212	22,477	_	_	I-Premise
213	dollars	_	_	I-Premise
214	for	_	_	I-Premise
215	single-agent	_	_	I-Premise
216	docetaxel	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	mean	_	_	I-Premise
220	cost	_	_	I-Premise
221	per	_	_	I-Premise
222	QALY	_	_	I-Premise
223	gained	_	_	I-Premise
224	with	_	_	I-Premise
225	combination	_	_	I-Premise
226	therapy	_	_	I-Premise
227	was	_	_	I-Premise
228	13,558	_	_	I-Premise
229	dollars	_	_	I-Premise
230	(	_	_	I-Premise
231	standard	_	_	I-Premise
232	deviation	_	_	I-Premise
233	,	_	_	I-Premise
234	6742	_	_	I-Premise
235	dollars	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Cost	_	_	B-Premise
239	savings	_	_	I-Premise
240	due	_	_	I-Premise
241	to	_	_	I-Premise
242	reduced	_	_	I-Premise
243	docetaxel	_	_	I-Premise
244	dose	_	_	I-Premise
245	and	_	_	I-Premise
246	hospital	_	_	I-Premise
247	use	_	_	I-Premise
248	were	_	_	I-Premise
249	the	_	_	I-Premise
250	major	_	_	I-Premise
251	cost	_	_	I-Premise
252	offsets	_	_	I-Premise
253	with	_	_	I-Premise
254	the	_	_	I-Premise
255	combination	_	_	I-Premise
256	.	_	_	I-Premise

257	Sensitivity	_	_	B-Premise
258	analyses	_	_	I-Premise
259	showed	_	_	I-Premise
260	that	_	_	I-Premise
261	varying	_	_	I-Premise
262	the	_	_	I-Premise
263	mean	_	_	I-Premise
264	hospital	_	_	I-Premise
265	cost	_	_	I-Premise
266	per	_	_	I-Premise
267	day	_	_	I-Premise
268	from	_	_	I-Premise
269	the	_	_	I-Premise
270	5th	_	_	I-Premise
271	to	_	_	I-Premise
272	the	_	_	I-Premise
273	95th	_	_	I-Premise
274	percentile	_	_	I-Premise
275	resulted	_	_	I-Premise
276	in	_	_	I-Premise
277	cost-utility	_	_	I-Premise
278	ratios	_	_	I-Premise
279	ranging	_	_	I-Premise
280	from	_	_	I-Premise
281	20,326	_	_	I-Premise
282	dollars	_	_	I-Premise
283	to	_	_	I-Premise
284	as	_	_	I-Premise
285	low	_	_	I-Premise
286	as	_	_	I-Premise
287	6360	_	_	I-Premise
288	dollars	_	_	I-Premise
289	.	_	_	I-Premise

290	Capecitabine/docetaxel	_	_	B-Claim
291	was	_	_	I-Claim
292	a	_	_	I-Claim
293	cost-effective	_	_	I-Claim
294	treatment	_	_	I-Claim
295	in	_	_	I-Claim
296	patients	_	_	I-Claim
297	with	_	_	I-Claim
298	anthracycline-pretreated	_	_	I-Claim
299	advanced	_	_	I-Claim
300	breast	_	_	I-Claim
301	carcinoma	_	_	I-Claim
302	,	_	_	I-Claim
303	and	_	_	I-Claim
304	had	_	_	I-Claim
305	an	_	_	I-Claim
306	incremental	_	_	I-Claim
307	cost-effectiveness	_	_	I-Claim
308	ratio	_	_	I-Claim
309	that	_	_	I-Claim
310	compares	_	_	I-Claim
311	very	_	_	I-Claim
312	favorably	_	_	I-Claim
313	with	_	_	I-Claim
314	that	_	_	I-Claim
315	of	_	_	I-Claim
316	many	_	_	I-Claim
317	other	_	_	I-Claim
318	oncology	_	_	I-Claim
319	therapies	_	_	I-Claim
320	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	determine	_	_	O
4	the	_	_	O
5	effect	_	_	O
6	of	_	_	O
7	dietary	_	_	O
8	counseling	_	_	O
9	or	_	_	O
10	oral	_	_	O
11	supplements	_	_	O
12	on	_	_	O
13	outcome	_	_	O
14	for	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	cancer	_	_	O
18	,	_	_	O
19	specifically	_	_	O
20	,	_	_	O
21	nutritional	_	_	O
22	outcome	_	_	O
23	,	_	_	O
24	morbidity	_	_	O
25	,	_	_	O
26	and	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	,	_	_	O
34	during	_	_	O
35	and	_	_	O
36	3	_	_	O
37	months	_	_	O
38	after	_	_	O
39	radiotherapy	_	_	O
40	.	_	_	O

41	Seventy-five	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	head	_	_	O
45	and	_	_	O
46	neck	_	_	O
47	cancer	_	_	O
48	who	_	_	O
49	were	_	_	O
50	referred	_	_	O
51	for	_	_	O
52	radiotherapy	_	_	O
53	(	_	_	O
54	RT	_	_	O
55	)	_	_	O
56	were	_	_	O
57	randomized	_	_	O
58	to	_	_	O
59	the	_	_	O
60	following	_	_	O
61	groups	_	_	O
62	:	_	_	O
63	group	_	_	O
64	1	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	25	_	_	O
69	)	_	_	O
70	,	_	_	O
71	patients	_	_	O
72	who	_	_	O
73	received	_	_	O
74	dietary	_	_	O
75	counseling	_	_	O
76	with	_	_	O
77	regular	_	_	O
78	foods	_	_	O
79	;	_	_	O
80	group	_	_	O
81	2	_	_	O
82	(	_	_	O
83	n	_	_	O
84	=	_	_	O
85	25	_	_	O
86	)	_	_	O
87	,	_	_	O
88	patients	_	_	O
89	who	_	_	O
90	maintained	_	_	O
91	usual	_	_	O
92	diet	_	_	O
93	plus	_	_	O
94	supplements	_	_	O
95	;	_	_	O
96	and	_	_	O
97	group	_	_	O
98	3	_	_	O
99	(	_	_	O
100	n	_	_	O
101	=	_	_	O
102	25	_	_	O
103	)	_	_	O
104	,	_	_	O
105	patients	_	_	O
106	who	_	_	O
107	maintained	_	_	O
108	intake	_	_	O
109	ad	_	_	O
110	lib	_	_	O
111	.	_	_	O

112	Nutritional	_	_	O
113	intake	_	_	O
114	(	_	_	O
115	determined	_	_	O
116	by	_	_	O
117	diet	_	_	O
118	history	_	_	O
119	)	_	_	O
120	and	_	_	O
121	status	_	_	O
122	(	_	_	O
123	determined	_	_	O
124	by	_	_	O
125	Ottery	_	_	O
126	's	_	_	O
127	Subjective	_	_	O
128	Global	_	_	O
129	Assessment	_	_	O
130	)	_	_	O
131	,	_	_	O
132	and	_	_	O
133	QOL	_	_	O
134	(	_	_	O
135	determined	_	_	O
136	by	_	_	O
137	the	_	_	O
138	European	_	_	O
139	Organization	_	_	O
140	for	_	_	O
141	the	_	_	O
142	Research	_	_	O
143	and	_	_	O
144	Treatment	_	_	O
145	of	_	_	O
146	Cancer	_	_	O
147	Quality	_	_	O
148	of	_	_	O
149	Life	_	_	O
150	Questionnaire	_	_	O
151	version	_	_	O
152	3.0	_	_	O
153	[	_	_	O
154	EORTC	_	_	O
155	QLQ-C30	_	_	O
156	]	_	_	O
157	)	_	_	O
158	were	_	_	O
159	evaluated	_	_	O
160	at	_	_	O
161	baseline	_	_	O
162	,	_	_	O
163	at	_	_	O
164	the	_	_	O
165	end	_	_	O
166	of	_	_	O
167	RT	_	_	O
168	,	_	_	O
169	and	_	_	O
170	at	_	_	O
171	3	_	_	O
172	months	_	_	O
173	.	_	_	O

174	Energy	_	_	B-Premise
175	intake	_	_	I-Premise
176	after	_	_	I-Premise
177	RT	_	_	I-Premise
178	increased	_	_	I-Premise
179	in	_	_	I-Premise
180	both	_	_	I-Premise
181	groups	_	_	I-Premise
182	1	_	_	I-Premise
183	and	_	_	I-Premise
184	2	_	_	I-Premise
185	(	_	_	I-Premise
186	p	_	_	I-Premise
187	<	_	_	I-Premise
188	or	_	_	I-Premise
189	=	_	_	I-Premise
190	.05	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	Protein	_	_	B-Premise
194	intake	_	_	I-Premise
195	also	_	_	I-Premise
196	increased	_	_	I-Premise
197	in	_	_	I-Premise
198	both	_	_	I-Premise
199	groups	_	_	I-Premise
200	1	_	_	I-Premise
201	and	_	_	I-Premise
202	2	_	_	I-Premise
203	(	_	_	I-Premise
204	p	_	_	I-Premise
205	<	_	_	I-Premise
206	or	_	_	I-Premise
207	=	_	_	I-Premise
208	.006	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	Both	_	_	B-Premise
212	energy	_	_	I-Premise
213	and	_	_	I-Premise
214	protein	_	_	I-Premise
215	intake	_	_	I-Premise
216	decreased	_	_	I-Premise
217	significantly	_	_	I-Premise
218	in	_	_	I-Premise
219	group	_	_	I-Premise
220	3	_	_	I-Premise
221	(	_	_	I-Premise
222	p	_	_	I-Premise
223	<	_	_	I-Premise
224	.01	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	At	_	_	B-Premise
228	3	_	_	I-Premise
229	months	_	_	I-Premise
230	,	_	_	I-Premise
231	group	_	_	I-Premise
232	1	_	_	I-Premise
233	maintained	_	_	I-Premise
234	intakes	_	_	I-Premise
235	,	_	_	I-Premise
236	whereas	_	_	I-Premise
237	groups	_	_	I-Premise
238	2	_	_	I-Premise
239	and	_	_	I-Premise
240	3	_	_	I-Premise
241	returned	_	_	I-Premise
242	to	_	_	I-Premise
243	or	_	_	I-Premise
244	below	_	_	I-Premise
245	baseline	_	_	I-Premise
246	levels	_	_	I-Premise
247	.	_	_	I-Premise

248	After	_	_	B-Premise
249	RT	_	_	I-Premise
250	,	_	_	I-Premise
251	>	_	_	I-Premise
252	90	_	_	I-Premise
253	%	_	_	I-Premise
254	of	_	_	I-Premise
255	patients	_	_	I-Premise
256	experienced	_	_	I-Premise
257	RT	_	_	I-Premise
258	toxicity	_	_	I-Premise
259	;	_	_	I-Premise
260	this	_	_	B-Premise
261	was	_	_	I-Premise
262	not	_	_	I-Premise
263	significantly	_	_	I-Premise
264	different	_	_	I-Premise
265	between	_	_	I-Premise
266	groups	_	_	I-Premise
267	,	_	_	I-Premise
268	with	_	_	I-Premise
269	a	_	_	I-Premise
270	trend	_	_	I-Premise
271	for	_	_	I-Premise
272	reduced	_	_	I-Premise
273	symptomatology	_	_	I-Premise
274	in	_	_	I-Premise
275	group	_	_	I-Premise
276	1	_	_	I-Premise
277	versus	_	_	I-Premise
278	group	_	_	I-Premise
279	2/group	_	_	I-Premise
280	3	_	_	I-Premise
281	(	_	_	I-Premise
282	p	_	_	I-Premise
283	<	_	_	I-Premise
284	.07	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	At	_	_	B-Premise
288	3	_	_	I-Premise
289	months	_	_	I-Premise
290	,	_	_	I-Premise
291	the	_	_	I-Premise
292	reduction	_	_	I-Premise
293	of	_	_	I-Premise
294	incidence/severity	_	_	I-Premise
295	of	_	_	I-Premise
296	grade	_	_	I-Premise
297	1+2	_	_	I-Premise
298	anorexia	_	_	I-Premise
299	,	_	_	I-Premise
300	nausea/vomiting	_	_	I-Premise
301	,	_	_	I-Premise
302	xerostomia	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	dysgeusia	_	_	I-Premise
306	was	_	_	I-Premise
307	different	_	_	I-Premise
308	:	_	_	I-Premise
309	90	_	_	I-Premise
310	%	_	_	I-Premise
311	of	_	_	I-Premise
312	the	_	_	I-Premise
313	patients	_	_	I-Premise
314	improved	_	_	I-Premise
315	in	_	_	I-Premise
316	group	_	_	I-Premise
317	1	_	_	I-Premise
318	versus	_	_	I-Premise
319	67	_	_	I-Premise
320	%	_	_	I-Premise
321	in	_	_	I-Premise
322	group	_	_	I-Premise
323	2	_	_	I-Premise
324	versus	_	_	I-Premise
325	51	_	_	I-Premise
326	%	_	_	I-Premise
327	in	_	_	I-Premise
328	group	_	_	I-Premise
329	3	_	_	I-Premise
330	(	_	_	I-Premise
331	p	_	_	I-Premise
332	<	_	_	I-Premise
333	.0001	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	After	_	_	B-Premise
337	RT	_	_	I-Premise
338	,	_	_	I-Premise
339	QOL	_	_	I-Premise
340	function	_	_	I-Premise
341	scores	_	_	I-Premise
342	improved	_	_	I-Premise
343	(	_	_	I-Premise
344	p	_	_	I-Premise
345	<	_	_	I-Premise
346	.003	_	_	I-Premise
347	)	_	_	I-Premise
348	proportionally	_	_	I-Premise
349	with	_	_	I-Premise
350	improved	_	_	I-Premise
351	nutritional	_	_	I-Premise
352	intake	_	_	I-Premise
353	and	_	_	I-Premise
354	status	_	_	I-Premise
355	in	_	_	I-Premise
356	group	_	_	I-Premise
357	1/group	_	_	I-Premise
358	2	_	_	I-Premise
359	(	_	_	I-Premise
360	p	_	_	I-Premise
361	<	_	_	I-Premise
362	.05	_	_	I-Premise
363	)	_	_	I-Premise
364	and	_	_	I-Premise
365	worsened	_	_	I-Premise
366	in	_	_	I-Premise
367	group	_	_	I-Premise
368	3	_	_	I-Premise
369	(	_	_	I-Premise
370	p	_	_	I-Premise
371	<	_	_	I-Premise
372	.05	_	_	I-Premise
373	)	_	_	I-Premise
374	;	_	_	I-Premise
375	at	_	_	B-Premise
376	3	_	_	I-Premise
377	months	_	_	I-Premise
378	,	_	_	I-Premise
379	patients	_	_	I-Premise
380	in	_	_	I-Premise
381	group	_	_	I-Premise
382	1	_	_	I-Premise
383	maintained	_	_	I-Premise
384	or	_	_	I-Premise
385	improved	_	_	I-Premise
386	overall	_	_	I-Premise
387	QOL	_	_	I-Premise
388	,	_	_	I-Premise
389	whereas	_	_	I-Premise
390	patients	_	_	I-Premise
391	in	_	_	I-Premise
392	groups	_	_	I-Premise
393	2	_	_	I-Premise
394	and	_	_	I-Premise
395	3	_	_	I-Premise
396	maintained	_	_	I-Premise
397	or	_	_	I-Premise
398	worsened	_	_	I-Premise
399	overall	_	_	I-Premise
400	QOL	_	_	I-Premise
401	.	_	_	I-Premise

402	During	_	_	B-Claim
403	RT	_	_	I-Claim
404	,	_	_	I-Claim
405	nutritional	_	_	I-Claim
406	interventions	_	_	I-Claim
407	positively	_	_	I-Claim
408	influenced	_	_	I-Claim
409	outcomes	_	_	I-Claim
410	,	_	_	I-Claim
411	and	_	_	I-Claim
412	counseling	_	_	I-Claim
413	was	_	_	I-Claim
414	of	_	_	I-Claim
415	similar/higher	_	_	I-Claim
416	benefit	_	_	I-Claim
417	;	_	_	I-Claim
418	in	_	_	B-Claim
419	the	_	_	I-Claim
420	medium	_	_	I-Claim
421	term	_	_	I-Claim
422	,	_	_	I-Claim
423	only	_	_	I-Claim
424	counseling	_	_	I-Claim
425	exerted	_	_	I-Claim
426	a	_	_	I-Claim
427	significant	_	_	I-Claim
428	impact	_	_	I-Claim
429	on	_	_	I-Claim
430	patient	_	_	I-Claim
431	outcomes	_	_	I-Claim
432	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	a	_	_	O
6	psychoeducational	_	_	O
7	intervention	_	_	O
8	in	_	_	O
9	improving	_	_	O
10	cancer-related	_	_	O
11	fatigue	_	_	O
12	.	_	_	O

13	This	_	_	O
14	randomized	_	_	O
15	controlled	_	_	O
16	trial	_	_	O
17	involved	_	_	O
18	109	_	_	O
19	women	_	_	O
20	commencing	_	_	O
21	adjuvant	_	_	O
22	chemotherapy	_	_	O
23	for	_	_	O
24	stage	_	_	O
25	I	_	_	O
26	or	_	_	O
27	II	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	in	_	_	O
31	five	_	_	O
32	chemotherapy	_	_	O
33	treatment	_	_	O
34	centers	_	_	O
35	.	_	_	O

36	Intervention	_	_	O
37	group	_	_	O
38	patients	_	_	O
39	received	_	_	O
40	an	_	_	O
41	individualized	_	_	O
42	fatigue	_	_	O
43	education	_	_	O
44	and	_	_	O
45	support	_	_	O
46	program	_	_	O
47	delivered	_	_	O
48	in	_	_	O
49	the	_	_	O
50	clinic	_	_	O
51	and	_	_	O
52	by	_	_	O
53	phone	_	_	O
54	over	_	_	O
55	three	_	_	O
56	10-	_	_	O
57	to	_	_	O
58	20-minute	_	_	O
59	sessions	_	_	O
60	1	_	_	O
61	week	_	_	O
62	apart	_	_	O
63	.	_	_	O

64	Instruments	_	_	O
65	included	_	_	O
66	a	_	_	O
67	numeric	_	_	O
68	rating	_	_	O
69	scale	_	_	O
70	assessing	_	_	O
71	confidence	_	_	O
72	with	_	_	O
73	managing	_	_	O
74	fatigue	_	_	O
75	;	_	_	O
76	11-point	_	_	O
77	numeric	_	_	O
78	rating	_	_	O
79	scales	_	_	O
80	measuring	_	_	O
81	fatigue	_	_	O
82	at	_	_	O
83	worst	_	_	O
84	,	_	_	O
85	average	_	_	O
86	,	_	_	O
87	and	_	_	O
88	best	_	_	O
89	;	_	_	O
90	the	_	_	O
91	Functional	_	_	O
92	Assessment	_	_	O
93	of	_	_	O
94	Cancer	_	_	O
95	Therapy-Fatigue	_	_	O
96	and	_	_	O
97	Piper	_	_	O
98	Fatigue	_	_	O
99	Scales	_	_	O
100	;	_	_	O
101	the	_	_	O
102	Cancer	_	_	O
103	Self-Efficacy	_	_	O
104	Scale	_	_	O
105	;	_	_	O
106	the	_	_	O
107	European	_	_	O
108	Organisation	_	_	O
109	for	_	_	O
110	Research	_	_	O
111	and	_	_	O
112	Treatment	_	_	O
113	of	_	_	O
114	Cancer	_	_	O
115	Quality	_	_	O
116	of	_	_	O
117	Life	_	_	O
118	Questionnaire	_	_	O
119	C30	_	_	O
120	;	_	_	O
121	and	_	_	O
122	the	_	_	O
123	Hospital	_	_	O
124	Anxiety	_	_	O
125	and	_	_	O
126	Depression	_	_	O
127	Scale	_	_	O
128	.	_	_	O

129	For	_	_	O
130	each	_	_	O
131	outcome	_	_	O
132	,	_	_	O
133	separate	_	_	O
134	analyses	_	_	O
135	of	_	_	O
136	covariance	_	_	O
137	of	_	_	O
138	change	_	_	O
139	scores	_	_	O
140	between	_	_	O
141	baseline	_	_	O
142	(	_	_	O
143	T1	_	_	O
144	)	_	_	O
145	and	_	_	O
146	the	_	_	O
147	three	_	_	O
148	follow-up	_	_	O
149	time	_	_	O
150	points	_	_	O
151	(	_	_	O
152	T2	_	_	O
153	,	_	_	O
154	T3	_	_	O
155	,	_	_	O
156	and	_	_	O
157	T4	_	_	O
158	)	_	_	O
159	were	_	_	O
160	conducted	_	_	O
161	,	_	_	O
162	controlling	_	_	O
163	for	_	_	O
164	the	_	_	O
165	variable	_	_	O
166	's	_	_	O
167	corresponding	_	_	O
168	baseline	_	_	O
169	value	_	_	O
170	.	_	_	O

171	Compared	_	_	B-Premise
172	with	_	_	I-Premise
173	the	_	_	I-Premise
174	intervention	_	_	I-Premise
175	group	_	_	I-Premise
176	,	_	_	I-Premise
177	mean	_	_	I-Premise
178	difference	_	_	I-Premise
179	scores	_	_	I-Premise
180	between	_	_	I-Premise
181	the	_	_	I-Premise
182	baseline	_	_	I-Premise
183	(	_	_	I-Premise
184	T1	_	_	I-Premise
185	)	_	_	I-Premise
186	and	_	_	I-Premise
187	immediate	_	_	I-Premise
188	after	_	_	I-Premise
189	the	_	_	I-Premise
190	test	_	_	I-Premise
191	(	_	_	I-Premise
192	T2	_	_	I-Premise
193	)	_	_	I-Premise
194	assessments	_	_	I-Premise
195	increased	_	_	I-Premise
196	significantly	_	_	I-Premise
197	more	_	_	I-Premise
198	for	_	_	I-Premise
199	the	_	_	I-Premise
200	control	_	_	I-Premise
201	group	_	_	I-Premise
202	for	_	_	I-Premise
203	worst	_	_	I-Premise
204	and	_	_	I-Premise
205	average	_	_	I-Premise
206	fatigue	_	_	I-Premise
207	,	_	_	I-Premise
208	Functional	_	_	I-Premise
209	Assessment	_	_	I-Premise
210	of	_	_	I-Premise
211	Cancer	_	_	I-Premise
212	Therapy-Fatigue	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	Piper	_	_	I-Premise
216	fatigue	_	_	I-Premise
217	severity	_	_	I-Premise
218	and	_	_	I-Premise
219	interference	_	_	I-Premise
220	measures	_	_	I-Premise
221	.	_	_	I-Premise

222	These	_	_	B-Premise
223	differences	_	_	I-Premise
224	were	_	_	I-Premise
225	not	_	_	I-Premise
226	observed	_	_	I-Premise
227	between	_	_	I-Premise
228	baseline	_	_	I-Premise
229	and	_	_	I-Premise
230	T3	_	_	I-Premise
231	and	_	_	I-Premise
232	T4	_	_	I-Premise
233	assessments	_	_	I-Premise
234	.	_	_	I-Premise

235	No	_	_	B-Premise
236	significant	_	_	I-Premise
237	differences	_	_	I-Premise
238	were	_	_	I-Premise
239	identified	_	_	I-Premise
240	for	_	_	I-Premise
241	any	_	_	I-Premise
242	pre-	_	_	I-Premise
243	or	_	_	I-Premise
244	post-test	_	_	I-Premise
245	change	_	_	I-Premise
246	scores	_	_	I-Premise
247	for	_	_	I-Premise
248	confidence	_	_	I-Premise
249	with	_	_	I-Premise
250	managing	_	_	I-Premise
251	fatigue	_	_	I-Premise
252	,	_	_	I-Premise
253	cancer	_	_	I-Premise
254	self-efficacy	_	_	I-Premise
255	,	_	_	I-Premise
256	anxiety	_	_	I-Premise
257	,	_	_	I-Premise
258	depression	_	_	I-Premise
259	,	_	_	I-Premise
260	or	_	_	I-Premise
261	quality	_	_	I-Premise
262	of	_	_	I-Premise
263	life	_	_	I-Premise
264	.	_	_	I-Premise

265	Preparatory	_	_	B-Claim
266	education	_	_	I-Claim
267	and	_	_	I-Claim
268	support	_	_	I-Claim
269	has	_	_	I-Claim
270	the	_	_	I-Claim
271	potential	_	_	I-Claim
272	to	_	_	I-Claim
273	assist	_	_	I-Claim
274	women	_	_	I-Claim
275	to	_	_	I-Claim
276	cope	_	_	I-Claim
277	with	_	_	I-Claim
278	cancer-related	_	_	I-Claim
279	fatigue	_	_	I-Claim
280	in	_	_	I-Claim
281	the	_	_	I-Claim
282	short	_	_	I-Claim
283	term	_	_	I-Claim
284	.	_	_	I-Claim

285	However	_	_	B-Claim
286	,	_	_	I-Claim
287	further	_	_	I-Claim
288	research	_	_	I-Claim
289	is	_	_	I-Claim
290	needed	_	_	I-Claim
291	to	_	_	I-Claim
292	identify	_	_	I-Claim
293	ways	_	_	I-Claim
294	to	_	_	I-Claim
295	improve	_	_	I-Claim
296	the	_	_	I-Claim
297	potency	_	_	I-Claim
298	and	_	_	I-Claim
299	sustainability	_	_	I-Claim
300	of	_	_	I-Claim
301	psychoeducational	_	_	I-Claim
302	interventions	_	_	I-Claim
303	for	_	_	I-Claim
304	managing	_	_	I-Claim
305	cancer-related	_	_	I-Claim
306	fatigue	_	_	I-Claim
307	.	_	_	I-Claim


0	Approximately	_	_	O
1	30	_	_	O
2	%	_	_	O
3	of	_	_	O
4	lung	_	_	O
5	cancer	_	_	O
6	cases	_	_	O
7	are	_	_	O
8	diagnosed	_	_	O
9	in	_	_	O
10	patients	_	_	O
11	>	_	_	O
12	70	_	_	O
13	years	_	_	O
14	of	_	_	O
15	age	_	_	O
16	.	_	_	O

17	Standard	_	_	B-Claim
18	chemotherapy	_	_	I-Claim
19	regimens	_	_	I-Claim
20	are	_	_	I-Claim
21	generally	_	_	I-Claim
22	considered	_	_	I-Claim
23	too	_	_	I-Claim
24	toxic	_	_	I-Claim
25	for	_	_	I-Claim
26	elderly	_	_	I-Claim
27	patients	_	_	I-Claim
28	.	_	_	I-Claim

29	We	_	_	O
30	conducted	_	_	O
31	a	_	_	O
32	multicenter	_	_	O
33	phase	_	_	O
34	II	_	_	O
35	trial	_	_	O
36	to	_	_	O
37	determine	_	_	O
38	the	_	_	O
39	efficacy	_	_	O
40	and	_	_	O
41	safety	_	_	O
42	of	_	_	O
43	carboplatin	_	_	O
44	combined	_	_	O
45	with	_	_	O
46	vinorelbine	_	_	O
47	every	_	_	O
48	4	_	_	O
49	weeks	_	_	O
50	as	_	_	O
51	first-line	_	_	O
52	treatment	_	_	O
53	for	_	_	O
54	advanced	_	_	O
55	non-small-cell	_	_	O
56	lung	_	_	O
57	cancer	_	_	O
58	(	_	_	O
59	NSCLC	_	_	O
60	)	_	_	O
61	in	_	_	O
62	elderly	_	_	O
63	patients	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	were	_	_	O
67	eligible	_	_	O
68	if	_	_	O
69	they	_	_	O
70	were	_	_	O
71	aged	_	_	O
72	>	_	_	O
73	OR=	_	_	O
74	70	_	_	O
75	years	_	_	O
76	,	_	_	O
77	had	_	_	O
78	stage	_	_	O
79	IIIB	_	_	O
80	(	_	_	O
81	with	_	_	O
82	pleural	_	_	O
83	effusion	_	_	O
84	)	_	_	O
85	or	_	_	O
86	stage	_	_	O
87	IV	_	_	O
88	NSCLC	_	_	O
89	,	_	_	O
90	had	_	_	O
91	a	_	_	O
92	performance	_	_	O
93	status	_	_	O
94	of	_	_	O
95	0/1	_	_	O
96	,	_	_	O
97	had	_	_	O
98	not	_	_	O
99	previously	_	_	O
100	received	_	_	O
101	chemotherapy	_	_	O
102	,	_	_	O
103	and	_	_	O
104	had	_	_	O
105	normal	_	_	O
106	organ	_	_	O
107	function	_	_	O
108	.	_	_	O

109	Forty	_	_	O
110	patients	_	_	O
111	(	_	_	O
112	31	_	_	O
113	men	_	_	O
114	and	_	_	O
115	9	_	_	O
116	women	_	_	O
117	)	_	_	O
118	were	_	_	O
119	enrolled	_	_	O
120	and	_	_	O
121	received	_	_	O
122	3-5	_	_	O
123	courses	_	_	O
124	of	_	_	O
125	treatment	_	_	O
126	.	_	_	O

127	Median	_	_	O
128	age	_	_	O
129	was	_	_	O
130	72	_	_	O
131	years	_	_	O
132	(	_	_	O
133	range	_	_	O
134	,	_	_	O
135	70-82	_	_	O
136	years	_	_	O
137	)	_	_	O
138	.	_	_	O

139	Eighty	_	_	O
140	percent	_	_	O
141	of	_	_	O
142	patients	_	_	O
143	had	_	_	O
144	stage	_	_	O
145	IV	_	_	O
146	NSCLC	_	_	O
147	,	_	_	O
148	with	_	_	O
149	squamous	_	_	O
150	cell	_	_	O
151	(	_	_	O
152	n=21	_	_	O
153	)	_	_	O
154	,	_	_	O
155	adenocarcinoma	_	_	O
156	(	_	_	O
157	n=12	_	_	O
158	)	_	_	O
159	,	_	_	O
160	and	_	_	O
161	undifferentiated	_	_	O
162	(	_	_	O
163	n=7	_	_	O
164	)	_	_	O
165	histologies	_	_	O
166	.	_	_	O

167	Forty	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	assessable	_	_	O
171	for	_	_	O
172	toxicity	_	_	O
173	and	_	_	O
174	32	_	_	O
175	for	_	_	O
176	treatment	_	_	O
177	response	_	_	O
178	.	_	_	O

179	Among	_	_	B-Premise
180	these	_	_	I-Premise
181	32	_	_	I-Premise
182	patients	_	_	I-Premise
183	,	_	_	I-Premise
184	8	_	_	I-Premise
185	had	_	_	I-Premise
186	a	_	_	I-Premise
187	partial	_	_	I-Premise
188	response	_	_	I-Premise
189	(	_	_	I-Premise
190	intent-to-treat	_	_	I-Premise
191	response	_	_	I-Premise
192	rate	_	_	I-Premise
193	,	_	_	I-Premise
194	20	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	,	_	_	I-Premise
198	and	_	_	I-Premise
199	10	_	_	I-Premise
200	(	_	_	I-Premise
201	25	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	had	_	_	I-Premise
205	stable	_	_	I-Premise
206	disease	_	_	I-Premise
207	.	_	_	I-Premise

208	The	_	_	B-Premise
209	median	_	_	I-Premise
210	survival	_	_	I-Premise
211	was	_	_	I-Premise
212	7.8	_	_	I-Premise
213	months	_	_	I-Premise
214	(	_	_	I-Premise
215	range	_	_	I-Premise
216	,	_	_	I-Premise
217	4-11.6	_	_	I-Premise
218	months	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	The	_	_	B-Premise
222	1-	_	_	I-Premise
223	and	_	_	I-Premise
224	2-year	_	_	I-Premise
225	survival	_	_	I-Premise
226	rates	_	_	I-Premise
227	were	_	_	I-Premise
228	25	_	_	I-Premise
229	%	_	_	I-Premise
230	and	_	_	I-Premise
231	7	_	_	I-Premise
232	%	_	_	I-Premise
233	,	_	_	I-Premise
234	respectively	_	_	I-Premise
235	;	_	_	I-Premise
236	median	_	_	B-Premise
237	time	_	_	I-Premise
238	to	_	_	I-Premise
239	progression	_	_	I-Premise
240	was	_	_	I-Premise
241	4.3	_	_	I-Premise
242	months	_	_	I-Premise
243	(	_	_	I-Premise
244	range	_	_	I-Premise
245	,	_	_	I-Premise
246	0.2-13.8	_	_	I-Premise
247	months	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	Grade	_	_	B-Premise
251	3/4	_	_	I-Premise
252	neutropenia	_	_	I-Premise
253	was	_	_	I-Premise
254	seen	_	_	I-Premise
255	in	_	_	I-Premise
256	27	_	_	I-Premise
257	patients	_	_	I-Premise
258	(	_	_	I-Premise
259	68	_	_	I-Premise
260	%	_	_	I-Premise
261	)	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	grade	_	_	I-Premise
265	3/4	_	_	I-Premise
266	anemia	_	_	I-Premise
267	was	_	_	I-Premise
268	seen	_	_	I-Premise
269	in	_	_	I-Premise
270	5	_	_	I-Premise
271	patients	_	_	I-Premise
272	(	_	_	I-Premise
273	13	_	_	I-Premise
274	%	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	One	_	_	B-Premise
278	patient	_	_	I-Premise
279	died	_	_	I-Premise
280	of	_	_	I-Premise
281	febrile	_	_	I-Premise
282	neutropenia	_	_	I-Premise
283	during	_	_	I-Premise
284	treatment	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	main	_	_	I-Premise
288	nonhematologic	_	_	I-Premise
289	adverse	_	_	I-Premise
290	effect	_	_	I-Premise
291	was	_	_	I-Premise
292	fatigue	_	_	I-Premise
293	(	_	_	I-Premise
294	grade	_	_	I-Premise
295	3/4	_	_	I-Premise
296	in	_	_	I-Premise
297	18	_	_	I-Premise
298	%	_	_	I-Premise
299	of	_	_	I-Premise
300	patients	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	Carboplatin/vinorelbine	_	_	B-Claim
304	is	_	_	I-Claim
305	well	_	_	I-Claim
306	tolerated	_	_	I-Claim
307	by	_	_	I-Claim
308	elderly	_	_	I-Claim
309	patients	_	_	I-Claim
310	with	_	_	I-Claim
311	extensive-stage	_	_	I-Claim
312	NSCLC	_	_	I-Claim
313	.	_	_	I-Claim

314	Efficacy	_	_	B-Claim
315	is	_	_	I-Claim
316	low	_	_	I-Claim
317	but	_	_	I-Claim
318	similar	_	_	I-Claim
319	to	_	_	I-Claim
320	that	_	_	I-Claim
321	of	_	_	I-Claim
322	other	_	_	I-Claim
323	treatments	_	_	I-Claim
324	used	_	_	I-Claim
325	in	_	_	I-Claim
326	this	_	_	I-Claim
327	setting	_	_	I-Claim
328	.	_	_	I-Claim


0	The	_	_	B-Claim
1	combination	_	_	I-Claim
2	of	_	_	I-Claim
3	interferon	_	_	I-Claim
4	alfa	_	_	I-Claim
5	(	_	_	I-Claim
6	IFNalpha	_	_	I-Claim
7	)	_	_	I-Claim
8	and	_	_	I-Claim
9	isotretinoin	_	_	I-Claim
10	has	_	_	I-Claim
11	shown	_	_	I-Claim
12	a	_	_	I-Claim
13	direct	_	_	I-Claim
14	antiproliferative	_	_	I-Claim
15	effect	_	_	I-Claim
16	on	_	_	I-Claim
17	human	_	_	I-Claim
18	melanoma	_	_	I-Claim
19	cell	_	_	I-Claim
20	lines	_	_	I-Claim
21	,	_	_	I-Claim
22	but	_	_	B-Claim
23	it	_	_	I-Claim
24	remained	_	_	I-Claim
25	unclear	_	_	I-Claim
26	whether	_	_	I-Claim
27	this	_	_	I-Claim
28	combination	_	_	I-Claim
29	is	_	_	I-Claim
30	more	_	_	I-Claim
31	effective	_	_	I-Claim
32	than	_	_	I-Claim
33	IFNalpha	_	_	I-Claim
34	alone	_	_	I-Claim
35	in	_	_	I-Claim
36	patients	_	_	I-Claim
37	with	_	_	I-Claim
38	metastatic	_	_	I-Claim
39	melanoma	_	_	I-Claim
40	.	_	_	I-Claim

41	We	_	_	O
42	evaluated	_	_	O
43	safety	_	_	O
44	and	_	_	O
45	efficacy	_	_	O
46	of	_	_	O
47	IFNalpha	_	_	O
48	and	_	_	O
49	isotretinoin	_	_	O
50	compared	_	_	O
51	with	_	_	O
52	IFNalpha	_	_	O
53	alone	_	_	O
54	as	_	_	O
55	adjuvant	_	_	O
56	treatment	_	_	O
57	in	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	primary	_	_	O
61	malignant	_	_	O
62	melanoma	_	_	O
63	stage	_	_	O
64	IIA	_	_	O
65	and	_	_	O
66	IIB	_	_	O
67	.	_	_	O

68	In	_	_	O
69	a	_	_	O
70	prospective	_	_	O
71	,	_	_	O
72	randomized	_	_	O
73	,	_	_	O
74	double-blind	_	_	O
75	,	_	_	O
76	placebo-controlled	_	_	O
77	trial	_	_	O
78	,	_	_	O
79	407	_	_	O
80	melanoma	_	_	O
81	patients	_	_	O
82	in	_	_	O
83	stage	_	_	O
84	IIA	_	_	O
85	(	_	_	O
86	301	_	_	O
87	patients	_	_	O
88	)	_	_	O
89	and	_	_	O
90	IIB	_	_	O
91	(	_	_	O
92	106	_	_	O
93	patients	_	_	O
94	)	_	_	O
95	were	_	_	O
96	randomly	_	_	O
97	assigned	_	_	O
98	to	_	_	O
99	either	_	_	O
100	IFNalpha	_	_	O
101	and	_	_	O
102	isotretinoin	_	_	O
103	(	_	_	O
104	isotretinoin	_	_	O
105	group	_	_	O
106	;	_	_	O
107	206	_	_	O
108	patients	_	_	O
109	)	_	_	O
110	or	_	_	O
111	IFNalpha	_	_	O
112	and	_	_	O
113	placebo	_	_	O
114	(	_	_	O
115	placebo	_	_	O
116	group	_	_	O
117	;	_	_	O
118	201	_	_	O
119	patients	_	_	O
120	)	_	_	O
121	after	_	_	O
122	excision	_	_	O
123	of	_	_	O
124	the	_	_	O
125	primary	_	_	O
126	tumor	_	_	O
127	.	_	_	O

128	IFNalpha	_	_	O
129	was	_	_	O
130	administered	_	_	O
131	three	_	_	O
132	times	_	_	O
133	a	_	_	O
134	week	_	_	O
135	at	_	_	O
136	a	_	_	O
137	dose	_	_	O
138	of	_	_	O
139	3	_	_	O
140	million	_	_	O
141	units	_	_	O
142	subcutaneously	_	_	O
143	for	_	_	O
144	24	_	_	O
145	months	_	_	O
146	.	_	_	O

147	Isotretinoin	_	_	O
148	at	_	_	O
149	a	_	_	O
150	dose	_	_	O
151	of	_	_	O
152	20	_	_	O
153	mg	_	_	O
154	for	_	_	O
155	patients	_	_	O
156	<	_	_	O
157	or	_	_	O
158	=	_	_	O
159	73	_	_	O
160	kg	_	_	O
161	,	_	_	O
162	30	_	_	O
163	mg	_	_	O
164	for	_	_	O
165	patients	_	_	O
166	greater	_	_	O
167	than	_	_	O
168	73	_	_	O
169	kg	_	_	O
170	,	_	_	O
171	or	_	_	O
172	placebo	_	_	O
173	daily	_	_	O
174	for	_	_	O
175	24	_	_	O
176	months	_	_	O
177	.	_	_	O

178	A	_	_	B-Premise
179	scheduled	_	_	I-Premise
180	interim	_	_	I-Premise
181	analysis	_	_	I-Premise
182	revealed	_	_	I-Premise
183	no	_	_	I-Premise
184	significant	_	_	I-Premise
185	differences	_	_	I-Premise
186	in	_	_	I-Premise
187	survival	_	_	I-Premise
188	rates	_	_	I-Premise
189	,	_	_	I-Premise
190	with	_	_	I-Premise
191	the	_	_	I-Premise
192	isotretinoin	_	_	I-Premise
193	group	_	_	I-Premise
194	and	_	_	I-Premise
195	the	_	_	I-Premise
196	placebo	_	_	I-Premise
197	group	_	_	I-Premise
198	showing	_	_	I-Premise
199	5-year	_	_	I-Premise
200	disease-free	_	_	I-Premise
201	survival	_	_	I-Premise
202	rates	_	_	I-Premise
203	of	_	_	I-Premise
204	55	_	_	I-Premise
205	%	_	_	I-Premise
206	(	_	_	I-Premise
207	95	_	_	I-Premise
208	%	_	_	I-Premise
209	CI	_	_	I-Premise
210	,	_	_	I-Premise
211	46	_	_	I-Premise
212	%	_	_	I-Premise
213	to	_	_	I-Premise
214	65	_	_	I-Premise
215	%	_	_	I-Premise
216	)	_	_	I-Premise
217	and	_	_	I-Premise
218	67	_	_	I-Premise
219	%	_	_	I-Premise
220	(	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	CI	_	_	I-Premise
224	,	_	_	I-Premise
225	59	_	_	I-Premise
226	%	_	_	I-Premise
227	to	_	_	I-Premise
228	75	_	_	I-Premise
229	%	_	_	I-Premise
230	)	_	_	I-Premise
231	,	_	_	I-Premise
232	respectively	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	overall	_	_	I-Premise
236	5-year	_	_	I-Premise
237	survival	_	_	I-Premise
238	rates	_	_	I-Premise
239	of	_	_	I-Premise
240	76	_	_	I-Premise
241	%	_	_	I-Premise
242	(	_	_	I-Premise
243	95	_	_	I-Premise
244	%	_	_	I-Premise
245	CI	_	_	I-Premise
246	,	_	_	I-Premise
247	67	_	_	I-Premise
248	%	_	_	I-Premise
249	to	_	_	I-Premise
250	84	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	and	_	_	I-Premise
254	81	_	_	I-Premise
255	%	_	_	I-Premise
256	(	_	_	I-Premise
257	95	_	_	I-Premise
258	%	_	_	I-Premise
259	CI	_	_	I-Premise
260	,	_	_	I-Premise
261	74	_	_	I-Premise
262	%	_	_	I-Premise
263	to	_	_	I-Premise
264	88	_	_	I-Premise
265	%	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	respectively	_	_	I-Premise
269	.	_	_	I-Premise

270	The	_	_	O
271	trial	_	_	O
272	was	_	_	O
273	stopped	_	_	O
274	for	_	_	O
275	futility	_	_	O
276	.	_	_	O

277	The	_	_	B-Claim
278	addition	_	_	I-Claim
279	of	_	_	I-Claim
280	isotretinoin	_	_	I-Claim
281	to	_	_	I-Claim
282	an	_	_	I-Claim
283	adjuvant	_	_	I-Claim
284	treatment	_	_	I-Claim
285	of	_	_	I-Claim
286	low-dose	_	_	I-Claim
287	IFNalpha	_	_	I-Claim
288	in	_	_	I-Claim
289	patients	_	_	I-Claim
290	with	_	_	I-Claim
291	stage	_	_	I-Claim
292	IIA	_	_	I-Claim
293	and	_	_	I-Claim
294	IIB	_	_	I-Claim
295	melanoma	_	_	I-Claim
296	had	_	_	I-Claim
297	no	_	_	I-Claim
298	significant	_	_	I-Claim
299	effect	_	_	I-Claim
300	on	_	_	I-Claim
301	disease-free	_	_	I-Claim
302	or	_	_	I-Claim
303	overall	_	_	I-Claim
304	survival	_	_	I-Claim
305	and	_	_	I-Claim
306	is	_	_	I-Claim
307	therefore	_	_	I-Claim
308	not	_	_	I-Claim
309	recommended	_	_	I-Claim
310	.	_	_	I-Claim


0	The	_	_	O
1	majority	_	_	O
2	of	_	_	O
3	prostate	_	_	O
4	carcinoma	_	_	O
5	survivors	_	_	O
6	experience	_	_	O
7	enduring	_	_	O
8	sexual	_	_	O
9	difficulties	_	_	O
10	and	_	_	O
11	associated	_	_	O
12	distress	_	_	O
13	in	_	_	O
14	the	_	_	O
15	years	_	_	O
16	after	_	_	O
17	definitive	_	_	O
18	treatment	_	_	O
19	.	_	_	O

20	A	_	_	O
21	counseling	_	_	O
22	intervention	_	_	O
23	aimed	_	_	O
24	at	_	_	O
25	improving	_	_	O
26	levels	_	_	O
27	of	_	_	O
28	sexual	_	_	O
29	satisfaction	_	_	O
30	and	_	_	O
31	increasing	_	_	O
32	successful	_	_	O
33	utilization	_	_	O
34	of	_	_	O
35	medical	_	_	O
36	treatment	_	_	O
37	for	_	_	O
38	erectile	_	_	O
39	dysfunction	_	_	O
40	(	_	_	O
41	ED	_	_	O
42	)	_	_	O
43	was	_	_	O
44	developed	_	_	O
45	and	_	_	O
46	pilot-tested	_	_	O
47	for	_	_	O
48	both	_	_	O
49	the	_	_	O
50	survivor	_	_	O
51	of	_	_	O
52	prostate	_	_	O
53	carcinoma	_	_	O
54	and	_	_	O
55	his	_	_	O
56	partner	_	_	O
57	.	_	_	O

58	All	_	_	O
59	male	_	_	O
60	participants	_	_	O
61	were	_	_	O
62	3-month	_	_	O
63	to	_	_	O
64	5-year	_	_	O
65	survivors	_	_	O
66	of	_	_	O
67	localized	_	_	O
68	prostate	_	_	O
69	carcinoma	_	_	O
70	who	_	_	O
71	had	_	_	O
72	been	_	_	O
73	treated	_	_	O
74	with	_	_	O
75	radical	_	_	O
76	prostatectomy	_	_	O
77	or	_	_	O
78	radiation	_	_	O
79	therapy	_	_	O
80	,	_	_	O
81	and	_	_	O
82	were	_	_	O
83	married	_	_	O
84	or	_	_	O
85	in	_	_	O
86	a	_	_	O
87	committed	_	_	O
88	relationship	_	_	O
89	.	_	_	O

90	Couples	_	_	O
91	were	_	_	O
92	randomized	_	_	O
93	to	_	_	O
94	attend	_	_	O
95	four	_	_	O
96	sessions	_	_	O
97	of	_	_	O
98	counseling	_	_	O
99	together	_	_	O
100	or	_	_	O
101	to	_	_	O
102	have	_	_	O
103	the	_	_	O
104	man	_	_	O
105	attend	_	_	O
106	alone	_	_	O
107	.	_	_	O

108	In	_	_	O
109	both	_	_	O
110	groups	_	_	O
111	,	_	_	O
112	partners	_	_	O
113	completed	_	_	O
114	behavioral	_	_	O
115	homework	_	_	O
116	.	_	_	O

117	The	_	_	O
118	sessions	_	_	O
119	included	_	_	O
120	education	_	_	O
121	on	_	_	O
122	prostate	_	_	O
123	carcinoma	_	_	O
124	and	_	_	O
125	sexual	_	_	O
126	function	_	_	O
127	and	_	_	O
128	options	_	_	O
129	to	_	_	O
130	treat	_	_	O
131	ED	_	_	O
132	as	_	_	O
133	well	_	_	O
134	as	_	_	O
135	sexual	_	_	O
136	communication	_	_	O
137	and	_	_	O
138	stimulation	_	_	O
139	skills	_	_	O
140	.	_	_	O

141	Standardized	_	_	O
142	questionnaires	_	_	O
143	at	_	_	O
144	baseline	_	_	O
145	,	_	_	O
146	posttreatment	_	_	O
147	,	_	_	O
148	and	_	_	O
149	at	_	_	O
150	3-month	_	_	O
151	and	_	_	O
152	6-month	_	_	O
153	follow-up	_	_	O
154	assessed	_	_	O
155	sexual	_	_	O
156	function	_	_	O
157	,	_	_	O
158	marital	_	_	O
159	adjustment	_	_	O
160	,	_	_	O
161	psychologic	_	_	O
162	distress	_	_	O
163	,	_	_	O
164	and	_	_	O
165	utilization	_	_	O
166	of	_	_	O
167	treatments	_	_	O
168	for	_	_	O
169	ED	_	_	O
170	.	_	_	O

171	Fifty-one	_	_	O
172	of	_	_	O
173	84	_	_	O
174	couples	_	_	O
175	randomized	_	_	O
176	to	_	_	O
177	treatment	_	_	O
178	completed	_	_	O
179	the	_	_	O
180	intervention	_	_	O
181	(	_	_	O
182	61	_	_	O
183	%	_	_	O
184	)	_	_	O
185	.	_	_	O

186	Attendance	_	_	O
187	by	_	_	O
188	the	_	_	O
189	partner	_	_	O
190	did	_	_	O
191	not	_	_	O
192	affect	_	_	O
193	outcomes	_	_	O
194	.	_	_	O

195	Participants	_	_	B-Premise
196	completing	_	_	I-Premise
197	the	_	_	I-Premise
198	intervention	_	_	I-Premise
199	demonstrated	_	_	I-Premise
200	improvement	_	_	I-Premise
201	in	_	_	I-Premise
202	male	_	_	I-Premise
203	overall	_	_	I-Premise
204	distress	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	0.01	_	_	I-Premise
209	)	_	_	I-Premise
210	,	_	_	I-Premise
211	male	_	_	I-Premise
212	global	_	_	I-Premise
213	sexual	_	_	I-Premise
214	function	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	<	_	_	I-Premise
218	0.0001	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	and	_	_	I-Premise
222	female	_	_	I-Premise
223	global	_	_	I-Premise
224	sexual	_	_	I-Premise
225	function	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0.05	_	_	I-Premise
230	)	_	_	I-Premise
231	at	_	_	I-Premise
232	3-month	_	_	I-Premise
233	follow-up	_	_	I-Premise
234	,	_	_	I-Premise
235	but	_	_	B-Premise
236	regression	_	_	I-Premise
237	toward	_	_	I-Premise
238	baseline	_	_	I-Premise
239	was	_	_	I-Premise
240	noted	_	_	I-Premise
241	at	_	_	I-Premise
242	6-month	_	_	I-Premise
243	follow-up	_	_	I-Premise
244	.	_	_	I-Premise

245	However	_	_	B-Premise
246	,	_	_	I-Premise
247	utilization	_	_	I-Premise
248	of	_	_	I-Premise
249	ED	_	_	I-Premise
250	treatments	_	_	I-Premise
251	increased	_	_	I-Premise
252	from	_	_	I-Premise
253	31	_	_	I-Premise
254	%	_	_	I-Premise
255	at	_	_	I-Premise
256	the	_	_	I-Premise
257	time	_	_	I-Premise
258	of	_	_	I-Premise
259	study	_	_	I-Premise
260	entry	_	_	I-Premise
261	to	_	_	I-Premise
262	49	_	_	I-Premise
263	%	_	_	I-Premise
264	at	_	_	I-Premise
265	the	_	_	I-Premise
266	6-month	_	_	I-Premise
267	follow-up	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	0.003	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	B-Claim
275	results	_	_	I-Claim
276	of	_	_	I-Claim
277	this	_	_	I-Claim
278	brief	_	_	I-Claim
279	pilot	_	_	I-Claim
280	counseling	_	_	I-Claim
281	intervention	_	_	I-Claim
282	demonstrated	_	_	I-Claim
283	significant	_	_	I-Claim
284	gains	_	_	I-Claim
285	in	_	_	I-Claim
286	sexual	_	_	I-Claim
287	function	_	_	I-Claim
288	and	_	_	I-Claim
289	satisfaction	_	_	I-Claim
290	and	_	_	I-Claim
291	increased	_	_	I-Claim
292	utilization	_	_	I-Claim
293	of	_	_	I-Claim
294	treatments	_	_	I-Claim
295	for	_	_	I-Claim
296	ED	_	_	I-Claim
297	.	_	_	I-Claim

298	However	_	_	B-Claim
299	,	_	_	I-Claim
300	modifications	_	_	I-Claim
301	are	_	_	I-Claim
302	needed	_	_	I-Claim
303	in	_	_	I-Claim
304	future	_	_	I-Claim
305	randomized	_	_	I-Claim
306	trials	_	_	I-Claim
307	to	_	_	I-Claim
308	reduce	_	_	I-Claim
309	the	_	_	I-Claim
310	rate	_	_	I-Claim
311	of	_	_	I-Claim
312	premature	_	_	I-Claim
313	termination	_	_	I-Claim
314	and	_	_	I-Claim
315	to	_	_	I-Claim
316	improve	_	_	I-Claim
317	long-term	_	_	I-Claim
318	maintenance	_	_	I-Claim
319	of	_	_	I-Claim
320	gains	_	_	I-Claim
321	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcomes	_	_	O
4	of	_	_	O
5	uterine	_	_	O
6	artery	_	_	O
7	embolization	_	_	O
8	(	_	_	O
9	UAE	_	_	O
10	)	_	_	O
11	for	_	_	O
12	leiomyomas	_	_	O
13	with	_	_	O
14	use	_	_	O
15	of	_	_	O
16	tris-acryl	_	_	O
17	gelatin	_	_	O
18	microspheres	_	_	O
19	(	_	_	O
20	TAGM	_	_	O
21	)	_	_	O
22	versus	_	_	O
23	spherical	_	_	O
24	polyvinyl	_	_	O
25	alcohol	_	_	O
26	(	_	_	O
27	PVA	_	_	O
28	)	_	_	O
29	particles	_	_	O
30	.	_	_	O

31	Patients	_	_	O
32	undergoing	_	_	O
33	UAE	_	_	O
34	were	_	_	O
35	randomly	_	_	O
36	assigned	_	_	O
37	to	_	_	O
38	receive	_	_	O
39	TAGMs	_	_	O
40	or	_	_	O
41	PVA	_	_	O
42	.	_	_	O

43	Embolization	_	_	O
44	was	_	_	O
45	performed	_	_	O
46	in	_	_	O
47	a	_	_	O
48	standardized	_	_	O
49	manner	_	_	O
50	.	_	_	O

51	Outcome	_	_	O
52	data	_	_	O
53	were	_	_	O
54	collected	_	_	O
55	at	_	_	O
56	3	_	_	O
57	months	_	_	O
58	after	_	_	O
59	embolization	_	_	O
60	,	_	_	O
61	including	_	_	O
62	assessment	_	_	O
63	of	_	_	O
64	clinical	_	_	O
65	symptoms	_	_	O
66	,	_	_	O
67	scores	_	_	O
68	from	_	_	O
69	a	_	_	O
70	fibroid	_	_	O
71	tumor-specific	_	_	O
72	symptom	_	_	O
73	and	_	_	O
74	quality	_	_	O
75	of	_	_	O
76	life	_	_	O
77	(	_	_	O
78	QOL	_	_	O
79	)	_	_	O
80	questionnaire	_	_	O
81	,	_	_	O
82	and	_	_	O
83	findings	_	_	O
84	on	_	_	O
85	contrast	_	_	O
86	material-enhanced	_	_	O
87	magnetic	_	_	O
88	resonance	_	_	O
89	(	_	_	O
90	MR	_	_	O
91	)	_	_	O
92	imaging	_	_	O
93	,	_	_	O
94	including	_	_	O
95	the	_	_	O
96	degree	_	_	O
97	of	_	_	O
98	tumor	_	_	O
99	infarction	_	_	O
100	and	_	_	O
101	volume	_	_	O
102	reduction	_	_	O
103	.	_	_	O

104	Data	_	_	O
105	were	_	_	O
106	analyzed	_	_	O
107	with	_	_	O
108	use	_	_	O
109	of	_	_	O
110	t	_	_	O
111	tests	_	_	O
112	,	_	_	O
113	the	_	_	O
114	Mann-Whitney	_	_	O
115	U	_	_	O
116	test	_	_	O
117	,	_	_	O
118	and	_	_	O
119	chi2	_	_	O
120	tests	_	_	O
121	as	_	_	O
122	appropriate	_	_	O
123	.	_	_	O

124	Thirty-six	_	_	O
125	patients	_	_	O
126	were	_	_	O
127	treated	_	_	O
128	.	_	_	O

129	There	_	_	O
130	were	_	_	O
131	no	_	_	O
132	differences	_	_	O
133	in	_	_	O
134	the	_	_	O
135	two	_	_	O
136	treatment	_	_	O
137	groups	_	_	O
138	at	_	_	O
139	baseline	_	_	O
140	.	_	_	O

141	Clinical	_	_	O
142	follow-up	_	_	O
143	was	_	_	O
144	obtained	_	_	O
145	in	_	_	O
146	35	_	_	O
147	patients	_	_	O
148	.	_	_	O

149	Among	_	_	B-Premise
150	the	_	_	I-Premise
151	clinical	_	_	I-Premise
152	outcome	_	_	I-Premise
153	measures	_	_	I-Premise
154	,	_	_	I-Premise
155	QOL	_	_	I-Premise
156	score	_	_	I-Premise
157	improvement	_	_	I-Premise
158	was	_	_	I-Premise
159	greater	_	_	I-Premise
160	for	_	_	I-Premise
161	UAE	_	_	I-Premise
162	with	_	_	I-Premise
163	TAGMs	_	_	I-Premise
164	compared	_	_	I-Premise
165	with	_	_	I-Premise
166	PVA	_	_	I-Premise
167	(	_	_	I-Premise
168	49.0	_	_	I-Premise
169	vs	_	_	I-Premise
170	27.9	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.02	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	but	_	_	B-Premise
178	no	_	_	I-Premise
179	other	_	_	I-Premise
180	differences	_	_	I-Premise
181	were	_	_	I-Premise
182	noted	_	_	I-Premise
183	.	_	_	I-Premise

184	Of	_	_	B-Premise
185	the	_	_	I-Premise
186	25	_	_	I-Premise
187	patients	_	_	I-Premise
188	in	_	_	I-Premise
189	whom	_	_	I-Premise
190	3-month	_	_	I-Premise
191	MR	_	_	I-Premise
192	imaging	_	_	I-Premise
193	follow-up	_	_	I-Premise
194	was	_	_	I-Premise
195	completed	_	_	I-Premise
196	,	_	_	I-Premise
197	those	_	_	I-Premise
198	treated	_	_	I-Premise
199	with	_	_	I-Premise
200	TAGM	_	_	I-Premise
201	were	_	_	I-Premise
202	significantly	_	_	I-Premise
203	more	_	_	I-Premise
204	likely	_	_	I-Premise
205	to	_	_	I-Premise
206	have	_	_	I-Premise
207	complete	_	_	I-Premise
208	infarction	_	_	I-Premise
209	of	_	_	I-Premise
210	all	_	_	I-Premise
211	leiomyomas	_	_	I-Premise
212	(	_	_	I-Premise
213	six	_	_	I-Premise
214	patients	_	_	I-Premise
215	vs	_	_	I-Premise
216	one	_	_	I-Premise
217	patient	_	_	I-Premise
218	;	_	_	I-Premise
219	P	_	_	I-Premise
220	=	_	_	I-Premise
221	.02	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	were	_	_	I-Premise
225	more	_	_	I-Premise
226	likely	_	_	I-Premise
227	to	_	_	I-Premise
228	have	_	_	I-Premise
229	at	_	_	I-Premise
230	least	_	_	I-Premise
231	90	_	_	I-Premise
232	%	_	_	I-Premise
233	tumor	_	_	I-Premise
234	infarction	_	_	I-Premise
235	(	_	_	I-Premise
236	eight	_	_	I-Premise
237	patients	_	_	I-Premise
238	vs	_	_	I-Premise
239	four	_	_	I-Premise
240	patients	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.03	_	_	I-Premise
245	)	_	_	I-Premise
246	,	_	_	I-Premise
247	and	_	_	I-Premise
248	had	_	_	I-Premise
249	a	_	_	I-Premise
250	lower	_	_	I-Premise
251	mean	_	_	I-Premise
252	percent	_	_	I-Premise
253	of	_	_	I-Premise
254	residual	_	_	I-Premise
255	perfused	_	_	I-Premise
256	fibroid	_	_	I-Premise
257	tumor	_	_	I-Premise
258	tissue	_	_	I-Premise
259	(	_	_	I-Premise
260	9.6	_	_	I-Premise
261	%	_	_	I-Premise
262	vs	_	_	I-Premise
263	44.3	_	_	I-Premise
264	%	_	_	I-Premise
265	;	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	.004	_	_	I-Premise
269	)	_	_	I-Premise
270	compared	_	_	I-Premise
271	with	_	_	I-Premise
272	patients	_	_	I-Premise
273	treated	_	_	I-Premise
274	with	_	_	I-Premise
275	PVA	_	_	I-Premise
276	.	_	_	I-Premise

277	Based	_	_	O
278	on	_	_	O
279	these	_	_	O
280	differences	_	_	O
281	between	_	_	O
282	the	_	_	O
283	embolic	_	_	O
284	agents	_	_	O
285	,	_	_	O
286	enrollment	_	_	O
287	in	_	_	O
288	this	_	_	O
289	study	_	_	O
290	was	_	_	O
291	terminated	_	_	O
292	.	_	_	O

293	The	_	_	B-Claim
294	use	_	_	I-Claim
295	of	_	_	I-Claim
296	spherical	_	_	I-Claim
297	PVA	_	_	I-Claim
298	particles	_	_	I-Claim
299	in	_	_	I-Claim
300	the	_	_	I-Claim
301	manner	_	_	I-Claim
302	described	_	_	I-Claim
303	herein	_	_	I-Claim
304	results	_	_	I-Claim
305	in	_	_	I-Claim
306	an	_	_	I-Claim
307	unacceptably	_	_	I-Claim
308	high	_	_	I-Claim
309	rate	_	_	I-Claim
310	of	_	_	I-Claim
311	failed	_	_	I-Claim
312	tumor	_	_	I-Claim
313	infarction	_	_	I-Claim
314	in	_	_	I-Claim
315	UAE	_	_	I-Claim
316	.	_	_	I-Claim


0	A	_	_	O
1	randomised	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	of	_	_	O
5	radiotherapy	_	_	O
6	alone	_	_	O
7	versus	_	_	O
8	radiotherapy	_	_	O
9	with	_	_	O
10	concomitant	_	_	O
11	and	_	_	O
12	adjuvant	_	_	O
13	temozolomide	_	_	O
14	for	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	glioblastoma	_	_	O
18	showed	_	_	O
19	that	_	_	O
20	survival	_	_	O
21	was	_	_	O
22	higher	_	_	O
23	for	_	_	O
24	patients	_	_	O
25	assigned	_	_	O
26	combination	_	_	O
27	treatment	_	_	O
28	compared	_	_	O
29	with	_	_	O
30	those	_	_	O
31	assigned	_	_	O
32	standard	_	_	O
33	radiotherapy	_	_	O
34	alone	_	_	O
35	.	_	_	O

36	This	_	_	O
37	paper	_	_	O
38	reports	_	_	O
39	the	_	_	O
40	health-related	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	(	_	_	O
45	HRQOL	_	_	O
46	)	_	_	O
47	of	_	_	O
48	the	_	_	O
49	patients	_	_	O
50	in	_	_	O
51	this	_	_	O
52	trial	_	_	O
53	.	_	_	O

54	573	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	newly	_	_	O
58	diagnosed	_	_	O
59	glioblastoma	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	allocated	_	_	O
63	either	_	_	O
64	radiotherapy	_	_	O
65	alone	_	_	O
66	or	_	_	O
67	radiotherapy	_	_	O
68	and	_	_	O
69	temozolomide	_	_	O
70	.	_	_	O

71	The	_	_	O
72	primary	_	_	O
73	endpoint	_	_	O
74	was	_	_	O
75	survival	_	_	O
76	,	_	_	O
77	and	_	_	O
78	HRQOL	_	_	O
79	was	_	_	O
80	a	_	_	O
81	secondary	_	_	O
82	endpoint	_	_	O
83	.	_	_	O

84	We	_	_	O
85	assessed	_	_	O
86	HRQOL	_	_	O
87	at	_	_	O
88	baseline	_	_	O
89	and	_	_	O
90	at	_	_	O
91	every	_	_	O
92	3	_	_	O
93	months	_	_	O
94	during	_	_	O
95	treatment	_	_	O
96	until	_	_	O
97	progression	_	_	O
98	using	_	_	O
99	the	_	_	O
100	European	_	_	O
101	Organisation	_	_	O
102	for	_	_	O
103	Research	_	_	O
104	and	_	_	O
105	Treatment	_	_	O
106	of	_	_	O
107	Cancer	_	_	O
108	(	_	_	O
109	EORTC	_	_	O
110	)	_	_	O
111	quality	_	_	O
112	of	_	_	O
113	life	_	_	O
114	questionnaire	_	_	O
115	core-30	_	_	O
116	(	_	_	O
117	QLQ-C30	_	_	O
118	)	_	_	O
119	and	_	_	O
120	the	_	_	O
121	EORTC	_	_	O
122	brain	_	_	O
123	cancer	_	_	O
124	module	_	_	O
125	(	_	_	O
126	EORTC	_	_	O
127	BN-20	_	_	O
128	)	_	_	O
129	.	_	_	O

130	We	_	_	O
131	calculated	_	_	O
132	changes	_	_	O
133	from	_	_	O
134	baseline	_	_	O
135	score	_	_	O
136	for	_	_	O
137	seven	_	_	O
138	predefined	_	_	O
139	HRQOL	_	_	O
140	measures	_	_	O
141	(	_	_	O
142	fatigue	_	_	O
143	,	_	_	O
144	overall	_	_	O
145	health	_	_	O
146	,	_	_	O
147	social	_	_	O
148	function	_	_	O
149	,	_	_	O
150	emotional	_	_	O
151	function	_	_	O
152	,	_	_	O
153	future	_	_	O
154	uncertainty	_	_	O
155	,	_	_	O
156	insomnia	_	_	O
157	,	_	_	O
158	and	_	_	O
159	communication	_	_	O
160	deficit	_	_	O
161	)	_	_	O
162	and	_	_	O
163	differences	_	_	O
164	between	_	_	O
165	groups	_	_	O
166	for	_	_	O
167	these	_	_	O
168	measures	_	_	O
169	at	_	_	O
170	every	_	_	O
171	time	_	_	O
172	point	_	_	O
173	.	_	_	O

174	The	_	_	O
175	significance	_	_	O
176	of	_	_	O
177	,	_	_	O
178	and	_	_	O
179	proportions	_	_	O
180	of	_	_	O
181	patients	_	_	O
182	with	_	_	O
183	,	_	_	O
184	improved	_	_	O
185	HRQOL	_	_	O
186	scores	_	_	O
187	--	_	_	O
188	defined	_	_	O
189	as	_	_	O
190	a	_	_	O
191	change	_	_	O
192	of	_	_	O
193	10	_	_	O
194	points	_	_	O
195	or	_	_	O
196	more	_	_	O
197	--	_	_	O
198	were	_	_	O
199	recorded	_	_	O
200	.	_	_	O

201	Baseline	_	_	O
202	questionnaires	_	_	O
203	were	_	_	O
204	available	_	_	O
205	for	_	_	O
206	490	_	_	O
207	(	_	_	O
208	86	_	_	O
209	%	_	_	O
210	)	_	_	O
211	patients	_	_	O
212	.	_	_	O

213	Baseline	_	_	O
214	HRQOL	_	_	O
215	scores	_	_	O
216	did	_	_	O
217	not	_	_	O
218	differ	_	_	O
219	between	_	_	O
220	groups	_	_	O
221	.	_	_	O

222	At	_	_	B-Premise
223	first	_	_	I-Premise
224	follow-up	_	_	I-Premise
225	,	_	_	I-Premise
226	groups	_	_	I-Premise
227	differed	_	_	I-Premise
228	only	_	_	I-Premise
229	in	_	_	I-Premise
230	social	_	_	I-Premise
231	functioning	_	_	I-Premise
232	,	_	_	I-Premise
233	favouring	_	_	I-Premise
234	the	_	_	I-Premise
235	radiotherapy-only	_	_	I-Premise
236	group	_	_	I-Premise
237	(	_	_	I-Premise
238	mean	_	_	I-Premise
239	score	_	_	I-Premise
240	79.0	_	_	I-Premise
241	[	_	_	I-Premise
242	SD	_	_	I-Premise
243	3.2	_	_	I-Premise
244	]	_	_	I-Premise
245	for	_	_	I-Premise
246	patients	_	_	I-Premise
247	assigned	_	_	I-Premise
248	radiotherapy	_	_	I-Premise
249	vs	_	_	I-Premise
250	67.4	_	_	I-Premise
251	[	_	_	I-Premise
252	2.7	_	_	I-Premise
253	]	_	_	I-Premise
254	for	_	_	I-Premise
255	those	_	_	I-Premise
256	assigned	_	_	I-Premise
257	radiotherapy	_	_	I-Premise
258	and	_	_	I-Premise
259	temozolomide	_	_	I-Premise
260	;	_	_	I-Premise
261	difference	_	_	I-Premise
262	between	_	_	I-Premise
263	groups	_	_	I-Premise
264	11.6	_	_	I-Premise
265	points	_	_	I-Premise
266	[	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	3.5-19.7	_	_	I-Premise
271	]	_	_	I-Premise
272	,	_	_	I-Premise
273	p=0.0052	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Over	_	_	B-Premise
277	subsequent	_	_	I-Premise
278	assessments	_	_	I-Premise
279	,	_	_	I-Premise
280	HRQOL	_	_	I-Premise
281	was	_	_	I-Premise
282	much	_	_	I-Premise
283	the	_	_	I-Premise
284	same	_	_	I-Premise
285	between	_	_	I-Premise
286	treatment	_	_	I-Premise
287	groups	_	_	I-Premise
288	.	_	_	I-Premise

289	Addition	_	_	B-Claim
290	of	_	_	I-Claim
291	temozolomide	_	_	I-Claim
292	during	_	_	I-Claim
293	and	_	_	I-Claim
294	after	_	_	I-Claim
295	radiotherapy	_	_	I-Claim
296	for	_	_	I-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	newly	_	_	I-Claim
300	diagnosed	_	_	I-Claim
301	glioblastoma	_	_	I-Claim
302	significantly	_	_	I-Claim
303	improved	_	_	I-Claim
304	survival	_	_	I-Claim
305	without	_	_	I-Claim
306	a	_	_	I-Claim
307	negative	_	_	I-Claim
308	effect	_	_	I-Claim
309	on	_	_	I-Claim
310	HRQOL	_	_	I-Claim
311	.	_	_	I-Claim


0	After	_	_	O
1	surgery	_	_	O
2	for	_	_	O
3	differentiated	_	_	O
4	thyroid	_	_	O
5	carcinoma	_	_	O
6	,	_	_	O
7	many	_	_	O
8	patients	_	_	O
9	are	_	_	O
10	treated	_	_	O
11	with	_	_	O
12	radioiodine	_	_	O
13	to	_	_	O
14	ablate	_	_	O
15	remnant	_	_	O
16	thyroid	_	_	O
17	tissue	_	_	O
18	.	_	_	O

19	This	_	_	B-Claim
20	procedure	_	_	I-Claim
21	has	_	_	I-Claim
22	been	_	_	I-Claim
23	performed	_	_	I-Claim
24	with	_	_	I-Claim
25	the	_	_	I-Claim
26	patient	_	_	I-Claim
27	in	_	_	I-Claim
28	the	_	_	I-Claim
29	hypothyroid	_	_	I-Claim
30	state	_	_	I-Claim
31	to	_	_	I-Claim
32	promote	_	_	I-Claim
33	endogenous	_	_	I-Claim
34	TSH	_	_	I-Claim
35	stimulation	_	_	I-Claim
36	and	_	_	I-Claim
37	is	_	_	I-Claim
38	often	_	_	I-Claim
39	associated	_	_	I-Claim
40	with	_	_	I-Claim
41	hypothyroid	_	_	I-Claim
42	symptoms	_	_	I-Claim
43	and	_	_	I-Claim
44	impaired	_	_	I-Claim
45	quality	_	_	I-Claim
46	of	_	_	I-Claim
47	life	_	_	I-Claim
48	.	_	_	I-Claim

49	This	_	_	O
50	international	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	,	_	_	O
54	controlled	_	_	O
55	,	_	_	O
56	multicenter	_	_	O
57	trial	_	_	O
58	aimed	_	_	O
59	to	_	_	O
60	compare	_	_	O
61	the	_	_	O
62	efficacy	_	_	O
63	and	_	_	O
64	safety	_	_	O
65	of	_	_	O
66	recombinant	_	_	O
67	human	_	_	O
68	TSH	_	_	O
69	(	_	_	O
70	rhTSH	_	_	O
71	)	_	_	O
72	to	_	_	O
73	prepare	_	_	O
74	euthyroid	_	_	O
75	patients	_	_	O
76	on	_	_	O
77	L-thyroxine	_	_	O
78	therapy	_	_	O
79	(	_	_	O
80	euthyroid	_	_	O
81	group	_	_	O
82	)	_	_	O
83	to	_	_	O
84	ablate	_	_	O
85	remnant	_	_	O
86	thyroid	_	_	O
87	tissue	_	_	O
88	with	_	_	O
89	3.7	_	_	O
90	GBq	_	_	O
91	(	_	_	O
92	100	_	_	O
93	mCi	_	_	O
94	)	_	_	O
95	131I	_	_	O
96	,	_	_	O
97	compared	_	_	O
98	with	_	_	O
99	that	_	_	O
100	with	_	_	O
101	conventional	_	_	O
102	remnant	_	_	O
103	ablation	_	_	O
104	performed	_	_	O
105	in	_	_	O
106	the	_	_	O
107	hypothyroid	_	_	O
108	state	_	_	O
109	(	_	_	O
110	hypothyroid	_	_	O
111	group	_	_	O
112	)	_	_	O
113	.	_	_	O

114	Quality	_	_	O
115	of	_	_	O
116	life	_	_	O
117	was	_	_	O
118	determined	_	_	O
119	at	_	_	O
120	the	_	_	O
121	time	_	_	O
122	of	_	_	O
123	randomization	_	_	O
124	and	_	_	O
125	ablation	_	_	O
126	.	_	_	O

127	After	_	_	O
128	the	_	_	O
129	administration	_	_	O
130	of	_	_	O
131	the	_	_	O
132	131-I	_	_	O
133	dose	_	_	O
134	,	_	_	O
135	the	_	_	O
136	rate	_	_	O
137	of	_	_	O
138	radiation	_	_	O
139	clearance	_	_	O
140	from	_	_	O
141	blood	_	_	O
142	,	_	_	O
143	thyroid	_	_	O
144	remnant	_	_	O
145	,	_	_	O
146	and	_	_	O
147	whole	_	_	O
148	body	_	_	O
149	was	_	_	O
150	measured	_	_	O
151	.	_	_	O

152	The	_	_	O
153	predefined	_	_	O
154	primary	_	_	O
155	criterion	_	_	O
156	for	_	_	O
157	successful	_	_	O
158	ablation	_	_	O
159	was	_	_	O
160	no	_	_	O
161	visible	_	_	O
162	uptake	_	_	O
163	in	_	_	O
164	the	_	_	O
165	thyroid	_	_	O
166	bed	_	_	O
167	,	_	_	O
168	or	_	_	O
169	if	_	_	O
170	visible	_	_	O
171	,	_	_	O
172	fractional	_	_	O
173	uptake	_	_	O
174	less	_	_	O
175	than	_	_	O
176	0.1	_	_	O
177	%	_	_	O
178	on	_	_	I-Claim
179	neck	_	_	O
180	scans	_	_	O
181	performed	_	_	O
182	8	_	_	O
183	months	_	_	O
184	after	_	_	O
185	therapy	_	_	O
186	and	_	_	O
187	was	_	_	O
188	satisfied	_	_	O
189	in	_	_	O
190	100	_	_	O
191	%	_	_	O
192	of	_	_	O
193	patients	_	_	O
194	in	_	_	O
195	both	_	_	O
196	groups	_	_	O
197	.	_	_	O

198	A	_	_	O
199	secondary	_	_	O
200	criterion	_	_	O
201	for	_	_	O
202	ablation	_	_	O
203	,	_	_	O
204	an	_	_	O
205	rhTSH-stimulated	_	_	O
206	serum	_	_	O
207	thyroglobulin	_	_	O
208	concentration	_	_	O
209	less	_	_	O
210	than	_	_	O
211	2	_	_	O
212	ng/ml	_	_	O
213	,	_	_	O
214	was	_	_	O
215	fulfilled	_	_	O
216	by	_	_	O
217	23	_	_	O
218	of	_	_	O
219	24	_	_	O
220	(	_	_	O
221	96	_	_	O
222	%	_	_	O
223	)	_	_	O
224	euthyroid	_	_	O
225	patients	_	_	O
226	and	_	_	O
227	18	_	_	O
228	of	_	_	O
229	21	_	_	O
230	(	_	_	O
231	86	_	_	O
232	%	_	_	O
233	)	_	_	O
234	hypothyroid	_	_	O
235	patients	_	_	O
236	(	_	_	O
237	P	_	_	O
238	=	_	_	O
239	0.2341	_	_	O
240	)	_	_	O
241	.	_	_	O

242	Quality	_	_	B-Premise
243	of	_	_	I-Premise
244	life	_	_	I-Premise
245	was	_	_	I-Premise
246	well	_	_	I-Premise
247	preserved	_	_	I-Premise
248	in	_	_	I-Premise
249	the	_	_	I-Premise
250	euthyroid	_	_	I-Premise
251	group	_	_	I-Premise
252	,	_	_	I-Premise
253	compared	_	_	I-Premise
254	with	_	_	I-Premise
255	the	_	_	I-Premise
256	hypothyroid	_	_	I-Premise
257	group	_	_	I-Premise
258	,	_	_	I-Premise
259	as	_	_	I-Premise
260	demonstrated	_	_	I-Premise
261	by	_	_	I-Premise
262	their	_	_	I-Premise
263	lower	_	_	I-Premise
264	pretreatment	_	_	I-Premise
265	scores	_	_	I-Premise
266	on	_	_	I-Premise
267	the	_	_	I-Premise
268	Billewicz	_	_	I-Premise
269	scale	_	_	I-Premise
270	for	_	_	I-Premise
271	hypothyroid	_	_	I-Premise
272	signs	_	_	I-Premise
273	and	_	_	I-Premise
274	symptoms	_	_	I-Premise
275	,	_	_	I-Premise
276	27	_	_	I-Premise
277	+/-	_	_	I-Premise
278	7	_	_	I-Premise
279	vs.	_	_	I-Premise
280	18	_	_	I-Premise
281	+/-	_	_	I-Premise
282	4	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	<	_	_	I-Premise
286	0.0001	_	_	I-Premise
287	)	_	_	I-Premise
288	and	_	_	I-Premise
289	their	_	_	I-Premise
290	significantly	_	_	I-Premise
291	higher	_	_	I-Premise
292	Short	_	_	I-Premise
293	Form-36	_	_	I-Premise
294	Health	_	_	I-Premise
295	Assessment	_	_	I-Premise
296	Scale	_	_	I-Premise
297	scores	_	_	I-Premise
298	in	_	_	I-Premise
299	five	_	_	I-Premise
300	of	_	_	I-Premise
301	eight	_	_	I-Premise
302	categories	_	_	I-Premise
303	.	_	_	I-Premise

304	Euthyroid	_	_	B-Premise
305	patients	_	_	I-Premise
306	had	_	_	I-Premise
307	a	_	_	I-Premise
308	statistically	_	_	I-Premise
309	significant	_	_	I-Premise
310	one	_	_	I-Premise
311	third	_	_	I-Premise
312	lower	_	_	I-Premise
313	radiation	_	_	I-Premise
314	dose	_	_	I-Premise
315	to	_	_	I-Premise
316	the	_	_	I-Premise
317	blood	_	_	I-Premise
318	,	_	_	I-Premise
319	compared	_	_	I-Premise
320	with	_	_	I-Premise
321	patients	_	_	I-Premise
322	in	_	_	I-Premise
323	the	_	_	I-Premise
324	hypothyroid	_	_	I-Premise
325	group	_	_	I-Premise
326	.	_	_	I-Premise

327	This	_	_	B-Claim
328	study	_	_	I-Claim
329	demonstrates	_	_	I-Claim
330	comparable	_	_	I-Claim
331	remnant	_	_	I-Claim
332	ablation	_	_	I-Claim
333	rates	_	_	I-Claim
334	in	_	_	I-Claim
335	patients	_	_	I-Claim
336	prepared	_	_	I-Claim
337	for	_	_	I-Claim
338	131I	_	_	I-Claim
339	remnant	_	_	I-Claim
340	ablation	_	_	I-Claim
341	with	_	_	I-Claim
342	3.7	_	_	I-Claim
343	GBq	_	_	I-Claim
344	by	_	_	I-Claim
345	either	_	_	I-Claim
346	administering	_	_	I-Claim
347	rhTSH	_	_	I-Claim
348	or	_	_	I-Claim
349	withholding	_	_	I-Claim
350	thyroid	_	_	I-Claim
351	hormone	_	_	I-Claim
352	.	_	_	I-Claim

353	rhTSH-prepared	_	_	B-Claim
354	patients	_	_	I-Claim
355	maintained	_	_	I-Claim
356	a	_	_	I-Claim
357	higher	_	_	I-Claim
358	quality	_	_	I-Claim
359	of	_	_	I-Claim
360	life	_	_	I-Claim
361	and	_	_	I-Claim
362	received	_	_	I-Claim
363	less	_	_	I-Claim
364	radiation	_	_	I-Claim
365	exposure	_	_	I-Claim
366	to	_	_	I-Claim
367	the	_	_	I-Claim
368	blood	_	_	I-Claim
369	.	_	_	I-Claim


0	Patients	_	_	O
1	with	_	_	O
2	cancer	_	_	O
3	are	_	_	O
4	characterized	_	_	O
5	by	_	_	O
6	a	_	_	O
7	profound	_	_	O
8	impairment	_	_	O
9	of	_	_	O
10	glucose	_	_	O
11	utilization	_	_	O
12	,	_	_	O
13	with	_	_	O
14	lipids	_	_	O
15	being	_	_	O
16	the	_	_	O
17	preferred	_	_	O
18	metabolic	_	_	O
19	fuel	_	_	O
20	.	_	_	O

21	In	_	_	O
22	contrast	_	_	O
23	,	_	_	O
24	the	_	_	O
25	energy	_	_	O
26	needs	_	_	O
27	of	_	_	O
28	malignant	_	_	O
29	tumors	_	_	O
30	are	_	_	O
31	almost	_	_	O
32	entirely	_	_	O
33	met	_	_	O
34	by	_	_	O
35	glucose	_	_	O
36	.	_	_	O

37	We	_	_	O
38	therefore	_	_	O
39	studied	_	_	O
40	the	_	_	O
41	effects	_	_	O
42	of	_	_	O
43	a	_	_	O
44	high-fat	_	_	O
45	diet	_	_	O
46	,	_	_	O
47	particularly	_	_	O
48	on	_	_	O
49	body	_	_	O
50	composition	_	_	O
51	.	_	_	O

52	Twenty-three	_	_	O
53	moderately	_	_	O
54	malnourished	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	gastrointestinal	_	_	O
58	carcinomas	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	receive	_	_	O
63	either	_	_	O
64	a	_	_	O
65	conventional	_	_	O
66	diet	_	_	O
67	supplying	_	_	O
68	35	_	_	O
69	nonprotein	_	_	O
70	kcal	_	_	O
71	and	_	_	O
72	1.1	_	_	O
73	g	_	_	O
74	of	_	_	O
75	protein/kg	_	_	O
76	per	_	_	O
77	day	_	_	O
78	(	_	_	O
79	group	_	_	O
80	A	_	_	O
81	,	_	_	O
82	n	_	_	O
83	=	_	_	O
84	11	_	_	O
85	)	_	_	O
86	or	_	_	O
87	a	_	_	O
88	fat-enriched	_	_	O
89	artificial	_	_	O
90	liquid	_	_	O
91	diet	_	_	O
92	(	_	_	O
93	20	_	_	O
94	nonprotein	_	_	O
95	kcal/kg	_	_	O
96	per	_	_	O
97	day	_	_	O
98	)	_	_	O
99	plus	_	_	O
100	normal	_	_	O
101	meals	_	_	O
102	(	_	_	O
103	group	_	_	O
104	B	_	_	O
105	,	_	_	O
106	n	_	_	O
107	=	_	_	O
108	12	_	_	O
109	)	_	_	O
110	for	_	_	O
111	a	_	_	O
112	period	_	_	O
113	of	_	_	O
114	eight	_	_	O
115	weeks	_	_	O
116	,	_	_	O
117	i.e.	_	_	O
118	,	_	_	O
119	from	_	_	O
120	the	_	_	O
121	first	_	_	O
122	to	_	_	O
123	the	_	_	O
124	third	_	_	O
125	chemotherapy	_	_	O
126	cycle	_	_	O
127	.	_	_	O

128	The	_	_	O
129	fat	_	_	O
130	content	_	_	O
131	of	_	_	O
132	the	_	_	O
133	artificial	_	_	O
134	diet	_	_	O
135	was	_	_	O
136	66	_	_	O
137	%	_	_	O
138	of	_	_	O
139	the	_	_	O
140	nonprotein	_	_	O
141	calories	_	_	O
142	.	_	_	O

143	The	_	_	O
144	day	_	_	O
145	before	_	_	O
146	the	_	_	O
147	nutritional	_	_	O
148	interventions	_	_	O
149	,	_	_	O
150	and	_	_	O
151	again	_	_	O
152	after	_	_	O
153	four	_	_	O
154	and	_	_	O
155	eight	_	_	O
156	weeks	_	_	O
157	,	_	_	O
158	body	_	_	O
159	compartments	_	_	O
160	were	_	_	O
161	determined	_	_	O
162	using	_	_	O
163	bioelectrical	_	_	O
164	impedance	_	_	O
165	analysis	_	_	O
166	,	_	_	O
167	lymphocyte	_	_	O
168	subpopulations	_	_	O
169	were	_	_	O
170	quantified	_	_	O
171	using	_	_	O
172	flow	_	_	O
173	cytometry	_	_	O
174	,	_	_	O
175	and	_	_	O
176	some	_	_	O
177	aspects	_	_	O
178	of	_	_	O
179	the	_	_	O
180	quality	_	_	O
181	of	_	_	O
182	life	_	_	O
183	were	_	_	O
184	rated	_	_	O
185	using	_	_	O
186	four	_	_	O
187	linear	_	_	O
188	analog	_	_	O
189	self-assessment	_	_	O
190	(	_	_	O
191	LASA	_	_	O
192	)	_	_	O
193	scales	_	_	O
194	.	_	_	O

195	The	_	_	O
196	statistical	_	_	O
197	calculations	_	_	O
198	were	_	_	O
199	done	_	_	O
200	as	_	_	O
201	an	_	_	O
202	exploratory	_	_	O
203	data	_	_	O
204	analysis	_	_	O
205	.	_	_	O

206	The	_	_	O
207	consumption	_	_	O
208	of	_	_	O
209	non-protein	_	_	O
210	calories	_	_	O
211	did	_	_	O
212	not	_	_	O
213	differ	_	_	O
214	significantly	_	_	O
215	between	_	_	O
216	the	_	_	O
217	two	_	_	O
218	patient	_	_	O
219	groups	_	_	O
220	.	_	_	O

221	An	_	_	B-Premise
222	average	_	_	I-Premise
223	weight	_	_	I-Premise
224	gain	_	_	I-Premise
225	in	_	_	I-Premise
226	group	_	_	I-Premise
227	B	_	_	I-Premise
228	contrasted	_	_	I-Premise
229	with	_	_	I-Premise
230	an	_	_	I-Premise
231	average	_	_	I-Premise
232	weight	_	_	I-Premise
233	loss	_	_	I-Premise
234	in	_	_	I-Premise
235	group	_	_	I-Premise
236	A	_	_	I-Premise
237	after	_	_	I-Premise
238	four	_	_	I-Premise
239	(	_	_	I-Premise
240	P	_	_	I-Premise
241	<	_	_	I-Premise
242	0.01	_	_	I-Premise
243	)	_	_	I-Premise
244	and	_	_	I-Premise
245	eight	_	_	I-Premise
246	weeks	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	<	_	_	I-Premise
250	0.05	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	Fat-free	_	_	B-Premise
254	mass	_	_	I-Premise
255	showed	_	_	I-Premise
256	an	_	_	I-Premise
257	intergroup	_	_	I-Premise
258	difference	_	_	I-Premise
259	in	_	_	I-Premise
260	favor	_	_	I-Premise
261	of	_	_	I-Premise
262	group	_	_	I-Premise
263	B	_	_	I-Premise
264	after	_	_	I-Premise
265	eight	_	_	I-Premise
266	weeks	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	<	_	_	I-Premise
270	0.05	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Body	_	_	B-Premise
274	cell	_	_	I-Premise
275	mass	_	_	I-Premise
276	was	_	_	I-Premise
277	maintained	_	_	I-Premise
278	throughout	_	_	I-Premise
279	the	_	_	I-Premise
280	study	_	_	I-Premise
281	in	_	_	I-Premise
282	group	_	_	I-Premise
283	B	_	_	I-Premise
284	,	_	_	I-Premise
285	but	_	_	I-Premise
286	declined	_	_	I-Premise
287	significantly	_	_	I-Premise
288	up	_	_	I-Premise
289	to	_	_	I-Premise
290	weeks	_	_	I-Premise
291	4	_	_	I-Premise
292	and	_	_	I-Premise
293	8	_	_	I-Premise
294	in	_	_	I-Premise
295	group	_	_	I-Premise
296	A	_	_	I-Premise
297	(	_	_	I-Premise
298	intergroup	_	_	I-Premise
299	difference	_	_	I-Premise
300	:	_	_	I-Premise
301	P	_	_	I-Premise
302	<	_	_	I-Premise
303	0.05	_	_	I-Premise
304	and	_	_	I-Premise
305	0.01	_	_	I-Premise
306	,	_	_	I-Premise
307	respectively	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	A	_	_	B-Premise
311	decrease	_	_	I-Premise
312	in	_	_	I-Premise
313	the	_	_	I-Premise
314	total	_	_	I-Premise
315	lymphocyte	_	_	I-Premise
316	count	_	_	I-Premise
317	by	_	_	I-Premise
318	559	_	_	I-Premise
319	cells/mul	_	_	I-Premise
320	occurred	_	_	I-Premise
321	with	_	_	I-Premise
322	the	_	_	I-Premise
323	fat-enriched	_	_	I-Premise
324	diet	_	_	I-Premise
325	(	_	_	I-Premise
326	P	_	_	I-Premise
327	<	_	_	I-Premise
328	0.05	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	Several	_	_	B-Premise
332	aspects	_	_	I-Premise
333	of	_	_	I-Premise
334	the	_	_	I-Premise
335	quality	_	_	I-Premise
336	of	_	_	I-Premise
337	life	_	_	I-Premise
338	were	_	_	I-Premise
339	rated	_	_	I-Premise
340	to	_	_	I-Premise
341	be	_	_	I-Premise
342	better	_	_	I-Premise
343	in	_	_	I-Premise
344	group	_	_	I-Premise
345	B	_	_	I-Premise
346	than	_	_	I-Premise
347	in	_	_	I-Premise
348	group	_	_	I-Premise
349	A	_	_	I-Premise
350	,	_	_	I-Premise
351	although	_	_	B-Premise
352	not	_	_	I-Premise
353	all	_	_	I-Premise
354	differences	_	_	I-Premise
355	reached	_	_	I-Premise
356	statistical	_	_	I-Premise
357	significance	_	_	I-Premise
358	.	_	_	I-Premise

359	In	_	_	B-Claim
360	patients	_	_	I-Claim
361	with	_	_	I-Claim
362	cancer	_	_	I-Claim
363	,	_	_	I-Claim
364	a	_	_	I-Claim
365	high-fat	_	_	I-Claim
366	diet	_	_	I-Claim
367	may	_	_	I-Claim
368	possibly	_	_	I-Claim
369	support	_	_	I-Claim
370	the	_	_	I-Claim
371	maintenance	_	_	I-Claim
372	of	_	_	I-Claim
373	both	_	_	I-Claim
374	body	_	_	I-Claim
375	weight	_	_	I-Claim
376	and	_	_	I-Claim
377	body	_	_	I-Claim
378	cell	_	_	I-Claim
379	mass	_	_	I-Claim
380	.	_	_	I-Claim

381	However	_	_	B-Claim
382	,	_	_	I-Claim
383	monitoring	_	_	I-Claim
384	the	_	_	I-Claim
385	lymphocyte	_	_	I-Claim
386	count	_	_	I-Claim
387	is	_	_	I-Claim
388	advisable	_	_	I-Claim
389	.	_	_	I-Claim


0	For	_	_	B-Claim
1	malignant	_	_	I-Claim
2	pleural	_	_	I-Claim
3	mesothelioma	_	_	I-Claim
4	(	_	_	I-Claim
5	MPM	_	_	I-Claim
6	)	_	_	I-Claim
7	patients	_	_	I-Claim
8	with	_	_	I-Claim
9	a	_	_	I-Claim
10	poor	_	_	I-Claim
11	prognosis	_	_	I-Claim
12	,	_	_	I-Claim
13	maintaining	_	_	I-Claim
14	health-related	_	_	I-Claim
15	quality	_	_	I-Claim
16	of	_	_	I-Claim
17	life	_	_	I-Claim
18	(	_	_	I-Claim
19	HRQOL	_	_	I-Claim
20	)	_	_	I-Claim
21	is	_	_	I-Claim
22	important	_	_	I-Claim
23	.	_	_	I-Claim

24	This	_	_	O
25	article	_	_	O
26	compares	_	_	O
27	the	_	_	O
28	impact	_	_	O
29	on	_	_	O
30	HRQOL	_	_	O
31	of	_	_	O
32	first-line	_	_	O
33	treatment	_	_	O
34	with	_	_	O
35	cisplatin	_	_	O
36	versus	_	_	O
37	raltitrexed	_	_	O
38	and	_	_	O
39	cisplatin	_	_	O
40	.	_	_	O

41	Patients	_	_	O
42	with	_	_	O
43	histologically-proven	_	_	O
44	unresectable	_	_	O
45	MPM	_	_	O
46	,	_	_	O
47	not	_	_	O
48	pretreated	_	_	O
49	with	_	_	O
50	chemotherapy	_	_	O
51	were	_	_	O
52	randomly	_	_	O
53	assigned	_	_	O
54	to	_	_	O
55	receive	_	_	O
56	cisplatin	_	_	O
57	80	_	_	O
58	mg/m2	_	_	O
59	intravenously	_	_	O
60	on	_	_	O
61	day	_	_	O
62	1	_	_	O
63	,	_	_	O
64	with	_	_	O
65	or	_	_	O
66	without	_	_	O
67	preceding	_	_	O
68	infusion	_	_	O
69	of	_	_	O
70	raltitrexed	_	_	O
71	3	_	_	O
72	mg/m2	_	_	O
73	.	_	_	O

74	HRQOL	_	_	O
75	was	_	_	O
76	assessed	_	_	O
77	with	_	_	O
78	the	_	_	O
79	European	_	_	O
80	Organisation	_	_	O
81	for	_	_	O
82	Research	_	_	O
83	and	_	_	O
84	Treatment	_	_	O
85	of	_	_	O
86	Cancer	_	_	O
87	Core	_	_	O
88	Quality	_	_	O
89	of	_	_	O
90	Life	_	_	O
91	Questionnaire	_	_	O
92	C30	_	_	O
93	(	_	_	O
94	EORTC	_	_	O
95	QLQ-C30	_	_	O
96	)	_	_	O
97	and	_	_	O
98	EORTC	_	_	O
99	Lung	_	_	O
100	Cancer	_	_	O
101	Module	_	_	O
102	(	_	_	O
103	QLQ-LC13	_	_	O
104	)	_	_	O
105	tools	_	_	O
106	.	_	_	O

107	Assessments	_	_	O
108	were	_	_	O
109	conducted	_	_	O
110	at	_	_	O
111	baseline	_	_	O
112	,	_	_	O
113	immediately	_	_	O
114	before	_	_	O
115	every	_	_	O
116	treatment	_	_	O
117	cycle	_	_	O
118	,	_	_	O
119	at	_	_	O
120	the	_	_	O
121	end	_	_	O
122	of	_	_	O
123	treatment	_	_	O
124	,	_	_	O
125	and	_	_	O
126	every	_	_	O
127	six	_	_	O
128	weeks	_	_	O
129	for	_	_	O
130	12	_	_	O
131	months	_	_	O
132	.	_	_	O

133	Two	_	_	O
134	hundred	_	_	O
135	fifty	_	_	O
136	patients	_	_	O
137	were	_	_	O
138	randomly	_	_	O
139	assigned	_	_	O
140	,	_	_	O
141	80	_	_	O
142	%	_	_	O
143	were	_	_	O
144	male	_	_	O
145	with	_	_	O
146	a	_	_	O
147	median	_	_	O
148	age	_	_	O
149	of	_	_	O
150	58	_	_	O
151	years	_	_	O
152	,	_	_	O
153	WHO	_	_	O
154	performance	_	_	O
155	status	_	_	O
156	0	_	_	O
157	,	_	_	O
158	1	_	_	O
159	,	_	_	O
160	and	_	_	O
161	2	_	_	O
162	,	_	_	O
163	in	_	_	O
164	25	_	_	O
165	%	_	_	O
166	,	_	_	O
167	62	_	_	O
168	%	_	_	O
169	,	_	_	O
170	and	_	_	O
171	13	_	_	O
172	%	_	_	O
173	of	_	_	O
174	cases	_	_	O
175	.	_	_	O

176	The	_	_	B-Premise
177	clinical	_	_	I-Premise
178	results	_	_	I-Premise
179	found	_	_	I-Premise
180	raltitrexed	_	_	I-Premise
181	and	_	_	I-Premise
182	cisplatin	_	_	I-Premise
183	to	_	_	I-Premise
184	be	_	_	I-Premise
185	superior	_	_	I-Premise
186	to	_	_	I-Premise
187	cisplatin	_	_	I-Premise
188	with	_	_	I-Premise
189	regard	_	_	I-Premise
190	to	_	_	I-Premise
191	overall	_	_	I-Premise
192	survival	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	=	_	_	I-Premise
196	.048	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	The	_	_	B-Premise
200	global	_	_	I-Premise
201	HRQOL	_	_	I-Premise
202	scale	_	_	I-Premise
203	was	_	_	I-Premise
204	comparable	_	_	I-Premise
205	at	_	_	I-Premise
206	baseline	_	_	I-Premise
207	on	_	_	I-Premise
208	both	_	_	I-Premise
209	treatment	_	_	I-Premise
210	arms	_	_	I-Premise
211	(	_	_	I-Premise
212	P	_	_	I-Premise
213	=	_	_	I-Premise
214	.848	_	_	I-Premise
215	)	_	_	I-Premise
216	;	_	_	I-Premise
217	at	_	_	B-Premise
218	no	_	_	I-Premise
219	point	_	_	I-Premise
220	was	_	_	I-Premise
221	any	_	_	I-Premise
222	significant	_	_	I-Premise
223	difference	_	_	I-Premise
224	apparent	_	_	I-Premise
225	on	_	_	I-Premise
226	this	_	_	I-Premise
227	end	_	_	I-Premise
228	point	_	_	I-Premise
229	.	_	_	I-Premise

230	Both	_	_	B-Premise
231	treatments	_	_	I-Premise
232	led	_	_	I-Premise
233	to	_	_	I-Premise
234	an	_	_	I-Premise
235	improvement	_	_	I-Premise
236	,	_	_	I-Premise
237	over	_	_	I-Premise
238	time	_	_	I-Premise
239	,	_	_	I-Premise
240	in	_	_	I-Premise
241	dyspnoea	_	_	I-Premise
242	.	_	_	I-Premise

243	This	_	_	B-Claim
244	effect	_	_	I-Claim
245	is	_	_	I-Claim
246	an	_	_	I-Claim
247	important	_	_	I-Claim
248	clinically	_	_	I-Claim
249	meaningful	_	_	I-Claim
250	reduction	_	_	I-Claim
251	from	_	_	I-Claim
252	baseline	_	_	I-Claim
253	in	_	_	I-Claim
254	the	_	_	I-Claim
255	cisplatin/raltitrexed	_	_	I-Claim
256	arm	_	_	I-Claim
257	.	_	_	I-Claim

258	However	_	_	B-Premise
259	,	_	_	I-Premise
260	the	_	_	I-Premise
261	majority	_	_	I-Premise
262	of	_	_	I-Premise
263	scales	_	_	I-Premise
264	of	_	_	I-Premise
265	the	_	_	I-Premise
266	EORTC	_	_	I-Premise
267	QLQ-C30	_	_	I-Premise
268	or	_	_	I-Premise
269	LC13	_	_	I-Premise
270	showed	_	_	I-Premise
271	stabilization	_	_	I-Premise
272	of	_	_	I-Premise
273	HRQOL	_	_	I-Premise
274	with	_	_	I-Premise
275	few	_	_	I-Premise
276	clinically	_	_	I-Premise
277	significant	_	_	I-Premise
278	differences	_	_	I-Premise
279	between	_	_	I-Premise
280	the	_	_	I-Premise
281	treatment	_	_	I-Premise
282	arms	_	_	I-Premise
283	.	_	_	I-Premise

284	This	_	_	B-Claim
285	study	_	_	I-Claim
286	provides	_	_	I-Claim
287	important	_	_	I-Claim
288	information	_	_	I-Claim
289	about	_	_	I-Claim
290	the	_	_	I-Claim
291	HRQOL	_	_	I-Claim
292	of	_	_	I-Claim
293	chemotherapy-treated	_	_	I-Claim
294	MPM	_	_	I-Claim
295	patients	_	_	I-Claim
296	.	_	_	I-Claim


0	The	_	_	O
1	objective	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QoL	_	_	O
14	)	_	_	O
15	of	_	_	O
16	ovarian	_	_	O
17	cancer	_	_	O
18	patients	_	_	O
19	treated	_	_	O
20	with	_	_	O
21	paclitaxel/carboplatin	_	_	O
22	(	_	_	O
23	TC	_	_	O
24	)	_	_	O
25	versus	_	_	O
26	paclitaxel/cisplatin	_	_	O
27	(	_	_	O
28	PT	_	_	O
29	)	_	_	O
30	and	_	_	O
31	to	_	_	O
32	determine	_	_	O
33	the	_	_	O
34	impact	_	_	O
35	of	_	_	O
36	treatment	_	_	O
37	toxicity	_	_	O
38	on	_	_	O
39	the	_	_	O
40	various	_	_	O
41	QoL	_	_	O
42	domains	_	_	O
43	.	_	_	O

44	In	_	_	O
45	this	_	_	O
46	phase	_	_	O
47	III	_	_	O
48	trial	_	_	O
49	,	_	_	O
50	798	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	ovarian	_	_	O
54	cancer	_	_	O
55	stages	_	_	O
56	IIB-IV	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	assigned	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	TC	_	_	O
63	or	_	_	O
64	PT	_	_	O
65	.	_	_	O

66	The	_	_	O
67	primary	_	_	O
68	end	_	_	O
69	point	_	_	O
70	was	_	_	O
71	progression-free	_	_	O
72	survival	_	_	O
73	;	_	_	O
74	secondary	_	_	O
75	end	_	_	O
76	points	_	_	O
77	included	_	_	O
78	toxicity	_	_	O
79	,	_	_	O
80	QoL	_	_	O
81	,	_	_	O
82	and	_	_	O
83	response	_	_	O
84	to	_	_	O
85	treatment	_	_	O
86	.	_	_	O

87	Patients	_	_	O
88	completed	_	_	O
89	the	_	_	O
90	European	_	_	O
91	Organisation	_	_	O
92	for	_	_	O
93	Research	_	_	O
94	and	_	_	O
95	Treatment	_	_	O
96	of	_	_	O
97	Cancer	_	_	O
98	QLQ-C30	_	_	O
99	before	_	_	O
100	treatment	_	_	O
101	,	_	_	O
102	within	_	_	O
103	3	_	_	O
104	days	_	_	O
105	before	_	_	O
106	the	_	_	O
107	second	_	_	O
108	and	_	_	O
109	the	_	_	O
110	fourth	_	_	O
111	chemotherapy	_	_	O
112	cycle	_	_	O
113	,	_	_	O
114	and	_	_	O
115	3	_	_	O
116	weeks	_	_	O
117	after	_	_	O
118	completion	_	_	O
119	of	_	_	O
120	chemotherapy	_	_	O
121	.	_	_	O

122	Previously	_	_	O
123	reported	_	_	O
124	data	_	_	O
125	showed	_	_	O
126	that	_	_	O
127	patients	_	_	O
128	undergoing	_	_	O
129	TC	_	_	O
130	or	_	_	O
131	PT	_	_	O
132	did	_	_	O
133	not	_	_	O
134	differ	_	_	O
135	in	_	_	O
136	progression-free	_	_	O
137	survival	_	_	O
138	and	_	_	O
139	overall	_	_	O
140	survival	_	_	O
141	.	_	_	O

142	However	_	_	O
143	,	_	_	O
144	the	_	_	O
145	TC	_	_	O
146	arm	_	_	O
147	was	_	_	O
148	superior	_	_	O
149	,	_	_	O
150	indicating	_	_	O
151	a	_	_	O
152	better	_	_	O
153	overall	_	_	O
154	QoL	_	_	O
155	compared	_	_	O
156	with	_	_	O
157	the	_	_	O
158	PT	_	_	O
159	arm	_	_	O
160	.	_	_	O

161	Controlling	_	_	O
162	for	_	_	O
163	toxicity	_	_	O
164	and	_	_	O
165	age	_	_	O
166	,	_	_	O
167	a	_	_	O
168	significant	_	_	O
169	treatment	_	_	O
170	by	_	_	O
171	assessment	_	_	O
172	time	_	_	O
173	interaction	_	_	O
174	was	_	_	O
175	found	_	_	O
176	for	_	_	O
177	four	_	_	O
178	QoL	_	_	O
179	functioning	_	_	O
180	scales	_	_	O
181	and	_	_	O
182	three	_	_	O
183	symptoms	_	_	O
184	scales	_	_	O
185	.	_	_	O

186	Patients	_	_	B-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	TC	_	_	I-Premise
190	arm	_	_	I-Premise
191	showed	_	_	I-Premise
192	better	_	_	I-Premise
193	means	_	_	I-Premise
194	scores	_	_	I-Premise
195	after	_	_	I-Premise
196	treatment	_	_	I-Premise
197	on	_	_	I-Premise
198	overall	_	_	I-Premise
199	QoL	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	.012	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	physical	_	_	I-Premise
207	functioning	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	.012	_	_	I-Premise
212	)	_	_	I-Premise
213	,	_	_	I-Premise
214	role	_	_	I-Premise
215	functioning	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	.005	_	_	I-Premise
220	)	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	cognitive	_	_	I-Premise
224	functioning	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.024	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	compared	_	_	I-Premise
232	with	_	_	I-Premise
233	the	_	_	I-Premise
234	PT	_	_	I-Premise
235	arm	_	_	I-Premise
236	.	_	_	I-Premise

237	Concerning	_	_	B-Premise
238	symptom	_	_	I-Premise
239	experience	_	_	I-Premise
240	,	_	_	I-Premise
241	patients	_	_	I-Premise
242	undergoing	_	_	I-Premise
243	TC	_	_	I-Premise
244	showed	_	_	I-Premise
245	less	_	_	I-Premise
246	nausea	_	_	I-Premise
247	and	_	_	I-Premise
248	vomiting	_	_	I-Premise
249	(	_	_	I-Premise
250	P	_	_	I-Premise
251	<	_	_	I-Premise
252	.001	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	less	_	_	I-Premise
256	appetite	_	_	I-Premise
257	loss	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	.001	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	less	_	_	I-Premise
266	fatigue	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	.033	_	_	I-Premise
271	)	_	_	I-Premise
272	after	_	_	I-Premise
273	completion	_	_	I-Premise
274	of	_	_	I-Premise
275	treatment	_	_	I-Premise
276	compared	_	_	I-Premise
277	with	_	_	I-Premise
278	patients	_	_	I-Premise
279	undergoing	_	_	I-Premise
280	PT	_	_	I-Premise
281	.	_	_	I-Premise

282	The	_	_	B-Claim
283	TC	_	_	I-Claim
284	regimen	_	_	I-Claim
285	achieved	_	_	I-Claim
286	better	_	_	I-Claim
287	QoL	_	_	I-Claim
288	outcomes	_	_	I-Claim
289	compared	_	_	I-Claim
290	with	_	_	I-Claim
291	the	_	_	I-Claim
292	PT	_	_	I-Claim
293	regimen	_	_	I-Claim
294	.	_	_	I-Claim

295	Thus	_	_	B-Claim
296	,	_	_	I-Claim
297	clinicians	_	_	I-Claim
298	may	_	_	I-Claim
299	consider	_	_	I-Claim
300	replacing	_	_	I-Claim
301	cisplatin	_	_	I-Claim
302	with	_	_	I-Claim
303	carboplatin	_	_	I-Claim
304	when	_	_	I-Claim
305	treating	_	_	I-Claim
306	ovarian	_	_	I-Claim
307	cancer	_	_	I-Claim
308	patients	_	_	I-Claim
309	with	_	_	I-Claim
310	chemotherapy	_	_	I-Claim
311	.	_	_	I-Claim


0	The	_	_	O
1	primary	_	_	O
2	goal	_	_	O
3	of	_	_	O
4	this	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	evaluate	_	_	O
9	the	_	_	O
10	feasibility	_	_	O
11	and	_	_	O
12	effectiveness	_	_	O
13	of	_	_	O
14	a	_	_	O
15	structured	_	_	O
16	,	_	_	O
17	multidisciplinary	_	_	O
18	intervention	_	_	O
19	targeted	_	_	O
20	to	_	_	O
21	maintain	_	_	O
22	the	_	_	O
23	overall	_	_	O
24	quality	_	_	O
25	of	_	_	O
26	life	_	_	O
27	(	_	_	O
28	QOL	_	_	O
29	)	_	_	O
30	,	_	_	O
31	which	_	_	O
32	is	_	_	O
33	more	_	_	O
34	comprehensive	_	_	O
35	than	_	_	O
36	psychosocial	_	_	O
37	distress	_	_	O
38	,	_	_	O
39	of	_	_	O
40	patients	_	_	O
41	undergoing	_	_	O
42	radiation	_	_	O
43	therapy	_	_	O
44	for	_	_	O
45	advanced-stage	_	_	O
46	cancer	_	_	O
47	.	_	_	O

48	Radiation	_	_	O
49	therapy	_	_	O
50	patients	_	_	O
51	with	_	_	O
52	advanced	_	_	O
53	cancer	_	_	O
54	and	_	_	O
55	an	_	_	O
56	estimated	_	_	O
57	5-year	_	_	O
58	survival	_	_	O
59	rate	_	_	O
60	of	_	_	O
61	0	_	_	O
62	%	_	_	O
63	to	_	_	O
64	50	_	_	O
65	%	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	assigned	_	_	O
69	to	_	_	O
70	either	_	_	O
71	an	_	_	O
72	eight-session	_	_	O
73	structured	_	_	O
74	multidisciplinary	_	_	O
75	intervention	_	_	O
76	arm	_	_	O
77	or	_	_	O
78	a	_	_	O
79	standard	_	_	O
80	care	_	_	O
81	arm	_	_	O
82	.	_	_	O

83	The	_	_	O
84	eight	_	_	O
85	90-minute	_	_	O
86	sessions	_	_	O
87	addressed	_	_	O
88	the	_	_	O
89	five	_	_	O
90	domains	_	_	O
91	of	_	_	O
92	QOL	_	_	O
93	including	_	_	O
94	cognitive	_	_	O
95	,	_	_	O
96	physical	_	_	O
97	,	_	_	O
98	emotional	_	_	O
99	,	_	_	O
100	spiritual	_	_	O
101	,	_	_	O
102	and	_	_	O
103	social	_	_	O
104	functioning	_	_	O
105	.	_	_	O

106	The	_	_	O
107	primary	_	_	O
108	end	_	_	O
109	point	_	_	O
110	of	_	_	O
111	maintaining	_	_	O
112	overall	_	_	O
113	QOL	_	_	O
114	was	_	_	O
115	assessed	_	_	O
116	by	_	_	O
117	a	_	_	O
118	single-item	_	_	O
119	linear	_	_	O
120	analog	_	_	O
121	scale	_	_	O
122	(	_	_	O
123	Linear	_	_	O
124	Analog	_	_	O
125	Scale	_	_	O
126	of	_	_	O
127	Assessment	_	_	O
128	or	_	_	O
129	modified	_	_	O
130	Spitzer	_	_	O
131	Uniscale	_	_	O
132	)	_	_	O
133	.	_	_	O

134	QOL	_	_	O
135	was	_	_	O
136	assessed	_	_	O
137	at	_	_	O
138	baseline	_	_	O
139	,	_	_	O
140	week	_	_	O
141	4	_	_	O
142	(	_	_	O
143	end	_	_	O
144	of	_	_	O
145	multidisciplinary	_	_	O
146	intervention	_	_	O
147	)	_	_	O
148	,	_	_	O
149	week	_	_	O
150	8	_	_	O
151	,	_	_	O
152	and	_	_	O
153	week	_	_	O
154	27	_	_	O
155	.	_	_	O

156	Of	_	_	B-Premise
157	the	_	_	I-Premise
158	103	_	_	I-Premise
159	participants	_	_	I-Premise
160	,	_	_	I-Premise
161	overall	_	_	I-Premise
162	QOL	_	_	I-Premise
163	at	_	_	I-Premise
164	week	_	_	I-Premise
165	4	_	_	I-Premise
166	was	_	_	I-Premise
167	maintained	_	_	I-Premise
168	by	_	_	I-Premise
169	the	_	_	I-Premise
170	patients	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	intervention	_	_	I-Premise
174	(	_	_	I-Premise
175	n	_	_	I-Premise
176	=	_	_	I-Premise
177	49	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	whereas	_	_	I-Premise
181	QOL	_	_	I-Premise
182	at	_	_	I-Premise
183	week	_	_	I-Premise
184	4	_	_	I-Premise
185	significantly	_	_	I-Premise
186	decreased	_	_	I-Premise
187	for	_	_	I-Premise
188	patients	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	control	_	_	I-Premise
192	group	_	_	I-Premise
193	(	_	_	I-Premise
194	n	_	_	I-Premise
195	=	_	_	I-Premise
196	54	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	This	_	_	B-Premise
200	change	_	_	I-Premise
201	reflected	_	_	I-Premise
202	a	_	_	I-Premise
203	3-point	_	_	I-Premise
204	increase	_	_	I-Premise
205	from	_	_	I-Premise
206	baseline	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	intervention	_	_	I-Premise
210	group	_	_	I-Premise
211	and	_	_	I-Premise
212	a	_	_	I-Premise
213	9-point	_	_	I-Premise
214	decrease	_	_	I-Premise
215	from	_	_	I-Premise
216	baseline	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	control	_	_	I-Premise
220	group	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	.009	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	Intervention	_	_	B-Premise
228	participants	_	_	I-Premise
229	maintained	_	_	I-Premise
230	their	_	_	I-Premise
231	QOL	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	controls	_	_	I-Premise
235	gradually	_	_	I-Premise
236	returned	_	_	I-Premise
237	to	_	_	I-Premise
238	baseline	_	_	I-Premise
239	by	_	_	I-Premise
240	the	_	_	I-Premise
241	end	_	_	I-Premise
242	of	_	_	I-Premise
243	the	_	_	I-Premise
244	6-month	_	_	I-Premise
245	follow-up	_	_	I-Premise
246	period	_	_	I-Premise
247	.	_	_	I-Premise

248	Although	_	_	B-Claim
249	intervention	_	_	I-Claim
250	participants	_	_	I-Claim
251	maintained	_	_	I-Claim
252	and	_	_	I-Claim
253	actually	_	_	I-Claim
254	improved	_	_	I-Claim
255	their	_	_	I-Claim
256	QOL	_	_	I-Claim
257	during	_	_	I-Claim
258	radiation	_	_	I-Claim
259	therapy	_	_	I-Claim
260	,	_	_	I-Claim
261	control	_	_	I-Claim
262	participants	_	_	I-Claim
263	experienced	_	_	I-Claim
264	a	_	_	I-Claim
265	significant	_	_	I-Claim
266	decrease	_	_	I-Claim
267	in	_	_	I-Claim
268	their	_	_	I-Claim
269	QOL	_	_	I-Claim
270	.	_	_	O

271	Thus	_	_	B-Claim
272	,	_	_	I-Claim
273	a	_	_	I-Claim
274	structured	_	_	I-Claim
275	multidisciplinary	_	_	I-Claim
276	intervention	_	_	I-Claim
277	can	_	_	I-Claim
278	help	_	_	I-Claim
279	maintain	_	_	I-Claim
280	or	_	_	I-Claim
281	even	_	_	I-Claim
282	improve	_	_	I-Claim
283	QOL	_	_	I-Claim
284	in	_	_	I-Claim
285	patients	_	_	I-Claim
286	with	_	_	I-Claim
287	advanced	_	_	I-Claim
288	cancer	_	_	I-Claim
289	who	_	_	I-Claim
290	are	_	_	I-Claim
291	undergoing	_	_	I-Claim
292	cancer	_	_	I-Claim
293	treatment	_	_	I-Claim
294	.	_	_	I-Claim


0	The	_	_	B-Claim
1	impact	_	_	I-Claim
2	of	_	_	I-Claim
3	prolonged	_	_	I-Claim
4	subclinical	_	_	I-Claim
5	hyperthyroidism	_	_	I-Claim
6	on	_	_	I-Claim
7	quality	_	_	I-Claim
8	of	_	_	I-Claim
9	life	_	_	I-Claim
10	is	_	_	I-Claim
11	unclear	_	_	I-Claim
12	.	_	_	I-Claim

13	Therefore	_	_	O
14	,	_	_	O
15	we	_	_	O
16	evaluated	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	differentiated	_	_	O
24	thyroid	_	_	O
25	carcinoma	_	_	O
26	(	_	_	O
27	DTC	_	_	O
28	)	_	_	O
29	on	_	_	O
30	TSH-suppressive	_	_	O
31	thyroxine	_	_	O
32	therapy	_	_	O
33	as	_	_	O
34	a	_	_	O
35	model	_	_	O
36	for	_	_	O
37	subclinical	_	_	O
38	hyperthyroidism	_	_	O
39	and	_	_	O
40	we	_	_	O
41	investigated	_	_	O
42	whether	_	_	O
43	restoration	_	_	O
44	to	_	_	O
45	euthyroidism	_	_	O
46	affects	_	_	O
47	quality	_	_	O
48	of	_	_	O
49	life	_	_	O
50	.	_	_	O

51	We	_	_	O
52	performed	_	_	O
53	a	_	_	O
54	prospective	_	_	O
55	,	_	_	O
56	single-blinded	_	_	O
57	,	_	_	O
58	placebo-controlled	_	_	O
59	,	_	_	O
60	randomized	_	_	O
61	trial	_	_	O
62	of	_	_	O
63	6	_	_	O
64	months	_	_	O
65	'	_	_	O
66	duration	_	_	O
67	with	_	_	O
68	two	_	_	O
69	parallel	_	_	O
70	groups	_	_	O
71	.	_	_	O

72	Twenty-four	_	_	O
73	subjects	_	_	O
74	with	_	_	O
75	a	_	_	O
76	history	_	_	O
77	of	_	_	O
78	differentiated	_	_	O
79	thyroid	_	_	O
80	carcinoma	_	_	O
81	with	_	_	O
82	>	_	_	O
83	10	_	_	O
84	years	_	_	O
85	TSH-suppressive	_	_	O
86	therapy	_	_	O
87	with	_	_	O
88	L-thyroxine	_	_	O
89	completed	_	_	O
90	the	_	_	O
91	study	_	_	O
92	.	_	_	O

93	L-thyroxine	_	_	O
94	dose	_	_	O
95	was	_	_	O
96	replaced	_	_	O
97	by	_	_	O
98	study	_	_	O
99	medication	_	_	O
100	containing	_	_	O
101	L-thyroxine	_	_	O
102	or	_	_	O
103	L-thyroxine	_	_	O
104	plus	_	_	O
105	placebo	_	_	O
106	.	_	_	O

107	Medication	_	_	O
108	was	_	_	O
109	titrated	_	_	O
110	to	_	_	O
111	establish	_	_	O
112	continuation	_	_	O
113	of	_	_	O
114	TSH	_	_	O
115	suppression	_	_	O
116	(	_	_	O
117	low-TSH	_	_	O
118	group	_	_	O
119	)	_	_	O
120	and	_	_	O
121	euthyroidism	_	_	O
122	(	_	_	O
123	euthyroid	_	_	O
124	group	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Both	_	_	O
128	groups	_	_	O
129	consisted	_	_	O
130	of	_	_	O
131	12	_	_	O
132	patients	_	_	O
133	.	_	_	O

134	We	_	_	O
135	evaluated	_	_	O
136	quality	_	_	O
137	of	_	_	O
138	life	_	_	O
139	using	_	_	O
140	five	_	_	O
141	validated	_	_	O
142	questionnaires	_	_	O
143	.	_	_	O

144	At	_	_	O
145	baseline	_	_	O
146	,	_	_	O
147	the	_	_	O
148	somatic	_	_	O
149	disorder	_	_	O
150	questionnaire	_	_	O
151	(	_	_	O
152	SDQ	_	_	O
153	)	_	_	O
154	indicated	_	_	O
155	more	_	_	O
156	somatic	_	_	O
157	dysfunction	_	_	O
158	in	_	_	O
159	patients	_	_	O
160	as	_	_	O
161	compared	_	_	O
162	with	_	_	O
163	reference	_	_	O
164	values	_	_	O
165	,	_	_	O
166	whereas	_	_	O
167	the	_	_	O
168	depression	_	_	O
169	score	_	_	O
170	(	_	_	O
171	HADS	_	_	O
172	)	_	_	O
173	revealed	_	_	O
174	a	_	_	O
175	better	_	_	O
176	score	_	_	O
177	than	_	_	O
178	the	_	_	O
179	reference	_	_	O
180	group	_	_	O
181	.	_	_	O

182	All	_	_	O
183	other	_	_	O
184	quality	_	_	O
185	of	_	_	O
186	life	_	_	O
187	parameters	_	_	O
188	were	_	_	O
189	normal	_	_	O
190	.	_	_	O

191	At	_	_	O
192	baseline	_	_	O
193	,	_	_	O
194	no	_	_	O
195	significant	_	_	O
196	differences	_	_	O
197	between	_	_	O
198	the	_	_	O
199	low-TSH	_	_	O
200	and	_	_	O
201	the	_	_	O
202	euthyroidism	_	_	O
203	groups	_	_	O
204	were	_	_	O
205	observed	_	_	O
206	.	_	_	O

207	After	_	_	B-Premise
208	6	_	_	I-Premise
209	months	_	_	I-Premise
210	,	_	_	I-Premise
211	none	_	_	I-Premise
212	of	_	_	I-Premise
213	the	_	_	I-Premise
214	quality	_	_	I-Premise
215	of	_	_	I-Premise
216	life	_	_	I-Premise
217	parameters	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	low-TSH	_	_	I-Premise
221	group	_	_	I-Premise
222	was	_	_	I-Premise
223	different	_	_	I-Premise
224	from	_	_	I-Premise
225	baseline	_	_	I-Premise
226	values	_	_	I-Premise
227	.	_	_	I-Premise

228	In	_	_	B-Premise
229	the	_	_	I-Premise
230	euthyroid	_	_	I-Premise
231	group	_	_	I-Premise
232	,	_	_	I-Premise
233	motivation	_	_	I-Premise
234	was	_	_	I-Premise
235	significantly	_	_	I-Premise
236	improved	_	_	I-Premise
237	(	_	_	I-Premise
238	Multidimensional	_	_	I-Premise
239	Fatigue	_	_	I-Premise
240	Index-20	_	_	I-Premise
241	,	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.003	_	_	I-Premise
245	)	_	_	I-Premise
246	,	_	_	I-Premise
247	although	_	_	B-Premise
248	this	_	_	I-Premise
249	parameter	_	_	I-Premise
250	did	_	_	I-Premise
251	not	_	_	I-Premise
252	differ	_	_	I-Premise
253	from	_	_	I-Premise
254	the	_	_	I-Premise
255	reference	_	_	I-Premise
256	group	_	_	I-Premise
257	at	_	_	I-Premise
258	baseline	_	_	I-Premise
259	.	_	_	I-Premise

260	A	_	_	B-Premise
261	probable	_	_	I-Premise
262	worsening	_	_	I-Premise
263	in	_	_	I-Premise
264	role	_	_	I-Premise
265	limitations	_	_	I-Premise
266	as	_	_	I-Premise
267	a	_	_	I-Premise
268	result	_	_	I-Premise
269	of	_	_	I-Premise
270	physical	_	_	I-Premise
271	problems	_	_	I-Premise
272	(	_	_	I-Premise
273	Short	_	_	I-Premise
274	Form-36	_	_	I-Premise
275	;	_	_	I-Premise
276	P	_	_	I-Premise
277	=	_	_	I-Premise
278	0.050	_	_	I-Premise
279	)	_	_	I-Premise
280	was	_	_	I-Premise
281	observed	_	_	I-Premise
282	.	_	_	I-Premise

283	No	_	_	B-Premise
284	improvement	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	SDQ	_	_	I-Premise
288	score	_	_	I-Premise
289	was	_	_	I-Premise
290	observed	_	_	I-Premise
291	.	_	_	I-Premise

292	In	_	_	B-Claim
293	summary	_	_	I-Claim
294	,	_	_	I-Claim
295	quality	_	_	I-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	in	_	_	I-Claim
299	patients	_	_	I-Claim
300	with	_	_	I-Claim
301	DTC	_	_	I-Claim
302	and	_	_	I-Claim
303	long-term	_	_	I-Claim
304	subclinical	_	_	I-Claim
305	hyperthyroidism	_	_	I-Claim
306	in	_	_	I-Claim
307	general	_	_	I-Claim
308	is	_	_	I-Claim
309	preserved	_	_	I-Claim
310	.	_	_	I-Claim

311	Restoration	_	_	B-Claim
312	of	_	_	I-Claim
313	euthyroidism	_	_	I-Claim
314	in	_	_	I-Claim
315	general	_	_	I-Claim
316	does	_	_	I-Claim
317	not	_	_	I-Claim
318	affect	_	_	I-Claim
319	quality	_	_	I-Claim
320	of	_	_	I-Claim
321	life	_	_	I-Claim
322	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	cost-effectiveness	_	_	O
4	of	_	_	O
5	Mohs	_	_	O
6	micrographic	_	_	O
7	surgery	_	_	O
8	(	_	_	O
9	MMS	_	_	O
10	)	_	_	O
11	compared	_	_	O
12	with	_	_	O
13	the	_	_	O
14	surgical	_	_	O
15	excision	_	_	O
16	for	_	_	O
17	both	_	_	O
18	primary	_	_	O
19	and	_	_	O
20	recurrent	_	_	O
21	basal	_	_	O
22	cell	_	_	O
23	carcinoma	_	_	O
24	(	_	_	O
25	BCC	_	_	O
26	)	_	_	O
27	.	_	_	O

28	A	_	_	O
29	cost-effectiveness	_	_	O
30	study	_	_	O
31	performed	_	_	O
32	alongside	_	_	O
33	a	_	_	O
34	prospective	_	_	O
35	randomized	_	_	O
36	clinical	_	_	O
37	trial	_	_	O
38	in	_	_	O
39	which	_	_	O
40	MMS	_	_	O
41	was	_	_	O
42	compared	_	_	O
43	with	_	_	O
44	surgical	_	_	O
45	excision	_	_	O
46	.	_	_	O

47	The	_	_	O
48	study	_	_	O
49	was	_	_	O
50	carried	_	_	O
51	out	_	_	O
52	from	_	_	O
53	1999	_	_	O
54	to	_	_	O
55	2002	_	_	O
56	at	_	_	O
57	the	_	_	O
58	dermatology	_	_	O
59	outpatient	_	_	O
60	clinic	_	_	O
61	of	_	_	O
62	the	_	_	O
63	University	_	_	O
64	Hospital	_	_	O
65	Maastricht	_	_	O
66	,	_	_	O
67	Maastricht	_	_	O
68	,	_	_	O
69	The	_	_	O
70	Netherlands	_	_	O
71	.	_	_	O

72	A	_	_	O
73	total	_	_	O
74	of	_	_	O
75	408	_	_	O
76	primary	_	_	O
77	(	_	_	O
78	374	_	_	O
79	patients	_	_	O
80	)	_	_	O
81	and	_	_	O
82	204	_	_	O
83	recurrent	_	_	O
84	(	_	_	O
85	191	_	_	O
86	patients	_	_	O
87	)	_	_	O
88	cases	_	_	O
89	of	_	_	O
90	facial	_	_	O
91	BCC	_	_	O
92	were	_	_	O
93	included	_	_	O
94	.	_	_	O

95	The	_	_	O
96	mean	_	_	O
97	total	_	_	O
98	treatment	_	_	O
99	costs	_	_	O
100	of	_	_	O
101	MMS	_	_	O
102	and	_	_	O
103	surgical	_	_	O
104	excision	_	_	O
105	for	_	_	O
106	both	_	_	O
107	primary	_	_	O
108	and	_	_	O
109	recurrent	_	_	O
110	BCC	_	_	O
111	and	_	_	O
112	the	_	_	O
113	incremental	_	_	O
114	cost-effectiveness	_	_	O
115	ratio	_	_	O
116	,	_	_	O
117	calculated	_	_	O
118	as	_	_	O
119	the	_	_	O
120	difference	_	_	O
121	in	_	_	O
122	costs	_	_	O
123	between	_	_	O
124	MMS	_	_	O
125	and	_	_	O
126	surgical	_	_	O
127	excision	_	_	O
128	divided	_	_	O
129	by	_	_	O
130	their	_	_	O
131	difference	_	_	O
132	in	_	_	O
133	effectiveness	_	_	O
134	.	_	_	O

135	The	_	_	O
136	resulting	_	_	O
137	ratio	_	_	O
138	is	_	_	O
139	defined	_	_	O
140	as	_	_	O
141	the	_	_	O
142	incremental	_	_	O
143	costs	_	_	O
144	of	_	_	O
145	MMS	_	_	O
146	compared	_	_	O
147	with	_	_	O
148	surgical	_	_	O
149	excision	_	_	O
150	to	_	_	O
151	prevent	_	_	O
152	1	_	_	O
153	additional	_	_	O
154	recurrence	_	_	O
155	.	_	_	O

156	Compared	_	_	B-Premise
157	with	_	_	I-Premise
158	surgical	_	_	I-Premise
159	excision	_	_	I-Premise
160	,	_	_	I-Premise
161	the	_	_	I-Premise
162	total	_	_	I-Premise
163	treatment	_	_	I-Premise
164	costs	_	_	I-Premise
165	of	_	_	I-Premise
166	MMS	_	_	I-Premise
167	are	_	_	I-Premise
168	significantly	_	_	I-Premise
169	higher	_	_	I-Premise
170	(	_	_	I-Premise
171	cost	_	_	I-Premise
172	difference	_	_	I-Premise
173	:	_	_	I-Premise
174	primary	_	_	I-Premise
175	BCC	_	_	I-Premise
176	,	_	_	I-Premise
177	254	_	_	I-Premise
178	euros	_	_	I-Premise
179	;	_	_	I-Premise
180	95	_	_	I-Premise
181	%	_	_	I-Premise
182	confidence	_	_	I-Premise
183	interval	_	_	I-Premise
184	,	_	_	I-Premise
185	181-324	_	_	I-Premise
186	euros	_	_	I-Premise
187	;	_	_	I-Premise
188	recurrent	_	_	I-Premise
189	BCC	_	_	I-Premise
190	,	_	_	I-Premise
191	249	_	_	I-Premise
192	euros	_	_	I-Premise
193	;	_	_	I-Premise
194	95	_	_	I-Premise
195	%	_	_	I-Premise
196	confidence	_	_	I-Premise
197	interval	_	_	I-Premise
198	,	_	_	I-Premise
199	175-323	_	_	I-Premise
200	euros	_	_	I-Premise
201	)	_	_	I-Premise
202	.	_	_	I-Premise

203	For	_	_	B-Premise
204	primary	_	_	I-Premise
205	BCC	_	_	I-Premise
206	,	_	_	I-Premise
207	the	_	_	I-Premise
208	incremental	_	_	I-Premise
209	cost-effectiveness	_	_	I-Premise
210	ratio	_	_	I-Premise
211	was	_	_	I-Premise
212	29,231	_	_	I-Premise
213	euros	_	_	I-Premise
214	,	_	_	I-Premise
215	while	_	_	I-Premise
216	the	_	_	I-Premise
217	ratio	_	_	I-Premise
218	for	_	_	I-Premise
219	recurrent	_	_	I-Premise
220	BCC	_	_	I-Premise
221	amounted	_	_	I-Premise
222	to	_	_	I-Premise
223	8094	_	_	I-Premise
224	euros	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	acceptability	_	_	I-Premise
228	curves	_	_	I-Premise
229	showed	_	_	I-Premise
230	that	_	_	I-Premise
231	for	_	_	I-Premise
232	these	_	_	I-Premise
233	ratios	_	_	I-Premise
234	,	_	_	I-Premise
235	the	_	_	I-Premise
236	probability	_	_	I-Premise
237	of	_	_	I-Premise
238	MMS	_	_	I-Premise
239	being	_	_	I-Premise
240	more	_	_	I-Premise
241	cost-effective	_	_	I-Premise
242	than	_	_	I-Premise
243	surgical	_	_	I-Premise
244	excision	_	_	I-Premise
245	never	_	_	I-Premise
246	reached	_	_	I-Premise
247	50	_	_	I-Premise
248	%	_	_	I-Premise
249	.	_	_	I-Premise

250	At	_	_	B-Claim
251	present	_	_	I-Claim
252	,	_	_	I-Claim
253	it	_	_	I-Claim
254	does	_	_	I-Claim
255	not	_	_	I-Claim
256	seem	_	_	I-Claim
257	cost-effective	_	_	I-Claim
258	to	_	_	I-Claim
259	introduce	_	_	I-Claim
260	MMS	_	_	I-Claim
261	on	_	_	I-Claim
262	a	_	_	I-Claim
263	large	_	_	I-Claim
264	scale	_	_	I-Claim
265	for	_	_	I-Claim
266	both	_	_	I-Claim
267	primary	_	_	I-Claim
268	and	_	_	I-Claim
269	recurrent	_	_	I-Claim
270	BCC	_	_	I-Claim
271	.	_	_	I-Claim

272	However	_	_	O
273	,	_	_	O
274	because	_	_	B-Premise
275	a	_	_	I-Premise
276	5-year	_	_	I-Premise
277	period	_	_	I-Premise
278	is	_	_	I-Premise
279	normally	_	_	I-Premise
280	required	_	_	I-Premise
281	to	_	_	I-Premise
282	determine	_	_	I-Premise
283	definite	_	_	I-Premise
284	recurrence	_	_	I-Premise
285	rates	_	_	I-Premise
286	,	_	_	O
287	it	_	_	B-Claim
288	is	_	_	I-Claim
289	possible	_	_	I-Claim
290	that	_	_	I-Claim
291	MMS	_	_	I-Claim
292	may	_	_	I-Claim
293	become	_	_	I-Claim
294	a	_	_	I-Claim
295	cost-effective	_	_	I-Claim
296	treatment	_	_	I-Claim
297	for	_	_	I-Claim
298	recurrent	_	_	I-Claim
299	BCC	_	_	I-Claim
300	.	_	_	I-Claim


0	Hepatic	_	_	O
1	metastases	_	_	O
2	derive	_	_	O
3	most	_	_	O
4	of	_	_	O
5	their	_	_	O
6	blood	_	_	O
7	supply	_	_	O
8	from	_	_	O
9	the	_	_	O
10	hepatic	_	_	O
11	artery	_	_	O
12	;	_	_	O
13	therefore	_	_	O
14	,	_	_	O
15	for	_	_	B-Claim
16	patients	_	_	I-Claim
17	with	_	_	I-Claim
18	hepatic	_	_	I-Claim
19	metastases	_	_	I-Claim
20	from	_	_	I-Claim
21	colorectal	_	_	I-Claim
22	cancer	_	_	I-Claim
23	,	_	_	I-Claim
24	hepatic	_	_	I-Claim
25	arterial	_	_	I-Claim
26	infusion	_	_	I-Claim
27	(	_	_	I-Claim
28	HAI	_	_	I-Claim
29	)	_	_	I-Claim
30	of	_	_	I-Claim
31	chemotherapy	_	_	I-Claim
32	may	_	_	I-Claim
33	improve	_	_	I-Claim
34	outcome	_	_	I-Claim
35	.	_	_	I-Claim

36	In	_	_	O
37	a	_	_	O
38	multi-institutional	_	_	O
39	trial	_	_	O
40	,	_	_	O
41	135	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomly	_	_	O
45	assigned	_	_	O
46	to	_	_	O
47	receive	_	_	O
48	HAI	_	_	O
49	versus	_	_	O
50	systemic	_	_	O
51	bolus	_	_	O
52	fluorouracil	_	_	O
53	and	_	_	O
54	leucovorin	_	_	O
55	.	_	_	O

56	The	_	_	O
57	primary	_	_	O
58	end	_	_	O
59	point	_	_	O
60	was	_	_	O
61	survival	_	_	O
62	;	_	_	O
63	secondary	_	_	O
64	end	_	_	O
65	points	_	_	O
66	were	_	_	O
67	response	_	_	O
68	,	_	_	O
69	recurrence	_	_	O
70	,	_	_	O
71	toxicity	_	_	O
72	,	_	_	O
73	quality	_	_	O
74	of	_	_	O
75	life	_	_	O
76	,	_	_	O
77	cost	_	_	O
78	,	_	_	O
79	and	_	_	O
80	the	_	_	O
81	influence	_	_	O
82	of	_	_	O
83	molecular	_	_	O
84	markers	_	_	O
85	.	_	_	O

86	Overall	_	_	B-Premise
87	survival	_	_	I-Premise
88	was	_	_	I-Premise
89	significantly	_	_	I-Premise
90	longer	_	_	I-Premise
91	for	_	_	I-Premise
92	HAI	_	_	I-Premise
93	versus	_	_	I-Premise
94	systemic	_	_	I-Premise
95	treatment	_	_	I-Premise
96	(	_	_	I-Premise
97	median	_	_	I-Premise
98	,	_	_	I-Premise
99	24.4	_	_	I-Premise
100	v	_	_	I-Premise
101	20	_	_	I-Premise
102	months	_	_	I-Premise
103	;	_	_	I-Premise
104	P	_	_	I-Premise
105	=	_	_	I-Premise
106	.0034	_	_	I-Premise
107	)	_	_	I-Premise
108	,	_	_	I-Premise
109	as	_	_	I-Premise
110	were	_	_	I-Premise
111	response	_	_	I-Premise
112	rates	_	_	I-Premise
113	(	_	_	I-Premise
114	47	_	_	I-Premise
115	%	_	_	I-Premise
116	and	_	_	I-Premise
117	24	_	_	I-Premise
118	%	_	_	I-Premise
119	;	_	_	I-Premise
120	P	_	_	I-Premise
121	=	_	_	I-Premise
122	.012	_	_	I-Premise
123	)	_	_	I-Premise
124	and	_	_	I-Premise
125	time	_	_	I-Premise
126	to	_	_	I-Premise
127	hepatic	_	_	I-Premise
128	progression	_	_	I-Premise
129	(	_	_	I-Premise
130	THP	_	_	I-Premise
131	;	_	_	I-Premise
132	9.8	_	_	I-Premise
133	v	_	_	I-Premise
134	7.3	_	_	I-Premise
135	months	_	_	I-Premise
136	;	_	_	I-Premise
137	P	_	_	I-Premise
138	=	_	_	I-Premise
139	.034	_	_	I-Premise
140	)	_	_	I-Premise
141	.	_	_	I-Premise

142	Time	_	_	B-Premise
143	to	_	_	I-Premise
144	extrahepatic	_	_	I-Premise
145	progression	_	_	I-Premise
146	(	_	_	I-Premise
147	7.7	_	_	I-Premise
148	v	_	_	I-Premise
149	14.8	_	_	I-Premise
150	months	_	_	I-Premise
151	;	_	_	I-Premise
152	P	_	_	I-Premise
153	=	_	_	I-Premise
154	.029	_	_	I-Premise
155	)	_	_	I-Premise
156	was	_	_	I-Premise
157	significantly	_	_	I-Premise
158	shorter	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	HAI	_	_	I-Premise
162	group	_	_	I-Premise
163	.	_	_	I-Premise

164	Quality-of-life	_	_	B-Premise
165	measurements	_	_	I-Premise
166	showed	_	_	I-Premise
167	improved	_	_	I-Premise
168	physical	_	_	I-Premise
169	functioning	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	HAI	_	_	I-Premise
173	group	_	_	I-Premise
174	at	_	_	I-Premise
175	the	_	_	I-Premise
176	3-	_	_	I-Premise
177	and	_	_	I-Premise
178	6-month	_	_	I-Premise
179	follow-up	_	_	I-Premise
180	assessments	_	_	I-Premise
181	.	_	_	I-Premise

182	Toxicity	_	_	B-Premise
183	included	_	_	I-Premise
184	grade	_	_	I-Premise
185	>	_	_	I-Premise
186	or	_	_	I-Premise
187	=	_	_	I-Premise
188	3	_	_	I-Premise
189	neutropenia	_	_	I-Premise
190	(	_	_	I-Premise
191	2	_	_	I-Premise
192	%	_	_	I-Premise
193	and	_	_	I-Premise
194	45	_	_	I-Premise
195	%	_	_	I-Premise
196	;	_	_	I-Premise
197	P	_	_	I-Premise
198	<	_	_	I-Premise
199	.01	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	stomatitis	_	_	I-Premise
203	(	_	_	I-Premise
204	0	_	_	I-Premise
205	%	_	_	I-Premise
206	and	_	_	I-Premise
207	24	_	_	I-Premise
208	%	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	.01	_	_	I-Premise
213	)	_	_	I-Premise
214	,	_	_	I-Premise
215	and	_	_	I-Premise
216	bilirubin	_	_	I-Premise
217	elevation	_	_	I-Premise
218	(	_	_	I-Premise
219	18.6	_	_	I-Premise
220	%	_	_	I-Premise
221	and	_	_	I-Premise
222	0	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	.01	_	_	I-Premise
227	)	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	HAI	_	_	I-Premise
231	and	_	_	I-Premise
232	systemic	_	_	I-Premise
233	treatment	_	_	I-Premise
234	groups	_	_	I-Premise
235	,	_	_	I-Premise
236	respectively	_	_	I-Premise
237	.	_	_	I-Premise

238	A	_	_	B-Premise
239	greater	_	_	I-Premise
240	proportion	_	_	I-Premise
241	of	_	_	I-Premise
242	men	_	_	I-Premise
243	versus	_	_	I-Premise
244	women	_	_	I-Premise
245	receiving	_	_	I-Premise
246	HAI	_	_	I-Premise
247	experienced	_	_	I-Premise
248	biliary	_	_	I-Premise
249	toxicity	_	_	I-Premise
250	(	_	_	I-Premise
251	37	_	_	I-Premise
252	%	_	_	I-Premise
253	and	_	_	I-Premise
254	15	_	_	I-Premise
255	%	_	_	I-Premise
256	,	_	_	I-Premise
257	respectively	_	_	I-Premise
258	;	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	.05	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	For	_	_	B-Premise
265	HAI	_	_	I-Premise
266	patients	_	_	I-Premise
267	with	_	_	I-Premise
268	thymidylate	_	_	I-Premise
269	synthase	_	_	I-Premise
270	levels	_	_	I-Premise
271	in	_	_	I-Premise
272	tumor	_	_	I-Premise
273	less	_	_	I-Premise
274	than	_	_	I-Premise
275	or	_	_	I-Premise
276	>	_	_	I-Premise
277	or	_	_	I-Premise
278	=	_	_	I-Premise
279	4	_	_	I-Premise
280	,	_	_	I-Premise
281	the	_	_	I-Premise
282	median	_	_	I-Premise
283	survival	_	_	I-Premise
284	was	_	_	I-Premise
285	24	_	_	I-Premise
286	and	_	_	I-Premise
287	14	_	_	I-Premise
288	months	_	_	I-Premise
289	,	_	_	I-Premise
290	respectively	_	_	I-Premise
291	(	_	_	I-Premise
292	P	_	_	I-Premise
293	=	_	_	I-Premise
294	.17	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	HAI	_	_	B-Claim
298	therapy	_	_	I-Claim
299	increased	_	_	I-Claim
300	overall	_	_	I-Claim
301	survival	_	_	I-Claim
302	,	_	_	I-Claim
303	response	_	_	I-Claim
304	rate	_	_	I-Claim
305	,	_	_	I-Claim
306	THP	_	_	I-Claim
307	,	_	_	I-Claim
308	and	_	_	I-Claim
309	was	_	_	I-Claim
310	associated	_	_	I-Claim
311	with	_	_	I-Claim
312	better	_	_	I-Claim
313	physical	_	_	I-Claim
314	functioning	_	_	I-Claim
315	compared	_	_	I-Claim
316	with	_	_	I-Claim
317	systemic	_	_	I-Claim
318	therapy	_	_	I-Claim
319	.	_	_	I-Claim

320	Additional	_	_	B-Claim
321	studies	_	_	I-Claim
322	need	_	_	I-Claim
323	to	_	_	I-Claim
324	address	_	_	I-Claim
325	the	_	_	I-Claim
326	overall	_	_	I-Claim
327	benefit	_	_	I-Claim
328	and	_	_	I-Claim
329	cost	_	_	I-Claim
330	of	_	_	I-Claim
331	new	_	_	I-Claim
332	chemotherapy	_	_	I-Claim
333	agents	_	_	I-Claim
334	versus	_	_	I-Claim
335	HAI	_	_	I-Claim
336	alone	_	_	I-Claim
337	or	_	_	I-Claim
338	the	_	_	I-Claim
339	combination	_	_	I-Claim
340	of	_	_	I-Claim
341	HAI	_	_	I-Claim
342	with	_	_	I-Claim
343	new	_	_	I-Claim
344	agents	_	_	I-Claim
345	.	_	_	I-Claim


0	Prospective	_	_	B-Claim
1	investigations	_	_	I-Claim
2	of	_	_	I-Claim
3	complete	_	_	I-Claim
4	decongestive	_	_	I-Claim
5	lymphatic	_	_	I-Claim
6	physiotherapy	_	_	I-Claim
7	(	_	_	I-Claim
8	CDPT	_	_	I-Claim
9	)	_	_	I-Claim
10	,	_	_	I-Claim
11	including	_	_	I-Claim
12	manual	_	_	I-Claim
13	lymphatic	_	_	I-Claim
14	drainage	_	_	I-Claim
15	(	_	_	I-Claim
16	MLD	_	_	I-Claim
17	)	_	_	I-Claim
18	,	_	_	I-Claim
19	have	_	_	I-Claim
20	validated	_	_	I-Claim
21	the	_	_	I-Claim
22	efficacy	_	_	I-Claim
23	of	_	_	I-Claim
24	these	_	_	I-Claim
25	interventions	_	_	I-Claim
26	for	_	_	I-Claim
27	the	_	_	I-Claim
28	initial	_	_	I-Claim
29	reduction	_	_	I-Claim
30	of	_	_	I-Claim
31	edema	_	_	I-Claim
32	and	_	_	I-Claim
33	long-term	_	_	I-Claim
34	maintenance	_	_	I-Claim
35	of	_	_	I-Claim
36	limb	_	_	I-Claim
37	volume	_	_	I-Claim
38	in	_	_	I-Claim
39	lymphedema	_	_	I-Claim
40	.	_	_	I-Claim

41	However	_	_	O
42	,	_	_	O
43	CDPT	_	_	O
44	demands	_	_	O
45	substantial	_	_	O
46	time	_	_	O
47	and	_	_	O
48	effort	_	_	O
49	from	_	_	O
50	patients	_	_	O
51	to	_	_	O
52	maintain	_	_	O
53	these	_	_	O
54	benefits	_	_	O
55	;	_	_	O
56	the	_	_	B-Claim
57	treatments	_	_	I-Claim
58	are	_	_	I-Claim
59	not	_	_	I-Claim
60	always	_	_	I-Claim
61	well-accepted	_	_	I-Claim
62	,	_	_	I-Claim
63	and	_	_	O
64	patients	_	_	B-Claim
65	may	_	_	I-Claim
66	suffer	_	_	I-Claim
67	from	_	_	I-Claim
68	a	_	_	I-Claim
69	deterioration	_	_	I-Claim
70	in	_	_	I-Claim
71	quality-of-life	_	_	I-Claim
72	or	_	_	I-Claim
73	a	_	_	I-Claim
74	time-dependent	_	_	I-Claim
75	loss	_	_	I-Claim
76	of	_	_	I-Claim
77	initial	_	_	I-Claim
78	treatment	_	_	I-Claim
79	benefits	_	_	I-Claim
80	.	_	_	I-Claim

81	A	_	_	O
82	new	_	_	O
83	device	_	_	O
84	designed	_	_	O
85	for	_	_	O
86	home	_	_	O
87	use	_	_	O
88	by	_	_	O
89	the	_	_	O
90	patient	_	_	O
91	,	_	_	O
92	the	_	_	O
93	Flexitouch	_	_	O
94	,	_	_	O
95	has	_	_	O
96	been	_	_	O
97	developed	_	_	O
98	to	_	_	O
99	mechanically	_	_	O
100	simulate	_	_	O
101	MLD	_	_	O
102	.	_	_	O

103	We	_	_	O
104	have	_	_	O
105	undertaken	_	_	O
106	a	_	_	O
107	prospective	_	_	O
108	,	_	_	O
109	randomized	_	_	O
110	,	_	_	O
111	crossover	_	_	O
112	study	_	_	O
113	of	_	_	O
114	the	_	_	O
115	efficacy	_	_	O
116	of	_	_	O
117	the	_	_	O
118	Flexitouch	_	_	O
119	,	_	_	O
120	when	_	_	O
121	compared	_	_	O
122	to	_	_	O
123	massage	_	_	O
124	,	_	_	O
125	in	_	_	O
126	the	_	_	O
127	self-administered	_	_	O
128	maintenance	_	_	O
129	therapy	_	_	O
130	of	_	_	O
131	lymphedema	_	_	O
132	.	_	_	O

133	A	_	_	O
134	prospective	_	_	O
135	,	_	_	O
136	randomized	_	_	O
137	,	_	_	O
138	crossover	_	_	O
139	study	_	_	O
140	of	_	_	O
141	maintenance	_	_	O
142	therapy	_	_	O
143	was	_	_	O
144	performed	_	_	O
145	in	_	_	O
146	10	_	_	O
147	patients	_	_	O
148	with	_	_	O
149	unilateral	_	_	O
150	breast	_	_	O
151	cancer-associated	_	_	O
152	lymphedema	_	_	O
153	of	_	_	O
154	the	_	_	O
155	arm	_	_	O
156	.	_	_	O

157	Each	_	_	O
158	observation	_	_	O
159	phase	_	_	O
160	included	_	_	O
161	self-administered	_	_	O
162	treatment	_	_	O
163	with	_	_	O
164	the	_	_	O
165	Flexitouch	_	_	O
166	or	_	_	O
167	massage	_	_	O
168	,	_	_	O
169	1	_	_	O
170	hour	_	_	O
171	daily	_	_	O
172	for	_	_	O
173	14	_	_	O
174	days	_	_	O
175	,	_	_	O
176	respectively	_	_	O
177	,	_	_	O
178	followed	_	_	O
179	by	_	_	O
180	crossover	_	_	O
181	to	_	_	O
182	the	_	_	O
183	alternate	_	_	O
184	treatment	_	_	O
185	phase	_	_	O
186	.	_	_	O

187	Each	_	_	O
188	treatment	_	_	O
189	phase	_	_	O
190	was	_	_	O
191	preceded	_	_	O
192	by	_	_	O
193	a	_	_	O
194	1	_	_	O
195	week	_	_	O
196	treatment	_	_	O
197	washout	_	_	O
198	,	_	_	O
199	with	_	_	O
200	use	_	_	O
201	of	_	_	O
202	garment	_	_	O
203	only	_	_	O
204	.	_	_	O

205	The	_	_	O
206	sequence	_	_	O
207	of	_	_	O
208	treatment	_	_	O
209	was	_	_	O
210	randomly	_	_	O
211	assigned	_	_	O
212	.	_	_	O

213	The	_	_	O
214	potential	_	_	O
215	impact	_	_	O
216	of	_	_	O
217	treatment	_	_	O
218	modality	_	_	O
219	on	_	_	O
220	quality	_	_	O
221	of	_	_	O
222	life	_	_	O
223	was	_	_	O
224	assessed	_	_	O
225	with	_	_	O
226	serial	_	_	O
227	administration	_	_	O
228	of	_	_	O
229	the	_	_	O
230	SF-36	_	_	O
231	.	_	_	O

232	Statistical	_	_	O
233	analysis	_	_	O
234	disclosed	_	_	O
235	that	_	_	O
236	the	_	_	O
237	order	_	_	O
238	of	_	_	O
239	treatment	_	_	O
240	had	_	_	O
241	no	_	_	O
242	outcome	_	_	O
243	influence	_	_	O
244	,	_	_	O
245	permitting	_	_	O
246	10	_	_	O
247	comparisons	_	_	O
248	within	_	_	O
249	each	_	_	O
250	treatment	_	_	O
251	group	_	_	O
252	.	_	_	O

253	Post-treatment	_	_	B-Premise
254	arm	_	_	I-Premise
255	volume	_	_	I-Premise
256	reduced	_	_	I-Premise
257	significantly	_	_	I-Premise
258	after	_	_	I-Premise
259	the	_	_	I-Premise
260	Flexitouch	_	_	I-Premise
261	,	_	_	I-Premise
262	but	_	_	I-Premise
263	not	_	_	I-Premise
264	after	_	_	I-Premise
265	self-administered	_	_	I-Premise
266	massage	_	_	I-Premise
267	.	_	_	I-Premise

268	The	_	_	B-Premise
269	patients	_	_	I-Premise
270	'	_	_	I-Premise
271	mean	_	_	I-Premise
272	weight	_	_	I-Premise
273	decreased	_	_	I-Premise
274	significantly	_	_	I-Premise
275	with	_	_	I-Premise
276	Flexitouch	_	_	I-Premise
277	use	_	_	I-Premise
278	,	_	_	I-Premise
279	but	_	_	I-Premise
280	not	_	_	I-Premise
281	with	_	_	I-Premise
282	massage	_	_	I-Premise
283	.	_	_	I-Premise

284	The	_	_	B-Premise
285	Flexitouch	_	_	I-Premise
286	device	_	_	I-Premise
287	was	_	_	I-Premise
288	apparently	_	_	I-Premise
289	well-tolerated	_	_	I-Premise
290	and	_	_	I-Premise
291	accepted	_	_	I-Premise
292	by	_	_	I-Premise
293	patients	_	_	I-Premise
294	.	_	_	I-Premise

295	Serial	_	_	B-Premise
296	SF-36	_	_	I-Premise
297	administration	_	_	I-Premise
298	showed	_	_	I-Premise
299	no	_	_	I-Premise
300	deterioration	_	_	I-Premise
301	in	_	_	I-Premise
302	physical	_	_	I-Premise
303	or	_	_	I-Premise
304	psychosocial	_	_	I-Premise
305	scores	_	_	I-Premise
306	compared	_	_	I-Premise
307	to	_	_	I-Premise
308	baseline	_	_	I-Premise
309	measurements	_	_	I-Premise
310	;	_	_	I-Premise
311	there	_	_	B-Premise
312	were	_	_	I-Premise
313	no	_	_	I-Premise
314	statistical	_	_	I-Premise
315	differences	_	_	I-Premise
316	in	_	_	I-Premise
317	scores	_	_	I-Premise
318	when	_	_	I-Premise
319	the	_	_	I-Premise
320	two	_	_	I-Premise
321	treatment	_	_	I-Premise
322	modalities	_	_	I-Premise
323	were	_	_	I-Premise
324	compared	_	_	I-Premise
325	.	_	_	I-Premise

326	This	_	_	B-Claim
327	short-term	_	_	I-Claim
328	prospective	_	_	I-Claim
329	evaluation	_	_	I-Claim
330	of	_	_	I-Claim
331	the	_	_	I-Claim
332	Flexitouch	_	_	I-Claim
333	suggests	_	_	I-Claim
334	that	_	_	I-Claim
335	the	_	_	I-Claim
336	device	_	_	I-Claim
337	may	_	_	I-Claim
338	provide	_	_	I-Claim
339	better	_	_	I-Claim
340	maintenance	_	_	I-Claim
341	edema	_	_	I-Claim
342	control	_	_	I-Claim
343	than	_	_	I-Claim
344	self-adiminstered	_	_	I-Claim
345	massage	_	_	I-Claim
346	in	_	_	I-Claim
347	breast	_	_	I-Claim
348	cancer-associated	_	_	I-Claim
349	lymphedema	_	_	I-Claim
350	.	_	_	I-Claim

351	The	_	_	B-Claim
352	apparent	_	_	I-Claim
353	ease	_	_	I-Claim
354	of	_	_	I-Claim
355	use	_	_	I-Claim
356	and	_	_	I-Claim
357	reliability	_	_	I-Claim
358	of	_	_	I-Claim
359	response	_	_	I-Claim
360	to	_	_	I-Claim
361	the	_	_	I-Claim
362	device	_	_	I-Claim
363	suggest	_	_	I-Claim
364	that	_	_	I-Claim
365	further	_	_	I-Claim
366	broad-scale	_	_	I-Claim
367	testing	_	_	I-Claim
368	is	_	_	I-Claim
369	warranted	_	_	I-Claim
370	.	_	_	I-Claim


0	The	_	_	O
1	goal	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	impact	_	_	O
10	of	_	_	O
11	neuronavigation	_	_	O
12	on	_	_	O
13	the	_	_	O
14	cytoreductive	_	_	O
15	treatment	_	_	O
16	of	_	_	O
17	solitary	_	_	O
18	contrast-enhancing	_	_	O
19	intracerebral	_	_	O
20	tumors	_	_	O
21	and	_	_	O
22	outcomes	_	_	O
23	of	_	_	O
24	this	_	_	O
25	treatment	_	_	O
26	in	_	_	O
27	cases	_	_	O
28	in	_	_	O
29	which	_	_	O
30	neuronavigation	_	_	O
31	was	_	_	O
32	preoperatively	_	_	O
33	judged	_	_	O
34	to	_	_	O
35	be	_	_	O
36	redundant	_	_	O
37	.	_	_	O

38	The	_	_	O
39	authors	_	_	O
40	conducted	_	_	O
41	a	_	_	O
42	prospective	_	_	O
43	randomized	_	_	O
44	study	_	_	O
45	in	_	_	O
46	which	_	_	O
47	45	_	_	O
48	patients	_	_	O
49	,	_	_	O
50	each	_	_	O
51	harboring	_	_	O
52	a	_	_	O
53	solitary	_	_	O
54	contrast-enhancing	_	_	O
55	intracerebral	_	_	O
56	tumor	_	_	O
57	,	_	_	O
58	were	_	_	O
59	randomized	_	_	O
60	for	_	_	O
61	surgery	_	_	O
62	with	_	_	O
63	or	_	_	O
64	without	_	_	O
65	neuronavigation	_	_	O
66	.	_	_	O

67	Peri-	_	_	O
68	and	_	_	O
69	postoperative	_	_	O
70	parameters	_	_	O
71	under	_	_	O
72	investigation	_	_	O
73	included	_	_	O
74	the	_	_	O
75	following	_	_	O
76	:	_	_	O
77	duration	_	_	O
78	of	_	_	O
79	the	_	_	O
80	procedure	_	_	O
81	;	_	_	O
82	surgeon	_	_	O
83	's	_	_	O
84	estimate	_	_	O
85	of	_	_	O
86	the	_	_	O
87	usefulness	_	_	O
88	of	_	_	O
89	neuronavigation	_	_	O
90	;	_	_	O
91	quantification	_	_	O
92	of	_	_	O
93	the	_	_	O
94	extent	_	_	O
95	of	_	_	O
96	resection	_	_	O
97	,	_	_	O
98	determined	_	_	O
99	using	_	_	O
100	magnetic	_	_	O
101	resonance	_	_	O
102	imaging	_	_	O
103	;	_	_	O
104	and	_	_	O
105	the	_	_	O
106	postoperative	_	_	O
107	course	_	_	O
108	,	_	_	O
109	as	_	_	O
110	evaluated	_	_	O
111	by	_	_	O
112	neurological	_	_	O
113	examinations	_	_	O
114	,	_	_	O
115	the	_	_	O
116	patient	_	_	O
117	's	_	_	O
118	quality-of-life	_	_	O
119	self-assessment	_	_	O
120	,	_	_	O
121	application	_	_	O
122	of	_	_	O
123	the	_	_	O
124	Barthel	_	_	O
125	index	_	_	O
126	and	_	_	O
127	the	_	_	O
128	Karnofsky	_	_	O
129	Performance	_	_	O
130	Scale	_	_	O
131	score	_	_	O
132	,	_	_	O
133	and	_	_	O
134	the	_	_	O
135	patient	_	_	O
136	's	_	_	O
137	time	_	_	O
138	of	_	_	O
139	death	_	_	O
140	.	_	_	O

141	The	_	_	B-Premise
142	mean	_	_	I-Premise
143	amount	_	_	I-Premise
144	of	_	_	I-Premise
145	residual	_	_	I-Premise
146	tumor	_	_	I-Premise
147	tissue	_	_	I-Premise
148	was	_	_	I-Premise
149	28.9	_	_	I-Premise
150	%	_	_	I-Premise
151	for	_	_	I-Premise
152	standard	_	_	I-Premise
153	surgery	_	_	I-Premise
154	(	_	_	I-Premise
155	SS	_	_	I-Premise
156	)	_	_	I-Premise
157	and	_	_	I-Premise
158	13.8	_	_	I-Premise
159	%	_	_	I-Premise
160	for	_	_	I-Premise
161	surgery	_	_	I-Premise
162	involving	_	_	I-Premise
163	neuronavigation	_	_	I-Premise
164	(	_	_	I-Premise
165	SN	_	_	I-Premise
166	)	_	_	I-Premise
167	.	_	_	I-Premise

168	The	_	_	B-Premise
169	corresponding	_	_	I-Premise
170	mean	_	_	I-Premise
171	amounts	_	_	I-Premise
172	of	_	_	I-Premise
173	residual	_	_	I-Premise
174	contrast-enhancing	_	_	I-Premise
175	tumor	_	_	I-Premise
176	tissue	_	_	I-Premise
177	were	_	_	I-Premise
178	29.2	_	_	I-Premise
179	and	_	_	I-Premise
180	24.4	_	_	I-Premise
181	%	_	_	I-Premise
182	,	_	_	I-Premise
183	respectively	_	_	I-Premise
184	.	_	_	I-Premise

185	These	_	_	B-Premise
186	differences	_	_	I-Premise
187	were	_	_	I-Premise
188	not	_	_	I-Premise
189	significant	_	_	I-Premise
190	.	_	_	I-Premise

191	Gross-total	_	_	B-Premise
192	removal	_	_	I-Premise
193	(	_	_	I-Premise
194	GTR	_	_	I-Premise
195	)	_	_	I-Premise
196	was	_	_	I-Premise
197	achieved	_	_	I-Premise
198	in	_	_	I-Premise
199	five	_	_	I-Premise
200	patients	_	_	I-Premise
201	who	_	_	I-Premise
202	underwent	_	_	I-Premise
203	SS	_	_	I-Premise
204	and	_	_	I-Premise
205	in	_	_	I-Premise
206	three	_	_	I-Premise
207	who	_	_	I-Premise
208	underwent	_	_	I-Premise
209	SN	_	_	I-Premise
210	.	_	_	I-Premise

211	Median	_	_	B-Premise
212	survival	_	_	I-Premise
213	was	_	_	I-Premise
214	significantly	_	_	I-Premise
215	shorter	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	SN	_	_	I-Premise
219	group	_	_	I-Premise
220	(	_	_	I-Premise
221	5.6	_	_	I-Premise
222	months	_	_	I-Premise
223	compared	_	_	I-Premise
224	with	_	_	I-Premise
225	9	_	_	I-Premise
226	months	_	_	I-Premise
227	,	_	_	I-Premise
228	unadjusted	_	_	I-Premise
229	hazard	_	_	I-Premise
230	ratio	_	_	I-Premise
231	=	_	_	I-Premise
232	1.6	_	_	I-Premise
233	)	_	_	I-Premise
234	;	_	_	I-Premise
235	however	_	_	B-Premise
236	,	_	_	I-Premise
237	this	_	_	I-Premise
238	difference	_	_	I-Premise
239	may	_	_	I-Premise
240	be	_	_	I-Premise
241	attributable	_	_	I-Premise
242	to	_	_	I-Premise
243	the	_	_	I-Premise
244	coincidental	_	_	I-Premise
245	early	_	_	I-Premise
246	death	_	_	I-Premise
247	of	_	_	I-Premise
248	three	_	_	I-Premise
249	patients	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	SN	_	_	I-Premise
253	group	_	_	I-Premise
254	.	_	_	I-Premise

255	No	_	_	B-Premise
256	discernible	_	_	I-Premise
257	important	_	_	I-Premise
258	effect	_	_	I-Premise
259	on	_	_	I-Premise
260	the	_	_	I-Premise
261	patients	_	_	I-Premise
262	'	_	_	I-Premise
263	3-month	_	_	I-Premise
264	postoperative	_	_	I-Premise
265	course	_	_	I-Premise
266	was	_	_	I-Premise
267	identified	_	_	I-Premise
268	.	_	_	I-Premise

269	There	_	_	B-Claim
270	is	_	_	I-Claim
271	no	_	_	I-Claim
272	rationale	_	_	I-Claim
273	for	_	_	I-Claim
274	the	_	_	I-Claim
275	routine	_	_	I-Claim
276	use	_	_	I-Claim
277	of	_	_	I-Claim
278	neuronavigation	_	_	I-Claim
279	to	_	_	I-Claim
280	improve	_	_	I-Claim
281	the	_	_	I-Claim
282	extent	_	_	I-Claim
283	of	_	_	I-Claim
284	tumor	_	_	I-Claim
285	resection	_	_	I-Claim
286	and	_	_	I-Claim
287	prognosis	_	_	I-Claim
288	in	_	_	I-Claim
289	patients	_	_	I-Claim
290	harboring	_	_	I-Claim
291	a	_	_	I-Claim
292	solitary	_	_	I-Claim
293	enhancing	_	_	I-Claim
294	intracerebral	_	_	I-Claim
295	lesion	_	_	I-Claim
296	when	_	_	I-Claim
297	neuronavigation	_	_	I-Claim
298	is	_	_	I-Claim
299	not	_	_	I-Claim
300	already	_	_	I-Claim
301	deemed	_	_	I-Claim
302	advantageous	_	_	I-Claim
303	because	_	_	I-Claim
304	of	_	_	I-Claim
305	the	_	_	I-Claim
306	size	_	_	I-Claim
307	or	_	_	I-Claim
308	location	_	_	I-Claim
309	of	_	_	I-Claim
310	the	_	_	I-Claim
311	lesion	_	_	I-Claim
312	.	_	_	I-Claim


0	Experimental	_	_	B-Claim
1	and	_	_	I-Claim
2	early	_	_	I-Claim
3	clinical	_	_	I-Claim
4	investigations	_	_	I-Claim
5	have	_	_	I-Claim
6	demonstrated	_	_	I-Claim
7	encouraging	_	_	I-Claim
8	results	_	_	I-Claim
9	for	_	_	I-Claim
10	estramustine	_	_	I-Claim
11	in	_	_	I-Claim
12	the	_	_	I-Claim
13	treatment	_	_	I-Claim
14	of	_	_	I-Claim
15	malignant	_	_	I-Claim
16	glioma	_	_	I-Claim
17	.	_	_	O

18	The	_	_	O
19	present	_	_	O
20	study	_	_	O
21	is	_	_	O
22	an	_	_	O
23	open	_	_	O
24	randomized	_	_	O
25	clinical	_	_	O
26	trial	_	_	O
27	comparing	_	_	O
28	estramustine	_	_	O
29	phosphate	_	_	O
30	(	_	_	O
31	Estracyt	_	_	O
32	)	_	_	O
33	in	_	_	O
34	addition	_	_	O
35	to	_	_	O
36	radiotherapy	_	_	O
37	with	_	_	O
38	radiotherapy	_	_	O
39	alone	_	_	O
40	as	_	_	O
41	first	_	_	O
42	line	_	_	O
43	treatment	_	_	O
44	of	_	_	O
45	astrocytoma	_	_	O
46	grade	_	_	O
47	III	_	_	O
48	and	_	_	O
49	IV	_	_	O
50	.	_	_	O

51	The	_	_	O
52	140	_	_	O
53	patients	_	_	O
54	included	_	_	O
55	were	_	_	O
56	in	_	_	O
57	a	_	_	O
58	good	_	_	O
59	clinical	_	_	O
60	condition	_	_	O
61	with	_	_	O
62	a	_	_	O
63	median	_	_	O
64	age	_	_	O
65	of	_	_	O
66	55	_	_	O
67	years	_	_	O
68	(	_	_	O
69	range	_	_	O
70	22-87	_	_	O
71	)	_	_	O
72	.	_	_	O

73	Estramustine	_	_	O
74	was	_	_	O
75	given	_	_	O
76	orally	_	_	O
77	,	_	_	O
78	280	_	_	O
79	mg	_	_	O
80	twice	_	_	O
81	daily	_	_	O
82	,	_	_	O
83	as	_	_	O
84	soon	_	_	O
85	as	_	_	O
86	the	_	_	O
87	diagnosis	_	_	O
88	was	_	_	O
89	established	_	_	O
90	,	_	_	O
91	during	_	_	O
92	and	_	_	O
93	after	_	_	O
94	the	_	_	O
95	radiotherapy	_	_	O
96	for	_	_	O
97	a	_	_	O
98	period	_	_	O
99	of	_	_	O
100	in	_	_	O
101	total	_	_	O
102	3	_	_	O
103	months	_	_	O
104	.	_	_	O

105	Radiotherapy	_	_	O
106	was	_	_	O
107	delivered	_	_	O
108	on	_	_	O
109	weekdays	_	_	O
110	2	_	_	O
111	Gy	_	_	O
112	daily	_	_	O
113	up	_	_	O
114	to	_	_	O
115	56	_	_	O
116	Gy	_	_	O
117	.	_	_	O

118	Eighteen	_	_	O
119	patients	_	_	O
120	were	_	_	O
121	excluded	_	_	O
122	due	_	_	O
123	to	_	_	O
124	misclassification	_	_	O
125	,	_	_	O
126	leaving	_	_	O
127	122	_	_	O
128	patients	_	_	O
129	eligible	_	_	O
130	for	_	_	O
131	evaluation	_	_	O
132	.	_	_	O

133	Overall	_	_	B-Premise
134	the	_	_	I-Premise
135	treatment	_	_	I-Premise
136	was	_	_	I-Premise
137	well	_	_	I-Premise
138	tolerated	_	_	I-Premise
139	.	_	_	O

140	Mild	_	_	B-Premise
141	or	_	_	I-Premise
142	moderate	_	_	I-Premise
143	nausea	_	_	I-Premise
144	was	_	_	I-Premise
145	the	_	_	I-Premise
146	most	_	_	I-Premise
147	common	_	_	I-Premise
148	side	_	_	I-Premise
149	effect	_	_	I-Premise
150	of	_	_	I-Premise
151	estramustine	_	_	I-Premise
152	.	_	_	I-Premise

153	The	_	_	O
154	minimum	_	_	O
155	follow-up	_	_	O
156	time	_	_	O
157	was	_	_	O
158	5.2	_	_	O
159	years	_	_	O
160	for	_	_	O
161	the	_	_	O
162	surviving	_	_	O
163	patients	_	_	O
164	.	_	_	O

165	For	_	_	B-Premise
166	astrocytoma	_	_	I-Premise
167	grade	_	_	I-Premise
168	III	_	_	I-Premise
169	the	_	_	I-Premise
170	median	_	_	I-Premise
171	survival	_	_	I-Premise
172	time	_	_	I-Premise
173	was	_	_	I-Premise
174	10.6	_	_	I-Premise
175	(	_	_	I-Premise
176	1.3-92.7	_	_	I-Premise
177	)	_	_	I-Premise
178	months	_	_	I-Premise
179	for	_	_	I-Premise
180	the	_	_	I-Premise
181	radiotherapy	_	_	I-Premise
182	only	_	_	I-Premise
183	group	_	_	I-Premise
184	and	_	_	I-Premise
185	17.3	_	_	I-Premise
186	(	_	_	I-Premise
187	0.4-96.9+	_	_	I-Premise
188	)	_	_	I-Premise
189	months	_	_	I-Premise
190	for	_	_	I-Premise
191	the	_	_	I-Premise
192	estramustine	_	_	I-Premise
193	+	_	_	I-Premise
194	radiotherapy	_	_	I-Premise
195	group	_	_	I-Premise
196	.	_	_	I-Premise

197	In	_	_	B-Premise
198	grade	_	_	I-Premise
199	IV	_	_	I-Premise
200	the	_	_	I-Premise
201	corresponding	_	_	I-Premise
202	median	_	_	I-Premise
203	survival	_	_	I-Premise
204	time	_	_	I-Premise
205	was	_	_	I-Premise
206	12.3	_	_	I-Premise
207	(	_	_	I-Premise
208	2.1-89.2	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	10.3	_	_	I-Premise
212	(	_	_	I-Premise
213	0.3-91.7+	_	_	I-Premise
214	)	_	_	I-Premise
215	months	_	_	I-Premise
216	,	_	_	I-Premise
217	respectively	_	_	I-Premise
218	.	_	_	I-Premise

219	Median	_	_	B-Premise
220	time	_	_	I-Premise
221	to	_	_	I-Premise
222	progress	_	_	I-Premise
223	for	_	_	I-Premise
224	radiotherapy	_	_	I-Premise
225	only	_	_	I-Premise
226	and	_	_	I-Premise
227	radiotherapy	_	_	I-Premise
228	and	_	_	I-Premise
229	estramustin	_	_	I-Premise
230	group	_	_	I-Premise
231	in	_	_	I-Premise
232	grade	_	_	I-Premise
233	III	_	_	I-Premise
234	tumours	_	_	I-Premise
235	was	_	_	I-Premise
236	6.5	_	_	I-Premise
237	and	_	_	I-Premise
238	10.1	_	_	I-Premise
239	months	_	_	I-Premise
240	,	_	_	I-Premise
241	respectively	_	_	I-Premise
242	.	_	_	I-Premise

243	In	_	_	B-Premise
244	grade	_	_	I-Premise
245	IV	_	_	I-Premise
246	tumours	_	_	I-Premise
247	the	_	_	I-Premise
248	corresponding	_	_	I-Premise
249	figures	_	_	I-Premise
250	were	_	_	I-Premise
251	5.1	_	_	I-Premise
252	and	_	_	I-Premise
253	3.3	_	_	I-Premise
254	months	_	_	I-Premise
255	,	_	_	I-Premise
256	respectively	_	_	I-Premise
257	.	_	_	I-Premise

258	Although	_	_	B-Premise
259	there	_	_	I-Premise
260	was	_	_	I-Premise
261	a	_	_	I-Premise
262	tendency	_	_	I-Premise
263	for	_	_	I-Premise
264	improved	_	_	I-Premise
265	survival	_	_	I-Premise
266	in	_	_	I-Premise
267	grade	_	_	I-Premise
268	III	_	_	I-Premise
269	,	_	_	I-Premise
270	no	_	_	I-Premise
271	statistical	_	_	I-Premise
272	significant	_	_	I-Premise
273	differences	_	_	I-Premise
274	were	_	_	I-Premise
275	found	_	_	I-Premise
276	between	_	_	I-Premise
277	the	_	_	I-Premise
278	treatment	_	_	I-Premise
279	groups	_	_	I-Premise
280	.	_	_	I-Premise

281	No	_	_	B-Premise
282	differences	_	_	I-Premise
283	between	_	_	I-Premise
284	the	_	_	I-Premise
285	two	_	_	I-Premise
286	treatment	_	_	I-Premise
287	groups	_	_	I-Premise
288	were	_	_	I-Premise
289	evident	_	_	I-Premise
290	with	_	_	I-Premise
291	respect	_	_	I-Premise
292	to	_	_	I-Premise
293	quality	_	_	I-Premise
294	of	_	_	I-Premise
295	life	_	_	I-Premise
296	according	_	_	I-Premise
297	to	_	_	I-Premise
298	the	_	_	I-Premise
299	EORTC	_	_	I-Premise
300	QLQ-protocol	_	_	I-Premise
301	.	_	_	I-Premise

302	In	_	_	B-Claim
303	conclusion	_	_	I-Claim
304	,	_	_	I-Claim
305	this	_	_	I-Claim
306	first	_	_	I-Claim
307	randomized	_	_	I-Claim
308	study	_	_	I-Claim
309	did	_	_	I-Claim
310	not	_	_	I-Claim
311	demonstrate	_	_	I-Claim
312	any	_	_	I-Claim
313	significant	_	_	I-Claim
314	improvement	_	_	I-Claim
315	of	_	_	I-Claim
316	using	_	_	I-Claim
317	estramustine	_	_	I-Claim
318	in	_	_	I-Claim
319	addition	_	_	I-Claim
320	to	_	_	I-Claim
321	conventional	_	_	I-Claim
322	radiotherapy	_	_	I-Claim
323	,	_	_	I-Claim
324	however	_	_	B-Claim
325	,	_	_	I-Claim
326	a	_	_	I-Claim
327	trend	_	_	I-Claim
328	for	_	_	I-Claim
329	a	_	_	I-Claim
330	positive	_	_	I-Claim
331	response	_	_	I-Claim
332	for	_	_	I-Claim
333	the	_	_	I-Claim
334	estramustine	_	_	I-Claim
335	group	_	_	I-Claim
336	was	_	_	I-Claim
337	found	_	_	I-Claim
338	in	_	_	I-Claim
339	patients	_	_	I-Claim
340	with	_	_	I-Claim
341	grade	_	_	I-Claim
342	III	_	_	I-Claim
343	glioma	_	_	I-Claim
344	.	_	_	I-Claim


0	Sentinel	_	_	B-Claim
1	lymph	_	_	I-Claim
2	node	_	_	I-Claim
3	biopsy	_	_	I-Claim
4	in	_	_	I-Claim
5	women	_	_	I-Claim
6	with	_	_	I-Claim
7	operable	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	is	_	_	I-Claim
11	routinely	_	_	I-Claim
12	used	_	_	I-Claim
13	in	_	_	I-Claim
14	some	_	_	I-Claim
15	countries	_	_	I-Claim
16	for	_	_	I-Claim
17	staging	_	_	I-Claim
18	the	_	_	I-Claim
19	axilla	_	_	I-Claim
20	despite	_	_	I-Claim
21	limited	_	_	I-Claim
22	data	_	_	I-Claim
23	from	_	_	I-Claim
24	randomized	_	_	I-Claim
25	trials	_	_	I-Claim
26	on	_	_	I-Claim
27	morbidity	_	_	I-Claim
28	and	_	_	I-Claim
29	mortality	_	_	I-Claim
30	outcomes	_	_	I-Claim
31	.	_	_	I-Claim

32	We	_	_	O
33	conducted	_	_	O
34	a	_	_	O
35	multicenter	_	_	O
36	randomized	_	_	O
37	trial	_	_	O
38	to	_	_	O
39	compare	_	_	O
40	quality-of-life	_	_	O
41	outcomes	_	_	O
42	between	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	clinically	_	_	O
46	node-negative	_	_	O
47	invasive	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	who	_	_	O
51	received	_	_	O
52	sentinel	_	_	O
53	lymph	_	_	O
54	node	_	_	O
55	biopsy	_	_	O
56	and	_	_	O
57	patients	_	_	O
58	who	_	_	O
59	received	_	_	O
60	standard	_	_	O
61	axillary	_	_	O
62	treatment	_	_	O
63	.	_	_	O

64	The	_	_	O
65	primary	_	_	O
66	outcome	_	_	O
67	measures	_	_	O
68	were	_	_	O
69	arm	_	_	O
70	and	_	_	O
71	shoulder	_	_	O
72	morbidity	_	_	O
73	and	_	_	O
74	quality	_	_	O
75	of	_	_	O
76	life	_	_	O
77	.	_	_	O

78	From	_	_	O
79	November	_	_	O
80	1999	_	_	O
81	to	_	_	O
82	October	_	_	O
83	2003	_	_	O
84	,	_	_	O
85	1031	_	_	O
86	patients	_	_	O
87	were	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	to	_	_	O
91	undergo	_	_	O
92	sentinel	_	_	O
93	lymph	_	_	O
94	node	_	_	O
95	biopsy	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	515	_	_	O
100	)	_	_	O
101	or	_	_	O
102	standard	_	_	O
103	axillary	_	_	O
104	surgery	_	_	O
105	(	_	_	O
106	n	_	_	O
107	=	_	_	O
108	516	_	_	O
109	)	_	_	O
110	.	_	_	O

111	Patients	_	_	O
112	with	_	_	O
113	sentinel	_	_	O
114	lymph	_	_	O
115	node	_	_	O
116	metastases	_	_	O
117	proceeded	_	_	O
118	to	_	_	O
119	delayed	_	_	O
120	axillary	_	_	O
121	clearance	_	_	O
122	or	_	_	O
123	received	_	_	O
124	axillary	_	_	O
125	radiotherapy	_	_	O
126	(	_	_	O
127	depending	_	_	O
128	on	_	_	O
129	the	_	_	O
130	protocol	_	_	O
131	at	_	_	O
132	the	_	_	O
133	treating	_	_	O
134	institution	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Intention-to-treat	_	_	O
138	analyses	_	_	O
139	of	_	_	O
140	data	_	_	O
141	at	_	_	O
142	1	_	_	O
143	,	_	_	O
144	3	_	_	O
145	,	_	_	O
146	6	_	_	O
147	,	_	_	O
148	and	_	_	O
149	12	_	_	O
150	months	_	_	O
151	after	_	_	O
152	surgery	_	_	O
153	are	_	_	O
154	presented	_	_	O
155	.	_	_	O

156	All	_	_	O
157	statistical	_	_	O
158	tests	_	_	O
159	were	_	_	O
160	two-sided	_	_	O
161	.	_	_	O

162	The	_	_	B-Premise
163	relative	_	_	I-Premise
164	risks	_	_	I-Premise
165	of	_	_	I-Premise
166	any	_	_	I-Premise
167	lymphedema	_	_	I-Premise
168	and	_	_	I-Premise
169	sensory	_	_	I-Premise
170	loss	_	_	I-Premise
171	for	_	_	I-Premise
172	the	_	_	I-Premise
173	sentinel	_	_	I-Premise
174	lymph	_	_	I-Premise
175	node	_	_	I-Premise
176	biopsy	_	_	I-Premise
177	group	_	_	I-Premise
178	compared	_	_	I-Premise
179	with	_	_	I-Premise
180	the	_	_	I-Premise
181	standard	_	_	I-Premise
182	axillary	_	_	I-Premise
183	treatment	_	_	I-Premise
184	group	_	_	I-Premise
185	at	_	_	I-Premise
186	12	_	_	I-Premise
187	months	_	_	I-Premise
188	were	_	_	I-Premise
189	0.37	_	_	I-Premise
190	(	_	_	I-Premise
191	95	_	_	I-Premise
192	%	_	_	I-Premise
193	confidence	_	_	I-Premise
194	interval	_	_	I-Premise
195	[	_	_	I-Premise
196	CI	_	_	I-Premise
197	]	_	_	I-Premise
198	=	_	_	I-Premise
199	0.23	_	_	I-Premise
200	to	_	_	I-Premise
201	0.60	_	_	I-Premise
202	;	_	_	I-Premise
203	absolute	_	_	I-Premise
204	rates	_	_	I-Premise
205	:	_	_	I-Premise
206	5	_	_	I-Premise
207	%	_	_	I-Premise
208	versus	_	_	I-Premise
209	13	_	_	I-Premise
210	%	_	_	I-Premise
211	)	_	_	I-Premise
212	and	_	_	I-Premise
213	0.37	_	_	I-Premise
214	(	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	=	_	_	I-Premise
219	0.27	_	_	I-Premise
220	to	_	_	I-Premise
221	0.50	_	_	I-Premise
222	;	_	_	I-Premise
223	absolute	_	_	I-Premise
224	rates	_	_	I-Premise
225	:	_	_	I-Premise
226	11	_	_	I-Premise
227	%	_	_	I-Premise
228	versus	_	_	I-Premise
229	31	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	respectively	_	_	I-Premise
234	.	_	_	I-Premise

235	Drain	_	_	B-Premise
236	usage	_	_	I-Premise
237	,	_	_	I-Premise
238	length	_	_	I-Premise
239	of	_	_	I-Premise
240	hospital	_	_	I-Premise
241	stay	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	time	_	_	I-Premise
245	to	_	_	I-Premise
246	resumption	_	_	I-Premise
247	of	_	_	I-Premise
248	normal	_	_	I-Premise
249	day-to-day	_	_	I-Premise
250	activities	_	_	I-Premise
251	after	_	_	I-Premise
252	surgery	_	_	I-Premise
253	were	_	_	I-Premise
254	statistically	_	_	I-Premise
255	significantly	_	_	I-Premise
256	lower	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	sentinel	_	_	I-Premise
260	lymph	_	_	I-Premise
261	node	_	_	I-Premise
262	biopsy	_	_	I-Premise
263	group	_	_	I-Premise
264	(	_	_	I-Premise
265	all	_	_	I-Premise
266	P	_	_	I-Premise
267	<	_	_	I-Premise
268	.001	_	_	I-Premise
269	)	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	axillary	_	_	I-Premise
273	operative	_	_	I-Premise
274	time	_	_	I-Premise
275	was	_	_	I-Premise
276	reduced	_	_	I-Premise
277	(	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	.055	_	_	I-Premise
281	)	_	_	I-Premise
282	.	_	_	I-Premise

283	Overall	_	_	B-Premise
284	patient-recorded	_	_	I-Premise
285	quality	_	_	I-Premise
286	of	_	_	I-Premise
287	life	_	_	I-Premise
288	and	_	_	I-Premise
289	arm	_	_	I-Premise
290	functioning	_	_	I-Premise
291	scores	_	_	I-Premise
292	were	_	_	I-Premise
293	statistically	_	_	I-Premise
294	significantly	_	_	I-Premise
295	better	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	sentinel	_	_	I-Premise
299	lymph	_	_	I-Premise
300	node	_	_	I-Premise
301	biopsy	_	_	I-Premise
302	group	_	_	I-Premise
303	throughout	_	_	I-Premise
304	(	_	_	I-Premise
305	all	_	_	I-Premise
306	P	_	_	I-Premise
307	<	_	_	I-Premise
308	or	_	_	I-Premise
309	=	_	_	I-Premise
310	.003	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	These	_	_	B-Premise
314	benefits	_	_	I-Premise
315	were	_	_	I-Premise
316	seen	_	_	I-Premise
317	with	_	_	I-Premise
318	no	_	_	I-Premise
319	increase	_	_	I-Premise
320	in	_	_	I-Premise
321	anxiety	_	_	I-Premise
322	levels	_	_	I-Premise
323	in	_	_	I-Premise
324	the	_	_	I-Premise
325	sentinel	_	_	I-Premise
326	lymph	_	_	I-Premise
327	node	_	_	I-Premise
328	biopsy	_	_	I-Premise
329	group	_	_	I-Premise
330	(	_	_	I-Premise
331	P	_	_	I-Premise
332	>	_	_	I-Premise
333	.05	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	Sentinel	_	_	B-Claim
337	lymph	_	_	I-Claim
338	node	_	_	I-Claim
339	biopsy	_	_	I-Claim
340	is	_	_	I-Claim
341	associated	_	_	I-Claim
342	with	_	_	I-Claim
343	reduced	_	_	I-Claim
344	arm	_	_	I-Claim
345	morbidity	_	_	I-Claim
346	and	_	_	I-Claim
347	better	_	_	I-Claim
348	quality	_	_	I-Claim
349	of	_	_	I-Claim
350	life	_	_	I-Claim
351	than	_	_	I-Claim
352	standard	_	_	I-Claim
353	axillary	_	_	I-Claim
354	treatment	_	_	I-Claim
355	and	_	_	I-Claim
356	should	_	_	I-Claim
357	be	_	_	I-Claim
358	the	_	_	I-Claim
359	treatment	_	_	I-Claim
360	of	_	_	I-Claim
361	choice	_	_	I-Claim
362	for	_	_	I-Claim
363	patients	_	_	I-Claim
364	who	_	_	I-Claim
365	have	_	_	I-Claim
366	early-stage	_	_	I-Claim
367	breast	_	_	I-Claim
368	cancer	_	_	I-Claim
369	with	_	_	I-Claim
370	clinically	_	_	I-Claim
371	negative	_	_	I-Claim
372	nodes	_	_	I-Claim
373	.	_	_	I-Claim


0	Patients	_	_	B-Claim
1	with	_	_	I-Claim
2	advanced	_	_	I-Claim
3	non-small	_	_	I-Claim
4	cell	_	_	I-Claim
5	lung	_	_	I-Claim
6	cancer	_	_	I-Claim
7	(	_	_	I-Claim
8	NSCLC	_	_	I-Claim
9	)	_	_	I-Claim
10	do	_	_	I-Claim
11	not	_	_	I-Claim
12	have	_	_	I-Claim
13	curative	_	_	I-Claim
14	treatment	_	_	I-Claim
15	options	_	_	I-Claim
16	;	_	_	I-Claim
17	therefore	_	_	O
18	,	_	_	O
19	treatments	_	_	O
20	should	_	_	O
21	prolong	_	_	O
22	survival	_	_	O
23	and	_	_	O
24	improve	_	_	O
25	quality	_	_	O
26	of	_	_	O
27	life	_	_	O
28	(	_	_	O
29	QoL	_	_	O
30	)	_	_	O
31	.	_	_	O

32	We	_	_	O
33	compared	_	_	O
34	the	_	_	O
35	effect	_	_	O
36	on	_	_	O
37	QoL	_	_	O
38	of	_	_	O
39	two	_	_	O
40	docetaxel-platinum	_	_	O
41	regimens	_	_	O
42	with	_	_	O
43	vinorelbine-cisplatin	_	_	O
44	.	_	_	O

45	QoL	_	_	O
46	was	_	_	O
47	assessed	_	_	O
48	by	_	_	O
49	the	_	_	O
50	Lung	_	_	O
51	Cancer	_	_	O
52	Symptom	_	_	O
53	Scale	_	_	O
54	(	_	_	O
55	LCSS	_	_	O
56	)	_	_	O
57	and	_	_	O
58	the	_	_	O
59	general	_	_	O
60	EuroQol	_	_	O
61	five-dimensional	_	_	O
62	questionnaire	_	_	O
63	(	_	_	O
64	EQ-5D	_	_	O
65	)	_	_	O
66	in	_	_	O
67	926	_	_	O
68	chemotherapy-naïve	_	_	O
69	patients	_	_	O
70	with	_	_	O
71	stages	_	_	O
72	IIIB	_	_	O
73	to	_	_	O
74	IV	_	_	O
75	NSCLC	_	_	O
76	.	_	_	O

77	Patients	_	_	O
78	were	_	_	O
79	randomly	_	_	O
80	assigned	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	:	_	_	O
84	docetaxel	_	_	O
85	75	_	_	O
86	mg/m2	_	_	O
87	plus	_	_	O
88	cisplatin	_	_	O
89	75	_	_	O
90	mg/m2	_	_	O
91	,	_	_	O
92	every	_	_	O
93	3	_	_	O
94	weeks	_	_	O
95	(	_	_	O
96	DC	_	_	O
97	)	_	_	O
98	;	_	_	O
99	docetaxel	_	_	O
100	75	_	_	O
101	mg/m2	_	_	O
102	and	_	_	O
103	carboplatin	_	_	O
104	6	_	_	O
105	mg/ml	_	_	O
106	min	_	_	O
107	,	_	_	O
108	every	_	_	O
109	3	_	_	O
110	weeks	_	_	O
111	(	_	_	O
112	DCb	_	_	O
113	)	_	_	O
114	;	_	_	O
115	or	_	_	O
116	vinorelbine	_	_	O
117	25	_	_	O
118	mg/m2/week	_	_	O
119	plus	_	_	O
120	cisplatin	_	_	O
121	100	_	_	O
122	mg/m2	_	_	O
123	,	_	_	O
124	every	_	_	O
125	4	_	_	O
126	weeks	_	_	O
127	(	_	_	O
128	VC	_	_	O
129	)	_	_	O
130	.	_	_	O

131	Overall	_	_	B-Premise
132	,	_	_	I-Premise
133	patients	_	_	I-Premise
134	treated	_	_	I-Premise
135	with	_	_	I-Premise
136	either	_	_	I-Premise
137	docetaxel-containing	_	_	I-Premise
138	regimen	_	_	I-Premise
139	had	_	_	I-Premise
140	better	_	_	I-Premise
141	QoL	_	_	I-Premise
142	than	_	_	I-Premise
143	VC-treated	_	_	I-Premise
144	patients	_	_	I-Premise
145	(	_	_	I-Premise
146	LCSS	_	_	I-Premise
147	global	_	_	I-Premise
148	item	_	_	I-Premise
149	QoL	_	_	O
150	today	_	_	I-Premise
151	:	_	_	O
152	P=0.064	_	_	I-Premise
153	for	_	_	I-Premise
154	DC	_	_	I-Premise
155	and	_	_	I-Premise
156	P=0.016	_	_	I-Premise
157	for	_	_	I-Premise
158	DCb	_	_	I-Premise
159	versus	_	_	I-Premise
160	VC	_	_	I-Premise
161	;	_	_	I-Premise
162	EQ-5D	_	_	I-Premise
163	global	_	_	I-Premise
164	item	_	_	I-Premise
165	health	_	_	I-Premise
166	state	_	_	I-Premise
167	today	_	_	I-Premise
168	:	_	_	O
169	P=0.016	_	_	I-Premise
170	for	_	_	I-Premise
171	DC	_	_	I-Premise
172	and	_	_	I-Premise
173	P	_	_	I-Premise
174	<	_	_	I-Premise
175	0.001	_	_	I-Premise
176	for	_	_	I-Premise
177	DCb	_	_	I-Premise
178	versus	_	_	I-Premise
179	VC	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	DC-treated	_	_	B-Premise
183	patients	_	_	I-Premise
184	experienced	_	_	I-Premise
185	improved	_	_	I-Premise
186	pain	_	_	I-Premise
187	relief	_	_	I-Premise
188	compared	_	_	I-Premise
189	with	_	_	I-Premise
190	VC	_	_	I-Premise
191	(	_	_	I-Premise
192	P=0.033	_	_	I-Premise
193	)	_	_	I-Premise
194	,	_	_	I-Premise
195	whereas	_	_	O
196	pain	_	_	B-Premise
197	relief	_	_	I-Premise
198	with	_	_	I-Premise
199	DCb	_	_	I-Premise
200	and	_	_	I-Premise
201	VC	_	_	I-Premise
202	was	_	_	I-Premise
203	similar	_	_	I-Premise
204	.	_	_	I-Premise

205	Patients	_	_	B-Premise
206	treated	_	_	I-Premise
207	with	_	_	I-Premise
208	either	_	_	I-Premise
209	docetaxel	_	_	I-Premise
210	regimen	_	_	I-Premise
211	had	_	_	I-Premise
212	more	_	_	I-Premise
213	favorable	_	_	I-Premise
214	changes	_	_	I-Premise
215	in	_	_	I-Premise
216	performance	_	_	I-Premise
217	status	_	_	I-Premise
218	(	_	_	I-Premise
219	P=0.065	_	_	I-Premise
220	for	_	_	I-Premise
221	DC	_	_	I-Premise
222	and	_	_	I-Premise
223	P	_	_	I-Premise
224	<	_	_	I-Premise
225	0.001	_	_	I-Premise
226	for	_	_	I-Premise
227	DCb	_	_	I-Premise
228	versus	_	_	I-Premise
229	VC	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	mean	_	_	I-Premise
233	weight	_	_	I-Premise
234	loss	_	_	I-Premise
235	(	_	_	I-Premise
236	0.06	_	_	I-Premise
237	kg	_	_	I-Premise
238	,	_	_	I-Premise
239	gain	_	_	I-Premise
240	of	_	_	I-Premise
241	0.08	_	_	I-Premise
242	kg	_	_	I-Premise
243	,	_	_	I-Premise
244	and	_	_	I-Premise
245	2.27	_	_	I-Premise
246	kg	_	_	I-Premise
247	for	_	_	I-Premise
248	DC	_	_	I-Premise
249	,	_	_	I-Premise
250	DCb	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	VC	_	_	I-Premise
254	,	_	_	I-Premise
255	respectively	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	<	_	_	I-Premise
259	0.001	_	_	I-Premise
260	for	_	_	I-Premise
261	both	_	_	I-Premise
262	DC	_	_	I-Premise
263	versus	_	_	I-Premise
264	VC	_	_	I-Premise
265	and	_	_	I-Premise
266	DCb	_	_	I-Premise
267	versus	_	_	I-Premise
268	VC	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	The	_	_	B-Claim
272	TAX	_	_	I-Claim
273	326	_	_	I-Claim
274	study	_	_	I-Claim
275	shows	_	_	I-Claim
276	that	_	_	I-Claim
277	docetaxel-platinum	_	_	I-Claim
278	regimens	_	_	I-Claim
279	relieve	_	_	I-Claim
280	symptoms	_	_	I-Claim
281	and	_	_	I-Claim
282	improve	_	_	I-Claim
283	QoL	_	_	I-Claim
284	in	_	_	I-Claim
285	patients	_	_	I-Claim
286	with	_	_	I-Claim
287	advanced	_	_	I-Claim
288	NSCLC	_	_	I-Claim
289	.	_	_	I-Claim

290	DCb	_	_	B-Claim
291	and	_	_	I-Claim
292	DC	_	_	I-Claim
293	were	_	_	I-Claim
294	superior	_	_	I-Claim
295	to	_	_	I-Claim
296	VC	_	_	I-Claim
297	in	_	_	I-Claim
298	all	_	_	I-Claim
299	QoL	_	_	I-Claim
300	outcomes	_	_	I-Claim
301	assessed	_	_	I-Claim
302	except	_	_	I-Claim
303	for	_	_	I-Claim
304	the	_	_	I-Claim
305	difference	_	_	I-Claim
306	between	_	_	I-Claim
307	DC	_	_	I-Claim
308	and	_	_	I-Claim
309	VC	_	_	I-Claim
310	in	_	_	I-Claim
311	LCSS	_	_	I-Claim
312	QoL	_	_	O
313	today	_	_	I-Premise
314	,	_	_	O
315	which	_	_	I-Claim
316	was	_	_	I-Claim
317	not	_	_	I-Claim
318	significant	_	_	I-Claim
319	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	pilot	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	examine	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	a	_	_	O
13	combined	_	_	O
14	cardiorespiratory	_	_	O
15	and	_	_	O
16	resistance	_	_	O
17	exercise	_	_	O
18	training	_	_	O
19	program	_	_	O
20	of	_	_	O
21	short	_	_	O
22	duration	_	_	O
23	on	_	_	O
24	the	_	_	O
25	cardiorespiratory	_	_	O
26	fitness	_	_	O
27	,	_	_	O
28	strength	_	_	O
29	endurance	_	_	O
30	,	_	_	O
31	task	_	_	O
32	specific	_	_	O
33	functional	_	_	O
34	muscle	_	_	O
35	capacity	_	_	O
36	,	_	_	O
37	body	_	_	O
38	composition	_	_	O
39	and	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	in	_	_	O
47	women	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	survivors	_	_	O
51	.	_	_	O

52	Sixteen	_	_	O
53	subjects	_	_	O
54	were	_	_	O
55	randomly	_	_	O
56	assigned	_	_	O
57	to	_	_	O
58	either	_	_	O
59	a	_	_	O
60	training	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	8	_	_	O
65	;	_	_	O
66	age	_	_	O
67	:	_	_	O
68	50	_	_	O
69	+/-	_	_	O
70	5	_	_	O
71	yrs	_	_	O
72	)	_	_	O
73	or	_	_	O
74	control	_	_	O
75	non-exercising	_	_	O
76	group	_	_	O
77	(	_	_	O
78	n	_	_	O
79	=	_	_	O
80	8	_	_	O
81	;	_	_	O
82	age	_	_	O
83	:	_	_	O
84	51	_	_	O
85	+/-	_	_	O
86	10	_	_	O
87	yrs	_	_	O
88	)	_	_	O
89	.	_	_	O

90	The	_	_	O
91	training	_	_	O
92	group	_	_	O
93	followed	_	_	O
94	an	_	_	O
95	8-week	_	_	O
96	exercise	_	_	O
97	program	_	_	O
98	consisting	_	_	O
99	of	_	_	O
100	3	_	_	O
101	weekly	_	_	O
102	sessions	_	_	O
103	of	_	_	O
104	90-min	_	_	O
105	duration	_	_	O
106	,	_	_	O
107	supervised	_	_	O
108	by	_	_	O
109	an	_	_	O
110	experienced	_	_	O
111	investigator	_	_	O
112	and	_	_	O
113	divided	_	_	O
114	into	_	_	O
115	resistance	_	_	O
116	exercises	_	_	O
117	and	_	_	O
118	aerobic	_	_	O
119	training	_	_	O
120	.	_	_	O

121	Before	_	_	O
122	and	_	_	O
123	after	_	_	O
124	the	_	_	O
125	intervention	_	_	O
126	period	_	_	O
127	,	_	_	O
128	all	_	_	O
129	of	_	_	O
130	the	_	_	O
131	subjects	_	_	O
132	performed	_	_	O
133	a	_	_	O
134	cardiorespiratory	_	_	O
135	test	_	_	O
136	to	_	_	O
137	measure	_	_	O
138	peak	_	_	O
139	oxygen	_	_	O
140	uptake	_	_	O
141	(	_	_	O
142	VO2peak	_	_	O
143	)	_	_	O
144	,	_	_	O
145	a	_	_	O
146	dynamic	_	_	O
147	strength	_	_	O
148	endurance	_	_	O
149	test	_	_	O
150	(	_	_	O
151	maximum	_	_	O
152	number	_	_	O
153	of	_	_	O
154	repetitions	_	_	O
155	for	_	_	O
156	chest	_	_	O
157	and	_	_	O
158	leg	_	_	O
159	press	_	_	O
160	exercise	_	_	O
161	at	_	_	O
162	30	_	_	O
163	-	_	_	O
164	35	_	_	O
165	%	_	_	O
166	and	_	_	O
167	100	_	_	O
168	-	_	_	O
169	110	_	_	O
170	%	_	_	O
171	of	_	_	O
172	body	_	_	O
173	mass	_	_	O
174	,	_	_	O
175	respectively	_	_	O
176	)	_	_	O
177	and	_	_	O
178	a	_	_	O
179	sit-stand	_	_	O
180	test	_	_	O
181	.	_	_	O

182	Quality	_	_	O
183	of	_	_	O
184	life	_	_	O
185	was	_	_	O
186	assessed	_	_	O
187	using	_	_	O
188	the	_	_	O
189	European	_	_	O
190	Organization	_	_	O
191	for	_	_	O
192	Research	_	_	O
193	and	_	_	O
194	Treatment	_	_	O
195	of	_	_	O
196	Cancer	_	_	O
197	QLQ-C30	_	_	O
198	(	_	_	O
199	EORTC-C30	_	_	O
200	)	_	_	O
201	questionnaire	_	_	O
202	.	_	_	O

203	In	_	_	B-Premise
204	response	_	_	I-Premise
205	to	_	_	I-Premise
206	training	_	_	I-Premise
207	,	_	_	I-Premise
208	QOL	_	_	I-Premise
209	,	_	_	I-Premise
210	VO2peak	_	_	I-Premise
211	(	_	_	I-Premise
212	mean	_	_	I-Premise
213	3.9	_	_	I-Premise
214	ml/kg/min	_	_	I-Premise
215	;	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	,	_	_	I-Premise
220	0.93	_	_	I-Premise
221	,	_	_	I-Premise
222	6.90	_	_	I-Premise
223	)	_	_	I-Premise
224	performance	_	_	I-Premise
225	in	_	_	I-Premise
226	leg	_	_	I-Premise
227	press	_	_	I-Premise
228	(	_	_	I-Premise
229	17.9	_	_	I-Premise
230	kg	_	_	I-Premise
231	;	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	CI	_	_	I-Premise
235	,	_	_	I-Premise
236	12.8	_	_	I-Premise
237	,	_	_	I-Premise
238	22.4	_	_	I-Premise
239	)	_	_	I-Premise
240	and	_	_	I-Premise
241	sit-stand	_	_	I-Premise
242	test	_	_	I-Premise
243	(	_	_	I-Premise
244	-	_	_	I-Premise
245	0.67	_	_	I-Premise
246	s	_	_	I-Premise
247	;	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	,	_	_	I-Premise
252	-	_	_	I-Premise
253	0.52	_	_	I-Premise
254	,	_	_	I-Premise
255	-	_	_	I-Premise
256	1.2	_	_	I-Premise
257	)	_	_	I-Premise
258	improved	_	_	I-Premise
259	(	_	_	I-Premise
260	p	_	_	I-Premise
261	<	_	_	I-Premise
262	or	_	_	I-Premise
263	=	_	_	I-Premise
264	0.05	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	We	_	_	B-Premise
268	observed	_	_	I-Premise
269	no	_	_	I-Premise
270	significant	_	_	I-Premise
271	changes	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	control	_	_	I-Premise
275	group	_	_	I-Premise
276	.	_	_	I-Premise

277	Combined	_	_	B-Claim
278	cardiorespiratory	_	_	I-Claim
279	and	_	_	I-Claim
280	resistance	_	_	I-Claim
281	training	_	_	I-Claim
282	,	_	_	I-Claim
283	even	_	_	I-Claim
284	of	_	_	I-Claim
285	very	_	_	I-Claim
286	brief	_	_	I-Claim
287	duration	_	_	I-Claim
288	,	_	_	I-Claim
289	improves	_	_	I-Claim
290	the	_	_	I-Claim
291	QOL	_	_	I-Claim
292	and	_	_	I-Claim
293	the	_	_	I-Claim
294	overall	_	_	I-Claim
295	physical	_	_	I-Claim
296	fitness	_	_	I-Claim
297	of	_	_	I-Claim
298	women	_	_	I-Claim
299	breast	_	_	I-Claim
300	cancer	_	_	I-Claim
301	survivors	_	_	I-Claim
302	.	_	_	I-Claim


0	LV5FU2	_	_	O
1	with	_	_	O
2	high-dose	_	_	O
3	leucovorin	_	_	O
4	(	_	_	O
5	LV	_	_	O
6	)	_	_	O
7	,	_	_	O
8	weekly	_	_	O
9	infusional	_	_	O
10	5-fluorouracil	_	_	O
11	(	_	_	O
12	5FU	_	_	O
13	)	_	_	O
14	(	_	_	O
15	AIO	_	_	O
16	schedule	_	_	O
17	)	_	_	O
18	and	_	_	O
19	raltitrexed	_	_	O
20	have	_	_	O
21	been	_	_	O
22	demonstrated	_	_	O
23	to	_	_	O
24	be	_	_	O
25	active	_	_	O
26	agents	_	_	O
27	in	_	_	O
28	first-line	_	_	O
29	treatment	_	_	O
30	of	_	_	O
31	colorectal	_	_	O
32	cancer	_	_	O
33	.	_	_	O

34	We	_	_	O
35	performed	_	_	O
36	a	_	_	O
37	4-arm	_	_	O
38	randomised	_	_	O
39	trial	_	_	O
40	to	_	_	O
41	compare	_	_	O
42	(	_	_	O
43	1	_	_	O
44	)	_	_	O
45	a	_	_	O
46	low-dose	_	_	O
47	intravenous	_	_	O
48	bolus	_	_	O
49	of	_	_	O
50	LV	_	_	O
51	(	_	_	O
52	20	_	_	O
53	mg/m2	_	_	O
54	)	_	_	O
55	,	_	_	O
56	followed	_	_	O
57	by	_	_	O
58	an	_	_	O
59	intravenous	_	_	O
60	bolus	_	_	O
61	of	_	_	O
62	5FU	_	_	O
63	(	_	_	O
64	400	_	_	O
65	mg/m2	_	_	O
66	)	_	_	O
67	,	_	_	O
68	followed	_	_	O
69	by	_	_	O
70	a	_	_	O
71	22-hour	_	_	O
72	continuous	_	_	O
73	infusion	_	_	O
74	of	_	_	O
75	5FU	_	_	O
76	(	_	_	O
77	600	_	_	O
78	mg/m2	_	_	O
79	)	_	_	O
80	on	_	_	O
81	day	_	_	O
82	1	_	_	O
83	and	_	_	O
84	day	_	_	O
85	2/2	_	_	O
86	weeks	_	_	O
87	(	_	_	O
88	ldLV5FU2	_	_	O
89	arm	_	_	O
90	)	_	_	O
91	,	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	a	_	_	O
96	weekly	_	_	O
97	continuous	_	_	O
98	infusion	_	_	O
99	of	_	_	O
100	high-dose	_	_	O
101	5FU	_	_	O
102	(	_	_	O
103	2.6	_	_	O
104	g/m2/week	_	_	O
105	)	_	_	O
106	for	_	_	O
107	6	_	_	O
108	weeks	_	_	O
109	followed	_	_	O
110	by	_	_	O
111	a	_	_	O
112	rest	_	_	O
113	week	_	_	O
114	(	_	_	O
115	HD-FU	_	_	O
116	arm	_	_	O
117	)	_	_	O
118	and	_	_	O
119	(	_	_	O
120	3	_	_	O
121	)	_	_	O
122	raltitrexed	_	_	O
123	(	_	_	O
124	Tomudex	_	_	O
125	arm	_	_	O
126	;	_	_	O
127	3	_	_	O
128	mg/m2/3	_	_	O
129	weeks	_	_	O
130	)	_	_	O
131	to	_	_	O
132	standard	_	_	O
133	LV5FU2	_	_	O
134	.	_	_	O

135	From	_	_	O
136	1997	_	_	O
137	to	_	_	O
138	2001	_	_	O
139	,	_	_	O
140	294	_	_	O
141	patients	_	_	O
142	were	_	_	O
143	included	_	_	O
144	.	_	_	O

145	The	_	_	O
146	4	_	_	O
147	arms	_	_	O
148	were	_	_	O
149	well	_	_	O
150	balanced	_	_	O
151	for	_	_	O
152	sex	_	_	O
153	ratio	_	_	O
154	,	_	_	O
155	age	_	_	O
156	,	_	_	O
157	WHO	_	_	O
158	performance	_	_	O
159	status	_	_	O
160	,	_	_	O
161	the	_	_	O
162	primary	_	_	O
163	tumour	_	_	O
164	site	_	_	O
165	and	_	_	O
166	prior	_	_	O
167	adjuvant	_	_	O
168	chemotherapy	_	_	O
169	.	_	_	O

170	Treatment	_	_	O
171	was	_	_	O
172	stopped	_	_	O
173	due	_	_	O
174	to	_	_	O
175	low	_	_	O
176	accrual	_	_	O
177	.	_	_	O

178	Two	_	_	B-Premise
179	toxicity-related	_	_	I-Premise
180	deaths	_	_	I-Premise
181	were	_	_	I-Premise
182	observed	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	Tomudex	_	_	I-Premise
186	arm	_	_	I-Premise
187	.	_	_	I-Premise

188	The	_	_	B-Premise
189	treatments	_	_	I-Premise
190	gave	_	_	I-Premise
191	rise	_	_	I-Premise
192	to	_	_	I-Premise
193	different	_	_	I-Premise
194	rates	_	_	I-Premise
195	of	_	_	I-Premise
196	grade	_	_	I-Premise
197	3-4	_	_	I-Premise
198	neutropenia	_	_	I-Premise
199	(	_	_	I-Premise
200	3	_	_	I-Premise
201	,	_	_	I-Premise
202	4	_	_	I-Premise
203	,	_	_	I-Premise
204	11	_	_	I-Premise
205	and	_	_	I-Premise
206	14	_	_	I-Premise
207	%	_	_	I-Premise
208	of	_	_	I-Premise
209	the	_	_	I-Premise
210	patients	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	LV5FU2	_	_	I-Premise
214	,	_	_	I-Premise
215	ldLV5FU2	_	_	I-Premise
216	,	_	_	I-Premise
217	HD-FU	_	_	I-Premise
218	and	_	_	I-Premise
219	Tomudex	_	_	I-Premise
220	arms	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	,	_	_	I-Premise
224	p	_	_	I-Premise
225	=	_	_	I-Premise
226	0.028	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	leucopenia	_	_	I-Premise
230	and	_	_	I-Premise
231	vomiting	_	_	I-Premise
232	.	_	_	I-Premise

233	At	_	_	B-Premise
234	least	_	_	I-Premise
235	one	_	_	I-Premise
236	episode	_	_	I-Premise
237	of	_	_	I-Premise
238	grade	_	_	I-Premise
239	3-4	_	_	I-Premise
240	toxicity	_	_	I-Premise
241	was	_	_	I-Premise
242	observed	_	_	I-Premise
243	in	_	_	I-Premise
244	27	_	_	I-Premise
245	,	_	_	I-Premise
246	25	_	_	I-Premise
247	,	_	_	I-Premise
248	38	_	_	I-Premise
249	and	_	_	I-Premise
250	47	_	_	I-Premise
251	%	_	_	I-Premise
252	of	_	_	I-Premise
253	the	_	_	I-Premise
254	patients	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	LV5FU2	_	_	I-Premise
258	,	_	_	I-Premise
259	ldLV5FU2	_	_	I-Premise
260	,	_	_	I-Premise
261	HD-FU	_	_	I-Premise
262	and	_	_	I-Premise
263	Tomudex	_	_	I-Premise
264	arms	_	_	I-Premise
265	,	_	_	I-Premise
266	respectively	_	_	I-Premise
267	(	_	_	I-Premise
268	p	_	_	I-Premise
269	=	_	_	I-Premise
270	0.016	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	An	_	_	B-Premise
274	objective	_	_	I-Premise
275	response	_	_	I-Premise
276	was	_	_	I-Premise
277	observed	_	_	I-Premise
278	in	_	_	I-Premise
279	28	_	_	I-Premise
280	,	_	_	I-Premise
281	21	_	_	I-Premise
282	,	_	_	I-Premise
283	22	_	_	I-Premise
284	and	_	_	I-Premise
285	10	_	_	I-Premise
286	%	_	_	I-Premise
287	of	_	_	I-Premise
288	the	_	_	I-Premise
289	patients	_	_	I-Premise
290	in	_	_	I-Premise
291	the	_	_	I-Premise
292	LV5FU2	_	_	I-Premise
293	,	_	_	I-Premise
294	ldLV5FU2	_	_	I-Premise
295	,	_	_	I-Premise
296	HD-FU	_	_	I-Premise
297	and	_	_	I-Premise
298	Tomudex	_	_	I-Premise
299	arms	_	_	I-Premise
300	,	_	_	I-Premise
301	respectively	_	_	I-Premise
302	(	_	_	I-Premise
303	p	_	_	I-Premise
304	=	_	_	I-Premise
305	0.04	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	Progression-free	_	_	B-Premise
309	survival	_	_	I-Premise
310	(	_	_	I-Premise
311	PFS	_	_	I-Premise
312	)	_	_	I-Premise
313	of	_	_	I-Premise
314	the	_	_	I-Premise
315	patients	_	_	I-Premise
316	in	_	_	I-Premise
317	the	_	_	I-Premise
318	Tomudex	_	_	I-Premise
319	arm	_	_	I-Premise
320	was	_	_	I-Premise
321	statistically	_	_	I-Premise
322	lower	_	_	I-Premise
323	compared	_	_	I-Premise
324	to	_	_	I-Premise
325	that	_	_	I-Premise
326	of	_	_	I-Premise
327	patients	_	_	I-Premise
328	treated	_	_	I-Premise
329	with	_	_	I-Premise
330	LV5FU2	_	_	I-Premise
331	or	_	_	I-Premise
332	ldLV5FU2	_	_	I-Premise
333	(	_	_	I-Premise
334	combined	_	_	I-Premise
335	group	_	_	I-Premise
336	;	_	_	I-Premise
337	p	_	_	I-Premise
338	=	_	_	I-Premise
339	0.013	_	_	I-Premise
340	,	_	_	I-Premise
341	log	_	_	I-Premise
342	rank	_	_	I-Premise
343	test	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	In	_	_	B-Claim
347	conclusion	_	_	I-Claim
348	,	_	_	I-Claim
349	Tomudex	_	_	I-Claim
350	is	_	_	I-Claim
351	more	_	_	I-Claim
352	toxic	_	_	I-Claim
353	and	_	_	I-Claim
354	yields	_	_	I-Claim
355	shorter	_	_	I-Claim
356	PFS	_	_	I-Claim
357	than	_	_	I-Claim
358	infusional	_	_	I-Claim
359	5FU	_	_	I-Claim
360	.	_	_	I-Claim

361	Despite	_	_	B-Claim
362	the	_	_	I-Claim
363	early	_	_	I-Claim
364	closure	_	_	I-Claim
365	of	_	_	I-Claim
366	the	_	_	I-Claim
367	study	_	_	I-Claim
368	and	_	_	I-Claim
369	the	_	_	I-Claim
370	lack	_	_	I-Claim
371	of	_	_	I-Claim
372	power	_	_	I-Claim
373	of	_	_	I-Claim
374	the	_	_	I-Claim
375	comparison	_	_	I-Claim
376	,	_	_	I-Claim
377	it	_	_	I-Claim
378	seems	_	_	I-Claim
379	that	_	_	I-Claim
380	ldLV5FU2	_	_	I-Claim
381	could	_	_	I-Claim
382	be	_	_	I-Claim
383	considered	_	_	I-Claim
384	as	_	_	I-Claim
385	an	_	_	I-Claim
386	active	_	_	I-Claim
387	,	_	_	I-Claim
388	easier	_	_	I-Claim
389	and	_	_	I-Claim
390	less	_	_	I-Claim
391	expensive	_	_	I-Claim
392	option	_	_	I-Claim
393	for	_	_	I-Claim
394	the	_	_	I-Claim
395	treatment	_	_	I-Claim
396	of	_	_	I-Claim
397	metastatic	_	_	I-Claim
398	colorectal	_	_	I-Claim
399	cancer	_	_	I-Claim
400	compared	_	_	I-Claim
401	to	_	_	I-Claim
402	classic	_	_	I-Claim
403	LV5FU2	_	_	I-Claim
404	or	_	_	I-Claim
405	weekly	_	_	I-Claim
406	HD-FU	_	_	I-Claim
407	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	cannabis	_	_	O
6	extract	_	_	O
7	(	_	_	O
8	CE	_	_	O
9	)	_	_	O
10	,	_	_	O
11	delta-9-tetrahydrocannabinol	_	_	O
12	(	_	_	O
13	THC	_	_	O
14	)	_	_	O
15	,	_	_	O
16	and	_	_	O
17	placebo	_	_	O
18	(	_	_	O
19	PL	_	_	O
20	)	_	_	O
21	on	_	_	O
22	appetite	_	_	O
23	and	_	_	O
24	quality	_	_	O
25	of	_	_	O
26	life	_	_	O
27	(	_	_	O
28	QOL	_	_	O
29	)	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	cancer-related	_	_	O
34	anorexia-cachexia	_	_	O
35	syndrome	_	_	O
36	(	_	_	O
37	CACS	_	_	O
38	)	_	_	O
39	.	_	_	O

40	Adult	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	advanced	_	_	O
44	cancer	_	_	O
45	,	_	_	O
46	CACS	_	_	O
47	,	_	_	O
48	weight	_	_	O
49	loss	_	_	O
50	(	_	_	O
51	>	_	_	O
52	or	_	_	O
53	=	_	_	O
54	5	_	_	O
55	%	_	_	O
56	over	_	_	O
57	6	_	_	O
58	months	_	_	O
59	)	_	_	O
60	,	_	_	O
61	and	_	_	O
62	Eastern	_	_	O
63	Cooperative	_	_	O
64	Oncology	_	_	O
65	Group	_	_	O
66	(	_	_	O
67	ECOG	_	_	O
68	)	_	_	O
69	performance	_	_	O
70	status	_	_	O
71	(	_	_	O
72	PS	_	_	O
73	)	_	_	O
74	<	_	_	O
75	or	_	_	O
76	=	_	_	O
77	2	_	_	O
78	were	_	_	O
79	randomly	_	_	O
80	assigned	_	_	O
81	(	_	_	O
82	2:2:1	_	_	O
83	)	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	CE	_	_	O
87	(	_	_	O
88	standardized	_	_	O
89	for	_	_	O
90	2.5	_	_	O
91	mg	_	_	O
92	THC	_	_	O
93	and	_	_	O
94	1	_	_	O
95	mg	_	_	O
96	cannabidiol	_	_	O
97	)	_	_	O
98	or	_	_	O
99	THC	_	_	O
100	(	_	_	O
101	2.5	_	_	O
102	mg	_	_	O
103	)	_	_	O
104	or	_	_	O
105	PL	_	_	O
106	orally	_	_	O
107	,	_	_	O
108	twice	_	_	O
109	daily	_	_	O
110	for	_	_	O
111	6	_	_	O
112	weeks	_	_	O
113	.	_	_	O

114	Appetite	_	_	O
115	,	_	_	O
116	mood	_	_	O
117	,	_	_	O
118	and	_	_	O
119	nausea	_	_	O
120	were	_	_	O
121	monitored	_	_	O
122	daily	_	_	O
123	with	_	_	O
124	a	_	_	O
125	visual	_	_	O
126	analog	_	_	O
127	scale	_	_	O
128	(	_	_	O
129	VAS	_	_	O
130	)	_	_	O
131	;	_	_	O
132	QOL	_	_	O
133	was	_	_	O
134	assessed	_	_	O
135	with	_	_	O
136	the	_	_	O
137	European	_	_	O
138	Organisation	_	_	O
139	for	_	_	O
140	Research	_	_	O
141	and	_	_	O
142	Treatment	_	_	O
143	of	_	_	O
144	Cancer	_	_	O
145	Quality	_	_	O
146	of	_	_	O
147	Life	_	_	O
148	Questionnaire	_	_	O
149	C30	_	_	O
150	(	_	_	O
151	composite	_	_	O
152	score	_	_	O
153	:	_	_	O
154	questions	_	_	O
155	29	_	_	O
156	and	_	_	O
157	30	_	_	O
158	)	_	_	O
159	.	_	_	O

160	Cannabinoid-related	_	_	O
161	toxicity	_	_	O
162	was	_	_	O
163	assessed	_	_	O
164	every	_	_	O
165	2	_	_	O
166	weeks	_	_	O
167	.	_	_	O

168	Of	_	_	O
169	289	_	_	O
170	patients	_	_	O
171	screened	_	_	O
172	,	_	_	O
173	243	_	_	O
174	were	_	_	O
175	randomly	_	_	O
176	assigned	_	_	O
177	and	_	_	O
178	164	_	_	O
179	(	_	_	O
180	CE	_	_	O
181	,	_	_	O
182	66	_	_	O
183	of	_	_	O
184	95	_	_	O
185	patients	_	_	O
186	;	_	_	O
187	THC	_	_	O
188	,	_	_	O
189	65	_	_	O
190	of	_	_	O
191	100	_	_	O
192	patients	_	_	O
193	;	_	_	O
194	and	_	_	O
195	PL	_	_	O
196	,	_	_	O
197	33	_	_	O
198	of	_	_	O
199	48	_	_	O
200	patients	_	_	O
201	)	_	_	O
202	completed	_	_	O
203	treatment	_	_	O
204	.	_	_	O

205	At	_	_	O
206	baseline	_	_	O
207	,	_	_	O
208	groups	_	_	O
209	were	_	_	O
210	comparable	_	_	O
211	for	_	_	O
212	age	_	_	O
213	(	_	_	O
214	mean	_	_	O
215	,	_	_	O
216	61	_	_	O
217	years	_	_	O
218	)	_	_	O
219	,	_	_	O
220	sex	_	_	O
221	(	_	_	O
222	54	_	_	O
223	%	_	_	O
224	men	_	_	O
225	)	_	_	O
226	,	_	_	O
227	weight	_	_	O
228	loss	_	_	O
229	(	_	_	O
230	32	_	_	O
231	%	_	_	O
232	>	_	_	O
233	or	_	_	O
234	=	_	_	O
235	10	_	_	O
236	%	_	_	O
237	)	_	_	O
238	,	_	_	O
239	PS	_	_	O
240	(	_	_	O
241	13	_	_	O
242	%	_	_	O
243	ECOG	_	_	O
244	=	_	_	O
245	2	_	_	O
246	)	_	_	O
247	,	_	_	O
248	antineoplastic	_	_	O
249	treatment	_	_	O
250	(	_	_	O
251	50	_	_	O
252	%	_	_	O
253	)	_	_	O
254	,	_	_	O
255	appetite	_	_	O
256	(	_	_	O
257	mean	_	_	O
258	VAS	_	_	O
259	score	_	_	O
260	,	_	_	O
261	31/100	_	_	O
262	mm	_	_	O
263	)	_	_	O
264	,	_	_	O
265	and	_	_	O
266	QOL	_	_	O
267	(	_	_	O
268	mean	_	_	O
269	score	_	_	O
270	,	_	_	O
271	30/100	_	_	O
272	)	_	_	O
273	.	_	_	O

274	Intent-to-treat	_	_	B-Premise
275	analysis	_	_	I-Premise
276	showed	_	_	I-Premise
277	no	_	_	I-Premise
278	significant	_	_	I-Premise
279	differences	_	_	I-Premise
280	between	_	_	I-Premise
281	the	_	_	I-Premise
282	three	_	_	I-Premise
283	arms	_	_	I-Premise
284	for	_	_	I-Premise
285	appetite	_	_	I-Premise
286	,	_	_	I-Premise
287	QOL	_	_	I-Premise
288	,	_	_	I-Premise
289	or	_	_	I-Premise
290	cannabinoid-related	_	_	I-Premise
291	toxicity	_	_	I-Premise
292	.	_	_	I-Premise

293	Increased	_	_	B-Premise
294	appetite	_	_	I-Premise
295	was	_	_	I-Premise
296	reported	_	_	I-Premise
297	by	_	_	I-Premise
298	73	_	_	I-Premise
299	%	_	_	I-Premise
300	,	_	_	I-Premise
301	58	_	_	I-Premise
302	%	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	69	_	_	I-Premise
306	%	_	_	I-Premise
307	of	_	_	I-Premise
308	patients	_	_	I-Premise
309	receiving	_	_	I-Premise
310	CE	_	_	I-Premise
311	,	_	_	I-Premise
312	THC	_	_	I-Premise
313	,	_	_	I-Premise
314	or	_	_	I-Premise
315	PL	_	_	I-Premise
316	,	_	_	I-Premise
317	respectively	_	_	I-Premise
318	.	_	_	I-Premise

319	An	_	_	O
320	independent	_	_	O
321	data	_	_	O
322	review	_	_	O
323	board	_	_	O
324	recommended	_	_	O
325	termination	_	_	O
326	of	_	_	O
327	recruitment	_	_	O
328	because	_	_	O
329	of	_	_	O
330	insufficient	_	_	O
331	differences	_	_	O
332	between	_	_	O
333	study	_	_	O
334	arms	_	_	O
335	.	_	_	O

336	CE	_	_	B-Premise
337	at	_	_	I-Premise
338	the	_	_	I-Premise
339	oral	_	_	I-Premise
340	dose	_	_	I-Premise
341	administered	_	_	I-Premise
342	was	_	_	I-Premise
343	well	_	_	I-Premise
344	tolerated	_	_	I-Premise
345	by	_	_	I-Premise
346	these	_	_	I-Premise
347	patients	_	_	I-Premise
348	with	_	_	I-Premise
349	CACS	_	_	I-Premise
350	.	_	_	I-Premise

351	No	_	_	B-Claim
352	differences	_	_	I-Claim
353	in	_	_	I-Claim
354	patients	_	_	I-Claim
355	'	_	_	I-Claim
356	appetite	_	_	I-Claim
357	or	_	_	I-Claim
358	QOL	_	_	I-Claim
359	were	_	_	I-Claim
360	found	_	_	I-Claim
361	either	_	_	I-Claim
362	between	_	_	I-Claim
363	CE	_	_	I-Claim
364	,	_	_	I-Claim
365	THC	_	_	I-Claim
366	,	_	_	I-Claim
367	and	_	_	I-Claim
368	PL	_	_	I-Claim
369	or	_	_	I-Claim
370	between	_	_	I-Claim
371	CE	_	_	I-Claim
372	and	_	_	I-Claim
373	THC	_	_	I-Claim
374	at	_	_	I-Claim
375	the	_	_	I-Claim
376	dosages	_	_	I-Claim
377	investigated	_	_	I-Claim
378	.	_	_	I-Claim


0	Docetaxel	_	_	B-Claim
1	has	_	_	I-Claim
2	shown	_	_	I-Claim
3	activity	_	_	I-Claim
4	in	_	_	I-Claim
5	elderly	_	_	I-Claim
6	patients	_	_	I-Claim
7	with	_	_	I-Claim
8	advanced	_	_	I-Claim
9	non-small-cell	_	_	I-Claim
10	lung	_	_	I-Claim
11	cancer	_	_	I-Claim
12	(	_	_	I-Claim
13	NSCLC	_	_	I-Claim
14	)	_	_	I-Claim
15	.	_	_	I-Claim

16	This	_	_	O
17	randomized	_	_	O
18	phase	_	_	O
19	III	_	_	O
20	trial	_	_	O
21	evaluated	_	_	O
22	the	_	_	O
23	efficacy	_	_	O
24	and	_	_	O
25	safety	_	_	O
26	of	_	_	O
27	docetaxel	_	_	O
28	versus	_	_	O
29	vinorelbine	_	_	O
30	(	_	_	O
31	the	_	_	O
32	current	_	_	O
33	standard	_	_	O
34	treatment	_	_	O
35	)	_	_	O
36	in	_	_	O
37	elderly	_	_	O
38	patients	_	_	O
39	.	_	_	O

40	Chemotherapy-naïve	_	_	O
41	patients	_	_	O
42	age	_	_	O
43	70	_	_	O
44	years	_	_	O
45	or	_	_	O
46	older	_	_	O
47	with	_	_	O
48	stage	_	_	O
49	IIIB/IV	_	_	O
50	NSCLC	_	_	O
51	and	_	_	O
52	performance	_	_	O
53	status	_	_	O
54	2	_	_	O
55	or	_	_	O
56	lower	_	_	O
57	were	_	_	O
58	eligible	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	randomly	_	_	O
62	received	_	_	O
63	docetaxel	_	_	O
64	60	_	_	O
65	mg/m2	_	_	O
66	(	_	_	O
67	day	_	_	O
68	1	_	_	O
69	)	_	_	O
70	or	_	_	O
71	vinorelbine	_	_	O
72	25	_	_	O
73	mg/m2	_	_	O
74	(	_	_	O
75	days	_	_	O
76	1	_	_	O
77	and	_	_	O
78	8	_	_	O
79	)	_	_	O
80	every	_	_	O
81	21	_	_	O
82	days	_	_	O
83	for	_	_	O
84	four	_	_	O
85	cycles	_	_	O
86	.	_	_	O

87	The	_	_	O
88	primary	_	_	O
89	end	_	_	O
90	point	_	_	O
91	was	_	_	O
92	overall	_	_	O
93	survival	_	_	O
94	.	_	_	O

95	Overall	_	_	O
96	disease-related	_	_	O
97	symptom	_	_	O
98	improvement	_	_	O
99	was	_	_	O
100	assessed	_	_	O
101	using	_	_	O
102	an	_	_	O
103	eight-item	_	_	O
104	questionnaire	_	_	O
105	.	_	_	O

106	In	_	_	O
107	total	_	_	O
108	,	_	_	O
109	182	_	_	O
110	patients	_	_	O
111	were	_	_	O
112	enrolled	_	_	O
113	.	_	_	O

114	Median	_	_	O
115	age	_	_	O
116	was	_	_	O
117	76	_	_	O
118	years	_	_	O
119	(	_	_	O
120	range	_	_	O
121	,	_	_	O
122	70	_	_	O
123	years	_	_	O
124	to	_	_	O
125	86	_	_	O
126	years	_	_	O
127	)	_	_	O
128	.	_	_	O

129	There	_	_	B-Premise
130	was	_	_	I-Premise
131	no	_	_	I-Premise
132	statistical	_	_	I-Premise
133	difference	_	_	I-Premise
134	in	_	_	I-Premise
135	median	_	_	I-Premise
136	overall	_	_	I-Premise
137	survival	_	_	I-Premise
138	with	_	_	I-Premise
139	docetaxel	_	_	I-Premise
140	versus	_	_	I-Premise
141	vinorelbine	_	_	I-Premise
142	(	_	_	I-Premise
143	14.3	_	_	I-Premise
144	months	_	_	I-Premise
145	v	_	_	I-Premise
146	9.9	_	_	I-Premise
147	months	_	_	I-Premise
148	;	_	_	I-Premise
149	hazard	_	_	I-Premise
150	ratio	_	_	I-Premise
151	,	_	_	I-Premise
152	0.780	_	_	I-Premise
153	;	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	,	_	_	I-Premise
158	0.561	_	_	I-Premise
159	to	_	_	I-Premise
160	1.085	_	_	I-Premise
161	;	_	_	I-Premise
162	P	_	_	I-Premise
163	=	_	_	I-Premise
164	.138	_	_	I-Premise
165	)	_	_	I-Premise
166	.	_	_	I-Premise

167	There	_	_	B-Premise
168	was	_	_	I-Premise
169	a	_	_	I-Premise
170	significant	_	_	I-Premise
171	difference	_	_	I-Premise
172	in	_	_	I-Premise
173	median	_	_	I-Premise
174	progression-free	_	_	I-Premise
175	survival	_	_	I-Premise
176	(	_	_	I-Premise
177	5.5	_	_	I-Premise
178	months	_	_	I-Premise
179	v	_	_	I-Premise
180	3.1	_	_	I-Premise
181	months	_	_	I-Premise
182	;	_	_	I-Premise
183	P	_	_	I-Premise
184	<	_	_	I-Premise
185	.001	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	Response	_	_	B-Premise
189	rates	_	_	I-Premise
190	were	_	_	I-Premise
191	also	_	_	I-Premise
192	significantly	_	_	I-Premise
193	improved	_	_	I-Premise
194	with	_	_	I-Premise
195	docetaxel	_	_	I-Premise
196	versus	_	_	I-Premise
197	vinorelbine	_	_	I-Premise
198	(	_	_	I-Premise
199	22.7	_	_	I-Premise
200	%	_	_	I-Premise
201	v	_	_	I-Premise
202	9.9	_	_	I-Premise
203	%	_	_	I-Premise
204	;	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	.019	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	The	_	_	B-Premise
211	most	_	_	I-Premise
212	common	_	_	I-Premise
213	grade	_	_	I-Premise
214	3	_	_	I-Premise
215	to	_	_	I-Premise
216	4	_	_	I-Premise
217	toxicities	_	_	I-Premise
218	were	_	_	I-Premise
219	neutropenia	_	_	I-Premise
220	(	_	_	I-Premise
221	82.9	_	_	I-Premise
222	%	_	_	I-Premise
223	for	_	_	I-Premise
224	docetaxel	_	_	I-Premise
225	;	_	_	I-Premise
226	69.2	_	_	I-Premise
227	%	_	_	I-Premise
228	for	_	_	I-Premise
229	vinorelbine	_	_	I-Premise
230	;	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.031	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	leukopenia	_	_	I-Premise
237	(	_	_	I-Premise
238	58.0	_	_	I-Premise
239	%	_	_	I-Premise
240	for	_	_	I-Premise
241	docetaxel	_	_	I-Premise
242	;	_	_	I-Premise
243	51.7	_	_	I-Premise
244	%	_	_	I-Premise
245	for	_	_	I-Premise
246	vinorelbine	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	Other	_	_	B-Premise
250	toxicities	_	_	I-Premise
251	were	_	_	I-Premise
252	mild	_	_	I-Premise
253	and	_	_	I-Premise
254	generally	_	_	I-Premise
255	well	_	_	I-Premise
256	tolerated	_	_	I-Premise
257	.	_	_	I-Premise

258	Docetaxel	_	_	B-Premise
259	improved	_	_	I-Premise
260	overall	_	_	I-Premise
261	disease-related	_	_	I-Premise
262	symptoms	_	_	I-Premise
263	over	_	_	I-Premise
264	vinorelbine	_	_	I-Premise
265	(	_	_	I-Premise
266	odds	_	_	I-Premise
267	ratio	_	_	I-Premise
268	,	_	_	I-Premise
269	1.86	_	_	I-Premise
270	;	_	_	I-Premise
271	95	_	_	I-Premise
272	%	_	_	I-Premise
273	CI	_	_	I-Premise
274	,	_	_	I-Premise
275	1.09	_	_	I-Premise
276	to	_	_	I-Premise
277	3.20	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Docetaxel	_	_	B-Premise
281	improved	_	_	I-Premise
282	progression-free	_	_	I-Premise
283	survival	_	_	I-Premise
284	,	_	_	I-Premise
285	response	_	_	I-Premise
286	rate	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	disease-related	_	_	I-Premise
290	symptoms	_	_	I-Premise
291	versus	_	_	I-Premise
292	vinorelbine	_	_	I-Premise
293	.	_	_	I-Premise

294	Overall	_	_	B-Claim
295	survival	_	_	I-Claim
296	was	_	_	I-Claim
297	not	_	_	I-Claim
298	statistically	_	_	I-Claim
299	significantly	_	_	I-Claim
300	improved	_	_	I-Claim
301	at	_	_	I-Claim
302	this	_	_	I-Claim
303	time	_	_	I-Claim
304	.	_	_	I-Claim

305	Docetaxel	_	_	B-Claim
306	monotherapy	_	_	I-Claim
307	may	_	_	I-Claim
308	be	_	_	I-Claim
309	considered	_	_	I-Claim
310	as	_	_	I-Claim
311	an	_	_	I-Claim
312	option	_	_	I-Claim
313	in	_	_	I-Claim
314	the	_	_	I-Claim
315	standard	_	_	I-Claim
316	treatment	_	_	I-Claim
317	of	_	_	I-Claim
318	elderly	_	_	I-Claim
319	patients	_	_	I-Claim
320	with	_	_	I-Claim
321	advanced	_	_	I-Claim
322	NSCLC	_	_	I-Claim
323	.	_	_	I-Claim


0	The	_	_	O
1	combination	_	_	O
2	of	_	_	O
3	carboplatin	_	_	O
4	and	_	_	O
5	paclitaxel	_	_	O
6	is	_	_	O
7	the	_	_	O
8	standard	_	_	O
9	of	_	_	O
10	care	_	_	O
11	for	_	_	O
12	the	_	_	O
13	treatment	_	_	O
14	of	_	_	O
15	ovarian	_	_	O
16	cancer	_	_	O
17	,	_	_	O
18	yet	_	_	O
19	rates	_	_	O
20	of	_	_	O
21	recurrence	_	_	O
22	and	_	_	O
23	death	_	_	O
24	remain	_	_	O
25	high	_	_	O
26	.	_	_	O

27	We	_	_	O
28	performed	_	_	O
29	a	_	_	O
30	prospective	_	_	O
31	randomized	_	_	O
32	phase	_	_	O
33	III	_	_	O
34	study	_	_	O
35	to	_	_	O
36	examine	_	_	O
37	whether	_	_	O
38	sequential	_	_	O
39	administration	_	_	O
40	of	_	_	O
41	topotecan	_	_	O
42	can	_	_	O
43	improve	_	_	O
44	the	_	_	O
45	efficacy	_	_	O
46	of	_	_	O
47	carboplatin	_	_	O
48	and	_	_	O
49	paclitaxel	_	_	O
50	in	_	_	O
51	first-line	_	_	O
52	treatment	_	_	O
53	of	_	_	O
54	advanced	_	_	O
55	epithelial	_	_	O
56	ovarian	_	_	O
57	cancer	_	_	O
58	.	_	_	O

59	A	_	_	O
60	total	_	_	O
61	of	_	_	O
62	1308	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	previously	_	_	O
66	untreated	_	_	O
67	ovarian	_	_	O
68	cancer	_	_	O
69	(	_	_	O
70	International	_	_	O
71	Federation	_	_	O
72	of	_	_	O
73	Gynecology	_	_	O
74	and	_	_	O
75	Obstetrics	_	_	O
76	stages	_	_	O
77	IIB-IV	_	_	O
78	)	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	six	_	_	O
85	cycles	_	_	O
86	of	_	_	O
87	paclitaxel	_	_	O
88	and	_	_	O
89	carboplatin	_	_	O
90	followed	_	_	O
91	by	_	_	O
92	either	_	_	O
93	four	_	_	O
94	cycles	_	_	O
95	of	_	_	O
96	topotecan	_	_	O
97	(	_	_	O
98	TC-Top	_	_	O
99	;	_	_	O
100	658	_	_	O
101	patients	_	_	O
102	)	_	_	O
103	or	_	_	O
104	surveillance	_	_	O
105	(	_	_	O
106	TC	_	_	O
107	;	_	_	O
108	650	_	_	O
109	patients	_	_	O
110	)	_	_	O
111	on	_	_	O
112	a	_	_	O
113	3-week	_	_	O
114	per	_	_	O
115	cycle	_	_	O
116	schedule	_	_	O
117	.	_	_	O

118	The	_	_	O
119	primary	_	_	O
120	endpoint	_	_	O
121	was	_	_	O
122	overall	_	_	O
123	survival	_	_	O
124	,	_	_	O
125	and	_	_	O
126	secondary	_	_	O
127	endpoints	_	_	O
128	were	_	_	O
129	progression-free	_	_	O
130	survival	_	_	O
131	,	_	_	O
132	response	_	_	O
133	rate	_	_	O
134	,	_	_	O
135	toxicity	_	_	O
136	,	_	_	O
137	and	_	_	O
138	quality	_	_	O
139	of	_	_	O
140	life	_	_	O
141	.	_	_	O

142	Time-to-event	_	_	O
143	data	_	_	O
144	were	_	_	O
145	analyzed	_	_	O
146	using	_	_	O
147	the	_	_	O
148	Kaplan-Meier	_	_	O
149	method	_	_	O
150	,	_	_	O
151	and	_	_	O
152	a	_	_	O
153	stratified	_	_	O
154	log-rank	_	_	O
155	test	_	_	O
156	was	_	_	O
157	used	_	_	O
158	to	_	_	O
159	compare	_	_	O
160	distributions	_	_	O
161	between	_	_	O
162	treatment	_	_	O
163	groups	_	_	O
164	.	_	_	O

165	Hazard	_	_	O
166	ratios	_	_	O
167	(	_	_	O
168	HRs	_	_	O
169	)	_	_	O
170	with	_	_	O
171	95	_	_	O
172	%	_	_	O
173	confidence	_	_	O
174	intervals	_	_	O
175	(	_	_	O
176	CIs	_	_	O
177	)	_	_	O
178	were	_	_	O
179	estimated	_	_	O
180	using	_	_	O
181	a	_	_	O
182	Cox	_	_	O
183	proportional	_	_	O
184	hazards	_	_	O
185	model	_	_	O
186	.	_	_	O

187	Categorical	_	_	O
188	data	_	_	O
189	were	_	_	O
190	compared	_	_	O
191	using	_	_	O
192	a	_	_	O
193	stratified	_	_	O
194	Cochran-Mantel-Haenszel	_	_	O
195	test	_	_	O
196	.	_	_	O

197	All	_	_	O
198	statistical	_	_	O
199	tests	_	_	O
200	were	_	_	O
201	two-sided	_	_	O
202	.	_	_	O

203	Median	_	_	B-Premise
204	progression-free	_	_	I-Premise
205	survival	_	_	I-Premise
206	was	_	_	I-Premise
207	18.2	_	_	I-Premise
208	months	_	_	I-Premise
209	in	_	_	I-Premise
210	the	_	_	I-Premise
211	TC-Top	_	_	I-Premise
212	arm	_	_	I-Premise
213	versus	_	_	I-Premise
214	18.5	_	_	I-Premise
215	months	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	TC	_	_	I-Premise
219	arm	_	_	I-Premise
220	(	_	_	I-Premise
221	stratum-adjusted	_	_	I-Premise
222	HR	_	_	I-Premise
223	=	_	_	I-Premise
224	0.97	_	_	I-Premise
225	[	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	=	_	_	I-Premise
230	0.85	_	_	I-Premise
231	to	_	_	I-Premise
232	1.10	_	_	I-Premise
233	]	_	_	I-Premise
234	;	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	.688	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	Median	_	_	B-Premise
241	overall	_	_	I-Premise
242	survival	_	_	I-Premise
243	was	_	_	I-Premise
244	43.1	_	_	I-Premise
245	months	_	_	I-Premise
246	for	_	_	I-Premise
247	the	_	_	I-Premise
248	TC-Top	_	_	I-Premise
249	arm	_	_	I-Premise
250	versus	_	_	I-Premise
251	44.5	_	_	I-Premise
252	months	_	_	I-Premise
253	for	_	_	I-Premise
254	the	_	_	I-Premise
255	TC	_	_	I-Premise
256	arm	_	_	I-Premise
257	(	_	_	I-Premise
258	stratum-adjusted	_	_	I-Premise
259	HR	_	_	I-Premise
260	=	_	_	I-Premise
261	1.01	_	_	I-Premise
262	[	_	_	I-Premise
263	95	_	_	I-Premise
264	%	_	_	I-Premise
265	CI	_	_	I-Premise
266	=	_	_	I-Premise
267	0.86	_	_	I-Premise
268	to	_	_	I-Premise
269	1.18	_	_	I-Premise
270	]	_	_	I-Premise
271	;	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	.885	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	At	_	_	B-Premise
278	3	_	_	I-Premise
279	years	_	_	I-Premise
280	,	_	_	I-Premise
281	overall	_	_	I-Premise
282	survival	_	_	I-Premise
283	in	_	_	I-Premise
284	both	_	_	I-Premise
285	arms	_	_	I-Premise
286	was	_	_	I-Premise
287	57	_	_	I-Premise
288	%	_	_	I-Premise
289	(	_	_	I-Premise
290	58.5	_	_	I-Premise
291	%	_	_	I-Premise
292	in	_	_	I-Premise
293	the	_	_	I-Premise
294	TC	_	_	I-Premise
295	arm	_	_	I-Premise
296	and	_	_	I-Premise
297	55.7	_	_	I-Premise
298	%	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	TC-Top	_	_	I-Premise
302	arm	_	_	I-Premise
303	)	_	_	I-Premise
304	.	_	_	I-Premise

305	Compared	_	_	B-Premise
306	with	_	_	I-Premise
307	patients	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	TC	_	_	I-Premise
311	arm	_	_	I-Premise
312	,	_	_	I-Premise
313	patients	_	_	I-Premise
314	in	_	_	I-Premise
315	the	_	_	I-Premise
316	TC-Top	_	_	I-Premise
317	arm	_	_	I-Premise
318	had	_	_	I-Premise
319	more	_	_	I-Premise
320	grade	_	_	I-Premise
321	3-4	_	_	I-Premise
322	hematologic	_	_	I-Premise
323	toxic	_	_	I-Premise
324	effects	_	_	I-Premise
325	(	_	_	I-Premise
326	requiring	_	_	I-Premise
327	more	_	_	I-Premise
328	supportive	_	_	I-Premise
329	care	_	_	I-Premise
330	)	_	_	I-Premise
331	and	_	_	I-Premise
332	more	_	_	I-Premise
333	grade	_	_	I-Premise
334	3-4	_	_	I-Premise
335	infections	_	_	I-Premise
336	(	_	_	I-Premise
337	5.1	_	_	I-Premise
338	%	_	_	I-Premise
339	versus	_	_	I-Premise
340	2.7	_	_	I-Premise
341	%	_	_	I-Premise
342	;	_	_	I-Premise
343	P	_	_	I-Premise
344	=	_	_	I-Premise
345	.034	_	_	I-Premise
346	)	_	_	I-Premise
347	but	_	_	I-Premise
348	did	_	_	I-Premise
349	not	_	_	I-Premise
350	have	_	_	I-Premise
351	a	_	_	I-Premise
352	statistically	_	_	I-Premise
353	significant	_	_	I-Premise
354	increase	_	_	I-Premise
355	in	_	_	I-Premise
356	febrile	_	_	I-Premise
357	neutropenia	_	_	I-Premise
358	(	_	_	I-Premise
359	3.3	_	_	I-Premise
360	%	_	_	I-Premise
361	versus	_	_	I-Premise
362	3.1	_	_	I-Premise
363	%	_	_	I-Premise
364	;	_	_	I-Premise
365	P	_	_	I-Premise
366	=	_	_	I-Premise
367	.80	_	_	I-Premise
368	)	_	_	I-Premise
369	.	_	_	I-Premise

370	Among	_	_	B-Premise
371	patients	_	_	I-Premise
372	who	_	_	I-Premise
373	had	_	_	I-Premise
374	measurable	_	_	I-Premise
375	disease	_	_	I-Premise
376	(	_	_	I-Premise
377	TC	_	_	I-Premise
378	,	_	_	I-Premise
379	n	_	_	I-Premise
380	=	_	_	I-Premise
381	147	_	_	I-Premise
382	;	_	_	I-Premise
383	TC-Top	_	_	I-Premise
384	,	_	_	I-Premise
385	n	_	_	I-Premise
386	=	_	_	I-Premise
387	145	_	_	I-Premise
388	)	_	_	I-Premise
389	,	_	_	I-Premise
390	overall	_	_	I-Premise
391	(	_	_	I-Premise
392	i.e.	_	_	I-Premise
393	,	_	_	I-Premise
394	complete	_	_	I-Premise
395	or	_	_	I-Premise
396	partial	_	_	I-Premise
397	)	_	_	I-Premise
398	response	_	_	I-Premise
399	was	_	_	I-Premise
400	69.0	_	_	I-Premise
401	%	_	_	I-Premise
402	(	_	_	I-Premise
403	95	_	_	I-Premise
404	%	_	_	I-Premise
405	CI	_	_	I-Premise
406	=	_	_	I-Premise
407	61.4	_	_	I-Premise
408	%	_	_	I-Premise
409	to	_	_	I-Premise
410	76.5	_	_	I-Premise
411	%	_	_	I-Premise
412	)	_	_	I-Premise
413	in	_	_	I-Premise
414	the	_	_	I-Premise
415	TC-Top	_	_	I-Premise
416	arm	_	_	I-Premise
417	and	_	_	I-Premise
418	76.2	_	_	I-Premise
419	%	_	_	I-Premise
420	(	_	_	I-Premise
421	95	_	_	I-Premise
422	%	_	_	I-Premise
423	CI	_	_	I-Premise
424	=	_	_	I-Premise
425	69.3	_	_	I-Premise
426	%	_	_	I-Premise
427	to	_	_	I-Premise
428	83.1	_	_	I-Premise
429	%	_	_	I-Premise
430	)	_	_	I-Premise
431	in	_	_	I-Premise
432	the	_	_	I-Premise
433	TC	_	_	I-Premise
434	arm	_	_	I-Premise
435	(	_	_	I-Premise
436	P	_	_	I-Premise
437	=	_	_	I-Premise
438	.166	_	_	I-Premise
439	)	_	_	I-Premise
440	.	_	_	I-Premise

441	The	_	_	B-Claim
442	sequential	_	_	I-Claim
443	addition	_	_	I-Claim
444	of	_	_	I-Claim
445	topotecan	_	_	I-Claim
446	to	_	_	I-Claim
447	carboplatin-paclitaxel	_	_	I-Claim
448	did	_	_	I-Claim
449	not	_	_	I-Claim
450	result	_	_	I-Claim
451	in	_	_	I-Claim
452	superior	_	_	I-Claim
453	overall	_	_	I-Claim
454	response	_	_	I-Claim
455	or	_	_	I-Claim
456	progression-free	_	_	I-Claim
457	or	_	_	I-Claim
458	overall	_	_	I-Claim
459	survival	_	_	I-Claim
460	.	_	_	I-Claim

461	Therefore	_	_	B-Claim
462	,	_	_	I-Claim
463	this	_	_	I-Claim
464	regimen	_	_	I-Claim
465	is	_	_	I-Claim
466	not	_	_	I-Claim
467	recommended	_	_	I-Claim
468	as	_	_	I-Claim
469	standard	_	_	I-Claim
470	of	_	_	I-Claim
471	care	_	_	I-Claim
472	treatment	_	_	I-Claim
473	for	_	_	I-Claim
474	ovarian	_	_	I-Claim
475	cancer	_	_	I-Claim
476	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	selective	_	_	O
3	laser	_	_	O
4	trabeculoplasty	_	_	O
5	(	_	_	O
6	SLT	_	_	O
7	)	_	_	O
8	and	_	_	O
9	argon	_	_	O
10	laser	_	_	O
11	trabeculoplasty	_	_	O
12	(	_	_	O
13	ALT	_	_	O
14	)	_	_	O
15	,	_	_	O
16	in	_	_	O
17	terms	_	_	O
18	of	_	_	O
19	intraocular	_	_	O
20	pressure	_	_	O
21	(	_	_	O
22	IOP	_	_	O
23	)	_	_	O
24	lowering	_	_	O
25	,	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	open-angle	_	_	O
30	glaucoma	_	_	O
31	.	_	_	O

32	176	_	_	O
33	eyes	_	_	O
34	of	_	_	O
35	152	_	_	O
36	patients	_	_	O
37	were	_	_	O
38	enrolled	_	_	O
39	in	_	_	O
40	this	_	_	O
41	study	_	_	O
42	,	_	_	O
43	89	_	_	O
44	in	_	_	O
45	the	_	_	O
46	SLT	_	_	O
47	and	_	_	O
48	87	_	_	O
49	in	_	_	O
50	the	_	_	O
51	ALT	_	_	O
52	groups	_	_	O
53	.	_	_	O

54	Patients	_	_	O
55	were	_	_	O
56	randomised	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	either	_	_	O
60	SLT	_	_	O
61	or	_	_	O
62	ALT	_	_	O
63	treatment	_	_	O
64	to	_	_	O
65	180	_	_	O
66	degrees	_	_	O
67	of	_	_	O
68	the	_	_	O
69	trabecular	_	_	O
70	meshwork	_	_	O
71	.	_	_	O

72	Patients	_	_	O
73	were	_	_	O
74	followed	_	_	O
75	up	_	_	O
76	to	_	_	O
77	12	_	_	O
78	months	_	_	O
79	after	_	_	O
80	treatment	_	_	O
81	.	_	_	O

82	The	_	_	O
83	main	_	_	O
84	outcome	_	_	O
85	measured	_	_	O
86	was	_	_	O
87	IOP	_	_	O
88	lowering	_	_	O
89	at	_	_	O
90	12	_	_	O
91	months	_	_	O
92	after	_	_	O
93	treatment	_	_	O
94	,	_	_	O
95	compared	_	_	O
96	between	_	_	O
97	the	_	_	O
98	SLT	_	_	O
99	and	_	_	O
100	ALT	_	_	O
101	groups	_	_	O
102	.	_	_	O

103	No	_	_	B-Premise
104	significant	_	_	I-Premise
105	difference	_	_	I-Premise
106	(	_	_	I-Premise
107	p	_	_	I-Premise
108	=	_	_	I-Premise
109	0.846	_	_	I-Premise
110	)	_	_	I-Premise
111	was	_	_	I-Premise
112	found	_	_	I-Premise
113	in	_	_	I-Premise
114	mean	_	_	I-Premise
115	decrease	_	_	I-Premise
116	in	_	_	I-Premise
117	IOP	_	_	I-Premise
118	between	_	_	I-Premise
119	the	_	_	I-Premise
120	SLT	_	_	I-Premise
121	(	_	_	I-Premise
122	5.86	_	_	I-Premise
123	mm	_	_	I-Premise
124	Hg	_	_	I-Premise
125	)	_	_	I-Premise
126	and	_	_	I-Premise
127	ALT	_	_	I-Premise
128	(	_	_	I-Premise
129	6.04	_	_	I-Premise
130	mm	_	_	I-Premise
131	Hg	_	_	I-Premise
132	)	_	_	I-Premise
133	groups	_	_	I-Premise
134	at	_	_	I-Premise
135	1	_	_	I-Premise
136	year	_	_	I-Premise
137	or	_	_	I-Premise
138	at	_	_	I-Premise
139	any	_	_	I-Premise
140	other	_	_	I-Premise
141	time	_	_	I-Premise
142	points	_	_	I-Premise
143	,	_	_	I-Premise
144	nor	_	_	I-Premise
145	were	_	_	I-Premise
146	there	_	_	I-Premise
147	any	_	_	I-Premise
148	significant	_	_	I-Premise
149	differences	_	_	I-Premise
150	in	_	_	I-Premise
151	the	_	_	I-Premise
152	rate	_	_	I-Premise
153	of	_	_	I-Premise
154	early	_	_	I-Premise
155	or	_	_	I-Premise
156	late	_	_	I-Premise
157	complications	_	_	I-Premise
158	between	_	_	I-Premise
159	the	_	_	I-Premise
160	two	_	_	I-Premise
161	groups	_	_	I-Premise
162	.	_	_	I-Premise

163	SLT	_	_	B-Claim
164	is	_	_	I-Claim
165	equivalent	_	_	I-Claim
166	to	_	_	I-Claim
167	ALT	_	_	I-Claim
168	in	_	_	I-Claim
169	terms	_	_	I-Claim
170	of	_	_	I-Claim
171	IOP	_	_	I-Claim
172	lowering	_	_	I-Claim
173	at	_	_	I-Claim
174	1	_	_	I-Claim
175	year	_	_	I-Claim
176	,	_	_	I-Claim
177	and	_	_	I-Claim
178	is	_	_	I-Claim
179	a	_	_	I-Claim
180	safe	_	_	I-Claim
181	and	_	_	I-Claim
182	effective	_	_	I-Claim
183	procedure	_	_	I-Claim
184	for	_	_	I-Claim
185	patients	_	_	I-Claim
186	with	_	_	I-Claim
187	open-angle	_	_	I-Claim
188	glaucoma	_	_	I-Claim
189	.	_	_	I-Claim


0	This	_	_	O
1	report	_	_	O
2	describes	_	_	O
3	the	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	QOL	_	_	O
9	)	_	_	O
10	findings	_	_	O
11	of	_	_	O
12	a	_	_	O
13	randomized	_	_	O
14	placebo	_	_	O
15	controlled	_	_	O
16	study	_	_	O
17	of	_	_	O
18	erlotinib	_	_	O
19	,	_	_	O
20	an	_	_	O
21	epidermal	_	_	O
22	growth	_	_	O
23	factor	_	_	O
24	receptor	_	_	O
25	inhibitor	_	_	O
26	,	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	non-small-cell	_	_	O
31	lung	_	_	O
32	cancer	_	_	O
33	(	_	_	O
34	NSCLC	_	_	O
35	)	_	_	O
36	.	_	_	O

37	This	_	_	O
38	double-blind	_	_	O
39	phase	_	_	O
40	III	_	_	O
41	trial	_	_	O
42	randomly	_	_	O
43	assigned	_	_	O
44	731	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	NSCLC	_	_	O
48	who	_	_	O
49	had	_	_	O
50	progressed	_	_	O
51	after	_	_	O
52	prior	_	_	O
53	chemotherapy	_	_	O
54	to	_	_	O
55	erlotinib	_	_	O
56	150	_	_	O
57	mg	_	_	O
58	daily	_	_	O
59	or	_	_	O
60	placebo	_	_	O
61	,	_	_	O
62	with	_	_	O
63	survival	_	_	O
64	as	_	_	O
65	the	_	_	O
66	primary	_	_	O
67	study	_	_	O
68	outcome	_	_	O
69	.	_	_	O

70	QOL	_	_	O
71	was	_	_	O
72	assessed	_	_	O
73	by	_	_	O
74	European	_	_	O
75	Organisation	_	_	O
76	for	_	_	O
77	Research	_	_	O
78	and	_	_	O
79	Treatment	_	_	O
80	of	_	_	O
81	Cancer	_	_	O
82	QLQ-C30	_	_	O
83	and	_	_	O
84	the	_	_	O
85	lung	_	_	O
86	cancer	_	_	O
87	module	_	_	O
88	QLQ-LC13	_	_	O
89	.	_	_	O

90	The	_	_	O
91	primary	_	_	O
92	end	_	_	O
93	points	_	_	O
94	for	_	_	O
95	QOL	_	_	O
96	analysis	_	_	O
97	were	_	_	O
98	time	_	_	O
99	to	_	_	O
100	deterioration	_	_	O
101	of	_	_	O
102	three	_	_	O
103	common	_	_	O
104	lung	_	_	O
105	cancer	_	_	O
106	symptoms	_	_	O
107	:	_	_	O
108	cough	_	_	O
109	,	_	_	O
110	dyspnea	_	_	O
111	,	_	_	O
112	and	_	_	O
113	pain	_	_	O
114	.	_	_	O

115	Survival	_	_	B-Premise
116	was	_	_	I-Premise
117	significantly	_	_	I-Premise
118	longer	_	_	I-Premise
119	(	_	_	I-Premise
120	hazard	_	_	I-Premise
121	ratio	_	_	I-Premise
122	,	_	_	I-Premise
123	0.70	_	_	I-Premise
124	;	_	_	I-Premise
125	P	_	_	I-Premise
126	<	_	_	I-Premise
127	.0001	_	_	I-Premise
128	)	_	_	I-Premise
129	in	_	_	I-Premise
130	the	_	_	I-Premise
131	erlotinib	_	_	I-Premise
132	arm	_	_	I-Premise
133	.	_	_	I-Premise

134	Compliance	_	_	B-Premise
135	with	_	_	I-Premise
136	QOL	_	_	I-Premise
137	was	_	_	I-Premise
138	87	_	_	I-Premise
139	%	_	_	I-Premise
140	at	_	_	I-Premise
141	baseline	_	_	I-Premise
142	and	_	_	I-Premise
143	more	_	_	I-Premise
144	than	_	_	I-Premise
145	70	_	_	I-Premise
146	%	_	_	I-Premise
147	during	_	_	I-Premise
148	treatment	_	_	I-Premise
149	.	_	_	I-Premise

150	Patients	_	_	B-Premise
151	receiving	_	_	I-Premise
152	erlotinib	_	_	I-Premise
153	had	_	_	I-Premise
154	significantly	_	_	I-Premise
155	longer	_	_	I-Premise
156	median	_	_	I-Premise
157	time	_	_	I-Premise
158	to	_	_	I-Premise
159	deterioration	_	_	I-Premise
160	for	_	_	I-Premise
161	all	_	_	I-Premise
162	three	_	_	I-Premise
163	symptoms	_	_	I-Premise
164	(	_	_	I-Premise
165	4.9	_	_	I-Premise
166	v	_	_	I-Premise
167	3.7	_	_	I-Premise
168	months	_	_	I-Premise
169	for	_	_	I-Premise
170	cough	_	_	I-Premise
171	[	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.04	_	_	I-Premise
175	]	_	_	I-Premise
176	;	_	_	I-Premise
177	4.7	_	_	I-Premise
178	v	_	_	I-Premise
179	2.9	_	_	I-Premise
180	months	_	_	I-Premise
181	for	_	_	I-Premise
182	dyspnea	_	_	I-Premise
183	[	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.04	_	_	I-Premise
187	]	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	2.8	_	_	I-Premise
191	v	_	_	I-Premise
192	1.9	_	_	I-Premise
193	months	_	_	I-Premise
194	for	_	_	I-Premise
195	pain	_	_	I-Premise
196	[	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.03	_	_	I-Premise
200	]	_	_	I-Premise
201	)	_	_	I-Premise
202	.	_	_	I-Premise

203	QOL	_	_	B-Premise
204	response	_	_	I-Premise
205	analyses	_	_	I-Premise
206	showed	_	_	I-Premise
207	that	_	_	I-Premise
208	44	_	_	I-Premise
209	%	_	_	I-Premise
210	,	_	_	I-Premise
211	34	_	_	I-Premise
212	%	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	42	_	_	I-Premise
216	%	_	_	I-Premise
217	of	_	_	I-Premise
218	patients	_	_	I-Premise
219	receiving	_	_	I-Premise
220	erlotinib	_	_	I-Premise
221	had	_	_	I-Premise
222	improvement	_	_	I-Premise
223	in	_	_	I-Premise
224	these	_	_	I-Premise
225	three	_	_	I-Premise
226	symptoms	_	_	I-Premise
227	,	_	_	I-Premise
228	respectively	_	_	I-Premise
229	.	_	_	I-Premise

230	This	_	_	B-Premise
231	was	_	_	I-Premise
232	accompanied	_	_	I-Premise
233	by	_	_	I-Premise
234	a	_	_	I-Premise
235	significant	_	_	I-Premise
236	improvement	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	physical	_	_	I-Premise
240	function	_	_	I-Premise
241	(	_	_	I-Premise
242	31	_	_	I-Premise
243	%	_	_	I-Premise
244	erlotinib	_	_	I-Premise
245	v	_	_	I-Premise
246	19	_	_	I-Premise
247	%	_	_	I-Premise
248	placebo	_	_	I-Premise
249	,	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	.01	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	and	_	_	I-Premise
256	global	_	_	I-Premise
257	QOL	_	_	I-Premise
258	(	_	_	I-Premise
259	35	_	_	I-Premise
260	%	_	_	I-Premise
261	v	_	_	I-Premise
262	26	_	_	I-Premise
263	%	_	_	I-Premise
264	,	_	_	I-Premise
265	P	_	_	I-Premise
266	<	_	_	I-Premise
267	.0001	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	Patients	_	_	B-Premise
271	with	_	_	I-Premise
272	complete	_	_	I-Premise
273	or	_	_	I-Premise
274	partial	_	_	I-Premise
275	response	_	_	I-Premise
276	were	_	_	I-Premise
277	more	_	_	I-Premise
278	likely	_	_	I-Premise
279	to	_	_	I-Premise
280	have	_	_	I-Premise
281	improvement	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	QOL	_	_	I-Premise
285	response	_	_	I-Premise
286	than	_	_	I-Premise
287	patients	_	_	I-Premise
288	with	_	_	I-Premise
289	stable	_	_	I-Premise
290	or	_	_	I-Premise
291	progressive	_	_	I-Premise
292	disease	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	<	_	_	I-Premise
296	.01	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Erlotinib	_	_	B-Claim
300	not	_	_	I-Claim
301	only	_	_	I-Claim
302	improves	_	_	I-Claim
303	survival	_	_	I-Claim
304	in	_	_	I-Claim
305	previously	_	_	I-Claim
306	treated	_	_	I-Claim
307	patients	_	_	I-Claim
308	with	_	_	I-Claim
309	NSCLC	_	_	I-Claim
310	,	_	_	I-Claim
311	but	_	_	I-Claim
312	also	_	_	I-Claim
313	improves	_	_	I-Claim
314	tumor-related	_	_	I-Claim
315	symptoms	_	_	I-Claim
316	and	_	_	I-Claim
317	important	_	_	I-Claim
318	aspects	_	_	I-Claim
319	of	_	_	I-Claim
320	QOL	_	_	I-Claim
321	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	health-related	_	_	O
6	quality	_	_	O
7	of	_	_	O
8	life	_	_	O
9	(	_	_	O
10	HRQOL	_	_	O
11	)	_	_	O
12	of	_	_	O
13	continuous	_	_	O
14	combined	_	_	O
15	hormone	_	_	O
16	replacement	_	_	O
17	therapy	_	_	O
18	(	_	_	O
19	ccHRT	_	_	O
20	)	_	_	O
21	with	_	_	O
22	estradiol	_	_	O
23	valerate/medroxyprogesterone	_	_	O
24	acetate	_	_	O
25	(	_	_	O
26	E	_	_	O
27	(	_	_	O
28	2	_	_	O
29	)	_	_	O
30	V/MPA	_	_	O
31	)	_	_	O
32	over	_	_	O
33	nine	_	_	O
34	years	_	_	O
35	and	_	_	O
36	at	_	_	O
37	follow-up	_	_	O
38	one	_	_	O
39	year	_	_	O
40	after	_	_	O
41	discontinuation	_	_	O
42	.	_	_	O

43	A	_	_	O
44	total	_	_	O
45	of	_	_	O
46	419	_	_	O
47	women	_	_	O
48	were	_	_	O
49	randomized	_	_	O
50	to	_	_	O
51	one	_	_	O
52	of	_	_	O
53	four	_	_	O
54	treatments	_	_	O
55	:	_	_	O
56	once-daily	_	_	O
57	1	_	_	O
58	mg	_	_	O
59	E2V/2.5	_	_	O
60	mg	_	_	O
61	MPA	_	_	O
62	(	_	_	O
63	1	_	_	O
64	+	_	_	O
65	2.5	_	_	O
66	group	_	_	O
67	)	_	_	O
68	;	_	_	O
69	1	_	_	O
70	mg	_	_	O
71	E2V/5	_	_	O
72	mg	_	_	O
73	MPA	_	_	O
74	daily	_	_	O
75	(	_	_	O
76	1	_	_	O
77	+	_	_	O
78	5	_	_	O
79	group	_	_	O
80	)	_	_	O
81	;	_	_	O
82	2	_	_	O
83	mg	_	_	O
84	E2V/2.5	_	_	O
85	mg	_	_	O
86	MPA	_	_	O
87	daily	_	_	O
88	(	_	_	O
89	2	_	_	O
90	+	_	_	O
91	2.5	_	_	O
92	group	_	_	O
93	)	_	_	O
94	;	_	_	O
95	2	_	_	O
96	mg	_	_	O
97	E2V/5	_	_	O
98	mg	_	_	O
99	MPA	_	_	O
100	daily	_	_	O
101	(	_	_	O
102	2	_	_	O
103	+	_	_	O
104	5	_	_	O
105	group	_	_	O
106	)	_	_	O
107	(	_	_	O
108	Indivina	_	_	O
109	,	_	_	O
110	Orion	_	_	O
111	Pharma	_	_	O
112	)	_	_	O
113	.	_	_	O

114	For	_	_	O
115	the	_	_	O
116	last	_	_	O
117	six	_	_	O
118	months	_	_	O
119	,	_	_	O
120	all	_	_	O
121	received	_	_	O
122	the	_	_	O
123	1	_	_	O
124	+	_	_	O
125	2.5	_	_	O
126	dosage	_	_	O
127	.	_	_	O

128	The	_	_	O
129	2	_	_	O
130	+	_	_	O
131	2.5	_	_	O
132	dosage	_	_	O
133	was	_	_	O
134	discontinued	_	_	O
135	at	_	_	O
136	the	_	_	O
137	end	_	_	O
138	of	_	_	O
139	year	_	_	O
140	7	_	_	O
141	.	_	_	O

142	A	_	_	O
143	total	_	_	O
144	of	_	_	O
145	198	_	_	O
146	women	_	_	O
147	continued	_	_	O
148	after	_	_	O
149	year	_	_	O
150	7	_	_	O
151	.	_	_	O

152	Annualized	_	_	O
153	percentage	_	_	O
154	rates	_	_	O
155	for	_	_	O
156	cardiovascular	_	_	O
157	events	_	_	O
158	[	_	_	O
159	corrected	_	_	O
160	]	_	_	O
161	and	_	_	O
162	endometrial	_	_	O
163	cancers	_	_	O
164	[	_	_	O
165	corrected	_	_	O
166	]	_	_	O
167	were	_	_	O
168	below	_	_	O
169	national	_	_	O
170	rates	_	_	O
171	for	_	_	O
172	Finland	_	_	O
173	and	_	_	O
174	those	_	_	O
175	reported	_	_	O
176	for	_	_	O
177	the	_	_	O
178	Women	_	_	O
179	's	_	_	O
180	Health	_	_	O
181	Initiative	_	_	O
182	.	_	_	O

183	There	_	_	B-Premise
184	were	_	_	I-Premise
185	no	_	_	I-Premise
186	serious	_	_	I-Premise
187	events	_	_	I-Premise
188	with	_	_	I-Premise
189	the	_	_	I-Premise
190	1	_	_	I-Premise
191	+	_	_	I-Premise
192	2.5	_	_	I-Premise
193	dosage	_	_	I-Premise
194	or	_	_	I-Premise
195	after	_	_	I-Premise
196	ccHRT	_	_	I-Premise
197	discontinuation	_	_	I-Premise
198	.	_	_	I-Premise

199	Climacteric	_	_	B-Premise
200	symptoms	_	_	I-Premise
201	remained	_	_	I-Premise
202	significantly	_	_	I-Premise
203	below	_	_	I-Premise
204	baseline	_	_	I-Premise
205	values	_	_	I-Premise
206	after	_	_	I-Premise
207	dosage	_	_	I-Premise
208	reduction	_	_	I-Premise
209	;	_	_	I-Premise
210	some	_	_	B-Premise
211	symptoms	_	_	I-Premise
212	recurred	_	_	I-Premise
213	after	_	_	I-Premise
214	discontinuation	_	_	I-Premise
215	of	_	_	I-Premise
216	ccHRT	_	_	I-Premise
217	.	_	_	I-Premise

218	HRQOL	_	_	B-Premise
219	ratings	_	_	I-Premise
220	improved	_	_	I-Premise
221	with	_	_	I-Premise
222	ccHRT	_	_	I-Premise
223	,	_	_	I-Premise
224	irrespective	_	_	I-Premise
225	of	_	_	I-Premise
226	dosage	_	_	I-Premise
227	,	_	_	I-Premise
228	including	_	_	I-Premise
229	depressed	_	_	I-Premise
230	mood	_	_	I-Premise
231	,	_	_	I-Premise
232	anxiety	_	_	I-Premise
233	,	_	_	I-Premise
234	health	_	_	I-Premise
235	perception	_	_	I-Premise
236	and	_	_	I-Premise
237	sexual	_	_	I-Premise
238	interest	_	_	I-Premise
239	.	_	_	I-Premise

240	Scores	_	_	B-Premise
241	on	_	_	I-Premise
242	a	_	_	I-Premise
243	scale	_	_	I-Premise
244	assessing	_	_	I-Premise
245	daily	_	_	I-Premise
246	functioning	_	_	I-Premise
247	and	_	_	I-Premise
248	enjoyment	_	_	I-Premise
249	(	_	_	I-Premise
250	Q-LES-Q	_	_	I-Premise
251	)	_	_	I-Premise
252	improved	_	_	I-Premise
253	from	_	_	I-Premise
254	year	_	_	I-Premise
255	7	_	_	I-Premise
256	to	_	_	I-Premise
257	year	_	_	I-Premise
258	9	_	_	I-Premise
259	.	_	_	I-Premise

260	They	_	_	B-Premise
261	deteriorated	_	_	I-Premise
262	during	_	_	I-Premise
263	follow-up	_	_	I-Premise
264	in	_	_	I-Premise
265	women	_	_	I-Premise
266	not	_	_	I-Premise
267	continuing	_	_	I-Premise
268	ccHRT	_	_	I-Premise
269	.	_	_	I-Premise

270	Lower	_	_	B-Claim
271	dosages	_	_	I-Claim
272	of	_	_	I-Claim
273	HRT	_	_	I-Claim
274	were	_	_	I-Claim
275	as	_	_	I-Claim
276	effective	_	_	I-Claim
277	as	_	_	I-Claim
278	higher	_	_	I-Claim
279	doses	_	_	I-Claim
280	in	_	_	I-Claim
281	improving	_	_	I-Claim
282	climacteric	_	_	I-Claim
283	symptoms	_	_	I-Claim
284	and	_	_	I-Claim
285	HRQOL	_	_	I-Claim
286	ratings	_	_	I-Claim
287	and	_	_	I-Claim
288	had	_	_	I-Claim
289	fewer	_	_	I-Claim
290	safety	_	_	I-Claim
291	concerns	_	_	I-Claim
292	.	_	_	I-Claim

293	Following	_	_	B-Premise
294	discontinuation	_	_	I-Premise
295	of	_	_	I-Premise
296	ccHRT	_	_	I-Premise
297	,	_	_	I-Premise
298	patient	_	_	I-Premise
299	satisfaction	_	_	I-Premise
300	was	_	_	I-Premise
301	variable	_	_	I-Premise
302	,	_	_	I-Premise
303	with	_	_	I-Premise
304	15	_	_	I-Premise
305	%	_	_	I-Premise
306	electing	_	_	I-Premise
307	to	_	_	I-Premise
308	continue	_	_	I-Premise
309	or	_	_	I-Premise
310	restart	_	_	I-Premise
311	HRT	_	_	I-Premise
312	and	_	_	I-Premise
313	7	_	_	I-Premise
314	%	_	_	I-Premise
315	resuming	_	_	I-Premise
316	at	_	_	I-Premise
317	follow-up	_	_	I-Premise
318	.	_	_	I-Premise

319	This	_	_	B-Claim
320	supports	_	_	I-Claim
321	the	_	_	I-Claim
322	need	_	_	I-Claim
323	for	_	_	I-Claim
324	an	_	_	I-Claim
325	individualized	_	_	I-Claim
326	approach	_	_	I-Claim
327	to	_	_	I-Claim
328	therapy	_	_	I-Claim
329	recommendations	_	_	I-Claim
330	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	toxicity	_	_	O
10	and	_	_	O
11	efficacy	_	_	O
12	of	_	_	O
13	radiation	_	_	O
14	therapy	_	_	O
15	(	_	_	O
16	RT	_	_	O
17	)	_	_	O
18	for	_	_	O
19	localized	_	_	O
20	carcinoma	_	_	O
21	of	_	_	O
22	the	_	_	O
23	prostate	_	_	O
24	,	_	_	O
25	using	_	_	O
26	a	_	_	O
27	hypofractionated	_	_	O
28	(	_	_	O
29	55	_	_	O
30	Gy/20	_	_	O
31	fractions/4	_	_	O
32	weeks	_	_	O
33	)	_	_	O
34	vs.	_	_	O
35	a	_	_	O
36	conventionally	_	_	O
37	fractionated	_	_	O
38	(	_	_	O
39	64	_	_	O
40	Gy/32	_	_	O
41	fractions/6.5	_	_	O
42	weeks	_	_	O
43	)	_	_	O
44	dose	_	_	O
45	schedule	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	217	_	_	O
51	patients	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	either	_	_	O
56	the	_	_	O
57	hypofractionated	_	_	O
58	(	_	_	O
59	108	_	_	O
60	patients	_	_	O
61	)	_	_	O
62	or	_	_	O
63	the	_	_	O
64	conventional	_	_	O
65	(	_	_	O
66	109	_	_	O
67	patients	_	_	O
68	)	_	_	O
69	dose	_	_	O
70	schedule	_	_	O
71	,	_	_	O
72	with	_	_	O
73	planning	_	_	O
74	with	_	_	O
75	two-dimensional	_	_	O
76	(	_	_	O
77	2D	_	_	O
78	)	_	_	O
79	CT	_	_	O
80	scan	_	_	O
81	planning	_	_	O
82	methodology	_	_	O
83	in	_	_	O
84	the	_	_	O
85	majority	_	_	O
86	of	_	_	O
87	cases	_	_	O
88	.	_	_	O

89	All	_	_	O
90	patients	_	_	O
91	were	_	_	O
92	followed	_	_	O
93	for	_	_	O
94	a	_	_	O
95	median	_	_	O
96	of	_	_	O
97	48	_	_	O
98	(	_	_	O
99	6-108	_	_	O
100	)	_	_	O
101	months	_	_	O
102	.	_	_	O

103	Gastrointestinal	_	_	O
104	(	_	_	O
105	GI	_	_	O
106	)	_	_	O
107	and	_	_	O
108	genitourinary	_	_	O
109	(	_	_	O
110	GU	_	_	O
111	)	_	_	O
112	toxicity	_	_	O
113	was	_	_	O
114	evaluated	_	_	O
115	before	_	_	O
116	RT	_	_	O
117	and	_	_	O
118	after	_	_	O
119	its	_	_	O
120	completion	_	_	O
121	using	_	_	O
122	modified	_	_	O
123	late	_	_	O
124	effects	_	_	O
125	of	_	_	O
126	normal	_	_	O
127	tissue-subjective	_	_	O
128	,	_	_	O
129	objective	_	_	O
130	,	_	_	O
131	management	_	_	O
132	,	_	_	O
133	analytic	_	_	O
134	(	_	_	O
135	LENT-SOMA	_	_	O
136	)	_	_	O
137	scales	_	_	O
138	and	_	_	O
139	the	_	_	O
140	European	_	_	O
141	Organization	_	_	O
142	for	_	_	O
143	Research	_	_	O
144	and	_	_	O
145	Treatment	_	_	O
146	of	_	_	O
147	Cancer	_	_	O
148	sexual	_	_	O
149	function	_	_	O
150	questionnaire	_	_	O
151	.	_	_	O

152	Efficacy	_	_	O
153	of	_	_	O
154	RT	_	_	O
155	based	_	_	O
156	on	_	_	O
157	clinical	_	_	O
158	,	_	_	O
159	radiologic	_	_	O
160	,	_	_	O
161	and	_	_	O
162	prostate-specific	_	_	O
163	antigen	_	_	O
164	data	_	_	O
165	were	_	_	O
166	also	_	_	O
167	evaluated	_	_	O
168	at	_	_	O
169	baseline	_	_	O
170	and	_	_	O
171	after	_	_	O
172	RT	_	_	O
173	.	_	_	O

174	Gastrointestinal	_	_	B-Premise
175	and	_	_	I-Premise
176	GU	_	_	I-Premise
177	toxicity	_	_	I-Premise
178	persisted	_	_	I-Premise
179	5	_	_	I-Premise
180	years	_	_	I-Premise
181	after	_	_	I-Premise
182	RT	_	_	I-Premise
183	and	_	_	I-Premise
184	did	_	_	I-Premise
185	not	_	_	I-Premise
186	differ	_	_	I-Premise
187	between	_	_	I-Premise
188	the	_	_	I-Premise
189	two	_	_	I-Premise
190	dose	_	_	I-Premise
191	schedules	_	_	I-Premise
192	other	_	_	I-Premise
193	than	_	_	I-Premise
194	in	_	_	I-Premise
195	regard	_	_	I-Premise
196	to	_	_	I-Premise
197	urgency	_	_	I-Premise
198	of	_	_	I-Premise
199	defecation	_	_	I-Premise
200	.	_	_	I-Premise

201	However	_	_	B-Premise
202	,	_	_	I-Premise
203	1-month	_	_	I-Premise
204	GI	_	_	I-Premise
205	toxicity	_	_	I-Premise
206	was	_	_	I-Premise
207	not	_	_	I-Premise
208	only	_	_	I-Premise
209	worse	_	_	I-Premise
210	in	_	_	I-Premise
211	patients	_	_	I-Premise
212	with	_	_	I-Premise
213	the	_	_	I-Premise
214	hypofractionated	_	_	I-Premise
215	RT	_	_	I-Premise
216	schedule	_	_	I-Premise
217	but	_	_	I-Premise
218	also	_	_	I-Premise
219	adversely	_	_	I-Premise
220	affected	_	_	I-Premise
221	daily	_	_	I-Premise
222	activities	_	_	I-Premise
223	.	_	_	I-Premise

224	Nadir	_	_	B-Premise
225	prostate-specific	_	_	I-Premise
226	antigen	_	_	I-Premise
227	values	_	_	I-Premise
228	occurred	_	_	I-Premise
229	at	_	_	I-Premise
230	a	_	_	I-Premise
231	median	_	_	I-Premise
232	of	_	_	I-Premise
233	18.0	_	_	I-Premise
234	(	_	_	I-Premise
235	3.0-54.0	_	_	I-Premise
236	)	_	_	I-Premise
237	months	_	_	I-Premise
238	after	_	_	I-Premise
239	RT	_	_	I-Premise
240	.	_	_	I-Premise

241	A	_	_	B-Premise
242	total	_	_	I-Premise
243	of	_	_	I-Premise
244	76	_	_	I-Premise
245	biochemical	_	_	I-Premise
246	relapses	_	_	I-Premise
247	,	_	_	I-Premise
248	with	_	_	I-Premise
249	or	_	_	I-Premise
250	without	_	_	I-Premise
251	clinical	_	_	I-Premise
252	relapses	_	_	I-Premise
253	,	_	_	I-Premise
254	have	_	_	I-Premise
255	occurred	_	_	I-Premise
256	since	_	_	I-Premise
257	;	_	_	I-Premise
258	of	_	_	I-Premise
259	these	_	_	I-Premise
260	,	_	_	I-Premise
261	37	_	_	I-Premise
262	were	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	hypofractionated	_	_	I-Premise
266	and	_	_	I-Premise
267	39	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	conventional	_	_	I-Premise
271	schedule	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	5-year	_	_	I-Premise
275	biochemical	_	_	I-Premise
276	+/-	_	_	I-Premise
277	clinical	_	_	I-Premise
278	relapse-free	_	_	I-Premise
279	and	_	_	I-Premise
280	overall	_	_	I-Premise
281	survival	_	_	I-Premise
282	was	_	_	I-Premise
283	55.9	_	_	I-Premise
284	%	_	_	I-Premise
285	and	_	_	I-Premise
286	85.3	_	_	I-Premise
287	%	_	_	I-Premise
288	respectively	_	_	I-Premise
289	for	_	_	I-Premise
290	all	_	_	I-Premise
291	patients	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	did	_	_	I-Premise
295	not	_	_	I-Premise
296	differ	_	_	I-Premise
297	between	_	_	I-Premise
298	the	_	_	I-Premise
299	two	_	_	I-Premise
300	schedules	_	_	I-Premise
301	.	_	_	I-Premise

302	Radiation	_	_	B-Claim
303	therapy	_	_	I-Claim
304	for	_	_	I-Claim
305	prostate	_	_	I-Claim
306	carcinoma	_	_	I-Claim
307	causes	_	_	I-Claim
308	persistent	_	_	I-Claim
309	GI	_	_	I-Claim
310	toxicity	_	_	I-Claim
311	that	_	_	I-Claim
312	is	_	_	I-Claim
313	largely	_	_	I-Claim
314	independent	_	_	I-Claim
315	of	_	_	I-Claim
316	the	_	_	I-Claim
317	two	_	_	I-Claim
318	dose	_	_	I-Claim
319	schedules	_	_	I-Claim
320	.	_	_	I-Claim

321	The	_	_	B-Claim
322	hypofractionated	_	_	I-Claim
323	schedule	_	_	I-Claim
324	is	_	_	I-Claim
325	equivalent	_	_	I-Claim
326	in	_	_	I-Claim
327	efficacy	_	_	I-Claim
328	to	_	_	I-Claim
329	the	_	_	I-Claim
330	conventional	_	_	I-Claim
331	schedule	_	_	I-Claim
332	.	_	_	I-Claim


0	Most	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	advanced	_	_	I-Claim
4	ovarian	_	_	I-Claim
5	cancer	_	_	I-Claim
6	develop	_	_	I-Claim
7	recurrent	_	_	I-Claim
8	disease	_	_	I-Claim
9	.	_	_	I-Claim

10	For	_	_	B-Claim
11	those	_	_	I-Claim
12	patients	_	_	I-Claim
13	who	_	_	I-Claim
14	recur	_	_	I-Claim
15	at	_	_	I-Claim
16	least	_	_	I-Claim
17	6	_	_	I-Claim
18	months	_	_	I-Claim
19	after	_	_	I-Claim
20	initial	_	_	I-Claim
21	therapy	_	_	I-Claim
22	,	_	_	I-Claim
23	paclitaxel	_	_	I-Claim
24	platinum	_	_	I-Claim
25	has	_	_	I-Claim
26	shown	_	_	I-Claim
27	a	_	_	I-Claim
28	modest	_	_	I-Claim
29	survival	_	_	I-Claim
30	advantage	_	_	I-Claim
31	over	_	_	I-Claim
32	platinum	_	_	I-Claim
33	without	_	_	I-Claim
34	paclitaxel	_	_	I-Claim
35	;	_	_	I-Claim
36	however	_	_	B-Premise
37	,	_	_	I-Premise
38	many	_	_	I-Premise
39	patients	_	_	I-Premise
40	develop	_	_	I-Premise
41	clinically	_	_	I-Premise
42	relevant	_	_	I-Premise
43	neurotoxicity	_	_	I-Premise
44	,	_	_	I-Premise
45	frequently	_	_	I-Premise
46	resulting	_	_	I-Premise
47	in	_	_	I-Premise
48	treatment	_	_	I-Premise
49	discontinuation	_	_	I-Premise
50	.	_	_	O

51	Thus	_	_	O
52	,	_	_	O
53	an	_	_	O
54	alternative	_	_	O
55	regimen	_	_	O
56	without	_	_	O
57	significant	_	_	O
58	neurotoxicity	_	_	O
59	was	_	_	O
60	evaluated	_	_	O
61	by	_	_	O
62	comparing	_	_	O
63	gemcitabine	_	_	O
64	plus	_	_	O
65	carboplatin	_	_	O
66	with	_	_	O
67	single-agent	_	_	O
68	carboplatin	_	_	O
69	in	_	_	O
70	platinum-sensitive	_	_	O
71	recurrent	_	_	O
72	ovarian	_	_	O
73	cancer	_	_	O
74	patients	_	_	O
75	.	_	_	O

76	Patients	_	_	O
77	with	_	_	O
78	platinum-sensitive	_	_	O
79	recurrent	_	_	O
80	ovarian	_	_	O
81	cancer	_	_	O
82	were	_	_	O
83	randomly	_	_	O
84	assigned	_	_	O
85	to	_	_	O
86	receive	_	_	O
87	either	_	_	O
88	gemcitabine	_	_	O
89	plus	_	_	O
90	carboplatin	_	_	O
91	or	_	_	O
92	carboplatin	_	_	O
93	alone	_	_	O
94	,	_	_	O
95	every	_	_	O
96	21	_	_	O
97	days	_	_	O
98	.	_	_	O

99	The	_	_	O
100	primary	_	_	O
101	objective	_	_	O
102	was	_	_	O
103	to	_	_	O
104	compare	_	_	O
105	progression-free	_	_	O
106	survival	_	_	O
107	(	_	_	O
108	PFS	_	_	O
109	)	_	_	O
110	.	_	_	O

111	Three	_	_	O
112	hundred	_	_	O
113	fifty-six	_	_	O
114	patients	_	_	O
115	(	_	_	O
116	178	_	_	O
117	gemcitabine	_	_	O
118	plus	_	_	O
119	carboplatin	_	_	O
120	;	_	_	O
121	178	_	_	O
122	carboplatin	_	_	O
123	)	_	_	O
124	were	_	_	O
125	randomly	_	_	O
126	assigned	_	_	O
127	.	_	_	O

128	Patients	_	_	O
129	received	_	_	O
130	a	_	_	O
131	median	_	_	O
132	of	_	_	O
133	six	_	_	O
134	cycles	_	_	O
135	in	_	_	O
136	both	_	_	O
137	arms	_	_	O
138	.	_	_	O

139	With	_	_	B-Premise
140	a	_	_	I-Premise
141	median	_	_	I-Premise
142	follow-up	_	_	I-Premise
143	of	_	_	I-Premise
144	17	_	_	I-Premise
145	months	_	_	I-Premise
146	,	_	_	I-Premise
147	median	_	_	I-Premise
148	PFS	_	_	I-Premise
149	was	_	_	I-Premise
150	8.6	_	_	I-Premise
151	months	_	_	I-Premise
152	(	_	_	I-Premise
153	95	_	_	I-Premise
154	%	_	_	I-Premise
155	CI	_	_	I-Premise
156	,	_	_	I-Premise
157	7.9	_	_	I-Premise
158	to	_	_	I-Premise
159	9.7	_	_	I-Premise
160	months	_	_	I-Premise
161	)	_	_	I-Premise
162	for	_	_	I-Premise
163	gemcitabine	_	_	I-Premise
164	plus	_	_	I-Premise
165	carboplatin	_	_	I-Premise
166	and	_	_	I-Premise
167	5.8	_	_	I-Premise
168	months	_	_	I-Premise
169	(	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	,	_	_	I-Premise
174	5.2	_	_	I-Premise
175	to	_	_	I-Premise
176	7.1	_	_	I-Premise
177	months	_	_	I-Premise
178	)	_	_	I-Premise
179	for	_	_	I-Premise
180	carboplatin	_	_	I-Premise
181	.	_	_	I-Premise

182	The	_	_	B-Premise
183	hazard	_	_	I-Premise
184	ration	_	_	I-Premise
185	(	_	_	I-Premise
186	HR	_	_	I-Premise
187	)	_	_	I-Premise
188	for	_	_	I-Premise
189	PFS	_	_	I-Premise
190	was	_	_	I-Premise
191	0.72	_	_	I-Premise
192	(	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	,	_	_	I-Premise
197	0.58	_	_	I-Premise
198	to	_	_	I-Premise
199	0.90	_	_	I-Premise
200	;	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	.0031	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Response	_	_	B-Premise
207	rate	_	_	I-Premise
208	was	_	_	I-Premise
209	47.2	_	_	I-Premise
210	%	_	_	I-Premise
211	(	_	_	I-Premise
212	95	_	_	I-Premise
213	%	_	_	I-Premise
214	CI	_	_	I-Premise
215	,	_	_	I-Premise
216	39.9	_	_	I-Premise
217	%	_	_	I-Premise
218	to	_	_	I-Premise
219	54.5	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	for	_	_	I-Premise
223	gemcitabine	_	_	I-Premise
224	plus	_	_	I-Premise
225	carboplatin	_	_	I-Premise
226	and	_	_	I-Premise
227	30.9	_	_	I-Premise
228	%	_	_	I-Premise
229	(	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	,	_	_	I-Premise
234	24.1	_	_	I-Premise
235	%	_	_	I-Premise
236	to	_	_	I-Premise
237	37.7	_	_	I-Premise
238	%	_	_	I-Premise
239	)	_	_	I-Premise
240	for	_	_	I-Premise
241	carboplatin	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.0016	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	The	_	_	B-Premise
249	HR	_	_	I-Premise
250	for	_	_	I-Premise
251	overall	_	_	I-Premise
252	survival	_	_	I-Premise
253	was	_	_	I-Premise
254	0.96	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.75	_	_	I-Premise
261	to1.23	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	.7349	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	While	_	_	B-Premise
269	myelosuppression	_	_	I-Premise
270	was	_	_	I-Premise
271	significantly	_	_	I-Premise
272	more	_	_	I-Premise
273	common	_	_	I-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	combination	_	_	I-Premise
277	,	_	_	I-Premise
278	sequelae	_	_	I-Premise
279	such	_	_	I-Premise
280	as	_	_	I-Premise
281	febrile	_	_	I-Premise
282	neutropenia	_	_	I-Premise
283	or	_	_	I-Premise
284	infections	_	_	I-Premise
285	were	_	_	I-Premise
286	uncommon	_	_	I-Premise
287	.	_	_	I-Premise

288	No	_	_	B-Premise
289	statistically	_	_	I-Premise
290	significant	_	_	I-Premise
291	differences	_	_	I-Premise
292	in	_	_	I-Premise
293	quality	_	_	I-Premise
294	of	_	_	I-Premise
295	life	_	_	I-Premise
296	scores	_	_	I-Premise
297	between	_	_	I-Premise
298	arms	_	_	I-Premise
299	were	_	_	I-Premise
300	noted	_	_	I-Premise
301	.	_	_	I-Premise

302	Gemcitabine	_	_	B-Claim
303	plus	_	_	I-Claim
304	carboplatin	_	_	I-Claim
305	significantly	_	_	I-Claim
306	improves	_	_	I-Claim
307	PFS	_	_	I-Claim
308	and	_	_	I-Claim
309	response	_	_	I-Claim
310	rate	_	_	I-Claim
311	without	_	_	I-Claim
312	worsening	_	_	I-Claim
313	quality	_	_	I-Claim
314	of	_	_	I-Claim
315	life	_	_	I-Claim
316	for	_	_	I-Claim
317	patients	_	_	I-Claim
318	with	_	_	I-Claim
319	platinum-sensitive	_	_	I-Claim
320	recurrent	_	_	I-Claim
321	ovarian	_	_	I-Claim
322	cancer	_	_	I-Claim
323	.	_	_	I-Claim


0	Radiation-induced	_	_	O
1	mucositis	_	_	O
2	is	_	_	O
3	an	_	_	O
4	acute	_	_	O
5	reaction	_	_	O
6	of	_	_	O
7	the	_	_	O
8	mucosa	_	_	O
9	of	_	_	O
10	patients	_	_	O
11	undergoing	_	_	O
12	head	_	_	O
13	and	_	_	O
14	neck	_	_	O
15	radiotherapy	_	_	O
16	.	_	_	O

17	It	_	_	O
18	can	_	_	O
19	have	_	_	O
20	debilitating	_	_	O
21	and	_	_	O
22	dose-limiting	_	_	O
23	consequences	_	_	O
24	.	_	_	O

25	There	_	_	B-Claim
26	is	_	_	I-Claim
27	no	_	_	I-Claim
28	consensus	_	_	I-Claim
29	on	_	_	I-Claim
30	an	_	_	I-Claim
31	accepted	_	_	I-Claim
32	intervention	_	_	I-Claim
33	that	_	_	I-Claim
34	significantly	_	_	I-Claim
35	reduces	_	_	I-Claim
36	its	_	_	I-Claim
37	severity	_	_	I-Claim
38	.	_	_	I-Claim

39	Misoprostol	_	_	O
40	is	_	_	O
41	a	_	_	O
42	synthetic	_	_	O
43	prostaglandin	_	_	O
44	E1	_	_	O
45	analogue	_	_	O
46	,	_	_	O
47	with	_	_	O
48	properties	_	_	O
49	of	_	_	O
50	a	_	_	O
51	mucosal	_	_	O
52	cytoprotectant	_	_	O
53	.	_	_	O

54	We	_	_	O
55	designed	_	_	O
56	a	_	_	O
57	randomized	_	_	O
58	,	_	_	O
59	double-blind	_	_	O
60	,	_	_	O
61	placebo-controlled	_	_	O
62	trial	_	_	O
63	of	_	_	O
64	misoprostol	_	_	O
65	in	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	head	_	_	O
69	and	_	_	O
70	neck	_	_	O
71	cancer	_	_	O
72	.	_	_	O

73	The	_	_	O
74	aim	_	_	O
75	of	_	_	O
76	this	_	_	O
77	study	_	_	O
78	was	_	_	O
79	to	_	_	O
80	determine	_	_	O
81	if	_	_	O
82	topical	_	_	O
83	misoprostol	_	_	O
84	was	_	_	O
85	effective	_	_	O
86	in	_	_	O
87	reducing	_	_	O
88	the	_	_	O
89	severity	_	_	O
90	of	_	_	O
91	radiation-induced	_	_	O
92	mucositis	_	_	O
93	in	_	_	O
94	patients	_	_	O
95	receiving	_	_	O
96	radical	_	_	O
97	dose	_	_	O
98	radiotherapy	_	_	O
99	.	_	_	O

100	The	_	_	O
101	effect	_	_	O
102	of	_	_	O
103	this	_	_	O
104	intervention	_	_	O
105	on	_	_	O
106	a	_	_	O
107	patient	_	_	O
108	's	_	_	O
109	general	_	_	O
110	well-being	_	_	O
111	was	_	_	O
112	also	_	_	O
113	investigated	_	_	O
114	.	_	_	O

115	The	_	_	O
116	primary	_	_	O
117	end-point	_	_	O
118	of	_	_	O
119	the	_	_	O
120	study	_	_	O
121	was	_	_	O
122	the	_	_	O
123	incidence	_	_	O
124	of	_	_	O
125	Radiation	_	_	O
126	Therapy	_	_	O
127	Oncology	_	_	O
128	Group	_	_	O
129	grade	_	_	O
130	3	_	_	O
131	mucositis	_	_	O
132	.	_	_	O

133	Between	_	_	O
134	1999	_	_	O
135	and	_	_	O
136	2002	_	_	O
137	,	_	_	O
138	83	_	_	O
139	patients	_	_	O
140	were	_	_	O
141	recruited	_	_	O
142	into	_	_	O
143	the	_	_	O
144	study	_	_	O
145	at	_	_	O
146	Westmead	_	_	O
147	and	_	_	O
148	Nepean	_	_	O
149	Hospitals	_	_	O
150	,	_	_	O
151	Sydney	_	_	O
152	.	_	_	O

153	Forty-two	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	randomized	_	_	O
157	to	_	_	O
158	receive	_	_	O
159	misoprostol	_	_	O
160	and	_	_	O
161	41	_	_	O
162	to	_	_	O
163	receive	_	_	O
164	a	_	_	O
165	placebo	_	_	O
166	.	_	_	O

167	Most	_	_	O
168	patients	_	_	O
169	received	_	_	O
170	radiotherapy	_	_	O
171	in	_	_	O
172	the	_	_	O
173	adjuvant	_	_	O
174	setting	_	_	O
175	(	_	_	O
176	52	_	_	O
177	of	_	_	O
178	the	_	_	O
179	83	_	_	O
180	)	_	_	O
181	and	_	_	O
182	had	_	_	O
183	either	_	_	O
184	an	_	_	O
185	oral	_	_	O
186	cavity	_	_	O
187	(	_	_	O
188	42	_	_	O
189	of	_	_	O
190	the	_	_	O
191	83	_	_	O
192	)	_	_	O
193	or	_	_	O
194	an	_	_	O
195	oropharyngeal	_	_	O
196	(	_	_	O
197	16	_	_	O
198	of	_	_	O
199	the	_	_	O
200	83	_	_	O
201	)	_	_	O
202	cancer	_	_	O
203	.	_	_	O

204	We	_	_	B-Claim
205	could	_	_	I-Claim
206	not	_	_	I-Claim
207	identify	_	_	I-Claim
208	any	_	_	I-Claim
209	significant	_	_	I-Claim
210	difference	_	_	I-Claim
211	in	_	_	I-Claim
212	the	_	_	I-Claim
213	incidence	_	_	I-Claim
214	of	_	_	I-Claim
215	severe	_	_	I-Claim
216	mucositis	_	_	I-Claim
217	based	_	_	I-Claim
218	on	_	_	I-Claim
219	whether	_	_	I-Claim
220	patients	_	_	I-Claim
221	were	_	_	I-Claim
222	allocated	_	_	I-Claim
223	to	_	_	I-Claim
224	receive	_	_	I-Claim
225	misoprostol	_	_	I-Claim
226	or	_	_	I-Claim
227	placebo	_	_	I-Claim
228	.	_	_	I-Claim

229	There	_	_	B-Premise
230	was	_	_	I-Premise
231	no	_	_	I-Premise
232	significant	_	_	I-Premise
233	difference	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	mean	_	_	I-Premise
237	area	_	_	I-Premise
238	under	_	_	I-Premise
239	the	_	_	I-Premise
240	mucositis	_	_	I-Premise
241	curve	_	_	I-Premise
242	(	_	_	I-Premise
243	13.2	_	_	I-Premise
244	vs	_	_	I-Premise
245	16.6	_	_	I-Premise
246	;	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	0.1	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Patients	_	_	B-Premise
253	allocated	_	_	I-Premise
254	to	_	_	I-Premise
255	misoprostol	_	_	I-Premise
256	did	_	_	I-Premise
257	report	_	_	I-Premise
258	slightly	_	_	I-Premise
259	increased	_	_	I-Premise
260	soreness	_	_	I-Premise
261	(	_	_	I-Premise
262	7.6	_	_	I-Premise
263	vs	_	_	I-Premise
264	6.9	_	_	I-Premise
265	;	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	0.04	_	_	I-Premise
269	)	_	_	I-Premise
270	and	_	_	I-Premise
271	a	_	_	I-Premise
272	greater	_	_	I-Premise
273	use	_	_	I-Premise
274	of	_	_	I-Premise
275	analgesics	_	_	I-Premise
276	.	_	_	I-Premise

277	However	_	_	B-Premise
278	,	_	_	I-Premise
279	this	_	_	I-Premise
280	difference	_	_	I-Premise
281	did	_	_	I-Premise
282	not	_	_	I-Premise
283	translate	_	_	I-Premise
284	into	_	_	I-Premise
285	a	_	_	I-Premise
286	worse	_	_	I-Premise
287	feeling	_	_	I-Premise
288	of	_	_	I-Premise
289	general	_	_	I-Premise
290	well-being	_	_	I-Premise
291	as	_	_	I-Premise
292	measured	_	_	I-Premise
293	by	_	_	I-Premise
294	a	_	_	I-Premise
295	simple	_	_	I-Premise
296	visual	_	_	I-Premise
297	analogue	_	_	I-Premise
298	scale	_	_	I-Premise
299	(	_	_	I-Premise
300	5.8	_	_	I-Premise
301	vs	_	_	I-Premise
302	5.2	_	_	I-Premise
303	;	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	0.3	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	In	_	_	B-Claim
310	conclusion	_	_	I-Claim
311	,	_	_	I-Claim
312	we	_	_	I-Claim
313	were	_	_	I-Claim
314	unable	_	_	I-Claim
315	to	_	_	I-Claim
316	identify	_	_	I-Claim
317	a	_	_	I-Claim
318	reduction	_	_	I-Claim
319	in	_	_	I-Claim
320	radiation-induced	_	_	I-Claim
321	mucositis	_	_	I-Claim
322	in	_	_	I-Claim
323	patients	_	_	I-Claim
324	receiving	_	_	I-Claim
325	misoprostol	_	_	I-Claim
326	.	_	_	I-Claim

327	There	_	_	B-Claim
328	is	_	_	I-Claim
329	a	_	_	I-Claim
330	paucity	_	_	I-Claim
331	of	_	_	I-Claim
332	high-level	_	_	I-Claim
333	evidence	_	_	I-Claim
334	on	_	_	I-Claim
335	potentially	_	_	I-Claim
336	useful	_	_	I-Claim
337	interventions	_	_	I-Claim
338	and	_	_	I-Claim
339	a	_	_	I-Claim
340	continued	_	_	I-Claim
341	need	_	_	I-Claim
342	for	_	_	I-Claim
343	new	_	_	I-Claim
344	and	_	_	I-Claim
345	innovative	_	_	I-Claim
346	research	_	_	I-Claim
347	,	_	_	I-Claim
348	incorporating	_	_	I-Claim
349	quality-of-life	_	_	I-Claim
350	measurements	_	_	I-Claim
351	,	_	_	I-Claim
352	in	_	_	I-Claim
353	patients	_	_	I-Claim
354	experiencing	_	_	I-Claim
355	radiation-induced	_	_	I-Claim
356	mucositis	_	_	I-Claim
357	.	_	_	I-Claim


0	In	_	_	B-Claim
1	vivo	_	_	I-Claim
2	data	_	_	I-Claim
3	have	_	_	I-Claim
4	shown	_	_	I-Claim
5	a	_	_	I-Claim
6	more	_	_	I-Claim
7	potent	_	_	I-Claim
8	antiangiogenic	_	_	I-Claim
9	effect	_	_	I-Claim
10	and	_	_	I-Claim
11	a	_	_	I-Claim
12	higher	_	_	I-Claim
13	antitumor	_	_	I-Claim
14	activity	_	_	I-Claim
15	of	_	_	I-Claim
16	low-dose	_	_	I-Claim
17	interferon	_	_	I-Claim
18	(	_	_	I-Claim
19	IFN	_	_	I-Claim
20	)	_	_	I-Claim
21	given	_	_	I-Claim
22	twice	_	_	I-Claim
23	daily	_	_	I-Claim
24	.	_	_	I-Claim

25	In	_	_	O
26	a	_	_	O
27	randomized	_	_	O
28	Phase	_	_	O
29	II	_	_	O
30	trial	_	_	O
31	,	_	_	O
32	the	_	_	O
33	authors	_	_	O
34	tested	_	_	O
35	the	_	_	O
36	hypothesis	_	_	O
37	that	_	_	O
38	twice-daily	_	_	O
39	low-dose	_	_	O
40	IFN	_	_	O
41	is	_	_	O
42	more	_	_	O
43	effective	_	_	O
44	than	_	_	O
45	daily	_	_	O
46	intermediate-dose	_	_	O
47	IFN	_	_	O
48	in	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	metastatic	_	_	O
52	renal	_	_	O
53	cell	_	_	O
54	cancer	_	_	O
55	(	_	_	O
56	MRCC	_	_	O
57	)	_	_	O
58	.	_	_	O

59	A	_	_	O
60	total	_	_	O
61	of	_	_	O
62	118	_	_	O
63	patients	_	_	O
64	(	_	_	O
65	59	_	_	O
66	per	_	_	O
67	arm	_	_	O
68	)	_	_	O
69	were	_	_	O
70	randomly	_	_	O
71	assigned	_	_	O
72	to	_	_	O
73	receive	_	_	O
74	IFN	_	_	O
75	at	_	_	O
76	a	_	_	O
77	dose	_	_	O
78	of	_	_	O
79	0.5	_	_	O
80	million	_	_	O
81	units	_	_	O
82	(	_	_	O
83	MU	_	_	O
84	)	_	_	O
85	given	_	_	O
86	subcutaneously	_	_	O
87	twice	_	_	O
88	daily	_	_	O
89	(	_	_	O
90	IFN1	_	_	O
91	)	_	_	O
92	or	_	_	O
93	IFN	_	_	O
94	at	_	_	O
95	a	_	_	O
96	dose	_	_	O
97	of	_	_	O
98	5	_	_	O
99	MU	_	_	O
100	given	_	_	O
101	subcutaneously	_	_	O
102	daily	_	_	O
103	(	_	_	O
104	IFN5	_	_	O
105	)	_	_	O
106	.	_	_	O

107	The	_	_	O
108	primary	_	_	O
109	endpoint	_	_	O
110	was	_	_	O
111	progression-free	_	_	O
112	survival	_	_	O
113	(	_	_	O
114	PFS	_	_	O
115	)	_	_	O
116	.	_	_	O

117	Secondary	_	_	O
118	endpoints	_	_	O
119	included	_	_	O
120	response	_	_	O
121	rate	_	_	O
122	(	_	_	O
123	RR	_	_	O
124	)	_	_	O
125	,	_	_	O
126	overall	_	_	O
127	survival	_	_	O
128	(	_	_	O
129	OS	_	_	O
130	)	_	_	O
131	,	_	_	O
132	toxicity	_	_	O
133	,	_	_	O
134	and	_	_	O
135	quality	_	_	O
136	of	_	_	O
137	life	_	_	O
138	(	_	_	O
139	QOL	_	_	O
140	)	_	_	O
141	.	_	_	O

142	There	_	_	B-Premise
143	were	_	_	I-Premise
144	no	_	_	I-Premise
145	significant	_	_	I-Premise
146	differences	_	_	I-Premise
147	in	_	_	I-Premise
148	either	_	_	I-Premise
149	PFS	_	_	I-Premise
150	or	_	_	I-Premise
151	OS	_	_	I-Premise
152	between	_	_	I-Premise
153	IFN1	_	_	I-Premise
154	and	_	_	I-Premise
155	IFN5	_	_	I-Premise
156	(	_	_	I-Premise
157	median	_	_	I-Premise
158	of	_	_	I-Premise
159	3.7	_	_	I-Premise
160	months	_	_	I-Premise
161	and	_	_	I-Premise
162	median	_	_	I-Premise
163	of	_	_	I-Premise
164	3.4	_	_	I-Premise
165	months	_	_	I-Premise
166	PFS	_	_	I-Premise
167	,	_	_	I-Premise
168	respectively	_	_	I-Premise
169	;	_	_	I-Premise
170	median	_	_	I-Premise
171	of	_	_	I-Premise
172	25.5	_	_	I-Premise
173	months	_	_	I-Premise
174	and	_	_	I-Premise
175	median	_	_	I-Premise
176	of	_	_	I-Premise
177	17.5	_	_	I-Premise
178	months	_	_	I-Premise
179	OS	_	_	I-Premise
180	,	_	_	I-Premise
181	respectively	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	The	_	_	B-Premise
185	RRs	_	_	I-Premise
186	were	_	_	I-Premise
187	identical	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	2	_	_	I-Premise
191	arms	_	_	I-Premise
192	(	_	_	I-Premise
193	6.7	_	_	I-Premise
194	%	_	_	I-Premise
195	;	_	_	I-Premise
196	95	_	_	I-Premise
197	%	_	_	I-Premise
198	confidence	_	_	I-Premise
199	interval	_	_	I-Premise
200	[	_	_	I-Premise
201	95	_	_	I-Premise
202	%	_	_	I-Premise
203	CI	_	_	I-Premise
204	]	_	_	I-Premise
205	,	_	_	I-Premise
206	1.8-16.5	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	Two	_	_	B-Premise
211	patients	_	_	I-Premise
212	,	_	_	I-Premise
213	1	_	_	I-Premise
214	in	_	_	I-Premise
215	each	_	_	I-Premise
216	arm	_	_	I-Premise
217	,	_	_	I-Premise
218	remained	_	_	I-Premise
219	in	_	_	I-Premise
220	complete	_	_	I-Premise
221	remission	_	_	I-Premise
222	at	_	_	I-Premise
223	the	_	_	I-Premise
224	time	_	_	I-Premise
225	of	_	_	I-Premise
226	last	_	_	I-Premise
227	follow-up	_	_	I-Premise
228	,	_	_	I-Premise
229	at	_	_	I-Premise
230	45+	_	_	I-Premise
231	and	_	_	I-Premise
232	38+	_	_	I-Premise
233	months	_	_	I-Premise
234	from	_	_	I-Premise
235	treatment	_	_	I-Premise
236	.	_	_	I-Premise

237	Thirty-two	_	_	B-Premise
238	patients	_	_	I-Premise
239	receiving	_	_	I-Premise
240	IFN5	_	_	I-Premise
241	and	_	_	I-Premise
242	19	_	_	I-Premise
243	patients	_	_	I-Premise
244	receiving	_	_	I-Premise
245	IFN1	_	_	I-Premise
246	experienced	_	_	I-Premise
247	Grade	_	_	I-Premise
248	3	_	_	I-Premise
249	or	_	_	I-Premise
250	higher	_	_	I-Premise
251	adverse	_	_	I-Premise
252	events	_	_	I-Premise
253	(	_	_	I-Premise
254	graded	_	_	I-Premise
255	using	_	_	I-Premise
256	the	_	_	I-Premise
257	National	_	_	I-Premise
258	Cancer	_	_	I-Premise
259	Institute	_	_	I-Premise
260	Common	_	_	I-Premise
261	Toxicity	_	_	I-Premise
262	Criteria	_	_	I-Premise
263	[	_	_	I-Premise
264	version	_	_	I-Premise
265	2.0	_	_	I-Premise
266	]	_	_	I-Premise
267	)	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.025	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Eighteen	_	_	B-Premise
275	patients	_	_	I-Premise
276	receiving	_	_	I-Premise
277	IFN5	_	_	I-Premise
278	and	_	_	I-Premise
279	4	_	_	I-Premise
280	patients	_	_	I-Premise
281	receiving	_	_	I-Premise
282	IFN1	_	_	I-Premise
283	had	_	_	I-Premise
284	dose	_	_	I-Premise
285	reductions	_	_	I-Premise
286	(	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	.002	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	There	_	_	B-Premise
293	was	_	_	I-Premise
294	a	_	_	I-Premise
295	significant	_	_	I-Premise
296	deterioration	_	_	I-Premise
297	in	_	_	I-Premise
298	QOL	_	_	I-Premise
299	and	_	_	I-Premise
300	an	_	_	I-Premise
301	increase	_	_	I-Premise
302	in	_	_	I-Premise
303	depression	_	_	I-Premise
304	associated	_	_	I-Premise
305	with	_	_	I-Premise
306	IFN5	_	_	I-Premise
307	but	_	_	I-Premise
308	no	_	_	I-Premise
309	change	_	_	I-Premise
310	was	_	_	I-Premise
311	noted	_	_	I-Premise
312	with	_	_	I-Premise
313	IFN1	_	_	I-Premise
314	.	_	_	I-Premise

315	Compared	_	_	B-Claim
316	with	_	_	I-Claim
317	IFN5	_	_	I-Claim
318	,	_	_	I-Claim
319	IFN1	_	_	I-Claim
320	is	_	_	I-Claim
321	neither	_	_	I-Claim
322	more	_	_	I-Claim
323	nor	_	_	I-Claim
324	less	_	_	I-Claim
325	effective	_	_	I-Claim
326	but	_	_	I-Claim
327	is	_	_	I-Claim
328	less	_	_	I-Claim
329	toxic	_	_	I-Claim
330	,	_	_	I-Claim
331	with	_	_	I-Claim
332	a	_	_	I-Claim
333	better	_	_	I-Claim
334	reported	_	_	I-Claim
335	QOL	_	_	I-Claim
336	.	_	_	I-Claim

337	These	_	_	B-Claim
338	results	_	_	I-Claim
339	may	_	_	I-Claim
340	have	_	_	I-Claim
341	implications	_	_	I-Claim
342	for	_	_	I-Claim
343	the	_	_	I-Claim
344	design	_	_	I-Claim
345	of	_	_	I-Claim
346	combination	_	_	I-Claim
347	regimens	_	_	I-Claim
348	incorporating	_	_	I-Claim
349	IFN	_	_	I-Claim
350	with	_	_	I-Claim
351	targeted	_	_	I-Claim
352	agents	_	_	I-Claim
353	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	multicentre	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	conducted	_	_	O
6	to	_	_	O
7	establish	_	_	O
8	the	_	_	O
9	optimal	_	_	O
10	duration	_	_	O
11	of	_	_	O
12	palliative	_	_	O
13	chemotherapy	_	_	O
14	in	_	_	O
15	advanced	_	_	O
16	non-small-cell	_	_	O
17	lung	_	_	O
18	cancer	_	_	O
19	(	_	_	O
20	NSCLC	_	_	O
21	)	_	_	O
22	.	_	_	O

23	We	_	_	O
24	compared	_	_	O
25	a	_	_	O
26	policy	_	_	O
27	of	_	_	O
28	three	_	_	O
29	vs	_	_	O
30	six	_	_	O
31	courses	_	_	O
32	of	_	_	O
33	new-generation	_	_	O
34	platinum-based	_	_	O
35	combination	_	_	O
36	chemotherapy	_	_	O
37	with	_	_	O
38	regard	_	_	O
39	to	_	_	O
40	effects	_	_	O
41	on	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	(	_	_	O
46	QoL	_	_	O
47	)	_	_	O
48	and	_	_	O
49	survival	_	_	O
50	.	_	_	O

51	Patients	_	_	O
52	with	_	_	O
53	stage	_	_	O
54	IIIB	_	_	O
55	or	_	_	O
56	IV	_	_	O
57	NSCLC	_	_	O
58	and	_	_	O
59	WHO	_	_	O
60	performance	_	_	O
61	status	_	_	O
62	(	_	_	O
63	PS	_	_	O
64	)	_	_	O
65	0-2	_	_	O
66	were	_	_	O
67	randomised	_	_	O
68	to	_	_	O
69	receive	_	_	O
70	three	_	_	O
71	(	_	_	O
72	C3	_	_	O
73	)	_	_	O
74	or	_	_	O
75	six	_	_	O
76	(	_	_	O
77	C6	_	_	O
78	)	_	_	O
79	courses	_	_	O
80	of	_	_	O
81	carboplatin	_	_	O
82	(	_	_	O
83	area	_	_	O
84	under	_	_	O
85	the	_	_	O
86	curve	_	_	O
87	(	_	_	O
88	AUC	_	_	O
89	)	_	_	O
90	4	_	_	O
91	,	_	_	O
92	Chatelut	_	_	O
93	's	_	_	O
94	formula	_	_	O
95	,	_	_	O
96	equivalent	_	_	O
97	to	_	_	O
98	Calvert	_	_	O
99	's	_	_	O
100	AUC	_	_	O
101	5	_	_	O
102	)	_	_	O
103	on	_	_	O
104	day	_	_	O
105	1	_	_	O
106	and	_	_	O
107	vinorelbine	_	_	O
108	25	_	_	O
109	mg	_	_	O
110	m	_	_	O
111	(	_	_	O
112	-2	_	_	O
113	)	_	_	O
114	on	_	_	O
115	days	_	_	O
116	1	_	_	O
117	and	_	_	O
118	8	_	_	O
119	of	_	_	O
120	a	_	_	O
121	3-week	_	_	O
122	cycle	_	_	O
123	.	_	_	O

124	Key	_	_	O
125	end	_	_	O
126	points	_	_	O
127	were	_	_	O
128	QoL	_	_	O
129	at	_	_	O
130	18	_	_	O
131	weeks	_	_	O
132	,	_	_	O
133	measured	_	_	O
134	with	_	_	O
135	EORTC	_	_	O
136	Quality	_	_	O
137	of	_	_	O
138	Life	_	_	O
139	Questionnaire	_	_	O
140	(	_	_	O
141	QLQ	_	_	O
142	)	_	_	O
143	-C30	_	_	O
144	and	_	_	O
145	QLQ-LC13	_	_	O
146	,	_	_	O
147	and	_	_	O
148	overall	_	_	O
149	survival	_	_	O
150	.	_	_	O

151	Secondary	_	_	O
152	end	_	_	O
153	points	_	_	O
154	were	_	_	O
155	progression-free	_	_	O
156	survival	_	_	O
157	and	_	_	O
158	need	_	_	O
159	of	_	_	O
160	palliative	_	_	O
161	radiotherapy	_	_	O
162	.	_	_	O

163	Two	_	_	O
164	hundred	_	_	O
165	and	_	_	O
166	ninety-seven	_	_	O
167	patients	_	_	O
168	were	_	_	O
169	randomised	_	_	O
170	(	_	_	O
171	C3	_	_	O
172	150	_	_	O
173	,	_	_	O
174	C6	_	_	O
175	147	_	_	O
176	)	_	_	O
177	.	_	_	O

178	Their	_	_	O
179	median	_	_	O
180	age	_	_	O
181	was	_	_	O
182	65	_	_	O
183	years	_	_	O
184	,	_	_	O
185	30	_	_	O
186	%	_	_	O
187	had	_	_	O
188	PS	_	_	O
189	2	_	_	O
190	and	_	_	O
191	76	_	_	O
192	%	_	_	O
193	stage	_	_	O
194	IV	_	_	O
195	disease	_	_	O
196	.	_	_	O

197	Seventy-eight	_	_	O
198	and	_	_	O
199	54	_	_	O
200	%	_	_	O
201	of	_	_	O
202	C3	_	_	O
203	and	_	_	O
204	C6	_	_	O
205	patients	_	_	O
206	,	_	_	O
207	respectively	_	_	O
208	,	_	_	O
209	completed	_	_	O
210	all	_	_	O
211	scheduled	_	_	O
212	chemotherapy	_	_	O
213	courses	_	_	O
214	.	_	_	O

215	Compliance	_	_	O
216	with	_	_	O
217	QoL	_	_	O
218	questionnaires	_	_	O
219	was	_	_	O
220	88	_	_	O
221	%	_	_	O
222	.	_	_	O

223	There	_	_	B-Premise
224	were	_	_	I-Premise
225	no	_	_	I-Premise
226	significant	_	_	I-Premise
227	group	_	_	I-Premise
228	differences	_	_	I-Premise
229	in	_	_	I-Premise
230	global	_	_	I-Premise
231	QoL	_	_	I-Premise
232	,	_	_	I-Premise
233	pain	_	_	I-Premise
234	or	_	_	I-Premise
235	fatigue	_	_	I-Premise
236	up	_	_	I-Premise
237	to	_	_	I-Premise
238	26	_	_	I-Premise
239	weeks	_	_	I-Premise
240	.	_	_	I-Premise

241	The	_	_	B-Premise
242	dyspnoea	_	_	I-Premise
243	palliation	_	_	I-Premise
244	rate	_	_	I-Premise
245	was	_	_	I-Premise
246	lower	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	C3	_	_	I-Premise
250	arm	_	_	I-Premise
251	at	_	_	I-Premise
252	18	_	_	I-Premise
253	and	_	_	I-Premise
254	26	_	_	I-Premise
255	weeks	_	_	I-Premise
256	(	_	_	I-Premise
257	P	_	_	I-Premise
258	<	_	_	I-Premise
259	0.05	_	_	I-Premise
260	)	_	_	I-Premise
261	,	_	_	I-Premise
262	but	_	_	B-Premise
263	this	_	_	I-Premise
264	finding	_	_	I-Premise
265	was	_	_	I-Premise
266	inconsistent	_	_	I-Premise
267	across	_	_	I-Premise
268	different	_	_	I-Premise
269	methods	_	_	I-Premise
270	of	_	_	I-Premise
271	analysis	_	_	I-Premise
272	.	_	_	I-Premise

273	Median	_	_	B-Premise
274	survival	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	C3	_	_	I-Premise
278	group	_	_	I-Premise
279	was	_	_	I-Premise
280	28	_	_	I-Premise
281	vs	_	_	I-Premise
282	32	_	_	I-Premise
283	weeks	_	_	I-Premise
284	in	_	_	I-Premise
285	the	_	_	I-Premise
286	C6	_	_	I-Premise
287	group	_	_	I-Premise
288	(	_	_	I-Premise
289	P=0.75	_	_	I-Premise
290	,	_	_	I-Premise
291	HR	_	_	I-Premise
292	1.04	_	_	I-Premise
293	,	_	_	I-Premise
294	95	_	_	I-Premise
295	%	_	_	I-Premise
296	CI	_	_	I-Premise
297	0.82-1.31	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	One-	_	_	B-Premise
301	and	_	_	I-Premise
302	2-year	_	_	I-Premise
303	survival	_	_	I-Premise
304	rates	_	_	I-Premise
305	were	_	_	I-Premise
306	25	_	_	I-Premise
307	and	_	_	I-Premise
308	9	_	_	I-Premise
309	%	_	_	I-Premise
310	vs	_	_	I-Premise
311	25	_	_	I-Premise
312	and	_	_	I-Premise
313	5	_	_	I-Premise
314	%	_	_	I-Premise
315	in	_	_	I-Premise
316	the	_	_	I-Premise
317	C3	_	_	I-Premise
318	and	_	_	I-Premise
319	C6	_	_	I-Premise
320	arm	_	_	I-Premise
321	,	_	_	I-Premise
322	respectively	_	_	I-Premise
323	.	_	_	I-Premise

324	Median	_	_	B-Premise
325	progression-free	_	_	I-Premise
326	survival	_	_	I-Premise
327	was	_	_	I-Premise
328	16	_	_	I-Premise
329	and	_	_	I-Premise
330	21	_	_	I-Premise
331	weeks	_	_	I-Premise
332	in	_	_	I-Premise
333	the	_	_	I-Premise
334	C3	_	_	I-Premise
335	and	_	_	I-Premise
336	C6	_	_	I-Premise
337	groups	_	_	I-Premise
338	,	_	_	I-Premise
339	respectively	_	_	I-Premise
340	(	_	_	I-Premise
341	P=0.21	_	_	I-Premise
342	,	_	_	I-Premise
343	HR	_	_	I-Premise
344	0.86	_	_	I-Premise
345	,	_	_	I-Premise
346	95	_	_	I-Premise
347	%	_	_	I-Premise
348	CI	_	_	I-Premise
349	0.68-1.08	_	_	I-Premise
350	)	_	_	I-Premise
351	.	_	_	I-Premise

352	In	_	_	B-Claim
353	conclusion	_	_	I-Claim
354	,	_	_	I-Claim
355	palliative	_	_	I-Claim
356	chemotherapy	_	_	I-Claim
357	with	_	_	I-Claim
358	carboplatin	_	_	I-Claim
359	and	_	_	I-Claim
360	vinorelbine	_	_	I-Claim
361	beyond	_	_	I-Claim
362	three	_	_	I-Claim
363	courses	_	_	I-Claim
364	conveys	_	_	I-Claim
365	no	_	_	I-Claim
366	survival	_	_	I-Claim
367	or	_	_	I-Claim
368	consistent	_	_	I-Claim
369	QoL	_	_	I-Claim
370	benefits	_	_	I-Claim
371	in	_	_	I-Claim
372	advanced	_	_	I-Claim
373	NSCLC	_	_	I-Claim
374	.	_	_	I-Claim


0	To	_	_	O
1	report	_	_	O
2	one-year	_	_	O
3	results	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Tube	_	_	O
7	Versus	_	_	O
8	Trabeculectomy	_	_	O
9	(	_	_	O
10	TVT	_	_	O
11	)	_	_	O
12	Study	_	_	O
13	.	_	_	O

14	Multicenter	_	_	O
15	randomized	_	_	O
16	clinical	_	_	O
17	trial	_	_	O
18	.	_	_	O

19	Setting	_	_	O
20	:	_	_	O
21	17	_	_	O
22	Clinical	_	_	O
23	Centers	_	_	O
24	.	_	_	O

25	Study	_	_	O
26	Population	_	_	O
27	:	_	_	O
28	Patients	_	_	O
29	18	_	_	O
30	to	_	_	O
31	85	_	_	O
32	years	_	_	O
33	of	_	_	O
34	age	_	_	O
35	who	_	_	O
36	had	_	_	O
37	previous	_	_	O
38	trabeculectomy	_	_	O
39	and/or	_	_	O
40	cataract	_	_	O
41	extraction	_	_	O
42	with	_	_	O
43	intraocular	_	_	O
44	lens	_	_	O
45	implantation	_	_	O
46	and	_	_	O
47	uncontrolled	_	_	O
48	glaucoma	_	_	O
49	with	_	_	O
50	intraocular	_	_	O
51	pressure	_	_	O
52	(	_	_	O
53	IOP	_	_	O
54	)	_	_	O
55	>	_	_	O
56	or	_	_	O
57	=18	_	_	O
58	mm	_	_	O
59	Hg	_	_	O
60	and	_	_	O
61	<	_	_	O
62	or	_	_	O
63	=40	_	_	O
64	mm	_	_	O
65	Hg	_	_	O
66	on	_	_	O
67	maximum	_	_	O
68	tolerated	_	_	O
69	medical	_	_	O
70	therapy	_	_	O
71	.	_	_	O

72	Interventions	_	_	O
73	:	_	_	O
74	350	_	_	O
75	mm	_	_	O
76	(	_	_	O
77	2	_	_	O
78	)	_	_	O
79	Baerveldt	_	_	O
80	glaucoma	_	_	O
81	implant	_	_	O
82	or	_	_	O
83	trabeculectomy	_	_	O
84	with	_	_	O
85	mitomycin	_	_	O
86	C	_	_	O
87	(	_	_	O
88	MMC	_	_	O
89	)	_	_	O
90	.	_	_	O

91	Main	_	_	O
92	Outcome	_	_	O
93	Measures	_	_	O
94	:	_	_	O
95	IOP	_	_	O
96	,	_	_	O
97	visual	_	_	O
98	acuity	_	_	O
99	,	_	_	O
100	and	_	_	O
101	reoperation	_	_	O
102	for	_	_	O
103	glaucoma	_	_	O
104	.	_	_	O

105	A	_	_	O
106	total	_	_	O
107	of	_	_	O
108	212	_	_	O
109	eyes	_	_	O
110	of	_	_	O
111	212	_	_	O
112	patients	_	_	O
113	were	_	_	O
114	enrolled	_	_	O
115	,	_	_	O
116	including	_	_	O
117	107	_	_	O
118	in	_	_	O
119	the	_	_	O
120	tube	_	_	O
121	group	_	_	O
122	and	_	_	O
123	105	_	_	O
124	in	_	_	O
125	the	_	_	O
126	trabeculectomy	_	_	O
127	group	_	_	O
128	.	_	_	O

129	At	_	_	O
130	one	_	_	O
131	year	_	_	O
132	,	_	_	O
133	IOP	_	_	O
134	(	_	_	O
135	mean	_	_	O
136	+/-	_	_	O
137	SD	_	_	O
138	)	_	_	O
139	was	_	_	O
140	12.4	_	_	O
141	+/-	_	_	O
142	3.9	_	_	O
143	mm	_	_	O
144	Hg	_	_	O
145	in	_	_	O
146	the	_	_	O
147	tube	_	_	O
148	group	_	_	O
149	and	_	_	O
150	12.7	_	_	O
151	+/-	_	_	O
152	5.8	_	_	O
153	mm	_	_	O
154	Hg	_	_	O
155	in	_	_	O
156	the	_	_	O
157	trabeculectomy	_	_	O
158	group	_	_	O
159	(	_	_	O
160	P	_	_	O
161	=	_	_	O
162	.73	_	_	O
163	)	_	_	O
164	.	_	_	O

165	The	_	_	B-Premise
166	number	_	_	I-Premise
167	of	_	_	I-Premise
168	glaucoma	_	_	I-Premise
169	medications	_	_	I-Premise
170	(	_	_	I-Premise
171	mean	_	_	I-Premise
172	+/-	_	_	I-Premise
173	SD	_	_	I-Premise
174	)	_	_	I-Premise
175	was	_	_	I-Premise
176	1.3	_	_	I-Premise
177	+/-	_	_	I-Premise
178	1.3	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	tube	_	_	I-Premise
182	group	_	_	I-Premise
183	and	_	_	I-Premise
184	0.5	_	_	I-Premise
185	+/-	_	_	I-Premise
186	0.9	_	_	I-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	trabeculectomy	_	_	I-Premise
190	group	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	<	_	_	I-Premise
194	.001	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	cumulative	_	_	I-Premise
199	probability	_	_	I-Premise
200	of	_	_	I-Premise
201	failure	_	_	I-Premise
202	during	_	_	I-Premise
203	the	_	_	I-Premise
204	first	_	_	I-Premise
205	year	_	_	I-Premise
206	of	_	_	I-Premise
207	follow-up	_	_	I-Premise
208	was	_	_	I-Premise
209	3.9	_	_	I-Premise
210	%	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	tube	_	_	I-Premise
214	group	_	_	I-Premise
215	and	_	_	I-Premise
216	13.5	_	_	I-Premise
217	%	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	trabeculectomy	_	_	I-Premise
221	group	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.017	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Nonvalved	_	_	B-Premise
229	tube	_	_	I-Premise
230	shunt	_	_	I-Premise
231	surgery	_	_	I-Premise
232	was	_	_	I-Premise
233	more	_	_	I-Premise
234	likely	_	_	I-Premise
235	to	_	_	I-Premise
236	maintain	_	_	I-Premise
237	IOP	_	_	I-Premise
238	control	_	_	I-Premise
239	and	_	_	I-Premise
240	avoid	_	_	I-Premise
241	persistent	_	_	I-Premise
242	hypotony	_	_	I-Premise
243	or	_	_	I-Premise
244	reoperation	_	_	I-Premise
245	for	_	_	I-Premise
246	glaucoma	_	_	I-Premise
247	than	_	_	I-Premise
248	trabeculectomy	_	_	I-Premise
249	with	_	_	I-Premise
250	MMC	_	_	I-Premise
251	during	_	_	I-Premise
252	the	_	_	I-Premise
253	first	_	_	I-Premise
254	year	_	_	I-Premise
255	of	_	_	I-Premise
256	follow-up	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	TVT	_	_	I-Premise
260	Study	_	_	I-Premise
261	.	_	_	I-Premise

262	Both	_	_	B-Claim
263	surgical	_	_	I-Claim
264	procedures	_	_	I-Claim
265	produced	_	_	I-Claim
266	similar	_	_	I-Claim
267	IOP	_	_	I-Claim
268	reduction	_	_	I-Claim
269	at	_	_	I-Claim
270	one	_	_	I-Claim
271	year	_	_	I-Claim
272	,	_	_	O
273	but	_	_	O
274	there	_	_	B-Claim
275	was	_	_	I-Claim
276	less	_	_	I-Claim
277	need	_	_	I-Claim
278	for	_	_	I-Claim
279	supplemental	_	_	I-Claim
280	medical	_	_	I-Claim
281	therapy	_	_	I-Claim
282	following	_	_	I-Claim
283	trabeculectomy	_	_	I-Claim
284	with	_	_	I-Claim
285	MMC	_	_	I-Claim
286	.	_	_	I-Claim


0	In	_	_	O
1	Lithuania	_	_	O
2	,	_	_	O
3	about	_	_	O
4	400	_	_	O
5	cases	_	_	O
6	of	_	_	O
7	pancreatic	_	_	O
8	cancer	_	_	O
9	are	_	_	O
10	diagnosed	_	_	O
11	each	_	_	O
12	year	_	_	O
13	,	_	_	O
14	and	_	_	O
15	more	_	_	O
16	than	_	_	O
17	50	_	_	O
18	%	_	_	O
19	of	_	_	O
20	patients	_	_	O
21	are	_	_	O
22	diagnosed	_	_	O
23	with	_	_	O
24	stage	_	_	O
25	IV	_	_	O
26	disease	_	_	O
27	.	_	_	O

28	Quality	_	_	B-Claim
29	of	_	_	I-Claim
30	life	_	_	I-Claim
31	is	_	_	I-Claim
32	an	_	_	I-Claim
33	important	_	_	I-Claim
34	issue	_	_	I-Claim
35	in	_	_	I-Claim
36	pancreatic	_	_	I-Claim
37	cancer	_	_	I-Claim
38	patients	_	_	I-Claim
39	.	_	_	I-Claim

40	A	_	_	O
41	prospective	_	_	O
42	randomized	_	_	O
43	clinical	_	_	O
44	study	_	_	O
45	on	_	_	O
46	the	_	_	O
47	treatment	_	_	O
48	of	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	resectable	_	_	O
52	and	_	_	O
53	unresectable	_	_	O
54	pancreatic	_	_	O
55	cancer	_	_	O
56	was	_	_	O
57	conducted	_	_	O
58	at	_	_	O
59	the	_	_	O
60	Department	_	_	O
61	of	_	_	O
62	Oncology	_	_	O
63	of	_	_	O
64	Kaunas	_	_	O
65	University	_	_	O
66	of	_	_	O
67	Medicine	_	_	O
68	Hospital	_	_	O
69	,	_	_	O
70	and	_	_	O
71	in	_	_	O
72	this	_	_	O
73	study	_	_	O
74	,	_	_	O
75	quality	_	_	O
76	of	_	_	O
77	life	_	_	O
78	was	_	_	O
79	analyzed	_	_	O
80	.	_	_	O

81	The	_	_	O
82	aim	_	_	O
83	of	_	_	O
84	the	_	_	O
85	study	_	_	O
86	was	_	_	O
87	to	_	_	O
88	analyze	_	_	O
89	the	_	_	O
90	effect	_	_	O
91	of	_	_	O
92	combined	_	_	O
93	treatment	_	_	O
94	methods	_	_	O
95	on	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	in	_	_	O
100	patients	_	_	O
101	diagnosed	_	_	O
102	with	_	_	O
103	pancreatic	_	_	O
104	cancer	_	_	O
105	.	_	_	O

106	During	_	_	O
107	2000-2005	_	_	O
108	,	_	_	O
109	two	_	_	O
110	concomitant	_	_	O
111	chemoradiation	_	_	O
112	treatment	_	_	O
113	methods	_	_	O
114	(	_	_	O
115	radiotherapy	_	_	O
116	with	_	_	O
117	5-fluorouracil	_	_	O
118	and	_	_	O
119	radiotherapy	_	_	O
120	with	_	_	O
121	gemcitabine	_	_	O
122	)	_	_	O
123	were	_	_	O
124	analyzed	_	_	O
125	in	_	_	O
126	the	_	_	O
127	study	_	_	O
128	.	_	_	O

129	A	_	_	O
130	total	_	_	O
131	of	_	_	O
132	60	_	_	O
133	patients	_	_	O
134	were	_	_	O
135	enrolled	_	_	O
136	:	_	_	O
137	41	_	_	O
138	patients	_	_	O
139	diagnosed	_	_	O
140	with	_	_	O
141	resectable	_	_	O
142	and	_	_	O
143	19	_	_	O
144	patients	_	_	O
145	diagnosed	_	_	O
146	with	_	_	O
147	unresectable	_	_	O
148	pancreatic	_	_	O
149	cancer	_	_	O
150	.	_	_	O

151	Quality	_	_	O
152	of	_	_	O
153	life	_	_	O
154	was	_	_	O
155	assessed	_	_	O
156	using	_	_	O
157	European	_	_	O
158	Organization	_	_	O
159	for	_	_	O
160	Research	_	_	O
161	and	_	_	O
162	Treatment	_	_	O
163	of	_	_	O
164	Cancer	_	_	O
165	Quality	_	_	O
166	of	_	_	O
167	Life	_	_	O
168	Core	_	_	O
169	30	_	_	O
170	(	_	_	O
171	EORTC	_	_	O
172	QLQ-C30	_	_	O
173	)	_	_	O
174	questionnaire	_	_	O
175	.	_	_	O

176	Three	_	_	O
177	main	_	_	O
178	quality	_	_	O
179	of	_	_	O
180	life	_	_	O
181	scales	_	_	O
182	(	_	_	O
183	general	_	_	O
184	health	_	_	O
185	status	_	_	O
186	,	_	_	O
187	functional	_	_	O
188	,	_	_	O
189	and	_	_	O
190	symptom	_	_	O
191	scales	_	_	O
192	)	_	_	O
193	were	_	_	O
194	assessed	_	_	O
195	and	_	_	O
196	compared	_	_	O
197	between	_	_	O
198	two	_	_	O
199	treatment	_	_	O
200	groups	_	_	O
201	.	_	_	O

202	The	_	_	B-Premise
203	analysis	_	_	I-Premise
204	of	_	_	I-Premise
205	quality	_	_	I-Premise
206	of	_	_	I-Premise
207	live	_	_	I-Premise
208	assessment	_	_	I-Premise
209	showed	_	_	I-Premise
210	a	_	_	I-Premise
211	statistically	_	_	I-Premise
212	significant	_	_	I-Premise
213	decrease	_	_	I-Premise
214	in	_	_	I-Premise
215	quality	_	_	I-Premise
216	of	_	_	I-Premise
217	life	_	_	I-Premise
218	after	_	_	I-Premise
219	treatment	_	_	I-Premise
220	in	_	_	I-Premise
221	patients	_	_	I-Premise
222	with	_	_	I-Premise
223	resectable	_	_	I-Premise
224	pancreatic	_	_	I-Premise
225	cancer	_	_	I-Premise
226	and	_	_	I-Premise
227	treated	_	_	I-Premise
228	with	_	_	I-Premise
229	radiotherapy	_	_	I-Premise
230	and	_	_	I-Premise
231	gemcitabine	_	_	I-Premise
232	.	_	_	I-Premise

233	Decreased	_	_	B-Premise
234	quality	_	_	I-Premise
235	of	_	_	I-Premise
236	life	_	_	I-Premise
237	later	_	_	I-Premise
238	after	_	_	I-Premise
239	treatment	_	_	I-Premise
240	was	_	_	I-Premise
241	also	_	_	I-Premise
242	observed	_	_	I-Premise
243	in	_	_	I-Premise
244	patients	_	_	I-Premise
245	diagnosed	_	_	I-Premise
246	with	_	_	I-Premise
247	unresectable	_	_	I-Premise
248	pancreatic	_	_	I-Premise
249	cancer	_	_	I-Premise
250	and	_	_	I-Premise
251	treated	_	_	I-Premise
252	with	_	_	I-Premise
253	the	_	_	I-Premise
254	same	_	_	I-Premise
255	regimen	_	_	I-Premise
256	.	_	_	I-Premise

257	Treatment	_	_	B-Claim
258	with	_	_	I-Claim
259	radiotherapy	_	_	I-Claim
260	and	_	_	I-Claim
261	5-fluorouracil	_	_	I-Claim
262	changed	_	_	I-Claim
263	only	_	_	I-Claim
264	some	_	_	I-Claim
265	aspects	_	_	I-Claim
266	of	_	_	I-Claim
267	quality	_	_	I-Claim
268	of	_	_	I-Claim
269	life	_	_	I-Claim
270	and	_	_	I-Claim
271	did	_	_	I-Claim
272	not	_	_	I-Claim
273	have	_	_	I-Claim
274	a	_	_	I-Claim
275	significant	_	_	I-Claim
276	impact	_	_	I-Claim
277	on	_	_	I-Claim
278	quality	_	_	I-Claim
279	of	_	_	I-Claim
280	life	_	_	I-Claim
281	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	directly	_	_	O
3	the	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	intensity-modulated	_	_	O
7	radiotherapy	_	_	O
8	(	_	_	O
9	IMRT	_	_	O
10	)	_	_	O
11	vs.	_	_	O
12	conventional	_	_	O
13	radiotherapy	_	_	O
14	(	_	_	O
15	CRT	_	_	O
16	)	_	_	O
17	on	_	_	O
18	salivary	_	_	O
19	flow	_	_	O
20	and	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QoL	_	_	O
26	)	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	early-stage	_	_	O
31	nasopharyngeal	_	_	O
32	carcinoma	_	_	O
33	(	_	_	O
34	NPC	_	_	O
35	)	_	_	O
36	.	_	_	O

37	Fifty-one	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	T2	_	_	O
41	,	_	_	O
42	N0/N1	_	_	O
43	,	_	_	O
44	M0	_	_	O
45	NPC	_	_	O
46	took	_	_	O
47	part	_	_	O
48	in	_	_	O
49	a	_	_	O
50	randomized	_	_	O
51	controlled	_	_	O
52	clinical	_	_	O
53	study	_	_	O
54	and	_	_	O
55	received	_	_	O
56	IMRT	_	_	O
57	or	_	_	O
58	CRT	_	_	O
59	.	_	_	O

60	Stimulated	_	_	O
61	whole	_	_	O
62	(	_	_	O
63	SWS	_	_	O
64	)	_	_	O
65	and	_	_	O
66	parotid	_	_	O
67	(	_	_	O
68	SPS	_	_	O
69	)	_	_	O
70	saliva	_	_	O
71	flow	_	_	O
72	were	_	_	O
73	measured	_	_	O
74	and	_	_	O
75	Medical	_	_	O
76	Outcomes	_	_	O
77	Short	_	_	O
78	Form	_	_	O
79	36	_	_	O
80	(	_	_	O
81	SF-36	_	_	O
82	)	_	_	O
83	,	_	_	O
84	European	_	_	O
85	Organization	_	_	O
86	for	_	_	O
87	Research	_	_	O
88	and	_	_	O
89	Treatment	_	_	O
90	of	_	_	O
91	Cancer	_	_	O
92	(	_	_	O
93	EORTC	_	_	O
94	)	_	_	O
95	core	_	_	O
96	quetionnaire	_	_	O
97	,	_	_	O
98	and	_	_	O
99	EORTC	_	_	O
100	head-and-neck	_	_	O
101	module	_	_	O
102	(	_	_	O
103	QLQ-H	_	_	O
104	&	_	_	O
105	amp	_	_	O
106	;	_	_	O
107	N35	_	_	O
108	)	_	_	O
109	were	_	_	O
110	completed	_	_	O
111	at	_	_	O
112	baseline	_	_	O
113	and	_	_	O
114	2	_	_	O
115	,	_	_	O
116	6	_	_	O
117	,	_	_	O
118	and	_	_	O
119	12	_	_	O
120	months	_	_	O
121	after	_	_	O
122	radiotherapy	_	_	O
123	.	_	_	O

124	Forty-six	_	_	B-Premise
125	patients	_	_	I-Premise
126	(	_	_	I-Premise
127	88	_	_	I-Premise
128	%	_	_	I-Premise
129	)	_	_	I-Premise
130	were	_	_	I-Premise
131	in	_	_	I-Premise
132	disease	_	_	I-Premise
133	remission	_	_	I-Premise
134	12	_	_	I-Premise
135	months	_	_	I-Premise
136	after	_	_	I-Premise
137	radiotherapy	_	_	I-Premise
138	.	_	_	I-Premise

139	At	_	_	B-Premise
140	12	_	_	I-Premise
141	months	_	_	I-Premise
142	postradiotherapy	_	_	I-Premise
143	,	_	_	I-Premise
144	12	_	_	I-Premise
145	(	_	_	I-Premise
146	50.0	_	_	I-Premise
147	%	_	_	I-Premise
148	)	_	_	I-Premise
149	and	_	_	I-Premise
150	20	_	_	I-Premise
151	patients	_	_	I-Premise
152	(	_	_	I-Premise
153	83.3	_	_	I-Premise
154	%	_	_	I-Premise
155	)	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	IMRT	_	_	I-Premise
159	group	_	_	I-Premise
160	had	_	_	I-Premise
161	recovered	_	_	I-Premise
162	at	_	_	I-Premise
163	least	_	_	I-Premise
164	25	_	_	I-Premise
165	%	_	_	I-Premise
166	of	_	_	I-Premise
167	preradiotherapy	_	_	I-Premise
168	SWS	_	_	I-Premise
169	and	_	_	I-Premise
170	SPS	_	_	I-Premise
171	flow	_	_	I-Premise
172	respectively	_	_	I-Premise
173	,	_	_	I-Premise
174	compared	_	_	I-Premise
175	with	_	_	I-Premise
176	1	_	_	I-Premise
177	(	_	_	I-Premise
178	4.8	_	_	I-Premise
179	%	_	_	I-Premise
180	)	_	_	I-Premise
181	and	_	_	I-Premise
182	2	_	_	I-Premise
183	patients	_	_	I-Premise
184	(	_	_	I-Premise
185	9.5	_	_	I-Premise
186	%	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	respectively	_	_	I-Premise
190	,	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	CRT	_	_	I-Premise
194	group	_	_	I-Premise
195	.	_	_	I-Premise

196	Global	_	_	B-Premise
197	health	_	_	I-Premise
198	scores	_	_	I-Premise
199	showed	_	_	I-Premise
200	continuous	_	_	I-Premise
201	improvement	_	_	I-Premise
202	in	_	_	I-Premise
203	QoL	_	_	I-Premise
204	after	_	_	I-Premise
205	both	_	_	I-Premise
206	treatments	_	_	I-Premise
207	(	_	_	I-Premise
208	p	_	_	I-Premise
209	<	_	_	I-Premise
210	0.001	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	However	_	_	B-Premise
214	,	_	_	I-Premise
215	after	_	_	I-Premise
216	12	_	_	I-Premise
217	months	_	_	I-Premise
218	subscale	_	_	I-Premise
219	scores	_	_	I-Premise
220	for	_	_	I-Premise
221	role-physical	_	_	I-Premise
222	,	_	_	I-Premise
223	bodily	_	_	I-Premise
224	pain	_	_	I-Premise
225	,	_	_	I-Premise
226	and	_	_	I-Premise
227	physical	_	_	I-Premise
228	function	_	_	I-Premise
229	were	_	_	I-Premise
230	significantly	_	_	I-Premise
231	higher	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	IMRT	_	_	I-Premise
235	group	_	_	I-Premise
236	,	_	_	I-Premise
237	indicating	_	_	I-Premise
238	a	_	_	I-Premise
239	better	_	_	I-Premise
240	condition	_	_	I-Premise
241	(	_	_	I-Premise
242	p	_	_	I-Premise
243	<	_	_	I-Premise
244	0.05	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Dry	_	_	B-Premise
248	mouth	_	_	I-Premise
249	and	_	_	I-Premise
250	sticky	_	_	I-Premise
251	saliva	_	_	I-Premise
252	were	_	_	I-Premise
253	problems	_	_	I-Premise
254	in	_	_	I-Premise
255	both	_	_	I-Premise
256	groups	_	_	I-Premise
257	2	_	_	I-Premise
258	months	_	_	I-Premise
259	after	_	_	I-Premise
260	treatment	_	_	I-Premise
261	.	_	_	I-Premise

262	In	_	_	B-Premise
263	the	_	_	I-Premise
264	IMRT	_	_	I-Premise
265	group	_	_	I-Premise
266	,	_	_	I-Premise
267	there	_	_	I-Premise
268	was	_	_	I-Premise
269	consistent	_	_	I-Premise
270	improvement	_	_	I-Premise
271	over	_	_	I-Premise
272	time	_	_	I-Premise
273	with	_	_	I-Premise
274	xerostomia-related	_	_	I-Premise
275	symptoms	_	_	I-Premise
276	significantly	_	_	I-Premise
277	less	_	_	I-Premise
278	common	_	_	I-Premise
279	than	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	CRT	_	_	I-Premise
283	group	_	_	I-Premise
284	at	_	_	I-Premise
285	12	_	_	I-Premise
286	months	_	_	I-Premise
287	postradiotherapy	_	_	I-Premise
288	.	_	_	I-Premise

289	IMRT	_	_	B-Claim
290	was	_	_	I-Claim
291	significantly	_	_	I-Claim
292	better	_	_	I-Claim
293	than	_	_	I-Claim
294	CRT	_	_	I-Claim
295	in	_	_	I-Claim
296	terms	_	_	I-Claim
297	of	_	_	I-Claim
298	parotid	_	_	I-Claim
299	sparing	_	_	I-Claim
300	and	_	_	I-Claim
301	improved	_	_	I-Claim
302	QoL	_	_	I-Claim
303	for	_	_	I-Claim
304	early-stage	_	_	I-Claim
305	disease	_	_	I-Claim
306	.	_	_	I-Claim

307	The	_	_	B-Claim
308	findings	_	_	I-Claim
309	support	_	_	I-Claim
310	the	_	_	I-Claim
311	case	_	_	I-Claim
312	for	_	_	I-Claim
313	assessment	_	_	I-Claim
314	of	_	_	I-Claim
315	health-related	_	_	I-Claim
316	QoL	_	_	I-Claim
317	in	_	_	I-Claim
318	relation	_	_	I-Claim
319	to	_	_	I-Claim
320	head-and-neck	_	_	I-Claim
321	cancer	_	_	I-Claim
322	using	_	_	I-Claim
323	a	_	_	I-Claim
324	site-specific	_	_	I-Claim
325	approach	_	_	I-Claim
326	.	_	_	O


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	article	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	and	_	_	O
15	menopausal	_	_	O
16	symptoms	_	_	O
17	among	_	_	O
18	premenopausal	_	_	O
19	patients	_	_	O
20	with	_	_	O
21	lymph	_	_	O
22	node-negative	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	receiving	_	_	O
26	chemotherapy	_	_	O
27	,	_	_	O
28	goserelin	_	_	O
29	,	_	_	O
30	or	_	_	O
31	their	_	_	O
32	sequential	_	_	O
33	combination	_	_	O
34	,	_	_	O
35	and	_	_	O
36	to	_	_	O
37	investigate	_	_	O
38	differential	_	_	O
39	effects	_	_	O
40	by	_	_	O
41	age	_	_	O
42	.	_	_	O

43	We	_	_	O
44	evaluated	_	_	O
45	QOL	_	_	O
46	data	_	_	O
47	from	_	_	O
48	874	_	_	O
49	pre-	_	_	O
50	and	_	_	O
51	perimenopausal	_	_	O
52	women	_	_	O
53	with	_	_	O
54	lymph	_	_	O
55	node-negative	_	_	O
56	breast	_	_	O
57	cancer	_	_	O
58	who	_	_	O
59	were	_	_	O
60	randomly	_	_	O
61	assigned	_	_	O
62	to	_	_	O
63	receive	_	_	O
64	six	_	_	O
65	courses	_	_	O
66	of	_	_	O
67	classical	_	_	O
68	cyclophosphamide	_	_	O
69	,	_	_	O
70	methotrexate	_	_	O
71	,	_	_	O
72	and	_	_	O
73	fluorouracil	_	_	O
74	(	_	_	O
75	CMF	_	_	O
76	)	_	_	O
77	chemotherapy	_	_	O
78	,	_	_	O
79	ovarian	_	_	O
80	suppression	_	_	O
81	with	_	_	O
82	goserelin	_	_	O
83	for	_	_	O
84	24	_	_	O
85	months	_	_	O
86	,	_	_	O
87	or	_	_	O
88	six	_	_	O
89	courses	_	_	O
90	of	_	_	O
91	classical	_	_	O
92	CMF	_	_	O
93	followed	_	_	O
94	by	_	_	O
95	18	_	_	O
96	months	_	_	O
97	of	_	_	O
98	goserelin	_	_	O
99	.	_	_	O

100	We	_	_	O
101	report	_	_	O
102	QOL	_	_	O
103	data	_	_	O
104	collected	_	_	O
105	during	_	_	O
106	3	_	_	O
107	years	_	_	O
108	after	_	_	O
109	random	_	_	O
110	assignment	_	_	O
111	in	_	_	O
112	patients	_	_	O
113	without	_	_	O
114	disease	_	_	O
115	recurrence	_	_	O
116	.	_	_	O

117	Overall	_	_	B-Premise
118	,	_	_	I-Premise
119	patients	_	_	I-Premise
120	receiving	_	_	I-Premise
121	goserelin	_	_	I-Premise
122	alone	_	_	I-Premise
123	showed	_	_	I-Premise
124	a	_	_	I-Premise
125	marked	_	_	I-Premise
126	improvement	_	_	I-Premise
127	or	_	_	I-Premise
128	less	_	_	I-Premise
129	deterioration	_	_	I-Premise
130	in	_	_	I-Premise
131	QOL	_	_	I-Premise
132	measures	_	_	I-Premise
133	over	_	_	I-Premise
134	the	_	_	I-Premise
135	first	_	_	I-Premise
136	6	_	_	I-Premise
137	months	_	_	I-Premise
138	than	_	_	I-Premise
139	those	_	_	I-Premise
140	patients	_	_	I-Premise
141	treated	_	_	I-Premise
142	with	_	_	I-Premise
143	CMF	_	_	I-Premise
144	.	_	_	I-Premise

145	There	_	_	B-Premise
146	were	_	_	I-Premise
147	no	_	_	I-Premise
148	differences	_	_	I-Premise
149	at	_	_	I-Premise
150	3	_	_	I-Premise
151	years	_	_	I-Premise
152	after	_	_	I-Premise
153	random	_	_	I-Premise
154	assignment	_	_	I-Premise
155	according	_	_	I-Premise
156	to	_	_	I-Premise
157	treatment	_	_	I-Premise
158	except	_	_	I-Premise
159	for	_	_	I-Premise
160	hot	_	_	I-Premise
161	flashes	_	_	I-Premise
162	.	_	_	I-Premise

163	As	_	_	B-Premise
164	reflected	_	_	I-Premise
165	in	_	_	I-Premise
166	the	_	_	I-Premise
167	hot	_	_	I-Premise
168	flashes	_	_	I-Premise
169	scores	_	_	I-Premise
170	,	_	_	I-Premise
171	patients	_	_	I-Premise
172	in	_	_	I-Premise
173	all	_	_	I-Premise
174	three	_	_	I-Premise
175	treatment	_	_	I-Premise
176	groups	_	_	I-Premise
177	experienced	_	_	I-Premise
178	induced	_	_	I-Premise
179	amenorrhea	_	_	I-Premise
180	,	_	_	I-Premise
181	but	_	_	B-Premise
182	the	_	_	I-Premise
183	onset	_	_	I-Premise
184	of	_	_	I-Premise
185	ovarian	_	_	I-Premise
186	function	_	_	I-Premise
187	suppression	_	_	I-Premise
188	was	_	_	I-Premise
189	slightly	_	_	I-Premise
190	delayed	_	_	I-Premise
191	for	_	_	I-Premise
192	patients	_	_	I-Premise
193	receiving	_	_	I-Premise
194	chemotherapy	_	_	I-Premise
195	.	_	_	I-Premise

196	Younger	_	_	B-Premise
197	patients	_	_	I-Premise
198	(	_	_	I-Premise
199	<	_	_	I-Premise
200	40	_	_	I-Premise
201	years	_	_	I-Premise
202	)	_	_	I-Premise
203	who	_	_	I-Premise
204	received	_	_	I-Premise
205	goserelin	_	_	I-Premise
206	alone	_	_	I-Premise
207	returned	_	_	I-Premise
208	to	_	_	I-Premise
209	their	_	_	I-Premise
210	premenopausal	_	_	I-Premise
211	status	_	_	I-Premise
212	at	_	_	I-Premise
213	6	_	_	I-Premise
214	months	_	_	I-Premise
215	after	_	_	I-Premise
216	the	_	_	I-Premise
217	cessation	_	_	I-Premise
218	of	_	_	I-Premise
219	therapy	_	_	I-Premise
220	,	_	_	I-Premise
221	while	_	_	I-Premise
222	those	_	_	I-Premise
223	who	_	_	I-Premise
224	received	_	_	I-Premise
225	CMF	_	_	I-Premise
226	showed	_	_	I-Premise
227	marginal	_	_	I-Premise
228	changes	_	_	I-Premise
229	from	_	_	I-Premise
230	their	_	_	I-Premise
231	baseline	_	_	I-Premise
232	hot	_	_	I-Premise
233	flashes	_	_	I-Premise
234	scores	_	_	I-Premise
235	.	_	_	I-Premise

236	Age-adjusted	_	_	B-Claim
237	risk	_	_	I-Claim
238	profiles	_	_	I-Claim
239	that	_	_	I-Claim
240	consider	_	_	I-Claim
241	patient-reported	_	_	I-Claim
242	outcomes	_	_	I-Claim
243	enable	_	_	I-Claim
244	patients	_	_	I-Claim
245	to	_	_	I-Claim
246	adapt	_	_	I-Claim
247	to	_	_	I-Claim
248	their	_	_	I-Claim
249	disease	_	_	I-Claim
250	and	_	_	I-Claim
251	treatment	_	_	I-Claim
252	,	_	_	I-Claim
253	such	_	_	I-Claim
254	as	_	_	I-Claim
255	considering	_	_	I-Claim
256	the	_	_	I-Claim
257	trade-offs	_	_	I-Claim
258	between	_	_	I-Claim
259	delayed	_	_	I-Claim
260	endocrine	_	_	I-Claim
261	symptoms	_	_	I-Claim
262	,	_	_	I-Claim
263	but	_	_	I-Claim
264	higher	_	_	I-Claim
265	risk	_	_	I-Claim
266	of	_	_	I-Claim
267	permanent	_	_	I-Claim
268	menopause	_	_	I-Claim
269	with	_	_	I-Claim
270	chemotherapy	_	_	I-Claim
271	,	_	_	I-Claim
272	and	_	_	I-Claim
273	immediate	_	_	I-Claim
274	but	_	_	I-Claim
275	reversible	_	_	I-Claim
276	endocrine	_	_	I-Claim
277	symptoms	_	_	I-Claim
278	with	_	_	I-Claim
279	goserelin	_	_	I-Claim
280	,	_	_	I-Claim
281	in	_	_	I-Claim
282	younger	_	_	I-Claim
283	premenopausal	_	_	I-Claim
284	patients	_	_	I-Claim
285	.	_	_	I-Claim


0	Although	_	_	O
1	numerous	_	_	O
2	treatment	_	_	O
3	modalities	_	_	O
4	have	_	_	O
5	been	_	_	O
6	explored	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	advanced	_	_	O
11	HCC	_	_	O
12	,	_	_	O
13	the	_	_	O
14	therapeutic	_	_	O
15	options	_	_	O
16	are	_	_	O
17	still	_	_	O
18	limited	_	_	O
19	.	_	_	O

20	Somatostatin	_	_	B-Claim
21	has	_	_	I-Claim
22	been	_	_	I-Claim
23	shown	_	_	I-Claim
24	to	_	_	I-Claim
25	have	_	_	I-Claim
26	antimitotic	_	_	I-Claim
27	activity	_	_	I-Claim
28	in	_	_	I-Claim
29	endocrine	_	_	I-Claim
30	as	_	_	I-Claim
31	well	_	_	I-Claim
32	as	_	_	I-Claim
33	in	_	_	I-Claim
34	a	_	_	I-Claim
35	variety	_	_	I-Claim
36	of	_	_	I-Claim
37	nonendocrine	_	_	I-Claim
38	tumors	_	_	I-Claim
39	.	_	_	I-Claim

40	Expression	_	_	B-Premise
41	of	_	_	I-Premise
42	somatostatin	_	_	I-Premise
43	receptors	_	_	I-Premise
44	is	_	_	I-Premise
45	found	_	_	I-Premise
46	in	_	_	I-Premise
47	HCCs	_	_	I-Premise
48	,	_	_	I-Premise
49	but	_	_	O
50	the	_	_	B-Claim
51	efficacy	_	_	I-Claim
52	of	_	_	I-Claim
53	the	_	_	I-Claim
54	somatostatin	_	_	I-Claim
55	analogue	_	_	I-Claim
56	octreotide	_	_	I-Claim
57	remains	_	_	I-Claim
58	controversial	_	_	I-Claim
59	.	_	_	I-Claim

60	Therefore	_	_	O
61	,	_	_	O
62	a	_	_	O
63	randomized	_	_	O
64	double-blind	_	_	O
65	placebo-controlled	_	_	O
66	multicenter	_	_	O
67	trial	_	_	O
68	was	_	_	O
69	performed	_	_	O
70	to	_	_	O
71	assess	_	_	O
72	the	_	_	O
73	efficacy	_	_	O
74	of	_	_	O
75	long-acting	_	_	O
76	octreotide	_	_	O
77	for	_	_	O
78	the	_	_	O
79	treatment	_	_	O
80	of	_	_	O
81	advanced	_	_	O
82	HCC	_	_	O
83	.	_	_	O

84	One	_	_	O
85	hundred	_	_	O
86	twenty	_	_	O
87	untreated	_	_	O
88	patients	_	_	O
89	with	_	_	O
90	histologically	_	_	O
91	confirmed	_	_	O
92	HCC	_	_	O
93	were	_	_	O
94	randomized	_	_	O
95	to	_	_	O
96	receive	_	_	O
97	either	_	_	O
98	long-acting	_	_	O
99	octreotide	_	_	O
100	(	_	_	O
101	Sandostation	_	_	O
102	LAR	_	_	O
103	30	_	_	O
104	mg	_	_	O
105	)	_	_	O
106	intramuscularly	_	_	O
107	every	_	_	O
108	4	_	_	O
109	weeks	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	.	_	_	O

113	The	_	_	O
114	study	_	_	O
115	groups	_	_	O
116	were	_	_	O
117	comparable	_	_	O
118	with	_	_	O
119	respect	_	_	O
120	to	_	_	O
121	clinical	_	_	O
122	characteristics	_	_	O
123	.	_	_	O

124	There	_	_	B-Premise
125	was	_	_	I-Premise
126	no	_	_	I-Premise
127	difference	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	cumulative	_	_	I-Premise
131	survival	_	_	I-Premise
132	.	_	_	I-Premise

133	The	_	_	B-Premise
134	median	_	_	I-Premise
135	survival	_	_	I-Premise
136	time	_	_	I-Premise
137	was	_	_	I-Premise
138	4.7	_	_	I-Premise
139	months	_	_	I-Premise
140	in	_	_	I-Premise
141	the	_	_	I-Premise
142	octreotide	_	_	I-Premise
143	group	_	_	I-Premise
144	compared	_	_	I-Premise
145	with	_	_	I-Premise
146	5.3	_	_	I-Premise
147	months	_	_	I-Premise
148	in	_	_	I-Premise
149	the	_	_	I-Premise
150	control	_	_	I-Premise
151	group	_	_	I-Premise
152	.	_	_	I-Premise

153	Six-month	_	_	B-Premise
154	survival	_	_	I-Premise
155	rates	_	_	I-Premise
156	were	_	_	I-Premise
157	41	_	_	I-Premise
158	%	_	_	I-Premise
159	for	_	_	I-Premise
160	octreotide	_	_	I-Premise
161	patients	_	_	I-Premise
162	and	_	_	I-Premise
163	42	_	_	I-Premise
164	%	_	_	I-Premise
165	for	_	_	I-Premise
166	control	_	_	I-Premise
167	patients	_	_	I-Premise
168	,	_	_	I-Premise
169	respectively	_	_	I-Premise
170	.	_	_	I-Premise

171	The	_	_	B-Premise
172	unadjusted	_	_	I-Premise
173	relative	_	_	I-Premise
174	risk	_	_	I-Premise
175	for	_	_	I-Premise
176	mortality	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	octreotide	_	_	I-Premise
180	group	_	_	I-Premise
181	compared	_	_	I-Premise
182	with	_	_	I-Premise
183	patients	_	_	I-Premise
184	in	_	_	I-Premise
185	the	_	_	I-Premise
186	control	_	_	I-Premise
187	group	_	_	I-Premise
188	was	_	_	I-Premise
189	1.11	_	_	I-Premise
190	(	_	_	I-Premise
191	95	_	_	I-Premise
192	%	_	_	I-Premise
193	CI	_	_	I-Premise
194	0.76-1.63	_	_	I-Premise
195	;	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	0.59	_	_	I-Premise
199	)	_	_	I-Premise
200	.	_	_	I-Premise

201	When	_	_	B-Premise
202	adjusted	_	_	I-Premise
203	for	_	_	I-Premise
204	Okuda	_	_	I-Premise
205	,	_	_	I-Premise
206	CTP	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	Cancer	_	_	I-Premise
210	of	_	_	I-Premise
211	the	_	_	I-Premise
212	Liver	_	_	I-Premise
213	Italian	_	_	I-Premise
214	Program	_	_	I-Premise
215	(	_	_	I-Premise
216	CLIP	_	_	I-Premise
217	)	_	_	I-Premise
218	scores	_	_	I-Premise
219	,	_	_	I-Premise
220	the	_	_	I-Premise
221	relative	_	_	I-Premise
222	risk	_	_	I-Premise
223	for	_	_	I-Premise
224	octreotide	_	_	I-Premise
225	did	_	_	I-Premise
226	not	_	_	I-Premise
227	change	_	_	I-Premise
228	markedly	_	_	I-Premise
229	and	_	_	I-Premise
230	was	_	_	I-Premise
231	1.05	_	_	I-Premise
232	(	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	0.71-1.55	_	_	I-Premise
237	;	_	_	I-Premise
238	P	_	_	I-Premise
239	=	_	_	I-Premise
240	0.83	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Claim
244	CLIP	_	_	I-Claim
245	score	_	_	I-Claim
246	seems	_	_	I-Claim
247	to	_	_	I-Claim
248	predict	_	_	I-Claim
249	survival	_	_	I-Claim
250	better	_	_	I-Claim
251	than	_	_	I-Claim
252	both	_	_	I-Claim
253	Okuda	_	_	I-Claim
254	and	_	_	I-Claim
255	CTP	_	_	I-Claim
256	score	_	_	I-Claim
257	.	_	_	I-Claim

258	The	_	_	B-Claim
259	randomized	_	_	I-Claim
260	controlled	_	_	I-Claim
261	double-blind	_	_	I-Claim
262	HECTOR	_	_	I-Claim
263	trial	_	_	I-Claim
264	showed	_	_	I-Claim
265	no	_	_	I-Claim
266	survival	_	_	I-Claim
267	benefit	_	_	I-Claim
268	for	_	_	I-Claim
269	HCC	_	_	I-Claim
270	patients	_	_	I-Claim
271	treated	_	_	I-Claim
272	with	_	_	I-Claim
273	long-acting	_	_	I-Claim
274	octreotide	_	_	I-Claim
275	compared	_	_	I-Claim
276	with	_	_	I-Claim
277	placebo	_	_	I-Claim
278	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	evaluate	_	_	O
6	the	_	_	O
7	impact	_	_	O
8	of	_	_	O
9	laparoscopic	_	_	O
10	rectal	_	_	O
11	resection	_	_	O
12	on	_	_	O
13	short-term	_	_	O
14	postoperative	_	_	O
15	morbidity	_	_	O
16	and	_	_	O
17	costs	_	_	O
18	.	_	_	O

19	A	_	_	O
20	total	_	_	O
21	of	_	_	O
22	168	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	rectal	_	_	O
26	cancer	_	_	O
27	were	_	_	O
28	randomly	_	_	O
29	assigned	_	_	O
30	to	_	_	O
31	laparoscopic	_	_	O
32	(	_	_	O
33	n	_	_	O
34	=	_	_	O
35	83	_	_	O
36	)	_	_	O
37	or	_	_	O
38	open	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	85	_	_	O
43	)	_	_	O
44	resection	_	_	O
45	.	_	_	O

46	Outcome	_	_	O
47	parameters	_	_	O
48	were	_	_	O
49	:	_	_	O
50	postoperative	_	_	O
51	morbidity	_	_	O
52	,	_	_	O
53	length	_	_	O
54	of	_	_	O
55	hospital	_	_	O
56	stay	_	_	O
57	,	_	_	O
58	quality	_	_	O
59	of	_	_	O
60	life	_	_	O
61	,	_	_	O
62	long-term	_	_	O
63	survival	_	_	O
64	,	_	_	O
65	and	_	_	O
66	local	_	_	O
67	recurrences	_	_	O
68	.	_	_	O

69	The	_	_	O
70	mean	_	_	O
71	follow-up	_	_	O
72	period	_	_	O
73	was	_	_	O
74	53.6	_	_	O
75	months	_	_	O
76	.	_	_	O

77	Cost-benefit	_	_	O
78	analysis	_	_	O
79	was	_	_	O
80	based	_	_	O
81	on	_	_	O
82	hospital	_	_	O
83	costs	_	_	O
84	.	_	_	O

85	Operative	_	_	B-Premise
86	time	_	_	I-Premise
87	was	_	_	I-Premise
88	53	_	_	I-Premise
89	minutes	_	_	I-Premise
90	longer	_	_	I-Premise
91	in	_	_	I-Premise
92	the	_	_	I-Premise
93	laparoscopic	_	_	I-Premise
94	group	_	_	I-Premise
95	(	_	_	I-Premise
96	P	_	_	I-Premise
97	<	_	_	I-Premise
98	0.0001	_	_	I-Premise
99	)	_	_	I-Premise
100	.	_	_	I-Premise

101	Postoperative	_	_	B-Premise
102	morbidity	_	_	I-Premise
103	rate	_	_	I-Premise
104	was	_	_	I-Premise
105	28.9	_	_	I-Premise
106	percent	_	_	I-Premise
107	in	_	_	I-Premise
108	the	_	_	I-Premise
109	laparoscopic	_	_	I-Premise
110	vs.	_	_	I-Premise
111	40	_	_	I-Premise
112	percent	_	_	I-Premise
113	in	_	_	I-Premise
114	the	_	_	I-Premise
115	open	_	_	I-Premise
116	group	_	_	I-Premise
117	(	_	_	I-Premise
118	P	_	_	I-Premise
119	=	_	_	I-Premise
120	0.18	_	_	I-Premise
121	)	_	_	I-Premise
122	.	_	_	I-Premise

123	The	_	_	B-Premise
124	mean	_	_	I-Premise
125	length	_	_	I-Premise
126	of	_	_	I-Premise
127	hospital	_	_	I-Premise
128	stay	_	_	I-Premise
129	was	_	_	I-Premise
130	10	_	_	I-Premise
131	(	_	_	I-Premise
132	4.9	_	_	I-Premise
133	)	_	_	I-Premise
134	days	_	_	I-Premise
135	in	_	_	I-Premise
136	the	_	_	I-Premise
137	laparoscopic	_	_	I-Premise
138	group	_	_	I-Premise
139	and	_	_	I-Premise
140	13.6	_	_	I-Premise
141	(	_	_	I-Premise
142	10	_	_	I-Premise
143	)	_	_	I-Premise
144	days	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	open	_	_	I-Premise
148	group	_	_	I-Premise
149	(	_	_	I-Premise
150	P	_	_	I-Premise
151	=	_	_	I-Premise
152	0.004	_	_	I-Premise
153	)	_	_	I-Premise
154	.	_	_	I-Premise

155	Local	_	_	B-Premise
156	recurrence	_	_	I-Premise
157	rate	_	_	I-Premise
158	and	_	_	I-Premise
159	five-year	_	_	I-Premise
160	survival	_	_	I-Premise
161	were	_	_	I-Premise
162	similar	_	_	I-Premise
163	in	_	_	I-Premise
164	both	_	_	I-Premise
165	groups	_	_	I-Premise
166	;	_	_	I-Premise
167	however	_	_	B-Claim
168	,	_	_	I-Claim
169	the	_	_	I-Claim
170	limited	_	_	I-Claim
171	number	_	_	I-Claim
172	of	_	_	I-Claim
173	patients	_	_	I-Claim
174	does	_	_	I-Claim
175	not	_	_	I-Claim
176	allow	_	_	I-Claim
177	firm	_	_	I-Claim
178	conclusions	_	_	I-Claim
179	.	_	_	I-Claim

180	Quality	_	_	B-Premise
181	of	_	_	I-Premise
182	life	_	_	I-Premise
183	was	_	_	I-Premise
184	better	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	laparoscopic	_	_	I-Premise
188	group	_	_	I-Premise
189	only	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	first	_	_	I-Premise
193	year	_	_	I-Premise
194	after	_	_	I-Premise
195	surgery	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	<	_	_	I-Premise
199	0.0001	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	The	_	_	B-Premise
203	additional	_	_	I-Premise
204	charge	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	laparoscopic	_	_	I-Premise
208	group	_	_	I-Premise
209	was	_	_	I-Premise
210	$	_	_	I-Premise
211	1,748	_	_	I-Premise
212	per	_	_	I-Premise
213	patient	_	_	I-Premise
214	randomized	_	_	I-Premise
215	(	_	_	I-Premise
216	$	_	_	I-Premise
217	1,194	_	_	I-Premise
218	the	_	_	I-Premise
219	result	_	_	I-Premise
220	of	_	_	I-Premise
221	surgical	_	_	I-Premise
222	instruments	_	_	I-Premise
223	and	_	_	I-Premise
224	$	_	_	I-Premise
225	554	_	_	I-Premise
226	the	_	_	I-Premise
227	result	_	_	I-Premise
228	of	_	_	I-Premise
229	longer	_	_	I-Premise
230	operative	_	_	I-Premise
231	time	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	The	_	_	B-Premise
235	saving	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	laparoscopic	_	_	I-Premise
239	group	_	_	I-Premise
240	was	_	_	I-Premise
241	$	_	_	I-Premise
242	1,396	_	_	I-Premise
243	per	_	_	I-Premise
244	patient	_	_	I-Premise
245	randomized	_	_	I-Premise
246	(	_	_	I-Premise
247	$	_	_	I-Premise
248	647	_	_	I-Premise
249	the	_	_	I-Premise
250	result	_	_	I-Premise
251	of	_	_	I-Premise
252	shorter	_	_	I-Premise
253	length	_	_	I-Premise
254	of	_	_	I-Premise
255	hospital	_	_	I-Premise
256	stay	_	_	I-Premise
257	and	_	_	I-Premise
258	$	_	_	I-Premise
259	749	_	_	I-Premise
260	the	_	_	I-Premise
261	result	_	_	I-Premise
262	of	_	_	I-Premise
263	the	_	_	I-Premise
264	lower	_	_	I-Premise
265	cost	_	_	I-Premise
266	of	_	_	I-Premise
267	postoperative	_	_	I-Premise
268	complications	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	The	_	_	B-Premise
272	net	_	_	I-Premise
273	balance	_	_	I-Premise
274	resulted	_	_	I-Premise
275	in	_	_	I-Premise
276	$	_	_	I-Premise
277	351	_	_	I-Premise
278	extra	_	_	I-Premise
279	cost	_	_	I-Premise
280	per	_	_	I-Premise
281	patient	_	_	I-Premise
282	randomly	_	_	I-Premise
283	allocated	_	_	I-Premise
284	to	_	_	I-Premise
285	the	_	_	I-Premise
286	laparoscopic	_	_	I-Premise
287	group	_	_	I-Premise
288	.	_	_	I-Premise

289	Short-term	_	_	B-Claim
290	postoperative	_	_	I-Claim
291	morbidity	_	_	I-Claim
292	was	_	_	I-Claim
293	similar	_	_	I-Claim
294	in	_	_	I-Claim
295	the	_	_	I-Claim
296	two	_	_	I-Claim
297	groups	_	_	I-Claim
298	.	_	_	I-Claim

299	Laparoscopic	_	_	B-Claim
300	resection	_	_	I-Claim
301	reduced	_	_	I-Claim
302	length	_	_	I-Claim
303	of	_	_	I-Claim
304	hospital	_	_	I-Claim
305	stay	_	_	I-Claim
306	,	_	_	I-Claim
307	improved	_	_	I-Claim
308	first-year	_	_	I-Claim
309	quality	_	_	I-Claim
310	of	_	_	I-Claim
311	life	_	_	I-Claim
312	,	_	_	I-Claim
313	and	_	_	I-Claim
314	slightly	_	_	I-Claim
315	increased	_	_	I-Claim
316	hospital	_	_	I-Claim
317	costs	_	_	I-Claim
318	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	ocular	_	_	O
4	hypotensive	_	_	O
5	efficacy	_	_	O
6	and	_	_	O
7	safety	_	_	O
8	of	_	_	O
9	topical	_	_	O
10	bimatoprost	_	_	O
11	and	_	_	O
12	timolol-dorzolamide	_	_	O
13	combination	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	primary	_	_	O
18	open-angle	_	_	O
19	glaucoma	_	_	O
20	(	_	_	O
21	POAG	_	_	O
22	)	_	_	O
23	or	_	_	O
24	ocular	_	_	O
25	hypertension	_	_	O
26	during	_	_	O
27	6	_	_	O
28	months	_	_	O
29	of	_	_	O
30	treatment	_	_	O
31	.	_	_	O

32	A	_	_	O
33	sample	_	_	O
34	of	_	_	O
35	65	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	a	_	_	O
39	diagnosis	_	_	O
40	of	_	_	O
41	POAG	_	_	O
42	or	_	_	O
43	ocular	_	_	O
44	hypertension	_	_	O
45	were	_	_	O
46	randomized	_	_	O
47	to	_	_	O
48	receive	_	_	O
49	either	_	_	O
50	bimatoprost	_	_	O
51	0.03	_	_	O
52	%	_	_	O
53	once	_	_	O
54	daily	_	_	O
55	or	_	_	O
56	timolol-dorzolamide	_	_	O
57	combination	_	_	O
58	twice	_	_	O
59	daily	_	_	O
60	.	_	_	O

61	Study	_	_	O
62	visits	_	_	O
63	occurred	_	_	O
64	at	_	_	O
65	baseline	_	_	O
66	and	_	_	O
67	after	_	_	O
68	2	_	_	O
69	weeks	_	_	O
70	and	_	_	O
71	1	_	_	O
72	,	_	_	O
73	3	_	_	O
74	and	_	_	O
75	6	_	_	O
76	months	_	_	O
77	of	_	_	O
78	therapy	_	_	O
79	.	_	_	O

80	Intraocular	_	_	O
81	pressure	_	_	O
82	(	_	_	O
83	IOP	_	_	O
84	)	_	_	O
85	measurements	_	_	O
86	were	_	_	O
87	performed	_	_	O
88	at	_	_	O
89	12.00	_	_	O
90	hours	_	_	O
91	at	_	_	O
92	all	_	_	O
93	study	_	_	O
94	visits	_	_	O
95	and	_	_	O
96	also	_	_	O
97	at	_	_	O
98	08.00	_	_	O
99	hours	_	_	O
100	and	_	_	O
101	16.00	_	_	O
102	hours	_	_	O
103	at	_	_	O
104	baseline	_	_	O
105	and	_	_	O
106	6-month	_	_	O
107	visits	_	_	O
108	.	_	_	O

109	At	_	_	O
110	each	_	_	O
111	visit	_	_	O
112	,	_	_	O
113	local	_	_	O
114	and	_	_	O
115	systemic	_	_	O
116	side-effects	_	_	O
117	that	_	_	O
118	occurred	_	_	O
119	during	_	_	O
120	the	_	_	O
121	treatment	_	_	O
122	period	_	_	O
123	were	_	_	O
124	recorded	_	_	O
125	.	_	_	O

126	Student	_	_	O
127	's	_	_	O
128	t-test	_	_	O
129	was	_	_	O
130	used	_	_	O
131	to	_	_	O
132	compare	_	_	O
133	the	_	_	O
134	differences	_	_	O
135	between	_	_	O
136	IOP	_	_	O
137	values	_	_	O
138	.	_	_	O

139	Differences	_	_	O
140	in	_	_	O
141	IOP	_	_	O
142	between	_	_	O
143	the	_	_	O
144	bimatoprost	_	_	O
145	and	_	_	O
146	timolol-dorzolamide	_	_	O
147	groups	_	_	O
148	were	_	_	O
149	statistically	_	_	O
150	insignificant	_	_	O
151	at	_	_	O
152	all	_	_	O
153	study	_	_	O
154	visits	_	_	O
155	(	_	_	O
156	p	_	_	O
157	>	_	_	O
158	0.05	_	_	O
159	)	_	_	O
160	.	_	_	O

161	In	_	_	B-Premise
162	the	_	_	I-Premise
163	bimatoprost-treated	_	_	I-Premise
164	group	_	_	I-Premise
165	,	_	_	I-Premise
166	the	_	_	I-Premise
167	IOP	_	_	I-Premise
168	reduction	_	_	I-Premise
169	was	_	_	I-Premise
170	6.2	_	_	I-Premise
171	+/-	_	_	I-Premise
172	1.8	_	_	I-Premise
173	mmHg	_	_	I-Premise
174	,	_	_	I-Premise
175	whereas	_	_	I-Premise
176	it	_	_	I-Premise
177	was	_	_	I-Premise
178	6.5	_	_	I-Premise
179	+/-	_	_	I-Premise
180	2.3	_	_	I-Premise
181	mmHg	_	_	I-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	timolol-dorzolamide	_	_	I-Premise
185	group	_	_	I-Premise
186	after	_	_	I-Premise
187	6	_	_	I-Premise
188	months	_	_	I-Premise
189	of	_	_	I-Premise
190	treatment	_	_	I-Premise
191	.	_	_	I-Premise

192	The	_	_	B-Premise
193	difference	_	_	I-Premise
194	was	_	_	I-Premise
195	not	_	_	I-Premise
196	statistically	_	_	I-Premise
197	significant	_	_	I-Premise
198	(	_	_	I-Premise
199	p	_	_	I-Premise
200	=	_	_	I-Premise
201	0.48	_	_	I-Premise
202	)	_	_	I-Premise
203	.	_	_	I-Premise

204	The	_	_	B-Premise
205	IOP-lowering	_	_	I-Premise
206	efficacies	_	_	I-Premise
207	of	_	_	I-Premise
208	bimatoprost	_	_	I-Premise
209	and	_	_	I-Premise
210	timolol-dorzolamide	_	_	I-Premise
211	combination	_	_	I-Premise
212	were	_	_	I-Premise
213	similar	_	_	I-Premise
214	over	_	_	I-Premise
215	a	_	_	I-Premise
216	6-month	_	_	I-Premise
217	follow-up	_	_	I-Premise
218	.	_	_	I-Premise

219	Both	_	_	B-Claim
220	bimatoprost	_	_	I-Claim
221	and	_	_	I-Claim
222	the	_	_	I-Claim
223	timolol-dorzolamide	_	_	I-Claim
224	combination	_	_	I-Claim
225	were	_	_	I-Claim
226	well	_	_	I-Claim
227	tolerated	_	_	I-Claim
228	.	_	_	I-Claim

229	Bimatoprost	_	_	B-Claim
230	can	_	_	I-Claim
231	be	_	_	I-Claim
232	used	_	_	I-Claim
233	as	_	_	I-Claim
234	a	_	_	I-Claim
235	longterm	_	_	I-Claim
236	monotherapy	_	_	I-Claim
237	agent	_	_	I-Claim
238	in	_	_	I-Claim
239	the	_	_	I-Claim
240	treatment	_	_	I-Claim
241	of	_	_	I-Claim
242	POAG	_	_	I-Claim
243	and	_	_	I-Claim
244	ocular	_	_	I-Claim
245	hypertension	_	_	I-Claim
246	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	randomized	_	_	O
5	clinical	_	_	O
6	trial	_	_	O
7	was	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	the	_	_	O
11	effectiveness	_	_	O
12	and	_	_	O
13	safety	_	_	O
14	of	_	_	O
15	viscocanalostomy	_	_	O
16	(	_	_	O
17	visco	_	_	O
18	)	_	_	O
19	with	_	_	O
20	trabeculectomy	_	_	O
21	(	_	_	O
22	trab	_	_	O
23	)	_	_	O
24	in	_	_	O
25	the	_	_	O
26	management	_	_	O
27	of	_	_	O
28	primary	_	_	O
29	open	_	_	O
30	angle	_	_	O
31	glaucoma	_	_	O
32	(	_	_	O
33	POAG	_	_	O
34	)	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	were	_	_	O
38	randomized	_	_	O
39	to	_	_	O
40	have	_	_	O
41	a	_	_	O
42	viscocanalostomy	_	_	O
43	(	_	_	O
44	25	_	_	O
45	eyes	_	_	O
46	)	_	_	O
47	or	_	_	O
48	a	_	_	O
49	trabeculectomy	_	_	O
50	(	_	_	O
51	25	_	_	O
52	eyes	_	_	O
53	)	_	_	O
54	performed	_	_	O
55	by	_	_	O
56	one	_	_	O
57	surgeon	_	_	O
58	(	_	_	O
59	TDM	_	_	O
60	)	_	_	O
61	and	_	_	O
62	followed	_	_	O
63	up	_	_	O
64	prospectively	_	_	O
65	.	_	_	O

66	Patients	_	_	O
67	were	_	_	O
68	examined	_	_	O
69	preoperatively	_	_	O
70	,	_	_	O
71	at	_	_	O
72	day	_	_	O
73	1	_	_	O
74	,	_	_	O
75	day	_	_	O
76	3	_	_	O
77	if	_	_	O
78	required	_	_	O
79	,	_	_	O
80	day	_	_	O
81	6	_	_	O
82	,	_	_	O
83	week	_	_	O
84	2	_	_	O
85	and	_	_	O
86	thereafter	_	_	O
87	as	_	_	O
88	near	_	_	O
89	as	_	_	O
90	possible	_	_	O
91	to	_	_	O
92	1	_	_	O
93	,	_	_	O
94	3	_	_	O
95	,	_	_	O
96	6	_	_	O
97	,	_	_	O
98	12	_	_	O
99	,	_	_	O
100	18	_	_	O
101	,	_	_	O
102	24	_	_	O
103	,	_	_	O
104	30	_	_	O
105	,	_	_	O
106	36	_	_	O
107	,	_	_	O
108	48	_	_	O
109	,	_	_	O
110	54	_	_	O
111	,	_	_	O
112	and	_	_	O
113	60	_	_	O
114	months	_	_	O
115	.	_	_	O

116	We	_	_	O
117	recorded	_	_	O
118	intraocular	_	_	O
119	pressure	_	_	O
120	(	_	_	O
121	IOP	_	_	O
122	)	_	_	O
123	,	_	_	O
124	presence	_	_	O
125	or	_	_	O
126	absence	_	_	O
127	of	_	_	O
128	any	_	_	O
129	complications	_	_	O
130	,	_	_	O
131	presence	_	_	O
132	and	_	_	O
133	description	_	_	O
134	of	_	_	O
135	any	_	_	O
136	bleb	_	_	O
137	,	_	_	O
138	visual	_	_	O
139	acuity	_	_	O
140	with	_	_	O
141	glasses	_	_	O
142	,	_	_	O
143	and	_	_	O
144	full	_	_	O
145	examinations	_	_	O
146	as	_	_	O
147	routine	_	_	O
148	to	_	_	O
149	monitor	_	_	O
150	any	_	_	O
151	progression	_	_	O
152	of	_	_	O
153	the	_	_	O
154	glaucoma	_	_	O
155	.	_	_	O

156	Bleb	_	_	O
157	interventions	_	_	O
158	including	_	_	O
159	needling	_	_	O
160	and	_	_	O
161	antimetabolites	_	_	O
162	were	_	_	O
163	allowed	_	_	O
164	and	_	_	O
165	recorded	_	_	O
166	in	_	_	O
167	both	_	_	O
168	groups	_	_	O
169	.	_	_	O

170	YAG	_	_	O
171	laser	_	_	O
172	goniopuncture	_	_	O
173	was	_	_	O
174	allowed	_	_	O
175	in	_	_	O
176	the	_	_	O
177	viscocanalostomy	_	_	O
178	group	_	_	O
179	.	_	_	O

180	Mean	_	_	O
181	follow-up	_	_	O
182	was	_	_	O
183	40	_	_	O
184	months	_	_	O
185	(	_	_	O
186	SD	_	_	O
187	15	_	_	O
188	)	_	_	O
189	,	_	_	O
190	with	_	_	O
191	a	_	_	O
192	range	_	_	O
193	from	_	_	O
194	6	_	_	O
195	to	_	_	O
196	60	_	_	O
197	months	_	_	O
198	.	_	_	O

199	Forty-two	_	_	B-Premise
200	percent	_	_	I-Premise
201	(	_	_	I-Premise
202	n=10	_	_	I-Premise
203	)	_	_	I-Premise
204	of	_	_	I-Premise
205	the	_	_	I-Premise
206	patients	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	trabeculectomy	_	_	I-Premise
210	group	_	_	I-Premise
211	had	_	_	I-Premise
212	a	_	_	I-Premise
213	successful	_	_	I-Premise
214	outcome	_	_	I-Premise
215	(	_	_	I-Premise
216	IOP	_	_	I-Premise
217	<	_	_	I-Premise
218	18	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	with	_	_	I-Premise
222	no	_	_	I-Premise
223	treatment	_	_	I-Premise
224	)	_	_	I-Premise
225	at	_	_	I-Premise
226	last	_	_	I-Premise
227	follow-up	_	_	I-Premise
228	visit	_	_	I-Premise
229	,	_	_	I-Premise
230	compared	_	_	I-Premise
231	to	_	_	I-Premise
232	21	_	_	I-Premise
233	%	_	_	I-Premise
234	(	_	_	I-Premise
235	n=5	_	_	I-Premise
236	)	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	viscocanalostomy	_	_	I-Premise
240	group	_	_	I-Premise
241	.	_	_	I-Premise

242	IOP	_	_	B-Premise
243	was	_	_	I-Premise
244	lower	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	trab	_	_	I-Premise
248	group	_	_	I-Premise
249	with	_	_	I-Premise
250	differences	_	_	I-Premise
251	in	_	_	I-Premise
252	IOP	_	_	I-Premise
253	being	_	_	I-Premise
254	statistically	_	_	I-Premise
255	significant	_	_	I-Premise
256	at	_	_	I-Premise
257	month	_	_	I-Premise
258	12	_	_	I-Premise
259	(	_	_	I-Premise
260	P=	_	_	I-Premise
261	<	_	_	I-Premise
262	0.001	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	24	_	_	I-Premise
266	(	_	_	I-Premise
267	P=	_	_	I-Premise
268	<	_	_	I-Premise
269	0.001	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	30	_	_	I-Premise
273	(	_	_	I-Premise
274	P=0.030	_	_	I-Premise
275	)	_	_	I-Premise
276	,	_	_	I-Premise
277	36	_	_	I-Premise
278	(	_	_	I-Premise
279	P=	_	_	I-Premise
280	<	_	_	I-Premise
281	0.001	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	and	_	_	I-Premise
285	48	_	_	I-Premise
286	(	_	_	I-Premise
287	P=0.018	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	The	_	_	B-Premise
291	trabeculectomy	_	_	I-Premise
292	group	_	_	I-Premise
293	required	_	_	I-Premise
294	less	_	_	I-Premise
295	postoperative	_	_	I-Premise
296	topical	_	_	I-Premise
297	IOP-lowering	_	_	I-Premise
298	medication	_	_	I-Premise
299	(	_	_	I-Premise
300	P=0.011	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	In	_	_	O
304	this	_	_	O
305	study	_	_	O
306	,	_	_	O
307	we	_	_	B-Claim
308	found	_	_	I-Claim
309	trabeculectomy	_	_	I-Claim
310	to	_	_	I-Claim
311	be	_	_	I-Claim
312	more	_	_	I-Claim
313	effective	_	_	I-Claim
314	at	_	_	I-Claim
315	lowering	_	_	I-Claim
316	IOP	_	_	I-Claim
317	than	_	_	I-Claim
318	viscocanalostomy	_	_	I-Claim
319	in	_	_	I-Claim
320	POAG	_	_	I-Claim
321	patients	_	_	I-Claim
322	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	functional	_	_	O
3	and	_	_	O
4	psychological	_	_	O
5	benefits	_	_	O
6	of	_	_	O
7	a	_	_	O
8	12	_	_	O
9	week	_	_	O
10	supervised	_	_	O
11	group	_	_	O
12	exercise	_	_	O
13	programme	_	_	O
14	during	_	_	O
15	treatment	_	_	O
16	for	_	_	O
17	early	_	_	O
18	stage	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	,	_	_	O
22	with	_	_	O
23	six	_	_	O
24	month	_	_	O
25	follow-up	_	_	O
26	.	_	_	O

27	Pragmatic	_	_	O
28	randomised	_	_	O
29	controlled	_	_	O
30	prospective	_	_	O
31	open	_	_	O
32	trial	_	_	O
33	.	_	_	O

34	Three	_	_	O
35	National	_	_	O
36	Health	_	_	O
37	Service	_	_	O
38	oncology	_	_	O
39	clinics	_	_	O
40	in	_	_	O
41	Scotland	_	_	O
42	and	_	_	O
43	community	_	_	O
44	exercise	_	_	O
45	facilities	_	_	O
46	.	_	_	O

47	203	_	_	O
48	women	_	_	O
49	entered	_	_	O
50	the	_	_	O
51	study	_	_	O
52	;	_	_	O
53	177	_	_	O
54	completed	_	_	O
55	the	_	_	O
56	six	_	_	O
57	month	_	_	O
58	follow-up	_	_	O
59	.	_	_	O

60	Supervised	_	_	O
61	12	_	_	O
62	week	_	_	O
63	group	_	_	O
64	exercise	_	_	O
65	programme	_	_	O
66	in	_	_	O
67	addition	_	_	O
68	to	_	_	O
69	usual	_	_	O
70	care	_	_	O
71	,	_	_	O
72	compared	_	_	O
73	with	_	_	O
74	usual	_	_	O
75	care	_	_	O
76	.	_	_	O

77	Functional	_	_	O
78	assessment	_	_	O
79	of	_	_	O
80	cancer	_	_	O
81	therapy	_	_	O
82	(	_	_	O
83	FACT	_	_	O
84	)	_	_	O
85	questionnaire	_	_	O
86	,	_	_	O
87	Beck	_	_	O
88	depression	_	_	O
89	inventory	_	_	O
90	,	_	_	O
91	positive	_	_	O
92	and	_	_	O
93	negative	_	_	O
94	affect	_	_	O
95	scale	_	_	O
96	,	_	_	O
97	body	_	_	O
98	mass	_	_	O
99	index	_	_	O
100	,	_	_	O
101	seven	_	_	O
102	day	_	_	O
103	recall	_	_	O
104	of	_	_	O
105	physical	_	_	O
106	activity	_	_	O
107	,	_	_	O
108	12	_	_	O
109	minute	_	_	O
110	walk	_	_	O
111	test	_	_	O
112	,	_	_	O
113	and	_	_	O
114	assessment	_	_	O
115	of	_	_	O
116	shoulder	_	_	O
117	mobility	_	_	O
118	.	_	_	O

119	Mixed	_	_	B-Premise
120	effects	_	_	I-Premise
121	models	_	_	I-Premise
122	with	_	_	I-Premise
123	adjustment	_	_	I-Premise
124	for	_	_	I-Premise
125	baseline	_	_	I-Premise
126	values	_	_	I-Premise
127	,	_	_	I-Premise
128	study	_	_	I-Premise
129	site	_	_	I-Premise
130	,	_	_	I-Premise
131	treatment	_	_	I-Premise
132	at	_	_	I-Premise
133	baseline	_	_	I-Premise
134	,	_	_	I-Premise
135	and	_	_	I-Premise
136	age	_	_	I-Premise
137	gave	_	_	I-Premise
138	intervention	_	_	I-Premise
139	effect	_	_	I-Premise
140	estimates	_	_	I-Premise
141	(	_	_	I-Premise
142	intervention	_	_	I-Premise
143	minus	_	_	I-Premise
144	control	_	_	I-Premise
145	)	_	_	I-Premise
146	at	_	_	I-Premise
147	12	_	_	I-Premise
148	weeks	_	_	I-Premise
149	of	_	_	I-Premise
150	129	_	_	I-Premise
151	(	_	_	I-Premise
152	95	_	_	I-Premise
153	%	_	_	I-Premise
154	confidence	_	_	I-Premise
155	interval	_	_	I-Premise
156	83	_	_	I-Premise
157	to	_	_	I-Premise
158	176	_	_	I-Premise
159	)	_	_	I-Premise
160	for	_	_	I-Premise
161	metres	_	_	I-Premise
162	walked	_	_	I-Premise
163	in	_	_	I-Premise
164	12	_	_	I-Premise
165	minutes	_	_	I-Premise
166	,	_	_	I-Premise
167	182	_	_	I-Premise
168	(	_	_	I-Premise
169	75	_	_	I-Premise
170	to	_	_	I-Premise
171	289	_	_	I-Premise
172	)	_	_	I-Premise
173	for	_	_	I-Premise
174	minutes	_	_	I-Premise
175	of	_	_	I-Premise
176	moderate	_	_	I-Premise
177	intensity	_	_	I-Premise
178	activity	_	_	I-Premise
179	reported	_	_	I-Premise
180	in	_	_	I-Premise
181	a	_	_	I-Premise
182	week	_	_	I-Premise
183	,	_	_	I-Premise
184	2.6	_	_	I-Premise
185	(	_	_	I-Premise
186	1.6	_	_	I-Premise
187	to	_	_	I-Premise
188	3.7	_	_	I-Premise
189	)	_	_	I-Premise
190	for	_	_	I-Premise
191	shoulder	_	_	I-Premise
192	mobility	_	_	I-Premise
193	,	_	_	I-Premise
194	2.5	_	_	I-Premise
195	(	_	_	I-Premise
196	1.0	_	_	I-Premise
197	to	_	_	I-Premise
198	3.9	_	_	I-Premise
199	)	_	_	I-Premise
200	for	_	_	I-Premise
201	breast	_	_	I-Premise
202	cancer	_	_	I-Premise
203	specific	_	_	I-Premise
204	subscale	_	_	I-Premise
205	of	_	_	I-Premise
206	quality	_	_	I-Premise
207	of	_	_	I-Premise
208	life	_	_	I-Premise
209	,	_	_	I-Premise
210	and	_	_	I-Premise
211	4.0	_	_	I-Premise
212	(	_	_	I-Premise
213	1.8	_	_	I-Premise
214	to	_	_	I-Premise
215	6.3	_	_	I-Premise
216	)	_	_	I-Premise
217	for	_	_	I-Premise
218	positive	_	_	I-Premise
219	mood	_	_	I-Premise
220	.	_	_	I-Premise

221	No	_	_	B-Premise
222	significant	_	_	I-Premise
223	effect	_	_	I-Premise
224	was	_	_	I-Premise
225	seen	_	_	I-Premise
226	for	_	_	I-Premise
227	general	_	_	I-Premise
228	quality	_	_	I-Premise
229	of	_	_	I-Premise
230	life	_	_	I-Premise
231	(	_	_	I-Premise
232	FACT-G	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	which	_	_	I-Premise
236	was	_	_	I-Premise
237	the	_	_	I-Premise
238	primary	_	_	I-Premise
239	outcome	_	_	I-Premise
240	.	_	_	I-Premise

241	At	_	_	B-Premise
242	the	_	_	I-Premise
243	six	_	_	I-Premise
244	month	_	_	I-Premise
245	follow-up	_	_	I-Premise
246	,	_	_	I-Premise
247	most	_	_	I-Premise
248	of	_	_	I-Premise
249	these	_	_	I-Premise
250	effects	_	_	I-Premise
251	were	_	_	I-Premise
252	maintained	_	_	I-Premise
253	and	_	_	I-Premise
254	an	_	_	I-Premise
255	intervention	_	_	I-Premise
256	effect	_	_	I-Premise
257	for	_	_	I-Premise
258	breast	_	_	I-Premise
259	cancer	_	_	I-Premise
260	specific	_	_	I-Premise
261	quality	_	_	I-Premise
262	of	_	_	I-Premise
263	life	_	_	I-Premise
264	emerged	_	_	I-Premise
265	.	_	_	I-Premise

266	No	_	_	B-Premise
267	adverse	_	_	I-Premise
268	effects	_	_	I-Premise
269	were	_	_	I-Premise
270	noted	_	_	I-Premise
271	.	_	_	I-Premise

272	Supervised	_	_	B-Claim
273	group	_	_	I-Claim
274	exercise	_	_	I-Claim
275	provided	_	_	I-Claim
276	functional	_	_	I-Claim
277	and	_	_	I-Claim
278	psychological	_	_	I-Claim
279	benefit	_	_	I-Claim
280	after	_	_	I-Claim
281	a	_	_	I-Claim
282	12	_	_	I-Claim
283	week	_	_	I-Claim
284	intervention	_	_	I-Claim
285	and	_	_	I-Claim
286	six	_	_	I-Claim
287	months	_	_	I-Claim
288	later	_	_	I-Claim
289	.	_	_	I-Claim

290	Clinicians	_	_	B-Claim
291	should	_	_	I-Claim
292	encourage	_	_	I-Claim
293	activity	_	_	I-Claim
294	for	_	_	I-Claim
295	their	_	_	I-Claim
296	patients	_	_	I-Claim
297	.	_	_	I-Claim

298	Policy	_	_	B-Claim
299	makers	_	_	I-Claim
300	should	_	_	I-Claim
301	consider	_	_	I-Claim
302	the	_	_	I-Claim
303	inclusion	_	_	I-Claim
304	of	_	_	I-Claim
305	exercise	_	_	I-Claim
306	opportunities	_	_	I-Claim
307	in	_	_	I-Claim
308	cancer	_	_	I-Claim
309	rehabilitation	_	_	I-Claim
310	services	_	_	I-Claim
311	.	_	_	I-Claim


0	Previous	_	_	B-Claim
1	trials	_	_	I-Claim
2	have	_	_	I-Claim
3	suggested	_	_	I-Claim
4	a	_	_	I-Claim
5	quality-of-life	_	_	I-Claim
6	(	_	_	I-Claim
7	QOL	_	_	I-Claim
8	)	_	_	I-Claim
9	improvement	_	_	I-Claim
10	for	_	_	I-Claim
11	anemic	_	_	I-Claim
12	cancer	_	_	I-Claim
13	patients	_	_	I-Claim
14	treated	_	_	I-Claim
15	with	_	_	I-Claim
16	erythropoietin	_	_	I-Claim
17	,	_	_	I-Claim
18	but	_	_	I-Claim
19	few	_	_	I-Claim
20	used	_	_	I-Claim
21	QOL	_	_	I-Claim
22	as	_	_	I-Claim
23	the	_	_	I-Claim
24	primary	_	_	I-Claim
25	outcome	_	_	I-Claim
26	.	_	_	I-Claim

27	We	_	_	O
28	designed	_	_	O
29	a	_	_	O
30	trial	_	_	O
31	to	_	_	O
32	investigate	_	_	O
33	the	_	_	O
34	effects	_	_	O
35	of	_	_	O
36	epoetin	_	_	O
37	alfa	_	_	O
38	therapy	_	_	O
39	on	_	_	O
40	the	_	_	O
41	QOL	_	_	O
42	of	_	_	O
43	anemic	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	advanced	_	_	O
47	non-small-cell	_	_	O
48	carcinoma	_	_	O
49	of	_	_	O
50	the	_	_	O
51	lung	_	_	O
52	(	_	_	O
53	NSCLC	_	_	O
54	)	_	_	O
55	.	_	_	O

56	A	_	_	O
57	multicenter	_	_	O
58	,	_	_	O
59	randomized	_	_	O
60	,	_	_	O
61	double-blind	_	_	O
62	,	_	_	O
63	placebo-controlled	_	_	O
64	trial	_	_	O
65	was	_	_	O
66	conducted	_	_	O
67	.	_	_	O

68	The	_	_	O
69	proposed	_	_	O
70	sample	_	_	O
71	size	_	_	O
72	was	_	_	O
73	300	_	_	O
74	patients	_	_	O
75	.	_	_	O

76	Eligible	_	_	O
77	patients	_	_	O
78	were	_	_	O
79	required	_	_	O
80	to	_	_	O
81	have	_	_	O
82	NSCLC	_	_	O
83	unsuitable	_	_	O
84	for	_	_	O
85	curative	_	_	O
86	therapy	_	_	O
87	and	_	_	O
88	baseline	_	_	O
89	hemoglobin	_	_	O
90	(	_	_	O
91	Hgb	_	_	O
92	)	_	_	O
93	levels	_	_	O
94	less	_	_	O
95	than	_	_	O
96	121	_	_	O
97	g/L	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	assigned	_	_	O
102	to	_	_	O
103	12	_	_	O
104	weekly	_	_	O
105	injections	_	_	O
106	of	_	_	O
107	subcutaneous	_	_	O
108	epoetin	_	_	O
109	alpha	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	,	_	_	O
113	targeting	_	_	O
114	Hgb	_	_	O
115	levels	_	_	O
116	between	_	_	O
117	120	_	_	O
118	and	_	_	O
119	140	_	_	O
120	g/L	_	_	O
121	.	_	_	O

122	The	_	_	O
123	primary	_	_	O
124	outcome	_	_	O
125	was	_	_	O
126	the	_	_	O
127	difference	_	_	O
128	in	_	_	O
129	the	_	_	O
130	change	_	_	O
131	in	_	_	O
132	Functional	_	_	O
133	Assessment	_	_	O
134	of	_	_	O
135	Cancer	_	_	O
136	Therapy-Anemia	_	_	O
137	scores	_	_	O
138	between	_	_	O
139	baseline	_	_	O
140	and	_	_	O
141	12	_	_	O
142	weeks	_	_	O
143	.	_	_	O

144	Reports	_	_	O
145	of	_	_	O
146	thrombotic	_	_	O
147	events	_	_	O
148	in	_	_	O
149	other	_	_	O
150	epoetin	_	_	O
151	trials	_	_	O
152	prompted	_	_	O
153	an	_	_	O
154	unplanned	_	_	O
155	safety	_	_	O
156	analysis	_	_	O
157	after	_	_	O
158	70	_	_	O
159	patients	_	_	O
160	had	_	_	O
161	been	_	_	O
162	randomly	_	_	O
163	assigned	_	_	O
164	(	_	_	O
165	33	_	_	O
166	to	_	_	O
167	the	_	_	O
168	active	_	_	O
169	arm	_	_	O
170	and	_	_	O
171	37	_	_	O
172	to	_	_	O
173	the	_	_	O
174	placebo	_	_	O
175	arm	_	_	O
176	)	_	_	O
177	.	_	_	O

178	This	_	_	B-Premise
179	revealed	_	_	I-Premise
180	a	_	_	I-Premise
181	significant	_	_	I-Premise
182	difference	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	median	_	_	I-Premise
186	survival	_	_	I-Premise
187	in	_	_	I-Premise
188	favor	_	_	I-Premise
189	of	_	_	I-Premise
190	the	_	_	I-Premise
191	patients	_	_	I-Premise
192	on	_	_	I-Premise
193	the	_	_	I-Premise
194	placebo	_	_	I-Premise
195	arm	_	_	I-Premise
196	of	_	_	I-Premise
197	the	_	_	I-Premise
198	trial	_	_	I-Premise
199	(	_	_	I-Premise
200	63	_	_	I-Premise
201	v	_	_	I-Premise
202	129	_	_	I-Premise
203	days	_	_	I-Premise
204	;	_	_	I-Premise
205	hazard	_	_	I-Premise
206	ratio	_	_	I-Premise
207	,	_	_	I-Premise
208	1.84	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	.04	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	The	_	_	O
216	Steering	_	_	O
217	Committee	_	_	O
218	closed	_	_	O
219	the	_	_	O
220	trial	_	_	O
221	.	_	_	O

222	Patient	_	_	B-Premise
223	numbers	_	_	I-Premise
224	compromised	_	_	I-Premise
225	the	_	_	I-Premise
226	interpretation	_	_	I-Premise
227	of	_	_	I-Premise
228	the	_	_	I-Premise
229	QOL	_	_	I-Premise
230	analysis	_	_	I-Premise
231	,	_	_	I-Premise
232	but	_	_	O
233	a	_	_	B-Premise
234	positive	_	_	I-Premise
235	Hgb	_	_	I-Premise
236	response	_	_	I-Premise
237	was	_	_	I-Premise
238	noted	_	_	I-Premise
239	with	_	_	I-Premise
240	epoetin	_	_	I-Premise
241	alfa	_	_	I-Premise
242	treatment	_	_	I-Premise
243	.	_	_	I-Premise

244	An	_	_	B-Claim
245	unplanned	_	_	I-Claim
246	safety	_	_	I-Claim
247	analysis	_	_	I-Claim
248	suggested	_	_	I-Claim
249	decreased	_	_	I-Claim
250	overall	_	_	I-Claim
251	survival	_	_	I-Claim
252	in	_	_	I-Claim
253	patients	_	_	I-Claim
254	with	_	_	I-Claim
255	advanced	_	_	I-Claim
256	NSCLC	_	_	I-Claim
257	treated	_	_	I-Claim
258	with	_	_	I-Claim
259	epoetin	_	_	I-Claim
260	alfa	_	_	I-Claim
261	.	_	_	I-Claim

262	Although	_	_	O
263	infrequent	_	_	O
264	,	_	_	O
265	other	_	_	O
266	similar	_	_	O
267	reports	_	_	O
268	highlight	_	_	O
269	the	_	_	O
270	need	_	_	O
271	for	_	_	O
272	ongoing	_	_	O
273	trials	_	_	O
274	evaluating	_	_	O
275	erythropoietin	_	_	O
276	receptor	_	_	O
277	agonists	_	_	O
278	to	_	_	O
279	ensure	_	_	O
280	that	_	_	O
281	overall	_	_	O
282	survival	_	_	O
283	is	_	_	O
284	monitored	_	_	O
285	closely	_	_	O
286	.	_	_	O


0	A	_	_	O
1	randomized	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	previously	_	_	O
5	conducted	_	_	O
6	in	_	_	O
7	radiation	_	_	O
8	oncology	_	_	O
9	patients	_	_	O
10	demonstrated	_	_	O
11	that	_	_	O
12	nutrition	_	_	O
13	intervention	_	_	O
14	had	_	_	O
15	a	_	_	O
16	beneficial	_	_	O
17	impact	_	_	O
18	on	_	_	O
19	body	_	_	O
20	weight	_	_	O
21	,	_	_	O
22	nutritional	_	_	O
23	status	_	_	O
24	,	_	_	O
25	and	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	compared	_	_	O
30	with	_	_	O
31	standard	_	_	O
32	practice	_	_	O
33	,	_	_	O
34	but	_	_	O
35	it	_	_	O
36	did	_	_	O
37	not	_	_	O
38	report	_	_	O
39	on	_	_	O
40	dietary	_	_	O
41	intake	_	_	O
42	data	_	_	O
43	.	_	_	O

44	To	_	_	O
45	determine	_	_	O
46	the	_	_	O
47	impact	_	_	O
48	of	_	_	O
49	nutrition	_	_	O
50	intervention	_	_	O
51	compared	_	_	O
52	with	_	_	O
53	standard	_	_	O
54	practice	_	_	O
55	on	_	_	O
56	dietary	_	_	O
57	intake	_	_	O
58	in	_	_	O
59	outpatients	_	_	O
60	receiving	_	_	O
61	radiotherapy	_	_	O
62	.	_	_	O

63	Prospective	_	_	O
64	,	_	_	O
65	randomized	_	_	O
66	,	_	_	O
67	controlled	_	_	O
68	trial	_	_	O
69	.	_	_	O

70	Sixty	_	_	O
71	consecutive	_	_	O
72	radiation	_	_	O
73	oncology	_	_	O
74	outpatients	_	_	O
75	(	_	_	O
76	51	_	_	O
77	men	_	_	O
78	and	_	_	O
79	nine	_	_	O
80	women	_	_	O
81	;	_	_	O
82	age	_	_	O
83	61.9+/-14	_	_	O
84	years	_	_	O
85	[	_	_	O
86	mean+/-standard	_	_	O
87	deviation	_	_	O
88	]	_	_	O
89	)	_	_	O
90	.	_	_	O

91	Australian	_	_	O
92	private	_	_	O
93	radiotherapy	_	_	O
94	facility	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	either	_	_	O
103	nutrition	_	_	O
104	intervention	_	_	O
105	(	_	_	O
106	n=29	_	_	O
107	)	_	_	O
108	(	_	_	O
109	nutrition	_	_	O
110	counseling	_	_	O
111	following	_	_	O
112	the	_	_	O
113	American	_	_	O
114	Dietetic	_	_	O
115	Association	_	_	O
116	[	_	_	O
117	ADA	_	_	O
118	]	_	_	O
119	medical	_	_	O
120	nutrition	_	_	O
121	therapy	_	_	O
122	[	_	_	O
123	MNT	_	_	O
124	]	_	_	O
125	protocol	_	_	O
126	for	_	_	O
127	radiation	_	_	O
128	oncology	_	_	O
129	)	_	_	O
130	or	_	_	O
131	standard	_	_	O
132	practice	_	_	O
133	(	_	_	O
134	n=31	_	_	O
135	)	_	_	O
136	(	_	_	O
137	general	_	_	O
138	nutrition	_	_	O
139	talk	_	_	O
140	and	_	_	O
141	booklet	_	_	O
142	)	_	_	O
143	.	_	_	O

144	Dietary	_	_	O
145	intake	_	_	O
146	(	_	_	O
147	protein	_	_	O
148	,	_	_	O
149	energy	_	_	O
150	,	_	_	O
151	fiber	_	_	O
152	)	_	_	O
153	assessed	_	_	O
154	at	_	_	O
155	baseline	_	_	O
156	and	_	_	O
157	at	_	_	O
158	4	_	_	O
159	,	_	_	O
160	8	_	_	O
161	,	_	_	O
162	and	_	_	O
163	12	_	_	O
164	weeks	_	_	O
165	after	_	_	O
166	starting	_	_	O
167	radiotherapy	_	_	O
168	.	_	_	O

169	Repeated-measures	_	_	O
170	analysis	_	_	O
171	of	_	_	O
172	variance	_	_	O
173	done	_	_	O
174	on	_	_	O
175	an	_	_	O
176	intention	_	_	O
177	to	_	_	O
178	treat	_	_	O
179	basis	_	_	O
180	.	_	_	O

181	The	_	_	B-Premise
182	nutrition	_	_	I-Premise
183	intervention	_	_	I-Premise
184	group	_	_	I-Premise
185	had	_	_	I-Premise
186	a	_	_	I-Premise
187	higher	_	_	I-Premise
188	mean	_	_	I-Premise
189	total	_	_	I-Premise
190	energy	_	_	I-Premise
191	(	_	_	I-Premise
192	P=0.029	_	_	I-Premise
193	)	_	_	I-Premise
194	and	_	_	I-Premise
195	protein	_	_	I-Premise
196	intake	_	_	I-Premise
197	(	_	_	I-Premise
198	P	_	_	I-Premise
199	<	_	_	I-Premise
200	0.001	_	_	I-Premise
201	)	_	_	I-Premise
202	compared	_	_	I-Premise
203	with	_	_	I-Premise
204	the	_	_	I-Premise
205	standard	_	_	I-Premise
206	practice	_	_	I-Premise
207	group	_	_	I-Premise
208	.	_	_	I-Premise

209	Mean	_	_	B-Premise
210	intake	_	_	I-Premise
211	per	_	_	I-Premise
212	kilogram	_	_	I-Premise
213	of	_	_	I-Premise
214	body	_	_	I-Premise
215	weight	_	_	I-Premise
216	for	_	_	I-Premise
217	the	_	_	I-Premise
218	nutrition	_	_	I-Premise
219	intervention	_	_	I-Premise
220	group	_	_	I-Premise
221	ranged	_	_	I-Premise
222	from	_	_	I-Premise
223	28	_	_	I-Premise
224	to	_	_	I-Premise
225	31	_	_	I-Premise
226	kcal/kg/day	_	_	I-Premise
227	compared	_	_	I-Premise
228	with	_	_	I-Premise
229	25	_	_	I-Premise
230	to	_	_	I-Premise
231	29	_	_	I-Premise
232	kcal/kg/day	_	_	I-Premise
233	for	_	_	I-Premise
234	the	_	_	I-Premise
235	standard	_	_	I-Premise
236	practice	_	_	I-Premise
237	group	_	_	I-Premise
238	(	_	_	I-Premise
239	P=0.022	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	The	_	_	B-Premise
243	nutrition	_	_	I-Premise
244	intervention	_	_	I-Premise
245	group	_	_	I-Premise
246	had	_	_	I-Premise
247	a	_	_	I-Premise
248	higher	_	_	I-Premise
249	mean	_	_	I-Premise
250	protein	_	_	I-Premise
251	intake	_	_	I-Premise
252	(	_	_	I-Premise
253	1.1	_	_	I-Premise
254	to	_	_	I-Premise
255	1.3	_	_	I-Premise
256	g/kg/day	_	_	I-Premise
257	)	_	_	I-Premise
258	compared	_	_	I-Premise
259	with	_	_	I-Premise
260	the	_	_	I-Premise
261	standard	_	_	I-Premise
262	practice	_	_	I-Premise
263	group	_	_	I-Premise
264	(	_	_	I-Premise
265	1.0	_	_	I-Premise
266	to	_	_	I-Premise
267	1.1	_	_	I-Premise
268	g/kg/day	_	_	I-Premise
269	)	_	_	I-Premise
270	(	_	_	I-Premise
271	P=0.001	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Although	_	_	B-Premise
275	the	_	_	I-Premise
276	change	_	_	I-Premise
277	in	_	_	I-Premise
278	fiber	_	_	I-Premise
279	intake	_	_	I-Premise
280	between	_	_	I-Premise
281	the	_	_	I-Premise
282	groups	_	_	I-Premise
283	was	_	_	I-Premise
284	not	_	_	I-Premise
285	significant	_	_	I-Premise
286	,	_	_	I-Premise
287	there	_	_	B-Premise
288	was	_	_	I-Premise
289	a	_	_	I-Premise
290	trend	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	anticipated	_	_	I-Premise
294	direction	_	_	I-Premise
295	(	_	_	I-Premise
296	P=0.083	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Intensive	_	_	B-Claim
300	nutrition	_	_	I-Claim
301	intervention	_	_	I-Claim
302	following	_	_	I-Claim
303	the	_	_	I-Claim
304	ADA	_	_	I-Claim
305	MNT	_	_	I-Claim
306	protocol	_	_	I-Claim
307	results	_	_	I-Claim
308	in	_	_	I-Claim
309	improved	_	_	I-Claim
310	dietary	_	_	I-Claim
311	intake	_	_	I-Claim
312	compared	_	_	I-Claim
313	with	_	_	I-Claim
314	standard	_	_	I-Claim
315	practice	_	_	I-Claim
316	and	_	_	I-Claim
317	seems	_	_	I-Claim
318	to	_	_	I-Claim
319	beneficially	_	_	I-Claim
320	impact	_	_	I-Claim
321	nutrition-related	_	_	I-Claim
322	outcomes	_	_	I-Claim
323	previously	_	_	I-Claim
324	observed	_	_	I-Claim
325	in	_	_	I-Claim
326	oncology	_	_	I-Claim
327	outpatients	_	_	I-Claim
328	receiving	_	_	I-Claim
329	radiotherapy	_	_	I-Claim
330	.	_	_	I-Claim

331	The	_	_	B-Claim
332	ADA	_	_	I-Claim
333	MNT	_	_	I-Claim
334	protocol	_	_	I-Claim
335	for	_	_	I-Claim
336	radiation	_	_	I-Claim
337	oncology	_	_	I-Claim
338	is	_	_	I-Claim
339	a	_	_	I-Claim
340	useful	_	_	I-Claim
341	guide	_	_	I-Claim
342	to	_	_	I-Claim
343	the	_	_	I-Claim
344	level	_	_	I-Claim
345	of	_	_	I-Claim
346	nutrition	_	_	I-Claim
347	support	_	_	I-Claim
348	required	_	_	I-Claim
349	.	_	_	I-Claim


0	Imatinib	_	_	O
1	is	_	_	O
2	the	_	_	O
3	standard	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	advanced	_	_	O
7	GI	_	_	O
8	stromal	_	_	O
9	tumors	_	_	O
10	(	_	_	O
11	GISTs	_	_	O
12	)	_	_	O
13	.	_	_	O

14	It	_	_	B-Claim
15	is	_	_	I-Claim
16	not	_	_	I-Claim
17	known	_	_	I-Claim
18	whether	_	_	I-Claim
19	imatinib	_	_	I-Claim
20	may	_	_	I-Claim
21	be	_	_	I-Claim
22	stopped	_	_	I-Claim
23	in	_	_	I-Claim
24	patients	_	_	I-Claim
25	in	_	_	I-Claim
26	whom	_	_	I-Claim
27	disease	_	_	I-Claim
28	is	_	_	I-Claim
29	controlled	_	_	I-Claim
30	.	_	_	I-Claim

31	This	_	_	O
32	prospective	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	multicentric	_	_	O
37	phase	_	_	O
38	III	_	_	O
39	study	_	_	O
40	was	_	_	O
41	designed	_	_	O
42	to	_	_	O
43	compare	_	_	O
44	continuous	_	_	O
45	(	_	_	O
46	CONT	_	_	O
47	)	_	_	O
48	compared	_	_	O
49	with	_	_	O
50	interrupted	_	_	O
51	(	_	_	O
52	INT	_	_	O
53	)	_	_	O
54	imatinib	_	_	O
55	beyond	_	_	O
56	1	_	_	O
57	year	_	_	O
58	of	_	_	O
59	treatment	_	_	O
60	in	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	advanced	_	_	O
64	GIST	_	_	O
65	.	_	_	O

66	The	_	_	O
67	primary	_	_	O
68	end	_	_	O
69	point	_	_	O
70	was	_	_	O
71	progression-free	_	_	O
72	survival	_	_	O
73	.	_	_	O

74	Secondary	_	_	O
75	end	_	_	O
76	points	_	_	O
77	included	_	_	O
78	overall	_	_	O
79	survival	_	_	O
80	,	_	_	O
81	response	_	_	O
82	rate	_	_	O
83	after	_	_	O
84	reinitiation	_	_	O
85	of	_	_	O
86	imatinib	_	_	O
87	,	_	_	O
88	and	_	_	O
89	quality	_	_	O
90	of	_	_	O
91	life	_	_	O
92	.	_	_	O

93	Early	_	_	O
94	stopping	_	_	O
95	rules	_	_	O
96	in	_	_	O
97	cases	_	_	O
98	of	_	_	O
99	rapid	_	_	O
100	progression	_	_	O
101	of	_	_	O
102	disease	_	_	O
103	were	_	_	O
104	defined	_	_	O
105	,	_	_	O
106	with	_	_	O
107	preplanned	_	_	O
108	interim	_	_	O
109	analyses	_	_	O
110	.	_	_	O

111	Between	_	_	O
112	May	_	_	O
113	2002	_	_	O
114	and	_	_	O
115	April	_	_	O
116	2004	_	_	O
117	,	_	_	O
118	182	_	_	O
119	patients	_	_	O
120	with	_	_	O
121	advanced	_	_	O
122	GIST	_	_	O
123	were	_	_	O
124	enrolled	_	_	O
125	.	_	_	O

126	Between	_	_	O
127	May	_	_	O
128	2003	_	_	O
129	and	_	_	O
130	April	_	_	O
131	2004	_	_	O
132	,	_	_	O
133	98	_	_	O
134	patients	_	_	O
135	in	_	_	O
136	response	_	_	O
137	or	_	_	O
138	stable	_	_	O
139	disease	_	_	O
140	under	_	_	O
141	imatinib	_	_	O
142	reached	_	_	O
143	more	_	_	O
144	than	_	_	O
145	1	_	_	O
146	year	_	_	O
147	of	_	_	O
148	follow-up	_	_	O
149	.	_	_	O

150	Forty	_	_	O
151	were	_	_	O
152	not	_	_	O
153	eligible	_	_	O
154	for	_	_	O
155	randomization	_	_	O
156	,	_	_	O
157	and	_	_	O
158	58	_	_	O
159	patients	_	_	O
160	were	_	_	O
161	randomly	_	_	O
162	assigned	_	_	O
163	,	_	_	O
164	32	_	_	O
165	and	_	_	O
166	26	_	_	O
167	patients	_	_	O
168	in	_	_	O
169	the	_	_	O
170	INT	_	_	O
171	and	_	_	O
172	CONT	_	_	O
173	arms	_	_	O
174	,	_	_	O
175	respectively	_	_	O
176	.	_	_	O

177	As	_	_	B-Premise
178	of	_	_	I-Premise
179	October	_	_	I-Premise
180	15	_	_	I-Premise
181	,	_	_	I-Premise
182	2005	_	_	I-Premise
183	,	_	_	I-Premise
184	eight	_	_	I-Premise
185	of	_	_	I-Premise
186	26	_	_	I-Premise
187	patients	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	CONT	_	_	I-Premise
191	group	_	_	I-Premise
192	and	_	_	I-Premise
193	26	_	_	I-Premise
194	of	_	_	I-Premise
195	32	_	_	I-Premise
196	patients	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	INT	_	_	I-Premise
200	group	_	_	I-Premise
201	had	_	_	I-Premise
202	documented	_	_	I-Premise
203	disease	_	_	I-Premise
204	progression	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.0001	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	Twenty-four	_	_	B-Premise
212	of	_	_	I-Premise
213	26	_	_	I-Premise
214	patients	_	_	I-Premise
215	with	_	_	I-Premise
216	documented	_	_	I-Premise
217	progression	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	INT	_	_	I-Premise
221	arm	_	_	I-Premise
222	responded	_	_	I-Premise
223	to	_	_	I-Premise
224	imatinib	_	_	I-Premise
225	reintroduction	_	_	I-Premise
226	.	_	_	I-Premise

227	No	_	_	B-Premise
228	differences	_	_	I-Premise
229	in	_	_	I-Premise
230	overall	_	_	I-Premise
231	survival	_	_	I-Premise
232	or	_	_	I-Premise
233	imatinib	_	_	I-Premise
234	resistance	_	_	I-Premise
235	were	_	_	I-Premise
236	observed	_	_	I-Premise
237	between	_	_	I-Premise
238	the	_	_	I-Premise
239	two	_	_	I-Premise
240	arms	_	_	I-Premise
241	.	_	_	I-Premise

242	Quality	_	_	B-Premise
243	of	_	_	I-Premise
244	life	_	_	I-Premise
245	evaluated	_	_	I-Premise
246	6	_	_	I-Premise
247	months	_	_	I-Premise
248	after	_	_	I-Premise
249	random	_	_	I-Premise
250	assignment	_	_	I-Premise
251	using	_	_	I-Premise
252	the	_	_	I-Premise
253	30-item	_	_	I-Premise
254	Quality	_	_	I-Premise
255	of	_	_	I-Premise
256	Life	_	_	I-Premise
257	Questionnaire	_	_	I-Premise
258	was	_	_	I-Premise
259	not	_	_	I-Premise
260	significantly	_	_	I-Premise
261	different	_	_	I-Premise
262	between	_	_	I-Premise
263	the	_	_	I-Premise
264	two	_	_	I-Premise
265	groups	_	_	I-Premise
266	of	_	_	I-Premise
267	randomly	_	_	I-Premise
268	assigned	_	_	I-Premise
269	patients	_	_	I-Premise
270	.	_	_	I-Premise

271	Imatinib	_	_	B-Claim
272	interruption	_	_	I-Claim
273	results	_	_	I-Claim
274	in	_	_	I-Claim
275	rapid	_	_	I-Claim
276	progression	_	_	I-Claim
277	in	_	_	I-Claim
278	most	_	_	I-Claim
279	patients	_	_	I-Claim
280	with	_	_	I-Claim
281	advanced	_	_	I-Claim
282	GIST	_	_	I-Claim
283	,	_	_	I-Claim
284	and	_	_	I-Claim
285	can	_	_	I-Claim
286	not	_	_	I-Claim
287	be	_	_	I-Claim
288	recommended	_	_	I-Claim
289	in	_	_	I-Claim
290	routine	_	_	I-Claim
291	practice	_	_	I-Claim
292	unless	_	_	I-Claim
293	patient	_	_	I-Claim
294	experience	_	_	I-Claim
295	significant	_	_	I-Claim
296	toxicity	_	_	I-Claim
297	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	effect	_	_	O
10	of	_	_	O
11	combined	_	_	O
12	viscocanalostomy	_	_	O
13	and	_	_	O
14	phacoemulsification	_	_	O
15	and	_	_	O
16	combined	_	_	O
17	trabeculectomy	_	_	O
18	and	_	_	O
19	phacoemulsification	_	_	O
20	with	_	_	O
21	mitomycin	_	_	O
22	C	_	_	O
23	in	_	_	O
24	eyes	_	_	O
25	with	_	_	O
26	primary	_	_	O
27	open-angle	_	_	O
28	glaucoma	_	_	O
29	.	_	_	O

30	Prospective	_	_	O
31	randomized	_	_	O
32	1-year	_	_	O
33	trial	_	_	O
34	.	_	_	O

35	Forty	_	_	O
36	consecutive	_	_	O
37	patients	_	_	O
38	(	_	_	O
39	40	_	_	O
40	eyes	_	_	O
41	)	_	_	O
42	with	_	_	O
43	primary	_	_	O
44	open-angle	_	_	O
45	glaucoma	_	_	O
46	and	_	_	O
47	cataract	_	_	O
48	.	_	_	O

49	Eyes	_	_	O
50	were	_	_	O
51	assigned	_	_	O
52	randomly	_	_	O
53	either	_	_	O
54	to	_	_	O
55	trabeculectomy	_	_	O
56	with	_	_	O
57	mitomycin	_	_	O
58	C	_	_	O
59	or	_	_	O
60	to	_	_	O
61	viscocanalostomy	_	_	O
62	in	_	_	O
63	combination	_	_	O
64	with	_	_	O
65	phacoemulsification	_	_	O
66	and	_	_	O
67	intraocular	_	_	O
68	lens	_	_	O
69	implantation	_	_	O
70	.	_	_	O

71	Success	_	_	O
72	rate	_	_	O
73	based	_	_	O
74	on	_	_	O
75	IOP	_	_	O
76	.	_	_	O

77	Mean	_	_	B-Premise
78	baseline	_	_	I-Premise
79	IOP	_	_	I-Premise
80	was	_	_	I-Premise
81	24.0+/-2.0	_	_	I-Premise
82	mmHg	_	_	I-Premise
83	in	_	_	I-Premise
84	the	_	_	I-Premise
85	viscocanalostomy	_	_	I-Premise
86	group	_	_	I-Premise
87	and	_	_	I-Premise
88	23.7+/-2.6	_	_	I-Premise
89	mmHg	_	_	I-Premise
90	in	_	_	I-Premise
91	the	_	_	I-Premise
92	trabeculectomy	_	_	I-Premise
93	group	_	_	I-Premise
94	(	_	_	I-Premise
95	P	_	_	I-Premise
96	=	_	_	I-Premise
97	0.7	_	_	I-Premise
98	)	_	_	I-Premise
99	.	_	_	I-Premise

100	Mean	_	_	I-Premise
101	postoperative	_	_	I-Premise
102	IOP	_	_	I-Premise
103	was	_	_	I-Premise
104	13.7+/-2.2	_	_	I-Premise
105	mmHg	_	_	I-Premise
106	at	_	_	I-Premise
107	3	_	_	I-Premise
108	months	_	_	I-Premise
109	,	_	_	I-Premise
110	14.8+/-3.3	_	_	I-Premise
111	mmHg	_	_	I-Premise
112	at	_	_	I-Premise
113	6	_	_	I-Premise
114	months	_	_	I-Premise
115	,	_	_	I-Premise
116	and	_	_	I-Premise
117	14.9+/-3.0	_	_	I-Premise
118	mmHg	_	_	I-Premise
119	at	_	_	I-Premise
120	12	_	_	I-Premise
121	months	_	_	I-Premise
122	in	_	_	I-Premise
123	the	_	_	I-Premise
124	viscocanalostomy	_	_	I-Premise
125	group	_	_	I-Premise
126	and	_	_	I-Premise
127	12.1+/-4.0	_	_	I-Premise
128	mmHg	_	_	I-Premise
129	at	_	_	I-Premise
130	3	_	_	I-Premise
131	months	_	_	I-Premise
132	,	_	_	I-Premise
133	13.8+/-4.7	_	_	I-Premise
134	mmHg	_	_	I-Premise
135	at	_	_	I-Premise
136	6	_	_	I-Premise
137	months	_	_	I-Premise
138	,	_	_	I-Premise
139	and	_	_	I-Premise
140	14.1+/-4.4	_	_	I-Premise
141	mmHg	_	_	I-Premise
142	at	_	_	I-Premise
143	12	_	_	I-Premise
144	months	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	trabeculectomy	_	_	I-Premise
148	group	_	_	I-Premise
149	.	_	_	I-Premise

150	There	_	_	O
151	was	_	_	O
152	no	_	_	O
153	significant	_	_	O
154	difference	_	_	O
155	in	_	_	O
156	the	_	_	O
157	mean	_	_	O
158	IOP	_	_	O
159	between	_	_	O
160	the	_	_	O
161	groups	_	_	O
162	at	_	_	O
163	any	_	_	O
164	time	_	_	O
165	.	_	_	O

166	At	_	_	B-Premise
167	12	_	_	I-Premise
168	months	_	_	I-Premise
169	,	_	_	I-Premise
170	17	_	_	I-Premise
171	patients	_	_	I-Premise
172	(	_	_	I-Premise
173	85	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	viscocanalostomy	_	_	I-Premise
179	group	_	_	I-Premise
180	and	_	_	I-Premise
181	16	_	_	I-Premise
182	patients	_	_	I-Premise
183	(	_	_	I-Premise
184	80	_	_	I-Premise
185	%	_	_	I-Premise
186	)	_	_	I-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	trabeculectomy	_	_	I-Premise
190	group	_	_	I-Premise
191	achieved	_	_	I-Premise
192	an	_	_	I-Premise
193	IOP	_	_	I-Premise
194	of	_	_	I-Premise
195	20	_	_	I-Premise
196	mmHg	_	_	I-Premise
197	or	_	_	I-Premise
198	less	_	_	I-Premise
199	without	_	_	I-Premise
200	medication	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	0.7	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Complications	_	_	O
208	included	_	_	O
209	2	_	_	O
210	cases	_	_	O
211	(	_	_	O
212	10	_	_	O
213	%	_	_	O
214	)	_	_	O
215	of	_	_	O
216	flat/shallow	_	_	O
217	anterior	_	_	O
218	chamber	_	_	O
219	and	_	_	O
220	4	_	_	O
221	cases	_	_	O
222	(	_	_	O
223	20	_	_	O
224	%	_	_	O
225	)	_	_	O
226	of	_	_	O
227	hypotony	_	_	O
228	in	_	_	O
229	the	_	_	O
230	trabeculectomy	_	_	O
231	group	_	_	O
232	,	_	_	O
233	whereas	_	_	O
234	intraoperative	_	_	O
235	microperforation	_	_	O
236	of	_	_	O
237	Descemet	_	_	O
238	's	_	_	O
239	membrane	_	_	O
240	occurred	_	_	O
241	in	_	_	O
242	3	_	_	O
243	cases	_	_	O
244	(	_	_	O
245	15	_	_	O
246	%	_	_	O
247	)	_	_	O
248	in	_	_	O
249	the	_	_	O
250	viscocanalostomy	_	_	O
251	group	_	_	O
252	.	_	_	O

253	There	_	_	B-Claim
254	was	_	_	I-Claim
255	no	_	_	I-Claim
256	significant	_	_	I-Claim
257	difference	_	_	I-Claim
258	in	_	_	I-Claim
259	IOP	_	_	I-Claim
260	reduction	_	_	I-Claim
261	between	_	_	I-Claim
262	viscocanalostomy	_	_	I-Claim
263	and	_	_	I-Claim
264	trabeculectomy	_	_	I-Claim
265	with	_	_	I-Claim
266	mitomycin	_	_	I-Claim
267	C	_	_	I-Claim
268	in	_	_	I-Claim
269	combination	_	_	I-Claim
270	with	_	_	I-Claim
271	phacoemulsification	_	_	I-Claim
272	and	_	_	I-Claim
273	intraocular	_	_	I-Claim
274	lens	_	_	I-Claim
275	implantation	_	_	I-Claim
276	in	_	_	I-Claim
277	patients	_	_	I-Claim
278	with	_	_	I-Claim
279	primary	_	_	I-Claim
280	open-angle	_	_	I-Claim
281	glaucoma	_	_	I-Claim
282	.	_	_	I-Claim


0	Psychological	_	_	B-Claim
1	interventions	_	_	I-Claim
2	are	_	_	I-Claim
3	efficacious	_	_	I-Claim
4	in	_	_	I-Claim
5	reducing	_	_	I-Claim
6	emotional	_	_	I-Claim
7	distress	_	_	I-Claim
8	for	_	_	I-Claim
9	cancer	_	_	I-Claim
10	patients	_	_	I-Claim
11	.	_	_	I-Claim

12	However	_	_	B-Claim
13	,	_	_	I-Claim
14	it	_	_	I-Claim
15	is	_	_	I-Claim
16	not	_	_	I-Claim
17	clear	_	_	I-Claim
18	whether	_	_	I-Claim
19	psychological	_	_	I-Claim
20	improvements	_	_	I-Claim
21	are	_	_	I-Claim
22	,	_	_	I-Claim
23	in	_	_	I-Claim
24	turn	_	_	I-Claim
25	,	_	_	I-Claim
26	related	_	_	I-Claim
27	to	_	_	I-Claim
28	improved	_	_	I-Claim
29	health	_	_	I-Claim
30	.	_	_	I-Claim

31	A	_	_	O
32	clinical	_	_	O
33	trial	_	_	O
34	tests	_	_	O
35	whether	_	_	O
36	a	_	_	O
37	psychological	_	_	O
38	intervention	_	_	O
39	for	_	_	O
40	cancer	_	_	O
41	patients	_	_	O
42	can	_	_	O
43	do	_	_	O
44	so	_	_	O
45	,	_	_	O
46	and	_	_	O
47	also	_	_	O
48	tests	_	_	O
49	two	_	_	O
50	routes	_	_	O
51	to	_	_	O
52	achieve	_	_	O
53	better	_	_	O
54	health	_	_	O
55	:	_	_	O
56	(	_	_	O
57	a	_	_	O
58	)	_	_	O
59	reducing	_	_	O
60	patients	_	_	O
61	'	_	_	O
62	Emotional	_	_	O
63	Distress	_	_	O
64	,	_	_	O
65	and/or	_	_	O
66	(	_	_	O
67	b	_	_	O
68	)	_	_	O
69	enhancing	_	_	O
70	their	_	_	O
71	functional	_	_	O
72	immunity	_	_	O
73	.	_	_	O

74	Post-surgery	_	_	O
75	,	_	_	O
76	227	_	_	O
77	breast	_	_	O
78	cancer	_	_	O
79	patients	_	_	O
80	were	_	_	O
81	randomized	_	_	O
82	to	_	_	O
83	intervention	_	_	O
84	or	_	_	O
85	assessment	_	_	O
86	only	_	_	O
87	Study	_	_	O
88	Arms	_	_	O
89	.	_	_	O

90	Conducted	_	_	O
91	in	_	_	O
92	small	_	_	O
93	groups	_	_	O
94	,	_	_	O
95	intervention	_	_	O
96	sessions	_	_	O
97	were	_	_	O
98	offered	_	_	O
99	weekly	_	_	O
100	for	_	_	O
101	4	_	_	O
102	months	_	_	O
103	and	_	_	O
104	followed	_	_	O
105	by	_	_	O
106	monthly	_	_	O
107	sessions	_	_	O
108	for	_	_	O
109	8	_	_	O
110	months	_	_	O
111	.	_	_	O

112	Measures	_	_	O
113	included	_	_	O
114	psychological	_	_	O
115	(	_	_	O
116	distress	_	_	O
117	)	_	_	O
118	,	_	_	O
119	biological	_	_	O
120	(	_	_	O
121	immune	_	_	O
122	)	_	_	O
123	,	_	_	O
124	and	_	_	O
125	health	_	_	O
126	outcomes	_	_	O
127	(	_	_	O
128	performance	_	_	O
129	status	_	_	O
130	and	_	_	O
131	evaluations	_	_	O
132	of	_	_	O
133	patient	_	_	O
134	's	_	_	O
135	symptomatology	_	_	O
136	,	_	_	O
137	including	_	_	O
138	toxicity	_	_	O
139	from	_	_	O
140	cancer	_	_	O
141	treatment	_	_	O
142	,	_	_	O
143	lab	_	_	O
144	values	_	_	O
145	)	_	_	O
146	collected	_	_	O
147	at	_	_	O
148	baseline	_	_	O
149	,	_	_	O
150	4	_	_	O
151	months	_	_	O
152	,	_	_	O
153	and	_	_	O
154	12	_	_	O
155	months	_	_	O
156	.	_	_	O

157	A	_	_	B-Premise
158	path	_	_	I-Premise
159	model	_	_	I-Premise
160	revealed	_	_	I-Premise
161	that	_	_	I-Premise
162	intervention	_	_	I-Premise
163	participation	_	_	I-Premise
164	directly	_	_	I-Premise
165	improved	_	_	I-Premise
166	health	_	_	I-Premise
167	(	_	_	I-Premise
168	p	_	_	I-Premise
169	<	_	_	I-Premise
170	.05	_	_	I-Premise
171	)	_	_	I-Premise
172	at	_	_	I-Premise
173	12	_	_	I-Premise
174	months	_	_	I-Premise
175	.	_	_	I-Premise

176	These	_	_	B-Premise
177	effects	_	_	I-Premise
178	remained	_	_	I-Premise
179	when	_	_	I-Premise
180	statistically	_	_	I-Premise
181	controlling	_	_	I-Premise
182	for	_	_	I-Premise
183	baseline	_	_	I-Premise
184	levels	_	_	I-Premise
185	of	_	_	I-Premise
186	distress	_	_	I-Premise
187	,	_	_	I-Premise
188	immunity	_	_	I-Premise
189	,	_	_	I-Premise
190	and	_	_	I-Premise
191	health	_	_	I-Premise
192	as	_	_	I-Premise
193	well	_	_	I-Premise
194	as	_	_	I-Premise
195	sociodemographic	_	_	I-Premise
196	,	_	_	I-Premise
197	disease	_	_	I-Premise
198	,	_	_	I-Premise
199	and	_	_	I-Premise
200	cancer	_	_	I-Premise
201	treatment	_	_	I-Premise
202	variables	_	_	I-Premise
203	.	_	_	I-Premise

204	Regarding	_	_	B-Premise
205	the	_	_	I-Premise
206	mechanisms	_	_	I-Premise
207	for	_	_	I-Premise
208	achieving	_	_	I-Premise
209	better	_	_	I-Premise
210	health	_	_	I-Premise
211	,	_	_	I-Premise
212	support	_	_	I-Premise
213	was	_	_	I-Premise
214	found	_	_	I-Premise
215	for	_	_	I-Premise
216	an	_	_	I-Premise
217	indirect	_	_	I-Premise
218	effect	_	_	I-Premise
219	of	_	_	I-Premise
220	distress	_	_	I-Premise
221	reduction	_	_	I-Premise
222	.	_	_	I-Premise

223	That	_	_	B-Premise
224	is	_	_	I-Premise
225	,	_	_	I-Premise
226	by	_	_	I-Premise
227	specifically	_	_	I-Premise
228	lowering	_	_	I-Premise
229	intervention	_	_	I-Premise
230	patients	_	_	I-Premise
231	'	_	_	I-Premise
232	distress	_	_	I-Premise
233	at	_	_	I-Premise
234	4	_	_	I-Premise
235	months	_	_	I-Premise
236	,	_	_	I-Premise
237	their	_	_	I-Premise
238	health	_	_	I-Premise
239	was	_	_	I-Premise
240	improved	_	_	I-Premise
241	at	_	_	I-Premise
242	12	_	_	I-Premise
243	months	_	_	I-Premise
244	(	_	_	I-Premise
245	p	_	_	I-Premise
246	<	_	_	I-Premise
247	.05	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	Although	_	_	B-Premise
251	the	_	_	I-Premise
252	intervention	_	_	I-Premise
253	simultaneously	_	_	I-Premise
254	improved	_	_	I-Premise
255	patients	_	_	I-Premise
256	'	_	_	I-Premise
257	T-cell	_	_	I-Premise
258	blastogenesis	_	_	I-Premise
259	in	_	_	I-Premise
260	response	_	_	I-Premise
261	to	_	_	I-Premise
262	phytohemagglutinin	_	_	I-Premise
263	(	_	_	I-Premise
264	PHA	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	the	_	_	B-Premise
268	latter	_	_	I-Premise
269	increases	_	_	I-Premise
270	were	_	_	I-Premise
271	unrelated	_	_	I-Premise
272	to	_	_	I-Premise
273	improved	_	_	I-Premise
274	health	_	_	I-Premise
275	.	_	_	I-Premise

276	A	_	_	B-Premise
277	convergence	_	_	I-Premise
278	of	_	_	I-Premise
279	biobehavioral	_	_	I-Premise
280	effects	_	_	I-Premise
281	and	_	_	I-Premise
282	health	_	_	I-Premise
283	improvements	_	_	I-Premise
284	were	_	_	I-Premise
285	observed	_	_	I-Premise
286	.	_	_	I-Premise

287	Behavioral	_	_	B-Claim
288	change	_	_	I-Claim
289	,	_	_	I-Claim
290	rather	_	_	I-Claim
291	than	_	_	I-Claim
292	immunity	_	_	I-Claim
293	change	_	_	I-Claim
294	,	_	_	I-Claim
295	was	_	_	I-Claim
296	influential	_	_	I-Claim
297	in	_	_	I-Claim
298	achieving	_	_	I-Claim
299	lower	_	_	I-Claim
300	levels	_	_	I-Claim
301	of	_	_	I-Claim
302	symptomatology	_	_	I-Claim
303	and	_	_	I-Claim
304	higher	_	_	I-Claim
305	functional	_	_	I-Claim
306	status	_	_	I-Claim
307	.	_	_	I-Claim

308	Distress	_	_	B-Claim
309	reduction	_	_	I-Claim
310	is	_	_	I-Claim
311	highlighted	_	_	I-Claim
312	as	_	_	I-Claim
313	an	_	_	I-Claim
314	important	_	_	I-Claim
315	mechanism	_	_	I-Claim
316	by	_	_	I-Claim
317	which	_	_	I-Claim
318	health	_	_	I-Claim
319	can	_	_	I-Claim
320	be	_	_	I-Claim
321	improved	_	_	I-Claim
322	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	ocular	_	_	O
4	hypotensive	_	_	O
5	activity	_	_	O
6	and	_	_	O
7	safety	_	_	O
8	profile	_	_	O
9	of	_	_	O
10	long-acting	_	_	O
11	1	_	_	O
12	%	_	_	O
13	carteolol	_	_	O
14	hydrochloride	_	_	O
15	eye	_	_	O
16	drops	_	_	O
17	(	_	_	O
18	long-acting	_	_	O
19	formulation	_	_	O
20	)	_	_	O
21	to	_	_	O
22	those	_	_	O
23	of	_	_	O
24	1	_	_	O
25	%	_	_	O
26	carteolol	_	_	O
27	hydrochloride	_	_	O
28	eye	_	_	O
29	drops	_	_	O
30	(	_	_	O
31	currently	_	_	O
32	prescribed	_	_	O
33	drug	_	_	O
34	)	_	_	O
35	for	_	_	O
36	reduction	_	_	O
37	of	_	_	O
38	intraocular	_	_	O
39	pressure	_	_	O
40	.	_	_	O

41	Patients	_	_	O
42	with	_	_	O
43	primary	_	_	O
44	open-angle	_	_	O
45	glaucoma	_	_	O
46	or	_	_	O
47	ocular	_	_	O
48	hypertension	_	_	O
49	(	_	_	O
50	146	_	_	O
51	cases	_	_	O
52	)	_	_	O
53	were	_	_	O
54	assigned	_	_	O
55	randomly	_	_	O
56	to	_	_	O
57	the	_	_	O
58	long-acting	_	_	O
59	drug	_	_	O
60	group	_	_	O
61	(	_	_	O
62	74	_	_	O
63	cases	_	_	O
64	)	_	_	O
65	and	_	_	O
66	the	_	_	O
67	currently-prescribed	_	_	O
68	drug	_	_	O
69	group	_	_	O
70	(	_	_	O
71	72	_	_	O
72	cases	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Long-acting	_	_	O
76	eye	_	_	O
77	drops	_	_	O
78	were	_	_	O
79	instilled	_	_	O
80	once	_	_	O
81	a	_	_	O
82	day	_	_	O
83	in	_	_	O
84	the	_	_	O
85	morning	_	_	O
86	(	_	_	O
87	along	_	_	O
88	with	_	_	O
89	one	_	_	O
90	drop	_	_	O
91	of	_	_	O
92	placebo	_	_	O
93	at	_	_	O
94	night	_	_	O
95	)	_	_	O
96	,	_	_	O
97	and	_	_	O
98	currently-prescribed	_	_	O
99	eye	_	_	O
100	drops	_	_	O
101	were	_	_	O
102	instilled	_	_	O
103	twice	_	_	O
104	a	_	_	O
105	day	_	_	O
106	in	_	_	O
107	the	_	_	O
108	morning	_	_	O
109	and	_	_	O
110	at	_	_	O
111	night	_	_	O
112	.	_	_	O

113	Eye	_	_	O
114	drops	_	_	O
115	were	_	_	O
116	administered	_	_	O
117	for	_	_	O
118	8	_	_	O
119	weeks	_	_	O
120	.	_	_	O

121	Intraocular	_	_	O
122	pressure	_	_	O
123	was	_	_	O
124	monitored	_	_	O
125	at	_	_	O
126	2	_	_	O
127	,	_	_	O
128	4	_	_	O
129	,	_	_	O
130	and	_	_	O
131	8	_	_	O
132	weeks	_	_	O
133	after	_	_	O
134	the	_	_	O
135	initiation	_	_	O
136	of	_	_	O
137	drug	_	_	O
138	instillation	_	_	O
139	for	_	_	O
140	evaluation	_	_	O
141	of	_	_	O
142	equivalence	_	_	O
143	.	_	_	O

144	Intraocular	_	_	B-Premise
145	pressure	_	_	I-Premise
146	was	_	_	I-Premise
147	significantly	_	_	I-Premise
148	reduced	_	_	I-Premise
149	during	_	_	I-Premise
150	the	_	_	I-Premise
151	entire	_	_	I-Premise
152	follow-up	_	_	I-Premise
153	period	_	_	I-Premise
154	in	_	_	I-Premise
155	both	_	_	I-Premise
156	groups	_	_	I-Premise
157	.	_	_	I-Premise

158	In	_	_	B-Premise
159	the	_	_	I-Premise
160	long-acting	_	_	I-Premise
161	drug	_	_	I-Premise
162	group	_	_	I-Premise
163	,	_	_	I-Premise
164	the	_	_	I-Premise
165	reduction	_	_	I-Premise
166	of	_	_	I-Premise
167	intraocular	_	_	I-Premise
168	pressure	_	_	I-Premise
169	was	_	_	I-Premise
170	-3.5	_	_	I-Premise
171	+/-	_	_	I-Premise
172	0.2	_	_	I-Premise
173	,	_	_	I-Premise
174	-4.3	_	_	I-Premise
175	+/-	_	_	I-Premise
176	0.2	_	_	I-Premise
177	and	_	_	I-Premise
178	-4.6	_	_	I-Premise
179	+/-	_	_	I-Premise
180	0.3	_	_	I-Premise
181	mmHg	_	_	I-Premise
182	at	_	_	I-Premise
183	2	_	_	I-Premise
184	,	_	_	I-Premise
185	4	_	_	I-Premise
186	,	_	_	I-Premise
187	and	_	_	I-Premise
188	8	_	_	I-Premise
189	weeks	_	_	I-Premise
190	,	_	_	I-Premise
191	respectively	_	_	I-Premise
192	(	_	_	I-Premise
193	paired	_	_	I-Premise
194	t	_	_	I-Premise
195	test	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	In	_	_	B-Premise
199	the	_	_	I-Premise
200	currently-prescribed	_	_	I-Premise
201	drug	_	_	I-Premise
202	group	_	_	I-Premise
203	,	_	_	I-Premise
204	the	_	_	I-Premise
205	reduction	_	_	I-Premise
206	of	_	_	I-Premise
207	intraocular	_	_	I-Premise
208	pressure	_	_	I-Premise
209	was	_	_	I-Premise
210	-4.1	_	_	I-Premise
211	+/-	_	_	I-Premise
212	0.2	_	_	I-Premise
213	,	_	_	I-Premise
214	-4.4	_	_	I-Premise
215	+/-	_	_	I-Premise
216	0.3	_	_	I-Premise
217	and	_	_	I-Premise
218	--	_	_	I-Premise
219	4.6	_	_	I-Premise
220	+/-	_	_	I-Premise
221	0.2	_	_	I-Premise
222	mmHg	_	_	I-Premise
223	at	_	_	I-Premise
224	2	_	_	I-Premise
225	,	_	_	I-Premise
226	4	_	_	I-Premise
227	,	_	_	I-Premise
228	and	_	_	I-Premise
229	8	_	_	I-Premise
230	weeks	_	_	I-Premise
231	(	_	_	I-Premise
232	paired	_	_	I-Premise
233	t	_	_	I-Premise
234	test	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	The	_	_	B-Claim
238	safety	_	_	I-Claim
239	profile	_	_	I-Claim
240	was	_	_	I-Claim
241	similar	_	_	I-Claim
242	in	_	_	I-Claim
243	both	_	_	I-Claim
244	groups	_	_	I-Claim
245	,	_	_	I-Claim
246	and	_	_	I-Claim
247	the	_	_	I-Claim
248	tolerance	_	_	I-Claim
249	for	_	_	I-Claim
250	the	_	_	I-Claim
251	long-acting	_	_	I-Claim
252	eye	_	_	I-Claim
253	drops	_	_	I-Claim
254	was	_	_	I-Claim
255	as	_	_	I-Claim
256	good	_	_	I-Claim
257	as	_	_	I-Claim
258	for	_	_	I-Claim
259	the	_	_	I-Claim
260	currently-prescribed	_	_	I-Claim
261	eye	_	_	I-Claim
262	drops	_	_	I-Claim
263	.	_	_	I-Claim

264	Because	_	_	B-Claim
265	the	_	_	I-Claim
266	efficacy	_	_	I-Claim
267	of	_	_	I-Claim
268	both	_	_	I-Claim
269	drugs	_	_	I-Claim
270	was	_	_	I-Claim
271	equivalent	_	_	I-Claim
272	,	_	_	I-Claim
273	with	_	_	I-Claim
274	an	_	_	I-Claim
275	identical	_	_	I-Claim
276	safety	_	_	I-Claim
277	profile	_	_	I-Claim
278	,	_	_	I-Claim
279	the	_	_	B-Claim
280	long-acting	_	_	I-Claim
281	eye	_	_	I-Claim
282	drops	_	_	I-Claim
283	seem	_	_	I-Claim
284	to	_	_	I-Claim
285	be	_	_	I-Claim
286	an	_	_	I-Claim
287	efficacious	_	_	I-Claim
288	formulation	_	_	I-Claim
289	for	_	_	I-Claim
290	clinical	_	_	I-Claim
291	use	_	_	I-Claim
292	in	_	_	I-Claim
293	Japanese	_	_	I-Claim
294	glaucoma	_	_	I-Claim
295	patients	_	_	I-Claim
296	.	_	_	I-Claim


0	For	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	advanced	_	_	I-Claim
4	gastric	_	_	I-Claim
5	or	_	_	I-Claim
6	gastroesophageal	_	_	I-Claim
7	cancer	_	_	I-Claim
8	(	_	_	I-Claim
9	AGGEC	_	_	I-Claim
10	)	_	_	I-Claim
11	providing	_	_	I-Claim
12	clinical	_	_	I-Claim
13	benefit	_	_	I-Claim
14	with	_	_	I-Claim
15	improved	_	_	I-Claim
16	palliation	_	_	I-Claim
17	is	_	_	I-Claim
18	highly	_	_	I-Claim
19	desirable	_	_	I-Claim
20	.	_	_	I-Claim

21	However	_	_	O
22	,	_	_	O
23	a	_	_	O
24	prospective	_	_	O
25	evaluation	_	_	O
26	of	_	_	O
27	clinical	_	_	O
28	benefit	_	_	O
29	in	_	_	O
30	AGGEC	_	_	O
31	patients	_	_	O
32	has	_	_	O
33	never	_	_	O
34	before	_	_	O
35	been	_	_	O
36	reported	_	_	O
37	in	_	_	O
38	a	_	_	O
39	phase	_	_	O
40	III	_	_	O
41	setting	_	_	O
42	.	_	_	O

43	In	_	_	O
44	a	_	_	O
45	multinational	_	_	O
46	trial	_	_	O
47	(	_	_	O
48	V325	_	_	O
49	)	_	_	O
50	,	_	_	O
51	445	_	_	O
52	patients	_	_	O
53	were	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	and	_	_	O
57	treated	_	_	O
58	with	_	_	O
59	either	_	_	O
60	docetaxel	_	_	O
61	plus	_	_	O
62	cisplatin	_	_	O
63	and	_	_	O
64	fluorouracil	_	_	O
65	(	_	_	O
66	DCF	_	_	O
67	)	_	_	O
68	or	_	_	O
69	cisplatin	_	_	O
70	and	_	_	O
71	fluorouracil	_	_	O
72	(	_	_	O
73	CF	_	_	O
74	)	_	_	O
75	.	_	_	O

76	Clinical	_	_	O
77	benefit	_	_	O
78	was	_	_	O
79	prospectively	_	_	O
80	evaluated	_	_	O
81	in	_	_	O
82	this	_	_	O
83	trial	_	_	O
84	as	_	_	O
85	a	_	_	O
86	secondary	_	_	O
87	end	_	_	O
88	point	_	_	O
89	.	_	_	O

90	The	_	_	O
91	primary	_	_	O
92	measure	_	_	O
93	for	_	_	O
94	clinical	_	_	O
95	benefit	_	_	O
96	analysis	_	_	O
97	was	_	_	O
98	time	_	_	O
99	to	_	_	O
100	definitive	_	_	O
101	worsening	_	_	O
102	by	_	_	O
103	one	_	_	O
104	or	_	_	O
105	more	_	_	O
106	categories	_	_	O
107	of	_	_	O
108	Karnofsky	_	_	O
109	performance	_	_	O
110	status	_	_	O
111	(	_	_	O
112	KPS	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Secondary	_	_	O
116	clinical	_	_	O
117	benefit	_	_	O
118	end	_	_	O
119	points	_	_	O
120	included	_	_	O
121	time	_	_	O
122	to	_	_	O
123	5	_	_	O
124	%	_	_	O
125	definitive	_	_	O
126	weight	_	_	O
127	loss	_	_	O
128	,	_	_	O
129	time	_	_	O
130	to	_	_	O
131	definitive	_	_	O
132	worsening	_	_	O
133	of	_	_	O
134	appetite	_	_	O
135	by	_	_	O
136	one	_	_	O
137	grade	_	_	O
138	,	_	_	O
139	pain-free	_	_	O
140	survival	_	_	O
141	(	_	_	O
142	defined	_	_	O
143	as	_	_	O
144	time	_	_	O
145	to	_	_	O
146	first	_	_	O
147	appearance	_	_	O
148	of	_	_	O
149	pain	_	_	O
150	)	_	_	O
151	,	_	_	O
152	and	_	_	O
153	time	_	_	O
154	to	_	_	O
155	first	_	_	O
156	cancer	_	_	O
157	pain-related	_	_	O
158	opioid	_	_	O
159	intake	_	_	O
160	.	_	_	O

161	Clinical	_	_	O
162	benefit	_	_	O
163	assessments	_	_	O
164	were	_	_	O
165	recorded	_	_	O
166	at	_	_	O
167	each	_	_	O
168	clinic	_	_	O
169	visit	_	_	O
170	.	_	_	O

171	Clinical	_	_	O
172	benefit	_	_	O
173	assessments	_	_	O
174	were	_	_	O
175	performed	_	_	O
176	in	_	_	O
177	more	_	_	O
178	than	_	_	O
179	75	_	_	O
180	%	_	_	O
181	of	_	_	O
182	patients	_	_	O
183	throughout	_	_	O
184	V325	_	_	O
185	.	_	_	O

186	DCF	_	_	B-Premise
187	significantly	_	_	I-Premise
188	prolonged	_	_	I-Premise
189	time	_	_	I-Premise
190	to	_	_	I-Premise
191	definitive	_	_	I-Premise
192	worsening	_	_	I-Premise
193	of	_	_	I-Premise
194	KPS	_	_	I-Premise
195	compared	_	_	I-Premise
196	with	_	_	I-Premise
197	CF	_	_	I-Premise
198	(	_	_	I-Premise
199	median	_	_	I-Premise
200	,	_	_	I-Premise
201	6.1	_	_	I-Premise
202	v	_	_	I-Premise
203	4.8	_	_	I-Premise
204	months	_	_	I-Premise
205	;	_	_	I-Premise
206	hazard	_	_	I-Premise
207	ratio	_	_	I-Premise
208	,	_	_	I-Premise
209	1.38	_	_	I-Premise
210	;	_	_	I-Premise
211	95	_	_	I-Premise
212	%	_	_	I-Premise
213	CI	_	_	I-Premise
214	,	_	_	I-Premise
215	1.08	_	_	I-Premise
216	to	_	_	I-Premise
217	1.76	_	_	I-Premise
218	;	_	_	I-Premise
219	log-rank	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	.009	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Although	_	_	B-Premise
226	time	_	_	I-Premise
227	to	_	_	I-Premise
228	definitive	_	_	I-Premise
229	weight	_	_	I-Premise
230	loss	_	_	I-Premise
231	and	_	_	I-Premise
232	time	_	_	I-Premise
233	to	_	_	I-Premise
234	definitive	_	_	I-Premise
235	worsening	_	_	I-Premise
236	of	_	_	I-Premise
237	appetite	_	_	I-Premise
238	favored	_	_	I-Premise
239	DCF	_	_	I-Premise
240	,	_	_	I-Premise
241	the	_	_	B-Premise
242	results	_	_	I-Premise
243	were	_	_	I-Premise
244	not	_	_	I-Premise
245	statistically	_	_	I-Premise
246	significant	_	_	I-Premise
247	.	_	_	I-Premise

248	Pain-free	_	_	B-Premise
249	survival	_	_	I-Premise
250	and	_	_	I-Premise
251	time	_	_	I-Premise
252	to	_	_	I-Premise
253	first	_	_	I-Premise
254	cancer	_	_	I-Premise
255	pain-related	_	_	I-Premise
256	opioid	_	_	I-Premise
257	intake	_	_	I-Premise
258	were	_	_	I-Premise
259	comparable	_	_	I-Premise
260	.	_	_	I-Premise

261	To	_	_	O
262	our	_	_	O
263	knowledge	_	_	O
264	,	_	_	O
265	V325	_	_	O
266	is	_	_	O
267	the	_	_	O
268	first	_	_	O
269	phase	_	_	O
270	III	_	_	O
271	trial	_	_	O
272	to	_	_	O
273	report	_	_	O
274	clinical	_	_	O
275	benefit	_	_	O
276	in	_	_	O
277	AGGEC	_	_	O
278	patients	_	_	O
279	.	_	_	O

280	Clinical	_	_	O
281	benefit	_	_	O
282	was	_	_	O
283	assessed	_	_	O
284	beyond	_	_	O
285	protocol-specific	_	_	O
286	chemotherapy	_	_	O
287	.	_	_	O

288	The	_	_	B-Claim
289	addition	_	_	I-Claim
290	of	_	_	I-Claim
291	D	_	_	I-Claim
292	to	_	_	I-Claim
293	CF	_	_	I-Claim
294	not	_	_	I-Claim
295	only	_	_	I-Claim
296	significantly	_	_	I-Claim
297	improved	_	_	I-Claim
298	clinical	_	_	I-Claim
299	benefit	_	_	I-Claim
300	but	_	_	I-Claim
301	also	_	_	I-Claim
302	improved	_	_	I-Claim
303	quality	_	_	I-Claim
304	of	_	_	I-Claim
305	life	_	_	I-Claim
306	,	_	_	I-Claim
307	time	_	_	I-Claim
308	to	_	_	I-Claim
309	progression	_	_	I-Claim
310	,	_	_	I-Claim
311	and	_	_	I-Claim
312	overall	_	_	I-Claim
313	survival	_	_	I-Claim
314	compared	_	_	I-Claim
315	with	_	_	I-Claim
316	CF	_	_	I-Claim
317	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	phase	_	_	O
3	II	_	_	O
4	trial	_	_	O
5	evaluated	_	_	O
6	two	_	_	O
7	docetaxel-based	_	_	O
8	regimens	_	_	O
9	to	_	_	O
10	see	_	_	O
11	which	_	_	O
12	would	_	_	O
13	be	_	_	O
14	most	_	_	O
15	promising	_	_	O
16	according	_	_	O
17	to	_	_	O
18	overall	_	_	O
19	response	_	_	O
20	rate	_	_	O
21	(	_	_	O
22	ORR	_	_	O
23	)	_	_	O
24	for	_	_	O
25	comparison	_	_	O
26	in	_	_	O
27	a	_	_	O
28	phase	_	_	O
29	III	_	_	O
30	trial	_	_	O
31	with	_	_	O
32	epirubicin-cisplatin-fluorouracil	_	_	O
33	(	_	_	O
34	ECF	_	_	O
35	)	_	_	O
36	as	_	_	O
37	first-line	_	_	O
38	advanced	_	_	O
39	gastric	_	_	O
40	cancer	_	_	O
41	therapy	_	_	O
42	.	_	_	O

43	Chemotherapy-naïve	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	measurable	_	_	O
47	unresectable	_	_	O
48	and/or	_	_	O
49	metastatic	_	_	O
50	gastric	_	_	O
51	carcinoma	_	_	O
52	,	_	_	O
53	a	_	_	O
54	performance	_	_	O
55	status	_	_	O
56	<	_	_	O
57	or=	_	_	O
58	1	_	_	O
59	,	_	_	O
60	and	_	_	O
61	adequate	_	_	O
62	hematologic	_	_	O
63	,	_	_	O
64	hepatic	_	_	O
65	,	_	_	O
66	and	_	_	O
67	renal	_	_	O
68	function	_	_	O
69	randomly	_	_	O
70	received	_	_	O
71	<	_	_	O
72	or=	_	_	O
73	eight	_	_	O
74	3-weekly	_	_	O
75	cycles	_	_	O
76	of	_	_	O
77	ECF	_	_	O
78	(	_	_	O
79	epirubicin	_	_	O
80	50	_	_	O
81	mg/m	_	_	O
82	(	_	_	O
83	2	_	_	O
84	)	_	_	O
85	on	_	_	O
86	day	_	_	O
87	1	_	_	O
88	,	_	_	O
89	cisplatin	_	_	O
90	60	_	_	O
91	mg/m	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	on	_	_	O
96	day	_	_	O
97	1	_	_	O
98	,	_	_	O
99	and	_	_	O
100	fluorouracil	_	_	O
101	[	_	_	O
102	FU	_	_	O
103	]	_	_	O
104	200	_	_	O
105	mg/m	_	_	O
106	(	_	_	O
107	2	_	_	O
108	)	_	_	O
109	/d	_	_	O
110	on	_	_	O
111	days	_	_	O
112	1	_	_	O
113	to	_	_	O
114	21	_	_	O
115	)	_	_	O
116	,	_	_	O
117	TC	_	_	O
118	(	_	_	O
119	docetaxel	_	_	O
120	initially	_	_	O
121	85	_	_	O
122	mg/m	_	_	O
123	(	_	_	O
124	2	_	_	O
125	)	_	_	O
126	on	_	_	O
127	day	_	_	O
128	1	_	_	O
129	[	_	_	O
130	later	_	_	O
131	reduced	_	_	O
132	to	_	_	O
133	75	_	_	O
134	mg/m	_	_	O
135	(	_	_	O
136	2	_	_	O
137	)	_	_	O
138	as	_	_	O
139	a	_	_	O
140	result	_	_	O
141	of	_	_	O
142	toxicity	_	_	O
143	]	_	_	O
144	and	_	_	O
145	cisplatin	_	_	O
146	75	_	_	O
147	mg/m	_	_	O
148	(	_	_	O
149	2	_	_	O
150	)	_	_	O
151	on	_	_	O
152	day	_	_	O
153	1	_	_	O
154	)	_	_	O
155	,	_	_	O
156	or	_	_	O
157	TCF	_	_	O
158	(	_	_	O
159	TC	_	_	O
160	plus	_	_	O
161	FU	_	_	O
162	300	_	_	O
163	mg/m	_	_	O
164	(	_	_	O
165	2	_	_	O
166	)	_	_	O
167	/d	_	_	O
168	on	_	_	O
169	days	_	_	O
170	1	_	_	O
171	to	_	_	O
172	14	_	_	O
173	)	_	_	O
174	.	_	_	O

175	Study	_	_	O
176	objectives	_	_	O
177	included	_	_	O
178	response	_	_	O
179	(	_	_	O
180	primary	_	_	O
181	)	_	_	O
182	,	_	_	O
183	survival	_	_	O
184	,	_	_	O
185	toxicity	_	_	O
186	,	_	_	O
187	and	_	_	O
188	quality	_	_	O
189	of	_	_	O
190	life	_	_	O
191	(	_	_	O
192	QOL	_	_	O
193	)	_	_	O
194	.	_	_	O

195	ORR	_	_	B-Premise
196	was	_	_	I-Premise
197	25.0	_	_	I-Premise
198	%	_	_	I-Premise
199	(	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	CI	_	_	I-Premise
203	,	_	_	I-Premise
204	13	_	_	I-Premise
205	%	_	_	I-Premise
206	to	_	_	I-Premise
207	41	_	_	I-Premise
208	%	_	_	I-Premise
209	)	_	_	I-Premise
210	for	_	_	I-Premise
211	ECF	_	_	I-Premise
212	,	_	_	I-Premise
213	18.5	_	_	I-Premise
214	%	_	_	I-Premise
215	(	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	,	_	_	I-Premise
220	9	_	_	I-Premise
221	%	_	_	I-Premise
222	to	_	_	I-Premise
223	34	_	_	I-Premise
224	%	_	_	I-Premise
225	)	_	_	I-Premise
226	for	_	_	I-Premise
227	TC	_	_	I-Premise
228	,	_	_	I-Premise
229	and	_	_	I-Premise
230	36.6	_	_	I-Premise
231	%	_	_	I-Premise
232	(	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	,	_	_	I-Premise
237	23	_	_	I-Premise
238	%	_	_	I-Premise
239	to	_	_	I-Premise
240	53	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	for	_	_	I-Premise
244	TCF	_	_	I-Premise
245	(	_	_	I-Premise
246	n	_	_	I-Premise
247	=	_	_	I-Premise
248	119	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	Median	_	_	B-Premise
252	overall	_	_	I-Premise
253	survival	_	_	I-Premise
254	times	_	_	I-Premise
255	were	_	_	I-Premise
256	8.3	_	_	I-Premise
257	,	_	_	I-Premise
258	11.0	_	_	I-Premise
259	,	_	_	I-Premise
260	and	_	_	I-Premise
261	10.4	_	_	I-Premise
262	months	_	_	I-Premise
263	for	_	_	I-Premise
264	ECF	_	_	I-Premise
265	,	_	_	I-Premise
266	TC	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	TCF	_	_	I-Premise
270	,	_	_	I-Premise
271	respectively	_	_	I-Premise
272	.	_	_	I-Premise

273	Toxicity	_	_	B-Premise
274	was	_	_	I-Premise
275	acceptable	_	_	I-Premise
276	,	_	_	I-Premise
277	with	_	_	I-Premise
278	one	_	_	I-Premise
279	toxic	_	_	I-Premise
280	death	_	_	I-Premise
281	(	_	_	I-Premise
282	TC	_	_	I-Premise
283	arm	_	_	I-Premise
284	)	_	_	I-Premise
285	.	_	_	I-Premise

286	Grade	_	_	B-Premise
287	3	_	_	I-Premise
288	or	_	_	I-Premise
289	4	_	_	I-Premise
290	neutropenia	_	_	I-Premise
291	occurred	_	_	I-Premise
292	in	_	_	I-Premise
293	more	_	_	I-Premise
294	treatment	_	_	I-Premise
295	cycles	_	_	I-Premise
296	with	_	_	I-Premise
297	docetaxel	_	_	I-Premise
298	(	_	_	I-Premise
299	TC	_	_	I-Premise
300	,	_	_	I-Premise
301	49	_	_	I-Premise
302	%	_	_	I-Premise
303	;	_	_	I-Premise
304	TCF	_	_	I-Premise
305	,	_	_	I-Premise
306	57	_	_	I-Premise
307	%	_	_	I-Premise
308	;	_	_	I-Premise
309	ECF	_	_	I-Premise
310	,	_	_	I-Premise
311	34	_	_	I-Premise
312	%	_	_	I-Premise
313	)	_	_	I-Premise
314	.	_	_	I-Premise

315	Global	_	_	B-Claim
316	health	_	_	I-Claim
317	status/QOL	_	_	I-Claim
318	substantially	_	_	I-Claim
319	improved	_	_	I-Claim
320	with	_	_	I-Claim
321	ECF	_	_	I-Claim
322	and	_	_	I-Claim
323	remained	_	_	I-Claim
324	similar	_	_	I-Claim
325	to	_	_	I-Claim
326	baseline	_	_	I-Claim
327	with	_	_	I-Claim
328	both	_	_	I-Claim
329	docetaxel	_	_	I-Claim
330	regimens	_	_	I-Claim
331	.	_	_	I-Claim

332	Time	_	_	B-Premise
333	to	_	_	I-Premise
334	response	_	_	I-Premise
335	and	_	_	I-Premise
336	ORR	_	_	I-Premise
337	favor	_	_	I-Premise
338	TCF	_	_	I-Premise
339	over	_	_	I-Premise
340	TC	_	_	I-Premise
341	for	_	_	I-Premise
342	further	_	_	I-Premise
343	evaluation	_	_	I-Premise
344	,	_	_	I-Premise
345	particularly	_	_	I-Premise
346	in	_	_	I-Premise
347	the	_	_	I-Premise
348	neoadjuvant	_	_	I-Premise
349	setting	_	_	I-Premise
350	.	_	_	I-Premise

351	A	_	_	B-Premise
352	trend	_	_	I-Premise
353	towards	_	_	I-Premise
354	increased	_	_	I-Premise
355	myelosuppression	_	_	I-Premise
356	and	_	_	I-Premise
357	infectious	_	_	I-Premise
358	complications	_	_	I-Premise
359	with	_	_	I-Premise
360	TCF	_	_	I-Premise
361	versus	_	_	I-Premise
362	TC	_	_	I-Premise
363	or	_	_	I-Premise
364	ECF	_	_	I-Premise
365	was	_	_	I-Premise
366	observed	_	_	I-Premise
367	.	_	_	I-Premise


0	To	_	_	O
1	assess	_	_	O
2	whether	_	_	O
3	omission	_	_	O
4	of	_	_	O
5	postoperative	_	_	O
6	radiotherapy	_	_	O
7	in	_	_	O
8	women	_	_	O
9	with	_	_	O
10	'low-risk	_	_	O
11	'	_	_	O
12	axillary	_	_	O
13	node	_	_	O
14	negative	_	_	O
15	breast	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	T0-2	_	_	O
19	)	_	_	O
20	treated	_	_	O
21	by	_	_	O
22	breast-conserving	_	_	O
23	surgery	_	_	O
24	and	_	_	O
25	endocrine	_	_	O
26	therapy	_	_	O
27	improves	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	and	_	_	O
32	is	_	_	O
33	more	_	_	O
34	cost-effective	_	_	O
35	.	_	_	O

36	A	_	_	O
37	randomised	_	_	O
38	controlled	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	,	_	_	O
42	using	_	_	O
43	a	_	_	O
44	method	_	_	O
45	of	_	_	O
46	minimisation	_	_	O
47	balanced	_	_	O
48	by	_	_	O
49	centre	_	_	O
50	,	_	_	O
51	grade	_	_	O
52	of	_	_	O
53	cancer	_	_	O
54	,	_	_	O
55	age	_	_	O
56	,	_	_	O
57	lymphatic/vascular	_	_	O
58	invasion	_	_	O
59	and	_	_	O
60	preoperative	_	_	O
61	endocrine	_	_	O
62	therapy	_	_	O
63	,	_	_	O
64	was	_	_	O
65	performed	_	_	O
66	.	_	_	O

67	A	_	_	O
68	non-randomised	_	_	O
69	cohort	_	_	O
70	was	_	_	O
71	also	_	_	O
72	recruited	_	_	O
73	,	_	_	O
74	in	_	_	O
75	order	_	_	O
76	to	_	_	O
77	complete	_	_	O
78	a	_	_	O
79	comprehensive	_	_	O
80	cohort	_	_	O
81	study	_	_	O
82	.	_	_	O

83	The	_	_	O
84	setting	_	_	O
85	was	_	_	O
86	breast	_	_	O
87	cancer	_	_	O
88	clinics	_	_	O
89	in	_	_	O
90	cancer	_	_	O
91	centres	_	_	O
92	in	_	_	O
93	the	_	_	O
94	UK	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	aged	_	_	O
98	65	_	_	O
99	years	_	_	O
100	or	_	_	O
101	more	_	_	O
102	were	_	_	O
103	eligible	_	_	O
104	provided	_	_	O
105	that	_	_	O
106	their	_	_	O
107	cancers	_	_	O
108	were	_	_	O
109	considered	_	_	O
110	to	_	_	O
111	be	_	_	O
112	at	_	_	O
113	low	_	_	O
114	risk	_	_	O
115	of	_	_	O
116	local	_	_	O
117	recurrence	_	_	O
118	,	_	_	O
119	were	_	_	O
120	suitable	_	_	O
121	for	_	_	O
122	breast-conservation	_	_	O
123	surgery	_	_	O
124	,	_	_	O
125	were	_	_	O
126	receiving	_	_	O
127	endocrine	_	_	O
128	therapy	_	_	O
129	and	_	_	O
130	were	_	_	O
131	able	_	_	O
132	and	_	_	O
133	willing	_	_	O
134	to	_	_	O
135	give	_	_	O
136	informed	_	_	O
137	consent	_	_	O
138	.	_	_	O

139	The	_	_	O
140	standard	_	_	O
141	treatment	_	_	O
142	of	_	_	O
143	postoperative	_	_	O
144	breast	_	_	O
145	irradiation	_	_	O
146	or	_	_	O
147	the	_	_	O
148	omission	_	_	O
149	of	_	_	O
150	radiotherapy	_	_	O
151	.	_	_	O

152	Quality	_	_	O
153	of	_	_	O
154	life	_	_	O
155	was	_	_	O
156	the	_	_	O
157	primary	_	_	O
158	outcome	_	_	O
159	measure	_	_	O
160	,	_	_	O
161	together	_	_	O
162	with	_	_	O
163	anxiety	_	_	O
164	and	_	_	O
165	depression	_	_	O
166	and	_	_	O
167	cost-effectiveness	_	_	O
168	.	_	_	O

169	Secondary	_	_	O
170	outcome	_	_	O
171	measures	_	_	O
172	were	_	_	O
173	recurrence	_	_	O
174	rates	_	_	O
175	,	_	_	O
176	functional	_	_	O
177	status	_	_	O
178	,	_	_	O
179	treatment-related	_	_	O
180	morbidity	_	_	O
181	and	_	_	O
182	cosmesis	_	_	O
183	.	_	_	O

184	The	_	_	O
185	principal	_	_	O
186	method	_	_	O
187	of	_	_	O
188	data	_	_	O
189	collection	_	_	O
190	was	_	_	O
191	by	_	_	O
192	questionnaire	_	_	O
193	,	_	_	O
194	completed	_	_	O
195	at	_	_	O
196	home	_	_	O
197	with	_	_	O
198	a	_	_	O
199	research	_	_	O
200	nurse	_	_	O
201	at	_	_	O
202	four	_	_	O
203	times	_	_	O
204	over	_	_	O
205	15	_	_	O
206	months	_	_	O
207	.	_	_	O

208	The	_	_	B-Claim
209	hypothesised	_	_	I-Claim
210	improvement	_	_	I-Claim
211	in	_	_	I-Claim
212	overall	_	_	I-Claim
213	quality	_	_	I-Claim
214	of	_	_	I-Claim
215	life	_	_	I-Claim
216	with	_	_	I-Claim
217	the	_	_	I-Claim
218	omission	_	_	I-Claim
219	of	_	_	I-Claim
220	radiotherapy	_	_	I-Claim
221	was	_	_	I-Claim
222	not	_	_	I-Claim
223	seen	_	_	I-Claim
224	in	_	_	I-Claim
225	the	_	_	I-Claim
226	EuroQol	_	_	I-Claim
227	assessment	_	_	I-Claim
228	or	_	_	I-Claim
229	in	_	_	I-Claim
230	the	_	_	I-Claim
231	functionality	_	_	I-Claim
232	and	_	_	I-Claim
233	symptoms	_	_	I-Claim
234	summary	_	_	I-Claim
235	domains	_	_	I-Claim
236	of	_	_	I-Claim
237	the	_	_	I-Claim
238	European	_	_	I-Claim
239	Organisation	_	_	I-Claim
240	for	_	_	I-Claim
241	Research	_	_	I-Claim
242	in	_	_	I-Claim
243	the	_	_	I-Claim
244	Treatment	_	_	I-Claim
245	of	_	_	I-Claim
246	Cancer	_	_	I-Claim
247	(	_	_	I-Claim
248	EORTC	_	_	I-Claim
249	)	_	_	I-Claim
250	scales	_	_	I-Claim
251	.	_	_	I-Claim

252	Some	_	_	O
253	differences	_	_	O
254	were	_	_	O
255	apparent	_	_	O
256	within	_	_	O
257	subscales	_	_	O
258	of	_	_	O
259	the	_	_	O
260	EORTC	_	_	O
261	questionnaires	_	_	O
262	,	_	_	O
263	and	_	_	O
264	insights	_	_	O
265	into	_	_	O
266	the	_	_	O
267	impact	_	_	O
268	of	_	_	O
269	treatment	_	_	O
270	were	_	_	O
271	also	_	_	O
272	provided	_	_	O
273	by	_	_	O
274	the	_	_	O
275	qualitative	_	_	O
276	data	_	_	O
277	obtained	_	_	O
278	by	_	_	O
279	open-ended	_	_	O
280	questions	_	_	O
281	.	_	_	O

282	Differences	_	_	B-Premise
283	were	_	_	I-Premise
284	most	_	_	I-Premise
285	apparent	_	_	I-Premise
286	shortly	_	_	I-Premise
287	after	_	_	I-Premise
288	the	_	_	I-Premise
289	time	_	_	I-Premise
290	of	_	_	I-Premise
291	completion	_	_	I-Premise
292	of	_	_	I-Premise
293	radiotherapy	_	_	I-Premise
294	.	_	_	I-Premise

295	Radiotherapy	_	_	B-Claim
296	was	_	_	I-Claim
297	then	_	_	I-Claim
298	associated	_	_	I-Claim
299	with	_	_	I-Claim
300	increased	_	_	I-Claim
301	breast	_	_	I-Claim
302	symptoms	_	_	I-Claim
303	and	_	_	I-Claim
304	with	_	_	I-Claim
305	greater	_	_	I-Claim
306	fatigue	_	_	I-Claim
307	but	_	_	I-Claim
308	with	_	_	I-Claim
309	less	_	_	I-Claim
310	insomnia	_	_	I-Claim
311	and	_	_	I-Claim
312	endocrine	_	_	I-Claim
313	side-effects	_	_	I-Claim
314	.	_	_	I-Claim

315	Patients	_	_	B-Premise
316	had	_	_	I-Premise
317	significant	_	_	I-Premise
318	concerns	_	_	I-Premise
319	about	_	_	I-Premise
320	the	_	_	I-Premise
321	delivery	_	_	I-Premise
322	of	_	_	I-Premise
323	radiotherapy	_	_	I-Premise
324	services	_	_	I-Premise
325	,	_	_	I-Premise
326	such	_	_	I-Premise
327	as	_	_	I-Premise
328	transport	_	_	I-Premise
329	,	_	_	I-Premise
330	accommodation	_	_	I-Premise
331	and	_	_	I-Premise
332	travel	_	_	I-Premise
333	costs	_	_	I-Premise
334	associated	_	_	I-Premise
335	with	_	_	I-Premise
336	receiving	_	_	I-Premise
337	radiotherapy	_	_	I-Premise
338	.	_	_	I-Premise

339	By	_	_	B-Premise
340	the	_	_	I-Premise
341	end	_	_	I-Premise
342	of	_	_	I-Premise
343	follow-up	_	_	I-Premise
344	,	_	_	I-Premise
345	patients	_	_	I-Premise
346	receiving	_	_	I-Premise
347	radiotherapy	_	_	I-Premise
348	were	_	_	I-Premise
349	expressing	_	_	I-Premise
350	less	_	_	I-Premise
351	anxiety	_	_	I-Premise
352	about	_	_	I-Premise
353	recurrence	_	_	I-Premise
354	than	_	_	I-Premise
355	those	_	_	I-Premise
356	who	_	_	I-Premise
357	had	_	_	I-Premise
358	not	_	_	I-Premise
359	received	_	_	I-Premise
360	radiotherapy	_	_	I-Premise
361	.	_	_	I-Premise

362	Functionality	_	_	B-Premise
363	was	_	_	I-Premise
364	not	_	_	I-Premise
365	greatly	_	_	I-Premise
366	affected	_	_	I-Premise
367	by	_	_	I-Premise
368	treatment	_	_	I-Premise
369	.	_	_	I-Premise

370	Within	_	_	B-Premise
371	the	_	_	I-Premise
372	randomised	_	_	I-Premise
373	controlled	_	_	I-Premise
374	trial	_	_	I-Premise
375	,	_	_	I-Premise
376	the	_	_	I-Premise
377	Barthel	_	_	I-Premise
378	Index	_	_	I-Premise
379	demonstrated	_	_	I-Premise
380	a	_	_	I-Premise
381	small	_	_	I-Premise
382	but	_	_	I-Premise
383	significant	_	_	I-Premise
384	fall	_	_	I-Premise
385	in	_	_	I-Premise
386	functionality	_	_	I-Premise
387	with	_	_	I-Premise
388	radiotherapy	_	_	I-Premise
389	compared	_	_	I-Premise
390	with	_	_	I-Premise
391	the	_	_	I-Premise
392	no	_	_	I-Premise
393	radiotherapy	_	_	I-Premise
394	arm	_	_	I-Premise
395	of	_	_	I-Premise
396	the	_	_	I-Premise
397	trial	_	_	I-Premise
398	.	_	_	I-Premise

399	Results	_	_	B-Premise
400	from	_	_	I-Premise
401	the	_	_	I-Premise
402	non-randomised	_	_	I-Premise
403	patients	_	_	I-Premise
404	did	_	_	I-Premise
405	not	_	_	I-Premise
406	confirm	_	_	I-Premise
407	this	_	_	I-Premise
408	effect	_	_	I-Premise
409	,	_	_	I-Premise
410	however	_	_	I-Premise
411	.	_	_	I-Premise

412	Cosmetic	_	_	B-Premise
413	results	_	_	I-Premise
414	were	_	_	I-Premise
415	better	_	_	I-Premise
416	in	_	_	I-Premise
417	those	_	_	I-Premise
418	not	_	_	I-Premise
419	receiving	_	_	I-Premise
420	radiotherapy	_	_	I-Premise
421	but	_	_	B-Premise
422	this	_	_	I-Premise
423	did	_	_	I-Premise
424	not	_	_	I-Premise
425	appear	_	_	I-Premise
426	to	_	_	I-Premise
427	be	_	_	I-Premise
428	an	_	_	I-Premise
429	important	_	_	I-Premise
430	issue	_	_	I-Premise
431	to	_	_	I-Premise
432	the	_	_	I-Premise
433	patients	_	_	I-Premise
434	.	_	_	I-Premise

435	The	_	_	B-Claim
436	use	_	_	I-Claim
437	of	_	_	I-Claim
438	home-based	_	_	I-Claim
439	assessments	_	_	I-Claim
440	by	_	_	I-Claim
441	a	_	_	I-Claim
442	research	_	_	I-Claim
443	nurse	_	_	I-Claim
444	proved	_	_	I-Claim
445	to	_	_	I-Claim
446	be	_	_	I-Claim
447	an	_	_	I-Claim
448	effective	_	_	I-Claim
449	way	_	_	I-Claim
450	of	_	_	I-Claim
451	obtaining	_	_	I-Claim
452	high-quality	_	_	I-Claim
453	data	_	_	I-Claim
454	.	_	_	I-Claim

455	Costs	_	_	O
456	to	_	_	O
457	the	_	_	O
458	NHS	_	_	O
459	associated	_	_	O
460	with	_	_	O
461	postoperative	_	_	O
462	radiotherapy	_	_	O
463	were	_	_	O
464	calculated	_	_	O
465	to	_	_	O
466	be	_	_	O
467	of	_	_	O
468	the	_	_	O
469	order	_	_	O
470	of	_	_	O
471	2000	_	_	O
472	pounds	_	_	O
473	per	_	_	O
474	patient	_	_	O
475	.	_	_	O

476	In	_	_	B-Premise
477	the	_	_	I-Premise
478	follow-up	_	_	I-Premise
479	in	_	_	I-Premise
480	this	_	_	I-Premise
481	study	_	_	I-Premise
482	,	_	_	I-Premise
483	there	_	_	I-Premise
484	were	_	_	I-Premise
485	no	_	_	I-Premise
486	recurrences	_	_	I-Premise
487	,	_	_	I-Premise
488	and	_	_	I-Premise
489	the	_	_	I-Premise
490	quality	_	_	I-Premise
491	of	_	_	I-Premise
492	life	_	_	I-Premise
493	utilities	_	_	I-Premise
494	from	_	_	I-Premise
495	EuroQol	_	_	I-Premise
496	were	_	_	I-Premise
497	almost	_	_	I-Premise
498	identical	_	_	I-Premise
499	.	_	_	I-Premise

500	Although	_	_	B-Premise
501	there	_	_	I-Premise
502	are	_	_	I-Premise
503	no	_	_	I-Premise
504	differences	_	_	I-Premise
505	in	_	_	I-Premise
506	overall	_	_	I-Premise
507	quality	_	_	I-Premise
508	of	_	_	I-Premise
509	life	_	_	I-Premise
510	scores	_	_	I-Premise
511	between	_	_	I-Premise
512	the	_	_	I-Premise
513	patients	_	_	I-Premise
514	treated	_	_	I-Premise
515	with	_	_	I-Premise
516	and	_	_	I-Premise
517	without	_	_	I-Premise
518	radiotherapy	_	_	I-Premise
519	,	_	_	I-Premise
520	there	_	_	I-Premise
521	are	_	_	I-Premise
522	several	_	_	I-Premise
523	dimensions	_	_	I-Premise
524	that	_	_	I-Premise
525	exhibit	_	_	I-Premise
526	significant	_	_	I-Premise
527	advantage	_	_	I-Premise
528	to	_	_	I-Premise
529	the	_	_	I-Premise
530	omission	_	_	I-Premise
531	of	_	_	I-Premise
532	irradiation	_	_	I-Premise
533	.	_	_	I-Premise

534	Over	_	_	B-Premise
535	the	_	_	I-Premise
536	first	_	_	I-Premise
537	15	_	_	I-Premise
538	months	_	_	I-Premise
539	,	_	_	I-Premise
540	radiotherapy	_	_	I-Premise
541	for	_	_	I-Premise
542	this	_	_	I-Premise
543	population	_	_	I-Premise
544	is	_	_	I-Premise
545	not	_	_	I-Premise
546	a	_	_	I-Premise
547	cost-effective	_	_	I-Premise
548	treatment	_	_	I-Premise
549	.	_	_	I-Premise

550	However	_	_	O
551	,	_	_	O
552	the	_	_	O
553	early	_	_	B-Claim
554	postoperative	_	_	I-Claim
555	outcome	_	_	I-Claim
556	does	_	_	I-Claim
557	not	_	_	I-Claim
558	give	_	_	I-Claim
559	a	_	_	I-Claim
560	complete	_	_	I-Claim
561	answer	_	_	I-Claim
562	and	_	_	O
563	the	_	_	B-Claim
564	eventual	_	_	I-Claim
565	cost-effectiveness	_	_	I-Claim
566	will	_	_	I-Claim
567	only	_	_	I-Claim
568	become	_	_	I-Claim
569	clear	_	_	I-Claim
570	after	_	_	I-Claim
571	long-term	_	_	I-Claim
572	follow-up	_	_	I-Claim
573	.	_	_	I-Claim

574	Extrapolations	_	_	B-Claim
575	from	_	_	I-Claim
576	these	_	_	I-Claim
577	data	_	_	I-Claim
578	suggest	_	_	I-Claim
579	that	_	_	I-Claim
580	radiotherapy	_	_	I-Claim
581	may	_	_	I-Claim
582	not	_	_	I-Claim
583	be	_	_	I-Claim
584	a	_	_	I-Claim
585	cost-effective	_	_	I-Claim
586	treatment	_	_	I-Claim
587	unless	_	_	I-Claim
588	it	_	_	I-Claim
589	results	_	_	I-Claim
590	in	_	_	I-Claim
591	a	_	_	I-Claim
592	recurrence	_	_	I-Claim
593	rate	_	_	I-Claim
594	that	_	_	I-Claim
595	is	_	_	I-Claim
596	at	_	_	I-Claim
597	least	_	_	I-Claim
598	5	_	_	I-Claim
599	%	_	_	I-Claim
600	lower	_	_	I-Claim
601	in	_	_	I-Claim
602	absolute	_	_	I-Claim
603	terms	_	_	I-Claim
604	than	_	_	I-Claim
605	those	_	_	I-Claim
606	treated	_	_	I-Claim
607	without	_	_	I-Claim
608	radiotherapy	_	_	I-Claim
609	.	_	_	I-Claim

610	Further	_	_	B-Claim
611	research	_	_	I-Claim
612	is	_	_	I-Claim
613	needed	_	_	I-Claim
614	into	_	_	I-Claim
615	a	_	_	I-Claim
616	number	_	_	I-Claim
617	of	_	_	I-Claim
618	areas	_	_	I-Claim
619	including	_	_	I-Claim
620	the	_	_	I-Claim
621	long-term	_	_	I-Claim
622	aspects	_	_	I-Claim
623	of	_	_	I-Claim
624	quality	_	_	I-Claim
625	of	_	_	I-Claim
626	life	_	_	I-Claim
627	,	_	_	I-Claim
628	clinical	_	_	I-Claim
629	outcomes	_	_	I-Claim
630	,	_	_	I-Claim
631	costs	_	_	I-Claim
632	and	_	_	I-Claim
633	consequences	_	_	I-Claim
634	of	_	_	I-Claim
635	omitting	_	_	I-Claim
636	radiotherapy	_	_	I-Claim
637	.	_	_	I-Claim


0	Colonic	_	_	O
1	pouches	_	_	O
2	have	_	_	O
3	been	_	_	O
4	used	_	_	O
5	for	_	_	O
6	20	_	_	O
7	years	_	_	O
8	to	_	_	O
9	provide	_	_	O
10	reservoir	_	_	O
11	function	_	_	O
12	after	_	_	O
13	reconstructive	_	_	O
14	proctectomy	_	_	O
15	for	_	_	O
16	rectal	_	_	O
17	cancer	_	_	O
18	.	_	_	O

19	More	_	_	B-Claim
20	recently	_	_	I-Claim
21	coloplasty	_	_	I-Claim
22	has	_	_	I-Claim
23	been	_	_	I-Claim
24	advocated	_	_	I-Claim
25	as	_	_	I-Claim
26	an	_	_	I-Claim
27	alternative	_	_	I-Claim
28	to	_	_	I-Claim
29	a	_	_	I-Claim
30	colonic	_	_	I-Claim
31	pouch	_	_	I-Claim
32	.	_	_	I-Claim

33	However	_	_	O
34	there	_	_	O
35	have	_	_	O
36	been	_	_	O
37	no	_	_	O
38	long-term	_	_	O
39	randomized	_	_	O
40	,	_	_	O
41	controlled	_	_	O
42	trials	_	_	O
43	to	_	_	O
44	compare	_	_	O
45	functional	_	_	O
46	outcomes	_	_	O
47	of	_	_	O
48	coloplasty	_	_	O
49	,	_	_	O
50	colonic	_	_	O
51	J-Pouch	_	_	O
52	(	_	_	O
53	JP	_	_	O
54	)	_	_	O
55	,	_	_	O
56	or	_	_	O
57	a	_	_	O
58	straight	_	_	O
59	anastomosis	_	_	O
60	(	_	_	O
61	SA	_	_	O
62	)	_	_	O
63	after	_	_	O
64	the	_	_	O
65	treatment	_	_	O
66	of	_	_	O
67	low	_	_	O
68	rectal	_	_	O
69	cancer	_	_	O
70	.	_	_	O

71	:	_	_	O
72	To	_	_	O
73	compare	_	_	O
74	the	_	_	O
75	complications	_	_	O
76	,	_	_	O
77	long-term	_	_	O
78	functional	_	_	O
79	outcome	_	_	O
80	,	_	_	O
81	and	_	_	O
82	quality	_	_	O
83	of	_	_	O
84	life	_	_	O
85	(	_	_	O
86	QOL	_	_	O
87	)	_	_	O
88	of	_	_	O
89	patients	_	_	O
90	undergoing	_	_	O
91	a	_	_	O
92	coloplasty	_	_	O
93	,	_	_	O
94	JP	_	_	O
95	,	_	_	O
96	or	_	_	O
97	an	_	_	O
98	SA	_	_	O
99	in	_	_	O
100	reconstruction	_	_	O
101	of	_	_	O
102	the	_	_	O
103	lower	_	_	O
104	gastrointestinal	_	_	O
105	tract	_	_	O
106	after	_	_	O
107	proctectomy	_	_	O
108	for	_	_	O
109	low	_	_	O
110	rectal	_	_	O
111	cancer	_	_	O
112	.	_	_	O

113	A	_	_	O
114	multicenter	_	_	O
115	study	_	_	O
116	enrolled	_	_	O
117	patients	_	_	O
118	with	_	_	O
119	low	_	_	O
120	rectal	_	_	O
121	cancer	_	_	O
122	,	_	_	O
123	who	_	_	O
124	were	_	_	O
125	randomized	_	_	O
126	intraoperatively	_	_	O
127	to	_	_	O
128	coloplasty	_	_	O
129	(	_	_	O
130	CP-1	_	_	O
131	)	_	_	O
132	or	_	_	O
133	SA	_	_	O
134	if	_	_	O
135	JP	_	_	O
136	was	_	_	O
137	not	_	_	O
138	feasible	_	_	O
139	,	_	_	O
140	or	_	_	O
141	JP	_	_	O
142	or	_	_	O
143	coloplasty	_	_	O
144	(	_	_	O
145	CP-2	_	_	O
146	)	_	_	O
147	if	_	_	O
148	a	_	_	O
149	JP	_	_	O
150	was	_	_	O
151	feasible	_	_	O
152	.	_	_	O

153	Patients	_	_	O
154	were	_	_	O
155	followed	_	_	O
156	for	_	_	O
157	24	_	_	O
158	months	_	_	O
159	with	_	_	O
160	SF-36	_	_	O
161	surveys	_	_	O
162	to	_	_	O
163	evaluate	_	_	O
164	the	_	_	O
165	QOL	_	_	O
166	.	_	_	O

167	Bowel	_	_	O
168	function	_	_	O
169	was	_	_	O
170	measured	_	_	O
171	quantitatively	_	_	O
172	and	_	_	O
173	using	_	_	O
174	Fecal	_	_	O
175	Incontinence	_	_	O
176	Severity	_	_	O
177	Index	_	_	O
178	(	_	_	O
179	FISI	_	_	O
180	)	_	_	O
181	.	_	_	O

182	Urinary	_	_	O
183	function	_	_	O
184	and	_	_	O
185	sexual	_	_	O
186	function	_	_	O
187	were	_	_	O
188	also	_	_	O
189	assessed	_	_	O
190	.	_	_	O

191	Three	_	_	O
192	hundred	_	_	O
193	sixty-four	_	_	O
194	patients	_	_	O
195	were	_	_	O
196	randomized	_	_	O
197	.	_	_	O

198	All	_	_	O
199	patients	_	_	O
200	were	_	_	O
201	evaluated	_	_	O
202	for	_	_	O
203	complications	_	_	O
204	and	_	_	O
205	recurrence	_	_	O
206	.	_	_	O

207	Mean	_	_	O
208	age	_	_	O
209	was	_	_	O
210	60	_	_	O
211	+/-12	_	_	O
212	years	_	_	O
213	,	_	_	O
214	71	_	_	O
215	%	_	_	O
216	were	_	_	O
217	male	_	_	O
218	.	_	_	O

219	Twenty-three	_	_	B-Premise
220	(	_	_	I-Premise
221	7.4	_	_	I-Premise
222	%	_	_	I-Premise
223	)	_	_	I-Premise
224	died	_	_	I-Premise
225	within	_	_	I-Premise
226	24	_	_	I-Premise
227	months	_	_	I-Premise
228	of	_	_	I-Premise
229	surgery	_	_	I-Premise
230	.	_	_	I-Premise

231	No	_	_	B-Premise
232	significant	_	_	I-Premise
233	difference	_	_	I-Premise
234	was	_	_	I-Premise
235	observed	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	complications	_	_	I-Premise
239	among	_	_	I-Premise
240	the	_	_	I-Premise
241	4	_	_	I-Premise
242	groups	_	_	I-Premise
243	.	_	_	I-Premise

244	Two	_	_	O
245	hundred	_	_	O
246	ninety-seven	_	_	O
247	of	_	_	O
248	364	_	_	O
249	were	_	_	O
250	evaluated	_	_	O
251	for	_	_	O
252	functional	_	_	O
253	outcome	_	_	O
254	at	_	_	O
255	24	_	_	O
256	months	_	_	O
257	.	_	_	O

258	There	_	_	B-Premise
259	was	_	_	I-Premise
260	no	_	_	I-Premise
261	difference	_	_	I-Premise
262	in	_	_	I-Premise
263	bowel	_	_	I-Premise
264	function	_	_	I-Premise
265	between	_	_	I-Premise
266	the	_	_	I-Premise
267	CP-1	_	_	I-Premise
268	and	_	_	I-Premise
269	SA	_	_	I-Premise
270	groups	_	_	I-Premise
271	.	_	_	I-Premise

272	JP	_	_	B-Premise
273	patients	_	_	I-Premise
274	had	_	_	I-Premise
275	fewer	_	_	I-Premise
276	bowel	_	_	I-Premise
277	movements	_	_	I-Premise
278	,	_	_	I-Premise
279	less	_	_	I-Premise
280	clustering	_	_	I-Premise
281	,	_	_	I-Premise
282	used	_	_	I-Premise
283	fewer	_	_	I-Premise
284	pads	_	_	I-Premise
285	and	_	_	I-Premise
286	had	_	_	I-Premise
287	a	_	_	I-Premise
288	lower	_	_	I-Premise
289	FISI	_	_	I-Premise
290	than	_	_	I-Premise
291	the	_	_	I-Premise
292	CP-2	_	_	I-Premise
293	group	_	_	I-Premise
294	.	_	_	I-Premise

295	Other	_	_	B-Premise
296	parameters	_	_	I-Premise
297	were	_	_	I-Premise
298	not	_	_	I-Premise
299	statistically	_	_	I-Premise
300	different	_	_	I-Premise
301	.	_	_	I-Premise

302	QOL	_	_	B-Premise
303	scores	_	_	I-Premise
304	at	_	_	I-Premise
305	24	_	_	I-Premise
306	months	_	_	I-Premise
307	were	_	_	I-Premise
308	similar	_	_	I-Premise
309	for	_	_	I-Premise
310	each	_	_	I-Premise
311	of	_	_	I-Premise
312	the	_	_	I-Premise
313	4	_	_	I-Premise
314	groups	_	_	I-Premise
315	.	_	_	I-Premise

316	In	_	_	B-Claim
317	patients	_	_	I-Claim
318	undergoing	_	_	I-Claim
319	a	_	_	I-Claim
320	restorative	_	_	I-Claim
321	resection	_	_	I-Claim
322	for	_	_	I-Claim
323	low	_	_	I-Claim
324	rectal	_	_	I-Claim
325	cancer	_	_	I-Claim
326	,	_	_	I-Claim
327	a	_	_	I-Claim
328	colonic	_	_	I-Claim
329	JP	_	_	I-Claim
330	offers	_	_	I-Claim
331	significant	_	_	I-Claim
332	advantages	_	_	I-Claim
333	in	_	_	I-Claim
334	function	_	_	I-Claim
335	over	_	_	I-Claim
336	an	_	_	I-Claim
337	SA	_	_	I-Claim
338	or	_	_	I-Claim
339	a	_	_	I-Claim
340	coloplasty	_	_	I-Claim
341	.	_	_	I-Claim

342	In	_	_	B-Claim
343	patients	_	_	I-Claim
344	who	_	_	I-Claim
345	can	_	_	I-Claim
346	not	_	_	I-Claim
347	have	_	_	I-Claim
348	a	_	_	I-Claim
349	pouch	_	_	I-Claim
350	,	_	_	I-Claim
351	coloplasty	_	_	I-Claim
352	seems	_	_	I-Claim
353	not	_	_	I-Claim
354	to	_	_	I-Claim
355	improve	_	_	I-Claim
356	the	_	_	I-Claim
357	bowel	_	_	I-Claim
358	function	_	_	I-Claim
359	of	_	_	I-Claim
360	patients	_	_	I-Claim
361	over	_	_	I-Claim
362	that	_	_	I-Claim
363	with	_	_	I-Claim
364	an	_	_	I-Claim
365	SA	_	_	I-Claim
366	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	intraocular	_	_	O
3	pressure	_	_	O
4	(	_	_	O
5	IOP	_	_	O
6	)	_	_	O
7	control	_	_	O
8	and	_	_	O
9	other	_	_	O
10	clinical	_	_	O
11	outcomes	_	_	O
12	after	_	_	O
13	1-site	_	_	O
14	fornix-based	_	_	O
15	and	_	_	O
16	2-site	_	_	O
17	limbus-based	_	_	O
18	phacotrabeculectomy	_	_	O
19	.	_	_	O

20	Prospective	_	_	O
21	randomized	_	_	O
22	controlled	_	_	O
23	trial	_	_	O
24	.	_	_	O

25	A	_	_	O
26	total	_	_	O
27	of	_	_	O
28	90	_	_	O
29	eyes	_	_	O
30	of	_	_	O
31	76	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	cataract	_	_	O
35	and	_	_	O
36	glaucoma	_	_	O
37	were	_	_	O
38	treated	_	_	O
39	.	_	_	O

40	Forty-four	_	_	O
41	eyes	_	_	O
42	were	_	_	O
43	assigned	_	_	O
44	randomly	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	a	_	_	O
48	1-site	_	_	O
49	phacotrabeculectomy	_	_	O
50	with	_	_	O
51	a	_	_	O
52	fornix-based	_	_	O
53	conjunctival	_	_	O
54	flap	_	_	O
55	,	_	_	O
56	and	_	_	O
57	46	_	_	O
58	eyes	_	_	O
59	were	_	_	O
60	assigned	_	_	O
61	randomly	_	_	O
62	to	_	_	O
63	receive	_	_	O
64	a	_	_	O
65	2-site	_	_	O
66	phacotrabeculectomy	_	_	O
67	with	_	_	O
68	a	_	_	O
69	limbus-based	_	_	O
70	conjunctival	_	_	O
71	flap	_	_	O
72	.	_	_	O

73	All	_	_	O
74	operations	_	_	O
75	were	_	_	O
76	performed	_	_	O
77	with	_	_	O
78	mitomycin	_	_	O
79	C.	_	_	O
80	Intraocular	_	_	O
81	pressure	_	_	O
82	and	_	_	O
83	number	_	_	O
84	of	_	_	O
85	antiglaucoma	_	_	O
86	medications	_	_	O
87	were	_	_	O
88	recorded	_	_	O
89	at	_	_	O
90	baseline	_	_	O
91	and	_	_	O
92	during	_	_	O
93	a	_	_	O
94	3-year	_	_	O
95	follow-up	_	_	O
96	period	_	_	O
97	.	_	_	O

98	Mean	_	_	B-Premise
99	preoperative	_	_	I-Premise
100	IOP	_	_	I-Premise
101	was	_	_	I-Premise
102	20.1+/-3.8	_	_	I-Premise
103	mmHg	_	_	I-Premise
104	in	_	_	I-Premise
105	the	_	_	I-Premise
106	1-site	_	_	I-Premise
107	group	_	_	I-Premise
108	and	_	_	I-Premise
109	19.5+/-5.3	_	_	I-Premise
110	mmHg	_	_	I-Premise
111	in	_	_	I-Premise
112	the	_	_	I-Premise
113	2-site	_	_	I-Premise
114	group	_	_	I-Premise
115	(	_	_	I-Premise
116	P	_	_	I-Premise
117	=	_	_	I-Premise
118	0.56	_	_	I-Premise
119	)	_	_	I-Premise
120	using	_	_	I-Premise
121	a	_	_	I-Premise
122	mean	_	_	I-Premise
123	of	_	_	I-Premise
124	2.3+/-0.9	_	_	I-Premise
125	and	_	_	I-Premise
126	2.5+/-0.9	_	_	I-Premise
127	antiglaucoma	_	_	I-Premise
128	medications	_	_	I-Premise
129	,	_	_	I-Premise
130	respectively	_	_	I-Premise
131	(	_	_	I-Premise
132	P	_	_	I-Premise
133	=	_	_	I-Premise
134	0.27	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	After	_	_	B-Premise
138	3	_	_	I-Premise
139	years	_	_	I-Premise
140	of	_	_	I-Premise
141	follow-up	_	_	I-Premise
142	,	_	_	I-Premise
143	the	_	_	I-Premise
144	mean	_	_	I-Premise
145	IOP	_	_	I-Premise
146	was	_	_	I-Premise
147	12.6+/-4.8	_	_	I-Premise
148	mmHg	_	_	I-Premise
149	in	_	_	I-Premise
150	the	_	_	I-Premise
151	1-site	_	_	I-Premise
152	group	_	_	I-Premise
153	and	_	_	I-Premise
154	11.7+/-4.0	_	_	I-Premise
155	mmHg	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	2-site	_	_	I-Premise
159	group	_	_	I-Premise
160	(	_	_	I-Premise
161	P	_	_	I-Premise
162	=	_	_	I-Premise
163	0.40	_	_	I-Premise
164	)	_	_	I-Premise
165	,	_	_	I-Premise
166	receiving	_	_	I-Premise
167	a	_	_	I-Premise
168	mean	_	_	I-Premise
169	of	_	_	I-Premise
170	0.3+/-0.7	_	_	I-Premise
171	and	_	_	I-Premise
172	0.4+/-0.9	_	_	I-Premise
173	medications	_	_	I-Premise
174	,	_	_	I-Premise
175	respectively	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	=	_	_	I-Premise
179	0.59	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	At	_	_	B-Premise
183	the	_	_	I-Premise
184	end	_	_	I-Premise
185	of	_	_	I-Premise
186	the	_	_	I-Premise
187	study	_	_	I-Premise
188	,	_	_	I-Premise
189	73	_	_	I-Premise
190	%	_	_	I-Premise
191	of	_	_	I-Premise
192	1-site	_	_	I-Premise
193	eyes	_	_	I-Premise
194	and	_	_	I-Premise
195	78.4	_	_	I-Premise
196	%	_	_	I-Premise
197	of	_	_	I-Premise
198	2-site	_	_	I-Premise
199	eyes	_	_	I-Premise
200	had	_	_	I-Premise
201	IOPs	_	_	I-Premise
202	of	_	_	I-Premise
203	less	_	_	I-Premise
204	than	_	_	I-Premise
205	18	_	_	I-Premise
206	mmHg	_	_	I-Premise
207	while	_	_	I-Premise
208	receiving	_	_	I-Premise
209	no	_	_	I-Premise
210	antiglaucoma	_	_	I-Premise
211	medications	_	_	I-Premise
212	(	_	_	I-Premise
213	P	_	_	I-Premise
214	=	_	_	I-Premise
215	0.59	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	Visual	_	_	B-Premise
219	acuity	_	_	I-Premise
220	was	_	_	I-Premise
221	similar	_	_	I-Premise
222	for	_	_	I-Premise
223	both	_	_	I-Premise
224	groups	_	_	I-Premise
225	at	_	_	I-Premise
226	3	_	_	I-Premise
227	months	_	_	I-Premise
228	after	_	_	I-Premise
229	surgery	_	_	I-Premise
230	.	_	_	I-Premise

231	There	_	_	B-Premise
232	were	_	_	I-Premise
233	no	_	_	I-Premise
234	significant	_	_	I-Premise
235	differences	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	need	_	_	I-Premise
239	for	_	_	I-Premise
240	digital	_	_	I-Premise
241	pressure	_	_	I-Premise
242	,	_	_	I-Premise
243	postoperative	_	_	I-Premise
244	bleb	_	_	I-Premise
245	needling	_	_	I-Premise
246	with	_	_	I-Premise
247	5-fluorouracil	_	_	I-Premise
248	,	_	_	I-Premise
249	or	_	_	I-Premise
250	number	_	_	I-Premise
251	of	_	_	I-Premise
252	postoperative	_	_	I-Premise
253	visits	_	_	I-Premise
254	.	_	_	I-Premise

255	There	_	_	O
256	were	_	_	O
257	2	_	_	O
258	major	_	_	O
259	complications	_	_	O
260	in	_	_	O
261	each	_	_	O
262	group	_	_	O
263	during	_	_	O
264	follow-up	_	_	O
265	.	_	_	O

266	Early	_	_	B-Premise
267	leaks	_	_	I-Premise
268	of	_	_	I-Premise
269	the	_	_	I-Premise
270	conjunctival	_	_	I-Premise
271	wound	_	_	I-Premise
272	closure	_	_	I-Premise
273	occurred	_	_	I-Premise
274	in	_	_	I-Premise
275	6	_	_	I-Premise
276	eyes	_	_	I-Premise
277	in	_	_	I-Premise
278	the	_	_	I-Premise
279	1-site	_	_	I-Premise
280	group	_	_	I-Premise
281	and	_	_	I-Premise
282	in	_	_	I-Premise
283	0	_	_	I-Premise
284	eyes	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	2-site	_	_	I-Premise
288	group	_	_	I-Premise
289	(	_	_	I-Premise
290	P	_	_	I-Premise
291	=	_	_	I-Premise
292	0.03	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Operating	_	_	O
296	time	_	_	O
297	(	_	_	O
298	in	_	_	O
299	minutes	_	_	O
300	)	_	_	O
301	was	_	_	O
302	less	_	_	O
303	in	_	_	O
304	the	_	_	O
305	1-site	_	_	O
306	surgery	_	_	O
307	group	_	_	O
308	(	_	_	O
309	P	_	_	O
310	<	_	_	O
311	0.0001	_	_	O
312	)	_	_	O
313	.	_	_	O

314	Day	_	_	O
315	one	_	_	O
316	postoperative	_	_	O
317	IOP	_	_	O
318	was	_	_	O
319	higher	_	_	O
320	in	_	_	O
321	the	_	_	O
322	2-site	_	_	O
323	group	_	_	O
324	(	_	_	O
325	P	_	_	O
326	=	_	_	O
327	0.0.01	_	_	O
328	)	_	_	O
329	.	_	_	O

330	One-site	_	_	B-Claim
331	fornix-based	_	_	I-Claim
332	and	_	_	I-Claim
333	2-site	_	_	I-Claim
334	limbus-based	_	_	I-Claim
335	phacotrabeculectomy	_	_	I-Claim
336	were	_	_	I-Claim
337	similarly	_	_	I-Claim
338	effective	_	_	I-Claim
339	in	_	_	I-Claim
340	lowering	_	_	I-Claim
341	IOP	_	_	I-Claim
342	and	_	_	I-Claim
343	reducing	_	_	I-Claim
344	the	_	_	I-Claim
345	need	_	_	I-Claim
346	for	_	_	I-Claim
347	antiglaucoma	_	_	I-Claim
348	medications	_	_	I-Claim
349	over	_	_	I-Claim
350	a	_	_	I-Claim
351	3-year	_	_	I-Claim
352	follow-up	_	_	I-Claim
353	period	_	_	I-Claim
354	.	_	_	I-Claim


0	This	_	_	O
1	double-blind	_	_	O
2	randomized	_	_	O
3	phase	_	_	O
4	II	_	_	O
5	trial	_	_	O
6	examined	_	_	O
7	whether	_	_	O
8	vandetanib	_	_	O
9	,	_	_	O
10	an	_	_	O
11	inhibitor	_	_	O
12	of	_	_	O
13	vascular	_	_	O
14	endothelial	_	_	O
15	and	_	_	O
16	epidermal	_	_	O
17	growth	_	_	O
18	factor	_	_	O
19	receptors	_	_	O
20	,	_	_	O
21	could	_	_	O
22	prolong	_	_	O
23	progression-free	_	_	O
24	survival	_	_	O
25	in	_	_	O
26	responding	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	small-cell	_	_	O
30	lung	_	_	O
31	cancer	_	_	O
32	.	_	_	O

33	Eligible	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	complete	_	_	O
37	response	_	_	O
38	(	_	_	O
39	CR	_	_	O
40	)	_	_	O
41	or	_	_	O
42	partial	_	_	O
43	response	_	_	O
44	(	_	_	O
45	PR	_	_	O
46	)	_	_	O
47	to	_	_	O
48	combination	_	_	O
49	chemotherapy	_	_	O
50	(	_	_	O
51	+/-	_	_	O
52	thoracic	_	_	O
53	or	_	_	O
54	prophylactic	_	_	O
55	cranial	_	_	O
56	radiation	_	_	O
57	)	_	_	O
58	received	_	_	O
59	oral	_	_	O
60	vandetanib	_	_	O
61	300	_	_	O
62	mg/d	_	_	O
63	or	_	_	O
64	matched	_	_	O
65	placebo	_	_	O
66	.	_	_	O

67	With	_	_	O
68	100	_	_	O
69	patients	_	_	O
70	and	_	_	O
71	77	_	_	O
72	events	_	_	O
73	,	_	_	O
74	the	_	_	O
75	study	_	_	O
76	had	_	_	O
77	80	_	_	O
78	%	_	_	O
79	power	_	_	O
80	to	_	_	O
81	detect	_	_	O
82	an	_	_	O
83	improvement	_	_	O
84	in	_	_	O
85	median	_	_	O
86	progression-free	_	_	O
87	survival	_	_	O
88	from	_	_	O
89	4	_	_	O
90	to	_	_	O
91	6.5	_	_	O
92	months	_	_	O
93	(	_	_	O
94	one-sided	_	_	O
95	,	_	_	O
96	10	_	_	O
97	%	_	_	O
98	-level	_	_	O
99	test	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Between	_	_	O
103	May	_	_	O
104	2003	_	_	O
105	and	_	_	O
106	March	_	_	O
107	2006	_	_	O
108	,	_	_	O
109	107	_	_	O
110	patients	_	_	O
111	were	_	_	O
112	accrued	_	_	O
113	;	_	_	O
114	46	_	_	O
115	had	_	_	O
116	limited	_	_	O
117	disease	_	_	O
118	and	_	_	O
119	61	_	_	O
120	extensive	_	_	O
121	disease	_	_	O
122	.	_	_	O

123	There	_	_	O
124	were	_	_	O
125	fewer	_	_	O
126	patients	_	_	O
127	with	_	_	O
128	a	_	_	O
129	performance	_	_	O
130	status	_	_	O
131	of	_	_	O
132	0	_	_	O
133	(	_	_	O
134	n	_	_	O
135	=	_	_	O
136	11	_	_	O
137	v	_	_	O
138	20	_	_	O
139	)	_	_	O
140	,	_	_	O
141	and	_	_	O
142	fewer	_	_	O
143	had	_	_	O
144	CR	_	_	O
145	to	_	_	O
146	initial	_	_	O
147	therapy	_	_	O
148	(	_	_	O
149	n	_	_	O
150	=	_	_	O
151	4	_	_	O
152	v	_	_	O
153	8	_	_	O
154	)	_	_	O
155	in	_	_	O
156	the	_	_	O
157	vandetanib	_	_	O
158	arm	_	_	O
159	.	_	_	O

160	Vandetanib	_	_	B-Premise
161	patients	_	_	I-Premise
162	had	_	_	I-Premise
163	more	_	_	I-Premise
164	toxicity	_	_	I-Premise
165	and	_	_	I-Premise
166	required	_	_	I-Premise
167	more	_	_	I-Premise
168	dose	_	_	I-Premise
169	modifications	_	_	I-Premise
170	for	_	_	I-Premise
171	gastrointestinal	_	_	I-Premise
172	toxicity	_	_	I-Premise
173	and	_	_	I-Premise
174	rash	_	_	I-Premise
175	.	_	_	I-Premise

176	Asymptomatic	_	_	B-Premise
177	Corrected	_	_	I-Premise
178	QT	_	_	I-Premise
179	interval	_	_	I-Premise
180	(	_	_	I-Premise
181	QTC	_	_	I-Premise
182	)	_	_	I-Premise
183	prolongation	_	_	I-Premise
184	was	_	_	I-Premise
185	observed	_	_	I-Premise
186	in	_	_	I-Premise
187	eight	_	_	I-Premise
188	vandetanib	_	_	I-Premise
189	patients	_	_	I-Premise
190	.	_	_	I-Premise

191	Median	_	_	B-Premise
192	progression-free	_	_	I-Premise
193	survival	_	_	I-Premise
194	for	_	_	I-Premise
195	vandetanib	_	_	I-Premise
196	and	_	_	I-Premise
197	placebo	_	_	I-Premise
198	was	_	_	I-Premise
199	2.7	_	_	I-Premise
200	and	_	_	I-Premise
201	2.8	_	_	I-Premise
202	months	_	_	I-Premise
203	,	_	_	I-Premise
204	respectively	_	_	I-Premise
205	(	_	_	I-Premise
206	hazard	_	_	I-Premise
207	ratio	_	_	I-Premise
208	[	_	_	I-Premise
209	HR	_	_	I-Premise
210	]	_	_	I-Premise
211	,	_	_	I-Premise
212	1.01	_	_	I-Premise
213	;	_	_	I-Premise
214	80	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	,	_	_	I-Premise
218	0.75	_	_	I-Premise
219	to	_	_	I-Premise
220	1.36	_	_	I-Premise
221	;	_	_	I-Premise
222	one-sided	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.51	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Overall	_	_	B-Premise
229	survival	_	_	I-Premise
230	for	_	_	I-Premise
231	vandetanib	_	_	I-Premise
232	was	_	_	I-Premise
233	10.6	_	_	I-Premise
234	versus	_	_	I-Premise
235	11.9	_	_	I-Premise
236	months	_	_	I-Premise
237	for	_	_	I-Premise
238	placebo	_	_	I-Premise
239	(	_	_	I-Premise
240	HR	_	_	I-Premise
241	,	_	_	I-Premise
242	1.43	_	_	I-Premise
243	;	_	_	I-Premise
244	80	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	,	_	_	I-Premise
248	1.00	_	_	I-Premise
249	to	_	_	I-Premise
250	2.05	_	_	I-Premise
251	;	_	_	I-Premise
252	one-sided	_	_	I-Premise
253	P	_	_	I-Premise
254	=	_	_	I-Premise
255	0.9	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	In	_	_	B-Premise
259	planned	_	_	I-Premise
260	subgroup	_	_	I-Premise
261	analyses	_	_	I-Premise
262	,	_	_	I-Premise
263	a	_	_	I-Premise
264	significant	_	_	I-Premise
265	interaction	_	_	I-Premise
266	was	_	_	I-Premise
267	noted	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.01	_	_	I-Premise
272	)	_	_	I-Premise
273	:	_	_	I-Premise
274	limited-stage	_	_	I-Premise
275	vandetanib	_	_	I-Premise
276	patients	_	_	I-Premise
277	had	_	_	I-Premise
278	longer	_	_	I-Premise
279	overall	_	_	I-Premise
280	survival	_	_	I-Premise
281	(	_	_	I-Premise
282	HR	_	_	I-Premise
283	,	_	_	I-Premise
284	0.45	_	_	I-Premise
285	;	_	_	I-Premise
286	one-sided	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	.07	_	_	I-Premise
290	)	_	_	I-Premise
291	and	_	_	I-Premise
292	extensive-stage	_	_	I-Premise
293	vandetanib	_	_	I-Premise
294	patients	_	_	I-Premise
295	shorter	_	_	I-Premise
296	survival	_	_	I-Premise
297	compared	_	_	I-Premise
298	with	_	_	I-Premise
299	placebo	_	_	I-Premise
300	(	_	_	I-Premise
301	HR	_	_	I-Premise
302	,	_	_	I-Premise
303	2.27	_	_	I-Premise
304	;	_	_	I-Premise
305	one-sided	_	_	I-Premise
306	P	_	_	I-Premise
307	=	_	_	I-Premise
308	.996	_	_	I-Premise
309	)	_	_	I-Premise
310	.	_	_	I-Premise

311	Vandetanib	_	_	B-Claim
312	failed	_	_	I-Claim
313	to	_	_	I-Claim
314	demonstrate	_	_	I-Claim
315	efficacy	_	_	I-Claim
316	as	_	_	I-Claim
317	maintenance	_	_	I-Claim
318	therapy	_	_	I-Claim
319	for	_	_	I-Claim
320	small-cell	_	_	I-Claim
321	lung	_	_	I-Claim
322	cancer	_	_	I-Claim
323	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	the	_	_	O
3	prospectively	_	_	O
4	collected	_	_	O
5	health-related	_	_	O
6	quality-of-life	_	_	O
7	(	_	_	O
8	HRQOL	_	_	O
9	)	_	_	O
10	data	_	_	O
11	from	_	_	O
12	patients	_	_	O
13	enrolled	_	_	O
14	in	_	_	O
15	two	_	_	O
16	Radiation	_	_	O
17	Therapy	_	_	O
18	Oncology	_	_	O
19	Group	_	_	O
20	randomized	_	_	O
21	Phase	_	_	O
22	III	_	_	O
23	head	_	_	O
24	and	_	_	O
25	neck	_	_	O
26	cancer	_	_	O
27	trials	_	_	O
28	(	_	_	O
29	90-03	_	_	O
30	and	_	_	O
31	91-11	_	_	O
32	)	_	_	O
33	to	_	_	O
34	assess	_	_	O
35	their	_	_	O
36	value	_	_	O
37	as	_	_	O
38	an	_	_	O
39	independent	_	_	O
40	prognostic	_	_	O
41	factor	_	_	O
42	for	_	_	O
43	locoregional	_	_	O
44	control	_	_	O
45	(	_	_	O
46	LRC	_	_	O
47	)	_	_	O
48	and/or	_	_	O
49	overall	_	_	O
50	survival	_	_	O
51	(	_	_	O
52	OS	_	_	O
53	)	_	_	O
54	.	_	_	O

55	HRQOL	_	_	O
56	questionnaires	_	_	O
57	,	_	_	O
58	using	_	_	O
59	a	_	_	O
60	validated	_	_	O
61	instrument	_	_	O
62	,	_	_	O
63	the	_	_	O
64	Functional	_	_	O
65	Assessment	_	_	O
66	of	_	_	O
67	Cancer	_	_	O
68	Therapy-Head	_	_	O
69	and	_	_	O
70	Neck	_	_	O
71	(	_	_	O
72	FACT-H	_	_	O
73	&	_	_	O
74	amp	_	_	O
75	;	_	_	O
76	N	_	_	O
77	)	_	_	O
78	,	_	_	O
79	version	_	_	O
80	2	_	_	O
81	,	_	_	O
82	were	_	_	O
83	completed	_	_	O
84	by	_	_	O
85	patients	_	_	O
86	before	_	_	O
87	the	_	_	O
88	start	_	_	O
89	of	_	_	O
90	treatment	_	_	O
91	.	_	_	O

92	OS	_	_	O
93	and	_	_	O
94	LRC	_	_	O
95	were	_	_	O
96	the	_	_	O
97	outcome	_	_	O
98	measures	_	_	O
99	analyzed	_	_	O
100	using	_	_	O
101	a	_	_	O
102	multivariate	_	_	O
103	Cox	_	_	O
104	proportional	_	_	O
105	hazard	_	_	O
106	model	_	_	O
107	.	_	_	O

108	Baseline	_	_	O
109	FACT-H	_	_	O
110	&	_	_	O
111	amp	_	_	O
112	;	_	_	O
113	N	_	_	O
114	data	_	_	O
115	were	_	_	O
116	available	_	_	O
117	for	_	_	O
118	1,093	_	_	O
119	patients	_	_	O
120	and	_	_	O
121	missing	_	_	O
122	for	_	_	O
123	417	_	_	O
124	patients	_	_	O
125	.	_	_	O

126	No	_	_	O
127	significant	_	_	O
128	difference	_	_	O
129	in	_	_	O
130	outcome	_	_	O
131	was	_	_	O
132	found	_	_	O
133	between	_	_	O
134	the	_	_	O
135	patients	_	_	O
136	with	_	_	O
137	and	_	_	O
138	without	_	_	O
139	baseline	_	_	O
140	FACT-H	_	_	O
141	&	_	_	O
142	amp	_	_	O
143	;	_	_	O
144	N	_	_	O
145	data	_	_	O
146	(	_	_	O
147	p	_	_	O
148	=	_	_	O
149	0.58	_	_	O
150	)	_	_	O
151	.	_	_	O

152	The	_	_	O
153	median	_	_	O
154	follow-up	_	_	O
155	time	_	_	O
156	was	_	_	O
157	27.2	_	_	O
158	months	_	_	O
159	for	_	_	O
160	all	_	_	O
161	patients	_	_	O
162	and	_	_	O
163	49	_	_	O
164	months	_	_	O
165	for	_	_	O
166	surviving	_	_	O
167	patients	_	_	O
168	.	_	_	O

169	Multivariate	_	_	O
170	analyses	_	_	O
171	were	_	_	O
172	performed	_	_	O
173	for	_	_	O
174	both	_	_	O
175	OS	_	_	O
176	and	_	_	O
177	LRC	_	_	O
178	.	_	_	O

179	Beyond	_	_	B-Premise
180	tumor	_	_	I-Premise
181	and	_	_	I-Premise
182	nodal	_	_	I-Premise
183	stage	_	_	I-Premise
184	,	_	_	I-Premise
185	Karnofsky	_	_	I-Premise
186	performance	_	_	I-Premise
187	status	_	_	I-Premise
188	,	_	_	I-Premise
189	primary	_	_	I-Premise
190	site	_	_	I-Premise
191	,	_	_	I-Premise
192	cigarette	_	_	I-Premise
193	use	_	_	I-Premise
194	,	_	_	I-Premise
195	use	_	_	I-Premise
196	of	_	_	I-Premise
197	concurrent	_	_	I-Premise
198	chemotherapy	_	_	I-Premise
199	,	_	_	I-Premise
200	and	_	_	I-Premise
201	altered	_	_	I-Premise
202	fractionation	_	_	I-Premise
203	schedules	_	_	I-Premise
204	,	_	_	I-Premise
205	the	_	_	I-Premise
206	FACT-H	_	_	I-Premise
207	&	_	_	I-Premise
208	amp	_	_	I-Premise
209	;	_	_	I-Premise
210	N	_	_	I-Premise
211	score	_	_	I-Premise
212	was	_	_	I-Premise
213	independently	_	_	I-Premise
214	predictive	_	_	I-Premise
215	of	_	_	I-Premise
216	LRC	_	_	I-Premise
217	(	_	_	I-Premise
218	but	_	_	I-Premise
219	not	_	_	I-Premise
220	OS	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	with	_	_	I-Premise
224	p	_	_	I-Premise
225	=	_	_	I-Premise
226	0.0038	_	_	I-Premise
227	.	_	_	I-Premise

228	The	_	_	B-Premise
229	functional	_	_	I-Premise
230	well-being	_	_	I-Premise
231	component	_	_	I-Premise
232	of	_	_	I-Premise
233	the	_	_	I-Premise
234	FACT-H	_	_	I-Premise
235	&	_	_	I-Premise
236	amp	_	_	I-Premise
237	;	_	_	I-Premise
238	N	_	_	I-Premise
239	predicted	_	_	I-Premise
240	most	_	_	I-Premise
241	significantly	_	_	I-Premise
242	for	_	_	I-Premise
243	LRC	_	_	I-Premise
244	(	_	_	I-Premise
245	p	_	_	I-Premise
246	=	_	_	I-Premise
247	0.0004	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	This	_	_	B-Claim
251	study	_	_	I-Claim
252	represents	_	_	I-Claim
253	,	_	_	I-Claim
254	to	_	_	I-Claim
255	our	_	_	I-Claim
256	knowledge	_	_	I-Claim
257	,	_	_	I-Claim
258	the	_	_	I-Claim
259	largest	_	_	I-Claim
260	analysis	_	_	I-Claim
261	of	_	_	I-Claim
262	HRQOL	_	_	I-Claim
263	as	_	_	I-Claim
264	a	_	_	I-Claim
265	prognostic	_	_	I-Claim
266	factor	_	_	I-Claim
267	in	_	_	I-Claim
268	locally	_	_	I-Claim
269	advanced	_	_	I-Claim
270	head	_	_	I-Claim
271	and	_	_	I-Claim
272	neck	_	_	I-Claim
273	cancer	_	_	I-Claim
274	patients	_	_	I-Claim
275	.	_	_	I-Claim

276	The	_	_	B-Claim
277	results	_	_	I-Claim
278	of	_	_	I-Claim
279	this	_	_	I-Claim
280	study	_	_	I-Claim
281	have	_	_	I-Claim
282	demonstrated	_	_	I-Claim
283	the	_	_	I-Claim
284	importance	_	_	I-Claim
285	of	_	_	I-Claim
286	baseline	_	_	I-Claim
287	HRQOL	_	_	I-Claim
288	as	_	_	I-Claim
289	a	_	_	I-Claim
290	significant	_	_	I-Claim
291	and	_	_	I-Claim
292	independent	_	_	I-Claim
293	predictor	_	_	I-Claim
294	of	_	_	I-Claim
295	LRC	_	_	I-Claim
296	in	_	_	I-Claim
297	patients	_	_	I-Claim
298	with	_	_	I-Claim
299	locally	_	_	I-Claim
300	advanced	_	_	I-Claim
301	head	_	_	I-Claim
302	and	_	_	I-Claim
303	neck	_	_	I-Claim
304	cancer	_	_	I-Claim
305	.	_	_	I-Claim


0	Relapse	_	_	B-Claim
1	after	_	_	I-Claim
2	completing	_	_	I-Claim
3	adjuvant	_	_	I-Claim
4	tamoxifen	_	_	I-Claim
5	therapy	_	_	I-Claim
6	is	_	_	I-Claim
7	a	_	_	I-Claim
8	persistent	_	_	I-Claim
9	threat	_	_	I-Claim
10	for	_	_	I-Claim
11	women	_	_	I-Claim
12	with	_	_	I-Claim
13	hormone-responsive	_	_	I-Claim
14	breast	_	_	I-Claim
15	cancer	_	_	I-Claim
16	.	_	_	I-Claim

17	Third-generation	_	_	O
18	aromatase	_	_	O
19	inhibitors	_	_	O
20	,	_	_	O
21	such	_	_	O
22	as	_	_	O
23	letrozole	_	_	O
24	,	_	_	O
25	provide	_	_	O
26	a	_	_	O
27	new	_	_	O
28	option	_	_	O
29	for	_	_	O
30	extended	_	_	O
31	adjuvant	_	_	O
32	hormonal	_	_	O
33	therapy	_	_	O
34	after	_	_	O
35	5	_	_	O
36	years	_	_	O
37	of	_	_	O
38	tamoxifen	_	_	O
39	.	_	_	O

40	MA.17	_	_	O
41	was	_	_	O
42	conducted	_	_	O
43	to	_	_	O
44	determine	_	_	O
45	whether	_	_	O
46	letrozole	_	_	O
47	improves	_	_	O
48	outcome	_	_	O
49	after	_	_	O
50	discontinuation	_	_	O
51	of	_	_	O
52	tamoxifen	_	_	O
53	.	_	_	O

54	Postmenopausal	_	_	O
55	women	_	_	O
56	with	_	_	O
57	hormone	_	_	O
58	receptor-positive	_	_	O
59	breast	_	_	O
60	cancer	_	_	O
61	(	_	_	O
62	N=5,187	_	_	O
63	)	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	letrozole	_	_	O
68	2.5	_	_	O
69	mg	_	_	O
70	or	_	_	O
71	placebo	_	_	O
72	once	_	_	O
73	daily	_	_	O
74	for	_	_	O
75	5	_	_	O
76	years	_	_	O
77	.	_	_	O

78	At	_	_	B-Premise
79	a	_	_	I-Premise
80	median	_	_	I-Premise
81	follow-up	_	_	I-Premise
82	of	_	_	I-Premise
83	30	_	_	I-Premise
84	months	_	_	I-Premise
85	,	_	_	I-Premise
86	letrozole	_	_	I-Premise
87	significantly	_	_	I-Premise
88	improved	_	_	I-Premise
89	disease-free	_	_	I-Premise
90	survival	_	_	I-Premise
91	(	_	_	I-Premise
92	DFS	_	_	I-Premise
93	;	_	_	I-Premise
94	P	_	_	I-Premise
95	<	_	_	I-Premise
96	0.001	_	_	I-Premise
97	)	_	_	I-Premise
98	,	_	_	I-Premise
99	the	_	_	I-Premise
100	primary	_	_	I-Premise
101	end	_	_	I-Premise
102	point	_	_	I-Premise
103	,	_	_	I-Premise
104	compared	_	_	I-Premise
105	with	_	_	I-Premise
106	placebo	_	_	I-Premise
107	(	_	_	I-Premise
108	hazard	_	_	I-Premise
109	ratio	_	_	I-Premise
110	[	_	_	I-Premise
111	HR	_	_	I-Premise
112	]	_	_	I-Premise
113	for	_	_	I-Premise
114	recurrence	_	_	I-Premise
115	or	_	_	I-Premise
116	contralateral	_	_	I-Premise
117	breast	_	_	I-Premise
118	cancer	_	_	I-Premise
119	0.58	_	_	I-Premise
120	;	_	_	I-Premise
121	95	_	_	I-Premise
122	%	_	_	I-Premise
123	confidence	_	_	I-Premise
124	interval	_	_	I-Premise
125	[	_	_	I-Premise
126	CI	_	_	I-Premise
127	]	_	_	I-Premise
128	0.45	_	_	I-Premise
129	,	_	_	I-Premise
130	0.76	_	_	I-Premise
131	]	_	_	I-Premise
132	P	_	_	I-Premise
133	<	_	_	I-Premise
134	0.001	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	Furthermore	_	_	B-Premise
138	,	_	_	I-Premise
139	letrozole	_	_	I-Premise
140	significantly	_	_	I-Premise
141	improved	_	_	I-Premise
142	distant	_	_	I-Premise
143	DFS	_	_	I-Premise
144	(	_	_	I-Premise
145	HR=0.60	_	_	I-Premise
146	;	_	_	I-Premise
147	95	_	_	I-Premise
148	%	_	_	I-Premise
149	CI	_	_	I-Premise
150	0.43	_	_	I-Premise
151	,	_	_	I-Premise
152	0.84	_	_	I-Premise
153	;	_	_	I-Premise
154	P=0.002	_	_	I-Premise
155	)	_	_	I-Premise
156	and	_	_	I-Premise
157	,	_	_	I-Premise
158	in	_	_	I-Premise
159	women	_	_	I-Premise
160	with	_	_	I-Premise
161	node-positive	_	_	I-Premise
162	tumors	_	_	I-Premise
163	,	_	_	I-Premise
164	overall	_	_	I-Premise
165	survival	_	_	I-Premise
166	(	_	_	I-Premise
167	HR=0.61	_	_	I-Premise
168	;	_	_	I-Premise
169	95	_	_	I-Premise
170	%	_	_	I-Premise
171	CI	_	_	I-Premise
172	0.38	_	_	I-Premise
173	,	_	_	I-Premise
174	0.98	_	_	I-Premise
175	;	_	_	I-Premise
176	P=0.04	_	_	I-Premise
177	)	_	_	I-Premise
178	.	_	_	I-Premise

179	Clinical	_	_	B-Premise
180	benefits	_	_	I-Premise
181	,	_	_	I-Premise
182	including	_	_	I-Premise
183	an	_	_	I-Premise
184	overall	_	_	I-Premise
185	survival	_	_	I-Premise
186	advantage	_	_	I-Premise
187	,	_	_	I-Premise
188	were	_	_	I-Premise
189	also	_	_	I-Premise
190	seen	_	_	I-Premise
191	in	_	_	I-Premise
192	women	_	_	I-Premise
193	who	_	_	I-Premise
194	crossed	_	_	I-Premise
195	over	_	_	I-Premise
196	from	_	_	I-Premise
197	placebo	_	_	I-Premise
198	to	_	_	I-Premise
199	letrozole	_	_	I-Premise
200	after	_	_	I-Premise
201	unblinding	_	_	I-Premise
202	,	_	_	I-Premise
203	indicating	_	_	I-Premise
204	that	_	_	I-Premise
205	tumors	_	_	I-Premise
206	remain	_	_	I-Premise
207	sensitive	_	_	I-Premise
208	to	_	_	I-Premise
209	hormone	_	_	I-Premise
210	therapy	_	_	I-Premise
211	despite	_	_	I-Premise
212	a	_	_	I-Premise
213	prolonged	_	_	I-Premise
214	period	_	_	I-Premise
215	since	_	_	I-Premise
216	discontinuation	_	_	I-Premise
217	of	_	_	I-Premise
218	tamoxifen	_	_	I-Premise
219	.	_	_	I-Premise

220	The	_	_	O
221	efficacy	_	_	O
222	and	_	_	O
223	safety	_	_	O
224	of	_	_	O
225	letrozole	_	_	O
226	therapy	_	_	O
227	beyond	_	_	O
228	5	_	_	O
229	years	_	_	O
230	is	_	_	O
231	being	_	_	O
232	assessed	_	_	O
233	in	_	_	O
234	a	_	_	O
235	re-randomization	_	_	O
236	study	_	_	O
237	,	_	_	O
238	following	_	_	O
239	the	_	_	O
240	emergence	_	_	O
241	of	_	_	O
242	new	_	_	O
243	data	_	_	O
244	suggesting	_	_	O
245	that	_	_	O
246	clinical	_	_	O
247	benefit	_	_	O
248	correlates	_	_	O
249	with	_	_	O
250	the	_	_	O
251	duration	_	_	O
252	of	_	_	O
253	letrozole	_	_	O
254	.	_	_	O

255	MA.17	_	_	B-Claim
256	showed	_	_	I-Claim
257	that	_	_	I-Claim
258	letrozole	_	_	I-Claim
259	is	_	_	I-Claim
260	extremely	_	_	I-Claim
261	well-tolerated	_	_	I-Claim
262	relative	_	_	I-Claim
263	to	_	_	I-Claim
264	placebo	_	_	I-Claim
265	.	_	_	I-Claim

266	Letrozole	_	_	B-Claim
267	should	_	_	I-Claim
268	be	_	_	I-Claim
269	considered	_	_	I-Claim
270	for	_	_	I-Claim
271	all	_	_	I-Claim
272	women	_	_	I-Claim
273	completing	_	_	I-Claim
274	tamoxifen	_	_	I-Claim
275	;	_	_	I-Claim
276	new	_	_	B-Claim
277	results	_	_	I-Claim
278	from	_	_	I-Claim
279	the	_	_	I-Claim
280	post-unblinding	_	_	I-Claim
281	analysis	_	_	I-Claim
282	suggest	_	_	I-Claim
283	that	_	_	I-Claim
284	letrozole	_	_	I-Claim
285	treatment	_	_	I-Claim
286	should	_	_	I-Claim
287	also	_	_	I-Claim
288	be	_	_	I-Claim
289	considered	_	_	I-Claim
290	for	_	_	I-Claim
291	all	_	_	I-Claim
292	disease-free	_	_	I-Claim
293	women	_	_	I-Claim
294	for	_	_	I-Claim
295	periods	_	_	I-Claim
296	up	_	_	I-Claim
297	to	_	_	I-Claim
298	5	_	_	I-Claim
299	years	_	_	I-Claim
300	following	_	_	I-Claim
301	completion	_	_	I-Claim
302	of	_	_	I-Claim
303	adjuvant	_	_	I-Claim
304	tamoxifen	_	_	I-Claim
305	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	abatacept	_	_	O
8	during	_	_	O
9	2	_	_	O
10	years	_	_	O
11	of	_	_	O
12	the	_	_	O
13	ATTAIN	_	_	O
14	(	_	_	O
15	Abatacept	_	_	O
16	Trial	_	_	O
17	in	_	_	O
18	Treatment	_	_	O
19	of	_	_	O
20	Anti-TNF	_	_	O
21	INadequate	_	_	O
22	responders	_	_	O
23	)	_	_	O
24	trial	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	rheumatoid	_	_	O
29	arthritis	_	_	O
30	.	_	_	O

31	Patients	_	_	O
32	completing	_	_	O
33	the	_	_	O
34	6-month	_	_	O
35	,	_	_	O
36	double-blind	_	_	O
37	period	_	_	O
38	were	_	_	O
39	eligible	_	_	O
40	to	_	_	O
41	enter	_	_	O
42	the	_	_	O
43	long-term	_	_	O
44	extension	_	_	O
45	;	_	_	O
46	patients	_	_	O
47	received	_	_	O
48	abatacept	_	_	O
49	approximately	_	_	O
50	10	_	_	O
51	mg/kg	_	_	O
52	,	_	_	O
53	plus	_	_	O
54	disease-modifying	_	_	O
55	antirheumatic	_	_	O
56	drugs	_	_	O
57	.	_	_	O

58	Safety	_	_	O
59	and	_	_	O
60	efficacy	_	_	O
61	(	_	_	O
62	American	_	_	O
63	College	_	_	O
64	of	_	_	O
65	Rheumatology	_	_	O
66	(	_	_	O
67	ACR	_	_	O
68	)	_	_	O
69	criteria	_	_	O
70	responses	_	_	O
71	,	_	_	O
72	DAS28	_	_	O
73	(	_	_	O
74	C-reactive	_	_	O
75	protein	_	_	O
76	)	_	_	O
77	,	_	_	O
78	HAQ-DI	_	_	O
79	,	_	_	O
80	SF-36	_	_	O
81	,	_	_	O
82	Medical	_	_	O
83	Outcomes	_	_	O
84	Study	_	_	O
85	Sleep	_	_	O
86	Problems	_	_	O
87	Index	_	_	O
88	,	_	_	O
89	fatigue	_	_	O
90	VAS	_	_	O
91	)	_	_	O
92	were	_	_	O
93	assessed	_	_	O
94	through	_	_	O
95	2	_	_	O
96	years	_	_	O
97	.	_	_	O

98	317	_	_	O
99	patients	_	_	O
100	(	_	_	O
101	218	_	_	O
102	from	_	_	O
103	the	_	_	O
104	abatacept	_	_	O
105	and	_	_	O
106	99	_	_	O
107	from	_	_	O
108	the	_	_	O
109	placebo	_	_	O
110	group	_	_	O
111	)	_	_	O
112	entered	_	_	O
113	and	_	_	O
114	222	_	_	O
115	(	_	_	O
116	70	_	_	O
117	%	_	_	O
118	)	_	_	O
119	completed	_	_	O
120	18	_	_	O
121	months	_	_	O
122	of	_	_	O
123	long-term	_	_	O
124	extension	_	_	O
125	treatment	_	_	O
126	.	_	_	O

127	The	_	_	B-Premise
128	incidence	_	_	I-Premise
129	and	_	_	I-Premise
130	type	_	_	I-Premise
131	of	_	_	I-Premise
132	adverse	_	_	I-Premise
133	events	_	_	I-Premise
134	were	_	_	I-Premise
135	consistent	_	_	I-Premise
136	between	_	_	I-Premise
137	the	_	_	I-Premise
138	double-blind	_	_	I-Premise
139	and	_	_	I-Premise
140	cumulative	_	_	I-Premise
141	(	_	_	I-Premise
142	double-blind	_	_	I-Premise
143	plus	_	_	I-Premise
144	long-term	_	_	I-Premise
145	extension	_	_	I-Premise
146	)	_	_	I-Premise
147	periods	_	_	I-Premise
148	.	_	_	I-Premise

149	Rates	_	_	B-Premise
150	of	_	_	I-Premise
151	serious	_	_	I-Premise
152	adverse	_	_	I-Premise
153	events	_	_	I-Premise
154	were	_	_	I-Premise
155	25.6	_	_	I-Premise
156	and	_	_	I-Premise
157	23.4	_	_	I-Premise
158	per	_	_	I-Premise
159	100	_	_	I-Premise
160	patient-years	_	_	I-Premise
161	in	_	_	I-Premise
162	the	_	_	I-Premise
163	double-blind	_	_	I-Premise
164	versus	_	_	I-Premise
165	cumulative	_	_	I-Premise
166	period	_	_	I-Premise
167	.	_	_	I-Premise

168	At	_	_	B-Premise
169	6	_	_	I-Premise
170	months	_	_	I-Premise
171	and	_	_	I-Premise
172	2	_	_	I-Premise
173	years	_	_	I-Premise
174	,	_	_	I-Premise
175	using	_	_	I-Premise
176	non-responder	_	_	I-Premise
177	analyses	_	_	I-Premise
178	,	_	_	I-Premise
179	ACR	_	_	I-Premise
180	responses	_	_	I-Premise
181	in	_	_	I-Premise
182	abatacept-treated	_	_	I-Premise
183	patients	_	_	I-Premise
184	were	_	_	I-Premise
185	:	_	_	I-Premise
186	ACR	_	_	I-Premise
187	20	_	_	I-Premise
188	,	_	_	I-Premise
189	59.4	_	_	I-Premise
190	%	_	_	I-Premise
191	and	_	_	I-Premise
192	56.2	_	_	I-Premise
193	%	_	_	I-Premise
194	;	_	_	I-Premise
195	ACR	_	_	I-Premise
196	50	_	_	I-Premise
197	,	_	_	I-Premise
198	23.5	_	_	I-Premise
199	%	_	_	I-Premise
200	and	_	_	I-Premise
201	33.2	_	_	I-Premise
202	%	_	_	I-Premise
203	;	_	_	I-Premise
204	ACR	_	_	I-Premise
205	70	_	_	I-Premise
206	,	_	_	I-Premise
207	11.5	_	_	I-Premise
208	%	_	_	I-Premise
209	and	_	_	I-Premise
210	16.1	_	_	I-Premise
211	%	_	_	I-Premise
212	;	_	_	I-Premise
213	HAQ-DI	_	_	I-Premise
214	responses	_	_	I-Premise
215	were	_	_	I-Premise
216	54.4	_	_	I-Premise
217	%	_	_	I-Premise
218	and	_	_	I-Premise
219	47.9	_	_	I-Premise
220	%	_	_	I-Premise
221	.	_	_	I-Premise

222	At	_	_	B-Premise
223	6	_	_	I-Premise
224	months	_	_	I-Premise
225	and	_	_	I-Premise
226	2	_	_	I-Premise
227	years	_	_	I-Premise
228	,	_	_	I-Premise
229	using	_	_	I-Premise
230	post-hoc	_	_	I-Premise
231	as-observed	_	_	I-Premise
232	analyses	_	_	I-Premise
233	,	_	_	I-Premise
234	the	_	_	I-Premise
235	percentage	_	_	I-Premise
236	of	_	_	I-Premise
237	patients	_	_	I-Premise
238	(	_	_	I-Premise
239	95	_	_	I-Premise
240	%	_	_	I-Premise
241	confidence	_	_	I-Premise
242	interval	_	_	I-Premise
243	)	_	_	I-Premise
244	achieving	_	_	I-Premise
245	DAS28	_	_	I-Premise
246	(	_	_	I-Premise
247	C-reactive	_	_	I-Premise
248	protein	_	_	I-Premise
249	)	_	_	I-Premise
250	low	_	_	I-Premise
251	disease	_	_	I-Premise
252	activity	_	_	I-Premise
253	score	_	_	I-Premise
254	(	_	_	I-Premise
255	<	_	_	I-Premise
256	or	_	_	I-Premise
257	=	_	_	I-Premise
258	3.2	_	_	I-Premise
259	)	_	_	I-Premise
260	and	_	_	I-Premise
261	DAS28	_	_	I-Premise
262	(	_	_	I-Premise
263	C-reactive	_	_	I-Premise
264	protein	_	_	I-Premise
265	)	_	_	I-Premise
266	-defined	_	_	I-Premise
267	remission	_	_	I-Premise
268	(	_	_	I-Premise
269	<	_	_	I-Premise
270	2.6	_	_	I-Premise
271	)	_	_	I-Premise
272	increased	_	_	I-Premise
273	from	_	_	I-Premise
274	18.3	_	_	I-Premise
275	%	_	_	I-Premise
276	(	_	_	I-Premise
277	13.0	_	_	I-Premise
278	,	_	_	I-Premise
279	23.5	_	_	I-Premise
280	)	_	_	I-Premise
281	to	_	_	I-Premise
282	32.0	_	_	I-Premise
283	%	_	_	I-Premise
284	(	_	_	I-Premise
285	24.6	_	_	I-Premise
286	,	_	_	I-Premise
287	39.4	_	_	I-Premise
288	)	_	_	I-Premise
289	and	_	_	I-Premise
290	11.1	_	_	I-Premise
291	%	_	_	I-Premise
292	(	_	_	I-Premise
293	6.8	_	_	I-Premise
294	,	_	_	I-Premise
295	15.3	_	_	I-Premise
296	)	_	_	I-Premise
297	to	_	_	I-Premise
298	20.3	_	_	I-Premise
299	%	_	_	I-Premise
300	(	_	_	I-Premise
301	13.9	_	_	I-Premise
302	,	_	_	I-Premise
303	26.6	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	Clinically	_	_	B-Premise
307	meaningful	_	_	I-Premise
308	improvements	_	_	I-Premise
309	in	_	_	I-Premise
310	SF-36	_	_	I-Premise
311	,	_	_	I-Premise
312	pain	_	_	I-Premise
313	,	_	_	I-Premise
314	fatigue	_	_	I-Premise
315	and	_	_	I-Premise
316	sleep	_	_	I-Premise
317	problems	_	_	I-Premise
318	were	_	_	I-Premise
319	also	_	_	I-Premise
320	maintained	_	_	I-Premise
321	throughout	_	_	I-Premise
322	the	_	_	I-Premise
323	2	_	_	I-Premise
324	years	_	_	I-Premise
325	of	_	_	I-Premise
326	abatacept	_	_	I-Premise
327	treatment	_	_	I-Premise
328	.	_	_	I-Premise

329	No	_	_	B-Premise
330	unique	_	_	I-Premise
331	safety	_	_	I-Premise
332	observations	_	_	I-Premise
333	were	_	_	I-Premise
334	reported	_	_	I-Premise
335	during	_	_	I-Premise
336	open-label	_	_	I-Premise
337	exposure	_	_	I-Premise
338	.	_	_	I-Premise

339	Improvements	_	_	B-Premise
340	in	_	_	I-Premise
341	the	_	_	I-Premise
342	signs	_	_	I-Premise
343	and	_	_	I-Premise
344	symptoms	_	_	I-Premise
345	of	_	_	I-Premise
346	rheumatoid	_	_	I-Premise
347	arthritis	_	_	I-Premise
348	,	_	_	I-Premise
349	physical	_	_	I-Premise
350	function	_	_	I-Premise
351	and	_	_	I-Premise
352	health-related	_	_	I-Premise
353	quality	_	_	I-Premise
354	of	_	_	I-Premise
355	life	_	_	I-Premise
356	observed	_	_	I-Premise
357	after	_	_	I-Premise
358	6	_	_	I-Premise
359	months	_	_	I-Premise
360	,	_	_	I-Premise
361	were	_	_	I-Premise
362	maintained	_	_	I-Premise
363	throughout	_	_	I-Premise
364	the	_	_	I-Premise
365	2	_	_	I-Premise
366	years	_	_	I-Premise
367	in	_	_	I-Premise
368	this	_	_	I-Premise
369	population	_	_	I-Premise
370	with	_	_	I-Premise
371	difficult-to-treat	_	_	I-Premise
372	disease	_	_	I-Premise
373	.	_	_	I-Premise


0	Few	_	_	O
1	randomized	_	_	O
2	trials	_	_	O
3	have	_	_	O
4	compared	_	_	O
5	the	_	_	O
6	survival	_	_	O
7	benefit	_	_	O
8	of	_	_	O
9	interferon-alfa	_	_	O
10	over	_	_	O
11	controls	_	_	O
12	in	_	_	O
13	metastatic	_	_	O
14	renal	_	_	O
15	cell	_	_	O
16	carcinoma	_	_	O
17	,	_	_	O
18	and	_	_	O
19	none	_	_	O
20	has	_	_	O
21	been	_	_	O
22	performed	_	_	O
23	using	_	_	O
24	interleukin-2	_	_	O
25	.	_	_	O

26	The	_	_	O
27	Programme	_	_	O
28	Etude	_	_	O
29	Rein	_	_	O
30	Cytokines	_	_	O
31	(	_	_	O
32	PERCY	_	_	O
33	)	_	_	O
34	Quattro	_	_	O
35	trial	_	_	O
36	was	_	_	O
37	designed	_	_	O
38	to	_	_	O
39	evaluate	_	_	O
40	both	_	_	O
41	cytokines	_	_	O
42	for	_	_	O
43	their	_	_	O
44	survival	_	_	O
45	benefit	_	_	O
46	to	_	_	O
47	intermediate	_	_	O
48	prognosis	_	_	O
49	patients	_	_	O
50	,	_	_	O
51	who	_	_	O
52	represent	_	_	O
53	the	_	_	O
54	majority	_	_	O
55	of	_	_	O
56	candidates	_	_	O
57	for	_	_	O
58	these	_	_	O
59	treatments	_	_	O
60	.	_	_	O

61	Patients	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	in	_	_	O
65	a	_	_	O
66	2-by-2	_	_	O
67	factorial	_	_	O
68	design	_	_	O
69	to	_	_	O
70	medroxyprogesterone	_	_	O
71	acetate	_	_	O
72	200	_	_	O
73	mg	_	_	O
74	daily	_	_	O
75	,	_	_	O
76	interferon-alfa	_	_	O
77	9	_	_	O
78	million	_	_	O
79	IU	_	_	O
80	3	_	_	O
81	times	_	_	O
82	a	_	_	O
83	week	_	_	O
84	,	_	_	O
85	subcutaneous	_	_	O
86	interleukin-2	_	_	O
87	9	_	_	O
88	million	_	_	O
89	IU	_	_	O
90	daily	_	_	O
91	,	_	_	O
92	or	_	_	O
93	a	_	_	O
94	combination	_	_	O
95	of	_	_	O
96	both	_	_	O
97	cytokines	_	_	O
98	.	_	_	O

99	Tumor	_	_	O
100	response	_	_	O
101	was	_	_	O
102	evaluated	_	_	O
103	at	_	_	O
104	Week	_	_	O
105	12	_	_	O
106	and	_	_	O
107	Month	_	_	O
108	6	_	_	O
109	;	_	_	O
110	progression-free	_	_	O
111	patients	_	_	O
112	received	_	_	O
113	further	_	_	O
114	identical	_	_	O
115	treatment	_	_	O
116	for	_	_	O
117	a	_	_	O
118	maximum	_	_	O
119	of	_	_	O
120	3	_	_	O
121	additional	_	_	O
122	months	_	_	O
123	.	_	_	O

124	Primary	_	_	O
125	endpoint	_	_	O
126	was	_	_	O
127	overall	_	_	O
128	survival	_	_	O
129	;	_	_	O
130	secondary	_	_	O
131	endpoints	_	_	O
132	were	_	_	O
133	disease-free	_	_	O
134	survival	_	_	O
135	,	_	_	O
136	response	_	_	O
137	rate	_	_	O
138	,	_	_	O
139	toxicity	_	_	O
140	,	_	_	O
141	and	_	_	O
142	quality	_	_	O
143	of	_	_	O
144	life	_	_	O
145	.	_	_	O

146	Survival	_	_	O
147	was	_	_	O
148	analyzed	_	_	O
149	on	_	_	O
150	an	_	_	O
151	intent-to-treat	_	_	O
152	basis	_	_	O
153	.	_	_	O

154	From	_	_	O
155	January	_	_	O
156	2000	_	_	O
157	to	_	_	O
158	July	_	_	O
159	2004	_	_	O
160	,	_	_	O
161	492	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	enrolled	_	_	O
165	.	_	_	O

166	Analysis	_	_	O
167	was	_	_	O
168	performed	_	_	O
169	after	_	_	O
170	a	_	_	O
171	29.2-month	_	_	O
172	median	_	_	O
173	follow-up	_	_	O
174	(	_	_	O
175	range	_	_	O
176	,	_	_	O
177	0	_	_	O
178	months	_	_	O
179	to	_	_	O
180	54.6	_	_	O
181	months	_	_	O
182	)	_	_	O
183	.	_	_	O

184	There	_	_	B-Premise
185	were	_	_	I-Premise
186	no	_	_	I-Premise
187	significant	_	_	I-Premise
188	survival	_	_	I-Premise
189	differences	_	_	I-Premise
190	between	_	_	I-Premise
191	the	_	_	I-Premise
192	244	_	_	I-Premise
193	interferon-alfa-treated	_	_	I-Premise
194	patients	_	_	I-Premise
195	and	_	_	I-Premise
196	248	_	_	I-Premise
197	noninterferon-alfa	_	_	I-Premise
198	patients	_	_	I-Premise
199	(	_	_	I-Premise
200	hazard	_	_	I-Premise
201	ratio	_	_	I-Premise
202	,	_	_	I-Premise
203	1.00	_	_	I-Premise
204	;	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	CI	_	_	I-Premise
208	,	_	_	I-Premise
209	0.81-1.24	_	_	I-Premise
210	)	_	_	I-Premise
211	or	_	_	I-Premise
212	between	_	_	I-Premise
213	the	_	_	I-Premise
214	247	_	_	I-Premise
215	interleukin-2	_	_	I-Premise
216	and	_	_	I-Premise
217	245	_	_	I-Premise
218	noninterleukin-2-treated	_	_	I-Premise
219	patients	_	_	I-Premise
220	(	_	_	I-Premise
221	hazard	_	_	I-Premise
222	ratio	_	_	I-Premise
223	,	_	_	I-Premise
224	1.07	_	_	I-Premise
225	;	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	,	_	_	I-Premise
230	0.87-1.33	_	_	I-Premise
231	;	_	_	I-Premise
232	log	_	_	I-Premise
233	rank	_	_	I-Premise
234	,	_	_	I-Premise
235	0.99	_	_	I-Premise
236	and	_	_	I-Premise
237	0.52	_	_	I-Premise
238	,	_	_	I-Premise
239	respectively	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Grade	_	_	B-Premise
243	3-4	_	_	I-Premise
244	toxicities	_	_	I-Premise
245	were	_	_	I-Premise
246	significantly	_	_	I-Premise
247	more	_	_	I-Premise
248	frequent	_	_	I-Premise
249	in	_	_	I-Premise
250	cytokine-treated	_	_	I-Premise
251	patients	_	_	I-Premise
252	than	_	_	I-Premise
253	in	_	_	I-Premise
254	medroxyprogesterone-treated	_	_	I-Premise
255	patients	_	_	I-Premise
256	.	_	_	I-Premise

257	Subcutaneous	_	_	B-Claim
258	interleukin-2	_	_	I-Claim
259	and/or	_	_	I-Claim
260	interferon-alfa	_	_	I-Claim
261	provide	_	_	I-Claim
262	no	_	_	I-Claim
263	survival	_	_	I-Claim
264	benefit	_	_	I-Claim
265	in	_	_	I-Claim
266	metastatic	_	_	I-Claim
267	renal	_	_	I-Claim
268	cancers	_	_	I-Claim
269	of	_	_	I-Claim
270	intermediate	_	_	I-Claim
271	prognosis	_	_	I-Claim
272	,	_	_	I-Claim
273	and	_	_	I-Claim
274	they	_	_	I-Claim
275	induce	_	_	I-Claim
276	a	_	_	I-Claim
277	significant	_	_	I-Claim
278	risk	_	_	I-Claim
279	of	_	_	I-Claim
280	toxicity	_	_	I-Claim
281	.	_	_	I-Claim

282	Newly	_	_	B-Claim
283	available	_	_	I-Claim
284	angiogenesis	_	_	I-Claim
285	inhibitors	_	_	I-Claim
286	should	_	_	I-Claim
287	be	_	_	I-Claim
288	preferred	_	_	I-Claim
289	for	_	_	I-Claim
290	these	_	_	I-Claim
291	patients	_	_	I-Claim
292	.	_	_	I-Claim


0	Hormonal	_	_	B-Claim
1	breast	_	_	I-Claim
2	cancer	_	_	I-Claim
3	treatment	_	_	I-Claim
4	increases	_	_	I-Claim
5	menopausal	_	_	I-Claim
6	symptoms	_	_	I-Claim
7	in	_	_	I-Claim
8	women	_	_	I-Claim
9	.	_	_	I-Claim

10	This	_	_	O
11	study	_	_	O
12	investigated	_	_	O
13	differences	_	_	O
14	between	_	_	O
15	the	_	_	O
16	symptoms	_	_	O
17	associated	_	_	O
18	with	_	_	O
19	either	_	_	O
20	adjuvant	_	_	O
21	tamoxifen	_	_	O
22	or	_	_	O
23	exemestane	_	_	O
24	.	_	_	O

25	Ten	_	_	O
26	common	_	_	O
27	symptoms	_	_	O
28	were	_	_	O
29	assessed	_	_	O
30	by	_	_	O
31	self-report	_	_	O
32	questionnaire	_	_	O
33	administered	_	_	O
34	to	_	_	O
35	1,614	_	_	O
36	consecutive	_	_	O
37	patients	_	_	O
38	at	_	_	O
39	baseline	_	_	O
40	and	_	_	O
41	every	_	_	O
42	3	_	_	O
43	months	_	_	O
44	during	_	_	O
45	the	_	_	O
46	first	_	_	O
47	year	_	_	O
48	of	_	_	O
49	a	_	_	O
50	double-blind	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	trial	_	_	O
54	of	_	_	O
55	postmenopausal	_	_	O
56	women	_	_	O
57	with	_	_	O
58	early	_	_	O
59	hormone	_	_	O
60	receptor-positive	_	_	O
61	breast	_	_	O
62	cancer	_	_	O
63	.	_	_	O

64	Symptoms	_	_	O
65	were	_	_	O
66	categorized	_	_	O
67	as	_	_	O
68	none	_	_	O
69	,	_	_	O
70	mild	_	_	O
71	,	_	_	O
72	moderate	_	_	O
73	,	_	_	O
74	or	_	_	O
75	severe	_	_	O
76	.	_	_	O

77	A	_	_	O
78	hot	_	_	O
79	flash	_	_	O
80	score	_	_	O
81	was	_	_	O
82	calculated	_	_	O
83	at	_	_	O
84	each	_	_	O
85	time	_	_	O
86	point	_	_	O
87	.	_	_	O

88	Symptoms	_	_	O
89	were	_	_	O
90	analyzed	_	_	O
91	by	_	_	O
92	repeated-measures	_	_	O
93	analysis	_	_	O
94	of	_	_	O
95	variance	_	_	O
96	.	_	_	O

97	Each	_	_	O
98	time	_	_	O
99	period	_	_	O
100	was	_	_	O
101	tested	_	_	O
102	repeatedly	_	_	O
103	against	_	_	O
104	the	_	_	O
105	baseline	_	_	O
106	;	_	_	O
107	an	_	_	O
108	overall	_	_	O
109	P	_	_	O
110	value	_	_	O
111	was	_	_	O
112	assigned	_	_	O
113	for	_	_	O
114	each	_	_	O
115	reported	_	_	O
116	symptom	_	_	O
117	.	_	_	O

118	Compliance	_	_	O
119	was	_	_	O
120	excellent	_	_	O
121	,	_	_	O
122	with	_	_	O
123	7,286	_	_	O
124	questionnaires	_	_	O
125	analyzed	_	_	O
126	.	_	_	O

127	Baseline	_	_	O
128	symptom	_	_	O
129	prevalence	_	_	O
130	ranged	_	_	O
131	from	_	_	O
132	2	_	_	O
133	%	_	_	O
134	(	_	_	O
135	vaginal	_	_	O
136	bleeding	_	_	O
137	)	_	_	O
138	to	_	_	O
139	60	_	_	O
140	%	_	_	O
141	to	_	_	O
142	70	_	_	O
143	%	_	_	O
144	(	_	_	O
145	bone/muscle	_	_	O
146	aches	_	_	O
147	and	_	_	O
148	low	_	_	O
149	energy	_	_	O
150	)	_	_	O
151	.	_	_	O

152	There	_	_	B-Premise
153	were	_	_	I-Premise
154	no	_	_	I-Premise
155	significant	_	_	I-Premise
156	differences	_	_	I-Premise
157	in	_	_	I-Premise
158	vaginal	_	_	I-Premise
159	bleeding	_	_	I-Premise
160	,	_	_	I-Premise
161	mood	_	_	I-Premise
162	alteration	_	_	I-Premise
163	,	_	_	I-Premise
164	or	_	_	I-Premise
165	low	_	_	I-Premise
166	energy	_	_	I-Premise
167	.	_	_	I-Premise

168	Patients	_	_	B-Premise
169	receiving	_	_	I-Premise
170	tamoxifen	_	_	I-Premise
171	had	_	_	I-Premise
172	significantly	_	_	I-Premise
173	more	_	_	I-Premise
174	vaginal	_	_	I-Premise
175	discharge	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	<	_	_	I-Premise
179	.0001	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	Exemestane	_	_	B-Premise
183	patients	_	_	I-Premise
184	reported	_	_	I-Premise
185	more	_	_	I-Premise
186	bone/muscle	_	_	I-Premise
187	aches	_	_	I-Premise
188	(	_	_	I-Premise
189	P	_	_	I-Premise
190	<	_	_	I-Premise
191	.0001	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	vaginal	_	_	I-Premise
195	dryness	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.0004	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	and	_	_	I-Premise
203	difficulty	_	_	I-Premise
204	sleeping	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	.03	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	In	_	_	B-Premise
212	both	_	_	I-Premise
213	groups	_	_	I-Premise
214	,	_	_	I-Premise
215	the	_	_	I-Premise
216	hot	_	_	I-Premise
217	flash	_	_	I-Premise
218	score	_	_	I-Premise
219	peaked	_	_	I-Premise
220	at	_	_	I-Premise
221	3	_	_	I-Premise
222	months	_	_	I-Premise
223	and	_	_	I-Premise
224	decreased	_	_	I-Premise
225	thereafter	_	_	I-Premise
226	.	_	_	I-Premise

227	At	_	_	B-Premise
228	12	_	_	I-Premise
229	months	_	_	I-Premise
230	,	_	_	I-Premise
231	patients	_	_	I-Premise
232	receiving	_	_	I-Premise
233	tamoxifen	_	_	I-Premise
234	had	_	_	I-Premise
235	a	_	_	I-Premise
236	significantly	_	_	I-Premise
237	higher	_	_	I-Premise
238	mean	_	_	I-Premise
239	hot	_	_	I-Premise
240	flash	_	_	I-Premise
241	score	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.03	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	with	_	_	I-Premise
249	daily	_	_	I-Premise
250	hot	_	_	I-Premise
251	flashes	_	_	I-Premise
252	increasing	_	_	I-Premise
253	from	_	_	I-Premise
254	baseline	_	_	I-Premise
255	by	_	_	I-Premise
256	33	_	_	I-Premise
257	%	_	_	I-Premise
258	compared	_	_	I-Premise
259	with	_	_	I-Premise
260	a	_	_	I-Premise
261	7	_	_	I-Premise
262	%	_	_	I-Premise
263	increase	_	_	I-Premise
264	from	_	_	I-Premise
265	baseline	_	_	I-Premise
266	with	_	_	I-Premise
267	exemestane	_	_	I-Premise
268	.	_	_	I-Premise

269	At	_	_	B-Premise
270	12	_	_	I-Premise
271	months	_	_	I-Premise
272	,	_	_	I-Premise
273	exemestane	_	_	I-Premise
274	was	_	_	I-Premise
275	associated	_	_	I-Premise
276	with	_	_	I-Premise
277	fewer	_	_	I-Premise
278	hot	_	_	I-Premise
279	flashes	_	_	I-Premise
280	and	_	_	I-Premise
281	less	_	_	I-Premise
282	vaginal	_	_	I-Premise
283	discharge	_	_	I-Premise
284	than	_	_	I-Premise
285	tamoxifen	_	_	I-Premise
286	,	_	_	I-Premise
287	but	_	_	I-Premise
288	with	_	_	I-Premise
289	more	_	_	I-Premise
290	vaginal	_	_	I-Premise
291	dryness	_	_	I-Premise
292	,	_	_	I-Premise
293	bone/muscle	_	_	I-Premise
294	aches	_	_	I-Premise
295	,	_	_	I-Premise
296	and	_	_	I-Premise
297	difficulty	_	_	I-Premise
298	sleeping	_	_	I-Premise
299	.	_	_	I-Premise

300	Symptoms	_	_	B-Claim
301	were	_	_	I-Claim
302	common	_	_	I-Claim
303	in	_	_	I-Claim
304	both	_	_	I-Claim
305	groups	_	_	I-Claim
306	.	_	_	I-Claim


0	Few	_	_	O
1	intervention	_	_	O
2	studies	_	_	O
3	have	_	_	O
4	been	_	_	O
5	conducted	_	_	O
6	to	_	_	O
7	help	_	_	O
8	couples	_	_	O
9	manage	_	_	O
10	the	_	_	O
11	effects	_	_	O
12	of	_	_	O
13	prostate	_	_	O
14	cancer	_	_	O
15	and	_	_	O
16	maintain	_	_	O
17	their	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	.	_	_	O

22	The	_	_	O
23	objective	_	_	O
24	of	_	_	O
25	this	_	_	O
26	study	_	_	O
27	was	_	_	O
28	to	_	_	O
29	determine	_	_	O
30	whether	_	_	O
31	a	_	_	O
32	family-based	_	_	O
33	intervention	_	_	O
34	could	_	_	O
35	improve	_	_	O
36	appraisal	_	_	O
37	variables	_	_	O
38	(	_	_	O
39	appraisal	_	_	O
40	of	_	_	O
41	illness	_	_	O
42	or	_	_	O
43	caregiving	_	_	O
44	,	_	_	O
45	uncertainty	_	_	O
46	,	_	_	O
47	hopelessness	_	_	O
48	)	_	_	O
49	,	_	_	O
50	coping	_	_	O
51	resources	_	_	O
52	(	_	_	O
53	coping	_	_	O
54	strategies	_	_	O
55	,	_	_	O
56	self-efficacy	_	_	O
57	,	_	_	O
58	communication	_	_	O
59	)	_	_	O
60	,	_	_	O
61	symptom	_	_	O
62	distress	_	_	O
63	,	_	_	O
64	and	_	_	O
65	quality	_	_	O
66	of	_	_	O
67	life	_	_	O
68	in	_	_	O
69	men	_	_	O
70	with	_	_	O
71	prostate	_	_	O
72	cancer	_	_	O
73	and	_	_	O
74	their	_	_	O
75	spouses	_	_	O
76	.	_	_	O

77	For	_	_	O
78	this	_	_	O
79	clinical	_	_	O
80	trial	_	_	O
81	,	_	_	O
82	263	_	_	O
83	patient-spouse	_	_	O
84	dyads	_	_	O
85	were	_	_	O
86	stratified	_	_	O
87	by	_	_	O
88	research	_	_	O
89	site	_	_	O
90	,	_	_	O
91	phase	_	_	O
92	of	_	_	O
93	illness	_	_	O
94	,	_	_	O
95	and	_	_	O
96	treatment	_	_	O
97	;	_	_	O
98	then	_	_	O
99	,	_	_	O
100	they	_	_	O
101	were	_	_	O
102	randomized	_	_	O
103	to	_	_	O
104	the	_	_	O
105	control	_	_	O
106	group	_	_	O
107	(	_	_	O
108	standard	_	_	O
109	care	_	_	O
110	)	_	_	O
111	or	_	_	O
112	the	_	_	O
113	experimental	_	_	O
114	group	_	_	O
115	(	_	_	O
116	standard	_	_	O
117	care	_	_	O
118	plus	_	_	O
119	a	_	_	O
120	5-session	_	_	O
121	family	_	_	O
122	intervention	_	_	O
123	)	_	_	O
124	.	_	_	O

125	The	_	_	O
126	intervention	_	_	O
127	targeted	_	_	O
128	couples	_	_	O
129	'	_	_	O
130	communication	_	_	O
131	,	_	_	O
132	hope	_	_	O
133	,	_	_	O
134	coping	_	_	O
135	,	_	_	O
136	uncertainty	_	_	O
137	,	_	_	O
138	and	_	_	O
139	symptom	_	_	O
140	management	_	_	O
141	.	_	_	O

142	The	_	_	O
143	final	_	_	O
144	sample	_	_	O
145	consisted	_	_	O
146	of	_	_	O
147	235	_	_	O
148	couples	_	_	O
149	:	_	_	O
150	123	_	_	O
151	couples	_	_	O
152	in	_	_	O
153	the	_	_	O
154	control	_	_	O
155	group	_	_	O
156	and	_	_	O
157	112	_	_	O
158	couples	_	_	O
159	in	_	_	O
160	the	_	_	O
161	experimental	_	_	O
162	group	_	_	O
163	.	_	_	O

164	Data	_	_	O
165	collection	_	_	O
166	occurred	_	_	O
167	at	_	_	O
168	baseline	_	_	O
169	before	_	_	O
170	randomization	_	_	O
171	and	_	_	O
172	at	_	_	O
173	4	_	_	O
174	months	_	_	O
175	,	_	_	O
176	8	_	_	O
177	months	_	_	O
178	,	_	_	O
179	and	_	_	O
180	12	_	_	O
181	months	_	_	O
182	.	_	_	O

183	At	_	_	B-Premise
184	4-month	_	_	I-Premise
185	follow-up	_	_	I-Premise
186	,	_	_	I-Premise
187	intervention	_	_	I-Premise
188	patients	_	_	I-Premise
189	reported	_	_	I-Premise
190	less	_	_	I-Premise
191	uncertainty	_	_	I-Premise
192	and	_	_	I-Premise
193	better	_	_	I-Premise
194	communication	_	_	I-Premise
195	with	_	_	I-Premise
196	spouses	_	_	I-Premise
197	than	_	_	I-Premise
198	control	_	_	I-Premise
199	patients	_	_	I-Premise
200	,	_	_	I-Premise
201	but	_	_	B-Premise
202	they	_	_	I-Premise
203	reported	_	_	I-Premise
204	no	_	_	I-Premise
205	other	_	_	I-Premise
206	effects	_	_	I-Premise
207	.	_	_	I-Premise

208	Intervention	_	_	B-Premise
209	spouses	_	_	I-Premise
210	reported	_	_	I-Premise
211	higher	_	_	I-Premise
212	quality	_	_	I-Premise
213	of	_	_	I-Premise
214	life	_	_	I-Premise
215	,	_	_	I-Premise
216	more	_	_	I-Premise
217	self-efficacy	_	_	I-Premise
218	,	_	_	I-Premise
219	better	_	_	I-Premise
220	communication	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	less	_	_	I-Premise
224	negative	_	_	I-Premise
225	appraisal	_	_	I-Premise
226	of	_	_	I-Premise
227	caregiving	_	_	I-Premise
228	,	_	_	I-Premise
229	uncertainty	_	_	I-Premise
230	,	_	_	I-Premise
231	hopelessness	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	symptom	_	_	I-Premise
235	distress	_	_	I-Premise
236	at	_	_	I-Premise
237	4	_	_	I-Premise
238	months	_	_	I-Premise
239	compared	_	_	I-Premise
240	with	_	_	I-Premise
241	controls	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	some	_	_	I-Premise
245	effects	_	_	I-Premise
246	were	_	_	I-Premise
247	sustained	_	_	I-Premise
248	to	_	_	I-Premise
249	8	_	_	I-Premise
250	months	_	_	I-Premise
251	and	_	_	I-Premise
252	12	_	_	I-Premise
253	months	_	_	I-Premise
254	.	_	_	I-Premise

255	Men	_	_	B-Premise
256	with	_	_	I-Premise
257	prostate	_	_	I-Premise
258	cancer	_	_	I-Premise
259	and	_	_	I-Premise
260	their	_	_	I-Premise
261	spouses	_	_	I-Premise
262	reported	_	_	I-Premise
263	positive	_	_	I-Premise
264	outcomes	_	_	I-Premise
265	from	_	_	I-Premise
266	a	_	_	I-Premise
267	family	_	_	I-Premise
268	intervention	_	_	I-Premise
269	that	_	_	I-Premise
270	offered	_	_	I-Premise
271	them	_	_	I-Premise
272	information	_	_	I-Premise
273	and	_	_	I-Premise
274	support	_	_	I-Premise
275	.	_	_	I-Premise

276	Programs	_	_	B-Claim
277	of	_	_	I-Claim
278	care	_	_	I-Claim
279	need	_	_	I-Claim
280	to	_	_	I-Claim
281	be	_	_	I-Claim
282	extended	_	_	I-Claim
283	to	_	_	I-Claim
284	spouses	_	_	I-Claim
285	who	_	_	I-Claim
286	likely	_	_	I-Claim
287	will	_	_	I-Claim
288	experience	_	_	I-Claim
289	multiple	_	_	I-Claim
290	benefits	_	_	I-Claim
291	from	_	_	I-Claim
292	intervention	_	_	I-Claim
293	.	_	_	I-Claim


0	We	_	_	O
1	conducted	_	_	O
2	a	_	_	O
3	multicenter	_	_	O
4	,	_	_	O
5	randomized	_	_	O
6	trial	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	progression-free	_	_	O
10	survival	_	_	O
11	(	_	_	O
12	PFS	_	_	O
13	)	_	_	O
14	,	_	_	O
15	overall	_	_	O
16	survival	_	_	O
17	(	_	_	O
18	OS	_	_	O
19	)	_	_	O
20	,	_	_	O
21	and	_	_	O
22	quality	_	_	O
23	of	_	_	O
24	life	_	_	O
25	in	_	_	O
26	women	_	_	O
27	with	_	_	O
28	metastatic	_	_	O
29	breast	_	_	O
30	cancer	_	_	O
31	(	_	_	O
32	MBC	_	_	O
33	)	_	_	O
34	receiving	_	_	O
35	high-dose	_	_	O
36	chemotherapy	_	_	O
37	plus	_	_	O
38	autologous	_	_	O
39	stem-cell	_	_	O
40	transplantation	_	_	O
41	(	_	_	O
42	ASCT	_	_	O
43	;	_	_	O
44	HDCT	_	_	O
45	)	_	_	O
46	compared	_	_	O
47	with	_	_	O
48	standard-dose	_	_	O
49	therapy	_	_	O
50	.	_	_	O

51	Between	_	_	O
52	April	_	_	O
53	1997	_	_	O
54	and	_	_	O
55	December	_	_	O
56	2000	_	_	O
57	,	_	_	O
58	386	_	_	O
59	women	_	_	O
60	with	_	_	O
61	MBC	_	_	O
62	and	_	_	O
63	no	_	_	O
64	prior	_	_	O
65	chemotherapy	_	_	O
66	for	_	_	O
67	metastatic	_	_	O
68	disease	_	_	O
69	were	_	_	O
70	registered	_	_	O
71	.	_	_	O

72	After	_	_	O
73	initial	_	_	O
74	response	_	_	O
75	to	_	_	O
76	anthracycline-	_	_	O
77	or	_	_	O
78	taxane-based	_	_	O
79	induction	_	_	O
80	chemotherapy	_	_	O
81	,	_	_	O
82	224	_	_	O
83	patients	_	_	O
84	were	_	_	O
85	randomly	_	_	O
86	assigned	_	_	O
87	:	_	_	O
88	112	_	_	O
89	to	_	_	O
90	high-dose	_	_	O
91	cyclophosphamide	_	_	O
92	,	_	_	O
93	mitoxantrone	_	_	O
94	,	_	_	O
95	and	_	_	O
96	carboplatin	_	_	O
97	chemotherapy	_	_	O
98	and	_	_	O
99	ASCT	_	_	O
100	(	_	_	O
101	HDCT	_	_	O
102	)	_	_	O
103	,	_	_	O
104	and	_	_	O
105	112	_	_	O
106	to	_	_	O
107	standard	_	_	O
108	therapy	_	_	O
109	(	_	_	O
110	ST	_	_	O
111	)	_	_	O
112	.	_	_	O

113	Median	_	_	O
114	age	_	_	O
115	was	_	_	O
116	47	_	_	O
117	years	_	_	O
118	(	_	_	O
119	range	_	_	O
120	,	_	_	O
121	25	_	_	O
122	to	_	_	O
123	67	_	_	O
124	years	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Thirty	_	_	O
128	two	_	_	O
129	percent	_	_	O
130	of	_	_	O
131	women	_	_	O
132	randomly	_	_	O
133	assigned	_	_	O
134	had	_	_	O
135	estrogen	_	_	O
136	and	_	_	O
137	progesterone	_	_	O
138	receptor-negative	_	_	O
139	breast	_	_	O
140	cancer	_	_	O
141	,	_	_	O
142	42	_	_	O
143	%	_	_	O
144	had	_	_	O
145	visceral	_	_	O
146	metastases	_	_	O
147	,	_	_	O
148	and	_	_	O
149	58	_	_	O
150	%	_	_	O
151	had	_	_	O
152	bone	_	_	O
153	metastases	_	_	O
154	.	_	_	O

155	Complete	_	_	O
156	remission	_	_	O
157	rates	_	_	O
158	before	_	_	O
159	random	_	_	O
160	assignment	_	_	O
161	were	_	_	O
162	11	_	_	O
163	%	_	_	O
164	for	_	_	O
165	those	_	_	O
166	receiving	_	_	O
167	HDCT	_	_	O
168	and	_	_	O
169	12	_	_	O
170	%	_	_	O
171	for	_	_	O
172	those	_	_	O
173	receiving	_	_	O
174	ST.	_	_	O
175	After	_	_	B-Premise
176	a	_	_	I-Premise
177	median	_	_	I-Premise
178	follow-up	_	_	I-Premise
179	of	_	_	I-Premise
180	48	_	_	I-Premise
181	months	_	_	I-Premise
182	,	_	_	I-Premise
183	79	_	_	I-Premise
184	deaths	_	_	I-Premise
185	were	_	_	I-Premise
186	observed	_	_	I-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	HDCT	_	_	I-Premise
190	arm	_	_	I-Premise
191	and	_	_	I-Premise
192	77	_	_	I-Premise
193	deaths	_	_	I-Premise
194	were	_	_	I-Premise
195	observed	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	ST	_	_	I-Premise
199	arm	_	_	I-Premise
200	;	_	_	I-Premise
201	seven	_	_	B-Premise
202	patients	_	_	I-Premise
203	(	_	_	I-Premise
204	6	_	_	I-Premise
205	%	_	_	I-Premise
206	)	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	HDCT	_	_	I-Premise
210	arm	_	_	I-Premise
211	died	_	_	I-Premise
212	as	_	_	I-Premise
213	a	_	_	I-Premise
214	result	_	_	I-Premise
215	of	_	_	I-Premise
216	toxicity	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	median	_	_	I-Premise
220	OS	_	_	I-Premise
221	was	_	_	I-Premise
222	24	_	_	I-Premise
223	months	_	_	I-Premise
224	for	_	_	I-Premise
225	the	_	_	I-Premise
226	HDCT	_	_	I-Premise
227	arm	_	_	I-Premise
228	(	_	_	I-Premise
229	95	_	_	I-Premise
230	%	_	_	I-Premise
231	CI	_	_	I-Premise
232	,	_	_	I-Premise
233	21	_	_	I-Premise
234	to	_	_	I-Premise
235	35	_	_	I-Premise
236	months	_	_	I-Premise
237	)	_	_	I-Premise
238	and	_	_	I-Premise
239	28	_	_	I-Premise
240	months	_	_	I-Premise
241	for	_	_	I-Premise
242	ST	_	_	I-Premise
243	(	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	,	_	_	I-Premise
248	22	_	_	I-Premise
249	to	_	_	I-Premise
250	33	_	_	I-Premise
251	months	_	_	I-Premise
252	;	_	_	I-Premise
253	hazard	_	_	I-Premise
254	ratio	_	_	I-Premise
255	[	_	_	I-Premise
256	HR	_	_	I-Premise
257	]	_	_	I-Premise
258	,	_	_	I-Premise
259	0.9	_	_	I-Premise
260	;	_	_	I-Premise
261	95	_	_	I-Premise
262	%	_	_	I-Premise
263	CI	_	_	I-Premise
264	,	_	_	I-Premise
265	0.6	_	_	I-Premise
266	to	_	_	I-Premise
267	1.2	_	_	I-Premise
268	;	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.43	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	PFS	_	_	B-Premise
275	was	_	_	I-Premise
276	11	_	_	I-Premise
277	months	_	_	I-Premise
278	for	_	_	I-Premise
279	HDCT	_	_	I-Premise
280	and	_	_	I-Premise
281	9	_	_	I-Premise
282	months	_	_	I-Premise
283	for	_	_	I-Premise
284	ST	_	_	I-Premise
285	(	_	_	I-Premise
286	HR	_	_	I-Premise
287	,	_	_	I-Premise
288	0.6	_	_	I-Premise
289	in	_	_	I-Premise
290	favor	_	_	I-Premise
291	of	_	_	I-Premise
292	HDCT	_	_	I-Premise
293	;	_	_	I-Premise
294	95	_	_	I-Premise
295	%	_	_	I-Premise
296	CI	_	_	I-Premise
297	,	_	_	I-Premise
298	0.5	_	_	I-Premise
299	to	_	_	I-Premise
300	0.9	_	_	I-Premise
301	;	_	_	I-Premise
302	P	_	_	I-Premise
303	=	_	_	I-Premise
304	.006	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	HDCT	_	_	B-Claim
308	did	_	_	I-Claim
309	not	_	_	I-Claim
310	improve	_	_	I-Claim
311	OS	_	_	I-Claim
312	in	_	_	I-Claim
313	women	_	_	I-Claim
314	with	_	_	I-Claim
315	MBC	_	_	I-Claim
316	when	_	_	I-Claim
317	used	_	_	I-Claim
318	as	_	_	I-Claim
319	consolidation	_	_	I-Claim
320	after	_	_	I-Claim
321	response	_	_	I-Claim
322	to	_	_	I-Claim
323	induction	_	_	I-Claim
324	chemotherapy	_	_	I-Claim
325	.	_	_	I-Claim


0	Few	_	_	O
1	exercise	_	_	O
2	trials	_	_	O
3	in	_	_	O
4	cancer	_	_	O
5	patients	_	_	O
6	have	_	_	O
7	reported	_	_	O
8	longer-term	_	_	O
9	follow-up	_	_	O
10	.	_	_	O

11	Here	_	_	O
12	,	_	_	O
13	we	_	_	O
14	report	_	_	O
15	a	_	_	O
16	6-month	_	_	O
17	follow-up	_	_	O
18	of	_	_	O
19	exercise	_	_	O
20	behavior	_	_	O
21	and	_	_	O
22	patient-rated	_	_	O
23	outcomes	_	_	O
24	from	_	_	O
25	an	_	_	O
26	exercise	_	_	O
27	trial	_	_	O
28	in	_	_	O
29	breast	_	_	O
30	cancer	_	_	O
31	patients	_	_	O
32	.	_	_	O

33	Breast	_	_	O
34	cancer	_	_	O
35	patients	_	_	O
36	initiating	_	_	O
37	adjuvant	_	_	O
38	chemotherapy	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	242	_	_	O
43	)	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	usual	_	_	O
49	care	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	82	_	_	O
54	)	_	_	O
55	,	_	_	O
56	resistance	_	_	O
57	exercise	_	_	O
58	training	_	_	O
59	(	_	_	O
60	RET	_	_	O
61	;	_	_	O
62	n	_	_	O
63	=	_	_	O
64	82	_	_	O
65	)	_	_	O
66	,	_	_	O
67	or	_	_	O
68	aerobic	_	_	O
69	exercise	_	_	O
70	training	_	_	O
71	(	_	_	O
72	AET	_	_	O
73	;	_	_	O
74	n	_	_	O
75	=	_	_	O
76	78	_	_	O
77	)	_	_	O
78	for	_	_	O
79	the	_	_	O
80	duration	_	_	O
81	of	_	_	O
82	their	_	_	O
83	chemotherapy	_	_	O
84	.	_	_	O

85	At	_	_	O
86	6-month	_	_	O
87	follow-up	_	_	O
88	,	_	_	O
89	participants	_	_	O
90	were	_	_	O
91	mailed	_	_	O
92	a	_	_	O
93	questionnaire	_	_	O
94	that	_	_	O
95	assessed	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	,	_	_	O
100	self-esteem	_	_	O
101	,	_	_	O
102	fatigue	_	_	O
103	,	_	_	O
104	anxiety	_	_	O
105	,	_	_	O
106	depression	_	_	O
107	,	_	_	O
108	and	_	_	O
109	exercise	_	_	O
110	behavior	_	_	O
111	.	_	_	O

112	Two	_	_	O
113	hundred	_	_	O
114	one	_	_	O
115	(	_	_	O
116	83.1	_	_	O
117	%	_	_	O
118	)	_	_	O
119	participants	_	_	O
120	provided	_	_	O
121	6-month	_	_	O
122	follow-up	_	_	O
123	data	_	_	O
124	.	_	_	O

125	Adjusted	_	_	B-Premise
126	linear	_	_	I-Premise
127	mixed-model	_	_	I-Premise
128	analyses	_	_	I-Premise
129	showed	_	_	I-Premise
130	that	_	_	I-Premise
131	,	_	_	I-Premise
132	at	_	_	I-Premise
133	6-month	_	_	I-Premise
134	follow-up	_	_	I-Premise
135	,	_	_	I-Premise
136	the	_	_	I-Premise
137	RET	_	_	I-Premise
138	group	_	_	I-Premise
139	reported	_	_	I-Premise
140	higher	_	_	I-Premise
141	self-esteem	_	_	I-Premise
142	[	_	_	I-Premise
143	adjusted	_	_	I-Premise
144	mean	_	_	I-Premise
145	difference	_	_	I-Premise
146	,	_	_	I-Premise
147	1.6	_	_	I-Premise
148	;	_	_	I-Premise
149	95	_	_	I-Premise
150	%	_	_	I-Premise
151	confidence	_	_	I-Premise
152	interval	_	_	I-Premise
153	(	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	)	_	_	I-Premise
158	,	_	_	I-Premise
159	0.1-3.2	_	_	I-Premise
160	;	_	_	I-Premise
161	P	_	_	I-Premise
162	=	_	_	I-Premise
163	0.032	_	_	I-Premise
164	]	_	_	I-Premise
165	and	_	_	I-Premise
166	the	_	_	I-Premise
167	AET	_	_	I-Premise
168	group	_	_	I-Premise
169	reported	_	_	I-Premise
170	lower	_	_	I-Premise
171	anxiety	_	_	I-Premise
172	(	_	_	I-Premise
173	adjusted	_	_	I-Premise
174	mean	_	_	I-Premise
175	difference	_	_	I-Premise
176	,	_	_	I-Premise
177	-4.7	_	_	I-Premise
178	;	_	_	I-Premise
179	95	_	_	I-Premise
180	%	_	_	I-Premise
181	CI	_	_	I-Premise
182	,	_	_	I-Premise
183	-0.0	_	_	I-Premise
184	to	_	_	I-Premise
185	-9.3	_	_	I-Premise
186	;	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	0.049	_	_	I-Premise
190	)	_	_	I-Premise
191	compared	_	_	I-Premise
192	with	_	_	I-Premise
193	the	_	_	I-Premise
194	usual	_	_	I-Premise
195	care	_	_	I-Premise
196	group	_	_	I-Premise
197	.	_	_	I-Premise

198	Moreover	_	_	O
199	,	_	_	O
200	compared	_	_	B-Premise
201	with	_	_	I-Premise
202	participants	_	_	I-Premise
203	reporting	_	_	I-Premise
204	no	_	_	I-Premise
205	regular	_	_	I-Premise
206	exercise	_	_	I-Premise
207	during	_	_	I-Premise
208	the	_	_	I-Premise
209	follow-up	_	_	I-Premise
210	period	_	_	I-Premise
211	,	_	_	I-Premise
212	those	_	_	I-Premise
213	reporting	_	_	I-Premise
214	regular	_	_	I-Premise
215	aerobic	_	_	I-Premise
216	and	_	_	I-Premise
217	resistance	_	_	I-Premise
218	exercise	_	_	I-Premise
219	also	_	_	I-Premise
220	reported	_	_	I-Premise
221	better	_	_	I-Premise
222	patient-rated	_	_	I-Premise
223	outcomes	_	_	I-Premise
224	,	_	_	I-Premise
225	including	_	_	I-Premise
226	quality	_	_	I-Premise
227	of	_	_	I-Premise
228	life	_	_	I-Premise
229	(	_	_	I-Premise
230	adjusted	_	_	I-Premise
231	mean	_	_	I-Premise
232	difference	_	_	I-Premise
233	,	_	_	I-Premise
234	9.5	_	_	I-Premise
235	;	_	_	I-Premise
236	95	_	_	I-Premise
237	%	_	_	I-Premise
238	CI	_	_	I-Premise
239	,	_	_	I-Premise
240	1.2-17.8	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.025	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Improvements	_	_	B-Premise
248	in	_	_	I-Premise
249	self-esteem	_	_	I-Premise
250	observed	_	_	I-Premise
251	with	_	_	I-Premise
252	RET	_	_	I-Premise
253	during	_	_	I-Premise
254	breast	_	_	I-Premise
255	cancer	_	_	I-Premise
256	chemotherapy	_	_	I-Premise
257	were	_	_	I-Premise
258	maintained	_	_	I-Premise
259	at	_	_	I-Premise
260	6-month	_	_	I-Premise
261	follow-up	_	_	I-Premise
262	whereas	_	_	O
263	reductions	_	_	B-Premise
264	in	_	_	I-Premise
265	anxiety	_	_	I-Premise
266	not	_	_	I-Premise
267	observed	_	_	I-Premise
268	with	_	_	I-Premise
269	AET	_	_	I-Premise
270	during	_	_	I-Premise
271	breast	_	_	I-Premise
272	cancer	_	_	I-Premise
273	chemotherapy	_	_	I-Premise
274	emerged	_	_	I-Premise
275	at	_	_	I-Premise
276	6-month	_	_	I-Premise
277	follow-up	_	_	I-Premise
278	.	_	_	I-Premise

279	Moreover	_	_	O
280	,	_	_	O
281	adopting	_	_	B-Premise
282	a	_	_	I-Premise
283	combined	_	_	I-Premise
284	aerobic	_	_	I-Premise
285	and	_	_	I-Premise
286	resistance	_	_	I-Premise
287	exercise	_	_	I-Premise
288	program	_	_	I-Premise
289	after	_	_	I-Premise
290	breast	_	_	I-Premise
291	cancer	_	_	I-Premise
292	chemotherapy	_	_	I-Premise
293	was	_	_	I-Premise
294	associated	_	_	I-Premise
295	with	_	_	I-Premise
296	further	_	_	I-Premise
297	improvements	_	_	I-Premise
298	in	_	_	I-Premise
299	patient-rated	_	_	I-Premise
300	outcomes	_	_	I-Premise
301	.	_	_	I-Premise

302	Exercise	_	_	B-Claim
303	training	_	_	I-Claim
304	during	_	_	I-Claim
305	breast	_	_	I-Claim
306	cancer	_	_	I-Claim
307	chemotherapy	_	_	I-Claim
308	may	_	_	I-Claim
309	result	_	_	I-Claim
310	in	_	_	I-Claim
311	some	_	_	I-Claim
312	longer-term	_	_	I-Claim
313	and	_	_	I-Claim
314	late	_	_	I-Claim
315	effects	_	_	I-Claim
316	for	_	_	I-Claim
317	selected	_	_	I-Claim
318	patient-rated	_	_	I-Claim
319	outcomes	_	_	I-Claim
320	.	_	_	I-Claim


0	Standard	_	_	O
1	guidelines	_	_	O
2	for	_	_	O
3	cancer	_	_	O
4	pain	_	_	O
5	treatment	_	_	O
6	routinely	_	_	O
7	recommend	_	_	O
8	training	_	_	O
9	patients	_	_	O
10	to	_	_	O
11	reduce	_	_	O
12	barriers	_	_	O
13	to	_	_	O
14	pain	_	_	O
15	relief	_	_	O
16	,	_	_	O
17	use	_	_	O
18	medications	_	_	O
19	appropriately	_	_	O
20	,	_	_	O
21	and	_	_	O
22	communicate	_	_	O
23	their	_	_	O
24	pain-related	_	_	O
25	needs	_	_	O
26	.	_	_	O

27	Methods	_	_	B-Claim
28	are	_	_	I-Claim
29	needed	_	_	I-Claim
30	to	_	_	I-Claim
31	reduce	_	_	I-Claim
32	professional	_	_	I-Claim
33	time	_	_	I-Claim
34	required	_	_	I-Claim
35	while	_	_	I-Claim
36	achieving	_	_	I-Claim
37	sustained	_	_	I-Claim
38	intervention	_	_	I-Claim
39	effectiveness	_	_	I-Claim
40	.	_	_	I-Claim

41	In	_	_	O
42	a	_	_	O
43	multisite	_	_	O
44	,	_	_	O
45	randomized	_	_	O
46	controlled	_	_	O
47	trial	_	_	O
48	,	_	_	O
49	this	_	_	O
50	study	_	_	O
51	tested	_	_	O
52	a	_	_	O
53	pain	_	_	O
54	training	_	_	O
55	method	_	_	O
56	versus	_	_	O
57	a	_	_	O
58	nutrition	_	_	O
59	control	_	_	O
60	.	_	_	O

61	At	_	_	O
62	six	_	_	O
63	oncology	_	_	O
64	clinics	_	_	O
65	,	_	_	O
66	physicians	_	_	O
67	(	_	_	O
68	N=22	_	_	O
69	)	_	_	O
70	and	_	_	O
71	nurses	_	_	O
72	(	_	_	O
73	N=23	_	_	O
74	)	_	_	O
75	enrolled	_	_	O
76	patients	_	_	O
77	(	_	_	O
78	N=93	_	_	O
79	)	_	_	O
80	who	_	_	O
81	were	_	_	O
82	over	_	_	O
83	18	_	_	O
84	years	_	_	O
85	of	_	_	O
86	age	_	_	O
87	,	_	_	O
88	with	_	_	O
89	cancer	_	_	O
90	diagnoses	_	_	O
91	,	_	_	O
92	pain	_	_	O
93	,	_	_	O
94	and	_	_	O
95	a	_	_	O
96	life	_	_	O
97	expectancy	_	_	O
98	of	_	_	O
99	at	_	_	O
100	least	_	_	O
101	6	_	_	O
102	months	_	_	O
103	.	_	_	O

104	Pain	_	_	O
105	training	_	_	O
106	and	_	_	O
107	control	_	_	O
108	interventions	_	_	O
109	were	_	_	O
110	matched	_	_	O
111	for	_	_	O
112	materials	_	_	O
113	and	_	_	O
114	method	_	_	O
115	.	_	_	O

116	Patients	_	_	O
117	watched	_	_	O
118	a	_	_	O
119	video	_	_	O
120	followed	_	_	O
121	by	_	_	O
122	about	_	_	O
123	20	_	_	O
124	min	_	_	O
125	of	_	_	O
126	manual-standardized	_	_	O
127	training	_	_	O
128	with	_	_	O
129	an	_	_	O
130	oncology	_	_	O
131	nurse	_	_	O
132	focused	_	_	O
133	on	_	_	O
134	reviewing	_	_	O
135	the	_	_	O
136	printed	_	_	O
137	material	_	_	O
138	and	_	_	O
139	adapted	_	_	O
140	to	_	_	O
141	individual	_	_	O
142	concerns	_	_	O
143	of	_	_	O
144	patients	_	_	O
145	.	_	_	O

146	A	_	_	O
147	follow-up	_	_	O
148	phone	_	_	O
149	call	_	_	O
150	after	_	_	O
151	72	_	_	O
152	h	_	_	O
153	addressed	_	_	O
154	individualized	_	_	O
155	treatment	_	_	O
156	content	_	_	O
157	and	_	_	O
158	pain	_	_	O
159	communication	_	_	O
160	.	_	_	O

161	Assessments	_	_	O
162	at	_	_	O
163	baseline	_	_	O
164	,	_	_	O
165	one	_	_	O
166	,	_	_	O
167	three	_	_	O
168	,	_	_	O
169	and	_	_	O
170	6	_	_	O
171	months	_	_	O
172	included	_	_	O
173	barriers	_	_	O
174	,	_	_	O
175	the	_	_	O
176	Brief	_	_	O
177	Pain	_	_	O
178	Inventory	_	_	O
179	,	_	_	O
180	opioid	_	_	O
181	use	_	_	O
182	,	_	_	O
183	and	_	_	O
184	physician	_	_	O
185	and	_	_	O
186	nurse	_	_	O
187	ratings	_	_	O
188	of	_	_	O
189	their	_	_	O
190	patients	_	_	O
191	'	_	_	O
192	pain	_	_	O
193	.	_	_	O

194	Trained	_	_	B-Premise
195	versus	_	_	I-Premise
196	control	_	_	I-Premise
197	patients	_	_	I-Premise
198	reported	_	_	I-Premise
199	reduced	_	_	I-Premise
200	barriers	_	_	I-Premise
201	to	_	_	I-Premise
202	pain	_	_	I-Premise
203	relief	_	_	I-Premise
204	(	_	_	I-Premise
205	P	_	_	I-Premise
206	<	_	_	I-Premise
207	.001	_	_	I-Premise
208	)	_	_	I-Premise
209	,	_	_	I-Premise
210	lower	_	_	I-Premise
211	usual	_	_	I-Premise
212	pain	_	_	I-Premise
213	(	_	_	I-Premise
214	P=.03	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	greater	_	_	I-Premise
219	opioid	_	_	I-Premise
220	use	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	<	_	_	I-Premise
224	.001	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	No	_	_	B-Premise
228	pain	_	_	I-Premise
229	training	_	_	I-Premise
230	patients	_	_	I-Premise
231	reported	_	_	I-Premise
232	severe	_	_	I-Premise
233	pain	_	_	I-Premise
234	(	_	_	I-Premise
235	>	_	_	I-Premise
236	6	_	_	I-Premise
237	on	_	_	I-Premise
238	a	_	_	I-Premise
239	0-10	_	_	I-Premise
240	scale	_	_	I-Premise
241	)	_	_	I-Premise
242	at	_	_	I-Premise
243	1-month	_	_	I-Premise
244	outcomes	_	_	I-Premise
245	(	_	_	I-Premise
246	P=.03	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	Physician	_	_	O
250	and	_	_	O
251	nurse	_	_	O
252	ratings	_	_	O
253	were	_	_	O
254	closer	_	_	O
255	to	_	_	O
256	patients	_	_	O
257	'	_	_	O
258	ratings	_	_	O
259	of	_	_	O
260	pain	_	_	O
261	for	_	_	O
262	trained	_	_	O
263	versus	_	_	O
264	nutrition	_	_	O
265	groups	_	_	O
266	(	_	_	O
267	P=.04	_	_	O
268	and	_	_	O
269	<	_	_	O
270	.001	_	_	O
271	,	_	_	O
272	respectively	_	_	O
273	)	_	_	O
274	.	_	_	O

275	Training	_	_	O
276	efficacy	_	_	O
277	was	_	_	O
278	not	_	_	O
279	modified	_	_	O
280	by	_	_	O
281	patient	_	_	O
282	characteristics	_	_	O
283	.	_	_	O

284	Using	_	_	B-Claim
285	video	_	_	I-Claim
286	and	_	_	I-Claim
287	print	_	_	I-Claim
288	materials	_	_	I-Claim
289	,	_	_	I-Claim
290	with	_	_	I-Claim
291	brief	_	_	I-Claim
292	individualized	_	_	I-Claim
293	training	_	_	I-Claim
294	,	_	_	I-Claim
295	effectively	_	_	I-Claim
296	improved	_	_	I-Claim
297	pain	_	_	I-Claim
298	management	_	_	I-Claim
299	over	_	_	I-Claim
300	time	_	_	I-Claim
301	for	_	_	I-Claim
302	cancer	_	_	I-Claim
303	patients	_	_	I-Claim
304	of	_	_	I-Claim
305	varying	_	_	I-Claim
306	diagnostic	_	_	I-Claim
307	and	_	_	I-Claim
308	demographic	_	_	I-Claim
309	groups	_	_	I-Claim
310	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Ahmed	_	_	O
7	S2	_	_	O
8	Glaucoma	_	_	O
9	Valve	_	_	O
10	with	_	_	O
11	the	_	_	O
12	Baerveldt	_	_	O
13	250-mm	_	_	O
14	(	_	_	O
15	2	_	_	O
16	)	_	_	O
17	Glaucoma	_	_	O
18	Implant	_	_	O
19	in	_	_	O
20	the	_	_	O
21	treatment	_	_	O
22	of	_	_	O
23	adult	_	_	O
24	glaucoma	_	_	O
25	.	_	_	O

26	Comparative	_	_	O
27	case	_	_	O
28	series	_	_	O
29	.	_	_	O

30	Fifty-nine	_	_	O
31	eyes	_	_	O
32	of	_	_	O
33	59	_	_	O
34	patients	_	_	O
35	who	_	_	O
36	received	_	_	O
37	the	_	_	O
38	Ahmed	_	_	O
39	S2	_	_	O
40	Glaucoma	_	_	O
41	Valve	_	_	O
42	and	_	_	O
43	133	_	_	O
44	eyes	_	_	O
45	of	_	_	O
46	133	_	_	O
47	patients	_	_	O
48	who	_	_	O
49	received	_	_	O
50	the	_	_	O
51	Baerveldt	_	_	O
52	250-mm	_	_	O
53	(	_	_	O
54	2	_	_	O
55	)	_	_	O
56	Glaucoma	_	_	O
57	Implant	_	_	O
58	by	_	_	O
59	the	_	_	O
60	Indiana	_	_	O
61	University	_	_	O
62	Glaucoma	_	_	O
63	Service	_	_	O
64	from	_	_	O
65	1996	_	_	O
66	to	_	_	O
67	2003	_	_	O
68	.	_	_	O

69	Eyes	_	_	O
70	that	_	_	O
71	had	_	_	O
72	previous	_	_	O
73	drainage	_	_	O
74	implant	_	_	O
75	procedures	_	_	O
76	were	_	_	O
77	excluded	_	_	O
78	from	_	_	O
79	both	_	_	O
80	groups	_	_	O
81	.	_	_	O

82	If	_	_	O
83	both	_	_	O
84	eyes	_	_	O
85	of	_	_	O
86	a	_	_	O
87	single	_	_	O
88	patient	_	_	O
89	received	_	_	O
90	an	_	_	O
91	implant	_	_	O
92	,	_	_	O
93	the	_	_	O
94	second	_	_	O
95	eye	_	_	O
96	to	_	_	O
97	undergo	_	_	O
98	implantation	_	_	O
99	was	_	_	O
100	excluded	_	_	O
101	from	_	_	O
102	the	_	_	O
103	study	_	_	O
104	.	_	_	O

105	Kaplan-Meier	_	_	O
106	survival	_	_	O
107	with	_	_	O
108	success	_	_	O
109	defined	_	_	O
110	as	_	_	O
111	intraocular	_	_	O
112	pressure	_	_	O
113	(	_	_	O
114	IOP	_	_	O
115	)	_	_	O
116	>	_	_	O
117	5	_	_	O
118	mmHg	_	_	O
119	and	_	_	O
120	<	_	_	O
121	22	_	_	O
122	mmHg	_	_	O
123	and	_	_	O
124	at	_	_	O
125	least	_	_	O
126	20	_	_	O
127	%	_	_	O
128	reduction	_	_	O
129	from	_	_	O
130	preoperative	_	_	O
131	IOP	_	_	O
132	(	_	_	O
133	with	_	_	O
134	or	_	_	O
135	without	_	_	O
136	antiglaucoma	_	_	O
137	medications	_	_	O
138	)	_	_	O
139	and	_	_	O
140	without	_	_	O
141	loss	_	_	O
142	of	_	_	O
143	light	_	_	O
144	perception	_	_	O
145	.	_	_	O

146	Secondary	_	_	O
147	outcome	_	_	O
148	measures	_	_	O
149	included	_	_	O
150	intraocular	_	_	O
151	pressure	_	_	O
152	,	_	_	O
153	visual	_	_	O
154	acuity	_	_	O
155	,	_	_	O
156	number	_	_	O
157	of	_	_	O
158	glaucoma	_	_	O
159	medications	_	_	O
160	,	_	_	O
161	and	_	_	O
162	surgical	_	_	O
163	complications	_	_	O
164	.	_	_	O

165	The	_	_	O
166	2	_	_	O
167	groups	_	_	O
168	were	_	_	O
169	similar	_	_	O
170	with	_	_	O
171	regards	_	_	O
172	to	_	_	O
173	age	_	_	O
174	,	_	_	O
175	gender	_	_	O
176	,	_	_	O
177	race	_	_	O
178	,	_	_	O
179	neovascular	_	_	O
180	glaucoma	_	_	O
181	diagnosis	_	_	O
182	,	_	_	O
183	number	_	_	O
184	of	_	_	O
185	prior	_	_	O
186	ocular	_	_	O
187	surgeries	_	_	O
188	,	_	_	O
189	preoperative	_	_	O
190	IOP	_	_	O
191	,	_	_	O
192	and	_	_	O
193	number	_	_	O
194	of	_	_	O
195	preoperative	_	_	O
196	glaucoma	_	_	O
197	medications	_	_	O
198	.	_	_	O

199	Mean	_	_	O
200	durations	_	_	O
201	of	_	_	O
202	follow-up	_	_	O
203	were	_	_	O
204	20.0	_	_	O
205	months	_	_	O
206	for	_	_	O
207	Ahmed	_	_	O
208	eyes	_	_	O
209	and	_	_	O
210	22.9	_	_	O
211	months	_	_	O
212	for	_	_	O
213	Baerveldt	_	_	O
214	eyes	_	_	O
215	.	_	_	O

216	Cumulative	_	_	B-Premise
217	successes	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	Ahmed	_	_	I-Premise
221	group	_	_	I-Premise
222	were	_	_	I-Premise
223	0.73	_	_	I-Premise
224	at	_	_	I-Premise
225	1	_	_	I-Premise
226	year	_	_	I-Premise
227	and	_	_	I-Premise
228	0.62	_	_	I-Premise
229	at	_	_	I-Premise
230	2	_	_	I-Premise
231	years	_	_	I-Premise
232	,	_	_	I-Premise
233	whereas	_	_	I-Premise
234	cumulative	_	_	I-Premise
235	successes	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	Baerveldt	_	_	I-Premise
239	group	_	_	I-Premise
240	were	_	_	I-Premise
241	0.92	_	_	I-Premise
242	at	_	_	I-Premise
243	1	_	_	I-Premise
244	year	_	_	I-Premise
245	and	_	_	I-Premise
246	0.85	_	_	I-Premise
247	at	_	_	I-Premise
248	2	_	_	I-Premise
249	years	_	_	I-Premise
250	(	_	_	I-Premise
251	Kaplan-Meier	_	_	I-Premise
252	survival	_	_	I-Premise
253	functions	_	_	I-Premise
254	:	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	0.03	_	_	I-Premise
258	,	_	_	I-Premise
259	log	_	_	I-Premise
260	rank	_	_	I-Premise
261	test	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Male	_	_	B-Claim
265	gender	_	_	I-Claim
266	,	_	_	I-Claim
267	African	_	_	I-Claim
268	descent	_	_	I-Claim
269	,	_	_	I-Claim
270	neovascular	_	_	I-Claim
271	glaucoma	_	_	I-Claim
272	,	_	_	I-Claim
273	and	_	_	I-Claim
274	Ahmed	_	_	I-Claim
275	implantation	_	_	I-Claim
276	were	_	_	I-Claim
277	found	_	_	I-Claim
278	to	_	_	I-Claim
279	be	_	_	I-Claim
280	significant	_	_	I-Claim
281	predictors	_	_	I-Claim
282	of	_	_	I-Claim
283	failure	_	_	I-Claim
284	.	_	_	I-Claim

285	At	_	_	B-Premise
286	last	_	_	I-Premise
287	follow-up	_	_	I-Premise
288	visit	_	_	I-Premise
289	,	_	_	I-Premise
290	eyes	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	Ahmed	_	_	I-Premise
294	group	_	_	I-Premise
295	had	_	_	I-Premise
296	a	_	_	I-Premise
297	significantly	_	_	I-Premise
298	higher	_	_	I-Premise
299	mean	_	_	I-Premise
300	IOP	_	_	I-Premise
301	(	_	_	I-Premise
302	19.8+/-9.5	_	_	I-Premise
303	vs.	_	_	I-Premise
304	15.8+/-7.9	_	_	I-Premise
305	mmHg	_	_	I-Premise
306	,	_	_	I-Premise
307	P	_	_	I-Premise
308	=	_	_	I-Premise
309	0.003	_	_	I-Premise
310	,	_	_	I-Premise
311	t	_	_	I-Premise
312	test	_	_	I-Premise
313	)	_	_	I-Premise
314	and	_	_	I-Premise
315	more	_	_	I-Premise
316	antiglaucoma	_	_	I-Premise
317	medications	_	_	I-Premise
318	(	_	_	I-Premise
319	1.4+/-1.2	_	_	I-Premise
320	vs.	_	_	I-Premise
321	0.9+/-1.1	_	_	I-Premise
322	medications	_	_	I-Premise
323	,	_	_	I-Premise
324	P	_	_	I-Premise
325	=	_	_	I-Premise
326	0.008	_	_	I-Premise
327	,	_	_	I-Premise
328	Mann-Whitney	_	_	I-Premise
329	test	_	_	I-Premise
330	)	_	_	I-Premise
331	than	_	_	I-Premise
332	eyes	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	Baerveldt	_	_	I-Premise
336	group	_	_	I-Premise
337	.	_	_	I-Premise

338	Two	_	_	O
339	methods	_	_	O
340	for	_	_	O
341	avoiding	_	_	O
342	hypotony	_	_	O
343	after	_	_	O
344	Baerveldt	_	_	O
345	250-mm	_	_	O
346	(	_	_	O
347	2	_	_	O
348	)	_	_	O
349	implantation	_	_	O
350	had	_	_	O
351	similar	_	_	O
352	outcomes	_	_	O
353	.	_	_	O

354	Our	_	_	B-Claim
355	study	_	_	I-Claim
356	suggests	_	_	I-Claim
357	that	_	_	I-Claim
358	the	_	_	I-Claim
359	Ahmed	_	_	I-Claim
360	S2	_	_	I-Claim
361	Glaucoma	_	_	I-Claim
362	Valve	_	_	I-Claim
363	may	_	_	I-Claim
364	be	_	_	I-Claim
365	less	_	_	I-Claim
366	effective	_	_	I-Claim
367	at	_	_	I-Claim
368	lowering	_	_	I-Claim
369	IOP	_	_	I-Claim
370	than	_	_	I-Claim
371	the	_	_	I-Claim
372	Baerveldt	_	_	I-Claim
373	250-mm	_	_	I-Claim
374	(	_	_	I-Claim
375	2	_	_	I-Claim
376	)	_	_	I-Claim
377	Glaucoma	_	_	I-Claim
378	Implant	_	_	I-Claim
379	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	short-	_	_	O
3	and	_	_	O
4	long-term	_	_	O
5	effects	_	_	O
6	of	_	_	O
7	adjuvant	_	_	O
8	treatment	_	_	O
9	versus	_	_	O
10	observation	_	_	O
11	after	_	_	O
12	surgery	_	_	O
13	on	_	_	O
14	health-related	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	(	_	_	O
19	HRQL	_	_	O
20	)	_	_	O
21	of	_	_	O
22	prostate	_	_	O
23	cancer	_	_	O
24	patients	_	_	O
25	.	_	_	O

26	The	_	_	O
27	Southwest	_	_	O
28	Oncology	_	_	O
29	Group	_	_	O
30	(	_	_	O
31	SWOG	_	_	O
32	)	_	_	O
33	intergroup	_	_	O
34	trial	_	_	O
35	compared	_	_	O
36	radical	_	_	O
37	prostatectomy	_	_	O
38	(	_	_	O
39	RP	_	_	O
40	)	_	_	O
41	plus	_	_	O
42	observation	_	_	O
43	versus	_	_	O
44	RP	_	_	O
45	plus	_	_	O
46	adjuvant	_	_	O
47	radiation	_	_	O
48	therapy	_	_	O
49	(	_	_	O
50	RT	_	_	O
51	)	_	_	O
52	.	_	_	O

53	Two-hundred	_	_	O
54	seventeen	_	_	O
55	of	_	_	O
56	425	_	_	O
57	therapeutic	_	_	O
58	trial	_	_	O
59	patients	_	_	O
60	were	_	_	O
61	eligible	_	_	O
62	and	_	_	O
63	registered	_	_	O
64	to	_	_	O
65	the	_	_	O
66	HRQL	_	_	O
67	study	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	completed	_	_	O
71	the	_	_	O
72	SWOG	_	_	O
73	Quality	_	_	O
74	of	_	_	O
75	Life	_	_	O
76	Questionnaire	_	_	O
77	(	_	_	O
78	emotional	_	_	O
79	,	_	_	O
80	physical	_	_	O
81	,	_	_	O
82	social	_	_	O
83	,	_	_	O
84	and	_	_	O
85	role	_	_	O
86	function	_	_	O
87	;	_	_	O
88	general	_	_	O
89	symptom	_	_	O
90	status	_	_	O
91	;	_	_	O
92	treatment/disease-specific	_	_	O
93	symptoms	_	_	O
94	;	_	_	O
95	and	_	_	O
96	global	_	_	O
97	HRQL	_	_	O
98	[	_	_	O
99	GHRQL	_	_	O
100	]	_	_	O
101	)	_	_	O
102	at	_	_	O
103	baseline	_	_	O
104	,	_	_	O
105	6	_	_	O
106	weeks	_	_	O
107	,	_	_	O
108	6	_	_	O
109	months	_	_	O
110	,	_	_	O
111	and	_	_	O
112	annually	_	_	O
113	for	_	_	O
114	5	_	_	O
115	years	_	_	O
116	.	_	_	O

117	Prespecified	_	_	O
118	outcomes	_	_	O
119	were	_	_	O
120	three	_	_	O
121	genitourinary	_	_	O
122	symptoms	_	_	O
123	(	_	_	O
124	bowel	_	_	O
125	function	_	_	O
126	tenderness	_	_	O
127	,	_	_	O
128	frequent	_	_	O
129	urination	_	_	O
130	,	_	_	O
131	and	_	_	O
132	erectile	_	_	O
133	dysfunction	_	_	O
134	[	_	_	O
135	ED	_	_	O
136	]	_	_	O
137	)	_	_	O
138	and	_	_	O
139	measures	_	_	O
140	of	_	_	O
141	physical	_	_	O
142	and	_	_	O
143	emotional	_	_	O
144	function	_	_	O
145	.	_	_	O

146	Adjustments	_	_	O
147	were	_	_	O
148	made	_	_	O
149	for	_	_	O
150	the	_	_	O
151	baseline	_	_	O
152	score	_	_	O
153	.	_	_	O

154	Patients	_	_	O
155	receiving	_	_	O
156	adjuvant	_	_	O
157	RT	_	_	O
158	reported	_	_	O
159	worse	_	_	O
160	bowel	_	_	O
161	function	_	_	O
162	(	_	_	O
163	through	_	_	O
164	approximately	_	_	O
165	2	_	_	O
166	years	_	_	O
167	)	_	_	O
168	and	_	_	O
169	worse	_	_	O
170	urinary	_	_	O
171	function	_	_	O
172	.	_	_	O

173	There	_	_	O
174	were	_	_	O
175	no	_	_	O
176	statistically	_	_	O
177	significant	_	_	O
178	differences	_	_	O
179	for	_	_	O
180	ED	_	_	O
181	.	_	_	O

182	GHRQL	_	_	B-Premise
183	was	_	_	I-Premise
184	initially	_	_	I-Premise
185	worse	_	_	I-Premise
186	for	_	_	I-Premise
187	the	_	_	I-Premise
188	RP+RT	_	_	I-Premise
189	arm	_	_	I-Premise
190	but	_	_	I-Premise
191	improved	_	_	I-Premise
192	over	_	_	I-Premise
193	time	_	_	I-Premise
194	and	_	_	I-Premise
195	was	_	_	I-Premise
196	better	_	_	I-Premise
197	at	_	_	I-Premise
198	the	_	_	I-Premise
199	end	_	_	I-Premise
200	of	_	_	I-Premise
201	the	_	_	I-Premise
202	period	_	_	I-Premise
203	than	_	_	I-Premise
204	the	_	_	I-Premise
205	GHRQL	_	_	I-Premise
206	reported	_	_	I-Premise
207	for	_	_	I-Premise
208	RP	_	_	I-Premise
209	alone	_	_	I-Premise
210	(	_	_	I-Premise
211	treatment	_	_	I-Premise
212	arm	_	_	I-Premise
213	x	_	_	I-Premise
214	time	_	_	I-Premise
215	interaction	_	_	I-Premise
216	,	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	.0004	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Symptom	_	_	B-Premise
223	distress	_	_	I-Premise
224	was	_	_	I-Premise
225	significantly	_	_	I-Premise
226	worse	_	_	I-Premise
227	for	_	_	I-Premise
228	the	_	_	I-Premise
229	RP+RT	_	_	I-Premise
230	arm	_	_	I-Premise
231	compared	_	_	I-Premise
232	with	_	_	I-Premise
233	the	_	_	I-Premise
234	RP	_	_	I-Premise
235	alone	_	_	I-Premise
236	arm	_	_	I-Premise
237	,	_	_	O
238	but	_	_	B-Premise
239	the	_	_	I-Premise
240	treatment	_	_	I-Premise
241	arms	_	_	I-Premise
242	did	_	_	I-Premise
243	not	_	_	I-Premise
244	differ	_	_	I-Premise
245	with	_	_	I-Premise
246	respect	_	_	I-Premise
247	to	_	_	I-Premise
248	other	_	_	I-Premise
249	general	_	_	I-Premise
250	measures	_	_	I-Premise
251	of	_	_	I-Premise
252	HRQL	_	_	I-Premise
253	.	_	_	I-Premise

254	The	_	_	B-Premise
255	addition	_	_	I-Premise
256	of	_	_	I-Premise
257	RT	_	_	I-Premise
258	to	_	_	I-Premise
259	surgery	_	_	I-Premise
260	resulted	_	_	I-Premise
261	in	_	_	I-Premise
262	more	_	_	I-Premise
263	frequent	_	_	I-Premise
264	urination	_	_	I-Premise
265	,	_	_	I-Premise
266	as	_	_	I-Premise
267	well	_	_	I-Premise
268	as	_	_	I-Premise
269	early	_	_	I-Premise
270	report	_	_	I-Premise
271	of	_	_	I-Premise
272	more	_	_	I-Premise
273	bowel	_	_	I-Premise
274	dysfunction	_	_	I-Premise
275	,	_	_	O
276	although	_	_	B-Premise
277	bowel	_	_	I-Premise
278	function	_	_	I-Premise
279	differences	_	_	I-Premise
280	disappeared	_	_	I-Premise
281	over	_	_	I-Premise
282	the	_	_	I-Premise
283	5-year	_	_	I-Premise
284	period	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Claim
287	addition	_	_	I-Claim
288	of	_	_	I-Claim
289	RT	_	_	I-Claim
290	did	_	_	I-Claim
291	not	_	_	I-Claim
292	negatively	_	_	I-Claim
293	impact	_	_	I-Claim
294	ED	_	_	I-Claim
295	.	_	_	I-Claim


0	The	_	_	O
1	TAX	_	_	O
2	327	_	_	O
3	study	_	_	O
4	compared	_	_	O
5	docetaxel	_	_	O
6	administered	_	_	O
7	every	_	_	O
8	3	_	_	O
9	weeks	_	_	O
10	(	_	_	O
11	D3	_	_	O
12	)	_	_	O
13	,	_	_	O
14	weekly	_	_	O
15	docetaxel	_	_	O
16	(	_	_	O
17	D1	_	_	O
18	)	_	_	O
19	,	_	_	O
20	and	_	_	O
21	mitoxantrone	_	_	O
22	(	_	_	O
23	M	_	_	O
24	)	_	_	O
25	,	_	_	O
26	each	_	_	O
27	with	_	_	O
28	prednisone	_	_	O
29	(	_	_	O
30	P	_	_	O
31	)	_	_	O
32	,	_	_	O
33	in	_	_	O
34	1,006	_	_	O
35	men	_	_	O
36	with	_	_	O
37	metastatic	_	_	O
38	hormone-resistant	_	_	O
39	prostate	_	_	O
40	cancer	_	_	O
41	(	_	_	O
42	HRPC	_	_	O
43	)	_	_	O
44	.	_	_	O

45	The	_	_	O
46	original	_	_	O
47	analysis	_	_	O
48	,	_	_	O
49	undertaken	_	_	O
50	in	_	_	O
51	August	_	_	O
52	2003	_	_	O
53	when	_	_	O
54	557	_	_	O
55	deaths	_	_	O
56	had	_	_	O
57	occurred	_	_	O
58	,	_	_	O
59	showed	_	_	O
60	significantly	_	_	O
61	better	_	_	O
62	survival	_	_	O
63	and	_	_	O
64	response	_	_	O
65	rates	_	_	O
66	for	_	_	O
67	pain	_	_	O
68	,	_	_	O
69	prostate-specific	_	_	O
70	antigen	_	_	O
71	(	_	_	O
72	PSA	_	_	O
73	)	_	_	O
74	,	_	_	O
75	and	_	_	O
76	quality	_	_	O
77	of	_	_	O
78	life	_	_	O
79	for	_	_	O
80	D3P	_	_	O
81	when	_	_	O
82	compared	_	_	O
83	with	_	_	O
84	MP	_	_	O
85	.	_	_	O

86	Here	_	_	O
87	,	_	_	O
88	we	_	_	O
89	report	_	_	O
90	an	_	_	O
91	updated	_	_	O
92	analysis	_	_	O
93	of	_	_	O
94	survival	_	_	O
95	.	_	_	O

96	Investigators	_	_	O
97	were	_	_	O
98	asked	_	_	O
99	to	_	_	O
100	provide	_	_	O
101	the	_	_	O
102	date	_	_	O
103	of	_	_	O
104	death	_	_	O
105	or	_	_	O
106	last	_	_	O
107	follow-up	_	_	O
108	for	_	_	O
109	all	_	_	O
110	participants	_	_	O
111	who	_	_	O
112	were	_	_	O
113	alive	_	_	O
114	in	_	_	O
115	August	_	_	O
116	2003	_	_	O
117	.	_	_	O

118	By	_	_	O
119	March	_	_	O
120	2007	_	_	O
121	,	_	_	O
122	data	_	_	O
123	on	_	_	O
124	310	_	_	O
125	additional	_	_	O
126	deaths	_	_	O
127	were	_	_	O
128	obtained	_	_	O
129	(	_	_	O
130	total	_	_	O
131	=	_	_	O
132	867	_	_	O
133	deaths	_	_	O
134	)	_	_	O
135	.	_	_	O

136	The	_	_	B-Premise
137	survival	_	_	I-Premise
138	benefit	_	_	I-Premise
139	of	_	_	I-Premise
140	D3P	_	_	I-Premise
141	compared	_	_	I-Premise
142	with	_	_	I-Premise
143	MP	_	_	I-Premise
144	has	_	_	I-Premise
145	persisted	_	_	I-Premise
146	with	_	_	I-Premise
147	extended	_	_	I-Premise
148	follow-up	_	_	I-Premise
149	(	_	_	I-Premise
150	P	_	_	I-Premise
151	=	_	_	I-Premise
152	.004	_	_	I-Premise
153	)	_	_	I-Premise
154	.	_	_	I-Premise

155	Median	_	_	O
156	survival	_	_	O
157	time	_	_	O
158	was	_	_	O
159	19.2	_	_	O
160	months	_	_	O
161	(	_	_	O
162	95	_	_	O
163	%	_	_	O
164	CI	_	_	O
165	,	_	_	O
166	17.5	_	_	O
167	to	_	_	O
168	21.3	_	_	O
169	months	_	_	O
170	)	_	_	O
171	in	_	_	O
172	the	_	_	O
173	D3P	_	_	O
174	arm	_	_	O
175	,	_	_	O
176	17.8	_	_	O
177	months	_	_	O
178	(	_	_	O
179	95	_	_	O
180	%	_	_	O
181	CI	_	_	O
182	,	_	_	O
183	16.2	_	_	O
184	to	_	_	O
185	19.2	_	_	O
186	months	_	_	O
187	)	_	_	O
188	in	_	_	O
189	the	_	_	O
190	D1P	_	_	O
191	arm	_	_	O
192	,	_	_	O
193	and	_	_	O
194	16.3	_	_	O
195	months	_	_	O
196	(	_	_	O
197	95	_	_	O
198	%	_	_	O
199	CI	_	_	O
200	,	_	_	O
201	14.3	_	_	O
202	to	_	_	O
203	17.9	_	_	O
204	months	_	_	O
205	)	_	_	O
206	in	_	_	O
207	the	_	_	O
208	MP	_	_	O
209	arm	_	_	O
210	.	_	_	O

211	More	_	_	B-Premise
212	patients	_	_	I-Premise
213	survived	_	_	I-Premise
214	>	_	_	I-Premise
215	/=	_	_	I-Premise
216	3	_	_	I-Premise
217	years	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	D3P	_	_	I-Premise
221	and	_	_	I-Premise
222	D1P	_	_	I-Premise
223	arms	_	_	I-Premise
224	(	_	_	I-Premise
225	18.6	_	_	I-Premise
226	%	_	_	I-Premise
227	and	_	_	I-Premise
228	16.6	_	_	I-Premise
229	%	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	)	_	_	I-Premise
233	compared	_	_	I-Premise
234	with	_	_	I-Premise
235	the	_	_	I-Premise
236	MP	_	_	I-Premise
237	arm	_	_	I-Premise
238	(	_	_	I-Premise
239	13.5	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	Similar	_	_	B-Premise
244	trends	_	_	I-Premise
245	in	_	_	I-Premise
246	survival	_	_	I-Premise
247	between	_	_	I-Premise
248	treatment	_	_	I-Premise
249	arms	_	_	I-Premise
250	were	_	_	I-Premise
251	seen	_	_	I-Premise
252	for	_	_	I-Premise
253	men	_	_	I-Premise
254	greater	_	_	I-Premise
255	than	_	_	I-Premise
256	and	_	_	I-Premise
257	less	_	_	I-Premise
258	than	_	_	I-Premise
259	65	_	_	I-Premise
260	years	_	_	I-Premise
261	of	_	_	I-Premise
262	age	_	_	I-Premise
263	,	_	_	I-Premise
264	for	_	_	I-Premise
265	those	_	_	I-Premise
266	with	_	_	I-Premise
267	and	_	_	I-Premise
268	without	_	_	I-Premise
269	pain	_	_	I-Premise
270	at	_	_	I-Premise
271	baseline	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	I-Premise
274	for	_	_	I-Premise
275	those	_	_	I-Premise
276	with	_	_	I-Premise
277	baseline	_	_	I-Premise
278	PSA	_	_	I-Premise
279	greater	_	_	I-Premise
280	than	_	_	I-Premise
281	and	_	_	I-Premise
282	less	_	_	I-Premise
283	than	_	_	I-Premise
284	the	_	_	I-Premise
285	median	_	_	I-Premise
286	value	_	_	I-Premise
287	of	_	_	I-Premise
288	115	_	_	I-Premise
289	ng/mL	_	_	I-Premise
290	.	_	_	I-Premise

291	The	_	_	B-Claim
292	present	_	_	I-Claim
293	analysis	_	_	I-Claim
294	confirms	_	_	I-Claim
295	that	_	_	I-Claim
296	survival	_	_	I-Claim
297	of	_	_	I-Claim
298	men	_	_	I-Claim
299	with	_	_	I-Claim
300	metastatic	_	_	I-Claim
301	HRPC	_	_	I-Claim
302	is	_	_	I-Claim
303	significantly	_	_	I-Claim
304	longer	_	_	I-Claim
305	after	_	_	I-Claim
306	treatment	_	_	I-Claim
307	with	_	_	I-Claim
308	D3P	_	_	I-Claim
309	than	_	_	I-Claim
310	with	_	_	I-Claim
311	MP	_	_	I-Claim
312	.	_	_	I-Claim

313	Consistent	_	_	O
314	results	_	_	O
315	are	_	_	O
316	observed	_	_	O
317	across	_	_	O
318	subgroups	_	_	O
319	of	_	_	O
320	patients	_	_	O
321	.	_	_	O


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	multicenter	_	_	O
5	randomized	_	_	O
6	trial	_	_	O
7	was	_	_	O
8	to	_	_	O
9	assess	_	_	O
10	the	_	_	O
11	efficacy	_	_	O
12	and	_	_	O
13	safety	_	_	O
14	of	_	_	O
15	sentinel	_	_	O
16	lymph	_	_	O
17	node	_	_	O
18	(	_	_	O
19	SLN	_	_	O
20	)	_	_	O
21	biopsy	_	_	O
22	compared	_	_	O
23	with	_	_	O
24	axillary	_	_	O
25	lymph	_	_	O
26	node	_	_	O
27	dissection	_	_	O
28	(	_	_	O
29	ALND	_	_	O
30	)	_	_	O
31	.	_	_	O

32	All	_	_	O
33	studies	_	_	O
34	on	_	_	O
35	SLN	_	_	O
36	biopsy	_	_	O
37	in	_	_	O
38	breast	_	_	O
39	cancer	_	_	O
40	report	_	_	O
41	a	_	_	O
42	variable	_	_	O
43	false	_	_	O
44	negative	_	_	O
45	rate	_	_	O
46	,	_	_	O
47	whose	_	_	O
48	prognostic	_	_	O
49	consequences	_	_	O
50	are	_	_	O
51	still	_	_	O
52	unclear	_	_	O
53	.	_	_	O

54	From	_	_	O
55	May	_	_	O
56	1999	_	_	O
57	to	_	_	O
58	December	_	_	O
59	2004	_	_	O
60	,	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	breast	_	_	O
64	cancer	_	_	O
65	<	_	_	O
66	or	_	_	O
67	=3	_	_	O
68	cm	_	_	O
69	were	_	_	O
70	randomly	_	_	O
71	assigned	_	_	O
72	to	_	_	O
73	receive	_	_	O
74	SLN	_	_	O
75	biopsy	_	_	O
76	associated	_	_	O
77	with	_	_	O
78	ALND	_	_	O
79	(	_	_	O
80	ALND	_	_	O
81	arm	_	_	O
82	)	_	_	O
83	or	_	_	O
84	SLN	_	_	O
85	biopsy	_	_	O
86	followed	_	_	O
87	by	_	_	O
88	ALND	_	_	O
89	only	_	_	O
90	if	_	_	O
91	the	_	_	O
92	SLN	_	_	O
93	was	_	_	O
94	metastatic	_	_	O
95	(	_	_	O
96	SLN	_	_	O
97	arm	_	_	O
98	)	_	_	O
99	.	_	_	O

100	The	_	_	O
101	main	_	_	O
102	aim	_	_	O
103	was	_	_	O
104	the	_	_	O
105	comparison	_	_	O
106	of	_	_	O
107	disease-free	_	_	O
108	survival	_	_	O
109	in	_	_	O
110	the	_	_	O
111	2	_	_	O
112	arms	_	_	O
113	.	_	_	O

114	A	_	_	O
115	total	_	_	O
116	of	_	_	O
117	749	_	_	O
118	patients	_	_	O
119	were	_	_	O
120	randomized	_	_	O
121	and	_	_	O
122	697	_	_	O
123	were	_	_	O
124	available	_	_	O
125	for	_	_	O
126	analysis	_	_	O
127	.	_	_	O

128	SLNs	_	_	O
129	were	_	_	O
130	identified	_	_	O
131	in	_	_	O
132	662	_	_	O
133	of	_	_	O
134	697	_	_	O
135	patients	_	_	O
136	(	_	_	O
137	95	_	_	O
138	%	_	_	O
139	)	_	_	O
140	and	_	_	O
141	positive	_	_	O
142	SLNs	_	_	O
143	were	_	_	O
144	found	_	_	O
145	in	_	_	O
146	189	_	_	O
147	of	_	_	O
148	662	_	_	O
149	patients	_	_	O
150	(	_	_	O
151	28.5	_	_	O
152	%	_	_	O
153	)	_	_	O
154	.	_	_	O

155	In	_	_	O
156	the	_	_	O
157	ALND	_	_	O
158	group	_	_	O
159	,	_	_	O
160	positive	_	_	O
161	non-SLNs	_	_	O
162	were	_	_	O
163	found	_	_	O
164	in	_	_	O
165	18	_	_	O
166	patients	_	_	O
167	with	_	_	O
168	negative	_	_	O
169	SLN	_	_	O
170	,	_	_	O
171	giving	_	_	O
172	a	_	_	O
173	false	_	_	O
174	negative	_	_	O
175	rate	_	_	O
176	of	_	_	O
177	16.7	_	_	O
178	%	_	_	O
179	(	_	_	O
180	18	_	_	O
181	of	_	_	O
182	108	_	_	O
183	)	_	_	O
184	.	_	_	O

185	Postoperative	_	_	B-Premise
186	side	_	_	I-Premise
187	effects	_	_	I-Premise
188	were	_	_	I-Premise
189	significantly	_	_	I-Premise
190	less	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	SLN	_	_	I-Premise
194	group	_	_	I-Premise
195	and	_	_	I-Premise
196	there	_	_	I-Premise
197	was	_	_	I-Premise
198	no	_	_	I-Premise
199	negative	_	_	I-Premise
200	impact	_	_	I-Premise
201	of	_	_	I-Premise
202	the	_	_	I-Premise
203	SLN	_	_	I-Premise
204	procedure	_	_	I-Premise
205	on	_	_	I-Premise
206	psychologic	_	_	I-Premise
207	well	_	_	I-Premise
208	being	_	_	I-Premise
209	.	_	_	I-Premise

210	At	_	_	O
211	a	_	_	O
212	median	_	_	O
213	follow-up	_	_	O
214	of	_	_	O
215	56	_	_	O
216	months	_	_	O
217	,	_	_	O
218	there	_	_	O
219	were	_	_	O
220	more	_	_	O
221	locoregional	_	_	O
222	recurrences	_	_	O
223	in	_	_	O
224	the	_	_	O
225	SLN	_	_	O
226	arm	_	_	O
227	,	_	_	O
228	and	_	_	O
229	the	_	_	O
230	5-year	_	_	O
231	disease-free	_	_	O
232	survival	_	_	O
233	was	_	_	O
234	89.9	_	_	O
235	%	_	_	O
236	in	_	_	O
237	the	_	_	O
238	ALND	_	_	O
239	arm	_	_	O
240	and	_	_	O
241	87.6	_	_	O
242	%	_	_	O
243	in	_	_	O
244	the	_	_	O
245	SLN	_	_	O
246	arm	_	_	O
247	,	_	_	O
248	with	_	_	O
249	a	_	_	O
250	difference	_	_	O
251	of	_	_	O
252	2.3	_	_	O
253	%	_	_	O
254	(	_	_	O
255	95	_	_	O
256	%	_	_	O
257	confidence	_	_	O
258	interval	_	_	O
259	:	_	_	O
260	-3.1	_	_	O
261	%	_	_	O
262	to	_	_	O
263	7.6	_	_	O
264	%	_	_	O
265	)	_	_	O
266	.	_	_	O

267	However	_	_	B-Premise
268	,	_	_	I-Premise
269	the	_	_	I-Premise
270	number	_	_	I-Premise
271	of	_	_	I-Premise
272	enrolled	_	_	I-Premise
273	patients	_	_	I-Premise
274	was	_	_	I-Premise
275	not	_	_	I-Premise
276	sufficient	_	_	I-Premise
277	to	_	_	I-Premise
278	draw	_	_	I-Premise
279	definitive	_	_	I-Premise
280	conclusions	_	_	I-Premise
281	.	_	_	I-Premise

282	SLN	_	_	B-Claim
283	biopsy	_	_	I-Claim
284	is	_	_	I-Claim
285	an	_	_	I-Claim
286	effective	_	_	I-Claim
287	and	_	_	I-Claim
288	well-tolerated	_	_	I-Claim
289	procedure	_	_	I-Claim
290	.	_	_	I-Claim

291	However	_	_	B-Claim
292	,	_	_	I-Claim
293	its	_	_	I-Claim
294	safety	_	_	I-Claim
295	should	_	_	I-Claim
296	be	_	_	I-Claim
297	confirmed	_	_	I-Claim
298	by	_	_	I-Claim
299	the	_	_	I-Claim
300	results	_	_	I-Claim
301	of	_	_	I-Claim
302	larger	_	_	I-Claim
303	randomized	_	_	I-Claim
304	trials	_	_	I-Claim
305	and	_	_	I-Claim
306	meta-analyses	_	_	I-Claim
307	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	analysis	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	impact	_	_	O
10	of	_	_	O
11	pretreatment	_	_	O
12	factors	_	_	O
13	on	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	QOL	_	_	O
19	)	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	locally	_	_	O
24	advanced	_	_	O
25	nonsmall	_	_	O
26	cell	_	_	O
27	lung	_	_	O
28	cancer	_	_	O
29	(	_	_	O
30	NSCLC	_	_	O
31	)	_	_	O
32	.	_	_	O

33	In	_	_	O
34	particular	_	_	O
35	,	_	_	O
36	this	_	_	O
37	study	_	_	O
38	focused	_	_	O
39	on	_	_	O
40	the	_	_	O
41	possible	_	_	O
42	interaction	_	_	O
43	between	_	_	O
44	gender-specific	_	_	O
45	baseline	_	_	O
46	health-related	_	_	O
47	QOL	_	_	O
48	and	_	_	O
49	Karnofsky	_	_	O
50	performance	_	_	O
51	score	_	_	O
52	(	_	_	O
53	KPS	_	_	O
54	)	_	_	O
55	in	_	_	O
56	a	_	_	O
57	prospective	_	_	O
58	randomized	_	_	O
59	lung	_	_	O
60	cancer	_	_	O
61	trial	_	_	O
62	.	_	_	O

63	QOL	_	_	O
64	information	_	_	O
65	,	_	_	O
66	using	_	_	O
67	validated	_	_	O
68	instruments	_	_	O
69	(	_	_	O
70	Functional	_	_	O
71	Assessment	_	_	O
72	of	_	_	O
73	Cancer	_	_	O
74	Therapy-Lung	_	_	O
75	[	_	_	O
76	FACT-L	_	_	O
77	]	_	_	O
78	,	_	_	O
79	version	_	_	O
80	2	_	_	O
81	,	_	_	O
82	and	_	_	O
83	Functional	_	_	O
84	Living	_	_	O
85	Index-Cancer	_	_	O
86	[	_	_	O
87	FLIC	_	_	O
88	]	_	_	O
89	)	_	_	O
90	,	_	_	O
91	was	_	_	O
92	prospectively	_	_	O
93	collected	_	_	O
94	in	_	_	O
95	patients	_	_	O
96	with	_	_	O
97	locally	_	_	O
98	advanced	_	_	O
99	NSCLC	_	_	O
100	treated	_	_	O
101	on	_	_	O
102	Radiation	_	_	O
103	Therapy	_	_	O
104	Oncology	_	_	O
105	Group	_	_	O
106	(	_	_	O
107	RTOG	_	_	O
108	)	_	_	O
109	trial	_	_	O
110	89-01	_	_	O
111	.	_	_	O

112	Between	_	_	O
113	April	_	_	O
114	1990	_	_	O
115	and	_	_	O
116	April	_	_	O
117	1994	_	_	O
118	,	_	_	O
119	70	_	_	O
120	eligible	_	_	O
121	patients	_	_	O
122	participated	_	_	O
123	in	_	_	O
124	a	_	_	O
125	phase	_	_	O
126	III	_	_	O
127	trial	_	_	O
128	comparing	_	_	O
129	a	_	_	O
130	regimen	_	_	O
131	containing	_	_	O
132	sequential	_	_	O
133	chemotherapy	_	_	O
134	and	_	_	O
135	radiation	_	_	O
136	therapy	_	_	O
137	versus	_	_	O
138	sequential	_	_	O
139	chemotherapy	_	_	O
140	plus	_	_	O
141	surgery	_	_	O
142	.	_	_	O

143	Of	_	_	O
144	these	_	_	O
145	70	_	_	O
146	patients	_	_	O
147	,	_	_	O
148	46	_	_	O
149	underwent	_	_	O
150	pretreatment	_	_	O
151	FLIC	_	_	O
152	and	_	_	O
153	49	_	_	O
154	underwent	_	_	O
155	pretreatment	_	_	O
156	FACT-L	_	_	O
157	.	_	_	O

158	There	_	_	B-Premise
159	was	_	_	I-Premise
160	a	_	_	I-Premise
161	significant	_	_	I-Premise
162	interaction	_	_	I-Premise
163	between	_	_	I-Premise
164	gender	_	_	I-Premise
165	and	_	_	I-Premise
166	KPS	_	_	I-Premise
167	using	_	_	I-Premise
168	FLIC	_	_	I-Premise
169	(	_	_	I-Premise
170	P	_	_	I-Premise
171	=	_	_	I-Premise
172	0.009	_	_	I-Premise
173	)	_	_	I-Premise
174	,	_	_	I-Premise
175	which	_	_	I-Premise
176	also	_	_	I-Premise
177	showed	_	_	I-Premise
178	a	_	_	I-Premise
179	trend	_	_	I-Premise
180	toward	_	_	I-Premise
181	significance	_	_	I-Premise
182	with	_	_	I-Premise
183	FACT	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	0.09	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	Significant	_	_	B-Premise
191	KPS-by-gender	_	_	I-Premise
192	interactions	_	_	I-Premise
193	were	_	_	I-Premise
194	noted	_	_	I-Premise
195	for	_	_	I-Premise
196	FACT-L	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	physical	_	_	I-Premise
200	well-being	_	_	I-Premise
201	and	_	_	I-Premise
202	additional	_	_	I-Premise
203	concerns-lung	_	_	I-Premise
204	subscales	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	0.012	_	_	I-Premise
209	and	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	0.0003	_	_	I-Premise
213	,	_	_	I-Premise
214	respectively	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	The	_	_	B-Premise
218	results	_	_	I-Premise
219	of	_	_	I-Premise
220	both	_	_	I-Premise
221	the	_	_	I-Premise
222	FLIC	_	_	I-Premise
223	and	_	_	I-Premise
224	FACT-L	_	_	I-Premise
225	demonstrated	_	_	I-Premise
226	significantly	_	_	I-Premise
227	lower	_	_	I-Premise
228	scores	_	_	I-Premise
229	corresponding	_	_	I-Premise
230	to	_	_	I-Premise
231	lower	_	_	I-Premise
232	KPS	_	_	I-Premise
233	values	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	0.009	_	_	I-Premise
238	and	_	_	I-Premise
239	P	_	_	I-Premise
240	=	_	_	I-Premise
241	0.016	_	_	I-Premise
242	,	_	_	I-Premise
243	respectively	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	Results	_	_	B-Claim
247	of	_	_	I-Claim
248	this	_	_	I-Claim
249	randomized	_	_	I-Claim
250	study	_	_	I-Claim
251	incorporating	_	_	I-Claim
252	prospective	_	_	I-Claim
253	QOL	_	_	I-Claim
254	measurements	_	_	I-Claim
255	suggested	_	_	I-Claim
256	that	_	_	I-Claim
257	in	_	_	I-Claim
258	patients	_	_	I-Claim
259	with	_	_	I-Claim
260	locally	_	_	I-Claim
261	advanced	_	_	I-Claim
262	NSCLC	_	_	I-Claim
263	,	_	_	I-Claim
264	analyzing	_	_	I-Claim
265	QOL	_	_	I-Claim
266	data	_	_	I-Claim
267	by	_	_	I-Claim
268	either	_	_	I-Claim
269	gender	_	_	I-Claim
270	or	_	_	I-Claim
271	performance	_	_	I-Claim
272	status	_	_	I-Claim
273	alone	_	_	I-Claim
274	may	_	_	I-Claim
275	not	_	_	I-Claim
276	accurately	_	_	I-Claim
277	reflect	_	_	I-Claim
278	how	_	_	I-Claim
279	these	_	_	I-Claim
280	factors	_	_	I-Claim
281	depend	_	_	I-Claim
282	upon	_	_	I-Claim
283	each	_	_	I-Claim
284	another	_	_	I-Claim
285	.	_	_	I-Claim

286	Understanding	_	_	O
287	the	_	_	O
288	interaction	_	_	O
289	between	_	_	O
290	gender	_	_	O
291	and	_	_	O
292	performance	_	_	O
293	status	_	_	O
294	could	_	_	O
295	lead	_	_	O
296	to	_	_	O
297	better	_	_	O
298	prognosticators	_	_	O
299	and	_	_	O
300	potentially	_	_	O
301	could	_	_	O
302	tailor	_	_	O
303	interventions	_	_	O
304	for	_	_	O
305	specific	_	_	O
306	groups	_	_	O
307	of	_	_	O
308	patients	_	_	O
309	with	_	_	O
310	lung	_	_	O
311	cancer	_	_	O
312	.	_	_	O


0	Dermatitis	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	frequent	_	_	I-Claim
4	adverse	_	_	I-Claim
5	effect	_	_	I-Claim
6	of	_	_	I-Claim
7	adjuvant	_	_	I-Claim
8	breast	_	_	I-Claim
9	radiotherapy	_	_	I-Claim
10	.	_	_	I-Claim

11	It	_	_	B-Claim
12	is	_	_	I-Claim
13	more	_	_	I-Claim
14	likely	_	_	I-Claim
15	in	_	_	I-Claim
16	full-breasted	_	_	I-Claim
17	women	_	_	I-Claim
18	and	_	_	I-Claim
19	when	_	_	I-Claim
20	the	_	_	I-Claim
21	radiation	_	_	I-Claim
22	is	_	_	I-Claim
23	distributed	_	_	I-Claim
24	nonhomogeneously	_	_	I-Claim
25	in	_	_	I-Claim
26	the	_	_	I-Claim
27	breast	_	_	I-Claim
28	.	_	_	I-Claim

29	Breast	_	_	O
30	intensity-modulated	_	_	O
31	radiation	_	_	O
32	therapy	_	_	O
33	(	_	_	O
34	IMRT	_	_	O
35	)	_	_	O
36	is	_	_	O
37	a	_	_	O
38	technique	_	_	O
39	that	_	_	O
40	ensures	_	_	O
41	a	_	_	O
42	more	_	_	O
43	homogeneous	_	_	O
44	dose	_	_	O
45	distribution	_	_	O
46	.	_	_	O

47	A	_	_	O
48	multicenter	_	_	O
49	,	_	_	O
50	double-blind	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	clinical	_	_	O
54	trial	_	_	O
55	was	_	_	O
56	performed	_	_	O
57	to	_	_	O
58	test	_	_	O
59	if	_	_	O
60	breast	_	_	O
61	IMRT	_	_	O
62	would	_	_	O
63	reduce	_	_	O
64	the	_	_	O
65	rate	_	_	O
66	of	_	_	O
67	acute	_	_	O
68	skin	_	_	O
69	reaction	_	_	O
70	(	_	_	O
71	notably	_	_	O
72	moist	_	_	O
73	desquamation	_	_	O
74	)	_	_	O
75	,	_	_	O
76	decrease	_	_	O
77	pain	_	_	O
78	,	_	_	O
79	and	_	_	O
80	improve	_	_	O
81	quality	_	_	O
82	of	_	_	O
83	life	_	_	O
84	compared	_	_	O
85	with	_	_	O
86	standard	_	_	O
87	radiotherapy	_	_	O
88	using	_	_	O
89	wedges	_	_	O
90	.	_	_	O

91	Patients	_	_	O
92	were	_	_	O
93	assessed	_	_	O
94	each	_	_	O
95	week	_	_	O
96	during	_	_	O
97	and	_	_	O
98	up	_	_	O
99	to	_	_	O
100	6	_	_	O
101	weeks	_	_	O
102	after	_	_	O
103	radiotherapy	_	_	O
104	.	_	_	O

105	A	_	_	O
106	total	_	_	O
107	of	_	_	O
108	358	_	_	O
109	patients	_	_	O
110	were	_	_	O
111	randomly	_	_	O
112	assigned	_	_	O
113	between	_	_	O
114	July	_	_	O
115	2003	_	_	O
116	and	_	_	O
117	March	_	_	O
118	2005	_	_	O
119	in	_	_	O
120	two	_	_	O
121	Canadian	_	_	O
122	centers	_	_	O
123	,	_	_	O
124	and	_	_	O
125	331	_	_	O
126	were	_	_	O
127	included	_	_	O
128	in	_	_	O
129	the	_	_	O
130	analysis	_	_	O
131	.	_	_	O

132	Breast	_	_	B-Premise
133	IMRT	_	_	I-Premise
134	significantly	_	_	I-Premise
135	improved	_	_	I-Premise
136	the	_	_	I-Premise
137	dose	_	_	I-Premise
138	distribution	_	_	I-Premise
139	compared	_	_	I-Premise
140	with	_	_	I-Premise
141	standard	_	_	I-Premise
142	radiation	_	_	I-Premise
143	.	_	_	I-Premise

144	This	_	_	B-Premise
145	translated	_	_	I-Premise
146	into	_	_	I-Premise
147	a	_	_	I-Premise
148	lower	_	_	I-Premise
149	proportion	_	_	I-Premise
150	of	_	_	I-Premise
151	patients	_	_	I-Premise
152	experiencing	_	_	I-Premise
153	moist	_	_	I-Premise
154	desquamation	_	_	I-Premise
155	during	_	_	I-Premise
156	or	_	_	I-Premise
157	up	_	_	I-Premise
158	to	_	_	I-Premise
159	6	_	_	I-Premise
160	weeks	_	_	I-Premise
161	after	_	_	I-Premise
162	their	_	_	I-Premise
163	radiation	_	_	I-Premise
164	treatment	_	_	I-Premise
165	;	_	_	I-Premise
166	31.2	_	_	I-Premise
167	%	_	_	I-Premise
168	with	_	_	I-Premise
169	IMRT	_	_	I-Premise
170	compared	_	_	I-Premise
171	with	_	_	I-Premise
172	47.8	_	_	I-Premise
173	%	_	_	I-Premise
174	with	_	_	I-Premise
175	standard	_	_	I-Premise
176	treatment	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	.002	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	A	_	_	B-Premise
184	multivariate	_	_	I-Premise
185	analysis	_	_	I-Premise
186	found	_	_	I-Premise
187	the	_	_	I-Premise
188	use	_	_	I-Premise
189	of	_	_	I-Premise
190	breast	_	_	I-Premise
191	IMRT	_	_	I-Premise
192	(	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	.003	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	smaller	_	_	I-Premise
199	breast	_	_	I-Premise
200	size	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	.001	_	_	I-Premise
205	)	_	_	I-Premise
206	were	_	_	I-Premise
207	significantly	_	_	I-Premise
208	associated	_	_	I-Premise
209	with	_	_	I-Premise
210	a	_	_	I-Premise
211	decreased	_	_	I-Premise
212	risk	_	_	I-Premise
213	of	_	_	I-Premise
214	moist	_	_	I-Premise
215	desquamation	_	_	I-Premise
216	.	_	_	I-Premise

217	The	_	_	B-Premise
218	use	_	_	I-Premise
219	of	_	_	I-Premise
220	IMRT	_	_	I-Premise
221	did	_	_	I-Premise
222	not	_	_	I-Premise
223	correlate	_	_	I-Premise
224	with	_	_	I-Premise
225	pain	_	_	I-Premise
226	and	_	_	I-Premise
227	quality	_	_	I-Premise
228	of	_	_	I-Premise
229	life	_	_	I-Premise
230	,	_	_	O
231	but	_	_	O
232	the	_	_	B-Premise
233	presence	_	_	I-Premise
234	of	_	_	I-Premise
235	moist	_	_	I-Premise
236	desquamation	_	_	I-Premise
237	did	_	_	I-Premise
238	significantly	_	_	I-Premise
239	correlate	_	_	I-Premise
240	with	_	_	I-Premise
241	pain	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.002	_	_	I-Premise
246	)	_	_	I-Premise
247	and	_	_	I-Premise
248	a	_	_	I-Premise
249	reduced	_	_	I-Premise
250	quality	_	_	I-Premise
251	of	_	_	I-Premise
252	life	_	_	I-Premise
253	(	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.003	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Breast	_	_	B-Claim
260	IMRT	_	_	I-Claim
261	significantly	_	_	I-Claim
262	reduced	_	_	I-Claim
263	the	_	_	I-Claim
264	occurrence	_	_	I-Claim
265	of	_	_	I-Claim
266	moist	_	_	I-Claim
267	desquamation	_	_	I-Claim
268	compared	_	_	I-Claim
269	with	_	_	I-Claim
270	a	_	_	I-Claim
271	standard	_	_	I-Claim
272	wedged	_	_	I-Claim
273	technique	_	_	I-Claim
274	.	_	_	I-Claim

275	Moist	_	_	B-Claim
276	desquamation	_	_	I-Claim
277	was	_	_	I-Claim
278	correlated	_	_	I-Claim
279	with	_	_	I-Claim
280	increased	_	_	I-Claim
281	pain	_	_	I-Claim
282	and	_	_	I-Claim
283	reduction	_	_	I-Claim
284	in	_	_	I-Claim
285	the	_	_	I-Claim
286	quality	_	_	I-Claim
287	of	_	_	I-Claim
288	life	_	_	I-Claim
289	.	_	_	I-Claim


0	Cancer	_	_	O
1	cachexia	_	_	O
2	is	_	_	O
3	a	_	_	O
4	common	_	_	O
5	problem	_	_	O
6	among	_	_	O
7	advanced	_	_	O
8	cancer	_	_	O
9	patients	_	_	O
10	.	_	_	O

11	A	_	_	O
12	mixture	_	_	O
13	of	_	_	O
14	beta-hydroxyl	_	_	O
15	beta-methyl	_	_	O
16	butyrate	_	_	O
17	,	_	_	O
18	glutamine	_	_	O
19	,	_	_	O
20	and	_	_	O
21	arginine	_	_	O
22	(	_	_	O
23	HMB/Arg/Gln	_	_	O
24	)	_	_	O
25	previously	_	_	O
26	showed	_	_	O
27	activity	_	_	O
28	for	_	_	O
29	increasing	_	_	O
30	lean	_	_	O
31	body	_	_	O
32	mass	_	_	O
33	(	_	_	O
34	LBM	_	_	O
35	)	_	_	O
36	among	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	cancer	_	_	O
40	cachexia	_	_	O
41	.	_	_	O

42	Therefore	_	_	O
43	a	_	_	O
44	phase	_	_	O
45	III	_	_	O
46	trial	_	_	O
47	was	_	_	O
48	implemented	_	_	O
49	to	_	_	O
50	confirm	_	_	O
51	this	_	_	O
52	activity	_	_	O
53	.	_	_	O

54	Four	_	_	O
55	hundred	_	_	O
56	seventy-two	_	_	O
57	advanced	_	_	O
58	cancer	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	between	_	_	O
62	2	_	_	O
63	%	_	_	O
64	and	_	_	O
65	10	_	_	O
66	%	_	_	O
67	weight	_	_	O
68	loss	_	_	O
69	were	_	_	O
70	randomized	_	_	O
71	to	_	_	O
72	a	_	_	O
73	mixture	_	_	O
74	of	_	_	O
75	beta-hydroxyl	_	_	O
76	beta-methyl	_	_	O
77	butyrate	_	_	O
78	,	_	_	O
79	glutamine	_	_	O
80	,	_	_	O
81	and	_	_	O
82	arginine	_	_	O
83	or	_	_	O
84	an	_	_	O
85	isonitrogenous	_	_	O
86	,	_	_	O
87	isocaloric	_	_	O
88	control	_	_	O
89	mixture	_	_	O
90	taken	_	_	O
91	twice	_	_	O
92	a	_	_	O
93	day	_	_	O
94	for	_	_	O
95	8	_	_	O
96	weeks	_	_	O
97	.	_	_	O

98	Lean	_	_	O
99	body	_	_	O
100	mass	_	_	O
101	was	_	_	O
102	estimated	_	_	O
103	by	_	_	O
104	bioimpedance	_	_	O
105	and	_	_	O
106	skin-fold	_	_	O
107	measurements	_	_	O
108	.	_	_	O

109	Body	_	_	O
110	plethysmography	_	_	O
111	was	_	_	O
112	used	_	_	O
113	when	_	_	O
114	available	_	_	O
115	.	_	_	O

116	Weight	_	_	O
117	,	_	_	O
118	the	_	_	O
119	Schwartz	_	_	O
120	Fatigue	_	_	O
121	Scale	_	_	O
122	,	_	_	O
123	and	_	_	O
124	the	_	_	O
125	Spitzer	_	_	O
126	Quality	_	_	O
127	of	_	_	O
128	Life	_	_	O
129	Scale	_	_	O
130	were	_	_	O
131	also	_	_	O
132	measured	_	_	O
133	.	_	_	O

134	Only	_	_	O
135	37	_	_	O
136	%	_	_	O
137	of	_	_	O
138	the	_	_	O
139	patients	_	_	O
140	completed	_	_	O
141	protocol	_	_	O
142	treatment	_	_	O
143	.	_	_	O

144	The	_	_	O
145	majority	_	_	O
146	of	_	_	O
147	the	_	_	O
148	patient	_	_	O
149	loss	_	_	O
150	was	_	_	O
151	because	_	_	O
152	of	_	_	O
153	patient	_	_	O
154	preference	_	_	O
155	(	_	_	O
156	45	_	_	O
157	%	_	_	O
158	of	_	_	O
159	enrolled	_	_	O
160	patients	_	_	O
161	)	_	_	O
162	.	_	_	O

163	However	_	_	O
164	,	_	_	O
165	loss	_	_	O
166	of	_	_	O
167	power	_	_	O
168	was	_	_	O
169	not	_	_	O
170	an	_	_	O
171	issue	_	_	O
172	because	_	_	O
173	of	_	_	O
174	the	_	_	O
175	planned	_	_	O
176	large	_	_	O
177	target	_	_	O
178	sample	_	_	O
179	size	_	_	O
180	.	_	_	O

181	Based	_	_	O
182	on	_	_	O
183	an	_	_	O
184	intention	_	_	O
185	to	_	_	O
186	treat	_	_	O
187	analysis	_	_	O
188	,	_	_	O
189	there	_	_	O
190	was	_	_	O
191	no	_	_	O
192	statistically	_	_	O
193	significant	_	_	O
194	difference	_	_	O
195	in	_	_	O
196	the	_	_	O
197	8-week	_	_	O
198	lean	_	_	O
199	body	_	_	O
200	mass	_	_	O
201	between	_	_	O
202	the	_	_	O
203	two	_	_	O
204	arms	_	_	O
205	.	_	_	O

206	The	_	_	O
207	secondary	_	_	O
208	endpoints	_	_	O
209	were	_	_	O
210	also	_	_	O
211	not	_	_	O
212	significantly	_	_	O
213	different	_	_	O
214	between	_	_	O
215	the	_	_	O
216	arms	_	_	O
217	.	_	_	O

218	Based	_	_	B-Premise
219	on	_	_	I-Premise
220	the	_	_	I-Premise
221	results	_	_	I-Premise
222	of	_	_	I-Premise
223	the	_	_	I-Premise
224	area	_	_	I-Premise
225	under	_	_	I-Premise
226	the	_	_	I-Premise
227	curve	_	_	I-Premise
228	(	_	_	I-Premise
229	AUC	_	_	I-Premise
230	)	_	_	I-Premise
231	analysis	_	_	I-Premise
232	,	_	_	I-Premise
233	patients	_	_	I-Premise
234	receiving	_	_	I-Premise
235	HMB/Arg/Gln	_	_	I-Premise
236	had	_	_	I-Premise
237	a	_	_	I-Premise
238	strong	_	_	I-Premise
239	trend	_	_	I-Premise
240	higher	_	_	I-Premise
241	LBM	_	_	I-Premise
242	throughout	_	_	I-Premise
243	the	_	_	I-Premise
244	study	_	_	I-Premise
245	as	_	_	I-Premise
246	measured	_	_	I-Premise
247	by	_	_	I-Premise
248	both	_	_	I-Premise
249	bioimpedance	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.08	_	_	I-Premise
254	)	_	_	I-Premise
255	and	_	_	I-Premise
256	skin-fold	_	_	I-Premise
257	measurements	_	_	I-Premise
258	(	_	_	I-Premise
259	p	_	_	I-Premise
260	=	_	_	I-Premise
261	0.08	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Among	_	_	B-Premise
265	the	_	_	I-Premise
266	subset	_	_	I-Premise
267	of	_	_	I-Premise
268	patients	_	_	I-Premise
269	receiving	_	_	I-Premise
270	concurrent	_	_	I-Premise
271	chemotherapy	_	_	I-Premise
272	,	_	_	I-Premise
273	there	_	_	I-Premise
274	were	_	_	I-Premise
275	again	_	_	I-Premise
276	no	_	_	I-Premise
277	significant	_	_	I-Premise
278	differences	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	endpoints	_	_	I-Premise
282	.	_	_	I-Premise

283	The	_	_	B-Premise
284	secondary	_	_	I-Premise
285	endpoints	_	_	I-Premise
286	were	_	_	I-Premise
287	also	_	_	I-Premise
288	not	_	_	I-Premise
289	significantly	_	_	I-Premise
290	different	_	_	I-Premise
291	between	_	_	I-Premise
292	the	_	_	I-Premise
293	arms	_	_	I-Premise
294	.	_	_	I-Premise

295	This	_	_	B-Claim
296	trial	_	_	I-Claim
297	was	_	_	I-Claim
298	unable	_	_	I-Claim
299	to	_	_	I-Claim
300	adequately	_	_	I-Claim
301	test	_	_	I-Claim
302	the	_	_	I-Claim
303	ability	_	_	I-Claim
304	of	_	_	I-Claim
305	beta-hydroxy	_	_	I-Claim
306	beta-methylbutyrate	_	_	I-Claim
307	,	_	_	I-Claim
308	glutamine	_	_	I-Claim
309	,	_	_	I-Claim
310	and	_	_	I-Claim
311	arginine	_	_	I-Claim
312	to	_	_	I-Claim
313	reverse	_	_	I-Claim
314	or	_	_	I-Claim
315	prevent	_	_	I-Claim
316	lean	_	_	I-Claim
317	body	_	_	I-Claim
318	mass	_	_	I-Claim
319	wasting	_	_	I-Claim
320	among	_	_	I-Claim
321	cancer	_	_	I-Claim
322	patients	_	_	I-Claim
323	.	_	_	I-Claim

324	Possible	_	_	O
325	contributing	_	_	O
326	factors	_	_	O
327	beyond	_	_	O
328	the	_	_	O
329	efficacy	_	_	O
330	of	_	_	O
331	the	_	_	O
332	intervention	_	_	O
333	were	_	_	O
334	the	_	_	O
335	inability	_	_	O
336	of	_	_	O
337	patients	_	_	O
338	to	_	_	O
339	complete	_	_	O
340	an	_	_	O
341	8-week	_	_	O
342	course	_	_	O
343	of	_	_	O
344	treatment	_	_	O
345	and	_	_	O
346	return	_	_	O
347	in	_	_	O
348	a	_	_	O
349	timely	_	_	O
350	fashion	_	_	O
351	for	_	_	O
352	follow-up	_	_	O
353	assessment	_	_	O
354	,	_	_	O
355	and	_	_	O
356	because	_	_	O
357	the	_	_	O
358	patients	_	_	O
359	may	_	_	O
360	have	_	_	O
361	only	_	_	O
362	had	_	_	O
363	weight	_	_	O
364	loss	_	_	O
365	possible	_	_	O
366	not	_	_	O
367	related	_	_	O
368	to	_	_	O
369	cachexia	_	_	O
370	,	_	_	O
371	but	_	_	O
372	other	_	_	O
373	causes	_	_	O
374	of	_	_	O
375	weight	_	_	O
376	loss	_	_	O
377	,	_	_	O
378	such	_	_	O
379	as	_	_	O
380	decreased	_	_	O
381	appetite	_	_	O
382	.	_	_	O

383	However	_	_	O
384	,	_	_	O
385	there	_	_	O
386	was	_	_	O
387	a	_	_	O
388	strong	_	_	O
389	trend	_	_	O
390	towards	_	_	O
391	an	_	_	O
392	increased	_	_	O
393	body	_	_	O
394	mass	_	_	O
395	among	_	_	O
396	patients	_	_	O
397	taking	_	_	O
398	the	_	_	O
399	Juven	_	_	O
400	compound	_	_	O
401	using	_	_	O
402	the	_	_	O
403	secondary	_	_	O
404	endpoint	_	_	O
405	of	_	_	O
406	AUC	_	_	O
407	.	_	_	O


0	Exercise	_	_	O
1	training	_	_	O
2	improves	_	_	O
3	supportive	_	_	O
4	care	_	_	O
5	outcomes	_	_	O
6	in	_	_	O
7	patients	_	_	O
8	with	_	_	O
9	breast	_	_	O
10	cancer	_	_	O
11	who	_	_	O
12	are	_	_	O
13	receiving	_	_	O
14	adjuvant	_	_	O
15	therapy	_	_	O
16	,	_	_	O
17	but	_	_	O
18	the	_	_	O
19	responses	_	_	O
20	are	_	_	O
21	heterogeneous	_	_	O
22	.	_	_	O

23	In	_	_	O
24	this	_	_	O
25	study	_	_	O
26	,	_	_	O
27	the	_	_	O
28	authors	_	_	O
29	examined	_	_	O
30	personal	_	_	O
31	and	_	_	O
32	clinical	_	_	O
33	factors	_	_	O
34	that	_	_	O
35	may	_	_	O
36	predict	_	_	O
37	exercise	_	_	O
38	training	_	_	O
39	responses	_	_	O
40	.	_	_	O

41	Breast	_	_	O
42	cancer	_	_	O
43	patients	_	_	O
44	who	_	_	O
45	were	_	_	O
46	initiating	_	_	O
47	adjuvant	_	_	O
48	chemotherapy	_	_	O
49	(	_	_	O
50	N=242	_	_	O
51	)	_	_	O
52	were	_	_	O
53	assigned	_	_	O
54	randomly	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	usual	_	_	O
58	care	_	_	O
59	(	_	_	O
60	UC	_	_	O
61	)	_	_	O
62	(	_	_	O
63	n=82	_	_	O
64	)	_	_	O
65	,	_	_	O
66	resistance	_	_	O
67	exercise	_	_	O
68	training	_	_	O
69	(	_	_	O
70	RET	_	_	O
71	)	_	_	O
72	(	_	_	O
73	n=82	_	_	O
74	)	_	_	O
75	,	_	_	O
76	or	_	_	O
77	aerobic	_	_	O
78	exercise	_	_	O
79	training	_	_	O
80	(	_	_	O
81	AET	_	_	O
82	)	_	_	O
83	(	_	_	O
84	n=78	_	_	O
85	)	_	_	O
86	for	_	_	O
87	the	_	_	O
88	duration	_	_	O
89	of	_	_	O
90	chemotherapy	_	_	O
91	.	_	_	O

92	Endpoints	_	_	O
93	were	_	_	O
94	quality	_	_	O
95	of	_	_	O
96	life	_	_	O
97	(	_	_	O
98	QoL	_	_	O
99	)	_	_	O
100	,	_	_	O
101	aerobic	_	_	O
102	fitness	_	_	O
103	,	_	_	O
104	muscular	_	_	O
105	strength	_	_	O
106	,	_	_	O
107	lean	_	_	O
108	body	_	_	O
109	mass	_	_	O
110	,	_	_	O
111	and	_	_	O
112	body	_	_	O
113	fat	_	_	O
114	.	_	_	O

115	Moderators	_	_	O
116	were	_	_	O
117	patient	_	_	O
118	preference	_	_	O
119	for	_	_	O
120	group	_	_	O
121	assignment	_	_	O
122	,	_	_	O
123	marital	_	_	O
124	status	_	_	O
125	,	_	_	O
126	age	_	_	O
127	,	_	_	O
128	disease	_	_	O
129	stage	_	_	O
130	,	_	_	O
131	and	_	_	O
132	chemotherapy	_	_	O
133	regimen	_	_	O
134	.	_	_	O

135	Adjusted	_	_	O
136	linear	_	_	O
137	mixed-model	_	_	O
138	analyses	_	_	O
139	demonstrated	_	_	O
140	that	_	_	O
141	patient	_	_	O
142	preference	_	_	O
143	moderated	_	_	O
144	QoL	_	_	O
145	response	_	_	O
146	(	_	_	O
147	P=	_	_	O
148	.005	_	_	O
149	)	_	_	O
150	.	_	_	O

151	Patients	_	_	B-Premise
152	who	_	_	I-Premise
153	preferred	_	_	I-Premise
154	RET	_	_	I-Premise
155	improved	_	_	I-Premise
156	QoL	_	_	I-Premise
157	when	_	_	I-Premise
158	they	_	_	I-Premise
159	were	_	_	I-Premise
160	assigned	_	_	I-Premise
161	to	_	_	I-Premise
162	receive	_	_	I-Premise
163	RET	_	_	I-Premise
164	compared	_	_	I-Premise
165	with	_	_	I-Premise
166	UC	_	_	I-Premise
167	(	_	_	I-Premise
168	mean	_	_	I-Premise
169	difference	_	_	I-Premise
170	,	_	_	I-Premise
171	16.5	_	_	I-Premise
172	;	_	_	I-Premise
173	95	_	_	I-Premise
174	%	_	_	I-Premise
175	confidence	_	_	I-Premise
176	interval	_	_	I-Premise
177	[	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	CI	_	_	I-Premise
181	]	_	_	I-Premise
182	,	_	_	I-Premise
183	4.3-28.7	_	_	I-Premise
184	;	_	_	I-Premise
185	P=	_	_	I-Premise
186	.008	_	_	I-Premise
187	)	_	_	I-Premise
188	or	_	_	I-Premise
189	AET	_	_	I-Premise
190	(	_	_	I-Premise
191	mean	_	_	I-Premise
192	difference	_	_	I-Premise
193	,	_	_	I-Premise
194	11	_	_	I-Premise
195	;	_	_	I-Premise
196	95	_	_	I-Premise
197	%	_	_	I-Premise
198	CI	_	_	I-Premise
199	,	_	_	I-Premise
200	-1.1-23.4	_	_	I-Premise
201	;	_	_	I-Premise
202	P=	_	_	I-Premise
203	.076	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Patients	_	_	B-Premise
207	who	_	_	I-Premise
208	had	_	_	I-Premise
209	no	_	_	I-Premise
210	preference	_	_	I-Premise
211	had	_	_	I-Premise
212	improved	_	_	I-Premise
213	QoL	_	_	I-Premise
214	when	_	_	I-Premise
215	they	_	_	I-Premise
216	were	_	_	I-Premise
217	assigned	_	_	I-Premise
218	to	_	_	I-Premise
219	receive	_	_	I-Premise
220	AET	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	RET	_	_	I-Premise
224	(	_	_	I-Premise
225	mean	_	_	I-Premise
226	difference	_	_	I-Premise
227	,	_	_	I-Premise
228	23	_	_	I-Premise
229	;	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	,	_	_	I-Premise
234	4.9-41	_	_	I-Premise
235	;	_	_	I-Premise
236	P=	_	_	I-Premise
237	.014	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	Marital	_	_	B-Premise
241	status	_	_	I-Premise
242	also	_	_	I-Premise
243	moderated	_	_	I-Premise
244	QoL	_	_	I-Premise
245	response	_	_	I-Premise
246	(	_	_	I-Premise
247	P=	_	_	I-Premise
248	.026	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	age	_	_	I-Premise
252	moderated	_	_	I-Premise
253	aerobic	_	_	I-Premise
254	fitness	_	_	I-Premise
255	response	_	_	I-Premise
256	(	_	_	I-Premise
257	P=	_	_	I-Premise
258	.029	_	_	I-Premise
259	)	_	_	I-Premise
260	,	_	_	I-Premise
261	chemotherapy	_	_	I-Premise
262	regimen	_	_	I-Premise
263	moderated	_	_	I-Premise
264	strength	_	_	I-Premise
265	gain	_	_	I-Premise
266	(	_	_	I-Premise
267	P=	_	_	I-Premise
268	.009	_	_	I-Premise
269	)	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	disease	_	_	I-Premise
273	stage	_	_	I-Premise
274	moderated	_	_	I-Premise
275	both	_	_	I-Premise
276	lean	_	_	I-Premise
277	body	_	_	I-Premise
278	mass	_	_	I-Premise
279	gain	_	_	I-Premise
280	(	_	_	I-Premise
281	P	_	_	I-Premise
282	<	_	_	I-Premise
283	.001	_	_	I-Premise
284	)	_	_	I-Premise
285	and	_	_	I-Premise
286	fat	_	_	I-Premise
287	loss	_	_	I-Premise
288	(	_	_	I-Premise
289	P=	_	_	I-Premise
290	.059	_	_	I-Premise
291	)	_	_	I-Premise
292	.	_	_	I-Premise

293	Unmarried	_	_	B-Premise
294	,	_	_	I-Premise
295	younger	_	_	I-Premise
296	patients	_	_	I-Premise
297	who	_	_	I-Premise
298	were	_	_	I-Premise
299	receiving	_	_	I-Premise
300	nontaxane-based	_	_	I-Premise
301	therapies	_	_	I-Premise
302	and	_	_	I-Premise
303	had	_	_	I-Premise
304	more	_	_	I-Premise
305	advanced	_	_	I-Premise
306	disease	_	_	I-Premise
307	stage	_	_	I-Premise
308	experienced	_	_	I-Premise
309	better	_	_	I-Premise
310	outcomes	_	_	I-Premise
311	.	_	_	I-Premise

312	The	_	_	O
313	findings	_	_	O
314	were	_	_	O
315	not	_	_	O
316	explained	_	_	O
317	by	_	_	O
318	differences	_	_	O
319	in	_	_	O
320	adherence	_	_	O
321	.	_	_	O

322	Patient	_	_	B-Claim
323	preference	_	_	I-Claim
324	,	_	_	I-Claim
325	demographic	_	_	I-Claim
326	variables	_	_	I-Claim
327	,	_	_	I-Claim
328	and	_	_	I-Claim
329	medical	_	_	I-Claim
330	variables	_	_	I-Claim
331	moderated	_	_	I-Claim
332	the	_	_	I-Claim
333	effects	_	_	I-Claim
334	of	_	_	I-Claim
335	exercise	_	_	I-Claim
336	training	_	_	I-Claim
337	in	_	_	I-Claim
338	breast	_	_	I-Claim
339	cancer	_	_	I-Claim
340	patients	_	_	I-Claim
341	who	_	_	I-Claim
342	were	_	_	I-Claim
343	receiving	_	_	I-Claim
344	chemotherapy	_	_	I-Claim
345	.	_	_	I-Claim

346	If	_	_	O
347	replicated	_	_	O
348	,	_	_	O
349	these	_	_	O
350	results	_	_	O
351	may	_	_	O
352	inform	_	_	O
353	clinical	_	_	O
354	practice	_	_	O
355	.	_	_	O


0	A	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	randomized	_	_	O
4	trial	_	_	O
5	was	_	_	O
6	carried	_	_	O
7	out	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	two	_	_	O
11	schedules	_	_	O
12	of	_	_	O
13	the	_	_	O
14	vinorelbine	_	_	O
15	(	_	_	O
16	VNR	_	_	O
17	)	_	_	O
18	-cisplatin	_	_	O
19	(	_	_	O
20	CDDP	_	_	O
21	)	_	_	O
22	regimen	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	locally	_	_	O
27	advanced	_	_	O
28	unresectable	_	_	O
29	poor	_	_	O
30	prognosis	_	_	O
31	stage	_	_	O
32	IIIB	_	_	O
33	or	_	_	O
34	metastatic	_	_	O
35	stage	_	_	O
36	IV	_	_	O
37	non-small	_	_	O
38	cell	_	_	O
39	lung	_	_	O
40	cancer	_	_	O
41	.	_	_	O

42	The	_	_	O
43	primary	_	_	O
44	endpoints	_	_	O
45	were	_	_	O
46	overall	_	_	O
47	survival	_	_	O
48	(	_	_	O
49	OS	_	_	O
50	)	_	_	O
51	and	_	_	O
52	analysis	_	_	O
53	of	_	_	O
54	toxicity	_	_	O
55	,	_	_	O
56	while	_	_	O
57	secondary	_	_	O
58	endpoints	_	_	O
59	included	_	_	O
60	response	_	_	O
61	rates	_	_	O
62	,	_	_	O
63	time-to-progression	_	_	O
64	(	_	_	O
65	TTP	_	_	O
66	)	_	_	O
67	and	_	_	O
68	quality	_	_	O
69	of	_	_	O
70	life	_	_	O
71	(	_	_	O
72	QoL	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Eligible	_	_	O
76	patients	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	:	_	_	O
82	(	_	_	O
83	a	_	_	O
84	)	_	_	O
85	VNR	_	_	O
86	25mg/m	_	_	O
87	(	_	_	O
88	2	_	_	O
89	)	_	_	O
90	on	_	_	O
91	day	_	_	O
92	1	_	_	O
93	,	_	_	O
94	8	_	_	O
95	and	_	_	O
96	15	_	_	O
97	plus	_	_	O
98	CDDP	_	_	O
99	100mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	on	_	_	O
104	day	_	_	O
105	1	_	_	O
106	every	_	_	O
107	4	_	_	O
108	weeks	_	_	O
109	or	_	_	O
110	(	_	_	O
111	b	_	_	O
112	)	_	_	O
113	VNR	_	_	O
114	30	_	_	O
115	mg/m	_	_	O
116	(	_	_	O
117	2	_	_	O
118	)	_	_	O
119	on	_	_	O
120	day	_	_	O
121	1	_	_	O
122	and	_	_	O
123	8	_	_	O
124	plus	_	_	O
125	CDDP	_	_	O
126	80	_	_	O
127	mg/m	_	_	O
128	(	_	_	O
129	2	_	_	O
130	)	_	_	O
131	on	_	_	O
132	day	_	_	O
133	1	_	_	O
134	every	_	_	O
135	3	_	_	O
136	weeks	_	_	O
137	.	_	_	O

138	All	_	_	O
139	patients	_	_	O
140	were	_	_	O
141	chemotherapy-naïve	_	_	O
142	and	_	_	O
143	had	_	_	O
144	an	_	_	O
145	ECOG	_	_	O
146	performance	_	_	O
147	status	_	_	O
148	(	_	_	O
149	PS	_	_	O
150	)	_	_	O
151	of	_	_	O
152	0-1	_	_	O
153	.	_	_	O

154	Overall	_	_	O
155	278	_	_	O
156	patients	_	_	O
157	were	_	_	O
158	enrolled	_	_	O
159	into	_	_	O
160	the	_	_	O
161	trial	_	_	O
162	.	_	_	O

163	Overall	_	_	O
164	response	_	_	O
165	rate	_	_	O
166	was	_	_	O
167	34	_	_	O
168	%	_	_	O
169	(	_	_	O
170	95	_	_	O
171	%	_	_	O
172	CL	_	_	O
173	26-42	_	_	O
174	%	_	_	O
175	)	_	_	O
176	in	_	_	O
177	the	_	_	O
178	weekly	_	_	O
179	VNR/CDDP	_	_	O
180	arm	_	_	O
181	,	_	_	O
182	and	_	_	O
183	32	_	_	O
184	%	_	_	O
185	(	_	_	O
186	95	_	_	O
187	%	_	_	O
188	CL	_	_	O
189	24-40	_	_	O
190	%	_	_	O
191	)	_	_	O
192	in	_	_	O
193	patients	_	_	O
194	treated	_	_	O
195	with	_	_	O
196	day	_	_	O
197	1-8	_	_	O
198	VNR/CDDP	_	_	O
199	without	_	_	O
200	any	_	_	O
201	statistically	_	_	O
202	significant	_	_	O
203	difference	_	_	O
204	.	_	_	O

205	Median	_	_	B-Premise
206	TTP	_	_	I-Premise
207	was	_	_	I-Premise
208	4.5	_	_	I-Premise
209	and	_	_	I-Premise
210	4.6	_	_	I-Premise
211	months	_	_	I-Premise
212	respectively	_	_	I-Premise
213	for	_	_	I-Premise
214	weekly	_	_	I-Premise
215	VNR/CDDP	_	_	I-Premise
216	arm	_	_	I-Premise
217	and	_	_	I-Premise
218	the	_	_	I-Premise
219	day	_	_	I-Premise
220	1-8	_	_	I-Premise
221	VNR/CDDP	_	_	I-Premise
222	one	_	_	I-Premise
223	.	_	_	I-Premise

224	This	_	_	B-Premise
225	difference	_	_	I-Premise
226	was	_	_	I-Premise
227	not	_	_	I-Premise
228	statistically	_	_	I-Premise
229	significant	_	_	I-Premise
230	(	_	_	I-Premise
231	log-rank	_	_	I-Premise
232	test	_	_	I-Premise
233	,	_	_	I-Premise
234	p=0.818	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	Median	_	_	B-Premise
238	OS	_	_	I-Premise
239	was	_	_	I-Premise
240	9.45	_	_	I-Premise
241	and	_	_	I-Premise
242	10	_	_	I-Premise
243	months	_	_	I-Premise
244	respectively	_	_	I-Premise
245	for	_	_	I-Premise
246	weekly	_	_	I-Premise
247	VNR/CDDP	_	_	I-Premise
248	arm	_	_	I-Premise
249	and	_	_	I-Premise
250	the	_	_	I-Premise
251	day	_	_	I-Premise
252	1-8	_	_	I-Premise
253	VNR/CDDP	_	_	I-Premise
254	one	_	_	I-Premise
255	without	_	_	I-Premise
256	statistically	_	_	I-Premise
257	a	_	_	I-Premise
258	significant	_	_	I-Premise
259	difference	_	_	I-Premise
260	(	_	_	I-Premise
261	log-rank	_	_	I-Premise
262	test	_	_	I-Premise
263	,	_	_	I-Premise
264	p=0.259	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	The	_	_	B-Premise
268	1-	_	_	I-Premise
269	and	_	_	I-Premise
270	2-year	_	_	I-Premise
271	survival	_	_	I-Premise
272	rates	_	_	I-Premise
273	were	_	_	I-Premise
274	31	_	_	I-Premise
275	and	_	_	I-Premise
276	36	_	_	I-Premise
277	%	_	_	I-Premise
278	,	_	_	I-Premise
279	and	_	_	I-Premise
280	10	_	_	I-Premise
281	and	_	_	I-Premise
282	11	_	_	I-Premise
283	%	_	_	I-Premise
284	respectively	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	incidence	_	_	I-Premise
288	of	_	_	I-Premise
289	severe	_	_	I-Premise
290	neutropenia	_	_	I-Premise
291	(	_	_	I-Premise
292	34	_	_	I-Premise
293	%	_	_	I-Premise
294	versus	_	_	I-Premise
295	68	_	_	I-Premise
296	%	_	_	I-Premise
297	;	_	_	I-Premise
298	p=0.0001	_	_	I-Premise
299	)	_	_	I-Premise
300	and	_	_	I-Premise
301	of	_	_	I-Premise
302	febrile	_	_	I-Premise
303	neutropenia	_	_	I-Premise
304	(	_	_	I-Premise
305	5	_	_	I-Premise
306	%	_	_	I-Premise
307	versus	_	_	I-Premise
308	12	_	_	I-Premise
309	%	_	_	I-Premise
310	;	_	_	I-Premise
311	p=0.026	_	_	I-Premise
312	)	_	_	I-Premise
313	,	_	_	I-Premise
314	as	_	_	I-Premise
315	well	_	_	I-Premise
316	as	_	_	I-Premise
317	the	_	_	I-Premise
318	rate	_	_	I-Premise
319	of	_	_	I-Premise
320	therapy	_	_	I-Premise
321	omissions	_	_	I-Premise
322	(	_	_	I-Premise
323	10	_	_	I-Premise
324	%	_	_	I-Premise
325	versus	_	_	I-Premise
326	24	_	_	I-Premise
327	%	_	_	I-Premise
328	;	_	_	I-Premise
329	p=0.0037	_	_	I-Premise
330	)	_	_	I-Premise
331	were	_	_	I-Premise
332	higher	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	weekly	_	_	I-Premise
336	VNR/CDDP	_	_	I-Premise
337	arm	_	_	I-Premise
338	than	_	_	I-Premise
339	in	_	_	I-Premise
340	the	_	_	I-Premise
341	day	_	_	I-Premise
342	1-8	_	_	I-Premise
343	VNR/CDDP	_	_	I-Premise
344	one	_	_	I-Premise
345	.	_	_	I-Premise

346	The	_	_	B-Premise
347	weekly	_	_	I-Premise
348	VNR/CDDP	_	_	I-Premise
349	regimen	_	_	I-Premise
350	was	_	_	I-Premise
351	associated	_	_	I-Premise
352	with	_	_	I-Premise
353	a	_	_	I-Premise
354	lower	_	_	I-Premise
355	received	_	_	I-Premise
356	dose	_	_	I-Premise
357	intensity	_	_	I-Premise
358	in	_	_	I-Premise
359	a	_	_	I-Premise
360	statistically	_	_	I-Premise
361	significant	_	_	I-Premise
362	fashion	_	_	I-Premise
363	(	_	_	I-Premise
364	9	_	_	I-Premise
365	%	_	_	I-Premise
366	versus	_	_	I-Premise
367	22	_	_	I-Premise
368	%	_	_	I-Premise
369	;	_	_	I-Premise
370	p=0.0001	_	_	I-Premise
371	)	_	_	I-Premise
372	and	_	_	I-Premise
373	with	_	_	I-Premise
374	a	_	_	I-Premise
375	lower	_	_	I-Premise
376	non-statistically	_	_	I-Premise
377	significant	_	_	I-Premise
378	quality	_	_	I-Premise
379	of	_	_	I-Premise
380	life	_	_	I-Premise
381	score	_	_	I-Premise
382	as	_	_	I-Premise
383	compared	_	_	I-Premise
384	to	_	_	I-Premise
385	the	_	_	I-Premise
386	day	_	_	I-Premise
387	1-8	_	_	I-Premise
388	VNR/CDDP	_	_	I-Premise
389	schedule	_	_	I-Premise
390	.	_	_	I-Premise

391	The	_	_	B-Claim
392	combination	_	_	I-Claim
393	of	_	_	I-Claim
394	day	_	_	I-Claim
395	1-8	_	_	I-Claim
396	VNR	_	_	I-Claim
397	plus	_	_	I-Claim
398	CDDP	_	_	I-Claim
399	every	_	_	I-Claim
400	3	_	_	I-Claim
401	weeks	_	_	I-Claim
402	is	_	_	I-Claim
403	less	_	_	I-Claim
404	toxic	_	_	I-Claim
405	and	_	_	I-Claim
406	better	_	_	I-Claim
407	tolerated	_	_	I-Claim
408	than	_	_	I-Claim
409	the	_	_	I-Claim
410	regimen	_	_	I-Claim
411	of	_	_	I-Claim
412	weekly	_	_	I-Claim
413	VNR	_	_	I-Claim
414	plus	_	_	I-Claim
415	CDDP	_	_	I-Claim
416	every	_	_	I-Claim
417	4	_	_	I-Claim
418	weeks	_	_	I-Claim
419	.	_	_	I-Claim

420	The	_	_	B-Claim
421	two	_	_	I-Claim
422	schedules	_	_	I-Claim
423	are	_	_	I-Claim
424	equivalent	_	_	I-Claim
425	in	_	_	I-Claim
426	terms	_	_	I-Claim
427	of	_	_	I-Claim
428	overall	_	_	I-Claim
429	response	_	_	I-Claim
430	rate	_	_	I-Claim
431	,	_	_	I-Claim
432	median	_	_	I-Claim
433	time-to-progression	_	_	I-Claim
434	and	_	_	I-Claim
435	overall	_	_	I-Claim
436	survival	_	_	I-Claim
437	.	_	_	I-Claim

438	The	_	_	B-Claim
439	combination	_	_	I-Claim
440	of	_	_	I-Claim
441	VNR	_	_	I-Claim
442	on	_	_	I-Claim
443	day	_	_	I-Claim
444	1-8	_	_	I-Claim
445	plus	_	_	I-Claim
446	CDDP	_	_	I-Claim
447	every	_	_	I-Claim
448	3	_	_	I-Claim
449	weeks	_	_	I-Claim
450	may	_	_	I-Claim
451	be	_	_	I-Claim
452	considered	_	_	I-Claim
453	as	_	_	I-Claim
454	a	_	_	I-Claim
455	reference	_	_	I-Claim
456	regimen	_	_	I-Claim
457	for	_	_	I-Claim
458	the	_	_	I-Claim
459	treatment	_	_	I-Claim
460	of	_	_	I-Claim
461	patients	_	_	I-Claim
462	with	_	_	I-Claim
463	advanced	_	_	I-Claim
464	disease	_	_	I-Claim
465	and	_	_	I-Claim
466	those	_	_	I-Claim
467	who	_	_	I-Claim
468	deserve	_	_	I-Claim
469	a	_	_	I-Claim
470	postoperative	_	_	I-Claim
471	therapy	_	_	I-Claim
472	,	_	_	I-Claim
473	and	_	_	I-Claim
474	for	_	_	I-Claim
475	future	_	_	I-Claim
476	studies	_	_	I-Claim
477	.	_	_	I-Claim


0	Efficacy	_	_	O
1	of	_	_	O
2	the	_	_	O
3	latanoprost	_	_	O
4	versus	_	_	O
5	timolol/dorzolamide	_	_	O
6	combination	_	_	O
7	therapy	_	_	O
8	in	_	_	O
9	patients	_	_	O
10	with	_	_	O
11	primary	_	_	O
12	open	_	_	O
13	angle	_	_	O
14	glaucoma	_	_	O
15	The	_	_	O
16	study	_	_	O
17	was	_	_	O
18	designed	_	_	O
19	as	_	_	O
20	a	_	_	O
21	6	_	_	O
22	months	_	_	O
23	randomized	_	_	O
24	,	_	_	O
25	observer-masked	_	_	O
26	study	_	_	O
27	comprising	_	_	O
28	120	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	primary	_	_	O
32	open-angle	_	_	O
33	glaucoma	_	_	O
34	in	_	_	O
35	Feiz	_	_	O
36	Hospital	_	_	O
37	,	_	_	O
38	Isfahan	_	_	O
39	,	_	_	O
40	Iran	_	_	O
41	,	_	_	O
42	from	_	_	O
43	2006	_	_	O
44	to	_	_	O
45	2007	_	_	O
46	.	_	_	O

47	The	_	_	O
48	patients	_	_	O
49	were	_	_	O
50	randomized	_	_	O
51	(	_	_	O
52	latanoprost	_	_	O
53	,	_	_	O
54	n	_	_	O
55	=	_	_	O
56	60	_	_	O
57	;	_	_	O
58	dorzolamide/timolol	_	_	O
59	,	_	_	O
60	n	_	_	O
61	=	_	_	O
62	60	_	_	O
63	)	_	_	O
64	to	_	_	O
65	treatment	_	_	O
66	with	_	_	O
67	either	_	_	O
68	latanoprost	_	_	O
69	,	_	_	O
70	0.005	_	_	O
71	%	_	_	O
72	once	_	_	O
73	daily	_	_	O
74	,	_	_	O
75	or	_	_	O
76	the	_	_	O
77	combination	_	_	O
78	of	_	_	O
79	timolol	_	_	O
80	0.5	_	_	O
81	%	_	_	O
82	twice	_	_	O
83	daily	_	_	O
84	,	_	_	O
85	and	_	_	O
86	dorzolamide	_	_	O
87	2	_	_	O
88	%	_	_	O
89	3	_	_	O
90	times	_	_	O
91	daily	_	_	O
92	.	_	_	O

93	The	_	_	O
94	mean	_	_	O
95	intraocular	_	_	O
96	pressure	_	_	O
97	(	_	_	O
98	IOP	_	_	O
99	)	_	_	O
100	after	_	_	O
101	one	_	_	O
102	,	_	_	O
103	3	_	_	O
104	,	_	_	O
105	and	_	_	O
106	6	_	_	O
107	months	_	_	O
108	of	_	_	O
109	treatment	_	_	O
110	was	_	_	O
111	compared	_	_	O
112	with	_	_	O
113	baseline	_	_	O
114	in	_	_	O
115	the	_	_	O
116	2	_	_	O
117	groups	_	_	O
118	.	_	_	O

119	A	_	_	O
120	total	_	_	O
121	of	_	_	O
122	120	_	_	O
123	patients	_	_	O
124	were	_	_	O
125	randomized	_	_	O
126	to	_	_	O
127	2	_	_	O
128	equal	_	_	O
129	treatment	_	_	O
130	groups	_	_	O
131	.	_	_	O

132	The	_	_	O
133	mean	_	_	O
134	baseline	_	_	O
135	IOP	_	_	O
136	values	_	_	O
137	were	_	_	O
138	similar	_	_	O
139	between	_	_	O
140	the	_	_	O
141	2	_	_	O
142	groups	_	_	O
143	.	_	_	O

144	The	_	_	B-Premise
145	mean	_	_	I-Premise
146	(	_	_	I-Premise
147	standard	_	_	I-Premise
148	error	_	_	I-Premise
149	of	_	_	I-Premise
150	mean	_	_	I-Premise
151	[	_	_	I-Premise
152	SE	_	_	I-Premise
153	]	_	_	I-Premise
154	)	_	_	I-Premise
155	IOP	_	_	I-Premise
156	reductions	_	_	I-Premise
157	at	_	_	I-Premise
158	months	_	_	I-Premise
159	one	_	_	I-Premise
160	was	_	_	I-Premise
161	7.2	_	_	I-Premise
162	(	_	_	I-Premise
163	0.4	_	_	I-Premise
164	)	_	_	I-Premise
165	,	_	_	I-Premise
166	at	_	_	I-Premise
167	month	_	_	I-Premise
168	3	_	_	I-Premise
169	was	_	_	I-Premise
170	7.3	_	_	I-Premise
171	(	_	_	I-Premise
172	0.4	_	_	I-Premise
173	)	_	_	I-Premise
174	,	_	_	I-Premise
175	and	_	_	I-Premise
176	at	_	_	I-Premise
177	month	_	_	I-Premise
178	6	_	_	I-Premise
179	was	_	_	I-Premise
180	7.1	_	_	I-Premise
181	(	_	_	I-Premise
182	0.3	_	_	I-Premise
183	)	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	for	_	_	I-Premise
187	the	_	_	I-Premise
188	latanoprost	_	_	I-Premise
189	group	_	_	I-Premise
190	and	_	_	I-Premise
191	7.5	_	_	I-Premise
192	(	_	_	I-Premise
193	0.3	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	7.8	_	_	I-Premise
197	(	_	_	I-Premise
198	0.3	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	7.4	_	_	I-Premise
203	(	_	_	I-Premise
204	0.3	_	_	I-Premise
205	)	_	_	I-Premise
206	mm	_	_	I-Premise
207	Hg	_	_	I-Premise
208	for	_	_	I-Premise
209	the	_	_	I-Premise
210	dorzolamide/timolol	_	_	I-Premise
211	group	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Claim
214	2	_	_	I-Claim
215	therapies	_	_	I-Claim
216	were	_	_	I-Claim
217	similarly	_	_	I-Claim
218	effective	_	_	I-Claim
219	.	_	_	I-Claim

220	The	_	_	B-Claim
221	latanoprost	_	_	I-Claim
222	and	_	_	I-Claim
223	dorzolamide/timolol	_	_	I-Claim
224	combination	_	_	I-Claim
225	were	_	_	I-Claim
226	equally	_	_	I-Claim
227	effective	_	_	I-Claim
228	at	_	_	I-Claim
229	lowering	_	_	I-Claim
230	IOP	_	_	I-Claim
231	compared	_	_	I-Claim
232	to	_	_	I-Claim
233	untreated	_	_	I-Claim
234	baseline	_	_	I-Claim
235	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	analgesic	_	_	O
10	and	_	_	O
11	adverse	_	_	O
12	effects	_	_	O
13	,	_	_	O
14	doses	_	_	O
15	,	_	_	O
16	as	_	_	O
17	well	_	_	O
18	as	_	_	O
19	cost	_	_	O
20	of	_	_	O
21	opioid	_	_	O
22	drugs	_	_	O
23	,	_	_	O
24	supportive	_	_	O
25	drug	_	_	O
26	therapy	_	_	O
27	and	_	_	O
28	other	_	_	O
29	analgesic	_	_	O
30	drugs	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	treated	_	_	O
34	with	_	_	O
35	oral	_	_	O
36	sustained-release	_	_	O
37	morphine	_	_	O
38	,	_	_	O
39	transdermal	_	_	O
40	fentanyl	_	_	O
41	,	_	_	O
42	and	_	_	O
43	oral	_	_	O
44	methadone	_	_	O
45	.	_	_	O

46	One	_	_	O
47	hundred	_	_	O
48	and	_	_	O
49	eight	_	_	O
50	cancer	_	_	O
51	patients	_	_	O
52	,	_	_	O
53	no	_	_	O
54	longer	_	_	O
55	responsive	_	_	O
56	to	_	_	O
57	opioids	_	_	O
58	for	_	_	O
59	moderate	_	_	O
60	pain	_	_	O
61	,	_	_	O
62	were	_	_	O
63	selected	_	_	O
64	to	_	_	O
65	randomly	_	_	O
66	receive	_	_	O
67	initial	_	_	O
68	daily	_	_	O
69	doses	_	_	O
70	of	_	_	O
71	60	_	_	O
72	mg	_	_	O
73	of	_	_	O
74	oral	_	_	O
75	sustained-release	_	_	O
76	morphine	_	_	O
77	,	_	_	O
78	15	_	_	O
79	mg	_	_	O
80	of	_	_	O
81	oral	_	_	O
82	methadone	_	_	O
83	,	_	_	O
84	or	_	_	O
85	0.6	_	_	O
86	mg	_	_	O
87	(	_	_	O
88	25	_	_	O
89	microg/h	_	_	O
90	)	_	_	O
91	of	_	_	O
92	transdermal	_	_	O
93	fentanyl	_	_	O
94	.	_	_	O

95	Oral	_	_	O
96	morphine	_	_	O
97	was	_	_	O
98	used	_	_	O
99	as	_	_	O
100	breakthrough	_	_	O
101	pain	_	_	O
102	medication	_	_	O
103	during	_	_	O
104	opioid	_	_	O
105	titration	_	_	O
106	.	_	_	O

107	Opioid	_	_	O
108	doses	_	_	O
109	,	_	_	O
110	pain	_	_	O
111	intensity	_	_	O
112	,	_	_	O
113	adverse	_	_	O
114	effects	_	_	O
115	,	_	_	O
116	symptomatic	_	_	O
117	drugs	_	_	O
118	,	_	_	O
119	were	_	_	O
120	recorded	_	_	O
121	at	_	_	O
122	week	_	_	O
123	intervals	_	_	O
124	for	_	_	O
125	4	_	_	O
126	weeks	_	_	O
127	.	_	_	O

128	Costs	_	_	O
129	of	_	_	O
130	opioid	_	_	O
131	therapy	_	_	O
132	,	_	_	O
133	supportive	_	_	O
134	drugs	_	_	O
135	,	_	_	O
136	and	_	_	O
137	other	_	_	O
138	analgesic	_	_	O
139	drugs	_	_	O
140	were	_	_	O
141	also	_	_	O
142	evaluated	_	_	O
143	.	_	_	O

144	Seventy	_	_	O
145	patients	_	_	O
146	completed	_	_	O
147	the	_	_	O
148	4	_	_	O
149	weeks	_	_	O
150	period	_	_	O
151	of	_	_	O
152	study	_	_	O
153	.	_	_	O

154	Five	_	_	O
155	,	_	_	O
156	five	_	_	O
157	,	_	_	O
158	and	_	_	O
159	four	_	_	O
160	patients	_	_	O
161	,	_	_	O
162	treated	_	_	O
163	with	_	_	O
164	oral	_	_	O
165	morphine	_	_	O
166	,	_	_	O
167	transdermal	_	_	O
168	fentanyl	_	_	O
169	,	_	_	O
170	and	_	_	O
171	oral	_	_	O
172	methadone	_	_	O
173	,	_	_	O
174	respectively	_	_	O
175	,	_	_	O
176	required	_	_	O
177	opioid	_	_	O
178	switching	_	_	O
179	.	_	_	O

180	No	_	_	B-Premise
181	differences	_	_	I-Premise
182	in	_	_	I-Premise
183	pain	_	_	I-Premise
184	and	_	_	I-Premise
185	symptom	_	_	I-Premise
186	intensity	_	_	I-Premise
187	were	_	_	I-Premise
188	observed	_	_	I-Premise
189	.	_	_	I-Premise

190	Opioid	_	_	B-Premise
191	escalation	_	_	I-Premise
192	index	_	_	I-Premise
193	was	_	_	I-Premise
194	significantly	_	_	I-Premise
195	lower	_	_	I-Premise
196	in	_	_	I-Premise
197	patients	_	_	I-Premise
198	receiving	_	_	I-Premise
199	methadone	_	_	I-Premise
200	(	_	_	I-Premise
201	p	_	_	I-Premise
202	<	_	_	I-Premise
203	0.0001	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	although	_	_	I-Premise
207	requiring	_	_	I-Premise
208	up	_	_	I-Premise
209	and	_	_	I-Premise
210	down	_	_	I-Premise
211	changes	_	_	I-Premise
212	in	_	_	I-Premise
213	doses	_	_	I-Premise
214	.	_	_	I-Premise

215	At	_	_	B-Premise
216	the	_	_	I-Premise
217	doses	_	_	I-Premise
218	used	_	_	I-Premise
219	,	_	_	I-Premise
220	methadone	_	_	I-Premise
221	was	_	_	I-Premise
222	significantly	_	_	I-Premise
223	less	_	_	I-Premise
224	expensive	_	_	I-Premise
225	(	_	_	I-Premise
226	p	_	_	I-Premise
227	<	_	_	I-Premise
228	0.0001	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	while	_	_	I-Premise
232	the	_	_	I-Premise
233	use	_	_	I-Premise
234	and	_	_	I-Premise
235	costs	_	_	I-Premise
236	of	_	_	I-Premise
237	supportive	_	_	I-Premise
238	drugs	_	_	I-Premise
239	and	_	_	I-Premise
240	other	_	_	I-Premise
241	analgesics	_	_	I-Premise
242	were	_	_	I-Premise
243	similar	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	three	_	_	I-Premise
247	groups	_	_	I-Premise
248	.	_	_	I-Premise

249	No	_	_	B-Premise
250	relevant	_	_	I-Premise
251	differences	_	_	I-Premise
252	in	_	_	I-Premise
253	adverse	_	_	I-Premise
254	effects	_	_	I-Premise
255	were	_	_	I-Premise
256	observed	_	_	I-Premise
257	among	_	_	I-Premise
258	the	_	_	I-Premise
259	groups	_	_	I-Premise
260	during	_	_	I-Premise
261	either	_	_	I-Premise
262	the	_	_	I-Premise
263	titration	_	_	I-Premise
264	phase	_	_	I-Premise
265	and	_	_	I-Premise
266	chronic	_	_	I-Premise
267	treatment	_	_	I-Premise
268	.	_	_	I-Premise

269	All	_	_	B-Claim
270	the	_	_	I-Claim
271	three	_	_	I-Claim
272	opioids	_	_	I-Claim
273	used	_	_	I-Claim
274	as	_	_	I-Claim
275	first-line	_	_	I-Claim
276	therapy	_	_	I-Claim
277	were	_	_	I-Claim
278	effective	_	_	I-Claim
279	,	_	_	I-Claim
280	well	_	_	I-Claim
281	tolerated	_	_	I-Claim
282	,	_	_	I-Claim
283	and	_	_	I-Claim
284	required	_	_	I-Claim
285	similar	_	_	I-Claim
286	amounts	_	_	I-Claim
287	of	_	_	I-Claim
288	symptomatic	_	_	I-Claim
289	drugs	_	_	I-Claim
290	or	_	_	I-Claim
291	co-analgesics	_	_	I-Claim
292	.	_	_	I-Claim

293	Methadone	_	_	B-Claim
294	was	_	_	I-Claim
295	significantly	_	_	I-Claim
296	less	_	_	I-Claim
297	expensive	_	_	I-Claim
298	,	_	_	I-Claim
299	but	_	_	I-Claim
300	required	_	_	I-Claim
301	more	_	_	I-Claim
302	changes	_	_	I-Claim
303	,	_	_	I-Claim
304	up	_	_	I-Claim
305	and	_	_	I-Claim
306	down	_	_	I-Claim
307	,	_	_	I-Claim
308	of	_	_	I-Claim
309	the	_	_	I-Claim
310	doses	_	_	I-Claim
311	,	_	_	I-Claim
312	suggesting	_	_	I-Claim
313	that	_	_	I-Claim
314	dose	_	_	I-Claim
315	titration	_	_	I-Claim
316	of	_	_	I-Claim
317	this	_	_	I-Claim
318	drug	_	_	I-Claim
319	requires	_	_	I-Claim
320	major	_	_	I-Claim
321	clinical	_	_	I-Claim
322	expertise	_	_	I-Claim
323	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	brimonidine	_	_	O
8	purite	_	_	O
9	0.1	_	_	O
10	%	_	_	O
11	in	_	_	O
12	comparison	_	_	O
13	to	_	_	O
14	brinzolamide	_	_	O
15	1	_	_	O
16	%	_	_	O
17	when	_	_	O
18	used	_	_	O
19	as	_	_	O
20	adjunctive	_	_	O
21	therapy	_	_	O
22	to	_	_	O
23	latanoprost	_	_	O
24	0.005	_	_	O
25	%	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	.	_	_	O

34	Randomized	_	_	O
35	,	_	_	O
36	single-center	_	_	O
37	,	_	_	O
38	investigator-masked	_	_	O
39	,	_	_	O
40	parallel-group	_	_	O
41	clinical	_	_	O
42	study	_	_	O
43	.	_	_	O

44	Patients	_	_	O
45	with	_	_	O
46	IOP	_	_	O
47	>	_	_	O
48	or=	_	_	O
49	18	_	_	O
50	mmHg	_	_	O
51	while	_	_	O
52	on	_	_	O
53	once-daily	_	_	O
54	latanoprost	_	_	O
55	were	_	_	O
56	randomized	_	_	O
57	to	_	_	O
58	adjunctive	_	_	O
59	treatment	_	_	O
60	with	_	_	O
61	brimonidine	_	_	O
62	purite	_	_	O
63	TID	_	_	O
64	(	_	_	O
65	n	_	_	O
66	=	_	_	O
67	20	_	_	O
68	)	_	_	O
69	or	_	_	O
70	brinzolamide	_	_	O
71	TID	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	20	_	_	O
76	)	_	_	O
77	for	_	_	O
78	3	_	_	O
79	months	_	_	O
80	.	_	_	O

81	Intraocular	_	_	O
82	pressure	_	_	O
83	(	_	_	O
84	IOP	_	_	O
85	)	_	_	O
86	was	_	_	O
87	measured	_	_	O
88	at	_	_	O
89	8	_	_	O
90	a.m.	_	_	O
91	,	_	_	O
92	10	_	_	O
93	a.m.	_	_	O
94	,	_	_	O
95	and	_	_	O
96	4	_	_	O
97	p.m.	_	_	O
98	at	_	_	O
99	latanoprost-treated	_	_	O
100	baseline	_	_	O
101	and	_	_	O
102	after	_	_	O
103	1	_	_	O
104	and	_	_	O
105	3	_	_	O
106	months	_	_	O
107	of	_	_	O
108	latanoprost	_	_	O
109	and	_	_	O
110	adjunctive	_	_	O
111	therapy	_	_	O
112	.	_	_	O

113	A	_	_	O
114	patient	_	_	O
115	questionnaire	_	_	O
116	was	_	_	O
117	administered	_	_	O
118	to	_	_	O
119	evaluate	_	_	O
120	the	_	_	O
121	tolerability	_	_	O
122	of	_	_	O
123	eye	_	_	O
124	drop	_	_	O
125	instillation	_	_	O
126	.	_	_	O

127	Baseline	_	_	B-Premise
128	mean	_	_	I-Premise
129	diurnal	_	_	I-Premise
130	IOP	_	_	I-Premise
131	(	_	_	I-Premise
132	+/-	_	_	I-Premise
133	standard	_	_	I-Premise
134	deviation	_	_	I-Premise
135	,	_	_	I-Premise
136	mmHg	_	_	I-Premise
137	)	_	_	I-Premise
138	on	_	_	I-Premise
139	latanoprost	_	_	I-Premise
140	was	_	_	I-Premise
141	comparable	_	_	I-Premise
142	between	_	_	I-Premise
143	groups	_	_	I-Premise
144	(	_	_	I-Premise
145	brimonidine	_	_	I-Premise
146	purite	_	_	I-Premise
147	:	_	_	I-Premise
148	19.6	_	_	I-Premise
149	+/-	_	_	I-Premise
150	2.94	_	_	I-Premise
151	;	_	_	I-Premise
152	brinzolamide	_	_	I-Premise
153	:	_	_	I-Premise
154	19.8	_	_	I-Premise
155	+/-	_	_	I-Premise
156	3.25	_	_	I-Premise
157	;	_	_	I-Premise
158	p	_	_	I-Premise
159	=	_	_	I-Premise
160	0.846	_	_	I-Premise
161	)	_	_	I-Premise
162	.	_	_	I-Premise

163	Mean	_	_	B-Premise
164	diurnal	_	_	I-Premise
165	IOP	_	_	I-Premise
166	at	_	_	I-Premise
167	Month	_	_	I-Premise
168	3	_	_	I-Premise
169	was	_	_	I-Premise
170	16.3	_	_	I-Premise
171	+/-	_	_	I-Premise
172	2.63	_	_	I-Premise
173	mmHg	_	_	I-Premise
174	with	_	_	I-Premise
175	brimonidine	_	_	I-Premise
176	purite	_	_	I-Premise
177	and	_	_	I-Premise
178	17.8	_	_	I-Premise
179	+/-	_	_	I-Premise
180	2.19	_	_	I-Premise
181	mmHg	_	_	I-Premise
182	with	_	_	I-Premise
183	brinzolamide	_	_	I-Premise
184	(	_	_	I-Premise
185	p	_	_	I-Premise
186	=	_	_	I-Premise
187	0.028	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	Adjunctive	_	_	B-Premise
191	use	_	_	I-Premise
192	of	_	_	I-Premise
193	brimonidine	_	_	I-Premise
194	purite	_	_	I-Premise
195	provided	_	_	I-Premise
196	greater	_	_	I-Premise
197	IOP	_	_	I-Premise
198	lowering	_	_	I-Premise
199	than	_	_	I-Premise
200	brinzolamide	_	_	I-Premise
201	at	_	_	I-Premise
202	10	_	_	I-Premise
203	a.m.	_	_	I-Premise
204	(	_	_	I-Premise
205	p	_	_	I-Premise
206	<	_	_	I-Premise
207	0.001	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	4	_	_	I-Premise
211	p.m.	_	_	I-Premise
212	(	_	_	I-Premise
213	p	_	_	I-Premise
214	=	_	_	I-Premise
215	0.050	_	_	I-Premise
216	)	_	_	I-Premise
217	and	_	_	I-Premise
218	equivalent	_	_	I-Premise
219	IOP	_	_	I-Premise
220	lowering	_	_	I-Premise
221	to	_	_	I-Premise
222	brinzolamide	_	_	I-Premise
223	at	_	_	I-Premise
224	8	_	_	I-Premise
225	a.m.	_	_	I-Premise
226	(	_	_	I-Premise
227	p	_	_	I-Premise
228	=	_	_	I-Premise
229	0.716	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Blurred	_	_	B-Premise
233	vision	_	_	I-Premise
234	at	_	_	I-Premise
235	Month	_	_	I-Premise
236	1	_	_	I-Premise
237	and	_	_	I-Premise
238	bitter	_	_	I-Premise
239	taste	_	_	I-Premise
240	at	_	_	I-Premise
241	Months	_	_	I-Premise
242	1	_	_	I-Premise
243	and	_	_	I-Premise
244	3	_	_	I-Premise
245	were	_	_	I-Premise
246	more	_	_	I-Premise
247	common	_	_	I-Premise
248	upon	_	_	I-Premise
249	instillation	_	_	I-Premise
250	of	_	_	I-Premise
251	brinzolamide	_	_	I-Premise
252	eye	_	_	I-Premise
253	drops	_	_	I-Premise
254	.	_	_	I-Premise

255	Brimonidine	_	_	B-Claim
256	purite	_	_	I-Claim
257	0.1	_	_	I-Claim
258	%	_	_	I-Claim
259	provided	_	_	I-Claim
260	significantly	_	_	I-Claim
261	lower	_	_	I-Claim
262	IOP	_	_	I-Claim
263	compared	_	_	I-Claim
264	with	_	_	I-Claim
265	brinzolamide	_	_	I-Claim
266	1	_	_	I-Claim
267	%	_	_	I-Claim
268	when	_	_	I-Claim
269	used	_	_	I-Claim
270	as	_	_	I-Claim
271	adjunctive	_	_	I-Claim
272	therapy	_	_	I-Claim
273	to	_	_	I-Claim
274	latanoprost	_	_	I-Claim
275	.	_	_	I-Claim

276	Both	_	_	B-Claim
277	adjunctive	_	_	I-Claim
278	therapies	_	_	I-Claim
279	were	_	_	I-Claim
280	well	_	_	I-Claim
281	tolerated	_	_	I-Claim
282	.	_	_	I-Claim

283	Limitations	_	_	B-Premise
284	of	_	_	I-Premise
285	this	_	_	I-Premise
286	study	_	_	I-Premise
287	include	_	_	I-Premise
288	the	_	_	I-Premise
289	use	_	_	I-Premise
290	of	_	_	I-Premise
291	a	_	_	I-Premise
292	single	_	_	I-Premise
293	site	_	_	I-Premise
294	and	_	_	I-Premise
295	the	_	_	I-Premise
296	sample	_	_	I-Premise
297	size	_	_	I-Premise
298	.	_	_	I-Premise

299	Additional	_	_	B-Claim
300	studies	_	_	I-Claim
301	are	_	_	I-Claim
302	needed	_	_	I-Claim
303	to	_	_	I-Claim
304	further	_	_	I-Claim
305	evaluate	_	_	I-Claim
306	these	_	_	I-Claim
307	drugs	_	_	I-Claim
308	as	_	_	I-Claim
309	adjunctive	_	_	I-Claim
310	therapy	_	_	I-Claim
311	to	_	_	I-Claim
312	prostaglandin	_	_	I-Claim
313	analogs	_	_	I-Claim
314	.	_	_	I-Claim


0	We	_	_	O
1	conducted	_	_	O
2	a	_	_	O
3	prospective	_	_	O
4	,	_	_	O
5	randomized	_	_	O
6	study	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	mitomycin	_	_	O
10	with	_	_	O
11	fluorouracil	_	_	O
12	for	_	_	O
13	efficacy	_	_	O
14	and	_	_	O
15	safety	_	_	O
16	as	_	_	O
17	an	_	_	O
18	adjunct	_	_	O
19	to	_	_	O
20	trabeculectomy	_	_	O
21	in	_	_	O
22	eyes	_	_	O
23	with	_	_	O
24	glaucoma	_	_	O
25	with	_	_	O
26	poor	_	_	O
27	surgical	_	_	O
28	prognosis	_	_	O
29	.	_	_	O

30	Thirty-two	_	_	O
31	eyes	_	_	O
32	of	_	_	O
33	32	_	_	O
34	patients	_	_	O
35	were	_	_	O
36	randomly	_	_	O
37	allocated	_	_	O
38	to	_	_	O
39	either	_	_	O
40	mitomycin	_	_	O
41	(	_	_	O
42	17	_	_	O
43	eyes	_	_	O
44	)	_	_	O
45	or	_	_	O
46	fluorouracil	_	_	O
47	therapy	_	_	O
48	(	_	_	O
49	15	_	_	O
50	eyes	_	_	O
51	)	_	_	O
52	.	_	_	O

53	Mitomycin	_	_	O
54	(	_	_	O
55	0.2	_	_	O
56	mg	_	_	O
57	)	_	_	O
58	was	_	_	O
59	applied	_	_	O
60	only	_	_	O
61	once	_	_	O
62	during	_	_	O
63	trabeculectomy	_	_	O
64	,	_	_	O
65	and	_	_	O
66	fluorouracil	_	_	O
67	(	_	_	O
68	5	_	_	O
69	mg	_	_	O
70	)	_	_	O
71	was	_	_	O
72	subconjunctivally	_	_	O
73	injected	_	_	O
74	10	_	_	O
75	times	_	_	O
76	in	_	_	O
77	the	_	_	O
78	2	_	_	O
79	weeks	_	_	O
80	after	_	_	O
81	surgery	_	_	O
82	.	_	_	O

83	Fifteen	_	_	B-Premise
84	eyes	_	_	I-Premise
85	(	_	_	I-Premise
86	88	_	_	I-Premise
87	%	_	_	I-Premise
88	)	_	_	I-Premise
89	in	_	_	I-Premise
90	the	_	_	I-Premise
91	mitomycin	_	_	I-Premise
92	group	_	_	I-Premise
93	and	_	_	I-Premise
94	seven	_	_	I-Premise
95	(	_	_	I-Premise
96	47	_	_	I-Premise
97	%	_	_	I-Premise
98	)	_	_	I-Premise
99	in	_	_	I-Premise
100	the	_	_	I-Premise
101	fluorouracil	_	_	I-Premise
102	group	_	_	I-Premise
103	achieved	_	_	I-Premise
104	an	_	_	I-Premise
105	intraocular	_	_	I-Premise
106	pressure	_	_	I-Premise
107	of	_	_	I-Premise
108	less	_	_	I-Premise
109	than	_	_	I-Premise
110	or	_	_	I-Premise
111	equal	_	_	I-Premise
112	to	_	_	I-Premise
113	20	_	_	I-Premise
114	mm	_	_	I-Premise
115	Hg	_	_	I-Premise
116	without	_	_	I-Premise
117	antiglaucoma	_	_	I-Premise
118	medication	_	_	I-Premise
119	.	_	_	I-Premise

120	The	_	_	O
121	follow-up	_	_	O
122	period	_	_	O
123	was	_	_	O
124	7	_	_	O
125	to	_	_	O
126	12	_	_	O
127	months	_	_	O
128	.	_	_	O

129	Corneal	_	_	B-Premise
130	complications	_	_	I-Premise
131	were	_	_	I-Premise
132	less	_	_	I-Premise
133	common	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	group	_	_	I-Premise
137	given	_	_	I-Premise
138	mitomycin	_	_	I-Premise
139	than	_	_	I-Premise
140	in	_	_	I-Premise
141	that	_	_	I-Premise
142	given	_	_	I-Premise
143	fluorouracil	_	_	I-Premise
144	(	_	_	I-Premise
145	12	_	_	I-Premise
146	%	_	_	I-Premise
147	vs	_	_	I-Premise
148	53	_	_	I-Premise
149	%	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	The	_	_	B-Claim
153	incidence	_	_	I-Claim
154	of	_	_	I-Claim
155	other	_	_	I-Claim
156	complications	_	_	I-Claim
157	was	_	_	I-Claim
158	similar	_	_	I-Claim
159	between	_	_	I-Claim
160	the	_	_	I-Claim
161	two	_	_	I-Claim
162	groups	_	_	I-Claim
163	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	whether	_	_	O
3	3-month	_	_	O
4	administration	_	_	O
5	of	_	_	O
6	CDB-2914	_	_	O
7	,	_	_	O
8	a	_	_	O
9	selective	_	_	O
10	progesterone	_	_	O
11	receptor	_	_	O
12	modulator	_	_	O
13	,	_	_	O
14	reduces	_	_	O
15	leiomyoma	_	_	O
16	size	_	_	O
17	and	_	_	O
18	symptoms	_	_	O
19	.	_	_	O

20	Premenopausal	_	_	O
21	women	_	_	O
22	with	_	_	O
23	symptomatic	_	_	O
24	uterine	_	_	O
25	leiomyomata	_	_	O
26	were	_	_	O
27	randomly	_	_	O
28	assigned	_	_	O
29	to	_	_	O
30	CDB-2914	_	_	O
31	at	_	_	O
32	10	_	_	O
33	mg	_	_	O
34	(	_	_	O
35	T1	_	_	O
36	)	_	_	O
37	or	_	_	O
38	20	_	_	O
39	mg	_	_	O
40	(	_	_	O
41	T2	_	_	O
42	)	_	_	O
43	daily	_	_	O
44	or	_	_	O
45	to	_	_	O
46	placebo	_	_	O
47	(	_	_	O
48	PLC	_	_	O
49	)	_	_	O
50	for	_	_	O
51	3	_	_	O
52	cycles	_	_	O
53	or	_	_	O
54	90-102	_	_	O
55	days	_	_	O
56	if	_	_	O
57	no	_	_	O
58	menses	_	_	O
59	occurred	_	_	O
60	.	_	_	O

61	The	_	_	O
62	primary	_	_	O
63	outcome	_	_	O
64	was	_	_	O
65	leiomyoma	_	_	O
66	volume	_	_	O
67	change	_	_	O
68	determined	_	_	O
69	by	_	_	O
70	magnetic	_	_	O
71	resonance	_	_	O
72	imaging	_	_	O
73	at	_	_	O
74	study	_	_	O
75	entry	_	_	O
76	and	_	_	O
77	within	_	_	O
78	2	_	_	O
79	weeks	_	_	O
80	of	_	_	O
81	hysterectomy	_	_	O
82	.	_	_	O

83	Secondary	_	_	O
84	outcomes	_	_	O
85	included	_	_	O
86	the	_	_	O
87	proportion	_	_	O
88	of	_	_	O
89	amenorrhea	_	_	O
90	,	_	_	O
91	change	_	_	O
92	in	_	_	O
93	hemoglobin	_	_	O
94	and	_	_	O
95	hematocrit	_	_	O
96	,	_	_	O
97	ovulation	_	_	O
98	inhibition	_	_	O
99	,	_	_	O
100	and	_	_	O
101	quality-of-life	_	_	O
102	assessment	_	_	O
103	.	_	_	O

104	Twenty-two	_	_	O
105	patients	_	_	O
106	were	_	_	O
107	allocated	_	_	O
108	,	_	_	O
109	and	_	_	O
110	18	_	_	O
111	completed	_	_	O
112	the	_	_	O
113	trial	_	_	O
114	.	_	_	O

115	Age	_	_	O
116	and	_	_	O
117	body	_	_	O
118	mass	_	_	O
119	index	_	_	O
120	were	_	_	O
121	similar	_	_	O
122	among	_	_	O
123	groups	_	_	O
124	.	_	_	O

125	Leiomyoma	_	_	O
126	volume	_	_	O
127	was	_	_	O
128	significantly	_	_	O
129	reduced	_	_	O
130	with	_	_	O
131	CDB-2914	_	_	O
132	administration	_	_	O
133	(	_	_	O
134	PLC	_	_	O
135	6	_	_	O
136	%	_	_	O
137	;	_	_	O
138	CDB-2914	_	_	O
139	-29	_	_	O
140	%	_	_	O
141	;	_	_	O
142	P=.01	_	_	O
143	)	_	_	O
144	,	_	_	O
145	decreasing	_	_	O
146	36	_	_	O
147	%	_	_	O
148	and	_	_	O
149	21	_	_	O
150	%	_	_	O
151	in	_	_	O
152	the	_	_	O
153	T1	_	_	O
154	and	_	_	O
155	T2	_	_	O
156	groups	_	_	O
157	,	_	_	O
158	respectively	_	_	O
159	.	_	_	O

160	During	_	_	O
161	treatment	_	_	O
162	,	_	_	O
163	hemoglobin	_	_	O
164	was	_	_	O
165	unchanged	_	_	O
166	,	_	_	O
167	and	_	_	O
168	the	_	_	O
169	median	_	_	O
170	estradiol	_	_	O
171	was	_	_	O
172	greater	_	_	O
173	than	_	_	O
174	50	_	_	O
175	pg/mL	_	_	O
176	in	_	_	O
177	all	_	_	O
178	groups	_	_	O
179	.	_	_	O

180	CDB-2914	_	_	O
181	eliminated	_	_	O
182	menstrual	_	_	O
183	bleeding	_	_	O
184	and	_	_	O
185	inhibited	_	_	O
186	ovulation	_	_	O
187	(	_	_	O
188	%	_	_	O
189	ovulatory	_	_	O
190	cycles	_	_	O
191	:	_	_	O
192	CDB-2914	_	_	O
193	,	_	_	O
194	20	_	_	O
195	%	_	_	O
196	;	_	_	O
197	PLC	_	_	O
198	,	_	_	O
199	83	_	_	O
200	%	_	_	O
201	;	_	_	O
202	P=.001	_	_	O
203	)	_	_	O
204	.	_	_	O

205	CDB-2914	_	_	O
206	improved	_	_	O
207	the	_	_	O
208	concern	_	_	O
209	scores	_	_	O
210	of	_	_	O
211	the	_	_	O
212	uterine	_	_	O
213	leiomyoma	_	_	O
214	symptom	_	_	O
215	quality-of-life	_	_	O
216	subscale	_	_	O
217	(	_	_	O
218	P=.04	_	_	O
219	)	_	_	O
220	.	_	_	O

221	One	_	_	O
222	CDB-2914	_	_	O
223	woman	_	_	O
224	developed	_	_	O
225	endometrial	_	_	O
226	cystic	_	_	O
227	hyperplasia	_	_	O
228	without	_	_	O
229	evidence	_	_	O
230	of	_	_	O
231	atypia	_	_	O
232	.	_	_	O

233	No	_	_	B-Premise
234	serious	_	_	I-Premise
235	adverse	_	_	I-Premise
236	events	_	_	I-Premise
237	were	_	_	I-Premise
238	reported	_	_	I-Premise
239	.	_	_	I-Premise

240	Compared	_	_	B-Premise
241	with	_	_	I-Premise
242	PLC	_	_	I-Premise
243	,	_	_	I-Premise
244	CDB-2914	_	_	I-Premise
245	significantly	_	_	I-Premise
246	reduced	_	_	I-Premise
247	leiomyoma	_	_	I-Premise
248	volume	_	_	I-Premise
249	after	_	_	I-Premise
250	three	_	_	I-Premise
251	cycles	_	_	I-Premise
252	,	_	_	I-Premise
253	or	_	_	I-Premise
254	90-102	_	_	I-Premise
255	days	_	_	I-Premise
256	.	_	_	I-Premise

257	CDB-2914	_	_	B-Premise
258	treatment	_	_	I-Premise
259	resulted	_	_	I-Premise
260	in	_	_	I-Premise
261	improvements	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	concern	_	_	I-Premise
265	subscale	_	_	I-Premise
266	of	_	_	I-Premise
267	the	_	_	I-Premise
268	Uterine	_	_	I-Premise
269	Fibroid	_	_	I-Premise
270	Symptom	_	_	I-Premise
271	Quality	_	_	I-Premise
272	of	_	_	I-Premise
273	Life	_	_	I-Premise
274	assessment	_	_	I-Premise
275	.	_	_	I-Premise

276	In	_	_	B-Claim
277	this	_	_	I-Claim
278	small	_	_	I-Claim
279	study	_	_	I-Claim
280	,	_	_	I-Claim
281	CDB-2914	_	_	I-Claim
282	was	_	_	I-Claim
283	well-tolerated	_	_	I-Claim
284	without	_	_	I-Claim
285	serious	_	_	I-Claim
286	adverse	_	_	I-Claim
287	events	_	_	I-Claim
288	.	_	_	I-Claim

289	Thus	_	_	B-Claim
290	,	_	_	I-Claim
291	there	_	_	I-Claim
292	may	_	_	I-Claim
293	be	_	_	I-Claim
294	a	_	_	I-Claim
295	role	_	_	I-Claim
296	for	_	_	I-Claim
297	CDB-2914	_	_	I-Claim
298	in	_	_	I-Claim
299	the	_	_	I-Claim
300	treatment	_	_	I-Claim
301	of	_	_	I-Claim
302	leiomyomata	_	_	I-Claim
303	.	_	_	I-Claim


0	Shoulder	_	_	O
1	pain	_	_	O
2	and	_	_	O
3	disability	_	_	O
4	are	_	_	O
5	well	_	_	O
6	recognized	_	_	O
7	complications	_	_	O
8	associated	_	_	O
9	with	_	_	O
10	surgery	_	_	O
11	for	_	_	O
12	head	_	_	O
13	and	_	_	O
14	neck	_	_	O
15	cancer	_	_	O
16	.	_	_	O

17	This	_	_	O
18	study	_	_	O
19	was	_	_	O
20	designed	_	_	O
21	to	_	_	O
22	examine	_	_	O
23	the	_	_	O
24	effects	_	_	O
25	of	_	_	O
26	progressive	_	_	O
27	resistance	_	_	O
28	exercise	_	_	O
29	training	_	_	O
30	(	_	_	O
31	PRET	_	_	O
32	)	_	_	O
33	on	_	_	O
34	upper	_	_	O
35	extremity	_	_	O
36	pain	_	_	O
37	and	_	_	O
38	dysfunction	_	_	O
39	in	_	_	O
40	postsurgical	_	_	O
41	head	_	_	O
42	and	_	_	O
43	neck	_	_	O
44	cancer	_	_	O
45	survivors	_	_	O
46	.	_	_	O

47	Fifty-two	_	_	O
48	head	_	_	O
49	and	_	_	O
50	neck	_	_	O
51	cancer	_	_	O
52	survivors	_	_	O
53	were	_	_	O
54	assigned	_	_	O
55	randomly	_	_	O
56	to	_	_	O
57	PRET	_	_	O
58	(	_	_	O
59	n	_	_	O
60	=	_	_	O
61	27	_	_	O
62	)	_	_	O
63	or	_	_	O
64	a	_	_	O
65	standardized	_	_	O
66	therapeutic	_	_	O
67	exercise	_	_	O
68	protocol	_	_	O
69	(	_	_	O
70	TP	_	_	O
71	)	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	25	_	_	O
76	)	_	_	O
77	for	_	_	O
78	12	_	_	O
79	weeks	_	_	O
80	.	_	_	O

81	The	_	_	O
82	primary	_	_	O
83	endpoint	_	_	O
84	was	_	_	O
85	change	_	_	O
86	in	_	_	O
87	patient-rated	_	_	O
88	shoulder	_	_	O
89	pain	_	_	O
90	and	_	_	O
91	disability	_	_	O
92	from	_	_	O
93	baseline	_	_	O
94	to	_	_	O
95	postintervention	_	_	O
96	.	_	_	O

97	Secondary	_	_	O
98	endpoints	_	_	O
99	were	_	_	O
100	upper	_	_	O
101	extremity	_	_	O
102	strength	_	_	O
103	and	_	_	O
104	endurance	_	_	O
105	,	_	_	O
106	range	_	_	O
107	of	_	_	O
108	motion	_	_	O
109	,	_	_	O
110	fatigue	_	_	O
111	,	_	_	O
112	and	_	_	O
113	quality	_	_	O
114	of	_	_	O
115	life	_	_	O
116	.	_	_	O

117	Follow-up	_	_	O
118	assessment	_	_	O
119	for	_	_	O
120	the	_	_	O
121	primary	_	_	O
122	outcome	_	_	O
123	was	_	_	O
124	92	_	_	O
125	%	_	_	O
126	,	_	_	O
127	and	_	_	O
128	adherence	_	_	O
129	to	_	_	O
130	the	_	_	O
131	supervised	_	_	O
132	PRET	_	_	O
133	and	_	_	O
134	TP	_	_	O
135	programs	_	_	O
136	were	_	_	O
137	95	_	_	O
138	%	_	_	O
139	and	_	_	O
140	87	_	_	O
141	%	_	_	O
142	,	_	_	O
143	respectively	_	_	O
144	.	_	_	O

145	On	_	_	B-Premise
146	the	_	_	I-Premise
147	basis	_	_	I-Premise
148	of	_	_	I-Premise
149	intention-to-treat	_	_	I-Premise
150	analyses	_	_	I-Premise
151	,	_	_	I-Premise
152	PRET	_	_	I-Premise
153	was	_	_	I-Premise
154	superior	_	_	I-Premise
155	to	_	_	I-Premise
156	TP	_	_	I-Premise
157	for	_	_	I-Premise
158	improving	_	_	I-Premise
159	shoulder	_	_	I-Premise
160	pain	_	_	I-Premise
161	and	_	_	I-Premise
162	disability	_	_	I-Premise
163	(	_	_	I-Premise
164	-9.6	_	_	I-Premise
165	;	_	_	I-Premise
166	95	_	_	I-Premise
167	%	_	_	I-Premise
168	confidence	_	_	I-Premise
169	interval	_	_	I-Premise
170	[	_	_	I-Premise
171	95	_	_	I-Premise
172	%	_	_	I-Premise
173	CI	_	_	I-Premise
174	]	_	_	I-Premise
175	,	_	_	I-Premise
176	-16.4	_	_	I-Premise
177	to	_	_	I-Premise
178	-4.5	_	_	I-Premise
179	;	_	_	I-Premise
180	P	_	_	I-Premise
181	=	_	_	I-Premise
182	.001	_	_	I-Premise
183	)	_	_	I-Premise
184	,	_	_	I-Premise
185	upper	_	_	I-Premise
186	extremity	_	_	I-Premise
187	strength	_	_	I-Premise
188	(	_	_	I-Premise
189	+10.8	_	_	I-Premise
190	kg	_	_	I-Premise
191	;	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	,	_	_	I-Premise
196	5.4-16.2	_	_	I-Premise
197	kg	_	_	I-Premise
198	;	_	_	I-Premise
199	P	_	_	I-Premise
200	<	_	_	I-Premise
201	.001	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	and	_	_	I-Premise
205	upper	_	_	I-Premise
206	extremity	_	_	I-Premise
207	endurance	_	_	I-Premise
208	(	_	_	I-Premise
209	+194	_	_	I-Premise
210	repetitions	_	_	I-Premise
211	x	_	_	I-Premise
212	kg	_	_	I-Premise
213	;	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	,	_	_	I-Premise
218	10-378	_	_	I-Premise
219	repetitions	_	_	I-Premise
220	x	_	_	I-Premise
221	kg	_	_	I-Premise
222	;	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.039	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Changes	_	_	B-Premise
229	in	_	_	I-Premise
230	neck	_	_	I-Premise
231	dissection	_	_	I-Premise
232	impairment	_	_	I-Premise
233	,	_	_	I-Premise
234	fatigue	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	quality	_	_	I-Premise
238	of	_	_	I-Premise
239	life	_	_	I-Premise
240	favored	_	_	I-Premise
241	the	_	_	I-Premise
242	PRET	_	_	I-Premise
243	group	_	_	I-Premise
244	but	_	_	B-Premise
245	did	_	_	I-Premise
246	not	_	_	I-Premise
247	reach	_	_	I-Premise
248	statistical	_	_	I-Premise
249	significance	_	_	I-Premise
250	.	_	_	I-Premise

251	The	_	_	B-Premise
252	PRET	_	_	I-Premise
253	program	_	_	I-Premise
254	significantly	_	_	I-Premise
255	reduced	_	_	I-Premise
256	shoulder	_	_	I-Premise
257	pain	_	_	I-Premise
258	and	_	_	I-Premise
259	disability	_	_	I-Premise
260	and	_	_	I-Premise
261	improved	_	_	I-Premise
262	upper	_	_	I-Premise
263	extremity	_	_	I-Premise
264	muscular	_	_	I-Premise
265	strength	_	_	I-Premise
266	and	_	_	I-Premise
267	endurance	_	_	I-Premise
268	in	_	_	I-Premise
269	head	_	_	I-Premise
270	and	_	_	I-Premise
271	neck	_	_	I-Premise
272	cancer	_	_	I-Premise
273	survivors	_	_	I-Premise
274	who	_	_	I-Premise
275	had	_	_	I-Premise
276	shoulder	_	_	I-Premise
277	dysfunction	_	_	I-Premise
278	because	_	_	I-Premise
279	of	_	_	I-Premise
280	spinal	_	_	I-Premise
281	accessory	_	_	I-Premise
282	nerve	_	_	I-Premise
283	damage	_	_	I-Premise
284	.	_	_	I-Premise

285	Clinicians	_	_	B-Claim
286	should	_	_	I-Claim
287	consider	_	_	I-Claim
288	the	_	_	I-Claim
289	addition	_	_	I-Claim
290	of	_	_	I-Claim
291	PRET	_	_	I-Claim
292	in	_	_	I-Claim
293	the	_	_	I-Claim
294	rehabilitation	_	_	I-Claim
295	of	_	_	I-Claim
296	postsurgical	_	_	I-Claim
297	head	_	_	I-Claim
298	and	_	_	I-Claim
299	neck	_	_	I-Claim
300	cancer	_	_	I-Claim
301	survivors	_	_	I-Claim
302	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	uterine	_	_	O
4	artery	_	_	O
5	embolization	_	_	O
6	(	_	_	O
7	UAE	_	_	O
8	)	_	_	O
9	is	_	_	O
10	a	_	_	O
11	cost-effective	_	_	O
12	alternative	_	_	O
13	to	_	_	O
14	hysterectomy	_	_	O
15	for	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	symptomatic	_	_	O
19	uterine	_	_	O
20	fibroids	_	_	O
21	,	_	_	O
22	the	_	_	O
23	authors	_	_	O
24	performed	_	_	O
25	an	_	_	O
26	economic	_	_	O
27	evaluation	_	_	O
28	alongside	_	_	O
29	the	_	_	O
30	multicenter	_	_	O
31	randomized	_	_	O
32	EMMY	_	_	O
33	(	_	_	O
34	EMbolization	_	_	O
35	versus	_	_	O
36	hysterectoMY	_	_	O
37	)	_	_	O
38	trial	_	_	O
39	.	_	_	O

40	Between	_	_	O
41	February	_	_	O
42	2002	_	_	O
43	and	_	_	O
44	February	_	_	O
45	2004	_	_	O
46	,	_	_	O
47	177	_	_	O
48	patients	_	_	O
49	were	_	_	O
50	randomized	_	_	O
51	to	_	_	O
52	undergo	_	_	O
53	UAE	_	_	O
54	(	_	_	O
55	n	_	_	O
56	=	_	_	O
57	88	_	_	O
58	)	_	_	O
59	or	_	_	O
60	hysterectomy	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	89	_	_	O
65	)	_	_	O
66	and	_	_	O
67	followed	_	_	O
68	up	_	_	O
69	until	_	_	O
70	24	_	_	O
71	months	_	_	O
72	after	_	_	O
73	initial	_	_	O
74	treatment	_	_	O
75	allocation	_	_	O
76	.	_	_	O

77	Conditional	_	_	O
78	on	_	_	O
79	the	_	_	O
80	equivalence	_	_	O
81	of	_	_	O
82	clinical	_	_	O
83	outcome	_	_	O
84	,	_	_	O
85	a	_	_	O
86	cost	_	_	O
87	minimization	_	_	O
88	analysis	_	_	O
89	was	_	_	O
90	performed	_	_	O
91	according	_	_	O
92	to	_	_	O
93	the	_	_	O
94	intention	_	_	O
95	to	_	_	O
96	treat	_	_	O
97	principle	_	_	O
98	.	_	_	O

99	Costs	_	_	O
100	included	_	_	O
101	health	_	_	O
102	care	_	_	O
103	costs	_	_	O
104	inside	_	_	O
105	and	_	_	O
106	outside	_	_	O
107	the	_	_	O
108	hospital	_	_	O
109	as	_	_	O
110	well	_	_	O
111	as	_	_	O
112	costs	_	_	O
113	related	_	_	O
114	to	_	_	O
115	absence	_	_	O
116	from	_	_	O
117	work	_	_	O
118	(	_	_	O
119	societal	_	_	O
120	perspective	_	_	O
121	)	_	_	O
122	.	_	_	O

123	Cumulative	_	_	O
124	standardized	_	_	O
125	costs	_	_	O
126	were	_	_	O
127	estimated	_	_	O
128	as	_	_	O
129	volumes	_	_	O
130	multiplied	_	_	O
131	with	_	_	O
132	prices	_	_	O
133	.	_	_	O

134	The	_	_	O
135	nonparametric	_	_	O
136	bootstrap	_	_	O
137	method	_	_	O
138	was	_	_	O
139	used	_	_	O
140	to	_	_	O
141	quantify	_	_	O
142	differences	_	_	O
143	in	_	_	O
144	mean	_	_	O
145	(	_	_	O
146	95	_	_	O
147	%	_	_	O
148	confidence	_	_	O
149	interval	_	_	O
150	[	_	_	O
151	CI	_	_	O
152	]	_	_	O
153	)	_	_	O
154	costs	_	_	O
155	between	_	_	O
156	the	_	_	O
157	strategies	_	_	O
158	.	_	_	O

159	In	_	_	O
160	total	_	_	O
161	,	_	_	O
162	81	_	_	O
163	patients	_	_	O
164	underwent	_	_	O
165	UAE	_	_	O
166	and	_	_	O
167	75	_	_	O
168	underwent	_	_	O
169	hysterectomy	_	_	O
170	.	_	_	O

171	In	_	_	O
172	the	_	_	O
173	UAE	_	_	O
174	group	_	_	O
175	,	_	_	O
176	19	_	_	O
177	patients	_	_	O
178	(	_	_	O
179	23	_	_	O
180	%	_	_	O
181	)	_	_	O
182	underwent	_	_	O
183	secondary	_	_	O
184	hysterectomies	_	_	O
185	.	_	_	O

186	The	_	_	B-Premise
187	mean	_	_	I-Premise
188	total	_	_	I-Premise
189	costs	_	_	I-Premise
190	per	_	_	I-Premise
191	patient	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	UAE	_	_	I-Premise
195	group	_	_	I-Premise
196	were	_	_	I-Premise
197	significantly	_	_	I-Premise
198	lower	_	_	I-Premise
199	than	_	_	I-Premise
200	those	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	hysterectomy	_	_	I-Premise
204	group	_	_	I-Premise
205	(	_	_	I-Premise
206	$	_	_	I-Premise
207	11,626	_	_	I-Premise
208	vs	_	_	I-Premise
209	$	_	_	I-Premise
210	18,563	_	_	I-Premise
211	;	_	_	I-Premise
212	mean	_	_	I-Premise
213	difference	_	_	I-Premise
214	,	_	_	I-Premise
215	-	_	_	I-Premise
216	$	_	_	I-Premise
217	6,936	_	_	I-Premise
218	[	_	_	I-Premise
219	-37	_	_	I-Premise
220	%	_	_	I-Premise
221	]	_	_	I-Premise
222	,	_	_	I-Premise
223	95	_	_	I-Premise
224	%	_	_	I-Premise
225	CI	_	_	I-Premise
226	:	_	_	I-Premise
227	-	_	_	I-Premise
228	$	_	_	I-Premise
229	9,548	_	_	I-Premise
230	,	_	_	I-Premise
231	$	_	_	I-Premise
232	4,281	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	The	_	_	B-Premise
236	direct	_	_	I-Premise
237	medical	_	_	I-Premise
238	in-hospital	_	_	I-Premise
239	costs	_	_	I-Premise
240	were	_	_	I-Premise
241	significantly	_	_	I-Premise
242	lower	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	UAE	_	_	I-Premise
246	group	_	_	I-Premise
247	:	_	_	I-Premise
248	$	_	_	I-Premise
249	6,688	_	_	I-Premise
250	vs	_	_	I-Premise
251	$	_	_	I-Premise
252	8,313	_	_	I-Premise
253	(	_	_	I-Premise
254	mean	_	_	I-Premise
255	difference	_	_	I-Premise
256	,	_	_	I-Premise
257	-	_	_	I-Premise
258	$	_	_	I-Premise
259	1,624	_	_	I-Premise
260	[	_	_	I-Premise
261	-20	_	_	I-Premise
262	%	_	_	I-Premise
263	]	_	_	I-Premise
264	,	_	_	I-Premise
265	95	_	_	I-Premise
266	%	_	_	I-Premise
267	CI	_	_	I-Premise
268	:	_	_	I-Premise
269	-	_	_	I-Premise
270	$	_	_	I-Premise
271	2,605	_	_	I-Premise
272	,	_	_	I-Premise
273	-	_	_	I-Premise
274	$	_	_	I-Premise
275	586	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	Direct	_	_	B-Premise
279	medical	_	_	I-Premise
280	out-of-hospital	_	_	I-Premise
281	and	_	_	I-Premise
282	direct	_	_	I-Premise
283	nonmedical	_	_	I-Premise
284	costs	_	_	I-Premise
285	were	_	_	I-Premise
286	low	_	_	I-Premise
287	in	_	_	I-Premise
288	both	_	_	I-Premise
289	groups	_	_	I-Premise
290	(	_	_	I-Premise
291	mean	_	_	I-Premise
292	cost	_	_	I-Premise
293	difference	_	_	I-Premise
294	,	_	_	I-Premise
295	$	_	_	I-Premise
296	156	_	_	I-Premise
297	in	_	_	I-Premise
298	favor	_	_	I-Premise
299	of	_	_	I-Premise
300	hysterectomy	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	B-Premise
304	costs	_	_	I-Premise
305	related	_	_	I-Premise
306	to	_	_	I-Premise
307	absence	_	_	I-Premise
308	from	_	_	I-Premise
309	work	_	_	I-Premise
310	differed	_	_	I-Premise
311	significantly	_	_	I-Premise
312	between	_	_	I-Premise
313	the	_	_	I-Premise
314	treatment	_	_	I-Premise
315	strategies	_	_	I-Premise
316	in	_	_	I-Premise
317	favor	_	_	I-Premise
318	of	_	_	I-Premise
319	UAE	_	_	I-Premise
320	(	_	_	I-Premise
321	mean	_	_	I-Premise
322	difference	_	_	I-Premise
323	,	_	_	I-Premise
324	-	_	_	I-Premise
325	$	_	_	I-Premise
326	5,453	_	_	I-Premise
327	;	_	_	I-Premise
328	95	_	_	I-Premise
329	%	_	_	I-Premise
330	CI	_	_	I-Premise
331	:	_	_	I-Premise
332	-	_	_	I-Premise
333	$	_	_	I-Premise
334	7,718	_	_	I-Premise
335	,	_	_	I-Premise
336	-	_	_	I-Premise
337	$	_	_	I-Premise
338	3,107	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	The	_	_	O
342	costs	_	_	O
343	of	_	_	O
344	absence	_	_	O
345	from	_	_	O
346	work	_	_	O
347	accounted	_	_	O
348	for	_	_	O
349	79	_	_	O
350	%	_	_	O
351	of	_	_	O
352	the	_	_	O
353	difference	_	_	O
354	in	_	_	O
355	total	_	_	O
356	costs	_	_	O
357	.	_	_	O

358	The	_	_	B-Premise
359	24-month	_	_	I-Premise
360	cumulative	_	_	I-Premise
361	cost	_	_	I-Premise
362	of	_	_	I-Premise
363	UAE	_	_	I-Premise
364	is	_	_	I-Premise
365	lower	_	_	I-Premise
366	than	_	_	I-Premise
367	that	_	_	I-Premise
368	of	_	_	I-Premise
369	hysterectomy	_	_	I-Premise
370	.	_	_	I-Premise

371	From	_	_	B-Claim
372	a	_	_	I-Claim
373	societal	_	_	I-Claim
374	economic	_	_	I-Claim
375	perspective	_	_	I-Claim
376	,	_	_	I-Claim
377	UAE	_	_	I-Claim
378	is	_	_	I-Claim
379	the	_	_	I-Claim
380	superior	_	_	I-Claim
381	treatment	_	_	I-Claim
382	strategy	_	_	I-Claim
383	in	_	_	I-Claim
384	women	_	_	I-Claim
385	with	_	_	I-Claim
386	symptomatic	_	_	I-Claim
387	uterine	_	_	I-Claim
388	fibroids	_	_	I-Claim
389	.	_	_	I-Claim


0	Persistent	_	_	O
1	insomnia	_	_	O
2	is	_	_	O
3	a	_	_	O
4	common	_	_	O
5	complaint	_	_	O
6	in	_	_	O
7	cancer	_	_	O
8	survivors	_	_	O
9	,	_	_	O
10	but	_	_	O
11	is	_	_	O
12	seldom	_	_	O
13	satisfactorily	_	_	O
14	addressed	_	_	O
15	.	_	_	O

16	The	_	_	O
17	adaptation	_	_	O
18	to	_	_	O
19	cancer	_	_	O
20	care	_	_	O
21	of	_	_	O
22	a	_	_	O
23	validated	_	_	O
24	,	_	_	O
25	cost-effective	_	_	O
26	intervention	_	_	O
27	may	_	_	O
28	offer	_	_	O
29	a	_	_	O
30	practicable	_	_	O
31	solution	_	_	O
32	.	_	_	O

33	The	_	_	O
34	aim	_	_	O
35	of	_	_	O
36	this	_	_	O
37	study	_	_	O
38	was	_	_	O
39	to	_	_	O
40	investigate	_	_	O
41	the	_	_	O
42	clinical	_	_	O
43	effectiveness	_	_	O
44	of	_	_	O
45	protocol-driven	_	_	O
46	cognitive	_	_	O
47	behavior	_	_	O
48	therapy	_	_	O
49	(	_	_	O
50	CBT	_	_	O
51	)	_	_	O
52	for	_	_	O
53	insomnia	_	_	O
54	,	_	_	O
55	delivered	_	_	O
56	by	_	_	O
57	oncology	_	_	O
58	nurses	_	_	O
59	.	_	_	O

60	Randomized	_	_	O
61	,	_	_	O
62	controlled	_	_	O
63	,	_	_	O
64	pragmatic	_	_	O
65	,	_	_	O
66	two-center	_	_	O
67	trial	_	_	O
68	of	_	_	O
69	CBT	_	_	O
70	versus	_	_	O
71	treatment	_	_	O
72	as	_	_	O
73	usual	_	_	O
74	(	_	_	O
75	TAU	_	_	O
76	)	_	_	O
77	in	_	_	O
78	150	_	_	O
79	patients	_	_	O
80	(	_	_	O
81	103	_	_	O
82	females	_	_	O
83	;	_	_	O
84	mean	_	_	O
85	age	_	_	O
86	,	_	_	O
87	61	_	_	O
88	years	_	_	O
89	.	_	_	O
90	)	_	_	O

91	who	_	_	O
92	had	_	_	O
93	completed	_	_	O
94	active	_	_	O
95	therapy	_	_	O
96	for	_	_	O
97	breast	_	_	O
98	,	_	_	O
99	prostate	_	_	O
100	,	_	_	O
101	colorectal	_	_	O
102	,	_	_	O
103	or	_	_	O
104	gynecological	_	_	O
105	cancer	_	_	O
106	.	_	_	O

107	The	_	_	O
108	study	_	_	O
109	conformed	_	_	O
110	to	_	_	O
111	CONSORT	_	_	O
112	guidelines	_	_	O
113	.	_	_	O

114	Primary	_	_	O
115	outcomes	_	_	O
116	were	_	_	O
117	sleep	_	_	O
118	diary	_	_	O
119	measures	_	_	O
120	at	_	_	O
121	baseline	_	_	O
122	,	_	_	O
123	post-treatment	_	_	O
124	,	_	_	O
125	and	_	_	O
126	6-month	_	_	O
127	follow-up	_	_	O
128	.	_	_	O

129	Actigraphic	_	_	O
130	sleep	_	_	O
131	,	_	_	O
132	health-related	_	_	O
133	quality	_	_	O
134	of	_	_	O
135	life	_	_	O
136	(	_	_	O
137	QOL	_	_	O
138	)	_	_	O
139	,	_	_	O
140	psychopathology	_	_	O
141	,	_	_	O
142	and	_	_	O
143	fatigue	_	_	O
144	were	_	_	O
145	secondary	_	_	O
146	measures	_	_	O
147	.	_	_	O

148	CBT	_	_	O
149	comprised	_	_	O
150	five	_	_	O
151	,	_	_	O
152	small	_	_	O
153	group	_	_	O
154	sessions	_	_	O
155	across	_	_	O
156	consecutive	_	_	O
157	weeks	_	_	O
158	,	_	_	O
159	after	_	_	O
160	a	_	_	O
161	manualized	_	_	O
162	protocol	_	_	O
163	.	_	_	O

164	TAU	_	_	O
165	represented	_	_	O
166	normal	_	_	O
167	clinical	_	_	O
168	practice	_	_	O
169	;	_	_	O
170	the	_	_	O
171	appropriate	_	_	O
172	control	_	_	O
173	for	_	_	O
174	a	_	_	O
175	clinical	_	_	O
176	effectiveness	_	_	O
177	study	_	_	O
178	.	_	_	O

179	CBT	_	_	B-Premise
180	was	_	_	I-Premise
181	associated	_	_	I-Premise
182	with	_	_	I-Premise
183	mean	_	_	I-Premise
184	reductions	_	_	I-Premise
185	in	_	_	I-Premise
186	wakefulness	_	_	I-Premise
187	of	_	_	I-Premise
188	55	_	_	I-Premise
189	minutes	_	_	I-Premise
190	per	_	_	I-Premise
191	night	_	_	I-Premise
192	compared	_	_	I-Premise
193	with	_	_	I-Premise
194	no	_	_	I-Premise
195	change	_	_	I-Premise
196	in	_	_	I-Premise
197	TAU	_	_	I-Premise
198	.	_	_	I-Premise

199	These	_	_	O
200	outcomes	_	_	O
201	were	_	_	O
202	sustained	_	_	O
203	6	_	_	O
204	months	_	_	O
205	after	_	_	O
206	treatment	_	_	O
207	.	_	_	O

208	Standardized	_	_	B-Premise
209	relative	_	_	I-Premise
210	effect	_	_	I-Premise
211	sizes	_	_	I-Premise
212	were	_	_	I-Premise
213	large	_	_	I-Premise
214	for	_	_	I-Premise
215	complaints	_	_	I-Premise
216	of	_	_	I-Premise
217	difficulty	_	_	I-Premise
218	initiating	_	_	I-Premise
219	sleep	_	_	I-Premise
220	,	_	_	I-Premise
221	waking	_	_	I-Premise
222	from	_	_	I-Premise
223	sleep	_	_	I-Premise
224	during	_	_	I-Premise
225	the	_	_	I-Premise
226	night	_	_	I-Premise
227	,	_	_	I-Premise
228	and	_	_	I-Premise
229	for	_	_	I-Premise
230	sleep	_	_	I-Premise
231	efficiency	_	_	I-Premise
232	(	_	_	I-Premise
233	percentage	_	_	I-Premise
234	of	_	_	I-Premise
235	time	_	_	I-Premise
236	in	_	_	I-Premise
237	bed	_	_	I-Premise
238	spent	_	_	I-Premise
239	asleep	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	CBT	_	_	B-Premise
243	was	_	_	I-Premise
244	associated	_	_	I-Premise
245	with	_	_	I-Premise
246	moderate	_	_	I-Premise
247	to	_	_	I-Premise
248	large	_	_	I-Premise
249	effect	_	_	I-Premise
250	sizes	_	_	I-Premise
251	for	_	_	I-Premise
252	five	_	_	I-Premise
253	of	_	_	I-Premise
254	seven	_	_	I-Premise
255	QOL	_	_	I-Premise
256	outcomes	_	_	I-Premise
257	,	_	_	I-Premise
258	including	_	_	I-Premise
259	significant	_	_	I-Premise
260	reduction	_	_	I-Premise
261	in	_	_	I-Premise
262	daytime	_	_	I-Premise
263	fatigue	_	_	I-Premise
264	.	_	_	I-Premise

265	There	_	_	B-Premise
266	was	_	_	I-Premise
267	no	_	_	I-Premise
268	significant	_	_	I-Premise
269	interaction	_	_	I-Premise
270	effect	_	_	I-Premise
271	between	_	_	I-Premise
272	any	_	_	I-Premise
273	of	_	_	I-Premise
274	these	_	_	I-Premise
275	outcomes	_	_	I-Premise
276	and	_	_	I-Premise
277	baseline	_	_	I-Premise
278	demographic	_	_	I-Premise
279	,	_	_	I-Premise
280	clinical	_	_	I-Premise
281	,	_	_	I-Premise
282	or	_	_	I-Premise
283	sleep	_	_	I-Premise
284	characteristics	_	_	I-Premise
285	.	_	_	I-Premise

286	CBT	_	_	B-Claim
287	for	_	_	I-Claim
288	insomnia	_	_	I-Claim
289	may	_	_	I-Claim
290	be	_	_	I-Claim
291	both	_	_	I-Claim
292	clinically	_	_	I-Claim
293	effective	_	_	I-Claim
294	and	_	_	I-Claim
295	feasible	_	_	I-Claim
296	to	_	_	I-Claim
297	deliver	_	_	I-Claim
298	in	_	_	I-Claim
299	real	_	_	I-Claim
300	world	_	_	I-Claim
301	practice	_	_	I-Claim
302	.	_	_	I-Claim


0	In	_	_	O
1	an	_	_	O
2	international	_	_	O
3	,	_	_	O
4	randomized	_	_	O
5	phase	_	_	O
6	III	_	_	O
7	trial	_	_	O
8	,	_	_	O
9	sunitinib	_	_	O
10	demonstrated	_	_	O
11	statistically	_	_	O
12	significant	_	_	O
13	efficacy	_	_	O
14	over	_	_	O
15	interferon	_	_	O
16	alfa	_	_	O
17	(	_	_	O
18	IFN-alpha	_	_	O
19	)	_	_	O
20	as	_	_	O
21	first-line	_	_	O
22	therapy	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	metastatic	_	_	O
27	renal	_	_	O
28	cell	_	_	O
29	carcinoma	_	_	O
30	(	_	_	O
31	mRCC	_	_	O
32	)	_	_	O
33	(	_	_	O
34	progression-free	_	_	O
35	survival	_	_	O
36	time	_	_	O
37	,	_	_	O
38	11	_	_	O
39	v	_	_	O
40	5	_	_	O
41	months	_	_	O
42	,	_	_	O
43	respectively	_	_	O
44	;	_	_	O
45	P	_	_	O
46	<	_	_	O
47	.001	_	_	O
48	;	_	_	O
49	objective	_	_	O
50	response	_	_	O
51	rate	_	_	O
52	,	_	_	O
53	31	_	_	O
54	%	_	_	O
55	v	_	_	O
56	6	_	_	O
57	%	_	_	O
58	,	_	_	O
59	respectively	_	_	O
60	;	_	_	O
61	P	_	_	O
62	<	_	_	O
63	.001	_	_	O
64	)	_	_	O
65	.	_	_	O

66	We	_	_	O
67	report	_	_	O
68	health-related	_	_	O
69	quality-of-life	_	_	O
70	(	_	_	O
71	QOL	_	_	O
72	)	_	_	O
73	results	_	_	O
74	from	_	_	O
75	this	_	_	O
76	trial	_	_	O
77	.	_	_	O

78	Seven	_	_	O
79	hundred	_	_	O
80	fifty	_	_	O
81	mRCC	_	_	O
82	patients	_	_	O
83	were	_	_	O
84	randomly	_	_	O
85	assigned	_	_	O
86	to	_	_	O
87	sunitinib	_	_	O
88	(	_	_	O
89	6-week	_	_	O
90	cycles	_	_	O
91	:	_	_	O
92	50	_	_	O
93	mg	_	_	O
94	orally	_	_	O
95	once	_	_	O
96	daily	_	_	O
97	for	_	_	O
98	4	_	_	O
99	weeks	_	_	O
100	,	_	_	O
101	followed	_	_	O
102	by	_	_	O
103	2	_	_	O
104	weeks	_	_	O
105	off	_	_	O
106	)	_	_	O
107	or	_	_	O
108	IFN-alpha	_	_	O
109	(	_	_	O
110	9	_	_	O
111	million	_	_	O
112	units	_	_	O
113	subcutaneous	_	_	O
114	injections	_	_	O
115	,	_	_	O
116	three	_	_	O
117	times	_	_	O
118	weekly	_	_	O
119	)	_	_	O
120	.	_	_	O

121	QOL	_	_	O
122	measures	_	_	O
123	included	_	_	O
124	the	_	_	O
125	Functional	_	_	O
126	Assessment	_	_	O
127	of	_	_	O
128	Cancer	_	_	O
129	Therapy-General	_	_	O
130	(	_	_	O
131	FACT-G	_	_	O
132	)	_	_	O
133	,	_	_	O
134	the	_	_	O
135	FACT-Kidney	_	_	O
136	Symptom	_	_	O
137	Index-15	_	_	O
138	item	_	_	O
139	(	_	_	O
140	FKSI-15	_	_	O
141	)	_	_	O
142	,	_	_	O
143	and	_	_	O
144	the	_	_	O
145	EuroQoL-5D	_	_	O
146	's	_	_	O
147	utility	_	_	O
148	score	_	_	O
149	(	_	_	O
150	EQ-5D	_	_	O
151	Index	_	_	O
152	)	_	_	O
153	and	_	_	O
154	its	_	_	O
155	visual	_	_	O
156	analog	_	_	O
157	scale	_	_	O
158	(	_	_	O
159	EQ-VAS	_	_	O
160	)	_	_	O
161	.	_	_	O

162	The	_	_	O
163	primary	_	_	O
164	QOL	_	_	O
165	end	_	_	O
166	point	_	_	O
167	was	_	_	O
168	the	_	_	O
169	FKSI	_	_	O
170	Disease-Related	_	_	O
171	Symptoms	_	_	O
172	(	_	_	O
173	FKSI-DRS	_	_	O
174	)	_	_	O
175	subscale	_	_	O
176	.	_	_	O

177	Higher	_	_	O
178	scores	_	_	O
179	indicated	_	_	O
180	better	_	_	O
181	outcomes	_	_	O
182	(	_	_	O
183	better	_	_	O
184	QOL	_	_	O
185	or	_	_	O
186	fewer	_	_	O
187	symptoms	_	_	O
188	)	_	_	O
189	.	_	_	O

190	Data	_	_	O
191	were	_	_	O
192	analyzed	_	_	O
193	for	_	_	O
194	the	_	_	O
195	intent-to-treat	_	_	O
196	population	_	_	O
197	using	_	_	O
198	mixed-effects	_	_	O
199	models	_	_	O
200	,	_	_	O
201	supplemented	_	_	O
202	with	_	_	O
203	pattern-mixture	_	_	O
204	models	_	_	O
205	.	_	_	O

206	Patients	_	_	B-Premise
207	receiving	_	_	I-Premise
208	sunitinib	_	_	I-Premise
209	reported	_	_	I-Premise
210	higher	_	_	I-Premise
211	FKSI-15	_	_	I-Premise
212	and	_	_	I-Premise
213	FKSI-DRS	_	_	I-Premise
214	scores	_	_	I-Premise
215	at	_	_	I-Premise
216	each	_	_	I-Premise
217	cycle	_	_	I-Premise
218	than	_	_	I-Premise
219	those	_	_	I-Premise
220	receiving	_	_	I-Premise
221	IFN-alpha	_	_	I-Premise
222	,	_	_	I-Premise
223	with	_	_	I-Premise
224	a	_	_	I-Premise
225	significant	_	_	I-Premise
226	difference	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	overall	_	_	I-Premise
230	least	_	_	I-Premise
231	squares	_	_	I-Premise
232	means	_	_	I-Premise
233	(	_	_	I-Premise
234	3.27	_	_	I-Premise
235	and	_	_	I-Premise
236	1.98	_	_	I-Premise
237	,	_	_	I-Premise
238	respectively	_	_	I-Premise
239	;	_	_	I-Premise
240	P	_	_	I-Premise
241	<	_	_	I-Premise
242	.0001	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	Similarly	_	_	O
246	,	_	_	O
247	differences	_	_	B-Premise
248	in	_	_	I-Premise
249	least	_	_	I-Premise
250	squares	_	_	I-Premise
251	means	_	_	I-Premise
252	for	_	_	I-Premise
253	FACT-G	_	_	I-Premise
254	(	_	_	I-Premise
255	and	_	_	I-Premise
256	all	_	_	I-Premise
257	subscales	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	EQ-5D	_	_	I-Premise
261	Index	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	EQ-VAS	_	_	I-Premise
265	were	_	_	I-Premise
266	all	_	_	I-Premise
267	significantly	_	_	I-Premise
268	favorable	_	_	I-Premise
269	for	_	_	I-Premise
270	sunitinib	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	<	_	_	I-Premise
274	.01	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	Per	_	_	O
278	pre-established	_	_	O
279	thresholds	_	_	O
280	,	_	_	O
281	between-treatment	_	_	O
282	differences	_	_	O
283	in	_	_	O
284	the	_	_	O
285	mean	_	_	O
286	scores	_	_	O
287	were	_	_	O
288	clinically	_	_	O
289	meaningful	_	_	O
290	after	_	_	O
291	cycle	_	_	O
292	4	_	_	O
293	for	_	_	O
294	FKSI-DRS	_	_	O
295	and	_	_	O
296	at	_	_	O
297	all	_	_	O
298	assessments	_	_	O
299	for	_	_	O
300	FKSI-15	_	_	O
301	,	_	_	O
302	FACT-G	_	_	O
303	,	_	_	O
304	and	_	_	O
305	the	_	_	O
306	FACT-G	_	_	O
307	functional	_	_	O
308	well-being	_	_	O
309	subscale	_	_	O
310	.	_	_	O

311	Sunitinib	_	_	B-Claim
312	provides	_	_	I-Claim
313	superior	_	_	I-Claim
314	QOL	_	_	I-Claim
315	compared	_	_	I-Claim
316	with	_	_	I-Claim
317	IFN-alpha	_	_	I-Claim
318	in	_	_	I-Claim
319	mRCC	_	_	I-Claim
320	patients	_	_	I-Claim
321	.	_	_	I-Claim


0	Anaemia	_	_	O
1	is	_	_	O
2	common	_	_	O
3	in	_	_	O
4	patients	_	_	O
5	receiving	_	_	O
6	chemotherapy	_	_	O
7	,	_	_	O
8	causing	_	_	O
9	symptoms	_	_	O
10	that	_	_	O
11	have	_	_	O
12	a	_	_	O
13	major	_	_	O
14	impact	_	_	O
15	on	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QoL	_	_	O
21	)	_	_	O
22	.	_	_	O

23	Epoetin	_	_	O
24	beta	_	_	O
25	rapidly	_	_	O
26	increases	_	_	O
27	haemoglobin	_	_	O
28	(	_	_	O
29	Hb	_	_	O
30	)	_	_	O
31	levels	_	_	O
32	and	_	_	O
33	improves	_	_	O
34	QoL	_	_	O
35	in	_	_	O
36	anaemic	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	a	_	_	O
40	variety	_	_	O
41	of	_	_	O
42	tumours	_	_	O
43	.	_	_	O

44	This	_	_	O
45	was	_	_	O
46	a	_	_	O
47	randomized	_	_	O
48	,	_	_	O
49	double-blind	_	_	O
50	,	_	_	O
51	parallel-group	_	_	O
52	,	_	_	O
53	dose-finding	_	_	O
54	study	_	_	O
55	assessing	_	_	O
56	the	_	_	O
57	efficacy	_	_	O
58	and	_	_	O
59	safety	_	_	O
60	of	_	_	O
61	once-weekly	_	_	O
62	epoetin	_	_	O
63	beta	_	_	O
64	in	_	_	O
65	patients	_	_	O
66	with	_	_	O
67	solid	_	_	O
68	tumours	_	_	O
69	receiving	_	_	O
70	chemotherapy	_	_	O
71	.	_	_	O

72	Adult	_	_	O
73	patients	_	_	O
74	with	_	_	O
75	anaemia	_	_	O
76	(	_	_	O
77	Hb	_	_	O
78	<	_	_	O
79	11	_	_	O
80	g/dL	_	_	O
81	)	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	epoetin	_	_	O
87	beta	_	_	O
88	30,000	_	_	O
89	IU	_	_	O
90	or	_	_	O
91	20,000	_	_	O
92	IU	_	_	O
93	once	_	_	O
94	weekly	_	_	O
95	for	_	_	O
96	12	_	_	O
97	weeks	_	_	O
98	.	_	_	O

99	All	_	_	O
100	patients	_	_	O
101	received	_	_	O
102	oral	_	_	O
103	iron	_	_	O
104	supplementation	_	_	O
105	.	_	_	O

106	Haemoglobin	_	_	O
107	levels	_	_	O
108	,	_	_	O
109	transfusion	_	_	O
110	need	_	_	O
111	and	_	_	O
112	QoL	_	_	O
113	[	_	_	O
114	Functional	_	_	O
115	Assessment	_	_	O
116	of	_	_	O
117	Cancer	_	_	O
118	Therapy-fatigue	_	_	O
119	(	_	_	O
120	FACT-F	_	_	O
121	)	_	_	O
122	subscale	_	_	O
123	score	_	_	O
124	]	_	_	O
125	were	_	_	O
126	assessed	_	_	O
127	at	_	_	O
128	regular	_	_	O
129	intervals	_	_	O
130	.	_	_	O

131	Fifty	_	_	O
132	patients	_	_	O
133	were	_	_	O
134	randomized	_	_	O
135	;	_	_	O
136	30	_	_	O
137	patients	_	_	O
138	received	_	_	O
139	epoetin	_	_	O
140	beta	_	_	O
141	30,000	_	_	O
142	IU	_	_	O
143	once	_	_	O
144	weekly	_	_	O
145	and	_	_	O
146	20	_	_	O
147	received	_	_	O
148	20,000	_	_	O
149	IU	_	_	O
150	once	_	_	O
151	weekly	_	_	O
152	.	_	_	O

153	Mean	_	_	B-Premise
154	(	_	_	I-Premise
155	+/-	_	_	I-Premise
156	SD	_	_	I-Premise
157	)	_	_	I-Premise
158	increase	_	_	I-Premise
159	in	_	_	I-Premise
160	Hb	_	_	I-Premise
161	from	_	_	I-Premise
162	baseline	_	_	I-Premise
163	to	_	_	I-Premise
164	week	_	_	I-Premise
165	12	_	_	I-Premise
166	was	_	_	I-Premise
167	1.75	_	_	I-Premise
168	+/-	_	_	I-Premise
169	2.15	_	_	I-Premise
170	g/dL	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	30,000	_	_	I-Premise
174	IU	_	_	I-Premise
175	group	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	=	_	_	I-Premise
179	0.008	_	_	I-Premise
180	vs.	_	_	I-Premise
181	baseline	_	_	I-Premise
182	)	_	_	I-Premise
183	and	_	_	I-Premise
184	1.04	_	_	I-Premise
185	+/-	_	_	I-Premise
186	1.75	_	_	I-Premise
187	g/dL	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	20,000	_	_	I-Premise
191	IU	_	_	I-Premise
192	group	_	_	I-Premise
193	(	_	_	I-Premise
194	non-significant	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	Haemoglobin	_	_	B-Premise
198	response	_	_	I-Premise
199	(	_	_	I-Premise
200	increase	_	_	I-Premise
201	in	_	_	I-Premise
202	Hb	_	_	I-Premise
203	>	_	_	I-Premise
204	or=2	_	_	I-Premise
205	g/dL	_	_	I-Premise
206	from	_	_	I-Premise
207	baseline	_	_	I-Premise
208	)	_	_	I-Premise
209	was	_	_	I-Premise
210	observed	_	_	I-Premise
211	in	_	_	I-Premise
212	78.3	_	_	I-Premise
213	%	_	_	I-Premise
214	of	_	_	I-Premise
215	patients	_	_	I-Premise
216	receiving	_	_	I-Premise
217	epoetin	_	_	I-Premise
218	beta	_	_	I-Premise
219	30,000	_	_	I-Premise
220	IU	_	_	I-Premise
221	and	_	_	I-Premise
222	66.7	_	_	I-Premise
223	%	_	_	I-Premise
224	receiving	_	_	I-Premise
225	epoetin	_	_	I-Premise
226	beta	_	_	I-Premise
227	20,000	_	_	I-Premise
228	IU	_	_	I-Premise
229	.	_	_	I-Premise

230	Improvements	_	_	O
231	in	_	_	O
232	FACT-F	_	_	O
233	subscale	_	_	O
234	score	_	_	O
235	were	_	_	O
236	significantly	_	_	O
237	(	_	_	O
238	P	_	_	O
239	<	_	_	O
240	0.001	_	_	O
241	)	_	_	O
242	correlated	_	_	O
243	with	_	_	O
244	increases	_	_	O
245	in	_	_	O
246	Hb	_	_	O
247	level	_	_	O
248	.	_	_	O

249	Transfusion	_	_	O
250	use	_	_	O
251	was	_	_	O
252	low	_	_	O
253	during	_	_	O
254	the	_	_	O
255	study	_	_	O
256	in	_	_	O
257	both	_	_	O
258	groups	_	_	O
259	.	_	_	O

260	Both	_	_	B-Premise
261	epoetin	_	_	I-Premise
262	beta	_	_	I-Premise
263	regiments	_	_	I-Premise
264	were	_	_	I-Premise
265	well	_	_	I-Premise
266	tolerated	_	_	I-Premise
267	and	_	_	I-Premise
268	there	_	_	I-Premise
269	were	_	_	I-Premise
270	no	_	_	I-Premise
271	dose-dependent	_	_	I-Premise
272	adverse	_	_	I-Premise
273	events	_	_	I-Premise
274	.	_	_	I-Premise

275	Epoetin	_	_	B-Claim
276	beta	_	_	I-Claim
277	30,000	_	_	I-Claim
278	IU	_	_	I-Claim
279	once	_	_	I-Claim
280	weekly	_	_	I-Claim
281	is	_	_	I-Claim
282	an	_	_	I-Claim
283	effective	_	_	I-Claim
284	and	_	_	I-Claim
285	well-tolerated	_	_	I-Claim
286	treatment	_	_	I-Claim
287	of	_	_	I-Claim
288	anaemia	_	_	I-Claim
289	in	_	_	I-Claim
290	patients	_	_	I-Claim
291	with	_	_	I-Claim
292	solid	_	_	I-Claim
293	tumours	_	_	I-Claim
294	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Alleviating	_	_	O
7	Depression	_	_	O
8	Among	_	_	O
9	Patients	_	_	O
10	With	_	_	O
11	Cancer	_	_	O
12	(	_	_	O
13	ADAPt-C	_	_	O
14	)	_	_	O
15	collaborative	_	_	O
16	care	_	_	O
17	management	_	_	O
18	for	_	_	O
19	major	_	_	O
20	depression	_	_	O
21	or	_	_	O
22	dysthymia	_	_	O
23	.	_	_	O

24	Study	_	_	O
25	patients	_	_	O
26	included	_	_	O
27	472	_	_	O
28	low-income	_	_	O
29	,	_	_	O
30	predominantly	_	_	O
31	female	_	_	O
32	Hispanic	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	cancer	_	_	O
36	age	_	_	O
37	>	_	_	O
38	or=	_	_	O
39	18	_	_	O
40	years	_	_	O
41	with	_	_	O
42	major	_	_	O
43	depression	_	_	O
44	(	_	_	O
45	49	_	_	O
46	%	_	_	O
47	)	_	_	O
48	,	_	_	O
49	dysthymia	_	_	O
50	(	_	_	O
51	5	_	_	O
52	%	_	_	O
53	)	_	_	O
54	,	_	_	O
55	or	_	_	O
56	both	_	_	O
57	(	_	_	O
58	46	_	_	O
59	%	_	_	O
60	)	_	_	O
61	.	_	_	O

62	Patients	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	to	_	_	O
67	intervention	_	_	O
68	(	_	_	O
69	n	_	_	O
70	=	_	_	O
71	242	_	_	O
72	)	_	_	O
73	or	_	_	O
74	enhanced	_	_	O
75	usual	_	_	O
76	care	_	_	O
77	(	_	_	O
78	EUC	_	_	O
79	;	_	_	O
80	n	_	_	O
81	=	_	_	O
82	230	_	_	O
83	)	_	_	O
84	.	_	_	O

85	Intervention	_	_	O
86	patients	_	_	O
87	had	_	_	O
88	access	_	_	O
89	for	_	_	O
90	up	_	_	O
91	to	_	_	O
92	12	_	_	O
93	months	_	_	O
94	to	_	_	O
95	a	_	_	O
96	depression	_	_	O
97	clinical	_	_	O
98	specialist	_	_	O
99	(	_	_	O
100	supervised	_	_	O
101	by	_	_	O
102	a	_	_	O
103	psychiatrist	_	_	O
104	)	_	_	O
105	who	_	_	O
106	offered	_	_	O
107	education	_	_	O
108	,	_	_	O
109	structured	_	_	O
110	psychotherapy	_	_	O
111	,	_	_	O
112	and	_	_	O
113	maintenance/relapse	_	_	O
114	prevention	_	_	O
115	support	_	_	O
116	.	_	_	O

117	The	_	_	O
118	psychiatrist	_	_	O
119	prescribed	_	_	O
120	antidepressant	_	_	O
121	medications	_	_	O
122	for	_	_	O
123	patients	_	_	O
124	preferring	_	_	O
125	or	_	_	O
126	assessed	_	_	O
127	to	_	_	O
128	require	_	_	O
129	medication	_	_	O
130	.	_	_	O

131	At	_	_	B-Premise
132	12	_	_	I-Premise
133	months	_	_	I-Premise
134	,	_	_	I-Premise
135	63	_	_	I-Premise
136	%	_	_	I-Premise
137	of	_	_	I-Premise
138	intervention	_	_	I-Premise
139	patients	_	_	I-Premise
140	had	_	_	I-Premise
141	a	_	_	I-Premise
142	50	_	_	I-Premise
143	%	_	_	I-Premise
144	or	_	_	I-Premise
145	greater	_	_	I-Premise
146	reduction	_	_	I-Premise
147	in	_	_	I-Premise
148	depressive	_	_	I-Premise
149	symptoms	_	_	I-Premise
150	from	_	_	I-Premise
151	baseline	_	_	I-Premise
152	as	_	_	I-Premise
153	assessed	_	_	I-Premise
154	by	_	_	I-Premise
155	the	_	_	I-Premise
156	Patient	_	_	I-Premise
157	Health	_	_	I-Premise
158	Questionnaire-9	_	_	I-Premise
159	(	_	_	I-Premise
160	PHQ-9	_	_	I-Premise
161	)	_	_	I-Premise
162	depression	_	_	I-Premise
163	scale	_	_	I-Premise
164	compared	_	_	I-Premise
165	with	_	_	I-Premise
166	50	_	_	I-Premise
167	%	_	_	I-Premise
168	of	_	_	I-Premise
169	EUC	_	_	I-Premise
170	patients	_	_	I-Premise
171	(	_	_	I-Premise
172	odds	_	_	I-Premise
173	ratio	_	_	I-Premise
174	[	_	_	I-Premise
175	OR	_	_	I-Premise
176	]	_	_	I-Premise
177	=	_	_	I-Premise
178	1.98	_	_	I-Premise
179	;	_	_	I-Premise
180	95	_	_	I-Premise
181	%	_	_	I-Premise
182	CI	_	_	I-Premise
183	,	_	_	I-Premise
184	1.16	_	_	I-Premise
185	to	_	_	I-Premise
186	3.38	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	.01	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	Improvement	_	_	B-Premise
194	was	_	_	I-Premise
195	also	_	_	I-Premise
196	found	_	_	I-Premise
197	for	_	_	I-Premise
198	5-point	_	_	I-Premise
199	decrease	_	_	I-Premise
200	in	_	_	I-Premise
201	PHQ-9	_	_	I-Premise
202	score	_	_	I-Premise
203	among	_	_	I-Premise
204	72.2	_	_	I-Premise
205	%	_	_	I-Premise
206	of	_	_	I-Premise
207	intervention	_	_	I-Premise
208	patients	_	_	I-Premise
209	compared	_	_	I-Premise
210	with	_	_	I-Premise
211	59.7	_	_	I-Premise
212	%	_	_	I-Premise
213	of	_	_	I-Premise
214	EUC	_	_	I-Premise
215	patients	_	_	I-Premise
216	(	_	_	I-Premise
217	OR	_	_	I-Premise
218	=	_	_	I-Premise
219	1.99	_	_	I-Premise
220	;	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	CI	_	_	I-Premise
224	,	_	_	I-Premise
225	1.14	_	_	I-Premise
226	to	_	_	I-Premise
227	3.50	_	_	I-Premise
228	;	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	.02	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	Intervention	_	_	B-Premise
235	patients	_	_	I-Premise
236	also	_	_	I-Premise
237	experienced	_	_	I-Premise
238	greater	_	_	I-Premise
239	rates	_	_	I-Premise
240	of	_	_	I-Premise
241	depression	_	_	I-Premise
242	treatment	_	_	I-Premise
243	(	_	_	I-Premise
244	72.3	_	_	I-Premise
245	%	_	_	I-Premise
246	v	_	_	I-Premise
247	10.4	_	_	I-Premise
248	%	_	_	I-Premise
249	of	_	_	I-Premise
250	EUC	_	_	I-Premise
251	patients	_	_	I-Premise
252	;	_	_	I-Premise
253	P	_	_	I-Premise
254	<	_	_	I-Premise
255	.0001	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	significantly	_	_	I-Premise
259	better	_	_	I-Premise
260	quality-of-life	_	_	I-Premise
261	outcomes	_	_	I-Premise
262	,	_	_	I-Premise
263	including	_	_	I-Premise
264	social/family	_	_	I-Premise
265	(	_	_	I-Premise
266	adjusted	_	_	I-Premise
267	mean	_	_	I-Premise
268	difference	_	_	I-Premise
269	between	_	_	I-Premise
270	groups	_	_	I-Premise
271	,	_	_	I-Premise
272	2.7	_	_	I-Premise
273	;	_	_	I-Premise
274	95	_	_	I-Premise
275	%	_	_	I-Premise
276	CI	_	_	I-Premise
277	,	_	_	I-Premise
278	1.22	_	_	I-Premise
279	to	_	_	I-Premise
280	4.17	_	_	I-Premise
281	;	_	_	I-Premise
282	P	_	_	I-Premise
283	<	_	_	I-Premise
284	.001	_	_	I-Premise
285	)	_	_	I-Premise
286	,	_	_	I-Premise
287	emotional	_	_	I-Premise
288	(	_	_	I-Premise
289	adjusted	_	_	I-Premise
290	mean	_	_	I-Premise
291	difference	_	_	I-Premise
292	,	_	_	I-Premise
293	1.29	_	_	I-Premise
294	;	_	_	I-Premise
295	95	_	_	I-Premise
296	%	_	_	I-Premise
297	CI	_	_	I-Premise
298	,	_	_	I-Premise
299	0.26	_	_	I-Premise
300	to	_	_	I-Premise
301	2.22	_	_	I-Premise
302	;	_	_	I-Premise
303	P	_	_	I-Premise
304	=	_	_	I-Premise
305	.01	_	_	I-Premise
306	)	_	_	I-Premise
307	,	_	_	I-Premise
308	functional	_	_	I-Premise
309	(	_	_	I-Premise
310	adjusted	_	_	I-Premise
311	mean	_	_	I-Premise
312	difference	_	_	I-Premise
313	,	_	_	I-Premise
314	1.34	_	_	I-Premise
315	;	_	_	I-Premise
316	95	_	_	I-Premise
317	%	_	_	I-Premise
318	CI	_	_	I-Premise
319	,	_	_	I-Premise
320	0.08	_	_	I-Premise
321	to	_	_	I-Premise
322	2.59	_	_	I-Premise
323	;	_	_	I-Premise
324	P	_	_	I-Premise
325	=	_	_	I-Premise
326	.04	_	_	I-Premise
327	)	_	_	I-Premise
328	,	_	_	I-Premise
329	and	_	_	I-Premise
330	physical	_	_	I-Premise
331	well-being	_	_	I-Premise
332	(	_	_	I-Premise
333	adjusted	_	_	I-Premise
334	mean	_	_	I-Premise
335	difference	_	_	I-Premise
336	,	_	_	I-Premise
337	2.79	_	_	I-Premise
338	;	_	_	I-Premise
339	95	_	_	I-Premise
340	%	_	_	I-Premise
341	CI	_	_	I-Premise
342	,	_	_	I-Premise
343	0.49	_	_	I-Premise
344	to	_	_	I-Premise
345	5.1	_	_	I-Premise
346	;	_	_	I-Premise
347	P	_	_	I-Premise
348	=	_	_	I-Premise
349	.02	_	_	I-Premise
350	)	_	_	I-Premise
351	.	_	_	I-Premise

352	ADAPt-C	_	_	B-Claim
353	collaborative	_	_	I-Claim
354	care	_	_	I-Claim
355	is	_	_	I-Claim
356	feasible	_	_	I-Claim
357	and	_	_	I-Claim
358	results	_	_	I-Claim
359	in	_	_	I-Claim
360	significant	_	_	I-Claim
361	reduction	_	_	I-Claim
362	in	_	_	I-Claim
363	depressive	_	_	I-Claim
364	symptoms	_	_	I-Claim
365	,	_	_	I-Claim
366	improvement	_	_	I-Claim
367	in	_	_	I-Claim
368	quality	_	_	I-Claim
369	of	_	_	I-Claim
370	life	_	_	I-Claim
371	,	_	_	I-Claim
372	and	_	_	I-Claim
373	lower	_	_	I-Claim
374	pain	_	_	I-Claim
375	levels	_	_	I-Claim
376	compared	_	_	I-Claim
377	with	_	_	I-Claim
378	EUC	_	_	I-Claim
379	for	_	_	I-Claim
380	patients	_	_	I-Claim
381	with	_	_	I-Claim
382	depressive	_	_	I-Claim
383	disorders	_	_	I-Claim
384	in	_	_	I-Claim
385	a	_	_	I-Claim
386	low-income	_	_	I-Claim
387	,	_	_	I-Claim
388	predominantly	_	_	I-Claim
389	Hispanic	_	_	I-Claim
390	population	_	_	I-Claim
391	in	_	_	I-Claim
392	public	_	_	I-Claim
393	sector	_	_	I-Claim
394	oncology	_	_	I-Claim
395	clinics	_	_	I-Claim
396	.	_	_	I-Claim


0	Recombinant	_	_	O
1	human	_	_	O
2	TSH	_	_	O
3	(	_	_	O
4	rhTSH	_	_	O
5	)	_	_	O
6	has	_	_	O
7	become	_	_	O
8	the	_	_	O
9	modality	_	_	O
10	of	_	_	O
11	choice	_	_	O
12	for	_	_	O
13	radioiodine	_	_	O
14	remnant	_	_	O
15	ablation	_	_	O
16	(	_	_	O
17	RRA	_	_	O
18	)	_	_	O
19	in	_	_	O
20	low-risk	_	_	O
21	thyroid	_	_	O
22	cancer	_	_	O
23	patients	_	_	O
24	.	_	_	O

25	The	_	_	O
26	aims	_	_	O
27	of	_	_	O
28	the	_	_	O
29	present	_	_	O
30	prospective	_	_	O
31	randomized	_	_	O
32	study	_	_	O
33	were	_	_	O
34	to	_	_	O
35	evaluate	_	_	O
36	the	_	_	O
37	impact	_	_	O
38	of	_	_	O
39	TSH	_	_	O
40	stimulation	_	_	O
41	procedure	_	_	O
42	(	_	_	O
43	hypothyroidism	_	_	O
44	vs.	_	_	O
45	rhTSH	_	_	O
46	)	_	_	O
47	on	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	(	_	_	O
52	QoL	_	_	O
53	)	_	_	O
54	of	_	_	O
55	thyroid	_	_	O
56	cancer	_	_	O
57	patients	_	_	O
58	undergoing	_	_	O
59	RRA	_	_	O
60	and	_	_	O
61	to	_	_	O
62	evaluate	_	_	O
63	efficacy	_	_	O
64	of	_	_	O
65	both	_	_	O
66	procedures	_	_	O
67	.	_	_	O

68	L-T4	_	_	O
69	was	_	_	O
70	initiated	_	_	O
71	in	_	_	O
72	both	_	_	O
73	groups	_	_	O
74	after	_	_	O
75	thyroidectomy	_	_	O
76	.	_	_	O

77	After	_	_	O
78	randomization	_	_	O
79	,	_	_	O
80	L-T4	_	_	O
81	was	_	_	O
82	discontinued	_	_	O
83	in	_	_	O
84	hypothyroid	_	_	O
85	(	_	_	O
86	hypo	_	_	O
87	)	_	_	O
88	group	_	_	O
89	and	_	_	O
90	continued	_	_	O
91	in	_	_	O
92	rhTSH	_	_	O
93	group	_	_	O
94	.	_	_	O

95	A	_	_	O
96	measure	_	_	O
97	of	_	_	O
98	3.7	_	_	O
99	GBq	_	_	O
100	of	_	_	O
101	radioiodine	_	_	O
102	was	_	_	O
103	given	_	_	O
104	to	_	_	O
105	both	_	_	O
106	groups	_	_	O
107	.	_	_	O

108	The	_	_	O
109	functional	_	_	O
110	assessment	_	_	O
111	of	_	_	O
112	chronic	_	_	O
113	illness	_	_	O
114	therapy-fatigue	_	_	O
115	(	_	_	O
116	FACIT-F	_	_	O
117	)	_	_	O
118	was	_	_	O
119	administered	_	_	O
120	from	_	_	O
121	the	_	_	O
122	early	_	_	O
123	postoperative	_	_	O
124	period	_	_	O
125	to	_	_	O
126	9	_	_	O
127	months	_	_	O
128	.	_	_	O

129	Socio-demographic	_	_	O
130	parameters	_	_	O
131	,	_	_	O
132	anxiety	_	_	O
133	and	_	_	O
134	depression	_	_	O
135	scales	_	_	O
136	were	_	_	O
137	also	_	_	O
138	evaluated	_	_	O
139	(	_	_	O
140	CES-D	_	_	O
141	,	_	_	O
142	BDI	_	_	O
143	and	_	_	O
144	Spielberger	_	_	O
145	state-trait	_	_	O
146	questionnaires	_	_	O
147	)	_	_	O
148	.	_	_	O

149	At	_	_	O
150	9	_	_	O
151	months	_	_	O
152	,	_	_	O
153	patients	_	_	O
154	underwent	_	_	O
155	an	_	_	O
156	rhTSH	_	_	O
157	stimulation	_	_	O
158	test	_	_	O
159	,	_	_	O
160	diagnostic	_	_	O
161	(	_	_	O
162	131	_	_	O
163	)	_	_	O
164	I	_	_	O
165	whole	_	_	O
166	body	_	_	O
167	scan	_	_	O
168	(	_	_	O
169	dxWBS	_	_	O
170	)	_	_	O
171	and	_	_	O
172	neck	_	_	O
173	ultrasonography	_	_	O
174	.	_	_	O

175	A	_	_	O
176	total	_	_	O
177	of	_	_	O
178	74	_	_	O
179	patients	_	_	O
180	were	_	_	O
181	enrolled	_	_	O
182	for	_	_	O
183	the	_	_	O
184	study	_	_	O
185	.	_	_	O

186	There	_	_	B-Premise
187	was	_	_	I-Premise
188	a	_	_	I-Premise
189	significant	_	_	I-Premise
190	decrease	_	_	I-Premise
191	in	_	_	I-Premise
192	QoL	_	_	I-Premise
193	from	_	_	I-Premise
194	baseline	_	_	I-Premise
195	(	_	_	I-Premise
196	t0	_	_	I-Premise
197	)	_	_	I-Premise
198	to	_	_	I-Premise
199	t1	_	_	I-Premise
200	(	_	_	I-Premise
201	RRA	_	_	I-Premise
202	period	_	_	I-Premise
203	)	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	hypothyroid	_	_	I-Premise
207	group	_	_	I-Premise
208	with	_	_	I-Premise
209	significant	_	_	I-Premise
210	differences	_	_	I-Premise
211	in	_	_	I-Premise
212	FACIT-F	_	_	I-Premise
213	TOI	_	_	I-Premise
214	(	_	_	I-Premise
215	P	_	_	I-Premise
216	<	_	_	I-Premise
217	10	_	_	I-Premise
218	(	_	_	I-Premise
219	-3	_	_	I-Premise
220	)	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	FACT-G	_	_	I-Premise
224	total	_	_	I-Premise
225	score	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.005	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	FACIT-F	_	_	I-Premise
233	total	_	_	I-Premise
234	score	_	_	I-Premise
235	(	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	0.003	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	By	_	_	B-Premise
242	contrast	_	_	I-Premise
243	,	_	_	I-Premise
244	QoL	_	_	I-Premise
245	was	_	_	I-Premise
246	preserved	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	rhTSH	_	_	I-Premise
250	group	_	_	I-Premise
251	.	_	_	I-Premise

252	In	_	_	O
253	the	_	_	O
254	multivariate	_	_	O
255	analysis	_	_	O
256	,	_	_	O
257	FACIT-TOI	_	_	O
258	changes	_	_	O
259	were	_	_	O
260	only	_	_	O
261	affected	_	_	O
262	by	_	_	O
263	the	_	_	O
264	modality	_	_	O
265	of	_	_	O
266	TSH	_	_	O
267	stimulation	_	_	O
268	performed	_	_	O
269	for	_	_	O
270	RRA	_	_	O
271	.	_	_	O

272	From	_	_	B-Premise
273	3	_	_	I-Premise
274	to	_	_	I-Premise
275	9	_	_	I-Premise
276	months	_	_	I-Premise
277	,	_	_	I-Premise
278	changes	_	_	I-Premise
279	of	_	_	I-Premise
280	QoL	_	_	I-Premise
281	scales	_	_	I-Premise
282	and	_	_	I-Premise
283	subscales	_	_	I-Premise
284	were	_	_	I-Premise
285	no	_	_	I-Premise
286	longer	_	_	I-Premise
287	statistically	_	_	I-Premise
288	different	_	_	I-Premise
289	in	_	_	I-Premise
290	both	_	_	I-Premise
291	groups	_	_	I-Premise
292	of	_	_	I-Premise
293	patients	_	_	I-Premise
294	.	_	_	I-Premise

295	Based	_	_	B-Premise
296	on	_	_	I-Premise
297	serum	_	_	I-Premise
298	rhTSH-stimulated	_	_	I-Premise
299	Tg	_	_	I-Premise
300	alone	_	_	I-Premise
301	(	_	_	I-Premise
302	Tg	_	_	I-Premise
303	<	_	_	I-Premise
304	0.8	_	_	I-Premise
305	microg/l	_	_	I-Premise
306	,	_	_	I-Premise
307	BRAHMS	_	_	I-Premise
308	Tg	_	_	I-Premise
309	Kryptor	_	_	I-Premise
310	)	_	_	I-Premise
311	,	_	_	I-Premise
312	no	_	_	I-Premise
313	difference	_	_	I-Premise
314	in	_	_	I-Premise
315	ablation	_	_	I-Premise
316	success	_	_	I-Premise
317	was	_	_	I-Premise
318	observed	_	_	I-Premise
319	between	_	_	I-Premise
320	rhTSH	_	_	I-Premise
321	and	_	_	I-Premise
322	hypothyroidism	_	_	I-Premise
323	groups	_	_	I-Premise
324	,	_	_	I-Premise
325	91.7	_	_	I-Premise
326	%	_	_	I-Premise
327	and	_	_	I-Premise
328	97.1	_	_	I-Premise
329	%	_	_	I-Premise
330	,	_	_	I-Premise
331	respectively	_	_	I-Premise
332	.	_	_	I-Premise

333	A	_	_	B-Premise
334	higher	_	_	I-Premise
335	rate	_	_	I-Premise
336	of	_	_	I-Premise
337	persistent	_	_	I-Premise
338	thyroid	_	_	I-Premise
339	remnants	_	_	I-Premise
340	was	_	_	I-Premise
341	observed	_	_	I-Premise
342	in	_	_	I-Premise
343	the	_	_	I-Premise
344	rhTSH	_	_	I-Premise
345	arm	_	_	I-Premise
346	,	_	_	I-Premise
347	although	_	_	B-Premise
348	in	_	_	I-Premise
349	most	_	_	I-Premise
350	cases	_	_	I-Premise
351	uptake	_	_	I-Premise
352	was	_	_	I-Premise
353	<	_	_	I-Premise
354	0.1	_	_	I-Premise
355	%	_	_	I-Premise
356	and	_	_	I-Premise
357	of	_	_	I-Premise
358	no	_	_	I-Premise
359	clinical	_	_	I-Premise
360	significance	_	_	I-Premise
361	.	_	_	I-Premise

362	rhTSH	_	_	B-Claim
363	preserves	_	_	I-Claim
364	QoL	_	_	I-Claim
365	of	_	_	I-Claim
366	patients	_	_	I-Claim
367	undergoing	_	_	I-Claim
368	RRA	_	_	I-Claim
369	with	_	_	I-Claim
370	similar	_	_	I-Claim
371	rates	_	_	I-Claim
372	of	_	_	I-Claim
373	ablation	_	_	I-Claim
374	success	_	_	I-Claim
375	compared	_	_	I-Claim
376	to	_	_	I-Claim
377	hypothyrodism	_	_	I-Claim
378	.	_	_	I-Claim

379	However	_	_	O
380	,	_	_	O
381	there	_	_	O
382	is	_	_	O
383	a	_	_	O
384	wide	_	_	O
385	heterogeneity	_	_	O
386	in	_	_	O
387	the	_	_	O
388	clinical	_	_	O
389	impact	_	_	O
390	of	_	_	O
391	hypothyroidism	_	_	O
392	.	_	_	O


0	Hot	_	_	B-Claim
1	flashes	_	_	I-Claim
2	are	_	_	I-Claim
3	a	_	_	I-Claim
4	significant	_	_	I-Claim
5	problem	_	_	I-Claim
6	for	_	_	I-Claim
7	many	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	survivors	_	_	I-Claim
11	.	_	_	I-Claim

12	Hot	_	_	B-Claim
13	flashes	_	_	I-Claim
14	can	_	_	I-Claim
15	cause	_	_	I-Claim
16	discomfort	_	_	I-Claim
17	,	_	_	I-Claim
18	disrupted	_	_	I-Claim
19	sleep	_	_	I-Claim
20	,	_	_	I-Claim
21	anxiety	_	_	I-Claim
22	,	_	_	I-Claim
23	and	_	_	I-Claim
24	decreased	_	_	I-Claim
25	quality	_	_	I-Claim
26	of	_	_	I-Claim
27	life	_	_	I-Claim
28	.	_	_	I-Claim

29	A	_	_	O
30	well-tolerated	_	_	O
31	and	_	_	O
32	effective	_	_	O
33	mind-body	_	_	O
34	treatment	_	_	O
35	for	_	_	O
36	hot	_	_	O
37	flashes	_	_	O
38	would	_	_	O
39	be	_	_	O
40	of	_	_	O
41	great	_	_	O
42	value	_	_	O
43	.	_	_	O

44	On	_	_	O
45	the	_	_	O
46	basis	_	_	O
47	of	_	_	O
48	previous	_	_	O
49	case	_	_	O
50	studies	_	_	O
51	,	_	_	O
52	this	_	_	O
53	study	_	_	O
54	was	_	_	O
55	developed	_	_	O
56	to	_	_	O
57	evaluate	_	_	O
58	the	_	_	O
59	effect	_	_	O
60	of	_	_	O
61	a	_	_	O
62	hypnosis	_	_	O
63	intervention	_	_	O
64	for	_	_	O
65	hot	_	_	O
66	flashes	_	_	O
67	.	_	_	O

68	Sixty	_	_	O
69	female	_	_	O
70	breast	_	_	O
71	cancer	_	_	O
72	survivors	_	_	O
73	with	_	_	O
74	hot	_	_	O
75	flashes	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	hypnosis	_	_	O
82	intervention	_	_	O
83	(	_	_	O
84	five	_	_	O
85	weekly	_	_	O
86	sessions	_	_	O
87	)	_	_	O
88	or	_	_	O
89	no	_	_	O
90	treatment	_	_	O
91	.	_	_	O

92	Eligible	_	_	O
93	patients	_	_	O
94	had	_	_	O
95	to	_	_	O
96	have	_	_	O
97	a	_	_	O
98	history	_	_	O
99	of	_	_	O
100	primary	_	_	O
101	breast	_	_	O
102	cancer	_	_	O
103	without	_	_	O
104	evidence	_	_	O
105	of	_	_	O
106	detectable	_	_	O
107	disease	_	_	O
108	and	_	_	O
109	14	_	_	O
110	or	_	_	O
111	more	_	_	O
112	weekly	_	_	O
113	hot	_	_	O
114	flashes	_	_	O
115	for	_	_	O
116	at	_	_	O
117	least	_	_	O
118	1	_	_	O
119	month	_	_	O
120	.	_	_	O

121	The	_	_	O
122	major	_	_	O
123	outcome	_	_	O
124	measure	_	_	O
125	was	_	_	O
126	a	_	_	O
127	bivariate	_	_	O
128	construct	_	_	O
129	that	_	_	O
130	represented	_	_	O
131	hot	_	_	O
132	flash	_	_	O
133	frequency	_	_	O
134	and	_	_	O
135	hot	_	_	O
136	flash	_	_	O
137	score	_	_	O
138	,	_	_	O
139	which	_	_	O
140	was	_	_	O
141	analyzed	_	_	O
142	by	_	_	O
143	a	_	_	O
144	classic	_	_	O
145	sums	_	_	O
146	and	_	_	O
147	differences	_	_	O
148	comparison	_	_	O
149	.	_	_	O

150	Secondary	_	_	O
151	outcome	_	_	O
152	measures	_	_	O
153	were	_	_	O
154	self-reports	_	_	O
155	of	_	_	O
156	interference	_	_	O
157	of	_	_	O
158	hot	_	_	O
159	flashes	_	_	O
160	on	_	_	O
161	daily	_	_	O
162	activities	_	_	O
163	.	_	_	O

164	Fifty-one	_	_	O
165	randomly	_	_	O
166	assigned	_	_	O
167	women	_	_	O
168	completed	_	_	O
169	the	_	_	O
170	study	_	_	O
171	.	_	_	O

172	By	_	_	B-Premise
173	the	_	_	I-Premise
174	end	_	_	I-Premise
175	of	_	_	I-Premise
176	the	_	_	I-Premise
177	treatment	_	_	I-Premise
178	period	_	_	I-Premise
179	,	_	_	I-Premise
180	hot	_	_	I-Premise
181	flash	_	_	I-Premise
182	scores	_	_	I-Premise
183	(	_	_	I-Premise
184	frequency	_	_	I-Premise
185	x	_	_	I-Premise
186	average	_	_	I-Premise
187	severity	_	_	I-Premise
188	)	_	_	I-Premise
189	decreased	_	_	I-Premise
190	68	_	_	I-Premise
191	%	_	_	I-Premise
192	from	_	_	I-Premise
193	baseline	_	_	I-Premise
194	to	_	_	I-Premise
195	end	_	_	I-Premise
196	point	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	hypnosis	_	_	I-Premise
200	arm	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	.001	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Significant	_	_	B-Premise
208	improvements	_	_	I-Premise
209	in	_	_	I-Premise
210	self-reported	_	_	I-Premise
211	anxiety	_	_	I-Premise
212	,	_	_	I-Premise
213	depression	_	_	I-Premise
214	,	_	_	I-Premise
215	interference	_	_	I-Premise
216	of	_	_	I-Premise
217	hot	_	_	I-Premise
218	flashes	_	_	I-Premise
219	on	_	_	I-Premise
220	daily	_	_	I-Premise
221	activities	_	_	I-Premise
222	,	_	_	I-Premise
223	and	_	_	I-Premise
224	sleep	_	_	I-Premise
225	were	_	_	I-Premise
226	observed	_	_	I-Premise
227	for	_	_	I-Premise
228	patients	_	_	I-Premise
229	who	_	_	I-Premise
230	received	_	_	I-Premise
231	the	_	_	I-Premise
232	hypnosis	_	_	I-Premise
233	intervention	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	<	_	_	I-Premise
237	.005	_	_	I-Premise
238	)	_	_	I-Premise
239	in	_	_	I-Premise
240	comparison	_	_	I-Premise
241	to	_	_	I-Premise
242	the	_	_	I-Premise
243	no	_	_	I-Premise
244	treatment	_	_	I-Premise
245	control	_	_	I-Premise
246	group	_	_	I-Premise
247	.	_	_	I-Premise

248	Hypnosis	_	_	B-Claim
249	appears	_	_	I-Claim
250	to	_	_	I-Claim
251	reduce	_	_	I-Claim
252	perceived	_	_	I-Claim
253	hot	_	_	I-Claim
254	flashes	_	_	I-Claim
255	in	_	_	I-Claim
256	breast	_	_	I-Claim
257	cancer	_	_	I-Claim
258	survivors	_	_	I-Claim
259	and	_	_	I-Claim
260	may	_	_	I-Claim
261	have	_	_	I-Claim
262	additional	_	_	I-Claim
263	benefits	_	_	I-Claim
264	such	_	_	I-Claim
265	as	_	_	I-Claim
266	reduced	_	_	I-Claim
267	anxiety	_	_	I-Claim
268	and	_	_	I-Claim
269	depression	_	_	I-Claim
270	,	_	_	I-Claim
271	and	_	_	I-Claim
272	improved	_	_	I-Claim
273	sleep	_	_	I-Claim
274	.	_	_	I-Claim


0	Adjuvant	_	_	O
1	chemotherapy	_	_	O
2	for	_	_	O
3	early	_	_	O
4	stage	_	_	O
5	non-small-cell	_	_	O
6	lung	_	_	O
7	cancer	_	_	O
8	(	_	_	O
9	NSCLC	_	_	O
10	)	_	_	O
11	is	_	_	O
12	now	_	_	O
13	the	_	_	O
14	standard	_	_	O
15	of	_	_	O
16	care	_	_	O
17	,	_	_	O
18	but	_	_	O
19	there	_	_	O
20	is	_	_	O
21	little	_	_	O
22	information	_	_	O
23	regarding	_	_	O
24	its	_	_	O
25	impact	_	_	O
26	on	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	.	_	_	O

34	We	_	_	O
35	report	_	_	O
36	the	_	_	O
37	QOL	_	_	O
38	results	_	_	O
39	of	_	_	O
40	JBR.10	_	_	O
41	,	_	_	O
42	a	_	_	O
43	North	_	_	O
44	American	_	_	O
45	,	_	_	O
46	intergroup	_	_	O
47	,	_	_	O
48	randomized	_	_	O
49	trial	_	_	O
50	of	_	_	O
51	adjuvant	_	_	O
52	cisplatin	_	_	O
53	and	_	_	O
54	vinorelbine	_	_	O
55	compared	_	_	O
56	with	_	_	O
57	observation	_	_	O
58	in	_	_	O
59	patients	_	_	O
60	who	_	_	O
61	have	_	_	O
62	completely	_	_	O
63	resected	_	_	O
64	,	_	_	O
65	stages	_	_	O
66	IB	_	_	O
67	to	_	_	O
68	II	_	_	O
69	NSCLC	_	_	O
70	.	_	_	O

71	QOL	_	_	O
72	was	_	_	O
73	assessed	_	_	O
74	with	_	_	O
75	the	_	_	O
76	European	_	_	O
77	Organisation	_	_	O
78	for	_	_	O
79	Research	_	_	O
80	and	_	_	O
81	Treatment	_	_	O
82	of	_	_	O
83	Cancer	_	_	O
84	Quality	_	_	O
85	of	_	_	O
86	Life	_	_	O
87	Questionnaire	_	_	O
88	C30	_	_	O
89	and	_	_	O
90	a	_	_	O
91	trial-specific	_	_	O
92	checklist	_	_	O
93	at	_	_	O
94	baseline	_	_	O
95	and	_	_	O
96	at	_	_	O
97	weeks	_	_	O
98	5	_	_	O
99	and	_	_	O
100	9	_	_	O
101	for	_	_	O
102	those	_	_	O
103	who	_	_	O
104	received	_	_	O
105	chemotherapy	_	_	O
106	and	_	_	O
107	at	_	_	O
108	follow-up	_	_	O
109	months	_	_	O
110	3	_	_	O
111	,	_	_	O
112	6	_	_	O
113	,	_	_	O
114	9	_	_	O
115	,	_	_	O
116	12	_	_	O
117	,	_	_	O
118	18	_	_	O
119	,	_	_	O
120	24	_	_	O
121	,	_	_	O
122	30	_	_	O
123	and	_	_	O
124	36	_	_	O
125	.	_	_	O

126	A	_	_	O
127	10-point	_	_	O
128	change	_	_	O
129	in	_	_	O
130	QOL	_	_	O
131	scores	_	_	O
132	from	_	_	O
133	baseline	_	_	O
134	was	_	_	O
135	considered	_	_	O
136	clinically	_	_	O
137	significant	_	_	O
138	.	_	_	O

139	Four	_	_	O
140	hundred	_	_	O
141	eighty-two	_	_	O
142	patients	_	_	O
143	were	_	_	O
144	randomly	_	_	O
145	assigned	_	_	O
146	on	_	_	O
147	JBR.10	_	_	O
148	.	_	_	O

149	A	_	_	O
150	total	_	_	O
151	of	_	_	O
152	173	_	_	O
153	patients	_	_	O
154	(	_	_	O
155	82	_	_	O
156	%	_	_	O
157	of	_	_	O
158	the	_	_	O
159	expected	_	_	O
160	)	_	_	O
161	in	_	_	O
162	the	_	_	O
163	observation	_	_	O
164	arm	_	_	O
165	and	_	_	O
166	186	_	_	O
167	(	_	_	O
168	85	_	_	O
169	%	_	_	O
170	of	_	_	O
171	expected	_	_	O
172	)	_	_	O
173	in	_	_	O
174	the	_	_	O
175	chemotherapy	_	_	O
176	arm	_	_	O
177	completed	_	_	O
178	baseline	_	_	O
179	QOL	_	_	O
180	assessments	_	_	O
181	.	_	_	O

182	The	_	_	B-Premise
183	two	_	_	I-Premise
184	groups	_	_	I-Premise
185	were	_	_	I-Premise
186	comparable	_	_	I-Premise
187	,	_	_	I-Premise
188	with	_	_	I-Premise
189	low	_	_	I-Premise
190	global	_	_	I-Premise
191	QOL	_	_	I-Premise
192	scores	_	_	I-Premise
193	and	_	_	I-Premise
194	significant	_	_	I-Premise
195	symptom	_	_	I-Premise
196	burden	_	_	I-Premise
197	,	_	_	I-Premise
198	especially	_	_	I-Premise
199	pain	_	_	I-Premise
200	and	_	_	I-Premise
201	fatigue	_	_	I-Premise
202	,	_	_	I-Premise
203	after	_	_	I-Premise
204	thoracotomy	_	_	I-Premise
205	.	_	_	I-Premise

206	Changes	_	_	O
207	in	_	_	O
208	QOL	_	_	O
209	during	_	_	O
210	chemotherapy	_	_	O
211	were	_	_	O
212	relatively	_	_	O
213	modest	_	_	O
214	;	_	_	O
215	fatigue	_	_	B-Premise
216	,	_	_	I-Premise
217	nausea	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	vomiting	_	_	I-Premise
221	worsened	_	_	I-Premise
222	,	_	_	I-Premise
223	but	_	_	B-Premise
224	there	_	_	I-Premise
225	was	_	_	I-Premise
226	a	_	_	I-Premise
227	reduction	_	_	I-Premise
228	in	_	_	I-Premise
229	pain	_	_	I-Premise
230	and	_	_	I-Premise
231	no	_	_	I-Premise
232	change	_	_	I-Premise
233	in	_	_	I-Premise
234	global	_	_	I-Premise
235	QOL	_	_	I-Premise
236	.	_	_	I-Premise

237	Patients	_	_	B-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	observation	_	_	I-Premise
241	arm	_	_	I-Premise
242	showed	_	_	I-Premise
243	considerable	_	_	I-Premise
244	improvements	_	_	I-Premise
245	in	_	_	I-Premise
246	QOL	_	_	I-Premise
247	by	_	_	I-Premise
248	3	_	_	I-Premise
249	months	_	_	I-Premise
250	.	_	_	I-Premise

251	QOL	_	_	B-Premise
252	,	_	_	I-Premise
253	except	_	_	I-Premise
254	for	_	_	I-Premise
255	symptoms	_	_	I-Premise
256	of	_	_	I-Premise
257	sensory	_	_	I-Premise
258	neuropathy	_	_	I-Premise
259	and	_	_	I-Premise
260	hearing	_	_	I-Premise
261	loss	_	_	I-Premise
262	,	_	_	I-Premise
263	in	_	_	I-Premise
264	those	_	_	I-Premise
265	treated	_	_	I-Premise
266	with	_	_	I-Premise
267	chemotherapy	_	_	I-Premise
268	returned	_	_	I-Premise
269	to	_	_	I-Premise
270	baseline	_	_	I-Premise
271	by	_	_	I-Premise
272	9	_	_	I-Premise
273	months	_	_	I-Premise
274	.	_	_	I-Premise

275	The	_	_	B-Claim
276	findings	_	_	I-Claim
277	of	_	_	I-Claim
278	this	_	_	I-Claim
279	trial	_	_	I-Claim
280	indicate	_	_	I-Claim
281	that	_	_	I-Claim
282	the	_	_	I-Claim
283	negative	_	_	I-Claim
284	effects	_	_	I-Claim
285	of	_	_	I-Claim
286	adjuvant	_	_	I-Claim
287	chemotherapy	_	_	I-Claim
288	on	_	_	I-Claim
289	QOL	_	_	I-Claim
290	appear	_	_	I-Claim
291	to	_	_	I-Claim
292	be	_	_	I-Claim
293	temporary	_	_	I-Claim
294	,	_	_	I-Claim
295	and	_	_	I-Claim
296	that	_	_	I-Claim
297	improvements	_	_	I-Claim
298	(	_	_	I-Claim
299	with	_	_	I-Claim
300	a	_	_	I-Claim
301	return	_	_	I-Claim
302	to	_	_	I-Claim
303	baseline	_	_	I-Claim
304	function	_	_	I-Claim
305	)	_	_	I-Claim
306	are	_	_	I-Claim
307	likely	_	_	I-Claim
308	in	_	_	I-Claim
309	most	_	_	I-Claim
310	patients	_	_	I-Claim
311	.	_	_	I-Claim


0	Many	_	_	O
1	women	_	_	O
2	with	_	_	O
3	breast	_	_	O
4	cancer	_	_	O
5	need	_	_	O
6	psychological	_	_	O
7	help	_	_	O
8	to	_	_	O
9	cope	_	_	O
10	more	_	_	O
11	effectively	_	_	O
12	after	_	_	O
13	treatment	_	_	O
14	.	_	_	O

15	Cognitive	_	_	O
16	and	_	_	O
17	behavioural	_	_	O
18	techniques	_	_	O
19	are	_	_	O
20	not	_	_	O
21	yet	_	_	O
22	well	_	_	O
23	established	_	_	O
24	in	_	_	O
25	France	_	_	O
26	.	_	_	O

27	A	_	_	O
28	multi-site	_	_	O
29	randomized	_	_	O
30	study	_	_	O
31	was	_	_	O
32	conducted	_	_	O
33	to	_	_	O
34	evaluate	_	_	O
35	the	_	_	O
36	effects	_	_	O
37	of	_	_	O
38	a	_	_	O
39	psycho-educational	_	_	O
40	group	_	_	O
41	intervention	_	_	O
42	in	_	_	O
43	this	_	_	O
44	population	_	_	O
45	.	_	_	O

46	Two	_	_	O
47	hundred	_	_	O
48	and	_	_	O
49	three	_	_	O
50	patients	_	_	O
51	,	_	_	O
52	recruited	_	_	O
53	after	_	_	O
54	primary	_	_	O
55	treatment	_	_	O
56	,	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	assigned	_	_	O
60	either	_	_	O
61	to	_	_	O
62	a	_	_	O
63	treatment	_	_	O
64	group	_	_	O
65	(	_	_	O
66	psycho-educational	_	_	O
67	intervention	_	_	O
68	)	_	_	O
69	or	_	_	O
70	to	_	_	O
71	a	_	_	O
72	waiting-list	_	_	O
73	control	_	_	O
74	group	_	_	O
75	.	_	_	O

76	The	_	_	O
77	8-week	_	_	O
78	programme	_	_	O
79	of	_	_	O
80	2	_	_	O
81	h	_	_	O
82	sessions	_	_	O
83	comprised	_	_	O
84	of	_	_	O
85	thematic	_	_	O
86	discussions	_	_	O
87	,	_	_	O
88	information	_	_	O
89	and	_	_	O
90	training	_	_	O
91	in	_	_	O
92	stress	_	_	O
93	management	_	_	O
94	techniques	_	_	O
95	.	_	_	O

96	Evaluation	_	_	O
97	at	_	_	O
98	baseline	_	_	O
99	,	_	_	O
100	after	_	_	O
101	8	_	_	O
102	sessions	_	_	O
103	,	_	_	O
104	and	_	_	O
105	1	_	_	O
106	month	_	_	O
107	after	_	_	O
108	programme	_	_	O
109	completion	_	_	O
110	,	_	_	O
111	included	_	_	O
112	evaluations	_	_	O
113	using	_	_	O
114	the	_	_	O
115	STAI	_	_	O
116	,	_	_	O
117	POMS	_	_	O
118	,	_	_	O
119	MAC	_	_	O
120	,	_	_	O
121	EORTC	_	_	O
122	QLQ-C30	_	_	O
123	and	_	_	O
124	EORTC	_	_	O
125	QLQ-BR23	_	_	O
126	breast	_	_	O
127	module	_	_	O
128	scales	_	_	O
129	.	_	_	O

130	We	_	_	B-Premise
131	observed	_	_	I-Premise
132	a	_	_	I-Premise
133	significant	_	_	I-Premise
134	reduction	_	_	I-Premise
135	in	_	_	I-Premise
136	anxiety	_	_	I-Premise
137	(	_	_	I-Premise
138	STAI	_	_	I-Premise
139	,	_	_	I-Premise
140	POMS	_	_	I-Premise
141	)	_	_	I-Premise
142	among	_	_	I-Premise
143	group	_	_	I-Premise
144	participants	_	_	I-Premise
145	,	_	_	I-Premise
146	a	_	_	I-Premise
147	reduction	_	_	I-Premise
148	in	_	_	I-Premise
149	anger	_	_	I-Premise
150	,	_	_	I-Premise
151	depression	_	_	I-Premise
152	and	_	_	I-Premise
153	fatigue	_	_	I-Premise
154	(	_	_	I-Premise
155	POMS	_	_	I-Premise
156	)	_	_	I-Premise
157	,	_	_	I-Premise
158	a	_	_	I-Premise
159	significant	_	_	I-Premise
160	improvement	_	_	I-Premise
161	in	_	_	I-Premise
162	vigor	_	_	I-Premise
163	and	_	_	I-Premise
164	interpersonal	_	_	I-Premise
165	relationships	_	_	I-Premise
166	(	_	_	I-Premise
167	POMS	_	_	I-Premise
168	)	_	_	I-Premise
169	,	_	_	I-Premise
170	in	_	_	I-Premise
171	emotional	_	_	I-Premise
172	and	_	_	I-Premise
173	role	_	_	I-Premise
174	functioning	_	_	I-Premise
175	,	_	_	I-Premise
176	in	_	_	I-Premise
177	health	_	_	I-Premise
178	status	_	_	I-Premise
179	and	_	_	I-Premise
180	fatigue	_	_	I-Premise
181	level	_	_	I-Premise
182	(	_	_	I-Premise
183	EORTC	_	_	I-Premise
184	QLQ-C30	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	In	_	_	O
188	contrast	_	_	O
189	,	_	_	O
190	coping	_	_	B-Premise
191	strategies	_	_	I-Premise
192	(	_	_	I-Premise
193	MAC	_	_	I-Premise
194	)	_	_	I-Premise
195	were	_	_	I-Premise
196	not	_	_	I-Premise
197	significantly	_	_	I-Premise
198	different	_	_	I-Premise
199	between	_	_	I-Premise
200	groups	_	_	I-Premise
201	.	_	_	I-Premise

202	No	_	_	B-Premise
203	group-related	_	_	I-Premise
204	negative	_	_	I-Premise
205	effects	_	_	I-Premise
206	were	_	_	I-Premise
207	observed	_	_	I-Premise
208	and	_	_	I-Premise
209	the	_	_	I-Premise
210	global	_	_	I-Premise
211	satisfaction	_	_	I-Premise
212	levels	_	_	I-Premise
213	were	_	_	I-Premise
214	very	_	_	I-Premise
215	high	_	_	I-Premise
216	.	_	_	I-Premise

217	This	_	_	B-Claim
218	study	_	_	I-Claim
219	demonstrates	_	_	I-Claim
220	the	_	_	I-Claim
221	feasibility	_	_	I-Claim
222	and	_	_	I-Claim
223	effectiveness	_	_	I-Claim
224	of	_	_	I-Claim
225	a	_	_	I-Claim
226	psycho-educational	_	_	I-Claim
227	intervention	_	_	I-Claim
228	,	_	_	I-Claim
229	which	_	_	I-Claim
230	can	_	_	I-Claim
231	accelerate	_	_	I-Claim
232	the	_	_	I-Claim
233	reduction	_	_	I-Claim
234	of	_	_	I-Claim
235	those	_	_	I-Claim
236	negative	_	_	I-Claim
237	affects	_	_	I-Claim
238	which	_	_	I-Claim
239	are	_	_	I-Claim
240	present	_	_	I-Claim
241	at	_	_	I-Claim
242	the	_	_	I-Claim
243	end	_	_	I-Claim
244	of	_	_	I-Claim
245	treatment	_	_	I-Claim
246	.	_	_	I-Claim

247	It	_	_	B-Claim
248	represents	_	_	I-Claim
249	an	_	_	I-Claim
250	excellent	_	_	I-Claim
251	complement	_	_	I-Claim
252	or	_	_	I-Claim
253	an	_	_	I-Claim
254	alternative	_	_	I-Claim
255	to	_	_	I-Claim
256	individual	_	_	I-Claim
257	psycho-oncologic	_	_	I-Claim
258	therapeutic	_	_	I-Claim
259	support	_	_	I-Claim
260	,	_	_	I-Claim
261	widely	_	_	O
262	proposed	_	_	O
263	in	_	_	O
264	France	_	_	O
265	,	_	_	O
266	and	_	_	O
267	should	_	_	O
268	now	_	_	O
269	be	_	_	O
270	tested	_	_	O
271	in	_	_	O
272	groups	_	_	O
273	with	_	_	O
274	other	_	_	O
275	types	_	_	O
276	of	_	_	O
277	cancer	_	_	O
278	and	_	_	O
279	at	_	_	O
280	other	_	_	O
281	disease	_	_	O
282	phases	_	_	O
283	.	_	_	O


0	We	_	_	O
1	sought	_	_	O
2	the	_	_	O
3	extent	_	_	O
4	to	_	_	O
5	which	_	_	O
6	arm	_	_	O
7	morbidity	_	_	O
8	could	_	_	O
9	be	_	_	O
10	reduced	_	_	O
11	by	_	_	O
12	using	_	_	O
13	sentinel-lymph-node-based	_	_	O
14	management	_	_	O
15	in	_	_	O
16	women	_	_	O
17	with	_	_	O
18	clinically	_	_	O
19	node-negative	_	_	O
20	early	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	.	_	_	O

24	One	_	_	O
25	thousand	_	_	O
26	eighty-eight	_	_	O
27	women	_	_	O
28	were	_	_	O
29	randomly	_	_	O
30	allocated	_	_	O
31	to	_	_	O
32	sentinel-lymph-node	_	_	O
33	biopsy	_	_	O
34	followed	_	_	O
35	by	_	_	O
36	axillary	_	_	O
37	clearance	_	_	O
38	if	_	_	O
39	the	_	_	O
40	sentinel	_	_	O
41	node	_	_	O
42	was	_	_	O
43	positive	_	_	O
44	or	_	_	O
45	not	_	_	O
46	detected	_	_	O
47	(	_	_	O
48	SNBM	_	_	O
49	)	_	_	O
50	or	_	_	O
51	routine	_	_	O
52	axillary	_	_	O
53	clearance	_	_	O
54	(	_	_	O
55	RAC	_	_	O
56	,	_	_	O
57	sentinel-lymph-node	_	_	O
58	biopsy	_	_	O
59	followed	_	_	O
60	immediately	_	_	O
61	by	_	_	O
62	axillary	_	_	O
63	clearance	_	_	O
64	)	_	_	O
65	.	_	_	O

66	Sentinel	_	_	O
67	nodes	_	_	O
68	were	_	_	O
69	located	_	_	O
70	using	_	_	O
71	blue	_	_	O
72	dye	_	_	O
73	,	_	_	O
74	alone	_	_	O
75	or	_	_	O
76	with	_	_	O
77	technetium-labeled	_	_	O
78	antimony	_	_	O
79	sulfide	_	_	O
80	colloid	_	_	O
81	.	_	_	O

82	The	_	_	O
83	primary	_	_	O
84	endpoint	_	_	O
85	was	_	_	O
86	increase	_	_	O
87	in	_	_	O
88	arm	_	_	O
89	volume	_	_	O
90	from	_	_	O
91	baseline	_	_	O
92	to	_	_	O
93	the	_	_	O
94	average	_	_	O
95	of	_	_	O
96	measurements	_	_	O
97	at	_	_	O
98	6	_	_	O
99	and	_	_	O
100	12	_	_	O
101	months	_	_	O
102	.	_	_	O

103	Secondary	_	_	O
104	endpoints	_	_	O
105	were	_	_	O
106	the	_	_	O
107	proportions	_	_	O
108	of	_	_	O
109	women	_	_	O
110	with	_	_	O
111	at	_	_	O
112	least	_	_	O
113	15	_	_	O
114	%	_	_	O
115	increase	_	_	O
116	in	_	_	O
117	arm	_	_	O
118	volume	_	_	O
119	or	_	_	O
120	early	_	_	O
121	axillary	_	_	O
122	morbidity	_	_	O
123	,	_	_	O
124	and	_	_	O
125	average	_	_	O
126	scores	_	_	O
127	for	_	_	O
128	arm	_	_	O
129	symptoms	_	_	O
130	,	_	_	O
131	dysfunctions	_	_	O
132	,	_	_	O
133	and	_	_	O
134	disabilities	_	_	O
135	assessed	_	_	O
136	at	_	_	O
137	6	_	_	O
138	and	_	_	O
139	12	_	_	O
140	months	_	_	O
141	by	_	_	O
142	patients	_	_	O
143	with	_	_	O
144	the	_	_	O
145	SNAC	_	_	O
146	Study-Specific	_	_	O
147	Scales	_	_	O
148	and	_	_	O
149	other	_	_	O
150	quality-of-life	_	_	O
151	instruments	_	_	O
152	.	_	_	O

153	Sensitivity	_	_	O
154	,	_	_	O
155	false-negative	_	_	O
156	rates	_	_	O
157	,	_	_	O
158	and	_	_	O
159	negative	_	_	O
160	predictive	_	_	O
161	values	_	_	O
162	for	_	_	O
163	sentinel-lymph-node	_	_	O
164	biopsy	_	_	O
165	were	_	_	O
166	estimated	_	_	O
167	in	_	_	O
168	the	_	_	O
169	RAC	_	_	O
170	group	_	_	O
171	.	_	_	O

172	The	_	_	B-Premise
173	average	_	_	I-Premise
174	increase	_	_	I-Premise
175	in	_	_	I-Premise
176	arm	_	_	I-Premise
177	volume	_	_	I-Premise
178	was	_	_	I-Premise
179	2.8	_	_	I-Premise
180	%	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	SNBM	_	_	I-Premise
184	group	_	_	I-Premise
185	and	_	_	I-Premise
186	4.2	_	_	I-Premise
187	%	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	RAC	_	_	I-Premise
191	group	_	_	I-Premise
192	(	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	0.002	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	Patients	_	_	B-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	SNBM	_	_	I-Premise
202	group	_	_	I-Premise
203	gave	_	_	I-Premise
204	lower	_	_	I-Premise
205	ratings	_	_	I-Premise
206	for	_	_	I-Premise
207	arm	_	_	I-Premise
208	swelling	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	0.001	_	_	I-Premise
213	)	_	_	I-Premise
214	,	_	_	I-Premise
215	symptoms	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	<	_	_	I-Premise
219	0.001	_	_	I-Premise
220	)	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	dysfunctions	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	=	_	_	I-Premise
227	0.02	_	_	I-Premise
228	)	_	_	I-Premise
229	,	_	_	I-Premise
230	but	_	_	I-Premise
231	not	_	_	I-Premise
232	disabilities	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	0.5	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Sentinel	_	_	B-Premise
240	nodes	_	_	I-Premise
241	were	_	_	I-Premise
242	found	_	_	I-Premise
243	in	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	of	_	_	I-Premise
247	the	_	_	I-Premise
248	SNBM	_	_	I-Premise
249	group	_	_	I-Premise
250	(	_	_	I-Premise
251	29	_	_	I-Premise
252	%	_	_	I-Premise
253	positive	_	_	I-Premise
254	)	_	_	I-Premise
255	and	_	_	I-Premise
256	93	_	_	I-Premise
257	%	_	_	I-Premise
258	of	_	_	I-Premise
259	the	_	_	I-Premise
260	RAC	_	_	I-Premise
261	group	_	_	I-Premise
262	(	_	_	I-Premise
263	25	_	_	I-Premise
264	%	_	_	I-Premise
265	positive	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	SNB	_	_	O
269	had	_	_	O
270	sensitivity	_	_	O
271	94.5	_	_	O
272	%	_	_	O
273	,	_	_	O
274	false-negative	_	_	O
275	rate	_	_	O
276	5.5	_	_	O
277	%	_	_	O
278	,	_	_	O
279	and	_	_	O
280	negative	_	_	O
281	predictive	_	_	O
282	value	_	_	O
283	98	_	_	O
284	%	_	_	O
285	.	_	_	O

286	SNBM	_	_	B-Claim
287	was	_	_	I-Claim
288	successfully	_	_	I-Claim
289	undertaken	_	_	I-Claim
290	in	_	_	I-Claim
291	a	_	_	I-Claim
292	wide	_	_	I-Claim
293	range	_	_	I-Claim
294	of	_	_	I-Claim
295	surgical	_	_	I-Claim
296	centers	_	_	I-Claim
297	and	_	_	I-Claim
298	caused	_	_	I-Claim
299	significantly	_	_	I-Claim
300	less	_	_	I-Claim
301	morbidity	_	_	I-Claim
302	than	_	_	I-Claim
303	RAC	_	_	I-Claim
304	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	the	_	_	O
8	fixed	_	_	O
9	combination	_	_	O
10	of	_	_	O
11	timolol	_	_	O
12	maleate	_	_	O
13	0.5	_	_	O
14	%	_	_	O
15	/brimonidine	_	_	O
16	tartrate	_	_	O
17	0.2	_	_	O
18	%	_	_	O
19	versus	_	_	O
20	fixed	_	_	O
21	combination	_	_	O
22	of	_	_	O
23	timolol	_	_	O
24	maleate	_	_	O
25	0.5	_	_	O
26	%	_	_	O
27	/dorzolamide	_	_	O
28	2	_	_	O
29	%	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	elevated	_	_	O
34	intraocular	_	_	O
35	pressure	_	_	O
36	(	_	_	O
37	IOP	_	_	O
38	)	_	_	O
39	over	_	_	O
40	8	_	_	O
41	weeks	_	_	O
42	.	_	_	O

43	This	_	_	O
44	8-week	_	_	O
45	,	_	_	O
46	multicentric	_	_	O
47	,	_	_	O
48	interventional	_	_	O
49	,	_	_	O
50	randomized	_	_	O
51	,	_	_	O
52	open-label	_	_	O
53	,	_	_	O
54	parallel	_	_	O
55	group	_	_	O
56	study	_	_	O
57	was	_	_	O
58	conducted	_	_	O
59	at	_	_	O
60	4	_	_	O
61	centers	_	_	O
62	in	_	_	O
63	Brazil	_	_	O
64	and	_	_	O
65	1	_	_	O
66	center	_	_	O
67	in	_	_	O
68	Argentina	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	with	_	_	O
72	open-angle	_	_	O
73	glaucoma	_	_	O
74	or	_	_	O
75	ocular	_	_	O
76	hypertension	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	bilaterally	_	_	O
82	fixed	_	_	O
83	combination	_	_	O
84	of	_	_	O
85	brimonidine/timolol	_	_	O
86	maleate	_	_	O
87	0.5	_	_	O
88	%	_	_	O
89	or	_	_	O
90	fixed	_	_	O
91	combination	_	_	O
92	of	_	_	O
93	dorzolamide	_	_	O
94	2	_	_	O
95	%	_	_	O
96	/timolol	_	_	O
97	0.5	_	_	O
98	%	_	_	O
99	twice	_	_	O
100	daily	_	_	O
101	at	_	_	O
102	8:00	_	_	O
103	AM	_	_	O
104	and	_	_	O
105	8:00	_	_	O
106	PM	_	_	O
107	.	_	_	O

108	A	_	_	O
109	modified	_	_	O
110	diurnal	_	_	O
111	tension	_	_	O
112	curve	_	_	O
113	(	_	_	O
114	8:00	_	_	O
115	AM	_	_	O
116	,	_	_	O
117	10:30	_	_	O
118	AM	_	_	O
119	,	_	_	O
120	02:00	_	_	O
121	PM	_	_	O
122	,	_	_	O
123	and	_	_	O
124	4:00	_	_	O
125	PM	_	_	O
126	)	_	_	O
127	followed	_	_	O
128	by	_	_	O
129	the	_	_	O
130	water	_	_	O
131	drinking	_	_	O
132	test	_	_	O
133	(	_	_	O
134	WDT	_	_	O
135	)	_	_	O
136	,	_	_	O
137	which	_	_	O
138	estimates	_	_	O
139	IOP	_	_	O
140	peak	_	_	O
141	of	_	_	O
142	diurnal	_	_	O
143	tension	_	_	O
144	curve	_	_	O
145	,	_	_	O
146	were	_	_	O
147	performed	_	_	O
148	in	_	_	O
149	the	_	_	O
150	baseline	_	_	O
151	and	_	_	O
152	week-8	_	_	O
153	visits	_	_	O
154	.	_	_	O

155	Adverse	_	_	O
156	events	_	_	O
157	data	_	_	O
158	were	_	_	O
159	recorded	_	_	O
160	at	_	_	O
161	each	_	_	O
162	visit	_	_	O
163	.	_	_	O

164	A	_	_	O
165	total	_	_	O
166	of	_	_	O
167	210	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	randomized	_	_	O
171	(	_	_	O
172	brimonidine/timolol	_	_	O
173	,	_	_	O
174	n=111	_	_	O
175	;	_	_	O
176	dorzolamide/timolol	_	_	O
177	,	_	_	O
178	n=99	_	_	O
179	)	_	_	O
180	.	_	_	O

181	Mean	_	_	O
182	baseline	_	_	O
183	IOP	_	_	O
184	was	_	_	O
185	23.43+/-3.22	_	_	O
186	mm	_	_	O
187	Hg	_	_	O
188	and	_	_	O
189	23.43+/-4.06	_	_	O
190	mm	_	_	O
191	Hg	_	_	O
192	in	_	_	O
193	the	_	_	O
194	patients	_	_	O
195	treated	_	_	O
196	with	_	_	O
197	brimonidine/timolol	_	_	O
198	and	_	_	O
199	dorzolamide/timolol	_	_	O
200	,	_	_	O
201	respectively	_	_	O
202	(	_	_	O
203	P=0.993	_	_	O
204	)	_	_	O
205	.	_	_	O

206	Mean	_	_	B-Premise
207	diurnal	_	_	I-Premise
208	IOP	_	_	I-Premise
209	reduction	_	_	I-Premise
210	after	_	_	I-Premise
211	8	_	_	I-Premise
212	weeks	_	_	I-Premise
213	were	_	_	I-Premise
214	7.02+/-3.06	_	_	I-Premise
215	mm	_	_	I-Premise
216	Hg	_	_	I-Premise
217	and	_	_	I-Premise
218	6.91+/-3.67	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	(	_	_	I-Premise
224	P=0.811	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	The	_	_	B-Premise
228	adjusted	_	_	I-Premise
229	difference	_	_	I-Premise
230	between	_	_	I-Premise
231	groups	_	_	I-Premise
232	(	_	_	I-Premise
233	analysis	_	_	I-Premise
234	of	_	_	I-Premise
235	covariance	_	_	I-Premise
236	)	_	_	I-Premise
237	at	_	_	I-Premise
238	week	_	_	I-Premise
239	8	_	_	I-Premise
240	was	_	_	I-Premise
241	not	_	_	I-Premise
242	statistically	_	_	I-Premise
243	significant	_	_	I-Premise
244	(	_	_	I-Premise
245	P=0.847	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Mean	_	_	B-Premise
249	baseline	_	_	I-Premise
250	WDT	_	_	I-Premise
251	peak	_	_	I-Premise
252	was	_	_	I-Premise
253	27.79+/-4.29	_	_	I-Premise
254	mm	_	_	I-Premise
255	Hg	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	brimonidine/timolol	_	_	I-Premise
259	group	_	_	I-Premise
260	and	_	_	I-Premise
261	27.68+/-5.46	_	_	I-Premise
262	mm	_	_	I-Premise
263	Hg	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	dorzolamide/timolol	_	_	I-Premise
267	group	_	_	I-Premise
268	.	_	_	I-Premise

269	After	_	_	B-Premise
270	8	_	_	I-Premise
271	weeks	_	_	I-Premise
272	of	_	_	I-Premise
273	treatment	_	_	I-Premise
274	,	_	_	I-Premise
275	mean	_	_	I-Premise
276	WDT	_	_	I-Premise
277	peaks	_	_	I-Premise
278	were	_	_	I-Premise
279	20.94+/-3.76	_	_	I-Premise
280	mm	_	_	I-Premise
281	Hg	_	_	I-Premise
282	(	_	_	I-Premise
283	P	_	_	I-Premise
284	<	_	_	I-Premise
285	0.001	_	_	I-Premise
286	)	_	_	I-Premise
287	and	_	_	I-Premise
288	20.98+/-4.19	_	_	I-Premise
289	(	_	_	I-Premise
290	P	_	_	I-Premise
291	<	_	_	I-Premise
292	0.001	_	_	I-Premise
293	)	_	_	I-Premise
294	,	_	_	I-Premise
295	respectively	_	_	I-Premise
296	.	_	_	I-Premise

297	The	_	_	O
298	adjusted	_	_	O
299	difference	_	_	O
300	between	_	_	O
301	groups	_	_	O
302	(	_	_	O
303	analysis	_	_	O
304	of	_	_	O
305	covariance	_	_	O
306	)	_	_	O
307	was	_	_	O
308	not	_	_	O
309	statistically	_	_	O
310	significant	_	_	O
311	(	_	_	O
312	P=0.469	_	_	O
313	)	_	_	O
314	.	_	_	O

315	No	_	_	B-Premise
316	statistical	_	_	I-Premise
317	difference	_	_	I-Premise
318	in	_	_	I-Premise
319	terms	_	_	I-Premise
320	of	_	_	I-Premise
321	adverse	_	_	I-Premise
322	events	_	_	I-Premise
323	was	_	_	I-Premise
324	found	_	_	I-Premise
325	between	_	_	I-Premise
326	groups	_	_	I-Premise
327	.	_	_	I-Premise

328	Both	_	_	B-Claim
329	fixed	_	_	I-Claim
330	combinations	_	_	I-Claim
331	were	_	_	I-Claim
332	capable	_	_	I-Claim
333	of	_	_	I-Claim
334	significantly	_	_	I-Claim
335	reducing	_	_	I-Claim
336	the	_	_	I-Claim
337	mean	_	_	I-Claim
338	diurnal	_	_	I-Claim
339	IOP	_	_	I-Claim
340	,	_	_	I-Claim
341	mean	_	_	I-Claim
342	diurnal	_	_	I-Claim
343	peak	_	_	I-Claim
344	,	_	_	I-Claim
345	and	_	_	I-Claim
346	mean	_	_	I-Claim
347	WDT	_	_	I-Claim
348	peak	_	_	I-Claim
349	after	_	_	I-Claim
350	8	_	_	I-Claim
351	weeks	_	_	I-Claim
352	of	_	_	I-Claim
353	treatment	_	_	I-Claim
354	.	_	_	I-Claim

355	Also	_	_	O
356	,	_	_	O
357	both	_	_	B-Claim
358	fixed	_	_	I-Claim
359	combinations	_	_	I-Claim
360	are	_	_	I-Claim
361	well	_	_	I-Claim
362	tolerated	_	_	I-Claim
363	with	_	_	I-Claim
364	few	_	_	I-Claim
365	side	_	_	I-Claim
366	effects	_	_	I-Claim
367	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	a	_	_	O
8	once-daily	_	_	O
9	evening	_	_	O
10	dose	_	_	O
11	of	_	_	O
12	bimatoprost/timolol	_	_	O
13	fixed	_	_	O
14	combination	_	_	O
15	(	_	_	O
16	BTFC	_	_	O
17	)	_	_	O
18	with	_	_	O
19	that	_	_	O
20	of	_	_	O
21	a	_	_	O
22	once-daily	_	_	O
23	evening	_	_	O
24	dose	_	_	O
25	of	_	_	O
26	latanoprost/timolol	_	_	O
27	fixed	_	_	O
28	combination	_	_	O
29	(	_	_	O
30	LTFC	_	_	O
31	)	_	_	O
32	in	_	_	O
33	patients	_	_	O
34	not	_	_	O
35	controlled	_	_	O
36	with	_	_	O
37	prostaglandins	_	_	O
38	analogues	_	_	O
39	monotherapy	_	_	O
40	.	_	_	O

41	A	_	_	O
42	total	_	_	O
43	of	_	_	O
44	82	_	_	O
45	patients	_	_	O
46	on	_	_	O
47	prostaglandin	_	_	O
48	analogues	_	_	O
49	monotherapy	_	_	O
50	were	_	_	O
51	enrolled	_	_	O
52	in	_	_	O
53	this	_	_	O
54	prospective	_	_	O
55	,	_	_	O
56	multicenter	_	_	O
57	,	_	_	O
58	investigator	_	_	O
59	masked	_	_	O
60	,	_	_	O
61	clinical	_	_	O
62	study	_	_	O
63	and	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	either	_	_	O
68	BTFC	_	_	O
69	(	_	_	O
70	n=47	_	_	O
71	)	_	_	O
72	or	_	_	O
73	LTFC	_	_	O
74	(	_	_	O
75	n=35	_	_	O
76	)	_	_	O
77	topical	_	_	O
78	therapy	_	_	O
79	once	_	_	O
80	at	_	_	O
81	night	_	_	O
82	for	_	_	O
83	12	_	_	O
84	weeks	_	_	O
85	.	_	_	O

86	The	_	_	O
87	primary	_	_	O
88	endpoint	_	_	O
89	of	_	_	O
90	the	_	_	O
91	study	_	_	O
92	was	_	_	O
93	to	_	_	O
94	compare	_	_	O
95	the	_	_	O
96	mean	_	_	O
97	daily	_	_	O
98	intraocular	_	_	O
99	pressure	_	_	O
100	(	_	_	O
101	IOP	_	_	O
102	)	_	_	O
103	reduction	_	_	O
104	from	_	_	O
105	baseline	_	_	O
106	between	_	_	O
107	the	_	_	O
108	two	_	_	O
109	treatment	_	_	O
110	arms	_	_	O
111	.	_	_	O

112	Secondary	_	_	O
113	endpoints	_	_	O
114	included	_	_	O
115	the	_	_	O
116	mean	_	_	O
117	daily	_	_	O
118	IOP	_	_	O
119	at	_	_	O
120	1	_	_	O
121	and	_	_	O
122	3	_	_	O
123	months	_	_	O
124	compared	_	_	O
125	to	_	_	O
126	baseline	_	_	O
127	and	_	_	O
128	the	_	_	O
129	percentage	_	_	O
130	of	_	_	O
131	patients	_	_	O
132	showing	_	_	O
133	a	_	_	O
134	mean	_	_	O
135	IOP	_	_	O
136	reduction	_	_	O
137	from	_	_	O
138	baseline	_	_	O
139	greater	_	_	O
140	than	_	_	O
141	or	_	_	O
142	equal	_	_	O
143	to	_	_	O
144	15	_	_	O
145	%	_	_	O
146	or	_	_	O
147	20	_	_	O
148	%	_	_	O
149	.	_	_	O

150	Mean	_	_	O
151	IOP	_	_	O
152	at	_	_	O
153	baseline	_	_	O
154	was	_	_	O
155	22.7+/-2.0	_	_	O
156	and	_	_	O
157	22.1+/-2.6	_	_	O
158	mmHg	_	_	O
159	in	_	_	O
160	the	_	_	O
161	BTFC	_	_	O
162	and	_	_	O
163	LTFC	_	_	O
164	groups	_	_	O
165	,	_	_	O
166	respectively	_	_	O
167	(	_	_	O
168	p=0.23	_	_	O
169	)	_	_	O
170	.	_	_	O

171	Both	_	_	O
172	treatments	_	_	O
173	were	_	_	O
174	effective	_	_	O
175	in	_	_	O
176	reducing	_	_	O
177	the	_	_	O
178	IOP	_	_	O
179	from	_	_	O
180	baseline	_	_	O
181	.	_	_	O

182	The	_	_	B-Premise
183	mean	_	_	I-Premise
184	IOP	_	_	I-Premise
185	reduction	_	_	I-Premise
186	was	_	_	I-Premise
187	significantly	_	_	I-Premise
188	greater	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	BTFC	_	_	I-Premise
192	group	_	_	I-Premise
193	than	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	LTFC	_	_	I-Premise
197	group	_	_	I-Premise
198	(	_	_	I-Premise
199	-21.4	_	_	I-Premise
200	%	_	_	I-Premise
201	vs	_	_	I-Premise
202	-13.7	_	_	I-Premise
203	%	_	_	I-Premise
204	,	_	_	I-Premise
205	p	_	_	I-Premise
206	<	_	_	I-Premise
207	0.001	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	A	_	_	B-Premise
211	higher	_	_	I-Premise
212	percentage	_	_	I-Premise
213	of	_	_	I-Premise
214	patients	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	BTFC	_	_	I-Premise
218	group	_	_	I-Premise
219	showed	_	_	I-Premise
220	a	_	_	I-Premise
221	mean	_	_	I-Premise
222	IOP	_	_	I-Premise
223	reduction	_	_	I-Premise
224	from	_	_	I-Premise
225	baseline	_	_	I-Premise
226	>	_	_	I-Premise
227	or=15	_	_	I-Premise
228	%	_	_	I-Premise
229	(	_	_	I-Premise
230	72.3	_	_	I-Premise
231	%	_	_	I-Premise
232	vs	_	_	I-Premise
233	40.0	_	_	I-Premise
234	%	_	_	I-Premise
235	)	_	_	I-Premise
236	and	_	_	I-Premise
237	>	_	_	I-Premise
238	or=20	_	_	I-Premise
239	%	_	_	I-Premise
240	(	_	_	I-Premise
241	61.7	_	_	I-Premise
242	%	_	_	I-Premise
243	vs	_	_	I-Premise
244	17.1	_	_	I-Premise
245	%	_	_	I-Premise
246	)	_	_	I-Premise
247	compared	_	_	I-Premise
248	to	_	_	I-Premise
249	patients	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	LTFC	_	_	I-Premise
253	group	_	_	I-Premise
254	.	_	_	I-Premise

255	Both	_	_	B-Claim
256	BTFC	_	_	I-Claim
257	and	_	_	I-Claim
258	LTFC	_	_	I-Claim
259	were	_	_	I-Claim
260	more	_	_	I-Claim
261	effective	_	_	I-Claim
262	versus	_	_	I-Claim
263	the	_	_	I-Claim
264	monotherapy	_	_	I-Claim
265	with	_	_	I-Claim
266	prostaglandin	_	_	I-Claim
267	analogues	_	_	I-Claim
268	.	_	_	I-Claim

269	BTFC	_	_	B-Claim
270	demonstrated	_	_	I-Claim
271	higher	_	_	I-Claim
272	performance	_	_	I-Claim
273	than	_	_	I-Claim
274	LTFC	_	_	I-Claim
275	in	_	_	I-Claim
276	terms	_	_	I-Claim
277	of	_	_	I-Claim
278	relative	_	_	I-Claim
279	IOP	_	_	I-Claim
280	reduction	_	_	I-Claim
281	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	an	_	_	O
6	expressive	_	_	O
7	writing	_	_	O
8	(	_	_	O
9	EW	_	_	O
10	)	_	_	O
11	intervention	_	_	O
12	on	_	_	O
13	perceptions	_	_	O
14	of	_	_	O
15	emotional	_	_	O
16	support	_	_	O
17	in	_	_	O
18	women	_	_	O
19	completing	_	_	O
20	treatment	_	_	O
21	for	_	_	O
22	early	_	_	O
23	stage	_	_	O
24	breast	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	Women	_	_	O
28	were	_	_	O
29	recruited	_	_	O
30	to	_	_	O
31	the	_	_	O
32	study	_	_	O
33	during	_	_	O
34	their	_	_	O
35	final	_	_	O
36	week	_	_	O
37	of	_	_	O
38	treatment	_	_	O
39	.	_	_	O

40	Of	_	_	O
41	260	_	_	O
42	eligible	_	_	O
43	patients	_	_	O
44	,	_	_	O
45	104	_	_	O
46	(	_	_	O
47	40	_	_	O
48	%	_	_	O
49	)	_	_	O
50	agreed	_	_	O
51	to	_	_	O
52	participate	_	_	O
53	,	_	_	O
54	and	_	_	O
55	93	_	_	O
56	were	_	_	O
57	randomised	_	_	O
58	.	_	_	O

59	Women	_	_	O
60	in	_	_	O
61	the	_	_	O
62	writing	_	_	O
63	group	_	_	O
64	wrote	_	_	O
65	for	_	_	O
66	20	_	_	O
67	min	_	_	O
68	on	_	_	O
69	four	_	_	O
70	consecutive	_	_	O
71	days	_	_	O
72	.	_	_	O

73	The	_	_	O
74	control	_	_	O
75	group	_	_	O
76	received	_	_	O
77	normal	_	_	O
78	care	_	_	O
79	.	_	_	O

80	Women	_	_	O
81	's	_	_	O
82	perceptions	_	_	O
83	of	_	_	O
84	emotional	_	_	O
85	support	_	_	O
86	,	_	_	O
87	quality	_	_	O
88	of	_	_	O
89	life	_	_	O
90	(	_	_	O
91	QOL	_	_	O
92	)	_	_	O
93	,	_	_	O
94	mood	_	_	O
95	,	_	_	O
96	and	_	_	O
97	healthcare	_	_	O
98	utilisation	_	_	O
99	were	_	_	O
100	assessed	_	_	O
101	at	_	_	O
102	baseline	_	_	O
103	,	_	_	O
104	1	_	_	O
105	month	_	_	O
106	,	_	_	O
107	3	_	_	O
108	months	_	_	O
109	and	_	_	O
110	6	_	_	O
111	months	_	_	O
112	.	_	_	O

113	Interviews	_	_	O
114	were	_	_	O
115	conducted	_	_	O
116	to	_	_	O
117	explore	_	_	O
118	women	_	_	O
119	's	_	_	O
120	experience	_	_	O
121	of	_	_	O
122	writing	_	_	O
123	.	_	_	O

124	Eighty	_	_	O
125	participants	_	_	O
126	completed	_	_	O
127	all	_	_	O
128	follow-ups	_	_	O
129	.	_	_	O

130	There	_	_	B-Premise
131	was	_	_	I-Premise
132	a	_	_	I-Premise
133	significant	_	_	I-Premise
134	effect	_	_	I-Premise
135	of	_	_	I-Premise
136	group	_	_	I-Premise
137	on	_	_	I-Premise
138	women	_	_	I-Premise
139	's	_	_	I-Premise
140	perceptions	_	_	I-Premise
141	of	_	_	I-Premise
142	social	_	_	I-Premise
143	support	_	_	I-Premise
144	with	_	_	I-Premise
145	those	_	_	I-Premise
146	in	_	_	I-Premise
147	the	_	_	I-Premise
148	intervention	_	_	I-Premise
149	group	_	_	I-Premise
150	being	_	_	I-Premise
151	more	_	_	I-Premise
152	satisfied	_	_	I-Premise
153	with	_	_	I-Premise
154	the	_	_	I-Premise
155	emotional	_	_	I-Premise
156	support	_	_	I-Premise
157	they	_	_	I-Premise
158	received	_	_	I-Premise
159	(	_	_	I-Premise
160	p	_	_	I-Premise
161	<	_	_	I-Premise
162	0.05	_	_	I-Premise
163	)	_	_	I-Premise
164	.	_	_	I-Premise

165	Satisfaction	_	_	B-Premise
166	with	_	_	I-Premise
167	emotional	_	_	I-Premise
168	support	_	_	I-Premise
169	was	_	_	I-Premise
170	negatively	_	_	I-Premise
171	correlated	_	_	I-Premise
172	with	_	_	I-Premise
173	depression/dejection	_	_	I-Premise
174	(	_	_	I-Premise
175	p	_	_	I-Premise
176	<	_	_	I-Premise
177	0.05	_	_	I-Premise
178	)	_	_	I-Premise
179	and	_	_	I-Premise
180	anger/hostility	_	_	I-Premise
181	(	_	_	I-Premise
182	p	_	_	I-Premise
183	<	_	_	I-Premise
184	0.05	_	_	I-Premise
185	)	_	_	I-Premise
186	and	_	_	I-Premise
187	positively	_	_	I-Premise
188	correlated	_	_	I-Premise
189	with	_	_	I-Premise
190	social	_	_	I-Premise
191	and	_	_	I-Premise
192	family	_	_	I-Premise
193	well-being	_	_	I-Premise
194	(	_	_	I-Premise
195	p	_	_	I-Premise
196	<	_	_	I-Premise
197	0.001	_	_	I-Premise
198	)	_	_	I-Premise
199	6	_	_	I-Premise
200	months	_	_	I-Premise
201	post	_	_	I-Premise
202	intervention	_	_	I-Premise
203	.	_	_	I-Premise

204	There	_	_	B-Premise
205	were	_	_	I-Premise
206	no	_	_	I-Premise
207	significant	_	_	I-Premise
208	effects	_	_	I-Premise
209	of	_	_	I-Premise
210	the	_	_	I-Premise
211	intervention	_	_	I-Premise
212	on	_	_	I-Premise
213	mood	_	_	I-Premise
214	,	_	_	I-Premise
215	QOL	_	_	I-Premise
216	or	_	_	I-Premise
217	healthcare	_	_	I-Premise
218	utilisation	_	_	I-Premise
219	.	_	_	I-Premise

220	Most	_	_	B-Premise
221	participants	_	_	I-Premise
222	found	_	_	I-Premise
223	writing	_	_	I-Premise
224	valuable	_	_	I-Premise
225	and	_	_	I-Premise
226	did	_	_	I-Premise
227	not	_	_	I-Premise
228	report	_	_	I-Premise
229	any	_	_	I-Premise
230	long-term	_	_	I-Premise
231	negative	_	_	I-Premise
232	effects	_	_	I-Premise
233	.	_	_	I-Premise

234	EW	_	_	B-Claim
235	was	_	_	I-Claim
236	associated	_	_	I-Claim
237	with	_	_	I-Claim
238	a	_	_	I-Claim
239	higher	_	_	I-Claim
240	level	_	_	I-Claim
241	of	_	_	I-Claim
242	satisfaction	_	_	I-Claim
243	with	_	_	I-Claim
244	emotional	_	_	I-Claim
245	support	_	_	I-Claim
246	compared	_	_	I-Claim
247	with	_	_	I-Claim
248	controls	_	_	I-Claim
249	.	_	_	I-Claim

250	Given	_	_	O
251	the	_	_	O
252	existing	_	_	O
253	evidence	_	_	O
254	supporting	_	_	O
255	the	_	_	O
256	importance	_	_	O
257	of	_	_	O
258	social	_	_	O
259	support	_	_	O
260	in	_	_	O
261	adjustment	_	_	O
262	to	_	_	O
263	breast	_	_	O
264	cancer	_	_	O
265	,	_	_	O
266	it	_	_	B-Claim
267	seems	_	_	I-Claim
268	feasible	_	_	I-Claim
269	to	_	_	I-Claim
270	suggest	_	_	I-Claim
271	that	_	_	I-Claim
272	EW	_	_	I-Claim
273	may	_	_	I-Claim
274	be	_	_	I-Claim
275	a	_	_	I-Claim
276	cost	_	_	I-Claim
277	effective	_	_	I-Claim
278	accessible	_	_	I-Claim
279	treatment	_	_	I-Claim
280	that	_	_	I-Claim
281	could	_	_	I-Claim
282	be	_	_	I-Claim
283	incorporated	_	_	I-Claim
284	into	_	_	I-Claim
285	the	_	_	I-Claim
286	ongoing	_	_	I-Claim
287	care	_	_	I-Claim
288	of	_	_	I-Claim
289	women	_	_	I-Claim
290	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	treatment	_	_	O
10	and	_	_	O
11	retention	_	_	O
12	effects	_	_	O
13	between	_	_	O
14	standard	_	_	O
15	decongestive	_	_	O
16	lymphatic	_	_	O
17	therapy	_	_	O
18	(	_	_	O
19	DLT	_	_	O
20	)	_	_	O
21	combined	_	_	O
22	with	_	_	O
23	pneumatic	_	_	O
24	compression	_	_	O
25	(	_	_	O
26	PC	_	_	O
27	)	_	_	O
28	and	_	_	O
29	modified	_	_	O
30	DLT	_	_	O
31	,	_	_	O
32	in	_	_	O
33	which	_	_	O
34	the	_	_	O
35	use	_	_	O
36	of	_	_	O
37	a	_	_	O
38	short-stretch	_	_	O
39	bandage	_	_	O
40	is	_	_	O
41	replaced	_	_	O
42	with	_	_	O
43	the	_	_	O
44	use	_	_	O
45	of	_	_	O
46	Kinesio	_	_	O
47	tape	_	_	O
48	(	_	_	O
49	K-tape	_	_	O
50	)	_	_	O
51	combined	_	_	O
52	with	_	_	O
53	PC	_	_	O
54	.	_	_	O

55	Forty-one	_	_	O
56	patients	_	_	O
57	with	_	_	O
58	unilateral	_	_	O
59	breast-cancer-related	_	_	O
60	lymphedema	_	_	O
61	for	_	_	O
62	at	_	_	O
63	least	_	_	O
64	3	_	_	O
65	months	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	grouped	_	_	O
69	into	_	_	O
70	the	_	_	O
71	DLT	_	_	O
72	group	_	_	O
73	(	_	_	O
74	bandage	_	_	O
75	group	_	_	O
76	,	_	_	O
77	N	_	_	O
78	=	_	_	O
79	21	_	_	O
80	)	_	_	O
81	or	_	_	O
82	the	_	_	O
83	modified	_	_	O
84	DLT	_	_	O
85	group	_	_	O
86	(	_	_	O
87	K-tape	_	_	O
88	group	_	_	O
89	,	_	_	O
90	N	_	_	O
91	=	_	_	O
92	20	_	_	O
93	)	_	_	O
94	.	_	_	O

95	Skin	_	_	O
96	care	_	_	O
97	,	_	_	O
98	30-min	_	_	O
99	manual	_	_	O
100	lymphatic	_	_	O
101	drainage	_	_	O
102	,	_	_	O
103	1-h	_	_	O
104	pneumatic	_	_	O
105	compression	_	_	O
106	therapy	_	_	O
107	,	_	_	O
108	application	_	_	O
109	of	_	_	O
110	a	_	_	O
111	short-stretch	_	_	O
112	bandage	_	_	O
113	or	_	_	O
114	K-tape	_	_	O
115	for	_	_	O
116	each	_	_	O
117	group	_	_	O
118	,	_	_	O
119	and	_	_	O
120	a	_	_	O
121	20-min	_	_	O
122	physical	_	_	O
123	therapy	_	_	O
124	exercise	_	_	O
125	were	_	_	O
126	given	_	_	O
127	during	_	_	O
128	every	_	_	O
129	treatment	_	_	O
130	session	_	_	O
131	.	_	_	O

132	Patient	_	_	O
133	evaluation	_	_	O
134	items	_	_	O
135	included	_	_	O
136	physical	_	_	O
137	therapy	_	_	O
138	assessment	_	_	O
139	,	_	_	O
140	limb	_	_	O
141	size	_	_	O
142	,	_	_	O
143	water	_	_	O
144	composition	_	_	O
145	of	_	_	O
146	the	_	_	O
147	upper	_	_	O
148	extremity	_	_	O
149	,	_	_	O
150	lymphedema-related	_	_	O
151	symptoms	_	_	O
152	,	_	_	O
153	quality	_	_	O
154	of	_	_	O
155	life	_	_	O
156	,	_	_	O
157	and	_	_	O
158	patients	_	_	O
159	'	_	_	O
160	acceptance	_	_	O
161	to	_	_	O
162	the	_	_	O
163	bandage	_	_	O
164	or	_	_	O
165	tape	_	_	O
166	.	_	_	O

167	There	_	_	B-Premise
168	was	_	_	I-Premise
169	no	_	_	I-Premise
170	significant	_	_	I-Premise
171	difference	_	_	I-Premise
172	between	_	_	I-Premise
173	groups	_	_	I-Premise
174	in	_	_	I-Premise
175	all	_	_	I-Premise
176	outcome	_	_	I-Premise
177	variables	_	_	I-Premise
178	(	_	_	I-Premise
179	P	_	_	I-Premise
180	>	_	_	I-Premise
181	0.05	_	_	I-Premise
182	)	_	_	I-Premise
183	through	_	_	I-Premise
184	the	_	_	I-Premise
185	whole	_	_	I-Premise
186	study	_	_	I-Premise
187	period	_	_	I-Premise
188	.	_	_	I-Premise

189	Excess	_	_	B-Premise
190	limb	_	_	I-Premise
191	size	_	_	I-Premise
192	(	_	_	I-Premise
193	circumference	_	_	I-Premise
194	and	_	_	I-Premise
195	water	_	_	I-Premise
196	displacement	_	_	I-Premise
197	)	_	_	I-Premise
198	and	_	_	I-Premise
199	excess	_	_	I-Premise
200	water	_	_	I-Premise
201	composition	_	_	I-Premise
202	were	_	_	I-Premise
203	reduced	_	_	I-Premise
204	significantly	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	bandage	_	_	I-Premise
208	group	_	_	I-Premise
209	;	_	_	I-Premise
210	excess	_	_	B-Premise
211	circumference	_	_	I-Premise
212	and	_	_	I-Premise
213	excess	_	_	I-Premise
214	water	_	_	I-Premise
215	composition	_	_	I-Premise
216	were	_	_	I-Premise
217	reduced	_	_	I-Premise
218	significantly	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	tape	_	_	I-Premise
222	group	_	_	I-Premise
223	.	_	_	I-Premise

224	The	_	_	B-Premise
225	acceptance	_	_	I-Premise
226	of	_	_	I-Premise
227	K-tape	_	_	I-Premise
228	was	_	_	I-Premise
229	better	_	_	I-Premise
230	than	_	_	I-Premise
231	the	_	_	I-Premise
232	bandage	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	benefits	_	_	I-Premise
236	included	_	_	I-Premise
237	longer	_	_	I-Premise
238	wearing	_	_	I-Premise
239	time	_	_	I-Premise
240	,	_	_	I-Premise
241	less	_	_	I-Premise
242	difficulty	_	_	I-Premise
243	in	_	_	I-Premise
244	usage	_	_	I-Premise
245	,	_	_	I-Premise
246	and	_	_	I-Premise
247	increased	_	_	I-Premise
248	comfort	_	_	I-Premise
249	and	_	_	I-Premise
250	convenience	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	0.05	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	The	_	_	B-Claim
258	study	_	_	I-Claim
259	results	_	_	I-Claim
260	suggest	_	_	I-Claim
261	that	_	_	I-Claim
262	K-tape	_	_	I-Claim
263	could	_	_	I-Claim
264	replace	_	_	I-Claim
265	the	_	_	I-Claim
266	bandage	_	_	I-Claim
267	in	_	_	I-Claim
268	DLT	_	_	I-Claim
269	,	_	_	I-Claim
270	and	_	_	I-Claim
271	it	_	_	I-Claim
272	could	_	_	I-Claim
273	be	_	_	I-Claim
274	an	_	_	I-Claim
275	alternative	_	_	I-Claim
276	choice	_	_	I-Claim
277	for	_	_	I-Claim
278	the	_	_	I-Claim
279	breast-cancer-related	_	_	I-Claim
280	lymphedema	_	_	I-Claim
281	patient	_	_	I-Claim
282	with	_	_	I-Claim
283	poor	_	_	I-Claim
284	short-stretch	_	_	I-Claim
285	bandage	_	_	I-Claim
286	compliance	_	_	I-Claim
287	after	_	_	I-Claim
288	1-month	_	_	I-Claim
289	intervention	_	_	I-Claim
290	.	_	_	I-Claim

291	If	_	_	O
292	the	_	_	O
293	intervention	_	_	O
294	period	_	_	O
295	was	_	_	O
296	prolonged	_	_	O
297	,	_	_	O
298	we	_	_	O
299	might	_	_	O
300	get	_	_	O
301	different	_	_	O
302	conclusion	_	_	O
303	.	_	_	O

304	Moreover	_	_	O
305	,	_	_	O
306	these	_	_	B-Claim
307	two	_	_	I-Claim
308	treatment	_	_	I-Claim
309	protocols	_	_	I-Claim
310	are	_	_	I-Claim
311	inefficient	_	_	I-Claim
312	and	_	_	I-Claim
313	cost	_	_	I-Claim
314	time	_	_	I-Claim
315	in	_	_	I-Claim
316	application	_	_	I-Claim
317	.	_	_	I-Claim

318	More	_	_	B-Claim
319	efficient	_	_	I-Claim
320	treatment	_	_	I-Claim
321	protocol	_	_	I-Claim
322	is	_	_	I-Claim
323	needed	_	_	I-Claim
324	for	_	_	I-Claim
325	clinical	_	_	I-Claim
326	practice	_	_	I-Claim
327	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	phacoemulsification	_	_	O
3	alone	_	_	O
4	versus	_	_	O
5	combined	_	_	O
6	phacotrabeculectomy	_	_	O
7	in	_	_	O
8	medically	_	_	O
9	uncontrolled	_	_	O
10	chronic	_	_	O
11	angle	_	_	O
12	closure	_	_	O
13	glaucoma	_	_	O
14	(	_	_	O
15	CACG	_	_	O
16	)	_	_	O
17	with	_	_	O
18	coexisting	_	_	O
19	cataract	_	_	O
20	.	_	_	O

21	Prospective	_	_	O
22	randomized	_	_	O
23	clinical	_	_	O
24	trial	_	_	O
25	.	_	_	O

26	Fifty-one	_	_	O
27	medically	_	_	O
28	uncontrolled	_	_	O
29	CACG	_	_	O
30	eyes	_	_	O
31	with	_	_	O
32	coexisting	_	_	O
33	cataract	_	_	O
34	of	_	_	O
35	51	_	_	O
36	patients	_	_	O
37	.	_	_	O

38	Recruited	_	_	O
39	patients	_	_	O
40	were	_	_	O
41	randomized	_	_	O
42	into	_	_	O
43	group	_	_	O
44	1	_	_	O
45	(	_	_	O
46	phacoemulsification	_	_	O
47	alone	_	_	O
48	)	_	_	O
49	or	_	_	O
50	group	_	_	O
51	2	_	_	O
52	(	_	_	O
53	combined	_	_	O
54	phacotrabeculectomy	_	_	O
55	with	_	_	O
56	adjunctive	_	_	O
57	mitomycin	_	_	O
58	C	_	_	O
59	)	_	_	O
60	.	_	_	O

61	Postoperatively	_	_	O
62	,	_	_	O
63	patients	_	_	O
64	were	_	_	O
65	reviewed	_	_	O
66	every	_	_	O
67	3	_	_	O
68	months	_	_	O
69	for	_	_	O
70	2	_	_	O
71	years	_	_	O
72	.	_	_	O

73	Intraocular	_	_	O
74	pressure	_	_	O
75	(	_	_	O
76	IOP	_	_	O
77	)	_	_	O
78	and	_	_	O
79	requirement	_	_	O
80	for	_	_	O
81	topical	_	_	O
82	glaucoma	_	_	O
83	drugs	_	_	O
84	.	_	_	O

85	Twenty-seven	_	_	O
86	CACG	_	_	O
87	eyes	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	into	_	_	O
91	group	_	_	O
92	1	_	_	O
93	,	_	_	O
94	and	_	_	O
95	24	_	_	O
96	CACG	_	_	O
97	eyes	_	_	O
98	were	_	_	O
99	randomized	_	_	O
100	into	_	_	O
101	group	_	_	O
102	2	_	_	O
103	.	_	_	O

104	Combined	_	_	B-Premise
105	phacotrabeculectomy	_	_	I-Premise
106	resulted	_	_	I-Premise
107	in	_	_	I-Premise
108	lower	_	_	I-Premise
109	mean	_	_	I-Premise
110	postoperative	_	_	I-Premise
111	IOP	_	_	I-Premise
112	than	_	_	I-Premise
113	phacoemulsification	_	_	I-Premise
114	alone	_	_	I-Premise
115	at	_	_	I-Premise
116	3	_	_	I-Premise
117	months	_	_	I-Premise
118	(	_	_	I-Premise
119	14.0	_	_	I-Premise
120	vs	_	_	I-Premise
121	17.0	_	_	I-Premise
122	mmHg	_	_	I-Premise
123	,	_	_	I-Premise
124	P	_	_	I-Premise
125	=	_	_	I-Premise
126	0.01	_	_	I-Premise
127	)	_	_	I-Premise
128	,	_	_	I-Premise
129	15	_	_	I-Premise
130	months	_	_	I-Premise
131	(	_	_	I-Premise
132	13.2	_	_	I-Premise
133	vs	_	_	I-Premise
134	15.4	_	_	I-Premise
135	mmHg	_	_	I-Premise
136	,	_	_	I-Premise
137	P	_	_	I-Premise
138	=	_	_	I-Premise
139	0.02	_	_	I-Premise
140	)	_	_	I-Premise
141	,	_	_	I-Premise
142	and	_	_	I-Premise
143	18	_	_	I-Premise
144	months	_	_	I-Premise
145	(	_	_	I-Premise
146	13.6	_	_	I-Premise
147	vs	_	_	I-Premise
148	15.9	_	_	I-Premise
149	mmHg	_	_	I-Premise
150	,	_	_	I-Premise
151	P	_	_	I-Premise
152	=	_	_	I-Premise
153	0.01	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	Combined	_	_	B-Premise
157	phacotrabeculectomy	_	_	I-Premise
158	resulted	_	_	I-Premise
159	in	_	_	I-Premise
160	1.25	_	_	I-Premise
161	fewer	_	_	I-Premise
162	topical	_	_	I-Premise
163	glaucoma	_	_	I-Premise
164	drugs	_	_	I-Premise
165	(	_	_	I-Premise
166	P	_	_	I-Premise
167	<	_	_	I-Premise
168	0.001	_	_	I-Premise
169	)	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	24-month	_	_	I-Premise
173	postoperative	_	_	I-Premise
174	period	_	_	I-Premise
175	,	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	phacoemulsification	_	_	I-Premise
179	alone	_	_	I-Premise
180	.	_	_	I-Premise

181	Combined	_	_	B-Premise
182	surgery	_	_	I-Premise
183	was	_	_	I-Premise
184	associated	_	_	I-Premise
185	with	_	_	I-Premise
186	more	_	_	I-Premise
187	postoperative	_	_	I-Premise
188	complications	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	<	_	_	I-Premise
192	0.001	_	_	I-Premise
193	)	_	_	I-Premise
194	and	_	_	I-Premise
195	more	_	_	I-Premise
196	progression	_	_	I-Premise
197	of	_	_	I-Premise
198	optic	_	_	I-Premise
199	neuropathy	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	0.03	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	compared	_	_	I-Premise
207	with	_	_	I-Premise
208	phacoemulsification	_	_	I-Premise
209	alone	_	_	I-Premise
210	.	_	_	I-Premise

211	Combined	_	_	B-Claim
212	phacotrabeculectomy	_	_	I-Claim
213	with	_	_	I-Claim
214	adjunctive	_	_	I-Claim
215	mitomycin	_	_	I-Claim
216	C	_	_	I-Claim
217	is	_	_	I-Claim
218	more	_	_	I-Claim
219	effective	_	_	I-Claim
220	than	_	_	I-Claim
221	phacoemulsification	_	_	I-Claim
222	alone	_	_	I-Claim
223	in	_	_	I-Claim
224	controlling	_	_	I-Claim
225	IOP	_	_	I-Claim
226	in	_	_	I-Claim
227	medically	_	_	I-Claim
228	uncontrolled	_	_	I-Claim
229	CACG	_	_	I-Claim
230	eyes	_	_	I-Claim
231	with	_	_	I-Claim
232	coexisting	_	_	I-Claim
233	cataract	_	_	I-Claim
234	.	_	_	I-Claim

235	Combined	_	_	B-Claim
236	phacotrabeculectomy	_	_	I-Claim
237	is	_	_	I-Claim
238	associated	_	_	I-Claim
239	with	_	_	I-Claim
240	more	_	_	I-Claim
241	postoperative	_	_	I-Claim
242	complications	_	_	I-Claim
243	.	_	_	I-Claim


0	National	_	_	O
1	Cancer	_	_	O
2	Institute	_	_	O
3	of	_	_	O
4	Canada	_	_	O
5	Clinical	_	_	O
6	Trials	_	_	O
7	Group	_	_	O
8	CO.17	_	_	O
9	demonstrated	_	_	O
10	the	_	_	O
11	antiepidermal	_	_	O
12	growth	_	_	O
13	factor	_	_	O
14	receptor	_	_	O
15	(	_	_	O
16	anti-EGFR	_	_	O
17	)	_	_	O
18	monoclonal	_	_	O
19	antibody	_	_	O
20	cetuximab	_	_	O
21	improves	_	_	O
22	overall	_	_	O
23	and	_	_	O
24	progression-free	_	_	O
25	survival	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	advanced	_	_	O
30	,	_	_	O
31	chemotherapy-refractory	_	_	O
32	colorectal	_	_	O
33	cancer	_	_	O
34	(	_	_	O
35	CRC	_	_	O
36	)	_	_	O
37	,	_	_	O
38	particularly	_	_	O
39	in	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	wild-type	_	_	O
43	KRAS	_	_	O
44	tumors	_	_	O
45	.	_	_	O

46	This	_	_	O
47	article	_	_	O
48	reports	_	_	O
49	the	_	_	O
50	health-related	_	_	O
51	quality-of-life	_	_	O
52	(	_	_	O
53	HRQL	_	_	O
54	)	_	_	O
55	outcomes	_	_	O
56	from	_	_	O
57	CO.17	_	_	O
58	.	_	_	O

59	Patients	_	_	O
60	(	_	_	O
61	N	_	_	O
62	=	_	_	O
63	572	_	_	O
64	)	_	_	O
65	with	_	_	O
66	pretreated	_	_	O
67	EGFR-detectable	_	_	O
68	advanced	_	_	O
69	CRC	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	cetuximab	_	_	O
75	and	_	_	O
76	best	_	_	O
77	supportive	_	_	O
78	care	_	_	O
79	(	_	_	O
80	BSC	_	_	O
81	)	_	_	O
82	or	_	_	O
83	to	_	_	O
84	BSC	_	_	O
85	alone	_	_	O
86	.	_	_	O

87	HRQL	_	_	O
88	primary	_	_	O
89	end	_	_	O
90	points	_	_	O
91	assessed	_	_	O
92	by	_	_	O
93	the	_	_	O
94	EORTC	_	_	O
95	QLQ-C30	_	_	O
96	were	_	_	O
97	physical	_	_	O
98	function	_	_	O
99	(	_	_	O
100	PF	_	_	O
101	)	_	_	O
102	and	_	_	O
103	global	_	_	O
104	health	_	_	O
105	status	_	_	O
106	(	_	_	O
107	GHS	_	_	O
108	)	_	_	O
109	;	_	_	O
110	mean	_	_	O
111	changes	_	_	O
112	from	_	_	O
113	baseline	_	_	O
114	to	_	_	O
115	8	_	_	O
116	and	_	_	O
117	16	_	_	O
118	weeks	_	_	O
119	were	_	_	O
120	assessed	_	_	O
121	.	_	_	O

122	Post	_	_	O
123	hoc	_	_	O
124	analysis	_	_	O
125	by	_	_	O
126	KRAS	_	_	O
127	mutation	_	_	O
128	status	_	_	O
129	was	_	_	O
130	performed	_	_	O
131	.	_	_	O

132	Questionnaire	_	_	O
133	compliance	_	_	O
134	was	_	_	O
135	94	_	_	O
136	%	_	_	O
137	at	_	_	O
138	baseline	_	_	O
139	,	_	_	O
140	but	_	_	O
141	it	_	_	O
142	declined	_	_	O
143	differentially	_	_	O
144	(	_	_	O
145	67	_	_	O
146	%	_	_	O
147	v	_	_	O
148	47	_	_	O
149	%	_	_	O
150	for	_	_	O
151	cetuximab	_	_	O
152	v	_	_	O
153	BSC	_	_	O
154	at	_	_	O
155	16	_	_	O
156	weeks	_	_	O
157	)	_	_	O
158	.	_	_	O

159	PF	_	_	B-Premise
160	change	_	_	I-Premise
161	scores	_	_	I-Premise
162	were	_	_	I-Premise
163	-3.9	_	_	I-Premise
164	for	_	_	I-Premise
165	cetuximab	_	_	I-Premise
166	and	_	_	I-Premise
167	-8.6	_	_	I-Premise
168	for	_	_	I-Premise
169	BSC	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=	_	_	I-Premise
173	.046	_	_	I-Premise
174	)	_	_	I-Premise
175	at	_	_	I-Premise
176	8	_	_	I-Premise
177	weeks	_	_	I-Premise
178	and	_	_	I-Premise
179	were	_	_	I-Premise
180	-5.9	_	_	I-Premise
181	and	_	_	I-Premise
182	-12.5	_	_	I-Premise
183	for	_	_	I-Premise
184	cetuximab	_	_	I-Premise
185	and	_	_	I-Premise
186	BSC	_	_	I-Premise
187	,	_	_	I-Premise
188	respectively	_	_	I-Premise
189	,	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	=	_	_	I-Premise
193	.027	_	_	I-Premise
194	)	_	_	I-Premise
195	at	_	_	I-Premise
196	16	_	_	I-Premise
197	weeks	_	_	I-Premise
198	.	_	_	I-Premise

199	GHS	_	_	B-Premise
200	change	_	_	I-Premise
201	scores	_	_	I-Premise
202	were	_	_	I-Premise
203	-0.5	_	_	I-Premise
204	and	_	_	I-Premise
205	-7.1	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.008	_	_	I-Premise
210	)	_	_	I-Premise
211	at	_	_	I-Premise
212	8	_	_	I-Premise
213	weeks	_	_	I-Premise
214	and	_	_	I-Premise
215	were	_	_	I-Premise
216	-3.6	_	_	I-Premise
217	and	_	_	I-Premise
218	-15.2	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	.008	_	_	I-Premise
223	)	_	_	I-Premise
224	at	_	_	I-Premise
225	16	_	_	I-Premise
226	weeks	_	_	I-Premise
227	for	_	_	I-Premise
228	cetuximab	_	_	I-Premise
229	and	_	_	I-Premise
230	BSC	_	_	I-Premise
231	,	_	_	I-Premise
232	respectively	_	_	I-Premise
233	.	_	_	I-Premise

234	In	_	_	B-Premise
235	patients	_	_	I-Premise
236	who	_	_	I-Premise
237	had	_	_	I-Premise
238	tumors	_	_	I-Premise
239	with	_	_	I-Premise
240	wild-type	_	_	I-Premise
241	KRAS	_	_	I-Premise
242	status	_	_	I-Premise
243	,	_	_	I-Premise
244	cetuximab	_	_	I-Premise
245	resulted	_	_	I-Premise
246	in	_	_	I-Premise
247	less	_	_	I-Premise
248	PF	_	_	I-Premise
249	deterioration	_	_	I-Premise
250	at	_	_	I-Premise
251	8	_	_	I-Premise
252	weeks	_	_	I-Premise
253	(	_	_	I-Premise
254	-0.7	_	_	I-Premise
255	v	_	_	I-Premise
256	-7.2	_	_	I-Premise
257	;	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.11	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	16	_	_	I-Premise
264	weeks	_	_	I-Premise
265	(	_	_	I-Premise
266	-3.4	_	_	I-Premise
267	v	_	_	I-Premise
268	-13.8	_	_	I-Premise
269	;	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	.008	_	_	I-Premise
273	)	_	_	I-Premise
274	compared	_	_	I-Premise
275	with	_	_	I-Premise
276	BSC	_	_	I-Premise
277	.	_	_	I-Premise

278	Patients	_	_	B-Premise
279	with	_	_	I-Premise
280	wild-type	_	_	I-Premise
281	status	_	_	I-Premise
282	who	_	_	I-Premise
283	received	_	_	I-Premise
284	cetuximab	_	_	I-Premise
285	experienced	_	_	I-Premise
286	improved	_	_	I-Premise
287	GHS	_	_	I-Premise
288	at	_	_	I-Premise
289	8	_	_	I-Premise
290	weeks	_	_	I-Premise
291	,	_	_	I-Premise
292	whereas	_	_	I-Premise
293	patients	_	_	I-Premise
294	who	_	_	I-Premise
295	received	_	_	I-Premise
296	BSC	_	_	I-Premise
297	alone	_	_	I-Premise
298	deteriorated	_	_	I-Premise
299	(	_	_	I-Premise
300	3.2	_	_	I-Premise
301	v	_	_	I-Premise
302	-7.7	_	_	I-Premise
303	;	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	.002	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	Cetuximab	_	_	B-Premise
310	preserved	_	_	I-Premise
311	GHS	_	_	I-Premise
312	at	_	_	I-Premise
313	16	_	_	I-Premise
314	weeks	_	_	I-Premise
315	(	_	_	I-Premise
316	-0.2	_	_	I-Premise
317	v	_	_	I-Premise
318	-18.1	_	_	I-Premise
319	;	_	_	I-Premise
320	P	_	_	I-Premise
321	<	_	_	I-Premise
322	.001	_	_	I-Premise
323	)	_	_	I-Premise
324	.	_	_	I-Premise

325	No	_	_	B-Premise
326	significant	_	_	I-Premise
327	differences	_	_	I-Premise
328	were	_	_	I-Premise
329	noted	_	_	I-Premise
330	between	_	_	I-Premise
331	study	_	_	I-Premise
332	arms	_	_	I-Premise
333	for	_	_	I-Premise
334	patients	_	_	I-Premise
335	with	_	_	I-Premise
336	mutated	_	_	I-Premise
337	KRAS	_	_	I-Premise
338	tumors	_	_	I-Premise
339	.	_	_	I-Premise

340	Cetuximab	_	_	B-Claim
341	offers	_	_	I-Claim
342	important	_	_	I-Claim
343	HRQL	_	_	I-Claim
344	and	_	_	I-Claim
345	survival	_	_	I-Claim
346	benefits	_	_	I-Claim
347	for	_	_	I-Claim
348	pretreated	_	_	I-Claim
349	patients	_	_	I-Claim
350	with	_	_	I-Claim
351	advanced	_	_	I-Claim
352	,	_	_	I-Claim
353	wild-type	_	_	I-Claim
354	KRAS	_	_	I-Claim
355	CRC	_	_	I-Claim
356	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	clinical	_	_	O
9	outcomes	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	undergoing	_	_	O
17	surgery	_	_	O
18	for	_	_	O
19	pilonidal	_	_	O
20	disease	_	_	O
21	with	_	_	O
22	unroofing	_	_	O
23	and	_	_	O
24	marsupialization	_	_	O
25	(	_	_	O
26	UM	_	_	O
27	)	_	_	O
28	or	_	_	O
29	rhomboid	_	_	O
30	excision	_	_	O
31	and	_	_	O
32	Limberg	_	_	O
33	flap	_	_	O
34	(	_	_	O
35	RELP	_	_	O
36	)	_	_	O
37	procedures	_	_	O
38	.	_	_	O

39	One	_	_	O
40	hundred	_	_	O
41	forty	_	_	O
42	consecutive	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	pilonidal	_	_	O
46	sinus	_	_	O
47	were	_	_	O
48	randomly	_	_	O
49	assigned	_	_	O
50	to	_	_	O
51	receive	_	_	O
52	either	_	_	O
53	UM	_	_	O
54	or	_	_	O
55	RELP	_	_	O
56	procedures	_	_	O
57	.	_	_	O

58	A	_	_	O
59	specifically	_	_	O
60	designed	_	_	O
61	questionnaire	_	_	O
62	was	_	_	O
63	administered	_	_	O
64	at	_	_	O
65	three	_	_	O
66	months	_	_	O
67	to	_	_	O
68	assess	_	_	O
69	time	_	_	O
70	from	_	_	O
71	the	_	_	O
72	operation	_	_	O
73	until	_	_	O
74	the	_	_	O
75	patient	_	_	O
76	was	_	_	O
77	able	_	_	O
78	to	_	_	O
79	walk	_	_	O
80	,	_	_	O
81	return	_	_	O
82	to	_	_	O
83	daily	_	_	O
84	activities	_	_	O
85	,	_	_	O
86	or	_	_	O
87	sit	_	_	O
88	without	_	_	O
89	pain	_	_	O
90	,	_	_	O
91	time	_	_	O
92	to	_	_	O
93	return	_	_	O
94	to	_	_	O
95	work	_	_	O
96	or	_	_	O
97	school	_	_	O
98	,	_	_	O
99	and	_	_	O
100	time	_	_	O
101	to	_	_	O
102	healing	_	_	O
103	.	_	_	O

104	Postoperative	_	_	O
105	pain	_	_	O
106	was	_	_	O
107	assessed	_	_	O
108	with	_	_	O
109	a	_	_	O
110	visual	_	_	O
111	analog	_	_	O
112	scale	_	_	O
113	and	_	_	O
114	the	_	_	O
115	McGill	_	_	O
116	Pain	_	_	O
117	Questionnaire	_	_	O
118	.	_	_	O

119	Patients	_	_	O
120	'	_	_	O
121	quality	_	_	O
122	of	_	_	O
123	life	_	_	O
124	was	_	_	O
125	evaluated	_	_	O
126	with	_	_	O
127	the	_	_	O
128	Cardiff	_	_	O
129	Wound	_	_	O
130	Impact	_	_	O
131	Schedule	_	_	O
132	(	_	_	O
133	CWIS	_	_	O
134	)	_	_	O
135	.	_	_	O

136	Questionnaires	_	_	O
137	were	_	_	O
138	administered	_	_	O
139	by	_	_	O
140	a	_	_	O
141	clinician	_	_	O
142	blinded	_	_	O
143	to	_	_	O
144	treatment	_	_	O
145	.	_	_	O

146	Compared	_	_	B-Premise
147	with	_	_	I-Premise
148	RELP	_	_	I-Premise
149	,	_	_	I-Premise
150	patients	_	_	I-Premise
151	receiving	_	_	I-Premise
152	UM	_	_	I-Premise
153	had	_	_	I-Premise
154	significantly	_	_	I-Premise
155	shorter	_	_	I-Premise
156	duration	_	_	I-Premise
157	of	_	_	I-Premise
158	operation	_	_	I-Premise
159	and	_	_	I-Premise
160	hospital	_	_	I-Premise
161	stay	_	_	I-Premise
162	,	_	_	I-Premise
163	shorter	_	_	I-Premise
164	time	_	_	I-Premise
165	periods	_	_	I-Premise
166	to	_	_	I-Premise
167	walk	_	_	I-Premise
168	,	_	_	I-Premise
169	return	_	_	I-Premise
170	to	_	_	I-Premise
171	daily	_	_	I-Premise
172	activities	_	_	I-Premise
173	,	_	_	I-Premise
174	or	_	_	I-Premise
175	sit	_	_	I-Premise
176	without	_	_	I-Premise
177	pain	_	_	I-Premise
178	and	_	_	I-Premise
179	to	_	_	I-Premise
180	return	_	_	I-Premise
181	to	_	_	I-Premise
182	work	_	_	I-Premise
183	or	_	_	I-Premise
184	school	_	_	I-Premise
185	,	_	_	I-Premise
186	and	_	_	I-Premise
187	fewer	_	_	I-Premise
188	complications	_	_	I-Premise
189	.	_	_	I-Premise

190	Time	_	_	B-Premise
191	to	_	_	I-Premise
192	final	_	_	I-Premise
193	healing	_	_	I-Premise
194	was	_	_	I-Premise
195	significantly	_	_	I-Premise
196	shorter	_	_	I-Premise
197	and	_	_	I-Premise
198	quality	_	_	I-Premise
199	of	_	_	I-Premise
200	life	_	_	I-Premise
201	scores	_	_	I-Premise
202	on	_	_	I-Premise
203	the	_	_	I-Premise
204	CWIS	_	_	I-Premise
205	were	_	_	I-Premise
206	higher	_	_	I-Premise
207	in	_	_	I-Premise
208	patients	_	_	I-Premise
209	receiving	_	_	I-Premise
210	RELP	_	_	I-Premise
211	than	_	_	I-Premise
212	in	_	_	I-Premise
213	those	_	_	I-Premise
214	receiving	_	_	I-Premise
215	UM	_	_	I-Premise
216	.	_	_	I-Premise

217	Patients	_	_	B-Premise
218	with	_	_	I-Premise
219	UM	_	_	I-Premise
220	had	_	_	I-Premise
221	lower	_	_	I-Premise
222	levels	_	_	I-Premise
223	of	_	_	I-Premise
224	pain	_	_	I-Premise
225	one	_	_	I-Premise
226	week	_	_	I-Premise
227	after	_	_	I-Premise
228	surgery	_	_	I-Premise
229	.	_	_	I-Premise

230	The	_	_	B-Claim
231	unroofing	_	_	I-Claim
232	and	_	_	I-Claim
233	marsupialization	_	_	I-Claim
234	procedure	_	_	I-Claim
235	provides	_	_	I-Claim
236	more	_	_	I-Claim
237	clinical	_	_	I-Claim
238	benefits	_	_	I-Claim
239	in	_	_	I-Claim
240	the	_	_	I-Claim
241	treatment	_	_	I-Claim
242	of	_	_	I-Claim
243	pilonidal	_	_	I-Claim
244	disease	_	_	I-Claim
245	than	_	_	I-Claim
246	rhomboid	_	_	I-Claim
247	excision	_	_	I-Claim
248	and	_	_	I-Claim
249	Limberg	_	_	I-Claim
250	flap	_	_	I-Claim
251	and	_	_	I-Claim
252	should	_	_	I-Claim
253	be	_	_	I-Claim
254	considered	_	_	I-Claim
255	the	_	_	I-Claim
256	procedure	_	_	I-Claim
257	of	_	_	I-Claim
258	choice	_	_	I-Claim
259	.	_	_	I-Claim

260	However	_	_	B-Claim
261	,	_	_	I-Claim
262	it	_	_	I-Claim
263	may	_	_	I-Claim
264	be	_	_	I-Claim
265	associated	_	_	I-Claim
266	with	_	_	I-Claim
267	more	_	_	I-Claim
268	inconvenience	_	_	I-Claim
269	in	_	_	I-Claim
270	wound	_	_	I-Claim
271	care	_	_	I-Claim
272	and	_	_	I-Claim
273	longer	_	_	I-Claim
274	healing	_	_	I-Claim
275	time	_	_	I-Claim
276	than	_	_	I-Claim
277	rhomboid	_	_	I-Claim
278	excision	_	_	I-Claim
279	and	_	_	I-Claim
280	Lindberg	_	_	I-Claim
281	flap	_	_	I-Claim
282	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	establish	_	_	O
8	the	_	_	O
9	efficacy	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	the	_	_	O
14	Ex-PRESS	_	_	O
15	(	_	_	O
16	Optonol	_	_	O
17	Ltd.	_	_	O
18	,	_	_	O
19	Neve	_	_	O
20	Ilan	_	_	O
21	,	_	_	O
22	Israel	_	_	O
23	)	_	_	O
24	mini	_	_	O
25	glaucoma	_	_	O
26	shunt	_	_	O
27	in	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	.	_	_	O

31	This	_	_	O
32	was	_	_	O
33	a	_	_	O
34	prospective	_	_	O
35	,	_	_	O
36	randomized	_	_	O
37	trial	_	_	O
38	.	_	_	O

39	Eyes	_	_	O
40	from	_	_	O
41	enrolled	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomly	_	_	O
45	assigned	_	_	O
46	to	_	_	O
47	either	_	_	O
48	Ex-PRESS	_	_	O
49	implantation	_	_	O
50	under	_	_	O
51	a	_	_	O
52	scleral	_	_	O
53	flap	_	_	O
54	,	_	_	O
55	or	_	_	O
56	trabeculectomy	_	_	O
57	.	_	_	O

58	The	_	_	O
59	main	_	_	O
60	outcome	_	_	O
61	measures	_	_	O
62	were	_	_	O
63	:	_	_	O
64	mean	_	_	O
65	intraocular	_	_	O
66	pressure	_	_	O
67	(	_	_	O
68	IOP	_	_	O
69	)	_	_	O
70	,	_	_	O
71	postoperative	_	_	O
72	medication	_	_	O
73	use	_	_	O
74	,	_	_	O
75	visual	_	_	O
76	acuity	_	_	O
77	,	_	_	O
78	and	_	_	O
79	incidence	_	_	O
80	of	_	_	O
81	complications	_	_	O
82	.	_	_	O

83	Complete	_	_	O
84	success	_	_	O
85	was	_	_	O
86	defined	_	_	O
87	as	_	_	O
88	an	_	_	O
89	IOP	_	_	O
90	of	_	_	O
91	>	_	_	O
92	4	_	_	O
93	mmHg	_	_	O
94	and	_	_	O
95	<	_	_	O
96	or=18	_	_	O
97	mmHg	_	_	O
98	without	_	_	O
99	the	_	_	O
100	use	_	_	O
101	of	_	_	O
102	antiglaucoma	_	_	O
103	medications	_	_	O
104	.	_	_	O

105	A	_	_	O
106	more	_	_	O
107	stringent	_	_	O
108	target	_	_	O
109	of	_	_	O
110	IOP	_	_	O
111	>	_	_	O
112	4	_	_	O
113	mmHg	_	_	O
114	and	_	_	O
115	<	_	_	O
116	or=15	_	_	O
117	mmHg	_	_	O
118	was	_	_	O
119	also	_	_	O
120	noted	_	_	O
121	.	_	_	O

122	There	_	_	O
123	were	_	_	O
124	78	_	_	O
125	patients	_	_	O
126	(	_	_	O
127	80	_	_	O
128	eyes	_	_	O
129	)	_	_	O
130	with	_	_	O
131	primary	_	_	O
132	open-angle	_	_	O
133	,	_	_	O
134	pseudoexfoliative	_	_	O
135	,	_	_	O
136	or	_	_	O
137	pigmentary	_	_	O
138	glaucoma	_	_	O
139	enrolled	_	_	O
140	in	_	_	O
141	the	_	_	O
142	study	_	_	O
143	.	_	_	O

144	A	_	_	O
145	total	_	_	O
146	of	_	_	O
147	84.6	_	_	O
148	%	_	_	O
149	of	_	_	O
150	patients	_	_	O
151	receiving	_	_	O
152	Ex-PRESS	_	_	O
153	and	_	_	O
154	60.0	_	_	O
155	%	_	_	O
156	of	_	_	O
157	patients	_	_	O
158	receiving	_	_	O
159	trabeculectomy	_	_	O
160	(	_	_	O
161	P=0.0230	_	_	O
162	)	_	_	O
163	achieved	_	_	O
164	complete	_	_	O
165	success	_	_	O
166	.	_	_	O

167	The	_	_	O
168	respective	_	_	O
169	proportions	_	_	O
170	of	_	_	O
171	patients	_	_	O
172	achieving	_	_	O
173	an	_	_	O
174	IOP	_	_	O
175	>	_	_	O
176	4	_	_	O
177	mmHg	_	_	O
178	and	_	_	O
179	<	_	_	O
180	or=15	_	_	O
181	mmHg	_	_	O
182	were	_	_	O
183	76.9	_	_	O
184	%	_	_	O
185	and	_	_	O
186	50.0	_	_	O
187	%	_	_	O
188	(	_	_	O
189	P=0.0193	_	_	O
190	)	_	_	O
191	.	_	_	O

192	At	_	_	B-Premise
193	1-year	_	_	I-Premise
194	follow-up	_	_	I-Premise
195	,	_	_	I-Premise
196	complete	_	_	I-Premise
197	success	_	_	I-Premise
198	rates	_	_	I-Premise
199	were	_	_	I-Premise
200	81.8	_	_	I-Premise
201	%	_	_	I-Premise
202	for	_	_	I-Premise
203	Ex-PRESS	_	_	I-Premise
204	and	_	_	I-Premise
205	47.5	_	_	I-Premise
206	%	_	_	I-Premise
207	for	_	_	I-Premise
208	trabeculectomy	_	_	I-Premise
209	(	_	_	I-Premise
210	P=0.0020	_	_	I-Premise
211	)	_	_	I-Premise
212	,	_	_	I-Premise
213	and	_	_	I-Premise
214	71.7	_	_	I-Premise
215	%	_	_	I-Premise
216	and	_	_	I-Premise
217	37.5	_	_	I-Premise
218	%	_	_	I-Premise
219	(	_	_	I-Premise
220	P=0.0070	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	respectively	_	_	I-Premise
224	,	_	_	I-Premise
225	for	_	_	I-Premise
226	the	_	_	I-Premise
227	more	_	_	I-Premise
228	stringent	_	_	I-Premise
229	target	_	_	I-Premise
230	.	_	_	I-Premise

231	There	_	_	B-Premise
232	was	_	_	I-Premise
233	a	_	_	I-Premise
234	similar	_	_	I-Premise
235	level	_	_	I-Premise
236	of	_	_	I-Premise
237	postoperative	_	_	I-Premise
238	interventions	_	_	I-Premise
239	and	_	_	I-Premise
240	complications	_	_	I-Premise
241	for	_	_	I-Premise
242	each	_	_	I-Premise
243	group	_	_	I-Premise
244	.	_	_	I-Premise

245	In	_	_	B-Claim
246	open-angle	_	_	I-Claim
247	glaucoma	_	_	I-Claim
248	,	_	_	I-Claim
249	the	_	_	I-Claim
250	Ex-PRESS	_	_	I-Claim
251	mini	_	_	I-Claim
252	glaucoma	_	_	I-Claim
253	shunt	_	_	I-Claim
254	implanted	_	_	I-Claim
255	under	_	_	I-Claim
256	a	_	_	I-Claim
257	superficial	_	_	I-Claim
258	scleral	_	_	I-Claim
259	flap	_	_	I-Claim
260	produces	_	_	I-Claim
261	significantly	_	_	I-Claim
262	higher	_	_	I-Claim
263	success	_	_	I-Claim
264	rates	_	_	I-Claim
265	,	_	_	I-Claim
266	and	_	_	I-Claim
267	a	_	_	I-Claim
268	similar	_	_	I-Claim
269	complication	_	_	I-Claim
270	rate	_	_	I-Claim
271	,	_	_	I-Claim
272	compared	_	_	I-Claim
273	with	_	_	I-Claim
274	trabeculectomy	_	_	I-Claim
275	.	_	_	I-Claim

276	The	_	_	B-Claim
277	Ex-PRESS	_	_	I-Claim
278	is	_	_	I-Claim
279	a	_	_	I-Claim
280	safe	_	_	I-Claim
281	and	_	_	I-Claim
282	effective	_	_	I-Claim
283	device	_	_	I-Claim
284	for	_	_	I-Claim
285	treating	_	_	I-Claim
286	open-angle	_	_	I-Claim
287	glaucoma	_	_	I-Claim
288	.	_	_	I-Claim


0	We	_	_	O
1	evaluated	_	_	O
2	the	_	_	O
3	role	_	_	O
4	of	_	_	O
5	glutathione-related	_	_	O
6	genotypes	_	_	O
7	on	_	_	O
8	overall	_	_	O
9	survival	_	_	O
10	,	_	_	O
11	time	_	_	O
12	to	_	_	O
13	progression	_	_	O
14	,	_	_	O
15	adverse	_	_	O
16	events	_	_	O
17	,	_	_	O
18	and	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	in	_	_	O
26	stage	_	_	O
27	IIIB/IV	_	_	O
28	non-small	_	_	O
29	cell	_	_	O
30	lung	_	_	O
31	cancer	_	_	O
32	patients	_	_	O
33	who	_	_	O
34	were	_	_	O
35	stable	_	_	O
36	or	_	_	O
37	responding	_	_	O
38	from	_	_	O
39	initial	_	_	O
40	treatment	_	_	O
41	with	_	_	O
42	platinum-based	_	_	O
43	chemotherapy	_	_	O
44	and	_	_	O
45	subsequently	_	_	O
46	randomized	_	_	O
47	to	_	_	O
48	receive	_	_	O
49	daily	_	_	O
50	oral	_	_	O
51	carboxyaminoimidazole	_	_	O
52	or	_	_	O
53	a	_	_	O
54	placebo	_	_	O
55	.	_	_	O

56	Of	_	_	O
57	the	_	_	O
58	186	_	_	O
59	total	_	_	O
60	patients	_	_	O
61	,	_	_	O
62	113	_	_	O
63	had	_	_	O
64	initial	_	_	O
65	treatment	_	_	O
66	with	_	_	O
67	platinum	_	_	O
68	therapy	_	_	O
69	and	_	_	O
70	DNA	_	_	O
71	samples	_	_	O
72	of	_	_	O
73	whom	_	_	O
74	46	_	_	O
75	also	_	_	O
76	had	_	_	O
77	QOL	_	_	O
78	data	_	_	O
79	.	_	_	O

80	These	_	_	O
81	samples	_	_	O
82	were	_	_	O
83	analyzed	_	_	O
84	using	_	_	O
85	six	_	_	O
86	polymorphic	_	_	O
87	DNA	_	_	O
88	markers	_	_	O
89	that	_	_	O
90	encode	_	_	O
91	five	_	_	O
92	important	_	_	O
93	enzymes	_	_	O
94	in	_	_	O
95	the	_	_	O
96	glutathione	_	_	O
97	metabolic	_	_	O
98	pathway	_	_	O
99	.	_	_	O

100	Patient	_	_	O
101	QOL	_	_	O
102	was	_	_	O
103	assessed	_	_	O
104	using	_	_	O
105	the	_	_	O
106	Functional	_	_	O
107	Assessment	_	_	O
108	of	_	_	O
109	Cancer	_	_	O
110	Therapy-Lung	_	_	O
111	and	_	_	O
112	the	_	_	O
113	UNISCALE	_	_	O
114	QOL	_	_	O
115	questionnaires	_	_	O
116	.	_	_	O

117	A	_	_	O
118	clinically	_	_	O
119	significant	_	_	O
120	decline	_	_	O
121	in	_	_	O
122	QOL	_	_	O
123	was	_	_	O
124	defined	_	_	O
125	as	_	_	O
126	a	_	_	O
127	10	_	_	O
128	%	_	_	O
129	decrease	_	_	O
130	from	_	_	O
131	baseline	_	_	O
132	to	_	_	O
133	week-8	_	_	O
134	.	_	_	O

135	Multivariate	_	_	O
136	analyses	_	_	O
137	were	_	_	O
138	used	_	_	O
139	to	_	_	O
140	evaluate	_	_	O
141	the	_	_	O
142	association	_	_	O
143	of	_	_	O
144	the	_	_	O
145	genotypes	_	_	O
146	on	_	_	O
147	the	_	_	O
148	four	_	_	O
149	endpoints	_	_	O
150	.	_	_	O

151	Patients	_	_	B-Premise
152	carrying	_	_	I-Premise
153	a	_	_	I-Premise
154	GCLC	_	_	I-Premise
155	77	_	_	I-Premise
156	genotype	_	_	I-Premise
157	had	_	_	I-Premise
158	a	_	_	I-Premise
159	worse	_	_	I-Premise
160	overall	_	_	I-Premise
161	survival	_	_	I-Premise
162	(	_	_	I-Premise
163	hazard	_	_	I-Premise
164	ratio	_	_	I-Premise
165	(	_	_	I-Premise
166	HR	_	_	I-Premise
167	)	_	_	I-Premise
168	=	_	_	I-Premise
169	1.5	_	_	I-Premise
170	,	_	_	I-Premise
171	p	_	_	I-Premise
172	=	_	_	I-Premise
173	0.05	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	Patients	_	_	B-Premise
177	carrying	_	_	I-Premise
178	the	_	_	I-Premise
179	GPX1-CC	_	_	I-Premise
180	genotype	_	_	I-Premise
181	had	_	_	I-Premise
182	a	_	_	I-Premise
183	clinically	_	_	I-Premise
184	significant	_	_	I-Premise
185	decline	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	UNISCALE	_	_	I-Premise
189	(	_	_	I-Premise
190	odds	_	_	I-Premise
191	ratio	_	_	I-Premise
192	(	_	_	I-Premise
193	OR	_	_	I-Premise
194	)	_	_	I-Premise
195	:	_	_	I-Premise
196	7.5	_	_	I-Premise
197	;	_	_	I-Premise
198	p	_	_	I-Premise
199	=	_	_	I-Premise
200	0.04	_	_	I-Premise
201	)	_	_	I-Premise
202	,	_	_	I-Premise
203	total	_	_	I-Premise
204	Functional	_	_	I-Premise
205	Assessment	_	_	I-Premise
206	of	_	_	I-Premise
207	Cancer	_	_	I-Premise
208	Therapy-Lung	_	_	I-Premise
209	score	_	_	I-Premise
210	(	_	_	I-Premise
211	OR	_	_	I-Premise
212	:	_	_	I-Premise
213	11.0	_	_	I-Premise
214	;	_	_	I-Premise
215	p	_	_	I-Premise
216	=	_	_	I-Premise
217	0.04	_	_	I-Premise
218	)	_	_	I-Premise
219	,	_	_	I-Premise
220	physical	_	_	I-Premise
221	(	_	_	I-Premise
222	OR	_	_	I-Premise
223	:	_	_	I-Premise
224	7.1	_	_	I-Premise
225	;	_	_	I-Premise
226	p	_	_	I-Premise
227	=	_	_	I-Premise
228	0.03	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	functional	_	_	I-Premise
232	(	_	_	I-Premise
233	OR	_	_	I-Premise
234	:	_	_	I-Premise
235	5.2	_	_	I-Premise
236	;	_	_	I-Premise
237	p	_	_	I-Premise
238	=	_	_	I-Premise
239	0.04	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	emotional	_	_	I-Premise
244	well-being	_	_	I-Premise
245	constructs	_	_	I-Premise
246	(	_	_	I-Premise
247	OR	_	_	I-Premise
248	:	_	_	I-Premise
249	23.8	_	_	I-Premise
250	;	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.01	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Genotypes	_	_	B-Claim
257	of	_	_	I-Claim
258	glutathione-related	_	_	I-Claim
259	enzymes	_	_	I-Claim
260	,	_	_	I-Claim
261	especially	_	_	I-Claim
262	GCLC	_	_	I-Claim
263	,	_	_	I-Claim
264	may	_	_	I-Claim
265	be	_	_	I-Claim
266	used	_	_	I-Claim
267	as	_	_	I-Claim
268	host	_	_	I-Claim
269	factors	_	_	I-Claim
270	in	_	_	I-Claim
271	predicting	_	_	I-Claim
272	patients	_	_	I-Claim
273	'	_	_	I-Claim
274	survival	_	_	I-Claim
275	after	_	_	I-Claim
276	platinum-based	_	_	I-Claim
277	chemotherapy	_	_	I-Claim
278	.	_	_	I-Claim

279	GPX1	_	_	B-Claim
280	may	_	_	I-Claim
281	be	_	_	I-Claim
282	an	_	_	I-Claim
283	inherited	_	_	I-Claim
284	factor	_	_	I-Claim
285	in	_	_	I-Claim
286	predicting	_	_	I-Claim
287	patients	_	_	I-Claim
288	'	_	_	I-Claim
289	QOL	_	_	I-Claim
290	.	_	_	I-Claim

291	Further	_	_	B-Claim
292	investigation	_	_	I-Claim
293	to	_	_	I-Claim
294	define	_	_	I-Claim
295	and	_	_	I-Claim
296	measure	_	_	I-Claim
297	the	_	_	I-Claim
298	effects	_	_	I-Claim
299	of	_	_	I-Claim
300	these	_	_	I-Claim
301	genes	_	_	I-Claim
302	in	_	_	I-Claim
303	chemotherapeutic	_	_	I-Claim
304	regimens	_	_	I-Claim
305	,	_	_	I-Claim
306	drug	_	_	I-Claim
307	toxicities	_	_	I-Claim
308	,	_	_	I-Claim
309	disease	_	_	I-Claim
310	progression	_	_	I-Claim
311	,	_	_	I-Claim
312	and	_	_	I-Claim
313	QOL	_	_	I-Claim
314	are	_	_	I-Claim
315	critical	_	_	I-Claim
316	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	and	_	_	O
3	compare	_	_	O
4	radiologic	_	_	O
5	lung	_	_	O
6	expansion	_	_	O
7	after	_	_	O
8	talc	_	_	O
9	pleurodesis	_	_	O
10	performed	_	_	O
11	either	_	_	O
12	by	_	_	O
13	videothoracoscopy	_	_	O
14	or	_	_	O
15	chest	_	_	O
16	tube	_	_	O
17	and	_	_	O
18	correlate	_	_	O
19	it	_	_	O
20	with	_	_	O
21	clinical	_	_	O
22	outcome	_	_	O
23	.	_	_	O

24	Secondary	_	_	O
25	end	_	_	O
26	points	_	_	O
27	evaluated	_	_	O
28	were	_	_	O
29	as	_	_	O
30	follows	_	_	O
31	:	_	_	O
32	clinical	_	_	O
33	efficacy	_	_	O
34	;	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	;	_	_	O
39	safety	_	_	O
40	;	_	_	O
41	and	_	_	O
42	survival	_	_	O
43	.	_	_	O

44	Prospective	_	_	O
45	randomized	_	_	O
46	study	_	_	O
47	that	_	_	O
48	included	_	_	O
49	60	_	_	O
50	patients	_	_	O
51	(	_	_	O
52	45	_	_	O
53	women	_	_	O
54	,	_	_	O
55	15	_	_	O
56	men	_	_	O
57	;	_	_	O
58	mean	_	_	O
59	age	_	_	O
60	,	_	_	O
61	55.2	_	_	O
62	years	_	_	O
63	)	_	_	O
64	with	_	_	O
65	recurrent	_	_	O
66	malignant	_	_	O
67	pleural	_	_	O
68	effusion	_	_	O
69	between	_	_	O
70	January	_	_	O
71	2005	_	_	O
72	and	_	_	O
73	January	_	_	O
74	2008	_	_	O
75	.	_	_	O

76	They	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	into	_	_	O
80	the	_	_	O
81	following	_	_	O
82	two	_	_	O
83	groups	_	_	O
84	:	_	_	O
85	video-assisted	_	_	O
86	thoracic	_	_	O
87	surgery	_	_	O
88	(	_	_	O
89	VATS	_	_	O
90	)	_	_	O
91	talc	_	_	O
92	poudrage	_	_	O
93	;	_	_	O
94	and	_	_	O
95	talc	_	_	O
96	slurry	_	_	O
97	(	_	_	O
98	TS	_	_	O
99	)	_	_	O
100	administered	_	_	O
101	through	_	_	O
102	a	_	_	O
103	chest	_	_	O
104	tube	_	_	O
105	.	_	_	O

106	Lung	_	_	O
107	expansion	_	_	O
108	was	_	_	O
109	evaluated	_	_	O
110	through	_	_	O
111	chest	_	_	O
112	CT	_	_	O
113	scans	_	_	O
114	obtained	_	_	O
115	0	_	_	O
116	,	_	_	O
117	1	_	_	O
118	,	_	_	O
119	3	_	_	O
120	and	_	_	O
121	6	_	_	O
122	months	_	_	O
123	after	_	_	O
124	pleurodesis	_	_	O
125	.	_	_	O

126	Complications	_	_	O
127	,	_	_	O
128	drainage	_	_	O
129	time	_	_	O
130	,	_	_	O
131	hospital	_	_	O
132	stay	_	_	O
133	,	_	_	O
134	and	_	_	O
135	quality	_	_	O
136	of	_	_	O
137	life	_	_	O
138	(	_	_	O
139	Medical	_	_	O
140	Outcomes	_	_	O
141	Study	_	_	O
142	36-item	_	_	O
143	short	_	_	O
144	form	_	_	O
145	and	_	_	O
146	World	_	_	O
147	Health	_	_	O
148	Organization	_	_	O
149	quality-of-life	_	_	O
150	questionnaires	_	_	O
151	)	_	_	O
152	were	_	_	O
153	also	_	_	O
154	analyzed	_	_	O
155	.	_	_	O

156	There	_	_	O
157	were	_	_	O
158	no	_	_	O
159	significant	_	_	O
160	differences	_	_	O
161	in	_	_	O
162	preprocedure	_	_	O
163	clinical	_	_	O
164	and	_	_	O
165	pathologic	_	_	O
166	variables	_	_	O
167	between	_	_	O
168	groups	_	_	O
169	.	_	_	O

170	The	_	_	O
171	immediate	_	_	O
172	total	_	_	O
173	(	_	_	O
174	ie	_	_	O
175	,	_	_	O
176	>	_	_	O
177	90	_	_	O
178	%	_	_	O
179	)	_	_	O
180	lung	_	_	O
181	expansion	_	_	O
182	was	_	_	O
183	observed	_	_	O
184	in	_	_	O
185	27	_	_	O
186	patients	_	_	O
187	(	_	_	O
188	45	_	_	O
189	%	_	_	O
190	)	_	_	O
191	and	_	_	O
192	was	_	_	O
193	more	_	_	O
194	frequent	_	_	O
195	in	_	_	O
196	the	_	_	O
197	VATS	_	_	O
198	group	_	_	O
199	(	_	_	O
200	60	_	_	O
201	%	_	_	O
202	vs	_	_	O
203	30	_	_	O
204	%	_	_	O
205	,	_	_	O
206	respectively	_	_	O
207	;	_	_	O
208	p	_	_	O
209	=	_	_	O
210	0.027	_	_	O
211	)	_	_	O
212	.	_	_	O

213	During	_	_	B-Premise
214	follow-up	_	_	I-Premise
215	,	_	_	I-Premise
216	71	_	_	I-Premise
217	%	_	_	I-Premise
218	of	_	_	I-Premise
219	the	_	_	I-Premise
220	patients	_	_	I-Premise
221	showed	_	_	I-Premise
222	unaltered	_	_	I-Premise
223	or	_	_	I-Premise
224	improved	_	_	I-Premise
225	lung	_	_	I-Premise
226	expansion	_	_	I-Premise
227	and	_	_	I-Premise
228	9	_	_	I-Premise
229	patients	_	_	I-Premise
230	(	_	_	I-Premise
231	15	_	_	I-Premise
232	%	_	_	I-Premise
233	)	_	_	I-Premise
234	needed	_	_	I-Premise
235	new	_	_	I-Premise
236	pleural	_	_	I-Premise
237	procedures	_	_	I-Premise
238	(	_	_	I-Premise
239	VATS	_	_	I-Premise
240	group	_	_	I-Premise
241	,	_	_	I-Premise
242	5	_	_	I-Premise
243	recurrences	_	_	I-Premise
244	;	_	_	I-Premise
245	TS	_	_	I-Premise
246	group	_	_	I-Premise
247	,	_	_	I-Premise
248	4	_	_	I-Premise
249	recurrences	_	_	I-Premise
250	;	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.999	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	No	_	_	B-Premise
257	differences	_	_	I-Premise
258	were	_	_	I-Premise
259	found	_	_	I-Premise
260	between	_	_	I-Premise
261	groups	_	_	I-Premise
262	regarding	_	_	I-Premise
263	quality	_	_	I-Premise
264	of	_	_	I-Premise
265	life	_	_	I-Premise
266	,	_	_	I-Premise
267	complications	_	_	I-Premise
268	,	_	_	I-Premise
269	drainage	_	_	I-Premise
270	time	_	_	I-Premise
271	,	_	_	I-Premise
272	hospital	_	_	I-Premise
273	stay	_	_	I-Premise
274	,	_	_	I-Premise
275	and	_	_	I-Premise
276	survival	_	_	I-Premise
277	.	_	_	I-Premise

278	Immediate	_	_	B-Premise
279	lung	_	_	I-Premise
280	expansion	_	_	I-Premise
281	did	_	_	I-Premise
282	not	_	_	I-Premise
283	correlate	_	_	I-Premise
284	with	_	_	I-Premise
285	radiologic	_	_	I-Premise
286	recurrence	_	_	I-Premise
287	,	_	_	I-Premise
288	clinical	_	_	I-Premise
289	recurrence	_	_	I-Premise
290	,	_	_	I-Premise
291	or	_	_	I-Premise
292	complications	_	_	I-Premise
293	(	_	_	I-Premise
294	p	_	_	I-Premise
295	=	_	_	I-Premise
296	0.60	_	_	I-Premise
297	,	_	_	I-Premise
298	0.15	_	_	I-Premise
299	,	_	_	I-Premise
300	and	_	_	I-Premise
301	0.20	_	_	I-Premise
302	,	_	_	I-Premise
303	respectively	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	Immediate	_	_	B-Premise
307	partial	_	_	I-Premise
308	lung	_	_	I-Premise
309	expansion	_	_	I-Premise
310	was	_	_	I-Premise
311	a	_	_	I-Premise
312	frequent	_	_	I-Premise
313	finding	_	_	I-Premise
314	and	_	_	I-Premise
315	was	_	_	I-Premise
316	more	_	_	I-Premise
317	frequent	_	_	I-Premise
318	after	_	_	I-Premise
319	TS	_	_	I-Premise
320	.	_	_	I-Premise

321	Nonetheless	_	_	O
322	,	_	_	O
323	no	_	_	B-Claim
324	correlation	_	_	I-Claim
325	between	_	_	I-Claim
326	immediate	_	_	I-Claim
327	lung	_	_	I-Claim
328	expansion	_	_	I-Claim
329	and	_	_	I-Claim
330	clinical	_	_	I-Claim
331	outcome	_	_	I-Claim
332	was	_	_	I-Claim
333	found	_	_	I-Claim
334	in	_	_	I-Claim
335	this	_	_	I-Claim
336	study	_	_	I-Claim
337	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	latanoprost	_	_	O
3	and	_	_	O
4	timolol	_	_	O
5	with	_	_	O
6	regard	_	_	O
7	to	_	_	O
8	changes	_	_	O
9	in	_	_	O
10	the	_	_	O
11	intervisit	_	_	O
12	intraocular	_	_	O
13	pressure	_	_	O
14	(	_	_	O
15	IOP	_	_	O
16	)	_	_	O
17	range	_	_	O
18	,	_	_	O
19	a	_	_	O
20	measure	_	_	O
21	of	_	_	O
22	long-term	_	_	O
23	IOP	_	_	O
24	fluctuation	_	_	O
25	.	_	_	O

26	Post	_	_	O
27	hoc	_	_	O
28	analysis	_	_	O
29	of	_	_	O
30	three	_	_	O
31	6-month	_	_	O
32	,	_	_	O
33	multicenter	_	_	O
34	,	_	_	O
35	randomized	_	_	O
36	(	_	_	O
37	1:1	_	_	O
38	)	_	_	O
39	,	_	_	O
40	double-masked	_	_	O
41	registration	_	_	O
42	trials	_	_	O
43	of	_	_	O
44	latanoprost	_	_	O
45	(	_	_	O
46	n	_	_	O
47	=	_	_	O
48	313	_	_	O
49	)	_	_	O
50	vs	_	_	O
51	timolol	_	_	O
52	(	_	_	O
53	n	_	_	O
54	=	_	_	O
55	318	_	_	O
56	)	_	_	O
57	.	_	_	O

58	Analyses	_	_	O
59	included	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	glaucoma	_	_	O
63	or	_	_	O
64	ocular	_	_	O
65	hypertension	_	_	O
66	who	_	_	O
67	instilled	_	_	O
68	latanoprost	_	_	O
69	once	_	_	O
70	daily	_	_	O
71	in	_	_	O
72	the	_	_	O
73	evening	_	_	O
74	and	_	_	O
75	vehicle	_	_	O
76	in	_	_	O
77	the	_	_	O
78	morning	_	_	O
79	and	_	_	O
80	those	_	_	O
81	instilling	_	_	O
82	timolol	_	_	O
83	twice	_	_	O
84	daily	_	_	O
85	.	_	_	O

86	Pretreatment	_	_	O
87	intervisit	_	_	O
88	IOP	_	_	O
89	range	_	_	O
90	:	_	_	O
91	highest	_	_	O
92	IOP	_	_	O
93	minus	_	_	O
94	lowest	_	_	O
95	IOP	_	_	O
96	of	_	_	O
97	4	_	_	O
98	measurements	_	_	O
99	obtained	_	_	O
100	at	_	_	O
101	screening	_	_	O
102	and	_	_	O
103	baseline	_	_	O
104	.	_	_	O

105	Posttreatment	_	_	O
106	intervisit	_	_	O
107	IOP	_	_	O
108	range	_	_	O
109	:	_	_	O
110	highest	_	_	O
111	IOP	_	_	O
112	minus	_	_	O
113	lowest	_	_	O
114	IOP	_	_	O
115	of	_	_	O
116	4	_	_	O
117	measurements	_	_	O
118	obtained	_	_	O
119	at	_	_	O
120	weeks	_	_	O
121	18	_	_	O
122	and	_	_	O
123	26	_	_	O
124	.	_	_	O

125	Ranges	_	_	O
126	were	_	_	O
127	dichotomized	_	_	O
128	to	_	_	O
129	high	_	_	O
130	(	_	_	O
131	>	_	_	O
132	6	_	_	O
133	mm	_	_	O
134	Hg	_	_	O
135	)	_	_	O
136	and	_	_	O
137	low	_	_	O
138	(	_	_	O
139	<	_	_	O
140	or	_	_	O
141	=	_	_	O
142	6	_	_	O
143	mm	_	_	O
144	Hg	_	_	O
145	)	_	_	O
146	.	_	_	O

147	Both	_	_	B-Claim
148	treatments	_	_	I-Claim
149	resulted	_	_	I-Claim
150	in	_	_	I-Claim
151	significant	_	_	I-Claim
152	reductions	_	_	I-Claim
153	in	_	_	I-Claim
154	mean	_	_	I-Claim
155	intervisit	_	_	I-Claim
156	IOP	_	_	I-Claim
157	range	_	_	I-Claim
158	during	_	_	I-Claim
159	26	_	_	I-Claim
160	weeks	_	_	I-Claim
161	.	_	_	I-Claim

162	Pretreatment	_	_	O
163	,	_	_	O
164	comparable	_	_	O
165	proportions	_	_	O
166	of	_	_	O
167	patients	_	_	O
168	treated	_	_	O
169	with	_	_	O
170	latanoprost	_	_	O
171	and	_	_	O
172	timolol	_	_	O
173	had	_	_	O
174	high	_	_	O
175	intervisit	_	_	O
176	IOP	_	_	O
177	ranges	_	_	O
178	(	_	_	O
179	22	_	_	O
180	%	_	_	O
181	[	_	_	O
182	70/313	_	_	O
183	]	_	_	O
184	and	_	_	O
185	23	_	_	O
186	%	_	_	O
187	[	_	_	O
188	72/318	_	_	O
189	]	_	_	O
190	,	_	_	O
191	respectively	_	_	O
192	;	_	_	O
193	P	_	_	O
194	=	_	_	O
195	.934	_	_	O
196	)	_	_	O
197	.	_	_	O

198	After	_	_	B-Premise
199	treatment	_	_	I-Premise
200	,	_	_	I-Premise
201	6	_	_	I-Premise
202	%	_	_	I-Premise
203	(	_	_	I-Premise
204	19/313	_	_	I-Premise
205	)	_	_	I-Premise
206	and	_	_	I-Premise
207	11	_	_	I-Premise
208	%	_	_	I-Premise
209	(	_	_	I-Premise
210	35/318	_	_	I-Premise
211	)	_	_	I-Premise
212	of	_	_	I-Premise
213	patients	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	latanoprost	_	_	I-Premise
217	and	_	_	I-Premise
218	timolol	_	_	I-Premise
219	groups	_	_	I-Premise
220	,	_	_	I-Premise
221	respectively	_	_	I-Premise
222	,	_	_	I-Premise
223	had	_	_	I-Premise
224	high	_	_	I-Premise
225	intervisit	_	_	I-Premise
226	IOP	_	_	I-Premise
227	ranges	_	_	I-Premise
228	(	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	.026	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	Significant	_	_	B-Premise
235	risk	_	_	I-Premise
236	factors	_	_	I-Premise
237	for	_	_	I-Premise
238	high	_	_	I-Premise
239	posttreatment	_	_	I-Premise
240	intervisit	_	_	I-Premise
241	range	_	_	I-Premise
242	(	_	_	I-Premise
243	multivariate	_	_	I-Premise
244	logistic	_	_	I-Premise
245	regression	_	_	I-Premise
246	)	_	_	I-Premise
247	were	_	_	I-Premise
248	high	_	_	I-Premise
249	pretreatment	_	_	I-Premise
250	intervisit	_	_	I-Premise
251	IOP	_	_	I-Premise
252	range	_	_	I-Premise
253	,	_	_	I-Premise
254	treatment	_	_	I-Premise
255	with	_	_	I-Premise
256	timolol	_	_	I-Premise
257	,	_	_	I-Premise
258	Black	_	_	I-Premise
259	race	_	_	I-Premise
260	,	_	_	I-Premise
261	longer	_	_	I-Premise
262	time	_	_	I-Premise
263	since	_	_	I-Premise
264	diagnosis	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	higher	_	_	I-Premise
268	mean	_	_	I-Premise
269	pretreatment	_	_	I-Premise
270	IOP	_	_	I-Premise
271	.	_	_	I-Premise

272	Compared	_	_	B-Claim
273	with	_	_	I-Claim
274	timolol	_	_	I-Claim
275	,	_	_	I-Claim
276	treatment	_	_	I-Claim
277	with	_	_	I-Claim
278	latanoprost	_	_	I-Claim
279	results	_	_	I-Claim
280	in	_	_	I-Claim
281	significantly	_	_	I-Claim
282	fewer	_	_	I-Claim
283	patients	_	_	I-Claim
284	with	_	_	I-Claim
285	a	_	_	I-Claim
286	high	_	_	I-Claim
287	IOP	_	_	I-Claim
288	fluctuation	_	_	I-Claim
289	.	_	_	I-Claim

290	The	_	_	O
291	impact	_	_	O
292	of	_	_	O
293	reducing	_	_	O
294	high	_	_	O
295	IOP	_	_	O
296	fluctuation	_	_	O
297	on	_	_	O
298	progressive	_	_	O
299	glaucomatous	_	_	O
300	damage	_	_	O
301	deserves	_	_	O
302	further	_	_	O
303	investigation	_	_	O
304	in	_	_	O
305	prospective	_	_	O
306	studies	_	_	O
307	.	_	_	O


0	A	_	_	O
1	dramatic	_	_	O
2	rise	_	_	O
3	in	_	_	O
4	incidence	_	_	O
5	,	_	_	O
6	an	_	_	O
7	aging	_	_	O
8	population	_	_	O
9	,	_	_	O
10	and	_	_	O
11	expensive	_	_	O
12	palliative	_	_	O
13	treatments	_	_	O
14	have	_	_	O
15	led	_	_	O
16	to	_	_	O
17	an	_	_	O
18	escalating	_	_	O
19	burden	_	_	O
20	on	_	_	O
21	clinicians	_	_	O
22	managing	_	_	O
23	inoperable	_	_	O
24	esophageal	_	_	O
25	cancer	_	_	O
26	with	_	_	O
27	only	_	_	O
28	limited	_	_	O
29	evidence	_	_	O
30	of	_	_	O
31	effectiveness	_	_	O
32	.	_	_	O

33	This	_	_	O
34	study	_	_	O
35	compares	_	_	O
36	the	_	_	O
37	clinical	_	_	O
38	effectiveness	_	_	O
39	and	_	_	O
40	cost-effectiveness	_	_	O
41	of	_	_	O
42	self-expanding	_	_	O
43	metal	_	_	O
44	stents	_	_	O
45	(	_	_	O
46	SEMSs	_	_	O
47	)	_	_	O
48	with	_	_	O
49	other	_	_	O
50	palliative	_	_	O
51	therapies	_	_	O
52	to	_	_	O
53	aid	_	_	O
54	clinicians	_	_	O
55	in	_	_	O
56	making	_	_	O
57	an	_	_	O
58	evidence-based	_	_	O
59	treatment	_	_	O
60	choice	_	_	O
61	.	_	_	O

62	We	_	_	O
63	conducted	_	_	O
64	a	_	_	O
65	prospective	_	_	O
66	,	_	_	O
67	multicenter	_	_	O
68	,	_	_	O
69	randomized	_	_	O
70	,	_	_	O
71	controlled	_	_	O
72	,	_	_	O
73	clinical	_	_	O
74	trial	_	_	O
75	with	_	_	O
76	215	_	_	O
77	patients	_	_	O
78	followed	_	_	O
79	until	_	_	O
80	death	_	_	O
81	or	_	_	O
82	study	_	_	O
83	closure	_	_	O
84	.	_	_	O

85	The	_	_	O
86	primary	_	_	O
87	outcome	_	_	O
88	measures	_	_	O
89	were	_	_	O
90	dysphagia	_	_	O
91	,	_	_	O
92	quality	_	_	O
93	of	_	_	O
94	life	_	_	O
95	(	_	_	O
96	QL	_	_	O
97	)	_	_	O
98	6	_	_	O
99	weeks	_	_	O
100	following	_	_	O
101	treatment	_	_	O
102	,	_	_	O
103	and	_	_	O
104	total	_	_	O
105	cost	_	_	O
106	of	_	_	O
107	treatment	_	_	O
108	.	_	_	O

109	Secondary	_	_	O
110	outcome	_	_	O
111	measures	_	_	O
112	included	_	_	O
113	treatment-associated	_	_	O
114	morbidity	_	_	O
115	,	_	_	O
116	mortality	_	_	O
117	,	_	_	O
118	survival	_	_	O
119	,	_	_	O
120	and	_	_	O
121	cost-effectiveness	_	_	O
122	.	_	_	O

123	An	_	_	O
124	intention-to-treat	_	_	O
125	analysis	_	_	O
126	was	_	_	O
127	carried	_	_	O
128	out	_	_	O
129	.	_	_	O

130	There	_	_	B-Premise
131	was	_	_	I-Premise
132	a	_	_	I-Premise
133	significant	_	_	I-Premise
134	difference	_	_	I-Premise
135	in	_	_	I-Premise
136	mean	_	_	I-Premise
137	dysphagia	_	_	I-Premise
138	grade	_	_	I-Premise
139	between	_	_	I-Premise
140	treatment	_	_	I-Premise
141	arms	_	_	I-Premise
142	6	_	_	I-Premise
143	weeks	_	_	I-Premise
144	following	_	_	I-Premise
145	treatment	_	_	I-Premise
146	(	_	_	I-Premise
147	P=0.046	_	_	I-Premise
148	)	_	_	I-Premise
149	,	_	_	I-Premise
150	with	_	_	I-Premise
151	worse	_	_	I-Premise
152	swallowing	_	_	I-Premise
153	reported	_	_	I-Premise
154	by	_	_	I-Premise
155	rigid	_	_	I-Premise
156	stent-treated	_	_	I-Premise
157	patients	_	_	I-Premise
158	(	_	_	I-Premise
159	mean	_	_	I-Premise
160	dysphagia	_	_	I-Premise
161	score	_	_	I-Premise
162	difference=-0.49	_	_	I-Premise
163	;	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	confidence	_	_	I-Premise
167	interval	_	_	I-Premise
168	(	_	_	I-Premise
169	CI	_	_	I-Premise
170	)	_	_	I-Premise
171	-0.10	_	_	I-Premise
172	to	_	_	I-Premise
173	-0.89	_	_	I-Premise
174	,	_	_	I-Premise
175	P=0.014	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Global	_	_	B-Premise
179	QL	_	_	I-Premise
180	scores	_	_	I-Premise
181	were	_	_	I-Premise
182	lower	_	_	I-Premise
183	at	_	_	I-Premise
184	both	_	_	I-Premise
185	1	_	_	I-Premise
186	and	_	_	I-Premise
187	6	_	_	I-Premise
188	weeks	_	_	I-Premise
189	following	_	_	I-Premise
190	treatment	_	_	I-Premise
191	for	_	_	I-Premise
192	patients	_	_	I-Premise
193	treated	_	_	I-Premise
194	by	_	_	I-Premise
195	SEMSs	_	_	I-Premise
196	(	_	_	I-Premise
197	mean	_	_	I-Premise
198	difference	_	_	I-Premise
199	QL	_	_	I-Premise
200	index	_	_	I-Premise
201	week	_	_	I-Premise
202	1=-0.66	_	_	I-Premise
203	;	_	_	I-Premise
204	95	_	_	I-Premise
205	%	_	_	I-Premise
206	CI	_	_	I-Premise
207	:	_	_	I-Premise
208	-0.02	_	_	I-Premise
209	to	_	_	I-Premise
210	-1.30	_	_	I-Premise
211	,	_	_	I-Premise
212	P=0.04	_	_	I-Premise
213	;	_	_	I-Premise
214	mean	_	_	I-Premise
215	difference	_	_	I-Premise
216	QL	_	_	I-Premise
217	index	_	_	I-Premise
218	week	_	_	I-Premise
219	6=-1.01	_	_	I-Premise
220	;	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	CI	_	_	I-Premise
224	-0.30	_	_	I-Premise
225	to	_	_	I-Premise
226	-1.72	_	_	I-Premise
227	,	_	_	I-Premise
228	P=0.006	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	These	_	_	B-Premise
232	findings	_	_	I-Premise
233	were	_	_	I-Premise
234	associated	_	_	I-Premise
235	with	_	_	I-Premise
236	higher	_	_	I-Premise
237	post-procedure	_	_	I-Premise
238	pain	_	_	I-Premise
239	scores	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	SEMS	_	_	I-Premise
243	patient	_	_	I-Premise
244	group	_	_	I-Premise
245	(	_	_	I-Premise
246	mean	_	_	I-Premise
247	difference	_	_	I-Premise
248	of	_	_	I-Premise
249	the	_	_	I-Premise
250	European	_	_	I-Premise
251	Organisation	_	_	I-Premise
252	for	_	_	I-Premise
253	Research	_	_	I-Premise
254	and	_	_	I-Premise
255	Treatment	_	_	I-Premise
256	of	_	_	I-Premise
257	Cancer	_	_	I-Premise
258	QLQ	_	_	I-Premise
259	C-30	_	_	I-Premise
260	pain	_	_	I-Premise
261	symptom	_	_	I-Premise
262	score	_	_	I-Premise
263	at	_	_	I-Premise
264	week	_	_	I-Premise
265	1=11.13	_	_	I-Premise
266	;	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	:	_	_	I-Premise
271	2.89-19.4	_	_	I-Premise
272	;	_	_	I-Premise
273	P=0.01	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Although	_	_	B-Premise
277	mean	_	_	I-Premise
278	EQ-5D	_	_	I-Premise
279	QL	_	_	I-Premise
280	values	_	_	I-Premise
281	differed	_	_	I-Premise
282	between	_	_	I-Premise
283	the	_	_	I-Premise
284	treatments	_	_	I-Premise
285	(	_	_	I-Premise
286	P	_	_	I-Premise
287	<	_	_	I-Premise
288	0.001	_	_	I-Premise
289	)	_	_	I-Premise
290	,	_	_	I-Premise
291	this	_	_	I-Premise
292	difference	_	_	I-Premise
293	dissipated	_	_	I-Premise
294	following	_	_	I-Premise
295	generation	_	_	I-Premise
296	of	_	_	I-Premise
297	quality-adjusted	_	_	I-Premise
298	life	_	_	I-Premise
299	year	_	_	I-Premise
300	values	_	_	I-Premise
301	.	_	_	I-Premise

302	Total	_	_	O
303	costs	_	_	O
304	varied	_	_	O
305	between	_	_	O
306	treatment	_	_	O
307	arms	_	_	O
308	but	_	_	O
309	these	_	_	O
310	findings	_	_	O
311	canceled	_	_	O
312	out	_	_	O
313	when	_	_	O
314	SEMSs	_	_	O
315	were	_	_	O
316	compared	_	_	O
317	with	_	_	O
318	non-SEMS	_	_	O
319	therapies	_	_	O
320	(	_	_	O
321	95	_	_	O
322	%	_	_	O
323	CI	_	_	O
324	-845.15-1,332.62	_	_	O
325	)	_	_	O
326	.	_	_	O

327	These	_	_	O
328	results	_	_	O
329	were	_	_	O
330	robust	_	_	O
331	to	_	_	O
332	sensitivity	_	_	O
333	analysis	_	_	O
334	.	_	_	O

335	There	_	_	B-Premise
336	were	_	_	I-Premise
337	no	_	_	I-Premise
338	differences	_	_	I-Premise
339	in	_	_	I-Premise
340	the	_	_	I-Premise
341	in-hospital	_	_	I-Premise
342	mortality	_	_	I-Premise
343	or	_	_	I-Premise
344	early	_	_	I-Premise
345	complication	_	_	I-Premise
346	rates	_	_	I-Premise
347	,	_	_	I-Premise
348	but	_	_	B-Premise
349	late	_	_	I-Premise
350	complications	_	_	I-Premise
351	were	_	_	I-Premise
352	more	_	_	I-Premise
353	frequent	_	_	I-Premise
354	after	_	_	I-Premise
355	rigid	_	_	I-Premise
356	stenting	_	_	I-Premise
357	(	_	_	I-Premise
358	risk	_	_	I-Premise
359	ratio=2.47	_	_	I-Premise
360	;	_	_	I-Premise
361	95	_	_	I-Premise
362	%	_	_	I-Premise
363	CI	_	_	I-Premise
364	1.88-3.04	_	_	I-Premise
365	)	_	_	I-Premise
366	.	_	_	I-Premise

367	There	_	_	B-Premise
368	was	_	_	I-Premise
369	a	_	_	I-Premise
370	survival	_	_	I-Premise
371	advantage	_	_	I-Premise
372	for	_	_	I-Premise
373	non-stent-treated	_	_	I-Premise
374	patients	_	_	I-Premise
375	(	_	_	I-Premise
376	log-rank	_	_	I-Premise
377	statistic=4.21	_	_	I-Premise
378	,	_	_	I-Premise
379	P=0.04	_	_	I-Premise
380	)	_	_	I-Premise
381	.	_	_	I-Premise

382	The	_	_	B-Claim
383	treatment	_	_	I-Claim
384	choice	_	_	I-Claim
385	for	_	_	I-Claim
386	patients	_	_	I-Claim
387	with	_	_	I-Claim
388	inoperable	_	_	I-Claim
389	esophageal	_	_	I-Claim
390	cancer	_	_	I-Claim
391	should	_	_	I-Claim
392	be	_	_	I-Claim
393	between	_	_	I-Claim
394	a	_	_	I-Claim
395	SEMS	_	_	I-Claim
396	or	_	_	I-Claim
397	a	_	_	I-Claim
398	non-stent	_	_	I-Claim
399	treatment	_	_	I-Claim
400	after	_	_	I-Claim
401	consideration	_	_	I-Claim
402	has	_	_	I-Claim
403	been	_	_	I-Claim
404	given	_	_	I-Claim
405	to	_	_	I-Claim
406	both	_	_	I-Claim
407	patient	_	_	I-Claim
408	and	_	_	I-Claim
409	tumor	_	_	I-Claim
410	characteristics	_	_	I-Claim
411	and	_	_	I-Claim
412	clinician	_	_	I-Claim
413	and	_	_	I-Claim
414	patient	_	_	I-Claim
415	preferences	_	_	I-Claim
416	.	_	_	I-Claim


0	Fixed	_	_	B-Claim
1	combinations	_	_	I-Claim
2	of	_	_	I-Claim
3	0.2	_	_	I-Claim
4	%	_	_	I-Claim
5	brimonidine-0.5	_	_	I-Claim
6	%	_	_	I-Claim
7	timolol	_	_	I-Claim
8	and	_	_	I-Claim
9	2	_	_	I-Claim
10	%	_	_	I-Claim
11	dorzolamide-0.5	_	_	I-Claim
12	%	_	_	I-Claim
13	timolol	_	_	I-Claim
14	are	_	_	I-Claim
15	used	_	_	I-Claim
16	to	_	_	I-Claim
17	lower	_	_	I-Claim
18	intraocular	_	_	I-Claim
19	pressure	_	_	I-Claim
20	(	_	_	I-Claim
21	IOP	_	_	I-Claim
22	)	_	_	I-Claim
23	.	_	_	I-Claim

24	The	_	_	O
25	objective	_	_	O
26	of	_	_	O
27	this	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	evaluate	_	_	O
32	the	_	_	O
33	IOP-lowering	_	_	O
34	efficacy	_	_	O
35	and	_	_	O
36	ocular	_	_	O
37	tolerability	_	_	O
38	of	_	_	O
39	brimonidine-timolol	_	_	O
40	compared	_	_	O
41	with	_	_	O
42	dorzolamide-timolol	_	_	O
43	when	_	_	O
44	used	_	_	O
45	as	_	_	O
46	monotherapy	_	_	O
47	or	_	_	O
48	as	_	_	O
49	adjunctive	_	_	O
50	therapy	_	_	O
51	to	_	_	O
52	a	_	_	O
53	prostaglandin	_	_	O
54	analog	_	_	O
55	(	_	_	O
56	PGA	_	_	O
57	)	_	_	O
58	in	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	glaucoma	_	_	O
62	or	_	_	O
63	ocular	_	_	O
64	hypertension	_	_	O
65	.	_	_	O

66	Pooled	_	_	O
67	data	_	_	O
68	analysis	_	_	O
69	of	_	_	O
70	two	_	_	O
71	randomized	_	_	O
72	,	_	_	O
73	investigator-masked	_	_	O
74	,	_	_	O
75	3-month	_	_	O
76	,	_	_	O
77	parallel-group	_	_	O
78	studies	_	_	O
79	with	_	_	O
80	identical	_	_	O
81	protocols	_	_	O
82	(	_	_	O
83	ten	_	_	O
84	sites	_	_	O
85	)	_	_	O
86	.	_	_	O

87	In	_	_	O
88	all	_	_	O
89	,	_	_	O
90	180	_	_	O
91	patients	_	_	O
92	with	_	_	O
93	open-angle	_	_	O
94	glaucoma	_	_	O
95	or	_	_	O
96	ocular	_	_	O
97	hypertension	_	_	O
98	who	_	_	O
99	were	_	_	O
100	in	_	_	O
101	need	_	_	O
102	of	_	_	O
103	lower	_	_	O
104	IOP	_	_	O
105	received	_	_	O
106	topical	_	_	O
107	brimonidine-timolol	_	_	O
108	BID	_	_	O
109	or	_	_	O
110	dorzolamide-timolol	_	_	O
111	BID	_	_	O
112	as	_	_	O
113	monotherapy	_	_	O
114	(	_	_	O
115	n	_	_	O
116	=	_	_	O
117	101	_	_	O
118	)	_	_	O
119	or	_	_	O
120	as	_	_	O
121	adjunctive	_	_	O
122	therapy	_	_	O
123	to	_	_	O
124	a	_	_	O
125	PGA	_	_	O
126	(	_	_	O
127	latanoprost	_	_	O
128	,	_	_	O
129	bimatoprost	_	_	O
130	,	_	_	O
131	or	_	_	O
132	travoprost	_	_	O
133	)	_	_	O
134	(	_	_	O
135	n	_	_	O
136	=	_	_	O
137	79	_	_	O
138	)	_	_	O
139	.	_	_	O

140	IOP	_	_	O
141	was	_	_	O
142	measured	_	_	O
143	at	_	_	O
144	10	_	_	O
145	a.m.	_	_	O
146	(	_	_	O
147	peak	_	_	O
148	effect	_	_	O
149	)	_	_	O
150	at	_	_	O
151	baseline	_	_	O
152	and	_	_	O
153	at	_	_	O
154	months	_	_	O
155	1	_	_	O
156	and	_	_	O
157	3	_	_	O
158	.	_	_	O

159	Tolerability/comfort	_	_	O
160	was	_	_	O
161	evaluated	_	_	O
162	using	_	_	O
163	a	_	_	O
164	patient	_	_	O
165	questionnaire	_	_	O
166	.	_	_	O

167	There	_	_	O
168	were	_	_	O
169	no	_	_	O
170	statistically	_	_	O
171	significant	_	_	O
172	between-group	_	_	O
173	differences	_	_	O
174	in	_	_	O
175	patient	_	_	O
176	demographics	_	_	O
177	.	_	_	O

178	Most	_	_	O
179	patients	_	_	O
180	were	_	_	O
181	Caucasian	_	_	O
182	,	_	_	O
183	and	_	_	O
184	the	_	_	O
185	mean	_	_	O
186	age	_	_	O
187	was	_	_	O
188	68	_	_	O
189	years	_	_	O
190	.	_	_	O

191	There	_	_	O
192	were	_	_	O
193	also	_	_	O
194	no	_	_	O
195	statistically	_	_	O
196	significant	_	_	O
197	differences	_	_	O
198	between	_	_	O
199	treatment	_	_	O
200	groups	_	_	O
201	in	_	_	O
202	baseline	_	_	O
203	IOP	_	_	O
204	.	_	_	O

205	At	_	_	B-Premise
206	month	_	_	I-Premise
207	3	_	_	I-Premise
208	,	_	_	I-Premise
209	the	_	_	I-Premise
210	mean	_	_	I-Premise
211	(	_	_	I-Premise
212	SD	_	_	I-Premise
213	)	_	_	I-Premise
214	reduction	_	_	I-Premise
215	from	_	_	I-Premise
216	baseline	_	_	I-Premise
217	IOP	_	_	I-Premise
218	for	_	_	I-Premise
219	patients	_	_	I-Premise
220	on	_	_	I-Premise
221	fixed-combination	_	_	I-Premise
222	monotherapy	_	_	I-Premise
223	was	_	_	I-Premise
224	7.7	_	_	I-Premise
225	(	_	_	I-Premise
226	4.2	_	_	I-Premise
227	)	_	_	I-Premise
228	mmHg	_	_	I-Premise
229	(	_	_	I-Premise
230	32.3	_	_	I-Premise
231	%	_	_	I-Premise
232	)	_	_	I-Premise
233	with	_	_	I-Premise
234	brimonidine-timolol	_	_	I-Premise
235	versus	_	_	I-Premise
236	6.7	_	_	I-Premise
237	(	_	_	I-Premise
238	5.0	_	_	I-Premise
239	)	_	_	I-Premise
240	mmHg	_	_	I-Premise
241	(	_	_	I-Premise
242	26.1	_	_	I-Premise
243	%	_	_	I-Premise
244	)	_	_	I-Premise
245	with	_	_	I-Premise
246	dorzolamide-timolol	_	_	I-Premise
247	(	_	_	I-Premise
248	p	_	_	I-Premise
249	=	_	_	I-Premise
250	0.040	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Premise
254	mean	_	_	I-Premise
255	reduction	_	_	I-Premise
256	from	_	_	I-Premise
257	PGA-treated	_	_	I-Premise
258	baseline	_	_	I-Premise
259	IOP	_	_	I-Premise
260	for	_	_	I-Premise
261	patients	_	_	I-Premise
262	on	_	_	I-Premise
263	fixed-combination	_	_	I-Premise
264	adjunctive	_	_	I-Premise
265	therapy	_	_	I-Premise
266	was	_	_	I-Premise
267	6.9	_	_	I-Premise
268	(	_	_	I-Premise
269	4.8	_	_	I-Premise
270	)	_	_	I-Premise
271	mmHg	_	_	I-Premise
272	(	_	_	I-Premise
273	29.3	_	_	I-Premise
274	%	_	_	I-Premise
275	)	_	_	I-Premise
276	with	_	_	I-Premise
277	brimonidine-timolol	_	_	I-Premise
278	versus	_	_	I-Premise
279	5.2	_	_	I-Premise
280	(	_	_	I-Premise
281	3.7	_	_	I-Premise
282	)	_	_	I-Premise
283	mmHg	_	_	I-Premise
284	(	_	_	I-Premise
285	23.5	_	_	I-Premise
286	%	_	_	I-Premise
287	)	_	_	I-Premise
288	with	_	_	I-Premise
289	dorzolamide-timolol	_	_	I-Premise
290	(	_	_	I-Premise
291	p	_	_	I-Premise
292	=	_	_	I-Premise
293	0.213	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	Patients	_	_	B-Premise
297	on	_	_	I-Premise
298	brimonidine-timolol	_	_	I-Premise
299	reported	_	_	I-Premise
300	less	_	_	I-Premise
301	burning	_	_	I-Premise
302	(	_	_	I-Premise
303	p	_	_	I-Premise
304	<	_	_	I-Premise
305	0.001	_	_	I-Premise
306	)	_	_	I-Premise
307	,	_	_	I-Premise
308	stinging	_	_	I-Premise
309	(	_	_	I-Premise
310	p	_	_	I-Premise
311	<	_	_	I-Premise
312	0.001	_	_	I-Premise
313	)	_	_	I-Premise
314	,	_	_	I-Premise
315	and	_	_	I-Premise
316	unusual	_	_	I-Premise
317	taste	_	_	I-Premise
318	(	_	_	I-Premise
319	p	_	_	I-Premise
320	<	_	_	I-Premise
321	0.001	_	_	I-Premise
322	)	_	_	I-Premise
323	than	_	_	I-Premise
324	patients	_	_	I-Premise
325	on	_	_	I-Premise
326	dorzolamide-timolol	_	_	I-Premise
327	.	_	_	I-Premise

328	Fixed-combination	_	_	B-Claim
329	brimonidine-timolol	_	_	I-Claim
330	provided	_	_	I-Claim
331	the	_	_	I-Claim
332	same	_	_	I-Claim
333	or	_	_	I-Claim
334	greater	_	_	I-Claim
335	IOP	_	_	I-Claim
336	lowering	_	_	I-Claim
337	compared	_	_	I-Claim
338	with	_	_	I-Claim
339	fixed-combination	_	_	I-Claim
340	dorzolamide-timolol	_	_	I-Claim
341	.	_	_	I-Claim

342	Both	_	_	B-Claim
343	fixed-combination	_	_	I-Claim
344	medications	_	_	I-Claim
345	were	_	_	I-Claim
346	safe	_	_	I-Claim
347	and	_	_	I-Claim
348	well-tolerated	_	_	I-Claim
349	.	_	_	I-Claim

350	Brimonidine-timolol	_	_	O
351	received	_	_	O
352	higher	_	_	O
353	ratings	_	_	O
354	of	_	_	O
355	ocular	_	_	O
356	comfort	_	_	O
357	than	_	_	O
358	dorzolamide-timolol	_	_	O
359	.	_	_	O

360	The	_	_	O
361	duration	_	_	O
362	of	_	_	O
363	the	_	_	O
364	studies	_	_	O
365	was	_	_	O
366	3	_	_	O
367	months	_	_	O
368	,	_	_	O
369	and	_	_	O
370	additional	_	_	O
371	studies	_	_	O
372	will	_	_	O
373	be	_	_	O
374	needed	_	_	O
375	to	_	_	O
376	compare	_	_	O
377	the	_	_	O
378	efficacy	_	_	O
379	and	_	_	O
380	tolerability	_	_	O
381	of	_	_	O
382	brimonidine-timolol	_	_	O
383	and	_	_	O
384	dorzolamide-timolol	_	_	O
385	during	_	_	O
386	long-term	_	_	O
387	treatment	_	_	O
388	.	_	_	O


0	Lymphedema	_	_	O
1	is	_	_	O
2	an	_	_	O
3	adverse	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	breast	_	_	O
7	cancer	_	_	O
8	surgery	_	_	O
9	.	_	_	O

10	Aqua	_	_	O
11	lymphatic	_	_	O
12	therapy	_	_	O
13	(	_	_	O
14	ALT	_	_	O
15	)	_	_	O
16	is	_	_	O
17	a	_	_	O
18	novel	_	_	O
19	treatment	_	_	O
20	for	_	_	O
21	limb	_	_	O
22	volume	_	_	O
23	reduction	_	_	O
24	.	_	_	O

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	this	_	_	O
29	study	_	_	O
30	was	_	_	O
31	to	_	_	O
32	examine	_	_	O
33	whether	_	_	O
34	ALT	_	_	O
35	is	_	_	O
36	a	_	_	O
37	safe	_	_	O
38	method	_	_	O
39	and	_	_	O
40	whether	_	_	O
41	there	_	_	O
42	are	_	_	O
43	differences	_	_	O
44	in	_	_	O
45	adherence	_	_	O
46	,	_	_	O
47	limb	_	_	O
48	volume	_	_	O
49	,	_	_	O
50	and	_	_	O
51	quality	_	_	O
52	of	_	_	O
53	life	_	_	O
54	between	_	_	O
55	women	_	_	O
56	who	_	_	O
57	perform	_	_	O
58	only	_	_	O
59	self-management	_	_	O
60	treatment	_	_	O
61	and	_	_	O
62	women	_	_	O
63	who	_	_	O
64	participate	_	_	O
65	as	_	_	O
66	well	_	_	O
67	in	_	_	O
68	ALT	_	_	O
69	.	_	_	O

70	Design	_	_	O
71	of	_	_	O
72	the	_	_	O
73	study	_	_	O
74	was	_	_	O
75	single-blind	_	_	O
76	randomized	_	_	O
77	clinical	_	_	O
78	trial	_	_	O
79	.	_	_	O

80	The	_	_	O
81	setting	_	_	O
82	was	_	_	O
83	in	_	_	O
84	a	_	_	O
85	hydrotherapy	_	_	O
86	pool	_	_	O
87	,	_	_	O
88	1.2	_	_	O
89	m	_	_	O
90	depth	_	_	O
91	,	_	_	O
92	and	_	_	O
93	a	_	_	O
94	temperature	_	_	O
95	of	_	_	O
96	32-33	_	_	O
97	degrees	_	_	O
98	capital	_	_	O
99	ES	_	_	O
100	,	_	_	O
101	Cyrillic	_	_	O
102	.	_	_	O

103	Forty-eight	_	_	O
104	women	_	_	O
105	(	_	_	O
106	56	_	_	O
107	+/-	_	_	O
108	10	_	_	O
109	years	_	_	O
110	)	_	_	O
111	,	_	_	O
112	with	_	_	O
113	a	_	_	O
114	12.8	_	_	O
115	%	_	_	O
116	lymphedema	_	_	O
117	relative	_	_	O
118	volume	_	_	O
119	,	_	_	O
120	participated	_	_	O
121	in	_	_	O
122	the	_	_	O
123	study	_	_	O
124	.	_	_	O

125	The	_	_	O
126	control	_	_	O
127	group	_	_	O
128	was	_	_	O
129	instructed	_	_	O
130	to	_	_	O
131	perform	_	_	O
132	the	_	_	O
133	self-management	_	_	O
134	treatment	_	_	O
135	.	_	_	O

136	The	_	_	O
137	study	_	_	O
138	group	_	_	O
139	joined	_	_	O
140	a	_	_	O
141	weekly	_	_	O
142	session	_	_	O
143	of	_	_	O
144	ALT	_	_	O
145	for	_	_	O
146	3	_	_	O
147	months	_	_	O
148	in	_	_	O
149	addition	_	_	O
150	to	_	_	O
151	the	_	_	O
152	self-management	_	_	O
153	therapy	_	_	O
154	.	_	_	O

155	Adherence	_	_	O
156	was	_	_	O
157	assessed	_	_	O
158	by	_	_	O
159	a	_	_	O
160	self-reported	_	_	O
161	diary	_	_	O
162	,	_	_	O
163	limb	_	_	O
164	volume	_	_	O
165	by	_	_	O
166	a	_	_	O
167	water	_	_	O
168	displacement	_	_	O
169	device	_	_	O
170	,	_	_	O
171	quality	_	_	O
172	of	_	_	O
173	life	_	_	O
174	by	_	_	O
175	the	_	_	O
176	Upper	_	_	O
177	Limb	_	_	O
178	Lymphedema	_	_	O
179	Questionnaire	_	_	O
180	(	_	_	O
181	ULL27	_	_	O
182	)	_	_	O
183	,	_	_	O
184	prior	_	_	O
185	to	_	_	O
186	,	_	_	O
187	and	_	_	O
188	after	_	_	O
189	the	_	_	O
190	intervention	_	_	O
191	period	_	_	O
192	.	_	_	O

193	There	_	_	B-Premise
194	was	_	_	I-Premise
195	no	_	_	I-Premise
196	episode	_	_	I-Premise
197	of	_	_	I-Premise
198	arm	_	_	I-Premise
199	infection	_	_	I-Premise
200	or	_	_	I-Premise
201	aggravation	_	_	I-Premise
202	in	_	_	I-Premise
203	limb	_	_	I-Premise
204	volume	_	_	I-Premise
205	during	_	_	I-Premise
206	the	_	_	I-Premise
207	study	_	_	I-Premise
208	period	_	_	I-Premise
209	.	_	_	I-Premise

210	ALT	_	_	B-Premise
211	had	_	_	I-Premise
212	a	_	_	I-Premise
213	positive	_	_	I-Premise
214	,	_	_	I-Premise
215	statistically	_	_	I-Premise
216	and	_	_	I-Premise
217	clinically	_	_	I-Premise
218	significant	_	_	I-Premise
219	immediate	_	_	I-Premise
220	effect	_	_	I-Premise
221	on	_	_	I-Premise
222	limb	_	_	I-Premise
223	volume	_	_	I-Premise
224	but	_	_	B-Premise
225	no	_	_	I-Premise
226	long-term	_	_	I-Premise
227	effect	_	_	I-Premise
228	was	_	_	I-Premise
229	noted	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	adherence	_	_	I-Premise
233	rate	_	_	I-Premise
234	to	_	_	I-Premise
235	ALT	_	_	I-Premise
236	was	_	_	I-Premise
237	significantly	_	_	I-Premise
238	higher	_	_	I-Premise
239	than	_	_	I-Premise
240	the	_	_	I-Premise
241	adherence	_	_	I-Premise
242	to	_	_	I-Premise
243	self-management	_	_	I-Premise
244	therapy	_	_	I-Premise
245	.	_	_	I-Premise

246	QOL	_	_	B-Premise
247	improved	_	_	I-Premise
248	in	_	_	I-Premise
249	the	_	_	I-Premise
250	study	_	_	I-Premise
251	group	_	_	I-Premise
252	.	_	_	I-Premise

253	ALT	_	_	B-Claim
254	was	_	_	I-Claim
255	found	_	_	I-Claim
256	to	_	_	I-Claim
257	be	_	_	I-Claim
258	a	_	_	I-Claim
259	safe	_	_	I-Claim
260	method	_	_	I-Claim
261	,	_	_	I-Claim
262	with	_	_	I-Claim
263	high	_	_	I-Claim
264	adherence	_	_	I-Claim
265	,	_	_	I-Claim
266	in	_	_	I-Claim
267	treating	_	_	I-Claim
268	women	_	_	I-Claim
269	who	_	_	I-Claim
270	suffer	_	_	I-Claim
271	from	_	_	I-Claim
272	mild	_	_	I-Claim
273	to	_	_	I-Claim
274	moderate	_	_	I-Claim
275	lymphedema	_	_	I-Claim
276	.	_	_	I-Claim

277	A	_	_	B-Claim
278	significant	_	_	I-Claim
279	immediate	_	_	I-Claim
280	and	_	_	I-Claim
281	insignificant	_	_	I-Claim
282	long-term	_	_	I-Claim
283	effect	_	_	I-Claim
284	on	_	_	I-Claim
285	limb	_	_	I-Claim
286	volume	_	_	I-Claim
287	was	_	_	I-Claim
288	noted	_	_	I-Claim
289	.	_	_	I-Claim


0	The	_	_	O
1	combination	_	_	O
2	of	_	_	O
3	radiotherapy	_	_	O
4	plus	_	_	O
5	long-term	_	_	O
6	medical	_	_	O
7	suppression	_	_	O
8	of	_	_	O
9	androgens	_	_	O
10	(	_	_	O
11	>	_	_	O
12	or	_	_	O
13	=	_	_	O
14	2	_	_	O
15	years	_	_	O
16	)	_	_	O
17	improves	_	_	O
18	overall	_	_	O
19	survival	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	locally	_	_	O
24	advanced	_	_	O
25	prostate	_	_	O
26	cancer	_	_	O
27	.	_	_	O

28	We	_	_	O
29	compared	_	_	O
30	the	_	_	O
31	use	_	_	O
32	of	_	_	O
33	radiotherapy	_	_	O
34	plus	_	_	O
35	short-term	_	_	O
36	androgen	_	_	O
37	suppression	_	_	O
38	with	_	_	O
39	the	_	_	O
40	use	_	_	O
41	of	_	_	O
42	radiotherapy	_	_	O
43	plus	_	_	O
44	long-term	_	_	O
45	androgen	_	_	O
46	suppression	_	_	O
47	in	_	_	O
48	the	_	_	O
49	treatment	_	_	O
50	of	_	_	O
51	locally	_	_	O
52	advanced	_	_	O
53	prostate	_	_	O
54	cancer	_	_	O
55	.	_	_	O

56	We	_	_	O
57	randomly	_	_	O
58	assigned	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	locally	_	_	O
62	advanced	_	_	O
63	prostate	_	_	O
64	cancer	_	_	O
65	who	_	_	O
66	had	_	_	O
67	received	_	_	O
68	external-beam	_	_	O
69	radiotherapy	_	_	O
70	plus	_	_	O
71	6	_	_	O
72	months	_	_	O
73	of	_	_	O
74	androgen	_	_	O
75	suppression	_	_	O
76	to	_	_	O
77	two	_	_	O
78	groups	_	_	O
79	,	_	_	O
80	one	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	no	_	_	O
84	further	_	_	O
85	treatment	_	_	O
86	(	_	_	O
87	short-term	_	_	O
88	suppression	_	_	O
89	)	_	_	O
90	and	_	_	O
91	the	_	_	O
92	other	_	_	O
93	to	_	_	O
94	receive	_	_	O
95	2.5	_	_	O
96	years	_	_	O
97	of	_	_	O
98	further	_	_	O
99	treatment	_	_	O
100	with	_	_	O
101	a	_	_	O
102	luteinizing	_	_	O
103	hormone-releasing	_	_	O
104	hormone	_	_	O
105	agonist	_	_	O
106	(	_	_	O
107	long-term	_	_	O
108	suppression	_	_	O
109	)	_	_	O
110	.	_	_	O

111	An	_	_	O
112	outcome	_	_	O
113	of	_	_	O
114	noninferiority	_	_	O
115	of	_	_	O
116	short-term	_	_	O
117	androgen	_	_	O
118	suppression	_	_	O
119	as	_	_	O
120	compared	_	_	O
121	with	_	_	O
122	long-term	_	_	O
123	suppression	_	_	O
124	required	_	_	O
125	a	_	_	O
126	hazard	_	_	O
127	ratio	_	_	O
128	of	_	_	O
129	more	_	_	O
130	than	_	_	O
131	1.35	_	_	O
132	for	_	_	O
133	overall	_	_	O
134	survival	_	_	O
135	,	_	_	O
136	with	_	_	O
137	a	_	_	O
138	one-sided	_	_	O
139	alpha	_	_	O
140	level	_	_	O
141	of	_	_	O
142	0.05	_	_	O
143	.	_	_	O

144	An	_	_	O
145	interim	_	_	O
146	analysis	_	_	O
147	showed	_	_	O
148	futility	_	_	O
149	,	_	_	O
150	and	_	_	O
151	the	_	_	O
152	results	_	_	O
153	are	_	_	O
154	presented	_	_	O
155	with	_	_	O
156	an	_	_	O
157	adjusted	_	_	O
158	one-sided	_	_	O
159	alpha	_	_	O
160	level	_	_	O
161	of	_	_	O
162	0.0429	_	_	O
163	.	_	_	O

164	A	_	_	O
165	total	_	_	O
166	of	_	_	O
167	1113	_	_	O
168	men	_	_	O
169	were	_	_	O
170	registered	_	_	O
171	,	_	_	O
172	of	_	_	O
173	whom	_	_	O
174	970	_	_	O
175	were	_	_	O
176	randomly	_	_	O
177	assigned	_	_	O
178	,	_	_	O
179	483	_	_	O
180	to	_	_	O
181	short-term	_	_	O
182	suppression	_	_	O
183	and	_	_	O
184	487	_	_	O
185	to	_	_	O
186	long-term	_	_	O
187	suppression	_	_	O
188	.	_	_	O

189	After	_	_	B-Premise
190	a	_	_	I-Premise
191	median	_	_	I-Premise
192	follow-up	_	_	I-Premise
193	of	_	_	I-Premise
194	6.4	_	_	I-Premise
195	years	_	_	I-Premise
196	,	_	_	I-Premise
197	132	_	_	I-Premise
198	patients	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	short-term	_	_	I-Premise
202	group	_	_	I-Premise
203	and	_	_	I-Premise
204	98	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	long-term	_	_	I-Premise
208	group	_	_	I-Premise
209	had	_	_	I-Premise
210	died	_	_	I-Premise
211	;	_	_	I-Premise
212	the	_	_	B-Premise
213	number	_	_	I-Premise
214	of	_	_	I-Premise
215	deaths	_	_	I-Premise
216	due	_	_	I-Premise
217	to	_	_	I-Premise
218	prostate	_	_	I-Premise
219	cancer	_	_	I-Premise
220	was	_	_	I-Premise
221	47	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	short-term	_	_	I-Premise
225	group	_	_	I-Premise
226	and	_	_	I-Premise
227	29	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	long-term	_	_	I-Premise
231	group	_	_	I-Premise
232	.	_	_	I-Premise

233	The	_	_	B-Premise
234	5-year	_	_	I-Premise
235	overall	_	_	I-Premise
236	mortality	_	_	I-Premise
237	for	_	_	I-Premise
238	short-term	_	_	I-Premise
239	and	_	_	I-Premise
240	long-term	_	_	I-Premise
241	suppression	_	_	I-Premise
242	was	_	_	I-Premise
243	19.0	_	_	I-Premise
244	%	_	_	I-Premise
245	and	_	_	I-Premise
246	15.2	_	_	I-Premise
247	%	_	_	I-Premise
248	,	_	_	I-Premise
249	respectively	_	_	I-Premise
250	;	_	_	I-Premise
251	the	_	_	O
252	observed	_	_	O
253	hazard	_	_	O
254	ratio	_	_	O
255	was	_	_	O
256	1.42	_	_	O
257	(	_	_	O
258	upper	_	_	O
259	95.71	_	_	O
260	%	_	_	O
261	confidence	_	_	O
262	limit	_	_	O
263	,	_	_	O
264	1.79	_	_	O
265	;	_	_	O
266	P=0.65	_	_	O
267	for	_	_	O
268	noninferiority	_	_	O
269	)	_	_	O
270	.	_	_	O

271	Adverse	_	_	B-Premise
272	events	_	_	I-Premise
273	in	_	_	I-Premise
274	both	_	_	I-Premise
275	groups	_	_	I-Premise
276	included	_	_	I-Premise
277	fatigue	_	_	I-Premise
278	,	_	_	I-Premise
279	diminished	_	_	I-Premise
280	sexual	_	_	I-Premise
281	function	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	hot	_	_	I-Premise
285	flushes	_	_	I-Premise
286	.	_	_	I-Premise

287	The	_	_	B-Claim
288	combination	_	_	I-Claim
289	of	_	_	I-Claim
290	radiotherapy	_	_	I-Claim
291	plus	_	_	I-Claim
292	6	_	_	I-Claim
293	months	_	_	I-Claim
294	of	_	_	I-Claim
295	androgen	_	_	I-Claim
296	suppression	_	_	I-Claim
297	provides	_	_	I-Claim
298	inferior	_	_	I-Claim
299	survival	_	_	I-Claim
300	as	_	_	I-Claim
301	compared	_	_	I-Claim
302	with	_	_	I-Claim
303	radiotherapy	_	_	I-Claim
304	plus	_	_	I-Claim
305	3	_	_	I-Claim
306	years	_	_	I-Claim
307	of	_	_	I-Claim
308	androgen	_	_	I-Claim
309	suppression	_	_	I-Claim
310	in	_	_	I-Claim
311	the	_	_	I-Claim
312	treatment	_	_	I-Claim
313	of	_	_	I-Claim
314	locally	_	_	I-Claim
315	advanced	_	_	I-Claim
316	prostate	_	_	I-Claim
317	cancer	_	_	I-Claim
318	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	excimer	_	_	O
8	laser	_	_	O
9	trabeculotomy	_	_	O
10	(	_	_	O
11	ELT	_	_	O
12	)	_	_	O
13	ab	_	_	O
14	interno	_	_	O
15	vs	_	_	O
16	selective	_	_	O
17	laser	_	_	O
18	trabeculoplasty	_	_	O
19	(	_	_	O
20	SLT	_	_	O
21	)	_	_	O
22	over	_	_	O
23	24	_	_	O
24	months	_	_	O
25	of	_	_	O
26	follow-up	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	primary	_	_	O
31	open-angle	_	_	O
32	glaucoma	_	_	O
33	(	_	_	O
34	POAG	_	_	O
35	)	_	_	O
36	refractory	_	_	O
37	to	_	_	O
38	medical	_	_	O
39	therapy	_	_	O
40	.	_	_	O

41	This	_	_	O
42	prospective	_	_	O
43	,	_	_	O
44	randomized	_	_	O
45	study	_	_	O
46	included	_	_	O
47	30	_	_	O
48	consecutive	_	_	O
49	eyes	_	_	O
50	assigned	_	_	O
51	randomly	_	_	O
52	to	_	_	O
53	either	_	_	O
54	ELT	_	_	O
55	or	_	_	O
56	SLT	_	_	O
57	group	_	_	O
58	.	_	_	O

59	ELT	_	_	O
60	was	_	_	O
61	carried	_	_	O
62	out	_	_	O
63	using	_	_	O
64	a	_	_	O
65	XeCl	_	_	O
66	Excimer	_	_	O
67	Laser	_	_	O
68	with	_	_	O
69	an	_	_	O
70	emission	_	_	O
71	wavelength	_	_	O
72	of	_	_	O
73	308	_	_	O
74	nm	_	_	O
75	.	_	_	O

76	Eight	_	_	O
77	spots	_	_	O
78	were	_	_	O
79	equally	_	_	O
80	distributed	_	_	O
81	at	_	_	O
82	a	_	_	O
83	distance	_	_	O
84	of	_	_	O
85	500	_	_	O
86	microm	_	_	O
87	from	_	_	O
88	one	_	_	O
89	another	_	_	O
90	over	_	_	O
91	the	_	_	O
92	anterior	_	_	O
93	trabeculum	_	_	O
94	.	_	_	O

95	The	_	_	O
96	SLT	_	_	O
97	patients	_	_	O
98	were	_	_	O
99	treated	_	_	O
100	with	_	_	O
101	a	_	_	O
102	frequency-doubled	_	_	O
103	q-switched	_	_	O
104	neodymium	_	_	O
105	:	_	_	O
106	yytrium-aluminum-garnet	_	_	O
107	laser	_	_	O
108	(	_	_	O
109	wavelength	_	_	O
110	532	_	_	O
111	nm	_	_	O
112	)	_	_	O
113	.	_	_	O

114	Approximately	_	_	O
115	50	_	_	O
116	adjacent	_	_	O
117	,	_	_	O
118	but	_	_	O
119	not	_	_	O
120	overlapping	_	_	O
121	,	_	_	O
122	laser	_	_	O
123	spots	_	_	O
124	were	_	_	O
125	distributed	_	_	O
126	over	_	_	O
127	180	_	_	O
128	degrees	_	_	O
129	of	_	_	O
130	the	_	_	O
131	trabecular	_	_	O
132	meshwork	_	_	O
133	,	_	_	O
134	using	_	_	O
135	an	_	_	O
136	energy	_	_	O
137	level	_	_	O
138	ranging	_	_	O
139	from	_	_	O
140	0.7	_	_	O
141	to	_	_	O
142	1.0	_	_	O
143	mJ	_	_	O
144	per	_	_	O
145	pulse	_	_	O
146	.	_	_	O

147	The	_	_	O
148	main	_	_	O
149	outcome	_	_	O
150	measure	_	_	O
151	was	_	_	O
152	intraocular	_	_	O
153	pressure	_	_	O
154	(	_	_	O
155	IOP	_	_	O
156	)	_	_	O
157	lowering	_	_	O
158	after	_	_	O
159	ELT	_	_	O
160	and	_	_	O
161	SLT	_	_	O
162	.	_	_	O

163	Success	_	_	O
164	was	_	_	O
165	defined	_	_	O
166	as	_	_	O
167	>	_	_	O
168	or=20	_	_	O
169	%	_	_	O
170	reduction	_	_	O
171	in	_	_	O
172	IOP	_	_	O
173	without	_	_	O
174	further	_	_	O
175	glaucoma	_	_	O
176	intervention	_	_	O
177	.	_	_	O

178	At	_	_	B-Premise
179	24	_	_	I-Premise
180	months	_	_	I-Premise
181	,	_	_	I-Premise
182	complete	_	_	I-Premise
183	success	_	_	I-Premise
184	rates	_	_	I-Premise
185	were	_	_	I-Premise
186	53.3	_	_	I-Premise
187	%	_	_	I-Premise
188	for	_	_	I-Premise
189	the	_	_	I-Premise
190	ELT	_	_	I-Premise
191	group	_	_	I-Premise
192	and	_	_	I-Premise
193	40	_	_	I-Premise
194	%	_	_	I-Premise
195	for	_	_	I-Premise
196	the	_	_	I-Premise
197	SLT	_	_	I-Premise
198	group	_	_	I-Premise
199	(	_	_	I-Premise
200	P=0.35	_	_	I-Premise
201	,	_	_	I-Premise
202	Fisher	_	_	I-Premise
203	's	_	_	I-Premise
204	exact	_	_	I-Premise
205	test	_	_	I-Premise
206	)	_	_	I-Premise
207	;	_	_	I-Premise
208	qualified	_	_	B-Premise
209	success	_	_	I-Premise
210	rates	_	_	I-Premise
211	were	_	_	I-Premise
212	33.3	_	_	I-Premise
213	%	_	_	I-Premise
214	for	_	_	I-Premise
215	the	_	_	I-Premise
216	ELT	_	_	I-Premise
217	and	_	_	I-Premise
218	26.6	_	_	I-Premise
219	%	_	_	I-Premise
220	for	_	_	I-Premise
221	the	_	_	I-Premise
222	SLT	_	_	I-Premise
223	group	_	_	I-Premise
224	(	_	_	I-Premise
225	P=0.5	_	_	I-Premise
226	,	_	_	I-Premise
227	Fisher	_	_	I-Premise
228	's	_	_	I-Premise
229	exact	_	_	I-Premise
230	test	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Mean	_	_	B-Premise
234	IOP	_	_	I-Premise
235	decreased	_	_	I-Premise
236	from	_	_	I-Premise
237	25.0+/-1.9	_	_	I-Premise
238	to	_	_	I-Premise
239	17.6+/-2.2	_	_	I-Premise
240	mmHg	_	_	I-Premise
241	(	_	_	I-Premise
242	-29.6	_	_	I-Premise
243	%	_	_	I-Premise
244	;	_	_	I-Premise
245	P	_	_	I-Premise
246	<	_	_	I-Premise
247	0.0001	_	_	I-Premise
248	)	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	ELT	_	_	I-Premise
252	group	_	_	I-Premise
253	and	_	_	I-Premise
254	from	_	_	I-Premise
255	23.9+/-0.9	_	_	I-Premise
256	to	_	_	I-Premise
257	19.1+/-1.8	_	_	I-Premise
258	mmHg	_	_	I-Premise
259	(	_	_	I-Premise
260	-21	_	_	I-Premise
261	%	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	<	_	_	I-Premise
265	0.0001	_	_	I-Premise
266	)	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	SLT	_	_	I-Premise
270	group	_	_	I-Premise
271	.	_	_	I-Premise

272	Both	_	_	B-Claim
273	ELT	_	_	I-Claim
274	and	_	_	I-Claim
275	SLT	_	_	I-Claim
276	proved	_	_	I-Claim
277	to	_	_	I-Claim
278	be	_	_	I-Claim
279	effective	_	_	I-Claim
280	techniques	_	_	I-Claim
281	in	_	_	I-Claim
282	the	_	_	I-Claim
283	treatment	_	_	I-Claim
284	of	_	_	I-Claim
285	POAG	_	_	I-Claim
286	refractory	_	_	I-Claim
287	to	_	_	I-Claim
288	medical	_	_	I-Claim
289	therapy	_	_	I-Claim
290	.	_	_	I-Claim


0	Cancer	_	_	O
1	cells	_	_	O
2	rely	_	_	O
3	on	_	_	O
4	angiogenesis	_	_	O
5	for	_	_	O
6	growth	_	_	O
7	and	_	_	O
8	dissemination	_	_	O
9	,	_	_	O
10	and	_	_	O
11	small	_	_	O
12	cell	_	_	O
13	lung	_	_	O
14	cancer	_	_	O
15	(	_	_	O
16	SCLC	_	_	O
17	)	_	_	O
18	is	_	_	O
19	a	_	_	O
20	highly	_	_	O
21	angiogenic	_	_	O
22	tumor	_	_	O
23	.	_	_	O

24	We	_	_	O
25	evaluated	_	_	O
26	thalidomide	_	_	O
27	,	_	_	O
28	an	_	_	O
29	anti-angiogenic	_	_	O
30	agent	_	_	O
31	,	_	_	O
32	when	_	_	O
33	combined	_	_	O
34	with	_	_	O
35	chemotherapy	_	_	O
36	and	_	_	O
37	as	_	_	O
38	maintenance	_	_	O
39	treatment	_	_	O
40	.	_	_	O

41	A	_	_	O
42	total	_	_	O
43	of	_	_	O
44	724	_	_	O
45	patients	_	_	O
46	(	_	_	O
47	51	_	_	O
48	%	_	_	O
49	with	_	_	O
50	limited	_	_	O
51	and	_	_	O
52	49	_	_	O
53	%	_	_	O
54	with	_	_	O
55	extensive	_	_	O
56	disease	_	_	O
57	)	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	to	_	_	O
62	receive	_	_	O
63	placebo	_	_	O
64	or	_	_	O
65	thalidomide	_	_	O
66	capsules	_	_	O
67	,	_	_	O
68	100-200	_	_	O
69	mg	_	_	O
70	daily	_	_	O
71	for	_	_	O
72	up	_	_	O
73	to	_	_	O
74	2	_	_	O
75	years	_	_	O
76	.	_	_	O

77	All	_	_	O
78	patients	_	_	O
79	received	_	_	O
80	etoposide	_	_	O
81	and	_	_	O
82	carboplatin	_	_	O
83	every	_	_	O
84	3	_	_	O
85	weeks	_	_	O
86	for	_	_	O
87	up	_	_	O
88	to	_	_	O
89	six	_	_	O
90	cycles	_	_	O
91	.	_	_	O

92	Endpoints	_	_	O
93	were	_	_	O
94	overall	_	_	O
95	survival	_	_	O
96	,	_	_	O
97	progression-free	_	_	O
98	survival	_	_	O
99	,	_	_	O
100	tumor	_	_	O
101	response	_	_	O
102	rate	_	_	O
103	,	_	_	O
104	toxicity	_	_	O
105	,	_	_	O
106	and	_	_	O
107	quality	_	_	O
108	of	_	_	O
109	life	_	_	O
110	(	_	_	O
111	QoL	_	_	O
112	)	_	_	O
113	.	_	_	O

114	Hazard	_	_	O
115	ratios	_	_	O
116	(	_	_	O
117	HRs	_	_	O
118	)	_	_	O
119	for	_	_	O
120	comparing	_	_	O
121	thalidomide	_	_	O
122	against	_	_	O
123	placebo	_	_	O
124	were	_	_	O
125	estimated	_	_	O
126	using	_	_	O
127	Cox	_	_	O
128	regression	_	_	O
129	modeling	_	_	O
130	.	_	_	O

131	Statistical	_	_	O
132	tests	_	_	O
133	were	_	_	O
134	two-sided	_	_	O
135	.	_	_	O

136	The	_	_	B-Premise
137	median	_	_	I-Premise
138	overall	_	_	I-Premise
139	survival	_	_	I-Premise
140	was	_	_	I-Premise
141	10.5	_	_	I-Premise
142	months	_	_	I-Premise
143	(	_	_	I-Premise
144	placebo	_	_	I-Premise
145	)	_	_	I-Premise
146	and	_	_	I-Premise
147	10.1	_	_	I-Premise
148	months	_	_	I-Premise
149	(	_	_	I-Premise
150	thalidomide	_	_	I-Premise
151	)	_	_	I-Premise
152	(	_	_	I-Premise
153	HR	_	_	I-Premise
154	for	_	_	I-Premise
155	death	_	_	I-Premise
156	=	_	_	I-Premise
157	1.09	_	_	I-Premise
158	,	_	_	I-Premise
159	95	_	_	I-Premise
160	%	_	_	I-Premise
161	confidence	_	_	I-Premise
162	interval	_	_	I-Premise
163	[	_	_	I-Premise
164	CI	_	_	I-Premise
165	]	_	_	I-Premise
166	=	_	_	I-Premise
167	0.93	_	_	I-Premise
168	to	_	_	I-Premise
169	1.27	_	_	I-Premise
170	;	_	_	I-Premise
171	P	_	_	I-Premise
172	=	_	_	I-Premise
173	.28	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	Among	_	_	B-Premise
177	patients	_	_	I-Premise
178	with	_	_	I-Premise
179	limited-stage	_	_	I-Premise
180	disease	_	_	I-Premise
181	,	_	_	I-Premise
182	there	_	_	I-Premise
183	was	_	_	I-Premise
184	no	_	_	I-Premise
185	evidence	_	_	I-Premise
186	of	_	_	I-Premise
187	a	_	_	I-Premise
188	survival	_	_	I-Premise
189	difference	_	_	I-Premise
190	(	_	_	I-Premise
191	HR	_	_	I-Premise
192	for	_	_	I-Premise
193	death	_	_	I-Premise
194	=	_	_	I-Premise
195	0.91	_	_	I-Premise
196	,	_	_	I-Premise
197	95	_	_	I-Premise
198	%	_	_	I-Premise
199	CI	_	_	I-Premise
200	=	_	_	I-Premise
201	0.73	_	_	I-Premise
202	to	_	_	I-Premise
203	1.15	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	but	_	_	B-Premise
207	among	_	_	I-Premise
208	patients	_	_	I-Premise
209	with	_	_	I-Premise
210	extensive	_	_	I-Premise
211	disease	_	_	I-Premise
212	,	_	_	I-Premise
213	survival	_	_	I-Premise
214	was	_	_	I-Premise
215	worse	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	thalidomide	_	_	I-Premise
219	group	_	_	I-Premise
220	(	_	_	I-Premise
221	HR	_	_	I-Premise
222	for	_	_	I-Premise
223	death	_	_	I-Premise
224	=	_	_	I-Premise
225	1.36	_	_	I-Premise
226	,	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	=	_	_	I-Premise
231	1.10	_	_	I-Premise
232	to	_	_	I-Premise
233	1.68	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Progression-free	_	_	B-Premise
237	survival	_	_	I-Premise
238	rates	_	_	I-Premise
239	were	_	_	I-Premise
240	also	_	_	I-Premise
241	similar	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	two	_	_	I-Premise
245	groups	_	_	I-Premise
246	(	_	_	I-Premise
247	HR	_	_	I-Premise
248	=	_	_	I-Premise
249	1.07	_	_	I-Premise
250	,	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	CI	_	_	I-Premise
254	=	_	_	I-Premise
255	0.92	_	_	I-Premise
256	to	_	_	I-Premise
257	1.24	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Thalidomide	_	_	B-Premise
261	was	_	_	I-Premise
262	associated	_	_	I-Premise
263	with	_	_	I-Premise
264	an	_	_	I-Premise
265	increased	_	_	I-Premise
266	risk	_	_	I-Premise
267	of	_	_	I-Premise
268	having	_	_	I-Premise
269	a	_	_	I-Premise
270	thrombotic	_	_	I-Premise
271	event	_	_	I-Premise
272	,	_	_	I-Premise
273	mainly	_	_	I-Premise
274	pulmonary	_	_	I-Premise
275	embolus	_	_	I-Premise
276	and	_	_	I-Premise
277	deep	_	_	I-Premise
278	vein	_	_	I-Premise
279	thrombosis	_	_	I-Premise
280	(	_	_	I-Premise
281	19	_	_	I-Premise
282	%	_	_	I-Premise
283	thalidomide	_	_	I-Premise
284	vs	_	_	I-Premise
285	10	_	_	I-Premise
286	%	_	_	I-Premise
287	placebo	_	_	I-Premise
288	;	_	_	I-Premise
289	HR	_	_	I-Premise
290	=	_	_	I-Premise
291	2.13	_	_	I-Premise
292	,	_	_	I-Premise
293	95	_	_	I-Premise
294	%	_	_	I-Premise
295	CI	_	_	I-Premise
296	=	_	_	I-Premise
297	1.41	_	_	I-Premise
298	to	_	_	I-Premise
299	3.20	_	_	I-Premise
300	;	_	_	I-Premise
301	P	_	_	I-Premise
302	<	_	_	I-Premise
303	.001	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	There	_	_	B-Premise
307	were	_	_	I-Premise
308	no	_	_	I-Premise
309	statistically	_	_	I-Premise
310	significant	_	_	I-Premise
311	differences	_	_	I-Premise
312	between	_	_	I-Premise
313	treatments	_	_	I-Premise
314	in	_	_	I-Premise
315	hematological	_	_	I-Premise
316	and	_	_	I-Premise
317	nonhematological	_	_	I-Premise
318	toxic	_	_	I-Premise
319	effects	_	_	I-Premise
320	,	_	_	I-Premise
321	except	_	_	B-Premise
322	more	_	_	I-Premise
323	patients	_	_	I-Premise
324	in	_	_	I-Premise
325	the	_	_	I-Premise
326	thalidomide	_	_	I-Premise
327	group	_	_	I-Premise
328	had	_	_	I-Premise
329	rash	_	_	I-Premise
330	,	_	_	I-Premise
331	constipation	_	_	I-Premise
332	,	_	_	I-Premise
333	or	_	_	I-Premise
334	neuropathy	_	_	I-Premise
335	.	_	_	I-Premise

336	Overall	_	_	O
337	,	_	_	O
338	QoL	_	_	B-Claim
339	scores	_	_	I-Claim
340	were	_	_	I-Claim
341	similar	_	_	I-Claim
342	in	_	_	I-Claim
343	the	_	_	I-Claim
344	two	_	_	I-Claim
345	treatment	_	_	I-Claim
346	groups	_	_	I-Claim
347	,	_	_	I-Claim
348	but	_	_	B-Claim
349	thalidomide	_	_	I-Claim
350	was	_	_	I-Claim
351	associated	_	_	I-Claim
352	with	_	_	I-Claim
353	less	_	_	I-Claim
354	insomnia	_	_	I-Claim
355	and	_	_	I-Claim
356	diarrhea	_	_	I-Claim
357	and	_	_	I-Claim
358	more	_	_	I-Claim
359	constipation	_	_	I-Claim
360	and	_	_	I-Claim
361	peripheral	_	_	I-Claim
362	neuropathy	_	_	I-Claim
363	.	_	_	I-Claim

364	In	_	_	O
365	this	_	_	O
366	large	_	_	O
367	randomized	_	_	O
368	trial	_	_	O
369	,	_	_	O
370	thalidomide	_	_	B-Claim
371	in	_	_	I-Claim
372	combination	_	_	I-Claim
373	with	_	_	I-Claim
374	chemotherapy	_	_	I-Claim
375	did	_	_	I-Claim
376	not	_	_	I-Claim
377	improve	_	_	I-Claim
378	survival	_	_	I-Claim
379	of	_	_	I-Claim
380	patients	_	_	I-Claim
381	with	_	_	I-Claim
382	SCLC	_	_	I-Claim
383	but	_	_	I-Claim
384	was	_	_	I-Claim
385	associated	_	_	I-Claim
386	with	_	_	I-Claim
387	an	_	_	I-Claim
388	increased	_	_	I-Claim
389	risk	_	_	I-Claim
390	of	_	_	I-Claim
391	thrombotic	_	_	I-Claim
392	events	_	_	I-Claim
393	.	_	_	I-Claim


0	Sunitinib	_	_	O
1	has	_	_	O
2	demonstrated	_	_	O
3	antitumor	_	_	O
4	activity	_	_	O
5	in	_	_	O
6	metastatic	_	_	O
7	renal	_	_	O
8	cell	_	_	O
9	carcinoma	_	_	O
10	(	_	_	O
11	mRCC	_	_	O
12	)	_	_	O
13	when	_	_	O
14	given	_	_	O
15	at	_	_	O
16	50	_	_	O
17	mg/d	_	_	O
18	on	_	_	O
19	a	_	_	O
20	4-weeks-on	_	_	O
21	2-weeks-off	_	_	O
22	regimen	_	_	O
23	.	_	_	O

24	Herein	_	_	O
25	,	_	_	O
26	we	_	_	O
27	report	_	_	O
28	results	_	_	O
29	of	_	_	O
30	an	_	_	O
31	open-label	_	_	O
32	,	_	_	O
33	multicenter	_	_	O
34	phase	_	_	O
35	II	_	_	O
36	mRCC	_	_	O
37	study	_	_	O
38	of	_	_	O
39	sunitinib	_	_	O
40	administered	_	_	O
41	on	_	_	O
42	a	_	_	O
43	continuous	_	_	O
44	once-daily	_	_	O
45	dosing	_	_	O
46	regimen	_	_	O
47	.	_	_	O

48	Eligibility	_	_	O
49	criteria	_	_	O
50	included	_	_	O
51	histologically	_	_	O
52	proven	_	_	O
53	mRCC	_	_	O
54	with	_	_	O
55	measurable	_	_	O
56	disease	_	_	O
57	,	_	_	O
58	failure	_	_	O
59	of	_	_	O
60	one	_	_	O
61	prior	_	_	O
62	cytokine	_	_	O
63	regimen	_	_	O
64	,	_	_	O
65	and	_	_	O
66	good	_	_	O
67	performance	_	_	O
68	status	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	were	_	_	O
72	randomly	_	_	O
73	assigned	_	_	O
74	to	_	_	O
75	a	_	_	O
76	sunitinib	_	_	O
77	starting	_	_	O
78	dose	_	_	O
79	of	_	_	O
80	37.5	_	_	O
81	mg/d	_	_	O
82	in	_	_	O
83	the	_	_	O
84	morning	_	_	O
85	(	_	_	O
86	AM	_	_	O
87	)	_	_	O
88	or	_	_	O
89	evening	_	_	O
90	(	_	_	O
91	PM	_	_	O
92	)	_	_	O
93	.	_	_	O

94	RECIST-defined	_	_	O
95	objective	_	_	O
96	response	_	_	O
97	rate	_	_	O
98	(	_	_	O
99	ORR	_	_	O
100	)	_	_	O
101	was	_	_	O
102	the	_	_	O
103	primary	_	_	O
104	end	_	_	O
105	point	_	_	O
106	.	_	_	O

107	Secondary	_	_	O
108	end	_	_	O
109	points	_	_	O
110	included	_	_	O
111	progression-free	_	_	O
112	survival	_	_	O
113	(	_	_	O
114	PFS	_	_	O
115	)	_	_	O
116	,	_	_	O
117	overall	_	_	O
118	survival	_	_	O
119	(	_	_	O
120	OS	_	_	O
121	)	_	_	O
122	,	_	_	O
123	adverse	_	_	O
124	events	_	_	O
125	(	_	_	O
126	AEs	_	_	O
127	)	_	_	O
128	,	_	_	O
129	and	_	_	O
130	quality-of-life	_	_	O
131	measures	_	_	O
132	.	_	_	O

133	One	_	_	O
134	hundred	_	_	O
135	seven	_	_	O
136	patients	_	_	O
137	were	_	_	O
138	randomly	_	_	O
139	assigned	_	_	O
140	to	_	_	O
141	AM	_	_	O
142	(	_	_	O
143	n	_	_	O
144	=	_	_	O
145	54	_	_	O
146	)	_	_	O
147	or	_	_	O
148	PM	_	_	O
149	(	_	_	O
150	n	_	_	O
151	=	_	_	O
152	53	_	_	O
153	)	_	_	O
154	dosing	_	_	O
155	and	_	_	O
156	on	_	_	O
157	study	_	_	O
158	for	_	_	O
159	a	_	_	O
160	median	_	_	O
161	8.3	_	_	O
162	months	_	_	O
163	.	_	_	O

164	Eighty-three	_	_	O
165	patients	_	_	O
166	discontinued	_	_	O
167	,	_	_	O
168	65	_	_	O
169	due	_	_	O
170	to	_	_	O
171	disease	_	_	O
172	progression	_	_	O
173	and	_	_	O
174	16	_	_	O
175	because	_	_	O
176	of	_	_	O
177	AEs	_	_	O
178	;	_	_	O
179	two	_	_	O
180	patients	_	_	O
181	withdrew	_	_	O
182	consent	_	_	O
183	.	_	_	O

184	Dosing	_	_	O
185	was	_	_	O
186	reduced	_	_	O
187	to	_	_	O
188	25	_	_	O
189	mg/d	_	_	O
190	in	_	_	O
191	46	_	_	O
192	patients	_	_	O
193	(	_	_	O
194	43	_	_	O
195	%	_	_	O
196	)	_	_	O
197	due	_	_	O
198	to	_	_	O
199	grade	_	_	O
200	3/4	_	_	O
201	AEs	_	_	O
202	.	_	_	O

203	The	_	_	B-Premise
204	most	_	_	I-Premise
205	common	_	_	I-Premise
206	grade	_	_	I-Premise
207	3	_	_	I-Premise
208	treatment-related	_	_	I-Premise
209	AEs	_	_	I-Premise
210	were	_	_	I-Premise
211	asthenia/fatigue	_	_	I-Premise
212	(	_	_	I-Premise
213	16	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	diarrhea	_	_	I-Premise
218	(	_	_	I-Premise
219	11	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	hypertension	_	_	I-Premise
224	(	_	_	I-Premise
225	11	_	_	I-Premise
226	%	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	hand-foot	_	_	I-Premise
230	syndrome	_	_	I-Premise
231	(	_	_	I-Premise
232	9	_	_	I-Premise
233	%	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	anorexia	_	_	I-Premise
238	(	_	_	I-Premise
239	8	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	ORR	_	_	O
244	was	_	_	O
245	20	_	_	O
246	%	_	_	O
247	with	_	_	O
248	a	_	_	O
249	7.2-month	_	_	O
250	median	_	_	O
251	response	_	_	O
252	duration	_	_	O
253	.	_	_	O

254	Median	_	_	B-Premise
255	PFS	_	_	I-Premise
256	and	_	_	I-Premise
257	OS	_	_	I-Premise
258	were	_	_	I-Premise
259	8.2	_	_	I-Premise
260	and	_	_	I-Premise
261	19.8	_	_	I-Premise
262	months	_	_	I-Premise
263	,	_	_	I-Premise
264	respectively	_	_	I-Premise
265	,	_	_	I-Premise
266	at	_	_	I-Premise
267	median	_	_	I-Premise
268	follow-up	_	_	I-Premise
269	of	_	_	I-Premise
270	26.4	_	_	I-Premise
271	months	_	_	I-Premise
272	.	_	_	I-Premise

273	Efficacy	_	_	B-Premise
274	,	_	_	I-Premise
275	tolerability	_	_	I-Premise
276	,	_	_	I-Premise
277	and	_	_	I-Premise
278	quality-of-life	_	_	I-Premise
279	results	_	_	I-Premise
280	were	_	_	I-Premise
281	similar	_	_	I-Premise
282	between	_	_	I-Premise
283	patients	_	_	I-Premise
284	dosed	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	AM	_	_	I-Premise
288	or	_	_	I-Premise
289	PM	_	_	I-Premise
290	.	_	_	I-Premise

291	Sunitinib	_	_	B-Claim
292	37.5	_	_	I-Claim
293	mg	_	_	I-Claim
294	,	_	_	I-Claim
295	administered	_	_	I-Claim
296	on	_	_	I-Claim
297	a	_	_	I-Claim
298	continuous	_	_	I-Claim
299	once-daily	_	_	I-Claim
300	dosing	_	_	I-Claim
301	regimen	_	_	I-Claim
302	,	_	_	I-Claim
303	has	_	_	I-Claim
304	a	_	_	I-Claim
305	manageable	_	_	I-Claim
306	safety	_	_	I-Claim
307	profile	_	_	I-Claim
308	as	_	_	I-Claim
309	second-line	_	_	I-Claim
310	mRCC	_	_	I-Claim
311	therapy	_	_	I-Claim
312	,	_	_	I-Claim
313	providing	_	_	I-Claim
314	flexible	_	_	I-Claim
315	dosing	_	_	I-Claim
316	,	_	_	I-Claim
317	which	_	_	I-Claim
318	can	_	_	I-Claim
319	be	_	_	I-Claim
320	explored	_	_	I-Claim
321	in	_	_	I-Claim
322	combination	_	_	I-Claim
323	studies	_	_	I-Claim
324	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	few	_	_	O
3	randomized	_	_	O
4	controlled	_	_	O
5	trials	_	_	O
6	on	_	_	O
7	the	_	_	O
8	effectiveness	_	_	O
9	of	_	_	O
10	palliative	_	_	O
11	care	_	_	O
12	interventions	_	_	O
13	to	_	_	O
14	improve	_	_	O
15	the	_	_	O
16	care	_	_	O
17	of	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	advanced	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	To	_	_	O
24	determine	_	_	O
25	the	_	_	O
26	effect	_	_	O
27	of	_	_	O
28	a	_	_	O
29	nursing-led	_	_	O
30	intervention	_	_	O
31	on	_	_	O
32	quality	_	_	O
33	of	_	_	O
34	life	_	_	O
35	,	_	_	O
36	symptom	_	_	O
37	intensity	_	_	O
38	,	_	_	O
39	mood	_	_	O
40	,	_	_	O
41	and	_	_	O
42	resource	_	_	O
43	use	_	_	O
44	in	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	advanced	_	_	O
48	cancer	_	_	O
49	.	_	_	O

50	Randomized	_	_	O
51	controlled	_	_	O
52	trial	_	_	O
53	conducted	_	_	O
54	from	_	_	O
55	November	_	_	O
56	2003	_	_	O
57	through	_	_	O
58	May	_	_	O
59	2008	_	_	O
60	of	_	_	O
61	322	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	advanced	_	_	O
65	cancer	_	_	O
66	in	_	_	O
67	a	_	_	O
68	rural	_	_	O
69	,	_	_	O
70	National	_	_	O
71	Cancer	_	_	O
72	Institute-designated	_	_	O
73	comprehensive	_	_	O
74	cancer	_	_	O
75	center	_	_	O
76	in	_	_	O
77	New	_	_	O
78	Hampshire	_	_	O
79	and	_	_	O
80	affiliated	_	_	O
81	outreach	_	_	O
82	clinics	_	_	O
83	and	_	_	O
84	a	_	_	O
85	VA	_	_	O
86	medical	_	_	O
87	center	_	_	O
88	in	_	_	O
89	Vermont	_	_	O
90	.	_	_	O

91	A	_	_	O
92	multicomponent	_	_	O
93	,	_	_	O
94	psychoeducational	_	_	O
95	intervention	_	_	O
96	(	_	_	O
97	Project	_	_	O
98	ENABLE	_	_	O
99	[	_	_	O
100	Educate	_	_	O
101	,	_	_	O
102	Nurture	_	_	O
103	,	_	_	O
104	Advise	_	_	O
105	,	_	_	O
106	Before	_	_	O
107	Life	_	_	O
108	Ends	_	_	O
109	]	_	_	O
110	)	_	_	O
111	conducted	_	_	O
112	by	_	_	O
113	advanced	_	_	O
114	practice	_	_	O
115	nurses	_	_	O
116	consisting	_	_	O
117	of	_	_	O
118	4	_	_	O
119	weekly	_	_	O
120	educational	_	_	O
121	sessions	_	_	O
122	and	_	_	O
123	monthly	_	_	O
124	follow-up	_	_	O
125	sessions	_	_	O
126	until	_	_	O
127	death	_	_	O
128	or	_	_	O
129	study	_	_	O
130	completion	_	_	O
131	(	_	_	O
132	n	_	_	O
133	=	_	_	O
134	161	_	_	O
135	)	_	_	O
136	vs	_	_	O
137	usual	_	_	O
138	care	_	_	O
139	(	_	_	O
140	n	_	_	O
141	=	_	_	O
142	161	_	_	O
143	)	_	_	O
144	.	_	_	O

145	Quality	_	_	O
146	of	_	_	O
147	life	_	_	O
148	was	_	_	O
149	measured	_	_	O
150	by	_	_	O
151	the	_	_	O
152	Functional	_	_	O
153	Assessment	_	_	O
154	of	_	_	O
155	Chronic	_	_	O
156	Illness	_	_	O
157	Therapy	_	_	O
158	for	_	_	O
159	Palliative	_	_	O
160	Care	_	_	O
161	(	_	_	O
162	score	_	_	O
163	range	_	_	O
164	,	_	_	O
165	0-184	_	_	O
166	)	_	_	O
167	.	_	_	O

168	Symptom	_	_	O
169	intensity	_	_	O
170	was	_	_	O
171	measured	_	_	O
172	by	_	_	O
173	the	_	_	O
174	Edmonton	_	_	O
175	Symptom	_	_	O
176	Assessment	_	_	O
177	Scale	_	_	O
178	(	_	_	O
179	score	_	_	O
180	range	_	_	O
181	,	_	_	O
182	0-900	_	_	O
183	)	_	_	O
184	.	_	_	O

185	Mood	_	_	O
186	was	_	_	O
187	measured	_	_	O
188	by	_	_	O
189	the	_	_	O
190	Center	_	_	O
191	for	_	_	O
192	Epidemiological	_	_	O
193	Studies	_	_	O
194	Depression	_	_	O
195	Scale	_	_	O
196	(	_	_	O
197	range	_	_	O
198	,	_	_	O
199	0-60	_	_	O
200	)	_	_	O
201	.	_	_	O

202	These	_	_	O
203	measures	_	_	O
204	were	_	_	O
205	assessed	_	_	O
206	at	_	_	O
207	baseline	_	_	O
208	,	_	_	O
209	1	_	_	O
210	month	_	_	O
211	,	_	_	O
212	and	_	_	O
213	every	_	_	O
214	3	_	_	O
215	months	_	_	O
216	until	_	_	O
217	death	_	_	O
218	or	_	_	O
219	study	_	_	O
220	completion	_	_	O
221	.	_	_	O

222	Intensity	_	_	O
223	of	_	_	O
224	service	_	_	O
225	was	_	_	O
226	measured	_	_	O
227	as	_	_	O
228	the	_	_	O
229	number	_	_	O
230	of	_	_	O
231	days	_	_	O
232	in	_	_	O
233	the	_	_	O
234	hospital	_	_	O
235	and	_	_	O
236	in	_	_	O
237	the	_	_	O
238	intensive	_	_	O
239	care	_	_	O
240	unit	_	_	O
241	(	_	_	O
242	ICU	_	_	O
243	)	_	_	O
244	and	_	_	O
245	the	_	_	O
246	number	_	_	O
247	of	_	_	O
248	emergency	_	_	O
249	department	_	_	O
250	visits	_	_	O
251	recorded	_	_	O
252	in	_	_	O
253	the	_	_	O
254	electronic	_	_	O
255	medical	_	_	O
256	record	_	_	O
257	.	_	_	O

258	A	_	_	O
259	total	_	_	O
260	of	_	_	O
261	322	_	_	O
262	participants	_	_	O
263	with	_	_	O
264	cancer	_	_	O
265	of	_	_	O
266	the	_	_	O
267	gastrointestinal	_	_	O
268	tract	_	_	O
269	(	_	_	O
270	41	_	_	O
271	%	_	_	O
272	;	_	_	O
273	67	_	_	O
274	in	_	_	O
275	the	_	_	O
276	usual	_	_	O
277	care	_	_	O
278	group	_	_	O
279	vs	_	_	O
280	66	_	_	O
281	in	_	_	O
282	the	_	_	O
283	intervention	_	_	O
284	group	_	_	O
285	)	_	_	O
286	,	_	_	O
287	lung	_	_	O
288	(	_	_	O
289	36	_	_	O
290	%	_	_	O
291	;	_	_	O
292	58	_	_	O
293	vs	_	_	O
294	59	_	_	O
295	)	_	_	O
296	,	_	_	O
297	genitourinary	_	_	O
298	tract	_	_	O
299	(	_	_	O
300	12	_	_	O
301	%	_	_	O
302	;	_	_	O
303	20	_	_	O
304	vs	_	_	O
305	19	_	_	O
306	)	_	_	O
307	,	_	_	O
308	and	_	_	O
309	breast	_	_	O
310	(	_	_	O
311	10	_	_	O
312	%	_	_	O
313	;	_	_	O
314	16	_	_	O
315	vs	_	_	O
316	17	_	_	O
317	)	_	_	O
318	were	_	_	O
319	randomized	_	_	O
320	.	_	_	O

321	The	_	_	B-Premise
322	estimated	_	_	I-Premise
323	treatment	_	_	I-Premise
324	effects	_	_	I-Premise
325	(	_	_	I-Premise
326	intervention	_	_	I-Premise
327	minus	_	_	I-Premise
328	usual	_	_	I-Premise
329	care	_	_	I-Premise
330	)	_	_	I-Premise
331	for	_	_	I-Premise
332	all	_	_	I-Premise
333	participants	_	_	I-Premise
334	were	_	_	I-Premise
335	a	_	_	I-Premise
336	mean	_	_	I-Premise
337	(	_	_	I-Premise
338	SE	_	_	I-Premise
339	)	_	_	I-Premise
340	of	_	_	I-Premise
341	4.6	_	_	I-Premise
342	(	_	_	I-Premise
343	2	_	_	I-Premise
344	)	_	_	I-Premise
345	for	_	_	I-Premise
346	quality	_	_	I-Premise
347	of	_	_	I-Premise
348	life	_	_	I-Premise
349	(	_	_	I-Premise
350	P	_	_	I-Premise
351	=	_	_	I-Premise
352	.02	_	_	I-Premise
353	)	_	_	I-Premise
354	,	_	_	I-Premise
355	-27.8	_	_	I-Premise
356	(	_	_	I-Premise
357	15	_	_	I-Premise
358	)	_	_	I-Premise
359	for	_	_	I-Premise
360	symptom	_	_	I-Premise
361	intensity	_	_	I-Premise
362	(	_	_	I-Premise
363	P	_	_	I-Premise
364	=	_	_	I-Premise
365	.06	_	_	I-Premise
366	)	_	_	I-Premise
367	,	_	_	I-Premise
368	and	_	_	I-Premise
369	-1.8	_	_	I-Premise
370	(	_	_	I-Premise
371	0.81	_	_	I-Premise
372	)	_	_	I-Premise
373	for	_	_	I-Premise
374	depressed	_	_	I-Premise
375	mood	_	_	I-Premise
376	(	_	_	I-Premise
377	P	_	_	I-Premise
378	=	_	_	I-Premise
379	.02	_	_	I-Premise
380	)	_	_	I-Premise
381	.	_	_	I-Premise

382	The	_	_	B-Premise
383	estimated	_	_	I-Premise
384	treatment	_	_	I-Premise
385	effects	_	_	I-Premise
386	in	_	_	I-Premise
387	participants	_	_	I-Premise
388	who	_	_	I-Premise
389	died	_	_	I-Premise
390	during	_	_	I-Premise
391	the	_	_	I-Premise
392	study	_	_	I-Premise
393	were	_	_	I-Premise
394	a	_	_	I-Premise
395	mean	_	_	I-Premise
396	(	_	_	I-Premise
397	SE	_	_	I-Premise
398	)	_	_	I-Premise
399	of	_	_	I-Premise
400	8.6	_	_	I-Premise
401	(	_	_	I-Premise
402	3.6	_	_	I-Premise
403	)	_	_	I-Premise
404	for	_	_	I-Premise
405	quality	_	_	I-Premise
406	of	_	_	I-Premise
407	life	_	_	I-Premise
408	(	_	_	I-Premise
409	P	_	_	I-Premise
410	=	_	_	I-Premise
411	.02	_	_	I-Premise
412	)	_	_	I-Premise
413	,	_	_	I-Premise
414	-24.2	_	_	I-Premise
415	(	_	_	I-Premise
416	20.5	_	_	I-Premise
417	)	_	_	I-Premise
418	for	_	_	I-Premise
419	symptom	_	_	I-Premise
420	intensity	_	_	I-Premise
421	(	_	_	I-Premise
422	P	_	_	I-Premise
423	=	_	_	I-Premise
424	.24	_	_	I-Premise
425	)	_	_	I-Premise
426	,	_	_	I-Premise
427	and	_	_	I-Premise
428	-2.7	_	_	I-Premise
429	(	_	_	I-Premise
430	1.2	_	_	I-Premise
431	)	_	_	I-Premise
432	for	_	_	I-Premise
433	depressed	_	_	I-Premise
434	mood	_	_	I-Premise
435	(	_	_	I-Premise
436	P	_	_	I-Premise
437	=	_	_	I-Premise
438	.03	_	_	I-Premise
439	)	_	_	I-Premise
440	.	_	_	I-Premise

441	Intensity	_	_	O
442	of	_	_	O
443	service	_	_	O
444	did	_	_	O
445	not	_	_	O
446	differ	_	_	O
447	between	_	_	O
448	the	_	_	O
449	2	_	_	O
450	groups	_	_	O
451	.	_	_	O

452	Compared	_	_	B-Claim
453	with	_	_	I-Claim
454	participants	_	_	I-Claim
455	receiving	_	_	I-Claim
456	usual	_	_	I-Claim
457	oncology	_	_	I-Claim
458	care	_	_	I-Claim
459	,	_	_	I-Claim
460	those	_	_	I-Claim
461	receiving	_	_	I-Claim
462	a	_	_	I-Claim
463	nurse-led	_	_	I-Claim
464	,	_	_	I-Claim
465	palliative	_	_	I-Claim
466	care-focused	_	_	I-Claim
467	intervention	_	_	I-Claim
468	addressing	_	_	I-Claim
469	physical	_	_	I-Claim
470	,	_	_	I-Claim
471	psychosocial	_	_	I-Claim
472	,	_	_	I-Claim
473	and	_	_	I-Claim
474	care	_	_	I-Claim
475	coordination	_	_	I-Claim
476	provided	_	_	I-Claim
477	concurrently	_	_	I-Claim
478	with	_	_	I-Claim
479	oncology	_	_	I-Claim
480	care	_	_	I-Claim
481	had	_	_	I-Claim
482	higher	_	_	I-Claim
483	scores	_	_	I-Claim
484	for	_	_	I-Claim
485	quality	_	_	I-Claim
486	of	_	_	I-Claim
487	life	_	_	I-Claim
488	and	_	_	I-Claim
489	mood	_	_	I-Claim
490	,	_	_	I-Claim
491	but	_	_	B-Claim
492	did	_	_	I-Claim
493	not	_	_	I-Claim
494	have	_	_	I-Claim
495	improvements	_	_	I-Claim
496	in	_	_	I-Claim
497	symptom	_	_	I-Claim
498	intensity	_	_	I-Claim
499	scores	_	_	I-Claim
500	or	_	_	I-Claim
501	reduced	_	_	I-Claim
502	days	_	_	I-Claim
503	in	_	_	I-Claim
504	the	_	_	I-Claim
505	hospital	_	_	I-Claim
506	or	_	_	I-Claim
507	ICU	_	_	I-Claim
508	or	_	_	I-Claim
509	emergency	_	_	I-Claim
510	department	_	_	I-Claim
511	visits	_	_	I-Claim
512	.	_	_	I-Claim


0	A	_	_	O
1	recent	_	_	O
2	randomized	_	_	O
3	trial	_	_	O
4	to	_	_	O
5	compare	_	_	O
6	external	_	_	O
7	beam	_	_	O
8	radiation	_	_	O
9	therapy	_	_	O
10	(	_	_	O
11	EBRT	_	_	O
12	)	_	_	O
13	to	_	_	O
14	cryoablation	_	_	O
15	for	_	_	O
16	localized	_	_	O
17	disease	_	_	O
18	showed	_	_	O
19	cryoablation	_	_	O
20	to	_	_	O
21	be	_	_	O
22	noninferior	_	_	O
23	to	_	_	O
24	external	_	_	O
25	beam	_	_	O
26	EBRT	_	_	O
27	in	_	_	O
28	disease	_	_	O
29	progression	_	_	O
30	and	_	_	O
31	overall	_	_	O
32	and	_	_	O
33	disease-specific	_	_	O
34	survival	_	_	O
35	.	_	_	O

36	We	_	_	O
37	report	_	_	O
38	on	_	_	O
39	the	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	outcomes	_	_	O
47	for	_	_	O
48	this	_	_	O
49	trial	_	_	O
50	.	_	_	O

51	From	_	_	O
52	December	_	_	O
53	1997	_	_	O
54	through	_	_	O
55	February	_	_	O
56	2003	_	_	O
57	,	_	_	O
58	244	_	_	O
59	men	_	_	O
60	with	_	_	O
61	newly	_	_	O
62	diagnosed	_	_	O
63	localized	_	_	O
64	prostate	_	_	O
65	cancer	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	assigned	_	_	O
69	to	_	_	O
70	cryoablation	_	_	O
71	or	_	_	O
72	EBRT	_	_	O
73	(	_	_	O
74	median	_	_	O
75	dose	_	_	O
76	68	_	_	O
77	Gy	_	_	O
78	)	_	_	O
79	.	_	_	O

80	All	_	_	O
81	patients	_	_	O
82	received	_	_	O
83	neoadjuvant	_	_	O
84	antiandrogen	_	_	O
85	therapy	_	_	O
86	.	_	_	O

87	Patients	_	_	O
88	completed	_	_	O
89	the	_	_	O
90	EORTC	_	_	O
91	QLQ	_	_	O
92	C30	_	_	O
93	and	_	_	O
94	the	_	_	O
95	Prostate	_	_	O
96	Cancer	_	_	O
97	Index	_	_	O
98	(	_	_	O
99	PCI	_	_	O
100	)	_	_	O
101	before	_	_	O
102	treatment	_	_	O
103	and	_	_	O
104	at	_	_	O
105	1.5	_	_	O
106	,	_	_	O
107	3	_	_	O
108	,	_	_	O
109	6	_	_	O
110	,	_	_	O
111	12	_	_	O
112	,	_	_	O
113	18	_	_	O
114	,	_	_	O
115	24	_	_	O
116	,	_	_	O
117	and	_	_	O
118	36	_	_	O
119	months	_	_	O
120	post-treatment	_	_	O
121	.	_	_	O

122	Regardless	_	_	B-Premise
123	of	_	_	I-Premise
124	treatment	_	_	I-Premise
125	arm	_	_	I-Premise
126	,	_	_	I-Premise
127	participants	_	_	I-Premise
128	reported	_	_	I-Premise
129	high	_	_	I-Premise
130	levels	_	_	I-Premise
131	of	_	_	I-Premise
132	QOL	_	_	I-Premise
133	with	_	_	I-Premise
134	few	_	_	I-Premise
135	exceptions	_	_	I-Premise
136	.	_	_	I-Premise

137	cryoablation	_	_	B-Premise
138	was	_	_	I-Premise
139	associated	_	_	I-Premise
140	with	_	_	I-Premise
141	more	_	_	I-Premise
142	acute	_	_	I-Premise
143	urinary	_	_	I-Premise
144	dysfunction	_	_	I-Premise
145	(	_	_	I-Premise
146	mean	_	_	I-Premise
147	PCI	_	_	I-Premise
148	urinary	_	_	I-Premise
149	function	_	_	I-Premise
150	cryoablation=69.4	_	_	I-Premise
151	;	_	_	I-Premise
152	mean	_	_	I-Premise
153	EBRT=90.7	_	_	I-Premise
154	;	_	_	I-Premise
155	P	_	_	I-Premise
156	<	_	_	I-Premise
157	.001	_	_	I-Premise
158	)	_	_	I-Premise
159	,	_	_	I-Premise
160	which	_	_	I-Premise
161	resolved	_	_	I-Premise
162	over	_	_	I-Premise
163	time	_	_	I-Premise
164	.	_	_	I-Premise

165	No	_	_	B-Premise
166	late	_	_	I-Premise
167	arising	_	_	I-Premise
168	QOL	_	_	I-Premise
169	issues	_	_	I-Premise
170	were	_	_	I-Premise
171	observed	_	_	I-Premise
172	.	_	_	I-Premise

173	Both	_	_	B-Premise
174	EBRT	_	_	I-Premise
175	and	_	_	I-Premise
176	cryoablation	_	_	I-Premise
177	participants	_	_	I-Premise
178	reported	_	_	I-Premise
179	decreases	_	_	I-Premise
180	in	_	_	I-Premise
181	sexual	_	_	I-Premise
182	function	_	_	I-Premise
183	at	_	_	I-Premise
184	3	_	_	I-Premise
185	months	_	_	I-Premise
186	with	_	_	I-Premise
187	the	_	_	I-Premise
188	cryoablation	_	_	I-Premise
189	patients	_	_	I-Premise
190	reporting	_	_	I-Premise
191	poorer	_	_	I-Premise
192	functioning	_	_	I-Premise
193	(	_	_	I-Premise
194	mean	_	_	I-Premise
195	cryoablation=7.2	_	_	I-Premise
196	:	_	_	I-Premise
197	mean	_	_	I-Premise
198	EBRT=32.9	_	_	I-Premise
199	;	_	_	I-Premise
200	P	_	_	I-Premise
201	<	_	_	I-Premise
202	.001	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Mean	_	_	B-Premise
206	sexual	_	_	I-Premise
207	function	_	_	I-Premise
208	score	_	_	I-Premise
209	was	_	_	I-Premise
210	15	_	_	I-Premise
211	points	_	_	I-Premise
212	lower	_	_	I-Premise
213	at	_	_	I-Premise
214	3	_	_	I-Premise
215	years	_	_	I-Premise
216	for	_	_	I-Premise
217	the	_	_	I-Premise
218	cryoablation	_	_	I-Premise
219	group	_	_	I-Premise
220	and	_	_	I-Premise
221	13	_	_	I-Premise
222	%	_	_	I-Premise
223	more	_	_	I-Premise
224	of	_	_	I-Premise
225	the	_	_	I-Premise
226	cryoablation	_	_	I-Premise
227	men	_	_	I-Premise
228	said	_	_	I-Premise
229	that	_	_	I-Premise
230	sexuality	_	_	I-Premise
231	was	_	_	I-Premise
232	a	_	_	I-Premise
233	moderate	_	_	I-Premise
234	or	_	_	I-Premise
235	big	_	_	I-Premise
236	problem	_	_	I-Premise
237	.	_	_	I-Premise

238	In	_	_	B-Claim
239	this	_	_	I-Claim
240	randomized	_	_	I-Claim
241	trial	_	_	I-Claim
242	,	_	_	I-Claim
243	no	_	_	I-Claim
244	long-term	_	_	I-Claim
245	QOL	_	_	I-Claim
246	advantage	_	_	I-Claim
247	for	_	_	I-Claim
248	either	_	_	I-Claim
249	treatment	_	_	I-Claim
250	was	_	_	I-Claim
251	apparent	_	_	I-Claim
252	with	_	_	B-Claim
253	the	_	_	I-Claim
254	exception	_	_	I-Claim
255	of	_	_	I-Claim
256	poorer	_	_	I-Claim
257	sexual	_	_	I-Claim
258	function	_	_	I-Claim
259	reported	_	_	I-Claim
260	by	_	_	I-Claim
261	those	_	_	I-Claim
262	treated	_	_	I-Claim
263	with	_	_	I-Claim
264	cryoablation	_	_	I-Claim
265	.	_	_	I-Claim

266	Men	_	_	O
267	who	_	_	O
268	wish	_	_	O
269	to	_	_	O
270	increase	_	_	O
271	their	_	_	O
272	odds	_	_	O
273	of	_	_	O
274	retaining	_	_	O
275	sexual	_	_	O
276	function	_	_	O
277	might	_	_	O
278	be	_	_	O
279	counseled	_	_	O
280	to	_	_	O
281	choose	_	_	O
282	EBRT	_	_	O
283	over	_	_	O
284	cryoablation	_	_	O
285	.	_	_	O


0	Somatostatin	_	_	O
1	analogs	_	_	O
2	are	_	_	O
3	indicated	_	_	O
4	for	_	_	O
5	symptom	_	_	O
6	control	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	gastroenteropancreatic	_	_	O
11	neuroendocrine	_	_	O
12	tumors	_	_	O
13	(	_	_	O
14	NETs	_	_	O
15	)	_	_	O
16	.	_	_	O

17	The	_	_	O
18	ability	_	_	O
19	of	_	_	O
20	somatostatin	_	_	O
21	analogs	_	_	O
22	to	_	_	O
23	control	_	_	O
24	the	_	_	O
25	growth	_	_	O
26	of	_	_	O
27	well-differentiated	_	_	O
28	metastatic	_	_	O
29	NETs	_	_	O
30	is	_	_	O
31	a	_	_	O
32	matter	_	_	O
33	of	_	_	O
34	debate	_	_	O
35	.	_	_	O

36	We	_	_	O
37	performed	_	_	O
38	a	_	_	O
39	placebo-controlled	_	_	O
40	,	_	_	O
41	double-blind	_	_	O
42	,	_	_	O
43	phase	_	_	O
44	IIIB	_	_	O
45	study	_	_	O
46	in	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	well-differentiated	_	_	O
50	metastatic	_	_	O
51	midgut	_	_	O
52	NETs	_	_	O
53	.	_	_	O

54	The	_	_	O
55	hypothesis	_	_	O
56	was	_	_	O
57	that	_	_	O
58	octreotide	_	_	O
59	LAR	_	_	O
60	prolongs	_	_	O
61	time	_	_	O
62	to	_	_	O
63	tumor	_	_	O
64	progression	_	_	O
65	and	_	_	O
66	survival	_	_	O
67	.	_	_	O

68	Treatment-naive	_	_	O
69	patients	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	either	_	_	O
75	placebo	_	_	O
76	or	_	_	O
77	octreotide	_	_	O
78	LAR	_	_	O
79	30	_	_	O
80	mg	_	_	O
81	intramuscularly	_	_	O
82	in	_	_	O
83	monthly	_	_	O
84	intervals	_	_	O
85	until	_	_	O
86	tumor	_	_	O
87	progression	_	_	O
88	or	_	_	O
89	death	_	_	O
90	.	_	_	O

91	The	_	_	O
92	primary	_	_	O
93	efficacy	_	_	O
94	end	_	_	O
95	point	_	_	O
96	was	_	_	O
97	time	_	_	O
98	to	_	_	O
99	tumor	_	_	O
100	progression	_	_	O
101	.	_	_	O

102	Secondary	_	_	O
103	end	_	_	O
104	points	_	_	O
105	were	_	_	O
106	survival	_	_	O
107	time	_	_	O
108	and	_	_	O
109	tumor	_	_	O
110	response	_	_	O
111	.	_	_	O

112	This	_	_	O
113	report	_	_	O
114	is	_	_	O
115	based	_	_	O
116	on	_	_	O
117	67	_	_	O
118	tumor	_	_	O
119	progressions	_	_	O
120	and	_	_	O
121	16	_	_	O
122	observed	_	_	O
123	deaths	_	_	O
124	in	_	_	O
125	85	_	_	O
126	patients	_	_	O
127	at	_	_	O
128	the	_	_	O
129	time	_	_	O
130	of	_	_	O
131	the	_	_	O
132	planned	_	_	O
133	interim	_	_	O
134	analysis	_	_	O
135	.	_	_	O

136	Median	_	_	B-Premise
137	time	_	_	I-Premise
138	to	_	_	I-Premise
139	tumor	_	_	I-Premise
140	progression	_	_	I-Premise
141	in	_	_	I-Premise
142	the	_	_	I-Premise
143	octreotide	_	_	I-Premise
144	LAR	_	_	I-Premise
145	and	_	_	I-Premise
146	placebo	_	_	I-Premise
147	groups	_	_	I-Premise
148	was	_	_	I-Premise
149	14.3	_	_	I-Premise
150	and	_	_	I-Premise
151	6	_	_	I-Premise
152	months	_	_	I-Premise
153	,	_	_	I-Premise
154	respectively	_	_	I-Premise
155	(	_	_	I-Premise
156	hazard	_	_	I-Premise
157	ratio	_	_	I-Premise
158	[	_	_	I-Premise
159	HR	_	_	I-Premise
160	]	_	_	I-Premise
161	=	_	_	I-Premise
162	0.34	_	_	I-Premise
163	;	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	CI	_	_	I-Premise
167	,	_	_	I-Premise
168	0.20	_	_	I-Premise
169	to	_	_	I-Premise
170	0.59	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.000072	_	_	I-Premise
175	)	_	_	I-Premise
176	.	_	_	I-Premise

177	After	_	_	B-Premise
178	6	_	_	I-Premise
179	months	_	_	I-Premise
180	of	_	_	I-Premise
181	treatment	_	_	I-Premise
182	,	_	_	I-Premise
183	stable	_	_	I-Premise
184	disease	_	_	I-Premise
185	was	_	_	I-Premise
186	observed	_	_	I-Premise
187	in	_	_	I-Premise
188	66.7	_	_	I-Premise
189	%	_	_	I-Premise
190	of	_	_	I-Premise
191	patients	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	octreotide	_	_	I-Premise
195	LAR	_	_	I-Premise
196	group	_	_	I-Premise
197	and	_	_	I-Premise
198	37.2	_	_	I-Premise
199	%	_	_	I-Premise
200	of	_	_	I-Premise
201	patients	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	placebo	_	_	I-Premise
205	group	_	_	I-Premise
206	.	_	_	I-Premise

207	Functionally	_	_	O
208	active	_	_	O
209	and	_	_	O
210	inactive	_	_	O
211	tumors	_	_	O
212	responded	_	_	O
213	similarly	_	_	O
214	.	_	_	O

215	The	_	_	B-Premise
216	most	_	_	I-Premise
217	favorable	_	_	I-Premise
218	effect	_	_	I-Premise
219	was	_	_	I-Premise
220	observed	_	_	I-Premise
221	in	_	_	I-Premise
222	patients	_	_	I-Premise
223	with	_	_	I-Premise
224	low	_	_	I-Premise
225	hepatic	_	_	I-Premise
226	tumor	_	_	I-Premise
227	load	_	_	I-Premise
228	and	_	_	I-Premise
229	resected	_	_	I-Premise
230	primary	_	_	I-Premise
231	tumor	_	_	I-Premise
232	.	_	_	I-Premise

233	Seven	_	_	B-Premise
234	and	_	_	I-Premise
235	nine	_	_	I-Premise
236	deaths	_	_	I-Premise
237	were	_	_	I-Premise
238	observed	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	octreotide	_	_	I-Premise
242	LAR	_	_	I-Premise
243	and	_	_	I-Premise
244	placebo	_	_	I-Premise
245	groups	_	_	I-Premise
246	,	_	_	I-Premise
247	respectively	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	HR	_	_	I-Premise
251	for	_	_	I-Premise
252	overall	_	_	I-Premise
253	survival	_	_	I-Premise
254	was	_	_	I-Premise
255	0.81	_	_	I-Premise
256	(	_	_	I-Premise
257	95	_	_	I-Premise
258	%	_	_	I-Premise
259	CI	_	_	I-Premise
260	,	_	_	I-Premise
261	0.30	_	_	I-Premise
262	to	_	_	I-Premise
263	2.18	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	Octreotide	_	_	B-Claim
267	LAR	_	_	I-Claim
268	significantly	_	_	I-Claim
269	lengthens	_	_	I-Claim
270	time	_	_	I-Claim
271	to	_	_	I-Claim
272	tumor	_	_	I-Claim
273	progression	_	_	I-Claim
274	compared	_	_	I-Claim
275	with	_	_	I-Claim
276	placebo	_	_	I-Claim
277	in	_	_	I-Claim
278	patients	_	_	I-Claim
279	with	_	_	I-Claim
280	functionally	_	_	I-Claim
281	active	_	_	I-Claim
282	and	_	_	I-Claim
283	inactive	_	_	I-Claim
284	metastatic	_	_	I-Claim
285	midgut	_	_	I-Claim
286	NETs	_	_	I-Claim
287	.	_	_	I-Claim

288	Because	_	_	B-Premise
289	of	_	_	I-Premise
290	the	_	_	I-Premise
291	low	_	_	I-Premise
292	number	_	_	I-Premise
293	of	_	_	I-Premise
294	observed	_	_	I-Premise
295	deaths	_	_	I-Premise
296	,	_	_	I-Premise
297	survival	_	_	I-Premise
298	analysis	_	_	I-Premise
299	was	_	_	I-Premise
300	not	_	_	I-Premise
301	confirmatory	_	_	I-Premise
302	.	_	_	I-Premise


0	Gemcitabine	_	_	O
1	(	_	_	O
2	G	_	_	O
3	)	_	_	O
4	is	_	_	O
5	standard	_	_	O
6	therapy	_	_	O
7	for	_	_	O
8	pancreatic	_	_	O
9	cancer	_	_	O
10	.	_	_	O

11	Enzastaurin	_	_	O
12	(	_	_	O
13	E	_	_	O
14	)	_	_	O
15	inhibits	_	_	O
16	PKCβ	_	_	O
17	and	_	_	O
18	PI3K/AKT	_	_	O
19	signaling	_	_	O
20	pathways	_	_	O
21	with	_	_	O
22	a	_	_	O
23	dose-dependent	_	_	O
24	effect	_	_	O
25	on	_	_	O
26	growth	_	_	O
27	of	_	_	O
28	pancreatic	_	_	O
29	carcinoma	_	_	O
30	xenografts	_	_	O
31	.	_	_	O

32	Data	_	_	B-Claim
33	suggest	_	_	I-Claim
34	that	_	_	I-Claim
35	the	_	_	I-Claim
36	GE	_	_	I-Claim
37	combination	_	_	I-Claim
38	may	_	_	I-Claim
39	improve	_	_	I-Claim
40	clinical	_	_	I-Claim
41	outcomes	_	_	I-Claim
42	.	_	_	I-Claim

43	Primary	_	_	O
44	objective	_	_	O
45	was	_	_	O
46	overall	_	_	O
47	survival	_	_	O
48	(	_	_	O
49	OS	_	_	O
50	)	_	_	O
51	;	_	_	O
52	secondary	_	_	O
53	objectives	_	_	O
54	assessed	_	_	O
55	progression-free	_	_	O
56	survival	_	_	O
57	(	_	_	O
58	PFS	_	_	O
59	)	_	_	O
60	,	_	_	O
61	response	_	_	O
62	rate	_	_	O
63	(	_	_	O
64	RR	_	_	O
65	)	_	_	O
66	,	_	_	O
67	quality	_	_	O
68	of	_	_	O
69	life	_	_	O
70	(	_	_	O
71	QOL	_	_	O
72	)	_	_	O
73	,	_	_	O
74	toxicity	_	_	O
75	,	_	_	O
76	and	_	_	O
77	relationships	_	_	O
78	between	_	_	O
79	biomarker	_	_	O
80	expression	_	_	O
81	and	_	_	O
82	clinical	_	_	O
83	outcomes	_	_	O
84	.	_	_	O

85	Patients	_	_	O
86	were	_	_	O
87	randomly	_	_	O
88	assigned	_	_	O
89	(	_	_	O
90	2:1	_	_	O
91	)	_	_	O
92	to	_	_	O
93	GE	_	_	O
94	or	_	_	O
95	G	_	_	O
96	treatment	_	_	O
97	;	_	_	O
98	GE	_	_	O
99	arm	_	_	O
100	:	_	_	O
101	E	_	_	O
102	500	_	_	O
103	mg	_	_	O
104	p.o	_	_	O
105	.	_	_	O

106	daily	_	_	O
107	;	_	_	O
108	loading-dose	_	_	O
109	(	_	_	O
110	1200	_	_	O
111	mg	_	_	O
112	;	_	_	O
113	Day	_	_	O
114	1	_	_	O
115	Cycle	_	_	O
116	1	_	_	O
117	only	_	_	O
118	)	_	_	O
119	and	_	_	O
120	G	_	_	O
121	1000	_	_	O
122	mg/m	_	_	O
123	(	_	_	O
124	2	_	_	O
125	)	_	_	O
126	i.v	_	_	O
127	.	_	_	O

128	Days	_	_	O
129	1	_	_	O
130	,	_	_	O
131	8	_	_	O
132	,	_	_	O
133	and	_	_	O
134	15	_	_	O
135	in	_	_	O
136	28-day	_	_	O
137	cycles	_	_	O
138	;	_	_	O
139	G	_	_	O
140	arm	_	_	O
141	:	_	_	O
142	G	_	_	O
143	as	_	_	O
144	in	_	_	O
145	GE	_	_	O
146	.	_	_	O

147	Biomarker	_	_	O
148	expression	_	_	O
149	was	_	_	O
150	assessed	_	_	O
151	by	_	_	O
152	immunohistochemistry	_	_	O
153	.	_	_	O

154	Randomization	_	_	O
155	totaled	_	_	O
156	130	_	_	O
157	patients	_	_	O
158	(	_	_	O
159	GE	_	_	O
160	=	_	_	O
161	86	_	_	O
162	,	_	_	O
163	G	_	_	O
164	=	_	_	O
165	44	_	_	O
166	)	_	_	O
167	;	_	_	O
168	121	_	_	O
169	patients	_	_	O
170	were	_	_	O
171	treated	_	_	O
172	(	_	_	O
173	GE	_	_	O
174	=	_	_	O
175	82	_	_	O
176	,	_	_	O
177	G	_	_	O
178	=	_	_	O
179	39	_	_	O
180	)	_	_	O
181	.	_	_	O

182	GE/G	_	_	O
183	median	_	_	O
184	OS	_	_	O
185	was	_	_	O
186	5.6/5.1	_	_	O
187	months	_	_	O
188	;	_	_	O
189	median	_	_	O
190	PFS	_	_	O
191	was	_	_	O
192	3.4/3.0	_	_	O
193	months	_	_	O
194	.	_	_	O

195	GE	_	_	O
196	responses	_	_	O
197	:	_	_	O
198	1	_	_	O
199	complete	_	_	O
200	response	_	_	O
201	(	_	_	O
202	CR	_	_	O
203	,	_	_	O
204	1.2	_	_	O
205	%	_	_	O
206	)	_	_	O
207	,	_	_	O
208	6	_	_	O
209	partial	_	_	O
210	response	_	_	O
211	(	_	_	O
212	PR	_	_	O
213	,	_	_	O
214	7.4	_	_	O
215	%	_	_	O
216	)	_	_	O
217	,	_	_	O
218	and	_	_	O
219	33	_	_	O
220	stable	_	_	O
221	disease	_	_	O
222	(	_	_	O
223	SD	_	_	O
224	,	_	_	O
225	40.7	_	_	O
226	%	_	_	O
227	)	_	_	O
228	;	_	_	O
229	disease	_	_	O
230	control	_	_	O
231	rate	_	_	O
232	(	_	_	O
233	DCR=CR+PR+SD	_	_	O
234	,	_	_	O
235	49.4	_	_	O
236	%	_	_	O
237	)	_	_	O
238	.	_	_	O

239	G	_	_	O
240	responses	_	_	O
241	:	_	_	O
242	2	_	_	O
243	PR	_	_	O
244	(	_	_	O
245	5.3	_	_	O
246	%	_	_	O
247	)	_	_	O
248	and	_	_	O
249	16	_	_	O
250	SD	_	_	O
251	(	_	_	O
252	42.1	_	_	O
253	%	_	_	O
254	)	_	_	O
255	;	_	_	O
256	DCR	_	_	O
257	(	_	_	O
258	47.4	_	_	O
259	%	_	_	O
260	)	_	_	O
261	.	_	_	O

262	No	_	_	B-Premise
263	QOL	_	_	I-Premise
264	differences	_	_	I-Premise
265	were	_	_	I-Premise
266	noted	_	_	I-Premise
267	between	_	_	I-Premise
268	arms	_	_	I-Premise
269	.	_	_	I-Premise

270	GE/G	_	_	B-Premise
271	Grade	_	_	I-Premise
272	3-4	_	_	I-Premise
273	toxicities	_	_	I-Premise
274	included	_	_	I-Premise
275	:	_	_	I-Premise
276	neutropenia	_	_	I-Premise
277	(	_	_	I-Premise
278	18.3	_	_	I-Premise
279	%	_	_	I-Premise
280	/28.2	_	_	I-Premise
281	%	_	_	I-Premise
282	)	_	_	I-Premise
283	;	_	_	I-Premise
284	thrombocytopenia	_	_	I-Premise
285	(	_	_	I-Premise
286	14.6	_	_	I-Premise
287	%	_	_	I-Premise
288	/25.6	_	_	I-Premise
289	%	_	_	I-Premise
290	)	_	_	I-Premise
291	;	_	_	I-Premise
292	and	_	_	I-Premise
293	fatigue	_	_	I-Premise
294	(	_	_	I-Premise
295	11.0	_	_	I-Premise
296	%	_	_	I-Premise
297	/7.7	_	_	I-Premise
298	%	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	No	_	_	B-Premise
302	statistically	_	_	I-Premise
303	significant	_	_	I-Premise
304	relationships	_	_	I-Premise
305	between	_	_	I-Premise
306	biomarker	_	_	I-Premise
307	expression	_	_	I-Premise
308	and	_	_	I-Premise
309	outcomes	_	_	I-Premise
310	were	_	_	I-Premise
311	observed	_	_	I-Premise
312	.	_	_	I-Premise

313	However	_	_	O
314	,	_	_	O
315	patients	_	_	B-Premise
316	with	_	_	I-Premise
317	low	_	_	I-Premise
318	expression	_	_	I-Premise
319	of	_	_	I-Premise
320	cytoplasmic	_	_	I-Premise
321	pGSK-3β	_	_	I-Premise
322	trended	_	_	I-Premise
323	toward	_	_	I-Premise
324	greater	_	_	I-Premise
325	OS	_	_	I-Premise
326	with	_	_	I-Premise
327	GE	_	_	I-Premise
328	treatment	_	_	I-Premise
329	.	_	_	I-Premise

330	OS	_	_	B-Premise
331	,	_	_	I-Premise
332	PFS	_	_	I-Premise
333	,	_	_	I-Premise
334	QOL	_	_	I-Premise
335	,	_	_	I-Premise
336	and	_	_	I-Premise
337	RR	_	_	I-Premise
338	were	_	_	I-Premise
339	comparable	_	_	I-Premise
340	between	_	_	I-Premise
341	arms	_	_	I-Premise
342	.	_	_	I-Premise

343	Adding	_	_	B-Claim
344	E	_	_	I-Claim
345	to	_	_	I-Claim
346	G	_	_	I-Claim
347	did	_	_	I-Claim
348	not	_	_	I-Claim
349	increase	_	_	I-Claim
350	hematologic	_	_	I-Claim
351	toxicities	_	_	I-Claim
352	.	_	_	I-Claim

353	GE	_	_	O
354	does	_	_	O
355	not	_	_	O
356	warrant	_	_	O
357	further	_	_	O
358	investigation	_	_	O
359	in	_	_	O
360	unselected	_	_	O
361	pancreatic	_	_	O
362	cancer	_	_	O
363	patients	_	_	O
364	.	_	_	O


0	Assess	_	_	O
1	toxicity	_	_	O
2	and	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	cisplatin	_	_	O
6	(	_	_	O
7	Cis	_	_	O
8	)	_	_	O
9	doublet	_	_	O
10	combinations	_	_	O
11	in	_	_	O
12	advanced	_	_	O
13	and	_	_	O
14	recurrent	_	_	O
15	cervical	_	_	O
16	carcinoma	_	_	O
17	.	_	_	O

18	Patients	_	_	O
19	were	_	_	O
20	randomly	_	_	O
21	assigned	_	_	O
22	to	_	_	O
23	paclitaxel	_	_	O
24	135	_	_	O
25	mg/m	_	_	O
26	(	_	_	O
27	2	_	_	O
28	)	_	_	O
29	over	_	_	O
30	24	_	_	O
31	hours	_	_	O
32	plus	_	_	O
33	Cis	_	_	O
34	50	_	_	O
35	mg/m	_	_	O
36	(	_	_	O
37	2	_	_	O
38	)	_	_	O
39	day	_	_	O
40	2	_	_	O
41	every	_	_	O
42	3	_	_	O
43	weeks	_	_	O
44	(	_	_	O
45	PC	_	_	O
46	,	_	_	O
47	reference	_	_	O
48	arm	_	_	O
49	)	_	_	O
50	;	_	_	O
51	vinorelbine	_	_	O
52	30	_	_	O
53	mg/m	_	_	O
54	(	_	_	O
55	2	_	_	O
56	)	_	_	O
57	days	_	_	O
58	1	_	_	O
59	and	_	_	O
60	8	_	_	O
61	plus	_	_	O
62	Cis	_	_	O
63	50	_	_	O
64	mg/m	_	_	O
65	(	_	_	O
66	2	_	_	O
67	)	_	_	O
68	day	_	_	O
69	1	_	_	O
70	every	_	_	O
71	3	_	_	O
72	weeks	_	_	O
73	(	_	_	O
74	VC	_	_	O
75	)	_	_	O
76	;	_	_	O
77	gemcitabine	_	_	O
78	1,000	_	_	O
79	mg/m	_	_	O
80	(	_	_	O
81	2	_	_	O
82	)	_	_	O
83	day	_	_	O
84	1	_	_	O
85	and	_	_	O
86	8	_	_	O
87	plus	_	_	O
88	Cis	_	_	O
89	50	_	_	O
90	mg/m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	day	_	_	O
95	1	_	_	O
96	every	_	_	O
97	3	_	_	O
98	weeks	_	_	O
99	(	_	_	O
100	GC	_	_	O
101	)	_	_	O
102	;	_	_	O
103	or	_	_	O
104	topotecan	_	_	O
105	0.75	_	_	O
106	mg/m	_	_	O
107	(	_	_	O
108	2	_	_	O
109	)	_	_	O
110	days	_	_	O
111	1	_	_	O
112	,	_	_	O
113	2	_	_	O
114	,	_	_	O
115	and	_	_	O
116	3	_	_	O
117	plus	_	_	O
118	Cis	_	_	O
119	50	_	_	O
120	mg/m	_	_	O
121	(	_	_	O
122	2	_	_	O
123	)	_	_	O
124	day	_	_	O
125	1	_	_	O
126	every	_	_	O
127	3	_	_	O
128	weeks	_	_	O
129	(	_	_	O
130	TC	_	_	O
131	)	_	_	O
132	.	_	_	O

133	Survival	_	_	O
134	was	_	_	O
135	the	_	_	O
136	primary	_	_	O
137	end	_	_	O
138	point	_	_	O
139	with	_	_	O
140	a	_	_	O
141	33	_	_	O
142	%	_	_	O
143	improvement	_	_	O
144	relative	_	_	O
145	to	_	_	O
146	PC	_	_	O
147	considered	_	_	O
148	important	_	_	O
149	(	_	_	O
150	85	_	_	O
151	%	_	_	O
152	power	_	_	O
153	,	_	_	O
154	alpha	_	_	O
155	=	_	_	O
156	5	_	_	O
157	%	_	_	O
158	)	_	_	O
159	.	_	_	O

160	Quality-of-life	_	_	O
161	data	_	_	O
162	were	_	_	O
163	prospectively	_	_	O
164	collected	_	_	O
165	.	_	_	O

166	A	_	_	O
167	total	_	_	O
168	of	_	_	O
169	513	_	_	O
170	patients	_	_	O
171	were	_	_	O
172	enrolled	_	_	O
173	when	_	_	O
174	a	_	_	O
175	planned	_	_	O
176	interim	_	_	O
177	analysis	_	_	O
178	recommended	_	_	O
179	early	_	_	O
180	closure	_	_	O
181	for	_	_	O
182	futility	_	_	O
183	.	_	_	O

184	The	_	_	B-Premise
185	experimental-to-PC	_	_	I-Premise
186	hazard	_	_	I-Premise
187	ratios	_	_	I-Premise
188	of	_	_	I-Premise
189	death	_	_	I-Premise
190	were	_	_	I-Premise
191	1.15	_	_	I-Premise
192	(	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	,	_	_	I-Premise
197	0.79	_	_	I-Premise
198	to	_	_	I-Premise
199	1.67	_	_	I-Premise
200	)	_	_	I-Premise
201	for	_	_	I-Premise
202	VC	_	_	I-Premise
203	,	_	_	I-Premise
204	1.32	_	_	I-Premise
205	(	_	_	I-Premise
206	95	_	_	I-Premise
207	%	_	_	I-Premise
208	CI	_	_	I-Premise
209	,	_	_	I-Premise
210	0.91	_	_	I-Premise
211	to	_	_	I-Premise
212	1.92	_	_	I-Premise
213	)	_	_	I-Premise
214	for	_	_	I-Premise
215	GC	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	1.26	_	_	I-Premise
219	(	_	_	I-Premise
220	95	_	_	I-Premise
221	%	_	_	I-Premise
222	CI	_	_	I-Premise
223	,	_	_	I-Premise
224	0.86	_	_	I-Premise
225	to	_	_	I-Premise
226	1.82	_	_	I-Premise
227	)	_	_	I-Premise
228	for	_	_	I-Premise
229	TC	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	hazard	_	_	I-Premise
233	ratios	_	_	I-Premise
234	for	_	_	I-Premise
235	progression-free	_	_	I-Premise
236	survival	_	_	I-Premise
237	(	_	_	I-Premise
238	PFS	_	_	I-Premise
239	)	_	_	I-Premise
240	were	_	_	I-Premise
241	1.36	_	_	I-Premise
242	(	_	_	I-Premise
243	95	_	_	I-Premise
244	%	_	_	I-Premise
245	CI	_	_	I-Premise
246	,	_	_	I-Premise
247	0.97	_	_	I-Premise
248	to	_	_	I-Premise
249	1.90	_	_	I-Premise
250	)	_	_	I-Premise
251	for	_	_	I-Premise
252	VC	_	_	I-Premise
253	,	_	_	I-Premise
254	1.39	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.99	_	_	I-Premise
261	to	_	_	I-Premise
262	1.96	_	_	I-Premise
263	)	_	_	I-Premise
264	for	_	_	I-Premise
265	GC	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	1.27	_	_	I-Premise
269	(	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	CI	_	_	I-Premise
273	,	_	_	I-Premise
274	0.90	_	_	I-Premise
275	to	_	_	I-Premise
276	1.78	_	_	I-Premise
277	)	_	_	I-Premise
278	for	_	_	I-Premise
279	TC	_	_	I-Premise
280	.	_	_	I-Premise

281	Response	_	_	B-Premise
282	rates	_	_	I-Premise
283	(	_	_	I-Premise
284	RRs	_	_	I-Premise
285	)	_	_	I-Premise
286	for	_	_	I-Premise
287	PC	_	_	I-Premise
288	,	_	_	I-Premise
289	VC	_	_	I-Premise
290	,	_	_	I-Premise
291	GC	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	TC	_	_	I-Premise
295	were	_	_	I-Premise
296	29.1	_	_	I-Premise
297	%	_	_	I-Premise
298	,	_	_	I-Premise
299	25.9	_	_	I-Premise
300	%	_	_	I-Premise
301	,	_	_	I-Premise
302	22.3	_	_	I-Premise
303	%	_	_	I-Premise
304	,	_	_	I-Premise
305	and	_	_	I-Premise
306	23.4	_	_	I-Premise
307	%	_	_	I-Premise
308	,	_	_	I-Premise
309	respectively	_	_	I-Premise
310	.	_	_	I-Premise

311	The	_	_	B-Premise
312	arms	_	_	I-Premise
313	were	_	_	I-Premise
314	comparable	_	_	I-Premise
315	with	_	_	I-Premise
316	respect	_	_	I-Premise
317	to	_	_	I-Premise
318	toxicity	_	_	I-Premise
319	except	_	_	I-Premise
320	for	_	_	I-Premise
321	leucopenia	_	_	I-Premise
322	,	_	_	I-Premise
323	neutropenia	_	_	I-Premise
324	,	_	_	I-Premise
325	infection	_	_	I-Premise
326	,	_	_	I-Premise
327	and	_	_	I-Premise
328	alopecia	_	_	I-Premise
329	.	_	_	I-Premise

330	VC	_	_	B-Claim
331	,	_	_	I-Claim
332	GC	_	_	I-Claim
333	,	_	_	I-Claim
334	and	_	_	I-Claim
335	TC	_	_	I-Claim
336	are	_	_	I-Claim
337	not	_	_	I-Claim
338	superior	_	_	I-Claim
339	to	_	_	I-Claim
340	PC	_	_	I-Claim
341	in	_	_	I-Claim
342	terms	_	_	I-Claim
343	of	_	_	I-Claim
344	overall	_	_	I-Claim
345	survival	_	_	I-Claim
346	(	_	_	I-Claim
347	OS	_	_	I-Claim
348	)	_	_	I-Claim
349	.	_	_	I-Claim

350	However	_	_	B-Claim
351	,	_	_	I-Claim
352	the	_	_	I-Claim
353	trend	_	_	I-Claim
354	in	_	_	I-Claim
355	RR	_	_	I-Claim
356	,	_	_	I-Claim
357	PFS	_	_	I-Claim
358	,	_	_	I-Claim
359	and	_	_	I-Claim
360	OS	_	_	I-Claim
361	favors	_	_	I-Claim
362	PC	_	_	I-Claim
363	.	_	_	I-Claim

364	Differences	_	_	B-Claim
365	in	_	_	I-Claim
366	chemotherapy	_	_	I-Claim
367	scheduling	_	_	I-Claim
368	,	_	_	I-Claim
369	pre-existing	_	_	I-Claim
370	morbidity	_	_	I-Claim
371	,	_	_	I-Claim
372	and	_	_	I-Claim
373	toxicity	_	_	I-Claim
374	are	_	_	I-Claim
375	important	_	_	I-Claim
376	in	_	_	I-Claim
377	individualizing	_	_	I-Claim
378	therapy	_	_	I-Claim
379	.	_	_	I-Claim


0	Depression	_	_	O
1	is	_	_	O
2	common	_	_	O
3	among	_	_	O
4	older	_	_	O
5	cancer	_	_	O
6	patients	_	_	O
7	,	_	_	O
8	but	_	_	O
9	little	_	_	O
10	is	_	_	O
11	known	_	_	O
12	about	_	_	O
13	the	_	_	O
14	optimal	_	_	O
15	approach	_	_	O
16	to	_	_	O
17	caring	_	_	O
18	for	_	_	O
19	this	_	_	O
20	population	_	_	O
21	.	_	_	O

22	This	_	_	O
23	analysis	_	_	O
24	evaluates	_	_	O
25	the	_	_	O
26	effectiveness	_	_	O
27	of	_	_	O
28	the	_	_	O
29	Improving	_	_	O
30	Mood-Promoting	_	_	O
31	Access	_	_	O
32	to	_	_	O
33	Collaborative	_	_	O
34	Treatment	_	_	O
35	(	_	_	O
36	IMPACT	_	_	O
37	)	_	_	O
38	program	_	_	O
39	,	_	_	O
40	a	_	_	O
41	stepped	_	_	O
42	care	_	_	O
43	management	_	_	O
44	program	_	_	O
45	for	_	_	O
46	depression	_	_	O
47	in	_	_	O
48	primary	_	_	O
49	care	_	_	O
50	patients	_	_	O
51	who	_	_	O
52	had	_	_	O
53	an	_	_	O
54	ICD-9	_	_	O
55	cancer	_	_	O
56	diagnosis	_	_	O
57	.	_	_	O

58	Two	_	_	O
59	hundred	_	_	O
60	fifteen	_	_	O
61	cancer	_	_	O
62	patients	_	_	O
63	were	_	_	O
64	identified	_	_	O
65	from	_	_	O
66	the	_	_	O
67	1,801	_	_	O
68	participants	_	_	O
69	in	_	_	O
70	the	_	_	O
71	parent	_	_	O
72	study	_	_	O
73	.	_	_	O

74	Subjects	_	_	O
75	were	_	_	O
76	60	_	_	O
77	years	_	_	O
78	or	_	_	O
79	older	_	_	O
80	with	_	_	O
81	major	_	_	O
82	depression	_	_	O
83	(	_	_	O
84	18	_	_	O
85	%	_	_	O
86	)	_	_	O
87	,	_	_	O
88	dysthymic	_	_	O
89	disorder	_	_	O
90	(	_	_	O
91	33	_	_	O
92	%	_	_	O
93	)	_	_	O
94	,	_	_	O
95	or	_	_	O
96	both	_	_	O
97	(	_	_	O
98	49	_	_	O
99	%	_	_	O
100	)	_	_	O
101	,	_	_	O
102	recruited	_	_	O
103	from	_	_	O
104	18	_	_	O
105	primary	_	_	O
106	care	_	_	O
107	clinics	_	_	O
108	belonging	_	_	O
109	to	_	_	O
110	8	_	_	O
111	health-care	_	_	O
112	organizations	_	_	O
113	in	_	_	O
114	5	_	_	O
115	states	_	_	O
116	.	_	_	O

117	Patients	_	_	O
118	were	_	_	O
119	randomly	_	_	O
120	assigned	_	_	O
121	to	_	_	O
122	the	_	_	O
123	IMPACT	_	_	O
124	intervention	_	_	O
125	(	_	_	O
126	n	_	_	O
127	=	_	_	O
128	112	_	_	O
129	)	_	_	O
130	or	_	_	O
131	usual	_	_	O
132	care	_	_	O
133	(	_	_	O
134	n	_	_	O
135	=	_	_	O
136	103	_	_	O
137	)	_	_	O
138	.	_	_	O

139	Intervention	_	_	O
140	patients	_	_	O
141	had	_	_	O
142	access	_	_	O
143	for	_	_	O
144	up	_	_	O
145	to	_	_	O
146	12	_	_	O
147	months	_	_	O
148	to	_	_	O
149	a	_	_	O
150	depression	_	_	O
151	care	_	_	O
152	manager	_	_	O
153	who	_	_	O
154	was	_	_	O
155	supervised	_	_	O
156	by	_	_	O
157	a	_	_	O
158	psychiatrist	_	_	O
159	and	_	_	O
160	a	_	_	O
161	primary	_	_	O
162	care	_	_	O
163	provider	_	_	O
164	and	_	_	O
165	who	_	_	O
166	offered	_	_	O
167	education	_	_	O
168	,	_	_	O
169	care	_	_	O
170	management	_	_	O
171	,	_	_	O
172	support	_	_	O
173	of	_	_	O
174	antidepressant	_	_	O
175	management	_	_	O
176	,	_	_	O
177	and	_	_	O
178	brief	_	_	O
179	,	_	_	O
180	structured	_	_	O
181	psychosocial	_	_	O
182	interventions	_	_	O
183	including	_	_	O
184	behavioral	_	_	O
185	activation	_	_	O
186	and	_	_	O
187	problem-solving	_	_	O
188	treatment	_	_	O
189	.	_	_	O

190	At	_	_	B-Premise
191	6	_	_	I-Premise
192	and	_	_	I-Premise
193	12	_	_	I-Premise
194	months	_	_	I-Premise
195	,	_	_	I-Premise
196	55	_	_	I-Premise
197	%	_	_	I-Premise
198	and	_	_	I-Premise
199	39	_	_	I-Premise
200	%	_	_	I-Premise
201	of	_	_	I-Premise
202	intervention	_	_	I-Premise
203	patients	_	_	I-Premise
204	had	_	_	I-Premise
205	a	_	_	I-Premise
206	50	_	_	I-Premise
207	%	_	_	I-Premise
208	or	_	_	I-Premise
209	greater	_	_	I-Premise
210	reduction	_	_	I-Premise
211	in	_	_	I-Premise
212	depressive	_	_	I-Premise
213	symptoms	_	_	I-Premise
214	(	_	_	I-Premise
215	SCL-20	_	_	I-Premise
216	)	_	_	I-Premise
217	from	_	_	I-Premise
218	baseline	_	_	I-Premise
219	compared	_	_	I-Premise
220	to	_	_	I-Premise
221	34	_	_	I-Premise
222	%	_	_	I-Premise
223	and	_	_	I-Premise
224	20	_	_	I-Premise
225	%	_	_	I-Premise
226	of	_	_	I-Premise
227	usual	_	_	I-Premise
228	care	_	_	I-Premise
229	participants	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	0.003	_	_	I-Premise
234	and	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	0.029	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	Intervention	_	_	B-Premise
241	patients	_	_	I-Premise
242	also	_	_	I-Premise
243	experienced	_	_	I-Premise
244	greater	_	_	I-Premise
245	remission	_	_	I-Premise
246	rates	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	0.031	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	more	_	_	I-Premise
254	depression-free	_	_	I-Premise
255	days	_	_	I-Premise
256	(	_	_	I-Premise
257	P	_	_	I-Premise
258	<	_	_	I-Premise
259	0.001	_	_	I-Premise
260	)	_	_	I-Premise
261	,	_	_	I-Premise
262	less	_	_	I-Premise
263	functional	_	_	I-Premise
264	impairment	_	_	I-Premise
265	(	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	0.011	_	_	I-Premise
269	)	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	greater	_	_	I-Premise
273	quality	_	_	I-Premise
274	of	_	_	I-Premise
275	life	_	_	I-Premise
276	(	_	_	I-Premise
277	P	_	_	I-Premise
278	=	_	_	I-Premise
279	0.039	_	_	I-Premise
280	)	_	_	I-Premise
281	at	_	_	I-Premise
282	12	_	_	I-Premise
283	months	_	_	I-Premise
284	than	_	_	I-Premise
285	usual	_	_	I-Premise
286	care	_	_	I-Premise
287	participants	_	_	I-Premise
288	.	_	_	I-Premise

289	The	_	_	B-Claim
290	IMPACT	_	_	I-Claim
291	collaborative	_	_	I-Claim
292	care	_	_	I-Claim
293	program	_	_	I-Claim
294	appears	_	_	I-Claim
295	to	_	_	I-Claim
296	be	_	_	I-Claim
297	feasible	_	_	I-Claim
298	and	_	_	I-Claim
299	effective	_	_	I-Claim
300	for	_	_	I-Claim
301	depression	_	_	I-Claim
302	among	_	_	I-Claim
303	older	_	_	I-Claim
304	cancer	_	_	I-Claim
305	patients	_	_	I-Claim
306	in	_	_	I-Claim
307	diverse	_	_	I-Claim
308	primary	_	_	I-Claim
309	care	_	_	I-Claim
310	settings	_	_	I-Claim
311	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	1-year	_	_	O
3	outcomes	_	_	O
4	of	_	_	O
5	a	_	_	O
6	four-component	_	_	O
7	behavioral	_	_	O
8	therapy	_	_	O
9	(	_	_	O
10	BT	_	_	O
11	)	_	_	O
12	sleep	_	_	O
13	intervention	_	_	O
14	(	_	_	O
15	Individualized	_	_	O
16	Sleep	_	_	O
17	Promotion	_	_	O
18	Plan	_	_	O
19	[	_	_	O
20	ISPP	_	_	O
21	]	_	_	O
22	)	_	_	O
23	versus	_	_	O
24	a	_	_	O
25	healthy	_	_	O
26	eating	_	_	O
27	control	_	_	O
28	(	_	_	O
29	HEC	_	_	O
30	)	_	_	O
31	on	_	_	O
32	cancer-related	_	_	O
33	fatigue	_	_	O
34	in	_	_	O
35	women	_	_	O
36	receiving	_	_	O
37	breast	_	_	O
38	cancer	_	_	O
39	adjuvant	_	_	O
40	chemotherapy	_	_	O
41	treatment	_	_	O
42	(	_	_	O
43	CTX	_	_	O
44	)	_	_	O
45	.	_	_	O

46	A	_	_	O
47	total	_	_	O
48	of	_	_	O
49	219	_	_	O
50	participants	_	_	O
51	from	_	_	O
52	12	_	_	O
53	oncology	_	_	O
54	clinics	_	_	O
55	were	_	_	O
56	randomly	_	_	O
57	assigned	_	_	O
58	in	_	_	O
59	a	_	_	O
60	clinical	_	_	O
61	trial	_	_	O
62	.	_	_	O

63	Before	_	_	O
64	CTX	_	_	O
65	,	_	_	O
66	research	_	_	O
67	nurses	_	_	O
68	coached	_	_	O
69	intervention	_	_	O
70	participants	_	_	O
71	to	_	_	O
72	develop	_	_	O
73	a	_	_	O
74	BT	_	_	O
75	plan	_	_	O
76	including	_	_	O
77	stimulus	_	_	O
78	control	_	_	O
79	,	_	_	O
80	modified	_	_	O
81	sleep	_	_	O
82	restriction	_	_	O
83	,	_	_	O
84	relaxation	_	_	O
85	therapy	_	_	O
86	,	_	_	O
87	and	_	_	O
88	sleep	_	_	O
89	hygiene	_	_	O
90	.	_	_	O

91	BT	_	_	O
92	plans	_	_	O
93	were	_	_	O
94	revised	_	_	O
95	before	_	_	O
96	each	_	_	O
97	CTX	_	_	O
98	and	_	_	O
99	30	_	_	O
100	,	_	_	O
101	60	_	_	O
102	,	_	_	O
103	and	_	_	O
104	90	_	_	O
105	days	_	_	O
106	after	_	_	O
107	the	_	_	O
108	last	_	_	O
109	CTX	_	_	O
110	and	_	_	O
111	reinforced	_	_	O
112	7	_	_	O
113	to	_	_	O
114	9	_	_	O
115	days	_	_	O
116	later	_	_	O
117	.	_	_	O

118	HEC	_	_	O
119	participants	_	_	O
120	received	_	_	O
121	nutritional	_	_	O
122	information	_	_	O
123	and	_	_	O
124	equal	_	_	O
125	attention	_	_	O
126	.	_	_	O

127	Pittsburgh	_	_	O
128	Sleep	_	_	O
129	Quality	_	_	O
130	Index	_	_	O
131	(	_	_	O
132	PSQI	_	_	O
133	)	_	_	O
134	,	_	_	O
135	Daily	_	_	O
136	Diary	_	_	O
137	,	_	_	O
138	Wrist	_	_	O
139	Actigraph	_	_	O
140	,	_	_	O
141	and	_	_	O
142	Piper	_	_	O
143	Fatigue	_	_	O
144	Scale	_	_	O
145	measures	_	_	O
146	and	_	_	O
147	Repeated	_	_	O
148	Linear	_	_	O
149	Mixed	_	_	O
150	Model	_	_	O
151	analysis	_	_	O
152	following	_	_	O
153	the	_	_	O
154	Intent	_	_	O
155	to	_	_	O
156	Treat	_	_	O
157	paradigm	_	_	O
158	were	_	_	O
159	used	_	_	O
160	.	_	_	O

161	Sleep	_	_	B-Premise
162	quality	_	_	I-Premise
163	differed	_	_	I-Premise
164	over	_	_	I-Premise
165	1	_	_	I-Premise
166	years	_	_	I-Premise
167	time	_	_	I-Premise
168	(	_	_	I-Premise
169	F	_	_	I-Premise
170	[	_	_	I-Premise
171	4,162	_	_	I-Premise
172	]	_	_	I-Premise
173	=	_	_	I-Premise
174	7.7	_	_	I-Premise
175	,	_	_	I-Premise
176	P	_	_	I-Premise
177	<	_	_	I-Premise
178	.001	_	_	I-Premise
179	;	_	_	I-Premise
180	by	_	_	I-Premise
181	group	_	_	I-Premise
182	,	_	_	I-Premise
183	F	_	_	I-Premise
184	[	_	_	I-Premise
185	1,173	_	_	I-Premise
186	]	_	_	I-Premise
187	=	_	_	I-Premise
188	4.8	_	_	I-Premise
189	,	_	_	I-Premise
190	P	_	_	I-Premise
191	=	_	_	I-Premise
192	.029	_	_	I-Premise
193	;	_	_	I-Premise
194	and	_	_	I-Premise
195	over	_	_	I-Premise
196	time	_	_	I-Premise
197	by	_	_	I-Premise
198	group	_	_	I-Premise
199	,	_	_	I-Premise
200	F	_	_	I-Premise
201	[	_	_	I-Premise
202	4,162	_	_	I-Premise
203	]	_	_	I-Premise
204	=	_	_	I-Premise
205	3.3	_	_	I-Premise
206	,	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.013	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	Pairwise	_	_	B-Premise
213	comparisons	_	_	I-Premise
214	revealed	_	_	I-Premise
215	significant	_	_	I-Premise
216	differences	_	_	I-Premise
217	between	_	_	I-Premise
218	groups	_	_	I-Premise
219	at	_	_	I-Premise
220	90	_	_	I-Premise
221	days	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.002	_	_	I-Premise
226	)	_	_	I-Premise
227	but	_	_	B-Premise
228	not	_	_	I-Premise
229	at	_	_	I-Premise
230	1	_	_	I-Premise
231	year	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	.052	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Seven	_	_	O
239	days	_	_	O
240	of	_	_	O
241	diary	_	_	O
242	and	_	_	O
243	actigraphy	_	_	O
244	data	_	_	O
245	did	_	_	O
246	not	_	_	O
247	corroborate	_	_	O
248	with	_	_	O
249	monthly	_	_	O
250	reflections	_	_	O
251	(	_	_	O
252	PSQI	_	_	O
253	)	_	_	O
254	.	_	_	O

255	The	_	_	B-Premise
256	night	_	_	I-Premise
257	awakenings	_	_	I-Premise
258	(	_	_	I-Premise
259	Actigraph	_	_	I-Premise
260	)	_	_	I-Premise
261	pattern	_	_	I-Premise
262	was	_	_	I-Premise
263	significantly	_	_	I-Premise
264	different	_	_	I-Premise
265	by	_	_	I-Premise
266	group	_	_	I-Premise
267	over	_	_	I-Premise
268	time	_	_	I-Premise
269	(	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	.046	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	with	_	_	I-Premise
276	no	_	_	I-Premise
277	differences	_	_	I-Premise
278	between	_	_	I-Premise
279	groups	_	_	I-Premise
280	at	_	_	I-Premise
281	90	_	_	I-Premise
282	days	_	_	I-Premise
283	or	_	_	I-Premise
284	at	_	_	I-Premise
285	1	_	_	I-Premise
286	year	_	_	I-Premise
287	.	_	_	I-Premise

288	Fatigue	_	_	B-Premise
289	was	_	_	I-Premise
290	lower	_	_	I-Premise
291	at	_	_	I-Premise
292	1	_	_	I-Premise
293	year	_	_	I-Premise
294	than	_	_	I-Premise
295	before	_	_	I-Premise
296	CTX	_	_	I-Premise
297	;	_	_	I-Premise
298	no	_	_	B-Premise
299	group	_	_	I-Premise
300	effects	_	_	I-Premise
301	were	_	_	I-Premise
302	found	_	_	I-Premise
303	.	_	_	I-Premise

304	The	_	_	B-Claim
305	BT	_	_	I-Claim
306	group	_	_	I-Claim
307	,	_	_	I-Claim
308	on	_	_	I-Claim
309	average	_	_	I-Claim
310	,	_	_	I-Claim
311	experienced	_	_	I-Claim
312	significant	_	_	I-Claim
313	improvement	_	_	I-Claim
314	on	_	_	I-Claim
315	global	_	_	I-Claim
316	sleep	_	_	I-Claim
317	quality	_	_	I-Claim
318	compared	_	_	I-Claim
319	with	_	_	I-Claim
320	the	_	_	I-Claim
321	HEC	_	_	I-Claim
322	group	_	_	I-Claim
323	,	_	_	I-Claim
324	but	_	_	B-Claim
325	not	_	_	I-Claim
326	on	_	_	I-Claim
327	objective	_	_	I-Claim
328	sleep	_	_	I-Claim
329	or	_	_	I-Claim
330	fatigue	_	_	I-Claim
331	outcomes	_	_	I-Claim
332	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	time	_	_	O
6	on	_	_	O
7	therapy	_	_	O
8	,	_	_	O
9	efficacy	_	_	O
10	,	_	_	O
11	tolerability	_	_	O
12	and	_	_	O
13	resource	_	_	O
14	utilization	_	_	O
15	of	_	_	O
16	latanoprost	_	_	O
17	or	_	_	O
18	non-prostaglandin	_	_	O
19	analogues	_	_	O
20	(	_	_	O
21	non-PGs	_	_	O
22	)	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	who	_	_	O
26	required	_	_	O
27	a	_	_	O
28	change	_	_	O
29	in	_	_	O
30	intraocular	_	_	O
31	pressure	_	_	O
32	(	_	_	O
33	IOP	_	_	O
34	)	_	_	O
35	-lowering	_	_	O
36	monotherapy	_	_	O
37	.	_	_	O

38	This	_	_	O
39	open-label	_	_	O
40	,	_	_	O
41	multicentre	_	_	O
42	study	_	_	O
43	(	_	_	O
44	Sweden	_	_	O
45	,	_	_	O
46	19	_	_	O
47	sites	_	_	O
48	;	_	_	O
49	Finland	_	_	O
50	,	_	_	O
51	seven	_	_	O
52	sites	_	_	O
53	)	_	_	O
54	included	_	_	O
55	adults	_	_	O
56	with	_	_	O
57	glaucoma	_	_	O
58	or	_	_	O
59	ocular	_	_	O
60	hypertension	_	_	O
61	with	_	_	O
62	mean	_	_	O
63	diurnal	_	_	O
64	IOP	_	_	O
65	>	_	_	O
66	or	_	_	O
67	=	_	_	O
68	21	_	_	O
69	mmHg	_	_	O
70	on	_	_	O
71	ocular	_	_	O
72	hypotensive	_	_	O
73	monotherapy	_	_	O
74	.	_	_	O

75	Patients	_	_	O
76	were	_	_	O
77	randomized	_	_	O
78	to	_	_	O
79	latanoprost	_	_	O
80	monotherapy	_	_	O
81	or	_	_	O
82	non-PG	_	_	O
83	therapy	_	_	O
84	(	_	_	O
85	commercially	_	_	O
86	available	_	_	O
87	therapy	_	_	O
88	other	_	_	O
89	than	_	_	O
90	a	_	_	O
91	PG	_	_	O
92	)	_	_	O
93	and	_	_	O
94	followed	_	_	O
95	for	_	_	O
96	36	_	_	O
97	months	_	_	O
98	.	_	_	O

99	End-points	_	_	O
100	included	_	_	O
101	:	_	_	O
102	time	_	_	O
103	to	_	_	O
104	treatment	_	_	O
105	failure	_	_	O
106	(	_	_	O
107	baseline	_	_	O
108	to	_	_	O
109	visit	_	_	O
110	with	_	_	O
111	a	_	_	O
112	change	_	_	O
113	in/addition	_	_	O
114	to	_	_	O
115	treatment	_	_	O
116	)	_	_	O
117	;	_	_	O
118	diurnal	_	_	O
119	IOP	_	_	O
120	(	_	_	O
121	mean	_	_	O
122	of	_	_	O
123	08.00	_	_	O
124	,	_	_	O
125	12.00	_	_	O
126	and	_	_	O
127	16:00	_	_	O
128	hr	_	_	O
129	measurements	_	_	O
130	)	_	_	O
131	at	_	_	O
132	months	_	_	O
133	6	_	_	O
134	,	_	_	O
135	12	_	_	O
136	,	_	_	O
137	24	_	_	O
138	and	_	_	O
139	36	_	_	O
140	;	_	_	O
141	tolerability	_	_	O
142	;	_	_	O
143	and	_	_	O
144	resource	_	_	O
145	utilization	_	_	O
146	,	_	_	O
147	where	_	_	O
148	analyses	_	_	O
149	used	_	_	O
150	Swedish	_	_	O
151	and	_	_	O
152	Finnish	_	_	O
153	2006	_	_	O
154	unit	_	_	O
155	costs	_	_	O
156	.	_	_	O

157	Three	_	_	O
158	hundred	_	_	O
159	and	_	_	O
160	twenty-six	_	_	O
161	patients	_	_	O
162	received	_	_	O
163	>	_	_	O
164	or	_	_	O
165	=	_	_	O
166	1	_	_	O
167	dose	_	_	O
168	of	_	_	O
169	latanoprost	_	_	O
170	(	_	_	O
171	n	_	_	O
172	=	_	_	O
173	162	_	_	O
174	)	_	_	O
175	or	_	_	O
176	non-PGs	_	_	O
177	(	_	_	O
178	n	_	_	O
179	=	_	_	O
180	164	_	_	O
181	)	_	_	O
182	.	_	_	O

183	Median	_	_	O
184	time	_	_	O
185	to	_	_	O
186	treatment	_	_	O
187	failure	_	_	O
188	was	_	_	O
189	longer	_	_	O
190	for	_	_	O
191	latanoprost	_	_	O
192	(	_	_	O
193	36	_	_	O
194	months	_	_	O
195	)	_	_	O
196	than	_	_	O
197	for	_	_	O
198	non-PGs	_	_	O
199	(	_	_	O
200	12	_	_	O
201	months	_	_	O
202	;	_	_	O
203	p	_	_	O
204	<	_	_	O
205	0.001	_	_	O
206	)	_	_	O
207	;	_	_	O
208	51	_	_	O
209	%	_	_	O
210	and	_	_	O
211	24	_	_	O
212	%	_	_	O
213	of	_	_	O
214	patients	_	_	O
215	remained	_	_	O
216	on	_	_	O
217	randomized	_	_	O
218	therapy	_	_	O
219	after	_	_	O
220	36	_	_	O
221	months	_	_	O
222	,	_	_	O
223	respectively	_	_	O
224	(	_	_	O
225	p	_	_	O
226	<	_	_	O
227	0.001	_	_	O
228	)	_	_	O
229	.	_	_	O

230	Decreases	_	_	B-Premise
231	in	_	_	I-Premise
232	mean	_	_	I-Premise
233	diurnal	_	_	I-Premise
234	IOP	_	_	I-Premise
235	from	_	_	I-Premise
236	baseline	_	_	I-Premise
237	were	_	_	I-Premise
238	significantly	_	_	I-Premise
239	greater	_	_	I-Premise
240	for	_	_	I-Premise
241	latanoprost	_	_	I-Premise
242	than	_	_	I-Premise
243	for	_	_	I-Premise
244	non-PGs	_	_	I-Premise
245	at	_	_	I-Premise
246	months	_	_	I-Premise
247	6	_	_	I-Premise
248	and	_	_	I-Premise
249	12	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	<	_	_	I-Premise
253	0.01	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	No	_	_	B-Premise
257	serious	_	_	I-Premise
258	adverse	_	_	I-Premise
259	events	_	_	I-Premise
260	were	_	_	I-Premise
261	judged	_	_	I-Premise
262	to	_	_	I-Premise
263	be	_	_	I-Premise
264	treatment-related	_	_	I-Premise
265	.	_	_	O

266	Mean	_	_	B-Premise
267	total	_	_	I-Premise
268	36-month	_	_	I-Premise
269	direct	_	_	I-Premise
270	costs	_	_	I-Premise
271	were	_	_	I-Premise
272	similar	_	_	I-Premise
273	in	_	_	I-Premise
274	patients	_	_	I-Premise
275	initiated	_	_	I-Premise
276	with	_	_	I-Premise
277	latanoprost	_	_	I-Premise
278	and	_	_	I-Premise
279	non-PGs	_	_	I-Premise
280	.	_	_	I-Premise

281	Patients	_	_	B-Premise
282	who	_	_	I-Premise
283	failed	_	_	I-Premise
284	previous	_	_	I-Premise
285	monotherapy	_	_	I-Premise
286	remained	_	_	I-Premise
287	on	_	_	I-Premise
288	therapy	_	_	I-Premise
289	longer	_	_	I-Premise
290	when	_	_	I-Premise
291	switched	_	_	I-Premise
292	to	_	_	I-Premise
293	latanoprost	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Claim
296	IOP-reducing	_	_	I-Claim
297	effect	_	_	I-Claim
298	of	_	_	I-Claim
299	latanoprost	_	_	I-Claim
300	and	_	_	I-Claim
301	tolerability	_	_	I-Claim
302	were	_	_	I-Claim
303	sustained	_	_	I-Claim
304	over	_	_	I-Claim
305	the	_	_	I-Claim
306	long	_	_	I-Claim
307	term	_	_	I-Claim
308	.	_	_	I-Claim

309	Resource	_	_	B-Claim
310	utilization	_	_	I-Claim
311	and	_	_	I-Claim
312	costs	_	_	I-Claim
313	were	_	_	I-Claim
314	generally	_	_	I-Claim
315	similar	_	_	I-Claim
316	in	_	_	I-Claim
317	those	_	_	I-Claim
318	initiating	_	_	I-Claim
319	latanoprost	_	_	I-Claim
320	or	_	_	I-Claim
321	non-PG	_	_	I-Claim
322	therapy	_	_	I-Claim
323	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	combination	_	_	O
4	of	_	_	O
5	the	_	_	O
6	gastrin	_	_	O
7	antagonist	_	_	O
8	Z-360	_	_	O
9	and	_	_	O
10	gemcitabine	_	_	O
11	for	_	_	O
12	advanced	_	_	O
13	pancreatic	_	_	O
14	cancer	_	_	O
15	.	_	_	O

16	Previously	_	_	O
17	untreated	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	PC	_	_	O
21	were	_	_	O
22	randomly	_	_	O
23	allocated	_	_	O
24	to	_	_	O
25	Z-360	_	_	O
26	120	_	_	O
27	mg	_	_	O
28	,	_	_	O
29	240	_	_	O
30	mg	_	_	O
31	or	_	_	O
32	placebo	_	_	O
33	.	_	_	O

34	Z-360/placebo	_	_	O
35	was	_	_	O
36	given	_	_	O
37	on	_	_	O
38	day	_	_	O
39	-3	_	_	O
40	and	_	_	O
41	gemcitabine	_	_	O
42	1000	_	_	O
43	mg/m	_	_	O
44	(	_	_	O
45	2	_	_	O
46	)	_	_	O
47	commenced	_	_	O
48	on	_	_	O
49	day	_	_	O
50	1	_	_	O
51	followed	_	_	O
52	by	_	_	O
53	Z-360	_	_	O
54	on	_	_	O
55	day	_	_	O
56	2	_	_	O
57	.	_	_	O

58	Thereafter	_	_	O
59	Z-360/placebo	_	_	O
60	was	_	_	O
61	given	_	_	O
62	twice	_	_	O
63	daily	_	_	O
64	concurrently	_	_	O
65	with	_	_	O
66	standard	_	_	O
67	dose	_	_	O
68	of	_	_	O
69	gemcitabine	_	_	O
70	.	_	_	O

71	Pharmacokinetics	_	_	O
72	for	_	_	O
73	both	_	_	O
74	drugs	_	_	O
75	was	_	_	O
76	measured	_	_	O
77	alone	_	_	O
78	and	_	_	O
79	in	_	_	O
80	combination	_	_	O
81	.	_	_	O

82	Toxicity	_	_	O
83	,	_	_	O
84	response	_	_	O
85	and	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	were	_	_	O
90	also	_	_	O
91	recorded	_	_	O
92	.	_	_	O

93	Thirty-three	_	_	O
94	patients	_	_	O
95	with	_	_	O
96	a	_	_	O
97	median	_	_	O
98	age	_	_	O
99	of	_	_	O
100	62	_	_	O
101	years	_	_	O
102	were	_	_	O
103	randomised	_	_	O
104	of	_	_	O
105	which	_	_	O
106	six	_	_	O
107	had	_	_	O
108	locally	_	_	O
109	advanced	_	_	O
110	disease	_	_	O
111	and	_	_	O
112	26	_	_	O
113	had	_	_	O
114	metastatic	_	_	O
115	disease	_	_	O
116	.	_	_	O

117	Analysis	_	_	O
118	of	_	_	O
119	the	_	_	O
120	area	_	_	O
121	under	_	_	O
122	the	_	_	O
123	plasma	_	_	O
124	concentration	_	_	O
125	versus	_	_	O
126	time	_	_	O
127	curve	_	_	O
128	(	_	_	O
129	AUC	_	_	O
130	)	_	_	O
131	,	_	_	O
132	the	_	_	O
133	maximum	_	_	O
134	observed	_	_	O
135	concentration	_	_	O
136	(	_	_	O
137	Cmax	_	_	O
138	(	_	_	O
139	obs	_	_	O
140	)	_	_	O
141	)	_	_	O
142	and	_	_	O
143	the	_	_	O
144	time	_	_	O
145	of	_	_	O
146	the	_	_	O
147	maximum	_	_	O
148	observed	_	_	O
149	concentration	_	_	O
150	(	_	_	O
151	Tmax	_	_	O
152	(	_	_	O
153	obs	_	_	O
154	)	_	_	O
155	)	_	_	O
156	for	_	_	O
157	Z-360	_	_	O
158	,	_	_	O
159	gemcitabine	_	_	O
160	and	_	_	O
161	2,2-difluorodeoxyuridine	_	_	O
162	(	_	_	O
163	dFdU	_	_	O
164	)	_	_	O
165	,	_	_	O
166	could	_	_	O
167	not	_	_	O
168	exclude	_	_	O
169	an	_	_	O
170	effect	_	_	O
171	on	_	_	O
172	the	_	_	O
173	systemic	_	_	O
174	exposure	_	_	O
175	to	_	_	O
176	Z-360	_	_	O
177	,	_	_	O
178	gemcitabine	_	_	O
179	and	_	_	O
180	dFdU	_	_	O
181	when	_	_	O
182	co-administration	_	_	O
183	of	_	_	O
184	Z-360	_	_	O
185	and	_	_	O
186	gemcitabine	_	_	O
187	was	_	_	O
188	compared	_	_	O
189	with	_	_	O
190	single	_	_	O
191	agent	_	_	O
192	administration	_	_	O
193	.	_	_	O

194	The	_	_	B-Premise
195	most	_	_	I-Premise
196	commonly	_	_	I-Premise
197	reported	_	_	I-Premise
198	adverse	_	_	I-Premise
199	events	_	_	I-Premise
200	were	_	_	I-Premise
201	nausea	_	_	I-Premise
202	,	_	_	I-Premise
203	abdominal	_	_	I-Premise
204	pain	_	_	I-Premise
205	,	_	_	I-Premise
206	vomiting	_	_	I-Premise
207	and	_	_	I-Premise
208	fatigue	_	_	I-Premise
209	.	_	_	I-Premise

210	At	_	_	B-Premise
211	the	_	_	I-Premise
212	end	_	_	I-Premise
213	of	_	_	I-Premise
214	the	_	_	I-Premise
215	study	_	_	I-Premise
216	,	_	_	I-Premise
217	62.5	_	_	I-Premise
218	%	_	_	I-Premise
219	,	_	_	I-Premise
220	25	_	_	I-Premise
221	%	_	_	I-Premise
222	and	_	_	I-Premise
223	60	_	_	I-Premise
224	%	_	_	I-Premise
225	had	_	_	I-Premise
226	stable	_	_	I-Premise
227	disease	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	120	_	_	I-Premise
231	mg	_	_	I-Premise
232	,	_	_	I-Premise
233	240	_	_	I-Premise
234	mg	_	_	I-Premise
235	and	_	_	I-Premise
236	placebo	_	_	I-Premise
237	group	_	_	I-Premise
238	,	_	_	I-Premise
239	respectively	_	_	I-Premise
240	.	_	_	I-Premise

241	A	_	_	B-Premise
242	higher	_	_	I-Premise
243	proportion	_	_	I-Premise
244	of	_	_	I-Premise
245	patients	_	_	I-Premise
246	in	_	_	I-Premise
247	Z-360	_	_	I-Premise
248	groups	_	_	I-Premise
249	reported	_	_	I-Premise
250	improvement	_	_	I-Premise
251	in	_	_	I-Premise
252	pain	_	_	I-Premise
253	.	_	_	I-Premise

254	Z-360	_	_	B-Claim
255	is	_	_	I-Claim
256	safe	_	_	I-Claim
257	and	_	_	I-Claim
258	well	_	_	I-Claim
259	tolerated	_	_	I-Claim
260	when	_	_	I-Claim
261	combined	_	_	I-Claim
262	with	_	_	I-Claim
263	gemcitabine	_	_	I-Claim
264	.	_	_	I-Claim

265	A	_	_	O
266	Phase	_	_	O
267	III	_	_	O
268	trial	_	_	O
269	is	_	_	O
270	needed	_	_	O
271	to	_	_	O
272	determine	_	_	O
273	whether	_	_	O
274	the	_	_	O
275	combination	_	_	O
276	of	_	_	O
277	Z-360	_	_	O
278	and	_	_	O
279	gemcitabine	_	_	O
280	is	_	_	O
281	superior	_	_	O
282	to	_	_	O
283	gemcitabine	_	_	O
284	alone	_	_	O
285	in	_	_	O
286	advanced	_	_	O
287	PC	_	_	O
288	.	_	_	O


0	To	_	_	O
1	assess	_	_	O
2	toxicities	_	_	O
3	,	_	_	O
4	functional	_	_	O
5	outcomes	_	_	O
6	,	_	_	O
7	and	_	_	O
8	health-related	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	associated	_	_	O
13	with	_	_	O
14	concurrent	_	_	O
15	chemoradiation	_	_	O
16	therapy	_	_	O
17	(	_	_	O
18	CRT	_	_	O
19	)	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	head	_	_	O
24	and	_	_	O
25	neck	_	_	O
26	cancer	_	_	O
27	.	_	_	O

28	Prospective	_	_	O
29	and	_	_	O
30	retrospective	_	_	O
31	outcomes	_	_	O
32	study	_	_	O
33	.	_	_	O

34	Tertiary	_	_	O
35	care	_	_	O
36	institution	_	_	O
37	.	_	_	O

38	Participants	_	_	O
39	in	_	_	O
40	the	_	_	O
41	longitudinal	_	_	O
42	Outcomes	_	_	O
43	Assessment	_	_	O
44	Project	_	_	O
45	whose	_	_	O
46	head	_	_	O
47	and	_	_	O
48	neck	_	_	O
49	cancer	_	_	O
50	was	_	_	O
51	treated	_	_	O
52	with	_	_	O
53	CRT	_	_	O
54	between	_	_	O
55	February	_	_	O
56	1	_	_	O
57	,	_	_	O
58	2000	_	_	O
59	,	_	_	O
60	and	_	_	O
61	March	_	_	O
62	1	_	_	O
63	,	_	_	O
64	2007	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	104	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Patients	_	_	O
72	prospectively	_	_	O
73	provided	_	_	O
74	functional	_	_	O
75	and	_	_	O
76	health-related	_	_	O
77	quality	_	_	O
78	of	_	_	O
79	life	_	_	O
80	information	_	_	O
81	,	_	_	O
82	including	_	_	O
83	data	_	_	O
84	from	_	_	O
85	the	_	_	O
86	1-year	_	_	O
87	and	_	_	O
88	most	_	_	O
89	current	_	_	O
90	follow-up	_	_	O
91	visits	_	_	O
92	.	_	_	O

93	Medical	_	_	O
94	records	_	_	O
95	were	_	_	O
96	reviewed	_	_	O
97	to	_	_	O
98	determine	_	_	O
99	toxicity	_	_	O
100	and	_	_	O
101	survival	_	_	O
102	rates	_	_	O
103	.	_	_	O

104	Well-defined	_	_	O
105	acute	_	_	O
106	and	_	_	O
107	late	_	_	O
108	toxicities	_	_	O
109	;	_	_	O
110	functional	_	_	O
111	outcomes	_	_	O
112	(	_	_	O
113	diet	_	_	O
114	,	_	_	O
115	dentition	_	_	O
116	,	_	_	O
117	tracheostomies	_	_	O
118	)	_	_	O
119	;	_	_	O
120	head	_	_	O
121	and	_	_	O
122	neck	_	_	O
123	cancer-specific	_	_	O
124	,	_	_	O
125	general	_	_	O
126	health	_	_	O
127	,	_	_	O
128	and	_	_	O
129	depression	_	_	O
130	outcomes	_	_	O
131	;	_	_	O
132	and	_	_	O
133	survival	_	_	O
134	rates	_	_	O
135	.	_	_	O

136	Most	_	_	O
137	patients	_	_	O
138	had	_	_	O
139	oropharyngeal	_	_	O
140	or	_	_	O
141	laryngeal	_	_	O
142	tumors	_	_	O
143	(	_	_	O
144	87.5	_	_	O
145	%	_	_	O
146	)	_	_	O
147	and	_	_	O
148	advanced-stage	_	_	O
149	disease	_	_	O
150	(	_	_	O
151	75.0	_	_	O
152	%	_	_	O
153	)	_	_	O
154	.	_	_	O

155	Approximately	_	_	B-Premise
156	one-half	_	_	I-Premise
157	had	_	_	I-Premise
158	hematologic	_	_	I-Premise
159	toxicities	_	_	I-Premise
160	and	_	_	I-Premise
161	toxicity-related	_	_	I-Premise
162	treatment	_	_	I-Premise
163	delays	_	_	I-Premise
164	.	_	_	I-Premise

165	Approximately	_	_	B-Premise
166	one-quarter	_	_	I-Premise
167	had	_	_	I-Premise
168	neurotoxicities	_	_	I-Premise
169	and/or	_	_	I-Premise
170	ototoxicites	_	_	I-Premise
171	,	_	_	I-Premise
172	moist	_	_	I-Premise
173	desquamation	_	_	I-Premise
174	,	_	_	I-Premise
175	pneumonia	_	_	I-Premise
176	,	_	_	I-Premise
177	nausea	_	_	I-Premise
178	and	_	_	I-Premise
179	vomiting	_	_	I-Premise
180	requiring	_	_	I-Premise
181	hospitalization	_	_	I-Premise
182	or	_	_	I-Premise
183	intravenous	_	_	I-Premise
184	fluids	_	_	I-Premise
185	,	_	_	I-Premise
186	dehydration	_	_	I-Premise
187	or	_	_	I-Premise
188	malnutrition	_	_	I-Premise
189	requiring	_	_	I-Premise
190	hospitalization	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	mild	_	_	I-Premise
194	or	_	_	I-Premise
195	moderate	_	_	I-Premise
196	fever	_	_	I-Premise
197	.	_	_	I-Premise

198	Although	_	_	B-Premise
199	patients	_	_	I-Premise
200	receiving	_	_	I-Premise
201	the	_	_	I-Premise
202	current	_	_	I-Premise
203	intensity-modulated	_	_	I-Premise
204	radiation	_	_	I-Premise
205	therapy	_	_	I-Premise
206	(	_	_	I-Premise
207	IMRT	_	_	I-Premise
208	)	_	_	I-Premise
209	protocol	_	_	I-Premise
210	using	_	_	I-Premise
211	the	_	_	I-Premise
212	Pinnacle	_	_	I-Premise
213	(	_	_	I-Premise
214	3	_	_	I-Premise
215	)	_	_	I-Premise
216	planning	_	_	I-Premise
217	system	_	_	I-Premise
218	had	_	_	I-Premise
219	more	_	_	I-Premise
220	toxicity-related	_	_	I-Premise
221	treatment	_	_	I-Premise
222	delays	_	_	I-Premise
223	,	_	_	I-Premise
224	they	_	_	B-Premise
225	had	_	_	I-Premise
226	fewer	_	_	I-Premise
227	toxicities	_	_	I-Premise
228	and	_	_	I-Premise
229	better	_	_	I-Premise
230	functional	_	_	I-Premise
231	and	_	_	I-Premise
232	health-related	_	_	I-Premise
233	quality	_	_	I-Premise
234	of	_	_	I-Premise
235	life	_	_	I-Premise
236	outcomes	_	_	I-Premise
237	compared	_	_	I-Premise
238	with	_	_	I-Premise
239	those	_	_	I-Premise
240	receiving	_	_	I-Premise
241	conventional	_	_	I-Premise
242	lateral	_	_	I-Premise
243	opposing-field	_	_	I-Premise
244	radiation	_	_	I-Premise
245	or	_	_	I-Premise
246	the	_	_	I-Premise
247	initial	_	_	I-Premise
248	IMRT	_	_	I-Premise
249	protocol	_	_	I-Premise
250	using	_	_	I-Premise
251	the	_	_	I-Premise
252	Best	_	_	I-Premise
253	nomos	_	_	I-Premise
254	PEACOCK	_	_	I-Premise
255	planning	_	_	I-Premise
256	system	_	_	I-Premise
257	.	_	_	I-Premise

258	Patients	_	_	B-Claim
259	receiving	_	_	I-Claim
260	CRT	_	_	I-Claim
261	experience	_	_	I-Claim
262	a	_	_	I-Claim
263	substantial	_	_	I-Claim
264	number	_	_	I-Claim
265	of	_	_	I-Claim
266	treatment-related	_	_	I-Claim
267	adverse	_	_	I-Claim
268	events	_	_	I-Claim
269	,	_	_	I-Claim
270	primarily	_	_	I-Claim
271	affecting	_	_	I-Claim
272	oropharyngeal	_	_	I-Claim
273	and	_	_	I-Claim
274	laryngeal	_	_	I-Claim
275	function	_	_	I-Claim
276	,	_	_	I-Claim
277	with	_	_	I-Claim
278	improvement	_	_	I-Claim
279	noted	_	_	I-Claim
280	for	_	_	I-Claim
281	the	_	_	I-Claim
282	current	_	_	I-Claim
283	IMRT	_	_	I-Claim
284	protocol	_	_	I-Claim
285	.	_	_	I-Claim

286	Improving	_	_	O
287	dental	_	_	O
288	prosthetic	_	_	O
289	rehabilitation	_	_	O
290	and	_	_	O
291	including	_	_	O
292	evaluations	_	_	O
293	with	_	_	O
294	speech	_	_	O
295	and	_	_	O
296	swallowing	_	_	O
297	pathologists	_	_	O
298	before	_	_	O
299	and	_	_	O
300	during	_	_	O
301	treatment	_	_	O
302	may	_	_	O
303	enhance	_	_	O
304	patient	_	_	O
305	outcomes	_	_	O
306	.	_	_	O


0	Vasomotor	_	_	O
1	symptoms	_	_	O
2	are	_	_	O
3	common	_	_	O
4	adverse	_	_	O
5	effects	_	_	O
6	of	_	_	O
7	antiestrogen	_	_	O
8	hormone	_	_	O
9	treatment	_	_	O
10	in	_	_	O
11	conventional	_	_	O
12	breast	_	_	O
13	cancer	_	_	O
14	care	_	_	O
15	.	_	_	O

16	Hormone	_	_	O
17	replacement	_	_	O
18	therapy	_	_	O
19	is	_	_	O
20	contraindicated	_	_	O
21	in	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	breast	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	Venlafaxine	_	_	O
28	(	_	_	O
29	Effexor	_	_	O
30	)	_	_	O
31	,	_	_	O
32	the	_	_	O
33	therapy	_	_	O
34	of	_	_	O
35	choice	_	_	O
36	for	_	_	O
37	these	_	_	O
38	symptoms	_	_	O
39	,	_	_	O
40	has	_	_	O
41	numerous	_	_	O
42	adverse	_	_	O
43	effects	_	_	O
44	.	_	_	O

45	Recent	_	_	O
46	studies	_	_	O
47	suggest	_	_	O
48	acupuncture	_	_	O
49	may	_	_	O
50	be	_	_	O
51	effective	_	_	O
52	in	_	_	O
53	reducing	_	_	O
54	vasomotor	_	_	O
55	symptoms	_	_	O
56	in	_	_	O
57	menopausal	_	_	O
58	women	_	_	O
59	.	_	_	O

60	This	_	_	O
61	randomized	_	_	O
62	controlled	_	_	O
63	trial	_	_	O
64	tested	_	_	O
65	whether	_	_	O
66	acupuncture	_	_	O
67	reduces	_	_	O
68	vasomotor	_	_	O
69	symptoms	_	_	O
70	and	_	_	O
71	produces	_	_	O
72	fewer	_	_	O
73	adverse	_	_	O
74	effects	_	_	O
75	than	_	_	O
76	venlafaxine	_	_	O
77	.	_	_	O

78	Fifty	_	_	O
79	patients	_	_	O
80	were	_	_	O
81	randomly	_	_	O
82	assigned	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	12	_	_	O
86	weeks	_	_	O
87	of	_	_	O
88	acupuncture	_	_	O
89	(	_	_	O
90	n	_	_	O
91	=	_	_	O
92	25	_	_	O
93	)	_	_	O
94	or	_	_	O
95	venlafaxine	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	25	_	_	O
100	)	_	_	O
101	treatment	_	_	O
102	.	_	_	O

103	Health	_	_	O
104	outcomes	_	_	O
105	were	_	_	O
106	measured	_	_	O
107	for	_	_	O
108	up	_	_	O
109	to	_	_	O
110	1	_	_	O
111	year	_	_	O
112	post-treatment	_	_	O
113	.	_	_	O

114	Both	_	_	B-Premise
115	groups	_	_	I-Premise
116	exhibited	_	_	I-Premise
117	significant	_	_	I-Premise
118	decreases	_	_	I-Premise
119	in	_	_	I-Premise
120	hot	_	_	I-Premise
121	flashes	_	_	I-Premise
122	,	_	_	I-Premise
123	depressive	_	_	I-Premise
124	symptoms	_	_	I-Premise
125	,	_	_	I-Premise
126	and	_	_	I-Premise
127	other	_	_	I-Premise
128	quality-of-life	_	_	I-Premise
129	symptoms	_	_	I-Premise
130	,	_	_	I-Premise
131	including	_	_	I-Premise
132	significant	_	_	I-Premise
133	improvements	_	_	I-Premise
134	in	_	_	I-Premise
135	mental	_	_	I-Premise
136	health	_	_	I-Premise
137	from	_	_	I-Premise
138	pre-	_	_	I-Premise
139	to	_	_	I-Premise
140	post-treatment	_	_	I-Premise
141	.	_	_	I-Premise

142	These	_	_	B-Premise
143	changes	_	_	I-Premise
144	were	_	_	I-Premise
145	similar	_	_	I-Premise
146	in	_	_	I-Premise
147	both	_	_	I-Premise
148	groups	_	_	I-Premise
149	,	_	_	I-Premise
150	indicating	_	_	I-Premise
151	that	_	_	I-Premise
152	acupuncture	_	_	I-Premise
153	was	_	_	I-Premise
154	as	_	_	I-Premise
155	effective	_	_	I-Premise
156	as	_	_	I-Premise
157	venlafaxine	_	_	I-Premise
158	.	_	_	I-Premise

159	By	_	_	B-Premise
160	2	_	_	I-Premise
161	weeks	_	_	I-Premise
162	post-treatment	_	_	I-Premise
163	,	_	_	I-Premise
164	the	_	_	I-Premise
165	venlafaxine	_	_	I-Premise
166	group	_	_	I-Premise
167	experienced	_	_	I-Premise
168	significant	_	_	I-Premise
169	increases	_	_	I-Premise
170	in	_	_	I-Premise
171	hot	_	_	I-Premise
172	flashes	_	_	I-Premise
173	,	_	_	I-Premise
174	whereas	_	_	I-Premise
175	hot	_	_	I-Premise
176	flashes	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	acupuncture	_	_	I-Premise
180	group	_	_	I-Premise
181	remained	_	_	I-Premise
182	at	_	_	I-Premise
183	low	_	_	I-Premise
184	levels	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	venlafaxine	_	_	I-Premise
188	group	_	_	I-Premise
189	experienced	_	_	I-Premise
190	18	_	_	I-Premise
191	incidences	_	_	I-Premise
192	of	_	_	I-Premise
193	adverse	_	_	I-Premise
194	effects	_	_	I-Premise
195	(	_	_	I-Premise
196	eg	_	_	I-Premise
197	,	_	_	I-Premise
198	nausea	_	_	I-Premise
199	,	_	_	I-Premise
200	dry	_	_	I-Premise
201	mouth	_	_	I-Premise
202	,	_	_	I-Premise
203	dizziness	_	_	I-Premise
204	,	_	_	I-Premise
205	anxiety	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	whereas	_	_	I-Premise
209	the	_	_	I-Premise
210	acupuncture	_	_	I-Premise
211	group	_	_	I-Premise
212	experienced	_	_	I-Premise
213	no	_	_	I-Premise
214	negative	_	_	I-Premise
215	adverse	_	_	I-Premise
216	effects	_	_	I-Premise
217	.	_	_	I-Premise

218	Acupuncture	_	_	B-Premise
219	had	_	_	I-Premise
220	the	_	_	I-Premise
221	additional	_	_	I-Premise
222	benefit	_	_	I-Premise
223	of	_	_	I-Premise
224	increased	_	_	I-Premise
225	sex	_	_	I-Premise
226	drive	_	_	I-Premise
227	in	_	_	I-Premise
228	some	_	_	I-Premise
229	women	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	most	_	_	I-Premise
233	reported	_	_	I-Premise
234	an	_	_	I-Premise
235	improvement	_	_	I-Premise
236	in	_	_	I-Premise
237	their	_	_	I-Premise
238	energy	_	_	I-Premise
239	,	_	_	I-Premise
240	clarity	_	_	I-Premise
241	of	_	_	I-Premise
242	thought	_	_	I-Premise
243	,	_	_	I-Premise
244	and	_	_	I-Premise
245	sense	_	_	I-Premise
246	of	_	_	I-Premise
247	well-being	_	_	I-Premise
248	.	_	_	I-Premise

249	Acupuncture	_	_	B-Claim
250	appears	_	_	I-Claim
251	to	_	_	I-Claim
252	be	_	_	I-Claim
253	equivalent	_	_	I-Claim
254	to	_	_	I-Claim
255	drug	_	_	I-Claim
256	therapy	_	_	I-Claim
257	in	_	_	I-Claim
258	these	_	_	I-Claim
259	patients	_	_	I-Claim
260	.	_	_	I-Claim

261	It	_	_	B-Claim
262	is	_	_	I-Claim
263	a	_	_	I-Claim
264	safe	_	_	I-Claim
265	,	_	_	I-Claim
266	effective	_	_	I-Claim
267	and	_	_	I-Claim
268	durable	_	_	I-Claim
269	treatment	_	_	I-Claim
270	for	_	_	I-Claim
271	vasomotor	_	_	I-Claim
272	symptoms	_	_	I-Claim
273	secondary	_	_	I-Claim
274	to	_	_	I-Claim
275	long-term	_	_	I-Claim
276	antiestrogen	_	_	I-Claim
277	hormone	_	_	I-Claim
278	use	_	_	I-Claim
279	in	_	_	I-Claim
280	patients	_	_	I-Claim
281	with	_	_	I-Claim
282	breast	_	_	I-Claim
283	cancer	_	_	I-Claim
284	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	if	_	_	O
3	postoperative	_	_	O
4	topical	_	_	O
5	cyclosporine	_	_	O
6	0.05	_	_	O
7	%	_	_	O
8	has	_	_	O
9	any	_	_	O
10	beneficial	_	_	O
11	effect	_	_	O
12	following	_	_	O
13	trabeculectomy	_	_	O
14	.	_	_	O

15	This	_	_	O
16	was	_	_	O
17	an	_	_	O
18	interventional	_	_	O
19	,	_	_	O
20	randomized	_	_	O
21	,	_	_	O
22	prospective	_	_	O
23	,	_	_	O
24	double-masked	_	_	O
25	clinical	_	_	O
26	trial	_	_	O
27	of	_	_	O
28	44	_	_	O
29	consecutive	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	uncontrolled	_	_	O
33	glaucoma	_	_	O
34	requiring	_	_	O
35	filtration	_	_	O
36	surgery	_	_	O
37	.	_	_	O

38	Ocular	_	_	O
39	surface	_	_	O
40	disease	_	_	O
41	index	_	_	O
42	questionnaire	_	_	O
43	and	_	_	O
44	comprehensive	_	_	O
45	ocular	_	_	O
46	exam	_	_	O
47	,	_	_	O
48	including	_	_	O
49	Schirmer	_	_	O
50	's	_	_	O
51	tear	_	_	O
52	test	_	_	O
53	1	_	_	O
54	,	_	_	O
55	were	_	_	O
56	performed	_	_	O
57	.	_	_	O

58	Patients	_	_	O
59	underwent	_	_	O
60	routine	_	_	O
61	trabeculectomy	_	_	O
62	,	_	_	O
63	with	_	_	O
64	or	_	_	O
65	without	_	_	O
66	phacoemulsification	_	_	O
67	.	_	_	O

68	The	_	_	O
69	study	_	_	O
70	group	_	_	O
71	(	_	_	O
72	n	_	_	O
73	=	_	_	O
74	22	_	_	O
75	)	_	_	O
76	received	_	_	O
77	cyclosporine	_	_	O
78	0.05	_	_	O
79	%	_	_	O
80	,	_	_	O
81	and	_	_	O
82	the	_	_	O
83	control	_	_	O
84	group	_	_	O
85	(	_	_	O
86	n	_	_	O
87	=	_	_	O
88	22	_	_	O
89	)	_	_	O
90	received	_	_	O
91	artificial	_	_	O
92	tears	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	evaluated	_	_	O
97	at	_	_	O
98	1	_	_	O
99	and	_	_	O
100	6	_	_	O
101	months	_	_	O
102	post	_	_	O
103	surgery	_	_	O
104	.	_	_	O

105	Outcome	_	_	O
106	measures	_	_	O
107	were	_	_	O
108	intraocular	_	_	O
109	pressure	_	_	O
110	,	_	_	O
111	success	_	_	O
112	rate	_	_	O
113	,	_	_	O
114	bleb	_	_	O
115	appearance	_	_	O
116	,	_	_	O
117	ocular	_	_	O
118	surface	_	_	O
119	disease	_	_	O
120	index	_	_	O
121	,	_	_	O
122	Schirmer	_	_	O
123	's	_	_	O
124	tear	_	_	O
125	test	_	_	O
126	1	_	_	O
127	and	_	_	O
128	conjunctival	_	_	O
129	inflammation	_	_	O
130	.	_	_	O

131	Thirty-nine	_	_	O
132	patients	_	_	O
133	completed	_	_	O
134	the	_	_	O
135	study	_	_	O
136	(	_	_	O
137	19	_	_	O
138	in	_	_	O
139	the	_	_	O
140	study	_	_	O
141	group	_	_	O
142	,	_	_	O
143	20	_	_	O
144	in	_	_	O
145	the	_	_	O
146	control	_	_	O
147	group	_	_	O
148	)	_	_	O
149	.	_	_	O

150	The	_	_	B-Premise
151	mean	_	_	I-Premise
152	baseline	_	_	I-Premise
153	intraocular	_	_	I-Premise
154	pressure	_	_	I-Premise
155	was	_	_	I-Premise
156	23.8	_	_	I-Premise
157	+/-	_	_	I-Premise
158	12.6	_	_	I-Premise
159	mmHg	_	_	I-Premise
160	in	_	_	I-Premise
161	the	_	_	I-Premise
162	study	_	_	I-Premise
163	group	_	_	I-Premise
164	and	_	_	I-Premise
165	25.9	_	_	I-Premise
166	+/-	_	_	I-Premise
167	10.6	_	_	I-Premise
168	mmHg	_	_	I-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	control	_	_	I-Premise
172	group	_	_	I-Premise
173	(	_	_	I-Premise
174	P	_	_	I-Premise
175	=	_	_	I-Premise
176	0.513	_	_	I-Premise
177	)	_	_	I-Premise
178	.	_	_	I-Premise

179	Mean	_	_	B-Premise
180	intraocular	_	_	I-Premise
181	pressure	_	_	I-Premise
182	at	_	_	I-Premise
183	postoperative	_	_	I-Premise
184	month	_	_	I-Premise
185	6	_	_	I-Premise
186	was	_	_	I-Premise
187	14.88	_	_	I-Premise
188	+/-	_	_	I-Premise
189	6.2	_	_	I-Premise
190	and	_	_	I-Premise
191	14.62	_	_	I-Premise
192	+/-	_	_	I-Premise
193	5.46	_	_	I-Premise
194	mmHg	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	study	_	_	I-Premise
198	group	_	_	I-Premise
199	and	_	_	I-Premise
200	control	_	_	I-Premise
201	group	_	_	I-Premise
202	,	_	_	I-Premise
203	respectively	_	_	I-Premise
204	(	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	0.837	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	There	_	_	B-Premise
211	was	_	_	I-Premise
212	no	_	_	I-Premise
213	statistically	_	_	I-Premise
214	significant	_	_	I-Premise
215	difference	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	mean	_	_	I-Premise
219	values	_	_	I-Premise
220	of	_	_	I-Premise
221	Schirmer	_	_	I-Premise
222	's	_	_	I-Premise
223	tear	_	_	I-Premise
224	test	_	_	I-Premise
225	1	_	_	I-Premise
226	and	_	_	I-Premise
227	the	_	_	I-Premise
228	level	_	_	I-Premise
229	of	_	_	I-Premise
230	conjunctival	_	_	I-Premise
231	hyperaemia	_	_	I-Premise
232	between	_	_	I-Premise
233	the	_	_	I-Premise
234	two	_	_	I-Premise
235	groups	_	_	I-Premise
236	at	_	_	I-Premise
237	baseline	_	_	I-Premise
238	,	_	_	I-Premise
239	months	_	_	I-Premise
240	1	_	_	I-Premise
241	and	_	_	I-Premise
242	6	_	_	I-Premise
243	post	_	_	I-Premise
244	surgery	_	_	I-Premise
245	.	_	_	I-Premise

246	The	_	_	B-Premise
247	treatment	_	_	I-Premise
248	group	_	_	I-Premise
249	had	_	_	I-Premise
250	a	_	_	I-Premise
251	statistically	_	_	I-Premise
252	significant	_	_	I-Premise
253	decrease	_	_	I-Premise
254	in	_	_	I-Premise
255	ocular	_	_	I-Premise
256	surface	_	_	I-Premise
257	disease	_	_	I-Premise
258	index	_	_	I-Premise
259	score	_	_	I-Premise
260	at	_	_	I-Premise
261	6	_	_	I-Premise
262	months	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	0.003	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	indicating	_	_	I-Premise
270	less	_	_	I-Premise
271	severity	_	_	I-Premise
272	of	_	_	I-Premise
273	dry	_	_	I-Premise
274	eye	_	_	I-Premise
275	symptoms	_	_	I-Premise
276	and	_	_	I-Premise
277	significant	_	_	I-Premise
278	reduction	_	_	I-Premise
279	in	_	_	I-Premise
280	ocular	_	_	I-Premise
281	pain	_	_	I-Premise
282	.	_	_	I-Premise

283	Topical	_	_	B-Claim
284	cyclosporine	_	_	I-Claim
285	0.05	_	_	I-Claim
286	%	_	_	I-Claim
287	had	_	_	I-Claim
288	no	_	_	I-Claim
289	effect	_	_	I-Claim
290	on	_	_	I-Claim
291	postoperative	_	_	I-Claim
292	bleb	_	_	I-Claim
293	function	_	_	I-Claim
294	and	_	_	I-Claim
295	intraocular	_	_	I-Claim
296	pressure	_	_	I-Claim
297	following	_	_	I-Claim
298	trabeculectomy	_	_	I-Claim
299	,	_	_	I-Claim
300	but	_	_	I-Claim
301	improved	_	_	I-Claim
302	subjective	_	_	I-Claim
303	ocular	_	_	I-Claim
304	surface	_	_	I-Claim
305	symptoms	_	_	I-Claim
306	in	_	_	I-Claim
307	these	_	_	I-Claim
308	patients	_	_	I-Claim
309	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	fixed-combination	_	_	O
8	latanoprost-timolol	_	_	O
9	(	_	_	O
10	FCLT	_	_	O
11	)	_	_	O
12	vs	_	_	O
13	latanoprost	_	_	O
14	or	_	_	O
15	timolol	_	_	O
16	monotherapy	_	_	O
17	.	_	_	O

18	This	_	_	O
19	12-week	_	_	O
20	,	_	_	O
21	randomized	_	_	O
22	,	_	_	O
23	double-masked	_	_	O
24	,	_	_	O
25	parallel-group	_	_	O
26	study	_	_	O
27	included	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	open-angle	_	_	O
31	glaucoma	_	_	O
32	or	_	_	O
33	ocular	_	_	O
34	hypertension	_	_	O
35	treated	_	_	O
36	with	_	_	O
37	a	_	_	O
38	beta-blocker	_	_	O
39	and	_	_	O
40	with	_	_	O
41	baseline	_	_	O
42	intraocular	_	_	O
43	pressure	_	_	O
44	(	_	_	O
45	IOP	_	_	O
46	)	_	_	O
47	of	_	_	O
48	26	_	_	O
49	through	_	_	O
50	36	_	_	O
51	mm	_	_	O
52	Hg	_	_	O
53	.	_	_	O

54	Following	_	_	O
55	washout	_	_	O
56	,	_	_	O
57	eligible	_	_	O
58	patients	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	once-daily	_	_	O
63	FCLT	_	_	O
64	in	_	_	O
65	the	_	_	O
66	evening	_	_	O
67	,	_	_	O
68	latanoprost	_	_	O
69	in	_	_	O
70	the	_	_	O
71	evening	_	_	O
72	,	_	_	O
73	or	_	_	O
74	timolol	_	_	O
75	in	_	_	O
76	the	_	_	O
77	morning	_	_	O
78	.	_	_	O

79	Postbaseline	_	_	O
80	IOP	_	_	O
81	assessments	_	_	O
82	at	_	_	O
83	8	_	_	O
84	am	_	_	O
85	,	_	_	O
86	10	_	_	O
87	am	_	_	O
88	,	_	_	O
89	and	_	_	O
90	4	_	_	O
91	pm	_	_	O
92	at	_	_	O
93	weeks	_	_	O
94	2	_	_	O
95	,	_	_	O
96	6	_	_	O
97	,	_	_	O
98	and	_	_	O
99	12	_	_	O
100	;	_	_	O
101	statistical	_	_	O
102	superiority	_	_	O
103	of	_	_	O
104	FCLT	_	_	O
105	for	_	_	O
106	the	_	_	O
107	18	_	_	O
108	pairwise	_	_	O
109	comparisons	_	_	O
110	between	_	_	O
111	FCLT	_	_	O
112	and	_	_	O
113	the	_	_	O
114	2	_	_	O
115	monotherapies	_	_	O
116	,	_	_	O
117	using	_	_	O
118	analysis	_	_	O
119	of	_	_	O
120	variance	_	_	O
121	.	_	_	O

122	All	_	_	O
123	therapies	_	_	O
124	resulted	_	_	O
125	in	_	_	O
126	significant	_	_	O
127	IOP	_	_	O
128	reductions	_	_	O
129	from	_	_	O
130	baseline	_	_	O
131	.	_	_	O

132	Pairwise	_	_	O
133	comparisons	_	_	O
134	favored	_	_	O
135	FCLT	_	_	O
136	at	_	_	O
137	all	_	_	O
138	time	_	_	O
139	points	_	_	O
140	.	_	_	O

141	When	_	_	O
142	the	_	_	O
143	18	_	_	O
144	comparisons	_	_	O
145	were	_	_	O
146	tested	_	_	O
147	simultaneously	_	_	O
148	,	_	_	O
149	FCLT	_	_	B-Premise
150	was	_	_	I-Premise
151	statistically	_	_	I-Premise
152	superior	_	_	I-Premise
153	to	_	_	I-Premise
154	latanoprost	_	_	I-Premise
155	at	_	_	I-Premise
156	7	_	_	I-Premise
157	of	_	_	I-Premise
158	9	_	_	I-Premise
159	time	_	_	I-Premise
160	points	_	_	I-Premise
161	and	_	_	I-Premise
162	at	_	_	I-Premise
163	all	_	_	I-Premise
164	9	_	_	I-Premise
165	time	_	_	I-Premise
166	points	_	_	I-Premise
167	when	_	_	I-Premise
168	compared	_	_	I-Premise
169	with	_	_	I-Premise
170	timolol	_	_	I-Premise
171	.	_	_	I-Premise

172	In	_	_	O
173	addition	_	_	O
174	,	_	_	O
175	FCLT	_	_	B-Premise
176	was	_	_	I-Premise
177	associated	_	_	I-Premise
178	with	_	_	I-Premise
179	greater	_	_	I-Premise
180	percentage	_	_	I-Premise
181	reductions	_	_	I-Premise
182	in	_	_	I-Premise
183	diurnal	_	_	I-Premise
184	IOP	_	_	I-Premise
185	levels	_	_	I-Premise
186	and	_	_	I-Premise
187	a	_	_	I-Premise
188	greater	_	_	I-Premise
189	likelihood	_	_	I-Premise
190	of	_	_	I-Premise
191	achieving	_	_	I-Premise
192	lower	_	_	I-Premise
193	mean	_	_	I-Premise
194	diurnal	_	_	I-Premise
195	IOP	_	_	I-Premise
196	levels	_	_	I-Premise
197	.	_	_	I-Premise

198	Diurnal	_	_	B-Premise
199	IOP	_	_	I-Premise
200	reductions	_	_	I-Premise
201	of	_	_	I-Premise
202	30	_	_	I-Premise
203	%	_	_	I-Premise
204	or	_	_	I-Premise
205	more	_	_	I-Premise
206	from	_	_	I-Premise
207	baseline	_	_	I-Premise
208	to	_	_	I-Premise
209	week	_	_	I-Premise
210	12	_	_	I-Premise
211	were	_	_	I-Premise
212	achieved	_	_	I-Premise
213	by	_	_	I-Premise
214	73.5	_	_	I-Premise
215	%	_	_	I-Premise
216	,	_	_	I-Premise
217	57.5	_	_	I-Premise
218	%	_	_	I-Premise
219	,	_	_	I-Premise
220	and	_	_	I-Premise
221	32.8	_	_	I-Premise
222	%	_	_	I-Premise
223	of	_	_	I-Premise
224	those	_	_	I-Premise
225	treated	_	_	I-Premise
226	with	_	_	I-Premise
227	FCLT	_	_	I-Premise
228	,	_	_	I-Premise
229	latanoprost	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	timolol	_	_	I-Premise
233	,	_	_	I-Premise
234	respectively	_	_	I-Premise
235	(	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	.007	_	_	I-Premise
239	for	_	_	I-Premise
240	FCLT	_	_	I-Premise
241	vs	_	_	I-Premise
242	timolol	_	_	I-Premise
243	;	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	.001	_	_	I-Premise
247	for	_	_	I-Premise
248	FCLT	_	_	I-Premise
249	vs	_	_	I-Premise
250	latanoprost	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	All	_	_	B-Claim
254	therapies	_	_	I-Claim
255	were	_	_	I-Claim
256	well	_	_	I-Claim
257	tolerated	_	_	I-Claim
258	.	_	_	I-Claim

259	Fixed-combination	_	_	B-Claim
260	latanoprost-timolol	_	_	I-Claim
261	therapy	_	_	I-Claim
262	is	_	_	I-Claim
263	as	_	_	I-Claim
264	safe	_	_	I-Claim
265	and	_	_	I-Claim
266	effective	_	_	I-Claim
267	in	_	_	I-Claim
268	lowering	_	_	I-Claim
269	IOP	_	_	I-Claim
270	in	_	_	I-Claim
271	patients	_	_	I-Claim
272	with	_	_	I-Claim
273	either	_	_	I-Claim
274	ocular	_	_	I-Claim
275	hypertension	_	_	I-Claim
276	or	_	_	I-Claim
277	glaucoma	_	_	I-Claim
278	as	_	_	I-Claim
279	monotherapy	_	_	I-Claim
280	with	_	_	I-Claim
281	latanoprost	_	_	I-Claim
282	or	_	_	I-Claim
283	timolol	_	_	I-Claim
284	.	_	_	I-Claim

285	Combination	_	_	B-Claim
286	therapy	_	_	I-Claim
287	can	_	_	I-Claim
288	be	_	_	I-Claim
289	used	_	_	I-Claim
290	to	_	_	I-Claim
291	treat	_	_	I-Claim
292	patients	_	_	I-Claim
293	for	_	_	I-Claim
294	whom	_	_	I-Claim
295	monotherapy	_	_	I-Claim
296	does	_	_	I-Claim
297	not	_	_	I-Claim
298	provide	_	_	I-Claim
299	sufficient	_	_	I-Claim
300	IOP	_	_	I-Claim
301	reduction	_	_	I-Claim
302	.	_	_	I-Claim

303	The	_	_	B-Claim
304	simplicity	_	_	I-Claim
305	,	_	_	I-Claim
306	efficacy	_	_	I-Claim
307	,	_	_	I-Claim
308	and	_	_	I-Claim
309	tolerability	_	_	I-Claim
310	of	_	_	I-Claim
311	FCLT	_	_	I-Claim
312	contribute	_	_	I-Claim
313	to	_	_	I-Claim
314	its	_	_	I-Claim
315	utility	_	_	I-Claim
316	in	_	_	I-Claim
317	clinical	_	_	I-Claim
318	practice	_	_	I-Claim
319	.	_	_	I-Claim


0	Few	_	_	O
1	reports	_	_	O
2	have	_	_	O
3	examined	_	_	O
4	the	_	_	O
5	use	_	_	O
6	of	_	_	O
7	recombinant	_	_	O
8	human	_	_	O
9	thyroid-stimulating	_	_	O
10	hormone	_	_	O
11	(	_	_	O
12	rhTSH	_	_	O
13	)	_	_	O
14	for	_	_	O
15	ablation	_	_	O
16	of	_	_	O
17	postsurgical	_	_	O
18	thyroid	_	_	O
19	remnants	_	_	O
20	after	_	_	O
21	low-dose	_	_	O
22	radioactive	_	_	O
23	iodine	_	_	O
24	(	_	_	O
25	RI	_	_	O
26	)	_	_	O
27	therapy	_	_	O
28	,	_	_	O
29	compared	_	_	O
30	with	_	_	O
31	conventional	_	_	O
32	thyroid	_	_	O
33	hormone	_	_	O
34	withdrawal	_	_	O
35	.	_	_	O

36	We	_	_	O
37	investigated	_	_	O
38	whether	_	_	O
39	patient	_	_	O
40	preparation	_	_	O
41	using	_	_	O
42	rhTSH	_	_	O
43	was	_	_	O
44	comparable	_	_	O
45	to	_	_	O
46	conventional	_	_	O
47	thyroid	_	_	O
48	hormone	_	_	O
49	withdrawal	_	_	O
50	with	_	_	O
51	respect	_	_	O
52	to	_	_	O
53	efficacy	_	_	O
54	of	_	_	O
55	postsurgical	_	_	O
56	remnant	_	_	O
57	ablation	_	_	O
58	in	_	_	O
59	low-risk	_	_	O
60	patients	_	_	O
61	receiving	_	_	O
62	a	_	_	O
63	30	_	_	O
64	mCi	_	_	O
65	RI	_	_	O
66	.	_	_	O

67	In	_	_	O
68	addition	_	_	O
69	,	_	_	O
70	we	_	_	O
71	also	_	_	O
72	evaluated	_	_	O
73	the	_	_	O
74	impact	_	_	O
75	of	_	_	O
76	rhTSH	_	_	O
77	(	_	_	O
78	rhTSH	_	_	O
79	vs.	_	_	O
80	conventional	_	_	O
81	thyroid	_	_	O
82	hormone	_	_	O
83	withdrawal	_	_	O
84	)	_	_	O
85	on	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	(	_	_	O
90	QoL	_	_	O
91	)	_	_	O
92	of	_	_	O
93	thyroid	_	_	O
94	cancer	_	_	O
95	patients	_	_	O
96	undergoing	_	_	O
97	RI	_	_	O
98	ablation	_	_	O
99	.	_	_	O

100	This	_	_	O
101	study	_	_	O
102	included	_	_	O
103	three	_	_	O
104	groups	_	_	O
105	of	_	_	O
106	patients	_	_	O
107	,	_	_	O
108	enrolled	_	_	O
109	consecutively	_	_	O
110	.	_	_	O

111	From	_	_	O
112	February	_	_	O
113	2006	_	_	O
114	to	_	_	O
115	March	_	_	O
116	2007	_	_	O
117	,	_	_	O
118	291	_	_	O
119	patients	_	_	O
120	were	_	_	O
121	enrolled	_	_	O
122	and	_	_	O
123	randomized	_	_	O
124	,	_	_	O
125	after	_	_	O
126	total	_	_	O
127	thyroidectomy	_	_	O
128	:	_	_	O
129	(	_	_	O
130	1	_	_	O
131	)	_	_	O
132	withdrawal	_	_	O
133	of	_	_	O
134	levothyroxine	_	_	O
135	(	_	_	O
136	LT4	_	_	O
137	)	_	_	O
138	for	_	_	O
139	4	_	_	O
140	weeks	_	_	O
141	(	_	_	O
142	T4-WD	_	_	O
143	Group	_	_	O
144	,	_	_	O
145	n	_	_	O
146	=	_	_	O
147	89	_	_	O
148	)	_	_	O
149	,	_	_	O
150	(	_	_	O
151	2	_	_	O
152	)	_	_	O
153	withdrawal	_	_	O
154	of	_	_	O
155	LT4	_	_	O
156	for	_	_	O
157	4	_	_	O
158	weeks	_	_	O
159	plus	_	_	O
160	2	_	_	O
161	weeks	_	_	O
162	on	_	_	O
163	and	_	_	O
164	then	_	_	O
165	2	_	_	O
166	weeks	_	_	O
167	off	_	_	O
168	liothyronine	_	_	O
169	(	_	_	O
170	LT3	_	_	O
171	)	_	_	O
172	(	_	_	O
173	T3-WD	_	_	O
174	Group	_	_	O
175	,	_	_	O
176	n	_	_	O
177	=	_	_	O
178	133	_	_	O
179	)	_	_	O
180	,	_	_	O
181	and	_	_	O
182	(	_	_	O
183	3	_	_	O
184	)	_	_	O
185	rhTSH	_	_	O
186	administration	_	_	O
187	(	_	_	O
188	rhTSH	_	_	O
189	Group	_	_	O
190	,	_	_	O
191	n	_	_	O
192	=	_	_	O
193	69	_	_	O
194	)	_	_	O
195	.	_	_	O

196	QoL	_	_	O
197	was	_	_	O
198	determined	_	_	O
199	at	_	_	O
200	the	_	_	O
201	time	_	_	O
202	of	_	_	O
203	ablation	_	_	O
204	.	_	_	O

205	Patients	_	_	O
206	in	_	_	O
207	the	_	_	O
208	three	_	_	O
209	groups	_	_	O
210	did	_	_	O
211	not	_	_	O
212	differ	_	_	O
213	significantly	_	_	O
214	in	_	_	O
215	baseline	_	_	O
216	characteristics	_	_	O
217	or	_	_	O
218	tumor	_	_	O
219	,	_	_	O
220	node	_	_	O
221	and	_	_	O
222	metastasis	_	_	O
223	(	_	_	O
224	TNM	_	_	O
225	)	_	_	O
226	staging	_	_	O
227	.	_	_	O

228	In	_	_	B-Premise
229	all	_	_	I-Premise
230	study	_	_	I-Premise
231	groups	_	_	I-Premise
232	,	_	_	I-Premise
233	serum	_	_	I-Premise
234	TSH	_	_	I-Premise
235	levels	_	_	I-Premise
236	showed	_	_	I-Premise
237	very	_	_	I-Premise
238	good	_	_	I-Premise
239	stimulation	_	_	I-Premise
240	(	_	_	I-Premise
241	mean	_	_	I-Premise
242	,	_	_	I-Premise
243	82.24	_	_	I-Premise
244	+/-	_	_	I-Premise
245	18.21	_	_	I-Premise
246	mU/L	_	_	I-Premise
247	)	_	_	I-Premise
248	,	_	_	I-Premise
249	without	_	_	I-Premise
250	significant	_	_	I-Premise
251	between-group	_	_	I-Premise
252	differences	_	_	I-Premise
253	(	_	_	I-Premise
254	p	_	_	I-Premise
255	=	_	_	I-Premise
256	0.5213	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Follow-up	_	_	O
260	examinations	_	_	O
261	were	_	_	O
262	performed	_	_	O
263	12	_	_	O
264	months	_	_	O
265	after	_	_	O
266	ablation	_	_	O
267	to	_	_	O
268	assess	_	_	O
269	ablation	_	_	O
270	outcome	_	_	O
271	in	_	_	O
272	each	_	_	O
273	group	_	_	O
274	by	_	_	O
275	131	_	_	O
276	whole	_	_	O
277	body	_	_	O
278	scans	_	_	O
279	(	_	_	O
280	WBSs	_	_	O
281	)	_	_	O
282	,	_	_	O
283	serum	_	_	O
284	thyroglobulin	_	_	O
285	measurement	_	_	O
286	after	_	_	O
287	TSH	_	_	O
288	stimulation	_	_	O
289	,	_	_	O
290	and	_	_	O
291	neck	_	_	O
292	ultrasonography	_	_	O
293	.	_	_	O

294	The	_	_	B-Premise
295	successful	_	_	I-Premise
296	ablation	_	_	I-Premise
297	rate	_	_	I-Premise
298	was	_	_	I-Premise
299	91.0	_	_	I-Premise
300	%	_	_	I-Premise
301	in	_	_	I-Premise
302	T4-WD	_	_	I-Premise
303	Group	_	_	I-Premise
304	,	_	_	I-Premise
305	91.7	_	_	I-Premise
306	%	_	_	I-Premise
307	in	_	_	I-Premise
308	T3-WD	_	_	I-Premise
309	Group	_	_	I-Premise
310	,	_	_	I-Premise
311	and	_	_	I-Premise
312	91.3	_	_	I-Premise
313	%	_	_	I-Premise
314	in	_	_	I-Premise
315	rhTSH	_	_	I-Premise
316	Group	_	_	I-Premise
317	,	_	_	I-Premise
318	without	_	_	I-Premise
319	significant	_	_	I-Premise
320	between-preparation	_	_	I-Premise
321	differences	_	_	I-Premise
322	(	_	_	I-Premise
323	p	_	_	I-Premise
324	=	_	_	I-Premise
325	0.2061	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	QoL	_	_	B-Premise
329	was	_	_	I-Premise
330	better	_	_	I-Premise
331	preserved	_	_	I-Premise
332	in	_	_	I-Premise
333	rhTSH	_	_	I-Premise
334	Group	_	_	I-Premise
335	than	_	_	I-Premise
336	in	_	_	I-Premise
337	T4-WD	_	_	I-Premise
338	and	_	_	I-Premise
339	T3-WD	_	_	I-Premise
340	Groups	_	_	I-Premise
341	(	_	_	I-Premise
342	p	_	_	I-Premise
343	<	_	_	I-Premise
344	0.0001	_	_	I-Premise
345	)	_	_	I-Premise
346	.	_	_	I-Premise

347	However	_	_	B-Premise
348	,	_	_	I-Premise
349	there	_	_	I-Premise
350	was	_	_	I-Premise
351	no	_	_	I-Premise
352	QoL	_	_	I-Premise
353	difference	_	_	I-Premise
354	at	_	_	I-Premise
355	the	_	_	I-Premise
356	time	_	_	I-Premise
357	of	_	_	I-Premise
358	ablation	_	_	I-Premise
359	between	_	_	I-Premise
360	T4-WD	_	_	I-Premise
361	and	_	_	I-Premise
362	T3-WD	_	_	I-Premise
363	Groups	_	_	I-Premise
364	.	_	_	I-Premise

365	Our	_	_	B-Claim
366	study	_	_	I-Claim
367	indicates	_	_	I-Claim
368	that	_	_	I-Claim
369	use	_	_	I-Claim
370	of	_	_	I-Claim
371	rhTSH	_	_	I-Claim
372	preserves	_	_	I-Claim
373	QoL	_	_	I-Claim
374	in	_	_	I-Claim
375	patients	_	_	I-Claim
376	undergoing	_	_	I-Claim
377	RI	_	_	I-Claim
378	ablation	_	_	I-Claim
379	and	_	_	I-Claim
380	affords	_	_	I-Claim
381	an	_	_	I-Claim
382	ablation	_	_	I-Claim
383	success	_	_	I-Claim
384	rate	_	_	I-Claim
385	comparable	_	_	I-Claim
386	to	_	_	I-Claim
387	that	_	_	I-Claim
388	seen	_	_	I-Claim
389	after	_	_	I-Claim
390	thyroid	_	_	I-Claim
391	hormone	_	_	I-Claim
392	withdrawal	_	_	I-Claim
393	.	_	_	I-Claim

394	Notably	_	_	O
395	,	_	_	O
396	ablation	_	_	O
397	preparation	_	_	O
398	using	_	_	O
399	withdrawal	_	_	O
400	of	_	_	O
401	LT3	_	_	O
402	for	_	_	O
403	2	_	_	O
404	weeks	_	_	O
405	did	_	_	O
406	not	_	_	O
407	prevent	_	_	O
408	development	_	_	O
409	of	_	_	O
410	profound	_	_	O
411	hypothyroidism	_	_	O
412	,	_	_	O
413	as	_	_	O
414	also	_	_	O
415	occurred	_	_	O
416	when	_	_	O
417	LT4	_	_	O
418	alone	_	_	O
419	was	_	_	O
420	withdrawn	_	_	O
421	for	_	_	O
422	4	_	_	O
423	weeks	_	_	O
424	.	_	_	O


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	feasibility	_	_	O
4	of	_	_	O
5	administering	_	_	O
6	a	_	_	O
7	flavonoid-rich	_	_	O
8	adjunctive	_	_	O
9	treatment	_	_	O
10	(	_	_	O
11	Concord	_	_	O
12	grape	_	_	O
13	juice	_	_	O
14	)	_	_	O
15	for	_	_	O
16	the	_	_	O
17	management	_	_	O
18	of	_	_	O
19	chemotherapy-induced	_	_	O
20	nausea	_	_	O
21	and	_	_	O
22	vomiting	_	_	O
23	(	_	_	O
24	CINV	_	_	O
25	)	_	_	O
26	;	_	_	O
27	to	_	_	O
28	evaluate	_	_	O
29	the	_	_	O
30	usefulness	_	_	O
31	of	_	_	O
32	existing	_	_	O
33	measures	_	_	O
34	for	_	_	O
35	assessing	_	_	O
36	CINV	_	_	O
37	frequency	_	_	O
38	and	_	_	O
39	severity	_	_	O
40	,	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	,	_	_	O
45	control	_	_	O
46	over	_	_	O
47	life	_	_	O
48	events	_	_	O
49	,	_	_	O
50	and	_	_	O
51	psychological	_	_	O
52	state	_	_	O
53	;	_	_	O
54	to	_	_	O
55	identify	_	_	O
56	any	_	_	O
57	actual	_	_	O
58	or	_	_	O
59	potential	_	_	O
60	adverse	_	_	O
61	events	_	_	O
62	associated	_	_	O
63	with	_	_	O
64	frequent	_	_	O
65	grape	_	_	O
66	juice	_	_	O
67	intake	_	_	O
68	;	_	_	O
69	and	_	_	O
70	to	_	_	O
71	provide	_	_	O
72	preliminary	_	_	O
73	data	_	_	O
74	concerning	_	_	O
75	the	_	_	O
76	effect	_	_	O
77	of	_	_	O
78	Concord	_	_	O
79	grape	_	_	O
80	juice	_	_	O
81	on	_	_	O
82	CINV	_	_	O
83	,	_	_	O
84	quality	_	_	O
85	of	_	_	O
86	life	_	_	O
87	,	_	_	O
88	perceived	_	_	O
89	control	_	_	O
90	over	_	_	O
91	life	_	_	O
92	events	_	_	O
93	,	_	_	O
94	and	_	_	O
95	psychological	_	_	O
96	state	_	_	O
97	.	_	_	O

98	Double-blind	_	_	O
99	,	_	_	O
100	randomized	_	_	O
101	clinical	_	_	O
102	trial	_	_	O
103	.	_	_	O

104	A	_	_	O
105	cancer	_	_	O
106	center	_	_	O
107	in	_	_	O
108	an	_	_	O
109	academic	_	_	O
110	health	_	_	O
111	science	_	_	O
112	center	_	_	O
113	in	_	_	O
114	the	_	_	O
115	northeastern	_	_	O
116	United	_	_	O
117	States	_	_	O
118	.	_	_	O

119	77	_	_	O
120	adult	_	_	O
121	patients	_	_	O
122	with	_	_	O
123	cancer	_	_	O
124	receiving	_	_	O
125	moderately	_	_	O
126	or	_	_	O
127	highly	_	_	O
128	emetogenic	_	_	O
129	chemotherapy	_	_	O
130	agents	_	_	O
131	.	_	_	O

132	Participants	_	_	O
133	drank	_	_	O
134	4	_	_	O
135	oz	_	_	O
136	.	_	_	O

137	of	_	_	O
138	grape	_	_	O
139	juice	_	_	O
140	or	_	_	O
141	placebo	_	_	O
142	prior	_	_	O
143	to	_	_	O
144	meals	_	_	O
145	for	_	_	O
146	one	_	_	O
147	week	_	_	O
148	following	_	_	O
149	each	_	_	O
150	of	_	_	O
151	four	_	_	O
152	chemotherapy	_	_	O
153	treatment	_	_	O
154	cycles	_	_	O
155	.	_	_	O

156	They	_	_	O
157	recorded	_	_	O
158	frequency	_	_	O
159	,	_	_	O
160	duration	_	_	O
161	,	_	_	O
162	and	_	_	O
163	distress	_	_	O
164	of	_	_	O
165	nausea	_	_	O
166	,	_	_	O
167	vomiting	_	_	O
168	,	_	_	O
169	and	_	_	O
170	retching	_	_	O
171	daily	_	_	O
172	,	_	_	O
173	beginning	_	_	O
174	the	_	_	O
175	evening	_	_	O
176	of	_	_	O
177	chemotherapy	_	_	O
178	administration	_	_	O
179	and	_	_	O
180	continuing	_	_	O
181	for	_	_	O
182	seven	_	_	O
183	days	_	_	O
184	.	_	_	O

185	Data	_	_	O
186	were	_	_	O
187	analyzed	_	_	O
188	with	_	_	O
189	generalized	_	_	O
190	estimating	_	_	O
191	equations	_	_	O
192	methodology	_	_	O
193	to	_	_	O
194	model	_	_	O
195	differences	_	_	O
196	between	_	_	O
197	groups	_	_	O
198	over	_	_	O
199	time	_	_	O
200	.	_	_	O

201	Nausea	_	_	B-Premise
202	and	_	_	I-Premise
203	vomiting	_	_	I-Premise
204	frequency	_	_	I-Premise
205	,	_	_	I-Premise
206	duration	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	distress	_	_	I-Premise
210	were	_	_	I-Premise
211	lower	_	_	I-Premise
212	for	_	_	I-Premise
213	experimental	_	_	I-Premise
214	group	_	_	I-Premise
215	members	_	_	I-Premise
216	,	_	_	I-Premise
217	although	_	_	B-Premise
218	a	_	_	I-Premise
219	high	_	_	I-Premise
220	attrition	_	_	I-Premise
221	rate	_	_	I-Premise
222	(	_	_	I-Premise
223	50	_	_	I-Premise
224	%	_	_	I-Premise
225	)	_	_	I-Premise
226	resulted	_	_	I-Premise
227	in	_	_	I-Premise
228	insufficient	_	_	I-Premise
229	power	_	_	I-Premise
230	to	_	_	I-Premise
231	detect	_	_	I-Premise
232	statistically	_	_	I-Premise
233	significant	_	_	I-Premise
234	differences	_	_	I-Premise
235	over	_	_	I-Premise
236	time	_	_	I-Premise
237	.	_	_	I-Premise

238	Greater	_	_	O
239	levels	_	_	O
240	of	_	_	O
241	anxiety	_	_	O
242	,	_	_	O
243	depression	_	_	O
244	,	_	_	O
245	and	_	_	O
246	hostility	_	_	O
247	at	_	_	O
248	baseline	_	_	O
249	were	_	_	O
250	related	_	_	O
251	to	_	_	O
252	nausea	_	_	O
253	and	_	_	O
254	vomiting	_	_	O
255	,	_	_	O
256	quality	_	_	O
257	of	_	_	O
258	life	_	_	O
259	,	_	_	O
260	and	_	_	O
261	perceived	_	_	O
262	control	_	_	O
263	over	_	_	O
264	decision	_	_	O
265	making	_	_	O
266	.	_	_	O

267	The	_	_	B-Claim
268	effect	_	_	I-Claim
269	of	_	_	I-Claim
270	grape	_	_	I-Claim
271	juice	_	_	I-Claim
272	flavonoids	_	_	I-Claim
273	on	_	_	I-Claim
274	CINV	_	_	I-Claim
275	should	_	_	I-Claim
276	be	_	_	I-Claim
277	investigated	_	_	I-Claim
278	further	_	_	I-Claim
279	with	_	_	I-Claim
280	a	_	_	I-Claim
281	larger	_	_	I-Claim
282	sample	_	_	I-Claim
283	to	_	_	I-Claim
284	determine	_	_	I-Claim
285	whether	_	_	I-Claim
286	preliminary	_	_	I-Claim
287	findings	_	_	I-Claim
288	are	_	_	I-Claim
289	supported	_	_	I-Claim
290	.	_	_	I-Claim

291	Alterations	_	_	O
292	to	_	_	O
293	the	_	_	O
294	study	_	_	O
295	protocol	_	_	O
296	will	_	_	O
297	be	_	_	O
298	necessary	_	_	O
299	to	_	_	O
300	decrease	_	_	O
301	attrition	_	_	O
302	.	_	_	O

303	Flavonoid-rich	_	_	B-Claim
304	fruits	_	_	I-Claim
305	and	_	_	I-Claim
306	vegetables	_	_	I-Claim
307	may	_	_	I-Claim
308	provide	_	_	I-Claim
309	additional	_	_	I-Claim
310	protection	_	_	I-Claim
311	against	_	_	I-Claim
312	CINV	_	_	I-Claim
313	.	_	_	I-Claim

314	If	_	_	O
315	the	_	_	O
316	compounds	_	_	O
317	work	_	_	O
318	,	_	_	O
319	they	_	_	O
320	would	_	_	O
321	offer	_	_	O
322	a	_	_	O
323	low-cost	_	_	O
324	,	_	_	O
325	readily	_	_	O
326	available	_	_	O
327	adjunctive	_	_	O
328	treatment	_	_	O
329	for	_	_	O
330	the	_	_	O
331	management	_	_	O
332	of	_	_	O
333	CINV	_	_	O
334	.	_	_	O


0	Despite	_	_	O
1	improvements	_	_	O
2	in	_	_	O
3	surgical	_	_	O
4	techniques	_	_	O
5	,	_	_	O
6	urinary	_	_	O
7	incontinence	_	_	O
8	(	_	_	O
9	UI	_	_	O
10	)	_	_	O
11	is	_	_	O
12	not	_	_	O
13	uncommon	_	_	O
14	after	_	_	O
15	radical	_	_	O
16	prostatectomy	_	_	O
17	(	_	_	O
18	RP	_	_	O
19	)	_	_	O
20	,	_	_	O
21	and	_	_	O
22	it	_	_	O
23	may	_	_	O
24	dramatically	_	_	O
25	worsen	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	(	_	_	O
30	QoL	_	_	O
31	)	_	_	O
32	.	_	_	O

33	To	_	_	O
34	determine	_	_	O
35	the	_	_	O
36	benefit	_	_	O
37	of	_	_	O
38	starting	_	_	O
39	pelvic	_	_	O
40	floor	_	_	O
41	muscle	_	_	O
42	exercise	_	_	O
43	(	_	_	O
44	PFME	_	_	O
45	)	_	_	O
46	30d	_	_	O
47	before	_	_	O
48	RP	_	_	O
49	and	_	_	O
50	of	_	_	O
51	continuing	_	_	O
52	PFME	_	_	O
53	postoperatively	_	_	O
54	for	_	_	O
55	early	_	_	O
56	recovery	_	_	O
57	of	_	_	O
58	continence	_	_	O
59	.	_	_	O

60	A	_	_	O
61	randomised	_	_	O
62	,	_	_	O
63	prospective	_	_	O
64	study	_	_	O
65	was	_	_	O
66	designed	_	_	O
67	.	_	_	O

68	Men	_	_	O
69	with	_	_	O
70	localised	_	_	O
71	prostate	_	_	O
72	cancer	_	_	O
73	(	_	_	O
74	PCa	_	_	O
75	)	_	_	O
76	who	_	_	O
77	underwent	_	_	O
78	an	_	_	O
79	open	_	_	O
80	radical	_	_	O
81	retropubic	_	_	O
82	prostatectomy	_	_	O
83	(	_	_	O
84	RRP	_	_	O
85	)	_	_	O
86	at	_	_	O
87	our	_	_	O
88	department	_	_	O
89	of	_	_	O
90	urology	_	_	O
91	were	_	_	O
92	included	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	randomised	_	_	O
97	to	_	_	O
98	start	_	_	O
99	PFME	_	_	O
100	preoperatively	_	_	O
101	and	_	_	O
102	continue	_	_	O
103	postoperatively	_	_	O
104	(	_	_	O
105	active	_	_	O
106	group	_	_	O
107	:	_	_	O
108	A	_	_	O
109	)	_	_	O
110	or	_	_	O
111	to	_	_	O
112	start	_	_	O
113	PFME	_	_	O
114	postoperatively	_	_	O
115	alone	_	_	O
116	(	_	_	O
117	control	_	_	O
118	group	_	_	O
119	:	_	_	O
120	B	_	_	O
121	)	_	_	O
122	.	_	_	O

123	The	_	_	O
124	primary	_	_	O
125	outcome	_	_	O
126	measure	_	_	O
127	was	_	_	O
128	self-reported	_	_	O
129	continence	_	_	O
130	after	_	_	O
131	surgery	_	_	O
132	.	_	_	O

133	Secondary	_	_	O
134	outcome	_	_	O
135	measures	_	_	O
136	were	_	_	O
137	assessed	_	_	O
138	by	_	_	O
139	degree	_	_	O
140	of	_	_	O
141	UI	_	_	O
142	based	_	_	O
143	on	_	_	O
144	a	_	_	O
145	24-h	_	_	O
146	pad	_	_	O
147	test	_	_	O
148	and	_	_	O
149	QoL	_	_	O
150	instruments	_	_	O
151	(	_	_	O
152	International	_	_	O
153	Continence	_	_	O
154	Society	_	_	O
155	[	_	_	O
156	ICS	_	_	O
157	]	_	_	O
158	male	_	_	O
159	short	_	_	O
160	form	_	_	O
161	[	_	_	O
162	SF	_	_	O
163	]	_	_	O
164	)	_	_	O
165	.	_	_	O

166	Of	_	_	O
167	143	_	_	O
168	men	_	_	O
169	evaluated	_	_	O
170	for	_	_	O
171	the	_	_	O
172	study	_	_	O
173	,	_	_	O
174	118	_	_	O
175	were	_	_	O
176	randomised	_	_	O
177	either	_	_	O
178	to	_	_	O
179	start	_	_	O
180	PFME	_	_	O
181	preoperatively	_	_	O
182	and	_	_	O
183	continue	_	_	O
184	postoperatively	_	_	O
185	(	_	_	O
186	group	_	_	O
187	A	_	_	O
188	;	_	_	O
189	n=59	_	_	O
190	)	_	_	O
191	or	_	_	O
192	to	_	_	O
193	start	_	_	O
194	postoperative	_	_	O
195	PFME	_	_	O
196	(	_	_	O
197	group	_	_	O
198	B	_	_	O
199	;	_	_	O
200	n=59	_	_	O
201	)	_	_	O
202	.	_	_	O

203	After	_	_	B-Premise
204	1	_	_	I-Premise
205	mo	_	_	I-Premise
206	,	_	_	I-Premise
207	44.1	_	_	I-Premise
208	%	_	_	I-Premise
209	(	_	_	I-Premise
210	26	_	_	I-Premise
211	of	_	_	I-Premise
212	59	_	_	I-Premise
213	)	_	_	I-Premise
214	of	_	_	I-Premise
215	patients	_	_	I-Premise
216	were	_	_	I-Premise
217	continent	_	_	I-Premise
218	in	_	_	I-Premise
219	group	_	_	I-Premise
220	A	_	_	I-Premise
221	,	_	_	I-Premise
222	while	_	_	I-Premise
223	20.3	_	_	I-Premise
224	%	_	_	I-Premise
225	(	_	_	I-Premise
226	12	_	_	I-Premise
227	of	_	_	I-Premise
228	59	_	_	I-Premise
229	)	_	_	I-Premise
230	were	_	_	I-Premise
231	continent	_	_	I-Premise
232	in	_	_	I-Premise
233	group	_	_	I-Premise
234	B	_	_	I-Premise
235	(	_	_	I-Premise
236	p=0.018	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	At	_	_	B-Premise
240	3	_	_	I-Premise
241	mo	_	_	I-Premise
242	,	_	_	I-Premise
243	59.3	_	_	I-Premise
244	%	_	_	I-Premise
245	(	_	_	I-Premise
246	35	_	_	I-Premise
247	of	_	_	I-Premise
248	59	_	_	I-Premise
249	)	_	_	I-Premise
250	and	_	_	I-Premise
251	37.3	_	_	I-Premise
252	%	_	_	I-Premise
253	(	_	_	I-Premise
254	22	_	_	I-Premise
255	of	_	_	I-Premise
256	59	_	_	I-Premise
257	)	_	_	I-Premise
258	patients	_	_	I-Premise
259	were	_	_	I-Premise
260	continent	_	_	I-Premise
261	in	_	_	I-Premise
262	group	_	_	I-Premise
263	A	_	_	I-Premise
264	and	_	_	I-Premise
265	group	_	_	I-Premise
266	B	_	_	I-Premise
267	,	_	_	I-Premise
268	respectively	_	_	I-Premise
269	(	_	_	I-Premise
270	p=0.028	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	ICS	_	_	I-Premise
275	male	_	_	I-Premise
276	SF	_	_	I-Premise
277	mean	_	_	I-Premise
278	score	_	_	I-Premise
279	showed	_	_	I-Premise
280	better	_	_	I-Premise
281	results	_	_	I-Premise
282	in	_	_	I-Premise
283	group	_	_	I-Premise
284	A	_	_	I-Premise
285	than	_	_	I-Premise
286	in	_	_	I-Premise
287	group	_	_	I-Premise
288	B	_	_	I-Premise
289	patients	_	_	I-Premise
290	at	_	_	I-Premise
291	both	_	_	I-Premise
292	1	_	_	I-Premise
293	mo	_	_	I-Premise
294	(	_	_	I-Premise
295	14.6	_	_	I-Premise
296	vs	_	_	I-Premise
297	18.3	_	_	I-Premise
298	)	_	_	I-Premise
299	and	_	_	I-Premise
300	3	_	_	I-Premise
301	mo	_	_	I-Premise
302	(	_	_	I-Premise
303	8.1	_	_	I-Premise
304	vs	_	_	I-Premise
305	12.2	_	_	I-Premise
306	)	_	_	I-Premise
307	after	_	_	I-Premise
308	RP	_	_	I-Premise
309	(	_	_	I-Premise
310	p=0.002	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	In	_	_	B-Premise
314	age-adjusted	_	_	I-Premise
315	logistic	_	_	I-Premise
316	regression	_	_	I-Premise
317	analyses	_	_	I-Premise
318	,	_	_	I-Premise
319	patients	_	_	I-Premise
320	who	_	_	I-Premise
321	performed	_	_	I-Premise
322	preoperative	_	_	I-Premise
323	PFME	_	_	I-Premise
324	had	_	_	I-Premise
325	a	_	_	I-Premise
326	0.41-fold	_	_	I-Premise
327	lower	_	_	I-Premise
328	risk	_	_	I-Premise
329	of	_	_	I-Premise
330	being	_	_	I-Premise
331	incontinent	_	_	I-Premise
332	1	_	_	I-Premise
333	mo	_	_	I-Premise
334	after	_	_	I-Premise
335	RP	_	_	I-Premise
336	and	_	_	I-Premise
337	a	_	_	I-Premise
338	0.38-fold	_	_	I-Premise
339	lower	_	_	I-Premise
340	risk	_	_	I-Premise
341	of	_	_	I-Premise
342	being	_	_	I-Premise
343	incontinent	_	_	I-Premise
344	3	_	_	I-Premise
345	mo	_	_	I-Premise
346	after	_	_	I-Premise
347	RP	_	_	I-Premise
348	(	_	_	I-Premise
349	p≤0.001	_	_	I-Premise
350	)	_	_	I-Premise
351	.	_	_	I-Premise

352	Preoperative	_	_	B-Claim
353	PFME	_	_	I-Claim
354	may	_	_	I-Claim
355	improve	_	_	I-Claim
356	early	_	_	I-Claim
357	continence	_	_	I-Claim
358	and	_	_	I-Claim
359	QoL	_	_	I-Claim
360	outcomes	_	_	I-Claim
361	after	_	_	I-Claim
362	RP	_	_	I-Claim
363	.	_	_	I-Claim

364	Further	_	_	B-Claim
365	studies	_	_	I-Claim
366	are	_	_	I-Claim
367	needed	_	_	I-Claim
368	to	_	_	I-Claim
369	corroborate	_	_	I-Claim
370	our	_	_	I-Claim
371	results	_	_	I-Claim
372	.	_	_	I-Claim


0	In	_	_	O
1	anorectal	_	_	O
2	cancer	_	_	O
3	patients	_	_	O
4	,	_	_	O
5	an	_	_	O
6	acute	_	_	O
7	side	_	_	O
8	effect	_	_	O
9	of	_	_	O
10	chemoradiotherapy	_	_	O
11	is	_	_	O
12	gastrointestinal	_	_	O
13	toxicity	_	_	O
14	,	_	_	O
15	which	_	_	O
16	often	_	_	O
17	impedes	_	_	O
18	treatment	_	_	O
19	delivery	_	_	O
20	.	_	_	O

21	Based	_	_	O
22	on	_	_	O
23	previous	_	_	O
24	trials	_	_	O
25	,	_	_	O
26	octreotide	_	_	O
27	acetate	_	_	O
28	is	_	_	O
29	widely	_	_	O
30	recommended	_	_	O
31	for	_	_	O
32	the	_	_	O
33	control	_	_	O
34	of	_	_	O
35	chemotherapy-induced	_	_	O
36	diarrhea	_	_	O
37	.	_	_	O

38	However	_	_	O
39	,	_	_	O
40	the	_	_	O
41	effectiveness	_	_	O
42	of	_	_	O
43	octreotide	_	_	O
44	in	_	_	O
45	preventing	_	_	O
46	or	_	_	O
47	controlling	_	_	O
48	radiation-	_	_	O
49	and	_	_	O
50	chemoradiation-induced	_	_	O
51	diarrhea	_	_	O
52	is	_	_	O
53	not	_	_	O
54	known	_	_	O
55	.	_	_	O

56	A	_	_	O
57	randomized	_	_	O
58	,	_	_	O
59	double-blinded	_	_	O
60	,	_	_	O
61	placebo-controlled	_	_	O
62	trial	_	_	O
63	was	_	_	O
64	designed	_	_	O
65	to	_	_	O
66	determine	_	_	O
67	the	_	_	O
68	efficacy	_	_	O
69	of	_	_	O
70	long-acting	_	_	O
71	octreotide	_	_	O
72	acetate	_	_	O
73	(	_	_	O
74	LAO	_	_	O
75	)	_	_	O
76	in	_	_	O
77	preventing	_	_	O
78	the	_	_	O
79	onset	_	_	O
80	of	_	_	O
81	acute	_	_	O
82	diarrhea	_	_	O
83	in	_	_	O
84	patients	_	_	O
85	undergoing	_	_	O
86	chemoradiation	_	_	O
87	therapy	_	_	O
88	for	_	_	O
89	rectal	_	_	O
90	or	_	_	O
91	anal	_	_	O
92	cancer	_	_	O
93	.	_	_	O

94	Between	_	_	O
95	4	_	_	O
96	and	_	_	O
97	7	_	_	O
98	days	_	_	O
99	before	_	_	O
100	the	_	_	O
101	start	_	_	O
102	of	_	_	O
103	radiation	_	_	O
104	therapy	_	_	O
105	,	_	_	O
106	patients	_	_	O
107	received	_	_	O
108	a	_	_	O
109	30-mg	_	_	O
110	dose	_	_	O
111	of	_	_	O
112	LAO	_	_	O
113	(	_	_	O
114	109	_	_	O
115	patients	_	_	O
116	)	_	_	O
117	or	_	_	O
118	placebo	_	_	O
119	(	_	_	O
120	106	_	_	O
121	patients	_	_	O
122	)	_	_	O
123	via	_	_	O
124	intramuscular	_	_	O
125	injection	_	_	O
126	.	_	_	O

127	A	_	_	O
128	second	_	_	O
129	dose	_	_	O
130	was	_	_	O
131	given	_	_	O
132	on	_	_	O
133	day	_	_	O
134	22	_	_	O
135	(	_	_	O
136	+/-3	_	_	O
137	days	_	_	O
138	)	_	_	O
139	of	_	_	O
140	radiation	_	_	O
141	treatment	_	_	O
142	.	_	_	O

143	A	_	_	O
144	total	_	_	O
145	of	_	_	O
146	215	_	_	O
147	patients	_	_	O
148	were	_	_	O
149	included	_	_	O
150	in	_	_	O
151	the	_	_	O
152	final	_	_	O
153	analysis	_	_	O
154	.	_	_	O

155	The	_	_	O
156	primary	_	_	O
157	endpoint	_	_	O
158	was	_	_	O
159	the	_	_	O
160	incidence	_	_	O
161	of	_	_	O
162	grade	_	_	O
163	2-4	_	_	O
164	acute	_	_	O
165	diarrhea	_	_	O
166	;	_	_	O
167	secondary	_	_	O
168	endpoints	_	_	O
169	included	_	_	O
170	treatment	_	_	O
171	compliance	_	_	O
172	,	_	_	O
173	medical	_	_	O
174	resource	_	_	O
175	utilization	_	_	O
176	,	_	_	O
177	patient-reported	_	_	O
178	bowel	_	_	O
179	function	_	_	O
180	,	_	_	O
181	and	_	_	O
182	quality	_	_	O
183	of	_	_	O
184	life	_	_	O
185	(	_	_	O
186	QoL	_	_	O
187	)	_	_	O
188	.	_	_	O

189	Statistical	_	_	O
190	tests	_	_	O
191	were	_	_	O
192	one-	_	_	O
193	or	_	_	O
194	two-sided	_	_	O
195	,	_	_	O
196	as	_	_	O
197	specified	_	_	O
198	.	_	_	O

199	After	_	_	B-Premise
200	a	_	_	I-Premise
201	median	_	_	I-Premise
202	follow-up	_	_	I-Premise
203	time	_	_	I-Premise
204	of	_	_	I-Premise
205	9.64	_	_	I-Premise
206	months	_	_	I-Premise
207	,	_	_	I-Premise
208	incidence	_	_	I-Premise
209	rates	_	_	I-Premise
210	of	_	_	I-Premise
211	grades	_	_	I-Premise
212	2-4	_	_	I-Premise
213	acute	_	_	I-Premise
214	diarrhea	_	_	I-Premise
215	were	_	_	I-Premise
216	similar	_	_	I-Premise
217	in	_	_	I-Premise
218	both	_	_	I-Premise
219	groups	_	_	I-Premise
220	(	_	_	I-Premise
221	49	_	_	I-Premise
222	%	_	_	I-Premise
223	placebo	_	_	I-Premise
224	vs	_	_	I-Premise
225	44	_	_	I-Premise
226	%	_	_	I-Premise
227	LAO	_	_	I-Premise
228	;	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	.21	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	No	_	_	B-Premise
235	statistically	_	_	I-Premise
236	significant	_	_	I-Premise
237	treatment	_	_	I-Premise
238	differences	_	_	I-Premise
239	in	_	_	I-Premise
240	chemotherapy	_	_	I-Premise
241	or	_	_	I-Premise
242	radiation	_	_	I-Premise
243	delivery	_	_	I-Premise
244	,	_	_	I-Premise
245	medical	_	_	I-Premise
246	resource	_	_	I-Premise
247	utilization	_	_	I-Premise
248	,	_	_	I-Premise
249	patient-reported	_	_	I-Premise
250	bowel	_	_	I-Premise
251	function	_	_	I-Premise
252	,	_	_	I-Premise
253	or	_	_	I-Premise
254	QoL	_	_	I-Premise
255	were	_	_	I-Premise
256	observed	_	_	I-Premise
257	.	_	_	I-Premise

258	In	_	_	B-Claim
259	this	_	_	I-Claim
260	study	_	_	I-Claim
261	,	_	_	I-Claim
262	the	_	_	I-Claim
263	prophylactic	_	_	I-Claim
264	use	_	_	I-Claim
265	of	_	_	I-Claim
266	LAO	_	_	I-Claim
267	did	_	_	I-Claim
268	not	_	_	I-Claim
269	prevent	_	_	I-Claim
270	the	_	_	I-Claim
271	incidence	_	_	I-Claim
272	or	_	_	I-Claim
273	reduce	_	_	I-Claim
274	the	_	_	I-Claim
275	severity	_	_	I-Claim
276	of	_	_	I-Claim
277	diarrhea	_	_	I-Claim
278	and	_	_	I-Claim
279	had	_	_	I-Claim
280	no	_	_	I-Claim
281	notable	_	_	I-Claim
282	impact	_	_	I-Claim
283	on	_	_	I-Claim
284	patient-reported	_	_	I-Claim
285	bowel	_	_	I-Claim
286	function	_	_	I-Claim
287	or	_	_	I-Claim
288	QoL	_	_	I-Claim
289	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	vinflunine	_	_	O
3	(	_	_	O
4	VFL	_	_	O
5	)	_	_	O
6	to	_	_	O
7	docetaxel	_	_	O
8	in	_	_	O
9	patients	_	_	O
10	with	_	_	O
11	stage	_	_	O
12	IIIB/IV	_	_	O
13	non-small-cell	_	_	O
14	lung	_	_	O
15	cancer	_	_	O
16	(	_	_	O
17	NSCLC	_	_	O
18	)	_	_	O
19	who	_	_	O
20	have	_	_	O
21	experienced	_	_	O
22	treatment	_	_	O
23	failure	_	_	O
24	with	_	_	O
25	first-line	_	_	O
26	platinum-based	_	_	O
27	chemotherapy	_	_	O
28	.	_	_	O

29	Randomized	_	_	O
30	,	_	_	O
31	multicenter	_	_	O
32	,	_	_	O
33	phase	_	_	O
34	III	_	_	O
35	study	_	_	O
36	,	_	_	O
37	551	_	_	O
38	patients	_	_	O
39	received	_	_	O
40	either	_	_	O
41	vinflunine	_	_	O
42	320	_	_	O
43	mg/m	_	_	O
44	(	_	_	O
45	2	_	_	O
46	)	_	_	O
47	or	_	_	O
48	docetaxel	_	_	O
49	75	_	_	O
50	mg/m	_	_	O
51	(	_	_	O
52	2	_	_	O
53	)	_	_	O
54	every	_	_	O
55	21	_	_	O
56	days	_	_	O
57	until	_	_	O
58	disease	_	_	O
59	progression	_	_	O
60	or	_	_	O
61	serious	_	_	O
62	toxicity	_	_	O
63	.	_	_	O

64	The	_	_	O
65	primary	_	_	O
66	end	_	_	O
67	point	_	_	O
68	was	_	_	O
69	progression-free	_	_	O
70	survival	_	_	O
71	(	_	_	O
72	PFS	_	_	O
73	)	_	_	O
74	.	_	_	O

75	The	_	_	O
76	noninferiority	_	_	O
77	analysis	_	_	O
78	was	_	_	O
79	based	_	_	O
80	on	_	_	O
81	a	_	_	O
82	10	_	_	O
83	%	_	_	O
84	difference	_	_	O
85	(	_	_	O
86	types	_	_	O
87	I/II	_	_	O
88	error	_	_	O
89	rates	_	_	O
90	:	_	_	O
91	5	_	_	O
92	%	_	_	O
93	/20	_	_	O
94	%	_	_	O
95	)	_	_	O
96	.	_	_	O

97	Secondary	_	_	O
98	end	_	_	O
99	points	_	_	O
100	included	_	_	O
101	response	_	_	O
102	rate	_	_	O
103	(	_	_	O
104	ORR	_	_	O
105	)	_	_	O
106	,	_	_	O
107	response	_	_	O
108	duration	_	_	O
109	,	_	_	O
110	overall	_	_	O
111	survival	_	_	O
112	(	_	_	O
113	OS	_	_	O
114	)	_	_	O
115	,	_	_	O
116	clinical	_	_	O
117	benefit	_	_	O
118	,	_	_	O
119	quality	_	_	O
120	of	_	_	O
121	life	_	_	O
122	(	_	_	O
123	QOL	_	_	O
124	)	_	_	O
125	,	_	_	O
126	and	_	_	O
127	safety	_	_	O
128	.	_	_	O

129	Median	_	_	B-Premise
130	PFS	_	_	I-Premise
131	was	_	_	I-Premise
132	2.3	_	_	I-Premise
133	months	_	_	I-Premise
134	for	_	_	I-Premise
135	each	_	_	I-Premise
136	arm	_	_	I-Premise
137	(	_	_	I-Premise
138	HR	_	_	I-Premise
139	,	_	_	I-Premise
140	1.004	_	_	I-Premise
141	;	_	_	I-Premise
142	95	_	_	I-Premise
143	%	_	_	I-Premise
144	CI	_	_	I-Premise
145	,	_	_	I-Premise
146	0.841	_	_	I-Premise
147	to	_	_	I-Premise
148	1.199	_	_	I-Premise
149	)	_	_	I-Premise
150	.	_	_	I-Premise

151	ORR	_	_	B-Premise
152	,	_	_	I-Premise
153	stable	_	_	I-Premise
154	disease	_	_	I-Premise
155	,	_	_	I-Premise
156	median	_	_	I-Premise
157	OS	_	_	I-Premise
158	,	_	_	I-Premise
159	were	_	_	I-Premise
160	4.4	_	_	I-Premise
161	%	_	_	I-Premise
162	versus	_	_	I-Premise
163	5.5	_	_	I-Premise
164	%	_	_	I-Premise
165	,	_	_	I-Premise
166	36.0	_	_	I-Premise
167	%	_	_	I-Premise
168	versus	_	_	I-Premise
169	39.6	_	_	I-Premise
170	%	_	_	I-Premise
171	,	_	_	I-Premise
172	6.7	_	_	I-Premise
173	versus	_	_	I-Premise
174	7.2	_	_	I-Premise
175	months	_	_	I-Premise
176	(	_	_	I-Premise
177	HR	_	_	I-Premise
178	,	_	_	I-Premise
179	0.973	_	_	I-Premise
180	;	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	,	_	_	I-Premise
185	0.805	_	_	I-Premise
186	to	_	_	I-Premise
187	1.176	_	_	I-Premise
188	)	_	_	I-Premise
189	,	_	_	I-Premise
190	respectively	_	_	I-Premise
191	.	_	_	I-Premise

192	No	_	_	B-Premise
193	significant	_	_	I-Premise
194	difference	_	_	I-Premise
195	in	_	_	I-Premise
196	patient	_	_	I-Premise
197	benefit	_	_	I-Premise
198	and	_	_	I-Premise
199	QOL	_	_	I-Premise
200	(	_	_	I-Premise
201	Functional	_	_	I-Premise
202	Assessment	_	_	I-Premise
203	of	_	_	I-Premise
204	Cancer	_	_	I-Premise
205	Therapy-Lung	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	No	_	_	B-Premise
209	unexpected	_	_	I-Premise
210	adverse	_	_	I-Premise
211	events	_	_	I-Premise
212	were	_	_	I-Premise
213	observed	_	_	I-Premise
214	.	_	_	I-Premise

215	Grade	_	_	B-Premise
216	higher	_	_	I-Premise
217	than	_	_	I-Premise
218	0	_	_	I-Premise
219	(	_	_	I-Premise
220	vinflunine	_	_	I-Premise
221	v	_	_	I-Premise
222	docetaxel	_	_	I-Premise
223	)	_	_	I-Premise
224	anemia	_	_	I-Premise
225	(	_	_	I-Premise
226	82.1	_	_	I-Premise
227	%	_	_	I-Premise
228	v	_	_	I-Premise
229	79.8	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	neutropenia	_	_	I-Premise
234	(	_	_	I-Premise
235	49.3	_	_	I-Premise
236	v	_	_	I-Premise
237	39.02	_	_	I-Premise
238	%	_	_	I-Premise
239	)	_	_	I-Premise
240	,	_	_	I-Premise
241	thrombocytopenia	_	_	I-Premise
242	(	_	_	I-Premise
243	30.6	_	_	I-Premise
244	%	_	_	I-Premise
245	v	_	_	I-Premise
246	14.3	_	_	I-Premise
247	%	_	_	I-Premise
248	)	_	_	I-Premise
249	,	_	_	I-Premise
250	febrile	_	_	I-Premise
251	neutropenia	_	_	I-Premise
252	(	_	_	I-Premise
253	3.3	_	_	I-Premise
254	%	_	_	I-Premise
255	v	_	_	I-Premise
256	4.7	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	constipation	_	_	I-Premise
261	(	_	_	I-Premise
262	39.2	_	_	I-Premise
263	%	_	_	I-Premise
264	v	_	_	I-Premise
265	11.7	_	_	I-Premise
266	%	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	fatigue	_	_	I-Premise
270	(	_	_	I-Premise
271	36.6	_	_	I-Premise
272	%	_	_	I-Premise
273	v	_	_	I-Premise
274	33.9	_	_	I-Premise
275	%	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	injection	_	_	I-Premise
279	site	_	_	I-Premise
280	reaction	_	_	I-Premise
281	(	_	_	I-Premise
282	31.9	_	_	I-Premise
283	%	_	_	I-Premise
284	v	_	_	I-Premise
285	0.7	_	_	I-Premise
286	%	_	_	I-Premise
287	)	_	_	I-Premise
288	,	_	_	I-Premise
289	nausea	_	_	I-Premise
290	(	_	_	I-Premise
291	26.7	_	_	I-Premise
292	%	_	_	I-Premise
293	v	_	_	I-Premise
294	23.7	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	,	_	_	I-Premise
298	vomiting	_	_	I-Premise
299	(	_	_	I-Premise
300	23.8	_	_	I-Premise
301	%	_	_	I-Premise
302	v	_	_	I-Premise
303	14.2	_	_	I-Premise
304	%	_	_	I-Premise
305	)	_	_	I-Premise
306	,	_	_	I-Premise
307	alopecia	_	_	I-Premise
308	(	_	_	I-Premise
309	19.8	_	_	I-Premise
310	%	_	_	I-Premise
311	v	_	_	I-Premise
312	35.4	_	_	I-Premise
313	%	_	_	I-Premise
314	)	_	_	I-Premise
315	,	_	_	I-Premise
316	stomatis	_	_	I-Premise
317	(	_	_	I-Premise
318	19.4	_	_	I-Premise
319	%	_	_	I-Premise
320	v	_	_	I-Premise
321	12.4	_	_	I-Premise
322	%	_	_	I-Premise
323	)	_	_	I-Premise
324	,	_	_	I-Premise
325	abdominal	_	_	I-Premise
326	pain	_	_	I-Premise
327	(	_	_	I-Premise
328	20.1	_	_	I-Premise
329	%	_	_	I-Premise
330	v	_	_	I-Premise
331	3.6	_	_	I-Premise
332	%	_	_	I-Premise
333	)	_	_	I-Premise
334	,	_	_	I-Premise
335	myalgia	_	_	I-Premise
336	(	_	_	I-Premise
337	14.7	_	_	I-Premise
338	%	_	_	I-Premise
339	v	_	_	I-Premise
340	6.6	_	_	I-Premise
341	%	_	_	I-Premise
342	)	_	_	I-Premise
343	,	_	_	I-Premise
344	peripheral	_	_	I-Premise
345	neuropathy	_	_	I-Premise
346	(	_	_	I-Premise
347	10.7	_	_	I-Premise
348	%	_	_	I-Premise
349	v	_	_	I-Premise
350	15.0	_	_	I-Premise
351	%	_	_	I-Premise
352	)	_	_	I-Premise
353	,	_	_	I-Premise
354	arthralgia	_	_	I-Premise
355	(	_	_	I-Premise
356	7.0	_	_	I-Premise
357	%	_	_	I-Premise
358	v	_	_	I-Premise
359	7.7	_	_	I-Premise
360	%	_	_	I-Premise
361	)	_	_	I-Premise
362	,	_	_	I-Premise
363	diarrhea	_	_	I-Premise
364	(	_	_	I-Premise
365	6.2	_	_	I-Premise
366	%	_	_	I-Premise
367	v	_	_	I-Premise
368	12.4	_	_	I-Premise
369	%	_	_	I-Premise
370	)	_	_	I-Premise
371	,	_	_	I-Premise
372	edema	_	_	I-Premise
373	(	_	_	I-Premise
374	1.5	_	_	I-Premise
375	%	_	_	I-Premise
376	v	_	_	I-Premise
377	5.4	_	_	I-Premise
378	%	_	_	I-Premise
379	)	_	_	I-Premise
380	,	_	_	I-Premise
381	and	_	_	I-Premise
382	nail	_	_	I-Premise
383	disorders	_	_	I-Premise
384	(	_	_	I-Premise
385	1.1	_	_	I-Premise
386	%	_	_	I-Premise
387	v	_	_	I-Premise
388	5	_	_	I-Premise
389	;	_	_	I-Premise
390	1	_	_	I-Premise
391	%	_	_	I-Premise
392	)	_	_	I-Premise
393	were	_	_	I-Premise
394	observed	_	_	I-Premise
395	.	_	_	I-Premise

396	This	_	_	B-Claim
397	noninferiority	_	_	I-Claim
398	phase	_	_	I-Claim
399	III	_	_	I-Claim
400	study	_	_	I-Claim
401	showed	_	_	I-Claim
402	similar	_	_	I-Claim
403	efficacy	_	_	I-Claim
404	end	_	_	I-Claim
405	points	_	_	I-Claim
406	for	_	_	I-Claim
407	vinflunine	_	_	I-Claim
408	and	_	_	I-Claim
409	docetaxel	_	_	I-Claim
410	.	_	_	I-Claim

411	Despite	_	_	B-Claim
412	higher	_	_	I-Claim
413	rates	_	_	I-Claim
414	of	_	_	I-Claim
415	some	_	_	I-Claim
416	adverse	_	_	I-Claim
417	effects	_	_	I-Claim
418	(	_	_	I-Claim
419	anemia	_	_	I-Claim
420	,	_	_	I-Claim
421	abdominal	_	_	I-Claim
422	pain	_	_	I-Claim
423	,	_	_	I-Claim
424	constipation	_	_	I-Claim
425	,	_	_	I-Claim
426	fatigue	_	_	I-Claim
427	)	_	_	I-Claim
428	the	_	_	B-Claim
429	overall	_	_	I-Claim
430	toxicity	_	_	I-Claim
431	profile	_	_	I-Claim
432	of	_	_	I-Claim
433	vinflunine	_	_	I-Claim
434	was	_	_	I-Claim
435	manageable	_	_	I-Claim
436	.	_	_	I-Claim

437	Therefore	_	_	O
438	,	_	_	O
439	VFL	_	_	B-Claim
440	may	_	_	I-Claim
441	be	_	_	I-Claim
442	another	_	_	I-Claim
443	option	_	_	I-Claim
444	in	_	_	I-Claim
445	the	_	_	I-Claim
446	second-line	_	_	I-Claim
447	treatment	_	_	I-Claim
448	of	_	_	I-Claim
449	patients	_	_	I-Claim
450	with	_	_	I-Claim
451	advanced	_	_	I-Claim
452	NSCLC	_	_	I-Claim
453	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	two	_	_	O
3	intraocular	_	_	O
4	irrigating	_	_	O
5	solutions	_	_	O
6	,	_	_	O
7	Balanced	_	_	O
8	Salt	_	_	O
9	Solution	_	_	O
10	Plus	_	_	O
11	(	_	_	O
12	BSS	_	_	O
13	Plus	_	_	O
14	)	_	_	O
15	versus	_	_	O
16	Lactated	_	_	O
17	Ringer	_	_	O
18	's	_	_	O
19	(	_	_	O
20	Ringer	_	_	O
21	)	_	_	O
22	,	_	_	O
23	for	_	_	O
24	the	_	_	O
25	preservation	_	_	O
26	of	_	_	O
27	corneal	_	_	O
28	integrity	_	_	O
29	after	_	_	O
30	phacoemulsification	_	_	O
31	.	_	_	O

32	110	_	_	O
33	patients	_	_	O
34	undergoing	_	_	O
35	phacoemulsification	_	_	O
36	were	_	_	O
37	randomised	_	_	O
38	to	_	_	O
39	either	_	_	O
40	BSS	_	_	O
41	Plus	_	_	O
42	(	_	_	O
43	n=55	_	_	O
44	)	_	_	O
45	or	_	_	O
46	Ringer	_	_	O
47	(	_	_	O
48	n=55	_	_	O
49	)	_	_	O
50	as	_	_	O
51	the	_	_	O
52	irrigating	_	_	O
53	solution	_	_	O
54	.	_	_	O

55	Patients	_	_	O
56	were	_	_	O
57	examined	_	_	O
58	at	_	_	O
59	baseline	_	_	O
60	and	_	_	O
61	at	_	_	O
62	1	_	_	O
63	,	_	_	O
64	8	_	_	O
65	,	_	_	O
66	15	_	_	O
67	,	_	_	O
68	30	_	_	O
69	and	_	_	O
70	60	_	_	O
71	days	_	_	O
72	postoperatively	_	_	O
73	.	_	_	O

74	Evaluations	_	_	O
75	included	_	_	O
76	specular	_	_	O
77	microscopy	_	_	O
78	to	_	_	O
79	evaluate	_	_	O
80	endothelial	_	_	O
81	cell	_	_	O
82	density	_	_	O
83	(	_	_	O
84	ECD	_	_	O
85	)	_	_	O
86	and	_	_	O
87	endothelial	_	_	O
88	cell	_	_	O
89	size	_	_	O
90	variability	_	_	O
91	(	_	_	O
92	CV	_	_	O
93	)	_	_	O
94	,	_	_	O
95	and	_	_	O
96	corneal	_	_	O
97	pachymetry	_	_	O
98	for	_	_	O
99	central	_	_	O
100	corneal	_	_	O
101	thickness	_	_	O
102	(	_	_	O
103	CCT	_	_	O
104	)	_	_	O
105	measurement	_	_	O
106	.	_	_	O

107	Groups	_	_	O
108	were	_	_	O
109	well	_	_	O
110	balanced	_	_	O
111	regarding	_	_	O
112	baseline	_	_	O
113	ECD	_	_	O
114	,	_	_	O
115	CV	_	_	O
116	and	_	_	O
117	CCT	_	_	O
118	(	_	_	O
119	p	_	_	O
120	>	_	_	O
121	0.05	_	_	O
122	)	_	_	O
123	.	_	_	O

124	There	_	_	B-Premise
125	was	_	_	I-Premise
126	no	_	_	I-Premise
127	statistically	_	_	I-Premise
128	significant	_	_	I-Premise
129	difference	_	_	I-Premise
130	between	_	_	I-Premise
131	ECD	_	_	I-Premise
132	reduction	_	_	I-Premise
133	in	_	_	I-Premise
134	group	_	_	I-Premise
135	BSS	_	_	I-Premise
136	Plus	_	_	I-Premise
137	13.1	_	_	I-Premise
138	±	_	_	I-Premise
139	2.0	_	_	I-Premise
140	%	_	_	I-Premise
141	and	_	_	I-Premise
142	Ringer	_	_	I-Premise
143	9.2	_	_	I-Premise
144	±	_	_	I-Premise
145	1.9	_	_	I-Premise
146	%	_	_	I-Premise
147	(	_	_	I-Premise
148	p	_	_	I-Premise
149	<	_	_	I-Premise
150	0.05	_	_	I-Premise
151	)	_	_	I-Premise
152	at	_	_	I-Premise
153	day	_	_	I-Premise
154	60	_	_	I-Premise
155	or	_	_	I-Premise
156	in	_	_	I-Premise
157	any	_	_	I-Premise
158	study	_	_	I-Premise
159	visit	_	_	I-Premise
160	.	_	_	I-Premise

161	There	_	_	B-Premise
162	was	_	_	I-Premise
163	no	_	_	I-Premise
164	statistically	_	_	I-Premise
165	significant	_	_	I-Premise
166	difference	_	_	I-Premise
167	between	_	_	I-Premise
168	CV	_	_	I-Premise
169	increase	_	_	I-Premise
170	in	_	_	I-Premise
171	group	_	_	I-Premise
172	BSS	_	_	I-Premise
173	Plus	_	_	I-Premise
174	23.0	_	_	I-Premise
175	±	_	_	I-Premise
176	3.0	_	_	I-Premise
177	%	_	_	I-Premise
178	and	_	_	I-Premise
179	Ringer	_	_	I-Premise
180	20.2	_	_	I-Premise
181	±	_	_	I-Premise
182	4.0	_	_	I-Premise
183	%	_	_	I-Premise
184	(	_	_	I-Premise
185	p	_	_	I-Premise
186	<	_	_	I-Premise
187	0.05	_	_	I-Premise
188	)	_	_	I-Premise
189	at	_	_	I-Premise
190	day	_	_	I-Premise
191	60	_	_	I-Premise
192	or	_	_	I-Premise
193	in	_	_	I-Premise
194	any	_	_	I-Premise
195	study	_	_	I-Premise
196	visit	_	_	I-Premise
197	.	_	_	I-Premise

198	CCT	_	_	B-Premise
199	was	_	_	I-Premise
200	significantly	_	_	I-Premise
201	increased	_	_	I-Premise
202	(	_	_	I-Premise
203	p	_	_	I-Premise
204	<	_	_	I-Premise
205	0.05	_	_	I-Premise
206	)	_	_	I-Premise
207	at	_	_	I-Premise
208	1	_	_	I-Premise
209	,	_	_	I-Premise
210	8	_	_	I-Premise
211	,	_	_	I-Premise
212	15	_	_	I-Premise
213	and	_	_	I-Premise
214	30	_	_	I-Premise
215	days	_	_	I-Premise
216	postoperatively	_	_	I-Premise
217	,	_	_	I-Premise
218	returning	_	_	I-Premise
219	to	_	_	I-Premise
220	baseline	_	_	I-Premise
221	at	_	_	I-Premise
222	60	_	_	I-Premise
223	days	_	_	I-Premise
224	in	_	_	I-Premise
225	both	_	_	I-Premise
226	groups	_	_	I-Premise
227	.	_	_	I-Premise

228	There	_	_	B-Premise
229	was	_	_	I-Premise
230	no	_	_	I-Premise
231	significant	_	_	I-Premise
232	difference	_	_	I-Premise
233	in	_	_	I-Premise
234	CCT	_	_	I-Premise
235	increase	_	_	I-Premise
236	in	_	_	I-Premise
237	both	_	_	I-Premise
238	groups	_	_	I-Premise
239	at	_	_	I-Premise
240	any	_	_	I-Premise
241	visit	_	_	I-Premise
242	.	_	_	I-Premise

243	Interestingly	_	_	O
244	,	_	_	O
245	there	_	_	B-Premise
246	were	_	_	I-Premise
247	statistically	_	_	I-Premise
248	significant	_	_	I-Premise
249	correlations	_	_	I-Premise
250	between	_	_	I-Premise
251	ECD	_	_	I-Premise
252	loss	_	_	I-Premise
253	and	_	_	I-Premise
254	phacoemulsification	_	_	I-Premise
255	time	_	_	I-Premise
256	(	_	_	I-Premise
257	p	_	_	I-Premise
258	<	_	_	I-Premise
259	0.0001	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	ECD	_	_	I-Premise
263	loss	_	_	I-Premise
264	and	_	_	I-Premise
265	irrigation	_	_	I-Premise
266	solution	_	_	I-Premise
267	volume	_	_	I-Premise
268	(	_	_	I-Premise
269	p	_	_	I-Premise
270	<	_	_	I-Premise
271	0.0001	_	_	I-Premise
272	)	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	Ringer	_	_	I-Premise
276	group	_	_	I-Premise
277	,	_	_	I-Premise
278	but	_	_	I-Premise
279	not	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	BSS	_	_	I-Premise
283	Plus	_	_	I-Premise
284	group	_	_	I-Premise
285	.	_	_	I-Premise

286	Ringers	_	_	B-Claim
287	solution	_	_	I-Claim
288	was	_	_	I-Claim
289	similar	_	_	I-Claim
290	to	_	_	I-Claim
291	BSS	_	_	I-Claim
292	Plus	_	_	I-Claim
293	for	_	_	I-Claim
294	corneal	_	_	I-Claim
295	preservation	_	_	I-Claim
296	in	_	_	I-Claim
297	atraumatic	_	_	I-Claim
298	cataract	_	_	I-Claim
299	surgery	_	_	I-Claim
300	.	_	_	I-Claim

301	However	_	_	B-Claim
302	,	_	_	I-Claim
303	our	_	_	I-Claim
304	study	_	_	I-Claim
305	demonstrates	_	_	I-Claim
306	that	_	_	I-Claim
307	there	_	_	I-Claim
308	is	_	_	I-Claim
309	a	_	_	I-Claim
310	trend	_	_	I-Claim
311	towards	_	_	I-Claim
312	lower	_	_	I-Claim
313	postoperative	_	_	I-Claim
314	endothelial	_	_	I-Claim
315	cell	_	_	I-Claim
316	density	_	_	I-Claim
317	for	_	_	I-Claim
318	surgeries	_	_	I-Claim
319	with	_	_	I-Claim
320	longer	_	_	I-Claim
321	phacoemulsification	_	_	I-Claim
322	time	_	_	I-Claim
323	and	_	_	I-Claim
324	higher	_	_	I-Claim
325	irrigation	_	_	I-Claim
326	volumes	_	_	I-Claim
327	if	_	_	I-Claim
328	Ringer	_	_	I-Claim
329	is	_	_	I-Claim
330	used	_	_	I-Claim
331	.	_	_	I-Claim


0	Patients	_	_	O
1	receiving	_	_	O
2	chemoradiation	_	_	O
3	for	_	_	O
4	cervical	_	_	O
5	cancer	_	_	O
6	are	_	_	O
7	at	_	_	O
8	risk	_	_	O
9	for	_	_	O
10	distress	_	_	O
11	,	_	_	O
12	chemoradiation-related	_	_	O
13	side-effects	_	_	O
14	,	_	_	O
15	and	_	_	O
16	immunosuppression	_	_	O
17	.	_	_	O

18	This	_	_	O
19	prospective	_	_	O
20	randomized	_	_	O
21	clinical	_	_	O
22	trial	_	_	O
23	examined	_	_	O
24	effects	_	_	O
25	of	_	_	O
26	a	_	_	O
27	complementary	_	_	O
28	therapy	_	_	O
29	,	_	_	O
30	Healing	_	_	O
31	Touch	_	_	O
32	(	_	_	O
33	HT	_	_	O
34	)	_	_	O
35	,	_	_	O
36	versus	_	_	O
37	relaxation	_	_	O
38	training	_	_	O
39	(	_	_	O
40	RT	_	_	O
41	)	_	_	O
42	and	_	_	O
43	usual	_	_	O
44	care	_	_	O
45	(	_	_	O
46	UC	_	_	O
47	)	_	_	O
48	for	_	_	O
49	(	_	_	O
50	1	_	_	O
51	)	_	_	O
52	supporting	_	_	O
53	cellular	_	_	O
54	immunity	_	_	O
55	,	_	_	O
56	(	_	_	O
57	2	_	_	O
58	)	_	_	O
59	improving	_	_	O
60	mood	_	_	O
61	and	_	_	O
62	quality	_	_	O
63	of	_	_	O
64	life	_	_	O
65	(	_	_	O
66	QOL	_	_	O
67	)	_	_	O
68	,	_	_	O
69	and	_	_	O
70	(	_	_	O
71	3	_	_	O
72	)	_	_	O
73	reducing	_	_	O
74	treatment-associated	_	_	O
75	toxicities	_	_	O
76	and	_	_	O
77	treatment	_	_	O
78	delay	_	_	O
79	in	_	_	O
80	cervical	_	_	O
81	cancer	_	_	O
82	patients	_	_	O
83	receiving	_	_	O
84	chemoradiation	_	_	O
85	.	_	_	O

86	Sixty	_	_	O
87	women	_	_	O
88	with	_	_	O
89	stages	_	_	O
90	IB1	_	_	O
91	to	_	_	O
92	IVA	_	_	O
93	cervical	_	_	O
94	cancer	_	_	O
95	were	_	_	O
96	randomly	_	_	O
97	assigned	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	UC	_	_	O
101	or	_	_	O
102	4	_	_	O
103	×/weekly	_	_	O
104	individual	_	_	O
105	sessions	_	_	O
106	of	_	_	O
107	either	_	_	O
108	HT	_	_	O
109	or	_	_	O
110	RT	_	_	O
111	immediately	_	_	O
112	following	_	_	O
113	radiation	_	_	O
114	during	_	_	O
115	their	_	_	O
116	6-week	_	_	O
117	chemoradiation	_	_	O
118	treatment	_	_	O
119	.	_	_	O

120	Patients	_	_	O
121	completed	_	_	O
122	psychosocial	_	_	O
123	assessments	_	_	O
124	and	_	_	O
125	blood	_	_	O
126	sampling	_	_	O
127	before	_	_	O
128	chemoradiation	_	_	O
129	at	_	_	O
130	baseline	_	_	O
131	,	_	_	O
132	weeks	_	_	O
133	4	_	_	O
134	and	_	_	O
135	6	_	_	O
136	.	_	_	O

137	Multilevel	_	_	O
138	regression	_	_	O
139	analyses	_	_	O
140	using	_	_	O
141	orthogonal	_	_	O
142	contrasts	_	_	O
143	tested	_	_	O
144	for	_	_	O
145	differences	_	_	O
146	between	_	_	O
147	treatment	_	_	O
148	conditions	_	_	O
149	over	_	_	O
150	time	_	_	O
151	.	_	_	O

152	HT	_	_	B-Premise
153	patients	_	_	I-Premise
154	had	_	_	I-Premise
155	a	_	_	I-Premise
156	minimal	_	_	I-Premise
157	decrease	_	_	I-Premise
158	in	_	_	I-Premise
159	natural	_	_	I-Premise
160	killer	_	_	I-Premise
161	cell	_	_	I-Premise
162	cytotoxicity	_	_	I-Premise
163	(	_	_	I-Premise
164	NKCC	_	_	I-Premise
165	)	_	_	I-Premise
166	over	_	_	I-Premise
167	the	_	_	I-Premise
168	course	_	_	I-Premise
169	of	_	_	I-Premise
170	treatment	_	_	I-Premise
171	whereas	_	_	I-Premise
172	NKCC	_	_	I-Premise
173	of	_	_	I-Premise
174	RT	_	_	I-Premise
175	and	_	_	I-Premise
176	UC	_	_	I-Premise
177	patients	_	_	I-Premise
178	declined	_	_	I-Premise
179	sharply	_	_	I-Premise
180	during	_	_	I-Premise
181	chemoradiation	_	_	I-Premise
182	(	_	_	I-Premise
183	group	_	_	I-Premise
184	by	_	_	I-Premise
185	time	_	_	I-Premise
186	interaction	_	_	I-Premise
187	:	_	_	I-Premise
188	p	_	_	I-Premise
189	=	_	_	I-Premise
190	0.018	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	HT	_	_	B-Premise
194	patients	_	_	I-Premise
195	showed	_	_	I-Premise
196	greater	_	_	I-Premise
197	decreases	_	_	I-Premise
198	in	_	_	I-Premise
199	two	_	_	I-Premise
200	different	_	_	I-Premise
201	indicators	_	_	I-Premise
202	of	_	_	I-Premise
203	depressed	_	_	I-Premise
204	mood	_	_	I-Premise
205	(	_	_	I-Premise
206	CES-D	_	_	I-Premise
207	depressed	_	_	I-Premise
208	mood	_	_	I-Premise
209	subscale	_	_	I-Premise
210	and	_	_	I-Premise
211	POMS	_	_	I-Premise
212	depression	_	_	I-Premise
213	scale	_	_	I-Premise
214	)	_	_	I-Premise
215	compared	_	_	I-Premise
216	to	_	_	I-Premise
217	RT	_	_	I-Premise
218	and	_	_	I-Premise
219	UC	_	_	I-Premise
220	(	_	_	I-Premise
221	group	_	_	I-Premise
222	by	_	_	I-Premise
223	time	_	_	I-Premise
224	interactions	_	_	I-Premise
225	:	_	_	I-Premise
226	p	_	_	I-Premise
227	<	_	_	I-Premise
228	0.05	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	No	_	_	B-Premise
232	between	_	_	I-Premise
233	group	_	_	I-Premise
234	differences	_	_	I-Premise
235	were	_	_	I-Premise
236	observed	_	_	I-Premise
237	in	_	_	I-Premise
238	QOL	_	_	I-Premise
239	,	_	_	I-Premise
240	treatment	_	_	I-Premise
241	delay	_	_	I-Premise
242	,	_	_	I-Premise
243	or	_	_	I-Premise
244	clinically-rated	_	_	I-Premise
245	toxicities	_	_	I-Premise
246	.	_	_	I-Premise

247	HT	_	_	B-Claim
248	may	_	_	I-Claim
249	benefit	_	_	I-Claim
250	cervical	_	_	I-Claim
251	cancer	_	_	I-Claim
252	patients	_	_	I-Claim
253	by	_	_	I-Claim
254	moderating	_	_	I-Claim
255	effects	_	_	I-Claim
256	of	_	_	I-Claim
257	chemoradiation	_	_	I-Claim
258	on	_	_	I-Claim
259	depressed	_	_	I-Claim
260	mood	_	_	I-Claim
261	and	_	_	I-Claim
262	cellular	_	_	I-Claim
263	immunity	_	_	I-Claim
264	.	_	_	I-Claim

265	Effects	_	_	B-Claim
266	of	_	_	I-Claim
267	HT	_	_	I-Claim
268	on	_	_	I-Claim
269	toxicities	_	_	I-Claim
270	,	_	_	I-Claim
271	treatment	_	_	I-Claim
272	delay	_	_	I-Claim
273	,	_	_	I-Claim
274	QOL	_	_	I-Claim
275	,	_	_	I-Claim
276	and	_	_	I-Claim
277	fatigue	_	_	I-Claim
278	were	_	_	I-Claim
279	not	_	_	I-Claim
280	observed	_	_	I-Claim
281	.	_	_	I-Claim

282	Long-term	_	_	O
283	clinical	_	_	O
284	implications	_	_	O
285	of	_	_	O
286	findings	_	_	O
287	are	_	_	O
288	not	_	_	O
289	known	_	_	O
290	.	_	_	O


0	The	_	_	O
1	Australian	_	_	O
2	and	_	_	O
3	New	_	_	O
4	Zealand	_	_	O
5	Germ	_	_	O
6	Cell	_	_	O
7	Trials	_	_	O
8	Group	_	_	O
9	conducted	_	_	O
10	a	_	_	O
11	multicenter	_	_	O
12	randomized	_	_	O
13	phase	_	_	O
14	III	_	_	O
15	trial	_	_	O
16	in	_	_	O
17	men	_	_	O
18	with	_	_	O
19	good-prognosis	_	_	O
20	germ	_	_	O
21	cell	_	_	O
22	tumors	_	_	O
23	of	_	_	O
24	two	_	_	O
25	standard	_	_	O
26	chemotherapy	_	_	O
27	regimens	_	_	O
28	that	_	_	O
29	contained	_	_	O
30	bleomycin	_	_	O
31	,	_	_	O
32	etoposide	_	_	O
33	,	_	_	O
34	and	_	_	O
35	cisplatin	_	_	O
36	but	_	_	O
37	differed	_	_	O
38	in	_	_	O
39	the	_	_	O
40	scheduling	_	_	O
41	and	_	_	O
42	total	_	_	O
43	dose	_	_	O
44	of	_	_	O
45	cisplatin	_	_	O
46	,	_	_	O
47	the	_	_	O
48	total	_	_	O
49	dose	_	_	O
50	of	_	_	O
51	bleomycin	_	_	O
52	,	_	_	O
53	and	_	_	O
54	the	_	_	O
55	scheduling	_	_	O
56	and	_	_	O
57	dose	_	_	O
58	intensity	_	_	O
59	of	_	_	O
60	etoposide	_	_	O
61	.	_	_	O

62	The	_	_	O
63	trial	_	_	O
64	was	_	_	O
65	stopped	_	_	O
66	early	_	_	O
67	at	_	_	O
68	a	_	_	O
69	median	_	_	O
70	follow-up	_	_	O
71	of	_	_	O
72	33	_	_	O
73	months	_	_	O
74	after	_	_	O
75	a	_	_	O
76	planned	_	_	O
77	interim	_	_	O
78	analysis	_	_	O
79	found	_	_	O
80	a	_	_	O
81	survival	_	_	O
82	benefit	_	_	O
83	for	_	_	O
84	the	_	_	O
85	more	_	_	O
86	dose-intense	_	_	O
87	regimen	_	_	O
88	.	_	_	O

89	The	_	_	O
90	aim	_	_	O
91	of	_	_	O
92	this	_	_	O
93	analysis	_	_	O
94	was	_	_	O
95	to	_	_	O
96	determine	_	_	O
97	if	_	_	O
98	this	_	_	O
99	survival	_	_	O
100	benefit	_	_	O
101	was	_	_	O
102	maintained	_	_	O
103	with	_	_	O
104	long-term	_	_	O
105	follow-up	_	_	O
106	.	_	_	O

107	Between	_	_	O
108	February	_	_	O
109	1994	_	_	O
110	and	_	_	O
111	April	_	_	O
112	2000	_	_	O
113	,	_	_	O
114	166	_	_	O
115	men	_	_	O
116	with	_	_	O
117	good-prognosis	_	_	O
118	metastatic	_	_	O
119	germ	_	_	O
120	cell	_	_	O
121	tumors	_	_	O
122	defined	_	_	O
123	by	_	_	O
124	modified	_	_	O
125	Memorial	_	_	O
126	Sloan-Kettering	_	_	O
127	criteria	_	_	O
128	were	_	_	O
129	randomly	_	_	O
130	assigned	_	_	O
131	to	_	_	O
132	receive	_	_	O
133	3B	_	_	O
134	(	_	_	O
135	90	_	_	O
136	)	_	_	O
137	E	_	_	O
138	(	_	_	O
139	500	_	_	O
140	)	_	_	O
141	P	_	_	O
142	(	_	_	O
143	three	_	_	O
144	cycles	_	_	O
145	,	_	_	O
146	repeated	_	_	O
147	every	_	_	O
148	21	_	_	O
149	days	_	_	O
150	,	_	_	O
151	of	_	_	O
152	30	_	_	O
153	kU	_	_	O
154	bleomycin	_	_	O
155	on	_	_	O
156	days	_	_	O
157	1	_	_	O
158	,	_	_	O
159	8	_	_	O
160	,	_	_	O
161	and	_	_	O
162	15	_	_	O
163	;	_	_	O
164	100	_	_	O
165	mg/m	_	_	O
166	(	_	_	O
167	2	_	_	O
168	)	_	_	O
169	etoposide	_	_	O
170	on	_	_	O
171	days	_	_	O
172	1-5	_	_	O
173	;	_	_	O
174	and	_	_	O
175	20	_	_	O
176	mg/m	_	_	O
177	(	_	_	O
178	2	_	_	O
179	)	_	_	O
180	cisplatin	_	_	O
181	on	_	_	O
182	days	_	_	O
183	1-5	_	_	O
184	;	_	_	O
185	n	_	_	O
186	=	_	_	O
187	83	_	_	O
188	)	_	_	O
189	or	_	_	O
190	4B	_	_	O
191	(	_	_	O
192	30	_	_	O
193	)	_	_	O
194	E	_	_	O
195	(	_	_	O
196	360	_	_	O
197	)	_	_	O
198	P	_	_	O
199	(	_	_	O
200	four	_	_	O
201	cycles	_	_	O
202	,	_	_	O
203	repeated	_	_	O
204	every	_	_	O
205	21	_	_	O
206	days	_	_	O
207	,	_	_	O
208	of	_	_	O
209	30	_	_	O
210	kU	_	_	O
211	bleomycin	_	_	O
212	on	_	_	O
213	day	_	_	O
214	1	_	_	O
215	,	_	_	O
216	120	_	_	O
217	mg/m	_	_	O
218	(	_	_	O
219	2	_	_	O
220	)	_	_	O
221	etoposide	_	_	O
222	on	_	_	O
223	days	_	_	O
224	1-3	_	_	O
225	,	_	_	O
226	and	_	_	O
227	100	_	_	O
228	mg/m	_	_	O
229	(	_	_	O
230	2	_	_	O
231	)	_	_	O
232	cisplatin	_	_	O
233	on	_	_	O
234	day	_	_	O
235	1	_	_	O
236	;	_	_	O
237	n	_	_	O
238	=	_	_	O
239	83	_	_	O
240	)	_	_	O
241	.	_	_	O

242	Endpoints	_	_	O
243	included	_	_	O
244	overall	_	_	O
245	survival	_	_	O
246	,	_	_	O
247	progression-free	_	_	O
248	survival	_	_	O
249	,	_	_	O
250	and	_	_	O
251	quality	_	_	O
252	of	_	_	O
253	life	_	_	O
254	and	_	_	O
255	side	_	_	O
256	effects	_	_	O
257	,	_	_	O
258	which	_	_	O
259	were	_	_	O
260	assessed	_	_	O
261	using	_	_	O
262	the	_	_	O
263	Spitzer	_	_	O
264	Quality	_	_	O
265	of	_	_	O
266	Life	_	_	O
267	Index	_	_	O
268	and	_	_	O
269	the	_	_	O
270	GLQ-8	_	_	O
271	,	_	_	O
272	respectively	_	_	O
273	,	_	_	O
274	before	_	_	O
275	random	_	_	O
276	assignment	_	_	O
277	and	_	_	O
278	during	_	_	O
279	and	_	_	O
280	after	_	_	O
281	treatment	_	_	O
282	.	_	_	O

283	All	_	_	O
284	analyses	_	_	O
285	were	_	_	O
286	by	_	_	O
287	intention	_	_	O
288	to	_	_	O
289	treat	_	_	O
290	.	_	_	O

291	All	_	_	O
292	P	_	_	O
293	values	_	_	O
294	are	_	_	O
295	two-sided	_	_	O
296	.	_	_	O

297	The	_	_	O
298	median	_	_	O
299	follow-up	_	_	O
300	was	_	_	O
301	8.5	_	_	O
302	years	_	_	O
303	.	_	_	O

304	All	_	_	O
305	but	_	_	O
306	five	_	_	O
307	survivors	_	_	O
308	(	_	_	O
309	3	_	_	O
310	%	_	_	O
311	)	_	_	O
312	were	_	_	O
313	followed	_	_	O
314	up	_	_	O
315	for	_	_	O
316	at	_	_	O
317	least	_	_	O
318	5	_	_	O
319	years	_	_	O
320	.	_	_	O

321	Overall	_	_	B-Premise
322	survival	_	_	I-Premise
323	remained	_	_	I-Premise
324	better	_	_	I-Premise
325	in	_	_	I-Premise
326	those	_	_	I-Premise
327	assigned	_	_	I-Premise
328	to	_	_	I-Premise
329	3B	_	_	I-Premise
330	(	_	_	I-Premise
331	90	_	_	I-Premise
332	)	_	_	I-Premise
333	E	_	_	I-Premise
334	(	_	_	I-Premise
335	500	_	_	I-Premise
336	)	_	_	I-Premise
337	P	_	_	I-Premise
338	than	_	_	I-Premise
339	in	_	_	I-Premise
340	those	_	_	I-Premise
341	assigned	_	_	I-Premise
342	to	_	_	I-Premise
343	4B	_	_	I-Premise
344	(	_	_	I-Premise
345	30	_	_	I-Premise
346	)	_	_	I-Premise
347	E	_	_	I-Premise
348	(	_	_	I-Premise
349	360	_	_	I-Premise
350	)	_	_	I-Premise
351	P	_	_	I-Premise
352	(	_	_	I-Premise
353	8-year	_	_	I-Premise
354	survival	_	_	I-Premise
355	:	_	_	I-Premise
356	92	_	_	I-Premise
357	%	_	_	I-Premise
358	vs	_	_	I-Premise
359	83	_	_	I-Premise
360	%	_	_	I-Premise
361	;	_	_	I-Premise
362	hazard	_	_	I-Premise
363	ratio	_	_	I-Premise
364	of	_	_	I-Premise
365	death	_	_	I-Premise
366	=	_	_	I-Premise
367	0.38	_	_	I-Premise
368	,	_	_	I-Premise
369	95	_	_	I-Premise
370	%	_	_	I-Premise
371	confidence	_	_	I-Premise
372	interval	_	_	I-Premise
373	=	_	_	I-Premise
374	0.15	_	_	I-Premise
375	to	_	_	I-Premise
376	0.97	_	_	I-Premise
377	,	_	_	I-Premise
378	P	_	_	I-Premise
379	=	_	_	I-Premise
380	.037	_	_	I-Premise
381	)	_	_	I-Premise
382	.	_	_	I-Premise

383	Progression-free	_	_	B-Premise
384	survival	_	_	I-Premise
385	favored	_	_	I-Premise
386	3B	_	_	I-Premise
387	(	_	_	I-Premise
388	90	_	_	I-Premise
389	)	_	_	I-Premise
390	E	_	_	I-Premise
391	(	_	_	I-Premise
392	500	_	_	I-Premise
393	)	_	_	I-Premise
394	P	_	_	I-Premise
395	but	_	_	I-Premise
396	was	_	_	I-Premise
397	not	_	_	I-Premise
398	statistically	_	_	I-Premise
399	significantly	_	_	I-Premise
400	different	_	_	I-Premise
401	between	_	_	I-Premise
402	the	_	_	I-Premise
403	treatment	_	_	I-Premise
404	groups	_	_	I-Premise
405	(	_	_	I-Premise
406	8-year	_	_	I-Premise
407	progression-free	_	_	I-Premise
408	survival	_	_	I-Premise
409	,	_	_	I-Premise
410	3B	_	_	I-Premise
411	(	_	_	I-Premise
412	90	_	_	I-Premise
413	)	_	_	I-Premise
414	E	_	_	I-Premise
415	(	_	_	I-Premise
416	500	_	_	I-Premise
417	)	_	_	I-Premise
418	P	_	_	I-Premise
419	vs	_	_	I-Premise
420	4B	_	_	I-Premise
421	(	_	_	I-Premise
422	30	_	_	I-Premise
423	)	_	_	I-Premise
424	E	_	_	I-Premise
425	(	_	_	I-Premise
426	360	_	_	I-Premise
427	)	_	_	I-Premise
428	P	_	_	I-Premise
429	:	_	_	I-Premise
430	86	_	_	I-Premise
431	%	_	_	I-Premise
432	vs	_	_	I-Premise
433	79	_	_	I-Premise
434	%	_	_	I-Premise
435	;	_	_	I-Premise
436	hazard	_	_	I-Premise
437	ratio	_	_	I-Premise
438	of	_	_	I-Premise
439	progression	_	_	I-Premise
440	=	_	_	I-Premise
441	0.6	_	_	I-Premise
442	,	_	_	I-Premise
443	95	_	_	I-Premise
444	%	_	_	I-Premise
445	confidence	_	_	I-Premise
446	interval	_	_	I-Premise
447	=	_	_	I-Premise
448	0.3	_	_	I-Premise
449	to	_	_	I-Premise
450	1.1	_	_	I-Premise
451	,	_	_	I-Premise
452	P	_	_	I-Premise
453	=	_	_	I-Premise
454	.15	_	_	I-Premise
455	)	_	_	I-Premise
456	.	_	_	I-Premise

457	At	_	_	B-Claim
458	the	_	_	I-Claim
459	end	_	_	I-Claim
460	of	_	_	I-Claim
461	treatment	_	_	I-Claim
462	,	_	_	I-Claim
463	average	_	_	I-Claim
464	scores	_	_	I-Claim
465	for	_	_	I-Claim
466	most	_	_	I-Claim
467	side	_	_	I-Claim
468	effect	_	_	I-Claim
469	scales	_	_	I-Claim
470	favored	_	_	I-Claim
471	3B	_	_	I-Claim
472	(	_	_	I-Claim
473	90	_	_	I-Claim
474	)	_	_	I-Claim
475	E	_	_	I-Claim
476	(	_	_	I-Claim
477	500	_	_	I-Claim
478	)	_	_	I-Claim
479	P.	_	_	I-Claim
480	After	_	_	B-Premise
481	the	_	_	I-Premise
482	completion	_	_	I-Premise
483	of	_	_	I-Premise
484	treatment	_	_	I-Premise
485	,	_	_	I-Premise
486	average	_	_	I-Premise
487	GLQ-8	_	_	I-Premise
488	scores	_	_	I-Premise
489	for	_	_	I-Premise
490	numbness	_	_	I-Premise
491	(	_	_	I-Premise
492	P	_	_	I-Premise
493	=	_	_	I-Premise
494	.003	_	_	I-Premise
495	)	_	_	I-Premise
496	and	_	_	I-Premise
497	hair	_	_	I-Premise
498	loss	_	_	I-Premise
499	(	_	_	I-Premise
500	P	_	_	I-Premise
501	=	_	_	I-Premise
502	.04	_	_	I-Premise
503	)	_	_	I-Premise
504	and	_	_	I-Premise
505	the	_	_	I-Premise
506	Spitzer	_	_	I-Premise
507	Quality	_	_	I-Premise
508	of	_	_	I-Premise
509	Life	_	_	I-Premise
510	Index	_	_	I-Premise
511	(	_	_	I-Premise
512	P	_	_	I-Premise
513	=	_	_	I-Premise
514	.05	_	_	I-Premise
515	)	_	_	I-Premise
516	favored	_	_	I-Premise
517	3B	_	_	I-Premise
518	(	_	_	I-Premise
519	90	_	_	I-Premise
520	)	_	_	I-Premise
521	E	_	_	I-Premise
522	(	_	_	I-Premise
523	500	_	_	I-Premise
524	)	_	_	I-Premise
525	P.	_	_	I-Premise
526	The	_	_	B-Claim
527	survival	_	_	I-Claim
528	benefit	_	_	I-Claim
529	of	_	_	I-Claim
530	3B	_	_	I-Claim
531	(	_	_	I-Claim
532	90	_	_	I-Claim
533	)	_	_	I-Claim
534	E	_	_	I-Claim
535	(	_	_	I-Claim
536	500	_	_	I-Claim
537	)	_	_	I-Claim
538	P	_	_	I-Claim
539	over	_	_	I-Claim
540	4B	_	_	I-Claim
541	(	_	_	I-Claim
542	30	_	_	I-Claim
543	)	_	_	I-Claim
544	E	_	_	I-Claim
545	(	_	_	I-Claim
546	360	_	_	I-Claim
547	)	_	_	I-Claim
548	P	_	_	I-Claim
549	was	_	_	I-Claim
550	maintained	_	_	I-Claim
551	with	_	_	I-Claim
552	long-term	_	_	I-Claim
553	follow-up	_	_	I-Claim
554	.	_	_	I-Claim


0	Research	_	_	O
1	suggests	_	_	O
2	that	_	_	O
3	cancer	_	_	O
4	rehabilitation	_	_	O
5	reduces	_	_	O
6	fatigue	_	_	O
7	in	_	_	O
8	survivors	_	_	O
9	of	_	_	O
10	cancer	_	_	O
11	.	_	_	O

12	To	_	_	O
13	date	_	_	O
14	,	_	_	O
15	it	_	_	O
16	is	_	_	O
17	unclear	_	_	O
18	what	_	_	O
19	type	_	_	O
20	of	_	_	O
21	rehabilitation	_	_	O
22	is	_	_	O
23	most	_	_	O
24	beneficial	_	_	O
25	.	_	_	O

26	This	_	_	O
27	randomized	_	_	O
28	controlled	_	_	O
29	trial	_	_	O
30	compared	_	_	O
31	the	_	_	O
32	effect	_	_	O
33	on	_	_	O
34	cancer-related	_	_	O
35	fatigue	_	_	O
36	of	_	_	O
37	physical	_	_	O
38	training	_	_	O
39	combined	_	_	O
40	with	_	_	O
41	cognitive	_	_	O
42	behavioral	_	_	O
43	therapy	_	_	O
44	with	_	_	O
45	physical	_	_	O
46	training	_	_	O
47	alone	_	_	O
48	and	_	_	O
49	with	_	_	O
50	no	_	_	O
51	intervention	_	_	O
52	.	_	_	O

53	In	_	_	O
54	this	_	_	O
55	multicenter	_	_	O
56	randomized	_	_	O
57	controlled	_	_	O
58	trial	_	_	O
59	,	_	_	O
60	147	_	_	O
61	survivors	_	_	O
62	of	_	_	O
63	cancer	_	_	O
64	were	_	_	O
65	randomly	_	_	O
66	assigned	_	_	O
67	to	_	_	O
68	a	_	_	O
69	group	_	_	O
70	that	_	_	O
71	received	_	_	O
72	physical	_	_	O
73	training	_	_	O
74	combined	_	_	O
75	with	_	_	O
76	cognitive-behavioral	_	_	O
77	therapy	_	_	O
78	(	_	_	O
79	PT+CBT	_	_	O
80	group	_	_	O
81	,	_	_	O
82	n=76	_	_	O
83	)	_	_	O
84	or	_	_	O
85	to	_	_	O
86	a	_	_	O
87	group	_	_	O
88	that	_	_	O
89	received	_	_	O
90	physical	_	_	O
91	training	_	_	O
92	alone	_	_	O
93	(	_	_	O
94	PT	_	_	O
95	group	_	_	O
96	,	_	_	O
97	n=71	_	_	O
98	)	_	_	O
99	.	_	_	O

100	In	_	_	O
101	addition	_	_	O
102	,	_	_	O
103	a	_	_	O
104	nonintervention	_	_	O
105	control	_	_	O
106	group	_	_	O
107	(	_	_	O
108	WLC	_	_	O
109	group	_	_	O
110	)	_	_	O
111	consisting	_	_	O
112	of	_	_	O
113	62	_	_	O
114	survivors	_	_	O
115	of	_	_	O
116	cancer	_	_	O
117	who	_	_	O
118	were	_	_	O
119	on	_	_	O
120	the	_	_	O
121	waiting	_	_	O
122	lists	_	_	O
123	of	_	_	O
124	rehabilitation	_	_	O
125	centers	_	_	O
126	elsewhere	_	_	O
127	was	_	_	O
128	included	_	_	O
129	.	_	_	O

130	The	_	_	O
131	study	_	_	O
132	was	_	_	O
133	conducted	_	_	O
134	at	_	_	O
135	4	_	_	O
136	rehabilitation	_	_	O
137	centers	_	_	O
138	in	_	_	O
139	the	_	_	O
140	Netherlands	_	_	O
141	.	_	_	O

142	All	_	_	O
143	patients	_	_	O
144	were	_	_	O
145	survivors	_	_	O
146	of	_	_	O
147	cancer	_	_	O
148	.	_	_	O

149	Physical	_	_	O
150	training	_	_	O
151	consisting	_	_	O
152	of	_	_	O
153	2	_	_	O
154	hours	_	_	O
155	of	_	_	O
156	individual	_	_	O
157	training	_	_	O
158	and	_	_	O
159	group	_	_	O
160	sports	_	_	O
161	took	_	_	O
162	place	_	_	O
163	twice	_	_	O
164	weekly	_	_	O
165	,	_	_	O
166	and	_	_	O
167	cognitive-behavioral	_	_	O
168	therapy	_	_	O
169	took	_	_	O
170	place	_	_	O
171	once	_	_	O
172	weekly	_	_	O
173	for	_	_	O
174	2	_	_	O
175	hours	_	_	O
176	.	_	_	O

177	Fatigue	_	_	O
178	was	_	_	O
179	assessed	_	_	O
180	with	_	_	O
181	the	_	_	O
182	Multidimensional	_	_	O
183	Fatigue	_	_	O
184	Inventory	_	_	O
185	before	_	_	O
186	and	_	_	O
187	immediately	_	_	O
188	after	_	_	O
189	intervention	_	_	O
190	(	_	_	O
191	12	_	_	O
192	weeks	_	_	O
193	after	_	_	O
194	enrollment	_	_	O
195	)	_	_	O
196	.	_	_	O

197	The	_	_	O
198	WLC	_	_	O
199	group	_	_	O
200	completed	_	_	O
201	questionnaires	_	_	O
202	at	_	_	O
203	the	_	_	O
204	same	_	_	O
205	time	_	_	O
206	points	_	_	O
207	.	_	_	O

208	Baseline	_	_	O
209	fatigue	_	_	O
210	did	_	_	O
211	not	_	_	O
212	differ	_	_	O
213	significantly	_	_	O
214	among	_	_	O
215	the	_	_	O
216	3	_	_	O
217	groups	_	_	O
218	.	_	_	O

219	Over	_	_	B-Premise
220	time	_	_	I-Premise
221	,	_	_	I-Premise
222	levels	_	_	I-Premise
223	of	_	_	I-Premise
224	fatigue	_	_	I-Premise
225	significantly	_	_	I-Premise
226	decreased	_	_	I-Premise
227	in	_	_	I-Premise
228	all	_	_	I-Premise
229	domains	_	_	I-Premise
230	in	_	_	I-Premise
231	all	_	_	I-Premise
232	groups	_	_	I-Premise
233	,	_	_	I-Premise
234	except	_	_	B-Premise
235	in	_	_	I-Premise
236	mental	_	_	I-Premise
237	fatigue	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	WLC	_	_	I-Premise
241	group	_	_	I-Premise
242	.	_	_	I-Premise

243	Analyses	_	_	B-Premise
244	of	_	_	I-Premise
245	variance	_	_	I-Premise
246	of	_	_	I-Premise
247	postintervention	_	_	I-Premise
248	fatigue	_	_	I-Premise
249	showed	_	_	I-Premise
250	statistically	_	_	I-Premise
251	significant	_	_	I-Premise
252	group	_	_	I-Premise
253	effects	_	_	I-Premise
254	on	_	_	I-Premise
255	general	_	_	I-Premise
256	fatigue	_	_	I-Premise
257	,	_	_	I-Premise
258	on	_	_	I-Premise
259	physical	_	_	I-Premise
260	and	_	_	I-Premise
261	mental	_	_	I-Premise
262	fatigue	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	on	_	_	I-Premise
266	reduced	_	_	I-Premise
267	activation	_	_	I-Premise
268	but	_	_	I-Premise
269	not	_	_	I-Premise
270	on	_	_	I-Premise
271	reduced	_	_	I-Premise
272	motivation	_	_	I-Premise
273	.	_	_	I-Premise

274	Compared	_	_	B-Premise
275	with	_	_	I-Premise
276	the	_	_	I-Premise
277	WLC	_	_	I-Premise
278	group	_	_	I-Premise
279	,	_	_	I-Premise
280	the	_	_	I-Premise
281	PT	_	_	I-Premise
282	group	_	_	I-Premise
283	reported	_	_	I-Premise
284	significantly	_	_	I-Premise
285	greater	_	_	I-Premise
286	decline	_	_	I-Premise
287	in	_	_	I-Premise
288	4	_	_	I-Premise
289	domains	_	_	I-Premise
290	of	_	_	I-Premise
291	fatigue	_	_	I-Premise
292	,	_	_	I-Premise
293	whereas	_	_	I-Premise
294	the	_	_	I-Premise
295	PT+CBT	_	_	I-Premise
296	group	_	_	I-Premise
297	reported	_	_	I-Premise
298	significantly	_	_	I-Premise
299	greater	_	_	I-Premise
300	decline	_	_	I-Premise
301	in	_	_	I-Premise
302	physical	_	_	I-Premise
303	fatigue	_	_	I-Premise
304	only	_	_	I-Premise
305	.	_	_	I-Premise

306	No	_	_	B-Premise
307	significant	_	_	I-Premise
308	differences	_	_	I-Premise
309	in	_	_	I-Premise
310	decline	_	_	I-Premise
311	in	_	_	I-Premise
312	fatigue	_	_	I-Premise
313	were	_	_	I-Premise
314	found	_	_	I-Premise
315	between	_	_	I-Premise
316	the	_	_	I-Premise
317	PT+CBT	_	_	I-Premise
318	and	_	_	I-Premise
319	PT	_	_	I-Premise
320	groups	_	_	I-Premise
321	.	_	_	I-Premise

322	Physical	_	_	B-Premise
323	training	_	_	I-Premise
324	combined	_	_	I-Premise
325	with	_	_	I-Premise
326	cognitive-behavioral	_	_	I-Premise
327	therapy	_	_	I-Premise
328	and	_	_	I-Premise
329	physical	_	_	I-Premise
330	training	_	_	I-Premise
331	alone	_	_	I-Premise
332	had	_	_	I-Premise
333	significant	_	_	I-Premise
334	and	_	_	I-Premise
335	beneficial	_	_	I-Premise
336	effects	_	_	I-Premise
337	on	_	_	I-Premise
338	fatigue	_	_	I-Premise
339	compared	_	_	I-Premise
340	with	_	_	I-Premise
341	no	_	_	I-Premise
342	intervention	_	_	I-Premise
343	.	_	_	I-Premise

344	Physical	_	_	B-Claim
345	training	_	_	I-Claim
346	was	_	_	I-Claim
347	equally	_	_	I-Claim
348	effective	_	_	I-Claim
349	as	_	_	I-Claim
350	or	_	_	I-Claim
351	more	_	_	I-Claim
352	effective	_	_	I-Claim
353	than	_	_	I-Claim
354	physical	_	_	I-Claim
355	training	_	_	I-Claim
356	combined	_	_	I-Claim
357	with	_	_	I-Claim
358	cognitive-behavioral	_	_	I-Claim
359	therapy	_	_	I-Claim
360	in	_	_	I-Claim
361	reducing	_	_	I-Claim
362	cancer-related	_	_	I-Claim
363	fatigue	_	_	I-Claim
364	,	_	_	I-Claim
365	suggesting	_	_	O
366	that	_	_	O
367	cognitive-behavioral	_	_	B-Claim
368	therapy	_	_	I-Claim
369	did	_	_	I-Claim
370	not	_	_	I-Claim
371	have	_	_	I-Claim
372	additional	_	_	I-Claim
373	beneficial	_	_	I-Claim
374	effects	_	_	I-Claim
375	beyond	_	_	I-Claim
376	the	_	_	I-Claim
377	benefits	_	_	I-Claim
378	of	_	_	I-Claim
379	physical	_	_	I-Claim
380	training	_	_	I-Claim
381	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	effects	_	_	O
10	on	_	_	O
11	health-related	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	(	_	_	O
16	HRQOL	_	_	O
17	)	_	_	O
18	of	_	_	O
19	two	_	_	O
20	treatment	_	_	O
21	regimens	_	_	O
22	in	_	_	O
23	the	_	_	O
24	TEX	_	_	O
25	trial	_	_	O
26	during	_	_	O
27	9	_	_	O
28	month	_	_	O
29	from	_	_	O
30	random	_	_	O
31	assignment	_	_	O
32	,	_	_	O
33	with	_	_	O
34	emphasis	_	_	O
35	on	_	_	O
36	the	_	_	O
37	2-	_	_	O
38	and	_	_	O
39	9-months	_	_	O
40	assessments	_	_	O
41	.	_	_	O

42	A	_	_	O
43	total	_	_	O
44	of	_	_	O
45	287	_	_	O
46	patients	_	_	O
47	were	_	_	O
48	randomized	_	_	O
49	to	_	_	O
50	treatment	_	_	O
51	in	_	_	O
52	3-week	_	_	O
53	cycles	_	_	O
54	with	_	_	O
55	either	_	_	O
56	epirubicin	_	_	O
57	plus	_	_	O
58	paclitaxel	_	_	O
59	(	_	_	O
60	ET	_	_	O
61	,	_	_	O
62	143	_	_	O
63	patients	_	_	O
64	)	_	_	O
65	,	_	_	O
66	or	_	_	O
67	epirubicin	_	_	O
68	,	_	_	O
69	paclitaxel	_	_	O
70	and	_	_	O
71	capecitabine	_	_	O
72	(	_	_	O
73	TEX	_	_	O
74	,	_	_	O
75	144	_	_	O
76	patients	_	_	O
77	)	_	_	O
78	.	_	_	O

79	HRQOL	_	_	O
80	was	_	_	O
81	assessed	_	_	O
82	by	_	_	O
83	the	_	_	O
84	EORTC-QLQ	_	_	O
85	C30	_	_	O
86	and	_	_	O
87	EORTC	_	_	O
88	QLQ-BR23	_	_	O
89	questionnaires	_	_	O
90	at	_	_	O
91	five	_	_	O
92	points	_	_	O
93	during	_	_	O
94	9	_	_	O
95	months	_	_	O
96	.	_	_	O

97	A	_	_	O
98	total	_	_	O
99	of	_	_	O
100	252	_	_	O
101	(	_	_	O
102	88	_	_	O
103	%	_	_	O
104	)	_	_	O
105	completed	_	_	O
106	questionnaires	_	_	O
107	before	_	_	O
108	randomization	_	_	O
109	.	_	_	O

110	Response	_	_	O
111	rate	_	_	O
112	for	_	_	O
113	the	_	_	O
114	following	_	_	O
115	assessments	_	_	O
116	was	_	_	O
117	>	_	_	O
118	75	_	_	O
119	%	_	_	O
120	.	_	_	O

121	There	_	_	B-Premise
122	were	_	_	I-Premise
123	no	_	_	I-Premise
124	statistically	_	_	I-Premise
125	significant	_	_	I-Premise
126	differences	_	_	I-Premise
127	between	_	_	I-Premise
128	the	_	_	I-Premise
129	TEX	_	_	I-Premise
130	group	_	_	I-Premise
131	and	_	_	I-Premise
132	the	_	_	I-Premise
133	ET	_	_	I-Premise
134	group	_	_	I-Premise
135	on	_	_	I-Premise
136	any	_	_	I-Premise
137	of	_	_	I-Premise
138	the	_	_	I-Premise
139	subscales	_	_	I-Premise
140	2	_	_	I-Premise
141	months	_	_	I-Premise
142	after	_	_	I-Premise
143	randomization	_	_	I-Premise
144	.	_	_	I-Premise

145	Small	_	_	B-Premise
146	clinical	_	_	I-Premise
147	differences	_	_	I-Premise
148	(	_	_	I-Premise
149	5-10	_	_	I-Premise
150	points	_	_	I-Premise
151	)	_	_	I-Premise
152	in	_	_	I-Premise
153	favor	_	_	I-Premise
154	of	_	_	I-Premise
155	the	_	_	I-Premise
156	ET	_	_	I-Premise
157	group	_	_	I-Premise
158	were	_	_	I-Premise
159	found	_	_	I-Premise
160	for	_	_	I-Premise
161	global	_	_	I-Premise
162	quality	_	_	I-Premise
163	of	_	_	I-Premise
164	life	_	_	I-Premise
165	,	_	_	I-Premise
166	role	_	_	I-Premise
167	functioning	_	_	I-Premise
168	,	_	_	I-Premise
169	social	_	_	I-Premise
170	functioning	_	_	I-Premise
171	,	_	_	I-Premise
172	and	_	_	I-Premise
173	insomnia	_	_	I-Premise
174	.	_	_	I-Premise

175	At	_	_	B-Premise
176	the	_	_	I-Premise
177	9-months	_	_	I-Premise
178	assessment	_	_	I-Premise
179	,	_	_	I-Premise
180	the	_	_	I-Premise
181	TEX	_	_	I-Premise
182	group	_	_	I-Premise
183	scored	_	_	I-Premise
184	statistically	_	_	I-Premise
185	significantly	_	_	I-Premise
186	higher	_	_	I-Premise
187	on	_	_	I-Premise
188	global	_	_	I-Premise
189	quality	_	_	I-Premise
190	of	_	_	I-Premise
191	life	_	_	I-Premise
192	and	_	_	I-Premise
193	physical	_	_	I-Premise
194	functioning	_	_	I-Premise
195	.	_	_	I-Premise

196	Small	_	_	B-Premise
197	clinically	_	_	I-Premise
198	significant	_	_	I-Premise
199	differences	_	_	I-Premise
200	were	_	_	I-Premise
201	found	_	_	I-Premise
202	for	_	_	I-Premise
203	global	_	_	I-Premise
204	quality	_	_	I-Premise
205	of	_	_	I-Premise
206	life	_	_	I-Premise
207	,	_	_	I-Premise
208	physical	_	_	I-Premise
209	functioning	_	_	I-Premise
210	,	_	_	I-Premise
211	role	_	_	I-Premise
212	functioning	_	_	I-Premise
213	,	_	_	I-Premise
214	emotional	_	_	I-Premise
215	functioning	_	_	I-Premise
216	,	_	_	I-Premise
217	dyspnoea	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	insomnia	_	_	I-Premise
221	,	_	_	I-Premise
222	all	_	_	I-Premise
223	in	_	_	I-Premise
224	favour	_	_	I-Premise
225	of	_	_	I-Premise
226	the	_	_	I-Premise
227	TEX	_	_	I-Premise
228	group	_	_	I-Premise
229	.	_	_	I-Premise

230	At	_	_	B-Claim
231	the	_	_	I-Claim
232	2-months	_	_	I-Claim
233	assessment	_	_	I-Claim
234	,	_	_	I-Claim
235	when	_	_	I-Claim
236	side-effects	_	_	I-Claim
237	of	_	_	I-Claim
238	chemotherapy	_	_	I-Claim
239	were	_	_	I-Claim
240	present	_	_	I-Claim
241	,	_	_	I-Claim
242	patients	_	_	I-Claim
243	in	_	_	I-Claim
244	the	_	_	I-Claim
245	TEX	_	_	I-Claim
246	group	_	_	I-Claim
247	appeared	_	_	I-Claim
248	to	_	_	I-Claim
249	fare	_	_	I-Claim
250	a	_	_	I-Claim
251	bit	_	_	I-Claim
252	worse	_	_	I-Claim
253	than	_	_	I-Claim
254	those	_	_	I-Claim
255	receiving	_	_	I-Claim
256	ET	_	_	I-Claim
257	.	_	_	I-Claim

258	However	_	_	O
259	,	_	_	O
260	after	_	_	B-Claim
261	9	_	_	I-Claim
262	months	_	_	I-Claim
263	,	_	_	I-Claim
264	when	_	_	I-Claim
265	the	_	_	I-Claim
266	patients	_	_	I-Claim
267	had	_	_	I-Claim
268	adapted	_	_	I-Claim
269	to	_	_	I-Claim
270	treatment	_	_	I-Claim
271	,	_	_	I-Claim
272	the	_	_	I-Claim
273	TEX	_	_	I-Claim
274	group	_	_	I-Claim
275	seemed	_	_	I-Claim
276	to	_	_	I-Claim
277	have	_	_	I-Claim
278	a	_	_	I-Claim
279	slightly	_	_	I-Claim
280	better	_	_	I-Claim
281	quality	_	_	I-Claim
282	of	_	_	I-Claim
283	life	_	_	I-Claim
284	.	_	_	I-Claim


0	One	_	_	O
1	attempt	_	_	O
2	to	_	_	O
3	improve	_	_	O
4	long-term	_	_	O
5	survival	_	_	O
6	in	_	_	O
7	patients	_	_	O
8	with	_	_	O
9	advanced	_	_	O
10	ovarian	_	_	O
11	cancer	_	_	O
12	was	_	_	O
13	thought	_	_	O
14	to	_	_	O
15	be	_	_	O
16	the	_	_	O
17	addition	_	_	O
18	of	_	_	O
19	more	_	_	O
20	non-cross-resistant	_	_	O
21	drugs	_	_	O
22	to	_	_	O
23	platinum-paclitaxel	_	_	O
24	combination	_	_	O
25	regimens	_	_	O
26	.	_	_	O

27	Gemcitabine	_	_	O
28	was	_	_	O
29	among	_	_	O
30	the	_	_	O
31	candidates	_	_	O
32	for	_	_	O
33	a	_	_	O
34	third	_	_	O
35	drug	_	_	O
36	.	_	_	O

37	We	_	_	O
38	performed	_	_	O
39	a	_	_	O
40	prospective	_	_	O
41	,	_	_	O
42	randomized	_	_	O
43	,	_	_	O
44	phase	_	_	O
45	III	_	_	O
46	,	_	_	O
47	intergroup	_	_	O
48	trial	_	_	O
49	to	_	_	O
50	compare	_	_	O
51	carboplatin	_	_	O
52	plus	_	_	O
53	paclitaxel	_	_	O
54	(	_	_	O
55	TC	_	_	O
56	;	_	_	O
57	area	_	_	O
58	under	_	_	O
59	the	_	_	O
60	curve	_	_	O
61	[	_	_	O
62	AUC	_	_	O
63	]	_	_	O
64	5	_	_	O
65	and	_	_	O
66	175	_	_	O
67	mg/m	_	_	O
68	(	_	_	O
69	2	_	_	O
70	)	_	_	O
71	,	_	_	O
72	respectively	_	_	O
73	)	_	_	O
74	with	_	_	O
75	the	_	_	O
76	same	_	_	O
77	combination	_	_	O
78	and	_	_	O
79	additional	_	_	O
80	gemcitabine	_	_	O
81	800	_	_	O
82	mg/m	_	_	O
83	(	_	_	O
84	2	_	_	O
85	)	_	_	O
86	on	_	_	O
87	days	_	_	O
88	1	_	_	O
89	and	_	_	O
90	8	_	_	O
91	(	_	_	O
92	TCG	_	_	O
93	)	_	_	O
94	in	_	_	O
95	previously	_	_	O
96	untreated	_	_	O
97	patients	_	_	O
98	with	_	_	O
99	advanced	_	_	O
100	epithelial	_	_	O
101	ovarian	_	_	O
102	cancer	_	_	O
103	.	_	_	O

104	TC	_	_	O
105	was	_	_	O
106	administered	_	_	O
107	intravenously	_	_	O
108	(	_	_	O
109	IV	_	_	O
110	)	_	_	O
111	on	_	_	O
112	day	_	_	O
113	1	_	_	O
114	every	_	_	O
115	21	_	_	O
116	days	_	_	O
117	for	_	_	O
118	a	_	_	O
119	planned	_	_	O
120	minimum	_	_	O
121	of	_	_	O
122	six	_	_	O
123	courses	_	_	O
124	.	_	_	O

125	Gemcitabine	_	_	O
126	was	_	_	O
127	administered	_	_	O
128	by	_	_	O
129	IV	_	_	O
130	on	_	_	O
131	days	_	_	O
132	1	_	_	O
133	and	_	_	O
134	8	_	_	O
135	of	_	_	O
136	each	_	_	O
137	cycle	_	_	O
138	in	_	_	O
139	the	_	_	O
140	TCG	_	_	O
141	arm	_	_	O
142	.	_	_	O

143	Between	_	_	O
144	2002	_	_	O
145	and	_	_	O
146	2004	_	_	O
147	,	_	_	O
148	1,742	_	_	O
149	patients	_	_	O
150	were	_	_	O
151	randomly	_	_	O
152	assigned	_	_	O
153	;	_	_	O
154	882	_	_	O
155	and	_	_	O
156	860	_	_	O
157	patients	_	_	O
158	received	_	_	O
159	TC	_	_	O
160	and	_	_	O
161	TCG	_	_	O
162	,	_	_	O
163	respectively	_	_	O
164	.	_	_	O

165	Grades	_	_	B-Premise
166	3	_	_	I-Premise
167	to	_	_	I-Premise
168	4	_	_	I-Premise
169	hematologic	_	_	I-Premise
170	toxicity	_	_	I-Premise
171	and	_	_	I-Premise
172	fatigue	_	_	I-Premise
173	occurred	_	_	I-Premise
174	more	_	_	I-Premise
175	frequently	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	TCG	_	_	I-Premise
179	arm	_	_	I-Premise
180	.	_	_	I-Premise

181	Accordingly	_	_	O
182	,	_	_	O
183	quality-of-life	_	_	B-Claim
184	analysis	_	_	I-Claim
185	during	_	_	I-Claim
186	chemotherapy	_	_	I-Claim
187	showed	_	_	I-Claim
188	a	_	_	I-Claim
189	disadvantage	_	_	I-Claim
190	in	_	_	I-Claim
191	the	_	_	I-Claim
192	TCG	_	_	I-Claim
193	arm	_	_	I-Claim
194	.	_	_	I-Claim

195	Although	_	_	B-Premise
196	objective	_	_	I-Premise
197	response	_	_	I-Premise
198	was	_	_	I-Premise
199	slightly	_	_	I-Premise
200	higher	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	TCG	_	_	I-Premise
204	arm	_	_	I-Premise
205	,	_	_	I-Premise
206	this	_	_	B-Premise
207	did	_	_	I-Premise
208	not	_	_	I-Premise
209	translate	_	_	I-Premise
210	into	_	_	I-Premise
211	improved	_	_	I-Premise
212	progression-free	_	_	I-Premise
213	survival	_	_	I-Premise
214	(	_	_	I-Premise
215	PFS	_	_	I-Premise
216	)	_	_	I-Premise
217	or	_	_	I-Premise
218	overall	_	_	I-Premise
219	survival	_	_	I-Premise
220	(	_	_	I-Premise
221	OS	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	Median	_	_	B-Premise
225	PFS	_	_	I-Premise
226	was	_	_	I-Premise
227	17.8	_	_	I-Premise
228	months	_	_	I-Premise
229	for	_	_	I-Premise
230	the	_	_	I-Premise
231	TCG	_	_	I-Premise
232	arm	_	_	I-Premise
233	and	_	_	I-Premise
234	19.3	_	_	I-Premise
235	months	_	_	I-Premise
236	for	_	_	I-Premise
237	the	_	_	I-Premise
238	TC	_	_	I-Premise
239	arm	_	_	I-Premise
240	(	_	_	I-Premise
241	hazard	_	_	I-Premise
242	ratio	_	_	I-Premise
243	[	_	_	I-Premise
244	HR	_	_	I-Premise
245	]	_	_	I-Premise
246	,	_	_	I-Premise
247	1.18	_	_	I-Premise
248	;	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	,	_	_	I-Premise
253	1.06	_	_	I-Premise
254	to	_	_	I-Premise
255	1.32	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=	_	_	I-Premise
259	.0044	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Median	_	_	B-Premise
263	OS	_	_	I-Premise
264	was	_	_	I-Premise
265	49.5	_	_	I-Premise
266	for	_	_	I-Premise
267	the	_	_	I-Premise
268	TCG	_	_	I-Premise
269	arm	_	_	I-Premise
270	and	_	_	I-Premise
271	51.5	_	_	I-Premise
272	months	_	_	I-Premise
273	for	_	_	I-Premise
274	the	_	_	I-Premise
275	TC	_	_	I-Premise
276	arm	_	_	I-Premise
277	(	_	_	I-Premise
278	HR	_	_	I-Premise
279	,	_	_	I-Premise
280	1.05	_	_	I-Premise
281	;	_	_	I-Premise
282	95	_	_	I-Premise
283	%	_	_	I-Premise
284	CI	_	_	I-Premise
285	,	_	_	I-Premise
286	0.91	_	_	I-Premise
287	to	_	_	I-Premise
288	1.20	_	_	I-Premise
289	;	_	_	I-Premise
290	P	_	_	I-Premise
291	=	_	_	I-Premise
292	.5106	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Claim
296	addition	_	_	I-Claim
297	of	_	_	I-Claim
298	gemcitabine	_	_	I-Claim
299	to	_	_	I-Claim
300	carboplatin	_	_	I-Claim
301	plus	_	_	I-Claim
302	paclitaxel	_	_	I-Claim
303	increased	_	_	I-Claim
304	treatment	_	_	I-Claim
305	burden	_	_	I-Claim
306	,	_	_	I-Claim
307	reduced	_	_	I-Claim
308	PFS	_	_	I-Claim
309	time	_	_	I-Claim
310	,	_	_	I-Claim
311	and	_	_	I-Claim
312	did	_	_	I-Claim
313	not	_	_	I-Claim
314	improve	_	_	I-Claim
315	OS	_	_	I-Claim
316	in	_	_	I-Claim
317	patients	_	_	I-Claim
318	with	_	_	I-Claim
319	advanced	_	_	I-Claim
320	epithelial	_	_	I-Claim
321	ovarian	_	_	I-Claim
322	cancer	_	_	I-Claim
323	.	_	_	I-Claim

324	Therefore	_	_	B-Claim
325	,	_	_	I-Claim
326	we	_	_	I-Claim
327	recommend	_	_	I-Claim
328	no	_	_	I-Claim
329	additional	_	_	I-Claim
330	clinical	_	_	I-Claim
331	use	_	_	I-Claim
332	of	_	_	I-Claim
333	TCG	_	_	I-Claim
334	in	_	_	I-Claim
335	this	_	_	I-Claim
336	population	_	_	I-Claim
337	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	efficacy	_	_	O
10	and	_	_	O
11	complications	_	_	O
12	of	_	_	O
13	trabeculectomy	_	_	O
14	with	_	_	O
15	a	_	_	O
16	biodegradable	_	_	O
17	implant	_	_	O
18	(	_	_	O
19	ologen	_	_	O
20	implant	_	_	O
21	)	_	_	O
22	vs	_	_	O
23	trabeculectomy	_	_	O
24	using	_	_	O
25	mitomycin	_	_	O
26	C	_	_	O
27	(	_	_	O
28	MMC	_	_	O
29	)	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	medically	_	_	O
34	uncontrolled	_	_	O
35	open-angle	_	_	O
36	glaucoma	_	_	O
37	in	_	_	O
38	a	_	_	O
39	prospective	_	_	O
40	randomised	_	_	O
41	clinical	_	_	O
42	trial	_	_	O
43	.	_	_	O

44	In	_	_	O
45	the	_	_	O
46	MMC	_	_	O
47	group	_	_	O
48	(	_	_	O
49	10	_	_	O
50	patients	_	_	O
51	)	_	_	O
52	,	_	_	O
53	trabeculectomy	_	_	O
54	was	_	_	O
55	performed	_	_	O
56	according	_	_	O
57	to	_	_	O
58	standard	_	_	O
59	protocols	_	_	O
60	.	_	_	O

61	In	_	_	O
62	the	_	_	O
63	ologen	_	_	O
64	group	_	_	O
65	(	_	_	O
66	10	_	_	O
67	patients	_	_	O
68	)	_	_	O
69	after	_	_	O
70	standard	_	_	O
71	trabeculectomy	_	_	O
72	the	_	_	O
73	implant	_	_	O
74	was	_	_	O
75	positioned	_	_	O
76	on	_	_	O
77	top	_	_	O
78	of	_	_	O
79	the	_	_	O
80	scleral	_	_	O
81	flap	_	_	O
82	and	_	_	O
83	no	_	_	O
84	MMC	_	_	O
85	was	_	_	O
86	applied	_	_	O
87	.	_	_	O

88	Follow-up	_	_	O
89	was	_	_	O
90	continued	_	_	O
91	for	_	_	O
92	12	_	_	O
93	months	_	_	O
94	after	_	_	O
95	surgery	_	_	O
96	and	_	_	O
97	included	_	_	O
98	testing	_	_	O
99	of	_	_	O
100	intraocular	_	_	O
101	pressure	_	_	O
102	(	_	_	O
103	IOP	_	_	O
104	)	_	_	O
105	,	_	_	O
106	visual	_	_	O
107	acuity	_	_	O
108	,	_	_	O
109	visual	_	_	O
110	field	_	_	O
111	,	_	_	O
112	ultrasound	_	_	O
113	biomicroscopy	_	_	O
114	,	_	_	O
115	and	_	_	O
116	filtering	_	_	O
117	bleb	_	_	O
118	score	_	_	O
119	.	_	_	O

120	The	_	_	O
121	mean	_	_	O
122	preoperative	_	_	O
123	IOP	_	_	O
124	was	_	_	O
125	24.8+/-8.9	_	_	O
126	mm	_	_	O
127	Hg	_	_	O
128	for	_	_	O
129	all	_	_	O
130	patients	_	_	O
131	enrolled	_	_	O
132	.	_	_	O

133	At	_	_	B-Premise
134	1	_	_	I-Premise
135	year	_	_	I-Premise
136	after	_	_	I-Premise
137	surgery	_	_	I-Premise
138	,	_	_	I-Premise
139	the	_	_	I-Premise
140	mean	_	_	I-Premise
141	IOP	_	_	I-Premise
142	was	_	_	I-Premise
143	15.6+/-2.4mm	_	_	I-Premise
144	Hg	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	ologen	_	_	I-Premise
148	group	_	_	I-Premise
149	(	_	_	I-Premise
150	P	_	_	I-Premise
151	<	_	_	I-Premise
152	0.01	_	_	I-Premise
153	,	_	_	I-Premise
154	43	_	_	I-Premise
155	%	_	_	I-Premise
156	reduction	_	_	I-Premise
157	)	_	_	I-Premise
158	and	_	_	I-Premise
159	11.5+/-4.1	_	_	I-Premise
160	mm	_	_	I-Premise
161	Hg	_	_	I-Premise
162	in	_	_	I-Premise
163	the	_	_	I-Premise
164	MMC	_	_	I-Premise
165	group	_	_	I-Premise
166	(	_	_	I-Premise
167	P	_	_	I-Premise
168	<	_	_	I-Premise
169	0.01	_	_	I-Premise
170	,	_	_	I-Premise
171	50	_	_	I-Premise
172	%	_	_	I-Premise
173	reduction	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	No	_	_	B-Premise
177	anti-glaucomatous	_	_	I-Premise
178	medication	_	_	I-Premise
179	was	_	_	I-Premise
180	necessary	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	MMC	_	_	I-Premise
184	group	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	first	_	_	I-Premise
188	year	_	_	I-Premise
189	of	_	_	I-Premise
190	follow-up	_	_	I-Premise
191	,	_	_	I-Premise
192	whereas	_	_	I-Premise
193	five	_	_	I-Premise
194	patients	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	ologen	_	_	I-Premise
198	group	_	_	I-Premise
199	required	_	_	I-Premise
200	topical	_	_	I-Premise
201	treatment	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	absolute	_	_	I-Premise
205	success	_	_	I-Premise
206	rate	_	_	I-Premise
207	was	_	_	I-Premise
208	100	_	_	I-Premise
209	%	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	MMC	_	_	I-Premise
213	group	_	_	I-Premise
214	and	_	_	I-Premise
215	50	_	_	I-Premise
216	%	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	ologen	_	_	I-Premise
220	group	_	_	I-Premise
221	(	_	_	I-Premise
222	P=0.01	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	After	_	_	B-Premise
226	1	_	_	I-Premise
227	year	_	_	I-Premise
228	,	_	_	I-Premise
229	filtering	_	_	I-Premise
230	blebs	_	_	I-Premise
231	developed	_	_	I-Premise
232	significantly	_	_	I-Premise
233	more	_	_	I-Premise
234	avascular	_	_	I-Premise
235	areas	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	MMC	_	_	I-Premise
239	group	_	_	I-Premise
240	(	_	_	I-Premise
241	score=1.4	_	_	I-Premise
242	)	_	_	I-Premise
243	than	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	ologen	_	_	I-Premise
247	group	_	_	I-Premise
248	(	_	_	I-Premise
249	score=2.8	_	_	I-Premise
250	;	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	0.01	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	The	_	_	B-Claim
257	complete	_	_	I-Claim
258	success	_	_	I-Claim
259	rate	_	_	I-Claim
260	using	_	_	I-Claim
261	trabeculectomy	_	_	I-Claim
262	with	_	_	I-Claim
263	the	_	_	I-Claim
264	ologen	_	_	I-Claim
265	implant	_	_	I-Claim
266	is	_	_	I-Claim
267	lower	_	_	I-Claim
268	than	_	_	I-Claim
269	that	_	_	I-Claim
270	achieved	_	_	I-Claim
271	by	_	_	I-Claim
272	trabeculectomy	_	_	I-Claim
273	with	_	_	I-Claim
274	MMC	_	_	I-Claim
275	.	_	_	I-Claim

276	However	_	_	B-Claim
277	,	_	_	I-Claim
278	the	_	_	I-Claim
279	bleb	_	_	I-Claim
280	morphology	_	_	I-Claim
281	caused	_	_	I-Claim
282	more	_	_	I-Claim
283	problems	_	_	I-Claim
284	in	_	_	I-Claim
285	the	_	_	I-Claim
286	MMC	_	_	I-Claim
287	group	_	_	I-Claim
288	(	_	_	I-Claim
289	avascularity	_	_	I-Claim
290	score	_	_	I-Claim
291	)	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	economic	_	_	O
6	efficiency	_	_	O
7	of	_	_	O
8	a	_	_	O
9	multimedia	_	_	O
10	,	_	_	O
11	multimodal	_	_	O
12	physical	_	_	O
13	activity	_	_	O
14	program	_	_	O
15	for	_	_	O
16	women	_	_	O
17	undergoing	_	_	O
18	adjuvant	_	_	O
19	therapy	_	_	O
20	following	_	_	O
21	surgery	_	_	O
22	for	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	.	_	_	O

26	We	_	_	O
27	conducted	_	_	O
28	a	_	_	O
29	randomized	_	_	O
30	trial	_	_	O
31	with	_	_	O
32	concurrent	_	_	O
33	incremental	_	_	O
34	cost-effectiveness	_	_	O
35	analysis	_	_	O
36	and	_	_	O
37	blinded	_	_	O
38	baseline	_	_	O
39	,	_	_	O
40	3	_	_	O
41	,	_	_	O
42	6	_	_	O
43	and	_	_	O
44	12-month	_	_	O
45	follow-up	_	_	O
46	assessments	_	_	O
47	amongst	_	_	O
48	women	_	_	O
49	undergoing	_	_	O
50	adjuvant	_	_	O
51	therapy	_	_	O
52	following	_	_	O
53	surgery	_	_	O
54	for	_	_	O
55	breast	_	_	O
56	cancer	_	_	O
57	(	_	_	O
58	n	_	_	O
59	=	_	_	O
60	89	_	_	O
61	)	_	_	O
62	.	_	_	O

63	The	_	_	O
64	intervention	_	_	O
65	was	_	_	O
66	a	_	_	O
67	multimedia	_	_	O
68	,	_	_	O
69	multimodal	_	_	O
70	exercise	_	_	O
71	program	_	_	O
72	comprising	_	_	O
73	strength	_	_	O
74	,	_	_	O
75	balance	_	_	O
76	and	_	_	O
77	endurance	_	_	O
78	training	_	_	O
79	elements	_	_	O
80	.	_	_	O

81	The	_	_	O
82	control	_	_	O
83	was	_	_	O
84	sham	_	_	O
85	flexibility	_	_	O
86	and	_	_	O
87	relaxation	_	_	O
88	program	_	_	O
89	delivered	_	_	O
90	using	_	_	O
91	similar	_	_	O
92	materials	_	_	O
93	.	_	_	O

94	The	_	_	O
95	primary	_	_	O
96	outcome	_	_	O
97	was	_	_	O
98	health-related	_	_	O
99	quality	_	_	O
100	of	_	_	O
101	life	_	_	O
102	(	_	_	O
103	EQ-5D	_	_	O
104	&	_	_	O
105	amp	_	_	O
106	;	_	_	O
107	VAS	_	_	O
108	,	_	_	O
109	EORTC	_	_	O
110	C30	_	_	O
111	,	_	_	O
112	BR23	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Economic	_	_	O
116	outcomes	_	_	O
117	included	_	_	O
118	direct	_	_	O
119	health	_	_	O
120	care	_	_	O
121	costs	_	_	O
122	and	_	_	O
123	productivity	_	_	O
124	gains	_	_	O
125	and	_	_	O
126	losses	_	_	O
127	.	_	_	O

128	Participants	_	_	B-Premise
129	in	_	_	I-Premise
130	the	_	_	I-Premise
131	intervention	_	_	I-Premise
132	group	_	_	I-Premise
133	demonstrated	_	_	I-Premise
134	greater	_	_	I-Premise
135	improvement	_	_	I-Premise
136	in	_	_	I-Premise
137	health-related	_	_	I-Premise
138	quality	_	_	I-Premise
139	of	_	_	I-Premise
140	life	_	_	I-Premise
141	between	_	_	I-Premise
142	baseline	_	_	I-Premise
143	and	_	_	I-Premise
144	the	_	_	I-Premise
145	3-month	_	_	I-Premise
146	assessment	_	_	I-Premise
147	[	_	_	I-Premise
148	mean	_	_	I-Premise
149	(	_	_	I-Premise
150	sd	_	_	I-Premise
151	)	_	_	I-Premise
152	EQ-5D	_	_	I-Premise
153	VAS	_	_	I-Premise
154	(	_	_	I-Premise
155	0-100	_	_	I-Premise
156	)	_	_	I-Premise
157	baseline	_	_	I-Premise
158	:	_	_	I-Premise
159	72.6	_	_	I-Premise
160	(	_	_	I-Premise
161	15.6	_	_	I-Premise
162	)	_	_	I-Premise
163	,	_	_	I-Premise
164	3	_	_	I-Premise
165	month	_	_	I-Premise
166	:	_	_	I-Premise
167	80.6	_	_	I-Premise
168	(	_	_	I-Premise
169	11.6	_	_	I-Premise
170	)	_	_	I-Premise
171	]	_	_	I-Premise
172	when	_	_	I-Premise
173	compared	_	_	I-Premise
174	to	_	_	I-Premise
175	control	_	_	I-Premise
176	group	_	_	I-Premise
177	participants	_	_	I-Premise
178	[	_	_	I-Premise
179	baseline	_	_	I-Premise
180	:	_	_	I-Premise
181	77.5	_	_	I-Premise
182	(	_	_	I-Premise
183	13.5	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	3	_	_	I-Premise
187	month	_	_	I-Premise
188	:	_	_	I-Premise
189	74.1	_	_	I-Premise
190	(	_	_	I-Premise
191	20.6	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	P	_	_	I-Premise
195	=	_	_	I-Premise
196	0.006	_	_	I-Premise
197	]	_	_	I-Premise
198	and	_	_	I-Premise
199	also	_	_	I-Premise
200	improved	_	_	I-Premise
201	more	_	_	I-Premise
202	in	_	_	I-Premise
203	terms	_	_	I-Premise
204	of	_	_	I-Premise
205	physical	_	_	I-Premise
206	function	_	_	I-Premise
207	[	_	_	I-Premise
208	mean	_	_	I-Premise
209	(	_	_	I-Premise
210	sd	_	_	I-Premise
211	)	_	_	I-Premise
212	EORTC	_	_	I-Premise
213	C30	_	_	I-Premise
214	physical	_	_	I-Premise
215	function	_	_	I-Premise
216	scale	_	_	I-Premise
217	intervention	_	_	I-Premise
218	(	_	_	I-Premise
219	0-100	_	_	I-Premise
220	)	_	_	I-Premise
221	baseline	_	_	I-Premise
222	:	_	_	I-Premise
223	84.9	_	_	I-Premise
224	(	_	_	I-Premise
225	14.8	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	3	_	_	I-Premise
229	month	_	_	I-Premise
230	:	_	_	I-Premise
231	86.9	_	_	I-Premise
232	(	_	_	I-Premise
233	10.7	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	control	_	_	I-Premise
237	baseline	_	_	I-Premise
238	:	_	_	I-Premise
239	91.3	_	_	I-Premise
240	(	_	_	I-Premise
241	9.6	_	_	I-Premise
242	)	_	_	I-Premise
243	,	_	_	I-Premise
244	3	_	_	I-Premise
245	month	_	_	I-Premise
246	:	_	_	I-Premise
247	86.7	_	_	I-Premise
248	(	_	_	I-Premise
249	14.9	_	_	I-Premise
250	)	_	_	I-Premise
251	,	_	_	I-Premise
252	P	_	_	I-Premise
253	=	_	_	I-Premise
254	0.02	_	_	I-Premise
255	]	_	_	I-Premise
256	.	_	_	I-Premise

257	These	_	_	O
258	improvements	_	_	O
259	were	_	_	O
260	not	_	_	O
261	sustained	_	_	O
262	beyond	_	_	O
263	this	_	_	O
264	point	_	_	O
265	.	_	_	O

266	Upper	_	_	B-Premise
267	limb	_	_	I-Premise
268	volumes	_	_	I-Premise
269	were	_	_	I-Premise
270	also	_	_	I-Premise
271	lower	_	_	I-Premise
272	amongst	_	_	I-Premise
273	intervention	_	_	I-Premise
274	group	_	_	I-Premise
275	participants	_	_	I-Premise
276	.	_	_	I-Premise

277	However	_	_	O
278	,	_	_	O
279	there	_	_	B-Premise
280	was	_	_	I-Premise
281	low	_	_	I-Premise
282	probability	_	_	I-Premise
283	that	_	_	I-Premise
284	the	_	_	I-Premise
285	intervention	_	_	I-Premise
286	would	_	_	I-Premise
287	be	_	_	I-Premise
288	both	_	_	I-Premise
289	less	_	_	I-Premise
290	costly	_	_	I-Premise
291	and	_	_	I-Premise
292	more	_	_	I-Premise
293	effective	_	_	I-Premise
294	than	_	_	I-Premise
295	the	_	_	I-Premise
296	control	_	_	I-Premise
297	condition	_	_	I-Premise
298	(	_	_	I-Premise
299	range	_	_	I-Premise
300	probability	_	_	I-Premise
301	=	_	_	I-Premise
302	0.05-50.02	_	_	I-Premise
303	%	_	_	I-Premise
304	depending	_	_	I-Premise
305	on	_	_	I-Premise
306	approach	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	Provision	_	_	B-Claim
310	of	_	_	I-Claim
311	multimodal	_	_	I-Claim
312	exercise	_	_	I-Claim
313	programs	_	_	I-Claim
314	will	_	_	I-Claim
315	improve	_	_	I-Claim
316	the	_	_	I-Claim
317	short-term	_	_	I-Claim
318	health	_	_	I-Claim
319	of	_	_	I-Claim
320	women	_	_	I-Claim
321	undergoing	_	_	I-Claim
322	adjuvant	_	_	I-Claim
323	therapy	_	_	I-Claim
324	for	_	_	I-Claim
325	breast	_	_	I-Claim
326	cancer	_	_	I-Claim
327	but	_	_	I-Claim
328	are	_	_	I-Claim
329	of	_	_	I-Claim
330	questionable	_	_	I-Claim
331	economic	_	_	I-Claim
332	efficiency	_	_	I-Claim
333	.	_	_	I-Claim


0	Quality	_	_	O
1	of	_	_	O
2	life	_	_	O
3	is	_	_	O
4	an	_	_	O
5	important	_	_	O
6	outcome	_	_	O
7	measure	_	_	O
8	in	_	_	O
9	the	_	_	O
10	care	_	_	O
11	of	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	cancer	_	_	O
15	.	_	_	O

16	We	_	_	O
17	developed	_	_	O
18	a	_	_	O
19	new	_	_	O
20	scoring	_	_	O
21	system	_	_	O
22	specifically	_	_	O
23	for	_	_	O
24	the	_	_	O
25	evaluation	_	_	O
26	of	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	upper	_	_	O
30	gastrointestinal	_	_	O
31	cancer	_	_	O
32	and	_	_	O
33	postoperative	_	_	O
34	gastrointestinal	_	_	O
35	dysfunction	_	_	O
36	.	_	_	O

37	This	_	_	O
38	study	_	_	O
39	was	_	_	O
40	undertaken	_	_	O
41	to	_	_	O
42	evaluate	_	_	O
43	the	_	_	O
44	scoring	_	_	O
45	system	_	_	O
46	's	_	_	O
47	validity	_	_	O
48	in	_	_	O
49	comparing	_	_	O
50	outcomes	_	_	O
51	after	_	_	O
52	gastric	_	_	O
53	resection	_	_	O
54	.	_	_	O

55	Patients	_	_	O
56	with	_	_	O
57	gastric	_	_	O
58	cancer	_	_	O
59	,	_	_	O
60	3	_	_	O
61	months	_	_	O
62	to	_	_	O
63	3	_	_	O
64	years	_	_	O
65	postoperatively	_	_	O
66	,	_	_	O
67	were	_	_	O
68	surveyed	_	_	O
69	using	_	_	O
70	the	_	_	O
71	survey	_	_	O
72	instrument	_	_	O
73	.	_	_	O

74	Postoperative	_	_	O
75	dysfunction	_	_	O
76	scores	_	_	O
77	and	_	_	O
78	the	_	_	O
79	status	_	_	O
80	of	_	_	O
81	resuming	_	_	O
82	activities	_	_	O
83	of	_	_	O
84	daily	_	_	O
85	living	_	_	O
86	were	_	_	O
87	compared	_	_	O
88	with	_	_	O
89	the	_	_	O
90	surgical	_	_	O
91	procedure	_	_	O
92	performed	_	_	O
93	by	_	_	O
94	analysis	_	_	O
95	of	_	_	O
96	variance	_	_	O
97	and	_	_	O
98	multiple-comparison	_	_	O
99	techniques	_	_	O
100	.	_	_	O

101	Of	_	_	O
102	211	_	_	O
103	patients	_	_	O
104	surveyed	_	_	O
105	,	_	_	O
106	165	_	_	O
107	(	_	_	O
108	119	_	_	O
109	men	_	_	O
110	,	_	_	O
111	46	_	_	O
112	women	_	_	O
113	;	_	_	O
114	mean	_	_	O
115	age	_	_	O
116	,	_	_	O
117	65.1	_	_	O
118	±	_	_	O
119	10.5	_	_	O
120	years	_	_	O
121	)	_	_	O
122	responded	_	_	O
123	.	_	_	O

124	Procedures	_	_	O
125	included	_	_	O
126	distal	_	_	O
127	gastrectomy	_	_	O
128	in	_	_	O
129	100	_	_	O
130	,	_	_	O
131	total	_	_	O
132	gastrectomy	_	_	O
133	in	_	_	O
134	57	_	_	O
135	,	_	_	O
136	and	_	_	O
137	pylorus-preserving	_	_	O
138	gastrectomy	_	_	O
139	in	_	_	O
140	8	_	_	O
141	.	_	_	O

142	The	_	_	O
143	overall	_	_	O
144	dysfunction	_	_	O
145	score	_	_	O
146	was	_	_	O
147	61.8	_	_	O
148	±	_	_	O
149	15.5	_	_	O
150	.	_	_	O

151	The	_	_	B-Premise
152	dysfunction	_	_	I-Premise
153	score	_	_	I-Premise
154	was	_	_	I-Premise
155	58.9	_	_	I-Premise
156	±	_	_	I-Premise
157	15.0	_	_	I-Premise
158	after	_	_	I-Premise
159	distal	_	_	I-Premise
160	gastrectomy	_	_	I-Premise
161	,	_	_	I-Premise
162	66.8	_	_	I-Premise
163	±	_	_	I-Premise
164	14.1	_	_	I-Premise
165	after	_	_	I-Premise
166	total	_	_	I-Premise
167	gastrectomy	_	_	I-Premise
168	,	_	_	I-Premise
169	and	_	_	I-Premise
170	62.4	_	_	I-Premise
171	±	_	_	I-Premise
172	21.6	_	_	I-Premise
173	after	_	_	I-Premise
174	pylorus-preserving	_	_	I-Premise
175	gastrectomy	_	_	I-Premise
176	.	_	_	I-Premise

177	These	_	_	B-Premise
178	values	_	_	I-Premise
179	differed	_	_	I-Premise
180	significantly	_	_	I-Premise
181	among	_	_	I-Premise
182	the	_	_	I-Premise
183	groups	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	.007	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	Dysfunction	_	_	B-Premise
191	scores	_	_	I-Premise
192	according	_	_	I-Premise
193	to	_	_	I-Premise
194	postoperative	_	_	I-Premise
195	activity	_	_	I-Premise
196	status	_	_	I-Premise
197	were	_	_	I-Premise
198	49.1	_	_	I-Premise
199	±	_	_	I-Premise
200	15.6	_	_	I-Premise
201	in	_	_	I-Premise
202	71	_	_	I-Premise
203	patients	_	_	I-Premise
204	who	_	_	I-Premise
205	resumed	_	_	I-Premise
206	their	_	_	I-Premise
207	activities	_	_	I-Premise
208	,	_	_	I-Premise
209	56.9	_	_	I-Premise
210	±	_	_	I-Premise
211	15.7	_	_	I-Premise
212	in	_	_	I-Premise
213	39	_	_	I-Premise
214	patients	_	_	I-Premise
215	with	_	_	I-Premise
216	reduced	_	_	I-Premise
217	activities	_	_	I-Premise
218	,	_	_	I-Premise
219	57.3	_	_	I-Premise
220	±	_	_	I-Premise
221	8.8	_	_	I-Premise
222	in	_	_	I-Premise
223	15	_	_	I-Premise
224	patients	_	_	I-Premise
225	with	_	_	I-Premise
226	minimal	_	_	I-Premise
227	activities	_	_	I-Premise
228	,	_	_	I-Premise
229	and	_	_	I-Premise
230	63.3	_	_	I-Premise
231	±	_	_	I-Premise
232	11.8	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	<	_	_	I-Premise
236	.05	_	_	I-Premise
237	)	_	_	I-Premise
238	in	_	_	I-Premise
239	16	_	_	I-Premise
240	patients	_	_	I-Premise
241	who	_	_	I-Premise
242	did	_	_	I-Premise
243	not	_	_	I-Premise
244	resume	_	_	I-Premise
245	activities	_	_	I-Premise
246	because	_	_	I-Premise
247	of	_	_	I-Premise
248	poor	_	_	I-Premise
249	physical	_	_	I-Premise
250	condition	_	_	I-Premise
251	.	_	_	I-Premise

252	This	_	_	B-Claim
253	scoring	_	_	I-Claim
254	system	_	_	I-Claim
255	for	_	_	I-Claim
256	postoperative	_	_	I-Claim
257	gastrointestinal	_	_	I-Claim
258	dysfunction	_	_	I-Claim
259	provides	_	_	I-Claim
260	an	_	_	I-Claim
261	objective	_	_	I-Claim
262	measure	_	_	I-Claim
263	of	_	_	I-Claim
264	dysfunction	_	_	I-Claim
265	related	_	_	I-Claim
266	to	_	_	I-Claim
267	specific	_	_	I-Claim
268	surgical	_	_	I-Claim
269	procedures	_	_	I-Claim
270	and	_	_	I-Claim
271	correlates	_	_	I-Claim
272	with	_	_	I-Claim
273	activities	_	_	I-Claim
274	of	_	_	I-Claim
275	daily	_	_	I-Claim
276	living	_	_	I-Claim
277	in	_	_	I-Claim
278	the	_	_	I-Claim
279	postoperative	_	_	I-Claim
280	period	_	_	I-Claim
281	.	_	_	I-Claim


0	Previous	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	demonstrated	_	_	O
4	that	_	_	O
5	both	_	_	O
6	anastrozole	_	_	O
7	and	_	_	O
8	letrozole	_	_	O
9	are	_	_	O
10	well	_	_	O
11	tolerated	_	_	O
12	.	_	_	O

13	Letrozole	_	_	O
14	suppresses	_	_	O
15	estrogen	_	_	O
16	to	_	_	O
17	a	_	_	O
18	greater	_	_	O
19	degree	_	_	O
20	than	_	_	O
21	anastrozole	_	_	O
22	in	_	_	O
23	the	_	_	O
24	serum	_	_	O
25	and	_	_	O
26	breast	_	_	O
27	tumor	_	_	O
28	.	_	_	O

29	Concerns	_	_	O
30	have	_	_	O
31	been	_	_	O
32	raised	_	_	O
33	that	_	_	O
34	greater	_	_	O
35	potency	_	_	O
36	may	_	_	O
37	adversely	_	_	O
38	affect	_	_	O
39	patients	_	_	O
40	'	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	(	_	_	O
45	QOL	_	_	O
46	)	_	_	O
47	.	_	_	O

48	One	_	_	O
49	hundred	_	_	O
50	eighty-one	_	_	O
51	postmenopausal	_	_	O
52	women	_	_	O
53	with	_	_	O
54	invasive	_	_	O
55	estrogen	_	_	O
56	receptor-positive	_	_	O
57	breast	_	_	O
58	cancers	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	receive	_	_	O
63	either	_	_	O
64	12	_	_	O
65	weeks	_	_	O
66	of	_	_	O
67	letrozole	_	_	O
68	followed	_	_	O
69	by	_	_	O
70	12	_	_	O
71	weeks	_	_	O
72	of	_	_	O
73	anastrozole	_	_	O
74	or	_	_	O
75	the	_	_	O
76	reverse	_	_	O
77	sequence	_	_	O
78	.	_	_	O

79	One	_	_	O
80	hundred	_	_	O
81	and	_	_	O
82	six	_	_	O
83	received	_	_	O
84	immediate	_	_	O
85	adjuvant	_	_	O
86	aromatase	_	_	O
87	inhibitors	_	_	O
88	(	_	_	O
89	AIs	_	_	O
90	)	_	_	O
91	following	_	_	O
92	surgery	_	_	O
93	,	_	_	O
94	and	_	_	O
95	75	_	_	O
96	received	_	_	O
97	extended	_	_	O
98	adjuvant	_	_	O
99	therapy	_	_	O
100	.	_	_	O

101	The	_	_	O
102	Functional	_	_	O
103	Assessment	_	_	O
104	of	_	_	O
105	Cancer	_	_	O
106	Therapy	_	_	O
107	Endocrine	_	_	O
108	Subscale	_	_	O
109	(	_	_	O
110	FACT-B-ES	_	_	O
111	)	_	_	O
112	QOL	_	_	O
113	questionnaires	_	_	O
114	were	_	_	O
115	completed	_	_	O
116	to	_	_	O
117	assess	_	_	O
118	QOL	_	_	O
119	on	_	_	O
120	each	_	_	O
121	drug	_	_	O
122	.	_	_	O

123	Additional	_	_	O
124	side-effect	_	_	O
125	profiles	_	_	O
126	were	_	_	O
127	collected	_	_	O
128	.	_	_	O

129	Each	_	_	O
130	patient	_	_	O
131	completed	_	_	O
132	a	_	_	O
133	patient	_	_	O
134	preference	_	_	O
135	form	_	_	O
136	.	_	_	O

137	Twenty-one	_	_	O
138	patients	_	_	O
139	withdrew	_	_	O
140	before	_	_	O
141	study	_	_	O
142	end	_	_	O
143	,	_	_	O
144	10/179	_	_	O
145	(	_	_	O
146	5.6	_	_	O
147	%	_	_	O
148	)	_	_	O
149	while	_	_	O
150	taking	_	_	O
151	letrozole	_	_	O
152	and	_	_	O
153	4/173	_	_	O
154	(	_	_	O
155	2.3	_	_	O
156	%	_	_	O
157	)	_	_	O
158	while	_	_	O
159	taking	_	_	O
160	anastrozole	_	_	O
161	(	_	_	O
162	P	_	_	O
163	=	_	_	O
164	0.12	_	_	O
165	)	_	_	O
166	.	_	_	O

167	Tamoxifen-naïve	_	_	B-Premise
168	patients	_	_	I-Premise
169	had	_	_	I-Premise
170	a	_	_	I-Premise
171	higher	_	_	I-Premise
172	mean	_	_	I-Premise
173	ES	_	_	I-Premise
174	(	_	_	I-Premise
175	endocrine	_	_	I-Premise
176	symptoms	_	_	I-Premise
177	subscale	_	_	I-Premise
178	)	_	_	I-Premise
179	score	_	_	I-Premise
180	at	_	_	I-Premise
181	entry	_	_	I-Premise
182	versus	_	_	I-Premise
183	those	_	_	I-Premise
184	having	_	_	I-Premise
185	extended	_	_	I-Premise
186	therapy	_	_	I-Premise
187	(	_	_	I-Premise
188	66.0	_	_	I-Premise
189	vs.	_	_	I-Premise
190	61.9	_	_	I-Premise
191	;	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0.001	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	There	_	_	B-Premise
198	was	_	_	I-Premise
199	no	_	_	I-Premise
200	significant	_	_	I-Premise
201	change	_	_	I-Premise
202	in	_	_	I-Premise
203	FACT-B-ES	_	_	I-Premise
204	(	_	_	I-Premise
205	overall	_	_	I-Premise
206	)	_	_	I-Premise
207	scores	_	_	I-Premise
208	or	_	_	I-Premise
209	ES	_	_	I-Premise
210	scores	_	_	I-Premise
211	while	_	_	I-Premise
212	patients	_	_	I-Premise
213	were	_	_	I-Premise
214	taking	_	_	I-Premise
215	anastrozole	_	_	I-Premise
216	or	_	_	I-Premise
217	letrozole	_	_	I-Premise
218	and	_	_	I-Premise
219	no	_	_	I-Premise
220	significant	_	_	I-Premise
221	differences	_	_	I-Premise
222	between	_	_	I-Premise
223	drugs	_	_	I-Premise
224	.	_	_	I-Premise

225	Nearly	_	_	B-Premise
226	80	_	_	I-Premise
227	%	_	_	I-Premise
228	of	_	_	I-Premise
229	patients	_	_	I-Premise
230	reported	_	_	I-Premise
231	one	_	_	I-Premise
232	or	_	_	I-Premise
233	more	_	_	I-Premise
234	side	_	_	I-Premise
235	effects	_	_	I-Premise
236	with	_	_	I-Premise
237	either	_	_	I-Premise
238	agent	_	_	I-Premise
239	.	_	_	I-Premise

240	No	_	_	B-Premise
241	differences	_	_	I-Premise
242	in	_	_	I-Premise
243	frequency	_	_	I-Premise
244	,	_	_	I-Premise
245	grade	_	_	I-Premise
246	,	_	_	I-Premise
247	or	_	_	I-Premise
248	range	_	_	I-Premise
249	of	_	_	I-Premise
250	side	_	_	I-Premise
251	effects	_	_	I-Premise
252	were	_	_	I-Premise
253	seen	_	_	I-Premise
254	between	_	_	I-Premise
255	drugs	_	_	I-Premise
256	.	_	_	I-Premise

257	Of	_	_	O
258	160	_	_	O
259	patients	_	_	O
260	,	_	_	O
261	49	_	_	O
262	(	_	_	O
263	30.6	_	_	O
264	%	_	_	O
265	)	_	_	O
266	preferred	_	_	O
267	letrozole	_	_	O
268	,	_	_	O
269	57	_	_	O
270	(	_	_	O
271	35.6	_	_	O
272	%	_	_	O
273	)	_	_	O
274	preferred	_	_	O
275	anastrozole	_	_	O
276	,	_	_	O
277	and	_	_	O
278	54	_	_	O
279	(	_	_	O
280	33.8	_	_	O
281	%	_	_	O
282	)	_	_	O
283	had	_	_	O
284	no	_	_	O
285	preference	_	_	O
286	(	_	_	O
287	P	_	_	O
288	=	_	_	O
289	0.26	_	_	O
290	,	_	_	O
291	Pearson	_	_	O
292	's	_	_	O
293	Chi-squared	_	_	O
294	test	_	_	O
295	)	_	_	O
296	.	_	_	O

297	In	_	_	O
298	conclusion	_	_	O
299	,	_	_	O
300	both	_	_	B-Claim
301	AIs	_	_	I-Claim
302	are	_	_	I-Claim
303	equally	_	_	I-Claim
304	well	_	_	I-Claim
305	tolerated	_	_	I-Claim
306	.	_	_	I-Claim

307	There	_	_	B-Claim
308	were	_	_	I-Claim
309	no	_	_	I-Claim
310	significant	_	_	I-Claim
311	differences	_	_	I-Claim
312	in	_	_	I-Claim
313	QOL	_	_	I-Claim
314	scores	_	_	I-Claim
315	between	_	_	I-Claim
316	the	_	_	I-Claim
317	two	_	_	I-Claim
318	drugs	_	_	I-Claim
319	.	_	_	I-Claim


0	Lung	_	_	O
1	cancer	_	_	O
2	is	_	_	O
3	one	_	_	O
4	of	_	_	O
5	the	_	_	O
6	most	_	_	O
7	common	_	_	O
8	cancers	_	_	O
9	in	_	_	O
10	the	_	_	O
11	United	_	_	O
12	States	_	_	O
13	and	_	_	O
14	is	_	_	O
15	associated	_	_	O
16	with	_	_	O
17	high	_	_	O
18	levels	_	_	O
19	of	_	_	O
20	symptoms	_	_	O
21	,	_	_	O
22	including	_	_	O
23	pain	_	_	O
24	,	_	_	O
25	fatigue	_	_	O
26	,	_	_	O
27	shortness	_	_	O
28	of	_	_	O
29	breath	_	_	O
30	,	_	_	O
31	and	_	_	O
32	psychological	_	_	O
33	distress	_	_	O
34	.	_	_	O

35	Caregivers	_	_	O
36	and	_	_	O
37	patients	_	_	O
38	are	_	_	O
39	adversely	_	_	O
40	affected	_	_	O
41	.	_	_	O

42	However	_	_	O
43	,	_	_	O
44	previous	_	_	O
45	studies	_	_	O
46	of	_	_	O
47	coping	_	_	O
48	skills	_	_	O
49	training	_	_	O
50	(	_	_	O
51	CST	_	_	O
52	)	_	_	O
53	interventions	_	_	O
54	have	_	_	O
55	not	_	_	O
56	been	_	_	O
57	tested	_	_	O
58	in	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	lung	_	_	O
62	cancer	_	_	O
63	nor	_	_	O
64	have	_	_	O
65	systematically	_	_	O
66	included	_	_	O
67	caregivers	_	_	O
68	.	_	_	O

69	This	_	_	O
70	study	_	_	O
71	tested	_	_	O
72	the	_	_	O
73	efficacy	_	_	O
74	of	_	_	O
75	a	_	_	O
76	caregiver-assisted	_	_	O
77	CST	_	_	O
78	protocol	_	_	O
79	in	_	_	O
80	a	_	_	O
81	sample	_	_	O
82	of	_	_	O
83	patients	_	_	O
84	with	_	_	O
85	lung	_	_	O
86	cancer	_	_	O
87	.	_	_	O

88	Two	_	_	O
89	hundred	_	_	O
90	thirty-three	_	_	O
91	lung	_	_	O
92	cancer	_	_	O
93	patients	_	_	O
94	and	_	_	O
95	their	_	_	O
96	caregivers	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	14	_	_	O
103	telephone-based	_	_	O
104	sessions	_	_	O
105	of	_	_	O
106	either	_	_	O
107	caregiver-assisted	_	_	O
108	CST	_	_	O
109	or	_	_	O
110	education/support	_	_	O
111	involving	_	_	O
112	the	_	_	O
113	caregiver	_	_	O
114	.	_	_	O

115	Patients	_	_	O
116	completed	_	_	O
117	measures	_	_	O
118	assessing	_	_	O
119	pain	_	_	O
120	,	_	_	O
121	psychological	_	_	O
122	distress	_	_	O
123	,	_	_	O
124	quality	_	_	O
125	of	_	_	O
126	life	_	_	O
127	(	_	_	O
128	QOL	_	_	O
129	)	_	_	O
130	,	_	_	O
131	and	_	_	O
132	self-efficacy	_	_	O
133	for	_	_	O
134	symptom	_	_	O
135	management	_	_	O
136	;	_	_	O
137	caregivers	_	_	O
138	completed	_	_	O
139	measures	_	_	O
140	assessing	_	_	O
141	psychological	_	_	O
142	distress	_	_	O
143	,	_	_	O
144	caregiver	_	_	O
145	strain	_	_	O
146	,	_	_	O
147	and	_	_	O
148	self-efficacy	_	_	O
149	for	_	_	O
150	helping	_	_	O
151	the	_	_	O
152	patient	_	_	O
153	manage	_	_	O
154	symptoms	_	_	O
155	.	_	_	O

156	Patients	_	_	B-Premise
157	in	_	_	I-Premise
158	both	_	_	I-Premise
159	treatment	_	_	I-Premise
160	conditions	_	_	I-Premise
161	showed	_	_	I-Premise
162	improvements	_	_	I-Premise
163	in	_	_	I-Premise
164	pain	_	_	I-Premise
165	,	_	_	I-Premise
166	depression	_	_	I-Premise
167	,	_	_	I-Premise
168	QOL	_	_	I-Premise
169	,	_	_	I-Premise
170	and	_	_	I-Premise
171	self-efficacy	_	_	I-Premise
172	,	_	_	I-Premise
173	and	_	_	I-Premise
174	caregivers	_	_	I-Premise
175	in	_	_	I-Premise
176	both	_	_	I-Premise
177	conditions	_	_	I-Premise
178	showed	_	_	I-Premise
179	improvements	_	_	I-Premise
180	in	_	_	I-Premise
181	anxiety	_	_	I-Premise
182	and	_	_	I-Premise
183	self-efficacy	_	_	I-Premise
184	from	_	_	I-Premise
185	baseline	_	_	I-Premise
186	to	_	_	I-Premise
187	four-month	_	_	I-Premise
188	follow-up	_	_	I-Premise
189	.	_	_	I-Premise

190	Results	_	_	B-Premise
191	of	_	_	I-Premise
192	exploratory	_	_	I-Premise
193	analyses	_	_	I-Premise
194	suggested	_	_	I-Premise
195	that	_	_	I-Premise
196	the	_	_	I-Premise
197	CST	_	_	I-Premise
198	intervention	_	_	I-Premise
199	was	_	_	I-Premise
200	more	_	_	I-Premise
201	beneficial	_	_	I-Premise
202	to	_	_	I-Premise
203	patients/caregivers	_	_	I-Premise
204	with	_	_	I-Premise
205	Stage	_	_	I-Premise
206	II	_	_	I-Premise
207	and	_	_	I-Premise
208	III	_	_	I-Premise
209	cancers	_	_	I-Premise
210	,	_	_	I-Premise
211	whereas	_	_	O
212	the	_	_	B-Premise
213	education/support	_	_	I-Premise
214	intervention	_	_	I-Premise
215	was	_	_	I-Premise
216	more	_	_	I-Premise
217	beneficial	_	_	I-Premise
218	to	_	_	I-Premise
219	patients/caregivers	_	_	I-Premise
220	with	_	_	I-Premise
221	Stage	_	_	I-Premise
222	I	_	_	I-Premise
223	cancer	_	_	I-Premise
224	.	_	_	I-Premise

225	Taken	_	_	B-Premise
226	together	_	_	I-Premise
227	with	_	_	I-Premise
228	the	_	_	I-Premise
229	broader	_	_	I-Premise
230	literature	_	_	I-Premise
231	in	_	_	I-Premise
232	this	_	_	I-Premise
233	area	_	_	I-Premise
234	,	_	_	I-Premise
235	results	_	_	B-Claim
236	from	_	_	I-Claim
237	this	_	_	I-Claim
238	study	_	_	I-Claim
239	suggest	_	_	I-Claim
240	that	_	_	I-Claim
241	psychosocial	_	_	I-Claim
242	interventions	_	_	I-Claim
243	can	_	_	I-Claim
244	lead	_	_	I-Claim
245	to	_	_	I-Claim
246	improvements	_	_	I-Claim
247	in	_	_	I-Claim
248	a	_	_	I-Claim
249	range	_	_	I-Claim
250	of	_	_	I-Claim
251	outcomes	_	_	I-Claim
252	for	_	_	I-Claim
253	cancer	_	_	I-Claim
254	patients	_	_	I-Claim
255	.	_	_	I-Claim

256	Suggestions	_	_	O
257	for	_	_	O
258	future	_	_	O
259	studies	_	_	O
260	include	_	_	O
261	the	_	_	O
262	use	_	_	O
263	of	_	_	O
264	three-group	_	_	O
265	designs	_	_	O
266	(	_	_	O
267	e.g.	_	_	O
268	,	_	_	O
269	comparing	_	_	O
270	two	_	_	O
271	active	_	_	O
272	interventions	_	_	O
273	with	_	_	O
274	a	_	_	O
275	standard-care	_	_	O
276	control	_	_	O
277	)	_	_	O
278	and	_	_	O
279	examining	_	_	O
280	mechanisms	_	_	O
281	of	_	_	O
282	change	_	_	O
283	.	_	_	O


0	We	_	_	O
1	compared	_	_	O
2	fulvestrant	_	_	O
3	500	_	_	O
4	mg	_	_	O
5	regimen	_	_	O
6	with	_	_	O
7	the	_	_	O
8	approved	_	_	O
9	dose	_	_	O
10	of	_	_	O
11	fulvestrant	_	_	O
12	250	_	_	O
13	mg	_	_	O
14	per	_	_	O
15	month	_	_	O
16	for	_	_	O
17	treatment	_	_	O
18	of	_	_	O
19	postmenopausal	_	_	O
20	women	_	_	O
21	with	_	_	O
22	estrogen	_	_	O
23	receptor-positive	_	_	O
24	advanced	_	_	O
25	breast	_	_	O
26	cancer	_	_	O
27	who	_	_	O
28	experienced	_	_	O
29	progression	_	_	O
30	after	_	_	O
31	prior	_	_	O
32	endocrine	_	_	O
33	therapy	_	_	O
34	.	_	_	O

35	Comparison	_	_	O
36	of	_	_	O
37	Faslodex	_	_	O
38	in	_	_	O
39	Recurrent	_	_	O
40	or	_	_	O
41	Metastatic	_	_	O
42	Breast	_	_	O
43	Cancer	_	_	O
44	(	_	_	O
45	CONFIRM	_	_	O
46	)	_	_	O
47	is	_	_	O
48	a	_	_	O
49	double-blind	_	_	O
50	,	_	_	O
51	parallel-group	_	_	O
52	,	_	_	O
53	multicenter	_	_	O
54	,	_	_	O
55	phase	_	_	O
56	III	_	_	O
57	study	_	_	O
58	.	_	_	O

59	Patients	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	fulvestrant	_	_	O
65	500	_	_	O
66	mg	_	_	O
67	(	_	_	O
68	500	_	_	O
69	mg	_	_	O
70	intramuscularly	_	_	O
71	[	_	_	O
72	IM	_	_	O
73	]	_	_	O
74	on	_	_	O
75	day	_	_	O
76	0	_	_	O
77	,	_	_	O
78	then	_	_	O
79	500	_	_	O
80	mg	_	_	O
81	IM	_	_	O
82	on	_	_	O
83	days	_	_	O
84	14	_	_	O
85	and	_	_	O
86	28	_	_	O
87	and	_	_	O
88	every	_	_	O
89	28	_	_	O
90	days	_	_	O
91	thereafter	_	_	O
92	)	_	_	O
93	or	_	_	O
94	250	_	_	O
95	mg	_	_	O
96	every	_	_	O
97	28	_	_	O
98	days	_	_	O
99	.	_	_	O

100	Primary	_	_	O
101	end	_	_	O
102	point	_	_	O
103	was	_	_	O
104	progression-free	_	_	O
105	survival	_	_	O
106	(	_	_	O
107	PFS	_	_	O
108	)	_	_	O
109	.	_	_	O

110	Secondary	_	_	O
111	end	_	_	O
112	points	_	_	O
113	included	_	_	O
114	objective	_	_	O
115	response	_	_	O
116	rate	_	_	O
117	,	_	_	O
118	clinical	_	_	O
119	benefit	_	_	O
120	rate	_	_	O
121	(	_	_	O
122	CBR	_	_	O
123	)	_	_	O
124	,	_	_	O
125	duration	_	_	O
126	of	_	_	O
127	clinical	_	_	O
128	benefit	_	_	O
129	(	_	_	O
130	DoCB	_	_	O
131	)	_	_	O
132	,	_	_	O
133	overall	_	_	O
134	survival	_	_	O
135	(	_	_	O
136	OS	_	_	O
137	)	_	_	O
138	,	_	_	O
139	and	_	_	O
140	quality	_	_	O
141	of	_	_	O
142	life	_	_	O
143	(	_	_	O
144	QOL	_	_	O
145	)	_	_	O
146	.	_	_	O

147	PFS	_	_	B-Premise
148	was	_	_	I-Premise
149	significantly	_	_	I-Premise
150	longer	_	_	I-Premise
151	for	_	_	I-Premise
152	fulvestrant	_	_	I-Premise
153	500	_	_	I-Premise
154	mg	_	_	I-Premise
155	(	_	_	I-Premise
156	n	_	_	I-Premise
157	=	_	_	I-Premise
158	362	_	_	I-Premise
159	)	_	_	I-Premise
160	than	_	_	I-Premise
161	250	_	_	I-Premise
162	mg	_	_	I-Premise
163	(	_	_	I-Premise
164	n	_	_	I-Premise
165	=	_	_	I-Premise
166	374	_	_	I-Premise
167	)	_	_	I-Premise
168	(	_	_	I-Premise
169	hazard	_	_	I-Premise
170	ratio	_	_	I-Premise
171	[	_	_	I-Premise
172	HR	_	_	I-Premise
173	]	_	_	I-Premise
174	=	_	_	I-Premise
175	0.80	_	_	I-Premise
176	;	_	_	I-Premise
177	95	_	_	I-Premise
178	%	_	_	I-Premise
179	CI	_	_	I-Premise
180	,	_	_	I-Premise
181	0.68	_	_	I-Premise
182	to	_	_	I-Premise
183	0.94	_	_	I-Premise
184	;	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	.006	_	_	I-Premise
188	)	_	_	I-Premise
189	,	_	_	I-Premise
190	corresponding	_	_	I-Premise
191	to	_	_	I-Premise
192	a	_	_	I-Premise
193	20	_	_	I-Premise
194	%	_	_	I-Premise
195	reduction	_	_	I-Premise
196	in	_	_	I-Premise
197	risk	_	_	I-Premise
198	of	_	_	I-Premise
199	progression	_	_	I-Premise
200	.	_	_	I-Premise

201	Objective	_	_	B-Premise
202	response	_	_	I-Premise
203	rate	_	_	I-Premise
204	was	_	_	I-Premise
205	similar	_	_	I-Premise
206	for	_	_	I-Premise
207	fulvestrant	_	_	I-Premise
208	500	_	_	I-Premise
209	mg	_	_	I-Premise
210	and	_	_	I-Premise
211	250	_	_	I-Premise
212	mg	_	_	I-Premise
213	(	_	_	I-Premise
214	9.1	_	_	I-Premise
215	%	_	_	I-Premise
216	v	_	_	I-Premise
217	10.2	_	_	I-Premise
218	%	_	_	I-Premise
219	,	_	_	I-Premise
220	respectively	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	CBR	_	_	B-Premise
224	was	_	_	I-Premise
225	45.6	_	_	I-Premise
226	%	_	_	I-Premise
227	for	_	_	I-Premise
228	fulvestrant	_	_	I-Premise
229	500	_	_	I-Premise
230	mg	_	_	I-Premise
231	and	_	_	I-Premise
232	39.6	_	_	I-Premise
233	%	_	_	I-Premise
234	for	_	_	I-Premise
235	fulvestrant	_	_	I-Premise
236	250	_	_	I-Premise
237	mg.	_	_	I-Premise
238	DoCB	_	_	B-Premise
239	and	_	_	I-Premise
240	OS	_	_	I-Premise
241	were	_	_	I-Premise
242	16.6	_	_	I-Premise
243	and	_	_	I-Premise
244	25.1	_	_	I-Premise
245	months	_	_	I-Premise
246	,	_	_	I-Premise
247	respectively	_	_	I-Premise
248	,	_	_	I-Premise
249	for	_	_	I-Premise
250	the	_	_	I-Premise
251	500-mg	_	_	I-Premise
252	group	_	_	I-Premise
253	,	_	_	I-Premise
254	whereas	_	_	I-Premise
255	DoCB	_	_	I-Premise
256	and	_	_	I-Premise
257	OS	_	_	I-Premise
258	were	_	_	I-Premise
259	13.9	_	_	I-Premise
260	and	_	_	I-Premise
261	22.8	_	_	I-Premise
262	months	_	_	I-Premise
263	,	_	_	I-Premise
264	respectively	_	_	I-Premise
265	,	_	_	I-Premise
266	in	_	_	I-Premise
267	the	_	_	I-Premise
268	250-mg	_	_	I-Premise
269	group	_	_	I-Premise
270	.	_	_	I-Premise

271	Fulvestrant	_	_	B-Claim
272	500	_	_	I-Claim
273	mg	_	_	I-Claim
274	was	_	_	I-Claim
275	well	_	_	I-Claim
276	tolerated	_	_	I-Claim
277	with	_	_	I-Claim
278	no	_	_	I-Claim
279	dose-dependent	_	_	I-Claim
280	adverse	_	_	I-Claim
281	events	_	_	I-Claim
282	.	_	_	I-Claim

283	QOL	_	_	B-Claim
284	was	_	_	I-Claim
285	similar	_	_	I-Claim
286	for	_	_	I-Claim
287	both	_	_	I-Claim
288	arms	_	_	I-Claim
289	.	_	_	I-Claim

290	Fulvestrant	_	_	B-Claim
291	500	_	_	I-Claim
292	mg	_	_	I-Claim
293	was	_	_	I-Claim
294	associated	_	_	I-Claim
295	with	_	_	I-Claim
296	a	_	_	I-Claim
297	statistically	_	_	I-Claim
298	significant	_	_	I-Claim
299	increase	_	_	I-Claim
300	in	_	_	I-Claim
301	PFS	_	_	I-Claim
302	and	_	_	I-Claim
303	not	_	_	I-Claim
304	associated	_	_	I-Claim
305	with	_	_	I-Claim
306	increased	_	_	I-Claim
307	toxicity	_	_	I-Claim
308	,	_	_	I-Claim
309	corresponding	_	_	O
310	to	_	_	O
311	a	_	_	O
312	clinically	_	_	O
313	meaningful	_	_	O
314	improvement	_	_	O
315	in	_	_	O
316	benefit	_	_	O
317	versus	_	_	O
318	risk	_	_	O
319	compared	_	_	O
320	with	_	_	O
321	fulvestrant	_	_	O
322	250	_	_	O
323	mg	_	_	O
324	.	_	_	O


0	Temozolomide	_	_	O
1	(	_	_	O
2	TMZ	_	_	O
3	)	_	_	O
4	is	_	_	O
5	an	_	_	O
6	alkylating	_	_	O
7	agent	_	_	O
8	licensed	_	_	O
9	for	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	high-grade	_	_	O
13	glioma	_	_	O
14	(	_	_	O
15	HGG	_	_	O
16	)	_	_	O
17	.	_	_	O

18	No	_	_	O
19	prospective	_	_	O
20	comparison	_	_	O
21	with	_	_	O
22	nitrosourea-based	_	_	O
23	chemotherapy	_	_	O
24	exists	_	_	O
25	.	_	_	O

26	We	_	_	O
27	report	_	_	O
28	,	_	_	O
29	to	_	_	O
30	our	_	_	O
31	knowledge	_	_	O
32	,	_	_	O
33	the	_	_	O
34	first	_	_	O
35	randomized	_	_	O
36	trial	_	_	O
37	of	_	_	O
38	procarbazine	_	_	O
39	,	_	_	O
40	lomustine	_	_	O
41	,	_	_	O
42	and	_	_	O
43	vincristine	_	_	O
44	(	_	_	O
45	PCV	_	_	O
46	)	_	_	O
47	versus	_	_	O
48	TMZ	_	_	O
49	in	_	_	O
50	chemotherapy-naive	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	recurrent	_	_	O
54	HGG	_	_	O
55	.	_	_	O

56	Four	_	_	O
57	hundred	_	_	O
58	forty-seven	_	_	O
59	patients	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	PCV	_	_	O
65	(	_	_	O
66	224	_	_	O
67	patients	_	_	O
68	)	_	_	O
69	or	_	_	O
70	TMZ	_	_	O
71	(	_	_	O
72	sub-random	_	_	O
73	assignment	_	_	O
74	:	_	_	O
75	TMZ-5	_	_	O
76	[	_	_	O
77	200	_	_	O
78	mg/m	_	_	O
79	(	_	_	O
80	2	_	_	O
81	)	_	_	O
82	for	_	_	O
83	5	_	_	O
84	days	_	_	O
85	,	_	_	O
86	112	_	_	O
87	patients	_	_	O
88	]	_	_	O
89	or	_	_	O
90	TMZ-21	_	_	O
91	[	_	_	O
92	100	_	_	O
93	mg/m	_	_	O
94	(	_	_	O
95	2	_	_	O
96	)	_	_	O
97	for	_	_	O
98	21	_	_	O
99	days	_	_	O
100	,	_	_	O
101	111	_	_	O
102	patients	_	_	O
103	]	_	_	O
104	)	_	_	O
105	for	_	_	O
106	up	_	_	O
107	to	_	_	O
108	9	_	_	O
109	months	_	_	O
110	or	_	_	O
111	until	_	_	O
112	progression	_	_	O
113	.	_	_	O

114	The	_	_	O
115	primary	_	_	O
116	outcomes	_	_	O
117	were	_	_	O
118	survival	_	_	O
119	(	_	_	O
120	PCV	_	_	O
121	v	_	_	O
122	TMZ	_	_	O
123	)	_	_	O
124	and	_	_	O
125	12-week	_	_	O
126	progression-free	_	_	O
127	survival	_	_	O
128	(	_	_	O
129	PFS	_	_	O
130	;	_	_	O
131	TMZ-5	_	_	O
132	v	_	_	O
133	TMZ-21	_	_	O
134	)	_	_	O
135	.	_	_	O

136	This	_	_	O
137	study	_	_	O
138	is	_	_	O
139	registered	_	_	O
140	as	_	_	O
141	ISRCTN83176944	_	_	O
142	.	_	_	O

143	Percentages	_	_	O
144	of	_	_	O
145	patients	_	_	O
146	completing	_	_	O
147	9	_	_	O
148	months	_	_	O
149	of	_	_	O
150	treatment	_	_	O
151	in	_	_	O
152	the	_	_	O
153	PCV	_	_	O
154	,	_	_	O
155	TMZ-5	_	_	O
156	,	_	_	O
157	and	_	_	O
158	TMZ-21	_	_	O
159	arms	_	_	O
160	were	_	_	O
161	17	_	_	O
162	%	_	_	O
163	,	_	_	O
164	26	_	_	O
165	%	_	_	O
166	,	_	_	O
167	and	_	_	O
168	13	_	_	O
169	%	_	_	O
170	,	_	_	O
171	respectively	_	_	O
172	.	_	_	O

173	Major	_	_	B-Premise
174	toxicity	_	_	I-Premise
175	was	_	_	I-Premise
176	similar	_	_	I-Premise
177	across	_	_	I-Premise
178	all	_	_	I-Premise
179	three	_	_	I-Premise
180	groups	_	_	I-Premise
181	.	_	_	I-Premise

182	With	_	_	B-Premise
183	a	_	_	I-Premise
184	median	_	_	I-Premise
185	follow-up	_	_	I-Premise
186	time	_	_	I-Premise
187	of	_	_	I-Premise
188	12	_	_	I-Premise
189	months	_	_	I-Premise
190	and	_	_	I-Premise
191	382	_	_	I-Premise
192	deaths	_	_	I-Premise
193	,	_	_	I-Premise
194	there	_	_	I-Premise
195	was	_	_	I-Premise
196	no	_	_	I-Premise
197	clear	_	_	I-Premise
198	survival	_	_	I-Premise
199	benefit	_	_	I-Premise
200	when	_	_	I-Premise
201	comparing	_	_	I-Premise
202	PCV	_	_	I-Premise
203	with	_	_	I-Premise
204	TMZ	_	_	I-Premise
205	(	_	_	I-Premise
206	hazard	_	_	I-Premise
207	ratio	_	_	I-Premise
208	[	_	_	I-Premise
209	HR	_	_	I-Premise
210	]	_	_	I-Premise
211	,	_	_	I-Premise
212	0.91	_	_	I-Premise
213	;	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	,	_	_	I-Premise
218	0.74	_	_	I-Premise
219	to	_	_	I-Premise
220	1.11	_	_	I-Premise
221	;	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	.350	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	For	_	_	B-Premise
228	TMZ-5	_	_	I-Premise
229	versus	_	_	I-Premise
230	TMZ-21	_	_	I-Premise
231	,	_	_	I-Premise
232	12-week	_	_	I-Premise
233	PFS	_	_	I-Premise
234	rates	_	_	I-Premise
235	were	_	_	I-Premise
236	similar	_	_	I-Premise
237	(	_	_	I-Premise
238	63.6	_	_	I-Premise
239	%	_	_	I-Premise
240	and	_	_	I-Premise
241	65.7	_	_	I-Premise
242	%	_	_	I-Premise
243	,	_	_	I-Premise
244	respectively	_	_	I-Premise
245	;	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.745	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	but	_	_	B-Premise
252	TMZ-5	_	_	I-Premise
253	improved	_	_	I-Premise
254	overall	_	_	I-Premise
255	PFS	_	_	I-Premise
256	(	_	_	I-Premise
257	HR	_	_	I-Premise
258	,	_	_	I-Premise
259	1.38	_	_	I-Premise
260	;	_	_	I-Premise
261	95	_	_	I-Premise
262	%	_	_	I-Premise
263	CI	_	_	I-Premise
264	,	_	_	I-Premise
265	1.05	_	_	I-Premise
266	to	_	_	I-Premise
267	1.82	_	_	I-Premise
268	;	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.023	_	_	I-Premise
272	)	_	_	I-Premise
273	,	_	_	I-Premise
274	survival	_	_	I-Premise
275	(	_	_	I-Premise
276	HR	_	_	I-Premise
277	,	_	_	I-Premise
278	1.32	_	_	I-Premise
279	;	_	_	I-Premise
280	95	_	_	I-Premise
281	%	_	_	I-Premise
282	CI	_	_	I-Premise
283	,	_	_	I-Premise
284	0.99	_	_	I-Premise
285	to	_	_	I-Premise
286	1.75	_	_	I-Premise
287	;	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.056	_	_	I-Premise
291	)	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	global	_	_	I-Premise
295	quality	_	_	I-Premise
296	of	_	_	I-Premise
297	life	_	_	I-Premise
298	(	_	_	I-Premise
299	49	_	_	I-Premise
300	%	_	_	I-Premise
301	v	_	_	I-Premise
302	19	_	_	I-Premise
303	%	_	_	I-Premise
304	improved	_	_	I-Premise
305	>	_	_	I-Premise
306	10	_	_	I-Premise
307	points	_	_	I-Premise
308	at	_	_	I-Premise
309	6	_	_	I-Premise
310	months	_	_	I-Premise
311	,	_	_	I-Premise
312	respectively	_	_	I-Premise
313	;	_	_	I-Premise
314	P	_	_	I-Premise
315	=	_	_	I-Premise
316	.005	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	Although	_	_	B-Claim
320	TMZ	_	_	I-Claim
321	(	_	_	I-Claim
322	both	_	_	I-Claim
323	arms	_	_	I-Claim
324	combined	_	_	I-Claim
325	)	_	_	I-Claim
326	did	_	_	I-Claim
327	not	_	_	I-Claim
328	show	_	_	I-Claim
329	a	_	_	I-Claim
330	clear	_	_	I-Claim
331	benefit	_	_	I-Claim
332	compared	_	_	I-Claim
333	with	_	_	I-Claim
334	PCV	_	_	I-Claim
335	,	_	_	I-Claim
336	comparison	_	_	I-Claim
337	of	_	_	I-Claim
338	the	_	_	I-Claim
339	TMZ	_	_	I-Claim
340	schedules	_	_	I-Claim
341	demonstrated	_	_	I-Claim
342	that	_	_	I-Claim
343	the	_	_	I-Claim
344	21-day	_	_	I-Claim
345	schedule	_	_	I-Claim
346	was	_	_	I-Claim
347	inferior	_	_	I-Claim
348	to	_	_	I-Claim
349	the	_	_	I-Claim
350	5-day	_	_	I-Claim
351	schedule	_	_	I-Claim
352	in	_	_	I-Claim
353	this	_	_	I-Claim
354	setting	_	_	I-Claim
355	.	_	_	I-Claim

356	This	_	_	B-Claim
357	challenges	_	_	I-Claim
358	the	_	_	I-Claim
359	current	_	_	I-Claim
360	understanding	_	_	I-Claim
361	of	_	_	I-Claim
362	increasing	_	_	I-Claim
363	TMZ	_	_	I-Claim
364	dose-intensity	_	_	I-Claim
365	by	_	_	I-Claim
366	prolonged	_	_	I-Claim
367	scheduling	_	_	I-Claim
368	.	_	_	I-Claim


0	Before	_	_	O
1	the	_	_	O
2	knowledge	_	_	O
3	that	_	_	O
4	5	_	_	O
5	years	_	_	O
6	of	_	_	O
7	adjuvant	_	_	O
8	tamoxifen	_	_	O
9	is	_	_	O
10	less	_	_	O
11	efficacious	_	_	O
12	than	_	_	O
13	2	_	_	O
14	to	_	_	O
15	3	_	_	O
16	years	_	_	O
17	of	_	_	O
18	tamoxifen	_	_	O
19	followed	_	_	O
20	by	_	_	O
21	2	_	_	O
22	to	_	_	O
23	3	_	_	O
24	years	_	_	O
25	of	_	_	O
26	anastrozole/exemestane	_	_	O
27	,	_	_	O
28	we	_	_	O
29	designed	_	_	O
30	a	_	_	O
31	multicenter	_	_	O
32	double-blind	_	_	O
33	randomized	_	_	O
34	controlled	_	_	O
35	trial	_	_	O
36	in	_	_	O
37	women	_	_	O
38	taking	_	_	O
39	tamoxifen	_	_	O
40	with	_	_	O
41	a	_	_	O
42	thickened	_	_	O
43	endometrium	_	_	O
44	to	_	_	O
45	compare	_	_	O
46	uterine	_	_	O
47	and	_	_	O
48	quality-of-life	_	_	O
49	parameters	_	_	O
50	between	_	_	O
51	those	_	_	O
52	switching	_	_	O
53	to	_	_	O
54	anastrozole	_	_	O
55	and	_	_	O
56	those	_	_	O
57	continuing	_	_	O
58	tamoxifen	_	_	O
59	.	_	_	O

60	Asymptomatic	_	_	O
61	postmenopausal	_	_	O
62	women	_	_	O
63	who	_	_	O
64	took	_	_	O
65	adjuvant	_	_	O
66	tamoxifen	_	_	O
67	for	_	_	O
68	2	_	_	O
69	to	_	_	O
70	3	_	_	O
71	years	_	_	O
72	for	_	_	O
73	operable	_	_	O
74	breast	_	_	O
75	cancer	_	_	O
76	with	_	_	O
77	a	_	_	O
78	double	_	_	O
79	endometrial	_	_	O
80	thickness	_	_	O
81	greater	_	_	O
82	than	_	_	O
83	7	_	_	O
84	mm	_	_	O
85	were	_	_	O
86	randomized	_	_	O
87	to	_	_	O
88	20	_	_	O
89	mg	_	_	O
90	tamoxifen	_	_	O
91	or	_	_	O
92	1	_	_	O
93	mg	_	_	O
94	anastrozole	_	_	O
95	for	_	_	O
96	the	_	_	O
97	remaining	_	_	O
98	duration	_	_	O
99	,	_	_	O
100	totaling	_	_	O
101	5	_	_	O
102	years	_	_	O
103	.	_	_	O

104	Tablets	_	_	O
105	were	_	_	O
106	unrecognizable	_	_	O
107	for	_	_	O
108	drug	_	_	O
109	assignment	_	_	O
110	.	_	_	O

111	The	_	_	O
112	primary	_	_	O
113	endpoints	_	_	O
114	were	_	_	O
115	the	_	_	O
116	differences	_	_	O
117	in	_	_	O
118	double	_	_	O
119	endometrial	_	_	O
120	thickness	_	_	O
121	and	_	_	O
122	uterine	_	_	O
123	volume	_	_	O
124	after	_	_	O
125	1	_	_	O
126	year	_	_	O
127	.	_	_	O

128	Uterine	_	_	O
129	and	_	_	O
130	quality-of-life	_	_	O
131	data	_	_	O
132	were	_	_	O
133	analyzed	_	_	O
134	using	_	_	O
135	regression	_	_	O
136	methods	_	_	O
137	,	_	_	O
138	and	_	_	O
139	missing	_	_	O
140	values	_	_	O
141	were	_	_	O
142	handled	_	_	O
143	using	_	_	O
144	multiple	_	_	O
145	imputation	_	_	O
146	.	_	_	O

147	Seventy-two	_	_	O
148	women	_	_	O
149	(	_	_	O
150	median	_	_	O
151	age	_	_	O
152	,	_	_	O
153	60	_	_	O
154	y	_	_	O
155	)	_	_	O
156	were	_	_	O
157	randomized	_	_	O
158	in	_	_	O
159	five	_	_	O
160	hospitals	_	_	O
161	.	_	_	O

162	Relative	_	_	B-Premise
163	to	_	_	I-Premise
164	women	_	_	I-Premise
165	continuing	_	_	I-Premise
166	tamoxifen	_	_	I-Premise
167	,	_	_	I-Premise
168	women	_	_	I-Premise
169	switching	_	_	I-Premise
170	to	_	_	I-Premise
171	anastrozole	_	_	I-Premise
172	experienced	_	_	I-Premise
173	a	_	_	I-Premise
174	decrease	_	_	I-Premise
175	of	_	_	I-Premise
176	53	_	_	I-Premise
177	%	_	_	I-Premise
178	(	_	_	I-Premise
179	95	_	_	I-Premise
180	%	_	_	I-Premise
181	CI	_	_	I-Premise
182	,	_	_	I-Premise
183	41	_	_	I-Premise
184	%	_	_	I-Premise
185	-63	_	_	I-Premise
186	%	_	_	I-Premise
187	)	_	_	I-Premise
188	in	_	_	I-Premise
189	double	_	_	I-Premise
190	endometrial	_	_	I-Premise
191	thickness	_	_	I-Premise
192	and	_	_	I-Premise
193	a	_	_	I-Premise
194	decrease	_	_	I-Premise
195	of	_	_	I-Premise
196	51	_	_	I-Premise
197	%	_	_	I-Premise
198	(	_	_	I-Premise
199	95	_	_	I-Premise
200	%	_	_	I-Premise
201	CI	_	_	I-Premise
202	,	_	_	I-Premise
203	39	_	_	I-Premise
204	%	_	_	I-Premise
205	-60	_	_	I-Premise
206	%	_	_	I-Premise
207	)	_	_	I-Premise
208	in	_	_	I-Premise
209	uterine	_	_	I-Premise
210	volume	_	_	I-Premise
211	.	_	_	I-Premise

212	Vaginal	_	_	B-Premise
213	dryness	_	_	I-Premise
214	(	_	_	I-Premise
215	b	_	_	I-Premise
216	=	_	_	I-Premise
217	0.064	_	_	I-Premise
218	;	_	_	I-Premise
219	95	_	_	I-Premise
220	%	_	_	I-Premise
221	CI	_	_	I-Premise
222	,	_	_	I-Premise
223	0.016-0.112	_	_	I-Premise
224	)	_	_	I-Premise
225	and	_	_	I-Premise
226	sexual	_	_	I-Premise
227	problems	_	_	I-Premise
228	(	_	_	I-Premise
229	b	_	_	I-Premise
230	=	_	_	I-Premise
231	0.054	_	_	I-Premise
232	;	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	,	_	_	I-Premise
237	0.007-0.102	_	_	I-Premise
238	)	_	_	I-Premise
239	increased	_	_	I-Premise
240	in	_	_	I-Premise
241	women	_	_	I-Premise
242	taking	_	_	I-Premise
243	anastrozole	_	_	I-Premise
244	compared	_	_	I-Premise
245	with	_	_	I-Premise
246	women	_	_	I-Premise
247	taking	_	_	I-Premise
248	tamoxifen	_	_	I-Premise
249	.	_	_	I-Premise

250	Treatment	_	_	B-Premise
251	arms	_	_	I-Premise
252	did	_	_	I-Premise
253	not	_	_	I-Premise
254	differ	_	_	I-Premise
255	regarding	_	_	I-Premise
256	withdrawal	_	_	I-Premise
257	rate	_	_	I-Premise
258	and	_	_	I-Premise
259	the	_	_	I-Premise
260	experience	_	_	I-Premise
261	of	_	_	I-Premise
262	(	_	_	I-Premise
263	serious	_	_	I-Premise
264	)	_	_	I-Premise
265	adverse	_	_	I-Premise
266	events	_	_	I-Premise
267	.	_	_	I-Premise

268	Despite	_	_	O
269	premature	_	_	O
270	trial	_	_	O
271	closure	_	_	O
272	,	_	_	O
273	our	_	_	O
274	data	_	_	O
275	provided	_	_	O
276	valuable	_	_	O
277	insights	_	_	O
278	.	_	_	O

279	Switching	_	_	B-Claim
280	to	_	_	I-Claim
281	anastrozole	_	_	I-Claim
282	strongly	_	_	I-Claim
283	decreased	_	_	I-Claim
284	the	_	_	I-Claim
285	endometrial	_	_	I-Claim
286	thickness	_	_	I-Claim
287	and	_	_	I-Claim
288	uterine	_	_	I-Claim
289	volume	_	_	I-Claim
290	but	_	_	I-Claim
291	increased	_	_	I-Claim
292	sexual	_	_	I-Claim
293	disturbances	_	_	I-Claim
294	.	_	_	I-Claim

295	Safe	_	_	B-Claim
296	and	_	_	I-Claim
297	effective	_	_	I-Claim
298	interventions	_	_	I-Claim
299	are	_	_	I-Claim
300	needed	_	_	I-Claim
301	to	_	_	I-Claim
302	alleviate	_	_	I-Claim
303	sexual	_	_	I-Claim
304	dysfunction	_	_	I-Claim
305	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	bimatoprost	_	_	O
6	and	_	_	O
7	travoprost	_	_	O
8	on	_	_	O
9	intraocular	_	_	O
10	pressure	_	_	O
11	(	_	_	O
12	IOP	_	_	O
13	)	_	_	O
14	reduction	_	_	O
15	in	_	_	O
16	an	_	_	O
17	Egyptian	_	_	O
18	population	_	_	O
19	.	_	_	O

20	Patients	_	_	O
21	with	_	_	O
22	primary	_	_	O
23	open-angle	_	_	O
24	glaucoma	_	_	O
25	or	_	_	O
26	ocular	_	_	O
27	hypertension	_	_	O
28	were	_	_	O
29	randomized	_	_	O
30	to	_	_	O
31	receive	_	_	O
32	either	_	_	O
33	bimatoprost	_	_	O
34	0.03	_	_	O
35	%	_	_	O
36	or	_	_	O
37	travoprost	_	_	O
38	0.004	_	_	O
39	%	_	_	O
40	once	_	_	O
41	daily	_	_	O
42	.	_	_	O

43	IOPs	_	_	O
44	were	_	_	O
45	measured	_	_	O
46	at	_	_	O
47	baseline	_	_	O
48	;	_	_	O
49	2	_	_	O
50	weeks	_	_	O
51	;	_	_	O
52	and	_	_	O
53	1	_	_	O
54	,	_	_	O
55	2	_	_	O
56	,	_	_	O
57	4	_	_	O
58	,	_	_	O
59	and	_	_	O
60	6	_	_	O
61	months	_	_	O
62	using	_	_	O
63	Goldman	_	_	O
64	applanation	_	_	O
65	tonometery	_	_	O
66	.	_	_	O

67	Seventy-two	_	_	O
68	patients	_	_	O
69	were	_	_	O
70	included	_	_	O
71	:	_	_	O
72	34	_	_	O
73	and	_	_	O
74	38	_	_	O
75	(	_	_	O
76	P=0.142	_	_	O
77	)	_	_	O
78	with	_	_	O
79	a	_	_	O
80	baseline	_	_	O
81	mean	_	_	O
82	IOP	_	_	O
83	26.52	_	_	O
84	±	_	_	O
85	5.185	_	_	O
86	and	_	_	O
87	26.36	_	_	O
88	±	_	_	O
89	1.605	_	_	O
90	mm	_	_	O
91	Hg	_	_	O
92	(	_	_	O
93	P=0.629	_	_	O
94	)	_	_	O
95	for	_	_	O
96	bimatoprost	_	_	O
97	and	_	_	O
98	travoprost	_	_	O
99	,	_	_	O
100	respectively	_	_	O
101	.	_	_	O

102	Both	_	_	B-Premise
103	drops	_	_	I-Premise
104	provided	_	_	I-Premise
105	statistically	_	_	I-Premise
106	significant	_	_	I-Premise
107	IOP	_	_	I-Premise
108	reductions	_	_	I-Premise
109	from	_	_	I-Premise
110	baseline	_	_	I-Premise
111	at	_	_	I-Premise
112	all	_	_	I-Premise
113	visits	_	_	I-Premise
114	(	_	_	I-Premise
115	P	_	_	I-Premise
116	<	_	_	I-Premise
117	0.001	_	_	I-Premise
118	)	_	_	I-Premise
119	.	_	_	I-Premise

120	Bimatoprost	_	_	B-Claim
121	provided	_	_	I-Claim
122	greater	_	_	I-Claim
123	(	_	_	I-Claim
124	nonsignificant	_	_	I-Claim
125	)	_	_	I-Claim
126	mean	_	_	I-Claim
127	IOP	_	_	I-Claim
128	reductions	_	_	I-Claim
129	from	_	_	I-Claim
130	baseline	_	_	I-Claim
131	than	_	_	I-Claim
132	travoprost	_	_	I-Claim
133	at	_	_	I-Claim
134	each	_	_	I-Claim
135	visit	_	_	I-Claim
136	.	_	_	I-Claim

137	Mean	_	_	B-Premise
138	IOP	_	_	I-Premise
139	reduction	_	_	I-Premise
140	was	_	_	I-Premise
141	8.77	_	_	I-Premise
142	mm	_	_	I-Premise
143	Hg	_	_	I-Premise
144	(	_	_	I-Premise
145	33.39	_	_	I-Premise
146	%	_	_	I-Premise
147	)	_	_	I-Premise
148	and	_	_	I-Premise
149	8.42	_	_	I-Premise
150	mm	_	_	I-Premise
151	Hg	_	_	I-Premise
152	(	_	_	I-Premise
153	31.54	_	_	I-Premise
154	%	_	_	I-Premise
155	)	_	_	I-Premise
156	at	_	_	I-Premise
157	2	_	_	I-Premise
158	weeks	_	_	I-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	=	_	_	I-Premise
162	0.703	_	_	I-Premise
163	)	_	_	I-Premise
164	,	_	_	I-Premise
165	and	_	_	I-Premise
166	8.47	_	_	I-Premise
167	mm	_	_	I-Premise
168	Hg	_	_	I-Premise
169	(	_	_	I-Premise
170	31.61	_	_	I-Premise
171	%	_	_	I-Premise
172	)	_	_	I-Premise
173	and	_	_	I-Premise
174	7.84	_	_	I-Premise
175	mm	_	_	I-Premise
176	Hg	_	_	I-Premise
177	(	_	_	I-Premise
178	29.50	_	_	I-Premise
179	%	_	_	I-Premise
180	)	_	_	I-Premise
181	at	_	_	I-Premise
182	6	_	_	I-Premise
183	months	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	0.536	_	_	I-Premise
188	)	_	_	I-Premise
189	for	_	_	I-Premise
190	bimatoprost	_	_	I-Premise
191	and	_	_	I-Premise
192	travoprost	_	_	I-Premise
193	,	_	_	I-Premise
194	respectively	_	_	I-Premise
195	.	_	_	I-Premise

196	IOPs	_	_	B-Premise
197	at	_	_	I-Premise
198	2	_	_	I-Premise
199	weeks	_	_	I-Premise
200	were	_	_	I-Premise
201	18	_	_	I-Premise
202	mm	_	_	I-Premise
203	Hg	_	_	I-Premise
204	in	_	_	I-Premise
205	20	_	_	I-Premise
206	(	_	_	I-Premise
207	58.8	_	_	I-Premise
208	%	_	_	I-Premise
209	)	_	_	I-Premise
210	versus	_	_	I-Premise
211	19	_	_	I-Premise
212	(	_	_	I-Premise
213	50	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	eyes	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	0.603	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	and	_	_	I-Premise
224	16	_	_	I-Premise
225	mm	_	_	I-Premise
226	Hg	_	_	I-Premise
227	in	_	_	I-Premise
228	12	_	_	I-Premise
229	(	_	_	I-Premise
230	35	_	_	I-Premise
231	%	_	_	I-Premise
232	)	_	_	I-Premise
233	versus	_	_	I-Premise
234	12	_	_	I-Premise
235	(	_	_	I-Premise
236	32	_	_	I-Premise
237	%	_	_	I-Premise
238	)	_	_	I-Premise
239	eyes	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	0.456	_	_	I-Premise
244	)	_	_	I-Premise
245	;	_	_	I-Premise
246	and	_	_	I-Premise
247	at	_	_	I-Premise
248	6	_	_	I-Premise
249	months	_	_	I-Premise
250	18	_	_	I-Premise
251	mm	_	_	I-Premise
252	Hg	_	_	I-Premise
253	in	_	_	I-Premise
254	22	_	_	I-Premise
255	(	_	_	I-Premise
256	65	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	versus	_	_	I-Premise
260	14	_	_	I-Premise
261	(	_	_	I-Premise
262	37	_	_	I-Premise
263	%	_	_	I-Premise
264	)	_	_	I-Premise
265	eyes	_	_	I-Premise
266	(	_	_	I-Premise
267	P	_	_	I-Premise
268	=	_	_	I-Premise
269	0.045	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	and	_	_	I-Premise
273	16	_	_	I-Premise
274	mm	_	_	I-Premise
275	Hg	_	_	I-Premise
276	in	_	_	I-Premise
277	12	_	_	I-Premise
278	(	_	_	I-Premise
279	35	_	_	I-Premise
280	%	_	_	I-Premise
281	)	_	_	I-Premise
282	versus	_	_	I-Premise
283	7	_	_	I-Premise
284	(	_	_	I-Premise
285	18	_	_	I-Premise
286	%	_	_	I-Premise
287	)	_	_	I-Premise
288	eyes	_	_	I-Premise
289	(	_	_	I-Premise
290	P	_	_	I-Premise
291	=	_	_	I-Premise
292	0.037	_	_	I-Premise
293	)	_	_	I-Premise
294	for	_	_	I-Premise
295	bimatoprost	_	_	I-Premise
296	and	_	_	I-Premise
297	travoprost	_	_	I-Premise
298	,	_	_	I-Premise
299	respectively	_	_	I-Premise
300	.	_	_	I-Premise

301	Ocular	_	_	B-Claim
302	adverse	_	_	I-Claim
303	and	_	_	I-Claim
304	clinical	_	_	I-Claim
305	success	_	_	I-Claim
306	occurred	_	_	I-Claim
307	equally	_	_	I-Claim
308	with	_	_	I-Claim
309	both	_	_	I-Claim
310	drops	_	_	I-Claim
311	.	_	_	I-Claim

312	Both	_	_	B-Claim
313	drops	_	_	I-Claim
314	lowered	_	_	I-Claim
315	IOP	_	_	I-Claim
316	effectively	_	_	I-Claim
317	but	_	_	B-Claim
318	bimatoprost	_	_	I-Claim
319	showed	_	_	I-Claim
320	a	_	_	I-Claim
321	greater	_	_	I-Claim
322	non-significant	_	_	I-Claim
323	reductions	_	_	I-Claim
324	in	_	_	I-Claim
325	mean	_	_	I-Claim
326	IOP	_	_	I-Claim
327	from	_	_	I-Claim
328	baseline	_	_	I-Claim
329	.	_	_	I-Claim


0	trabeculectomy	_	_	O
1	is	_	_	O
2	the	_	_	O
3	standard	_	_	O
4	surgical	_	_	O
5	procedure	_	_	O
6	for	_	_	O
7	management	_	_	O
8	of	_	_	O
9	glaucoma	_	_	O
10	.	_	_	O

11	to	_	_	O
12	compare	_	_	O
13	the	_	_	O
14	outcome	_	_	O
15	of	_	_	O
16	triangular	_	_	O
17	and	_	_	O
18	rectangular	_	_	O
19	scleral	_	_	O
20	flaps	_	_	O
21	in	_	_	O
22	trabeculectomy	_	_	O
23	.	_	_	O

24	this	_	_	O
25	study	_	_	O
26	was	_	_	O
27	carried	_	_	O
28	out	_	_	O
29	in	_	_	O
30	the	_	_	O
31	Department	_	_	O
32	ofOphthalmology	_	_	O
33	,	_	_	O
34	BPKIHS	_	_	O
35	,	_	_	O
36	Dharan	_	_	O
37	,	_	_	O
38	over	_	_	O
39	a	_	_	O
40	period	_	_	O
41	of	_	_	O
42	one	_	_	O
43	year	_	_	O
44	.	_	_	O

45	A	_	_	O
46	total	_	_	O
47	of	_	_	O
48	22	_	_	O
49	patients	_	_	O
50	undergoing	_	_	O
51	trabeculectomy	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	undergo	_	_	O
56	either	_	_	O
57	trabeculectomy	_	_	O
58	with	_	_	O
59	triangular	_	_	O
60	scleral	_	_	O
61	flap	_	_	O
62	(	_	_	O
63	Group	_	_	O
64	A=	_	_	O
65	11	_	_	O
66	eyes	_	_	O
67	)	_	_	O
68	or	_	_	O
69	trabeculectomy	_	_	O
70	with	_	_	O
71	rectangular	_	_	O
72	flap	_	_	O
73	(	_	_	O
74	Group	_	_	O
75	B	_	_	O
76	=	_	_	O
77	11	_	_	O
78	eyes	_	_	O
79	)	_	_	O
80	.	_	_	O

81	the	_	_	O
82	parameters	_	_	O
83	studied	_	_	O
84	were	_	_	O
85	intraocular	_	_	O
86	pressure	_	_	O
87	(	_	_	O
88	IOP	_	_	O
89	)	_	_	O
90	,	_	_	O
91	anterior	_	_	O
92	chamber	_	_	O
93	depth	_	_	O
94	(	_	_	O
95	ACD	_	_	O
96	)	_	_	O
97	,	_	_	O
98	bleb	_	_	O
99	characteristics	_	_	O
100	and	_	_	O
101	surgical	_	_	O
102	complications	_	_	O
103	.	_	_	O

104	P	_	_	O
105	value	_	_	O
106	of	_	_	O
107	<	_	_	O
108	0.05	_	_	O
109	was	_	_	O
110	considered	_	_	O
111	significant	_	_	O
112	.	_	_	O

113	All	_	_	O
114	calculations	_	_	O
115	were	_	_	O
116	executed	_	_	O
117	using	_	_	O
118	SPSS	_	_	O
119	11.0	_	_	O
120	software	_	_	O
121	program	_	_	O
122	.	_	_	O

123	the	_	_	O
124	age	_	_	O
125	ranged	_	_	O
126	between	_	_	O
127	40	_	_	O
128	to	_	_	O
129	76	_	_	O
130	years	_	_	O
131	with	_	_	O
132	the	_	_	O
133	mean	_	_	O
134	of	_	_	O
135	56.5	_	_	O
136	+/-	_	_	O
137	9.25	_	_	O
138	years	_	_	O
139	.	_	_	O

140	The	_	_	O
141	most	_	_	O
142	common	_	_	O
143	preoperative	_	_	O
144	diagnosis	_	_	O
145	was	_	_	O
146	angle	_	_	O
147	closure	_	_	O
148	glaucoma	_	_	O
149	.	_	_	O

150	The	_	_	B-Premise
151	postoperative	_	_	I-Premise
152	percentage	_	_	I-Premise
153	of	_	_	I-Premise
154	IOP	_	_	I-Premise
155	reduction	_	_	I-Premise
156	(	_	_	I-Premise
157	Group	_	_	I-Premise
158	A	_	_	I-Premise
159	68.9	_	_	I-Premise
160	%	_	_	I-Premise
161	;	_	_	I-Premise
162	Group	_	_	I-Premise
163	B	_	_	I-Premise
164	66.51	_	_	I-Premise
165	%	_	_	I-Premise
166	)	_	_	I-Premise
167	was	_	_	I-Premise
168	statically	_	_	I-Premise
169	significant	_	_	I-Premise
170	in	_	_	I-Premise
171	both	_	_	I-Premise
172	the	_	_	I-Premise
173	groups	_	_	I-Premise
174	(	_	_	I-Premise
175	p=0.001	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Trabeculectomy	_	_	B-Premise
179	was	_	_	I-Premise
180	almost	_	_	I-Premise
181	equally	_	_	I-Premise
182	effective	_	_	I-Premise
183	with	_	_	I-Premise
184	complete	_	_	I-Premise
185	surgical	_	_	I-Premise
186	success	_	_	I-Premise
187	of	_	_	I-Premise
188	91	_	_	I-Premise
189	%	_	_	I-Premise
190	in	_	_	I-Premise
191	group	_	_	I-Premise
192	A	_	_	I-Premise
193	,	_	_	I-Premise
194	and	_	_	I-Premise
195	82	_	_	I-Premise
196	%	_	_	I-Premise
197	in	_	_	I-Premise
198	group	_	_	I-Premise
199	B	_	_	I-Premise
200	(	_	_	I-Premise
201	p=0.534	_	_	I-Premise
202	)	_	_	I-Premise
203	.	_	_	I-Premise

204	Final	_	_	B-Premise
205	bleb	_	_	I-Premise
206	scores	_	_	I-Premise
207	were	_	_	I-Premise
208	almost	_	_	I-Premise
209	similar	_	_	I-Premise
210	in	_	_	I-Premise
211	both	_	_	I-Premise
212	the	_	_	I-Premise
213	groups	_	_	I-Premise
214	with	_	_	I-Premise
215	3.27	_	_	I-Premise
216	+/-	_	_	I-Premise
217	1.5	_	_	I-Premise
218	in	_	_	I-Premise
219	group	_	_	I-Premise
220	A	_	_	I-Premise
221	and	_	_	I-Premise
222	3.36	_	_	I-Premise
223	+/-	_	_	I-Premise
224	1.21	_	_	I-Premise
225	in	_	_	I-Premise
226	group	_	_	I-Premise
227	B	_	_	I-Premise
228	(	_	_	I-Premise
229	p=0.877	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Hypotony	_	_	B-Premise
233	with	_	_	I-Premise
234	the	_	_	I-Premise
235	IOP	_	_	I-Premise
236	less	_	_	I-Premise
237	than	_	_	I-Premise
238	6	_	_	I-Premise
239	mmHg	_	_	I-Premise
240	was	_	_	I-Premise
241	found	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	first	_	_	I-Premise
245	post-operative	_	_	I-Premise
246	day	_	_	I-Premise
247	in	_	_	I-Premise
248	2	_	_	I-Premise
249	patients	_	_	I-Premise
250	in	_	_	I-Premise
251	Group	_	_	I-Premise
252	A	_	_	I-Premise
253	and	_	_	I-Premise
254	in	_	_	I-Premise
255	1	_	_	I-Premise
256	in	_	_	I-Premise
257	Group	_	_	I-Premise
258	B	_	_	I-Premise
259	.	_	_	I-Premise

260	All	_	_	O
261	of	_	_	O
262	them	_	_	O
263	improved	_	_	O
264	spontaneously	_	_	O
265	within	_	_	O
266	a	_	_	O
267	week	_	_	O
268	.	_	_	O

269	both	_	_	B-Claim
270	triangular	_	_	I-Claim
271	and	_	_	I-Claim
272	rectangular	_	_	I-Claim
273	scleral	_	_	I-Claim
274	flaps	_	_	I-Claim
275	in	_	_	I-Claim
276	trabeculectomy	_	_	I-Claim
277	are	_	_	I-Claim
278	equally	_	_	I-Claim
279	effective	_	_	I-Claim
280	in	_	_	I-Claim
281	terms	_	_	I-Claim
282	of	_	_	I-Claim
283	post	_	_	I-Claim
284	surgical	_	_	I-Claim
285	IOP	_	_	I-Claim
286	control	_	_	I-Claim
287	,	_	_	I-Claim
288	bleb	_	_	I-Claim
289	characteristics	_	_	I-Claim
290	and	_	_	I-Claim
291	complications	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	perform	_	_	O
2	a	_	_	O
3	randomized	_	_	O
4	trial	_	_	O
5	comparing	_	_	O
6	70	_	_	O
7	and	_	_	O
8	80	_	_	O
9	Gy	_	_	O
10	radiotherapy	_	_	O
11	for	_	_	O
12	prostate	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	A	_	_	O
16	total	_	_	O
17	of	_	_	O
18	306	_	_	O
19	patients	_	_	O
20	with	_	_	O
21	localized	_	_	O
22	prostate	_	_	O
23	cancer	_	_	O
24	were	_	_	O
25	randomized	_	_	O
26	.	_	_	O

27	No	_	_	O
28	androgen	_	_	O
29	deprivation	_	_	O
30	was	_	_	O
31	allowed	_	_	O
32	.	_	_	O

33	The	_	_	O
34	primary	_	_	O
35	endpoint	_	_	O
36	was	_	_	O
37	biochemical	_	_	O
38	relapse	_	_	O
39	according	_	_	O
40	to	_	_	O
41	the	_	_	O
42	modified	_	_	O
43	1997-American	_	_	O
44	Society	_	_	O
45	for	_	_	O
46	Therapeutic	_	_	O
47	Radiology	_	_	O
48	and	_	_	O
49	Oncology	_	_	O
50	and	_	_	O
51	Phoenix	_	_	O
52	definitions	_	_	O
53	.	_	_	O

54	Toxicity	_	_	O
55	was	_	_	O
56	graded	_	_	O
57	using	_	_	O
58	the	_	_	O
59	Radiation	_	_	O
60	Therapy	_	_	O
61	Oncology	_	_	O
62	Group	_	_	O
63	1991	_	_	O
64	criteria	_	_	O
65	and	_	_	O
66	the	_	_	O
67	late	_	_	O
68	effects	_	_	O
69	on	_	_	O
70	normal	_	_	O
71	tissues-subjective	_	_	O
72	,	_	_	O
73	objective	_	_	O
74	,	_	_	O
75	management	_	_	O
76	,	_	_	O
77	analytic	_	_	O
78	scales	_	_	O
79	(	_	_	O
80	LENT-SOMA	_	_	O
81	)	_	_	O
82	scales	_	_	O
83	.	_	_	O

84	The	_	_	O
85	patients	_	_	O
86	'	_	_	O
87	quality	_	_	O
88	of	_	_	O
89	life	_	_	O
90	was	_	_	O
91	scored	_	_	O
92	using	_	_	O
93	the	_	_	O
94	European	_	_	O
95	Organization	_	_	O
96	for	_	_	O
97	Research	_	_	O
98	and	_	_	O
99	Treatment	_	_	O
100	of	_	_	O
101	Cancer	_	_	O
102	Quality	_	_	O
103	of	_	_	O
104	Life	_	_	O
105	Questionnaire	_	_	O
106	30-item	_	_	O
107	cancer-specific	_	_	O
108	and	_	_	O
109	25-item	_	_	O
110	prostate-specific	_	_	O
111	modules	_	_	O
112	.	_	_	O

113	The	_	_	O
114	median	_	_	O
115	follow-up	_	_	O
116	was	_	_	O
117	61	_	_	O
118	months	_	_	O
119	.	_	_	O

120	According	_	_	O
121	to	_	_	O
122	the	_	_	O
123	1997-American	_	_	O
124	Society	_	_	O
125	for	_	_	O
126	Therapeutic	_	_	O
127	Radiology	_	_	O
128	and	_	_	O
129	Oncology	_	_	O
130	definition	_	_	O
131	,	_	_	O
132	the	_	_	O
133	5-year	_	_	O
134	biochemical	_	_	O
135	relapse	_	_	O
136	rate	_	_	O
137	was	_	_	O
138	39	_	_	O
139	%	_	_	O
140	and	_	_	O
141	28	_	_	O
142	%	_	_	O
143	in	_	_	O
144	the	_	_	O
145	70-	_	_	O
146	and	_	_	O
147	80-Gy	_	_	O
148	arms	_	_	O
149	,	_	_	O
150	respectively	_	_	O
151	(	_	_	O
152	p	_	_	O
153	=	_	_	O
154	.036	_	_	O
155	)	_	_	O
156	.	_	_	O

157	Using	_	_	O
158	the	_	_	O
159	Phoenix	_	_	O
160	definition	_	_	O
161	,	_	_	O
162	the	_	_	O
163	5-year	_	_	O
164	biochemical	_	_	O
165	relapse	_	_	O
166	rate	_	_	O
167	was	_	_	O
168	32	_	_	O
169	%	_	_	O
170	and	_	_	O
171	23.5	_	_	O
172	%	_	_	O
173	,	_	_	O
174	respectively	_	_	O
175	(	_	_	O
176	p	_	_	O
177	=	_	_	O
178	.09	_	_	O
179	)	_	_	O
180	.	_	_	O

181	The	_	_	O
182	subgroup	_	_	O
183	analysis	_	_	O
184	showed	_	_	O
185	a	_	_	O
186	better	_	_	O
187	biochemical	_	_	O
188	outcome	_	_	O
189	for	_	_	O
190	the	_	_	O
191	higher	_	_	O
192	dose	_	_	O
193	group	_	_	O
194	with	_	_	O
195	an	_	_	O
196	initial	_	_	O
197	prostate-specific	_	_	O
198	antigen	_	_	O
199	level	_	_	O
200	>	_	_	O
201	15	_	_	O
202	ng/mL	_	_	O
203	.	_	_	O

204	At	_	_	O
205	the	_	_	O
206	last	_	_	O
207	follow-up	_	_	O
208	date	_	_	O
209	,	_	_	O
210	26	_	_	O
211	patients	_	_	O
212	had	_	_	O
213	died	_	_	O
214	,	_	_	O
215	10	_	_	O
216	of	_	_	O
217	their	_	_	O
218	disease	_	_	O
219	and	_	_	O
220	none	_	_	O
221	of	_	_	O
222	toxicity	_	_	O
223	,	_	_	O
224	with	_	_	O
225	no	_	_	O
226	differences	_	_	O
227	between	_	_	O
228	the	_	_	O
229	two	_	_	O
230	arms	_	_	O
231	.	_	_	O

232	According	_	_	B-Premise
233	to	_	_	I-Premise
234	the	_	_	I-Premise
235	Radiation	_	_	I-Premise
236	Therapy	_	_	I-Premise
237	Oncology	_	_	I-Premise
238	Group	_	_	I-Premise
239	scale	_	_	I-Premise
240	,	_	_	I-Premise
241	the	_	_	I-Premise
242	Grade	_	_	I-Premise
243	2	_	_	I-Premise
244	or	_	_	I-Premise
245	greater	_	_	I-Premise
246	rectal	_	_	I-Premise
247	toxicity	_	_	I-Premise
248	rate	_	_	I-Premise
249	was	_	_	I-Premise
250	14	_	_	I-Premise
251	%	_	_	I-Premise
252	and	_	_	I-Premise
253	19.5	_	_	I-Premise
254	%	_	_	I-Premise
255	for	_	_	I-Premise
256	the	_	_	I-Premise
257	70-	_	_	I-Premise
258	and	_	_	I-Premise
259	80-Gy	_	_	I-Premise
260	arms	_	_	I-Premise
261	(	_	_	I-Premise
262	p	_	_	I-Premise
263	=	_	_	I-Premise
264	.22	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	respectively	_	_	I-Premise
268	.	_	_	I-Premise

269	The	_	_	B-Premise
270	Grade	_	_	I-Premise
271	2	_	_	I-Premise
272	or	_	_	I-Premise
273	greater	_	_	I-Premise
274	urinary	_	_	I-Premise
275	toxicity	_	_	I-Premise
276	was	_	_	I-Premise
277	10	_	_	I-Premise
278	%	_	_	I-Premise
279	at	_	_	I-Premise
280	70	_	_	I-Premise
281	Gy	_	_	I-Premise
282	and	_	_	I-Premise
283	17.5	_	_	I-Premise
284	%	_	_	I-Premise
285	at	_	_	I-Premise
286	80	_	_	I-Premise
287	Gy	_	_	I-Premise
288	(	_	_	I-Premise
289	p	_	_	I-Premise
290	=	_	_	I-Premise
291	.046	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	Similar	_	_	B-Premise
295	results	_	_	I-Premise
296	were	_	_	I-Premise
297	observed	_	_	I-Premise
298	using	_	_	I-Premise
299	the	_	_	I-Premise
300	LENT-SOMA	_	_	I-Premise
301	scale	_	_	I-Premise
302	.	_	_	I-Premise

303	Bladder	_	_	B-Premise
304	toxicity	_	_	I-Premise
305	was	_	_	I-Premise
306	more	_	_	I-Premise
307	frequent	_	_	I-Premise
308	at	_	_	I-Premise
309	80	_	_	I-Premise
310	Gy	_	_	I-Premise
311	than	_	_	I-Premise
312	at	_	_	I-Premise
313	70	_	_	I-Premise
314	Gy	_	_	I-Premise
315	(	_	_	I-Premise
316	p	_	_	I-Premise
317	=	_	_	I-Premise
318	.039	_	_	I-Premise
319	)	_	_	I-Premise
320	.	_	_	I-Premise

321	The	_	_	B-Premise
322	quality-of-life	_	_	I-Premise
323	questionnaire	_	_	I-Premise
324	results	_	_	I-Premise
325	before	_	_	I-Premise
326	and	_	_	I-Premise
327	5	_	_	I-Premise
328	years	_	_	I-Premise
329	after	_	_	I-Premise
330	treatment	_	_	I-Premise
331	were	_	_	I-Premise
332	available	_	_	I-Premise
333	for	_	_	I-Premise
334	103	_	_	I-Premise
335	patients	_	_	I-Premise
336	with	_	_	I-Premise
337	no	_	_	I-Premise
338	differences	_	_	I-Premise
339	found	_	_	I-Premise
340	between	_	_	I-Premise
341	the	_	_	I-Premise
342	70-	_	_	I-Premise
343	and	_	_	I-Premise
344	80-Gy	_	_	I-Premise
345	arms	_	_	I-Premise
346	.	_	_	I-Premise

347	High-dose	_	_	B-Claim
348	radiotherapy	_	_	I-Claim
349	provided	_	_	I-Claim
350	a	_	_	I-Claim
351	better	_	_	I-Claim
352	5-year	_	_	I-Claim
353	biochemical	_	_	I-Claim
354	outcome	_	_	I-Claim
355	with	_	_	I-Claim
356	slightly	_	_	I-Claim
357	greater	_	_	I-Claim
358	toxicity	_	_	I-Claim
359	.	_	_	I-Claim


0	Numerous	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	examined	_	_	O
4	the	_	_	O
5	comorbidity	_	_	O
6	of	_	_	O
7	depression	_	_	O
8	with	_	_	O
9	cancer	_	_	O
10	,	_	_	O
11	and	_	_	O
12	some	_	_	O
13	have	_	_	O
14	indicated	_	_	O
15	that	_	_	O
16	depression	_	_	O
17	may	_	_	O
18	be	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	cancer	_	_	O
22	progression	_	_	O
23	or	_	_	O
24	survival	_	_	O
25	.	_	_	O

26	However	_	_	O
27	,	_	_	O
28	few	_	_	O
29	studies	_	_	O
30	have	_	_	O
31	assessed	_	_	O
32	whether	_	_	O
33	changes	_	_	O
34	in	_	_	O
35	depression	_	_	O
36	symptoms	_	_	O
37	are	_	_	O
38	associated	_	_	O
39	with	_	_	O
40	survival	_	_	O
41	.	_	_	O

42	In	_	_	O
43	a	_	_	O
44	secondary	_	_	O
45	analysis	_	_	O
46	of	_	_	O
47	a	_	_	O
48	randomized	_	_	O
49	trial	_	_	O
50	of	_	_	O
51	supportive-expressive	_	_	O
52	group	_	_	O
53	therapy	_	_	O
54	,	_	_	O
55	125	_	_	O
56	women	_	_	O
57	with	_	_	O
58	metastatic	_	_	O
59	breast	_	_	O
60	cancer	_	_	O
61	(	_	_	O
62	MBC	_	_	O
63	)	_	_	O
64	completed	_	_	O
65	a	_	_	O
66	depression	_	_	O
67	symptom	_	_	O
68	measure	_	_	O
69	(	_	_	O
70	Center	_	_	O
71	for	_	_	O
72	Epidemiologic	_	_	O
73	Studies-Depression	_	_	O
74	Scale	_	_	O
75	[	_	_	O
76	CES-D	_	_	O
77	]	_	_	O
78	)	_	_	O
79	at	_	_	O
80	baseline	_	_	O
81	and	_	_	O
82	were	_	_	O
83	randomly	_	_	O
84	assigned	_	_	O
85	to	_	_	O
86	a	_	_	O
87	treatment	_	_	O
88	group	_	_	O
89	or	_	_	O
90	to	_	_	O
91	a	_	_	O
92	control	_	_	O
93	group	_	_	O
94	that	_	_	O
95	received	_	_	O
96	educational	_	_	O
97	materials	_	_	O
98	.	_	_	O

99	At	_	_	O
100	baseline	_	_	O
101	and	_	_	O
102	three	_	_	O
103	follow-up	_	_	O
104	points	_	_	O
105	,	_	_	O
106	101	_	_	O
107	of	_	_	O
108	125	_	_	O
109	women	_	_	O
110	completed	_	_	O
111	a	_	_	O
112	depression	_	_	O
113	symptom	_	_	O
114	measure	_	_	O
115	.	_	_	O

116	We	_	_	O
117	used	_	_	O
118	these	_	_	O
119	data	_	_	O
120	in	_	_	O
121	a	_	_	O
122	Cox	_	_	O
123	proportional	_	_	O
124	hazards	_	_	O
125	analysis	_	_	O
126	to	_	_	O
127	examine	_	_	O
128	whether	_	_	O
129	decreasing	_	_	O
130	depression	_	_	O
131	symptoms	_	_	O
132	over	_	_	O
133	the	_	_	O
134	first	_	_	O
135	year	_	_	O
136	of	_	_	O
137	the	_	_	O
138	study	_	_	O
139	(	_	_	O
140	the	_	_	O
141	length	_	_	O
142	of	_	_	O
143	the	_	_	O
144	intervention	_	_	O
145	)	_	_	O
146	would	_	_	O
147	be	_	_	O
148	associated	_	_	O
149	with	_	_	O
150	longer	_	_	O
151	survival	_	_	O
152	.	_	_	O

153	Median	_	_	B-Premise
154	survival	_	_	I-Premise
155	time	_	_	I-Premise
156	was	_	_	I-Premise
157	53.6	_	_	I-Premise
158	months	_	_	I-Premise
159	for	_	_	I-Premise
160	women	_	_	I-Premise
161	with	_	_	I-Premise
162	decreasing	_	_	I-Premise
163	CES-D	_	_	I-Premise
164	scores	_	_	I-Premise
165	over	_	_	I-Premise
166	1	_	_	I-Premise
167	year	_	_	I-Premise
168	and	_	_	I-Premise
169	25.1	_	_	I-Premise
170	months	_	_	I-Premise
171	for	_	_	I-Premise
172	women	_	_	I-Premise
173	with	_	_	I-Premise
174	increasing	_	_	I-Premise
175	CES-D	_	_	I-Premise
176	scores	_	_	I-Premise
177	.	_	_	I-Premise

178	There	_	_	B-Premise
179	was	_	_	I-Premise
180	a	_	_	I-Premise
181	significant	_	_	I-Premise
182	effect	_	_	I-Premise
183	of	_	_	I-Premise
184	change	_	_	I-Premise
185	in	_	_	I-Premise
186	CES-D	_	_	I-Premise
187	over	_	_	I-Premise
188	the	_	_	I-Premise
189	first	_	_	I-Premise
190	year	_	_	I-Premise
191	on	_	_	I-Premise
192	survival	_	_	I-Premise
193	out	_	_	I-Premise
194	to	_	_	I-Premise
195	14	_	_	I-Premise
196	years	_	_	I-Premise
197	(	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	.007	_	_	I-Premise
201	)	_	_	I-Premise
202	but	_	_	B-Premise
203	no	_	_	I-Premise
204	significant	_	_	I-Premise
205	interaction	_	_	I-Premise
206	between	_	_	I-Premise
207	treatment	_	_	I-Premise
208	condition	_	_	I-Premise
209	and	_	_	I-Premise
210	CES-D	_	_	I-Premise
211	change	_	_	I-Premise
212	on	_	_	I-Premise
213	survival	_	_	I-Premise
214	.	_	_	I-Premise

215	Neither	_	_	O
216	demographic	_	_	O
217	nor	_	_	O
218	medical	_	_	O
219	variables	_	_	O
220	explained	_	_	O
221	this	_	_	O
222	association	_	_	O
223	.	_	_	O

224	Decreasing	_	_	B-Claim
225	depression	_	_	I-Claim
226	symptoms	_	_	I-Claim
227	over	_	_	I-Claim
228	the	_	_	I-Claim
229	first	_	_	I-Claim
230	year	_	_	I-Claim
231	were	_	_	I-Claim
232	associated	_	_	I-Claim
233	with	_	_	I-Claim
234	longer	_	_	I-Claim
235	subsequent	_	_	I-Claim
236	survival	_	_	I-Claim
237	for	_	_	I-Claim
238	women	_	_	I-Claim
239	with	_	_	I-Claim
240	MBC	_	_	I-Claim
241	in	_	_	I-Claim
242	this	_	_	I-Claim
243	sample	_	_	I-Claim
244	.	_	_	I-Claim

245	Further	_	_	B-Claim
246	research	_	_	I-Claim
247	is	_	_	I-Claim
248	necessary	_	_	I-Claim
249	to	_	_	I-Claim
250	confirm	_	_	I-Claim
251	this	_	_	I-Claim
252	hypothesis	_	_	I-Claim
253	in	_	_	I-Claim
254	other	_	_	I-Claim
255	samples	_	_	I-Claim
256	,	_	_	I-Claim
257	and	_	_	I-Claim
258	causation	_	_	I-Claim
259	can	_	_	I-Claim
260	not	_	_	I-Claim
261	be	_	_	I-Claim
262	assumed	_	_	I-Claim
263	based	_	_	I-Claim
264	on	_	_	I-Claim
265	this	_	_	I-Claim
266	analysis	_	_	I-Claim
267	.	_	_	I-Claim


0	The	_	_	O
1	American	_	_	O
2	College	_	_	O
3	of	_	_	O
4	Surgeons	_	_	O
5	Oncology	_	_	O
6	Group	_	_	O
7	phase	_	_	O
8	III	_	_	O
9	Surgical	_	_	O
10	Prostatectomy	_	_	O
11	Versus	_	_	O
12	Interstitial	_	_	O
13	Radiation	_	_	O
14	Intervention	_	_	O
15	Trial	_	_	O
16	comparing	_	_	O
17	radical	_	_	O
18	prostatectomy	_	_	O
19	(	_	_	O
20	RP	_	_	O
21	)	_	_	O
22	and	_	_	O
23	brachytherapy	_	_	O
24	(	_	_	O
25	BT	_	_	O
26	)	_	_	O
27	closed	_	_	O
28	after	_	_	O
29	2	_	_	O
30	years	_	_	O
31	due	_	_	O
32	to	_	_	O
33	poor	_	_	O
34	accrual	_	_	O
35	.	_	_	O

36	We	_	_	O
37	report	_	_	O
38	health-related	_	_	O
39	quality	_	_	O
40	of	_	_	O
41	life	_	_	O
42	(	_	_	O
43	HRQOL	_	_	O
44	)	_	_	O
45	at	_	_	O
46	a	_	_	O
47	mean	_	_	O
48	of	_	_	O
49	5.3	_	_	O
50	years	_	_	O
51	for	_	_	O
52	168	_	_	O
53	trial-eligible	_	_	O
54	men	_	_	O
55	who	_	_	O
56	either	_	_	O
57	chose	_	_	O
58	or	_	_	O
59	were	_	_	O
60	randomly	_	_	O
61	assigned	_	_	O
62	to	_	_	O
63	RP	_	_	O
64	or	_	_	O
65	BT	_	_	O
66	following	_	_	O
67	a	_	_	O
68	multidisciplinary	_	_	O
69	educational	_	_	O
70	session	_	_	O
71	.	_	_	O

72	After	_	_	O
73	initial	_	_	O
74	lack	_	_	O
75	of	_	_	O
76	accrual	_	_	O
77	,	_	_	O
78	a	_	_	O
79	multidisciplinary	_	_	O
80	educational	_	_	O
81	session	_	_	O
82	was	_	_	O
83	introduced	_	_	O
84	for	_	_	O
85	eligible	_	_	O
86	patients	_	_	O
87	.	_	_	O

88	In	_	_	O
89	all	_	_	O
90	,	_	_	O
91	263	_	_	O
92	men	_	_	O
93	attended	_	_	O
94	47	_	_	O
95	sessions	_	_	O
96	.	_	_	O

97	Of	_	_	O
98	those	_	_	O
99	,	_	_	O
100	34	_	_	O
101	consented	_	_	O
102	to	_	_	O
103	random	_	_	O
104	assignment	_	_	O
105	,	_	_	O
106	62	_	_	O
107	chose	_	_	O
108	RP	_	_	O
109	,	_	_	O
110	and	_	_	O
111	94	_	_	O
112	chose	_	_	O
113	BT	_	_	O
114	.	_	_	O

115	Five	_	_	O
116	years	_	_	O
117	later	_	_	O
118	,	_	_	O
119	these	_	_	O
120	190	_	_	O
121	men	_	_	O
122	underwent	_	_	O
123	HRQOL	_	_	O
124	evaluation	_	_	O
125	by	_	_	O
126	using	_	_	O
127	the	_	_	O
128	cancer-specific	_	_	O
129	50-item	_	_	O
130	Expanded	_	_	O
131	Prostate	_	_	O
132	Cancer	_	_	O
133	Index	_	_	O
134	Composite	_	_	O
135	,	_	_	O
136	the	_	_	O
137	Short	_	_	O
138	Form	_	_	O
139	12	_	_	O
140	Physical	_	_	O
141	Component	_	_	O
142	Score	_	_	O
143	,	_	_	O
144	and	_	_	O
145	Short	_	_	O
146	Form	_	_	O
147	12	_	_	O
148	Mental	_	_	O
149	Component	_	_	O
150	Score	_	_	O
151	.	_	_	O

152	Response	_	_	O
153	rate	_	_	O
154	was	_	_	O
155	88.4	_	_	O
156	%	_	_	O
157	.	_	_	O

158	The	_	_	O
159	Wilcoxon	_	_	O
160	rank	_	_	O
161	sum	_	_	O
162	test	_	_	O
163	was	_	_	O
164	used	_	_	O
165	to	_	_	O
166	compare	_	_	O
167	summary	_	_	O
168	scores	_	_	O
169	between	_	_	O
170	the	_	_	O
171	two	_	_	O
172	interventions	_	_	O
173	.	_	_	O

174	Of	_	_	O
175	168	_	_	O
176	survey	_	_	O
177	responders	_	_	O
178	,	_	_	O
179	60.7	_	_	O
180	%	_	_	O
181	had	_	_	O
182	BT	_	_	O
183	(	_	_	O
184	9.5	_	_	O
185	%	_	_	O
186	randomly	_	_	O
187	assigned	_	_	O
188	)	_	_	O
189	and	_	_	O
190	39.3	_	_	O
191	%	_	_	O
192	had	_	_	O
193	RP	_	_	O
194	(	_	_	O
195	9.5	_	_	O
196	%	_	_	O
197	randomly	_	_	O
198	assigned	_	_	O
199	)	_	_	O
200	.	_	_	O

201	Median	_	_	O
202	age	_	_	O
203	was	_	_	O
204	61.4	_	_	O
205	years	_	_	O
206	for	_	_	O
207	BT	_	_	O
208	and	_	_	O
209	59.4	_	_	O
210	for	_	_	O
211	RP	_	_	O
212	(	_	_	O
213	P	_	_	O
214	=	_	_	O
215	.05	_	_	O
216	)	_	_	O
217	.	_	_	O

218	Median	_	_	O
219	follow-up	_	_	O
220	was	_	_	O
221	5.2	_	_	O
222	years	_	_	O
223	(	_	_	O
224	range	_	_	O
225	,	_	_	O
226	3.2	_	_	O
227	to	_	_	O
228	6.5	_	_	O
229	years	_	_	O
230	)	_	_	O
231	.	_	_	O

232	For	_	_	B-Premise
233	BT	_	_	I-Premise
234	versus	_	_	I-Premise
235	RP	_	_	I-Premise
236	,	_	_	I-Premise
237	there	_	_	I-Premise
238	was	_	_	I-Premise
239	no	_	_	I-Premise
240	difference	_	_	I-Premise
241	in	_	_	I-Premise
242	bowel	_	_	I-Premise
243	or	_	_	I-Premise
244	hormonal	_	_	I-Premise
245	domains	_	_	I-Premise
246	,	_	_	I-Premise
247	but	_	_	O
248	men	_	_	B-Premise
249	treated	_	_	I-Premise
250	with	_	_	I-Premise
251	BT	_	_	I-Premise
252	scored	_	_	I-Premise
253	better	_	_	I-Premise
254	in	_	_	I-Premise
255	urinary	_	_	I-Premise
256	(	_	_	I-Premise
257	91.8	_	_	I-Premise
258	v	_	_	I-Premise
259	88.1	_	_	I-Premise
260	;	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.02	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	I-Premise
266	sexual	_	_	I-Premise
267	(	_	_	I-Premise
268	52.5	_	_	I-Premise
269	v	_	_	I-Premise
270	39.2	_	_	I-Premise
271	;	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	.001	_	_	I-Premise
275	)	_	_	I-Premise
276	domains	_	_	I-Premise
277	,	_	_	I-Premise
278	and	_	_	I-Premise
279	in	_	_	I-Premise
280	patient	_	_	I-Premise
281	satisfaction	_	_	I-Premise
282	(	_	_	I-Premise
283	93.6	_	_	I-Premise
284	v	_	_	I-Premise
285	76.9	_	_	I-Premise
286	;	_	_	I-Premise
287	P	_	_	I-Premise
288	<	_	_	I-Premise
289	.001	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	Although	_	_	O
293	treatment	_	_	O
294	allocation	_	_	O
295	was	_	_	O
296	random	_	_	O
297	in	_	_	O
298	only	_	_	O
299	19	_	_	O
300	%	_	_	O
301	,	_	_	O
302	all	_	_	O
303	patients	_	_	O
304	received	_	_	O
305	identical	_	_	O
306	information	_	_	O
307	in	_	_	O
308	a	_	_	O
309	multidisciplinary	_	_	O
310	setting	_	_	O
311	before	_	_	O
312	selecting	_	_	O
313	RP	_	_	O
314	,	_	_	O
315	BT	_	_	O
316	,	_	_	O
317	or	_	_	O
318	random	_	_	O
319	assignment	_	_	O
320	.	_	_	O

321	HRQOL	_	_	B-Claim
322	evaluated	_	_	I-Claim
323	3.2	_	_	I-Claim
324	to	_	_	I-Claim
325	6.5	_	_	I-Claim
326	years	_	_	I-Claim
327	after	_	_	I-Claim
328	treatment	_	_	I-Claim
329	showed	_	_	I-Claim
330	an	_	_	I-Claim
331	advantage	_	_	I-Claim
332	for	_	_	I-Claim
333	BT	_	_	I-Claim
334	in	_	_	I-Claim
335	urinary	_	_	I-Claim
336	and	_	_	I-Claim
337	sexual	_	_	I-Claim
338	domains	_	_	I-Claim
339	and	_	_	I-Claim
340	in	_	_	I-Claim
341	patient	_	_	I-Claim
342	satisfaction	_	_	I-Claim
343	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	analgesic	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	supplemental	_	_	O
7	intracameral	_	_	O
8	lidocaine	_	_	O
9	1	_	_	O
10	%	_	_	O
11	during	_	_	O
12	phacoemulsification	_	_	O
13	under	_	_	O
14	topical	_	_	O
15	anaesthesia	_	_	O
16	,	_	_	O
17	and	_	_	O
18	to	_	_	O
19	assess	_	_	O
20	the	_	_	O
21	risk	_	_	O
22	factors	_	_	O
23	associated	_	_	O
24	with	_	_	O
25	pain	_	_	O
26	.	_	_	O

27	In	_	_	O
28	a	_	_	O
29	double-masked	_	_	O
30	,	_	_	O
31	randomised	_	_	O
32	,	_	_	O
33	clinical	_	_	O
34	trial	_	_	O
35	,	_	_	O
36	506	_	_	O
37	patients	_	_	O
38	undergoing	_	_	O
39	phacoemulsification	_	_	O
40	under	_	_	O
41	topical	_	_	O
42	anaesthesia	_	_	O
43	were	_	_	O
44	randomised	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	a	_	_	O
48	supplemental	_	_	O
49	intracameral	_	_	O
50	injection	_	_	O
51	of	_	_	O
52	either	_	_	O
53	0.5	_	_	O
54	cc	_	_	O
55	of	_	_	O
56	1	_	_	O
57	%	_	_	O
58	lidocaine	_	_	O
59	(	_	_	O
60	277	_	_	O
61	patients	_	_	O
62	,	_	_	O
63	54.7	_	_	O
64	%	_	_	O
65	)	_	_	O
66	or	_	_	O
67	balanced	_	_	O
68	salt	_	_	O
69	solution	_	_	O
70	(	_	_	O
71	BSS	_	_	O
72	)	_	_	O
73	(	_	_	O
74	229	_	_	O
75	patients	_	_	O
76	,	_	_	O
77	45.3	_	_	O
78	%	_	_	O
79	)	_	_	O
80	.	_	_	O

81	Patients	_	_	O
82	were	_	_	O
83	interviewed	_	_	O
84	by	_	_	O
85	a	_	_	O
86	trained	_	_	O
87	interviewer	_	_	O
88	using	_	_	O
89	a	_	_	O
90	standardised	_	_	O
91	questionnaire	_	_	O
92	.	_	_	O

93	The	_	_	O
94	main	_	_	O
95	outcome	_	_	O
96	measure	_	_	O
97	was	_	_	O
98	intraoperative	_	_	O
99	pain	_	_	O
100	,	_	_	O
101	scored	_	_	O
102	on	_	_	O
103	a	_	_	O
104	visual	_	_	O
105	analogue	_	_	O
106	scale	_	_	O
107	of	_	_	O
108	0-10	_	_	O
109	.	_	_	O

110	Logistic	_	_	O
111	regression	_	_	O
112	was	_	_	O
113	performed	_	_	O
114	to	_	_	O
115	assess	_	_	O
116	ORs	_	_	O
117	.	_	_	O

118	125	_	_	B-Premise
119	of	_	_	I-Premise
120	277	_	_	I-Premise
121	patients	_	_	I-Premise
122	(	_	_	I-Premise
123	45.1	_	_	I-Premise
124	%	_	_	I-Premise
125	)	_	_	I-Premise
126	experienced	_	_	I-Premise
127	pain	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	lidocaine	_	_	I-Premise
131	group	_	_	I-Premise
132	,	_	_	I-Premise
133	compared	_	_	I-Premise
134	with	_	_	I-Premise
135	123	_	_	I-Premise
136	of	_	_	I-Premise
137	229	_	_	I-Premise
138	patients	_	_	I-Premise
139	(	_	_	I-Premise
140	53.7	_	_	I-Premise
141	%	_	_	I-Premise
142	)	_	_	I-Premise
143	in	_	_	I-Premise
144	the	_	_	I-Premise
145	BSS	_	_	I-Premise
146	group	_	_	I-Premise
147	.	_	_	I-Premise

148	The	_	_	B-Claim
149	proportion	_	_	I-Claim
150	of	_	_	I-Claim
151	patients	_	_	I-Claim
152	who	_	_	I-Claim
153	experienced	_	_	I-Claim
154	pain	_	_	I-Claim
155	was	_	_	I-Claim
156	significantly	_	_	I-Claim
157	lower	_	_	I-Claim
158	in	_	_	I-Claim
159	the	_	_	I-Claim
160	intracameral	_	_	I-Claim
161	lidocaine	_	_	I-Claim
162	group	_	_	I-Claim
163	compared	_	_	I-Claim
164	with	_	_	I-Claim
165	the	_	_	I-Claim
166	BSS	_	_	I-Claim
167	group	_	_	I-Claim
168	(	_	_	I-Claim
169	multivariate	_	_	I-Claim
170	OR	_	_	I-Claim
171	0.68	_	_	I-Claim
172	,	_	_	I-Claim
173	95	_	_	I-Claim
174	%	_	_	I-Claim
175	CI	_	_	I-Claim
176	0.47	_	_	I-Claim
177	to	_	_	I-Claim
178	0.97	_	_	I-Claim
179	;	_	_	I-Claim
180	p=0.034	_	_	I-Claim
181	)	_	_	I-Claim
182	.	_	_	I-Claim

183	The	_	_	B-Premise
184	median	_	_	I-Premise
185	pain	_	_	I-Premise
186	score	_	_	I-Premise
187	(	_	_	I-Premise
188	range	_	_	I-Premise
189	)	_	_	I-Premise
190	was	_	_	I-Premise
191	0.0	_	_	I-Premise
192	for	_	_	I-Premise
193	intracameral	_	_	I-Premise
194	lidocaine	_	_	I-Premise
195	group	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	1.0	_	_	I-Premise
199	for	_	_	I-Premise
200	BSS	_	_	I-Premise
201	group	_	_	I-Premise
202	(	_	_	I-Premise
203	p=0.039	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Pain	_	_	B-Premise
207	was	_	_	I-Premise
208	more	_	_	I-Premise
209	common	_	_	I-Premise
210	in	_	_	I-Premise
211	females	_	_	I-Premise
212	(	_	_	I-Premise
213	54.3	_	_	I-Premise
214	%	_	_	I-Premise
215	vs	_	_	I-Premise
216	43.6	_	_	I-Premise
217	%	_	_	I-Premise
218	;	_	_	I-Premise
219	OR	_	_	I-Premise
220	1.56	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	non-Chinese	_	_	I-Premise
224	(	_	_	I-Premise
225	62.3	_	_	I-Premise
226	%	_	_	I-Premise
227	vs	_	_	I-Premise
228	46.9	_	_	I-Premise
229	%	_	_	I-Premise
230	;	_	_	I-Premise
231	OR	_	_	I-Premise
232	2.13	_	_	I-Premise
233	)	_	_	I-Premise
234	and	_	_	I-Premise
235	those	_	_	I-Premise
236	who	_	_	I-Premise
237	had	_	_	I-Premise
238	previous	_	_	I-Premise
239	cataract	_	_	I-Premise
240	surgery	_	_	I-Premise
241	to	_	_	I-Premise
242	the	_	_	I-Premise
243	fellow	_	_	I-Premise
244	eye	_	_	I-Premise
245	(	_	_	I-Premise
246	55.3	_	_	I-Premise
247	%	_	_	I-Premise
248	vs	_	_	I-Premise
249	44.7	_	_	I-Premise
250	%	_	_	I-Premise
251	;	_	_	I-Premise
252	OR	_	_	I-Premise
253	1.61	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	The	_	_	B-Claim
257	use	_	_	I-Claim
258	of	_	_	I-Claim
259	0.5	_	_	I-Claim
260	cc	_	_	I-Claim
261	of	_	_	I-Claim
262	1	_	_	I-Claim
263	%	_	_	I-Claim
264	intracameral	_	_	I-Claim
265	lidocaine	_	_	I-Claim
266	during	_	_	I-Claim
267	phacoemulsification	_	_	I-Claim
268	under	_	_	I-Claim
269	topical	_	_	I-Claim
270	anaesthesia	_	_	I-Claim
271	significantly	_	_	I-Claim
272	reduces	_	_	I-Claim
273	pain	_	_	I-Claim
274	experienced	_	_	I-Claim
275	by	_	_	I-Claim
276	patients	_	_	I-Claim
277	.	_	_	I-Claim

278	Risk	_	_	B-Claim
279	factors	_	_	I-Claim
280	for	_	_	I-Claim
281	pain	_	_	I-Claim
282	include	_	_	I-Claim
283	females	_	_	I-Claim
284	,	_	_	I-Claim
285	non-Chinese	_	_	I-Claim
286	and	_	_	I-Claim
287	previous	_	_	I-Claim
288	cataract	_	_	I-Claim
289	surgery	_	_	I-Claim
290	.	_	_	I-Claim


0	Bone-cancer	_	_	O
1	pain	_	_	O
2	is	_	_	O
3	a	_	_	O
4	common	_	_	O
5	and	_	_	O
6	refractory	_	_	O
7	cancer	_	_	O
8	pain	_	_	O
9	.	_	_	O

10	Opioids	_	_	O
11	,	_	_	O
12	on	_	_	O
13	their	_	_	O
14	own	_	_	O
15	,	_	_	O
16	do	_	_	O
17	not	_	_	O
18	control	_	_	O
19	this	_	_	O
20	type	_	_	O
21	of	_	_	O
22	pain	_	_	O
23	well	_	_	O
24	enough	_	_	O
25	,	_	_	O
26	and	_	_	O
27	co-analgesics	_	_	O
28	are	_	_	O
29	necessary	_	_	O
30	.	_	_	O

31	Patients	_	_	O
32	with	_	_	O
33	bone	_	_	O
34	metastasis-related	_	_	O
35	pain	_	_	O
36	at	_	_	O
37	Numeric	_	_	O
38	Rating	_	_	O
39	Scale	_	_	O
40	≥4	_	_	O
41	were	_	_	O
42	enrolled	_	_	O
43	to	_	_	O
44	this	_	_	O
45	randomized	_	_	O
46	placebo-controlled	_	_	O
47	trial	_	_	O
48	.	_	_	O

49	They	_	_	O
50	had	_	_	O
51	also	_	_	O
52	received	_	_	O
53	morphine	_	_	O
54	or	_	_	O
55	transdermal	_	_	O
56	fentanyl	_	_	O
57	patches	_	_	O
58	for	_	_	O
59	at	_	_	O
60	least	_	_	O
61	1	_	_	O
62	week	_	_	O
63	.	_	_	O

64	During	_	_	O
65	the	_	_	O
66	3-day	_	_	O
67	efficacy	_	_	O
68	phase	_	_	O
69	,	_	_	O
70	patients	_	_	O
71	received	_	_	O
72	placebo	_	_	O
73	or	_	_	O
74	1-3	_	_	O
75	tablets	_	_	O
76	of	_	_	O
77	oxycodone/paracetamol	_	_	O
78	(	_	_	O
79	5/325	_	_	O
80	mg	_	_	O
81	)	_	_	O
82	,	_	_	O
83	four	_	_	O
84	times	_	_	O
85	daily	_	_	O
86	for	_	_	O
87	3	_	_	O
88	days	_	_	O
89	.	_	_	O

90	All	_	_	O
91	patients	_	_	O
92	kept	_	_	O
93	a	_	_	O
94	daily	_	_	O
95	pain	_	_	O
96	diary	_	_	O
97	.	_	_	O

98	The	_	_	O
99	primary	_	_	O
100	endpoint	_	_	O
101	was	_	_	O
102	the	_	_	O
103	Pain	_	_	O
104	Intensity	_	_	O
105	Difference	_	_	O
106	(	_	_	O
107	PID	_	_	O
108	)	_	_	O
109	.	_	_	O

110	Secondary	_	_	O
111	endpoints	_	_	O
112	were	_	_	O
113	cases	_	_	O
114	of	_	_	O
115	breakthrough	_	_	O
116	pain	_	_	O
117	and	_	_	O
118	rescue	_	_	O
119	morphine	_	_	O
120	consumption	_	_	O
121	.	_	_	O

122	Additional	_	_	O
123	analyses	_	_	O
124	included	_	_	O
125	the	_	_	O
126	Short	_	_	O
127	Form-6	_	_	O
128	Dimensions	_	_	O
129	(	_	_	O
130	SF-6D	_	_	O
131	)	_	_	O
132	quality-of-life	_	_	O
133	scale	_	_	O
134	and	_	_	O
135	a	_	_	O
136	general	_	_	O
137	impression	_	_	O
138	(	_	_	O
139	GI	_	_	O
140	)	_	_	O
141	of	_	_	O
142	patient	_	_	O
143	satisfaction	_	_	O
144	with	_	_	O
145	treatment	_	_	O
146	at	_	_	O
147	the	_	_	O
148	end	_	_	O
149	of	_	_	O
150	the	_	_	O
151	phase	_	_	O
152	.	_	_	O

153	Of	_	_	O
154	the	_	_	O
155	246	_	_	O
156	patients	_	_	O
157	in	_	_	O
158	the	_	_	O
159	intent-to-treat	_	_	O
160	set	_	_	O
161	,	_	_	O
162	89·4	_	_	O
163	%	_	_	O
164	completed	_	_	O
165	the	_	_	O
166	3-day	_	_	O
167	efficacy	_	_	O
168	phase	_	_	O
169	.	_	_	O

170	PIDs	_	_	B-Premise
171	were	_	_	I-Premise
172	0·9	_	_	I-Premise
173	and	_	_	I-Premise
174	0·3	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	oxycodone/paracetamol	_	_	I-Premise
178	and	_	_	I-Premise
179	placebo	_	_	I-Premise
180	groups	_	_	I-Premise
181	respectively	_	_	I-Premise
182	,	_	_	I-Premise
183	on	_	_	I-Premise
184	day	_	_	I-Premise
185	1	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	<	_	_	I-Premise
189	0·001	_	_	I-Premise
190	)	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	1·5	_	_	I-Premise
194	and	_	_	I-Premise
195	0·3	_	_	I-Premise
196	respectively	_	_	I-Premise
197	on	_	_	I-Premise
198	day	_	_	I-Premise
199	3	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	<	_	_	I-Premise
203	0·001	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Thirty-eight	_	_	B-Premise
207	patients	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	treatment	_	_	I-Premise
211	group	_	_	I-Premise
212	,	_	_	I-Premise
213	and	_	_	I-Premise
214	58	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	placebo	_	_	I-Premise
218	group	_	_	I-Premise
219	,	_	_	I-Premise
220	suffered	_	_	I-Premise
221	breakthrough	_	_	I-Premise
222	pain	_	_	I-Premise
223	on	_	_	I-Premise
224	day	_	_	I-Premise
225	3	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0·001	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	The	_	_	B-Premise
233	SF-6D	_	_	I-Premise
234	score	_	_	I-Premise
235	decreased	_	_	I-Premise
236	to	_	_	I-Premise
237	21·2	_	_	I-Premise
238	±	_	_	I-Premise
239	2·5	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	oxycodone/paracetamol	_	_	I-Premise
243	group	_	_	I-Premise
244	at	_	_	I-Premise
245	the	_	_	I-Premise
246	end	_	_	I-Premise
247	of	_	_	I-Premise
248	the	_	_	I-Premise
249	phase	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	0·001	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	In	_	_	B-Premise
257	the	_	_	I-Premise
258	oxycodone/paracetamol	_	_	I-Premise
259	group	_	_	I-Premise
260	,	_	_	I-Premise
261	67	_	_	I-Premise
262	%	_	_	I-Premise
263	rated	_	_	I-Premise
264	GI	_	_	I-Premise
265	as	_	_	I-Premise
266	good	_	_	I-Premise
267	,	_	_	I-Premise
268	very	_	_	I-Premise
269	good	_	_	I-Premise
270	,	_	_	I-Premise
271	or	_	_	I-Premise
272	excellent	_	_	I-Premise
273	.	_	_	I-Premise

274	Patients	_	_	B-Claim
275	with	_	_	I-Claim
276	bone-cancer	_	_	I-Claim
277	pain	_	_	I-Claim
278	,	_	_	I-Claim
279	already	_	_	I-Claim
280	on	_	_	I-Claim
281	opioids	_	_	I-Claim
282	,	_	_	I-Claim
283	obtain	_	_	I-Claim
284	clinically	_	_	I-Claim
285	important	_	_	I-Claim
286	,	_	_	I-Claim
287	additional	_	_	I-Claim
288	pain-control	_	_	I-Claim
289	,	_	_	I-Claim
290	with	_	_	I-Claim
291	regular	_	_	I-Claim
292	oxycodone/paracetamol	_	_	I-Claim
293	dosing	_	_	I-Claim
294	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	very	_	_	O
3	few	_	_	O
4	randomized	_	_	O
5	controlled	_	_	O
6	studies	_	_	O
7	on	_	_	O
8	exercise	_	_	O
9	in	_	_	O
10	cancer	_	_	O
11	patients	_	_	O
12	.	_	_	O

13	Consequently	_	_	O
14	,	_	_	O
15	there	_	_	O
16	are	_	_	O
17	no	_	_	O
18	guidelines	_	_	O
19	available	_	_	O
20	with	_	_	O
21	regard	_	_	O
22	to	_	_	O
23	the	_	_	O
24	exercises	_	_	O
25	that	_	_	O
26	can	_	_	O
27	be	_	_	O
28	recommended	_	_	O
29	and	_	_	O
30	difficulties	_	_	O
31	are	_	_	O
32	encountered	_	_	O
33	in	_	_	O
34	the	_	_	O
35	clinical	_	_	O
36	practice	_	_	O
37	as	_	_	O
38	to	_	_	O
39	which	_	_	O
40	exercise	_	_	O
41	is	_	_	O
42	more	_	_	O
43	suitable	_	_	O
44	to	_	_	O
45	the	_	_	O
46	patients	_	_	O
47	.	_	_	O

48	The	_	_	O
49	purpose	_	_	O
50	of	_	_	O
51	this	_	_	O
52	study	_	_	O
53	was	_	_	O
54	to	_	_	O
55	investigate	_	_	O
56	the	_	_	O
57	impact	_	_	O
58	of	_	_	O
59	pilates	_	_	O
60	exercises	_	_	O
61	on	_	_	O
62	physical	_	_	O
63	performance	_	_	O
64	,	_	_	O
65	flexibility	_	_	O
66	,	_	_	O
67	fatigue	_	_	O
68	,	_	_	O
69	depression	_	_	O
70	and	_	_	O
71	quality	_	_	O
72	of	_	_	O
73	life	_	_	O
74	in	_	_	O
75	women	_	_	O
76	who	_	_	O
77	had	_	_	O
78	been	_	_	O
79	treated	_	_	O
80	for	_	_	O
81	breast	_	_	O
82	cancer	_	_	O
83	.	_	_	O

84	Randomized	_	_	O
85	controlled	_	_	O
86	trial	_	_	O
87	.	_	_	O

88	Out	_	_	O
89	patient	_	_	O
90	group	_	_	O
91	,	_	_	O
92	Department	_	_	O
93	of	_	_	O
94	Physical	_	_	O
95	Medicine	_	_	O
96	and	_	_	O
97	Rehabilitation	_	_	O
98	and	_	_	O
99	Medical	_	_	O
100	Oncology	_	_	O
101	Department	_	_	O
102	,	_	_	O
103	University	_	_	O
104	Hospital	_	_	O
105	.	_	_	O

106	Fifty-two	_	_	O
107	patients	_	_	O
108	with	_	_	O
109	breast	_	_	O
110	cancer	_	_	O
111	were	_	_	O
112	divided	_	_	O
113	into	_	_	O
114	either	_	_	O
115	pilates	_	_	O
116	exercise	_	_	O
117	(	_	_	O
118	group	_	_	O
119	1	_	_	O
120	)	_	_	O
121	and	_	_	O
122	control	_	_	O
123	group	_	_	O
124	(	_	_	O
125	group	_	_	O
126	2	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Patients	_	_	O
130	in	_	_	O
131	Group	_	_	O
132	1	_	_	O
133	performed	_	_	O
134	pilates	_	_	O
135	and	_	_	O
136	home	_	_	O
137	exercises	_	_	O
138	and	_	_	O
139	patients	_	_	O
140	in	_	_	O
141	group	_	_	O
142	2	_	_	O
143	performed	_	_	O
144	only	_	_	O
145	home	_	_	O
146	exercises	_	_	O
147	.	_	_	O

148	Pilates	_	_	O
149	exercise	_	_	O
150	sessions	_	_	O
151	were	_	_	O
152	performed	_	_	O
153	three	_	_	O
154	times	_	_	O
155	a	_	_	O
156	week	_	_	O
157	for	_	_	O
158	a	_	_	O
159	period	_	_	O
160	of	_	_	O
161	eight	_	_	O
162	weeks	_	_	O
163	in	_	_	O
164	the	_	_	O
165	rehabilitation	_	_	O
166	unit	_	_	O
167	.	_	_	O

168	Subjects	_	_	O
169	were	_	_	O
170	assessed	_	_	O
171	before	_	_	O
172	and	_	_	O
173	after	_	_	O
174	rehabilitation	_	_	O
175	program	_	_	O
176	,	_	_	O
177	with	_	_	O
178	respect	_	_	O
179	to	_	_	O
180	,	_	_	O
181	6-min	_	_	O
182	walk	_	_	O
183	test	_	_	O
184	(	_	_	O
185	6MWT	_	_	O
186	)	_	_	O
187	,	_	_	O
188	modified	_	_	O
189	sit	_	_	O
190	and	_	_	O
191	reach	_	_	O
192	test	_	_	O
193	,	_	_	O
194	Brief	_	_	O
195	Fatigue	_	_	O
196	Inventory	_	_	O
197	(	_	_	O
198	BFI	_	_	O
199	)	_	_	O
200	,	_	_	O
201	Beck	_	_	O
202	Depression	_	_	O
203	Index	_	_	O
204	(	_	_	O
205	BDI	_	_	O
206	)	_	_	O
207	and	_	_	O
208	the	_	_	O
209	European	_	_	O
210	Organisation	_	_	O
211	for	_	_	O
212	Research	_	_	O
213	and	_	_	O
214	Treatment	_	_	O
215	of	_	_	O
216	Cancer	_	_	O
217	Quality	_	_	O
218	of	_	_	O
219	Life	_	_	O
220	C30	_	_	O
221	(	_	_	O
222	EORTC	_	_	O
223	QLQ-C30	_	_	O
224	)	_	_	O
225	and	_	_	O
226	EORTC	_	_	O
227	QLQ	_	_	O
228	BR23	_	_	O
229	.	_	_	O

230	After	_	_	B-Premise
231	the	_	_	I-Premise
232	exercise	_	_	I-Premise
233	program	_	_	I-Premise
234	,	_	_	I-Premise
235	improvements	_	_	I-Premise
236	were	_	_	I-Premise
237	observed	_	_	I-Premise
238	in	_	_	I-Premise
239	Group	_	_	I-Premise
240	1	_	_	I-Premise
241	in	_	_	I-Premise
242	6-minute	_	_	I-Premise
243	walk	_	_	I-Premise
244	test	_	_	I-Premise
245	,	_	_	I-Premise
246	BDI	_	_	I-Premise
247	,	_	_	I-Premise
248	EORTC	_	_	I-Premise
249	QLQ-C30	_	_	I-Premise
250	functional	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	EORTC	_	_	I-Premise
254	QLQ-C30	_	_	I-Premise
255	BR23	_	_	I-Premise
256	functional	_	_	I-Premise
257	scores	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	0.05	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	In	_	_	O
265	contrast	_	_	O
266	,	_	_	O
267	no	_	_	B-Premise
268	significant	_	_	I-Premise
269	improvement	_	_	I-Premise
270	was	_	_	I-Premise
271	observed	_	_	I-Premise
272	in	_	_	I-Premise
273	Group	_	_	I-Premise
274	2	_	_	I-Premise
275	after	_	_	I-Premise
276	the	_	_	I-Premise
277	exercise	_	_	I-Premise
278	program	_	_	I-Premise
279	in	_	_	I-Premise
280	any	_	_	I-Premise
281	of	_	_	I-Premise
282	parameters	_	_	I-Premise
283	in	_	_	I-Premise
284	comparison	_	_	I-Premise
285	to	_	_	I-Premise
286	the	_	_	I-Premise
287	pre-exercise	_	_	I-Premise
288	period	_	_	I-Premise
289	(	_	_	I-Premise
290	P	_	_	I-Premise
291	>	_	_	I-Premise
292	0.05	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	When	_	_	B-Premise
296	the	_	_	I-Premise
297	two	_	_	I-Premise
298	exercise	_	_	I-Premise
299	groups	_	_	I-Premise
300	were	_	_	I-Premise
301	compared	_	_	I-Premise
302	,	_	_	I-Premise
303	there	_	_	I-Premise
304	were	_	_	I-Premise
305	significant	_	_	I-Premise
306	differences	_	_	I-Premise
307	in	_	_	I-Premise
308	6MWT	_	_	I-Premise
309	in	_	_	I-Premise
310	pilates-exercise	_	_	I-Premise
311	group	_	_	I-Premise
312	(	_	_	I-Premise
313	P	_	_	I-Premise
314	<	_	_	I-Premise
315	0.05	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	Pilates	_	_	B-Claim
319	exercises	_	_	I-Claim
320	are	_	_	I-Claim
321	effective	_	_	I-Claim
322	and	_	_	I-Claim
323	safe	_	_	I-Claim
324	in	_	_	I-Claim
325	female	_	_	I-Claim
326	breast	_	_	I-Claim
327	cancer	_	_	I-Claim
328	patients	_	_	I-Claim
329	.	_	_	I-Claim

330	There	_	_	B-Claim
331	is	_	_	I-Claim
332	a	_	_	I-Claim
333	need	_	_	I-Claim
334	for	_	_	I-Claim
335	further	_	_	I-Claim
336	studies	_	_	I-Claim
337	so	_	_	I-Claim
338	that	_	_	I-Claim
339	its	_	_	I-Claim
340	effect	_	_	I-Claim
341	can	_	_	I-Claim
342	be	_	_	I-Claim
343	confirmed	_	_	I-Claim
344	.	_	_	I-Claim

345	This	_	_	O
346	study	_	_	O
347	addressed	_	_	O
348	the	_	_	O
349	effects	_	_	O
350	of	_	_	O
351	pilates	_	_	O
352	exercise	_	_	O
353	,	_	_	O
354	as	_	_	O
355	a	_	_	O
356	new	_	_	O
357	approach	_	_	O
358	,	_	_	O
359	on	_	_	O
360	functional	_	_	O
361	capacity	_	_	O
362	,	_	_	O
363	fatigue	_	_	O
364	,	_	_	O
365	depression	_	_	O
366	and	_	_	O
367	quality	_	_	O
368	of	_	_	O
369	life	_	_	O
370	in	_	_	O
371	breast	_	_	O
372	cancer	_	_	O
373	patients	_	_	O
374	in	_	_	O
375	whom	_	_	O
376	there	_	_	O
377	are	_	_	O
378	doubts	_	_	O
379	regarding	_	_	O
380	the	_	_	O
381	efficacy	_	_	O
382	and	_	_	O
383	usefulness	_	_	O
384	of	_	_	O
385	the	_	_	O
386	exercise	_	_	O
387	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	alpha2-adrenergic	_	_	O
4	agonist	_	_	O
5	brimonidine	_	_	O
6	tartrate	_	_	O
7	0.2	_	_	O
8	%	_	_	O
9	to	_	_	O
10	the	_	_	O
11	beta-adrenergic	_	_	O
12	antagonist	_	_	O
13	timolol	_	_	O
14	maleate	_	_	O
15	0.5	_	_	O
16	%	_	_	O
17	in	_	_	O
18	preserving	_	_	O
19	visual	_	_	O
20	function	_	_	O
21	in	_	_	O
22	low-pressure	_	_	O
23	glaucoma	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	,	_	_	O
27	double-masked	_	_	O
28	,	_	_	O
29	multicenter	_	_	O
30	clinical	_	_	O
31	trial	_	_	O
32	.	_	_	O

33	Exclusion	_	_	O
34	criteria	_	_	O
35	included	_	_	O
36	untreated	_	_	O
37	intraocular	_	_	O
38	pressure	_	_	O
39	(	_	_	O
40	IOP	_	_	O
41	)	_	_	O
42	>	_	_	O
43	21	_	_	O
44	mm	_	_	O
45	Hg	_	_	O
46	,	_	_	O
47	visual	_	_	O
48	field	_	_	O
49	mean	_	_	O
50	deviation	_	_	O
51	worse	_	_	O
52	than	_	_	O
53	-16	_	_	O
54	decibels	_	_	O
55	,	_	_	O
56	or	_	_	O
57	contraindications	_	_	O
58	to	_	_	O
59	study	_	_	O
60	medications	_	_	O
61	.	_	_	O

62	Both	_	_	O
63	eyes	_	_	O
64	received	_	_	O
65	twice-daily	_	_	O
66	monotherapy	_	_	O
67	randomized	_	_	O
68	in	_	_	O
69	blocks	_	_	O
70	of	_	_	O
71	7	_	_	O
72	(	_	_	O
73	4	_	_	O
74	brimonidine	_	_	O
75	to	_	_	O
76	3	_	_	O
77	timolol	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Standard	_	_	O
81	automated	_	_	O
82	perimetry	_	_	O
83	and	_	_	O
84	tonometry	_	_	O
85	were	_	_	O
86	performed	_	_	O
87	at	_	_	O
88	4-month	_	_	O
89	intervals	_	_	O
90	.	_	_	O

91	Main	_	_	O
92	outcome	_	_	O
93	measure	_	_	O
94	was	_	_	O
95	field	_	_	O
96	progression	_	_	O
97	in	_	_	O
98	either	_	_	O
99	eye	_	_	O
100	,	_	_	O
101	defined	_	_	O
102	as	_	_	O
103	the	_	_	O
104	same	_	_	O
105	3	_	_	O
106	or	_	_	O
107	more	_	_	O
108	points	_	_	O
109	with	_	_	O
110	a	_	_	O
111	negative	_	_	O
112	slope	_	_	O
113	-1	_	_	O
114	dB/year	_	_	O
115	at	_	_	O
116	P	_	_	O
117	<	_	_	O
118	5	_	_	O
119	%	_	_	O
120	,	_	_	O
121	on	_	_	O
122	3	_	_	O
123	consecutive	_	_	O
124	tests	_	_	O
125	,	_	_	O
126	assessed	_	_	O
127	by	_	_	O
128	pointwise	_	_	O
129	linear	_	_	O
130	regression	_	_	O
131	.	_	_	O

132	Secondary	_	_	O
133	outcome	_	_	O
134	measures	_	_	O
135	were	_	_	O
136	progression	_	_	O
137	based	_	_	O
138	on	_	_	O
139	glaucoma	_	_	O
140	change	_	_	O
141	probability	_	_	O
142	maps	_	_	O
143	(	_	_	O
144	GCPM	_	_	O
145	)	_	_	O
146	of	_	_	O
147	pattern	_	_	O
148	deviation	_	_	O
149	and	_	_	O
150	the	_	_	O
151	3-omitting	_	_	O
152	method	_	_	O
153	for	_	_	O
154	pointwise	_	_	O
155	linear	_	_	O
156	regression	_	_	O
157	.	_	_	O

158	Ninety-nine	_	_	O
159	patients	_	_	O
160	were	_	_	O
161	randomized	_	_	O
162	to	_	_	O
163	brimonidine	_	_	O
164	and	_	_	O
165	79	_	_	O
166	to	_	_	O
167	timolol	_	_	O
168	.	_	_	O

169	Mean	_	_	O
170	(	_	_	O
171	+/-	_	_	O
172	SE	_	_	O
173	)	_	_	O
174	months	_	_	O
175	of	_	_	O
176	follow-up	_	_	O
177	for	_	_	O
178	all	_	_	O
179	patients	_	_	O
180	was	_	_	O
181	30.0	_	_	O
182	+/-	_	_	O
183	2	_	_	O
184	.	_	_	O

185	Statistically	_	_	B-Premise
186	fewer	_	_	I-Premise
187	brimonidine-treated	_	_	I-Premise
188	patients	_	_	I-Premise
189	(	_	_	I-Premise
190	9	_	_	I-Premise
191	,	_	_	I-Premise
192	9.1	_	_	I-Premise
193	%	_	_	I-Premise
194	)	_	_	I-Premise
195	had	_	_	I-Premise
196	visual	_	_	I-Premise
197	field	_	_	I-Premise
198	progression	_	_	I-Premise
199	by	_	_	I-Premise
200	pointwise	_	_	I-Premise
201	linear	_	_	I-Premise
202	regression	_	_	I-Premise
203	than	_	_	I-Premise
204	timolol-treated	_	_	I-Premise
205	patients	_	_	I-Premise
206	(	_	_	I-Premise
207	31	_	_	I-Premise
208	,	_	_	I-Premise
209	39.2	_	_	I-Premise
210	%	_	_	I-Premise
211	,	_	_	I-Premise
212	log-rank	_	_	I-Premise
213	12.4	_	_	I-Premise
214	,	_	_	I-Premise
215	P=.001	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	Mean	_	_	B-Premise
219	treated	_	_	I-Premise
220	IOP	_	_	I-Premise
221	was	_	_	I-Premise
222	similar	_	_	I-Premise
223	for	_	_	I-Premise
224	brimonidine-	_	_	I-Premise
225	and	_	_	I-Premise
226	timolol-treated	_	_	I-Premise
227	patients	_	_	I-Premise
228	at	_	_	I-Premise
229	all	_	_	I-Premise
230	time	_	_	I-Premise
231	points	_	_	I-Premise
232	.	_	_	I-Premise

233	More	_	_	B-Premise
234	brimonidine-treated	_	_	I-Premise
235	(	_	_	I-Premise
236	28	_	_	I-Premise
237	,	_	_	I-Premise
238	28.3	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	than	_	_	I-Premise
242	timolol-treated	_	_	I-Premise
243	(	_	_	I-Premise
244	9	_	_	I-Premise
245	,	_	_	I-Premise
246	11.4	_	_	I-Premise
247	%	_	_	I-Premise
248	)	_	_	I-Premise
249	patients	_	_	I-Premise
250	discontinued	_	_	I-Premise
251	study	_	_	I-Premise
252	participation	_	_	I-Premise
253	because	_	_	I-Premise
254	of	_	_	I-Premise
255	drug-related	_	_	I-Premise
256	adverse	_	_	I-Premise
257	events	_	_	I-Premise
258	(	_	_	I-Premise
259	P=.008	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Similar	_	_	B-Claim
263	differences	_	_	I-Claim
264	in	_	_	I-Claim
265	progression	_	_	I-Claim
266	were	_	_	I-Claim
267	observed	_	_	I-Claim
268	when	_	_	I-Claim
269	analyzed	_	_	I-Claim
270	by	_	_	I-Claim
271	GCPM	_	_	I-Claim
272	and	_	_	I-Claim
273	the	_	_	I-Claim
274	3-omitting	_	_	I-Claim
275	method	_	_	I-Claim
276	.	_	_	I-Claim

277	Low-pressure	_	_	B-Claim
278	glaucoma	_	_	I-Claim
279	patients	_	_	I-Claim
280	treated	_	_	I-Claim
281	with	_	_	I-Claim
282	brimonidine	_	_	I-Claim
283	0.2	_	_	I-Claim
284	%	_	_	I-Claim
285	who	_	_	I-Claim
286	do	_	_	I-Claim
287	not	_	_	I-Claim
288	develop	_	_	I-Claim
289	ocular	_	_	I-Claim
290	allergy	_	_	I-Claim
291	are	_	_	I-Claim
292	less	_	_	I-Claim
293	likely	_	_	I-Claim
294	to	_	_	I-Claim
295	have	_	_	I-Claim
296	field	_	_	I-Claim
297	progression	_	_	I-Claim
298	than	_	_	I-Claim
299	patients	_	_	I-Claim
300	treated	_	_	I-Claim
301	with	_	_	I-Claim
302	timolol	_	_	I-Claim
303	0.5	_	_	I-Claim
304	%	_	_	I-Claim
305	.	_	_	I-Claim


0	The	_	_	O
1	role	_	_	O
2	of	_	_	O
3	chemotherapy	_	_	O
4	for	_	_	O
5	advanced	_	_	O
6	NSCLC	_	_	O
7	patients	_	_	O
8	and	_	_	O
9	ECOG	_	_	O
10	PS2	_	_	O
11	remains	_	_	O
12	controversial	_	_	O
13	.	_	_	O

14	We	_	_	O
15	evaluated	_	_	O
16	4	_	_	O
17	doses	_	_	O
18	of	_	_	O
19	3-weekly	_	_	O
20	docetaxel	_	_	O
21	to	_	_	O
22	identify	_	_	O
23	a	_	_	O
24	less	_	_	O
25	toxic	_	_	O
26	,	_	_	O
27	clinically	_	_	O
28	effective	_	_	O
29	dose	_	_	O
30	.	_	_	O

31	Seventy-three	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	stage	_	_	O
35	III	_	_	O
36	(	_	_	O
37	22	_	_	O
38	%	_	_	O
39	)	_	_	O
40	(	_	_	O
41	unsuitable	_	_	O
42	for	_	_	O
43	radical	_	_	O
44	surgery/radiotherapy	_	_	O
45	)	_	_	O
46	and	_	_	O
47	IV	_	_	O
48	(	_	_	O
49	78	_	_	O
50	%	_	_	O
51	)	_	_	O
52	NSCLC	_	_	O
53	were	_	_	O
54	randomized	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	4	_	_	O
58	doses	_	_	O
59	of	_	_	O
60	3-weekly	_	_	O
61	docetaxel	_	_	O
62	,	_	_	O
63	for	_	_	O
64	4	_	_	O
65	cycles	_	_	O
66	:	_	_	O
67	arm	_	_	O
68	(	_	_	O
69	A	_	_	O
70	)	_	_	O
71	40	_	_	O
72	mg/m	_	_	O
73	(	_	_	O
74	2	_	_	O
75	)	_	_	O
76	(	_	_	O
77	n=17	_	_	O
78	)	_	_	O
79	,	_	_	O
80	arm	_	_	O
81	(	_	_	O
82	B	_	_	O
83	)	_	_	O
84	50	_	_	O
85	mg/m	_	_	O
86	(	_	_	O
87	2	_	_	O
88	)	_	_	O
89	(	_	_	O
90	n=17	_	_	O
91	)	_	_	O
92	,	_	_	O
93	arm	_	_	O
94	(	_	_	O
95	C	_	_	O
96	)	_	_	O
97	60	_	_	O
98	mg/m	_	_	O
99	(	_	_	O
100	2	_	_	O
101	)	_	_	O
102	(	_	_	O
103	n=19	_	_	O
104	)	_	_	O
105	,	_	_	O
106	arm	_	_	O
107	(	_	_	O
108	D	_	_	O
109	)	_	_	O
110	50	_	_	O
111	mg/m	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	escalated	_	_	O
116	by	_	_	O
117	10	_	_	O
118	mg/m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	to	_	_	O
123	a	_	_	O
124	maximum	_	_	O
125	of	_	_	O
126	70	_	_	O
127	mg/m	_	_	O
128	(	_	_	O
129	2	_	_	O
130	)	_	_	O
131	(	_	_	O
132	n=19	_	_	O
133	)	_	_	O
134	.	_	_	O

135	Primary	_	_	O
136	endpoints	_	_	O
137	:	_	_	O
138	maximum	_	_	O
139	tolerated	_	_	O
140	dose	_	_	O
141	,	_	_	O
142	RR	_	_	O
143	,	_	_	O
144	duration	_	_	O
145	of	_	_	O
146	response	_	_	O
147	,	_	_	O
148	symptom	_	_	O
149	improvement	_	_	O
150	,	_	_	O
151	toxicity	_	_	O
152	and	_	_	O
153	QoL	_	_	O
154	.	_	_	O

155	Secondary	_	_	O
156	endpoint	_	_	O
157	:	_	_	O
158	overall	_	_	O
159	survival	_	_	O
160	(	_	_	O
161	OS	_	_	O
162	)	_	_	O
163	.	_	_	O

164	Patients	_	_	O
165	and	_	_	O
166	disease	_	_	O
167	characteristics	_	_	O
168	were	_	_	O
169	well	_	_	O
170	balanced	_	_	O
171	.	_	_	O

172	Median	_	_	O
173	age	_	_	O
174	was	_	_	O
175	67	_	_	O
176	(	_	_	O
177	range	_	_	O
178	45-81	_	_	O
179	)	_	_	O
180	,	_	_	O
181	there	_	_	O
182	were	_	_	O
183	32	_	_	O
184	male	_	_	O
185	and	_	_	O
186	41	_	_	O
187	female	_	_	O
188	,	_	_	O
189	histology	_	_	O
190	subtype	_	_	O
191	:	_	_	O
192	squamous/adenocarcinoma/mixed/NOS=42	_	_	O
193	%	_	_	O
194	/49	_	_	O
195	%	_	_	O
196	/4	_	_	O
197	%	_	_	O
198	/5	_	_	O
199	%	_	_	O
200	.	_	_	O

201	Seven	_	_	O
202	patients	_	_	O
203	did	_	_	O
204	not	_	_	O
205	receive	_	_	O
206	any	_	_	O
207	treatment	_	_	O
208	because	_	_	O
209	of	_	_	O
210	deterioration	_	_	O
211	in	_	_	O
212	PS	_	_	O
213	or	_	_	O
214	death	_	_	O
215	.	_	_	O

216	50	_	_	O
217	%	_	_	O
218	of	_	_	O
219	patients	_	_	O
220	in	_	_	O
221	arm	_	_	O
222	D	_	_	O
223	,	_	_	O
224	who	_	_	O
225	received	_	_	O
226	more	_	_	O
227	than	_	_	O
228	one	_	_	O
229	cycle	_	_	O
230	,	_	_	O
231	received	_	_	O
232	dose	_	_	O
233	escalation	_	_	O
234	.	_	_	O

235	There	_	_	B-Premise
236	was	_	_	I-Premise
237	no	_	_	I-Premise
238	statistical	_	_	I-Premise
239	difference	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	number	_	_	I-Premise
243	of	_	_	I-Premise
244	cycles	_	_	I-Premise
245	administered	_	_	I-Premise
246	(	_	_	I-Premise
247	arms	_	_	I-Premise
248	A	_	_	I-Premise
249	,	_	_	I-Premise
250	B	_	_	I-Premise
251	and	_	_	I-Premise
252	D	_	_	I-Premise
253	:	_	_	I-Premise
254	median	_	_	I-Premise
255	2	_	_	I-Premise
256	cycles	_	_	I-Premise
257	and	_	_	I-Premise
258	arm	_	_	I-Premise
259	C	_	_	I-Premise
260	:	_	_	I-Premise
261	median	_	_	I-Premise
262	3	_	_	I-Premise
263	cycles	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	I-Premise
266	no	_	_	I-Premise
267	difference	_	_	I-Premise
268	in	_	_	I-Premise
269	RR	_	_	I-Premise
270	:	_	_	I-Premise
271	arm	_	_	I-Premise
272	A=6	_	_	I-Premise
273	%	_	_	I-Premise
274	,	_	_	I-Premise
275	arm	_	_	I-Premise
276	B=6	_	_	I-Premise
277	%	_	_	I-Premise
278	,	_	_	I-Premise
279	arm	_	_	I-Premise
280	C=10	_	_	I-Premise
281	%	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	arm	_	_	I-Premise
285	D=0	_	_	I-Premise
286	%	_	_	I-Premise
287	.	_	_	I-Premise

288	There	_	_	B-Premise
289	was	_	_	I-Premise
290	no	_	_	I-Premise
291	statistically	_	_	I-Premise
292	significant	_	_	I-Premise
293	difference	_	_	I-Premise
294	in	_	_	I-Premise
295	grade	_	_	I-Premise
296	3/4	_	_	I-Premise
297	neutropenia	_	_	I-Premise
298	and	_	_	I-Premise
299	thrombocytopenia	_	_	I-Premise
300	between	_	_	I-Premise
301	the	_	_	I-Premise
302	four	_	_	I-Premise
303	arms	_	_	I-Premise
304	.	_	_	I-Premise

305	No	_	_	B-Premise
306	difference	_	_	I-Premise
307	was	_	_	I-Premise
308	observed	_	_	I-Premise
309	in	_	_	I-Premise
310	hospitalization	_	_	I-Premise
311	rate	_	_	I-Premise
312	,	_	_	I-Premise
313	blood	_	_	I-Premise
314	transfusions	_	_	I-Premise
315	,	_	_	I-Premise
316	antibiotics	_	_	I-Premise
317	administration	_	_	I-Premise
318	and	_	_	I-Premise
319	non-haematological	_	_	I-Premise
320	toxicity	_	_	I-Premise
321	.	_	_	I-Premise

322	QoL	_	_	O
323	:	_	_	O
324	no	_	_	O
325	difference	_	_	O
326	in	_	_	O
327	total	_	_	O
328	scores	_	_	O
329	between	_	_	O
330	baseline	_	_	O
331	and	_	_	O
332	cycles	_	_	O
333	1-4	_	_	O
334	.	_	_	O

335	There	_	_	B-Premise
336	was	_	_	I-Premise
337	a	_	_	I-Premise
338	significant	_	_	I-Premise
339	decrease	_	_	I-Premise
340	in	_	_	I-Premise
341	pain	_	_	I-Premise
342	scores	_	_	I-Premise
343	from	_	_	I-Premise
344	baseline	_	_	I-Premise
345	to	_	_	I-Premise
346	post	_	_	I-Premise
347	cycles	_	_	I-Premise
348	2	_	_	I-Premise
349	and	_	_	I-Premise
350	3	_	_	I-Premise
351	(	_	_	I-Premise
352	p=0.025	_	_	I-Premise
353	and	_	_	I-Premise
354	p=0.002	_	_	I-Premise
355	,	_	_	I-Premise
356	respectively	_	_	I-Premise
357	)	_	_	I-Premise
358	.	_	_	I-Premise

359	There	_	_	B-Premise
360	was	_	_	I-Premise
361	no	_	_	I-Premise
362	difference	_	_	I-Premise
363	in	_	_	I-Premise
364	OS	_	_	I-Premise
365	(	_	_	I-Premise
366	p=0.992	_	_	I-Premise
367	)	_	_	I-Premise
368	.	_	_	I-Premise

369	Median	_	_	B-Premise
370	survival	_	_	I-Premise
371	and	_	_	I-Premise
372	6-month	_	_	I-Premise
373	survival	_	_	I-Premise
374	were	_	_	I-Premise
375	61	_	_	I-Premise
376	,	_	_	I-Premise
377	86	_	_	I-Premise
378	,	_	_	I-Premise
379	88	_	_	I-Premise
380	and	_	_	I-Premise
381	97	_	_	I-Premise
382	days	_	_	I-Premise
383	and	_	_	I-Premise
384	29	_	_	I-Premise
385	%	_	_	I-Premise
386	,	_	_	I-Premise
387	33	_	_	I-Premise
388	%	_	_	I-Premise
389	,	_	_	I-Premise
390	21	_	_	I-Premise
391	%	_	_	I-Premise
392	and	_	_	I-Premise
393	26	_	_	I-Premise
394	%	_	_	I-Premise
395	for	_	_	I-Premise
396	arms	_	_	I-Premise
397	A	_	_	I-Premise
398	,	_	_	I-Premise
399	B	_	_	I-Premise
400	,	_	_	I-Premise
401	C	_	_	I-Premise
402	,	_	_	I-Premise
403	and	_	_	I-Premise
404	D	_	_	I-Premise
405	,	_	_	I-Premise
406	respectively	_	_	I-Premise
407	.	_	_	I-Premise

408	Clinical	_	_	B-Claim
409	efficacy	_	_	I-Claim
410	of	_	_	I-Claim
411	docetaxel	_	_	I-Claim
412	was	_	_	I-Claim
413	observed	_	_	I-Claim
414	at	_	_	I-Claim
415	all	_	_	I-Claim
416	dose	_	_	I-Claim
417	levels	_	_	I-Claim
418	.	_	_	I-Claim

419	Higher	_	_	B-Claim
420	dose	_	_	I-Claim
421	levels	_	_	I-Claim
422	were	_	_	I-Claim
423	not	_	_	I-Claim
424	associated	_	_	I-Claim
425	with	_	_	I-Claim
426	increased	_	_	I-Claim
427	toxicities	_	_	I-Claim
428	,	_	_	I-Claim
429	use	_	_	I-Claim
430	of	_	_	I-Claim
431	IV	_	_	I-Claim
432	antibiotics	_	_	I-Claim
433	or	_	_	I-Claim
434	hospitalization	_	_	I-Claim
435	rates	_	_	I-Claim
436	.	_	_	I-Claim

437	However	_	_	O
438	,	_	_	O
439	the	_	_	B-Premise
440	median	_	_	I-Premise
441	survival	_	_	I-Premise
442	observed	_	_	I-Premise
443	is	_	_	I-Premise
444	shorter	_	_	I-Premise
445	than	_	_	I-Premise
446	historical	_	_	I-Premise
447	data	_	_	I-Premise
448	and	_	_	I-Premise
449	do	_	_	I-Premise
450	not	_	_	I-Premise
451	support	_	_	I-Premise
452	further	_	_	I-Premise
453	evaluation	_	_	I-Premise
454	of	_	_	I-Premise
455	these	_	_	I-Premise
456	doses	_	_	I-Premise
457	of	_	_	I-Premise
458	single	_	_	I-Premise
459	agent	_	_	I-Premise
460	docetaxel	_	_	I-Premise
461	in	_	_	I-Premise
462	this	_	_	I-Premise
463	population	_	_	I-Premise
464	.	_	_	I-Premise


0	A	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	trial	_	_	O
4	(	_	_	O
5	Cancer	_	_	O
6	and	_	_	O
7	Leukemia	_	_	O
8	Group	_	_	O
9	B	_	_	O
10	CALGB-49907	_	_	O
11	)	_	_	O
12	was	_	_	O
13	conducted	_	_	O
14	to	_	_	O
15	test	_	_	O
16	whether	_	_	O
17	older	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	early-stage	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	would	_	_	O
24	have	_	_	O
25	equivalent	_	_	O
26	relapse-free	_	_	O
27	and	_	_	O
28	overall	_	_	O
29	survival	_	_	O
30	with	_	_	O
31	capecitabine	_	_	O
32	compared	_	_	O
33	with	_	_	O
34	standard	_	_	O
35	chemotherapy	_	_	O
36	.	_	_	O

37	The	_	_	O
38	quality	_	_	O
39	of	_	_	O
40	life	_	_	O
41	(	_	_	O
42	QoL	_	_	O
43	)	_	_	O
44	substudy	_	_	O
45	tested	_	_	O
46	whether	_	_	O
47	capecitabine	_	_	O
48	treatment	_	_	O
49	would	_	_	O
50	be	_	_	O
51	associated	_	_	O
52	with	_	_	O
53	a	_	_	O
54	better	_	_	O
55	QoL	_	_	O
56	than	_	_	O
57	standard	_	_	O
58	chemotherapy	_	_	O
59	.	_	_	O

60	QoL	_	_	O
61	was	_	_	O
62	assessed	_	_	O
63	in	_	_	O
64	350	_	_	O
65	patients	_	_	O
66	randomly	_	_	O
67	assigned	_	_	O
68	to	_	_	O
69	either	_	_	O
70	standard	_	_	O
71	chemotherapy	_	_	O
72	(	_	_	O
73	cyclophosphamide	_	_	O
74	,	_	_	O
75	methotrexate	_	_	O
76	,	_	_	O
77	and	_	_	O
78	fluorouracil	_	_	O
79	[	_	_	O
80	CMF	_	_	O
81	]	_	_	O
82	or	_	_	O
83	doxorubicin	_	_	O
84	and	_	_	O
85	cyclophosphamide	_	_	O
86	[	_	_	O
87	AC	_	_	O
88	]	_	_	O
89	;	_	_	O
90	n	_	_	O
91	=	_	_	O
92	182	_	_	O
93	)	_	_	O
94	or	_	_	O
95	capecitabine	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	168	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Patients	_	_	O
103	were	_	_	O
104	interviewed	_	_	O
105	by	_	_	O
106	telephone	_	_	O
107	before	_	_	O
108	treatment	_	_	O
109	(	_	_	O
110	baseline	_	_	O
111	)	_	_	O
112	,	_	_	O
113	midtreatment	_	_	O
114	,	_	_	O
115	within	_	_	O
116	1	_	_	O
117	month	_	_	O
118	post-treatment	_	_	O
119	,	_	_	O
120	and	_	_	O
121	at	_	_	O
122	12	_	_	O
123	,	_	_	O
124	18	_	_	O
125	,	_	_	O
126	and	_	_	O
127	24	_	_	O
128	months	_	_	O
129	postbaseline	_	_	O
130	by	_	_	O
131	using	_	_	O
132	questionnaires	_	_	O
133	from	_	_	O
134	the	_	_	O
135	European	_	_	O
136	Organisation	_	_	O
137	for	_	_	O
138	Research	_	_	O
139	and	_	_	O
140	Treatment	_	_	O
141	of	_	_	O
142	Cancer	_	_	O
143	Quality	_	_	O
144	of	_	_	O
145	Life	_	_	O
146	Questionnaire	_	_	O
147	C30	_	_	O
148	(	_	_	O
149	EORTC	_	_	O
150	QLQ-C30	_	_	O
151	)	_	_	O
152	,	_	_	O
153	a	_	_	O
154	breast	_	_	O
155	systemic	_	_	O
156	adverse	_	_	O
157	effects	_	_	O
158	scale	_	_	O
159	(	_	_	O
160	EORTC	_	_	O
161	BR23	_	_	O
162	)	_	_	O
163	,	_	_	O
164	and	_	_	O
165	the	_	_	O
166	Hospital	_	_	O
167	Anxiety	_	_	O
168	and	_	_	O
169	Depression	_	_	O
170	Scale	_	_	O
171	(	_	_	O
172	HADS	_	_	O
173	)	_	_	O
174	.	_	_	O

175	Compared	_	_	B-Premise
176	with	_	_	I-Premise
177	patients	_	_	I-Premise
178	who	_	_	I-Premise
179	were	_	_	I-Premise
180	treated	_	_	I-Premise
181	with	_	_	I-Premise
182	standard	_	_	I-Premise
183	chemotherapy	_	_	I-Premise
184	,	_	_	I-Premise
185	patients	_	_	I-Premise
186	who	_	_	I-Premise
187	were	_	_	I-Premise
188	treated	_	_	I-Premise
189	with	_	_	I-Premise
190	capecitabine	_	_	I-Premise
191	had	_	_	I-Premise
192	significantly	_	_	I-Premise
193	better	_	_	I-Premise
194	QoL	_	_	I-Premise
195	,	_	_	I-Premise
196	role	_	_	I-Premise
197	function	_	_	I-Premise
198	,	_	_	I-Premise
199	and	_	_	I-Premise
200	social	_	_	I-Premise
201	function	_	_	I-Premise
202	,	_	_	I-Premise
203	fewer	_	_	I-Premise
204	systemic	_	_	I-Premise
205	adverse	_	_	I-Premise
206	effects	_	_	I-Premise
207	,	_	_	I-Premise
208	less	_	_	I-Premise
209	psychological	_	_	I-Premise
210	distress	_	_	I-Premise
211	,	_	_	I-Premise
212	and	_	_	I-Premise
213	less	_	_	I-Premise
214	fatigue	_	_	I-Premise
215	during	_	_	I-Premise
216	and	_	_	I-Premise
217	at	_	_	I-Premise
218	the	_	_	I-Premise
219	completion	_	_	I-Premise
220	of	_	_	I-Premise
221	treatment	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	≤	_	_	I-Premise
225	.005	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Capecitabine	_	_	B-Premise
229	treatment	_	_	I-Premise
230	was	_	_	I-Premise
231	associated	_	_	I-Premise
232	with	_	_	I-Premise
233	less	_	_	I-Premise
234	nausea	_	_	I-Premise
235	,	_	_	I-Premise
236	vomiting	_	_	I-Premise
237	,	_	_	I-Premise
238	and	_	_	I-Premise
239	constipation	_	_	I-Premise
240	and	_	_	I-Premise
241	with	_	_	I-Premise
242	better	_	_	I-Premise
243	appetite	_	_	I-Premise
244	than	_	_	I-Premise
245	standard	_	_	I-Premise
246	treatment	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	≤	_	_	I-Premise
250	.004	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	but	_	_	I-Premise
254	worse	_	_	I-Premise
255	hand-foot	_	_	I-Premise
256	syndrome	_	_	I-Premise
257	and	_	_	I-Premise
258	diarrhea	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	<	_	_	I-Premise
262	.005	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	These	_	_	O
266	differences	_	_	O
267	all	_	_	O
268	resolved	_	_	O
269	by	_	_	O
270	12	_	_	O
271	months	_	_	O
272	.	_	_	O

273	Standard	_	_	B-Claim
274	chemotherapy	_	_	I-Claim
275	was	_	_	I-Claim
276	superior	_	_	I-Claim
277	to	_	_	I-Claim
278	capecitabine	_	_	I-Claim
279	in	_	_	I-Claim
280	improving	_	_	I-Claim
281	relapse-free	_	_	I-Claim
282	and	_	_	I-Claim
283	overall	_	_	I-Claim
284	survival	_	_	I-Claim
285	for	_	_	I-Claim
286	older	_	_	I-Claim
287	women	_	_	I-Claim
288	with	_	_	I-Claim
289	early-stage	_	_	I-Claim
290	breast	_	_	I-Claim
291	cancer	_	_	I-Claim
292	.	_	_	I-Claim

293	Although	_	_	O
294	capecitabine	_	_	B-Claim
295	was	_	_	I-Claim
296	associated	_	_	I-Claim
297	with	_	_	I-Claim
298	better	_	_	I-Claim
299	QoL	_	_	I-Claim
300	during	_	_	I-Claim
301	treatment	_	_	I-Claim
302	,	_	_	O
303	QoL	_	_	B-Premise
304	was	_	_	I-Premise
305	similar	_	_	I-Premise
306	for	_	_	I-Premise
307	both	_	_	I-Premise
308	groups	_	_	I-Premise
309	at	_	_	I-Premise
310	1	_	_	I-Premise
311	year	_	_	I-Premise
312	.	_	_	I-Premise

313	The	_	_	O
314	brief	_	_	O
315	period	_	_	O
316	of	_	_	O
317	poorer	_	_	O
318	QoL	_	_	O
319	with	_	_	O
320	standard	_	_	O
321	treatment	_	_	O
322	is	_	_	O
323	a	_	_	O
324	modest	_	_	O
325	price	_	_	O
326	to	_	_	O
327	pay	_	_	O
328	for	_	_	O
329	a	_	_	O
330	chance	_	_	O
331	at	_	_	O
332	improved	_	_	O
333	survival	_	_	O
334	.	_	_	O


0	Premenopausal	_	_	O
1	women	_	_	O
2	with	_	_	O
3	breast	_	_	O
4	cancer	_	_	O
5	receiving	_	_	O
6	adjuvant	_	_	O
7	chemotherapy	_	_	O
8	are	_	_	O
9	at	_	_	O
10	risk	_	_	O
11	for	_	_	O
12	amenorrhea	_	_	O
13	.	_	_	O

14	The	_	_	O
15	National	_	_	O
16	Surgical	_	_	O
17	Adjuvant	_	_	O
18	Breast	_	_	O
19	and	_	_	O
20	Bowel	_	_	O
21	Project	_	_	O
22	B-30	_	_	O
23	trial	_	_	O
24	included	_	_	O
25	menstrual	_	_	O
26	history	_	_	O
27	(	_	_	O
28	MH	_	_	O
29	)	_	_	O
30	and	_	_	O
31	quality-of-life	_	_	O
32	(	_	_	O
33	QOL	_	_	O
34	)	_	_	O
35	studies	_	_	O
36	to	_	_	O
37	compare	_	_	O
38	treatments	_	_	O
39	on	_	_	O
40	these	_	_	O
41	outcomes	_	_	O
42	.	_	_	O

43	Patients	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	sequential	_	_	O
49	doxorubicin	_	_	O
50	(	_	_	O
51	A	_	_	O
52	)	_	_	O
53	and	_	_	O
54	cyclophosphamide	_	_	O
55	(	_	_	O
56	C	_	_	O
57	)	_	_	O
58	followed	_	_	O
59	by	_	_	O
60	docetaxel	_	_	O
61	(	_	_	O
62	T	_	_	O
63	;	_	_	O
64	AC→T	_	_	O
65	)	_	_	O
66	,	_	_	O
67	concurrent	_	_	O
68	TAC	_	_	O
69	,	_	_	O
70	or	_	_	O
71	AT	_	_	O
72	,	_	_	O
73	which	_	_	O
74	varied	_	_	O
75	in	_	_	O
76	duration	_	_	O
77	(	_	_	O
78	24	_	_	O
79	,	_	_	O
80	12	_	_	O
81	,	_	_	O
82	12	_	_	O
83	weeks	_	_	O
84	,	_	_	O
85	respectively	_	_	O
86	)	_	_	O
87	,	_	_	O
88	and	_	_	O
89	use	_	_	O
90	of	_	_	O
91	C.	_	_	O
92	Endocrine	_	_	O
93	therapy	_	_	O
94	was	_	_	O
95	prescribed	_	_	O
96	for	_	_	O
97	women	_	_	O
98	with	_	_	O
99	hormone	_	_	O
100	receptor-positive	_	_	O
101	tumors	_	_	O
102	.	_	_	O

103	MH	_	_	O
104	and	_	_	O
105	QOL	_	_	O
106	were	_	_	O
107	assessed	_	_	O
108	with	_	_	O
109	standardized	_	_	O
110	questionnaires	_	_	O
111	at	_	_	O
112	baseline	_	_	O
113	;	_	_	O
114	cycle	_	_	O
115	4	_	_	O
116	,	_	_	O
117	day	_	_	O
118	1	_	_	O
119	;	_	_	O
120	and	_	_	O
121	every	_	_	O
122	6	_	_	O
123	months	_	_	O
124	through	_	_	O
125	24	_	_	O
126	months	_	_	O
127	.	_	_	O

128	Prespecified	_	_	O
129	analyses	_	_	O
130	examined	_	_	O
131	rates	_	_	O
132	of	_	_	O
133	amenorrhea	_	_	O
134	by	_	_	O
135	treatment	_	_	O
136	arm	_	_	O
137	,	_	_	O
138	the	_	_	O
139	relationship	_	_	O
140	between	_	_	O
141	amenorrhea	_	_	O
142	and	_	_	O
143	QOL	_	_	O
144	,	_	_	O
145	and	_	_	O
146	QOL	_	_	O
147	by	_	_	O
148	treatment	_	_	O
149	arm	_	_	O
150	.	_	_	O

151	Amenorrhea	_	_	B-Premise
152	12	_	_	I-Premise
153	months	_	_	I-Premise
154	after	_	_	I-Premise
155	random	_	_	I-Premise
156	assignment	_	_	I-Premise
157	was	_	_	I-Premise
158	significantly	_	_	I-Premise
159	different	_	_	I-Premise
160	between	_	_	I-Premise
161	treatment	_	_	I-Premise
162	groups	_	_	I-Premise
163	:	_	_	I-Premise
164	69.8	_	_	I-Premise
165	%	_	_	I-Premise
166	for	_	_	I-Premise
167	AC→T	_	_	I-Premise
168	,	_	_	I-Premise
169	57.7	_	_	I-Premise
170	%	_	_	I-Premise
171	for	_	_	I-Premise
172	TAC	_	_	I-Premise
173	,	_	_	I-Premise
174	and	_	_	I-Premise
175	37.9	_	_	I-Premise
176	%	_	_	I-Premise
177	for	_	_	I-Premise
178	AT	_	_	I-Premise
179	(	_	_	I-Premise
180	P	_	_	I-Premise
181	<	_	_	I-Premise
182	.001	_	_	I-Premise
183	)	_	_	I-Premise
184	.	_	_	I-Premise

185	The	_	_	B-Premise
186	AT	_	_	I-Premise
187	group	_	_	I-Premise
188	without	_	_	I-Premise
189	tamoxifen	_	_	I-Premise
190	had	_	_	I-Premise
191	the	_	_	I-Premise
192	lowest	_	_	I-Premise
193	rate	_	_	I-Premise
194	of	_	_	I-Premise
195	amenorrhea	_	_	I-Premise
196	.	_	_	I-Premise

197	QOL	_	_	B-Premise
198	was	_	_	I-Premise
199	poorer	_	_	I-Premise
200	for	_	_	I-Premise
201	patients	_	_	I-Premise
202	receiving	_	_	I-Premise
203	AC→T	_	_	I-Premise
204	at	_	_	I-Premise
205	6	_	_	I-Premise
206	months	_	_	I-Premise
207	but	_	_	I-Premise
208	similar	_	_	I-Premise
209	to	_	_	I-Premise
210	others	_	_	I-Premise
211	by	_	_	I-Premise
212	12	_	_	I-Premise
213	months	_	_	I-Premise
214	.	_	_	I-Premise

215	Post-treatment	_	_	B-Premise
216	symptoms	_	_	I-Premise
217	were	_	_	I-Premise
218	increased	_	_	I-Premise
219	above	_	_	I-Premise
220	baseline	_	_	I-Premise
221	for	_	_	I-Premise
222	all	_	_	I-Premise
223	treatments	_	_	I-Premise
224	.	_	_	I-Premise

225	Multivariable	_	_	B-Premise
226	repeated	_	_	I-Premise
227	measures	_	_	I-Premise
228	modeling	_	_	I-Premise
229	demonstrated	_	_	I-Premise
230	that	_	_	I-Premise
231	treatment	_	_	I-Premise
232	arm	_	_	I-Premise
233	,	_	_	I-Premise
234	time	_	_	I-Premise
235	point	_	_	I-Premise
236	,	_	_	I-Premise
237	age	_	_	I-Premise
238	,	_	_	I-Premise
239	and	_	_	I-Premise
240	tamoxifen	_	_	I-Premise
241	use	_	_	I-Premise
242	were	_	_	I-Premise
243	significantly	_	_	I-Premise
244	associated	_	_	I-Premise
245	with	_	_	I-Premise
246	symptom	_	_	I-Premise
247	severity	_	_	I-Premise
248	(	_	_	I-Premise
249	all	_	_	I-Premise
250	P	_	_	I-Premise
251	values	_	_	I-Premise
252	<	_	_	I-Premise
253	.002	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Amenorrhea	_	_	B-Claim
257	rates	_	_	I-Claim
258	differed	_	_	I-Claim
259	significantly	_	_	I-Claim
260	by	_	_	I-Claim
261	treatment	_	_	I-Claim
262	arm	_	_	I-Claim
263	,	_	_	I-Claim
264	with	_	_	I-Claim
265	the	_	_	I-Claim
266	AT	_	_	I-Claim
267	arm	_	_	I-Claim
268	having	_	_	I-Claim
269	the	_	_	I-Claim
270	lowest	_	_	I-Claim
271	rate	_	_	I-Claim
272	.	_	_	I-Claim

273	Patients	_	_	B-Claim
274	treated	_	_	I-Claim
275	with	_	_	I-Claim
276	longer	_	_	I-Claim
277	duration	_	_	I-Claim
278	therapy	_	_	I-Claim
279	(	_	_	I-Claim
280	AC→T	_	_	I-Claim
281	)	_	_	I-Claim
282	had	_	_	I-Claim
283	greater	_	_	I-Claim
284	symptom	_	_	I-Claim
285	severity	_	_	I-Claim
286	and	_	_	I-Claim
287	poorer	_	_	I-Claim
288	QOL	_	_	I-Claim
289	at	_	_	I-Claim
290	6	_	_	I-Claim
291	months	_	_	I-Claim
292	,	_	_	I-Claim
293	but	_	_	I-Claim
294	did	_	_	I-Claim
295	not	_	_	I-Claim
296	differ	_	_	I-Claim
297	from	_	_	I-Claim
298	shorter	_	_	I-Claim
299	duration	_	_	I-Claim
300	treatments	_	_	I-Claim
301	at	_	_	I-Claim
302	12	_	_	I-Claim
303	months	_	_	I-Claim
304	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	whether	_	_	O
3	omission	_	_	O
4	of	_	_	O
5	post-operative	_	_	O
6	radiotherapy	_	_	O
7	(	_	_	O
8	RT	_	_	O
9	)	_	_	O
10	in	_	_	O
11	women	_	_	O
12	with	_	_	O
13	'low-risk	_	_	O
14	'	_	_	O
15	axillary	_	_	O
16	node-negative	_	_	O
17	breast	_	_	O
18	cancer	_	_	O
19	[	_	_	O
20	tumour	_	_	O
21	size	_	_	O
22	of	_	_	O
23	less	_	_	O
24	than	_	_	O
25	5	_	_	O
26	cm	_	_	O
27	(	_	_	O
28	T0-2	_	_	O
29	)	_	_	O
30	although	_	_	O
31	the	_	_	O
32	eligibility	_	_	O
33	criteria	_	_	O
34	further	_	_	O
35	reduce	_	_	O
36	the	_	_	O
37	eligible	_	_	O
38	size	_	_	O
39	to	_	_	O
40	a	_	_	O
41	maximum	_	_	O
42	of	_	_	O
43	3	_	_	O
44	cm	_	_	O
45	]	_	_	O
46	treated	_	_	O
47	by	_	_	O
48	breast-conserving	_	_	O
49	surgery	_	_	O
50	and	_	_	O
51	endocrine	_	_	O
52	therapy	_	_	O
53	improves	_	_	O
54	quality	_	_	O
55	of	_	_	O
56	life	_	_	O
57	and	_	_	O
58	is	_	_	O
59	more	_	_	O
60	cost-effective	_	_	O
61	.	_	_	O

62	A	_	_	O
63	randomised	_	_	O
64	controlled	_	_	O
65	clinical	_	_	O
66	trial	_	_	O
67	,	_	_	O
68	using	_	_	O
69	a	_	_	O
70	method	_	_	O
71	of	_	_	O
72	minimisation	_	_	O
73	balanced	_	_	O
74	by	_	_	O
75	centre	_	_	O
76	,	_	_	O
77	grade	_	_	O
78	of	_	_	O
79	cancer	_	_	O
80	,	_	_	O
81	age	_	_	O
82	,	_	_	O
83	lymphovascular	_	_	O
84	invasion	_	_	O
85	and	_	_	O
86	preoperative	_	_	O
87	endocrine	_	_	O
88	therapy	_	_	O
89	was	_	_	O
90	performed	_	_	O
91	.	_	_	O

92	Breast	_	_	O
93	cancer	_	_	O
94	clinics	_	_	O
95	in	_	_	O
96	cancer	_	_	O
97	centres	_	_	O
98	in	_	_	O
99	the	_	_	O
100	UK	_	_	O
101	.	_	_	O

102	Patients	_	_	O
103	aged	_	_	O
104	≥	_	_	O
105	65	_	_	O
106	years	_	_	O
107	were	_	_	O
108	eligible	_	_	O
109	provided	_	_	O
110	that	_	_	O
111	their	_	_	O
112	breast	_	_	O
113	cancers	_	_	O
114	were	_	_	O
115	considered	_	_	O
116	to	_	_	O
117	be	_	_	O
118	at	_	_	O
119	low	_	_	O
120	risk	_	_	O
121	of	_	_	O
122	local	_	_	O
123	recurrence	_	_	O
124	,	_	_	O
125	they	_	_	O
126	were	_	_	O
127	suitable	_	_	O
128	for	_	_	O
129	breast	_	_	O
130	conservation	_	_	O
131	surgery	_	_	O
132	,	_	_	O
133	they	_	_	O
134	were	_	_	O
135	receiving	_	_	O
136	endocrine	_	_	O
137	therapy	_	_	O
138	and	_	_	O
139	they	_	_	O
140	were	_	_	O
141	willing	_	_	O
142	and	_	_	O
143	able	_	_	O
144	to	_	_	O
145	give	_	_	O
146	informed	_	_	O
147	consent	_	_	O
148	.	_	_	O

149	The	_	_	O
150	standard	_	_	O
151	treatment	_	_	O
152	of	_	_	O
153	post-operative	_	_	O
154	whole	_	_	O
155	breast	_	_	O
156	irradiation	_	_	O
157	or	_	_	O
158	the	_	_	O
159	omission	_	_	O
160	of	_	_	O
161	RT	_	_	O
162	.	_	_	O

163	Quality	_	_	O
164	of	_	_	O
165	life	_	_	O
166	was	_	_	O
167	the	_	_	O
168	primary	_	_	O
169	outcome	_	_	O
170	measure	_	_	O
171	,	_	_	O
172	together	_	_	O
173	with	_	_	O
174	anxiety	_	_	O
175	and	_	_	O
176	depression	_	_	O
177	and	_	_	O
178	cost-effectiveness	_	_	O
179	.	_	_	O

180	Secondary	_	_	O
181	outcome	_	_	O
182	measures	_	_	O
183	were	_	_	O
184	recurrence	_	_	O
185	rates	_	_	O
186	and	_	_	O
187	survival	_	_	O
188	,	_	_	O
189	and	_	_	O
190	treatment-related	_	_	O
191	morbidity	_	_	O
192	.	_	_	O

193	The	_	_	O
194	principal	_	_	O
195	method	_	_	O
196	of	_	_	O
197	data	_	_	O
198	collection	_	_	O
199	was	_	_	O
200	by	_	_	O
201	questionnaire	_	_	O
202	,	_	_	O
203	completed	_	_	O
204	at	_	_	O
205	home	_	_	O
206	with	_	_	O
207	a	_	_	O
208	research	_	_	O
209	nurse	_	_	O
210	on	_	_	O
211	four	_	_	O
212	occasions	_	_	O
213	over	_	_	O
214	15	_	_	O
215	months	_	_	O
216	,	_	_	O
217	then	_	_	O
218	by	_	_	O
219	postal	_	_	O
220	questionnaire	_	_	O
221	at	_	_	O
222	3	_	_	O
223	and	_	_	O
224	5	_	_	O
225	years	_	_	O
226	after	_	_	O
227	surgery	_	_	O
228	.	_	_	O

229	The	_	_	O
230	hypothesised	_	_	O
231	improvement	_	_	O
232	in	_	_	O
233	overall	_	_	O
234	quality	_	_	O
235	of	_	_	O
236	life	_	_	O
237	with	_	_	O
238	the	_	_	O
239	omission	_	_	O
240	of	_	_	O
241	RT	_	_	O
242	was	_	_	O
243	not	_	_	O
244	seen	_	_	O
245	in	_	_	O
246	the	_	_	O
247	summary	_	_	O
248	domains	_	_	O
249	of	_	_	O
250	the	_	_	O
251	European	_	_	O
252	Organisation	_	_	O
253	for	_	_	O
254	Research	_	_	O
255	in	_	_	O
256	the	_	_	O
257	Treatment	_	_	O
258	of	_	_	O
259	Cancer	_	_	O
260	(	_	_	O
261	EORTC	_	_	O
262	)	_	_	O
263	scales	_	_	O
264	.	_	_	O

265	Some	_	_	O
266	differences	_	_	O
267	were	_	_	O
268	apparent	_	_	O
269	within	_	_	O
270	subscales	_	_	O
271	of	_	_	O
272	the	_	_	O
273	EORTC	_	_	O
274	questionnaires	_	_	O
275	,	_	_	O
276	and	_	_	O
277	insights	_	_	O
278	into	_	_	O
279	the	_	_	O
280	impact	_	_	O
281	of	_	_	O
282	treatment	_	_	O
283	were	_	_	O
284	also	_	_	O
285	provided	_	_	O
286	by	_	_	O
287	the	_	_	O
288	qualitative	_	_	O
289	data	_	_	O
290	obtained	_	_	O
291	by	_	_	O
292	open-ended	_	_	O
293	questions	_	_	O
294	added	_	_	O
295	by	_	_	O
296	the	_	_	O
297	trial	_	_	O
298	team	_	_	O
299	.	_	_	O

300	Differences	_	_	O
301	were	_	_	O
302	most	_	_	O
303	apparent	_	_	O
304	shortly	_	_	O
305	after	_	_	O
306	the	_	_	O
307	time	_	_	O
308	of	_	_	O
309	completion	_	_	O
310	of	_	_	O
311	RT	_	_	O
312	.	_	_	O

313	RT	_	_	B-Premise
314	was	_	_	I-Premise
315	then	_	_	I-Premise
316	associated	_	_	I-Premise
317	with	_	_	I-Premise
318	increased	_	_	I-Premise
319	breast	_	_	I-Premise
320	symptoms	_	_	I-Premise
321	and	_	_	I-Premise
322	with	_	_	I-Premise
323	greater	_	_	I-Premise
324	(	_	_	I-Premise
325	self-reported	_	_	I-Premise
326	)	_	_	I-Premise
327	fatigue	_	_	I-Premise
328	,	_	_	I-Premise
329	but	_	_	I-Premise
330	with	_	_	I-Premise
331	lower	_	_	I-Premise
332	levels	_	_	I-Premise
333	of	_	_	I-Premise
334	insomnia	_	_	I-Premise
335	and	_	_	I-Premise
336	endocrine	_	_	I-Premise
337	side	_	_	I-Premise
338	effects	_	_	I-Premise
339	.	_	_	I-Premise

340	These	_	_	B-Premise
341	statistically	_	_	I-Premise
342	significant	_	_	I-Premise
343	differences	_	_	I-Premise
344	in	_	_	I-Premise
345	breast	_	_	I-Premise
346	symptoms	_	_	I-Premise
347	persisted	_	_	I-Premise
348	for	_	_	I-Premise
349	up	_	_	I-Premise
350	to	_	_	I-Premise
351	5	_	_	I-Premise
352	years	_	_	I-Premise
353	after	_	_	I-Premise
354	RT	_	_	I-Premise
355	[	_	_	I-Premise
356	mean	_	_	I-Premise
357	difference	_	_	I-Premise
358	,	_	_	I-Premise
359	RT	_	_	I-Premise
360	was	_	_	I-Premise
361	5.27	_	_	I-Premise
362	units	_	_	I-Premise
363	greater	_	_	I-Premise
364	than	_	_	I-Premise
365	no	_	_	I-Premise
366	RT	_	_	I-Premise
367	,	_	_	I-Premise
368	95	_	_	I-Premise
369	%	_	_	I-Premise
370	confidence	_	_	I-Premise
371	interval	_	_	I-Premise
372	(	_	_	I-Premise
373	CI	_	_	I-Premise
374	)	_	_	I-Premise
375	of	_	_	I-Premise
376	1.46	_	_	I-Premise
377	to	_	_	I-Premise
378	9.07	_	_	I-Premise
379	]	_	_	I-Premise
380	,	_	_	I-Premise
381	with	_	_	I-Premise
382	similar	_	_	I-Premise
383	,	_	_	I-Premise
384	though	_	_	I-Premise
385	non-significant	_	_	I-Premise
386	,	_	_	I-Premise
387	trends	_	_	I-Premise
388	in	_	_	I-Premise
389	insomnia	_	_	I-Premise
390	.	_	_	I-Premise

391	No	_	_	B-Premise
392	significant	_	_	I-Premise
393	difference	_	_	I-Premise
394	was	_	_	I-Premise
395	found	_	_	I-Premise
396	in	_	_	I-Premise
397	the	_	_	I-Premise
398	overall	_	_	I-Premise
399	quality	_	_	I-Premise
400	of	_	_	I-Premise
401	life	_	_	I-Premise
402	measure	_	_	I-Premise
403	,	_	_	I-Premise
404	with	_	_	I-Premise
405	the	_	_	I-Premise
406	no	_	_	I-Premise
407	RT	_	_	I-Premise
408	group	_	_	I-Premise
409	having	_	_	I-Premise
410	0.36	_	_	I-Premise
411	units	_	_	I-Premise
412	greater	_	_	I-Premise
413	quality	_	_	I-Premise
414	of	_	_	I-Premise
415	life	_	_	I-Premise
416	than	_	_	I-Premise
417	the	_	_	I-Premise
418	RT	_	_	I-Premise
419	group	_	_	I-Premise
420	(	_	_	I-Premise
421	95	_	_	I-Premise
422	%	_	_	I-Premise
423	CI	_	_	I-Premise
424	-5.09	_	_	I-Premise
425	to	_	_	I-Premise
426	5.81	_	_	I-Premise
427	)	_	_	I-Premise
428	.	_	_	I-Premise

429	Breast	_	_	B-Claim
430	RT	_	_	I-Claim
431	is	_	_	I-Claim
432	tolerated	_	_	I-Claim
433	well	_	_	I-Claim
434	by	_	_	I-Claim
435	most	_	_	I-Claim
436	older	_	_	I-Claim
437	breast	_	_	I-Claim
438	cancer	_	_	I-Claim
439	patients	_	_	I-Claim
440	without	_	_	I-Claim
441	impairing	_	_	I-Claim
442	their	_	_	I-Claim
443	overall	_	_	I-Claim
444	health-related	_	_	I-Claim
445	quality	_	_	I-Claim
446	of	_	_	I-Claim
447	life	_	_	I-Claim
448	(	_	_	I-Claim
449	HRQoL	_	_	I-Claim
450	)	_	_	I-Claim
451	.	_	_	I-Claim

452	Although	_	_	O
453	HRQoL	_	_	O
454	should	_	_	O
455	always	_	_	O
456	be	_	_	O
457	taken	_	_	O
458	into	_	_	O
459	account	_	_	O
460	when	_	_	O
461	determining	_	_	O
462	treatment	_	_	O
463	,	_	_	O
464	our	_	_	B-Claim
465	results	_	_	I-Claim
466	show	_	_	I-Claim
467	that	_	_	I-Claim
468	the	_	_	I-Claim
469	addition	_	_	I-Claim
470	of	_	_	I-Claim
471	RT	_	_	I-Claim
472	does	_	_	I-Claim
473	not	_	_	I-Claim
474	impair	_	_	I-Claim
475	overall	_	_	I-Claim
476	quality	_	_	I-Claim
477	of	_	_	I-Claim
478	life	_	_	I-Claim
479	.	_	_	I-Claim

480	Further	_	_	B-Claim
481	economic	_	_	I-Claim
482	modelling	_	_	I-Claim
483	on	_	_	I-Claim
484	the	_	_	I-Claim
485	longer-term	_	_	I-Claim
486	costs	_	_	I-Claim
487	and	_	_	I-Claim
488	consequences	_	_	I-Claim
489	of	_	_	I-Claim
490	omitting	_	_	I-Claim
491	RT	_	_	I-Claim
492	is	_	_	I-Claim
493	required	_	_	I-Claim
494	.	_	_	I-Claim


0	The	_	_	O
1	objective	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	explore	_	_	O
8	the	_	_	O
9	inflammatory	_	_	O
10	modulation	_	_	O
11	effect	_	_	O
12	of	_	_	O
13	glutamine-enriched	_	_	O
14	total	_	_	O
15	parenteral	_	_	O
16	nutrition	_	_	O
17	(	_	_	O
18	TPN	_	_	O
19	)	_	_	O
20	by	_	_	O
21	investigating	_	_	O
22	the	_	_	O
23	alterations	_	_	O
24	of	_	_	O
25	inflammation-related	_	_	O
26	cytokines	_	_	O
27	in	_	_	O
28	gastrointestinal	_	_	O
29	(	_	_	O
30	GI	_	_	O
31	)	_	_	O
32	cancer	_	_	O
33	patients	_	_	O
34	postoperatively	_	_	O
35	.	_	_	O

36	Fifty	_	_	O
37	GI	_	_	O
38	cancer	_	_	O
39	patients	_	_	O
40	received	_	_	O
41	postoperative	_	_	O
42	7	_	_	O
43	days	_	_	O
44	of	_	_	O
45	isocaloric	_	_	O
46	and	_	_	O
47	isonitrogenous	_	_	O
48	TPN	_	_	O
49	after	_	_	O
50	operation	_	_	O
51	.	_	_	O

52	They	_	_	O
53	were	_	_	O
54	randomly	_	_	O
55	divided	_	_	O
56	to	_	_	O
57	receive	_	_	O
58	either	_	_	O
59	glutamine-enriched	_	_	O
60	TPN	_	_	O
61	or	_	_	O
62	standard	_	_	O
63	TPN	_	_	O
64	.	_	_	O

65	The	_	_	O
66	inflammation-related	_	_	O
67	cytokines	_	_	O
68	including	_	_	O
69	interleukin-6	_	_	O
70	,	_	_	O
71	interleukin-10	_	_	O
72	,	_	_	O
73	and	_	_	O
74	tumor	_	_	O
75	necrosis	_	_	O
76	factor-α	_	_	O
77	were	_	_	O
78	also	_	_	O
79	determined	_	_	O
80	.	_	_	O

81	Records	_	_	O
82	of	_	_	O
83	nutritional	_	_	O
84	assessments	_	_	O
85	,	_	_	O
86	inflammatory	_	_	O
87	status	_	_	O
88	,	_	_	O
89	and	_	_	O
90	postoperative	_	_	O
91	complications	_	_	O
92	were	_	_	O
93	compared	_	_	O
94	between	_	_	O
95	the	_	_	O
96	two	_	_	O
97	groups	_	_	O
98	.	_	_	O

99	Of	_	_	O
100	50	_	_	O
101	enrolled	_	_	O
102	patients	_	_	O
103	,	_	_	O
104	25	_	_	O
105	patients	_	_	O
106	were	_	_	O
107	classified	_	_	O
108	as	_	_	O
109	the	_	_	O
110	intervention	_	_	O
111	group	_	_	O
112	,	_	_	O
113	and	_	_	O
114	the	_	_	O
115	control	_	_	O
116	group	_	_	O
117	also	_	_	O
118	comprised	_	_	O
119	25	_	_	O
120	patients	_	_	O
121	.	_	_	O

122	The	_	_	O
123	differences	_	_	O
124	of	_	_	O
125	gender	_	_	O
126	,	_	_	O
127	age	_	_	O
128	,	_	_	O
129	primary	_	_	O
130	GI	_	_	O
131	malignancies	_	_	O
132	,	_	_	O
133	and	_	_	O
134	hematological	_	_	O
135	and	_	_	O
136	biochemical	_	_	O
137	data	_	_	O
138	between	_	_	O
139	the	_	_	O
140	two	_	_	O
141	compared	_	_	O
142	groups	_	_	O
143	were	_	_	O
144	not	_	_	O
145	statistically	_	_	O
146	significant	_	_	O
147	(	_	_	O
148	all	_	_	O
149	P	_	_	O
150	>	_	_	O
151	0.05	_	_	O
152	)	_	_	O
153	.	_	_	O

154	Compared	_	_	B-Premise
155	with	_	_	I-Premise
156	standard	_	_	I-Premise
157	TPN	_	_	I-Premise
158	,	_	_	I-Premise
159	a	_	_	I-Premise
160	higher	_	_	I-Premise
161	serum	_	_	I-Premise
162	prealbumin	_	_	I-Premise
163	level	_	_	I-Premise
164	and	_	_	I-Premise
165	better	_	_	I-Premise
166	nitrogen	_	_	I-Premise
167	balance	_	_	I-Premise
168	were	_	_	I-Premise
169	observed	_	_	I-Premise
170	in	_	_	I-Premise
171	glutamine-enriched	_	_	I-Premise
172	TPN	_	_	I-Premise
173	(	_	_	I-Premise
174	P	_	_	I-Premise
175	=	_	_	I-Premise
176	0.039	_	_	I-Premise
177	and	_	_	I-Premise
178	0.048	_	_	I-Premise
179	respectively	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	A	_	_	B-Premise
183	significantly	_	_	I-Premise
184	lower	_	_	I-Premise
185	serum	_	_	I-Premise
186	interleukin-6	_	_	I-Premise
187	level	_	_	I-Premise
188	was	_	_	I-Premise
189	found	_	_	I-Premise
190	in	_	_	I-Premise
191	comparing	_	_	I-Premise
192	glutamine-enriched	_	_	I-Premise
193	with	_	_	I-Premise
194	standard	_	_	I-Premise
195	TPN	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	0.01	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	but	_	_	B-Premise
203	not	_	_	I-Premise
204	in	_	_	I-Premise
205	interleukin-10	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0.374	_	_	I-Premise
210	)	_	_	I-Premise
211	and	_	_	I-Premise
212	tumor	_	_	I-Premise
213	necrosis	_	_	I-Premise
214	factor-α	_	_	I-Premise
215	levels	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	0.653	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Moreover	_	_	O
223	,	_	_	O
224	a	_	_	B-Premise
225	significant	_	_	I-Premise
226	lower	_	_	I-Premise
227	serum	_	_	I-Premise
228	C-reactive	_	_	I-Premise
229	protein	_	_	I-Premise
230	level	_	_	I-Premise
231	was	_	_	I-Premise
232	detected	_	_	I-Premise
233	in	_	_	I-Premise
234	glutamine-enriched	_	_	I-Premise
235	TPN	_	_	I-Premise
236	compared	_	_	I-Premise
237	with	_	_	I-Premise
238	standard	_	_	I-Premise
239	TPN	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	0.013	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	Indeed	_	_	O
247	,	_	_	O
248	four	_	_	B-Premise
249	cases	_	_	I-Premise
250	of	_	_	I-Premise
251	postoperative	_	_	I-Premise
252	infectious	_	_	I-Premise
253	complications	_	_	I-Premise
254	were	_	_	I-Premise
255	noted	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	control	_	_	I-Premise
259	group	_	_	I-Premise
260	,	_	_	I-Premise
261	but	_	_	I-Premise
262	no	_	_	I-Premise
263	postoperative	_	_	I-Premise
264	infectious	_	_	I-Premise
265	complications	_	_	I-Premise
266	were	_	_	I-Premise
267	observed	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	interventional	_	_	I-Premise
271	group	_	_	I-Premise
272	(	_	_	I-Premise
273	P	_	_	I-Premise
274	=	_	_	I-Premise
275	0.037	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	Our	_	_	B-Claim
279	present	_	_	I-Claim
280	study	_	_	I-Claim
281	shows	_	_	I-Claim
282	that	_	_	I-Claim
283	glutamine-enriched	_	_	I-Claim
284	TPN	_	_	I-Claim
285	may	_	_	I-Claim
286	be	_	_	I-Claim
287	beneficial	_	_	I-Claim
288	in	_	_	I-Claim
289	improving	_	_	I-Claim
290	the	_	_	I-Claim
291	inflammatory	_	_	I-Claim
292	status	_	_	I-Claim
293	and	_	_	I-Claim
294	decreasing	_	_	I-Claim
295	the	_	_	I-Claim
296	infectious	_	_	I-Claim
297	morbidity	_	_	I-Claim
298	in	_	_	I-Claim
299	postoperative	_	_	I-Claim
300	GI	_	_	I-Claim
301	cancer	_	_	I-Claim
302	patients	_	_	I-Claim
303	.	_	_	I-Claim


0	﻿	_	_	O
1	To	_	_	O
2	compare	_	_	O
3	the	_	_	O
4	effect	_	_	O
5	on	_	_	O
6	intraocular	_	_	O
7	pressure	_	_	O
8	(	_	_	O
9	IOP	_	_	O
10	)	_	_	O
11	of	_	_	O
12	the	_	_	O
13	silicone	_	_	O
14	Ahmed	_	_	O
15	glaucoma	_	_	O
16	valve	_	_	O
17	with	_	_	O
18	and	_	_	O
19	without	_	_	O
20	an	_	_	O
21	intravitreal	_	_	O
22	injection	_	_	O
23	of	_	_	O
24	triamcinolone	_	_	O
25	acetonide	_	_	O
26	.	_	_	O

27	Forty-nine	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	clinically	_	_	O
31	uncontrolled	_	_	O
32	neovascular	_	_	O
33	glaucoma	_	_	O
34	were	_	_	O
35	included	_	_	O
36	in	_	_	O
37	the	_	_	O
38	study	_	_	O
39	;	_	_	O
40	22	_	_	O
41	were	_	_	O
42	randomly	_	_	O
43	assigned	_	_	O
44	to	_	_	O
45	the	_	_	O
46	study	_	_	O
47	group	_	_	O
48	(	_	_	O
49	silicone	_	_	O
50	Ahmed	_	_	O
51	glaucoma	_	_	O
52	valve	_	_	O
53	implant	_	_	O
54	with	_	_	O
55	intravitreal	_	_	O
56	triamcinolone	_	_	O
57	acetonide	_	_	O
58	)	_	_	O
59	and	_	_	O
60	27	_	_	O
61	to	_	_	O
62	the	_	_	O
63	control	_	_	O
64	group	_	_	O
65	(	_	_	O
66	silicone	_	_	O
67	Ahmed	_	_	O
68	glaucoma	_	_	O
69	valve	_	_	O
70	)	_	_	O
71	.	_	_	O

72	IOP	_	_	O
73	was	_	_	O
74	the	_	_	O
75	primary	_	_	O
76	outcome	_	_	O
77	measure	_	_	O
78	in	_	_	O
79	this	_	_	O
80	study	_	_	O
81	.	_	_	O

82	The	_	_	O
83	secondary	_	_	O
84	outcome	_	_	O
85	measure	_	_	O
86	was	_	_	O
87	success	_	_	O
88	,	_	_	O
89	defined	_	_	O
90	by	_	_	O
91	IOP	_	_	O
92	lower	_	_	O
93	than	_	_	O
94	22	_	_	O
95	mm	_	_	O
96	Hg	_	_	O
97	and	_	_	O
98	higher	_	_	O
99	than	_	_	O
100	5	_	_	O
101	mm	_	_	O
102	Hg	_	_	O
103	,	_	_	O
104	and	_	_	O
105	no	_	_	O
106	serious	_	_	O
107	complications	_	_	O
108	.	_	_	O

109	Success	_	_	O
110	rates	_	_	O
111	in	_	_	O
112	both	_	_	O
113	the	_	_	O
114	groups	_	_	O
115	were	_	_	O
116	compared	_	_	O
117	using	_	_	O
118	Kaplan-Meier	_	_	O
119	survival	_	_	O
120	curves	_	_	O
121	and	_	_	O
122	the	_	_	O
123	log-rank	_	_	O
124	test	_	_	O
125	.	_	_	O

126	IOP	_	_	O
127	levels	_	_	O
128	were	_	_	O
129	compared	_	_	O
130	using	_	_	O
131	mixed	_	_	O
132	linear	_	_	O
133	model	_	_	O
134	analysis	_	_	O
135	to	_	_	O
136	correct	_	_	O
137	for	_	_	O
138	repeated	_	_	O
139	measures	_	_	O
140	correlation	_	_	O
141	.	_	_	O

142	Forty-three	_	_	O
143	patients	_	_	O
144	,	_	_	O
145	18	_	_	O
146	in	_	_	O
147	the	_	_	O
148	study	_	_	O
149	group	_	_	O
150	and	_	_	O
151	25	_	_	O
152	in	_	_	O
153	the	_	_	O
154	control	_	_	O
155	group	_	_	O
156	,	_	_	O
157	completed	_	_	O
158	the	_	_	O
159	study	_	_	O
160	(	_	_	O
161	follow-up	_	_	O
162	of	_	_	O
163	12	_	_	O
164	mo	_	_	O
165	)	_	_	O
166	.	_	_	O

167	The	_	_	B-Premise
168	mean	_	_	I-Premise
169	IOP	_	_	I-Premise
170	was	_	_	I-Premise
171	significantly	_	_	I-Premise
172	lower	_	_	I-Premise
173	after	_	_	I-Premise
174	1	_	_	I-Premise
175	year	_	_	I-Premise
176	in	_	_	I-Premise
177	both	_	_	I-Premise
178	the	_	_	I-Premise
179	groups	_	_	I-Premise
180	(	_	_	I-Premise
181	P	_	_	I-Premise
182	<	_	_	I-Premise
183	0.001	_	_	I-Premise
184	)	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	mean	_	_	I-Premise
188	IOP	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	first	_	_	I-Premise
192	month	_	_	I-Premise
193	of	_	_	I-Premise
194	follow-up	_	_	I-Premise
195	was	_	_	I-Premise
196	lower	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	study	_	_	I-Premise
200	group	_	_	I-Premise
201	(	_	_	I-Premise
202	control	_	_	I-Premise
203	;	_	_	I-Premise
204	20.4±9.7	_	_	I-Premise
205	,	_	_	I-Premise
206	study	_	_	I-Premise
207	;	_	_	I-Premise
208	13.6±6.5	_	_	I-Premise
209	,	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	0.01	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	The	_	_	B-Premise
216	success	_	_	I-Premise
217	rate	_	_	I-Premise
218	at	_	_	I-Premise
219	1	_	_	I-Premise
220	year	_	_	I-Premise
221	was	_	_	I-Premise
222	78	_	_	I-Premise
223	%	_	_	I-Premise
224	for	_	_	I-Premise
225	the	_	_	I-Premise
226	study	_	_	I-Premise
227	group	_	_	I-Premise
228	and	_	_	I-Premise
229	76	_	_	I-Premise
230	%	_	_	I-Premise
231	for	_	_	I-Premise
232	the	_	_	I-Premise
233	control	_	_	I-Premise
234	group	_	_	I-Premise
235	(	_	_	I-Premise
236	P=0.82	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Complication	_	_	B-Premise
240	rates	_	_	I-Premise
241	were	_	_	I-Premise
242	not	_	_	I-Premise
243	different	_	_	I-Premise
244	between	_	_	I-Premise
245	the	_	_	I-Premise
246	groups	_	_	I-Premise
247	.	_	_	I-Premise

248	Intravitreal	_	_	B-Claim
249	injection	_	_	I-Claim
250	of	_	_	I-Claim
251	triamcinolone	_	_	I-Claim
252	acetonide	_	_	I-Claim
253	in	_	_	I-Claim
254	neovascular	_	_	I-Claim
255	glaucoma	_	_	I-Claim
256	did	_	_	I-Claim
257	not	_	_	I-Claim
258	affect	_	_	I-Claim
259	the	_	_	I-Claim
260	intermediate-term	_	_	I-Claim
261	success	_	_	I-Claim
262	of	_	_	I-Claim
263	the	_	_	I-Claim
264	silicone	_	_	I-Claim
265	Ahmed	_	_	I-Claim
266	valve	_	_	I-Claim
267	nor	_	_	I-Claim
268	reduce	_	_	I-Claim
269	the	_	_	I-Claim
270	incidence	_	_	I-Claim
271	of	_	_	I-Claim
272	complications	_	_	I-Claim
273	.	_	_	I-Claim

274	The	_	_	B-Premise
275	mean	_	_	I-Premise
276	IOP	_	_	I-Premise
277	spike	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	first	_	_	I-Premise
281	month	_	_	I-Premise
282	was	_	_	I-Premise
283	lower	_	_	I-Premise
284	in	_	_	I-Premise
285	the	_	_	I-Premise
286	triamcinolone	_	_	I-Premise
287	group	_	_	I-Premise
288	.	_	_	I-Premise


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	determine	_	_	O
4	the	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	a	_	_	O
8	lay-administered	_	_	O
9	tailored	_	_	O
10	education	_	_	O
11	and	_	_	O
12	coaching	_	_	O
13	(	_	_	O
14	TEC	_	_	O
15	)	_	_	O
16	intervention	_	_	O
17	(	_	_	O
18	aimed	_	_	O
19	at	_	_	O
20	reducing	_	_	O
21	pain	_	_	O
22	misconceptions	_	_	O
23	and	_	_	O
24	enhancing	_	_	O
25	self-efficacy	_	_	O
26	for	_	_	O
27	communicating	_	_	O
28	with	_	_	O
29	physicians	_	_	O
30	)	_	_	O
31	on	_	_	O
32	cancer	_	_	O
33	pain	_	_	O
34	severity	_	_	O
35	,	_	_	O
36	pain-related	_	_	O
37	impairment	_	_	O
38	,	_	_	O
39	and	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	.	_	_	O

44	Cancer	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	baseline	_	_	O
48	worst	_	_	O
49	pain	_	_	O
50	of	_	_	O
51	≥4	_	_	O
52	on	_	_	O
53	a	_	_	O
54	0-10	_	_	O
55	scale	_	_	O
56	or	_	_	O
57	at	_	_	O
58	least	_	_	O
59	moderate	_	_	O
60	functional	_	_	O
61	impairment	_	_	O
62	due	_	_	O
63	to	_	_	O
64	pain	_	_	O
65	were	_	_	O
66	randomly	_	_	O
67	assigned	_	_	O
68	to	_	_	O
69	TEC	_	_	O
70	or	_	_	O
71	enhanced	_	_	O
72	usual	_	_	O
73	care	_	_	O
74	(	_	_	O
75	EUC	_	_	O
76	)	_	_	O
77	during	_	_	O
78	a	_	_	O
79	telephone	_	_	O
80	interview	_	_	O
81	conducted	_	_	O
82	in	_	_	O
83	advance	_	_	O
84	of	_	_	O
85	a	_	_	O
86	planned	_	_	O
87	oncology	_	_	O
88	office	_	_	O
89	visit	_	_	O
90	(	_	_	O
91	265	_	_	O
92	patients	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	TEC	_	_	O
96	or	_	_	O
97	EUC	_	_	O
98	;	_	_	O
99	258	_	_	O
100	completed	_	_	O
101	at	_	_	O
102	least	_	_	O
103	one	_	_	O
104	follow-up	_	_	O
105	)	_	_	O
106	.	_	_	O

107	Patients	_	_	O
108	completed	_	_	O
109	questionnaires	_	_	O
110	before	_	_	O
111	and	_	_	O
112	after	_	_	O
113	the	_	_	O
114	visit	_	_	O
115	and	_	_	O
116	were	_	_	O
117	interviewed	_	_	O
118	by	_	_	O
119	telephone	_	_	O
120	at	_	_	O
121	2	_	_	O
122	,	_	_	O
123	6	_	_	O
124	,	_	_	O
125	and	_	_	O
126	12	_	_	O
127	weeks	_	_	O
128	.	_	_	O

129	Mixed	_	_	O
130	effects	_	_	O
131	regressions	_	_	O
132	were	_	_	O
133	used	_	_	O
134	to	_	_	O
135	evaluate	_	_	O
136	the	_	_	O
137	intervention	_	_	O
138	adjusting	_	_	O
139	for	_	_	O
140	patient	_	_	O
141	,	_	_	O
142	practice	_	_	O
143	,	_	_	O
144	and	_	_	O
145	site	_	_	O
146	characteristics	_	_	O
147	.	_	_	O

148	Compared	_	_	B-Premise
149	to	_	_	I-Premise
150	EUC	_	_	I-Premise
151	,	_	_	I-Premise
152	TEC	_	_	I-Premise
153	was	_	_	I-Premise
154	associated	_	_	I-Premise
155	with	_	_	I-Premise
156	increased	_	_	I-Premise
157	pain	_	_	I-Premise
158	communication	_	_	I-Premise
159	self-efficacy	_	_	I-Premise
160	after	_	_	I-Premise
161	the	_	_	I-Premise
162	intervention	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	<	_	_	I-Premise
166	.001	_	_	I-Premise
167	)	_	_	I-Premise
168	;	_	_	I-Premise
169	both	_	_	B-Premise
170	groups	_	_	I-Premise
171	showed	_	_	I-Premise
172	significant	_	_	I-Premise
173	(	_	_	I-Premise
174	P	_	_	I-Premise
175	<	_	_	I-Premise
176	.0001	_	_	I-Premise
177	)	_	_	I-Premise
178	,	_	_	I-Premise
179	similar	_	_	I-Premise
180	,	_	_	I-Premise
181	reductions	_	_	I-Premise
182	in	_	_	I-Premise
183	pain	_	_	I-Premise
184	misconceptions	_	_	I-Premise
185	.	_	_	I-Premise

186	At	_	_	B-Premise
187	2	_	_	I-Premise
188	weeks	_	_	I-Premise
189	,	_	_	I-Premise
190	assignment	_	_	I-Premise
191	to	_	_	I-Premise
192	TEC	_	_	I-Premise
193	was	_	_	I-Premise
194	associated	_	_	I-Premise
195	with	_	_	I-Premise
196	improvement	_	_	I-Premise
197	in	_	_	I-Premise
198	pain-related	_	_	I-Premise
199	impairment	_	_	I-Premise
200	(	_	_	I-Premise
201	-0.25	_	_	I-Premise
202	points	_	_	I-Premise
203	on	_	_	I-Premise
204	a	_	_	I-Premise
205	5-point	_	_	I-Premise
206	scale	_	_	I-Premise
207	,	_	_	I-Premise
208	95	_	_	I-Premise
209	%	_	_	I-Premise
210	confidence	_	_	I-Premise
211	interval	_	_	I-Premise
212	-0.43	_	_	I-Premise
213	to	_	_	I-Premise
214	-0.06	_	_	I-Premise
215	,	_	_	I-Premise
216	P=.01	_	_	I-Premise
217	)	_	_	I-Premise
218	but	_	_	B-Premise
219	not	_	_	I-Premise
220	in	_	_	I-Premise
221	pain	_	_	I-Premise
222	severity	_	_	I-Premise
223	(	_	_	I-Premise
224	-0.21	_	_	I-Premise
225	points	_	_	I-Premise
226	on	_	_	I-Premise
227	an	_	_	I-Premise
228	11-point	_	_	I-Premise
229	scale	_	_	I-Premise
230	,	_	_	I-Premise
231	-0.60	_	_	I-Premise
232	to	_	_	I-Premise
233	0.17	_	_	I-Premise
234	,	_	_	I-Premise
235	P=.27	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	The	_	_	B-Premise
239	improvement	_	_	I-Premise
240	in	_	_	I-Premise
241	pain-related	_	_	I-Premise
242	impairment	_	_	I-Premise
243	was	_	_	I-Premise
244	not	_	_	I-Premise
245	sustained	_	_	I-Premise
246	at	_	_	I-Premise
247	6	_	_	I-Premise
248	and	_	_	I-Premise
249	12	_	_	I-Premise
250	weeks	_	_	I-Premise
251	.	_	_	I-Premise

252	There	_	_	B-Premise
253	were	_	_	I-Premise
254	no	_	_	I-Premise
255	significant	_	_	I-Premise
256	intervention	_	_	I-Premise
257	by	_	_	I-Premise
258	subgroup	_	_	I-Premise
259	interactions	_	_	I-Premise
260	(	_	_	I-Premise
261	P	_	_	I-Premise
262	>	_	_	I-Premise
263	.10	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	We	_	_	B-Claim
267	conclude	_	_	I-Claim
268	that	_	_	I-Claim
269	TEC	_	_	I-Claim
270	,	_	_	I-Claim
271	compared	_	_	I-Claim
272	with	_	_	I-Claim
273	EUC	_	_	I-Claim
274	,	_	_	I-Claim
275	resulted	_	_	I-Claim
276	in	_	_	I-Claim
277	improved	_	_	I-Claim
278	pain	_	_	I-Claim
279	communication	_	_	I-Claim
280	self-efficacy	_	_	I-Claim
281	and	_	_	I-Claim
282	temporary	_	_	I-Claim
283	improvement	_	_	I-Claim
284	in	_	_	I-Claim
285	pain-related	_	_	I-Claim
286	impairment	_	_	I-Claim
287	,	_	_	I-Claim
288	but	_	_	I-Claim
289	no	_	_	I-Claim
290	improvement	_	_	I-Claim
291	in	_	_	I-Claim
292	pain	_	_	I-Claim
293	severity	_	_	I-Claim
294	.	_	_	I-Claim


0	Postoperative	_	_	B-Claim
1	outcomes	_	_	I-Claim
2	of	_	_	I-Claim
3	patients	_	_	I-Claim
4	undergoing	_	_	I-Claim
5	laparoscopic-assisted	_	_	I-Claim
6	colectomy	_	_	I-Claim
7	(	_	_	I-Claim
8	LAC	_	_	I-Claim
9	)	_	_	I-Claim
10	have	_	_	I-Claim
11	shown	_	_	I-Claim
12	modest	_	_	I-Claim
13	improvements	_	_	I-Claim
14	in	_	_	I-Claim
15	recovery	_	_	I-Claim
16	but	_	_	I-Claim
17	only	_	_	I-Claim
18	minimal	_	_	I-Claim
19	differences	_	_	I-Claim
20	in	_	_	I-Claim
21	quality	_	_	I-Claim
22	of	_	_	I-Claim
23	life	_	_	I-Claim
24	(	_	_	I-Claim
25	QOL	_	_	I-Claim
26	)	_	_	I-Claim
27	compared	_	_	I-Claim
28	with	_	_	I-Claim
29	open	_	_	I-Claim
30	colectomy	_	_	I-Claim
31	.	_	_	I-Claim

32	We	_	_	O
33	therefore	_	_	O
34	sought	_	_	O
35	to	_	_	O
36	assess	_	_	O
37	the	_	_	O
38	effect	_	_	O
39	of	_	_	O
40	LAC	_	_	O
41	on	_	_	O
42	QOL	_	_	O
43	in	_	_	O
44	the	_	_	O
45	short	_	_	O
46	and	_	_	O
47	long	_	_	O
48	term	_	_	O
49	,	_	_	O
50	using	_	_	O
51	individual	_	_	O
52	item	_	_	O
53	analysis	_	_	O
54	of	_	_	O
55	multi-item	_	_	O
56	QOL	_	_	O
57	assessments	_	_	O
58	.	_	_	O

59	QOL	_	_	O
60	variables	_	_	O
61	were	_	_	O
62	analyzed	_	_	O
63	in	_	_	O
64	449	_	_	O
65	randomized	_	_	O
66	patients	_	_	O
67	from	_	_	O
68	the	_	_	O
69	COST	_	_	O
70	trial	_	_	O
71	93-46-53	_	_	O
72	(	_	_	O
73	INT	_	_	O
74	0146	_	_	O
75	)	_	_	O
76	.	_	_	O

77	Both	_	_	O
78	cross-sectional	_	_	O
79	single-time	_	_	O
80	and	_	_	O
81	change	_	_	O
82	from	_	_	O
83	baseline	_	_	O
84	assessments	_	_	O
85	were	_	_	O
86	run	_	_	O
87	at	_	_	O
88	day	_	_	O
89	2	_	_	O
90	,	_	_	O
91	week	_	_	O
92	2	_	_	O
93	,	_	_	O
94	month	_	_	O
95	2	_	_	O
96	,	_	_	O
97	and	_	_	O
98	month	_	_	O
99	18	_	_	O
100	postoperatively	_	_	O
101	in	_	_	O
102	an	_	_	O
103	intention-to-treat	_	_	O
104	analysis	_	_	O
105	using	_	_	O
106	Wilcoxon	_	_	O
107	rank-sum	_	_	O
108	tests	_	_	O
109	.	_	_	O

110	Stepwise	_	_	O
111	regression	_	_	O
112	models	_	_	O
113	were	_	_	O
114	used	_	_	O
115	to	_	_	O
116	determine	_	_	O
117	predictors	_	_	O
118	of	_	_	O
119	QOL	_	_	O
120	.	_	_	O

121	Of	_	_	O
122	449	_	_	O
123	colon	_	_	O
124	cancer	_	_	O
125	patients	_	_	O
126	,	_	_	O
127	230	_	_	O
128	underwent	_	_	O
129	LAC	_	_	O
130	and	_	_	O
131	219	_	_	O
132	underwent	_	_	O
133	open	_	_	O
134	colectomy	_	_	O
135	.	_	_	O

136	Subdomain	_	_	B-Premise
137	analysis	_	_	I-Premise
138	revealed	_	_	I-Premise
139	a	_	_	I-Premise
140	clinically	_	_	I-Premise
141	moderate	_	_	I-Premise
142	improvement	_	_	I-Premise
143	from	_	_	I-Premise
144	baseline	_	_	I-Premise
145	for	_	_	I-Premise
146	LAC	_	_	I-Premise
147	in	_	_	I-Premise
148	total	_	_	I-Premise
149	QOL	_	_	I-Premise
150	index	_	_	I-Premise
151	at	_	_	I-Premise
152	18	_	_	I-Premise
153	months	_	_	I-Premise
154	(	_	_	I-Premise
155	P	_	_	I-Premise
156	=	_	_	I-Premise
157	0.02	_	_	I-Premise
158	)	_	_	I-Premise
159	as	_	_	I-Premise
160	well	_	_	I-Premise
161	as	_	_	I-Premise
162	other	_	_	I-Premise
163	small	_	_	I-Premise
164	symptomatic	_	_	I-Premise
165	improvements	_	_	I-Premise
166	.	_	_	I-Premise

167	Poor	_	_	O
168	preoperative	_	_	O
169	QOL	_	_	O
170	as	_	_	O
171	indicated	_	_	O
172	by	_	_	O
173	a	_	_	O
174	rating	_	_	O
175	scale	_	_	O
176	of	_	_	O
177	≤	_	_	O
178	50	_	_	O
179	was	_	_	O
180	an	_	_	O
181	independent	_	_	O
182	predictor	_	_	O
183	of	_	_	O
184	poor	_	_	O
185	QOL	_	_	O
186	at	_	_	O
187	2	_	_	O
188	months	_	_	O
189	postoperatively	_	_	O
190	.	_	_	O

191	QOL	_	_	O
192	variables	_	_	O
193	related	_	_	O
194	to	_	_	O
195	survival	_	_	O
196	were	_	_	O
197	baseline	_	_	O
198	support	_	_	O
199	(	_	_	O
200	P	_	_	O
201	=	_	_	O
202	0.001	_	_	O
203	)	_	_	O
204	and	_	_	O
205	baseline	_	_	O
206	outlook	_	_	O
207	(	_	_	O
208	P	_	_	O
209	=	_	_	O
210	0.01	_	_	O
211	)	_	_	O
212	.	_	_	O

213	Eighteen	_	_	B-Premise
214	months	_	_	I-Premise
215	after	_	_	I-Premise
216	surgery	_	_	I-Premise
217	,	_	_	I-Premise
218	any	_	_	I-Premise
219	differences	_	_	I-Premise
220	in	_	_	I-Premise
221	quality	_	_	I-Premise
222	of	_	_	I-Premise
223	life	_	_	I-Premise
224	between	_	_	I-Premise
225	patients	_	_	I-Premise
226	randomized	_	_	I-Premise
227	to	_	_	I-Premise
228	LAC	_	_	I-Premise
229	or	_	_	I-Premise
230	open	_	_	I-Premise
231	colectomy	_	_	I-Premise
232	favored	_	_	I-Premise
233	LAC	_	_	I-Premise
234	.	_	_	I-Premise

235	However	_	_	B-Premise
236	,	_	_	I-Premise
237	the	_	_	I-Premise
238	magnitude	_	_	I-Premise
239	of	_	_	I-Premise
240	the	_	_	I-Premise
241	benefits	_	_	I-Premise
242	was	_	_	I-Premise
243	small	_	_	I-Premise
244	.	_	_	I-Premise

245	Patients	_	_	B-Claim
246	with	_	_	I-Claim
247	poor	_	_	I-Claim
248	preoperative	_	_	I-Claim
249	QOL	_	_	I-Claim
250	appear	_	_	I-Claim
251	to	_	_	I-Claim
252	be	_	_	I-Claim
253	at	_	_	I-Claim
254	higher	_	_	I-Claim
255	risk	_	_	I-Claim
256	for	_	_	I-Claim
257	difficult	_	_	I-Claim
258	postoperative	_	_	I-Claim
259	courses	_	_	I-Claim
260	,	_	_	I-Claim
261	and	_	_	I-Claim
262	may	_	_	I-Claim
263	be	_	_	I-Claim
264	candidates	_	_	I-Claim
265	for	_	_	I-Claim
266	enhanced	_	_	I-Claim
267	ancillary	_	_	I-Claim
268	services	_	_	I-Claim
269	to	_	_	I-Claim
270	address	_	_	I-Claim
271	their	_	_	I-Claim
272	particular	_	_	I-Claim
273	needs	_	_	I-Claim
274	.	_	_	I-Claim


0	Improvements	_	_	O
1	can	_	_	O
2	be	_	_	O
3	made	_	_	O
4	in	_	_	O
5	the	_	_	O
6	quality	_	_	O
7	of	_	_	O
8	cancer	_	_	O
9	care	_	_	O
10	if	_	_	O
11	supportive	_	_	O
12	care	_	_	O
13	needs	_	_	O
14	are	_	_	O
15	addressed	_	_	O
16	;	_	_	O
17	however	_	_	O
18	,	_	_	O
19	there	_	_	O
20	are	_	_	O
21	few	_	_	O
22	trials	_	_	O
23	of	_	_	O
24	supportive	_	_	O
25	care	_	_	O
26	interventions	_	_	O
27	to	_	_	O
28	guide	_	_	O
29	policy	_	_	O
30	and	_	_	O
31	practice	_	_	O
32	.	_	_	O

33	This	_	_	O
34	study	_	_	O
35	aimed	_	_	O
36	to	_	_	O
37	determine	_	_	O
38	the	_	_	O
39	effectiveness	_	_	O
40	of	_	_	O
41	a	_	_	O
42	nurse-delivered	_	_	O
43	telephone	_	_	O
44	supportive	_	_	O
45	intervention	_	_	O
46	(	_	_	O
47	the	_	_	O
48	CONNECT	_	_	O
49	intervention	_	_	O
50	)	_	_	O
51	.	_	_	O

52	This	_	_	O
53	study	_	_	O
54	was	_	_	O
55	a	_	_	O
56	pilot	_	_	O
57	randomized	_	_	O
58	controlled	_	_	O
59	trial	_	_	O
60	.	_	_	O

61	Intervention	_	_	O
62	group	_	_	O
63	patients	_	_	O
64	received	_	_	O
65	5	_	_	O
66	calls	_	_	O
67	from	_	_	O
68	a	_	_	O
69	specialist	_	_	O
70	colorectal	_	_	O
71	nurse	_	_	O
72	in	_	_	O
73	the	_	_	O
74	6	_	_	O
75	months	_	_	O
76	after	_	_	O
77	hospital	_	_	O
78	discharge	_	_	O
79	.	_	_	O

80	Each	_	_	O
81	call	_	_	O
82	was	_	_	O
83	standardized	_	_	O
84	,	_	_	O
85	comprising	_	_	O
86	the	_	_	O
87	assessment	_	_	O
88	of	_	_	O
89	unmet	_	_	O
90	need	_	_	O
91	and	_	_	O
92	the	_	_	O
93	provision	_	_	O
94	of	_	_	O
95	information	_	_	O
96	and	_	_	O
97	emotional	_	_	O
98	support	_	_	O
99	.	_	_	O

100	CONNECT	_	_	O
101	was	_	_	O
102	in	_	_	O
103	addition	_	_	O
104	to	_	_	O
105	standard	_	_	O
106	clinical	_	_	O
107	follow-up	_	_	O
108	.	_	_	O

109	Patients	_	_	O
110	allocated	_	_	O
111	to	_	_	O
112	the	_	_	O
113	control	_	_	O
114	group	_	_	O
115	received	_	_	O
116	standard	_	_	O
117	follow-up	_	_	O
118	only	_	_	O
119	.	_	_	O

120	This	_	_	O
121	study	_	_	O
122	took	_	_	O
123	place	_	_	O
124	at	_	_	O
125	the	_	_	O
126	Royal	_	_	O
127	Prince	_	_	O
128	Alfred	_	_	O
129	Hospital	_	_	O
130	,	_	_	O
131	Sydney	_	_	O
132	,	_	_	O
133	Australia	_	_	O
134	.	_	_	O

135	Patients	_	_	O
136	(	_	_	O
137	n	_	_	O
138	=	_	_	O
139	75	_	_	O
140	)	_	_	O
141	were	_	_	O
142	included	_	_	O
143	who	_	_	O
144	had	_	_	O
145	been	_	_	O
146	surgically	_	_	O
147	treated	_	_	O
148	for	_	_	O
149	colorectal	_	_	O
150	cancer	_	_	O
151	(	_	_	O
152	any	_	_	O
153	stage	_	_	O
154	)	_	_	O
155	.	_	_	O

156	The	_	_	O
157	main	_	_	O
158	outcome	_	_	O
159	measures	_	_	O
160	were	_	_	O
161	the	_	_	O
162	unmet	_	_	O
163	supportive	_	_	O
164	care	_	_	O
165	needs	_	_	O
166	,	_	_	O
167	health	_	_	O
168	service	_	_	O
169	utilization	_	_	O
170	,	_	_	O
171	and	_	_	O
172	quality	_	_	O
173	of	_	_	O
174	life	_	_	O
175	at	_	_	O
176	1	_	_	O
177	,	_	_	O
178	3	_	_	O
179	,	_	_	O
180	and	_	_	O
181	6	_	_	O
182	months	_	_	O
183	postdischarge	_	_	O
184	.	_	_	O

185	Of	_	_	O
186	87	_	_	O
187	eligible	_	_	O
188	patients	_	_	O
189	,	_	_	O
190	75	_	_	O
191	consented	_	_	O
192	(	_	_	O
193	86	_	_	O
194	%	_	_	O
195	consent	_	_	O
196	rate	_	_	O
197	)	_	_	O
198	.	_	_	O

199	Thirty-nine	_	_	O
200	patients	_	_	O
201	were	_	_	O
202	randomly	_	_	O
203	assigned	_	_	O
204	to	_	_	O
205	CONNECT	_	_	O
206	and	_	_	O
207	36	_	_	O
208	to	_	_	O
209	usual	_	_	O
210	care	_	_	O
211	.	_	_	O

212	At	_	_	B-Premise
213	6	_	_	I-Premise
214	months	_	_	I-Premise
215	,	_	_	I-Premise
216	there	_	_	I-Premise
217	was	_	_	I-Premise
218	a	_	_	I-Premise
219	clinically	_	_	I-Premise
220	relevant	_	_	I-Premise
221	,	_	_	I-Premise
222	but	_	_	I-Premise
223	nonsignificant	_	_	I-Premise
224	reduction	_	_	I-Premise
225	in	_	_	I-Premise
226	presentations	_	_	I-Premise
227	to	_	_	I-Premise
228	emergency	_	_	I-Premise
229	departments	_	_	I-Premise
230	(	_	_	I-Premise
231	21	_	_	I-Premise
232	%	_	_	I-Premise
233	vs	_	_	I-Premise
234	33	_	_	I-Premise
235	%	_	_	I-Premise
236	;	_	_	I-Premise
237	χ1	_	_	I-Premise
238	=	_	_	I-Premise
239	1.41	_	_	I-Premise
240	,	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	.23	_	_	I-Premise
244	)	_	_	I-Premise
245	and	_	_	I-Premise
246	readmission	_	_	I-Premise
247	to	_	_	I-Premise
248	the	_	_	I-Premise
249	hospital	_	_	I-Premise
250	(	_	_	I-Premise
251	37	_	_	I-Premise
252	%	_	_	I-Premise
253	vs	_	_	I-Premise
254	47	_	_	I-Premise
255	%	_	_	I-Premise
256	;	_	_	I-Premise
257	χ1	_	_	I-Premise
258	=	_	_	I-Premise
259	0.82	_	_	I-Premise
260	,	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.37	_	_	I-Premise
264	)	_	_	I-Premise
265	among	_	_	I-Premise
266	intervention	_	_	I-Premise
267	compared	_	_	I-Premise
268	with	_	_	I-Premise
269	control	_	_	I-Premise
270	group	_	_	I-Premise
271	participants	_	_	I-Premise
272	.	_	_	I-Premise

273	Nonsignificant	_	_	B-Premise
274	differences	_	_	I-Premise
275	between	_	_	I-Premise
276	groups	_	_	I-Premise
277	were	_	_	I-Premise
278	found	_	_	I-Premise
279	for	_	_	I-Premise
280	all	_	_	I-Premise
281	unmet	_	_	I-Premise
282	supportive	_	_	I-Premise
283	care	_	_	I-Premise
284	need	_	_	I-Premise
285	and	_	_	I-Premise
286	quality-of-life	_	_	I-Premise
287	scores	_	_	I-Premise
288	,	_	_	I-Premise
289	change	_	_	I-Premise
290	scores	_	_	I-Premise
291	,	_	_	I-Premise
292	and	_	_	I-Premise
293	trends	_	_	I-Premise
294	.	_	_	I-Premise

295	However	_	_	B-Premise
296	,	_	_	I-Premise
297	at	_	_	I-Premise
298	6	_	_	I-Premise
299	months	_	_	I-Premise
300	,	_	_	I-Premise
301	total	_	_	I-Premise
302	quality-of-life	_	_	I-Premise
303	scores	_	_	I-Premise
304	were	_	_	I-Premise
305	higher	_	_	I-Premise
306	for	_	_	I-Premise
307	intervention	_	_	I-Premise
308	group	_	_	I-Premise
309	patients	_	_	I-Premise
310	than	_	_	I-Premise
311	controls	_	_	I-Premise
312	(	_	_	I-Premise
313	106.0	_	_	I-Premise
314	vs	_	_	I-Premise
315	98.6	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	This	_	_	O
319	difference	_	_	O
320	(	_	_	O
321	7.4	_	_	O
322	)	_	_	O
323	was	_	_	O
324	clinically	_	_	O
325	relevant	_	_	O
326	.	_	_	O

327	Improvements	_	_	B-Claim
328	in	_	_	I-Claim
329	total	_	_	I-Claim
330	quality-of-life	_	_	I-Claim
331	change	_	_	I-Claim
332	scores	_	_	I-Claim
333	demonstrated	_	_	I-Claim
334	that	_	_	I-Claim
335	at	_	_	I-Claim
336	6	_	_	I-Claim
337	months	_	_	I-Claim
338	,	_	_	I-Claim
339	improvements	_	_	I-Claim
340	were	_	_	I-Claim
341	more	_	_	I-Claim
342	than	_	_	I-Claim
343	twice	_	_	I-Claim
344	as	_	_	I-Claim
345	large	_	_	I-Claim
346	and	_	_	I-Claim
347	clinically	_	_	I-Claim
348	significant	_	_	I-Claim
349	in	_	_	I-Claim
350	the	_	_	I-Claim
351	intervention	_	_	I-Claim
352	compared	_	_	I-Claim
353	with	_	_	I-Claim
354	the	_	_	I-Claim
355	control	_	_	I-Claim
356	group	_	_	I-Claim
357	.	_	_	I-Claim

358	CONNECT	_	_	B-Claim
359	has	_	_	I-Claim
360	shown	_	_	I-Claim
361	promising	_	_	I-Claim
362	indications	_	_	I-Claim
363	on	_	_	I-Claim
364	health	_	_	I-Claim
365	system	_	_	I-Claim
366	and	_	_	I-Claim
367	patient	_	_	I-Claim
368	outcomes	_	_	I-Claim
369	that	_	_	I-Claim
370	warrant	_	_	I-Claim
371	a	_	_	I-Claim
372	larger	_	_	I-Claim
373	study	_	_	I-Claim
374	to	_	_	I-Claim
375	further	_	_	I-Claim
376	investigate	_	_	I-Claim
377	the	_	_	I-Claim
378	potential	_	_	I-Claim
379	of	_	_	I-Claim
380	this	_	_	I-Claim
381	intervention	_	_	I-Claim
382	.	_	_	I-Claim


0	Thalidomide	_	_	O
1	with	_	_	O
2	melphalan/prednisone	_	_	O
3	(	_	_	O
4	MPT	_	_	O
5	)	_	_	O
6	was	_	_	O
7	defined	_	_	O
8	as	_	_	O
9	standard	_	_	O
10	treatment	_	_	O
11	in	_	_	O
12	elderly	_	_	O
13	patients	_	_	O
14	with	_	_	O
15	multiple	_	_	O
16	myeloma	_	_	O
17	(	_	_	O
18	MM	_	_	O
19	)	_	_	O
20	based	_	_	O
21	on	_	_	O
22	five	_	_	O
23	randomized	_	_	O
24	trials	_	_	O
25	.	_	_	O

26	In	_	_	O
27	one	_	_	O
28	of	_	_	O
29	these	_	_	O
30	trials	_	_	O
31	,	_	_	O
32	HOVON49	_	_	O
33	,	_	_	O
34	a	_	_	O
35	prospective	_	_	O
36	health-related	_	_	O
37	quality-of-life	_	_	O
38	(	_	_	O
39	HRQoL	_	_	O
40	)	_	_	O
41	study	_	_	O
42	was	_	_	O
43	initiated	_	_	O
44	in	_	_	O
45	order	_	_	O
46	to	_	_	O
47	assess	_	_	O
48	the	_	_	O
49	impact	_	_	O
50	of	_	_	O
51	thalidomide	_	_	O
52	on	_	_	O
53	QoL	_	_	O
54	.	_	_	O

55	Patients	_	_	O
56	aged	_	_	O
57	>	_	_	O
58	65	_	_	O
59	years	_	_	O
60	with	_	_	O
61	newly	_	_	O
62	diagnosed	_	_	O
63	MM	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	receive	_	_	O
68	melphalan	_	_	O
69	plus	_	_	O
70	prednisone	_	_	O
71	(	_	_	O
72	MP	_	_	O
73	)	_	_	O
74	or	_	_	O
75	MPT	_	_	O
76	,	_	_	O
77	followed	_	_	O
78	by	_	_	O
79	thalidomide	_	_	O
80	maintenance	_	_	O
81	in	_	_	O
82	the	_	_	O
83	MPT	_	_	O
84	arm	_	_	O
85	.	_	_	O

86	Two	_	_	O
87	hundred	_	_	O
88	eighty-four	_	_	O
89	patients	_	_	O
90	were	_	_	O
91	included	_	_	O
92	in	_	_	O
93	this	_	_	O
94	side	_	_	O
95	study	_	_	O
96	(	_	_	O
97	MP	_	_	O
98	,	_	_	O
99	n=149	_	_	O
100	;	_	_	O
101	MPT	_	_	O
102	n=135	_	_	O
103	)	_	_	O
104	.	_	_	O

105	HRQoL	_	_	O
106	was	_	_	O
107	assessed	_	_	O
108	with	_	_	O
109	the	_	_	O
110	EORTC	_	_	O
111	Core	_	_	O
112	QoL	_	_	O
113	Questionnaire	_	_	O
114	(	_	_	O
115	QLQ-C30	_	_	O
116	)	_	_	O
117	and	_	_	O
118	the	_	_	O
119	myeloma-specific	_	_	O
120	module	_	_	O
121	(	_	_	O
122	QLQ-MY24	_	_	O
123	)	_	_	O
124	at	_	_	O
125	baseline	_	_	O
126	and	_	_	O
127	at	_	_	O
128	predetermined	_	_	O
129	intervals	_	_	O
130	during	_	_	O
131	treatment	_	_	O
132	.	_	_	O

133	The	_	_	B-Premise
134	QLQ-C30	_	_	I-Premise
135	subscales	_	_	I-Premise
136	physical	_	_	I-Premise
137	function	_	_	I-Premise
138	(	_	_	I-Premise
139	P=0.044	_	_	I-Premise
140	)	_	_	I-Premise
141	and	_	_	I-Premise
142	constipation	_	_	I-Premise
143	(	_	_	I-Premise
144	P	_	_	I-Premise
145	<	_	_	I-Premise
146	0.001	_	_	I-Premise
147	)	_	_	I-Premise
148	showed	_	_	I-Premise
149	an	_	_	I-Premise
150	improvement	_	_	I-Premise
151	during	_	_	I-Premise
152	induction	_	_	I-Premise
153	in	_	_	I-Premise
154	favour	_	_	I-Premise
155	of	_	_	I-Premise
156	the	_	_	I-Premise
157	MP	_	_	I-Premise
158	arm	_	_	I-Premise
159	.	_	_	I-Premise

160	During	_	_	B-Premise
161	thalidomide	_	_	I-Premise
162	maintenance	_	_	I-Premise
163	,	_	_	I-Premise
164	the	_	_	I-Premise
165	scores	_	_	I-Premise
166	for	_	_	I-Premise
167	the	_	_	I-Premise
168	QLQ-MY24	_	_	I-Premise
169	paraesthesia	_	_	I-Premise
170	became	_	_	I-Premise
171	significantly	_	_	I-Premise
172	higher	_	_	I-Premise
173	in	_	_	I-Premise
174	the	_	_	I-Premise
175	MPT	_	_	I-Premise
176	arm	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	<	_	_	I-Premise
180	0.001	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	The	_	_	B-Premise
184	QLQ-C30	_	_	I-Premise
185	subscales	_	_	I-Premise
186	pain	_	_	I-Premise
187	(	_	_	I-Premise
188	P=0.12	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	insomnia	_	_	I-Premise
192	(	_	_	I-Premise
193	P=0.068	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	appetite	_	_	I-Premise
197	loss	_	_	I-Premise
198	(	_	_	I-Premise
199	P=0.074	_	_	I-Premise
200	)	_	_	I-Premise
201	and	_	_	I-Premise
202	the	_	_	I-Premise
203	QLQ-MY24	_	_	I-Premise
204	item	_	_	I-Premise
205	sick	_	_	I-Premise
206	(	_	_	I-Premise
207	P=0.086	_	_	I-Premise
208	)	_	_	I-Premise
209	scored	_	_	I-Premise
210	marginally	_	_	I-Premise
211	better	_	_	I-Premise
212	during	_	_	I-Premise
213	thalidomide	_	_	I-Premise
214	maintenance	_	_	I-Premise
215	.	_	_	I-Premise

216	The	_	_	B-Premise
217	overall	_	_	I-Premise
218	QoL-scale	_	_	I-Premise
219	QLQ-C30-HRQoL	_	_	I-Premise
220	showed	_	_	I-Premise
221	a	_	_	I-Premise
222	significant	_	_	I-Premise
223	time	_	_	I-Premise
224	trend	_	_	I-Premise
225	towards	_	_	I-Premise
226	more	_	_	I-Premise
227	favourable	_	_	I-Premise
228	mean	_	_	I-Premise
229	values	_	_	I-Premise
230	during	_	_	I-Premise
231	protocol	_	_	I-Premise
232	treatment	_	_	I-Premise
233	without	_	_	I-Premise
234	differences	_	_	I-Premise
235	between	_	_	I-Premise
236	MP	_	_	I-Premise
237	and	_	_	I-Premise
238	MPT	_	_	I-Premise
239	.	_	_	I-Premise

240	For	_	_	B-Premise
241	the	_	_	I-Premise
242	QLQ-C30	_	_	I-Premise
243	subscales	_	_	I-Premise
244	emotional	_	_	I-Premise
245	function	_	_	I-Premise
246	and	_	_	I-Premise
247	future	_	_	I-Premise
248	perspectives	_	_	I-Premise
249	,	_	_	I-Premise
250	difference	_	_	I-Premise
251	in	_	_	I-Premise
252	favour	_	_	I-Premise
253	of	_	_	I-Premise
254	the	_	_	I-Premise
255	MPT	_	_	I-Premise
256	arm	_	_	I-Premise
257	from	_	_	I-Premise
258	the	_	_	I-Premise
259	start	_	_	I-Premise
260	of	_	_	I-Premise
261	treatment	_	_	I-Premise
262	was	_	_	I-Premise
263	observed	_	_	I-Premise
264	(	_	_	I-Premise
265	P=0.018	_	_	I-Premise
266	and	_	_	I-Premise
267	P=0.045	_	_	I-Premise
268	,	_	_	I-Premise
269	respectively	_	_	I-Premise
270	)	_	_	I-Premise
271	with	_	_	I-Premise
272	no	_	_	I-Premise
273	significant	_	_	I-Premise
274	'time	_	_	I-Premise
275	×	_	_	I-Premise
276	arm	_	_	I-Premise
277	'	_	_	I-Premise
278	interaction	_	_	I-Premise
279	,	_	_	I-Premise
280	indicating	_	_	I-Premise
281	a	_	_	I-Premise
282	persistent	_	_	I-Premise
283	better	_	_	I-Premise
284	patient	_	_	I-Premise
285	perspective	_	_	I-Premise
286	with	_	_	I-Premise
287	MPT	_	_	I-Premise
288	treatment	_	_	I-Premise
289	.	_	_	I-Premise

290	This	_	_	B-Claim
291	study	_	_	I-Claim
292	shows	_	_	I-Claim
293	that	_	_	I-Claim
294	the	_	_	I-Claim
295	higher	_	_	I-Claim
296	frequency	_	_	I-Claim
297	of	_	_	I-Claim
298	toxicity	_	_	I-Claim
299	associated	_	_	I-Claim
300	with	_	_	I-Claim
301	MPT	_	_	I-Claim
302	does	_	_	I-Claim
303	not	_	_	I-Claim
304	translate	_	_	I-Claim
305	into	_	_	I-Claim
306	a	_	_	I-Claim
307	negative	_	_	I-Claim
308	effect	_	_	I-Claim
309	on	_	_	I-Claim
310	HRQoL	_	_	I-Claim
311	and	_	_	I-Claim
312	that	_	_	I-Claim
313	MPT	_	_	I-Claim
314	holds	_	_	I-Claim
315	a	_	_	I-Claim
316	better	_	_	I-Claim
317	patient	_	_	I-Claim
318	perspective	_	_	I-Claim
319	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	oral	_	_	O
8	clonidine	_	_	O
9	in	_	_	O
10	decreasing	_	_	O
11	the	_	_	O
12	prevalence	_	_	O
13	and	_	_	O
14	intensity	_	_	O
15	of	_	_	O
16	postoperative	_	_	O
17	intraocular	_	_	O
18	pressure	_	_	O
19	(	_	_	O
20	IOP	_	_	O
21	)	_	_	O
22	rise	_	_	O
23	in	_	_	O
24	those	_	_	O
25	undergoing	_	_	O
26	phacoemulsification	_	_	O
27	.	_	_	O

28	This	_	_	O
29	was	_	_	O
30	a	_	_	O
31	prospective	_	_	O
32	randomized	_	_	O
33	,	_	_	O
34	double-blind	_	_	O
35	,	_	_	O
36	placebo-controlled	_	_	O
37	,	_	_	O
38	clinical	_	_	O
39	trial	_	_	O
40	including	_	_	O
41	62	_	_	O
42	patients	_	_	O
43	(	_	_	O
44	each	_	_	O
45	with	_	_	O
46	1	_	_	O
47	affected	_	_	O
48	aye	_	_	O
49	)	_	_	O
50	with	_	_	O
51	senile	_	_	O
52	cataract	_	_	O
53	scheduled	_	_	O
54	for	_	_	O
55	phacoemulsification	_	_	O
56	who	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	assigned	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	preoperative	_	_	O
63	oral	_	_	O
64	clonidine	_	_	O
65	(	_	_	O
66	5g/kg	_	_	O
67	,	_	_	O
68	31	_	_	O
69	patients	_	_	O
70	)	_	_	O
71	or	_	_	O
72	placebo	_	_	O
73	(	_	_	O
74	1	_	_	O
75	tablet	_	_	O
76	,	_	_	O
77	31	_	_	O
78	patients	_	_	O
79	)	_	_	O
80	.	_	_	O

81	The	_	_	O
82	IOP	_	_	O
83	was	_	_	O
84	measured	_	_	O
85	preoperatively	_	_	O
86	and	_	_	O
87	at	_	_	O
88	6	_	_	O
89	,	_	_	O
90	12	_	_	O
91	,	_	_	O
92	and	_	_	O
93	24h	_	_	O
94	postoperatively	_	_	O
95	.	_	_	O

96	The	_	_	O
97	prevalence	_	_	O
98	and	_	_	O
99	intensity	_	_	O
100	of	_	_	O
101	the	_	_	O
102	acute	_	_	O
103	postoperative	_	_	O
104	IOP	_	_	O
105	rise	_	_	O
106	was	_	_	O
107	compared	_	_	O
108	between	_	_	O
109	and	_	_	O
110	within	_	_	O
111	the	_	_	O
112	groups	_	_	O
113	.	_	_	O

114	There	_	_	B-Premise
115	was	_	_	I-Premise
116	no	_	_	I-Premise
117	significant	_	_	I-Premise
118	difference	_	_	I-Premise
119	between	_	_	I-Premise
120	the	_	_	I-Premise
121	2	_	_	I-Premise
122	study	_	_	I-Premise
123	groups	_	_	I-Premise
124	regarding	_	_	I-Premise
125	the	_	_	I-Premise
126	baseline	_	_	I-Premise
127	characteristics	_	_	I-Premise
128	and	_	_	I-Premise
129	the	_	_	I-Premise
130	baseline	_	_	I-Premise
131	IOP	_	_	I-Premise
132	(	_	_	I-Premise
133	P=0.628	_	_	I-Premise
134	)	_	_	I-Premise
135	.	_	_	I-Premise

136	Patients	_	_	B-Premise
137	who	_	_	I-Premise
138	received	_	_	I-Premise
139	placebo	_	_	I-Premise
140	as	_	_	I-Premise
141	premedication	_	_	I-Premise
142	had	_	_	I-Premise
143	significantly	_	_	I-Premise
144	higher	_	_	I-Premise
145	IOP	_	_	I-Premise
146	at	_	_	I-Premise
147	6	_	_	I-Premise
148	(	_	_	I-Premise
149	17.96±5.49	_	_	I-Premise
150	vs	_	_	I-Premise
151	13.61±4.09	_	_	I-Premise
152	;	_	_	I-Premise
153	P	_	_	I-Premise
154	<	_	_	I-Premise
155	0.001	_	_	I-Premise
156	)	_	_	I-Premise
157	and	_	_	I-Premise
158	12	_	_	I-Premise
159	(	_	_	I-Premise
160	16.90±4.11	_	_	I-Premise
161	vs	_	_	I-Premise
162	13.96±3.25	_	_	I-Premise
163	;	_	_	I-Premise
164	P=0.003	_	_	I-Premise
165	)	_	_	I-Premise
166	h	_	_	I-Premise
167	postoperatively	_	_	I-Premise
168	compared	_	_	I-Premise
169	with	_	_	I-Premise
170	those	_	_	I-Premise
171	who	_	_	I-Premise
172	received	_	_	I-Premise
173	oral	_	_	I-Premise
174	clonidine	_	_	I-Premise
175	.	_	_	I-Premise

176	However	_	_	O
177	,	_	_	O
178	there	_	_	B-Premise
179	was	_	_	I-Premise
180	no	_	_	I-Premise
181	significant	_	_	I-Premise
182	difference	_	_	I-Premise
183	between	_	_	I-Premise
184	the	_	_	I-Premise
185	2	_	_	I-Premise
186	groups	_	_	I-Premise
187	regarding	_	_	I-Premise
188	the	_	_	I-Premise
189	IOP	_	_	I-Premise
190	at	_	_	I-Premise
191	24h	_	_	I-Premise
192	after	_	_	I-Premise
193	operation	_	_	I-Premise
194	(	_	_	I-Premise
195	15.41±3.96	_	_	I-Premise
196	vs	_	_	I-Premise
197	16.01±3.41	_	_	I-Premise
198	;	_	_	I-Premise
199	P=0.0539	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	The	_	_	B-Premise
203	prevalence	_	_	I-Premise
204	of	_	_	I-Premise
205	acute	_	_	I-Premise
206	IOP	_	_	I-Premise
207	rise	_	_	I-Premise
208	(	_	_	I-Premise
209	>	_	_	I-Premise
210	21	_	_	I-Premise
211	mmHg	_	_	I-Premise
212	)	_	_	I-Premise
213	was	_	_	I-Premise
214	significantly	_	_	I-Premise
215	higher	_	_	I-Premise
216	in	_	_	I-Premise
217	placebo	_	_	I-Premise
218	group	_	_	I-Premise
219	compared	_	_	I-Premise
220	with	_	_	I-Premise
221	clonidine	_	_	I-Premise
222	group	_	_	I-Premise
223	(	_	_	I-Premise
224	25.8	_	_	I-Premise
225	%	_	_	I-Premise
226	vs	_	_	I-Premise
227	9.6	_	_	I-Premise
228	%	_	_	I-Premise
229	;	_	_	I-Premise
230	P=0.091	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Administering	_	_	B-Claim
234	preoperative	_	_	I-Claim
235	oral	_	_	I-Claim
236	clonidine	_	_	I-Claim
237	in	_	_	I-Claim
238	a	_	_	I-Claim
239	dosage	_	_	I-Claim
240	of	_	_	I-Claim
241	5g/kg	_	_	I-Claim
242	,	_	_	I-Claim
243	2h	_	_	I-Claim
244	before	_	_	I-Claim
245	phacoemulsification	_	_	I-Claim
246	,	_	_	I-Claim
247	significantly	_	_	I-Claim
248	decreases	_	_	I-Claim
249	the	_	_	I-Claim
250	prevalence	_	_	I-Claim
251	and	_	_	I-Claim
252	intensity	_	_	I-Claim
253	of	_	_	I-Claim
254	acute	_	_	I-Claim
255	postoperative	_	_	I-Claim
256	IOP	_	_	I-Claim
257	rise	_	_	I-Claim
258	in	_	_	I-Claim
259	those	_	_	I-Claim
260	undergoing	_	_	I-Claim
261	general	_	_	I-Claim
262	anesthesia	_	_	I-Claim
263	.	_	_	I-Claim

264	Oral	_	_	B-Claim
265	clonidine	_	_	I-Claim
266	is	_	_	I-Claim
267	safe	_	_	I-Claim
268	,	_	_	I-Claim
269	cheap	_	_	I-Claim
270	,	_	_	I-Claim
271	and	_	_	I-Claim
272	easily	_	_	I-Claim
273	accessible	_	_	I-Claim
274	and	_	_	I-Claim
275	,	_	_	I-Claim
276	thus	_	_	I-Claim
277	,	_	_	I-Claim
278	it	_	_	I-Claim
279	is	_	_	I-Claim
280	recommended	_	_	I-Claim
281	for	_	_	I-Claim
282	controlling	_	_	I-Claim
283	the	_	_	I-Claim
284	IOP	_	_	I-Claim
285	after	_	_	I-Claim
286	phacoemulsification	_	_	I-Claim
287	,	_	_	I-Claim
288	especially	_	_	I-Claim
289	in	_	_	I-Claim
290	high-risk	_	_	I-Claim
291	patients	_	_	I-Claim
292	.	_	_	I-Claim


0	Insomnia	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	common	_	_	I-Claim
4	complaint	_	_	I-Claim
5	among	_	_	I-Claim
6	cancer	_	_	I-Claim
7	survivors	_	_	I-Claim
8	.	_	_	I-Claim

9	Fortunately	_	_	O
10	,	_	_	O
11	cognitive-behavioral	_	_	O
12	therapy	_	_	O
13	for	_	_	O
14	insomnia	_	_	O
15	(	_	_	O
16	CBT-I	_	_	O
17	)	_	_	O
18	has	_	_	O
19	been	_	_	O
20	shown	_	_	O
21	to	_	_	O
22	be	_	_	O
23	an	_	_	O
24	effective	_	_	O
25	treatment	_	_	O
26	in	_	_	O
27	this	_	_	O
28	population	_	_	O
29	.	_	_	O

30	However	_	_	O
31	,	_	_	O
32	it	_	_	O
33	is	_	_	O
34	rarely	_	_	O
35	implemented	_	_	O
36	given	_	_	O
37	its	_	_	O
38	limited	_	_	O
39	availability	_	_	O
40	.	_	_	O

41	To	_	_	O
42	address	_	_	O
43	this	_	_	O
44	barrier	_	_	O
45	,	_	_	O
46	we	_	_	O
47	examined	_	_	O
48	the	_	_	O
49	ability	_	_	O
50	of	_	_	O
51	an	_	_	O
52	easily	_	_	O
53	accessible	_	_	O
54	online	_	_	O
55	CBT-I	_	_	O
56	program	_	_	O
57	to	_	_	O
58	improve	_	_	O
59	insomnia	_	_	O
60	symptoms	_	_	O
61	in	_	_	O
62	cancer	_	_	O
63	survivors	_	_	O
64	.	_	_	O

65	Twenty-eight	_	_	O
66	cancer	_	_	O
67	survivors	_	_	O
68	with	_	_	O
69	insomnia	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	either	_	_	O
75	an	_	_	O
76	Internet	_	_	O
77	insomnia	_	_	O
78	intervention	_	_	O
79	(	_	_	O
80	n	_	_	O
81	=	_	_	O
82	14	_	_	O
83	)	_	_	O
84	or	_	_	O
85	to	_	_	O
86	a	_	_	O
87	waitlist	_	_	O
88	control	_	_	O
89	group	_	_	O
90	(	_	_	O
91	n	_	_	O
92	=	_	_	O
93	14	_	_	O
94	)	_	_	O
95	.	_	_	O

96	The	_	_	O
97	online	_	_	O
98	program	_	_	O
99	,	_	_	O
100	Sleep	_	_	O
101	Healthy	_	_	O
102	Using	_	_	O
103	The	_	_	O
104	Internet	_	_	O
105	,	_	_	O
106	delivers	_	_	O
107	the	_	_	O
108	primary	_	_	O
109	components	_	_	O
110	of	_	_	O
111	CBT-I	_	_	O
112	(	_	_	O
113	sleep	_	_	O
114	restriction	_	_	O
115	,	_	_	O
116	stimulus	_	_	O
117	control	_	_	O
118	,	_	_	O
119	cognitive	_	_	O
120	restructuring	_	_	O
121	,	_	_	O
122	sleep	_	_	O
123	hygiene	_	_	O
124	,	_	_	O
125	and	_	_	O
126	relapse	_	_	O
127	prevention	_	_	O
128	)	_	_	O
129	.	_	_	O

130	Pre-	_	_	O
131	and	_	_	O
132	post-assessment	_	_	O
133	data	_	_	O
134	were	_	_	O
135	collected	_	_	O
136	via	_	_	O
137	online	_	_	O
138	questionnaires	_	_	O
139	and	_	_	O
140	daily	_	_	O
141	sleep	_	_	O
142	diaries	_	_	O
143	.	_	_	O

144	Participants	_	_	B-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	Internet	_	_	I-Premise
148	group	_	_	I-Premise
149	showed	_	_	I-Premise
150	significant	_	_	I-Premise
151	improvements	_	_	I-Premise
152	at	_	_	I-Premise
153	post-assessment	_	_	I-Premise
154	compared	_	_	I-Premise
155	with	_	_	I-Premise
156	those	_	_	I-Premise
157	in	_	_	I-Premise
158	the	_	_	I-Premise
159	control	_	_	I-Premise
160	group	_	_	I-Premise
161	in	_	_	I-Premise
162	overall	_	_	I-Premise
163	insomnia	_	_	I-Premise
164	severity	_	_	I-Premise
165	(	_	_	I-Premise
166	F	_	_	I-Premise
167	(	_	_	I-Premise
168	1,26	_	_	I-Premise
169	)	_	_	I-Premise
170	=	_	_	I-Premise
171	22.8	_	_	I-Premise
172	;	_	_	I-Premise
173	p	_	_	I-Premise
174	<	_	_	I-Premise
175	0.001	_	_	I-Premise
176	)	_	_	I-Premise
177	,	_	_	I-Premise
178	sleep	_	_	I-Premise
179	efficiency	_	_	I-Premise
180	(	_	_	I-Premise
181	F	_	_	I-Premise
182	(	_	_	I-Premise
183	1,24	_	_	I-Premise
184	)	_	_	I-Premise
185	=	_	_	I-Premise
186	11.45	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	0.002	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	sleep	_	_	I-Premise
194	onset	_	_	I-Premise
195	latency	_	_	I-Premise
196	(	_	_	I-Premise
197	F	_	_	I-Premise
198	(	_	_	I-Premise
199	1,24	_	_	I-Premise
200	)	_	_	I-Premise
201	=	_	_	I-Premise
202	5.18	_	_	I-Premise
203	;	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.03	_	_	I-Premise
207	)	_	_	I-Premise
208	,	_	_	I-Premise
209	soundness	_	_	I-Premise
210	of	_	_	I-Premise
211	sleep	_	_	I-Premise
212	(	_	_	I-Premise
213	F	_	_	I-Premise
214	(	_	_	I-Premise
215	1,24	_	_	I-Premise
216	)	_	_	I-Premise
217	=	_	_	I-Premise
218	9.34	_	_	I-Premise
219	;	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	0.005	_	_	I-Premise
223	)	_	_	I-Premise
224	,	_	_	I-Premise
225	restored	_	_	I-Premise
226	feeling	_	_	I-Premise
227	upon	_	_	I-Premise
228	awakening	_	_	I-Premise
229	(	_	_	I-Premise
230	F	_	_	I-Premise
231	(	_	_	I-Premise
232	1,24	_	_	I-Premise
233	)	_	_	I-Premise
234	=	_	_	I-Premise
235	11.95	_	_	I-Premise
236	;	_	_	I-Premise
237	P	_	_	I-Premise
238	=	_	_	I-Premise
239	0.002	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	general	_	_	I-Premise
244	fatigue	_	_	I-Premise
245	(	_	_	I-Premise
246	F	_	_	I-Premise
247	(	_	_	I-Premise
248	1,26	_	_	I-Premise
249	)	_	_	I-Premise
250	=	_	_	I-Premise
251	13.88	_	_	I-Premise
252	;	_	_	I-Premise
253	P	_	_	I-Premise
254	=	_	_	I-Premise
255	0.001	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	Although	_	_	B-Premise
259	other	_	_	I-Premise
260	group	_	_	I-Premise
261	×	_	_	I-Premise
262	time	_	_	I-Premise
263	interactions	_	_	I-Premise
264	were	_	_	I-Premise
265	not	_	_	I-Premise
266	significant	_	_	I-Premise
267	,	_	_	I-Premise
268	overall	_	_	I-Premise
269	adjusted	_	_	I-Premise
270	effect	_	_	I-Premise
271	sizes	_	_	I-Premise
272	for	_	_	I-Premise
273	all	_	_	I-Premise
274	sleep	_	_	I-Premise
275	variables	_	_	I-Premise
276	as	_	_	I-Premise
277	well	_	_	I-Premise
278	as	_	_	I-Premise
279	for	_	_	I-Premise
280	fatigue	_	_	I-Premise
281	,	_	_	I-Premise
282	depression	_	_	I-Premise
283	,	_	_	I-Premise
284	anxiety	_	_	I-Premise
285	,	_	_	I-Premise
286	and	_	_	I-Premise
287	quality	_	_	I-Premise
288	of	_	_	I-Premise
289	life	_	_	I-Premise
290	ranged	_	_	I-Premise
291	from	_	_	I-Premise
292	small	_	_	I-Premise
293	to	_	_	I-Premise
294	large	_	_	I-Premise
295	.	_	_	I-Premise

296	CBT-I	_	_	B-Claim
297	delivered	_	_	I-Claim
298	through	_	_	I-Claim
299	an	_	_	I-Claim
300	interactive	_	_	I-Claim
301	,	_	_	I-Claim
302	individually	_	_	I-Claim
303	tailored	_	_	I-Claim
304	Internet	_	_	I-Claim
305	intervention	_	_	I-Claim
306	may	_	_	I-Claim
307	be	_	_	I-Claim
308	a	_	_	I-Claim
309	viable	_	_	I-Claim
310	treatment	_	_	I-Claim
311	option	_	_	I-Claim
312	for	_	_	I-Claim
313	cancer	_	_	I-Claim
314	survivors	_	_	I-Claim
315	experiencing	_	_	I-Claim
316	insomnia	_	_	I-Claim
317	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	outcomes	_	_	O
3	of	_	_	O
4	selective	_	_	O
5	laser	_	_	O
6	trabeculoplasty	_	_	O
7	(	_	_	O
8	SLT	_	_	O
9	)	_	_	O
10	with	_	_	O
11	drug	_	_	O
12	therapy	_	_	O
13	for	_	_	O
14	glaucoma	_	_	O
15	patients	_	_	O
16	in	_	_	O
17	a	_	_	O
18	prospective	_	_	O
19	randomized	_	_	O
20	clinical	_	_	O
21	trial	_	_	O
22	.	_	_	O

23	Sixty-nine	_	_	O
24	patients	_	_	O
25	(	_	_	O
26	127	_	_	O
27	eyes	_	_	O
28	)	_	_	O
29	with	_	_	O
30	open-angle	_	_	O
31	glaucoma	_	_	O
32	or	_	_	O
33	ocular	_	_	O
34	hypertension	_	_	O
35	were	_	_	O
36	randomized	_	_	O
37	to	_	_	O
38	SLT	_	_	O
39	or	_	_	O
40	medical	_	_	O
41	therapy	_	_	O
42	.	_	_	O

43	Target	_	_	O
44	intraocular	_	_	O
45	pressure	_	_	O
46	(	_	_	O
47	IOP	_	_	O
48	)	_	_	O
49	was	_	_	O
50	determined	_	_	O
51	using	_	_	O
52	the	_	_	O
53	Collaborative	_	_	O
54	Initial	_	_	O
55	Glaucoma	_	_	O
56	Treatment	_	_	O
57	Study	_	_	O
58	formula	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	were	_	_	O
62	treated	_	_	O
63	with	_	_	O
64	SLT	_	_	O
65	(	_	_	O
66	100	_	_	O
67	applications	_	_	O
68	360	_	_	O
69	degrees	_	_	O
70	)	_	_	O
71	or	_	_	O
72	medical	_	_	O
73	therapy	_	_	O
74	(	_	_	O
75	prostaglandin	_	_	O
76	analog	_	_	O
77	)	_	_	O
78	.	_	_	O

79	Six	_	_	O
80	visits	_	_	O
81	over	_	_	O
82	1	_	_	O
83	year	_	_	O
84	followed	_	_	O
85	initial	_	_	O
86	treatment	_	_	O
87	.	_	_	O

88	If	_	_	O
89	target	_	_	O
90	IOP	_	_	O
91	range	_	_	O
92	was	_	_	O
93	not	_	_	O
94	attained	_	_	O
95	with	_	_	O
96	SLT	_	_	O
97	,	_	_	O
98	additional	_	_	O
99	SLT	_	_	O
100	was	_	_	O
101	the	_	_	O
102	next	_	_	O
103	step	_	_	O
104	,	_	_	O
105	or	_	_	O
106	in	_	_	O
107	the	_	_	O
108	medical	_	_	O
109	arm	_	_	O
110	additional	_	_	O
111	medications	_	_	O
112	were	_	_	O
113	added	_	_	O
114	.	_	_	O

115	Primary	_	_	O
116	outcome	_	_	O
117	:	_	_	O
118	IOP	_	_	O
119	;	_	_	O
120	secondary	_	_	O
121	:	_	_	O
122	number	_	_	O
123	of	_	_	O
124	steps	_	_	O
125	.	_	_	O

126	Sixty-nine	_	_	O
127	patients	_	_	O
128	were	_	_	O
129	treated	_	_	O
130	.	_	_	O

131	Data	_	_	O
132	collection	_	_	O
133	terminated	_	_	O
134	with	_	_	O
135	54	_	_	O
136	patients	_	_	O
137	reaching	_	_	O
138	9	_	_	O
139	to	_	_	O
140	12-months	_	_	O
141	follow-up	_	_	O
142	.	_	_	O

143	Twenty-nine	_	_	O
144	patients	_	_	O
145	were	_	_	O
146	in	_	_	O
147	the	_	_	O
148	SLT	_	_	O
149	group	_	_	O
150	,	_	_	O
151	25	_	_	O
152	patients	_	_	O
153	in	_	_	O
154	the	_	_	O
155	medical	_	_	O
156	group	_	_	O
157	.	_	_	O

158	Baseline	_	_	B-Premise
159	mean	_	_	I-Premise
160	IOP	_	_	I-Premise
161	for	_	_	I-Premise
162	all	_	_	I-Premise
163	eyes	_	_	I-Premise
164	was	_	_	I-Premise
165	24.5	_	_	I-Premise
166	mm	_	_	I-Premise
167	Hg	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	SLT	_	_	I-Premise
171	group	_	_	I-Premise
172	,	_	_	I-Premise
173	24.7	_	_	I-Premise
174	mm	_	_	I-Premise
175	Hg	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	medical	_	_	I-Premise
179	group	_	_	I-Premise
180	.	_	_	I-Premise

181	Mean	_	_	I-Premise
182	IOP	_	_	I-Premise
183	(	_	_	I-Premise
184	both	_	_	I-Premise
185	eyes	_	_	I-Premise
186	)	_	_	I-Premise
187	at	_	_	I-Premise
188	last	_	_	I-Premise
189	follow-up	_	_	I-Premise
190	was	_	_	I-Premise
191	18.2	_	_	I-Premise
192	mm	_	_	I-Premise
193	Hg	_	_	I-Premise
194	(	_	_	I-Premise
195	6.3	_	_	I-Premise
196	mm	_	_	I-Premise
197	Hg	_	_	I-Premise
198	reduction	_	_	I-Premise
199	)	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	SLT	_	_	I-Premise
203	arm	_	_	I-Premise
204	,	_	_	I-Premise
205	17.7	_	_	I-Premise
206	mm	_	_	I-Premise
207	Hg	_	_	I-Premise
208	(	_	_	I-Premise
209	7.0	_	_	I-Premise
210	mm	_	_	I-Premise
211	Hg	_	_	I-Premise
212	reduction	_	_	I-Premise
213	)	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	medical	_	_	I-Premise
217	arm	_	_	I-Premise
218	.	_	_	I-Premise

219	By	_	_	B-Premise
220	last	_	_	I-Premise
221	follow-up	_	_	I-Premise
222	,	_	_	I-Premise
223	11	_	_	I-Premise
224	%	_	_	I-Premise
225	of	_	_	I-Premise
226	eyes	_	_	I-Premise
227	received	_	_	I-Premise
228	additional	_	_	I-Premise
229	SLT	_	_	I-Premise
230	,	_	_	I-Premise
231	27	_	_	I-Premise
232	%	_	_	I-Premise
233	required	_	_	I-Premise
234	additional	_	_	I-Premise
235	medication	_	_	I-Premise
236	.	_	_	I-Premise

237	There	_	_	B-Premise
238	was	_	_	I-Premise
239	not	_	_	I-Premise
240	a	_	_	I-Premise
241	statistically	_	_	I-Premise
242	significant	_	_	I-Premise
243	difference	_	_	I-Premise
244	between	_	_	I-Premise
245	the	_	_	I-Premise
246	SLT	_	_	I-Premise
247	and	_	_	I-Premise
248	medication	_	_	I-Premise
249	groups	_	_	I-Premise
250	.	_	_	I-Premise

251	IOP	_	_	B-Premise
252	reduction	_	_	I-Premise
253	was	_	_	I-Premise
254	similar	_	_	I-Premise
255	in	_	_	I-Premise
256	both	_	_	I-Premise
257	arms	_	_	I-Premise
258	after	_	_	I-Premise
259	9	_	_	I-Premise
260	to	_	_	I-Premise
261	12-months	_	_	I-Premise
262	follow-up	_	_	I-Premise
263	.	_	_	I-Premise

264	More	_	_	O
265	treatment	_	_	O
266	steps	_	_	O
267	were	_	_	O
268	necessary	_	_	O
269	to	_	_	O
270	maintain	_	_	O
271	target	_	_	O
272	IOP	_	_	O
273	in	_	_	O
274	the	_	_	O
275	medication	_	_	O
276	group	_	_	O
277	,	_	_	O
278	although	_	_	O
279	there	_	_	O
280	was	_	_	O
281	not	_	_	O
282	a	_	_	O
283	statistically	_	_	O
284	significant	_	_	O
285	difference	_	_	O
286	between	_	_	O
287	groups	_	_	O
288	.	_	_	O

289	These	_	_	B-Claim
290	results	_	_	I-Claim
291	support	_	_	I-Claim
292	the	_	_	I-Claim
293	option	_	_	I-Claim
294	of	_	_	I-Claim
295	SLT	_	_	I-Claim
296	as	_	_	I-Claim
297	a	_	_	I-Claim
298	safe	_	_	I-Claim
299	and	_	_	I-Claim
300	effective	_	_	I-Claim
301	initial	_	_	I-Claim
302	therapy	_	_	I-Claim
303	in	_	_	I-Claim
304	open-angle	_	_	I-Claim
305	glaucoma	_	_	I-Claim
306	or	_	_	I-Claim
307	ocular	_	_	I-Claim
308	hypertension	_	_	I-Claim
309	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	the	_	_	O
3	predictive	_	_	O
4	value	_	_	O
5	of	_	_	O
6	PSA	_	_	O
7	for	_	_	O
8	progression	_	_	O
9	and	_	_	O
10	the	_	_	O
11	role	_	_	O
12	of	_	_	O
13	testosterone	_	_	O
14	for	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	(	_	_	O
19	QOL	_	_	O
20	)	_	_	O
21	in	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	androgen	_	_	O
25	deprivation	_	_	O
26	therapy	_	_	O
27	(	_	_	O
28	ADT	_	_	O
29	)	_	_	O
30	for	_	_	O
31	metastatic	_	_	O
32	prostate	_	_	O
33	cancer	_	_	O
34	.	_	_	O

35	PSA	_	_	O
36	and	_	_	O
37	testosterone	_	_	O
38	data	_	_	O
39	were	_	_	O
40	used	_	_	O
41	from	_	_	O
42	a	_	_	O
43	phase	_	_	O
44	III	_	_	O
45	trial	_	_	O
46	randomizing	_	_	O
47	patients	_	_	O
48	without	_	_	O
49	progression	_	_	O
50	and	_	_	O
51	PSA	_	_	O
52	<	_	_	O
53	4	_	_	O
54	ng/ml	_	_	O
55	(	_	_	O
56	n	_	_	O
57	=	_	_	O
58	193	_	_	O
59	)	_	_	O
60	,	_	_	O
61	after	_	_	O
62	6	_	_	O
63	months	_	_	O
64	induction	_	_	O
65	course	_	_	O
66	,	_	_	O
67	between	_	_	O
68	continuous	_	_	O
69	(	_	_	O
70	CAD	_	_	O
71	)	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	96	_	_	O
76	)	_	_	O
77	and	_	_	O
78	intermittent	_	_	O
79	(	_	_	O
80	IAD	_	_	O
81	)	_	_	O
82	(	_	_	O
83	n	_	_	O
84	=	_	_	O
85	97	_	_	O
86	)	_	_	O
87	ADT	_	_	O
88	.	_	_	O

89	The	_	_	O
90	2-year	_	_	O
91	risk	_	_	O
92	of	_	_	O
93	progression	_	_	O
94	was	_	_	O
95	calculated	_	_	O
96	for	_	_	O
97	baseline	_	_	O
98	PSA	_	_	O
99	,	_	_	O
100	'fast	_	_	O
101	'	_	_	O
102	and	_	_	O
103	'slow	_	_	O
104	'	_	_	O
105	PSA	_	_	O
106	decline	_	_	O
107	to	_	_	O
108	<	_	_	O
109	4	_	_	O
110	ng/ml	_	_	O
111	(	_	_	O
112	60	_	_	O
113	days	_	_	O
114	cut-off	_	_	O
115	)	_	_	O
116	,	_	_	O
117	PSA	_	_	O
118	nadir	_	_	O
119	,	_	_	O
120	performance	_	_	O
121	status	_	_	O
122	and	_	_	O
123	pain	_	_	O
124	.	_	_	O

125	Testosterone	_	_	O
126	kinetics	_	_	O
127	and	_	_	O
128	QOL	_	_	O
129	were	_	_	O
130	also	_	_	O
131	evaluated	_	_	O
132	.	_	_	O

133	Univariate	_	_	O
134	Kaplan	_	_	O
135	Meier	_	_	O
136	survival	_	_	O
137	analysis	_	_	O
138	and	_	_	O
139	log	_	_	O
140	rank	_	_	O
141	tests	_	_	O
142	were	_	_	O
143	used	_	_	O
144	to	_	_	O
145	compare	_	_	O
146	the	_	_	O
147	risk	_	_	O
148	of	_	_	O
149	progression	_	_	O
150	.	_	_	O

151	For	_	_	O
152	progression	_	_	O
153	analysis	_	_	O
154	,	_	_	O
155	173	_	_	O
156	patients	_	_	O
157	'	_	_	O
158	data	_	_	O
159	were	_	_	O
160	available	_	_	O
161	.	_	_	O

162	The	_	_	O
163	2-year	_	_	O
164	risk	_	_	O
165	of	_	_	O
166	progression	_	_	O
167	for	_	_	O
168	baseline	_	_	O
169	PSA	_	_	O
170	<	_	_	O
171	50	_	_	O
172	ng/ml	_	_	O
173	,	_	_	O
174	50	_	_	O
175	to	_	_	O
176	<	_	_	O
177	500	_	_	O
178	ng/ml	_	_	O
179	,	_	_	O
180	and	_	_	O
181	≥	_	_	O
182	500	_	_	O
183	ng/ml	_	_	O
184	was	_	_	O
185	25	_	_	O
186	%	_	_	O
187	,	_	_	O
188	55	_	_	O
189	%	_	_	O
190	,	_	_	O
191	and	_	_	O
192	76	_	_	O
193	%	_	_	O
194	(	_	_	O
195	P	_	_	O
196	=	_	_	O
197	0.03	_	_	O
198	)	_	_	O
199	in	_	_	O
200	CAD	_	_	O
201	,	_	_	O
202	and	_	_	O
203	38	_	_	O
204	%	_	_	O
205	,	_	_	O
206	64	_	_	O
207	%	_	_	O
208	,	_	_	O
209	and	_	_	O
210	85	_	_	O
211	%	_	_	O
212	(	_	_	O
213	P	_	_	O
214	=	_	_	O
215	0.006	_	_	O
216	)	_	_	O
217	in	_	_	O
218	IAD	_	_	O
219	,	_	_	O
220	respectively	_	_	O
221	.	_	_	O

222	The	_	_	B-Premise
223	2-year	_	_	I-Premise
224	risk	_	_	I-Premise
225	of	_	_	I-Premise
226	progression	_	_	I-Premise
227	for	_	_	I-Premise
228	PSA	_	_	I-Premise
229	nadir	_	_	I-Premise
230	≤	_	_	I-Premise
231	0.2	_	_	I-Premise
232	ng/ml	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	>	_	_	I-Premise
236	0.2	_	_	I-Premise
237	to	_	_	I-Premise
238	4	_	_	I-Premise
239	ng/ml	_	_	I-Premise
240	in	_	_	I-Premise
241	CAD	_	_	I-Premise
242	was	_	_	I-Premise
243	31	_	_	I-Premise
244	%	_	_	I-Premise
245	and	_	_	I-Premise
246	70	_	_	I-Premise
247	%	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	0.001	_	_	I-Premise
252	)	_	_	I-Premise
253	,	_	_	I-Premise
254	respectively	_	_	I-Premise
255	.	_	_	I-Premise

256	In	_	_	B-Premise
257	the	_	_	I-Premise
258	IAD	_	_	I-Premise
259	group	_	_	I-Premise
260	,	_	_	I-Premise
261	a	_	_	I-Premise
262	similar	_	_	I-Premise
263	trend	_	_	I-Premise
264	was	_	_	I-Premise
265	seen	_	_	I-Premise
266	.	_	_	I-Premise

267	Patients	_	_	B-Premise
268	with	_	_	I-Premise
269	PSA	_	_	I-Premise
270	nadir	_	_	I-Premise
271	≤	_	_	I-Premise
272	0.2	_	_	I-Premise
273	ng/ml	_	_	I-Premise
274	,	_	_	I-Premise
275	though	_	_	I-Premise
276	had	_	_	I-Premise
277	significantly	_	_	I-Premise
278	higher	_	_	I-Premise
279	2-year	_	_	I-Premise
280	risk	_	_	I-Premise
281	of	_	_	I-Premise
282	progression	_	_	I-Premise
283	compared	_	_	I-Premise
284	to	_	_	I-Premise
285	CAD	_	_	I-Premise
286	(	_	_	I-Premise
287	53	_	_	I-Premise
288	%	_	_	I-Premise
289	vs.	_	_	I-Premise
290	31	_	_	I-Premise
291	%	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	0.03	_	_	I-Premise
296	)	_	_	I-Premise
297	,	_	_	I-Premise
298	respectively	_	_	I-Premise
299	.	_	_	I-Premise

300	PSA	_	_	O
301	decline	_	_	O
302	showed	_	_	O
303	no	_	_	O
304	predictive	_	_	O
305	value	_	_	O
306	.	_	_	O

307	Patients	_	_	B-Premise
308	without	_	_	I-Premise
309	pain	_	_	I-Premise
310	had	_	_	I-Premise
311	a	_	_	I-Premise
312	significantly	_	_	I-Premise
313	lower	_	_	I-Premise
314	2-year	_	_	I-Premise
315	risk	_	_	I-Premise
316	of	_	_	I-Premise
317	progression	_	_	I-Premise
318	in	_	_	I-Premise
319	both	_	_	I-Premise
320	groups	_	_	I-Premise
321	.	_	_	I-Premise

322	Without	_	_	B-Premise
323	ADT	_	_	I-Premise
324	testosterone	_	_	I-Premise
325	remained	_	_	I-Premise
326	at	_	_	I-Premise
327	castrate	_	_	I-Premise
328	level	_	_	I-Premise
329	for	_	_	I-Premise
330	4	_	_	I-Premise
331	months	_	_	I-Premise
332	.	_	_	I-Premise

333	After	_	_	O
334	the	_	_	O
335	first	_	_	O
336	and	_	_	O
337	second	_	_	O
338	IAD	_	_	O
339	cycle	_	_	O
340	92	_	_	O
341	%	_	_	O
342	and	_	_	O
343	46	_	_	O
344	%	_	_	O
345	,	_	_	O
346	respectively	_	_	O
347	,	_	_	O
348	had	_	_	O
349	a	_	_	O
350	normalized	_	_	O
351	testosterone	_	_	O
352	.	_	_	O

353	No	_	_	B-Premise
354	QOL	_	_	I-Premise
355	difference	_	_	I-Premise
356	was	_	_	I-Premise
357	found	_	_	I-Premise
358	,	_	_	I-Premise
359	although	_	_	I-Premise
360	more	_	_	I-Premise
361	side	_	_	I-Premise
362	effects	_	_	I-Premise
363	occurred	_	_	I-Premise
364	in	_	_	I-Premise
365	CAD	_	_	I-Premise
366	.	_	_	I-Premise

367	Metastatic	_	_	B-Claim
368	prostate	_	_	I-Claim
369	cancer	_	_	I-Claim
370	patients	_	_	I-Claim
371	with	_	_	I-Claim
372	high	_	_	I-Claim
373	baseline	_	_	I-Claim
374	PSA	_	_	I-Claim
375	,	_	_	I-Claim
376	pain	_	_	I-Claim
377	,	_	_	I-Claim
378	and	_	_	I-Claim
379	high	_	_	I-Claim
380	PSA	_	_	I-Claim
381	nadir	_	_	I-Claim
382	have	_	_	I-Claim
383	a	_	_	I-Claim
384	poor	_	_	I-Claim
385	prognosis	_	_	I-Claim
386	with	_	_	I-Claim
387	ADT	_	_	I-Claim
388	.	_	_	I-Claim

389	Patients	_	_	B-Claim
390	with	_	_	I-Claim
391	low	_	_	I-Claim
392	PSA	_	_	I-Claim
393	nadir	_	_	I-Claim
394	do	_	_	I-Claim
395	significantly	_	_	I-Claim
396	worse	_	_	I-Claim
397	with	_	_	I-Claim
398	IAD	_	_	I-Claim
399	compared	_	_	I-Claim
400	with	_	_	I-Claim
401	CAD	_	_	I-Claim
402	.	_	_	I-Claim

403	Low	_	_	O
404	testosterone	_	_	O
405	after	_	_	O
406	ADT	_	_	O
407	and	_	_	O
408	incomplete	_	_	O
409	testosterone	_	_	O
410	recovery	_	_	O
411	may	_	_	O
412	explain	_	_	O
413	similar	_	_	O
414	QOL	_	_	O
415	.	_	_	O

416	Therefore	_	_	O
417	,	_	_	O
418	IAD	_	_	B-Claim
419	is	_	_	I-Claim
420	not	_	_	I-Claim
421	a	_	_	I-Claim
422	good	_	_	I-Claim
423	treatment	_	_	I-Claim
424	option	_	_	I-Claim
425	for	_	_	I-Claim
426	many	_	_	I-Claim
427	metastatic	_	_	I-Claim
428	prostate	_	_	I-Claim
429	cancer	_	_	I-Claim
430	patients	_	_	I-Claim
431	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	non-inferiority	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	designed	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	whether	_	_	O
9	radiosurgery	_	_	O
10	plus	_	_	O
11	adjuvant	_	_	O
12	whole	_	_	O
13	brain	_	_	O
14	radiotherapy	_	_	O
15	(	_	_	O
16	RS	_	_	O
17	+	_	_	O
18	WBRT	_	_	O
19	)	_	_	O
20	is	_	_	O
21	as	_	_	O
22	effective	_	_	O
23	as	_	_	O
24	surgery	_	_	O
25	plus	_	_	O
26	whole	_	_	O
27	brain	_	_	O
28	radiotherapy	_	_	O
29	(	_	_	O
30	S	_	_	O
31	+	_	_	O
32	WBRT	_	_	O
33	)	_	_	O
34	for	_	_	O
35	cancer	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	a	_	_	O
39	solitary	_	_	O
40	brain	_	_	O
41	metastasis	_	_	O
42	,	_	_	O
43	with	_	_	O
44	respect	_	_	O
45	to	_	_	O
46	overall	_	_	O
47	survival	_	_	O
48	and	_	_	O
49	quality	_	_	O
50	of	_	_	O
51	life	_	_	O
52	.	_	_	O

53	Major	_	_	O
54	inclusion	_	_	O
55	criteria	_	_	O
56	were	_	_	O
57	a	_	_	O
58	history	_	_	O
59	of	_	_	O
60	systemic	_	_	O
61	cancer	_	_	O
62	within	_	_	O
63	5	_	_	O
64	years	_	_	O
65	and	_	_	O
66	enhanced	_	_	O
67	magnetic	_	_	O
68	resonance	_	_	O
69	imaging-confirmed	_	_	O
70	solitary	_	_	O
71	brain	_	_	O
72	metastasis	_	_	O
73	suitable	_	_	O
74	for	_	_	O
75	both	_	_	O
76	radiosurgery	_	_	O
77	and	_	_	O
78	surgery	_	_	O
79	.	_	_	O

80	All	_	_	O
81	patients	_	_	O
82	were	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	WBRT	_	_	O
86	(	_	_	O
87	30	_	_	O
88	Gy	_	_	O
89	in	_	_	O
90	10	_	_	O
91	fractions	_	_	O
92	)	_	_	O
93	.	_	_	O

94	Between	_	_	O
95	February	_	_	O
96	2003	_	_	O
97	and	_	_	O
98	April	_	_	O
99	2009	_	_	O
100	,	_	_	O
101	40	_	_	O
102	patients	_	_	O
103	were	_	_	O
104	considered	_	_	O
105	eligible	_	_	O
106	,	_	_	O
107	22	_	_	O
108	consented	_	_	O
109	to	_	_	O
110	randomisation	_	_	O
111	and	_	_	O
112	21	_	_	O
113	were	_	_	O
114	analysed	_	_	O
115	(	_	_	O
116	11	_	_	O
117	RS	_	_	O
118	+	_	_	O
119	WBRT	_	_	O
120	,	_	_	O
121	10	_	_	O
122	S	_	_	O
123	+	_	_	O
124	WBRT	_	_	O
125	)	_	_	O
126	.	_	_	O

127	The	_	_	O
128	trial	_	_	O
129	was	_	_	O
130	closed	_	_	O
131	early	_	_	O
132	due	_	_	O
133	to	_	_	O
134	slow	_	_	O
135	accrual	_	_	O
136	.	_	_	O

137	The	_	_	B-Premise
138	estimated	_	_	I-Premise
139	median	_	_	I-Premise
140	overall	_	_	I-Premise
141	survival	_	_	I-Premise
142	times	_	_	I-Premise
143	for	_	_	I-Premise
144	RS	_	_	I-Premise
145	+	_	_	I-Premise
146	WBRT	_	_	I-Premise
147	and	_	_	I-Premise
148	S	_	_	I-Premise
149	+	_	_	I-Premise
150	WBRT	_	_	I-Premise
151	patients	_	_	I-Premise
152	were	_	_	I-Premise
153	6.2	_	_	I-Premise
154	and	_	_	I-Premise
155	2.8	_	_	I-Premise
156	months	_	_	I-Premise
157	,	_	_	I-Premise
158	respectively	_	_	I-Premise
159	(	_	_	I-Premise
160	hazard	_	_	I-Premise
161	ratio	_	_	I-Premise
162	0.53	_	_	I-Premise
163	,	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	confidence	_	_	I-Premise
167	interval	_	_	I-Premise
168	0.20-1.43	_	_	I-Premise
169	,	_	_	I-Premise
170	P	_	_	I-Premise
171	=	_	_	I-Premise
172	0.20	_	_	I-Premise
173	)	_	_	I-Premise
174	.	_	_	I-Premise

175	Corresponding	_	_	B-Premise
176	median	_	_	I-Premise
177	failure-free	_	_	I-Premise
178	survival	_	_	I-Premise
179	times	_	_	I-Premise
180	were	_	_	I-Premise
181	3.1	_	_	I-Premise
182	and	_	_	I-Premise
183	1.7	_	_	I-Premise
184	months	_	_	I-Premise
185	(	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	0.20	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	For	_	_	B-Premise
192	19	_	_	I-Premise
193	'per	_	_	I-Premise
194	protocol	_	_	I-Premise
195	'	_	_	I-Premise
196	patients	_	_	I-Premise
197	,	_	_	I-Premise
198	2/10	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	RS	_	_	I-Premise
202	+	_	_	I-Premise
203	WBRT	_	_	I-Premise
204	arm	_	_	I-Premise
205	had	_	_	I-Premise
206	distant	_	_	I-Premise
207	intracranial	_	_	I-Premise
208	failure	_	_	I-Premise
209	(	_	_	I-Premise
210	one	_	_	I-Premise
211	also	_	_	I-Premise
212	had	_	_	I-Premise
213	local	_	_	I-Premise
214	failure	_	_	I-Premise
215	)	_	_	I-Premise
216	and	_	_	I-Premise
217	3/9	_	_	I-Premise
218	S	_	_	I-Premise
219	+	_	_	I-Premise
220	WBRT	_	_	I-Premise
221	patients	_	_	I-Premise
222	had	_	_	I-Premise
223	distant	_	_	I-Premise
224	intracranial	_	_	I-Premise
225	failure	_	_	I-Premise
226	(	_	_	I-Premise
227	no	_	_	I-Premise
228	local	_	_	I-Premise
229	failures	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	There	_	_	B-Premise
233	were	_	_	I-Premise
234	no	_	_	I-Premise
235	grade	_	_	I-Premise
236	3-4	_	_	I-Premise
237	late	_	_	I-Premise
238	radiation	_	_	I-Premise
239	toxicities	_	_	I-Premise
240	.	_	_	I-Premise

241	Two	_	_	B-Claim
242	months	_	_	I-Claim
243	after	_	_	I-Claim
244	starting	_	_	I-Claim
245	treatment	_	_	I-Claim
246	there	_	_	I-Claim
247	were	_	_	I-Claim
248	no	_	_	I-Claim
249	significant	_	_	I-Claim
250	differences	_	_	I-Claim
251	in	_	_	I-Claim
252	quality	_	_	I-Claim
253	of	_	_	I-Claim
254	life	_	_	I-Claim
255	between	_	_	I-Claim
256	the	_	_	I-Claim
257	arms	_	_	I-Claim
258	.	_	_	I-Claim

259	This	_	_	B-Claim
260	randomised	_	_	I-Claim
261	trial	_	_	I-Claim
262	encountered	_	_	I-Claim
263	the	_	_	I-Claim
264	accrual	_	_	I-Claim
265	difficulties	_	_	I-Claim
266	and	_	_	I-Claim
267	consequent	_	_	I-Claim
268	low	_	_	I-Claim
269	statistical	_	_	I-Claim
270	power	_	_	I-Claim
271	commonly	_	_	I-Claim
272	associated	_	_	I-Claim
273	with	_	_	I-Claim
274	interdisciplinary	_	_	I-Claim
275	studies	_	_	I-Claim
276	drawing	_	_	I-Claim
277	from	_	_	I-Claim
278	a	_	_	I-Claim
279	small	_	_	I-Claim
280	eligible	_	_	I-Claim
281	population	_	_	I-Claim
282	,	_	_	I-Claim
283	but	_	_	O
284	can	_	_	O
285	contribute	_	_	O
286	to	_	_	O
287	future	_	_	O
288	overviews	_	_	O
289	on	_	_	O
290	the	_	_	O
291	management	_	_	O
292	of	_	_	O
293	solitary	_	_	O
294	brain	_	_	O
295	metastases	_	_	O
296	.	_	_	O


0	Regularly	_	_	O
1	collecting	_	_	O
2	patient-reported	_	_	O
3	outcomes	_	_	O
4	(	_	_	O
5	PROs	_	_	O
6	)	_	_	O
7	of	_	_	O
8	health-related	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	with	_	_	O
13	feedback	_	_	O
14	to	_	_	O
15	oncologists	_	_	O
16	may	_	_	O
17	assist	_	_	O
18	in	_	_	O
19	eliciting	_	_	O
20	and	_	_	O
21	monitoring	_	_	O
22	patients	_	_	O
23	'	_	_	O
24	problems	_	_	O
25	during	_	_	O
26	cancer	_	_	O
27	treatment	_	_	O
28	.	_	_	O

29	This	_	_	O
30	study	_	_	O
31	examined	_	_	O
32	how	_	_	O
33	PRO	_	_	O
34	feedback	_	_	O
35	had	_	_	O
36	an	_	_	O
37	impact	_	_	O
38	on	_	_	O
39	patient-physician	_	_	O
40	communication	_	_	O
41	over	_	_	O
42	time	_	_	O
43	to	_	_	O
44	gain	_	_	O
45	a	_	_	O
46	better	_	_	O
47	understanding	_	_	O
48	of	_	_	O
49	how	_	_	O
50	it	_	_	O
51	may	_	_	O
52	influence	_	_	O
53	patient	_	_	O
54	care	_	_	O
55	.	_	_	O

56	Exploratory	_	_	O
57	analyses	_	_	O
58	were	_	_	O
59	performed	_	_	O
60	on	_	_	O
61	a	_	_	O
62	data	_	_	O
63	set	_	_	O
64	from	_	_	O
65	a	_	_	O
66	previous	_	_	O
67	study	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	intervention	_	_	O
75	(	_	_	O
76	regular	_	_	O
77	completion	_	_	O
78	of	_	_	O
79	European	_	_	O
80	Organisation	_	_	O
81	for	_	_	O
82	Research	_	_	O
83	and	_	_	O
84	Treatment	_	_	O
85	of	_	_	O
86	Cancer	_	_	O
87	Quality	_	_	O
88	of	_	_	O
89	Life	_	_	O
90	Questionnaire-Core	_	_	O
91	30	_	_	O
92	and	_	_	O
93	Hospital	_	_	O
94	Anxiety	_	_	O
95	and	_	_	O
96	Depression	_	_	O
97	Scale	_	_	O
98	with	_	_	O
99	feedback	_	_	O
100	to	_	_	O
101	oncologists	_	_	O
102	)	_	_	O
103	,	_	_	O
104	attention-control	_	_	O
105	(	_	_	O
106	completion	_	_	O
107	of	_	_	O
108	same	_	_	O
109	questionnaires	_	_	O
110	without	_	_	O
111	feedback	_	_	O
112	)	_	_	O
113	,	_	_	O
114	and	_	_	O
115	control	_	_	O
116	(	_	_	O
117	standard	_	_	O
118	care	_	_	O
119	)	_	_	O
120	arms	_	_	O
121	.	_	_	O

122	The	_	_	O
123	content	_	_	O
124	of	_	_	O
125	consultation	_	_	O
126	audio	_	_	O
127	recordings	_	_	O
128	between	_	_	O
129	28	_	_	O
130	oncologists	_	_	O
131	and	_	_	O
132	198	_	_	O
133	patients	_	_	O
134	over	_	_	O
135	four	_	_	O
136	consecutive	_	_	O
137	visits	_	_	O
138	(	_	_	O
139	792	_	_	O
140	consultations	_	_	O
141	)	_	_	O
142	was	_	_	O
143	analyzed	_	_	O
144	.	_	_	O

145	Mixed-effects	_	_	O
146	models	_	_	O
147	and	_	_	O
148	multivariate	_	_	O
149	regressions	_	_	O
150	were	_	_	O
151	used	_	_	O
152	to	_	_	O
153	examine	_	_	O
154	the	_	_	O
155	longitudinal	_	_	O
156	impact	_	_	O
157	of	_	_	O
158	the	_	_	O
159	intervention	_	_	O
160	on	_	_	O
161	patient-physician	_	_	O
162	communication	_	_	O
163	,	_	_	O
164	dynamics	_	_	O
165	of	_	_	O
166	patient-physician	_	_	O
167	interaction	_	_	O
168	,	_	_	O
169	and	_	_	O
170	the	_	_	O
171	association	_	_	O
172	between	_	_	O
173	PROs	_	_	O
174	and	_	_	O
175	the	_	_	O
176	content	_	_	O
177	of	_	_	O
178	clinic	_	_	O
179	discussion	_	_	O
180	.	_	_	O

181	Patients	_	_	B-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	intervention	_	_	I-Premise
185	arm	_	_	I-Premise
186	discussed	_	_	I-Premise
187	more	_	_	I-Premise
188	symptoms	_	_	I-Premise
189	over	_	_	I-Premise
190	time	_	_	I-Premise
191	compared	_	_	I-Premise
192	with	_	_	I-Premise
193	patients	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	attention-control	_	_	I-Premise
197	(	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	.008	_	_	I-Premise
201	)	_	_	I-Premise
202	and	_	_	I-Premise
203	control	_	_	I-Premise
204	(	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	.04	_	_	I-Premise
208	)	_	_	I-Premise
209	arms	_	_	I-Premise
210	.	_	_	I-Premise

211	No	_	_	B-Premise
212	study	_	_	I-Premise
213	arm	_	_	I-Premise
214	effect	_	_	I-Premise
215	was	_	_	I-Premise
216	observed	_	_	I-Premise
217	for	_	_	I-Premise
218	function	_	_	I-Premise
219	discussions	_	_	I-Premise
220	.	_	_	I-Premise

221	Discussion	_	_	O
222	topics	_	_	O
223	were	_	_	O
224	predominantly	_	_	O
225	raised	_	_	O
226	by	_	_	O
227	patients/relatives	_	_	O
228	,	_	_	O
229	regardless	_	_	O
230	of	_	_	O
231	arm	_	_	O
232	allocation	_	_	O
233	.	_	_	O

234	Clinic	_	_	B-Premise
235	discussions	_	_	I-Premise
236	were	_	_	I-Premise
237	associated	_	_	I-Premise
238	with	_	_	I-Premise
239	severity	_	_	I-Premise
240	of	_	_	I-Premise
241	patient-reported	_	_	I-Premise
242	symptoms	_	_	I-Premise
243	but	_	_	I-Premise
244	not	_	_	I-Premise
245	with	_	_	I-Premise
246	patient-reported	_	_	I-Premise
247	functional	_	_	I-Premise
248	concerns	_	_	I-Premise
249	.	_	_	I-Premise

250	A	_	_	B-Premise
251	positive	_	_	I-Premise
252	longitudinal	_	_	I-Premise
253	impact	_	_	I-Premise
254	of	_	_	I-Premise
255	the	_	_	I-Premise
256	intervention	_	_	I-Premise
257	on	_	_	I-Premise
258	symptom	_	_	I-Premise
259	discussion	_	_	I-Premise
260	was	_	_	I-Premise
261	observed	_	_	I-Premise
262	,	_	_	I-Premise
263	but	_	_	B-Premise
264	not	_	_	I-Premise
265	for	_	_	I-Premise
266	function	_	_	I-Premise
267	discussion	_	_	I-Premise
268	,	_	_	I-Premise
269	suggesting	_	_	I-Premise
270	that	_	_	I-Premise
271	potentially	_	_	I-Premise
272	serious	_	_	I-Premise
273	problems	_	_	I-Premise
274	may	_	_	I-Premise
275	remain	_	_	I-Premise
276	unaddressed	_	_	I-Premise
277	.	_	_	I-Premise

278	Training	_	_	B-Claim
279	oncologists	_	_	I-Claim
280	in	_	_	I-Claim
281	responding	_	_	I-Claim
282	to	_	_	I-Claim
283	patient-reported	_	_	I-Claim
284	functional	_	_	I-Claim
285	concerns	_	_	I-Claim
286	may	_	_	I-Claim
287	increase	_	_	I-Claim
288	the	_	_	I-Claim
289	impact	_	_	I-Claim
290	of	_	_	I-Claim
291	this	_	_	I-Claim
292	intervention	_	_	I-Claim
293	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	conducted	_	_	O
6	to	_	_	O
7	test	_	_	O
8	whether	_	_	O
9	the	_	_	O
10	novel	_	_	O
11	vascular	_	_	O
12	disrupting	_	_	O
13	agent	_	_	O
14	ASA404	_	_	O
15	(	_	_	O
16	vadimezan	_	_	O
17	)	_	_	O
18	,	_	_	O
19	when	_	_	O
20	combined	_	_	O
21	with	_	_	O
22	first-line	_	_	O
23	platinum-based	_	_	O
24	chemotherapy	_	_	O
25	,	_	_	O
26	improves	_	_	O
27	survival	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	advanced	_	_	O
32	non-small-cell	_	_	O
33	lung	_	_	O
34	cancer	_	_	O
35	(	_	_	O
36	NSCLC	_	_	O
37	)	_	_	O
38	versus	_	_	O
39	chemotherapy	_	_	O
40	alone	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	with	_	_	O
44	advanced	_	_	O
45	stage	_	_	O
46	IIIB	_	_	O
47	or	_	_	O
48	IV	_	_	O
49	NSCLC	_	_	O
50	,	_	_	O
51	stratified	_	_	O
52	by	_	_	O
53	sex	_	_	O
54	and	_	_	O
55	tumor	_	_	O
56	histology	_	_	O
57	,	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	1:1	_	_	O
62	to	_	_	O
63	paclitaxel	_	_	O
64	(	_	_	O
65	200	_	_	O
66	mg/m	_	_	O
67	(	_	_	O
68	2	_	_	O
69	)	_	_	O
70	)	_	_	O
71	and	_	_	O
72	carboplatin	_	_	O
73	(	_	_	O
74	area	_	_	O
75	under	_	_	O
76	the	_	_	O
77	curve	_	_	O
78	,	_	_	O
79	6.0	_	_	O
80	)	_	_	O
81	with	_	_	O
82	or	_	_	O
83	without	_	_	O
84	ASA404	_	_	O
85	(	_	_	O
86	1,800	_	_	O
87	mg	_	_	O
88	m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	)	_	_	O
93	,	_	_	O
94	given	_	_	O
95	intravenously	_	_	O
96	once	_	_	O
97	every	_	_	O
98	3	_	_	O
99	weeks	_	_	O
100	for	_	_	O
101	six	_	_	O
102	cycles	_	_	O
103	followed	_	_	O
104	by	_	_	O
105	maintenance	_	_	O
106	ASA404	_	_	O
107	or	_	_	O
108	placebo	_	_	O
109	.	_	_	O

110	Primary	_	_	O
111	end	_	_	O
112	point	_	_	O
113	was	_	_	O
114	overall	_	_	O
115	survival	_	_	O
116	(	_	_	O
117	OS	_	_	O
118	)	_	_	O
119	;	_	_	O
120	secondary	_	_	O
121	end	_	_	O
122	points	_	_	O
123	included	_	_	O
124	overall	_	_	O
125	response	_	_	O
126	rate	_	_	O
127	(	_	_	O
128	ORR	_	_	O
129	)	_	_	O
130	and	_	_	O
131	progression-free	_	_	O
132	survival	_	_	O
133	(	_	_	O
134	PFS	_	_	O
135	)	_	_	O
136	.	_	_	O

137	One	_	_	O
138	thousand	_	_	O
139	two	_	_	O
140	hundred	_	_	O
141	ninety-nine	_	_	O
142	patients	_	_	O
143	were	_	_	O
144	randomly	_	_	O
145	assigned	_	_	O
146	.	_	_	O

147	The	_	_	O
148	trial	_	_	O
149	was	_	_	O
150	stopped	_	_	O
151	for	_	_	O
152	futility	_	_	O
153	at	_	_	O
154	interim	_	_	O
155	analysis	_	_	O
156	.	_	_	O

157	At	_	_	O
158	final	_	_	O
159	analysis	_	_	O
160	,	_	_	O
161	there	_	_	B-Premise
162	was	_	_	I-Premise
163	no	_	_	I-Premise
164	difference	_	_	I-Premise
165	in	_	_	I-Premise
166	OS	_	_	I-Premise
167	seen	_	_	I-Premise
168	between	_	_	I-Premise
169	ASA404	_	_	I-Premise
170	(	_	_	I-Premise
171	n	_	_	I-Premise
172	=	_	_	I-Premise
173	649	_	_	I-Premise
174	)	_	_	I-Premise
175	and	_	_	I-Premise
176	placebo	_	_	I-Premise
177	(	_	_	I-Premise
178	n	_	_	I-Premise
179	=	_	_	I-Premise
180	650	_	_	I-Premise
181	)	_	_	I-Premise
182	arms	_	_	I-Premise
183	:	_	_	I-Premise
184	median	_	_	I-Premise
185	OS	_	_	I-Premise
186	was	_	_	I-Premise
187	13.4	_	_	I-Premise
188	and	_	_	I-Premise
189	12.7	_	_	I-Premise
190	months	_	_	I-Premise
191	respectively	_	_	I-Premise
192	(	_	_	I-Premise
193	hazard	_	_	I-Premise
194	ratio	_	_	I-Premise
195	[	_	_	I-Premise
196	HR	_	_	I-Premise
197	]	_	_	I-Premise
198	,	_	_	I-Premise
199	1.01	_	_	I-Premise
200	;	_	_	I-Premise
201	95	_	_	I-Premise
202	%	_	_	I-Premise
203	CI	_	_	I-Premise
204	,	_	_	I-Premise
205	0.85	_	_	I-Premise
206	to	_	_	I-Premise
207	1.19	_	_	I-Premise
208	;	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	.535	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	Similarly	_	_	O
215	,	_	_	O
216	no	_	_	B-Premise
217	OS	_	_	I-Premise
218	difference	_	_	I-Premise
219	was	_	_	I-Premise
220	seen	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	histologic	_	_	I-Premise
224	(	_	_	I-Premise
225	squamous	_	_	I-Premise
226	or	_	_	I-Premise
227	nonsquamous	_	_	I-Premise
228	)	_	_	I-Premise
229	and	_	_	I-Premise
230	sex	_	_	I-Premise
231	(	_	_	I-Premise
232	male	_	_	I-Premise
233	or	_	_	I-Premise
234	female	_	_	I-Premise
235	)	_	_	I-Premise
236	strata	_	_	I-Premise
237	.	_	_	I-Premise

238	Median	_	_	B-Premise
239	PFS	_	_	I-Premise
240	was	_	_	I-Premise
241	5.5	_	_	I-Premise
242	months	_	_	I-Premise
243	in	_	_	I-Premise
244	both	_	_	I-Premise
245	arms	_	_	I-Premise
246	(	_	_	I-Premise
247	HR	_	_	I-Premise
248	,	_	_	I-Premise
249	1.04	_	_	I-Premise
250	;	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	.727	_	_	I-Premise
254	)	_	_	I-Premise
255	,	_	_	I-Premise
256	while	_	_	I-Premise
257	ORR	_	_	I-Premise
258	was	_	_	I-Premise
259	25	_	_	I-Premise
260	%	_	_	I-Premise
261	in	_	_	I-Premise
262	both	_	_	I-Premise
263	arms	_	_	I-Premise
264	(	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	1.0	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	Overall	_	_	B-Premise
271	rate	_	_	I-Premise
272	of	_	_	I-Premise
273	adverse	_	_	I-Premise
274	events	_	_	I-Premise
275	(	_	_	I-Premise
276	AEs	_	_	I-Premise
277	)	_	_	I-Premise
278	was	_	_	I-Premise
279	comparable	_	_	I-Premise
280	between	_	_	I-Premise
281	the	_	_	I-Premise
282	ASA404	_	_	I-Premise
283	and	_	_	I-Premise
284	placebo	_	_	I-Premise
285	arms	_	_	I-Premise
286	.	_	_	I-Premise

287	Grade	_	_	B-Premise
288	4	_	_	I-Premise
289	neutropenia	_	_	I-Premise
290	(	_	_	I-Premise
291	27	_	_	I-Premise
292	%	_	_	I-Premise
293	v	_	_	I-Premise
294	19	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	and	_	_	I-Premise
298	infusion	_	_	I-Premise
299	site	_	_	I-Premise
300	pain	_	_	I-Premise
301	(	_	_	I-Premise
302	10	_	_	I-Premise
303	%	_	_	I-Premise
304	v	_	_	I-Premise
305	0.5	_	_	I-Premise
306	%	_	_	I-Premise
307	)	_	_	I-Premise
308	were	_	_	I-Premise
309	reported	_	_	I-Premise
310	more	_	_	I-Premise
311	frequently	_	_	I-Premise
312	in	_	_	I-Premise
313	the	_	_	I-Premise
314	ASA404	_	_	I-Premise
315	arm	_	_	I-Premise
316	.	_	_	I-Premise

317	The	_	_	B-Claim
318	addition	_	_	I-Claim
319	of	_	_	I-Claim
320	ASA404	_	_	I-Claim
321	to	_	_	I-Claim
322	carboplatin	_	_	I-Claim
323	and	_	_	I-Claim
324	paclitaxel	_	_	I-Claim
325	,	_	_	I-Claim
326	although	_	_	I-Claim
327	generally	_	_	I-Claim
328	well	_	_	I-Claim
329	tolerated	_	_	I-Claim
330	,	_	_	I-Claim
331	failed	_	_	I-Claim
332	to	_	_	I-Claim
333	improve	_	_	I-Claim
334	frontline	_	_	I-Claim
335	efficacy	_	_	I-Claim
336	in	_	_	I-Claim
337	advanced	_	_	I-Claim
338	NSCLC	_	_	I-Claim
339	.	_	_	I-Claim


0	The	_	_	B-Claim
1	addition	_	_	I-Claim
2	of	_	_	I-Claim
3	bevacizumab	_	_	I-Claim
4	to	_	_	I-Claim
5	paclitaxel	_	_	I-Claim
6	improved	_	_	I-Claim
7	progression-free	_	_	I-Claim
8	survival	_	_	I-Claim
9	(	_	_	I-Claim
10	PFS	_	_	I-Claim
11	)	_	_	I-Claim
12	of	_	_	I-Claim
13	patients	_	_	I-Claim
14	with	_	_	I-Claim
15	metastatic	_	_	I-Claim
16	breast	_	_	I-Claim
17	cancer	_	_	I-Claim
18	(	_	_	I-Claim
19	MBC	_	_	I-Claim
20	)	_	_	I-Claim
21	.	_	_	I-Claim

22	We	_	_	O
23	examined	_	_	O
24	the	_	_	O
25	efficacy	_	_	O
26	and	_	_	O
27	safety	_	_	O
28	of	_	_	O
29	adding	_	_	O
30	gemcitabine	_	_	O
31	to	_	_	O
32	paclitaxel/bevacizumab	_	_	O
33	(	_	_	O
34	PB	_	_	O
35	)	_	_	O
36	.	_	_	O

37	In	_	_	O
38	this	_	_	O
39	multicenter	_	_	O
40	,	_	_	O
41	open-label	_	_	O
42	,	_	_	O
43	randomized	_	_	O
44	phase	_	_	O
45	II	_	_	O
46	trial	_	_	O
47	,	_	_	O
48	women	_	_	O
49	with	_	_	O
50	locally	_	_	O
51	advanced	_	_	O
52	or	_	_	O
53	MBC	_	_	O
54	were	_	_	O
55	randomly	_	_	O
56	assigned	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	paclitaxel	_	_	O
60	90	_	_	O
61	mg/m	_	_	O
62	(	_	_	O
63	2	_	_	O
64	)	_	_	O
65	(	_	_	O
66	days	_	_	O
67	1	_	_	O
68	,	_	_	O
69	8	_	_	O
70	,	_	_	O
71	15	_	_	O
72	)	_	_	O
73	and	_	_	O
74	bevacizumab	_	_	O
75	10	_	_	O
76	mg/kg	_	_	O
77	(	_	_	O
78	days	_	_	O
79	1	_	_	O
80	,	_	_	O
81	15	_	_	O
82	)	_	_	O
83	with	_	_	O
84	or	_	_	O
85	without	_	_	O
86	gemcitabine	_	_	O
87	1500	_	_	O
88	mg/m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	(	_	_	O
93	days	_	_	O
94	1	_	_	O
95	,	_	_	O
96	15	_	_	O
97	)	_	_	O
98	in	_	_	O
99	28-day	_	_	O
100	cycles	_	_	O
101	.	_	_	O

102	Patients	_	_	O
103	with	_	_	O
104	prior	_	_	O
105	cytotoxic	_	_	O
106	therapy	_	_	O
107	for	_	_	O
108	MBC	_	_	O
109	were	_	_	O
110	ineligible	_	_	O
111	.	_	_	O

112	The	_	_	O
113	primary	_	_	O
114	endpoint	_	_	O
115	was	_	_	O
116	investigator-assessed	_	_	O
117	overall	_	_	O
118	response	_	_	O
119	rate	_	_	O
120	(	_	_	O
121	ORR	_	_	O
122	)	_	_	O
123	;	_	_	O
124	secondary	_	_	O
125	endpoints	_	_	O
126	were	_	_	O
127	PFS	_	_	O
128	,	_	_	O
129	overall	_	_	O
130	survival	_	_	O
131	(	_	_	O
132	OS	_	_	O
133	)	_	_	O
134	,	_	_	O
135	safety	_	_	O
136	,	_	_	O
137	and	_	_	O
138	quality	_	_	O
139	of	_	_	O
140	life	_	_	O
141	.	_	_	O

142	Ninety-four	_	_	O
143	patients	_	_	O
144	received	_	_	O
145	PB	_	_	O
146	,	_	_	O
147	and	_	_	O
148	93	_	_	O
149	received	_	_	O
150	paclitaxel/bevacizumab/gemcitabine	_	_	O
151	(	_	_	O
152	PB+G	_	_	O
153	)	_	_	O
154	.	_	_	O

155	The	_	_	B-Premise
156	ORRs	_	_	I-Premise
157	were	_	_	I-Premise
158	48.9	_	_	I-Premise
159	%	_	_	I-Premise
160	(	_	_	I-Premise
161	95	_	_	I-Premise
162	%	_	_	I-Premise
163	confidence	_	_	I-Premise
164	interval	_	_	I-Premise
165	[	_	_	I-Premise
166	CI	_	_	I-Premise
167	]	_	_	I-Premise
168	,	_	_	I-Premise
169	38.5	_	_	I-Premise
170	%	_	_	I-Premise
171	-59.5	_	_	I-Premise
172	%	_	_	I-Premise
173	)	_	_	I-Premise
174	and	_	_	I-Premise
175	58.7	_	_	I-Premise
176	%	_	_	I-Premise
177	(	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	CI	_	_	I-Premise
181	,	_	_	I-Premise
182	47.9	_	_	I-Premise
183	%	_	_	I-Premise
184	-68.9	_	_	I-Premise
185	%	_	_	I-Premise
186	;	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	.117	_	_	I-Premise
190	)	_	_	I-Premise
191	with	_	_	I-Premise
192	PB	_	_	I-Premise
193	and	_	_	I-Premise
194	PB+G	_	_	I-Premise
195	,	_	_	I-Premise
196	respectively	_	_	I-Premise
197	.	_	_	I-Premise

198	The	_	_	B-Premise
199	median	_	_	I-Premise
200	PFS	_	_	I-Premise
201	was	_	_	I-Premise
202	8.8	_	_	I-Premise
203	months	_	_	I-Premise
204	(	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	CI	_	_	I-Premise
208	,	_	_	I-Premise
209	8.1-10.4	_	_	I-Premise
210	months	_	_	I-Premise
211	)	_	_	I-Premise
212	and	_	_	I-Premise
213	11.3	_	_	I-Premise
214	months	_	_	I-Premise
215	(	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	,	_	_	I-Premise
220	9.7-12.7	_	_	I-Premise
221	months	_	_	I-Premise
222	;	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.247	_	_	I-Premise
226	;	_	_	I-Premise
227	hazard	_	_	I-Premise
228	ratio	_	_	I-Premise
229	,	_	_	I-Premise
230	0.82	_	_	I-Premise
231	)	_	_	I-Premise
232	;	_	_	I-Premise
233	the	_	_	I-Premise
234	median	_	_	I-Premise
235	OS	_	_	I-Premise
236	was	_	_	I-Premise
237	25.0	_	_	I-Premise
238	months	_	_	I-Premise
239	(	_	_	I-Premise
240	95	_	_	I-Premise
241	%	_	_	I-Premise
242	CI	_	_	I-Premise
243	,	_	_	I-Premise
244	18.8-not	_	_	I-Premise
245	assessable	_	_	I-Premise
246	[	_	_	I-Premise
247	N/A	_	_	I-Premise
248	]	_	_	I-Premise
249	months	_	_	I-Premise
250	)	_	_	I-Premise
251	and	_	_	I-Premise
252	24.3	_	_	I-Premise
253	months	_	_	I-Premise
254	(	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	,	_	_	I-Premise
259	20.3-N/A	_	_	I-Premise
260	months	_	_	I-Premise
261	;	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.475	_	_	I-Premise
265	;	_	_	I-Premise
266	hazard	_	_	I-Premise
267	ratio	_	_	I-Premise
268	,	_	_	I-Premise
269	0.84	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	with	_	_	I-Premise
273	PB	_	_	I-Premise
274	and	_	_	I-Premise
275	PB+G	_	_	I-Premise
276	,	_	_	I-Premise
277	respectively	_	_	I-Premise
278	.	_	_	I-Premise

279	There	_	_	B-Premise
280	was	_	_	I-Premise
281	significantly	_	_	I-Premise
282	more	_	_	I-Premise
283	grade	_	_	I-Premise
284	3-4	_	_	I-Premise
285	neutropenia	_	_	I-Premise
286	(	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	.001	_	_	I-Premise
290	)	_	_	I-Premise
291	and	_	_	I-Premise
292	dyspnea	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	.014	_	_	I-Premise
297	)	_	_	I-Premise
298	with	_	_	I-Premise
299	PB+G	_	_	I-Premise
300	.	_	_	I-Premise

301	Patients	_	_	B-Premise
302	treated	_	_	I-Premise
303	with	_	_	I-Premise
304	PB	_	_	I-Premise
305	experienced	_	_	I-Premise
306	more	_	_	I-Premise
307	improvement	_	_	I-Premise
308	in	_	_	I-Premise
309	total	_	_	I-Premise
310	FACT-B	_	_	I-Premise
311	(	_	_	I-Premise
312	Functional	_	_	I-Premise
313	Assessment	_	_	I-Premise
314	of	_	_	I-Premise
315	Cancer	_	_	I-Premise
316	Therapy-Breast	_	_	I-Premise
317	)	_	_	I-Premise
318	(	_	_	I-Premise
319	P	_	_	I-Premise
320	=	_	_	I-Premise
321	.021	_	_	I-Premise
322	)	_	_	I-Premise
323	,	_	_	I-Premise
324	FACT-B	_	_	I-Premise
325	Social/Family	_	_	I-Premise
326	Well-being	_	_	I-Premise
327	(	_	_	I-Premise
328	P	_	_	I-Premise
329	=	_	_	I-Premise
330	.041	_	_	I-Premise
331	)	_	_	I-Premise
332	,	_	_	I-Premise
333	and	_	_	I-Premise
334	Breast	_	_	I-Premise
335	Cancer-Additional	_	_	I-Premise
336	Concerns	_	_	I-Premise
337	(	_	_	I-Premise
338	P	_	_	I-Premise
339	=	_	_	I-Premise
340	.008	_	_	I-Premise
341	)	_	_	I-Premise
342	scores	_	_	I-Premise
343	than	_	_	I-Premise
344	patients	_	_	I-Premise
345	treated	_	_	I-Premise
346	with	_	_	I-Premise
347	PB+G	_	_	I-Premise
348	.	_	_	I-Premise

349	The	_	_	B-Claim
350	addition	_	_	I-Claim
351	of	_	_	I-Claim
352	gemcitabine	_	_	I-Claim
353	to	_	_	I-Claim
354	PB	_	_	I-Claim
355	was	_	_	I-Claim
356	not	_	_	I-Claim
357	associated	_	_	I-Claim
358	with	_	_	I-Claim
359	a	_	_	I-Claim
360	statistically	_	_	I-Claim
361	significant	_	_	I-Claim
362	improvement	_	_	I-Claim
363	in	_	_	I-Claim
364	ORR	_	_	I-Claim
365	.	_	_	I-Claim

366	Treatment	_	_	B-Claim
367	with	_	_	I-Claim
368	PB+G	_	_	I-Claim
369	increased	_	_	I-Claim
370	the	_	_	I-Claim
371	incidence	_	_	I-Claim
372	of	_	_	I-Claim
373	severe	_	_	I-Claim
374	neutropenia	_	_	I-Claim
375	and	_	_	I-Claim
376	dyspnea	_	_	I-Claim
377	,	_	_	I-Claim
378	although	_	_	B-Claim
379	the	_	_	I-Claim
380	regimen	_	_	I-Claim
381	generally	_	_	I-Claim
382	was	_	_	I-Claim
383	well	_	_	I-Claim
384	tolerated	_	_	I-Claim
385	.	_	_	I-Claim


0	Dignity	_	_	O
1	therapy	_	_	O
2	is	_	_	O
3	a	_	_	O
4	unique	_	_	O
5	,	_	_	O
6	individualised	_	_	O
7	,	_	_	O
8	short-term	_	_	O
9	psychotherapy	_	_	O
10	that	_	_	O
11	was	_	_	O
12	developed	_	_	O
13	for	_	_	O
14	patients	_	_	O
15	(	_	_	O
16	and	_	_	O
17	their	_	_	O
18	families	_	_	O
19	)	_	_	O
20	living	_	_	O
21	with	_	_	O
22	life-threatening	_	_	O
23	or	_	_	O
24	life-limiting	_	_	O
25	illness	_	_	O
26	.	_	_	O

27	We	_	_	O
28	investigated	_	_	O
29	whether	_	_	O
30	dignity	_	_	O
31	therapy	_	_	O
32	could	_	_	O
33	mitigate	_	_	O
34	distress	_	_	O
35	or	_	_	O
36	bolster	_	_	O
37	the	_	_	O
38	experience	_	_	O
39	in	_	_	O
40	patients	_	_	O
41	nearing	_	_	O
42	the	_	_	O
43	end	_	_	O
44	of	_	_	O
45	their	_	_	O
46	lives	_	_	O
47	.	_	_	O

48	Patients	_	_	O
49	(	_	_	O
50	aged	_	_	O
51	≥18	_	_	O
52	years	_	_	O
53	)	_	_	O
54	with	_	_	O
55	a	_	_	O
56	terminal	_	_	O
57	prognosis	_	_	O
58	(	_	_	O
59	life	_	_	O
60	expectancy	_	_	O
61	≤6	_	_	O
62	months	_	_	O
63	)	_	_	O
64	who	_	_	O
65	were	_	_	O
66	receiving	_	_	O
67	palliative	_	_	O
68	care	_	_	O
69	in	_	_	O
70	a	_	_	O
71	hospital	_	_	O
72	or	_	_	O
73	community	_	_	O
74	setting	_	_	O
75	(	_	_	O
76	hospice	_	_	O
77	or	_	_	O
78	home	_	_	O
79	)	_	_	O
80	in	_	_	O
81	Canada	_	_	O
82	,	_	_	O
83	USA	_	_	O
84	,	_	_	O
85	and	_	_	O
86	Australia	_	_	O
87	were	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	to	_	_	O
91	dignity	_	_	O
92	therapy	_	_	O
93	,	_	_	O
94	client-centred	_	_	O
95	care	_	_	O
96	,	_	_	O
97	or	_	_	O
98	standard	_	_	O
99	palliative	_	_	O
100	care	_	_	O
101	in	_	_	O
102	a	_	_	O
103	1:1:1	_	_	O
104	ratio	_	_	O
105	.	_	_	O

106	Randomisation	_	_	O
107	was	_	_	O
108	by	_	_	O
109	use	_	_	O
110	of	_	_	O
111	a	_	_	O
112	computer-generated	_	_	O
113	table	_	_	O
114	of	_	_	O
115	random	_	_	O
116	numbers	_	_	O
117	in	_	_	O
118	blocks	_	_	O
119	of	_	_	O
120	30	_	_	O
121	.	_	_	O

122	Allocation	_	_	O
123	concealment	_	_	O
124	was	_	_	O
125	by	_	_	O
126	use	_	_	O
127	of	_	_	O
128	opaque	_	_	O
129	sealed	_	_	O
130	envelopes	_	_	O
131	.	_	_	O

132	The	_	_	O
133	primary	_	_	O
134	outcomes	_	_	O
135	--	_	_	O
136	reductions	_	_	O
137	in	_	_	O
138	various	_	_	O
139	dimensions	_	_	O
140	of	_	_	O
141	distress	_	_	O
142	before	_	_	O
143	and	_	_	O
144	after	_	_	O
145	completion	_	_	O
146	of	_	_	O
147	the	_	_	O
148	study	_	_	O
149	--	_	_	O
150	were	_	_	O
151	measured	_	_	O
152	with	_	_	O
153	the	_	_	O
154	Functional	_	_	O
155	Assessment	_	_	O
156	of	_	_	O
157	Chronic	_	_	O
158	Illness	_	_	O
159	Therapy	_	_	O
160	Spiritual	_	_	O
161	Well-Being	_	_	O
162	Scale	_	_	O
163	,	_	_	O
164	Patient	_	_	O
165	Dignity	_	_	O
166	Inventory	_	_	O
167	,	_	_	O
168	Hospital	_	_	O
169	Anxiety	_	_	O
170	and	_	_	O
171	Depression	_	_	O
172	Scale	_	_	O
173	,	_	_	O
174	items	_	_	O
175	from	_	_	O
176	the	_	_	O
177	Structured	_	_	O
178	Interview	_	_	O
179	for	_	_	O
180	Symptoms	_	_	O
181	and	_	_	O
182	Concerns	_	_	O
183	,	_	_	O
184	Quality	_	_	O
185	of	_	_	O
186	Life	_	_	O
187	Scale	_	_	O
188	,	_	_	O
189	and	_	_	O
190	modified	_	_	O
191	Edmonton	_	_	O
192	Symptom	_	_	O
193	Assessment	_	_	O
194	Scale	_	_	O
195	.	_	_	O

196	Secondary	_	_	O
197	outcomes	_	_	O
198	of	_	_	O
199	self-reported	_	_	O
200	end-of-life	_	_	O
201	experiences	_	_	O
202	were	_	_	O
203	assessed	_	_	O
204	in	_	_	O
205	a	_	_	O
206	survey	_	_	O
207	that	_	_	O
208	was	_	_	O
209	undertaken	_	_	O
210	after	_	_	O
211	the	_	_	O
212	completion	_	_	O
213	of	_	_	O
214	the	_	_	O
215	study	_	_	O
216	.	_	_	O

217	Outcomes	_	_	O
218	were	_	_	O
219	assessed	_	_	O
220	by	_	_	O
221	research	_	_	O
222	staff	_	_	O
223	with	_	_	O
224	whom	_	_	O
225	the	_	_	O
226	participant	_	_	O
227	had	_	_	O
228	no	_	_	O
229	previous	_	_	O
230	contact	_	_	O
231	to	_	_	O
232	avoid	_	_	O
233	any	_	_	O
234	possible	_	_	O
235	response	_	_	O
236	bias	_	_	O
237	or	_	_	O
238	contamination	_	_	O
239	.	_	_	O

240	Analyses	_	_	O
241	were	_	_	O
242	done	_	_	O
243	on	_	_	O
244	all	_	_	O
245	patients	_	_	O
246	with	_	_	O
247	available	_	_	O
248	data	_	_	O
249	at	_	_	O
250	baseline	_	_	O
251	and	_	_	O
252	at	_	_	O
253	the	_	_	O
254	end	_	_	O
255	of	_	_	O
256	the	_	_	O
257	study	_	_	O
258	intervention	_	_	O
259	.	_	_	O

260	165	_	_	O
261	of	_	_	O
262	441	_	_	O
263	patients	_	_	O
264	were	_	_	O
265	assigned	_	_	O
266	to	_	_	O
267	dignity	_	_	O
268	therapy	_	_	O
269	,	_	_	O
270	140	_	_	O
271	standard	_	_	O
272	palliative	_	_	O
273	care	_	_	O
274	,	_	_	O
275	and	_	_	O
276	136	_	_	O
277	client-centred	_	_	O
278	care	_	_	O
279	.	_	_	O

280	108	_	_	O
281	,	_	_	O
282	111	_	_	O
283	,	_	_	O
284	and	_	_	O
285	107	_	_	O
286	patients	_	_	O
287	,	_	_	O
288	respectively	_	_	O
289	,	_	_	O
290	were	_	_	O
291	analysed	_	_	O
292	.	_	_	O

293	No	_	_	B-Premise
294	significant	_	_	I-Premise
295	differences	_	_	I-Premise
296	were	_	_	I-Premise
297	noted	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	distress	_	_	I-Premise
301	levels	_	_	I-Premise
302	before	_	_	I-Premise
303	and	_	_	I-Premise
304	after	_	_	I-Premise
305	completion	_	_	I-Premise
306	of	_	_	I-Premise
307	the	_	_	I-Premise
308	study	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	three	_	_	I-Premise
312	groups	_	_	I-Premise
313	.	_	_	I-Premise

314	For	_	_	B-Premise
315	the	_	_	I-Premise
316	secondary	_	_	I-Premise
317	outcomes	_	_	I-Premise
318	,	_	_	I-Premise
319	patients	_	_	I-Premise
320	reported	_	_	I-Premise
321	that	_	_	I-Premise
322	dignity	_	_	I-Premise
323	therapy	_	_	I-Premise
324	was	_	_	I-Premise
325	significantly	_	_	I-Premise
326	more	_	_	I-Premise
327	likely	_	_	I-Premise
328	than	_	_	I-Premise
329	the	_	_	I-Premise
330	other	_	_	I-Premise
331	two	_	_	I-Premise
332	interventions	_	_	I-Premise
333	to	_	_	I-Premise
334	have	_	_	I-Premise
335	been	_	_	I-Premise
336	helpful	_	_	I-Premise
337	(	_	_	I-Premise
338	χ	_	_	I-Premise
339	(	_	_	I-Premise
340	2	_	_	I-Premise
341	)	_	_	I-Premise
342	=35·50	_	_	I-Premise
343	,	_	_	I-Premise
344	df=2	_	_	I-Premise
345	;	_	_	I-Premise
346	p	_	_	I-Premise
347	<	_	_	I-Premise
348	0·0001	_	_	I-Premise
349	)	_	_	I-Premise
350	,	_	_	I-Premise
351	improve	_	_	I-Premise
352	quality	_	_	I-Premise
353	of	_	_	I-Premise
354	life	_	_	I-Premise
355	(	_	_	I-Premise
356	χ	_	_	I-Premise
357	(	_	_	I-Premise
358	2	_	_	I-Premise
359	)	_	_	I-Premise
360	=14·52	_	_	I-Premise
361	;	_	_	I-Premise
362	p=0·001	_	_	I-Premise
363	)	_	_	I-Premise
364	,	_	_	I-Premise
365	increase	_	_	I-Premise
366	sense	_	_	I-Premise
367	of	_	_	I-Premise
368	dignity	_	_	I-Premise
369	(	_	_	I-Premise
370	χ	_	_	I-Premise
371	(	_	_	I-Premise
372	2	_	_	I-Premise
373	)	_	_	I-Premise
374	=12·66	_	_	I-Premise
375	;	_	_	I-Premise
376	p=0·002	_	_	I-Premise
377	)	_	_	I-Premise
378	,	_	_	I-Premise
379	change	_	_	I-Premise
380	how	_	_	I-Premise
381	their	_	_	I-Premise
382	family	_	_	I-Premise
383	saw	_	_	I-Premise
384	and	_	_	I-Premise
385	appreciated	_	_	I-Premise
386	them	_	_	I-Premise
387	(	_	_	I-Premise
388	χ	_	_	I-Premise
389	(	_	_	I-Premise
390	2	_	_	I-Premise
391	)	_	_	I-Premise
392	=33·81	_	_	I-Premise
393	;	_	_	I-Premise
394	p	_	_	I-Premise
395	<	_	_	I-Premise
396	0·0001	_	_	I-Premise
397	)	_	_	I-Premise
398	,	_	_	I-Premise
399	and	_	_	I-Premise
400	be	_	_	I-Premise
401	helpful	_	_	I-Premise
402	to	_	_	I-Premise
403	their	_	_	I-Premise
404	family	_	_	I-Premise
405	(	_	_	I-Premise
406	χ	_	_	I-Premise
407	(	_	_	I-Premise
408	2	_	_	I-Premise
409	)	_	_	I-Premise
410	=33·86	_	_	I-Premise
411	;	_	_	I-Premise
412	p	_	_	I-Premise
413	<	_	_	I-Premise
414	0·0001	_	_	I-Premise
415	)	_	_	I-Premise
416	.	_	_	I-Premise

417	Dignity	_	_	B-Premise
418	therapy	_	_	I-Premise
419	was	_	_	I-Premise
420	significantly	_	_	I-Premise
421	better	_	_	I-Premise
422	than	_	_	I-Premise
423	client-centred	_	_	I-Premise
424	care	_	_	I-Premise
425	in	_	_	I-Premise
426	improving	_	_	I-Premise
427	spiritual	_	_	I-Premise
428	wellbeing	_	_	I-Premise
429	(	_	_	I-Premise
430	χ	_	_	I-Premise
431	(	_	_	I-Premise
432	2	_	_	I-Premise
433	)	_	_	I-Premise
434	=10·35	_	_	I-Premise
435	;	_	_	I-Premise
436	p=0·006	_	_	I-Premise
437	)	_	_	I-Premise
438	,	_	_	I-Premise
439	and	_	_	I-Premise
440	was	_	_	I-Premise
441	significantly	_	_	I-Premise
442	better	_	_	I-Premise
443	than	_	_	I-Premise
444	standard	_	_	I-Premise
445	palliative	_	_	I-Premise
446	care	_	_	I-Premise
447	in	_	_	I-Premise
448	terms	_	_	I-Premise
449	of	_	_	I-Premise
450	lessening	_	_	I-Premise
451	sadness	_	_	I-Premise
452	or	_	_	I-Premise
453	depression	_	_	I-Premise
454	(	_	_	I-Premise
455	χ	_	_	I-Premise
456	(	_	_	I-Premise
457	2	_	_	I-Premise
458	)	_	_	I-Premise
459	=9·38	_	_	I-Premise
460	;	_	_	I-Premise
461	p=0·009	_	_	I-Premise
462	)	_	_	I-Premise
463	;	_	_	I-Premise
464	significantly	_	_	B-Premise
465	more	_	_	I-Premise
466	patients	_	_	I-Premise
467	who	_	_	I-Premise
468	had	_	_	I-Premise
469	received	_	_	I-Premise
470	dignity	_	_	I-Premise
471	therapy	_	_	I-Premise
472	reported	_	_	I-Premise
473	that	_	_	I-Premise
474	the	_	_	I-Premise
475	study	_	_	I-Premise
476	group	_	_	I-Premise
477	had	_	_	I-Premise
478	been	_	_	I-Premise
479	satisfactory	_	_	I-Premise
480	,	_	_	I-Premise
481	compared	_	_	I-Premise
482	with	_	_	I-Premise
483	those	_	_	I-Premise
484	who	_	_	I-Premise
485	received	_	_	I-Premise
486	standard	_	_	I-Premise
487	palliative	_	_	I-Premise
488	care	_	_	I-Premise
489	(	_	_	I-Premise
490	χ	_	_	I-Premise
491	(	_	_	I-Premise
492	2	_	_	I-Premise
493	)	_	_	I-Premise
494	=29·58	_	_	I-Premise
495	;	_	_	I-Premise
496	p	_	_	I-Premise
497	<	_	_	I-Premise
498	0·0001	_	_	I-Premise
499	)	_	_	I-Premise
500	.	_	_	I-Premise

501	Although	_	_	B-Claim
502	the	_	_	I-Claim
503	ability	_	_	I-Claim
504	of	_	_	I-Claim
505	dignity	_	_	I-Claim
506	therapy	_	_	I-Claim
507	to	_	_	I-Claim
508	mitigate	_	_	I-Claim
509	outright	_	_	I-Claim
510	distress	_	_	I-Claim
511	,	_	_	I-Claim
512	such	_	_	I-Claim
513	as	_	_	I-Claim
514	depression	_	_	I-Claim
515	,	_	_	I-Claim
516	desire	_	_	I-Claim
517	for	_	_	I-Claim
518	death	_	_	I-Claim
519	or	_	_	I-Claim
520	suicidality	_	_	I-Claim
521	,	_	_	I-Claim
522	has	_	_	I-Claim
523	yet	_	_	I-Claim
524	to	_	_	I-Claim
525	be	_	_	I-Claim
526	proven	_	_	I-Claim
527	,	_	_	I-Claim
528	its	_	_	B-Claim
529	benefits	_	_	I-Claim
530	in	_	_	I-Claim
531	terms	_	_	I-Claim
532	of	_	_	I-Claim
533	self-reported	_	_	I-Claim
534	end-of-life	_	_	I-Claim
535	experiences	_	_	I-Claim
536	support	_	_	I-Claim
537	its	_	_	I-Claim
538	clinical	_	_	I-Claim
539	application	_	_	I-Claim
540	for	_	_	I-Claim
541	patients	_	_	I-Claim
542	nearing	_	_	I-Claim
543	death	_	_	I-Claim
544	.	_	_	I-Claim


0	The	_	_	B-Claim
1	generalizability	_	_	I-Claim
2	of	_	_	I-Claim
3	palliative	_	_	I-Claim
4	care	_	_	I-Claim
5	intervention	_	_	I-Claim
6	research	_	_	I-Claim
7	is	_	_	I-Claim
8	often	_	_	I-Claim
9	limited	_	_	I-Claim
10	by	_	_	I-Claim
11	high	_	_	I-Claim
12	rates	_	_	I-Claim
13	of	_	_	I-Claim
14	study	_	_	I-Claim
15	attrition	_	_	I-Claim
16	.	_	_	I-Claim

17	This	_	_	O
18	study	_	_	O
19	examined	_	_	O
20	factors	_	_	O
21	associated	_	_	O
22	with	_	_	O
23	attrition	_	_	O
24	from	_	_	O
25	a	_	_	O
26	randomized	_	_	O
27	controlled	_	_	O
28	trial	_	_	O
29	comparing	_	_	O
30	meaning-centered	_	_	O
31	group	_	_	O
32	psychotherapy	_	_	O
33	(	_	_	O
34	MCGP	_	_	O
35	)	_	_	O
36	,	_	_	O
37	an	_	_	O
38	intervention	_	_	O
39	designed	_	_	O
40	to	_	_	O
41	help	_	_	O
42	advanced	_	_	O
43	cancer	_	_	O
44	patients	_	_	O
45	sustain	_	_	O
46	or	_	_	O
47	enhance	_	_	O
48	their	_	_	O
49	sense	_	_	O
50	of	_	_	O
51	meaning	_	_	O
52	to	_	_	O
53	the	_	_	O
54	supportive	_	_	O
55	group	_	_	O
56	psychotherapy	_	_	O
57	(	_	_	O
58	SGP	_	_	O
59	)	_	_	O
60	,	_	_	O
61	a	_	_	O
62	standardized	_	_	O
63	support	_	_	O
64	group	_	_	O
65	.	_	_	O

66	Patients	_	_	O
67	with	_	_	O
68	advanced	_	_	O
69	solid	_	_	O
70	tumor	_	_	O
71	cancers	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	153	_	_	O
76	)	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	eight	_	_	O
81	sessions	_	_	O
82	of	_	_	O
83	either	_	_	O
84	the	_	_	O
85	MCGP	_	_	O
86	or	_	_	O
87	SGP	_	_	O
88	.	_	_	O

89	They	_	_	O
90	completed	_	_	O
91	assessments	_	_	O
92	of	_	_	O
93	psychosocial	_	_	O
94	,	_	_	O
95	spiritual	_	_	O
96	,	_	_	O
97	and	_	_	O
98	physical	_	_	O
99	well-being	_	_	O
100	pretreatment	_	_	O
101	,	_	_	O
102	midtreatment	_	_	O
103	,	_	_	O
104	and	_	_	O
105	2	_	_	O
106	months	_	_	O
107	post-treatment	_	_	O
108	.	_	_	O

109	Attrition	_	_	O
110	was	_	_	O
111	assessed	_	_	O
112	in	_	_	O
113	terms	_	_	O
114	of	_	_	O
115	the	_	_	O
116	percent	_	_	O
117	of	_	_	O
118	participants	_	_	O
119	who	_	_	O
120	failed	_	_	O
121	to	_	_	O
122	complete	_	_	O
123	these	_	_	O
124	assessments	_	_	O
125	,	_	_	O
126	and	_	_	O
127	demographic	_	_	O
128	,	_	_	O
129	psychiatric	_	_	O
130	,	_	_	O
131	medical	_	_	O
132	,	_	_	O
133	and	_	_	O
134	study-related	_	_	O
135	correlates	_	_	O
136	of	_	_	O
137	attrition	_	_	O
138	were	_	_	O
139	examined	_	_	O
140	for	_	_	O
141	the	_	_	O
142	participants	_	_	O
143	in	_	_	O
144	each	_	_	O
145	of	_	_	O
146	these	_	_	O
147	categories	_	_	O
148	.	_	_	O

149	The	_	_	B-Premise
150	rates	_	_	I-Premise
151	of	_	_	I-Premise
152	attrition	_	_	I-Premise
153	at	_	_	I-Premise
154	these	_	_	I-Premise
155	time	_	_	I-Premise
156	points	_	_	I-Premise
157	were	_	_	I-Premise
158	28.1	_	_	I-Premise
159	%	_	_	I-Premise
160	,	_	_	I-Premise
161	17.7	_	_	I-Premise
162	%	_	_	I-Premise
163	,	_	_	I-Premise
164	and	_	_	I-Premise
165	11.1	_	_	I-Premise
166	%	_	_	I-Premise
167	,	_	_	I-Premise
168	respectively	_	_	I-Premise
169	;	_	_	I-Premise
170	43.1	_	_	I-Premise
171	%	_	_	I-Premise
172	of	_	_	I-Premise
173	the	_	_	I-Premise
174	participants	_	_	I-Premise
175	(	_	_	I-Premise
176	66	_	_	I-Premise
177	of	_	_	I-Premise
178	153	_	_	I-Premise
179	)	_	_	I-Premise
180	completed	_	_	I-Premise
181	the	_	_	I-Premise
182	entire	_	_	I-Premise
183	study	_	_	I-Premise
184	.	_	_	I-Premise

185	The	_	_	B-Premise
186	most	_	_	I-Premise
187	common	_	_	I-Premise
188	reason	_	_	I-Premise
189	for	_	_	I-Premise
190	dropout	_	_	I-Premise
191	was	_	_	I-Premise
192	patients	_	_	I-Premise
193	feeling	_	_	I-Premise
194	too	_	_	I-Premise
195	ill	_	_	I-Premise
196	.	_	_	I-Premise

197	Attrition	_	_	B-Premise
198	rates	_	_	I-Premise
199	did	_	_	I-Premise
200	not	_	_	I-Premise
201	vary	_	_	I-Premise
202	significantly	_	_	I-Premise
203	between	_	_	I-Premise
204	study	_	_	I-Premise
205	arms	_	_	I-Premise
206	.	_	_	I-Premise

207	The	_	_	O
208	participants	_	_	O
209	who	_	_	O
210	dropped	_	_	O
211	out	_	_	O
212	pretreatment	_	_	O
213	reported	_	_	O
214	less	_	_	O
215	financial	_	_	O
216	concerns	_	_	O
217	than	_	_	O
218	post-treatment	_	_	O
219	dropouts	_	_	O
220	,	_	_	O
221	and	_	_	O
222	the	_	_	O
223	participants	_	_	O
224	who	_	_	O
225	dropped	_	_	O
226	out	_	_	O
227	of	_	_	O
228	the	_	_	O
229	study	_	_	O
230	midtreatment	_	_	O
231	had	_	_	O
232	poorer	_	_	O
233	physical	_	_	O
234	health	_	_	O
235	than	_	_	O
236	treatment	_	_	O
237	completers	_	_	O
238	.	_	_	O

239	There	_	_	B-Premise
240	were	_	_	I-Premise
241	no	_	_	I-Premise
242	other	_	_	I-Premise
243	significant	_	_	I-Premise
244	associations	_	_	I-Premise
245	between	_	_	I-Premise
246	attrition	_	_	I-Premise
247	and	_	_	I-Premise
248	any	_	_	I-Premise
249	demographic	_	_	I-Premise
250	,	_	_	I-Premise
251	medical	_	_	I-Premise
252	,	_	_	I-Premise
253	psychiatric	_	_	I-Premise
254	,	_	_	I-Premise
255	or	_	_	I-Premise
256	study-related	_	_	I-Premise
257	variables	_	_	I-Premise
258	.	_	_	I-Premise

259	These	_	_	B-Claim
260	findings	_	_	I-Claim
261	highlight	_	_	I-Claim
262	the	_	_	I-Claim
263	challenge	_	_	I-Claim
264	of	_	_	I-Claim
265	maintaining	_	_	I-Claim
266	advanced	_	_	I-Claim
267	cancer	_	_	I-Claim
268	patients	_	_	I-Claim
269	in	_	_	I-Claim
270	longitudinal	_	_	I-Claim
271	research	_	_	I-Claim
272	and	_	_	I-Claim
273	suggest	_	_	I-Claim
274	the	_	_	I-Claim
275	need	_	_	I-Claim
276	to	_	_	I-Claim
277	consider	_	_	I-Claim
278	alternative	_	_	I-Claim
279	approaches	_	_	I-Claim
280	(	_	_	I-Claim
281	e.g.	_	_	I-Claim
282	,	_	_	I-Claim
283	telemedicine	_	_	I-Claim
284	)	_	_	I-Claim
285	for	_	_	I-Claim
286	patients	_	_	I-Claim
287	who	_	_	I-Claim
288	might	_	_	I-Claim
289	benefit	_	_	I-Claim
290	from	_	_	I-Claim
291	group	_	_	I-Claim
292	interventions	_	_	I-Claim
293	but	_	_	I-Claim
294	are	_	_	I-Claim
295	too	_	_	I-Claim
296	ill	_	_	I-Claim
297	to	_	_	I-Claim
298	travel	_	_	I-Claim
299	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	additive	_	_	O
4	intraocular	_	_	O
5	pressure	_	_	O
6	(	_	_	O
7	IOP	_	_	O
8	)	_	_	O
9	-lowering	_	_	O
10	efficacy	_	_	O
11	and	_	_	O
12	safety	_	_	O
13	of	_	_	O
14	fixed	_	_	O
15	combination	_	_	O
16	brimonidine	_	_	O
17	0.2	_	_	O
18	%	_	_	O
19	/timolol	_	_	O
20	0.5	_	_	O
21	%	_	_	O
22	compared	_	_	O
23	with	_	_	O
24	timolol	_	_	O
25	0.5	_	_	O
26	%	_	_	O
27	at	_	_	O
28	peak	_	_	O
29	and	_	_	O
30	trough	_	_	O
31	effect	_	_	O
32	when	_	_	O
33	used	_	_	O
34	as	_	_	O
35	therapy	_	_	O
36	adjunctive	_	_	O
37	to	_	_	O
38	latanoprost	_	_	O
39	0.005	_	_	O
40	%	_	_	O
41	in	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	glaucoma	_	_	O
45	or	_	_	O
46	ocular	_	_	O
47	hypertension	_	_	O
48	who	_	_	O
49	require	_	_	O
50	additional	_	_	O
51	IOP	_	_	O
52	lowering	_	_	O
53	.	_	_	O

54	In	_	_	O
55	this	_	_	O
56	prospective	_	_	O
57	,	_	_	O
58	randomized	_	_	O
59	,	_	_	O
60	multicenter	_	_	O
61	,	_	_	O
62	investigator-masked	_	_	O
63	,	_	_	O
64	parallel-group	_	_	O
65	study	_	_	O
66	,	_	_	O
67	patients	_	_	O
68	were	_	_	O
69	treated	_	_	O
70	with	_	_	O
71	latanoprost	_	_	O
72	monotherapy	_	_	O
73	for	_	_	O
74	at	_	_	O
75	least	_	_	O
76	four	_	_	O
77	weeks	_	_	O
78	prior	_	_	O
79	to	_	_	O
80	baseline	_	_	O
81	.	_	_	O

82	At	_	_	O
83	baseline	_	_	O
84	on	_	_	O
85	latanoprost	_	_	O
86	,	_	_	O
87	patients	_	_	O
88	with	_	_	O
89	IOP	_	_	O
90	21	_	_	O
91	mmHg	_	_	O
92	in	_	_	O
93	at	_	_	O
94	least	_	_	O
95	one	_	_	O
96	eye	_	_	O
97	were	_	_	O
98	randomized	_	_	O
99	to	_	_	O
100	twice-daily	_	_	O
101	fixed	_	_	O
102	brimonidine-timolol	_	_	O
103	(	_	_	O
104	n	_	_	O
105	=	_	_	O
106	102	_	_	O
107	)	_	_	O
108	or	_	_	O
109	timolol	_	_	O
110	(	_	_	O
111	n	_	_	O
112	=	_	_	O
113	102	_	_	O
114	)	_	_	O
115	,	_	_	O
116	each	_	_	O
117	adjunctive	_	_	O
118	to	_	_	O
119	latanoprost	_	_	O
120	for	_	_	O
121	12	_	_	O
122	weeks	_	_	O
123	.	_	_	O

124	IOP	_	_	O
125	was	_	_	O
126	measured	_	_	O
127	at	_	_	O
128	8	_	_	O
129	am	_	_	O
130	and	_	_	O
131	10	_	_	O
132	am	_	_	O
133	at	_	_	O
134	baseline	_	_	O
135	,	_	_	O
136	week	_	_	O
137	6	_	_	O
138	,	_	_	O
139	and	_	_	O
140	week	_	_	O
141	12	_	_	O
142	and	_	_	O
143	evaluated	_	_	O
144	in	_	_	O
145	the	_	_	O
146	per	_	_	O
147	protocol	_	_	O
148	population	_	_	O
149	.	_	_	O

150	The	_	_	O
151	primary	_	_	O
152	efficacy	_	_	O
153	endpoint	_	_	O
154	was	_	_	O
155	peak	_	_	O
156	IOP	_	_	O
157	lowering	_	_	O
158	at	_	_	O
159	10	_	_	O
160	am	_	_	O
161	,	_	_	O
162	week	_	_	O
163	12	_	_	O
164	.	_	_	O

165	Safety	_	_	O
166	measures	_	_	O
167	included	_	_	O
168	adverse	_	_	O
169	events	_	_	O
170	.	_	_	O

171	Baseline	_	_	O
172	mean	_	_	O
173	IOP	_	_	O
174	was	_	_	O
175	similar	_	_	O
176	at	_	_	O
177	10	_	_	O
178	am	_	_	O
179	in	_	_	O
180	the	_	_	O
181	treatment	_	_	O
182	groups	_	_	O
183	(	_	_	O
184	brimonidine-timolol	_	_	O
185	23.4	_	_	O
186	mmHg	_	_	O
187	;	_	_	O
188	timolol	_	_	O
189	23.0	_	_	O
190	mmHg	_	_	O
191	)	_	_	O
192	.	_	_	O

193	The	_	_	B-Premise
194	mean	_	_	I-Premise
195	additional	_	_	I-Premise
196	reduction	_	_	I-Premise
197	from	_	_	I-Premise
198	latanoprost-treated	_	_	I-Premise
199	baseline	_	_	I-Premise
200	IOP	_	_	I-Premise
201	was	_	_	I-Premise
202	8.3	_	_	I-Premise
203	mmHg	_	_	I-Premise
204	(	_	_	I-Premise
205	35.5	_	_	I-Premise
206	%	_	_	I-Premise
207	)	_	_	I-Premise
208	with	_	_	I-Premise
209	fixed	_	_	I-Premise
210	brimonidine-timolol	_	_	I-Premise
211	and	_	_	I-Premise
212	6.2	_	_	I-Premise
213	mmHg	_	_	I-Premise
214	(	_	_	I-Premise
215	27.0	_	_	I-Premise
216	%	_	_	I-Premise
217	)	_	_	I-Premise
218	with	_	_	I-Premise
219	timolol	_	_	I-Premise
220	at	_	_	I-Premise
221	10	_	_	I-Premise
222	am	_	_	I-Premise
223	,	_	_	I-Premise
224	week	_	_	I-Premise
225	12	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0.001	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Patients	_	_	B-Premise
233	treated	_	_	I-Premise
234	with	_	_	I-Premise
235	fixed	_	_	I-Premise
236	brimonidine-timolol	_	_	I-Premise
237	adjunctive	_	_	I-Premise
238	to	_	_	I-Premise
239	latanoprost	_	_	I-Premise
240	were	_	_	I-Premise
241	significantly	_	_	I-Premise
242	more	_	_	I-Premise
243	likely	_	_	I-Premise
244	than	_	_	I-Premise
245	patients	_	_	I-Premise
246	treated	_	_	I-Premise
247	with	_	_	I-Premise
248	adjunctive	_	_	I-Premise
249	timolol	_	_	I-Premise
250	to	_	_	I-Premise
251	achieve	_	_	I-Premise
252	an	_	_	I-Premise
253	IOP	_	_	I-Premise
254	<	_	_	I-Premise
255	18	_	_	I-Premise
256	mmHg	_	_	I-Premise
257	(	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	0.028	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	a	_	_	I-Premise
264	20	_	_	I-Premise
265	%	_	_	I-Premise
266	reduction	_	_	I-Premise
267	in	_	_	I-Premise
268	IOP	_	_	I-Premise
269	from	_	_	I-Premise
270	baseline	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	0.047	_	_	I-Premise
275	)	_	_	I-Premise
276	at	_	_	I-Premise
277	both	_	_	I-Premise
278	8	_	_	I-Premise
279	am	_	_	I-Premise
280	and	_	_	I-Premise
281	10	_	_	I-Premise
282	am	_	_	I-Premise
283	in	_	_	I-Premise
284	week	_	_	I-Premise
285	12	_	_	I-Premise
286	.	_	_	I-Premise

287	Adverse	_	_	B-Premise
288	events	_	_	I-Premise
289	occurred	_	_	I-Premise
290	in	_	_	I-Premise
291	14.7	_	_	I-Premise
292	%	_	_	I-Premise
293	of	_	_	I-Premise
294	fixed	_	_	I-Premise
295	brimonidine-timolol	_	_	I-Premise
296	patients	_	_	I-Premise
297	and	_	_	I-Premise
298	12.7	_	_	I-Premise
299	%	_	_	I-Premise
300	of	_	_	I-Premise
301	timolol	_	_	I-Premise
302	patients	_	_	I-Premise
303	.	_	_	I-Premise

304	Biomicroscopy	_	_	B-Premise
305	findings	_	_	I-Premise
306	were	_	_	I-Premise
307	similar	_	_	I-Premise
308	between	_	_	I-Premise
309	the	_	_	I-Premise
310	treatment	_	_	I-Premise
311	groups	_	_	I-Premise
312	after	_	_	I-Premise
313	12	_	_	I-Premise
314	weeks	_	_	I-Premise
315	of	_	_	I-Premise
316	treatment	_	_	I-Premise
317	.	_	_	I-Premise

318	Fixed-combination	_	_	B-Claim
319	brimonidine-timolol	_	_	I-Claim
320	reduced	_	_	I-Claim
321	IOP	_	_	I-Claim
322	significantly	_	_	I-Claim
323	more	_	_	I-Claim
324	effectively	_	_	I-Claim
325	than	_	_	I-Claim
326	timolol	_	_	I-Claim
327	when	_	_	I-Claim
328	used	_	_	I-Claim
329	as	_	_	I-Claim
330	adjunctive	_	_	I-Claim
331	therapy	_	_	I-Claim
332	to	_	_	I-Claim
333	latanoprost	_	_	I-Claim
334	in	_	_	I-Claim
335	patients	_	_	I-Claim
336	with	_	_	I-Claim
337	glaucoma	_	_	I-Claim
338	and	_	_	I-Claim
339	ocular	_	_	I-Claim
340	hypertension	_	_	I-Claim
341	.	_	_	I-Claim

342	Both	_	_	B-Claim
343	fixed	_	_	I-Claim
344	brimonidine-timolol	_	_	I-Claim
345	and	_	_	I-Claim
346	timolol	_	_	I-Claim
347	were	_	_	I-Claim
348	well	_	_	I-Claim
349	tolerated	_	_	I-Claim
350	as	_	_	I-Claim
351	agents	_	_	I-Claim
352	adjunctive	_	_	I-Claim
353	to	_	_	I-Claim
354	latanoprost	_	_	I-Claim
355	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	health-related	_	_	O
3	quality	_	_	O
4	of	_	_	O
5	life	_	_	O
6	,	_	_	O
7	we	_	_	O
8	investigated	_	_	O
9	the	_	_	O
10	effect	_	_	O
11	of	_	_	O
12	adjuvant	_	_	O
13	chemotherapy	_	_	O
14	regimens	_	_	O
15	on	_	_	O
16	utility	_	_	O
17	scores	_	_	O
18	assessed	_	_	O
19	by	_	_	O
20	the	_	_	O
21	EuroQoL-5D	_	_	O
22	(	_	_	O
23	EQ-5D	_	_	O
24	)	_	_	O
25	instrument	_	_	O
26	in	_	_	O
27	a	_	_	O
28	randomized	_	_	O
29	,	_	_	O
30	controlled	_	_	O
31	trial	_	_	O
32	for	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	patients	_	_	O
36	after	_	_	O
37	surgery	_	_	O
38	.	_	_	O

39	We	_	_	O
40	also	_	_	O
41	investigated	_	_	O
42	the	_	_	O
43	relationship	_	_	O
44	between	_	_	O
45	Functional	_	_	O
46	Assessment	_	_	O
47	of	_	_	O
48	Cancer	_	_	O
49	Therapy	_	_	O
50	(	_	_	O
51	FACT	_	_	O
52	)	_	_	O
53	scale	_	_	O
54	scores	_	_	O
55	and	_	_	O
56	EQ-5D	_	_	O
57	utilities	_	_	O
58	.	_	_	O

59	Patients	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	the	_	_	O
65	following	_	_	O
66	four	_	_	O
67	chemotherapy	_	_	O
68	regimens	_	_	O
69	:	_	_	O
70	four	_	_	O
71	cycles	_	_	O
72	of	_	_	O
73	anthracycline	_	_	O
74	followed	_	_	O
75	by	_	_	O
76	paclitaxel	_	_	O
77	(	_	_	O
78	ACP	_	_	O
79	)	_	_	O
80	,	_	_	O
81	four	_	_	O
82	cycles	_	_	O
83	of	_	_	O
84	anthracycline-containing	_	_	O
85	regimens	_	_	O
86	followed	_	_	O
87	by	_	_	O
88	docetaxel	_	_	O
89	(	_	_	O
90	ACD	_	_	O
91	)	_	_	O
92	,	_	_	O
93	eight	_	_	O
94	cycles	_	_	O
95	of	_	_	O
96	paclitaxel	_	_	O
97	(	_	_	O
98	PTX	_	_	O
99	)	_	_	O
100	,	_	_	O
101	and	_	_	O
102	eight	_	_	O
103	cycles	_	_	O
104	of	_	_	O
105	docetaxel	_	_	O
106	(	_	_	O
107	DTX	_	_	O
108	)	_	_	O
109	.	_	_	O

110	Of	_	_	O
111	1060	_	_	O
112	registered	_	_	O
113	,	_	_	O
114	the	_	_	O
115	first	_	_	O
116	300	_	_	O
117	consecutive	_	_	O
118	patients	_	_	O
119	were	_	_	O
120	included	_	_	O
121	in	_	_	O
122	the	_	_	O
123	current	_	_	O
124	utility	_	_	O
125	study	_	_	O
126	.	_	_	O

127	Utility	_	_	O
128	scores	_	_	O
129	were	_	_	O
130	assessed	_	_	O
131	using	_	_	O
132	the	_	_	O
133	EQ-5D	_	_	O
134	instrument	_	_	O
135	at	_	_	O
136	baseline	_	_	O
137	;	_	_	O
138	cycles	_	_	O
139	3	_	_	O
140	,	_	_	O
141	5	_	_	O
142	,	_	_	O
143	and	_	_	O
144	7	_	_	O
145	;	_	_	O
146	7	_	_	O
147	months	_	_	O
148	;	_	_	O
149	and	_	_	O
150	1	_	_	O
151	year	_	_	O
152	.	_	_	O

153	We	_	_	O
154	also	_	_	O
155	evaluated	_	_	O
156	the	_	_	O
157	correlation	_	_	O
158	between	_	_	O
159	these	_	_	O
160	scores	_	_	O
161	and	_	_	O
162	FACT-G	_	_	O
163	,	_	_	O
164	-B	_	_	O
165	,	_	_	O
166	and	_	_	O
167	-Taxane	_	_	O
168	scores	_	_	O
169	at	_	_	O
170	each	_	_	O
171	time	_	_	O
172	point	_	_	O
173	.	_	_	O

174	Utility	_	_	B-Premise
175	scores	_	_	I-Premise
176	were	_	_	I-Premise
177	significantly	_	_	I-Premise
178	lower	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	DTX	_	_	I-Premise
182	group	_	_	I-Premise
183	than	_	_	I-Premise
184	in	_	_	I-Premise
185	the	_	_	I-Premise
186	ACP	_	_	I-Premise
187	and	_	_	I-Premise
188	ACD	_	_	I-Premise
189	groups	_	_	I-Premise
190	.	_	_	I-Premise

191	Mean	_	_	B-Premise
192	utility	_	_	I-Premise
193	scores	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	DTX	_	_	I-Premise
197	group	_	_	I-Premise
198	were	_	_	I-Premise
199	lowest	_	_	I-Premise
200	at	_	_	I-Premise
201	7	_	_	I-Premise
202	months	_	_	I-Premise
203	and	_	_	I-Premise
204	tended	_	_	I-Premise
205	to	_	_	I-Premise
206	remain	_	_	I-Premise
207	low	_	_	I-Premise
208	for	_	_	I-Premise
209	a	_	_	I-Premise
210	long	_	_	I-Premise
211	time	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	combined	_	_	I-Premise
215	anthracycline	_	_	I-Premise
216	followed	_	_	I-Premise
217	by	_	_	I-Premise
218	taxane	_	_	I-Premise
219	group	_	_	I-Premise
220	had	_	_	I-Premise
221	significantly	_	_	I-Premise
222	higher	_	_	I-Premise
223	utility	_	_	I-Premise
224	scores	_	_	I-Premise
225	that	_	_	I-Premise
226	the	_	_	I-Premise
227	taxane-alone	_	_	I-Premise
228	group	_	_	I-Premise
229	,	_	_	I-Premise
230	with	_	_	I-Premise
231	no	_	_	I-Premise
232	significant	_	_	I-Premise
233	difference	_	_	I-Premise
234	depending	_	_	I-Premise
235	on	_	_	I-Premise
236	the	_	_	I-Premise
237	type	_	_	I-Premise
238	of	_	_	I-Premise
239	taxane	_	_	I-Premise
240	.	_	_	I-Premise

241	Only	_	_	B-Premise
242	the	_	_	I-Premise
243	FACT-G	_	_	I-Premise
244	social/family	_	_	I-Premise
245	well-being	_	_	I-Premise
246	subscale	_	_	I-Premise
247	had	_	_	I-Premise
248	no	_	_	I-Premise
249	relationship	_	_	I-Premise
250	with	_	_	I-Premise
251	EQ-5D	_	_	I-Premise
252	responses	_	_	I-Premise
253	and	_	_	I-Premise
254	utility	_	_	I-Premise
255	scores	_	_	I-Premise
256	.	_	_	I-Premise

257	Although	_	_	B-Claim
258	the	_	_	I-Claim
259	regimens	_	_	I-Claim
260	in	_	_	I-Claim
261	this	_	_	I-Claim
262	study	_	_	I-Claim
263	were	_	_	I-Claim
264	similar	_	_	I-Claim
265	in	_	_	I-Claim
266	that	_	_	I-Claim
267	they	_	_	I-Claim
268	included	_	_	I-Claim
269	taxane	_	_	I-Claim
270	,	_	_	I-Claim
271	the	_	_	I-Claim
272	mean	_	_	I-Claim
273	utility	_	_	I-Claim
274	scores	_	_	I-Claim
275	and	_	_	I-Claim
276	longitudinal	_	_	I-Claim
277	patterns	_	_	I-Claim
278	of	_	_	I-Claim
279	utility	_	_	I-Claim
280	scores	_	_	I-Claim
281	were	_	_	I-Claim
282	different	_	_	I-Claim
283	among	_	_	I-Claim
284	regimens	_	_	I-Claim
285	.	_	_	I-Claim


0	The	_	_	B-Claim
1	postoperative	_	_	I-Claim
2	clinical	_	_	I-Claim
3	superiority	_	_	I-Claim
4	of	_	_	I-Claim
5	the	_	_	I-Claim
6	interposition	_	_	I-Claim
7	of	_	_	I-Claim
8	jejunum	_	_	I-Claim
9	reconstruction	_	_	I-Claim
10	(	_	_	I-Claim
11	INT	_	_	I-Claim
12	)	_	_	I-Claim
13	to	_	_	I-Claim
14	Roux-en-Y	_	_	I-Claim
15	reconstruction	_	_	I-Claim
16	(	_	_	I-Claim
17	RY	_	_	I-Claim
18	)	_	_	I-Claim
19	after	_	_	I-Claim
20	total	_	_	I-Claim
21	gastrectomy	_	_	I-Claim
22	has	_	_	I-Claim
23	not	_	_	I-Claim
24	been	_	_	I-Claim
25	clarified	_	_	I-Claim
26	.	_	_	I-Claim

27	Postoperative	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	(	_	_	O
32	QOL	_	_	O
33	)	_	_	O
34	was	_	_	O
35	evaluated	_	_	O
36	between	_	_	O
37	the	_	_	O
38	2	_	_	O
39	methods	_	_	O
40	by	_	_	O
41	a	_	_	O
42	multi-institutional	_	_	O
43	prospective	_	_	O
44	randomized	_	_	O
45	trial	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	103	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	gastric	_	_	O
54	cancer	_	_	O
55	were	_	_	O
56	prospectively	_	_	O
57	randomly	_	_	O
58	divided	_	_	O
59	into	_	_	O
60	groups	_	_	O
61	for	_	_	O
62	RY	_	_	O
63	(	_	_	O
64	n	_	_	O
65	=	_	_	O
66	51	_	_	O
67	)	_	_	O
68	or	_	_	O
69	INT	_	_	O
70	reconstruction	_	_	O
71	(	_	_	O
72	n	_	_	O
73	=	_	_	O
74	52	_	_	O
75	)	_	_	O
76	after	_	_	O
77	total	_	_	O
78	gastrectomy	_	_	O
79	.	_	_	O

80	They	_	_	O
81	were	_	_	O
82	stratified	_	_	O
83	by	_	_	O
84	sex	_	_	O
85	,	_	_	O
86	age	_	_	O
87	,	_	_	O
88	institute	_	_	O
89	,	_	_	O
90	histology	_	_	O
91	,	_	_	O
92	and	_	_	O
93	degree	_	_	O
94	of	_	_	O
95	lymph	_	_	O
96	node	_	_	O
97	dissection	_	_	O
98	.	_	_	O

99	Postoperatively	_	_	O
100	,	_	_	O
101	body	_	_	O
102	mass	_	_	O
103	index	_	_	O
104	(	_	_	O
105	BMI	_	_	O
106	)	_	_	O
107	and	_	_	O
108	nutritional	_	_	O
109	conditions	_	_	O
110	were	_	_	O
111	measured	_	_	O
112	serially	_	_	O
113	,	_	_	O
114	and	_	_	O
115	QOL	_	_	O
116	and	_	_	O
117	postoperative	_	_	O
118	squalor	_	_	O
119	scores	_	_	O
120	were	_	_	O
121	evaluated	_	_	O
122	at	_	_	O
123	3	_	_	O
124	,	_	_	O
125	12	_	_	O
126	,	_	_	O
127	and	_	_	O
128	60	_	_	O
129	months	_	_	O
130	and	_	_	O
131	compared	_	_	O
132	between	_	_	O
133	the	_	_	O
134	2	_	_	O
135	groups	_	_	O
136	.	_	_	O

137	After	_	_	O
138	removing	_	_	O
139	patients	_	_	O
140	who	_	_	O
141	did	_	_	O
142	not	_	_	O
143	complete	_	_	O
144	the	_	_	O
145	follow-up	_	_	O
146	survey	_	_	O
147	or	_	_	O
148	censured	_	_	O
149	cases	_	_	O
150	,	_	_	O
151	24	_	_	O
152	patients	_	_	O
153	in	_	_	O
154	the	_	_	O
155	RY	_	_	O
156	group	_	_	O
157	and	_	_	O
158	18	_	_	O
159	patients	_	_	O
160	in	_	_	O
161	the	_	_	O
162	INT	_	_	O
163	group	_	_	O
164	were	_	_	O
165	clinically	_	_	O
166	available	_	_	O
167	and	_	_	O
168	their	_	_	O
169	postoperative	_	_	O
170	status	_	_	O
171	was	_	_	O
172	assessed	_	_	O
173	.	_	_	O

174	QOL	_	_	B-Premise
175	scores	_	_	I-Premise
176	were	_	_	I-Premise
177	increased	_	_	I-Premise
178	and	_	_	I-Premise
179	complication	_	_	I-Premise
180	scores	_	_	I-Premise
181	were	_	_	I-Premise
182	improved	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	postoperative	_	_	I-Premise
186	periods	_	_	I-Premise
187	(	_	_	I-Premise
188	P	_	_	I-Premise
189	<	_	_	I-Premise
190	.01	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	Postoperative	_	_	B-Premise
194	BMI	_	_	I-Premise
195	significantly	_	_	I-Premise
196	deteriorated	_	_	I-Premise
197	compared	_	_	I-Premise
198	with	_	_	I-Premise
199	preoperative	_	_	I-Premise
200	BMI	_	_	I-Premise
201	in	_	_	I-Premise
202	each	_	_	I-Premise
203	group	_	_	I-Premise
204	.	_	_	I-Premise

205	The	_	_	B-Premise
206	postoperative	_	_	I-Premise
207	QOL	_	_	I-Premise
208	and	_	_	I-Premise
209	complication	_	_	I-Premise
210	scores	_	_	I-Premise
211	at	_	_	I-Premise
212	60	_	_	I-Premise
213	months	_	_	I-Premise
214	after	_	_	I-Premise
215	surgery	_	_	I-Premise
216	were	_	_	I-Premise
217	significantly	_	_	I-Premise
218	better	_	_	I-Premise
219	than	_	_	I-Premise
220	those	_	_	I-Premise
221	at	_	_	I-Premise
222	3	_	_	I-Premise
223	months	_	_	I-Premise
224	after	_	_	I-Premise
225	surgery	_	_	I-Premise
226	in	_	_	I-Premise
227	each	_	_	I-Premise
228	group	_	_	I-Premise
229	(	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	.01	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	However	_	_	O
236	,	_	_	O
237	there	_	_	B-Premise
238	was	_	_	I-Premise
239	no	_	_	I-Premise
240	significant	_	_	I-Premise
241	difference	_	_	I-Premise
242	of	_	_	I-Premise
243	QOL	_	_	I-Premise
244	scores	_	_	I-Premise
245	and	_	_	I-Premise
246	postoperative	_	_	I-Premise
247	complication	_	_	I-Premise
248	scores	_	_	I-Premise
249	between	_	_	I-Premise
250	the	_	_	I-Premise
251	2	_	_	I-Premise
252	reconstruction	_	_	I-Premise
253	groups	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Premise
256	nutritional	_	_	I-Premise
257	condition	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	INT	_	_	I-Premise
261	group	_	_	I-Premise
262	was	_	_	I-Premise
263	nearly	_	_	I-Premise
264	the	_	_	I-Premise
265	same	_	_	I-Premise
266	as	_	_	I-Premise
267	that	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	RY	_	_	I-Premise
271	group	_	_	I-Premise
272	.	_	_	I-Premise

273	Although	_	_	B-Premise
274	our	_	_	I-Premise
275	patient	_	_	I-Premise
276	sample	_	_	I-Premise
277	was	_	_	I-Premise
278	small	_	_	I-Premise
279	and	_	_	I-Premise
280	patients	_	_	I-Premise
281	who	_	_	I-Premise
282	did	_	_	I-Premise
283	not	_	_	I-Premise
284	complete	_	_	I-Premise
285	the	_	_	I-Premise
286	follow-up	_	_	I-Premise
287	survey	_	_	I-Premise
288	were	_	_	I-Premise
289	present	_	_	I-Premise
290	,	_	_	I-Premise
291	we	_	_	B-Claim
292	could	_	_	I-Claim
293	not	_	_	I-Claim
294	identify	_	_	I-Claim
295	any	_	_	I-Claim
296	clinical	_	_	I-Claim
297	difference	_	_	I-Claim
298	between	_	_	I-Claim
299	INT	_	_	I-Claim
300	and	_	_	I-Claim
301	RY	_	_	I-Claim
302	after	_	_	I-Claim
303	total	_	_	I-Claim
304	gastrectomy	_	_	I-Claim
305	60	_	_	I-Claim
306	months	_	_	I-Claim
307	after	_	_	I-Claim
308	surgery	_	_	I-Claim
309	.	_	_	I-Claim

310	The	_	_	B-Claim
311	safer	_	_	I-Claim
312	and	_	_	I-Claim
313	simpler	_	_	I-Claim
314	RY	_	_	I-Claim
315	method	_	_	I-Claim
316	may	_	_	I-Claim
317	be	_	_	I-Claim
318	a	_	_	I-Claim
319	more	_	_	I-Claim
320	suitable	_	_	I-Claim
321	reconstruction	_	_	I-Claim
322	method	_	_	I-Claim
323	than	_	_	I-Claim
324	INT	_	_	I-Claim
325	after	_	_	I-Claim
326	total	_	_	I-Claim
327	gastrectomy	_	_	I-Claim
328	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	patients	_	_	O
3	with	_	_	O
4	stage	_	_	O
5	I-III	_	_	O
6	non-small	_	_	O
7	cell	_	_	O
8	lung	_	_	O
9	cancer	_	_	O
10	(	_	_	O
11	NSCLC	_	_	O
12	)	_	_	O
13	who	_	_	O
14	are	_	_	O
15	not	_	_	O
16	suitable	_	_	O
17	for	_	_	O
18	curative	_	_	O
19	radical	_	_	O
20	chemoradiation	_	_	O
21	therapy	_	_	O
22	.	_	_	O

23	There	_	_	O
24	are	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	an	_	_	O
28	isolated	_	_	O
29	solitary	_	_	O
30	extracranial	_	_	O
31	metastasis	_	_	O
32	who	_	_	O
33	have	_	_	O
34	improved	_	_	O
35	outcomes	_	_	O
36	compared	_	_	O
37	with	_	_	O
38	those	_	_	O
39	with	_	_	O
40	cranial	_	_	O
41	or	_	_	O
42	multiple	_	_	O
43	metastases	_	_	O
44	.	_	_	O

45	Patients	_	_	O
46	of	_	_	O
47	good	_	_	O
48	performance	_	_	O
49	status	_	_	O
50	receiving	_	_	O
51	moderate	_	_	O
52	dose	_	_	O
53	radiation	_	_	O
54	therapy	_	_	O
55	have	_	_	O
56	improved	_	_	O
57	survival	_	_	O
58	.	_	_	O

59	Two	_	_	O
60	regimens	_	_	O
61	of	_	_	O
62	moderate	_	_	O
63	dose	_	_	O
64	chemoradiation	_	_	O
65	therapy	_	_	O
66	for	_	_	O
67	such	_	_	O
68	patients	_	_	O
69	were	_	_	O
70	compared	_	_	O
71	in	_	_	O
72	a	_	_	O
73	randomized	_	_	O
74	phase	_	_	O
75	II	_	_	O
76	trial	_	_	O
77	.	_	_	O

78	Patients	_	_	O
79	were	_	_	O
80	eligible	_	_	O
81	if	_	_	O
82	they	_	_	O
83	had	_	_	O
84	stage	_	_	O
85	I-IIIB	_	_	O
86	NSCLC	_	_	O
87	,	_	_	O
88	unsuitable	_	_	O
89	for	_	_	O
90	curative	_	_	O
91	therapy	_	_	O
92	,	_	_	O
93	or	_	_	O
94	stage	_	_	O
95	IV	_	_	O
96	with	_	_	O
97	a	_	_	O
98	PET-detected	_	_	O
99	extracranial	_	_	O
100	solitary	_	_	O
101	metastasis	_	_	O
102	.	_	_	O

103	Patients	_	_	O
104	were	_	_	O
105	randomized	_	_	O
106	to	_	_	O
107	the	_	_	O
108	following	_	_	O
109	groups-arm	_	_	O
110	A	_	_	O
111	:	_	_	O
112	40	_	_	O
113	Gy/20	_	_	O
114	fractions/4	_	_	O
115	weeks	_	_	O
116	with	_	_	O
117	concurrent	_	_	O
118	weekly	_	_	O
119	vinorelbine	_	_	O
120	25	_	_	O
121	mg/m	_	_	O
122	+	_	_	O
123	cisplatin	_	_	O
124	20	_	_	O
125	mg/m	_	_	O
126	or	_	_	O
127	arm	_	_	O
128	B	_	_	O
129	:	_	_	O
130	30	_	_	O
131	Gy/15	_	_	O
132	fractions/3	_	_	O
133	weeks	_	_	O
134	with	_	_	O
135	concurrent	_	_	O
136	weekly	_	_	O
137	gemcitabine	_	_	O
138	200	_	_	O
139	mg.	_	_	O
140	Primary	_	_	O
141	end	_	_	O
142	points	_	_	O
143	were	_	_	O
144	feasibility	_	_	O
145	,	_	_	O
146	response	_	_	O
147	rates	_	_	O
148	,	_	_	O
149	and	_	_	O
150	toxicity	_	_	O
151	.	_	_	O

152	Secondary	_	_	O
153	end	_	_	O
154	points	_	_	O
155	were	_	_	O
156	progression-free	_	_	O
157	survival	_	_	O
158	,	_	_	O
159	overall	_	_	O
160	survival	_	_	O
161	,	_	_	O
162	and	_	_	O
163	quality	_	_	O
164	of	_	_	O
165	life	_	_	O
166	.	_	_	O

167	Eighty-four	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	randomized	_	_	O
171	.	_	_	O

172	Compliance	_	_	O
173	was	_	_	O
174	above	_	_	O
175	90	_	_	O
176	%	_	_	O
177	for	_	_	O
178	both	_	_	O
179	arms	_	_	O
180	.	_	_	O

181	The	_	_	B-Premise
182	overall	_	_	I-Premise
183	response	_	_	I-Premise
184	rate	_	_	I-Premise
185	was	_	_	I-Premise
186	51	_	_	I-Premise
187	%	_	_	I-Premise
188	in	_	_	I-Premise
189	arm	_	_	I-Premise
190	A	_	_	I-Premise
191	and	_	_	I-Premise
192	38	_	_	I-Premise
193	%	_	_	I-Premise
194	in	_	_	I-Premise
195	arm	_	_	I-Premise
196	B	_	_	I-Premise
197	(	_	_	I-Premise
198	p	_	_	I-Premise
199	=	_	_	I-Premise
200	0.147	_	_	I-Premise
201	)	_	_	I-Premise
202	.	_	_	I-Premise

203	Grade	_	_	B-Premise
204	3/4	_	_	I-Premise
205	toxicity	_	_	I-Premise
206	in	_	_	I-Premise
207	both	_	_	I-Premise
208	arms	_	_	I-Premise
209	was	_	_	I-Premise
210	acceptable	_	_	I-Premise
211	.	_	_	I-Premise

212	There	_	_	B-Premise
213	was	_	_	I-Premise
214	no	_	_	I-Premise
215	difference	_	_	I-Premise
216	in	_	_	I-Premise
217	median	_	_	I-Premise
218	progression-free	_	_	I-Premise
219	survival	_	_	I-Premise
220	between	_	_	I-Premise
221	the	_	_	I-Premise
222	two	_	_	I-Premise
223	arms	_	_	I-Premise
224	(	_	_	I-Premise
225	5.5	_	_	I-Premise
226	versus	_	_	I-Premise
227	5.0	_	_	I-Premise
228	months	_	_	I-Premise
229	,	_	_	I-Premise
230	p	_	_	I-Premise
231	=	_	_	I-Premise
232	0.19	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	Patients	_	_	B-Premise
236	in	_	_	I-Premise
237	arm	_	_	I-Premise
238	A	_	_	I-Premise
239	had	_	_	I-Premise
240	longer	_	_	I-Premise
241	median	_	_	I-Premise
242	survival	_	_	I-Premise
243	but	_	_	B-Premise
244	this	_	_	I-Premise
245	did	_	_	I-Premise
246	not	_	_	I-Premise
247	reach	_	_	I-Premise
248	statistical	_	_	I-Premise
249	significance	_	_	I-Premise
250	(	_	_	I-Premise
251	13.1	_	_	I-Premise
252	versus	_	_	I-Premise
253	8.3	_	_	I-Premise
254	months	_	_	I-Premise
255	,	_	_	I-Premise
256	p	_	_	I-Premise
257	=	_	_	I-Premise
258	0.25	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	No	_	_	B-Claim
262	difference	_	_	I-Claim
263	in	_	_	I-Claim
264	quality	_	_	I-Claim
265	of	_	_	I-Claim
266	life	_	_	I-Claim
267	was	_	_	I-Claim
268	observed	_	_	I-Claim
269	.	_	_	I-Claim

270	Arm	_	_	O
271	A	_	_	O
272	was	_	_	O
273	chosen	_	_	O
274	for	_	_	O
275	a	_	_	O
276	future	_	_	O
277	phase	_	_	O
278	II	_	_	O
279	comparison	_	_	O
280	with	_	_	O
281	radiation	_	_	B-Claim
282	therapy	_	_	I-Claim
283	alone	_	_	I-Claim
284	as	_	_	I-Claim
285	it	_	_	I-Claim
286	demonstrated	_	_	I-Claim
287	a	_	_	I-Claim
288	response	_	_	I-Claim
289	rate	_	_	I-Claim
290	greater	_	_	I-Claim
291	than	_	_	I-Claim
292	50	_	_	I-Claim
293	%	_	_	I-Claim
294	,	_	_	I-Claim
295	and	_	_	I-Claim
296	data	_	_	I-Claim
297	suggested	_	_	I-Claim
298	that	_	_	I-Claim
299	arm	_	_	I-Claim
300	A	_	_	I-Claim
301	had	_	_	I-Claim
302	superior	_	_	I-Claim
303	survival	_	_	I-Claim
304	to	_	_	I-Claim
305	arm	_	_	I-Claim
306	B	_	_	I-Claim
307	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	determine	_	_	O
7	the	_	_	O
8	effectiveness	_	_	O
9	of	_	_	O
10	a	_	_	O
11	mindfulness-based	_	_	O
12	stress-reduction	_	_	O
13	(	_	_	O
14	MBSR	_	_	O
15	)	_	_	O
16	program	_	_	O
17	on	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	(	_	_	O
22	QOL	_	_	O
23	)	_	_	O
24	and	_	_	O
25	psychosocial	_	_	O
26	outcomes	_	_	O
27	in	_	_	O
28	women	_	_	O
29	with	_	_	O
30	early-stage	_	_	O
31	breast	_	_	O
32	cancer	_	_	O
33	,	_	_	O
34	using	_	_	O
35	a	_	_	O
36	three-arm	_	_	O
37	randomized	_	_	O
38	controlled	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	(	_	_	O
42	RCT	_	_	O
43	)	_	_	O
44	.	_	_	O

45	This	_	_	O
46	RCT	_	_	O
47	consisting	_	_	O
48	of	_	_	O
49	172	_	_	O
50	women	_	_	O
51	,	_	_	O
52	aged	_	_	O
53	20-65	_	_	O
54	with	_	_	O
55	stage	_	_	O
56	I	_	_	O
57	or	_	_	O
58	II	_	_	O
59	breast	_	_	O
60	cancer	_	_	O
61	consisted	_	_	O
62	of	_	_	O
63	the	_	_	O
64	8-week	_	_	O
65	MBSR	_	_	O
66	,	_	_	O
67	which	_	_	O
68	was	_	_	O
69	compared	_	_	O
70	to	_	_	O
71	a	_	_	O
72	nutrition	_	_	O
73	education	_	_	O
74	program	_	_	O
75	(	_	_	O
76	NEP	_	_	O
77	)	_	_	O
78	and	_	_	O
79	usual	_	_	O
80	supportive	_	_	O
81	care	_	_	O
82	(	_	_	O
83	UC	_	_	O
84	)	_	_	O
85	.	_	_	O

86	Follow-up	_	_	O
87	was	_	_	O
88	performed	_	_	O
89	at	_	_	O
90	three	_	_	O
91	post-intervention	_	_	O
92	points	_	_	O
93	:	_	_	O
94	4	_	_	O
95	months	_	_	O
96	,	_	_	O
97	1	_	_	O
98	,	_	_	O
99	and	_	_	O
100	2	_	_	O
101	years	_	_	O
102	.	_	_	O

103	Standardized	_	_	O
104	,	_	_	O
105	validated	_	_	O
106	self-administered	_	_	O
107	questionnaires	_	_	O
108	were	_	_	O
109	adopted	_	_	O
110	to	_	_	O
111	assess	_	_	O
112	psychosocial	_	_	O
113	variables	_	_	O
114	.	_	_	O

115	Statistical	_	_	O
116	analysis	_	_	O
117	included	_	_	O
118	descriptive	_	_	O
119	and	_	_	O
120	regression	_	_	O
121	analyses	_	_	O
122	incorporating	_	_	O
123	both	_	_	O
124	intention-to-treat	_	_	O
125	and	_	_	O
126	post	_	_	O
127	hoc	_	_	O
128	multivariable	_	_	O
129	approaches	_	_	O
130	of	_	_	O
131	the	_	_	O
132	163	_	_	O
133	women	_	_	O
134	with	_	_	O
135	complete	_	_	O
136	data	_	_	O
137	at	_	_	O
138	baseline	_	_	O
139	,	_	_	O
140	those	_	_	O
141	who	_	_	O
142	were	_	_	O
143	randomized	_	_	O
144	to	_	_	O
145	MBSR	_	_	O
146	experienced	_	_	O
147	a	_	_	O
148	significant	_	_	O
149	improvement	_	_	O
150	in	_	_	O
151	the	_	_	O
152	primary	_	_	O
153	measures	_	_	O
154	of	_	_	O
155	QOL	_	_	O
156	and	_	_	O
157	coping	_	_	O
158	outcomes	_	_	O
159	compared	_	_	O
160	to	_	_	O
161	the	_	_	O
162	NEP	_	_	O
163	,	_	_	O
164	UC	_	_	O
165	,	_	_	O
166	or	_	_	O
167	both	_	_	O
168	,	_	_	O
169	including	_	_	O
170	the	_	_	O
171	spirituality	_	_	O
172	subscale	_	_	O
173	of	_	_	O
174	the	_	_	O
175	FACT-B	_	_	O
176	as	_	_	O
177	well	_	_	O
178	as	_	_	O
179	dealing	_	_	O
180	with	_	_	O
181	illness	_	_	O
182	scale	_	_	O
183	increases	_	_	O
184	in	_	_	O
185	active	_	_	O
186	behavioral	_	_	O
187	coping	_	_	O
188	and	_	_	O
189	active	_	_	O
190	cognitive	_	_	O
191	coping	_	_	O
192	.	_	_	O

193	Secondary	_	_	B-Premise
194	outcome	_	_	I-Premise
195	improvements	_	_	I-Premise
196	resulting	_	_	I-Premise
197	in	_	_	I-Premise
198	significant	_	_	I-Premise
199	between-group	_	_	I-Premise
200	contrasts	_	_	I-Premise
201	favoring	_	_	I-Premise
202	the	_	_	I-Premise
203	MBSR	_	_	I-Premise
204	group	_	_	I-Premise
205	at	_	_	I-Premise
206	4	_	_	I-Premise
207	months	_	_	I-Premise
208	included	_	_	I-Premise
209	meaningfulness	_	_	I-Premise
210	,	_	_	I-Premise
211	depression	_	_	I-Premise
212	,	_	_	I-Premise
213	paranoid	_	_	I-Premise
214	ideation	_	_	I-Premise
215	,	_	_	I-Premise
216	hostility	_	_	I-Premise
217	,	_	_	I-Premise
218	anxiety	_	_	I-Premise
219	,	_	_	I-Premise
220	unhappiness	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	emotional	_	_	I-Premise
224	control	_	_	I-Premise
225	.	_	_	I-Premise

226	Results	_	_	B-Premise
227	tended	_	_	I-Premise
228	to	_	_	I-Premise
229	decline	_	_	I-Premise
230	at	_	_	I-Premise
231	12	_	_	I-Premise
232	months	_	_	I-Premise
233	and	_	_	I-Premise
234	even	_	_	I-Premise
235	more	_	_	I-Premise
236	at	_	_	I-Premise
237	24	_	_	I-Premise
238	months	_	_	I-Premise
239	,	_	_	I-Premise
240	though	_	_	I-Premise
241	at	_	_	I-Premise
242	all	_	_	I-Premise
243	times	_	_	I-Premise
244	,	_	_	I-Premise
245	they	_	_	I-Premise
246	were	_	_	I-Premise
247	as	_	_	I-Premise
248	robust	_	_	I-Premise
249	in	_	_	I-Premise
250	women	_	_	I-Premise
251	with	_	_	I-Premise
252	lower	_	_	I-Premise
253	expectation	_	_	I-Premise
254	of	_	_	I-Premise
255	effect	_	_	I-Premise
256	as	_	_	I-Premise
257	in	_	_	I-Premise
258	those	_	_	I-Premise
259	with	_	_	I-Premise
260	higher	_	_	I-Premise
261	expectation	_	_	I-Premise
262	.	_	_	I-Premise

263	The	_	_	B-Claim
264	MBSR	_	_	I-Claim
265	intervention	_	_	I-Claim
266	appears	_	_	I-Claim
267	to	_	_	I-Claim
268	benefit	_	_	I-Claim
269	psychosocial	_	_	I-Claim
270	adjustment	_	_	I-Claim
271	in	_	_	I-Claim
272	cancer	_	_	I-Claim
273	patients	_	_	I-Claim
274	,	_	_	I-Claim
275	over	_	_	I-Claim
276	and	_	_	I-Claim
277	above	_	_	I-Claim
278	the	_	_	I-Claim
279	effects	_	_	I-Claim
280	of	_	_	I-Claim
281	usual	_	_	I-Claim
282	care	_	_	I-Claim
283	or	_	_	I-Claim
284	a	_	_	I-Claim
285	credible	_	_	I-Claim
286	control	_	_	I-Claim
287	condition	_	_	I-Claim
288	.	_	_	I-Claim

289	The	_	_	B-Claim
290	universality	_	_	I-Claim
291	of	_	_	I-Claim
292	effects	_	_	I-Claim
293	across	_	_	I-Claim
294	levels	_	_	I-Claim
295	of	_	_	I-Claim
296	expectation	_	_	I-Claim
297	indicates	_	_	I-Claim
298	a	_	_	I-Claim
299	potential	_	_	I-Claim
300	to	_	_	I-Claim
301	utilize	_	_	I-Claim
302	this	_	_	I-Claim
303	stress	_	_	I-Claim
304	reduction	_	_	I-Claim
305	approach	_	_	I-Claim
306	as	_	_	I-Claim
307	complementary	_	_	I-Claim
308	therapy	_	_	I-Claim
309	in	_	_	I-Claim
310	oncologic	_	_	I-Claim
311	practice	_	_	I-Claim
312	.	_	_	I-Claim


0	The	_	_	O
1	efficacy	_	_	O
2	of	_	_	O
3	a	_	_	O
4	home-based	_	_	O
5	physical	_	_	O
6	activity	_	_	O
7	(	_	_	O
8	PA	_	_	O
9	)	_	_	O
10	intervention	_	_	O
11	for	_	_	O
12	colorectal	_	_	O
13	cancer	_	_	O
14	patients	_	_	O
15	versus	_	_	O
16	contact	_	_	O
17	control	_	_	O
18	was	_	_	O
19	evaluated	_	_	O
20	in	_	_	O
21	a	_	_	O
22	randomized	_	_	O
23	controlled	_	_	O
24	trial	_	_	O
25	.	_	_	O

26	Forty-six	_	_	O
27	patients	_	_	O
28	(	_	_	O
29	mean	_	_	O
30	age	_	_	O
31	=	_	_	O
32	57.3	_	_	O
33	years	_	_	O
34	[	_	_	O
35	SD	_	_	O
36	=	_	_	O
37	9.7	_	_	O
38	]	_	_	O
39	,	_	_	O
40	57	_	_	O
41	%	_	_	O
42	female	_	_	O
43	,	_	_	O
44	mean	_	_	O
45	=	_	_	O
46	2.99	_	_	O
47	years	_	_	O
48	post-diagnosis	_	_	O
49	[	_	_	O
50	SD	_	_	O
51	=	_	_	O
52	1.64	_	_	O
53	]	_	_	O
54	)	_	_	O
55	who	_	_	O
56	had	_	_	O
57	completed	_	_	O
58	treatment	_	_	O
59	for	_	_	O
60	stages	_	_	O
61	1-3	_	_	O
62	colorectal	_	_	O
63	cancer	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	telephone	_	_	O
68	counseling	_	_	O
69	to	_	_	O
70	support	_	_	O
71	PA	_	_	O
72	(	_	_	O
73	PA	_	_	O
74	group	_	_	O
75	,	_	_	O
76	n	_	_	O
77	=	_	_	O
78	20	_	_	O
79	)	_	_	O
80	or	_	_	O
81	contact	_	_	O
82	control	_	_	O
83	(	_	_	O
84	control	_	_	O
85	group	_	_	O
86	,	_	_	O
87	n	_	_	O
88	=	_	_	O
89	26	_	_	O
90	)	_	_	O
91	.	_	_	O

92	PA	_	_	O
93	group	_	_	O
94	participants	_	_	O
95	received	_	_	O
96	3	_	_	O
97	months	_	_	O
98	of	_	_	O
99	PA	_	_	O
100	counseling	_	_	O
101	(	_	_	O
102	based	_	_	O
103	on	_	_	O
104	the	_	_	O
105	transtheoretical	_	_	O
106	model	_	_	O
107	and	_	_	O
108	the	_	_	O
109	social	_	_	O
110	cognitive	_	_	O
111	theory	_	_	O
112	)	_	_	O
113	delivered	_	_	O
114	via	_	_	O
115	telephone	_	_	O
116	,	_	_	O
117	as	_	_	O
118	well	_	_	O
119	as	_	_	O
120	weekly	_	_	O
121	PA	_	_	O
122	tip	_	_	O
123	sheets	_	_	O
124	.	_	_	O

125	Assessments	_	_	O
126	of	_	_	O
127	PA	_	_	O
128	(	_	_	O
129	Seven-day	_	_	O
130	Physical	_	_	O
131	Activity	_	_	O
132	Recall	_	_	O
133	[	_	_	O
134	7-day	_	_	O
135	PAR	_	_	O
136	]	_	_	O
137	and	_	_	O
138	Community	_	_	O
139	Healthy	_	_	O
140	Activities	_	_	O
141	Model	_	_	O
142	Program	_	_	O
143	for	_	_	O
144	Seniors	_	_	O
145	[	_	_	O
146	CHAMPS	_	_	O
147	]	_	_	O
148	)	_	_	O
149	,	_	_	O
150	submaximal	_	_	O
151	aerobic	_	_	O
152	fitness	_	_	O
153	(	_	_	O
154	Treadwalk	_	_	O
155	test	_	_	O
156	)	_	_	O
157	,	_	_	O
158	motivational	_	_	O
159	readiness	_	_	O
160	for	_	_	O
161	PA	_	_	O
162	,	_	_	O
163	and	_	_	O
164	psychosocial	_	_	O
165	outcomes	_	_	O
166	were	_	_	O
167	conducted	_	_	O
168	at	_	_	O
169	baseline	_	_	O
170	,	_	_	O
171	3	_	_	O
172	,	_	_	O
173	6	_	_	O
174	,	_	_	O
175	and	_	_	O
176	12	_	_	O
177	months	_	_	O
178	post-baseline	_	_	O
179	.	_	_	O

180	Objective	_	_	O
181	accelerometer	_	_	O
182	data	_	_	O
183	were	_	_	O
184	collected	_	_	O
185	at	_	_	O
186	the	_	_	O
187	same	_	_	O
188	time	_	_	O
189	points	_	_	O
190	.	_	_	O

191	The	_	_	B-Premise
192	PA	_	_	I-Premise
193	group	_	_	I-Premise
194	reported	_	_	I-Premise
195	significant	_	_	I-Premise
196	increases	_	_	I-Premise
197	in	_	_	I-Premise
198	minutes	_	_	I-Premise
199	of	_	_	I-Premise
200	PA	_	_	I-Premise
201	at	_	_	I-Premise
202	3	_	_	I-Premise
203	months	_	_	I-Premise
204	(	_	_	I-Premise
205	7-day	_	_	I-Premise
206	PAR	_	_	I-Premise
207	)	_	_	I-Premise
208	and	_	_	I-Premise
209	caloric	_	_	I-Premise
210	expenditure	_	_	I-Premise
211	(	_	_	I-Premise
212	CHAMPS	_	_	I-Premise
213	)	_	_	I-Premise
214	compared	_	_	I-Premise
215	with	_	_	I-Premise
216	the	_	_	I-Premise
217	control	_	_	I-Premise
218	group	_	_	I-Premise
219	,	_	_	I-Premise
220	but	_	_	B-Premise
221	the	_	_	I-Premise
222	group	_	_	I-Premise
223	differences	_	_	I-Premise
224	were	_	_	I-Premise
225	attenuated	_	_	I-Premise
226	over	_	_	I-Premise
227	time	_	_	I-Premise
228	.	_	_	I-Premise

229	The	_	_	B-Premise
230	PA	_	_	I-Premise
231	group	_	_	I-Premise
232	showed	_	_	I-Premise
233	significant	_	_	I-Premise
234	improvements	_	_	I-Premise
235	in	_	_	I-Premise
236	fitness	_	_	I-Premise
237	at	_	_	I-Premise
238	3	_	_	I-Premise
239	,	_	_	I-Premise
240	6	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	12	_	_	I-Premise
244	months	_	_	I-Premise
245	versus	_	_	I-Premise
246	the	_	_	I-Premise
247	control	_	_	I-Premise
248	group	_	_	I-Premise
249	.	_	_	I-Premise

250	Improvements	_	_	B-Premise
251	in	_	_	I-Premise
252	motivational	_	_	I-Premise
253	readiness	_	_	I-Premise
254	for	_	_	I-Premise
255	PA	_	_	I-Premise
256	were	_	_	I-Premise
257	reported	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	PA	_	_	I-Premise
261	group	_	_	I-Premise
262	only	_	_	I-Premise
263	at	_	_	I-Premise
264	3	_	_	I-Premise
265	months	_	_	I-Premise
266	.	_	_	I-Premise

267	No	_	_	B-Premise
268	significant	_	_	I-Premise
269	group	_	_	I-Premise
270	differences	_	_	I-Premise
271	were	_	_	I-Premise
272	found	_	_	I-Premise
273	for	_	_	I-Premise
274	fatigue	_	_	I-Premise
275	,	_	_	I-Premise
276	self-reported	_	_	I-Premise
277	physical	_	_	I-Premise
278	functioning	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	quality	_	_	I-Premise
282	of	_	_	I-Premise
283	life	_	_	I-Premise
284	at	_	_	I-Premise
285	3	_	_	I-Premise
286	,	_	_	I-Premise
287	6	_	_	I-Premise
288	,	_	_	I-Premise
289	and	_	_	I-Premise
290	12	_	_	I-Premise
291	months	_	_	I-Premise
292	.	_	_	I-Premise

293	A	_	_	B-Claim
294	home-based	_	_	I-Claim
295	intervention	_	_	I-Claim
296	improved	_	_	I-Claim
297	survivors	_	_	I-Claim
298	'	_	_	I-Claim
299	PA	_	_	I-Claim
300	and	_	_	I-Claim
301	motivational	_	_	I-Claim
302	readiness	_	_	I-Claim
303	at	_	_	I-Claim
304	3	_	_	I-Claim
305	months	_	_	I-Claim
306	and	_	_	I-Claim
307	increased	_	_	I-Claim
308	submaximal	_	_	I-Claim
309	aerobic	_	_	I-Claim
310	fitness	_	_	I-Claim
311	at	_	_	I-Claim
312	3	_	_	I-Claim
313	,	_	_	I-Claim
314	6	_	_	I-Claim
315	,	_	_	I-Claim
316	and	_	_	I-Claim
317	12	_	_	I-Claim
318	months	_	_	I-Claim
319	.	_	_	I-Claim


0	Somatostatin	_	_	O
1	analogs	_	_	O
2	act	_	_	O
3	directly	_	_	O
4	on	_	_	O
5	breast	_	_	O
6	cancer	_	_	O
7	cells	_	_	O
8	and	_	_	O
9	indirectly	_	_	O
10	on	_	_	O
11	insulin	_	_	O
12	and	_	_	O
13	insulin-like	_	_	O
14	growth	_	_	O
15	factor	_	_	O
16	1	_	_	O
17	(	_	_	O
18	IGF-1	_	_	O
19	)	_	_	O
20	levels	_	_	O
21	.	_	_	O

22	This	_	_	O
23	trial	_	_	O
24	was	_	_	O
25	undertaken	_	_	O
26	to	_	_	O
27	assess	_	_	O
28	whether	_	_	O
29	octreotide	_	_	B-Claim
30	would	_	_	I-Claim
31	lower	_	_	I-Claim
32	insulin	_	_	I-Claim
33	and	_	_	I-Claim
34	IGF-1	_	_	I-Claim
35	levels	_	_	I-Claim
36	and	_	_	I-Claim
37	reduce	_	_	I-Claim
38	risk	_	_	I-Claim
39	of	_	_	I-Claim
40	breast	_	_	I-Claim
41	cancer	_	_	I-Claim
42	recurrence	_	_	I-Claim
43	.	_	_	I-Claim

44	The	_	_	O
45	NCIC	_	_	O
46	CTG	_	_	O
47	MA.14	_	_	O
48	(	_	_	O
49	NCIC	_	_	O
50	Clinical	_	_	O
51	Trials	_	_	O
52	Group	_	_	O
53	MA.14	_	_	O
54	)	_	_	O
55	trial	_	_	O
56	randomly	_	_	O
57	assigned	_	_	O
58	postmenopausal	_	_	O
59	women	_	_	O
60	to	_	_	O
61	5	_	_	O
62	years	_	_	O
63	of	_	_	O
64	tamoxifen	_	_	O
65	20	_	_	O
66	mg	_	_	O
67	daily	_	_	O
68	(	_	_	O
69	TAM	_	_	O
70	)	_	_	O
71	or	_	_	O
72	TAM	_	_	O
73	plus	_	_	O
74	2	_	_	O
75	years	_	_	O
76	of	_	_	O
77	octreotide	_	_	O
78	90	_	_	O
79	mg	_	_	O
80	depot	_	_	O
81	intramuscular	_	_	O
82	injections	_	_	O
83	monthly	_	_	O
84	(	_	_	O
85	TAM-OCT	_	_	O
86	)	_	_	O
87	as	_	_	O
88	adjuvant	_	_	O
89	therapy	_	_	O
90	.	_	_	O

91	The	_	_	O
92	primary	_	_	O
93	end	_	_	O
94	point	_	_	O
95	was	_	_	O
96	event-free	_	_	O
97	survival	_	_	O
98	(	_	_	O
99	EFS	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Secondary	_	_	O
103	end	_	_	O
104	points	_	_	O
105	were	_	_	O
106	relapse-free	_	_	O
107	survival	_	_	O
108	(	_	_	O
109	RFS	_	_	O
110	)	_	_	O
111	,	_	_	O
112	overall	_	_	O
113	survival	_	_	O
114	(	_	_	O
115	OS	_	_	O
116	)	_	_	O
117	,	_	_	O
118	toxicity	_	_	O
119	,	_	_	O
120	and	_	_	O
121	effects	_	_	O
122	of	_	_	O
123	treatment	_	_	O
124	on	_	_	O
125	IGF	_	_	O
126	physiology	_	_	O
127	.	_	_	O

128	Among	_	_	O
129	667	_	_	O
130	women	_	_	O
131	with	_	_	O
132	a	_	_	O
133	median	_	_	O
134	follow-up	_	_	O
135	of	_	_	O
136	7.9	_	_	O
137	years	_	_	O
138	,	_	_	O
139	220	_	_	O
140	events	_	_	O
141	occurred-108	_	_	O
142	with	_	_	O
143	TAM-OCT	_	_	O
144	and	_	_	O
145	112	_	_	O
146	with	_	_	O
147	TAM	_	_	O
148	.	_	_	O

149	Adjusted	_	_	B-Premise
150	hazard	_	_	I-Premise
151	ratios	_	_	I-Premise
152	(	_	_	I-Premise
153	HRs	_	_	I-Premise
154	;	_	_	I-Premise
155	TAM-OCT	_	_	I-Premise
156	to	_	_	I-Premise
157	TAM	_	_	I-Premise
158	)	_	_	I-Premise
159	were	_	_	I-Premise
160	0.93	_	_	I-Premise
161	for	_	_	I-Premise
162	EFS	_	_	I-Premise
163	(	_	_	I-Premise
164	95	_	_	I-Premise
165	%	_	_	I-Premise
166	CI	_	_	I-Premise
167	,	_	_	I-Premise
168	0.71	_	_	I-Premise
169	to	_	_	I-Premise
170	1.22	_	_	I-Premise
171	;	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.62	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	0.84	_	_	I-Premise
178	for	_	_	I-Premise
179	RFS	_	_	I-Premise
180	(	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	,	_	_	I-Premise
185	0.59	_	_	I-Premise
186	to	_	_	I-Premise
187	1.18	_	_	I-Premise
188	;	_	_	I-Premise
189	P	_	_	I-Premise
190	=	_	_	I-Premise
191	.31	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	and	_	_	I-Premise
195	0.97	_	_	I-Premise
196	for	_	_	I-Premise
197	OS	_	_	I-Premise
198	(	_	_	I-Premise
199	95	_	_	I-Premise
200	%	_	_	I-Premise
201	CI	_	_	I-Premise
202	,	_	_	I-Premise
203	0.69	_	_	I-Premise
204	to	_	_	I-Premise
205	1.37	_	_	I-Premise
206	;	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	.86	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	Among	_	_	B-Premise
213	patients	_	_	I-Premise
214	with	_	_	I-Premise
215	normal	_	_	I-Premise
216	baseline	_	_	I-Premise
217	gallbladder	_	_	I-Premise
218	imaging	_	_	I-Premise
219	,	_	_	I-Premise
220	cholecystectomy	_	_	I-Premise
221	was	_	_	I-Premise
222	required	_	_	I-Premise
223	in	_	_	I-Premise
224	23.0	_	_	I-Premise
225	%	_	_	I-Premise
226	of	_	_	I-Premise
227	those	_	_	I-Premise
228	receiving	_	_	I-Premise
229	TAM-OCT	_	_	I-Premise
230	but	_	_	I-Premise
231	in	_	_	I-Premise
232	only	_	_	I-Premise
233	1.4	_	_	I-Premise
234	%	_	_	I-Premise
235	of	_	_	I-Premise
236	those	_	_	I-Premise
237	receiving	_	_	I-Premise
238	TAM	_	_	I-Premise
239	(	_	_	I-Premise
240	P	_	_	I-Premise
241	<	_	_	I-Premise
242	.001	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	At	_	_	B-Premise
246	4	_	_	I-Premise
247	months	_	_	I-Premise
248	,	_	_	I-Premise
249	TAM-OCT	_	_	I-Premise
250	had	_	_	I-Premise
251	significantly	_	_	I-Premise
252	(	_	_	I-Premise
253	P	_	_	I-Premise
254	<	_	_	I-Premise
255	.001	_	_	I-Premise
256	)	_	_	I-Premise
257	lowered	_	_	I-Premise
258	IGF-1	_	_	I-Premise
259	,	_	_	I-Premise
260	IGF	_	_	I-Premise
261	binding	_	_	I-Premise
262	protein	_	_	I-Premise
263	3	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	C-peptide	_	_	I-Premise
267	levels	_	_	I-Premise
268	.	_	_	I-Premise

269	Older	_	_	B-Premise
270	age	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	.02	_	_	I-Premise
275	)	_	_	I-Premise
276	,	_	_	I-Premise
277	tumor	_	_	I-Premise
278	size	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	=	_	_	I-Premise
282	.001	_	_	I-Premise
283	)	_	_	I-Premise
284	,	_	_	I-Premise
285	nodal	_	_	I-Premise
286	status	_	_	I-Premise
287	(	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.01	_	_	I-Premise
291	)	_	_	I-Premise
292	,	_	_	I-Premise
293	high	_	_	I-Premise
294	C-peptide	_	_	I-Premise
295	levels	_	_	I-Premise
296	(	_	_	I-Premise
297	P	_	_	I-Premise
298	<	_	_	I-Premise
299	.001	_	_	I-Premise
300	)	_	_	I-Premise
301	,	_	_	I-Premise
302	and	_	_	I-Premise
303	higher	_	_	I-Premise
304	body	_	_	I-Premise
305	mass	_	_	I-Premise
306	index	_	_	I-Premise
307	(	_	_	I-Premise
308	BMI	_	_	I-Premise
309	)	_	_	I-Premise
310	in	_	_	I-Premise
311	models	_	_	I-Premise
312	excluding	_	_	I-Premise
313	C-peptide	_	_	I-Premise
314	(	_	_	I-Premise
315	P	_	_	I-Premise
316	<	_	_	I-Premise
317	.001	_	_	I-Premise
318	)	_	_	I-Premise
319	were	_	_	I-Premise
320	associated	_	_	I-Premise
321	with	_	_	I-Premise
322	poorer	_	_	I-Premise
323	EFS	_	_	I-Premise
324	in	_	_	I-Premise
325	multivariate	_	_	I-Premise
326	analysis	_	_	I-Premise
327	.	_	_	I-Premise

328	Octreotide-related	_	_	O
329	changes	_	_	O
330	in	_	_	O
331	circulating	_	_	O
332	IGF-1	_	_	O
333	and	_	_	O
334	C-peptide	_	_	O
335	levels	_	_	O
336	were	_	_	O
337	statistically	_	_	O
338	significant	_	_	O
339	.	_	_	O

340	Octreotide	_	_	B-Claim
341	did	_	_	I-Claim
342	not	_	_	I-Claim
343	add	_	_	I-Claim
344	significant	_	_	I-Claim
345	clinical	_	_	I-Claim
346	benefit	_	_	I-Claim
347	.	_	_	I-Claim

348	High	_	_	B-Claim
349	C-peptide	_	_	I-Claim
350	levels	_	_	I-Claim
351	(	_	_	I-Claim
352	surrogate	_	_	I-Claim
353	for	_	_	I-Claim
354	insulin	_	_	I-Claim
355	secretion	_	_	I-Claim
356	rate	_	_	I-Claim
357	)	_	_	I-Claim
358	and	_	_	I-Claim
359	high	_	_	I-Claim
360	BMI	_	_	I-Claim
361	were	_	_	I-Claim
362	associated	_	_	I-Claim
363	with	_	_	I-Claim
364	poor	_	_	I-Claim
365	outcome	_	_	I-Claim
366	.	_	_	I-Claim


0	﻿	_	_	O
1	To	_	_	O
2	verify	_	_	O
3	the	_	_	O
4	safety	_	_	O
5	and	_	_	O
6	efficacy	_	_	O
7	of	_	_	O
8	Ologen	_	_	O
9	(	_	_	O
10	OLO	_	_	O
11	)	_	_	O
12	implant	_	_	O
13	as	_	_	O
14	adjuvant	_	_	O
15	compared	_	_	O
16	with	_	_	O
17	low-dosage	_	_	O
18	mitomycin-C	_	_	O
19	(	_	_	O
20	MMC	_	_	O
21	)	_	_	O
22	in	_	_	O
23	trabeculectomy	_	_	O
24	.	_	_	O

25	This	_	_	O
26	was	_	_	O
27	a	_	_	O
28	prospective	_	_	O
29	randomized	_	_	O
30	clinical	_	_	O
31	trial	_	_	O
32	with	_	_	O
33	a	_	_	O
34	24-month	_	_	O
35	follow-up	_	_	O
36	.	_	_	O

37	Forty	_	_	O
38	glaucoma	_	_	O
39	patients	_	_	O
40	(	_	_	O
41	40	_	_	O
42	eyes	_	_	O
43	)	_	_	O
44	were	_	_	O
45	assigned	_	_	O
46	to	_	_	O
47	trabeculectomy	_	_	O
48	with	_	_	O
49	MMC	_	_	O
50	or	_	_	O
51	OLO	_	_	O
52	.	_	_	O

53	Primary	_	_	O
54	outcome	_	_	O
55	includes	_	_	O
56	target	_	_	O
57	IOP	_	_	O
58	at	_	_	O
59	≤21	_	_	O
60	,	_	_	O
61	≤17	_	_	O
62	,	_	_	O
63	and	_	_	O
64	≤15	_	_	O
65	mmHg	_	_	O
66	;	_	_	O
67	complete	_	_	O
68	(	_	_	O
69	target	_	_	O
70	IOP	_	_	O
71	without	_	_	O
72	medications	_	_	O
73	)	_	_	O
74	,	_	_	O
75	and	_	_	O
76	qualified	_	_	O
77	success	_	_	O
78	(	_	_	O
79	target	_	_	O
80	IOP	_	_	O
81	regardless	_	_	O
82	of	_	_	O
83	medications	_	_	O
84	)	_	_	O
85	.	_	_	O

86	Secondary	_	_	O
87	outcomes	_	_	O
88	include	_	_	O
89	bleb	_	_	O
90	evaluation	_	_	O
91	,	_	_	O
92	according	_	_	O
93	to	_	_	O
94	Moorfields	_	_	O
95	Bleb	_	_	O
96	Grading	_	_	O
97	System	_	_	O
98	(	_	_	O
99	MBGS	_	_	O
100	)	_	_	O
101	;	_	_	O
102	spectral	_	_	O
103	domain	_	_	O
104	optical	_	_	O
105	coherence	_	_	O
106	tomography	_	_	O
107	(	_	_	O
108	SD-OCT	_	_	O
109	)	_	_	O
110	examination	_	_	O
111	;	_	_	O
112	number	_	_	O
113	of	_	_	O
114	glaucoma	_	_	O
115	medications	_	_	O
116	;	_	_	O
117	and	_	_	O
118	frequency	_	_	O
119	of	_	_	O
120	postoperative	_	_	O
121	adjunctive	_	_	O
122	procedures	_	_	O
123	and	_	_	O
124	complications	_	_	O
125	.	_	_	O

126	The	_	_	O
127	mean	_	_	O
128	preoperative	_	_	O
129	IOP	_	_	O
130	was	_	_	O
131	26.5	_	_	O
132	(	_	_	O
133	±5.2	_	_	O
134	)	_	_	O
135	in	_	_	O
136	MMC	_	_	O
137	and	_	_	O
138	27.3	_	_	O
139	(	_	_	O
140	±6.0	_	_	O
141	)	_	_	O
142	in	_	_	O
143	OLO	_	_	O
144	eyes	_	_	O
145	,	_	_	O
146	without	_	_	O
147	statistical	_	_	O
148	significance	_	_	O
149	.	_	_	O

150	One-day	_	_	B-Premise
151	postoperatively	_	_	I-Premise
152	,	_	_	I-Premise
153	the	_	_	I-Premise
154	IOP	_	_	I-Premise
155	dropped	_	_	I-Premise
156	to	_	_	I-Premise
157	5.2	_	_	I-Premise
158	(	_	_	I-Premise
159	±3.5	_	_	I-Premise
160	)	_	_	I-Premise
161	and	_	_	I-Premise
162	9.2	_	_	I-Premise
163	(	_	_	I-Premise
164	±5.5	_	_	I-Premise
165	)	_	_	I-Premise
166	mm	_	_	I-Premise
167	Hg	_	_	I-Premise
168	,	_	_	I-Premise
169	respectively	_	_	I-Premise
170	(	_	_	I-Premise
171	P=0.009	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	The	_	_	B-Premise
175	IOP	_	_	I-Premise
176	reduction	_	_	I-Premise
177	was	_	_	I-Premise
178	significant	_	_	I-Premise
179	at	_	_	I-Premise
180	end	_	_	I-Premise
181	point	_	_	I-Premise
182	in	_	_	I-Premise
183	all	_	_	I-Premise
184	groups	_	_	I-Premise
185	(	_	_	I-Premise
186	P=0.01	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	with	_	_	I-Premise
190	a	_	_	I-Premise
191	mean	_	_	I-Premise
192	IOP	_	_	I-Premise
193	of	_	_	I-Premise
194	16.0	_	_	I-Premise
195	(	_	_	I-Premise
196	±2.9	_	_	I-Premise
197	)	_	_	I-Premise
198	and	_	_	I-Premise
199	16.5	_	_	I-Premise
200	(	_	_	I-Premise
201	±2.1	_	_	I-Premise
202	)	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	in	_	_	I-Premise
206	MMC	_	_	I-Premise
207	and	_	_	I-Premise
208	OLO	_	_	I-Premise
209	,	_	_	I-Premise
210	respectively	_	_	I-Premise
211	.	_	_	I-Premise

212	The	_	_	B-Premise
213	rates	_	_	I-Premise
214	and	_	_	I-Premise
215	Kaplan-Meier	_	_	I-Premise
216	curves	_	_	I-Premise
217	did	_	_	I-Premise
218	not	_	_	I-Premise
219	differ	_	_	I-Premise
220	for	_	_	I-Premise
221	both	_	_	I-Premise
222	complete	_	_	I-Premise
223	and	_	_	I-Premise
224	qualified	_	_	I-Premise
225	success	_	_	I-Premise
226	at	_	_	I-Premise
227	any	_	_	I-Premise
228	target	_	_	I-Premise
229	IOP	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	bleb	_	_	I-Premise
233	height	_	_	I-Premise
234	in	_	_	I-Premise
235	OLO	_	_	I-Premise
236	group	_	_	I-Premise
237	was	_	_	I-Premise
238	higher	_	_	I-Premise
239	than	_	_	I-Premise
240	MMC	_	_	I-Premise
241	one	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	0.05	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	SD-OCT	_	_	B-Premise
249	analysis	_	_	I-Premise
250	of	_	_	I-Premise
251	successful/unsuccessful	_	_	I-Premise
252	bleb	_	_	I-Premise
253	in	_	_	I-Premise
254	patients	_	_	I-Premise
255	with	_	_	I-Premise
256	or	_	_	I-Premise
257	without	_	_	I-Premise
258	complete	_	_	I-Premise
259	success	_	_	I-Premise
260	at	_	_	I-Premise
261	IOP	_	_	I-Premise
262	=17	_	_	I-Premise
263	mm	_	_	I-Premise
264	Hg	_	_	I-Premise
265	indicated	_	_	I-Premise
266	a	_	_	I-Premise
267	sensitivity	_	_	I-Premise
268	of	_	_	I-Premise
269	83	_	_	I-Premise
270	%	_	_	I-Premise
271	and	_	_	I-Premise
272	73	_	_	I-Premise
273	%	_	_	I-Premise
274	and	_	_	I-Premise
275	a	_	_	I-Premise
276	specificity	_	_	I-Premise
277	of	_	_	I-Premise
278	75	_	_	I-Premise
279	%	_	_	I-Premise
280	and	_	_	I-Premise
281	67	_	_	I-Premise
282	%	_	_	I-Premise
283	,	_	_	I-Premise
284	respectively	_	_	I-Premise
285	,	_	_	I-Premise
286	for	_	_	I-Premise
287	MMC	_	_	I-Premise
288	and	_	_	I-Premise
289	OLO	_	_	I-Premise
290	groups	_	_	I-Premise
291	.	_	_	I-Premise

292	No	_	_	B-Premise
293	adverse	_	_	I-Premise
294	reaction	_	_	I-Premise
295	to	_	_	I-Premise
296	OLO	_	_	I-Premise
297	was	_	_	I-Premise
298	noted	_	_	I-Premise
299	.	_	_	I-Premise

300	Our	_	_	B-Claim
301	results	_	_	I-Claim
302	suggest	_	_	I-Claim
303	that	_	_	I-Claim
304	OLO	_	_	I-Claim
305	implant	_	_	I-Claim
306	could	_	_	I-Claim
307	be	_	_	I-Claim
308	a	_	_	I-Claim
309	new	_	_	I-Claim
310	,	_	_	I-Claim
311	safe	_	_	I-Claim
312	,	_	_	I-Claim
313	and	_	_	I-Claim
314	effective	_	_	I-Claim
315	alternative	_	_	I-Claim
316	to	_	_	I-Claim
317	MMC	_	_	I-Claim
318	,	_	_	I-Claim
319	with	_	_	I-Claim
320	similar	_	_	I-Claim
321	long-term	_	_	I-Claim
322	success	_	_	I-Claim
323	rate	_	_	I-Claim
324	.	_	_	I-Claim


0	Evaluation	_	_	O
1	of	_	_	O
2	health-related	_	_	O
3	quality-of-life	_	_	O
4	(	_	_	O
5	HRQoL	_	_	O
6	)	_	_	O
7	and	_	_	O
8	symptom	_	_	O
9	improvement	_	_	O
10	were	_	_	O
11	preplanned	_	_	O
12	secondary	_	_	O
13	objectives	_	_	O
14	for	_	_	O
15	the	_	_	O
16	overall	_	_	O
17	population	_	_	O
18	and	_	_	O
19	posthoc	_	_	O
20	analyses	_	_	O
21	for	_	_	O
22	epidermal	_	_	O
23	growth	_	_	O
24	factor	_	_	O
25	receptor	_	_	O
26	(	_	_	O
27	EGFR	_	_	O
28	)	_	_	O
29	mutation-positive/negative	_	_	O
30	subgroups	_	_	O
31	in	_	_	O
32	IPASS	_	_	O
33	.	_	_	O

34	HRQoL	_	_	O
35	was	_	_	O
36	assessed	_	_	O
37	using	_	_	O
38	the	_	_	O
39	Functional	_	_	O
40	Assessment	_	_	O
41	of	_	_	O
42	Cancer	_	_	O
43	Therapy-Lung	_	_	O
44	(	_	_	O
45	FACT-L	_	_	O
46	)	_	_	O
47	and	_	_	O
48	Trial	_	_	O
49	Outcome	_	_	O
50	Index	_	_	O
51	(	_	_	O
52	TOI	_	_	O
53	)	_	_	O
54	;	_	_	O
55	symptom	_	_	O
56	improvement	_	_	O
57	by	_	_	O
58	the	_	_	O
59	Lung	_	_	O
60	Cancer	_	_	O
61	Subscale	_	_	O
62	(	_	_	O
63	LCS	_	_	O
64	)	_	_	O
65	.	_	_	O

66	Improvements	_	_	O
67	defined	_	_	O
68	as	_	_	O
69	:	_	_	O
70	6	_	_	O
71	or	_	_	O
72	more	_	_	O
73	(	_	_	O
74	FACT-L	_	_	O
75	;	_	_	O
76	TOI	_	_	O
77	)	_	_	O
78	,	_	_	O
79	2	_	_	O
80	or	_	_	O
81	more	_	_	O
82	(	_	_	O
83	LCS	_	_	O
84	)	_	_	O
85	points	_	_	O
86	increase	_	_	O
87	maintained	_	_	O
88	for	_	_	O
89	21	_	_	O
90	or	_	_	O
91	more	_	_	O
92	days	_	_	O
93	.	_	_	O

94	Overall	_	_	O
95	(	_	_	O
96	n	_	_	O
97	=	_	_	O
98	1151/1217	_	_	O
99	evaluable	_	_	O
100	)	_	_	O
101	,	_	_	O
102	HRQoL	_	_	O
103	improvement	_	_	O
104	rates	_	_	O
105	were	_	_	O
106	significantly	_	_	O
107	greater	_	_	O
108	with	_	_	O
109	gefitinib	_	_	O
110	versus	_	_	O
111	carboplatin/paclitaxel	_	_	O
112	;	_	_	O
113	symptom	_	_	O
114	improvement	_	_	O
115	rates	_	_	O
116	were	_	_	O
117	similar	_	_	O
118	for	_	_	O
119	both	_	_	O
120	treatments	_	_	O
121	.	_	_	O

122	Significantly	_	_	B-Premise
123	more	_	_	I-Premise
124	patients	_	_	I-Premise
125	recorded	_	_	I-Premise
126	improvements	_	_	I-Premise
127	in	_	_	I-Premise
128	HRQoL	_	_	I-Premise
129	and	_	_	I-Premise
130	symptoms	_	_	I-Premise
131	with	_	_	I-Premise
132	gefitinib	_	_	I-Premise
133	in	_	_	I-Premise
134	the	_	_	I-Premise
135	EGFR	_	_	I-Premise
136	mutation-positive	_	_	I-Premise
137	subgroup	_	_	I-Premise
138	(	_	_	I-Premise
139	n	_	_	I-Premise
140	=	_	_	I-Premise
141	259	_	_	I-Premise
142	;	_	_	I-Premise
143	FACT-L	_	_	I-Premise
144	70.2	_	_	I-Premise
145	%	_	_	I-Premise
146	versus	_	_	I-Premise
147	44.5	_	_	I-Premise
148	%	_	_	I-Premise
149	;	_	_	I-Premise
150	odds	_	_	I-Premise
151	ratio	_	_	I-Premise
152	,	_	_	I-Premise
153	3.01	_	_	I-Premise
154	[	_	_	I-Premise
155	95	_	_	I-Premise
156	%	_	_	I-Premise
157	confidence	_	_	I-Premise
158	interval	_	_	I-Premise
159	,	_	_	I-Premise
160	1.79-5.07	_	_	I-Premise
161	]	_	_	I-Premise
162	;	_	_	I-Premise
163	p	_	_	I-Premise
164	<	_	_	I-Premise
165	0.001	_	_	I-Premise
166	;	_	_	I-Premise
167	TOI	_	_	I-Premise
168	70.2	_	_	I-Premise
169	%	_	_	I-Premise
170	versus	_	_	I-Premise
171	38.3	_	_	I-Premise
172	%	_	_	I-Premise
173	;	_	_	I-Premise
174	3.96	_	_	I-Premise
175	[	_	_	I-Premise
176	2.33-6.71	_	_	I-Premise
177	]	_	_	I-Premise
178	;	_	_	I-Premise
179	p	_	_	I-Premise
180	<	_	_	I-Premise
181	0.001	_	_	I-Premise
182	;	_	_	I-Premise
183	LCS	_	_	I-Premise
184	75.6	_	_	I-Premise
185	%	_	_	I-Premise
186	versus	_	_	I-Premise
187	53.9	_	_	I-Premise
188	%	_	_	I-Premise
189	;	_	_	I-Premise
190	2.70	_	_	I-Premise
191	[	_	_	I-Premise
192	1.58-4.62	_	_	I-Premise
193	]	_	_	I-Premise
194	;	_	_	I-Premise
195	p	_	_	I-Premise
196	<	_	_	I-Premise
197	0.001	_	_	I-Premise
198	)	_	_	I-Premise
199	,	_	_	I-Premise
200	and	_	_	I-Premise
201	with	_	_	I-Premise
202	carboplatin/paclitaxel	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	EGFR	_	_	I-Premise
206	mutation-negative	_	_	I-Premise
207	subgroup	_	_	I-Premise
208	(	_	_	I-Premise
209	n	_	_	I-Premise
210	=	_	_	I-Premise
211	169	_	_	I-Premise
212	;	_	_	I-Premise
213	FACT-L	_	_	I-Premise
214	14.6	_	_	I-Premise
215	%	_	_	I-Premise
216	versus	_	_	I-Premise
217	36.3	_	_	I-Premise
218	%	_	_	I-Premise
219	;	_	_	I-Premise
220	odds	_	_	I-Premise
221	ratio	_	_	I-Premise
222	,	_	_	I-Premise
223	0.31	_	_	I-Premise
224	[	_	_	I-Premise
225	0.15-0.65	_	_	I-Premise
226	]	_	_	I-Premise
227	;	_	_	I-Premise
228	p	_	_	I-Premise
229	=	_	_	I-Premise
230	0.002	_	_	I-Premise
231	;	_	_	I-Premise
232	TOI	_	_	I-Premise
233	12.4	_	_	I-Premise
234	%	_	_	I-Premise
235	versus	_	_	I-Premise
236	28.8	_	_	I-Premise
237	%	_	_	I-Premise
238	;	_	_	I-Premise
239	0.35	_	_	I-Premise
240	[	_	_	I-Premise
241	0.16-0.79	_	_	I-Premise
242	]	_	_	I-Premise
243	;	_	_	I-Premise
244	p	_	_	I-Premise
245	=	_	_	I-Premise
246	0.011	_	_	I-Premise
247	;	_	_	I-Premise
248	LCS	_	_	I-Premise
249	20.2	_	_	I-Premise
250	%	_	_	I-Premise
251	versus	_	_	I-Premise
252	47.5	_	_	I-Premise
253	%	_	_	I-Premise
254	;	_	_	I-Premise
255	0.28	_	_	I-Premise
256	[	_	_	I-Premise
257	0.14-0.55	_	_	I-Premise
258	]	_	_	I-Premise
259	;	_	_	I-Premise
260	p	_	_	I-Premise
261	<	_	_	I-Premise
262	0.001	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Median	_	_	B-Premise
266	time-to-worsening	_	_	I-Premise
267	(	_	_	I-Premise
268	months	_	_	I-Premise
269	)	_	_	I-Premise
270	FACT-L	_	_	I-Premise
271	score	_	_	I-Premise
272	was	_	_	I-Premise
273	longer	_	_	I-Premise
274	with	_	_	I-Premise
275	gefitinib	_	_	I-Premise
276	versus	_	_	I-Premise
277	carboplatin/paclitaxel	_	_	I-Premise
278	for	_	_	I-Premise
279	the	_	_	I-Premise
280	overall	_	_	I-Premise
281	population	_	_	I-Premise
282	(	_	_	I-Premise
283	8.3	_	_	I-Premise
284	versus	_	_	I-Premise
285	2.5	_	_	I-Premise
286	)	_	_	I-Premise
287	and	_	_	I-Premise
288	EGFR	_	_	I-Premise
289	mutation-positive	_	_	I-Premise
290	subgroup	_	_	I-Premise
291	(	_	_	I-Premise
292	15.6	_	_	I-Premise
293	versus	_	_	I-Premise
294	3.0	_	_	I-Premise
295	)	_	_	I-Premise
296	,	_	_	I-Premise
297	and	_	_	I-Premise
298	similar	_	_	I-Premise
299	for	_	_	I-Premise
300	both	_	_	I-Premise
301	treatments	_	_	I-Premise
302	in	_	_	I-Premise
303	the	_	_	I-Premise
304	EGFR	_	_	I-Premise
305	mutation-negative	_	_	I-Premise
306	subgroup	_	_	I-Premise
307	(	_	_	I-Premise
308	1.4	_	_	I-Premise
309	versus	_	_	I-Premise
310	1.4	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Median	_	_	B-Premise
314	time-to-improvement	_	_	I-Premise
315	with	_	_	I-Premise
316	gefitinib	_	_	I-Premise
317	was	_	_	I-Premise
318	8	_	_	I-Premise
319	days	_	_	I-Premise
320	in	_	_	I-Premise
321	patients	_	_	I-Premise
322	with	_	_	I-Premise
323	EGFR	_	_	I-Premise
324	mutation-positive	_	_	I-Premise
325	tumors	_	_	I-Premise
326	who	_	_	I-Premise
327	improved	_	_	I-Premise
328	.	_	_	I-Premise

329	HRQoL	_	_	B-Claim
330	and	_	_	I-Claim
331	symptom	_	_	I-Claim
332	endpoints	_	_	I-Claim
333	were	_	_	I-Claim
334	consistent	_	_	I-Claim
335	with	_	_	I-Claim
336	efficacy	_	_	I-Claim
337	outcomes	_	_	I-Claim
338	in	_	_	I-Claim
339	IPASS	_	_	I-Claim
340	and	_	_	I-Claim
341	favored	_	_	I-Claim
342	gefitinib	_	_	I-Claim
343	in	_	_	I-Claim
344	patients	_	_	I-Claim
345	with	_	_	I-Claim
346	EGFR	_	_	I-Claim
347	mutation-positive	_	_	I-Claim
348	tumors	_	_	I-Claim
349	and	_	_	I-Claim
350	carboplatin/paclitaxel	_	_	I-Claim
351	in	_	_	I-Claim
352	patients	_	_	I-Claim
353	with	_	_	I-Claim
354	EGFR	_	_	I-Claim
355	mutation-negative	_	_	I-Claim
356	tumors	_	_	I-Claim
357	.	_	_	I-Claim


0	Gemcitabine	_	_	O
1	for	_	_	O
2	advanced	_	_	O
3	pancreatic	_	_	O
4	cancer	_	_	O
5	(	_	_	O
6	APC	_	_	O
7	)	_	_	O
8	is	_	_	O
9	palliative	_	_	O
10	and	_	_	O
11	the	_	_	O
12	prognosis	_	_	O
13	is	_	_	O
14	poor	_	_	O
15	,	_	_	O
16	making	_	_	O
17	health-related	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	(	_	_	O
22	HRQOL	_	_	O
23	)	_	_	O
24	particularly	_	_	O
25	important	_	_	O
26	.	_	_	O

27	We	_	_	O
28	evaluated	_	_	O
29	HRQOL	_	_	O
30	with	_	_	O
31	the	_	_	O
32	EuroQol	_	_	O
33	(	_	_	O
34	EQ-5D™	_	_	O
35	)	_	_	O
36	in	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	APC	_	_	O
40	participating	_	_	O
41	in	_	_	O
42	Cancer	_	_	O
43	and	_	_	O
44	Leukemia	_	_	O
45	Group	_	_	O
46	B	_	_	O
47	80303	_	_	O
48	,	_	_	O
49	a	_	_	O
50	multicenter	_	_	O
51	,	_	_	O
52	double-blind	_	_	O
53	,	_	_	O
54	randomized	_	_	O
55	trial	_	_	O
56	comparing	_	_	O
57	overall	_	_	O
58	survival	_	_	O
59	(	_	_	O
60	OS	_	_	O
61	)	_	_	O
62	between	_	_	O
63	two	_	_	O
64	treatment	_	_	O
65	arms	_	_	O
66	:	_	_	O
67	gemcitabine	_	_	O
68	with	_	_	O
69	bevacizumab	_	_	O
70	or	_	_	O
71	gemcitabine	_	_	O
72	with	_	_	O
73	placebo	_	_	O
74	.	_	_	O

75	A	_	_	O
76	consecutive	_	_	O
77	subsample	_	_	O
78	of	_	_	O
79	patients	_	_	O
80	was	_	_	O
81	invited	_	_	O
82	to	_	_	O
83	complete	_	_	O
84	the	_	_	O
85	EQ-5D	_	_	O
86	surveys	_	_	O
87	.	_	_	O

88	Because	_	_	O
89	neither	_	_	O
90	clinical	_	_	O
91	nor	_	_	O
92	HRQOL	_	_	O
93	outcomes	_	_	O
94	differed	_	_	O
95	based	_	_	O
96	on	_	_	O
97	the	_	_	O
98	study	_	_	O
99	arm	_	_	O
100	,	_	_	O
101	analyses	_	_	O
102	were	_	_	O
103	pooled	_	_	O
104	.	_	_	O

105	Changes	_	_	O
106	in	_	_	O
107	mean	_	_	O
108	scores	_	_	O
109	from	_	_	O
110	baseline	_	_	O
111	to	_	_	O
112	eight	_	_	O
113	weeks	_	_	O
114	and	_	_	O
115	the	_	_	O
116	prognostic	_	_	O
117	value	_	_	O
118	of	_	_	O
119	the	_	_	O
120	EQ-5D	_	_	O
121	were	_	_	O
122	evaluated	_	_	O
123	.	_	_	O

124	Mean	_	_	B-Premise
125	index	_	_	I-Premise
126	scores	_	_	I-Premise
127	remained	_	_	I-Premise
128	stable	_	_	I-Premise
129	(	_	_	I-Premise
130	0.78	_	_	I-Premise
131	at	_	_	I-Premise
132	baseline	_	_	I-Premise
133	[	_	_	I-Premise
134	n=267	_	_	I-Premise
135	]	_	_	I-Premise
136	,	_	_	I-Premise
137	0.79	_	_	I-Premise
138	at	_	_	I-Premise
139	eight	_	_	I-Premise
140	weeks	_	_	I-Premise
141	[	_	_	I-Premise
142	n=186	_	_	I-Premise
143	]	_	_	I-Premise
144	,	_	_	I-Premise
145	P=0.34	_	_	I-Premise
146	,	_	_	I-Premise
147	Wilcoxon	_	_	I-Premise
148	signed	_	_	I-Premise
149	rank	_	_	I-Premise
150	test	_	_	I-Premise
151	)	_	_	I-Premise
152	,	_	_	I-Premise
153	attributable	_	_	I-Premise
154	to	_	_	I-Premise
155	a	_	_	I-Premise
156	modest	_	_	I-Premise
157	deterioration	_	_	I-Premise
158	of	_	_	I-Premise
159	physical	_	_	I-Premise
160	function	_	_	I-Premise
161	domain	_	_	I-Premise
162	scores	_	_	I-Premise
163	coincident	_	_	I-Premise
164	with	_	_	I-Premise
165	small	_	_	I-Premise
166	improvements	_	_	I-Premise
167	in	_	_	I-Premise
168	pain	_	_	I-Premise
169	and	_	_	I-Premise
170	anxiety/depression	_	_	I-Premise
171	scores	_	_	I-Premise
172	.	_	_	I-Premise

173	A	_	_	B-Premise
174	small	_	_	I-Premise
175	decline	_	_	I-Premise
176	in	_	_	I-Premise
177	visual	_	_	I-Premise
178	analogue	_	_	I-Premise
179	scale	_	_	I-Premise
180	scores	_	_	I-Premise
181	was	_	_	I-Premise
182	observed	_	_	I-Premise
183	(	_	_	I-Premise
184	70.7	_	_	I-Premise
185	vs.	_	_	I-Premise
186	68.2	_	_	I-Premise
187	,	_	_	I-Premise
188	P=0.026	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	HRQOL	_	_	B-Premise
192	changes	_	_	I-Premise
193	within	_	_	I-Premise
194	chemotherapy	_	_	I-Premise
195	response	_	_	I-Premise
196	strata	_	_	I-Premise
197	revealed	_	_	I-Premise
198	stable	_	_	I-Premise
199	index	_	_	I-Premise
200	scores	_	_	I-Premise
201	but	_	_	B-Premise
202	a	_	_	I-Premise
203	trend	_	_	I-Premise
204	of	_	_	I-Premise
205	worsened	_	_	I-Premise
206	physical	_	_	I-Premise
207	function	_	_	I-Premise
208	among	_	_	I-Premise
209	patients	_	_	I-Premise
210	with	_	_	I-Premise
211	disease	_	_	I-Premise
212	progression	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	those	_	_	I-Premise
216	with	_	_	I-Premise
217	stable	_	_	I-Premise
218	or	_	_	I-Premise
219	improved	_	_	I-Premise
220	disease	_	_	I-Premise
221	.	_	_	I-Premise

222	Visual	_	_	B-Premise
223	analogue	_	_	I-Premise
224	scale	_	_	I-Premise
225	scores	_	_	I-Premise
226	trended	_	_	I-Premise
227	downward	_	_	I-Premise
228	over	_	_	I-Premise
229	time	_	_	I-Premise
230	irrespective	_	_	I-Premise
231	of	_	_	I-Premise
232	chemotherapy	_	_	I-Premise
233	response	_	_	I-Premise
234	status	_	_	I-Premise
235	,	_	_	I-Premise
236	with	_	_	I-Premise
237	a	_	_	I-Premise
238	statistically	_	_	I-Premise
239	meaningful	_	_	I-Premise
240	deterioration	_	_	I-Premise
241	in	_	_	I-Premise
242	patients	_	_	I-Premise
243	who	_	_	I-Premise
244	progressed	_	_	I-Premise
245	(	_	_	I-Premise
246	68.9	_	_	I-Premise
247	vs.	_	_	I-Premise
248	64.4	_	_	I-Premise
249	,	_	_	I-Premise
250	P=0.029	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	Baseline	_	_	O
254	scores	_	_	O
255	from	_	_	O
256	both	_	_	O
257	EQ-5D	_	_	O
258	scales	_	_	O
259	were	_	_	O
260	significant	_	_	O
261	predictors	_	_	O
262	of	_	_	O
263	OS	_	_	O
264	in	_	_	O
265	Cox	_	_	O
266	proportional	_	_	O
267	hazard	_	_	O
268	models	_	_	O
269	.	_	_	O

270	Response	_	_	B-Claim
271	to	_	_	I-Claim
272	gemcitabine	_	_	I-Claim
273	treatment	_	_	I-Claim
274	in	_	_	I-Claim
275	APC	_	_	I-Claim
276	is	_	_	I-Claim
277	not	_	_	I-Claim
278	associated	_	_	I-Claim
279	with	_	_	I-Claim
280	appreciable	_	_	I-Claim
281	improvement	_	_	I-Claim
282	of	_	_	I-Claim
283	global	_	_	I-Claim
284	HRQOL	_	_	I-Claim
285	.	_	_	I-Claim

286	Small	_	_	O
287	improvements	_	_	O
288	in	_	_	O
289	pain	_	_	O
290	and	_	_	O
291	mood	_	_	O
292	are	_	_	O
293	observed	_	_	O
294	despite	_	_	O
295	progressive	_	_	O
296	functional	_	_	O
297	decline	_	_	O
298	.	_	_	O

299	Those	_	_	B-Claim
300	who	_	_	I-Claim
301	respond	_	_	I-Claim
302	to	_	_	I-Claim
303	gemcitabine	_	_	I-Claim
304	may	_	_	I-Claim
305	experience	_	_	I-Claim
306	a	_	_	I-Claim
307	slight	_	_	I-Claim
308	slowing	_	_	I-Claim
309	of	_	_	I-Claim
310	functional	_	_	I-Claim
311	deterioration	_	_	I-Claim
312	.	_	_	I-Claim


0	Observational	_	_	O
1	studies	_	_	O
2	demonstrate	_	_	O
3	an	_	_	O
4	association	_	_	O
5	between	_	_	O
6	physical	_	_	O
7	activity	_	_	O
8	and	_	_	O
9	improved	_	_	O
10	outcomes	_	_	O
11	in	_	_	O
12	breast	_	_	O
13	and	_	_	O
14	colon	_	_	O
15	cancer	_	_	O
16	survivors	_	_	O
17	.	_	_	O

18	To	_	_	O
19	test	_	_	O
20	these	_	_	O
21	observations	_	_	O
22	with	_	_	O
23	a	_	_	O
24	large	_	_	O
25	,	_	_	O
26	randomized	_	_	O
27	clinical	_	_	O
28	trial	_	_	O
29	,	_	_	O
30	an	_	_	O
31	intervention	_	_	O
32	that	_	_	O
33	significantly	_	_	O
34	impacts	_	_	O
35	physical	_	_	O
36	activity	_	_	O
37	in	_	_	O
38	these	_	_	O
39	patients	_	_	O
40	is	_	_	O
41	needed	_	_	O
42	.	_	_	O

43	The	_	_	O
44	Active	_	_	O
45	After	_	_	O
46	Cancer	_	_	O
47	Trial	_	_	O
48	(	_	_	O
49	AACT	_	_	O
50	)	_	_	O
51	was	_	_	O
52	a	_	_	O
53	multicenter	_	_	O
54	pilot	_	_	O
55	study	_	_	O
56	evaluating	_	_	O
57	the	_	_	O
58	feasibility	_	_	O
59	of	_	_	O
60	a	_	_	O
61	telephone-based	_	_	O
62	exercise	_	_	O
63	intervention	_	_	O
64	in	_	_	O
65	a	_	_	O
66	cooperative	_	_	O
67	group	_	_	O
68	setting	_	_	O
69	.	_	_	O

70	Sedentary	_	_	O
71	(	_	_	O
72	engaging	_	_	O
73	in	_	_	O
74	<	_	_	O
75	60	_	_	O
76	min	_	_	O
77	of	_	_	O
78	recreational	_	_	O
79	activity/week	_	_	O
80	)	_	_	O
81	breast	_	_	O
82	and	_	_	O
83	colorectal	_	_	O
84	cancer	_	_	O
85	survivors	_	_	O
86	were	_	_	O
87	randomized	_	_	O
88	to	_	_	O
89	a	_	_	O
90	telephone-based	_	_	O
91	exercise	_	_	O
92	intervention	_	_	O
93	or	_	_	O
94	usual	_	_	O
95	care	_	_	O
96	control	_	_	O
97	group	_	_	O
98	.	_	_	O

99	The	_	_	O
100	intervention	_	_	O
101	was	_	_	O
102	delivered	_	_	O
103	through	_	_	O
104	the	_	_	O
105	University	_	_	O
106	of	_	_	O
107	California	_	_	O
108	at	_	_	O
109	San	_	_	O
110	Diego	_	_	O
111	;	_	_	O
112	participants	_	_	O
113	received	_	_	O
114	ten	_	_	O
115	phone	_	_	O
116	calls	_	_	O
117	over	_	_	O
118	the	_	_	O
119	course	_	_	O
120	of	_	_	O
121	the	_	_	O
122	16-week	_	_	O
123	intervention	_	_	O
124	.	_	_	O

125	All	_	_	O
126	participants	_	_	O
127	underwent	_	_	O
128	assessment	_	_	O
129	of	_	_	O
130	physical	_	_	O
131	activity	_	_	O
132	,	_	_	O
133	fitness	_	_	O
134	,	_	_	O
135	physical	_	_	O
136	functioning	_	_	O
137	,	_	_	O
138	fatigue	_	_	O
139	and	_	_	O
140	exercise	_	_	O
141	self-efficacy	_	_	O
142	at	_	_	O
143	baseline	_	_	O
144	and	_	_	O
145	after	_	_	O
146	the	_	_	O
147	16-week	_	_	O
148	intervention	_	_	O
149	.	_	_	O

150	One	_	_	O
151	hundred	_	_	O
152	and	_	_	O
153	twenty-one	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	enrolled	_	_	O
157	through	_	_	O
158	ten	_	_	O
159	Cancer	_	_	O
160	and	_	_	O
161	Leukemia	_	_	O
162	Group	_	_	O
163	B	_	_	O
164	(	_	_	O
165	CALGB	_	_	O
166	)	_	_	O
167	institutions	_	_	O
168	;	_	_	O
169	100	_	_	O
170	patients	_	_	O
171	had	_	_	O
172	breast	_	_	O
173	cancer	_	_	O
174	and	_	_	O
175	21	_	_	O
176	had	_	_	O
177	colorectal	_	_	O
178	cancer	_	_	O
179	.	_	_	O

180	Participants	_	_	B-Premise
181	randomized	_	_	I-Premise
182	to	_	_	I-Premise
183	the	_	_	I-Premise
184	exercise	_	_	I-Premise
185	group	_	_	I-Premise
186	increased	_	_	I-Premise
187	physical	_	_	I-Premise
188	activity	_	_	I-Premise
189	by	_	_	I-Premise
190	more	_	_	I-Premise
191	than	_	_	I-Premise
192	100	_	_	I-Premise
193	versus	_	_	I-Premise
194	22	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	controls	_	_	I-Premise
198	(	_	_	I-Premise
199	54.5	_	_	I-Premise
200	vs.	_	_	I-Premise
201	14.6	_	_	I-Premise
202	min	_	_	I-Premise
203	,	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.13	_	_	I-Premise
207	)	_	_	I-Premise
208	,	_	_	I-Premise
209	and	_	_	I-Premise
210	experienced	_	_	I-Premise
211	significant	_	_	I-Premise
212	increases	_	_	I-Premise
213	in	_	_	I-Premise
214	fitness	_	_	I-Premise
215	(	_	_	I-Premise
216	increased	_	_	I-Premise
217	6-min	_	_	I-Premise
218	walk	_	_	I-Premise
219	test	_	_	I-Premise
220	distance	_	_	I-Premise
221	by	_	_	I-Premise
222	186.9	_	_	I-Premise
223	vs.	_	_	I-Premise
224	81.9	_	_	I-Premise
225	feet	_	_	I-Premise
226	,	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.006	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	physical	_	_	I-Premise
233	functioning	_	_	I-Premise
234	(	_	_	I-Premise
235	7.1	_	_	I-Premise
236	vs.	_	_	I-Premise
237	2.6	_	_	I-Premise
238	,	_	_	I-Premise
239	P	_	_	I-Premise
240	=	_	_	I-Premise
241	0.04	_	_	I-Premise
242	)	_	_	I-Premise
243	as	_	_	I-Premise
244	compared	_	_	I-Premise
245	to	_	_	I-Premise
246	the	_	_	I-Premise
247	control	_	_	I-Premise
248	group	_	_	I-Premise
249	.	_	_	I-Premise

250	Breast	_	_	B-Claim
251	and	_	_	I-Claim
252	colorectal	_	_	I-Claim
253	cancer	_	_	I-Claim
254	survivors	_	_	I-Claim
255	enrolled	_	_	I-Claim
256	in	_	_	I-Claim
257	a	_	_	I-Claim
258	multicenter	_	_	I-Claim
259	,	_	_	I-Claim
260	telephone-based	_	_	I-Claim
261	physical	_	_	I-Claim
262	activity	_	_	I-Claim
263	intervention	_	_	I-Claim
264	increased	_	_	I-Claim
265	physical	_	_	I-Claim
266	activity	_	_	I-Claim
267	and	_	_	I-Claim
268	experienced	_	_	I-Claim
269	significant	_	_	I-Claim
270	improvements	_	_	I-Claim
271	in	_	_	I-Claim
272	fitness	_	_	I-Claim
273	and	_	_	I-Claim
274	physical	_	_	I-Claim
275	functioning	_	_	I-Claim
276	.	_	_	I-Claim

277	Lifestyle	_	_	B-Claim
278	intervention	_	_	I-Claim
279	research	_	_	I-Claim
280	is	_	_	I-Claim
281	feasible	_	_	I-Claim
282	in	_	_	I-Claim
283	a	_	_	I-Claim
284	cooperative	_	_	I-Claim
285	group	_	_	I-Claim
286	setting	_	_	I-Claim
287	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	sought	_	_	O
3	to	_	_	O
4	evaluate	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	autologous	_	_	O
8	dendritic	_	_	O
9	cell	_	_	O
10	vaccine	_	_	O
11	(	_	_	O
12	immunotherapy	_	_	O
13	)	_	_	O
14	for	_	_	O
15	glioblastoma	_	_	O
16	multiforme	_	_	O
17	(	_	_	O
18	GBM	_	_	O
19	)	_	_	O
20	.	_	_	O

21	Patients	_	_	O
22	14	_	_	O
23	to	_	_	O
24	70	_	_	O
25	years	_	_	O
26	of	_	_	O
27	age	_	_	O
28	with	_	_	O
29	newly	_	_	O
30	diagnosed	_	_	O
31	GBM	_	_	O
32	and	_	_	O
33	Karnofsky	_	_	O
34	Performance	_	_	O
35	Scale	_	_	O
36	(	_	_	O
37	KPS	_	_	O
38	)	_	_	O
39	score	_	_	O
40	>	_	_	O
41	70	_	_	O
42	who	_	_	O
43	were	_	_	O
44	receiving	_	_	O
45	initial	_	_	O
46	treatment	_	_	O
47	were	_	_	O
48	enrolled	_	_	O
49	and	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	into	_	_	O
53	2	_	_	O
54	groups	_	_	O
55	during	_	_	O
56	the	_	_	O
57	5-year	_	_	O
58	study	_	_	O
59	period	_	_	O
60	.	_	_	O

61	Eighteen	_	_	O
62	patients	_	_	O
63	underwent	_	_	O
64	conventional	_	_	O
65	treatment	_	_	O
66	(	_	_	O
67	surgery	_	_	O
68	,	_	_	O
69	radiotherapy	_	_	O
70	,	_	_	O
71	and	_	_	O
72	chemotherapy	_	_	O
73	)	_	_	O
74	and	_	_	O
75	received	_	_	O
76	adjuvant	_	_	O
77	autologous	_	_	O
78	dendritic	_	_	O
79	cell	_	_	O
80	vaccine	_	_	O
81	,	_	_	O
82	and	_	_	O
83	16	_	_	O
84	patients	_	_	O
85	(	_	_	O
86	control	_	_	O
87	group	_	_	O
88	)	_	_	O
89	underwent	_	_	O
90	conventional	_	_	O
91	treatment	_	_	O
92	only	_	_	O
93	.	_	_	O

94	Administration	_	_	O
95	of	_	_	O
96	the	_	_	O
97	vaccine	_	_	O
98	was	_	_	O
99	begun	_	_	O
100	within	_	_	O
101	1	_	_	O
102	to	_	_	O
103	2	_	_	O
104	months	_	_	O
105	postoperatively	_	_	O
106	,	_	_	O
107	with	_	_	O
108	10	_	_	O
109	inoculations	_	_	O
110	given	_	_	O
111	over	_	_	O
112	6	_	_	O
113	months	_	_	O
114	.	_	_	O

115	Outcome	_	_	O
116	measures	_	_	O
117	were	_	_	O
118	overall	_	_	O
119	survival	_	_	O
120	(	_	_	O
121	OS	_	_	O
122	)	_	_	O
123	;	_	_	O
124	progression-free	_	_	O
125	survival	_	_	O
126	(	_	_	O
127	PFS	_	_	O
128	)	_	_	O
129	;	_	_	O
130	1-	_	_	O
131	,	_	_	O
132	2-	_	_	O
133	,	_	_	O
134	and	_	_	O
135	3-year	_	_	O
136	survival	_	_	O
137	rates	_	_	O
138	,	_	_	O
139	and	_	_	O
140	quality	_	_	O
141	of	_	_	O
142	life	_	_	O
143	(	_	_	O
144	QoL	_	_	O
145	)	_	_	O
146	.	_	_	O

147	Follow-up	_	_	O
148	time	_	_	O
149	ranged	_	_	O
150	from	_	_	O
151	14	_	_	O
152	to	_	_	O
153	56	_	_	O
154	months	_	_	O
155	(	_	_	O
156	median	_	_	O
157	,	_	_	O
158	33	_	_	O
159	months	_	_	O
160	)	_	_	O
161	.	_	_	O

162	The	_	_	B-Premise
163	1-	_	_	I-Premise
164	,	_	_	I-Premise
165	2-	_	_	I-Premise
166	,	_	_	I-Premise
167	and	_	_	I-Premise
168	3-year	_	_	I-Premise
169	survival	_	_	I-Premise
170	rates	_	_	I-Premise
171	were	_	_	I-Premise
172	88.9	_	_	I-Premise
173	%	_	_	I-Premise
174	,	_	_	I-Premise
175	44.4	_	_	I-Premise
176	%	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	16.7	_	_	I-Premise
180	%	_	_	I-Premise
181	for	_	_	I-Premise
182	the	_	_	I-Premise
183	vaccine	_	_	I-Premise
184	group	_	_	I-Premise
185	,	_	_	I-Premise
186	respectively	_	_	I-Premise
187	,	_	_	I-Premise
188	and	_	_	I-Premise
189	75.0	_	_	I-Premise
190	%	_	_	I-Premise
191	,	_	_	I-Premise
192	18.8	_	_	I-Premise
193	%	_	_	I-Premise
194	,	_	_	I-Premise
195	and	_	_	I-Premise
196	0	_	_	I-Premise
197	%	_	_	I-Premise
198	,	_	_	I-Premise
199	respectively	_	_	I-Premise
200	,	_	_	I-Premise
201	for	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	,	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0.299	_	_	I-Premise
210	,	_	_	I-Premise
211	0.0035	_	_	I-Premise
212	,	_	_	I-Premise
213	0.0014	_	_	I-Premise
214	,	_	_	I-Premise
215	respectively	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	median	_	_	I-Premise
220	OS	_	_	I-Premise
221	for	_	_	I-Premise
222	the	_	_	I-Premise
223	vaccine	_	_	I-Premise
224	group	_	_	I-Premise
225	was	_	_	I-Premise
226	31.9	_	_	I-Premise
227	months	_	_	I-Premise
228	and	_	_	I-Premise
229	for	_	_	I-Premise
230	the	_	_	I-Premise
231	control	_	_	I-Premise
232	group	_	_	I-Premise
233	was	_	_	I-Premise
234	15.0	_	_	I-Premise
235	months	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	<	_	_	I-Premise
239	0.002	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	The	_	_	B-Premise
243	median	_	_	I-Premise
244	progression-free	_	_	I-Premise
245	survival	_	_	I-Premise
246	(	_	_	I-Premise
247	PFS	_	_	I-Premise
248	)	_	_	I-Premise
249	for	_	_	I-Premise
250	the	_	_	I-Premise
251	vaccine	_	_	I-Premise
252	group	_	_	I-Premise
253	was	_	_	I-Premise
254	8.5	_	_	I-Premise
255	months	_	_	I-Premise
256	,	_	_	I-Premise
257	and	_	_	I-Premise
258	8.0	_	_	I-Premise
259	months	_	_	I-Premise
260	for	_	_	I-Premise
261	the	_	_	I-Premise
262	control	_	_	I-Premise
263	group	_	_	I-Premise
264	(	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	0.075	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	The	_	_	B-Premise
271	surviving	_	_	I-Premise
272	fraction	_	_	I-Premise
273	was	_	_	I-Premise
274	significantly	_	_	I-Premise
275	higher	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	vaccine	_	_	I-Premise
279	group	_	_	I-Premise
280	based	_	_	I-Premise
281	on	_	_	I-Premise
282	Kaplan-Meier	_	_	I-Premise
283	analysis	_	_	I-Premise
284	.	_	_	I-Premise

285	Adjuvant	_	_	B-Claim
286	immunotherapy	_	_	I-Claim
287	with	_	_	I-Claim
288	whole-cell	_	_	I-Claim
289	lysate	_	_	I-Claim
290	dendritic	_	_	I-Claim
291	cell	_	_	I-Claim
292	vaccine	_	_	I-Claim
293	may	_	_	I-Claim
294	improve	_	_	I-Claim
295	short-term	_	_	I-Claim
296	survival	_	_	I-Claim
297	.	_	_	I-Claim

298	It	_	_	B-Claim
299	seems	_	_	I-Claim
300	to	_	_	I-Claim
301	be	_	_	I-Claim
302	safe	_	_	I-Claim
303	,	_	_	I-Claim
304	and	_	_	I-Claim
305	its	_	_	I-Claim
306	long-term	_	_	I-Claim
307	effectiveness	_	_	I-Claim
308	is	_	_	I-Claim
309	worthy	_	_	I-Claim
310	of	_	_	I-Claim
311	further	_	_	I-Claim
312	investigation	_	_	I-Claim
313	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	low-frequency	_	_	O
6	low-intensity	_	_	O
7	electrotherapy	_	_	O
8	and	_	_	O
9	manual	_	_	O
10	lymphatic	_	_	O
11	drainage	_	_	O
12	in	_	_	O
13	the	_	_	O
14	treatment	_	_	O
15	of	_	_	O
16	chronic	_	_	O
17	upper	_	_	O
18	limb	_	_	O
19	breast	_	_	O
20	cancer-related	_	_	O
21	lymphoedema	_	_	O
22	.	_	_	O

23	Cross-over	_	_	O
24	single-blind	_	_	O
25	random	_	_	O
26	clinical	_	_	O
27	trial	_	_	O
28	.	_	_	O

29	Rehabilitation	_	_	O
30	service	_	_	O
31	.	_	_	O

32	Thirty-six	_	_	O
33	women	_	_	O
34	with	_	_	O
35	chronic	_	_	O
36	upper	_	_	O
37	limb	_	_	O
38	breast	_	_	O
39	cancer-related	_	_	O
40	lymphoedema	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	to	_	_	O
46	undergo	_	_	O
47	10	_	_	O
48	sessions	_	_	O
49	of	_	_	O
50	manual	_	_	O
51	lymphatic	_	_	O
52	drainage	_	_	O
53	followed	_	_	O
54	by	_	_	O
55	10	_	_	O
56	sessions	_	_	O
57	of	_	_	O
58	low-frequency	_	_	O
59	low-intensity	_	_	O
60	electrotherapy	_	_	O
61	or	_	_	O
62	to	_	_	O
63	undergo	_	_	O
64	first	_	_	O
65	low-frequency	_	_	O
66	low-intensity	_	_	O
67	electrotherapy	_	_	O
68	followed	_	_	O
69	by	_	_	O
70	manual	_	_	O
71	lymphatic	_	_	O
72	drainage	_	_	O
73	.	_	_	O

74	There	_	_	O
75	was	_	_	O
76	a	_	_	O
77	month	_	_	O
78	of	_	_	O
79	washout	_	_	O
80	time	_	_	O
81	between	_	_	O
82	treatments	_	_	O
83	.	_	_	O

84	Each	_	_	O
85	patient	_	_	O
86	was	_	_	O
87	examined	_	_	O
88	just	_	_	O
89	before	_	_	O
90	and	_	_	O
91	after	_	_	O
92	each	_	_	O
93	treatment	_	_	O
94	.	_	_	O

95	Researchers	_	_	O
96	and	_	_	O
97	outcome	_	_	O
98	assessors	_	_	O
99	were	_	_	O
100	blinded	_	_	O
101	for	_	_	O
102	assigned	_	_	O
103	treatment	_	_	O
104	.	_	_	O

105	Outcomes	_	_	O
106	were	_	_	O
107	lymphoedema	_	_	O
108	volume	_	_	O
109	,	_	_	O
110	pain	_	_	O
111	,	_	_	O
112	heaviness	_	_	O
113	and	_	_	O
114	tightness	_	_	O
115	,	_	_	O
116	and	_	_	O
117	health-related	_	_	O
118	quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	measured	_	_	O
122	with	_	_	O
123	the	_	_	O
124	Functional	_	_	O
125	Assessment	_	_	O
126	of	_	_	O
127	Cancer	_	_	O
128	Therapy	_	_	O
129	Questionnaire	_	_	O
130	for	_	_	O
131	Breast	_	_	O
132	Cancer	_	_	O
133	version	_	_	O
134	4	_	_	O
135	(	_	_	O
136	FACT-B+4	_	_	O
137	)	_	_	O
138	.	_	_	O

139	Carry-over	_	_	O
140	,	_	_	O
141	period	_	_	O
142	and	_	_	O
143	treatment	_	_	O
144	effects	_	_	O
145	were	_	_	O
146	analysed	_	_	O
147	.	_	_	O

148	Treatment	_	_	O
149	effect	_	_	O
150	was	_	_	O
151	assessed	_	_	O
152	using	_	_	O
153	paired	_	_	O
154	t-test	_	_	O
155	.	_	_	O

156	Thirty	_	_	O
157	patients	_	_	O
158	finalized	_	_	O
159	treatment	_	_	O
160	.	_	_	O

161	Comparing	_	_	B-Premise
162	the	_	_	I-Premise
163	changes	_	_	I-Premise
164	in	_	_	I-Premise
165	low-frequency	_	_	I-Premise
166	low-intensity	_	_	I-Premise
167	electrotherapy	_	_	I-Premise
168	with	_	_	I-Premise
169	manual	_	_	I-Premise
170	lymphatic	_	_	I-Premise
171	drainage	_	_	I-Premise
172	changes	_	_	I-Premise
173	,	_	_	I-Premise
174	there	_	_	I-Premise
175	were	_	_	I-Premise
176	no	_	_	I-Premise
177	significant	_	_	I-Premise
178	differences	_	_	I-Premise
179	.	_	_	I-Premise

180	Low-frequency	_	_	B-Premise
181	low-intensity	_	_	I-Premise
182	electrotherapy	_	_	I-Premise
183	did	_	_	I-Premise
184	not	_	_	I-Premise
185	reduce	_	_	I-Premise
186	lymphoedema	_	_	I-Premise
187	volume	_	_	I-Premise
188	(	_	_	I-Premise
189	mean	_	_	I-Premise
190	of	_	_	I-Premise
191	change	_	_	I-Premise
192	=	_	_	I-Premise
193	19.77	_	_	I-Premise
194	mL	_	_	I-Premise
195	,	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	0.36	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	but	_	_	O
202	significant	_	_	B-Premise
203	reductions	_	_	I-Premise
204	were	_	_	I-Premise
205	observed	_	_	I-Premise
206	in	_	_	I-Premise
207	pain	_	_	I-Premise
208	,	_	_	I-Premise
209	heaviness	_	_	I-Premise
210	and	_	_	I-Premise
211	tightness	_	_	I-Premise
212	(	_	_	I-Premise
213	mean	_	_	I-Premise
214	of	_	_	I-Premise
215	change	_	_	I-Premise
216	=	_	_	I-Premise
217	13.1	_	_	I-Premise
218	,	_	_	I-Premise
219	16.2	_	_	I-Premise
220	and	_	_	I-Premise
221	6.4	_	_	I-Premise
222	mm	_	_	I-Premise
223	,	_	_	I-Premise
224	respectively	_	_	I-Premise
225	)	_	_	I-Premise
226	,	_	_	I-Premise
227	and	_	_	I-Premise
228	FACT-B+4	_	_	I-Premise
229	summaries	_	_	I-Premise
230	improved	_	_	I-Premise
231	significantly	_	_	I-Premise
232	(	_	_	I-Premise
233	Trial	_	_	I-Premise
234	Outcome	_	_	I-Premise
235	Index	_	_	I-Premise
236	mean	_	_	I-Premise
237	of	_	_	I-Premise
238	change	_	_	I-Premise
239	=	_	_	I-Premise
240	5.4	_	_	I-Premise
241	,	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.015	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Manual	_	_	B-Premise
248	lymphatic	_	_	I-Premise
249	drainage	_	_	I-Premise
250	showed	_	_	I-Premise
251	no	_	_	I-Premise
252	significant	_	_	I-Premise
253	changes	_	_	I-Premise
254	in	_	_	I-Premise
255	any	_	_	I-Premise
256	of	_	_	I-Premise
257	the	_	_	I-Premise
258	outcomes	_	_	I-Premise
259	.	_	_	I-Premise

260	Although	_	_	B-Claim
261	there	_	_	I-Claim
262	are	_	_	I-Claim
263	no	_	_	I-Claim
264	significant	_	_	I-Claim
265	differences	_	_	I-Claim
266	between	_	_	I-Claim
267	treatment	_	_	I-Claim
268	changes	_	_	I-Claim
269	,	_	_	I-Claim
270	the	_	_	B-Claim
271	observed	_	_	I-Claim
272	trend	_	_	I-Claim
273	towards	_	_	I-Claim
274	a	_	_	I-Claim
275	better	_	_	I-Claim
276	health-related	_	_	I-Claim
277	quality	_	_	I-Claim
278	of	_	_	I-Claim
279	life	_	_	I-Claim
280	is	_	_	I-Claim
281	remarkable	_	_	I-Claim
282	in	_	_	I-Claim
283	low-frequency	_	_	I-Claim
284	low-intensity	_	_	I-Claim
285	electrotherapy	_	_	I-Claim
286	.	_	_	I-Claim


0	Pain	_	_	O
1	is	_	_	O
2	1	_	_	O
3	of	_	_	O
4	the	_	_	O
5	most	_	_	O
6	common	_	_	O
7	symptoms	_	_	O
8	that	_	_	O
9	a	_	_	O
10	cancer	_	_	O
11	patient	_	_	O
12	would	_	_	O
13	experience	_	_	O
14	.	_	_	O

15	A	_	_	O
16	significant	_	_	O
17	barrier	_	_	O
18	to	_	_	O
19	positive	_	_	O
20	pain	_	_	O
21	management	_	_	O
22	is	_	_	O
23	patients	_	_	O
24	'	_	_	O
25	misconceptions	_	_	O
26	regarding	_	_	O
27	analgesics	_	_	O
28	and	_	_	O
29	inadequate	_	_	O
30	use	_	_	O
31	of	_	_	O
32	nonpharmacological	_	_	O
33	strategies	_	_	O
34	as	_	_	O
35	pain	_	_	O
36	relief	_	_	O
37	.	_	_	O

38	The	_	_	O
39	purpose	_	_	O
40	of	_	_	O
41	this	_	_	O
42	study	_	_	O
43	was	_	_	O
44	to	_	_	O
45	investigate	_	_	O
46	the	_	_	O
47	effectiveness	_	_	O
48	of	_	_	O
49	a	_	_	O
50	pain	_	_	O
51	management	_	_	O
52	program	_	_	O
53	(	_	_	O
54	PMP	_	_	O
55	)	_	_	O
56	on	_	_	O
57	pain	_	_	O
58	intensity	_	_	O
59	,	_	_	O
60	use	_	_	O
61	of	_	_	O
62	PRN	_	_	O
63	drugs	_	_	O
64	and	_	_	O
65	nonpharmacological	_	_	O
66	strategies	_	_	O
67	as	_	_	O
68	pain	_	_	O
69	relief	_	_	O
70	,	_	_	O
71	and	_	_	O
72	barriers	_	_	O
73	to	_	_	O
74	managing	_	_	O
75	pain	_	_	O
76	in	_	_	O
77	cancer	_	_	O
78	patients	_	_	O
79	.	_	_	O

80	The	_	_	O
81	study	_	_	O
82	was	_	_	O
83	conducted	_	_	O
84	in	_	_	O
85	the	_	_	O
86	palliative	_	_	O
87	care	_	_	O
88	and	_	_	O
89	hospice	_	_	O
90	ward	_	_	O
91	of	_	_	O
92	a	_	_	O
93	public	_	_	O
94	hospital	_	_	O
95	in	_	_	O
96	Hong	_	_	O
97	Kong	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	randomized	_	_	O
102	to	_	_	O
103	either	_	_	O
104	an	_	_	O
105	experimental	_	_	O
106	group	_	_	O
107	(	_	_	O
108	receiving	_	_	O
109	the	_	_	O
110	PMP	_	_	O
111	)	_	_	O
112	or	_	_	O
113	a	_	_	O
114	control	_	_	O
115	group	_	_	O
116	(	_	_	O
117	routine	_	_	O
118	care	_	_	O
119	)	_	_	O
120	.	_	_	O

121	There	_	_	O
122	were	_	_	O
123	38	_	_	O
124	hospitalized	_	_	O
125	patients	_	_	O
126	,	_	_	O
127	with	_	_	O
128	20	_	_	O
129	(	_	_	O
130	13	_	_	O
131	males	_	_	O
132	and	_	_	O
133	7	_	_	O
134	females	_	_	O
135	)	_	_	O
136	in	_	_	O
137	the	_	_	O
138	experimental	_	_	O
139	group	_	_	O
140	and	_	_	O
141	18	_	_	O
142	(	_	_	O
143	11	_	_	O
144	males	_	_	O
145	and	_	_	O
146	7	_	_	O
147	females	_	_	O
148	)	_	_	O
149	in	_	_	O
150	the	_	_	O
151	control	_	_	O
152	group	_	_	O
153	;	_	_	O
154	mean	_	_	O
155	age	_	_	O
156	was	_	_	O
157	61.95	_	_	O
158	years	_	_	O
159	(	_	_	O
160	experimental	_	_	O
161	group	_	_	O
162	)	_	_	O
163	to	_	_	O
164	63.94	_	_	O
165	years	_	_	O
166	(	_	_	O
167	control	_	_	O
168	group	_	_	O
169	)	_	_	O
170	.	_	_	O

171	Upon	_	_	B-Premise
172	the	_	_	I-Premise
173	completion	_	_	I-Premise
174	of	_	_	I-Premise
175	PMP	_	_	I-Premise
176	,	_	_	I-Premise
177	pain	_	_	I-Premise
178	scores	_	_	I-Premise
179	were	_	_	I-Premise
180	significantly	_	_	I-Premise
181	reduced	_	_	I-Premise
182	in	_	_	I-Premise
183	both	_	_	I-Premise
184	groups	_	_	I-Premise
185	,	_	_	I-Premise
186	yet	_	_	B-Premise
187	patients	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	experimental	_	_	I-Premise
191	group	_	_	I-Premise
192	showed	_	_	I-Premise
193	a	_	_	I-Premise
194	significant	_	_	I-Premise
195	increase	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	use	_	_	I-Premise
199	of	_	_	I-Premise
200	PRN	_	_	I-Premise
201	analgesics	_	_	I-Premise
202	and	_	_	I-Premise
203	nonpharmacological	_	_	I-Premise
204	strategies	_	_	I-Premise
205	to	_	_	I-Premise
206	relieve	_	_	I-Premise
207	pain	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	<	_	_	I-Premise
211	.05	_	_	I-Premise
212	)	_	_	I-Premise
213	and	_	_	I-Premise
214	significantly	_	_	I-Premise
215	reduce	_	_	I-Premise
216	barriers	_	_	I-Premise
217	to	_	_	I-Premise
218	managing	_	_	I-Premise
219	their	_	_	I-Premise
220	cancer	_	_	I-Premise
221	pain	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	<	_	_	I-Premise
225	.05	_	_	I-Premise
226	)	_	_	I-Premise
227	compared	_	_	I-Premise
228	with	_	_	I-Premise
229	the	_	_	I-Premise
230	control	_	_	I-Premise
231	group	_	_	I-Premise
232	.	_	_	I-Premise

233	Cancer	_	_	B-Claim
234	patients	_	_	I-Claim
235	should	_	_	I-Claim
236	be	_	_	I-Claim
237	empowered	_	_	I-Claim
238	with	_	_	I-Claim
239	pain	_	_	I-Claim
240	management	_	_	I-Claim
241	education	_	_	I-Claim
242	to	_	_	I-Claim
243	gain	_	_	I-Claim
244	knowledge	_	_	I-Claim
245	and	_	_	I-Claim
246	correct	_	_	I-Claim
247	misconceptions	_	_	I-Claim
248	in	_	_	I-Claim
249	managing	_	_	I-Claim
250	their	_	_	I-Claim
251	cancer	_	_	I-Claim
252	pain	_	_	I-Claim
253	.	_	_	I-Claim

254	Integration	_	_	B-Claim
255	of	_	_	I-Claim
256	the	_	_	I-Claim
257	PMP	_	_	I-Claim
258	into	_	_	I-Claim
259	routine	_	_	I-Claim
260	clinical	_	_	I-Claim
261	work	_	_	I-Claim
262	may	_	_	I-Claim
263	help	_	_	I-Claim
264	to	_	_	I-Claim
265	improve	_	_	I-Claim
266	the	_	_	I-Claim
267	standard	_	_	I-Claim
268	of	_	_	I-Claim
269	care	_	_	I-Claim
270	for	_	_	I-Claim
271	cancer	_	_	I-Claim
272	patients	_	_	I-Claim
273	.	_	_	I-Claim

274	It	_	_	O
275	is	_	_	O
276	recommended	_	_	O
277	to	_	_	O
278	provide	_	_	O
279	pain	_	_	O
280	management	_	_	O
281	education	_	_	O
282	to	_	_	O
283	all	_	_	O
284	cancer	_	_	O
285	patients	_	_	O
286	.	_	_	O


0	Health-related	_	_	O
1	quality	_	_	O
2	of	_	_	O
3	life	_	_	O
4	(	_	_	O
5	HRQOL	_	_	O
6	)	_	_	O
7	,	_	_	O
8	symptoms	_	_	O
9	of	_	_	O
10	depression	_	_	O
11	,	_	_	O
12	and	_	_	O
13	adverse	_	_	O
14	events	_	_	O
15	(	_	_	O
16	AEs	_	_	O
17	)	_	_	O
18	were	_	_	O
19	compared	_	_	O
20	between	_	_	O
21	Japanese	_	_	O
22	postmenopausal	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	hormone-sensitive	_	_	O
26	breast	_	_	O
27	cancer	_	_	O
28	(	_	_	O
29	BC	_	_	O
30	)	_	_	O
31	who	_	_	O
32	received	_	_	O
33	adjuvant	_	_	O
34	tamoxifen	_	_	O
35	,	_	_	O
36	exemestane	_	_	O
37	,	_	_	O
38	or	_	_	O
39	anastrozole	_	_	O
40	in	_	_	O
41	an	_	_	O
42	open-labeled	_	_	O
43	,	_	_	O
44	randomized	_	_	O
45	,	_	_	O
46	multicenter	_	_	O
47	trial	_	_	O
48	designated	_	_	O
49	as	_	_	O
50	the	_	_	O
51	National	_	_	O
52	Surgical	_	_	O
53	Adjuvant	_	_	O
54	Study	_	_	O
55	of	_	_	O
56	Breast	_	_	O
57	Cancer	_	_	O
58	(	_	_	O
59	N-SAS	_	_	O
60	BC	_	_	O
61	)	_	_	O
62	04	_	_	O
63	substudy	_	_	O
64	of	_	_	O
65	the	_	_	O
66	Tamoxifen	_	_	O
67	Exemestane	_	_	O
68	Adjuvant	_	_	O
69	Multinational	_	_	O
70	(	_	_	O
71	TEAM	_	_	O
72	)	_	_	O
73	trial	_	_	O
74	.	_	_	O

75	During	_	_	O
76	the	_	_	O
77	first	_	_	O
78	year	_	_	O
79	of	_	_	O
80	treatment	_	_	O
81	,	_	_	O
82	HRQOL	_	_	O
83	and	_	_	O
84	symptoms	_	_	O
85	of	_	_	O
86	depression	_	_	O
87	were	_	_	O
88	analyzed	_	_	O
89	using	_	_	O
90	the	_	_	O
91	Functional	_	_	O
92	Assessment	_	_	O
93	of	_	_	O
94	Cancer	_	_	O
95	Therapy-Breast	_	_	O
96	(	_	_	O
97	FACT-B	_	_	O
98	)	_	_	O
99	and	_	_	O
100	its	_	_	O
101	Endocrine	_	_	O
102	Symptom	_	_	O
103	Subscale	_	_	O
104	(	_	_	O
105	ES	_	_	O
106	)	_	_	O
107	,	_	_	O
108	and	_	_	O
109	the	_	_	O
110	Center	_	_	O
111	for	_	_	O
112	Epidemiologic	_	_	O
113	Studies	_	_	O
114	Depression	_	_	O
115	Scale	_	_	O
116	(	_	_	O
117	CES-D	_	_	O
118	)	_	_	O
119	,	_	_	O
120	respectively	_	_	O
121	.	_	_	O

122	In	_	_	O
123	addition	_	_	O
124	,	_	_	O
125	predefined	_	_	O
126	AEs	_	_	O
127	were	_	_	O
128	analyzed	_	_	O
129	.	_	_	O

130	A	_	_	O
131	total	_	_	O
132	of	_	_	O
133	166	_	_	O
134	eligible	_	_	O
135	patients	_	_	O
136	were	_	_	O
137	randomly	_	_	O
138	assigned	_	_	O
139	to	_	_	O
140	receive	_	_	O
141	adjuvant	_	_	O
142	tamoxifen	_	_	O
143	,	_	_	O
144	exemestane	_	_	O
145	,	_	_	O
146	or	_	_	O
147	anastrozole	_	_	O
148	.	_	_	O

149	FACT-B	_	_	B-Premise
150	scores	_	_	I-Premise
151	increased	_	_	I-Premise
152	after	_	_	I-Premise
153	treatment	_	_	I-Premise
154	began	_	_	I-Premise
155	and	_	_	I-Premise
156	remained	_	_	I-Premise
157	significantly	_	_	I-Premise
158	higher	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	tamoxifen	_	_	I-Premise
162	group	_	_	I-Premise
163	than	_	_	I-Premise
164	in	_	_	I-Premise
165	the	_	_	I-Premise
166	exemestane	_	_	I-Premise
167	group	_	_	I-Premise
168	or	_	_	I-Premise
169	anastrozole	_	_	I-Premise
170	group	_	_	I-Premise
171	during	_	_	I-Premise
172	the	_	_	I-Premise
173	first	_	_	I-Premise
174	year	_	_	I-Premise
175	(	_	_	I-Premise
176	P	_	_	I-Premise
177	=	_	_	I-Premise
178	0.045	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	FACT-B	_	_	B-Premise
182	scores	_	_	I-Premise
183	were	_	_	I-Premise
184	similar	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	exemestane	_	_	I-Premise
188	group	_	_	I-Premise
189	and	_	_	I-Premise
190	anastrozole	_	_	I-Premise
191	group	_	_	I-Premise
192	.	_	_	I-Premise

193	ES	_	_	B-Premise
194	scores	_	_	I-Premise
195	and	_	_	I-Premise
196	CES-D	_	_	I-Premise
197	scores	_	_	I-Premise
198	were	_	_	I-Premise
199	similar	_	_	I-Premise
200	in	_	_	I-Premise
201	all	_	_	I-Premise
202	treatment	_	_	I-Premise
203	groups	_	_	I-Premise
204	.	_	_	I-Premise

205	Arthralgia	_	_	B-Premise
206	and	_	_	I-Premise
207	fatigue	_	_	I-Premise
208	were	_	_	I-Premise
209	less	_	_	I-Premise
210	frequent	_	_	I-Premise
211	,	_	_	I-Premise
212	but	_	_	I-Premise
213	vaginal	_	_	I-Premise
214	discharge	_	_	I-Premise
215	was	_	_	I-Premise
216	more	_	_	I-Premise
217	frequent	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	tamoxifen	_	_	I-Premise
221	group	_	_	I-Premise
222	than	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	exemestane	_	_	I-Premise
226	group	_	_	I-Premise
227	or	_	_	I-Premise
228	anastrozole	_	_	I-Premise
229	group	_	_	I-Premise
230	.	_	_	I-Premise

231	HRQOL	_	_	B-Claim
232	was	_	_	I-Claim
233	better	_	_	I-Claim
234	in	_	_	I-Claim
235	Japanese	_	_	I-Claim
236	postmenopausal	_	_	I-Claim
237	women	_	_	I-Claim
238	treated	_	_	I-Claim
239	with	_	_	I-Claim
240	tamoxifen	_	_	I-Claim
241	than	_	_	I-Claim
242	those	_	_	I-Claim
243	treated	_	_	I-Claim
244	with	_	_	I-Claim
245	exemestane	_	_	I-Claim
246	or	_	_	I-Claim
247	anastrozole	_	_	I-Claim
248	.	_	_	I-Claim

249	HRQOL	_	_	B-Claim
250	and	_	_	I-Claim
251	AEs	_	_	I-Claim
252	were	_	_	I-Claim
253	similar	_	_	I-Claim
254	with	_	_	I-Claim
255	exemestane	_	_	I-Claim
256	and	_	_	I-Claim
257	anastrozole	_	_	I-Claim
258	.	_	_	I-Claim

259	Given	_	_	B-Claim
260	the	_	_	I-Claim
261	results	_	_	I-Claim
262	of	_	_	I-Claim
263	the	_	_	I-Claim
264	TEAM	_	_	I-Claim
265	trial	_	_	I-Claim
266	,	_	_	I-Claim
267	upfront	_	_	I-Claim
268	use	_	_	I-Claim
269	of	_	_	I-Claim
270	tamoxifen	_	_	I-Claim
271	followed	_	_	I-Claim
272	by	_	_	I-Claim
273	an	_	_	I-Claim
274	aromatase	_	_	I-Claim
275	inhibitor	_	_	I-Claim
276	(	_	_	I-Claim
277	AI	_	_	I-Claim
278	)	_	_	I-Claim
279	may	_	_	I-Claim
280	be	_	_	I-Claim
281	an	_	_	I-Claim
282	important	_	_	I-Claim
283	option	_	_	I-Claim
284	for	_	_	I-Claim
285	adjuvant	_	_	I-Claim
286	endocrine	_	_	I-Claim
287	therapy	_	_	I-Claim
288	in	_	_	I-Claim
289	Japanese	_	_	I-Claim
290	postmenopausal	_	_	I-Claim
291	women	_	_	I-Claim
292	.	_	_	I-Claim


0	Cisplatin	_	_	B-Claim
1	reduces	_	_	I-Claim
2	plasma	_	_	I-Claim
3	ghrelin	_	_	I-Claim
4	levels	_	_	I-Claim
5	through	_	_	I-Claim
6	the	_	_	I-Claim
7	5-hydroxytryptamine	_	_	I-Claim
8	(	_	_	I-Claim
9	5-HT	_	_	I-Claim
10	)	_	_	I-Claim
11	receptor	_	_	I-Claim
12	.	_	_	I-Claim

13	This	_	_	O
14	may	_	_	O
15	cause	_	_	O
16	cisplatin-induced	_	_	O
17	gastrointestinal	_	_	O
18	disorders	_	_	O
19	and	_	_	O
20	hinders	_	_	O
21	the	_	_	O
22	continuation	_	_	O
23	of	_	_	O
24	chemotherapy	_	_	O
25	.	_	_	O

26	The	_	_	O
27	authors	_	_	O
28	of	_	_	O
29	this	_	_	O
30	report	_	_	O
31	conducted	_	_	O
32	a	_	_	O
33	prospective	_	_	O
34	,	_	_	O
35	randomized	_	_	O
36	phase	_	_	O
37	2	_	_	O
38	trial	_	_	O
39	to	_	_	O
40	evaluate	_	_	O
41	the	_	_	O
42	effects	_	_	O
43	of	_	_	O
44	exogenous	_	_	O
45	ghrelin	_	_	O
46	during	_	_	O
47	cisplatin-based	_	_	O
48	chemotherapy	_	_	O
49	.	_	_	O

50	Forty-two	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	esophageal	_	_	O
54	cancer	_	_	O
55	who	_	_	O
56	were	_	_	O
57	receiving	_	_	O
58	cisplatin-based	_	_	O
59	neoadjuvant	_	_	O
60	chemotherapy	_	_	O
61	were	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	either	_	_	O
65	a	_	_	O
66	ghrelin	_	_	O
67	group	_	_	O
68	(	_	_	O
69	n	_	_	O
70	=	_	_	O
71	21	_	_	O
72	)	_	_	O
73	or	_	_	O
74	a	_	_	O
75	placebo	_	_	O
76	group	_	_	O
77	(	_	_	O
78	n	_	_	O
79	=	_	_	O
80	21	_	_	O
81	)	_	_	O
82	.	_	_	O

83	They	_	_	O
84	received	_	_	O
85	either	_	_	O
86	intravenous	_	_	O
87	infusions	_	_	O
88	of	_	_	O
89	synthetic	_	_	O
90	human	_	_	O
91	ghrelin	_	_	O
92	(	_	_	O
93	3	_	_	O
94	μg/kg	_	_	O
95	)	_	_	O
96	or	_	_	O
97	saline	_	_	O
98	twice	_	_	O
99	daily	_	_	O
100	for	_	_	O
101	1	_	_	O
102	week	_	_	O
103	with	_	_	O
104	cisplatin	_	_	O
105	administration	_	_	O
106	.	_	_	O

107	The	_	_	O
108	primary	_	_	O
109	endpoint	_	_	O
110	was	_	_	O
111	changes	_	_	O
112	in	_	_	O
113	oral	_	_	O
114	calorie	_	_	O
115	intake	_	_	O
116	,	_	_	O
117	and	_	_	O
118	the	_	_	O
119	secondary	_	_	O
120	endpoints	_	_	O
121	were	_	_	O
122	chemotherapy-related	_	_	O
123	adverse	_	_	O
124	events	_	_	O
125	;	_	_	O
126	appetite	_	_	O
127	visual	_	_	O
128	analog	_	_	O
129	scale	_	_	O
130	(	_	_	O
131	VAS	_	_	O
132	)	_	_	O
133	scores	_	_	O
134	;	_	_	O
135	changes	_	_	O
136	in	_	_	O
137	gastrointestinal	_	_	O
138	hormones	_	_	O
139	and	_	_	O
140	nutritional	_	_	O
141	status	_	_	O
142	,	_	_	O
143	including	_	_	O
144	rapid	_	_	O
145	turnover	_	_	O
146	proteins	_	_	O
147	,	_	_	O
148	and	_	_	O
149	quality	_	_	O
150	of	_	_	O
151	life	_	_	O
152	(	_	_	O
153	QoL	_	_	O
154	)	_	_	O
155	estimated	_	_	O
156	with	_	_	O
157	the	_	_	O
158	European	_	_	O
159	Organization	_	_	O
160	for	_	_	O
161	Research	_	_	O
162	and	_	_	O
163	Treatment	_	_	O
164	of	_	_	O
165	Cancer	_	_	O
166	QoL	_	_	O
167	core	_	_	O
168	questionnaire	_	_	O
169	(	_	_	O
170	QLQ-C30	_	_	O
171	)	_	_	O
172	.	_	_	O

173	Two	_	_	O
174	patients	_	_	O
175	were	_	_	O
176	excluded	_	_	O
177	from	_	_	O
178	the	_	_	O
179	final	_	_	O
180	analysis	_	_	O
181	:	_	_	O
182	One	_	_	O
183	patient	_	_	O
184	suspended	_	_	O
185	ghrelin	_	_	O
186	administration	_	_	O
187	because	_	_	O
188	of	_	_	O
189	excessive	_	_	O
190	diaphoresis	_	_	O
191	,	_	_	O
192	and	_	_	O
193	another	_	_	O
194	patient	_	_	O
195	in	_	_	O
196	the	_	_	O
197	placebo	_	_	O
198	group	_	_	O
199	failed	_	_	O
200	to	_	_	O
201	monitor	_	_	O
202	the	_	_	O
203	self-questionnaire	_	_	O
204	.	_	_	O

205	Food	_	_	B-Premise
206	intake	_	_	I-Premise
207	and	_	_	I-Premise
208	appetite	_	_	I-Premise
209	VAS	_	_	I-Premise
210	scores	_	_	I-Premise
211	were	_	_	I-Premise
212	significantly	_	_	I-Premise
213	higher	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	ghrelin	_	_	I-Premise
217	group	_	_	I-Premise
218	than	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	placebo	_	_	I-Premise
222	group	_	_	I-Premise
223	(	_	_	I-Premise
224	18.2	_	_	I-Premise
225	±	_	_	I-Premise
226	5.2	_	_	I-Premise
227	kcal/kg/day	_	_	I-Premise
228	vs	_	_	I-Premise
229	12.7	_	_	I-Premise
230	±	_	_	I-Premise
231	3.4	_	_	I-Premise
232	kcal/kg/day	_	_	I-Premise
233	[	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	.001	_	_	I-Premise
237	]	_	_	I-Premise
238	and	_	_	I-Premise
239	6.2	_	_	I-Premise
240	±	_	_	I-Premise
241	0.9	_	_	I-Premise
242	vs	_	_	I-Premise
243	4.1	_	_	I-Premise
244	±	_	_	I-Premise
245	0.9	_	_	I-Premise
246	[	_	_	I-Premise
247	P	_	_	I-Premise
248	<	_	_	I-Premise
249	.0001	_	_	I-Premise
250	]	_	_	I-Premise
251	,	_	_	I-Premise
252	respectively	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Patients	_	_	B-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	ghrelin	_	_	I-Premise
259	group	_	_	I-Premise
260	had	_	_	I-Premise
261	fewer	_	_	I-Premise
262	adverse	_	_	I-Premise
263	events	_	_	I-Premise
264	during	_	_	I-Premise
265	chemotherapy	_	_	I-Premise
266	related	_	_	I-Premise
267	to	_	_	I-Premise
268	anorexia	_	_	I-Premise
269	and	_	_	I-Premise
270	nausea	_	_	I-Premise
271	than	_	_	I-Premise
272	patients	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	control	_	_	I-Premise
276	group	_	_	I-Premise
277	.	_	_	I-Premise

278	Significant	_	_	B-Premise
279	deterioration	_	_	I-Premise
280	was	_	_	I-Premise
281	noted	_	_	I-Premise
282	after	_	_	I-Premise
283	chemotherapy	_	_	I-Premise
284	in	_	_	I-Premise
285	the	_	_	I-Premise
286	placebo	_	_	I-Premise
287	group	_	_	I-Premise
288	in	_	_	I-Premise
289	QoL	_	_	I-Premise
290	scores	_	_	I-Premise
291	,	_	_	I-Premise
292	appetite	_	_	I-Premise
293	,	_	_	I-Premise
294	nausea	_	_	I-Premise
295	and	_	_	I-Premise
296	vomiting	_	_	I-Premise
297	,	_	_	I-Premise
298	and	_	_	I-Premise
299	global	_	_	I-Premise
300	health	_	_	I-Premise
301	status	_	_	I-Premise
302	.	_	_	I-Premise

303	Short-term	_	_	B-Claim
304	administration	_	_	I-Claim
305	of	_	_	I-Claim
306	exogenous	_	_	I-Claim
307	ghrelin	_	_	I-Claim
308	at	_	_	I-Claim
309	the	_	_	I-Claim
310	start	_	_	I-Claim
311	of	_	_	I-Claim
312	cisplatin-based	_	_	I-Claim
313	chemotherapy	_	_	I-Claim
314	stimulated	_	_	I-Claim
315	food	_	_	I-Claim
316	intake	_	_	I-Claim
317	and	_	_	I-Claim
318	minimized	_	_	I-Claim
319	adverse	_	_	I-Claim
320	events	_	_	I-Claim
321	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	tafluprost	_	_	O
8	,	_	_	O
9	a	_	_	O
10	preservative-free	_	_	O
11	(	_	_	O
12	PF	_	_	O
13	)	_	_	O
14	prostaglandin	_	_	O
15	analogue	_	_	O
16	,	_	_	O
17	with	_	_	O
18	PF	_	_	O
19	timolol	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	open-angle	_	_	O
24	glaucoma	_	_	O
25	or	_	_	O
26	ocular	_	_	O
27	hypertension	_	_	O
28	.	_	_	O

29	Randomized	_	_	O
30	,	_	_	O
31	double-masked	_	_	O
32	,	_	_	O
33	multicenter	_	_	O
34	clinical	_	_	O
35	trial	_	_	O
36	.	_	_	O

37	After	_	_	O
38	discontinuation	_	_	O
39	and	_	_	O
40	washout	_	_	O
41	of	_	_	O
42	existing	_	_	O
43	ocular	_	_	O
44	hypotensive	_	_	O
45	treatment	_	_	O
46	,	_	_	O
47	patients	_	_	O
48	who	_	_	O
49	had	_	_	O
50	intraocular	_	_	O
51	pressure	_	_	O
52	(	_	_	O
53	IOP	_	_	O
54	)	_	_	O
55	=23	_	_	O
56	and	_	_	O
57	=36	_	_	O
58	mm	_	_	O
59	Hg	_	_	O
60	in	_	_	O
61	at	_	_	O
62	least	_	_	O
63	1	_	_	O
64	eye	_	_	O
65	at	_	_	O
66	the	_	_	O
67	08:00	_	_	O
68	hour	_	_	O
69	time	_	_	O
70	point	_	_	O
71	were	_	_	O
72	randomized	_	_	O
73	1:1	_	_	O
74	to	_	_	O
75	12	_	_	O
76	weeks	_	_	O
77	of	_	_	O
78	treatment	_	_	O
79	with	_	_	O
80	either	_	_	O
81	PF	_	_	O
82	tafluprost	_	_	O
83	0.0015	_	_	O
84	%	_	_	O
85	or	_	_	O
86	PF	_	_	O
87	timolol	_	_	O
88	0.5	_	_	O
89	%	_	_	O
90	.	_	_	O

91	IOP	_	_	O
92	was	_	_	O
93	measured	_	_	O
94	3	_	_	O
95	times	_	_	O
96	during	_	_	O
97	the	_	_	O
98	day	_	_	O
99	(	_	_	O
100	08:00	_	_	O
101	,	_	_	O
102	10:00	_	_	O
103	,	_	_	O
104	16:00	_	_	O
105	hours	_	_	O
106	)	_	_	O
107	at	_	_	O
108	baseline	_	_	O
109	and	_	_	O
110	at	_	_	O
111	weeks	_	_	O
112	2	_	_	O
113	,	_	_	O
114	6	_	_	O
115	,	_	_	O
116	and	_	_	O
117	12	_	_	O
118	.	_	_	O

119	It	_	_	O
120	was	_	_	O
121	hypothesized	_	_	O
122	that	_	_	O
123	PF	_	_	O
124	tafluprost	_	_	O
125	would	_	_	O
126	be	_	_	O
127	noninferior	_	_	O
128	to	_	_	O
129	PF	_	_	O
130	timolol	_	_	O
131	over	_	_	O
132	12	_	_	O
133	weeks	_	_	O
134	with	_	_	O
135	regard	_	_	O
136	to	_	_	O
137	change	_	_	O
138	from	_	_	O
139	baseline	_	_	O
140	IOP	_	_	O
141	.	_	_	O

142	The	_	_	O
143	trial	_	_	O
144	was	_	_	O
145	powered	_	_	O
146	for	_	_	O
147	a	_	_	O
148	noninferiority	_	_	O
149	margin	_	_	O
150	of	_	_	O
151	1.5	_	_	O
152	mm	_	_	O
153	Hg	_	_	O
154	at	_	_	O
155	each	_	_	O
156	of	_	_	O
157	the	_	_	O
158	9	_	_	O
159	time	_	_	O
160	points	_	_	O
161	assessed	_	_	O
162	.	_	_	O

163	A	_	_	O
164	total	_	_	O
165	of	_	_	O
166	643	_	_	O
167	patients	_	_	O
168	were	_	_	O
169	randomized	_	_	O
170	and	_	_	O
171	618	_	_	O
172	completed	_	_	O
173	(	_	_	O
174	PF	_	_	O
175	tafluprost	_	_	O
176	=	_	_	O
177	306	_	_	O
178	,	_	_	O
179	PF	_	_	O
180	timolol	_	_	O
181	=	_	_	O
182	312	_	_	O
183	)	_	_	O
184	.	_	_	O

185	IOPs	_	_	B-Premise
186	at	_	_	I-Premise
187	the	_	_	I-Premise
188	3	_	_	I-Premise
189	time	_	_	I-Premise
190	points	_	_	I-Premise
191	assessed	_	_	I-Premise
192	during	_	_	I-Premise
193	the	_	_	I-Premise
194	baseline	_	_	I-Premise
195	visit	_	_	I-Premise
196	ranged	_	_	I-Premise
197	from	_	_	I-Premise
198	23.8	_	_	I-Premise
199	to	_	_	I-Premise
200	26.1	_	_	I-Premise
201	mm	_	_	I-Premise
202	Hg	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	PF	_	_	I-Premise
206	tafluprost	_	_	I-Premise
207	group	_	_	I-Premise
208	and	_	_	I-Premise
209	23.5	_	_	I-Premise
210	to	_	_	I-Premise
211	26.0	_	_	I-Premise
212	mm	_	_	I-Premise
213	Hg	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	PF	_	_	I-Premise
217	timolol	_	_	I-Premise
218	group	_	_	I-Premise
219	.	_	_	I-Premise

220	IOPs	_	_	B-Premise
221	at	_	_	I-Premise
222	the	_	_	I-Premise
223	3	_	_	I-Premise
224	time	_	_	I-Premise
225	points	_	_	I-Premise
226	assessed	_	_	I-Premise
227	during	_	_	I-Premise
228	the	_	_	I-Premise
229	12-week	_	_	I-Premise
230	visit	_	_	I-Premise
231	ranged	_	_	I-Premise
232	from	_	_	I-Premise
233	17.4	_	_	I-Premise
234	to	_	_	I-Premise
235	18.6	_	_	I-Premise
236	mm	_	_	I-Premise
237	Hg	_	_	I-Premise
238	for	_	_	I-Premise
239	PF	_	_	I-Premise
240	tafluprost	_	_	I-Premise
241	and	_	_	I-Premise
242	17.9	_	_	I-Premise
243	to	_	_	I-Premise
244	18.5	_	_	I-Premise
245	mm	_	_	I-Premise
246	Hg	_	_	I-Premise
247	for	_	_	I-Premise
248	PF	_	_	I-Premise
249	timolol	_	_	I-Premise
250	.	_	_	I-Premise

251	At	_	_	O
252	all	_	_	O
253	9	_	_	O
254	time	_	_	O
255	points	_	_	O
256	,	_	_	O
257	the	_	_	O
258	upper	_	_	O
259	limits	_	_	O
260	of	_	_	O
261	the	_	_	O
262	2-sided	_	_	O
263	95	_	_	O
264	%	_	_	O
265	confidence	_	_	O
266	intervals	_	_	O
267	for	_	_	O
268	the	_	_	O
269	difference	_	_	O
270	between	_	_	O
271	treatments	_	_	O
272	in	_	_	O
273	IOP	_	_	O
274	lowering	_	_	O
275	were	_	_	O
276	less	_	_	O
277	than	_	_	O
278	the	_	_	O
279	prespecified	_	_	O
280	noninferiority	_	_	O
281	margin	_	_	O
282	.	_	_	O

283	Similar	_	_	B-Premise
284	percentages	_	_	I-Premise
285	of	_	_	I-Premise
286	PF	_	_	I-Premise
287	tafluprost	_	_	I-Premise
288	and	_	_	I-Premise
289	PF	_	_	I-Premise
290	timolol	_	_	I-Premise
291	patients	_	_	I-Premise
292	reported	_	_	I-Premise
293	ocular	_	_	I-Premise
294	pain/stinging/irritation	_	_	I-Premise
295	(	_	_	I-Premise
296	4.4	_	_	I-Premise
297	%	_	_	I-Premise
298	vs	_	_	I-Premise
299	4.6	_	_	I-Premise
300	%	_	_	I-Premise
301	)	_	_	I-Premise
302	and	_	_	I-Premise
303	pruritus	_	_	I-Premise
304	(	_	_	I-Premise
305	2.5	_	_	I-Premise
306	%	_	_	I-Premise
307	vs	_	_	I-Premise
308	1.5	_	_	I-Premise
309	%	_	_	I-Premise
310	)	_	_	I-Premise
311	.	_	_	I-Premise

312	The	_	_	B-Premise
313	percentages	_	_	I-Premise
314	of	_	_	I-Premise
315	PF	_	_	I-Premise
316	tafluprost	_	_	I-Premise
317	and	_	_	I-Premise
318	PF	_	_	I-Premise
319	timolol	_	_	I-Premise
320	patients	_	_	I-Premise
321	reporting	_	_	I-Premise
322	conjunctival	_	_	I-Premise
323	hyperemia	_	_	I-Premise
324	were	_	_	I-Premise
325	4.4	_	_	I-Premise
326	%	_	_	I-Premise
327	vs	_	_	I-Premise
328	1.2	_	_	I-Premise
329	%	_	_	I-Premise
330	(	_	_	I-Premise
331	nominal	_	_	I-Premise
332	P	_	_	I-Premise
333	=	_	_	I-Premise
334	.016	_	_	I-Premise
335	)	_	_	I-Premise
336	.	_	_	I-Premise

337	The	_	_	B-Claim
338	IOP-lowering	_	_	I-Claim
339	effect	_	_	I-Claim
340	of	_	_	I-Claim
341	PF	_	_	I-Claim
342	tafluprost	_	_	I-Claim
343	was	_	_	I-Claim
344	noninferior	_	_	I-Claim
345	to	_	_	I-Claim
346	that	_	_	I-Claim
347	of	_	_	I-Claim
348	PF	_	_	I-Claim
349	timolol	_	_	I-Claim
350	.	_	_	I-Claim

351	PF	_	_	B-Claim
352	tafluprost	_	_	I-Claim
353	is	_	_	I-Claim
354	an	_	_	I-Claim
355	efficacious	_	_	I-Claim
356	and	_	_	I-Claim
357	generally	_	_	I-Claim
358	well-tolerated	_	_	I-Claim
359	ocular	_	_	I-Claim
360	hypotensive	_	_	I-Claim
361	agent	_	_	I-Claim
362	.	_	_	I-Claim


0	Pemetrexed	_	_	O
1	maintenance	_	_	O
2	therapy	_	_	O
3	significantly	_	_	O
4	improved	_	_	O
5	overall	_	_	O
6	survival	_	_	O
7	and	_	_	O
8	progression-free	_	_	O
9	survival	_	_	O
10	compared	_	_	O
11	with	_	_	O
12	placebo	_	_	O
13	,	_	_	O
14	and	_	_	O
15	had	_	_	O
16	a	_	_	O
17	good	_	_	O
18	safety	_	_	O
19	profile	_	_	O
20	in	_	_	O
21	a	_	_	O
22	phase	_	_	O
23	3	_	_	O
24	placebo-controlled	_	_	O
25	study	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	advanced	_	_	O
30	non-small-cell	_	_	O
31	lung	_	_	O
32	cancer	_	_	O
33	(	_	_	O
34	NSCLC	_	_	O
35	)	_	_	O
36	.	_	_	O

37	Results	_	_	O
38	for	_	_	O
39	quality	_	_	O
40	of	_	_	O
41	life	_	_	O
42	,	_	_	O
43	symptom	_	_	O
44	palliation	_	_	O
45	,	_	_	O
46	and	_	_	O
47	tolerability	_	_	O
48	are	_	_	O
49	presented	_	_	O
50	here	_	_	O
51	.	_	_	O

52	After	_	_	O
53	four	_	_	O
54	cycles	_	_	O
55	of	_	_	O
56	platinum-based	_	_	O
57	induction	_	_	O
58	therapy	_	_	O
59	,	_	_	O
60	663	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	stage	_	_	O
64	IIIB	_	_	O
65	or	_	_	O
66	stage	_	_	O
67	IV	_	_	O
68	NSCLC	_	_	O
69	and	_	_	O
70	Eastern	_	_	O
71	Cooperative	_	_	O
72	Oncology	_	_	O
73	Group	_	_	O
74	performance	_	_	O
75	status	_	_	O
76	of	_	_	O
77	0	_	_	O
78	or	_	_	O
79	1	_	_	O
80	were	_	_	O
81	randomly	_	_	O
82	assigned	_	_	O
83	(	_	_	O
84	in	_	_	O
85	a	_	_	O
86	2:1	_	_	O
87	ratio	_	_	O
88	)	_	_	O
89	from	_	_	O
90	March	_	_	O
91	15	_	_	O
92	,	_	_	O
93	2005	_	_	O
94	,	_	_	O
95	to	_	_	O
96	July	_	_	O
97	20	_	_	O
98	,	_	_	O
99	2007	_	_	O
100	,	_	_	O
101	using	_	_	O
102	the	_	_	O
103	Pocock	_	_	O
104	and	_	_	O
105	Simon	_	_	O
106	minimisation	_	_	O
107	method	_	_	O
108	to	_	_	O
109	receive	_	_	O
110	pemetrexed	_	_	O
111	(	_	_	O
112	500	_	_	O
113	mg/m	_	_	O
114	(	_	_	O
115	2	_	_	O
116	)	_	_	O
117	every	_	_	O
118	21	_	_	O
119	days	_	_	O
120	;	_	_	O
121	n=441	_	_	O
122	)	_	_	O
123	or	_	_	O
124	placebo	_	_	O
125	(	_	_	O
126	n=222	_	_	O
127	)	_	_	O
128	plus	_	_	O
129	best	_	_	O
130	supportive	_	_	O
131	care	_	_	O
132	until	_	_	O
133	disease	_	_	O
134	progression	_	_	O
135	.	_	_	O

136	The	_	_	O
137	primary	_	_	O
138	efficacy	_	_	O
139	data	_	_	O
140	have	_	_	O
141	been	_	_	O
142	reported	_	_	O
143	previously	_	_	O
144	.	_	_	O

145	Patients	_	_	O
146	completed	_	_	O
147	the	_	_	O
148	Lung	_	_	O
149	Cancer	_	_	O
150	Symptom	_	_	O
151	Scale	_	_	O
152	(	_	_	O
153	LCSS	_	_	O
154	)	_	_	O
155	at	_	_	O
156	baseline	_	_	O
157	,	_	_	O
158	after	_	_	O
159	each	_	_	O
160	cycle	_	_	O
161	,	_	_	O
162	and	_	_	O
163	post-discontinuation	_	_	O
164	.	_	_	O

165	Worsening	_	_	O
166	of	_	_	O
167	symptoms	_	_	O
168	was	_	_	O
169	defined	_	_	O
170	as	_	_	O
171	an	_	_	O
172	increase	_	_	O
173	of	_	_	O
174	15	_	_	O
175	mm	_	_	O
176	or	_	_	O
177	more	_	_	O
178	from	_	_	O
179	baseline	_	_	O
180	on	_	_	O
181	a	_	_	O
182	100	_	_	O
183	mm	_	_	O
184	scale	_	_	O
185	for	_	_	O
186	each	_	_	O
187	LCSS	_	_	O
188	item	_	_	O
189	.	_	_	O

190	The	_	_	O
191	primary	_	_	O
192	outcome	_	_	O
193	for	_	_	O
194	these	_	_	O
195	quality-of-life	_	_	O
196	analyses	_	_	O
197	was	_	_	O
198	time	_	_	O
199	to	_	_	O
200	worsening	_	_	O
201	of	_	_	O
202	symptoms	_	_	O
203	,	_	_	O
204	analysed	_	_	O
205	for	_	_	O
206	all	_	_	O
207	randomised	_	_	O
208	patients	_	_	O
209	.	_	_	O

210	Baseline	_	_	O
211	characteristics	_	_	O
212	,	_	_	O
213	including	_	_	O
214	LCSS	_	_	O
215	scores	_	_	O
216	,	_	_	O
217	were	_	_	O
218	well	_	_	O
219	balanced	_	_	O
220	between	_	_	O
221	groups	_	_	O
222	.	_	_	O

223	Baseline	_	_	O
224	LCSS	_	_	O
225	scores	_	_	O
226	were	_	_	O
227	low	_	_	O
228	,	_	_	O
229	indicating	_	_	O
230	low	_	_	O
231	symptom	_	_	O
232	burden	_	_	O
233	for	_	_	O
234	patients	_	_	O
235	without	_	_	O
236	disease	_	_	O
237	progression	_	_	O
238	after	_	_	O
239	completion	_	_	O
240	of	_	_	O
241	first-line	_	_	O
242	treatment	_	_	O
243	.	_	_	O

244	Longer	_	_	B-Premise
245	time	_	_	I-Premise
246	to	_	_	I-Premise
247	worsening	_	_	I-Premise
248	was	_	_	I-Premise
249	recorded	_	_	I-Premise
250	for	_	_	I-Premise
251	pain	_	_	I-Premise
252	(	_	_	I-Premise
253	hazard	_	_	I-Premise
254	ratio	_	_	I-Premise
255	[	_	_	I-Premise
256	HR	_	_	I-Premise
257	]	_	_	I-Premise
258	0·76	_	_	I-Premise
259	,	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	CI	_	_	I-Premise
263	0·59-0·99	_	_	I-Premise
264	;	_	_	I-Premise
265	p=0·041	_	_	I-Premise
266	)	_	_	I-Premise
267	and	_	_	I-Premise
268	haemoptysis	_	_	I-Premise
269	(	_	_	I-Premise
270	HR	_	_	I-Premise
271	0·58	_	_	I-Premise
272	,	_	_	I-Premise
273	95	_	_	I-Premise
274	%	_	_	I-Premise
275	CI	_	_	I-Premise
276	0·34-0·97	_	_	I-Premise
277	;	_	_	I-Premise
278	p=0·038	_	_	I-Premise
279	)	_	_	I-Premise
280	with	_	_	I-Premise
281	pemetrexed	_	_	I-Premise
282	than	_	_	I-Premise
283	with	_	_	I-Premise
284	placebo	_	_	I-Premise
285	;	_	_	I-Premise
286	no	_	_	B-Premise
287	other	_	_	I-Premise
288	significant	_	_	I-Premise
289	differences	_	_	I-Premise
290	in	_	_	I-Premise
291	analyses	_	_	I-Premise
292	of	_	_	I-Premise
293	time	_	_	I-Premise
294	to	_	_	I-Premise
295	worsening	_	_	I-Premise
296	were	_	_	I-Premise
297	noted	_	_	I-Premise
298	.	_	_	I-Premise

299	Additional	_	_	B-Premise
300	longitudinal	_	_	I-Premise
301	analyses	_	_	I-Premise
302	showed	_	_	I-Premise
303	a	_	_	I-Premise
304	greater	_	_	I-Premise
305	increase	_	_	I-Premise
306	in	_	_	I-Premise
307	loss	_	_	I-Premise
308	of	_	_	I-Premise
309	appetite	_	_	I-Premise
310	in	_	_	I-Premise
311	the	_	_	I-Premise
312	pemetrexed	_	_	I-Premise
313	group	_	_	I-Premise
314	than	_	_	I-Premise
315	in	_	_	I-Premise
316	the	_	_	I-Premise
317	placebo	_	_	I-Premise
318	group	_	_	I-Premise
319	(	_	_	I-Premise
320	4·3	_	_	I-Premise
321	mm	_	_	I-Premise
322	vs	_	_	I-Premise
323	0·2	_	_	I-Premise
324	mm	_	_	I-Premise
325	;	_	_	I-Premise
326	p=0·028	_	_	I-Premise
327	)	_	_	I-Premise
328	.	_	_	I-Premise

329	Rates	_	_	B-Premise
330	of	_	_	I-Premise
331	resource	_	_	I-Premise
332	use	_	_	I-Premise
333	were	_	_	I-Premise
334	statistically	_	_	I-Premise
335	higher	_	_	I-Premise
336	for	_	_	I-Premise
337	pemetrexed	_	_	I-Premise
338	than	_	_	I-Premise
339	for	_	_	I-Premise
340	placebo	_	_	I-Premise
341	:	_	_	I-Premise
342	admissions	_	_	I-Premise
343	to	_	_	I-Premise
344	hospital	_	_	I-Premise
345	for	_	_	I-Premise
346	drug-related	_	_	I-Premise
347	adverse	_	_	I-Premise
348	events	_	_	I-Premise
349	(	_	_	I-Premise
350	19	_	_	I-Premise
351	[	_	_	I-Premise
352	4	_	_	I-Premise
353	%	_	_	I-Premise
354	]	_	_	I-Premise
355	vs	_	_	I-Premise
356	none	_	_	I-Premise
357	;	_	_	I-Premise
358	p=0·001	_	_	I-Premise
359	)	_	_	I-Premise
360	,	_	_	I-Premise
361	transfusions	_	_	I-Premise
362	(	_	_	I-Premise
363	42	_	_	I-Premise
364	[	_	_	I-Premise
365	10	_	_	I-Premise
366	%	_	_	I-Premise
367	]	_	_	I-Premise
368	vs	_	_	I-Premise
369	seven	_	_	I-Premise
370	[	_	_	I-Premise
371	3	_	_	I-Premise
372	%	_	_	I-Premise
373	]	_	_	I-Premise
374	;	_	_	I-Premise
375	p=0·003	_	_	I-Premise
376	)	_	_	I-Premise
377	,	_	_	I-Premise
378	and	_	_	I-Premise
379	erythropoiesis-stimulating	_	_	I-Premise
380	agents	_	_	I-Premise
381	(	_	_	I-Premise
382	26	_	_	I-Premise
383	[	_	_	I-Premise
384	6	_	_	I-Premise
385	%	_	_	I-Premise
386	]	_	_	I-Premise
387	vs	_	_	I-Premise
388	four	_	_	I-Premise
389	[	_	_	I-Premise
390	2	_	_	I-Premise
391	%	_	_	I-Premise
392	]	_	_	I-Premise
393	;	_	_	I-Premise
394	p=0·017	_	_	I-Premise
395	)	_	_	I-Premise
396	.	_	_	I-Premise

397	Quality	_	_	B-Claim
398	of	_	_	I-Claim
399	life	_	_	I-Claim
400	during	_	_	I-Claim
401	maintenance	_	_	I-Claim
402	therapy	_	_	I-Claim
403	with	_	_	I-Claim
404	pemetrexed	_	_	I-Claim
405	is	_	_	I-Claim
406	similar	_	_	I-Claim
407	to	_	_	I-Claim
408	placebo	_	_	I-Claim
409	,	_	_	I-Claim
410	except	_	_	B-Claim
411	for	_	_	I-Claim
412	a	_	_	I-Claim
413	small	_	_	I-Claim
414	increase	_	_	I-Claim
415	in	_	_	I-Claim
416	loss	_	_	I-Claim
417	of	_	_	I-Claim
418	appetite	_	_	I-Claim
419	,	_	_	I-Claim
420	and	_	_	I-Claim
421	significantly	_	_	I-Claim
422	delayed	_	_	I-Claim
423	worsening	_	_	I-Claim
424	of	_	_	I-Claim
425	pain	_	_	I-Claim
426	and	_	_	I-Claim
427	haemoptysis	_	_	I-Claim
428	.	_	_	I-Claim

429	In	_	_	O
430	view	_	_	O
431	of	_	_	O
432	the	_	_	O
433	improvements	_	_	O
434	in	_	_	O
435	overall	_	_	O
436	and	_	_	O
437	progression-free	_	_	O
438	survival	_	_	O
439	noted	_	_	O
440	with	_	_	O
441	pemetrexed	_	_	O
442	maintenance	_	_	O
443	therapy	_	_	O
444	,	_	_	O
445	such	_	_	B-Claim
446	treatment	_	_	I-Claim
447	is	_	_	I-Claim
448	an	_	_	I-Claim
449	option	_	_	I-Claim
450	for	_	_	I-Claim
451	patients	_	_	I-Claim
452	with	_	_	I-Claim
453	advanced	_	_	I-Claim
454	non-squamous	_	_	I-Claim
455	NSCLC	_	_	I-Claim
456	who	_	_	I-Claim
457	have	_	_	I-Claim
458	not	_	_	I-Claim
459	progressed	_	_	I-Claim
460	after	_	_	I-Claim
461	platinum-based	_	_	I-Claim
462	induction	_	_	I-Claim
463	therapy	_	_	I-Claim
464	.	_	_	I-Claim


0	Topical	_	_	O
1	photodynamic	_	_	O
2	therapy	_	_	O
3	(	_	_	O
4	PDT	_	_	O
5	)	_	_	O
6	with	_	_	O
7	aminolevulinic	_	_	O
8	acid	_	_	O
9	(	_	_	O
10	ALA	_	_	O
11	)	_	_	O
12	and	_	_	O
13	5	_	_	O
14	%	_	_	O
15	imiquimod	_	_	O
16	cream	_	_	O
17	are	_	_	O
18	effective	_	_	O
19	therapies	_	_	O
20	for	_	_	O
21	the	_	_	O
22	treatment	_	_	O
23	of	_	_	O
24	actinic	_	_	O
25	keratoses	_	_	O
26	(	_	_	O
27	AKs	_	_	O
28	)	_	_	O
29	,	_	_	O
30	but	_	_	O
31	no	_	_	O
32	split-face	_	_	O
33	studies	_	_	O
34	directly	_	_	O
35	comparing	_	_	O
36	these	_	_	O
37	treatment	_	_	O
38	options	_	_	O
39	are	_	_	O
40	available	_	_	O
41	in	_	_	O
42	the	_	_	O
43	literature	_	_	O
44	.	_	_	O

45	To	_	_	O
46	compare	_	_	O
47	the	_	_	O
48	efficacy	_	_	O
49	and	_	_	O
50	tolerability	_	_	O
51	of	_	_	O
52	ALA-PDT	_	_	O
53	and	_	_	O
54	imiquimod	_	_	O
55	5	_	_	O
56	%	_	_	O
57	cream	_	_	O
58	for	_	_	O
59	the	_	_	O
60	treatment	_	_	O
61	of	_	_	O
62	AKs	_	_	O
63	.	_	_	O

64	Sixty-one	_	_	O
65	patients	_	_	O
66	were	_	_	O
67	enrolled	_	_	O
68	from	_	_	O
69	the	_	_	O
70	Salt	_	_	O
71	Lake	_	_	O
72	City	_	_	O
73	Veterans	_	_	O
74	Affairs	_	_	O
75	Hospital	_	_	O
76	;	_	_	O
77	51	_	_	O
78	completed	_	_	O
79	the	_	_	O
80	study	_	_	O
81	and	_	_	O
82	were	_	_	O
83	included	_	_	O
84	in	_	_	O
85	the	_	_	O
86	analysis	_	_	O
87	.	_	_	O

88	All	_	_	O
89	patients	_	_	O
90	were	_	_	O
91	randomized	_	_	O
92	to	_	_	O
93	receive	_	_	O
94	half	_	_	O
95	of	_	_	O
96	a	_	_	O
97	sachet	_	_	O
98	of	_	_	O
99	imiquimod	_	_	O
100	5	_	_	O
101	%	_	_	O
102	cream	_	_	O
103	twice	_	_	O
104	weekly	_	_	O
105	on	_	_	O
106	half	_	_	O
107	of	_	_	O
108	their	_	_	O
109	face	_	_	O
110	and	_	_	O
111	two	_	_	O
112	sessions	_	_	O
113	of	_	_	O
114	PDT	_	_	O
115	with	_	_	O
116	20	_	_	O
117	%	_	_	O
118	solution	_	_	O
119	of	_	_	O
120	ALA	_	_	O
121	applied	_	_	O
122	for	_	_	O
123	1	_	_	O
124	hour	_	_	O
125	to	_	_	O
126	the	_	_	O
127	other	_	_	O
128	side	_	_	O
129	of	_	_	O
130	the	_	_	O
131	face	_	_	O
132	.	_	_	O

133	The	_	_	B-Premise
134	75	_	_	I-Premise
135	%	_	_	I-Premise
136	AK	_	_	I-Premise
137	clearance	_	_	I-Premise
138	rate	_	_	I-Premise
139	was	_	_	I-Premise
140	34.6	_	_	I-Premise
141	%	_	_	I-Premise
142	for	_	_	I-Premise
143	ALA-PDT	_	_	I-Premise
144	and	_	_	I-Premise
145	25	_	_	I-Premise
146	%	_	_	I-Premise
147	for	_	_	I-Premise
148	imiquimod	_	_	I-Premise
149	5	_	_	I-Premise
150	%	_	_	I-Premise
151	cream	_	_	I-Premise
152	(	_	_	I-Premise
153	p	_	_	I-Premise
154	=	_	_	I-Premise
155	.30	_	_	I-Premise
156	)	_	_	I-Premise
157	.	_	_	I-Premise

158	The	_	_	B-Premise
159	mean	_	_	I-Premise
160	reduction	_	_	I-Premise
161	in	_	_	I-Premise
162	AK	_	_	I-Premise
163	count	_	_	I-Premise
164	was	_	_	I-Premise
165	59.2	_	_	I-Premise
166	%	_	_	I-Premise
167	for	_	_	I-Premise
168	ALA-PDT	_	_	I-Premise
169	and	_	_	I-Premise
170	41.4	_	_	I-Premise
171	%	_	_	I-Premise
172	for	_	_	I-Premise
173	imiquimod	_	_	I-Premise
174	5	_	_	I-Premise
175	%	_	_	I-Premise
176	cream	_	_	I-Premise
177	(	_	_	I-Premise
178	p	_	_	I-Premise
179	=	_	_	I-Premise
180	.002	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	Dermatology	_	_	B-Premise
184	Life	_	_	I-Premise
185	Quality	_	_	I-Premise
186	Index	_	_	I-Premise
187	(	_	_	I-Premise
188	DLQI	_	_	I-Premise
189	)	_	_	I-Premise
190	scores	_	_	I-Premise
191	were	_	_	I-Premise
192	assessed	_	_	I-Premise
193	for	_	_	I-Premise
194	each	_	_	I-Premise
195	treatment	_	_	I-Premise
196	modality	_	_	I-Premise
197	at	_	_	I-Premise
198	week	_	_	I-Premise
199	4	_	_	I-Premise
200	and	_	_	I-Premise
201	were	_	_	I-Premise
202	1.95	_	_	I-Premise
203	and	_	_	I-Premise
204	1.38	_	_	I-Premise
205	,	_	_	I-Premise
206	respectively	_	_	I-Premise
207	(	_	_	I-Premise
208	p	_	_	I-Premise
209	=	_	_	I-Premise
210	.20	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	sample	_	_	I-Premise
215	size	_	_	I-Premise
216	was	_	_	I-Premise
217	small	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	patients	_	_	I-Premise
221	applied	_	_	I-Premise
222	a	_	_	I-Premise
223	small	_	_	I-Premise
224	amount	_	_	I-Premise
225	of	_	_	I-Premise
226	imiquimod	_	_	I-Premise
227	5	_	_	I-Premise
228	%	_	_	I-Premise
229	cream	_	_	I-Premise
230	(	_	_	I-Premise
231	half	_	_	I-Premise
232	a	_	_	I-Premise
233	sachet	_	_	I-Premise
234	)	_	_	I-Premise
235	to	_	_	I-Premise
236	a	_	_	I-Premise
237	large	_	_	I-Premise
238	surface	_	_	I-Premise
239	area	_	_	I-Premise
240	.	_	_	I-Premise

241	There	_	_	B-Claim
242	was	_	_	I-Claim
243	no	_	_	I-Claim
244	statistically	_	_	I-Claim
245	significant	_	_	I-Claim
246	difference	_	_	I-Claim
247	in	_	_	I-Claim
248	treatment	_	_	I-Claim
249	response	_	_	I-Claim
250	when	_	_	I-Claim
251	the	_	_	I-Claim
252	100	_	_	I-Claim
253	%	_	_	I-Claim
254	or	_	_	I-Claim
255	75	_	_	I-Claim
256	%	_	_	I-Claim
257	clearance	_	_	I-Claim
258	rate	_	_	I-Claim
259	cutoff	_	_	I-Claim
260	was	_	_	I-Claim
261	used	_	_	I-Claim
262	,	_	_	I-Claim
263	but	_	_	B-Claim
264	our	_	_	I-Claim
265	secondary	_	_	I-Claim
266	outcome	_	_	I-Claim
267	suggests	_	_	I-Claim
268	that	_	_	I-Claim
269	two	_	_	I-Claim
270	sessions	_	_	I-Claim
271	of	_	_	I-Claim
272	ALA-PDT	_	_	I-Claim
273	is	_	_	I-Claim
274	superior	_	_	I-Claim
275	to	_	_	I-Claim
276	imiquimod	_	_	I-Claim
277	5	_	_	I-Claim
278	%	_	_	I-Claim
279	cream	_	_	I-Claim
280	for	_	_	I-Claim
281	the	_	_	I-Claim
282	treatment	_	_	I-Claim
283	of	_	_	I-Claim
284	AKs	_	_	I-Claim
285	.	_	_	I-Claim

286	There	_	_	B-Claim
287	was	_	_	I-Claim
288	no	_	_	I-Claim
289	statistically	_	_	I-Claim
290	significant	_	_	I-Claim
291	difference	_	_	I-Claim
292	in	_	_	I-Claim
293	effect	_	_	I-Claim
294	on	_	_	I-Claim
295	quality	_	_	I-Claim
296	of	_	_	I-Claim
297	life	_	_	I-Claim
298	as	_	_	I-Claim
299	assessed	_	_	I-Claim
300	using	_	_	I-Claim
301	the	_	_	I-Claim
302	DLQI	_	_	I-Claim
303	.	_	_	I-Claim


0	Hot	_	_	O
1	flushes	_	_	O
2	and	_	_	O
3	night	_	_	O
4	sweats	_	_	O
5	(	_	_	O
6	HFNS	_	_	O
7	)	_	_	O
8	affect	_	_	O
9	65-85	_	_	O
10	%	_	_	O
11	of	_	_	O
12	women	_	_	O
13	after	_	_	O
14	breast	_	_	O
15	cancer	_	_	O
16	treatment	_	_	O
17	;	_	_	O
18	they	_	_	O
19	are	_	_	O
20	distressing	_	_	O
21	,	_	_	O
22	causing	_	_	O
23	sleep	_	_	O
24	problems	_	_	O
25	and	_	_	O
26	decreased	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	.	_	_	O

31	Hormone	_	_	B-Claim
32	replacement	_	_	I-Claim
33	therapy	_	_	I-Claim
34	is	_	_	I-Claim
35	often	_	_	I-Claim
36	either	_	_	I-Claim
37	undesirable	_	_	I-Claim
38	or	_	_	I-Claim
39	contraindicated	_	_	I-Claim
40	.	_	_	I-Claim

41	Safe	_	_	B-Claim
42	,	_	_	I-Claim
43	effective	_	_	I-Claim
44	non-hormonal	_	_	I-Claim
45	treatments	_	_	I-Claim
46	are	_	_	I-Claim
47	needed	_	_	I-Claim
48	.	_	_	I-Claim

49	We	_	_	O
50	investigated	_	_	O
51	whether	_	_	O
52	cognitive	_	_	O
53	behavioural	_	_	O
54	therapy	_	_	O
55	(	_	_	O
56	CBT	_	_	O
57	)	_	_	O
58	can	_	_	O
59	help	_	_	O
60	breast	_	_	O
61	cancer	_	_	O
62	survivors	_	_	O
63	to	_	_	O
64	effectively	_	_	O
65	manage	_	_	O
66	HFNS	_	_	O
67	.	_	_	O

68	In	_	_	O
69	this	_	_	O
70	randomised	_	_	O
71	controlled	_	_	O
72	trial	_	_	O
73	,	_	_	O
74	we	_	_	O
75	recruited	_	_	O
76	women	_	_	O
77	from	_	_	O
78	breast	_	_	O
79	clinics	_	_	O
80	in	_	_	O
81	London	_	_	O
82	,	_	_	O
83	UK	_	_	O
84	,	_	_	O
85	who	_	_	O
86	had	_	_	O
87	problematic	_	_	O
88	HFNS	_	_	O
89	(	_	_	O
90	minimum	_	_	O
91	ten	_	_	O
92	problematic	_	_	O
93	episodes	_	_	O
94	a	_	_	O
95	week	_	_	O
96	)	_	_	O
97	after	_	_	O
98	breast-cancer	_	_	O
99	treatment	_	_	O
100	.	_	_	O

101	Participants	_	_	O
102	were	_	_	O
103	randomly	_	_	O
104	allocated	_	_	O
105	to	_	_	O
106	receive	_	_	O
107	either	_	_	O
108	usual	_	_	O
109	care	_	_	O
110	or	_	_	O
111	usual	_	_	O
112	care	_	_	O
113	plus	_	_	O
114	group	_	_	O
115	CBT	_	_	O
116	(	_	_	O
117	1:1	_	_	O
118	)	_	_	O
119	.	_	_	O

120	Randomisation	_	_	O
121	was	_	_	O
122	done	_	_	O
123	in	_	_	O
124	blocks	_	_	O
125	of	_	_	O
126	12-20	_	_	O
127	participants	_	_	O
128	,	_	_	O
129	stratifying	_	_	O
130	by	_	_	O
131	age	_	_	O
132	(	_	_	O
133	younger	_	_	O
134	than	_	_	O
135	50	_	_	O
136	years	_	_	O
137	,	_	_	O
138	50	_	_	O
139	years	_	_	O
140	or	_	_	O
141	older	_	_	O
142	)	_	_	O
143	,	_	_	O
144	and	_	_	O
145	was	_	_	O
146	done	_	_	O
147	with	_	_	O
148	a	_	_	O
149	computer-generated	_	_	O
150	sequence	_	_	O
151	.	_	_	O

152	The	_	_	O
153	trial	_	_	O
154	statistician	_	_	O
155	and	_	_	O
156	researchers	_	_	O
157	collecting	_	_	O
158	outcome	_	_	O
159	measures	_	_	O
160	were	_	_	O
161	masked	_	_	O
162	to	_	_	O
163	group	_	_	O
164	allocation	_	_	O
165	.	_	_	O

166	Group	_	_	O
167	CBT	_	_	O
168	comprised	_	_	O
169	one	_	_	O
170	90	_	_	O
171	min	_	_	O
172	session	_	_	O
173	a	_	_	O
174	week	_	_	O
175	for	_	_	O
176	6	_	_	O
177	weeks	_	_	O
178	,	_	_	O
179	and	_	_	O
180	included	_	_	O
181	psycho-education	_	_	O
182	,	_	_	O
183	paced	_	_	O
184	breathing	_	_	O
185	,	_	_	O
186	and	_	_	O
187	cognitive	_	_	O
188	and	_	_	O
189	behavioural	_	_	O
190	strategies	_	_	O
191	to	_	_	O
192	manage	_	_	O
193	HFNS	_	_	O
194	.	_	_	O

195	Assessments	_	_	O
196	were	_	_	O
197	done	_	_	O
198	at	_	_	O
199	baseline	_	_	O
200	,	_	_	O
201	9	_	_	O
202	weeks	_	_	O
203	,	_	_	O
204	and	_	_	O
205	26	_	_	O
206	weeks	_	_	O
207	after	_	_	O
208	randomisation	_	_	O
209	.	_	_	O

210	The	_	_	O
211	primary	_	_	O
212	outcome	_	_	O
213	was	_	_	O
214	the	_	_	O
215	adjusted	_	_	O
216	mean	_	_	O
217	difference	_	_	O
218	in	_	_	O
219	HFNS	_	_	O
220	problem	_	_	O
221	rating	_	_	O
222	(	_	_	O
223	1-10	_	_	O
224	)	_	_	O
225	between	_	_	O
226	CBT	_	_	O
227	and	_	_	O
228	usual	_	_	O
229	care	_	_	O
230	groups	_	_	O
231	at	_	_	O
232	9	_	_	O
233	weeks	_	_	O
234	after	_	_	O
235	randomisation	_	_	O
236	.	_	_	O

237	Analysis	_	_	O
238	of	_	_	O
239	the	_	_	O
240	primary	_	_	O
241	endpoint	_	_	O
242	was	_	_	O
243	done	_	_	O
244	by	_	_	O
245	modified	_	_	O
246	intention	_	_	O
247	to	_	_	O
248	treat	_	_	O
249	.	_	_	O

250	The	_	_	O
251	trial	_	_	O
252	is	_	_	O
253	registered	_	_	O
254	,	_	_	O
255	ISRCTN13771934	_	_	O
256	,	_	_	O
257	and	_	_	O
258	was	_	_	O
259	closed	_	_	O
260	March	_	_	O
261	15	_	_	O
262	,	_	_	O
263	2011	_	_	O
264	.	_	_	O

265	Between	_	_	O
266	May	_	_	O
267	5	_	_	O
268	,	_	_	O
269	2009	_	_	O
270	,	_	_	O
271	and	_	_	O
272	Aug	_	_	O
273	27	_	_	O
274	,	_	_	O
275	2010	_	_	O
276	,	_	_	O
277	96	_	_	O
278	women	_	_	O
279	were	_	_	O
280	randomly	_	_	O
281	allocated	_	_	O
282	to	_	_	O
283	group	_	_	O
284	CBT	_	_	O
285	(	_	_	O
286	n=47	_	_	O
287	)	_	_	O
288	or	_	_	O
289	usual	_	_	O
290	care	_	_	O
291	(	_	_	O
292	n=49	_	_	O
293	)	_	_	O
294	.	_	_	O

295	Group	_	_	B-Premise
296	CBT	_	_	I-Premise
297	significantly	_	_	I-Premise
298	reduced	_	_	I-Premise
299	HFNS	_	_	I-Premise
300	problem	_	_	I-Premise
301	rating	_	_	I-Premise
302	at	_	_	I-Premise
303	9	_	_	I-Premise
304	weeks	_	_	I-Premise
305	after	_	_	I-Premise
306	randomisation	_	_	I-Premise
307	compared	_	_	I-Premise
308	with	_	_	I-Premise
309	usual	_	_	I-Premise
310	care	_	_	I-Premise
311	(	_	_	I-Premise
312	mean	_	_	I-Premise
313	difference	_	_	I-Premise
314	-1·67	_	_	I-Premise
315	,	_	_	I-Premise
316	95	_	_	I-Premise
317	%	_	_	I-Premise
318	CI	_	_	I-Premise
319	-2·43	_	_	I-Premise
320	to	_	_	I-Premise
321	-0·91	_	_	I-Premise
322	;	_	_	I-Premise
323	p	_	_	I-Premise
324	<	_	_	I-Premise
325	0·0001	_	_	I-Premise
326	)	_	_	I-Premise
327	and	_	_	I-Premise
328	improvements	_	_	I-Premise
329	were	_	_	I-Premise
330	maintained	_	_	I-Premise
331	at	_	_	I-Premise
332	26	_	_	I-Premise
333	weeks	_	_	I-Premise
334	(	_	_	I-Premise
335	mean	_	_	I-Premise
336	difference	_	_	I-Premise
337	-1·76	_	_	I-Premise
338	,	_	_	I-Premise
339	-2·54	_	_	I-Premise
340	to	_	_	I-Premise
341	-0·99	_	_	I-Premise
342	;	_	_	I-Premise
343	p	_	_	I-Premise
344	<	_	_	I-Premise
345	0·0001	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	We	_	_	B-Premise
349	recorded	_	_	I-Premise
350	no	_	_	I-Premise
351	CBT-related	_	_	I-Premise
352	adverse	_	_	I-Premise
353	events	_	_	I-Premise
354	.	_	_	I-Premise

355	Group	_	_	B-Claim
356	CBT	_	_	I-Claim
357	seems	_	_	I-Claim
358	to	_	_	I-Claim
359	be	_	_	I-Claim
360	a	_	_	I-Claim
361	safe	_	_	I-Claim
362	and	_	_	I-Claim
363	effective	_	_	I-Claim
364	treatment	_	_	I-Claim
365	for	_	_	I-Claim
366	women	_	_	I-Claim
367	who	_	_	I-Claim
368	have	_	_	I-Claim
369	problematic	_	_	I-Claim
370	HFNS	_	_	I-Claim
371	after	_	_	I-Claim
372	breast	_	_	I-Claim
373	cancer	_	_	I-Claim
374	treatment	_	_	I-Claim
375	with	_	_	I-Claim
376	additional	_	_	I-Claim
377	benefits	_	_	I-Claim
378	to	_	_	I-Claim
379	mood	_	_	I-Claim
380	,	_	_	I-Claim
381	sleep	_	_	I-Claim
382	,	_	_	I-Claim
383	and	_	_	I-Claim
384	quality	_	_	I-Claim
385	of	_	_	I-Claim
386	life	_	_	I-Claim
387	.	_	_	I-Claim

388	The	_	_	O
389	treatment	_	_	O
390	could	_	_	O
391	be	_	_	O
392	incorporated	_	_	O
393	into	_	_	O
394	breast	_	_	O
395	cancer	_	_	O
396	survivorship	_	_	O
397	programmes	_	_	O
398	and	_	_	O
399	delivered	_	_	O
400	by	_	_	O
401	trained	_	_	O
402	breast	_	_	O
403	cancer	_	_	O
404	nurses	_	_	O
405	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	intraocular	_	_	O
3	pressure	_	_	O
4	(	_	_	O
5	IOP	_	_	O
6	)	_	_	O
7	over	_	_	O
8	time	_	_	O
9	after	_	_	O
10	standard	_	_	O
11	trabeculectomy	_	_	O
12	vs	_	_	O
13	Ex-PRESS	_	_	O
14	implantation	_	_	O
15	in	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	bilateral	_	_	O
19	primary	_	_	O
20	open-angle	_	_	O
21	glaucoma	_	_	O
22	(	_	_	O
23	POAG	_	_	O
24	)	_	_	O
25	.	_	_	O

26	Prospective	_	_	O
27	,	_	_	O
28	randomised	_	_	O
29	study	_	_	O
30	.	_	_	O

31	This	_	_	O
32	study	_	_	O
33	included	_	_	O
34	adult	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	bilateral	_	_	O
38	POAG	_	_	O
39	necessitating	_	_	O
40	surgery	_	_	O
41	.	_	_	O

42	Each	_	_	O
43	patient	_	_	O
44	underwent	_	_	O
45	trabeculectomy	_	_	O
46	in	_	_	O
47	one	_	_	O
48	eye	_	_	O
49	and	_	_	O
50	Ex-PRESS	_	_	O
51	implantation	_	_	O
52	under	_	_	O
53	a	_	_	O
54	scleral	_	_	O
55	flap	_	_	O
56	in	_	_	O
57	the	_	_	O
58	other	_	_	O
59	eye	_	_	O
60	according	_	_	O
61	to	_	_	O
62	randomised	_	_	O
63	contralateral	_	_	O
64	allocations	_	_	O
65	.	_	_	O

66	Efficacy	_	_	O
67	was	_	_	O
68	assessed	_	_	O
69	by	_	_	O
70	IOP	_	_	O
71	values	_	_	O
72	and	_	_	O
73	success	_	_	O
74	rates	_	_	O
75	(	_	_	O
76	IOP	_	_	O
77	threshold	_	_	O
78	and/or	_	_	O
79	need	_	_	O
80	for	_	_	O
81	topical	_	_	O
82	glaucoma	_	_	O
83	medication	_	_	O
84	)	_	_	O
85	during	_	_	O
86	30	_	_	O
87	months	_	_	O
88	.	_	_	O

89	Statistical	_	_	O
90	analysis	_	_	O
91	included	_	_	O
92	Generalised	_	_	O
93	Estimate	_	_	O
94	Equation	_	_	O
95	and	_	_	O
96	Cox	_	_	O
97	Survival	_	_	O
98	models	_	_	O
99	,	_	_	O
100	and	_	_	O
101	paired	_	_	O
102	t-tests	_	_	O
103	.	_	_	O

104	Thirty	_	_	O
105	eyes	_	_	O
106	of	_	_	O
107	15	_	_	O
108	patients	_	_	O
109	were	_	_	O
110	studied	_	_	O
111	for	_	_	O
112	a	_	_	O
113	mean	_	_	O
114	of	_	_	O
115	23.6	_	_	O
116	months	_	_	O
117	(	_	_	O
118	SD	_	_	O
119	,	_	_	O
120	±	_	_	O
121	6.9	_	_	O
122	)	_	_	O
123	.	_	_	O

124	At	_	_	B-Premise
125	the	_	_	I-Premise
126	last	_	_	I-Premise
127	follow-up	_	_	I-Premise
128	visit	_	_	I-Premise
129	,	_	_	I-Premise
130	mean	_	_	I-Premise
131	pre-operative	_	_	I-Premise
132	IOP	_	_	I-Premise
133	decreased	_	_	I-Premise
134	from	_	_	I-Premise
135	31.1	_	_	I-Premise
136	(	_	_	I-Premise
137	±	_	_	I-Premise
138	14.2	_	_	I-Premise
139	)	_	_	I-Premise
140	to	_	_	I-Premise
141	16.2	_	_	I-Premise
142	(	_	_	I-Premise
143	±	_	_	I-Premise
144	1.5	_	_	I-Premise
145	)	_	_	I-Premise
146	mm	_	_	I-Premise
147	Hg	_	_	I-Premise
148	after	_	_	I-Premise
149	trabeculectomy	_	_	I-Premise
150	,	_	_	I-Premise
151	and	_	_	I-Premise
152	from	_	_	I-Premise
153	28.1	_	_	I-Premise
154	(	_	_	I-Premise
155	±	_	_	I-Premise
156	9.0	_	_	I-Premise
157	)	_	_	I-Premise
158	to	_	_	I-Premise
159	15.7	_	_	I-Premise
160	(	_	_	I-Premise
161	±	_	_	I-Premise
162	1.8	_	_	I-Premise
163	)	_	_	I-Premise
164	mm	_	_	I-Premise
165	Hg	_	_	I-Premise
166	after	_	_	I-Premise
167	Ex-PRESS	_	_	I-Premise
168	implantation	_	_	I-Premise
169	(	_	_	I-Premise
170	P=0.001	_	_	I-Premise
171	)	_	_	I-Premise
172	.	_	_	I-Premise

173	The	_	_	B-Premise
174	mean	_	_	I-Premise
175	number	_	_	I-Premise
176	of	_	_	I-Premise
177	anti-glaucoma	_	_	I-Premise
178	medicines	_	_	I-Premise
179	prescribed	_	_	I-Premise
180	at	_	_	I-Premise
181	the	_	_	I-Premise
182	last	_	_	I-Premise
183	follow-up	_	_	I-Premise
184	decreased	_	_	I-Premise
185	from	_	_	I-Premise
186	3.7	_	_	I-Premise
187	pre-operatively	_	_	I-Premise
188	(	_	_	I-Premise
189	both	_	_	I-Premise
190	groups	_	_	I-Premise
191	)	_	_	I-Premise
192	to	_	_	I-Premise
193	0.9	_	_	I-Premise
194	after	_	_	I-Premise
195	trabeculectomy	_	_	I-Premise
196	vs	_	_	I-Premise
197	0.3	_	_	I-Premise
198	after	_	_	I-Premise
199	Ex-PRESS	_	_	I-Premise
200	implantation	_	_	I-Premise
201	(	_	_	I-Premise
202	P=0.001	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Complete	_	_	B-Premise
206	success	_	_	I-Premise
207	rates	_	_	I-Premise
208	(	_	_	I-Premise
209	5	_	_	I-Premise
210	<	_	_	I-Premise
211	IOP	_	_	I-Premise
212	<	_	_	I-Premise
213	18	_	_	I-Premise
214	mm	_	_	I-Premise
215	Hg	_	_	I-Premise
216	without	_	_	I-Premise
217	medications	_	_	I-Premise
218	)	_	_	I-Premise
219	were	_	_	I-Premise
220	higher	_	_	I-Premise
221	with	_	_	I-Premise
222	Ex-PRESS	_	_	I-Premise
223	compared	_	_	I-Premise
224	with	_	_	I-Premise
225	trabeculectomy	_	_	I-Premise
226	(	_	_	I-Premise
227	P=0.0024	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Postoperative	_	_	B-Premise
231	complications	_	_	I-Premise
232	were	_	_	I-Premise
233	more	_	_	I-Premise
234	frequent	_	_	I-Premise
235	after	_	_	I-Premise
236	trabeculectomy	_	_	I-Premise
237	(	_	_	I-Premise
238	33	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	compared	_	_	I-Premise
242	with	_	_	I-Premise
243	Ex-PRESS	_	_	I-Premise
244	(	_	_	I-Premise
245	20	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	,	_	_	I-Premise
249	with	_	_	I-Premise
250	four	_	_	I-Premise
251	trabeculectomy	_	_	I-Premise
252	eyes	_	_	I-Premise
253	(	_	_	I-Premise
254	27	_	_	I-Premise
255	%	_	_	I-Premise
256	)	_	_	I-Premise
257	needing	_	_	I-Premise
258	postoperative	_	_	I-Premise
259	interventions	_	_	I-Premise
260	,	_	_	I-Premise
261	compared	_	_	I-Premise
262	with	_	_	I-Premise
263	none	_	_	I-Premise
264	with	_	_	I-Premise
265	Ex-PRESS	_	_	I-Premise
266	.	_	_	I-Premise

267	Trabeculectomy	_	_	B-Claim
268	and	_	_	I-Claim
269	Ex-PRESS	_	_	I-Claim
270	implantation	_	_	I-Claim
271	provided	_	_	I-Claim
272	similar	_	_	I-Claim
273	IOP	_	_	I-Claim
274	control	_	_	I-Claim
275	,	_	_	I-Claim
276	but	_	_	O
277	the	_	_	B-Claim
278	Ex-PRESS	_	_	I-Claim
279	group	_	_	I-Claim
280	had	_	_	I-Claim
281	a	_	_	I-Claim
282	lower	_	_	I-Claim
283	rate	_	_	I-Claim
284	of	_	_	I-Claim
285	complications	_	_	I-Claim
286	,	_	_	I-Claim
287	fewer	_	_	I-Claim
288	postoperative	_	_	I-Claim
289	interventions	_	_	I-Claim
290	,	_	_	I-Claim
291	and	_	_	I-Claim
292	needed	_	_	I-Claim
293	less	_	_	I-Claim
294	glaucoma	_	_	I-Claim
295	medications	_	_	I-Claim
296	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	analgesic	_	_	O
4	effect	_	_	O
5	,	_	_	O
6	safety	_	_	O
7	,	_	_	O
8	and	_	_	O
9	cost-effectiveness	_	_	O
10	of	_	_	O
11	controlled-release	_	_	O
12	oxycodone	_	_	O
13	(	_	_	O
14	CRO	_	_	O
15	)	_	_	O
16	to	_	_	O
17	control	_	_	O
18	postoperative	_	_	O
19	pain	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	liver	_	_	O
24	cancer	_	_	O
25	who	_	_	O
26	are	_	_	O
27	undergoing	_	_	O
28	transarterial	_	_	O
29	chemoembolization	_	_	O
30	.	_	_	O

31	This	_	_	O
32	randomized	_	_	O
33	,	_	_	O
34	double-blind	_	_	O
35	,	_	_	O
36	placebo-controlled	_	_	O
37	,	_	_	O
38	prospective	_	_	O
39	clinical	_	_	O
40	study	_	_	O
41	received	_	_	O
42	institutional	_	_	O
43	review	_	_	O
44	board	_	_	O
45	approval	_	_	O
46	.	_	_	O

47	After	_	_	O
48	written	_	_	O
49	informed	_	_	O
50	consent	_	_	O
51	was	_	_	O
52	obtained	_	_	O
53	,	_	_	O
54	210	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	liver	_	_	O
58	cancer	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	into	_	_	O
62	three	_	_	O
63	groups	_	_	O
64	of	_	_	O
65	70	_	_	O
66	patients	_	_	O
67	.	_	_	O

68	Group	_	_	O
69	1	_	_	O
70	received	_	_	O
71	20	_	_	O
72	mg	_	_	O
73	of	_	_	O
74	CRO	_	_	O
75	,	_	_	O
76	group	_	_	O
77	2	_	_	O
78	received	_	_	O
79	10	_	_	O
80	mg	_	_	O
81	of	_	_	O
82	CRO	_	_	O
83	,	_	_	O
84	and	_	_	O
85	group	_	_	O
86	3	_	_	O
87	received	_	_	O
88	a	_	_	O
89	placebo	_	_	O
90	at	_	_	O
91	1	_	_	O
92	hour	_	_	O
93	before	_	_	O
94	transarterial	_	_	O
95	chemoembolization	_	_	O
96	(	_	_	O
97	T	_	_	O
98	(	_	_	O
99	0	_	_	O
100	)	_	_	O
101	)	_	_	O
102	and	_	_	O
103	12	_	_	O
104	(	_	_	O
105	T	_	_	O
106	(	_	_	O
107	12	_	_	O
108	)	_	_	O
109	)	_	_	O
110	and	_	_	O
111	24	_	_	O
112	(	_	_	O
113	T	_	_	O
114	(	_	_	O
115	24	_	_	O
116	)	_	_	O
117	)	_	_	O
118	hours	_	_	O
119	after	_	_	O
120	T	_	_	O
121	(	_	_	O
122	0	_	_	O
123	)	_	_	O
124	.	_	_	O

125	Pain	_	_	O
126	intensity	_	_	O
127	on	_	_	O
128	a	_	_	O
129	numeric	_	_	O
130	rating	_	_	O
131	scale	_	_	O
132	,	_	_	O
133	percentage	_	_	O
134	of	_	_	O
135	patients	_	_	O
136	with	_	_	O
137	each	_	_	O
138	degree	_	_	O
139	of	_	_	O
140	pain	_	_	O
141	,	_	_	O
142	quality	_	_	O
143	of	_	_	O
144	life	_	_	O
145	,	_	_	O
146	adverse	_	_	O
147	reactions	_	_	O
148	,	_	_	O
149	analgesic	_	_	O
150	costs	_	_	O
151	,	_	_	O
152	and	_	_	O
153	hospital	_	_	O
154	stays	_	_	O
155	were	_	_	O
156	evaluated	_	_	O
157	and	_	_	O
158	compared	_	_	O
159	among	_	_	O
160	the	_	_	O
161	three	_	_	O
162	groups	_	_	O
163	.	_	_	O

164	Numeric	_	_	B-Premise
165	rating	_	_	I-Premise
166	scale	_	_	I-Premise
167	scores	_	_	I-Premise
168	for	_	_	I-Premise
169	pain	_	_	I-Premise
170	intensity	_	_	I-Premise
171	in	_	_	I-Premise
172	group	_	_	I-Premise
173	1	_	_	I-Premise
174	and	_	_	I-Premise
175	group	_	_	I-Premise
176	2	_	_	I-Premise
177	were	_	_	I-Premise
178	significantly	_	_	I-Premise
179	lower	_	_	I-Premise
180	than	_	_	I-Premise
181	those	_	_	I-Premise
182	in	_	_	I-Premise
183	group	_	_	I-Premise
184	3	_	_	I-Premise
185	at	_	_	I-Premise
186	T	_	_	I-Premise
187	(	_	_	I-Premise
188	0-12	_	_	I-Premise
189	)	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	<	_	_	I-Premise
193	.001	_	_	I-Premise
194	)	_	_	I-Premise
195	;	_	_	I-Premise
196	T	_	_	I-Premise
197	(	_	_	I-Premise
198	12-24	_	_	I-Premise
199	)	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	<	_	_	I-Premise
203	.001	_	_	I-Premise
204	)	_	_	I-Premise
205	;	_	_	I-Premise
206	and	_	_	I-Premise
207	T	_	_	I-Premise
208	(	_	_	I-Premise
209	24-48	_	_	I-Premise
210	)	_	_	I-Premise
211	(	_	_	I-Premise
212	P	_	_	I-Premise
213	<	_	_	I-Premise
214	.001	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	When	_	_	B-Premise
218	group	_	_	I-Premise
219	1	_	_	I-Premise
220	with	_	_	I-Premise
221	group	_	_	I-Premise
222	2	_	_	I-Premise
223	were	_	_	I-Premise
224	compared	_	_	I-Premise
225	,	_	_	I-Premise
226	numeric	_	_	I-Premise
227	rating	_	_	I-Premise
228	scale	_	_	I-Premise
229	scores	_	_	I-Premise
230	were	_	_	I-Premise
231	significantly	_	_	I-Premise
232	lower	_	_	I-Premise
233	in	_	_	I-Premise
234	group	_	_	I-Premise
235	1	_	_	I-Premise
236	than	_	_	I-Premise
237	in	_	_	I-Premise
238	group	_	_	I-Premise
239	2	_	_	I-Premise
240	during	_	_	I-Premise
241	the	_	_	I-Premise
242	period	_	_	I-Premise
243	of	_	_	I-Premise
244	T	_	_	I-Premise
245	(	_	_	I-Premise
246	0-12	_	_	I-Premise
247	)	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	.001	_	_	I-Premise
252	)	_	_	I-Premise
253	but	_	_	B-Premise
254	were	_	_	I-Premise
255	not	_	_	I-Premise
256	significantly	_	_	I-Premise
257	different	_	_	I-Premise
258	at	_	_	I-Premise
259	T	_	_	I-Premise
260	(	_	_	I-Premise
261	12-24	_	_	I-Premise
262	)	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.68	_	_	I-Premise
267	)	_	_	I-Premise
268	and	_	_	I-Premise
269	T	_	_	I-Premise
270	(	_	_	I-Premise
271	24-48	_	_	I-Premise
272	)	_	_	I-Premise
273	(	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	.10	_	_	I-Premise
277	)	_	_	I-Premise
278	.	_	_	I-Premise

279	Analgesic	_	_	B-Premise
280	cost	_	_	I-Premise
281	and	_	_	I-Premise
282	hospital	_	_	I-Premise
283	stay	_	_	I-Premise
284	were	_	_	I-Premise
285	significantly	_	_	I-Premise
286	lower	_	_	I-Premise
287	in	_	_	I-Premise
288	treated	_	_	I-Premise
289	groups	_	_	I-Premise
290	than	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	placebo	_	_	I-Premise
294	group	_	_	I-Premise
295	.	_	_	I-Premise

296	No	_	_	B-Premise
297	significant	_	_	I-Premise
298	difference	_	_	I-Premise
299	was	_	_	I-Premise
300	observed	_	_	I-Premise
301	in	_	_	I-Premise
302	quality	_	_	I-Premise
303	of	_	_	I-Premise
304	life	_	_	I-Premise
305	and	_	_	I-Premise
306	adverse	_	_	I-Premise
307	events	_	_	I-Premise
308	between	_	_	I-Premise
309	the	_	_	I-Premise
310	treated	_	_	I-Premise
311	groups	_	_	I-Premise
312	and	_	_	I-Premise
313	the	_	_	I-Premise
314	placebo	_	_	I-Premise
315	group	_	_	I-Premise
316	.	_	_	I-Premise

317	CRO	_	_	B-Claim
318	is	_	_	I-Claim
319	effective	_	_	I-Claim
320	,	_	_	I-Claim
321	safe	_	_	I-Claim
322	,	_	_	I-Claim
323	and	_	_	I-Claim
324	cost-effective	_	_	I-Claim
325	in	_	_	I-Claim
326	the	_	_	I-Claim
327	control	_	_	I-Claim
328	of	_	_	I-Claim
329	postoperative	_	_	I-Claim
330	pain	_	_	I-Claim
331	after	_	_	I-Claim
332	transarterial	_	_	I-Claim
333	chemoembolization	_	_	I-Claim
334	for	_	_	I-Claim
335	patients	_	_	I-Claim
336	with	_	_	I-Claim
337	inoperable	_	_	I-Claim
338	liver	_	_	I-Claim
339	cancer	_	_	I-Claim
340	.	_	_	I-Claim


0	Gefitinib	_	_	O
1	has	_	_	O
2	shown	_	_	O
3	high	_	_	O
4	response	_	_	O
5	rate	_	_	O
6	and	_	_	O
7	improved	_	_	O
8	progression-free	_	_	O
9	survival	_	_	O
10	(	_	_	O
11	PFS	_	_	O
12	)	_	_	O
13	in	_	_	O
14	never-smokers	_	_	O
15	with	_	_	O
16	lung	_	_	O
17	adenocarcinoma	_	_	O
18	(	_	_	O
19	NSLAs	_	_	O
20	)	_	_	O
21	.	_	_	O

22	We	_	_	O
23	compared	_	_	O
24	efficacy	_	_	O
25	of	_	_	O
26	gefitinib	_	_	O
27	with	_	_	O
28	gemcitabine	_	_	O
29	and	_	_	O
30	cisplatin	_	_	O
31	(	_	_	O
32	GP	_	_	O
33	)	_	_	O
34	chemotherapy	_	_	O
35	in	_	_	O
36	this	_	_	O
37	group	_	_	O
38	of	_	_	O
39	patients	_	_	O
40	as	_	_	O
41	first-line	_	_	O
42	therapy	_	_	O
43	.	_	_	O

44	In	_	_	O
45	this	_	_	O
46	randomized	_	_	O
47	phase	_	_	O
48	III	_	_	O
49	trial	_	_	O
50	,	_	_	O
51	a	_	_	O
52	total	_	_	O
53	of	_	_	O
54	313	_	_	O
55	Korean	_	_	O
56	never-smokers	_	_	O
57	with	_	_	O
58	stage	_	_	O
59	IIIB	_	_	O
60	or	_	_	O
61	IV	_	_	O
62	lung	_	_	O
63	adenocarcinoma	_	_	O
64	,	_	_	O
65	Eastern	_	_	O
66	Cooperative	_	_	O
67	Oncology	_	_	O
68	Group	_	_	O
69	performance	_	_	O
70	status	_	_	O
71	0	_	_	O
72	to	_	_	O
73	2	_	_	O
74	,	_	_	O
75	and	_	_	O
76	adequate	_	_	O
77	organ	_	_	O
78	function	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	either	_	_	O
85	gefitinib	_	_	O
86	(	_	_	O
87	250	_	_	O
88	mg	_	_	O
89	daily	_	_	O
90	)	_	_	O
91	or	_	_	O
92	GP	_	_	O
93	chemotherapy	_	_	O
94	(	_	_	O
95	gemcitabine	_	_	O
96	1,250	_	_	O
97	mg/m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	on	_	_	O
102	days	_	_	O
103	1	_	_	O
104	and	_	_	O
105	8	_	_	O
106	;	_	_	O
107	cisplatin	_	_	O
108	80	_	_	O
109	mg/m	_	_	O
110	(	_	_	O
111	2	_	_	O
112	)	_	_	O
113	on	_	_	O
114	day	_	_	O
115	1	_	_	O
116	every	_	_	O
117	3	_	_	O
118	weeks	_	_	O
119	,	_	_	O
120	for	_	_	O
121	up	_	_	O
122	to	_	_	O
123	nine	_	_	O
124	courses	_	_	O
125	)	_	_	O
126	.	_	_	O

127	The	_	_	O
128	primary	_	_	O
129	objective	_	_	O
130	was	_	_	O
131	to	_	_	O
132	demonstrate	_	_	O
133	better	_	_	O
134	overall	_	_	O
135	survival	_	_	O
136	(	_	_	O
137	OS	_	_	O
138	)	_	_	O
139	for	_	_	O
140	gefitinib	_	_	O
141	compared	_	_	O
142	with	_	_	O
143	GP	_	_	O
144	in	_	_	O
145	chemotherapy-naive	_	_	O
146	NSLAs	_	_	O
147	.	_	_	O

148	Three	_	_	O
149	hundred	_	_	O
150	nine	_	_	O
151	patients	_	_	O
152	were	_	_	O
153	analyzed	_	_	O
154	per	_	_	O
155	protocol	_	_	O
156	(	_	_	O
157	gefitinib	_	_	O
158	arm	_	_	O
159	,	_	_	O
160	n	_	_	O
161	=	_	_	O
162	159	_	_	O
163	;	_	_	O
164	GP	_	_	O
165	arm	_	_	O
166	,	_	_	O
167	n	_	_	O
168	=	_	_	O
169	150	_	_	O
170	)	_	_	O
171	.	_	_	O

172	Gefitinib	_	_	B-Premise
173	did	_	_	I-Premise
174	not	_	_	I-Premise
175	show	_	_	I-Premise
176	better	_	_	I-Premise
177	OS	_	_	I-Premise
178	compared	_	_	I-Premise
179	with	_	_	I-Premise
180	GP	_	_	I-Premise
181	(	_	_	I-Premise
182	hazard	_	_	I-Premise
183	ratio	_	_	I-Premise
184	[	_	_	I-Premise
185	HR	_	_	I-Premise
186	]	_	_	I-Premise
187	,	_	_	I-Premise
188	0.932	_	_	I-Premise
189	;	_	_	I-Premise
190	95	_	_	I-Premise
191	%	_	_	I-Premise
192	CI	_	_	I-Premise
193	,	_	_	I-Premise
194	0.716	_	_	I-Premise
195	to	_	_	I-Premise
196	1.213	_	_	I-Premise
197	;	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	.604	_	_	I-Premise
201	;	_	_	I-Premise
202	median	_	_	I-Premise
203	OS	_	_	I-Premise
204	,	_	_	I-Premise
205	22.3	_	_	I-Premise
206	v	_	_	I-Premise
207	22.9	_	_	I-Premise
208	months	_	_	I-Premise
209	,	_	_	I-Premise
210	respectively	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	1-year	_	_	I-Premise
215	PFS	_	_	I-Premise
216	rates	_	_	I-Premise
217	were	_	_	I-Premise
218	16.7	_	_	I-Premise
219	%	_	_	I-Premise
220	with	_	_	I-Premise
221	gefitinib	_	_	I-Premise
222	and	_	_	I-Premise
223	2.8	_	_	I-Premise
224	%	_	_	I-Premise
225	with	_	_	I-Premise
226	GP	_	_	I-Premise
227	(	_	_	I-Premise
228	HR	_	_	I-Premise
229	,	_	_	I-Premise
230	1.198	_	_	I-Premise
231	;	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	CI	_	_	I-Premise
235	,	_	_	I-Premise
236	0.944	_	_	I-Premise
237	to	_	_	I-Premise
238	1.520	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	Response	_	_	B-Premise
242	rates	_	_	I-Premise
243	were	_	_	I-Premise
244	55	_	_	I-Premise
245	%	_	_	I-Premise
246	with	_	_	I-Premise
247	gefitinib	_	_	I-Premise
248	and	_	_	I-Premise
249	46	_	_	I-Premise
250	%	_	_	I-Premise
251	with	_	_	I-Premise
252	GP	_	_	I-Premise
253	(	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.101	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Myelosuppression	_	_	B-Premise
260	,	_	_	I-Premise
261	renal	_	_	I-Premise
262	insufficiency	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	fatigue	_	_	I-Premise
266	were	_	_	I-Premise
267	more	_	_	I-Premise
268	common	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	GP	_	_	I-Premise
272	arm	_	_	I-Premise
273	,	_	_	I-Premise
274	but	_	_	O
275	skin	_	_	B-Premise
276	toxicities	_	_	I-Premise
277	and	_	_	I-Premise
278	liver	_	_	I-Premise
279	dysfunction	_	_	I-Premise
280	were	_	_	I-Premise
281	more	_	_	I-Premise
282	common	_	_	I-Premise
283	in	_	_	I-Premise
284	the	_	_	I-Premise
285	gefitinib	_	_	I-Premise
286	arm	_	_	I-Premise
287	.	_	_	I-Premise

288	Two	_	_	B-Premise
289	patients	_	_	I-Premise
290	(	_	_	I-Premise
291	1.3	_	_	I-Premise
292	%	_	_	I-Premise
293	)	_	_	I-Premise
294	in	_	_	I-Premise
295	the	_	_	I-Premise
296	gefitinib	_	_	I-Premise
297	arm	_	_	I-Premise
298	developed	_	_	I-Premise
299	interstitial	_	_	I-Premise
300	lung	_	_	I-Premise
301	disease	_	_	I-Premise
302	and	_	_	I-Premise
303	died	_	_	I-Premise
304	.	_	_	I-Premise

305	Gefitinib	_	_	B-Claim
306	failed	_	_	I-Claim
307	to	_	_	I-Claim
308	demonstrate	_	_	I-Claim
309	superior	_	_	I-Claim
310	OS	_	_	I-Claim
311	compared	_	_	I-Claim
312	with	_	_	I-Claim
313	GP	_	_	I-Claim
314	as	_	_	I-Claim
315	first-line	_	_	I-Claim
316	therapy	_	_	I-Claim
317	for	_	_	I-Claim
318	NSLAs	_	_	I-Claim
319	.	_	_	I-Claim


0	Spiritual	_	_	O
1	well-being	_	_	O
2	and	_	_	O
3	sense	_	_	O
4	of	_	_	O
5	meaning	_	_	O
6	are	_	_	O
7	important	_	_	O
8	concerns	_	_	O
9	for	_	_	O
10	clinicians	_	_	O
11	who	_	_	O
12	care	_	_	O
13	for	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	cancer	_	_	O
17	.	_	_	O

18	We	_	_	O
19	developed	_	_	O
20	Individual	_	_	O
21	Meaning-Centered	_	_	O
22	Psychotherapy	_	_	O
23	(	_	_	O
24	IMCP	_	_	O
25	)	_	_	O
26	to	_	_	O
27	address	_	_	O
28	the	_	_	O
29	need	_	_	O
30	for	_	_	O
31	brief	_	_	O
32	interventions	_	_	O
33	targeting	_	_	O
34	spiritual	_	_	O
35	well-being	_	_	O
36	and	_	_	O
37	meaning	_	_	O
38	for	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	advanced	_	_	O
42	cancer	_	_	O
43	.	_	_	O

44	Patients	_	_	O
45	with	_	_	O
46	stage	_	_	O
47	III	_	_	O
48	or	_	_	O
49	IV	_	_	O
50	cancer	_	_	O
51	(	_	_	O
52	N	_	_	O
53	=	_	_	O
54	120	_	_	O
55	)	_	_	O
56	were	_	_	O
57	randomly	_	_	O
58	assigned	_	_	O
59	to	_	_	O
60	seven	_	_	O
61	sessions	_	_	O
62	of	_	_	O
63	either	_	_	O
64	IMCP	_	_	O
65	or	_	_	O
66	therapeutic	_	_	O
67	massage	_	_	O
68	(	_	_	O
69	TM	_	_	O
70	)	_	_	O
71	.	_	_	O

72	Patients	_	_	O
73	were	_	_	O
74	assessed	_	_	O
75	before	_	_	O
76	and	_	_	O
77	after	_	_	O
78	completing	_	_	O
79	the	_	_	O
80	intervention	_	_	O
81	and	_	_	O
82	2	_	_	O
83	months	_	_	O
84	postintervention	_	_	O
85	.	_	_	O

86	Primary	_	_	O
87	outcome	_	_	O
88	measures	_	_	O
89	assessed	_	_	O
90	spiritual	_	_	O
91	well-being	_	_	O
92	and	_	_	O
93	quality	_	_	O
94	of	_	_	O
95	life	_	_	O
96	;	_	_	O
97	secondary	_	_	O
98	outcomes	_	_	O
99	included	_	_	O
100	anxiety	_	_	O
101	,	_	_	O
102	depression	_	_	O
103	,	_	_	O
104	hopelessness	_	_	O
105	,	_	_	O
106	symptom	_	_	O
107	burden	_	_	O
108	,	_	_	O
109	and	_	_	O
110	symptom-related	_	_	O
111	distress	_	_	O
112	.	_	_	O

113	Of	_	_	O
114	the	_	_	O
115	120	_	_	O
116	participants	_	_	O
117	randomly	_	_	O
118	assigned	_	_	O
119	,	_	_	O
120	78	_	_	O
121	(	_	_	O
122	65	_	_	O
123	%	_	_	O
124	)	_	_	O
125	completed	_	_	O
126	the	_	_	O
127	post-treatment	_	_	O
128	assessment	_	_	O
129	and	_	_	O
130	67	_	_	O
131	(	_	_	O
132	56	_	_	O
133	%	_	_	O
134	)	_	_	O
135	completed	_	_	O
136	the	_	_	O
137	2-month	_	_	O
138	follow-up	_	_	O
139	.	_	_	O

140	At	_	_	B-Premise
141	the	_	_	I-Premise
142	post-treatment	_	_	I-Premise
143	assessment	_	_	I-Premise
144	,	_	_	I-Premise
145	IMCP	_	_	I-Premise
146	participants	_	_	I-Premise
147	demonstrated	_	_	I-Premise
148	significantly	_	_	I-Premise
149	greater	_	_	I-Premise
150	improvement	_	_	I-Premise
151	than	_	_	I-Premise
152	the	_	_	I-Premise
153	control	_	_	I-Premise
154	condition	_	_	I-Premise
155	for	_	_	I-Premise
156	the	_	_	I-Premise
157	primary	_	_	I-Premise
158	outcomes	_	_	I-Premise
159	of	_	_	I-Premise
160	spiritual	_	_	I-Premise
161	well-being	_	_	I-Premise
162	(	_	_	I-Premise
163	b	_	_	I-Premise
164	=	_	_	I-Premise
165	0.39	_	_	I-Premise
166	;	_	_	I-Premise
167	P	_	_	I-Premise
168	<	_	_	I-Premise
169	.001	_	_	I-Premise
170	,	_	_	I-Premise
171	including	_	_	I-Premise
172	both	_	_	I-Premise
173	components	_	_	I-Premise
174	of	_	_	I-Premise
175	spiritual	_	_	I-Premise
176	well-being	_	_	I-Premise
177	(	_	_	I-Premise
178	sense	_	_	I-Premise
179	of	_	_	I-Premise
180	meaning	_	_	I-Premise
181	:	_	_	I-Premise
182	b	_	_	I-Premise
183	=	_	_	I-Premise
184	0.34	_	_	I-Premise
185	;	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	.003	_	_	I-Premise
189	and	_	_	I-Premise
190	faith	_	_	I-Premise
191	:	_	_	I-Premise
192	b	_	_	I-Premise
193	=	_	_	I-Premise
194	0.42	_	_	I-Premise
195	;	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	.03	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	quality	_	_	I-Premise
203	of	_	_	I-Premise
204	life	_	_	I-Premise
205	(	_	_	I-Premise
206	b	_	_	I-Premise
207	=	_	_	I-Premise
208	0.76	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	.013	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	Significantly	_	_	B-Premise
216	greater	_	_	I-Premise
217	improvements	_	_	I-Premise
218	for	_	_	I-Premise
219	IMCP	_	_	I-Premise
220	patients	_	_	I-Premise
221	were	_	_	I-Premise
222	also	_	_	I-Premise
223	observed	_	_	I-Premise
224	for	_	_	I-Premise
225	the	_	_	I-Premise
226	secondary	_	_	I-Premise
227	outcomes	_	_	I-Premise
228	of	_	_	I-Premise
229	symptom	_	_	I-Premise
230	burden	_	_	I-Premise
231	(	_	_	I-Premise
232	b	_	_	I-Premise
233	=	_	_	I-Premise
234	-6.56	_	_	I-Premise
235	;	_	_	I-Premise
236	P	_	_	I-Premise
237	<	_	_	I-Premise
238	.001	_	_	I-Premise
239	)	_	_	I-Premise
240	and	_	_	I-Premise
241	symptom-related	_	_	I-Premise
242	distress	_	_	I-Premise
243	(	_	_	I-Premise
244	b	_	_	I-Premise
245	=	_	_	I-Premise
246	-0.47	_	_	I-Premise
247	;	_	_	I-Premise
248	P	_	_	I-Premise
249	<	_	_	I-Premise
250	.001	_	_	I-Premise
251	)	_	_	I-Premise
252	but	_	_	I-Premise
253	not	_	_	I-Premise
254	for	_	_	I-Premise
255	anxiety	_	_	I-Premise
256	,	_	_	I-Premise
257	depression	_	_	I-Premise
258	,	_	_	I-Premise
259	or	_	_	I-Premise
260	hopelessness	_	_	I-Premise
261	.	_	_	I-Premise

262	At	_	_	B-Premise
263	the	_	_	I-Premise
264	2-month	_	_	I-Premise
265	follow-up	_	_	I-Premise
266	assessment	_	_	I-Premise
267	,	_	_	I-Premise
268	the	_	_	I-Premise
269	improvements	_	_	I-Premise
270	observed	_	_	I-Premise
271	for	_	_	I-Premise
272	the	_	_	I-Premise
273	IMCP	_	_	I-Premise
274	group	_	_	I-Premise
275	were	_	_	I-Premise
276	no	_	_	I-Premise
277	longer	_	_	I-Premise
278	significantly	_	_	I-Premise
279	greater	_	_	I-Premise
280	than	_	_	I-Premise
281	those	_	_	I-Premise
282	observed	_	_	I-Premise
283	for	_	_	I-Premise
284	the	_	_	I-Premise
285	TM	_	_	I-Premise
286	group	_	_	I-Premise
287	.	_	_	I-Premise

288	IMCP	_	_	B-Claim
289	has	_	_	I-Claim
290	clear	_	_	I-Claim
291	short-term	_	_	I-Claim
292	benefits	_	_	I-Claim
293	for	_	_	I-Claim
294	spiritual	_	_	I-Claim
295	suffering	_	_	I-Claim
296	and	_	_	I-Claim
297	quality	_	_	I-Claim
298	of	_	_	I-Claim
299	life	_	_	I-Claim
300	in	_	_	I-Claim
301	patients	_	_	I-Claim
302	with	_	_	I-Claim
303	advanced	_	_	I-Claim
304	cancer	_	_	I-Claim
305	.	_	_	I-Claim

306	Clinicians	_	_	O
307	working	_	_	O
308	with	_	_	O
309	patients	_	_	O
310	who	_	_	O
311	have	_	_	O
312	advanced	_	_	O
313	cancer	_	_	O
314	should	_	_	O
315	consider	_	_	O
316	IMCP	_	_	O
317	as	_	_	O
318	an	_	_	O
319	approach	_	_	O
320	to	_	_	O
321	enhance	_	_	O
322	quality	_	_	O
323	of	_	_	O
324	life	_	_	O
325	and	_	_	O
326	spiritual	_	_	O
327	well-being	_	_	O
328	.	_	_	O


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	an	_	_	O
4	Internet-based	_	_	B-Claim
5	tailored	_	_	I-Claim
6	education	_	_	I-Claim
7	program	_	_	I-Claim
8	is	_	_	I-Claim
9	effective	_	_	I-Claim
10	for	_	_	I-Claim
11	disease-free	_	_	I-Claim
12	cancer	_	_	I-Claim
13	survivors	_	_	I-Claim
14	with	_	_	I-Claim
15	cancer-related	_	_	I-Claim
16	fatigue	_	_	I-Claim
17	(	_	_	I-Claim
18	CRF	_	_	I-Claim
19	)	_	_	I-Claim
20	.	_	_	I-Claim

21	We	_	_	O
22	randomly	_	_	O
23	assigned	_	_	O
24	patients	_	_	O
25	who	_	_	O
26	had	_	_	O
27	completed	_	_	O
28	primary	_	_	O
29	cancer	_	_	O
30	treatment	_	_	O
31	within	_	_	O
32	the	_	_	O
33	past	_	_	O
34	24	_	_	O
35	months	_	_	O
36	in	_	_	O
37	any	_	_	O
38	of	_	_	O
39	four	_	_	O
40	Korean	_	_	O
41	hospitals	_	_	O
42	and	_	_	O
43	had	_	_	O
44	reported	_	_	O
45	moderate	_	_	O
46	to	_	_	O
47	severe	_	_	O
48	fatigue	_	_	O
49	for	_	_	O
50	at	_	_	O
51	least	_	_	O
52	1	_	_	O
53	week	_	_	O
54	to	_	_	O
55	participate	_	_	O
56	in	_	_	O
57	a	_	_	O
58	12-week	_	_	O
59	,	_	_	O
60	Internet-based	_	_	O
61	,	_	_	O
62	individually	_	_	O
63	tailored	_	_	O
64	CRF	_	_	O
65	education	_	_	O
66	program	_	_	O
67	or	_	_	O
68	to	_	_	O
69	receive	_	_	O
70	routine	_	_	O
71	care	_	_	O
72	.	_	_	O

73	We	_	_	O
74	based	_	_	O
75	the	_	_	O
76	program	_	_	O
77	on	_	_	O
78	the	_	_	O
79	CRF	_	_	O
80	guidelines	_	_	O
81	of	_	_	O
82	the	_	_	O
83	National	_	_	O
84	Comprehensive	_	_	O
85	Cancer	_	_	O
86	Network	_	_	O
87	(	_	_	O
88	NCCN	_	_	O
89	)	_	_	O
90	and	_	_	O
91	incorporated	_	_	O
92	the	_	_	O
93	transtheoretic	_	_	O
94	model	_	_	O
95	(	_	_	O
96	TTM	_	_	O
97	)	_	_	O
98	.	_	_	O

99	At	_	_	O
100	baseline	_	_	O
101	and	_	_	O
102	12	_	_	O
103	weeks	_	_	O
104	,	_	_	O
105	we	_	_	O
106	used	_	_	O
107	the	_	_	O
108	Brief	_	_	O
109	Fatigue	_	_	O
110	Inventory	_	_	O
111	(	_	_	O
112	BFI	_	_	O
113	)	_	_	O
114	and	_	_	O
115	Fatigue	_	_	O
116	Severity	_	_	O
117	Scale	_	_	O
118	(	_	_	O
119	FSS	_	_	O
120	)	_	_	O
121	as	_	_	O
122	primary	_	_	O
123	outcomes	_	_	O
124	and	_	_	O
125	the	_	_	O
126	Hospital	_	_	O
127	Anxiety	_	_	O
128	and	_	_	O
129	Depression	_	_	O
130	Scale	_	_	O
131	(	_	_	O
132	HADS	_	_	O
133	)	_	_	O
134	and	_	_	O
135	European	_	_	O
136	Organisation	_	_	O
137	for	_	_	O
138	Research	_	_	O
139	and	_	_	O
140	Treatment	_	_	O
141	of	_	_	O
142	Cancer	_	_	O
143	Quality	_	_	O
144	of	_	_	O
145	Life	_	_	O
146	Questionnaire	_	_	O
147	C30	_	_	O
148	(	_	_	O
149	EORTC	_	_	O
150	QLQ-C30	_	_	O
151	)	_	_	O
152	for	_	_	O
153	secondary	_	_	O
154	outcomes	_	_	O
155	.	_	_	O

156	We	_	_	O
157	recruited	_	_	O
158	273	_	_	O
159	participants	_	_	O
160	and	_	_	O
161	randomly	_	_	O
162	assigned	_	_	O
163	136	_	_	O
164	to	_	_	O
165	the	_	_	O
166	intervention	_	_	O
167	group	_	_	O
168	.	_	_	O

169	Compared	_	_	B-Premise
170	with	_	_	I-Premise
171	the	_	_	I-Premise
172	control	_	_	I-Premise
173	group	_	_	I-Premise
174	,	_	_	I-Premise
175	the	_	_	I-Premise
176	intervention	_	_	I-Premise
177	group	_	_	I-Premise
178	had	_	_	I-Premise
179	an	_	_	I-Premise
180	improvement	_	_	I-Premise
181	in	_	_	I-Premise
182	fatigue	_	_	I-Premise
183	as	_	_	I-Premise
184	shown	_	_	I-Premise
185	by	_	_	I-Premise
186	a	_	_	I-Premise
187	significantly	_	_	I-Premise
188	greater	_	_	I-Premise
189	decrease	_	_	I-Premise
190	in	_	_	I-Premise
191	BFI	_	_	I-Premise
192	global	_	_	I-Premise
193	score	_	_	I-Premise
194	(	_	_	I-Premise
195	-0.66	_	_	I-Premise
196	points	_	_	I-Premise
197	;	_	_	I-Premise
198	95	_	_	I-Premise
199	%	_	_	I-Premise
200	CI	_	_	I-Premise
201	-1.04	_	_	I-Premise
202	to	_	_	I-Premise
203	-0.27	_	_	I-Premise
204	)	_	_	I-Premise
205	and	_	_	I-Premise
206	FSS	_	_	I-Premise
207	total	_	_	I-Premise
208	score	_	_	I-Premise
209	(	_	_	I-Premise
210	-0.49	_	_	I-Premise
211	;	_	_	I-Premise
212	95	_	_	I-Premise
213	%	_	_	I-Premise
214	CI	_	_	I-Premise
215	,	_	_	I-Premise
216	-0.78	_	_	I-Premise
217	to	_	_	I-Premise
218	-0.21	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	In	_	_	B-Premise
222	secondary	_	_	I-Premise
223	outcomes	_	_	I-Premise
224	,	_	_	I-Premise
225	the	_	_	I-Premise
226	intervention	_	_	I-Premise
227	group	_	_	I-Premise
228	experienced	_	_	I-Premise
229	a	_	_	I-Premise
230	significantly	_	_	I-Premise
231	greater	_	_	I-Premise
232	decrease	_	_	I-Premise
233	in	_	_	I-Premise
234	HADS	_	_	I-Premise
235	anxiety	_	_	I-Premise
236	score	_	_	I-Premise
237	(	_	_	I-Premise
238	-0.90	_	_	I-Premise
239	;	_	_	I-Premise
240	95	_	_	I-Premise
241	%	_	_	I-Premise
242	CI	_	_	I-Premise
243	,	_	_	I-Premise
244	-1.51	_	_	I-Premise
245	to	_	_	I-Premise
246	-0.29	_	_	I-Premise
247	)	_	_	I-Premise
248	as	_	_	I-Premise
249	well	_	_	I-Premise
250	as	_	_	I-Premise
251	global	_	_	I-Premise
252	quality	_	_	I-Premise
253	of	_	_	I-Premise
254	life	_	_	I-Premise
255	(	_	_	I-Premise
256	5.22	_	_	I-Premise
257	;	_	_	I-Premise
258	95	_	_	I-Premise
259	%	_	_	I-Premise
260	CI	_	_	I-Premise
261	,	_	_	I-Premise
262	0.93	_	_	I-Premise
263	to	_	_	I-Premise
264	9.50	_	_	I-Premise
265	)	_	_	I-Premise
266	and	_	_	I-Premise
267	several	_	_	I-Premise
268	functioning	_	_	I-Premise
269	scores	_	_	I-Premise
270	of	_	_	I-Premise
271	the	_	_	I-Premise
272	EORTC	_	_	I-Premise
273	QLQ-C30	_	_	I-Premise
274	.	_	_	I-Premise

275	An	_	_	B-Claim
276	Internet-based	_	_	I-Claim
277	education	_	_	I-Claim
278	program	_	_	I-Claim
279	based	_	_	I-Claim
280	on	_	_	I-Claim
281	NCCN	_	_	I-Claim
282	guidelines	_	_	I-Claim
283	and	_	_	I-Claim
284	TTM	_	_	I-Claim
285	may	_	_	I-Claim
286	help	_	_	I-Claim
287	patients	_	_	I-Claim
288	manage	_	_	I-Claim
289	CRF	_	_	I-Claim
290	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	examined	_	_	O
3	the	_	_	O
4	feasibility	_	_	O
5	and	_	_	O
6	acceptability	_	_	O
7	of	_	_	O
8	an	_	_	O
9	Individual	_	_	O
10	Internet	_	_	O
11	Intervention	_	_	O
12	(	_	_	O
13	III	_	_	O
14	)	_	_	O
15	embedded	_	_	O
16	and	_	_	O
17	integrated	_	_	O
18	into	_	_	O
19	an	_	_	O
20	Internet	_	_	O
21	Support	_	_	O
22	Group	_	_	O
23	(	_	_	O
24	ISG	_	_	O
25	)	_	_	O
26	with	_	_	O
27	the	_	_	O
28	ultimate	_	_	O
29	goal	_	_	O
30	of	_	_	O
31	enhancing	_	_	O
32	adherence	_	_	O
33	and	_	_	O
34	learning	_	_	O
35	,	_	_	O
36	compared	_	_	O
37	with	_	_	O
38	an	_	_	O
39	individual	_	_	O
40	internet	_	_	O
41	invention	_	_	O
42	alone	_	_	O
43	.	_	_	O

44	Thirty-one	_	_	O
45	posttreatment	_	_	O
46	cancer	_	_	O
47	survivors	_	_	O
48	were	_	_	O
49	randomized	_	_	O
50	in	_	_	O
51	groups	_	_	O
52	of	_	_	O
53	seven	_	_	O
54	to	_	_	O
55	nine	_	_	O
56	to	_	_	O
57	either	_	_	O
58	the	_	_	O
59	8-week	_	_	O
60	III	_	_	O
61	+	_	_	O
62	ISG	_	_	O
63	intervention	_	_	O
64	or	_	_	O
65	the	_	_	O
66	8-week	_	_	O
67	III	_	_	O
68	condition	_	_	O
69	.	_	_	O

70	Seventeen	_	_	O
71	participants	_	_	O
72	met	_	_	O
73	the	_	_	O
74	Hospital	_	_	O
75	Anxiety	_	_	O
76	and	_	_	O
77	Depression	_	_	O
78	Scale	_	_	O
79	(	_	_	O
80	HADS	_	_	O
81	)	_	_	O
82	criteria	_	_	O
83	for	_	_	O
84	depressive	_	_	O
85	symptoms	_	_	O
86	(	_	_	O
87	HADS	_	_	O
88	≥	_	_	O
89	8	_	_	O
90	)	_	_	O
91	.	_	_	O

92	Among	_	_	O
93	all	_	_	O
94	participants	_	_	O
95	,	_	_	O
96	the	_	_	O
97	mean	_	_	O
98	number	_	_	O
99	of	_	_	O
100	logins	_	_	O
101	over	_	_	O
102	8	_	_	O
103	weeks	_	_	O
104	was	_	_	O
105	20.8	_	_	O
106	±	_	_	O
107	17.7	_	_	O
108	logins	_	_	O
109	for	_	_	O
110	the	_	_	O
111	III	_	_	O
112	+	_	_	O
113	ISG	_	_	O
114	compared	_	_	O
115	with	_	_	O
116	12.5	_	_	O
117	±	_	_	O
118	12.5	_	_	O
119	in	_	_	O
120	III-only	_	_	O
121	(	_	_	O
122	p	_	_	O
123	=	_	_	O
124	0.15	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Two	_	_	O
128	participants	_	_	O
129	in	_	_	O
130	the	_	_	O
131	III	_	_	O
132	+	_	_	O
133	ISG	_	_	O
134	dropped	_	_	O
135	out	_	_	O
136	,	_	_	O
137	compared	_	_	O
138	with	_	_	O
139	five	_	_	O
140	in	_	_	O
141	III	_	_	O
142	(	_	_	O
143	p	_	_	O
144	=	_	_	O
145	0.39	_	_	O
146	)	_	_	O
147	.	_	_	O

148	Among	_	_	B-Premise
149	the	_	_	I-Premise
150	17	_	_	I-Premise
151	participants	_	_	I-Premise
152	with	_	_	I-Premise
153	depressive	_	_	I-Premise
154	symptoms	_	_	I-Premise
155	at	_	_	I-Premise
156	baseline	_	_	I-Premise
157	,	_	_	I-Premise
158	both	_	_	I-Premise
159	the	_	_	I-Premise
160	Onward	_	_	I-Premise
161	and	_	_	I-Premise
162	the	_	_	I-Premise
163	III-only	_	_	I-Premise
164	condition	_	_	I-Premise
165	showed	_	_	I-Premise
166	large	_	_	I-Premise
167	reductions	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	depression	_	_	I-Premise
171	scale	_	_	I-Premise
172	of	_	_	I-Premise
173	HADS	_	_	I-Premise
174	(	_	_	I-Premise
175	d	_	_	I-Premise
176	=	_	_	I-Premise
177	1.27	_	_	I-Premise
178	and	_	_	I-Premise
179	0.89	_	_	I-Premise
180	,	_	_	I-Premise
181	respectively	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	Improvement	_	_	B-Premise
185	over	_	_	I-Premise
186	time	_	_	I-Premise
187	and	_	_	I-Premise
188	time	_	_	I-Premise
189	x	_	_	I-Premise
190	treatment	_	_	I-Premise
191	effects	_	_	I-Premise
192	only	_	_	I-Premise
193	reached	_	_	I-Premise
194	trend	_	_	I-Premise
195	significance	_	_	I-Premise
196	levels	_	_	I-Premise
197	(	_	_	I-Premise
198	ps	_	_	I-Premise
199	=	_	_	I-Premise
200	0.07	_	_	I-Premise
201	&	_	_	I-Premise
202	amp	_	_	I-Premise
203	;	_	_	I-Premise
204	0.12	_	_	I-Premise
205	)	_	_	I-Premise
206	as	_	_	I-Premise
207	this	_	_	I-Premise
208	pilot	_	_	I-Premise
209	was	_	_	I-Premise
210	not	_	_	I-Premise
211	powered	_	_	I-Premise
212	to	_	_	I-Premise
213	detect	_	_	I-Premise
214	these	_	_	I-Premise
215	differences	_	_	I-Premise
216	.	_	_	I-Premise

217	Both	_	_	B-Claim
218	the	_	_	I-Claim
219	III	_	_	I-Claim
220	+	_	_	I-Claim
221	ISG	_	_	I-Claim
222	and	_	_	I-Claim
223	III-only	_	_	I-Claim
224	demonstrated	_	_	I-Claim
225	pre-post	_	_	I-Claim
226	reductions	_	_	I-Claim
227	in	_	_	I-Claim
228	depressive	_	_	I-Claim
229	symptoms	_	_	I-Claim
230	and	_	_	I-Claim
231	high	_	_	I-Claim
232	rates	_	_	I-Claim
233	of	_	_	I-Claim
234	utilization	_	_	I-Claim
235	compared	_	_	I-Claim
236	with	_	_	I-Claim
237	other	_	_	I-Claim
238	web-based	_	_	I-Claim
239	treatments	_	_	I-Claim
240	for	_	_	I-Claim
241	depression	_	_	I-Claim
242	.	_	_	I-Claim

243	Although	_	_	B-Claim
244	it	_	_	I-Claim
245	is	_	_	I-Claim
246	premature	_	_	I-Claim
247	to	_	_	I-Claim
248	make	_	_	I-Claim
249	any	_	_	I-Claim
250	determination	_	_	I-Claim
251	as	_	_	I-Claim
252	to	_	_	I-Claim
253	the	_	_	I-Claim
254	efficacy	_	_	I-Claim
255	of	_	_	I-Claim
256	the	_	_	I-Claim
257	interventions	_	_	I-Claim
258	tested	_	_	I-Claim
259	in	_	_	I-Claim
260	this	_	_	I-Claim
261	feasibility	_	_	I-Claim
262	study	_	_	I-Claim
263	,	_	_	I-Claim
264	these	_	_	B-Claim
265	results	_	_	I-Claim
266	indicate	_	_	I-Claim
267	that	_	_	I-Claim
268	pursuing	_	_	I-Claim
269	the	_	_	I-Claim
270	III	_	_	I-Claim
271	+	_	_	I-Claim
272	ISG	_	_	I-Claim
273	model	_	_	I-Claim
274	,	_	_	I-Claim
275	as	_	_	I-Claim
276	well	_	_	I-Claim
277	as	_	_	I-Claim
278	standard	_	_	I-Claim
279	IIIs	_	_	I-Claim
280	,	_	_	I-Claim
281	may	_	_	I-Claim
282	be	_	_	I-Claim
283	fruitful	_	_	I-Claim
284	areas	_	_	I-Claim
285	of	_	_	I-Claim
286	future	_	_	I-Claim
287	research	_	_	I-Claim
288	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	efficacy	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	fixed-combination	_	_	O
14	brimonidine	_	_	O
15	0.2	_	_	O
16	%	_	_	O
17	-timolol	_	_	O
18	0.5	_	_	O
19	%	_	_	O
20	compared	_	_	O
21	with	_	_	O
22	latanoprost	_	_	O
23	0.005	_	_	O
24	%	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	glaucoma	_	_	O
29	or	_	_	O
30	ocular	_	_	O
31	hypertension	_	_	O
32	.	_	_	O

33	This	_	_	O
34	was	_	_	O
35	a	_	_	O
36	prospective	_	_	O
37	,	_	_	O
38	randomized	_	_	O
39	,	_	_	O
40	multicenter	_	_	O
41	,	_	_	O
42	investigator-masked	_	_	O
43	clinical	_	_	O
44	trial	_	_	O
45	.	_	_	O

46	After	_	_	O
47	washout	_	_	O
48	of	_	_	O
49	any	_	_	O
50	previous	_	_	O
51	IOP-lowering	_	_	O
52	medications	_	_	O
53	,	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	IOP	_	_	O
57	of	_	_	O
58	24	_	_	O
59	mmHg	_	_	O
60	or	_	_	O
61	higher	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	twice-daily	_	_	O
66	fixed-combination	_	_	O
67	brimonidine	_	_	O
68	0.2	_	_	O
69	%	_	_	O
70	-timolol	_	_	O
71	0.5	_	_	O
72	%	_	_	O
73	(	_	_	O
74	n	_	_	O
75	=	_	_	O
76	73	_	_	O
77	)	_	_	O
78	or	_	_	O
79	once-daily	_	_	O
80	latanoprost	_	_	O
81	0.005	_	_	O
82	%	_	_	O
83	(	_	_	O
84	n	_	_	O
85	=	_	_	O
86	75	_	_	O
87	,	_	_	O
88	dosed	_	_	O
89	in	_	_	O
90	the	_	_	O
91	evening	_	_	O
92	,	_	_	O
93	with	_	_	O
94	vehicle	_	_	O
95	control	_	_	O
96	in	_	_	O
97	the	_	_	O
98	morning	_	_	O
99	to	_	_	O
100	maintain	_	_	O
101	masking	_	_	O
102	)	_	_	O
103	for	_	_	O
104	12	_	_	O
105	weeks	_	_	O
106	.	_	_	O

107	IOP	_	_	O
108	was	_	_	O
109	measured	_	_	O
110	at	_	_	O
111	8	_	_	O
112	a.m.	_	_	O
113	(	_	_	O
114	before	_	_	O
115	dosing	_	_	O
116	)	_	_	O
117	,	_	_	O
118	10	_	_	O
119	a.m.	_	_	O
120	,	_	_	O
121	and	_	_	O
122	3	_	_	O
123	p.m.	_	_	O
124	at	_	_	O
125	baseline	_	_	O
126	,	_	_	O
127	week	_	_	O
128	6	_	_	O
129	,	_	_	O
130	and	_	_	O
131	week	_	_	O
132	12	_	_	O
133	.	_	_	O

134	The	_	_	O
135	primary	_	_	O
136	efficacy	_	_	O
137	endpoint	_	_	O
138	was	_	_	O
139	diurnal	_	_	O
140	IOP	_	_	O
141	(	_	_	O
142	averaged	_	_	O
143	over	_	_	O
144	8	_	_	O
145	a.m.	_	_	O
146	,	_	_	O
147	10	_	_	O
148	a.m.	_	_	O
149	,	_	_	O
150	and	_	_	O
151	3	_	_	O
152	p.m.	_	_	O
153	)	_	_	O
154	at	_	_	O
155	week	_	_	O
156	12	_	_	O
157	.	_	_	O

158	Safety	_	_	O
159	measures	_	_	O
160	included	_	_	O
161	biomicroscopy	_	_	O
162	.	_	_	O

163	There	_	_	O
164	was	_	_	O
165	no	_	_	O
166	statistically	_	_	O
167	significant	_	_	O
168	difference	_	_	O
169	between	_	_	O
170	the	_	_	O
171	treatment	_	_	O
172	groups	_	_	O
173	in	_	_	O
174	mean	_	_	O
175	diurnal	_	_	O
176	IOP	_	_	O
177	at	_	_	O
178	baseline	_	_	O
179	(	_	_	O
180	p	_	_	O
181	=	_	_	O
182	0.118	_	_	O
183	)	_	_	O
184	.	_	_	O

185	At	_	_	B-Premise
186	week	_	_	I-Premise
187	12	_	_	I-Premise
188	,	_	_	I-Premise
189	the	_	_	I-Premise
190	mean	_	_	I-Premise
191	(	_	_	I-Premise
192	SD	_	_	I-Premise
193	)	_	_	I-Premise
194	diurnal	_	_	I-Premise
195	IOP	_	_	I-Premise
196	was	_	_	I-Premise
197	17.8	_	_	I-Premise
198	(	_	_	I-Premise
199	2.9	_	_	I-Premise
200	)	_	_	I-Premise
201	mmHg	_	_	I-Premise
202	with	_	_	I-Premise
203	brimonidine-timolol	_	_	I-Premise
204	and	_	_	I-Premise
205	17.9	_	_	I-Premise
206	(	_	_	I-Premise
207	3.9	_	_	I-Premise
208	)	_	_	I-Premise
209	mmHg	_	_	I-Premise
210	with	_	_	I-Premise
211	latanoprost	_	_	I-Premise
212	(	_	_	I-Premise
213	p	_	_	I-Premise
214	=	_	_	I-Premise
215	0.794	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	percentage	_	_	I-Premise
220	of	_	_	I-Premise
221	patients	_	_	I-Premise
222	achieving	_	_	I-Premise
223	at	_	_	I-Premise
224	least	_	_	I-Premise
225	a	_	_	I-Premise
226	20	_	_	I-Premise
227	%	_	_	I-Premise
228	decrease	_	_	I-Premise
229	from	_	_	I-Premise
230	baseline	_	_	I-Premise
231	diurnal	_	_	I-Premise
232	IOP	_	_	I-Premise
233	at	_	_	I-Premise
234	week	_	_	I-Premise
235	12	_	_	I-Premise
236	was	_	_	I-Premise
237	87.7	_	_	I-Premise
238	%	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	brimonidine-timolol	_	_	I-Premise
242	group	_	_	I-Premise
243	and	_	_	I-Premise
244	77.3	_	_	I-Premise
245	%	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	latanoprost	_	_	I-Premise
249	group	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.131	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Measured	_	_	B-Premise
257	biomicroscopic	_	_	I-Premise
258	changes	_	_	I-Premise
259	from	_	_	I-Premise
260	baseline	_	_	I-Premise
261	to	_	_	I-Premise
262	week	_	_	I-Premise
263	12	_	_	I-Premise
264	were	_	_	I-Premise
265	infrequent	_	_	I-Premise
266	in	_	_	I-Premise
267	both	_	_	I-Premise
268	groups	_	_	I-Premise
269	.	_	_	I-Premise

270	Fixed-combination	_	_	B-Claim
271	brimonidine-timolol	_	_	I-Claim
272	was	_	_	I-Claim
273	as	_	_	I-Claim
274	effective	_	_	I-Claim
275	as	_	_	I-Claim
276	latanoprost	_	_	I-Claim
277	in	_	_	I-Claim
278	reducing	_	_	I-Claim
279	IOP	_	_	I-Claim
280	in	_	_	I-Claim
281	patients	_	_	I-Claim
282	with	_	_	I-Claim
283	glaucoma	_	_	I-Claim
284	or	_	_	I-Claim
285	ocular	_	_	I-Claim
286	hypertension	_	_	I-Claim
287	.	_	_	I-Claim

288	Both	_	_	B-Claim
289	treatments	_	_	I-Claim
290	demonstrated	_	_	I-Claim
291	favorable	_	_	I-Claim
292	ocular	_	_	I-Claim
293	tolerability	_	_	I-Claim
294	.	_	_	I-Claim

295	The	_	_	O
296	duration	_	_	O
297	of	_	_	O
298	the	_	_	O
299	study	_	_	O
300	was	_	_	O
301	12	_	_	O
302	weeks	_	_	O
303	,	_	_	O
304	and	_	_	O
305	additional	_	_	O
306	studies	_	_	O
307	will	_	_	O
308	be	_	_	O
309	needed	_	_	O
310	to	_	_	O
311	compare	_	_	O
312	the	_	_	O
313	efficacy	_	_	O
314	and	_	_	O
315	safety	_	_	O
316	of	_	_	O
317	fixed-combination	_	_	O
318	brimonidine-timolol	_	_	O
319	and	_	_	O
320	latanoprost	_	_	O
321	during	_	_	O
322	long-term	_	_	O
323	treatment	_	_	O
324	.	_	_	O


0	Maintenance	_	_	O
1	therapy	_	_	O
2	,	_	_	O
3	commenced	_	_	O
4	immediately	_	_	O
5	after	_	_	O
6	the	_	_	O
7	completion	_	_	O
8	of	_	_	O
9	first-line	_	_	O
10	chemotherapy	_	_	O
11	,	_	_	O
12	is	_	_	O
13	a	_	_	O
14	promising	_	_	O
15	strategy	_	_	O
16	for	_	_	O
17	improving	_	_	O
18	treatment	_	_	O
19	outcomes	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	non-small-cell	_	_	O
24	lung	_	_	O
25	cancer	_	_	O
26	(	_	_	O
27	NSCLC	_	_	O
28	)	_	_	O
29	.	_	_	O

30	The	_	_	O
31	global	_	_	O
32	phase	_	_	O
33	III	_	_	O
34	SequentiAl	_	_	O
35	Tarceva	_	_	O
36	in	_	_	O
37	UnResectable	_	_	O
38	NSCLC	_	_	O
39	(	_	_	O
40	SATURN	_	_	O
41	)	_	_	O
42	study	_	_	O
43	evaluated	_	_	O
44	the	_	_	O
45	efficacy	_	_	O
46	and	_	_	O
47	safety	_	_	O
48	of	_	_	O
49	the	_	_	O
50	epidermal	_	_	O
51	growth	_	_	O
52	factor	_	_	O
53	receptor	_	_	O
54	(	_	_	O
55	EGFR	_	_	O
56	)	_	_	O
57	tyrosine-kinase	_	_	O
58	inhibitor	_	_	O
59	erlotinib	_	_	O
60	as	_	_	O
61	maintenance	_	_	O
62	treatment	_	_	O
63	in	_	_	O
64	NSCLC	_	_	O
65	patients	_	_	O
66	without	_	_	O
67	progression	_	_	O
68	after	_	_	O
69	first-line	_	_	O
70	chemotherapy	_	_	O
71	.	_	_	O

72	We	_	_	O
73	report	_	_	O
74	a	_	_	O
75	retrospective	_	_	O
76	subanalysis	_	_	O
77	of	_	_	O
78	Asian	_	_	O
79	patients	_	_	O
80	enrolled	_	_	O
81	in	_	_	O
82	SATURN	_	_	O
83	.	_	_	O

84	Patients	_	_	O
85	with	_	_	O
86	advanced	_	_	O
87	NSCLC	_	_	O
88	with	_	_	O
89	no	_	_	O
90	evidence	_	_	O
91	of	_	_	O
92	progression	_	_	O
93	after	_	_	O
94	four	_	_	O
95	cycles	_	_	O
96	of	_	_	O
97	chemotherapy	_	_	O
98	were	_	_	O
99	randomized	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	erlotinib	_	_	O
103	150	_	_	O
104	mg/day	_	_	O
105	or	_	_	O
106	placebo	_	_	O
107	,	_	_	O
108	until	_	_	O
109	progressive	_	_	O
110	disease	_	_	O
111	or	_	_	O
112	limiting	_	_	O
113	toxicity	_	_	O
114	.	_	_	O

115	The	_	_	O
116	co-primary	_	_	O
117	endpoints	_	_	O
118	of	_	_	O
119	SATURN	_	_	O
120	were	_	_	O
121	progression-free	_	_	O
122	survival	_	_	O
123	(	_	_	O
124	PFS	_	_	O
125	)	_	_	O
126	in	_	_	O
127	all	_	_	O
128	patients	_	_	O
129	and	_	_	O
130	in	_	_	O
131	those	_	_	O
132	with	_	_	O
133	positive	_	_	O
134	EGFR	_	_	O
135	immunohistochemistry	_	_	O
136	(	_	_	O
137	IHC	_	_	O
138	)	_	_	O
139	status	_	_	O
140	.	_	_	O

141	Secondary	_	_	O
142	endpoints	_	_	O
143	included	_	_	O
144	overall	_	_	O
145	survival	_	_	O
146	(	_	_	O
147	OS	_	_	O
148	)	_	_	O
149	,	_	_	O
150	disease	_	_	O
151	control	_	_	O
152	rate	_	_	O
153	,	_	_	O
154	safety	_	_	O
155	,	_	_	O
156	quality	_	_	O
157	of	_	_	O
158	life	_	_	O
159	(	_	_	O
160	QoL	_	_	O
161	)	_	_	O
162	and	_	_	O
163	biomarker	_	_	O
164	analyses	_	_	O
165	.	_	_	O

166	In	_	_	O
167	total	_	_	O
168	,	_	_	O
169	126	_	_	O
170	patients	_	_	O
171	from	_	_	O
172	East	_	_	O
173	and	_	_	O
174	South-East	_	_	O
175	Asian	_	_	O
176	centers	_	_	O
177	were	_	_	O
178	randomized	_	_	O
179	(	_	_	O
180	14	_	_	O
181	%	_	_	O
182	of	_	_	O
183	the	_	_	O
184	intent-to-treat	_	_	O
185	population	_	_	O
186	)	_	_	O
187	:	_	_	O
188	88	_	_	O
189	from	_	_	O
190	Korea	_	_	O
191	,	_	_	O
192	28	_	_	O
193	from	_	_	O
194	China	_	_	O
195	and	_	_	O
196	10	_	_	O
197	from	_	_	O
198	Malaysia	_	_	O
199	;	_	_	O
200	one	_	_	O
201	patient	_	_	O
202	was	_	_	O
203	excluded	_	_	O
204	from	_	_	O
205	this	_	_	O
206	analysis	_	_	O
207	due	_	_	O
208	to	_	_	O
209	Indian	_	_	O
210	ethnicity	_	_	O
211	.	_	_	O

212	PFS	_	_	B-Premise
213	was	_	_	I-Premise
214	significantly	_	_	I-Premise
215	prolonged	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	erlotinib	_	_	I-Premise
219	treatment	_	_	I-Premise
220	arm	_	_	I-Premise
221	,	_	_	I-Premise
222	both	_	_	I-Premise
223	overall	_	_	I-Premise
224	(	_	_	I-Premise
225	hazard	_	_	I-Premise
226	ratio	_	_	I-Premise
227	[	_	_	I-Premise
228	HR	_	_	I-Premise
229	]	_	_	I-Premise
230	:	_	_	I-Premise
231	0.57	_	_	I-Premise
232	;	_	_	I-Premise
233	p=0.0067	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	in	_	_	I-Premise
237	patients	_	_	I-Premise
238	with	_	_	I-Premise
239	EGFR	_	_	I-Premise
240	IHC-positive	_	_	I-Premise
241	disease	_	_	I-Premise
242	(	_	_	I-Premise
243	HR=0.50	_	_	I-Premise
244	;	_	_	I-Premise
245	p=0.0057	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	There	_	_	B-Premise
249	was	_	_	I-Premise
250	a	_	_	I-Premise
251	trend	_	_	I-Premise
252	towards	_	_	I-Premise
253	an	_	_	I-Premise
254	increase	_	_	I-Premise
255	in	_	_	I-Premise
256	OS	_	_	I-Premise
257	,	_	_	I-Premise
258	which	_	_	I-Premise
259	reached	_	_	I-Premise
260	statistical	_	_	I-Premise
261	significance	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	EGFR	_	_	I-Premise
265	IHC-positive	_	_	I-Premise
266	subgroup	_	_	I-Premise
267	(	_	_	I-Premise
268	p=0.0233	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	The	_	_	B-Premise
272	overall	_	_	I-Premise
273	response	_	_	I-Premise
274	rate	_	_	I-Premise
275	was	_	_	I-Premise
276	significantly	_	_	I-Premise
277	higher	_	_	I-Premise
278	with	_	_	I-Premise
279	erlotinib	_	_	I-Premise
280	compared	_	_	I-Premise
281	with	_	_	I-Premise
282	placebo	_	_	I-Premise
283	(	_	_	I-Premise
284	24	_	_	I-Premise
285	%	_	_	I-Premise
286	versus	_	_	I-Premise
287	5	_	_	I-Premise
288	%	_	_	I-Premise
289	;	_	_	I-Premise
290	p=0.0025	_	_	I-Premise
291	)	_	_	I-Premise
292	.	_	_	I-Premise

293	Erlotinib	_	_	B-Claim
294	was	_	_	I-Claim
295	generally	_	_	I-Claim
296	well	_	_	I-Claim
297	tolerated	_	_	I-Claim
298	and	_	_	I-Claim
299	had	_	_	I-Claim
300	no	_	_	I-Claim
301	negative	_	_	I-Claim
302	impact	_	_	I-Claim
303	on	_	_	I-Claim
304	QoL	_	_	I-Claim
305	in	_	_	I-Claim
306	this	_	_	I-Claim
307	subpopulation	_	_	I-Claim
308	.	_	_	I-Claim

309	The	_	_	B-Premise
310	most	_	_	I-Premise
311	common	_	_	I-Premise
312	treatment-related	_	_	I-Premise
313	adverse	_	_	I-Premise
314	events	_	_	I-Premise
315	were	_	_	I-Premise
316	rash	_	_	I-Premise
317	,	_	_	I-Premise
318	diarrhea	_	_	I-Premise
319	and	_	_	I-Premise
320	pruritus	_	_	I-Premise
321	.	_	_	I-Premise

322	Erlotinib	_	_	B-Claim
323	was	_	_	I-Claim
324	effective	_	_	I-Claim
325	and	_	_	I-Claim
326	well	_	_	I-Claim
327	tolerated	_	_	I-Claim
328	in	_	_	I-Claim
329	Asian	_	_	I-Claim
330	patients	_	_	I-Claim
331	,	_	_	I-Claim
332	producing	_	_	I-Claim
333	benefits	_	_	I-Claim
334	consistent	_	_	I-Claim
335	with	_	_	I-Claim
336	those	_	_	I-Claim
337	observed	_	_	I-Claim
338	in	_	_	I-Claim
339	the	_	_	I-Claim
340	overall	_	_	I-Claim
341	SATURN	_	_	I-Claim
342	population	_	_	I-Claim
343	.	_	_	I-Claim

344	Maintenance	_	_	B-Claim
345	treatment	_	_	I-Claim
346	with	_	_	I-Claim
347	erlotinib	_	_	I-Claim
348	appears	_	_	I-Claim
349	to	_	_	I-Claim
350	be	_	_	I-Claim
351	a	_	_	I-Claim
352	useful	_	_	I-Claim
353	option	_	_	I-Claim
354	for	_	_	I-Claim
355	the	_	_	I-Claim
356	management	_	_	I-Claim
357	of	_	_	I-Claim
358	Asian	_	_	I-Claim
359	patients	_	_	I-Claim
360	with	_	_	I-Claim
361	advanced	_	_	I-Claim
362	NSCLC	_	_	I-Claim
363	without	_	_	I-Claim
364	progression	_	_	I-Claim
365	after	_	_	I-Claim
366	first-line	_	_	I-Claim
367	chemotherapy	_	_	I-Claim
368	.	_	_	I-Claim


0	Study	_	_	O
1	Type	_	_	O
2	--	_	_	O
3	Therapy	_	_	O
4	(	_	_	O
5	RCT	_	_	O
6	)	_	_	O
7	Level	_	_	O
8	of	_	_	O
9	Evidence	_	_	O
10	1b	_	_	O
11	.	_	_	O

12	What	_	_	O
13	's	_	_	O
14	known	_	_	O
15	on	_	_	O
16	the	_	_	O
17	subject	_	_	O
18	?	_	_	O

19	and	_	_	O
20	What	_	_	O
21	does	_	_	O
22	the	_	_	O
23	study	_	_	O
24	add	_	_	O
25	?	_	_	O

26	Androgen	_	_	O
27	deprivation	_	_	O
28	therapy	_	_	O
29	(	_	_	O
30	ADT	_	_	O
31	)	_	_	O
32	is	_	_	O
33	commonly	_	_	O
34	used	_	_	O
35	as	_	_	O
36	a	_	_	O
37	primary	_	_	O
38	treatment	_	_	O
39	for	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	prostate	_	_	O
43	cancer	_	_	O
44	(	_	_	O
45	PCa	_	_	O
46	)	_	_	O
47	who	_	_	O
48	are	_	_	O
49	not	_	_	O
50	eligible	_	_	O
51	for	_	_	O
52	radical	_	_	O
53	treatment	_	_	O
54	options	_	_	O
55	.	_	_	O

56	ADT	_	_	O
57	is	_	_	O
58	also	_	_	O
59	used	_	_	O
60	in	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	PCa	_	_	O
64	as	_	_	O
65	neo-adjuvant	_	_	O
66	hormone	_	_	O
67	therapy	_	_	O
68	to	_	_	O
69	reduce	_	_	O
70	prostate	_	_	O
71	volume	_	_	O
72	and	_	_	O
73	down-stage	_	_	O
74	the	_	_	O
75	disease	_	_	O
76	before	_	_	O
77	radiotherapy	_	_	O
78	with	_	_	O
79	curative	_	_	O
80	intent	_	_	O
81	.	_	_	O

82	The	_	_	O
83	present	_	_	O
84	study	_	_	O
85	showed	_	_	O
86	that	_	_	O
87	ADT	_	_	O
88	with	_	_	O
89	the	_	_	O
90	gonadotropin	_	_	O
91	hormone-releasing	_	_	O
92	hormone	_	_	O
93	(	_	_	O
94	GhRH	_	_	O
95	)	_	_	O
96	antagonist	_	_	O
97	degarelix	_	_	O
98	is	_	_	O
99	non-inferior	_	_	O
100	to	_	_	O
101	combined	_	_	O
102	treatment	_	_	O
103	with	_	_	O
104	the	_	_	O
105	LHRH	_	_	O
106	agonist	_	_	O
107	goserelin	_	_	O
108	and	_	_	O
109	bicalutamide	_	_	O
110	in	_	_	O
111	terms	_	_	O
112	of	_	_	O
113	reducing	_	_	O
114	prostate	_	_	O
115	volume	_	_	O
116	during	_	_	O
117	the	_	_	O
118	treatment	_	_	O
119	period	_	_	O
120	of	_	_	O
121	3	_	_	O
122	months	_	_	O
123	.	_	_	O

124	Degarelix	_	_	O
125	treatment	_	_	O
126	evokes	_	_	O
127	,	_	_	O
128	however	_	_	O
129	,	_	_	O
130	significantly	_	_	O
131	better	_	_	O
132	relief	_	_	O
133	of	_	_	O
134	lower	_	_	O
135	urinary	_	_	O
136	tract	_	_	O
137	symptoms	_	_	O
138	in	_	_	O
139	patients	_	_	O
140	having	_	_	O
141	moderate	_	_	O
142	and	_	_	O
143	severe	_	_	O
144	voiding	_	_	O
145	problems	_	_	O
146	.	_	_	O

147	To	_	_	O
148	assess	_	_	O
149	the	_	_	O
150	efficacy	_	_	O
151	of	_	_	O
152	monthly	_	_	O
153	degarelix	_	_	O
154	treatment	_	_	O
155	for	_	_	O
156	reduction	_	_	O
157	of	_	_	O
158	total	_	_	O
159	prostate	_	_	O
160	volume	_	_	O
161	(	_	_	O
162	TPV	_	_	O
163	)	_	_	O
164	,	_	_	O
165	relief	_	_	O
166	of	_	_	O
167	lower	_	_	O
168	urinary	_	_	O
169	tract	_	_	O
170	symptoms	_	_	O
171	(	_	_	O
172	LUTS	_	_	O
173	)	_	_	O
174	and	_	_	O
175	improvement	_	_	O
176	of	_	_	O
177	quality	_	_	O
178	of	_	_	O
179	life	_	_	O
180	(	_	_	O
181	QoL	_	_	O
182	)	_	_	O
183	in	_	_	O
184	patients	_	_	O
185	with	_	_	O
186	prostate	_	_	O
187	cancer	_	_	O
188	(	_	_	O
189	PCa	_	_	O
190	)	_	_	O
191	using	_	_	O
192	monthly	_	_	O
193	goserelin	_	_	O
194	as	_	_	O
195	active	_	_	O
196	control	_	_	O
197	.	_	_	O

198	This	_	_	O
199	was	_	_	O
200	a	_	_	O
201	randomized	_	_	O
202	,	_	_	O
203	parallel-arm	_	_	O
204	,	_	_	O
205	active-controlled	_	_	O
206	,	_	_	O
207	open-label	_	_	O
208	,	_	_	O
209	multicentre	_	_	O
210	trial	_	_	O
211	on	_	_	O
212	182	_	_	O
213	patients	_	_	O
214	treated	_	_	O
215	with	_	_	O
216	either	_	_	O
217	monthly	_	_	O
218	degarelix	_	_	O
219	(	_	_	O
220	240/80	_	_	O
221	mg	_	_	O
222	)	_	_	O
223	or	_	_	O
224	goserelin	_	_	O
225	(	_	_	O
226	3.6	_	_	O
227	mg	_	_	O
228	)	_	_	O
229	for	_	_	O
230	12	_	_	O
231	weeks	_	_	O
232	.	_	_	O

233	For	_	_	O
234	flare	_	_	O
235	protection	_	_	O
236	,	_	_	O
237	goserelin-treated	_	_	O
238	patients	_	_	O
239	also	_	_	O
240	received	_	_	O
241	daily	_	_	O
242	bicalutamide	_	_	O
243	(	_	_	O
244	50	_	_	O
245	mg	_	_	O
246	)	_	_	O
247	during	_	_	O
248	the	_	_	O
249	initial	_	_	O
250	28	_	_	O
251	days	_	_	O
252	.	_	_	O

253	Key	_	_	O
254	trial	_	_	O
255	variables	_	_	O
256	monitored	_	_	O
257	monthly	_	_	O
258	were	_	_	O
259	TPV	_	_	O
260	(	_	_	O
261	primary	_	_	O
262	endpoint	_	_	O
263	)	_	_	O
264	,	_	_	O
265	serum	_	_	O
266	testosterone	_	_	O
267	,	_	_	O
268	prostate-specific	_	_	O
269	antigen	_	_	O
270	(	_	_	O
271	PSA	_	_	O
272	)	_	_	O
273	,	_	_	O
274	the	_	_	O
275	International	_	_	O
276	Prostate	_	_	O
277	Symptom	_	_	O
278	Score	_	_	O
279	(	_	_	O
280	IPSS	_	_	O
281	)	_	_	O
282	and	_	_	O
283	the	_	_	O
284	Benign	_	_	O
285	Prostate	_	_	O
286	Hyperplasia	_	_	O
287	Impact	_	_	O
288	Index	_	_	O
289	.	_	_	O

290	In	_	_	O
291	all	_	_	O
292	,	_	_	O
293	175	_	_	O
294	patients	_	_	O
295	completed	_	_	O
296	the	_	_	O
297	trial	_	_	O
298	(	_	_	O
299	96.1	_	_	O
300	%	_	_	O
301	)	_	_	O
302	.	_	_	O

303	At	_	_	B-Premise
304	week	_	_	I-Premise
305	12	_	_	I-Premise
306	,	_	_	I-Premise
307	changes	_	_	I-Premise
308	in	_	_	I-Premise
309	TPV	_	_	I-Premise
310	for	_	_	I-Premise
311	degarelix	_	_	I-Premise
312	and	_	_	I-Premise
313	goserelin	_	_	I-Premise
314	were	_	_	I-Premise
315	similar	_	_	I-Premise
316	(	_	_	I-Premise
317	-37.2	_	_	I-Premise
318	%	_	_	I-Premise
319	vs	_	_	I-Premise
320	-39.0	_	_	I-Premise
321	%	_	_	I-Premise
322	)	_	_	I-Premise
323	and	_	_	I-Premise
324	met	_	_	I-Premise
325	the	_	_	I-Premise
326	predefined	_	_	I-Premise
327	non-inferiority	_	_	I-Premise
328	criterion	_	_	I-Premise
329	.	_	_	I-Premise

330	Decreases	_	_	B-Premise
331	in	_	_	I-Premise
332	IPSS	_	_	I-Premise
333	were	_	_	I-Premise
334	greater	_	_	I-Premise
335	in	_	_	I-Premise
336	degarelix	_	_	I-Premise
337	than	_	_	I-Premise
338	in	_	_	I-Premise
339	goserelin-treated	_	_	I-Premise
340	patients	_	_	I-Premise
341	,	_	_	I-Premise
342	differences	_	_	I-Premise
343	being	_	_	I-Premise
344	statistically	_	_	I-Premise
345	significant	_	_	I-Premise
346	in	_	_	I-Premise
347	patients	_	_	I-Premise
348	with	_	_	I-Premise
349	baseline	_	_	I-Premise
350	IPSS	_	_	I-Premise
351	>	_	_	I-Premise
352	13	_	_	I-Premise
353	(	_	_	I-Premise
354	-6.7	_	_	I-Premise
355	±	_	_	I-Premise
356	1.8	_	_	I-Premise
357	vs	_	_	I-Premise
358	-4.0	_	_	I-Premise
359	±	_	_	I-Premise
360	1.0	_	_	I-Premise
361	;	_	_	I-Premise
362	P	_	_	I-Premise
363	=	_	_	I-Premise
364	0.02	_	_	I-Premise
365	)	_	_	I-Premise
366	.	_	_	I-Premise

367	The	_	_	B-Premise
368	number	_	_	I-Premise
369	of	_	_	I-Premise
370	patients	_	_	I-Premise
371	with	_	_	I-Premise
372	an	_	_	I-Premise
373	IPSS	_	_	I-Premise
374	change	_	_	I-Premise
375	of	_	_	I-Premise
376	≥	_	_	I-Premise
377	3	_	_	I-Premise
378	over	_	_	I-Premise
379	baseline	_	_	I-Premise
380	was	_	_	I-Premise
381	also	_	_	I-Premise
382	significantly	_	_	I-Premise
383	higher	_	_	I-Premise
384	in	_	_	I-Premise
385	patients	_	_	I-Premise
386	treated	_	_	I-Premise
387	with	_	_	I-Premise
388	degarelix	_	_	I-Premise
389	(	_	_	I-Premise
390	61.0	_	_	I-Premise
391	vs	_	_	I-Premise
392	44.3	_	_	I-Premise
393	%	_	_	I-Premise
394	,	_	_	I-Premise
395	P	_	_	I-Premise
396	=	_	_	I-Premise
397	0.02	_	_	I-Premise
398	)	_	_	I-Premise
399	.	_	_	I-Premise

400	Both	_	_	B-Claim
401	treatments	_	_	I-Claim
402	were	_	_	I-Claim
403	safe	_	_	I-Claim
404	and	_	_	I-Claim
405	well	_	_	I-Claim
406	tolerated	_	_	I-Claim
407	.	_	_	I-Claim

408	Medical	_	_	B-Claim
409	castration	_	_	I-Claim
410	reduces	_	_	I-Claim
411	TPV	_	_	I-Claim
412	and	_	_	I-Claim
413	could	_	_	I-Claim
414	also	_	_	I-Claim
415	improve	_	_	I-Claim
416	LUTS	_	_	I-Claim
417	in	_	_	I-Claim
418	patients	_	_	I-Claim
419	with	_	_	I-Claim
420	PCa	_	_	I-Claim
421	.	_	_	I-Claim

422	While	_	_	O
423	the	_	_	B-Claim
424	short-term	_	_	I-Claim
425	efficacy	_	_	I-Claim
426	of	_	_	I-Claim
427	degarelix	_	_	I-Claim
428	and	_	_	I-Claim
429	goserelin	_	_	I-Claim
430	+	_	_	I-Claim
431	bicalutamide	_	_	I-Claim
432	was	_	_	I-Claim
433	the	_	_	I-Claim
434	same	_	_	I-Claim
435	in	_	_	I-Claim
436	terms	_	_	I-Claim
437	of	_	_	I-Claim
438	TPV	_	_	I-Claim
439	reduction	_	_	I-Claim
440	,	_	_	I-Claim
441	degarelix	_	_	B-Claim
442	showed	_	_	I-Claim
443	superiority	_	_	I-Claim
444	in	_	_	I-Claim
445	LUTS	_	_	I-Claim
446	relief	_	_	I-Claim
447	in	_	_	I-Claim
448	symptomatic	_	_	I-Claim
449	patients	_	_	I-Claim
450	,	_	_	I-Claim
451	which	_	_	I-Claim
452	could	_	_	I-Claim
453	highlight	_	_	I-Claim
454	the	_	_	I-Claim
455	different	_	_	I-Claim
456	actions	_	_	I-Claim
457	of	_	_	I-Claim
458	these	_	_	I-Claim
459	drugs	_	_	I-Claim
460	on	_	_	I-Claim
461	extrapituitary	_	_	I-Claim
462	gonadotrophin-releasing	_	_	I-Claim
463	hormone	_	_	I-Claim
464	(	_	_	I-Claim
465	GnRH	_	_	I-Claim
466	)	_	_	I-Claim
467	receptors	_	_	I-Claim
468	in	_	_	I-Claim
469	the	_	_	I-Claim
470	bladder	_	_	I-Claim
471	and/or	_	_	I-Claim
472	the	_	_	I-Claim
473	prostate	_	_	I-Claim
474	.	_	_	I-Claim


0	Treosulfan	_	_	O
1	,	_	_	O
2	an	_	_	O
3	alkylating	_	_	O
4	agent	_	_	O
5	,	_	_	O
6	has	_	_	O
7	demonstrated	_	_	O
8	activity	_	_	O
9	in	_	_	O
10	recurrent	_	_	O
11	ovarian	_	_	O
12	carcinoma	_	_	O
13	.	_	_	O

14	It	_	_	O
15	is	_	_	O
16	equieffective	_	_	O
17	as	_	_	O
18	oral	_	_	O
19	(	_	_	O
20	p.o	_	_	O
21	.	_	_	O
22	)	_	_	O

23	and	_	_	O
24	intravenous	_	_	O
25	(	_	_	O
26	i.v	_	_	O
27	.	_	_	O
28	)	_	_	O

29	formulation	_	_	O
30	.	_	_	O

31	To	_	_	O
32	explore	_	_	O
33	the	_	_	O
34	preference	_	_	O
35	and	_	_	O
36	compliance	_	_	O
37	of	_	_	O
38	elderly	_	_	O
39	patients	_	_	O
40	regarding	_	_	O
41	p.o	_	_	O
42	.	_	_	O

43	or	_	_	O
44	i.v	_	_	O
45	.	_	_	O

46	treosulfan	_	_	O
47	for	_	_	O
48	the	_	_	O
49	treatment	_	_	O
50	of	_	_	O
51	relapsed	_	_	O
52	ovarian	_	_	O
53	carcinoma	_	_	O
54	,	_	_	O
55	women	_	_	O
56	aged	_	_	O
57	65	_	_	O
58	years	_	_	O
59	or	_	_	O
60	older	_	_	O
61	were	_	_	O
62	included	_	_	O
63	in	_	_	O
64	this	_	_	O
65	prospective	_	_	O
66	multicenter	_	_	O
67	study	_	_	O
68	.	_	_	O

69	Since	_	_	O
70	elderly	_	_	O
71	patients	_	_	O
72	usually	_	_	O
73	have	_	_	O
74	several	_	_	O
75	concomitant	_	_	O
76	diseases	_	_	O
77	and	_	_	O
78	experience	_	_	O
79	more	_	_	O
80	treatment	_	_	O
81	toxicity	_	_	O
82	,	_	_	O
83	an	_	_	O
84	interim	_	_	O
85	safety	_	_	O
86	analysis	_	_	O
87	was	_	_	O
88	planned	_	_	O
89	and	_	_	O
90	performed	_	_	O
91	after	_	_	O
92	25	_	_	O
93	patients	_	_	O
94	finished	_	_	O
95	therapy	_	_	O
96	to	_	_	O
97	assess	_	_	O
98	the	_	_	O
99	tolerability	_	_	O
100	of	_	_	O
101	the	_	_	O
102	treatment	_	_	O
103	regimens	_	_	O
104	.	_	_	O

105	Patients	_	_	O
106	had	_	_	O
107	a	_	_	O
108	free	_	_	O
109	choice	_	_	O
110	of	_	_	O
111	treosulfan	_	_	O
112	i.v	_	_	O
113	.	_	_	O

114	(	_	_	O
115	7,000	_	_	O
116	mg/m	_	_	O
117	(	_	_	O
118	2	_	_	O
119	)	_	_	O
120	day	_	_	O
121	1	_	_	O
122	of	_	_	O
123	a	_	_	O
124	28-day	_	_	O
125	cycle	_	_	O
126	)	_	_	O
127	or	_	_	O
128	p.o	_	_	O
129	.	_	_	O

130	(	_	_	O
131	600	_	_	O
132	mg/m	_	_	O
133	(	_	_	O
134	2	_	_	O
135	)	_	_	O
136	day	_	_	O
137	1-28	_	_	O
138	of	_	_	O
139	a	_	_	O
140	56-day	_	_	O
141	cycle	_	_	O
142	)	_	_	O
143	for	_	_	O
144	a	_	_	O
145	maximum	_	_	O
146	of	_	_	O
147	12	_	_	O
148	cycles	_	_	O
149	(	_	_	O
150	i.v	_	_	O
151	.	_	_	O
152	)	_	_	O

153	or	_	_	O
154	12	_	_	O
155	months	_	_	O
156	(	_	_	O
157	p.o	_	_	O
158	.	_	_	O
159	)	_	_	O
160	.	_	_	O

161	Indecisive	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	randomized	_	_	O
165	.	_	_	O

166	Toxicity	_	_	O
167	was	_	_	O
168	evaluated	_	_	O
169	according	_	_	O
170	to	_	_	O
171	the	_	_	O
172	NCI-CTC	_	_	O
173	version	_	_	O
174	2.0	_	_	O
175	.	_	_	O

176	Twenty-five	_	_	O
177	of	_	_	O
178	51	_	_	O
179	recruited	_	_	O
180	patients	_	_	O
181	completed	_	_	O
182	therapy	_	_	O
183	at	_	_	O
184	the	_	_	O
185	time	_	_	O
186	of	_	_	O
187	the	_	_	O
188	planned	_	_	O
189	interim	_	_	O
190	analysis	_	_	O
191	(	_	_	O
192	median	_	_	O
193	age	_	_	O
194	,	_	_	O
195	75	_	_	O
196	years	_	_	O
197	;	_	_	O
198	range	_	_	O
199	,	_	_	O
200	70-82	_	_	O
201	)	_	_	O
202	.	_	_	O

203	Median	_	_	O
204	ECOG	_	_	O
205	was	_	_	O
206	1	_	_	O
207	,	_	_	O
208	and	_	_	O
209	median	_	_	O
210	number	_	_	O
211	of	_	_	O
212	prior	_	_	O
213	chemotherapy	_	_	O
214	regimens	_	_	O
215	was	_	_	O
216	2	_	_	O
217	.	_	_	O

218	A	_	_	O
219	median	_	_	O
220	number	_	_	O
221	of	_	_	O
222	4	_	_	O
223	cycles	_	_	O
224	(	_	_	O
225	range	_	_	O
226	,	_	_	O
227	1-12	_	_	O
228	)	_	_	O
229	were	_	_	O
230	administered	_	_	O
231	per	_	_	O
232	patient	_	_	O
233	.	_	_	O

234	Anemia	_	_	B-Premise
235	was	_	_	I-Premise
236	the	_	_	I-Premise
237	most	_	_	I-Premise
238	common	_	_	I-Premise
239	hematological	_	_	I-Premise
240	toxicity	_	_	I-Premise
241	(	_	_	I-Premise
242	88	_	_	I-Premise
243	%	_	_	I-Premise
244	of	_	_	I-Premise
245	patients	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Most	_	_	B-Premise
249	frequent	_	_	I-Premise
250	non-hematological	_	_	I-Premise
251	toxicities	_	_	I-Premise
252	were	_	_	I-Premise
253	nausea	_	_	I-Premise
254	(	_	_	I-Premise
255	76	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	,	_	_	I-Premise
259	constipation	_	_	I-Premise
260	(	_	_	I-Premise
261	68	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	fatigue	_	_	I-Premise
267	(	_	_	I-Premise
268	64	_	_	I-Premise
269	%	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	Treatment	_	_	B-Claim
273	was	_	_	I-Claim
274	generally	_	_	I-Claim
275	well	_	_	I-Claim
276	tolerated	_	_	I-Claim
277	despite	_	_	I-Claim
278	the	_	_	I-Claim
279	fact	_	_	I-Claim
280	that	_	_	I-Claim
281	most	_	_	I-Claim
282	patients	_	_	I-Claim
283	suffered	_	_	I-Claim
284	from	_	_	I-Claim
285	multiple	_	_	I-Claim
286	comorbidities	_	_	I-Claim
287	and	_	_	I-Claim
288	were	_	_	I-Claim
289	heavily	_	_	I-Claim
290	pretreated	_	_	I-Claim
291	.	_	_	I-Claim

292	There	_	_	B-Claim
293	were	_	_	I-Claim
294	no	_	_	I-Claim
295	unexpected	_	_	I-Claim
296	hematological	_	_	I-Claim
297	or	_	_	I-Claim
298	non-hematological	_	_	I-Claim
299	toxicities	_	_	I-Claim
300	.	_	_	I-Claim

301	Based	_	_	O
302	on	_	_	O
303	this	_	_	O
304	safety	_	_	O
305	analysis	_	_	O
306	,	_	_	O
307	the	_	_	O
308	next	_	_	O
309	step	_	_	O
310	of	_	_	O
311	study	_	_	O
312	recruitment	_	_	O
313	was	_	_	O
314	continued	_	_	O
315	.	_	_	O


0	It	_	_	O
1	is	_	_	O
2	not	_	_	O
3	clear	_	_	O
4	whether	_	_	O
5	the	_	_	O
6	administration	_	_	O
7	of	_	_	O
8	radioiodine	_	_	O
9	provides	_	_	O
10	any	_	_	O
11	benefit	_	_	O
12	to	_	_	O
13	patients	_	_	O
14	with	_	_	O
15	low-risk	_	_	O
16	thyroid	_	_	O
17	cancer	_	_	O
18	after	_	_	O
19	a	_	_	O
20	complete	_	_	O
21	surgical	_	_	O
22	resection	_	_	O
23	.	_	_	O

24	The	_	_	O
25	administration	_	_	O
26	of	_	_	O
27	the	_	_	O
28	smallest	_	_	O
29	possible	_	_	O
30	amount	_	_	O
31	of	_	_	O
32	radioiodine	_	_	O
33	would	_	_	O
34	improve	_	_	O
35	care	_	_	O
36	.	_	_	O

37	In	_	_	O
38	our	_	_	O
39	randomized	_	_	O
40	,	_	_	O
41	phase	_	_	O
42	3	_	_	O
43	trial	_	_	O
44	,	_	_	O
45	we	_	_	O
46	compared	_	_	O
47	two	_	_	O
48	thyrotropin-stimulation	_	_	O
49	methods	_	_	O
50	(	_	_	O
51	thyroid	_	_	O
52	hormone	_	_	O
53	withdrawal	_	_	O
54	and	_	_	O
55	use	_	_	O
56	of	_	_	O
57	recombinant	_	_	O
58	human	_	_	O
59	thyrotropin	_	_	O
60	)	_	_	O
61	and	_	_	O
62	two	_	_	O
63	radioiodine	_	_	O
64	(	_	_	O
65	(	_	_	O
66	131	_	_	O
67	)	_	_	O
68	I	_	_	O
69	)	_	_	O
70	doses	_	_	O
71	(	_	_	O
72	i.e.	_	_	O
73	,	_	_	O
74	administered	_	_	O
75	activities	_	_	O
76	)	_	_	O
77	(	_	_	O
78	1.1	_	_	O
79	GBq	_	_	O
80	and	_	_	O
81	3.7	_	_	O
82	GBq	_	_	O
83	)	_	_	O
84	in	_	_	O
85	a	_	_	O
86	2-by-2	_	_	O
87	design	_	_	O
88	.	_	_	O

89	Inclusion	_	_	O
90	criteria	_	_	O
91	were	_	_	O
92	an	_	_	O
93	age	_	_	O
94	of	_	_	O
95	18	_	_	O
96	years	_	_	O
97	or	_	_	O
98	older	_	_	O
99	;	_	_	O
100	total	_	_	O
101	thyroidectomy	_	_	O
102	for	_	_	O
103	differentiated	_	_	O
104	thyroid	_	_	O
105	carcinoma	_	_	O
106	;	_	_	O
107	tumor-node-metastasis	_	_	O
108	(	_	_	O
109	TNM	_	_	O
110	)	_	_	O
111	stage	_	_	O
112	,	_	_	O
113	ascertained	_	_	O
114	on	_	_	O
115	pathological	_	_	O
116	examination	_	_	O
117	(	_	_	O
118	p	_	_	O
119	)	_	_	O
120	of	_	_	O
121	a	_	_	O
122	surgical	_	_	O
123	specimen	_	_	O
124	,	_	_	O
125	of	_	_	O
126	pT1	_	_	O
127	(	_	_	O
128	with	_	_	O
129	tumor	_	_	O
130	diameter	_	_	O
131	≤1	_	_	O
132	cm	_	_	O
133	)	_	_	O
134	and	_	_	O
135	N1	_	_	O
136	or	_	_	O
137	Nx	_	_	O
138	,	_	_	O
139	pT1	_	_	O
140	(	_	_	O
141	with	_	_	O
142	tumor	_	_	O
143	diameter	_	_	O
144	>	_	_	O
145	1	_	_	O
146	to	_	_	O
147	2	_	_	O
148	cm	_	_	O
149	)	_	_	O
150	and	_	_	O
151	any	_	_	O
152	N	_	_	O
153	stage	_	_	O
154	,	_	_	O
155	or	_	_	O
156	pT2N0	_	_	O
157	;	_	_	O
158	absence	_	_	O
159	of	_	_	O
160	distant	_	_	O
161	metastasis	_	_	O
162	;	_	_	O
163	and	_	_	O
164	no	_	_	O
165	iodine	_	_	O
166	contamination	_	_	O
167	.	_	_	O

168	Thyroid	_	_	O
169	ablation	_	_	O
170	was	_	_	O
171	assessed	_	_	O
172	8	_	_	O
173	months	_	_	O
174	after	_	_	O
175	radioiodine	_	_	O
176	administration	_	_	O
177	by	_	_	O
178	neck	_	_	O
179	ultrasonography	_	_	O
180	and	_	_	O
181	measurement	_	_	O
182	of	_	_	O
183	recombinant	_	_	O
184	human	_	_	O
185	thyrotropin-stimulated	_	_	O
186	thyroglobulin	_	_	O
187	.	_	_	O

188	Comparisons	_	_	O
189	were	_	_	O
190	based	_	_	O
191	on	_	_	O
192	an	_	_	O
193	equivalence	_	_	O
194	framework	_	_	O
195	.	_	_	O

196	There	_	_	O
197	were	_	_	O
198	752	_	_	O
199	patients	_	_	O
200	enrolled	_	_	O
201	between	_	_	O
202	2007	_	_	O
203	and	_	_	O
204	2010	_	_	O
205	;	_	_	O
206	92	_	_	O
207	%	_	_	O
208	had	_	_	O
209	papillary	_	_	O
210	cancer	_	_	O
211	.	_	_	O

212	There	_	_	B-Premise
213	were	_	_	I-Premise
214	no	_	_	I-Premise
215	unexpected	_	_	I-Premise
216	serious	_	_	I-Premise
217	adverse	_	_	I-Premise
218	events	_	_	I-Premise
219	.	_	_	I-Premise

220	In	_	_	B-Premise
221	the	_	_	I-Premise
222	684	_	_	I-Premise
223	patients	_	_	I-Premise
224	with	_	_	I-Premise
225	data	_	_	I-Premise
226	that	_	_	I-Premise
227	could	_	_	I-Premise
228	be	_	_	I-Premise
229	evaluated	_	_	I-Premise
230	,	_	_	I-Premise
231	ultrasonography	_	_	I-Premise
232	of	_	_	I-Premise
233	the	_	_	I-Premise
234	neck	_	_	I-Premise
235	was	_	_	I-Premise
236	normal	_	_	I-Premise
237	in	_	_	I-Premise
238	652	_	_	I-Premise
239	(	_	_	I-Premise
240	95	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	,	_	_	I-Premise
244	and	_	_	I-Premise
245	the	_	_	I-Premise
246	stimulated	_	_	I-Premise
247	thyroglobulin	_	_	I-Premise
248	level	_	_	I-Premise
249	was	_	_	I-Premise
250	1.0	_	_	I-Premise
251	ng	_	_	I-Premise
252	per	_	_	I-Premise
253	milliliter	_	_	I-Premise
254	or	_	_	I-Premise
255	less	_	_	I-Premise
256	in	_	_	I-Premise
257	621	_	_	I-Premise
258	of	_	_	I-Premise
259	the	_	_	I-Premise
260	652	_	_	I-Premise
261	patients	_	_	I-Premise
262	(	_	_	I-Premise
263	95	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	without	_	_	I-Premise
267	detectable	_	_	I-Premise
268	thyroglobulin	_	_	I-Premise
269	antibodies	_	_	I-Premise
270	.	_	_	I-Premise

271	Thyroid	_	_	B-Premise
272	ablation	_	_	I-Premise
273	was	_	_	I-Premise
274	complete	_	_	I-Premise
275	in	_	_	I-Premise
276	631	_	_	I-Premise
277	of	_	_	I-Premise
278	the	_	_	I-Premise
279	684	_	_	I-Premise
280	patients	_	_	I-Premise
281	(	_	_	I-Premise
282	92	_	_	I-Premise
283	%	_	_	I-Premise
284	)	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	ablation	_	_	I-Premise
288	rate	_	_	I-Premise
289	was	_	_	I-Premise
290	equivalent	_	_	I-Premise
291	between	_	_	I-Premise
292	the	_	_	I-Premise
293	(	_	_	I-Premise
294	131	_	_	I-Premise
295	)	_	_	I-Premise
296	I	_	_	I-Premise
297	doses	_	_	I-Premise
298	and	_	_	I-Premise
299	between	_	_	I-Premise
300	the	_	_	I-Premise
301	thyrotropin-stimulation	_	_	I-Premise
302	methods	_	_	I-Premise
303	.	_	_	I-Premise

304	The	_	_	B-Claim
305	use	_	_	I-Claim
306	of	_	_	I-Claim
307	recombinant	_	_	I-Claim
308	human	_	_	I-Claim
309	thyrotropin	_	_	I-Claim
310	and	_	_	I-Claim
311	low-dose	_	_	I-Claim
312	(	_	_	I-Claim
313	1.1	_	_	I-Claim
314	GBq	_	_	I-Claim
315	)	_	_	I-Claim
316	postoperative	_	_	I-Claim
317	radioiodine	_	_	I-Claim
318	ablation	_	_	I-Claim
319	may	_	_	I-Claim
320	be	_	_	I-Claim
321	sufficient	_	_	I-Claim
322	for	_	_	I-Claim
323	the	_	_	I-Claim
324	management	_	_	I-Claim
325	of	_	_	I-Claim
326	low-risk	_	_	I-Claim
327	thyroid	_	_	I-Claim
328	cancer	_	_	I-Claim
329	.	_	_	I-Claim


0	It	_	_	O
1	is	_	_	O
2	not	_	_	O
3	known	_	_	O
4	whether	_	_	O
5	low-dose	_	_	O
6	radioiodine	_	_	O
7	(	_	_	O
8	1.1	_	_	O
9	GBq	_	_	O
10	[	_	_	O
11	30	_	_	O
12	mCi	_	_	O
13	]	_	_	O
14	)	_	_	O
15	is	_	_	O
16	as	_	_	O
17	effective	_	_	O
18	as	_	_	O
19	high-dose	_	_	O
20	radioiodine	_	_	O
21	(	_	_	O
22	3.7	_	_	O
23	GBq	_	_	O
24	[	_	_	O
25	100	_	_	O
26	mCi	_	_	O
27	]	_	_	O
28	)	_	_	O
29	for	_	_	O
30	treating	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	differentiated	_	_	O
34	thyroid	_	_	O
35	cancer	_	_	O
36	or	_	_	O
37	whether	_	_	O
38	the	_	_	O
39	effects	_	_	O
40	of	_	_	O
41	radioiodine	_	_	O
42	(	_	_	O
43	especially	_	_	O
44	at	_	_	O
45	a	_	_	O
46	low	_	_	O
47	dose	_	_	O
48	)	_	_	O
49	are	_	_	O
50	influenced	_	_	O
51	by	_	_	O
52	using	_	_	O
53	either	_	_	O
54	recombinant	_	_	O
55	human	_	_	O
56	thyrotropin	_	_	O
57	(	_	_	O
58	thyrotropin	_	_	O
59	alfa	_	_	O
60	)	_	_	O
61	or	_	_	O
62	thyroid	_	_	O
63	hormone	_	_	O
64	withdrawal	_	_	O
65	.	_	_	O

66	At	_	_	O
67	29	_	_	O
68	centers	_	_	O
69	in	_	_	O
70	the	_	_	O
71	United	_	_	O
72	Kingdom	_	_	O
73	,	_	_	O
74	we	_	_	O
75	conducted	_	_	O
76	a	_	_	O
77	randomized	_	_	O
78	noninferiority	_	_	O
79	trial	_	_	O
80	comparing	_	_	O
81	low-dose	_	_	O
82	and	_	_	O
83	high-dose	_	_	O
84	radioiodine	_	_	O
85	,	_	_	O
86	each	_	_	O
87	in	_	_	O
88	combination	_	_	O
89	with	_	_	O
90	either	_	_	O
91	thyrotropin	_	_	O
92	alfa	_	_	O
93	or	_	_	O
94	thyroid	_	_	O
95	hormone	_	_	O
96	withdrawal	_	_	O
97	before	_	_	O
98	ablation	_	_	O
99	.	_	_	O

100	Patients	_	_	O
101	(	_	_	O
102	age	_	_	O
103	range	_	_	O
104	,	_	_	O
105	16	_	_	O
106	to	_	_	O
107	80	_	_	O
108	years	_	_	O
109	)	_	_	O
110	had	_	_	O
111	tumor	_	_	O
112	stage	_	_	O
113	T1	_	_	O
114	to	_	_	O
115	T3	_	_	O
116	,	_	_	O
117	with	_	_	O
118	possible	_	_	O
119	spread	_	_	O
120	to	_	_	O
121	nearby	_	_	O
122	lymph	_	_	O
123	nodes	_	_	O
124	but	_	_	O
125	without	_	_	O
126	metastasis	_	_	O
127	.	_	_	O

128	End	_	_	O
129	points	_	_	O
130	were	_	_	O
131	the	_	_	O
132	rate	_	_	O
133	of	_	_	O
134	success	_	_	O
135	of	_	_	O
136	ablation	_	_	O
137	at	_	_	O
138	6	_	_	O
139	to	_	_	O
140	9	_	_	O
141	months	_	_	O
142	,	_	_	O
143	adverse	_	_	O
144	events	_	_	O
145	,	_	_	O
146	quality	_	_	O
147	of	_	_	O
148	life	_	_	O
149	,	_	_	O
150	and	_	_	O
151	length	_	_	O
152	of	_	_	O
153	hospital	_	_	O
154	stay	_	_	O
155	.	_	_	O

156	A	_	_	O
157	total	_	_	O
158	of	_	_	O
159	438	_	_	O
160	patients	_	_	O
161	underwent	_	_	O
162	randomization	_	_	O
163	;	_	_	O
164	data	_	_	O
165	could	_	_	O
166	be	_	_	O
167	analyzed	_	_	O
168	for	_	_	O
169	421	_	_	O
170	.	_	_	O

171	Ablation	_	_	B-Premise
172	success	_	_	I-Premise
173	rates	_	_	I-Premise
174	were	_	_	I-Premise
175	85.0	_	_	I-Premise
176	%	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	group	_	_	I-Premise
180	receiving	_	_	I-Premise
181	low-dose	_	_	I-Premise
182	radioiodine	_	_	I-Premise
183	versus	_	_	I-Premise
184	88.9	_	_	I-Premise
185	%	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	group	_	_	I-Premise
189	receiving	_	_	I-Premise
190	the	_	_	I-Premise
191	high	_	_	I-Premise
192	dose	_	_	I-Premise
193	and	_	_	I-Premise
194	87.1	_	_	I-Premise
195	%	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	thyrotropin	_	_	I-Premise
199	alfa	_	_	I-Premise
200	group	_	_	I-Premise
201	versus	_	_	I-Premise
202	86.7	_	_	I-Premise
203	%	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	group	_	_	I-Premise
207	undergoing	_	_	I-Premise
208	thyroid	_	_	I-Premise
209	hormone	_	_	I-Premise
210	withdrawal	_	_	I-Premise
211	.	_	_	I-Premise

212	All	_	_	B-Premise
213	95	_	_	I-Premise
214	%	_	_	I-Premise
215	confidence	_	_	I-Premise
216	intervals	_	_	I-Premise
217	for	_	_	I-Premise
218	the	_	_	I-Premise
219	differences	_	_	I-Premise
220	were	_	_	I-Premise
221	within	_	_	I-Premise
222	±10	_	_	I-Premise
223	percentage	_	_	I-Premise
224	points	_	_	I-Premise
225	,	_	_	I-Premise
226	indicating	_	_	I-Premise
227	noninferiority	_	_	I-Premise
228	.	_	_	I-Premise

229	Similar	_	_	B-Premise
230	results	_	_	I-Premise
231	were	_	_	I-Premise
232	found	_	_	I-Premise
233	for	_	_	I-Premise
234	low-dose	_	_	I-Premise
235	radioiodine	_	_	I-Premise
236	plus	_	_	I-Premise
237	thyrotropin	_	_	I-Premise
238	alfa	_	_	I-Premise
239	(	_	_	I-Premise
240	84.3	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	versus	_	_	I-Premise
244	high-dose	_	_	I-Premise
245	radioiodine	_	_	I-Premise
246	plus	_	_	I-Premise
247	thyroid	_	_	I-Premise
248	hormone	_	_	I-Premise
249	withdrawal	_	_	I-Premise
250	(	_	_	I-Premise
251	87.6	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	or	_	_	I-Premise
255	high-dose	_	_	I-Premise
256	radioiodine	_	_	I-Premise
257	plus	_	_	I-Premise
258	thyrotropin	_	_	I-Premise
259	alfa	_	_	I-Premise
260	(	_	_	I-Premise
261	90.2	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	More	_	_	B-Premise
266	patients	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	high-dose	_	_	I-Premise
270	group	_	_	I-Premise
271	than	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	low-dose	_	_	I-Premise
275	group	_	_	I-Premise
276	were	_	_	I-Premise
277	hospitalized	_	_	I-Premise
278	for	_	_	I-Premise
279	at	_	_	I-Premise
280	least	_	_	I-Premise
281	3	_	_	I-Premise
282	days	_	_	I-Premise
283	(	_	_	I-Premise
284	36.3	_	_	I-Premise
285	%	_	_	I-Premise
286	vs.	_	_	I-Premise
287	13.0	_	_	I-Premise
288	%	_	_	I-Premise
289	,	_	_	I-Premise
290	P	_	_	I-Premise
291	<	_	_	I-Premise
292	0.001	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Premise
296	proportions	_	_	I-Premise
297	of	_	_	I-Premise
298	patients	_	_	I-Premise
299	with	_	_	I-Premise
300	adverse	_	_	I-Premise
301	events	_	_	I-Premise
302	were	_	_	I-Premise
303	21	_	_	I-Premise
304	%	_	_	I-Premise
305	in	_	_	I-Premise
306	the	_	_	I-Premise
307	low-dose	_	_	I-Premise
308	group	_	_	I-Premise
309	versus	_	_	I-Premise
310	33	_	_	I-Premise
311	%	_	_	I-Premise
312	in	_	_	I-Premise
313	the	_	_	I-Premise
314	high-dose	_	_	I-Premise
315	group	_	_	I-Premise
316	(	_	_	I-Premise
317	P=0.007	_	_	I-Premise
318	)	_	_	I-Premise
319	and	_	_	I-Premise
320	23	_	_	I-Premise
321	%	_	_	I-Premise
322	in	_	_	I-Premise
323	the	_	_	I-Premise
324	thyrotropin	_	_	I-Premise
325	alfa	_	_	I-Premise
326	group	_	_	I-Premise
327	versus	_	_	I-Premise
328	30	_	_	I-Premise
329	%	_	_	I-Premise
330	in	_	_	I-Premise
331	the	_	_	I-Premise
332	group	_	_	I-Premise
333	undergoing	_	_	I-Premise
334	thyroid	_	_	I-Premise
335	hormone	_	_	I-Premise
336	withdrawal	_	_	I-Premise
337	(	_	_	I-Premise
338	P=0.11	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	Low-dose	_	_	B-Claim
342	radioiodine	_	_	I-Claim
343	plus	_	_	I-Claim
344	thyrotropin	_	_	I-Claim
345	alfa	_	_	I-Claim
346	was	_	_	I-Claim
347	as	_	_	I-Claim
348	effective	_	_	I-Claim
349	as	_	_	I-Claim
350	high-dose	_	_	I-Claim
351	radioiodine	_	_	I-Claim
352	,	_	_	I-Claim
353	with	_	_	I-Claim
354	a	_	_	I-Claim
355	lower	_	_	I-Claim
356	rate	_	_	I-Claim
357	of	_	_	I-Claim
358	adverse	_	_	I-Claim
359	events	_	_	I-Claim
360	.	_	_	I-Claim


0	Older	_	_	O
1	breast	_	_	O
2	cancer	_	_	O
3	survivors	_	_	O
4	(	_	_	O
5	BCSs	_	_	O
6	)	_	_	O
7	are	_	_	O
8	at	_	_	O
9	risk	_	_	O
10	for	_	_	O
11	late	_	_	O
12	and	_	_	O
13	long-term	_	_	O
14	treatment	_	_	O
15	effects	_	_	O
16	on	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	(	_	_	O
21	QOL	_	_	O
22	)	_	_	O
23	,	_	_	O
24	including	_	_	O
25	lower	_	_	O
26	physical	_	_	O
27	functioning	_	_	O
28	and	_	_	O
29	fear	_	_	O
30	of	_	_	O
31	recurrence	_	_	O
32	.	_	_	O

33	Two	_	_	O
34	promising	_	_	O
35	approaches	_	_	O
36	to	_	_	O
37	address	_	_	O
38	this	_	_	O
39	include	_	_	O
40	dance/movement	_	_	O
41	therapy	_	_	O
42	and	_	_	O
43	mindfulness	_	_	O
44	.	_	_	O

45	The	_	_	O
46	purpose	_	_	O
47	of	_	_	O
48	this	_	_	O
49	2-group	_	_	O
50	randomized	_	_	O
51	controlled	_	_	O
52	pilot	_	_	O
53	feasibility	_	_	O
54	study	_	_	O
55	was	_	_	O
56	to	_	_	O
57	test	_	_	O
58	short-term	_	_	O
59	effects	_	_	O
60	of	_	_	O
61	a	_	_	O
62	12-week	_	_	O
63	Mindful	_	_	O
64	Movement	_	_	O
65	Program	_	_	O
66	(	_	_	O
67	MMP	_	_	O
68	)	_	_	O
69	intervention	_	_	O
70	combining	_	_	O
71	mindfulness	_	_	O
72	with	_	_	O
73	self-directed	_	_	O
74	movement	_	_	O
75	on	_	_	O
76	QOL	_	_	O
77	and	_	_	O
78	mindfulness	_	_	O
79	in	_	_	O
80	female	_	_	O
81	BCSs	_	_	O
82	50	_	_	O
83	years	_	_	O
84	or	_	_	O
85	older	_	_	O
86	and	_	_	O
87	at	_	_	O
88	12	_	_	O
89	months	_	_	O
90	or	_	_	O
91	more	_	_	O
92	following	_	_	O
93	treatment	_	_	O
94	.	_	_	O

95	Consented	_	_	O
96	participants	_	_	O
97	were	_	_	O
98	randomized	_	_	O
99	to	_	_	O
100	an	_	_	O
101	experimental	_	_	O
102	group	_	_	O
103	(	_	_	O
104	EG	_	_	O
105	)	_	_	O
106	(	_	_	O
107	12	_	_	O
108	weekly	_	_	O
109	MMP	_	_	O
110	sessions	_	_	O
111	)	_	_	O
112	or	_	_	O
113	a	_	_	O
114	control	_	_	O
115	group	_	_	O
116	(	_	_	O
117	no	_	_	O
118	sessions	_	_	O
119	)	_	_	O
120	.	_	_	O

121	All	_	_	O
122	completed	_	_	O
123	questionnaires	_	_	O
124	3	_	_	O
125	times	_	_	O
126	.	_	_	O

127	The	_	_	O
128	EG	_	_	O
129	participants	_	_	O
130	kept	_	_	O
131	home	_	_	O
132	practice	_	_	O
133	diaries	_	_	O
134	.	_	_	O

135	Analysis	_	_	O
136	was	_	_	O
137	conducted	_	_	O
138	after	_	_	O
139	intervention	_	_	O
140	for	_	_	O
141	immediate	_	_	O
142	effects	_	_	O
143	on	_	_	O
144	outcome	_	_	O
145	variables	_	_	O
146	and	_	_	O
147	6	_	_	O
148	weeks	_	_	O
149	later	_	_	O
150	for	_	_	O
151	maintenance	_	_	O
152	of	_	_	O
153	effects	_	_	O
154	.	_	_	O

155	Participants	_	_	O
156	(	_	_	O
157	n	_	_	O
158	=	_	_	O
159	49	_	_	O
160	)	_	_	O
161	ranged	_	_	O
162	in	_	_	O
163	age	_	_	O
164	from	_	_	O
165	50	_	_	O
166	to	_	_	O
167	90	_	_	O
168	years	_	_	O
169	(	_	_	O
170	average	_	_	O
171	,	_	_	O
172	65.6	_	_	O
173	years	_	_	O
174	)	_	_	O
175	and	_	_	O
176	were	_	_	O
177	at	_	_	O
178	9.8	_	_	O
179	years	_	_	O
180	since	_	_	O
181	diagnosis	_	_	O
182	(	_	_	O
183	range	_	_	O
184	,	_	_	O
185	1-32	_	_	O
186	years	_	_	O
187	)	_	_	O
188	,	_	_	O
189	and	_	_	O
190	the	_	_	O
191	majority	_	_	O
192	were	_	_	O
193	white	_	_	O
194	,	_	_	O
195	unpartnered	_	_	O
196	,	_	_	O
197	and	_	_	O
198	retired	_	_	O
199	.	_	_	O

200	After	_	_	B-Premise
201	intervention	_	_	I-Premise
202	,	_	_	I-Premise
203	EG	_	_	I-Premise
204	participants	_	_	I-Premise
205	showed	_	_	I-Premise
206	improved	_	_	I-Premise
207	QOL	_	_	I-Premise
208	via	_	_	I-Premise
209	decreased	_	_	I-Premise
210	fear	_	_	I-Premise
211	of	_	_	I-Premise
212	recurrence	_	_	I-Premise
213	and	_	_	I-Premise
214	increased	_	_	I-Premise
215	mindfulness	_	_	I-Premise
216	attitude	_	_	I-Premise
217	.	_	_	I-Premise

218	At	_	_	B-Premise
219	6	_	_	I-Premise
220	weeks	_	_	I-Premise
221	,	_	_	I-Premise
222	initial	_	_	I-Premise
223	effects	_	_	I-Premise
224	were	_	_	I-Premise
225	retained	_	_	I-Premise
226	.	_	_	I-Premise

227	The	_	_	B-Premise
228	MMP	_	_	I-Premise
229	appears	_	_	I-Premise
230	to	_	_	I-Premise
231	benefit	_	_	I-Premise
232	older	_	_	I-Premise
233	BCSs	_	_	I-Premise
234	by	_	_	I-Premise
235	reducing	_	_	I-Premise
236	fear	_	_	I-Premise
237	of	_	_	I-Premise
238	recurrence	_	_	I-Premise
239	and	_	_	I-Premise
240	improving	_	_	I-Premise
241	mindfulness	_	_	I-Premise
242	attitude	_	_	I-Premise
243	.	_	_	I-Premise

244	Although	_	_	B-Claim
245	these	_	_	I-Claim
246	findings	_	_	I-Claim
247	are	_	_	I-Claim
248	promising	_	_	I-Claim
249	,	_	_	I-Claim
250	a	_	_	I-Claim
251	larger	_	_	I-Claim
252	study	_	_	I-Claim
253	is	_	_	I-Claim
254	needed	_	_	I-Claim
255	to	_	_	I-Claim
256	determine	_	_	I-Claim
257	more	_	_	I-Claim
258	specifically	_	_	I-Claim
259	what	_	_	I-Claim
260	short-	_	_	I-Claim
261	and	_	_	I-Claim
262	long-term	_	_	I-Claim
263	effects	_	_	I-Claim
264	are	_	_	I-Claim
265	possible	_	_	I-Claim
266	.	_	_	I-Claim

267	The	_	_	B-Claim
268	combination	_	_	I-Claim
269	of	_	_	I-Claim
270	self-directed	_	_	I-Claim
271	movement	_	_	I-Claim
272	and	_	_	I-Claim
273	mindfulness	_	_	I-Claim
274	,	_	_	I-Claim
275	as	_	_	I-Claim
276	tested	_	_	I-Claim
277	here	_	_	I-Claim
278	,	_	_	I-Claim
279	may	_	_	I-Claim
280	be	_	_	I-Claim
281	a	_	_	I-Claim
282	valuable	_	_	I-Claim
283	tool	_	_	I-Claim
284	for	_	_	I-Claim
285	promoting	_	_	I-Claim
286	health	_	_	I-Claim
287	and	_	_	I-Claim
288	well-being	_	_	I-Claim
289	in	_	_	I-Claim
290	older	_	_	I-Claim
291	long-term	_	_	I-Claim
292	survivors	_	_	I-Claim
293	of	_	_	I-Claim
294	breast	_	_	I-Claim
295	cancer	_	_	I-Claim
296	.	_	_	I-Claim


0	Research	_	_	O
1	has	_	_	O
2	shown	_	_	O
3	that	_	_	O
4	self-directed	_	_	O
5	stress	_	_	O
6	management	_	_	O
7	training	_	_	O
8	improves	_	_	O
9	mental	_	_	O
10	well-being	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	undergoing	_	_	O
14	chemotherapy	_	_	O
15	.	_	_	O

16	The	_	_	O
17	present	_	_	O
18	study	_	_	O
19	extends	_	_	O
20	this	_	_	O
21	work	_	_	O
22	by	_	_	O
23	evaluating	_	_	O
24	separate	_	_	O
25	and	_	_	O
26	combined	_	_	O
27	effects	_	_	O
28	of	_	_	O
29	stress	_	_	O
30	management	_	_	O
31	training	_	_	O
32	and	_	_	O
33	home-based	_	_	O
34	exercise	_	_	O
35	.	_	_	O

36	Following	_	_	O
37	assessment	_	_	O
38	of	_	_	O
39	mental	_	_	O
40	and	_	_	O
41	physical	_	_	O
42	well-being	_	_	O
43	,	_	_	O
44	depression	_	_	O
45	,	_	_	O
46	anxiety	_	_	O
47	,	_	_	O
48	exercise	_	_	O
49	,	_	_	O
50	and	_	_	O
51	stress	_	_	O
52	reduction	_	_	O
53	activity	_	_	O
54	before	_	_	O
55	chemotherapy	_	_	O
56	started	_	_	O
57	,	_	_	O
58	patients	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	stress	_	_	O
63	management	_	_	O
64	training	_	_	O
65	(	_	_	O
66	SM	_	_	O
67	)	_	_	O
68	,	_	_	O
69	exercise	_	_	O
70	(	_	_	O
71	EX	_	_	O
72	)	_	_	O
73	,	_	_	O
74	combined	_	_	O
75	stress	_	_	O
76	management	_	_	O
77	and	_	_	O
78	exercise	_	_	O
79	(	_	_	O
80	SMEX	_	_	O
81	)	_	_	O
82	,	_	_	O
83	or	_	_	O
84	usual	_	_	O
85	care	_	_	O
86	only	_	_	O
87	(	_	_	O
88	UCO	_	_	O
89	)	_	_	O
90	.	_	_	O

91	Outcomes	_	_	O
92	were	_	_	O
93	reassessed	_	_	O
94	6	_	_	O
95	and	_	_	O
96	12	_	_	O
97	weeks	_	_	O
98	after	_	_	O
99	chemotherapy	_	_	O
100	started	_	_	O
101	.	_	_	O

102	Significance	_	_	O
103	testing	_	_	O
104	of	_	_	O
105	group-by-time	_	_	O
106	interactions	_	_	O
107	in	_	_	O
108	286	_	_	O
109	patients	_	_	O
110	who	_	_	O
111	completed	_	_	O
112	all	_	_	O
113	assessments	_	_	O
114	was	_	_	O
115	used	_	_	O
116	to	_	_	O
117	evaluate	_	_	O
118	intervention	_	_	O
119	efficacy	_	_	O
120	.	_	_	O

121	Interaction	_	_	B-Premise
122	effects	_	_	I-Premise
123	for	_	_	I-Premise
124	mental	_	_	I-Premise
125	and	_	_	I-Premise
126	physical	_	_	I-Premise
127	well-being	_	_	I-Premise
128	scores	_	_	I-Premise
129	were	_	_	I-Premise
130	not	_	_	I-Premise
131	significant	_	_	I-Premise
132	.	_	_	I-Premise

133	Depression	_	_	B-Premise
134	scores	_	_	I-Premise
135	yielded	_	_	I-Premise
136	a	_	_	I-Premise
137	linear	_	_	I-Premise
138	interaction	_	_	I-Premise
139	comparing	_	_	I-Premise
140	UCO	_	_	I-Premise
141	and	_	_	I-Premise
142	SMEX	_	_	I-Premise
143	(	_	_	I-Premise
144	p	_	_	I-Premise
145	=	_	_	I-Premise
146	0.019	_	_	I-Premise
147	)	_	_	I-Premise
148	,	_	_	I-Premise
149	with	_	_	I-Premise
150	decreases	_	_	I-Premise
151	in	_	_	I-Premise
152	SMEX	_	_	I-Premise
153	but	_	_	I-Premise
154	not	_	_	I-Premise
155	UCO	_	_	I-Premise
156	.	_	_	I-Premise

157	Anxiety	_	_	B-Premise
158	scores	_	_	I-Premise
159	yielded	_	_	I-Premise
160	a	_	_	I-Premise
161	quadratic	_	_	I-Premise
162	interaction	_	_	I-Premise
163	comparing	_	_	I-Premise
164	UCO	_	_	I-Premise
165	and	_	_	I-Premise
166	SMEX	_	_	I-Premise
167	(	_	_	I-Premise
168	p	_	_	I-Premise
169	=	_	_	I-Premise
170	0.049	_	_	I-Premise
171	)	_	_	I-Premise
172	,	_	_	I-Premise
173	with	_	_	I-Premise
174	trends	_	_	I-Premise
175	for	_	_	I-Premise
176	changes	_	_	I-Premise
177	in	_	_	I-Premise
178	SMEX	_	_	I-Premise
179	but	_	_	I-Premise
180	not	_	_	I-Premise
181	UCO	_	_	I-Premise
182	.	_	_	I-Premise

183	Additional	_	_	B-Premise
184	analyses	_	_	I-Premise
185	yielded	_	_	I-Premise
186	quadratic	_	_	I-Premise
187	interactions	_	_	I-Premise
188	for	_	_	I-Premise
189	exercise	_	_	I-Premise
190	activity	_	_	I-Premise
191	comparing	_	_	I-Premise
192	UCO	_	_	I-Premise
193	and	_	_	I-Premise
194	SMEX	_	_	I-Premise
195	(	_	_	I-Premise
196	p	_	_	I-Premise
197	=	_	_	I-Premise
198	0.022	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	with	_	_	I-Premise
202	positive	_	_	I-Premise
203	changes	_	_	I-Premise
204	in	_	_	I-Premise
205	SMEX	_	_	I-Premise
206	but	_	_	I-Premise
207	not	_	_	I-Premise
208	UCO	_	_	I-Premise
209	,	_	_	I-Premise
210	and	_	_	I-Premise
211	for	_	_	I-Premise
212	stress	_	_	I-Premise
213	management	_	_	I-Premise
214	activity	_	_	I-Premise
215	comparing	_	_	I-Premise
216	UCO	_	_	I-Premise
217	and	_	_	I-Premise
218	SM	_	_	I-Premise
219	(	_	_	I-Premise
220	p	_	_	I-Premise
221	<	_	_	I-Premise
222	0.001	_	_	I-Premise
223	)	_	_	I-Premise
224	and	_	_	I-Premise
225	UCO	_	_	I-Premise
226	and	_	_	I-Premise
227	SMEX	_	_	I-Premise
228	(	_	_	I-Premise
229	p	_	_	I-Premise
230	=	_	_	I-Premise
231	0.013	_	_	I-Premise
232	)	_	_	I-Premise
233	,	_	_	I-Premise
234	with	_	_	I-Premise
235	positive	_	_	I-Premise
236	changes	_	_	I-Premise
237	in	_	_	I-Premise
238	SM	_	_	I-Premise
239	and	_	_	I-Premise
240	SMEX	_	_	I-Premise
241	but	_	_	I-Premise
242	not	_	_	I-Premise
243	UCO	_	_	I-Premise
244	.	_	_	I-Premise

245	Only	_	_	B-Claim
246	the	_	_	I-Claim
247	combined	_	_	I-Claim
248	intervention	_	_	I-Claim
249	yielded	_	_	I-Claim
250	effects	_	_	I-Claim
251	on	_	_	I-Claim
252	quality	_	_	I-Claim
253	of	_	_	I-Claim
254	life	_	_	I-Claim
255	outcomes	_	_	I-Claim
256	,	_	_	I-Claim
257	and	_	_	I-Claim
258	these	_	_	I-Claim
259	were	_	_	I-Claim
260	limited	_	_	I-Claim
261	to	_	_	I-Claim
262	anxiety	_	_	I-Claim
263	and	_	_	I-Claim
264	depression	_	_	I-Claim
265	.	_	_	I-Claim

266	These	_	_	B-Premise
267	findings	_	_	I-Premise
268	are	_	_	I-Premise
269	consistent	_	_	I-Premise
270	with	_	_	I-Premise
271	evidence	_	_	I-Premise
272	that	_	_	I-Premise
273	only	_	_	I-Premise
274	the	_	_	I-Premise
275	combined	_	_	I-Premise
276	intervention	_	_	I-Premise
277	yielded	_	_	I-Premise
278	increases	_	_	I-Premise
279	in	_	_	I-Premise
280	both	_	_	I-Premise
281	exercise	_	_	I-Premise
282	and	_	_	I-Premise
283	stress	_	_	I-Premise
284	management	_	_	I-Premise
285	activity	_	_	I-Premise
286	.	_	_	I-Premise

287	Future	_	_	O
288	research	_	_	O
289	should	_	_	O
290	investigate	_	_	O
291	ways	_	_	O
292	to	_	_	O
293	augment	_	_	O
294	this	_	_	O
295	intervention	_	_	O
296	to	_	_	O
297	enhance	_	_	O
298	its	_	_	O
299	benefits	_	_	O
300	.	_	_	O


0	﻿	_	_	O
1	Ocular	_	_	O
2	blood	_	_	O
3	flow	_	_	O
4	dysregulation	_	_	O
5	has	_	_	O
6	been	_	_	O
7	implicated	_	_	O
8	in	_	_	O
9	the	_	_	O
10	pathogenesis	_	_	O
11	of	_	_	O
12	glaucoma	_	_	O
13	.	_	_	O

14	Whereas	_	_	O
15	the	_	_	O
16	effect	_	_	O
17	of	_	_	O
18	single	_	_	O
19	antiglaucoma	_	_	O
20	substances	_	_	O
21	on	_	_	O
22	ocular	_	_	O
23	blood	_	_	O
24	flow	_	_	O
25	has	_	_	O
26	been	_	_	O
27	addressed	_	_	O
28	in	_	_	O
29	various	_	_	O
30	experiments	_	_	O
31	,	_	_	O
32	evidence	_	_	O
33	for	_	_	O
34	fixed	_	_	O
35	combinations	_	_	O
36	is	_	_	O
37	sparse	_	_	O
38	.	_	_	O

39	In	_	_	O
40	the	_	_	O
41	present	_	_	O
42	study	_	_	O
43	,	_	_	O
44	we	_	_	O
45	set	_	_	O
46	out	_	_	O
47	to	_	_	O
48	compare	_	_	O
49	the	_	_	O
50	effects	_	_	O
51	of	_	_	O
52	latanoprost	_	_	O
53	0.005	_	_	O
54	%	_	_	O
55	/timolol	_	_	O
56	0.5	_	_	O
57	%	_	_	O
58	(	_	_	O
59	LT	_	_	O
60	)	_	_	O
61	fixed	_	_	O
62	combination	_	_	O
63	and	_	_	O
64	brimonidine	_	_	O
65	0.2	_	_	O
66	%	_	_	O
67	/timolol	_	_	O
68	0.5	_	_	O
69	%	_	_	O
70	(	_	_	O
71	BT	_	_	O
72	)	_	_	O
73	fixed	_	_	O
74	combination	_	_	O
75	on	_	_	O
76	intraocular	_	_	O
77	pressure	_	_	O
78	(	_	_	O
79	IOP	_	_	O
80	)	_	_	O
81	and	_	_	O
82	ocular	_	_	O
83	blood	_	_	O
84	flow	_	_	O
85	.	_	_	O

86	In	_	_	O
87	the	_	_	O
88	present	_	_	O
89	study	_	_	O
90	,	_	_	O
91	which	_	_	O
92	followed	_	_	O
93	a	_	_	O
94	randomized	_	_	O
95	,	_	_	O
96	double-masked	_	_	O
97	2-way	_	_	O
98	crossover	_	_	O
99	design	_	_	O
100	,	_	_	O
101	16	_	_	O
102	patients	_	_	O
103	with	_	_	O
104	primary	_	_	O
105	open-angle	_	_	O
106	glaucoma	_	_	O
107	and	_	_	O
108	2	_	_	O
109	patients	_	_	O
110	with	_	_	O
111	ocular	_	_	O
112	hypertension	_	_	O
113	were	_	_	O
114	included	_	_	O
115	.	_	_	O

116	The	_	_	O
117	patients	_	_	O
118	underwent	_	_	O
119	a	_	_	O
120	6-week	_	_	O
121	treatment	_	_	O
122	with	_	_	O
123	LT	_	_	O
124	and	_	_	O
125	a	_	_	O
126	6-week	_	_	O
127	treatment	_	_	O
128	with	_	_	O
129	BT	_	_	O
130	after	_	_	O
131	a	_	_	O
132	washout	_	_	O
133	for	_	_	O
134	previous	_	_	O
135	antiglaucoma	_	_	O
136	medication	_	_	O
137	.	_	_	O

138	Optic	_	_	O
139	nerve	_	_	O
140	head	_	_	O
141	blood	_	_	O
142	flow	_	_	O
143	(	_	_	O
144	ONHBF	_	_	O
145	)	_	_	O
146	was	_	_	O
147	measured	_	_	O
148	using	_	_	O
149	laser	_	_	O
150	Doppler	_	_	O
151	flowmetry	_	_	O
152	;	_	_	O
153	retrobulbar	_	_	O
154	flow	_	_	O
155	velocities	_	_	O
156	were	_	_	O
157	measured	_	_	O
158	using	_	_	O
159	color	_	_	O
160	Doppler	_	_	O
161	imaging	_	_	O
162	in	_	_	O
163	the	_	_	O
164	ophthalmic	_	_	O
165	artery	_	_	O
166	,	_	_	O
167	the	_	_	O
168	central	_	_	O
169	retinal	_	_	O
170	artery	_	_	O
171	,	_	_	O
172	and	_	_	O
173	the	_	_	O
174	posterior	_	_	O
175	ciliary	_	_	O
176	arteries	_	_	O
177	.	_	_	O

178	IOP	_	_	O
179	was	_	_	O
180	measured	_	_	O
181	at	_	_	O
182	8	_	_	O
183	AM	_	_	O
184	,	_	_	O
185	12	_	_	O
186	PM	_	_	O
187	,	_	_	O
188	and	_	_	O
189	4	_	_	O
190	PM	_	_	O
191	.	_	_	O

192	The	_	_	O
193	mean	_	_	O
194	baseline	_	_	O
195	IOP	_	_	O
196	was	_	_	O
197	25.3	_	_	O
198	±2.8	_	_	O
199	mmHg	_	_	O
200	.	_	_	O

201	Both	_	_	B-Premise
202	drugs	_	_	I-Premise
203	were	_	_	I-Premise
204	equally	_	_	I-Premise
205	effective	_	_	I-Premise
206	in	_	_	I-Premise
207	reducing	_	_	I-Premise
208	IOP	_	_	I-Premise
209	(	_	_	I-Premise
210	LT	_	_	I-Premise
211	:	_	_	I-Premise
212	-35.0	_	_	I-Premise
213	%	_	_	I-Premise
214	±10.0	_	_	I-Premise
215	%	_	_	I-Premise
216	;	_	_	I-Premise
217	BT	_	_	I-Premise
218	:	_	_	I-Premise
219	-33.6	_	_	I-Premise
220	%	_	_	I-Premise
221	±8.8	_	_	I-Premise
222	%	_	_	I-Premise
223	,	_	_	I-Premise
224	P=0.463	_	_	I-Premise
225	between	_	_	I-Premise
226	groups	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	In	_	_	O
230	addition	_	_	O
231	,	_	_	O
232	no	_	_	B-Premise
233	difference	_	_	I-Premise
234	in	_	_	I-Premise
235	ocular	_	_	I-Premise
236	perfusion	_	_	I-Premise
237	pressure	_	_	I-Premise
238	was	_	_	I-Premise
239	observed	_	_	I-Premise
240	between	_	_	I-Premise
241	the	_	_	I-Premise
242	2	_	_	I-Premise
243	treatment	_	_	I-Premise
244	groups	_	_	I-Premise
245	(	_	_	I-Premise
246	P=0.1	_	_	I-Premise
247	,	_	_	I-Premise
248	between	_	_	I-Premise
249	groups	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Neither	_	_	B-Premise
253	LT	_	_	I-Premise
254	nor	_	_	I-Premise
255	BT	_	_	I-Premise
256	altered	_	_	I-Premise
257	ONHBF	_	_	I-Premise
258	(	_	_	I-Premise
259	P=0.4	_	_	I-Premise
260	,	_	_	I-Premise
261	baseline	_	_	I-Premise
262	vs.	_	_	I-Premise
263	treatment	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	O
266	no	_	_	B-Premise
267	effect	_	_	I-Premise
268	on	_	_	I-Premise
269	flow	_	_	I-Premise
270	velocities	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	retrobulbar	_	_	I-Premise
274	vessels	_	_	I-Premise
275	was	_	_	I-Premise
276	seen	_	_	I-Premise
277	with	_	_	I-Premise
278	either	_	_	I-Premise
279	of	_	_	I-Premise
280	the	_	_	I-Premise
281	2	_	_	I-Premise
282	treatments	_	_	I-Premise
283	.	_	_	I-Premise

284	In	_	_	O
285	the	_	_	O
286	present	_	_	O
287	study	_	_	O
288	,	_	_	O
289	a	_	_	B-Claim
290	6-week	_	_	I-Claim
291	treatment	_	_	I-Claim
292	with	_	_	I-Claim
293	LT	_	_	I-Claim
294	or	_	_	I-Claim
295	BT	_	_	I-Claim
296	was	_	_	I-Claim
297	equally	_	_	I-Claim
298	effective	_	_	I-Claim
299	in	_	_	I-Claim
300	reducing	_	_	I-Claim
301	IOP	_	_	I-Claim
302	.	_	_	I-Claim

303	In	_	_	O
304	addition	_	_	O
305	,	_	_	O
306	none	_	_	B-Claim
307	of	_	_	I-Claim
308	the	_	_	I-Claim
309	administered	_	_	I-Claim
310	drugs	_	_	I-Claim
311	induced	_	_	I-Claim
312	a	_	_	I-Claim
313	significant	_	_	I-Claim
314	effect	_	_	I-Claim
315	on	_	_	I-Claim
316	ocular	_	_	I-Claim
317	blood	_	_	I-Claim
318	flow	_	_	I-Claim
319	parameters	_	_	I-Claim
320	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	risk	_	_	O
3	factors	_	_	O
4	associated	_	_	O
5	with	_	_	O
6	visual	_	_	O
7	field	_	_	O
8	progression	_	_	O
9	in	_	_	O
10	the	_	_	O
11	Low-pressure	_	_	O
12	Glaucoma	_	_	O
13	Treatment	_	_	O
14	Study	_	_	O
15	,	_	_	O
16	a	_	_	O
17	prospective	_	_	O
18	trial	_	_	O
19	designed	_	_	O
20	to	_	_	O
21	compare	_	_	O
22	the	_	_	O
23	effects	_	_	O
24	of	_	_	O
25	the	_	_	O
26	alpha2-adrenergic	_	_	O
27	agonist	_	_	O
28	brimonidine	_	_	O
29	tartrate	_	_	O
30	0.2	_	_	O
31	%	_	_	O
32	to	_	_	O
33	the	_	_	O
34	beta-adrenergic	_	_	O
35	antagonist	_	_	O
36	timolol	_	_	O
37	maleate	_	_	O
38	0.5	_	_	O
39	%	_	_	O
40	on	_	_	O
41	visual	_	_	O
42	function	_	_	O
43	in	_	_	O
44	low-pressure	_	_	O
45	glaucoma	_	_	O
46	.	_	_	O

47	Prospective	_	_	O
48	cohort	_	_	O
49	study	_	_	O
50	.	_	_	O

51	Low-pressure	_	_	O
52	Glaucoma	_	_	O
53	Treatment	_	_	O
54	Study	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	≥5	_	_	O
58	visual	_	_	O
59	field	_	_	O
60	tests	_	_	O
61	during	_	_	O
62	follow-up	_	_	O
63	were	_	_	O
64	included	_	_	O
65	.	_	_	O

66	Progression	_	_	O
67	was	_	_	O
68	determined	_	_	O
69	using	_	_	O
70	pointwise	_	_	O
71	linear	_	_	O
72	regression	_	_	O
73	analysis	_	_	O
74	,	_	_	O
75	defined	_	_	O
76	as	_	_	O
77	the	_	_	O
78	same	_	_	O
79	3	_	_	O
80	or	_	_	O
81	more	_	_	O
82	visual	_	_	O
83	field	_	_	O
84	locations	_	_	O
85	with	_	_	O
86	a	_	_	O
87	slope	_	_	O
88	more	_	_	O
89	negative	_	_	O
90	than	_	_	O
91	-1.0	_	_	O
92	dB/year	_	_	O
93	at	_	_	O
94	P	_	_	O
95	<	_	_	O
96	5	_	_	O
97	%	_	_	O
98	,	_	_	O
99	on	_	_	O
100	3	_	_	O
101	consecutive	_	_	O
102	tests	_	_	O
103	.	_	_	O

104	Ocular	_	_	O
105	and	_	_	O
106	systemic	_	_	O
107	risk	_	_	O
108	factors	_	_	O
109	were	_	_	O
110	analyzed	_	_	O
111	using	_	_	O
112	Cox	_	_	O
113	proportional	_	_	O
114	hazards	_	_	O
115	model	_	_	O
116	and	_	_	O
117	further	_	_	O
118	tested	_	_	O
119	for	_	_	O
120	independence	_	_	O
121	in	_	_	O
122	a	_	_	O
123	multivariate	_	_	O
124	model	_	_	O
125	.	_	_	O

126	A	_	_	O
127	total	_	_	O
128	of	_	_	O
129	253	_	_	O
130	eyes	_	_	O
131	of	_	_	O
132	127	_	_	O
133	subjects	_	_	O
134	(	_	_	O
135	mean	_	_	O
136	age	_	_	O
137	,	_	_	O
138	64.7	_	_	O
139	10.9	_	_	O
140	years	_	_	O
141	;	_	_	O
142	mean	_	_	O
143	follow-up	_	_	O
144	,	_	_	O
145	40.6	_	_	O
146	12	_	_	O
147	months	_	_	O
148	)	_	_	O
149	were	_	_	O
150	analyzed	_	_	O
151	.	_	_	O

152	Eyes	_	_	B-Premise
153	randomized	_	_	I-Premise
154	to	_	_	I-Premise
155	timolol	_	_	I-Premise
156	progressed	_	_	I-Premise
157	faster	_	_	I-Premise
158	than	_	_	I-Premise
159	those	_	_	I-Premise
160	randomized	_	_	I-Premise
161	to	_	_	I-Premise
162	brimonidine	_	_	I-Premise
163	(	_	_	I-Premise
164	mean	_	_	I-Premise
165	rates	_	_	I-Premise
166	of	_	_	I-Premise
167	progression	_	_	I-Premise
168	,	_	_	I-Premise
169	-0.38	_	_	I-Premise
170	0.9	_	_	I-Premise
171	vs	_	_	I-Premise
172	0.02	_	_	I-Premise
173	0.7	_	_	I-Premise
174	dB/y	_	_	I-Premise
175	,	_	_	I-Premise
176	P	_	_	I-Premise
177	<	_	_	I-Premise
178	.01	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	In	_	_	O
182	the	_	_	O
183	final	_	_	O
184	multivariate	_	_	O
185	model	_	_	O
186	adjusting	_	_	O
187	for	_	_	O
188	all	_	_	O
189	tested	_	_	O
190	covariates	_	_	O
191	,	_	_	O
192	older	_	_	B-Premise
193	age	_	_	I-Premise
194	(	_	_	I-Premise
195	hazard	_	_	I-Premise
196	ratio	_	_	I-Premise
197	[	_	_	I-Premise
198	HR	_	_	I-Premise
199	]	_	_	I-Premise
200	=	_	_	I-Premise
201	1.41/decade	_	_	I-Premise
202	older	_	_	I-Premise
203	,	_	_	I-Premise
204	95	_	_	I-Premise
205	%	_	_	I-Premise
206	confidence	_	_	I-Premise
207	interval	_	_	I-Premise
208	[	_	_	I-Premise
209	CI	_	_	I-Premise
210	]	_	_	I-Premise
211	=	_	_	I-Premise
212	1.05	_	_	I-Premise
213	to	_	_	I-Premise
214	1.90	_	_	I-Premise
215	,	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.022	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	use	_	_	I-Premise
222	of	_	_	I-Premise
223	systemic	_	_	I-Premise
224	antihypertensives	_	_	I-Premise
225	(	_	_	I-Premise
226	HR	_	_	I-Premise
227	=	_	_	I-Premise
228	2.53	_	_	I-Premise
229	,	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	=	_	_	I-Premise
234	1.32	_	_	I-Premise
235	to	_	_	I-Premise
236	4.87	_	_	I-Premise
237	,	_	_	I-Premise
238	P	_	_	I-Premise
239	=	_	_	I-Premise
240	.005	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	mean	_	_	I-Premise
245	ocular	_	_	I-Premise
246	perfusion	_	_	I-Premise
247	pressure	_	_	I-Premise
248	(	_	_	I-Premise
249	HR	_	_	I-Premise
250	=	_	_	I-Premise
251	1.21/mm	_	_	I-Premise
252	Hg	_	_	I-Premise
253	lower	_	_	I-Premise
254	,	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	=	_	_	I-Premise
259	1.12	_	_	I-Premise
260	to	_	_	I-Premise
261	1.31	_	_	I-Premise
262	,	_	_	I-Premise
263	P	_	_	I-Premise
264	<	_	_	I-Premise
265	.001	_	_	I-Premise
266	)	_	_	I-Premise
267	were	_	_	I-Premise
268	associated	_	_	I-Premise
269	with	_	_	I-Premise
270	progression	_	_	I-Premise
271	whereas	_	_	O
272	randomization	_	_	B-Premise
273	to	_	_	I-Premise
274	brimonidine	_	_	I-Premise
275	revealed	_	_	I-Premise
276	a	_	_	I-Premise
277	protective	_	_	I-Premise
278	effect	_	_	I-Premise
279	(	_	_	I-Premise
280	HR	_	_	I-Premise
281	=	_	_	I-Premise
282	0.26	_	_	I-Premise
283	,	_	_	I-Premise
284	95	_	_	I-Premise
285	%	_	_	I-Premise
286	CI	_	_	I-Premise
287	=	_	_	I-Premise
288	0.12	_	_	I-Premise
289	to	_	_	I-Premise
290	0.55	_	_	I-Premise
291	,	_	_	I-Premise
292	P	_	_	I-Premise
293	<	_	_	I-Premise
294	.001	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	While	_	_	O
298	randomization	_	_	B-Premise
299	to	_	_	I-Premise
300	brimonidine	_	_	I-Premise
301	0.2	_	_	I-Premise
302	%	_	_	I-Premise
303	was	_	_	I-Premise
304	protective	_	_	I-Premise
305	compared	_	_	I-Premise
306	to	_	_	I-Premise
307	timolol	_	_	I-Premise
308	0.5	_	_	I-Premise
309	%	_	_	I-Premise
310	,	_	_	I-Premise
311	lower	_	_	O
312	mean	_	_	I-Premise
313	ocular	_	_	I-Premise
314	perfusion	_	_	I-Premise
315	pressure	_	_	I-Premise
316	increased	_	_	I-Premise
317	the	_	_	I-Premise
318	risk	_	_	I-Premise
319	for	_	_	I-Premise
320	reaching	_	_	I-Premise
321	a	_	_	I-Premise
322	progression	_	_	I-Premise
323	outcome	_	_	I-Premise
324	in	_	_	I-Premise
325	the	_	_	I-Premise
326	Low-pressure	_	_	I-Premise
327	Glaucoma	_	_	I-Premise
328	Treatment	_	_	I-Premise
329	Study	_	_	I-Premise
330	.	_	_	I-Premise

331	This	_	_	B-Claim
332	suggests	_	_	I-Claim
333	that	_	_	I-Claim
334	the	_	_	I-Claim
335	beneficial	_	_	I-Claim
336	effect	_	_	I-Claim
337	of	_	_	I-Claim
338	randomization	_	_	I-Claim
339	to	_	_	I-Claim
340	the	_	_	I-Claim
341	brimonidine	_	_	I-Claim
342	arm	_	_	I-Claim
343	was	_	_	I-Claim
344	independent	_	_	I-Claim
345	of	_	_	I-Claim
346	possible	_	_	I-Claim
347	differences	_	_	I-Claim
348	in	_	_	I-Claim
349	ocular	_	_	I-Claim
350	perfusion	_	_	I-Claim
351	pressures	_	_	I-Claim
352	between	_	_	I-Claim
353	the	_	_	I-Claim
354	2	_	_	I-Claim
355	treatment	_	_	I-Claim
356	arms	_	_	I-Claim
357	.	_	_	I-Claim

358	The	_	_	B-Claim
359	current	_	_	I-Claim
360	results	_	_	I-Claim
361	and	_	_	I-Claim
362	large	_	_	I-Claim
363	number	_	_	I-Claim
364	of	_	_	I-Claim
365	drop-outs	_	_	I-Claim
366	in	_	_	I-Claim
367	the	_	_	I-Claim
368	brimonidine	_	_	I-Claim
369	0.2	_	_	I-Claim
370	%	_	_	I-Claim
371	arm	_	_	I-Claim
372	suggest	_	_	I-Claim
373	that	_	_	I-Claim
374	more	_	_	I-Claim
375	research	_	_	I-Claim
376	is	_	_	I-Claim
377	necessary	_	_	I-Claim
378	before	_	_	I-Claim
379	altering	_	_	I-Claim
380	clinical	_	_	I-Claim
381	practice	_	_	I-Claim
382	paradigms	_	_	I-Claim
383	.	_	_	I-Claim


0	Intermittent	_	_	O
1	dosing	_	_	O
2	may	_	_	O
3	reduce	_	_	O
4	the	_	_	O
5	adverse	_	_	O
6	events	_	_	O
7	(	_	_	O
8	AEs	_	_	O
9	)	_	_	O
10	of	_	_	O
11	androgen-deprivation	_	_	O
12	therapy	_	_	O
13	(	_	_	O
14	ADT	_	_	O
15	)	_	_	O
16	.	_	_	O

17	To	_	_	O
18	compare	_	_	O
19	intermittent	_	_	O
20	androgen	_	_	O
21	deprivation	_	_	O
22	(	_	_	O
23	IAD	_	_	O
24	)	_	_	O
25	and	_	_	O
26	continuous	_	_	O
27	androgen	_	_	O
28	deprivation	_	_	O
29	(	_	_	O
30	CAD	_	_	O
31	)	_	_	O
32	with	_	_	O
33	regard	_	_	O
34	to	_	_	O
35	health-related	_	_	O
36	quality	_	_	O
37	of	_	_	O
38	life	_	_	O
39	(	_	_	O
40	QoL	_	_	O
41	)	_	_	O
42	.	_	_	O

43	A	_	_	O
44	total	_	_	O
45	of	_	_	O
46	852	_	_	O
47	men	_	_	O
48	with	_	_	O
49	advanced	_	_	O
50	prostate	_	_	O
51	cancer	_	_	O
52	(	_	_	O
53	PCa	_	_	O
54	)	_	_	O
55	were	_	_	O
56	enrolled	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	goserelin	_	_	O
60	acetate	_	_	O
61	3.6	_	_	O
62	mg	_	_	O
63	every	_	_	O
64	28	_	_	O
65	d	_	_	O
66	for	_	_	O
67	24	_	_	O
68	wk	_	_	O
69	.	_	_	O

70	A	_	_	O
71	total	_	_	O
72	of	_	_	O
73	554	_	_	O
74	patients	_	_	O
75	whose	_	_	O
76	prostate-specific	_	_	O
77	antigen	_	_	O
78	(	_	_	O
79	PSA	_	_	O
80	)	_	_	O
81	decreased	_	_	O
82	to	_	_	O
83	<	_	_	O
84	10	_	_	O
85	ng/ml	_	_	O
86	or	_	_	O
87	by	_	_	O
88	≥50	_	_	O
89	%	_	_	O
90	(	_	_	O
91	<	_	_	O
92	20	_	_	O
93	ng/ml	_	_	O
94	at	_	_	O
95	baseline	_	_	O
96	)	_	_	O
97	were	_	_	O
98	randomised	_	_	O
99	to	_	_	O
100	IAD	_	_	O
101	or	_	_	O
102	CAD	_	_	O
103	.	_	_	O

104	In	_	_	O
105	the	_	_	O
106	IAD	_	_	O
107	arm	_	_	O
108	,	_	_	O
109	ADT	_	_	O
110	was	_	_	O
111	resumed	_	_	O
112	for	_	_	O
113	at	_	_	O
114	least	_	_	O
115	24	_	_	O
116	wk	_	_	O
117	whenever	_	_	O
118	PSA	_	_	O
119	increased	_	_	O
120	>	_	_	O
121	20	_	_	O
122	ng/ml	_	_	O
123	or	_	_	O
124	above	_	_	O
125	baseline	_	_	O
126	.	_	_	O

127	QoL	_	_	O
128	was	_	_	O
129	monitored	_	_	O
130	with	_	_	O
131	a	_	_	O
132	validated	_	_	O
133	Cleary	_	_	O
134	30-item	_	_	O
135	questionnaire	_	_	O
136	and	_	_	O
137	analysed	_	_	O
138	by	_	_	O
139	the	_	_	O
140	Mann-Whitney	_	_	O
141	U	_	_	O
142	test	_	_	O
143	,	_	_	O
144	0.5	_	_	O
145	standard	_	_	O
146	deviation	_	_	O
147	rule	_	_	O
148	,	_	_	O
149	and	_	_	O
150	repeated	_	_	O
151	measures	_	_	O
152	analysis	_	_	O
153	of	_	_	O
154	variance	_	_	O
155	.	_	_	O

156	AEs	_	_	O
157	and	_	_	O
158	adverse	_	_	O
159	drug	_	_	O
160	reactions	_	_	O
161	(	_	_	O
162	ADRs	_	_	O
163	)	_	_	O
164	were	_	_	O
165	analysed	_	_	O
166	by	_	_	O
167	the	_	_	O
168	chi-square	_	_	O
169	test	_	_	O
170	.	_	_	O

171	Median	_	_	O
172	follow-up	_	_	O
173	was	_	_	O
174	65	_	_	O
175	mo	_	_	O
176	.	_	_	O

177	Significant	_	_	B-Premise
178	differences	_	_	I-Premise
179	in	_	_	I-Premise
180	QoL	_	_	I-Premise
181	emerged	_	_	I-Premise
182	in	_	_	I-Premise
183	activity	_	_	I-Premise
184	limitation	_	_	I-Premise
185	,	_	_	I-Premise
186	physical	_	_	I-Premise
187	capacity	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	sexual	_	_	I-Premise
191	functioning	_	_	I-Premise
192	,	_	_	I-Premise
193	favouring	_	_	I-Premise
194	IAD	_	_	I-Premise
195	.	_	_	I-Premise

196	No	_	_	B-Premise
197	significant	_	_	I-Premise
198	differences	_	_	I-Premise
199	emerged	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	prevalence	_	_	I-Premise
203	of	_	_	I-Premise
204	AEs	_	_	I-Premise
205	:	_	_	I-Premise
206	87	_	_	I-Premise
207	patients	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	IAD	_	_	I-Premise
211	arm	_	_	I-Premise
212	(	_	_	I-Premise
213	31.8	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	and	_	_	I-Premise
217	95	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	CAD	_	_	I-Premise
221	arm	_	_	I-Premise
222	(	_	_	I-Premise
223	33.9	_	_	I-Premise
224	%	_	_	I-Premise
225	)	_	_	I-Premise
226	had	_	_	I-Premise
227	cardiovascular	_	_	I-Premise
228	(	_	_	I-Premise
229	CV	_	_	I-Premise
230	)	_	_	I-Premise
231	AEs	_	_	I-Premise
232	(	_	_	I-Premise
233	p=0.59	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	with	_	_	I-Premise
237	25	_	_	I-Premise
238	(	_	_	I-Premise
239	9.1	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	and	_	_	I-Premise
243	29	_	_	I-Premise
244	(	_	_	I-Premise
245	10.4	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	withdrawn	_	_	I-Premise
249	(	_	_	I-Premise
250	p=0.62	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	and	_	_	I-Premise
254	21	_	_	I-Premise
255	(	_	_	I-Premise
256	7.7	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	and	_	_	I-Premise
260	24	_	_	I-Premise
261	(	_	_	I-Premise
262	8.6	_	_	I-Premise
263	%	_	_	I-Premise
264	)	_	_	I-Premise
265	dying	_	_	I-Premise
266	because	_	_	I-Premise
267	of	_	_	I-Premise
268	a	_	_	I-Premise
269	CV	_	_	I-Premise
270	event	_	_	I-Premise
271	(	_	_	I-Premise
272	p=0.70	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	respectively	_	_	I-Premise
276	;	_	_	I-Premise
277	bone	_	_	B-Premise
278	fractures	_	_	I-Premise
279	occurred	_	_	I-Premise
280	in	_	_	I-Premise
281	19	_	_	I-Premise
282	(	_	_	I-Premise
283	6.9	_	_	I-Premise
284	%	_	_	I-Premise
285	)	_	_	I-Premise
286	and	_	_	I-Premise
287	15	_	_	I-Premise
288	(	_	_	I-Premise
289	5.4	_	_	I-Premise
290	%	_	_	I-Premise
291	)	_	_	I-Premise
292	patients	_	_	I-Premise
293	(	_	_	I-Premise
294	p=0.44	_	_	I-Premise
295	)	_	_	I-Premise
296	,	_	_	I-Premise
297	respectively	_	_	I-Premise
298	.	_	_	I-Premise

299	Hot	_	_	B-Premise
300	flushes	_	_	I-Premise
301	or	_	_	I-Premise
302	night	_	_	I-Premise
303	sweats	_	_	I-Premise
304	were	_	_	I-Premise
305	the	_	_	I-Premise
306	most	_	_	I-Premise
307	common	_	_	I-Premise
308	ADRs	_	_	I-Premise
309	(	_	_	I-Premise
310	47.1	_	_	I-Premise
311	%	_	_	I-Premise
312	vs	_	_	I-Premise
313	50.4	_	_	I-Premise
314	%	_	_	I-Premise
315	;	_	_	I-Premise
316	p=0.44	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	Erectile	_	_	B-Premise
320	dysfunction	_	_	I-Premise
321	(	_	_	I-Premise
322	15.7	_	_	I-Premise
323	%	_	_	I-Premise
324	vs	_	_	I-Premise
325	7.9	_	_	I-Premise
326	%	_	_	I-Premise
327	;	_	_	I-Premise
328	p=0.042	_	_	I-Premise
329	)	_	_	I-Premise
330	and	_	_	I-Premise
331	depressed	_	_	I-Premise
332	mood	_	_	I-Premise
333	(	_	_	I-Premise
334	2.2	_	_	I-Premise
335	vs	_	_	I-Premise
336	0	_	_	I-Premise
337	%	_	_	I-Premise
338	;	_	_	I-Premise
339	p=0.032	_	_	I-Premise
340	)	_	_	I-Premise
341	were	_	_	I-Premise
342	more	_	_	I-Premise
343	common	_	_	I-Premise
344	in	_	_	I-Premise
345	the	_	_	I-Premise
346	IAD	_	_	I-Premise
347	arm	_	_	I-Premise
348	.	_	_	I-Premise

349	IAD	_	_	B-Claim
350	showed	_	_	I-Claim
351	benefits	_	_	I-Claim
352	in	_	_	I-Claim
353	the	_	_	I-Claim
354	treatment	_	_	I-Claim
355	of	_	_	I-Claim
356	advanced	_	_	I-Claim
357	PCa	_	_	I-Claim
358	with	_	_	I-Claim
359	respect	_	_	I-Claim
360	to	_	_	I-Claim
361	QoL	_	_	I-Claim
362	.	_	_	I-Claim

363	The	_	_	B-Claim
364	prevalence	_	_	I-Claim
365	of	_	_	I-Claim
366	AEs	_	_	I-Claim
367	was	_	_	I-Claim
368	not	_	_	I-Claim
369	significantly	_	_	I-Claim
370	lower	_	_	I-Claim
371	with	_	_	I-Claim
372	IAD	_	_	I-Claim
373	.	_	_	I-Claim


0	Patients	_	_	O
1	who	_	_	O
2	develop	_	_	O
3	castration-resistant	_	_	O
4	prostate	_	_	O
5	cancer	_	_	O
6	(	_	_	O
7	CRPCa	_	_	O
8	)	_	_	O
9	typically	_	_	O
10	continue	_	_	O
11	on	_	_	O
12	androgen	_	_	O
13	deprivation	_	_	O
14	therapy	_	_	O
15	(	_	_	O
16	ADT	_	_	O
17	)	_	_	O
18	.	_	_	O

19	Whether	_	_	O
20	these	_	_	O
21	patients	_	_	O
22	need	_	_	O
23	to	_	_	O
24	remain	_	_	O
25	on	_	_	O
26	ADT	_	_	O
27	has	_	_	O
28	not	_	_	O
29	been	_	_	O
30	well	_	_	O
31	studied	_	_	O
32	.	_	_	O

33	We	_	_	O
34	conducted	_	_	O
35	a	_	_	O
36	multicenter	_	_	O
37	randomized	_	_	O
38	trial	_	_	O
39	to	_	_	O
40	compare	_	_	O
41	an	_	_	O
42	intermittent	_	_	O
43	versus	_	_	O
44	continuous	_	_	O
45	approach	_	_	O
46	to	_	_	O
47	ADT	_	_	O
48	in	_	_	O
49	CRPCa	_	_	O
50	patients	_	_	O
51	.	_	_	O

52	Overall	_	_	O
53	survival	_	_	O
54	,	_	_	O
55	health-related	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	(	_	_	O
60	QOL	_	_	O
61	)	_	_	O
62	,	_	_	O
63	and	_	_	O
64	cost	_	_	O
65	were	_	_	O
66	the	_	_	O
67	main	_	_	O
68	endpoints	_	_	O
69	.	_	_	O

70	CRPCa	_	_	O
71	patients	_	_	O
72	were	_	_	O
73	randomized	_	_	O
74	2:1	_	_	O
75	to	_	_	O
76	intermittent	_	_	O
77	or	_	_	O
78	continuous	_	_	O
79	luteinizing	_	_	O
80	hormone-releasing	_	_	O
81	hormone	_	_	O
82	agonists	_	_	O
83	(	_	_	O
84	LHRHa	_	_	O
85	)	_	_	O
86	.	_	_	O

87	Patients	_	_	O
88	were	_	_	O
89	followed	_	_	O
90	with	_	_	O
91	clinical	_	_	O
92	assessments	_	_	O
93	,	_	_	O
94	laboratory	_	_	O
95	investigations	_	_	O
96	,	_	_	O
97	and	_	_	O
98	QOL	_	_	O
99	questionnaires	_	_	O
100	(	_	_	O
101	EORTC	_	_	O
102	QLQ-C30	_	_	O
103	or	_	_	O
104	PROSQOLI	_	_	O
105	)	_	_	O
106	every	_	_	O
107	2	_	_	O
108	months	_	_	O
109	.	_	_	O

110	If	_	_	O
111	the	_	_	O
112	serum	_	_	O
113	testosterone	_	_	O
114	rose	_	_	O
115	above	_	_	O
116	castrate	_	_	O
117	levels	_	_	O
118	(	_	_	O
119	1.75	_	_	O
120	nmol/L	_	_	O
121	)	_	_	O
122	,	_	_	O
123	LHRHa	_	_	O
124	were	_	_	O
125	reinitiated	_	_	O
126	.	_	_	O

127	The	_	_	O
128	study	_	_	O
129	was	_	_	O
130	designed	_	_	O
131	to	_	_	O
132	close	_	_	O
133	if	_	_	O
134	>	_	_	O
135	50	_	_	O
136	%	_	_	O
137	of	_	_	O
138	patients	_	_	O
139	needed	_	_	O
140	to	_	_	O
141	restart	_	_	O
142	ADT	_	_	O
143	in	_	_	O
144	the	_	_	O
145	intermittent	_	_	O
146	arm	_	_	O
147	.	_	_	O

148	Thirty-one	_	_	O
149	patients	_	_	O
150	were	_	_	O
151	followed	_	_	O
152	with	_	_	O
153	a	_	_	O
154	median	_	_	O
155	follow-up	_	_	O
156	of	_	_	O
157	26.8	_	_	O
158	months-18	_	_	O
159	in	_	_	O
160	the	_	_	O
161	intermittent	_	_	O
162	arm	_	_	O
163	and	_	_	O
164	13	_	_	O
165	in	_	_	O
166	the	_	_	O
167	continuous	_	_	O
168	.	_	_	O

169	Twelve	_	_	O
170	of	_	_	O
171	18	_	_	O
172	patients	_	_	O
173	on	_	_	O
174	the	_	_	O
175	intermittent	_	_	O
176	arm	_	_	O
177	were	_	_	O
178	reinitiated	_	_	O
179	on	_	_	O
180	LHRHa	_	_	O
181	at	_	_	O
182	a	_	_	O
183	median	_	_	O
184	time	_	_	O
185	of	_	_	O
186	17.9	_	_	O
187	months	_	_	O
188	.	_	_	O

189	There	_	_	B-Premise
190	was	_	_	I-Premise
191	no	_	_	I-Premise
192	difference	_	_	I-Premise
193	in	_	_	I-Premise
194	overall	_	_	I-Premise
195	or	_	_	I-Premise
196	cancer-specific	_	_	I-Premise
197	survival	_	_	I-Premise
198	between	_	_	I-Premise
199	the	_	_	I-Premise
200	2	_	_	I-Premise
201	arms	_	_	I-Premise
202	.	_	_	I-Premise

203	There	_	_	B-Premise
204	was	_	_	I-Premise
205	no	_	_	I-Premise
206	statistically	_	_	I-Premise
207	significant	_	_	I-Premise
208	difference	_	_	I-Premise
209	in	_	_	I-Premise
210	QOL	_	_	I-Premise
211	between	_	_	I-Premise
212	the	_	_	I-Premise
213	2	_	_	I-Premise
214	arms	_	_	I-Premise
215	at	_	_	I-Premise
216	0	_	_	I-Premise
217	and	_	_	I-Premise
218	12	_	_	I-Premise
219	months	_	_	I-Premise
220	.	_	_	I-Premise

221	The	_	_	B-Premise
222	total	_	_	I-Premise
223	mean	_	_	I-Premise
224	costs	_	_	I-Premise
225	at	_	_	I-Premise
226	24	_	_	I-Premise
227	months	_	_	I-Premise
228	were	_	_	I-Premise
229	significantly	_	_	I-Premise
230	lower	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	intermittent	_	_	I-Premise
234	arm	_	_	I-Premise
235	(	_	_	I-Premise
236	$	_	_	I-Premise
237	3135	_	_	I-Premise
238	vs.	_	_	I-Premise
239	$	_	_	I-Premise
240	8253	_	_	I-Premise
241	Canadian	_	_	I-Premise
242	dollars	_	_	I-Premise
243	,	_	_	I-Premise
244	P=0.0167	_	_	I-Premise
245	)	_	_	I-Premise
246	compared	_	_	I-Premise
247	with	_	_	I-Premise
248	the	_	_	I-Premise
249	continuous	_	_	I-Premise
250	.	_	_	I-Premise

251	The	_	_	B-Premise
252	main	_	_	I-Premise
253	limitation	_	_	I-Premise
254	of	_	_	I-Premise
255	this	_	_	I-Premise
256	study	_	_	I-Premise
257	is	_	_	I-Premise
258	the	_	_	I-Premise
259	small	_	_	I-Premise
260	sample	_	_	I-Premise
261	size	_	_	I-Premise
262	.	_	_	I-Premise

263	We	_	_	B-Claim
264	have	_	_	I-Claim
265	observed	_	_	I-Claim
266	that	_	_	I-Claim
267	intermittent	_	_	I-Claim
268	ADT	_	_	I-Claim
269	in	_	_	I-Claim
270	patients	_	_	I-Claim
271	with	_	_	I-Claim
272	CRPCa	_	_	I-Claim
273	,	_	_	I-Claim
274	using	_	_	I-Claim
275	a	_	_	I-Claim
276	testosterone	_	_	I-Claim
277	of	_	_	I-Claim
278	>	_	_	I-Claim
279	1.75	_	_	I-Claim
280	ngmol/L	_	_	I-Claim
281	as	_	_	I-Claim
282	a	_	_	I-Claim
283	trigger	_	_	I-Claim
284	to	_	_	I-Claim
285	reinitiate	_	_	I-Claim
286	LHRHa	_	_	I-Claim
287	,	_	_	I-Claim
288	results	_	_	I-Claim
289	in	_	_	I-Claim
290	a	_	_	I-Claim
291	substantial	_	_	I-Claim
292	cost	_	_	I-Claim
293	savings	_	_	I-Claim
294	with	_	_	I-Claim
295	no	_	_	I-Claim
296	negative	_	_	I-Claim
297	impact	_	_	I-Claim
298	on	_	_	I-Claim
299	oncologic	_	_	I-Claim
300	and	_	_	I-Claim
301	QOL	_	_	I-Claim
302	outcomes	_	_	I-Claim
303	.	_	_	I-Claim


0	Most	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	glioblastoma	_	_	O
4	are	_	_	O
5	older	_	_	O
6	than	_	_	O
7	60	_	_	O
8	years	_	_	O
9	,	_	_	O
10	but	_	_	O
11	treatment	_	_	O
12	guidelines	_	_	O
13	are	_	_	O
14	based	_	_	O
15	on	_	_	O
16	trials	_	_	O
17	in	_	_	O
18	patients	_	_	O
19	aged	_	_	O
20	only	_	_	O
21	up	_	_	O
22	to	_	_	O
23	70	_	_	O
24	years	_	_	O
25	.	_	_	O

26	We	_	_	O
27	did	_	_	O
28	a	_	_	O
29	randomised	_	_	O
30	trial	_	_	O
31	to	_	_	O
32	assess	_	_	O
33	the	_	_	O
34	optimum	_	_	O
35	palliative	_	_	O
36	treatment	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	aged	_	_	O
40	60	_	_	O
41	years	_	_	O
42	and	_	_	O
43	older	_	_	O
44	with	_	_	O
45	glioblastoma	_	_	O
46	.	_	_	O

47	Patients	_	_	O
48	with	_	_	O
49	newly	_	_	O
50	diagnosed	_	_	O
51	glioblastoma	_	_	O
52	were	_	_	O
53	recruited	_	_	O
54	from	_	_	O
55	Austria	_	_	O
56	,	_	_	O
57	Denmark	_	_	O
58	,	_	_	O
59	France	_	_	O
60	,	_	_	O
61	Norway	_	_	O
62	,	_	_	O
63	Sweden	_	_	O
64	,	_	_	O
65	Switzerland	_	_	O
66	,	_	_	O
67	and	_	_	O
68	Turkey	_	_	O
69	.	_	_	O

70	They	_	_	O
71	were	_	_	O
72	assigned	_	_	O
73	by	_	_	O
74	a	_	_	O
75	computer-generated	_	_	O
76	randomisation	_	_	O
77	schedule	_	_	O
78	,	_	_	O
79	stratified	_	_	O
80	by	_	_	O
81	centre	_	_	O
82	,	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	temozolomide	_	_	O
86	(	_	_	O
87	200	_	_	O
88	mg/m	_	_	O
89	(	_	_	O
90	2	_	_	O
91	)	_	_	O
92	on	_	_	O
93	days	_	_	O
94	1-5	_	_	O
95	of	_	_	O
96	every	_	_	O
97	28	_	_	O
98	days	_	_	O
99	for	_	_	O
100	up	_	_	O
101	to	_	_	O
102	six	_	_	O
103	cycles	_	_	O
104	)	_	_	O
105	,	_	_	O
106	hypofractionated	_	_	O
107	radiotherapy	_	_	O
108	(	_	_	O
109	34·0	_	_	O
110	Gy	_	_	O
111	administered	_	_	O
112	in	_	_	O
113	3·4	_	_	O
114	Gy	_	_	O
115	fractions	_	_	O
116	over	_	_	O
117	2	_	_	O
118	weeks	_	_	O
119	)	_	_	O
120	,	_	_	O
121	or	_	_	O
122	standard	_	_	O
123	radiotherapy	_	_	O
124	(	_	_	O
125	60·0	_	_	O
126	Gy	_	_	O
127	administered	_	_	O
128	in	_	_	O
129	2·0	_	_	O
130	Gy	_	_	O
131	fractions	_	_	O
132	over	_	_	O
133	6	_	_	O
134	weeks	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Patients	_	_	O
138	and	_	_	O
139	study	_	_	O
140	staff	_	_	O
141	were	_	_	O
142	aware	_	_	O
143	of	_	_	O
144	treatment	_	_	O
145	assignment	_	_	O
146	.	_	_	O

147	The	_	_	O
148	primary	_	_	O
149	endpoint	_	_	O
150	was	_	_	O
151	overall	_	_	O
152	survival	_	_	O
153	.	_	_	O

154	Analyses	_	_	O
155	were	_	_	O
156	done	_	_	O
157	by	_	_	O
158	intention	_	_	O
159	to	_	_	O
160	treat	_	_	O
161	.	_	_	O

162	This	_	_	O
163	trial	_	_	O
164	is	_	_	O
165	registered	_	_	O
166	,	_	_	O
167	number	_	_	O
168	ISRCTN81470623	_	_	O
169	.	_	_	O

170	342	_	_	O
171	patients	_	_	O
172	were	_	_	O
173	enrolled	_	_	O
174	,	_	_	O
175	of	_	_	O
176	whom	_	_	O
177	291	_	_	O
178	were	_	_	O
179	randomised	_	_	O
180	across	_	_	O
181	three	_	_	O
182	treatment	_	_	O
183	groups	_	_	O
184	(	_	_	O
185	temozolomide	_	_	O
186	n=93	_	_	O
187	,	_	_	O
188	hypofractionated	_	_	O
189	radiotherapy	_	_	O
190	n=98	_	_	O
191	,	_	_	O
192	standard	_	_	O
193	radiotherapy	_	_	O
194	n=100	_	_	O
195	)	_	_	O
196	and	_	_	O
197	51	_	_	O
198	of	_	_	O
199	whom	_	_	O
200	were	_	_	O
201	randomised	_	_	O
202	across	_	_	O
203	only	_	_	O
204	two	_	_	O
205	groups	_	_	O
206	(	_	_	O
207	temozolomide	_	_	O
208	n=26	_	_	O
209	,	_	_	O
210	hypofractionated	_	_	O
211	radiotherapy	_	_	O
212	n=25	_	_	O
213	)	_	_	O
214	.	_	_	O

215	In	_	_	B-Premise
216	the	_	_	I-Premise
217	three-group	_	_	I-Premise
218	randomisation	_	_	I-Premise
219	,	_	_	I-Premise
220	in	_	_	I-Premise
221	comparison	_	_	I-Premise
222	with	_	_	I-Premise
223	standard	_	_	I-Premise
224	radiotherapy	_	_	I-Premise
225	,	_	_	I-Premise
226	median	_	_	I-Premise
227	overall	_	_	I-Premise
228	survival	_	_	I-Premise
229	was	_	_	I-Premise
230	significantly	_	_	I-Premise
231	longer	_	_	I-Premise
232	with	_	_	I-Premise
233	temozolomide	_	_	I-Premise
234	(	_	_	I-Premise
235	8·3	_	_	I-Premise
236	months	_	_	I-Premise
237	[	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	CI	_	_	I-Premise
241	7·1-9·5	_	_	I-Premise
242	;	_	_	I-Premise
243	n=93	_	_	I-Premise
244	]	_	_	I-Premise
245	vs	_	_	I-Premise
246	6·0	_	_	I-Premise
247	months	_	_	I-Premise
248	[	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	5·1-6·8	_	_	I-Premise
253	;	_	_	I-Premise
254	n=100	_	_	I-Premise
255	]	_	_	I-Premise
256	,	_	_	I-Premise
257	hazard	_	_	I-Premise
258	ratio	_	_	I-Premise
259	[	_	_	I-Premise
260	HR	_	_	I-Premise
261	]	_	_	I-Premise
262	0·70	_	_	I-Premise
263	;	_	_	I-Premise
264	95	_	_	I-Premise
265	%	_	_	I-Premise
266	CI	_	_	I-Premise
267	0·52-0·93	_	_	I-Premise
268	,	_	_	I-Premise
269	p=0·01	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	but	_	_	I-Premise
273	not	_	_	I-Premise
274	with	_	_	I-Premise
275	hypofractionated	_	_	I-Premise
276	radiotherapy	_	_	I-Premise
277	(	_	_	I-Premise
278	7·5	_	_	I-Premise
279	months	_	_	I-Premise
280	[	_	_	I-Premise
281	6·5-8·6	_	_	I-Premise
282	;	_	_	I-Premise
283	n=98	_	_	I-Premise
284	]	_	_	I-Premise
285	,	_	_	I-Premise
286	HR	_	_	I-Premise
287	0·85	_	_	I-Premise
288	[	_	_	I-Premise
289	0·64-1·12	_	_	I-Premise
290	]	_	_	I-Premise
291	,	_	_	I-Premise
292	p=0·24	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	For	_	_	B-Premise
296	all	_	_	I-Premise
297	patients	_	_	I-Premise
298	who	_	_	I-Premise
299	received	_	_	I-Premise
300	temozolomide	_	_	I-Premise
301	or	_	_	I-Premise
302	hypofractionated	_	_	I-Premise
303	radiotherapy	_	_	I-Premise
304	(	_	_	I-Premise
305	n=242	_	_	I-Premise
306	)	_	_	I-Premise
307	overall	_	_	I-Premise
308	survival	_	_	I-Premise
309	was	_	_	I-Premise
310	similar	_	_	I-Premise
311	(	_	_	I-Premise
312	8·4	_	_	I-Premise
313	months	_	_	I-Premise
314	[	_	_	I-Premise
315	7·3-9·4	_	_	I-Premise
316	;	_	_	I-Premise
317	n=119	_	_	I-Premise
318	]	_	_	I-Premise
319	vs	_	_	I-Premise
320	7·4	_	_	I-Premise
321	months	_	_	I-Premise
322	[	_	_	I-Premise
323	6·4-8·4	_	_	I-Premise
324	;	_	_	I-Premise
325	n=123	_	_	I-Premise
326	]	_	_	I-Premise
327	;	_	_	I-Premise
328	HR	_	_	I-Premise
329	0·82	_	_	I-Premise
330	,	_	_	I-Premise
331	95	_	_	I-Premise
332	%	_	_	I-Premise
333	CI	_	_	I-Premise
334	0·63-1·06	_	_	I-Premise
335	;	_	_	I-Premise
336	p=0·12	_	_	I-Premise
337	)	_	_	I-Premise
338	.	_	_	I-Premise

339	For	_	_	B-Premise
340	age	_	_	I-Premise
341	older	_	_	I-Premise
342	than	_	_	I-Premise
343	70	_	_	I-Premise
344	years	_	_	I-Premise
345	,	_	_	I-Premise
346	survival	_	_	I-Premise
347	was	_	_	I-Premise
348	better	_	_	I-Premise
349	with	_	_	I-Premise
350	temozolomide	_	_	I-Premise
351	and	_	_	I-Premise
352	with	_	_	I-Premise
353	hypofractionated	_	_	I-Premise
354	radiotherapy	_	_	I-Premise
355	than	_	_	I-Premise
356	with	_	_	I-Premise
357	standard	_	_	I-Premise
358	radiotherapy	_	_	I-Premise
359	(	_	_	I-Premise
360	HR	_	_	I-Premise
361	for	_	_	I-Premise
362	temozolomide	_	_	I-Premise
363	vs	_	_	I-Premise
364	standard	_	_	I-Premise
365	radiotherapy	_	_	I-Premise
366	0·35	_	_	I-Premise
367	[	_	_	I-Premise
368	0·21-0·56	_	_	I-Premise
369	]	_	_	I-Premise
370	,	_	_	I-Premise
371	p	_	_	I-Premise
372	<	_	_	I-Premise
373	0·0001	_	_	I-Premise
374	;	_	_	I-Premise
375	HR	_	_	I-Premise
376	for	_	_	I-Premise
377	hypofractionated	_	_	I-Premise
378	vs	_	_	I-Premise
379	standard	_	_	I-Premise
380	radiotherapy	_	_	I-Premise
381	0·59	_	_	I-Premise
382	[	_	_	I-Premise
383	95	_	_	I-Premise
384	%	_	_	I-Premise
385	CI	_	_	I-Premise
386	0·37-0·93	_	_	I-Premise
387	]	_	_	I-Premise
388	,	_	_	I-Premise
389	p=0·02	_	_	I-Premise
390	)	_	_	I-Premise
391	.	_	_	I-Premise

392	Patients	_	_	B-Premise
393	treated	_	_	I-Premise
394	with	_	_	I-Premise
395	temozolomide	_	_	I-Premise
396	who	_	_	I-Premise
397	had	_	_	I-Premise
398	tumour	_	_	I-Premise
399	MGMT	_	_	I-Premise
400	promoter	_	_	I-Premise
401	methylation	_	_	I-Premise
402	had	_	_	I-Premise
403	significantly	_	_	I-Premise
404	longer	_	_	I-Premise
405	survival	_	_	I-Premise
406	than	_	_	I-Premise
407	those	_	_	I-Premise
408	without	_	_	I-Premise
409	MGMT	_	_	I-Premise
410	promoter	_	_	I-Premise
411	methylation	_	_	I-Premise
412	(	_	_	I-Premise
413	9·7	_	_	I-Premise
414	months	_	_	I-Premise
415	[	_	_	I-Premise
416	95	_	_	I-Premise
417	%	_	_	I-Premise
418	CI	_	_	I-Premise
419	8·0-11·4	_	_	I-Premise
420	]	_	_	I-Premise
421	vs	_	_	I-Premise
422	6·8	_	_	I-Premise
423	months	_	_	I-Premise
424	[	_	_	I-Premise
425	5·9-7·7	_	_	I-Premise
426	]	_	_	I-Premise
427	;	_	_	I-Premise
428	HR	_	_	I-Premise
429	0·56	_	_	I-Premise
430	[	_	_	I-Premise
431	95	_	_	I-Premise
432	%	_	_	I-Premise
433	CI	_	_	I-Premise
434	0·34-0·93	_	_	I-Premise
435	]	_	_	I-Premise
436	,	_	_	I-Premise
437	p=0·02	_	_	I-Premise
438	)	_	_	I-Premise
439	,	_	_	I-Premise
440	but	_	_	I-Premise
441	no	_	_	I-Premise
442	difference	_	_	I-Premise
443	was	_	_	I-Premise
444	noted	_	_	I-Premise
445	between	_	_	I-Premise
446	those	_	_	I-Premise
447	with	_	_	I-Premise
448	methylated	_	_	I-Premise
449	and	_	_	I-Premise
450	unmethylated	_	_	I-Premise
451	MGMT	_	_	I-Premise
452	promoter	_	_	I-Premise
453	treated	_	_	I-Premise
454	with	_	_	I-Premise
455	radiotherapy	_	_	I-Premise
456	(	_	_	I-Premise
457	HR	_	_	I-Premise
458	0·97	_	_	I-Premise
459	[	_	_	I-Premise
460	95	_	_	I-Premise
461	%	_	_	I-Premise
462	CI	_	_	I-Premise
463	0·69-1·38	_	_	I-Premise
464	]	_	_	I-Premise
465	;	_	_	I-Premise
466	p=0·81	_	_	I-Premise
467	)	_	_	I-Premise
468	.	_	_	I-Premise

469	As	_	_	O
470	expected	_	_	O
471	,	_	_	O
472	the	_	_	B-Premise
473	most	_	_	I-Premise
474	common	_	_	I-Premise
475	grade	_	_	I-Premise
476	3-4	_	_	I-Premise
477	adverse	_	_	I-Premise
478	events	_	_	I-Premise
479	in	_	_	I-Premise
480	the	_	_	I-Premise
481	temozolomide	_	_	I-Premise
482	group	_	_	I-Premise
483	were	_	_	I-Premise
484	neutropenia	_	_	I-Premise
485	(	_	_	I-Premise
486	n=12	_	_	I-Premise
487	)	_	_	I-Premise
488	and	_	_	I-Premise
489	thrombocytopenia	_	_	I-Premise
490	(	_	_	I-Premise
491	n=18	_	_	I-Premise
492	)	_	_	I-Premise
493	.	_	_	I-Premise

494	Grade	_	_	B-Premise
495	3-5	_	_	I-Premise
496	infections	_	_	I-Premise
497	in	_	_	I-Premise
498	all	_	_	I-Premise
499	randomisation	_	_	I-Premise
500	groups	_	_	I-Premise
501	were	_	_	I-Premise
502	reported	_	_	I-Premise
503	in	_	_	I-Premise
504	18	_	_	I-Premise
505	patients	_	_	I-Premise
506	.	_	_	I-Premise

507	Two	_	_	B-Premise
508	patients	_	_	I-Premise
509	had	_	_	I-Premise
510	fatal	_	_	I-Premise
511	infections	_	_	I-Premise
512	(	_	_	I-Premise
513	one	_	_	I-Premise
514	in	_	_	I-Premise
515	the	_	_	I-Premise
516	temozolomide	_	_	I-Premise
517	group	_	_	I-Premise
518	and	_	_	I-Premise
519	one	_	_	I-Premise
520	in	_	_	I-Premise
521	the	_	_	I-Premise
522	standard	_	_	I-Premise
523	radiotherapy	_	_	I-Premise
524	group	_	_	I-Premise
525	)	_	_	I-Premise
526	and	_	_	I-Premise
527	one	_	_	I-Premise
528	in	_	_	I-Premise
529	the	_	_	I-Premise
530	temozolomide	_	_	I-Premise
531	group	_	_	I-Premise
532	with	_	_	I-Premise
533	grade	_	_	I-Premise
534	2	_	_	I-Premise
535	thrombocytopenia	_	_	I-Premise
536	died	_	_	I-Premise
537	from	_	_	I-Premise
538	complications	_	_	I-Premise
539	after	_	_	I-Premise
540	surgery	_	_	I-Premise
541	for	_	_	I-Premise
542	a	_	_	I-Premise
543	gastrointestinal	_	_	I-Premise
544	bleed	_	_	I-Premise
545	.	_	_	I-Premise

546	Standard	_	_	B-Claim
547	radiotherapy	_	_	I-Claim
548	was	_	_	I-Claim
549	associated	_	_	I-Claim
550	with	_	_	I-Claim
551	poor	_	_	I-Claim
552	outcomes	_	_	I-Claim
553	,	_	_	I-Claim
554	especially	_	_	I-Claim
555	in	_	_	I-Claim
556	patients	_	_	I-Claim
557	older	_	_	I-Claim
558	than	_	_	I-Claim
559	70	_	_	I-Claim
560	years	_	_	I-Claim
561	.	_	_	I-Claim

562	Both	_	_	B-Claim
563	temozolomide	_	_	I-Claim
564	and	_	_	I-Claim
565	hypofractionated	_	_	I-Claim
566	radiotherapy	_	_	I-Claim
567	should	_	_	I-Claim
568	be	_	_	I-Claim
569	considered	_	_	I-Claim
570	as	_	_	I-Claim
571	standard	_	_	I-Claim
572	treatment	_	_	I-Claim
573	options	_	_	I-Claim
574	in	_	_	I-Claim
575	elderly	_	_	I-Claim
576	patients	_	_	I-Claim
577	with	_	_	I-Claim
578	glioblastoma	_	_	I-Claim
579	.	_	_	I-Claim

580	MGMT	_	_	B-Claim
581	promoter	_	_	I-Claim
582	methylation	_	_	I-Claim
583	status	_	_	I-Claim
584	might	_	_	I-Claim
585	be	_	_	I-Claim
586	a	_	_	I-Claim
587	useful	_	_	I-Claim
588	predictive	_	_	I-Claim
589	marker	_	_	I-Claim
590	for	_	_	I-Claim
591	benefit	_	_	I-Claim
592	from	_	_	I-Claim
593	temozolomide	_	_	I-Claim
594	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	,	_	_	O
3	placebo-controlled	_	_	O
4	single-blind	_	_	O
5	trial	_	_	O
6	investigated	_	_	O
7	the	_	_	O
8	safety	_	_	O
9	and	_	_	O
10	efficacy	_	_	O
11	of	_	_	O
12	SAMITAL®	_	_	O
13	,	_	_	O
14	a	_	_	O
15	formulation	_	_	O
16	of	_	_	O
17	highly	_	_	O
18	standardised	_	_	O
19	botanical	_	_	O
20	extracts	_	_	O
21	,	_	_	O
22	in	_	_	O
23	the	_	_	O
24	treatment	_	_	O
25	of	_	_	O
26	chemo/radiotherapy-induced	_	_	O
27	oral	_	_	O
28	mucositis	_	_	O
29	(	_	_	O
30	OM	_	_	O
31	)	_	_	O
32	in	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	head	_	_	O
36	and	_	_	O
37	neck	_	_	O
38	cancer	_	_	O
39	.	_	_	O

40	Patients	_	_	O
41	received	_	_	O
42	SAMITAL®	_	_	O
43	or	_	_	O
44	placebo	_	_	O
45	four	_	_	O
46	times	_	_	O
47	daily	_	_	O
48	for	_	_	O
49	up	_	_	O
50	to	_	_	O
51	50	_	_	O
52	days	_	_	O
53	during	_	_	O
54	scheduled	_	_	O
55	chemo/radiotherapy	_	_	O
56	.	_	_	O

57	Severity	_	_	O
58	of	_	_	O
59	OM	_	_	O
60	was	_	_	O
61	monitored	_	_	O
62	according	_	_	O
63	to	_	_	O
64	a	_	_	O
65	modified	_	_	O
66	WHO	_	_	O
67	severity	_	_	O
68	scale	_	_	O
69	,	_	_	O
70	and	_	_	O
71	pain	_	_	O
72	and	_	_	O
73	quality-of-life	_	_	O
74	assessments	_	_	O
75	were	_	_	O
76	based	_	_	O
77	on	_	_	O
78	the	_	_	O
79	effect	_	_	O
80	of	_	_	O
81	symptoms	_	_	O
82	of	_	_	O
83	OM	_	_	O
84	on	_	_	O
85	relevant	_	_	O
86	daily	_	_	O
87	activities	_	_	O
88	,	_	_	O
89	according	_	_	O
90	to	_	_	O
91	a	_	_	O
92	visual	_	_	O
93	analogue	_	_	O
94	scale	_	_	O
95	.	_	_	O

96	Mean	_	_	B-Premise
97	scores	_	_	I-Premise
98	for	_	_	I-Premise
99	the	_	_	I-Premise
100	severity	_	_	I-Premise
101	of	_	_	I-Premise
102	OM	_	_	I-Premise
103	were	_	_	I-Premise
104	significantly	_	_	I-Premise
105	(	_	_	I-Premise
106	p	_	_	I-Premise
107	<	_	_	I-Premise
108	0.05	_	_	I-Premise
109	versus	_	_	I-Premise
110	baseline	_	_	I-Premise
111	)	_	_	I-Premise
112	reduced	_	_	I-Premise
113	from	_	_	I-Premise
114	day	_	_	I-Premise
115	31	_	_	I-Premise
116	until	_	_	I-Premise
117	the	_	_	I-Premise
118	end	_	_	I-Premise
119	of	_	_	I-Premise
120	treatment	_	_	I-Premise
121	in	_	_	I-Premise
122	patients	_	_	I-Premise
123	treated	_	_	I-Premise
124	with	_	_	I-Premise
125	SAMITAL®	_	_	I-Premise
126	(	_	_	I-Premise
127	n	_	_	I-Premise
128	=	_	_	I-Premise
129	20	_	_	I-Premise
130	)	_	_	I-Premise
131	.	_	_	I-Premise

132	No	_	_	B-Premise
133	significant	_	_	I-Premise
134	improvement	_	_	I-Premise
135	was	_	_	I-Premise
136	observed	_	_	I-Premise
137	in	_	_	I-Premise
138	the	_	_	I-Premise
139	placebo	_	_	I-Premise
140	group	_	_	I-Premise
141	(	_	_	I-Premise
142	n	_	_	I-Premise
143	=	_	_	I-Premise
144	10	_	_	I-Premise
145	)	_	_	I-Premise
146	.	_	_	I-Premise

147	Pain	_	_	B-Premise
148	reduction	_	_	I-Premise
149	was	_	_	I-Premise
150	significant	_	_	I-Premise
151	from	_	_	I-Premise
152	day	_	_	I-Premise
153	4	_	_	I-Premise
154	till	_	_	I-Premise
155	end	_	_	I-Premise
156	of	_	_	I-Premise
157	treatment	_	_	I-Premise
158	with	_	_	I-Premise
159	SAMITAL®	_	_	I-Premise
160	and	_	_	I-Premise
161	from	_	_	I-Premise
162	days	_	_	I-Premise
163	7	_	_	I-Premise
164	to	_	_	I-Premise
165	21	_	_	I-Premise
166	in	_	_	I-Premise
167	placebo	_	_	I-Premise
168	patients	_	_	I-Premise
169	.	_	_	I-Premise

170	SAMITAL®	_	_	B-Premise
171	also	_	_	I-Premise
172	significantly	_	_	I-Premise
173	improved	_	_	I-Premise
174	quality	_	_	I-Premise
175	of	_	_	I-Premise
176	life	_	_	I-Premise
177	,	_	_	I-Premise
178	as	_	_	I-Premise
179	shown	_	_	I-Premise
180	by	_	_	I-Premise
181	improvements	_	_	I-Premise
182	in	_	_	I-Premise
183	scores	_	_	I-Premise
184	for	_	_	I-Premise
185	relevant	_	_	I-Premise
186	daily	_	_	I-Premise
187	activities	_	_	I-Premise
188	including	_	_	I-Premise
189	eating	_	_	I-Premise
190	,	_	_	I-Premise
191	drinking	_	_	I-Premise
192	and	_	_	I-Premise
193	sleeping	_	_	I-Premise
194	.	_	_	I-Premise

195	All	_	_	O
196	SAMITAL®	_	_	O
197	patients	_	_	O
198	completed	_	_	O
199	the	_	_	O
200	treatment	_	_	O
201	period	_	_	O
202	,	_	_	O
203	but	_	_	O
204	no	_	_	O
205	placebo	_	_	O
206	recipients	_	_	O
207	completed	_	_	O
208	treatment	_	_	O
209	.	_	_	O

210	No	_	_	B-Premise
211	severe	_	_	I-Premise
212	adverse	_	_	I-Premise
213	events	_	_	I-Premise
214	were	_	_	I-Premise
215	observed	_	_	I-Premise
216	with	_	_	I-Premise
217	SAMITAL®	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	systemic	_	_	I-Premise
221	absorption	_	_	I-Premise
222	of	_	_	I-Premise
223	relevant	_	_	I-Premise
224	active	_	_	I-Premise
225	ingredients	_	_	I-Premise
226	was	_	_	I-Premise
227	undetectable	_	_	I-Premise
228	.	_	_	I-Premise

229	SAMITAL®	_	_	B-Claim
230	significantly	_	_	I-Claim
231	decreased	_	_	I-Claim
232	the	_	_	I-Claim
233	severity	_	_	I-Claim
234	of	_	_	I-Claim
235	chemo/radiotherapy-induced	_	_	I-Claim
236	OM	_	_	I-Claim
237	in	_	_	I-Claim
238	patients	_	_	I-Claim
239	with	_	_	I-Claim
240	head	_	_	I-Claim
241	and	_	_	I-Claim
242	neck	_	_	I-Claim
243	cancer	_	_	I-Claim
244	,	_	_	I-Claim
245	with	_	_	I-Claim
246	no	_	_	I-Claim
247	treatment-related	_	_	I-Claim
248	adverse	_	_	I-Claim
249	events	_	_	I-Claim
250	.	_	_	I-Claim

251	Pain	_	_	B-Claim
252	relief	_	_	I-Claim
253	lasted	_	_	I-Claim
254	through	_	_	I-Claim
255	the	_	_	I-Claim
256	treatment	_	_	I-Claim
257	period	_	_	I-Claim
258	,	_	_	I-Claim
259	and	_	_	I-Claim
260	improvements	_	_	I-Claim
261	in	_	_	I-Claim
262	quality	_	_	I-Claim
263	of	_	_	I-Claim
264	life	_	_	I-Claim
265	were	_	_	I-Claim
266	reflected	_	_	I-Claim
267	by	_	_	I-Claim
268	the	_	_	I-Claim
269	significant	_	_	I-Claim
270	benefits	_	_	I-Claim
271	of	_	_	I-Claim
272	SAMITAL®	_	_	I-Claim
273	on	_	_	I-Claim
274	activities	_	_	I-Claim
275	like	_	_	I-Claim
276	drinking	_	_	I-Claim
277	,	_	_	I-Claim
278	eating	_	_	I-Claim
279	and	_	_	I-Claim
280	speaking	_	_	I-Claim
281	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	prospective	_	_	O
5	controlled	_	_	O
6	study	_	_	O
7	was	_	_	O
8	to	_	_	O
9	assess	_	_	O
10	the	_	_	O
11	efficacy	_	_	O
12	of	_	_	O
13	two	_	_	O
14	different	_	_	O
15	combination	_	_	O
16	treatment	_	_	O
17	modalities	_	_	O
18	of	_	_	O
19	lymphedema	_	_	O
20	(	_	_	O
21	LE	_	_	O
22	)	_	_	O
23	.	_	_	O

24	Manual	_	_	O
25	lymphatic	_	_	O
26	drainage	_	_	O
27	(	_	_	O
28	MLD	_	_	O
29	)	_	_	O
30	and	_	_	O
31	compression	_	_	O
32	bandage	_	_	O
33	combination	_	_	O
34	(	_	_	O
35	complex	_	_	O
36	decongestive	_	_	O
37	therapy	_	_	O
38	)	_	_	O
39	have	_	_	O
40	been	_	_	O
41	compared	_	_	O
42	with	_	_	O
43	intermittent	_	_	O
44	pneumatic	_	_	O
45	compression	_	_	O
46	(	_	_	O
47	IPC	_	_	O
48	)	_	_	O
49	plus	_	_	O
50	self-lymphatic	_	_	O
51	drainage	_	_	O
52	(	_	_	O
53	SLD	_	_	O
54	)	_	_	O
55	.	_	_	O

56	Both	_	_	O
57	MLD	_	_	O
58	with	_	_	O
59	compression	_	_	O
60	bandage	_	_	O
61	(	_	_	O
62	complex	_	_	O
63	decongestive	_	_	O
64	therapy	_	_	O
65	)	_	_	O
66	group	_	_	O
67	(	_	_	O
68	Group	_	_	O
69	I	_	_	O
70	,	_	_	O
71	n=15	_	_	O
72	)	_	_	O
73	and	_	_	O
74	IPC	_	_	O
75	with	_	_	O
76	SLD	_	_	O
77	group	_	_	O
78	(	_	_	O
79	Group	_	_	O
80	II	_	_	O
81	,	_	_	O
82	n=15	_	_	O
83	)	_	_	O
84	received	_	_	O
85	treatment	_	_	O
86	for	_	_	O
87	LE	_	_	O
88	3	_	_	O
89	days	_	_	O
90	in	_	_	O
91	a	_	_	O
92	week	_	_	O
93	and	_	_	O
94	every	_	_	O
95	other	_	_	O
96	day	_	_	O
97	for	_	_	O
98	6	_	_	O
99	weeks	_	_	O
100	.	_	_	O

101	Arm	_	_	O
102	circumferences	_	_	O
103	were	_	_	O
104	measured	_	_	O
105	before	_	_	O
106	and	_	_	O
107	the	_	_	O
108	1st	_	_	O
109	,	_	_	O
110	3rd	_	_	O
111	,	_	_	O
112	and	_	_	O
113	6th	_	_	O
114	weeks	_	_	O
115	of	_	_	O
116	the	_	_	O
117	treatment	_	_	O
118	.	_	_	O

119	EORTC-QLQ	_	_	O
120	and	_	_	O
121	ASES-tests	_	_	O
122	were	_	_	O
123	performed	_	_	O
124	to	_	_	O
125	assess	_	_	O
126	the	_	_	O
127	quality	_	_	O
128	of	_	_	O
129	life	_	_	O
130	before	_	_	O
131	and	_	_	O
132	after	_	_	O
133	6	_	_	O
134	week-treatment	_	_	O
135	.	_	_	O

136	Patients	_	_	O
137	in	_	_	O
138	both	_	_	O
139	groups	_	_	O
140	had	_	_	O
141	similar	_	_	O
142	demographic	_	_	O
143	and	_	_	O
144	clinical	_	_	O
145	characteristics	_	_	O
146	.	_	_	O

147	Even	_	_	O
148	though	_	_	O
149	both	_	_	B-Premise
150	treatment	_	_	I-Premise
151	modalities	_	_	I-Premise
152	resulted	_	_	I-Premise
153	in	_	_	I-Premise
154	significant	_	_	I-Premise
155	decrease	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	total	_	_	I-Premise
159	arm	_	_	I-Premise
160	volume	_	_	I-Premise
161	(	_	_	I-Premise
162	12.2	_	_	I-Premise
163	%	_	_	I-Premise
164	decrease	_	_	I-Premise
165	in	_	_	I-Premise
166	Group	_	_	I-Premise
167	II	_	_	I-Premise
168	and	_	_	I-Premise
169	14.9	_	_	I-Premise
170	%	_	_	I-Premise
171	decrease	_	_	I-Premise
172	in	_	_	I-Premise
173	Group	_	_	I-Premise
174	I	_	_	I-Premise
175	)	_	_	I-Premise
176	(	_	_	I-Premise
177	p	_	_	I-Premise
178	<	_	_	I-Premise
179	0.001	_	_	I-Premise
180	)	_	_	I-Premise
181	,	_	_	I-Premise
182	no	_	_	B-Premise
183	significant	_	_	I-Premise
184	difference	_	_	I-Premise
185	(	_	_	I-Premise
186	p=0.582	_	_	I-Premise
187	)	_	_	I-Premise
188	was	_	_	I-Premise
189	found	_	_	I-Premise
190	between	_	_	I-Premise
191	those	_	_	I-Premise
192	two	_	_	I-Premise
193	groups	_	_	I-Premise
194	.	_	_	I-Premise

195	Similarly	_	_	B-Premise
196	,	_	_	I-Premise
197	ASES	_	_	I-Premise
198	scores	_	_	I-Premise
199	were	_	_	I-Premise
200	significantly	_	_	I-Premise
201	(	_	_	I-Premise
202	p=0.001	_	_	I-Premise
203	)	_	_	I-Premise
204	improved	_	_	I-Premise
205	in	_	_	I-Premise
206	both	_	_	I-Premise
207	Group	_	_	I-Premise
208	I	_	_	I-Premise
209	and	_	_	I-Premise
210	II	_	_	I-Premise
211	without	_	_	I-Premise
212	any	_	_	I-Premise
213	significant	_	_	I-Premise
214	difference	_	_	I-Premise
215	between	_	_	I-Premise
216	the	_	_	I-Premise
217	groups	_	_	I-Premise
218	.	_	_	I-Premise

219	While	_	_	B-Premise
220	emotional	_	_	I-Premise
221	functioning	_	_	I-Premise
222	,	_	_	I-Premise
223	fatigue	_	_	I-Premise
224	,	_	_	I-Premise
225	and	_	_	I-Premise
226	pain	_	_	I-Premise
227	scores	_	_	I-Premise
228	were	_	_	I-Premise
229	significantly	_	_	I-Premise
230	improved	_	_	I-Premise
231	in	_	_	I-Premise
232	both	_	_	I-Premise
233	groups	_	_	I-Premise
234	,	_	_	I-Premise
235	global	_	_	I-Premise
236	health	_	_	I-Premise
237	status	_	_	I-Premise
238	,	_	_	I-Premise
239	functional	_	_	I-Premise
240	and	_	_	I-Premise
241	cognitive	_	_	I-Premise
242	functioning	_	_	I-Premise
243	scores	_	_	I-Premise
244	appeared	_	_	I-Premise
245	to	_	_	I-Premise
246	be	_	_	I-Premise
247	improved	_	_	I-Premise
248	only	_	_	I-Premise
249	in	_	_	I-Premise
250	patients	_	_	I-Premise
251	of	_	_	I-Premise
252	group	_	_	I-Premise
253	I	_	_	I-Premise
254	.	_	_	I-Premise

255	Different	_	_	B-Claim
256	treatment	_	_	I-Claim
257	modalities	_	_	I-Claim
258	consisting	_	_	I-Claim
259	of	_	_	I-Claim
260	MLD	_	_	I-Claim
261	and	_	_	I-Claim
262	compression	_	_	I-Claim
263	bandage	_	_	I-Claim
264	(	_	_	I-Claim
265	complex	_	_	I-Claim
266	decongestive	_	_	I-Claim
267	therapy	_	_	I-Claim
268	)	_	_	I-Claim
269	or	_	_	I-Claim
270	IPC	_	_	I-Claim
271	and	_	_	I-Claim
272	SLD	_	_	I-Claim
273	appear	_	_	I-Claim
274	to	_	_	I-Claim
275	be	_	_	I-Claim
276	effective	_	_	I-Claim
277	in	_	_	I-Claim
278	the	_	_	I-Claim
279	treatment	_	_	I-Claim
280	of	_	_	I-Claim
281	LE	_	_	I-Claim
282	with	_	_	I-Claim
283	similar	_	_	I-Claim
284	therapeutic	_	_	I-Claim
285	efficacy	_	_	I-Claim
286	in	_	_	I-Claim
287	patients	_	_	I-Claim
288	with	_	_	I-Claim
289	breast	_	_	I-Claim
290	cancer	_	_	I-Claim
291	.	_	_	I-Claim

292	However	_	_	B-Claim
293	,	_	_	I-Claim
294	combination	_	_	I-Claim
295	modalities	_	_	I-Claim
296	including	_	_	I-Claim
297	IPC	_	_	I-Claim
298	and	_	_	I-Claim
299	SLD	_	_	I-Claim
300	may	_	_	I-Claim
301	be	_	_	I-Claim
302	the	_	_	I-Claim
303	preferred	_	_	I-Claim
304	choices	_	_	I-Claim
305	for	_	_	I-Claim
306	their	_	_	I-Claim
307	applicability	_	_	I-Claim
308	at	_	_	I-Claim
309	home	_	_	I-Claim
310	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	phacoemulsification	_	_	O
3	versus	_	_	O
4	trabeculectomy	_	_	O
5	with	_	_	O
6	adjunctive	_	_	O
7	mitomycin	_	_	O
8	C	_	_	O
9	in	_	_	O
10	medically	_	_	O
11	uncontrolled	_	_	O
12	chronic	_	_	O
13	angle-closure	_	_	O
14	glaucoma	_	_	O
15	(	_	_	O
16	CACG	_	_	O
17	)	_	_	O
18	without	_	_	O
19	cataract	_	_	O
20	.	_	_	O

21	Prospective	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	.	_	_	O

27	Fifty	_	_	O
28	medically	_	_	O
29	uncontrolled	_	_	O
30	CACG	_	_	O
31	eyes	_	_	O
32	without	_	_	O
33	cataract	_	_	O
34	of	_	_	O
35	50	_	_	O
36	patients	_	_	O
37	.	_	_	O

38	Patients	_	_	O
39	were	_	_	O
40	randomized	_	_	O
41	into	_	_	O
42	undergoing	_	_	O
43	either	_	_	O
44	phacoemulsification	_	_	O
45	or	_	_	O
46	trabeculectomy	_	_	O
47	with	_	_	O
48	adjunctive	_	_	O
49	mitomycin	_	_	O
50	C.	_	_	O
51	After	_	_	O
52	surgery	_	_	O
53	,	_	_	O
54	patients	_	_	O
55	were	_	_	O
56	followed	_	_	O
57	up	_	_	O
58	every	_	_	O
59	3	_	_	O
60	months	_	_	O
61	for	_	_	O
62	2	_	_	O
63	years	_	_	O
64	.	_	_	O

65	Intraocular	_	_	O
66	pressure	_	_	O
67	(	_	_	O
68	IOP	_	_	O
69	)	_	_	O
70	and	_	_	O
71	requirement	_	_	O
72	for	_	_	O
73	glaucoma	_	_	O
74	drugs	_	_	O
75	.	_	_	O

76	Twenty-six	_	_	O
77	CACG	_	_	O
78	eyes	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	phacoemulsification	_	_	O
84	,	_	_	O
85	and	_	_	O
86	24	_	_	O
87	eyes	_	_	O
88	underwent	_	_	O
89	trabeculectomy	_	_	O
90	with	_	_	O
91	mitomycin	_	_	O
92	C.	_	_	O
93	Phacoemulsification	_	_	B-Premise
94	and	_	_	I-Premise
95	trabeculectomy	_	_	I-Premise
96	resulted	_	_	I-Premise
97	in	_	_	I-Premise
98	significant	_	_	I-Premise
99	and	_	_	I-Premise
100	comparable	_	_	I-Premise
101	IOP	_	_	I-Premise
102	reduction	_	_	I-Premise
103	at	_	_	I-Premise
104	24	_	_	I-Premise
105	months	_	_	I-Premise
106	after	_	_	I-Premise
107	surgery	_	_	I-Premise
108	(	_	_	I-Premise
109	reduction	_	_	I-Premise
110	of	_	_	I-Premise
111	8.4	_	_	I-Premise
112	mmHg	_	_	I-Premise
113	or	_	_	I-Premise
114	34	_	_	I-Premise
115	%	_	_	I-Premise
116	for	_	_	I-Premise
117	phacoemulsification	_	_	I-Premise
118	vs	_	_	I-Premise
119	8.9	_	_	I-Premise
120	mmHg	_	_	I-Premise
121	or	_	_	I-Premise
122	36	_	_	I-Premise
123	%	_	_	I-Premise
124	for	_	_	I-Premise
125	trabeculectomy	_	_	I-Premise
126	;	_	_	I-Premise
127	P=0.76	_	_	I-Premise
128	)	_	_	I-Premise
129	.	_	_	I-Premise

130	Over	_	_	B-Premise
131	first	_	_	I-Premise
132	24	_	_	I-Premise
133	months	_	_	I-Premise
134	,	_	_	I-Premise
135	trabeculectomy-treated	_	_	I-Premise
136	eyes	_	_	I-Premise
137	required	_	_	I-Premise
138	on	_	_	I-Premise
139	average	_	_	I-Premise
140	1.1	_	_	I-Premise
141	fewer	_	_	I-Premise
142	drugs	_	_	I-Premise
143	than	_	_	I-Premise
144	phacoemulsification-treated	_	_	I-Premise
145	eyes	_	_	I-Premise
146	(	_	_	I-Premise
147	P	_	_	I-Premise
148	<	_	_	I-Premise
149	0.001	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	However	_	_	O
153	,	_	_	O
154	trabeculectomy	_	_	B-Premise
155	was	_	_	I-Premise
156	associated	_	_	I-Premise
157	with	_	_	I-Premise
158	significantly	_	_	I-Premise
159	more	_	_	I-Premise
160	surgical	_	_	I-Premise
161	complications	_	_	I-Premise
162	than	_	_	I-Premise
163	phacoemulsification	_	_	I-Premise
164	(	_	_	I-Premise
165	46	_	_	I-Premise
166	%	_	_	I-Premise
167	vs	_	_	I-Premise
168	4	_	_	I-Premise
169	%	_	_	I-Premise
170	;	_	_	I-Premise
171	P=0.001	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Eight	_	_	B-Premise
175	(	_	_	I-Premise
176	33	_	_	I-Premise
177	%	_	_	I-Premise
178	)	_	_	I-Premise
179	of	_	_	I-Premise
180	24	_	_	I-Premise
181	trabeculectomy	_	_	I-Premise
182	eyes	_	_	I-Premise
183	demonstrated	_	_	I-Premise
184	cataract	_	_	I-Premise
185	during	_	_	I-Premise
186	follow-up	_	_	I-Premise
187	.	_	_	I-Premise

188	Both	_	_	B-Claim
189	phacoemulsification	_	_	I-Claim
190	and	_	_	I-Claim
191	trabeculectomy	_	_	I-Claim
192	are	_	_	I-Claim
193	effective	_	_	I-Claim
194	in	_	_	I-Claim
195	reducing	_	_	I-Claim
196	IOP	_	_	I-Claim
197	in	_	_	I-Claim
198	medically	_	_	I-Claim
199	uncontrolled	_	_	I-Claim
200	CACG	_	_	I-Claim
201	eyes	_	_	I-Claim
202	without	_	_	I-Claim
203	cataract	_	_	I-Claim
204	.	_	_	I-Claim

205	Trabeculectomy	_	_	B-Claim
206	is	_	_	I-Claim
207	more	_	_	I-Claim
208	effective	_	_	I-Claim
209	than	_	_	I-Claim
210	phacoemulsification	_	_	I-Claim
211	in	_	_	I-Claim
212	reducing	_	_	I-Claim
213	dependence	_	_	I-Claim
214	on	_	_	I-Claim
215	glaucoma	_	_	I-Claim
216	drugs	_	_	I-Claim
217	,	_	_	I-Claim
218	but	_	_	I-Claim
219	is	_	_	I-Claim
220	associated	_	_	I-Claim
221	with	_	_	I-Claim
222	more	_	_	I-Claim
223	complications	_	_	I-Claim
224	.	_	_	I-Claim


0	We	_	_	O
1	investigated	_	_	O
2	the	_	_	O
3	influence	_	_	O
4	of	_	_	O
5	bladder	_	_	O
6	neck	_	_	O
7	preservation	_	_	O
8	on	_	_	O
9	urinary	_	_	O
10	continence	_	_	O
11	,	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	and	_	_	O
16	surgical	_	_	O
17	margins	_	_	O
18	after	_	_	O
19	radical	_	_	O
20	prostatectomy	_	_	O
21	.	_	_	O

22	A	_	_	O
23	total	_	_	O
24	of	_	_	O
25	208	_	_	O
26	men	_	_	O
27	who	_	_	O
28	presented	_	_	O
29	for	_	_	O
30	radical	_	_	O
31	prostatectomy	_	_	O
32	were	_	_	O
33	randomized	_	_	O
34	to	_	_	O
35	complete	_	_	O
36	bladder	_	_	O
37	neck	_	_	O
38	preservation	_	_	O
39	with	_	_	O
40	subsequent	_	_	O
41	urethro-urethral	_	_	O
42	anastomosis	_	_	O
43	or	_	_	O
44	to	_	_	O
45	no	_	_	O
46	preservation	_	_	O
47	as	_	_	O
48	controls	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	with	_	_	O
52	failed	_	_	O
53	bladder	_	_	O
54	neck	_	_	O
55	preservation	_	_	O
56	were	_	_	O
57	not	_	_	O
58	included	_	_	O
59	in	_	_	O
60	study	_	_	O
61	.	_	_	O

62	We	_	_	O
63	documented	_	_	O
64	objective	_	_	O
65	continence	_	_	O
66	by	_	_	O
67	the	_	_	O
68	24-hour	_	_	O
69	pad	_	_	O
70	test	_	_	O
71	,	_	_	O
72	social	_	_	O
73	continence	_	_	O
74	by	_	_	O
75	the	_	_	O
76	number	_	_	O
77	of	_	_	O
78	pads	_	_	O
79	per	_	_	O
80	day	_	_	O
81	and	_	_	O
82	quality	_	_	O
83	of	_	_	O
84	life	_	_	O
85	outcomes	_	_	O
86	by	_	_	O
87	the	_	_	O
88	validated	_	_	O
89	Incontinence	_	_	O
90	Quality	_	_	O
91	of	_	_	O
92	Life	_	_	O
93	questionnaire	_	_	O
94	in	_	_	O
95	a	_	_	O
96	single	_	_	O
97	blind	_	_	O
98	setting	_	_	O
99	.	_	_	O

100	Cancer	_	_	O
101	resection	_	_	O
102	was	_	_	O
103	assessed	_	_	O
104	by	_	_	O
105	surgical	_	_	O
106	margin	_	_	O
107	status	_	_	O
108	.	_	_	O

109	At	_	_	B-Premise
110	0	_	_	I-Premise
111	,	_	_	I-Premise
112	3	_	_	I-Premise
113	,	_	_	I-Premise
114	6	_	_	I-Premise
115	and	_	_	I-Premise
116	12	_	_	I-Premise
117	months	_	_	I-Premise
118	mean	_	_	I-Premise
119	urine	_	_	I-Premise
120	loss	_	_	I-Premise
121	in	_	_	I-Premise
122	the	_	_	I-Premise
123	control	_	_	I-Premise
124	vs	_	_	I-Premise
125	the	_	_	I-Premise
126	bladder	_	_	I-Premise
127	neck	_	_	I-Premise
128	preservation	_	_	I-Premise
129	group	_	_	I-Premise
130	was	_	_	I-Premise
131	713.3	_	_	I-Premise
132	vs	_	_	I-Premise
133	237.0	_	_	I-Premise
134	,	_	_	I-Premise
135	49.6	_	_	I-Premise
136	vs	_	_	I-Premise
137	15.6	_	_	I-Premise
138	,	_	_	I-Premise
139	44.4	_	_	I-Premise
140	vs	_	_	I-Premise
141	5.5	_	_	I-Premise
142	and	_	_	I-Premise
143	25.4	_	_	I-Premise
144	vs	_	_	I-Premise
145	3.1	_	_	I-Premise
146	gm	_	_	I-Premise
147	,	_	_	I-Premise
148	respectively	_	_	I-Premise
149	(	_	_	I-Premise
150	each	_	_	I-Premise
151	p	_	_	I-Premise
152	<	_	_	I-Premise
153	0.001	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	At	_	_	B-Premise
157	3	_	_	I-Premise
158	,	_	_	I-Premise
159	6	_	_	I-Premise
160	and	_	_	I-Premise
161	12	_	_	I-Premise
162	months	_	_	I-Premise
163	in	_	_	I-Premise
164	the	_	_	I-Premise
165	control	_	_	I-Premise
166	vs	_	_	I-Premise
167	the	_	_	I-Premise
168	preservation	_	_	I-Premise
169	group	_	_	I-Premise
170	the	_	_	I-Premise
171	social	_	_	I-Premise
172	continence	_	_	I-Premise
173	rate	_	_	I-Premise
174	was	_	_	I-Premise
175	55.3	_	_	I-Premise
176	%	_	_	I-Premise
177	vs	_	_	I-Premise
178	84.2	_	_	I-Premise
179	%	_	_	I-Premise
180	(	_	_	I-Premise
181	p	_	_	I-Premise
182	<	_	_	I-Premise
183	0.001	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	74.8	_	_	I-Premise
187	%	_	_	I-Premise
188	vs	_	_	I-Premise
189	89.5	_	_	I-Premise
190	%	_	_	I-Premise
191	(	_	_	I-Premise
192	p	_	_	I-Premise
193	=	_	_	I-Premise
194	0.05	_	_	I-Premise
195	)	_	_	I-Premise
196	and	_	_	I-Premise
197	81.4	_	_	I-Premise
198	%	_	_	I-Premise
199	vs	_	_	I-Premise
200	94.7	_	_	I-Premise
201	%	_	_	I-Premise
202	(	_	_	I-Premise
203	p	_	_	I-Premise
204	=	_	_	I-Premise
205	0.027	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	the	_	_	I-Premise
210	quality	_	_	I-Premise
211	of	_	_	I-Premise
212	life	_	_	I-Premise
213	score	_	_	I-Premise
214	was	_	_	I-Premise
215	80.4	_	_	I-Premise
216	vs	_	_	I-Premise
217	90.3	_	_	I-Premise
218	(	_	_	I-Premise
219	p	_	_	I-Premise
220	<	_	_	I-Premise
221	0.001	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	85.4	_	_	I-Premise
225	vs	_	_	I-Premise
226	91.7	_	_	I-Premise
227	(	_	_	I-Premise
228	p	_	_	I-Premise
229	=	_	_	I-Premise
230	0.016	_	_	I-Premise
231	)	_	_	I-Premise
232	and	_	_	I-Premise
233	86.0	_	_	I-Premise
234	vs	_	_	I-Premise
235	93.8	_	_	I-Premise
236	(	_	_	I-Premise
237	p	_	_	I-Premise
238	=	_	_	I-Premise
239	0.001	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	.	_	_	I-Premise

244	We	_	_	B-Premise
245	noted	_	_	I-Premise
246	significantly	_	_	I-Premise
247	less	_	_	I-Premise
248	urine	_	_	I-Premise
249	loss	_	_	I-Premise
250	,	_	_	I-Premise
251	higher	_	_	I-Premise
252	objective	_	_	I-Premise
253	and	_	_	I-Premise
254	social	_	_	I-Premise
255	continence	_	_	I-Premise
256	rates	_	_	I-Premise
257	,	_	_	I-Premise
258	and	_	_	I-Premise
259	higher	_	_	I-Premise
260	quality	_	_	I-Premise
261	of	_	_	I-Premise
262	life	_	_	I-Premise
263	scores	_	_	I-Premise
264	after	_	_	I-Premise
265	complete	_	_	I-Premise
266	bladder	_	_	I-Premise
267	neck	_	_	I-Premise
268	preservation	_	_	I-Premise
269	at	_	_	I-Premise
270	all	_	_	I-Premise
271	followup	_	_	I-Premise
272	points	_	_	I-Premise
273	.	_	_	I-Premise

274	On	_	_	O
275	multiple	_	_	O
276	logistic	_	_	O
277	regression	_	_	O
278	analysis	_	_	O
279	complete	_	_	O
280	bladder	_	_	O
281	neck	_	_	O
282	preservation	_	_	O
283	was	_	_	O
284	an	_	_	O
285	independent	_	_	O
286	positive	_	_	O
287	predictor	_	_	O
288	of	_	_	O
289	continence	_	_	O
290	.	_	_	O

291	No	_	_	B-Premise
292	significant	_	_	I-Premise
293	difference	_	_	I-Premise
294	was	_	_	I-Premise
295	found	_	_	I-Premise
296	in	_	_	I-Premise
297	surgical	_	_	I-Premise
298	margin	_	_	I-Premise
299	status	_	_	I-Premise
300	between	_	_	I-Premise
301	the	_	_	I-Premise
302	control	_	_	I-Premise
303	and	_	_	I-Premise
304	bladder	_	_	I-Premise
305	neck	_	_	I-Premise
306	preservation	_	_	I-Premise
307	groups	_	_	I-Premise
308	(	_	_	I-Premise
309	12.5	_	_	I-Premise
310	%	_	_	I-Premise
311	vs	_	_	I-Premise
312	14.7	_	_	I-Premise
313	%	_	_	I-Premise
314	,	_	_	I-Premise
315	p	_	_	I-Premise
316	=	_	_	I-Premise
317	0.65	_	_	I-Premise
318	)	_	_	I-Premise
319	.	_	_	I-Premise

320	In	_	_	B-Claim
321	what	_	_	I-Claim
322	is	_	_	I-Claim
323	to	_	_	I-Claim
324	our	_	_	I-Claim
325	knowledge	_	_	I-Claim
326	the	_	_	I-Claim
327	first	_	_	I-Claim
328	prospective	_	_	I-Claim
329	,	_	_	I-Claim
330	randomized	_	_	I-Claim
331	,	_	_	I-Claim
332	controlled	_	_	I-Claim
333	,	_	_	I-Claim
334	single	_	_	I-Claim
335	blind	_	_	I-Claim
336	trial	_	_	I-Claim
337	complete	_	_	I-Claim
338	bladder	_	_	I-Claim
339	neck	_	_	I-Claim
340	preservation	_	_	I-Claim
341	during	_	_	I-Claim
342	radical	_	_	I-Claim
343	prostatectomy	_	_	I-Claim
344	was	_	_	I-Claim
345	associated	_	_	I-Claim
346	with	_	_	I-Claim
347	a	_	_	I-Claim
348	significantly	_	_	I-Claim
349	higher	_	_	I-Claim
350	urinary	_	_	I-Claim
351	continence	_	_	I-Claim
352	rate	_	_	I-Claim
353	and	_	_	I-Claim
354	increased	_	_	I-Claim
355	patient	_	_	I-Claim
356	satisfaction	_	_	I-Claim
357	without	_	_	I-Claim
358	compromising	_	_	I-Claim
359	resection	_	_	I-Claim
360	margins	_	_	I-Claim
361	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	postoperative	_	_	O
4	intraocular	_	_	O
5	pressure	_	_	O
6	(	_	_	O
7	IOP	_	_	O
8	)	_	_	O
9	and	_	_	O
10	incidence	_	_	O
11	of	_	_	O
12	early	_	_	O
13	complications	_	_	O
14	after	_	_	O
15	trabeculectomy	_	_	O
16	with	_	_	O
17	releasable	_	_	O
18	suture	_	_	O
19	to	_	_	O
20	standard	_	_	O
21	trabeculectomy	_	_	O
22	in	_	_	O
23	Chinese	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	primary	_	_	O
27	angle-closure	_	_	O
28	glaucoma	_	_	O
29	.	_	_	O

30	One	_	_	O
31	hundred	_	_	O
32	seventy-five	_	_	O
33	patients	_	_	O
34	diagnosed	_	_	O
35	as	_	_	O
36	primary	_	_	O
37	angle-closure	_	_	O
38	glaucoma	_	_	O
39	with	_	_	O
40	6	_	_	O
41	clock-hours	_	_	O
42	or	_	_	O
43	more	_	_	O
44	of	_	_	O
45	peripheral	_	_	O
46	anterior	_	_	O
47	synechia	_	_	O
48	were	_	_	O
49	randomly	_	_	O
50	allocated	_	_	O
51	to	_	_	O
52	2	_	_	O
53	treatment	_	_	O
54	groups	_	_	O
55	:	_	_	O
56	87	_	_	O
57	underwent	_	_	O
58	standard	_	_	O
59	trabeculectomy	_	_	O
60	(	_	_	O
61	S	_	_	O
62	group	_	_	O
63	:	_	_	O
64	2	_	_	O
65	interrupted	_	_	O
66	permanent	_	_	O
67	sutures	_	_	O
68	to	_	_	O
69	the	_	_	O
70	scleral	_	_	O
71	flap	_	_	O
72	)	_	_	O
73	and	_	_	O
74	88	_	_	O
75	received	_	_	O
76	trabeculectomy	_	_	O
77	with	_	_	O
78	2	_	_	O
79	permanent	_	_	O
80	and	_	_	O
81	2	_	_	O
82	releasable	_	_	O
83	sutures	_	_	O
84	(	_	_	O
85	R	_	_	O
86	group	_	_	O
87	)	_	_	O
88	.	_	_	O

89	The	_	_	O
90	postoperative	_	_	O
91	IOP	_	_	O
92	and	_	_	O
93	complications	_	_	O
94	during	_	_	O
95	the	_	_	O
96	first	_	_	O
97	3	_	_	O
98	months	_	_	O
99	after	_	_	O
100	surgery	_	_	O
101	were	_	_	O
102	compared	_	_	O
103	.	_	_	O

104	One	_	_	O
105	hundred	_	_	O
106	seventy-one	_	_	O
107	patients	_	_	O
108	(	_	_	O
109	97.7	_	_	O
110	%	_	_	O
111	)	_	_	O
112	attended	_	_	O
113	the	_	_	O
114	3-month	_	_	O
115	visit	_	_	O
116	.	_	_	O

117	The	_	_	B-Premise
118	IOP	_	_	I-Premise
119	in	_	_	I-Premise
120	the	_	_	I-Premise
121	first	_	_	I-Premise
122	week	_	_	I-Premise
123	after	_	_	I-Premise
124	trabeculectomy	_	_	I-Premise
125	was	_	_	I-Premise
126	significantly	_	_	I-Premise
127	higher	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	R	_	_	I-Premise
131	group	_	_	I-Premise
132	:	_	_	I-Premise
133	day	_	_	I-Premise
134	1	_	_	I-Premise
135	,	_	_	I-Premise
136	17.3	_	_	I-Premise
137	±	_	_	I-Premise
138	8.6	_	_	I-Premise
139	versus	_	_	I-Premise
140	12.7	_	_	I-Premise
141	±	_	_	I-Premise
142	6.0	_	_	I-Premise
143	mm	_	_	I-Premise
144	Hg	_	_	I-Premise
145	(	_	_	I-Premise
146	P	_	_	I-Premise
147	<	_	_	I-Premise
148	0.001	_	_	I-Premise
149	)	_	_	I-Premise
150	;	_	_	I-Premise
151	day	_	_	I-Premise
152	3	_	_	I-Premise
153	,	_	_	I-Premise
154	18.0	_	_	I-Premise
155	±	_	_	I-Premise
156	7.3	_	_	I-Premise
157	versus	_	_	I-Premise
158	12.9	_	_	I-Premise
159	±	_	_	I-Premise
160	6.3	_	_	I-Premise
161	mm	_	_	I-Premise
162	Hg	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	<	_	_	I-Premise
166	0.001	_	_	I-Premise
167	)	_	_	I-Premise
168	;	_	_	I-Premise
169	day	_	_	I-Premise
170	7	_	_	I-Premise
171	,	_	_	I-Premise
172	14.8	_	_	I-Premise
173	±	_	_	I-Premise
174	6.3	_	_	I-Premise
175	versus	_	_	I-Premise
176	12.0	_	_	I-Premise
177	±	_	_	I-Premise
178	4.9	_	_	I-Premise
179	mm	_	_	I-Premise
180	Hg	_	_	I-Premise
181	(	_	_	I-Premise
182	P=0.001	_	_	I-Premise
183	)	_	_	I-Premise
184	,	_	_	I-Premise
185	but	_	_	O
186	no	_	_	B-Premise
187	difference	_	_	I-Premise
188	was	_	_	I-Premise
189	observed	_	_	I-Premise
190	after	_	_	I-Premise
191	the	_	_	I-Premise
192	second	_	_	I-Premise
193	week	_	_	I-Premise
194	(	_	_	I-Premise
195	P=0.659	_	_	I-Premise
196	to	_	_	I-Premise
197	0.753	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	The	_	_	B-Premise
201	incidence	_	_	I-Premise
202	of	_	_	I-Premise
203	transient	_	_	I-Premise
204	hypotony	_	_	I-Premise
205	was	_	_	I-Premise
206	higher	_	_	I-Premise
207	in	_	_	I-Premise
208	S	_	_	I-Premise
209	group	_	_	I-Premise
210	(	_	_	I-Premise
211	20.4	_	_	I-Premise
212	%	_	_	I-Premise
213	)	_	_	I-Premise
214	than	_	_	I-Premise
215	the	_	_	I-Premise
216	R	_	_	I-Premise
217	group	_	_	I-Premise
218	(	_	_	I-Premise
219	9.1	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	(	_	_	I-Premise
223	P=0.046	_	_	I-Premise
224	)	_	_	I-Premise
225	;	_	_	I-Premise
226	hypotony	_	_	B-Premise
227	recovered	_	_	I-Premise
228	in	_	_	I-Premise
229	80.8	_	_	I-Premise
230	%	_	_	I-Premise
231	(	_	_	I-Premise
232	21/26	_	_	I-Premise
233	)	_	_	I-Premise
234	within	_	_	I-Premise
235	1	_	_	I-Premise
236	week	_	_	I-Premise
237	.	_	_	I-Premise

238	There	_	_	B-Premise
239	was	_	_	I-Premise
240	no	_	_	I-Premise
241	difference	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	occurrence	_	_	I-Premise
245	of	_	_	I-Premise
246	shallow	_	_	I-Premise
247	chamber	_	_	I-Premise
248	,	_	_	I-Premise
249	choroidal	_	_	I-Premise
250	detachment	_	_	I-Premise
251	,	_	_	I-Premise
252	macular	_	_	I-Premise
253	edema	_	_	I-Premise
254	,	_	_	I-Premise
255	additional	_	_	I-Premise
256	surgery	_	_	I-Premise
257	,	_	_	I-Premise
258	or	_	_	I-Premise
259	hyphema	_	_	I-Premise
260	(	_	_	I-Premise
261	P=0.56	_	_	I-Premise
262	to	_	_	I-Premise
263	1.0	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	The	_	_	B-Claim
267	technique	_	_	I-Claim
268	of	_	_	I-Claim
269	releasable	_	_	I-Claim
270	sutures	_	_	I-Claim
271	for	_	_	I-Claim
272	trabeculectomy	_	_	I-Claim
273	used	_	_	I-Claim
274	in	_	_	I-Claim
275	this	_	_	I-Claim
276	study	_	_	I-Claim
277	did	_	_	I-Claim
278	not	_	_	I-Claim
279	demonstrate	_	_	I-Claim
280	significant	_	_	I-Claim
281	advantages	_	_	I-Claim
282	over	_	_	I-Claim
283	standard	_	_	I-Claim
284	trabeculectomy	_	_	I-Claim
285	.	_	_	I-Claim

286	Releasable	_	_	B-Claim
287	sutures	_	_	I-Claim
288	were	_	_	I-Claim
289	associated	_	_	I-Claim
290	with	_	_	I-Claim
291	some	_	_	I-Claim
292	decrease	_	_	I-Claim
293	in	_	_	I-Claim
294	visual	_	_	I-Claim
295	acuity	_	_	I-Claim
296	and	_	_	I-Claim
297	increase	_	_	I-Claim
298	in	_	_	I-Claim
299	postoperative	_	_	I-Claim
300	complaints	_	_	I-Claim
301	.	_	_	I-Claim


0	To	_	_	O
1	report	_	_	O
2	5-year	_	_	O
3	contrast-enhanced	_	_	O
4	magnetic	_	_	O
5	resonance	_	_	O
6	imaging	_	_	O
7	findings	_	_	O
8	of	_	_	O
9	the	_	_	O
10	REST	_	_	O
11	trial	_	_	O
12	recruits	_	_	O
13	who	_	_	O
14	underwent	_	_	O
15	either	_	_	O
16	uterine	_	_	O
17	artery	_	_	O
18	embolization	_	_	O
19	(	_	_	O
20	UAE	_	_	O
21	)	_	_	O
22	or	_	_	O
23	myomectomy	_	_	O
24	.	_	_	O

25	A	_	_	O
26	total	_	_	O
27	of	_	_	O
28	157	_	_	O
29	patients	_	_	O
30	were	_	_	O
31	randomized	_	_	O
32	to	_	_	O
33	UAE	_	_	O
34	or	_	_	O
35	surgery	_	_	O
36	(	_	_	O
37	hysterectomy	_	_	O
38	or	_	_	O
39	myomectomy	_	_	O
40	)	_	_	O
41	.	_	_	O

42	Ninety-nine	_	_	O
43	patients	_	_	O
44	who	_	_	O
45	had	_	_	O
46	UAE	_	_	O
47	and	_	_	O
48	eight	_	_	O
49	patients	_	_	O
50	who	_	_	O
51	had	_	_	O
52	myomectomy	_	_	O
53	were	_	_	O
54	analyzed	_	_	O
55	.	_	_	O

56	MRI	_	_	O
57	scans	_	_	O
58	at	_	_	O
59	baseline	_	_	O
60	,	_	_	O
61	6	_	_	O
62	months	_	_	O
63	,	_	_	O
64	and	_	_	O
65	5	_	_	O
66	years	_	_	O
67	were	_	_	O
68	independently	_	_	O
69	interpreted	_	_	O
70	by	_	_	O
71	two	_	_	O
72	radiologists	_	_	O
73	.	_	_	O

74	Dominant	_	_	O
75	fibroid	_	_	O
76	diameter	_	_	O
77	,	_	_	O
78	uterine	_	_	O
79	volume	_	_	O
80	,	_	_	O
81	total	_	_	O
82	fibroid	_	_	O
83	infarction	_	_	O
84	(	_	_	O
85	complete	_	_	O
86	100	_	_	O
87	%	_	_	O
88	,	_	_	O
89	almost	_	_	O
90	complete	_	_	O
91	90-99	_	_	O
92	%	_	_	O
93	,	_	_	O
94	partial	_	_	O
95	<	_	_	O
96	90	_	_	O
97	%	_	_	O
98	)	_	_	O
99	,	_	_	O
100	and	_	_	O
101	new	_	_	O
102	fibroid	_	_	O
103	formation	_	_	O
104	were	_	_	O
105	the	_	_	O
106	main	_	_	O
107	parameters	_	_	O
108	assessed	_	_	O
109	and	_	_	O
110	related	_	_	O
111	to	_	_	O
112	the	_	_	O
113	need	_	_	O
114	for	_	_	O
115	reintervention	_	_	O
116	.	_	_	O

117	In	_	_	B-Premise
118	the	_	_	I-Premise
119	UAE	_	_	I-Premise
120	group	_	_	I-Premise
121	,	_	_	I-Premise
122	mean	_	_	I-Premise
123	±	_	_	I-Premise
124	standard	_	_	I-Premise
125	deviation	_	_	I-Premise
126	uterine	_	_	I-Premise
127	volume	_	_	I-Premise
128	was	_	_	I-Premise
129	670	_	_	I-Premise
130	±	_	_	I-Premise
131	503	_	_	I-Premise
132	,	_	_	I-Premise
133	422	_	_	I-Premise
134	±	_	_	I-Premise
135	353	_	_	I-Premise
136	,	_	_	I-Premise
137	and	_	_	I-Premise
138	292	_	_	I-Premise
139	±	_	_	I-Premise
140	287	_	_	I-Premise
141	mL	_	_	I-Premise
142	at	_	_	I-Premise
143	baseline	_	_	I-Premise
144	,	_	_	I-Premise
145	6	_	_	I-Premise
146	months	_	_	I-Premise
147	,	_	_	I-Premise
148	and	_	_	I-Premise
149	5	_	_	I-Premise
150	years	_	_	I-Premise
151	,	_	_	I-Premise
152	respectively	_	_	I-Premise
153	.	_	_	I-Premise

154	Mean	_	_	B-Premise
155	dominant	_	_	I-Premise
156	fibroid	_	_	I-Premise
157	diameter	_	_	I-Premise
158	was	_	_	I-Premise
159	7.6	_	_	I-Premise
160	±	_	_	I-Premise
161	3.0	_	_	I-Premise
162	,	_	_	I-Premise
163	5.8	_	_	I-Premise
164	±	_	_	I-Premise
165	2.9	_	_	I-Premise
166	,	_	_	I-Premise
167	and	_	_	I-Premise
168	5	_	_	I-Premise
169	±	_	_	I-Premise
170	2.9	_	_	I-Premise
171	cm	_	_	I-Premise
172	at	_	_	I-Premise
173	baseline	_	_	I-Premise
174	,	_	_	I-Premise
175	6	_	_	I-Premise
176	months	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	5	_	_	I-Premise
180	years	_	_	I-Premise
181	.	_	_	I-Premise

182	Fibroid	_	_	B-Premise
183	infarction	_	_	I-Premise
184	at	_	_	I-Premise
185	6	_	_	I-Premise
186	months	_	_	I-Premise
187	was	_	_	I-Premise
188	complete	_	_	I-Premise
189	in	_	_	I-Premise
190	35	_	_	I-Premise
191	%	_	_	I-Premise
192	of	_	_	I-Premise
193	women	_	_	I-Premise
194	,	_	_	I-Premise
195	almost	_	_	I-Premise
196	complete	_	_	I-Premise
197	in	_	_	I-Premise
198	29	_	_	I-Premise
199	%	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	partial	_	_	I-Premise
203	in	_	_	I-Premise
204	36	_	_	I-Premise
205	%	_	_	I-Premise
206	.	_	_	I-Premise

207	Need	_	_	B-Premise
208	for	_	_	I-Premise
209	reintervention	_	_	I-Premise
210	was	_	_	I-Premise
211	19	_	_	I-Premise
212	,	_	_	I-Premise
213	10	_	_	I-Premise
214	,	_	_	I-Premise
215	and	_	_	I-Premise
216	33	_	_	I-Premise
217	%	_	_	I-Premise
218	in	_	_	I-Premise
219	these	_	_	I-Premise
220	groups	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	(	_	_	I-Premise
224	p	_	_	I-Premise
225	=	_	_	I-Premise
226	0.123	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	No	_	_	B-Premise
230	myomectomy	_	_	I-Premise
231	cases	_	_	I-Premise
232	had	_	_	I-Premise
233	further	_	_	I-Premise
234	intervention	_	_	I-Premise
235	.	_	_	I-Premise

236	At	_	_	B-Premise
237	5	_	_	I-Premise
238	years	_	_	I-Premise
239	,	_	_	I-Premise
240	the	_	_	I-Premise
241	prevalence	_	_	I-Premise
242	of	_	_	I-Premise
243	new	_	_	I-Premise
244	fibroid	_	_	I-Premise
245	was	_	_	I-Premise
246	60	_	_	I-Premise
247	%	_	_	I-Premise
248	in	_	_	I-Premise
249	the	_	_	I-Premise
250	myomectomy	_	_	I-Premise
251	group	_	_	I-Premise
252	and	_	_	I-Premise
253	7	_	_	I-Premise
254	%	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	UAE	_	_	I-Premise
258	group	_	_	I-Premise
259	(	_	_	I-Premise
260	p	_	_	I-Premise
261	=	_	_	I-Premise
262	0.008	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	There	_	_	B-Premise
266	is	_	_	I-Premise
267	a	_	_	I-Premise
268	further	_	_	I-Premise
269	significant	_	_	I-Premise
270	reduction	_	_	I-Premise
271	in	_	_	I-Premise
272	both	_	_	I-Premise
273	uterine	_	_	I-Premise
274	volume	_	_	I-Premise
275	and	_	_	I-Premise
276	dominant	_	_	I-Premise
277	fibroid	_	_	I-Premise
278	diameter	_	_	I-Premise
279	between	_	_	I-Premise
280	6	_	_	I-Premise
281	months	_	_	I-Premise
282	and	_	_	I-Premise
283	5	_	_	I-Premise
284	years	_	_	I-Premise
285	after	_	_	I-Premise
286	UAE	_	_	I-Premise
287	.	_	_	I-Premise

288	Complete	_	_	B-Claim
289	fibroid	_	_	I-Claim
290	infarction	_	_	I-Claim
291	does	_	_	I-Claim
292	not	_	_	I-Claim
293	translate	_	_	I-Claim
294	into	_	_	I-Claim
295	total	_	_	I-Claim
296	freedom	_	_	I-Claim
297	from	_	_	I-Claim
298	a	_	_	I-Claim
299	subsequent	_	_	I-Claim
300	reintervention	_	_	I-Claim
301	.	_	_	I-Claim

302	New	_	_	B-Claim
303	fibroid	_	_	I-Claim
304	formation	_	_	I-Claim
305	is	_	_	I-Claim
306	significantly	_	_	I-Claim
307	higher	_	_	I-Claim
308	after	_	_	I-Claim
309	myomectomy	_	_	I-Claim
310	.	_	_	I-Claim


0	Due	_	_	O
1	to	_	_	O
2	the	_	_	O
3	various	_	_	O
4	inter-individual	_	_	O
5	differences	_	_	O
6	in	_	_	O
7	the	_	_	O
8	biological	_	_	O
9	characteristics	_	_	O
10	of	_	_	O
11	tumor	_	_	O
12	cells	_	_	O
13	,	_	_	O
14	as	_	_	O
15	well	_	_	O
16	as	_	_	O
17	issues	_	_	O
18	on	_	_	O
19	the	_	_	O
20	efficacy	_	_	O
21	,	_	_	O
22	adverse	_	_	O
23	reactions	_	_	O
24	,	_	_	O
25	and	_	_	O
26	defects	_	_	O
27	of	_	_	O
28	existing	_	_	O
29	drugs	_	_	O
30	,	_	_	O
31	we	_	_	O
32	compared	_	_	O
33	the	_	_	O
34	clinical	_	_	O
35	efficacy	_	_	O
36	and	_	_	O
37	toxicity	_	_	O
38	of	_	_	O
39	pemetrexed	_	_	O
40	and	_	_	O
41	gemcitabine	_	_	O
42	combined	_	_	O
43	with	_	_	O
44	cisplatin	_	_	O
45	for	_	_	O
46	the	_	_	O
47	treatment	_	_	O
48	of	_	_	O
49	previously	_	_	O
50	untreated	_	_	O
51	advanced	_	_	O
52	non-small	_	_	O
53	cell	_	_	O
54	lung	_	_	O
55	cancer	_	_	O
56	(	_	_	O
57	NSCLC	_	_	O
58	)	_	_	O
59	.	_	_	O

60	251	_	_	O
61	patients	_	_	O
62	were	_	_	O
63	randomly	_	_	O
64	divided	_	_	O
65	into	_	_	O
66	pemetrexed	_	_	O
67	combined	_	_	O
68	with	_	_	O
69	cisplatin	_	_	O
70	group	_	_	O
71	(	_	_	O
72	PP	_	_	O
73	group	_	_	O
74	)	_	_	O
75	with	_	_	O
76	127	_	_	O
77	cases	_	_	O
78	and	_	_	O
79	gemcitabine	_	_	O
80	combined	_	_	O
81	with	_	_	O
82	cisplatin	_	_	O
83	group	_	_	O
84	(	_	_	O
85	GP	_	_	O
86	group	_	_	O
87	)	_	_	O
88	with	_	_	O
89	124	_	_	O
90	cases	_	_	O
91	.	_	_	O

92	PP	_	_	O
93	group	_	_	O
94	received	_	_	O
95	pemetrexed	_	_	O
96	500	_	_	O
97	mg/m²	_	_	O
98	iv	_	_	O
99	infusion	_	_	O
100	d1	_	_	O
101	and	_	_	O
102	cisplatin	_	_	O
103	75	_	_	O
104	mg/m²	_	_	O
105	iv	_	_	O
106	infusion	_	_	O
107	d1	_	_	O
108	,	_	_	O
109	whereas	_	_	O
110	GP	_	_	O
111	group	_	_	O
112	received	_	_	O
113	gemcitabine	_	_	O
114	1,000	_	_	O
115	mg/m²	_	_	O
116	iv	_	_	O
117	infusion	_	_	O
118	d1,8	_	_	O
119	and	_	_	O
120	cisplatin	_	_	O
121	75	_	_	O
122	mg/m²	_	_	O
123	iv	_	_	O
124	infusion	_	_	O
125	d1	_	_	O
126	.	_	_	O

127	The	_	_	O
128	treatment	_	_	O
129	cycle	_	_	O
130	was	_	_	O
131	once	_	_	O
132	every	_	_	O
133	three	_	_	O
134	weeks	_	_	O
135	.	_	_	O

136	In	_	_	O
137	addition	_	_	O
138	,	_	_	O
139	folic	_	_	O
140	acid	_	_	O
141	,	_	_	O
142	vitamin	_	_	O
143	B12	_	_	O
144	,	_	_	O
145	and	_	_	O
146	dexamethasone	_	_	O
147	were	_	_	O
148	administered	_	_	O
149	in	_	_	O
150	both	_	_	O
151	groups	_	_	O
152	.	_	_	O

153	The	_	_	B-Premise
154	total	_	_	I-Premise
155	clinical	_	_	I-Premise
156	effective	_	_	I-Premise
157	rates	_	_	I-Premise
158	in	_	_	I-Premise
159	PP	_	_	I-Premise
160	group	_	_	I-Premise
161	and	_	_	I-Premise
162	GP	_	_	I-Premise
163	group	_	_	I-Premise
164	were	_	_	I-Premise
165	25.20	_	_	I-Premise
166	%	_	_	I-Premise
167	and	_	_	I-Premise
168	17.74	_	_	I-Premise
169	%	_	_	I-Premise
170	,	_	_	I-Premise
171	respectively	_	_	I-Premise
172	.	_	_	I-Premise

173	The	_	_	B-Premise
174	total	_	_	I-Premise
175	efficiencies	_	_	I-Premise
176	of	_	_	I-Premise
177	non-squamous	_	_	I-Premise
178	cell	_	_	I-Premise
179	carcinoma	_	_	I-Premise
180	were	_	_	I-Premise
181	27.62	_	_	I-Premise
182	%	_	_	I-Premise
183	and	_	_	I-Premise
184	16.00	_	_	I-Premise
185	%	_	_	I-Premise
186	.	_	_	I-Premise

187	The	_	_	B-Premise
188	tumor	_	_	I-Premise
189	progression	_	_	I-Premise
190	duration	_	_	I-Premise
191	in	_	_	I-Premise
192	these	_	_	I-Premise
193	two	_	_	I-Premise
194	groups	_	_	I-Premise
195	was	_	_	I-Premise
196	6.5	_	_	I-Premise
197	and	_	_	I-Premise
198	5.6	_	_	I-Premise
199	months	_	_	I-Premise
200	,	_	_	I-Premise
201	respectively	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	median	_	_	I-Premise
205	survival	_	_	I-Premise
206	time	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	two	_	_	I-Premise
210	groups	_	_	I-Premise
211	was	_	_	I-Premise
212	16.9	_	_	I-Premise
213	and	_	_	I-Premise
214	17.0	_	_	I-Premise
215	months	_	_	I-Premise
216	,	_	_	I-Premise
217	respectively	_	_	I-Premise
218	,	_	_	I-Premise
219	with	_	_	I-Premise
220	59.62	_	_	I-Premise
221	%	_	_	I-Premise
222	and	_	_	I-Premise
223	65.87	_	_	I-Premise
224	%	_	_	I-Premise
225	survival	_	_	I-Premise
226	rates	_	_	I-Premise
227	of	_	_	I-Premise
228	1	_	_	I-Premise
229	year	_	_	I-Premise
230	and	_	_	I-Premise
231	27.28	_	_	I-Premise
232	%	_	_	I-Premise
233	and	_	_	I-Premise
234	27.93	_	_	I-Premise
235	%	_	_	I-Premise
236	survival	_	_	I-Premise
237	rates	_	_	I-Premise
238	of	_	_	I-Premise
239	2	_	_	I-Premise
240	years	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	total	_	_	I-Premise
246	efficacy	_	_	I-Premise
247	of	_	_	I-Premise
248	non-squamous	_	_	I-Premise
249	cell	_	_	I-Premise
250	carcinoma	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	PP	_	_	I-Premise
254	group	_	_	I-Premise
255	was	_	_	I-Premise
256	significantly	_	_	I-Premise
257	higher	_	_	I-Premise
258	than	_	_	I-Premise
259	that	_	_	I-Premise
260	in	_	_	I-Premise
261	GP	_	_	I-Premise
262	group	_	_	I-Premise
263	.	_	_	I-Premise

264	The	_	_	B-Premise
265	results	_	_	I-Premise
266	were	_	_	I-Premise
267	statistically	_	_	I-Premise
268	significant	_	_	I-Premise
269	.	_	_	I-Premise

270	However	_	_	O
271	,	_	_	O
272	there	_	_	O
273	were	_	_	O
274	no	_	_	O
275	significant	_	_	O
276	differences	_	_	O
277	in	_	_	O
278	total	_	_	O
279	response	_	_	O
280	rates	_	_	O
281	,	_	_	O
282	tumor	_	_	O
283	progression	_	_	O
284	duration	_	_	O
285	,	_	_	O
286	and	_	_	O
287	median	_	_	O
288	survival	_	_	O
289	rates	_	_	O
290	of	_	_	O
291	1	_	_	O
292	and	_	_	O
293	2	_	_	O
294	years	_	_	O
295	.	_	_	O

296	The	_	_	B-Premise
297	rate	_	_	I-Premise
298	of	_	_	I-Premise
299	adverse	_	_	I-Premise
300	reactions	_	_	I-Premise
301	,	_	_	I-Premise
302	including	_	_	I-Premise
303	white	_	_	I-Premise
304	blood	_	_	I-Premise
305	cell	_	_	I-Premise
306	reduction	_	_	I-Premise
307	,	_	_	I-Premise
308	lower	_	_	I-Premise
309	platelet	_	_	I-Premise
310	count	_	_	I-Premise
311	,	_	_	I-Premise
312	lower	_	_	I-Premise
313	hemoglobin	_	_	I-Premise
314	,	_	_	I-Premise
315	and	_	_	I-Premise
316	hair	_	_	I-Premise
317	loss	_	_	I-Premise
318	in	_	_	I-Premise
319	the	_	_	I-Premise
320	PP	_	_	I-Premise
321	group	_	_	I-Premise
322	was	_	_	I-Premise
323	significantly	_	_	I-Premise
324	lower	_	_	I-Premise
325	than	_	_	I-Premise
326	that	_	_	I-Premise
327	in	_	_	I-Premise
328	the	_	_	I-Premise
329	GP	_	_	I-Premise
330	group	_	_	I-Premise
331	.	_	_	I-Premise

332	The	_	_	B-Premise
333	results	_	_	I-Premise
334	were	_	_	I-Premise
335	statistically	_	_	I-Premise
336	significant	_	_	I-Premise
337	.	_	_	I-Premise

338	The	_	_	B-Claim
339	clinical	_	_	I-Claim
340	efficacy	_	_	I-Claim
341	of	_	_	I-Claim
342	pemetrexed	_	_	I-Claim
343	and	_	_	I-Claim
344	gemcitabine	_	_	I-Claim
345	combined	_	_	I-Claim
346	with	_	_	I-Claim
347	cisplatin	_	_	I-Claim
348	for	_	_	I-Claim
349	the	_	_	I-Claim
350	treatment	_	_	I-Claim
351	of	_	_	I-Claim
352	previously	_	_	I-Claim
353	untreated	_	_	I-Claim
354	advanced	_	_	I-Claim
355	NSCLC	_	_	I-Claim
356	was	_	_	I-Claim
357	roughly	_	_	I-Claim
358	the	_	_	I-Claim
359	same	_	_	I-Claim
360	,	_	_	I-Claim
361	but	_	_	B-Claim
362	the	_	_	I-Claim
363	adverse	_	_	I-Claim
364	reactions	_	_	I-Claim
365	decreased	_	_	I-Claim
366	significantly	_	_	I-Claim
367	in	_	_	I-Claim
368	the	_	_	I-Claim
369	PP	_	_	I-Claim
370	group	_	_	I-Claim
371	compared	_	_	I-Claim
372	with	_	_	I-Claim
373	those	_	_	I-Claim
374	in	_	_	I-Claim
375	the	_	_	I-Claim
376	GP	_	_	I-Claim
377	group	_	_	I-Claim
378	.	_	_	I-Claim

379	Therefore	_	_	B-Claim
380	,	_	_	I-Claim
381	pemetrexed	_	_	I-Claim
382	combined	_	_	I-Claim
383	with	_	_	I-Claim
384	cisplatin	_	_	I-Claim
385	can	_	_	I-Claim
386	be	_	_	I-Claim
387	used	_	_	I-Claim
388	as	_	_	I-Claim
389	a	_	_	I-Claim
390	safe	_	_	I-Claim
391	and	_	_	I-Claim
392	effective	_	_	I-Claim
393	drug	_	_	I-Claim
394	for	_	_	I-Claim
395	clinical	_	_	I-Claim
396	first-line	_	_	I-Claim
397	treatment	_	_	I-Claim
398	for	_	_	I-Claim
399	previously	_	_	I-Claim
400	untreated	_	_	I-Claim
401	NSCLC	_	_	I-Claim
402	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	assess	_	_	O
4	the	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	acupuncture	_	_	O
8	for	_	_	O
9	cancer-related	_	_	O
10	fatigue	_	_	O
11	(	_	_	O
12	CRF	_	_	O
13	)	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	breast	_	_	O
18	cancer	_	_	O
19	.	_	_	O

20	We	_	_	O
21	conducted	_	_	O
22	a	_	_	O
23	pragmatic	_	_	O
24	,	_	_	O
25	randomized	_	_	O
26	controlled	_	_	O
27	trial	_	_	O
28	comparing	_	_	O
29	acupuncture	_	_	O
30	with	_	_	O
31	enhanced	_	_	O
32	usual	_	_	O
33	care	_	_	O
34	.	_	_	O

35	Three	_	_	O
36	hundred	_	_	O
37	two	_	_	O
38	outpatients	_	_	O
39	with	_	_	O
40	breast	_	_	O
41	cancer	_	_	O
42	participated	_	_	O
43	.	_	_	O

44	We	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	75	_	_	O
48	patients	_	_	O
49	to	_	_	O
50	usual	_	_	O
51	care	_	_	O
52	and	_	_	O
53	227	_	_	O
54	patients	_	_	O
55	to	_	_	O
56	acupuncture	_	_	O
57	plus	_	_	O
58	usual	_	_	O
59	care	_	_	O
60	(	_	_	O
61	random	_	_	O
62	assignment	_	_	O
63	of	_	_	O
64	1:3	_	_	O
65	respectively	_	_	O
66	)	_	_	O
67	with	_	_	O
68	minimization	_	_	O
69	controlling	_	_	O
70	for	_	_	O
71	baseline	_	_	O
72	general	_	_	O
73	fatigue	_	_	O
74	and	_	_	O
75	maintenance	_	_	O
76	treatment	_	_	O
77	.	_	_	O

78	Treatment	_	_	O
79	was	_	_	O
80	delivered	_	_	O
81	by	_	_	O
82	acupuncturists	_	_	O
83	once	_	_	O
84	a	_	_	O
85	week	_	_	O
86	for	_	_	O
87	6	_	_	O
88	weeks	_	_	O
89	through	_	_	O
90	needling	_	_	O
91	three	_	_	O
92	pairs	_	_	O
93	of	_	_	O
94	acupoints	_	_	O
95	.	_	_	O

96	The	_	_	O
97	usual	_	_	O
98	care	_	_	O
99	group	_	_	O
100	received	_	_	O
101	a	_	_	O
102	booklet	_	_	O
103	with	_	_	O
104	information	_	_	O
105	about	_	_	O
106	fatigue	_	_	O
107	and	_	_	O
108	its	_	_	O
109	management	_	_	O
110	.	_	_	O

111	Primary	_	_	O
112	outcome	_	_	O
113	was	_	_	O
114	general	_	_	O
115	fatigue	_	_	O
116	at	_	_	O
117	6	_	_	O
118	weeks	_	_	O
119	,	_	_	O
120	measured	_	_	O
121	with	_	_	O
122	the	_	_	O
123	Multidimensional	_	_	O
124	Fatigue	_	_	O
125	Inventory	_	_	O
126	(	_	_	O
127	MFI	_	_	O
128	)	_	_	O
129	.	_	_	O

130	Other	_	_	O
131	measurements	_	_	O
132	included	_	_	O
133	the	_	_	O
134	Hospital	_	_	O
135	Anxiety	_	_	O
136	and	_	_	O
137	Depression	_	_	O
138	Scale	_	_	O
139	,	_	_	O
140	Functional	_	_	O
141	Assessment	_	_	O
142	of	_	_	O
143	Cancer	_	_	O
144	Therapy-General	_	_	O
145	quality-of-life	_	_	O
146	scale	_	_	O
147	,	_	_	O
148	and	_	_	O
149	expectation	_	_	O
150	of	_	_	O
151	acupuncture	_	_	O
152	effect	_	_	O
153	.	_	_	O

154	Analyses	_	_	O
155	were	_	_	O
156	by	_	_	O
157	intention	_	_	O
158	to	_	_	O
159	treat	_	_	O
160	.	_	_	O

161	Two	_	_	O
162	hundred	_	_	O
163	forty-six	_	_	O
164	of	_	_	O
165	302	_	_	O
166	patients	_	_	O
167	randomly	_	_	O
168	assigned	_	_	O
169	provided	_	_	O
170	complete	_	_	O
171	data	_	_	O
172	at	_	_	O
173	6	_	_	O
174	weeks	_	_	O
175	.	_	_	O

176	The	_	_	B-Premise
177	difference	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	mean	_	_	I-Premise
181	General	_	_	I-Premise
182	Fatigue	_	_	I-Premise
183	score	_	_	I-Premise
184	,	_	_	I-Premise
185	between	_	_	I-Premise
186	those	_	_	I-Premise
187	who	_	_	I-Premise
188	received	_	_	I-Premise
189	the	_	_	I-Premise
190	intervention	_	_	I-Premise
191	and	_	_	I-Premise
192	those	_	_	I-Premise
193	who	_	_	I-Premise
194	did	_	_	I-Premise
195	not	_	_	I-Premise
196	,	_	_	I-Premise
197	was	_	_	I-Premise
198	-3.11	_	_	I-Premise
199	(	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	CI	_	_	I-Premise
203	,	_	_	I-Premise
204	-3.97	_	_	I-Premise
205	to	_	_	I-Premise
206	-2.25	_	_	I-Premise
207	;	_	_	I-Premise
208	P	_	_	I-Premise
209	<	_	_	I-Premise
210	.001	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	intervention	_	_	I-Premise
215	also	_	_	I-Premise
216	improved	_	_	I-Premise
217	all	_	_	I-Premise
218	other	_	_	I-Premise
219	fatigue	_	_	I-Premise
220	aspects	_	_	I-Premise
221	measured	_	_	I-Premise
222	by	_	_	I-Premise
223	MFI	_	_	I-Premise
224	,	_	_	I-Premise
225	including	_	_	I-Premise
226	Physical	_	_	I-Premise
227	Fatigue	_	_	I-Premise
228	and	_	_	I-Premise
229	Mental	_	_	I-Premise
230	Fatigue	_	_	I-Premise
231	(	_	_	I-Premise
232	acupuncture	_	_	I-Premise
233	effect	_	_	I-Premise
234	,	_	_	I-Premise
235	-2.36	_	_	I-Premise
236	and	_	_	I-Premise
237	-1.94	_	_	I-Premise
238	,	_	_	I-Premise
239	respectively	_	_	I-Premise
240	;	_	_	I-Premise
241	both	_	_	I-Premise
242	at	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	.001	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	anxiety	_	_	I-Premise
249	and	_	_	I-Premise
250	depression	_	_	I-Premise
251	(	_	_	I-Premise
252	acupuncture	_	_	I-Premise
253	effect	_	_	I-Premise
254	,	_	_	I-Premise
255	-1.83	_	_	I-Premise
256	and	_	_	I-Premise
257	-2.13	_	_	I-Premise
258	,	_	_	I-Premise
259	respectively	_	_	I-Premise
260	;	_	_	I-Premise
261	both	_	_	I-Premise
262	at	_	_	I-Premise
263	P	_	_	I-Premise
264	<	_	_	I-Premise
265	.001	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	quality	_	_	I-Premise
270	of	_	_	I-Premise
271	life	_	_	I-Premise
272	(	_	_	I-Premise
273	Physical	_	_	I-Premise
274	Well-Being	_	_	I-Premise
275	effect	_	_	I-Premise
276	,	_	_	I-Premise
277	3.30	_	_	I-Premise
278	;	_	_	I-Premise
279	Functional	_	_	I-Premise
280	Well-Being	_	_	I-Premise
281	effect	_	_	I-Premise
282	,	_	_	I-Premise
283	3.57	_	_	I-Premise
284	;	_	_	I-Premise
285	both	_	_	I-Premise
286	at	_	_	I-Premise
287	P	_	_	I-Premise
288	<	_	_	I-Premise
289	.001	_	_	I-Premise
290	;	_	_	I-Premise
291	Emotional	_	_	I-Premise
292	Well-Being	_	_	I-Premise
293	effect	_	_	I-Premise
294	,	_	_	I-Premise
295	1.93	_	_	I-Premise
296	;	_	_	I-Premise
297	P	_	_	I-Premise
298	=	_	_	I-Premise
299	.001	_	_	I-Premise
300	;	_	_	I-Premise
301	and	_	_	I-Premise
302	Social	_	_	I-Premise
303	Functioning	_	_	I-Premise
304	Well-Being	_	_	I-Premise
305	effect	_	_	I-Premise
306	,	_	_	I-Premise
307	1.05	_	_	I-Premise
308	;	_	_	I-Premise
309	P	_	_	I-Premise
310	<	_	_	I-Premise
311	.05	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	Acupuncture	_	_	B-Claim
315	is	_	_	I-Claim
316	an	_	_	I-Claim
317	effective	_	_	I-Claim
318	intervention	_	_	I-Claim
319	for	_	_	I-Claim
320	managing	_	_	I-Claim
321	the	_	_	I-Claim
322	symptom	_	_	I-Claim
323	of	_	_	I-Claim
324	CRF	_	_	I-Claim
325	and	_	_	I-Claim
326	improving	_	_	I-Claim
327	patients	_	_	I-Claim
328	'	_	_	I-Claim
329	quality	_	_	I-Claim
330	of	_	_	I-Claim
331	life	_	_	I-Claim
332	.	_	_	I-Claim


0	﻿	_	_	O
1	To	_	_	O
2	compare	_	_	O
3	efficacy	_	_	O
4	(	_	_	O
5	intraocular	_	_	O
6	pressure	_	_	O
7	(	_	_	O
8	IOP	_	_	O
9	)	_	_	O
10	reduction	_	_	O
11	)	_	_	O
12	and	_	_	O
13	safety	_	_	O
14	of	_	_	O
15	preservative-free	_	_	O
16	latanoprost	_	_	O
17	(	_	_	O
18	T2345	_	_	O
19	)	_	_	O
20	to	_	_	O
21	benzalkonium	_	_	O
22	chloride	_	_	O
23	(	_	_	O
24	BAK	_	_	O
25	)	_	_	O
26	-preserved	_	_	O
27	latanoprost	_	_	O
28	(	_	_	O
29	BPL	_	_	O
30	;	_	_	O
31	Xalatan	_	_	O
32	)	_	_	O
33	in	_	_	O
34	ocular	_	_	O
35	hypertension	_	_	O
36	(	_	_	O
37	OHT	_	_	O
38	)	_	_	O
39	or	_	_	O
40	primary	_	_	O
41	open	_	_	O
42	angle	_	_	O
43	glaucoma	_	_	O
44	(	_	_	O
45	POAG	_	_	O
46	)	_	_	O
47	patients	_	_	O
48	.	_	_	O

49	Prospective	_	_	O
50	,	_	_	O
51	international	_	_	O
52	,	_	_	O
53	multicentre	_	_	O
54	,	_	_	O
55	randomised	_	_	O
56	,	_	_	O
57	investigator-masked	_	_	O
58	,	_	_	O
59	parallel-group	_	_	O
60	trial	_	_	O
61	.	_	_	O

62	After	_	_	O
63	a	_	_	O
64	wash-out	_	_	O
65	period	_	_	O
66	,	_	_	O
67	POAG	_	_	O
68	or	_	_	O
69	OHT	_	_	O
70	patients	_	_	O
71	,	_	_	O
72	previously	_	_	O
73	managed	_	_	O
74	by	_	_	O
75	BPL	_	_	O
76	monotherapy	_	_	O
77	,	_	_	O
78	randomly	_	_	O
79	received	_	_	O
80	T2345	_	_	O
81	or	_	_	O
82	BPL	_	_	O
83	(	_	_	O
84	one	_	_	O
85	drop	_	_	O
86	into	_	_	O
87	the	_	_	O
88	affected	_	_	O
89	eye	_	_	O
90	(	_	_	O
91	s	_	_	O
92	)	_	_	O
93	)	_	_	O
94	once	_	_	O
95	daily	_	_	O
96	from	_	_	O
97	D0	_	_	O
98	to	_	_	O
99	D84	_	_	O
100	.	_	_	O

101	Change	_	_	O
102	in	_	_	O
103	IOP	_	_	O
104	was	_	_	O
105	measured	_	_	O
106	at	_	_	O
107	09:00	_	_	O
108	(	_	_	O
109	±1	_	_	O
110	h	_	_	O
111	)	_	_	O
112	from	_	_	O
113	D0	_	_	O
114	to	_	_	O
115	D84	_	_	O
116	in	_	_	O
117	the	_	_	O
118	worse	_	_	O
119	eye	_	_	O
120	.	_	_	O

121	Mean	_	_	B-Premise
122	IOP	_	_	I-Premise
123	reduction	_	_	I-Premise
124	(	_	_	I-Premise
125	D0-D84	_	_	I-Premise
126	)	_	_	I-Premise
127	was	_	_	I-Premise
128	-8.6	_	_	I-Premise
129	±2.6	_	_	I-Premise
130	mm	_	_	I-Premise
131	Hg	_	_	I-Premise
132	(	_	_	I-Premise
133	-36	_	_	I-Premise
134	%	_	_	I-Premise
135	)	_	_	I-Premise
136	on	_	_	I-Premise
137	T2345	_	_	I-Premise
138	and	_	_	I-Premise
139	-9.0	_	_	I-Premise
140	±2.4	_	_	I-Premise
141	mm	_	_	I-Premise
142	Hg	_	_	I-Premise
143	(	_	_	I-Premise
144	-38	_	_	I-Premise
145	%	_	_	I-Premise
146	)	_	_	I-Premise
147	on	_	_	I-Premise
148	BPL	_	_	I-Premise
149	,	_	_	I-Premise
150	confirming	_	_	I-Premise
151	non-inferiority	_	_	I-Premise
152	of	_	_	I-Premise
153	T2345	_	_	I-Premise
154	to	_	_	I-Premise
155	BPL	_	_	I-Premise
156	.	_	_	I-Premise

157	Non-inferiority	_	_	O
158	of	_	_	O
159	T2345	_	_	O
160	was	_	_	O
161	observed	_	_	O
162	from	_	_	O
163	D15	_	_	O
164	.	_	_	O

165	The	_	_	B-Premise
166	most	_	_	I-Premise
167	frequent	_	_	I-Premise
168	ocular	_	_	I-Premise
169	adverse	_	_	I-Premise
170	event	_	_	I-Premise
171	,	_	_	I-Premise
172	drug	_	_	I-Premise
173	intolerance	_	_	I-Premise
174	,	_	_	I-Premise
175	was	_	_	I-Premise
176	reported	_	_	I-Premise
177	in	_	_	I-Premise
178	1	_	_	I-Premise
179	(	_	_	I-Premise
180	0.5	_	_	I-Premise
181	%	_	_	I-Premise
182	)	_	_	I-Premise
183	patient	_	_	I-Premise
184	on	_	_	I-Premise
185	T2345	_	_	I-Premise
186	versus	_	_	I-Premise
187	4	_	_	I-Premise
188	(	_	_	I-Premise
189	2.1	_	_	I-Premise
190	%	_	_	I-Premise
191	)	_	_	I-Premise
192	patients	_	_	I-Premise
193	on	_	_	I-Premise
194	BPL	_	_	I-Premise
195	.	_	_	I-Premise

196	Moderate	_	_	B-Premise
197	to	_	_	I-Premise
198	severe	_	_	I-Premise
199	conjunctival	_	_	I-Premise
200	hyperaemia	_	_	I-Premise
201	was	_	_	I-Premise
202	less	_	_	I-Premise
203	frequent	_	_	I-Premise
204	on	_	_	I-Premise
205	T2345	_	_	I-Premise
206	than	_	_	I-Premise
207	on	_	_	I-Premise
208	BPL	_	_	I-Premise
209	at	_	_	I-Premise
210	D42	_	_	I-Premise
211	(	_	_	I-Premise
212	20.2	_	_	I-Premise
213	%	_	_	I-Premise
214	vs	_	_	I-Premise
215	30.6	_	_	I-Premise
216	%	_	_	I-Premise
217	;	_	_	I-Premise
218	p=0.003	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	D84	_	_	I-Premise
222	(	_	_	I-Premise
223	21.4	_	_	I-Premise
224	%	_	_	I-Premise
225	vs	_	_	I-Premise
226	29.1	_	_	I-Premise
227	%	_	_	I-Premise
228	;	_	_	I-Premise
229	p=0.02	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Upon	_	_	B-Premise
233	instillation	_	_	I-Premise
234	,	_	_	I-Premise
235	the	_	_	I-Premise
236	global	_	_	I-Premise
237	subjective	_	_	I-Premise
238	ocular	_	_	I-Premise
239	symptom	_	_	I-Premise
240	score	_	_	I-Premise
241	was	_	_	I-Premise
242	significantly	_	_	I-Premise
243	lower	_	_	I-Premise
244	on	_	_	I-Premise
245	T2345	_	_	I-Premise
246	than	_	_	I-Premise
247	BPL	_	_	I-Premise
248	on	_	_	I-Premise
249	D42	_	_	I-Premise
250	(	_	_	I-Premise
251	0.15	_	_	I-Premise
252	vs	_	_	I-Premise
253	0.41	_	_	I-Premise
254	;	_	_	I-Premise
255	p=0.001	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	D84	_	_	I-Premise
259	(	_	_	I-Premise
260	0.18	_	_	I-Premise
261	vs	_	_	I-Premise
262	0.46	_	_	I-Premise
263	;	_	_	I-Premise
264	p=0.001	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Preservative-free	_	_	B-Claim
268	latanoprost	_	_	I-Claim
269	has	_	_	I-Claim
270	the	_	_	I-Claim
271	same	_	_	I-Claim
272	efficacy	_	_	I-Claim
273	as	_	_	I-Claim
274	BPL	_	_	I-Claim
275	,	_	_	I-Claim
276	with	_	_	I-Claim
277	improved	_	_	I-Claim
278	local	_	_	I-Claim
279	tolerance	_	_	I-Claim
280	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	blinded	_	_	O
5	,	_	_	O
6	randomized	_	_	O
7	clinical	_	_	O
8	trial	_	_	O
9	was	_	_	O
10	to	_	_	O
11	compare	_	_	O
12	two	_	_	O
13	topical	_	_	O
14	agents	_	_	O
15	(	_	_	O
16	Calendula	_	_	O
17	Weleda	_	_	O
18	cream	_	_	O
19	vs.	_	_	O
20	Essex	_	_	O
21	cream	_	_	O
22	)	_	_	O
23	in	_	_	O
24	reducing	_	_	O
25	the	_	_	O
26	risk	_	_	O
27	of	_	_	O
28	severe	_	_	O
29	acute	_	_	O
30	radiation	_	_	O
31	skin	_	_	O
32	reactions	_	_	O
33	(	_	_	O
34	ARSR	_	_	O
35	)	_	_	O
36	in	_	_	O
37	relation	_	_	O
38	to	_	_	O
39	adjuvant	_	_	O
40	radiotherapy	_	_	O
41	(	_	_	O
42	RT	_	_	O
43	)	_	_	O
44	for	_	_	O
45	breast	_	_	O
46	cancer	_	_	O
47	.	_	_	O

48	The	_	_	O
49	primary	_	_	O
50	endpoint	_	_	O
51	was	_	_	O
52	the	_	_	O
53	difference	_	_	O
54	in	_	_	O
55	proportion	_	_	O
56	of	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	ARSR	_	_	O
60	,	_	_	O
61	assessed	_	_	O
62	with	_	_	O
63	the	_	_	O
64	Radiation	_	_	O
65	Therapy	_	_	O
66	Oncology	_	_	O
67	Group/The	_	_	O
68	Organization	_	_	O
69	for	_	_	O
70	Research	_	_	O
71	and	_	_	O
72	Treatment	_	_	O
73	of	_	_	O
74	Cancer	_	_	O
75	Acute	_	_	O
76	Radiation	_	_	O
77	Morbidity	_	_	O
78	Scoring	_	_	O
79	Criteria	_	_	O
80	(	_	_	O
81	RTOG/EORTC	_	_	O
82	scale	_	_	O
83	)	_	_	O
84	at	_	_	O
85	follow-up	_	_	O
86	.	_	_	O

87	The	_	_	O
88	secondary	_	_	O
89	endpoints	_	_	O
90	included	_	_	O
91	patient	_	_	O
92	reported	_	_	O
93	outcome	_	_	O
94	measures	_	_	O
95	;	_	_	O
96	Quality	_	_	O
97	of	_	_	O
98	Life	_	_	O
99	Questionnaire	_	_	O
100	(	_	_	O
101	QLQ-C30	_	_	O
102	)	_	_	O
103	,	_	_	O
104	Sleep	_	_	O
105	disturbances	_	_	O
106	(	_	_	O
107	MOS-sleep	_	_	O
108	questionnaire	_	_	O
109	)	_	_	O
110	and	_	_	O
111	symptoms	_	_	O
112	from	_	_	O
113	the	_	_	O
114	irradiated	_	_	O
115	area	_	_	O
116	(	_	_	O
117	visual	_	_	O
118	analogue	_	_	O
119	scale	_	_	O
120	)	_	_	O
121	.	_	_	O

122	Patients	_	_	O
123	'	_	_	O
124	experiences	_	_	O
125	and	_	_	O
126	adherence	_	_	O
127	to	_	_	O
128	the	_	_	O
129	topical	_	_	O
130	agents	_	_	O
131	were	_	_	O
132	also	_	_	O
133	evaluated	_	_	O
134	.	_	_	O

135	A	_	_	O
136	total	_	_	O
137	of	_	_	O
138	420	_	_	O
139	patients	_	_	O
140	were	_	_	O
141	randomised	_	_	O
142	and	_	_	O
143	411	_	_	O
144	were	_	_	O
145	analysed	_	_	O
146	.	_	_	O

147	With	_	_	O
148	the	_	_	O
149	exception	_	_	O
150	of	_	_	O
151	previous	_	_	O
152	chemotherapy	_	_	O
153	,	_	_	O
154	the	_	_	O
155	treatment	_	_	O
156	groups	_	_	O
157	were	_	_	O
158	well	_	_	O
159	balanced	_	_	O
160	,	_	_	O
161	both	_	_	O
162	regarding	_	_	O
163	treatment-	_	_	O
164	and	_	_	O
165	patient-related	_	_	O
166	factors	_	_	O
167	.	_	_	O

168	The	_	_	B-Premise
169	incidence	_	_	I-Premise
170	of	_	_	I-Premise
171	severe	_	_	I-Premise
172	ARSR	_	_	I-Premise
173	(	_	_	I-Premise
174	RTOG/EORTC	_	_	I-Premise
175	grade	_	_	I-Premise
176	≤2	_	_	I-Premise
177	)	_	_	I-Premise
178	at	_	_	I-Premise
179	the	_	_	I-Premise
180	follow-up	_	_	I-Premise
181	visit	_	_	I-Premise
182	was	_	_	I-Premise
183	23	_	_	I-Premise
184	%	_	_	I-Premise
185	(	_	_	I-Premise
186	n	_	_	I-Premise
187	=	_	_	I-Premise
188	45	_	_	I-Premise
189	)	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	Calendula	_	_	I-Premise
193	group	_	_	I-Premise
194	and	_	_	I-Premise
195	19	_	_	I-Premise
196	%	_	_	I-Premise
197	(	_	_	I-Premise
198	n	_	_	I-Premise
199	=	_	_	I-Premise
200	38	_	_	I-Premise
201	)	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	Essex	_	_	I-Premise
205	group	_	_	I-Premise
206	.	_	_	I-Premise

207	We	_	_	B-Premise
208	found	_	_	I-Premise
209	no	_	_	I-Premise
210	difference	_	_	I-Premise
211	in	_	_	I-Premise
212	severe	_	_	I-Premise
213	ARSR	_	_	I-Premise
214	between	_	_	I-Premise
215	the	_	_	I-Premise
216	groups	_	_	I-Premise
217	at	_	_	I-Premise
218	any	_	_	I-Premise
219	point	_	_	I-Premise
220	of	_	_	I-Premise
221	assessment	_	_	I-Premise
222	.	_	_	I-Premise

223	The	_	_	B-Premise
224	patients	_	_	I-Premise
225	reported	_	_	I-Premise
226	low	_	_	I-Premise
227	levels	_	_	I-Premise
228	of	_	_	I-Premise
229	skin	_	_	I-Premise
230	related	_	_	I-Premise
231	symptoms	_	_	I-Premise
232	and	_	_	I-Premise
233	no	_	_	I-Premise
234	statistically	_	_	I-Premise
235	significant	_	_	I-Premise
236	differences	_	_	I-Premise
237	between	_	_	I-Premise
238	the	_	_	I-Premise
239	groups	_	_	I-Premise
240	were	_	_	I-Premise
241	found	_	_	I-Premise
242	.	_	_	I-Premise

243	No	_	_	B-Claim
244	differences	_	_	I-Claim
245	in	_	_	I-Claim
246	ARSR	_	_	I-Claim
247	between	_	_	I-Claim
248	patients	_	_	I-Claim
249	randomised	_	_	I-Claim
250	to	_	_	I-Claim
251	Calendula	_	_	I-Claim
252	or	_	_	I-Claim
253	Essex	_	_	I-Claim
254	cream	_	_	I-Claim
255	was	_	_	I-Claim
256	found	_	_	I-Claim
257	.	_	_	I-Claim

258	ARSR	_	_	B-Claim
259	seem	_	_	I-Claim
260	to	_	_	I-Claim
261	be	_	_	I-Claim
262	a	_	_	I-Claim
263	relatively	_	_	I-Claim
264	limited	_	_	I-Claim
265	problem	_	_	I-Claim
266	,	_	_	I-Claim
267	probably	_	_	I-Claim
268	more	_	_	I-Claim
269	influenced	_	_	I-Claim
270	by	_	_	I-Claim
271	treatment	_	_	I-Claim
272	related	_	_	I-Claim
273	factors	_	_	I-Claim
274	than	_	_	I-Claim
275	by	_	_	I-Claim
276	choice	_	_	I-Claim
277	of	_	_	I-Claim
278	skin	_	_	I-Claim
279	care	_	_	I-Claim
280	products	_	_	I-Claim
281	in	_	_	I-Claim
282	this	_	_	I-Claim
283	patient	_	_	I-Claim
284	group	_	_	I-Claim
285	.	_	_	I-Claim


0	With	_	_	O
1	the	_	_	O
2	adoption	_	_	O
3	of	_	_	O
4	enhanced	_	_	O
5	recovery	_	_	O
6	and	_	_	O
7	emerging	_	_	O
8	new	_	_	O
9	modalities	_	_	O
10	of	_	_	O
11	analgesia	_	_	O
12	after	_	_	O
13	laparoscopic	_	_	O
14	colorectal	_	_	O
15	resection	_	_	O
16	(	_	_	O
17	LCR	_	_	O
18	)	_	_	O
19	,	_	_	O
20	the	_	_	O
21	role	_	_	O
22	of	_	_	O
23	epidural	_	_	O
24	analgesia	_	_	O
25	has	_	_	O
26	been	_	_	O
27	questioned	_	_	O
28	.	_	_	O

29	This	_	_	O
30	pilot	_	_	O
31	trial	_	_	O
32	assessed	_	_	O
33	the	_	_	O
34	feasibility	_	_	O
35	of	_	_	O
36	a	_	_	O
37	randomized	_	_	O
38	controlled	_	_	O
39	trial	_	_	O
40	(	_	_	O
41	RCT	_	_	O
42	)	_	_	O
43	comparing	_	_	O
44	epidural	_	_	O
45	analgesia	_	_	O
46	and	_	_	O
47	use	_	_	O
48	of	_	_	O
49	a	_	_	O
50	local	_	_	O
51	anaesthetic	_	_	O
52	wound	_	_	O
53	infusion	_	_	O
54	catheter	_	_	O
55	(	_	_	O
56	WIC	_	_	O
57	)	_	_	O
58	following	_	_	O
59	LCR	_	_	O
60	.	_	_	O

61	Between	_	_	O
62	April	_	_	O
63	2010	_	_	O
64	and	_	_	O
65	May	_	_	O
66	2011	_	_	O
67	,	_	_	O
68	patients	_	_	O
69	undergoing	_	_	O
70	elective	_	_	O
71	LCR	_	_	O
72	in	_	_	O
73	two	_	_	O
74	centres	_	_	O
75	were	_	_	O
76	randomized	_	_	O
77	to	_	_	O
78	analgesia	_	_	O
79	via	_	_	O
80	epidural	_	_	O
81	or	_	_	O
82	WIC	_	_	O
83	.	_	_	O

84	Sham	_	_	O
85	procedures	_	_	O
86	were	_	_	O
87	used	_	_	O
88	to	_	_	O
89	blind	_	_	O
90	surgeons	_	_	O
91	,	_	_	O
92	patients	_	_	O
93	and	_	_	O
94	outcome	_	_	O
95	assessors	_	_	O
96	.	_	_	O

97	The	_	_	O
98	primary	_	_	O
99	outcome	_	_	O
100	was	_	_	O
101	the	_	_	O
102	feasibility	_	_	O
103	of	_	_	O
104	a	_	_	O
105	large	_	_	O
106	RCT	_	_	O
107	,	_	_	O
108	and	_	_	O
109	all	_	_	O
110	outcomes	_	_	O
111	for	_	_	O
112	a	_	_	O
113	definitive	_	_	O
114	trial	_	_	O
115	were	_	_	O
116	tested	_	_	O
117	.	_	_	O

118	The	_	_	O
119	success	_	_	O
120	of	_	_	O
121	blinding	_	_	O
122	was	_	_	O
123	assessed	_	_	O
124	using	_	_	O
125	a	_	_	O
126	mixed-methods	_	_	O
127	approach	_	_	O
128	.	_	_	O

129	Forty-five	_	_	O
130	patients	_	_	O
131	were	_	_	O
132	eligible	_	_	O
133	,	_	_	O
134	of	_	_	O
135	whom	_	_	O
136	34	_	_	O
137	were	_	_	O
138	randomized	_	_	O
139	(	_	_	O
140	mean	_	_	O
141	(	_	_	O
142	s.d	_	_	O
143	.	_	_	O
144	)	_	_	O

145	age	_	_	O
146	70	_	_	O
147	(	_	_	O
148	11·8	_	_	O
149	)	_	_	O
150	years	_	_	O
151	)	_	_	O
152	.	_	_	O

153	Patients	_	_	O
154	were	_	_	O
155	followed	_	_	O
156	up	_	_	O
157	per-protocol	_	_	O
158	;	_	_	O
159	there	_	_	O
160	were	_	_	O
161	no	_	_	O
162	deaths	_	_	O
163	,	_	_	O
164	and	_	_	O
165	five	_	_	O
166	patients	_	_	O
167	had	_	_	O
168	a	_	_	O
169	total	_	_	O
170	of	_	_	O
171	six	_	_	O
172	complications	_	_	O
173	.	_	_	O

174	Challenges	_	_	O
175	with	_	_	O
176	capturing	_	_	O
177	pain	_	_	O
178	data	_	_	O
179	were	_	_	O
180	identified	_	_	O
181	and	_	_	O
182	resolved	_	_	O
183	.	_	_	O

184	Mean	_	_	B-Premise
185	(	_	_	I-Premise
186	s.d	_	_	I-Premise
187	.	_	_	I-Premise
188	)	_	_	I-Premise

189	pain	_	_	I-Premise
190	scores	_	_	I-Premise
191	on	_	_	I-Premise
192	the	_	_	I-Premise
193	day	_	_	I-Premise
194	of	_	_	I-Premise
195	discharge	_	_	I-Premise
196	were	_	_	I-Premise
197	1·9	_	_	I-Premise
198	(	_	_	I-Premise
199	3·1	_	_	I-Premise
200	)	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	epidural	_	_	I-Premise
204	group	_	_	I-Premise
205	and	_	_	I-Premise
206	0·7	_	_	I-Premise
207	(	_	_	I-Premise
208	0·7	_	_	I-Premise
209	)	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	WIC	_	_	I-Premise
213	group	_	_	I-Premise
214	.	_	_	I-Premise

215	Median	_	_	B-Premise
216	length	_	_	I-Premise
217	of	_	_	I-Premise
218	stay	_	_	I-Premise
219	was	_	_	I-Premise
220	4	_	_	I-Premise
221	(	_	_	I-Premise
222	range	_	_	I-Premise
223	2-35	_	_	I-Premise
224	,	_	_	I-Premise
225	interquartile	_	_	I-Premise
226	range	_	_	I-Premise
227	3-5	_	_	I-Premise
228	)	_	_	I-Premise
229	days	_	_	I-Premise
230	.	_	_	I-Premise

231	Mean	_	_	B-Premise
232	use	_	_	I-Premise
233	of	_	_	I-Premise
234	additional	_	_	I-Premise
235	analgesia	_	_	I-Premise
236	(	_	_	I-Premise
237	intravenous	_	_	I-Premise
238	morphine	_	_	I-Premise
239	equivalents	_	_	I-Premise
240	)	_	_	I-Premise
241	was	_	_	I-Premise
242	12	_	_	I-Premise
243	mg	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	WIC	_	_	I-Premise
247	arm	_	_	I-Premise
248	and	_	_	I-Premise
249	9	_	_	I-Premise
250	mg	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	epidural	_	_	I-Premise
254	arm	_	_	I-Premise
255	.	_	_	I-Premise

256	Patient	_	_	O
257	blinding	_	_	O
258	was	_	_	O
259	successful	_	_	O
260	in	_	_	O
261	both	_	_	O
262	arms	_	_	O
263	.	_	_	O

264	Qualitative	_	_	B-Claim
265	interviews	_	_	I-Claim
266	suggested	_	_	I-Claim
267	that	_	_	I-Claim
268	patients	_	_	I-Claim
269	found	_	_	I-Claim
270	participation	_	_	I-Claim
271	in	_	_	I-Claim
272	the	_	_	I-Claim
273	trial	_	_	I-Claim
274	acceptable	_	_	I-Claim
275	and	_	_	I-Claim
276	that	_	_	I-Claim
277	they	_	_	I-Claim
278	would	_	_	I-Claim
279	consider	_	_	I-Claim
280	participating	_	_	I-Claim
281	in	_	_	I-Claim
282	a	_	_	I-Claim
283	future	_	_	I-Claim
284	trial	_	_	I-Claim
285	.	_	_	I-Claim

286	A	_	_	B-Claim
287	blinded	_	_	I-Claim
288	RCT	_	_	I-Claim
289	investigating	_	_	I-Claim
290	the	_	_	I-Claim
291	role	_	_	I-Claim
292	of	_	_	I-Claim
293	epidural	_	_	I-Claim
294	and	_	_	I-Claim
295	WIC	_	_	I-Claim
296	administration	_	_	I-Claim
297	for	_	_	I-Claim
298	postoperative	_	_	I-Claim
299	analgesia	_	_	I-Claim
300	following	_	_	I-Claim
301	LCR	_	_	I-Claim
302	is	_	_	I-Claim
303	feasible	_	_	I-Claim
304	.	_	_	I-Claim

305	Rigorous	_	_	B-Claim
306	standard	_	_	I-Claim
307	operating	_	_	I-Claim
308	procedures	_	_	I-Claim
309	for	_	_	I-Claim
310	data	_	_	I-Claim
311	collection	_	_	I-Claim
312	are	_	_	I-Claim
313	required	_	_	I-Claim
314	.	_	_	I-Claim


0	Several	_	_	O
1	guidelines	_	_	O
2	on	_	_	O
3	the	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	cancer-related	_	_	O
7	fatigue	_	_	O
8	recommend	_	_	O
9	optimizing	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	accompanying	_	_	O
13	symptoms	_	_	O
14	.	_	_	O

15	However	_	_	O
16	,	_	_	O
17	evidence	_	_	O
18	for	_	_	O
19	this	_	_	O
20	recommendation	_	_	O
21	from	_	_	O
22	randomized	_	_	O
23	clinical	_	_	O
24	trials	_	_	O
25	is	_	_	O
26	lacking	_	_	O
27	.	_	_	O

28	We	_	_	O
29	investigated	_	_	O
30	whether	_	_	O
31	monitoring	_	_	O
32	and	_	_	O
33	protocolized	_	_	O
34	treatment	_	_	O
35	of	_	_	O
36	physical	_	_	O
37	symptoms	_	_	O
38	alleviates	_	_	O
39	fatigue	_	_	O
40	.	_	_	O

41	In	_	_	O
42	all	_	_	O
43	,	_	_	O
44	152	_	_	O
45	fatigued	_	_	O
46	patients	_	_	O
47	with	_	_	O
48	advanced	_	_	O
49	cancer	_	_	O
50	were	_	_	O
51	randomly	_	_	O
52	assigned	_	_	O
53	to	_	_	O
54	protocolized	_	_	O
55	patient-tailored	_	_	O
56	treatment	_	_	O
57	(	_	_	O
58	PPT	_	_	O
59	)	_	_	O
60	of	_	_	O
61	symptoms	_	_	O
62	or	_	_	O
63	care	_	_	O
64	as	_	_	O
65	usual	_	_	O
66	.	_	_	O

67	The	_	_	O
68	PPT	_	_	O
69	group	_	_	O
70	had	_	_	O
71	four	_	_	O
72	appointments	_	_	O
73	with	_	_	O
74	a	_	_	O
75	nurse	_	_	O
76	who	_	_	O
77	assessed	_	_	O
78	nine	_	_	O
79	symptoms	_	_	O
80	on	_	_	O
81	a	_	_	O
82	0	_	_	O
83	to	_	_	O
84	10	_	_	O
85	numeric	_	_	O
86	rating	_	_	O
87	scale	_	_	O
88	(	_	_	O
89	NRS	_	_	O
90	)	_	_	O
91	.	_	_	O

92	Patients	_	_	O
93	received	_	_	O
94	a	_	_	O
95	nonpharmacologic	_	_	O
96	intervention	_	_	O
97	for	_	_	O
98	symptoms	_	_	O
99	with	_	_	O
100	a	_	_	O
101	score	_	_	O
102	≥	_	_	O
103	1	_	_	O
104	and	_	_	O
105	a	_	_	O
106	medical	_	_	O
107	intervention	_	_	O
108	for	_	_	O
109	symptoms	_	_	O
110	with	_	_	O
111	a	_	_	O
112	score	_	_	O
113	≥	_	_	O
114	4	_	_	O
115	.	_	_	O

116	Fatigue	_	_	O
117	dimensions	_	_	O
118	,	_	_	O
119	fatigue	_	_	O
120	NRS	_	_	O
121	score	_	_	O
122	,	_	_	O
123	interference	_	_	O
124	of	_	_	O
125	fatigue	_	_	O
126	with	_	_	O
127	daily	_	_	O
128	life	_	_	O
129	,	_	_	O
130	symptom	_	_	O
131	burden	_	_	O
132	,	_	_	O
133	quality	_	_	O
134	of	_	_	O
135	life	_	_	O
136	,	_	_	O
137	anxiety	_	_	O
138	,	_	_	O
139	and	_	_	O
140	depression	_	_	O
141	were	_	_	O
142	measured	_	_	O
143	at	_	_	O
144	baseline	_	_	O
145	and	_	_	O
146	after	_	_	O
147	1	_	_	O
148	,	_	_	O
149	2	_	_	O
150	,	_	_	O
151	and	_	_	O
152	3	_	_	O
153	months	_	_	O
154	.	_	_	O

155	Differences	_	_	O
156	between	_	_	O
157	the	_	_	O
158	groups	_	_	O
159	over	_	_	O
160	time	_	_	O
161	were	_	_	O
162	assessed	_	_	O
163	by	_	_	O
164	using	_	_	O
165	mixed	_	_	O
166	modeling	_	_	O
167	.	_	_	O

168	Seventy-six	_	_	O
169	patients	_	_	O
170	were	_	_	O
171	randomly	_	_	O
172	assigned	_	_	O
173	to	_	_	O
174	each	_	_	O
175	study	_	_	O
176	arm	_	_	O
177	.	_	_	O

178	Mean	_	_	O
179	age	_	_	O
180	was	_	_	O
181	58	_	_	O
182	±	_	_	O
183	10	_	_	O
184	years	_	_	O
185	,	_	_	O
186	57	_	_	O
187	%	_	_	O
188	were	_	_	O
189	female	_	_	O
190	,	_	_	O
191	and	_	_	O
192	65	_	_	O
193	%	_	_	O
194	were	_	_	O
195	given	_	_	O
196	palliative	_	_	O
197	chemotherapy	_	_	O
198	.	_	_	O

199	We	_	_	B-Premise
200	found	_	_	I-Premise
201	significant	_	_	I-Premise
202	improvements	_	_	I-Premise
203	over	_	_	I-Premise
204	time	_	_	I-Premise
205	in	_	_	I-Premise
206	favor	_	_	I-Premise
207	of	_	_	I-Premise
208	PPT	_	_	I-Premise
209	for	_	_	I-Premise
210	the	_	_	I-Premise
211	primary	_	_	I-Premise
212	outcome	_	_	I-Premise
213	general	_	_	I-Premise
214	fatigue	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.01	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	with	_	_	I-Premise
222	significant	_	_	I-Premise
223	group	_	_	I-Premise
224	differences	_	_	I-Premise
225	at	_	_	I-Premise
226	month	_	_	I-Premise
227	1	_	_	I-Premise
228	(	_	_	I-Premise
229	effect	_	_	I-Premise
230	size	_	_	I-Premise
231	,	_	_	I-Premise
232	0.26	_	_	I-Premise
233	;	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	.007	_	_	I-Premise
237	)	_	_	I-Premise
238	and	_	_	I-Premise
239	month	_	_	I-Premise
240	2	_	_	I-Premise
241	(	_	_	I-Premise
242	effect	_	_	I-Premise
243	size	_	_	I-Premise
244	,	_	_	I-Premise
245	0.35	_	_	I-Premise
246	;	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	.005	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Improvements	_	_	B-Premise
253	in	_	_	I-Premise
254	favor	_	_	I-Premise
255	of	_	_	I-Premise
256	PPT	_	_	I-Premise
257	were	_	_	I-Premise
258	also	_	_	I-Premise
259	found	_	_	I-Premise
260	for	_	_	I-Premise
261	the	_	_	I-Premise
262	following	_	_	I-Premise
263	secondary	_	_	I-Premise
264	outcomes	_	_	I-Premise
265	:	_	_	I-Premise
266	fatigue	_	_	I-Premise
267	dimensions	_	_	I-Premise
268	reduced	_	_	I-Premise
269	activity	_	_	I-Premise
270	and	_	_	O
271	reduced	_	_	I-Premise
272	motivation	_	_	I-Premise
273	,	_	_	I-Premise
274	fatigue	_	_	O
275	NRS	_	_	O
276	,	_	_	O
277	symptom	_	_	O
278	burden	_	_	O
279	,	_	_	O
280	interference	_	_	I-Premise
281	of	_	_	I-Premise
282	fatigue	_	_	I-Premise
283	with	_	_	I-Premise
284	daily	_	_	I-Premise
285	life	_	_	I-Premise
286	,	_	_	I-Premise
287	and	_	_	I-Premise
288	anxiety	_	_	I-Premise
289	(	_	_	I-Premise
290	all	_	_	I-Premise
291	P	_	_	I-Premise
292	≤	_	_	I-Premise
293	.03	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	In	_	_	B-Claim
297	fatigued	_	_	I-Claim
298	patients	_	_	I-Claim
299	with	_	_	I-Claim
300	advanced	_	_	I-Claim
301	cancer	_	_	I-Claim
302	,	_	_	I-Claim
303	nurse-led	_	_	I-Claim
304	monitoring	_	_	I-Claim
305	and	_	_	I-Claim
306	protocolized	_	_	I-Claim
307	treatment	_	_	I-Claim
308	of	_	_	I-Claim
309	physical	_	_	I-Claim
310	symptoms	_	_	I-Claim
311	is	_	_	I-Claim
312	effective	_	_	I-Claim
313	in	_	_	I-Claim
314	alleviating	_	_	I-Claim
315	fatigue	_	_	I-Claim
316	.	_	_	I-Claim


0	Docetaxel	_	_	O
1	administered	_	_	O
2	every	_	_	O
3	3	_	_	O
4	weeks	_	_	O
5	is	_	_	O
6	a	_	_	O
7	standard	_	_	O
8	treatment	_	_	O
9	for	_	_	O
10	castration-resistant	_	_	O
11	advanced	_	_	O
12	prostate	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	We	_	_	O
16	hypothesised	_	_	O
17	that	_	_	O
18	2-weekly	_	_	O
19	administration	_	_	O
20	of	_	_	O
21	docetaxel	_	_	O
22	would	_	_	O
23	be	_	_	O
24	better	_	_	O
25	tolerated	_	_	O
26	than	_	_	O
27	3-weekly	_	_	O
28	docetaxel	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	castration-resistant	_	_	O
33	advanced	_	_	O
34	prostate	_	_	O
35	cancer	_	_	O
36	,	_	_	O
37	and	_	_	O
38	did	_	_	O
39	a	_	_	O
40	prospective	_	_	O
41	,	_	_	O
42	multicentre	_	_	O
43	,	_	_	O
44	randomised	_	_	O
45	,	_	_	O
46	phase	_	_	O
47	3	_	_	O
48	study	_	_	O
49	to	_	_	O
50	compare	_	_	O
51	efficacy	_	_	O
52	and	_	_	O
53	safety	_	_	O
54	.	_	_	O

55	Eligible	_	_	O
56	patients	_	_	O
57	had	_	_	O
58	advanced	_	_	O
59	prostate	_	_	O
60	cancer	_	_	O
61	(	_	_	O
62	metastasis	_	_	O
63	,	_	_	O
64	a	_	_	O
65	prostate-specific-antigen	_	_	O
66	test	_	_	O
67	result	_	_	O
68	of	_	_	O
69	more	_	_	O
70	than	_	_	O
71	10·0	_	_	O
72	ng/mL	_	_	O
73	,	_	_	O
74	and	_	_	O
75	WHO	_	_	O
76	performance	_	_	O
77	status	_	_	O
78	score	_	_	O
79	of	_	_	O
80	0-2	_	_	O
81	)	_	_	O
82	,	_	_	O
83	had	_	_	O
84	received	_	_	O
85	no	_	_	O
86	chemotherapy	_	_	O
87	(	_	_	O
88	except	_	_	O
89	with	_	_	O
90	estramustine	_	_	O
91	)	_	_	O
92	,	_	_	O
93	had	_	_	O
94	undergone	_	_	O
95	surgical	_	_	O
96	or	_	_	O
97	chemical	_	_	O
98	castration	_	_	O
99	,	_	_	O
100	and	_	_	O
101	had	_	_	O
102	been	_	_	O
103	referred	_	_	O
104	to	_	_	O
105	a	_	_	O
106	treatment	_	_	O
107	centre	_	_	O
108	in	_	_	O
109	Finland	_	_	O
110	,	_	_	O
111	Ireland	_	_	O
112	,	_	_	O
113	or	_	_	O
114	Sweden	_	_	O
115	.	_	_	O

116	Enrolment	_	_	O
117	and	_	_	O
118	treatment	_	_	O
119	were	_	_	O
120	done	_	_	O
121	between	_	_	O
122	March	_	_	O
123	1	_	_	O
124	,	_	_	O
125	2004	_	_	O
126	,	_	_	O
127	and	_	_	O
128	May	_	_	O
129	31	_	_	O
130	,	_	_	O
131	2009	_	_	O
132	.	_	_	O

133	Randomisation	_	_	O
134	was	_	_	O
135	done	_	_	O
136	centrally	_	_	O
137	and	_	_	O
138	stratified	_	_	O
139	by	_	_	O
140	centre	_	_	O
141	and	_	_	O
142	WHO	_	_	O
143	performance	_	_	O
144	status	_	_	O
145	score	_	_	O
146	of	_	_	O
147	0-1	_	_	O
148	vs	_	_	O
149	2	_	_	O
150	.	_	_	O

151	Patients	_	_	O
152	were	_	_	O
153	assigned	_	_	O
154	75	_	_	O
155	mg/m	_	_	O
156	(	_	_	O
157	2	_	_	O
158	)	_	_	O
159	docetaxel	_	_	O
160	intravenously	_	_	O
161	on	_	_	O
162	day	_	_	O
163	1	_	_	O
164	of	_	_	O
165	a	_	_	O
166	3-week	_	_	O
167	cycle	_	_	O
168	,	_	_	O
169	or	_	_	O
170	50	_	_	O
171	mg/m	_	_	O
172	(	_	_	O
173	2	_	_	O
174	)	_	_	O
175	docetaxel	_	_	O
176	intravenously	_	_	O
177	on	_	_	O
178	days	_	_	O
179	1	_	_	O
180	and	_	_	O
181	15	_	_	O
182	of	_	_	O
183	a	_	_	O
184	4-week	_	_	O
185	cycle	_	_	O
186	.	_	_	O

187	10	_	_	O
188	mg	_	_	O
189	oral	_	_	O
190	prednisolone	_	_	O
191	was	_	_	O
192	administered	_	_	O
193	daily	_	_	O
194	to	_	_	O
195	all	_	_	O
196	patients	_	_	O
197	.	_	_	O

198	The	_	_	O
199	primary	_	_	O
200	endpoint	_	_	O
201	was	_	_	O
202	time	_	_	O
203	to	_	_	O
204	treatment	_	_	O
205	failure	_	_	O
206	(	_	_	O
207	TTTF	_	_	O
208	)	_	_	O
209	.	_	_	O

210	We	_	_	O
211	assessed	_	_	O
212	data	_	_	O
213	in	_	_	O
214	the	_	_	O
215	per-protocol	_	_	O
216	population	_	_	O
217	.	_	_	O

218	177	_	_	O
219	patients	_	_	O
220	were	_	_	O
221	randomly	_	_	O
222	assigned	_	_	O
223	to	_	_	O
224	the	_	_	O
225	2-weekly	_	_	O
226	docetaxel	_	_	O
227	group	_	_	O
228	and	_	_	O
229	184	_	_	O
230	to	_	_	O
231	the	_	_	O
232	3-weekly	_	_	O
233	group	_	_	O
234	.	_	_	O

235	170	_	_	O
236	patients	_	_	O
237	in	_	_	O
238	the	_	_	O
239	2-weekly	_	_	O
240	group	_	_	O
241	and	_	_	O
242	176	_	_	O
243	in	_	_	O
244	the	_	_	O
245	3-weekly	_	_	O
246	group	_	_	O
247	were	_	_	O
248	included	_	_	O
249	in	_	_	O
250	the	_	_	O
251	analysis	_	_	O
252	.	_	_	O

253	The	_	_	B-Premise
254	2-weekly	_	_	I-Premise
255	administration	_	_	I-Premise
256	was	_	_	I-Premise
257	associated	_	_	I-Premise
258	with	_	_	I-Premise
259	significantly	_	_	I-Premise
260	longer	_	_	I-Premise
261	TTTF	_	_	I-Premise
262	than	_	_	I-Premise
263	was	_	_	I-Premise
264	3-weekly	_	_	I-Premise
265	administration	_	_	I-Premise
266	(	_	_	I-Premise
267	5·6	_	_	I-Premise
268	months	_	_	I-Premise
269	,	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	CI	_	_	I-Premise
273	5·0-6·2	_	_	I-Premise
274	vs	_	_	I-Premise
275	4·9	_	_	I-Premise
276	months	_	_	I-Premise
277	,	_	_	I-Premise
278	4·5-5·4	_	_	I-Premise
279	;	_	_	I-Premise
280	hazard	_	_	I-Premise
281	ratio	_	_	I-Premise
282	1·3	_	_	I-Premise
283	,	_	_	I-Premise
284	95	_	_	I-Premise
285	%	_	_	I-Premise
286	CI	_	_	I-Premise
287	1·1-1·6	_	_	I-Premise
288	,	_	_	I-Premise
289	p=0·014	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	Grade	_	_	B-Premise
293	3-4	_	_	I-Premise
294	adverse	_	_	I-Premise
295	events	_	_	I-Premise
296	occurred	_	_	I-Premise
297	more	_	_	I-Premise
298	frequently	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	3-weekly	_	_	I-Premise
302	than	_	_	I-Premise
303	in	_	_	I-Premise
304	the	_	_	I-Premise
305	2-weekly	_	_	I-Premise
306	administration	_	_	I-Premise
307	group	_	_	I-Premise
308	,	_	_	I-Premise
309	including	_	_	I-Premise
310	neutropenia	_	_	I-Premise
311	(	_	_	I-Premise
312	93	_	_	I-Premise
313	[	_	_	I-Premise
314	53	_	_	I-Premise
315	%	_	_	I-Premise
316	]	_	_	I-Premise
317	vs	_	_	I-Premise
318	61	_	_	I-Premise
319	[	_	_	I-Premise
320	36	_	_	I-Premise
321	%	_	_	I-Premise
322	]	_	_	I-Premise
323	)	_	_	I-Premise
324	,	_	_	I-Premise
325	leucopenia	_	_	I-Premise
326	(	_	_	I-Premise
327	51	_	_	I-Premise
328	[	_	_	I-Premise
329	29	_	_	I-Premise
330	%	_	_	I-Premise
331	]	_	_	I-Premise
332	vs	_	_	I-Premise
333	22	_	_	I-Premise
334	[	_	_	I-Premise
335	13	_	_	I-Premise
336	%	_	_	I-Premise
337	]	_	_	I-Premise
338	)	_	_	I-Premise
339	,	_	_	I-Premise
340	and	_	_	I-Premise
341	febrile	_	_	I-Premise
342	neutropenia	_	_	I-Premise
343	(	_	_	I-Premise
344	25	_	_	I-Premise
345	[	_	_	I-Premise
346	14	_	_	I-Premise
347	%	_	_	I-Premise
348	]	_	_	I-Premise
349	vs	_	_	I-Premise
350	six	_	_	I-Premise
351	[	_	_	I-Premise
352	4	_	_	I-Premise
353	%	_	_	I-Premise
354	]	_	_	I-Premise
355	)	_	_	I-Premise
356	.	_	_	I-Premise

357	Neutropenic	_	_	B-Premise
358	infections	_	_	I-Premise
359	were	_	_	I-Premise
360	reported	_	_	I-Premise
361	more	_	_	I-Premise
362	frequently	_	_	I-Premise
363	in	_	_	I-Premise
364	patients	_	_	I-Premise
365	who	_	_	I-Premise
366	received	_	_	I-Premise
367	docetaxel	_	_	I-Premise
368	every	_	_	I-Premise
369	3	_	_	I-Premise
370	weeks	_	_	I-Premise
371	(	_	_	I-Premise
372	43	_	_	I-Premise
373	[	_	_	I-Premise
374	24	_	_	I-Premise
375	%	_	_	I-Premise
376	]	_	_	I-Premise
377	vs	_	_	I-Premise
378	11	_	_	I-Premise
379	[	_	_	I-Premise
380	6	_	_	I-Premise
381	%	_	_	I-Premise
382	]	_	_	I-Premise
383	,	_	_	I-Premise
384	p=0·002	_	_	I-Premise
385	)	_	_	I-Premise
386	.	_	_	I-Premise

387	Administration	_	_	B-Claim
388	of	_	_	I-Claim
389	docetaxel	_	_	I-Claim
390	every	_	_	I-Claim
391	2	_	_	I-Claim
392	weeks	_	_	I-Claim
393	seems	_	_	I-Claim
394	to	_	_	I-Claim
395	be	_	_	I-Claim
396	well	_	_	I-Claim
397	tolerated	_	_	I-Claim
398	in	_	_	I-Claim
399	patients	_	_	I-Claim
400	with	_	_	I-Claim
401	castration-resistant	_	_	I-Claim
402	advanced	_	_	I-Claim
403	prostate	_	_	I-Claim
404	cancer	_	_	I-Claim
405	and	_	_	I-Claim
406	could	_	_	I-Claim
407	be	_	_	I-Claim
408	a	_	_	I-Claim
409	useful	_	_	I-Claim
410	option	_	_	I-Claim
411	when	_	_	I-Claim
412	3-weekly	_	_	I-Claim
413	single-dose	_	_	I-Claim
414	administration	_	_	I-Claim
415	is	_	_	I-Claim
416	unlikely	_	_	I-Claim
417	to	_	_	I-Claim
418	be	_	_	I-Claim
419	tolerated	_	_	I-Claim
420	.	_	_	I-Claim


0	In	_	_	O
1	the	_	_	O
2	Gynecologic	_	_	O
3	Cancer	_	_	O
4	Intergroup	_	_	O
5	International	_	_	O
6	Collaboration	_	_	O
7	on	_	_	O
8	Ovarian	_	_	O
9	Neoplasms	_	_	O
10	7	_	_	O
11	(	_	_	O
12	ICON7	_	_	O
13	)	_	_	O
14	trial	_	_	O
15	,	_	_	O
16	bevacizumab	_	_	O
17	improved	_	_	O
18	progression-free	_	_	O
19	survival	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	ovarian	_	_	O
24	cancer	_	_	O
25	when	_	_	O
26	used	_	_	O
27	in	_	_	O
28	combination	_	_	O
29	with	_	_	O
30	first-line	_	_	O
31	chemotherapy	_	_	O
32	and	_	_	O
33	as	_	_	O
34	a	_	_	O
35	single-drug	_	_	O
36	continuation	_	_	O
37	treatment	_	_	O
38	for	_	_	O
39	18	_	_	O
40	cycles	_	_	O
41	.	_	_	O

42	In	_	_	O
43	a	_	_	O
44	preliminary	_	_	O
45	analysis	_	_	O
46	of	_	_	O
47	a	_	_	O
48	high-risk	_	_	O
49	subset	_	_	O
50	of	_	_	O
51	patients	_	_	O
52	,	_	_	O
53	there	_	_	O
54	was	_	_	O
55	also	_	_	O
56	an	_	_	O
57	improvement	_	_	O
58	in	_	_	O
59	overall	_	_	O
60	survival	_	_	O
61	.	_	_	O

62	This	_	_	O
63	study	_	_	O
64	aims	_	_	O
65	to	_	_	O
66	describe	_	_	O
67	the	_	_	O
68	health-related	_	_	O
69	quality-of-life	_	_	O
70	(	_	_	O
71	QoL	_	_	O
72	)	_	_	O
73	outcomes	_	_	O
74	from	_	_	O
75	ICON7	_	_	O
76	.	_	_	O

77	ICON7	_	_	O
78	is	_	_	O
79	a	_	_	O
80	randomised	_	_	O
81	,	_	_	O
82	multicentre	_	_	O
83	,	_	_	O
84	open-label	_	_	O
85	phase	_	_	O
86	3	_	_	O
87	trial	_	_	O
88	.	_	_	O

89	Between	_	_	O
90	Dec	_	_	O
91	18	_	_	O
92	,	_	_	O
93	2006	_	_	O
94	,	_	_	O
95	and	_	_	O
96	Feb	_	_	O
97	16	_	_	O
98	,	_	_	O
99	2009	_	_	O
100	,	_	_	O
101	after	_	_	O
102	a	_	_	O
103	surgical	_	_	O
104	procedure	_	_	O
105	aiming	_	_	O
106	to	_	_	O
107	debulk	_	_	O
108	the	_	_	O
109	disease	_	_	O
110	,	_	_	O
111	women	_	_	O
112	with	_	_	O
113	International	_	_	O
114	Federation	_	_	O
115	of	_	_	O
116	Gynecology	_	_	O
117	and	_	_	O
118	Obstetrics	_	_	O
119	(	_	_	O
120	FIGO	_	_	O
121	)	_	_	O
122	high-risk	_	_	O
123	stage	_	_	O
124	I-IV	_	_	O
125	epithelial	_	_	O
126	ovarian	_	_	O
127	cancer	_	_	O
128	were	_	_	O
129	randomly	_	_	O
130	allocated	_	_	O
131	(	_	_	O
132	1:1	_	_	O
133	)	_	_	O
134	by	_	_	O
135	computer	_	_	O
136	program	_	_	O
137	and	_	_	O
138	block	_	_	O
139	randomisation	_	_	O
140	to	_	_	O
141	receive	_	_	O
142	either	_	_	O
143	six	_	_	O
144	cycles	_	_	O
145	of	_	_	O
146	standard	_	_	O
147	chemotherapy	_	_	O
148	(	_	_	O
149	total	_	_	O
150	18	_	_	O
151	weeks	_	_	O
152	)	_	_	O
153	with	_	_	O
154	carboplatin	_	_	O
155	(	_	_	O
156	area	_	_	O
157	under	_	_	O
158	the	_	_	O
159	curve	_	_	O
160	5	_	_	O
161	or	_	_	O
162	6	_	_	O
163	)	_	_	O
164	and	_	_	O
165	paclitaxel	_	_	O
166	(	_	_	O
167	175	_	_	O
168	mg/m	_	_	O
169	(	_	_	O
170	2	_	_	O
171	)	_	_	O
172	)	_	_	O
173	alone	_	_	O
174	or	_	_	O
175	with	_	_	O
176	bevacizumab	_	_	O
177	(	_	_	O
178	7·5	_	_	O
179	mg/kg	_	_	O
180	)	_	_	O
181	given	_	_	O
182	intravenously	_	_	O
183	with	_	_	O
184	chemotherapy	_	_	O
185	and	_	_	O
186	continued	_	_	O
187	as	_	_	O
188	a	_	_	O
189	single	_	_	O
190	drug	_	_	O
191	thereafter	_	_	O
192	(	_	_	O
193	total	_	_	O
194	54	_	_	O
195	weeks	_	_	O
196	)	_	_	O
197	.	_	_	O

198	The	_	_	O
199	primary	_	_	O
200	QoL	_	_	O
201	endpoint	_	_	O
202	was	_	_	O
203	global	_	_	O
204	QoL	_	_	O
205	from	_	_	O
206	the	_	_	O
207	European	_	_	O
208	Organisation	_	_	O
209	for	_	_	O
210	Research	_	_	O
211	and	_	_	O
212	Treatment	_	_	O
213	of	_	_	O
214	Cancer	_	_	O
215	quality-of-life	_	_	O
216	questionnaire-core	_	_	O
217	30	_	_	O
218	at	_	_	O
219	week	_	_	O
220	54	_	_	O
221	,	_	_	O
222	analysed	_	_	O
223	by	_	_	O
224	ANOVA	_	_	O
225	and	_	_	O
226	adjusted	_	_	O
227	for	_	_	O
228	baseline	_	_	O
229	score	_	_	O
230	.	_	_	O

231	Analyses	_	_	O
232	were	_	_	O
233	by	_	_	O
234	intention	_	_	O
235	to	_	_	O
236	treat	_	_	O
237	.	_	_	O

238	The	_	_	O
239	ICON7	_	_	O
240	trial	_	_	O
241	has	_	_	O
242	completed	_	_	O
243	recruitment	_	_	O
244	and	_	_	O
245	remains	_	_	O
246	in	_	_	O
247	follow-up	_	_	O
248	.	_	_	O

249	This	_	_	O
250	study	_	_	O
251	is	_	_	O
252	registered	_	_	O
253	,	_	_	O
254	number	_	_	O
255	ISRCTN91273375	_	_	O
256	.	_	_	O

257	764	_	_	O
258	women	_	_	O
259	were	_	_	O
260	randomly	_	_	O
261	assigned	_	_	O
262	to	_	_	O
263	the	_	_	O
264	standard	_	_	O
265	chemotherapy	_	_	O
266	group	_	_	O
267	and	_	_	O
268	764	_	_	O
269	to	_	_	O
270	the	_	_	O
271	bevacizumab	_	_	O
272	group	_	_	O
273	.	_	_	O

274	At	_	_	O
275	baseline	_	_	O
276	,	_	_	O
277	684	_	_	O
278	(	_	_	O
279	90	_	_	O
280	%	_	_	O
281	)	_	_	O
282	of	_	_	O
283	women	_	_	O
284	in	_	_	O
285	the	_	_	O
286	standard	_	_	O
287	chemotherapy	_	_	O
288	group	_	_	O
289	and	_	_	O
290	691	_	_	O
291	(	_	_	O
292	90	_	_	O
293	%	_	_	O
294	)	_	_	O
295	of	_	_	O
296	those	_	_	O
297	in	_	_	O
298	the	_	_	O
299	bevacizumab	_	_	O
300	group	_	_	O
301	had	_	_	O
302	completed	_	_	O
303	QoL	_	_	O
304	questionnaires	_	_	O
305	.	_	_	O

306	At	_	_	O
307	week	_	_	O
308	54	_	_	O
309	,	_	_	O
310	502	_	_	O
311	(	_	_	O
312	66	_	_	O
313	%	_	_	O
314	)	_	_	O
315	women	_	_	O
316	in	_	_	O
317	the	_	_	O
318	bevacizumab	_	_	O
319	group	_	_	O
320	and	_	_	O
321	388	_	_	O
322	(	_	_	O
323	51	_	_	O
324	%	_	_	O
325	)	_	_	O
326	women	_	_	O
327	in	_	_	O
328	the	_	_	O
329	standard	_	_	O
330	chemotherapy	_	_	O
331	group	_	_	O
332	provided	_	_	O
333	QoL	_	_	O
334	data	_	_	O
335	.	_	_	O

336	Overall	_	_	B-Premise
337	,	_	_	I-Premise
338	the	_	_	I-Premise
339	mean	_	_	I-Premise
340	global	_	_	I-Premise
341	QoL	_	_	I-Premise
342	score	_	_	I-Premise
343	improved	_	_	I-Premise
344	during	_	_	I-Premise
345	chemotherapy	_	_	I-Premise
346	by	_	_	I-Premise
347	7·2	_	_	I-Premise
348	points	_	_	I-Premise
349	(	_	_	I-Premise
350	SD	_	_	I-Premise
351	24·4	_	_	I-Premise
352	)	_	_	I-Premise
353	when	_	_	I-Premise
354	analysed	_	_	I-Premise
355	for	_	_	I-Premise
356	all	_	_	I-Premise
357	women	_	_	I-Premise
358	with	_	_	I-Premise
359	data	_	_	I-Premise
360	at	_	_	I-Premise
361	baseline	_	_	I-Premise
362	and	_	_	I-Premise
363	week	_	_	I-Premise
364	18	_	_	I-Premise
365	.	_	_	I-Premise

366	The	_	_	B-Premise
367	mean	_	_	I-Premise
368	global	_	_	I-Premise
369	QoL	_	_	I-Premise
370	score	_	_	I-Premise
371	at	_	_	I-Premise
372	54	_	_	I-Premise
373	weeks	_	_	I-Premise
374	was	_	_	I-Premise
375	higher	_	_	I-Premise
376	in	_	_	I-Premise
377	the	_	_	I-Premise
378	standard	_	_	I-Premise
379	chemotherapy	_	_	I-Premise
380	group	_	_	I-Premise
381	than	_	_	I-Premise
382	in	_	_	I-Premise
383	the	_	_	I-Premise
384	bevacizumab	_	_	I-Premise
385	group	_	_	I-Premise
386	(	_	_	I-Premise
387	76·1	_	_	I-Premise
388	[	_	_	I-Premise
389	SD	_	_	I-Premise
390	18·2	_	_	I-Premise
391	]	_	_	I-Premise
392	vs	_	_	I-Premise
393	69·7	_	_	I-Premise
394	[	_	_	I-Premise
395	19·1	_	_	I-Premise
396	]	_	_	I-Premise
397	points	_	_	I-Premise
398	;	_	_	I-Premise
399	difference	_	_	I-Premise
400	6·4	_	_	I-Premise
401	points	_	_	I-Premise
402	,	_	_	I-Premise
403	95	_	_	I-Premise
404	%	_	_	I-Premise
405	CI	_	_	I-Premise
406	3·7-9·0	_	_	I-Premise
407	,	_	_	I-Premise
408	p	_	_	I-Premise
409	<	_	_	I-Premise
410	0·0001	_	_	I-Premise
411	)	_	_	I-Premise
412	.	_	_	I-Premise

413	Bevacizumab	_	_	B-Claim
414	continuation	_	_	I-Claim
415	treatment	_	_	I-Claim
416	seems	_	_	I-Claim
417	to	_	_	I-Claim
418	be	_	_	I-Claim
419	associated	_	_	I-Claim
420	with	_	_	I-Claim
421	a	_	_	I-Claim
422	small	_	_	I-Claim
423	but	_	_	I-Claim
424	clinically	_	_	I-Claim
425	significant	_	_	I-Claim
426	decrement	_	_	I-Claim
427	in	_	_	I-Claim
428	QoL	_	_	I-Claim
429	compared	_	_	I-Claim
430	with	_	_	I-Claim
431	standard	_	_	I-Claim
432	treatment	_	_	I-Claim
433	for	_	_	I-Claim
434	women	_	_	I-Claim
435	with	_	_	I-Claim
436	ovarian	_	_	I-Claim
437	cancer	_	_	I-Claim
438	.	_	_	I-Claim

439	The	_	_	O
440	trade-off	_	_	O
441	between	_	_	O
442	the	_	_	O
443	prolongation	_	_	O
444	of	_	_	O
445	progression-free	_	_	O
446	survival	_	_	O
447	and	_	_	O
448	the	_	_	O
449	quality	_	_	O
450	of	_	_	O
451	that	_	_	O
452	period	_	_	O
453	of	_	_	O
454	time	_	_	O
455	needs	_	_	O
456	to	_	_	O
457	be	_	_	O
458	considered	_	_	O
459	in	_	_	O
460	clinical	_	_	O
461	practice	_	_	O
462	when	_	_	O
463	making	_	_	O
464	treatment	_	_	O
465	decisions	_	_	O
466	.	_	_	O


0	The	_	_	O
1	management	_	_	O
2	of	_	_	O
3	cancer-related	_	_	O
4	anorexia/cachexia	_	_	O
5	syndrome	_	_	O
6	(	_	_	O
7	CACS	_	_	O
8	)	_	_	O
9	is	_	_	O
10	a	_	_	O
11	great	_	_	O
12	challenge	_	_	O
13	in	_	_	O
14	clinical	_	_	O
15	practice	_	_	O
16	.	_	_	O

17	To	_	_	O
18	date	_	_	O
19	,	_	_	O
20	practice	_	_	O
21	guidelines	_	_	O
22	for	_	_	O
23	the	_	_	O
24	prevention	_	_	O
25	and	_	_	O
26	treatment	_	_	O
27	of	_	_	O
28	CACS	_	_	O
29	are	_	_	O
30	lacking	_	_	O
31	.	_	_	O

32	The	_	_	O
33	authors	_	_	O
34	conducted	_	_	O
35	a	_	_	O
36	randomized	_	_	O
37	study	_	_	O
38	to	_	_	O
39	confirm	_	_	O
40	the	_	_	O
41	effectiveness	_	_	O
42	and	_	_	O
43	safety	_	_	O
44	of	_	_	O
45	treatment	_	_	O
46	of	_	_	O
47	CACS	_	_	O
48	utilizing	_	_	O
49	megestrol	_	_	O
50	acetate	_	_	O
51	(	_	_	O
52	MA	_	_	O
53	)	_	_	O
54	plus	_	_	O
55	thalidomide	_	_	O
56	.	_	_	O

57	One	_	_	O
58	hundred	_	_	O
59	and	_	_	O
60	two	_	_	O
61	candidates	_	_	O
62	with	_	_	O
63	CACS	_	_	O
64	were	_	_	O
65	randomly	_	_	O
66	assigned	_	_	O
67	to	_	_	O
68	two	_	_	O
69	treatment	_	_	O
70	groups	_	_	O
71	(	_	_	O
72	trial	_	_	O
73	group	_	_	O
74	and	_	_	O
75	control	_	_	O
76	group	_	_	O
77	)	_	_	O
78	:	_	_	O
79	the	_	_	O
80	trial	_	_	O
81	group	_	_	O
82	received	_	_	O
83	MA	_	_	O
84	(	_	_	O
85	160	_	_	O
86	mg	_	_	O
87	po	_	_	O
88	,	_	_	O
89	bid	_	_	O
90	)	_	_	O
91	plus	_	_	O
92	thalidomide	_	_	O
93	(	_	_	O
94	50	_	_	O
95	mg	_	_	O
96	po	_	_	O
97	,	_	_	O
98	bid	_	_	O
99	)	_	_	O
100	,	_	_	O
101	while	_	_	O
102	the	_	_	O
103	control	_	_	O
104	group	_	_	O
105	received	_	_	O
106	MA	_	_	O
107	(	_	_	O
108	160	_	_	O
109	mg	_	_	O
110	po	_	_	O
111	,	_	_	O
112	bid	_	_	O
113	)	_	_	O
114	alone	_	_	O
115	.	_	_	O

116	Treatment	_	_	O
117	duration	_	_	O
118	was	_	_	O
119	8	_	_	O
120	weeks	_	_	O
121	.	_	_	O

122	Analysis	_	_	B-Premise
123	of	_	_	I-Premise
124	the	_	_	I-Premise
125	trial	_	_	I-Premise
126	group	_	_	I-Premise
127	demonstrated	_	_	I-Premise
128	a	_	_	I-Premise
129	significant	_	_	I-Premise
130	increase	_	_	I-Premise
131	from	_	_	I-Premise
132	baseline	_	_	I-Premise
133	in	_	_	I-Premise
134	body	_	_	I-Premise
135	weight	_	_	I-Premise
136	(	_	_	I-Premise
137	<	_	_	I-Premise
138	0.01	_	_	I-Premise
139	)	_	_	I-Premise
140	,	_	_	I-Premise
141	quality	_	_	I-Premise
142	of	_	_	I-Premise
143	life	_	_	I-Premise
144	(	_	_	I-Premise
145	p	_	_	I-Premise
146	=	_	_	I-Premise
147	0.02	_	_	I-Premise
148	)	_	_	I-Premise
149	,	_	_	I-Premise
150	appetite	_	_	I-Premise
151	(	_	_	I-Premise
152	p	_	_	I-Premise
153	=	_	_	I-Premise
154	0.01	_	_	I-Premise
155	)	_	_	I-Premise
156	,	_	_	I-Premise
157	and	_	_	I-Premise
158	grip	_	_	I-Premise
159	strength	_	_	I-Premise
160	(	_	_	I-Premise
161	p	_	_	I-Premise
162	=	_	_	I-Premise
163	0.01	_	_	I-Premise
164	)	_	_	I-Premise
165	,	_	_	I-Premise
166	and	_	_	I-Premise
167	a	_	_	I-Premise
168	significant	_	_	I-Premise
169	decrease	_	_	I-Premise
170	in	_	_	I-Premise
171	fatigue	_	_	I-Premise
172	,	_	_	I-Premise
173	Glasgow	_	_	I-Premise
174	Prognostic	_	_	I-Premise
175	Score	_	_	I-Premise
176	(	_	_	I-Premise
177	p	_	_	I-Premise
178	=	_	_	I-Premise
179	0.05	_	_	I-Premise
180	)	_	_	I-Premise
181	,	_	_	I-Premise
182	Eastern	_	_	I-Premise
183	Cooperative	_	_	I-Premise
184	Oncology	_	_	I-Premise
185	Group	_	_	I-Premise
186	performance	_	_	I-Premise
187	status	_	_	I-Premise
188	(	_	_	I-Premise
189	p	_	_	I-Premise
190	=	_	_	I-Premise
191	0.03	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	IL-6	_	_	I-Premise
195	(	_	_	I-Premise
196	p	_	_	I-Premise
197	<	_	_	I-Premise
198	0.01	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	tumor	_	_	I-Premise
203	necrosis	_	_	I-Premise
204	factor-α	_	_	I-Premise
205	(	_	_	I-Premise
206	p	_	_	I-Premise
207	=	_	_	I-Premise
208	0.02	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	In	_	_	B-Premise
212	contrast	_	_	I-Premise
213	,	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	control	_	_	I-Premise
217	group	_	_	I-Premise
218	,	_	_	I-Premise
219	endpoints	_	_	I-Premise
220	with	_	_	I-Premise
221	a	_	_	I-Premise
222	significant	_	_	I-Premise
223	improvement	_	_	I-Premise
224	from	_	_	I-Premise
225	baseline	_	_	I-Premise
226	included	_	_	I-Premise
227	body	_	_	I-Premise
228	weight	_	_	I-Premise
229	(	_	_	I-Premise
230	p	_	_	I-Premise
231	<	_	_	I-Premise
232	0.02	_	_	I-Premise
233	)	_	_	I-Premise
234	and	_	_	I-Premise
235	appetite	_	_	I-Premise
236	(	_	_	I-Premise
237	p	_	_	I-Premise
238	=	_	_	I-Premise
239	0.02	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	The	_	_	B-Premise
243	mean	_	_	I-Premise
244	changes	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	endpoints	_	_	I-Premise
248	from	_	_	I-Premise
249	baseline	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	trial	_	_	I-Premise
253	group	_	_	I-Premise
254	were	_	_	I-Premise
255	significantly	_	_	I-Premise
256	greater	_	_	I-Premise
257	compared	_	_	I-Premise
258	with	_	_	I-Premise
259	the	_	_	I-Premise
260	control	_	_	I-Premise
261	group	_	_	I-Premise
262	:	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	primary	_	_	I-Premise
266	endpoints	_	_	I-Premise
267	,	_	_	I-Premise
268	body	_	_	I-Premise
269	weight	_	_	I-Premise
270	(	_	_	I-Premise
271	p	_	_	I-Premise
272	=	_	_	I-Premise
273	0.05	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	fatigue	_	_	I-Premise
277	(	_	_	I-Premise
278	p	_	_	I-Premise
279	<	_	_	I-Premise
280	0.01	_	_	I-Premise
281	)	_	_	I-Premise
282	and	_	_	I-Premise
283	quality	_	_	I-Premise
284	of	_	_	I-Premise
285	life	_	_	I-Premise
286	(	_	_	I-Premise
287	p	_	_	I-Premise
288	=	_	_	I-Premise
289	0.01	_	_	I-Premise
290	)	_	_	I-Premise
291	,	_	_	I-Premise
292	and	_	_	I-Premise
293	in	_	_	I-Premise
294	the	_	_	I-Premise
295	secondary	_	_	I-Premise
296	endpoints	_	_	I-Premise
297	,	_	_	I-Premise
298	grip	_	_	I-Premise
299	strength	_	_	I-Premise
300	(	_	_	I-Premise
301	p	_	_	I-Premise
302	=	_	_	I-Premise
303	0.05	_	_	I-Premise
304	)	_	_	I-Premise
305	,	_	_	I-Premise
306	Glasgow	_	_	I-Premise
307	Prognostic	_	_	I-Premise
308	Score	_	_	I-Premise
309	(	_	_	I-Premise
310	p	_	_	I-Premise
311	=	_	_	I-Premise
312	0.02	_	_	I-Premise
313	)	_	_	I-Premise
314	,	_	_	I-Premise
315	Eastern	_	_	I-Premise
316	Cooperative	_	_	I-Premise
317	Oncology	_	_	I-Premise
318	Group	_	_	I-Premise
319	performance	_	_	I-Premise
320	status	_	_	I-Premise
321	(	_	_	I-Premise
322	p	_	_	I-Premise
323	=	_	_	I-Premise
324	0.02	_	_	I-Premise
325	)	_	_	I-Premise
326	,	_	_	I-Premise
327	IL-6	_	_	I-Premise
328	(	_	_	I-Premise
329	p	_	_	I-Premise
330	<	_	_	I-Premise
331	0.01	_	_	I-Premise
332	)	_	_	I-Premise
333	and	_	_	I-Premise
334	tumor	_	_	I-Premise
335	necrosis	_	_	I-Premise
336	factor-α	_	_	I-Premise
337	(	_	_	I-Premise
338	p	_	_	I-Premise
339	=	_	_	I-Premise
340	0.01	_	_	I-Premise
341	)	_	_	I-Premise
342	.	_	_	I-Premise

343	Toxicity	_	_	B-Premise
344	was	_	_	I-Premise
345	found	_	_	I-Premise
346	to	_	_	I-Premise
347	be	_	_	I-Premise
348	relatively	_	_	I-Premise
349	negligible	_	_	I-Premise
350	in	_	_	I-Premise
351	both	_	_	I-Premise
352	groups	_	_	I-Premise
353	.	_	_	I-Premise

354	A	_	_	B-Claim
355	combination	_	_	I-Claim
356	regimen	_	_	I-Claim
357	of	_	_	I-Claim
358	MA	_	_	I-Claim
359	and	_	_	I-Claim
360	thalidomide	_	_	I-Claim
361	is	_	_	I-Claim
362	more	_	_	I-Claim
363	effective	_	_	I-Claim
364	than	_	_	I-Claim
365	MA	_	_	I-Claim
366	alone	_	_	I-Claim
367	in	_	_	I-Claim
368	the	_	_	I-Claim
369	treatment	_	_	I-Claim
370	of	_	_	I-Claim
371	CACS	_	_	I-Claim
372	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	bimatoprost/timolol	_	_	O
6	(	_	_	O
7	BTFC	_	_	O
8	)	_	_	O
9	or	_	_	O
10	travoprost/timolol	_	_	O
11	(	_	_	O
12	TTFC	_	_	O
13	)	_	_	O
14	fixed	_	_	O
15	combinations	_	_	O
16	on	_	_	O
17	intraocular	_	_	O
18	pressure	_	_	O
19	(	_	_	O
20	IOP	_	_	O
21	)	_	_	O
22	reduction	_	_	O
23	in	_	_	O
24	an	_	_	O
25	Egyptian	_	_	O
26	population	_	_	O
27	.	_	_	O

28	Patients	_	_	O
29	with	_	_	O
30	primary	_	_	O
31	open	_	_	O
32	angle	_	_	O
33	glaucoma	_	_	O
34	were	_	_	O
35	randomized	_	_	O
36	to	_	_	O
37	receive	_	_	O
38	either	_	_	O
39	BTFC	_	_	O
40	or	_	_	O
41	TTFC	_	_	O
42	.	_	_	O

43	IOPs	_	_	O
44	were	_	_	O
45	measured	_	_	O
46	at	_	_	O
47	baseline	_	_	O
48	,	_	_	O
49	2	_	_	O
50	weeks	_	_	O
51	,	_	_	O
52	and	_	_	O
53	1	_	_	O
54	,	_	_	O
55	2	_	_	O
56	,	_	_	O
57	4	_	_	O
58	,	_	_	O
59	and	_	_	O
60	6	_	_	O
61	months	_	_	O
62	.	_	_	O

63	The	_	_	O
64	primary	_	_	O
65	outcome	_	_	O
66	measure	_	_	O
67	was	_	_	O
68	the	_	_	O
69	mean	_	_	O
70	change	_	_	O
71	in	_	_	O
72	IOP	_	_	O
73	from	_	_	O
74	baseline	_	_	O
75	at	_	_	O
76	each	_	_	O
77	visit	_	_	O
78	.	_	_	O

79	Secondary	_	_	O
80	outcome	_	_	O
81	measures	_	_	O
82	included	_	_	O
83	the	_	_	O
84	incidence	_	_	O
85	of	_	_	O
86	adverse	_	_	O
87	events	_	_	O
88	.	_	_	O

89	Eighty	_	_	O
90	patients	_	_	O
91	(	_	_	O
92	80	_	_	O
93	eyes	_	_	O
94	)	_	_	O
95	were	_	_	O
96	included	_	_	O
97	finally	_	_	O
98	:	_	_	O
99	40	_	_	O
100	eyes	_	_	O
101	in	_	_	O
102	each	_	_	O
103	group	_	_	O
104	.	_	_	O

105	Baseline	_	_	O
106	mean	_	_	O
107	IOPs	_	_	O
108	were	_	_	O
109	24.78±3.53	_	_	O
110	and	_	_	O
111	25.26±3.51	_	_	O
112	mm	_	_	O
113	Hg	_	_	O
114	for	_	_	O
115	BTFC	_	_	O
116	and	_	_	O
117	TTFC	_	_	O
118	,	_	_	O
119	respectively	_	_	O
120	(	_	_	O
121	P=0.344	_	_	O
122	)	_	_	O
123	.	_	_	O

124	Both	_	_	B-Premise
125	drops	_	_	I-Premise
126	provided	_	_	I-Premise
127	statistically	_	_	I-Premise
128	significant	_	_	I-Premise
129	IOP	_	_	I-Premise
130	reductions	_	_	I-Premise
131	from	_	_	I-Premise
132	baseline	_	_	I-Premise
133	at	_	_	I-Premise
134	all	_	_	I-Premise
135	visits	_	_	I-Premise
136	(	_	_	I-Premise
137	P	_	_	I-Premise
138	<	_	_	I-Premise
139	0.001	_	_	I-Premise
140	)	_	_	I-Premise
141	.	_	_	I-Premise

142	BTFC	_	_	B-Premise
143	provided	_	_	I-Premise
144	greater	_	_	I-Premise
145	significant	_	_	I-Premise
146	mean	_	_	I-Premise
147	IOP	_	_	I-Premise
148	reductions	_	_	I-Premise
149	from	_	_	I-Premise
150	baseline	_	_	I-Premise
151	than	_	_	I-Premise
152	TTFC	_	_	I-Premise
153	at	_	_	I-Premise
154	each	_	_	I-Premise
155	visit	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	<	_	_	I-Premise
159	0.001	_	_	I-Premise
160	)	_	_	I-Premise
161	.	_	_	I-Premise

162	Mean	_	_	B-Premise
163	IOP	_	_	I-Premise
164	reductions	_	_	I-Premise
165	were	_	_	I-Premise
166	11.34	_	_	I-Premise
167	and	_	_	I-Premise
168	6.42	_	_	I-Premise
169	mm	_	_	I-Premise
170	Hg	_	_	I-Premise
171	at	_	_	I-Premise
172	2	_	_	I-Premise
173	weeks	_	_	I-Premise
174	(	_	_	I-Premise
175	P=0.000	_	_	I-Premise
176	)	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	11.17	_	_	I-Premise
180	and	_	_	I-Premise
181	7.89	_	_	I-Premise
182	mmHg	_	_	I-Premise
183	at	_	_	I-Premise
184	6	_	_	I-Premise
185	months	_	_	I-Premise
186	(	_	_	I-Premise
187	P=0.001	_	_	I-Premise
188	)	_	_	I-Premise
189	for	_	_	I-Premise
190	BTFC	_	_	I-Premise
191	and	_	_	I-Premise
192	TTFC	_	_	I-Premise
193	,	_	_	I-Premise
194	respectively	_	_	I-Premise
195	.	_	_	I-Premise

196	IOPs	_	_	B-Premise
197	at	_	_	I-Premise
198	2	_	_	I-Premise
199	weeks	_	_	I-Premise
200	were	_	_	I-Premise
201	18	_	_	I-Premise
202	mm	_	_	I-Premise
203	Hg	_	_	I-Premise
204	in	_	_	I-Premise
205	36	_	_	I-Premise
206	(	_	_	I-Premise
207	90.8	_	_	I-Premise
208	%	_	_	I-Premise
209	)	_	_	I-Premise
210	versus	_	_	I-Premise
211	22	_	_	I-Premise
212	(	_	_	I-Premise
213	55	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	eyes	_	_	I-Premise
217	and	_	_	I-Premise
218	16	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	in	_	_	I-Premise
222	28	_	_	I-Premise
223	(	_	_	I-Premise
224	70	_	_	I-Premise
225	%	_	_	I-Premise
226	)	_	_	I-Premise
227	versus	_	_	I-Premise
228	16	_	_	I-Premise
229	(	_	_	I-Premise
230	40	_	_	I-Premise
231	%	_	_	I-Premise
232	)	_	_	I-Premise
233	eyes	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	<	_	_	I-Premise
237	0.001	_	_	I-Premise
238	)	_	_	I-Premise
239	,	_	_	I-Premise
240	and	_	_	I-Premise
241	at	_	_	I-Premise
242	6	_	_	I-Premise
243	months	_	_	I-Premise
244	,	_	_	I-Premise
245	18	_	_	I-Premise
246	mm	_	_	I-Premise
247	Hg	_	_	I-Premise
248	in	_	_	I-Premise
249	38	_	_	I-Premise
250	(	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	versus	_	_	I-Premise
255	28	_	_	I-Premise
256	(	_	_	I-Premise
257	70	_	_	I-Premise
258	%	_	_	I-Premise
259	)	_	_	I-Premise
260	eyes	_	_	I-Premise
261	and	_	_	I-Premise
262	16	_	_	I-Premise
263	mm	_	_	I-Premise
264	Hg	_	_	I-Premise
265	in	_	_	I-Premise
266	30	_	_	I-Premise
267	(	_	_	I-Premise
268	75	_	_	I-Premise
269	%	_	_	I-Premise
270	)	_	_	I-Premise
271	versus	_	_	I-Premise
272	18	_	_	I-Premise
273	(	_	_	I-Premise
274	45	_	_	I-Premise
275	%	_	_	I-Premise
276	)	_	_	I-Premise
277	eyes	_	_	I-Premise
278	for	_	_	I-Premise
279	BTFC	_	_	I-Premise
280	and	_	_	I-Premise
281	TTFC	_	_	I-Premise
282	,	_	_	I-Premise
283	respectively	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	0.001	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Both	_	_	B-Claim
291	drops	_	_	I-Claim
292	provided	_	_	I-Claim
293	effective	_	_	I-Claim
294	IOP	_	_	I-Claim
295	reduction	_	_	I-Claim
296	that	_	_	I-Claim
297	was	_	_	I-Claim
298	greater	_	_	I-Claim
299	and	_	_	O
300	patients	_	_	B-Claim
301	were	_	_	I-Claim
302	more	_	_	I-Claim
303	likely	_	_	I-Claim
304	to	_	_	I-Claim
305	achieve	_	_	I-Claim
306	lower	_	_	I-Claim
307	target	_	_	I-Claim
308	pressures	_	_	I-Claim
309	with	_	_	I-Claim
310	BTFC	_	_	I-Claim
311	than	_	_	I-Claim
312	with	_	_	I-Claim
313	TTFC	_	_	I-Claim
314	.	_	_	I-Claim


0	Prior	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	suggested	_	_	O
4	that	_	_	O
5	melatonin	_	_	O
6	,	_	_	O
7	a	_	_	O
8	frequently	_	_	O
9	used	_	_	O
10	integrative	_	_	O
11	medicine	_	_	O
12	,	_	_	O
13	can	_	_	O
14	attenuate	_	_	O
15	weight	_	_	O
16	loss	_	_	O
17	,	_	_	O
18	anorexia	_	_	O
19	,	_	_	O
20	and	_	_	O
21	fatigue	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	These	_	_	O
28	studies	_	_	O
29	were	_	_	O
30	limited	_	_	O
31	by	_	_	O
32	a	_	_	O
33	lack	_	_	O
34	of	_	_	O
35	blinding	_	_	O
36	and	_	_	O
37	absence	_	_	O
38	of	_	_	O
39	placebo	_	_	O
40	controls	_	_	O
41	.	_	_	O

42	The	_	_	O
43	primary	_	_	O
44	purpose	_	_	O
45	of	_	_	O
46	this	_	_	O
47	study	_	_	O
48	was	_	_	O
49	to	_	_	O
50	compare	_	_	O
51	melatonin	_	_	O
52	with	_	_	O
53	placebo	_	_	O
54	for	_	_	O
55	appetite	_	_	O
56	improvement	_	_	O
57	in	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	cancer	_	_	O
61	cachexia	_	_	O
62	.	_	_	O

63	We	_	_	O
64	performed	_	_	O
65	a	_	_	O
66	randomized	_	_	O
67	,	_	_	O
68	double-blind	_	_	O
69	,	_	_	O
70	28-day	_	_	O
71	trial	_	_	O
72	of	_	_	O
73	melatonin	_	_	O
74	20	_	_	O
75	mg	_	_	O
76	versus	_	_	O
77	placebo	_	_	O
78	in	_	_	O
79	patients	_	_	O
80	with	_	_	O
81	advanced	_	_	O
82	lung	_	_	O
83	or	_	_	O
84	GI	_	_	O
85	cancer	_	_	O
86	,	_	_	O
87	appetite	_	_	O
88	scores	_	_	O
89	≥	_	_	O
90	4	_	_	O
91	on	_	_	O
92	a	_	_	O
93	0	_	_	O
94	to	_	_	O
95	10	_	_	O
96	scale	_	_	O
97	(	_	_	O
98	10	_	_	O
99	=	_	_	O
100	worst	_	_	O
101	appetite	_	_	O
102	)	_	_	O
103	,	_	_	O
104	and	_	_	O
105	history	_	_	O
106	of	_	_	O
107	weight	_	_	O
108	loss	_	_	O
109	≥	_	_	O
110	5	_	_	O
111	%	_	_	O
112	.	_	_	O

113	Assessments	_	_	O
114	included	_	_	O
115	weight	_	_	O
116	,	_	_	O
117	symptoms	_	_	O
118	by	_	_	O
119	the	_	_	O
120	Edmonton	_	_	O
121	Symptom	_	_	O
122	Assessment	_	_	O
123	Scale	_	_	O
124	,	_	_	O
125	and	_	_	O
126	quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	by	_	_	O
130	the	_	_	O
131	Functional	_	_	O
132	Assessment	_	_	O
133	of	_	_	O
134	Anorexia/Cachexia	_	_	O
135	Therapy	_	_	O
136	(	_	_	O
137	FAACT	_	_	O
138	)	_	_	O
139	questionnaire	_	_	O
140	.	_	_	O

141	Differences	_	_	O
142	between	_	_	O
143	groups	_	_	O
144	from	_	_	O
145	baseline	_	_	O
146	to	_	_	O
147	day	_	_	O
148	28	_	_	O
149	were	_	_	O
150	analyzed	_	_	O
151	using	_	_	O
152	one-sided	_	_	O
153	,	_	_	O
154	two-sample	_	_	O
155	t	_	_	O
156	tests	_	_	O
157	or	_	_	O
158	Wilcoxon	_	_	O
159	two-sample	_	_	O
160	tests	_	_	O
161	.	_	_	O

162	Interim	_	_	O
163	analysis	_	_	O
164	halfway	_	_	O
165	through	_	_	O
166	the	_	_	O
167	trial	_	_	O
168	had	_	_	O
169	a	_	_	O
170	Lan-DeMets	_	_	O
171	monitoring	_	_	O
172	boundary	_	_	O
173	with	_	_	O
174	an	_	_	O
175	O'Brien-Fleming	_	_	O
176	stopping	_	_	O
177	rule	_	_	O
178	.	_	_	O

179	Decision	_	_	O
180	boundaries	_	_	O
181	were	_	_	O
182	to	_	_	O
183	accept	_	_	O
184	the	_	_	O
185	null	_	_	O
186	hypothesis	_	_	O
187	of	_	_	O
188	futility	_	_	O
189	if	_	_	O
190	the	_	_	O
191	test	_	_	O
192	statistic	_	_	O
193	z	_	_	O
194	<	_	_	O
195	0.39	_	_	O
196	(	_	_	O
197	P	_	_	O
198	≥	_	_	O
199	.348	_	_	O
200	)	_	_	O
201	and	_	_	O
202	reject	_	_	O
203	the	_	_	O
204	null	_	_	O
205	hypothesis	_	_	O
206	if	_	_	O
207	z	_	_	O
208	>	_	_	O
209	2.54	_	_	O
210	(	_	_	O
211	P	_	_	O
212	≤	_	_	O
213	.0056	_	_	O
214	)	_	_	O
215	.	_	_	O

216	After	_	_	O
217	interim	_	_	O
218	analysis	_	_	O
219	of	_	_	O
220	48	_	_	O
221	patients	_	_	O
222	,	_	_	O
223	the	_	_	O
224	study	_	_	O
225	was	_	_	O
226	closed	_	_	O
227	for	_	_	O
228	futility	_	_	O
229	.	_	_	O

230	There	_	_	B-Premise
231	were	_	_	I-Premise
232	no	_	_	I-Premise
233	significant	_	_	I-Premise
234	differences	_	_	I-Premise
235	between	_	_	I-Premise
236	groups	_	_	I-Premise
237	for	_	_	I-Premise
238	appetite	_	_	I-Premise
239	(	_	_	I-Premise
240	P	_	_	I-Premise
241	=	_	_	I-Premise
242	.78	_	_	I-Premise
243	)	_	_	I-Premise
244	or	_	_	I-Premise
245	other	_	_	I-Premise
246	symptoms	_	_	I-Premise
247	,	_	_	I-Premise
248	weight	_	_	I-Premise
249	(	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	.17	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	FAACT	_	_	I-Premise
256	score	_	_	I-Premise
257	(	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.95	_	_	I-Premise
261	)	_	_	I-Premise
262	,	_	_	I-Premise
263	toxicity	_	_	I-Premise
264	,	_	_	I-Premise
265	or	_	_	I-Premise
266	survival	_	_	I-Premise
267	from	_	_	I-Premise
268	baseline	_	_	I-Premise
269	to	_	_	I-Premise
270	day	_	_	I-Premise
271	28	_	_	I-Premise
272	.	_	_	I-Premise

273	In	_	_	B-Claim
274	cachectic	_	_	I-Claim
275	patients	_	_	I-Claim
276	with	_	_	I-Claim
277	advanced	_	_	I-Claim
278	cancer	_	_	I-Claim
279	,	_	_	I-Claim
280	oral	_	_	I-Claim
281	melatonin	_	_	I-Claim
282	20	_	_	I-Claim
283	mg	_	_	I-Claim
284	at	_	_	I-Claim
285	night	_	_	I-Claim
286	did	_	_	I-Claim
287	not	_	_	I-Claim
288	improve	_	_	I-Claim
289	appetite	_	_	I-Claim
290	,	_	_	I-Claim
291	weight	_	_	I-Claim
292	,	_	_	I-Claim
293	or	_	_	I-Claim
294	quality	_	_	I-Claim
295	of	_	_	I-Claim
296	life	_	_	I-Claim
297	compared	_	_	I-Claim
298	with	_	_	I-Claim
299	placebo	_	_	I-Claim
300	.	_	_	I-Claim


0	Treatment	_	_	O
1	of	_	_	O
2	patients	_	_	O
3	with	_	_	O
4	advanced	_	_	O
5	or	_	_	O
6	metastatic	_	_	O
7	esophagogastric	_	_	O
8	adenocarcinoma	_	_	O
9	should	_	_	O
10	not	_	_	O
11	only	_	_	O
12	prolong	_	_	O
13	life	_	_	O
14	but	_	_	O
15	also	_	_	O
16	provide	_	_	O
17	relief	_	_	O
18	of	_	_	O
19	symptoms	_	_	O
20	and	_	_	O
21	improve	_	_	O
22	quality	_	_	O
23	of	_	_	O
24	life	_	_	O
25	(	_	_	O
26	QOL	_	_	O
27	)	_	_	O
28	.	_	_	O

29	Esophagogastric	_	_	O
30	adenocarcinoma	_	_	O
31	mainly	_	_	O
32	occurs	_	_	O
33	in	_	_	O
34	elderly	_	_	O
35	patients	_	_	O
36	,	_	_	O
37	but	_	_	O
38	they	_	_	O
39	are	_	_	O
40	underrepresented	_	_	O
41	in	_	_	O
42	most	_	_	O
43	clinical	_	_	O
44	trials	_	_	O
45	and	_	_	O
46	often	_	_	O
47	do	_	_	O
48	not	_	_	O
49	receive	_	_	O
50	effective	_	_	O
51	combination	_	_	O
52	chemotherapy	_	_	O
53	,	_	_	O
54	most	_	_	O
55	probably	_	_	O
56	for	_	_	O
57	fear	_	_	O
58	of	_	_	O
59	intolerance	_	_	O
60	.	_	_	O

61	Using	_	_	O
62	validated	_	_	O
63	instruments	_	_	O
64	,	_	_	O
65	we	_	_	O
66	prospectively	_	_	O
67	assessed	_	_	O
68	QOL	_	_	O
69	within	_	_	O
70	the	_	_	O
71	randomized	_	_	O
72	FLOT65+	_	_	O
73	phase	_	_	O
74	II	_	_	O
75	trial	_	_	O
76	.	_	_	O

77	Within	_	_	O
78	the	_	_	O
79	FLOT65+	_	_	O
80	trial	_	_	O
81	,	_	_	O
82	a	_	_	O
83	total	_	_	O
84	of	_	_	O
85	143	_	_	O
86	patients	_	_	O
87	aged	_	_	O
88	≥65	_	_	O
89	years	_	_	O
90	were	_	_	O
91	randomly	_	_	O
92	allocated	_	_	O
93	to	_	_	O
94	receive	_	_	O
95	biweekly	_	_	O
96	oxaliplatin	_	_	O
97	plus	_	_	O
98	5-fluorouracil	_	_	O
99	(	_	_	O
100	5-FU	_	_	O
101	)	_	_	O
102	continuous	_	_	O
103	infusion	_	_	O
104	and	_	_	O
105	folinic	_	_	O
106	acid	_	_	O
107	(	_	_	O
108	FLO	_	_	O
109	)	_	_	O
110	or	_	_	O
111	the	_	_	O
112	same	_	_	O
113	regimen	_	_	O
114	in	_	_	O
115	combination	_	_	O
116	with	_	_	O
117	docetaxel	_	_	O
118	50	_	_	O
119	mg/m	_	_	O
120	(	_	_	O
121	2	_	_	O
122	)	_	_	O
123	(	_	_	O
124	FLOT	_	_	O
125	)	_	_	O
126	.	_	_	O

127	The	_	_	O
128	European	_	_	O
129	Organisation	_	_	O
130	for	_	_	O
131	Research	_	_	O
132	and	_	_	O
133	Treatment	_	_	O
134	of	_	_	O
135	Cancer	_	_	O
136	Quality	_	_	O
137	of	_	_	O
138	Life	_	_	O
139	Questionnaire	_	_	O
140	C30	_	_	O
141	(	_	_	O
142	EORTC	_	_	O
143	QLQ-C30	_	_	O
144	)	_	_	O
145	and	_	_	O
146	the	_	_	O
147	gastric	_	_	O
148	module	_	_	O
149	STO22	_	_	O
150	were	_	_	O
151	administered	_	_	O
152	every	_	_	O
153	8	_	_	O
154	weeks	_	_	O
155	until	_	_	O
156	progression	_	_	O
157	.	_	_	O

158	Time	_	_	O
159	to	_	_	O
160	definitive	_	_	O
161	deterioration	_	_	O
162	of	_	_	O
163	QOL	_	_	O
164	parameters	_	_	O
165	was	_	_	O
166	analyzed	_	_	O
167	and	_	_	O
168	compared	_	_	O
169	within	_	_	O
170	the	_	_	O
171	treatment	_	_	O
172	arms	_	_	O
173	.	_	_	O

174	The	_	_	O
175	median	_	_	O
176	age	_	_	O
177	of	_	_	O
178	patients	_	_	O
179	was	_	_	O
180	70	_	_	O
181	years	_	_	O
182	.	_	_	O

183	Patients	_	_	B-Premise
184	receiving	_	_	I-Premise
185	FLOT	_	_	I-Premise
186	exhibited	_	_	I-Premise
187	higher	_	_	I-Premise
188	response	_	_	I-Premise
189	rates	_	_	I-Premise
190	and	_	_	I-Premise
191	had	_	_	I-Premise
192	improved	_	_	I-Premise
193	disease-free	_	_	I-Premise
194	and	_	_	I-Premise
195	progression-free	_	_	I-Premise
196	survival	_	_	I-Premise
197	(	_	_	I-Premise
198	PFS	_	_	I-Premise
199	)	_	_	I-Premise
200	.	_	_	I-Premise

201	The	_	_	O
202	proportions	_	_	O
203	of	_	_	O
204	patients	_	_	O
205	with	_	_	O
206	evaluable	_	_	O
207	baseline	_	_	O
208	EORTC	_	_	O
209	QLQ-C30	_	_	O
210	and	_	_	O
211	STO22	_	_	O
212	questionnaires	_	_	O
213	were	_	_	O
214	balanced	_	_	O
215	(	_	_	O
216	83	_	_	O
217	%	_	_	O
218	in	_	_	O
219	FLOT	_	_	O
220	and	_	_	O
221	89	_	_	O
222	%	_	_	O
223	in	_	_	O
224	FLO	_	_	O
225	)	_	_	O
226	.	_	_	O

227	Considering	_	_	O
228	evaluable	_	_	O
229	patients	_	_	O
230	with	_	_	O
231	assessable	_	_	O
232	questionnaires	_	_	O
233	(	_	_	O
234	n	_	_	O
235	=	_	_	O
236	123	_	_	O
237	)	_	_	O
238	,	_	_	O
239	neither	_	_	O
240	functioning	_	_	O
241	nor	_	_	O
242	symptom	_	_	O
243	parameters	_	_	O
244	differed	_	_	O
245	significantly	_	_	O
246	in	_	_	O
247	favor	_	_	O
248	of	_	_	O
249	one	_	_	O
250	of	_	_	O
251	the	_	_	O
252	two	_	_	O
253	treatment	_	_	O
254	groups	_	_	O
255	.	_	_	O

256	Particularly	_	_	O
257	,	_	_	O
258	there	_	_	B-Premise
259	was	_	_	I-Premise
260	no	_	_	I-Premise
261	significant	_	_	I-Premise
262	difference	_	_	I-Premise
263	regarding	_	_	I-Premise
264	time	_	_	I-Premise
265	to	_	_	I-Premise
266	definitive	_	_	I-Premise
267	deterioration	_	_	I-Premise
268	of	_	_	I-Premise
269	global	_	_	I-Premise
270	health	_	_	I-Premise
271	status/quality	_	_	I-Premise
272	of	_	_	I-Premise
273	life	_	_	I-Premise
274	from	_	_	I-Premise
275	baseline	_	_	I-Premise
276	(	_	_	I-Premise
277	primary	_	_	I-Premise
278	endpoint	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	Notably	_	_	O
282	,	_	_	O
283	patients	_	_	B-Premise
284	receiving	_	_	I-Premise
285	FLO	_	_	I-Premise
286	or	_	_	I-Premise
287	FLOT	_	_	I-Premise
288	as	_	_	I-Premise
289	palliative	_	_	I-Premise
290	treatment	_	_	I-Premise
291	(	_	_	I-Premise
292	n	_	_	I-Premise
293	=	_	_	I-Premise
294	98	_	_	I-Premise
295	)	_	_	I-Premise
296	achieved	_	_	I-Premise
297	comparable	_	_	I-Premise
298	QOL	_	_	I-Premise
299	results	_	_	I-Premise
300	.	_	_	I-Premise

301	Although	_	_	B-Premise
302	toxicity	_	_	I-Premise
303	was	_	_	I-Premise
304	higher	_	_	I-Premise
305	in	_	_	I-Premise
306	patients	_	_	I-Premise
307	receiving	_	_	I-Premise
308	FLOT	_	_	I-Premise
309	,	_	_	I-Premise
310	no	_	_	B-Premise
311	negative	_	_	I-Premise
312	impact	_	_	I-Premise
313	of	_	_	I-Premise
314	the	_	_	I-Premise
315	addition	_	_	I-Premise
316	of	_	_	I-Premise
317	docetaxel	_	_	I-Premise
318	on	_	_	I-Premise
319	QOL	_	_	I-Premise
320	parameters	_	_	I-Premise
321	could	_	_	I-Premise
322	be	_	_	I-Premise
323	demonstrated	_	_	I-Premise
324	.	_	_	I-Premise

325	Thus	_	_	O
326	,	_	_	O
327	elderly	_	_	B-Claim
328	patients	_	_	I-Claim
329	in	_	_	I-Claim
330	need	_	_	I-Claim
331	of	_	_	I-Claim
332	intensified	_	_	I-Claim
333	chemotherapy	_	_	I-Claim
334	may	_	_	I-Claim
335	receive	_	_	I-Claim
336	FLOT	_	_	I-Claim
337	without	_	_	I-Claim
338	compromising	_	_	I-Claim
339	patient-reported	_	_	I-Claim
340	outcome	_	_	I-Claim
341	parameters	_	_	I-Claim
342	.	_	_	I-Claim


0	The	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	controlled	_	_	O
4	BOLERO-2	_	_	O
5	(	_	_	O
6	Breast	_	_	O
7	Cancer	_	_	O
8	Trials	_	_	O
9	of	_	_	O
10	Oral	_	_	O
11	Everolimus	_	_	O
12	)	_	_	O
13	trial	_	_	O
14	demonstrated	_	_	O
15	significantly	_	_	O
16	improved	_	_	O
17	progression-free	_	_	O
18	survival	_	_	O
19	with	_	_	O
20	the	_	_	O
21	use	_	_	O
22	of	_	_	O
23	everolimus	_	_	O
24	plus	_	_	O
25	exemestane	_	_	O
26	(	_	_	O
27	EVE	_	_	O
28	+	_	_	O
29	EXE	_	_	O
30	)	_	_	O
31	versus	_	_	O
32	placebo	_	_	O
33	plus	_	_	O
34	exemestane	_	_	O
35	(	_	_	O
36	PBO	_	_	O
37	+	_	_	O
38	EXE	_	_	O
39	)	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	advanced	_	_	O
44	breast	_	_	O
45	cancer	_	_	O
46	who	_	_	O
47	developed	_	_	O
48	disease	_	_	O
49	progression	_	_	O
50	after	_	_	O
51	treatment	_	_	O
52	with	_	_	O
53	nonsteroidal	_	_	O
54	aromatase	_	_	O
55	inhibitors	_	_	O
56	.	_	_	O

57	This	_	_	O
58	analysis	_	_	O
59	investigated	_	_	O
60	the	_	_	O
61	treatment	_	_	O
62	effects	_	_	O
63	on	_	_	O
64	health-related	_	_	O
65	quality	_	_	O
66	of	_	_	O
67	life	_	_	O
68	(	_	_	O
69	HRQOL	_	_	O
70	)	_	_	O
71	.	_	_	O

72	Using	_	_	O
73	the	_	_	O
74	European	_	_	O
75	Organisation	_	_	O
76	for	_	_	O
77	Research	_	_	O
78	and	_	_	O
79	Treatment	_	_	O
80	of	_	_	O
81	Cancer	_	_	O
82	Quality	_	_	O
83	of	_	_	O
84	Life	_	_	O
85	Questionnaire-Core	_	_	O
86	30	_	_	O
87	(	_	_	O
88	EORTC	_	_	O
89	QLQ-C30	_	_	O
90	)	_	_	O
91	questionnaire	_	_	O
92	,	_	_	O
93	HRQOL	_	_	O
94	was	_	_	O
95	assessed	_	_	O
96	at	_	_	O
97	baseline	_	_	O
98	and	_	_	O
99	every	_	_	O
100	6	_	_	O
101	weeks	_	_	O
102	thereafter	_	_	O
103	until	_	_	O
104	disease	_	_	O
105	progression	_	_	O
106	and/or	_	_	O
107	treatment	_	_	O
108	discontinuation	_	_	O
109	.	_	_	O

110	The	_	_	O
111	30	_	_	O
112	items	_	_	O
113	in	_	_	O
114	15	_	_	O
115	subscales	_	_	O
116	of	_	_	O
117	the	_	_	O
118	QLQ-C30	_	_	O
119	include	_	_	O
120	global	_	_	O
121	health	_	_	O
122	status	_	_	O
123	wherein	_	_	O
124	higher	_	_	O
125	scores	_	_	O
126	(	_	_	O
127	range	_	_	O
128	,	_	_	O
129	0-100	_	_	O
130	)	_	_	O
131	indicate	_	_	O
132	better	_	_	O
133	HRQOL	_	_	O
134	.	_	_	O

135	This	_	_	O
136	analysis	_	_	O
137	included	_	_	O
138	a	_	_	O
139	protocol-specified	_	_	O
140	time	_	_	O
141	to	_	_	O
142	definitive	_	_	O
143	deterioration	_	_	O
144	(	_	_	O
145	TDD	_	_	O
146	)	_	_	O
147	analysis	_	_	O
148	at	_	_	O
149	a	_	_	O
150	5	_	_	O
151	%	_	_	O
152	decrease	_	_	O
153	in	_	_	O
154	HRQOL	_	_	O
155	versus	_	_	O
156	baseline	_	_	O
157	,	_	_	O
158	with	_	_	O
159	no	_	_	O
160	subsequent	_	_	O
161	increase	_	_	O
162	above	_	_	O
163	this	_	_	O
164	threshold	_	_	O
165	.	_	_	O

166	The	_	_	O
167	authors	_	_	O
168	report	_	_	O
169	additional	_	_	O
170	sensitivity	_	_	O
171	analyses	_	_	O
172	using	_	_	O
173	10-point	_	_	O
174	minimal	_	_	O
175	important	_	_	O
176	difference	_	_	O
177	decreases	_	_	O
178	in	_	_	O
179	the	_	_	O
180	global	_	_	O
181	health	_	_	O
182	status	_	_	O
183	score	_	_	O
184	versus	_	_	O
185	baseline	_	_	O
186	.	_	_	O

187	Treatment	_	_	O
188	arms	_	_	O
189	were	_	_	O
190	compared	_	_	O
191	using	_	_	O
192	the	_	_	O
193	stratified	_	_	O
194	log-rank	_	_	O
195	test	_	_	O
196	and	_	_	O
197	Cox	_	_	O
198	proportional	_	_	O
199	hazards	_	_	O
200	model	_	_	O
201	adjusted	_	_	O
202	for	_	_	O
203	trial	_	_	O
204	stratum	_	_	O
205	(	_	_	O
206	visceral	_	_	O
207	metastases	_	_	O
208	,	_	_	O
209	previous	_	_	O
210	hormone	_	_	O
211	sensitivity	_	_	O
212	)	_	_	O
213	,	_	_	O
214	age	_	_	O
215	,	_	_	O
216	sex	_	_	O
217	,	_	_	O
218	race	_	_	O
219	,	_	_	O
220	baseline	_	_	O
221	global	_	_	O
222	health	_	_	O
223	status	_	_	O
224	score	_	_	O
225	and	_	_	O
226	Eastern	_	_	O
227	Cooperative	_	_	O
228	Oncology	_	_	O
229	Group	_	_	O
230	performance	_	_	O
231	status	_	_	O
232	,	_	_	O
233	prognostic	_	_	O
234	risk	_	_	O
235	factors	_	_	O
236	,	_	_	O
237	and	_	_	O
238	treatment	_	_	O
239	history	_	_	O
240	.	_	_	O

241	Baseline	_	_	O
242	global	_	_	O
243	health	_	_	O
244	status	_	_	O
245	scores	_	_	O
246	were	_	_	O
247	found	_	_	O
248	to	_	_	O
249	be	_	_	O
250	similar	_	_	O
251	between	_	_	O
252	treatment	_	_	O
253	groups	_	_	O
254	(	_	_	O
255	64.7	_	_	O
256	vs	_	_	O
257	65.3	_	_	O
258	)	_	_	O
259	.	_	_	O

260	The	_	_	B-Premise
261	median	_	_	I-Premise
262	TDD	_	_	I-Premise
263	in	_	_	I-Premise
264	HRQOL	_	_	I-Premise
265	was	_	_	I-Premise
266	8.3	_	_	I-Premise
267	months	_	_	I-Premise
268	with	_	_	I-Premise
269	EVE	_	_	I-Premise
270	+	_	_	I-Premise
271	EXE	_	_	I-Premise
272	versus	_	_	I-Premise
273	5.8	_	_	I-Premise
274	months	_	_	I-Premise
275	with	_	_	I-Premise
276	PBO	_	_	I-Premise
277	+	_	_	I-Premise
278	EXE	_	_	I-Premise
279	(	_	_	I-Premise
280	hazard	_	_	I-Premise
281	ratio	_	_	I-Premise
282	,	_	_	I-Premise
283	0.74	_	_	I-Premise
284	;	_	_	I-Premise
285	P	_	_	I-Premise
286	=	_	_	I-Premise
287	.0084	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	At	_	_	B-Premise
291	the	_	_	I-Premise
292	10-point	_	_	I-Premise
293	minimal	_	_	I-Premise
294	important	_	_	I-Premise
295	difference	_	_	I-Premise
296	,	_	_	I-Premise
297	the	_	_	I-Premise
298	median	_	_	I-Premise
299	TDD	_	_	I-Premise
300	with	_	_	I-Premise
301	EVE	_	_	I-Premise
302	+	_	_	I-Premise
303	EXE	_	_	I-Premise
304	was	_	_	I-Premise
305	11.7	_	_	I-Premise
306	months	_	_	I-Premise
307	versus	_	_	I-Premise
308	8.4	_	_	I-Premise
309	months	_	_	I-Premise
310	with	_	_	I-Premise
311	PBO	_	_	I-Premise
312	+	_	_	I-Premise
313	EXE	_	_	I-Premise
314	(	_	_	I-Premise
315	hazard	_	_	I-Premise
316	ratio	_	_	I-Premise
317	,	_	_	I-Premise
318	0.80	_	_	I-Premise
319	;	_	_	I-Premise
320	P	_	_	I-Premise
321	=	_	_	I-Premise
322	.1017	_	_	I-Premise
323	)	_	_	I-Premise
324	.	_	_	I-Premise

325	In	_	_	B-Claim
326	patients	_	_	I-Claim
327	with	_	_	I-Claim
328	advanced	_	_	I-Claim
329	breast	_	_	I-Claim
330	cancer	_	_	I-Claim
331	who	_	_	I-Claim
332	develop	_	_	I-Claim
333	disease	_	_	I-Claim
334	progression	_	_	I-Claim
335	after	_	_	I-Claim
336	treatment	_	_	I-Claim
337	with	_	_	I-Claim
338	nonsteroidal	_	_	I-Claim
339	aromatase	_	_	I-Claim
340	inhibitors	_	_	I-Claim
341	,	_	_	I-Claim
342	EVE	_	_	I-Claim
343	+	_	_	I-Claim
344	EXE	_	_	I-Claim
345	was	_	_	I-Claim
346	associated	_	_	I-Claim
347	with	_	_	I-Claim
348	a	_	_	I-Claim
349	longer	_	_	I-Claim
350	TDD	_	_	I-Claim
351	in	_	_	I-Claim
352	global	_	_	I-Claim
353	HRQOL	_	_	I-Claim
354	versus	_	_	I-Claim
355	PBO	_	_	I-Claim
356	+	_	_	I-Claim
357	EXE	_	_	I-Claim
358	.	_	_	I-Claim


0	Malignant	_	_	B-Claim
1	pleural	_	_	I-Claim
2	effusion	_	_	I-Claim
3	(	_	_	I-Claim
4	MPE	_	_	I-Claim
5	)	_	_	I-Claim
6	is	_	_	I-Claim
7	a	_	_	I-Claim
8	common	_	_	I-Claim
9	complication	_	_	I-Claim
10	of	_	_	I-Claim
11	advanced	_	_	I-Claim
12	non-small	_	_	I-Claim
13	cell	_	_	I-Claim
14	lung	_	_	I-Claim
15	cancer	_	_	I-Claim
16	(	_	_	I-Claim
17	NSCLC	_	_	I-Claim
18	)	_	_	I-Claim
19	.	_	_	I-Claim

20	Bevacizumab	_	_	B-Claim
21	,	_	_	I-Claim
22	a	_	_	I-Claim
23	humanized	_	_	I-Claim
24	monoclonal	_	_	I-Claim
25	antibody	_	_	I-Claim
26	against	_	_	I-Claim
27	vascular	_	_	I-Claim
28	endothelial	_	_	I-Claim
29	growth	_	_	I-Claim
30	factor	_	_	I-Claim
31	(	_	_	I-Claim
32	VEGF	_	_	I-Claim
33	)	_	_	I-Claim
34	,	_	_	I-Claim
35	has	_	_	I-Claim
36	been	_	_	I-Claim
37	shown	_	_	I-Claim
38	to	_	_	I-Claim
39	be	_	_	I-Claim
40	efficient	_	_	I-Claim
41	in	_	_	I-Claim
42	suppressing	_	_	I-Claim
43	the	_	_	I-Claim
44	accumulation	_	_	I-Claim
45	of	_	_	I-Claim
46	pleural	_	_	I-Claim
47	fluid	_	_	I-Claim
48	.	_	_	I-Claim

49	However	_	_	O
50	,	_	_	O
51	whether	_	_	O
52	intrapleural	_	_	O
53	delivery	_	_	O
54	of	_	_	O
55	bevacizumab	_	_	O
56	can	_	_	O
57	be	_	_	O
58	used	_	_	O
59	to	_	_	O
60	treat	_	_	O
61	MPE	_	_	O
62	remains	_	_	O
63	unknown	_	_	O
64	.	_	_	O

65	The	_	_	O
66	aim	_	_	O
67	of	_	_	O
68	the	_	_	O
69	present	_	_	O
70	study	_	_	O
71	was	_	_	O
72	to	_	_	O
73	evaluate	_	_	O
74	the	_	_	O
75	efficacy	_	_	O
76	and	_	_	O
77	safety	_	_	O
78	of	_	_	O
79	combined	_	_	O
80	intrapleural	_	_	O
81	therapy	_	_	O
82	with	_	_	O
83	bevacizumab	_	_	O
84	and	_	_	O
85	cisplatin	_	_	O
86	,	_	_	O
87	an	_	_	O
88	antineoplastic	_	_	O
89	agent	_	_	O
90	,	_	_	O
91	in	_	_	O
92	controlling	_	_	O
93	MPE	_	_	O
94	.	_	_	O

95	A	_	_	O
96	total	_	_	O
97	of	_	_	O
98	72	_	_	O
99	NSCLC	_	_	O
100	study	_	_	O
101	subjects	_	_	O
102	with	_	_	O
103	MPE	_	_	O
104	were	_	_	O
105	randomly	_	_	O
106	assigned	_	_	O
107	to	_	_	O
108	one	_	_	O
109	of	_	_	O
110	two	_	_	O
111	groups	_	_	O
112	.	_	_	O

113	The	_	_	O
114	first	_	_	O
115	group	_	_	O
116	received	_	_	O
117	intrapleural	_	_	O
118	bevacizumab	_	_	O
119	(	_	_	O
120	300	_	_	O
121	mg	_	_	O
122	)	_	_	O
123	with	_	_	O
124	cisplatin	_	_	O
125	(	_	_	O
126	30	_	_	O
127	mg	_	_	O
128	)	_	_	O
129	therapy	_	_	O
130	and	_	_	O
131	the	_	_	O
132	second	_	_	O
133	group	_	_	O
134	received	_	_	O
135	intrapleural	_	_	O
136	cisplatin	_	_	O
137	(	_	_	O
138	30	_	_	O
139	mg	_	_	O
140	)	_	_	O
141	therapy	_	_	O
142	alone	_	_	O
143	.	_	_	O

144	Pleural	_	_	O
145	fluid	_	_	O
146	was	_	_	O
147	collected	_	_	O
148	from	_	_	O
149	both	_	_	O
150	groups	_	_	O
151	prior	_	_	O
152	to	_	_	O
153	and	_	_	O
154	following	_	_	O
155	treatment	_	_	O
156	.	_	_	O

157	The	_	_	O
158	levels	_	_	O
159	of	_	_	O
160	VEGF	_	_	O
161	and	_	_	O
162	carcinoembryonic	_	_	O
163	antigen	_	_	O
164	(	_	_	O
165	CEA	_	_	O
166	)	_	_	O
167	in	_	_	O
168	the	_	_	O
169	pleural	_	_	O
170	fluid	_	_	O
171	were	_	_	O
172	determined	_	_	O
173	by	_	_	O
174	ELISA	_	_	O
175	.	_	_	O

176	In	_	_	B-Premise
177	70	_	_	I-Premise
178	evaluable	_	_	I-Premise
179	study	_	_	I-Premise
180	subjects	_	_	I-Premise
181	,	_	_	I-Premise
182	the	_	_	I-Premise
183	curative	_	_	I-Premise
184	efficacy	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	bevacizumab	_	_	I-Premise
188	group	_	_	I-Premise
189	was	_	_	I-Premise
190	significantly	_	_	I-Premise
191	higher	_	_	I-Premise
192	than	_	_	I-Premise
193	that	_	_	I-Premise
194	found	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	cisplatin	_	_	I-Premise
198	group	_	_	I-Premise
199	(	_	_	I-Premise
200	83.33	_	_	I-Premise
201	vs.	_	_	I-Premise
202	50.00	_	_	I-Premise
203	%	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	;	_	_	I-Premise
207	p	_	_	I-Premise
208	<	_	_	I-Premise
209	0.05	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	Therapy	_	_	B-Premise
213	with	_	_	I-Premise
214	combined	_	_	I-Premise
215	bevacizumab	_	_	I-Premise
216	plus	_	_	I-Premise
217	cisplatin	_	_	I-Premise
218	significantly	_	_	I-Premise
219	reduced	_	_	I-Premise
220	VEGF	_	_	I-Premise
221	levels	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	pleural	_	_	I-Premise
225	fluid	_	_	I-Premise
226	(	_	_	I-Premise
227	p	_	_	I-Premise
228	<	_	_	I-Premise
229	0.01	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	In	_	_	B-Premise
233	the	_	_	I-Premise
234	bevacizumab	_	_	I-Premise
235	group	_	_	I-Premise
236	,	_	_	I-Premise
237	the	_	_	I-Premise
238	levels	_	_	I-Premise
239	of	_	_	I-Premise
240	VEGF	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	pleural	_	_	I-Premise
244	fluid	_	_	I-Premise
245	were	_	_	I-Premise
246	significantly	_	_	I-Premise
247	lower	_	_	I-Premise
248	compared	_	_	I-Premise
249	to	_	_	I-Premise
250	those	_	_	I-Premise
251	of	_	_	I-Premise
252	the	_	_	I-Premise
253	cisplatin	_	_	I-Premise
254	group	_	_	I-Premise
255	after	_	_	I-Premise
256	treatment	_	_	I-Premise
257	,	_	_	I-Premise
258	which	_	_	I-Premise
259	showed	_	_	I-Premise
260	greater	_	_	I-Premise
261	efficacy	_	_	I-Premise
262	(	_	_	I-Premise
263	p	_	_	I-Premise
264	<	_	_	I-Premise
265	0.01	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	In	_	_	B-Premise
269	addition	_	_	I-Premise
270	,	_	_	I-Premise
271	combination	_	_	I-Premise
272	therapy	_	_	I-Premise
273	showed	_	_	I-Premise
274	greater	_	_	I-Premise
275	efficacy	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	patients	_	_	I-Premise
279	with	_	_	I-Premise
280	high	_	_	I-Premise
281	levels	_	_	I-Premise
282	of	_	_	I-Premise
283	VEGF	_	_	I-Premise
284	expression	_	_	I-Premise
285	(	_	_	I-Premise
286	p	_	_	I-Premise
287	<	_	_	I-Premise
288	0.01	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	There	_	_	B-Premise
292	was	_	_	I-Premise
293	no	_	_	I-Premise
294	significant	_	_	I-Premise
295	difference	_	_	I-Premise
296	in	_	_	I-Premise
297	grade	_	_	I-Premise
298	III/IV	_	_	I-Premise
299	adverse	_	_	I-Premise
300	events	_	_	I-Premise
301	between	_	_	I-Premise
302	the	_	_	I-Premise
303	two	_	_	I-Premise
304	groups	_	_	I-Premise
305	.	_	_	I-Premise

306	All	_	_	B-Premise
307	procedures	_	_	I-Premise
308	were	_	_	I-Premise
309	well	_	_	I-Premise
310	tolerated	_	_	I-Premise
311	by	_	_	I-Premise
312	the	_	_	I-Premise
313	patients	_	_	I-Premise
314	.	_	_	I-Premise

315	Combined	_	_	B-Claim
316	intrapleural	_	_	I-Claim
317	therapy	_	_	I-Claim
318	with	_	_	I-Claim
319	bevacizumab	_	_	I-Claim
320	and	_	_	I-Claim
321	cisplatin	_	_	I-Claim
322	was	_	_	I-Claim
323	effective	_	_	I-Claim
324	and	_	_	I-Claim
325	safe	_	_	I-Claim
326	in	_	_	I-Claim
327	managing	_	_	I-Claim
328	NSCLC-mediated	_	_	I-Claim
329	MPE	_	_	I-Claim
330	.	_	_	I-Claim

331	We	_	_	B-Claim
332	propose	_	_	I-Claim
333	that	_	_	I-Claim
334	VEGF	_	_	I-Claim
335	expression	_	_	I-Claim
336	levels	_	_	I-Claim
337	in	_	_	I-Claim
338	MPE	_	_	I-Claim
339	could	_	_	I-Claim
340	serve	_	_	I-Claim
341	as	_	_	I-Claim
342	a	_	_	I-Claim
343	prognostic	_	_	I-Claim
344	marker	_	_	I-Claim
345	for	_	_	I-Claim
346	bevacizumab	_	_	I-Claim
347	therapy	_	_	I-Claim
348	.	_	_	I-Claim


0	Bacillus	_	_	B-Claim
1	Calmette-Guérin	_	_	I-Claim
2	and	_	_	I-Claim
3	intravesical	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	represent	_	_	I-Claim
6	viable	_	_	I-Claim
7	adjuvant	_	_	I-Claim
8	options	_	_	I-Claim
9	for	_	_	I-Claim
10	intermediate	_	_	I-Claim
11	risk	_	_	I-Claim
12	nonmuscle	_	_	I-Claim
13	invasive	_	_	I-Claim
14	bladder	_	_	I-Claim
15	cancer	_	_	I-Claim
16	.	_	_	I-Claim

17	Although	_	_	O
18	bacillus	_	_	O
19	Calmette-Guérin	_	_	O
20	is	_	_	O
21	perceived	_	_	O
22	as	_	_	O
23	less	_	_	O
24	tolerable	_	_	O
25	than	_	_	O
26	intravesical	_	_	O
27	chemotherapy	_	_	O
28	,	_	_	O
29	to	_	_	O
30	our	_	_	O
31	knowledge	_	_	O
32	no	_	_	O
33	comparative	_	_	O
34	studies	_	_	O
35	have	_	_	O
36	addressed	_	_	O
37	quality	_	_	O
38	of	_	_	O
39	life	_	_	O
40	issues	_	_	O
41	.	_	_	O

42	We	_	_	O
43	compared	_	_	O
44	the	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	of	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	nonmuscle	_	_	O
52	invasive	_	_	O
53	bladder	_	_	O
54	cancer	_	_	O
55	who	_	_	O
56	received	_	_	O
57	adjuvant	_	_	O
58	intravesical	_	_	O
59	gemcitabine	_	_	O
60	or	_	_	O
61	1/3	_	_	O
62	dose	_	_	O
63	bacillus	_	_	O
64	Calmette-Guérin	_	_	O
65	.	_	_	O

66	Our	_	_	O
67	multicenter	_	_	O
68	,	_	_	O
69	prospective	_	_	O
70	,	_	_	O
71	randomized	_	_	O
72	,	_	_	O
73	phase	_	_	O
74	II	_	_	O
75	study	_	_	O
76	included	_	_	O
77	120	_	_	O
78	patients	_	_	O
79	with	_	_	O
80	intermediate	_	_	O
81	risk	_	_	O
82	nonmuscle	_	_	O
83	invasive	_	_	O
84	bladder	_	_	O
85	cancer	_	_	O
86	.	_	_	O

87	Of	_	_	O
88	these	_	_	O
89	patients	_	_	O
90	88	_	_	O
91	remained	_	_	O
92	assessable	_	_	O
93	at	_	_	O
94	1-year	_	_	O
95	followup	_	_	O
96	.	_	_	O

97	Only	_	_	O
98	1	_	_	O
99	patient	_	_	O
100	was	_	_	O
101	withdrawn	_	_	O
102	because	_	_	O
103	of	_	_	O
104	adverse	_	_	O
105	events	_	_	O
106	.	_	_	O

107	Overall	_	_	O
108	61	_	_	O
109	patients	_	_	O
110	received	_	_	O
111	2,000	_	_	O
112	mg/50	_	_	O
113	cc	_	_	O
114	gemcitabine	_	_	O
115	weekly	_	_	O
116	for	_	_	O
117	6	_	_	O
118	weeks	_	_	O
119	(	_	_	O
120	maintenance	_	_	O
121	monthly	_	_	O
122	for	_	_	O
123	1	_	_	O
124	year	_	_	O
125	)	_	_	O
126	while	_	_	O
127	59	_	_	O
128	received	_	_	O
129	1/3	_	_	O
130	dose	_	_	O
131	bacillus	_	_	O
132	Calmette-Guérin	_	_	O
133	Connaught	_	_	O
134	weekly	_	_	O
135	for	_	_	O
136	6	_	_	O
137	weeks	_	_	O
138	(	_	_	O
139	maintenance	_	_	O
140	3	_	_	O
141	weekly	_	_	O
142	instillations	_	_	O
143	at	_	_	O
144	3	_	_	O
145	,	_	_	O
146	6	_	_	O
147	and	_	_	O
148	12	_	_	O
149	months	_	_	O
150	)	_	_	O
151	.	_	_	O

152	Quality	_	_	O
153	of	_	_	O
154	life	_	_	O
155	was	_	_	O
156	measured	_	_	O
157	by	_	_	O
158	the	_	_	O
159	EORTC	_	_	O
160	QLQ-C30	_	_	O
161	(	_	_	O
162	European	_	_	O
163	Organization	_	_	O
164	for	_	_	O
165	the	_	_	O
166	Research	_	_	O
167	and	_	_	O
168	Treatment	_	_	O
169	of	_	_	O
170	Cancer	_	_	O
171	Quality	_	_	O
172	of	_	_	O
173	Life	_	_	O
174	Questionnaire	_	_	O
175	Core	_	_	O
176	30	_	_	O
177	version	_	_	O
178	3.0	_	_	O
179	)	_	_	O
180	and	_	_	O
181	QLQ-BLS24	_	_	O
182	(	_	_	O
183	Quality	_	_	O
184	of	_	_	O
185	Life	_	_	O
186	Superficial	_	_	O
187	Bladder	_	_	O
188	Cancer-Specific	_	_	O
189	24	_	_	O
190	)	_	_	O
191	questionnaires	_	_	O
192	.	_	_	O

193	Group	_	_	O
194	differences	_	_	O
195	were	_	_	O
196	calculated	_	_	O
197	using	_	_	O
198	ANOVA	_	_	O
199	(	_	_	O
200	ANOVA/MANOVA	_	_	O
201	)	_	_	O
202	.	_	_	O

203	Treatment	_	_	B-Premise
204	was	_	_	I-Premise
205	well	_	_	I-Premise
206	tolerated	_	_	I-Premise
207	in	_	_	I-Premise
208	both	_	_	I-Premise
209	groups	_	_	I-Premise
210	,	_	_	I-Premise
211	although	_	_	B-Premise
212	local	_	_	I-Premise
213	and	_	_	I-Premise
214	systemic	_	_	I-Premise
215	side	_	_	I-Premise
216	effects	_	_	I-Premise
217	were	_	_	I-Premise
218	more	_	_	I-Premise
219	frequently	_	_	I-Premise
220	reported	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	bacillus	_	_	I-Premise
224	Calmette-Guérin	_	_	I-Premise
225	arm	_	_	I-Premise
226	.	_	_	I-Premise

227	Multivariate	_	_	B-Premise
228	analyses	_	_	I-Premise
229	showed	_	_	I-Premise
230	no	_	_	I-Premise
231	significant	_	_	I-Premise
232	differences	_	_	I-Premise
233	between	_	_	I-Premise
234	the	_	_	I-Premise
235	2	_	_	I-Premise
236	groups	_	_	I-Premise
237	in	_	_	I-Premise
238	all	_	_	I-Premise
239	quality	_	_	I-Premise
240	of	_	_	I-Premise
241	life	_	_	I-Premise
242	dimensions	_	_	I-Premise
243	.	_	_	I-Premise

244	No	_	_	B-Premise
245	significant	_	_	I-Premise
246	changes	_	_	I-Premise
247	over	_	_	I-Premise
248	time	_	_	I-Premise
249	in	_	_	I-Premise
250	quality	_	_	I-Premise
251	of	_	_	I-Premise
252	life	_	_	I-Premise
253	domains	_	_	I-Premise
254	were	_	_	I-Premise
255	detected	_	_	I-Premise
256	for	_	_	I-Premise
257	patients	_	_	I-Premise
258	on	_	_	I-Premise
259	bacillus	_	_	I-Premise
260	Calmette-Guérin	_	_	I-Premise
261	and	_	_	I-Premise
262	gemcitabine	_	_	I-Premise
263	except	_	_	I-Premise
264	for	_	_	I-Premise
265	physical	_	_	I-Premise
266	functioning	_	_	I-Premise
267	,	_	_	I-Premise
268	which	_	_	I-Premise
269	decreased	_	_	I-Premise
270	significantly	_	_	I-Premise
271	in	_	_	I-Premise
272	both	_	_	I-Premise
273	groups	_	_	I-Premise
274	(	_	_	I-Premise
275	p	_	_	I-Premise
276	=	_	_	I-Premise
277	0.002	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	No	_	_	B-Premise
281	significant	_	_	I-Premise
282	differences	_	_	I-Premise
283	were	_	_	I-Premise
284	detected	_	_	I-Premise
285	in	_	_	I-Premise
286	terms	_	_	I-Premise
287	of	_	_	I-Premise
288	recurrence	_	_	I-Premise
289	and	_	_	I-Premise
290	progression	_	_	I-Premise
291	between	_	_	I-Premise
292	the	_	_	I-Premise
293	2	_	_	I-Premise
294	groups	_	_	I-Premise
295	at	_	_	I-Premise
296	1-year	_	_	I-Premise
297	followup	_	_	I-Premise
298	.	_	_	I-Premise

299	While	_	_	O
300	a	_	_	B-Claim
301	higher	_	_	I-Claim
302	rate	_	_	I-Claim
303	of	_	_	I-Claim
304	side	_	_	I-Claim
305	effects	_	_	I-Claim
306	,	_	_	I-Claim
307	albeit	_	_	I-Claim
308	mild	_	_	I-Claim
309	to	_	_	I-Claim
310	moderate	_	_	I-Claim
311	,	_	_	I-Claim
312	was	_	_	I-Claim
313	detected	_	_	I-Claim
314	with	_	_	I-Claim
315	1/3	_	_	I-Claim
316	dose	_	_	I-Claim
317	bacillus	_	_	I-Claim
318	Calmette-Guérin	_	_	I-Claim
319	compared	_	_	I-Claim
320	to	_	_	I-Claim
321	gemcitabine	_	_	I-Claim
322	,	_	_	I-Claim
323	our	_	_	B-Claim
324	study	_	_	I-Claim
325	failed	_	_	I-Claim
326	to	_	_	I-Claim
327	show	_	_	I-Claim
328	significant	_	_	I-Claim
329	differences	_	_	I-Claim
330	between	_	_	I-Claim
331	the	_	_	I-Claim
332	2	_	_	I-Claim
333	drugs	_	_	I-Claim
334	in	_	_	I-Claim
335	terms	_	_	I-Claim
336	of	_	_	I-Claim
337	quality	_	_	I-Claim
338	of	_	_	I-Claim
339	life	_	_	I-Claim
340	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	no	_	_	O
3	known	_	_	O
4	effective	_	_	O
5	treatments	_	_	O
6	for	_	_	O
7	painful	_	_	O
8	chemotherapy-induced	_	_	O
9	peripheral	_	_	O
10	neuropathy	_	_	O
11	.	_	_	O

12	To	_	_	O
13	determine	_	_	O
14	the	_	_	O
15	effect	_	_	O
16	of	_	_	O
17	duloxetine	_	_	O
18	,	_	_	O
19	60	_	_	O
20	mg	_	_	O
21	daily	_	_	O
22	,	_	_	O
23	on	_	_	O
24	average	_	_	O
25	pain	_	_	O
26	severity	_	_	O
27	.	_	_	O

28	Randomized	_	_	O
29	,	_	_	O
30	double-blind	_	_	O
31	,	_	_	O
32	placebo-controlled	_	_	O
33	crossover	_	_	O
34	trial	_	_	O
35	at	_	_	O
36	8	_	_	O
37	National	_	_	O
38	Cancer	_	_	O
39	Institute	_	_	O
40	(	_	_	O
41	NCI	_	_	O
42	)	_	_	O
43	-funded	_	_	O
44	cooperative	_	_	O
45	research	_	_	O
46	networks	_	_	O
47	that	_	_	O
48	enrolled	_	_	O
49	231	_	_	O
50	patients	_	_	O
51	who	_	_	O
52	were	_	_	O
53	25	_	_	O
54	years	_	_	O
55	or	_	_	O
56	older	_	_	O
57	being	_	_	O
58	treated	_	_	O
59	at	_	_	O
60	community	_	_	O
61	and	_	_	O
62	academic	_	_	O
63	settings	_	_	O
64	between	_	_	O
65	April	_	_	O
66	2008	_	_	O
67	and	_	_	O
68	March	_	_	O
69	2011	_	_	O
70	.	_	_	O

71	Study	_	_	O
72	follow-up	_	_	O
73	was	_	_	O
74	completed	_	_	O
75	July	_	_	O
76	2012	_	_	O
77	.	_	_	O

78	Stratified	_	_	O
79	by	_	_	O
80	chemotherapeutic	_	_	O
81	drug	_	_	O
82	and	_	_	O
83	comorbid	_	_	O
84	pain	_	_	O
85	risk	_	_	O
86	,	_	_	O
87	patients	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	to	_	_	O
91	receive	_	_	O
92	either	_	_	O
93	duloxetine	_	_	O
94	followed	_	_	O
95	by	_	_	O
96	placebo	_	_	O
97	or	_	_	O
98	placebo	_	_	O
99	followed	_	_	O
100	by	_	_	O
101	duloxetine	_	_	O
102	.	_	_	O

103	Eligibility	_	_	O
104	required	_	_	O
105	that	_	_	O
106	patients	_	_	O
107	have	_	_	O
108	grade	_	_	O
109	1	_	_	O
110	or	_	_	O
111	higher	_	_	O
112	sensory	_	_	O
113	neuropathy	_	_	O
114	according	_	_	O
115	to	_	_	O
116	the	_	_	O
117	NCI	_	_	O
118	Common	_	_	O
119	Terminology	_	_	O
120	Criteria	_	_	O
121	for	_	_	O
122	Adverse	_	_	O
123	Events	_	_	O
124	and	_	_	O
125	at	_	_	O
126	least	_	_	O
127	4	_	_	O
128	on	_	_	O
129	a	_	_	O
130	scale	_	_	O
131	of	_	_	O
132	0	_	_	O
133	to	_	_	O
134	10	_	_	O
135	,	_	_	O
136	representing	_	_	O
137	average	_	_	O
138	chemotherapy-induced	_	_	O
139	pain	_	_	O
140	,	_	_	O
141	after	_	_	O
142	paclitaxel	_	_	O
143	,	_	_	O
144	other	_	_	O
145	taxane	_	_	O
146	,	_	_	O
147	or	_	_	O
148	oxaliplatin	_	_	O
149	treatment	_	_	O
150	.	_	_	O

151	The	_	_	O
152	initial	_	_	O
153	treatment	_	_	O
154	consisted	_	_	O
155	of	_	_	O
156	taking	_	_	O
157	1	_	_	O
158	capsule	_	_	O
159	daily	_	_	O
160	of	_	_	O
161	either	_	_	O
162	30	_	_	O
163	mg	_	_	O
164	of	_	_	O
165	duloxetine	_	_	O
166	or	_	_	O
167	placebo	_	_	O
168	for	_	_	O
169	the	_	_	O
170	first	_	_	O
171	week	_	_	O
172	and	_	_	O
173	2	_	_	O
174	capsules	_	_	O
175	of	_	_	O
176	either	_	_	O
177	30	_	_	O
178	mg	_	_	O
179	of	_	_	O
180	duloxetine	_	_	O
181	or	_	_	O
182	placebo	_	_	O
183	daily	_	_	O
184	for	_	_	O
185	4	_	_	O
186	additional	_	_	O
187	weeks	_	_	O
188	.	_	_	O

189	The	_	_	O
190	primary	_	_	O
191	hypothesis	_	_	O
192	was	_	_	O
193	that	_	_	O
194	duloxetine	_	_	O
195	would	_	_	O
196	be	_	_	O
197	more	_	_	O
198	effective	_	_	O
199	than	_	_	O
200	placebo	_	_	O
201	in	_	_	O
202	decreasing	_	_	O
203	chemotherapy-induced	_	_	O
204	peripheral	_	_	O
205	neuropathic	_	_	O
206	pain	_	_	O
207	.	_	_	O

208	Pain	_	_	O
209	severity	_	_	O
210	was	_	_	O
211	assessed	_	_	O
212	using	_	_	O
213	the	_	_	O
214	Brief	_	_	O
215	Pain	_	_	O
216	Inventory-Short	_	_	O
217	Form	_	_	O
218	average	_	_	O
219	pain	_	_	O
220	item	_	_	O
221	with	_	_	O
222	0	_	_	O
223	representing	_	_	O
224	no	_	_	O
225	pain	_	_	O
226	and	_	_	O
227	10	_	_	O
228	representing	_	_	O
229	as	_	_	O
230	bad	_	_	O
231	as	_	_	O
232	can	_	_	O
233	be	_	_	O
234	imagined	_	_	O
235	.	_	_	O

236	Individuals	_	_	B-Premise
237	receiving	_	_	I-Premise
238	duloxetine	_	_	I-Premise
239	as	_	_	I-Premise
240	their	_	_	I-Premise
241	initial	_	_	I-Premise
242	5-week	_	_	I-Premise
243	treatment	_	_	I-Premise
244	reported	_	_	I-Premise
245	a	_	_	I-Premise
246	mean	_	_	I-Premise
247	decrease	_	_	I-Premise
248	in	_	_	I-Premise
249	average	_	_	I-Premise
250	pain	_	_	I-Premise
251	of	_	_	I-Premise
252	1.06	_	_	I-Premise
253	(	_	_	I-Premise
254	95	_	_	I-Premise
255	%	_	_	I-Premise
256	CI	_	_	I-Premise
257	,	_	_	I-Premise
258	0.72-1.40	_	_	I-Premise
259	)	_	_	I-Premise
260	vs	_	_	I-Premise
261	0.34	_	_	I-Premise
262	(	_	_	I-Premise
263	95	_	_	I-Premise
264	%	_	_	I-Premise
265	CI	_	_	I-Premise
266	,	_	_	I-Premise
267	0.01-0.66	_	_	I-Premise
268	)	_	_	I-Premise
269	among	_	_	I-Premise
270	those	_	_	I-Premise
271	who	_	_	I-Premise
272	received	_	_	I-Premise
273	placebo	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	=	_	_	I-Premise
277	.003	_	_	I-Premise
278	;	_	_	I-Premise
279	effect	_	_	I-Premise
280	size	_	_	I-Premise
281	,	_	_	I-Premise
282	0.513	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	The	_	_	B-Premise
286	observed	_	_	I-Premise
287	mean	_	_	I-Premise
288	difference	_	_	I-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	average	_	_	I-Premise
292	pain	_	_	I-Premise
293	score	_	_	I-Premise
294	between	_	_	I-Premise
295	duloxetine	_	_	I-Premise
296	and	_	_	I-Premise
297	placebo	_	_	I-Premise
298	was	_	_	I-Premise
299	0.73	_	_	I-Premise
300	(	_	_	I-Premise
301	95	_	_	I-Premise
302	%	_	_	I-Premise
303	CI	_	_	I-Premise
304	,	_	_	I-Premise
305	0.26-1.20	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	Fifty-nine	_	_	B-Premise
309	percent	_	_	I-Premise
310	of	_	_	I-Premise
311	those	_	_	I-Premise
312	initially	_	_	I-Premise
313	receiving	_	_	I-Premise
314	duloxetine	_	_	I-Premise
315	vs	_	_	I-Premise
316	38	_	_	I-Premise
317	%	_	_	I-Premise
318	of	_	_	I-Premise
319	those	_	_	I-Premise
320	initially	_	_	I-Premise
321	receiving	_	_	I-Premise
322	placebo	_	_	I-Premise
323	reported	_	_	I-Premise
324	decreased	_	_	I-Premise
325	pain	_	_	I-Premise
326	of	_	_	I-Premise
327	any	_	_	I-Premise
328	amount	_	_	I-Premise
329	.	_	_	I-Premise

330	Among	_	_	B-Claim
331	patients	_	_	I-Claim
332	with	_	_	I-Claim
333	painful	_	_	I-Claim
334	chemotherapy-induced	_	_	I-Claim
335	peripheral	_	_	I-Claim
336	neuropathy	_	_	I-Claim
337	,	_	_	I-Claim
338	the	_	_	I-Claim
339	use	_	_	I-Claim
340	of	_	_	I-Claim
341	duloxetine	_	_	I-Claim
342	compared	_	_	I-Claim
343	with	_	_	I-Claim
344	placebo	_	_	I-Claim
345	for	_	_	I-Claim
346	5	_	_	I-Claim
347	weeks	_	_	I-Claim
348	resulted	_	_	I-Claim
349	in	_	_	I-Claim
350	a	_	_	I-Claim
351	greater	_	_	I-Claim
352	reduction	_	_	I-Claim
353	in	_	_	I-Claim
354	pain	_	_	I-Claim
355	.	_	_	I-Claim


0	Sexual	_	_	O
1	dysfunction	_	_	O
2	represents	_	_	O
3	a	_	_	O
4	complex	_	_	O
5	and	_	_	O
6	multifactorial	_	_	O
7	construct	_	_	O
8	that	_	_	O
9	can	_	_	O
10	affect	_	_	O
11	both	_	_	O
12	men	_	_	O
13	and	_	_	O
14	women	_	_	O
15	and	_	_	O
16	has	_	_	O
17	been	_	_	O
18	noted	_	_	O
19	to	_	_	O
20	often	_	_	O
21	deteriorate	_	_	O
22	significantly	_	_	O
23	after	_	_	O
24	treatment	_	_	O
25	for	_	_	O
26	rectal	_	_	O
27	and	_	_	O
28	anal	_	_	O
29	cancer	_	_	O
30	.	_	_	O

31	Despite	_	_	O
32	this	_	_	O
33	,	_	_	O
34	it	_	_	O
35	remains	_	_	O
36	an	_	_	O
37	understudied	_	_	O
38	,	_	_	O
39	underreported	_	_	O
40	,	_	_	O
41	and	_	_	O
42	undertreated	_	_	O
43	issue	_	_	O
44	in	_	_	O
45	the	_	_	O
46	field	_	_	O
47	of	_	_	O
48	cancer	_	_	O
49	survivorship	_	_	O
50	.	_	_	O

51	This	_	_	O
52	study	_	_	O
53	examined	_	_	O
54	the	_	_	O
55	characteristics	_	_	O
56	of	_	_	O
57	women	_	_	O
58	enrolled	_	_	O
59	in	_	_	O
60	an	_	_	O
61	intervention	_	_	O
62	trial	_	_	O
63	to	_	_	O
64	treat	_	_	O
65	sexual	_	_	O
66	dysfunction	_	_	O
67	,	_	_	O
68	and	_	_	O
69	explored	_	_	O
70	the	_	_	O
71	relationship	_	_	O
72	between	_	_	O
73	sexual	_	_	O
74	functioning	_	_	O
75	and	_	_	O
76	psychological	_	_	O
77	well-being	_	_	O
78	.	_	_	O

79	There	_	_	O
80	were	_	_	O
81	70	_	_	O
82	female	_	_	O
83	posttreatment	_	_	O
84	anal	_	_	O
85	or	_	_	O
86	rectal	_	_	O
87	cancer	_	_	O
88	survivors	_	_	O
89	assessed	_	_	O
90	as	_	_	O
91	part	_	_	O
92	of	_	_	O
93	the	_	_	O
94	current	_	_	O
95	study	_	_	O
96	.	_	_	O

97	Participants	_	_	O
98	were	_	_	O
99	enrolled	_	_	O
100	in	_	_	O
101	a	_	_	O
102	randomized	_	_	O
103	intervention	_	_	O
104	trial	_	_	O
105	to	_	_	O
106	treat	_	_	O
107	sexual	_	_	O
108	dysfunction	_	_	O
109	and	_	_	O
110	completed	_	_	O
111	outcome	_	_	O
112	measures	_	_	O
113	prior	_	_	O
114	to	_	_	O
115	randomization	_	_	O
116	.	_	_	O

117	The	_	_	O
118	main	_	_	O
119	outcome	_	_	O
120	measures	_	_	O
121	are	_	_	O
122	quality	_	_	O
123	of	_	_	O
124	life	_	_	O
125	(	_	_	O
126	QOL	_	_	O
127	)	_	_	O
128	(	_	_	O
129	European	_	_	O
130	Organization	_	_	O
131	for	_	_	O
132	Research	_	_	O
133	and	_	_	O
134	Treatment	_	_	O
135	of	_	_	O
136	Cancer	_	_	O
137	Core	_	_	O
138	Quality	_	_	O
139	of	_	_	O
140	Life	_	_	O
141	Questionnaire	_	_	O
142	[	_	_	O
143	EORTC-QLQ-C30	_	_	O
144	]	_	_	O
145	and	_	_	O
146	Colorectal	_	_	O
147	Cancer-Specific	_	_	O
148	Module	_	_	O
149	[	_	_	O
150	QLQ-CR38	_	_	O
151	]	_	_	O
152	)	_	_	O
153	,	_	_	O
154	sexual	_	_	O
155	functioning	_	_	O
156	(	_	_	O
157	Female	_	_	O
158	Sexual	_	_	O
159	Functioning	_	_	O
160	Index	_	_	O
161	)	_	_	O
162	,	_	_	O
163	and	_	_	O
164	psychological	_	_	O
165	well-being	_	_	O
166	(	_	_	O
167	Brief	_	_	O
168	Symptom	_	_	O
169	Inventory	_	_	O
170	Depression/Anxiety	_	_	O
171	,	_	_	O
172	Impact	_	_	O
173	of	_	_	O
174	Events	_	_	O
175	Scale-Revised	_	_	O
176	,	_	_	O
177	CR-38	_	_	O
178	Body	_	_	O
179	Image	_	_	O
180	)	_	_	O
181	.	_	_	O

182	Women	_	_	O
183	enrolled	_	_	O
184	in	_	_	O
185	the	_	_	O
186	study	_	_	O
187	intervention	_	_	O
188	were	_	_	O
189	on	_	_	O
190	average	_	_	O
191	55	_	_	O
192	years	_	_	O
193	old	_	_	O
194	,	_	_	O
195	predominantly	_	_	O
196	Caucasian	_	_	O
197	(	_	_	O
198	79	_	_	O
199	%	_	_	O
200	)	_	_	O
201	,	_	_	O
202	married	_	_	O
203	(	_	_	O
204	57	_	_	O
205	%	_	_	O
206	)	_	_	O
207	,	_	_	O
208	and	_	_	O
209	a	_	_	O
210	median	_	_	O
211	of	_	_	O
212	4	_	_	O
213	years	_	_	O
214	postprimary	_	_	O
215	treatment	_	_	O
216	.	_	_	O

217	For	_	_	O
218	those	_	_	O
219	reporting	_	_	O
220	sexual	_	_	O
221	activity	_	_	O
222	at	_	_	O
223	baseline	_	_	O
224	(	_	_	O
225	N=41	_	_	O
226	)	_	_	O
227	,	_	_	O
228	sexual	_	_	O
229	dysfunction	_	_	O
230	was	_	_	O
231	associated	_	_	O
232	with	_	_	O
233	a	_	_	O
234	range	_	_	O
235	of	_	_	O
236	specific	_	_	O
237	measures	_	_	O
238	of	_	_	O
239	psychological	_	_	O
240	well-being	_	_	O
241	,	_	_	O
242	all	_	_	O
243	in	_	_	O
244	the	_	_	O
245	hypothesized	_	_	O
246	direction	_	_	O
247	.	_	_	O

248	The	_	_	B-Premise
249	Sexual/Relationship	_	_	I-Premise
250	Satisfaction	_	_	I-Premise
251	subscale	_	_	I-Premise
252	was	_	_	I-Premise
253	associated	_	_	I-Premise
254	with	_	_	I-Premise
255	all	_	_	I-Premise
256	measures	_	_	I-Premise
257	of	_	_	I-Premise
258	psychological	_	_	I-Premise
259	well-being	_	_	I-Premise
260	(	_	_	I-Premise
261	r=-0.45	_	_	I-Premise
262	to	_	_	I-Premise
263	-0.70	_	_	I-Premise
264	,	_	_	I-Premise
265	all	_	_	I-Premise
266	P	_	_	I-Premise
267	<	_	_	I-Premise
268	0.01	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	Body	_	_	B-Premise
272	image	_	_	I-Premise
273	,	_	_	I-Premise
274	anxiety	_	_	I-Premise
275	,	_	_	I-Premise
276	and	_	_	I-Premise
277	cancer-specific	_	_	I-Premise
278	posttraumatic	_	_	I-Premise
279	distress	_	_	I-Premise
280	were	_	_	I-Premise
281	notable	_	_	I-Premise
282	in	_	_	I-Premise
283	their	_	_	I-Premise
284	association	_	_	I-Premise
285	with	_	_	I-Premise
286	subscales	_	_	I-Premise
287	of	_	_	I-Premise
288	sexual	_	_	I-Premise
289	functioning	_	_	I-Premise
290	,	_	_	I-Premise
291	while	_	_	I-Premise
292	a	_	_	I-Premise
293	global	_	_	I-Premise
294	QOL	_	_	I-Premise
295	measure	_	_	I-Premise
296	was	_	_	I-Premise
297	largely	_	_	I-Premise
298	unrelated	_	_	I-Premise
299	.	_	_	I-Premise

300	For	_	_	B-Premise
301	sexually	_	_	I-Premise
302	active	_	_	I-Premise
303	female	_	_	I-Premise
304	rectal	_	_	I-Premise
305	and	_	_	I-Premise
306	anal	_	_	I-Premise
307	cancer	_	_	I-Premise
308	survivors	_	_	I-Premise
309	enrolled	_	_	I-Premise
310	in	_	_	I-Premise
311	a	_	_	I-Premise
312	sexual	_	_	I-Premise
313	health	_	_	I-Premise
314	intervention	_	_	I-Premise
315	,	_	_	I-Premise
316	sexual	_	_	I-Premise
317	dysfunction	_	_	I-Premise
318	was	_	_	I-Premise
319	significantly	_	_	I-Premise
320	and	_	_	I-Premise
321	consistently	_	_	I-Premise
322	associated	_	_	I-Premise
323	with	_	_	I-Premise
324	specific	_	_	I-Premise
325	measures	_	_	I-Premise
326	of	_	_	I-Premise
327	psychological	_	_	I-Premise
328	well-being	_	_	I-Premise
329	,	_	_	I-Premise
330	most	_	_	I-Premise
331	notably	_	_	I-Premise
332	Sexual/Relationship	_	_	I-Premise
333	Satisfaction	_	_	I-Premise
334	.	_	_	I-Premise

335	These	_	_	B-Claim
336	results	_	_	I-Claim
337	suggest	_	_	I-Claim
338	that	_	_	I-Claim
339	sexual	_	_	I-Claim
340	functioning	_	_	I-Claim
341	may	_	_	I-Claim
342	require	_	_	I-Claim
343	focused	_	_	I-Claim
344	assessment	_	_	I-Claim
345	by	_	_	I-Claim
346	providers	_	_	I-Claim
347	,	_	_	I-Claim
348	beyond	_	_	I-Claim
349	broad	_	_	I-Claim
350	QOL	_	_	I-Claim
351	assessments	_	_	I-Claim
352	,	_	_	I-Claim
353	and	_	_	O
354	that	_	_	O
355	attention	_	_	B-Claim
356	to	_	_	I-Claim
357	Sexual/Relationship	_	_	I-Claim
358	Satisfaction	_	_	I-Claim
359	may	_	_	I-Claim
360	be	_	_	I-Claim
361	critical	_	_	I-Claim
362	in	_	_	I-Claim
363	the	_	_	I-Claim
364	development	_	_	I-Claim
365	and	_	_	I-Claim
366	implementation	_	_	I-Claim
367	of	_	_	I-Claim
368	interventions	_	_	I-Claim
369	for	_	_	I-Claim
370	this	_	_	I-Claim
371	cohort	_	_	I-Claim
372	of	_	_	I-Claim
373	patients	_	_	I-Claim
374	.	_	_	I-Claim


0	To	_	_	O
1	prospectively	_	_	O
2	evaluate	_	_	O
3	and	_	_	O
4	compare	_	_	O
5	health-related	_	_	O
6	quality-of-life	_	_	O
7	(	_	_	O
8	QOL	_	_	O
9	)	_	_	O
10	outcomes	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	head-neck	_	_	O
15	squamous	_	_	O
16	cell	_	_	O
17	carcinoma	_	_	O
18	randomized	_	_	O
19	to	_	_	O
20	either	_	_	O
21	intensity-modulated	_	_	O
22	radiation	_	_	O
23	therapy	_	_	O
24	(	_	_	O
25	IMRT	_	_	O
26	)	_	_	O
27	or	_	_	O
28	three-dimensional	_	_	O
29	conformal	_	_	O
30	radiotherapy	_	_	O
31	(	_	_	O
32	3D-CRT	_	_	O
33	)	_	_	O
34	and	_	_	O
35	assess	_	_	O
36	serial	_	_	O
37	longitudinal	_	_	O
38	change	_	_	O
39	in	_	_	O
40	QOL	_	_	O
41	over	_	_	O
42	time	_	_	O
43	.	_	_	O

44	QOL	_	_	O
45	outcomes	_	_	O
46	were	_	_	O
47	assessed	_	_	O
48	using	_	_	O
49	the	_	_	O
50	European	_	_	O
51	Organization	_	_	O
52	for	_	_	O
53	Research	_	_	O
54	and	_	_	O
55	Treatment	_	_	O
56	of	_	_	O
57	Cancer	_	_	O
58	(	_	_	O
59	EORTC	_	_	O
60	)	_	_	O
61	QOL	_	_	O
62	questionnaire	_	_	O
63	(	_	_	O
64	QLQ-C30	_	_	O
65	)	_	_	O
66	and	_	_	O
67	Head-Neck	_	_	O
68	module	_	_	O
69	(	_	_	O
70	HN-35	_	_	O
71	)	_	_	O
72	at	_	_	O
73	baseline	_	_	O
74	(	_	_	O
75	pre-treatment	_	_	O
76	)	_	_	O
77	and	_	_	O
78	subsequently	_	_	O
79	periodically	_	_	O
80	on	_	_	O
81	follow-up	_	_	O
82	.	_	_	O

83	Mean	_	_	O
84	scores	_	_	O
85	of	_	_	O
86	individual	_	_	O
87	domains/scales	_	_	O
88	of	_	_	O
89	3D-CRT	_	_	O
90	and	_	_	O
91	IMRT	_	_	O
92	were	_	_	O
93	compared	_	_	O
94	using	_	_	O
95	't	_	_	O
96	'	_	_	O
97	test	_	_	O
98	at	_	_	O
99	each	_	_	O
100	time	_	_	O
101	point	_	_	O
102	;	_	_	O
103	while	_	_	O
104	longitudinal	_	_	O
105	change	_	_	O
106	in	_	_	O
107	mean	_	_	O
108	scores	_	_	O
109	of	_	_	O
110	both	_	_	O
111	groups	_	_	O
112	over	_	_	O
113	time	_	_	O
114	was	_	_	O
115	evaluated	_	_	O
116	by	_	_	O
117	repeated	_	_	O
118	measurement	_	_	O
119	analysis	_	_	O
120	of	_	_	O
121	variance	_	_	O
122	.	_	_	O

123	Fifty	_	_	O
124	eight	_	_	O
125	of	_	_	O
126	the	_	_	O
127	60	_	_	O
128	randomized	_	_	O
129	patients	_	_	O
130	who	_	_	O
131	filled	_	_	O
132	the	_	_	O
133	QOL	_	_	O
134	questionnaire	_	_	O
135	at	_	_	O
136	least	_	_	O
137	at	_	_	O
138	one	_	_	O
139	time	_	_	O
140	point	_	_	O
141	were	_	_	O
142	included	_	_	O
143	in	_	_	O
144	the	_	_	O
145	analysis	_	_	O
146	.	_	_	O

147	Several	_	_	O
148	general	_	_	O
149	(	_	_	O
150	emotional	_	_	O
151	functioning	_	_	O
152	,	_	_	O
153	role	_	_	O
154	functioning	_	_	O
155	,	_	_	O
156	social	_	_	O
157	contact	_	_	O
158	)	_	_	O
159	as	_	_	O
160	well	_	_	O
161	as	_	_	O
162	head	_	_	O
163	and	_	_	O
164	neck	_	_	O
165	cancer-specific	_	_	O
166	(	_	_	O
167	dry	_	_	O
168	mouth	_	_	O
169	,	_	_	O
170	opening	_	_	O
171	mouth	_	_	O
172	,	_	_	O
173	sticky	_	_	O
174	saliva	_	_	O
175	,	_	_	O
176	pain	_	_	O
177	,	_	_	O
178	senses	_	_	O
179	)	_	_	O
180	QOL	_	_	O
181	domains	_	_	O
182	were	_	_	O
183	better	_	_	O
184	preserved	_	_	O
185	with	_	_	O
186	IMRT	_	_	O
187	compared	_	_	O
188	to	_	_	O
189	3D-CRT	_	_	O
190	at	_	_	O
191	different	_	_	O
192	time	_	_	O
193	points	_	_	O
194	.	_	_	O

195	Importantly	_	_	O
196	,	_	_	O
197	none	_	_	O
198	of	_	_	O
199	the	_	_	O
200	QOL	_	_	O
201	domains	_	_	O
202	were	_	_	O
203	worse	_	_	O
204	with	_	_	O
205	IMRT	_	_	O
206	at	_	_	O
207	any	_	_	O
208	time	_	_	O
209	point	_	_	O
210	.	_	_	O

211	There	_	_	B-Premise
212	was	_	_	I-Premise
213	substantial	_	_	I-Premise
214	deterioration	_	_	I-Premise
215	in	_	_	I-Premise
216	QOL	_	_	I-Premise
217	scores	_	_	I-Premise
218	immediate	_	_	I-Premise
219	post-treatment	_	_	I-Premise
220	(	_	_	I-Premise
221	3-months	_	_	I-Premise
222	)	_	_	I-Premise
223	in	_	_	I-Premise
224	both	_	_	I-Premise
225	arms	_	_	I-Premise
226	.	_	_	I-Premise

227	However	_	_	B-Premise
228	,	_	_	I-Premise
229	QOL	_	_	I-Premise
230	scores	_	_	I-Premise
231	gradually	_	_	I-Premise
232	but	_	_	I-Premise
233	definitely	_	_	I-Premise
234	improved	_	_	I-Premise
235	over	_	_	I-Premise
236	time	_	_	I-Premise
237	for	_	_	I-Premise
238	most	_	_	I-Premise
239	domains	_	_	I-Premise
240	.	_	_	I-Premise

241	Global	_	_	B-Premise
242	QOL	_	_	I-Premise
243	,	_	_	I-Premise
244	emotional/role	_	_	I-Premise
245	functioning	_	_	I-Premise
246	,	_	_	I-Premise
247	nausea/vomiting	_	_	I-Premise
248	,	_	_	I-Premise
249	pain	_	_	I-Premise
250	,	_	_	I-Premise
251	swallowing	_	_	I-Premise
252	,	_	_	I-Premise
253	speech	_	_	I-Premise
254	,	_	_	I-Premise
255	social	_	_	I-Premise
256	contact/eating	_	_	I-Premise
257	,	_	_	I-Premise
258	insomnia	_	_	I-Premise
259	showed	_	_	I-Premise
260	rapid	_	_	I-Premise
261	recovery	_	_	I-Premise
262	(	_	_	I-Premise
263	<	_	_	I-Premise
264	6months	_	_	I-Premise
265	)	_	_	I-Premise
266	while	_	_	I-Premise
267	physical/cognitive	_	_	I-Premise
268	functioning	_	_	I-Premise
269	,	_	_	I-Premise
270	dry	_	_	I-Premise
271	mouth	_	_	I-Premise
272	,	_	_	I-Premise
273	sticky	_	_	I-Premise
274	saliva	_	_	I-Premise
275	,	_	_	I-Premise
276	fatigue	_	_	I-Premise
277	,	_	_	I-Premise
278	senses	_	_	I-Premise
279	showed	_	_	I-Premise
280	delayed	_	_	I-Premise
281	recovery	_	_	I-Premise
282	(	_	_	I-Premise
283	>	_	_	I-Premise
284	6months	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	There	_	_	B-Premise
288	were	_	_	I-Premise
289	no	_	_	I-Premise
290	significant	_	_	I-Premise
291	differences	_	_	I-Premise
292	in	_	_	I-Premise
293	loco-regional	_	_	I-Premise
294	or	_	_	I-Premise
295	survival	_	_	I-Premise
296	between	_	_	I-Premise
297	the	_	_	I-Premise
298	two	_	_	I-Premise
299	arms	_	_	I-Premise
300	.	_	_	I-Premise

301	There	_	_	B-Claim
302	is	_	_	I-Claim
303	substantial	_	_	I-Claim
304	deterioration	_	_	I-Claim
305	in	_	_	I-Claim
306	QOL	_	_	I-Claim
307	after	_	_	I-Claim
308	curative-intent	_	_	I-Claim
309	head-neck	_	_	I-Claim
310	irradiation	_	_	I-Claim
311	that	_	_	I-Claim
312	gradually	_	_	I-Claim
313	improves	_	_	I-Claim
314	over	_	_	I-Claim
315	time	_	_	I-Claim
316	.	_	_	I-Claim

317	IMRT	_	_	B-Claim
318	results	_	_	I-Claim
319	in	_	_	I-Claim
320	clinically	_	_	I-Claim
321	meaningful	_	_	I-Claim
322	and	_	_	I-Claim
323	statistically	_	_	I-Claim
324	better	_	_	I-Claim
325	QOL	_	_	I-Claim
326	scores	_	_	I-Claim
327	for	_	_	I-Claim
328	some	_	_	I-Claim
329	domains	_	_	I-Claim
330	compared	_	_	I-Claim
331	to	_	_	I-Claim
332	3D-CRT	_	_	I-Claim
333	at	_	_	I-Claim
334	several	_	_	I-Claim
335	time	_	_	I-Claim
336	points	_	_	I-Claim
337	with	_	_	I-Claim
338	comparable	_	_	I-Claim
339	disease	_	_	I-Claim
340	outcomes	_	_	I-Claim
341	that	_	_	I-Claim
342	could	_	_	I-Claim
343	support	_	_	I-Claim
344	its	_	_	I-Claim
345	widespread	_	_	I-Claim
346	adoption	_	_	I-Claim
347	in	_	_	I-Claim
348	routine	_	_	I-Claim
349	clinical	_	_	I-Claim
350	practice	_	_	I-Claim
351	.	_	_	I-Claim


0	The	_	_	O
1	AVEREL	_	_	O
2	trial	_	_	O
3	[	_	_	O
4	A	_	_	O
5	Study	_	_	O
6	of	_	_	O
7	Avastin	_	_	O
8	(	_	_	O
9	Bevacizumab	_	_	O
10	)	_	_	O
11	in	_	_	O
12	Combination	_	_	O
13	With	_	_	O
14	Herceptin	_	_	O
15	(	_	_	O
16	Trastuzumab	_	_	O
17	)	_	_	O
18	/Docetaxel	_	_	O
19	in	_	_	O
20	Patients	_	_	O
21	With	_	_	O
22	HER2-Positive	_	_	O
23	Metastatic	_	_	O
24	Breast	_	_	O
25	Cancer	_	_	O
26	]	_	_	O
27	evaluated	_	_	O
28	first-line	_	_	O
29	bevacizumab-containing	_	_	O
30	therapy	_	_	O
31	for	_	_	O
32	human	_	_	O
33	epidermal	_	_	O
34	growth	_	_	O
35	factor	_	_	O
36	receptor	_	_	O
37	2	_	_	O
38	(	_	_	O
39	HER2	_	_	O
40	)	_	_	O
41	-positive	_	_	O
42	locally	_	_	O
43	recurrent/metastatic	_	_	O
44	breast	_	_	O
45	cancer	_	_	O
46	(	_	_	O
47	LR/MBC	_	_	O
48	)	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	with	_	_	O
52	measurable/evaluable	_	_	O
53	HER2-positive	_	_	O
54	LR/MBC	_	_	O
55	who	_	_	O
56	had	_	_	O
57	not	_	_	O
58	received	_	_	O
59	trastuzumab	_	_	O
60	or	_	_	O
61	chemotherapy	_	_	O
62	for	_	_	O
63	LR/MBC	_	_	O
64	were	_	_	O
65	stratified	_	_	O
66	by	_	_	O
67	prior	_	_	O
68	adjuvant	_	_	O
69	trastuzumab	_	_	O
70	,	_	_	O
71	prior	_	_	O
72	(	_	_	O
73	neo	_	_	O
74	)	_	_	O
75	adjuvant	_	_	O
76	taxane	_	_	O
77	,	_	_	O
78	hormone	_	_	O
79	receptor	_	_	O
80	status	_	_	O
81	,	_	_	O
82	and	_	_	O
83	measurable	_	_	O
84	disease	_	_	O
85	and	_	_	O
86	were	_	_	O
87	randomly	_	_	O
88	assigned	_	_	O
89	to	_	_	O
90	receive	_	_	O
91	docetaxel	_	_	O
92	100	_	_	O
93	mg/m	_	_	O
94	(	_	_	O
95	2	_	_	O
96	)	_	_	O
97	plus	_	_	O
98	trastuzumab	_	_	O
99	8	_	_	O
100	mg/kg	_	_	O
101	loading	_	_	O
102	dose	_	_	O
103	followed	_	_	O
104	by	_	_	O
105	6	_	_	O
106	mg/kg	_	_	O
107	either	_	_	O
108	with	_	_	O
109	bevacizumab	_	_	O
110	15	_	_	O
111	mg/kg	_	_	O
112	or	_	_	O
113	without	_	_	O
114	bevacizumab	_	_	O
115	,	_	_	O
116	all	_	_	O
117	administered	_	_	O
118	every	_	_	O
119	3	_	_	O
120	weeks	_	_	O
121	.	_	_	O

122	The	_	_	O
123	primary	_	_	O
124	end	_	_	O
125	point	_	_	O
126	was	_	_	O
127	progression-free	_	_	O
128	survival	_	_	O
129	(	_	_	O
130	PFS	_	_	O
131	)	_	_	O
132	.	_	_	O

133	Additional	_	_	O
134	end	_	_	O
135	points	_	_	O
136	included	_	_	O
137	overall	_	_	O
138	survival	_	_	O
139	,	_	_	O
140	response	_	_	O
141	rate	_	_	O
142	(	_	_	O
143	RR	_	_	O
144	)	_	_	O
145	,	_	_	O
146	safety	_	_	O
147	,	_	_	O
148	quality	_	_	O
149	of	_	_	O
150	life	_	_	O
151	,	_	_	O
152	and	_	_	O
153	translational	_	_	O
154	research	_	_	O
155	.	_	_	O

156	Results	_	_	O
157	Baseline	_	_	O
158	characteristics	_	_	O
159	of	_	_	O
160	the	_	_	O
161	424	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	balanced	_	_	O
165	between	_	_	O
166	treatment	_	_	O
167	arms	_	_	O
168	.	_	_	O

169	Most	_	_	O
170	patients	_	_	O
171	had	_	_	O
172	visceral	_	_	O
173	metastases	_	_	O
174	,	_	_	O
175	43	_	_	O
176	%	_	_	O
177	had	_	_	O
178	a	_	_	O
179	disease-free	_	_	O
180	interval	_	_	O
181	less	_	_	O
182	than	_	_	O
183	12	_	_	O
184	months	_	_	O
185	,	_	_	O
186	and	_	_	O
187	85	_	_	O
188	%	_	_	O
189	had	_	_	O
190	measurable	_	_	O
191	disease	_	_	O
192	.	_	_	O

193	Median	_	_	O
194	follow-up	_	_	O
195	was	_	_	O
196	26	_	_	O
197	months	_	_	O
198	.	_	_	O

199	The	_	_	B-Premise
200	hazard	_	_	I-Premise
201	ratio	_	_	I-Premise
202	for	_	_	I-Premise
203	investigator-assessed	_	_	I-Premise
204	PFS	_	_	I-Premise
205	was	_	_	I-Premise
206	0.82	_	_	I-Premise
207	(	_	_	I-Premise
208	95	_	_	I-Premise
209	%	_	_	I-Premise
210	CI	_	_	I-Premise
211	,	_	_	I-Premise
212	0.65	_	_	I-Premise
213	to	_	_	I-Premise
214	1.02	_	_	I-Premise
215	;	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.0775	_	_	I-Premise
219	;	_	_	I-Premise
220	median	_	_	I-Premise
221	PFS	_	_	I-Premise
222	,	_	_	I-Premise
223	13.7	_	_	I-Premise
224	v	_	_	I-Premise
225	16.5	_	_	I-Premise
226	months	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	non-bevacizumab	_	_	I-Premise
230	and	_	_	I-Premise
231	bevacizumab	_	_	I-Premise
232	arms	_	_	I-Premise
233	,	_	_	I-Premise
234	respectively	_	_	I-Premise
235	;	_	_	I-Premise
236	PFS	_	_	I-Premise
237	events	_	_	I-Premise
238	in	_	_	I-Premise
239	72	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Premise
244	Independent	_	_	I-Premise
245	Review	_	_	I-Premise
246	Committee-assessed	_	_	I-Premise
247	PFS	_	_	I-Premise
248	hazard	_	_	I-Premise
249	ratio	_	_	I-Premise
250	was	_	_	I-Premise
251	0.72	_	_	I-Premise
252	(	_	_	I-Premise
253	95	_	_	I-Premise
254	%	_	_	I-Premise
255	CI	_	_	I-Premise
256	,	_	_	I-Premise
257	0.54	_	_	I-Premise
258	to	_	_	I-Premise
259	0.94	_	_	I-Premise
260	;	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.0162	_	_	I-Premise
264	;	_	_	I-Premise
265	median	_	_	I-Premise
266	PFS	_	_	I-Premise
267	,	_	_	I-Premise
268	13.9	_	_	I-Premise
269	v	_	_	I-Premise
270	16.8	_	_	I-Premise
271	months	_	_	I-Premise
272	,	_	_	I-Premise
273	respectively	_	_	I-Premise
274	;	_	_	I-Premise
275	PFS	_	_	I-Premise
276	events	_	_	I-Premise
277	in	_	_	I-Premise
278	53	_	_	I-Premise
279	%	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	The	_	_	B-Premise
283	RR	_	_	I-Premise
284	was	_	_	I-Premise
285	70	_	_	I-Premise
286	%	_	_	I-Premise
287	versus	_	_	I-Premise
288	74	_	_	I-Premise
289	%	_	_	I-Premise
290	,	_	_	I-Premise
291	respectively	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.3492	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Grade	_	_	B-Claim
299	≥	_	_	I-Claim
300	3	_	_	I-Claim
301	febrile	_	_	I-Claim
302	neutropenia	_	_	I-Claim
303	and	_	_	I-Claim
304	hypertension	_	_	I-Claim
305	were	_	_	I-Claim
306	more	_	_	I-Claim
307	common	_	_	I-Claim
308	with	_	_	I-Claim
309	bevacizumab-containing	_	_	I-Claim
310	therapy	_	_	I-Claim
311	.	_	_	I-Claim

312	High	_	_	B-Premise
313	baseline	_	_	I-Premise
314	plasma	_	_	I-Premise
315	vascular	_	_	I-Premise
316	endothelial	_	_	I-Premise
317	growth	_	_	I-Premise
318	factor	_	_	I-Premise
319	A	_	_	I-Premise
320	(	_	_	I-Premise
321	VEGF-A	_	_	I-Premise
322	)	_	_	I-Premise
323	concentrations	_	_	I-Premise
324	were	_	_	I-Premise
325	associated	_	_	I-Premise
326	with	_	_	I-Premise
327	greater	_	_	I-Premise
328	bevacizumab	_	_	I-Premise
329	benefit	_	_	I-Premise
330	(	_	_	I-Premise
331	not	_	_	I-Premise
332	statistically	_	_	I-Premise
333	significant	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	Combining	_	_	B-Claim
337	bevacizumab	_	_	I-Claim
338	with	_	_	I-Claim
339	docetaxel	_	_	I-Claim
340	and	_	_	I-Claim
341	trastuzumab	_	_	I-Claim
342	did	_	_	I-Claim
343	not	_	_	I-Claim
344	significantly	_	_	I-Claim
345	improve	_	_	I-Claim
346	investigator-assessed	_	_	I-Claim
347	PFS	_	_	I-Claim
348	.	_	_	I-Claim

349	The	_	_	O
350	potential	_	_	O
351	predictive	_	_	O
352	value	_	_	O
353	of	_	_	O
354	plasma	_	_	O
355	VEGF-A	_	_	O
356	is	_	_	O
357	consistent	_	_	O
358	with	_	_	O
359	findings	_	_	O
360	in	_	_	O
361	HER2-negative	_	_	O
362	LR/MBC	_	_	O
363	,	_	_	O
364	warranting	_	_	O
365	prospective	_	_	O
366	evaluation	_	_	O
367	.	_	_	O


0	There	_	_	O
1	are	_	_	O
2	few	_	_	O
3	reports	_	_	O
4	about	_	_	O
5	the	_	_	O
6	course	_	_	O
7	of	_	_	O
8	vestibular	_	_	O
9	schwannoma	_	_	O
10	(	_	_	O
11	VS	_	_	O
12	)	_	_	O
13	patients	_	_	O
14	following	_	_	O
15	gamma	_	_	O
16	knife	_	_	O
17	radiosurgery	_	_	O
18	(	_	_	O
19	GKRS	_	_	O
20	)	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	the	_	_	O
24	course	_	_	O
25	following	_	_	O
26	conservative	_	_	O
27	management	_	_	O
28	(	_	_	O
29	CM	_	_	O
30	)	_	_	O
31	.	_	_	O

32	In	_	_	O
33	this	_	_	O
34	study	_	_	O
35	,	_	_	O
36	we	_	_	O
37	present	_	_	O
38	prospectively	_	_	O
39	collected	_	_	O
40	data	_	_	O
41	of	_	_	O
42	237	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	unilateral	_	_	O
46	VS	_	_	O
47	extending	_	_	O
48	outside	_	_	O
49	the	_	_	O
50	internal	_	_	O
51	acoustic	_	_	O
52	canal	_	_	O
53	who	_	_	O
54	received	_	_	O
55	either	_	_	O
56	GKRS	_	_	O
57	(	_	_	O
58	113	_	_	O
59	)	_	_	O
60	or	_	_	O
61	CM	_	_	O
62	(	_	_	O
63	124	_	_	O
64	)	_	_	O
65	.	_	_	O

66	The	_	_	O
67	aim	_	_	O
68	was	_	_	O
69	to	_	_	O
70	measure	_	_	O
71	the	_	_	O
72	effect	_	_	O
73	of	_	_	O
74	GKRS	_	_	O
75	compared	_	_	O
76	with	_	_	O
77	the	_	_	O
78	natural	_	_	O
79	course	_	_	O
80	on	_	_	O
81	tumor	_	_	O
82	growth	_	_	O
83	rate	_	_	O
84	and	_	_	O
85	hearing	_	_	O
86	loss	_	_	O
87	.	_	_	O

88	Secondary	_	_	O
89	end	_	_	O
90	points	_	_	O
91	were	_	_	O
92	postinclusion	_	_	O
93	additional	_	_	O
94	treatment	_	_	O
95	,	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	(	_	_	O
100	QoL	_	_	O
101	)	_	_	O
102	,	_	_	O
103	and	_	_	O
104	symptom	_	_	O
105	development	_	_	O
106	.	_	_	O

107	The	_	_	O
108	patients	_	_	O
109	underwent	_	_	O
110	magnetic	_	_	O
111	resonance	_	_	O
112	imaging	_	_	O
113	scans	_	_	O
114	,	_	_	O
115	clinical	_	_	O
116	examination	_	_	O
117	,	_	_	O
118	and	_	_	O
119	QoL	_	_	O
120	assessment	_	_	O
121	by	_	_	O
122	SF-36	_	_	O
123	questionnaire	_	_	O
124	.	_	_	O

125	Statistics	_	_	O
126	were	_	_	O
127	performed	_	_	O
128	by	_	_	O
129	using	_	_	O
130	Spearman	_	_	O
131	correlation	_	_	O
132	coefficient	_	_	O
133	,	_	_	O
134	Kaplan-Meier	_	_	O
135	plot	_	_	O
136	,	_	_	O
137	Poisson	_	_	O
138	regression	_	_	O
139	model	_	_	O
140	,	_	_	O
141	mixed	_	_	O
142	linear	_	_	O
143	regression	_	_	O
144	models	_	_	O
145	,	_	_	O
146	and	_	_	O
147	mixed	_	_	O
148	logistic	_	_	O
149	regression	_	_	O
150	models	_	_	O
151	.	_	_	O

152	Mean	_	_	O
153	follow-up	_	_	O
154	time	_	_	O
155	was	_	_	O
156	55.0	_	_	O
157	months	_	_	O
158	(	_	_	O
159	26.1	_	_	O
160	standard	_	_	O
161	deviation	_	_	O
162	,	_	_	O
163	range	_	_	O
164	10-132	_	_	O
165	)	_	_	O
166	.	_	_	O

167	Thirteen	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	lost	_	_	O
171	to	_	_	O
172	follow-up	_	_	O
173	.	_	_	O

174	Serviceable	_	_	B-Premise
175	hearing	_	_	I-Premise
176	was	_	_	I-Premise
177	lost	_	_	I-Premise
178	in	_	_	I-Premise
179	54	_	_	I-Premise
180	of	_	_	I-Premise
181	71	_	_	I-Premise
182	(	_	_	I-Premise
183	76	_	_	I-Premise
184	%	_	_	I-Premise
185	)	_	_	I-Premise
186	(	_	_	I-Premise
187	CM	_	_	I-Premise
188	)	_	_	I-Premise
189	and	_	_	I-Premise
190	34	_	_	I-Premise
191	of	_	_	I-Premise
192	53	_	_	I-Premise
193	(	_	_	I-Premise
194	64	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	(	_	_	I-Premise
198	GKRS	_	_	I-Premise
199	)	_	_	I-Premise
200	patients	_	_	I-Premise
201	during	_	_	I-Premise
202	the	_	_	I-Premise
203	study	_	_	I-Premise
204	period	_	_	I-Premise
205	(	_	_	I-Premise
206	not	_	_	I-Premise
207	significant	_	_	I-Premise
208	,	_	_	I-Premise
209	log-rank	_	_	I-Premise
210	test	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	There	_	_	B-Premise
214	was	_	_	I-Premise
215	a	_	_	I-Premise
216	significant	_	_	I-Premise
217	reduction	_	_	I-Premise
218	in	_	_	I-Premise
219	tumor	_	_	I-Premise
220	volume	_	_	I-Premise
221	over	_	_	I-Premise
222	time	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	GKRS	_	_	I-Premise
226	group	_	_	I-Premise
227	.	_	_	I-Premise

228	The	_	_	B-Premise
229	need	_	_	I-Premise
230	for	_	_	I-Premise
231	treatment	_	_	I-Premise
232	following	_	_	I-Premise
233	initial	_	_	I-Premise
234	GKRS	_	_	I-Premise
235	or	_	_	I-Premise
236	CM	_	_	I-Premise
237	differed	_	_	I-Premise
238	at	_	_	I-Premise
239	highly	_	_	I-Premise
240	significant	_	_	I-Premise
241	levels	_	_	I-Premise
242	(	_	_	I-Premise
243	log-rank	_	_	I-Premise
244	test	_	_	I-Premise
245	,	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	.001	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	Symptom	_	_	B-Premise
252	and	_	_	I-Premise
253	QoL	_	_	I-Premise
254	development	_	_	I-Premise
255	did	_	_	I-Premise
256	not	_	_	I-Premise
257	differ	_	_	I-Premise
258	significantly	_	_	I-Premise
259	between	_	_	I-Premise
260	the	_	_	I-Premise
261	groups	_	_	I-Premise
262	.	_	_	I-Premise

263	In	_	_	B-Claim
264	VS	_	_	I-Claim
265	patients	_	_	I-Claim
266	,	_	_	I-Claim
267	GKRS	_	_	I-Claim
268	reduces	_	_	I-Claim
269	the	_	_	I-Claim
270	tumor	_	_	I-Claim
271	growth	_	_	I-Claim
272	rate	_	_	I-Claim
273	and	_	_	I-Claim
274	thereby	_	_	I-Claim
275	the	_	_	I-Claim
276	incidence	_	_	I-Claim
277	rate	_	_	I-Claim
278	of	_	_	I-Claim
279	new	_	_	I-Claim
280	treatment	_	_	I-Claim
281	about	_	_	I-Claim
282	tenfold	_	_	I-Claim
283	.	_	_	I-Claim

284	Hearing	_	_	B-Claim
285	is	_	_	I-Claim
286	lost	_	_	I-Claim
287	at	_	_	I-Claim
288	similar	_	_	I-Claim
289	rates	_	_	I-Claim
290	in	_	_	I-Claim
291	both	_	_	I-Claim
292	groups	_	_	I-Claim
293	.	_	_	I-Claim

294	Symptoms	_	_	B-Claim
295	and	_	_	I-Claim
296	QoL	_	_	I-Claim
297	seem	_	_	I-Claim
298	not	_	_	I-Claim
299	to	_	_	I-Claim
300	be	_	_	I-Claim
301	significantly	_	_	I-Claim
302	affected	_	_	I-Claim
303	by	_	_	I-Claim
304	GKRS	_	_	I-Claim
305	.	_	_	I-Claim


0	Patients	_	_	O
1	undergoing	_	_	O
2	gastrectomy	_	_	O
3	because	_	_	O
4	of	_	_	O
5	stomach	_	_	O
6	cancer	_	_	O
7	often	_	_	O
8	face	_	_	O
9	weight	_	_	O
10	loss	_	_	O
11	in	_	_	O
12	the	_	_	O
13	perioperational	_	_	O
14	period	_	_	O
15	,	_	_	O
16	which	_	_	O
17	can	_	_	O
18	lead	_	_	O
19	to	_	_	O
20	malnutrition	_	_	O
21	and	_	_	O
22	negative	_	_	O
23	treatment	_	_	O
24	outcomes	_	_	O
25	.	_	_	O

26	The	_	_	O
27	purpose	_	_	O
28	of	_	_	O
29	this	_	_	O
30	study	_	_	O
31	was	_	_	O
32	to	_	_	O
33	develop	_	_	O
34	a	_	_	O
35	patient	_	_	O
36	participation-based	_	_	O
37	dietary	_	_	O
38	intervention	_	_	O
39	(	_	_	O
40	PPDI	_	_	O
41	)	_	_	O
42	and	_	_	O
43	evaluate	_	_	O
44	its	_	_	O
45	effects	_	_	O
46	on	_	_	O
47	patient	_	_	O
48	outcomes	_	_	O
49	.	_	_	O

50	This	_	_	O
51	was	_	_	O
52	a	_	_	O
53	prospective	_	_	O
54	,	_	_	O
55	randomized	_	_	O
56	controlled	_	_	O
57	trial	_	_	O
58	in	_	_	O
59	which	_	_	O
60	the	_	_	O
61	patients	_	_	O
62	were	_	_	O
63	recruited	_	_	O
64	in	_	_	O
65	a	_	_	O
66	cancer	_	_	O
67	center	_	_	O
68	in	_	_	O
69	South	_	_	O
70	Korea	_	_	O
71	.	_	_	O

72	The	_	_	O
73	participants	_	_	O
74	(	_	_	O
75	N	_	_	O
76	=	_	_	O
77	56	_	_	O
78	)	_	_	O
79	,	_	_	O
80	who	_	_	O
81	underwent	_	_	O
82	gastrectomy	_	_	O
83	with	_	_	O
84	stomach	_	_	O
85	cancer	_	_	O
86	stage	_	_	O
87	I	_	_	O
88	to	_	_	O
89	III	_	_	O
90	,	_	_	O
91	were	_	_	O
92	randomly	_	_	O
93	assigned	_	_	O
94	into	_	_	O
95	either	_	_	O
96	the	_	_	O
97	experimental	_	_	O
98	or	_	_	O
99	the	_	_	O
100	control	_	_	O
101	group	_	_	O
102	.	_	_	O

103	The	_	_	O
104	PPDI	_	_	O
105	,	_	_	O
106	which	_	_	O
107	was	_	_	O
108	given	_	_	O
109	on	_	_	O
110	the	_	_	O
111	day	_	_	O
112	before	_	_	O
113	the	_	_	O
114	hospital	_	_	O
115	discharge	_	_	O
116	,	_	_	O
117	comprised	_	_	O
118	2	_	_	O
119	face-to-face	_	_	O
120	and	_	_	O
121	2	_	_	O
122	telephone	_	_	O
123	interventions	_	_	O
124	.	_	_	O

125	The	_	_	O
126	outcome	_	_	O
127	variables	_	_	O
128	included	_	_	O
129	body	_	_	O
130	weight	_	_	O
131	,	_	_	O
132	body	_	_	O
133	mass	_	_	O
134	index	_	_	O
135	,	_	_	O
136	muscle	_	_	O
137	mass	_	_	O
138	,	_	_	O
139	the	_	_	O
140	Patient-Generated	_	_	O
141	Subjective	_	_	O
142	Global	_	_	O
143	Assessment	_	_	O
144	,	_	_	O
145	Dietary	_	_	O
146	Symptom	_	_	O
147	Scale	_	_	O
148	,	_	_	O
149	Functional	_	_	O
150	Assessment	_	_	O
151	Cancer	_	_	O
152	Therapy-General	_	_	O
153	,	_	_	O
154	Karnofsky	_	_	O
155	Performance	_	_	O
156	Status	_	_	O
157	,	_	_	O
158	Adherence	_	_	O
159	to	_	_	O
160	Dietary	_	_	O
161	Guidelines	_	_	O
162	Scale	_	_	O
163	,	_	_	O
164	Scale	_	_	O
165	of	_	_	O
166	Dietary	_	_	O
167	Knowledge	_	_	O
168	,	_	_	O
169	Patient	_	_	O
170	Satisfaction	_	_	O
171	Scale	_	_	O
172	,	_	_	O
173	and	_	_	O
174	a	_	_	O
175	3-day	_	_	O
176	food	_	_	O
177	diary	_	_	O
178	.	_	_	O

179	Participants	_	_	B-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	PPDI	_	_	I-Premise
183	intervention	_	_	I-Premise
184	demonstrated	_	_	I-Premise
185	significant	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	<	_	_	I-Premise
189	.05	_	_	I-Premise
190	)	_	_	I-Premise
191	reductions	_	_	I-Premise
192	in	_	_	I-Premise
193	adverse	_	_	I-Premise
194	dietary	_	_	I-Premise
195	symptoms	_	_	I-Premise
196	and	_	_	I-Premise
197	significant	_	_	I-Premise
198	improvements	_	_	I-Premise
199	(	_	_	I-Premise
200	P	_	_	I-Premise
201	<	_	_	I-Premise
202	.05	_	_	I-Premise
203	)	_	_	I-Premise
204	in	_	_	I-Premise
205	functional	_	_	I-Premise
206	status	_	_	I-Premise
207	,	_	_	I-Premise
208	performance	_	_	I-Premise
209	status	_	_	I-Premise
210	,	_	_	I-Premise
211	dietary	_	_	I-Premise
212	intake	_	_	I-Premise
213	,	_	_	I-Premise
214	adherence	_	_	I-Premise
215	to	_	_	I-Premise
216	dietary	_	_	I-Premise
217	guidelines	_	_	I-Premise
218	,	_	_	I-Premise
219	dietary	_	_	I-Premise
220	knowledge	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	satisfaction	_	_	I-Premise
224	with	_	_	I-Premise
225	the	_	_	I-Premise
226	intervention	_	_	I-Premise
227	as	_	_	I-Premise
228	compared	_	_	I-Premise
229	with	_	_	I-Premise
230	the	_	_	I-Premise
231	control	_	_	I-Premise
232	group	_	_	I-Premise
233	over	_	_	I-Premise
234	time	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	B-Claim
237	PPDI	_	_	I-Claim
238	was	_	_	I-Claim
239	an	_	_	I-Claim
240	effective	_	_	I-Claim
241	dietary	_	_	I-Claim
242	intervention	_	_	I-Claim
243	for	_	_	I-Claim
244	patients	_	_	I-Claim
245	undergoing	_	_	I-Claim
246	a	_	_	I-Claim
247	gastrectomy	_	_	I-Claim
248	for	_	_	I-Claim
249	gastric	_	_	I-Claim
250	cancer	_	_	I-Claim
251	and	_	_	I-Claim
252	deserves	_	_	I-Claim
253	additional	_	_	I-Claim
254	study	_	_	I-Claim
255	in	_	_	I-Claim
256	other	_	_	I-Claim
257	populations	_	_	I-Claim
258	of	_	_	I-Claim
259	patients	_	_	I-Claim
260	.	_	_	I-Claim

261	Incorporating	_	_	B-Claim
262	patients	_	_	I-Claim
263	'	_	_	I-Claim
264	perspectives	_	_	I-Claim
265	into	_	_	I-Claim
266	a	_	_	I-Claim
267	dietary	_	_	I-Claim
268	intervention	_	_	I-Claim
269	after	_	_	I-Claim
270	gastrectomy	_	_	I-Claim
271	for	_	_	I-Claim
272	gastric	_	_	I-Claim
273	cancer	_	_	I-Claim
274	may	_	_	I-Claim
275	contribute	_	_	I-Claim
276	to	_	_	I-Claim
277	improved	_	_	I-Claim
278	patient	_	_	I-Claim
279	outcomes	_	_	I-Claim
280	and	_	_	I-Claim
281	quality	_	_	I-Claim
282	care	_	_	I-Claim
283	.	_	_	I-Claim


0	Restorative	_	_	O
1	proctocolectomy	_	_	O
2	with	_	_	O
3	ileal	_	_	O
4	pouch-anal	_	_	O
5	anastomosis	_	_	O
6	(	_	_	O
7	IPAA	_	_	O
8	)	_	_	O
9	is	_	_	O
10	the	_	_	O
11	standard	_	_	O
12	surgical	_	_	O
13	procedure	_	_	O
14	for	_	_	O
15	ulcerative	_	_	O
16	colitis	_	_	O
17	(	_	_	O
18	UC	_	_	O
19	)	_	_	O
20	and	_	_	O
21	familial	_	_	O
22	adenomatous	_	_	O
23	polyposis	_	_	O
24	(	_	_	O
25	FAP	_	_	O
26	)	_	_	O
27	.	_	_	O

28	While	_	_	O
29	minimal	_	_	O
30	invasive	_	_	O
31	techniques	_	_	O
32	have	_	_	O
33	been	_	_	O
34	applied	_	_	O
35	increasingly	_	_	O
36	,	_	_	O
37	clear	_	_	O
38	evidence	_	_	O
39	of	_	_	O
40	superiority	_	_	O
41	for	_	_	O
42	laparoscopic	_	_	O
43	pouch	_	_	O
44	procedures	_	_	O
45	is	_	_	O
46	not	_	_	O
47	yet	_	_	O
48	available	_	_	O
49	.	_	_	O

50	The	_	_	O
51	aim	_	_	O
52	of	_	_	O
53	the	_	_	O
54	LapConPouch	_	_	O
55	Trial	_	_	O
56	was	_	_	O
57	to	_	_	O
58	compare	_	_	O
59	the	_	_	O
60	effectiveness	_	_	O
61	of	_	_	O
62	laparoscopic	_	_	O
63	(	_	_	O
64	LAP	_	_	O
65	)	_	_	O
66	versus	_	_	O
67	conventional	_	_	O
68	(	_	_	O
69	CON	_	_	O
70	)	_	_	O
71	ileoanal	_	_	O
72	pouch	_	_	O
73	procedure	_	_	O
74	in	_	_	O
75	patients	_	_	O
76	undergoing	_	_	O
77	elective	_	_	O
78	restorative	_	_	O
79	proctocolectomy	_	_	O
80	.	_	_	O

81	The	_	_	O
82	trial	_	_	O
83	was	_	_	O
84	designed	_	_	O
85	as	_	_	O
86	a	_	_	O
87	single-centre	_	_	O
88	,	_	_	O
89	pre-operatively	_	_	O
90	randomized	_	_	O
91	,	_	_	O
92	controlled	_	_	O
93	trial	_	_	O
94	using	_	_	O
95	a	_	_	O
96	two-group	_	_	O
97	parallel	_	_	O
98	superiority	_	_	O
99	design	_	_	O
100	.	_	_	O

101	Eligible	_	_	O
102	for	_	_	O
103	participation	_	_	O
104	were	_	_	O
105	patients	_	_	O
106	scheduled	_	_	O
107	for	_	_	O
108	restorative	_	_	O
109	proctocolectomy	_	_	O
110	either	_	_	O
111	for	_	_	O
112	FAP	_	_	O
113	or	_	_	O
114	for	_	_	O
115	UC	_	_	O
116	.	_	_	O

117	Patients	_	_	O
118	and	_	_	O
119	outcome	_	_	O
120	assessors	_	_	O
121	were	_	_	O
122	blinded	_	_	O
123	to	_	_	O
124	group	_	_	O
125	assignment	_	_	O
126	.	_	_	O

127	The	_	_	O
128	primary	_	_	O
129	endpoint	_	_	O
130	was	_	_	O
131	defined	_	_	O
132	as	_	_	O
133	the	_	_	O
134	amount	_	_	O
135	of	_	_	O
136	blood	_	_	O
137	loss	_	_	O
138	.	_	_	O

139	Statistical	_	_	O
140	analyses	_	_	O
141	were	_	_	O
142	explorative	_	_	O
143	since	_	_	O
144	the	_	_	O
145	trial	_	_	O
146	had	_	_	O
147	to	_	_	O
148	be	_	_	O
149	stopped	_	_	O
150	prematurely	_	_	O
151	.	_	_	O

152	A	_	_	O
153	total	_	_	O
154	of	_	_	O
155	42	_	_	O
156	patients	_	_	O
157	(	_	_	O
158	21	_	_	O
159	LAP	_	_	O
160	(	_	_	O
161	50.0	_	_	O
162	%	_	_	O
163	)	_	_	O
164	;	_	_	O
165	21	_	_	O
166	CON	_	_	O
167	(	_	_	O
168	50.0	_	_	O
169	%	_	_	O
170	)	_	_	O
171	)	_	_	O
172	were	_	_	O
173	randomized	_	_	O
174	.	_	_	O

175	The	_	_	B-Premise
176	trial	_	_	I-Premise
177	had	_	_	I-Premise
178	to	_	_	I-Premise
179	be	_	_	I-Premise
180	stopped	_	_	I-Premise
181	prematurely	_	_	I-Premise
182	due	_	_	I-Premise
183	to	_	_	I-Premise
184	insufficient	_	_	I-Premise
185	patient	_	_	I-Premise
186	recruitment	_	_	I-Premise
187	.	_	_	I-Premise

188	There	_	_	B-Premise
189	was	_	_	I-Premise
190	no	_	_	I-Premise
191	difference	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	amount	_	_	I-Premise
195	of	_	_	I-Premise
196	blood	_	_	I-Premise
197	loss	_	_	I-Premise
198	between	_	_	I-Premise
199	both	_	_	I-Premise
200	groups	_	_	I-Premise
201	:	_	_	I-Premise
202	LAP	_	_	I-Premise
203	261.5	_	_	I-Premise
204	±	_	_	I-Premise
205	195.4	_	_	I-Premise
206	ml	_	_	I-Premise
207	,	_	_	I-Premise
208	CON	_	_	I-Premise
209	228.1	_	_	I-Premise
210	±	_	_	I-Premise
211	119.5	_	_	I-Premise
212	ml	_	_	I-Premise
213	.	_	_	I-Premise

214	Secondary	_	_	O
215	endpoints	_	_	O
216	differ	_	_	O
217	in	_	_	O
218	both	_	_	O
219	groups	_	_	O
220	.	_	_	O

221	Laparoscopic	_	_	B-Claim
222	surgery	_	_	I-Claim
223	was	_	_	I-Claim
224	superior	_	_	I-Claim
225	regarding	_	_	I-Claim
226	the	_	_	I-Claim
227	length	_	_	I-Claim
228	of	_	_	I-Claim
229	skin	_	_	I-Claim
230	incision	_	_	I-Claim
231	;	_	_	I-Claim
232	in	_	_	O
233	contrast	_	_	O
234	,	_	_	O
235	the	_	_	B-Claim
236	conventional	_	_	I-Claim
237	approach	_	_	I-Claim
238	was	_	_	I-Claim
239	superior	_	_	I-Claim
240	in	_	_	I-Claim
241	duration	_	_	I-Claim
242	of	_	_	I-Claim
243	operation	_	_	I-Claim
244	.	_	_	I-Claim

245	There	_	_	B-Premise
246	were	_	_	I-Premise
247	no	_	_	I-Premise
248	discrepancies	_	_	I-Premise
249	in	_	_	I-Premise
250	length	_	_	I-Premise
251	of	_	_	I-Premise
252	hospital	_	_	I-Premise
253	stay	_	_	I-Premise
254	,	_	_	I-Premise
255	postoperative	_	_	I-Premise
256	pain	_	_	I-Premise
257	,	_	_	I-Premise
258	bowel	_	_	I-Premise
259	function	_	_	I-Premise
260	,	_	_	I-Premise
261	and	_	_	I-Premise
262	quality	_	_	I-Premise
263	of	_	_	I-Premise
264	life	_	_	I-Premise
265	between	_	_	I-Premise
266	both	_	_	I-Premise
267	approaches	_	_	I-Premise
268	.	_	_	I-Premise

269	The	_	_	O
270	conversion	_	_	O
271	rate	_	_	O
272	from	_	_	O
273	LAP	_	_	O
274	to	_	_	O
275	CON	_	_	O
276	approach	_	_	O
277	was	_	_	O
278	23.8	_	_	O
279	%	_	_	O
280	.	_	_	O

281	There	_	_	B-Claim
282	was	_	_	I-Claim
283	no	_	_	I-Claim
284	difference	_	_	I-Claim
285	with	_	_	I-Claim
286	respect	_	_	I-Claim
287	to	_	_	I-Claim
288	blood	_	_	I-Claim
289	loss	_	_	I-Claim
290	between	_	_	I-Claim
291	the	_	_	I-Claim
292	LAP	_	_	I-Claim
293	and	_	_	I-Claim
294	the	_	_	I-Claim
295	CON	_	_	I-Claim
296	group	_	_	I-Claim
297	.	_	_	I-Claim

298	The	_	_	B-Claim
299	LAP	_	_	I-Claim
300	approach	_	_	I-Claim
301	is	_	_	I-Claim
302	feasible	_	_	I-Claim
303	for	_	_	I-Claim
304	restorative	_	_	I-Claim
305	proctocolectomy	_	_	I-Claim
306	,	_	_	I-Claim
307	and	_	_	I-Claim
308	IPAA	_	_	I-Claim
309	seems	_	_	I-Claim
310	at	_	_	I-Claim
311	least	_	_	I-Claim
312	as	_	_	I-Claim
313	safe	_	_	I-Claim
314	as	_	_	I-Claim
315	CON	_	_	I-Claim
316	surgery	_	_	I-Claim
317	.	_	_	I-Claim

318	The	_	_	O
319	most	_	_	O
320	obvious	_	_	O
321	advantage	_	_	O
322	of	_	_	O
323	the	_	_	O
324	minimal	_	_	O
325	invasive	_	_	O
326	technique	_	_	O
327	is	_	_	O
328	the	_	_	O
329	improved	_	_	O
330	cosmesis	_	_	O
331	.	_	_	O


0	Colorectal	_	_	O
1	cancer	_	_	O
2	survivors	_	_	O
3	are	_	_	O
4	at	_	_	O
5	risk	_	_	O
6	for	_	_	O
7	poor	_	_	O
8	health	_	_	O
9	outcomes	_	_	O
10	because	_	_	O
11	of	_	_	O
12	unhealthy	_	_	O
13	lifestyles	_	_	O
14	,	_	_	O
15	but	_	_	O
16	few	_	_	O
17	studies	_	_	O
18	have	_	_	O
19	developed	_	_	O
20	translatable	_	_	O
21	health	_	_	O
22	behavior	_	_	O
23	change	_	_	O
24	interventions	_	_	O
25	.	_	_	O

26	This	_	_	O
27	study	_	_	O
28	aimed	_	_	O
29	to	_	_	O
30	determine	_	_	O
31	the	_	_	O
32	effects	_	_	O
33	of	_	_	O
34	a	_	_	O
35	telephone-delivered	_	_	O
36	multiple	_	_	O
37	health	_	_	O
38	behavior	_	_	O
39	change	_	_	O
40	intervention	_	_	O
41	(	_	_	O
42	CanChange	_	_	O
43	)	_	_	O
44	on	_	_	O
45	health	_	_	O
46	and	_	_	O
47	behavioral	_	_	O
48	outcomes	_	_	O
49	among	_	_	O
50	colorectal	_	_	O
51	cancer	_	_	O
52	survivors	_	_	O
53	.	_	_	O

54	In	_	_	O
55	this	_	_	O
56	two-group	_	_	O
57	randomized	_	_	O
58	controlled	_	_	O
59	trial	_	_	O
60	,	_	_	O
61	410	_	_	O
62	colorectal	_	_	O
63	cancer	_	_	O
64	survivors	_	_	O
65	were	_	_	O
66	randomly	_	_	O
67	assigned	_	_	O
68	to	_	_	O
69	the	_	_	O
70	health	_	_	O
71	coaching	_	_	O
72	intervention	_	_	O
73	(	_	_	O
74	11	_	_	O
75	theory-based	_	_	O
76	telephone-delivered	_	_	O
77	health	_	_	O
78	coaching	_	_	O
79	sessions	_	_	O
80	delivered	_	_	O
81	over	_	_	O
82	6	_	_	O
83	months	_	_	O
84	focusing	_	_	O
85	on	_	_	O
86	physical	_	_	O
87	activity	_	_	O
88	,	_	_	O
89	weight	_	_	O
90	management	_	_	O
91	,	_	_	O
92	dietary	_	_	O
93	habits	_	_	O
94	,	_	_	O
95	alcohol	_	_	O
96	,	_	_	O
97	and	_	_	O
98	smoking	_	_	O
99	)	_	_	O
100	or	_	_	O
101	usual	_	_	O
102	care	_	_	O
103	.	_	_	O

104	Assessment	_	_	O
105	of	_	_	O
106	primary	_	_	O
107	(	_	_	O
108	ie	_	_	O
109	,	_	_	O
110	physical	_	_	O
111	activity	_	_	O
112	[	_	_	O
113	Godin	_	_	O
114	Leisure	_	_	O
115	Time	_	_	O
116	Index	_	_	O
117	]	_	_	O
118	,	_	_	O
119	health-related	_	_	O
120	quality	_	_	O
121	of	_	_	O
122	life	_	_	O
123	[	_	_	O
124	HRQoL	_	_	O
125	;	_	_	O
126	Short	_	_	O
127	Form-36	_	_	O
128	]	_	_	O
129	,	_	_	O
130	and	_	_	O
131	cancer-related	_	_	O
132	fatigue	_	_	O
133	[	_	_	O
134	Functional	_	_	O
135	Assessment	_	_	O
136	of	_	_	O
137	Chronic	_	_	O
138	Illness	_	_	O
139	Therapy	_	_	O
140	Fatigue	_	_	O
141	Scale	_	_	O
142	]	_	_	O
143	)	_	_	O
144	and	_	_	O
145	secondary	_	_	O
146	outcomes	_	_	O
147	(	_	_	O
148	ie	_	_	O
149	,	_	_	O
150	body	_	_	O
151	mass	_	_	O
152	index	_	_	O
153	[	_	_	O
154	kg/m	_	_	O
155	(	_	_	O
156	2	_	_	O
157	)	_	_	O
158	]	_	_	O
159	,	_	_	O
160	diet	_	_	O
161	and	_	_	O
162	alcohol	_	_	O
163	intake	_	_	O
164	[	_	_	O
165	Food	_	_	O
166	Frequency	_	_	O
167	Questionnaire	_	_	O
168	]	_	_	O
169	,	_	_	O
170	and	_	_	O
171	smoking	_	_	O
172	)	_	_	O
173	were	_	_	O
174	conducted	_	_	O
175	at	_	_	O
176	baseline	_	_	O
177	and	_	_	O
178	6	_	_	O
179	and	_	_	O
180	12	_	_	O
181	months	_	_	O
182	.	_	_	O

183	At	_	_	B-Premise
184	12	_	_	I-Premise
185	months	_	_	I-Premise
186	,	_	_	I-Premise
187	significant	_	_	I-Premise
188	intervention	_	_	I-Premise
189	effects	_	_	I-Premise
190	were	_	_	I-Premise
191	observed	_	_	I-Premise
192	for	_	_	I-Premise
193	moderate	_	_	I-Premise
194	physical	_	_	I-Premise
195	activity	_	_	I-Premise
196	(	_	_	I-Premise
197	28.5	_	_	I-Premise
198	minutes	_	_	I-Premise
199	;	_	_	I-Premise
200	P	_	_	I-Premise
201	=	_	_	I-Premise
202	.003	_	_	I-Premise
203	)	_	_	I-Premise
204	,	_	_	I-Premise
205	body	_	_	I-Premise
206	mass	_	_	I-Premise
207	index	_	_	I-Premise
208	(	_	_	I-Premise
209	-0.9	_	_	I-Premise
210	kg/m	_	_	I-Premise
211	(	_	_	I-Premise
212	2	_	_	I-Premise
213	)	_	_	I-Premise
214	;	_	_	I-Premise
215	P	_	_	I-Premise
216	=	_	_	I-Premise
217	.001	_	_	I-Premise
218	)	_	_	I-Premise
219	,	_	_	I-Premise
220	energy	_	_	I-Premise
221	from	_	_	I-Premise
222	total	_	_	I-Premise
223	fat	_	_	I-Premise
224	(	_	_	I-Premise
225	-7.0	_	_	I-Premise
226	%	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	.006	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	energy	_	_	I-Premise
235	from	_	_	I-Premise
236	saturated	_	_	I-Premise
237	fat	_	_	I-Premise
238	(	_	_	I-Premise
239	-2.8	_	_	I-Premise
240	%	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.016	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	A	_	_	B-Premise
248	significant	_	_	I-Premise
249	intervention	_	_	I-Premise
250	effect	_	_	I-Premise
251	was	_	_	I-Premise
252	reported	_	_	I-Premise
253	for	_	_	I-Premise
254	vegetable	_	_	I-Premise
255	intake	_	_	I-Premise
256	(	_	_	I-Premise
257	0.4	_	_	I-Premise
258	servings	_	_	I-Premise
259	per	_	_	I-Premise
260	day	_	_	I-Premise
261	;	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.001	_	_	I-Premise
265	)	_	_	I-Premise
266	at	_	_	I-Premise
267	6	_	_	I-Premise
268	months	_	_	I-Premise
269	.	_	_	I-Premise

270	No	_	_	B-Premise
271	significant	_	_	I-Premise
272	group	_	_	I-Premise
273	differences	_	_	I-Premise
274	were	_	_	I-Premise
275	found	_	_	I-Premise
276	at	_	_	I-Premise
277	6	_	_	I-Premise
278	or	_	_	I-Premise
279	12	_	_	I-Premise
280	months	_	_	I-Premise
281	for	_	_	I-Premise
282	HRQoL	_	_	I-Premise
283	,	_	_	I-Premise
284	cancer-related	_	_	I-Premise
285	fatigue	_	_	I-Premise
286	,	_	_	I-Premise
287	fruit	_	_	I-Premise
288	,	_	_	I-Premise
289	fiber	_	_	I-Premise
290	,	_	_	I-Premise
291	or	_	_	I-Premise
292	alcohol	_	_	I-Premise
293	intake	_	_	I-Premise
294	,	_	_	I-Premise
295	or	_	_	I-Premise
296	smoking	_	_	I-Premise
297	.	_	_	I-Premise

298	The	_	_	B-Claim
299	CanChange	_	_	I-Claim
300	intervention	_	_	I-Claim
301	was	_	_	I-Claim
302	effective	_	_	I-Claim
303	for	_	_	I-Claim
304	improving	_	_	I-Claim
305	physical	_	_	I-Claim
306	activity	_	_	I-Claim
307	,	_	_	I-Claim
308	dietary	_	_	I-Claim
309	habits	_	_	I-Claim
310	,	_	_	I-Claim
311	and	_	_	I-Claim
312	body	_	_	I-Claim
313	mass	_	_	I-Claim
314	index	_	_	I-Claim
315	in	_	_	I-Claim
316	colorectal	_	_	I-Claim
317	cancer	_	_	I-Claim
318	survivors	_	_	I-Claim
319	.	_	_	I-Claim

320	The	_	_	O
321	intervention	_	_	O
322	is	_	_	O
323	translatable	_	_	O
324	through	_	_	O
325	existing	_	_	O
326	telephone	_	_	O
327	cancer	_	_	O
328	support	_	_	O
329	and	_	_	O
330	information	_	_	O
331	services	_	_	O
332	in	_	_	O
333	Australia	_	_	O
334	and	_	_	O
335	other	_	_	O
336	countries	_	_	O
337	.	_	_	O


0	Enhanced	_	_	O
1	recovery	_	_	O
2	programmes	_	_	O
3	(	_	_	O
4	ERPs	_	_	O
5	)	_	_	O
6	have	_	_	O
7	been	_	_	O
8	shown	_	_	O
9	to	_	_	O
10	reduce	_	_	O
11	length	_	_	O
12	of	_	_	O
13	hospital	_	_	O
14	stay	_	_	O
15	(	_	_	O
16	LOS	_	_	O
17	)	_	_	O
18	and	_	_	O
19	complications	_	_	O
20	in	_	_	O
21	colorectal	_	_	O
22	surgery	_	_	O
23	.	_	_	O

24	Whether	_	_	O
25	ERPs	_	_	O
26	have	_	_	O
27	the	_	_	O
28	same	_	_	O
29	benefits	_	_	O
30	in	_	_	O
31	open	_	_	O
32	liver	_	_	O
33	resection	_	_	O
34	surgery	_	_	O
35	is	_	_	O
36	unclear	_	_	O
37	,	_	_	O
38	and	_	_	O
39	randomized	_	_	O
40	clinical	_	_	O
41	trials	_	_	O
42	are	_	_	O
43	lacking	_	_	O
44	.	_	_	O

45	Consecutive	_	_	O
46	patients	_	_	O
47	scheduled	_	_	O
48	for	_	_	O
49	open	_	_	O
50	liver	_	_	O
51	resection	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	an	_	_	O
56	ERP	_	_	O
57	group	_	_	O
58	or	_	_	O
59	standard	_	_	O
60	care	_	_	O
61	.	_	_	O

62	Primary	_	_	O
63	endpoints	_	_	O
64	were	_	_	O
65	time	_	_	O
66	until	_	_	O
67	medically	_	_	O
68	fit	_	_	O
69	for	_	_	O
70	discharge	_	_	O
71	(	_	_	O
72	MFD	_	_	O
73	)	_	_	O
74	and	_	_	O
75	LOS	_	_	O
76	.	_	_	O

77	Secondary	_	_	O
78	endpoints	_	_	O
79	were	_	_	O
80	postoperative	_	_	O
81	morbidity	_	_	O
82	,	_	_	O
83	pain	_	_	O
84	scores	_	_	O
85	,	_	_	O
86	readmission	_	_	O
87	rate	_	_	O
88	,	_	_	O
89	mortality	_	_	O
90	,	_	_	O
91	quality	_	_	O
92	of	_	_	O
93	life	_	_	O
94	(	_	_	O
95	QoL	_	_	O
96	)	_	_	O
97	and	_	_	O
98	patient	_	_	O
99	satisfaction	_	_	O
100	.	_	_	O

101	ERP	_	_	O
102	elements	_	_	O
103	included	_	_	O
104	greater	_	_	O
105	preoperative	_	_	O
106	education	_	_	O
107	,	_	_	O
108	preoperative	_	_	O
109	oral	_	_	O
110	carbohydrate	_	_	O
111	loading	_	_	O
112	,	_	_	O
113	postoperative	_	_	O
114	goal-directed	_	_	O
115	fluid	_	_	O
116	therapy	_	_	O
117	,	_	_	O
118	early	_	_	O
119	mobilization	_	_	O
120	and	_	_	O
121	physiotherapy	_	_	O
122	.	_	_	O

123	Both	_	_	O
124	groups	_	_	O
125	received	_	_	O
126	standardized	_	_	O
127	anaesthesia	_	_	O
128	with	_	_	O
129	epidural	_	_	O
130	analgesia	_	_	O
131	.	_	_	O

132	The	_	_	O
133	analysis	_	_	O
134	included	_	_	O
135	46	_	_	O
136	patients	_	_	O
137	in	_	_	O
138	the	_	_	O
139	ERP	_	_	O
140	group	_	_	O
141	and	_	_	O
142	45	_	_	O
143	in	_	_	O
144	the	_	_	O
145	standard	_	_	O
146	care	_	_	O
147	group	_	_	O
148	.	_	_	O

149	Median	_	_	B-Premise
150	MFD	_	_	I-Premise
151	time	_	_	I-Premise
152	was	_	_	I-Premise
153	reduced	_	_	I-Premise
154	in	_	_	I-Premise
155	the	_	_	I-Premise
156	ERP	_	_	I-Premise
157	group	_	_	I-Premise
158	(	_	_	I-Premise
159	3	_	_	I-Premise
160	days	_	_	I-Premise
161	versus	_	_	I-Premise
162	6	_	_	I-Premise
163	days	_	_	I-Premise
164	with	_	_	I-Premise
165	standard	_	_	I-Premise
166	care	_	_	I-Premise
167	;	_	_	I-Premise
168	P	_	_	I-Premise
169	<	_	_	I-Premise
170	0·001	_	_	I-Premise
171	)	_	_	I-Premise
172	,	_	_	I-Premise
173	as	_	_	I-Premise
174	was	_	_	I-Premise
175	LOS	_	_	I-Premise
176	(	_	_	I-Premise
177	4	_	_	I-Premise
178	days	_	_	I-Premise
179	versus	_	_	I-Premise
180	7	_	_	I-Premise
181	days	_	_	I-Premise
182	;	_	_	I-Premise
183	P	_	_	I-Premise
184	<	_	_	I-Premise
185	0·001	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	The	_	_	B-Premise
189	ERP	_	_	I-Premise
190	significantly	_	_	I-Premise
191	reduced	_	_	I-Premise
192	the	_	_	I-Premise
193	rate	_	_	I-Premise
194	of	_	_	I-Premise
195	medical	_	_	I-Premise
196	complications	_	_	I-Premise
197	(	_	_	I-Premise
198	7	_	_	I-Premise
199	versus	_	_	I-Premise
200	27	_	_	I-Premise
201	per	_	_	I-Premise
202	cent	_	_	I-Premise
203	;	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0·020	_	_	I-Premise
207	)	_	_	I-Premise
208	,	_	_	I-Premise
209	but	_	_	B-Premise
210	not	_	_	I-Premise
211	surgical	_	_	I-Premise
212	complications	_	_	I-Premise
213	(	_	_	I-Premise
214	15	_	_	I-Premise
215	versus	_	_	I-Premise
216	11	_	_	I-Premise
217	per	_	_	I-Premise
218	cent	_	_	I-Premise
219	;	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	0·612	_	_	I-Premise
223	)	_	_	I-Premise
224	,	_	_	I-Premise
225	readmissions	_	_	I-Premise
226	(	_	_	I-Premise
227	4	_	_	I-Premise
228	versus	_	_	I-Premise
229	0	_	_	I-Premise
230	per	_	_	I-Premise
231	cent	_	_	I-Premise
232	;	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	0·153	_	_	I-Premise
236	)	_	_	I-Premise
237	or	_	_	I-Premise
238	mortality	_	_	I-Premise
239	(	_	_	I-Premise
240	both	_	_	I-Premise
241	2	_	_	I-Premise
242	per	_	_	I-Premise
243	cent	_	_	I-Premise
244	;	_	_	I-Premise
245	P	_	_	I-Premise
246	=	_	_	I-Premise
247	0·987	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	QoL	_	_	B-Premise
251	over	_	_	I-Premise
252	28	_	_	I-Premise
253	days	_	_	I-Premise
254	was	_	_	I-Premise
255	significantly	_	_	I-Premise
256	better	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	ERP	_	_	I-Premise
260	group	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	0·002	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	There	_	_	B-Premise
268	was	_	_	I-Premise
269	no	_	_	I-Premise
270	difference	_	_	I-Premise
271	in	_	_	I-Premise
272	patient	_	_	I-Premise
273	satisfaction	_	_	I-Premise
274	.	_	_	I-Premise

275	ERPs	_	_	B-Claim
276	for	_	_	I-Claim
277	open	_	_	I-Claim
278	liver	_	_	I-Claim
279	resection	_	_	I-Claim
280	surgery	_	_	I-Claim
281	are	_	_	I-Claim
282	safe	_	_	I-Claim
283	and	_	_	I-Claim
284	effective	_	_	I-Claim
285	.	_	_	I-Claim

286	Patients	_	_	B-Claim
287	treated	_	_	I-Claim
288	in	_	_	I-Claim
289	the	_	_	I-Claim
290	ERP	_	_	I-Claim
291	recovered	_	_	I-Claim
292	faster	_	_	I-Claim
293	,	_	_	I-Claim
294	were	_	_	I-Claim
295	discharged	_	_	I-Claim
296	sooner	_	_	I-Claim
297	,	_	_	I-Claim
298	and	_	_	I-Claim
299	had	_	_	I-Claim
300	fewer	_	_	I-Claim
301	medical-related	_	_	I-Claim
302	complications	_	_	I-Claim
303	and	_	_	I-Claim
304	improved	_	_	I-Claim
305	QoL	_	_	I-Claim
306	.	_	_	I-Claim


0	There	_	_	O
1	will	_	_	O
2	be	_	_	O
3	a	_	_	O
4	detectable	_	_	O
5	increase	_	_	O
6	in	_	_	O
7	overall	_	_	O
8	survival	_	_	O
9	(	_	_	O
10	OS	_	_	O
11	)	_	_	O
12	using	_	_	O
13	preoperative	_	_	O
14	(	_	_	O
15	PRE	_	_	O
16	)	_	_	O
17	as	_	_	O
18	opposed	_	_	O
19	to	_	_	O
20	perioperative	_	_	O
21	(	_	_	O
22	PERI	_	_	O
23	)	_	_	O
24	chemotherapy	_	_	O
25	in	_	_	O
26	resectable	_	_	O
27	StageI-II	_	_	O
28	non-small-cell	_	_	O
29	lung	_	_	O
30	cancer	_	_	O
31	(	_	_	O
32	NSCLC	_	_	O
33	)	_	_	O
34	.	_	_	O

35	This	_	_	O
36	multicenter	_	_	O
37	,	_	_	O
38	open-label	_	_	O
39	,	_	_	O
40	randomised	_	_	O
41	trial	_	_	O
42	with	_	_	O
43	a	_	_	O
44	2×2	_	_	O
45	factorial	_	_	O
46	design	_	_	O
47	first	_	_	O
48	compared	_	_	O
49	two	_	_	O
50	chemotherapy	_	_	O
51	strategies	_	_	O
52	(	_	_	O
53	PRE	_	_	O
54	versus	_	_	O
55	PERI	_	_	O
56	)	_	_	O
57	,	_	_	O
58	then	_	_	O
59	two	_	_	O
60	chemotherapy	_	_	O
61	regimens	_	_	O
62	(	_	_	O
63	gemcitabine-cisplatin	_	_	O
64	[	_	_	O
65	GP	_	_	O
66	]	_	_	O
67	versus	_	_	O
68	paclitaxel-carboplatin	_	_	O
69	[	_	_	O
70	TC	_	_	O
71	]	_	_	O
72	)	_	_	O
73	.	_	_	O

74	The	_	_	O
75	PRE	_	_	O
76	group	_	_	O
77	received	_	_	O
78	two	_	_	O
79	preoperative	_	_	O
80	cycles	_	_	O
81	followed	_	_	O
82	by	_	_	O
83	two	_	_	O
84	additional	_	_	O
85	preoperative	_	_	O
86	cycles	_	_	O
87	,	_	_	O
88	while	_	_	O
89	the	_	_	O
90	PERI	_	_	O
91	group	_	_	O
92	underwent	_	_	O
93	two	_	_	O
94	preoperative	_	_	O
95	cycles	_	_	O
96	followed	_	_	O
97	by	_	_	O
98	two	_	_	O
99	postoperative	_	_	O
100	cycles	_	_	O
101	,	_	_	O
102	the	_	_	O
103	3rd	_	_	O
104	and	_	_	O
105	4th	_	_	O
106	cycles	_	_	O
107	being	_	_	O
108	given	_	_	O
109	only	_	_	O
110	to	_	_	O
111	responders	_	_	O
112	in	_	_	O
113	both	_	_	O
114	cases	_	_	O
115	.	_	_	O

116	A	_	_	O
117	total	_	_	O
118	of	_	_	O
119	528	_	_	O
120	patients	_	_	O
121	were	_	_	O
122	randomised	_	_	O
123	,	_	_	O
124	267	_	_	O
125	of	_	_	O
126	which	_	_	O
127	were	_	_	O
128	assigned	_	_	O
129	to	_	_	O
130	the	_	_	O
131	PRE	_	_	O
132	group	_	_	O
133	and	_	_	O
134	261	_	_	O
135	to	_	_	O
136	the	_	_	O
137	PERI	_	_	O
138	group	_	_	O
139	.	_	_	O

140	Three-year	_	_	O
141	OS	_	_	O
142	did	_	_	O
143	not	_	_	O
144	differ	_	_	O
145	between	_	_	O
146	the	_	_	O
147	two	_	_	O
148	groups	_	_	O
149	(	_	_	O
150	67.4	_	_	O
151	%	_	_	O
152	and	_	_	O
153	67.7	_	_	O
154	%	_	_	O
155	,	_	_	O
156	respectively	_	_	O
157	;	_	_	O
158	hazard	_	_	O
159	ratio	_	_	O
160	(	_	_	O
161	HR	_	_	O
162	)	_	_	O
163	=1.01	_	_	O
164	[	_	_	O
165	0.79-1.30	_	_	O
166	]	_	_	O
167	,	_	_	O
168	p=0.92	_	_	O
169	)	_	_	O
170	,	_	_	O
171	nor	_	_	O
172	did	_	_	O
173	3-year	_	_	O
174	disease-free	_	_	O
175	survival	_	_	O
176	,	_	_	O
177	response	_	_	O
178	rates	_	_	O
179	,	_	_	O
180	toxicity	_	_	O
181	,	_	_	O
182	or	_	_	O
183	postoperative	_	_	O
184	mortality	_	_	O
185	.	_	_	O

186	Pathological	_	_	B-Premise
187	complete	_	_	I-Premise
188	response	_	_	I-Premise
189	was	_	_	I-Premise
190	observed	_	_	I-Premise
191	in	_	_	I-Premise
192	22	_	_	I-Premise
193	(	_	_	I-Premise
194	8.2	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	16	_	_	I-Premise
199	patients	_	_	I-Premise
200	(	_	_	I-Premise
201	6.1	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	.	_	_	I-Premise

207	Although	_	_	B-Premise
208	quality	_	_	I-Premise
209	of	_	_	I-Premise
210	life	_	_	I-Premise
211	did	_	_	I-Premise
212	not	_	_	I-Premise
213	differ	_	_	I-Premise
214	significantly	_	_	I-Premise
215	,	_	_	I-Premise
216	chemotherapy	_	_	B-Premise
217	compliance	_	_	I-Premise
218	was	_	_	I-Premise
219	significantly	_	_	I-Premise
220	higher	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	PRE	_	_	I-Premise
224	group	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	proportion	_	_	I-Premise
228	of	_	_	I-Premise
229	responders	_	_	I-Premise
230	who	_	_	I-Premise
231	received	_	_	I-Premise
232	Cycles	_	_	I-Premise
233	3	_	_	I-Premise
234	and	_	_	I-Premise
235	4	_	_	I-Premise
236	was	_	_	I-Premise
237	significantly	_	_	I-Premise
238	higher	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	PRE	_	_	I-Premise
242	group	_	_	I-Premise
243	(	_	_	I-Premise
244	90.4	_	_	I-Premise
245	%	_	_	I-Premise
246	versus	_	_	I-Premise
247	75.2	_	_	I-Premise
248	%	_	_	I-Premise
249	,	_	_	I-Premise
250	p=0.001	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	In	_	_	B-Premise
254	responders	_	_	I-Premise
255	,	_	_	I-Premise
256	the	_	_	I-Premise
257	dose	_	_	I-Premise
258	intensity	_	_	I-Premise
259	of	_	_	I-Premise
260	Cycles	_	_	I-Premise
261	3	_	_	I-Premise
262	and	_	_	I-Premise
263	4	_	_	I-Premise
264	was	_	_	I-Premise
265	higher	_	_	I-Premise
266	in	_	_	I-Premise
267	the	_	_	I-Premise
268	PRE	_	_	I-Premise
269	group	_	_	I-Premise
270	than	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	PERI	_	_	I-Premise
274	group	_	_	I-Premise
275	(	_	_	I-Premise
276	mean	_	_	I-Premise
277	relative	_	_	I-Premise
278	dose	_	_	I-Premise
279	intensity	_	_	I-Premise
280	of	_	_	I-Premise
281	90.4	_	_	I-Premise
282	%	_	_	I-Premise
283	versus	_	_	I-Premise
284	82.6	_	_	I-Premise
285	%	_	_	I-Premise
286	,	_	_	I-Premise
287	respectively	_	_	I-Premise
288	;	_	_	I-Premise
289	p=0.0007	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	There	_	_	B-Premise
293	was	_	_	I-Premise
294	no	_	_	I-Premise
295	difference	_	_	I-Premise
296	between	_	_	I-Premise
297	GP	_	_	I-Premise
298	and	_	_	I-Premise
299	TC	_	_	I-Premise
300	in	_	_	I-Premise
301	3-year	_	_	I-Premise
302	OS	_	_	I-Premise
303	(	_	_	I-Premise
304	HR=0.97	_	_	I-Premise
305	[	_	_	I-Premise
306	95	_	_	I-Premise
307	%	_	_	I-Premise
308	confidence	_	_	I-Premise
309	interval	_	_	I-Premise
310	(	_	_	I-Premise
311	CI	_	_	I-Premise
312	)	_	_	I-Premise
313	:	_	_	I-Premise
314	0.76-1.25	_	_	I-Premise
315	]	_	_	I-Premise
316	,	_	_	I-Premise
317	p=0.80	_	_	I-Premise
318	)	_	_	I-Premise
319	or	_	_	I-Premise
320	response	_	_	I-Premise
321	rates	_	_	I-Premise
322	.	_	_	I-Premise

323	However	_	_	O
324	,	_	_	O
325	the	_	_	B-Premise
326	regimens	_	_	I-Premise
327	'	_	_	I-Premise
328	toxicity	_	_	I-Premise
329	profiles	_	_	I-Premise
330	differed	_	_	I-Premise
331	.	_	_	I-Premise

332	This	_	_	B-Claim
333	study	_	_	I-Claim
334	failed	_	_	I-Claim
335	to	_	_	I-Claim
336	demonstrate	_	_	I-Claim
337	any	_	_	I-Claim
338	difference	_	_	I-Claim
339	in	_	_	I-Claim
340	survival	_	_	I-Claim
341	between	_	_	I-Claim
342	patients	_	_	I-Claim
343	receiving	_	_	I-Claim
344	preoperative	_	_	I-Claim
345	and	_	_	I-Claim
346	perioperative	_	_	I-Claim
347	chemotherapy	_	_	I-Claim
348	in	_	_	I-Claim
349	early-stage	_	_	I-Claim
350	NSCLC	_	_	I-Claim
351	.	_	_	I-Claim

352	The	_	_	B-Claim
353	increase	_	_	I-Claim
354	from	_	_	I-Claim
355	two	_	_	I-Claim
356	to	_	_	I-Claim
357	four	_	_	I-Claim
358	preoperative	_	_	I-Claim
359	chemotherapy	_	_	I-Claim
360	cycles	_	_	I-Claim
361	did	_	_	I-Claim
362	not	_	_	I-Claim
363	increase	_	_	I-Claim
364	the	_	_	I-Claim
365	pathological	_	_	I-Claim
366	response	_	_	I-Claim
367	rate	_	_	I-Claim
368	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aims	_	_	O
3	to	_	_	O
4	evaluate	_	_	O
5	the	_	_	O
6	feasibility	_	_	O
7	and	_	_	O
8	efficacy	_	_	O
9	of	_	_	O
10	an	_	_	O
11	8-week	_	_	O
12	supervised	_	_	O
13	exercise	_	_	O
14	program	_	_	O
15	in	_	_	O
16	de-conditioned	_	_	O
17	cancer	_	_	O
18	survivors	_	_	O
19	within	_	_	O
20	2-6	_	_	O
21	months	_	_	O
22	of	_	_	O
23	chemotherapy	_	_	O
24	completion	_	_	O
25	.	_	_	O

26	Participants	_	_	O
27	were	_	_	O
28	randomly	_	_	O
29	assigned	_	_	O
30	to	_	_	O
31	an	_	_	O
32	8-week	_	_	O
33	,	_	_	O
34	twice-weekly	_	_	O
35	,	_	_	O
36	supervised	_	_	O
37	aerobic	_	_	O
38	exercise	_	_	O
39	training	_	_	O
40	regime	_	_	O
41	(	_	_	O
42	n	_	_	O
43	=	_	_	O
44	23	_	_	O
45	)	_	_	O
46	or	_	_	O
47	a	_	_	O
48	usual	_	_	O
49	care	_	_	O
50	group	_	_	O
51	(	_	_	O
52	n	_	_	O
53	=	_	_	O
54	20	_	_	O
55	)	_	_	O
56	.	_	_	O

57	Feasibility	_	_	O
58	was	_	_	O
59	assessed	_	_	O
60	by	_	_	O
61	recruitment	_	_	O
62	rate	_	_	O
63	,	_	_	O
64	program	_	_	O
65	adherence	_	_	O
66	and	_	_	O
67	participant	_	_	O
68	feedback	_	_	O
69	.	_	_	O

70	The	_	_	O
71	primary	_	_	O
72	outcome	_	_	O
73	was	_	_	O
74	aerobic	_	_	O
75	fitness	_	_	O
76	assessed	_	_	O
77	by	_	_	O
78	the	_	_	O
79	Modified	_	_	O
80	Bruce	_	_	O
81	fitness	_	_	O
82	test	_	_	O
83	at	_	_	O
84	baseline	_	_	O
85	(	_	_	O
86	0	_	_	O
87	weeks	_	_	O
88	)	_	_	O
89	,	_	_	O
90	post-intervention	_	_	O
91	(	_	_	O
92	8	_	_	O
93	weeks	_	_	O
94	)	_	_	O
95	and	_	_	O
96	at	_	_	O
97	3-month	_	_	O
98	follow-up	_	_	O
99	.	_	_	O

100	Secondary	_	_	O
101	outcomes	_	_	O
102	included	_	_	O
103	physical	_	_	O
104	activity	_	_	O
105	,	_	_	O
106	waist	_	_	O
107	circumference	_	_	O
108	,	_	_	O
109	fatigue	_	_	O
110	and	_	_	O
111	quality	_	_	O
112	of	_	_	O
113	life	_	_	O
114	.	_	_	O

115	The	_	_	O
116	recruitment	_	_	O
117	rate	_	_	O
118	was	_	_	O
119	81	_	_	O
120	%	_	_	O
121	and	_	_	O
122	adherence	_	_	O
123	to	_	_	O
124	the	_	_	O
125	supervised	_	_	O
126	exercise	_	_	O
127	was	_	_	O
128	78.3	_	_	O
129	%	_	_	O
130	.	_	_	O

131	Meaningful	_	_	B-Premise
132	differences	_	_	I-Premise
133	in	_	_	I-Premise
134	aerobic	_	_	I-Premise
135	fitness	_	_	I-Premise
136	between	_	_	I-Premise
137	the	_	_	I-Premise
138	exercise	_	_	I-Premise
139	and	_	_	I-Premise
140	usual	_	_	I-Premise
141	care	_	_	I-Premise
142	groups	_	_	I-Premise
143	at	_	_	I-Premise
144	both	_	_	I-Premise
145	the	_	_	I-Premise
146	8-week	_	_	I-Premise
147	[	_	_	I-Premise
148	mean	_	_	I-Premise
149	3.0	_	_	I-Premise
150	mL	_	_	I-Premise
151	kg	_	_	I-Premise
152	(	_	_	I-Premise
153	-1	_	_	I-Premise
154	)	_	_	I-Premise
155	min	_	_	I-Premise
156	(	_	_	I-Premise
157	-1	_	_	I-Premise
158	)	_	_	I-Premise
159	(	_	_	I-Premise
160	95	_	_	I-Premise
161	%	_	_	I-Premise
162	CI	_	_	I-Premise
163	-1.1-7.0	_	_	I-Premise
164	)	_	_	I-Premise
165	]	_	_	I-Premise
166	and	_	_	I-Premise
167	3-month	_	_	I-Premise
168	follow-up	_	_	I-Premise
169	[	_	_	I-Premise
170	2.1	_	_	I-Premise
171	mL	_	_	I-Premise
172	kg	_	_	I-Premise
173	(	_	_	I-Premise
174	-1	_	_	I-Premise
175	)	_	_	I-Premise
176	min	_	_	I-Premise
177	(	_	_	I-Premise
178	-1	_	_	I-Premise
179	)	_	_	I-Premise
180	(	_	_	I-Premise
181	-2.3-6.6	_	_	I-Premise
182	)	_	_	I-Premise
183	]	_	_	I-Premise
184	were	_	_	I-Premise
185	found	_	_	I-Premise
186	,	_	_	I-Premise
187	although	_	_	B-Premise
188	these	_	_	I-Premise
189	differences	_	_	I-Premise
190	did	_	_	I-Premise
191	not	_	_	I-Premise
192	achieve	_	_	I-Premise
193	statistical	_	_	I-Premise
194	significance	_	_	I-Premise
195	(	_	_	I-Premise
196	p	_	_	I-Premise
197	values	_	_	I-Premise
198	>	_	_	I-Premise
199	0.14	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Self-reported	_	_	B-Premise
203	physical	_	_	I-Premise
204	activity	_	_	I-Premise
205	increased	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	exercise	_	_	I-Premise
209	group	_	_	I-Premise
210	(	_	_	I-Premise
211	EG	_	_	I-Premise
212	)	_	_	I-Premise
213	compared	_	_	I-Premise
214	to	_	_	I-Premise
215	the	_	_	I-Premise
216	usual	_	_	I-Premise
217	care	_	_	I-Premise
218	group	_	_	I-Premise
219	at	_	_	I-Premise
220	both	_	_	I-Premise
221	8-week	_	_	I-Premise
222	(	_	_	I-Premise
223	p	_	_	I-Premise
224	=	_	_	I-Premise
225	0.01	_	_	I-Premise
226	)	_	_	I-Premise
227	and	_	_	I-Premise
228	3-month	_	_	I-Premise
229	follow-up	_	_	I-Premise
230	(	_	_	I-Premise
231	p	_	_	I-Premise
232	=	_	_	I-Premise
233	0.03	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	significant	_	_	I-Premise
237	differences	_	_	I-Premise
238	in	_	_	I-Premise
239	favour	_	_	I-Premise
240	of	_	_	I-Premise
241	the	_	_	I-Premise
242	EG	_	_	I-Premise
243	were	_	_	I-Premise
244	found	_	_	I-Premise
245	for	_	_	I-Premise
246	physical	_	_	I-Premise
247	well-being	_	_	I-Premise
248	at	_	_	I-Premise
249	both	_	_	I-Premise
250	the	_	_	I-Premise
251	8-week	_	_	I-Premise
252	(	_	_	I-Premise
253	p	_	_	I-Premise
254	=	_	_	I-Premise
255	0.03	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	3-month	_	_	I-Premise
259	follow-up	_	_	I-Premise
260	(	_	_	I-Premise
261	p	_	_	I-Premise
262	=	_	_	I-Premise
263	0.04	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	Improvements	_	_	B-Premise
267	in	_	_	I-Premise
268	fatigue	_	_	I-Premise
269	(	_	_	I-Premise
270	p	_	_	I-Premise
271	=	_	_	I-Premise
272	0.01	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	total	_	_	I-Premise
276	quality	_	_	I-Premise
277	of	_	_	I-Premise
278	life	_	_	I-Premise
279	plus	_	_	I-Premise
280	fatigue	_	_	I-Premise
281	(	_	_	I-Premise
282	p	_	_	I-Premise
283	=	_	_	I-Premise
284	0.04	_	_	I-Premise
285	)	_	_	I-Premise
286	,	_	_	I-Premise
287	and	_	_	I-Premise
288	a	_	_	I-Premise
289	composite	_	_	I-Premise
290	physical	_	_	I-Premise
291	functioning	_	_	I-Premise
292	score	_	_	I-Premise
293	(	_	_	I-Premise
294	p	_	_	I-Premise
295	=	_	_	I-Premise
296	0.01	_	_	I-Premise
297	)	_	_	I-Premise
298	at	_	_	I-Premise
299	the	_	_	I-Premise
300	3-month	_	_	I-Premise
301	follow-up	_	_	I-Premise
302	were	_	_	I-Premise
303	also	_	_	I-Premise
304	found	_	_	I-Premise
305	.	_	_	I-Premise

306	The	_	_	B-Claim
307	PEACH	_	_	I-Claim
308	trial	_	_	I-Claim
309	suggests	_	_	I-Claim
310	that	_	_	I-Claim
311	8	_	_	I-Claim
312	weeks	_	_	I-Claim
313	of	_	_	I-Claim
314	supervised	_	_	I-Claim
315	aerobic	_	_	I-Claim
316	exercise	_	_	I-Claim
317	training	_	_	I-Claim
318	was	_	_	I-Claim
319	feasible	_	_	I-Claim
320	and	_	_	I-Claim
321	may	_	_	I-Claim
322	improve	_	_	I-Claim
323	aerobic	_	_	I-Claim
324	fitness	_	_	I-Claim
325	,	_	_	I-Claim
326	fatigue	_	_	I-Claim
327	and	_	_	I-Claim
328	quality	_	_	I-Claim
329	of	_	_	I-Claim
330	life	_	_	I-Claim
331	in	_	_	I-Claim
332	de-conditioned	_	_	I-Claim
333	cancer	_	_	I-Claim
334	survivors	_	_	I-Claim
335	during	_	_	I-Claim
336	the	_	_	I-Claim
337	early	_	_	I-Claim
338	survivorship	_	_	I-Claim
339	phase	_	_	I-Claim
340	.	_	_	I-Claim

341	Exercise	_	_	B-Claim
342	interventions	_	_	I-Claim
343	commenced	_	_	I-Claim
344	in	_	_	I-Claim
345	the	_	_	I-Claim
346	early	_	_	I-Claim
347	survivorship	_	_	I-Claim
348	phase	_	_	I-Claim
349	appear	_	_	I-Claim
350	safe	_	_	I-Claim
351	,	_	_	I-Claim
352	feasible	_	_	I-Claim
353	and	_	_	I-Claim
354	may	_	_	I-Claim
355	lead	_	_	I-Claim
356	to	_	_	I-Claim
357	improvements	_	_	I-Claim
358	in	_	_	I-Claim
359	QOL	_	_	I-Claim
360	and	_	_	I-Claim
361	fatigue	_	_	I-Claim
362	.	_	_	I-Claim


0	Capecitabine/taxane	_	_	O
1	combinations	_	_	O
2	are	_	_	O
3	highly	_	_	O
4	active	_	_	O
5	in	_	_	O
6	metastatic	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	(	_	_	O
10	MBC	_	_	O
11	)	_	_	O
12	.	_	_	O

13	We	_	_	O
14	conducted	_	_	O
15	a	_	_	O
16	randomized	_	_	O
17	,	_	_	O
18	phase	_	_	O
19	III	_	_	O
20	,	_	_	O
21	noninferiority	_	_	O
22	trial	_	_	O
23	comparing	_	_	O
24	capecitabine	_	_	O
25	plus	_	_	O
26	paclitaxel	_	_	O
27	(	_	_	O
28	XP	_	_	O
29	)	_	_	O
30	with	_	_	O
31	epirubicin	_	_	O
32	plus	_	_	O
33	paclitaxel	_	_	O
34	(	_	_	O
35	EP	_	_	O
36	)	_	_	O
37	as	_	_	O
38	first-line	_	_	O
39	therapy	_	_	O
40	for	_	_	O
41	MBC	_	_	O
42	,	_	_	O
43	regarding	_	_	O
44	progression-free	_	_	O
45	survival	_	_	O
46	(	_	_	O
47	PFS	_	_	O
48	)	_	_	O
49	as	_	_	O
50	primary	_	_	O
51	efficacy	_	_	O
52	endpoint	_	_	O
53	.	_	_	O

54	Females	_	_	O
55	who	_	_	O
56	had	_	_	O
57	received	_	_	O
58	no	_	_	O
59	prior	_	_	O
60	chemotherapy	_	_	O
61	for	_	_	O
62	MBC	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	six	_	_	O
67	3-weekly	_	_	O
68	cycles	_	_	O
69	of	_	_	O
70	XP	_	_	O
71	(	_	_	O
72	capecitabine	_	_	O
73	1000	_	_	O
74	mg/m	_	_	O
75	(	_	_	O
76	2	_	_	O
77	)	_	_	O
78	b.i.d.	_	_	O
79	,	_	_	O
80	days	_	_	O
81	1-14	_	_	O
82	;	_	_	O
83	paclitaxel	_	_	O
84	175	_	_	O
85	mg/m	_	_	O
86	(	_	_	O
87	2	_	_	O
88	)	_	_	O
89	3-h	_	_	O
90	infusion	_	_	O
91	,	_	_	O
92	day	_	_	O
93	1	_	_	O
94	)	_	_	O
95	or	_	_	O
96	EP	_	_	O
97	(	_	_	O
98	epirubicin	_	_	O
99	60	_	_	O
100	mg/m	_	_	O
101	(	_	_	O
102	2	_	_	O
103	)	_	_	O
104	1-h	_	_	O
105	infusion	_	_	O
106	,	_	_	O
107	day	_	_	O
108	1	_	_	O
109	;	_	_	O
110	paclitaxel	_	_	O
111	as	_	_	O
112	above	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Secondary	_	_	O
116	endpoints	_	_	O
117	included	_	_	O
118	response	_	_	O
119	rate	_	_	O
120	,	_	_	O
121	overall	_	_	O
122	survival	_	_	O
123	,	_	_	O
124	tolerability	_	_	O
125	,	_	_	O
126	and	_	_	O
127	quality	_	_	O
128	of	_	_	O
129	life	_	_	O
130	(	_	_	O
131	QoL	_	_	O
132	)	_	_	O
133	.	_	_	O

134	Each	_	_	O
135	arm	_	_	O
136	included	_	_	O
137	170	_	_	O
138	patients	_	_	O
139	,	_	_	O
140	most	_	_	O
141	of	_	_	O
142	whom	_	_	O
143	received	_	_	O
144	all	_	_	O
145	six	_	_	O
146	cycles	_	_	O
147	as	_	_	O
148	planned	_	_	O
149	.	_	_	O

150	The	_	_	O
151	difference	_	_	O
152	in	_	_	O
153	means	_	_	O
154	of	_	_	O
155	(	_	_	O
156	logarithmic	_	_	O
157	)	_	_	O
158	PFS	_	_	O
159	times	_	_	O
160	(	_	_	O
161	-0.205	_	_	O
162	)	_	_	O
163	did	_	_	O
164	not	_	_	O
165	meet	_	_	O
166	the	_	_	O
167	pre-defined	_	_	O
168	level	_	_	O
169	for	_	_	O
170	noninferiority	_	_	O
171	(	_	_	O
172	-0.186	_	_	O
173	)	_	_	O
174	.	_	_	O

175	However	_	_	O
176	,	_	_	O
177	PFS	_	_	B-Premise
178	was	_	_	I-Premise
179	similar	_	_	I-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	two	_	_	I-Premise
183	arms	_	_	I-Premise
184	[	_	_	I-Premise
185	HR	_	_	I-Premise
186	:	_	_	I-Premise
187	XP	_	_	I-Premise
188	vs.	_	_	I-Premise
189	EP	_	_	I-Premise
190	:	_	_	I-Premise
191	1.012	_	_	I-Premise
192	(	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	0.785-1.304	_	_	I-Premise
197	)	_	_	I-Premise
198	;	_	_	I-Premise
199	median	_	_	I-Premise
200	10.4	_	_	I-Premise
201	months	_	_	I-Premise
202	XP	_	_	I-Premise
203	vs.	_	_	I-Premise
204	9.2	_	_	I-Premise
205	months	_	_	I-Premise
206	EP	_	_	I-Premise
207	]	_	_	I-Premise
208	.	_	_	I-Premise

209	Overall	_	_	B-Premise
210	survival	_	_	I-Premise
211	was	_	_	I-Premise
212	also	_	_	I-Premise
213	similar	_	_	I-Premise
214	[	_	_	I-Premise
215	HR	_	_	I-Premise
216	1.027	_	_	I-Premise
217	(	_	_	I-Premise
218	95	_	_	I-Premise
219	%	_	_	I-Premise
220	CI	_	_	I-Premise
221	0.740-1.424	_	_	I-Premise
222	)	_	_	I-Premise
223	;	_	_	I-Premise
224	median	_	_	I-Premise
225	22.0	_	_	I-Premise
226	vs.	_	_	I-Premise
227	26.1	_	_	I-Premise
228	months	_	_	I-Premise
229	]	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	response	_	_	I-Premise
233	rate	_	_	I-Premise
234	was	_	_	I-Premise
235	47	_	_	I-Premise
236	%	_	_	I-Premise
237	versus	_	_	I-Premise
238	42	_	_	I-Premise
239	%	_	_	I-Premise
240	.	_	_	I-Premise

241	Both	_	_	B-Premise
242	regimens	_	_	I-Premise
243	were	_	_	I-Premise
244	tolerable	_	_	I-Premise
245	:	_	_	I-Premise
246	there	_	_	I-Premise
247	were	_	_	I-Premise
248	more	_	_	I-Premise
249	grade	_	_	I-Premise
250	3/4	_	_	I-Premise
251	diarrhea	_	_	I-Premise
252	and	_	_	I-Premise
253	grade	_	_	I-Premise
254	3	_	_	I-Premise
255	hand-foot	_	_	I-Premise
256	syndromes	_	_	I-Premise
257	with	_	_	I-Premise
258	XP	_	_	I-Premise
259	and	_	_	I-Premise
260	more	_	_	I-Premise
261	grade	_	_	I-Premise
262	3/4	_	_	I-Premise
263	hematologic	_	_	I-Premise
264	toxicities	_	_	I-Premise
265	with	_	_	I-Premise
266	EP	_	_	I-Premise
267	.	_	_	I-Premise

268	There	_	_	B-Premise
269	were	_	_	I-Premise
270	no	_	_	I-Premise
271	major	_	_	I-Premise
272	differences	_	_	I-Premise
273	in	_	_	I-Premise
274	QoL	_	_	I-Premise
275	.	_	_	I-Premise

276	Although	_	_	B-Claim
277	,	_	_	I-Claim
278	noninferiority	_	_	I-Claim
279	of	_	_	I-Claim
280	XP	_	_	I-Claim
281	to	_	_	I-Claim
282	EP	_	_	I-Claim
283	was	_	_	I-Claim
284	formally	_	_	I-Claim
285	not	_	_	I-Claim
286	proven	_	_	I-Claim
287	,	_	_	I-Claim
288	first-line	_	_	B-Claim
289	XP	_	_	I-Claim
290	was	_	_	I-Claim
291	active	_	_	I-Claim
292	and	_	_	I-Claim
293	feasible	_	_	I-Claim
294	.	_	_	I-Claim

295	XP	_	_	B-Claim
296	is	_	_	I-Claim
297	a	_	_	I-Claim
298	valid	_	_	I-Claim
299	first-line	_	_	I-Claim
300	alternative	_	_	I-Claim
301	to	_	_	I-Claim
302	anthracycline/taxane	_	_	I-Claim
303	regimens	_	_	I-Claim
304	,	_	_	I-Claim
305	especially	_	_	I-Claim
306	in	_	_	I-Claim
307	patients	_	_	I-Claim
308	previously	_	_	I-Claim
309	treated	_	_	I-Claim
310	with	_	_	I-Claim
311	adjuvant	_	_	I-Claim
312	anthracyclines	_	_	I-Claim
313	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	laparoscopy-assisted	_	_	O
9	distal	_	_	O
10	gastrectomy	_	_	O
11	(	_	_	O
12	LADG	_	_	O
13	)	_	_	O
14	compared	_	_	O
15	to	_	_	O
16	open	_	_	O
17	distal	_	_	O
18	gastrectomy	_	_	O
19	(	_	_	O
20	ODG	_	_	O
21	)	_	_	O
22	in	_	_	O
23	the	_	_	O
24	treatment	_	_	O
25	of	_	_	O
26	early	_	_	O
27	gastric	_	_	O
28	cancer	_	_	O
29	with	_	_	O
30	respect	_	_	O
31	to	_	_	O
32	survival	_	_	O
33	,	_	_	O
34	surgical	_	_	O
35	outcomes	_	_	O
36	,	_	_	O
37	complications	_	_	O
38	,	_	_	O
39	and	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	.	_	_	O

47	One	_	_	O
48	hundred	_	_	O
49	sixty-four	_	_	O
50	patients	_	_	O
51	with	_	_	O
52	cT1N0M0	_	_	O
53	and	_	_	O
54	cT1N1M0	_	_	O
55	distal	_	_	O
56	gastric	_	_	O
57	cancer	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	to	_	_	O
62	either	_	_	O
63	the	_	_	O
64	LADG	_	_	O
65	group	_	_	O
66	or	_	_	O
67	the	_	_	O
68	ODG	_	_	O
69	group	_	_	O
70	.	_	_	O

71	The	_	_	O
72	primary	_	_	O
73	end	_	_	O
74	point	_	_	O
75	was	_	_	O
76	the	_	_	O
77	5-year	_	_	O
78	disease-free	_	_	O
79	survival	_	_	O
80	(	_	_	O
81	DFS	_	_	O
82	)	_	_	O
83	rate	_	_	O
84	.	_	_	O

85	Complications	_	_	O
86	were	_	_	O
87	classified	_	_	O
88	using	_	_	O
89	the	_	_	O
90	accordion	_	_	O
91	severity	_	_	O
92	classification	_	_	O
93	of	_	_	O
94	postoperative	_	_	O
95	complications	_	_	O
96	scheme	_	_	O
97	.	_	_	O

98	QOL	_	_	O
99	was	_	_	O
100	measured	_	_	O
101	using	_	_	O
102	the	_	_	O
103	European	_	_	O
104	Organization	_	_	O
105	for	_	_	O
106	Research	_	_	O
107	and	_	_	O
108	Treatment	_	_	O
109	of	_	_	O
110	Cancer	_	_	O
111	QLQ-C30	_	_	O
112	and	_	_	O
113	QLQ-STO22	_	_	O
114	preoperatively	_	_	O
115	and	_	_	O
116	postoperatively	_	_	O
117	during	_	_	O
118	regular	_	_	O
119	follow-up	_	_	O
120	visits	_	_	O
121	.	_	_	O

122	This	_	_	O
123	trial	_	_	O
124	is	_	_	O
125	registered	_	_	O
126	at	_	_	O
127	ClinicalTrials.gov	_	_	O
128	.	_	_	O

129	The	_	_	O
130	median	_	_	O
131	(	_	_	O
132	range	_	_	O
133	)	_	_	O
134	follow-up	_	_	O
135	period	_	_	O
136	was	_	_	O
137	74.3	_	_	O
138	(	_	_	O
139	24.8-90.8	_	_	O
140	)	_	_	O
141	months	_	_	O
142	.	_	_	O

143	The	_	_	B-Premise
144	LADG	_	_	I-Premise
145	and	_	_	I-Premise
146	ODG	_	_	I-Premise
147	groups	_	_	I-Premise
148	showed	_	_	I-Premise
149	similar	_	_	I-Premise
150	survival	_	_	I-Premise
151	[	_	_	I-Premise
152	5-year	_	_	I-Premise
153	DFS	_	_	I-Premise
154	rate	_	_	I-Premise
155	:	_	_	I-Premise
156	98.8	_	_	I-Premise
157	%	_	_	I-Premise
158	vs.	_	_	I-Premise
159	97.6	_	_	I-Premise
160	%	_	_	I-Premise
161	,	_	_	I-Premise
162	respectively	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	=	_	_	I-Premise
166	0.514	_	_	I-Premise
167	)	_	_	I-Premise
168	,	_	_	I-Premise
169	5-year	_	_	I-Premise
170	overall	_	_	I-Premise
171	survival	_	_	I-Premise
172	(	_	_	I-Premise
173	OS	_	_	I-Premise
174	)	_	_	I-Premise
175	rate	_	_	I-Premise
176	:	_	_	I-Premise
177	97.6	_	_	I-Premise
178	vs.	_	_	I-Premise
179	96.3	_	_	I-Premise
180	%	_	_	I-Premise
181	,	_	_	I-Premise
182	respectively	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	0.721	_	_	I-Premise
187	)	_	_	I-Premise
188	]	_	_	I-Premise
189	or	_	_	I-Premise
190	overall	_	_	I-Premise
191	complication	_	_	I-Premise
192	rate	_	_	I-Premise
193	(	_	_	I-Premise
194	29.3	_	_	I-Premise
195	vs.	_	_	I-Premise
196	42.7	_	_	I-Premise
197	%	_	_	I-Premise
198	,	_	_	I-Premise
199	respectively	_	_	I-Premise
200	;	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	0.073	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Mild	_	_	B-Premise
207	complications	_	_	I-Premise
208	were	_	_	I-Premise
209	significantly	_	_	I-Premise
210	less	_	_	I-Premise
211	frequent	_	_	I-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	LADG	_	_	I-Premise
215	group	_	_	I-Premise
216	than	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	ODG	_	_	I-Premise
220	group	_	_	I-Premise
221	(	_	_	I-Premise
222	23.2	_	_	I-Premise
223	vs.	_	_	I-Premise
224	41.5	_	_	I-Premise
225	%	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0.012	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	The	_	_	B-Premise
233	rates	_	_	I-Premise
234	of	_	_	I-Premise
235	moderate	_	_	I-Premise
236	,	_	_	I-Premise
237	severe	_	_	I-Premise
238	,	_	_	I-Premise
239	and	_	_	I-Premise
240	long-term	_	_	I-Premise
241	complications	_	_	I-Premise
242	(	_	_	I-Premise
243	i.e.	_	_	I-Premise
244	,	_	_	I-Premise
245	31	_	_	I-Premise
246	days	_	_	I-Premise
247	to	_	_	I-Premise
248	5	_	_	I-Premise
249	years	_	_	I-Premise
250	after	_	_	I-Premise
251	surgery	_	_	I-Premise
252	)	_	_	I-Premise
253	did	_	_	I-Premise
254	not	_	_	I-Premise
255	differ	_	_	I-Premise
256	significantly	_	_	I-Premise
257	between	_	_	I-Premise
258	groups	_	_	I-Premise
259	.	_	_	I-Premise

260	No	_	_	B-Premise
261	clinically	_	_	I-Premise
262	meaningful	_	_	I-Premise
263	differences	_	_	I-Premise
264	were	_	_	I-Premise
265	detected	_	_	I-Premise
266	between	_	_	I-Premise
267	the	_	_	I-Premise
268	two	_	_	I-Premise
269	groups	_	_	I-Premise
270	in	_	_	I-Premise
271	long-term	_	_	I-Premise
272	QOL	_	_	I-Premise
273	.	_	_	I-Premise

274	LADG	_	_	B-Claim
275	showed	_	_	I-Claim
276	similar	_	_	I-Claim
277	DFS	_	_	I-Claim
278	and	_	_	I-Claim
279	OS	_	_	I-Claim
280	compared	_	_	I-Claim
281	to	_	_	I-Claim
282	ODG	_	_	I-Claim
283	in	_	_	I-Claim
284	treating	_	_	I-Claim
285	early	_	_	I-Claim
286	gastric	_	_	I-Claim
287	cancer	_	_	I-Claim
288	.	_	_	I-Claim

289	Marginal	_	_	B-Claim
290	benefits	_	_	I-Claim
291	in	_	_	I-Claim
292	mild	_	_	I-Claim
293	complications	_	_	I-Claim
294	were	_	_	I-Claim
295	observed	_	_	I-Claim
296	with	_	_	I-Claim
297	LADG	_	_	I-Claim
298	.	_	_	I-Claim

299	LADG	_	_	B-Claim
300	did	_	_	I-Claim
301	not	_	_	I-Claim
302	show	_	_	I-Claim
303	advantages	_	_	I-Claim
304	over	_	_	I-Claim
305	ODG	_	_	I-Claim
306	regarding	_	_	I-Claim
307	other	_	_	I-Claim
308	complications	_	_	I-Claim
309	and	_	_	I-Claim
310	long-term	_	_	I-Claim
311	QOL	_	_	I-Claim
312	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aims	_	_	O
3	to	_	_	O
4	describe	_	_	O
5	and	_	_	O
6	compare	_	_	O
7	health-related	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	HRQL	_	_	O
13	)	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	node-positive	_	_	O
18	and	_	_	O
19	high-risk	_	_	O
20	node-negative	_	_	O
21	HER2-positive	_	_	O
22	early	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	receiving	_	_	O
26	adjuvant	_	_	O
27	docetaxel	_	_	O
28	and	_	_	O
29	trastuzumab-based	_	_	O
30	or	_	_	O
31	docetaxel-based	_	_	O
32	regimens	_	_	O
33	alone	_	_	O
34	.	_	_	O

35	Eligible	_	_	O
36	patients	_	_	O
37	(	_	_	O
38	n	_	_	O
39	=	_	_	O
40	3,222	_	_	O
41	)	_	_	O
42	were	_	_	O
43	randomly	_	_	O
44	assigned	_	_	O
45	to	_	_	O
46	either	_	_	O
47	four	_	_	O
48	cycles	_	_	O
49	of	_	_	O
50	adjuvant	_	_	O
51	doxorubicin	_	_	O
52	and	_	_	O
53	cyclophosphamide	_	_	O
54	followed	_	_	O
55	by	_	_	O
56	four	_	_	O
57	cycles	_	_	O
58	of	_	_	O
59	docetaxel	_	_	O
60	(	_	_	O
61	AC→T	_	_	O
62	)	_	_	O
63	or	_	_	O
64	one	_	_	O
65	of	_	_	O
66	two	_	_	O
67	trastuzumab-containing	_	_	O
68	regimens	_	_	O
69	:	_	_	O
70	adjuvant	_	_	O
71	doxorubicin	_	_	O
72	and	_	_	O
73	cyclophosphamide	_	_	O
74	followed	_	_	O
75	by	_	_	O
76	docetaxel	_	_	O
77	plus	_	_	O
78	trastuzumab	_	_	O
79	administered	_	_	O
80	for	_	_	O
81	1	_	_	O
82	year	_	_	O
83	(	_	_	O
84	AC→TH	_	_	O
85	)	_	_	O
86	or	_	_	O
87	six	_	_	O
88	cycles	_	_	O
89	of	_	_	O
90	docetaxel	_	_	O
91	plus	_	_	O
92	carboplatin	_	_	O
93	combined	_	_	O
94	with	_	_	O
95	trastuzumab	_	_	O
96	administered	_	_	O
97	for	_	_	O
98	1	_	_	O
99	year	_	_	O
100	(	_	_	O
101	TCH	_	_	O
102	)	_	_	O
103	.	_	_	O

104	The	_	_	O
105	European	_	_	O
106	Organization	_	_	O
107	for	_	_	O
108	Research	_	_	O
109	and	_	_	O
110	Treatment	_	_	O
111	of	_	_	O
112	Cancer	_	_	O
113	(	_	_	O
114	EORTC	_	_	O
115	)	_	_	O
116	Quality	_	_	O
117	of	_	_	O
118	Life	_	_	O
119	Questionnaire	_	_	O
120	C30	_	_	O
121	and	_	_	O
122	BR-23	_	_	O
123	were	_	_	O
124	administered	_	_	O
125	at	_	_	O
126	baseline	_	_	O
127	,	_	_	O
128	the	_	_	O
129	start	_	_	O
130	of	_	_	O
131	cycle	_	_	O
132	4	_	_	O
133	(	_	_	O
134	mid	_	_	O
135	)	_	_	O
136	,	_	_	O
137	and	_	_	O
138	the	_	_	O
139	end	_	_	O
140	of	_	_	O
141	chemotherapy	_	_	O
142	(	_	_	O
143	EOC	_	_	O
144	)	_	_	O
145	,	_	_	O
146	as	_	_	O
147	well	_	_	O
148	as	_	_	O
149	at	_	_	O
150	6	_	_	O
151	,	_	_	O
152	12	_	_	O
153	,	_	_	O
154	and	_	_	O
155	24	_	_	O
156	months	_	_	O
157	after	_	_	O
158	chemotherapy	_	_	O
159	.	_	_	O

160	Compliance	_	_	B-Premise
161	rates	_	_	I-Premise
162	for	_	_	I-Premise
163	the	_	_	I-Premise
164	EORTC	_	_	I-Premise
165	questionnaires	_	_	I-Premise
166	were	_	_	I-Premise
167	acceptable	_	_	I-Premise
168	at	_	_	I-Premise
169	72	_	_	I-Premise
170	%	_	_	I-Premise
171	-93	_	_	I-Premise
172	%	_	_	I-Premise
173	of	_	_	I-Premise
174	eligible	_	_	I-Premise
175	patients	_	_	I-Premise
176	out	_	_	I-Premise
177	to	_	_	I-Premise
178	the	_	_	I-Premise
179	12-month	_	_	I-Premise
180	assessment	_	_	I-Premise
181	.	_	_	I-Premise

182	Systemic	_	_	B-Premise
183	side	_	_	I-Premise
184	effect	_	_	I-Premise
185	(	_	_	I-Premise
186	SE	_	_	I-Premise
187	)	_	_	I-Premise
188	change	_	_	I-Premise
189	scores	_	_	I-Premise
190	were	_	_	I-Premise
191	significantly	_	_	I-Premise
192	improved	_	_	I-Premise
193	for	_	_	I-Premise
194	TCH-treated	_	_	I-Premise
195	patients	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	AC→TH	_	_	I-Premise
199	and	_	_	I-Premise
200	AC→T	_	_	I-Premise
201	at	_	_	I-Premise
202	EOC	_	_	I-Premise
203	,	_	_	I-Premise
204	suggesting	_	_	I-Premise
205	improved	_	_	I-Premise
206	tolerability	_	_	I-Premise
207	.	_	_	I-Premise

208	Physical	_	_	B-Premise
209	functioning	_	_	I-Premise
210	(	_	_	I-Premise
211	PF	_	_	I-Premise
212	)	_	_	I-Premise
213	was	_	_	I-Premise
214	only	_	_	I-Premise
215	slightly	_	_	I-Premise
216	worse	_	_	I-Premise
217	at	_	_	I-Premise
218	midpoint	_	_	I-Premise
219	for	_	_	I-Premise
220	those	_	_	I-Premise
221	receiving	_	_	I-Premise
222	TCH	_	_	I-Premise
223	,	_	_	I-Premise
224	compared	_	_	I-Premise
225	with	_	_	I-Premise
226	patients	_	_	I-Premise
227	who	_	_	I-Premise
228	were	_	_	I-Premise
229	just	_	_	I-Premise
230	starting	_	_	I-Premise
231	on	_	_	I-Premise
232	taxane	_	_	I-Premise
233	in	_	_	I-Premise
234	an	_	_	I-Premise
235	AC→TH	_	_	I-Premise
236	regimen	_	_	I-Premise
237	,	_	_	I-Premise
238	but	_	_	I-Premise
239	was	_	_	I-Premise
240	otherwise	_	_	I-Premise
241	similar	_	_	I-Premise
242	between	_	_	I-Premise
243	arms	_	_	I-Premise
244	.	_	_	I-Premise

245	All	_	_	B-Claim
246	treatment	_	_	I-Claim
247	arms	_	_	I-Claim
248	recovered	_	_	I-Claim
249	from	_	_	I-Claim
250	the	_	_	I-Claim
251	deterioration	_	_	I-Claim
252	in	_	_	I-Claim
253	SE	_	_	I-Claim
254	,	_	_	I-Claim
255	PF	_	_	I-Claim
256	,	_	_	I-Claim
257	and	_	_	I-Claim
258	Global	_	_	I-Claim
259	Health	_	_	I-Claim
260	Scale	_	_	I-Claim
261	scores	_	_	I-Claim
262	by	_	_	I-Claim
263	1	_	_	I-Claim
264	year	_	_	I-Claim
265	and	_	_	I-Claim
266	median	_	_	I-Claim
267	future	_	_	I-Claim
268	perspective	_	_	I-Claim
269	change	_	_	I-Claim
270	scores	_	_	I-Claim
271	continued	_	_	I-Claim
272	to	_	_	I-Claim
273	improve	_	_	I-Claim
274	throughout	_	_	I-Claim
275	treatment	_	_	I-Claim
276	and	_	_	I-Claim
277	follow-up	_	_	I-Claim
278	.	_	_	I-Claim

279	HRQL	_	_	B-Claim
280	outcomes	_	_	I-Claim
281	for	_	_	I-Claim
282	adjuvant	_	_	I-Claim
283	docetaxel	_	_	I-Claim
284	and	_	_	I-Claim
285	trastuzumab-based	_	_	I-Claim
286	regimens	_	_	I-Claim
287	are	_	_	I-Claim
288	favorable	_	_	I-Claim
289	and	_	_	I-Claim
290	support	_	_	I-Claim
291	TCH	_	_	I-Claim
292	as	_	_	I-Claim
293	a	_	_	I-Claim
294	more	_	_	I-Claim
295	tolerable	_	_	I-Claim
296	treatment	_	_	I-Claim
297	option	_	_	I-Claim
298	.	_	_	I-Claim


0	Patient-reported	_	_	O
1	symptoms	_	_	O
2	and	_	_	O
3	health-related	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	QoL	_	_	O
9	)	_	_	O
10	benefits	_	_	O
11	were	_	_	O
12	investigated	_	_	O
13	in	_	_	O
14	a	_	_	O
15	randomized	_	_	O
16	,	_	_	O
17	phase	_	_	O
18	III	_	_	O
19	trial	_	_	O
20	of	_	_	O
21	afatinib	_	_	O
22	or	_	_	O
23	cisplatin/pemetrexed	_	_	O
24	.	_	_	O

25	Three	_	_	O
26	hundred	_	_	O
27	forty-five	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	advanced	_	_	O
31	epidermal	_	_	O
32	growth	_	_	O
33	factor	_	_	O
34	receptor	_	_	O
35	(	_	_	O
36	EGFR	_	_	O
37	)	_	_	O
38	mutation-positive	_	_	O
39	lung	_	_	O
40	adenocarcinoma	_	_	O
41	were	_	_	O
42	randomly	_	_	O
43	assigned	_	_	O
44	2:1	_	_	O
45	to	_	_	O
46	afatinib	_	_	O
47	40	_	_	O
48	mg	_	_	O
49	per	_	_	O
50	day	_	_	O
51	or	_	_	O
52	up	_	_	O
53	to	_	_	O
54	six	_	_	O
55	cycles	_	_	O
56	of	_	_	O
57	cisplatin/pemetrexed	_	_	O
58	.	_	_	O

59	Lung	_	_	O
60	cancer	_	_	O
61	symptoms	_	_	O
62	and	_	_	O
63	health-related	_	_	O
64	QoL	_	_	O
65	were	_	_	O
66	assessed	_	_	O
67	every	_	_	O
68	21	_	_	O
69	days	_	_	O
70	until	_	_	O
71	progression	_	_	O
72	using	_	_	O
73	the	_	_	O
74	European	_	_	O
75	Organisation	_	_	O
76	for	_	_	O
77	Research	_	_	O
78	and	_	_	O
79	Treatment	_	_	O
80	of	_	_	O
81	Cancer	_	_	O
82	Quality	_	_	O
83	of	_	_	O
84	Life	_	_	O
85	Questionnaire	_	_	O
86	C30	_	_	O
87	and	_	_	O
88	Lung	_	_	O
89	Cancer-13	_	_	O
90	questionnaires	_	_	O
91	.	_	_	O

92	Analyses	_	_	O
93	of	_	_	O
94	cough	_	_	O
95	,	_	_	O
96	dyspnea	_	_	O
97	,	_	_	O
98	and	_	_	O
99	pain	_	_	O
100	were	_	_	O
101	preplanned	_	_	O
102	,	_	_	O
103	including	_	_	O
104	percentage	_	_	O
105	of	_	_	O
106	patients	_	_	O
107	who	_	_	O
108	improved	_	_	O
109	on	_	_	O
110	therapy	_	_	O
111	,	_	_	O
112	time	_	_	O
113	to	_	_	O
114	deterioration	_	_	O
115	of	_	_	O
116	symptoms	_	_	O
117	,	_	_	O
118	and	_	_	O
119	change	_	_	O
120	in	_	_	O
121	symptoms	_	_	O
122	over	_	_	O
123	time	_	_	O
124	.	_	_	O

125	Questionnaire	_	_	O
126	compliance	_	_	O
127	was	_	_	O
128	high	_	_	O
129	.	_	_	O

130	Compared	_	_	B-Premise
131	with	_	_	I-Premise
132	chemotherapy	_	_	I-Premise
133	,	_	_	I-Premise
134	afatinib	_	_	I-Premise
135	significantly	_	_	I-Premise
136	delayed	_	_	I-Premise
137	the	_	_	I-Premise
138	time	_	_	I-Premise
139	to	_	_	I-Premise
140	deterioration	_	_	I-Premise
141	for	_	_	I-Premise
142	cough	_	_	I-Premise
143	(	_	_	I-Premise
144	hazard	_	_	I-Premise
145	ratio	_	_	I-Premise
146	[	_	_	I-Premise
147	HR	_	_	I-Premise
148	]	_	_	I-Premise
149	,	_	_	I-Premise
150	0.60	_	_	I-Premise
151	;	_	_	I-Premise
152	95	_	_	I-Premise
153	%	_	_	I-Premise
154	CI	_	_	I-Premise
155	,	_	_	I-Premise
156	0.41	_	_	I-Premise
157	to	_	_	I-Premise
158	0.87	_	_	I-Premise
159	;	_	_	I-Premise
160	P	_	_	I-Premise
161	=	_	_	I-Premise
162	.007	_	_	I-Premise
163	)	_	_	I-Premise
164	and	_	_	I-Premise
165	dyspnea	_	_	I-Premise
166	(	_	_	I-Premise
167	HR	_	_	I-Premise
168	,	_	_	I-Premise
169	0.68	_	_	I-Premise
170	;	_	_	I-Premise
171	95	_	_	I-Premise
172	%	_	_	I-Premise
173	CI	_	_	I-Premise
174	,	_	_	I-Premise
175	0.50	_	_	I-Premise
176	to	_	_	I-Premise
177	0.93	_	_	I-Premise
178	;	_	_	I-Premise
179	P	_	_	I-Premise
180	=	_	_	I-Premise
181	.015	_	_	I-Premise
182	)	_	_	I-Premise
183	,	_	_	I-Premise
184	but	_	_	I-Premise
185	not	_	_	I-Premise
186	pain	_	_	I-Premise
187	(	_	_	I-Premise
188	HR	_	_	I-Premise
189	,	_	_	I-Premise
190	0.83	_	_	I-Premise
191	;	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	,	_	_	I-Premise
196	0.62	_	_	I-Premise
197	to	_	_	I-Premise
198	1.10	_	_	I-Premise
199	;	_	_	I-Premise
200	P	_	_	I-Premise
201	=	_	_	I-Premise
202	.19	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	More	_	_	B-Premise
206	patients	_	_	I-Premise
207	on	_	_	I-Premise
208	afatinib	_	_	I-Premise
209	(	_	_	I-Premise
210	64	_	_	I-Premise
211	%	_	_	I-Premise
212	)	_	_	I-Premise
213	versus	_	_	I-Premise
214	chemotherapy	_	_	I-Premise
215	(	_	_	I-Premise
216	50	_	_	I-Premise
217	%	_	_	I-Premise
218	)	_	_	I-Premise
219	experienced	_	_	I-Premise
220	improvements	_	_	I-Premise
221	in	_	_	I-Premise
222	dyspnea	_	_	I-Premise
223	scores	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	=	_	_	I-Premise
227	.010	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Differences	_	_	B-Premise
231	in	_	_	I-Premise
232	mean	_	_	I-Premise
233	scores	_	_	I-Premise
234	over	_	_	I-Premise
235	time	_	_	I-Premise
236	significantly	_	_	I-Premise
237	favored	_	_	I-Premise
238	afatinib	_	_	I-Premise
239	over	_	_	I-Premise
240	chemotherapy	_	_	I-Premise
241	for	_	_	I-Premise
242	cough	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	.001	_	_	I-Premise
247	)	_	_	I-Premise
248	and	_	_	I-Premise
249	dyspnea	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	.001	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Afatinib	_	_	B-Premise
257	showed	_	_	I-Premise
258	significantly	_	_	I-Premise
259	better	_	_	I-Premise
260	mean	_	_	I-Premise
261	scores	_	_	I-Premise
262	over	_	_	I-Premise
263	time	_	_	I-Premise
264	in	_	_	I-Premise
265	global	_	_	I-Premise
266	health	_	_	I-Premise
267	status/QoL	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.015	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	physical	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	<	_	_	I-Premise
278	.001	_	_	I-Premise
279	)	_	_	I-Premise
280	,	_	_	I-Premise
281	role	_	_	I-Premise
282	(	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	.004	_	_	I-Premise
286	)	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	cognitive	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	.007	_	_	I-Premise
294	)	_	_	I-Premise
295	functioning	_	_	I-Premise
296	compared	_	_	I-Premise
297	with	_	_	I-Premise
298	chemotherapy	_	_	I-Premise
299	.	_	_	I-Premise

300	Fatigue	_	_	B-Premise
301	and	_	_	I-Premise
302	nausea	_	_	I-Premise
303	were	_	_	I-Premise
304	worse	_	_	I-Premise
305	with	_	_	I-Premise
306	chemotherapy	_	_	I-Premise
307	,	_	_	I-Premise
308	whereas	_	_	I-Premise
309	diarrhea	_	_	I-Premise
310	,	_	_	I-Premise
311	dysphagia	_	_	I-Premise
312	,	_	_	I-Premise
313	and	_	_	I-Premise
314	sore	_	_	I-Premise
315	mouth	_	_	I-Premise
316	were	_	_	I-Premise
317	worse	_	_	I-Premise
318	with	_	_	I-Premise
319	afatinib	_	_	I-Premise
320	(	_	_	I-Premise
321	all	_	_	I-Premise
322	P	_	_	I-Premise
323	<	_	_	I-Premise
324	.01	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	In	_	_	B-Claim
328	patients	_	_	I-Claim
329	with	_	_	I-Claim
330	lung	_	_	I-Claim
331	adenocarcinoma	_	_	I-Claim
332	with	_	_	I-Claim
333	EGFR	_	_	I-Claim
334	mutations	_	_	I-Claim
335	,	_	_	I-Claim
336	first-line	_	_	I-Claim
337	afatinib	_	_	I-Claim
338	was	_	_	I-Claim
339	associated	_	_	I-Claim
340	with	_	_	I-Claim
341	better	_	_	I-Claim
342	control	_	_	I-Claim
343	of	_	_	I-Claim
344	cough	_	_	I-Claim
345	and	_	_	I-Claim
346	dyspnea	_	_	I-Claim
347	compared	_	_	I-Claim
348	with	_	_	I-Claim
349	chemotherapy	_	_	I-Claim
350	,	_	_	I-Claim
351	although	_	_	I-Claim
352	diarrhea	_	_	I-Claim
353	,	_	_	I-Claim
354	dysphagia	_	_	I-Claim
355	,	_	_	I-Claim
356	and	_	_	I-Claim
357	sore	_	_	I-Claim
358	mouth	_	_	I-Claim
359	were	_	_	I-Claim
360	worse	_	_	I-Claim
361	.	_	_	I-Claim

362	Global	_	_	B-Claim
363	health	_	_	I-Claim
364	status/QoL	_	_	I-Claim
365	was	_	_	I-Claim
366	also	_	_	I-Claim
367	improved	_	_	I-Claim
368	over	_	_	I-Claim
369	time	_	_	I-Claim
370	with	_	_	I-Claim
371	afatinib	_	_	I-Claim
372	compared	_	_	I-Claim
373	with	_	_	I-Claim
374	chemotherapy	_	_	I-Claim
375	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	health-related	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	narrow	_	_	O
11	gastric	_	_	O
12	tube	_	_	O
13	and	_	_	O
14	whole	_	_	O
15	stomach	_	_	O
16	reconstructions	_	_	O
17	after	_	_	O
18	oncologic	_	_	O
19	esophagectomy	_	_	O
20	.	_	_	O

21	In	_	_	O
22	a	_	_	O
23	prospective	_	_	O
24	randomized	_	_	O
25	single-center	_	_	O
26	study	_	_	O
27	from	_	_	O
28	2007	_	_	O
29	to	_	_	O
30	2008	_	_	O
31	,	_	_	O
32	104	_	_	O
33	patients	_	_	O
34	underwent	_	_	O
35	esophagectomy	_	_	O
36	for	_	_	O
37	cancer	_	_	O
38	.	_	_	O

39	To	_	_	O
40	assess	_	_	O
41	health-related	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	,	_	_	O
46	the	_	_	O
47	questionnaire	_	_	O
48	(	_	_	O
49	European	_	_	O
50	Organization	_	_	O
51	for	_	_	O
52	Research	_	_	O
53	and	_	_	O
54	Treatment	_	_	O
55	of	_	_	O
56	Cancer	_	_	O
57	Quality	_	_	O
58	of	_	_	O
59	Life	_	_	O
60	Questionnaire	_	_	O
61	Core	_	_	O
62	30	_	_	O
63	and	_	_	O
64	the	_	_	O
65	Oesophagus-Specific	_	_	O
66	Quality	_	_	O
67	of	_	_	O
68	Life	_	_	O
69	Questionnaire	_	_	O
70	18	_	_	O
71	)	_	_	O
72	was	_	_	O
73	administered	_	_	O
74	at	_	_	O
75	3	_	_	O
76	weeks	_	_	O
77	,	_	_	O
78	6	_	_	O
79	months	_	_	O
80	,	_	_	O
81	1	_	_	O
82	year	_	_	O
83	,	_	_	O
84	and	_	_	O
85	2	_	_	O
86	years	_	_	O
87	after	_	_	O
88	surgery	_	_	O
89	.	_	_	O

90	The	_	_	B-Premise
91	perioperative	_	_	I-Premise
92	complication	_	_	I-Premise
93	rate	_	_	I-Premise
94	was	_	_	I-Premise
95	26.9	_	_	I-Premise
96	%	_	_	I-Premise
97	in	_	_	I-Premise
98	narrow	_	_	I-Premise
99	gastric	_	_	I-Premise
100	tube	_	_	I-Premise
101	group	_	_	I-Premise
102	and	_	_	I-Premise
103	48.1	_	_	I-Premise
104	%	_	_	I-Premise
105	in	_	_	I-Premise
106	whole	_	_	I-Premise
107	stomach	_	_	I-Premise
108	group	_	_	I-Premise
109	(	_	_	I-Premise
110	P	_	_	I-Premise
111	=	_	_	I-Premise
112	0.31	_	_	I-Premise
113	)	_	_	I-Premise
114	.	_	_	I-Premise

115	At	_	_	B-Premise
116	the	_	_	I-Premise
117	time	_	_	I-Premise
118	of	_	_	I-Premise
119	3	_	_	I-Premise
120	weeks	_	_	I-Premise
121	after	_	_	I-Premise
122	surgery	_	_	I-Premise
123	,	_	_	I-Premise
124	the	_	_	I-Premise
125	reflux	_	_	I-Premise
126	and	_	_	I-Premise
127	dyspnea	_	_	I-Premise
128	scores	_	_	I-Premise
129	were	_	_	I-Premise
130	higher	_	_	I-Premise
131	in	_	_	I-Premise
132	whole	_	_	I-Premise
133	stomach	_	_	I-Premise
134	group	_	_	I-Premise
135	than	_	_	I-Premise
136	in	_	_	I-Premise
137	narrow	_	_	I-Premise
138	gastric	_	_	I-Premise
139	tube	_	_	I-Premise
140	group	_	_	I-Premise
141	,	_	_	I-Premise
142	which	_	_	I-Premise
143	meant	_	_	I-Premise
144	that	_	_	I-Premise
145	the	_	_	I-Premise
146	patients	_	_	I-Premise
147	in	_	_	I-Premise
148	whole	_	_	I-Premise
149	stomach	_	_	I-Premise
150	group	_	_	I-Premise
151	suffered	_	_	I-Premise
152	more	_	_	I-Premise
153	severe	_	_	I-Premise
154	problem	_	_	I-Premise
155	.	_	_	I-Premise

156	At	_	_	B-Premise
157	the	_	_	I-Premise
158	time	_	_	I-Premise
159	of	_	_	I-Premise
160	6	_	_	I-Premise
161	months	_	_	I-Premise
162	and	_	_	I-Premise
163	1	_	_	I-Premise
164	year	_	_	I-Premise
165	after	_	_	I-Premise
166	surgery	_	_	I-Premise
167	,	_	_	I-Premise
168	the	_	_	I-Premise
169	reflux	_	_	I-Premise
170	scores	_	_	I-Premise
171	were	_	_	I-Premise
172	lower	_	_	I-Premise
173	in	_	_	I-Premise
174	narrow	_	_	I-Premise
175	gastric	_	_	I-Premise
176	tube	_	_	I-Premise
177	group	_	_	I-Premise
178	than	_	_	I-Premise
179	in	_	_	I-Premise
180	whole	_	_	I-Premise
181	stomach	_	_	I-Premise
182	group	_	_	I-Premise
183	,	_	_	I-Premise
184	which	_	_	I-Premise
185	revealed	_	_	I-Premise
186	that	_	_	I-Premise
187	there	_	_	I-Premise
188	were	_	_	I-Premise
189	less	_	_	I-Premise
190	problems	_	_	I-Premise
191	of	_	_	I-Premise
192	reflux	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	patients	_	_	I-Premise
196	of	_	_	I-Premise
197	narrow	_	_	I-Premise
198	gastric	_	_	I-Premise
199	tube	_	_	I-Premise
200	group	_	_	I-Premise
201	;	_	_	I-Premise
202	meanwhile	_	_	O
203	,	_	_	O
204	the	_	_	B-Premise
205	score	_	_	I-Premise
206	of	_	_	I-Premise
207	physical	_	_	I-Premise
208	function	_	_	I-Premise
209	scale	_	_	I-Premise
210	in	_	_	I-Premise
211	narrow	_	_	I-Premise
212	gastric	_	_	I-Premise
213	tube	_	_	I-Premise
214	group	_	_	I-Premise
215	was	_	_	I-Premise
216	higher	_	_	I-Premise
217	conversely	_	_	I-Premise
218	,	_	_	I-Premise
219	which	_	_	I-Premise
220	suggested	_	_	I-Premise
221	that	_	_	I-Premise
222	the	_	_	I-Premise
223	patients	_	_	I-Premise
224	gain	_	_	I-Premise
225	a	_	_	I-Premise
226	better	_	_	I-Premise
227	status	_	_	I-Premise
228	in	_	_	I-Premise
229	physical	_	_	I-Premise
230	function	_	_	I-Premise
231	.	_	_	I-Premise

232	Nausea	_	_	B-Premise
233	and	_	_	I-Premise
234	vomiting	_	_	I-Premise
235	is	_	_	I-Premise
236	the	_	_	I-Premise
237	only	_	_	I-Premise
238	notable	_	_	I-Premise
239	symptom	_	_	I-Premise
240	that	_	_	I-Premise
241	was	_	_	I-Premise
242	worse	_	_	I-Premise
243	in	_	_	I-Premise
244	whole	_	_	I-Premise
245	stomach	_	_	I-Premise
246	group	_	_	I-Premise
247	at	_	_	I-Premise
248	the	_	_	I-Premise
249	time	_	_	I-Premise
250	of	_	_	I-Premise
251	2	_	_	I-Premise
252	years	_	_	I-Premise
253	after	_	_	I-Premise
254	surgery	_	_	I-Premise
255	,	_	_	I-Premise
256	which	_	_	O
257	suggested	_	_	O
258	that	_	_	O
259	patients	_	_	B-Claim
260	in	_	_	I-Claim
261	whole	_	_	I-Claim
262	stomach	_	_	I-Claim
263	group	_	_	I-Claim
264	suffered	_	_	I-Claim
265	more	_	_	I-Claim
266	severe	_	_	I-Claim
267	nausea	_	_	I-Claim
268	and	_	_	I-Claim
269	vomiting	_	_	I-Claim
270	.	_	_	I-Claim

271	Narrow	_	_	B-Claim
272	gastric	_	_	I-Claim
273	tube	_	_	I-Claim
274	reconstruction	_	_	I-Claim
275	may	_	_	I-Claim
276	be	_	_	I-Claim
277	a	_	_	I-Claim
278	good	_	_	I-Claim
279	alternative	_	_	I-Claim
280	choice	_	_	I-Claim
281	for	_	_	I-Claim
282	patients	_	_	I-Claim
283	undergoing	_	_	I-Claim
284	oncologic	_	_	I-Claim
285	esophagectomy	_	_	I-Claim
286	in	_	_	I-Claim
287	view	_	_	I-Claim
288	of	_	_	I-Claim
289	better	_	_	I-Claim
290	health-related	_	_	I-Claim
291	quality	_	_	I-Claim
292	of	_	_	I-Claim
293	life	_	_	I-Claim
294	after	_	_	I-Claim
295	the	_	_	I-Claim
296	surgery	_	_	I-Claim
297	.	_	_	I-Claim


0	Delirium	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	serious	_	_	I-Claim
4	and	_	_	I-Claim
5	common	_	_	I-Claim
6	postoperative	_	_	I-Claim
7	complication	_	_	I-Claim
8	,	_	_	O
9	especially	_	_	O
10	in	_	_	O
11	frail	_	_	O
12	elderly	_	_	O
13	patients	_	_	O
14	.	_	_	O

15	The	_	_	O
16	aim	_	_	O
17	of	_	_	O
18	this	_	_	O
19	study	_	_	O
20	was	_	_	O
21	to	_	_	O
22	evaluate	_	_	O
23	the	_	_	O
24	effect	_	_	O
25	of	_	_	O
26	a	_	_	O
27	geriatric	_	_	O
28	liaison	_	_	O
29	intervention	_	_	O
30	in	_	_	O
31	comparison	_	_	O
32	with	_	_	O
33	standard	_	_	O
34	care	_	_	O
35	on	_	_	O
36	the	_	_	O
37	incidence	_	_	O
38	of	_	_	O
39	postoperative	_	_	O
40	delirium	_	_	O
41	in	_	_	O
42	frail	_	_	O
43	elderly	_	_	O
44	cancer	_	_	O
45	patients	_	_	O
46	treated	_	_	O
47	with	_	_	O
48	an	_	_	O
49	elective	_	_	O
50	surgical	_	_	O
51	procedure	_	_	O
52	for	_	_	O
53	a	_	_	O
54	solid	_	_	O
55	tumour	_	_	O
56	.	_	_	O

57	Patients	_	_	O
58	over	_	_	O
59	65	_	_	O
60	years	_	_	O
61	of	_	_	O
62	age	_	_	O
63	who	_	_	O
64	were	_	_	O
65	undergoing	_	_	O
66	elective	_	_	O
67	surgery	_	_	O
68	for	_	_	O
69	a	_	_	O
70	solid	_	_	O
71	tumour	_	_	O
72	were	_	_	O
73	recruited	_	_	O
74	to	_	_	O
75	a	_	_	O
76	multicentre	_	_	O
77	,	_	_	O
78	prospective	_	_	O
79	,	_	_	O
80	randomized	_	_	O
81	,	_	_	O
82	controlled	_	_	O
83	trial	_	_	O
84	.	_	_	O

85	The	_	_	O
86	patients	_	_	O
87	were	_	_	O
88	randomized	_	_	O
89	to	_	_	O
90	standard	_	_	O
91	treatment	_	_	O
92	versus	_	_	O
93	a	_	_	O
94	geriatric	_	_	O
95	liaison	_	_	O
96	intervention	_	_	O
97	.	_	_	O

98	The	_	_	O
99	intervention	_	_	O
100	consisted	_	_	O
101	of	_	_	O
102	a	_	_	O
103	preoperative	_	_	O
104	geriatric	_	_	O
105	consultation	_	_	O
106	,	_	_	O
107	an	_	_	O
108	individual	_	_	O
109	treatment	_	_	O
110	plan	_	_	O
111	targeted	_	_	O
112	at	_	_	O
113	risk	_	_	O
114	factors	_	_	O
115	for	_	_	O
116	delirium	_	_	O
117	,	_	_	O
118	daily	_	_	O
119	visits	_	_	O
120	by	_	_	O
121	a	_	_	O
122	geriatric	_	_	O
123	nurse	_	_	O
124	during	_	_	O
125	the	_	_	O
126	hospital	_	_	O
127	stay	_	_	O
128	and	_	_	O
129	advice	_	_	O
130	on	_	_	O
131	managing	_	_	O
132	any	_	_	O
133	problems	_	_	O
134	encountered	_	_	O
135	.	_	_	O

136	The	_	_	O
137	primary	_	_	O
138	outcome	_	_	O
139	was	_	_	O
140	the	_	_	O
141	incidence	_	_	O
142	of	_	_	O
143	postoperative	_	_	O
144	delirium	_	_	O
145	.	_	_	O

146	The	_	_	O
147	secondary	_	_	O
148	outcome	_	_	O
149	measures	_	_	O
150	were	_	_	O
151	the	_	_	O
152	severity	_	_	O
153	of	_	_	O
154	delirium	_	_	O
155	,	_	_	O
156	length	_	_	O
157	of	_	_	O
158	hospital	_	_	O
159	stay	_	_	O
160	,	_	_	O
161	complications	_	_	O
162	,	_	_	O
163	mortality	_	_	O
164	,	_	_	O
165	care	_	_	O
166	dependency	_	_	O
167	,	_	_	O
168	quality	_	_	O
169	of	_	_	O
170	life	_	_	O
171	,	_	_	O
172	return	_	_	O
173	to	_	_	O
174	an	_	_	O
175	independent	_	_	O
176	preoperative	_	_	O
177	living	_	_	O
178	situation	_	_	O
179	and	_	_	O
180	additional	_	_	O
181	care	_	_	O
182	at	_	_	O
183	home	_	_	O
184	.	_	_	O

185	In	_	_	O
186	total	_	_	O
187	,	_	_	O
188	the	_	_	O
189	data	_	_	O
190	of	_	_	O
191	260	_	_	O
192	patients	_	_	O
193	were	_	_	O
194	analysed	_	_	O
195	.	_	_	O

196	Delirium	_	_	B-Premise
197	occurred	_	_	I-Premise
198	in	_	_	I-Premise
199	31	_	_	I-Premise
200	patients	_	_	I-Premise
201	(	_	_	I-Premise
202	11.9	_	_	I-Premise
203	%	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	and	_	_	I-Premise
207	there	_	_	I-Premise
208	was	_	_	I-Premise
209	no	_	_	I-Premise
210	significant	_	_	I-Premise
211	difference	_	_	I-Premise
212	between	_	_	I-Premise
213	the	_	_	I-Premise
214	incidence	_	_	I-Premise
215	of	_	_	I-Premise
216	delirium	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	intervention	_	_	I-Premise
220	group	_	_	I-Premise
221	and	_	_	I-Premise
222	the	_	_	I-Premise
223	usual-care	_	_	I-Premise
224	group	_	_	I-Premise
225	(	_	_	I-Premise
226	9.4	_	_	I-Premise
227	%	_	_	I-Premise
228	vs.	_	_	I-Premise
229	14.3	_	_	I-Premise
230	%	_	_	I-Premise
231	,	_	_	I-Premise
232	OR	_	_	I-Premise
233	:	_	_	I-Premise
234	0.63	_	_	I-Premise
235	,	_	_	I-Premise
236	95	_	_	I-Premise
237	%	_	_	I-Premise
238	CI	_	_	I-Premise
239	:	_	_	I-Premise
240	0.29-1.35	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	Within	_	_	B-Claim
244	this	_	_	I-Claim
245	study	_	_	I-Claim
246	,	_	_	I-Claim
247	a	_	_	I-Claim
248	geriatric	_	_	I-Claim
249	liaison	_	_	I-Claim
250	intervention	_	_	I-Claim
251	based	_	_	I-Claim
252	on	_	_	I-Claim
253	frailty	_	_	I-Claim
254	for	_	_	I-Claim
255	the	_	_	I-Claim
256	prevention	_	_	I-Claim
257	of	_	_	I-Claim
258	postoperative	_	_	I-Claim
259	delirium	_	_	I-Claim
260	in	_	_	I-Claim
261	frail	_	_	I-Claim
262	elderly	_	_	I-Claim
263	cancer	_	_	I-Claim
264	patients	_	_	I-Claim
265	undergoing	_	_	I-Claim
266	elective	_	_	I-Claim
267	surgery	_	_	I-Claim
268	for	_	_	I-Claim
269	a	_	_	I-Claim
270	solid	_	_	I-Claim
271	tumour	_	_	I-Claim
272	has	_	_	I-Claim
273	not	_	_	I-Claim
274	proven	_	_	I-Claim
275	to	_	_	I-Claim
276	be	_	_	I-Claim
277	effective	_	_	I-Claim
278	.	_	_	I-Claim


0	The	_	_	O
1	AGO-ETC	_	_	O
2	trial	_	_	O
3	compared	_	_	O
4	5-year	_	_	O
5	relapse-free	_	_	O
6	survival	_	_	O
7	of	_	_	O
8	intense	_	_	O
9	dose-dense	_	_	O
10	(	_	_	O
11	IDD	_	_	O
12	)	_	_	O
13	sequential	_	_	O
14	chemotherapy	_	_	O
15	with	_	_	O
16	epirubicin	_	_	O
17	(	_	_	O
18	E	_	_	O
19	)	_	_	O
20	,	_	_	O
21	paclitaxel	_	_	O
22	(	_	_	O
23	T	_	_	O
24	)	_	_	O
25	,	_	_	O
26	and	_	_	O
27	cyclophosphamide	_	_	O
28	(	_	_	O
29	C	_	_	O
30	)	_	_	O
31	(	_	_	O
32	IDD-ETC	_	_	O
33	)	_	_	O
34	every	_	_	O
35	2	_	_	O
36	weeks	_	_	O
37	vs	_	_	O
38	conventional	_	_	O
39	scheduled	_	_	O
40	epirubicin/cyclophosphamide	_	_	O
41	followed	_	_	O
42	by	_	_	O
43	paclitaxel	_	_	O
44	(	_	_	O
45	EC→T	_	_	O
46	)	_	_	O
47	(	_	_	O
48	every	_	_	O
49	3	_	_	O
50	weeks	_	_	O
51	)	_	_	O
52	as	_	_	O
53	adjuvant	_	_	O
54	treatment	_	_	O
55	in	_	_	O
56	high-risk	_	_	O
57	breast	_	_	O
58	cancer	_	_	O
59	patients	_	_	O
60	.	_	_	O

61	The	_	_	O
62	objective	_	_	O
63	of	_	_	O
64	this	_	_	O
65	study	_	_	O
66	was	_	_	O
67	to	_	_	O
68	evaluate	_	_	O
69	the	_	_	O
70	safety	_	_	O
71	and	_	_	O
72	efficacy	_	_	O
73	of	_	_	O
74	epoetin	_	_	O
75	alfa	_	_	O
76	in	_	_	O
77	a	_	_	O
78	second	_	_	O
79	randomization	_	_	O
80	of	_	_	O
81	the	_	_	O
82	intense	_	_	O
83	dose-dense	_	_	O
84	arm	_	_	O
85	.	_	_	O

86	One	_	_	O
87	thousand	_	_	O
88	two	_	_	O
89	hundred	_	_	O
90	eighty-four	_	_	O
91	patients	_	_	O
92	were	_	_	O
93	enrolled	_	_	O
94	;	_	_	O
95	658	_	_	O
96	patients	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	the	_	_	O
102	IDD-ETC	_	_	O
103	treatment	_	_	O
104	group	_	_	O
105	.	_	_	O

106	Within	_	_	O
107	the	_	_	O
108	IDD-ETC	_	_	O
109	group	_	_	O
110	,	_	_	O
111	324	_	_	O
112	patients	_	_	O
113	were	_	_	O
114	further	_	_	O
115	randomly	_	_	O
116	assigned	_	_	O
117	to	_	_	O
118	the	_	_	O
119	epoetin	_	_	O
120	alfa	_	_	O
121	group	_	_	O
122	,	_	_	O
123	and	_	_	O
124	319	_	_	O
125	were	_	_	O
126	randomly	_	_	O
127	assigned	_	_	O
128	to	_	_	O
129	the	_	_	O
130	non-erythropoiesis-stimulating	_	_	O
131	agent	_	_	O
132	(	_	_	O
133	ESA	_	_	O
134	)	_	_	O
135	control	_	_	O
136	group	_	_	O
137	.	_	_	O

138	Primary	_	_	O
139	efficacy	_	_	O
140	endpoints	_	_	O
141	included	_	_	O
142	change	_	_	O
143	in	_	_	O
144	hemoglobin	_	_	O
145	level	_	_	O
146	from	_	_	O
147	baseline	_	_	O
148	to	_	_	O
149	Cycle	_	_	O
150	9	_	_	O
151	and	_	_	O
152	the	_	_	O
153	percentage	_	_	O
154	of	_	_	O
155	subjects	_	_	O
156	requiring	_	_	O
157	red	_	_	O
158	blood	_	_	O
159	cell	_	_	O
160	transfusion	_	_	O
161	.	_	_	O

162	Relapse-free	_	_	O
163	survival	_	_	O
164	,	_	_	O
165	overall	_	_	O
166	survival	_	_	O
167	,	_	_	O
168	and	_	_	O
169	intramammary	_	_	O
170	relapse	_	_	O
171	were	_	_	O
172	secondary	_	_	O
173	endpoints	_	_	O
174	estimated	_	_	O
175	with	_	_	O
176	Kaplan-Meier	_	_	O
177	and	_	_	O
178	Cox	_	_	O
179	regression	_	_	O
180	methods	_	_	O
181	.	_	_	O

182	Except	_	_	O
183	for	_	_	O
184	the	_	_	O
185	primary	_	_	O
186	hypothesis	_	_	O
187	,	_	_	O
188	all	_	_	O
189	statistical	_	_	O
190	tests	_	_	O
191	were	_	_	O
192	two-sided	_	_	O
193	.	_	_	O

194	Epoetin	_	_	B-Premise
195	alfa	_	_	I-Premise
196	avoided	_	_	I-Premise
197	the	_	_	I-Premise
198	decrease	_	_	I-Premise
199	in	_	_	I-Premise
200	hemoglobin	_	_	I-Premise
201	level	_	_	I-Premise
202	(	_	_	I-Premise
203	no	_	_	I-Premise
204	decrease	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	epoetin	_	_	I-Premise
208	alfa	_	_	I-Premise
209	group	_	_	I-Premise
210	vs	_	_	I-Premise
211	-2.20g/dL	_	_	I-Premise
212	change	_	_	I-Premise
213	for	_	_	I-Premise
214	the	_	_	I-Premise
215	control	_	_	I-Premise
216	group	_	_	I-Premise
217	;	_	_	I-Premise
218	P	_	_	I-Premise
219	<	_	_	I-Premise
220	.001	_	_	I-Premise
221	)	_	_	I-Premise
222	and	_	_	I-Premise
223	statistically	_	_	I-Premise
224	significantly	_	_	I-Premise
225	reduced	_	_	I-Premise
226	the	_	_	I-Premise
227	percentage	_	_	I-Premise
228	of	_	_	I-Premise
229	subjects	_	_	I-Premise
230	requiring	_	_	I-Premise
231	red	_	_	I-Premise
232	blood	_	_	I-Premise
233	cell	_	_	I-Premise
234	transfusion	_	_	I-Premise
235	(	_	_	I-Premise
236	12.8	_	_	I-Premise
237	%	_	_	I-Premise
238	vs	_	_	I-Premise
239	28.1	_	_	I-Premise
240	%	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	<	_	_	I-Premise
244	.0001	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	The	_	_	B-Premise
248	incidence	_	_	I-Premise
249	of	_	_	I-Premise
250	thrombotic	_	_	I-Premise
251	events	_	_	I-Premise
252	was	_	_	I-Premise
253	7	_	_	I-Premise
254	%	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	epoetin	_	_	I-Premise
258	alfa	_	_	I-Premise
259	arm	_	_	I-Premise
260	vs	_	_	I-Premise
261	3	_	_	I-Premise
262	%	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	control	_	_	I-Premise
266	arm	_	_	I-Premise
267	.	_	_	I-Premise

268	After	_	_	B-Premise
269	a	_	_	I-Premise
270	median	_	_	I-Premise
271	follow-up	_	_	I-Premise
272	of	_	_	I-Premise
273	62	_	_	I-Premise
274	months	_	_	I-Premise
275	,	_	_	I-Premise
276	epoetin	_	_	I-Premise
277	alfa	_	_	I-Premise
278	treatment	_	_	I-Premise
279	did	_	_	I-Premise
280	not	_	_	I-Premise
281	affect	_	_	I-Premise
282	overall	_	_	I-Premise
283	survival	_	_	I-Premise
284	,	_	_	I-Premise
285	relapse-free	_	_	I-Premise
286	survival	_	_	I-Premise
287	,	_	_	I-Premise
288	or	_	_	I-Premise
289	intramammary	_	_	I-Premise
290	relapse	_	_	I-Premise
291	.	_	_	I-Premise

292	Epoetin	_	_	B-Claim
293	alfa	_	_	I-Claim
294	resulted	_	_	I-Claim
295	in	_	_	I-Claim
296	improved	_	_	I-Claim
297	hemoglobin	_	_	I-Claim
298	levels	_	_	I-Claim
299	and	_	_	I-Claim
300	decreased	_	_	I-Claim
301	transfusions	_	_	I-Claim
302	without	_	_	I-Claim
303	an	_	_	I-Claim
304	impact	_	_	I-Claim
305	on	_	_	I-Claim
306	relapse-free	_	_	I-Claim
307	or	_	_	I-Claim
308	overall	_	_	I-Claim
309	survival	_	_	I-Claim
310	.	_	_	I-Claim

311	However	_	_	B-Claim
312	,	_	_	I-Claim
313	epoetin	_	_	I-Claim
314	alfa	_	_	I-Claim
315	had	_	_	I-Claim
316	an	_	_	I-Claim
317	adverse	_	_	I-Claim
318	effect	_	_	I-Claim
319	,	_	_	I-Claim
320	resulting	_	_	I-Claim
321	in	_	_	I-Claim
322	increased	_	_	I-Claim
323	thrombosis	_	_	I-Claim
324	.	_	_	I-Claim


0	It	_	_	O
1	is	_	_	O
2	well	_	_	O
3	documented	_	_	O
4	that	_	_	O
5	stress	_	_	O
6	is	_	_	O
7	associated	_	_	O
8	with	_	_	O
9	negative	_	_	O
10	health	_	_	O
11	outcomes	_	_	O
12	in	_	_	O
13	cancer	_	_	O
14	patients	_	_	O
15	.	_	_	O

16	The	_	_	O
17	purpose	_	_	O
18	of	_	_	O
19	this	_	_	O
20	study	_	_	O
21	was	_	_	O
22	to	_	_	O
23	assess	_	_	O
24	the	_	_	O
25	effects	_	_	O
26	of	_	_	O
27	a	_	_	O
28	novel	_	_	O
29	mindfulness	_	_	O
30	intervention	_	_	O
31	called	_	_	O
32	mindfulness-based	_	_	O
33	art	_	_	O
34	therapy	_	_	O
35	(	_	_	O
36	MBAT	_	_	O
37	)	_	_	O
38	versus	_	_	O
39	standard	_	_	O
40	educational	_	_	O
41	support	_	_	O
42	,	_	_	O
43	on	_	_	O
44	indices	_	_	O
45	of	_	_	O
46	stress	_	_	O
47	and	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	in	_	_	O
52	breast	_	_	O
53	cancer	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	high	_	_	O
57	stress	_	_	O
58	levels	_	_	O
59	.	_	_	O

60	A	_	_	O
61	total	_	_	O
62	of	_	_	O
63	191	_	_	O
64	women	_	_	O
65	were	_	_	O
66	enrolled	_	_	O
67	,	_	_	O
68	stratified	_	_	O
69	by	_	_	O
70	age	_	_	O
71	and	_	_	O
72	stress	_	_	O
73	level	_	_	O
74	,	_	_	O
75	and	_	_	O
76	randomized	_	_	O
77	to	_	_	O
78	receive	_	_	O
79	either	_	_	O
80	an	_	_	O
81	8-week	_	_	O
82	MBAT	_	_	O
83	intervention	_	_	O
84	or	_	_	O
85	a	_	_	O
86	breast	_	_	O
87	cancer	_	_	O
88	educational	_	_	O
89	support	_	_	O
90	program	_	_	O
91	of	_	_	O
92	equal	_	_	O
93	time	_	_	O
94	and	_	_	O
95	duration	_	_	O
96	.	_	_	O

97	Psychosocial	_	_	O
98	stress	_	_	O
99	was	_	_	O
100	measured	_	_	O
101	using	_	_	O
102	the	_	_	O
103	Symptoms	_	_	O
104	Checklist-90-Revised	_	_	O
105	,	_	_	O
106	and	_	_	O
107	quality	_	_	O
108	of	_	_	O
109	life	_	_	O
110	was	_	_	O
111	measured	_	_	O
112	using	_	_	O
113	the	_	_	O
114	Medical	_	_	O
115	Outcomes	_	_	O
116	Study	_	_	O
117	Short-Form	_	_	O
118	Health	_	_	O
119	Survey	_	_	O
120	at	_	_	O
121	baseline	_	_	O
122	,	_	_	O
123	immediately	_	_	O
124	post-intervention	_	_	O
125	,	_	_	O
126	and	_	_	O
127	at	_	_	O
128	6	_	_	O
129	months	_	_	O
130	.	_	_	O

131	Results	_	_	B-Premise
132	showed	_	_	I-Premise
133	overall	_	_	I-Premise
134	significant	_	_	I-Premise
135	improvements	_	_	I-Premise
136	in	_	_	I-Premise
137	psychosocial	_	_	I-Premise
138	stress	_	_	I-Premise
139	and	_	_	I-Premise
140	quality	_	_	I-Premise
141	of	_	_	I-Premise
142	life	_	_	I-Premise
143	in	_	_	I-Premise
144	both	_	_	I-Premise
145	the	_	_	I-Premise
146	MBAT	_	_	I-Premise
147	and	_	_	I-Premise
148	educational	_	_	I-Premise
149	support	_	_	I-Premise
150	groups	_	_	I-Premise
151	immediately	_	_	I-Premise
152	post-intervention	_	_	I-Premise
153	;	_	_	I-Premise
154	however	_	_	B-Premise
155	,	_	_	I-Premise
156	participants	_	_	I-Premise
157	with	_	_	I-Premise
158	high	_	_	I-Premise
159	stress	_	_	I-Premise
160	levels	_	_	I-Premise
161	at	_	_	I-Premise
162	baseline	_	_	I-Premise
163	had	_	_	I-Premise
164	significantly	_	_	I-Premise
165	improved	_	_	I-Premise
166	overall	_	_	I-Premise
167	outcomes	_	_	I-Premise
168	only	_	_	I-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	MBAT	_	_	I-Premise
172	group	_	_	I-Premise
173	,	_	_	I-Premise
174	both	_	_	I-Premise
175	immediately	_	_	I-Premise
176	post-intervention	_	_	I-Premise
177	and	_	_	I-Premise
178	at	_	_	I-Premise
179	6	_	_	I-Premise
180	months	_	_	I-Premise
181	.	_	_	I-Premise

182	In	_	_	O
183	addition	_	_	O
184	,	_	_	O
185	at	_	_	B-Premise
186	6	_	_	I-Premise
187	months	_	_	I-Premise
188	follow-up	_	_	I-Premise
189	,	_	_	I-Premise
190	participants	_	_	I-Premise
191	attending	_	_	I-Premise
192	five	_	_	I-Premise
193	or	_	_	I-Premise
194	more	_	_	I-Premise
195	sessions	_	_	I-Premise
196	trended	_	_	I-Premise
197	toward	_	_	I-Premise
198	retaining	_	_	I-Premise
199	treatment	_	_	I-Premise
200	effects	_	_	I-Premise
201	better	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	MBAT	_	_	I-Premise
205	than	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	control	_	_	I-Premise
209	group	_	_	I-Premise
210	.	_	_	I-Premise

211	Finally	_	_	O
212	,	_	_	O
213	black	_	_	B-Premise
214	women	_	_	I-Premise
215	and	_	_	I-Premise
216	white	_	_	I-Premise
217	women	_	_	I-Premise
218	were	_	_	I-Premise
219	similar	_	_	I-Premise
220	in	_	_	I-Premise
221	terms	_	_	I-Premise
222	of	_	_	I-Premise
223	how	_	_	I-Premise
224	they	_	_	I-Premise
225	benefited	_	_	I-Premise
226	from	_	_	I-Premise
227	the	_	_	I-Premise
228	MBAT	_	_	I-Premise
229	intervention	_	_	I-Premise
230	,	_	_	I-Premise
231	even	_	_	I-Premise
232	though	_	_	I-Premise
233	white	_	_	I-Premise
234	participants	_	_	I-Premise
235	tended	_	_	I-Premise
236	to	_	_	I-Premise
237	have	_	_	I-Premise
238	higher	_	_	I-Premise
239	educational	_	_	I-Premise
240	level	_	_	I-Premise
241	and	_	_	I-Premise
242	marital	_	_	I-Premise
243	status	_	_	I-Premise
244	.	_	_	I-Premise

245	In	_	_	B-Claim
246	conclusion	_	_	I-Claim
247	,	_	_	I-Claim
248	MBAT	_	_	I-Claim
249	is	_	_	I-Claim
250	associated	_	_	I-Claim
251	with	_	_	I-Claim
252	significant	_	_	I-Claim
253	,	_	_	I-Claim
254	sustained	_	_	I-Claim
255	benefits	_	_	I-Claim
256	across	_	_	I-Claim
257	a	_	_	I-Claim
258	diverse	_	_	I-Claim
259	range	_	_	I-Claim
260	of	_	_	I-Claim
261	breast	_	_	I-Claim
262	cancer	_	_	I-Claim
263	patients	_	_	I-Claim
264	,	_	_	I-Claim
265	particularly	_	_	I-Claim
266	those	_	_	I-Claim
267	with	_	_	I-Claim
268	high	_	_	I-Claim
269	stress	_	_	I-Claim
270	levels	_	_	I-Claim
271	.	_	_	I-Claim


0	The	_	_	O
1	current	_	_	O
2	study	_	_	O
3	examined	_	_	O
4	the	_	_	O
5	effect	_	_	O
6	of	_	_	O
7	recombinant	_	_	O
8	human	_	_	O
9	deoxyribonuclease	_	_	O
10	(	_	_	O
11	rhDNase	_	_	O
12	)	_	_	O
13	on	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	QOL	_	_	O
19	)	_	_	O
20	measures	_	_	O
21	,	_	_	O
22	clinical	_	_	O
23	improvement	_	_	O
24	,	_	_	O
25	and	_	_	O
26	DNA	_	_	O
27	content	_	_	O
28	of	_	_	O
29	thick	_	_	O
30	oropharyngeal	_	_	O
31	secretions	_	_	O
32	(	_	_	O
33	OPS	_	_	O
34	)	_	_	O
35	in	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	head-and-neck	_	_	O
39	(	_	_	O
40	H	_	_	O
41	&	_	_	O
42	N	_	_	O
43	)	_	_	O
44	cancers	_	_	O
45	.	_	_	O

46	Thirty-six	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	local-regional	_	_	O
50	advanced	_	_	O
51	H	_	_	O
52	&	_	_	O
53	amp	_	_	O
54	;	_	_	O
55	N	_	_	O
56	cancer	_	_	O
57	receiving	_	_	O
58	chemoradiationtherapy	_	_	O
59	(	_	_	O
60	CRT	_	_	O
61	)	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	receive	_	_	O
66	either	_	_	O
67	placebo	_	_	O
68	or	_	_	O
69	rhDNase	_	_	O
70	.	_	_	O

71	Endpoints	_	_	O
72	included	_	_	O
73	MD	_	_	O
74	Anderson	_	_	O
75	Symptom	_	_	O
76	Inventory-Head	_	_	O
77	and	_	_	O
78	Neck	_	_	O
79	(	_	_	O
80	MDASI-HN	_	_	O
81	)	_	_	O
82	and	_	_	O
83	Functional	_	_	O
84	Assessment	_	_	O
85	of	_	_	O
86	Cancer	_	_	O
87	Therapy-Head	_	_	O
88	and	_	_	O
89	Neck	_	_	O
90	(	_	_	O
91	FACT-NH	_	_	O
92	)	_	_	O
93	scores	_	_	O
94	,	_	_	O
95	along	_	_	O
96	with	_	_	O
97	clinical	_	_	O
98	assessment	_	_	O
99	and	_	_	O
100	DNA	_	_	O
101	concentration	_	_	O
102	of	_	_	O
103	OPS	_	_	O
104	.	_	_	O

105	There	_	_	B-Premise
106	were	_	_	I-Premise
107	no	_	_	I-Premise
108	statistically	_	_	I-Premise
109	significant	_	_	I-Premise
110	differences	_	_	I-Premise
111	in	_	_	I-Premise
112	patients	_	_	I-Premise
113	'	_	_	I-Premise
114	QOL	_	_	I-Premise
115	outcomes	_	_	I-Premise
116	over	_	_	I-Premise
117	the	_	_	I-Premise
118	study	_	_	I-Premise
119	period	_	_	I-Premise
120	.	_	_	I-Premise

121	Both	_	_	B-Premise
122	groups	_	_	I-Premise
123	showed	_	_	I-Premise
124	an	_	_	I-Premise
125	increase	_	_	I-Premise
126	in	_	_	I-Premise
127	symptom	_	_	I-Premise
128	and	_	_	I-Premise
129	interference	_	_	I-Premise
130	scores	_	_	I-Premise
131	,	_	_	I-Premise
132	although	_	_	O
133	patients	_	_	B-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	rhDNase	_	_	I-Premise
137	group	_	_	I-Premise
138	showed	_	_	I-Premise
139	a	_	_	I-Premise
140	greater	_	_	I-Premise
141	decline	_	_	I-Premise
142	in	_	_	I-Premise
143	both	_	_	I-Premise
144	scores	_	_	I-Premise
145	during	_	_	I-Premise
146	the	_	_	I-Premise
147	3	_	_	I-Premise
148	months	_	_	I-Premise
149	posttreatment	_	_	I-Premise
150	.	_	_	I-Premise

151	Similarly	_	_	B-Premise
152	,	_	_	I-Premise
153	both	_	_	I-Premise
154	groups	_	_	I-Premise
155	showed	_	_	I-Premise
156	a	_	_	I-Premise
157	decline	_	_	I-Premise
158	in	_	_	I-Premise
159	physical	_	_	I-Premise
160	and	_	_	I-Premise
161	functional	_	_	I-Premise
162	well	_	_	I-Premise
163	being	_	_	I-Premise
164	but	_	_	I-Premise
165	recovered	_	_	I-Premise
166	in	_	_	I-Premise
167	the	_	_	I-Premise
168	3	_	_	I-Premise
169	months	_	_	I-Premise
170	posttreatment	_	_	I-Premise
171	follow-up	_	_	I-Premise
172	,	_	_	I-Premise
173	with	_	_	I-Premise
174	the	_	_	I-Premise
175	rhDNase	_	_	I-Premise
176	group	_	_	I-Premise
177	exhibiting	_	_	I-Premise
178	speedier	_	_	I-Premise
179	recovery	_	_	I-Premise
180	.	_	_	I-Premise

181	Patients	_	_	B-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	rhDNase	_	_	I-Premise
185	group	_	_	I-Premise
186	exhibited	_	_	I-Premise
187	significant	_	_	I-Premise
188	clinical	_	_	I-Premise
189	improvement	_	_	I-Premise
190	in	_	_	I-Premise
191	OPS	_	_	I-Premise
192	,	_	_	I-Premise
193	blindly	_	_	I-Premise
194	assessed	_	_	I-Premise
195	by	_	_	I-Premise
196	a	_	_	I-Premise
197	physician	_	_	I-Premise
198	,	_	_	I-Premise
199	compared	_	_	I-Premise
200	with	_	_	I-Premise
201	the	_	_	I-Premise
202	placebo	_	_	I-Premise
203	group	_	_	I-Premise
204	(	_	_	I-Premise
205	67	_	_	I-Premise
206	%	_	_	I-Premise
207	vs	_	_	I-Premise
208	27	_	_	I-Premise
209	%	_	_	I-Premise
210	,	_	_	I-Premise
211	respectively	_	_	I-Premise
212	;	_	_	I-Premise
213	P=.046	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	The	_	_	B-Premise
217	rhDNase	_	_	I-Premise
218	group	_	_	I-Premise
219	showed	_	_	I-Premise
220	no	_	_	I-Premise
221	change	_	_	I-Premise
222	in	_	_	I-Premise
223	OPS-DNA	_	_	I-Premise
224	concentration	_	_	I-Premise
225	,	_	_	I-Premise
226	although	_	_	O
227	the	_	_	B-Premise
228	placebo	_	_	I-Premise
229	group	_	_	I-Premise
230	showed	_	_	I-Premise
231	a	_	_	I-Premise
232	significant	_	_	I-Premise
233	increase	_	_	I-Premise
234	in	_	_	I-Premise
235	DNA	_	_	I-Premise
236	concentration	_	_	I-Premise
237	during	_	_	I-Premise
238	the	_	_	I-Premise
239	drug	_	_	I-Premise
240	trial	_	_	I-Premise
241	(	_	_	I-Premise
242	P=.045	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	There	_	_	B-Claim
246	was	_	_	I-Claim
247	no	_	_	I-Claim
248	differences	_	_	I-Claim
249	in	_	_	I-Claim
250	acute	_	_	I-Claim
251	toxicities	_	_	I-Claim
252	between	_	_	I-Claim
253	the	_	_	I-Claim
254	2	_	_	I-Claim
255	groups	_	_	I-Claim
256	.	_	_	I-Claim

257	Our	_	_	B-Claim
258	preliminary	_	_	I-Claim
259	data	_	_	I-Claim
260	suggest	_	_	I-Claim
261	that	_	_	I-Claim
262	rhDNase	_	_	I-Claim
263	did	_	_	I-Claim
264	not	_	_	I-Claim
265	significantly	_	_	I-Claim
266	improve	_	_	I-Claim
267	study	_	_	I-Claim
268	primary	_	_	I-Claim
269	endpoints	_	_	I-Claim
270	of	_	_	I-Claim
271	QOL	_	_	I-Claim
272	measures	_	_	I-Claim
273	compared	_	_	I-Claim
274	with	_	_	I-Claim
275	the	_	_	I-Claim
276	placebo	_	_	I-Claim
277	group	_	_	I-Claim
278	.	_	_	I-Claim

279	However	_	_	O
280	,	_	_	O
281	there	_	_	B-Claim
282	was	_	_	I-Claim
283	a	_	_	I-Claim
284	significant	_	_	I-Claim
285	improvement	_	_	I-Claim
286	in	_	_	I-Claim
287	secondary	_	_	I-Claim
288	endpoints	_	_	I-Claim
289	of	_	_	I-Claim
290	clinically	_	_	I-Claim
291	assessed	_	_	I-Claim
292	OPS	_	_	I-Claim
293	and	_	_	I-Claim
294	DNA	_	_	I-Claim
295	concentration	_	_	I-Claim
296	compared	_	_	I-Claim
297	with	_	_	I-Claim
298	placebo	_	_	I-Claim
299	in	_	_	I-Claim
300	H	_	_	I-Claim
301	&	_	_	I-Claim
302	N	_	_	I-Claim
303	cancer	_	_	I-Claim
304	patients	_	_	I-Claim
305	treated	_	_	I-Claim
306	with	_	_	I-Claim
307	CRT	_	_	I-Claim
308	.	_	_	I-Claim

309	Further	_	_	O
310	investigation	_	_	O
311	in	_	_	O
312	larger	_	_	O
313	numbers	_	_	O
314	of	_	_	O
315	patients	_	_	O
316	is	_	_	O
317	warranted	_	_	O
318	.	_	_	O


0	Due	_	_	O
1	to	_	_	O
2	concerns	_	_	O
3	of	_	_	O
4	fragility	_	_	O
5	fracture	_	_	O
6	,	_	_	O
7	exercise	_	_	O
8	is	_	_	O
9	a	_	_	O
10	perceived	_	_	O
11	contraindication	_	_	O
12	for	_	_	O
13	prostate	_	_	O
14	cancer	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	bone	_	_	O
18	metastases	_	_	O
19	.	_	_	O

20	These	_	_	O
21	patients	_	_	O
22	experience	_	_	O
23	significant	_	_	O
24	functional	_	_	O
25	impairment	_	_	O
26	and	_	_	O
27	muscle	_	_	O
28	atrophy	_	_	O
29	,	_	_	O
30	which	_	_	O
31	may	_	_	O
32	lead	_	_	O
33	to	_	_	O
34	an	_	_	O
35	increased	_	_	O
36	likelihood	_	_	O
37	of	_	_	O
38	skeletal	_	_	O
39	complicaTIOns	_	_	O
40	(	_	_	O
41	i.e.	_	_	O
42	,	_	_	O
43	pathological	_	_	O
44	fracture	_	_	O
45	,	_	_	O
46	bone	_	_	O
47	pain	_	_	O
48	)	_	_	O
49	and/or	_	_	O
50	falls	_	_	O
51	.	_	_	O

52	Safe	_	_	O
53	resistance	_	_	O
54	exercise	_	_	O
55	prescription	_	_	O
56	may	_	_	O
57	counteract	_	_	O
58	this	_	_	O
59	effect	_	_	O
60	.	_	_	O

61	The	_	_	O
62	aim	_	_	O
63	of	_	_	O
64	this	_	_	O
65	feasibility	_	_	O
66	trial	_	_	O
67	was	_	_	O
68	to	_	_	O
69	determine	_	_	O
70	the	_	_	O
71	safety	_	_	O
72	and	_	_	O
73	efficacy	_	_	O
74	of	_	_	O
75	resistance	_	_	O
76	exercise	_	_	O
77	by	_	_	O
78	prostate	_	_	O
79	cancer	_	_	O
80	survivors	_	_	O
81	with	_	_	O
82	bone	_	_	O
83	metastatic	_	_	O
84	disease	_	_	O
85	.	_	_	O

86	Twenty	_	_	O
87	men	_	_	O
88	with	_	_	O
89	established	_	_	O
90	bone	_	_	O
91	metastases	_	_	O
92	secondary	_	_	O
93	to	_	_	O
94	prostate	_	_	O
95	cancer	_	_	O
96	were	_	_	O
97	randomly	_	_	O
98	assigned	_	_	O
99	to	_	_	O
100	a	_	_	O
101	12-week	_	_	O
102	resistance	_	_	O
103	exercise	_	_	O
104	program	_	_	O
105	in	_	_	O
106	which	_	_	O
107	exercise	_	_	O
108	prescription	_	_	O
109	was	_	_	O
110	based	_	_	O
111	on	_	_	O
112	the	_	_	O
113	location	_	_	O
114	of	_	_	O
115	bone	_	_	O
116	lesions	_	_	O
117	(	_	_	O
118	n=10	_	_	O
119	)	_	_	O
120	or	_	_	O
121	usual	_	_	O
122	care	_	_	O
123	(	_	_	O
124	n=10	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Outcomes	_	_	O
128	included	_	_	O
129	safety	_	_	O
130	and	_	_	O
131	tolerance	_	_	O
132	of	_	_	O
133	the	_	_	O
134	exercise	_	_	O
135	program	_	_	O
136	,	_	_	O
137	physical	_	_	O
138	function	_	_	O
139	,	_	_	O
140	physical	_	_	O
141	activity	_	_	O
142	level	_	_	O
143	,	_	_	O
144	body	_	_	O
145	composition	_	_	O
146	,	_	_	O
147	fatigue	_	_	O
148	,	_	_	O
149	quality	_	_	O
150	of	_	_	O
151	life	_	_	O
152	and	_	_	O
153	psychological	_	_	O
154	distress	_	_	O
155	.	_	_	O

156	Outcomes	_	_	O
157	were	_	_	O
158	compared	_	_	O
159	between	_	_	O
160	groups	_	_	O
161	using	_	_	O
162	analysis	_	_	O
163	of	_	_	O
164	covariance	_	_	O
165	adjusted	_	_	O
166	for	_	_	O
167	baseline	_	_	O
168	values	_	_	O
169	.	_	_	O

170	Participants	_	_	O
171	had	_	_	O
172	significant	_	_	O
173	disease	_	_	O
174	load	_	_	O
175	with	_	_	O
176	65	_	_	O
177	%	_	_	O
178	of	_	_	O
179	participants	_	_	O
180	presenting	_	_	O
181	with	_	_	O
182	two	_	_	O
183	or	_	_	O
184	more	_	_	O
185	regions	_	_	O
186	affected	_	_	O
187	by	_	_	O
188	bone	_	_	O
189	metastases	_	_	O
190	and	_	_	O
191	an	_	_	O
192	average	_	_	O
193	Gleason	_	_	O
194	score	_	_	O
195	of	_	_	O
196	8.2±0.9	_	_	O
197	.	_	_	O

198	Five	_	_	O
199	participants	_	_	O
200	(	_	_	O
201	exercise=2	_	_	O
202	;	_	_	O
203	usual	_	_	O
204	care=3	_	_	O
205	)	_	_	O
206	did	_	_	O
207	not	_	_	O
208	complete	_	_	O
209	the	_	_	O
210	intervention	_	_	O
211	,	_	_	O
212	three	_	_	O
213	of	_	_	O
214	which	_	_	O
215	were	_	_	O
216	due	_	_	O
217	to	_	_	O
218	advancing	_	_	O
219	disease	_	_	O
220	(	_	_	O
221	exercise=2	_	_	O
222	;	_	_	O
223	usual	_	_	O
224	care=1	_	_	O
225	)	_	_	O
226	.	_	_	O

227	No	_	_	B-Premise
228	adverse	_	_	I-Premise
229	events	_	_	I-Premise
230	or	_	_	I-Premise
231	skeletal	_	_	I-Premise
232	complications	_	_	I-Premise
233	occurred	_	_	I-Premise
234	during	_	_	I-Premise
235	the	_	_	I-Premise
236	supervised	_	_	I-Premise
237	exercise	_	_	I-Premise
238	sessions	_	_	I-Premise
239	.	_	_	I-Premise

240	The	_	_	B-Premise
241	exercise	_	_	I-Premise
242	program	_	_	I-Premise
243	was	_	_	I-Premise
244	well	_	_	I-Premise
245	tolerated	_	_	I-Premise
246	as	_	_	I-Premise
247	evidenced	_	_	I-Premise
248	by	_	_	I-Premise
249	high	_	_	I-Premise
250	attendance	_	_	I-Premise
251	(	_	_	I-Premise
252	83	_	_	I-Premise
253	%	_	_	I-Premise
254	)	_	_	I-Premise
255	and	_	_	I-Premise
256	compliance	_	_	I-Premise
257	rates	_	_	I-Premise
258	(	_	_	I-Premise
259	93	_	_	I-Premise
260	%	_	_	I-Premise
261	)	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	the	_	_	I-Premise
265	ability	_	_	I-Premise
266	of	_	_	I-Premise
267	the	_	_	I-Premise
268	participants	_	_	I-Premise
269	to	_	_	I-Premise
270	exercise	_	_	I-Premise
271	at	_	_	I-Premise
272	an	_	_	I-Premise
273	intensity	_	_	I-Premise
274	within	_	_	I-Premise
275	the	_	_	I-Premise
276	target	_	_	I-Premise
277	range	_	_	I-Premise
278	for	_	_	I-Premise
279	cancer	_	_	I-Premise
280	survivors	_	_	I-Premise
281	(	_	_	I-Premise
282	rating	_	_	I-Premise
283	of	_	_	I-Premise
284	perceived	_	_	I-Premise
285	exertion	_	_	I-Premise
286	=13.8±1.5	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	The	_	_	B-Premise
290	change	_	_	I-Premise
291	in	_	_	I-Premise
292	physical	_	_	I-Premise
293	function	_	_	I-Premise
294	(	_	_	I-Premise
295	muscle	_	_	I-Premise
296	strength	_	_	I-Premise
297	∼11	_	_	I-Premise
298	%	_	_	I-Premise
299	;	_	_	I-Premise
300	submaximal	_	_	I-Premise
301	aerobic	_	_	I-Premise
302	exercise	_	_	I-Premise
303	capacity	_	_	I-Premise
304	∼5	_	_	I-Premise
305	%	_	_	I-Premise
306	and	_	_	I-Premise
307	ambulation	_	_	I-Premise
308	∼12	_	_	I-Premise
309	%	_	_	I-Premise
310	)	_	_	I-Premise
311	,	_	_	I-Premise
312	physical	_	_	I-Premise
313	activity	_	_	I-Premise
314	level	_	_	I-Premise
315	(	_	_	I-Premise
316	∼24	_	_	I-Premise
317	%	_	_	I-Premise
318	)	_	_	I-Premise
319	and	_	_	I-Premise
320	lean	_	_	I-Premise
321	mass	_	_	I-Premise
322	(	_	_	I-Premise
323	∼3	_	_	I-Premise
324	%	_	_	I-Premise
325	)	_	_	I-Premise
326	differed	_	_	I-Premise
327	significantly	_	_	I-Premise
328	between	_	_	I-Premise
329	groups	_	_	I-Premise
330	following	_	_	I-Premise
331	the	_	_	I-Premise
332	intervention	_	_	I-Premise
333	,	_	_	I-Premise
334	with	_	_	I-Premise
335	favorable	_	_	I-Premise
336	changes	_	_	I-Premise
337	in	_	_	I-Premise
338	the	_	_	I-Premise
339	exercise	_	_	I-Premise
340	group	_	_	I-Premise
341	compared	_	_	I-Premise
342	with	_	_	I-Premise
343	the	_	_	I-Premise
344	usual	_	_	I-Premise
345	care	_	_	I-Premise
346	group	_	_	I-Premise
347	.	_	_	I-Premise

348	No	_	_	B-Premise
349	significant	_	_	I-Premise
350	between-group	_	_	I-Premise
351	differences	_	_	I-Premise
352	were	_	_	I-Premise
353	observed	_	_	I-Premise
354	for	_	_	I-Premise
355	fatigue	_	_	I-Premise
356	,	_	_	I-Premise
357	quality	_	_	I-Premise
358	of	_	_	I-Premise
359	life	_	_	I-Premise
360	or	_	_	I-Premise
361	psychological	_	_	I-Premise
362	distress	_	_	I-Premise
363	.	_	_	I-Premise

364	This	_	_	B-Claim
365	initial	_	_	I-Claim
366	evidence	_	_	I-Claim
367	involving	_	_	I-Claim
368	a	_	_	I-Claim
369	small	_	_	I-Claim
370	sample	_	_	I-Claim
371	size	_	_	I-Claim
372	suggests	_	_	I-Claim
373	that	_	_	I-Claim
374	appropriately	_	_	I-Claim
375	designed	_	_	I-Claim
376	and	_	_	I-Claim
377	supervised	_	_	I-Claim
378	resistance	_	_	I-Claim
379	exercise	_	_	I-Claim
380	may	_	_	I-Claim
381	be	_	_	I-Claim
382	safe	_	_	I-Claim
383	and	_	_	I-Claim
384	well	_	_	I-Claim
385	tolerated	_	_	I-Claim
386	by	_	_	I-Claim
387	prostate	_	_	I-Claim
388	cancer	_	_	I-Claim
389	patients	_	_	I-Claim
390	with	_	_	I-Claim
391	bone	_	_	I-Claim
392	metastatic	_	_	I-Claim
393	disease	_	_	I-Claim
394	and	_	_	I-Claim
395	can	_	_	I-Claim
396	lead	_	_	I-Claim
397	to	_	_	I-Claim
398	improvements	_	_	I-Claim
399	in	_	_	I-Claim
400	physical	_	_	I-Claim
401	function	_	_	I-Claim
402	,	_	_	I-Claim
403	physical	_	_	I-Claim
404	activity	_	_	I-Claim
405	levels	_	_	I-Claim
406	and	_	_	I-Claim
407	lean	_	_	I-Claim
408	mass	_	_	I-Claim
409	.	_	_	I-Claim

410	Future	_	_	B-Claim
411	trials	_	_	I-Claim
412	involving	_	_	I-Claim
413	larger	_	_	I-Claim
414	sample	_	_	I-Claim
415	sizes	_	_	I-Claim
416	are	_	_	I-Claim
417	required	_	_	I-Claim
418	to	_	_	I-Claim
419	expand	_	_	I-Claim
420	these	_	_	I-Claim
421	preliminary	_	_	I-Claim
422	findings	_	_	I-Claim
423	.	_	_	I-Claim


0	Gefitinib	_	_	O
1	and	_	_	O
2	Pemetrexed	_	_	O
3	are	_	_	O
4	drugs	_	_	O
5	used	_	_	O
6	as	_	_	O
7	second-line	_	_	O
8	therapy	_	_	O
9	for	_	_	O
10	advanced	_	_	O
11	non-small	_	_	O
12	cell	_	_	O
13	lung	_	_	O
14	cancer	_	_	O
15	(	_	_	O
16	NSCLC	_	_	O
17	)	_	_	O
18	,	_	_	O
19	although	_	_	O
20	studies	_	_	O
21	comparing	_	_	O
22	the	_	_	O
23	two	_	_	O
24	drugs	_	_	O
25	are	_	_	O
26	limited	_	_	O
27	.	_	_	O

28	The	_	_	O
29	aim	_	_	O
30	of	_	_	O
31	this	_	_	O
32	study	_	_	O
33	is	_	_	O
34	to	_	_	O
35	explore	_	_	O
36	the	_	_	O
37	effects	_	_	O
38	,	_	_	O
39	safety	_	_	O
40	,	_	_	O
41	and	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	(	_	_	O
46	QoL	_	_	O
47	)	_	_	O
48	of	_	_	O
49	Gefitinib	_	_	O
50	and	_	_	O
51	Pemetrexed	_	_	O
52	on	_	_	O
53	patients	_	_	O
54	with	_	_	O
55	advanced	_	_	O
56	non-squamous	_	_	O
57	NSCLC	_	_	O
58	.	_	_	O

59	Forty-six	_	_	O
60	advanced	_	_	O
61	non-squamous	_	_	O
62	NSCLC	_	_	O
63	patients	_	_	O
64	who	_	_	O
65	failed	_	_	O
66	to	_	_	O
67	first-line	_	_	O
68	therapy	_	_	O
69	were	_	_	O
70	randomly	_	_	O
71	divided	_	_	O
72	into	_	_	O
73	two	_	_	O
74	groups	_	_	O
75	with	_	_	O
76	23	_	_	O
77	patients	_	_	O
78	each	_	_	O
79	,	_	_	O
80	one	_	_	O
81	using	_	_	O
82	oral	_	_	O
83	Gefitinib	_	_	O
84	(	_	_	O
85	Gefitinib	_	_	O
86	group	_	_	O
87	)	_	_	O
88	and	_	_	O
89	the	_	_	O
90	other	_	_	O
91	using	_	_	O
92	intravenous	_	_	O
93	injection	_	_	O
94	Pemetrexed	_	_	O
95	(	_	_	O
96	Pemetrexed	_	_	O
97	group	_	_	O
98	)	_	_	O
99	.	_	_	O

100	The	_	_	O
101	effects	_	_	O
102	,	_	_	O
103	safety	_	_	O
104	,	_	_	O
105	and	_	_	O
106	QoL	_	_	O
107	were	_	_	O
108	determined	_	_	O
109	and	_	_	O
110	analyzed	_	_	O
111	.	_	_	O

112	For	_	_	B-Premise
113	the	_	_	I-Premise
114	Pemetrexed	_	_	I-Premise
115	group	_	_	I-Premise
116	,	_	_	I-Premise
117	objective	_	_	I-Premise
118	response	_	_	I-Premise
119	rate	_	_	I-Premise
120	(	_	_	I-Premise
121	ORR	_	_	I-Premise
122	)	_	_	I-Premise
123	was	_	_	I-Premise
124	13.0	_	_	I-Premise
125	%	_	_	I-Premise
126	(	_	_	I-Premise
127	3/23	_	_	I-Premise
128	)	_	_	I-Premise
129	,	_	_	I-Premise
130	disease	_	_	I-Premise
131	control	_	_	I-Premise
132	rate	_	_	I-Premise
133	(	_	_	I-Premise
134	DCR	_	_	I-Premise
135	)	_	_	I-Premise
136	was	_	_	I-Premise
137	30.4	_	_	I-Premise
138	%	_	_	I-Premise
139	(	_	_	I-Premise
140	7/23	_	_	I-Premise
141	)	_	_	I-Premise
142	,	_	_	I-Premise
143	and	_	_	I-Premise
144	median	_	_	I-Premise
145	progression-free	_	_	I-Premise
146	survival	_	_	I-Premise
147	(	_	_	I-Premise
148	mPFS	_	_	I-Premise
149	)	_	_	I-Premise
150	was	_	_	I-Premise
151	3.1	_	_	I-Premise
152	months	_	_	I-Premise
153	.	_	_	I-Premise

154	In	_	_	B-Premise
155	the	_	_	I-Premise
156	Gefitinib	_	_	I-Premise
157	group	_	_	I-Premise
158	,	_	_	I-Premise
159	ORR	_	_	I-Premise
160	was	_	_	I-Premise
161	17.3	_	_	I-Premise
162	%	_	_	I-Premise
163	(	_	_	I-Premise
164	4/23	_	_	I-Premise
165	)	_	_	I-Premise
166	,	_	_	I-Premise
167	DCR	_	_	I-Premise
168	was	_	_	I-Premise
169	39.1	_	_	I-Premise
170	%	_	_	I-Premise
171	(	_	_	I-Premise
172	9/23	_	_	I-Premise
173	)	_	_	I-Premise
174	,	_	_	I-Premise
175	and	_	_	I-Premise
176	mPFS	_	_	I-Premise
177	was	_	_	I-Premise
178	4.4	_	_	I-Premise
179	months	_	_	I-Premise
180	.	_	_	I-Premise

181	Compared	_	_	B-Premise
182	with	_	_	I-Premise
183	the	_	_	I-Premise
184	Pemetrexed	_	_	I-Premise
185	group	_	_	I-Premise
186	,	_	_	I-Premise
187	the	_	_	I-Premise
188	ORR	_	_	I-Premise
189	,	_	_	I-Premise
190	DCR	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	mPFS	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	Gefitinib	_	_	I-Premise
197	group	_	_	I-Premise
198	exhibited	_	_	I-Premise
199	no	_	_	I-Premise
200	statistical	_	_	I-Premise
201	significance	_	_	I-Premise
202	(	_	_	I-Premise
203	P	_	_	I-Premise
204	>	_	_	I-Premise
205	0.05	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Furthermore	_	_	O
209	,	_	_	O
210	the	_	_	B-Premise
211	most	_	_	I-Premise
212	common	_	_	I-Premise
213	toxicities	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	Pemetrexed	_	_	I-Premise
217	group	_	_	I-Premise
218	were	_	_	I-Premise
219	neutropenia	_	_	I-Premise
220	(	_	_	I-Premise
221	n=9	_	_	I-Premise
222	,	_	_	I-Premise
223	39.13	_	_	I-Premise
224	%	_	_	I-Premise
225	)	_	_	I-Premise
226	and	_	_	I-Premise
227	fatigue	_	_	I-Premise
228	(	_	_	I-Premise
229	n=8	_	_	I-Premise
230	,	_	_	I-Premise
231	34.78	_	_	I-Premise
232	%	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	whereas	_	_	I-Premise
236	those	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	in	_	_	I-Premise
240	Gefitinib	_	_	I-Premise
241	group	_	_	I-Premise
242	were	_	_	I-Premise
243	skin	_	_	I-Premise
244	rash	_	_	I-Premise
245	(	_	_	I-Premise
246	n=8	_	_	I-Premise
247	,	_	_	I-Premise
248	34.78	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	and	_	_	I-Premise
252	diarrhea	_	_	I-Premise
253	(	_	_	I-Premise
254	n=4	_	_	I-Premise
255	,	_	_	I-Premise
256	17.39	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Compared	_	_	B-Premise
261	with	_	_	I-Premise
262	baseline	_	_	I-Premise
263	,	_	_	I-Premise
264	the	_	_	I-Premise
265	QoL	_	_	I-Premise
266	improved	_	_	I-Premise
267	in	_	_	I-Premise
268	both	_	_	I-Premise
269	groups	_	_	I-Premise
270	but	_	_	I-Premise
271	to	_	_	I-Premise
272	different	_	_	I-Premise
273	degrees	_	_	I-Premise
274	.	_	_	I-Premise

275	Likewise	_	_	O
276	,	_	_	O
277	emotional	_	_	B-Premise
278	,	_	_	I-Premise
279	functional	_	_	I-Premise
280	well-being	_	_	I-Premise
281	,	_	_	I-Premise
282	and	_	_	I-Premise
283	QoL	_	_	I-Premise
284	aspects	_	_	I-Premise
285	specifically	_	_	I-Premise
286	related	_	_	I-Premise
287	to	_	_	I-Premise
288	lung	_	_	I-Premise
289	cancer	_	_	I-Premise
290	were	_	_	I-Premise
291	better	_	_	I-Premise
292	improved	_	_	I-Premise
293	in	_	_	I-Premise
294	the	_	_	I-Premise
295	Gefitinib	_	_	I-Premise
296	group	_	_	I-Premise
297	than	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	Pemetrexed	_	_	I-Premise
301	group	_	_	I-Premise
302	(	_	_	I-Premise
303	P	_	_	I-Premise
304	<	_	_	I-Premise
305	0.05	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	The	_	_	B-Claim
309	effects	_	_	I-Claim
310	of	_	_	I-Claim
311	Pemetrexed	_	_	I-Claim
312	and	_	_	I-Claim
313	Gefitinib	_	_	I-Claim
314	as	_	_	I-Claim
315	second	_	_	I-Claim
316	line	_	_	I-Claim
317	therapy	_	_	I-Claim
318	were	_	_	I-Claim
319	similar	_	_	I-Claim
320	,	_	_	I-Claim
321	although	_	_	B-Premise
322	with	_	_	I-Premise
323	different	_	_	I-Premise
324	AEs	_	_	I-Premise
325	.	_	_	I-Premise

326	Both	_	_	B-Claim
327	drugs	_	_	I-Claim
328	could	_	_	I-Claim
329	improve	_	_	I-Claim
330	the	_	_	I-Claim
331	QoL	_	_	I-Claim
332	,	_	_	I-Claim
333	but	_	_	O
334	Gefitinib	_	_	B-Claim
335	showed	_	_	I-Claim
336	better	_	_	I-Claim
337	overall	_	_	I-Claim
338	results	_	_	I-Claim
339	than	_	_	I-Claim
340	Pemetrexed	_	_	I-Claim
341	.	_	_	I-Claim


0	Everolimus	_	_	O
1	(	_	_	O
2	EVE	_	_	O
3	)	_	_	O
4	+exemestane	_	_	O
5	(	_	_	O
6	EXE	_	_	O
7	;	_	_	O
8	n	_	_	O
9	=	_	_	O
10	485	_	_	O
11	)	_	_	O
12	more	_	_	O
13	than	_	_	O
14	doubled	_	_	O
15	median	_	_	O
16	progression-free	_	_	O
17	survival	_	_	O
18	versus	_	_	O
19	placebo	_	_	O
20	(	_	_	O
21	PBO	_	_	O
22	)	_	_	O
23	+	_	_	O
24	EXE	_	_	O
25	(	_	_	O
26	n	_	_	O
27	=	_	_	O
28	239	_	_	O
29	)	_	_	O
30	,	_	_	O
31	with	_	_	O
32	a	_	_	O
33	manageable	_	_	O
34	safety	_	_	O
35	profile	_	_	O
36	and	_	_	O
37	no	_	_	O
38	deterioration	_	_	O
39	in	_	_	O
40	health-related	_	_	O
41	quality-of-life	_	_	O
42	(	_	_	O
43	HRQOL	_	_	O
44	)	_	_	O
45	in	_	_	O
46	patients	_	_	O
47	with	_	_	O
48	hormone-receptor-positive	_	_	O
49	(	_	_	O
50	HR	_	_	O
51	(	_	_	O
52	+	_	_	O
53	)	_	_	O
54	)	_	_	O
55	advanced	_	_	O
56	breast	_	_	O
57	cancer	_	_	O
58	(	_	_	O
59	ABC	_	_	O
60	)	_	_	O
61	who	_	_	O
62	recurred	_	_	O
63	or	_	_	O
64	progressed	_	_	O
65	on/after	_	_	O
66	nonsteroidal	_	_	O
67	aromatase	_	_	O
68	inhibitor	_	_	O
69	(	_	_	O
70	NSAI	_	_	O
71	)	_	_	O
72	therapy	_	_	O
73	.	_	_	O

74	To	_	_	O
75	further	_	_	O
76	evaluate	_	_	O
77	EVE	_	_	O
78	+	_	_	O
79	EXE	_	_	O
80	impact	_	_	O
81	on	_	_	O
82	disease	_	_	O
83	burden	_	_	O
84	,	_	_	O
85	we	_	_	O
86	conducted	_	_	O
87	additional	_	_	O
88	post-hoc	_	_	O
89	analyses	_	_	O
90	of	_	_	O
91	patient-reported	_	_	O
92	HRQOL	_	_	O
93	.	_	_	O

94	HRQOL	_	_	O
95	was	_	_	O
96	assessed	_	_	O
97	using	_	_	O
98	EORTC	_	_	O
99	QLQ-C30	_	_	O
100	and	_	_	O
101	QLQ-BR23	_	_	O
102	questionnaires	_	_	O
103	at	_	_	O
104	baseline	_	_	O
105	and	_	_	O
106	every	_	_	O
107	6	_	_	O
108	weeks	_	_	O
109	thereafter	_	_	O
110	until	_	_	O
111	treatment	_	_	O
112	discontinuation	_	_	O
113	because	_	_	O
114	of	_	_	O
115	disease	_	_	O
116	progression	_	_	O
117	,	_	_	O
118	toxicity	_	_	O
119	,	_	_	O
120	or	_	_	O
121	consent	_	_	O
122	withdrawal	_	_	O
123	.	_	_	O

124	Endpoints	_	_	O
125	included	_	_	O
126	the	_	_	O
127	QLQ-C30	_	_	O
128	Global	_	_	O
129	Health	_	_	O
130	Status	_	_	O
131	(	_	_	O
132	QL2	_	_	O
133	)	_	_	O
134	scale	_	_	O
135	,	_	_	O
136	the	_	_	O
137	QLQ-BR23	_	_	O
138	breast	_	_	O
139	symptom	_	_	O
140	(	_	_	O
141	BRBS	_	_	O
142	)	_	_	O
143	,	_	_	O
144	and	_	_	O
145	arm	_	_	O
146	symptom	_	_	O
147	(	_	_	O
148	BRAS	_	_	O
149	)	_	_	O
150	scales	_	_	O
151	.	_	_	O

152	Between-group	_	_	O
153	differences	_	_	O
154	in	_	_	O
155	change	_	_	O
156	from	_	_	O
157	baseline	_	_	O
158	were	_	_	O
159	assessed	_	_	O
160	using	_	_	O
161	linear	_	_	O
162	mixed	_	_	O
163	models	_	_	O
164	with	_	_	O
165	selected	_	_	O
166	covariates	_	_	O
167	.	_	_	O

168	Sensitivity	_	_	O
169	analysis	_	_	O
170	using	_	_	O
171	pattern-mixture	_	_	O
172	models	_	_	O
173	determined	_	_	O
174	the	_	_	O
175	effect	_	_	O
176	of	_	_	O
177	study	_	_	O
178	discontinuation	_	_	O
179	on/before	_	_	O
180	week	_	_	O
181	24	_	_	O
182	.	_	_	O

183	Treatment	_	_	O
184	arms	_	_	O
185	were	_	_	O
186	compared	_	_	O
187	using	_	_	O
188	differences	_	_	O
189	of	_	_	O
190	least	_	_	O
191	squares	_	_	O
192	mean	_	_	O
193	(	_	_	O
194	LSM	_	_	O
195	)	_	_	O
196	changes	_	_	O
197	from	_	_	O
198	baseline	_	_	O
199	and	_	_	O
200	95	_	_	O
201	%	_	_	O
202	confidence	_	_	O
203	intervals	_	_	O
204	(	_	_	O
205	CIs	_	_	O
206	)	_	_	O
207	at	_	_	O
208	each	_	_	O
209	timepoint	_	_	O
210	and	_	_	O
211	overall	_	_	O
212	.	_	_	O

213	Progression-free	_	_	O
214	survival	_	_	O
215	,	_	_	O
216	survival	_	_	O
217	,	_	_	O
218	response	_	_	O
219	rate	_	_	O
220	,	_	_	O
221	safety	_	_	O
222	,	_	_	O
223	and	_	_	O
224	HRQOL	_	_	O
225	.	_	_	O

226	Linear	_	_	B-Premise
227	mixed	_	_	I-Premise
228	models	_	_	I-Premise
229	(	_	_	I-Premise
230	primary	_	_	I-Premise
231	model	_	_	I-Premise
232	)	_	_	I-Premise
233	demonstrated	_	_	I-Premise
234	no	_	_	I-Premise
235	statistically	_	_	I-Premise
236	significant	_	_	I-Premise
237	overall	_	_	I-Premise
238	difference	_	_	I-Premise
239	between	_	_	I-Premise
240	EVE	_	_	I-Premise
241	+	_	_	I-Premise
242	EXE	_	_	I-Premise
243	and	_	_	I-Premise
244	PBO	_	_	I-Premise
245	+	_	_	I-Premise
246	EXE	_	_	I-Premise
247	for	_	_	I-Premise
248	QL2	_	_	I-Premise
249	(	_	_	I-Premise
250	LSM	_	_	I-Premise
251	difference	_	_	I-Premise
252	=	_	_	I-Premise
253	-1.91	_	_	I-Premise
254	;	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	=	_	_	I-Premise
259	-4.61	_	_	I-Premise
260	,	_	_	I-Premise
261	0.78	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	BRBS	_	_	I-Premise
265	(	_	_	I-Premise
266	LSM	_	_	I-Premise
267	difference	_	_	I-Premise
268	=	_	_	I-Premise
269	-0.18	_	_	I-Premise
270	;	_	_	I-Premise
271	95	_	_	I-Premise
272	%	_	_	I-Premise
273	CI	_	_	I-Premise
274	=	_	_	I-Premise
275	-1.98	_	_	I-Premise
276	,	_	_	I-Premise
277	1.62	_	_	I-Premise
278	)	_	_	I-Premise
279	,	_	_	I-Premise
280	or	_	_	I-Premise
281	BRAS	_	_	I-Premise
282	(	_	_	I-Premise
283	LSM	_	_	I-Premise
284	difference	_	_	I-Premise
285	=	_	_	I-Premise
286	-0.42	_	_	I-Premise
287	;	_	_	I-Premise
288	95	_	_	I-Premise
289	%	_	_	I-Premise
290	CI	_	_	I-Premise
291	=	_	_	I-Premise
292	-2.94	_	_	I-Premise
293	,	_	_	I-Premise
294	2.10	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	Based	_	_	O
298	on	_	_	O
299	pattern-mixture	_	_	O
300	models	_	_	O
301	,	_	_	O
302	patients	_	_	O
303	who	_	_	O
304	dropped	_	_	O
305	out	_	_	O
306	early	_	_	O
307	had	_	_	O
308	worse	_	_	O
309	QL2	_	_	O
310	decline	_	_	O
311	on	_	_	O
312	both	_	_	O
313	treatments	_	_	O
314	.	_	_	O

315	In	_	_	B-Premise
316	the	_	_	I-Premise
317	expanded	_	_	I-Premise
318	pattern-mixture	_	_	I-Premise
319	model	_	_	I-Premise
320	,	_	_	I-Premise
321	EVE	_	_	I-Premise
322	+	_	_	I-Premise
323	EXE-treated	_	_	I-Premise
324	patients	_	_	I-Premise
325	who	_	_	I-Premise
326	did	_	_	I-Premise
327	not	_	_	I-Premise
328	drop	_	_	I-Premise
329	out	_	_	I-Premise
330	early	_	_	I-Premise
331	had	_	_	I-Premise
332	stable	_	_	I-Premise
333	BRBS	_	_	I-Premise
334	and	_	_	I-Premise
335	BRAS	_	_	I-Premise
336	relative	_	_	I-Premise
337	to	_	_	I-Premise
338	PBO	_	_	I-Premise
339	+	_	_	I-Premise
340	EXE	_	_	I-Premise
341	.	_	_	I-Premise

342	HRQOL	_	_	O
343	data	_	_	O
344	were	_	_	O
345	not	_	_	O
346	collected	_	_	O
347	after	_	_	O
348	disease	_	_	O
349	progression	_	_	O
350	.	_	_	O

351	These	_	_	B-Claim
352	analyses	_	_	I-Claim
353	confirm	_	_	I-Claim
354	that	_	_	I-Claim
355	EVE	_	_	I-Claim
356	+	_	_	I-Claim
357	EXE	_	_	I-Claim
358	provides	_	_	I-Claim
359	clinical	_	_	I-Claim
360	benefit	_	_	I-Claim
361	without	_	_	I-Claim
362	adversely	_	_	I-Claim
363	impacting	_	_	I-Claim
364	HRQOL	_	_	I-Claim
365	in	_	_	I-Claim
366	patients	_	_	I-Claim
367	with	_	_	I-Claim
368	HR	_	_	I-Claim
369	(	_	_	I-Claim
370	+	_	_	I-Claim
371	)	_	_	I-Claim
372	ABC	_	_	I-Claim
373	who	_	_	I-Claim
374	recurred/progressed	_	_	I-Claim
375	on	_	_	I-Claim
376	prior	_	_	I-Claim
377	NSAIs	_	_	I-Claim
378	versus	_	_	I-Claim
379	endocrine	_	_	I-Claim
380	therapy	_	_	I-Claim
381	alone	_	_	I-Claim
382	.	_	_	I-Claim


0	Care	_	_	O
1	closer	_	_	O
2	to	_	_	O
3	home	_	_	O
4	is	_	_	O
5	being	_	_	O
6	explored	_	_	O
7	as	_	_	O
8	a	_	_	O
9	means	_	_	O
10	of	_	_	O
11	improving	_	_	O
12	patient	_	_	O
13	experience	_	_	O
14	as	_	_	O
15	well	_	_	O
16	as	_	_	O
17	efficiency	_	_	O
18	in	_	_	O
19	terms	_	_	O
20	of	_	_	O
21	cost	_	_	O
22	savings	_	_	O
23	.	_	_	O

24	Evidence	_	_	O
25	that	_	_	O
26	community	_	_	O
27	cancer	_	_	O
28	services	_	_	O
29	improve	_	_	O
30	care	_	_	O
31	quality	_	_	O
32	and/or	_	_	O
33	generate	_	_	O
34	cost	_	_	O
35	savings	_	_	O
36	is	_	_	O
37	currently	_	_	O
38	limited	_	_	O
39	.	_	_	O

40	A	_	_	O
41	randomised	_	_	O
42	study	_	_	O
43	was	_	_	O
44	undertaken	_	_	O
45	to	_	_	O
46	compare	_	_	O
47	delivery	_	_	O
48	of	_	_	O
49	cancer	_	_	O
50	treatment	_	_	O
51	in	_	_	O
52	the	_	_	O
53	hospital	_	_	O
54	with	_	_	O
55	two	_	_	O
56	different	_	_	O
57	community	_	_	O
58	settings	_	_	O
59	.	_	_	O

60	Ninety-seven	_	_	O
61	patients	_	_	O
62	being	_	_	O
63	offered	_	_	O
64	outpatient-based	_	_	O
65	cancer	_	_	O
66	treatment	_	_	O
67	were	_	_	O
68	randomised	_	_	O
69	to	_	_	O
70	treatment	_	_	O
71	delivered	_	_	O
72	in	_	_	O
73	a	_	_	O
74	hospital	_	_	O
75	day	_	_	O
76	unit	_	_	O
77	,	_	_	O
78	at	_	_	O
79	the	_	_	O
80	patient	_	_	O
81	's	_	_	O
82	home	_	_	O
83	or	_	_	O
84	in	_	_	O
85	local	_	_	O
86	general	_	_	O
87	practice	_	_	O
88	(	_	_	O
89	GP	_	_	O
90	)	_	_	O
91	surgeries	_	_	O
92	.	_	_	O

93	The	_	_	O
94	primary	_	_	O
95	outcome	_	_	O
96	was	_	_	O
97	patient-perceived	_	_	O
98	benefits	_	_	O
99	,	_	_	O
100	using	_	_	O
101	the	_	_	O
102	emotional	_	_	O
103	function	_	_	O
104	domain	_	_	O
105	of	_	_	O
106	the	_	_	O
107	EORTC	_	_	O
108	quality	_	_	O
109	of	_	_	O
110	life	_	_	O
111	(	_	_	O
112	QOL	_	_	O
113	)	_	_	O
114	QLQC30	_	_	O
115	questionnaire	_	_	O
116	evaluated	_	_	O
117	after	_	_	O
118	12	_	_	O
119	weeks	_	_	O
120	.	_	_	O

121	Secondary	_	_	O
122	outcomes	_	_	O
123	included	_	_	O
124	additional	_	_	O
125	QOL	_	_	O
126	measures	_	_	O
127	,	_	_	O
128	patient	_	_	O
129	satisfaction	_	_	O
130	,	_	_	O
131	safety	_	_	O
132	and	_	_	O
133	health	_	_	O
134	economics	_	_	O
135	.	_	_	O

136	There	_	_	B-Premise
137	was	_	_	I-Premise
138	no	_	_	I-Premise
139	statistically	_	_	I-Premise
140	significant	_	_	I-Premise
141	QOL	_	_	I-Premise
142	difference	_	_	I-Premise
143	between	_	_	I-Premise
144	treatment	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	combined	_	_	I-Premise
148	community	_	_	I-Premise
149	locations	_	_	I-Premise
150	relative	_	_	I-Premise
151	to	_	_	I-Premise
152	hospital	_	_	I-Premise
153	(	_	_	I-Premise
154	difference	_	_	I-Premise
155	of	_	_	I-Premise
156	-7.2	_	_	I-Premise
157	,	_	_	I-Premise
158	95	_	_	I-Premise
159	%	_	_	I-Premise
160	confidence	_	_	I-Premise
161	interval	_	_	I-Premise
162	:	_	_	I-Premise
163	-19·5	_	_	I-Premise
164	to	_	_	I-Premise
165	+5·2	_	_	I-Premise
166	,	_	_	I-Premise
167	P=0.25	_	_	I-Premise
168	)	_	_	I-Premise
169	.	_	_	I-Premise

170	There	_	_	B-Premise
171	was	_	_	I-Premise
172	a	_	_	I-Premise
173	significant	_	_	I-Premise
174	difference	_	_	I-Premise
175	between	_	_	I-Premise
176	the	_	_	I-Premise
177	two	_	_	I-Premise
178	community	_	_	I-Premise
179	locations	_	_	I-Premise
180	in	_	_	I-Premise
181	favour	_	_	I-Premise
182	of	_	_	I-Premise
183	home	_	_	I-Premise
184	(	_	_	I-Premise
185	+15·2	_	_	I-Premise
186	,	_	_	I-Premise
187	1·3	_	_	I-Premise
188	to	_	_	I-Premise
189	29·1	_	_	I-Premise
190	,	_	_	I-Premise
191	P=0.033	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	Hospital	_	_	O
195	anxiety	_	_	O
196	and	_	_	O
197	depression	_	_	O
198	scale	_	_	O
199	scores	_	_	O
200	were	_	_	O
201	consistent	_	_	O
202	with	_	_	O
203	the	_	_	O
204	primary	_	_	O
205	outcome	_	_	O
206	measure	_	_	O
207	.	_	_	O

208	There	_	_	B-Premise
209	was	_	_	I-Premise
210	no	_	_	I-Premise
211	evidence	_	_	I-Premise
212	that	_	_	I-Premise
213	community	_	_	I-Premise
214	treatment	_	_	I-Premise
215	compromised	_	_	I-Premise
216	patient	_	_	I-Premise
217	safety	_	_	I-Premise
218	and	_	_	O
219	no	_	_	B-Premise
220	significant	_	_	I-Premise
221	difference	_	_	I-Premise
222	between	_	_	I-Premise
223	treatment	_	_	I-Premise
224	arms	_	_	I-Premise
225	in	_	_	I-Premise
226	terms	_	_	I-Premise
227	of	_	_	I-Premise
228	overall	_	_	I-Premise
229	costs	_	_	I-Premise
230	or	_	_	I-Premise
231	Quality	_	_	I-Premise
232	Adjusted	_	_	I-Premise
233	Life	_	_	I-Premise
234	Year	_	_	I-Premise
235	.	_	_	I-Premise

236	Seventy-eight	_	_	B-Premise
237	percent	_	_	I-Premise
238	of	_	_	I-Premise
239	patients	_	_	I-Premise
240	expressed	_	_	I-Premise
241	satisfaction	_	_	I-Premise
242	with	_	_	I-Premise
243	their	_	_	I-Premise
244	treatment	_	_	I-Premise
245	whatever	_	_	I-Premise
246	their	_	_	I-Premise
247	location	_	_	I-Premise
248	,	_	_	I-Premise
249	whereas	_	_	I-Premise
250	57	_	_	I-Premise
251	%	_	_	I-Premise
252	of	_	_	I-Premise
253	patients	_	_	I-Premise
254	preferred	_	_	I-Premise
255	future	_	_	I-Premise
256	treatment	_	_	I-Premise
257	to	_	_	I-Premise
258	continue	_	_	I-Premise
259	at	_	_	I-Premise
260	the	_	_	I-Premise
261	hospital	_	_	I-Premise
262	,	_	_	I-Premise
263	81	_	_	I-Premise
264	%	_	_	I-Premise
265	at	_	_	I-Premise
266	GP	_	_	I-Premise
267	surgeries	_	_	I-Premise
268	and	_	_	I-Premise
269	90	_	_	I-Premise
270	%	_	_	I-Premise
271	at	_	_	I-Premise
272	home	_	_	I-Premise
273	.	_	_	I-Premise

274	Although	_	_	O
275	initial	_	_	O
276	pre-trial	_	_	O
277	interviews	_	_	O
278	revealed	_	_	O
279	concerns	_	_	O
280	among	_	_	O
281	health-care	_	_	O
282	professionals	_	_	O
283	and	_	_	O
284	some	_	_	O
285	patients	_	_	O
286	regarding	_	_	O
287	community	_	_	O
288	treatment	_	_	O
289	,	_	_	O
290	opinions	_	_	O
291	were	_	_	O
292	largely	_	_	O
293	more	_	_	O
294	favourable	_	_	O
295	in	_	_	O
296	post-trial	_	_	O
297	interviews	_	_	O
298	.	_	_	O

299	Patient	_	_	B-Claim
300	QOL	_	_	I-Claim
301	favours	_	_	I-Claim
302	delivering	_	_	I-Claim
303	cancer	_	_	I-Claim
304	treatment	_	_	I-Claim
305	in	_	_	I-Claim
306	the	_	_	I-Claim
307	home	_	_	I-Claim
308	rather	_	_	I-Claim
309	than	_	_	I-Claim
310	GP	_	_	I-Claim
311	surgeries	_	_	I-Claim
312	.	_	_	I-Claim

313	Nevertheless	_	_	B-Claim
314	,	_	_	I-Claim
315	both	_	_	I-Claim
316	community	_	_	I-Claim
317	settings	_	_	I-Claim
318	were	_	_	I-Claim
319	acceptable	_	_	I-Claim
320	to	_	_	I-Claim
321	and	_	_	I-Claim
322	preferred	_	_	I-Claim
323	by	_	_	I-Claim
324	patients	_	_	I-Claim
325	compared	_	_	I-Claim
326	with	_	_	I-Claim
327	hospital	_	_	I-Claim
328	,	_	_	I-Claim
329	were	_	_	I-Claim
330	safe	_	_	I-Claim
331	,	_	_	I-Claim
332	with	_	_	I-Claim
333	no	_	_	I-Claim
334	detrimental	_	_	I-Claim
335	impact	_	_	I-Claim
336	on	_	_	I-Claim
337	overall	_	_	I-Claim
338	health-care	_	_	I-Claim
339	costs	_	_	I-Claim
340	.	_	_	I-Claim


0	The	_	_	O
1	optimal	_	_	O
2	duration	_	_	O
3	over	_	_	O
4	which	_	_	O
5	lung	_	_	O
6	SBRT	_	_	O
7	should	_	_	O
8	be	_	_	O
9	delivered	_	_	O
10	is	_	_	O
11	unknown	_	_	O
12	.	_	_	O

13	We	_	_	O
14	conducted	_	_	O
15	a	_	_	O
16	randomized	_	_	O
17	pilot	_	_	O
18	study	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	four	_	_	O
24	fractions	_	_	O
25	of	_	_	O
26	lung	_	_	O
27	SBRT	_	_	O
28	delivered	_	_	O
29	over	_	_	O
30	4	_	_	O
31	or	_	_	O
32	over	_	_	O
33	11	_	_	O
34	days	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	with	_	_	O
38	a	_	_	O
39	peripheral	_	_	O
40	solitary	_	_	O
41	lung	_	_	O
42	tumor	_	_	O
43	(	_	_	O
44	NSCLC	_	_	O
45	or	_	_	O
46	pulmonary	_	_	O
47	metastasis	_	_	O
48	)	_	_	O
49	≤	_	_	O
50	5	_	_	O
51	cm	_	_	O
52	were	_	_	O
53	eligible	_	_	O
54	.	_	_	O

55	For	_	_	O
56	NSCLC	_	_	O
57	lung	_	_	O
58	tumors	_	_	O
59	≤	_	_	O
60	3	_	_	O
61	cm	_	_	O
62	,	_	_	O
63	a	_	_	O
64	dose	_	_	O
65	of	_	_	O
66	48	_	_	O
67	Gy	_	_	O
68	in	_	_	O
69	4	_	_	O
70	fractions	_	_	O
71	was	_	_	O
72	used	_	_	O
73	,	_	_	O
74	otherwise	_	_	O
75	52	_	_	O
76	Gy	_	_	O
77	in	_	_	O
78	4	_	_	O
79	fractions	_	_	O
80	was	_	_	O
81	delivered	_	_	O
82	.	_	_	O

83	Patients	_	_	O
84	were	_	_	O
85	randomized	_	_	O
86	to	_	_	O
87	receive	_	_	O
88	treatment	_	_	O
89	over	_	_	O
90	4	_	_	O
91	consecutive	_	_	O
92	days	_	_	O
93	or	_	_	O
94	over	_	_	O
95	11	_	_	O
96	days	_	_	O
97	.	_	_	O

98	The	_	_	O
99	primary	_	_	O
100	end-point	_	_	O
101	was	_	_	O
102	acute	_	_	O
103	grade	_	_	O
104	≥	_	_	O
105	2	_	_	O
106	toxicity	_	_	O
107	.	_	_	O

108	Secondary	_	_	O
109	end-points	_	_	O
110	included	_	_	O
111	quality	_	_	O
112	of	_	_	O
113	life	_	_	O
114	(	_	_	O
115	QOL	_	_	O
116	)	_	_	O
117	assessed	_	_	O
118	using	_	_	O
119	the	_	_	O
120	EORTC	_	_	O
121	QLQ-C30	_	_	O
122	and	_	_	O
123	QLQ-LC13	_	_	O
124	questionnaires	_	_	O
125	.	_	_	O

126	Fifty	_	_	O
127	four	_	_	O
128	patients	_	_	O
129	were	_	_	O
130	enrolled	_	_	O
131	.	_	_	O

132	More	_	_	O
133	patients	_	_	O
134	in	_	_	O
135	the	_	_	O
136	11	_	_	O
137	day	_	_	O
138	group	_	_	O
139	had	_	_	O
140	respiratory	_	_	O
141	symptoms	_	_	O
142	at	_	_	O
143	baseline	_	_	O
144	.	_	_	O

145	55.6	_	_	B-Premise
146	%	_	_	I-Premise
147	patients	_	_	I-Premise
148	treated	_	_	I-Premise
149	over	_	_	I-Premise
150	4	_	_	I-Premise
151	days	_	_	I-Premise
152	and	_	_	I-Premise
153	33.3	_	_	I-Premise
154	%	_	_	I-Premise
155	of	_	_	I-Premise
156	patients	_	_	I-Premise
157	treated	_	_	I-Premise
158	over	_	_	I-Premise
159	11	_	_	I-Premise
160	days	_	_	I-Premise
161	experienced	_	_	I-Premise
162	acute	_	_	I-Premise
163	grade	_	_	I-Premise
164	≥	_	_	I-Premise
165	2	_	_	I-Premise
166	toxicity	_	_	I-Premise
167	(	_	_	I-Premise
168	p=0.085	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	Dyspnea	_	_	B-Premise
172	,	_	_	I-Premise
173	fatigue	_	_	I-Premise
174	and	_	_	I-Premise
175	coughing	_	_	I-Premise
176	domains	_	_	I-Premise
177	were	_	_	I-Premise
178	worse	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	11	_	_	I-Premise
182	day	_	_	I-Premise
183	group	_	_	I-Premise
184	at	_	_	I-Premise
185	baseline	_	_	I-Premise
186	.	_	_	I-Premise

187	At	_	_	B-Premise
188	1	_	_	I-Premise
189	and	_	_	I-Premise
190	4	_	_	I-Premise
191	months	_	_	I-Premise
192	,	_	_	I-Premise
193	more	_	_	I-Premise
194	patients	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	4	_	_	I-Premise
198	day	_	_	I-Premise
199	group	_	_	I-Premise
200	experienced	_	_	I-Premise
201	a	_	_	I-Premise
202	clinically	_	_	I-Premise
203	meaningful	_	_	I-Premise
204	worsening	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	dyspnea	_	_	I-Premise
208	QOL	_	_	I-Premise
209	domain	_	_	I-Premise
210	compared	_	_	I-Premise
211	to	_	_	I-Premise
212	the	_	_	I-Premise
213	11	_	_	I-Premise
214	day	_	_	I-Premise
215	group	_	_	I-Premise
216	(	_	_	I-Premise
217	44.5	_	_	I-Premise
218	%	_	_	I-Premise
219	vs	_	_	I-Premise
220	15.4	_	_	I-Premise
221	%	_	_	I-Premise
222	,	_	_	I-Premise
223	p=0.02	_	_	I-Premise
224	;	_	_	I-Premise
225	38.5	_	_	I-Premise
226	%	_	_	I-Premise
227	vs	_	_	I-Premise
228	12.0	_	_	I-Premise
229	%	_	_	I-Premise
230	,	_	_	I-Premise
231	p=0.03	_	_	I-Premise
232	,	_	_	I-Premise
233	respectively	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	However	_	_	B-Premise
237	,	_	_	I-Premise
238	raw	_	_	I-Premise
239	QOL	_	_	I-Premise
240	scores	_	_	I-Premise
241	were	_	_	I-Premise
242	not	_	_	I-Premise
243	different	_	_	I-Premise
244	at	_	_	I-Premise
245	these	_	_	I-Premise
246	time-points	_	_	I-Premise
247	between	_	_	I-Premise
248	treatment	_	_	I-Premise
249	groups	_	_	I-Premise
250	.	_	_	I-Premise

251	Grade	_	_	B-Claim
252	2	_	_	I-Claim
253	or	_	_	I-Claim
254	higher	_	_	I-Claim
255	acute	_	_	I-Claim
256	toxicity	_	_	I-Claim
257	was	_	_	I-Claim
258	more	_	_	I-Claim
259	common	_	_	I-Claim
260	in	_	_	I-Claim
261	the	_	_	I-Claim
262	4	_	_	I-Claim
263	day	_	_	I-Claim
264	group	_	_	I-Claim
265	,	_	_	I-Claim
266	approaching	_	_	I-Claim
267	statistical	_	_	I-Claim
268	significance	_	_	I-Claim
269	.	_	_	I-Claim

270	More	_	_	B-Claim
271	patients	_	_	I-Claim
272	treated	_	_	I-Claim
273	on	_	_	I-Claim
274	4	_	_	I-Claim
275	consecutive	_	_	I-Claim
276	days	_	_	I-Claim
277	reported	_	_	I-Claim
278	a	_	_	I-Claim
279	clinically	_	_	I-Claim
280	meaningful	_	_	I-Claim
281	increase	_	_	I-Claim
282	in	_	_	I-Claim
283	dyspnea	_	_	I-Claim
284	,	_	_	I-Claim
285	although	_	_	B-Claim
286	interpretation	_	_	I-Claim
287	of	_	_	I-Claim
288	these	_	_	I-Claim
289	results	_	_	I-Claim
290	is	_	_	I-Claim
291	challenging	_	_	I-Claim
292	due	_	_	I-Claim
293	to	_	_	I-Claim
294	baseline	_	_	I-Claim
295	imbalance	_	_	I-Claim
296	between	_	_	I-Claim
297	treatment	_	_	I-Claim
298	groups	_	_	I-Claim
299	.	_	_	I-Claim

300	Larger	_	_	B-Claim
301	studies	_	_	I-Claim
302	are	_	_	I-Claim
303	required	_	_	I-Claim
304	to	_	_	I-Claim
305	validate	_	_	I-Claim
306	these	_	_	I-Claim
307	results	_	_	I-Claim
308	.	_	_	I-Claim


0	Patients	_	_	O
1	experience	_	_	O
2	reductions	_	_	O
3	in	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	QOL	_	_	O
9	)	_	_	O
10	while	_	_	O
11	receiving	_	_	O
12	cancer	_	_	O
13	treatment	_	_	O
14	and	_	_	O
15	several	_	_	O
16	approaches	_	_	O
17	have	_	_	O
18	been	_	_	O
19	proposed	_	_	O
20	to	_	_	O
21	address	_	_	O
22	QOL	_	_	O
23	issues	_	_	O
24	.	_	_	O

25	In	_	_	O
26	this	_	_	O
27	project	_	_	O
28	,	_	_	O
29	the	_	_	O
30	QOL	_	_	O
31	differences	_	_	O
32	between	_	_	O
33	older	_	_	O
34	adult	_	_	O
35	(	_	_	O
36	age	_	_	O
37	65+	_	_	O
38	)	_	_	O
39	and	_	_	O
40	younger	_	_	O
41	adult	_	_	O
42	(	_	_	O
43	age	_	_	O
44	18-64	_	_	O
45	)	_	_	O
46	advanced	_	_	O
47	cancer	_	_	O
48	patients	_	_	O
49	in	_	_	O
50	response	_	_	O
51	to	_	_	O
52	a	_	_	O
53	multidisciplinary	_	_	O
54	intervention	_	_	O
55	designed	_	_	O
56	to	_	_	O
57	improve	_	_	O
58	QOL	_	_	O
59	were	_	_	O
60	examined	_	_	O
61	.	_	_	O

62	This	_	_	O
63	study	_	_	O
64	was	_	_	O
65	registered	_	_	O
66	on	_	_	O
67	ClinicalTrials.gov	_	_	O
68	.	_	_	O

69	Newly	_	_	O
70	diagnosed	_	_	O
71	advanced	_	_	O
72	cancer	_	_	O
73	patients	_	_	O
74	undergoing	_	_	O
75	radiation	_	_	O
76	therapy	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	active	_	_	O
81	QOL	_	_	O
82	intervention	_	_	O
83	or	_	_	O
84	control	_	_	O
85	groups	_	_	O
86	.	_	_	O

87	Those	_	_	O
88	in	_	_	O
89	the	_	_	O
90	intervention	_	_	O
91	group	_	_	O
92	received	_	_	O
93	six	_	_	O
94	multidisciplinary	_	_	O
95	90-minute	_	_	O
96	sessions	_	_	O
97	designed	_	_	O
98	to	_	_	O
99	address	_	_	O
100	the	_	_	O
101	five	_	_	O
102	major	_	_	O
103	domains	_	_	O
104	of	_	_	O
105	QOL	_	_	O
106	.	_	_	O

107	Outcomes	_	_	O
108	measured	_	_	O
109	at	_	_	O
110	baseline	_	_	O
111	and	_	_	O
112	weeks	_	_	O
113	4	_	_	O
114	,	_	_	O
115	27	_	_	O
116	,	_	_	O
117	and	_	_	O
118	52	_	_	O
119	included	_	_	O
120	QOL	_	_	O
121	(	_	_	O
122	Linear	_	_	O
123	Analogue	_	_	O
124	Self-Assessment	_	_	O
125	(	_	_	O
126	LASA	_	_	O
127	)	_	_	O
128	,	_	_	O
129	Functional	_	_	O
130	Assessment	_	_	O
131	of	_	_	O
132	Cancer	_	_	O
133	Therapy-General	_	_	O
134	(	_	_	O
135	FACT-G	_	_	O
136	)	_	_	O
137	)	_	_	O
138	and	_	_	O
139	mood	_	_	O
140	(	_	_	O
141	Profile	_	_	O
142	of	_	_	O
143	Mood	_	_	O
144	States	_	_	O
145	(	_	_	O
146	POMS	_	_	O
147	)	_	_	O
148	)	_	_	O
149	.	_	_	O

150	Kruskall-Wallis	_	_	O
151	methodology	_	_	O
152	was	_	_	O
153	used	_	_	O
154	to	_	_	O
155	compare	_	_	O
156	scores	_	_	O
157	between	_	_	O
158	older	_	_	O
159	and	_	_	O
160	younger	_	_	O
161	adult	_	_	O
162	patients	_	_	O
163	randomized	_	_	O
164	to	_	_	O
165	the	_	_	O
166	intervention	_	_	O
167	.	_	_	O

168	Of	_	_	O
169	131	_	_	O
170	patients	_	_	O
171	in	_	_	O
172	the	_	_	O
173	larger	_	_	O
174	randomized	_	_	O
175	controlled	_	_	O
176	study	_	_	O
177	,	_	_	O
178	we	_	_	O
179	report	_	_	O
180	data	_	_	O
181	on	_	_	O
182	54	_	_	O
183	evaluable	_	_	O
184	patients	_	_	O
185	(	_	_	O
186	16	_	_	O
187	older	_	_	O
188	adults	_	_	O
189	and	_	_	O
190	38	_	_	O
191	younger	_	_	O
192	adults	_	_	O
193	)	_	_	O
194	randomized	_	_	O
195	to	_	_	O
196	the	_	_	O
197	intervention	_	_	O
198	.	_	_	O

199	Older	_	_	B-Premise
200	adult	_	_	I-Premise
201	patients	_	_	I-Premise
202	reported	_	_	I-Premise
203	better	_	_	I-Premise
204	overall	_	_	I-Premise
205	QOL	_	_	I-Premise
206	(	_	_	I-Premise
207	LASA	_	_	I-Premise
208	74.4	_	_	I-Premise
209	vs.	_	_	I-Premise
210	62.9	_	_	I-Premise
211	,	_	_	I-Premise
212	p	_	_	I-Premise
213	=	_	_	I-Premise
214	0.040	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	higher	_	_	I-Premise
218	social	_	_	I-Premise
219	well-being	_	_	I-Premise
220	(	_	_	I-Premise
221	FACT-G	_	_	I-Premise
222	91.1	_	_	I-Premise
223	vs.	_	_	I-Premise
224	83.3	_	_	I-Premise
225	,	_	_	I-Premise
226	p	_	_	I-Premise
227	=	_	_	I-Premise
228	0.045	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	fewer	_	_	I-Premise
233	problems	_	_	I-Premise
234	with	_	_	I-Premise
235	anger	_	_	I-Premise
236	(	_	_	I-Premise
237	POMS	_	_	I-Premise
238	anger-hostility	_	_	I-Premise
239	95.0	_	_	I-Premise
240	vs.	_	_	I-Premise
241	86.4	_	_	I-Premise
242	,	_	_	I-Premise
243	p	_	_	I-Premise
244	=	_	_	I-Premise
245	0.028	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Long-term	_	_	B-Premise
249	benefits	_	_	I-Premise
250	for	_	_	I-Premise
251	older	_	_	I-Premise
252	patients	_	_	I-Premise
253	were	_	_	I-Premise
254	seen	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	anger-hostility	_	_	I-Premise
258	scale	_	_	I-Premise
259	at	_	_	I-Premise
260	week	_	_	I-Premise
261	27	_	_	I-Premise
262	(	_	_	I-Premise
263	92.2	_	_	I-Premise
264	vs.	_	_	I-Premise
265	84.2	_	_	I-Premise
266	,	_	_	I-Premise
267	p	_	_	I-Premise
268	=	_	_	I-Premise
269	0.027	_	_	I-Premise
270	)	_	_	I-Premise
271	and	_	_	I-Premise
272	week	_	_	I-Premise
273	52	_	_	I-Premise
274	(	_	_	I-Premise
275	96.3	_	_	I-Premise
276	vs.	_	_	I-Premise
277	85.9	_	_	I-Premise
278	,	_	_	I-Premise
279	p	_	_	I-Premise
280	=	_	_	I-Premise
281	0.005	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	Older	_	_	B-Claim
285	adult	_	_	I-Claim
286	patients	_	_	I-Claim
287	who	_	_	I-Claim
288	received	_	_	I-Claim
289	a	_	_	I-Claim
290	multidisciplinary	_	_	I-Claim
291	intervention	_	_	I-Claim
292	to	_	_	I-Claim
293	improve	_	_	I-Claim
294	QOL	_	_	I-Claim
295	while	_	_	I-Claim
296	undergoing	_	_	I-Claim
297	advanced	_	_	I-Claim
298	cancer	_	_	I-Claim
299	treatments	_	_	I-Claim
300	benefited	_	_	I-Claim
301	differently	_	_	I-Claim
302	in	_	_	I-Claim
303	some	_	_	I-Claim
304	QOL	_	_	I-Claim
305	domains	_	_	I-Claim
306	,	_	_	I-Claim
307	compared	_	_	I-Claim
308	to	_	_	I-Claim
309	younger	_	_	I-Claim
310	adult	_	_	I-Claim
311	patients	_	_	I-Claim
312	.	_	_	I-Claim

313	Future	_	_	O
314	studies	_	_	O
315	can	_	_	O
316	provide	_	_	O
317	further	_	_	O
318	insight	_	_	O
319	on	_	_	O
320	how	_	_	O
321	to	_	_	O
322	tailor	_	_	O
323	QOL	_	_	O
324	interventions	_	_	O
325	for	_	_	O
326	these	_	_	O
327	age	_	_	O
328	groups	_	_	O
329	.	_	_	O


0	Tivozanib	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	potent	_	_	I-Claim
4	and	_	_	I-Claim
5	selective	_	_	I-Claim
6	tyrosine	_	_	I-Claim
7	kinase	_	_	I-Claim
8	inhibitor	_	_	I-Claim
9	of	_	_	I-Claim
10	vascular	_	_	I-Claim
11	endothelial	_	_	I-Claim
12	growth	_	_	I-Claim
13	factor	_	_	I-Claim
14	receptor	_	_	I-Claim
15	1	_	_	I-Claim
16	(	_	_	I-Claim
17	VEGFR1	_	_	I-Claim
18	)	_	_	I-Claim
19	,	_	_	I-Claim
20	-2	_	_	I-Claim
21	,	_	_	I-Claim
22	and	_	_	I-Claim
23	-3	_	_	I-Claim
24	.	_	_	I-Claim

25	This	_	_	O
26	phase	_	_	O
27	III	_	_	O
28	trial	_	_	O
29	compared	_	_	O
30	tivozanib	_	_	O
31	with	_	_	O
32	sorafenib	_	_	O
33	as	_	_	O
34	initial	_	_	O
35	targeted	_	_	O
36	therapy	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	metastatic	_	_	O
41	renal	_	_	O
42	cell	_	_	O
43	carcinoma	_	_	O
44	(	_	_	O
45	RCC	_	_	O
46	)	_	_	O
47	.	_	_	O

48	Patients	_	_	O
49	with	_	_	O
50	metastatic	_	_	O
51	RCC	_	_	O
52	,	_	_	O
53	with	_	_	O
54	a	_	_	O
55	clear	_	_	O
56	cell	_	_	O
57	component	_	_	O
58	,	_	_	O
59	prior	_	_	O
60	nephrectomy	_	_	O
61	,	_	_	O
62	measurable	_	_	O
63	disease	_	_	O
64	,	_	_	O
65	and	_	_	O
66	0	_	_	O
67	or	_	_	O
68	1	_	_	O
69	prior	_	_	O
70	therapies	_	_	O
71	for	_	_	O
72	metastatic	_	_	O
73	RCC	_	_	O
74	were	_	_	O
75	randomly	_	_	O
76	assigned	_	_	O
77	to	_	_	O
78	tivozanib	_	_	O
79	or	_	_	O
80	sorafenib	_	_	O
81	.	_	_	O

82	Prior	_	_	O
83	VEGF-targeted	_	_	O
84	therapy	_	_	O
85	and	_	_	O
86	mammalian	_	_	O
87	target	_	_	O
88	of	_	_	O
89	rapamycin	_	_	O
90	inhibitor	_	_	O
91	were	_	_	O
92	not	_	_	O
93	permitted	_	_	O
94	.	_	_	O

95	The	_	_	O
96	primary	_	_	O
97	end	_	_	O
98	point	_	_	O
99	was	_	_	O
100	progression-free	_	_	O
101	survival	_	_	O
102	(	_	_	O
103	PFS	_	_	O
104	)	_	_	O
105	by	_	_	O
106	independent	_	_	O
107	review	_	_	O
108	.	_	_	O

109	A	_	_	O
110	total	_	_	O
111	of	_	_	O
112	517	_	_	O
113	patients	_	_	O
114	were	_	_	O
115	randomly	_	_	O
116	assigned	_	_	O
117	to	_	_	O
118	tivozanib	_	_	O
119	(	_	_	O
120	n	_	_	O
121	=	_	_	O
122	260	_	_	O
123	)	_	_	O
124	or	_	_	O
125	sorafenib	_	_	O
126	(	_	_	O
127	n	_	_	O
128	=	_	_	O
129	257	_	_	O
130	)	_	_	O
131	.	_	_	O

132	PFS	_	_	B-Premise
133	was	_	_	I-Premise
134	longer	_	_	I-Premise
135	with	_	_	I-Premise
136	tivozanib	_	_	I-Premise
137	than	_	_	I-Premise
138	with	_	_	I-Premise
139	sorafenib	_	_	I-Premise
140	in	_	_	I-Premise
141	the	_	_	I-Premise
142	overall	_	_	I-Premise
143	population	_	_	I-Premise
144	(	_	_	I-Premise
145	median	_	_	I-Premise
146	,	_	_	I-Premise
147	11.9	_	_	I-Premise
148	v	_	_	I-Premise
149	9.1	_	_	I-Premise
150	months	_	_	I-Premise
151	;	_	_	I-Premise
152	hazard	_	_	I-Premise
153	ratio	_	_	I-Premise
154	[	_	_	I-Premise
155	HR	_	_	I-Premise
156	]	_	_	I-Premise
157	,	_	_	I-Premise
158	0.797	_	_	I-Premise
159	;	_	_	I-Premise
160	95	_	_	I-Premise
161	%	_	_	I-Premise
162	CI	_	_	I-Premise
163	,	_	_	I-Premise
164	0.639	_	_	I-Premise
165	to	_	_	I-Premise
166	0.993	_	_	I-Premise
167	;	_	_	I-Premise
168	P	_	_	I-Premise
169	=	_	_	I-Premise
170	.042	_	_	I-Premise
171	)	_	_	I-Premise
172	.	_	_	I-Premise

173	One	_	_	O
174	hundred	_	_	O
175	fifty-six	_	_	O
176	patients	_	_	O
177	(	_	_	O
178	61	_	_	O
179	%	_	_	O
180	)	_	_	O
181	who	_	_	O
182	progressed	_	_	O
183	on	_	_	O
184	sorafenib	_	_	O
185	crossed	_	_	O
186	over	_	_	O
187	to	_	_	O
188	receive	_	_	O
189	tivozanib	_	_	O
190	.	_	_	O

191	The	_	_	B-Premise
192	final	_	_	I-Premise
193	overall	_	_	I-Premise
194	survival	_	_	I-Premise
195	(	_	_	I-Premise
196	OS	_	_	I-Premise
197	)	_	_	I-Premise
198	analysis	_	_	I-Premise
199	showed	_	_	I-Premise
200	a	_	_	I-Premise
201	trend	_	_	I-Premise
202	toward	_	_	I-Premise
203	longer	_	_	I-Premise
204	survival	_	_	I-Premise
205	on	_	_	I-Premise
206	the	_	_	I-Premise
207	sorafenib	_	_	I-Premise
208	arm	_	_	I-Premise
209	than	_	_	I-Premise
210	on	_	_	I-Premise
211	the	_	_	I-Premise
212	tivozanib	_	_	I-Premise
213	arm	_	_	I-Premise
214	(	_	_	I-Premise
215	median	_	_	I-Premise
216	,	_	_	I-Premise
217	29.3	_	_	I-Premise
218	v	_	_	I-Premise
219	28.8	_	_	I-Premise
220	months	_	_	I-Premise
221	;	_	_	I-Premise
222	HR	_	_	I-Premise
223	,	_	_	I-Premise
224	1.245	_	_	I-Premise
225	;	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	,	_	_	I-Premise
230	0.954	_	_	I-Premise
231	to	_	_	I-Premise
232	1.624	_	_	I-Premise
233	;	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	.105	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Adverse	_	_	B-Premise
240	events	_	_	I-Premise
241	(	_	_	I-Premise
242	AEs	_	_	I-Premise
243	)	_	_	I-Premise
244	more	_	_	I-Premise
245	common	_	_	I-Premise
246	with	_	_	I-Premise
247	tivozanib	_	_	I-Premise
248	than	_	_	I-Premise
249	with	_	_	I-Premise
250	sorafenib	_	_	I-Premise
251	were	_	_	I-Premise
252	hypertension	_	_	I-Premise
253	(	_	_	I-Premise
254	44	_	_	I-Premise
255	%	_	_	I-Premise
256	v	_	_	I-Premise
257	34	_	_	I-Premise
258	%	_	_	I-Premise
259	)	_	_	I-Premise
260	and	_	_	I-Premise
261	dysphonia	_	_	I-Premise
262	(	_	_	I-Premise
263	21	_	_	I-Premise
264	%	_	_	I-Premise
265	v	_	_	I-Premise
266	5	_	_	I-Premise
267	%	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	AEs	_	_	B-Premise
271	more	_	_	I-Premise
272	common	_	_	I-Premise
273	with	_	_	I-Premise
274	sorafenib	_	_	I-Premise
275	than	_	_	I-Premise
276	with	_	_	I-Premise
277	tivozanib	_	_	I-Premise
278	were	_	_	I-Premise
279	hand-foot	_	_	I-Premise
280	skin	_	_	I-Premise
281	reaction	_	_	I-Premise
282	(	_	_	I-Premise
283	54	_	_	I-Premise
284	%	_	_	I-Premise
285	v	_	_	I-Premise
286	14	_	_	I-Premise
287	%	_	_	I-Premise
288	)	_	_	I-Premise
289	and	_	_	I-Premise
290	diarrhea	_	_	I-Premise
291	(	_	_	I-Premise
292	33	_	_	I-Premise
293	%	_	_	I-Premise
294	v	_	_	I-Premise
295	23	_	_	I-Premise
296	%	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Tivozanib	_	_	B-Claim
300	demonstrated	_	_	I-Claim
301	improved	_	_	I-Claim
302	PFS	_	_	I-Claim
303	,	_	_	I-Claim
304	but	_	_	I-Claim
305	not	_	_	I-Claim
306	OS	_	_	I-Claim
307	,	_	_	I-Claim
308	and	_	_	I-Claim
309	a	_	_	I-Claim
310	differentiated	_	_	I-Claim
311	safety	_	_	I-Claim
312	profile	_	_	I-Claim
313	,	_	_	I-Claim
314	compared	_	_	I-Claim
315	with	_	_	I-Claim
316	sorafenib	_	_	I-Claim
317	,	_	_	I-Claim
318	as	_	_	I-Claim
319	initial	_	_	I-Claim
320	targeted	_	_	I-Claim
321	therapy	_	_	I-Claim
322	for	_	_	I-Claim
323	metastatic	_	_	I-Claim
324	RCC	_	_	I-Claim
325	.	_	_	I-Claim


0	We	_	_	O
1	analyzed	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	survival	_	_	O
5	of	_	_	O
6	children	_	_	O
7	under	_	_	O
8	6	_	_	O
9	years	_	_	O
10	of	_	_	O
11	age	_	_	O
12	(	_	_	O
13	<	_	_	O
14	6	_	_	O
15	years	_	_	O
16	)	_	_	O
17	enrolled	_	_	O
18	upon	_	_	O
19	the	_	_	O
20	Children	_	_	O
21	's	_	_	O
22	Cancer	_	_	O
23	Group	_	_	O
24	(	_	_	O
25	CCG	_	_	O
26	)	_	_	O
27	-945	_	_	O
28	high-grade	_	_	O
29	glioma	_	_	O
30	(	_	_	O
31	HGG	_	_	O
32	)	_	_	O
33	study	_	_	O
34	to	_	_	O
35	determine	_	_	O
36	the	_	_	O
37	impact	_	_	O
38	of	_	_	O
39	intrinsic	_	_	O
40	biological	_	_	O
41	characteristics	_	_	O
42	as	_	_	O
43	well	_	_	O
44	as	_	_	O
45	treatment	_	_	O
46	upon	_	_	O
47	both	_	_	O
48	survival	_	_	O
49	and	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	(	_	_	O
54	QOL	_	_	O
55	)	_	_	O
56	in	_	_	O
57	this	_	_	O
58	younger	_	_	O
59	age	_	_	O
60	population	_	_	O
61	.	_	_	O

62	Analyses	_	_	O
63	were	_	_	O
64	undertaken	_	_	O
65	on	_	_	O
66	patients	_	_	O
67	<	_	_	O
68	6	_	_	O
69	years	_	_	O
70	with	_	_	O
71	institutionally	_	_	O
72	diagnosed	_	_	O
73	HGG	_	_	O
74	enrolled	_	_	O
75	on	_	_	O
76	the	_	_	O
77	CCG-945	_	_	O
78	trial	_	_	O
79	.	_	_	O

80	Comparisons	_	_	O
81	of	_	_	O
82	survival	_	_	O
83	were	_	_	O
84	performed	_	_	O
85	for	_	_	O
86	patients	_	_	O
87	<	_	_	O
88	3	_	_	O
89	years	_	_	O
90	of	_	_	O
91	age	_	_	O
92	(	_	_	O
93	<	_	_	O
94	3	_	_	O
95	years	_	_	O
96	)	_	_	O
97	(	_	_	O
98	treated	_	_	O
99	with	_	_	O
100	intent	_	_	O
101	to	_	_	O
102	avoid	_	_	O
103	irradiation	_	_	O
104	)	_	_	O
105	versus	_	_	O
106	those	_	_	O
107	between	_	_	O
108	3	_	_	O
109	and	_	_	O
110	6	_	_	O
111	years	_	_	O
112	of	_	_	O
113	age	_	_	O
114	(	_	_	O
115	3-6	_	_	O
116	years	_	_	O
117	)	_	_	O
118	(	_	_	O
119	treated	_	_	O
120	with	_	_	O
121	irradiation	_	_	O
122	and	_	_	O
123	chemotherapy	_	_	O
124	)	_	_	O
125	at	_	_	O
126	diagnosis	_	_	O
127	.	_	_	O

128	Discordance	_	_	O
129	between	_	_	O
130	the	_	_	O
131	institutional	_	_	O
132	diagnoses	_	_	O
133	of	_	_	O
134	HGG	_	_	O
135	and	_	_	O
136	consensus-reviewed	_	_	O
137	diagnoses	_	_	O
138	led	_	_	O
139	us	_	_	O
140	to	_	_	O
141	perform	_	_	O
142	further	_	_	O
143	survival	_	_	O
144	analyses	_	_	O
145	for	_	_	O
146	both	_	_	O
147	groups	_	_	O
148	.	_	_	O

149	We	_	_	O
150	compared	_	_	O
151	the	_	_	O
152	two	_	_	O
153	groups	_	_	O
154	of	_	_	O
155	patients	_	_	O
156	for	_	_	O
157	biological	_	_	O
158	markers	_	_	O
159	,	_	_	O
160	and	_	_	O
161	evaluated	_	_	O
162	the	_	_	O
163	neuropsychological	_	_	O
164	and	_	_	O
165	QOL	_	_	O
166	outcomes	_	_	O
167	of	_	_	O
168	long-term	_	_	O
169	survivors	_	_	O
170	.	_	_	O

171	Patients	_	_	B-Premise
172	<	_	_	I-Premise
173	3	_	_	I-Premise
174	years	_	_	I-Premise
175	(	_	_	I-Premise
176	n	_	_	I-Premise
177	=	_	_	I-Premise
178	49	_	_	I-Premise
179	,	_	_	I-Premise
180	19.5	_	_	I-Premise
181	%	_	_	I-Premise
182	of	_	_	I-Premise
183	all	_	_	I-Premise
184	enrolled	_	_	I-Premise
185	patients	_	_	I-Premise
186	)	_	_	I-Premise
187	at	_	_	I-Premise
188	diagnosis	_	_	I-Premise
189	had	_	_	I-Premise
190	a	_	_	I-Premise
191	10-year	_	_	I-Premise
192	EFS	_	_	I-Premise
193	and	_	_	I-Premise
194	OS	_	_	I-Premise
195	of	_	_	I-Premise
196	29	_	_	I-Premise
197	±	_	_	I-Premise
198	6.5	_	_	I-Premise
199	%	_	_	I-Premise
200	and	_	_	I-Premise
201	37.5	_	_	I-Premise
202	±	_	_	I-Premise
203	7	_	_	I-Premise
204	%	_	_	I-Premise
205	,	_	_	I-Premise
206	respectively	_	_	I-Premise
207	,	_	_	I-Premise
208	while	_	_	I-Premise
209	for	_	_	I-Premise
210	patients	_	_	I-Premise
211	3-6	_	_	I-Premise
212	years	_	_	I-Premise
213	(	_	_	I-Premise
214	n	_	_	I-Premise
215	=	_	_	I-Premise
216	34	_	_	I-Premise
217	,	_	_	I-Premise
218	13.5	_	_	I-Premise
219	%	_	_	I-Premise
220	of	_	_	I-Premise
221	all	_	_	I-Premise
222	enrolled	_	_	I-Premise
223	patients	_	_	I-Premise
224	)	_	_	I-Premise
225	10-year	_	_	I-Premise
226	EFS	_	_	I-Premise
227	and	_	_	I-Premise
228	OS	_	_	I-Premise
229	were	_	_	I-Premise
230	35	_	_	I-Premise
231	±	_	_	I-Premise
232	8	_	_	I-Premise
233	%	_	_	I-Premise
234	and	_	_	I-Premise
235	36	_	_	I-Premise
236	±	_	_	I-Premise
237	8	_	_	I-Premise
238	%	_	_	I-Premise
239	,	_	_	I-Premise
240	respectively	_	_	I-Premise
241	.	_	_	I-Premise

242	Molecular	_	_	B-Premise
243	marker	_	_	I-Premise
244	analysis	_	_	I-Premise
245	showed	_	_	I-Premise
246	that	_	_	I-Premise
247	a	_	_	I-Premise
248	smaller	_	_	I-Premise
249	proportion	_	_	I-Premise
250	of	_	_	I-Premise
251	patients	_	_	I-Premise
252	<	_	_	I-Premise
253	3	_	_	I-Premise
254	years	_	_	I-Premise
255	harbored	_	_	I-Premise
256	TP53	_	_	I-Premise
257	mutations	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	0.05	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Analysis	_	_	B-Premise
265	of	_	_	I-Premise
266	QOL	_	_	I-Premise
267	outcomes	_	_	I-Premise
268	with	_	_	I-Premise
269	a	_	_	I-Premise
270	median	_	_	I-Premise
271	length	_	_	I-Premise
272	of	_	_	I-Premise
273	follow-up	_	_	I-Premise
274	of	_	_	I-Premise
275	15.1	_	_	I-Premise
276	years	_	_	I-Premise
277	(	_	_	I-Premise
278	9.5-19.2	_	_	I-Premise
279	)	_	_	I-Premise
280	showed	_	_	I-Premise
281	comparable	_	_	I-Premise
282	results	_	_	I-Premise
283	.	_	_	I-Premise

284	QOL	_	_	B-Claim
285	and	_	_	I-Claim
286	survival	_	_	I-Claim
287	data	_	_	I-Claim
288	were	_	_	I-Claim
289	similar	_	_	I-Claim
290	for	_	_	I-Claim
291	the	_	_	I-Claim
292	two	_	_	I-Claim
293	groups	_	_	I-Claim
294	.	_	_	I-Claim

295	A	_	_	B-Claim
296	larger	_	_	I-Claim
297	prospective	_	_	I-Claim
298	study	_	_	I-Claim
299	is	_	_	I-Claim
300	justified	_	_	I-Claim
301	to	_	_	I-Claim
302	study	_	_	I-Claim
303	the	_	_	I-Claim
304	efficacy	_	_	I-Claim
305	of	_	_	I-Claim
306	chemotherapy	_	_	I-Claim
307	only	_	_	I-Claim
308	regimens	_	_	I-Claim
309	in	_	_	I-Claim
310	younger	_	_	I-Claim
311	children	_	_	I-Claim
312	.	_	_	I-Claim


0	Postcancer	_	_	B-Claim
1	fatigue	_	_	I-Claim
2	is	_	_	I-Claim
3	a	_	_	I-Claim
4	frequently	_	_	I-Claim
5	occurring	_	_	I-Claim
6	problem	_	_	I-Claim
7	,	_	_	I-Claim
8	impairing	_	_	I-Claim
9	quality	_	_	I-Claim
10	of	_	_	I-Claim
11	life	_	_	I-Claim
12	.	_	_	I-Claim

13	Until	_	_	O
14	now	_	_	O
15	,	_	_	O
16	little	_	_	O
17	is	_	_	O
18	known	_	_	O
19	about	_	_	O
20	(	_	_	O
21	neuro	_	_	O
22	)	_	_	O
23	physiological	_	_	O
24	factors	_	_	O
25	determining	_	_	O
26	postcancer	_	_	O
27	fatigue	_	_	O
28	.	_	_	O

29	For	_	_	O
30	non-cancer	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	chronic	_	_	O
34	fatigue	_	_	O
35	syndrome	_	_	O
36	,	_	_	O
37	certain	_	_	O
38	characteristics	_	_	O
39	of	_	_	O
40	brain	_	_	O
41	morphology	_	_	O
42	and	_	_	O
43	metabolism	_	_	O
44	have	_	_	O
45	been	_	_	O
46	identified	_	_	O
47	in	_	_	O
48	previous	_	_	O
49	studies	_	_	O
50	.	_	_	O

51	We	_	_	O
52	investigated	_	_	O
53	whether	_	_	O
54	these	_	_	O
55	volumetric	_	_	O
56	and	_	_	O
57	metabolic	_	_	O
58	traits	_	_	O
59	are	_	_	O
60	a	_	_	O
61	reflection	_	_	O
62	of	_	_	O
63	fatigue	_	_	O
64	in	_	_	O
65	general	_	_	O
66	and	_	_	O
67	thus	_	_	O
68	also	_	_	O
69	of	_	_	O
70	importance	_	_	O
71	for	_	_	O
72	postcancer	_	_	O
73	fatigue	_	_	O
74	.	_	_	O

75	Fatigued	_	_	O
76	patients	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	either	_	_	O
82	the	_	_	O
83	intervention	_	_	O
84	condition	_	_	O
85	(	_	_	O
86	cognitive	_	_	O
87	behavior	_	_	O
88	therapy	_	_	O
89	)	_	_	O
90	or	_	_	O
91	the	_	_	O
92	waiting	_	_	O
93	list	_	_	O
94	condition	_	_	O
95	.	_	_	O

96	Twenty-five	_	_	O
97	patients	_	_	O
98	in	_	_	O
99	the	_	_	O
100	intervention	_	_	O
101	condition	_	_	O
102	and	_	_	O
103	fourteen	_	_	O
104	patients	_	_	O
105	in	_	_	O
106	the	_	_	O
107	waiting	_	_	O
108	list	_	_	O
109	condition	_	_	O
110	were	_	_	O
111	assessed	_	_	O
112	twice	_	_	O
113	,	_	_	O
114	at	_	_	O
115	baseline	_	_	O
116	and	_	_	O
117	six	_	_	O
118	months	_	_	O
119	later	_	_	O
120	.	_	_	O

121	Baseline	_	_	O
122	measurements	_	_	O
123	of	_	_	O
124	20	_	_	O
125	fatigued	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	compared	_	_	O
129	with	_	_	O
130	20	_	_	O
131	matched	_	_	O
132	non-fatigued	_	_	O
133	controls	_	_	O
134	.	_	_	O

135	All	_	_	O
136	participants	_	_	O
137	had	_	_	O
138	completed	_	_	O
139	treatment	_	_	O
140	of	_	_	O
141	a	_	_	O
142	malignant	_	_	O
143	,	_	_	O
144	solid	_	_	O
145	tumor	_	_	O
146	minimal	_	_	O
147	one	_	_	O
148	year	_	_	O
149	earlier	_	_	O
150	.	_	_	O

151	Global	_	_	O
152	brain	_	_	O
153	volumes	_	_	O
154	,	_	_	O
155	subcortical	_	_	O
156	brain	_	_	O
157	volumes	_	_	O
158	,	_	_	O
159	metabolite	_	_	O
160	tissue	_	_	O
161	concentrations	_	_	O
162	,	_	_	O
163	and	_	_	O
164	metabolite	_	_	O
165	ratios	_	_	O
166	were	_	_	O
167	primary	_	_	O
168	outcome	_	_	O
169	measures	_	_	O
170	.	_	_	O

171	Volumetric	_	_	O
172	and	_	_	O
173	metabolic	_	_	O
174	parameters	_	_	O
175	were	_	_	O
176	not	_	_	O
177	significantly	_	_	O
178	different	_	_	O
179	between	_	_	O
180	fatigued	_	_	O
181	and	_	_	O
182	non-fatigued	_	_	O
183	patients	_	_	O
184	.	_	_	O

185	Change	_	_	B-Premise
186	scores	_	_	I-Premise
187	of	_	_	I-Premise
188	volumetric	_	_	I-Premise
189	and	_	_	I-Premise
190	metabolic	_	_	I-Premise
191	parameters	_	_	I-Premise
192	from	_	_	I-Premise
193	baseline	_	_	I-Premise
194	to	_	_	I-Premise
195	follow-up	_	_	I-Premise
196	were	_	_	I-Premise
197	not	_	_	I-Premise
198	significantly	_	_	I-Premise
199	different	_	_	I-Premise
200	between	_	_	I-Premise
201	patients	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	therapy	_	_	I-Premise
205	and	_	_	I-Premise
206	the	_	_	I-Premise
207	waiting	_	_	I-Premise
208	list	_	_	I-Premise
209	group	_	_	I-Premise
210	.	_	_	I-Premise

211	Patients	_	_	B-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	therapy	_	_	I-Premise
215	group	_	_	I-Premise
216	reported	_	_	I-Premise
217	a	_	_	I-Premise
218	significant	_	_	I-Premise
219	larger	_	_	I-Premise
220	decrease	_	_	I-Premise
221	in	_	_	I-Premise
222	fatigue	_	_	I-Premise
223	scores	_	_	I-Premise
224	than	_	_	I-Premise
225	patients	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	waiting	_	_	I-Premise
229	list	_	_	I-Premise
230	group	_	_	I-Premise
231	.	_	_	I-Premise

232	No	_	_	B-Premise
233	relation	_	_	I-Premise
234	was	_	_	I-Premise
235	found	_	_	I-Premise
236	between	_	_	I-Premise
237	postcancer	_	_	I-Premise
238	fatigue	_	_	I-Premise
239	and	_	_	I-Premise
240	the	_	_	I-Premise
241	studied	_	_	I-Premise
242	volumetric	_	_	I-Premise
243	and	_	_	I-Premise
244	metabolic	_	_	I-Premise
245	markers	_	_	I-Premise
246	.	_	_	I-Premise

247	This	_	_	B-Claim
248	may	_	_	I-Claim
249	suggest	_	_	I-Claim
250	that	_	_	I-Claim
251	,	_	_	I-Claim
252	although	_	_	I-Claim
253	postcancer	_	_	I-Claim
254	fatigue	_	_	I-Claim
255	and	_	_	I-Claim
256	chronic	_	_	I-Claim
257	fatigue	_	_	I-Claim
258	syndrome	_	_	I-Claim
259	show	_	_	I-Claim
260	strong	_	_	I-Claim
261	resemblances	_	_	I-Claim
262	as	_	_	I-Claim
263	a	_	_	I-Claim
264	clinical	_	_	I-Claim
265	syndrome	_	_	I-Claim
266	,	_	_	I-Claim
267	the	_	_	I-Claim
268	underlying	_	_	I-Claim
269	physiology	_	_	I-Claim
270	is	_	_	I-Claim
271	different	_	_	I-Claim
272	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	course	_	_	O
5	,	_	_	O
6	treatment	_	_	O
7	,	_	_	O
8	complications	_	_	O
9	,	_	_	O
10	outcome	_	_	O
11	,	_	_	O
12	and	_	_	O
13	quality	_	_	O
14	of	_	_	O
15	life	_	_	O
16	(	_	_	O
17	QOL	_	_	O
18	)	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	perineal/perianal	_	_	O
23	rhabdomyosarcoma	_	_	O
24	(	_	_	O
25	PRMS	_	_	O
26	)	_	_	O
27	treated	_	_	O
28	within	_	_	O
29	the	_	_	O
30	CWS-86	_	_	O
31	,	_	_	O
32	-91	_	_	O
33	,	_	_	O
34	-96	_	_	O
35	,	_	_	O
36	and	_	_	O
37	-2002P	_	_	O
38	trials	_	_	O
39	.	_	_	O

40	Although	_	_	O
41	multiple	_	_	O
42	international	_	_	O
43	study	_	_	O
44	trials	_	_	O
45	exist	_	_	O
46	for	_	_	O
47	the	_	_	O
48	treatment	_	_	O
49	of	_	_	O
50	rhabdomyosarcoma	_	_	O
51	,	_	_	O
52	only	_	_	O
53	very	_	_	O
54	limited	_	_	O
55	information	_	_	O
56	is	_	_	O
57	given	_	_	O
58	on	_	_	O
59	treatment	_	_	O
60	,	_	_	O
61	outcome	_	_	O
62	,	_	_	O
63	and	_	_	O
64	QOL	_	_	O
65	in	_	_	O
66	PRMS	_	_	O
67	.	_	_	O

68	A	_	_	O
69	total	_	_	O
70	of	_	_	O
71	35	_	_	O
72	patients	_	_	O
73	suffering	_	_	O
74	from	_	_	O
75	PRMS	_	_	O
76	were	_	_	O
77	treated	_	_	O
78	with	_	_	O
79	neoadjuvant	_	_	O
80	chemotherapy	_	_	O
81	.	_	_	O

82	Local	_	_	O
83	therapy	_	_	O
84	with	_	_	O
85	radiation	_	_	O
86	and/or	_	_	O
87	surgery	_	_	O
88	was	_	_	O
89	performed	_	_	O
90	,	_	_	O
91	followed	_	_	O
92	by	_	_	O
93	adjuvant	_	_	O
94	chemotherapy	_	_	O
95	.	_	_	O

96	Functional	_	_	O
97	long-term	_	_	O
98	follow-up	_	_	O
99	was	_	_	O
100	evaluated	_	_	O
101	by	_	_	O
102	a	_	_	O
103	gastrointestinal/QOL	_	_	O
104	survey	_	_	O
105	.	_	_	O

106	Thirty-two	_	_	O
107	patients	_	_	O
108	were	_	_	O
109	evaluated	_	_	O
110	(	_	_	O
111	exclusion	_	_	O
112	n	_	_	O
113	=	_	_	O
114	3	_	_	O
115	)	_	_	O
116	.	_	_	O

117	Eight	_	_	O
118	patients	_	_	O
119	had	_	_	O
120	embryonal	_	_	O
121	histology	_	_	O
122	,	_	_	O
123	and	_	_	O
124	24	_	_	O
125	patients	_	_	O
126	had	_	_	O
127	alveolar	_	_	O
128	histology	_	_	O
129	.	_	_	O

130	The	_	_	O
131	median	_	_	O
132	age	_	_	O
133	was	_	_	O
134	108	_	_	O
135	months	_	_	O
136	(	_	_	O
137	median	_	_	O
138	follow-up	_	_	O
139	:	_	_	O
140	5.8	_	_	O
141	years	_	_	O
142	)	_	_	O
143	.	_	_	O

144	The	_	_	O
145	5-year	_	_	O
146	overall	_	_	O
147	survival	_	_	O
148	was	_	_	O
149	47	_	_	O
150	%	_	_	O
151	(	_	_	O
152	95	_	_	O
153	%	_	_	O
154	confidence	_	_	O
155	interval	_	_	O
156	:	_	_	O
157	29-64	_	_	O
158	)	_	_	O
159	.	_	_	O

160	Sixteen	_	_	O
161	IRS	_	_	O
162	(	_	_	O
163	Intergroup	_	_	O
164	Rhabdomyosarcoma	_	_	O
165	Study	_	_	O
166	)	_	_	O
167	III	_	_	O
168	and	_	_	O
169	IV	_	_	O
170	patients	_	_	O
171	had	_	_	O
172	locoregional	_	_	O
173	lymph	_	_	O
174	node	_	_	O
175	involvement	_	_	O
176	at	_	_	O
177	diagnosis	_	_	O
178	.	_	_	O

179	Seven	_	_	O
180	patients	_	_	O
181	were	_	_	O
182	treated	_	_	O
183	with	_	_	O
184	chemotherapy/surgery	_	_	O
185	alone	_	_	O
186	[	_	_	O
187	5-year	_	_	O
188	event-free	_	_	O
189	survival	_	_	O
190	(	_	_	O
191	EFS	_	_	O
192	)	_	_	O
193	:	_	_	O
194	85.7	_	_	O
195	%	_	_	O
196	]	_	_	O
197	.	_	_	O

198	Eleven	_	_	O
199	patients	_	_	O
200	received	_	_	O
201	only	_	_	O
202	radiochemotherapy	_	_	O
203	(	_	_	O
204	5-year	_	_	O
205	EFS	_	_	O
206	:	_	_	O
207	27.3	_	_	O
208	%	_	_	O
209	)	_	_	O
210	.	_	_	O

211	Combined	_	_	O
212	radiochemotherapy/surgery	_	_	O
213	was	_	_	O
214	used	_	_	O
215	in	_	_	O
216	12	_	_	O
217	patients	_	_	O
218	(	_	_	O
219	5-year	_	_	O
220	EFS	_	_	O
221	:	_	_	O
222	63.6	_	_	O
223	%	_	_	O
224	)	_	_	O
225	.	_	_	O

226	Two	_	_	O
227	patients	_	_	O
228	were	_	_	O
229	treated	_	_	O
230	only	_	_	O
231	with	_	_	O
232	chemotherapy	_	_	O
233	and	_	_	O
234	they	_	_	O
235	died	_	_	O
236	.	_	_	O

237	Patients	_	_	B-Premise
238	with	_	_	I-Premise
239	embryonal	_	_	I-Premise
240	histology	_	_	I-Premise
241	had	_	_	I-Premise
242	a	_	_	I-Premise
243	significantly	_	_	I-Premise
244	better	_	_	I-Premise
245	5-year	_	_	I-Premise
246	EFS	_	_	I-Premise
247	(	_	_	I-Premise
248	87.5	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	than	_	_	I-Premise
252	patients	_	_	I-Premise
253	with	_	_	I-Premise
254	alveolar	_	_	I-Premise
255	histology	_	_	I-Premise
256	(	_	_	I-Premise
257	39.1	_	_	I-Premise
258	%	_	_	I-Premise
259	;	_	_	I-Premise
260	P	_	_	I-Premise
261	=	_	_	I-Premise
262	0.013	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Some	_	_	B-Premise
266	patients	_	_	I-Premise
267	reported	_	_	I-Premise
268	symptoms	_	_	I-Premise
269	of	_	_	I-Premise
270	fecal	_	_	I-Premise
271	incontinence	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	median	_	_	I-Premise
275	Wexner	_	_	I-Premise
276	fecal	_	_	I-Premise
277	incontinence	_	_	I-Premise
278	score	_	_	I-Premise
279	was	_	_	I-Premise
280	9	_	_	I-Premise
281	(	_	_	I-Premise
282	possible	_	_	I-Premise
283	range	_	_	I-Premise
284	:	_	_	I-Premise
285	0-20	_	_	I-Premise
286	)	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	the	_	_	I-Premise
290	median	_	_	I-Premise
291	QOL	_	_	I-Premise
292	score	_	_	I-Premise
293	was	_	_	I-Premise
294	90.5	_	_	I-Premise
295	(	_	_	I-Premise
296	applicable	_	_	I-Premise
297	range	_	_	I-Premise
298	:	_	_	I-Premise
299	0-144	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	The	_	_	B-Claim
303	outcome	_	_	I-Claim
304	of	_	_	I-Claim
305	these	_	_	I-Claim
306	patients	_	_	I-Claim
307	remains	_	_	I-Claim
308	unsatisfactory	_	_	I-Claim
309	.	_	_	I-Claim

310	Prognostic	_	_	B-Premise
311	factors	_	_	I-Premise
312	for	_	_	I-Premise
313	a	_	_	I-Premise
314	favorable	_	_	I-Premise
315	outcome	_	_	I-Premise
316	are	_	_	I-Premise
317	tumor	_	_	I-Premise
318	size	_	_	I-Premise
319	of	_	_	I-Premise
320	smaller	_	_	I-Premise
321	than	_	_	I-Premise
322	5	_	_	I-Premise
323	cm	_	_	I-Premise
324	,	_	_	I-Premise
325	negative	_	_	I-Premise
326	locoregional	_	_	I-Premise
327	lymph	_	_	I-Premise
328	nodes	_	_	I-Premise
329	,	_	_	I-Premise
330	age	_	_	I-Premise
331	less	_	_	I-Premise
332	than	_	_	I-Premise
333	10	_	_	I-Premise
334	years	_	_	I-Premise
335	,	_	_	I-Premise
336	low	_	_	I-Premise
337	IRS	_	_	I-Premise
338	group	_	_	I-Premise
339	,	_	_	I-Premise
340	and	_	_	I-Premise
341	embryonal	_	_	I-Premise
342	histology	_	_	I-Premise
343	.	_	_	I-Premise

344	Fecal	_	_	B-Claim
345	incontinence	_	_	I-Claim
346	seems	_	_	I-Claim
347	to	_	_	I-Claim
348	be	_	_	I-Claim
349	a	_	_	I-Claim
350	problem	_	_	I-Claim
351	.	_	_	I-Claim


0	Chronic	_	_	O
1	gastrointestinal	_	_	O
2	symptoms	_	_	O
3	after	_	_	O
4	pelvic	_	_	O
5	radiotherapy	_	_	O
6	are	_	_	O
7	common	_	_	O
8	,	_	_	O
9	multifactorial	_	_	O
10	in	_	_	O
11	cause	_	_	O
12	,	_	_	O
13	and	_	_	O
14	affect	_	_	O
15	patients	_	_	O
16	'	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	.	_	_	O

21	We	_	_	O
22	assessed	_	_	O
23	whether	_	_	O
24	such	_	_	O
25	patients	_	_	O
26	could	_	_	O
27	be	_	_	O
28	helped	_	_	O
29	if	_	_	O
30	a	_	_	O
31	practitioner	_	_	O
32	followed	_	_	O
33	an	_	_	O
34	investigative	_	_	O
35	and	_	_	O
36	management	_	_	O
37	algorithm	_	_	O
38	,	_	_	O
39	and	_	_	O
40	whether	_	_	O
41	outcomes	_	_	O
42	differed	_	_	O
43	by	_	_	O
44	whether	_	_	O
45	a	_	_	O
46	nurse	_	_	O
47	or	_	_	O
48	a	_	_	O
49	gastroenterologist	_	_	O
50	led	_	_	O
51	this	_	_	O
52	algorithm-based	_	_	O
53	care	_	_	O
54	.	_	_	O

55	For	_	_	O
56	this	_	_	O
57	three-arm	_	_	O
58	randomised	_	_	O
59	controlled	_	_	O
60	trial	_	_	O
61	we	_	_	O
62	recruited	_	_	O
63	patients	_	_	O
64	(	_	_	O
65	aged	_	_	O
66	≥18	_	_	O
67	years	_	_	O
68	)	_	_	O
69	from	_	_	O
70	clinics	_	_	O
71	in	_	_	O
72	London	_	_	O
73	,	_	_	O
74	UK	_	_	O
75	,	_	_	O
76	with	_	_	O
77	new-onset	_	_	O
78	gastrointestinal	_	_	O
79	symptoms	_	_	O
80	persisting	_	_	O
81	6	_	_	O
82	months	_	_	O
83	after	_	_	O
84	pelvic	_	_	O
85	radiotherapy	_	_	O
86	.	_	_	O

87	Using	_	_	O
88	a	_	_	O
89	computer-generated	_	_	O
90	randomisation	_	_	O
91	sequence	_	_	O
92	,	_	_	O
93	we	_	_	O
94	randomly	_	_	O
95	allocated	_	_	O
96	patients	_	_	O
97	to	_	_	O
98	one	_	_	O
99	of	_	_	O
100	three	_	_	O
101	groups	_	_	O
102	(	_	_	O
103	1:1:1	_	_	O
104	;	_	_	O
105	stratified	_	_	O
106	by	_	_	O
107	tumour	_	_	O
108	site	_	_	O
109	[	_	_	O
110	urological	_	_	O
111	,	_	_	O
112	gynaecological	_	_	O
113	,	_	_	O
114	or	_	_	O
115	gastrointestinal	_	_	O
116	]	_	_	O
117	,	_	_	O
118	and	_	_	O
119	degree	_	_	O
120	of	_	_	O
121	bowel	_	_	O
122	dysfunction	_	_	O
123	[	_	_	O
124	IBDQ-B	_	_	O
125	score	_	_	O
126	<	_	_	O
127	60	_	_	O
128	vs	_	_	O
129	60-70	_	_	O
130	]	_	_	O
131	)	_	_	O
132	:	_	_	O
133	usual	_	_	O
134	care	_	_	O
135	(	_	_	O
136	a	_	_	O
137	detailed	_	_	O
138	self-help	_	_	O
139	booklet	_	_	O
140	)	_	_	O
141	,	_	_	O
142	gastroenterologist-led	_	_	O
143	algorithm-based	_	_	O
144	treatment	_	_	O
145	,	_	_	O
146	or	_	_	O
147	nurse-led	_	_	O
148	algorithm-based	_	_	O
149	treatment	_	_	O
150	.	_	_	O

151	The	_	_	O
152	primary	_	_	O
153	endpoint	_	_	O
154	was	_	_	O
155	change	_	_	O
156	in	_	_	O
157	Inflammatory	_	_	O
158	Bowel	_	_	O
159	Disease	_	_	O
160	Questionnaire-Bowel	_	_	O
161	subset	_	_	O
162	score	_	_	O
163	(	_	_	O
164	IBDQ-B	_	_	O
165	)	_	_	O
166	at	_	_	O
167	6	_	_	O
168	months	_	_	O
169	,	_	_	O
170	analysed	_	_	O
171	by	_	_	O
172	intention	_	_	O
173	to	_	_	O
174	treat	_	_	O
175	.	_	_	O

176	Between	_	_	O
177	Nov	_	_	O
178	26	_	_	O
179	,	_	_	O
180	2007	_	_	O
181	,	_	_	O
182	and	_	_	O
183	Dec	_	_	O
184	12	_	_	O
185	,	_	_	O
186	2011	_	_	O
187	,	_	_	O
188	we	_	_	O
189	enrolled	_	_	O
190	and	_	_	O
191	randomly	_	_	O
192	allocated	_	_	O
193	218	_	_	O
194	patients	_	_	O
195	to	_	_	O
196	treatment	_	_	O
197	:	_	_	O
198	80	_	_	O
199	to	_	_	O
200	the	_	_	O
201	nurse	_	_	O
202	group	_	_	O
203	,	_	_	O
204	70	_	_	O
205	to	_	_	O
206	the	_	_	O
207	gastroenterologist	_	_	O
208	group	_	_	O
209	,	_	_	O
210	and	_	_	O
211	68	_	_	O
212	to	_	_	O
213	the	_	_	O
214	booklet	_	_	O
215	group	_	_	O
216	(	_	_	O
217	figure	_	_	O
218	)	_	_	O
219	.	_	_	O

220	Most	_	_	O
221	had	_	_	O
222	a	_	_	O
223	baseline	_	_	O
224	IBDQ-B	_	_	O
225	score	_	_	O
226	indicating	_	_	O
227	moderate-to-severe	_	_	O
228	symptoms	_	_	O
229	.	_	_	O

230	We	_	_	B-Premise
231	recorded	_	_	I-Premise
232	the	_	_	I-Premise
233	following	_	_	I-Premise
234	pair-wise	_	_	I-Premise
235	mean	_	_	I-Premise
236	difference	_	_	I-Premise
237	in	_	_	I-Premise
238	change	_	_	I-Premise
239	in	_	_	I-Premise
240	IBDQ-B	_	_	I-Premise
241	score	_	_	I-Premise
242	between	_	_	I-Premise
243	groups	_	_	I-Premise
244	:	_	_	I-Premise
245	nurse	_	_	I-Premise
246	versus	_	_	I-Premise
247	booklet	_	_	I-Premise
248	4·12	_	_	I-Premise
249	(	_	_	I-Premise
250	95	_	_	I-Premise
251	%	_	_	I-Premise
252	CI	_	_	I-Premise
253	0·04-8·19	_	_	I-Premise
254	;	_	_	I-Premise
255	p=0·04	_	_	I-Premise
256	)	_	_	I-Premise
257	,	_	_	I-Premise
258	gastroenterologist	_	_	I-Premise
259	versus	_	_	I-Premise
260	booklet	_	_	I-Premise
261	5·47	_	_	I-Premise
262	(	_	_	I-Premise
263	1·14-9·81	_	_	I-Premise
264	;	_	_	I-Premise
265	p=0·01	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	Outcomes	_	_	B-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	nurse	_	_	I-Premise
272	group	_	_	I-Premise
273	were	_	_	I-Premise
274	not	_	_	I-Premise
275	inferior	_	_	I-Premise
276	to	_	_	I-Premise
277	outcomes	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	gastroenterologist	_	_	I-Premise
281	group	_	_	I-Premise
282	(	_	_	I-Premise
283	mean	_	_	I-Premise
284	difference	_	_	I-Premise
285	1·36	_	_	I-Premise
286	,	_	_	I-Premise
287	one	_	_	I-Premise
288	sided	_	_	I-Premise
289	95	_	_	I-Premise
290	%	_	_	I-Premise
291	CI	_	_	I-Premise
292	-1·48	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Patients	_	_	B-Claim
296	given	_	_	I-Claim
297	targeted	_	_	I-Claim
298	intervention	_	_	I-Claim
299	following	_	_	I-Claim
300	a	_	_	I-Claim
301	detailed	_	_	I-Claim
302	clinical	_	_	I-Claim
303	algorithm	_	_	I-Claim
304	had	_	_	I-Claim
305	better	_	_	I-Claim
306	improvements	_	_	I-Claim
307	in	_	_	I-Claim
308	radiotherapy-induced	_	_	I-Claim
309	gastrointestinal	_	_	I-Claim
310	symptoms	_	_	I-Claim
311	than	_	_	I-Claim
312	did	_	_	I-Claim
313	patients	_	_	I-Claim
314	given	_	_	I-Claim
315	usual	_	_	I-Claim
316	care	_	_	I-Claim
317	.	_	_	I-Claim

318	Our	_	_	B-Claim
319	findings	_	_	I-Claim
320	suggest	_	_	I-Claim
321	that	_	_	I-Claim
322	,	_	_	I-Claim
323	for	_	_	I-Claim
324	most	_	_	I-Claim
325	patients	_	_	I-Claim
326	,	_	_	I-Claim
327	this	_	_	I-Claim
328	algorithm-based	_	_	I-Claim
329	care	_	_	I-Claim
330	can	_	_	I-Claim
331	be	_	_	I-Claim
332	given	_	_	I-Claim
333	by	_	_	I-Claim
334	a	_	_	I-Claim
335	trained	_	_	I-Claim
336	nurse	_	_	I-Claim
337	.	_	_	I-Claim


0	Abiraterone	_	_	B-Claim
1	acetate	_	_	I-Claim
2	plus	_	_	I-Claim
3	prednisone	_	_	I-Claim
4	significantly	_	_	I-Claim
5	improves	_	_	I-Claim
6	radiographic	_	_	I-Claim
7	progression-free	_	_	I-Claim
8	survival	_	_	I-Claim
9	in	_	_	I-Claim
10	asymptomatic	_	_	I-Claim
11	or	_	_	I-Claim
12	mildly	_	_	I-Claim
13	symptomatic	_	_	I-Claim
14	,	_	_	I-Claim
15	chemotherapy-naive	_	_	I-Claim
16	patients	_	_	I-Claim
17	with	_	_	I-Claim
18	metastatic	_	_	I-Claim
19	castration-resistant	_	_	I-Claim
20	prostate	_	_	I-Claim
21	cancer	_	_	I-Claim
22	compared	_	_	I-Claim
23	with	_	_	I-Claim
24	prednisone	_	_	I-Claim
25	alone	_	_	I-Claim
26	.	_	_	I-Claim

27	We	_	_	O
28	describe	_	_	O
29	analyses	_	_	O
30	of	_	_	O
31	data	_	_	O
32	for	_	_	O
33	patient-reported	_	_	O
34	pain	_	_	O
35	and	_	_	O
36	functional	_	_	O
37	status	_	_	O
38	in	_	_	O
39	a	_	_	O
40	preplanned	_	_	O
41	interim	_	_	O
42	analysis	_	_	O
43	of	_	_	O
44	a	_	_	O
45	phase	_	_	O
46	3	_	_	O
47	trial	_	_	O
48	.	_	_	O

49	Between	_	_	O
50	April	_	_	O
51	28	_	_	O
52	,	_	_	O
53	2009	_	_	O
54	,	_	_	O
55	and	_	_	O
56	June	_	_	O
57	23	_	_	O
58	,	_	_	O
59	2010	_	_	O
60	,	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	progressive	_	_	O
64	,	_	_	O
65	metastatic	_	_	O
66	castration-resistant	_	_	O
67	prostate	_	_	O
68	cancer	_	_	O
69	were	_	_	O
70	enrolled	_	_	O
71	into	_	_	O
72	a	_	_	O
73	multinational	_	_	O
74	,	_	_	O
75	double-blind	_	_	O
76	,	_	_	O
77	placebo-controlled	_	_	O
78	trial	_	_	O
79	.	_	_	O

80	Patients	_	_	O
81	were	_	_	O
82	eligible	_	_	O
83	if	_	_	O
84	they	_	_	O
85	were	_	_	O
86	asymptomatic	_	_	O
87	(	_	_	O
88	score	_	_	O
89	of	_	_	O
90	0	_	_	O
91	or	_	_	O
92	1	_	_	O
93	on	_	_	O
94	item	_	_	O
95	three	_	_	O
96	of	_	_	O
97	the	_	_	O
98	Brief	_	_	O
99	Pain	_	_	O
100	Inventory	_	_	O
101	Short	_	_	O
102	Form	_	_	O
103	[	_	_	O
104	BPI-SF	_	_	O
105	]	_	_	O
106	questionnaire	_	_	O
107	)	_	_	O
108	or	_	_	O
109	mildly	_	_	O
110	symptomatic	_	_	O
111	(	_	_	O
112	score	_	_	O
113	of	_	_	O
114	2	_	_	O
115	or	_	_	O
116	3	_	_	O
117	)	_	_	O
118	and	_	_	O
119	had	_	_	O
120	not	_	_	O
121	previously	_	_	O
122	received	_	_	O
123	chemotherapy	_	_	O
124	.	_	_	O

125	Patients	_	_	O
126	were	_	_	O
127	randomly	_	_	O
128	assigned	_	_	O
129	(	_	_	O
130	1:1	_	_	O
131	)	_	_	O
132	to	_	_	O
133	receive	_	_	O
134	oral	_	_	O
135	abiraterone	_	_	O
136	(	_	_	O
137	1	_	_	O
138	g	_	_	O
139	daily	_	_	O
140	)	_	_	O
141	plus	_	_	O
142	prednisone	_	_	O
143	(	_	_	O
144	5	_	_	O
145	mg	_	_	O
146	twice	_	_	O
147	daily	_	_	O
148	)	_	_	O
149	or	_	_	O
150	placebo	_	_	O
151	plus	_	_	O
152	prednisone	_	_	O
153	in	_	_	O
154	continuous	_	_	O
155	4-week	_	_	O
156	cycles	_	_	O
157	.	_	_	O

158	Pain	_	_	O
159	was	_	_	O
160	assessed	_	_	O
161	with	_	_	O
162	the	_	_	O
163	BPI-SF	_	_	O
164	questionnaire	_	_	O
165	,	_	_	O
166	and	_	_	O
167	health-related	_	_	O
168	quality	_	_	O
169	of	_	_	O
170	life	_	_	O
171	(	_	_	O
172	HRQoL	_	_	O
173	)	_	_	O
174	with	_	_	O
175	the	_	_	O
176	Functional	_	_	O
177	Assessment	_	_	O
178	of	_	_	O
179	Cancer	_	_	O
180	Therapy-Prostate	_	_	O
181	(	_	_	O
182	FACT-P	_	_	O
183	)	_	_	O
184	questionnaire	_	_	O
185	.	_	_	O

186	We	_	_	O
187	analysed	_	_	O
188	data	_	_	O
189	with	_	_	O
190	prespecified	_	_	O
191	criteria	_	_	O
192	for	_	_	O
193	clinically	_	_	O
194	meaningful	_	_	O
195	pain	_	_	O
196	progression	_	_	O
197	and	_	_	O
198	deterioration	_	_	O
199	in	_	_	O
200	HRQoL	_	_	O
201	.	_	_	O

202	All	_	_	O
203	patients	_	_	O
204	who	_	_	O
205	underwent	_	_	O
206	randomisation	_	_	O
207	were	_	_	O
208	included	_	_	O
209	in	_	_	O
210	analyses	_	_	O
211	.	_	_	O

212	1088	_	_	O
213	patients	_	_	O
214	underwent	_	_	O
215	randomisation	_	_	O
216	:	_	_	O
217	546	_	_	O
218	were	_	_	O
219	assigned	_	_	O
220	to	_	_	O
221	abiraterone	_	_	O
222	plus	_	_	O
223	prednisone	_	_	O
224	and	_	_	O
225	542	_	_	O
226	to	_	_	O
227	placebo	_	_	O
228	plus	_	_	O
229	prednisone	_	_	O
230	.	_	_	O

231	At	_	_	O
232	the	_	_	O
233	time	_	_	O
234	of	_	_	O
235	the	_	_	O
236	second	_	_	O
237	prespecified	_	_	O
238	interim	_	_	O
239	analysis	_	_	O
240	,	_	_	O
241	median	_	_	O
242	follow-up	_	_	O
243	was	_	_	O
244	22·2	_	_	O
245	months	_	_	O
246	(	_	_	O
247	IQR	_	_	O
248	20·2-24·8	_	_	O
249	)	_	_	O
250	.	_	_	O

251	Median	_	_	B-Premise
252	time	_	_	I-Premise
253	to	_	_	I-Premise
254	progression	_	_	I-Premise
255	of	_	_	I-Premise
256	mean	_	_	I-Premise
257	pain	_	_	I-Premise
258	intensity	_	_	I-Premise
259	was	_	_	I-Premise
260	longer	_	_	I-Premise
261	in	_	_	I-Premise
262	patients	_	_	I-Premise
263	assigned	_	_	I-Premise
264	to	_	_	I-Premise
265	abiraterone	_	_	I-Premise
266	plus	_	_	I-Premise
267	prednisone	_	_	I-Premise
268	(	_	_	I-Premise
269	26·7	_	_	I-Premise
270	months	_	_	I-Premise
271	[	_	_	I-Premise
272	95	_	_	I-Premise
273	%	_	_	I-Premise
274	CI	_	_	I-Premise
275	19·3-not	_	_	I-Premise
276	estimable	_	_	I-Premise
277	]	_	_	I-Premise
278	)	_	_	I-Premise
279	than	_	_	I-Premise
280	in	_	_	I-Premise
281	those	_	_	I-Premise
282	assigned	_	_	I-Premise
283	to	_	_	I-Premise
284	placebo	_	_	I-Premise
285	plus	_	_	I-Premise
286	prednisone	_	_	I-Premise
287	(	_	_	I-Premise
288	18·4	_	_	I-Premise
289	months	_	_	I-Premise
290	[	_	_	I-Premise
291	14·9-not	_	_	I-Premise
292	estimable	_	_	I-Premise
293	]	_	_	I-Premise
294	;	_	_	I-Premise
295	hazard	_	_	I-Premise
296	ratio	_	_	I-Premise
297	[	_	_	I-Premise
298	HR	_	_	I-Premise
299	]	_	_	I-Premise
300	0·82	_	_	I-Premise
301	,	_	_	I-Premise
302	95	_	_	I-Premise
303	%	_	_	I-Premise
304	CI	_	_	I-Premise
305	0·67-1·00	_	_	I-Premise
306	;	_	_	I-Premise
307	p=0·0490	_	_	I-Premise
308	)	_	_	I-Premise
309	,	_	_	I-Premise
310	as	_	_	I-Premise
311	was	_	_	I-Premise
312	median	_	_	I-Premise
313	time	_	_	I-Premise
314	to	_	_	I-Premise
315	progression	_	_	I-Premise
316	of	_	_	I-Premise
317	pain	_	_	I-Premise
318	interference	_	_	I-Premise
319	with	_	_	I-Premise
320	daily	_	_	I-Premise
321	activities	_	_	I-Premise
322	(	_	_	I-Premise
323	10·3	_	_	I-Premise
324	months	_	_	I-Premise
325	[	_	_	I-Premise
326	95	_	_	I-Premise
327	%	_	_	I-Premise
328	CI	_	_	I-Premise
329	9·3-13·0	_	_	I-Premise
330	]	_	_	I-Premise
331	vs	_	_	I-Premise
332	7·4	_	_	I-Premise
333	months	_	_	I-Premise
334	[	_	_	I-Premise
335	6·4-8·6	_	_	I-Premise
336	]	_	_	I-Premise
337	;	_	_	I-Premise
338	HR	_	_	I-Premise
339	0·79	_	_	I-Premise
340	,	_	_	I-Premise
341	95	_	_	I-Premise
342	%	_	_	I-Premise
343	CI	_	_	I-Premise
344	0·67-0·93	_	_	I-Premise
345	;	_	_	I-Premise
346	p=0·005	_	_	I-Premise
347	)	_	_	I-Premise
348	.	_	_	I-Premise

349	Median	_	_	B-Premise
350	time	_	_	I-Premise
351	to	_	_	I-Premise
352	progression	_	_	I-Premise
353	of	_	_	I-Premise
354	worst	_	_	I-Premise
355	pain	_	_	I-Premise
356	was	_	_	I-Premise
357	also	_	_	I-Premise
358	longer	_	_	I-Premise
359	with	_	_	I-Premise
360	abiraterone	_	_	I-Premise
361	plus	_	_	I-Premise
362	prednisone	_	_	I-Premise
363	(	_	_	I-Premise
364	26·7	_	_	I-Premise
365	months	_	_	I-Premise
366	[	_	_	I-Premise
367	95	_	_	I-Premise
368	%	_	_	I-Premise
369	CI	_	_	I-Premise
370	19·4-not	_	_	I-Premise
371	estimable	_	_	I-Premise
372	]	_	_	I-Premise
373	)	_	_	I-Premise
374	than	_	_	I-Premise
375	with	_	_	I-Premise
376	placebo	_	_	I-Premise
377	plus	_	_	I-Premise
378	prednisone	_	_	I-Premise
379	(	_	_	I-Premise
380	19·4	_	_	I-Premise
381	months	_	_	I-Premise
382	[	_	_	I-Premise
383	16·6-not	_	_	I-Premise
384	estimable	_	_	I-Premise
385	]	_	_	I-Premise
386	)	_	_	I-Premise
387	,	_	_	I-Premise
388	but	_	_	I-Premise
389	the	_	_	I-Premise
390	difference	_	_	I-Premise
391	was	_	_	I-Premise
392	not	_	_	I-Premise
393	significant	_	_	I-Premise
394	(	_	_	I-Premise
395	HR	_	_	I-Premise
396	0·85	_	_	I-Premise
397	,	_	_	I-Premise
398	95	_	_	I-Premise
399	%	_	_	I-Premise
400	CI	_	_	I-Premise
401	0·69-1·04	_	_	I-Premise
402	;	_	_	I-Premise
403	p=0·109	_	_	I-Premise
404	)	_	_	I-Premise
405	.	_	_	I-Premise

406	Median	_	_	B-Premise
407	time	_	_	I-Premise
408	to	_	_	I-Premise
409	HRQoL	_	_	I-Premise
410	deterioration	_	_	I-Premise
411	was	_	_	I-Premise
412	longer	_	_	I-Premise
413	in	_	_	I-Premise
414	patients	_	_	I-Premise
415	assigned	_	_	I-Premise
416	to	_	_	I-Premise
417	abiraterone	_	_	I-Premise
418	plus	_	_	I-Premise
419	prednisone	_	_	I-Premise
420	than	_	_	I-Premise
421	in	_	_	I-Premise
422	those	_	_	I-Premise
423	assigned	_	_	I-Premise
424	to	_	_	I-Premise
425	placebo	_	_	I-Premise
426	plus	_	_	I-Premise
427	prednisone	_	_	I-Premise
428	as	_	_	I-Premise
429	assessed	_	_	I-Premise
430	by	_	_	I-Premise
431	the	_	_	I-Premise
432	FACT-P	_	_	I-Premise
433	total	_	_	I-Premise
434	score	_	_	I-Premise
435	(	_	_	I-Premise
436	12·7	_	_	I-Premise
437	months	_	_	I-Premise
438	[	_	_	I-Premise
439	95	_	_	I-Premise
440	%	_	_	I-Premise
441	CI	_	_	I-Premise
442	11·1-14·0	_	_	I-Premise
443	]	_	_	I-Premise
444	vs	_	_	I-Premise
445	8·3	_	_	I-Premise
446	months	_	_	I-Premise
447	[	_	_	I-Premise
448	7·4-10·6	_	_	I-Premise
449	]	_	_	I-Premise
450	;	_	_	I-Premise
451	HR	_	_	I-Premise
452	0·78	_	_	I-Premise
453	,	_	_	I-Premise
454	95	_	_	I-Premise
455	%	_	_	I-Premise
456	CI	_	_	I-Premise
457	0·66-0·92	_	_	I-Premise
458	;	_	_	I-Premise
459	p=0·003	_	_	I-Premise
460	)	_	_	I-Premise
461	and	_	_	I-Premise
462	by	_	_	I-Premise
463	the	_	_	I-Premise
464	score	_	_	I-Premise
465	on	_	_	I-Premise
466	its	_	_	I-Premise
467	prostate-cancer-specific	_	_	I-Premise
468	subscale	_	_	I-Premise
469	(	_	_	I-Premise
470	11·1	_	_	I-Premise
471	months	_	_	I-Premise
472	[	_	_	I-Premise
473	8·6-13·8	_	_	I-Premise
474	]	_	_	I-Premise
475	vs	_	_	I-Premise
476	5·8	_	_	I-Premise
477	months	_	_	I-Premise
478	[	_	_	I-Premise
479	5·5-8·3	_	_	I-Premise
480	]	_	_	I-Premise
481	;	_	_	I-Premise
482	HR	_	_	I-Premise
483	0·70	_	_	I-Premise
484	,	_	_	I-Premise
485	95	_	_	I-Premise
486	%	_	_	I-Premise
487	CI	_	_	I-Premise
488	0·60-0·83	_	_	I-Premise
489	;	_	_	I-Premise
490	p	_	_	I-Premise
491	<	_	_	I-Premise
492	0·0001	_	_	I-Premise
493	)	_	_	I-Premise
494	.	_	_	I-Premise

495	Abiraterone	_	_	B-Claim
496	plus	_	_	I-Claim
497	prednisone	_	_	I-Claim
498	delays	_	_	I-Claim
499	patient-reported	_	_	I-Claim
500	pain	_	_	I-Claim
501	progression	_	_	I-Claim
502	and	_	_	I-Claim
503	HRQoL	_	_	I-Claim
504	deterioration	_	_	I-Claim
505	in	_	_	I-Claim
506	chemotherapy-naive	_	_	I-Claim
507	patients	_	_	I-Claim
508	with	_	_	I-Claim
509	metastatic	_	_	I-Claim
510	castration-resistant	_	_	I-Claim
511	prostate	_	_	I-Claim
512	cancer	_	_	I-Claim
513	.	_	_	I-Claim

514	These	_	_	B-Claim
515	results	_	_	I-Claim
516	provide	_	_	I-Claim
517	further	_	_	I-Claim
518	support	_	_	I-Claim
519	for	_	_	I-Claim
520	the	_	_	I-Claim
521	efficacy	_	_	I-Claim
522	of	_	_	I-Claim
523	abiraterone	_	_	I-Claim
524	in	_	_	I-Claim
525	this	_	_	I-Claim
526	population	_	_	I-Claim
527	.	_	_	I-Claim


0	Menopausal	_	_	O
1	hormone	_	_	O
2	therapy	_	_	O
3	continues	_	_	O
4	in	_	_	O
5	clinical	_	_	O
6	use	_	_	O
7	but	_	_	O
8	questions	_	_	O
9	remain	_	_	O
10	regarding	_	_	O
11	its	_	_	O
12	risks	_	_	O
13	and	_	_	O
14	benefits	_	_	O
15	for	_	_	O
16	chronic	_	_	O
17	disease	_	_	O
18	prevention	_	_	O
19	.	_	_	O

20	To	_	_	O
21	report	_	_	O
22	a	_	_	O
23	comprehensive	_	_	O
24	,	_	_	O
25	integrated	_	_	O
26	overview	_	_	O
27	of	_	_	O
28	findings	_	_	O
29	from	_	_	O
30	the	_	_	O
31	2	_	_	O
32	Women	_	_	O
33	's	_	_	O
34	Health	_	_	O
35	Initiative	_	_	O
36	(	_	_	O
37	WHI	_	_	O
38	)	_	_	O
39	hormone	_	_	O
40	therapy	_	_	O
41	trials	_	_	O
42	with	_	_	O
43	extended	_	_	O
44	postintervention	_	_	O
45	follow-up	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	27,347	_	_	O
51	postmenopausal	_	_	O
52	women	_	_	O
53	aged	_	_	O
54	50	_	_	O
55	to	_	_	O
56	79	_	_	O
57	years	_	_	O
58	were	_	_	O
59	enrolled	_	_	O
60	at	_	_	O
61	40	_	_	O
62	US	_	_	O
63	centers	_	_	O
64	.	_	_	O

65	Women	_	_	O
66	with	_	_	O
67	an	_	_	O
68	intact	_	_	O
69	uterus	_	_	O
70	received	_	_	O
71	conjugated	_	_	O
72	equine	_	_	O
73	estrogens	_	_	O
74	(	_	_	O
75	CEE	_	_	O
76	;	_	_	O
77	0.625	_	_	O
78	mg/d	_	_	O
79	)	_	_	O
80	plus	_	_	O
81	medroxyprogesterone	_	_	O
82	acetate	_	_	O
83	(	_	_	O
84	MPA	_	_	O
85	;	_	_	O
86	2.5	_	_	O
87	mg/d	_	_	O
88	)	_	_	O
89	(	_	_	O
90	n	_	_	O
91	=	_	_	O
92	8506	_	_	O
93	)	_	_	O
94	or	_	_	O
95	placebo	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	8102	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Women	_	_	O
103	with	_	_	O
104	prior	_	_	O
105	hysterectomy	_	_	O
106	received	_	_	O
107	CEE	_	_	O
108	alone	_	_	O
109	(	_	_	O
110	0.625	_	_	O
111	mg/d	_	_	O
112	)	_	_	O
113	(	_	_	O
114	n	_	_	O
115	=	_	_	O
116	5310	_	_	O
117	)	_	_	O
118	or	_	_	O
119	placebo	_	_	O
120	(	_	_	O
121	n	_	_	O
122	=	_	_	O
123	5429	_	_	O
124	)	_	_	O
125	.	_	_	O

126	The	_	_	O
127	intervention	_	_	O
128	lasted	_	_	O
129	a	_	_	O
130	median	_	_	O
131	of	_	_	O
132	5.6	_	_	O
133	years	_	_	O
134	in	_	_	O
135	CEE	_	_	O
136	plus	_	_	O
137	MPA	_	_	O
138	trial	_	_	O
139	and	_	_	O
140	7.2	_	_	O
141	years	_	_	O
142	in	_	_	O
143	CEE	_	_	O
144	alone	_	_	O
145	trial	_	_	O
146	with	_	_	O
147	13	_	_	O
148	years	_	_	O
149	of	_	_	O
150	cumulative	_	_	O
151	follow-up	_	_	O
152	until	_	_	O
153	September	_	_	O
154	30	_	_	O
155	,	_	_	O
156	2010	_	_	O
157	.	_	_	O

158	Primary	_	_	O
159	efficacy	_	_	O
160	and	_	_	O
161	safety	_	_	O
162	outcomes	_	_	O
163	were	_	_	O
164	coronary	_	_	O
165	heart	_	_	O
166	disease	_	_	O
167	(	_	_	O
168	CHD	_	_	O
169	)	_	_	O
170	and	_	_	O
171	invasive	_	_	O
172	breast	_	_	O
173	cancer	_	_	O
174	,	_	_	O
175	respectively	_	_	O
176	.	_	_	O

177	A	_	_	O
178	global	_	_	O
179	index	_	_	O
180	also	_	_	O
181	included	_	_	O
182	stroke	_	_	O
183	,	_	_	O
184	pulmonary	_	_	O
185	embolism	_	_	O
186	,	_	_	O
187	colorectal	_	_	O
188	cancer	_	_	O
189	,	_	_	O
190	endometrial	_	_	O
191	cancer	_	_	O
192	,	_	_	O
193	hip	_	_	O
194	fracture	_	_	O
195	,	_	_	O
196	and	_	_	O
197	death	_	_	O
198	.	_	_	O

199	During	_	_	B-Premise
200	the	_	_	I-Premise
201	CEE	_	_	I-Premise
202	plus	_	_	I-Premise
203	MPA	_	_	I-Premise
204	intervention	_	_	I-Premise
205	phase	_	_	I-Premise
206	,	_	_	I-Premise
207	the	_	_	I-Premise
208	numbers	_	_	I-Premise
209	of	_	_	I-Premise
210	CHD	_	_	I-Premise
211	cases	_	_	I-Premise
212	were	_	_	I-Premise
213	196	_	_	I-Premise
214	for	_	_	I-Premise
215	CEE	_	_	I-Premise
216	plus	_	_	I-Premise
217	MPA	_	_	I-Premise
218	vs	_	_	I-Premise
219	159	_	_	I-Premise
220	for	_	_	I-Premise
221	placebo	_	_	I-Premise
222	(	_	_	I-Premise
223	hazard	_	_	I-Premise
224	ratio	_	_	I-Premise
225	[	_	_	I-Premise
226	HR	_	_	I-Premise
227	]	_	_	I-Premise
228	,	_	_	I-Premise
229	1.18	_	_	I-Premise
230	;	_	_	I-Premise
231	95	_	_	I-Premise
232	%	_	_	I-Premise
233	CI	_	_	I-Premise
234	,	_	_	I-Premise
235	0.95-1.45	_	_	I-Premise
236	)	_	_	I-Premise
237	and	_	_	I-Premise
238	206	_	_	I-Premise
239	vs	_	_	I-Premise
240	155	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	,	_	_	I-Premise
244	for	_	_	I-Premise
245	invasive	_	_	I-Premise
246	breast	_	_	I-Premise
247	cancer	_	_	I-Premise
248	(	_	_	I-Premise
249	HR	_	_	I-Premise
250	,	_	_	I-Premise
251	1.24	_	_	I-Premise
252	;	_	_	I-Premise
253	95	_	_	I-Premise
254	%	_	_	I-Premise
255	CI	_	_	I-Premise
256	,	_	_	I-Premise
257	1.01-1.53	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Other	_	_	B-Premise
261	risks	_	_	I-Premise
262	included	_	_	I-Premise
263	increased	_	_	I-Premise
264	stroke	_	_	I-Premise
265	,	_	_	I-Premise
266	pulmonary	_	_	I-Premise
267	embolism	_	_	I-Premise
268	,	_	_	I-Premise
269	dementia	_	_	I-Premise
270	(	_	_	I-Premise
271	in	_	_	I-Premise
272	women	_	_	I-Premise
273	aged	_	_	I-Premise
274	≥65	_	_	I-Premise
275	years	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	gallbladder	_	_	I-Premise
279	disease	_	_	I-Premise
280	,	_	_	I-Premise
281	and	_	_	I-Premise
282	urinary	_	_	I-Premise
283	incontinence	_	_	I-Premise
284	;	_	_	I-Premise
285	benefits	_	_	I-Premise
286	included	_	_	I-Premise
287	decreased	_	_	I-Premise
288	hip	_	_	I-Premise
289	fractures	_	_	I-Premise
290	,	_	_	I-Premise
291	diabetes	_	_	I-Premise
292	,	_	_	I-Premise
293	and	_	_	I-Premise
294	vasomotor	_	_	I-Premise
295	symptoms	_	_	I-Premise
296	.	_	_	I-Premise

297	Most	_	_	B-Premise
298	risks	_	_	I-Premise
299	and	_	_	I-Premise
300	benefits	_	_	I-Premise
301	dissipated	_	_	I-Premise
302	postintervention	_	_	I-Premise
303	,	_	_	I-Premise
304	although	_	_	B-Premise
305	some	_	_	I-Premise
306	elevation	_	_	I-Premise
307	in	_	_	I-Premise
308	breast	_	_	I-Premise
309	cancer	_	_	I-Premise
310	risk	_	_	I-Premise
311	persisted	_	_	I-Premise
312	during	_	_	I-Premise
313	cumulative	_	_	I-Premise
314	follow-up	_	_	I-Premise
315	(	_	_	I-Premise
316	434	_	_	I-Premise
317	cases	_	_	I-Premise
318	for	_	_	I-Premise
319	CEE	_	_	I-Premise
320	plus	_	_	I-Premise
321	MPA	_	_	I-Premise
322	vs	_	_	I-Premise
323	323	_	_	I-Premise
324	for	_	_	I-Premise
325	placebo	_	_	I-Premise
326	;	_	_	I-Premise
327	HR	_	_	I-Premise
328	,	_	_	I-Premise
329	1.28	_	_	I-Premise
330	[	_	_	I-Premise
331	95	_	_	I-Premise
332	%	_	_	I-Premise
333	CI	_	_	I-Premise
334	,	_	_	I-Premise
335	1.11-1.48	_	_	I-Premise
336	]	_	_	I-Premise
337	)	_	_	I-Premise
338	.	_	_	I-Premise

339	The	_	_	B-Premise
340	risks	_	_	I-Premise
341	and	_	_	I-Premise
342	benefits	_	_	I-Premise
343	were	_	_	I-Premise
344	more	_	_	I-Premise
345	balanced	_	_	I-Premise
346	during	_	_	I-Premise
347	the	_	_	I-Premise
348	CEE	_	_	I-Premise
349	alone	_	_	I-Premise
350	intervention	_	_	I-Premise
351	with	_	_	I-Premise
352	204	_	_	I-Premise
353	CHD	_	_	I-Premise
354	cases	_	_	I-Premise
355	for	_	_	I-Premise
356	CEE	_	_	I-Premise
357	alone	_	_	I-Premise
358	vs	_	_	I-Premise
359	222	_	_	I-Premise
360	cases	_	_	I-Premise
361	for	_	_	I-Premise
362	placebo	_	_	I-Premise
363	(	_	_	I-Premise
364	HR	_	_	I-Premise
365	,	_	_	I-Premise
366	0.94	_	_	I-Premise
367	;	_	_	I-Premise
368	95	_	_	I-Premise
369	%	_	_	I-Premise
370	CI	_	_	I-Premise
371	,	_	_	I-Premise
372	0.78-1.14	_	_	I-Premise
373	)	_	_	I-Premise
374	and	_	_	I-Premise
375	104	_	_	I-Premise
376	vs	_	_	I-Premise
377	135	_	_	I-Premise
378	,	_	_	I-Premise
379	respectively	_	_	I-Premise
380	,	_	_	I-Premise
381	for	_	_	I-Premise
382	invasive	_	_	I-Premise
383	breast	_	_	I-Premise
384	cancer	_	_	I-Premise
385	(	_	_	I-Premise
386	HR	_	_	I-Premise
387	,	_	_	I-Premise
388	0.79	_	_	I-Premise
389	;	_	_	I-Premise
390	95	_	_	I-Premise
391	%	_	_	I-Premise
392	CI	_	_	I-Premise
393	,	_	_	I-Premise
394	0.61-1.02	_	_	I-Premise
395	)	_	_	I-Premise
396	;	_	_	I-Premise
397	cumulatively	_	_	I-Premise
398	,	_	_	I-Premise
399	there	_	_	I-Premise
400	were	_	_	I-Premise
401	168	_	_	I-Premise
402	vs	_	_	I-Premise
403	216	_	_	I-Premise
404	,	_	_	I-Premise
405	respectively	_	_	I-Premise
406	,	_	_	I-Premise
407	cases	_	_	I-Premise
408	of	_	_	I-Premise
409	breast	_	_	I-Premise
410	cancer	_	_	I-Premise
411	diagnosed	_	_	I-Premise
412	(	_	_	I-Premise
413	HR	_	_	I-Premise
414	,	_	_	I-Premise
415	0.79	_	_	I-Premise
416	;	_	_	I-Premise
417	95	_	_	I-Premise
418	%	_	_	I-Premise
419	CI	_	_	I-Premise
420	,	_	_	I-Premise
421	0.65-0.97	_	_	I-Premise
422	)	_	_	I-Premise
423	.	_	_	I-Premise

424	Results	_	_	O
425	for	_	_	O
426	other	_	_	O
427	outcomes	_	_	O
428	were	_	_	O
429	similar	_	_	O
430	to	_	_	O
431	CEE	_	_	O
432	plus	_	_	O
433	MPA	_	_	O
434	.	_	_	O

435	Neither	_	_	O
436	regimen	_	_	O
437	affected	_	_	O
438	all-cause	_	_	O
439	mortality	_	_	O
440	.	_	_	O

441	For	_	_	B-Premise
442	CEE	_	_	I-Premise
443	alone	_	_	I-Premise
444	,	_	_	I-Premise
445	younger	_	_	I-Premise
446	women	_	_	I-Premise
447	(	_	_	I-Premise
448	aged	_	_	I-Premise
449	50-59	_	_	I-Premise
450	years	_	_	I-Premise
451	)	_	_	I-Premise
452	had	_	_	I-Premise
453	more	_	_	I-Premise
454	favorable	_	_	I-Premise
455	results	_	_	I-Premise
456	for	_	_	I-Premise
457	all-cause	_	_	I-Premise
458	mortality	_	_	I-Premise
459	,	_	_	I-Premise
460	myocardial	_	_	I-Premise
461	infarction	_	_	I-Premise
462	,	_	_	I-Premise
463	and	_	_	I-Premise
464	the	_	_	I-Premise
465	global	_	_	I-Premise
466	index	_	_	I-Premise
467	(	_	_	I-Premise
468	nominal	_	_	I-Premise
469	P	_	_	I-Premise
470	<	_	_	I-Premise
471	.05	_	_	I-Premise
472	for	_	_	I-Premise
473	trend	_	_	I-Premise
474	by	_	_	I-Premise
475	age	_	_	I-Premise
476	)	_	_	I-Premise
477	.	_	_	I-Premise

478	Absolute	_	_	B-Premise
479	risks	_	_	I-Premise
480	of	_	_	I-Premise
481	adverse	_	_	I-Premise
482	events	_	_	I-Premise
483	(	_	_	I-Premise
484	measured	_	_	I-Premise
485	by	_	_	I-Premise
486	the	_	_	I-Premise
487	global	_	_	I-Premise
488	index	_	_	I-Premise
489	)	_	_	I-Premise
490	per	_	_	I-Premise
491	10,000	_	_	I-Premise
492	women	_	_	I-Premise
493	annually	_	_	I-Premise
494	taking	_	_	I-Premise
495	CEE	_	_	I-Premise
496	plus	_	_	I-Premise
497	MPA	_	_	I-Premise
498	ranged	_	_	I-Premise
499	from	_	_	I-Premise
500	12	_	_	I-Premise
501	excess	_	_	I-Premise
502	cases	_	_	I-Premise
503	for	_	_	I-Premise
504	ages	_	_	I-Premise
505	of	_	_	I-Premise
506	50-59	_	_	I-Premise
507	years	_	_	I-Premise
508	to	_	_	I-Premise
509	38	_	_	I-Premise
510	for	_	_	I-Premise
511	ages	_	_	I-Premise
512	of	_	_	I-Premise
513	70-79	_	_	I-Premise
514	years	_	_	I-Premise
515	;	_	_	I-Premise
516	for	_	_	I-Premise
517	women	_	_	I-Premise
518	taking	_	_	I-Premise
519	CEE	_	_	I-Premise
520	alone	_	_	I-Premise
521	,	_	_	I-Premise
522	from	_	_	I-Premise
523	19	_	_	I-Premise
524	fewer	_	_	I-Premise
525	cases	_	_	I-Premise
526	for	_	_	I-Premise
527	ages	_	_	I-Premise
528	of	_	_	I-Premise
529	50-59	_	_	I-Premise
530	years	_	_	I-Premise
531	to	_	_	I-Premise
532	51	_	_	I-Premise
533	excess	_	_	I-Premise
534	cases	_	_	I-Premise
535	for	_	_	I-Premise
536	ages	_	_	I-Premise
537	of	_	_	I-Premise
538	70-79	_	_	I-Premise
539	years	_	_	I-Premise
540	.	_	_	I-Premise

541	Quality-of-life	_	_	O
542	outcomes	_	_	O
543	had	_	_	O
544	mixed	_	_	O
545	results	_	_	O
546	in	_	_	O
547	both	_	_	O
548	trials	_	_	O
549	.	_	_	O

550	Menopausal	_	_	B-Claim
551	hormone	_	_	I-Claim
552	therapy	_	_	I-Claim
553	has	_	_	I-Claim
554	a	_	_	I-Claim
555	complex	_	_	I-Claim
556	pattern	_	_	I-Claim
557	of	_	_	I-Claim
558	risks	_	_	I-Claim
559	and	_	_	I-Claim
560	benefits	_	_	I-Claim
561	.	_	_	I-Claim

562	Findings	_	_	B-Claim
563	from	_	_	I-Claim
564	the	_	_	I-Claim
565	intervention	_	_	I-Claim
566	and	_	_	I-Claim
567	extended	_	_	I-Claim
568	postintervention	_	_	I-Claim
569	follow-up	_	_	I-Claim
570	of	_	_	I-Claim
571	the	_	_	I-Claim
572	2	_	_	I-Claim
573	WHI	_	_	I-Claim
574	hormone	_	_	I-Claim
575	therapy	_	_	I-Claim
576	trials	_	_	I-Claim
577	do	_	_	I-Claim
578	not	_	_	I-Claim
579	support	_	_	I-Claim
580	use	_	_	I-Claim
581	of	_	_	I-Claim
582	this	_	_	I-Claim
583	therapy	_	_	I-Claim
584	for	_	_	I-Claim
585	chronic	_	_	I-Claim
586	disease	_	_	I-Claim
587	prevention	_	_	I-Claim
588	,	_	_	I-Claim
589	although	_	_	B-Claim
590	it	_	_	I-Claim
591	is	_	_	I-Claim
592	appropriate	_	_	I-Claim
593	for	_	_	I-Claim
594	symptom	_	_	I-Claim
595	management	_	_	I-Claim
596	in	_	_	I-Claim
597	some	_	_	I-Claim
598	women	_	_	I-Claim
599	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Chinese	_	_	O
7	medicine	_	_	O
8	(	_	_	O
9	CM	_	_	O
10	)	_	_	O
11	five-element	_	_	O
12	music	_	_	O
13	on	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	for	_	_	O
18	senior	_	_	O
19	and	_	_	O
20	non-senior	_	_	O
21	advanced	_	_	O
22	cancer	_	_	O
23	patients	_	_	O
24	.	_	_	O

25	With	_	_	O
26	a	_	_	O
27	randomized	_	_	O
28	controlled	_	_	O
29	trial	_	_	O
30	,	_	_	O
31	170	_	_	O
32	advanced	_	_	O
33	cancer	_	_	O
34	patients	_	_	O
35	were	_	_	O
36	randomly	_	_	O
37	assigned	_	_	O
38	to	_	_	O
39	three	_	_	O
40	groups	_	_	O
41	:	_	_	O
42	the	_	_	O
43	CM	_	_	O
44	five-element	_	_	O
45	music	_	_	O
46	group	_	_	O
47	(	_	_	O
48	68	_	_	O
49	patients	_	_	O
50	)	_	_	O
51	,	_	_	O
52	the	_	_	O
53	Western	_	_	O
54	music	_	_	O
55	therapy	_	_	O
56	group	_	_	O
57	(	_	_	O
58	68	_	_	O
59	cases	_	_	O
60	)	_	_	O
61	,	_	_	O
62	and	_	_	O
63	the	_	_	O
64	no	_	_	O
65	music	_	_	O
66	therapy	_	_	O
67	group	_	_	O
68	(	_	_	O
69	34	_	_	O
70	cases	_	_	O
71	)	_	_	O
72	.	_	_	O

73	All	_	_	O
74	patients	_	_	O
75	of	_	_	O
76	70	_	_	O
77	years	_	_	O
78	old	_	_	O
79	or	_	_	O
80	older	_	_	O
81	were	_	_	O
82	considered	_	_	O
83	seniors	_	_	O
84	and	_	_	O
85	the	_	_	O
86	remaining	_	_	O
87	patients	_	_	O
88	younger	_	_	O
89	than	_	_	O
90	70	_	_	O
91	years	_	_	O
92	were	_	_	O
93	considered	_	_	O
94	nonseniors	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	in	_	_	O
98	the	_	_	O
99	CM	_	_	O
100	five-element	_	_	O
101	music	_	_	O
102	group	_	_	O
103	listened	_	_	O
104	to	_	_	O
105	CM	_	_	O
106	five-element	_	_	O
107	music	_	_	O
108	,	_	_	O
109	the	_	_	O
110	patients	_	_	O
111	in	_	_	O
112	the	_	_	O
113	Western	_	_	O
114	music	_	_	O
115	group	_	_	O
116	listened	_	_	O
117	to	_	_	O
118	Western	_	_	O
119	music	_	_	O
120	,	_	_	O
121	and	_	_	O
122	the	_	_	O
123	patients	_	_	O
124	in	_	_	O
125	the	_	_	O
126	no	_	_	O
127	music	_	_	O
128	group	_	_	O
129	did	_	_	O
130	not	_	_	O
131	listen	_	_	O
132	to	_	_	O
133	music	_	_	O
134	.	_	_	O

135	A	_	_	O
136	course	_	_	O
137	of	_	_	O
138	treatment	_	_	O
139	was	_	_	O
140	3	_	_	O
141	weeks	_	_	O
142	,	_	_	O
143	with	_	_	O
144	30	_	_	O
145	min	_	_	O
146	each	_	_	O
147	day	_	_	O
148	,	_	_	O
149	5	_	_	O
150	days	_	_	O
151	a	_	_	O
152	week	_	_	O
153	.	_	_	O

154	The	_	_	O
155	Hospice	_	_	O
156	Quality	_	_	O
157	of	_	_	O
158	Life	_	_	O
159	Index-Revised	_	_	O
160	(	_	_	O
161	HQOLI-R	_	_	O
162	)	_	_	O
163	and	_	_	O
164	Karnofsky	_	_	O
165	performance	_	_	O
166	score	_	_	O
167	(	_	_	O
168	KPS	_	_	O
169	)	_	_	O
170	were	_	_	O
171	measured	_	_	O
172	in	_	_	O
173	the	_	_	O
174	three	_	_	O
175	groups	_	_	O
176	before	_	_	O
177	and	_	_	O
178	after	_	_	O
179	treatment	_	_	O
180	.	_	_	O

181	The	_	_	O
182	symptom	_	_	O
183	diary	_	_	O
184	score	_	_	O
185	was	_	_	O
186	measured	_	_	O
187	in	_	_	O
188	the	_	_	O
189	three	_	_	O
190	groups	_	_	O
191	every	_	_	O
192	3	_	_	O
193	days	_	_	O
194	,	_	_	O
195	7	_	_	O
196	times	_	_	O
197	in	_	_	O
198	total	_	_	O
199	.	_	_	O

200	CM	_	_	B-Premise
201	five-element	_	_	I-Premise
202	music	_	_	I-Premise
203	group	_	_	I-Premise
204	showed	_	_	I-Premise
205	a	_	_	I-Premise
206	significant	_	_	I-Premise
207	difference	_	_	I-Premise
208	of	_	_	I-Premise
209	HQOLI-R	_	_	I-Premise
210	,	_	_	I-Premise
211	KPS	_	_	I-Premise
212	and	_	_	I-Premise
213	symptom	_	_	I-Premise
214	diary	_	_	I-Premise
215	score	_	_	I-Premise
216	with	_	_	I-Premise
217	other	_	_	I-Premise
218	groups	_	_	I-Premise
219	(	_	_	I-Premise
220	all	_	_	I-Premise
221	P	_	_	I-Premise
222	<	_	_	I-Premise
223	0.01	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	There	_	_	B-Premise
227	were	_	_	I-Premise
228	significant	_	_	I-Premise
229	differences	_	_	I-Premise
230	of	_	_	I-Premise
231	HQOLI-R	_	_	I-Premise
232	,	_	_	I-Premise
233	symptom	_	_	I-Premise
234	diary	_	_	I-Premise
235	score	_	_	I-Premise
236	,	_	_	I-Premise
237	and	_	_	I-Premise
238	KPS	_	_	I-Premise
239	after	_	_	I-Premise
240	treatment	_	_	I-Premise
241	in	_	_	I-Premise
242	CM	_	_	I-Premise
243	five-element	_	_	I-Premise
244	music	_	_	I-Premise
245	group	_	_	I-Premise
246	and	_	_	I-Premise
247	other	_	_	I-Premise
248	groups	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	non-senior	_	_	I-Premise
252	subgroup	_	_	I-Premise
253	(	_	_	I-Premise
254	P	_	_	I-Premise
255	<	_	_	I-Premise
256	0.05	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Additionally	_	_	O
260	,	_	_	O
261	there	_	_	B-Premise
262	were	_	_	I-Premise
263	significant	_	_	I-Premise
264	differences	_	_	I-Premise
265	in	_	_	I-Premise
266	HQOLI-R	_	_	I-Premise
267	and	_	_	I-Premise
268	KPS	_	_	I-Premise
269	after	_	_	I-Premise
270	treatment	_	_	I-Premise
271	among	_	_	I-Premise
272	the	_	_	I-Premise
273	three	_	_	I-Premise
274	groups	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	senior	_	_	I-Premise
278	subgroup	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	<	_	_	I-Premise
282	0.05	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	CM	_	_	B-Claim
286	five-element	_	_	I-Claim
287	music	_	_	I-Claim
288	therapy	_	_	I-Claim
289	could	_	_	I-Claim
290	improve	_	_	I-Claim
291	the	_	_	I-Claim
292	quality	_	_	I-Claim
293	of	_	_	I-Claim
294	life	_	_	I-Claim
295	and	_	_	I-Claim
296	KPS	_	_	I-Claim
297	for	_	_	I-Claim
298	senior	_	_	I-Claim
299	and	_	_	I-Claim
300	non	_	_	I-Claim
301	senior	_	_	I-Claim
302	advanced	_	_	I-Claim
303	cancer	_	_	I-Claim
304	patients	_	_	I-Claim
305	,	_	_	I-Claim
306	and	_	_	I-Claim
307	it	_	_	I-Claim
308	could	_	_	I-Claim
309	improve	_	_	I-Claim
310	subjective	_	_	I-Claim
311	symptoms	_	_	I-Claim
312	for	_	_	I-Claim
313	non-senior	_	_	I-Claim
314	advanced	_	_	I-Claim
315	cancer	_	_	I-Claim
316	patients	_	_	I-Claim
317	.	_	_	I-Claim


0	Mediating	_	_	O
1	mechanisms	_	_	O
2	of	_	_	O
3	a	_	_	O
4	12-week	_	_	O
5	group-based	_	_	O
6	exercise	_	_	O
7	intervention	_	_	O
8	on	_	_	O
9	cancer	_	_	O
10	survivors	_	_	O
11	'	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	(	_	_	O
16	QoL	_	_	O
17	)	_	_	O
18	were	_	_	O
19	examined	_	_	O
20	to	_	_	O
21	inform	_	_	O
22	future	_	_	O
23	exercise	_	_	O
24	intervention	_	_	O
25	development	_	_	O
26	.	_	_	O

27	Two	_	_	O
28	hundred	_	_	O
29	nine	_	_	O
30	cancer	_	_	O
31	survivors	_	_	O
32	≥	_	_	O
33	3	_	_	O
34	months	_	_	O
35	posttreatment	_	_	O
36	(	_	_	O
37	57	_	_	O
38	%	_	_	O
39	breast	_	_	O
40	cancer	_	_	O
41	)	_	_	O
42	aged	_	_	O
43	49.5	_	_	O
44	(	_	_	O
45	±	_	_	O
46	10.4	_	_	O
47	)	_	_	O
48	years	_	_	O
49	were	_	_	O
50	assigned	_	_	O
51	to	_	_	O
52	physical	_	_	O
53	exercise	_	_	O
54	(	_	_	O
55	n	_	_	O
56	=	_	_	O
57	147	_	_	O
58	)	_	_	O
59	or	_	_	O
60	wait-list	_	_	O
61	control	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	62	_	_	O
66	)	_	_	O
67	.	_	_	O

68	QoL	_	_	O
69	,	_	_	O
70	fatigue	_	_	O
71	,	_	_	O
72	emotional	_	_	O
73	distress	_	_	O
74	,	_	_	O
75	physical	_	_	O
76	activity	_	_	O
77	,	_	_	O
78	general	_	_	O
79	self-efficacy	_	_	O
80	and	_	_	O
81	mastery	_	_	O
82	were	_	_	O
83	assessed	_	_	O
84	at	_	_	O
85	baseline	_	_	O
86	and	_	_	O
87	post-intervention	_	_	O
88	using	_	_	O
89	questionnaires	_	_	O
90	.	_	_	O

91	Path	_	_	O
92	analysis	_	_	O
93	was	_	_	O
94	conducted	_	_	O
95	using	_	_	O
96	Mplus	_	_	O
97	to	_	_	O
98	explore	_	_	O
99	whether	_	_	O
100	improved	_	_	O
101	physical	_	_	O
102	activity	_	_	O
103	,	_	_	O
104	general	_	_	O
105	self-efficacy	_	_	O
106	and	_	_	O
107	mastery	_	_	O
108	mediated	_	_	O
109	the	_	_	O
110	effects	_	_	O
111	of	_	_	O
112	exercise	_	_	O
113	on	_	_	O
114	fatigue	_	_	O
115	and	_	_	O
116	distress	_	_	O
117	and	_	_	O
118	consequently	_	_	O
119	QoL	_	_	O
120	.	_	_	O

121	The	_	_	B-Premise
122	intervention	_	_	I-Premise
123	was	_	_	I-Premise
124	associated	_	_	I-Premise
125	with	_	_	I-Premise
126	increased	_	_	I-Premise
127	physical	_	_	I-Premise
128	activity	_	_	I-Premise
129	(	_	_	I-Premise
130	β	_	_	I-Premise
131	=	_	_	I-Premise
132	0.46	_	_	I-Premise
133	,	_	_	I-Premise
134	95	_	_	I-Premise
135	%	_	_	I-Premise
136	confidence	_	_	I-Premise
137	interval	_	_	I-Premise
138	(	_	_	I-Premise
139	CI	_	_	I-Premise
140	)	_	_	I-Premise
141	=	_	_	I-Premise
142	0.14	_	_	I-Premise
143	;	_	_	I-Premise
144	0.59	_	_	I-Premise
145	)	_	_	I-Premise
146	,	_	_	I-Premise
147	general	_	_	I-Premise
148	self-efficacy	_	_	I-Premise
149	(	_	_	I-Premise
150	β	_	_	I-Premise
151	=	_	_	I-Premise
152	2.41	_	_	I-Premise
153	,	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	=	_	_	I-Premise
158	0.35	_	_	I-Premise
159	;	_	_	I-Premise
160	4.73	_	_	I-Premise
161	)	_	_	I-Premise
162	,	_	_	I-Premise
163	and	_	_	I-Premise
164	mastery	_	_	I-Premise
165	(	_	_	I-Premise
166	β	_	_	I-Premise
167	=	_	_	I-Premise
168	1.75	_	_	I-Premise
169	,	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	=	_	_	I-Premise
174	0.36	_	_	I-Premise
175	;	_	_	I-Premise
176	2.78	_	_	I-Premise
177	)	_	_	I-Premise
178	.	_	_	I-Premise

179	Further	_	_	O
180	,	_	_	O
181	the	_	_	B-Premise
182	intervention	_	_	I-Premise
183	had	_	_	I-Premise
184	both	_	_	I-Premise
185	a	_	_	I-Premise
186	direct	_	_	I-Premise
187	effect	_	_	I-Premise
188	on	_	_	I-Premise
189	fatigue	_	_	I-Premise
190	(	_	_	I-Premise
191	β	_	_	I-Premise
192	=	_	_	I-Premise
193	-1.09	_	_	I-Premise
194	,	_	_	I-Premise
195	95	_	_	I-Premise
196	%	_	_	I-Premise
197	CI	_	_	I-Premise
198	=	_	_	I-Premise
199	-2.12	_	_	I-Premise
200	;	_	_	I-Premise
201	0.01	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	and	_	_	I-Premise
205	an	_	_	I-Premise
206	indirect	_	_	I-Premise
207	effect	_	_	I-Premise
208	(	_	_	I-Premise
209	β	_	_	I-Premise
210	=	_	_	I-Premise
211	-0.54	_	_	I-Premise
212	,	_	_	I-Premise
213	95	_	_	I-Premise
214	%	_	_	I-Premise
215	CI	_	_	I-Premise
216	=	_	_	I-Premise
217	-1.00	_	_	I-Premise
218	;	_	_	I-Premise
219	-0.21	_	_	I-Premise
220	)	_	_	I-Premise
221	via	_	_	I-Premise
222	physical	_	_	I-Premise
223	activity	_	_	I-Premise
224	(	_	_	I-Premise
225	β	_	_	I-Premise
226	=	_	_	I-Premise
227	-0.29	_	_	I-Premise
228	,	_	_	I-Premise
229	95	_	_	I-Premise
230	%	_	_	I-Premise
231	CI	_	_	I-Premise
232	=	_	_	I-Premise
233	-0.64	_	_	I-Premise
234	;	_	_	I-Premise
235	-0.07	_	_	I-Premise
236	)	_	_	I-Premise
237	and	_	_	I-Premise
238	general	_	_	I-Premise
239	self-efficacy	_	_	I-Premise
240	(	_	_	I-Premise
241	β	_	_	I-Premise
242	=	_	_	I-Premise
243	-0.25	_	_	I-Premise
244	,	_	_	I-Premise
245	95	_	_	I-Premise
246	%	_	_	I-Premise
247	CI	_	_	I-Premise
248	=	_	_	I-Premise
249	-0.61	_	_	I-Premise
250	;	_	_	I-Premise
251	-0.05	_	_	I-Premise
252	)	_	_	I-Premise
253	.	_	_	I-Premise

254	The	_	_	B-Premise
255	intervention	_	_	I-Premise
256	had	_	_	I-Premise
257	a	_	_	I-Premise
258	borderline	_	_	I-Premise
259	significant	_	_	I-Premise
260	direct	_	_	I-Premise
261	effect	_	_	I-Premise
262	on	_	_	I-Premise
263	reduced	_	_	I-Premise
264	distress	_	_	I-Premise
265	(	_	_	I-Premise
266	β	_	_	I-Premise
267	=	_	_	I-Premise
268	-1.32	_	_	I-Premise
269	,	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	CI	_	_	I-Premise
273	=	_	_	I-Premise
274	-2.68	_	_	I-Premise
275	;	_	_	I-Premise
276	0.11	_	_	I-Premise
277	)	_	_	I-Premise
278	,	_	_	I-Premise
279	and	_	_	I-Premise
280	a	_	_	I-Premise
281	significant	_	_	I-Premise
282	indirect	_	_	I-Premise
283	effect	_	_	I-Premise
284	via	_	_	I-Premise
285	increased	_	_	I-Premise
286	general	_	_	I-Premise
287	self-efficacy	_	_	I-Premise
288	and	_	_	I-Premise
289	mastery	_	_	I-Premise
290	(	_	_	I-Premise
291	β	_	_	I-Premise
292	=	_	_	I-Premise
293	-1.06	_	_	I-Premise
294	,	_	_	I-Premise
295	95	_	_	I-Premise
296	%	_	_	I-Premise
297	CI	_	_	I-Premise
298	=	_	_	I-Premise
299	-1.89	_	_	I-Premise
300	;	_	_	I-Premise
301	-0.38	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	Reductions	_	_	B-Premise
305	in	_	_	I-Premise
306	fatigue	_	_	I-Premise
307	(	_	_	I-Premise
308	β	_	_	I-Premise
309	=	_	_	I-Premise
310	-1.33	_	_	I-Premise
311	,	_	_	I-Premise
312	95	_	_	I-Premise
313	%	_	_	I-Premise
314	CI	_	_	I-Premise
315	=-1.85	_	_	I-Premise
316	;	_	_	I-Premise
317	-0.83	_	_	I-Premise
318	)	_	_	I-Premise
319	and	_	_	I-Premise
320	distress	_	_	I-Premise
321	(	_	_	I-Premise
322	β	_	_	I-Premise
323	=	_	_	I-Premise
324	-0.86	_	_	I-Premise
325	,	_	_	I-Premise
326	95	_	_	I-Premise
327	%	_	_	I-Premise
328	CI	_	_	I-Premise
329	=	_	_	I-Premise
330	-1.25	_	_	I-Premise
331	;	_	_	I-Premise
332	-0.52	_	_	I-Premise
333	)	_	_	I-Premise
334	were	_	_	I-Premise
335	associated	_	_	I-Premise
336	with	_	_	I-Premise
337	improved	_	_	I-Premise
338	QoL	_	_	I-Premise
339	.	_	_	I-Premise

340	Further	_	_	O
341	,	_	_	O
342	increased	_	_	B-Premise
343	physical	_	_	I-Premise
344	activity	_	_	I-Premise
345	was	_	_	I-Premise
346	directly	_	_	I-Premise
347	associated	_	_	I-Premise
348	with	_	_	I-Premise
349	improved	_	_	I-Premise
350	QoL	_	_	I-Premise
351	(	_	_	I-Premise
352	β	_	_	I-Premise
353	=	_	_	I-Premise
354	3.37	_	_	I-Premise
355	,	_	_	I-Premise
356	95	_	_	I-Premise
357	%	_	_	I-Premise
358	CI	_	_	I-Premise
359	=	_	_	I-Premise
360	1.01	_	_	I-Premise
361	;	_	_	I-Premise
362	5.54	_	_	I-Premise
363	)	_	_	I-Premise
364	.	_	_	I-Premise

365	The	_	_	B-Claim
366	beneficial	_	_	I-Claim
367	effect	_	_	I-Claim
368	of	_	_	I-Claim
369	group-based	_	_	I-Claim
370	physical	_	_	I-Claim
371	exercise	_	_	I-Claim
372	on	_	_	I-Claim
373	QoL	_	_	I-Claim
374	was	_	_	I-Claim
375	mediated	_	_	I-Claim
376	by	_	_	I-Claim
377	increased	_	_	I-Claim
378	physical	_	_	I-Claim
379	activity	_	_	I-Claim
380	,	_	_	I-Claim
381	general	_	_	I-Claim
382	self-efficacy	_	_	I-Claim
383	and	_	_	I-Claim
384	mastery	_	_	I-Claim
385	,	_	_	I-Claim
386	and	_	_	I-Claim
387	subsequent	_	_	I-Claim
388	reductions	_	_	I-Claim
389	in	_	_	I-Claim
390	fatigue	_	_	I-Claim
391	and	_	_	I-Claim
392	distress	_	_	I-Claim
393	.	_	_	I-Claim

394	In	_	_	B-Claim
395	addition	_	_	I-Claim
396	to	_	_	I-Claim
397	physical	_	_	I-Claim
398	activity	_	_	I-Claim
399	,	_	_	I-Claim
400	future	_	_	I-Claim
401	interventions	_	_	I-Claim
402	should	_	_	I-Claim
403	target	_	_	I-Claim
404	self-efficacy	_	_	I-Claim
405	and	_	_	I-Claim
406	mastery	_	_	I-Claim
407	.	_	_	I-Claim

408	This	_	_	B-Claim
409	may	_	_	I-Claim
410	lead	_	_	I-Claim
411	to	_	_	I-Claim
412	reduced	_	_	I-Claim
413	distress	_	_	I-Claim
414	and	_	_	I-Claim
415	fatigue	_	_	I-Claim
416	,	_	_	I-Claim
417	and	_	_	I-Claim
418	consequently	_	_	I-Claim
419	improved	_	_	I-Claim
420	QoL	_	_	I-Claim
421	of	_	_	I-Claim
422	cancer	_	_	I-Claim
423	survivors	_	_	I-Claim
424	.	_	_	I-Claim


0	The	_	_	O
1	CO.20	_	_	O
2	trial	_	_	O
3	randomized	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	K-RAS	_	_	O
7	wild-type	_	_	O
8	,	_	_	O
9	chemotherapy-refractory	_	_	O
10	,	_	_	O
11	metastatic	_	_	O
12	colorectal	_	_	O
13	cancer	_	_	O
14	to	_	_	O
15	receive	_	_	O
16	cetuximab	_	_	O
17	(	_	_	O
18	CET	_	_	O
19	)	_	_	O
20	plus	_	_	O
21	brivanib	_	_	O
22	alaninate	_	_	O
23	(	_	_	O
24	BRIV	_	_	O
25	)	_	_	O
26	or	_	_	O
27	CET	_	_	O
28	plus	_	_	O
29	placebo	_	_	O
30	(	_	_	O
31	CET/placebo	_	_	O
32	)	_	_	O
33	.	_	_	O

34	Quality	_	_	O
35	of	_	_	O
36	life	_	_	O
37	(	_	_	O
38	QoL	_	_	O
39	)	_	_	O
40	was	_	_	O
41	assessed	_	_	O
42	using	_	_	O
43	the	_	_	O
44	European	_	_	O
45	Organization	_	_	O
46	for	_	_	O
47	Research	_	_	O
48	and	_	_	O
49	Treatment	_	_	O
50	of	_	_	O
51	Cancer	_	_	O
52	Quality	_	_	O
53	of	_	_	O
54	Life	_	_	O
55	Questionnaire	_	_	O
56	C30	_	_	O
57	at	_	_	O
58	baseline	_	_	O
59	and	_	_	O
60	at	_	_	O
61	2	_	_	O
62	,	_	_	O
63	4	_	_	O
64	,	_	_	O
65	6	_	_	O
66	,	_	_	O
67	8	_	_	O
68	,	_	_	O
69	12	_	_	O
70	,	_	_	O
71	16	_	_	O
72	,	_	_	O
73	and	_	_	O
74	24	_	_	O
75	weeks	_	_	O
76	until	_	_	O
77	disease	_	_	O
78	progression	_	_	O
79	.	_	_	O

80	Predefined	_	_	O
81	coprimary	_	_	O
82	QoL	_	_	O
83	endpoints	_	_	O
84	were	_	_	O
85	time	_	_	O
86	to	_	_	O
87	deterioration	_	_	O
88	(	_	_	O
89	first	_	_	O
90	worsening	_	_	O
91	from	_	_	O
92	baseline	_	_	O
93	of	_	_	O
94	≥	_	_	O
95	10	_	_	O
96	points	_	_	O
97	)	_	_	O
98	on	_	_	O
99	the	_	_	O
100	Physical	_	_	O
101	Function	_	_	O
102	(	_	_	O
103	PF	_	_	O
104	)	_	_	O
105	and	_	_	O
106	Global	_	_	O
107	(	_	_	O
108	GHS	_	_	O
109	)	_	_	O
110	scales	_	_	O
111	.	_	_	O

112	Of	_	_	O
113	750	_	_	O
114	randomized	_	_	O
115	patients	_	_	O
116	,	_	_	O
117	721	_	_	O
118	(	_	_	O
119	358	_	_	O
120	of	_	_	O
121	whom	_	_	O
122	received	_	_	O
123	CET/BRIV	_	_	O
124	)	_	_	O
125	were	_	_	O
126	assessable	_	_	O
127	for	_	_	O
128	QoL	_	_	O
129	.	_	_	O

130	QoL	_	_	O
131	compliance	_	_	O
132	and	_	_	O
133	baseline	_	_	O
134	PF	_	_	O
135	and	_	_	O
136	GHS	_	_	O
137	scores	_	_	O
138	did	_	_	O
139	not	_	_	O
140	differ	_	_	O
141	by	_	_	O
142	treatment	_	_	O
143	arm	_	_	O
144	.	_	_	O

145	The	_	_	B-Premise
146	median	_	_	I-Premise
147	time	_	_	I-Premise
148	to	_	_	I-Premise
149	deterioration	_	_	I-Premise
150	was	_	_	I-Premise
151	1.6	_	_	I-Premise
152	months	_	_	I-Premise
153	versus	_	_	I-Premise
154	1.1	_	_	I-Premise
155	months	_	_	I-Premise
156	for	_	_	I-Premise
157	GHS	_	_	I-Premise
158	(	_	_	I-Premise
159	P	_	_	I-Premise
160	=.02	_	_	I-Premise
161	)	_	_	I-Premise
162	and	_	_	I-Premise
163	5.6	_	_	I-Premise
164	months	_	_	I-Premise
165	versus	_	_	I-Premise
166	1.7	_	_	I-Premise
167	months	_	_	I-Premise
168	for	_	_	I-Premise
169	PF	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	<	_	_	I-Premise
173	.0001	_	_	I-Premise
174	)	_	_	I-Premise
175	favoring	_	_	I-Premise
176	CET/placebo	_	_	I-Premise
177	.	_	_	I-Premise

178	Secondary	_	_	B-Premise
179	analysis	_	_	I-Premise
180	favored	_	_	I-Premise
181	CET/placebo	_	_	I-Premise
182	for	_	_	I-Premise
183	QOL	_	_	I-Premise
184	response	_	_	I-Premise
185	on	_	_	I-Premise
186	the	_	_	I-Premise
187	PF	_	_	I-Premise
188	,	_	_	I-Premise
189	Cognitive	_	_	I-Premise
190	Function	_	_	I-Premise
191	,	_	_	I-Premise
192	Fatigue	_	_	I-Premise
193	,	_	_	I-Premise
194	Nausea	_	_	I-Premise
195	,	_	_	I-Premise
196	Appetite	_	_	I-Premise
197	,	_	_	I-Premise
198	and	_	_	I-Premise
199	Diarrhea	_	_	I-Premise
200	scales	_	_	I-Premise
201	.	_	_	I-Premise

202	A	_	_	B-Premise
203	greater	_	_	I-Premise
204	percentage	_	_	I-Premise
205	of	_	_	I-Premise
206	patients	_	_	I-Premise
207	on	_	_	I-Premise
208	the	_	_	I-Premise
209	CET/BRIV	_	_	I-Premise
210	arm	_	_	I-Premise
211	had	_	_	I-Premise
212	PF	_	_	I-Premise
213	worsening	_	_	I-Premise
214	at	_	_	I-Premise
215	6	_	_	I-Premise
216	weeks	_	_	I-Premise
217	(	_	_	I-Premise
218	31	_	_	I-Premise
219	%	_	_	I-Premise
220	vs	_	_	I-Premise
221	17	_	_	I-Premise
222	%	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Clinical	_	_	B-Premise
226	adverse	_	_	I-Premise
227	events	_	_	I-Premise
228	of	_	_	I-Premise
229	≥	_	_	I-Premise
230	grade	_	_	I-Premise
231	3	_	_	I-Premise
232	were	_	_	I-Premise
233	more	_	_	I-Premise
234	common	_	_	I-Premise
235	with	_	_	I-Premise
236	CET/BRIV	_	_	I-Premise
237	than	_	_	I-Premise
238	with	_	_	I-Premise
239	CET/placebo	_	_	I-Premise
240	,	_	_	I-Premise
241	including	_	_	I-Premise
242	fatigue	_	_	I-Premise
243	(	_	_	I-Premise
244	25	_	_	I-Premise
245	%	_	_	I-Premise
246	vs	_	_	I-Premise
247	11	_	_	I-Premise
248	%	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	hypertension	_	_	I-Premise
252	,	_	_	I-Premise
253	rash	_	_	I-Premise
254	,	_	_	I-Premise
255	diarrhea	_	_	I-Premise
256	,	_	_	I-Premise
257	abdominal	_	_	I-Premise
258	pain	_	_	I-Premise
259	,	_	_	I-Premise
260	dehydration	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	anorexia	_	_	I-Premise
264	.	_	_	I-Premise

265	Compared	_	_	B-Claim
266	with	_	_	I-Claim
267	CET/placebo	_	_	I-Claim
268	,	_	_	I-Claim
269	the	_	_	I-Claim
270	combination	_	_	I-Claim
271	of	_	_	I-Claim
272	CET/BRIV	_	_	I-Claim
273	worsened	_	_	I-Claim
274	time	_	_	I-Claim
275	to	_	_	I-Claim
276	QoL	_	_	I-Claim
277	deterioration	_	_	I-Claim
278	for	_	_	I-Claim
279	patients	_	_	I-Claim
280	with	_	_	I-Claim
281	K-RAS	_	_	I-Claim
282	wild-type	_	_	I-Claim
283	,	_	_	I-Claim
284	chemotherapy-refractory	_	_	I-Claim
285	,	_	_	I-Claim
286	metastatic	_	_	I-Claim
287	colorectal	_	_	I-Claim
288	cancer	_	_	I-Claim
289	on	_	_	I-Claim
290	the	_	_	I-Claim
291	PF	_	_	I-Claim
292	and	_	_	I-Claim
293	GHS	_	_	I-Claim
294	scales	_	_	I-Claim
295	of	_	_	I-Claim
296	European	_	_	I-Claim
297	Organization	_	_	I-Claim
298	for	_	_	I-Claim
299	Research	_	_	I-Claim
300	and	_	_	I-Claim
301	Treatment	_	_	I-Claim
302	of	_	_	I-Claim
303	Cancer	_	_	I-Claim
304	Quality	_	_	I-Claim
305	of	_	_	I-Claim
306	Life	_	_	I-Claim
307	Questionnaire	_	_	I-Claim
308	C30	_	_	I-Claim
309	.	_	_	I-Claim

310	This	_	_	B-Claim
311	result	_	_	I-Claim
312	may	_	_	I-Claim
313	be	_	_	I-Claim
314	due	_	_	I-Claim
315	to	_	_	I-Claim
316	higher	_	_	I-Claim
317	rates	_	_	I-Claim
318	of	_	_	I-Claim
319	fatigue	_	_	I-Claim
320	and	_	_	I-Claim
321	gastrointestinal	_	_	I-Claim
322	adverse	_	_	I-Claim
323	events	_	_	I-Claim
324	.	_	_	I-Claim


0	Exercise	_	_	O
1	improves	_	_	O
2	physical	_	_	O
3	functioning	_	_	O
4	and	_	_	O
5	symptom	_	_	O
6	management	_	_	O
7	during	_	_	O
8	breast	_	_	O
9	cancer	_	_	O
10	chemotherapy	_	_	O
11	,	_	_	O
12	but	_	_	O
13	the	_	_	O
14	effects	_	_	O
15	of	_	_	O
16	different	_	_	O
17	doses	_	_	O
18	and	_	_	O
19	types	_	_	O
20	of	_	_	O
21	exercise	_	_	O
22	are	_	_	O
23	unknown	_	_	O
24	.	_	_	O

25	A	_	_	O
26	multicenter	_	_	O
27	trial	_	_	O
28	in	_	_	O
29	Canada	_	_	O
30	randomized	_	_	O
31	301	_	_	O
32	breast	_	_	O
33	cancer	_	_	O
34	patients	_	_	O
35	to	_	_	O
36	thrice-weekly	_	_	O
37	supervised	_	_	O
38	exercise	_	_	O
39	during	_	_	O
40	chemotherapy	_	_	O
41	consisting	_	_	O
42	of	_	_	O
43	either	_	_	O
44	a	_	_	O
45	standard	_	_	O
46	dose	_	_	O
47	of	_	_	O
48	25	_	_	O
49	to	_	_	O
50	30	_	_	O
51	minutes	_	_	O
52	of	_	_	O
53	aerobic	_	_	O
54	exercise	_	_	O
55	(	_	_	O
56	STAN	_	_	O
57	;	_	_	O
58	n	_	_	O
59	=	_	_	O
60	96	_	_	O
61	)	_	_	O
62	,	_	_	O
63	a	_	_	O
64	higher	_	_	O
65	dose	_	_	O
66	of	_	_	O
67	50	_	_	O
68	to	_	_	O
69	60	_	_	O
70	minutes	_	_	O
71	of	_	_	O
72	aerobic	_	_	O
73	exercise	_	_	O
74	(	_	_	O
75	HIGH	_	_	O
76	;	_	_	O
77	n	_	_	O
78	=	_	_	O
79	101	_	_	O
80	)	_	_	O
81	,	_	_	O
82	or	_	_	O
83	a	_	_	O
84	combined	_	_	O
85	dose	_	_	O
86	of	_	_	O
87	50	_	_	O
88	to	_	_	O
89	60	_	_	O
90	minutes	_	_	O
91	of	_	_	O
92	aerobic	_	_	O
93	and	_	_	O
94	resistance	_	_	O
95	exercise	_	_	O
96	(	_	_	O
97	COMB	_	_	O
98	;	_	_	O
99	n	_	_	O
100	=	_	_	O
101	104	_	_	O
102	)	_	_	O
103	.	_	_	O

104	The	_	_	O
105	primary	_	_	O
106	endpoint	_	_	O
107	was	_	_	O
108	physical	_	_	O
109	functioning	_	_	O
110	assessed	_	_	O
111	by	_	_	O
112	the	_	_	O
113	Medical	_	_	O
114	Outcomes	_	_	O
115	Survey-Short	_	_	O
116	Form	_	_	O
117	(	_	_	O
118	SF	_	_	O
119	)	_	_	O
120	-36	_	_	O
121	.	_	_	O

122	Secondary	_	_	O
123	endpoints	_	_	O
124	were	_	_	O
125	other	_	_	O
126	physical	_	_	O
127	functioning	_	_	O
128	scales	_	_	O
129	,	_	_	O
130	symptoms	_	_	O
131	,	_	_	O
132	fitness	_	_	O
133	,	_	_	O
134	and	_	_	O
135	chemotherapy	_	_	O
136	completion	_	_	O
137	.	_	_	O

138	All	_	_	O
139	statistical	_	_	O
140	tests	_	_	O
141	were	_	_	O
142	linear	_	_	O
143	mixed	_	_	O
144	model	_	_	O
145	analyses	_	_	O
146	,	_	_	O
147	and	_	_	O
148	the	_	_	O
149	P	_	_	O
150	values	_	_	O
151	were	_	_	O
152	two-sided	_	_	O
153	.	_	_	O

154	Follow-up	_	_	O
155	assessment	_	_	O
156	of	_	_	O
157	patient-reported	_	_	O
158	outcomes	_	_	O
159	was	_	_	O
160	99.0	_	_	O
161	%	_	_	O
162	.	_	_	O

163	Adjusted	_	_	B-Premise
164	linear	_	_	I-Premise
165	mixed-model	_	_	I-Premise
166	analyses	_	_	I-Premise
167	showed	_	_	I-Premise
168	that	_	_	I-Premise
169	neither	_	_	I-Premise
170	HIGH	_	_	I-Premise
171	(	_	_	I-Premise
172	+0.8	_	_	I-Premise
173	;	_	_	I-Premise
174	95	_	_	I-Premise
175	%	_	_	I-Premise
176	confidence	_	_	I-Premise
177	interval	_	_	I-Premise
178	[	_	_	I-Premise
179	CI	_	_	I-Premise
180	]	_	_	I-Premise
181	=	_	_	I-Premise
182	-0.8	_	_	I-Premise
183	to	_	_	I-Premise
184	2.4	_	_	I-Premise
185	;	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	.30	_	_	I-Premise
189	)	_	_	I-Premise
190	nor	_	_	I-Premise
191	COMB	_	_	I-Premise
192	(	_	_	I-Premise
193	+0.5	_	_	I-Premise
194	;	_	_	I-Premise
195	95	_	_	I-Premise
196	%	_	_	I-Premise
197	CI	_	_	I-Premise
198	=	_	_	I-Premise
199	-1.1	_	_	I-Premise
200	to	_	_	I-Premise
201	2.1	_	_	I-Premise
202	;	_	_	I-Premise
203	P	_	_	I-Premise
204	=	_	_	I-Premise
205	.52	_	_	I-Premise
206	]	_	_	I-Premise
207	were	_	_	I-Premise
208	superior	_	_	I-Premise
209	to	_	_	I-Premise
210	STAN	_	_	I-Premise
211	for	_	_	I-Premise
212	the	_	_	I-Premise
213	primary	_	_	I-Premise
214	outcome	_	_	I-Premise
215	.	_	_	I-Premise

216	In	_	_	B-Premise
217	secondary	_	_	I-Premise
218	analyses	_	_	I-Premise
219	not	_	_	I-Premise
220	adjusted	_	_	I-Premise
221	for	_	_	I-Premise
222	multiple	_	_	I-Premise
223	comparisons	_	_	I-Premise
224	,	_	_	I-Premise
225	HIGH	_	_	I-Premise
226	was	_	_	I-Premise
227	superior	_	_	I-Premise
228	to	_	_	I-Premise
229	STAN	_	_	I-Premise
230	for	_	_	I-Premise
231	the	_	_	I-Premise
232	SF-36	_	_	I-Premise
233	physical	_	_	I-Premise
234	component	_	_	I-Premise
235	summary	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	=	_	_	I-Premise
239	.04	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	SF-36	_	_	I-Premise
243	bodily	_	_	I-Premise
244	pain	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.02	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	and	_	_	I-Premise
252	endocrine	_	_	I-Premise
253	symptoms	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	.02	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	COMB	_	_	B-Premise
261	was	_	_	I-Premise
262	superior	_	_	I-Premise
263	to	_	_	I-Premise
264	STAN	_	_	I-Premise
265	for	_	_	I-Premise
266	endocrine	_	_	I-Premise
267	symptoms	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.009	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	superior	_	_	I-Premise
275	to	_	_	I-Premise
276	STAN	_	_	I-Premise
277	(	_	_	I-Premise
278	P	_	_	I-Premise
279	<	_	_	I-Premise
280	.001	_	_	I-Premise
281	)	_	_	I-Premise
282	and	_	_	I-Premise
283	HIGH	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	.001	_	_	I-Premise
288	)	_	_	I-Premise
289	for	_	_	I-Premise
290	muscular	_	_	I-Premise
291	strength	_	_	I-Premise
292	.	_	_	I-Premise

293	HIGH	_	_	B-Premise
294	was	_	_	I-Premise
295	superior	_	_	I-Premise
296	to	_	_	I-Premise
297	COMB	_	_	I-Premise
298	for	_	_	I-Premise
299	the	_	_	I-Premise
300	SF-36	_	_	I-Premise
301	bodily	_	_	I-Premise
302	pain	_	_	I-Premise
303	(	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	.04	_	_	I-Premise
307	)	_	_	I-Premise
308	and	_	_	I-Premise
309	aerobic	_	_	I-Premise
310	fitness	_	_	I-Premise
311	(	_	_	I-Premise
312	P	_	_	I-Premise
313	=	_	_	I-Premise
314	.03	_	_	I-Premise
315	)	_	_	I-Premise
316	.	_	_	I-Premise

317	No	_	_	B-Premise
318	differences	_	_	I-Premise
319	emerged	_	_	I-Premise
320	for	_	_	I-Premise
321	body	_	_	I-Premise
322	composition	_	_	I-Premise
323	or	_	_	I-Premise
324	chemotherapy	_	_	I-Premise
325	completion	_	_	I-Premise
326	.	_	_	I-Premise

327	A	_	_	B-Claim
328	higher	_	_	I-Claim
329	volume	_	_	I-Claim
330	of	_	_	I-Claim
331	aerobic	_	_	I-Claim
332	or	_	_	I-Claim
333	combined	_	_	I-Claim
334	exercise	_	_	I-Claim
335	is	_	_	I-Claim
336	achievable	_	_	I-Claim
337	and	_	_	I-Claim
338	safe	_	_	I-Claim
339	during	_	_	I-Claim
340	breast	_	_	I-Claim
341	cancer	_	_	I-Claim
342	chemotherapy	_	_	I-Claim
343	and	_	_	I-Claim
344	may	_	_	I-Claim
345	manage	_	_	I-Claim
346	declines	_	_	I-Claim
347	in	_	_	I-Claim
348	physical	_	_	I-Claim
349	functioning	_	_	I-Claim
350	and	_	_	I-Claim
351	worsening	_	_	I-Claim
352	symptoms	_	_	I-Claim
353	better	_	_	I-Claim
354	than	_	_	I-Claim
355	standard	_	_	I-Claim
356	volumes	_	_	I-Claim
357	.	_	_	I-Claim


0	Intravenous	_	_	O
1	(	_	_	O
2	IV	_	_	O
3	)	_	_	O
4	granulocyte	_	_	O
5	colony	_	_	O
6	stimulating	_	_	O
7	factor	_	_	O
8	(	_	_	O
9	G-CSF	_	_	O
10	)	_	_	O
11	might	_	_	O
12	be	_	_	O
13	safer	_	_	O
14	and	_	_	O
15	more	_	_	O
16	convenient	_	_	O
17	than	_	_	O
18	subcutaneous	_	_	O
19	(	_	_	O
20	SC	_	_	O
21	)	_	_	O
22	administration	_	_	O
23	to	_	_	O
24	hospitalized	_	_	O
25	hemato-oncological	_	_	O
26	patients	_	_	O
27	receiving	_	_	O
28	chemotherapy	_	_	O
29	.	_	_	O

30	To	_	_	O
31	compare	_	_	O
32	IV	_	_	O
33	vs.	_	_	O
34	SC	_	_	O
35	G-CSF	_	_	O
36	administration	_	_	O
37	,	_	_	O
38	we	_	_	O
39	conducted	_	_	O
40	a	_	_	O
41	randomized	_	_	O
42	,	_	_	O
43	open-label	_	_	O
44	trial	_	_	O
45	.	_	_	O

46	We	_	_	O
47	included	_	_	O
48	inpatients	_	_	O
49	receiving	_	_	O
50	chemotherapy	_	_	O
51	for	_	_	O
52	acute	_	_	O
53	myeloid	_	_	O
54	leukemia	_	_	O
55	,	_	_	O
56	acute	_	_	O
57	lymphoblastic	_	_	O
58	leukemia	_	_	O
59	,	_	_	O
60	lymphoma	_	_	O
61	or	_	_	O
62	multiple	_	_	O
63	myeloma	_	_	O
64	,	_	_	O
65	and	_	_	O
66	allogeneic	_	_	O
67	or	_	_	O
68	autologous	_	_	O
69	hematopoietic	_	_	O
70	cell	_	_	O
71	transplantation	_	_	O
72	(	_	_	O
73	HCT	_	_	O
74	)	_	_	O
75	.	_	_	O

76	Patients	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	5	_	_	O
81	mcg/kg	_	_	O
82	single	_	_	O
83	daily	_	_	O
84	dose	_	_	O
85	of	_	_	O
86	IV	_	_	O
87	bolus	_	_	O
88	versus	_	_	O
89	SC	_	_	O
90	filgrastim	_	_	O
91	given	_	_	O
92	for	_	_	O
93	its	_	_	O
94	clinical	_	_	O
95	indications	_	_	O
96	.	_	_	O

97	Patients	_	_	O
98	were	_	_	O
99	crossed-over	_	_	O
100	to	_	_	O
101	the	_	_	O
102	alternate	_	_	O
103	study	_	_	O
104	arm	_	_	O
105	on	_	_	O
106	the	_	_	O
107	subsequent	_	_	O
108	chemotherapy	_	_	O
109	course	_	_	O
110	.	_	_	O

111	The	_	_	O
112	primary	_	_	O
113	outcomes	_	_	O
114	were	_	_	O
115	time	_	_	O
116	from	_	_	O
117	initiation	_	_	O
118	of	_	_	O
119	filgrastim	_	_	O
120	to	_	_	O
121	recovery	_	_	O
122	of	_	_	O
123	stable	_	_	O
124	neutrophil	_	_	O
125	count	_	_	O
126	of	_	_	O
127	>	_	_	O
128	500	_	_	O
129	cells/µL	_	_	O
130	and	_	_	O
131	a	_	_	O
132	composite	_	_	O
133	clinical	_	_	O
134	outcome	_	_	O
135	of	_	_	O
136	infection	_	_	O
137	or	_	_	O
138	death	_	_	O
139	assessed	_	_	O
140	for	_	_	O
141	the	_	_	O
142	first	_	_	O
143	course	_	_	O
144	post-randomization	_	_	O
145	.	_	_	O

146	The	_	_	O
147	study	_	_	O
148	was	_	_	O
149	stopped	_	_	O
150	on	_	_	O
151	the	_	_	O
152	second	_	_	O
153	interim	_	_	O
154	analysis	_	_	O
155	.	_	_	O

156	Of	_	_	O
157	120	_	_	O
158	patients	_	_	O
159	randomized	_	_	O
160	,	_	_	O
161	118	_	_	O
162	were	_	_	O
163	evaluated	_	_	O
164	in	_	_	O
165	the	_	_	O
166	first	_	_	O
167	treatment	_	_	O
168	course	_	_	O
169	.	_	_	O

170	The	_	_	B-Premise
171	mean	_	_	I-Premise
172	time	_	_	I-Premise
173	to	_	_	I-Premise
174	neutropenia	_	_	I-Premise
175	resolution	_	_	I-Premise
176	was	_	_	I-Premise
177	longer	_	_	I-Premise
178	with	_	_	I-Premise
179	IV	_	_	I-Premise
180	G-CSF	_	_	I-Premise
181	[	_	_	I-Premise
182	7.9	_	_	I-Premise
183	days	_	_	I-Premise
184	,	_	_	I-Premise
185	95	_	_	I-Premise
186	%	_	_	I-Premise
187	confidence	_	_	I-Premise
188	interval	_	_	I-Premise
189	(	_	_	I-Premise
190	CI	_	_	I-Premise
191	)	_	_	I-Premise
192	6.6-9.1	_	_	I-Premise
193	]	_	_	I-Premise
194	compared	_	_	I-Premise
195	with	_	_	I-Premise
196	SC	_	_	I-Premise
197	G-CSF	_	_	I-Premise
198	(	_	_	I-Premise
199	5.4	_	_	I-Premise
200	days	_	_	I-Premise
201	,	_	_	I-Premise
202	95	_	_	I-Premise
203	%	_	_	I-Premise
204	CI	_	_	I-Premise
205	4.6-6.2	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	log-rank	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	0.001	_	_	I-Premise
212	.	_	_	I-Premise

213	Longer	_	_	B-Premise
214	neutropenia	_	_	I-Premise
215	duration	_	_	I-Premise
216	was	_	_	I-Premise
217	observed	_	_	I-Premise
218	in	_	_	I-Premise
219	all	_	_	I-Premise
220	patient	_	_	I-Premise
221	subgroups	_	_	I-Premise
222	,	_	_	I-Premise
223	except	_	_	B-Premise
224	for	_	_	I-Premise
225	patients	_	_	I-Premise
226	undergoing	_	_	I-Premise
227	autologous	_	_	I-Premise
228	HCT	_	_	I-Premise
229	.	_	_	I-Premise

230	There	_	_	B-Premise
231	was	_	_	I-Premise
232	no	_	_	I-Premise
233	significant	_	_	I-Premise
234	difference	_	_	I-Premise
235	between	_	_	I-Premise
236	groups	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	occurrence	_	_	I-Premise
240	of	_	_	I-Premise
241	infection	_	_	I-Premise
242	or	_	_	I-Premise
243	death	_	_	I-Premise
244	,	_	_	I-Premise
245	but	_	_	B-Premise
246	more	_	_	I-Premise
247	deaths	_	_	I-Premise
248	were	_	_	I-Premise
249	observed	_	_	I-Premise
250	with	_	_	I-Premise
251	IV	_	_	I-Premise
252	(	_	_	I-Premise
253	4/57	_	_	I-Premise
254	,	_	_	I-Premise
255	7	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	versus	_	_	I-Premise
259	SC	_	_	I-Premise
260	(	_	_	I-Premise
261	1/61	_	_	I-Premise
262	,	_	_	I-Premise
263	1.6	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	G-CSF	_	_	I-Premise
267	administration	_	_	I-Premise
268	,	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	0.196	_	_	I-Premise
272	.	_	_	I-Premise

273	Similar	_	_	O
274	results	_	_	O
275	were	_	_	O
276	observed	_	_	O
277	when	_	_	O
278	all	_	_	O
279	158	_	_	O
280	courses	_	_	O
281	following	_	_	O
282	cross-over	_	_	O
283	were	_	_	O
284	analyzed	_	_	O
285	.	_	_	O

286	Patients	_	_	B-Claim
287	reported	_	_	I-Claim
288	similar	_	_	I-Claim
289	pain	_	_	I-Claim
290	and	_	_	I-Claim
291	satisfaction	_	_	I-Claim
292	scores	_	_	I-Claim
293	in	_	_	I-Claim
294	both	_	_	I-Claim
295	groups	_	_	I-Claim
296	.	_	_	I-Claim

297	Bolus	_	_	B-Claim
298	IV	_	_	I-Claim
299	administration	_	_	I-Claim
300	of	_	_	I-Claim
301	G-CSF	_	_	I-Claim
302	results	_	_	I-Claim
303	in	_	_	I-Claim
304	longer	_	_	I-Claim
305	neutropenia	_	_	I-Claim
306	duration	_	_	I-Claim
307	than	_	_	I-Claim
308	SC	_	_	I-Claim
309	administration	_	_	I-Claim
310	,	_	_	I-Claim
311	with	_	_	I-Claim
312	no	_	_	I-Claim
313	difference	_	_	I-Claim
314	in	_	_	I-Claim
315	clinical	_	_	I-Claim
316	or	_	_	I-Claim
317	quality-of-life	_	_	I-Claim
318	measures	_	_	I-Claim
319	.	_	_	I-Claim


0	Long-term	_	_	O
1	treatment	_	_	O
2	with	_	_	O
3	tenofovir	_	_	O
4	disoproxil	_	_	O
5	fumarate	_	_	O
6	(	_	_	O
7	TDF	_	_	O
8	)	_	_	O
9	alone	_	_	O
10	,	_	_	O
11	or	_	_	O
12	in	_	_	O
13	combination	_	_	O
14	with	_	_	O
15	emtricitabine	_	_	O
16	(	_	_	O
17	FTC	_	_	O
18	)	_	_	O
19	is	_	_	O
20	associated	_	_	O
21	with	_	_	O
22	sustained	_	_	O
23	viral	_	_	O
24	suppression	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	lamivudine	_	_	O
29	resistant	_	_	O
30	(	_	_	O
31	LAM-R	_	_	O
32	)	_	_	O
33	chronic	_	_	O
34	hepatitis	_	_	O
35	B	_	_	O
36	(	_	_	O
37	CHB	_	_	O
38	)	_	_	O
39	.	_	_	O

40	LAM-R	_	_	O
41	CHB	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomised	_	_	O
45	1:1	_	_	O
46	to	_	_	O
47	receive	_	_	O
48	TDF	_	_	O
49	300mg	_	_	O
50	or	_	_	O
51	FTC	_	_	O
52	200mg	_	_	O
53	and	_	_	O
54	TDF	_	_	O
55	300mg	_	_	O
56	once	_	_	O
57	daily	_	_	O
58	in	_	_	O
59	a	_	_	O
60	prospective	_	_	O
61	,	_	_	O
62	double	_	_	O
63	blind	_	_	O
64	,	_	_	O
65	study	_	_	O
66	.	_	_	O

67	The	_	_	O
68	proportion	_	_	O
69	of	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	plasma	_	_	O
73	hepatitis	_	_	O
74	B	_	_	O
75	virus	_	_	O
76	(	_	_	O
77	HBV	_	_	O
78	)	_	_	O
79	DNA	_	_	O
80	<	_	_	O
81	69IU/ml	_	_	O
82	(	_	_	O
83	<	_	_	O
84	400copies/ml	_	_	O
85	)	_	_	O
86	at	_	_	O
87	week	_	_	O
88	96	_	_	O
89	(	_	_	O
90	primary	_	_	O
91	efficacy	_	_	O
92	endpoint	_	_	O
93	)	_	_	O
94	was	_	_	O
95	reported	_	_	O
96	previously	_	_	O
97	.	_	_	O

98	Here	_	_	O
99	we	_	_	O
100	present	_	_	O
101	week	_	_	O
102	240	_	_	O
103	follow-up	_	_	O
104	data	_	_	O
105	.	_	_	O

106	Overall	_	_	O
107	,	_	_	O
108	280	_	_	O
109	patients	_	_	O
110	were	_	_	O
111	randomised	_	_	O
112	to	_	_	O
113	receive	_	_	O
114	TDF	_	_	O
115	(	_	_	O
116	n=141	_	_	O
117	)	_	_	O
118	or	_	_	O
119	FTC/TDF	_	_	O
120	(	_	_	O
121	n=139	_	_	O
122	)	_	_	O
123	,	_	_	O
124	and	_	_	O
125	85.4	_	_	O
126	%	_	_	O
127	completed	_	_	O
128	240	_	_	O
129	weeks	_	_	O
130	of	_	_	O
131	treatment	_	_	O
132	.	_	_	O

133	At	_	_	B-Premise
134	week	_	_	I-Premise
135	240	_	_	I-Premise
136	,	_	_	I-Premise
137	83.0	_	_	I-Premise
138	%	_	_	I-Premise
139	of	_	_	I-Premise
140	patients	_	_	I-Premise
141	in	_	_	I-Premise
142	the	_	_	I-Premise
143	TDF	_	_	I-Premise
144	arm	_	_	I-Premise
145	,	_	_	I-Premise
146	and	_	_	I-Premise
147	82.7	_	_	I-Premise
148	%	_	_	I-Premise
149	of	_	_	I-Premise
150	patients	_	_	I-Premise
151	in	_	_	I-Premise
152	the	_	_	I-Premise
153	FTC/TDF	_	_	I-Premise
154	treatment	_	_	I-Premise
155	arm	_	_	I-Premise
156	had	_	_	I-Premise
157	HBV	_	_	I-Premise
158	DNA	_	_	I-Premise
159	<	_	_	I-Premise
160	69IU/ml	_	_	I-Premise
161	(	_	_	I-Premise
162	p=0.96	_	_	I-Premise
163	)	_	_	I-Premise
164	.	_	_	I-Premise

165	Rates	_	_	B-Premise
166	of	_	_	I-Premise
167	normal	_	_	I-Premise
168	alanine	_	_	I-Premise
169	aminotransferase	_	_	I-Premise
170	(	_	_	I-Premise
171	ALT	_	_	I-Premise
172	)	_	_	I-Premise
173	and	_	_	I-Premise
174	normalised	_	_	I-Premise
175	ALT	_	_	I-Premise
176	were	_	_	I-Premise
177	similar	_	_	I-Premise
178	between	_	_	I-Premise
179	groups	_	_	I-Premise
180	(	_	_	I-Premise
181	p=0.41	_	_	I-Premise
182	and	_	_	I-Premise
183	p=0.97	_	_	I-Premise
184	respectively	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	Hepatitis	_	_	B-Premise
188	B	_	_	I-Premise
189	e	_	_	I-Premise
190	antigen	_	_	I-Premise
191	loss	_	_	I-Premise
192	and	_	_	I-Premise
193	seroconversion	_	_	I-Premise
194	at	_	_	I-Premise
195	week	_	_	I-Premise
196	240	_	_	I-Premise
197	were	_	_	I-Premise
198	similar	_	_	I-Premise
199	between	_	_	I-Premise
200	groups	_	_	I-Premise
201	,	_	_	I-Premise
202	(	_	_	I-Premise
203	p=0.41	_	_	I-Premise
204	and	_	_	I-Premise
205	p=0.67	_	_	I-Premise
206	respectively	_	_	I-Premise
207	)	_	_	I-Premise
208	.	_	_	I-Premise

209	Overall	_	_	B-Premise
210	,	_	_	I-Premise
211	six	_	_	I-Premise
212	patients	_	_	I-Premise
213	achieved	_	_	I-Premise
214	hepatitis	_	_	I-Premise
215	B	_	_	I-Premise
216	surface	_	_	I-Premise
217	antigen	_	_	I-Premise
218	(	_	_	I-Premise
219	HBsAg	_	_	I-Premise
220	)	_	_	I-Premise
221	loss	_	_	I-Premise
222	and	_	_	I-Premise
223	one	_	_	I-Premise
224	patient	_	_	I-Premise
225	(	_	_	I-Premise
226	FTC/TDF	_	_	I-Premise
227	arm	_	_	I-Premise
228	)	_	_	I-Premise
229	had	_	_	I-Premise
230	HBsAg	_	_	I-Premise
231	seroconversion	_	_	I-Premise
232	by	_	_	I-Premise
233	week	_	_	I-Premise
234	240	_	_	I-Premise
235	.	_	_	I-Premise

236	No	_	_	B-Premise
237	TDF	_	_	I-Premise
238	resistance	_	_	I-Premise
239	was	_	_	I-Premise
240	observed	_	_	I-Premise
241	up	_	_	I-Premise
242	to	_	_	I-Premise
243	week	_	_	I-Premise
244	240	_	_	I-Premise
245	.	_	_	I-Premise

246	Treatment	_	_	B-Premise
247	was	_	_	I-Premise
248	generally	_	_	I-Premise
249	well	_	_	I-Premise
250	tolerated	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	renal	_	_	I-Premise
254	events	_	_	I-Premise
255	were	_	_	I-Premise
256	mild	_	_	I-Premise
257	and	_	_	I-Premise
258	infrequent	_	_	I-Premise
259	(	_	_	I-Premise
260	∼8.6	_	_	I-Premise
261	%	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	The	_	_	B-Premise
265	mean	_	_	I-Premise
266	change	_	_	I-Premise
267	in	_	_	I-Premise
268	bone	_	_	I-Premise
269	mineral	_	_	I-Premise
270	density	_	_	I-Premise
271	at	_	_	I-Premise
272	week	_	_	I-Premise
273	240	_	_	I-Premise
274	was	_	_	I-Premise
275	-0.98	_	_	I-Premise
276	%	_	_	I-Premise
277	and	_	_	I-Premise
278	-2.54	_	_	I-Premise
279	%	_	_	I-Premise
280	at	_	_	I-Premise
281	the	_	_	I-Premise
282	spine	_	_	I-Premise
283	and	_	_	I-Premise
284	hip	_	_	I-Premise
285	,	_	_	I-Premise
286	respectively	_	_	I-Premise
287	.	_	_	I-Premise

288	TDF	_	_	B-Claim
289	monotherapy	_	_	I-Claim
290	was	_	_	I-Claim
291	effective	_	_	I-Claim
292	and	_	_	I-Claim
293	well	_	_	I-Claim
294	tolerated	_	_	I-Claim
295	in	_	_	I-Claim
296	LAM-R	_	_	I-Claim
297	CHB	_	_	I-Claim
298	patients	_	_	I-Claim
299	for	_	_	I-Claim
300	up	_	_	I-Claim
301	to	_	_	I-Claim
302	240	_	_	I-Claim
303	weeks	_	_	I-Claim
304	.	_	_	I-Claim

305	The	_	_	O
306	goal	_	_	O
307	of	_	_	O
308	oral	_	_	O
309	antiviral	_	_	O
310	treatment	_	_	O
311	for	_	_	O
312	chronic	_	_	O
313	hepatitis	_	_	O
314	B	_	_	O
315	(	_	_	O
316	CHB	_	_	O
317	)	_	_	O
318	is	_	_	O
319	to	_	_	O
320	achieve	_	_	O
321	and	_	_	O
322	maintain	_	_	O
323	undetectable	_	_	O
324	HBV	_	_	O
325	DNA	_	_	O
326	levels	_	_	O
327	.	_	_	O

328	Treatment	_	_	O
329	options	_	_	O
330	with	_	_	O
331	enhanced	_	_	O
332	potency	_	_	O
333	,	_	_	O
334	and	_	_	O
335	low	_	_	O
336	risk	_	_	O
337	of	_	_	O
338	resistance	_	_	O
339	development	_	_	O
340	for	_	_	O
341	patients	_	_	O
342	infected	_	_	O
343	with	_	_	O
344	lamivudine	_	_	O
345	resistant	_	_	O
346	(	_	_	O
347	LAM-R	_	_	O
348	)	_	_	O
349	HBV	_	_	O
350	are	_	_	O
351	required	_	_	O
352	.	_	_	O

353	Tenofovir	_	_	B-Claim
354	disoproxil	_	_	I-Claim
355	fumarate	_	_	I-Claim
356	(	_	_	I-Claim
357	TDF	_	_	I-Claim
358	)	_	_	I-Claim
359	monotherapy	_	_	I-Claim
360	was	_	_	I-Claim
361	effective	_	_	I-Claim
362	and	_	_	I-Claim
363	well	_	_	I-Claim
364	tolerated	_	_	I-Claim
365	without	_	_	I-Claim
366	TDF	_	_	I-Claim
367	resistance	_	_	I-Claim
368	development	_	_	I-Claim
369	in	_	_	I-Claim
370	CHB	_	_	I-Claim
371	patients	_	_	I-Claim
372	with	_	_	I-Claim
373	LAM-R	_	_	I-Claim
374	,	_	_	I-Claim
375	for	_	_	I-Claim
376	up	_	_	I-Claim
377	to	_	_	I-Claim
378	240weeks	_	_	I-Claim
379	.	_	_	I-Claim


0	Chronic	_	_	O
1	hepatitis	_	_	O
2	B	_	_	O
3	management	_	_	O
4	is	_	_	O
5	commonly	_	_	O
6	targeted	_	_	O
7	at	_	_	O
8	reducing	_	_	O
9	viral	_	_	O
10	replication	_	_	O
11	.	_	_	O

12	However	_	_	O
13	,	_	_	O
14	the	_	_	O
15	currently	_	_	O
16	available	_	_	O
17	antiviral	_	_	O
18	therapies	_	_	O
19	are	_	_	O
20	associated	_	_	O
21	with	_	_	O
22	some	_	_	O
23	problems	_	_	O
24	,	_	_	O
25	including	_	_	O
26	resistance	_	_	O
27	and	_	_	O
28	numerous	_	_	O
29	adverse	_	_	O
30	effects	_	_	O
31	.	_	_	O

32	Ginseng	_	_	O
33	has	_	_	O
34	been	_	_	O
35	reported	_	_	O
36	to	_	_	O
37	be	_	_	O
38	effective	_	_	O
39	for	_	_	O
40	treating	_	_	O
41	viral	_	_	O
42	infections	_	_	O
43	such	_	_	O
44	as	_	_	O
45	influenza	_	_	O
46	and	_	_	O
47	human	_	_	O
48	immunodeficiency	_	_	O
49	virus	_	_	O
50	.	_	_	O

51	However	_	_	O
52	,	_	_	O
53	there	_	_	O
54	are	_	_	O
55	currently	_	_	O
56	few	_	_	O
57	studies	_	_	O
58	on	_	_	O
59	the	_	_	O
60	effects	_	_	O
61	of	_	_	O
62	ginseng	_	_	O
63	in	_	_	O
64	chronic	_	_	O
65	hepatitis	_	_	O
66	B	_	_	O
67	.	_	_	O

68	Thus	_	_	O
69	,	_	_	O
70	this	_	_	O
71	study	_	_	O
72	investigated	_	_	O
73	the	_	_	O
74	effects	_	_	O
75	of	_	_	O
76	ginseng	_	_	O
77	together	_	_	O
78	with	_	_	O
79	antiviral	_	_	O
80	agents	_	_	O
81	in	_	_	O
82	chronic	_	_	O
83	hepatitis	_	_	O
84	B	_	_	O
85	.	_	_	O

86	This	_	_	O
87	was	_	_	O
88	a	_	_	O
89	prospective	_	_	O
90	,	_	_	O
91	single-blinded	_	_	O
92	,	_	_	O
93	randomized	_	_	O
94	controlled	_	_	O
95	trial	_	_	O
96	,	_	_	O
97	and	_	_	O
98	single-center	_	_	O
99	study	_	_	O
100	.	_	_	O

101	Thirty-eight	_	_	O
102	patients	_	_	O
103	were	_	_	O
104	enrolled	_	_	O
105	.	_	_	O

106	The	_	_	O
107	control	_	_	O
108	group	_	_	O
109	(	_	_	O
110	n	_	_	O
111	=	_	_	O
112	19	_	_	O
113	)	_	_	O
114	was	_	_	O
115	administered	_	_	O
116	antiviral	_	_	O
117	agents	_	_	O
118	alone	_	_	O
119	.	_	_	O

120	The	_	_	O
121	experimental	_	_	O
122	group	_	_	O
123	(	_	_	O
124	n	_	_	O
125	=	_	_	O
126	19	_	_	O
127	)	_	_	O
128	was	_	_	O
129	administered	_	_	O
130	antiviral	_	_	O
131	agents	_	_	O
132	along	_	_	O
133	with	_	_	O
134	Korean	_	_	O
135	Red	_	_	O
136	Ginseng	_	_	O
137	powder	_	_	O
138	capsules	_	_	O
139	(	_	_	O
140	each	_	_	O
141	dose	_	_	O
142	is	_	_	O
143	1	_	_	O
144	gram	_	_	O
145	(	_	_	O
146	two	_	_	O
147	capsules	_	_	O
148	)	_	_	O
149	,	_	_	O
150	a	_	_	O
151	one-day	_	_	O
152	dose	_	_	O
153	is	_	_	O
154	3	_	_	O
155	grams	_	_	O
156	)	_	_	O
157	.	_	_	O

158	The	_	_	O
159	baseline	_	_	O
160	characteristics	_	_	O
161	did	_	_	O
162	not	_	_	O
163	differ	_	_	O
164	between	_	_	O
165	the	_	_	O
166	two	_	_	O
167	groups	_	_	O
168	.	_	_	O

169	Differences	_	_	B-Premise
170	in	_	_	I-Premise
171	several	_	_	I-Premise
172	non-invasive	_	_	I-Premise
173	fibrosis	_	_	I-Premise
174	serologic	_	_	I-Premise
175	markers	_	_	I-Premise
176	(	_	_	I-Premise
177	type	_	_	I-Premise
178	IV	_	_	I-Premise
179	collagen	_	_	I-Premise
180	,	_	_	I-Premise
181	hyaluronic	_	_	I-Premise
182	acid	_	_	I-Premise
183	,	_	_	I-Premise
184	transforming	_	_	I-Premise
185	growth	_	_	I-Premise
186	factor-β	_	_	I-Premise
187	)	_	_	I-Premise
188	and	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	hepatitis	_	_	I-Premise
192	B	_	_	I-Premise
193	virus	_	_	I-Premise
194	DNA	_	_	I-Premise
195	levels	_	_	I-Premise
196	were	_	_	I-Premise
197	compared	_	_	I-Premise
198	between	_	_	I-Premise
199	the	_	_	I-Premise
200	groups	_	_	I-Premise
201	.	_	_	I-Premise

202	The	_	_	B-Premise
203	non-invasive	_	_	I-Premise
204	fibrosis	_	_	I-Premise
205	serologic	_	_	I-Premise
206	markers	_	_	I-Premise
207	were	_	_	I-Premise
208	further	_	_	I-Premise
209	decreased	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	experimental	_	_	I-Premise
213	group	_	_	I-Premise
214	,	_	_	I-Premise
215	with	_	_	I-Premise
216	significant	_	_	I-Premise
217	differences	_	_	I-Premise
218	after	_	_	I-Premise
219	treatment	_	_	I-Premise
220	observed	_	_	I-Premise
221	for	_	_	I-Premise
222	hyaluronic	_	_	I-Premise
223	acid	_	_	I-Premise
224	(	_	_	I-Premise
225	p	_	_	I-Premise
226	=	_	_	I-Premise
227	0.032	_	_	I-Premise
228	)	_	_	I-Premise
229	and	_	_	I-Premise
230	transforming	_	_	I-Premise
231	growth	_	_	I-Premise
232	factor-β	_	_	I-Premise
233	(	_	_	I-Premise
234	p	_	_	I-Premise
235	=	_	_	I-Premise
236	0.008	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	but	_	_	I-Premise
240	not	_	_	I-Premise
241	for	_	_	I-Premise
242	type	_	_	I-Premise
243	IV	_	_	I-Premise
244	collagen	_	_	I-Premise
245	(	_	_	I-Premise
246	p	_	_	I-Premise
247	=	_	_	I-Premise
248	0.174	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	This	_	_	B-Claim
252	study	_	_	I-Claim
253	suggests	_	_	I-Claim
254	the	_	_	I-Claim
255	possibility	_	_	I-Claim
256	of	_	_	I-Claim
257	Korean	_	_	I-Claim
258	Red	_	_	I-Claim
259	Ginseng	_	_	I-Claim
260	as	_	_	I-Claim
261	a	_	_	I-Claim
262	complementary	_	_	I-Claim
263	therapy	_	_	I-Claim
264	for	_	_	I-Claim
265	chronic	_	_	I-Claim
266	hepatitis	_	_	I-Claim
267	B	_	_	I-Claim
268	.	_	_	I-Claim


0	We	_	_	O
1	assessed	_	_	O
2	bleb	_	_	O
3	morphology	_	_	O
4	and	_	_	O
5	the	_	_	O
6	intraocular	_	_	O
7	pressure	_	_	O
8	(	_	_	O
9	IOP	_	_	O
10	)	_	_	O
11	-lowering	_	_	O
12	effect	_	_	O
13	of	_	_	O
14	trabeculectomy	_	_	O
15	with	_	_	O
16	ologen	_	_	O
17	compared	_	_	O
18	to	_	_	O
19	mitomycin	_	_	O
20	C	_	_	O
21	(	_	_	O
22	MMC	_	_	O
23	)	_	_	O
24	in	_	_	O
25	juvenile	_	_	O
26	open-angle	_	_	O
27	glaucoma	_	_	O
28	(	_	_	O
29	JOAG	_	_	O
30	)	_	_	O
31	.This	_	_	O
32	is	_	_	O
33	a	_	_	O
34	prospective	_	_	O
35	interventional	_	_	O
36	comparative	_	_	O
37	study	_	_	O
38	conducted	_	_	O
39	on	_	_	O
40	40	_	_	O
41	eyes	_	_	O
42	(	_	_	O
43	20	_	_	O
44	patients	_	_	O
45	)	_	_	O
46	with	_	_	O
47	medically	_	_	O
48	uncontrolled	_	_	O
49	JOAG	_	_	O
50	,	_	_	O
51	randomly	_	_	O
52	operating	_	_	O
53	one	_	_	O
54	eye	_	_	O
55	for	_	_	O
56	trabeculectomy	_	_	O
57	with	_	_	O
58	ologen	_	_	O
59	(	_	_	O
60	group	_	_	O
61	A	_	_	O
62	:	_	_	O
63	20	_	_	O
64	eyes	_	_	O
65	)	_	_	O
66	and	_	_	O
67	the	_	_	O
68	other	_	_	O
69	with	_	_	O
70	MMC	_	_	O
71	(	_	_	O
72	group	_	_	O
73	B	_	_	O
74	:	_	_	O
75	20	_	_	O
76	eyes	_	_	O
77	)	_	_	O
78	.	_	_	O

79	IOP	_	_	O
80	measurement	_	_	O
81	,	_	_	O
82	SITA	_	_	O
83	standard	_	_	O
84	perimetry	_	_	O
85	,	_	_	O
86	and	_	_	O
87	spectral	_	_	O
88	domain	_	_	O
89	optical	_	_	O
90	coherence	_	_	O
91	tomography	_	_	O
92	(	_	_	O
93	OCT	_	_	O
94	)	_	_	O
95	for	_	_	O
96	retinal	_	_	O
97	nerve	_	_	O
98	fiber	_	_	O
99	layer	_	_	O
100	(	_	_	O
101	RNFL	_	_	O
102	)	_	_	O
103	thickness	_	_	O
104	were	_	_	O
105	all	_	_	O
106	done	_	_	O
107	pre-	_	_	O
108	and	_	_	O
109	postoperatively	_	_	O
110	.	_	_	O

111	Postoperative	_	_	O
112	blebs	_	_	O
113	were	_	_	O
114	assessed	_	_	O
115	clinically	_	_	O
116	using	_	_	O
117	the	_	_	O
118	Moorfields	_	_	O
119	bleb	_	_	O
120	grading	_	_	O
121	system	_	_	O
122	(	_	_	O
123	MBGS	_	_	O
124	)	_	_	O
125	and	_	_	O
126	anterior	_	_	O
127	segment	_	_	O
128	OCT	_	_	O
129	(	_	_	O
130	AS-OCT	_	_	O
131	)	_	_	O
132	.	_	_	O

133	All	_	_	O
134	patients	_	_	O
135	were	_	_	O
136	examined	_	_	O
137	for	_	_	O
138	up	_	_	O
139	to	_	_	O
140	1	_	_	O
141	year	_	_	O
142	postoperatively	_	_	O
143	.	_	_	O

144	The	_	_	B-Premise
145	mean	_	_	I-Premise
146	postoperative	_	_	I-Premise
147	IOP	_	_	I-Premise
148	was	_	_	I-Premise
149	statistically	_	_	I-Premise
150	significantly	_	_	I-Premise
151	lower	_	_	I-Premise
152	than	_	_	I-Premise
153	the	_	_	I-Premise
154	mean	_	_	I-Premise
155	preoperative	_	_	I-Premise
156	IOP	_	_	I-Premise
157	at	_	_	I-Premise
158	each	_	_	I-Premise
159	follow-up	_	_	I-Premise
160	in	_	_	I-Premise
161	each	_	_	I-Premise
162	group	_	_	I-Premise
163	.	_	_	I-Premise

164	At	_	_	B-Premise
165	1	_	_	I-Premise
166	year	_	_	I-Premise
167	,	_	_	I-Premise
168	the	_	_	I-Premise
169	mean	_	_	I-Premise
170	postoperative	_	_	I-Premise
171	IOP	_	_	I-Premise
172	was	_	_	I-Premise
173	significantly	_	_	I-Premise
174	lower	_	_	I-Premise
175	in	_	_	I-Premise
176	group	_	_	I-Premise
177	A	_	_	I-Premise
178	.	_	_	I-Premise

179	According	_	_	B-Premise
180	to	_	_	I-Premise
181	the	_	_	I-Premise
182	MBGS	_	_	I-Premise
183	,	_	_	I-Premise
184	blebs	_	_	I-Premise
185	with	_	_	I-Premise
186	an	_	_	I-Premise
187	ologen	_	_	I-Premise
188	implant	_	_	I-Premise
189	showed	_	_	I-Premise
190	significantly	_	_	I-Premise
191	better	_	_	I-Premise
192	scoring	_	_	I-Premise
193	than	_	_	I-Premise
194	those	_	_	I-Premise
195	with	_	_	I-Premise
196	MMC	_	_	I-Premise
197	.	_	_	I-Premise

198	AS-OCT	_	_	B-Premise
199	showed	_	_	I-Premise
200	that	_	_	I-Premise
201	ologen-induced	_	_	I-Premise
202	blebs	_	_	I-Premise
203	had	_	_	I-Premise
204	significantly	_	_	I-Premise
205	more	_	_	I-Premise
206	fluid-filled	_	_	I-Premise
207	spaces	_	_	I-Premise
208	,	_	_	I-Premise
209	cleavage	_	_	I-Premise
210	planes	_	_	I-Premise
211	,	_	_	I-Premise
212	and	_	_	I-Premise
213	less	_	_	I-Premise
214	fibrosis	_	_	I-Premise
215	.	_	_	I-Premise

216	Ologen	_	_	B-Claim
217	resulted	_	_	I-Claim
218	in	_	_	I-Claim
219	a	_	_	I-Claim
220	lower	_	_	I-Claim
221	long-term	_	_	I-Claim
222	postoperative	_	_	I-Claim
223	IOP	_	_	I-Claim
224	,	_	_	I-Claim
225	a	_	_	I-Claim
226	better	_	_	I-Claim
227	bleb	_	_	I-Claim
228	morphology	_	_	I-Claim
229	,	_	_	I-Claim
230	and	_	_	I-Claim
231	fewer	_	_	I-Claim
232	complications	_	_	I-Claim
233	.	_	_	I-Claim

234	Our	_	_	B-Claim
235	results	_	_	I-Claim
236	suggest	_	_	I-Claim
237	that	_	_	I-Claim
238	ologen	_	_	I-Claim
239	may	_	_	I-Claim
240	be	_	_	I-Claim
241	a	_	_	I-Claim
242	useful	_	_	I-Claim
243	alternative	_	_	I-Claim
244	to	_	_	I-Claim
245	MMC	_	_	I-Claim
246	in	_	_	I-Claim
247	JOAG	_	_	I-Claim
248	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	work	_	_	O
5	is	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	tolerability	_	_	O
11	of	_	_	O
12	preservative	_	_	O
13	containing	_	_	O
14	0.0015	_	_	O
15	%	_	_	O
16	tafluprost	_	_	O
17	and	_	_	O
18	preservative-free	_	_	O
19	0.0015	_	_	O
20	%	_	_	O
21	tafluprost	_	_	O
22	using	_	_	O
23	a	_	_	O
24	prospective	_	_	O
25	crossover	_	_	O
26	study	_	_	O
27	.	_	_	O

28	Primary	_	_	O
29	open	_	_	O
30	angle	_	_	O
31	glaucoma	_	_	O
32	(	_	_	O
33	POAG	_	_	O
34	)	_	_	O
35	and	_	_	O
36	normotensive	_	_	O
37	glaucoma	_	_	O
38	(	_	_	O
39	NTG	_	_	O
40	)	_	_	O
41	patients	_	_	O
42	were	_	_	O
43	randomized	_	_	O
44	enrolled	_	_	O
45	.	_	_	O

46	Group	_	_	O
47	1	_	_	O
48	(	_	_	O
49	NPT	_	_	O
50	to	_	_	O
51	PT	_	_	O
52	)	_	_	O
53	patients	_	_	O
54	used	_	_	O
55	preservative-free	_	_	O
56	0.0015	_	_	O
57	%	_	_	O
58	tafluprost	_	_	O
59	(	_	_	O
60	NPT	_	_	O
61	)	_	_	O
62	for	_	_	O
63	6	_	_	O
64	months	_	_	O
65	and	_	_	O
66	then	_	_	O
67	changed	_	_	O
68	to	_	_	O
69	preservative	_	_	O
70	containing	_	_	O
71	0.0015	_	_	O
72	%	_	_	O
73	tafluprost	_	_	O
74	(	_	_	O
75	PT	_	_	O
76	)	_	_	O
77	for	_	_	O
78	6	_	_	O
79	months	_	_	O
80	.	_	_	O

81	Group	_	_	O
82	2	_	_	O
83	(	_	_	O
84	PT	_	_	O
85	to	_	_	O
86	NPT	_	_	O
87	)	_	_	O
88	patients	_	_	O
89	used	_	_	O
90	preservative	_	_	O
91	containing	_	_	O
92	0.0015	_	_	O
93	%	_	_	O
94	tafluprost	_	_	O
95	for	_	_	O
96	6	_	_	O
97	months	_	_	O
98	and	_	_	O
99	changed	_	_	O
100	to	_	_	O
101	preservative-free	_	_	O
102	0.0015	_	_	O
103	%	_	_	O
104	tafluprost	_	_	O
105	for	_	_	O
106	6	_	_	O
107	months	_	_	O
108	.	_	_	O

109	At	_	_	O
110	1	_	_	O
111	,	_	_	O
112	3	_	_	O
113	,	_	_	O
114	6	_	_	O
115	,	_	_	O
116	7	_	_	O
117	,	_	_	O
118	9	_	_	O
119	,	_	_	O
120	and	_	_	O
121	12	_	_	O
122	months	_	_	O
123	,	_	_	O
124	we	_	_	O
125	measured	_	_	O
126	intraocular	_	_	O
127	pressure	_	_	O
128	for	_	_	O
129	efficacy	_	_	O
130	and	_	_	O
131	graded	_	_	O
132	corneal	_	_	O
133	erosion	_	_	O
134	,	_	_	O
135	tear	_	_	O
136	break-up	_	_	O
137	time	_	_	O
138	(	_	_	O
139	TBUT	_	_	O
140	)	_	_	O
141	,	_	_	O
142	and	_	_	O
143	subjective	_	_	O
144	discomfort	_	_	O
145	.	_	_	O

146	A	_	_	O
147	total	_	_	O
148	of	_	_	O
149	20	_	_	O
150	patients	_	_	O
151	and	_	_	O
152	20	_	_	O
153	eyes	_	_	O
154	were	_	_	O
155	enrolled	_	_	O
156	.	_	_	O

157	In	_	_	B-Premise
158	Group	_	_	I-Premise
159	1	_	_	I-Premise
160	and	_	_	I-Premise
161	2	_	_	I-Premise
162	,	_	_	I-Premise
163	intraocular	_	_	I-Premise
164	pressure	_	_	I-Premise
165	was	_	_	I-Premise
166	well	_	_	I-Premise
167	controlled	_	_	I-Premise
168	to	_	_	I-Premise
169	approximately	_	_	I-Premise
170	14	_	_	I-Premise
171	mmHg	_	_	I-Premise
172	(	_	_	I-Premise
173	9.38-18.46	_	_	I-Premise
174	%	_	_	I-Premise
175	decrease	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Generally	_	_	B-Premise
179	,	_	_	I-Premise
180	subjective	_	_	I-Premise
181	satisfaction	_	_	I-Premise
182	was	_	_	I-Premise
183	improved	_	_	I-Premise
184	after	_	_	I-Premise
185	changing	_	_	I-Premise
186	from	_	_	I-Premise
187	PT	_	_	I-Premise
188	to	_	_	I-Premise
189	NPT	_	_	I-Premise
190	(	_	_	I-Premise
191	p	_	_	I-Premise
192	=	_	_	I-Premise
193	0.03	_	_	I-Premise
194	)	_	_	I-Premise
195	and	_	_	I-Premise
196	TBUT	_	_	I-Premise
197	using	_	_	I-Premise
198	PT	_	_	I-Premise
199	was	_	_	I-Premise
200	numerically	_	_	I-Premise
201	inferior	_	_	I-Premise
202	to	_	_	I-Premise
203	that	_	_	I-Premise
204	using	_	_	I-Premise
205	NPT	_	_	I-Premise
206	(	_	_	I-Premise
207	p	_	_	I-Premise
208	=	_	_	I-Premise
209	0.06	_	_	I-Premise
210	)	_	_	I-Premise
211	but	_	_	I-Premise
212	not	_	_	I-Premise
213	when	_	_	I-Premise
214	changing	_	_	I-Premise
215	from	_	_	I-Premise
216	NPT	_	_	I-Premise
217	to	_	_	I-Premise
218	PT	_	_	I-Premise
219	.	_	_	I-Premise

220	Both	_	_	B-Claim
221	preservative	_	_	I-Claim
222	containing	_	_	I-Claim
223	and	_	_	I-Claim
224	preservative-free	_	_	I-Claim
225	0.0015	_	_	I-Claim
226	%	_	_	I-Claim
227	tafluprost	_	_	I-Claim
228	reduced	_	_	I-Claim
229	intraocular	_	_	I-Claim
230	pressure	_	_	I-Claim
231	significantly	_	_	I-Claim
232	.	_	_	I-Claim

233	In	_	_	O
234	addition	_	_	O
235	,	_	_	O
236	changing	_	_	B-Claim
237	medication	_	_	I-Claim
238	from	_	_	I-Claim
239	PT	_	_	I-Claim
240	to	_	_	I-Claim
241	NPT	_	_	I-Claim
242	might	_	_	I-Claim
243	improve	_	_	I-Claim
244	subjective	_	_	I-Claim
245	satisfaction	_	_	I-Claim
246	and	_	_	I-Claim
247	tear	_	_	I-Claim
248	break	_	_	I-Claim
249	up	_	_	I-Claim
250	time	_	_	I-Claim
251	.	_	_	I-Claim


0	The	_	_	O
1	hepatitis	_	_	O
2	B	_	_	O
3	is	_	_	O
4	most	_	_	O
5	prevalent	_	_	O
6	diseases	_	_	O
7	(	_	_	O
8	along	_	_	O
9	with	_	_	O
10	morbidities	_	_	O
11	)	_	_	O
12	in	_	_	O
13	Asian	_	_	O
14	countries	_	_	O
15	.	_	_	O

16	This	_	_	O
17	research	_	_	O
18	study	_	_	O
19	has	_	_	O
20	been	_	_	O
21	conducted	_	_	O
22	to	_	_	O
23	provide	_	_	O
24	an	_	_	O
25	alternative	_	_	O
26	treatment	_	_	O
27	which	_	_	O
28	is	_	_	O
29	safe	_	_	O
30	,	_	_	O
31	effective	_	_	O
32	and	_	_	O
33	cost-effective	_	_	O
34	to	_	_	O
35	comprehend	_	_	O
36	relations	_	_	O
37	of	_	_	O
38	disease	_	_	O
39	,	_	_	O
40	symptoms	_	_	O
41	,	_	_	O
42	patients	_	_	O
43	response	_	_	O
44	and	_	_	O
45	the	_	_	O
46	clinical	_	_	O
47	response	_	_	O
48	via	_	_	O
49	better	_	_	O
50	management	_	_	O
51	of	_	_	O
52	hepatitis	_	_	O
53	B	_	_	O
54	.	_	_	O

55	The	_	_	O
56	goal	_	_	O
57	of	_	_	O
58	this	_	_	O
59	research	_	_	O
60	is	_	_	O
61	to	_	_	O
62	evaluate	_	_	O
63	efficacy	_	_	O
64	and	_	_	O
65	safety	_	_	O
66	of	_	_	O
67	herbal	_	_	O
68	medicine	_	_	O
69	as	_	_	O
70	compared	_	_	O
71	to	_	_	O
72	allopathic	_	_	O
73	medicine	_	_	O
74	in	_	_	O
75	patients	_	_	O
76	suffering	_	_	O
77	from	_	_	O
78	hepatitis	_	_	O
79	B	_	_	O
80	.	_	_	O

81	This	_	_	O
82	was	_	_	O
83	a	_	_	O
84	single	_	_	O
85	blind	_	_	O
86	,	_	_	O
87	randomized	_	_	O
88	controlled	_	_	O
89	clinical	_	_	O
90	trial	_	_	O
91	conducted	_	_	O
92	at	_	_	O
93	Shifa-ul-Mulk	_	_	O
94	Memorial	_	_	O
95	Hospital	_	_	O
96	Hamdard	_	_	O
97	University	_	_	O
98	,	_	_	O
99	Karachi	_	_	O
100	and	_	_	O
101	Dar	_	_	O
102	ul	_	_	O
103	Shifa	_	_	O
104	Unani	_	_	O
105	Dawakhana	_	_	O
106	Karachi	_	_	O
107	,	_	_	O
108	Pakistan	_	_	O
109	.	_	_	O

110	The	_	_	O
111	patients	_	_	O
112	of	_	_	O
113	both	_	_	O
114	genders	_	_	O
115	ranging	_	_	O
116	from	_	_	O
117	25	_	_	O
118	to	_	_	O
119	50	_	_	O
120	years	_	_	O
121	with	_	_	O
122	symptoms	_	_	O
123	and	_	_	O
124	diagnosed	_	_	O
125	for	_	_	O
126	hepatitis	_	_	O
127	B	_	_	O
128	that	_	_	O
129	fulfilled	_	_	O
130	the	_	_	O
131	criteria	_	_	O
132	for	_	_	O
133	membership	_	_	O
134	,	_	_	O
135	and	_	_	O
136	consented	_	_	O
137	for	_	_	O
138	participation	_	_	O
139	were	_	_	O
140	registered	_	_	O
141	.	_	_	O

142	Ethical	_	_	O
143	committee	_	_	O
144	clearance	_	_	O
145	and	_	_	O
146	permission	_	_	O
147	was	_	_	O
148	obtained	_	_	O
149	from	_	_	O
150	the	_	_	O
151	concerned	_	_	O
152	committee	_	_	O
153	at	_	_	O
154	Faculty	_	_	O
155	of	_	_	O
156	Eastern	_	_	O
157	Medicine	_	_	O
158	,	_	_	O
159	Hamdard	_	_	O
160	University	_	_	O
161	,	_	_	O
162	Karachi	_	_	O
163	,	_	_	O
164	Pakistan	_	_	O
165	.	_	_	O

166	No	_	_	B-Premise
167	significant	_	_	I-Premise
168	difference	_	_	I-Premise
169	was	_	_	I-Premise
170	identified	_	_	I-Premise
171	after	_	_	I-Premise
172	treatment	_	_	I-Premise
173	and	_	_	I-Premise
174	it	_	_	I-Premise
175	was	_	_	I-Premise
176	found	_	_	I-Premise
177	that	_	_	I-Premise
178	the	_	_	I-Premise
179	efficacy	_	_	I-Premise
180	of	_	_	I-Premise
181	Alpha	_	_	I-Premise
182	(	_	_	I-Premise
183	Control	_	_	I-Premise
184	drug	_	_	I-Premise
185	)	_	_	I-Premise
186	is	_	_	I-Premise
187	same	_	_	I-Premise
188	as	_	_	I-Premise
189	Safoof	_	_	I-Premise
190	akseer	_	_	I-Premise
191	e	_	_	I-Premise
192	jigar	_	_	I-Premise
193	(	_	_	I-Premise
194	Test	_	_	I-Premise
195	drug	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	The	_	_	B-Claim
199	data	_	_	I-Claim
200	offered	_	_	I-Claim
201	support	_	_	I-Claim
202	to	_	_	I-Claim
203	the	_	_	I-Claim
204	null	_	_	I-Claim
205	hypothesis	_	_	I-Claim
206	and	_	_	I-Claim
207	therefore	_	_	I-Claim
208	research	_	_	I-Claim
209	hypothesis	_	_	I-Claim
210	was	_	_	I-Claim
211	rejected	_	_	I-Claim
212	.	_	_	I-Claim

213	According	_	_	B-Premise
214	to	_	_	I-Premise
215	the	_	_	I-Premise
216	statistical	_	_	I-Premise
217	analysis	_	_	I-Premise
218	by	_	_	I-Premise
219	chi	_	_	I-Premise
220	square	_	_	I-Premise
221	,	_	_	I-Premise
222	hepatitis	_	_	I-Premise
223	B	_	_	I-Premise
224	was	_	_	I-Premise
225	recorded	_	_	I-Premise
226	as	_	_	I-Premise
227	negative	_	_	I-Premise
228	in	_	_	I-Premise
229	26	_	_	I-Premise
230	patients	_	_	I-Premise
231	(	_	_	I-Premise
232	57.77	_	_	I-Premise
233	%	_	_	I-Premise
234	)	_	_	I-Premise
235	out	_	_	I-Premise
236	of	_	_	I-Premise
237	45	_	_	I-Premise
238	patients	_	_	I-Premise
239	by	_	_	I-Premise
240	the	_	_	I-Premise
241	use	_	_	I-Premise
242	of	_	_	I-Premise
243	Interferon	_	_	I-Premise
244	Alpha	_	_	I-Premise
245	(	_	_	I-Premise
246	control	_	_	I-Premise
247	therapy	_	_	I-Premise
248	)	_	_	I-Premise
249	and	_	_	I-Premise
250	in	_	_	I-Premise
251	27	_	_	I-Premise
252	patients	_	_	I-Premise
253	(	_	_	I-Premise
254	64.28	_	_	I-Premise
255	%	_	_	I-Premise
256	)	_	_	I-Premise
257	out	_	_	I-Premise
258	of	_	_	I-Premise
259	42	_	_	I-Premise
260	patients	_	_	I-Premise
261	by	_	_	I-Premise
262	the	_	_	I-Premise
263	use	_	_	I-Premise
264	of	_	_	I-Premise
265	Safoof	_	_	I-Premise
266	akseer	_	_	I-Premise
267	e	_	_	I-Premise
268	jigar	_	_	I-Premise
269	(	_	_	I-Premise
270	test	_	_	I-Premise
271	drug	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Comparison	_	_	B-Premise
275	of	_	_	I-Premise
276	the	_	_	I-Premise
277	data	_	_	I-Premise
278	recorded	_	_	I-Premise
279	of	_	_	I-Premise
280	the	_	_	I-Premise
281	patients	_	_	I-Premise
282	was	_	_	I-Premise
283	determined	_	_	I-Premise
284	as	_	_	I-Premise
285	both	_	_	I-Premise
286	drugs	_	_	I-Premise
287	showed	_	_	I-Premise
288	significant	_	_	I-Premise
289	improvement	_	_	I-Premise
290	and	_	_	I-Premise
291	p	_	_	I-Premise
292	value	_	_	I-Premise
293	>	_	_	I-Premise
294	0.05	_	_	I-Premise
295	.	_	_	I-Premise

296	The	_	_	B-Claim
297	efficacy	_	_	I-Claim
298	response	_	_	I-Claim
299	is	_	_	I-Claim
300	equal	_	_	I-Claim
301	in	_	_	I-Claim
302	both	_	_	I-Claim
303	drugs	_	_	I-Claim
304	while	_	_	I-Claim
305	test	_	_	I-Claim
306	drug	_	_	I-Claim
307	showed	_	_	I-Claim
308	more	_	_	I-Claim
309	safety	_	_	I-Claim
310	response	_	_	I-Claim
311	.	_	_	I-Claim

312	It	_	_	B-Claim
313	is	_	_	I-Claim
314	concluded	_	_	I-Claim
315	that	_	_	I-Claim
316	Safoof	_	_	I-Claim
317	akseer	_	_	I-Claim
318	e	_	_	I-Claim
319	jigar	_	_	I-Claim
320	possesses	_	_	I-Claim
321	as	_	_	I-Claim
322	effective	_	_	I-Claim
323	a	_	_	I-Claim
324	therapeutic	_	_	I-Claim
325	value	_	_	I-Claim
326	in	_	_	I-Claim
327	treating	_	_	I-Claim
328	hepatitis	_	_	I-Claim
329	B	_	_	I-Claim
330	as	_	_	I-Claim
331	allopathic	_	_	I-Claim
332	medicine	_	_	I-Claim
333	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	1-year	_	_	O
3	outcomes	_	_	O
4	of	_	_	O
5	illuminated	_	_	O
6	microcatheter-assisted	_	_	O
7	circumferential	_	_	O
8	trabeculotomy	_	_	O
9	(	_	_	O
10	IMCT	_	_	O
11	)	_	_	O
12	vs	_	_	O
13	conventional	_	_	O
14	partial	_	_	O
15	trabeculotomy	_	_	O
16	(	_	_	O
17	CPT	_	_	O
18	)	_	_	O
19	for	_	_	O
20	primary	_	_	O
21	congenital	_	_	O
22	glaucoma	_	_	O
23	(	_	_	O
24	PCG	_	_	O
25	)	_	_	O
26	.	_	_	O

27	Forty	_	_	O
28	eyes	_	_	O
29	of	_	_	O
30	31	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	unilateral	_	_	O
34	or	_	_	O
35	bilateral	_	_	O
36	primary	_	_	O
37	congenital	_	_	O
38	glaucoma	_	_	O
39	aged	_	_	O
40	less	_	_	O
41	than	_	_	O
42	2	_	_	O
43	years	_	_	O
44	were	_	_	O
45	randomized	_	_	O
46	to	_	_	O
47	undergo	_	_	O
48	IMCT	_	_	O
49	(	_	_	O
50	20	_	_	O
51	eyes	_	_	O
52	)	_	_	O
53	or	_	_	O
54	CPT	_	_	O
55	(	_	_	O
56	20	_	_	O
57	eyes	_	_	O
58	)	_	_	O
59	.	_	_	O

60	Primary	_	_	O
61	outcome	_	_	O
62	measure	_	_	O
63	was	_	_	O
64	intraocular	_	_	O
65	pressure	_	_	O
66	(	_	_	O
67	IOP	_	_	O
68	)	_	_	O
69	reduction	_	_	O
70	.	_	_	O

71	The	_	_	O
72	success	_	_	O
73	criterion	_	_	O
74	was	_	_	O
75	defined	_	_	O
76	as	_	_	O
77	IOP	_	_	O
78	≤	_	_	O
79	12	_	_	O
80	mm	_	_	O
81	Hg	_	_	O
82	without	_	_	O
83	and	_	_	O
84	with	_	_	O
85	antiglaucoma	_	_	O
86	medications	_	_	O
87	(	_	_	O
88	absolute	_	_	O
89	success	_	_	O
90	and	_	_	O
91	qualified	_	_	O
92	success	_	_	O
93	,	_	_	O
94	respectively	_	_	O
95	)	_	_	O
96	.	_	_	O

97	The	_	_	O
98	mean	_	_	O
99	age	_	_	O
100	of	_	_	O
101	our	_	_	O
102	study	_	_	O
103	population	_	_	O
104	was	_	_	O
105	8.35	_	_	O
106	±	_	_	O
107	1.2	_	_	O
108	months	_	_	O
109	.	_	_	O

110	The	_	_	O
111	mean	_	_	O
112	preoperative	_	_	O
113	IOP	_	_	O
114	was	_	_	O
115	24.70	_	_	O
116	±	_	_	O
117	3.90	_	_	O
118	mm	_	_	O
119	Hg	_	_	O
120	in	_	_	O
121	the	_	_	O
122	IMCT	_	_	O
123	group	_	_	O
124	and	_	_	O
125	24.60	_	_	O
126	±	_	_	O
127	3.31	_	_	O
128	mm	_	_	O
129	Hg	_	_	O
130	in	_	_	O
131	the	_	_	O
132	CPT	_	_	O
133	group	_	_	O
134	.	_	_	O

135	Both	_	_	O
136	groups	_	_	O
137	were	_	_	O
138	comparable	_	_	O
139	with	_	_	O
140	respect	_	_	O
141	to	_	_	O
142	preoperative	_	_	O
143	IOP	_	_	O
144	,	_	_	O
145	corneal	_	_	O
146	clarity	_	_	O
147	,	_	_	O
148	corneal	_	_	O
149	diameter	_	_	O
150	,	_	_	O
151	vertical	_	_	O
152	cup-to-disc	_	_	O
153	ratio	_	_	O
154	,	_	_	O
155	and	_	_	O
156	refractive	_	_	O
157	error	_	_	O
158	.	_	_	O

159	In	_	_	B-Premise
160	the	_	_	I-Premise
161	IMCT	_	_	I-Premise
162	group	_	_	I-Premise
163	,	_	_	I-Premise
164	360-degree	_	_	I-Premise
165	cannulation	_	_	I-Premise
166	was	_	_	I-Premise
167	achieved	_	_	I-Premise
168	in	_	_	I-Premise
169	80	_	_	I-Premise
170	%	_	_	I-Premise
171	(	_	_	I-Premise
172	16/20	_	_	I-Premise
173	)	_	_	I-Premise
174	of	_	_	I-Premise
175	eyes	_	_	I-Premise
176	.	_	_	I-Premise

177	For	_	_	B-Premise
178	the	_	_	I-Premise
179	IMCT	_	_	I-Premise
180	group	_	_	I-Premise
181	and	_	_	I-Premise
182	CPT	_	_	I-Premise
183	groups	_	_	I-Premise
184	,	_	_	I-Premise
185	respectively	_	_	I-Premise
186	,	_	_	I-Premise
187	the	_	_	I-Premise
188	absolute	_	_	I-Premise
189	success	_	_	I-Premise
190	rates	_	_	I-Premise
191	were	_	_	I-Premise
192	80	_	_	I-Premise
193	%	_	_	I-Premise
194	(	_	_	I-Premise
195	16/20	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	60	_	_	I-Premise
199	%	_	_	I-Premise
200	(	_	_	I-Premise
201	12/20	_	_	I-Premise
202	)	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	<	_	_	I-Premise
206	.001	_	_	I-Premise
207	)	_	_	I-Premise
208	and	_	_	I-Premise
209	qualified	_	_	I-Premise
210	success	_	_	I-Premise
211	rates	_	_	I-Premise
212	were	_	_	I-Premise
213	90	_	_	I-Premise
214	%	_	_	I-Premise
215	(	_	_	I-Premise
216	18/20	_	_	I-Premise
217	)	_	_	I-Premise
218	and	_	_	I-Premise
219	70	_	_	I-Premise
220	%	_	_	I-Premise
221	(	_	_	I-Premise
222	14/20	_	_	I-Premise
223	)	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	<	_	_	I-Premise
227	.001	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Both	_	_	B-Claim
231	procedures	_	_	I-Claim
232	produced	_	_	I-Claim
233	a	_	_	I-Claim
234	statistically	_	_	I-Claim
235	significant	_	_	I-Claim
236	reduction	_	_	I-Claim
237	in	_	_	I-Claim
238	IOP	_	_	I-Claim
239	,	_	_	I-Claim
240	and	_	_	O
241	eyes	_	_	B-Premise
242	undergoing	_	_	I-Premise
243	IMCT	_	_	I-Premise
244	achieved	_	_	I-Premise
245	a	_	_	I-Premise
246	lower	_	_	I-Premise
247	IOP	_	_	I-Premise
248	than	_	_	I-Premise
249	CPT	_	_	I-Premise
250	group	_	_	I-Premise
251	eyes	_	_	I-Premise
252	at	_	_	I-Premise
253	12	_	_	I-Premise
254	months	_	_	I-Premise
255	follow-up	_	_	I-Premise
256	(	_	_	I-Premise
257	9.5	_	_	I-Premise
258	±	_	_	I-Premise
259	2.4	_	_	I-Premise
260	mm	_	_	I-Premise
261	Hg	_	_	I-Premise
262	and	_	_	I-Premise
263	11.7	_	_	I-Premise
264	±	_	_	I-Premise
265	2.1	_	_	I-Premise
266	mm	_	_	I-Premise
267	Hg	_	_	I-Premise
268	,	_	_	I-Premise
269	respectively	_	_	I-Premise
270	,	_	_	I-Premise
271	P	_	_	I-Premise
272	<	_	_	I-Premise
273	.001	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	In	_	_	B-Claim
277	primary	_	_	I-Claim
278	congential	_	_	I-Claim
279	glaucoma	_	_	I-Claim
280	,	_	_	I-Claim
281	illuminated	_	_	I-Claim
282	microcatheter-assisted	_	_	I-Claim
283	360-degree	_	_	I-Claim
284	circumferential	_	_	I-Claim
285	trabeculotomy	_	_	I-Claim
286	performed	_	_	I-Claim
287	better	_	_	I-Claim
288	than	_	_	I-Claim
289	conventional	_	_	I-Claim
290	partial	_	_	I-Claim
291	trabeculotomy	_	_	I-Claim
292	at	_	_	I-Claim
293	1	_	_	I-Claim
294	year	_	_	I-Claim
295	follow-up	_	_	I-Claim
296	and	_	_	I-Claim
297	resulted	_	_	I-Claim
298	in	_	_	I-Claim
299	significantly	_	_	I-Claim
300	lower	_	_	I-Claim
301	IOP	_	_	I-Claim
302	measurements	_	_	I-Claim
303	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcome	_	_	O
4	of	_	_	O
5	trabeculectomy	_	_	O
6	using	_	_	O
7	adjunctive	_	_	O
8	intracameral	_	_	O
9	bevacizumab	_	_	O
10	versus	_	_	O
11	intraoperative	_	_	O
12	mitomycin	_	_	O
13	C	_	_	O
14	(	_	_	O
15	MMC	_	_	O
16	)	_	_	O
17	.	_	_	O

18	In	_	_	O
19	this	_	_	O
20	double-blind	_	_	O
21	,	_	_	O
22	randomized	_	_	O
23	clinical	_	_	O
24	trial	_	_	O
25	87	_	_	O
26	eyes	_	_	O
27	of	_	_	O
28	87	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	primary	_	_	O
32	open-angle	_	_	O
33	or	_	_	O
34	pseudoexfoliation	_	_	O
35	glaucoma	_	_	O
36	were	_	_	O
37	assigned	_	_	O
38	to	_	_	O
39	each	_	_	O
40	treatment	_	_	O
41	group	_	_	O
42	(	_	_	O
43	44	_	_	O
44	cases	_	_	O
45	received	_	_	O
46	1.25	_	_	O
47	mg	_	_	O
48	intracameral	_	_	O
49	bevacizumab	_	_	O
50	at	_	_	O
51	the	_	_	O
52	end	_	_	O
53	of	_	_	O
54	operation	_	_	O
55	and	_	_	O
56	in	_	_	O
57	43	_	_	O
58	cases	_	_	O
59	MMC	_	_	O
60	was	_	_	O
61	applied	_	_	O
62	during	_	_	O
63	surgery	_	_	O
64	)	_	_	O
65	.	_	_	O

66	Success	_	_	O
67	was	_	_	O
68	defined	_	_	O
69	as	_	_	O
70	intraocular	_	_	O
71	pressure	_	_	O
72	(	_	_	O
73	IOP	_	_	O
74	)	_	_	O
75	between	_	_	O
76	6	_	_	O
77	and	_	_	O
78	21	_	_	O
79	mm	_	_	O
80	Hg	_	_	O
81	and	_	_	O
82	at	_	_	O
83	least	_	_	O
84	30	_	_	O
85	%	_	_	O
86	IOP	_	_	O
87	drop	_	_	O
88	with	_	_	O
89	(	_	_	O
90	qualified	_	_	O
91	)	_	_	O
92	or	_	_	O
93	without	_	_	O
94	(	_	_	O
95	complete	_	_	O
96	)	_	_	O
97	glaucoma	_	_	O
98	medications	_	_	O
99	without	_	_	O
100	additional	_	_	O
101	glaucoma	_	_	O
102	surgery	_	_	O
103	.	_	_	O

104	The	_	_	O
105	follow-up	_	_	O
106	time	_	_	O
107	was	_	_	O
108	17.12±2.58	_	_	O
109	months	_	_	O
110	in	_	_	O
111	the	_	_	O
112	bevacizumab	_	_	O
113	group	_	_	O
114	and	_	_	O
115	17.23±2.42	_	_	O
116	months	_	_	O
117	in	_	_	O
118	the	_	_	O
119	MMC	_	_	O
120	group	_	_	O
121	(	_	_	O
122	P=0.845	_	_	O
123	)	_	_	O
124	.	_	_	O

125	The	_	_	B-Premise
126	preoperative	_	_	I-Premise
127	IOP	_	_	I-Premise
128	was	_	_	I-Premise
129	29.17±3.94	_	_	I-Premise
130	and	_	_	I-Premise
131	28.8±4.08	_	_	I-Premise
132	mm	_	_	I-Premise
133	Hg	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	bevacizumab	_	_	I-Premise
137	and	_	_	I-Premise
138	MMC	_	_	I-Premise
139	groups	_	_	I-Premise
140	,	_	_	I-Premise
141	respectively	_	_	I-Premise
142	(	_	_	I-Premise
143	P=0.689	_	_	I-Premise
144	)	_	_	I-Premise
145	.	_	_	I-Premise

146	Last	_	_	B-Premise
147	visit	_	_	I-Premise
148	IOP	_	_	I-Premise
149	was	_	_	I-Premise
150	17.41±3.11	_	_	I-Premise
151	mm	_	_	I-Premise
152	Hg	_	_	I-Premise
153	in	_	_	I-Premise
154	the	_	_	I-Premise
155	bevacizumab	_	_	I-Premise
156	group	_	_	I-Premise
157	and	_	_	I-Premise
158	15.34±3.62	_	_	I-Premise
159	mm	_	_	I-Premise
160	Hg	_	_	I-Premise
161	in	_	_	I-Premise
162	the	_	_	I-Premise
163	MMC	_	_	I-Premise
164	group	_	_	I-Premise
165	(	_	_	I-Premise
166	P	_	_	I-Premise
167	<	_	_	I-Premise
168	0.009	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	Compared	_	_	B-Premise
172	with	_	_	I-Premise
173	baseline	_	_	I-Premise
174	,	_	_	I-Premise
175	IOP	_	_	I-Premise
176	drop	_	_	I-Premise
177	at	_	_	I-Premise
178	last	_	_	I-Premise
179	visit	_	_	I-Premise
180	was	_	_	I-Premise
181	11.76±5.51	_	_	I-Premise
182	and	_	_	I-Premise
183	13.43±5.92	_	_	I-Premise
184	in	_	_	I-Premise
185	the	_	_	I-Premise
186	bevacizumab	_	_	I-Premise
187	and	_	_	I-Premise
188	MMC	_	_	I-Premise
189	groups	_	_	I-Premise
190	,	_	_	I-Premise
191	respectively	_	_	I-Premise
192	(	_	_	I-Premise
193	P=0.207	_	_	I-Premise
194	)	_	_	I-Premise
195	.	_	_	I-Premise

196	At	_	_	B-Premise
197	last	_	_	I-Premise
198	visit	_	_	I-Premise
199	,	_	_	I-Premise
200	complete	_	_	I-Premise
201	success	_	_	I-Premise
202	was	_	_	I-Premise
203	achieved	_	_	I-Premise
204	in	_	_	I-Premise
205	25	_	_	I-Premise
206	cases	_	_	I-Premise
207	(	_	_	I-Premise
208	61	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	of	_	_	I-Premise
212	bevacizumab	_	_	I-Premise
213	group	_	_	I-Premise
214	and	_	_	I-Premise
215	23	_	_	I-Premise
216	cases	_	_	I-Premise
217	(	_	_	I-Premise
218	66	_	_	I-Premise
219	%	_	_	I-Premise
220	)	_	_	I-Premise
221	of	_	_	I-Premise
222	MMC	_	_	I-Premise
223	group	_	_	I-Premise
224	(	_	_	I-Premise
225	P=0.669	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Early	_	_	B-Premise
229	filtering	_	_	I-Premise
230	bleb	_	_	I-Premise
231	leak	_	_	I-Premise
232	was	_	_	I-Premise
233	more	_	_	I-Premise
234	prevalent	_	_	I-Premise
235	in	_	_	I-Premise
236	bevacizumab	_	_	I-Premise
237	group	_	_	I-Premise
238	(	_	_	I-Premise
239	29	_	_	I-Premise
240	%	_	_	I-Premise
241	vs.	_	_	I-Premise
242	11	_	_	I-Premise
243	%	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	A	_	_	B-Claim
247	single	_	_	I-Claim
248	1.25	_	_	I-Claim
249	mg	_	_	I-Claim
250	dose	_	_	I-Claim
251	of	_	_	I-Claim
252	intracameral	_	_	I-Claim
253	bevacizumab	_	_	I-Claim
254	improves	_	_	I-Claim
255	the	_	_	I-Claim
256	success	_	_	I-Claim
257	of	_	_	I-Claim
258	trabeculectomy	_	_	I-Claim
259	comparable	_	_	I-Claim
260	with	_	_	I-Claim
261	MMC	_	_	I-Claim
262	;	_	_	I-Claim
263	however	_	_	B-Claim
264	,	_	_	I-Claim
265	it	_	_	I-Claim
266	increases	_	_	I-Claim
267	the	_	_	I-Claim
268	risk	_	_	I-Claim
269	of	_	_	I-Claim
270	early	_	_	I-Claim
271	filtering	_	_	I-Claim
272	bleb	_	_	I-Claim
273	leakage	_	_	I-Claim
274	.	_	_	I-Claim


0	Few	_	_	O
1	controlled	_	_	O
2	clinical	_	_	O
3	trials	_	_	O
4	exist	_	_	O
5	to	_	_	O
6	support	_	_	O
7	oral	_	_	O
8	combination	_	_	O
9	therapy	_	_	O
10	in	_	_	O
11	pulmonary	_	_	O
12	arterial	_	_	O
13	hypertension	_	_	O
14	(	_	_	O
15	PAH	_	_	O
16	)	_	_	O
17	.	_	_	O

18	Patients	_	_	O
19	with	_	_	O
20	PAH	_	_	O
21	(	_	_	O
22	idiopathic	_	_	O
23	[	_	_	O
24	IPAH	_	_	O
25	]	_	_	O
26	or	_	_	O
27	associated	_	_	O
28	with	_	_	O
29	connective	_	_	O
30	tissue	_	_	O
31	disease	_	_	O
32	[	_	_	O
33	APAH-CTD	_	_	O
34	]	_	_	O
35	)	_	_	O
36	taking	_	_	O
37	bosentan	_	_	O
38	(	_	_	O
39	62.5	_	_	O
40	or	_	_	O
41	125	_	_	O
42	mg	_	_	O
43	twice	_	_	O
44	daily	_	_	O
45	at	_	_	O
46	a	_	_	O
47	stable	_	_	O
48	dose	_	_	O
49	for	_	_	O
50	≥3	_	_	O
51	months	_	_	O
52	)	_	_	O
53	were	_	_	O
54	randomized	_	_	O
55	(	_	_	O
56	1:1	_	_	O
57	)	_	_	O
58	to	_	_	O
59	sildenafil	_	_	O
60	(	_	_	O
61	20	_	_	O
62	mg	_	_	O
63	,	_	_	O
64	3	_	_	O
65	times	_	_	O
66	daily	_	_	O
67	;	_	_	O
68	n	_	_	O
69	=	_	_	O
70	50	_	_	O
71	)	_	_	O
72	or	_	_	O
73	placebo	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	53	_	_	O
78	)	_	_	O
79	.	_	_	O

80	The	_	_	O
81	primary	_	_	O
82	endpoint	_	_	O
83	was	_	_	O
84	change	_	_	O
85	from	_	_	O
86	baseline	_	_	O
87	in	_	_	O
88	6-min	_	_	O
89	walk	_	_	O
90	distance	_	_	O
91	(	_	_	O
92	6MWD	_	_	O
93	)	_	_	O
94	at	_	_	O
95	week	_	_	O
96	12	_	_	O
97	,	_	_	O
98	assessed	_	_	O
99	using	_	_	O
100	analysis	_	_	O
101	of	_	_	O
102	covariance	_	_	O
103	.	_	_	O

104	Patients	_	_	O
105	could	_	_	O
106	continue	_	_	O
107	in	_	_	O
108	a	_	_	O
109	52-week	_	_	O
110	extension	_	_	O
111	study	_	_	O
112	.	_	_	O

113	An	_	_	O
114	analysis	_	_	O
115	of	_	_	O
116	covariance	_	_	O
117	main-effects	_	_	O
118	model	_	_	O
119	was	_	_	O
120	used	_	_	O
121	,	_	_	O
122	which	_	_	O
123	included	_	_	O
124	categorical	_	_	O
125	terms	_	_	O
126	for	_	_	O
127	treatment	_	_	O
128	,	_	_	O
129	baseline	_	_	O
130	6MWD	_	_	O
131	(	_	_	O
132	<	_	_	O
133	325	_	_	O
134	m	_	_	O
135	;	_	_	O
136	≥325	_	_	O
137	m	_	_	O
138	)	_	_	O
139	,	_	_	O
140	and	_	_	O
141	baseline	_	_	O
142	aetiology	_	_	O
143	;	_	_	O
144	sensitivity	_	_	O
145	analyses	_	_	O
146	were	_	_	O
147	subsequently	_	_	O
148	performed	_	_	O
149	.	_	_	O

150	In	_	_	B-Premise
151	sildenafil	_	_	I-Premise
152	versus	_	_	I-Premise
153	placebo	_	_	I-Premise
154	arms	_	_	I-Premise
155	,	_	_	I-Premise
156	week-12	_	_	I-Premise
157	6MWD	_	_	I-Premise
158	increases	_	_	I-Premise
159	were	_	_	I-Premise
160	similar	_	_	I-Premise
161	(	_	_	I-Premise
162	least	_	_	I-Premise
163	squares	_	_	I-Premise
164	mean	_	_	I-Premise
165	difference	_	_	I-Premise
166	[	_	_	I-Premise
167	sildenafil-placebo	_	_	I-Premise
168	]	_	_	I-Premise
169	,	_	_	I-Premise
170	-2.4	_	_	I-Premise
171	m	_	_	I-Premise
172	[	_	_	I-Premise
173	90	_	_	I-Premise
174	%	_	_	I-Premise
175	CI	_	_	I-Premise
176	:	_	_	I-Premise
177	-21.8	_	_	I-Premise
178	to	_	_	I-Premise
179	17.1	_	_	I-Premise
180	m	_	_	I-Premise
181	]	_	_	I-Premise
182	;	_	_	I-Premise
183	P	_	_	I-Premise
184	=	_	_	I-Premise
185	0.6	_	_	I-Premise
186	)	_	_	I-Premise
187	;	_	_	I-Premise
188	mean	_	_	I-Premise
189	±	_	_	I-Premise
190	SD	_	_	I-Premise
191	changes	_	_	I-Premise
192	from	_	_	I-Premise
193	baseline	_	_	I-Premise
194	were	_	_	I-Premise
195	26.4	_	_	I-Premise
196	±	_	_	I-Premise
197	45.7	_	_	I-Premise
198	versus	_	_	I-Premise
199	11.8	_	_	I-Premise
200	±	_	_	I-Premise
201	57.4	_	_	I-Premise
202	m	_	_	I-Premise
203	,	_	_	I-Premise
204	respectively	_	_	I-Premise
205	,	_	_	I-Premise
206	in	_	_	I-Premise
207	IPAH	_	_	I-Premise
208	(	_	_	I-Premise
209	65	_	_	I-Premise
210	%	_	_	I-Premise
211	of	_	_	I-Premise
212	population	_	_	I-Premise
213	)	_	_	I-Premise
214	and	_	_	I-Premise
215	-18.3	_	_	I-Premise
216	±	_	_	I-Premise
217	82.0	_	_	I-Premise
218	versus	_	_	I-Premise
219	17.5	_	_	I-Premise
220	±	_	_	I-Premise
221	59.1	_	_	I-Premise
222	m	_	_	I-Premise
223	in	_	_	I-Premise
224	APAH-CTD	_	_	I-Premise
225	(	_	_	I-Premise
226	35	_	_	I-Premise
227	%	_	_	I-Premise
228	of	_	_	I-Premise
229	population	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	One-year	_	_	O
233	survival	_	_	O
234	was	_	_	O
235	96	_	_	O
236	%	_	_	O
237	;	_	_	O
238	patients	_	_	O
239	maintained	_	_	O
240	modest	_	_	O
241	6MWD	_	_	O
242	improvements	_	_	O
243	.	_	_	O

244	Changes	_	_	B-Premise
245	in	_	_	I-Premise
246	WHO	_	_	I-Premise
247	functional	_	_	I-Premise
248	class	_	_	I-Premise
249	and	_	_	I-Premise
250	Borg	_	_	I-Premise
251	dyspnoea	_	_	I-Premise
252	score	_	_	I-Premise
253	and	_	_	I-Premise
254	incidence	_	_	I-Premise
255	of	_	_	I-Premise
256	clinical	_	_	I-Premise
257	worsening	_	_	I-Premise
258	did	_	_	I-Premise
259	not	_	_	I-Premise
260	differ	_	_	I-Premise
261	.	_	_	I-Premise

262	Headache	_	_	B-Premise
263	,	_	_	I-Premise
264	diarrhoea	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	flushing	_	_	I-Premise
268	were	_	_	I-Premise
269	more	_	_	I-Premise
270	common	_	_	I-Premise
271	with	_	_	I-Premise
272	sildenafil	_	_	I-Premise
273	.	_	_	I-Premise

274	Sildenafil	_	_	B-Claim
275	,	_	_	I-Claim
276	in	_	_	I-Claim
277	addition	_	_	I-Claim
278	to	_	_	I-Claim
279	stable	_	_	I-Claim
280	(	_	_	I-Claim
281	≥3	_	_	I-Claim
282	months	_	_	I-Claim
283	)	_	_	I-Claim
284	bosentan	_	_	I-Claim
285	therapy	_	_	I-Claim
286	,	_	_	I-Claim
287	had	_	_	I-Claim
288	no	_	_	I-Claim
289	benefit	_	_	I-Claim
290	over	_	_	I-Claim
291	placebo	_	_	I-Claim
292	for	_	_	I-Claim
293	12-week	_	_	I-Claim
294	change	_	_	I-Claim
295	from	_	_	I-Claim
296	baseline	_	_	I-Claim
297	in	_	_	I-Claim
298	6MWD	_	_	I-Claim
299	.	_	_	I-Claim

300	The	_	_	O
301	influence	_	_	O
302	of	_	_	O
303	PAH	_	_	O
304	aetiology	_	_	O
305	warrants	_	_	O
306	future	_	_	O
307	study	_	_	O
308	.	_	_	O


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	the	_	_	O
6	combined	_	_	O
7	administration	_	_	O
8	of	_	_	O
9	entecavir	_	_	O
10	and	_	_	O
11	adefovir	_	_	O
12	dipivoxil	_	_	O
13	to	_	_	O
14	improve	_	_	O
15	hepatic	_	_	O
16	fibrosis	_	_	O
17	in	_	_	O
18	hepatitis	_	_	O
19	B	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	interferon	_	_	O
23	resistance	_	_	O
24	.	_	_	O

25	This	_	_	O
26	study	_	_	O
27	comprised	_	_	O
28	90	_	_	O
29	hepatitis	_	_	O
30	B	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	hepatic	_	_	O
34	fibrosis	_	_	O
35	and	_	_	O
36	interferon	_	_	O
37	(	_	_	O
38	IFN	_	_	O
39	)	_	_	O
40	resistance	_	_	O
41	who	_	_	O
42	were	_	_	O
43	admitted	_	_	O
44	in	_	_	O
45	the	_	_	O
46	hospital	_	_	O
47	's	_	_	O
48	department	_	_	O
49	of	_	_	O
50	infectious	_	_	O
51	disease	_	_	O
52	for	_	_	O
53	diagnosis	_	_	O
54	and	_	_	O
55	treatment	_	_	O
56	between	_	_	O
57	January	_	_	O
58	2013	_	_	O
59	and	_	_	O
60	September	_	_	O
61	2015	_	_	O
62	.	_	_	O

63	They	_	_	O
64	were	_	_	O
65	randomly	_	_	O
66	divided	_	_	O
67	into	_	_	O
68	two	_	_	O
69	groups	_	_	O
70	in	_	_	O
71	accordance	_	_	O
72	with	_	_	O
73	the	_	_	O
74	random	_	_	O
75	number	_	_	O
76	table	_	_	O
77	:	_	_	O
78	the	_	_	O
79	combination	_	_	O
80	treatment	_	_	O
81	group	_	_	O
82	(	_	_	O
83	N.=45	_	_	O
84	)	_	_	O
85	and	_	_	O
86	the	_	_	O
87	entecavir	_	_	O
88	group	_	_	O
89	(	_	_	O
90	N.=45	_	_	O
91	)	_	_	O
92	.	_	_	O

93	They	_	_	O
94	were	_	_	O
95	observed	_	_	O
96	for	_	_	O
97	any	_	_	O
98	variations	_	_	O
99	in	_	_	O
100	the	_	_	O
101	indexes	_	_	O
102	of	_	_	O
103	liver	_	_	O
104	function	_	_	O
105	and	_	_	O
106	fibrosis	_	_	O
107	,	_	_	O
108	as	_	_	O
109	well	_	_	O
110	as	_	_	O
111	the	_	_	O
112	Model	_	_	O
113	for	_	_	O
114	end-stage	_	_	O
115	liver	_	_	O
116	disease	_	_	O
117	(	_	_	O
118	MELD	_	_	O
119	)	_	_	O
120	scores	_	_	O
121	,	_	_	O
122	before	_	_	O
123	and	_	_	O
124	after	_	_	O
125	treatment	_	_	O
126	.	_	_	O

127	After	_	_	B-Premise
128	treatment	_	_	I-Premise
129	,	_	_	I-Premise
130	the	_	_	I-Premise
131	levels	_	_	I-Premise
132	of	_	_	I-Premise
133	the	_	_	I-Premise
134	indexes	_	_	I-Premise
135	in	_	_	I-Premise
136	both	_	_	I-Premise
137	groups	_	_	I-Premise
138	(	_	_	I-Premise
139	the	_	_	I-Premise
140	combination	_	_	I-Premise
141	treatment	_	_	I-Premise
142	group	_	_	I-Premise
143	vs.	_	_	I-Premise
144	the	_	_	I-Premise
145	entecavir	_	_	I-Premise
146	group	_	_	I-Premise
147	)	_	_	I-Premise
148	were	_	_	I-Premise
149	as	_	_	I-Premise
150	follows	_	_	I-Premise
151	:	_	_	I-Premise
152	bilirubin	_	_	I-Premise
153	(	_	_	I-Premise
154	67.5±7.7	_	_	I-Premise
155	vs.	_	_	I-Premise
156	82.4±13.5	_	_	I-Premise
157	μmol/L	_	_	I-Premise
158	)	_	_	I-Premise
159	;	_	_	I-Premise
160	International	_	_	I-Premise
161	Normalized	_	_	I-Premise
162	Ratio	_	_	I-Premise
163	(	_	_	I-Premise
164	INR	_	_	I-Premise
165	)	_	_	I-Premise
166	(	_	_	I-Premise
167	1.21±0.8	_	_	I-Premise
168	vs.	_	_	I-Premise
169	1.14±0.7	_	_	I-Premise
170	)	_	_	I-Premise
171	;	_	_	I-Premise
172	creatinine	_	_	I-Premise
173	(	_	_	I-Premise
174	147.3±12.4	_	_	I-Premise
175	vs.	_	_	I-Premise
176	287.4±21.6	_	_	I-Premise
177	mg/dL	_	_	I-Premise
178	)	_	_	I-Premise
179	;	_	_	I-Premise
180	GGT	_	_	I-Premise
181	(	_	_	I-Premise
182	67.4±23.2	_	_	I-Premise
183	vs.	_	_	I-Premise
184	88.4±23.7	_	_	I-Premise
185	U/L	_	_	I-Premise
186	)	_	_	I-Premise
187	;	_	_	I-Premise
188	and	_	_	I-Premise
189	ALT	_	_	I-Premise
190	(	_	_	I-Premise
191	63.4±40.8	_	_	I-Premise
192	vs.	_	_	I-Premise
193	96.5±23.5	_	_	I-Premise
194	U/L	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	In	_	_	B-Premise
198	comparison	_	_	I-Premise
199	of	_	_	I-Premise
200	the	_	_	I-Premise
201	indexes	_	_	I-Premise
202	of	_	_	I-Premise
203	hepatic	_	_	I-Premise
204	fibrosis	_	_	I-Premise
205	between	_	_	I-Premise
206	the	_	_	I-Premise
207	two	_	_	I-Premise
208	groups	_	_	I-Premise
209	,	_	_	I-Premise
210	we	_	_	I-Premise
211	found	_	_	I-Premise
212	the	_	_	I-Premise
213	following	_	_	I-Premise
214	differences	_	_	I-Premise
215	:	_	_	I-Premise
216	PCIII	_	_	I-Premise
217	(	_	_	I-Premise
218	67.5±7.7	_	_	I-Premise
219	vs.	_	_	I-Premise
220	82.4±13.5	_	_	I-Premise
221	μg/L	_	_	I-Premise
222	)	_	_	I-Premise
223	;	_	_	I-Premise
224	IV-C	_	_	I-Premise
225	(	_	_	I-Premise
226	61.3±18.7	_	_	I-Premise
227	vs.	_	_	I-Premise
228	74.5±17.9	_	_	I-Premise
229	μg/L	_	_	I-Premise
230	)	_	_	I-Premise
231	;	_	_	I-Premise
232	HA	_	_	I-Premise
233	(	_	_	I-Premise
234	147.3±12.4	_	_	I-Premise
235	vs.	_	_	I-Premise
236	87.4±31.6	_	_	I-Premise
237	μg/L	_	_	I-Premise
238	)	_	_	I-Premise
239	;	_	_	I-Premise
240	and	_	_	I-Premise
241	LN	_	_	I-Premise
242	(	_	_	I-Premise
243	88.7±13.2	_	_	I-Premise
244	vs	_	_	I-Premise
245	102.5±23.4	_	_	I-Premise
246	μg/L	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	results	_	_	I-Premise
251	showed	_	_	I-Premise
252	that	_	_	I-Premise
253	the	_	_	I-Premise
254	differences	_	_	I-Premise
255	in	_	_	I-Premise
256	comparison	_	_	I-Premise
257	of	_	_	I-Premise
258	the	_	_	I-Premise
259	indexes	_	_	I-Premise
260	before	_	_	I-Premise
261	and	_	_	I-Premise
262	after	_	_	I-Premise
263	the	_	_	I-Premise
264	treatment	_	_	I-Premise
265	were	_	_	I-Premise
266	statistically	_	_	I-Premise
267	significant	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	<	_	_	I-Premise
271	0.05	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	After	_	_	B-Premise
275	treatment	_	_	I-Premise
276	,	_	_	I-Premise
277	the	_	_	I-Premise
278	MELD	_	_	I-Premise
279	score	_	_	I-Premise
280	of	_	_	I-Premise
281	patients	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	combination	_	_	I-Premise
285	treatment	_	_	I-Premise
286	group	_	_	I-Premise
287	was	_	_	I-Premise
288	significantly	_	_	I-Premise
289	lower	_	_	I-Premise
290	than	_	_	I-Premise
291	that	_	_	I-Premise
292	in	_	_	I-Premise
293	the	_	_	I-Premise
294	entecavir	_	_	I-Premise
295	group	_	_	I-Premise
296	(	_	_	I-Premise
297	18.7±3.2	_	_	I-Premise
298	vs.	_	_	I-Premise
299	22.5±3.4	_	_	I-Premise
300	)	_	_	I-Premise
301	,	_	_	I-Premise
302	with	_	_	I-Premise
303	a	_	_	I-Premise
304	statistically	_	_	I-Premise
305	significant	_	_	I-Premise
306	difference	_	_	I-Premise
307	(	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	0.05	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	In	_	_	B-Claim
314	the	_	_	I-Claim
315	chronic	_	_	I-Claim
316	hepatitis	_	_	I-Claim
317	B	_	_	I-Claim
318	patients	_	_	I-Claim
319	with	_	_	I-Claim
320	interferon	_	_	I-Claim
321	resistance	_	_	I-Claim
322	,	_	_	I-Claim
323	the	_	_	I-Claim
324	combined	_	_	I-Claim
325	administration	_	_	I-Claim
326	of	_	_	I-Claim
327	entecavir	_	_	I-Claim
328	and	_	_	I-Claim
329	adefovir	_	_	I-Claim
330	dipivoxil	_	_	I-Claim
331	can	_	_	I-Claim
332	significantly	_	_	I-Claim
333	improve	_	_	I-Claim
334	liver	_	_	I-Claim
335	function	_	_	I-Claim
336	,	_	_	I-Claim
337	hepatic	_	_	I-Claim
338	fibrosis	_	_	I-Claim
339	and	_	_	I-Claim
340	MELD	_	_	I-Claim
341	scores	_	_	I-Claim
342	.	_	_	I-Claim

343	The	_	_	B-Claim
344	results	_	_	I-Claim
345	highlight	_	_	I-Claim
346	the	_	_	I-Claim
347	need	_	_	I-Claim
348	to	_	_	I-Claim
349	promote	_	_	I-Claim
350	the	_	_	I-Claim
351	benefits	_	_	I-Claim
352	of	_	_	I-Claim
353	this	_	_	I-Claim
354	drug	_	_	I-Claim
355	combination	_	_	I-Claim
356	in	_	_	I-Claim
357	helping	_	_	I-Claim
358	chronic	_	_	I-Claim
359	hepatitis	_	_	I-Claim
360	B	_	_	I-Claim
361	patients	_	_	I-Claim
362	with	_	_	I-Claim
363	interferon	_	_	I-Claim
364	resistance	_	_	I-Claim
365	,	_	_	I-Claim
366	and	_	_	I-Claim
367	to	_	_	I-Claim
368	promote	_	_	I-Claim
369	its	_	_	I-Claim
370	application	_	_	I-Claim
371	in	_	_	I-Claim
372	clinical	_	_	I-Claim
373	practices	_	_	I-Claim
374	.	_	_	I-Claim


0	Hepatitis	_	_	O
1	B	_	_	O
2	virus	_	_	O
3	(	_	_	O
4	HBV	_	_	O
5	)	_	_	O
6	reactivation	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	resolved	_	_	O
11	HBV	_	_	O
12	infection	_	_	O
13	(	_	_	O
14	HBsAg	_	_	O
15	negative	_	_	O
16	,	_	_	O
17	antiHBc	_	_	O
18	positive	_	_	O
19	)	_	_	O
20	is	_	_	O
21	uncommon	_	_	O
22	,	_	_	O
23	but	_	_	O
24	potentially	_	_	O
25	fatal	_	_	O
26	.	_	_	O

27	The	_	_	O
28	role	_	_	O
29	of	_	_	O
30	HBV	_	_	O
31	prophylaxis	_	_	O
32	in	_	_	O
33	this	_	_	O
34	setting	_	_	O
35	is	_	_	O
36	uncertain	_	_	O
37	.	_	_	O

38	The	_	_	O
39	aim	_	_	O
40	of	_	_	O
41	this	_	_	O
42	study	_	_	O
43	was	_	_	O
44	to	_	_	O
45	compare	_	_	O
46	the	_	_	O
47	efficacy	_	_	O
48	of	_	_	O
49	tenofovir	_	_	O
50	disoproxil	_	_	O
51	fumarate	_	_	O
52	(	_	_	O
53	TDF	_	_	O
54	)	_	_	O
55	prophylaxis	_	_	O
56	versus	_	_	O
57	close	_	_	O
58	monitoring	_	_	O
59	in	_	_	O
60	antiHBc-positive	_	_	O
61	,	_	_	O
62	HBsAg-negative	_	_	O
63	patients	_	_	O
64	under	_	_	O
65	treatment	_	_	O
66	with	_	_	O
67	rituximab	_	_	O
68	(	_	_	O
69	RTX	_	_	O
70	)	_	_	O
71	-based	_	_	O
72	regimens	_	_	O
73	for	_	_	O
74	hematologic	_	_	O
75	malignancy	_	_	O
76	.	_	_	O

77	PREBLIN	_	_	O
78	is	_	_	O
79	a	_	_	O
80	phase	_	_	O
81	IV	_	_	O
82	,	_	_	O
83	randomized	_	_	O
84	,	_	_	O
85	prospective	_	_	O
86	,	_	_	O
87	open-label	_	_	O
88	,	_	_	O
89	multicenter	_	_	O
90	,	_	_	O
91	parallel-group	_	_	O
92	trial	_	_	O
93	conducted	_	_	O
94	in	_	_	O
95	17	_	_	O
96	hospitals	_	_	O
97	throughout	_	_	O
98	Spain	_	_	O
99	.	_	_	O

100	Anti-HBc-positive	_	_	O
101	,	_	_	O
102	HBsAg-negative	_	_	O
103	patients	_	_	O
104	with	_	_	O
105	undetectable	_	_	O
106	HBV	_	_	O
107	DNA	_	_	O
108	were	_	_	O
109	randomized	_	_	O
110	to	_	_	O
111	receive	_	_	O
112	TDF	_	_	O
113	300	_	_	O
114	mg	_	_	O
115	once	_	_	O
116	daily	_	_	O
117	(	_	_	O
118	Group	_	_	O
119	I	_	_	O
120	)	_	_	O
121	or	_	_	O
122	observation	_	_	O
123	(	_	_	O
124	Group	_	_	O
125	II	_	_	O
126	)	_	_	O
127	.	_	_	O

128	The	_	_	O
129	primary	_	_	O
130	endpoint	_	_	O
131	was	_	_	O
132	the	_	_	O
133	percentage	_	_	O
134	of	_	_	O
135	patients	_	_	O
136	showing	_	_	O
137	HBV	_	_	O
138	reactivation	_	_	O
139	during	_	_	O
140	18	_	_	O
141	months	_	_	O
142	following	_	_	O
143	initiation	_	_	O
144	of	_	_	O
145	RTX	_	_	O
146	treatment	_	_	O
147	.	_	_	O

148	Patients	_	_	O
149	with	_	_	O
150	detectable	_	_	O
151	HBV	_	_	O
152	DNA	_	_	O
153	(	_	_	O
154	Group	_	_	O
155	III	_	_	O
156	)	_	_	O
157	received	_	_	O
158	the	_	_	O
159	same	_	_	O
160	dose	_	_	O
161	of	_	_	O
162	TDF	_	_	O
163	and	_	_	O
164	were	_	_	O
165	analyzed	_	_	O
166	together	_	_	O
167	with	_	_	O
168	Group	_	_	O
169	I	_	_	O
170	to	_	_	O
171	investigate	_	_	O
172	TDF	_	_	O
173	safety	_	_	O
174	.	_	_	O

175	Sixty-one	_	_	O
176	patients	_	_	O
177	were	_	_	O
178	enrolled	_	_	O
179	in	_	_	O
180	the	_	_	O
181	study	_	_	O
182	,	_	_	O
183	33	_	_	O
184	in	_	_	O
185	the	_	_	O
186	TDF	_	_	O
187	treatment	_	_	O
188	group	_	_	O
189	and	_	_	O
190	28	_	_	O
191	in	_	_	O
192	the	_	_	O
193	observation	_	_	O
194	group	_	_	O
195	.	_	_	O

196	By	_	_	B-Premise
197	ITT	_	_	I-Premise
198	analysis	_	_	I-Premise
199	,	_	_	I-Premise
200	HBV	_	_	I-Premise
201	reactivation	_	_	I-Premise
202	was	_	_	I-Premise
203	0	_	_	I-Premise
204	%	_	_	I-Premise
205	(	_	_	I-Premise
206	0/33	_	_	I-Premise
207	)	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	study	_	_	I-Premise
211	group	_	_	I-Premise
212	and	_	_	I-Premise
213	10.7	_	_	I-Premise
214	%	_	_	I-Premise
215	(	_	_	I-Premise
216	3/28	_	_	I-Premise
217	)	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	observation	_	_	I-Premise
221	group	_	_	I-Premise
222	(	_	_	I-Premise
223	p	_	_	I-Premise
224	=	_	_	I-Premise
225	0.091	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	None	_	_	B-Premise
229	of	_	_	I-Premise
230	the	_	_	I-Premise
231	patients	_	_	I-Premise
232	in	_	_	I-Premise
233	either	_	_	I-Premise
234	group	_	_	I-Premise
235	showed	_	_	I-Premise
236	significant	_	_	I-Premise
237	differences	_	_	I-Premise
238	in	_	_	I-Premise
239	liver	_	_	I-Premise
240	function	_	_	I-Premise
241	parameters	_	_	I-Premise
242	between	_	_	I-Premise
243	baseline	_	_	I-Premise
244	and	_	_	I-Premise
245	the	_	_	I-Premise
246	last	_	_	I-Premise
247	follow-up	_	_	I-Premise
248	sample	_	_	I-Premise
249	.	_	_	I-Premise

250	TDF	_	_	B-Claim
251	was	_	_	I-Claim
252	generally	_	_	I-Claim
253	well	_	_	I-Claim
254	tolerated	_	_	I-Claim
255	and	_	_	I-Claim
256	there	_	_	I-Claim
257	were	_	_	I-Claim
258	no	_	_	I-Claim
259	severe	_	_	I-Claim
260	treatment-related	_	_	I-Claim
261	adverse	_	_	I-Claim
262	events	_	_	I-Claim
263	.	_	_	I-Claim

264	In	_	_	B-Claim
265	patients	_	_	I-Claim
266	with	_	_	I-Claim
267	hematological	_	_	I-Claim
268	malignancy	_	_	I-Claim
269	and	_	_	I-Claim
270	resolved	_	_	I-Claim
271	hepatitis	_	_	I-Claim
272	B	_	_	I-Claim
273	infection	_	_	I-Claim
274	receiving	_	_	I-Claim
275	RTX-based	_	_	I-Claim
276	regimens	_	_	I-Claim
277	,	_	_	I-Claim
278	HBV	_	_	I-Claim
279	reactivation	_	_	I-Claim
280	did	_	_	I-Claim
281	not	_	_	I-Claim
282	occur	_	_	I-Claim
283	in	_	_	I-Claim
284	patients	_	_	I-Claim
285	given	_	_	I-Claim
286	TDF	_	_	I-Claim
287	prophylaxis	_	_	I-Claim
288	.	_	_	I-Claim


0	Vesatolimod	_	_	O
1	(	_	_	O
2	GS-9620	_	_	O
3	)	_	_	O
4	is	_	_	O
5	an	_	_	O
6	oral	_	_	O
7	agonist	_	_	O
8	of	_	_	O
9	toll-like	_	_	O
10	receptor	_	_	O
11	7	_	_	O
12	,	_	_	O
13	an	_	_	O
14	activator	_	_	O
15	of	_	_	O
16	innate	_	_	O
17	and	_	_	O
18	adaptive	_	_	O
19	immune	_	_	O
20	responses	_	_	O
21	.	_	_	O

22	Herein	_	_	O
23	the	_	_	O
24	safety	_	_	O
25	and	_	_	O
26	efficacy	_	_	O
27	of	_	_	O
28	vesatolimod	_	_	O
29	is	_	_	O
30	assessed	_	_	O
31	after	_	_	O
32	once-weekly	_	_	O
33	treatment	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	chronic	_	_	O
38	hepatitis	_	_	O
39	B	_	_	O
40	(	_	_	O
41	CHB	_	_	O
42	)	_	_	O
43	infection	_	_	O
44	suppressed	_	_	O
45	on	_	_	O
46	oral	_	_	O
47	antiviral	_	_	O
48	treatment	_	_	O
49	.	_	_	O

50	In	_	_	O
51	a	_	_	O
52	phase	_	_	O
53	II	_	_	O
54	,	_	_	O
55	double-blind	_	_	O
56	,	_	_	O
57	randomized	_	_	O
58	,	_	_	O
59	placebo	_	_	O
60	(	_	_	O
61	PBO	_	_	O
62	)	_	_	O
63	-controlled	_	_	O
64	study	_	_	O
65	,	_	_	O
66	162	_	_	O
67	patients	_	_	O
68	stratified	_	_	O
69	by	_	_	O
70	hepatitis	_	_	O
71	B	_	_	O
72	surface	_	_	O
73	antigen	_	_	O
74	(	_	_	O
75	HBsAg	_	_	O
76	)	_	_	O
77	levels	_	_	O
78	and	_	_	O
79	serum	_	_	O
80	hepatitis	_	_	O
81	B	_	_	O
82	e	_	_	O
83	antigen	_	_	O
84	(	_	_	O
85	HBeAg	_	_	O
86	)	_	_	O
87	status	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	1:3:3:3	_	_	O
91	to	_	_	O
92	once-weekly	_	_	O
93	oral	_	_	O
94	PBO	_	_	O
95	or	_	_	O
96	vesatolimod	_	_	O
97	(	_	_	O
98	1-	_	_	O
99	,	_	_	O
100	2-	_	_	O
101	,	_	_	O
102	or	_	_	O
103	4-mg	_	_	O
104	doses	_	_	O
105	)	_	_	O
106	for	_	_	O
107	4	_	_	O
108	,	_	_	O
109	8	_	_	O
110	or	_	_	O
111	12	_	_	O
112	weeks	_	_	O
113	per	_	_	O
114	cohort	_	_	O
115	.	_	_	O

116	Efficacy	_	_	O
117	was	_	_	O
118	assessed	_	_	O
119	by	_	_	O
120	change	_	_	O
121	in	_	_	O
122	baseline	_	_	O
123	HBsAg	_	_	O
124	(	_	_	O
125	log10	_	_	O
126	IU/ml	_	_	O
127	)	_	_	O
128	at	_	_	O
129	the	_	_	O
130	primary	_	_	O
131	endpoint	_	_	O
132	(	_	_	O
133	Week	_	_	O
134	24	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Safety	_	_	O
138	assessments	_	_	O
139	included	_	_	O
140	adverse	_	_	O
141	events	_	_	O
142	(	_	_	O
143	AE	_	_	O
144	)	_	_	O
145	and	_	_	O
146	laboratory	_	_	O
147	abnormality	_	_	O
148	monitoring	_	_	O
149	.	_	_	O

150	Pharmacodynamic	_	_	O
151	assessments	_	_	O
152	included	_	_	O
153	peripheral	_	_	O
154	cytokine	_	_	O
155	level	_	_	O
156	quantification	_	_	O
157	and	_	_	O
158	interferon-stimulated	_	_	O
159	gene	_	_	O
160	(	_	_	O
161	ISG	_	_	O
162	)	_	_	O
163	mRNA	_	_	O
164	expression	_	_	O
165	evaluation	_	_	O
166	.	_	_	O

167	The	_	_	O
168	majority	_	_	O
169	of	_	_	O
170	patients	_	_	O
171	were	_	_	O
172	male	_	_	O
173	(	_	_	O
174	76	_	_	O
175	%	_	_	O
176	)	_	_	O
177	and	_	_	O
178	HBeAg-negative	_	_	O
179	(	_	_	O
180	79	_	_	O
181	%	_	_	O
182	)	_	_	O
183	at	_	_	O
184	baseline	_	_	O
185	.	_	_	O

186	Most	_	_	B-Premise
187	(	_	_	I-Premise
188	41-80	_	_	I-Premise
189	%	_	_	I-Premise
190	)	_	_	I-Premise
191	experienced	_	_	I-Premise
192	≥1	_	_	I-Premise
193	AE	_	_	I-Premise
194	during	_	_	I-Premise
195	the	_	_	I-Premise
196	study	_	_	I-Premise
197	with	_	_	I-Premise
198	the	_	_	I-Premise
199	majority	_	_	I-Premise
200	of	_	_	I-Premise
201	AEs	_	_	I-Premise
202	mild	_	_	I-Premise
203	or	_	_	I-Premise
204	moderate	_	_	I-Premise
205	in	_	_	I-Premise
206	severity	_	_	I-Premise
207	.	_	_	I-Premise

208	No	_	_	B-Premise
209	significant	_	_	I-Premise
210	declines	_	_	I-Premise
211	in	_	_	I-Premise
212	HBsAg	_	_	I-Premise
213	were	_	_	I-Premise
214	observed	_	_	I-Premise
215	at	_	_	I-Premise
216	the	_	_	I-Premise
217	primary	_	_	I-Premise
218	(	_	_	I-Premise
219	Week	_	_	I-Premise
220	24	_	_	I-Premise
221	)	_	_	I-Premise
222	or	_	_	I-Premise
223	secondary	_	_	I-Premise
224	endpoints	_	_	I-Premise
225	(	_	_	I-Premise
226	Weeks	_	_	I-Premise
227	4	_	_	I-Premise
228	,	_	_	I-Premise
229	8	_	_	I-Premise
230	,	_	_	I-Premise
231	12	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	48	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	ISG15	_	_	B-Premise
238	induction	_	_	I-Premise
239	was	_	_	I-Premise
240	dose-dependent	_	_	I-Premise
241	and	_	_	I-Premise
242	consistent	_	_	I-Premise
243	after	_	_	I-Premise
244	repeat	_	_	I-Premise
245	dosing	_	_	I-Premise
246	,	_	_	I-Premise
247	returning	_	_	I-Premise
248	closer	_	_	I-Premise
249	to	_	_	I-Premise
250	baseline	_	_	I-Premise
251	by	_	_	I-Premise
252	one	_	_	I-Premise
253	week	_	_	I-Premise
254	after	_	_	I-Premise
255	treatment	_	_	I-Premise
256	at	_	_	I-Premise
257	all	_	_	I-Premise
258	dose	_	_	I-Premise
259	levels	_	_	I-Premise
260	;	_	_	I-Premise
261	no	_	_	B-Premise
262	patient	_	_	I-Premise
263	demonstrated	_	_	I-Premise
264	significant	_	_	I-Premise
265	serum	_	_	I-Premise
266	interferon	_	_	I-Premise
267	alpha	_	_	I-Premise
268	(	_	_	I-Premise
269	IFNα	_	_	I-Premise
270	)	_	_	I-Premise
271	expression	_	_	I-Premise
272	at	_	_	I-Premise
273	any	_	_	I-Premise
274	timepoint	_	_	I-Premise
275	evaluated	_	_	I-Premise
276	.	_	_	I-Premise

277	Multivariate	_	_	B-Premise
278	analyses	_	_	I-Premise
279	showed	_	_	I-Premise
280	that	_	_	I-Premise
281	≥2-fold	_	_	I-Premise
282	ISG15	_	_	I-Premise
283	induction	_	_	I-Premise
284	is	_	_	I-Premise
285	associated	_	_	I-Premise
286	with	_	_	I-Premise
287	2-	_	_	I-Premise
288	or	_	_	I-Premise
289	4-mg	_	_	I-Premise
290	vesatolimod	_	_	I-Premise
291	dose	_	_	I-Premise
292	and	_	_	I-Premise
293	female	_	_	I-Premise
294	sex	_	_	I-Premise
295	.	_	_	I-Premise

296	Vesatolimod	_	_	B-Claim
297	was	_	_	I-Claim
298	safe	_	_	I-Claim
299	and	_	_	I-Claim
300	well-tolerated	_	_	I-Claim
301	in	_	_	I-Claim
302	patients	_	_	I-Claim
303	with	_	_	I-Claim
304	CHB	_	_	I-Claim
305	,	_	_	I-Claim
306	demonstrating	_	_	I-Claim
307	consistent	_	_	I-Claim
308	dose-dependent	_	_	I-Claim
309	pharmacodynamic	_	_	I-Claim
310	induction	_	_	I-Claim
311	of	_	_	I-Claim
312	ISG15	_	_	I-Claim
313	without	_	_	I-Claim
314	significant	_	_	I-Claim
315	systemic	_	_	I-Claim
316	induction	_	_	I-Claim
317	of	_	_	I-Claim
318	IFNα	_	_	I-Claim
319	expression	_	_	I-Claim
320	or	_	_	I-Claim
321	related	_	_	I-Claim
322	symptoms	_	_	I-Claim
323	.	_	_	I-Claim

324	However	_	_	O
325	,	_	_	O
326	no	_	_	O
327	significant	_	_	O
328	HBsAg	_	_	O
329	declines	_	_	O
330	were	_	_	O
331	observed	_	_	O
332	.	_	_	O


0	In	_	_	O
1	China	_	_	O
2	,	_	_	O
3	the	_	_	O
4	clinical	_	_	O
5	management	_	_	O
6	of	_	_	O
7	chronic	_	_	O
8	hepatitis	_	_	O
9	B	_	_	O
10	(	_	_	O
11	CHB	_	_	O
12	)	_	_	O
13	is	_	_	O
14	complicated	_	_	O
15	by	_	_	O
16	the	_	_	O
17	use	_	_	O
18	of	_	_	O
19	various	_	_	O
20	nucleos	_	_	O
21	(	_	_	O
22	t	_	_	O
23	)	_	_	O
24	ide	_	_	O
25	analogue	_	_	O
26	(	_	_	O
27	NUC	_	_	O
28	)	_	_	O
29	regimens	_	_	O
30	in	_	_	O
31	treatment-naïve	_	_	O
32	patients	_	_	O
33	,	_	_	O
34	including	_	_	O
35	NUCs	_	_	O
36	with	_	_	O
37	low	_	_	O
38	genetic	_	_	O
39	barriers	_	_	O
40	to	_	_	O
41	resistance	_	_	O
42	,	_	_	O
43	with/without	_	_	O
44	add-on	_	_	O
45	therapy	_	_	O
46	and	_	_	O
47	de	_	_	O
48	novo	_	_	O
49	NUC	_	_	O
50	combinations	_	_	O
51	.	_	_	O

52	This	_	_	O
53	longitudinal	_	_	O
54	observational	_	_	O
55	study	_	_	O
56	therefore	_	_	O
57	investigated	_	_	O
58	the	_	_	O
59	real-world	_	_	O
60	clinical	_	_	O
61	management	_	_	O
62	and	_	_	O
63	efficacy	_	_	O
64	of	_	_	O
65	NUC	_	_	O
66	therapy	_	_	O
67	in	_	_	O
68	treatment-naïve	_	_	O
69	CHB	_	_	O
70	patients	_	_	O
71	in	_	_	O
72	China	_	_	O
73	.	_	_	O

74	Treatment-naïve	_	_	O
75	CHB	_	_	O
76	patients	_	_	O
77	initiated	_	_	O
78	on	_	_	O
79	NUC	_	_	O
80	therapy	_	_	O
81	were	_	_	O
82	enrolled	_	_	O
83	from	_	_	O
84	63	_	_	O
85	hospitals	_	_	O
86	in	_	_	O
87	tier-2	_	_	O
88	Chinese	_	_	O
89	cities	_	_	O
90	.	_	_	O

91	Demographic	_	_	O
92	and	_	_	O
93	treatment-specific	_	_	O
94	data	_	_	O
95	were	_	_	O
96	collected	_	_	O
97	,	_	_	O
98	with	_	_	O
99	the	_	_	O
100	objective	_	_	O
101	of	_	_	O
102	reporting	_	_	O
103	real-world	_	_	O
104	treatment	_	_	O
105	patterns	_	_	O
106	and	_	_	O
107	comparing	_	_	O
108	the	_	_	O
109	effectiveness	_	_	O
110	of	_	_	O
111	entecavir	_	_	O
112	(	_	_	O
113	ETV	_	_	O
114	)	_	_	O
115	treatment	_	_	O
116	and	_	_	O
117	lamivudine	_	_	O
118	(	_	_	O
119	LAM	_	_	O
120	)	_	_	O
121	-based	_	_	O
122	treatment	_	_	O
123	.	_	_	O

124	We	_	_	O
125	herein	_	_	O
126	report	_	_	O
127	the	_	_	O
128	first-year	_	_	O
129	data	_	_	O
130	.	_	_	O

131	3,408	_	_	O
132	NUC-naïve	_	_	O
133	patients	_	_	O
134	were	_	_	O
135	enrolled	_	_	O
136	and	_	_	O
137	treated	_	_	O
138	with	_	_	O
139	NUCs	_	_	O
140	(	_	_	O
141	53	_	_	O
142	%	_	_	O
143	ETV	_	_	O
144	,	_	_	O
145	18	_	_	O
146	%	_	_	O
147	LAM-based	_	_	O
148	,	_	_	O
149	29	_	_	O
150	%	_	_	O
151	other	_	_	O
152	)	_	_	O
153	.	_	_	O

154	Overall	_	_	B-Premise
155	,	_	_	I-Premise
156	6.6	_	_	I-Premise
157	%	_	_	I-Premise
158	of	_	_	I-Premise
159	patients	_	_	I-Premise
160	modified	_	_	I-Premise
161	their	_	_	I-Premise
162	initial	_	_	I-Premise
163	treatment	_	_	I-Premise
164	,	_	_	I-Premise
165	with	_	_	I-Premise
166	ETV	_	_	I-Premise
167	having	_	_	I-Premise
168	lower	_	_	I-Premise
169	rates	_	_	I-Premise
170	of	_	_	I-Premise
171	treatment	_	_	I-Premise
172	modification	_	_	I-Premise
173	than	_	_	I-Premise
174	other	_	_	I-Premise
175	major	_	_	I-Premise
176	NUCs	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	<	_	_	I-Premise
180	0.05	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	At	_	_	B-Premise
184	week	_	_	I-Premise
185	52	_	_	I-Premise
186	,	_	_	I-Premise
187	the	_	_	I-Premise
188	virologic	_	_	I-Premise
189	response	_	_	I-Premise
190	rate	_	_	I-Premise
191	was	_	_	I-Premise
192	higher	_	_	I-Premise
193	with	_	_	I-Premise
194	ETV	_	_	I-Premise
195	than	_	_	I-Premise
196	with	_	_	I-Premise
197	LAM-based	_	_	I-Premise
198	treatment	_	_	I-Premise
199	(	_	_	I-Premise
200	77.0	_	_	I-Premise
201	%	_	_	I-Premise
202	versus	_	_	I-Premise
203	61.4	_	_	I-Premise
204	%	_	_	I-Premise
205	,	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	0.0001	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	LAM-based	_	_	B-Premise
212	treatment	_	_	I-Premise
213	was	_	_	I-Premise
214	associated	_	_	I-Premise
215	with	_	_	I-Premise
216	a	_	_	I-Premise
217	higher	_	_	I-Premise
218	probability	_	_	I-Premise
219	of	_	_	I-Premise
220	virologic	_	_	I-Premise
221	breakthrough	_	_	I-Premise
222	and	_	_	I-Premise
223	genotypic	_	_	I-Premise
224	resistance	_	_	I-Premise
225	(	_	_	I-Premise
226	21.4	_	_	I-Premise
227	%	_	_	I-Premise
228	and	_	_	I-Premise
229	19.6	_	_	I-Premise
230	%	_	_	I-Premise
231	,	_	_	I-Premise
232	respectively	_	_	I-Premise
233	)	_	_	I-Premise
234	than	_	_	I-Premise
235	ETV	_	_	I-Premise
236	(	_	_	I-Premise
237	1.6	_	_	I-Premise
238	%	_	_	I-Premise
239	and	_	_	I-Premise
240	0.1	_	_	I-Premise
241	%	_	_	I-Premise
242	,	_	_	I-Premise
243	respectively	_	_	I-Premise
244	)	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	0.0001	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	Treatment-related	_	_	B-Premise
252	adverse	_	_	I-Premise
253	events	_	_	I-Premise
254	or	_	_	I-Premise
255	serious	_	_	I-Premise
256	adverse	_	_	I-Premise
257	events	_	_	I-Premise
258	were	_	_	I-Premise
259	uncommon	_	_	I-Premise
260	.	_	_	I-Premise

261	In	_	_	O
262	this	_	_	O
263	nationwide	_	_	O
264	observational	_	_	O
265	study	_	_	O
266	,	_	_	O
267	more	_	_	O
268	than	_	_	O
269	50	_	_	O
270	%	_	_	O
271	of	_	_	O
272	patients	_	_	O
273	with	_	_	O
274	CHB	_	_	O
275	in	_	_	O
276	tier-2	_	_	O
277	city	_	_	O
278	hospitals	_	_	O
279	in	_	_	O
280	China	_	_	O
281	initially	_	_	O
282	received	_	_	O
283	ETV	_	_	O
284	therapy	_	_	O
285	.	_	_	O

286	Consistent	_	_	B-Claim
287	with	_	_	I-Claim
288	clinical	_	_	I-Claim
289	trial	_	_	I-Claim
290	results	_	_	I-Claim
291	,	_	_	I-Claim
292	ETV	_	_	I-Claim
293	was	_	_	I-Claim
294	more	_	_	I-Claim
295	effective	_	_	I-Claim
296	than	_	_	I-Claim
297	LAM-based	_	_	I-Claim
298	treatments	_	_	I-Claim
299	in	_	_	I-Claim
300	a	_	_	I-Claim
301	real-world	_	_	I-Claim
302	setting	_	_	I-Claim
303	,	_	_	I-Claim
304	with	_	_	I-Claim
305	treatment	_	_	I-Claim
306	modification	_	_	I-Claim
307	being	_	_	I-Claim
308	relatively	_	_	I-Claim
309	low	_	_	I-Claim
310	in	_	_	I-Claim
311	ETV-treated	_	_	I-Claim
312	patients	_	_	I-Claim
313	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aimed	_	_	O
3	to	_	_	O
4	propose	_	_	O
5	the	_	_	O
6	role	_	_	O
7	of	_	_	O
8	amniotic	_	_	O
9	membrane	_	_	O
10	transplantation	_	_	O
11	(	_	_	O
12	AMT	_	_	O
13	)	_	_	O
14	as	_	_	O
15	an	_	_	O
16	additional	_	_	O
17	modulator	_	_	O
18	in	_	_	O
19	primary	_	_	O
20	Mitomycin	_	_	O
21	C	_	_	O
22	(	_	_	O
23	MMC	_	_	O
24	)	_	_	O
25	-augmented	_	_	O
26	trabeculectomy	_	_	O
27	.	_	_	O

28	This	_	_	O
29	was	_	_	O
30	a	_	_	O
31	randomized	_	_	O
32	prospective	_	_	O
33	interventional	_	_	O
34	study	_	_	O
35	.	_	_	O

36	Forty	_	_	O
37	eyes	_	_	O
38	of	_	_	O
39	39	_	_	O
40	adult	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	uncontrolled	_	_	O
44	primary	_	_	O
45	glaucoma	_	_	O
46	were	_	_	O
47	randomly	_	_	O
48	divided	_	_	O
49	into	_	_	O
50	two	_	_	O
51	equal	_	_	O
52	groups	_	_	O
53	.	_	_	O

54	Control	_	_	O
55	group	_	_	O
56	underwent	_	_	O
57	trabeculectomy	_	_	O
58	augmented	_	_	O
59	with	_	_	O
60	MMC	_	_	O
61	while	_	_	O
62	the	_	_	O
63	study	_	_	O
64	group	_	_	O
65	underwent	_	_	O
66	additional	_	_	O
67	AMT	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	were	_	_	O
71	followed	_	_	O
72	up	_	_	O
73	for	_	_	O
74	12	_	_	O
75	months	_	_	O
76	and	_	_	O
77	outcomes	_	_	O
78	measured	_	_	O
79	were	_	_	O
80	intraocular	_	_	O
81	pressure	_	_	O
82	(	_	_	O
83	IOP	_	_	O
84	)	_	_	O
85	,	_	_	O
86	need	_	_	O
87	for	_	_	O
88	additional	_	_	O
89	intervention	_	_	O
90	,	_	_	O
91	and	_	_	O
92	bleb	_	_	O
93	morphology	_	_	O
94	.	_	_	O

95	Complete	_	_	B-Premise
96	success	_	_	I-Premise
97	(	_	_	I-Premise
98	defined	_	_	I-Premise
99	as	_	_	I-Premise
100	IOP	_	_	I-Premise
101	<	_	_	I-Premise
102	16	_	_	I-Premise
103	mmHg	_	_	I-Premise
104	on	_	_	I-Premise
105	no	_	_	I-Premise
106	medication	_	_	I-Premise
107	)	_	_	I-Premise
108	could	_	_	I-Premise
109	be	_	_	I-Premise
110	achieved	_	_	I-Premise
111	in	_	_	I-Premise
112	85	_	_	I-Premise
113	%	_	_	I-Premise
114	eyes	_	_	I-Premise
115	in	_	_	I-Premise
116	study	_	_	I-Premise
117	group	_	_	I-Premise
118	while	_	_	I-Premise
119	it	_	_	I-Premise
120	was	_	_	I-Premise
121	60	_	_	I-Premise
122	%	_	_	I-Premise
123	in	_	_	I-Premise
124	control	_	_	I-Premise
125	group	_	_	I-Premise
126	(	_	_	I-Premise
127	P	_	_	I-Premise
128	=	_	_	I-Premise
129	0.04	_	_	I-Premise
130	)	_	_	I-Premise
131	.	_	_	I-Premise

132	IOP	_	_	B-Premise
133	reduced	_	_	I-Premise
134	by	_	_	I-Premise
135	71.1	_	_	I-Premise
136	%	_	_	I-Premise
137	in	_	_	I-Premise
138	study	_	_	I-Premise
139	group	_	_	I-Premise
140	from	_	_	I-Premise
141	41.9	_	_	I-Premise
142	±	_	_	I-Premise
143	10.6	_	_	I-Premise
144	to	_	_	I-Premise
145	12.1	_	_	I-Premise
146	±	_	_	I-Premise
147	2.7	_	_	I-Premise
148	mmHg	_	_	I-Premise
149	and	_	_	I-Premise
150	from	_	_	I-Premise
151	40.5	_	_	I-Premise
152	±	_	_	I-Premise
153	8.5	_	_	I-Premise
154	to	_	_	I-Premise
155	12.8	_	_	I-Premise
156	±	_	_	I-Premise
157	4.5	_	_	I-Premise
158	mmHg	_	_	I-Premise
159	in	_	_	I-Premise
160	control	_	_	I-Premise
161	group	_	_	I-Premise
162	,	_	_	I-Premise
163	a	_	_	I-Premise
164	decline	_	_	I-Premise
165	of	_	_	I-Premise
166	68.29	_	_	I-Premise
167	%	_	_	I-Premise
168	.	_	_	I-Premise

169	Blebs	_	_	B-Premise
170	in	_	_	I-Premise
171	AMT	_	_	I-Premise
172	group	_	_	I-Premise
173	showed	_	_	I-Premise
174	better	_	_	I-Premise
175	bleb	_	_	I-Premise
176	morphology	_	_	I-Premise
177	in	_	_	I-Premise
178	terms	_	_	I-Premise
179	of	_	_	I-Premise
180	significantly	_	_	I-Premise
181	better	_	_	I-Premise
182	extent	_	_	I-Premise
183	(	_	_	I-Premise
184	E3	_	_	I-Premise
185	)	_	_	I-Premise
186	on	_	_	I-Premise
187	day	_	_	I-Premise
188	1	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	=	_	_	I-Premise
192	0.03	_	_	I-Premise
193	)	_	_	I-Premise
194	and	_	_	I-Premise
195	better	_	_	I-Premise
196	height	_	_	I-Premise
197	(	_	_	I-Premise
198	H2	_	_	I-Premise
199	and	_	_	I-Premise
200	H3	_	_	I-Premise
201	)	_	_	I-Premise
202	(	_	_	I-Premise
203	P	_	_	I-Premise
204	=	_	_	I-Premise
205	0.04	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	according	_	_	I-Premise
209	to	_	_	I-Premise
210	the	_	_	I-Premise
211	Indiana	_	_	I-Premise
212	Bleb	_	_	I-Premise
213	Appearance	_	_	I-Premise
214	Grading	_	_	I-Premise
215	Scale	_	_	I-Premise
216	,	_	_	I-Premise
217	at	_	_	I-Premise
218	all	_	_	I-Premise
219	follow-up	_	_	I-Premise
220	visits	_	_	I-Premise
221	along	_	_	I-Premise
222	with	_	_	I-Premise
223	normal	_	_	I-Premise
224	vascularity	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	study	_	_	I-Premise
228	group	_	_	I-Premise
229	required	_	_	I-Premise
230	significantly	_	_	I-Premise
231	lesser	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	0.03	_	_	I-Premise
236	)	_	_	I-Premise
237	bleb	_	_	I-Premise
238	needlings	_	_	I-Premise
239	as	_	_	I-Premise
240	compared	_	_	I-Premise
241	to	_	_	I-Premise
242	control	_	_	I-Premise
243	group	_	_	I-Premise
244	.	_	_	I-Premise

245	Amnion	_	_	B-Claim
246	enhanced	_	_	I-Claim
247	the	_	_	I-Claim
248	efficacy	_	_	I-Claim
249	of	_	_	I-Claim
250	MMC-modulated	_	_	I-Claim
251	trabeculectomy	_	_	I-Claim
252	in	_	_	I-Claim
253	terms	_	_	I-Claim
254	of	_	_	I-Claim
255	eyes	_	_	I-Claim
256	with	_	_	I-Claim
257	complete	_	_	I-Claim
258	success	_	_	I-Claim
259	and	_	_	I-Claim
260	lesser	_	_	I-Claim
261	interventions	_	_	I-Claim
262	such	_	_	I-Claim
263	as	_	_	I-Claim
264	bleb	_	_	I-Claim
265	needling	_	_	I-Claim
266	.	_	_	I-Claim

267	This	_	_	B-Claim
268	reiterates	_	_	I-Claim
269	the	_	_	I-Claim
270	role	_	_	I-Claim
271	of	_	_	I-Claim
272	amnion	_	_	I-Claim
273	as	_	_	I-Claim
274	a	_	_	I-Claim
275	safe	_	_	I-Claim
276	and	_	_	I-Claim
277	effective	_	_	I-Claim
278	bleb	_	_	I-Claim
279	modulator	_	_	I-Claim
280	.	_	_	I-Claim

281	A	_	_	O
282	diffusely	_	_	O
283	elevated	_	_	O
284	bleb	_	_	O
285	with	_	_	O
286	healthier	_	_	O
287	conjunctiva	_	_	O
288	can	_	_	O
289	go	_	_	O
290	a	_	_	O
291	long	_	_	O
292	way	_	_	O
293	in	_	_	O
294	predicting	_	_	O
295	better	_	_	O
296	health	_	_	O
297	and	_	_	O
298	longevity	_	_	O
299	of	_	_	O
300	the	_	_	O
301	bleb	_	_	O
302	.	_	_	O


0	Pulmonary	_	_	O
1	arterial	_	_	O
2	hypertension	_	_	O
3	(	_	_	O
4	PAH	_	_	O
5	)	_	_	O
6	is	_	_	O
7	a	_	_	O
8	rare	_	_	O
9	and	_	_	O
10	life-threatening	_	_	O
11	disease	_	_	O
12	well-marked	_	_	O
13	by	_	_	O
14	under	_	_	O
15	diagnosis	_	_	O
16	,	_	_	O
17	delayed	_	_	O
18	diagnosis	_	_	O
19	and	_	_	O
20	atypical	_	_	O
21	treatments	_	_	O
22	.	_	_	O

23	Few	_	_	O
24	data	_	_	O
25	are	_	_	O
26	available	_	_	O
27	on	_	_	O
28	the	_	_	O
29	quality	_	_	O
30	of	_	_	O
31	life	_	_	O
32	(	_	_	O
33	QoL	_	_	O
34	)	_	_	O
35	and	_	_	O
36	psychosocial	_	_	O
37	characteristics	_	_	O
38	of	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	PAH	_	_	O
42	.	_	_	O

43	Our	_	_	O
44	aim	_	_	O
45	is	_	_	O
46	to	_	_	O
47	describe	_	_	O
48	the	_	_	O
49	impact	_	_	O
50	of	_	_	O
51	psychological	_	_	O
52	factors	_	_	O
53	on	_	_	O
54	the	_	_	O
55	health-related	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	(	_	_	O
60	HRQoL	_	_	O
61	)	_	_	O
62	of	_	_	O
63	treated	_	_	O
64	PAH	_	_	O
65	patients	_	_	O
66	in	_	_	O
67	a	_	_	O
68	cross-sectional	_	_	O
69	study	_	_	O
70	.	_	_	O

71	Consecutive	_	_	O
72	patients	_	_	O
73	presenting	_	_	O
74	at	_	_	O
75	our	_	_	O
76	Competency	_	_	O
77	Centre	_	_	O
78	for	_	_	O
79	PAH	_	_	O
80	were	_	_	O
81	recruited	_	_	O
82	.	_	_	O

83	The	_	_	O
84	aetiology	_	_	O
85	,	_	_	O
86	New	_	_	O
87	York	_	_	O
88	Heart	_	_	O
89	Association	_	_	O
90	(	_	_	O
91	NYHA	_	_	O
92	)	_	_	O
93	stage	_	_	O
94	,	_	_	O
95	haemodynamics	_	_	O
96	,	_	_	O
97	6-min	_	_	O
98	walk	_	_	O
99	distance	_	_	O
100	(	_	_	O
101	6MWD	_	_	O
102	)	_	_	O
103	,	_	_	O
104	delta	_	_	O
105	SPO2	_	_	O
106	(	_	_	O
107	Pulse	_	_	O
108	oximeter	_	_	O
109	oxygen	_	_	O
110	saturation	_	_	O
111	;	_	_	O
112	baseline	_	_	O
113	lowest	_	_	O
114	value	_	_	O
115	during	_	_	O
116	6-min	_	_	O
117	walk	_	_	O
118	test	_	_	O
119	(	_	_	O
120	6MWT	_	_	O
121	)	_	_	O
122	,	_	_	O
123	current	_	_	O
124	treatments	_	_	O
125	and	_	_	O
126	psychological	_	_	O
127	history	_	_	O
128	were	_	_	O
129	recorded	_	_	O
130	.	_	_	O

131	HRQoL	_	_	O
132	,	_	_	O
133	anxiety	_	_	O
134	,	_	_	O
135	depression	_	_	O
136	and	_	_	O
137	coping	_	_	O
138	strategies	_	_	O
139	were	_	_	O
140	explored	_	_	O
141	using	_	_	O
142	self-administered	_	_	O
143	questionnaires	_	_	O
144	(	_	_	O
145	SF-36	_	_	O
146	,	_	_	O
147	HADS	_	_	O
148	,	_	_	O
149	STAI-Y	_	_	O
150	,	_	_	O
151	CHIP	_	_	O
152	and	_	_	O
153	WCC	_	_	O
154	)	_	_	O
155	.	_	_	O

156	A	_	_	O
157	total	_	_	O
158	of	_	_	O
159	55	_	_	O
160	patients	_	_	O
161	were	_	_	O
162	included	_	_	O
163	.	_	_	O

164	The	_	_	O
165	HRQoL	_	_	O
166	of	_	_	O
167	PAH	_	_	O
168	patients	_	_	O
169	was	_	_	O
170	poor	_	_	O
171	with	_	_	O
172	altered	_	_	O
173	results	_	_	O
174	on	_	_	O
175	several	_	_	O
176	scales	_	_	O
177	.	_	_	O

178	Anxiety	_	_	O
179	and	_	_	O
180	depression	_	_	O
181	were	_	_	O
182	high	_	_	O
183	and	_	_	O
184	coping	_	_	O
185	was	_	_	O
186	focused	_	_	O
187	on	_	_	O
188	medical	_	_	O
189	information	_	_	O
190	strategies	_	_	O
191	.	_	_	O

192	Multivariate	_	_	B-Premise
193	analysis	_	_	I-Premise
194	indicated	_	_	I-Premise
195	a	_	_	I-Premise
196	positive	_	_	I-Premise
197	relationship	_	_	I-Premise
198	between	_	_	I-Premise
199	6MWD	_	_	I-Premise
200	and	_	_	I-Premise
201	the	_	_	I-Premise
202	Physical	_	_	I-Premise
203	Composite	_	_	I-Premise
204	Score	_	_	I-Premise
205	for	_	_	I-Premise
206	QoL	_	_	I-Premise
207	(	_	_	I-Premise
208	p=0.004	_	_	I-Premise
209	)	_	_	I-Premise
210	,	_	_	I-Premise
211	as	_	_	O
212	well	_	_	O
213	as	_	_	O
214	a	_	_	O
215	negative	_	_	B-Premise
216	relationship	_	_	I-Premise
217	between	_	_	I-Premise
218	delta	_	_	I-Premise
219	SPO2	_	_	I-Premise
220	and	_	_	I-Premise
221	the	_	_	I-Premise
222	Mental	_	_	I-Premise
223	Composite	_	_	I-Premise
224	Score	_	_	I-Premise
225	(	_	_	I-Premise
226	p=0.02	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	irrespective	_	_	I-Premise
230	of	_	_	I-Premise
231	other	_	_	I-Premise
232	known	_	_	I-Premise
233	prognostic	_	_	I-Premise
234	factors	_	_	I-Premise
235	(	_	_	I-Premise
236	such	_	_	I-Premise
237	as	_	_	I-Premise
238	haemodynamics	_	_	I-Premise
239	at	_	_	I-Premise
240	right	_	_	I-Premise
241	heart	_	_	I-Premise
242	catheterization	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	Depression	_	_	B-Premise
246	and	_	_	I-Premise
247	Trait-Anxiety	_	_	I-Premise
248	were	_	_	I-Premise
249	associated	_	_	I-Premise
250	with	_	_	I-Premise
251	a	_	_	I-Premise
252	lower	_	_	I-Premise
253	physical	_	_	I-Premise
254	(	_	_	I-Premise
255	p=0.001	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	mental	_	_	I-Premise
259	(	_	_	I-Premise
260	p	_	_	I-Premise
261	<	_	_	I-Premise
262	0.001	_	_	I-Premise
263	)	_	_	I-Premise
264	QoL	_	_	I-Premise
265	,	_	_	I-Premise
266	respectively	_	_	I-Premise
267	.	_	_	I-Premise

268	Psychological	_	_	B-Claim
269	factors	_	_	I-Claim
270	impact	_	_	I-Claim
271	the	_	_	I-Claim
272	HRQoL	_	_	I-Claim
273	of	_	_	I-Claim
274	treated	_	_	I-Claim
275	patients	_	_	I-Claim
276	.	_	_	I-Claim

277	A	_	_	B-Claim
278	longitudinal	_	_	I-Claim
279	and	_	_	I-Claim
280	qualitative	_	_	I-Claim
281	study	_	_	I-Claim
282	should	_	_	I-Claim
283	refine	_	_	I-Claim
284	these	_	_	I-Claim
285	results	_	_	I-Claim
286	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aimed	_	_	O
3	to	_	_	O
4	observe	_	_	O
5	and	_	_	O
6	compare	_	_	O
7	the	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	safety	_	_	O
11	of	_	_	O
12	the	_	_	O
13	combined	_	_	O
14	therapy	_	_	O
15	and	_	_	O
16	two	_	_	O
17	different	_	_	O
18	optimized	_	_	O
19	therapies	_	_	O
20	of	_	_	O
21	lamivudine	_	_	O
22	(	_	_	O
23	LAM	_	_	O
24	)	_	_	O
25	and	_	_	O
26	adefovir	_	_	O
27	dipivoxil	_	_	O
28	(	_	_	O
29	ADV	_	_	O
30	)	_	_	O
31	,	_	_	O
32	as	_	_	O
33	well	_	_	O
34	as	_	_	O
35	entecavir	_	_	O
36	(	_	_	O
37	ETV	_	_	O
38	)	_	_	O
39	monotherapy	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	hepatitis	_	_	O
44	B-induced	_	_	O
45	decompensated	_	_	O
46	cirrhosis	_	_	O
47	.	_	_	O

48	A	_	_	O
49	total	_	_	O
50	of	_	_	O
51	127	_	_	O
52	patients	_	_	O
53	with	_	_	O
54	decompensated	_	_	O
55	cirrhosis	_	_	O
56	were	_	_	O
57	divided	_	_	O
58	into	_	_	O
59	four	_	_	O
60	groups	_	_	O
61	,	_	_	O
62	and	_	_	O
63	each	_	_	O
64	group	_	_	O
65	received	_	_	O
66	different	_	_	O
67	doses	_	_	O
68	of	_	_	O
69	regimens	_	_	O
70	:	_	_	O
71	initial	_	_	O
72	combination	_	_	O
73	of	_	_	O
74	LAM	_	_	O
75	and	_	_	O
76	ADV	_	_	O
77	,	_	_	O
78	ADV	_	_	O
79	add-on	_	_	O
80	therapies	_	_	O
81	with	_	_	O
82	previous	_	_	O
83	12-week	_	_	O
84	LAM	_	_	O
85	,	_	_	O
86	ADV	_	_	O
87	add-on	_	_	O
88	therapies	_	_	O
89	with	_	_	O
90	previous	_	_	O
91	24-week	_	_	O
92	LAM	_	_	O
93	,	_	_	O
94	and	_	_	O
95	ETV	_	_	O
96	monotherapy	_	_	O
97	.	_	_	O

98	At	_	_	B-Premise
99	the	_	_	I-Premise
100	end	_	_	I-Premise
101	of	_	_	I-Premise
102	the	_	_	I-Premise
103	treatment	_	_	I-Premise
104	,	_	_	I-Premise
105	the	_	_	I-Premise
106	level	_	_	I-Premise
107	of	_	_	I-Premise
108	alanine	_	_	I-Premise
109	amino-transferase	_	_	I-Premise
110	(	_	_	I-Premise
111	ALT	_	_	I-Premise
112	)	_	_	I-Premise
113	,	_	_	I-Premise
114	albumin	_	_	I-Premise
115	(	_	_	I-Premise
116	ALB	_	_	I-Premise
117	)	_	_	I-Premise
118	and	_	_	I-Premise
119	total	_	_	I-Premise
120	bilirubin	_	_	I-Premise
121	(	_	_	I-Premise
122	TBIL	_	_	I-Premise
123	)	_	_	I-Premise
124	in	_	_	I-Premise
125	the	_	_	I-Premise
126	combination	_	_	I-Premise
127	therapy	_	_	I-Premise
128	group	_	_	I-Premise
129	and	_	_	I-Premise
130	12-week	_	_	I-Premise
131	optimized	_	_	I-Premise
132	therapy	_	_	I-Premise
133	group	_	_	I-Premise
134	were	_	_	I-Premise
135	significantly	_	_	I-Premise
136	improved	_	_	I-Premise
137	.	_	_	I-Premise

138	For	_	_	B-Premise
139	the	_	_	I-Premise
140	24-week	_	_	I-Premise
141	optimized	_	_	I-Premise
142	therapy	_	_	I-Premise
143	group	_	_	I-Premise
144	,	_	_	I-Premise
145	only	_	_	I-Premise
146	ALT	_	_	I-Premise
147	levels	_	_	I-Premise
148	revealed	_	_	I-Premise
149	a	_	_	I-Premise
150	significant	_	_	I-Premise
151	improvement	_	_	I-Premise
152	.	_	_	I-Premise

153	There	_	_	B-Premise
154	were	_	_	I-Premise
155	no	_	_	I-Premise
156	obvious	_	_	I-Premise
157	differences	_	_	I-Premise
158	in	_	_	I-Premise
159	the	_	_	I-Premise
160	normalization	_	_	I-Premise
161	rate	_	_	I-Premise
162	of	_	_	I-Premise
163	ALT	_	_	I-Premise
164	,	_	_	I-Premise
165	negative	_	_	I-Premise
166	conversion	_	_	I-Premise
167	rate	_	_	I-Premise
168	of	_	_	I-Premise
169	HBV	_	_	I-Premise
170	DNA	_	_	I-Premise
171	and	_	_	I-Premise
172	HBeAg	_	_	I-Premise
173	,	_	_	I-Premise
174	as	_	_	I-Premise
175	well	_	_	I-Premise
176	as	_	_	I-Premise
177	improvement	_	_	I-Premise
178	in	_	_	I-Premise
179	Child-Pugh	_	_	I-Premise
180	scores	_	_	I-Premise
181	among	_	_	I-Premise
182	the	_	_	I-Premise
183	combination	_	_	I-Premise
184	therapy	_	_	I-Premise
185	group	_	_	I-Premise
186	,	_	_	I-Premise
187	12-week	_	_	I-Premise
188	optimized	_	_	I-Premise
189	therapy	_	_	I-Premise
190	group	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	ETV	_	_	I-Premise
194	monotherapy	_	_	I-Premise
195	group	_	_	I-Premise
196	.	_	_	I-Premise

197	However	_	_	B-Premise
198	,	_	_	I-Premise
199	the	_	_	I-Premise
200	difference	_	_	I-Premise
201	among	_	_	I-Premise
202	these	_	_	I-Premise
203	three	_	_	I-Premise
204	groups	_	_	I-Premise
205	and	_	_	I-Premise
206	the	_	_	I-Premise
207	24-week	_	_	I-Premise
208	optimized	_	_	I-Premise
209	therapy	_	_	I-Premise
210	group	_	_	I-Premise
211	were	_	_	I-Premise
212	significant	_	_	I-Premise
213	.	_	_	I-Premise

214	Differences	_	_	B-Premise
215	were	_	_	I-Premise
216	not	_	_	I-Premise
217	observed	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	HBeAg	_	_	I-Premise
221	seroconversion	_	_	I-Premise
222	between	_	_	I-Premise
223	each	_	_	I-Premise
224	group	_	_	I-Premise
225	.	_	_	I-Premise

226	Differences	_	_	B-Premise
227	in	_	_	I-Premise
228	blood	_	_	I-Premise
229	urea	_	_	I-Premise
230	nitrogen	_	_	I-Premise
231	,	_	_	I-Premise
232	serum	_	_	I-Premise
233	creatinine	_	_	I-Premise
234	,	_	_	I-Premise
235	creatine	_	_	I-Premise
236	kinase	_	_	I-Premise
237	,	_	_	I-Premise
238	or	_	_	I-Premise
239	other	_	_	I-Premise
240	serious	_	_	I-Premise
241	adverse	_	_	I-Premise
242	effects	_	_	I-Premise
243	were	_	_	I-Premise
244	not	_	_	I-Premise
245	observed	_	_	I-Premise
246	in	_	_	I-Premise
247	each	_	_	I-Premise
248	group	_	_	I-Premise
249	at	_	_	I-Premise
250	the	_	_	I-Premise
251	end	_	_	I-Premise
252	of	_	_	I-Premise
253	the	_	_	I-Premise
254	96-week	_	_	I-Premise
255	treatment	_	_	I-Premise
256	.	_	_	I-Premise

257	Combination	_	_	B-Claim
258	therapy	_	_	I-Claim
259	and	_	_	I-Claim
260	early	_	_	I-Claim
261	ADV	_	_	I-Claim
262	addition	_	_	I-Claim
263	were	_	_	I-Claim
264	the	_	_	I-Claim
265	preferred	_	_	I-Claim
266	approaches	_	_	I-Claim
267	in	_	_	I-Claim
268	the	_	_	I-Claim
269	antiviral	_	_	I-Claim
270	strategy	_	_	I-Claim
271	for	_	_	I-Claim
272	the	_	_	I-Claim
273	treatment	_	_	I-Claim
274	of	_	_	I-Claim
275	hepatitis	_	_	I-Claim
276	B-induced	_	_	I-Claim
277	decompensated	_	_	I-Claim
278	cirrhosis	_	_	I-Claim
279	.	_	_	I-Claim


0	Hepatotoxicity	_	_	O
1	associated	_	_	O
2	with	_	_	O
3	isoniazid	_	_	O
4	preventive	_	_	O
5	therapy	_	_	O
6	(	_	_	O
7	IPT	_	_	O
8	)	_	_	O
9	and	_	_	O
10	antiretroviral	_	_	O
11	therapy	_	_	O
12	(	_	_	O
13	ART	_	_	O
14	)	_	_	O
15	has	_	_	O
16	not	_	_	O
17	been	_	_	O
18	well	_	_	O
19	studied	_	_	O
20	in	_	_	O
21	severely	_	_	O
22	immunosuppressed	_	_	O
23	people	_	_	O
24	with	_	_	O
25	HIV	_	_	O
26	.	_	_	O

27	Our	_	_	O
28	objective	_	_	O
29	was	_	_	O
30	to	_	_	O
31	determine	_	_	O
32	risk	_	_	O
33	factors	_	_	O
34	for	_	_	O
35	hepatotoxicity	_	_	O
36	in	_	_	O
37	severely	_	_	O
38	immunosuppressed	_	_	O
39	individuals	_	_	O
40	taking	_	_	O
41	IPT	_	_	O
42	and	_	_	O
43	ART	_	_	O
44	.	_	_	O

45	Multicenter	_	_	O
46	study	_	_	O
47	in	_	_	O
48	resource-limited	_	_	O
49	settings	_	_	O
50	with	_	_	O
51	high	_	_	O
52	burden	_	_	O
53	of	_	_	O
54	tuberculosis	_	_	O
55	.	_	_	O

56	We	_	_	O
57	conducted	_	_	O
58	a	_	_	O
59	secondary	_	_	O
60	analysis	_	_	O
61	of	_	_	O
62	data	_	_	O
63	from	_	_	O
64	1	_	_	O
65	randomized	_	_	O
66	arm	_	_	O
67	of	_	_	O
68	the	_	_	O
69	REMEMBER	_	_	O
70	trial	_	_	O
71	.	_	_	O

72	The	_	_	O
73	analysis	_	_	O
74	includes	_	_	O
75	participants	_	_	O
76	with	_	_	O
77	pre-ART	_	_	O
78	CD4	_	_	O
79	cell	_	_	O
80	counts	_	_	O
81	of	_	_	O
82	<	_	_	O
83	50	_	_	O
84	cells/μL	_	_	O
85	receiving	_	_	O
86	IPT	_	_	O
87	and	_	_	O
88	ART	_	_	O
89	for	_	_	O
90	24	_	_	O
91	weeks	_	_	O
92	.	_	_	O

93	Hepatotoxicity	_	_	O
94	was	_	_	O
95	defined	_	_	O
96	as	_	_	O
97	elevated	_	_	O
98	aspartate	_	_	O
99	aminotransferase	_	_	O
100	(	_	_	O
101	AST	_	_	O
102	)	_	_	O
103	or	_	_	O
104	alanine	_	_	O
105	aminotransferase	_	_	O
106	(	_	_	O
107	ALT	_	_	O
108	)	_	_	O
109	>	_	_	O
110	5	_	_	O
111	×	_	_	O
112	upper	_	_	O
113	limit	_	_	O
114	of	_	_	O
115	normal	_	_	O
116	or	_	_	O
117	symptomatic	_	_	O
118	hepatitis	_	_	O
119	during	_	_	O
120	IPT	_	_	O
121	and	_	_	O
122	ART	_	_	O
123	.	_	_	O

124	Logistic	_	_	O
125	regression	_	_	O
126	was	_	_	O
127	used	_	_	O
128	to	_	_	O
129	identify	_	_	O
130	baseline	_	_	O
131	risk	_	_	O
132	factors	_	_	O
133	for	_	_	O
134	hepatotoxicity	_	_	O
135	.	_	_	O

136	Time	_	_	O
137	to	_	_	O
138	occurrence	_	_	O
139	of	_	_	O
140	hepatotoxicity	_	_	O
141	was	_	_	O
142	estimated	_	_	O
143	by	_	_	O
144	the	_	_	O
145	Kaplan-Meier	_	_	O
146	method	_	_	O
147	.	_	_	O

148	Among	_	_	B-Premise
149	426	_	_	I-Premise
150	participants	_	_	I-Premise
151	(	_	_	I-Premise
152	53	_	_	I-Premise
153	%	_	_	I-Premise
154	male	_	_	I-Premise
155	,	_	_	I-Premise
156	median	_	_	I-Premise
157	age	_	_	I-Premise
158	35	_	_	I-Premise
159	years	_	_	I-Premise
160	,	_	_	I-Premise
161	median	_	_	I-Premise
162	CD4	_	_	I-Premise
163	count	_	_	I-Premise
164	19	_	_	I-Premise
165	cells/µL	_	_	I-Premise
166	)	_	_	I-Premise
167	,	_	_	I-Premise
168	31	_	_	I-Premise
169	developed	_	_	I-Premise
170	hepatotoxicity	_	_	I-Premise
171	(	_	_	I-Premise
172	7.3	_	_	I-Premise
173	%	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	Raised	_	_	B-Premise
177	pretreatment	_	_	I-Premise
178	AST/ALT	_	_	I-Premise
179	(	_	_	I-Premise
180	odds	_	_	I-Premise
181	ratio	_	_	I-Premise
182	[	_	_	I-Premise
183	OR	_	_	I-Premise
184	]	_	_	I-Premise
185	3.6	_	_	I-Premise
186	,	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	confidence	_	_	I-Premise
190	interval	_	_	I-Premise
191	[	_	_	I-Premise
192	CI	_	_	I-Premise
193	]	_	_	I-Premise
194	:	_	_	I-Premise
195	1.7	_	_	I-Premise
196	to	_	_	I-Premise
197	7.7	_	_	I-Premise
198	)	_	_	I-Premise
199	and	_	_	I-Premise
200	hepatitis	_	_	I-Premise
201	B	_	_	I-Premise
202	surface	_	_	I-Premise
203	antigen	_	_	I-Premise
204	(	_	_	I-Premise
205	HBsAg	_	_	I-Premise
206	)	_	_	I-Premise
207	seropositivity	_	_	I-Premise
208	at	_	_	I-Premise
209	baseline	_	_	I-Premise
210	(	_	_	I-Premise
211	OR	_	_	I-Premise
212	4.7	_	_	I-Premise
213	,	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	:	_	_	I-Premise
218	1.7	_	_	I-Premise
219	to	_	_	I-Premise
220	12.9	_	_	I-Premise
221	)	_	_	I-Premise
222	were	_	_	I-Premise
223	significantly	_	_	I-Premise
224	associated	_	_	I-Premise
225	with	_	_	I-Premise
226	an	_	_	I-Premise
227	increased	_	_	I-Premise
228	risk	_	_	I-Premise
229	of	_	_	I-Premise
230	developing	_	_	I-Premise
231	hepatotoxicity	_	_	I-Premise
232	.	_	_	I-Premise

233	Participants	_	_	B-Premise
234	with	_	_	I-Premise
235	both	_	_	I-Premise
236	raised	_	_	I-Premise
237	AST/ALT	_	_	I-Premise
238	and	_	_	I-Premise
239	positive	_	_	I-Premise
240	HBsAg	_	_	I-Premise
241	had	_	_	I-Premise
242	a	_	_	I-Premise
243	higher	_	_	I-Premise
244	risk	_	_	I-Premise
245	(	_	_	I-Premise
246	OR	_	_	I-Premise
247	19.9	_	_	I-Premise
248	,	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	:	_	_	I-Premise
253	5.3	_	_	I-Premise
254	to	_	_	I-Premise
255	74.3	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	earlier	_	_	I-Premise
259	onset	_	_	I-Premise
260	of	_	_	I-Premise
261	hepatotoxicity	_	_	I-Premise
262	than	_	_	I-Premise
263	participants	_	_	I-Premise
264	who	_	_	I-Premise
265	did	_	_	I-Premise
266	not	_	_	I-Premise
267	have	_	_	I-Premise
268	these	_	_	I-Premise
269	conditions	_	_	I-Premise
270	at	_	_	I-Premise
271	baseline	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Claim
274	incidence	_	_	I-Claim
275	of	_	_	I-Claim
276	hepatotoxicity	_	_	I-Claim
277	during	_	_	I-Claim
278	IPT	_	_	I-Claim
279	and	_	_	I-Claim
280	ART	_	_	I-Claim
281	was	_	_	I-Claim
282	high	_	_	I-Claim
283	.	_	_	I-Claim

284	Severely	_	_	B-Claim
285	immunosuppressed	_	_	I-Claim
286	individuals	_	_	I-Claim
287	with	_	_	I-Claim
288	raised	_	_	I-Claim
289	pretreatment	_	_	I-Claim
290	AST/ALT	_	_	I-Claim
291	or	_	_	I-Claim
292	HBsAg	_	_	I-Claim
293	seropositivity	_	_	I-Claim
294	need	_	_	I-Claim
295	closer	_	_	I-Claim
296	monitoring	_	_	I-Claim
297	for	_	_	I-Claim
298	hepatotoxicity	_	_	I-Claim
299	.	_	_	I-Claim


0	The	_	_	O
1	blood	_	_	O
2	pressure-lowering	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	fermented	_	_	O
6	milk	_	_	O
7	with	_	_	O
8	Lactococcus	_	_	O
9	lactis	_	_	O
10	NRRL	_	_	O
11	B-50571	_	_	O
12	was	_	_	O
13	evaluated	_	_	O
14	in	_	_	O
15	a	_	_	O
16	double-blind	_	_	O
17	randomized	_	_	O
18	controlled	_	_	O
19	clinical	_	_	O
20	trial	_	_	O
21	with	_	_	O
22	prehypertensive	_	_	O
23	subjects	_	_	O
24	.	_	_	O

25	Participants	_	_	O
26	were	_	_	O
27	randomized	_	_	O
28	into	_	_	O
29	2	_	_	O
30	groups	_	_	O
31	(	_	_	O
32	n	_	_	O
33	=	_	_	O
34	18	_	_	O
35	each	_	_	O
36	group	_	_	O
37	)	_	_	O
38	:	_	_	O
39	one	_	_	O
40	group	_	_	O
41	treated	_	_	O
42	with	_	_	O
43	fermented	_	_	O
44	milk	_	_	O
45	with	_	_	O
46	Lactococcus	_	_	O
47	lactis	_	_	O
48	NRRL	_	_	O
49	B-50571	_	_	O
50	and	_	_	O
51	a	_	_	O
52	control	_	_	O
53	group	_	_	O
54	treated	_	_	O
55	with	_	_	O
56	artificially	_	_	O
57	acidified	_	_	O
58	milk	_	_	O
59	.	_	_	O

60	Results	_	_	B-Premise
61	revealed	_	_	I-Premise
62	that	_	_	I-Premise
63	during	_	_	I-Premise
64	daily	_	_	I-Premise
65	consumption	_	_	I-Premise
66	of	_	_	I-Premise
67	fermented	_	_	I-Premise
68	milk	_	_	I-Premise
69	for	_	_	I-Premise
70	5	_	_	I-Premise
71	wk	_	_	I-Premise
72	,	_	_	I-Premise
73	systolic	_	_	I-Premise
74	[	_	_	I-Premise
75	(	_	_	I-Premise
76	116.55	_	_	I-Premise
77	±	_	_	I-Premise
78	12.26	_	_	I-Premise
79	mmHg	_	_	I-Premise
80	vs.	_	_	I-Premise
81	124.77	_	_	I-Premise
82	±	_	_	I-Premise
83	11.04	_	_	I-Premise
84	mmHg	_	_	I-Premise
85	)	_	_	I-Premise
86	and	_	_	I-Premise
87	diastolic	_	_	I-Premise
88	blood	_	_	I-Premise
89	pressure	_	_	I-Premise
90	(	_	_	I-Premise
91	80.7	_	_	I-Premise
92	±	_	_	I-Premise
93	9	_	_	I-Premise
94	vs.	_	_	I-Premise
95	84.5	_	_	I-Premise
96	±	_	_	I-Premise
97	8.5	_	_	I-Premise
98	mmHg	_	_	I-Premise
99	)	_	_	I-Premise
100	]	_	_	I-Premise
101	from	_	_	I-Premise
102	the	_	_	I-Premise
103	fermented	_	_	I-Premise
104	milk	_	_	I-Premise
105	group	_	_	I-Premise
106	was	_	_	I-Premise
107	lower	_	_	I-Premise
108	than	_	_	I-Premise
109	the	_	_	I-Premise
110	control	_	_	I-Premise
111	group	_	_	I-Premise
112	.	_	_	I-Premise

113	Additionally	_	_	B-Premise
114	,	_	_	I-Premise
115	triglyceride	_	_	I-Premise
116	,	_	_	I-Premise
117	total	_	_	I-Premise
118	cholesterol	_	_	I-Premise
119	,	_	_	I-Premise
120	and	_	_	I-Premise
121	low-density	_	_	I-Premise
122	lipoprotein	_	_	I-Premise
123	in	_	_	I-Premise
124	blood	_	_	I-Premise
125	serum	_	_	I-Premise
126	were	_	_	I-Premise
127	lower	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	fermented	_	_	I-Premise
131	milk	_	_	I-Premise
132	group	_	_	I-Premise
133	than	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	control	_	_	I-Premise
137	group	_	_	I-Premise
138	.	_	_	I-Premise

139	Results	_	_	B-Claim
140	demonstrated	_	_	I-Claim
141	that	_	_	I-Claim
142	daily	_	_	I-Claim
143	consumption	_	_	I-Claim
144	of	_	_	I-Claim
145	fermented	_	_	I-Claim
146	milk	_	_	I-Claim
147	with	_	_	I-Claim
148	Lactococcus	_	_	I-Claim
149	lactis	_	_	I-Claim
150	(	_	_	I-Claim
151	NRRL	_	_	I-Claim
152	B-50571	_	_	I-Claim
153	)	_	_	I-Claim
154	had	_	_	I-Claim
155	a	_	_	I-Claim
156	blood	_	_	I-Claim
157	pressure-lowering	_	_	I-Claim
158	effect	_	_	I-Claim
159	on	_	_	I-Claim
160	prehypertensive	_	_	I-Claim
161	subjects	_	_	I-Claim
162	.	_	_	I-Claim

163	Regular	_	_	B-Claim
164	consumption	_	_	I-Claim
165	of	_	_	I-Claim
166	this	_	_	I-Claim
167	product	_	_	I-Claim
168	may	_	_	I-Claim
169	be	_	_	I-Claim
170	used	_	_	I-Claim
171	as	_	_	I-Claim
172	a	_	_	I-Claim
173	potential	_	_	I-Claim
174	functional	_	_	I-Claim
175	food	_	_	I-Claim
176	.	_	_	I-Claim


0	Increasing	_	_	O
1	evidence	_	_	O
2	suggests	_	_	O
3	that	_	_	O
4	iron-containing	_	_	B-Claim
5	multiple	_	_	I-Claim
6	micronutrient	_	_	I-Claim
7	may	_	_	I-Claim
8	reduce	_	_	I-Claim
9	the	_	_	I-Claim
10	risk	_	_	I-Claim
11	of	_	_	I-Claim
12	pregnancy-induced	_	_	I-Claim
13	hypertension	_	_	I-Claim
14	including	_	_	I-Claim
15	gestational	_	_	I-Claim
16	hypertension	_	_	I-Claim
17	or	_	_	I-Claim
18	preeclampsia	_	_	I-Claim
19	.	_	_	I-Claim

20	We	_	_	O
21	aimed	_	_	O
22	to	_	_	O
23	examine	_	_	O
24	whether	_	_	O
25	30	_	_	O
26	mg	_	_	O
27	iron	_	_	O
28	plus	_	_	O
29	folic	_	_	O
30	acid	_	_	O
31	or	_	_	O
32	multiple	_	_	O
33	micronutrients	_	_	O
34	during	_	_	O
35	pregnancy	_	_	O
36	reduces	_	_	O
37	the	_	_	O
38	risk	_	_	O
39	of	_	_	O
40	pregnancy-induced	_	_	O
41	hypertension	_	_	O
42	.	_	_	O

43	We	_	_	O
44	conducted	_	_	O
45	a	_	_	O
46	secondary	_	_	O
47	data	_	_	O
48	analysis	_	_	O
49	by	_	_	O
50	the	_	_	O
51	dataset	_	_	O
52	from	_	_	O
53	a	_	_	O
54	double-blind	_	_	O
55	randomized	_	_	O
56	controlled	_	_	O
57	trial	_	_	O
58	in	_	_	O
59	China	_	_	O
60	from	_	_	O
61	2006	_	_	O
62	to	_	_	O
63	2009	_	_	O
64	that	_	_	O
65	was	_	_	O
66	conducted	_	_	O
67	to	_	_	O
68	investigate	_	_	O
69	the	_	_	O
70	effects	_	_	O
71	of	_	_	O
72	multiple	_	_	O
73	micronutrient	_	_	O
74	supplements	_	_	O
75	on	_	_	O
76	adverse	_	_	O
77	pregnancy	_	_	O
78	outcomes	_	_	O
79	when	_	_	O
80	provided	_	_	O
81	to	_	_	O
82	pregnant	_	_	O
83	women	_	_	O
84	with	_	_	O
85	no/mild	_	_	O
86	anemia	_	_	O
87	.	_	_	O

88	We	_	_	O
89	used	_	_	O
90	logistic	_	_	O
91	regression	_	_	O
92	to	_	_	O
93	estimate	_	_	O
94	the	_	_	O
95	adjusted	_	_	O
96	odds	_	_	O
97	ratio	_	_	O
98	and	_	_	O
99	95	_	_	O
100	%	_	_	O
101	confidence	_	_	O
102	interval	_	_	O
103	and	_	_	O
104	test	_	_	O
105	for	_	_	O
106	effect	_	_	O
107	modification	_	_	O
108	.	_	_	O

109	The	_	_	B-Premise
110	incidence	_	_	I-Premise
111	of	_	_	I-Premise
112	pregnancy-induced	_	_	I-Premise
113	hypertension	_	_	I-Premise
114	was	_	_	I-Premise
115	7.1	_	_	I-Premise
116	%	_	_	I-Premise
117	(	_	_	I-Premise
118	423/5923	_	_	I-Premise
119	)	_	_	I-Premise
120	,	_	_	I-Premise
121	6.3	_	_	I-Premise
122	%	_	_	I-Premise
123	(	_	_	I-Premise
124	374/5933	_	_	I-Premise
125	)	_	_	I-Premise
126	and	_	_	I-Premise
127	6.3	_	_	I-Premise
128	%	_	_	I-Premise
129	(	_	_	I-Premise
130	372/5914	_	_	I-Premise
131	)	_	_	I-Premise
132	among	_	_	I-Premise
133	the	_	_	I-Premise
134	pregnant	_	_	I-Premise
135	women	_	_	I-Premise
136	who	_	_	I-Premise
137	took	_	_	I-Premise
138	folic	_	_	I-Premise
139	acid	_	_	I-Premise
140	only	_	_	I-Premise
141	,	_	_	I-Premise
142	iron-folic	_	_	I-Premise
143	acid	_	_	I-Premise
144	and	_	_	I-Premise
145	multiple	_	_	I-Premise
146	micronutrient	_	_	I-Premise
147	supplements	_	_	I-Premise
148	,	_	_	I-Premise
149	respectively	_	_	I-Premise
150	.	_	_	I-Premise

151	The	_	_	B-Premise
152	adjusted	_	_	I-Premise
153	odds	_	_	I-Premise
154	ratios	_	_	I-Premise
155	associated	_	_	I-Premise
156	with	_	_	I-Premise
157	iron-folic	_	_	I-Premise
158	acid	_	_	I-Premise
159	supplements	_	_	I-Premise
160	and	_	_	I-Premise
161	multiple	_	_	I-Premise
162	micronutrient	_	_	I-Premise
163	supplements	_	_	I-Premise
164	for	_	_	I-Premise
165	pregnancy-induced	_	_	I-Premise
166	hypertension	_	_	I-Premise
167	were	_	_	I-Premise
168	both	_	_	I-Premise
169	nearly	_	_	I-Premise
170	0.88	_	_	I-Premise
171	(	_	_	I-Premise
172	95	_	_	I-Premise
173	%	_	_	I-Premise
174	confidence	_	_	I-Premise
175	interval	_	_	I-Premise
176	,	_	_	I-Premise
177	0.76-1.02	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	compared	_	_	I-Premise
181	with	_	_	I-Premise
182	folic	_	_	I-Premise
183	acid	_	_	I-Premise
184	supplements	_	_	I-Premise
185	only	_	_	I-Premise
186	.	_	_	I-Premise

187	Among	_	_	B-Premise
188	pregnant	_	_	I-Premise
189	women	_	_	I-Premise
190	aged	_	_	I-Premise
191	20-24	_	_	I-Premise
192	years	_	_	I-Premise
193	,	_	_	I-Premise
194	iron-folic	_	_	I-Premise
195	acid	_	_	I-Premise
196	(	_	_	I-Premise
197	adjusted	_	_	I-Premise
198	odds	_	_	I-Premise
199	ratios	_	_	I-Premise
200	:	_	_	I-Premise
201	0.81	_	_	I-Premise
202	,	_	_	I-Premise
203	95	_	_	I-Premise
204	%	_	_	I-Premise
205	confidence	_	_	I-Premise
206	interval	_	_	I-Premise
207	:	_	_	I-Premise
208	0.67-0.96	_	_	I-Premise
209	)	_	_	I-Premise
210	or	_	_	I-Premise
211	multiple	_	_	I-Premise
212	micronutrient	_	_	I-Premise
213	supplementation	_	_	I-Premise
214	(	_	_	I-Premise
215	adjusted	_	_	I-Premise
216	odds	_	_	I-Premise
217	ratios	_	_	I-Premise
218	:	_	_	I-Premise
219	0.83	_	_	I-Premise
220	,	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	confidence	_	_	I-Premise
224	interval	_	_	I-Premise
225	:	_	_	I-Premise
226	0.70-0.99	_	_	I-Premise
227	)	_	_	I-Premise
228	can	_	_	I-Premise
229	significantly	_	_	I-Premise
230	reduce	_	_	I-Premise
231	the	_	_	I-Premise
232	risk	_	_	I-Premise
233	of	_	_	I-Premise
234	pregnancy-induced	_	_	I-Premise
235	hypertension	_	_	I-Premise
236	compared	_	_	I-Premise
237	to	_	_	I-Premise
238	folic	_	_	I-Premise
239	acid	_	_	I-Premise
240	supplementation	_	_	I-Premise
241	.	_	_	I-Premise

242	Overall	_	_	O
243	,	_	_	O
244	there	_	_	O
245	were	_	_	O
246	no	_	_	O
247	significant	_	_	O
248	differences	_	_	O
249	in	_	_	O
250	pregnancy-induced	_	_	O
251	hypertension	_	_	O
252	across	_	_	O
253	supplement	_	_	O
254	groups	_	_	O
255	.	_	_	O

256	However	_	_	O
257	,	_	_	O
258	among	_	_	B-Claim
259	pregnant	_	_	I-Claim
260	women	_	_	I-Claim
261	aged	_	_	I-Claim
262	20-24	_	_	I-Claim
263	years	_	_	I-Claim
264	,	_	_	I-Claim
265	iron-containing	_	_	I-Claim
266	multiple	_	_	I-Claim
267	micronutrient	_	_	I-Claim
268	supplementation	_	_	I-Claim
269	was	_	_	I-Claim
270	associated	_	_	I-Claim
271	with	_	_	I-Claim
272	a	_	_	I-Claim
273	reduced	_	_	I-Claim
274	risk	_	_	I-Claim
275	of	_	_	I-Claim
276	pregnancy-induced	_	_	I-Claim
277	hypertension	_	_	I-Claim
278	compared	_	_	I-Claim
279	with	_	_	I-Claim
280	folic	_	_	I-Claim
281	acid	_	_	I-Claim
282	supplements	_	_	I-Claim
283	only	_	_	I-Claim
284	.	_	_	I-Claim


0	The	_	_	O
1	role	_	_	O
2	of	_	_	O
3	gut	_	_	O
4	microbiota	_	_	O
5	in	_	_	O
6	the	_	_	O
7	management	_	_	O
8	of	_	_	O
9	diabetes	_	_	O
10	is	_	_	O
11	shown	_	_	O
12	.	_	_	O

13	In	_	_	O
14	this	_	_	O
15	randomized	_	_	O
16	clinical	_	_	O
17	trial	_	_	O
18	we	_	_	O
19	assessed	_	_	O
20	the	_	_	O
21	effects	_	_	O
22	of	_	_	O
23	synbiotic	_	_	O
24	supplementation	_	_	O
25	on	_	_	O
26	insulin	_	_	O
27	,	_	_	O
28	lipid	_	_	O
29	profile	_	_	O
30	and	_	_	O
31	antioxidative	_	_	O
32	status	_	_	O
33	among	_	_	O
34	women	_	_	O
35	with	_	_	O
36	gestational	_	_	O
37	diabetes	_	_	O
38	mellitus	_	_	O
39	(	_	_	O
40	GDM	_	_	O
41	)	_	_	O
42	.	_	_	O

43	Ninety	_	_	O
44	pregnant	_	_	O
45	women	_	_	O
46	with	_	_	O
47	GDM	_	_	O
48	were	_	_	O
49	randomly	_	_	O
50	assigned	_	_	O
51	into	_	_	O
52	two	_	_	O
53	groups	_	_	O
54	to	_	_	O
55	receive	_	_	O
56	either	_	_	O
57	a	_	_	O
58	daily	_	_	O
59	synbiotic	_	_	O
60	capsule	_	_	O
61	-	_	_	O
62	consisting	_	_	O
63	of	_	_	O
64	L.	_	_	O
65	acidophilus	_	_	O
66	,	_	_	O
67	L.	_	_	O
68	plantarum	_	_	O
69	,	_	_	O
70	L.	_	_	O
71	fermentum	_	_	O
72	,	_	_	O
73	L.	_	_	O
74	gasseri	_	_	O
75	(	_	_	O
76	1.5-7.0	_	_	O
77	×	_	_	O
78	109-10	_	_	O
79	CFU/g	_	_	O
80	)	_	_	O
81	-	_	_	O
82	with	_	_	O
83	fructooligosaccharide	_	_	O
84	(	_	_	O
85	38.5	_	_	O
86	mg	_	_	O
87	)	_	_	O
88	,	_	_	O
89	or	_	_	O
90	placebo	_	_	O
91	for	_	_	O
92	6	_	_	O
93	weeks	_	_	O
94	.	_	_	O

95	Fasting	_	_	O
96	plasma	_	_	O
97	glucose	_	_	O
98	(	_	_	O
99	FPG	_	_	O
100	)	_	_	O
101	,	_	_	O
102	insulin	_	_	O
103	,	_	_	O
104	homeostasis	_	_	O
105	model	_	_	O
106	assessment-insulin	_	_	O
107	resistance	_	_	O
108	(	_	_	O
109	HOMA-IR	_	_	O
110	)	_	_	O
111	,	_	_	O
112	quantitative	_	_	O
113	insulin	_	_	O
114	sensitivity	_	_	O
115	check	_	_	O
116	index	_	_	O
117	(	_	_	O
118	QUICKI	_	_	O
119	)	_	_	O
120	,	_	_	O
121	high-	_	_	O
122	and	_	_	O
123	low	_	_	O
124	density	_	_	O
125	lipoprotein	_	_	O
126	cholesterol	_	_	O
127	(	_	_	O
128	HDL-C	_	_	O
129	,	_	_	O
130	LDL-C	_	_	O
131	)	_	_	O
132	,	_	_	O
133	total	_	_	O
134	cholesterol	_	_	O
135	(	_	_	O
136	TC	_	_	O
137	)	_	_	O
138	,	_	_	O
139	triglycerides	_	_	O
140	(	_	_	O
141	TG	_	_	O
142	)	_	_	O
143	,	_	_	O
144	total	_	_	O
145	antioxidant	_	_	O
146	capacity	_	_	O
147	(	_	_	O
148	TAC	_	_	O
149	)	_	_	O
150	,	_	_	O
151	and	_	_	O
152	systolic	_	_	O
153	and	_	_	O
154	diastolic	_	_	O
155	blood	_	_	O
156	pressure	_	_	O
157	(	_	_	O
158	SBP	_	_	O
159	,	_	_	O
160	DSP	_	_	O
161	)	_	_	O
162	were	_	_	O
163	assessed	_	_	O
164	before	_	_	O
165	and	_	_	O
166	after	_	_	O
167	the	_	_	O
168	intervention	_	_	O
169	.	_	_	O

170	No	_	_	B-Premise
171	significant	_	_	I-Premise
172	changes	_	_	I-Premise
173	in	_	_	I-Premise
174	FPG	_	_	I-Premise
175	,	_	_	I-Premise
176	insulin	_	_	I-Premise
177	resistance/sensitivity	_	_	I-Premise
178	,	_	_	I-Premise
179	lipid	_	_	I-Premise
180	profile	_	_	I-Premise
181	and	_	_	I-Premise
182	TAC	_	_	I-Premise
183	indices	_	_	I-Premise
184	were	_	_	I-Premise
185	seen	_	_	I-Premise
186	in	_	_	I-Premise
187	synbiotic	_	_	I-Premise
188	group	_	_	I-Premise
189	compared	_	_	I-Premise
190	to	_	_	I-Premise
191	the	_	_	I-Premise
192	placebo	_	_	I-Premise
193	one	_	_	I-Premise
194	(	_	_	I-Premise
195	p	_	_	I-Premise
196	>	_	_	I-Premise
197	0.05	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Significant	_	_	B-Premise
201	within	_	_	I-Premise
202	group	_	_	I-Premise
203	increases	_	_	I-Premise
204	for	_	_	I-Premise
205	HDL-C	_	_	I-Premise
206	and	_	_	I-Premise
207	TAC	_	_	I-Premise
208	levels	_	_	I-Premise
209	in	_	_	I-Premise
210	synbiotic	_	_	I-Premise
211	group	_	_	I-Premise
212	were	_	_	I-Premise
213	observed	_	_	I-Premise
214	(	_	_	I-Premise
215	p	_	_	I-Premise
216	<	_	_	I-Premise
217	0.05	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	LDL-C	_	_	B-Premise
221	showed	_	_	I-Premise
222	significant	_	_	I-Premise
223	increment	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	placebo	_	_	I-Premise
227	group	_	_	I-Premise
228	compared	_	_	I-Premise
229	to	_	_	I-Premise
230	the	_	_	I-Premise
231	baseline	_	_	I-Premise
232	of	_	_	I-Premise
233	the	_	_	I-Premise
234	study	_	_	I-Premise
235	(	_	_	I-Premise
236	6.9	_	_	I-Premise
237	mg/dL	_	_	I-Premise
238	,	_	_	I-Premise
239	p	_	_	I-Premise
240	<	_	_	I-Premise
241	0.05	_	_	I-Premise
242	)	_	_	I-Premise
243	.	_	_	I-Premise

244	Between	_	_	B-Premise
245	group	_	_	I-Premise
246	comparison	_	_	I-Premise
247	showed	_	_	I-Premise
248	significant	_	_	I-Premise
249	decrease	_	_	I-Premise
250	in	_	_	I-Premise
251	SBP	_	_	I-Premise
252	and	_	_	I-Premise
253	DBP	_	_	I-Premise
254	in	_	_	I-Premise
255	synbiotic	_	_	I-Premise
256	group	_	_	I-Premise
257	compared	_	_	I-Premise
258	to	_	_	I-Premise
259	placebo	_	_	I-Premise
260	(	_	_	I-Premise
261	-2.5	_	_	I-Premise
262	vs.	_	_	I-Premise
263	8.6	_	_	I-Premise
264	mmHg	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	-1.8	_	_	I-Premise
268	vs.	_	_	I-Premise
269	2.1	_	_	I-Premise
270	mmHg	_	_	I-Premise
271	,	_	_	I-Premise
272	p	_	_	I-Premise
273	<	_	_	I-Premise
274	0.05	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	The	_	_	B-Claim
278	results	_	_	I-Claim
279	showed	_	_	I-Claim
280	that	_	_	I-Claim
281	,	_	_	I-Claim
282	in	_	_	I-Claim
283	women	_	_	I-Claim
284	with	_	_	I-Claim
285	GDM	_	_	I-Claim
286	,	_	_	I-Claim
287	synbiotic	_	_	I-Claim
288	supplementation	_	_	I-Claim
289	had	_	_	I-Claim
290	no	_	_	I-Claim
291	effect	_	_	I-Claim
292	on	_	_	I-Claim
293	FPG	_	_	I-Claim
294	and	_	_	I-Claim
295	insulin	_	_	I-Claim
296	resistance/sensitivity	_	_	I-Claim
297	indices	_	_	I-Claim
298	.	_	_	I-Claim

299	Lipid	_	_	B-Claim
300	profile	_	_	I-Claim
301	and	_	_	I-Claim
302	TAC	_	_	I-Claim
303	status	_	_	I-Claim
304	may	_	_	I-Claim
305	be	_	_	I-Claim
306	affected	_	_	I-Claim
307	by	_	_	I-Claim
308	synbiotic	_	_	I-Claim
309	supplementation	_	_	I-Claim
310	.	_	_	I-Claim

311	Synbiotic	_	_	B-Claim
312	is	_	_	I-Claim
313	effective	_	_	I-Claim
314	in	_	_	I-Claim
315	reducing	_	_	I-Claim
316	of	_	_	I-Claim
317	blood	_	_	I-Claim
318	pressure	_	_	I-Claim
319	in	_	_	I-Claim
320	women	_	_	I-Claim
321	with	_	_	I-Claim
322	GDM	_	_	I-Claim
323	.	_	_	I-Claim


0	Chronic	_	_	O
1	infection	_	_	O
2	with	_	_	O
3	hepatitis	_	_	O
4	B	_	_	O
5	virus	_	_	O
6	(	_	_	O
7	HBV	_	_	O
8	)	_	_	O
9	in	_	_	O
10	children	_	_	O
11	is	_	_	O
12	a	_	_	O
13	serious	_	_	O
14	health	_	_	O
15	problem	_	_	O
16	worldwide	_	_	O
17	.	_	_	O

18	How	_	_	O
19	to	_	_	O
20	treat	_	_	O
21	children	_	_	O
22	with	_	_	O
23	immune-tolerant	_	_	O
24	chronic	_	_	O
25	hepatitis	_	_	O
26	B	_	_	O
27	infection	_	_	O
28	,	_	_	O
29	commonly	_	_	O
30	characterized	_	_	O
31	by	_	_	O
32	hepatitis	_	_	O
33	B	_	_	O
34	e	_	_	O
35	antigen	_	_	O
36	(	_	_	O
37	HBeAg	_	_	O
38	)	_	_	O
39	positivity	_	_	O
40	,	_	_	O
41	high	_	_	O
42	viral	_	_	O
43	load	_	_	O
44	,	_	_	O
45	normal	_	_	O
46	or	_	_	O
47	mildly	_	_	O
48	elevated	_	_	O
49	alanine	_	_	O
50	aminotransferase	_	_	O
51	and	_	_	O
52	no	_	_	O
53	or	_	_	O
54	minimal	_	_	O
55	inflammation	_	_	O
56	in	_	_	O
57	liver	_	_	O
58	histology	_	_	O
59	,	_	_	O
60	remains	_	_	O
61	unresolved	_	_	O
62	.	_	_	O

63	This	_	_	O
64	trial	_	_	O
65	aims	_	_	O
66	to	_	_	O
67	study	_	_	O
68	the	_	_	O
69	benefits	_	_	O
70	of	_	_	O
71	antiviral	_	_	O
72	therapy	_	_	O
73	in	_	_	O
74	children	_	_	O
75	with	_	_	O
76	these	_	_	O
77	characteristics	_	_	O
78	.	_	_	O

79	This	_	_	O
80	is	_	_	O
81	a	_	_	O
82	pilot	_	_	O
83	open-label	_	_	O
84	randomized	_	_	O
85	controlled	_	_	O
86	study	_	_	O
87	.	_	_	O

88	From	_	_	O
89	May	_	_	O
90	2014	_	_	O
91	to	_	_	O
92	April	_	_	O
93	2015	_	_	O
94	,	_	_	O
95	69	_	_	O
96	treatment-naive	_	_	O
97	chronically	_	_	O
98	HBV-infected	_	_	O
99	children	_	_	O
100	,	_	_	O
101	aged	_	_	O
102	1	_	_	O
103	to	_	_	O
104	16	_	_	O
105	years	_	_	O
106	,	_	_	O
107	who	_	_	O
108	had	_	_	O
109	immune-tolerant	_	_	O
110	characteristics	_	_	O
111	were	_	_	O
112	recruited	_	_	O
113	to	_	_	O
114	this	_	_	O
115	trial	_	_	O
116	and	_	_	O
117	randomly	_	_	O
118	assigned	_	_	O
119	,	_	_	O
120	in	_	_	O
121	a	_	_	O
122	2:1	_	_	O
123	ratio	_	_	O
124	,	_	_	O
125	to	_	_	O
126	treatment	_	_	O
127	group	_	_	O
128	and	_	_	O
129	control	_	_	O
130	group	_	_	O
131	.	_	_	O

132	Patients	_	_	O
133	in	_	_	O
134	the	_	_	O
135	treatment	_	_	O
136	group	_	_	O
137	received	_	_	O
138	either	_	_	O
139	interferon-α	_	_	O
140	(	_	_	O
141	IFN	_	_	O
142	)	_	_	O
143	monotherapy	_	_	O
144	or	_	_	O
145	consecutively	_	_	O
146	received	_	_	O
147	IFN	_	_	O
148	monotherapy	_	_	O
149	,	_	_	O
150	combination	_	_	O
151	therapy	_	_	O
152	of	_	_	O
153	IFN	_	_	O
154	and	_	_	O
155	lamivudine	_	_	O
156	(	_	_	O
157	LAM	_	_	O
158	)	_	_	O
159	,	_	_	O
160	and	_	_	O
161	LAM	_	_	O
162	therapy	_	_	O
163	alone	_	_	O
164	.	_	_	O

165	All	_	_	O
166	patients	_	_	O
167	were	_	_	O
168	observed	_	_	O
169	until	_	_	O
170	week	_	_	O
171	96	_	_	O
172	.	_	_	O

173	At	_	_	O
174	baseline	_	_	O
175	,	_	_	O
176	epidemiological	_	_	O
177	,	_	_	O
178	biochemical	_	_	O
179	,	_	_	O
180	serological	_	_	O
181	,	_	_	O
182	virological	_	_	O
183	and	_	_	O
184	histological	_	_	O
185	indices	_	_	O
186	were	_	_	O
187	consistent	_	_	O
188	across	_	_	O
189	the	_	_	O
190	treatment	_	_	O
191	and	_	_	O
192	control	_	_	O
193	groups	_	_	O
194	.	_	_	O

195	Of	_	_	B-Premise
196	the	_	_	I-Premise
197	46	_	_	I-Premise
198	patients	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	treatment	_	_	I-Premise
202	group	_	_	I-Premise
203	,	_	_	I-Premise
204	73.91	_	_	I-Premise
205	%	_	_	I-Premise
206	had	_	_	I-Premise
207	undetectable	_	_	I-Premise
208	serum	_	_	I-Premise
209	HBV	_	_	I-Premise
210	DNA	_	_	I-Premise
211	,	_	_	I-Premise
212	32.61	_	_	I-Premise
213	%	_	_	I-Premise
214	achieved	_	_	I-Premise
215	HBeAg	_	_	I-Premise
216	seroconversion	_	_	I-Premise
217	and	_	_	I-Premise
218	21.74	_	_	I-Premise
219	%	_	_	I-Premise
220	lost	_	_	I-Premise
221	hepatitis	_	_	I-Premise
222	B	_	_	I-Premise
223	surface	_	_	I-Premise
224	antigen	_	_	I-Premise
225	(	_	_	I-Premise
226	HBsAg	_	_	I-Premise
227	)	_	_	I-Premise
228	at	_	_	I-Premise
229	the	_	_	I-Premise
230	endpoint	_	_	I-Premise
231	.	_	_	I-Premise

232	No	_	_	B-Premise
233	LAM	_	_	I-Premise
234	resistance	_	_	I-Premise
235	emerged	_	_	I-Premise
236	at	_	_	I-Premise
237	week	_	_	I-Premise
238	96	_	_	I-Premise
239	.	_	_	I-Premise

240	In	_	_	B-Premise
241	the	_	_	I-Premise
242	control	_	_	I-Premise
243	group	_	_	I-Premise
244	,	_	_	I-Premise
245	only	_	_	I-Premise
246	one	_	_	I-Premise
247	(	_	_	I-Premise
248	4.35	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	patient	_	_	I-Premise
252	underwent	_	_	I-Premise
253	spontaneous	_	_	I-Premise
254	HBeAg	_	_	I-Premise
255	seroconversion	_	_	I-Premise
256	and	_	_	I-Premise
257	had	_	_	I-Premise
258	undetectable	_	_	I-Premise
259	serum	_	_	I-Premise
260	HBV	_	_	I-Premise
261	DNA	_	_	I-Premise
262	during	_	_	I-Premise
263	observation	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	moreover	_	_	I-Premise
267	,	_	_	I-Premise
268	none	_	_	I-Premise
269	developed	_	_	I-Premise
270	HBsAg	_	_	I-Premise
271	clearance	_	_	I-Premise
272	.	_	_	I-Premise

273	For	_	_	B-Premise
274	all	_	_	I-Premise
275	patients	_	_	I-Premise
276	,	_	_	I-Premise
277	no	_	_	I-Premise
278	serious	_	_	I-Premise
279	adverse	_	_	I-Premise
280	events	_	_	I-Premise
281	were	_	_	I-Premise
282	observed	_	_	I-Premise
283	.	_	_	I-Premise

284	Antiviral	_	_	B-Premise
285	treatment	_	_	I-Premise
286	with	_	_	I-Premise
287	a	_	_	I-Premise
288	sequential	_	_	I-Premise
289	combination	_	_	I-Premise
290	of	_	_	I-Premise
291	IFN	_	_	I-Premise
292	and	_	_	I-Premise
293	LAM	_	_	I-Premise
294	resulted	_	_	I-Premise
295	in	_	_	I-Premise
296	a	_	_	I-Premise
297	significant	_	_	I-Premise
298	improvement	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	rates	_	_	I-Premise
302	of	_	_	I-Premise
303	undetectable	_	_	I-Premise
304	serum	_	_	I-Premise
305	HBV	_	_	I-Premise
306	DNA	_	_	I-Premise
307	,	_	_	I-Premise
308	HBeAg	_	_	I-Premise
309	seroconversion	_	_	I-Premise
310	and	_	_	I-Premise
311	HBsAg	_	_	I-Premise
312	loss	_	_	I-Premise
313	in	_	_	I-Premise
314	children	_	_	I-Premise
315	with	_	_	I-Premise
316	chronic	_	_	I-Premise
317	HBV	_	_	I-Premise
318	infection	_	_	I-Premise
319	and	_	_	I-Premise
320	immune-tolerant	_	_	I-Premise
321	characteristics	_	_	I-Premise
322	.	_	_	I-Premise

323	There	_	_	O
324	is	_	_	O
325	a	_	_	O
326	lack	_	_	O
327	of	_	_	O
328	data	_	_	O
329	regarding	_	_	O
330	treatment	_	_	O
331	of	_	_	O
332	immune-tolerant	_	_	O
333	chronic	_	_	O
334	hepatitis	_	_	O
335	B	_	_	O
336	(	_	_	O
337	CHB	_	_	O
338	)	_	_	O
339	.	_	_	O

340	It	_	_	B-Claim
341	remains	_	_	I-Claim
342	unresolved	_	_	I-Claim
343	how	_	_	I-Claim
344	children	_	_	I-Claim
345	with	_	_	I-Claim
346	immune-tolerant	_	_	I-Claim
347	CHB	_	_	I-Claim
348	should	_	_	I-Claim
349	be	_	_	I-Claim
350	treated	_	_	I-Claim
351	.	_	_	I-Claim

352	This	_	_	O
353	paper	_	_	O
354	reports	_	_	O
355	the	_	_	O
356	outcomes	_	_	O
357	from	_	_	O
358	a	_	_	O
359	pilot	_	_	O
360	open-label	_	_	O
361	randomized	_	_	O
362	controlled	_	_	O
363	trial	_	_	O
364	on	_	_	O
365	antiviral	_	_	O
366	therapy	_	_	O
367	in	_	_	O
368	children	_	_	O
369	with	_	_	O
370	immune-tolerant	_	_	O
371	characteristics	_	_	O
372	.	_	_	O

373	It	_	_	B-Claim
374	shows	_	_	I-Claim
375	that	_	_	I-Claim
376	a	_	_	I-Claim
377	sequential	_	_	I-Claim
378	combination	_	_	I-Claim
379	of	_	_	I-Claim
380	interferon-α	_	_	I-Claim
381	and	_	_	I-Claim
382	lamivudine	_	_	I-Claim
383	was	_	_	I-Claim
384	beneficial	_	_	I-Claim
385	.	_	_	I-Claim


0	Efficacy	_	_	O
1	of	_	_	O
2	sequential	_	_	O
3	therapy	_	_	O
4	with	_	_	O
5	nucleos	_	_	O
6	(	_	_	O
7	t	_	_	O
8	)	_	_	O
9	ide	_	_	O
10	analogues	_	_	O
11	and	_	_	O
12	interferons	_	_	O
13	versus	_	_	O
14	monotherapy	_	_	O
15	in	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	hepatitis	_	_	O
19	B	_	_	O
20	e	_	_	O
21	antigen	_	_	O
22	(	_	_	O
23	HBeAg	_	_	O
24	)	_	_	O
25	-positive	_	_	O
26	chronic	_	_	O
27	hepatitis	_	_	O
28	B	_	_	O
29	(	_	_	O
30	CHB	_	_	O
31	)	_	_	O
32	remains	_	_	O
33	unexplored	_	_	O
34	.	_	_	O

35	We	_	_	O
36	aimed	_	_	O
37	to	_	_	O
38	assess	_	_	O
39	efficacy	_	_	O
40	and	_	_	O
41	safety	_	_	O
42	of	_	_	O
43	sequential	_	_	O
44	therapy	_	_	O
45	with	_	_	O
46	adefovir	_	_	O
47	(	_	_	O
48	ADV	_	_	O
49	)	_	_	O
50	or	_	_	O
51	entecavir	_	_	O
52	(	_	_	O
53	ETV	_	_	O
54	)	_	_	O
55	followed	_	_	O
56	by	_	_	O
57	peginterferon	_	_	O
58	(	_	_	O
59	PEG-IFN	_	_	O
60	)	_	_	O
61	alfa-2a	_	_	O
62	in	_	_	O
63	Taiwanese	_	_	O
64	patients	_	_	O
65	with	_	_	O
66	HBeAg-positive	_	_	O
67	.	_	_	O

68	This	_	_	O
69	randomized	_	_	O
70	,	_	_	O
71	placebo-controlled	_	_	O
72	,	_	_	O
73	double-blind	_	_	O
74	trial	_	_	O
75	was	_	_	O
76	conducted	_	_	O
77	at	_	_	O
78	nine	_	_	O
79	sites	_	_	O
80	in	_	_	O
81	Taiwan	_	_	O
82	from	_	_	O
83	April	_	_	O
84	2010	_	_	O
85	to	_	_	O
86	October	_	_	O
87	2013	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	(	_	_	O
91	N	_	_	O
92	=	_	_	O
93	280	_	_	O
94	)	_	_	O
95	were	_	_	O
96	randomized	_	_	O
97	1:1:1	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	placebo	_	_	O
101	,	_	_	O
102	ETV	_	_	O
103	or	_	_	O
104	ADV	_	_	O
105	alone	_	_	O
106	for	_	_	O
107	four	_	_	O
108	weeks	_	_	O
109	,	_	_	O
110	combined	_	_	O
111	with	_	_	O
112	PEG-IFN	_	_	O
113	alfa-2a	_	_	O
114	for	_	_	O
115	two	_	_	O
116	weeks	_	_	O
117	,	_	_	O
118	then	_	_	O
119	PEG-IFN	_	_	O
120	alfa-2a	_	_	O
121	alone	_	_	O
122	for	_	_	O
123	46	_	_	O
124	weeks	_	_	O
125	.	_	_	O

126	The	_	_	O
127	primary	_	_	O
128	efficacy	_	_	O
129	end	_	_	O
130	point	_	_	O
131	was	_	_	O
132	HBeAg	_	_	O
133	seroconversion	_	_	O
134	at	_	_	O
135	48	_	_	O
136	weeks	_	_	O
137	post-treatment	_	_	O
138	.	_	_	O

139	No	_	_	B-Premise
140	significant	_	_	I-Premise
141	differences	_	_	I-Premise
142	were	_	_	I-Premise
143	observed	_	_	I-Premise
144	among	_	_	I-Premise
145	groups	_	_	I-Premise
146	for	_	_	I-Premise
147	HBeAg	_	_	I-Premise
148	seroconversion	_	_	I-Premise
149	(	_	_	I-Premise
150	PEG-IFN	_	_	I-Premise
151	alfa-2a+placebo	_	_	I-Premise
152	,	_	_	I-Premise
153	36.3	_	_	I-Premise
154	%	_	_	I-Premise
155	;	_	_	I-Premise
156	PEG-IFN	_	_	I-Premise
157	alfa-2a+ETV	_	_	I-Premise
158	,	_	_	I-Premise
159	29.5	_	_	I-Premise
160	%	_	_	I-Premise
161	;	_	_	I-Premise
162	and	_	_	I-Premise
163	PEG-IFN	_	_	I-Premise
164	alfa-2a+ADV	_	_	I-Premise
165	,	_	_	I-Premise
166	27.4	_	_	I-Premise
167	%	_	_	I-Premise
168	)	_	_	I-Premise
169	,	_	_	I-Premise
170	HBeAg	_	_	I-Premise
171	loss	_	_	I-Premise
172	(	_	_	I-Premise
173	37.4	_	_	I-Premise
174	%	_	_	I-Premise
175	,	_	_	I-Premise
176	32.2	_	_	I-Premise
177	%	_	_	I-Premise
178	,	_	_	I-Premise
179	and	_	_	I-Premise
180	28.6	_	_	I-Premise
181	%	_	_	I-Premise
182	,	_	_	I-Premise
183	respectively	_	_	I-Premise
184	)	_	_	I-Premise
185	or	_	_	I-Premise
186	change	_	_	I-Premise
187	in	_	_	I-Premise
188	hepatitis	_	_	I-Premise
189	B	_	_	I-Premise
190	surface	_	_	I-Premise
191	antigen	_	_	I-Premise
192	(	_	_	I-Premise
193	HBsAg	_	_	I-Premise
194	)	_	_	I-Premise
195	levels	_	_	I-Premise
196	from	_	_	I-Premise
197	baseline	_	_	I-Premise
198	(	_	_	I-Premise
199	-0.56	_	_	I-Premise
200	IU/mL	_	_	I-Premise
201	,	_	_	I-Premise
202	-0.60	_	_	I-Premise
203	IU/mL	_	_	I-Premise
204	,	_	_	I-Premise
205	and	_	_	I-Premise
206	-0.41	_	_	I-Premise
207	IU/mL	_	_	I-Premise
208	,	_	_	I-Premise
209	respectively	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	However	_	_	B-Premise
213	,	_	_	I-Premise
214	hepatitis	_	_	I-Premise
215	B	_	_	I-Premise
216	virus	_	_	I-Premise
217	DNA	_	_	I-Premise
218	levels	_	_	I-Premise
219	were	_	_	I-Premise
220	higher	_	_	I-Premise
221	with	_	_	I-Premise
222	PEG-IFN	_	_	I-Premise
223	alfa-2a+placebo	_	_	I-Premise
224	than	_	_	I-Premise
225	PEG-IFN	_	_	I-Premise
226	alfa+ETV	_	_	I-Premise
227	at	_	_	I-Premise
228	week	_	_	I-Premise
229	64	_	_	I-Premise
230	(	_	_	I-Premise
231	p	_	_	I-Premise
232	=	_	_	I-Premise
233	0.0412	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	76	_	_	I-Premise
237	(	_	_	I-Premise
238	p	_	_	I-Premise
239	=	_	_	I-Premise
240	0.0311	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	88	_	_	I-Premise
245	(	_	_	I-Premise
246	p	_	_	I-Premise
247	=	_	_	I-Premise
248	0.0113	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	and	_	_	I-Premise
252	alanine	_	_	I-Premise
253	aminotransferase	_	_	I-Premise
254	(	_	_	I-Premise
255	ALT	_	_	I-Premise
256	)	_	_	I-Premise
257	normalization	_	_	I-Premise
258	rate	_	_	I-Premise
259	was	_	_	I-Premise
260	higher	_	_	I-Premise
261	with	_	_	I-Premise
262	PEG-IFN	_	_	I-Premise
263	alfa-2a+placebo	_	_	I-Premise
264	than	_	_	I-Premise
265	PEG-IFN	_	_	I-Premise
266	alfa-2a+ADV	_	_	I-Premise
267	(	_	_	I-Premise
268	p	_	_	I-Premise
269	=	_	_	I-Premise
270	0.0283	_	_	I-Premise
271	)	_	_	I-Premise
272	or	_	_	I-Premise
273	PEG-IFN	_	_	I-Premise
274	alfa-2a+ETV	_	_	I-Premise
275	(	_	_	I-Premise
276	p	_	_	I-Premise
277	=	_	_	I-Premise
278	0.0369	_	_	I-Premise
279	)	_	_	I-Premise
280	at	_	_	I-Premise
281	week	_	_	I-Premise
282	88	_	_	I-Premise
283	.	_	_	I-Premise

284	Sub-analysis	_	_	B-Premise
285	of	_	_	I-Premise
286	results	_	_	I-Premise
287	revealed	_	_	I-Premise
288	an	_	_	I-Premise
289	association	_	_	I-Premise
290	between	_	_	I-Premise
291	on-treatment	_	_	I-Premise
292	HBsAg	_	_	I-Premise
293	and	_	_	I-Premise
294	ALT	_	_	I-Premise
295	levels	_	_	I-Premise
296	and	_	_	I-Premise
297	efficacy	_	_	I-Premise
298	48	_	_	I-Premise
299	weeks	_	_	I-Premise
300	post-treatment	_	_	I-Premise
301	.	_	_	I-Premise

302	Safety	_	_	B-Premise
303	was	_	_	I-Premise
304	comparable	_	_	I-Premise
305	among	_	_	I-Premise
306	treatment	_	_	I-Premise
307	groups	_	_	I-Premise
308	.	_	_	I-Premise

309	Pre-therapy	_	_	B-Claim
310	with	_	_	I-Claim
311	ADV	_	_	I-Claim
312	or	_	_	I-Claim
313	ETV	_	_	I-Claim
314	followed	_	_	I-Claim
315	by	_	_	I-Claim
316	PEG-IFN	_	_	I-Claim
317	alfa-2a	_	_	I-Claim
318	is	_	_	I-Claim
319	not	_	_	I-Claim
320	superior	_	_	I-Claim
321	to	_	_	I-Claim
322	PEG-IFN	_	_	I-Claim
323	alfa-2a	_	_	I-Claim
324	monotherapy	_	_	I-Claim
325	in	_	_	I-Claim
326	Taiwanese	_	_	I-Claim
327	patients	_	_	I-Claim
328	with	_	_	I-Claim
329	HBeAg-positive	_	_	I-Claim
330	CHB	_	_	I-Claim
331	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	spironolactone	_	_	O
9	versus	_	_	O
10	clonidine	_	_	O
11	as	_	_	O
12	the	_	_	O
13	fourth	_	_	O
14	drug	_	_	O
15	in	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	resistant	_	_	O
19	hypertension	_	_	O
20	in	_	_	O
21	a	_	_	O
22	multicenter	_	_	O
23	,	_	_	O
24	randomized	_	_	O
25	trial	_	_	O
26	.	_	_	O

27	Medical	_	_	O
28	therapy	_	_	O
29	adherence	_	_	O
30	was	_	_	O
31	checked	_	_	O
32	by	_	_	O
33	pill	_	_	O
34	counting	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	with	_	_	O
38	resistant	_	_	O
39	hypertension	_	_	O
40	(	_	_	O
41	no	_	_	O
42	office	_	_	O
43	and	_	_	O
44	ambulatory	_	_	O
45	blood	_	_	O
46	pressure	_	_	O
47	[	_	_	O
48	BP	_	_	O
49	]	_	_	O
50	monitoring	_	_	O
51	control	_	_	O
52	,	_	_	O
53	despite	_	_	O
54	treatment	_	_	O
55	with	_	_	O
56	3	_	_	O
57	drugs	_	_	O
58	,	_	_	O
59	including	_	_	O
60	a	_	_	O
61	diuretic	_	_	O
62	,	_	_	O
63	for	_	_	O
64	12	_	_	O
65	weeks	_	_	O
66	)	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	to	_	_	O
70	an	_	_	O
71	additional	_	_	O
72	12-week	_	_	O
73	treatment	_	_	O
74	with	_	_	O
75	spironolactone	_	_	O
76	(	_	_	O
77	12.5-50	_	_	O
78	mg	_	_	O
79	QD	_	_	O
80	)	_	_	O
81	or	_	_	O
82	clonidine	_	_	O
83	(	_	_	O
84	0.1-0.3	_	_	O
85	mg	_	_	O
86	BID	_	_	O
87	)	_	_	O
88	.	_	_	O

89	The	_	_	O
90	primary	_	_	O
91	end	_	_	O
92	point	_	_	O
93	was	_	_	O
94	BP	_	_	O
95	control	_	_	O
96	during	_	_	O
97	office	_	_	O
98	(	_	_	O
99	<	_	_	O
100	140/90	_	_	O
101	mm	_	_	O
102	Hg	_	_	O
103	)	_	_	O
104	and	_	_	O
105	24-h	_	_	O
106	ambulatory	_	_	O
107	(	_	_	O
108	<	_	_	O
109	130/80	_	_	O
110	mm	_	_	O
111	Hg	_	_	O
112	)	_	_	O
113	BP	_	_	O
114	monitoring	_	_	O
115	.	_	_	O

116	Secondary	_	_	O
117	end	_	_	O
118	points	_	_	O
119	included	_	_	O
120	BP	_	_	O
121	control	_	_	O
122	from	_	_	O
123	each	_	_	O
124	method	_	_	O
125	and	_	_	O
126	absolute	_	_	O
127	BP	_	_	O
128	reduction	_	_	O
129	.	_	_	O

130	From	_	_	O
131	1597	_	_	O
132	patients	_	_	O
133	recruited	_	_	O
134	,	_	_	O
135	11.7	_	_	O
136	%	_	_	O
137	(	_	_	O
138	187	_	_	O
139	patients	_	_	O
140	)	_	_	O
141	fulfilled	_	_	O
142	the	_	_	O
143	resistant	_	_	O
144	hypertension	_	_	O
145	criteria	_	_	O
146	.	_	_	O

147	Compared	_	_	B-Premise
148	with	_	_	I-Premise
149	the	_	_	I-Premise
150	spironolactone	_	_	I-Premise
151	group	_	_	I-Premise
152	(	_	_	I-Premise
153	n=95	_	_	I-Premise
154	)	_	_	I-Premise
155	,	_	_	I-Premise
156	the	_	_	I-Premise
157	clonidine	_	_	I-Premise
158	group	_	_	I-Premise
159	(	_	_	I-Premise
160	n=92	_	_	I-Premise
161	)	_	_	I-Premise
162	presented	_	_	I-Premise
163	similar	_	_	I-Premise
164	rates	_	_	I-Premise
165	of	_	_	I-Premise
166	achieving	_	_	I-Premise
167	the	_	_	I-Premise
168	primary	_	_	I-Premise
169	end	_	_	I-Premise
170	point	_	_	I-Premise
171	(	_	_	I-Premise
172	20.5	_	_	I-Premise
173	%	_	_	I-Premise
174	versus	_	_	I-Premise
175	20.8	_	_	I-Premise
176	%	_	_	I-Premise
177	,	_	_	I-Premise
178	respectively	_	_	I-Premise
179	;	_	_	I-Premise
180	relative	_	_	I-Premise
181	risk	_	_	I-Premise
182	,	_	_	I-Premise
183	1.01	_	_	I-Premise
184	[	_	_	I-Premise
185	0.55-1.88	_	_	I-Premise
186	]	_	_	I-Premise
187	;	_	_	I-Premise
188	P=1.00	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	Secondary	_	_	B-Premise
192	end	_	_	I-Premise
193	point	_	_	I-Premise
194	analysis	_	_	I-Premise
195	showed	_	_	I-Premise
196	similar	_	_	I-Premise
197	office	_	_	I-Premise
198	BP	_	_	I-Premise
199	(	_	_	I-Premise
200	33.3	_	_	I-Premise
201	%	_	_	I-Premise
202	versus	_	_	I-Premise
203	29.3	_	_	I-Premise
204	%	_	_	I-Premise
205	)	_	_	I-Premise
206	and	_	_	I-Premise
207	ambulatory	_	_	I-Premise
208	BP	_	_	I-Premise
209	monitoring	_	_	I-Premise
210	(	_	_	I-Premise
211	44	_	_	I-Premise
212	%	_	_	I-Premise
213	versus	_	_	I-Premise
214	46.2	_	_	I-Premise
215	%	_	_	I-Premise
216	)	_	_	I-Premise
217	control	_	_	I-Premise
218	for	_	_	I-Premise
219	spironolactone	_	_	I-Premise
220	and	_	_	I-Premise
221	clonidine	_	_	I-Premise
222	,	_	_	I-Premise
223	respectively	_	_	I-Premise
224	.	_	_	I-Premise

225	However	_	_	O
226	,	_	_	O
227	spironolactone	_	_	B-Premise
228	promoted	_	_	I-Premise
229	greater	_	_	I-Premise
230	decrease	_	_	I-Premise
231	in	_	_	I-Premise
232	24-h	_	_	I-Premise
233	systolic	_	_	I-Premise
234	and	_	_	I-Premise
235	diastolic	_	_	I-Premise
236	BP	_	_	I-Premise
237	and	_	_	I-Premise
238	diastolic	_	_	I-Premise
239	daytime	_	_	I-Premise
240	ambulatory	_	_	I-Premise
241	BP	_	_	I-Premise
242	than	_	_	I-Premise
243	clonidine	_	_	I-Premise
244	.	_	_	I-Premise

245	Per-protocol	_	_	O
246	analysis	_	_	O
247	(	_	_	O
248	limited	_	_	O
249	to	_	_	O
250	patients	_	_	O
251	with	_	_	O
252	≥80	_	_	O
253	%	_	_	O
254	adherence	_	_	O
255	to	_	_	O
256	spironolactone/clonidine	_	_	O
257	treatment	_	_	O
258	)	_	_	O
259	showed	_	_	O
260	similar	_	_	O
261	results	_	_	O
262	regarding	_	_	O
263	the	_	_	O
264	primary	_	_	O
265	end	_	_	O
266	point	_	_	O
267	.	_	_	O

268	In	_	_	O
269	conclusion	_	_	O
270	,	_	_	O
271	clonidine	_	_	B-Claim
272	was	_	_	I-Claim
273	not	_	_	I-Claim
274	superior	_	_	I-Claim
275	to	_	_	I-Claim
276	spironolactone	_	_	I-Claim
277	in	_	_	I-Claim
278	true	_	_	I-Claim
279	resistant	_	_	I-Claim
280	hypertensive	_	_	I-Claim
281	patients	_	_	I-Claim
282	,	_	_	I-Claim
283	but	_	_	I-Claim
284	the	_	_	I-Claim
285	overall	_	_	I-Claim
286	BP	_	_	I-Claim
287	control	_	_	I-Claim
288	was	_	_	I-Claim
289	low	_	_	I-Claim
290	(	_	_	I-Claim
291	≈21	_	_	I-Claim
292	%	_	_	I-Claim
293	)	_	_	I-Claim
294	.	_	_	I-Claim

295	Considering	_	_	O
296	easier	_	_	O
297	posology	_	_	O
298	and	_	_	O
299	greater	_	_	O
300	decrease	_	_	O
301	in	_	_	O
302	secondary	_	_	O
303	end	_	_	O
304	points	_	_	O
305	,	_	_	O
306	spironolactone	_	_	B-Claim
307	is	_	_	I-Claim
308	preferable	_	_	I-Claim
309	for	_	_	I-Claim
310	the	_	_	I-Claim
311	fourth-drug	_	_	I-Claim
312	therapy	_	_	I-Claim
313	.	_	_	I-Claim


0	The	_	_	O
1	potential	_	_	O
2	protective	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	remote	_	_	O
6	ischemic	_	_	O
7	preconditioning	_	_	O
8	(	_	_	O
9	RIPC	_	_	O
10	)	_	_	O
11	on	_	_	O
12	contrast-induced	_	_	O
13	nephropathy	_	_	O
14	(	_	_	O
15	CIN	_	_	O
16	)	_	_	O
17	after	_	_	O
18	percutaneous	_	_	O
19	coronary	_	_	O
20	intervention	_	_	O
21	(	_	_	O
22	PCI	_	_	O
23	)	_	_	O
24	remain	_	_	O
25	to	_	_	O
26	be	_	_	O
27	defined	_	_	O
28	.	_	_	O

29	A	_	_	O
30	double	_	_	O
31	blind	_	_	O
32	,	_	_	O
33	randomized	_	_	O
34	,	_	_	O
35	placebo	_	_	O
36	controlled	_	_	O
37	multicenter	_	_	O
38	study	_	_	O
39	was	_	_	O
40	performed	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	younger	_	_	O
44	than	_	_	O
45	85years	_	_	O
46	old	_	_	O
47	,	_	_	O
48	with	_	_	O
49	a	_	_	O
50	renal	_	_	O
51	clearance	_	_	O
52	of	_	_	O
53	30-60ml/min/1.73m2	_	_	O
54	,	_	_	O
55	who	_	_	O
56	were	_	_	O
57	candidates	_	_	O
58	for	_	_	O
59	PCI	_	_	O
60	for	_	_	O
61	all	_	_	O
62	clinical	_	_	O
63	indications	_	_	O
64	except	_	_	O
65	for	_	_	O
66	primary	_	_	O
67	PCI	_	_	O
68	,	_	_	O
69	were	_	_	O
70	allocated	_	_	O
71	1:1	_	_	O
72	to	_	_	O
73	RIPC	_	_	O
74	or	_	_	O
75	to	_	_	O
76	standard	_	_	O
77	therapy	_	_	O
78	.	_	_	O

79	The	_	_	O
80	primary	_	_	O
81	endpoint	_	_	O
82	was	_	_	O
83	incidence	_	_	O
84	of	_	_	O
85	CIN	_	_	O
86	.	_	_	O

87	The	_	_	O
88	secondary	_	_	O
89	endpoint	_	_	O
90	was	_	_	O
91	incidence	_	_	O
92	of	_	_	O
93	peri-procedural	_	_	O
94	myocardial	_	_	O
95	infarction	_	_	O
96	(	_	_	O
97	PMI	_	_	O
98	)	_	_	O
99	.	_	_	O

100	From	_	_	O
101	February	_	_	O
102	2013	_	_	O
103	to	_	_	O
104	April	_	_	O
105	2014	_	_	O
106	,	_	_	O
107	3108	_	_	O
108	patients	_	_	O
109	who	_	_	O
110	were	_	_	O
111	scheduled	_	_	O
112	for	_	_	O
113	coronary	_	_	O
114	angiography	_	_	O
115	were	_	_	O
116	screened	_	_	O
117	for	_	_	O
118	the	_	_	O
119	study	_	_	O
120	.	_	_	O

121	442	_	_	O
122	fulfilled	_	_	O
123	the	_	_	O
124	inclusion	_	_	O
125	criteria	_	_	O
126	and	_	_	O
127	223	_	_	O
128	received	_	_	O
129	PCI	_	_	O
130	.	_	_	O

131	These	_	_	O
132	patients	_	_	O
133	were	_	_	O
134	randomized	_	_	O
135	to	_	_	O
136	sham	_	_	O
137	RIPC	_	_	O
138	(	_	_	O
139	n=107	_	_	O
140	)	_	_	O
141	or	_	_	O
142	treatment	_	_	O
143	group	_	_	O
144	(	_	_	O
145	n=116	_	_	O
146	)	_	_	O
147	.	_	_	O

148	The	_	_	O
149	only	_	_	O
150	pre-specified	_	_	O
151	subgroup	_	_	O
152	of	_	_	O
153	diabetic	_	_	O
154	patients	_	_	O
155	included	_	_	O
156	85	_	_	O
157	(	_	_	O
158	38	_	_	O
159	%	_	_	O
160	)	_	_	O
161	cases	_	_	O
162	.	_	_	O

163	RIPC	_	_	B-Premise
164	significantly	_	_	I-Premise
165	reduced	_	_	I-Premise
166	CIN	_	_	I-Premise
167	incidence	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	overall	_	_	I-Premise
171	population	_	_	I-Premise
172	(	_	_	I-Premise
173	12.1	_	_	I-Premise
174	%	_	_	I-Premise
175	vs.	_	_	I-Premise
176	26.1	_	_	I-Premise
177	%	_	_	I-Premise
178	,	_	_	I-Premise
179	p=0.01	_	_	I-Premise
180	,	_	_	I-Premise
181	with	_	_	I-Premise
182	a	_	_	I-Premise
183	NNT=9	_	_	I-Premise
184	)	_	_	I-Premise
185	and	_	_	I-Premise
186	in	_	_	I-Premise
187	non-diabetic	_	_	I-Premise
188	patients	_	_	I-Premise
189	(	_	_	I-Premise
190	9.2	_	_	I-Premise
191	%	_	_	I-Premise
192	vs.	_	_	I-Premise
193	25.0	_	_	I-Premise
194	%	_	_	I-Premise
195	,	_	_	I-Premise
196	p=0.02	_	_	I-Premise
197	)	_	_	I-Premise
198	,	_	_	I-Premise
199	but	_	_	I-Premise
200	showed	_	_	I-Premise
201	no	_	_	I-Premise
202	benefit	_	_	I-Premise
203	in	_	_	I-Premise
204	diabetics	_	_	I-Premise
205	(	_	_	I-Premise
206	16.7	_	_	I-Premise
207	%	_	_	I-Premise
208	vs.	_	_	I-Premise
209	28.2	_	_	I-Premise
210	%	_	_	I-Premise
211	,	_	_	I-Premise
212	p=0.21	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	A	_	_	B-Premise
216	trend	_	_	I-Premise
217	for	_	_	I-Premise
218	lower	_	_	I-Premise
219	PMI	_	_	I-Premise
220	was	_	_	I-Premise
221	seen	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	intervention	_	_	I-Premise
225	arm	_	_	I-Premise
226	(	_	_	I-Premise
227	creatine	_	_	I-Premise
228	kinase	_	_	I-Premise
229	-	_	_	I-Premise
230	muscle	_	_	I-Premise
231	brain	_	_	I-Premise
232	>	_	_	I-Premise
233	5	_	_	I-Premise
234	URL	_	_	I-Premise
235	;	_	_	I-Premise
236	8.4	_	_	I-Premise
237	%	_	_	I-Premise
238	vs.	_	_	I-Premise
239	16.4	_	_	I-Premise
240	%	_	_	I-Premise
241	,	_	_	I-Premise
242	p=0.07	_	_	I-Premise
243	;	_	_	I-Premise
244	troponin	_	_	I-Premise
245	T	_	_	I-Premise
246	>	_	_	I-Premise
247	5	_	_	I-Premise
248	URL	_	_	I-Premise
249	;	_	_	I-Premise
250	27	_	_	I-Premise
251	%	_	_	I-Premise
252	vs.	_	_	I-Premise
253	38	_	_	I-Premise
254	%	_	_	I-Premise
255	,	_	_	I-Premise
256	p=0.21	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Remote	_	_	B-Claim
260	ischemic	_	_	I-Claim
261	preconditioning	_	_	I-Claim
262	significantly	_	_	I-Claim
263	reduces	_	_	I-Claim
264	the	_	_	I-Claim
265	incidence	_	_	I-Claim
266	of	_	_	I-Claim
267	acute	_	_	I-Claim
268	kidney	_	_	I-Claim
269	injury	_	_	I-Claim
270	in	_	_	I-Claim
271	non-diabetic	_	_	I-Claim
272	patients	_	_	I-Claim
273	undergoing	_	_	I-Claim
274	PCI	_	_	I-Claim
275	.	_	_	I-Claim

276	Larger	_	_	B-Claim
277	sample	_	_	I-Claim
278	size	_	_	I-Claim
279	is	_	_	I-Claim
280	presumably	_	_	I-Claim
281	needed	_	_	I-Claim
282	to	_	_	I-Claim
283	assess	_	_	I-Claim
284	the	_	_	I-Claim
285	effect	_	_	I-Claim
286	of	_	_	I-Claim
287	RIPC	_	_	I-Claim
288	for	_	_	I-Claim
289	patients	_	_	I-Claim
290	with	_	_	I-Claim
291	diabetes	_	_	I-Claim
292	mellitus	_	_	I-Claim
293	.	_	_	I-Claim


0	Available	_	_	B-Claim
1	data	_	_	I-Claim
2	indicate	_	_	I-Claim
3	that	_	_	I-Claim
4	dietary	_	_	I-Claim
5	sodium	_	_	I-Claim
6	(	_	_	I-Claim
7	as	_	_	I-Claim
8	salt	_	_	I-Claim
9	)	_	_	I-Claim
10	relates	_	_	I-Claim
11	directly	_	_	I-Claim
12	to	_	_	I-Claim
13	blood	_	_	I-Claim
14	pressure	_	_	I-Claim
15	(	_	_	I-Claim
16	BP	_	_	I-Claim
17	)	_	_	I-Claim
18	.	_	_	I-Claim

19	Most	_	_	O
20	of	_	_	O
21	these	_	_	O
22	findings	_	_	O
23	are	_	_	O
24	from	_	_	O
25	studies	_	_	O
26	lacking	_	_	O
27	dietary	_	_	O
28	data	_	_	O
29	;	_	_	O
30	hence	_	_	O
31	,	_	_	O
32	it	_	_	O
33	is	_	_	O
34	unclear	_	_	O
35	whether	_	_	O
36	this	_	_	O
37	sodium-BP	_	_	O
38	relationship	_	_	O
39	is	_	_	O
40	modulated	_	_	O
41	by	_	_	O
42	other	_	_	O
43	dietary	_	_	O
44	factors	_	_	O
45	.	_	_	O

46	With	_	_	O
47	control	_	_	O
48	for	_	_	O
49	multiple	_	_	O
50	nondietary	_	_	O
51	factors	_	_	O
52	,	_	_	O
53	but	_	_	O
54	not	_	_	O
55	body	_	_	O
56	mass	_	_	O
57	index	_	_	O
58	,	_	_	O
59	there	_	_	O
60	were	_	_	O
61	direct	_	_	O
62	relations	_	_	O
63	to	_	_	O
64	BP	_	_	O
65	of	_	_	O
66	24-hour	_	_	O
67	urinary	_	_	O
68	sodium	_	_	O
69	excretion	_	_	O
70	and	_	_	O
71	the	_	_	O
72	urinary	_	_	O
73	sodium/potassium	_	_	O
74	ratio	_	_	O
75	among	_	_	O
76	4680	_	_	O
77	men	_	_	O
78	and	_	_	O
79	women	_	_	O
80	40	_	_	O
81	to	_	_	O
82	59	_	_	O
83	years	_	_	O
84	of	_	_	O
85	age	_	_	O
86	(	_	_	O
87	17	_	_	O
88	population	_	_	O
89	samples	_	_	O
90	in	_	_	O
91	China	_	_	O
92	,	_	_	O
93	Japan	_	_	O
94	,	_	_	O
95	United	_	_	O
96	Kingdom	_	_	O
97	,	_	_	O
98	and	_	_	O
99	United	_	_	O
100	States	_	_	O
101	)	_	_	O
102	in	_	_	O
103	the	_	_	O
104	INTERMAP	_	_	O
105	(	_	_	O
106	International	_	_	O
107	Study	_	_	O
108	on	_	_	O
109	Macro/Micronutrients	_	_	O
110	and	_	_	O
111	Blood	_	_	O
112	Pressure	_	_	O
113	)	_	_	O
114	,	_	_	O
115	and	_	_	O
116	among	_	_	O
117	its	_	_	O
118	2195	_	_	O
119	American	_	_	O
120	participants	_	_	O
121	,	_	_	O
122	for	_	_	O
123	example	_	_	O
124	,	_	_	O
125	2	_	_	O
126	SD	_	_	O
127	higher	_	_	O
128	24-hour	_	_	O
129	urinary	_	_	O
130	sodium	_	_	O
131	excretion	_	_	O
132	(	_	_	O
133	118.7	_	_	O
134	mmol	_	_	O
135	)	_	_	O
136	associated	_	_	O
137	with	_	_	O
138	systolic	_	_	O
139	BP	_	_	O
140	3.7	_	_	O
141	mm	_	_	O
142	Hg	_	_	O
143	higher	_	_	O
144	.	_	_	O

145	These	_	_	O
146	sodium-BP	_	_	O
147	relations	_	_	O
148	persisted	_	_	O
149	with	_	_	O
150	control	_	_	O
151	for	_	_	O
152	13	_	_	O
153	macronutrients	_	_	O
154	,	_	_	O
155	12	_	_	O
156	vitamins	_	_	O
157	,	_	_	O
158	7	_	_	O
159	minerals	_	_	O
160	,	_	_	O
161	and	_	_	O
162	18	_	_	O
163	amino	_	_	O
164	acids	_	_	O
165	,	_	_	O
166	for	_	_	O
167	both	_	_	O
168	sex	_	_	O
169	,	_	_	O
170	older	_	_	O
171	and	_	_	O
172	younger	_	_	O
173	,	_	_	O
174	blacks	_	_	O
175	,	_	_	O
176	Hispanics	_	_	O
177	,	_	_	O
178	whites	_	_	O
179	,	_	_	O
180	and	_	_	O
181	socioeconomic	_	_	O
182	strata	_	_	O
183	.	_	_	O

184	With	_	_	O
185	control	_	_	O
186	for	_	_	O
187	body	_	_	O
188	mass	_	_	O
189	index	_	_	O
190	,	_	_	O
191	sodium-BP-but	_	_	O
192	not	_	_	O
193	sodium/potassium-BP-relations	_	_	O
194	were	_	_	O
195	attenuated	_	_	O
196	.	_	_	O

197	Normal	_	_	B-Premise
198	weight	_	_	I-Premise
199	and	_	_	I-Premise
200	obese	_	_	I-Premise
201	participants	_	_	I-Premise
202	manifested	_	_	I-Premise
203	significant	_	_	I-Premise
204	positive	_	_	I-Premise
205	relations	_	_	I-Premise
206	to	_	_	I-Premise
207	BP	_	_	I-Premise
208	of	_	_	I-Premise
209	urinary	_	_	I-Premise
210	sodium	_	_	I-Premise
211	;	_	_	I-Premise
212	relations	_	_	I-Premise
213	were	_	_	I-Premise
214	weaker	_	_	I-Premise
215	for	_	_	I-Premise
216	overweight	_	_	I-Premise
217	people	_	_	I-Premise
218	.	_	_	I-Premise

219	At	_	_	B-Premise
220	lower	_	_	I-Premise
221	but	_	_	I-Premise
222	not	_	_	I-Premise
223	higher	_	_	I-Premise
224	levels	_	_	I-Premise
225	of	_	_	I-Premise
226	24-hour	_	_	I-Premise
227	sodium	_	_	I-Premise
228	excretion	_	_	I-Premise
229	,	_	_	I-Premise
230	potassium	_	_	I-Premise
231	intake	_	_	I-Premise
232	blunted	_	_	I-Premise
233	the	_	_	I-Premise
234	sodium-BP	_	_	I-Premise
235	relation	_	_	I-Premise
236	.	_	_	I-Premise

237	The	_	_	B-Claim
238	adverse	_	_	I-Claim
239	association	_	_	I-Claim
240	of	_	_	I-Claim
241	dietary	_	_	I-Claim
242	sodium	_	_	I-Claim
243	with	_	_	I-Claim
244	BP	_	_	I-Claim
245	is	_	_	I-Claim
246	minimally	_	_	I-Claim
247	attenuated	_	_	I-Claim
248	by	_	_	I-Claim
249	other	_	_	I-Claim
250	dietary	_	_	I-Claim
251	constituents	_	_	I-Claim
252	;	_	_	I-Claim
253	these	_	_	B-Claim
254	findings	_	_	I-Claim
255	underscore	_	_	I-Claim
256	the	_	_	I-Claim
257	importance	_	_	I-Claim
258	of	_	_	I-Claim
259	reducing	_	_	I-Claim
260	salt	_	_	I-Claim
261	intake	_	_	I-Claim
262	for	_	_	I-Claim
263	the	_	_	I-Claim
264	prevention	_	_	I-Claim
265	and	_	_	I-Claim
266	control	_	_	I-Claim
267	of	_	_	I-Claim
268	prehypertension	_	_	I-Claim
269	and	_	_	I-Claim
270	hypertension	_	_	I-Claim
271	.	_	_	I-Claim


0	Blood	_	_	O
1	pressure	_	_	O
2	(	_	_	O
3	BP	_	_	O
4	)	_	_	O
5	lowering	_	_	O
6	is	_	_	O
7	considered	_	_	O
8	neuroprotective	_	_	O
9	in	_	_	O
10	patients	_	_	O
11	with	_	_	O
12	cerebral	_	_	O
13	small	_	_	O
14	vessel	_	_	O
15	disease	_	_	O
16	;	_	_	O
17	however	_	_	O
18	,	_	_	O
19	more	_	_	O
20	intensive	_	_	O
21	regimens	_	_	O
22	may	_	_	O
23	increase	_	_	O
24	cerebral	_	_	O
25	hypoperfusion	_	_	O
26	.	_	_	O

27	This	_	_	O
28	study	_	_	O
29	examined	_	_	O
30	the	_	_	O
31	effect	_	_	O
32	of	_	_	O
33	standard	_	_	O
34	vs	_	_	O
35	intensive	_	_	O
36	BP	_	_	O
37	treatment	_	_	O
38	on	_	_	O
39	cerebral	_	_	O
40	perfusion	_	_	O
41	in	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	severe	_	_	O
45	small	_	_	O
46	vessel	_	_	O
47	disease	_	_	O
48	.	_	_	O

49	To	_	_	O
50	investigate	_	_	O
51	whether	_	_	O
52	standard	_	_	O
53	vs	_	_	O
54	intensive	_	_	O
55	BP	_	_	O
56	lowering	_	_	O
57	over	_	_	O
58	3	_	_	O
59	months	_	_	O
60	causes	_	_	O
61	decreased	_	_	O
62	cerebral	_	_	O
63	perfusion	_	_	O
64	in	_	_	O
65	small	_	_	O
66	vessel	_	_	O
67	disease	_	_	O
68	.	_	_	O

69	This	_	_	O
70	randomized	_	_	O
71	clinical	_	_	O
72	trial	_	_	O
73	took	_	_	O
74	place	_	_	O
75	at	_	_	O
76	2	_	_	O
77	English	_	_	O
78	university	_	_	O
79	medical	_	_	O
80	centers	_	_	O
81	.	_	_	O

82	Patients	_	_	O
83	were	_	_	O
84	randomized	_	_	O
85	via	_	_	O
86	a	_	_	O
87	central	_	_	O
88	online	_	_	O
89	system	_	_	O
90	(	_	_	O
91	in	_	_	O
92	a	_	_	O
93	1:1	_	_	O
94	ratio	_	_	O
95	)	_	_	O
96	.	_	_	O

97	Seventy	_	_	O
98	patients	_	_	O
99	with	_	_	O
100	hypertension	_	_	O
101	and	_	_	O
102	with	_	_	O
103	magnetic	_	_	O
104	resonance	_	_	O
105	imaging-confirmed	_	_	O
106	symptomatic	_	_	O
107	lacunar	_	_	O
108	infarct	_	_	O
109	and	_	_	O
110	confluent	_	_	O
111	white	_	_	O
112	matter	_	_	O
113	hyperintensities	_	_	O
114	were	_	_	O
115	recruited	_	_	O
116	between	_	_	O
117	February	_	_	O
118	29	_	_	O
119	,	_	_	O
120	2012	_	_	O
121	,	_	_	O
122	and	_	_	O
123	October	_	_	O
124	21	_	_	O
125	,	_	_	O
126	2015	_	_	O
127	,	_	_	O
128	and	_	_	O
129	randomized	_	_	O
130	(	_	_	O
131	36	_	_	O
132	in	_	_	O
133	the	_	_	O
134	standard	_	_	O
135	group	_	_	O
136	and	_	_	O
137	34	_	_	O
138	in	_	_	O
139	the	_	_	O
140	intensive	_	_	O
141	group	_	_	O
142	)	_	_	O
143	.	_	_	O

144	Analyzable	_	_	O
145	data	_	_	O
146	were	_	_	O
147	available	_	_	O
148	in	_	_	O
149	62	_	_	O
150	patients	_	_	O
151	,	_	_	O
152	33	_	_	O
153	in	_	_	O
154	the	_	_	O
155	standard	_	_	O
156	group	_	_	O
157	and	_	_	O
158	29	_	_	O
159	in	_	_	O
160	the	_	_	O
161	intensive	_	_	O
162	group	_	_	O
163	,	_	_	O
164	for	_	_	O
165	intent-to-treat	_	_	O
166	analysis	_	_	O
167	.	_	_	O

168	This	_	_	O
169	experiment	_	_	O
170	examines	_	_	O
171	the	_	_	O
172	3-month	_	_	O
173	follow-up	_	_	O
174	period	_	_	O
175	.	_	_	O

176	Patients	_	_	O
177	were	_	_	O
178	randomized	_	_	O
179	to	_	_	O
180	standard	_	_	O
181	(	_	_	O
182	systolic	_	_	O
183	,	_	_	O
184	130-140	_	_	O
185	mm	_	_	O
186	Hg	_	_	O
187	)	_	_	O
188	or	_	_	O
189	intensive	_	_	O
190	(	_	_	O
191	systolic	_	_	O
192	,	_	_	O
193	<	_	_	O
194	125	_	_	O
195	mm	_	_	O
196	Hg	_	_	O
197	)	_	_	O
198	BP	_	_	O
199	targets	_	_	O
200	,	_	_	O
201	to	_	_	O
202	be	_	_	O
203	achieved	_	_	O
204	through	_	_	O
205	medication	_	_	O
206	changes	_	_	O
207	.	_	_	O

208	Cerebral	_	_	O
209	perfusion	_	_	O
210	was	_	_	O
211	measured	_	_	O
212	using	_	_	O
213	arterial	_	_	O
214	spin	_	_	O
215	labeling	_	_	O
216	;	_	_	O
217	the	_	_	O
218	primary	_	_	O
219	end	_	_	O
220	point	_	_	O
221	was	_	_	O
222	change	_	_	O
223	in	_	_	O
224	global	_	_	O
225	perfusion	_	_	O
226	between	_	_	O
227	baseline	_	_	O
228	and	_	_	O
229	3	_	_	O
230	months	_	_	O
231	,	_	_	O
232	compared	_	_	O
233	between	_	_	O
234	treatment	_	_	O
235	groups	_	_	O
236	by	_	_	O
237	analysis	_	_	O
238	of	_	_	O
239	variance	_	_	O
240	.	_	_	O

241	Linear	_	_	O
242	regression	_	_	O
243	compared	_	_	O
244	change	_	_	O
245	in	_	_	O
246	perfusion	_	_	O
247	against	_	_	O
248	change	_	_	O
249	in	_	_	O
250	BP	_	_	O
251	.	_	_	O

252	Magnetic	_	_	O
253	resonance	_	_	O
254	imaging	_	_	O
255	scan	_	_	O
256	analysis	_	_	O
257	was	_	_	O
258	masked	_	_	O
259	to	_	_	O
260	treatment	_	_	O
261	group	_	_	O
262	.	_	_	O

263	Among	_	_	O
264	62	_	_	O
265	analyzable	_	_	O
266	patients	_	_	O
267	,	_	_	O
268	the	_	_	O
269	mean	_	_	O
270	age	_	_	O
271	was	_	_	O
272	69.3	_	_	O
273	years	_	_	O
274	,	_	_	O
275	and	_	_	O
276	60	_	_	O
277	%	_	_	O
278	(	_	_	O
279	n	_	_	O
280	=	_	_	O
281	37	_	_	O
282	)	_	_	O
283	were	_	_	O
284	male	_	_	O
285	.	_	_	O

286	The	_	_	B-Premise
287	mean	_	_	I-Premise
288	(	_	_	I-Premise
289	SD	_	_	I-Premise
290	)	_	_	I-Premise
291	systolic	_	_	I-Premise
292	BP	_	_	I-Premise
293	decreased	_	_	I-Premise
294	by	_	_	I-Premise
295	8	_	_	I-Premise
296	(	_	_	I-Premise
297	12	_	_	I-Premise
298	)	_	_	I-Premise
299	mm	_	_	I-Premise
300	Hg	_	_	I-Premise
301	in	_	_	I-Premise
302	the	_	_	I-Premise
303	standard	_	_	I-Premise
304	group	_	_	I-Premise
305	and	_	_	I-Premise
306	by	_	_	I-Premise
307	27	_	_	I-Premise
308	(	_	_	I-Premise
309	17	_	_	I-Premise
310	)	_	_	I-Premise
311	mm	_	_	I-Premise
312	Hg	_	_	I-Premise
313	in	_	_	I-Premise
314	the	_	_	I-Premise
315	intensive	_	_	I-Premise
316	group	_	_	I-Premise
317	(	_	_	I-Premise
318	P	_	_	I-Premise
319	<	_	_	I-Premise
320	.001	_	_	I-Premise
321	)	_	_	I-Premise
322	,	_	_	I-Premise
323	with	_	_	I-Premise
324	mean	_	_	I-Premise
325	(	_	_	I-Premise
326	SD	_	_	I-Premise
327	)	_	_	I-Premise
328	achieved	_	_	I-Premise
329	pressures	_	_	I-Premise
330	of	_	_	I-Premise
331	141	_	_	I-Premise
332	(	_	_	I-Premise
333	13	_	_	I-Premise
334	)	_	_	I-Premise
335	and	_	_	I-Premise
336	126	_	_	I-Premise
337	(	_	_	I-Premise
338	10	_	_	I-Premise
339	)	_	_	I-Premise
340	mm	_	_	I-Premise
341	Hg	_	_	I-Premise
342	,	_	_	I-Premise
343	respectively	_	_	I-Premise
344	.	_	_	I-Premise

345	Change	_	_	B-Premise
346	in	_	_	I-Premise
347	global	_	_	I-Premise
348	perfusion	_	_	I-Premise
349	did	_	_	I-Premise
350	not	_	_	I-Premise
351	differ	_	_	I-Premise
352	between	_	_	I-Premise
353	treatment	_	_	I-Premise
354	groups	_	_	I-Premise
355	:	_	_	I-Premise
356	the	_	_	I-Premise
357	mean	_	_	I-Premise
358	(	_	_	I-Premise
359	SD	_	_	I-Premise
360	)	_	_	I-Premise
361	change	_	_	I-Premise
362	was	_	_	I-Premise
363	-0.5	_	_	I-Premise
364	(	_	_	I-Premise
365	9.4	_	_	I-Premise
366	)	_	_	I-Premise
367	mL/min/100	_	_	I-Premise
368	g	_	_	I-Premise
369	in	_	_	I-Premise
370	the	_	_	I-Premise
371	standard	_	_	I-Premise
372	group	_	_	I-Premise
373	vs	_	_	I-Premise
374	0.7	_	_	I-Premise
375	(	_	_	I-Premise
376	8.6	_	_	I-Premise
377	)	_	_	I-Premise
378	mL/min/100	_	_	I-Premise
379	g	_	_	I-Premise
380	in	_	_	I-Premise
381	the	_	_	I-Premise
382	intensive	_	_	I-Premise
383	group	_	_	I-Premise
384	(	_	_	I-Premise
385	partial	_	_	I-Premise
386	η2	_	_	I-Premise
387	,	_	_	I-Premise
388	0.004	_	_	I-Premise
389	;	_	_	I-Premise
390	95	_	_	I-Premise
391	%	_	_	I-Premise
392	CI	_	_	I-Premise
393	,	_	_	I-Premise
394	-3.551	_	_	I-Premise
395	to	_	_	I-Premise
396	5.818	_	_	I-Premise
397	;	_	_	I-Premise
398	P	_	_	I-Premise
399	=	_	_	I-Premise
400	.63	_	_	I-Premise
401	)	_	_	I-Premise
402	.	_	_	I-Premise

403	No	_	_	B-Premise
404	differences	_	_	I-Premise
405	were	_	_	I-Premise
406	observed	_	_	I-Premise
407	when	_	_	I-Premise
408	the	_	_	I-Premise
409	analysis	_	_	I-Premise
410	examined	_	_	I-Premise
411	gray	_	_	I-Premise
412	or	_	_	I-Premise
413	white	_	_	I-Premise
414	matter	_	_	I-Premise
415	only	_	_	I-Premise
416	or	_	_	I-Premise
417	was	_	_	I-Premise
418	confined	_	_	I-Premise
419	to	_	_	I-Premise
420	those	_	_	I-Premise
421	achieving	_	_	I-Premise
422	target	_	_	I-Premise
423	BP	_	_	I-Premise
424	.	_	_	I-Premise

425	The	_	_	B-Premise
426	number	_	_	I-Premise
427	of	_	_	I-Premise
428	adverse	_	_	I-Premise
429	events	_	_	I-Premise
430	did	_	_	I-Premise
431	not	_	_	I-Premise
432	differ	_	_	I-Premise
433	between	_	_	I-Premise
434	treatment	_	_	I-Premise
435	groups	_	_	I-Premise
436	,	_	_	I-Premise
437	with	_	_	I-Premise
438	a	_	_	I-Premise
439	mean	_	_	I-Premise
440	(	_	_	I-Premise
441	SD	_	_	I-Premise
442	)	_	_	I-Premise
443	of	_	_	I-Premise
444	0.21	_	_	I-Premise
445	(	_	_	I-Premise
446	0.65	_	_	I-Premise
447	)	_	_	I-Premise
448	for	_	_	I-Premise
449	the	_	_	I-Premise
450	standard	_	_	I-Premise
451	group	_	_	I-Premise
452	and	_	_	I-Premise
453	0.32	_	_	I-Premise
454	(	_	_	I-Premise
455	0.75	_	_	I-Premise
456	)	_	_	I-Premise
457	for	_	_	I-Premise
458	the	_	_	I-Premise
459	intensive	_	_	I-Premise
460	group	_	_	I-Premise
461	(	_	_	I-Premise
462	P	_	_	I-Premise
463	=	_	_	I-Premise
464	.44	_	_	I-Premise
465	)	_	_	I-Premise
466	.	_	_	I-Premise

467	Intensive	_	_	B-Claim
468	BP	_	_	I-Claim
469	lowering	_	_	I-Claim
470	did	_	_	I-Claim
471	not	_	_	I-Claim
472	reduce	_	_	I-Claim
473	cerebral	_	_	I-Claim
474	perfusion	_	_	I-Claim
475	in	_	_	I-Claim
476	severe	_	_	I-Claim
477	small	_	_	I-Claim
478	vessel	_	_	I-Claim
479	disease	_	_	I-Claim
480	.	_	_	I-Claim


0	The	_	_	O
1	carbonic	_	_	O
2	anhydrase	_	_	O
3	inhibitor	_	_	O
4	acetazolamide	_	_	O
5	(	_	_	O
6	AZT	_	_	O
7	)	_	_	O
8	modulates	_	_	O
9	blood	_	_	O
10	pressure	_	_	O
11	at	_	_	O
12	high	_	_	O
13	altitude	_	_	O
14	and	_	_	O
15	reduces	_	_	O
16	sleep-disordered	_	_	O
17	breathing	_	_	O
18	in	_	_	O
19	patients	_	_	O
20	with	_	_	O
21	obstructive	_	_	O
22	sleep	_	_	O
23	apnea	_	_	O
24	(	_	_	O
25	OSA	_	_	O
26	)	_	_	O
27	.	_	_	O

28	We	_	_	O
29	aimed	_	_	O
30	to	_	_	O
31	investigate	_	_	O
32	the	_	_	O
33	treatment	_	_	O
34	effect	_	_	O
35	of	_	_	O
36	AZT	_	_	O
37	and	_	_	O
38	in	_	_	O
39	combination	_	_	O
40	with	_	_	O
41	continuous	_	_	O
42	positive	_	_	O
43	airway	_	_	O
44	pressure	_	_	O
45	(	_	_	O
46	CPAP	_	_	O
47	)	_	_	O
48	on	_	_	O
49	blood	_	_	O
50	pressure	_	_	O
51	in	_	_	O
52	patients	_	_	O
53	with	_	_	O
54	hypertension	_	_	O
55	and	_	_	O
56	OSA	_	_	O
57	.	_	_	O

58	In	_	_	O
59	a	_	_	O
60	prospective	_	_	O
61	,	_	_	O
62	randomized	_	_	O
63	,	_	_	O
64	three-way	_	_	O
65	crossover	_	_	O
66	study	_	_	O
67	,	_	_	O
68	13	_	_	O
69	male	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	hypertension	_	_	O
73	and	_	_	O
74	moderate	_	_	O
75	to	_	_	O
76	severe	_	_	O
77	OSA	_	_	O
78	(	_	_	O
79	age	_	_	O
80	64	_	_	O
81	±	_	_	O
82	7	_	_	O
83	years	_	_	O
84	,	_	_	O
85	body	_	_	O
86	mass	_	_	O
87	index	_	_	O
88	29	_	_	O
89	±	_	_	O
90	4	_	_	O
91	kg/m2	_	_	O
92	,	_	_	O
93	and	_	_	O
94	mean	_	_	O
95	apnea-hypopnea	_	_	O
96	index	_	_	O
97	37	_	_	O
98	±	_	_	O
99	23	_	_	O
100	events/h	_	_	O
101	)	_	_	O
102	received	_	_	O
103	AZT	_	_	O
104	,	_	_	O
105	CPAP	_	_	O
106	,	_	_	O
107	or	_	_	O
108	AZT	_	_	O
109	plus	_	_	O
110	CPAP	_	_	O
111	for	_	_	O
112	2-week	_	_	O
113	periods	_	_	O
114	.	_	_	O

115	Antihypertensive	_	_	O
116	medication	_	_	O
117	was	_	_	O
118	washed	_	_	O
119	out	_	_	O
120	.	_	_	O

121	Office	_	_	O
122	and	_	_	O
123	24-hour	_	_	O
124	blood	_	_	O
125	pressure	_	_	O
126	,	_	_	O
127	arterial	_	_	O
128	stiffness	_	_	O
129	,	_	_	O
130	polygraphic	_	_	O
131	sleep	_	_	O
132	study	_	_	O
133	data	_	_	O
134	,	_	_	O
135	and	_	_	O
136	blood	_	_	O
137	chemistry	_	_	O
138	were	_	_	O
139	compared	_	_	O
140	.	_	_	O

141	AZT	_	_	O
142	alone	_	_	O
143	and	_	_	O
144	AZT	_	_	O
145	plus	_	_	O
146	CPAP	_	_	O
147	,	_	_	O
148	but	_	_	O
149	not	_	_	O
150	CPAP	_	_	O
151	alone	_	_	O
152	,	_	_	O
153	reduced	_	_	O
154	office	_	_	O
155	mean	_	_	O
156	arterial	_	_	O
157	pressure	_	_	O
158	compared	_	_	O
159	to	_	_	O
160	baseline	_	_	O
161	(	_	_	O
162	-7	_	_	O
163	[	_	_	O
164	95	_	_	O
165	%	_	_	O
166	CI	_	_	O
167	-11	_	_	O
168	to	_	_	O
169	-4	_	_	O
170	]	_	_	O
171	,	_	_	O
172	-7	_	_	O
173	[	_	_	O
174	95	_	_	O
175	%	_	_	O
176	CI	_	_	O
177	-11	_	_	O
178	to	_	_	O
179	-4	_	_	O
180	]	_	_	O
181	and	_	_	O
182	-1	_	_	O
183	[	_	_	O
184	95	_	_	O
185	%	_	_	O
186	CI	_	_	O
187	-5	_	_	O
188	to	_	_	O
189	4	_	_	O
190	]	_	_	O
191	mmHg	_	_	O
192	,	_	_	O
193	respectively	_	_	O
194	;	_	_	O
195	repeated-	_	_	O
196	measures	_	_	O
197	analysis	_	_	O
198	of	_	_	O
199	variance	_	_	O
200	(	_	_	O
201	RM-ANOVA	_	_	O
202	;	_	_	O
203	P	_	_	O
204	=	_	_	O
205	.015	_	_	O
206	)	_	_	O
207	.	_	_	O

208	Aortic	_	_	B-Premise
209	systolic	_	_	I-Premise
210	pressure	_	_	I-Premise
211	and	_	_	I-Premise
212	augmentation	_	_	I-Premise
213	index	_	_	I-Premise
214	,	_	_	I-Premise
215	assessed	_	_	I-Premise
216	by	_	_	I-Premise
217	radial	_	_	I-Premise
218	artery	_	_	I-Premise
219	oscillatory	_	_	I-Premise
220	tonometry	_	_	I-Premise
221	,	_	_	I-Premise
222	were	_	_	I-Premise
223	unaffected	_	_	I-Premise
224	by	_	_	I-Premise
225	CPAP	_	_	I-Premise
226	but	_	_	I-Premise
227	decreased	_	_	I-Premise
228	after	_	_	I-Premise
229	AZT	_	_	I-Premise
230	and	_	_	I-Premise
231	AZT	_	_	I-Premise
232	plus	_	_	I-Premise
233	CPAP	_	_	I-Premise
234	(	_	_	I-Premise
235	RM-ANOVA	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	.030	_	_	I-Premise
239	and	_	_	I-Premise
240	.031	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	The	_	_	B-Premise
246	apnea-hypopnea	_	_	I-Premise
247	index	_	_	I-Premise
248	was	_	_	I-Premise
249	significantly	_	_	I-Premise
250	reduced	_	_	I-Premise
251	in	_	_	I-Premise
252	all	_	_	I-Premise
253	three	_	_	I-Premise
254	treatment	_	_	I-Premise
255	arms	_	_	I-Premise
256	,	_	_	I-Premise
257	most	_	_	I-Premise
258	prominently	_	_	I-Premise
259	by	_	_	I-Premise
260	AZT	_	_	I-Premise
261	plus	_	_	I-Premise
262	CPAP	_	_	I-Premise
263	(	_	_	I-Premise
264	RM-ANOVA	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	.003	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	The	_	_	B-Premise
271	reduction	_	_	I-Premise
272	of	_	_	I-Premise
273	venous	_	_	I-Premise
274	bicarbonate	_	_	I-Premise
275	concentration	_	_	I-Premise
276	following	_	_	I-Premise
277	AZT	_	_	I-Premise
278	was	_	_	I-Premise
279	correlated	_	_	I-Premise
280	with	_	_	I-Premise
281	the	_	_	I-Premise
282	change	_	_	I-Premise
283	of	_	_	I-Premise
284	apnea-hypopnea	_	_	I-Premise
285	index	_	_	I-Premise
286	(	_	_	I-Premise
287	r	_	_	I-Premise
288	=	_	_	I-Premise
289	0.66	_	_	I-Premise
290	,	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	.013	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	AZT	_	_	B-Claim
297	reduced	_	_	I-Claim
298	blood	_	_	I-Claim
299	pressure	_	_	I-Claim
300	,	_	_	I-Claim
301	vascular	_	_	I-Claim
302	stiffness	_	_	I-Claim
303	,	_	_	I-Claim
304	and	_	_	I-Claim
305	sleep-disordered	_	_	I-Claim
306	breathing	_	_	I-Claim
307	in	_	_	I-Claim
308	patients	_	_	I-Claim
309	with	_	_	I-Claim
310	OSA	_	_	I-Claim
311	and	_	_	I-Claim
312	comorbid	_	_	I-Claim
313	hypertension	_	_	I-Claim
314	.	_	_	I-Claim

315	Carbonic	_	_	B-Claim
316	anhydrase	_	_	I-Claim
317	inhibition	_	_	I-Claim
318	may	_	_	I-Claim
319	constitute	_	_	I-Claim
320	a	_	_	I-Claim
321	potential	_	_	I-Claim
322	target	_	_	I-Claim
323	for	_	_	I-Claim
324	drug	_	_	I-Claim
325	therapy	_	_	I-Claim
326	in	_	_	I-Claim
327	patients	_	_	I-Claim
328	with	_	_	I-Claim
329	sleep	_	_	I-Claim
330	apnea	_	_	I-Claim
331	and	_	_	I-Claim
332	comorbid	_	_	I-Claim
333	hypertension	_	_	I-Claim
334	.	_	_	I-Claim


0	Pregnant	_	_	O
1	women	_	_	O
2	with	_	_	O
3	an	_	_	O
4	elevated	_	_	O
5	viral	_	_	O
6	load	_	_	O
7	of	_	_	O
8	hepatitis	_	_	O
9	B	_	_	O
10	virus	_	_	O
11	(	_	_	O
12	HBV	_	_	O
13	)	_	_	O
14	have	_	_	O
15	a	_	_	O
16	risk	_	_	O
17	of	_	_	O
18	transmitting	_	_	O
19	infection	_	_	O
20	to	_	_	O
21	their	_	_	O
22	infants	_	_	O
23	,	_	_	O
24	despite	_	_	O
25	the	_	_	O
26	infants	_	_	O
27	'	_	_	O
28	receiving	_	_	O
29	hepatitis	_	_	O
30	B	_	_	O
31	immune	_	_	O
32	globulin	_	_	O
33	.	_	_	O

34	In	_	_	O
35	this	_	_	O
36	multicenter	_	_	O
37	,	_	_	O
38	double-blind	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	performed	_	_	O
42	in	_	_	O
43	Thailand	_	_	O
44	,	_	_	O
45	we	_	_	O
46	randomly	_	_	O
47	assigned	_	_	O
48	hepatitis	_	_	O
49	B	_	_	O
50	e	_	_	O
51	antigen	_	_	O
52	(	_	_	O
53	HBeAg	_	_	O
54	)	_	_	O
55	-positive	_	_	O
56	pregnant	_	_	O
57	women	_	_	O
58	with	_	_	O
59	an	_	_	O
60	alanine	_	_	O
61	aminotransferase	_	_	O
62	level	_	_	O
63	of	_	_	O
64	60	_	_	O
65	IU	_	_	O
66	or	_	_	O
67	less	_	_	O
68	per	_	_	O
69	liter	_	_	O
70	to	_	_	O
71	receive	_	_	O
72	tenofovir	_	_	O
73	disoproxil	_	_	O
74	fumarate	_	_	O
75	(	_	_	O
76	TDF	_	_	O
77	)	_	_	O
78	or	_	_	O
79	placebo	_	_	O
80	from	_	_	O
81	28	_	_	O
82	weeks	_	_	O
83	of	_	_	O
84	gestation	_	_	O
85	to	_	_	O
86	2	_	_	O
87	months	_	_	O
88	post	_	_	O
89	partum	_	_	O
90	.	_	_	O

91	Infants	_	_	O
92	received	_	_	O
93	hepatitis	_	_	O
94	B	_	_	O
95	immune	_	_	O
96	globulin	_	_	O
97	at	_	_	O
98	birth	_	_	O
99	and	_	_	O
100	hepatitis	_	_	O
101	B	_	_	O
102	vaccine	_	_	O
103	at	_	_	O
104	birth	_	_	O
105	and	_	_	O
106	at	_	_	O
107	1	_	_	O
108	,	_	_	O
109	2	_	_	O
110	,	_	_	O
111	4	_	_	O
112	,	_	_	O
113	and	_	_	O
114	6	_	_	O
115	months	_	_	O
116	.	_	_	O

117	The	_	_	O
118	primary	_	_	O
119	end	_	_	O
120	point	_	_	O
121	was	_	_	O
122	a	_	_	O
123	hepatitis	_	_	O
124	B	_	_	O
125	surface	_	_	O
126	antigen	_	_	O
127	(	_	_	O
128	HBsAg	_	_	O
129	)	_	_	O
130	-positive	_	_	O
131	status	_	_	O
132	in	_	_	O
133	the	_	_	O
134	infant	_	_	O
135	,	_	_	O
136	confirmed	_	_	O
137	by	_	_	O
138	the	_	_	O
139	HBV	_	_	O
140	DNA	_	_	O
141	level	_	_	O
142	at	_	_	O
143	6	_	_	O
144	months	_	_	O
145	of	_	_	O
146	age	_	_	O
147	.	_	_	O

148	We	_	_	O
149	calculated	_	_	O
150	that	_	_	O
151	a	_	_	O
152	sample	_	_	O
153	of	_	_	O
154	328	_	_	O
155	women	_	_	O
156	would	_	_	O
157	provide	_	_	O
158	the	_	_	O
159	trial	_	_	O
160	with	_	_	O
161	90	_	_	O
162	%	_	_	O
163	power	_	_	O
164	to	_	_	O
165	detect	_	_	O
166	a	_	_	O
167	difference	_	_	O
168	of	_	_	O
169	at	_	_	O
170	least	_	_	O
171	9	_	_	O
172	percentage	_	_	O
173	points	_	_	O
174	in	_	_	O
175	the	_	_	O
176	transmission	_	_	O
177	rate	_	_	O
178	(	_	_	O
179	expected	_	_	O
180	rate	_	_	O
181	,	_	_	O
182	3	_	_	O
183	%	_	_	O
184	in	_	_	O
185	the	_	_	O
186	TDF	_	_	O
187	group	_	_	O
188	vs.	_	_	O
189	12	_	_	O
190	%	_	_	O
191	in	_	_	O
192	the	_	_	O
193	placebo	_	_	O
194	group	_	_	O
195	)	_	_	O
196	.	_	_	O

197	From	_	_	O
198	January	_	_	O
199	2013	_	_	O
200	to	_	_	O
201	August	_	_	O
202	2015	_	_	O
203	,	_	_	O
204	we	_	_	O
205	enrolled	_	_	O
206	331	_	_	O
207	women	_	_	O
208	;	_	_	O
209	168	_	_	O
210	women	_	_	O
211	were	_	_	O
212	randomly	_	_	O
213	assigned	_	_	O
214	to	_	_	O
215	the	_	_	O
216	TDF	_	_	O
217	group	_	_	O
218	and	_	_	O
219	163	_	_	O
220	to	_	_	O
221	the	_	_	O
222	placebo	_	_	O
223	group	_	_	O
224	.	_	_	O

225	At	_	_	O
226	enrollment	_	_	O
227	,	_	_	O
228	the	_	_	O
229	median	_	_	O
230	gestational	_	_	O
231	age	_	_	O
232	was	_	_	O
233	28.3	_	_	O
234	weeks	_	_	O
235	,	_	_	O
236	and	_	_	O
237	the	_	_	O
238	median	_	_	O
239	HBV	_	_	O
240	DNA	_	_	O
241	level	_	_	O
242	was	_	_	O
243	8.0	_	_	O
244	log10	_	_	O
245	IU	_	_	O
246	per	_	_	O
247	milliliter	_	_	O
248	.	_	_	O

249	Among	_	_	O
250	322	_	_	O
251	deliveries	_	_	O
252	(	_	_	O
253	97	_	_	O
254	%	_	_	O
255	of	_	_	O
256	the	_	_	O
257	participants	_	_	O
258	)	_	_	O
259	,	_	_	O
260	there	_	_	O
261	were	_	_	O
262	319	_	_	O
263	singleton	_	_	O
264	births	_	_	O
265	,	_	_	O
266	two	_	_	O
267	twin	_	_	O
268	pairs	_	_	O
269	,	_	_	O
270	and	_	_	O
271	one	_	_	O
272	stillborn	_	_	O
273	infant	_	_	O
274	.	_	_	O

275	The	_	_	O
276	median	_	_	O
277	time	_	_	O
278	from	_	_	O
279	birth	_	_	O
280	to	_	_	O
281	administration	_	_	O
282	of	_	_	O
283	hepatitis	_	_	O
284	B	_	_	O
285	immune	_	_	O
286	globulin	_	_	O
287	was	_	_	O
288	1.3	_	_	O
289	hours	_	_	O
290	,	_	_	O
291	and	_	_	O
292	the	_	_	O
293	median	_	_	O
294	time	_	_	O
295	from	_	_	O
296	birth	_	_	O
297	to	_	_	O
298	administration	_	_	O
299	of	_	_	O
300	hepatitis	_	_	O
301	B	_	_	O
302	vaccine	_	_	O
303	was	_	_	O
304	1.2	_	_	O
305	hours	_	_	O
306	.	_	_	O

307	In	_	_	B-Premise
308	the	_	_	I-Premise
309	primary	_	_	I-Premise
310	analysis	_	_	I-Premise
311	,	_	_	I-Premise
312	none	_	_	I-Premise
313	of	_	_	I-Premise
314	the	_	_	I-Premise
315	147	_	_	I-Premise
316	infants	_	_	I-Premise
317	(	_	_	I-Premise
318	0	_	_	I-Premise
319	%	_	_	I-Premise
320	;	_	_	I-Premise
321	95	_	_	I-Premise
322	%	_	_	I-Premise
323	confidence	_	_	I-Premise
324	interval	_	_	I-Premise
325	[	_	_	I-Premise
326	CI	_	_	I-Premise
327	]	_	_	I-Premise
328	,	_	_	I-Premise
329	0	_	_	I-Premise
330	to	_	_	I-Premise
331	2	_	_	I-Premise
332	)	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	TDF	_	_	I-Premise
336	group	_	_	I-Premise
337	were	_	_	I-Premise
338	infected	_	_	I-Premise
339	,	_	_	I-Premise
340	as	_	_	I-Premise
341	compared	_	_	I-Premise
342	with	_	_	I-Premise
343	3	_	_	I-Premise
344	of	_	_	I-Premise
345	147	_	_	I-Premise
346	(	_	_	I-Premise
347	2	_	_	I-Premise
348	%	_	_	I-Premise
349	;	_	_	I-Premise
350	95	_	_	I-Premise
351	%	_	_	I-Premise
352	CI	_	_	I-Premise
353	,	_	_	I-Premise
354	0	_	_	I-Premise
355	to	_	_	I-Premise
356	6	_	_	I-Premise
357	)	_	_	I-Premise
358	in	_	_	I-Premise
359	the	_	_	I-Premise
360	placebo	_	_	I-Premise
361	group	_	_	I-Premise
362	(	_	_	I-Premise
363	P=0.12	_	_	I-Premise
364	)	_	_	I-Premise
365	.	_	_	I-Premise

366	The	_	_	B-Premise
367	rate	_	_	I-Premise
368	of	_	_	I-Premise
369	adverse	_	_	I-Premise
370	events	_	_	I-Premise
371	did	_	_	I-Premise
372	not	_	_	I-Premise
373	differ	_	_	I-Premise
374	significantly	_	_	I-Premise
375	between	_	_	I-Premise
376	groups	_	_	I-Premise
377	.	_	_	I-Premise

378	The	_	_	B-Premise
379	incidence	_	_	I-Premise
380	of	_	_	I-Premise
381	a	_	_	I-Premise
382	maternal	_	_	I-Premise
383	alanine	_	_	I-Premise
384	aminotransferase	_	_	I-Premise
385	level	_	_	I-Premise
386	of	_	_	I-Premise
387	more	_	_	I-Premise
388	than	_	_	I-Premise
389	300	_	_	I-Premise
390	IU	_	_	I-Premise
391	per	_	_	I-Premise
392	liter	_	_	I-Premise
393	after	_	_	I-Premise
394	discontinuation	_	_	I-Premise
395	of	_	_	I-Premise
396	the	_	_	I-Premise
397	trial	_	_	I-Premise
398	regimen	_	_	I-Premise
399	was	_	_	I-Premise
400	6	_	_	I-Premise
401	%	_	_	I-Premise
402	in	_	_	I-Premise
403	the	_	_	I-Premise
404	TDF	_	_	I-Premise
405	group	_	_	I-Premise
406	and	_	_	I-Premise
407	3	_	_	I-Premise
408	%	_	_	I-Premise
409	in	_	_	I-Premise
410	the	_	_	I-Premise
411	placebo	_	_	I-Premise
412	group	_	_	I-Premise
413	(	_	_	I-Premise
414	P=0.29	_	_	I-Premise
415	)	_	_	I-Premise
416	.	_	_	I-Premise

417	In	_	_	B-Claim
418	a	_	_	I-Claim
419	setting	_	_	I-Claim
420	in	_	_	I-Claim
421	which	_	_	I-Claim
422	the	_	_	I-Claim
423	rate	_	_	I-Claim
424	of	_	_	I-Claim
425	mother-to-child	_	_	I-Claim
426	HBV	_	_	I-Claim
427	transmission	_	_	I-Claim
428	was	_	_	I-Claim
429	low	_	_	I-Claim
430	with	_	_	I-Claim
431	the	_	_	I-Claim
432	administration	_	_	I-Claim
433	of	_	_	I-Claim
434	hepatitis	_	_	I-Claim
435	B	_	_	I-Claim
436	immune	_	_	I-Claim
437	globulin	_	_	I-Claim
438	and	_	_	I-Claim
439	hepatitis	_	_	I-Claim
440	B	_	_	I-Claim
441	vaccine	_	_	I-Claim
442	in	_	_	I-Claim
443	infants	_	_	I-Claim
444	born	_	_	I-Claim
445	to	_	_	I-Claim
446	HBeAg-positive	_	_	I-Claim
447	mothers	_	_	I-Claim
448	,	_	_	I-Claim
449	the	_	_	I-Claim
450	additional	_	_	I-Claim
451	maternal	_	_	I-Claim
452	use	_	_	I-Claim
453	of	_	_	I-Claim
454	TDF	_	_	I-Claim
455	did	_	_	I-Claim
456	not	_	_	I-Claim
457	result	_	_	I-Claim
458	in	_	_	I-Claim
459	a	_	_	I-Claim
460	significantly	_	_	I-Claim
461	lower	_	_	I-Claim
462	rate	_	_	I-Claim
463	of	_	_	I-Claim
464	transmission	_	_	I-Claim
465	.	_	_	I-Claim


0	Hypertension	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	generally	_	_	I-Claim
4	accepted	_	_	I-Claim
5	atherogenic	_	_	I-Claim
6	risk	_	_	I-Claim
7	factor	_	_	I-Claim
8	.	_	_	I-Claim

9	The	_	_	O
10	aim	_	_	O
11	of	_	_	O
12	this	_	_	O
13	prospective	_	_	O
14	longitudinal	_	_	O
15	study	_	_	O
16	was	_	_	O
17	to	_	_	O
18	evaluate	_	_	O
19	changes	_	_	O
20	in	_	_	O
21	carotid	_	_	O
22	intima-media	_	_	O
23	thickness	_	_	O
24	(	_	_	O
25	c-IMT	_	_	O
26	)	_	_	O
27	and	_	_	O
28	explore	_	_	O
29	the	_	_	O
30	association	_	_	O
31	of	_	_	O
32	cardiovascular	_	_	O
33	risk	_	_	O
34	factors	_	_	O
35	and	_	_	O
36	the	_	_	O
37	carotid	_	_	O
38	intima	_	_	O
39	thickness	_	_	O
40	in	_	_	O
41	adults	_	_	O
42	with	_	_	O
43	hypertension	_	_	O
44	using	_	_	O
45	standardized	_	_	O
46	methods	_	_	O
47	.	_	_	O

48	We	_	_	O
49	used	_	_	O
50	data	_	_	O
51	from	_	_	O
52	a	_	_	O
53	subgroup	_	_	O
54	of	_	_	O
55	Beijing	_	_	O
56	Vascular	_	_	O
57	Disease	_	_	O
58	Patients	_	_	O
59	Evaluation	_	_	O
60	Study	_	_	O
61	(	_	_	O
62	BEST	_	_	O
63	)	_	_	O
64	,	_	_	O
65	a	_	_	O
66	population-based	_	_	O
67	study	_	_	O
68	of	_	_	O
69	community-dwelling	_	_	O
70	adults	_	_	O
71	.	_	_	O

72	The	_	_	O
73	c-IMT	_	_	O
74	,	_	_	O
75	biomarkers	_	_	O
76	,	_	_	O
77	and	_	_	O
78	carotid-femoral-pulse	_	_	O
79	wave	_	_	O
80	velocity	_	_	O
81	(	_	_	O
82	PWV	_	_	O
83	)	_	_	O
84	were	_	_	O
85	measured	_	_	O
86	at	_	_	O
87	baseline	_	_	O
88	,	_	_	O
89	and	_	_	O
90	lifestyles	_	_	O
91	such	_	_	O
92	as	_	_	O
93	smoking	_	_	O
94	status	_	_	O
95	,	_	_	O
96	sleeping	_	_	O
97	habits	_	_	O
98	,	_	_	O
99	and	_	_	O
100	oil	_	_	O
101	or	_	_	O
102	salt	_	_	O
103	intake	_	_	O
104	level	_	_	O
105	were	_	_	O
106	determined	_	_	O
107	with	_	_	O
108	the	_	_	O
109	use	_	_	O
110	of	_	_	O
111	a	_	_	O
112	validated	_	_	O
113	questionnaire	_	_	O
114	in	_	_	O
115	the	_	_	O
116	follow-up	_	_	O
117	.	_	_	O

118	We	_	_	O
119	reevaluated	_	_	O
120	c-IMT	_	_	O
121	in	_	_	O
122	all	_	_	O
123	the	_	_	O
124	initial	_	_	O
125	1284	_	_	O
126	(	_	_	O
127	540	_	_	O
128	female	_	_	O
129	and	_	_	O
130	744	_	_	O
131	male	_	_	O
132	)	_	_	O
133	patients	_	_	O
134	with	_	_	O
135	hypertension	_	_	O
136	after	_	_	O
137	4	_	_	O
138	years	_	_	O
139	.	_	_	O

140	At	_	_	O
141	reevaluation	_	_	O
142	,	_	_	O
143	mean	_	_	O
144	(	_	_	O
145	±	_	_	O
146	SD	_	_	O
147	)	_	_	O
148	age	_	_	O
149	was	_	_	O
150	66	_	_	O
151	±	_	_	O
152	1.2	_	_	O
153	years	_	_	O
154	,	_	_	O
155	systolic	_	_	O
156	blood	_	_	O
157	pressure	_	_	O
158	was	_	_	O
159	138	_	_	O
160	±	_	_	O
161	19	_	_	O
162	mmHg	_	_	O
163	,	_	_	O
164	and	_	_	O
165	diastolic	_	_	O
166	blood	_	_	O
167	pressure	_	_	O
168	was	_	_	O
169	91	_	_	O
170	±	_	_	O
171	10	_	_	O
172	mmHg	_	_	O
173	.	_	_	O

174	The	_	_	B-Premise
175	results	_	_	I-Premise
176	showed	_	_	I-Premise
177	that	_	_	I-Premise
178	mean	_	_	I-Premise
179	c-IMT	_	_	I-Premise
180	z-scores	_	_	I-Premise
181	increased	_	_	I-Premise
182	significantly	_	_	I-Premise
183	during	_	_	I-Premise
184	4	_	_	I-Premise
185	years	_	_	I-Premise
186	(	_	_	I-Premise
187	0.002	_	_	I-Premise
188	±	_	_	I-Premise
189	0.003	_	_	I-Premise
190	,	_	_	I-Premise
191	p	_	_	I-Premise
192	<	_	_	I-Premise
193	0.001	_	_	I-Premise
194	)	_	_	I-Premise
195	as	_	_	I-Premise
196	well	_	_	I-Premise
197	as	_	_	I-Premise
198	carotid-femoral	_	_	I-Premise
199	PWV	_	_	I-Premise
200	(	_	_	I-Premise
201	13.99	_	_	I-Premise
202	±	_	_	I-Premise
203	2.74	_	_	I-Premise
204	,	_	_	I-Premise
205	p	_	_	I-Premise
206	<	_	_	I-Premise
207	0.01	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	total	_	_	I-Premise
211	cholesterol	_	_	I-Premise
212	(	_	_	I-Premise
213	6.97	_	_	I-Premise
214	±	_	_	I-Premise
215	1.08	_	_	I-Premise
216	,	_	_	I-Premise
217	p	_	_	I-Premise
218	<	_	_	I-Premise
219	0.001	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Linear	_	_	B-Premise
223	regression	_	_	I-Premise
224	showed	_	_	I-Premise
225	statistically	_	_	I-Premise
226	significant	_	_	I-Premise
227	associations	_	_	I-Premise
228	between	_	_	I-Premise
229	systolic	_	_	I-Premise
230	blood	_	_	I-Premise
231	pressure	_	_	I-Premise
232	,	_	_	I-Premise
233	diastolic	_	_	I-Premise
234	blood	_	_	I-Premise
235	pressure	_	_	I-Premise
236	,	_	_	I-Premise
237	C-reactive	_	_	I-Premise
238	protein	_	_	I-Premise
239	,	_	_	I-Premise
240	lip-line	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	heart	_	_	I-Premise
244	rate	_	_	I-Premise
245	with	_	_	I-Premise
246	c-IMT	_	_	I-Premise
247	z-scores	_	_	I-Premise
248	of	_	_	I-Premise
249	>	_	_	I-Premise
250	1.5SD	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	fully	_	_	I-Premise
254	adjusted	_	_	I-Premise
255	models	_	_	I-Premise
256	and	_	_	I-Premise
257	the	_	_	I-Premise
258	p	_	_	I-Premise
259	values	_	_	I-Premise
260	were	_	_	I-Premise
261	0.000	_	_	I-Premise
262	,	_	_	I-Premise
263	0.000	_	_	I-Premise
264	,	_	_	I-Premise
265	0.017	_	_	I-Premise
266	,	_	_	I-Premise
267	0.001	_	_	I-Premise
268	,	_	_	I-Premise
269	and	_	_	I-Premise
270	0.044	_	_	I-Premise
271	,	_	_	I-Premise
272	respectively	_	_	I-Premise
273	.	_	_	I-Premise

274	There	_	_	O
275	were	_	_	O
276	significant	_	_	O
277	predictors	_	_	O
278	for	_	_	O
279	the	_	_	O
280	mean	_	_	O
281	effect	_	_	O
282	on	_	_	O
283	c-IMT	_	_	O
284	z-score	_	_	O
285	.	_	_	O

286	In	_	_	B-Premise
287	a	_	_	I-Premise
288	full-model	_	_	I-Premise
289	logistic	_	_	I-Premise
290	regression	_	_	I-Premise
291	,	_	_	I-Premise
292	significant	_	_	I-Premise
293	risk	_	_	I-Premise
294	factors	_	_	I-Premise
295	for	_	_	I-Premise
296	an	_	_	I-Premise
297	increase	_	_	I-Premise
298	in	_	_	I-Premise
299	IMT	_	_	I-Premise
300	of	_	_	I-Premise
301	≥1.5	_	_	I-Premise
302	z-scores	_	_	I-Premise
303	were	_	_	I-Premise
304	carotid-femoral	_	_	I-Premise
305	PWV	_	_	I-Premise
306	(	_	_	I-Premise
307	odds	_	_	I-Premise
308	ratio	_	_	I-Premise
309	:	_	_	I-Premise
310	1.119	_	_	I-Premise
311	,	_	_	I-Premise
312	confidence	_	_	I-Premise
313	interval	_	_	I-Premise
314	:	_	_	I-Premise
315	1.018	_	_	I-Premise
316	,	_	_	I-Premise
317	1.230	_	_	I-Premise
318	,	_	_	I-Premise
319	p	_	_	I-Premise
320	=	_	_	I-Premise
321	0.020	_	_	I-Premise
322	<	_	_	I-Premise
323	0.05	_	_	I-Premise
324	)	_	_	I-Premise
325	at	_	_	I-Premise
326	first	_	_	I-Premise
327	measurement	_	_	I-Premise
328	.	_	_	I-Premise

329	The	_	_	B-Claim
330	conclusion	_	_	I-Claim
331	of	_	_	I-Claim
332	the	_	_	I-Claim
333	study	_	_	I-Claim
334	was	_	_	I-Claim
335	that	_	_	I-Claim
336	longitudinal	_	_	I-Claim
337	c-IMT	_	_	I-Claim
338	measurements	_	_	I-Claim
339	revealed	_	_	I-Claim
340	progression	_	_	I-Claim
341	in	_	_	I-Claim
342	subclinical	_	_	I-Claim
343	atherosclerosis	_	_	I-Claim
344	during	_	_	I-Claim
345	a	_	_	I-Claim
346	four-year	_	_	I-Claim
347	period	_	_	I-Claim
348	in	_	_	I-Claim
349	a	_	_	I-Claim
350	hypertensive	_	_	I-Claim
351	old-aged	_	_	I-Claim
352	cohort	_	_	I-Claim
353	.	_	_	I-Claim

354	Systolic	_	_	B-Claim
355	or	_	_	I-Claim
356	diastolic	_	_	I-Claim
357	blood	_	_	I-Claim
358	pressure	_	_	I-Claim
359	,	_	_	I-Claim
360	homocysteine	_	_	I-Claim
361	,	_	_	I-Claim
362	carotid-femoral	_	_	I-Claim
363	PWV	_	_	I-Claim
364	,	_	_	I-Claim
365	and	_	_	I-Claim
366	waistline	_	_	I-Claim
367	were	_	_	I-Claim
368	significantly	_	_	I-Claim
369	related	_	_	I-Claim
370	to	_	_	I-Claim
371	c-IMT	_	_	I-Claim
372	increment	_	_	I-Claim
373	.	_	_	I-Claim

374	By	_	_	B-Claim
375	lifestyle	_	_	I-Claim
376	and	_	_	I-Claim
377	medical	_	_	I-Claim
378	intervention	_	_	I-Claim
379	to	_	_	I-Claim
380	control	_	_	I-Claim
381	these	_	_	I-Claim
382	risk	_	_	I-Claim
383	factors	_	_	I-Claim
384	may	_	_	I-Claim
385	prevent	_	_	I-Claim
386	progression	_	_	I-Claim
387	of	_	_	I-Claim
388	c-IMT	_	_	I-Claim
389	in	_	_	I-Claim
390	old-aged	_	_	I-Claim
391	cohort	_	_	I-Claim
392	with	_	_	I-Claim
393	hypertension	_	_	I-Claim
394	.	_	_	I-Claim


0	Emerging	_	_	O
1	genetic	_	_	O
2	,	_	_	O
3	ex-vivo	_	_	O
4	,	_	_	O
5	and	_	_	O
6	clinical	_	_	O
7	trial	_	_	O
8	evidence	_	_	O
9	indicates	_	_	O
10	that	_	_	O
11	calcium	_	_	O
12	channel	_	_	O
13	blockers	_	_	O
14	(	_	_	O
15	CCB	_	_	O
16	)	_	_	O
17	can	_	_	O
18	improve	_	_	O
19	mood	_	_	O
20	and	_	_	O
21	cognitive	_	_	O
22	function	_	_	O
23	.	_	_	O

24	The	_	_	O
25	objective	_	_	O
26	of	_	_	O
27	this	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	examine	_	_	O
32	the	_	_	O
33	effect	_	_	O
34	of	_	_	O
35	selective	_	_	O
36	serotonin	_	_	O
37	reuptake	_	_	O
38	inhibitor	_	_	O
39	(	_	_	O
40	SSRI	_	_	O
41	)	_	_	O
42	therapy	_	_	O
43	augmented	_	_	O
44	with	_	_	O
45	CCB	_	_	O
46	on	_	_	O
47	depression	_	_	O
48	and	_	_	O
49	cognitive	_	_	O
50	decline	_	_	O
51	in	_	_	O
52	an	_	_	O
53	elderly	_	_	O
54	population	_	_	O
55	with	_	_	O
56	hypertension	_	_	O
57	.	_	_	O

58	Prospective	_	_	O
59	study	_	_	O
60	of	_	_	O
61	296	_	_	O
62	persons	_	_	O
63	treated	_	_	O
64	with	_	_	O
65	SSRI	_	_	O
66	and	_	_	O
67	antihypertensive	_	_	O
68	drugs	_	_	O
69	.	_	_	O

70	Baseline	_	_	O
71	and	_	_	O
72	two	_	_	O
73	year	_	_	O
74	clinic	_	_	O
75	assessments	_	_	O
76	were	_	_	O
77	used	_	_	O
78	to	_	_	O
79	categorize	_	_	O
80	participants	_	_	O
81	as	_	_	O
82	users	_	_	O
83	of	_	_	O
84	SSRI	_	_	O
85	+	_	_	O
86	CCB	_	_	O
87	(	_	_	O
88	n	_	_	O
89	=	_	_	O
90	53	_	_	O
91	)	_	_	O
92	or	_	_	O
93	users	_	_	O
94	of	_	_	O
95	SSRI	_	_	O
96	+	_	_	O
97	other	_	_	O
98	antihypertensives	_	_	O
99	(	_	_	O
100	n	_	_	O
101	=	_	_	O
102	243	_	_	O
103	)	_	_	O
104	.	_	_	O

105	Clinic	_	_	O
106	visits	_	_	O
107	were	_	_	O
108	performed	_	_	O
109	up	_	_	O
110	to	_	_	O
111	four	_	_	O
112	times	_	_	O
113	in	_	_	O
114	a	_	_	O
115	ten-year	_	_	O
116	period	_	_	O
117	to	_	_	O
118	assess	_	_	O
119	depression	_	_	O
120	and	_	_	O
121	cognitive	_	_	O
122	function	_	_	O
123	.	_	_	O

124	The	_	_	O
125	sample	_	_	O
126	mean	_	_	O
127	age	_	_	O
128	was	_	_	O
129	75.2	_	_	O
130	±	_	_	O
131	5.47	_	_	O
132	years	_	_	O
133	and	_	_	O
134	78	_	_	O
135	%	_	_	O
136	of	_	_	O
137	participants	_	_	O
138	were	_	_	O
139	female	_	_	O
140	.	_	_	O

141	At	_	_	B-Premise
142	two	_	_	I-Premise
143	year	_	_	I-Premise
144	follow-up	_	_	I-Premise
145	there	_	_	I-Premise
146	was	_	_	I-Premise
147	a	_	_	I-Premise
148	significant	_	_	I-Premise
149	group	_	_	I-Premise
150	by	_	_	I-Premise
151	time	_	_	I-Premise
152	interaction	_	_	I-Premise
153	showing	_	_	I-Premise
154	lower	_	_	I-Premise
155	Center	_	_	I-Premise
156	for	_	_	I-Premise
157	Epidemiological	_	_	I-Premise
158	Studies-Depression	_	_	I-Premise
159	(	_	_	I-Premise
160	CESD	_	_	I-Premise
161	)	_	_	I-Premise
162	scores	_	_	I-Premise
163	in	_	_	I-Premise
164	the	_	_	I-Premise
165	SSRI	_	_	I-Premise
166	+	_	_	I-Premise
167	CCB	_	_	I-Premise
168	group	_	_	I-Premise
169	,	_	_	I-Premise
170	F	_	_	I-Premise
171	(	_	_	I-Premise
172	1,291	_	_	I-Premise
173	)	_	_	I-Premise
174	=	_	_	I-Premise
175	4.13	_	_	I-Premise
176	,	_	_	I-Premise
177	p	_	_	I-Premise
178	=	_	_	I-Premise
179	0.043	_	_	I-Premise
180	,	_	_	I-Premise
181	η2	_	_	I-Premise
182	p	_	_	I-Premise
183	=	_	_	I-Premise
184	0.014	_	_	I-Premise
185	.	_	_	I-Premise

186	Over	_	_	B-Premise
187	ten-years	_	_	I-Premise
188	follow-up	_	_	I-Premise
189	,	_	_	I-Premise
190	SSRI	_	_	I-Premise
191	+	_	_	I-Premise
192	CCB	_	_	I-Premise
193	use	_	_	I-Premise
194	was	_	_	I-Premise
195	associated	_	_	I-Premise
196	with	_	_	I-Premise
197	improved	_	_	I-Premise
198	general	_	_	I-Premise
199	cognitive	_	_	I-Premise
200	function	_	_	I-Premise
201	(	_	_	I-Premise
202	Mini-Mental	_	_	I-Premise
203	State	_	_	I-Premise
204	Examination	_	_	I-Premise
205	:	_	_	I-Premise
206	β	_	_	I-Premise
207	=	_	_	I-Premise
208	0.97	_	_	I-Premise
209	;	_	_	I-Premise
210	95	_	_	I-Premise
211	%	_	_	I-Premise
212	CI	_	_	I-Premise
213	0.14	_	_	I-Premise
214	to	_	_	I-Premise
215	1.81	_	_	I-Premise
216	,	_	_	I-Premise
217	p	_	_	I-Premise
218	=	_	_	I-Premise
219	0.023	_	_	I-Premise
220	)	_	_	I-Premise
221	and	_	_	I-Premise
222	immediate	_	_	I-Premise
223	visual	_	_	I-Premise
224	memory	_	_	I-Premise
225	(	_	_	I-Premise
226	Boston	_	_	I-Premise
227	Visual	_	_	I-Premise
228	Retention	_	_	I-Premise
229	Test	_	_	I-Premise
230	:	_	_	I-Premise
231	β	_	_	I-Premise
232	=	_	_	I-Premise
233	0.69	_	_	I-Premise
234	;	_	_	I-Premise
235	95	_	_	I-Premise
236	%	_	_	I-Premise
237	CI	_	_	I-Premise
238	0.06	_	_	I-Premise
239	to	_	_	I-Premise
240	1.32	_	_	I-Premise
241	,	_	_	I-Premise
242	p	_	_	I-Premise
243	=	_	_	I-Premise
244	0.033	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	The	_	_	B-Claim
248	findings	_	_	I-Claim
249	provide	_	_	I-Claim
250	general	_	_	I-Claim
251	population	_	_	I-Claim
252	evidence	_	_	I-Claim
253	that	_	_	I-Claim
254	SSRI	_	_	I-Claim
255	augmentation	_	_	I-Claim
256	with	_	_	I-Claim
257	CCB	_	_	I-Claim
258	may	_	_	I-Claim
259	improve	_	_	I-Claim
260	depression	_	_	I-Claim
261	and	_	_	I-Claim
262	cognitive	_	_	I-Claim
263	function	_	_	I-Claim
264	.	_	_	I-Claim


0	Sodium	_	_	B-Claim
1	nitrite	_	_	I-Claim
2	has	_	_	I-Claim
3	been	_	_	I-Claim
4	reported	_	_	I-Claim
5	to	_	_	I-Claim
6	be	_	_	I-Claim
7	effective	_	_	I-Claim
8	in	_	_	I-Claim
9	reducing	_	_	I-Claim
10	chronic	_	_	I-Claim
11	peripheral	_	_	I-Claim
12	pain	_	_	I-Claim
13	.	_	_	I-Claim

14	To	_	_	O
15	evaluate	_	_	O
16	the	_	_	O
17	safety	_	_	O
18	and	_	_	O
19	efficacy	_	_	O
20	of	_	_	O
21	40	_	_	O
22	and	_	_	O
23	80	_	_	O
24	mg	_	_	O
25	,	_	_	O
26	BID	_	_	O
27	,	_	_	O
28	of	_	_	O
29	an	_	_	O
30	oral	_	_	O
31	sustained	_	_	O
32	release	_	_	O
33	formulation	_	_	O
34	of	_	_	O
35	sodium	_	_	O
36	nitrite	_	_	O
37	(	_	_	O
38	SR-nitrite	_	_	O
39	)	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	suffering	_	_	O
43	from	_	_	O
44	diabetic	_	_	O
45	neuropathy	_	_	O
46	,	_	_	O
47	and	_	_	O
48	to	_	_	O
49	determine	_	_	O
50	whether	_	_	O
51	SR-nitrite	_	_	O
52	would	_	_	O
53	reduce	_	_	O
54	the	_	_	O
55	frequency	_	_	O
56	of	_	_	O
57	headaches	_	_	O
58	reported	_	_	O
59	previously	_	_	O
60	by	_	_	O
61	subjects	_	_	O
62	receiving	_	_	O
63	the	_	_	O
64	same	_	_	O
65	doses	_	_	O
66	of	_	_	O
67	an	_	_	O
68	immediate	_	_	O
69	release	_	_	O
70	formulation	_	_	O
71	.	_	_	O

72	Phase	_	_	O
73	II	_	_	O
74	,	_	_	O
75	single-center	_	_	O
76	,	_	_	O
77	randomized	_	_	O
78	,	_	_	O
79	double-blind	_	_	O
80	,	_	_	O
81	placebo	_	_	O
82	controlled	_	_	O
83	clinical	_	_	O
84	trial	_	_	O
85	.	_	_	O

86	Twenty-four	_	_	O
87	patients	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	to	_	_	O
91	40	_	_	O
92	mg	_	_	O
93	or	_	_	O
94	80	_	_	O
95	mg	_	_	O
96	SR-nitrite	_	_	O
97	or	_	_	O
98	placebo	_	_	O
99	twice	_	_	O
100	daily	_	_	O
101	for	_	_	O
102	12	_	_	O
103	weeks	_	_	O
104	.	_	_	O

105	The	_	_	O
106	primary	_	_	O
107	objective	_	_	O
108	was	_	_	O
109	to	_	_	O
110	determine	_	_	O
111	whether	_	_	O
112	headaches	_	_	O
113	would	_	_	O
114	be	_	_	O
115	reduced	_	_	O
116	using	_	_	O
117	SR-nitrite	_	_	O
118	.	_	_	O

119	The	_	_	O
120	primary	_	_	O
121	efficacy	_	_	O
122	endpoint	_	_	O
123	was	_	_	O
124	the	_	_	O
125	mean	_	_	O
126	difference	_	_	O
127	in	_	_	O
128	the	_	_	O
129	change	_	_	O
130	of	_	_	O
131	the	_	_	O
132	Neuropathic	_	_	O
133	Pain	_	_	O
134	Symptom	_	_	O
135	Inventory	_	_	O
136	(	_	_	O
137	NPSI	_	_	O
138	)	_	_	O
139	pain	_	_	O
140	score	_	_	O
141	from	_	_	O
142	baseline	_	_	O
143	to	_	_	O
144	that	_	_	O
145	reported	_	_	O
146	after	_	_	O
147	12	_	_	O
148	weeks	_	_	O
149	of	_	_	O
150	treatment	_	_	O
151	.	_	_	O

152	Secondary	_	_	O
153	endpoints	_	_	O
154	included	_	_	O
155	changes	_	_	O
156	from	_	_	O
157	baseline	_	_	O
158	for	_	_	O
159	the	_	_	O
160	Brief	_	_	O
161	Pain	_	_	O
162	Inventory	_	_	O
163	(	_	_	O
164	BPI	_	_	O
165	)	_	_	O
166	Scale	_	_	O
167	,	_	_	O
168	the	_	_	O
169	RAND	_	_	O
170	36	_	_	O
171	questionnaire	_	_	O
172	,	_	_	O
173	Short	_	_	O
174	Form	_	_	O
175	McGill	_	_	O
176	Questionnaire	_	_	O
177	,	_	_	O
178	daily	_	_	O
179	patient	_	_	O
180	reported	_	_	O
181	score	_	_	O
182	for	_	_	O
183	neuropathic	_	_	O
184	pain	_	_	O
185	,	_	_	O
186	changes	_	_	O
187	in	_	_	O
188	HbA1c	_	_	O
189	,	_	_	O
190	PulseOx	_	_	O
191	and	_	_	O
192	quantitative	_	_	O
193	sensory	_	_	O
194	testing	_	_	O
195	.	_	_	O

196	The	_	_	B-Premise
197	number	_	_	I-Premise
198	of	_	_	I-Premise
199	subjects	_	_	I-Premise
200	reporting	_	_	I-Premise
201	adverse	_	_	I-Premise
202	events	_	_	I-Premise
203	and	_	_	I-Premise
204	the	_	_	I-Premise
205	number	_	_	I-Premise
206	of	_	_	I-Premise
207	adverse	_	_	I-Premise
208	events	_	_	I-Premise
209	did	_	_	I-Premise
210	not	_	_	I-Premise
211	change	_	_	I-Premise
212	with	_	_	I-Premise
213	dose	_	_	I-Premise
214	.	_	_	I-Premise

215	There	_	_	B-Premise
216	were	_	_	I-Premise
217	no	_	_	I-Premise
218	reports	_	_	I-Premise
219	of	_	_	I-Premise
220	treatment-related	_	_	I-Premise
221	headaches	_	_	I-Premise
222	.	_	_	I-Premise

223	Although	_	_	O
224	no	_	_	O
225	significant	_	_	O
226	differences	_	_	O
227	were	_	_	O
228	identified	_	_	O
229	in	_	_	O
230	patient	_	_	O
231	responses	_	_	O
232	to	_	_	O
233	the	_	_	O
234	questionnaires	_	_	O
235	,	_	_	O
236	a	_	_	O
237	trend	_	_	O
238	was	_	_	O
239	observed	_	_	O
240	.	_	_	O

241	In	_	_	B-Premise
242	the	_	_	I-Premise
243	NPSI	_	_	I-Premise
244	assessment	_	_	I-Premise
245	,	_	_	I-Premise
246	patients	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	40	_	_	I-Premise
250	mg	_	_	I-Premise
251	and	_	_	I-Premise
252	80	_	_	I-Premise
253	mg	_	_	I-Premise
254	dose	_	_	I-Premise
255	group	_	_	I-Premise
256	reported	_	_	I-Premise
257	a	_	_	I-Premise
258	12.7	_	_	I-Premise
259	%	_	_	I-Premise
260	and	_	_	I-Premise
261	22.0	_	_	I-Premise
262	%	_	_	I-Premise
263	reduction	_	_	I-Premise
264	in	_	_	I-Premise
265	pain	_	_	I-Premise
266	,	_	_	I-Premise
267	respectively	_	_	I-Premise
268	,	_	_	I-Premise
269	compared	_	_	I-Premise
270	to	_	_	I-Premise
271	an	_	_	I-Premise
272	8.4	_	_	I-Premise
273	%	_	_	I-Premise
274	reduction	_	_	I-Premise
275	by	_	_	I-Premise
276	patients	_	_	I-Premise
277	in	_	_	I-Premise
278	the	_	_	I-Premise
279	placebo	_	_	I-Premise
280	group	_	_	I-Premise
281	.	_	_	I-Premise

282	A	_	_	O
283	trend	_	_	O
284	was	_	_	O
285	also	_	_	O
286	observed	_	_	O
287	with	_	_	O
288	the	_	_	O
289	BPI	_	_	O
290	total	_	_	O
291	severity	_	_	O
292	score	_	_	O
293	.	_	_	O

294	However	_	_	O
295	,	_	_	O
296	the	_	_	B-Premise
297	40	_	_	I-Premise
298	mg	_	_	I-Premise
299	dosing	_	_	I-Premise
300	group	_	_	I-Premise
301	reported	_	_	I-Premise
302	the	_	_	I-Premise
303	greatest	_	_	I-Premise
304	reduction	_	_	I-Premise
305	in	_	_	I-Premise
306	pain	_	_	I-Premise
307	using	_	_	I-Premise
308	the	_	_	I-Premise
309	McGill	_	_	I-Premise
310	Pain	_	_	I-Premise
311	index	_	_	I-Premise
312	and	_	_	I-Premise
313	via	_	_	I-Premise
314	patient	_	_	I-Premise
315	logs	_	_	I-Premise
316	of	_	_	I-Premise
317	daily	_	_	I-Premise
318	pain	_	_	I-Premise
319	scores	_	_	I-Premise
320	,	_	_	I-Premise
321	where	_	_	O
322	the	_	_	B-Premise
323	mean	_	_	I-Premise
324	of	_	_	I-Premise
325	pain	_	_	I-Premise
326	scores	_	_	I-Premise
327	reported	_	_	I-Premise
328	by	_	_	I-Premise
329	subjects	_	_	I-Premise
330	in	_	_	I-Premise
331	the	_	_	I-Premise
332	40	_	_	I-Premise
333	mg	_	_	I-Premise
334	group	_	_	I-Premise
335	dropped	_	_	I-Premise
336	by	_	_	I-Premise
337	day	_	_	I-Premise
338	41	_	_	I-Premise
339	and	_	_	I-Premise
340	generally	_	_	I-Premise
341	stayed	_	_	I-Premise
342	lower	_	_	I-Premise
343	than	_	_	I-Premise
344	the	_	_	I-Premise
345	mean	_	_	I-Premise
346	of	_	_	I-Premise
347	scores	_	_	I-Premise
348	reported	_	_	I-Premise
349	by	_	_	I-Premise
350	subjects	_	_	I-Premise
351	in	_	_	I-Premise
352	either	_	_	I-Premise
353	of	_	_	I-Premise
354	the	_	_	I-Premise
355	other	_	_	I-Premise
356	two	_	_	I-Premise
357	groups	_	_	I-Premise
358	.	_	_	I-Premise

359	Patients	_	_	B-Premise
360	in	_	_	I-Premise
361	the	_	_	I-Premise
362	80	_	_	I-Premise
363	mg	_	_	I-Premise
364	SR-nitrite	_	_	I-Premise
365	group	_	_	I-Premise
366	had	_	_	I-Premise
367	an	_	_	I-Premise
368	improvement	_	_	I-Premise
369	in	_	_	I-Premise
370	both	_	_	I-Premise
371	Nerve	_	_	I-Premise
372	Sensory	_	_	I-Premise
373	Conductance	_	_	I-Premise
374	and	_	_	I-Premise
375	Nerve	_	_	I-Premise
376	Sensory	_	_	I-Premise
377	Velocity	_	_	I-Premise
378	.	_	_	I-Premise

379	No	_	_	B-Premise
380	changes	_	_	I-Premise
381	were	_	_	I-Premise
382	observed	_	_	I-Premise
383	in	_	_	I-Premise
384	HbA1c	_	_	I-Premise
385	levels	_	_	I-Premise
386	or	_	_	I-Premise
387	PulseOx	_	_	I-Premise
388	.	_	_	I-Premise

389	Sustained	_	_	B-Claim
390	release	_	_	I-Claim
391	sodium	_	_	I-Claim
392	nitrite	_	_	I-Claim
393	prevents	_	_	I-Claim
394	the	_	_	I-Claim
395	prevalent	_	_	I-Claim
396	reports	_	_	I-Claim
397	of	_	_	I-Claim
398	headaches	_	_	I-Claim
399	by	_	_	I-Claim
400	patients	_	_	I-Claim
401	treated	_	_	I-Claim
402	with	_	_	I-Claim
403	an	_	_	I-Claim
404	immediate	_	_	I-Claim
405	release	_	_	I-Claim
406	formulation	_	_	I-Claim
407	of	_	_	I-Claim
408	sodium	_	_	I-Claim
409	nitrite	_	_	I-Claim
410	.	_	_	I-Claim

411	In	_	_	B-Premise
412	a	_	_	I-Premise
413	previous	_	_	I-Premise
414	study	_	_	I-Premise
415	of	_	_	I-Premise
416	patients	_	_	I-Premise
417	with	_	_	I-Premise
418	peripheral	_	_	I-Premise
419	arterial	_	_	I-Premise
420	disease	_	_	I-Premise
421	(	_	_	I-Premise
422	PAD	_	_	I-Premise
423	)	_	_	I-Premise
424	,	_	_	I-Premise
425	40	_	_	I-Premise
426	mg	_	_	I-Premise
427	BID	_	_	I-Premise
428	treatment	_	_	I-Premise
429	led	_	_	I-Premise
430	to	_	_	I-Premise
431	a	_	_	I-Premise
432	statistically	_	_	I-Premise
433	significant	_	_	I-Premise
434	reduction	_	_	I-Premise
435	in	_	_	I-Premise
436	reported	_	_	I-Premise
437	pain	_	_	I-Premise
438	,	_	_	I-Premise
439	similar	_	_	I-Premise
440	trends	_	_	I-Premise
441	were	_	_	I-Premise
442	observed	_	_	I-Premise
443	at	_	_	I-Premise
444	the	_	_	I-Premise
445	end	_	_	I-Premise
446	of	_	_	I-Premise
447	the	_	_	I-Premise
448	trial	_	_	I-Premise
449	period	_	_	I-Premise
450	for	_	_	I-Premise
451	most	_	_	I-Premise
452	of	_	_	I-Premise
453	the	_	_	I-Premise
454	pain	_	_	I-Premise
455	questionnaires	_	_	I-Premise
456	used	_	_	I-Premise
457	in	_	_	I-Premise
458	the	_	_	I-Premise
459	study	_	_	I-Premise
460	.	_	_	I-Premise

461	The	_	_	B-Premise
462	80	_	_	I-Premise
463	mg	_	_	I-Premise
464	BID	_	_	I-Premise
465	treatment	_	_	I-Premise
466	had	_	_	I-Premise
467	the	_	_	I-Premise
468	more	_	_	I-Premise
469	pronounced	_	_	I-Premise
470	affect	_	_	I-Premise
471	on	_	_	I-Premise
472	bioactivity	_	_	I-Premise
473	(	_	_	I-Premise
474	quantitative	_	_	I-Premise
475	sensory	_	_	I-Premise
476	testing	_	_	I-Premise
477	)	_	_	I-Premise
478	,	_	_	I-Premise
479	which	_	_	I-Premise
480	was	_	_	I-Premise
481	similar	_	_	I-Premise
482	to	_	_	I-Premise
483	the	_	_	I-Premise
484	PAD	_	_	I-Premise
485	study	_	_	I-Premise
486	,	_	_	I-Premise
487	where	_	_	I-Premise
488	this	_	_	I-Premise
489	dose	_	_	I-Premise
490	group	_	_	I-Premise
491	had	_	_	I-Premise
492	the	_	_	I-Premise
493	greatest	_	_	I-Premise
494	improvement	_	_	I-Premise
495	in	_	_	I-Premise
496	FMD	_	_	I-Premise
497	{	_	_	I-Premise
498	AU	_	_	I-Premise
499	:	_	_	I-Premise
500	spell	_	_	I-Premise
501	out	_	_	I-Premise
502	FMD	_	_	I-Premise
503	}	_	_	I-Premise
504	.	_	_	I-Premise

505	The	_	_	B-Claim
506	ability	_	_	I-Claim
507	to	_	_	I-Claim
508	alleviate	_	_	I-Claim
509	pain	_	_	I-Claim
510	with	_	_	I-Claim
511	BID	_	_	I-Claim
512	treatment	_	_	I-Claim
513	of	_	_	I-Claim
514	SR-nitrite	_	_	I-Claim
515	offers	_	_	I-Claim
516	promise	_	_	I-Claim
517	for	_	_	I-Claim
518	a	_	_	I-Claim
519	new	_	_	I-Claim
520	non-addictive	_	_	I-Claim
521	,	_	_	I-Claim
522	non-sedating	_	_	I-Claim
523	treatment	_	_	I-Claim
524	of	_	_	I-Claim
525	chronic	_	_	I-Claim
526	pain	_	_	I-Claim
527	and	_	_	I-Claim
528	warrants	_	_	I-Claim
529	further	_	_	I-Claim
530	study	_	_	I-Claim
531	.	_	_	I-Claim


0	Recently	_	_	O
1	,	_	_	O
2	there	_	_	B-Claim
3	has	_	_	I-Claim
4	been	_	_	I-Claim
5	an	_	_	I-Claim
6	increasing	_	_	I-Claim
7	interest	_	_	I-Claim
8	in	_	_	I-Claim
9	the	_	_	I-Claim
10	influence	_	_	I-Claim
11	of	_	_	I-Claim
12	antioxidant	_	_	I-Claim
13	vitamins	_	_	I-Claim
14	on	_	_	I-Claim
15	the	_	_	I-Claim
16	efficacy	_	_	I-Claim
17	of	_	_	I-Claim
18	oral	_	_	I-Claim
19	hypoglycemic	_	_	I-Claim
20	therapy	_	_	I-Claim
21	in	_	_	I-Claim
22	type	_	_	I-Claim
23	2	_	_	I-Claim
24	diabetic	_	_	I-Claim
25	patients	_	_	I-Claim
26	(	_	_	I-Claim
27	T2DM	_	_	I-Claim
28	)	_	_	I-Claim
29	.	_	_	I-Claim

30	This	_	_	O
31	single-blinded	_	_	O
32	randomized	_	_	O
33	controlled	_	_	O
34	clinical	_	_	O
35	trial	_	_	O
36	aimed	_	_	O
37	to	_	_	O
38	investigate	_	_	O
39	the	_	_	O
40	effect	_	_	O
41	of	_	_	O
42	vitamin	_	_	O
43	C	_	_	O
44	and/or	_	_	O
45	E	_	_	O
46	supplementation	_	_	O
47	on	_	_	O
48	the	_	_	O
49	efficacy	_	_	O
50	of	_	_	O
51	oral	_	_	O
52	hypoglycemic	_	_	O
53	therapy	_	_	O
54	in	_	_	O
55	T2DM	_	_	O
56	Palestinian	_	_	O
57	male	_	_	O
58	patients	_	_	O
59	from	_	_	O
60	the	_	_	O
61	Gaza	_	_	O
62	Strip	_	_	O
63	.	_	_	O

64	Forty	_	_	O
65	T2DM	_	_	O
66	male	_	_	O
67	patients	_	_	O
68	aged	_	_	O
69	40-60	_	_	O
70	years	_	_	O
71	on	_	_	O
72	metformin	_	_	O
73	treatment	_	_	O
74	were	_	_	O
75	randomly	_	_	O
76	divided	_	_	O
77	into	_	_	O
78	four	_	_	O
79	groups	_	_	O
80	,	_	_	O
81	each	_	_	O
82	group	_	_	O
83	received	_	_	O
84	an	_	_	O
85	additional	_	_	O
86	one	_	_	O
87	of	_	_	O
88	the	_	_	O
89	following	_	_	O
90	daily	_	_	O
91	oral	_	_	O
92	supplements	_	_	O
93	for	_	_	O
94	90	_	_	O
95	days	_	_	O
96	:	_	_	O
97	placebo	_	_	O
98	;	_	_	O
99	vitamin	_	_	O
100	C	_	_	O
101	;	_	_	O
102	vitamin	_	_	O
103	E	_	_	O
104	and	_	_	O
105	vitamin	_	_	O
106	C	_	_	O
107	plus	_	_	O
108	vitamin	_	_	O
109	E.	_	_	O
110	After	_	_	O
111	overnight	_	_	O
112	fasting	_	_	O
113	,	_	_	O
114	venous	_	_	O
115	blood	_	_	O
116	specimens	_	_	O
117	were	_	_	O
118	collected	_	_	O
119	from	_	_	O
120	all	_	_	O
121	individuals	_	_	O
122	into	_	_	O
123	K3-EDTA	_	_	O
124	tubes	_	_	O
125	and	_	_	O
126	serum	_	_	O
127	tubes	_	_	O
128	for	_	_	O
129	measuring	_	_	O
130	the	_	_	O
131	biochemical	_	_	O
132	and	_	_	O
133	hematological	_	_	O
134	parameters	_	_	O
135	of	_	_	O
136	the	_	_	O
137	study	_	_	O
138	at	_	_	O
139	baseline	_	_	O
140	and	_	_	O
141	after	_	_	O
142	90	_	_	O
143	days	_	_	O
144	of	_	_	O
145	vitamins	_	_	O
146	supplementation	_	_	O
147	.	_	_	O

148	The	_	_	O
149	results	_	_	O
150	revealed	_	_	O
151	that	_	_	O
152	vitamin	_	_	B-Premise
153	C	_	_	I-Premise
154	and/or	_	_	I-Premise
155	E	_	_	I-Premise
156	improve	_	_	I-Premise
157	fasting	_	_	I-Premise
158	blood	_	_	I-Premise
159	sugar	_	_	I-Premise
160	(	_	_	I-Premise
161	FBS	_	_	I-Premise
162	)	_	_	I-Premise
163	,	_	_	I-Premise
164	HbA1c	_	_	I-Premise
165	,	_	_	I-Premise
166	lipid	_	_	I-Premise
167	profile	_	_	I-Premise
168	,	_	_	I-Premise
169	insulin	_	_	I-Premise
170	,	_	_	I-Premise
171	homeostasis	_	_	I-Premise
172	model	_	_	I-Premise
173	assessment	_	_	I-Premise
174	of	_	_	I-Premise
175	insulin	_	_	I-Premise
176	resistance	_	_	I-Premise
177	(	_	_	I-Premise
178	HOMA-IR	_	_	I-Premise
179	)	_	_	I-Premise
180	,	_	_	I-Premise
181	reduced	_	_	I-Premise
182	glutathione	_	_	I-Premise
183	(	_	_	I-Premise
184	GSH	_	_	I-Premise
185	)	_	_	I-Premise
186	;	_	_	I-Premise
187	and	_	_	I-Premise
188	Quantitative	_	_	I-Premise
189	Insulin	_	_	I-Premise
190	Sensitivity	_	_	I-Premise
191	Check	_	_	I-Premise
192	Index	_	_	I-Premise
193	(	_	_	I-Premise
194	QISCI	_	_	I-Premise
195	)	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	diabetic	_	_	I-Premise
199	patients	_	_	I-Premise
200	group	_	_	I-Premise
201	that	_	_	I-Premise
202	received	_	_	I-Premise
203	placebo	_	_	I-Premise
204	.	_	_	I-Premise

205	This	_	_	B-Claim
206	study	_	_	I-Claim
207	provided	_	_	I-Claim
208	additional	_	_	I-Claim
209	evidence	_	_	I-Claim
210	on	_	_	I-Claim
211	the	_	_	I-Claim
212	beneficial	_	_	I-Claim
213	effects	_	_	I-Claim
214	of	_	_	I-Claim
215	supplementing	_	_	I-Claim
216	antioxidant	_	_	I-Claim
217	vitamins	_	_	I-Claim
218	in	_	_	I-Claim
219	T2DM	_	_	I-Claim
220	which	_	_	I-Claim
221	could	_	_	I-Claim
222	improve	_	_	I-Claim
223	the	_	_	I-Claim
224	clinical	_	_	I-Claim
225	condition	_	_	I-Claim
226	and	_	_	I-Claim
227	attenuate	_	_	I-Claim
228	or	_	_	I-Claim
229	prevent	_	_	I-Claim
230	diabetic	_	_	I-Claim
231	pathogenesis	_	_	I-Claim
232	and	_	_	I-Claim
233	complications	_	_	I-Claim
234	that	_	_	I-Claim
235	,	_	_	I-Claim
236	secondly	_	_	I-Claim
237	to	_	_	I-Claim
238	poor	_	_	I-Claim
239	glycemic	_	_	I-Claim
240	control	_	_	I-Claim
241	,	_	_	I-Claim
242	could	_	_	I-Claim
243	attribute	_	_	I-Claim
244	to	_	_	I-Claim
245	the	_	_	I-Claim
246	imbalance	_	_	I-Claim
247	between	_	_	I-Claim
248	the	_	_	I-Claim
249	decline	_	_	I-Claim
250	in	_	_	I-Claim
251	the	_	_	I-Claim
252	endogenous	_	_	I-Claim
253	antioxidants	_	_	I-Claim
254	and	_	_	I-Claim
255	increasing	_	_	I-Claim
256	production	_	_	I-Claim
257	of	_	_	I-Claim
258	the	_	_	I-Claim
259	reactive	_	_	I-Claim
260	oxygen	_	_	I-Claim
261	species	_	_	I-Claim
262	leading	_	_	I-Claim
263	to	_	_	I-Claim
264	the	_	_	I-Claim
265	oxidant-mediated	_	_	I-Claim
266	damage	_	_	I-Claim
267	present	_	_	I-Claim
268	in	_	_	I-Claim
269	the	_	_	I-Claim
270	diabetic	_	_	I-Claim
271	context	_	_	I-Claim
272	.	_	_	I-Claim


0	Methionine	_	_	B-Claim
1	aminopeptidase	_	_	I-Claim
2	2	_	_	I-Claim
3	(	_	_	I-Claim
4	MetAP2	_	_	I-Claim
5	)	_	_	I-Claim
6	inhibition	_	_	I-Claim
7	has	_	_	I-Claim
8	been	_	_	I-Claim
9	shown	_	_	I-Claim
10	to	_	_	I-Claim
11	result	_	_	I-Claim
12	in	_	_	I-Claim
13	significant	_	_	I-Claim
14	weight	_	_	I-Claim
15	loss	_	_	I-Claim
16	and	_	_	I-Claim
17	improved	_	_	I-Claim
18	glucose	_	_	I-Claim
19	control	_	_	I-Claim
20	.	_	_	I-Claim

21	This	_	_	O
22	Phase	_	_	O
23	1	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	assessed	_	_	O
27	the	_	_	O
28	safety	_	_	O
29	and	_	_	O
30	tolerability	_	_	O
31	,	_	_	O
32	pharmacokinetics	_	_	O
33	,	_	_	O
34	and	_	_	O
35	preliminary	_	_	O
36	efficacy	_	_	O
37	of	_	_	O
38	a	_	_	O
39	novel	_	_	O
40	MetAP2	_	_	O
41	inhibitor	_	_	O
42	,	_	_	O
43	ZGN-1061	_	_	O
44	.	_	_	O

45	This	_	_	O
46	clinical	_	_	O
47	trial	_	_	O
48	included	_	_	O
49	a	_	_	O
50	single	_	_	O
51	ascending	_	_	O
52	dose	_	_	O
53	(	_	_	O
54	SAD	_	_	O
55	)	_	_	O
56	phase	_	_	O
57	in	_	_	O
58	healthy	_	_	O
59	subjects	_	_	O
60	(	_	_	O
61	BMI	_	_	O
62	23	_	_	O
63	to	_	_	O
64	<	_	_	O
65	30	_	_	O
66	kg/m2	_	_	O
67	)	_	_	O
68	and	_	_	O
69	a	_	_	O
70	multiple	_	_	O
71	ascending	_	_	O
72	dose	_	_	O
73	(	_	_	O
74	MAD	_	_	O
75	)	_	_	O
76	phase	_	_	O
77	in	_	_	O
78	otherwise	_	_	O
79	healthy	_	_	O
80	subjects	_	_	O
81	with	_	_	O
82	BMI	_	_	O
83	27	_	_	O
84	to	_	_	O
85	40	_	_	O
86	kg/m2	_	_	O
87	.	_	_	O

88	SAD	_	_	O
89	phase	_	_	O
90	doses	_	_	O
91	,	_	_	O
92	administered	_	_	O
93	subcutaneously	_	_	O
94	(	_	_	O
95	SC	_	_	O
96	)	_	_	O
97	were	_	_	O
98	0.2	_	_	O
99	,	_	_	O
100	0.6	_	_	O
101	,	_	_	O
102	1.2	_	_	O
103	,	_	_	O
104	2.4	_	_	O
105	,	_	_	O
106	3.6	_	_	O
107	,	_	_	O
108	and	_	_	O
109	4.8	_	_	O
110	mg	_	_	O
111	,	_	_	O
112	and	_	_	O
113	MAD	_	_	O
114	phase	_	_	O
115	evaluated	_	_	O
116	0.2	_	_	O
117	,	_	_	O
118	0.6	_	_	O
119	,	_	_	O
120	and	_	_	O
121	1.8	_	_	O
122	mg	_	_	O
123	twice	_	_	O
124	weekly	_	_	O
125	SC	_	_	O
126	for	_	_	O
127	4	_	_	O
128	weeks	_	_	O
129	.	_	_	O

130	SAD	_	_	O
131	phase	_	_	O
132	included	_	_	O
133	39	_	_	O
134	subjects	_	_	O
135	(	_	_	O
136	ZGN-1061	_	_	O
137	N=28	_	_	O
138	,	_	_	O
139	placebo	_	_	O
140	N=11	_	_	O
141	)	_	_	O
142	,	_	_	O
143	90	_	_	O
144	%	_	_	O
145	male	_	_	O
146	and	_	_	O
147	BMI	_	_	O
148	26.4	_	_	O
149	kg/m2	_	_	O
150	.	_	_	O

151	ZGN-1061	_	_	B-Premise
152	was	_	_	I-Premise
153	well	_	_	I-Premise
154	tolerated	_	_	I-Premise
155	across	_	_	I-Premise
156	all	_	_	I-Premise
157	doses	_	_	I-Premise
158	with	_	_	I-Premise
159	most	_	_	I-Premise
160	frequent	_	_	I-Premise
161	adverse	_	_	I-Premise
162	events	_	_	I-Premise
163	of	_	_	I-Premise
164	mild	_	_	I-Premise
165	headache	_	_	I-Premise
166	and	_	_	I-Premise
167	procedural-related	_	_	I-Premise
168	irritation	_	_	I-Premise
169	.	_	_	I-Premise

170	There	_	_	O
171	were	_	_	O
172	no	_	_	O
173	severe	_	_	O
174	or	_	_	O
175	serious	_	_	O
176	adverse	_	_	O
177	events	_	_	O
178	.	_	_	O

179	All	_	_	B-Premise
180	doses	_	_	I-Premise
181	of	_	_	I-Premise
182	ZGN-1061	_	_	I-Premise
183	were	_	_	I-Premise
184	rapidly	_	_	I-Premise
185	absorbed	_	_	I-Premise
186	and	_	_	I-Premise
187	cleared	_	_	I-Premise
188	,	_	_	I-Premise
189	resulting	_	_	I-Premise
190	in	_	_	I-Premise
191	short	_	_	I-Premise
192	duration	_	_	I-Premise
193	of	_	_	I-Premise
194	exposure	_	_	I-Premise
195	that	_	_	I-Premise
196	is	_	_	I-Premise
197	anticipated	_	_	I-Premise
198	to	_	_	I-Premise
199	minimize	_	_	I-Premise
200	potential	_	_	I-Premise
201	off-drug	_	_	I-Premise
202	target	_	_	I-Premise
203	risks	_	_	I-Premise
204	.	_	_	I-Premise

205	The	_	_	O
206	MAD	_	_	O
207	phase	_	_	O
208	included	_	_	O
209	29	_	_	O
210	subjects	_	_	O
211	(	_	_	O
212	ZGN-1061	_	_	O
213	N=22	_	_	O
214	,	_	_	O
215	placebo	_	_	O
216	N=7	_	_	O
217	)	_	_	O
218	,	_	_	O
219	76	_	_	O
220	%	_	_	O
221	male	_	_	O
222	and	_	_	O
223	BMI	_	_	O
224	33.5	_	_	O
225	kg/m2	_	_	O
226	.	_	_	O

227	Safety	_	_	B-Premise
228	observations	_	_	I-Premise
229	were	_	_	I-Premise
230	consistent	_	_	I-Premise
231	with	_	_	I-Premise
232	SAD	_	_	I-Premise
233	findings	_	_	I-Premise
234	.	_	_	I-Premise

235	Efficacy	_	_	B-Premise
236	measures	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	MAD	_	_	I-Premise
240	phase	_	_	I-Premise
241	indicated	_	_	I-Premise
242	trends	_	_	I-Premise
243	for	_	_	I-Premise
244	weight	_	_	I-Premise
245	change	_	_	I-Premise
246	(	_	_	I-Premise
247	-1.5	_	_	I-Premise
248	kg	_	_	I-Premise
249	total	_	_	I-Premise
250	ZGN-1061	_	_	I-Premise
251	vs	_	_	I-Premise
252	-0.2	_	_	I-Premise
253	kg	_	_	I-Premise
254	placebo	_	_	I-Premise
255	)	_	_	I-Premise
256	and	_	_	I-Premise
257	other	_	_	I-Premise
258	biomarker	_	_	I-Premise
259	changes	_	_	I-Premise
260	.	_	_	I-Premise

261	ZGN-1061	_	_	B-Claim
262	was	_	_	I-Claim
263	well	_	_	I-Claim
264	tolerated	_	_	I-Claim
265	with	_	_	I-Claim
266	no	_	_	I-Claim
267	safety	_	_	I-Claim
268	signals	_	_	I-Claim
269	in	_	_	I-Claim
270	all	_	_	I-Claim
271	doses	_	_	I-Claim
272	tested	_	_	I-Claim
273	.	_	_	I-Claim

274	In	_	_	O
275	addition	_	_	O
276	,	_	_	O
277	the	_	_	B-Claim
278	desired	_	_	I-Claim
279	pharmacokinetic	_	_	I-Claim
280	profile	_	_	I-Claim
281	and	_	_	I-Claim
282	preliminary	_	_	I-Claim
283	efficacy	_	_	I-Claim
284	observations	_	_	I-Claim
285	with	_	_	I-Claim
286	ZGN-1061	_	_	I-Claim
287	support	_	_	I-Claim
288	evaluation	_	_	I-Claim
289	in	_	_	I-Claim
290	larger	_	_	I-Claim
291	and	_	_	I-Claim
292	longer	_	_	I-Claim
293	clinical	_	_	I-Claim
294	trials	_	_	I-Claim
295	.	_	_	I-Claim


0	The	_	_	O
1	REVEAL	_	_	O
2	risk	_	_	O
3	score	_	_	O
4	(	_	_	O
5	RRS	_	_	O
6	)	_	_	O
7	was	_	_	O
8	developed	_	_	O
9	to	_	_	O
10	predict	_	_	O
11	survival	_	_	O
12	in	_	_	O
13	patients	_	_	O
14	with	_	_	O
15	pulmonary	_	_	O
16	arterial	_	_	O
17	hypertension	_	_	O
18	(	_	_	O
19	PAH	_	_	O
20	)	_	_	O
21	,	_	_	O
22	based	_	_	O
23	on	_	_	O
24	multiple	_	_	O
25	patient	_	_	O
26	characteristics	_	_	O
27	.	_	_	O

28	Herein	_	_	O
29	we	_	_	O
30	calculated	_	_	O
31	RRS	_	_	O
32	for	_	_	O
33	patients	_	_	O
34	in	_	_	O
35	the	_	_	O
36	randomized	_	_	O
37	CHEST-1	_	_	O
38	study	_	_	O
39	and	_	_	O
40	open-label	_	_	O
41	CHEST-2	_	_	O
42	extension	_	_	O
43	study	_	_	O
44	of	_	_	O
45	riociguat	_	_	O
46	in	_	_	O
47	inoperable	_	_	O
48	or	_	_	O
49	persistent/recurrent	_	_	O
50	chronic	_	_	O
51	thromboembolic	_	_	O
52	pulmonary	_	_	O
53	hypertension	_	_	O
54	(	_	_	O
55	CTEPH	_	_	O
56	)	_	_	O
57	.	_	_	O

58	We	_	_	O
59	investigated	_	_	O
60	the	_	_	O
61	effect	_	_	O
62	of	_	_	O
63	riociguat	_	_	O
64	vs	_	_	O
65	placebo	_	_	O
66	on	_	_	O
67	RRS	_	_	O
68	in	_	_	O
69	the	_	_	O
70	CHEST-1	_	_	O
71	study	_	_	O
72	,	_	_	O
73	and	_	_	O
74	the	_	_	O
75	relationship	_	_	O
76	between	_	_	O
77	RRS	_	_	O
78	and	_	_	O
79	long-term	_	_	O
80	outcomes	_	_	O
81	in	_	_	O
82	the	_	_	O
83	CHEST-2	_	_	O
84	study	_	_	O
85	.	_	_	O

86	RRS	_	_	O
87	was	_	_	O
88	calculated	_	_	O
89	post	_	_	O
90	hoc	_	_	O
91	for	_	_	O
92	baseline	_	_	O
93	and	_	_	O
94	Week	_	_	O
95	16	_	_	O
96	of	_	_	O
97	CHEST-1	_	_	O
98	and	_	_	O
99	Week	_	_	O
100	12	_	_	O
101	of	_	_	O
102	CHEST-2	_	_	O
103	,	_	_	O
104	based	_	_	O
105	on	_	_	O
106	9	_	_	O
107	evaluable	_	_	O
108	elements	_	_	O
109	.	_	_	O

110	Patients	_	_	O
111	were	_	_	O
112	grouped	_	_	O
113	into	_	_	O
114	risk	_	_	O
115	strata	_	_	O
116	by	_	_	O
117	RRS	_	_	O
118	.	_	_	O

119	Relationships	_	_	O
120	between	_	_	O
121	RRS	_	_	O
122	and	_	_	O
123	both	_	_	O
124	survival	_	_	O
125	and	_	_	O
126	clinical	_	_	O
127	worsening-free	_	_	O
128	survival	_	_	O
129	were	_	_	O
130	examined	_	_	O
131	by	_	_	O
132	Kaplan-Meier	_	_	O
133	and	_	_	O
134	Cox	_	_	O
135	proportional	_	_	O
136	hazards	_	_	O
137	analyses	_	_	O
138	.	_	_	O

139	Overall	_	_	O
140	,	_	_	O
141	237	_	_	O
142	patients	_	_	O
143	completed	_	_	O
144	CHEST-1	_	_	O
145	and	_	_	O
146	entered	_	_	O
147	CHEST-2	_	_	O
148	.	_	_	O

149	In	_	_	B-Premise
150	CHEST-1	_	_	I-Premise
151	,	_	_	I-Premise
152	riociguat	_	_	I-Premise
153	significantly	_	_	I-Premise
154	improved	_	_	I-Premise
155	RRS	_	_	I-Premise
156	(	_	_	I-Premise
157	p	_	_	I-Premise
158	<	_	_	I-Premise
159	0.0001	_	_	I-Premise
160	)	_	_	I-Premise
161	and	_	_	I-Premise
162	risk	_	_	I-Premise
163	stratum	_	_	I-Premise
164	(	_	_	I-Premise
165	p	_	_	I-Premise
166	<	_	_	I-Premise
167	0.001	_	_	I-Premise
168	)	_	_	I-Premise
169	vs	_	_	I-Premise
170	placebo	_	_	I-Premise
171	from	_	_	I-Premise
172	baseline	_	_	I-Premise
173	to	_	_	I-Premise
174	Week	_	_	I-Premise
175	16	_	_	I-Premise
176	.	_	_	I-Premise

177	RRS	_	_	B-Premise
178	at	_	_	I-Premise
179	baseline	_	_	I-Premise
180	,	_	_	I-Premise
181	and	_	_	I-Premise
182	at	_	_	I-Premise
183	Week	_	_	I-Premise
184	16	_	_	I-Premise
185	,	_	_	I-Premise
186	and	_	_	I-Premise
187	change	_	_	I-Premise
188	in	_	_	I-Premise
189	RRS	_	_	I-Premise
190	during	_	_	I-Premise
191	CHEST-1	_	_	I-Premise
192	were	_	_	I-Premise
193	significantly	_	_	I-Premise
194	associated	_	_	I-Premise
195	with	_	_	I-Premise
196	survival	_	_	I-Premise
197	(	_	_	I-Premise
198	hazard	_	_	I-Premise
199	ratios	_	_	I-Premise
200	for	_	_	I-Premise
201	a	_	_	I-Premise
202	1-point	_	_	I-Premise
203	reduction	_	_	I-Premise
204	in	_	_	I-Premise
205	RRS	_	_	I-Premise
206	:	_	_	I-Premise
207	0.702	_	_	I-Premise
208	,	_	_	I-Premise
209	0.692	_	_	I-Premise
210	,	_	_	I-Premise
211	and	_	_	I-Premise
212	0.682	_	_	I-Premise
213	,	_	_	I-Premise
214	respectively	_	_	I-Premise
215	)	_	_	I-Premise
216	and	_	_	I-Premise
217	clinical	_	_	I-Premise
218	worsening-free	_	_	I-Premise
219	survival	_	_	I-Premise
220	(	_	_	I-Premise
221	hazard	_	_	I-Premise
222	ratios	_	_	I-Premise
223	:	_	_	I-Premise
224	0.697	_	_	I-Premise
225	,	_	_	I-Premise
226	0.719	_	_	I-Premise
227	,	_	_	I-Premise
228	and	_	_	I-Premise
229	0.754	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	)	_	_	I-Premise
233	over	_	_	I-Premise
234	2	_	_	I-Premise
235	years	_	_	I-Premise
236	in	_	_	I-Premise
237	CHEST-2	_	_	I-Premise
238	.	_	_	I-Premise

239	Riociguat	_	_	B-Premise
240	improved	_	_	I-Premise
241	RRS	_	_	I-Premise
242	in	_	_	I-Premise
243	patients	_	_	I-Premise
244	with	_	_	I-Premise
245	inoperable	_	_	I-Premise
246	and	_	_	I-Premise
247	persistent/recurrent	_	_	I-Premise
248	CTEPH	_	_	I-Premise
249	.	_	_	I-Premise

250	RRS	_	_	B-Premise
251	at	_	_	I-Premise
252	baseline	_	_	I-Premise
253	and	_	_	I-Premise
254	Week	_	_	I-Premise
255	16	_	_	I-Premise
256	,	_	_	I-Premise
257	and	_	_	I-Premise
258	change	_	_	I-Premise
259	in	_	_	I-Premise
260	RRS	_	_	I-Premise
261	from	_	_	I-Premise
262	baseline	_	_	I-Premise
263	,	_	_	I-Premise
264	predicted	_	_	I-Premise
265	survival	_	_	I-Premise
266	and	_	_	I-Premise
267	clinical	_	_	I-Premise
268	worsening-free	_	_	I-Premise
269	survival	_	_	I-Premise
270	.	_	_	I-Premise

271	This	_	_	B-Claim
272	analysis	_	_	I-Claim
273	of	_	_	I-Claim
274	RRS	_	_	I-Claim
275	in	_	_	I-Claim
276	patients	_	_	I-Claim
277	with	_	_	I-Claim
278	inoperable	_	_	I-Claim
279	or	_	_	I-Claim
280	persistent/recurrent	_	_	I-Claim
281	CTEPH	_	_	I-Claim
282	suggests	_	_	I-Claim
283	utility	_	_	I-Claim
284	for	_	_	I-Claim
285	the	_	_	I-Claim
286	RRS	_	_	I-Claim
287	in	_	_	I-Claim
288	indications	_	_	I-Claim
289	beyond	_	_	I-Claim
290	PAH	_	_	I-Claim
291	.	_	_	I-Claim


0	Cardiovascular	_	_	B-Claim
1	complications	_	_	I-Claim
2	are	_	_	I-Claim
3	one	_	_	I-Claim
4	of	_	_	I-Claim
5	main	_	_	I-Claim
6	cause	_	_	I-Claim
7	of	_	_	I-Claim
8	increased	_	_	I-Claim
9	mortality	_	_	I-Claim
10	and	_	_	I-Claim
11	morbidity	_	_	I-Claim
12	among	_	_	I-Claim
13	Diabetes	_	_	I-Claim
14	Mellitus	_	_	I-Claim
15	(	_	_	I-Claim
16	DM	_	_	I-Claim
17	)	_	_	I-Claim
18	patients	_	_	I-Claim
19	.	_	_	I-Claim

20	Altered	_	_	B-Claim
21	metabolism	_	_	I-Claim
22	of	_	_	I-Claim
23	sulphur	_	_	I-Claim
24	amino	_	_	I-Claim
25	acids	_	_	I-Claim
26	in	_	_	I-Claim
27	diabetes	_	_	I-Claim
28	reflected	_	_	I-Claim
29	as	_	_	I-Claim
30	increases	_	_	I-Claim
31	in	_	_	I-Claim
32	concentration	_	_	I-Claim
33	of	_	_	I-Claim
34	methionine	_	_	I-Claim
35	and	_	_	I-Claim
36	cysteine/cystine	_	_	I-Claim
37	in	_	_	I-Claim
38	the	_	_	I-Claim
39	blood	_	_	I-Claim
40	which	_	_	I-Claim
41	known	_	_	I-Claim
42	as	_	_	I-Claim
43	a	_	_	I-Claim
44	markers	_	_	I-Claim
45	of	_	_	I-Claim
46	Cardiovascular	_	_	I-Claim
47	Diseases	_	_	I-Claim
48	(	_	_	I-Claim
49	CVD	_	_	I-Claim
50	)	_	_	I-Claim
51	.	_	_	I-Claim

52	The	_	_	O
53	aim	_	_	O
54	of	_	_	O
55	present	_	_	O
56	study	_	_	O
57	was	_	_	O
58	to	_	_	O
59	determine	_	_	O
60	the	_	_	O
61	effect	_	_	O
62	of	_	_	O
63	Eicosapentaenoic	_	_	O
64	acid	_	_	O
65	(	_	_	O
66	EPA	_	_	O
67	)	_	_	O
68	supplementation	_	_	O
69	on	_	_	O
70	sulfhydryl	_	_	O
71	amino	_	_	O
72	acids	_	_	O
73	and	_	_	O
74	Atherogenic	_	_	O
75	Index	_	_	O
76	of	_	_	O
77	Plasma	_	_	O
78	(	_	_	O
79	AIP	_	_	O
80	)	_	_	O
81	in	_	_	O
82	patients	_	_	O
83	with	_	_	O
84	type	_	_	O
85	2	_	_	O
86	DM	_	_	O
87	(	_	_	O
88	T2DM	_	_	O
89	)	_	_	O
90	.	_	_	O

91	A	_	_	O
92	randomized	_	_	O
93	,	_	_	O
94	double-blind	_	_	O
95	,	_	_	O
96	placebo-controlled	_	_	O
97	clinical	_	_	O
98	trial	_	_	O
99	was	_	_	O
100	performed	_	_	O
101	in	_	_	O
102	36	_	_	O
103	control	_	_	O
104	and	_	_	O
105	patients	_	_	O
106	with	_	_	O
107	DM	_	_	O
108	.	_	_	O

109	The	_	_	O
110	subjects	_	_	O
111	were	_	_	O
112	randomly	_	_	O
113	assigned	_	_	O
114	to	_	_	O
115	obtain	_	_	O
116	2	_	_	O
117	g/d	_	_	O
118	EPA	_	_	O
119	(	_	_	O
120	n	_	_	O
121	=	_	_	O
122	18	_	_	O
123	)	_	_	O
124	or	_	_	O
125	placebo	_	_	O
126	(	_	_	O
127	n	_	_	O
128	=	_	_	O
129	18	_	_	O
130	)	_	_	O
131	for	_	_	O
132	8	_	_	O
133	weeks	_	_	O
134	.	_	_	O

135	Fasting	_	_	O
136	serum	_	_	O
137	level	_	_	O
138	of	_	_	O
139	Cystein	_	_	O
140	and	_	_	O
141	Methionine	_	_	O
142	were	_	_	O
143	measured	_	_	O
144	using	_	_	O
145	HPLC	_	_	O
146	method	_	_	O
147	and	_	_	O
148	atherogenic	_	_	O
149	index	_	_	O
150	of	_	_	O
151	plasma	_	_	O
152	(	_	_	O
153	AIP	_	_	O
154	)	_	_	O
155	as	_	_	O
156	a	_	_	O
157	proxy	_	_	O
158	measure	_	_	O
159	of	_	_	O
160	atherosclerosis	_	_	O
161	was	_	_	O
162	computed	_	_	O
163	.	_	_	O

164	Eight	_	_	B-Premise
165	weeks	_	_	I-Premise
166	supplementation	_	_	I-Premise
167	with	_	_	I-Premise
168	EPA	_	_	I-Premise
169	led	_	_	I-Premise
170	to	_	_	I-Premise
171	significant	_	_	I-Premise
172	reductions	_	_	I-Premise
173	in	_	_	I-Premise
174	Met	_	_	I-Premise
175	(	_	_	I-Premise
176	p	_	_	I-Premise
177	<	_	_	I-Premise
178	0.002	_	_	I-Premise
179	)	_	_	I-Premise
180	and	_	_	I-Premise
181	Cys	_	_	I-Premise
182	(	_	_	I-Premise
183	p	_	_	I-Premise
184	<	_	_	I-Premise
185	0.001	_	_	I-Premise
186	)	_	_	I-Premise
187	compared	_	_	I-Premise
188	with	_	_	I-Premise
189	the	_	_	I-Premise
190	placebo	_	_	I-Premise
191	(	_	_	I-Premise
192	p	_	_	I-Premise
193	<	_	_	I-Premise
194	0.06	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	In	_	_	O
198	addition	_	_	O
199	,	_	_	O
200	compared	_	_	B-Premise
201	to	_	_	I-Premise
202	placebo	_	_	I-Premise
203	a	_	_	I-Premise
204	significant	_	_	I-Premise
205	reduction	_	_	I-Premise
206	in	_	_	I-Premise
207	AIP	_	_	I-Premise
208	were	_	_	I-Premise
209	seen	_	_	I-Premise
210	after	_	_	I-Premise
211	taking	_	_	I-Premise
212	EPA	_	_	I-Premise
213	(	_	_	I-Premise
214	p	_	_	I-Premise
215	<	_	_	I-Premise
216	0.04	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	EPA	_	_	B-Claim
220	supplementation	_	_	I-Claim
221	in	_	_	I-Claim
222	patients	_	_	I-Claim
223	with	_	_	I-Claim
224	T2DM	_	_	I-Claim
225	for	_	_	I-Claim
226	eight	_	_	I-Claim
227	weeks	_	_	I-Claim
228	had	_	_	I-Claim
229	beneficial	_	_	I-Claim
230	effects	_	_	I-Claim
231	on	_	_	I-Claim
232	Met	_	_	I-Claim
233	,	_	_	I-Claim
234	Cys	_	_	I-Claim
235	and	_	_	I-Claim
236	AIP	_	_	I-Claim
237	,	_	_	I-Claim
238	which	_	_	I-Claim
239	may	_	_	I-Claim
240	attribute	_	_	I-Claim
241	to	_	_	I-Claim
242	the	_	_	I-Claim
243	prevention	_	_	I-Claim
244	of	_	_	I-Claim
245	vascular	_	_	I-Claim
246	complications	_	_	I-Claim
247	in	_	_	I-Claim
248	the	_	_	I-Claim
249	T2DM	_	_	I-Claim
250	patients	_	_	I-Claim
251	.	_	_	I-Claim


0	Adherence	_	_	O
1	to	_	_	O
2	appropriate	_	_	O
3	nutrition	_	_	O
4	and	_	_	O
5	fluid	_	_	O
6	intake	_	_	O
7	is	_	_	O
8	one	_	_	O
9	of	_	_	O
10	the	_	_	O
11	essential	_	_	O
12	parts	_	_	O
13	of	_	_	O
14	chronic	_	_	O
15	renal	_	_	O
16	failure	_	_	O
17	treatment	_	_	O
18	for	_	_	O
19	achieving	_	_	O
20	the	_	_	O
21	desirable	_	_	O
22	results	_	_	O
23	among	_	_	O
24	the	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	hemodialysis	_	_	O
28	.	_	_	O

29	Among	_	_	O
30	various	_	_	O
31	training	_	_	O
32	methods	_	_	O
33	,	_	_	O
34	the	_	_	O
35	small	_	_	O
36	groups	_	_	O
37	'	_	_	O
38	method	_	_	O
39	,	_	_	O
40	as	_	_	O
41	an	_	_	O
42	advanced	_	_	O
43	method	_	_	O
44	,	_	_	O
45	can	_	_	O
46	be	_	_	O
47	performed	_	_	O
48	by	_	_	O
49	nurses	_	_	O
50	in	_	_	O
51	achieving	_	_	O
52	desirable	_	_	O
53	therapeutic	_	_	O
54	results	_	_	O
55	.	_	_	O

56	The	_	_	O
57	present	_	_	O
58	study	_	_	O
59	was	_	_	O
60	aimed	_	_	O
61	to	_	_	O
62	investigate	_	_	O
63	the	_	_	O
64	effect	_	_	O
65	of	_	_	O
66	appropriate	_	_	O
67	nutrition	_	_	O
68	training	_	_	O
69	in	_	_	O
70	small	_	_	O
71	groups	_	_	O
72	on	_	_	O
73	laboratory	_	_	O
74	parameters	_	_	O
75	in	_	_	O
76	hemodialysis	_	_	O
77	patients	_	_	O
78	.	_	_	O

79	In	_	_	O
80	this	_	_	O
81	clinical	_	_	O
82	trial	_	_	O
83	,	_	_	O
84	64	_	_	O
85	patients	_	_	O
86	who	_	_	O
87	met	_	_	O
88	the	_	_	O
89	inclusion	_	_	O
90	criteria	_	_	O
91	were	_	_	O
92	randomly	_	_	O
93	selected	_	_	O
94	and	_	_	O
95	divided	_	_	O
96	into	_	_	O
97	an	_	_	O
98	intervention	_	_	O
99	group	_	_	O
100	and	_	_	O
101	a	_	_	O
102	control	_	_	O
103	group	_	_	O
104	.	_	_	O

105	Subsequently	_	_	O
106	,	_	_	O
107	an	_	_	O
108	appropriate	_	_	O
109	nutritional	_	_	O
110	training	_	_	O
111	program	_	_	O
112	,	_	_	O
113	including	_	_	O
114	lectures	_	_	O
115	along	_	_	O
116	with	_	_	O
117	appropriate	_	_	O
118	nutrition	_	_	O
119	pamphlets	_	_	O
120	in	_	_	O
121	three	_	_	O
122	one	_	_	O
123	hour	_	_	O
124	question	_	_	O
125	and	_	_	O
126	answer	_	_	O
127	sessions	_	_	O
128	were	_	_	O
129	performed	_	_	O
130	.	_	_	O

131	Thirty	_	_	O
132	two	_	_	O
133	patients	_	_	O
134	in	_	_	O
135	each	_	_	O
136	group	_	_	O
137	were	_	_	O
138	assigned	_	_	O
139	to	_	_	O
140	intervention	_	_	O
141	groups	_	_	O
142	of	_	_	O
143	five	_	_	O
144	.	_	_	O

145	Then	_	_	O
146	,	_	_	O
147	the	_	_	O
148	laboratory	_	_	O
149	indicators	_	_	O
150	for	_	_	O
151	each	_	_	O
152	patient	_	_	O
153	were	_	_	O
154	measured	_	_	O
155	in	_	_	O
156	each	_	_	O
157	group	_	_	O
158	one	_	_	O
159	month	_	_	O
160	after	_	_	O
161	training	_	_	O
162	.	_	_	O

163	Thereafter	_	_	O
164	,	_	_	O
165	data	_	_	O
166	analysis	_	_	O
167	was	_	_	O
168	performed	_	_	O
169	using	_	_	O
170	descriptive	_	_	O
171	and	_	_	O
172	analytical	_	_	O
173	statistics	_	_	O
174	(	_	_	O
175	statistical	_	_	O
176	tests	_	_	O
177	including	_	_	O
178	independent	_	_	O
179	t-test	_	_	O
180	,	_	_	O
181	paired	_	_	O
182	t-test	_	_	O
183	,	_	_	O
184	repeated	_	_	O
185	measures	_	_	O
186	,	_	_	O
187	and	_	_	O
188	ANOVA	_	_	O
189	)	_	_	O
190	in	_	_	O
191	SPSS	_	_	O
192	V.16	_	_	O
193	software	_	_	O
194	.	_	_	O

195	The	_	_	O
196	mean	_	_	O
197	age	_	_	O
198	of	_	_	O
199	the	_	_	O
200	patients	_	_	O
201	was	_	_	O
202	50.1	_	_	O
203	±	_	_	O
204	13.1	_	_	O
205	years	_	_	O
206	;	_	_	O
207	47.5	_	_	O
208	%	_	_	O
209	of	_	_	O
210	them	_	_	O
211	had	_	_	O
212	undergone	_	_	O
213	dialysis	_	_	O
214	due	_	_	O
215	to	_	_	O
216	hypertension	_	_	O
217	and	_	_	O
218	55.7	_	_	O
219	%	_	_	O
220	had	_	_	O
221	a	_	_	O
222	history	_	_	O
223	of	_	_	O
224	1-5	_	_	O
225	years	_	_	O
226	of	_	_	O
227	hemodialysis	_	_	O
228	.	_	_	O

229	There	_	_	B-Premise
230	was	_	_	I-Premise
231	a	_	_	I-Premise
232	significant	_	_	I-Premise
233	difference	_	_	I-Premise
234	in	_	_	I-Premise
235	post-intervention	_	_	I-Premise
236	levels	_	_	I-Premise
237	of	_	_	I-Premise
238	urea	_	_	I-Premise
239	,	_	_	I-Premise
240	creatinine	_	_	I-Premise
241	,	_	_	I-Premise
242	sodium	_	_	I-Premise
243	,	_	_	I-Premise
244	potassium	_	_	I-Premise
245	,	_	_	I-Premise
246	calcium	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	phosphorus	_	_	I-Premise
250	between	_	_	I-Premise
251	the	_	_	I-Premise
252	two	_	_	I-Premise
253	groups	_	_	I-Premise
254	.	_	_	I-Premise

255	Appropriate	_	_	B-Claim
256	nutrition	_	_	I-Claim
257	training	_	_	I-Claim
258	via	_	_	I-Claim
259	small-group	_	_	I-Claim
260	method	_	_	I-Claim
261	for	_	_	I-Claim
262	patients	_	_	I-Claim
263	on	_	_	I-Claim
264	hemodialysis	_	_	I-Claim
265	can	_	_	I-Claim
266	impose	_	_	I-Claim
267	positive	_	_	I-Claim
268	effects	_	_	I-Claim
269	on	_	_	I-Claim
270	laboratory	_	_	I-Claim
271	parameters	_	_	I-Claim
272	.	_	_	I-Claim


0	Data	_	_	O
1	are	_	_	O
2	insufficient	_	_	O
3	regarding	_	_	O
4	the	_	_	O
5	survival	_	_	O
6	benefit	_	_	O
7	of	_	_	O
8	surveillance	_	_	O
9	for	_	_	O
10	hepatocellular	_	_	O
11	carcinoma	_	_	O
12	(	_	_	O
13	HCC	_	_	O
14	)	_	_	O
15	.	_	_	O

16	To	_	_	O
17	investigate	_	_	O
18	the	_	_	O
19	effectiveness	_	_	O
20	of	_	_	O
21	HCC	_	_	O
22	surveillance	_	_	O
23	in	_	_	O
24	a	_	_	O
25	hepatitis	_	_	O
26	B-endemic	_	_	O
27	population	_	_	O
28	.	_	_	O

29	This	_	_	O
30	retrospective	_	_	O
31	cohort	_	_	O
32	study	_	_	O
33	included	_	_	O
34	1402	_	_	O
35	consecutive	_	_	O
36	patients	_	_	O
37	who	_	_	O
38	were	_	_	O
39	newly	_	_	O
40	diagnosed	_	_	O
41	with	_	_	O
42	HCC	_	_	O
43	between	_	_	O
44	2005	_	_	O
45	and	_	_	O
46	2012	_	_	O
47	at	_	_	O
48	a	_	_	O
49	single	_	_	O
50	tertiary	_	_	O
51	hospital	_	_	O
52	in	_	_	O
53	Korea	_	_	O
54	.	_	_	O

55	The	_	_	O
56	primary	_	_	O
57	endpoint	_	_	O
58	was	_	_	O
59	overall	_	_	O
60	survival	_	_	O
61	.	_	_	O

62	Lead-time	_	_	O
63	and	_	_	O
64	length-time	_	_	O
65	biases	_	_	O
66	were	_	_	O
67	adjusted	_	_	O
68	(	_	_	O
69	sojourn	_	_	O
70	time	_	_	O
71	=	_	_	O
72	140	_	_	O
73	days	_	_	O
74	)	_	_	O
75	and	_	_	O
76	sensitivity	_	_	O
77	analyses	_	_	O
78	were	_	_	O
79	performed	_	_	O
80	.	_	_	O

81	The	_	_	O
82	most	_	_	O
83	common	_	_	O
84	aetiology	_	_	O
85	was	_	_	O
86	hepatitis	_	_	O
87	B	_	_	O
88	(	_	_	O
89	80.4	_	_	O
90	%	_	_	O
91	)	_	_	O
92	.	_	_	O

93	Cirrhosis	_	_	O
94	was	_	_	O
95	present	_	_	O
96	in	_	_	O
97	78.2	_	_	O
98	%	_	_	O
99	.	_	_	O

100	HCC	_	_	O
101	was	_	_	O
102	diagnosed	_	_	O
103	during	_	_	O
104	regular	_	_	O
105	surveillance	_	_	O
106	(	_	_	O
107	defined	_	_	O
108	as	_	_	O
109	mean	_	_	O
110	interval	_	_	O
111	of	_	_	O
112	ultrasonography	_	_	O
113	<	_	_	O
114	8	_	_	O
115	months	_	_	O
116	,	_	_	O
117	n	_	_	O
118	=	_	_	O
119	834	_	_	O
120	)	_	_	O
121	,	_	_	O
122	irregular	_	_	O
123	surveillance	_	_	O
124	(	_	_	O
125	n	_	_	O
126	=	_	_	O
127	104	_	_	O
128	)	_	_	O
129	or	_	_	O
130	nonsurveillance	_	_	O
131	(	_	_	O
132	n	_	_	O
133	=	_	_	O
134	464	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Patients	_	_	B-Premise
138	in	_	_	I-Premise
139	the	_	_	I-Premise
140	regular	_	_	I-Premise
141	surveillance	_	_	I-Premise
142	group	_	_	I-Premise
143	were	_	_	I-Premise
144	diagnosed	_	_	I-Premise
145	at	_	_	I-Premise
146	earlier	_	_	I-Premise
147	stages	_	_	I-Premise
148	(	_	_	I-Premise
149	[	_	_	I-Premise
150	very	_	_	I-Premise
151	]	_	_	I-Premise
152	early	_	_	I-Premise
153	stage	_	_	I-Premise
154	,	_	_	I-Premise
155	64.4	_	_	I-Premise
156	%	_	_	I-Premise
157	)	_	_	I-Premise
158	than	_	_	I-Premise
159	the	_	_	I-Premise
160	irregular	_	_	I-Premise
161	surveillance	_	_	I-Premise
162	(	_	_	I-Premise
163	40.4	_	_	I-Premise
164	%	_	_	I-Premise
165	)	_	_	I-Premise
166	or	_	_	I-Premise
167	nonsurveillance	_	_	I-Premise
168	(	_	_	I-Premise
169	26.9	_	_	I-Premise
170	%	_	_	I-Premise
171	)	_	_	I-Premise
172	groups	_	_	I-Premise
173	and	_	_	I-Premise
174	had	_	_	I-Premise
175	more	_	_	I-Premise
176	chance	_	_	I-Premise
177	for	_	_	I-Premise
178	curative	_	_	I-Premise
179	treatments	_	_	I-Premise
180	(	_	_	I-Premise
181	52.4	_	_	I-Premise
182	%	_	_	I-Premise
183	)	_	_	I-Premise
184	than	_	_	I-Premise
185	the	_	_	I-Premise
186	irregular	_	_	I-Premise
187	surveillance	_	_	I-Premise
188	(	_	_	I-Premise
189	39.4	_	_	I-Premise
190	%	_	_	I-Premise
191	)	_	_	I-Premise
192	or	_	_	I-Premise
193	nonsurveillance	_	_	I-Premise
194	(	_	_	I-Premise
195	23.3	_	_	I-Premise
196	%	_	_	I-Premise
197	)	_	_	I-Premise
198	groups	_	_	I-Premise
199	(	_	_	I-Premise
200	all	_	_	I-Premise
201	P	_	_	I-Premise
202	<	_	_	I-Premise
203	0.001	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Mortality	_	_	B-Premise
207	risk	_	_	I-Premise
208	was	_	_	I-Premise
209	significantly	_	_	I-Premise
210	lower	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	regular	_	_	I-Premise
214	surveillance	_	_	I-Premise
215	group	_	_	I-Premise
216	(	_	_	I-Premise
217	adjusted	_	_	I-Premise
218	hazard	_	_	I-Premise
219	ratio	_	_	I-Premise
220	[	_	_	I-Premise
221	aHR	_	_	I-Premise
222	]	_	_	I-Premise
223	,	_	_	I-Premise
224	0.69	_	_	I-Premise
225	;	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	[	_	_	I-Premise
229	CI	_	_	I-Premise
230	]	_	_	I-Premise
231	,	_	_	I-Premise
232	0.57-0.83	_	_	I-Premise
233	)	_	_	I-Premise
234	but	_	_	I-Premise
235	not	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	irregular	_	_	I-Premise
239	surveillance	_	_	I-Premise
240	group	_	_	I-Premise
241	(	_	_	I-Premise
242	aHR	_	_	I-Premise
243	,	_	_	I-Premise
244	0.94	_	_	I-Premise
245	;	_	_	I-Premise
246	95	_	_	I-Premise
247	%	_	_	I-Premise
248	CI	_	_	I-Premise
249	,	_	_	I-Premise
250	0.69-1.28	_	_	I-Premise
251	)	_	_	I-Premise
252	compared	_	_	I-Premise
253	with	_	_	I-Premise
254	the	_	_	I-Premise
255	nonsurveillance	_	_	I-Premise
256	group	_	_	I-Premise
257	after	_	_	I-Premise
258	adjusting	_	_	I-Premise
259	for	_	_	I-Premise
260	confounding	_	_	I-Premise
261	factors	_	_	I-Premise
262	and	_	_	I-Premise
263	lead-time	_	_	I-Premise
264	.	_	_	I-Premise

265	When	_	_	B-Premise
266	the	_	_	I-Premise
267	subjects	_	_	I-Premise
268	were	_	_	I-Premise
269	restricted	_	_	I-Premise
270	to	_	_	I-Premise
271	cirrhotic	_	_	I-Premise
272	patients	_	_	I-Premise
273	or	_	_	I-Premise
274	Child-Pugh	_	_	I-Premise
275	class	_	_	I-Premise
276	A/B	_	_	I-Premise
277	patients	_	_	I-Premise
278	,	_	_	I-Premise
279	similar	_	_	I-Premise
280	results	_	_	I-Premise
281	were	_	_	I-Premise
282	obtained	_	_	I-Premise
283	for	_	_	I-Premise
284	mortality	_	_	I-Premise
285	risk	_	_	I-Premise
286	reduction	_	_	I-Premise
287	between	_	_	I-Premise
288	groups	_	_	I-Premise
289	.	_	_	I-Premise

290	HCC	_	_	B-Claim
291	surveillance	_	_	I-Claim
292	was	_	_	I-Claim
293	associated	_	_	I-Claim
294	with	_	_	I-Claim
295	longer	_	_	I-Claim
296	survival	_	_	I-Claim
297	owing	_	_	I-Claim
298	to	_	_	I-Claim
299	earlier	_	_	I-Claim
300	diagnosis	_	_	I-Claim
301	and	_	_	I-Claim
302	curative	_	_	I-Claim
303	treatment	_	_	I-Claim
304	.	_	_	I-Claim

305	Survival	_	_	B-Claim
306	advantage	_	_	I-Claim
307	was	_	_	I-Claim
308	significant	_	_	I-Claim
309	with	_	_	I-Claim
310	regular	_	_	I-Claim
311	surveillance	_	_	I-Claim
312	but	_	_	I-Claim
313	not	_	_	I-Claim
314	with	_	_	I-Claim
315	irregular	_	_	I-Claim
316	surveillance	_	_	I-Claim
317	.	_	_	I-Claim


0	Evidence	_	_	B-Claim
1	has	_	_	I-Claim
2	shown	_	_	I-Claim
3	that	_	_	I-Claim
4	long-term	_	_	I-Claim
5	sodium	_	_	I-Claim
6	reduction	_	_	I-Claim
7	can	_	_	I-Claim
8	not	_	_	I-Claim
9	only	_	_	I-Claim
10	reduce	_	_	I-Claim
11	blood	_	_	I-Claim
12	pressure	_	_	I-Claim
13	,	_	_	I-Claim
14	but	_	_	I-Claim
15	also	_	_	I-Claim
16	provide	_	_	I-Claim
17	cardiovascular	_	_	I-Claim
18	benefits	_	_	I-Claim
19	.	_	_	I-Claim

20	To	_	_	O
21	date	_	_	O
22	,	_	_	O
23	there	_	_	O
24	is	_	_	O
25	little	_	_	O
26	evidence	_	_	O
27	related	_	_	O
28	to	_	_	O
29	the	_	_	O
30	effects	_	_	O
31	of	_	_	O
32	salt	_	_	O
33	reduction	_	_	O
34	on	_	_	O
35	isolated	_	_	O
36	systolic	_	_	O
37	hypertension	_	_	O
38	(	_	_	O
39	ISH	_	_	O
40	)	_	_	O
41	.A	_	_	O
42	total	_	_	O
43	of	_	_	O
44	126	_	_	O
45	hypertensive	_	_	O
46	patients	_	_	O
47	were	_	_	O
48	divided	_	_	O
49	into	_	_	O
50	an	_	_	O
51	ISH	_	_	O
52	group	_	_	O
53	(	_	_	O
54	n	_	_	O
55	=	_	_	O
56	51	_	_	O
57	)	_	_	O
58	and	_	_	O
59	a	_	_	O
60	non-ISH	_	_	O
61	(	_	_	O
62	NISH	_	_	O
63	)	_	_	O
64	group	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	75	_	_	O
69	)	_	_	O
70	.	_	_	O

71	The	_	_	O
72	members	_	_	O
73	of	_	_	O
74	each	_	_	O
75	group	_	_	O
76	were	_	_	O
77	then	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	low	_	_	O
82	sodium	_	_	O
83	salt	_	_	O
84	(	_	_	O
85	LSSalt	_	_	O
86	)	_	_	O
87	or	_	_	O
88	normal	_	_	O
89	salt	_	_	O
90	(	_	_	O
91	NSalt	_	_	O
92	)	_	_	O
93	diets	_	_	O
94	for	_	_	O
95	6	_	_	O
96	months	_	_	O
97	.	_	_	O

98	Their	_	_	O
99	blood	_	_	O
100	pressure	_	_	O
101	was	_	_	O
102	measured	_	_	O
103	every	_	_	O
104	2	_	_	O
105	months	_	_	O
106	.	_	_	O

107	Serum	_	_	O
108	plasma	_	_	O
109	renin-angiotensin	_	_	O
110	activity	_	_	O
111	,	_	_	O
112	blood	_	_	O
113	biochemical	_	_	O
114	assays	_	_	O
115	and	_	_	O
116	urinary	_	_	O
117	measurements	_	_	O
118	were	_	_	O
119	determined	_	_	O
120	at	_	_	O
121	the	_	_	O
122	baseline	_	_	O
123	and	_	_	O
124	at	_	_	O
125	the	_	_	O
126	end	_	_	O
127	of	_	_	O
128	the	_	_	O
129	6	_	_	O
130	months	_	_	O
131	.	_	_	O

132	At	_	_	B-Premise
133	the	_	_	I-Premise
134	end	_	_	I-Premise
135	of	_	_	I-Premise
136	the	_	_	I-Premise
137	study	_	_	I-Premise
138	,	_	_	I-Premise
139	the	_	_	I-Premise
140	mean	_	_	I-Premise
141	systolic	_	_	I-Premise
142	blood	_	_	I-Premise
143	pressure	_	_	I-Premise
144	(	_	_	I-Premise
145	SBP	_	_	I-Premise
146	)	_	_	I-Premise
147	of	_	_	I-Premise
148	the	_	_	I-Premise
149	ISH	_	_	I-Premise
150	LSSalt	_	_	I-Premise
151	group	_	_	I-Premise
152	had	_	_	I-Premise
153	significantly	_	_	I-Premise
154	decreased	_	_	I-Premise
155	by	_	_	I-Premise
156	10.18	_	_	I-Premise
157	mm	_	_	I-Premise
158	Hg	_	_	I-Premise
159	(	_	_	I-Premise
160	95	_	_	I-Premise
161	%	_	_	I-Premise
162	confidence	_	_	I-Premise
163	interval	_	_	I-Premise
164	(	_	_	I-Premise
165	CI	_	_	I-Premise
166	)	_	_	I-Premise
167	:	_	_	I-Premise
168	3.13	_	_	I-Premise
169	to	_	_	I-Premise
170	17.2	_	_	I-Premise
171	,	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.006	_	_	I-Premise
175	)	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	that	_	_	I-Premise
179	of	_	_	I-Premise
180	the	_	_	I-Premise
181	ISH	_	_	I-Premise
182	NSalt	_	_	I-Premise
183	group	_	_	I-Premise
184	,	_	_	I-Premise
185	while	_	_	O
186	the	_	_	B-Premise
187	mean	_	_	I-Premise
188	SBP	_	_	I-Premise
189	only	_	_	I-Premise
190	decreased	_	_	I-Premise
191	by	_	_	I-Premise
192	5.10	_	_	I-Premise
193	mm	_	_	I-Premise
194	Hg	_	_	I-Premise
195	(	_	_	I-Premise
196	95	_	_	I-Premise
197	%	_	_	I-Premise
198	CI	_	_	I-Premise
199	:	_	_	I-Premise
200	-2.02	_	_	I-Premise
201	to	_	_	I-Premise
202	12.2	_	_	I-Premise
203	,	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	.158	_	_	I-Premise
207	)	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	NISH	_	_	I-Premise
211	LSSalt	_	_	I-Premise
212	group	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	that	_	_	I-Premise
216	of	_	_	I-Premise
217	the	_	_	I-Premise
218	NISH	_	_	I-Premise
219	NSalt	_	_	I-Premise
220	group	_	_	I-Premise
221	.	_	_	I-Premise

222	The	_	_	B-Premise
223	mean	_	_	I-Premise
224	diastolic	_	_	I-Premise
225	blood	_	_	I-Premise
226	pressure	_	_	I-Premise
227	(	_	_	I-Premise
228	DBP	_	_	I-Premise
229	)	_	_	I-Premise
230	had	_	_	I-Premise
231	no	_	_	I-Premise
232	significant	_	_	I-Premise
233	differences	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	ISH	_	_	I-Premise
237	and	_	_	I-Premise
238	NISH	_	_	I-Premise
239	groups	_	_	I-Premise
240	.	_	_	I-Premise

241	No	_	_	B-Premise
242	obvious	_	_	I-Premise
243	renin	_	_	I-Premise
244	angiotensin	_	_	I-Premise
245	system	_	_	I-Premise
246	activation	_	_	I-Premise
247	was	_	_	I-Premise
248	found	_	_	I-Premise
249	after	_	_	I-Premise
250	LSSalt	_	_	I-Premise
251	intervention	_	_	I-Premise
252	.	_	_	I-Premise

253	Regarding	_	_	B-Premise
254	the	_	_	I-Premise
255	urinary	_	_	I-Premise
256	excretion	_	_	I-Premise
257	of	_	_	I-Premise
258	electrolytes	_	_	I-Premise
259	and	_	_	I-Premise
260	blood	_	_	I-Premise
261	biochemical	_	_	I-Premise
262	assays	_	_	I-Premise
263	,	_	_	I-Premise
264	the	_	_	I-Premise
265	LSSalt	_	_	I-Premise
266	treatment	_	_	I-Premise
267	had	_	_	I-Premise
268	the	_	_	I-Premise
269	same	_	_	I-Premise
270	effects	_	_	I-Premise
271	on	_	_	I-Premise
272	the	_	_	I-Premise
273	ISH	_	_	I-Premise
274	group	_	_	I-Premise
275	as	_	_	I-Premise
276	on	_	_	I-Premise
277	the	_	_	I-Premise
278	NISH	_	_	I-Premise
279	group	_	_	I-Premise
280	.	_	_	I-Premise

281	The	_	_	B-Claim
282	present	_	_	I-Claim
283	study	_	_	I-Claim
284	showed	_	_	I-Claim
285	that	_	_	I-Claim
286	the	_	_	I-Claim
287	SBP	_	_	I-Claim
288	of	_	_	I-Claim
289	ISH	_	_	I-Claim
290	patients	_	_	I-Claim
291	was	_	_	I-Claim
292	significantly	_	_	I-Claim
293	decreased	_	_	I-Claim
294	with	_	_	I-Claim
295	the	_	_	I-Claim
296	LSSalt	_	_	I-Claim
297	intervention	_	_	I-Claim
298	,	_	_	I-Claim
299	while	_	_	O
300	neither	_	_	B-Claim
301	the	_	_	I-Claim
302	SBP	_	_	I-Claim
303	of	_	_	I-Claim
304	the	_	_	I-Claim
305	NISH	_	_	I-Claim
306	patients	_	_	I-Claim
307	nor	_	_	I-Claim
308	the	_	_	I-Claim
309	DBP	_	_	I-Claim
310	of	_	_	I-Claim
311	either	_	_	I-Claim
312	group	_	_	I-Claim
313	were	_	_	I-Claim
314	similarly	_	_	I-Claim
315	decreased	_	_	I-Claim
316	,	_	_	I-Claim
317	which	_	_	I-Claim
318	indicated	_	_	I-Claim
319	that	_	_	I-Claim
320	ISH	_	_	I-Claim
321	patients	_	_	I-Claim
322	were	_	_	I-Claim
323	more	_	_	I-Claim
324	sensitive	_	_	I-Claim
325	to	_	_	I-Claim
326	salt	_	_	I-Claim
327	restriction	_	_	I-Claim
328	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	blood	_	_	O
3	pressure	_	_	O
4	and	_	_	O
5	urine	_	_	O
6	albumin-creatinine	_	_	O
7	ratio	_	_	O
8	over	_	_	O
9	time	_	_	O
10	for	_	_	O
11	participants	_	_	O
12	receiving	_	_	O
13	aflibercept	_	_	O
14	,	_	_	O
15	bevacizumab	_	_	O
16	,	_	_	O
17	or	_	_	O
18	ranibizumab	_	_	O
19	.	_	_	O

20	Preplanned	_	_	O
21	secondary	_	_	O
22	analyses	_	_	O
23	from	_	_	O
24	a	_	_	O
25	randomized	_	_	O
26	trial	_	_	O
27	comparing	_	_	O
28	aflibercept	_	_	O
29	,	_	_	O
30	bevacizumab	_	_	O
31	,	_	_	O
32	and	_	_	O
33	ranibizumab	_	_	O
34	for	_	_	O
35	diabetic	_	_	O
36	macular	_	_	O
37	edema	_	_	O
38	(	_	_	O
39	DME	_	_	O
40	)	_	_	O
41	.	_	_	O

42	The	_	_	O
43	Diabetic	_	_	O
44	Retinopathy	_	_	O
45	Clinical	_	_	O
46	Research	_	_	O
47	Network	_	_	O
48	(	_	_	O
49	DRCR.net	_	_	O
50	)	_	_	O
51	enrolled	_	_	O
52	660	_	_	O
53	participants	_	_	O
54	with	_	_	O
55	DME	_	_	O
56	and	_	_	O
57	visual	_	_	O
58	acuity	_	_	O
59	20/32	_	_	O
60	or	_	_	O
61	worse	_	_	O
62	in	_	_	O
63	at	_	_	O
64	least	_	_	O
65	one	_	_	O
66	eye	_	_	O
67	.	_	_	O

68	Eyes	_	_	O
69	received	_	_	O
70	intravitreous	_	_	O
71	injections	_	_	O
72	of	_	_	O
73	2.0	_	_	O
74	mg	_	_	O
75	aflibercept	_	_	O
76	,	_	_	O
77	1.25	_	_	O
78	mg	_	_	O
79	bevacizumab	_	_	O
80	,	_	_	O
81	or	_	_	O
82	0.3	_	_	O
83	mg	_	_	O
84	ranibizumab	_	_	O
85	based	_	_	O
86	on	_	_	O
87	a	_	_	O
88	structured	_	_	O
89	retreatment	_	_	O
90	protocol	_	_	O
91	over	_	_	O
92	2	_	_	O
93	years	_	_	O
94	.	_	_	O

95	Main	_	_	O
96	outcome	_	_	O
97	measures	_	_	O
98	were	_	_	O
99	(	_	_	O
100	1	_	_	O
101	)	_	_	O
102	a	_	_	O
103	change	_	_	O
104	in	_	_	O
105	blood	_	_	O
106	pressure	_	_	O
107	at	_	_	O
108	2	_	_	O
109	years	_	_	O
110	,	_	_	O
111	and	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	a	_	_	O
116	change	_	_	O
117	in	_	_	O
118	urine	_	_	O
119	albumin-creatinine	_	_	O
120	ratio	_	_	O
121	(	_	_	O
122	UACR	_	_	O
123	)	_	_	O
124	at	_	_	O
125	1	_	_	O
126	year	_	_	O
127	.	_	_	O

128	At	_	_	O
129	baseline	_	_	O
130	,	_	_	O
131	95	_	_	O
132	participants	_	_	O
133	(	_	_	O
134	14	_	_	O
135	%	_	_	O
136	)	_	_	O
137	had	_	_	O
138	normal	_	_	O
139	blood	_	_	O
140	pressure	_	_	O
141	,	_	_	O
142	220	_	_	O
143	(	_	_	O
144	33	_	_	O
145	%	_	_	O
146	)	_	_	O
147	had	_	_	O
148	borderline	_	_	O
149	blood	_	_	O
150	pressure	_	_	O
151	elevation	_	_	O
152	,	_	_	O
153	206	_	_	O
154	(	_	_	O
155	31	_	_	O
156	%	_	_	O
157	)	_	_	O
158	had	_	_	O
159	mild	_	_	O
160	blood	_	_	O
161	pressure	_	_	O
162	elevation	_	_	O
163	,	_	_	O
164	and	_	_	O
165	139	_	_	O
166	(	_	_	O
167	21	_	_	O
168	%	_	_	O
169	)	_	_	O
170	had	_	_	O
171	moderate	_	_	O
172	blood	_	_	O
173	pressure	_	_	O
174	elevation	_	_	O
175	.	_	_	O

176	Average	_	_	B-Premise
177	change	_	_	I-Premise
178	in	_	_	I-Premise
179	mean	_	_	I-Premise
180	arterial	_	_	I-Premise
181	pressure	_	_	I-Premise
182	from	_	_	I-Premise
183	baseline	_	_	I-Premise
184	to	_	_	I-Premise
185	2	_	_	I-Premise
186	years	_	_	I-Premise
187	was	_	_	I-Premise
188	-1.2	_	_	I-Premise
189	±	_	_	I-Premise
190	15	_	_	I-Premise
191	,	_	_	I-Premise
192	-1.8	_	_	I-Premise
193	±	_	_	I-Premise
194	13.5	_	_	I-Premise
195	,	_	_	I-Premise
196	-2.6	_	_	I-Premise
197	±	_	_	I-Premise
198	14.4	_	_	I-Premise
199	mm	_	_	I-Premise
200	Hg	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	aflibercept	_	_	I-Premise
204	,	_	_	I-Premise
205	bevacizumab	_	_	I-Premise
206	,	_	_	I-Premise
207	and	_	_	I-Premise
208	ranibizumab	_	_	I-Premise
209	groups	_	_	I-Premise
210	,	_	_	I-Premise
211	respectively	_	_	I-Premise
212	(	_	_	I-Premise
213	global	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	0.69	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	At	_	_	O
220	baseline	_	_	O
221	247	_	_	O
222	participants	_	_	O
223	(	_	_	O
224	38	_	_	O
225	%	_	_	O
226	)	_	_	O
227	had	_	_	O
228	no	_	_	O
229	albuminuria	_	_	O
230	(	_	_	O
231	<	_	_	O
232	30	_	_	O
233	mg/g	_	_	O
234	)	_	_	O
235	,	_	_	O
236	195	_	_	O
237	(	_	_	O
238	30	_	_	O
239	%	_	_	O
240	)	_	_	O
241	had	_	_	O
242	microalbuminuria	_	_	O
243	(	_	_	O
244	30-300	_	_	O
245	mg/g	_	_	O
246	)	_	_	O
247	,	_	_	O
248	and	_	_	O
249	212	_	_	O
250	(	_	_	O
251	32	_	_	O
252	%	_	_	O
253	)	_	_	O
254	had	_	_	O
255	macroalbuminuria	_	_	O
256	(	_	_	O
257	>	_	_	O
258	300	_	_	O
259	mg/g	_	_	O
260	)	_	_	O
261	.	_	_	O

262	Changes	_	_	B-Premise
263	in	_	_	I-Premise
264	UACR	_	_	I-Premise
265	category	_	_	I-Premise
266	were	_	_	I-Premise
267	not	_	_	I-Premise
268	different	_	_	I-Premise
269	among	_	_	I-Premise
270	treatment	_	_	I-Premise
271	groups	_	_	I-Premise
272	at	_	_	I-Premise
273	the	_	_	I-Premise
274	52-week	_	_	I-Premise
275	visit	_	_	I-Premise
276	(	_	_	I-Premise
277	global	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	0.29	_	_	I-Premise
281	)	_	_	I-Premise
282	.	_	_	I-Premise

283	There	_	_	B-Claim
284	do	_	_	I-Claim
285	not	_	_	I-Claim
286	appear	_	_	I-Claim
287	to	_	_	I-Claim
288	be	_	_	I-Claim
289	treatment	_	_	I-Claim
290	group	_	_	I-Claim
291	differences	_	_	I-Claim
292	for	_	_	I-Claim
293	changes	_	_	I-Claim
294	in	_	_	I-Claim
295	blood	_	_	I-Claim
296	pressure	_	_	I-Claim
297	or	_	_	I-Claim
298	UACR	_	_	I-Claim
299	as	_	_	I-Claim
300	a	_	_	I-Claim
301	reflection	_	_	I-Claim
302	of	_	_	I-Claim
303	kidney	_	_	I-Claim
304	function	_	_	I-Claim
305	in	_	_	I-Claim
306	patients	_	_	I-Claim
307	with	_	_	I-Claim
308	DME	_	_	I-Claim
309	treated	_	_	I-Claim
310	with	_	_	I-Claim
311	aflibercept	_	_	I-Claim
312	,	_	_	I-Claim
313	bevacizumab	_	_	I-Claim
314	,	_	_	I-Claim
315	or	_	_	I-Claim
316	ranibizumab	_	_	I-Claim
317	.	_	_	I-Claim


0	Although	_	_	O
1	anthracyclines	_	_	B-Claim
2	are	_	_	I-Claim
3	effective	_	_	I-Claim
4	chemotherapeutic	_	_	I-Claim
5	agents	_	_	I-Claim
6	for	_	_	I-Claim
7	treating	_	_	I-Claim
8	B-cell	_	_	I-Claim
9	lymphoma	_	_	I-Claim
10	,	_	_	I-Claim
11	adverse	_	_	B-Claim
12	effects	_	_	I-Claim
13	,	_	_	I-Claim
14	such	_	_	I-Claim
15	as	_	_	I-Claim
16	bone	_	_	I-Claim
17	marrow	_	_	I-Claim
18	suppression	_	_	I-Claim
19	and	_	_	I-Claim
20	cardiotoxicity	_	_	I-Claim
21	,	_	_	I-Claim
22	limit	_	_	I-Claim
23	their	_	_	I-Claim
24	clinical	_	_	I-Claim
25	application	_	_	I-Claim
26	.	_	_	I-Claim

27	We	_	_	O
28	assessed	_	_	O
29	whether	_	_	O
30	anthracycline	_	_	O
31	treatment	_	_	O
32	also	_	_	O
33	increases	_	_	O
34	the	_	_	O
35	risk	_	_	O
36	for	_	_	O
37	diabetes	_	_	O
38	mellitus	_	_	O
39	in	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	B-cell	_	_	O
43	lymphoma	_	_	O
44	.	_	_	O

45	Using	_	_	O
46	data	_	_	O
47	obtained	_	_	O
48	from	_	_	O
49	the	_	_	O
50	Taiwanese	_	_	O
51	National	_	_	O
52	Health	_	_	O
53	Insurance	_	_	O
54	Research	_	_	O
55	Database	_	_	O
56	from	_	_	O
57	2004	_	_	O
58	to	_	_	O
59	2011	_	_	O
60	,	_	_	O
61	we	_	_	O
62	compared	_	_	O
63	overall	_	_	O
64	survival	_	_	O
65	and	_	_	O
66	clinical	_	_	O
67	features	_	_	O
68	for	_	_	O
69	B-cell	_	_	O
70	lymphoma	_	_	O
71	patients	_	_	O
72	administered	_	_	O
73	anthracyclines	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	3147	_	_	O
78	)	_	_	O
79	and	_	_	O
80	those	_	_	O
81	not	_	_	O
82	administered	_	_	O
83	anthracyclines	_	_	O
84	(	_	_	O
85	n	_	_	O
86	=	_	_	O
87	837	_	_	O
88	)	_	_	O
89	.	_	_	O

90	The	_	_	O
91	impact	_	_	O
92	of	_	_	O
93	anthracycline	_	_	O
94	treatment	_	_	O
95	on	_	_	O
96	diabetes	_	_	O
97	risk	_	_	O
98	was	_	_	O
99	further	_	_	O
100	investigated	_	_	O
101	using	_	_	O
102	a	_	_	O
103	Gray	_	_	O
104	's	_	_	O
105	test	_	_	O
106	and	_	_	O
107	multivariate	_	_	O
108	competing-risk	_	_	O
109	regression	_	_	O
110	models	_	_	O
111	in	_	_	O
112	a	_	_	O
113	dose-dependent	_	_	O
114	manner	_	_	O
115	.	_	_	O

116	Anthracycline	_	_	B-Premise
117	administration	_	_	I-Premise
118	was	_	_	I-Premise
119	associated	_	_	I-Premise
120	with	_	_	I-Premise
121	a	_	_	I-Premise
122	higher	_	_	I-Premise
123	incidence	_	_	I-Premise
124	of	_	_	I-Premise
125	diabetes	_	_	I-Premise
126	(	_	_	I-Premise
127	HR	_	_	I-Premise
128	:	_	_	I-Premise
129	1.75	_	_	I-Premise
130	;	_	_	I-Premise
131	95	_	_	I-Premise
132	%	_	_	I-Premise
133	CI	_	_	I-Premise
134	1.11-2.75	_	_	I-Premise
135	;	_	_	I-Premise
136	p	_	_	I-Premise
137	=	_	_	I-Premise
138	0.0163	_	_	I-Premise
139	)	_	_	I-Premise
140	after	_	_	I-Premise
141	adjustments	_	_	I-Premise
142	for	_	_	I-Premise
143	age	_	_	I-Premise
144	,	_	_	I-Premise
145	gender	_	_	I-Premise
146	,	_	_	I-Premise
147	cumulative	_	_	I-Premise
148	dose	_	_	I-Premise
149	of	_	_	I-Premise
150	prednisolone	_	_	I-Premise
151	,	_	_	I-Premise
152	and	_	_	I-Premise
153	co-morbidities	_	_	I-Premise
154	.	_	_	I-Premise

155	Cumulative	_	_	B-Premise
156	anthracycline	_	_	I-Premise
157	doses	_	_	I-Premise
158	of	_	_	I-Premise
159	253-400	_	_	I-Premise
160	mg	_	_	I-Premise
161	(	_	_	I-Premise
162	HR	_	_	I-Premise
163	:	_	_	I-Premise
164	2.35	_	_	I-Premise
165	;	_	_	I-Premise
166	95	_	_	I-Premise
167	%	_	_	I-Premise
168	CI	_	_	I-Premise
169	1.41-3.91	_	_	I-Premise
170	;	_	_	I-Premise
171	p	_	_	I-Premise
172	=	_	_	I-Premise
173	0.0010	_	_	I-Premise
174	)	_	_	I-Premise
175	,	_	_	I-Premise
176	401-504	_	_	I-Premise
177	mg	_	_	I-Premise
178	(	_	_	I-Premise
179	HR	_	_	I-Premise
180	:	_	_	I-Premise
181	2.26	_	_	I-Premise
182	;	_	_	I-Premise
183	95	_	_	I-Premise
184	%	_	_	I-Premise
185	CI	_	_	I-Premise
186	1.26-4.05	_	_	I-Premise
187	;	_	_	I-Premise
188	p	_	_	I-Premise
189	=	_	_	I-Premise
190	0.0063	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	and	_	_	I-Premise
194	>	_	_	I-Premise
195	504	_	_	I-Premise
196	mg	_	_	I-Premise
197	(	_	_	I-Premise
198	HR	_	_	I-Premise
199	:	_	_	I-Premise
200	2.29	_	_	I-Premise
201	;	_	_	I-Premise
202	95	_	_	I-Premise
203	%	_	_	I-Premise
204	CI	_	_	I-Premise
205	1.25-4.18	_	_	I-Premise
206	;	_	_	I-Premise
207	p	_	_	I-Premise
208	=	_	_	I-Premise
209	0.0072	_	_	I-Premise
210	)	_	_	I-Premise
211	increased	_	_	I-Premise
212	the	_	_	I-Premise
213	incidence	_	_	I-Premise
214	density	_	_	I-Premise
215	of	_	_	I-Premise
216	diabetes	_	_	I-Premise
217	in	_	_	I-Premise
218	a	_	_	I-Premise
219	dose-dependent	_	_	I-Premise
220	manner	_	_	I-Premise
221	(	_	_	I-Premise
222	p	_	_	I-Premise
223	=	_	_	I-Premise
224	0.0006	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	The	_	_	B-Premise
228	annual	_	_	I-Premise
229	alteration	_	_	I-Premise
230	of	_	_	I-Premise
231	adapted	_	_	I-Premise
232	diabetes	_	_	I-Premise
233	complications	_	_	I-Premise
234	severity	_	_	I-Premise
235	index	_	_	I-Premise
236	score	_	_	I-Premise
237	was	_	_	I-Premise
238	not	_	_	I-Premise
239	significantly	_	_	I-Premise
240	different	_	_	I-Premise
241	between	_	_	I-Premise
242	B-cell	_	_	I-Premise
243	lymphoma	_	_	I-Premise
244	patients	_	_	I-Premise
245	with	_	_	I-Premise
246	or	_	_	I-Premise
247	without	_	_	I-Premise
248	anthracycline	_	_	I-Premise
249	treatment	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.4924	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Anthracycline	_	_	B-Claim
257	therapy	_	_	I-Claim
258	increases	_	_	I-Claim
259	diabetes	_	_	I-Claim
260	risk	_	_	I-Claim
261	in	_	_	I-Claim
262	a	_	_	I-Claim
263	dose-dependent	_	_	I-Claim
264	manner	_	_	I-Claim
265	in	_	_	I-Claim
266	B-cell	_	_	I-Claim
267	lymphoma	_	_	I-Claim
268	patients	_	_	I-Claim
269	.	_	_	I-Claim

270	Intensive	_	_	B-Claim
271	blood	_	_	I-Claim
272	glucose	_	_	I-Claim
273	monitoring	_	_	I-Claim
274	and	_	_	I-Claim
275	control	_	_	I-Claim
276	should	_	_	I-Claim
277	be	_	_	I-Claim
278	recommended	_	_	I-Claim
279	for	_	_	I-Claim
280	B-cell	_	_	I-Claim
281	lymphoma	_	_	I-Claim
282	patients	_	_	I-Claim
283	receiving	_	_	I-Claim
284	anthracycline	_	_	I-Claim
285	treatment	_	_	I-Claim
286	.	_	_	I-Claim


0	The	_	_	B-Claim
1	immunosuppressive	_	_	I-Claim
2	drug	_	_	I-Claim
3	rapamycin	_	_	I-Claim
4	may	_	_	I-Claim
5	influence	_	_	I-Claim
6	insulin	_	_	I-Claim
7	sensitivity	_	_	I-Claim
8	in	_	_	I-Claim
9	insulin-responsive	_	_	I-Claim
10	tissues	_	_	I-Claim
11	.	_	_	I-Claim

12	This	_	_	O
13	study	_	_	O
14	aimed	_	_	O
15	at	_	_	O
16	evaluating	_	_	O
17	the	_	_	O
18	effectiveness	_	_	O
19	of	_	_	O
20	rapamycin	_	_	O
21	pre-treatment	_	_	O
22	before	_	_	O
23	pancreatic	_	_	O
24	islet	_	_	O
25	allotransplantation	_	_	O
26	(	_	_	O
27	ITx	_	_	O
28	)	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	type	_	_	O
33	1	_	_	O
34	diabetes	_	_	O
35	mellitus	_	_	O
36	(	_	_	O
37	T1DM	_	_	O
38	)	_	_	O
39	.	_	_	O

40	Forty-one	_	_	O
41	T1DM	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	studied	_	_	O
45	.	_	_	O

46	Thirteen	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	poor	_	_	O
50	glycemic	_	_	O
51	control	_	_	O
52	underwent	_	_	O
53	a	_	_	O
54	short-term	_	_	O
55	rapamycin	_	_	O
56	treatment	_	_	O
57	before	_	_	O
58	ITx	_	_	O
59	(	_	_	O
60	Group	_	_	O
61	1	_	_	O
62	)	_	_	O
63	,	_	_	O
64	and	_	_	O
65	they	_	_	O
66	were	_	_	O
67	compared	_	_	O
68	to	_	_	O
69	28	_	_	O
70	patients	_	_	O
71	undergoing	_	_	O
72	ITx	_	_	O
73	without	_	_	O
74	rapamycin	_	_	O
75	pre-treatment	_	_	O
76	(	_	_	O
77	Group	_	_	O
78	2	_	_	O
79	)	_	_	O
80	.	_	_	O

81	Outcomes	_	_	O
82	were	_	_	O
83	daily	_	_	O
84	insulin	_	_	O
85	requirement	_	_	O
86	(	_	_	O
87	DIR	_	_	O
88	)	_	_	O
89	,	_	_	O
90	fasting	_	_	O
91	blood	_	_	O
92	glucose	_	_	O
93	,	_	_	O
94	HbA1c	_	_	O
95	,	_	_	O
96	C-peptide	_	_	O
97	and	_	_	O
98	the	_	_	O
99	SUITO	_	_	O
100	index	_	_	O
101	of	_	_	O
102	beta-cell	_	_	O
103	function	_	_	O
104	.	_	_	O

105	A	_	_	O
106	subgroup	_	_	O
107	of	_	_	O
108	patients	_	_	O
109	pre-treated	_	_	O
110	with	_	_	O
111	rapamycin	_	_	O
112	before	_	_	O
113	ITx	_	_	O
114	underwent	_	_	O
115	euglycemic	_	_	O
116	hyperinsulinemic	_	_	O
117	clamp	_	_	O
118	with	_	_	O
119	[	_	_	O
120	6,6-2H2	_	_	O
121	]	_	_	O
122	glucose	_	_	O
123	before	_	_	O
124	and	_	_	O
125	after	_	_	O
126	ITx	_	_	O
127	to	_	_	O
128	evaluate	_	_	O
129	insulin	_	_	O
130	sensitivity	_	_	O
131	.	_	_	O

132	We	_	_	B-Premise
133	found	_	_	I-Premise
134	a	_	_	I-Premise
135	significant	_	_	I-Premise
136	reduction	_	_	I-Premise
137	in	_	_	I-Premise
138	DIR	_	_	I-Premise
139	after	_	_	I-Premise
140	rapamycin	_	_	I-Premise
141	pre-treatment	_	_	I-Premise
142	(	_	_	I-Premise
143	-	_	_	I-Premise
144	8	_	_	I-Premise
145	±	_	_	I-Premise
146	6	_	_	I-Premise
147	U/day	_	_	I-Premise
148	,	_	_	I-Premise
149	mean	_	_	I-Premise
150	±	_	_	I-Premise
151	SD	_	_	I-Premise
152	,	_	_	I-Premise
153	p	_	_	I-Premise
154	<	_	_	I-Premise
155	0.001	_	_	I-Premise
156	)	_	_	I-Premise
157	and	_	_	I-Premise
158	1	_	_	I-Premise
159	year	_	_	I-Premise
160	after	_	_	I-Premise
161	ITx	_	_	I-Premise
162	.	_	_	I-Premise

163	DIR	_	_	B-Premise
164	reduction	_	_	I-Premise
165	1	_	_	I-Premise
166	year	_	_	I-Premise
167	after	_	_	I-Premise
168	ITx	_	_	I-Premise
169	was	_	_	I-Premise
170	greater	_	_	I-Premise
171	in	_	_	I-Premise
172	Group	_	_	I-Premise
173	1	_	_	I-Premise
174	as	_	_	I-Premise
175	compared	_	_	I-Premise
176	to	_	_	I-Premise
177	Group	_	_	I-Premise
178	2	_	_	I-Premise
179	(	_	_	I-Premise
180	-	_	_	I-Premise
181	37	_	_	I-Premise
182	±	_	_	I-Premise
183	15	_	_	I-Premise
184	vs.	_	_	I-Premise
185	-	_	_	I-Premise
186	19	_	_	I-Premise
187	±	_	_	I-Premise
188	13	_	_	I-Premise
189	U/day	_	_	I-Premise
190	,	_	_	I-Premise
191	p	_	_	I-Premise
192	=	_	_	I-Premise
193	0.005	_	_	I-Premise
194	)	_	_	I-Premise
195	and	_	_	I-Premise
196	remained	_	_	I-Premise
197	significant	_	_	I-Premise
198	after	_	_	I-Premise
199	adjusting	_	_	I-Premise
200	for	_	_	I-Premise
201	gender	_	_	I-Premise
202	,	_	_	I-Premise
203	age	_	_	I-Premise
204	,	_	_	I-Premise
205	glucose	_	_	I-Premise
206	and	_	_	I-Premise
207	baseline	_	_	I-Premise
208	HbA1c	_	_	I-Premise
209	(	_	_	I-Premise
210	beta	_	_	I-Premise
211	=	_	_	I-Premise
212	18.2	_	_	I-Premise
213	±	_	_	I-Premise
214	5.9	_	_	I-Premise
215	,	_	_	I-Premise
216	p	_	_	I-Premise
217	=	_	_	I-Premise
218	0.006	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	Fasting	_	_	B-Premise
222	glucose	_	_	I-Premise
223	and	_	_	I-Premise
224	HbA1c	_	_	I-Premise
225	significantly	_	_	I-Premise
226	decreased	_	_	I-Premise
227	1	_	_	I-Premise
228	year	_	_	I-Premise
229	after	_	_	I-Premise
230	ITx	_	_	I-Premise
231	in	_	_	I-Premise
232	Group	_	_	I-Premise
233	1	_	_	I-Premise
234	(	_	_	I-Premise
235	HbA1c	_	_	I-Premise
236	:	_	_	I-Premise
237	-	_	_	I-Premise
238	2.1	_	_	I-Premise
239	±	_	_	I-Premise
240	1.4	_	_	I-Premise
241	%	_	_	I-Premise
242	,	_	_	I-Premise
243	p	_	_	I-Premise
244	=	_	_	I-Premise
245	0.002	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	while	_	_	O
249	fasting	_	_	B-Premise
250	C-peptide	_	_	I-Premise
251	(	_	_	I-Premise
252	+0.5	_	_	I-Premise
253	±	_	_	I-Premise
254	0.3	_	_	I-Premise
255	nmol/l	_	_	I-Premise
256	,	_	_	I-Premise
257	p	_	_	I-Premise
258	=	_	_	I-Premise
259	0.002	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	SUITO	_	_	I-Premise
263	index	_	_	I-Premise
264	increased	_	_	I-Premise
265	(	_	_	I-Premise
266	+57.4	_	_	I-Premise
267	±	_	_	I-Premise
268	39.7	_	_	I-Premise
269	,	_	_	I-Premise
270	p	_	_	I-Premise
271	=	_	_	I-Premise
272	0.016	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	without	_	_	I-Premise
276	differences	_	_	I-Premise
277	between	_	_	I-Premise
278	the	_	_	I-Premise
279	two	_	_	I-Premise
280	groups	_	_	I-Premise
281	.	_	_	I-Premise

282	Hepatic	_	_	B-Premise
283	glucose	_	_	I-Premise
284	production	_	_	I-Premise
285	decreased	_	_	I-Premise
286	after	_	_	I-Premise
287	rapamycin	_	_	I-Premise
288	pre-treatment	_	_	I-Premise
289	(	_	_	I-Premise
290	-	_	_	I-Premise
291	1.1	_	_	I-Premise
292	±	_	_	I-Premise
293	1.1	_	_	I-Premise
294	mg/kg/min	_	_	I-Premise
295	,	_	_	I-Premise
296	p	_	_	I-Premise
297	=	_	_	I-Premise
298	0.04	_	_	I-Premise
299	)	_	_	I-Premise
300	and	_	_	I-Premise
301	after	_	_	I-Premise
302	ITx	_	_	I-Premise
303	(	_	_	I-Premise
304	-	_	_	I-Premise
305	1.6	_	_	I-Premise
306	±	_	_	I-Premise
307	0.6	_	_	I-Premise
308	mg/kg/min	_	_	I-Premise
309	,	_	_	I-Premise
310	p	_	_	I-Premise
311	=	_	_	I-Premise
312	0.015	_	_	I-Premise
313	)	_	_	I-Premise
314	,	_	_	I-Premise
315	while	_	_	O
316	no	_	_	B-Premise
317	changes	_	_	I-Premise
318	in	_	_	I-Premise
319	peripheral	_	_	I-Premise
320	glucose	_	_	I-Premise
321	disposal	_	_	I-Premise
322	were	_	_	I-Premise
323	observed	_	_	I-Premise
324	.	_	_	I-Premise

325	Rapamycin	_	_	B-Claim
326	pre-treatment	_	_	I-Claim
327	before	_	_	I-Claim
328	ITx	_	_	I-Claim
329	succeeds	_	_	I-Claim
330	in	_	_	I-Claim
331	reducing	_	_	I-Claim
332	insulin	_	_	I-Claim
333	requirement	_	_	I-Claim
334	,	_	_	I-Claim
335	enhancing	_	_	I-Claim
336	hepatic	_	_	I-Claim
337	insulin	_	_	I-Claim
338	sensitivity	_	_	I-Claim
339	.	_	_	I-Claim

340	This	_	_	B-Claim
341	treatment	_	_	I-Claim
342	may	_	_	I-Claim
343	improve	_	_	I-Claim
344	short-term	_	_	I-Claim
345	ITx	_	_	I-Claim
346	outcomes	_	_	I-Claim
347	,	_	_	I-Claim
348	possibly	_	_	I-Claim
349	in	_	_	I-Claim
350	selected	_	_	I-Claim
351	patients	_	_	I-Claim
352	with	_	_	I-Claim
353	T1DM	_	_	I-Claim
354	complicated	_	_	I-Claim
355	by	_	_	I-Claim
356	insulin	_	_	I-Claim
357	resistance	_	_	I-Claim
358	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	2-group	_	_	O
5	,	_	_	O
6	parallel	_	_	O
7	,	_	_	O
8	double	_	_	O
9	blind	_	_	O
10	single-centre	_	_	O
11	RCT	_	_	O
12	was	_	_	O
13	to	_	_	O
14	evaluate	_	_	O
15	the	_	_	O
16	acute	_	_	O
17	and	_	_	O
18	chronic	_	_	O
19	impacts	_	_	O
20	of	_	_	O
21	high	_	_	O
22	flavanol	_	_	O
23	high	_	_	O
24	theobromine	_	_	O
25	(	_	_	O
26	HFHT	_	_	O
27	)	_	_	O
28	chocolate	_	_	O
29	consumption	_	_	O
30	on	_	_	O
31	endothelial	_	_	O
32	function	_	_	O
33	,	_	_	O
34	arterial	_	_	O
35	stiffness	_	_	O
36	and	_	_	O
37	blood	_	_	O
38	pressure	_	_	O
39	(	_	_	O
40	BP	_	_	O
41	)	_	_	O
42	in	_	_	O
43	women	_	_	O
44	at	_	_	O
45	risk	_	_	O
46	of	_	_	O
47	preeclampsia	_	_	O
48	.	_	_	O

49	131	_	_	O
50	pregnant	_	_	O
51	women	_	_	O
52	considered	_	_	O
53	at	_	_	O
54	risk	_	_	O
55	of	_	_	O
56	preeclampsia	_	_	O
57	based	_	_	O
58	on	_	_	O
59	uterine	_	_	O
60	artery	_	_	O
61	Doppler	_	_	O
62	ultrasound	_	_	O
63	were	_	_	O
64	divided	_	_	O
65	into	_	_	O
66	two	_	_	O
67	groups	_	_	O
68	(	_	_	O
69	HFHT	_	_	O
70	or	_	_	O
71	low	_	_	O
72	flavanol	_	_	O
73	and	_	_	O
74	theobromine	_	_	O
75	chocolate	_	_	O
76	(	_	_	O
77	LFLT	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Acute	_	_	O
81	changes	_	_	O
82	in	_	_	O
83	plasma	_	_	O
84	flavanol	_	_	O
85	and	_	_	O
86	theobromine	_	_	O
87	,	_	_	O
88	peripheral	_	_	O
89	arterial	_	_	O
90	tonometry	_	_	O
91	and	_	_	O
92	BP	_	_	O
93	were	_	_	O
94	evaluated	_	_	O
95	at	_	_	O
96	randomization	_	_	O
97	(	_	_	O
98	0	_	_	O
99	,	_	_	O
100	60	_	_	O
101	and	_	_	O
102	120	_	_	O
103	min	_	_	O
104	after	_	_	O
105	a	_	_	O
106	single	_	_	O
107	40-g	_	_	O
108	dose	_	_	O
109	of	_	_	O
110	chocolate	_	_	O
111	)	_	_	O
112	and	_	_	O
113	again	_	_	O
114	6	_	_	O
115	and	_	_	O
116	12	_	_	O
117	weeks	_	_	O
118	after	_	_	O
119	daily	_	_	O
120	30-g	_	_	O
121	chocolate	_	_	O
122	intake	_	_	O
123	.	_	_	O

124	The	_	_	O
125	EndoPAT	_	_	O
126	2000	_	_	O
127	provided	_	_	O
128	reactive	_	_	O
129	hyperemia	_	_	O
130	index	_	_	O
131	(	_	_	O
132	RHI	_	_	O
133	)	_	_	O
134	and	_	_	O
135	adjusted	_	_	O
136	augmentation	_	_	O
137	index	_	_	O
138	(	_	_	O
139	AIx	_	_	O
140	)	_	_	O
141	as	_	_	O
142	markers	_	_	O
143	for	_	_	O
144	endothelial	_	_	O
145	function	_	_	O
146	and	_	_	O
147	arterial	_	_	O
148	stiffness	_	_	O
149	,	_	_	O
150	respectively	_	_	O
151	.	_	_	O

152	Compared	_	_	B-Premise
153	with	_	_	I-Premise
154	LFLT	_	_	I-Premise
155	,	_	_	I-Premise
156	acute	_	_	I-Premise
157	HFHT	_	_	I-Premise
158	intake	_	_	I-Premise
159	significantly	_	_	I-Premise
160	increased	_	_	I-Premise
161	plasma	_	_	I-Premise
162	epicatechin	_	_	I-Premise
163	and	_	_	I-Premise
164	theobromine	_	_	I-Premise
165	(	_	_	I-Premise
166	p	_	_	I-Premise
167	<	_	_	I-Premise
168	0.0001	_	_	I-Premise
169	)	_	_	I-Premise
170	,	_	_	I-Premise
171	decreased	_	_	I-Premise
172	AIx	_	_	I-Premise
173	(	_	_	I-Premise
174	p	_	_	I-Premise
175	<	_	_	I-Premise
176	0.0001	_	_	I-Premise
177	)	_	_	I-Premise
178	and	_	_	I-Premise
179	increased	_	_	I-Premise
180	diastolic	_	_	I-Premise
181	BP	_	_	I-Premise
182	(	_	_	I-Premise
183	3.49	_	_	I-Premise
184	±	_	_	I-Premise
185	3.40	_	_	I-Premise
186	mmHg	_	_	I-Premise
187	increase	_	_	I-Premise
188	in	_	_	I-Premise
189	HFHT	_	_	I-Premise
190	group	_	_	I-Premise
191	vs	_	_	I-Premise
192	1.55	_	_	I-Premise
193	±	_	_	I-Premise
194	2.59	_	_	I-Premise
195	mmHg	_	_	I-Premise
196	increase	_	_	I-Premise
197	in	_	_	I-Premise
198	LFLT	_	_	I-Premise
199	group	_	_	I-Premise
200	,	_	_	I-Premise
201	p	_	_	I-Premise
202	=	_	_	I-Premise
203	0.0008	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Chronic	_	_	B-Premise
207	HFHT	_	_	I-Premise
208	compared	_	_	I-Premise
209	with	_	_	I-Premise
210	LFLT	_	_	I-Premise
211	intake	_	_	I-Premise
212	significantly	_	_	I-Premise
213	increased	_	_	I-Premise
214	plasma	_	_	I-Premise
215	theobromine	_	_	I-Premise
216	(	_	_	I-Premise
217	p	_	_	I-Premise
218	<	_	_	I-Premise
219	0.0001	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	No	_	_	O
223	other	_	_	O
224	significant	_	_	O
225	within	_	_	O
226	group	_	_	O
227	or	_	_	O
228	between	_	_	O
229	group	_	_	O
230	changes	_	_	O
231	were	_	_	O
232	observed	_	_	O
233	.	_	_	O

234	Acute	_	_	B-Claim
235	consumption	_	_	I-Claim
236	of	_	_	I-Claim
237	HFHT	_	_	I-Claim
238	,	_	_	I-Claim
239	compared	_	_	I-Claim
240	to	_	_	I-Claim
241	LFLT	_	_	I-Claim
242	,	_	_	I-Claim
243	increased	_	_	I-Claim
244	plasma	_	_	I-Claim
245	epicatechin	_	_	I-Claim
246	and	_	_	I-Claim
247	theobromine	_	_	I-Claim
248	concentrations	_	_	I-Claim
249	and	_	_	I-Claim
250	decreased	_	_	I-Claim
251	arterial	_	_	I-Claim
252	stiffness	_	_	I-Claim
253	,	_	_	I-Claim
254	with	_	_	I-Claim
255	no	_	_	I-Claim
256	effect	_	_	I-Claim
257	on	_	_	I-Claim
258	endothelial	_	_	I-Claim
259	function	_	_	I-Claim
260	and	_	_	I-Claim
261	a	_	_	I-Claim
262	marginal	_	_	I-Claim
263	increase	_	_	I-Claim
264	in	_	_	I-Claim
265	diastolic	_	_	I-Claim
266	BP	_	_	I-Claim
267	.	_	_	I-Claim

268	Chronic	_	_	B-Claim
269	HFHT	_	_	I-Claim
270	intake	_	_	I-Claim
271	increased	_	_	I-Claim
272	plasma	_	_	I-Claim
273	theobromine	_	_	I-Claim
274	,	_	_	I-Claim
275	though	_	_	I-Claim
276	it	_	_	I-Claim
277	did	_	_	I-Claim
278	not	_	_	I-Claim
279	have	_	_	I-Claim
280	positive	_	_	I-Claim
281	impacts	_	_	I-Claim
282	on	_	_	I-Claim
283	endothelial	_	_	I-Claim
284	function	_	_	I-Claim
285	,	_	_	I-Claim
286	arterial	_	_	I-Claim
287	stiffness	_	_	I-Claim
288	or	_	_	I-Claim
289	BP	_	_	I-Claim
290	when	_	_	I-Claim
291	compared	_	_	I-Claim
292	to	_	_	I-Claim
293	LFLT	_	_	I-Claim
294	in	_	_	I-Claim
295	pregnant	_	_	I-Claim
296	women	_	_	I-Claim
297	at	_	_	I-Claim
298	risk	_	_	I-Claim
299	of	_	_	I-Claim
300	PE	_	_	I-Claim
301	.	_	_	I-Claim


0	Single-agent	_	_	O
1	therapy	_	_	O
2	with	_	_	O
3	bicalutamide	_	_	O
4	,	_	_	O
5	a	_	_	O
6	nonsteroidal	_	_	O
7	antiandrogen	_	_	O
8	,	_	_	O
9	was	_	_	O
10	compared	_	_	O
11	with	_	_	O
12	castration	_	_	O
13	,	_	_	O
14	either	_	_	O
15	surgical	_	_	O
16	or	_	_	O
17	medical	_	_	O
18	,	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	untreated	_	_	O
23	Stage	_	_	O
24	D2	_	_	O
25	prostate	_	_	O
26	cancer	_	_	O
27	.	_	_	O

28	In	_	_	O
29	an	_	_	O
30	open	_	_	O
31	,	_	_	O
32	randomized	_	_	O
33	,	_	_	O
34	multicenter	_	_	O
35	trial	_	_	O
36	,	_	_	O
37	patients	_	_	O
38	were	_	_	O
39	randomized	_	_	O
40	to	_	_	O
41	treatment	_	_	O
42	with	_	_	O
43	50	_	_	O
44	mg	_	_	O
45	bicalutamide	_	_	O
46	(	_	_	O
47	n	_	_	O
48	=	_	_	O
49	243	_	_	O
50	)	_	_	O
51	once	_	_	O
52	daily	_	_	O
53	or	_	_	O
54	to	_	_	O
55	castration	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	243	_	_	O
60	)	_	_	O
61	,	_	_	O
62	either	_	_	O
63	orchiectomy	_	_	O
64	or	_	_	O
65	depot	_	_	O
66	injection	_	_	O
67	of	_	_	O
68	goserelin	_	_	O
69	acetate	_	_	O
70	every	_	_	O
71	28	_	_	O
72	days	_	_	O
73	.	_	_	O

74	Primary	_	_	O
75	efficacy	_	_	O
76	endpoints	_	_	O
77	were	_	_	O
78	times	_	_	O
79	to	_	_	O
80	treatment	_	_	O
81	failure	_	_	O
82	and	_	_	O
83	objective	_	_	O
84	disease	_	_	O
85	progression	_	_	O
86	and	_	_	O
87	survival	_	_	O
88	.	_	_	O

89	Assessments	_	_	O
90	included	_	_	O
91	review	_	_	O
92	of	_	_	O
93	measurable	_	_	O
94	metastases	_	_	O
95	,	_	_	O
96	prostate	_	_	O
97	dimensions	_	_	O
98	,	_	_	O
99	Eastern	_	_	O
100	Cooperative	_	_	O
101	Oncology	_	_	O
102	Group	_	_	O
103	performance	_	_	O
104	status	_	_	O
105	,	_	_	O
106	pain	_	_	O
107	,	_	_	O
108	analgesic	_	_	O
109	requirements	_	_	O
110	,	_	_	O
111	and	_	_	O
112	quality	_	_	O
113	of	_	_	O
114	life	_	_	O
115	responses	_	_	O
116	.	_	_	O

117	The	_	_	O
118	median	_	_	O
119	duration	_	_	O
120	of	_	_	O
121	therapy	_	_	O
122	was	_	_	O
123	39	_	_	O
124	weeks	_	_	O
125	for	_	_	O
126	bicalutamide-treated	_	_	O
127	patients	_	_	O
128	and	_	_	O
129	42	_	_	O
130	weeks	_	_	O
131	for	_	_	O
132	castrated	_	_	O
133	patients	_	_	O
134	;	_	_	O
135	treatment	_	_	O
136	failure	_	_	O
137	occurred	_	_	O
138	in	_	_	O
139	53	_	_	O
140	%	_	_	O
141	and	_	_	O
142	42	_	_	O
143	%	_	_	O
144	and	_	_	O
145	disease	_	_	O
146	progression	_	_	O
147	in	_	_	O
148	43	_	_	O
149	%	_	_	O
150	and	_	_	O
151	33	_	_	O
152	%	_	_	O
153	,	_	_	O
154	respectively	_	_	O
155	.	_	_	O

156	Treatment	_	_	B-Premise
157	effects	_	_	I-Premise
158	favored	_	_	I-Premise
159	castration	_	_	I-Premise
160	for	_	_	I-Premise
161	both	_	_	I-Premise
162	endpoints	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	<	_	_	I-Premise
166	or	_	_	I-Premise
167	=	_	_	I-Premise
168	0.002	_	_	I-Premise
169	)	_	_	I-Premise
170	,	_	_	I-Premise
171	with	_	_	I-Premise
172	hazard	_	_	I-Premise
173	ratios	_	_	I-Premise
174	(	_	_	I-Premise
175	bicalutamide	_	_	I-Premise
176	:	_	_	I-Premise
177	castration	_	_	I-Premise
178	)	_	_	I-Premise
179	of	_	_	I-Premise
180	1.54	_	_	I-Premise
181	(	_	_	I-Premise
182	95	_	_	I-Premise
183	%	_	_	I-Premise
184	confidence	_	_	I-Premise
185	interval	_	_	I-Premise
186	[	_	_	I-Premise
187	CI	_	_	I-Premise
188	]	_	_	I-Premise
189	,	_	_	I-Premise
190	1.18	_	_	I-Premise
191	to	_	_	I-Premise
192	2.00	_	_	I-Premise
193	)	_	_	I-Premise
194	for	_	_	I-Premise
195	time	_	_	I-Premise
196	to	_	_	I-Premise
197	treatment	_	_	I-Premise
198	failure	_	_	I-Premise
199	and	_	_	I-Premise
200	1.6	_	_	I-Premise
201	(	_	_	I-Premise
202	95	_	_	I-Premise
203	%	_	_	I-Premise
204	CI	_	_	I-Premise
205	,	_	_	I-Premise
206	1.19	_	_	I-Premise
207	to	_	_	I-Premise
208	2.15	_	_	I-Premise
209	)	_	_	I-Premise
210	for	_	_	I-Premise
211	time	_	_	I-Premise
212	to	_	_	I-Premise
213	disease	_	_	I-Premise
214	progression	_	_	I-Premise
215	.	_	_	I-Premise

216	From	_	_	B-Premise
217	the	_	_	I-Premise
218	1-year	_	_	I-Premise
219	survival	_	_	I-Premise
220	analysis	_	_	I-Premise
221	,	_	_	I-Premise
222	the	_	_	I-Premise
223	hazard	_	_	I-Premise
224	ratio	_	_	I-Premise
225	for	_	_	I-Premise
226	probability	_	_	I-Premise
227	of	_	_	I-Premise
228	death	_	_	I-Premise
229	was	_	_	I-Premise
230	1.29	_	_	I-Premise
231	(	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	CI	_	_	I-Premise
235	,	_	_	I-Premise
236	0.96	_	_	I-Premise
237	to	_	_	I-Premise
238	1.72	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	Thus	_	_	B-Premise
242	far	_	_	I-Premise
243	,	_	_	I-Premise
244	with	_	_	I-Premise
245	a	_	_	I-Premise
246	median	_	_	I-Premise
247	follow-up	_	_	I-Premise
248	of	_	_	I-Premise
249	86	_	_	I-Premise
250	weeks	_	_	I-Premise
251	,	_	_	I-Premise
252	median	_	_	I-Premise
253	survival	_	_	I-Premise
254	has	_	_	I-Premise
255	not	_	_	I-Premise
256	been	_	_	I-Premise
257	reached	_	_	I-Premise
258	in	_	_	I-Premise
259	either	_	_	I-Premise
260	group	_	_	I-Premise
261	.	_	_	I-Premise

262	Changes	_	_	B-Premise
263	from	_	_	I-Premise
264	baseline	_	_	I-Premise
265	in	_	_	I-Premise
266	several	_	_	I-Premise
267	quality	_	_	I-Premise
268	of	_	_	I-Premise
269	life	_	_	I-Premise
270	variables	_	_	I-Premise
271	were	_	_	I-Premise
272	significantly	_	_	I-Premise
273	different	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	<	_	_	I-Premise
277	or	_	_	I-Premise
278	=	_	_	I-Premise
279	0.01	_	_	I-Premise
280	)	_	_	I-Premise
281	between	_	_	I-Premise
282	treatment	_	_	I-Premise
283	groups	_	_	I-Premise
284	periodically	_	_	I-Premise
285	from	_	_	I-Premise
286	months	_	_	I-Premise
287	1	_	_	I-Premise
288	to	_	_	I-Premise
289	6	_	_	I-Premise
290	,	_	_	I-Premise
291	and	_	_	I-Premise
292	all	_	_	I-Premise
293	favored	_	_	I-Premise
294	bicalutamide	_	_	I-Premise
295	.	_	_	I-Premise

296	Overall	_	_	B-Premise
297	,	_	_	I-Premise
298	the	_	_	I-Premise
299	antiandrogen	_	_	I-Premise
300	was	_	_	I-Premise
301	well	_	_	I-Premise
302	tolerated	_	_	I-Premise
303	compared	_	_	I-Premise
304	with	_	_	I-Premise
305	castration	_	_	I-Premise
306	;	_	_	I-Premise
307	with	_	_	B-Premise
308	bicalutamide	_	_	I-Premise
309	,	_	_	I-Premise
310	hot	_	_	I-Premise
311	flushes	_	_	I-Premise
312	occurred	_	_	I-Premise
313	less	_	_	I-Premise
314	often	_	_	I-Premise
315	and	_	_	I-Premise
316	breast	_	_	I-Premise
317	tenderness	_	_	I-Premise
318	and	_	_	I-Premise
319	gynecomastia	_	_	I-Premise
320	more	_	_	I-Premise
321	often	_	_	I-Premise
322	.	_	_	I-Premise

323	Although	_	_	B-Premise
324	a	_	_	I-Premise
325	dosage	_	_	I-Premise
326	of	_	_	I-Premise
327	50	_	_	I-Premise
328	mg	_	_	I-Premise
329	of	_	_	I-Premise
330	bicalutamide	_	_	I-Premise
331	once	_	_	I-Premise
332	daily	_	_	I-Premise
333	was	_	_	I-Premise
334	not	_	_	I-Premise
335	as	_	_	I-Premise
336	effective	_	_	I-Premise
337	as	_	_	I-Premise
338	castration	_	_	I-Premise
339	,	_	_	I-Premise
340	the	_	_	B-Claim
341	favorable	_	_	I-Claim
342	quality	_	_	I-Claim
343	of	_	_	I-Claim
344	life	_	_	I-Claim
345	outcomes	_	_	I-Claim
346	and	_	_	I-Claim
347	the	_	_	I-Claim
348	low	_	_	I-Claim
349	incidence	_	_	I-Claim
350	of	_	_	I-Claim
351	nonhormonal	_	_	I-Claim
352	adverse	_	_	I-Claim
353	events	_	_	I-Claim
354	provide	_	_	I-Claim
355	reasons	_	_	I-Claim
356	to	_	_	I-Claim
357	evaluate	_	_	I-Claim
358	bicalutamide	_	_	I-Claim
359	,	_	_	I-Claim
360	as	_	_	I-Claim
361	a	_	_	I-Claim
362	single	_	_	I-Claim
363	therapeutic	_	_	I-Claim
364	agent	_	_	I-Claim
365	,	_	_	I-Claim
366	at	_	_	I-Claim
367	higher	_	_	I-Claim
368	doses	_	_	I-Claim
369	.	_	_	I-Claim


0	From	_	_	O
1	1984	_	_	O
2	to	_	_	O
3	1989	_	_	O
4	,	_	_	O
5	the	_	_	O
6	Swiss	_	_	O
7	Group	_	_	O
8	for	_	_	O
9	Clinical	_	_	O
10	Cancer	_	_	O
11	Research	_	_	O
12	(	_	_	O
13	SAKK	_	_	O
14	)	_	_	O
15	performed	_	_	O
16	a	_	_	O
17	randomized	_	_	O
18	phase	_	_	O
19	III	_	_	O
20	trial	_	_	O
21	comparing	_	_	O
22	early	_	_	O
23	versus	_	_	O
24	late	_	_	O
25	alternating	_	_	O
26	chemotherapy	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	small-cell	_	_	O
31	lung	_	_	O
32	cancer	_	_	O
33	.	_	_	O

34	406	_	_	O
35	eligible	_	_	O
36	patients	_	_	O
37	were	_	_	O
38	entered	_	_	O
39	into	_	_	O
40	the	_	_	O
41	trial	_	_	O
42	.	_	_	O

43	Regimen	_	_	O
44	A	_	_	O
45	consisted	_	_	O
46	of	_	_	O
47	PAV	_	_	O
48	(	_	_	O
49	cisPlatin	_	_	O
50	,	_	_	O
51	Adriamycin	_	_	O
52	,	_	_	O
53	VP	_	_	O
54	16-213	_	_	O
55	,	_	_	O
56	and	_	_	O
57	Regimen	_	_	O
58	B	_	_	O
59	of	_	_	O
60	CyMOC	_	_	O
61	(	_	_	O
62	Cyclophosphamide	_	_	O
63	,	_	_	O
64	Methotrexate	_	_	O
65	,	_	_	O
66	Oncovin	_	_	O
67	,	_	_	O
68	CCNU	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Cycles	_	_	O
72	were	_	_	O
73	repeated	_	_	O
74	as	_	_	O
75	rapidly	_	_	O
76	as	_	_	O
77	possible	_	_	O
78	.	_	_	O

79	patients	_	_	O
80	were	_	_	O
81	randomized	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	either	_	_	O
85	ABABAB	_	_	O
86	(	_	_	O
87	early	_	_	O
88	alternating	_	_	O
89	chemotherapy	_	_	O
90	)	_	_	O
91	or	_	_	O
92	AAABBB	_	_	O
93	(	_	_	O
94	late	_	_	O
95	alternating	_	_	O
96	chemotherapy	_	_	O
97	)	_	_	O
98	.	_	_	O

99	After	_	_	O
100	six	_	_	O
101	cycles	_	_	O
102	patients	_	_	O
103	with	_	_	O
104	limited	_	_	O
105	disease	_	_	O
106	in	_	_	O
107	complete	_	_	O
108	or	_	_	O
109	partial	_	_	O
110	remission	_	_	O
111	and	_	_	O
112	those	_	_	O
113	with	_	_	O
114	extensive	_	_	O
115	disease	_	_	O
116	in	_	_	O
117	complete	_	_	O
118	remission	_	_	O
119	received	_	_	O
120	irradiation	_	_	O
121	to	_	_	O
122	the	_	_	O
123	primary	_	_	O
124	(	_	_	O
125	45	_	_	O
126	Gy	_	_	O
127	)	_	_	O
128	and	_	_	O
129	the	_	_	O
130	CNS	_	_	O
131	(	_	_	O
132	36	_	_	O
133	Gy	_	_	O
134	)	_	_	O
135	.	_	_	O

136	The	_	_	B-Premise
137	overall	_	_	I-Premise
138	remission	_	_	I-Premise
139	rate	_	_	I-Premise
140	was	_	_	I-Premise
141	87	_	_	I-Premise
142	%	_	_	I-Premise
143	with	_	_	I-Premise
144	31	_	_	I-Premise
145	%	_	_	I-Premise
146	complete	_	_	I-Premise
147	remissions	_	_	I-Premise
148	.	_	_	I-Premise

149	The	_	_	B-Premise
150	median	_	_	I-Premise
151	survival	_	_	I-Premise
152	of	_	_	I-Premise
153	all	_	_	I-Premise
154	406	_	_	I-Premise
155	eligible	_	_	I-Premise
156	patients	_	_	I-Premise
157	was	_	_	I-Premise
158	346	_	_	I-Premise
159	days	_	_	I-Premise
160	with	_	_	I-Premise
161	15	_	_	I-Premise
162	%	_	_	I-Premise
163	of	_	_	I-Premise
164	the	_	_	I-Premise
165	patients	_	_	I-Premise
166	alive	_	_	I-Premise
167	at	_	_	I-Premise
168	two	_	_	I-Premise
169	years	_	_	I-Premise
170	.	_	_	I-Premise

171	The	_	_	B-Premise
172	overall	_	_	I-Premise
173	remission	_	_	I-Premise
174	rate	_	_	I-Premise
175	,	_	_	I-Premise
176	the	_	_	I-Premise
177	rate	_	_	I-Premise
178	of	_	_	I-Premise
179	complete	_	_	I-Premise
180	remission	_	_	I-Premise
181	,	_	_	I-Premise
182	the	_	_	I-Premise
183	median	_	_	I-Premise
184	survival	_	_	I-Premise
185	and	_	_	I-Premise
186	the	_	_	I-Premise
187	rate	_	_	I-Premise
188	of	_	_	I-Premise
189	long-term	_	_	I-Premise
190	survival	_	_	I-Premise
191	were	_	_	I-Premise
192	not	_	_	I-Premise
193	significantly	_	_	I-Premise
194	different	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	two	_	_	I-Premise
198	treatment	_	_	I-Premise
199	arms	_	_	I-Premise
200	.	_	_	I-Premise

201	In	_	_	B-Premise
202	limited	_	_	I-Premise
203	disease	_	_	I-Premise
204	the	_	_	I-Premise
205	estimated	_	_	I-Premise
206	percentages	_	_	I-Premise
207	of	_	_	I-Premise
208	survival	_	_	I-Premise
209	at	_	_	I-Premise
210	2	_	_	I-Premise
211	years	_	_	I-Premise
212	were	_	_	I-Premise
213	33	_	_	I-Premise
214	%	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	early	_	_	I-Premise
218	and	_	_	I-Premise
219	24	_	_	I-Premise
220	%	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	late	_	_	I-Premise
224	alternating	_	_	I-Premise
225	chemotherapy	_	_	I-Premise
226	arms	_	_	I-Premise
227	.	_	_	I-Premise

228	Patients	_	_	B-Premise
229	with	_	_	I-Premise
230	extensive	_	_	I-Premise
231	disease	_	_	I-Premise
232	survived	_	_	I-Premise
233	significantly	_	_	I-Premise
234	longer	_	_	I-Premise
235	with	_	_	I-Premise
236	late	_	_	I-Premise
237	alternating	_	_	I-Premise
238	chemotherapy	_	_	I-Premise
239	than	_	_	I-Premise
240	on	_	_	I-Premise
241	the	_	_	I-Premise
242	early	_	_	I-Premise
243	alternation	_	_	I-Premise
244	regimen	_	_	I-Premise
245	(	_	_	I-Premise
246	median	_	_	I-Premise
247	survival	_	_	I-Premise
248	336	_	_	I-Premise
249	days	_	_	I-Premise
250	versus	_	_	I-Premise
251	301	_	_	I-Premise
252	days	_	_	I-Premise
253	,	_	_	I-Premise
254	p	_	_	I-Premise
255	=	_	_	I-Premise
256	0.01	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	In	_	_	B-Premise
260	the	_	_	I-Premise
261	latter	_	_	I-Premise
262	patients	_	_	I-Premise
263	the	_	_	I-Premise
264	received	_	_	I-Premise
265	dose	_	_	I-Premise
266	intensities	_	_	I-Premise
267	(	_	_	I-Premise
268	RDI	_	_	I-Premise
269	)	_	_	I-Premise
270	of	_	_	I-Premise
271	cisplatin	_	_	I-Premise
272	,	_	_	I-Premise
273	adriamycin	_	_	I-Premise
274	and	_	_	I-Premise
275	etoposide	_	_	I-Premise
276	were	_	_	I-Premise
277	significantly	_	_	I-Premise
278	higher	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	late-alternation	_	_	I-Premise
282	arm	_	_	I-Premise
283	.	_	_	I-Premise

284	Patients	_	_	B-Premise
285	treated	_	_	I-Premise
286	with	_	_	I-Premise
287	early	_	_	I-Premise
288	alternating	_	_	I-Premise
289	chemotherapy	_	_	I-Premise
290	rated	_	_	I-Premise
291	their	_	_	I-Premise
292	tumor	_	_	I-Premise
293	symptoms	_	_	I-Premise
294	,	_	_	I-Premise
295	functional	_	_	I-Premise
296	states	_	_	I-Premise
297	,	_	_	I-Premise
298	fatigue/malaise	_	_	I-Premise
299	and	_	_	I-Premise
300	restriction	_	_	I-Premise
301	of	_	_	I-Premise
302	social	_	_	I-Premise
303	activity	_	_	I-Premise
304	significantly	_	_	I-Premise
305	better	_	_	I-Premise
306	,	_	_	I-Premise
307	reflecting	_	_	I-Premise
308	an	_	_	I-Premise
309	improved	_	_	I-Premise
310	subjective	_	_	I-Premise
311	adjustment	_	_	I-Premise
312	.	_	_	I-Premise

313	Alternating	_	_	B-Claim
314	chemotherapy	_	_	I-Claim
315	with	_	_	I-Claim
316	PAV-CyMOC	_	_	I-Claim
317	plus	_	_	I-Claim
318	consolidating	_	_	I-Claim
319	radiotherapy	_	_	I-Claim
320	is	_	_	I-Claim
321	a	_	_	I-Claim
322	feasible	_	_	I-Claim
323	and	_	_	I-Claim
324	effective	_	_	I-Claim
325	treatment	_	_	I-Claim
326	for	_	_	I-Claim
327	small-cell	_	_	I-Claim
328	lung	_	_	I-Claim
329	cancer	_	_	I-Claim
330	,	_	_	I-Claim
331	with	_	_	I-Claim
332	acceptable	_	_	I-Claim
333	toxicity	_	_	I-Claim
334	.	_	_	I-Claim

335	Whereas	_	_	O
336	patients	_	_	B-Claim
337	with	_	_	I-Claim
338	early	_	_	I-Claim
339	alternating	_	_	I-Claim
340	chemotherapy	_	_	I-Claim
341	achieve	_	_	I-Claim
342	a	_	_	I-Claim
343	better	_	_	I-Claim
344	subjective	_	_	I-Claim
345	adjustment	_	_	I-Claim
346	,	_	_	I-Claim
347	late	_	_	B-Claim
348	alternating	_	_	I-Claim
349	chemotherapy	_	_	I-Claim
350	allows	_	_	I-Claim
351	for	_	_	I-Claim
352	a	_	_	I-Claim
353	higher	_	_	I-Claim
354	RDI	_	_	I-Claim
355	of	_	_	I-Claim
356	cisplatin	_	_	I-Claim
357	,	_	_	I-Claim
358	adriamycin	_	_	I-Claim
359	and	_	_	I-Claim
360	etoposide	_	_	I-Claim
361	,	_	_	I-Claim
362	which	_	_	I-Claim
363	results	_	_	I-Claim
364	in	_	_	I-Claim
365	a	_	_	I-Claim
366	significantly	_	_	I-Claim
367	longer	_	_	I-Claim
368	median	_	_	I-Claim
369	survival	_	_	I-Claim
370	of	_	_	I-Claim
371	patients	_	_	I-Claim
372	with	_	_	I-Claim
373	extensive	_	_	I-Claim
374	disease	_	_	I-Claim
375	.	_	_	I-Claim


0	Taxol	_	_	B-Premise
1	(	_	_	I-Premise
2	paclitaxel	_	_	I-Premise
3	;	_	_	I-Premise
4	Bristol-Myers	_	_	I-Premise
5	Squibb	_	_	I-Premise
6	,	_	_	I-Premise
7	Wallingford	_	_	I-Premise
8	,	_	_	I-Premise
9	CT	_	_	I-Premise
10	)	_	_	I-Premise
11	is	_	_	I-Premise
12	a	_	_	I-Premise
13	new	_	_	I-Premise
14	anticancer	_	_	I-Premise
15	agent	_	_	I-Premise
16	with	_	_	I-Premise
17	activity	_	_	I-Premise
18	in	_	_	I-Premise
19	a	_	_	I-Premise
20	number	_	_	I-Premise
21	of	_	_	I-Premise
22	human	_	_	I-Premise
23	tumors	_	_	I-Premise
24	,	_	_	I-Premise
25	including	_	_	I-Premise
26	epithelial	_	_	I-Premise
27	ovarian	_	_	I-Premise
28	cancer	_	_	I-Premise
29	.	_	_	I-Premise

30	In	_	_	O
31	nonrandomized	_	_	O
32	trials	_	_	O
33	,	_	_	O
34	doses	_	_	O
35	studied	_	_	O
36	have	_	_	O
37	ranged	_	_	O
38	from	_	_	O
39	135	_	_	O
40	mg/m2	_	_	O
41	to	_	_	O
42	250	_	_	O
43	mg/m2	_	_	O
44	administered	_	_	O
45	over	_	_	O
46	24	_	_	O
47	hours	_	_	O
48	with	_	_	O
49	premedication	_	_	O
50	to	_	_	O
51	avoid	_	_	O
52	hypersensitivity	_	_	O
53	reactions	_	_	O
54	(	_	_	O
55	HSRs	_	_	O
56	)	_	_	O
57	.	_	_	O

58	This	_	_	O
59	study	_	_	O
60	addressed	_	_	O
61	two	_	_	O
62	questions	_	_	O
63	:	_	_	O
64	the	_	_	O
65	dose-response	_	_	O
66	relationship	_	_	O
67	of	_	_	O
68	Taxol	_	_	O
69	in	_	_	O
70	relapsed	_	_	O
71	ovarian	_	_	O
72	cancer	_	_	O
73	and	_	_	O
74	the	_	_	O
75	safety	_	_	O
76	of	_	_	O
77	a	_	_	O
78	short	_	_	O
79	infusion	_	_	O
80	given	_	_	O
81	with	_	_	O
82	premedication	_	_	O
83	.	_	_	O

84	Women	_	_	O
85	with	_	_	O
86	platinum-pretreated	_	_	O
87	epithelial	_	_	O
88	ovarian	_	_	O
89	cancer	_	_	O
90	and	_	_	O
91	measurable	_	_	O
92	recurrent	_	_	O
93	disease	_	_	O
94	were	_	_	O
95	randomized	_	_	O
96	in	_	_	O
97	a	_	_	O
98	bifactorial	_	_	O
99	design	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	either	_	_	O
103	175	_	_	O
104	or	_	_	O
105	135	_	_	O
106	mg/m2	_	_	O
107	of	_	_	O
108	Taxol	_	_	O
109	over	_	_	O
110	either	_	_	O
111	24	_	_	O
112	or	_	_	O
113	3	_	_	O
114	hours	_	_	O
115	.	_	_	O

116	Major	_	_	O
117	end	_	_	O
118	points	_	_	O
119	were	_	_	O
120	the	_	_	O
121	frequency	_	_	O
122	of	_	_	O
123	significant	_	_	O
124	HSRs	_	_	O
125	and	_	_	O
126	objective	_	_	O
127	response	_	_	O
128	rate	_	_	O
129	.	_	_	O

130	Secondary	_	_	O
131	end	_	_	O
132	points	_	_	O
133	were	_	_	O
134	progression-free	_	_	O
135	and	_	_	O
136	overall	_	_	O
137	survival	_	_	O
138	.	_	_	O

139	Of	_	_	O
140	407	_	_	O
141	patients	_	_	O
142	randomized	_	_	O
143	,	_	_	O
144	391	_	_	O
145	were	_	_	O
146	eligible	_	_	O
147	and	_	_	O
148	382	_	_	O
149	assessable	_	_	O
150	for	_	_	O
151	response	_	_	O
152	.	_	_	O

153	Analysis	_	_	O
154	was	_	_	O
155	performed	_	_	O
156	according	_	_	O
157	to	_	_	O
158	the	_	_	O
159	bifactorial	_	_	O
160	design	_	_	O
161	.	_	_	O

162	Severe	_	_	B-Premise
163	HSRs	_	_	I-Premise
164	were	_	_	I-Premise
165	rare	_	_	I-Premise
166	(	_	_	I-Premise
167	1.5	_	_	I-Premise
168	%	_	_	I-Premise
169	patients	_	_	I-Premise
170	)	_	_	I-Premise
171	and	_	_	I-Premise
172	were	_	_	I-Premise
173	not	_	_	I-Premise
174	affected	_	_	I-Premise
175	by	_	_	I-Premise
176	either	_	_	I-Premise
177	dose	_	_	I-Premise
178	or	_	_	I-Premise
179	schedule	_	_	I-Premise
180	.	_	_	I-Premise

181	Response	_	_	B-Premise
182	was	_	_	I-Premise
183	slightly	_	_	I-Premise
184	higher	_	_	I-Premise
185	at	_	_	I-Premise
186	the	_	_	I-Premise
187	175-mg/m2	_	_	I-Premise
188	dose	_	_	I-Premise
189	(	_	_	I-Premise
190	20	_	_	I-Premise
191	%	_	_	I-Premise
192	)	_	_	I-Premise
193	than	_	_	I-Premise
194	at	_	_	I-Premise
195	135	_	_	I-Premise
196	mg/m2	_	_	I-Premise
197	(	_	_	I-Premise
198	15	_	_	I-Premise
199	%	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	but	_	_	B-Premise
203	this	_	_	I-Premise
204	was	_	_	I-Premise
205	not	_	_	I-Premise
206	statistically	_	_	I-Premise
207	significant	_	_	I-Premise
208	(	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	.2	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	However	_	_	B-Premise
215	,	_	_	I-Premise
216	progression-free	_	_	I-Premise
217	survival	_	_	I-Premise
218	was	_	_	I-Premise
219	significantly	_	_	I-Premise
220	longer	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	high-dose	_	_	I-Premise
224	group	_	_	I-Premise
225	(	_	_	I-Premise
226	19	_	_	I-Premise
227	v	_	_	I-Premise
228	14	_	_	I-Premise
229	weeks	_	_	I-Premise
230	;	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.02	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Significantly	_	_	B-Premise
237	more	_	_	I-Premise
238	neutropenia	_	_	I-Premise
239	was	_	_	I-Premise
240	seen	_	_	I-Premise
241	when	_	_	I-Premise
242	Taxol	_	_	I-Premise
243	was	_	_	I-Premise
244	administered	_	_	I-Premise
245	as	_	_	I-Premise
246	a	_	_	I-Premise
247	24-hour	_	_	I-Premise
248	infusion	_	_	I-Premise
249	.	_	_	I-Premise

250	Response	_	_	B-Premise
251	rates	_	_	I-Premise
252	were	_	_	I-Premise
253	similar	_	_	I-Premise
254	in	_	_	I-Premise
255	the	_	_	I-Premise
256	24-	_	_	I-Premise
257	and	_	_	I-Premise
258	3-hour	_	_	I-Premise
259	groups	_	_	I-Premise
260	(	_	_	I-Premise
261	19	_	_	I-Premise
262	%	_	_	I-Premise
263	and	_	_	I-Premise
264	16	_	_	I-Premise
265	%	_	_	I-Premise
266	,	_	_	I-Premise
267	respectively	_	_	I-Premise
268	;	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.6	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	No	_	_	B-Premise
275	survival	_	_	I-Premise
276	differences	_	_	I-Premise
277	were	_	_	I-Premise
278	noted	_	_	I-Premise
279	.	_	_	I-Premise

280	The	_	_	B-Claim
281	3-hour	_	_	I-Claim
282	infusion	_	_	I-Claim
283	of	_	_	I-Claim
284	Taxol	_	_	I-Claim
285	is	_	_	I-Claim
286	safe	_	_	I-Claim
287	when	_	_	I-Claim
288	given	_	_	I-Claim
289	with	_	_	I-Claim
290	premedication	_	_	I-Claim
291	and	_	_	I-Claim
292	is	_	_	I-Claim
293	associated	_	_	I-Claim
294	with	_	_	I-Claim
295	less	_	_	I-Claim
296	neutropenia	_	_	I-Claim
297	.	_	_	I-Claim

298	There	_	_	O
299	is	_	_	O
300	a	_	_	O
301	modest	_	_	O
302	dose	_	_	O
303	effect	_	_	O
304	with	_	_	O
305	longer	_	_	O
306	time	_	_	O
307	to	_	_	O
308	progression	_	_	O
309	at	_	_	O
310	175	_	_	O
311	mg/m2	_	_	O
312	.	_	_	O

313	The	_	_	B-Claim
314	observation	_	_	I-Claim
315	that	_	_	I-Claim
316	longer	_	_	I-Claim
317	infusion	_	_	I-Claim
318	produces	_	_	I-Claim
319	more	_	_	I-Claim
320	myelosuppression	_	_	I-Claim
321	but	_	_	I-Claim
322	does	_	_	I-Claim
323	not	_	_	I-Claim
324	yield	_	_	I-Claim
325	higher	_	_	I-Claim
326	response	_	_	I-Claim
327	rates	_	_	I-Claim
328	should	_	_	I-Claim
329	lead	_	_	I-Claim
330	to	_	_	I-Claim
331	further	_	_	I-Claim
332	studies	_	_	I-Claim
333	to	_	_	I-Claim
334	determine	_	_	I-Claim
335	the	_	_	I-Claim
336	optimal	_	_	I-Claim
337	dose	_	_	I-Claim
338	and	_	_	I-Claim
339	schedule	_	_	I-Claim
340	of	_	_	I-Claim
341	this	_	_	I-Claim
342	interesting	_	_	I-Claim
343	new	_	_	I-Claim
344	agent	_	_	I-Claim
345	.	_	_	I-Claim


0	The	_	_	O
1	Baerveldt	_	_	O
2	glaucoma	_	_	O
3	implant	_	_	O
4	is	_	_	O
5	a	_	_	O
6	large	_	_	O
7	equatorial	_	_	O
8	aqueous	_	_	O
9	shunting	_	_	O
10	device	_	_	O
11	that	_	_	O
12	is	_	_	O
13	installed	_	_	O
14	through	_	_	O
15	a	_	_	O
16	single-quadrant	_	_	O
17	conjunctival	_	_	O
18	incision	_	_	O
19	.	_	_	O

20	The	_	_	O
21	intermediate-term	_	_	O
22	results	_	_	O
23	of	_	_	O
24	a	_	_	O
25	randomized	_	_	O
26	study	_	_	O
27	comparing	_	_	O
28	the	_	_	O
29	350-	_	_	O
30	and	_	_	O
31	500-mm2	_	_	O
32	Baerveldt	_	_	O
33	implants	_	_	O
34	are	_	_	O
35	reported	_	_	O
36	.	_	_	O

37	Seventy-three	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	medically	_	_	O
41	uncontrollable	_	_	O
42	,	_	_	O
43	nonneovascular	_	_	O
44	glaucomas	_	_	O
45	associated	_	_	O
46	with	_	_	O
47	aphakia	_	_	O
48	,	_	_	O
49	pseudophakia	_	_	O
50	,	_	_	O
51	or	_	_	O
52	failed	_	_	O
53	filters	_	_	O
54	were	_	_	O
55	enrolled	_	_	O
56	in	_	_	O
57	a	_	_	O
58	randomized	_	_	O
59	,	_	_	O
60	prospective	_	_	O
61	study	_	_	O
62	comparing	_	_	O
63	350-	_	_	O
64	and	_	_	O
65	500-mm2	_	_	O
66	Baerveldt	_	_	O
67	implants	_	_	O
68	.	_	_	O

69	Surgical	_	_	O
70	success	_	_	O
71	was	_	_	O
72	defined	_	_	O
73	as	_	_	O
74	6	_	_	O
75	mmHg	_	_	O
76	<	_	_	O
77	or	_	_	O
78	=	_	_	O
79	final	_	_	O
80	intraocular	_	_	O
81	pressure	_	_	O
82	<	_	_	O
83	or	_	_	O
84	=	_	_	O
85	21	_	_	O
86	mmHg	_	_	O
87	without	_	_	O
88	glaucoma	_	_	O
89	reoperation	_	_	O
90	or	_	_	O
91	devastating	_	_	O
92	complication	_	_	O
93	.	_	_	O

94	Of	_	_	B-Premise
95	patients	_	_	I-Premise
96	with	_	_	I-Premise
97	350-	_	_	I-Premise
98	and	_	_	I-Premise
99	500-mm2	_	_	I-Premise
100	implants	_	_	I-Premise
101	,	_	_	I-Premise
102	93	_	_	I-Premise
103	%	_	_	I-Premise
104	and	_	_	I-Premise
105	88	_	_	I-Premise
106	%	_	_	I-Premise
107	,	_	_	I-Premise
108	respectively	_	_	I-Premise
109	,	_	_	I-Premise
110	achieved	_	_	I-Premise
111	surgical	_	_	I-Premise
112	success	_	_	I-Premise
113	(	_	_	I-Premise
114	18-month	_	_	I-Premise
115	life-table	_	_	I-Premise
116	analysis	_	_	I-Premise
117	,	_	_	I-Premise
118	P	_	_	I-Premise
119	=	_	_	I-Premise
120	0.93	_	_	I-Premise
121	)	_	_	I-Premise
122	.	_	_	I-Premise

123	The	_	_	B-Premise
124	500-mm2	_	_	I-Premise
125	implants	_	_	I-Premise
126	afforded	_	_	I-Premise
127	intraocular	_	_	I-Premise
128	pressure	_	_	I-Premise
129	control	_	_	I-Premise
130	with	_	_	I-Premise
131	significantly	_	_	I-Premise
132	fewer	_	_	I-Premise
133	medications	_	_	I-Premise
134	(	_	_	I-Premise
135	0.7	_	_	I-Premise
136	versus	_	_	I-Premise
137	1.3	_	_	I-Premise
138	;	_	_	I-Premise
139	P	_	_	I-Premise
140	=	_	_	I-Premise
141	0.006	_	_	I-Premise
142	)	_	_	I-Premise
143	.	_	_	I-Premise

144	The	_	_	B-Premise
145	postoperative	_	_	I-Premise
146	visual	_	_	I-Premise
147	acuities	_	_	I-Premise
148	remained	_	_	I-Premise
149	within	_	_	I-Premise
150	one	_	_	I-Premise
151	line	_	_	I-Premise
152	of	_	_	I-Premise
153	the	_	_	I-Premise
154	preoperative	_	_	I-Premise
155	visual	_	_	I-Premise
156	acuities	_	_	I-Premise
157	or	_	_	I-Premise
158	improved	_	_	I-Premise
159	in	_	_	I-Premise
160	62	_	_	I-Premise
161	%	_	_	I-Premise
162	and	_	_	I-Premise
163	66	_	_	I-Premise
164	%	_	_	I-Premise
165	of	_	_	I-Premise
166	patients	_	_	I-Premise
167	in	_	_	I-Premise
168	the	_	_	I-Premise
169	350-	_	_	I-Premise
170	and	_	_	I-Premise
171	500-mm2	_	_	I-Premise
172	groups	_	_	I-Premise
173	,	_	_	I-Premise
174	respectively	_	_	I-Premise
175	(	_	_	I-Premise
176	P	_	_	I-Premise
177	=	_	_	I-Premise
178	0.93	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	Complication	_	_	B-Claim
182	rates	_	_	I-Claim
183	were	_	_	I-Claim
184	statistically	_	_	I-Claim
185	similar	_	_	I-Claim
186	.	_	_	I-Claim

187	The	_	_	B-Premise
188	most	_	_	I-Premise
189	frequent	_	_	I-Premise
190	ones	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	350-	_	_	I-Premise
194	and	_	_	I-Premise
195	500-mm2	_	_	I-Premise
196	groups	_	_	I-Premise
197	,	_	_	I-Premise
198	respectively	_	_	I-Premise
199	,	_	_	I-Premise
200	were	_	_	I-Premise
201	serous	_	_	I-Premise
202	choroidal	_	_	I-Premise
203	effusion	_	_	I-Premise
204	(	_	_	I-Premise
205	16	_	_	I-Premise
206	%	_	_	I-Premise
207	and	_	_	I-Premise
208	32	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	strabismus	_	_	I-Premise
213	(	_	_	I-Premise
214	16	_	_	I-Premise
215	%	_	_	I-Premise
216	and	_	_	I-Premise
217	19	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	anterior	_	_	I-Premise
222	uveitis	_	_	I-Premise
223	(	_	_	I-Premise
224	14	_	_	I-Premise
225	%	_	_	I-Premise
226	and	_	_	I-Premise
227	11	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	corneal	_	_	I-Premise
233	or	_	_	I-Premise
234	corneal	_	_	I-Premise
235	graft	_	_	I-Premise
236	edema	_	_	I-Premise
237	(	_	_	I-Premise
238	11	_	_	I-Premise
239	%	_	_	I-Premise
240	each	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Claim
244	intermediate-term	_	_	I-Claim
245	results	_	_	I-Claim
246	of	_	_	I-Claim
247	the	_	_	I-Claim
248	350-	_	_	I-Claim
249	and	_	_	I-Claim
250	500-mm2	_	_	I-Claim
251	Baerveldt	_	_	I-Claim
252	implants	_	_	I-Claim
253	were	_	_	I-Claim
254	statistically	_	_	I-Claim
255	comparable	_	_	I-Claim
256	with	_	_	I-Claim
257	respect	_	_	I-Claim
258	to	_	_	I-Claim
259	surgical	_	_	I-Claim
260	and	_	_	I-Claim
261	visual	_	_	I-Claim
262	outcomes	_	_	I-Claim
263	,	_	_	I-Claim
264	as	_	_	I-Claim
265	well	_	_	I-Claim
266	as	_	_	I-Claim
267	complications	_	_	I-Claim
268	,	_	_	O
269	although	_	_	B-Claim
270	the	_	_	I-Claim
271	larger	_	_	I-Claim
272	implant	_	_	I-Claim
273	was	_	_	I-Claim
274	associated	_	_	I-Claim
275	with	_	_	I-Claim
276	a	_	_	I-Claim
277	higher	_	_	I-Claim
278	rate	_	_	I-Claim
279	of	_	_	I-Claim
280	some	_	_	I-Claim
281	complications	_	_	I-Claim
282	.	_	_	I-Claim

283	However	_	_	O
284	,	_	_	O
285	the	_	_	B-Claim
286	500-mm2	_	_	I-Claim
287	Baerveldt	_	_	I-Claim
288	implant	_	_	I-Claim
289	afforded	_	_	I-Claim
290	intraocular	_	_	I-Claim
291	pressure	_	_	I-Claim
292	control	_	_	I-Claim
293	with	_	_	I-Claim
294	fewer	_	_	I-Claim
295	medications	_	_	I-Claim
296	than	_	_	I-Claim
297	the	_	_	I-Claim
298	350-mm2	_	_	I-Claim
299	implant	_	_	I-Claim
300	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-reducing	_	_	O
9	effect	_	_	O
10	and	_	_	O
11	side	_	_	O
12	effects	_	_	O
13	of	_	_	O
14	0.005	_	_	O
15	%	_	_	O
16	latanoprost	_	_	O
17	administered	_	_	O
18	once	_	_	O
19	daily	_	_	O
20	with	_	_	O
21	0.5	_	_	O
22	%	_	_	O
23	timolol	_	_	O
24	administered	_	_	O
25	twice	_	_	O
26	daily	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	open-angle	_	_	O
31	glaucoma	_	_	O
32	or	_	_	O
33	ocular	_	_	O
34	hypertension	_	_	O
35	.	_	_	O

36	This	_	_	O
37	was	_	_	O
38	a	_	_	O
39	randomized	_	_	O
40	,	_	_	O
41	double-masked	_	_	O
42	study	_	_	O
43	with	_	_	O
44	two	_	_	O
45	parallel	_	_	O
46	groups	_	_	O
47	and	_	_	O
48	a	_	_	O
49	treatment	_	_	O
50	period	_	_	O
51	of	_	_	O
52	6	_	_	O
53	months	_	_	O
54	.	_	_	O

55	The	_	_	O
56	primary	_	_	O
57	objective	_	_	O
58	of	_	_	O
59	the	_	_	O
60	study	_	_	O
61	is	_	_	O
62	to	_	_	O
63	compare	_	_	O
64	the	_	_	O
65	IOP-reducing	_	_	O
66	effect	_	_	O
67	of	_	_	O
68	latanoprost	_	_	O
69	with	_	_	O
70	that	_	_	O
71	of	_	_	O
72	timolol	_	_	O
73	at	_	_	O
74	the	_	_	O
75	end	_	_	O
76	of	_	_	O
77	the	_	_	O
78	6-month	_	_	O
79	treatment	_	_	O
80	period	_	_	O
81	.	_	_	O

82	A	_	_	O
83	total	_	_	O
84	of	_	_	O
85	294	_	_	O
86	patients	_	_	O
87	were	_	_	O
88	included	_	_	O
89	:	_	_	O
90	149	_	_	O
91	were	_	_	O
92	in	_	_	O
93	the	_	_	O
94	latanoprost	_	_	O
95	group	_	_	O
96	and	_	_	O
97	145	_	_	O
98	were	_	_	O
99	in	_	_	O
100	timolol	_	_	O
101	group	_	_	O
102	.	_	_	O

103	Latanoprost	_	_	O
104	was	_	_	O
105	administered	_	_	O
106	in	_	_	O
107	the	_	_	O
108	evening	_	_	O
109	.	_	_	O

110	Diurnal	_	_	B-Premise
111	IOP	_	_	I-Premise
112	(	_	_	I-Premise
113	9:00	_	_	I-Premise
114	am	_	_	I-Premise
115	,	_	_	I-Premise
116	1:00	_	_	I-Premise
117	pm	_	_	I-Premise
118	,	_	_	I-Premise
119	5:00	_	_	I-Premise
120	pm	_	_	I-Premise
121	)	_	_	I-Premise
122	was	_	_	I-Premise
123	reduced	_	_	I-Premise
124	from	_	_	I-Premise
125	25.2	_	_	I-Premise
126	to	_	_	I-Premise
127	16.7	_	_	I-Premise
128	mmHg	_	_	I-Premise
129	(	_	_	I-Premise
130	33.7	_	_	I-Premise
131	%	_	_	I-Premise
132	)	_	_	I-Premise
133	with	_	_	I-Premise
134	lantanoprost	_	_	I-Premise
135	and	_	_	I-Premise
136	from	_	_	I-Premise
137	25.4	_	_	I-Premise
138	to	_	_	I-Premise
139	17.1	_	_	I-Premise
140	mmHg	_	_	I-Premise
141	(	_	_	I-Premise
142	32.7	_	_	I-Premise
143	%	_	_	I-Premise
144	)	_	_	I-Premise
145	with	_	_	I-Premise
146	timolol	_	_	I-Premise
147	as	_	_	I-Premise
148	determined	_	_	I-Premise
149	at	_	_	I-Premise
150	the	_	_	I-Premise
151	end	_	_	I-Premise
152	of	_	_	I-Premise
153	the	_	_	I-Premise
154	6-month	_	_	I-Premise
155	treatment	_	_	I-Premise
156	period	_	_	I-Premise
157	.	_	_	I-Premise

158	No	_	_	O
159	upward	_	_	O
160	drift	_	_	O
161	in	_	_	O
162	IOP	_	_	O
163	occurred	_	_	O
164	with	_	_	O
165	either	_	_	O
166	drug	_	_	O
167	during	_	_	O
168	the	_	_	O
169	treatment	_	_	O
170	period	_	_	O
171	.	_	_	O

172	Latanoprost	_	_	B-Premise
173	caused	_	_	I-Premise
174	a	_	_	I-Premise
175	somewhat	_	_	I-Premise
176	more	_	_	I-Premise
177	conjunctival	_	_	I-Premise
178	hyperemia	_	_	I-Premise
179	than	_	_	I-Premise
180	timolol	_	_	I-Premise
181	and	_	_	I-Premise
182	more	_	_	I-Premise
183	corneal	_	_	I-Premise
184	punctuate	_	_	I-Premise
185	epithelial	_	_	I-Premise
186	erosions	_	_	I-Premise
187	.	_	_	I-Premise

188	However	_	_	O
189	,	_	_	O
190	both	_	_	B-Premise
191	drugs	_	_	I-Premise
192	were	_	_	I-Premise
193	generally	_	_	I-Premise
194	well	_	_	I-Premise
195	tolerated	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	most	_	_	I-Premise
199	significant	_	_	I-Premise
200	side	_	_	I-Premise
201	effect	_	_	I-Premise
202	of	_	_	I-Premise
203	latanoprost	_	_	I-Premise
204	was	_	_	I-Premise
205	increased	_	_	I-Premise
206	pigmentation	_	_	I-Premise
207	of	_	_	I-Premise
208	the	_	_	I-Premise
209	iris	_	_	I-Premise
210	which	_	_	I-Premise
211	was	_	_	I-Premise
212	observed	_	_	I-Premise
213	in	_	_	I-Premise
214	15	_	_	I-Premise
215	patients	_	_	I-Premise
216	(	_	_	I-Premise
217	10.1	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	Timolol	_	_	B-Claim
222	caused	_	_	I-Claim
223	more	_	_	I-Claim
224	systemic	_	_	I-Claim
225	side	_	_	I-Claim
226	effects	_	_	I-Claim
227	than	_	_	I-Claim
228	latanoprost	_	_	I-Claim
229	.	_	_	I-Claim

230	Latanoprost	_	_	B-Claim
231	0.005	_	_	I-Claim
232	%	_	_	I-Claim
233	administered	_	_	I-Claim
234	once	_	_	I-Claim
235	daily	_	_	I-Claim
236	in	_	_	I-Claim
237	the	_	_	I-Claim
238	evening	_	_	I-Claim
239	reduced	_	_	I-Claim
240	IOP	_	_	I-Claim
241	at	_	_	I-Claim
242	least	_	_	I-Claim
243	as	_	_	I-Claim
244	well	_	_	I-Claim
245	as	_	_	I-Claim
246	timolol	_	_	I-Claim
247	0.5	_	_	I-Claim
248	%	_	_	I-Claim
249	administered	_	_	I-Claim
250	twice	_	_	I-Claim
251	daily	_	_	I-Claim
252	.	_	_	I-Claim

253	Latanoprost	_	_	B-Claim
254	was	_	_	I-Claim
255	generally	_	_	I-Claim
256	well	_	_	I-Claim
257	tolerated	_	_	I-Claim
258	systemically	_	_	I-Claim
259	and	_	_	I-Claim
260	in	_	_	I-Claim
261	the	_	_	I-Claim
262	eye	_	_	I-Claim
263	.	_	_	I-Claim

264	However	_	_	O
265	,	_	_	O
266	the	_	_	O
267	drug	_	_	O
268	has	_	_	O
269	an	_	_	O
270	unusual	_	_	O
271	side	_	_	O
272	effect	_	_	O
273	of	_	_	O
274	increasing	_	_	O
275	the	_	_	O
276	pigmentation	_	_	O
277	of	_	_	O
278	the	_	_	O
279	iris	_	_	O
280	,	_	_	O
281	particularly	_	_	O
282	in	_	_	O
283	individuals	_	_	O
284	with	_	_	O
285	green-brown	_	_	O
286	or	_	_	O
287	blue-brown	_	_	O
288	eyes	_	_	O
289	.	_	_	O


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	medroxyprogesterone	_	_	O
6	acetate	_	_	O
7	(	_	_	O
8	MPA	_	_	O
9	)	_	_	O
10	on	_	_	O
11	appetite	_	_	O
12	,	_	_	O
13	weight	_	_	O
14	,	_	_	O
15	and	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QL	_	_	O
21	)	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	advanced-stage	_	_	O
26	,	_	_	O
27	incurable	_	_	O
28	,	_	_	O
29	non-hormone-sensitive	_	_	O
30	cancer	_	_	O
31	.	_	_	O

32	Two	_	_	O
33	hundred	_	_	O
34	six	_	_	O
35	eligible	_	_	O
36	patients	_	_	O
37	were	_	_	O
38	randomized	_	_	O
39	between	_	_	O
40	double-blind	_	_	O
41	MPA	_	_	O
42	500	_	_	O
43	mg	_	_	O
44	twice	_	_	O
45	daily	_	_	O
46	or	_	_	O
47	placebo	_	_	O
48	.	_	_	O

49	Appetite	_	_	O
50	(	_	_	O
51	0	_	_	O
52	to	_	_	O
53	10	_	_	O
54	numerical	_	_	O
55	rating	_	_	O
56	scale	_	_	O
57	)	_	_	O
58	,	_	_	O
59	weight	_	_	O
60	,	_	_	O
61	and	_	_	O
62	QL	_	_	O
63	(	_	_	O
64	European	_	_	O
65	Organization	_	_	O
66	for	_	_	O
67	Research	_	_	O
68	and	_	_	O
69	Treatment	_	_	O
70	of	_	_	O
71	Cancer	_	_	O
72	Quality	_	_	O
73	of	_	_	O
74	Life	_	_	O
75	Questionnaire	_	_	O
76	[	_	_	O
77	EORTC-QLQ-C30	_	_	O
78	]	_	_	O
79	)	_	_	O
80	were	_	_	O
81	assessed	_	_	O
82	before	_	_	O
83	the	_	_	O
84	start	_	_	O
85	of	_	_	O
86	treatment	_	_	O
87	(	_	_	O
88	t	_	_	O
89	=	_	_	O
90	0	_	_	O
91	)	_	_	O
92	,	_	_	O
93	and	_	_	O
94	6	_	_	O
95	weeks	_	_	O
96	(	_	_	O
97	t	_	_	O
98	=	_	_	O
99	6	_	_	O
100	)	_	_	O
101	and	_	_	O
102	12	_	_	O
103	weeks	_	_	O
104	(	_	_	O
105	t	_	_	O
106	=	_	_	O
107	12	_	_	O
108	)	_	_	O
109	thereafter	_	_	O
110	.	_	_	O

111	One	_	_	O
112	hundred	_	_	O
113	thirty-four	_	_	O
114	patients	_	_	O
115	(	_	_	O
116	68	_	_	O
117	MPA	_	_	O
118	and	_	_	O
119	66	_	_	O
120	placebo	_	_	O
121	)	_	_	O
122	were	_	_	O
123	assessable	_	_	O
124	at	_	_	O
125	t	_	_	O
126	=	_	_	O
127	6	_	_	O
128	and	_	_	O
129	99	_	_	O
130	patients	_	_	O
131	(	_	_	O
132	53	_	_	O
133	MPA	_	_	O
134	and	_	_	O
135	46	_	_	O
136	placebo	_	_	O
137	)	_	_	O
138	at	_	_	O
139	t	_	_	O
140	=	_	_	O
141	12	_	_	O
142	.	_	_	O

143	A	_	_	B-Premise
144	beneficial	_	_	I-Premise
145	effect	_	_	I-Premise
146	of	_	_	I-Premise
147	MPA	_	_	I-Premise
148	on	_	_	I-Premise
149	appetite	_	_	I-Premise
150	was	_	_	I-Premise
151	observed	_	_	I-Premise
152	after	_	_	I-Premise
153	both	_	_	I-Premise
154	6	_	_	I-Premise
155	weeks	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	=	_	_	I-Premise
159	.008	_	_	I-Premise
160	)	_	_	I-Premise
161	and	_	_	I-Premise
162	12	_	_	I-Premise
163	weeks	_	_	I-Premise
164	(	_	_	I-Premise
165	P	_	_	I-Premise
166	=	_	_	I-Premise
167	.01	_	_	I-Premise
168	)	_	_	I-Premise
169	of	_	_	I-Premise
170	treatment	_	_	I-Premise
171	.	_	_	I-Premise

172	After	_	_	B-Premise
173	12	_	_	I-Premise
174	weeks	_	_	I-Premise
175	,	_	_	I-Premise
176	a	_	_	I-Premise
177	mean	_	_	I-Premise
178	weight	_	_	I-Premise
179	gain	_	_	I-Premise
180	of	_	_	I-Premise
181	0.6	_	_	I-Premise
182	+/-	_	_	I-Premise
183	4.4	_	_	I-Premise
184	kg	_	_	I-Premise
185	was	_	_	I-Premise
186	seen	_	_	I-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	MPA	_	_	I-Premise
190	,	_	_	I-Premise
191	versus	_	_	I-Premise
192	an	_	_	I-Premise
193	ongoing	_	_	I-Premise
194	mean	_	_	I-Premise
195	weight	_	_	I-Premise
196	loss	_	_	I-Premise
197	of	_	_	I-Premise
198	1.4	_	_	I-Premise
199	+/-	_	_	I-Premise
200	4.6	_	_	I-Premise
201	kg	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	placebo	_	_	I-Premise
205	group	_	_	I-Premise
206	.	_	_	I-Premise

207	This	_	_	B-Premise
208	difference	_	_	I-Premise
209	of	_	_	I-Premise
210	2.0	_	_	I-Premise
211	kg	_	_	I-Premise
212	was	_	_	I-Premise
213	statistically	_	_	I-Premise
214	significant	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.04	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	During	_	_	B-Premise
222	the	_	_	I-Premise
223	study	_	_	I-Premise
224	,	_	_	I-Premise
225	several	_	_	I-Premise
226	areas	_	_	I-Premise
227	of	_	_	I-Premise
228	QL	_	_	I-Premise
229	deteriorated	_	_	I-Premise
230	in	_	_	I-Premise
231	the	_	_	I-Premise
232	total	_	_	I-Premise
233	group	_	_	I-Premise
234	of	_	_	I-Premise
235	patients	_	_	I-Premise
236	.	_	_	I-Premise

237	With	_	_	B-Claim
238	the	_	_	I-Claim
239	exception	_	_	I-Claim
240	of	_	_	I-Claim
241	an	_	_	I-Claim
242	improvement	_	_	I-Claim
243	in	_	_	I-Claim
244	appetite	_	_	I-Claim
245	and	_	_	I-Claim
246	possible	_	_	I-Claim
247	also	_	_	I-Claim
248	a	_	_	I-Claim
249	reduction	_	_	I-Claim
250	in	_	_	I-Claim
251	nausea	_	_	I-Claim
252	and	_	_	I-Claim
253	vomiting	_	_	I-Claim
254	,	_	_	I-Claim
255	no	_	_	I-Claim
256	measurable	_	_	I-Claim
257	beneficial	_	_	I-Claim
258	effects	_	_	I-Claim
259	of	_	_	I-Claim
260	MPA	_	_	I-Claim
261	on	_	_	I-Claim
262	QL	_	_	I-Claim
263	could	_	_	I-Claim
264	be	_	_	I-Claim
265	demonstrated	_	_	I-Claim
266	.	_	_	I-Claim

267	The	_	_	B-Premise
268	side	_	_	I-Premise
269	effects	_	_	I-Premise
270	profile	_	_	I-Premise
271	of	_	_	I-Premise
272	MPA	_	_	I-Premise
273	was	_	_	I-Premise
274	favorable	_	_	I-Premise
275	:	_	_	I-Premise
276	only	_	_	I-Premise
277	a	_	_	I-Premise
278	trend	_	_	I-Premise
279	toward	_	_	I-Premise
280	an	_	_	I-Premise
281	increase	_	_	I-Premise
282	in	_	_	I-Premise
283	(	_	_	I-Premise
284	usually	_	_	I-Premise
285	mild	_	_	I-Premise
286	)	_	_	I-Premise
287	peripheral	_	_	I-Premise
288	edema	_	_	I-Premise
289	was	_	_	I-Premise
290	observed	_	_	I-Premise
291	.	_	_	I-Premise

292	In	_	_	B-Claim
293	weight-losing	_	_	I-Claim
294	,	_	_	I-Claim
295	advanced-stage	_	_	I-Claim
296	non-hormone-sensitive	_	_	I-Claim
297	cancer	_	_	I-Claim
298	patients	_	_	I-Claim
299	,	_	_	I-Claim
300	MPA	_	_	I-Claim
301	exhibits	_	_	I-Claim
302	a	_	_	I-Claim
303	mild	_	_	I-Claim
304	side	_	_	I-Claim
305	effects	_	_	I-Claim
306	profile	_	_	I-Claim
307	,	_	_	I-Claim
308	has	_	_	I-Claim
309	a	_	_	I-Claim
310	beneficial	_	_	I-Claim
311	effect	_	_	I-Claim
312	on	_	_	I-Claim
313	appetite	_	_	I-Claim
314	,	_	_	I-Claim
315	and	_	_	I-Claim
316	may	_	_	I-Claim
317	prevent	_	_	I-Claim
318	further	_	_	I-Claim
319	weight	_	_	I-Claim
320	loss	_	_	I-Claim
321	.	_	_	I-Claim

322	However	_	_	B-Claim
323	,	_	_	I-Claim
324	general	_	_	I-Claim
325	QL	_	_	I-Claim
326	in	_	_	I-Claim
327	the	_	_	I-Claim
328	present	_	_	I-Claim
329	study	_	_	I-Claim
330	was	_	_	I-Claim
331	not	_	_	I-Claim
332	measurably	_	_	I-Claim
333	influenced	_	_	I-Claim
334	by	_	_	I-Claim
335	MPA	_	_	I-Claim
336	treatment	_	_	I-Claim
337	.	_	_	I-Claim


0	Cerebral	_	_	B-Claim
1	metastasis	_	_	I-Claim
2	is	_	_	I-Claim
3	a	_	_	I-Claim
4	common	_	_	I-Claim
5	oncologic	_	_	I-Claim
6	problem	_	_	I-Claim
7	that	_	_	I-Claim
8	occurs	_	_	I-Claim
9	in	_	_	I-Claim
10	15-30	_	_	I-Claim
11	%	_	_	I-Claim
12	of	_	_	I-Claim
13	cancer	_	_	I-Claim
14	patients	_	_	I-Claim
15	;	_	_	I-Claim
16	approximately	_	_	O
17	half	_	_	O
18	such	_	_	O
19	metastases	_	_	O
20	are	_	_	O
21	single	_	_	O
22	.	_	_	O

23	Previous	_	_	O
24	retrospective	_	_	O
25	studies	_	_	O
26	and	_	_	O
27	two	_	_	O
28	randomized	_	_	O
29	trials	_	_	O
30	reported	_	_	O
31	that	_	_	O
32	the	_	_	O
33	addition	_	_	O
34	of	_	_	O
35	surgical	_	_	O
36	extirpation	_	_	O
37	prior	_	_	O
38	to	_	_	O
39	radiation	_	_	O
40	therapy	_	_	O
41	increased	_	_	O
42	survival	_	_	O
43	,	_	_	O
44	neurologic	_	_	O
45	function	_	_	O
46	,	_	_	O
47	and	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	compared	_	_	O
52	with	_	_	O
53	radiation	_	_	O
54	alone	_	_	O
55	in	_	_	O
56	patients	_	_	O
57	with	_	_	O
58	a	_	_	O
59	single	_	_	O
60	brain	_	_	O
61	metastasis	_	_	O
62	.	_	_	O

63	A	_	_	O
64	randomized	_	_	O
65	controlled	_	_	O
66	trial	_	_	O
67	was	_	_	O
68	conducted	_	_	O
69	in	_	_	O
70	which	_	_	O
71	patients	_	_	O
72	with	_	_	O
73	a	_	_	O
74	single	_	_	O
75	brain	_	_	O
76	metastasis	_	_	O
77	were	_	_	O
78	allocated	_	_	O
79	to	_	_	O
80	undergo	_	_	O
81	radiation	_	_	O
82	alone	_	_	O
83	or	_	_	O
84	surgery	_	_	O
85	plus	_	_	O
86	radiation	_	_	O
87	.	_	_	O

88	Radiation	_	_	O
89	consisted	_	_	O
90	of	_	_	O
91	3000	_	_	O
92	centigray	_	_	O
93	to	_	_	O
94	the	_	_	O
95	whole	_	_	O
96	brain	_	_	O
97	in	_	_	O
98	10	_	_	O
99	fractions	_	_	O
100	.	_	_	O

101	Forty-three	_	_	O
102	patients	_	_	O
103	received	_	_	O
104	radiation	_	_	O
105	alone	_	_	O
106	and	_	_	O
107	41	_	_	O
108	patients	_	_	O
109	surgery	_	_	O
110	plus	_	_	O
111	radiation	_	_	O
112	.	_	_	O

113	All	_	_	O
114	but	_	_	O
115	two	_	_	O
116	of	_	_	O
117	the	_	_	O
118	study	_	_	O
119	patients	_	_	O
120	died	_	_	O
121	.	_	_	O

122	No	_	_	B-Premise
123	difference	_	_	I-Premise
124	in	_	_	I-Premise
125	survival	_	_	I-Premise
126	was	_	_	I-Premise
127	detected	_	_	I-Premise
128	between	_	_	I-Premise
129	the	_	_	I-Premise
130	groups	_	_	I-Premise
131	;	_	_	I-Premise
132	the	_	_	B-Premise
133	median	_	_	I-Premise
134	survival	_	_	I-Premise
135	for	_	_	I-Premise
136	the	_	_	I-Premise
137	radiation	_	_	I-Premise
138	group	_	_	I-Premise
139	was	_	_	I-Premise
140	6.3	_	_	I-Premise
141	months	_	_	I-Premise
142	(	_	_	I-Premise
143	95	_	_	I-Premise
144	%	_	_	I-Premise
145	confidence	_	_	I-Premise
146	interval	_	_	I-Premise
147	,	_	_	I-Premise
148	3-11.4	_	_	I-Premise
149	)	_	_	I-Premise
150	compared	_	_	I-Premise
151	with	_	_	I-Premise
152	5.6	_	_	I-Premise
153	months	_	_	I-Premise
154	for	_	_	I-Premise
155	the	_	_	I-Premise
156	surgery	_	_	I-Premise
157	plus	_	_	I-Premise
158	radiation	_	_	I-Premise
159	group	_	_	I-Premise
160	(	_	_	I-Premise
161	95	_	_	I-Premise
162	%	_	_	I-Premise
163	confidence	_	_	I-Premise
164	interval	_	_	I-Premise
165	,	_	_	I-Premise
166	3.9-7.2	_	_	I-Premise
167	)	_	_	I-Premise
168	(	_	_	I-Premise
169	P	_	_	I-Premise
170	=	_	_	I-Premise
171	0.24	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Most	_	_	B-Premise
175	patients	_	_	I-Premise
176	died	_	_	I-Premise
177	within	_	_	I-Premise
178	the	_	_	I-Premise
179	first	_	_	I-Premise
180	year	_	_	I-Premise
181	(	_	_	I-Premise
182	69.8	_	_	I-Premise
183	%	_	_	I-Premise
184	in	_	_	I-Premise
185	the	_	_	I-Premise
186	radiation	_	_	I-Premise
187	arm	_	_	I-Premise
188	vs.	_	_	I-Premise
189	87.8	_	_	I-Premise
190	%	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	surgery	_	_	I-Premise
194	plus	_	_	I-Premise
195	radiation	_	_	I-Premise
196	arm	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	There	_	_	B-Premise
200	were	_	_	I-Premise
201	no	_	_	I-Premise
202	significant	_	_	I-Premise
203	differences	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	30-day	_	_	I-Premise
207	mortality	_	_	I-Premise
208	,	_	_	I-Premise
209	morbidity	_	_	I-Premise
210	,	_	_	I-Premise
211	or	_	_	I-Premise
212	causes	_	_	I-Premise
213	of	_	_	I-Premise
214	death	_	_	I-Premise
215	.	_	_	I-Premise

216	Extracranial	_	_	B-Premise
217	metastases	_	_	I-Premise
218	was	_	_	I-Premise
219	an	_	_	I-Premise
220	important	_	_	I-Premise
221	predictor	_	_	I-Premise
222	of	_	_	I-Premise
223	mortality	_	_	I-Premise
224	(	_	_	I-Premise
225	relative	_	_	I-Premise
226	risk	_	_	I-Premise
227	,	_	_	I-Premise
228	2.3	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	mean	_	_	I-Premise
233	proportion	_	_	I-Premise
234	of	_	_	I-Premise
235	days	_	_	I-Premise
236	that	_	_	I-Premise
237	the	_	_	I-Premise
238	Karnofsky	_	_	I-Premise
239	performance	_	_	I-Premise
240	status	_	_	I-Premise
241	was	_	_	I-Premise
242	>	_	_	I-Premise
243	or	_	_	I-Premise
244	=	_	_	I-Premise
245	70	_	_	I-Premise
246	%	_	_	I-Premise
247	did	_	_	I-Premise
248	not	_	_	I-Premise
249	differ	_	_	I-Premise
250	between	_	_	I-Premise
251	the	_	_	I-Premise
252	2	_	_	I-Premise
253	groups	_	_	I-Premise
254	.	_	_	I-Premise

255	This	_	_	B-Claim
256	trial	_	_	I-Claim
257	failed	_	_	I-Claim
258	to	_	_	I-Claim
259	demonstrate	_	_	I-Claim
260	that	_	_	I-Claim
261	the	_	_	I-Claim
262	addition	_	_	I-Claim
263	of	_	_	I-Claim
264	surgery	_	_	I-Claim
265	to	_	_	I-Claim
266	radiation	_	_	I-Claim
267	therapy	_	_	I-Claim
268	improved	_	_	I-Claim
269	outcome	_	_	I-Claim
270	of	_	_	I-Claim
271	patients	_	_	I-Claim
272	with	_	_	I-Claim
273	a	_	_	I-Claim
274	single	_	_	I-Claim
275	brain	_	_	I-Claim
276	metastasis	_	_	I-Claim
277	.	_	_	I-Claim

278	Thus	_	_	B-Claim
279	,	_	_	I-Claim
280	the	_	_	I-Claim
281	efficacy	_	_	I-Claim
282	of	_	_	I-Claim
283	surgery	_	_	I-Claim
284	plus	_	_	I-Claim
285	radiation	_	_	I-Claim
286	compared	_	_	I-Claim
287	with	_	_	I-Claim
288	radiation	_	_	I-Claim
289	alone	_	_	I-Claim
290	needs	_	_	I-Claim
291	to	_	_	I-Claim
292	be	_	_	I-Claim
293	addressed	_	_	I-Claim
294	by	_	_	I-Claim
295	further	_	_	I-Claim
296	clinical	_	_	I-Claim
297	trials	_	_	I-Claim
298	and/or	_	_	I-Claim
299	a	_	_	I-Claim
300	meta-analysis	_	_	I-Claim
301	.	_	_	I-Claim


0	Oral	_	_	O
1	etoposide	_	_	O
2	is	_	_	O
3	an	_	_	O
4	active	_	_	O
5	single	_	_	O
6	agent	_	_	O
7	in	_	_	O
8	small-cell	_	_	O
9	lung	_	_	O
10	cancer	_	_	O
11	(	_	_	O
12	SCLC	_	_	O
13	)	_	_	O
14	and	_	_	O
15	is	_	_	O
16	widely	_	_	O
17	prescribed	_	_	O
18	as	_	_	O
19	first-line	_	_	O
20	treatment	_	_	O
21	as	_	_	O
22	an	_	_	O
23	alternative	_	_	O
24	to	_	_	O
25	intravenous	_	_	O
26	combination	_	_	O
27	chemotherapy	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	extensive	_	_	O
32	disease	_	_	O
33	.	_	_	O

34	The	_	_	O
35	intention	_	_	O
36	of	_	_	O
37	this	_	_	O
38	study	_	_	O
39	was	_	_	O
40	to	_	_	O
41	determine	_	_	O
42	if	_	_	O
43	the	_	_	O
44	effects	_	_	O
45	of	_	_	O
46	oral	_	_	O
47	etoposide	_	_	O
48	therapy	_	_	O
49	on	_	_	O
50	survival	_	_	O
51	and	_	_	O
52	quality	_	_	O
53	of	_	_	O
54	life	_	_	O
55	are	_	_	O
56	equivalent	_	_	O
57	to	_	_	O
58	those	_	_	O
59	of	_	_	O
60	intravenous	_	_	O
61	chemotherapy	_	_	O
62	.	_	_	O

63	In	_	_	O
64	a	_	_	O
65	randomized	_	_	O
66	trial	_	_	O
67	of	_	_	O
68	palliative	_	_	O
69	treatment	_	_	O
70	in	_	_	O
71	advanced	_	_	O
72	SCLC	_	_	O
73	,	_	_	O
74	oral	_	_	O
75	etoposide	_	_	O
76	(	_	_	O
77	100	_	_	O
78	mg	_	_	O
79	given	_	_	O
80	twice	_	_	O
81	daily	_	_	O
82	for	_	_	O
83	5	_	_	O
84	days	_	_	O
85	)	_	_	O
86	was	_	_	O
87	compared	_	_	O
88	with	_	_	O
89	intravenous	_	_	O
90	chemotherapy	_	_	O
91	consisting	_	_	O
92	of	_	_	O
93	alternating	_	_	O
94	cycles	_	_	O
95	of	_	_	O
96	cisplatin	_	_	O
97	and	_	_	O
98	etoposide	_	_	O
99	(	_	_	O
100	PE	_	_	O
101	)	_	_	O
102	and	_	_	O
103	cyclophosphamide	_	_	O
104	,	_	_	O
105	doxorubicin	_	_	O
106	,	_	_	O
107	and	_	_	O
108	vincristine	_	_	O
109	(	_	_	O
110	CAV	_	_	O
111	)	_	_	O
112	.	_	_	O

113	Six	_	_	O
114	cycles	_	_	O
115	of	_	_	O
116	chemotherapy	_	_	O
117	were	_	_	O
118	administered	_	_	O
119	every	_	_	O
120	21	_	_	O
121	days	_	_	O
122	in	_	_	O
123	both	_	_	O
124	regimens	_	_	O
125	.	_	_	O

126	Symptom	_	_	O
127	control	_	_	O
128	and	_	_	O
129	quality	_	_	O
130	of	_	_	O
131	life	_	_	O
132	were	_	_	O
133	measured	_	_	O
134	with	_	_	O
135	the	_	_	O
136	Rotterdam	_	_	O
137	Symptom	_	_	O
138	Checklist	_	_	O
139	and	_	_	O
140	a	_	_	O
141	daily	_	_	O
142	diary	_	_	O
143	card	_	_	O
144	.	_	_	O

145	In	_	_	O
146	January	_	_	O
147	1996	_	_	O
148	,	_	_	O
149	after	_	_	O
150	155	_	_	O
151	patients	_	_	O
152	had	_	_	O
153	been	_	_	O
154	randomly	_	_	O
155	assigned	_	_	O
156	from	_	_	O
157	a	_	_	O
158	projected	_	_	O
159	intake	_	_	O
160	of	_	_	O
161	365	_	_	O
162	patients	_	_	O
163	,	_	_	O
164	an	_	_	O
165	independent	_	_	O
166	Data	_	_	O
167	Monitoring	_	_	O
168	Committee	_	_	O
169	examined	_	_	O
170	the	_	_	O
171	interim	_	_	O
172	results	_	_	O
173	.	_	_	O

174	Survival	_	_	O
175	was	_	_	O
176	determined	_	_	O
177	by	_	_	O
178	the	_	_	O
179	Kaplan-Meier	_	_	O
180	method	_	_	O
181	,	_	_	O
182	and	_	_	O
183	the	_	_	O
184	logrank	_	_	O
185	test	_	_	O
186	was	_	_	O
187	used	_	_	O
188	to	_	_	O
189	compare	_	_	O
190	treatments	_	_	O
191	.	_	_	O

192	For	_	_	O
193	quality-of-life	_	_	O
194	comparisons	_	_	O
195	,	_	_	O
196	average	_	_	O
197	scores	_	_	O
198	were	_	_	O
199	calculated	_	_	O
200	for	_	_	O
201	each	_	_	O
202	time	_	_	O
203	point	_	_	O
204	.	_	_	O

205	The	_	_	O
206	Mann-Whitney	_	_	O
207	U	_	_	O
208	test	_	_	O
209	was	_	_	O
210	used	_	_	O
211	to	_	_	O
212	determine	_	_	O
213	any	_	_	O
214	significant	_	_	O
215	overall	_	_	O
216	differences	_	_	O
217	between	_	_	O
218	treatments	_	_	O
219	.	_	_	O

220	For	_	_	O
221	the	_	_	O
222	Rotterdam	_	_	O
223	Symptom	_	_	O
224	Checklist	_	_	O
225	,	_	_	O
226	separate	_	_	O
227	analyses	_	_	O
228	were	_	_	O
229	done	_	_	O
230	for	_	_	O
231	each	_	_	O
232	subset	_	_	O
233	(	_	_	O
234	psychological	_	_	O
235	well-being	_	_	O
236	,	_	_	O
237	physical	_	_	O
238	symptoms	_	_	O
239	,	_	_	O
240	lung	_	_	O
241	cancer	_	_	O
242	symptoms	_	_	O
243	,	_	_	O
244	treatment	_	_	O
245	symptoms	_	_	O
246	,	_	_	O
247	activity	_	_	O
248	,	_	_	O
249	and	_	_	O
250	quality	_	_	O
251	of	_	_	O
252	life	_	_	O
253	)	_	_	O
254	.	_	_	O

255	Response	_	_	O
256	rates	_	_	O
257	and	_	_	O
258	toxicity	_	_	O
259	scores	_	_	O
260	were	_	_	O
261	compared	_	_	O
262	by	_	_	O
263	using	_	_	O
264	chi2	_	_	O
265	.	_	_	O

266	All	_	_	O
267	statistical	_	_	O
268	tests	_	_	O
269	were	_	_	O
270	two-sided	_	_	O
271	.	_	_	O

272	Survival	_	_	B-Premise
273	was	_	_	I-Premise
274	inferior	_	_	I-Premise
275	at	_	_	I-Premise
276	1	_	_	I-Premise
277	year	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	oral	_	_	I-Premise
281	etoposide	_	_	I-Premise
282	group	_	_	I-Premise
283	compared	_	_	I-Premise
284	with	_	_	I-Premise
285	intravenous	_	_	I-Premise
286	therapy	_	_	I-Premise
287	(	_	_	I-Premise
288	9.8	_	_	I-Premise
289	%	_	_	I-Premise
290	for	_	_	I-Premise
291	oral	_	_	I-Premise
292	versus	_	_	I-Premise
293	19.3	_	_	I-Premise
294	%	_	_	I-Premise
295	for	_	_	I-Premise
296	intravenous	_	_	I-Premise
297	;	_	_	I-Premise
298	difference	_	_	I-Premise
299	=	_	_	I-Premise
300	9.5	_	_	I-Premise
301	%	_	_	I-Premise
302	;	_	_	I-Premise
303	95	_	_	I-Premise
304	%	_	_	I-Premise
305	confidence	_	_	I-Premise
306	interval	_	_	I-Premise
307	of	_	_	I-Premise
308	difference	_	_	I-Premise
309	=	_	_	I-Premise
310	0.3	_	_	I-Premise
311	%	_	_	I-Premise
312	-18.7	_	_	I-Premise
313	%	_	_	I-Premise
314	;	_	_	I-Premise
315	P	_	_	I-Premise
316	<	_	_	I-Premise
317	.05	_	_	I-Premise
318	)	_	_	I-Premise
319	,	_	_	I-Premise
320	and	_	_	I-Premise
321	there	_	_	I-Premise
322	was	_	_	I-Premise
323	a	_	_	I-Premise
324	trend	_	_	I-Premise
325	toward	_	_	I-Premise
326	inferior	_	_	I-Premise
327	overall	_	_	I-Premise
328	survival	_	_	I-Premise
329	.	_	_	I-Premise

330	Median	_	_	B-Premise
331	survival	_	_	I-Premise
332	was	_	_	I-Premise
333	4.8	_	_	I-Premise
334	months	_	_	I-Premise
335	for	_	_	I-Premise
336	oral	_	_	I-Premise
337	treatment	_	_	I-Premise
338	and	_	_	I-Premise
339	5.9	_	_	I-Premise
340	months	_	_	I-Premise
341	for	_	_	I-Premise
342	intravenous	_	_	I-Premise
343	therapy	_	_	I-Premise
344	.	_	_	I-Premise

345	Progression-free	_	_	B-Premise
346	survival	_	_	I-Premise
347	was	_	_	I-Premise
348	worse	_	_	I-Premise
349	in	_	_	I-Premise
350	the	_	_	I-Premise
351	oral	_	_	I-Premise
352	etoposide	_	_	I-Premise
353	arm	_	_	I-Premise
354	(	_	_	I-Premise
355	median	_	_	I-Premise
356	=	_	_	I-Premise
357	3.6	_	_	I-Premise
358	months	_	_	I-Premise
359	versus	_	_	I-Premise
360	5.6	_	_	I-Premise
361	months	_	_	I-Premise
362	;	_	_	I-Premise
363	P	_	_	I-Premise
364	<	_	_	I-Premise
365	.001	_	_	I-Premise
366	)	_	_	I-Premise
367	,	_	_	I-Premise
368	as	_	_	I-Premise
369	well	_	_	I-Premise
370	as	_	_	I-Premise
371	overall	_	_	I-Premise
372	response	_	_	I-Premise
373	rate	_	_	I-Premise
374	(	_	_	I-Premise
375	32.9	_	_	I-Premise
376	%	_	_	I-Premise
377	versus	_	_	I-Premise
378	46.3	_	_	I-Premise
379	%	_	_	I-Premise
380	;	_	_	I-Premise
381	P	_	_	I-Premise
382	<	_	_	I-Premise
383	.01	_	_	I-Premise
384	)	_	_	I-Premise
385	.	_	_	I-Premise

386	With	_	_	B-Premise
387	the	_	_	I-Premise
388	exception	_	_	I-Premise
389	of	_	_	I-Premise
390	acute	_	_	I-Premise
391	nausea	_	_	I-Premise
392	and	_	_	I-Premise
393	vomiting	_	_	I-Premise
394	associated	_	_	I-Premise
395	with	_	_	I-Premise
396	intravenous	_	_	I-Premise
397	chemotherapy	_	_	I-Premise
398	,	_	_	I-Premise
399	all	_	_	B-Premise
400	aspects	_	_	I-Premise
401	of	_	_	I-Premise
402	symptom	_	_	I-Premise
403	control	_	_	I-Premise
404	and	_	_	I-Premise
405	quality	_	_	I-Premise
406	of	_	_	I-Premise
407	life	_	_	I-Premise
408	were	_	_	I-Premise
409	either	_	_	I-Premise
410	the	_	_	I-Premise
411	same	_	_	I-Premise
412	or	_	_	I-Premise
413	worse	_	_	I-Premise
414	in	_	_	I-Premise
415	the	_	_	I-Premise
416	oral	_	_	I-Premise
417	etoposide	_	_	I-Premise
418	group	_	_	I-Premise
419	.	_	_	I-Premise

420	Study	_	_	O
421	closure	_	_	O
422	was	_	_	O
423	recommended	_	_	O
424	.	_	_	O

425	These	_	_	B-Claim
426	interim	_	_	I-Claim
427	results	_	_	I-Claim
428	show	_	_	I-Claim
429	that	_	_	I-Claim
430	this	_	_	I-Claim
431	schedule	_	_	I-Claim
432	of	_	_	I-Claim
433	oral	_	_	I-Claim
434	etoposide	_	_	I-Claim
435	is	_	_	I-Claim
436	inferior	_	_	I-Claim
437	to	_	_	I-Claim
438	intravenous	_	_	I-Claim
439	chemotherapy	_	_	I-Claim
440	in	_	_	I-Claim
441	the	_	_	I-Claim
442	treatment	_	_	I-Claim
443	of	_	_	I-Claim
444	advanced	_	_	I-Claim
445	SCLC	_	_	I-Claim
446	and	_	_	I-Claim
447	should	_	_	I-Claim
448	not	_	_	I-Claim
449	be	_	_	I-Claim
450	used	_	_	I-Claim
451	as	_	_	I-Claim
452	first-line	_	_	I-Claim
453	treatment	_	_	I-Claim
454	of	_	_	I-Claim
455	this	_	_	I-Claim
456	disease	_	_	I-Claim
457	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	two	_	_	O
6	doses	_	_	O
7	of	_	_	O
8	megestrol	_	_	O
9	acetate	_	_	O
10	(	_	_	O
11	MA	_	_	O
12	)	_	_	O
13	compared	_	_	O
14	with	_	_	O
15	placebo	_	_	O
16	on	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	(	_	_	O
21	QoL	_	_	O
22	)	_	_	O
23	and	_	_	O
24	nutritional	_	_	O
25	status	_	_	O
26	(	_	_	O
27	NS	_	_	O
28	)	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	advanced	_	_	O
33	endocrine-insensitive	_	_	O
34	cancer	_	_	O
35	.	_	_	O

36	Two	_	_	O
37	hundred	_	_	O
38	forty	_	_	O
39	patients	_	_	O
40	were	_	_	O
41	randomised	_	_	O
42	to	_	_	O
43	double-blind	_	_	O
44	MA	_	_	O
45	480	_	_	O
46	mg/day	_	_	O
47	,	_	_	O
48	MA	_	_	O
49	160	_	_	O
50	mg/day	_	_	O
51	,	_	_	O
52	or	_	_	O
53	matching	_	_	O
54	placebo	_	_	O
55	for	_	_	O
56	12	_	_	O
57	weeks	_	_	O
58	.	_	_	O

59	Nutritional	_	_	O
60	status	_	_	O
61	(	_	_	O
62	including	_	_	O
63	weight	_	_	O
64	,	_	_	O
65	skinfold	_	_	O
66	thickness	_	_	O
67	and	_	_	O
68	midarm	_	_	O
69	circumference	_	_	O
70	)	_	_	O
71	and	_	_	O
72	QoL	_	_	O
73	(	_	_	O
74	using	_	_	O
75	6	_	_	O
76	linear	_	_	O
77	analogue	_	_	O
78	self-assessment	_	_	O
79	(	_	_	O
80	LASA	_	_	O
81	)	_	_	O
82	scales	_	_	O
83	)	_	_	O
84	were	_	_	O
85	assessed	_	_	O
86	at	_	_	O
87	randomisation	_	_	O
88	and	_	_	O
89	after	_	_	O
90	four	_	_	O
91	,	_	_	O
92	eight	_	_	O
93	and	_	_	O
94	12	_	_	O
95	weeks	_	_	O
96	.	_	_	O

97	A	_	_	O
98	QoL	_	_	O
99	ranking	_	_	O
100	incorporating	_	_	O
101	QoL	_	_	O
102	and	_	_	O
103	death	_	_	O
104	was	_	_	O
105	also	_	_	O
106	used	_	_	O
107	ranging	_	_	O
108	from	_	_	O
109	1	_	_	O
110	=	_	_	O
111	dead	_	_	O
112	to	_	_	O
113	5	_	_	O
114	=	_	_	O
115	much	_	_	O
116	better	_	_	O
117	QoL	_	_	O
118	.	_	_	O

119	One	_	_	O
120	hundred	_	_	O
121	seventy-four	_	_	O
122	patients	_	_	O
123	were	_	_	O
124	assessable	_	_	O
125	at	_	_	O
126	week	_	_	O
127	four	_	_	O
128	,	_	_	O
129	136	_	_	O
130	at	_	_	O
131	week	_	_	O
132	eight	_	_	O
133	and	_	_	O
134	103	_	_	O
135	patients	_	_	O
136	at	_	_	O
137	week	_	_	O
138	12	_	_	O
139	.	_	_	O

140	Patients	_	_	B-Premise
141	receiving	_	_	I-Premise
142	MA	_	_	I-Premise
143	reported	_	_	I-Premise
144	substantially	_	_	I-Premise
145	better	_	_	I-Premise
146	appetite	_	_	I-Premise
147	(	_	_	I-Premise
148	P	_	_	I-Premise
149	=	_	_	I-Premise
150	0.001	_	_	I-Premise
151	)	_	_	I-Premise
152	,	_	_	I-Premise
153	mood	_	_	I-Premise
154	(	_	_	I-Premise
155	P	_	_	I-Premise
156	=	_	_	I-Premise
157	0.001	_	_	I-Premise
158	)	_	_	I-Premise
159	and	_	_	I-Premise
160	overall	_	_	I-Premise
161	quality	_	_	I-Premise
162	of	_	_	I-Premise
163	life	_	_	I-Premise
164	(	_	_	I-Premise
165	P	_	_	I-Premise
166	<	_	_	I-Premise
167	0.001	_	_	I-Premise
168	)	_	_	I-Premise
169	,	_	_	I-Premise
170	and	_	_	I-Premise
171	possibly	_	_	I-Premise
172	less	_	_	I-Premise
173	nausea	_	_	I-Premise
174	and	_	_	I-Premise
175	vomiting	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	=	_	_	I-Premise
179	0.08	_	_	I-Premise
180	)	_	_	I-Premise
181	than	_	_	I-Premise
182	patients	_	_	I-Premise
183	receiving	_	_	I-Premise
184	placebo	_	_	I-Premise
185	,	_	_	I-Premise
186	based	_	_	I-Premise
187	on	_	_	I-Premise
188	a	_	_	I-Premise
189	test	_	_	I-Premise
190	for	_	_	I-Premise
191	trend	_	_	I-Premise
192	.	_	_	I-Premise

193	A	_	_	B-Premise
194	larger	_	_	I-Premise
195	benefit	_	_	I-Premise
196	was	_	_	I-Premise
197	seen	_	_	I-Premise
198	with	_	_	I-Premise
199	the	_	_	I-Premise
200	higher	_	_	I-Premise
201	dose	_	_	I-Premise
202	which	_	_	I-Premise
203	(	_	_	I-Premise
204	unlike	_	_	I-Premise
205	the	_	_	I-Premise
206	lower	_	_	I-Premise
207	dose	_	_	I-Premise
208	)	_	_	I-Premise
209	was	_	_	I-Premise
210	significantly	_	_	I-Premise
211	better	_	_	I-Premise
212	in	_	_	I-Premise
213	pairwise	_	_	I-Premise
214	comparisons	_	_	I-Premise
215	with	_	_	I-Premise
216	placebo	_	_	I-Premise
217	for	_	_	I-Premise
218	appetite	_	_	I-Premise
219	,	_	_	I-Premise
220	mood	_	_	I-Premise
221	and	_	_	I-Premise
222	overall	_	_	I-Premise
223	QoL	_	_	I-Premise
224	(	_	_	I-Premise
225	each	_	_	I-Premise
226	P	_	_	I-Premise
227	<	_	_	I-Premise
228	or	_	_	I-Premise
229	=	_	_	I-Premise
230	0.001	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Despite	_	_	B-Premise
234	some	_	_	I-Premise
235	missing	_	_	I-Premise
236	data	_	_	I-Premise
237	on	_	_	I-Premise
238	QoL	_	_	I-Premise
239	scores	_	_	I-Premise
240	,	_	_	I-Premise
241	QoL	_	_	I-Premise
242	ranking	_	_	I-Premise
243	was	_	_	I-Premise
244	available	_	_	I-Premise
245	on	_	_	I-Premise
246	227	_	_	I-Premise
247	(	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	of	_	_	I-Premise
252	patients	_	_	I-Premise
253	with	_	_	I-Premise
254	significantly	_	_	I-Premise
255	higher	_	_	I-Premise
256	QoL	_	_	I-Premise
257	ranking	_	_	I-Premise
258	associated	_	_	I-Premise
259	with	_	_	I-Premise
260	MA	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	0.002	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Improvements	_	_	B-Premise
268	in	_	_	I-Premise
269	QoL	_	_	I-Premise
270	occurred	_	_	I-Premise
271	early	_	_	I-Premise
272	within	_	_	I-Premise
273	four	_	_	I-Premise
274	weeks	_	_	I-Premise
275	and	_	_	I-Premise
276	were	_	_	I-Premise
277	sustained	_	_	I-Premise
278	.	_	_	I-Premise

279	No	_	_	B-Premise
280	statistically	_	_	I-Premise
281	significant	_	_	I-Premise
282	differences	_	_	I-Premise
283	were	_	_	I-Premise
284	observed	_	_	I-Premise
285	in	_	_	I-Premise
286	NS	_	_	I-Premise
287	measurements	_	_	I-Premise
288	,	_	_	I-Premise
289	including	_	_	I-Premise
290	weight	_	_	I-Premise
291	(	_	_	I-Premise
292	P	_	_	I-Premise
293	=	_	_	I-Premise
294	0.29	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	Side	_	_	B-Premise
298	effects	_	_	I-Premise
299	of	_	_	I-Premise
300	therapy	_	_	I-Premise
301	were	_	_	I-Premise
302	minor	_	_	I-Premise
303	and	_	_	I-Premise
304	did	_	_	I-Premise
305	not	_	_	I-Premise
306	differ	_	_	I-Premise
307	significantly	_	_	I-Premise
308	across	_	_	I-Premise
309	treatments	_	_	I-Premise
310	.	_	_	I-Premise

311	Megestrol	_	_	B-Claim
312	acetate	_	_	I-Claim
313	given	_	_	I-Claim
314	at	_	_	I-Claim
315	480	_	_	I-Claim
316	mg/day	_	_	I-Claim
317	is	_	_	I-Claim
318	useful	_	_	I-Claim
319	palliation	_	_	I-Claim
320	in	_	_	I-Claim
321	patients	_	_	I-Claim
322	with	_	_	I-Claim
323	endocrine-insensitive	_	_	I-Claim
324	advanced	_	_	I-Claim
325	cancer	_	_	I-Claim
326	.	_	_	I-Claim

327	It	_	_	B-Claim
328	improves	_	_	I-Claim
329	appetite	_	_	I-Claim
330	,	_	_	I-Claim
331	mood	_	_	I-Claim
332	and	_	_	I-Claim
333	overall	_	_	I-Claim
334	quality	_	_	I-Claim
335	of	_	_	I-Claim
336	life	_	_	I-Claim
337	in	_	_	I-Claim
338	these	_	_	I-Claim
339	patients	_	_	I-Claim
340	,	_	_	I-Claim
341	although	_	_	B-Claim
342	not	_	_	I-Claim
343	through	_	_	I-Claim
344	a	_	_	I-Claim
345	direct	_	_	I-Claim
346	effect	_	_	I-Claim
347	on	_	_	I-Claim
348	nutritional	_	_	I-Claim
349	status	_	_	I-Claim
350	.	_	_	I-Claim


0	The	_	_	B-Claim
1	choice	_	_	I-Claim
2	of	_	_	I-Claim
3	reconstruction	_	_	I-Claim
4	after	_	_	I-Claim
5	gastrectomy	_	_	I-Claim
6	and	_	_	I-Claim
7	the	_	_	I-Claim
8	significance	_	_	I-Claim
9	of	_	_	I-Claim
10	remaining	_	_	I-Claim
11	reservoir	_	_	I-Claim
12	function	_	_	I-Claim
13	is	_	_	I-Claim
14	a	_	_	I-Claim
15	matter	_	_	I-Claim
16	of	_	_	I-Claim
17	controversy	_	_	I-Claim
18	.	_	_	I-Claim

19	To	_	_	O
20	broaden	_	_	O
21	the	_	_	O
22	criteria	_	_	O
23	for	_	_	O
24	choice	_	_	O
25	of	_	_	O
26	treatment	_	_	O
27	,	_	_	O
28	we	_	_	O
29	conducted	_	_	O
30	a	_	_	O
31	prospective	_	_	O
32	randomized	_	_	O
33	clinical	_	_	O
34	trial	_	_	O
35	to	_	_	O
36	determine	_	_	O
37	the	_	_	O
38	impact	_	_	O
39	of	_	_	O
40	various	_	_	O
41	gastrectomy	_	_	O
42	procedures	_	_	O
43	on	_	_	O
44	quality	_	_	O
45	of	_	_	O
46	life	_	_	O
47	.	_	_	O

48	Consecutive	_	_	O
49	patients	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	64	_	_	O
54	)	_	_	O
55	eligible	_	_	O
56	for	_	_	O
57	curative	_	_	O
58	gastric	_	_	O
59	cancer	_	_	O
60	surgery	_	_	O
61	were	_	_	O
62	randomized	_	_	O
63	to	_	_	O
64	have	_	_	O
65	either	_	_	O
66	a	_	_	O
67	total	_	_	O
68	(	_	_	O
69	n	_	_	O
70	=	_	_	O
71	31	_	_	O
72	)	_	_	O
73	or	_	_	O
74	subtotal	_	_	O
75	(	_	_	O
76	n	_	_	O
77	=	_	_	O
78	13	_	_	O
79	)	_	_	O
80	gastrectomy	_	_	O
81	or	_	_	O
82	a	_	_	O
83	jejunal	_	_	O
84	S-shaped	_	_	O
85	pouch	_	_	O
86	(	_	_	O
87	n	_	_	O
88	=	_	_	O
89	20	_	_	O
90	)	_	_	O
91	implanted	_	_	O
92	as	_	_	O
93	a	_	_	O
94	gastric	_	_	O
95	substitute	_	_	O
96	.	_	_	O

97	The	_	_	O
98	quality-of-life	_	_	O
99	evaluation	_	_	O
100	was	_	_	O
101	based	_	_	O
102	on	_	_	O
103	a	_	_	O
104	battery	_	_	O
105	of	_	_	O
106	questionnaires	_	_	O
107	covering	_	_	O
108	both	_	_	O
109	general	_	_	O
110	and	_	_	O
111	specific	_	_	O
112	aspects	_	_	O
113	of	_	_	O
114	life	_	_	O
115	.	_	_	O

116	The	_	_	O
117	patients	_	_	O
118	were	_	_	O
119	rated	_	_	O
120	by	_	_	O
121	one	_	_	O
122	of	_	_	O
123	two	_	_	O
124	psychiatrists	_	_	O
125	who	_	_	O
126	were	_	_	O
127	blinded	_	_	O
128	to	_	_	O
129	the	_	_	O
130	patients	_	_	O
131	'	_	_	O
132	group	_	_	O
133	affiliation	_	_	O
134	.	_	_	O

135	Assessments	_	_	O
136	were	_	_	O
137	made	_	_	O
138	on	_	_	O
139	three	_	_	O
140	occasions	_	_	O
141	:	_	_	O
142	during	_	_	O
143	the	_	_	O
144	week	_	_	O
145	prior	_	_	O
146	to	_	_	O
147	surgery	_	_	O
148	and	_	_	O
149	3	_	_	O
150	and	_	_	O
151	12	_	_	O
152	months	_	_	O
153	after	_	_	O
154	the	_	_	O
155	surgical	_	_	O
156	intervention	_	_	O
157	.	_	_	O

158	The	_	_	B-Premise
159	postoperative	_	_	I-Premise
160	complication	_	_	I-Premise
161	and	_	_	I-Premise
162	mortality	_	_	I-Premise
163	rates	_	_	I-Premise
164	were	_	_	I-Premise
165	similar	_	_	I-Premise
166	in	_	_	I-Premise
167	all	_	_	I-Premise
168	treatment	_	_	I-Premise
169	groups	_	_	I-Premise
170	,	_	_	I-Premise
171	with	_	_	I-Premise
172	few	_	_	I-Premise
173	serious	_	_	I-Premise
174	complications	_	_	I-Premise
175	recorded	_	_	I-Premise
176	.	_	_	I-Premise

177	Irrespective	_	_	B-Premise
178	of	_	_	I-Premise
179	type	_	_	I-Premise
180	of	_	_	I-Premise
181	treatment	_	_	I-Premise
182	,	_	_	I-Premise
183	the	_	_	I-Premise
184	patients	_	_	I-Premise
185	suffered	_	_	I-Premise
186	from	_	_	I-Premise
187	alimentary	_	_	I-Premise
188	symptoms	_	_	I-Premise
189	and	_	_	I-Premise
190	functional	_	_	I-Premise
191	limitations	_	_	I-Premise
192	in	_	_	I-Premise
193	everyday	_	_	I-Premise
194	life	_	_	I-Premise
195	,	_	_	I-Premise
196	whereas	_	_	B-Premise
197	their	_	_	I-Premise
198	mental	_	_	I-Premise
199	well-being	_	_	I-Premise
200	improved	_	_	I-Premise
201	after	_	_	I-Premise
202	surgery	_	_	I-Premise
203	.	_	_	I-Premise

204	Patients	_	_	B-Premise
205	who	_	_	I-Premise
206	underwent	_	_	I-Premise
207	subtotal	_	_	I-Premise
208	gastrectomy	_	_	I-Premise
209	had	_	_	I-Premise
210	the	_	_	I-Premise
211	best	_	_	I-Premise
212	outcome	_	_	I-Premise
213	,	_	_	I-Premise
214	especially	_	_	I-Premise
215	with	_	_	I-Premise
216	respect	_	_	I-Premise
217	to	_	_	I-Premise
218	complaints	_	_	I-Premise
219	of	_	_	I-Premise
220	diarrhea	_	_	I-Premise
221	.	_	_	I-Premise

222	Patients	_	_	B-Premise
223	given	_	_	I-Premise
224	a	_	_	I-Premise
225	gastric	_	_	I-Premise
226	substitute	_	_	I-Premise
227	after	_	_	I-Premise
228	gastrectomy	_	_	I-Premise
229	showed	_	_	I-Premise
230	no	_	_	I-Premise
231	difference	_	_	I-Premise
232	from	_	_	I-Premise
233	those	_	_	I-Premise
234	who	_	_	I-Premise
235	had	_	_	I-Premise
236	only	_	_	I-Premise
237	a	_	_	I-Premise
238	total	_	_	I-Premise
239	gastrectomy	_	_	I-Premise
240	.	_	_	I-Premise

241	We	_	_	B-Claim
242	conclude	_	_	I-Claim
243	that	_	_	I-Claim
244	despite	_	_	I-Claim
245	significant	_	_	I-Claim
246	unfavorable	_	_	I-Claim
247	consequences	_	_	I-Claim
248	that	_	_	I-Claim
249	follow	_	_	I-Claim
250	gastrectomy	_	_	I-Claim
251	,	_	_	I-Claim
252	patients	_	_	I-Claim
253	recover	_	_	I-Claim
254	with	_	_	I-Claim
255	an	_	_	I-Claim
256	improved	_	_	I-Claim
257	mental	_	_	I-Claim
258	status	_	_	I-Claim
259	.	_	_	I-Claim

260	A	_	_	B-Claim
261	pouch	_	_	I-Claim
262	reconstruction	_	_	I-Claim
263	after	_	_	I-Claim
264	total	_	_	I-Claim
265	gastrectomy	_	_	I-Claim
266	does	_	_	I-Claim
267	not	_	_	I-Claim
268	improve	_	_	I-Claim
269	quality	_	_	I-Claim
270	of	_	_	I-Claim
271	life	_	_	I-Claim
272	,	_	_	I-Claim
273	but	_	_	O
274	a	_	_	B-Claim
275	subtotal	_	_	I-Claim
276	gastrectomy	_	_	I-Claim
277	has	_	_	I-Claim
278	advantages	_	_	I-Claim
279	that	_	_	I-Claim
280	must	_	_	I-Claim
281	be	_	_	I-Claim
282	considered	_	_	I-Claim
283	when	_	_	I-Claim
284	the	_	_	I-Claim
285	procedure	_	_	I-Claim
286	is	_	_	I-Claim
287	clinically	_	_	I-Claim
288	feasible	_	_	I-Claim
289	.	_	_	I-Claim


0	Brimonidin	_	_	O
1	tartrate	_	_	O
2	is	_	_	O
3	a	_	_	O
4	highly	_	_	O
5	selective	_	_	O
6	alpha	_	_	O
7	2-agonist	_	_	O
8	.	_	_	O

9	This	_	_	O
10	study	_	_	O
11	investigates	_	_	O
12	the	_	_	O
13	safety	_	_	O
14	and	_	_	O
15	efficacy	_	_	O
16	of	_	_	O
17	0.2	_	_	O
18	%	_	_	O
19	brimonidine	_	_	O
20	administered	_	_	O
21	twice	_	_	O
22	daily	_	_	O
23	for	_	_	O
24	1	_	_	O
25	year	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	.	_	_	O

34	The	_	_	O
35	study	_	_	O
36	design	_	_	O
37	was	_	_	O
38	a	_	_	O
39	multicenter	_	_	O
40	,	_	_	O
41	double-masked	_	_	O
42	,	_	_	O
43	randomized	_	_	O
44	,	_	_	O
45	parallel-group	_	_	O
46	,	_	_	O
47	active-controlled	_	_	O
48	comparison	_	_	O
49	clinical	_	_	O
50	trial	_	_	O
51	.	_	_	O

52	Subjects	_	_	O
53	instilled	_	_	O
54	0.2	_	_	O
55	%	_	_	O
56	brimonidine	_	_	O
57	or	_	_	O
58	0.5	_	_	O
59	%	_	_	O
60	timolol	_	_	O
61	maleate	_	_	O
62	twice	_	_	O
63	daily	_	_	O
64	for	_	_	O
65	12	_	_	O
66	months	_	_	O
67	.	_	_	O

68	Subjects	_	_	O
69	were	_	_	O
70	examined	_	_	O
71	at	_	_	O
72	baseline	_	_	O
73	,	_	_	O
74	week	_	_	O
75	1	_	_	O
76	,	_	_	O
77	and	_	_	O
78	months	_	_	O
79	1	_	_	O
80	,	_	_	O
81	2	_	_	O
82	,	_	_	O
83	3	_	_	O
84	,	_	_	O
85	6	_	_	O
86	,	_	_	O
87	9	_	_	O
88	,	_	_	O
89	and	_	_	O
90	12	_	_	O
91	.	_	_	O

92	A	_	_	O
93	subset	_	_	O
94	of	_	_	O
95	subjects	_	_	O
96	was	_	_	O
97	examined	_	_	O
98	at	_	_	O
99	week	_	_	O
100	2	_	_	O
101	.	_	_	O

102	Of	_	_	O
103	443	_	_	O
104	subjects	_	_	O
105	enrolled	_	_	O
106	in	_	_	O
107	this	_	_	O
108	study	_	_	O
109	,	_	_	O
110	374	_	_	O
111	met	_	_	O
112	the	_	_	O
113	entry	_	_	O
114	criteria	_	_	O
115	;	_	_	O
116	186	_	_	O
117	received	_	_	O
118	brimonidine	_	_	O
119	and	_	_	O
120	188	_	_	O
121	received	_	_	O
122	timolol	_	_	O
123	.	_	_	O

124	Brimonidine-treated	_	_	B-Premise
125	subjects	_	_	I-Premise
126	showed	_	_	I-Premise
127	an	_	_	I-Premise
128	overall	_	_	I-Premise
129	mean	_	_	I-Premise
130	peak	_	_	I-Premise
131	reduction	_	_	I-Premise
132	in	_	_	I-Premise
133	intraocular	_	_	I-Premise
134	pressure	_	_	I-Premise
135	(	_	_	I-Premise
136	IOP	_	_	I-Premise
137	)	_	_	I-Premise
138	of	_	_	I-Premise
139	6.5	_	_	I-Premise
140	mm	_	_	I-Premise
141	Hg	_	_	I-Premise
142	;	_	_	I-Premise
143	timolol-treated	_	_	I-Premise
144	subjects	_	_	I-Premise
145	had	_	_	I-Premise
146	a	_	_	I-Premise
147	mean	_	_	I-Premise
148	peak	_	_	I-Premise
149	reduction	_	_	I-Premise
150	in	_	_	I-Premise
151	IOP	_	_	I-Premise
152	of	_	_	I-Premise
153	6.1	_	_	I-Premise
154	mm	_	_	I-Premise
155	Hg	_	_	I-Premise
156	.	_	_	I-Premise

157	Brimonidine	_	_	B-Premise
158	lowered	_	_	I-Premise
159	mean	_	_	I-Premise
160	peak	_	_	I-Premise
161	IOP	_	_	I-Premise
162	significantly	_	_	I-Premise
163	more	_	_	I-Premise
164	than	_	_	I-Premise
165	timolol	_	_	I-Premise
166	at	_	_	I-Premise
167	week	_	_	I-Premise
168	2	_	_	I-Premise
169	and	_	_	I-Premise
170	month	_	_	I-Premise
171	3	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	<	_	_	I-Premise
175	.03	_	_	I-Premise
176	)	_	_	I-Premise
177	;	_	_	O
178	no	_	_	O
179	significant	_	_	O
180	difference	_	_	O
181	was	_	_	O
182	observed	_	_	O
183	between	_	_	O
184	the	_	_	O
185	groups	_	_	O
186	for	_	_	O
187	this	_	_	O
188	variable	_	_	O
189	at	_	_	O
190	other	_	_	O
191	visits	_	_	O
192	throughout	_	_	O
193	the	_	_	O
194	1-year	_	_	O
195	course	_	_	O
196	of	_	_	O
197	the	_	_	O
198	study	_	_	O
199	.	_	_	O

200	No	_	_	B-Premise
201	evidence	_	_	I-Premise
202	of	_	_	I-Premise
203	tachyphylaxis	_	_	I-Premise
204	was	_	_	I-Premise
205	seen	_	_	I-Premise
206	in	_	_	I-Premise
207	either	_	_	I-Premise
208	group	_	_	I-Premise
209	.	_	_	I-Premise

210	Allergy	_	_	B-Premise
211	was	_	_	I-Premise
212	seen	_	_	I-Premise
213	in	_	_	I-Premise
214	9	_	_	I-Premise
215	%	_	_	I-Premise
216	of	_	_	I-Premise
217	subjects	_	_	I-Premise
218	treated	_	_	I-Premise
219	with	_	_	I-Premise
220	brimonidine	_	_	I-Premise
221	.	_	_	I-Premise

222	Dry	_	_	B-Premise
223	mouth	_	_	I-Premise
224	was	_	_	I-Premise
225	more	_	_	I-Premise
226	common	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	brimonidine-treated	_	_	I-Premise
230	group	_	_	I-Premise
231	than	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	timolol-treated	_	_	I-Premise
235	group	_	_	I-Premise
236	(	_	_	I-Premise
237	33.0	_	_	I-Premise
238	%	_	_	I-Premise
239	vs	_	_	I-Premise
240	19.4	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	,	_	_	I-Premise
244	but	_	_	O
245	complaints	_	_	B-Premise
246	of	_	_	I-Premise
247	burning	_	_	I-Premise
248	and	_	_	I-Premise
249	stinging	_	_	I-Premise
250	were	_	_	I-Premise
251	more	_	_	I-Premise
252	common	_	_	I-Premise
253	in	_	_	I-Premise
254	the	_	_	I-Premise
255	timolol-treated	_	_	I-Premise
256	group	_	_	I-Premise
257	(	_	_	I-Premise
258	41.9	_	_	I-Premise
259	%	_	_	I-Premise
260	)	_	_	I-Premise
261	than	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	brimonidine-treated	_	_	I-Premise
265	patients	_	_	I-Premise
266	(	_	_	I-Premise
267	28.1	_	_	I-Premise
268	%	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	Headache	_	_	B-Premise
272	,	_	_	I-Premise
273	fatigue	_	_	I-Premise
274	,	_	_	I-Premise
275	and	_	_	I-Premise
276	drowsiness	_	_	I-Premise
277	were	_	_	I-Premise
278	similar	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	2	_	_	I-Premise
282	groups	_	_	I-Premise
283	.	_	_	I-Premise

284	In	_	_	O
285	general	_	_	O
286	,	_	_	O
287	the	_	_	O
288	tolerance	_	_	O
289	to	_	_	O
290	medication	_	_	O
291	was	_	_	O
292	acceptable	_	_	O
293	.	_	_	O

294	Brimonidine	_	_	B-Claim
295	is	_	_	I-Claim
296	safe	_	_	I-Claim
297	and	_	_	I-Claim
298	effective	_	_	I-Claim
299	in	_	_	I-Claim
300	lowering	_	_	I-Claim
301	IOP	_	_	I-Claim
302	in	_	_	I-Claim
303	glaucomatous	_	_	I-Claim
304	eyes	_	_	I-Claim
305	.	_	_	I-Claim

306	Brimonidine	_	_	B-Claim
307	provides	_	_	I-Claim
308	a	_	_	I-Claim
309	sustained	_	_	I-Claim
310	long-term	_	_	I-Claim
311	ocular	_	_	I-Claim
312	hypotensive	_	_	I-Claim
313	effect	_	_	I-Claim
314	,	_	_	I-Claim
315	is	_	_	I-Claim
316	well	_	_	I-Claim
317	tolerated	_	_	I-Claim
318	,	_	_	I-Claim
319	and	_	_	I-Claim
320	has	_	_	I-Claim
321	a	_	_	I-Claim
322	low	_	_	I-Claim
323	rate	_	_	I-Claim
324	of	_	_	I-Claim
325	allergic	_	_	I-Claim
326	response	_	_	I-Claim
327	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	protracted	_	_	O
3	venous	_	_	O
4	infusion	_	_	O
5	(	_	_	O
6	PVI	_	_	O
7	)	_	_	O
8	5-fluorouracil	_	_	O
9	(	_	_	O
10	5-FU	_	_	O
11	)	_	_	O
12	with	_	_	O
13	and	_	_	O
14	without	_	_	O
15	mitomycin	_	_	O
16	C	_	_	O
17	(	_	_	O
18	MMC	_	_	O
19	)	_	_	O
20	in	_	_	O
21	a	_	_	O
22	prospectively	_	_	O
23	randomised	_	_	O
24	study	_	_	O
25	and	_	_	O
26	analyse	_	_	O
27	for	_	_	O
28	tumour	_	_	O
29	response	_	_	O
30	,	_	_	O
31	survival	_	_	O
32	,	_	_	O
33	toxicity	_	_	O
34	and	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	(	_	_	O
39	QL	_	_	O
40	)	_	_	O
41	.	_	_	O

42	Two	_	_	O
43	hundred	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	advanced	_	_	O
47	colorectal	_	_	O
48	cancer	_	_	O
49	received	_	_	O
50	PVI	_	_	O
51	5-FU	_	_	O
52	300	_	_	O
53	mg/m2/day	_	_	O
54	for	_	_	O
55	a	_	_	O
56	maximum	_	_	O
57	of	_	_	O
58	24	_	_	O
59	weeks	_	_	O
60	and	_	_	O
61	were	_	_	O
62	randomised	_	_	O
63	to	_	_	O
64	PVI	_	_	O
65	5-FU	_	_	O
66	alone	_	_	O
67	or	_	_	O
68	PVI	_	_	O
69	5-FU	_	_	O
70	+	_	_	O
71	MMC	_	_	O
72	10	_	_	O
73	mg/m2	_	_	O
74	(	_	_	O
75	7	_	_	O
76	mg/m2	_	_	O
77	from	_	_	O
78	June	_	_	O
79	1995	_	_	O
80	)	_	_	O
81	6	_	_	O
82	weekly	_	_	O
83	for	_	_	O
84	4	_	_	O
85	courses	_	_	O
86	.	_	_	O

87	Overall	_	_	B-Premise
88	response	_	_	I-Premise
89	was	_	_	I-Premise
90	54	_	_	I-Premise
91	%	_	_	I-Premise
92	(	_	_	I-Premise
93	95	_	_	I-Premise
94	%	_	_	I-Premise
95	confidence	_	_	I-Premise
96	interval	_	_	I-Premise
97	[	_	_	I-Premise
98	CI	_	_	I-Premise
99	]	_	_	I-Premise
100	44.1	_	_	I-Premise
101	%	_	_	I-Premise
102	-63.9	_	_	I-Premise
103	%	_	_	I-Premise
104	)	_	_	I-Premise
105	with	_	_	I-Premise
106	PVI	_	_	I-Premise
107	5-FU	_	_	I-Premise
108	+	_	_	I-Premise
109	MMC	_	_	I-Premise
110	compared	_	_	I-Premise
111	to	_	_	I-Premise
112	38	_	_	I-Premise
113	%	_	_	I-Premise
114	(	_	_	I-Premise
115	95	_	_	I-Premise
116	%	_	_	I-Premise
117	CI	_	_	I-Premise
118	:	_	_	I-Premise
119	28.3	_	_	I-Premise
120	%	_	_	I-Premise
121	-47.7	_	_	I-Premise
122	%	_	_	I-Premise
123	)	_	_	I-Premise
124	for	_	_	I-Premise
125	PVI	_	_	I-Premise
126	5-FU	_	_	I-Premise
127	alone	_	_	I-Premise
128	(	_	_	I-Premise
129	P	_	_	I-Premise
130	=	_	_	I-Premise
131	0.024	_	_	I-Premise
132	)	_	_	I-Premise
133	.	_	_	I-Premise

134	The	_	_	B-Premise
135	median	_	_	I-Premise
136	failure	_	_	I-Premise
137	free	_	_	I-Premise
138	survival	_	_	I-Premise
139	was	_	_	I-Premise
140	7.9	_	_	I-Premise
141	months	_	_	I-Premise
142	in	_	_	I-Premise
143	PVI	_	_	I-Premise
144	5-FU	_	_	I-Premise
145	plus	_	_	I-Premise
146	MMC	_	_	I-Premise
147	and	_	_	I-Premise
148	5.4	_	_	I-Premise
149	months	_	_	I-Premise
150	with	_	_	I-Premise
151	PVI	_	_	I-Premise
152	5-FU	_	_	I-Premise
153	alone	_	_	I-Premise
154	(	_	_	I-Premise
155	P	_	_	I-Premise
156	=	_	_	I-Premise
157	0.033	_	_	I-Premise
158	)	_	_	I-Premise
159	and	_	_	I-Premise
160	at	_	_	I-Premise
161	one	_	_	I-Premise
162	year	_	_	I-Premise
163	31.9	_	_	I-Premise
164	%	_	_	I-Premise
165	for	_	_	I-Premise
166	the	_	_	I-Premise
167	combination	_	_	I-Premise
168	compared	_	_	I-Premise
169	to	_	_	I-Premise
170	17.7	_	_	I-Premise
171	%	_	_	I-Premise
172	for	_	_	I-Premise
173	PVI	_	_	I-Premise
174	5-FU	_	_	I-Premise
175	alone	_	_	I-Premise
176	.	_	_	I-Premise

177	Median	_	_	B-Premise
178	survival	_	_	I-Premise
179	was	_	_	I-Premise
180	14	_	_	I-Premise
181	months	_	_	I-Premise
182	with	_	_	I-Premise
183	MMC	_	_	I-Premise
184	and	_	_	I-Premise
185	15	_	_	I-Premise
186	months	_	_	I-Premise
187	in	_	_	I-Premise
188	5-FU	_	_	I-Premise
189	alone	_	_	I-Premise
190	;	_	_	I-Premise
191	one-year	_	_	I-Premise
192	survival	_	_	I-Premise
193	51.7	_	_	I-Premise
194	%	_	_	I-Premise
195	vs.	_	_	I-Premise
196	57.2	_	_	I-Premise
197	%	_	_	I-Premise
198	.	_	_	I-Premise

199	PVI	_	_	B-Premise
200	5-FU	_	_	I-Premise
201	+	_	_	I-Premise
202	MMC	_	_	I-Premise
203	caused	_	_	I-Premise
204	more	_	_	I-Premise
205	overall	_	_	I-Premise
206	haematological	_	_	I-Premise
207	toxicity	_	_	I-Premise
208	but	_	_	I-Premise
209	CTC	_	_	I-Premise
210	grades	_	_	I-Premise
211	3/4	_	_	I-Premise
212	was	_	_	I-Premise
213	increased	_	_	I-Premise
214	only	_	_	I-Premise
215	for	_	_	I-Premise
216	thrombocytopaenia	_	_	I-Premise
217	.	_	_	I-Premise

218	Two	_	_	B-Premise
219	patients	_	_	I-Premise
220	treated	_	_	I-Premise
221	with	_	_	I-Premise
222	a	_	_	I-Premise
223	cumulative	_	_	I-Premise
224	dose	_	_	I-Premise
225	of	_	_	I-Premise
226	MMC	_	_	I-Premise
227	of	_	_	I-Premise
228	40	_	_	I-Premise
229	mg/m2	_	_	I-Premise
230	developed	_	_	I-Premise
231	haemolytic	_	_	I-Premise
232	uraemic	_	_	I-Premise
233	syndrome	_	_	I-Premise
234	warranting	_	_	I-Premise
235	the	_	_	I-Premise
236	reduction	_	_	I-Premise
237	in	_	_	I-Premise
238	cumulative	_	_	I-Premise
239	MMC	_	_	I-Premise
240	dose	_	_	I-Premise
241	to	_	_	I-Premise
242	28	_	_	I-Premise
243	mg/m2	_	_	I-Premise
244	.	_	_	I-Premise

245	The	_	_	B-Premise
246	global	_	_	I-Premise
247	QL	_	_	I-Premise
248	scores	_	_	I-Premise
249	were	_	_	I-Premise
250	better	_	_	I-Premise
251	for	_	_	I-Premise
252	PVI	_	_	I-Premise
253	5-FU	_	_	I-Premise
254	+	_	_	I-Premise
255	MMC	_	_	I-Premise
256	arm	_	_	I-Premise
257	at	_	_	I-Premise
258	24	_	_	I-Premise
259	weeks	_	_	I-Premise
260	,	_	_	I-Premise
261	but	_	_	B-Premise
262	the	_	_	I-Premise
263	remaining	_	_	I-Premise
264	QL	_	_	I-Premise
265	data	_	_	I-Premise
266	showed	_	_	I-Premise
267	no	_	_	I-Premise
268	differences	_	_	I-Premise
269	.	_	_	I-Premise

270	PVI	_	_	B-Claim
271	5-FU	_	_	I-Claim
272	+	_	_	I-Claim
273	MMC	_	_	I-Claim
274	results	_	_	I-Claim
275	in	_	_	I-Claim
276	failure-free	_	_	I-Claim
277	survival	_	_	I-Claim
278	and	_	_	I-Claim
279	response	_	_	I-Claim
280	advantage	_	_	I-Claim
281	,	_	_	I-Claim
282	tolerable	_	_	I-Claim
283	toxicity	_	_	I-Claim
284	and	_	_	I-Claim
285	better	_	_	I-Claim
286	QL	_	_	I-Claim
287	when	_	_	I-Claim
288	compared	_	_	I-Claim
289	to	_	_	I-Claim
290	PVI	_	_	I-Claim
291	5-FU	_	_	I-Claim
292	alone	_	_	I-Claim
293	but	_	_	I-Claim
294	no	_	_	I-Claim
295	overall	_	_	I-Claim
296	survival	_	_	I-Claim
297	advantage	_	_	I-Claim
298	.	_	_	I-Claim

299	There	_	_	B-Premise
300	is	_	_	I-Premise
301	no	_	_	I-Premise
302	irreversible	_	_	I-Premise
303	toxicity	_	_	I-Premise
304	with	_	_	I-Premise
305	MMC	_	_	I-Premise
306	at	_	_	I-Premise
307	a	_	_	I-Premise
308	cumulative	_	_	I-Premise
309	dose	_	_	I-Premise
310	of	_	_	I-Premise
311	28	_	_	I-Premise
312	mg/m2	_	_	I-Premise
313	.	_	_	I-Premise


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	pamidronate	_	_	O
9	for	_	_	O
10	bone	_	_	O
11	pain	_	_	O
12	in	_	_	O
13	a	_	_	O
14	randomised	_	_	O
15	double-blind	_	_	O
16	trial	_	_	O
17	and	_	_	O
18	to	_	_	O
19	evaluate	_	_	O
20	the	_	_	O
21	contribution	_	_	O
22	of	_	_	O
23	new	_	_	O
24	markers	_	_	O
25	of	_	_	O
26	bone	_	_	O
27	resorption	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	bone	_	_	O
32	metastases	_	_	O
33	.	_	_	O

34	Fifty-two	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	painful	_	_	O
38	bone	_	_	O
39	metastases	_	_	O
40	were	_	_	O
41	randomised	_	_	O
42	to	_	_	O
43	receive	_	_	O
44	a	_	_	O
45	two-hour	_	_	O
46	infusion	_	_	O
47	of	_	_	O
48	pamidronate	_	_	O
49	120	_	_	O
50	mg	_	_	O
51	or	_	_	O
52	an	_	_	O
53	identical	_	_	O
54	infusion	_	_	O
55	of	_	_	O
56	saline	_	_	O
57	.	_	_	O

58	Four	_	_	O
59	weeks	_	_	O
60	later	_	_	O
61	,	_	_	O
62	all	_	_	O
63	patients	_	_	O
64	received	_	_	O
65	pamidronate	_	_	O
66	120	_	_	O
67	mg	_	_	O
68	.	_	_	O

69	Bone	_	_	O
70	resorption	_	_	O
71	markers	_	_	O
72	measured	_	_	O
73	included	_	_	O
74	urinary	_	_	O
75	calcium	_	_	O
76	(	_	_	O
77	uCa	_	_	O
78	)	_	_	O
79	,	_	_	O
80	hydroxyproline	_	_	O
81	(	_	_	O
82	Hyp	_	_	O
83	)	_	_	O
84	,	_	_	O
85	and	_	_	O
86	the	_	_	O
87	collagen	_	_	O
88	breakdown	_	_	O
89	products	_	_	O
90	:	_	_	O
91	NTx	_	_	O
92	,	_	_	O
93	Crosslaps	_	_	O
94	and	_	_	O
95	Free	_	_	O
96	Dpd	_	_	O
97	.	_	_	O

98	Symptomatic	_	_	B-Premise
99	response	_	_	I-Premise
100	during	_	_	I-Premise
101	the	_	_	I-Premise
102	first	_	_	I-Premise
103	four	_	_	I-Premise
104	weeks	_	_	I-Premise
105	was	_	_	I-Premise
106	seen	_	_	I-Premise
107	after	_	_	I-Premise
108	pamidronate	_	_	I-Premise
109	,	_	_	I-Premise
110	but	_	_	I-Premise
111	not	_	_	I-Premise
112	with	_	_	I-Premise
113	placebo	_	_	I-Premise
114	(	_	_	I-Premise
115	P	_	_	I-Premise
116	<	_	_	I-Premise
117	0.05	_	_	I-Premise
118	)	_	_	I-Premise
119	.	_	_	I-Premise

120	Quality	_	_	B-Premise
121	of	_	_	I-Premise
122	life	_	_	I-Premise
123	was	_	_	I-Premise
124	maintained	_	_	I-Premise
125	with	_	_	I-Premise
126	pamidronate	_	_	I-Premise
127	and	_	_	I-Premise
128	deteriorated	_	_	I-Premise
129	after	_	_	I-Premise
130	placebo	_	_	I-Premise
131	(	_	_	I-Premise
132	P	_	_	I-Premise
133	<	_	_	I-Premise
134	0.05	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	Resorption	_	_	B-Premise
138	markers	_	_	I-Premise
139	did	_	_	I-Premise
140	not	_	_	I-Premise
141	decrease	_	_	I-Premise
142	after	_	_	I-Premise
143	placebo	_	_	I-Premise
144	,	_	_	I-Premise
145	but	_	_	B-Premise
146	NTx	_	_	I-Premise
147	and	_	_	I-Premise
148	Crosslaps	_	_	I-Premise
149	both	_	_	I-Premise
150	decreased	_	_	I-Premise
151	by	_	_	I-Premise
152	70	_	_	I-Premise
153	%	_	_	I-Premise
154	after	_	_	I-Premise
155	pamidronate	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	=	_	_	I-Premise
159	0.001	_	_	I-Premise
160	)	_	_	I-Premise
161	.	_	_	I-Premise

162	A	_	_	B-Premise
163	second	_	_	I-Premise
164	infusion	_	_	I-Premise
165	of	_	_	I-Premise
166	pamidronate	_	_	I-Premise
167	did	_	_	I-Premise
168	not	_	_	I-Premise
169	decrease	_	_	I-Premise
170	resorption	_	_	I-Premise
171	further	_	_	I-Premise
172	,	_	_	I-Premise
173	but	_	_	B-Premise
174	maintained	_	_	I-Premise
175	the	_	_	I-Premise
176	suppression	_	_	I-Premise
177	of	_	_	I-Premise
178	resorption	_	_	I-Premise
179	at	_	_	I-Premise
180	similar	_	_	I-Premise
181	levels	_	_	I-Premise
182	for	_	_	I-Premise
183	a	_	_	I-Premise
184	further	_	_	I-Premise
185	four	_	_	I-Premise
186	weeks	_	_	I-Premise
187	.	_	_	I-Premise

188	Symptomatic	_	_	B-Premise
189	response	_	_	I-Premise
190	to	_	_	I-Premise
191	pamidronate	_	_	I-Premise
192	correlated	_	_	I-Premise
193	closely	_	_	I-Premise
194	with	_	_	I-Premise
195	the	_	_	I-Premise
196	rate	_	_	I-Premise
197	of	_	_	I-Premise
198	bone	_	_	I-Premise
199	resorption	_	_	I-Premise
200	;	_	_	I-Premise
201	it	_	_	B-Premise
202	was	_	_	I-Premise
203	more	_	_	I-Premise
204	frequent	_	_	I-Premise
205	in	_	_	I-Premise
206	those	_	_	I-Premise
207	patients	_	_	I-Premise
208	with	_	_	I-Premise
209	an	_	_	I-Premise
210	initial	_	_	I-Premise
211	NTx	_	_	I-Premise
212	value	_	_	I-Premise
213	of	_	_	I-Premise
214	<	_	_	I-Premise
215	2	_	_	I-Premise
216	times	_	_	I-Premise
217	the	_	_	I-Premise
218	upper	_	_	I-Premise
219	limit	_	_	I-Premise
220	of	_	_	I-Premise
221	normal	_	_	I-Premise
222	(	_	_	I-Premise
223	17	_	_	I-Premise
224	of	_	_	I-Premise
225	27	_	_	I-Premise
226	,	_	_	I-Premise
227	62	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	and	_	_	I-Premise
231	in	_	_	I-Premise
232	those	_	_	I-Premise
233	where	_	_	I-Premise
234	the	_	_	I-Premise
235	level	_	_	I-Premise
236	of	_	_	I-Premise
237	Ntx	_	_	I-Premise
238	returned	_	_	I-Premise
239	to	_	_	I-Premise
240	normal	_	_	I-Premise
241	(	_	_	I-Premise
242	19	_	_	I-Premise
243	of	_	_	I-Premise
244	32	_	_	I-Premise
245	,	_	_	I-Premise
246	59	_	_	I-Premise
247	%	_	_	I-Premise
248	)	_	_	I-Premise
249	,	_	_	I-Premise
250	than	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	patients	_	_	I-Premise
254	with	_	_	I-Premise
255	either	_	_	I-Premise
256	high	_	_	I-Premise
257	baseline	_	_	I-Premise
258	values	_	_	I-Premise
259	of	_	_	I-Premise
260	NTx	_	_	I-Premise
261	(	_	_	I-Premise
262	>	_	_	I-Premise
263	2	_	_	I-Premise
264	times	_	_	I-Premise
265	the	_	_	I-Premise
266	upper	_	_	I-Premise
267	limit	_	_	I-Premise
268	of	_	_	I-Premise
269	normal	_	_	I-Premise
270	)	_	_	I-Premise
271	or	_	_	I-Premise
272	Ntx	_	_	I-Premise
273	levels	_	_	I-Premise
274	which	_	_	I-Premise
275	failed	_	_	I-Premise
276	to	_	_	I-Premise
277	normalise	_	_	I-Premise
278	for	_	_	I-Premise
279	whom	_	_	I-Premise
280	the	_	_	I-Premise
281	response	_	_	I-Premise
282	frequencies	_	_	I-Premise
283	were	_	_	I-Premise
284	2	_	_	I-Premise
285	of	_	_	I-Premise
286	16	_	_	I-Premise
287	(	_	_	I-Premise
288	13	_	_	I-Premise
289	%	_	_	I-Premise
290	)	_	_	I-Premise
291	and	_	_	I-Premise
292	0	_	_	I-Premise
293	of	_	_	I-Premise
294	11	_	_	I-Premise
295	(	_	_	I-Premise
296	0	_	_	I-Premise
297	%	_	_	I-Premise
298	)	_	_	I-Premise
299	,	_	_	I-Premise
300	respectively	_	_	I-Premise
301	.	_	_	I-Premise

302	Subjective	_	_	B-Claim
303	benefit	_	_	I-Claim
304	after	_	_	I-Claim
305	intravenous	_	_	I-Claim
306	pamidronate	_	_	I-Claim
307	is	_	_	I-Claim
308	confirmed	_	_	I-Claim
309	in	_	_	I-Claim
310	this	_	_	I-Claim
311	placebo-controlled	_	_	I-Claim
312	study	_	_	I-Claim
313	.	_	_	I-Claim

314	The	_	_	B-Claim
315	new	_	_	I-Claim
316	bone	_	_	I-Claim
317	resorption	_	_	I-Claim
318	markers	_	_	I-Claim
319	of	_	_	I-Claim
320	collagen	_	_	I-Claim
321	breakdown	_	_	I-Claim
322	were	_	_	I-Claim
323	able	_	_	I-Claim
324	to	_	_	I-Claim
325	predict	_	_	I-Claim
326	clinical	_	_	I-Claim
327	response	_	_	I-Claim
328	to	_	_	I-Claim
329	pamidronate	_	_	I-Claim
330	.	_	_	I-Claim


0	We	_	_	O
1	conducted	_	_	O
2	a	_	_	O
3	prospective	_	_	O
4	,	_	_	O
5	randomized	_	_	O
6	,	_	_	O
7	multicentre	_	_	O
8	clinical	_	_	O
9	trial	_	_	O
10	comparing	_	_	O
11	the	_	_	O
12	effects	_	_	O
13	and	_	_	O
14	costs	_	_	O
15	of	_	_	O
16	GM-CSF	_	_	O
17	as	_	_	O
18	an	_	_	O
19	adjunct	_	_	O
20	to	_	_	O
21	intensive	_	_	O
22	chemotherapy	_	_	O
23	in	_	_	O
24	elderly	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	acute	_	_	O
28	myeloid	_	_	O
29	leukaemia	_	_	O
30	(	_	_	O
31	AML	_	_	O
32	)	_	_	O
33	.	_	_	O

34	The	_	_	O
35	patients	_	_	O
36	were	_	_	O
37	randomized	_	_	O
38	to	_	_	O
39	either	_	_	O
40	daunomycin-cytosine	_	_	O
41	arabinoside	_	_	O
42	(	_	_	O
43	control	_	_	O
44	arm	_	_	O
45	:	_	_	O
46	n	_	_	O
47	=	_	_	O
48	161	_	_	O
49	)	_	_	O
50	or	_	_	O
51	daunomycin-cytosine	_	_	O
52	arabinoside	_	_	O
53	with	_	_	O
54	GM-CSF	_	_	O
55	(	_	_	O
56	GM-CSF	_	_	O
57	arm	_	_	O
58	:	_	_	O
59	n	_	_	O
60	=	_	_	O
61	157	_	_	O
62	)	_	_	O
63	.	_	_	O

64	The	_	_	O
65	primary	_	_	O
66	end-point	_	_	O
67	was	_	_	O
68	the	_	_	O
69	effect	_	_	O
70	of	_	_	O
71	GM-CSF	_	_	O
72	on	_	_	O
73	the	_	_	O
74	percentage	_	_	O
75	of	_	_	O
76	complete	_	_	O
77	remissions	_	_	O
78	(	_	_	O
79	CR	_	_	O
80	)	_	_	O
81	.	_	_	O

82	Survival	_	_	O
83	duration	_	_	O
84	,	_	_	O
85	disease-free	_	_	O
86	survival	_	_	O
87	,	_	_	O
88	quality	_	_	O
89	of	_	_	O
90	life	_	_	O
91	and	_	_	O
92	costs	_	_	O
93	were	_	_	O
94	evaluated	_	_	O
95	separately	_	_	O
96	.	_	_	O

97	CR	_	_	B-Premise
98	after	_	_	I-Premise
99	remission	_	_	I-Premise
100	induction	_	_	I-Premise
101	treatment	_	_	I-Premise
102	was	_	_	I-Premise
103	achieved	_	_	I-Premise
104	in	_	_	I-Premise
105	55	_	_	I-Premise
106	%	_	_	I-Premise
107	of	_	_	I-Premise
108	the	_	_	I-Premise
109	patients	_	_	I-Premise
110	in	_	_	I-Premise
111	the	_	_	I-Premise
112	control	_	_	I-Premise
113	group	_	_	I-Premise
114	and	_	_	I-Premise
115	in	_	_	I-Premise
116	56	_	_	I-Premise
117	%	_	_	I-Premise
118	of	_	_	I-Premise
119	the	_	_	I-Premise
120	patients	_	_	I-Premise
121	in	_	_	I-Premise
122	the	_	_	I-Premise
123	GM-CSF	_	_	I-Premise
124	group	_	_	I-Premise
125	(	_	_	I-Premise
126	P	_	_	I-Premise
127	=	_	_	I-Premise
128	NS	_	_	I-Premise
129	)	_	_	I-Premise
130	.	_	_	I-Premise

131	The	_	_	B-Premise
132	duration	_	_	I-Premise
133	of	_	_	I-Premise
134	survival	_	_	I-Premise
135	and	_	_	I-Premise
136	disease-free	_	_	I-Premise
137	survival	_	_	I-Premise
138	at	_	_	I-Premise
139	2	_	_	I-Premise
140	years	_	_	I-Premise
141	after	_	_	I-Premise
142	randomization	_	_	I-Premise
143	were	_	_	I-Premise
144	estimated	_	_	I-Premise
145	at	_	_	I-Premise
146	22	_	_	I-Premise
147	%	_	_	I-Premise
148	and	_	_	I-Premise
149	19	_	_	I-Premise
150	%	_	_	I-Premise
151	for	_	_	I-Premise
152	the	_	_	I-Premise
153	control	_	_	I-Premise
154	group	_	_	I-Premise
155	and	_	_	I-Premise
156	22	_	_	I-Premise
157	%	_	_	I-Premise
158	and	_	_	I-Premise
159	14	_	_	I-Premise
160	%	_	_	I-Premise
161	for	_	_	I-Premise
162	the	_	_	I-Premise
163	GM-CSF	_	_	I-Premise
164	group	_	_	I-Premise
165	(	_	_	I-Premise
166	P	_	_	I-Premise
167	=	_	_	I-Premise
168	NS	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	Considering	_	_	B-Premise
172	the	_	_	I-Premise
173	short-term	_	_	I-Premise
174	quality	_	_	I-Premise
175	of	_	_	I-Premise
176	life	_	_	I-Premise
177	,	_	_	I-Premise
178	the	_	_	I-Premise
179	administration	_	_	I-Premise
180	of	_	_	I-Premise
181	GM-CSF	_	_	I-Premise
182	resulted	_	_	I-Premise
183	in	_	_	I-Premise
184	more	_	_	I-Premise
185	problems	_	_	I-Premise
186	with	_	_	I-Premise
187	regard	_	_	I-Premise
188	to	_	_	I-Premise
189	depressed	_	_	I-Premise
190	mood	_	_	I-Premise
191	,	_	_	I-Premise
192	diarrhoea	_	_	I-Premise
193	and	_	_	I-Premise
194	rash/eczema	_	_	I-Premise
195	.	_	_	I-Premise

196	With	_	_	B-Premise
197	regard	_	_	I-Premise
198	to	_	_	I-Premise
199	the	_	_	I-Premise
200	long-term	_	_	I-Premise
201	quality	_	_	I-Premise
202	of	_	_	I-Premise
203	life	_	_	I-Premise
204	there	_	_	I-Premise
205	were	_	_	I-Premise
206	no	_	_	I-Premise
207	significant	_	_	I-Premise
208	differences	_	_	I-Premise
209	between	_	_	I-Premise
210	the	_	_	I-Premise
211	two	_	_	I-Premise
212	groups	_	_	I-Premise
213	.	_	_	I-Premise

214	The	_	_	B-Premise
215	average	_	_	I-Premise
216	costs	_	_	I-Premise
217	of	_	_	I-Premise
218	the	_	_	I-Premise
219	primary	_	_	I-Premise
220	treatment	_	_	I-Premise
221	were	_	_	I-Premise
222	higher	_	_	I-Premise
223	in	_	_	I-Premise
224	GM-CSF-treated	_	_	I-Premise
225	patients	_	_	I-Premise
226	than	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	control	_	_	I-Premise
230	group	_	_	I-Premise
231	,	_	_	I-Premise
232	i.e	_	_	I-Premise
233	.	_	_	I-Premise

234	US	_	_	I-Premise
235	$	_	_	I-Premise
236	40782	_	_	I-Premise
237	and	_	_	I-Premise
238	US	_	_	I-Premise
239	$	_	_	I-Premise
240	34465	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	0.01	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	costs	_	_	I-Premise
251	during	_	_	I-Premise
252	the	_	_	I-Premise
253	follow-up	_	_	I-Premise
254	period	_	_	I-Premise
255	did	_	_	I-Premise
256	not	_	_	I-Premise
257	differ	_	_	I-Premise
258	between	_	_	I-Premise
259	the	_	_	I-Premise
260	two	_	_	I-Premise
261	groups	_	_	I-Premise
262	.	_	_	I-Premise

263	The	_	_	B-Claim
264	results	_	_	I-Claim
265	of	_	_	I-Claim
266	this	_	_	I-Claim
267	randomized	_	_	I-Claim
268	clinical	_	_	I-Claim
269	trial	_	_	I-Claim
270	indicate	_	_	I-Claim
271	that	_	_	I-Claim
272	daunomycin-cytosine	_	_	I-Claim
273	arabinoside	_	_	I-Claim
274	plus	_	_	I-Claim
275	GM-CSF	_	_	I-Claim
276	is	_	_	I-Claim
277	not	_	_	I-Claim
278	a	_	_	I-Claim
279	cost-effective	_	_	I-Claim
280	treatment	_	_	I-Claim
281	strategy	_	_	I-Claim
282	when	_	_	I-Claim
283	compared	_	_	I-Claim
284	with	_	_	I-Claim
285	daunomycin-cytosine	_	_	I-Claim
286	arabinoside	_	_	I-Claim
287	alone	_	_	I-Claim
288	.	_	_	I-Claim


0	In	_	_	O
1	1980	_	_	O
2	the	_	_	O
3	EORTC-BCCG	_	_	O
4	initiated	_	_	O
5	a	_	_	O
6	multicentre	_	_	O
7	randomised	_	_	O
8	clinical	_	_	O
9	trial	_	_	O
10	comparing	_	_	O
11	modified	_	_	O
12	radical	_	_	O
13	mastectomy	_	_	O
14	(	_	_	O
15	MRM	_	_	O
16	)	_	_	O
17	with	_	_	O
18	breast-conserving	_	_	O
19	therapy	_	_	O
20	(	_	_	O
21	BCT	_	_	O
22	)	_	_	O
23	in	_	_	O
24	stage	_	_	O
25	I	_	_	O
26	and	_	_	O
27	II	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	.	_	_	O

31	The	_	_	O
32	main	_	_	O
33	endpoint	_	_	O
34	of	_	_	O
35	the	_	_	O
36	trial	_	_	O
37	was	_	_	O
38	survival	_	_	O
39	.	_	_	O

40	A	_	_	O
41	brief	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	(	_	_	O
46	QoL	_	_	O
47	)	_	_	O
48	questionnaire	_	_	O
49	consisting	_	_	O
50	of	_	_	O
51	two	_	_	O
52	multi-item	_	_	O
53	scales	_	_	O
54	(	_	_	O
55	body	_	_	O
56	image	_	_	O
57	and	_	_	O
58	fear	_	_	O
59	of	_	_	O
60	recurrence	_	_	O
61	)	_	_	O
62	and	_	_	O
63	two	_	_	O
64	single	_	_	O
65	items	_	_	O
66	(	_	_	O
67	satisfaction	_	_	O
68	with	_	_	O
69	treatment	_	_	O
70	and	_	_	O
71	cosmetic	_	_	O
72	result	_	_	O
73	)	_	_	O
74	was	_	_	O
75	included	_	_	O
76	in	_	_	O
77	the	_	_	O
78	trial	_	_	O
79	.	_	_	O

80	A	_	_	O
81	cosmetic	_	_	O
82	evaluation	_	_	O
83	of	_	_	O
84	the	_	_	O
85	breast	_	_	O
86	after	_	_	O
87	conservative	_	_	O
88	surgery	_	_	O
89	was	_	_	O
90	also	_	_	O
91	performed	_	_	O
92	.	_	_	O

93	This	_	_	O
94	report	_	_	O
95	concentrates	_	_	O
96	on	_	_	O
97	the	_	_	O
98	results	_	_	O
99	of	_	_	O
100	the	_	_	O
101	QoL	_	_	O
102	study	_	_	O
103	and	_	_	O
104	the	_	_	O
105	cosmetic	_	_	O
106	evaluation	_	_	O
107	.	_	_	O

108	Multitrait	_	_	O
109	scaling	_	_	O
110	analysis	_	_	O
111	was	_	_	O
112	employed	_	_	O
113	to	_	_	O
114	verify	_	_	O
115	the	_	_	O
116	hypothesised	_	_	O
117	scale	_	_	O
118	structure	_	_	O
119	of	_	_	O
120	the	_	_	O
121	questionnaire	_	_	O
122	.	_	_	O

123	Treatment	_	_	O
124	comparison	_	_	O
125	of	_	_	O
126	the	_	_	O
127	QoL	_	_	O
128	scores	_	_	O
129	at	_	_	O
130	2	_	_	O
131	years	_	_	O
132	post-treatment	_	_	O
133	was	_	_	O
134	performed	_	_	O
135	using	_	_	O
136	a	_	_	O
137	stratified	_	_	O
138	Wilcoxon	_	_	O
139	rank	_	_	O
140	sum	_	_	O
141	test	_	_	O
142	.	_	_	O

143	Both	_	_	O
144	patients	_	_	O
145	'	_	_	O
146	and	_	_	O
147	doctors	_	_	O
148	'	_	_	O
149	ratings	_	_	O
150	of	_	_	O
151	the	_	_	O
152	cosmetic	_	_	O
153	result	_	_	O
154	were	_	_	O
155	documented	_	_	O
156	on	_	_	O
157	the	_	_	O
158	clinical	_	_	O
159	follow-up	_	_	O
160	form	_	_	O
161	.	_	_	O

162	A	_	_	O
163	multivariate	_	_	O
164	analysis	_	_	O
165	was	_	_	O
166	performed	_	_	O
167	to	_	_	O
168	identify	_	_	O
169	which	_	_	O
170	factors	_	_	O
171	influenced	_	_	O
172	the	_	_	O
173	cosmetic	_	_	O
174	outcome	_	_	O
175	.	_	_	O

176	In	_	_	O
177	total	_	_	O
178	,	_	_	O
179	127	_	_	O
180	patients	_	_	O
181	in	_	_	O
182	the	_	_	O
183	MRM	_	_	O
184	arm	_	_	O
185	and	_	_	O
186	151	_	_	O
187	in	_	_	O
188	the	_	_	O
189	BCT	_	_	O
190	arm	_	_	O
191	completed	_	_	O
192	a	_	_	O
193	QoL	_	_	O
194	questionnaire	_	_	O
195	at	_	_	O
196	approximately	_	_	O
197	2	_	_	O
198	years	_	_	O
199	after	_	_	O
200	randomisation	_	_	O
201	(	_	_	O
202	months	_	_	O
203	25-36	_	_	O
204	)	_	_	O
205	.	_	_	O

206	The	_	_	B-Premise
207	Cronbach	_	_	I-Premise
208	's	_	_	I-Premise
209	alpha	_	_	I-Premise
210	coefficients	_	_	I-Premise
211	were	_	_	I-Premise
212	0.79	_	_	I-Premise
213	and	_	_	I-Premise
214	0.73	_	_	I-Premise
215	for	_	_	I-Premise
216	the	_	_	I-Premise
217	body	_	_	I-Premise
218	image	_	_	I-Premise
219	and	_	_	I-Premise
220	fear	_	_	I-Premise
221	of	_	_	I-Premise
222	recurrence	_	_	I-Premise
223	scales	_	_	I-Premise
224	,	_	_	I-Premise
225	respectively	_	_	I-Premise
226	.	_	_	I-Premise

227	Significant	_	_	B-Premise
228	benefit	_	_	I-Premise
229	in	_	_	I-Premise
230	body	_	_	I-Premise
231	image	_	_	I-Premise
232	and	_	_	I-Premise
233	satisfaction	_	_	I-Premise
234	with	_	_	I-Premise
235	treatment	_	_	I-Premise
236	was	_	_	I-Premise
237	observed	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	BCT	_	_	I-Premise
241	patients	_	_	I-Premise
242	.	_	_	I-Premise

243	No	_	_	B-Premise
244	significant	_	_	I-Premise
245	difference	_	_	I-Premise
246	was	_	_	I-Premise
247	observed	_	_	I-Premise
248	in	_	_	I-Premise
249	fear	_	_	I-Premise
250	of	_	_	I-Premise
251	recurrence	_	_	I-Premise
252	between	_	_	I-Premise
253	the	_	_	I-Premise
254	two	_	_	I-Premise
255	groups	_	_	I-Premise
256	.	_	_	I-Premise

257	Ratings	_	_	B-Premise
258	of	_	_	I-Premise
259	cosmetic	_	_	I-Premise
260	results	_	_	I-Premise
261	decreased	_	_	I-Premise
262	with	_	_	I-Premise
263	time	_	_	I-Premise
264	,	_	_	I-Premise
265	in	_	_	I-Premise
266	line	_	_	I-Premise
267	with	_	_	I-Premise
268	clinical	_	_	I-Premise
269	observations	_	_	I-Premise
270	of	_	_	I-Premise
271	long-term	_	_	I-Premise
272	side-effects	_	_	I-Premise
273	of	_	_	I-Premise
274	radiotherapy	_	_	I-Premise
275	.	_	_	I-Premise

276	Wide	_	_	B-Claim
277	excision	_	_	I-Claim
278	appeared	_	_	I-Claim
279	to	_	_	I-Claim
280	be	_	_	I-Claim
281	the	_	_	I-Claim
282	most	_	_	I-Claim
283	important	_	_	I-Claim
284	predictive	_	_	I-Claim
285	factor	_	_	I-Claim
286	for	_	_	I-Claim
287	poor	_	_	I-Claim
288	cosmetic	_	_	I-Claim
289	result	_	_	I-Claim
290	.	_	_	I-Claim

291	In	_	_	B-Claim
292	this	_	_	I-Claim
293	multicentre	_	_	I-Claim
294	randomised	_	_	I-Claim
295	study	_	_	I-Claim
296	,	_	_	I-Claim
297	BCT	_	_	I-Claim
298	helped	_	_	I-Claim
299	to	_	_	I-Claim
300	maintain	_	_	I-Claim
301	the	_	_	I-Claim
302	patients	_	_	I-Claim
303	'	_	_	I-Claim
304	body	_	_	I-Claim
305	image	_	_	I-Claim
306	,	_	_	I-Claim
307	resulted	_	_	I-Claim
308	in	_	_	I-Claim
309	higher	_	_	I-Claim
310	satisfaction	_	_	I-Claim
311	with	_	_	I-Claim
312	treatment	_	_	I-Claim
313	and	_	_	I-Claim
314	yielded	_	_	I-Claim
315	no	_	_	I-Claim
316	significant	_	_	I-Claim
317	difference	_	_	I-Claim
318	from	_	_	I-Claim
319	MRM	_	_	I-Claim
320	with	_	_	I-Claim
321	respect	_	_	I-Claim
322	to	_	_	I-Claim
323	fear	_	_	I-Claim
324	of	_	_	I-Claim
325	recurrence	_	_	I-Claim
326	.	_	_	I-Claim


0	The	_	_	O
1	Intergroup	_	_	O
2	conducted	_	_	O
3	this	_	_	O
4	breast	_	_	O
5	cancer	_	_	O
6	adjuvant	_	_	O
7	trial	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	an	_	_	O
11	investigational	_	_	O
12	16-week	_	_	O
13	regimen	_	_	O
14	with	_	_	O
15	cyclophosphamide	_	_	O
16	,	_	_	O
17	doxorubicin	_	_	O
18	,	_	_	O
19	and	_	_	O
20	fluorouracil	_	_	O
21	(	_	_	O
22	5-FU	_	_	O
23	;	_	_	O
24	CAF	_	_	O
25	)	_	_	O
26	.	_	_	O

27	The	_	_	O
28	16-week	_	_	O
29	regimen	_	_	O
30	features	_	_	O
31	greater	_	_	O
32	doxorubicin	_	_	O
33	and	_	_	O
34	5-FU	_	_	O
35	dose-intensity	_	_	O
36	than	_	_	O
37	CAF	_	_	O
38	and	_	_	O
39	improved	_	_	O
40	scheduling	_	_	O
41	of	_	_	O
42	antimetabolites	_	_	O
43	with	_	_	O
44	sequential	_	_	O
45	methotrexate	_	_	O
46	and	_	_	O
47	5-FU	_	_	O
48	,	_	_	O
49	as	_	_	O
50	well	_	_	O
51	as	_	_	O
52	infusion	_	_	O
53	5-FU	_	_	O
54	.	_	_	O

55	A	_	_	O
56	total	_	_	O
57	of	_	_	O
58	646	_	_	O
59	node-positive	_	_	O
60	,	_	_	O
61	receptor-negative	_	_	O
62	patients	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	to	_	_	O
67	receive	_	_	O
68	either	_	_	O
69	the	_	_	O
70	1	_	_	O
71	6-week	_	_	O
72	regimen	_	_	O
73	or	_	_	O
74	six	_	_	O
75	cycles	_	_	O
76	of	_	_	O
77	CAF	_	_	O
78	.	_	_	O

79	Breast	_	_	O
80	cancer	_	_	O
81	outcomes	_	_	O
82	included	_	_	O
83	recurrence	_	_	O
84	as	_	_	O
85	well	_	_	O
86	as	_	_	O
87	disease-free	_	_	O
88	and	_	_	O
89	overall	_	_	O
90	survival	_	_	O
91	.	_	_	O

92	Toxicity	_	_	O
93	was	_	_	O
94	evaluated	_	_	O
95	by	_	_	O
96	the	_	_	O
97	Common	_	_	O
98	Toxicity	_	_	O
99	Criteria	_	_	O
100	(	_	_	O
101	CTC	_	_	O
102	)	_	_	O
103	.	_	_	O

104	Treatment-related	_	_	O
105	quality	_	_	O
106	of	_	_	O
107	life	_	_	O
108	was	_	_	O
109	assessed	_	_	O
110	by	_	_	O
111	the	_	_	O
112	Breast	_	_	O
113	Chemotherapy	_	_	O
114	Questionnaire	_	_	O
115	(	_	_	O
116	BCQ	_	_	O
117	)	_	_	O
118	before	_	_	O
119	,	_	_	O
120	during	_	_	O
121	,	_	_	O
122	and	_	_	O
123	4	_	_	O
124	months	_	_	O
125	after	_	_	O
126	treatment	_	_	O
127	in	_	_	O
128	163	_	_	O
129	patients	_	_	O
130	.	_	_	O

131	The	_	_	O
132	trial	_	_	O
133	was	_	_	O
134	designed	_	_	O
135	to	_	_	O
136	use	_	_	O
137	one-sided	_	_	O
138	tests	_	_	O
139	of	_	_	O
140	significance	_	_	O
141	for	_	_	O
142	power	_	_	O
143	calculations	_	_	O
144	,	_	_	O
145	but	_	_	O
146	is	_	_	O
147	now	_	_	O
148	reported	_	_	O
149	with	_	_	O
150	both	_	_	O
151	one-sided	_	_	O
152	and	_	_	O
153	the	_	_	O
154	traditional	_	_	O
155	two-sided	_	_	O
156	tests	_	_	O
157	of	_	_	O
158	significance	_	_	O
159	.	_	_	O

160	At	_	_	B-Premise
161	a	_	_	I-Premise
162	median	_	_	I-Premise
163	follow-up	_	_	I-Premise
164	of	_	_	I-Premise
165	3.9	_	_	I-Premise
166	years	_	_	I-Premise
167	,	_	_	I-Premise
168	the	_	_	I-Premise
169	estimated	_	_	I-Premise
170	4-year	_	_	I-Premise
171	recurrence-free	_	_	I-Premise
172	survival	_	_	I-Premise
173	rate	_	_	I-Premise
174	was	_	_	I-Premise
175	67.5	_	_	I-Premise
176	%	_	_	I-Premise
177	with	_	_	I-Premise
178	the	_	_	I-Premise
179	16-week	_	_	I-Premise
180	regimen	_	_	I-Premise
181	versus	_	_	I-Premise
182	62.7	_	_	I-Premise
183	%	_	_	I-Premise
184	with	_	_	I-Premise
185	CAF	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	.19	_	_	I-Premise
190	,	_	_	I-Premise
191	two-sided	_	_	I-Premise
192	;	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	.095	_	_	I-Premise
196	,	_	_	I-Premise
197	one-sided	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	The	_	_	B-Premise
201	estimated	_	_	I-Premise
202	4-year	_	_	I-Premise
203	survival	_	_	I-Premise
204	rate	_	_	I-Premise
205	was	_	_	I-Premise
206	78.1	_	_	I-Premise
207	%	_	_	I-Premise
208	with	_	_	I-Premise
209	the	_	_	I-Premise
210	16-week	_	_	I-Premise
211	regimen	_	_	I-Premise
212	versus	_	_	I-Premise
213	71.4	_	_	I-Premise
214	%	_	_	I-Premise
215	with	_	_	I-Premise
216	CAF	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	.10	_	_	I-Premise
221	,	_	_	I-Premise
222	two-sided	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	=	_	_	I-Premise
226	.05	_	_	I-Premise
227	,	_	_	I-Premise
228	one-sided	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	CAF	_	_	B-Premise
232	produced	_	_	I-Premise
233	significantly	_	_	I-Premise
234	higher	_	_	I-Premise
235	grades	_	_	I-Premise
236	of	_	_	I-Premise
237	leukopenia	_	_	I-Premise
238	,	_	_	I-Premise
239	granulocytopenia	_	_	I-Premise
240	,	_	_	I-Premise
241	and	_	_	I-Premise
242	thrombocytopenia	_	_	I-Premise
243	,	_	_	I-Premise
244	as	_	_	I-Premise
245	well	_	_	I-Premise
246	as	_	_	I-Premise
247	liver	_	_	I-Premise
248	and	_	_	I-Premise
249	cardiac	_	_	I-Premise
250	toxicity	_	_	I-Premise
251	,	_	_	I-Premise
252	whereas	_	_	O
253	the	_	_	B-Premise
254	16-week	_	_	I-Premise
255	regimen	_	_	I-Premise
256	produced	_	_	I-Premise
257	significantly	_	_	I-Premise
258	higher	_	_	I-Premise
259	grades	_	_	I-Premise
260	of	_	_	I-Premise
261	anemia	_	_	I-Premise
262	,	_	_	I-Premise
263	nausea	_	_	I-Premise
264	,	_	_	I-Premise
265	stomatitis	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	weight	_	_	I-Premise
269	loss	_	_	I-Premise
270	,	_	_	I-Premise
271	as	_	_	I-Premise
272	well	_	_	I-Premise
273	as	_	_	I-Premise
274	skin	_	_	I-Premise
275	and	_	_	I-Premise
276	neurotoxicity	_	_	I-Premise
277	.	_	_	I-Premise

278	There	_	_	B-Premise
279	were	_	_	I-Premise
280	three	_	_	I-Premise
281	treatment-related	_	_	I-Premise
282	deaths	_	_	I-Premise
283	with	_	_	I-Premise
284	CAF	_	_	I-Premise
285	but	_	_	B-Premise
286	none	_	_	I-Premise
287	with	_	_	I-Premise
288	the	_	_	I-Premise
289	16-week	_	_	I-Premise
290	regimen	_	_	I-Premise
291	.	_	_	I-Premise

292	During	_	_	B-Premise
293	treatment	_	_	I-Premise
294	,	_	_	I-Premise
295	quality	_	_	I-Premise
296	of	_	_	I-Premise
297	life	_	_	I-Premise
298	declined	_	_	I-Premise
299	significantly	_	_	I-Premise
300	more	_	_	I-Premise
301	with	_	_	I-Premise
302	the	_	_	I-Premise
303	16-week	_	_	I-Premise
304	regimen	_	_	I-Premise
305	than	_	_	I-Premise
306	CAF	_	_	I-Premise
307	,	_	_	I-Premise
308	but	_	_	B-Premise
309	by	_	_	I-Premise
310	4	_	_	I-Premise
311	months	_	_	I-Premise
312	posttreatment	_	_	I-Premise
313	,	_	_	I-Premise
314	there	_	_	I-Premise
315	was	_	_	I-Premise
316	no	_	_	I-Premise
317	difference	_	_	I-Premise
318	.	_	_	I-Premise

319	The	_	_	B-Premise
320	16-week	_	_	I-Premise
321	regimen	_	_	I-Premise
322	produced	_	_	I-Premise
323	marginally	_	_	I-Premise
324	better	_	_	I-Premise
325	breast	_	_	I-Premise
326	cancer	_	_	I-Premise
327	outcomes	_	_	I-Premise
328	than	_	_	I-Premise
329	CAF	_	_	I-Premise
330	with	_	_	I-Premise
331	similar	_	_	I-Premise
332	toxicity	_	_	I-Premise
333	but	_	_	I-Premise
334	a	_	_	I-Premise
335	greater	_	_	I-Premise
336	reduction	_	_	I-Premise
337	in	_	_	I-Premise
338	during-treatment	_	_	I-Premise
339	quality	_	_	I-Premise
340	of	_	_	I-Premise
341	life	_	_	I-Premise
342	.	_	_	I-Premise

343	The	_	_	B-Claim
344	16-week	_	_	I-Claim
345	regimen	_	_	I-Claim
346	should	_	_	I-Claim
347	not	_	_	I-Claim
348	be	_	_	I-Claim
349	used	_	_	I-Claim
350	instead	_	_	I-Claim
351	of	_	_	I-Claim
352	a	_	_	I-Claim
353	standard-dose	_	_	I-Claim
354	regimen	_	_	I-Claim
355	without	_	_	I-Claim
356	careful	_	_	I-Claim
357	consideration	_	_	I-Claim
358	of	_	_	I-Claim
359	the	_	_	I-Claim
360	16-week	_	_	I-Claim
361	regimen	_	_	I-Claim
362	's	_	_	I-Claim
363	pros	_	_	I-Claim
364	and	_	_	I-Claim
365	cons	_	_	I-Claim
366	,	_	_	I-Claim
367	which	_	_	I-Claim
368	include	_	_	I-Claim
369	its	_	_	I-Claim
370	complicated	_	_	I-Claim
371	schedule	_	_	I-Claim
372	.	_	_	I-Claim

373	It	_	_	B-Claim
374	should	_	_	I-Claim
375	probably	_	_	I-Claim
376	not	_	_	I-Claim
377	be	_	_	I-Claim
378	tested	_	_	I-Claim
379	further	_	_	I-Claim
380	,	_	_	I-Claim
381	but	_	_	B-Claim
382	its	_	_	I-Claim
383	antimetabolite	_	_	I-Claim
384	schedules	_	_	I-Claim
385	and	_	_	I-Claim
386	frequent	_	_	I-Claim
387	drug	_	_	I-Claim
388	administration	_	_	I-Claim
389	(	_	_	I-Claim
390	ie	_	_	I-Claim
391	,	_	_	I-Claim
392	dose	_	_	I-Claim
393	density	_	_	I-Claim
394	)	_	_	I-Claim
395	should	_	_	I-Claim
396	be	_	_	I-Claim
397	considered	_	_	I-Claim
398	in	_	_	I-Claim
399	the	_	_	I-Claim
400	development	_	_	I-Claim
401	of	_	_	I-Claim
402	new	_	_	I-Claim
403	regimens	_	_	I-Claim
404	.	_	_	I-Claim


0	For	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	metastatic	_	_	I-Claim
4	prostate	_	_	I-Claim
5	cancer	_	_	I-Claim
6	,	_	_	I-Claim
7	treatment	_	_	I-Claim
8	is	_	_	I-Claim
9	primarily	_	_	I-Claim
10	palliative	_	_	I-Claim
11	,	_	_	I-Claim
12	relying	_	_	I-Claim
13	mainly	_	_	I-Claim
14	on	_	_	I-Claim
15	the	_	_	I-Claim
16	suppression	_	_	I-Claim
17	of	_	_	I-Claim
18	systemic	_	_	I-Claim
19	androgen	_	_	I-Claim
20	hormone	_	_	I-Claim
21	levels	_	_	I-Claim
22	.	_	_	I-Claim

23	To	_	_	O
24	help	_	_	O
25	document	_	_	O
26	the	_	_	O
27	achievement	_	_	O
28	of	_	_	O
29	palliation	_	_	O
30	and	_	_	O
31	to	_	_	O
32	characterize	_	_	O
33	positive	_	_	O
34	and	_	_	O
35	negative	_	_	O
36	effects	_	_	O
37	of	_	_	O
38	treatment	_	_	O
39	,	_	_	O
40	we	_	_	O
41	evaluated	_	_	O
42	quality-of-life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	parameters	_	_	O
47	in	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	metastatic	_	_	O
51	prostate	_	_	O
52	cancer	_	_	O
53	who	_	_	O
54	were	_	_	O
55	randomly	_	_	O
56	assigned	_	_	O
57	to	_	_	O
58	two	_	_	O
59	methods	_	_	O
60	of	_	_	O
61	androgen	_	_	O
62	deprivation	_	_	O
63	.	_	_	O

64	Patients	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	739	_	_	O
69	)	_	_	O
70	with	_	_	O
71	stage	_	_	O
72	M1	_	_	O
73	(	_	_	O
74	bone	_	_	O
75	or	_	_	O
76	soft	_	_	O
77	tissue	_	_	O
78	metastasis	_	_	O
79	)	_	_	O
80	prostate	_	_	O
81	cancer	_	_	O
82	were	_	_	O
83	enrolled	_	_	O
84	in	_	_	O
85	a	_	_	O
86	QOL	_	_	O
87	protocol	_	_	O
88	that	_	_	O
89	was	_	_	O
90	a	_	_	O
91	companion	_	_	O
92	to	_	_	O
93	Southwest	_	_	O
94	Oncology	_	_	O
95	Group	_	_	O
96	INT-0105	_	_	O
97	,	_	_	O
98	a	_	_	O
99	randomized	_	_	O
100	double-blind	_	_	O
101	trial	_	_	O
102	comparing	_	_	O
103	treatment	_	_	O
104	with	_	_	O
105	bilateral	_	_	O
106	orchiectomy	_	_	O
107	(	_	_	O
108	surgical	_	_	O
109	castration	_	_	O
110	)	_	_	O
111	plus	_	_	O
112	either	_	_	O
113	flutamide	_	_	O
114	or	_	_	O
115	placebo	_	_	O
116	.	_	_	O

117	Patients	_	_	O
118	completed	_	_	O
119	a	_	_	O
120	comprehensive	_	_	O
121	battery	_	_	O
122	of	_	_	O
123	QOL	_	_	O
124	questionnaires	_	_	O
125	at	_	_	O
126	random	_	_	O
127	assignment	_	_	O
128	to	_	_	O
129	treatment	_	_	O
130	and	_	_	O
131	at	_	_	O
132	1	_	_	O
133	,	_	_	O
134	3	_	_	O
135	,	_	_	O
136	and	_	_	O
137	6	_	_	O
138	months	_	_	O
139	later	_	_	O
140	.	_	_	O

141	Data	_	_	O
142	were	_	_	O
143	collected	_	_	O
144	on	_	_	O
145	three	_	_	O
146	treatment-specific	_	_	O
147	symptoms	_	_	O
148	(	_	_	O
149	diarrhea	_	_	O
150	,	_	_	O
151	gas	_	_	O
152	pain	_	_	O
153	,	_	_	O
154	and	_	_	O
155	body	_	_	O
156	image	_	_	O
157	)	_	_	O
158	,	_	_	O
159	on	_	_	O
160	physical	_	_	O
161	functioning	_	_	O
162	,	_	_	O
163	and	_	_	O
164	on	_	_	O
165	emotional	_	_	O
166	functioning	_	_	O
167	.	_	_	O

168	All	_	_	O
169	P	_	_	O
170	values	_	_	O
171	are	_	_	O
172	two-sided	_	_	O
173	.	_	_	O

174	Questionnaire	_	_	O
175	return	_	_	O
176	rates	_	_	O
177	for	_	_	O
178	this	_	_	O
179	study	_	_	O
180	never	_	_	O
181	dropped	_	_	O
182	below	_	_	O
183	80	_	_	O
184	%	_	_	O
185	;	_	_	O
186	only	_	_	O
187	2	_	_	O
188	%	_	_	O
189	of	_	_	O
190	the	_	_	O
191	patients	_	_	O
192	did	_	_	O
193	not	_	_	O
194	submit	_	_	O
195	baseline	_	_	O
196	QOL	_	_	O
197	assessments	_	_	O
198	.	_	_	O

199	Cross-sectional	_	_	B-Premise
200	analyses	_	_	I-Premise
201	(	_	_	I-Premise
202	corrected	_	_	I-Premise
203	for	_	_	I-Premise
204	multiple	_	_	I-Premise
205	testing	_	_	I-Premise
206	)	_	_	I-Premise
207	identified	_	_	I-Premise
208	statistically	_	_	I-Premise
209	significant	_	_	I-Premise
210	differences	_	_	I-Premise
211	that	_	_	I-Premise
212	favored	_	_	I-Premise
213	orchiectomy	_	_	I-Premise
214	plus	_	_	I-Premise
215	placebo	_	_	I-Premise
216	for	_	_	I-Premise
217	two	_	_	I-Premise
218	of	_	_	I-Premise
219	the	_	_	I-Premise
220	five	_	_	I-Premise
221	primary	_	_	I-Premise
222	QOL	_	_	I-Premise
223	parameters	_	_	I-Premise
224	as	_	_	I-Premise
225	follows	_	_	I-Premise
226	:	_	_	I-Premise
227	patients	_	_	I-Premise
228	receiving	_	_	I-Premise
229	flutamide	_	_	I-Premise
230	reported	_	_	I-Premise
231	more	_	_	I-Premise
232	diarrhea	_	_	I-Premise
233	at	_	_	I-Premise
234	3	_	_	I-Premise
235	months	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	=	_	_	I-Premise
239	.001	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	worse	_	_	I-Premise
243	emotional	_	_	I-Premise
244	functioning	_	_	I-Premise
245	at	_	_	I-Premise
246	3	_	_	I-Premise
247	and	_	_	I-Premise
248	6	_	_	I-Premise
249	months	_	_	I-Premise
250	(	_	_	I-Premise
251	both	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.003	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Longitudinal	_	_	B-Premise
258	analyses	_	_	I-Premise
259	replicated	_	_	I-Premise
260	these	_	_	I-Premise
261	findings	_	_	I-Premise
262	.	_	_	I-Premise

263	Other	_	_	B-Premise
264	analyzed	_	_	I-Premise
265	QOL	_	_	I-Premise
266	parameters	_	_	I-Premise
267	favored	_	_	I-Premise
268	the	_	_	I-Premise
269	group	_	_	I-Premise
270	receiving	_	_	I-Premise
271	placebo	_	_	I-Premise
272	but	_	_	B-Premise
273	were	_	_	I-Premise
274	not	_	_	I-Premise
275	statistically	_	_	I-Premise
276	significant	_	_	I-Premise
277	after	_	_	I-Premise
278	adjustment	_	_	I-Premise
279	for	_	_	I-Premise
280	multiple	_	_	I-Premise
281	testing	_	_	I-Premise
282	.	_	_	I-Premise

283	We	_	_	B-Claim
284	found	_	_	I-Claim
285	a	_	_	I-Claim
286	consistent	_	_	I-Claim
287	pattern	_	_	I-Claim
288	of	_	_	I-Claim
289	better	_	_	I-Claim
290	QOL	_	_	I-Claim
291	outcomes	_	_	I-Claim
292	at	_	_	I-Claim
293	each	_	_	I-Claim
294	follow-up	_	_	I-Claim
295	assessment	_	_	I-Claim
296	during	_	_	I-Claim
297	the	_	_	I-Claim
298	first	_	_	I-Claim
299	6	_	_	I-Claim
300	months	_	_	I-Claim
301	of	_	_	I-Claim
302	treatment	_	_	I-Claim
303	for	_	_	I-Claim
304	orchiectomized	_	_	I-Claim
305	patients	_	_	I-Claim
306	with	_	_	I-Claim
307	metastatic	_	_	I-Claim
308	prostate	_	_	I-Claim
309	cancer	_	_	I-Claim
310	who	_	_	I-Claim
311	received	_	_	I-Claim
312	placebo	_	_	I-Claim
313	versus	_	_	I-Claim
314	flutamide	_	_	I-Claim
315	.	_	_	I-Claim

316	Improvement	_	_	B-Claim
317	over	_	_	I-Claim
318	time	_	_	I-Claim
319	was	_	_	I-Claim
320	evident	_	_	I-Claim
321	in	_	_	I-Claim
322	both	_	_	I-Claim
323	treatment	_	_	I-Claim
324	groups	_	_	I-Claim
325	but	_	_	I-Claim
326	more	_	_	I-Claim
327	so	_	_	I-Claim
328	for	_	_	I-Claim
329	patients	_	_	I-Claim
330	receiving	_	_	I-Claim
331	placebo	_	_	I-Claim
332	.	_	_	I-Claim


0	In	_	_	O
1	phase	_	_	O
2	II	_	_	O
3	studies	_	_	O
4	,	_	_	O
5	irinotecan	_	_	O
6	is	_	_	O
7	active	_	_	O
8	in	_	_	O
9	metastatic	_	_	O
10	colorectal	_	_	O
11	cancer	_	_	O
12	,	_	_	O
13	but	_	_	O
14	the	_	_	O
15	overall	_	_	O
16	benefit	_	_	O
17	has	_	_	O
18	not	_	_	O
19	been	_	_	O
20	assessed	_	_	O
21	in	_	_	O
22	a	_	_	O
23	randomised	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	.	_	_	O

27	Patients	_	_	O
28	with	_	_	O
29	proven	_	_	O
30	metastatic	_	_	O
31	colorectal	_	_	O
32	cancer	_	_	O
33	,	_	_	O
34	which	_	_	O
35	had	_	_	O
36	progressed	_	_	O
37	within	_	_	O
38	6	_	_	O
39	months	_	_	O
40	of	_	_	O
41	treatment	_	_	O
42	with	_	_	O
43	fluorouracil	_	_	O
44	,	_	_	O
45	were	_	_	O
46	randomly	_	_	O
47	assigned	_	_	O
48	either	_	_	O
49	300-350	_	_	O
50	mg/m2	_	_	O
51	irinotecan	_	_	O
52	every	_	_	O
53	3	_	_	O
54	weeks	_	_	O
55	with	_	_	O
56	supportive	_	_	O
57	care	_	_	O
58	or	_	_	O
59	supportive	_	_	O
60	care	_	_	O
61	alone	_	_	O
62	,	_	_	O
63	in	_	_	O
64	a	_	_	O
65	2:1	_	_	O
66	ratio	_	_	O
67	.	_	_	O

68	189	_	_	O
69	patients	_	_	O
70	were	_	_	O
71	allocated	_	_	O
72	irinotecan	_	_	O
73	and	_	_	O
74	supportive	_	_	O
75	care	_	_	O
76	and	_	_	O
77	90	_	_	O
78	supportive	_	_	O
79	care	_	_	O
80	alone	_	_	O
81	.	_	_	O

82	The	_	_	O
83	mean	_	_	O
84	age	_	_	O
85	of	_	_	O
86	the	_	_	O
87	participants	_	_	O
88	was	_	_	O
89	58.8	_	_	O
90	years	_	_	O
91	;	_	_	O
92	181	_	_	O
93	(	_	_	O
94	65	_	_	O
95	%	_	_	O
96	)	_	_	O
97	were	_	_	O
98	men	_	_	O
99	and	_	_	O
100	98	_	_	O
101	(	_	_	O
102	35	_	_	O
103	%	_	_	O
104	)	_	_	O
105	were	_	_	O
106	women	_	_	O
107	.	_	_	O

108	WHO	_	_	O
109	performance	_	_	O
110	status	_	_	O
111	was	_	_	O
112	0	_	_	O
113	in	_	_	O
114	79	_	_	O
115	(	_	_	O
116	42	_	_	O
117	%	_	_	O
118	)	_	_	O
119	patients	_	_	O
120	,	_	_	O
121	1	_	_	O
122	in	_	_	O
123	77	_	_	O
124	(	_	_	O
125	41	_	_	O
126	%	_	_	O
127	)	_	_	O
128	patients	_	_	O
129	,	_	_	O
130	and	_	_	O
131	2	_	_	O
132	in	_	_	O
133	32	_	_	O
134	(	_	_	O
135	17	_	_	O
136	%	_	_	O
137	)	_	_	O
138	patients	_	_	O
139	.	_	_	O

140	Tumour-related	_	_	O
141	symptoms	_	_	O
142	were	_	_	O
143	present	_	_	O
144	in	_	_	O
145	134	_	_	O
146	(	_	_	O
147	71	_	_	O
148	%	_	_	O
149	)	_	_	O
150	patients	_	_	O
151	and	_	_	O
152	weight	_	_	O
153	loss	_	_	O
154	of	_	_	O
155	more	_	_	O
156	than	_	_	O
157	5	_	_	O
158	%	_	_	O
159	was	_	_	O
160	seen	_	_	O
161	in	_	_	O
162	15	_	_	O
163	(	_	_	O
164	8	_	_	O
165	%	_	_	O
166	)	_	_	O
167	patients	_	_	O
168	.	_	_	O

169	With	_	_	B-Premise
170	a	_	_	I-Premise
171	median	_	_	I-Premise
172	follow-up	_	_	I-Premise
173	of	_	_	I-Premise
174	13	_	_	I-Premise
175	months	_	_	I-Premise
176	,	_	_	I-Premise
177	the	_	_	I-Premise
178	overall	_	_	I-Premise
179	survival	_	_	I-Premise
180	was	_	_	I-Premise
181	significantly	_	_	I-Premise
182	better	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	irinotecan	_	_	I-Premise
186	group	_	_	I-Premise
187	(	_	_	I-Premise
188	p=0.0001	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	with	_	_	I-Premise
192	36.2	_	_	I-Premise
193	%	_	_	I-Premise
194	1-year	_	_	I-Premise
195	survival	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	irinotecan	_	_	I-Premise
199	group	_	_	I-Premise
200	versus	_	_	I-Premise
201	13.8	_	_	I-Premise
202	%	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	supportive-care	_	_	I-Premise
206	group	_	_	I-Premise
207	.	_	_	I-Premise

208	The	_	_	B-Premise
209	survival	_	_	I-Premise
210	benefit	_	_	I-Premise
211	,	_	_	I-Premise
212	adjusted	_	_	I-Premise
213	for	_	_	I-Premise
214	prognostic	_	_	I-Premise
215	factors	_	_	I-Premise
216	in	_	_	I-Premise
217	a	_	_	I-Premise
218	multivariate	_	_	I-Premise
219	analysis	_	_	I-Premise
220	,	_	_	I-Premise
221	remained	_	_	I-Premise
222	significant	_	_	I-Premise
223	(	_	_	I-Premise
224	p=0.001	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	Survival	_	_	B-Premise
228	without	_	_	I-Premise
229	performance-status	_	_	I-Premise
230	deterioration	_	_	I-Premise
231	(	_	_	I-Premise
232	p=0.0001	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	without	_	_	I-Premise
236	weight	_	_	I-Premise
237	loss	_	_	I-Premise
238	of	_	_	I-Premise
239	more	_	_	I-Premise
240	than	_	_	I-Premise
241	5	_	_	I-Premise
242	%	_	_	I-Premise
243	(	_	_	I-Premise
244	p=0.018	_	_	I-Premise
245	)	_	_	I-Premise
246	,	_	_	I-Premise
247	and	_	_	I-Premise
248	pain-free	_	_	I-Premise
249	survival	_	_	I-Premise
250	(	_	_	I-Premise
251	p=0.003	_	_	I-Premise
252	)	_	_	I-Premise
253	were	_	_	I-Premise
254	significantly	_	_	I-Premise
255	better	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	patients	_	_	I-Premise
259	given	_	_	I-Premise
260	irinotecan	_	_	I-Premise
261	.	_	_	I-Premise

262	In	_	_	B-Premise
263	a	_	_	I-Premise
264	quality-of-life	_	_	I-Premise
265	analysis	_	_	I-Premise
266	,	_	_	I-Premise
267	all	_	_	I-Premise
268	significant	_	_	I-Premise
269	differences	_	_	I-Premise
270	,	_	_	I-Premise
271	except	_	_	I-Premise
272	on	_	_	I-Premise
273	diarrhoea	_	_	I-Premise
274	score	_	_	I-Premise
275	,	_	_	I-Premise
276	were	_	_	I-Premise
277	in	_	_	I-Premise
278	favour	_	_	I-Premise
279	of	_	_	I-Premise
280	the	_	_	I-Premise
281	irinotecan	_	_	I-Premise
282	group	_	_	I-Premise
283	.	_	_	I-Premise

284	Our	_	_	B-Claim
285	study	_	_	I-Claim
286	shows	_	_	I-Claim
287	that	_	_	I-Claim
288	despite	_	_	I-Claim
289	the	_	_	I-Claim
290	side-effects	_	_	I-Claim
291	of	_	_	I-Claim
292	treatment	_	_	I-Claim
293	,	_	_	I-Claim
294	patients	_	_	I-Claim
295	who	_	_	I-Claim
296	have	_	_	I-Claim
297	metastatic	_	_	I-Claim
298	colorectal	_	_	I-Claim
299	cancer	_	_	I-Claim
300	,	_	_	I-Claim
301	and	_	_	I-Claim
302	for	_	_	I-Claim
303	whom	_	_	I-Claim
304	fluorouracil	_	_	I-Claim
305	has	_	_	I-Claim
306	failed	_	_	I-Claim
307	,	_	_	I-Claim
308	have	_	_	I-Claim
309	a	_	_	I-Claim
310	longer	_	_	I-Claim
311	survival	_	_	I-Claim
312	,	_	_	I-Claim
313	fewer	_	_	I-Claim
314	tumour-related	_	_	I-Claim
315	symptoms	_	_	I-Claim
316	,	_	_	I-Claim
317	and	_	_	I-Claim
318	a	_	_	I-Claim
319	better	_	_	I-Claim
320	quality	_	_	I-Claim
321	of	_	_	I-Claim
322	life	_	_	I-Claim
323	when	_	_	I-Claim
324	treated	_	_	I-Claim
325	with	_	_	I-Claim
326	irinotecan	_	_	I-Claim
327	than	_	_	I-Claim
328	with	_	_	I-Claim
329	supportive	_	_	I-Claim
330	care	_	_	I-Claim
331	alone	_	_	I-Claim
332	.	_	_	I-Claim


0	The	_	_	O
1	second	_	_	O
2	International	_	_	O
3	Society	_	_	O
4	of	_	_	O
5	Paediatric	_	_	O
6	Oncology	_	_	O
7	(	_	_	O
8	SIOP	_	_	O
9	)	_	_	O
10	study	_	_	O
11	for	_	_	O
12	rhabdomyosarcoma	_	_	O
13	(	_	_	O
14	MMT84	_	_	O
15	)	_	_	O
16	had	_	_	O
17	several	_	_	O
18	goals	_	_	O
19	.	_	_	O

20	The	_	_	O
21	two	_	_	O
22	principal	_	_	O
23	aims	_	_	O
24	were	_	_	O
25	:	_	_	O
26	(	_	_	O
27	1	_	_	O
28	)	_	_	O
29	to	_	_	O
30	improve	_	_	O
31	the	_	_	O
32	survival	_	_	O
33	of	_	_	O
34	children	_	_	O
35	with	_	_	O
36	rhabdomyosarcoma	_	_	O
37	;	_	_	O
38	and	_	_	O
39	(	_	_	O
40	2	_	_	O
41	)	_	_	O
42	to	_	_	O
43	reduce	_	_	O
44	the	_	_	O
45	late	_	_	O
46	effects	_	_	O
47	from	_	_	O
48	therapy	_	_	O
49	by	_	_	O
50	restricting	_	_	O
51	the	_	_	O
52	indications	_	_	O
53	for	_	_	O
54	surgery	_	_	O
55	and/or	_	_	O
56	radiotherapy	_	_	O
57	after	_	_	O
58	good	_	_	O
59	response	_	_	O
60	to	_	_	O
61	initial	_	_	O
62	chemotherapy	_	_	O
63	.	_	_	O

64	A	_	_	O
65	further	_	_	O
66	aim	_	_	O
67	was	_	_	O
68	to	_	_	O
69	investigate	_	_	O
70	the	_	_	O
71	role	_	_	O
72	of	_	_	O
73	high-dose	_	_	O
74	chemotherapy	_	_	O
75	in	_	_	O
76	young	_	_	O
77	patients	_	_	O
78	with	_	_	O
79	parameningeal	_	_	O
80	primary	_	_	O
81	tumours	_	_	O
82	.	_	_	O

83	186	_	_	O
84	previously	_	_	O
85	untreated	_	_	O
86	eligible	_	_	O
87	patients	_	_	O
88	entered	_	_	O
89	the	_	_	O
90	study	_	_	O
91	.	_	_	O

92	Patients	_	_	O
93	with	_	_	O
94	completely	_	_	O
95	resected	_	_	O
96	primary	_	_	O
97	tumour	_	_	O
98	received	_	_	O
99	three	_	_	O
100	courses	_	_	O
101	of	_	_	O
102	IVA	_	_	O
103	(	_	_	O
104	ifosfamide	_	_	O
105	,	_	_	O
106	vincristine	_	_	O
107	and	_	_	O
108	actinomycin	_	_	O
109	D	_	_	O
110	)	_	_	O
111	.	_	_	O

112	Patients	_	_	O
113	with	_	_	O
114	incompletely	_	_	O
115	resected	_	_	O
116	tumour	_	_	O
117	received	_	_	O
118	six	_	_	O
119	to	_	_	O
120	10	_	_	O
121	courses	_	_	O
122	of	_	_	O
123	IVA	_	_	O
124	according	_	_	O
125	to	_	_	O
126	stage	_	_	O
127	.	_	_	O

128	Patients	_	_	O
129	achieving	_	_	O
130	complete	_	_	O
131	remission	_	_	O
132	with	_	_	O
133	chemotherapy	_	_	O
134	alone	_	_	O
135	did	_	_	O
136	not	_	_	O
137	usually	_	_	O
138	receive	_	_	O
139	radiotherapy	_	_	O
140	or	_	_	O
141	undergo	_	_	O
142	extensive	_	_	O
143	surgery	_	_	O
144	,	_	_	O
145	but	_	_	O
146	patients	_	_	O
147	remaining	_	_	O
148	in	_	_	O
149	partial	_	_	O
150	remission	_	_	O
151	received	_	_	O
152	local	_	_	O
153	therapy	_	_	O
154	with	_	_	O
155	surgery	_	_	O
156	and/or	_	_	O
157	radiotherapy	_	_	O
158	.	_	_	O

159	Only	_	_	O
160	patients	_	_	O
161	over	_	_	O
162	5	_	_	O
163	years	_	_	O
164	of	_	_	O
165	age	_	_	O
166	with	_	_	O
167	parameningeal	_	_	O
168	disease	_	_	O
169	and	_	_	O
170	patients	_	_	O
171	over	_	_	O
172	12	_	_	O
173	years	_	_	O
174	with	_	_	O
175	tumours	_	_	O
176	at	_	_	O
177	any	_	_	O
178	site	_	_	O
179	were	_	_	O
180	given	_	_	O
181	systematic	_	_	O
182	irradiation	_	_	O
183	.	_	_	O

184	Complete	_	_	B-Premise
185	remission	_	_	I-Premise
186	was	_	_	I-Premise
187	achieved	_	_	I-Premise
188	in	_	_	I-Premise
189	91	_	_	I-Premise
190	%	_	_	I-Premise
191	(	_	_	I-Premise
192	170/186	_	_	I-Premise
193	)	_	_	I-Premise
194	of	_	_	I-Premise
195	all	_	_	I-Premise
196	patients	_	_	I-Premise
197	.	_	_	I-Premise

198	With	_	_	B-Premise
199	a	_	_	I-Premise
200	median	_	_	I-Premise
201	follow-up	_	_	I-Premise
202	of	_	_	I-Premise
203	8	_	_	I-Premise
204	years	_	_	I-Premise
205	,	_	_	I-Premise
206	the	_	_	I-Premise
207	5-year	_	_	I-Premise
208	overall	_	_	I-Premise
209	survival	_	_	I-Premise
210	was	_	_	I-Premise
211	68	_	_	I-Premise
212	%	_	_	I-Premise
213	(	_	_	I-Premise
214	+/-	_	_	I-Premise
215	3	_	_	I-Premise
216	%	_	_	I-Premise
217	standard	_	_	I-Premise
218	error	_	_	I-Premise
219	of	_	_	I-Premise
220	the	_	_	I-Premise
221	mean	_	_	I-Premise
222	(	_	_	I-Premise
223	SEM	_	_	I-Premise
224	)	_	_	I-Premise
225	and	_	_	I-Premise
226	the	_	_	I-Premise
227	5-year	_	_	I-Premise
228	event-free	_	_	I-Premise
229	survival	_	_	I-Premise
230	53	_	_	I-Premise
231	%	_	_	I-Premise
232	(	_	_	I-Premise
233	+/-	_	_	I-Premise
234	4	_	_	I-Premise
235	%	_	_	I-Premise
236	SEM	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	These	_	_	B-Premise
240	results	_	_	I-Premise
241	show	_	_	I-Premise
242	an	_	_	I-Premise
243	improvement	_	_	I-Premise
244	over	_	_	I-Premise
245	previous	_	_	I-Premise
246	SIOP	_	_	I-Premise
247	study	_	_	I-Premise
248	(	_	_	I-Premise
249	RMS75	_	_	I-Premise
250	)	_	_	I-Premise
251	in	_	_	I-Premise
252	which	_	_	I-Premise
253	survival	_	_	I-Premise
254	was	_	_	I-Premise
255	52	_	_	I-Premise
256	%	_	_	I-Premise
257	and	_	_	I-Premise
258	event-free	_	_	I-Premise
259	survival	_	_	I-Premise
260	was	_	_	I-Premise
261	47	_	_	I-Premise
262	%	_	_	I-Premise
263	.	_	_	I-Premise

264	Among	_	_	B-Premise
265	the	_	_	I-Premise
266	54	_	_	I-Premise
267	patients	_	_	I-Premise
268	who	_	_	I-Premise
269	exhibited	_	_	I-Premise
270	isolated	_	_	I-Premise
271	local	_	_	I-Premise
272	relapse	_	_	I-Premise
273	,	_	_	I-Premise
274	35	_	_	I-Premise
275	%	_	_	I-Premise
276	(	_	_	I-Premise
277	19/54	_	_	I-Premise
278	)	_	_	I-Premise
279	survived	_	_	I-Premise
280	in	_	_	I-Premise
281	further	_	_	I-Premise
282	remission	_	_	I-Premise
283	longer	_	_	I-Premise
284	than	_	_	I-Premise
285	2	_	_	I-Premise
286	years	_	_	I-Premise
287	after	_	_	I-Premise
288	retreatment	_	_	I-Premise
289	,	_	_	I-Premise
290	including	_	_	I-Premise
291	local	_	_	I-Premise
292	therapy	_	_	I-Premise
293	(	_	_	I-Premise
294	surgery	_	_	I-Premise
295	+/-	_	_	I-Premise
296	radiotherapy	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Analysis	_	_	O
300	of	_	_	O
301	the	_	_	O
302	overall	_	_	O
303	burden	_	_	O
304	of	_	_	O
305	therapy	_	_	O
306	received	_	_	O
307	by	_	_	O
308	all	_	_	O
309	surviving	_	_	O
310	children	_	_	O
311	(	_	_	O
312	including	_	_	O
313	primary	_	_	O
314	treatment	_	_	O
315	and	_	_	O
316	treatment	_	_	O
317	for	_	_	O
318	relapse	_	_	O
319	if	_	_	O
320	required	_	_	O
321	)	_	_	O
322	showed	_	_	O
323	that	_	_	O
324	24	_	_	O
325	%	_	_	O
326	(	_	_	O
327	28/116	_	_	O
328	)	_	_	O
329	were	_	_	O
330	treated	_	_	O
331	by	_	_	O
332	limited	_	_	O
333	surgery	_	_	O
334	followed	_	_	O
335	by	_	_	O
336	three	_	_	O
337	courses	_	_	O
338	of	_	_	O
339	IVA	_	_	O
340	,	_	_	O
341	29	_	_	O
342	%	_	_	O
343	(	_	_	O
344	34/116	_	_	O
345	)	_	_	O
346	were	_	_	O
347	treated	_	_	O
348	by	_	_	O
349	chemotherapy	_	_	O
350	alone	_	_	O
351	(	_	_	O
352	after	_	_	O
353	initial	_	_	O
354	biopsy	_	_	O
355	)	_	_	O
356	and	_	_	O
357	13	_	_	O
358	%	_	_	O
359	(	_	_	O
360	15/116	_	_	O
361	)	_	_	O
362	received	_	_	O
363	chemotherapy	_	_	O
364	plus	_	_	O
365	conservative	_	_	O
366	local	_	_	O
367	treatment	_	_	O
368	(	_	_	O
369	limited	_	_	O
370	surgery	_	_	O
371	or	_	_	O
372	radiotherapy	_	_	O
373	for	_	_	O
374	residual	_	_	O
375	disease	_	_	O
376	)	_	_	O
377	.	_	_	O

378	Only	_	_	O
379	34	_	_	O
380	%	_	_	O
381	(	_	_	O
382	39/116	_	_	O
383	)	_	_	O
384	received	_	_	O
385	intensive	_	_	O
386	local	_	_	O
387	therapy	_	_	O
388	defined	_	_	O
389	as	_	_	O
390	radical	_	_	O
391	wide	_	_	O
392	field	_	_	O
393	radiotherapy	_	_	O
394	or	_	_	O
395	radical	_	_	O
396	surgery	_	_	O
397	or	_	_	O
398	both	_	_	O
399	.	_	_	O

400	Compared	_	_	B-Claim
401	with	_	_	I-Claim
402	the	_	_	I-Claim
403	results	_	_	I-Claim
404	obtained	_	_	I-Claim
405	in	_	_	I-Claim
406	the	_	_	I-Claim
407	previous	_	_	I-Claim
408	SIOP	_	_	I-Claim
409	study	_	_	I-Claim
410	,	_	_	I-Claim
411	treatment	_	_	I-Claim
412	in	_	_	I-Claim
413	MMT84	_	_	I-Claim
414	was	_	_	I-Claim
415	based	_	_	I-Claim
416	on	_	_	I-Claim
417	response	_	_	I-Claim
418	to	_	_	I-Claim
419	initial	_	_	I-Claim
420	chemotherapy	_	_	I-Claim
421	and	_	_	I-Claim
422	,	_	_	I-Claim
423	despite	_	_	I-Claim
424	an	_	_	I-Claim
425	overall	_	_	I-Claim
426	reduction	_	_	I-Claim
427	of	_	_	I-Claim
428	the	_	_	I-Claim
429	use	_	_	I-Claim
430	of	_	_	I-Claim
431	local	_	_	I-Claim
432	therapy	_	_	I-Claim
433	,	_	_	I-Claim
434	significantly	_	_	I-Claim
435	improved	_	_	I-Claim
436	survival	_	_	I-Claim
437	for	_	_	I-Claim
438	patients	_	_	I-Claim
439	with	_	_	I-Claim
440	non-metastatic	_	_	I-Claim
441	disease	_	_	I-Claim
442	.	_	_	I-Claim

443	This	_	_	B-Claim
444	trial	_	_	I-Claim
445	,	_	_	I-Claim
446	also	_	_	I-Claim
447	for	_	_	I-Claim
448	the	_	_	I-Claim
449	first	_	_	I-Claim
450	time	_	_	I-Claim
451	,	_	_	I-Claim
452	provides	_	_	I-Claim
453	evidence	_	_	I-Claim
454	that	_	_	I-Claim
455	retreatment	_	_	I-Claim
456	after	_	_	I-Claim
457	local	_	_	I-Claim
458	relapse	_	_	I-Claim
459	can	_	_	I-Claim
460	achieve	_	_	I-Claim
461	long-term	_	_	I-Claim
462	second	_	_	I-Claim
463	remissions	_	_	I-Claim
464	.	_	_	I-Claim


0	We	_	_	O
1	report	_	_	O
2	results	_	_	O
3	of	_	_	O
4	a	_	_	O
5	randomized	_	_	O
6	prospective	_	_	O
7	study	_	_	O
8	that	_	_	O
9	compared	_	_	O
10	single	_	_	O
11	agents	_	_	O
12	of	_	_	O
13	low	_	_	O
14	toxicity	_	_	O
15	given	_	_	O
16	both	_	_	O
17	as	_	_	O
18	the	_	_	O
19	first-line	_	_	O
20	and	_	_	O
21	second-line	_	_	O
22	chemotherapy	_	_	O
23	with	_	_	O
24	combination	_	_	O
25	chemotherapy	_	_	O
26	in	_	_	O
27	advanced	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	with	_	_	O
31	distant	_	_	O
32	metastases	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	in	_	_	O
36	the	_	_	O
37	single-agent	_	_	O
38	arm	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	153	_	_	O
43	)	_	_	O
44	received	_	_	O
45	weekly	_	_	O
46	epirubicin	_	_	O
47	(	_	_	O
48	E	_	_	O
49	)	_	_	O
50	20	_	_	O
51	mg/m2	_	_	O
52	until	_	_	O
53	progression	_	_	O
54	or	_	_	O
55	until	_	_	O
56	the	_	_	O
57	cumulative	_	_	O
58	dose	_	_	O
59	of	_	_	O
60	1,000	_	_	O
61	mg/m2	_	_	O
62	,	_	_	O
63	followed	_	_	O
64	by	_	_	O
65	mitomycin	_	_	O
66	(	_	_	O
67	M	_	_	O
68	)	_	_	O
69	8	_	_	O
70	mg/m2	_	_	O
71	every	_	_	O
72	4	_	_	O
73	weeks	_	_	O
74	,	_	_	O
75	and	_	_	O
76	those	_	_	O
77	in	_	_	O
78	the	_	_	O
79	combination	_	_	O
80	chemotherapy	_	_	O
81	arm	_	_	O
82	(	_	_	O
83	n	_	_	O
84	=	_	_	O
85	150	_	_	O
86	)	_	_	O
87	were	_	_	O
88	first	_	_	O
89	given	_	_	O
90	cyclophosphamide	_	_	O
91	500	_	_	O
92	mg/m2	_	_	O
93	,	_	_	O
94	E	_	_	O
95	60	_	_	O
96	mg/m2	_	_	O
97	,	_	_	O
98	and	_	_	O
99	fluorouracil	_	_	O
100	500	_	_	O
101	mg/m2	_	_	O
102	three	_	_	O
103	times	_	_	O
104	per	_	_	O
105	week	_	_	O
106	(	_	_	O
107	CEF	_	_	O
108	)	_	_	O
109	followed	_	_	O
110	by	_	_	O
111	M	_	_	O
112	8	_	_	O
113	mg/m2	_	_	O
114	plus	_	_	O
115	vinblastine	_	_	O
116	(	_	_	O
117	V	_	_	O
118	)	_	_	O
119	6	_	_	O
120	mg/m2	_	_	O
121	every	_	_	O
122	4	_	_	O
123	weeks	_	_	O
124	.	_	_	O

125	Exclusion	_	_	O
126	criteria	_	_	O
127	included	_	_	O
128	age	_	_	O
129	greater	_	_	O
130	than	_	_	O
131	70	_	_	O
132	years	_	_	O
133	,	_	_	O
134	World	_	_	O
135	Health	_	_	O
136	Organization	_	_	O
137	(	_	_	O
138	WHO	_	_	O
139	)	_	_	O
140	performance	_	_	O
141	status	_	_	O
142	greater	_	_	O
143	than	_	_	O
144	2	_	_	O
145	,	_	_	O
146	prior	_	_	O
147	chemotherapy	_	_	O
148	for	_	_	O
149	metastatic	_	_	O
150	disease	_	_	O
151	,	_	_	O
152	and	_	_	O
153	presence	_	_	O
154	of	_	_	O
155	liver	_	_	O
156	metastases	_	_	O
157	in	_	_	O
158	patients	_	_	O
159	younger	_	_	O
160	than	_	_	O
161	50	_	_	O
162	.	_	_	O

163	An	_	_	B-Premise
164	objective	_	_	I-Premise
165	response	_	_	I-Premise
166	(	_	_	I-Premise
167	complete	_	_	I-Premise
168	[	_	_	I-Premise
169	CR	_	_	I-Premise
170	]	_	_	I-Premise
171	or	_	_	I-Premise
172	partial	_	_	I-Premise
173	[	_	_	I-Premise
174	PR	_	_	I-Premise
175	]	_	_	I-Premise
176	)	_	_	I-Premise
177	was	_	_	I-Premise
178	obtained	_	_	I-Premise
179	in	_	_	I-Premise
180	55	_	_	I-Premise
181	%	_	_	I-Premise
182	,	_	_	I-Premise
183	48	_	_	I-Premise
184	%	_	_	I-Premise
185	,	_	_	I-Premise
186	16	_	_	I-Premise
187	%	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	7	_	_	I-Premise
191	%	_	_	I-Premise
192	of	_	_	I-Premise
193	patients	_	_	I-Premise
194	treated	_	_	I-Premise
195	with	_	_	I-Premise
196	CEF	_	_	I-Premise
197	,	_	_	I-Premise
198	E	_	_	I-Premise
199	,	_	_	I-Premise
200	M	_	_	I-Premise
201	,	_	_	I-Premise
202	and	_	_	I-Premise
203	MV	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	.	_	_	I-Premise

207	A	_	_	B-Premise
208	response	_	_	I-Premise
209	to	_	_	I-Premise
210	CEF	_	_	I-Premise
211	tended	_	_	I-Premise
212	to	_	_	I-Premise
213	last	_	_	I-Premise
214	longer	_	_	I-Premise
215	than	_	_	I-Premise
216	a	_	_	I-Premise
217	response	_	_	I-Premise
218	to	_	_	I-Premise
219	E	_	_	I-Premise
220	(	_	_	I-Premise
221	median	_	_	I-Premise
222	,	_	_	I-Premise
223	12	_	_	I-Premise
224	v	_	_	I-Premise
225	10.5	_	_	I-Premise
226	months	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	.07	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Treatment-related	_	_	B-Premise
234	toxicity	_	_	I-Premise
235	was	_	_	I-Premise
236	less	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	single-agent	_	_	I-Premise
240	arm	_	_	I-Premise
241	and	_	_	I-Premise
242	quality-of-life	_	_	I-Premise
243	(	_	_	I-Premise
244	QOL	_	_	I-Premise
245	)	_	_	I-Premise
246	analysis	_	_	I-Premise
247	favored	_	_	I-Premise
248	the	_	_	I-Premise
249	single-agent	_	_	I-Premise
250	arm	_	_	I-Premise
251	.	_	_	I-Premise

252	No	_	_	B-Premise
253	significant	_	_	I-Premise
254	difference	_	_	I-Premise
255	in	_	_	I-Premise
256	time	_	_	I-Premise
257	to	_	_	I-Premise
258	progression	_	_	I-Premise
259	or	_	_	I-Premise
260	survival	_	_	I-Premise
261	was	_	_	I-Premise
262	found	_	_	I-Premise
263	between	_	_	I-Premise
264	the	_	_	I-Premise
265	two	_	_	I-Premise
266	arms	_	_	I-Premise
267	.	_	_	I-Premise

268	Similarly	_	_	B-Premise
269	,	_	_	I-Premise
270	no	_	_	I-Premise
271	difference	_	_	I-Premise
272	in	_	_	I-Premise
273	survival	_	_	I-Premise
274	was	_	_	I-Premise
275	found	_	_	I-Premise
276	when	_	_	I-Premise
277	the	_	_	I-Premise
278	patients	_	_	I-Premise
279	who	_	_	I-Premise
280	received	_	_	I-Premise
281	both	_	_	I-Premise
282	the	_	_	I-Premise
283	planned	_	_	I-Premise
284	first-and	_	_	I-Premise
285	second-line	_	_	I-Premise
286	treatments	_	_	I-Premise
287	were	_	_	I-Premise
288	compared	_	_	I-Premise
289	or	_	_	I-Premise
290	when	_	_	I-Premise
291	survival	_	_	I-Premise
292	was	_	_	I-Premise
293	calculated	_	_	I-Premise
294	from	_	_	I-Premise
295	the	_	_	I-Premise
296	beginning	_	_	I-Premise
297	of	_	_	I-Premise
298	the	_	_	I-Premise
299	second-line	_	_	I-Premise
300	therapy	_	_	I-Premise
301	.	_	_	I-Premise

302	Patients	_	_	B-Claim
303	treated	_	_	I-Claim
304	with	_	_	I-Claim
305	single-agent	_	_	I-Claim
306	E	_	_	I-Claim
307	followed	_	_	I-Claim
308	by	_	_	I-Claim
309	single-agent	_	_	I-Claim
310	M	_	_	I-Claim
311	had	_	_	I-Claim
312	similar	_	_	I-Claim
313	survival	_	_	I-Claim
314	,	_	_	I-Claim
315	but	_	_	I-Claim
316	less	_	_	I-Claim
317	treatment-related	_	_	I-Claim
318	toxicity	_	_	I-Claim
319	and	_	_	I-Claim
320	better	_	_	I-Claim
321	QOL	_	_	I-Claim
322	as	_	_	I-Claim
323	compared	_	_	I-Claim
324	with	_	_	I-Claim
325	those	_	_	I-Claim
326	treated	_	_	I-Claim
327	with	_	_	I-Claim
328	CEF	_	_	I-Claim
329	followed	_	_	I-Claim
330	by	_	_	I-Claim
331	MV	_	_	I-Claim
332	.	_	_	I-Claim


0	Vinorelbine	_	_	B-Claim
1	,	_	_	I-Claim
2	a	_	_	I-Claim
3	semisynthetic	_	_	I-Claim
4	vinca	_	_	I-Claim
5	alkaloid	_	_	I-Claim
6	,	_	_	I-Claim
7	represents	_	_	I-Claim
8	a	_	_	I-Claim
9	well-tolerated	_	_	I-Claim
10	treatment	_	_	I-Claim
11	for	_	_	I-Claim
12	elderly	_	_	I-Claim
13	patients	_	_	I-Claim
14	with	_	_	I-Claim
15	advanced	_	_	I-Claim
16	non-small-cell	_	_	I-Claim
17	lung	_	_	I-Claim
18	cancer	_	_	I-Claim
19	(	_	_	I-Claim
20	NSCLC	_	_	I-Claim
21	)	_	_	I-Claim
22	.	_	_	I-Claim

23	We	_	_	O
24	explored	_	_	O
25	the	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	(	_	_	O
30	QoL	_	_	O
31	)	_	_	O
32	of	_	_	O
33	such	_	_	O
34	patients	_	_	O
35	in	_	_	O
36	a	_	_	O
37	multicenter	_	_	O
38	randomized	_	_	O
39	trial	_	_	O
40	that	_	_	O
41	compared	_	_	O
42	vinorelbine	_	_	O
43	treatment	_	_	O
44	with	_	_	O
45	supportive	_	_	O
46	care	_	_	O
47	alone	_	_	O
48	.	_	_	O

49	Eligible	_	_	O
50	patients	_	_	O
51	were	_	_	O
52	70	_	_	O
53	years	_	_	O
54	of	_	_	O
55	age	_	_	O
56	or	_	_	O
57	older	_	_	O
58	,	_	_	O
59	had	_	_	O
60	stage	_	_	O
61	IV	_	_	O
62	or	_	_	O
63	IIIB	_	_	O
64	NSCLC	_	_	O
65	that	_	_	O
66	was	_	_	O
67	ineligible	_	_	O
68	for	_	_	O
69	radiotherapy	_	_	O
70	,	_	_	O
71	and	_	_	O
72	had	_	_	O
73	a	_	_	O
74	performance	_	_	O
75	status	_	_	O
76	of	_	_	O
77	0-2	_	_	O
78	(	_	_	O
79	a	_	_	O
80	status	_	_	O
81	of	_	_	O
82	fully	_	_	O
83	active	_	_	O
84	to	_	_	O
85	a	_	_	O
86	status	_	_	O
87	of	_	_	O
88	capable	_	_	O
89	of	_	_	O
90	all	_	_	O
91	self-care	_	_	O
92	but	_	_	O
93	unable	_	_	O
94	to	_	_	O
95	work	_	_	O
96	)	_	_	O
97	.	_	_	O

98	Vinorelbine	_	_	O
99	was	_	_	O
100	given	_	_	O
101	intravenously	_	_	O
102	on	_	_	O
103	days	_	_	O
104	1	_	_	O
105	and	_	_	O
106	8	_	_	O
107	of	_	_	O
108	a	_	_	O
109	21-day	_	_	O
110	treatment	_	_	O
111	cycle	_	_	O
112	,	_	_	O
113	for	_	_	O
114	a	_	_	O
115	total	_	_	O
116	of	_	_	O
117	six	_	_	O
118	cycles	_	_	O
119	.	_	_	O

120	QoL	_	_	O
121	was	_	_	O
122	evaluated	_	_	O
123	with	_	_	O
124	European	_	_	O
125	Organization	_	_	O
126	for	_	_	O
127	Research	_	_	O
128	and	_	_	O
129	Treatment	_	_	O
130	of	_	_	O
131	Cancer	_	_	O
132	questionnaires	_	_	O
133	QLQ-C30	_	_	O
134	and	_	_	O
135	QLQ-LC13	_	_	O
136	,	_	_	O
137	and	_	_	O
138	the	_	_	O
139	QoL	_	_	O
140	data	_	_	O
141	were	_	_	O
142	analyzed	_	_	O
143	by	_	_	O
144	fitting	_	_	O
145	a	_	_	O
146	linear	_	_	O
147	mixed	_	_	O
148	model	_	_	O
149	for	_	_	O
150	each	_	_	O
151	QoL	_	_	O
152	scale	_	_	O
153	.	_	_	O

154	Survival	_	_	O
155	curves	_	_	O
156	were	_	_	O
157	plotted	_	_	O
158	and	_	_	O
159	were	_	_	O
160	compared	_	_	O
161	with	_	_	O
162	the	_	_	O
163	Mantel-Haenszel	_	_	O
164	test	_	_	O
165	.	_	_	O

166	Relative	_	_	O
167	hazards	_	_	O
168	of	_	_	O
169	death	_	_	O
170	and	_	_	O
171	95	_	_	O
172	%	_	_	O
173	confidence	_	_	O
174	intervals	_	_	O
175	(	_	_	O
176	CIs	_	_	O
177	)	_	_	O
178	were	_	_	O
179	estimated	_	_	O
180	by	_	_	O
181	the	_	_	O
182	Cox	_	_	O
183	model	_	_	O
184	.	_	_	O

185	Investigators	_	_	O
186	,	_	_	O
187	blinded	_	_	O
188	to	_	_	O
189	the	_	_	O
190	results	_	_	O
191	,	_	_	O
192	stopped	_	_	O
193	the	_	_	O
194	trial	_	_	O
195	early	_	_	O
196	because	_	_	O
197	of	_	_	O
198	a	_	_	O
199	low	_	_	O
200	enrollment	_	_	O
201	rate	_	_	O
202	.	_	_	O

203	(	_	_	O
204	From	_	_	O
205	April	_	_	O
206	1996	_	_	O
207	to	_	_	O
208	November	_	_	O
209	1997	_	_	O
210	,	_	_	O
211	191	_	_	O
212	of	_	_	O
213	the	_	_	O
214	350	_	_	O
215	targeted	_	_	O
216	patients	_	_	O
217	were	_	_	O
218	randomly	_	_	O
219	assigned	_	_	O
220	.	_	_	O
221	)	_	_	O

222	Data	_	_	O
223	from	_	_	O
224	161	_	_	O
225	patients	_	_	O
226	have	_	_	O
227	been	_	_	O
228	analyzed	_	_	O
229	.	_	_	O

230	Vinorelbine-treated	_	_	B-Premise
231	patients	_	_	I-Premise
232	scored	_	_	I-Premise
233	better	_	_	I-Premise
234	than	_	_	I-Premise
235	control	_	_	I-Premise
236	patients	_	_	I-Premise
237	on	_	_	I-Premise
238	QoL	_	_	I-Premise
239	functioning	_	_	I-Premise
240	scales	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	they	_	_	I-Premise
244	reported	_	_	I-Premise
245	fewer	_	_	I-Premise
246	lung	_	_	I-Premise
247	cancer-related	_	_	I-Premise
248	symptoms	_	_	I-Premise
249	but	_	_	I-Premise
250	reported	_	_	I-Premise
251	worse	_	_	I-Premise
252	toxicity-related	_	_	I-Premise
253	symptoms	_	_	I-Premise
254	.	_	_	I-Premise

255	There	_	_	B-Premise
256	was	_	_	I-Premise
257	a	_	_	I-Premise
258	statistically	_	_	I-Premise
259	significant	_	_	I-Premise
260	(	_	_	I-Premise
261	two-sided	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.03	_	_	I-Premise
265	)	_	_	I-Premise
266	survival	_	_	I-Premise
267	advantage	_	_	I-Premise
268	for	_	_	I-Premise
269	patients	_	_	I-Premise
270	receiving	_	_	I-Premise
271	vinorelbine	_	_	I-Premise
272	;	_	_	I-Premise
273	median	_	_	B-Premise
274	survival	_	_	I-Premise
275	increased	_	_	I-Premise
276	from	_	_	I-Premise
277	21	_	_	I-Premise
278	to	_	_	I-Premise
279	28	_	_	I-Premise
280	weeks	_	_	I-Premise
281	in	_	_	I-Premise
282	the	_	_	I-Premise
283	vinorelbine-treated	_	_	I-Premise
284	group	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	relative	_	_	I-Premise
288	hazard	_	_	I-Premise
289	of	_	_	I-Premise
290	death	_	_	I-Premise
291	for	_	_	I-Premise
292	vinorelbine-treated	_	_	I-Premise
293	patients	_	_	I-Premise
294	was	_	_	I-Premise
295	0.65	_	_	I-Premise
296	(	_	_	I-Premise
297	95	_	_	I-Premise
298	%	_	_	I-Premise
299	CI	_	_	I-Premise
300	=	_	_	I-Premise
301	0.45-0.93	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	Vinorelbine	_	_	B-Claim
305	improves	_	_	I-Claim
306	survival	_	_	I-Claim
307	of	_	_	I-Claim
308	elderly	_	_	I-Claim
309	patients	_	_	I-Claim
310	with	_	_	I-Claim
311	advanced	_	_	I-Claim
312	NSCLC	_	_	I-Claim
313	and	_	_	I-Claim
314	possibly	_	_	I-Claim
315	improves	_	_	I-Claim
316	overall	_	_	I-Claim
317	QoL	_	_	I-Claim
318	.	_	_	I-Claim

